<SEC-DOCUMENT>0000950170-23-004654.txt : 20230227
<SEC-HEADER>0000950170-23-004654.hdr.sgml : 20230227
<ACCEPTANCE-DATETIME>20230227161740
ACCESSION NUMBER:		0000950170-23-004654
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230227
DATE AS OF CHANGE:		20230227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vaxcyte, Inc.
		CENTRAL INDEX KEY:			0001649094
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				464233385
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39323
		FILM NUMBER:		23675118

	BUSINESS ADDRESS:	
		STREET 1:		825 INDUSTRIAL ROAD, STE. 300
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070
		BUSINESS PHONE:		650-837-0111

	MAIL ADDRESS:	
		STREET 1:		825 INDUSTRIAL ROAD, STE. 300
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SutroVax, Inc.
		DATE OF NAME CHANGE:	20150724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pcvx-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-27T10:44:07.9905+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:pcvx="http://www.vaxcyte.com/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e1ec8068-d2e5-4cc8-8234-52bb71f87e0c" name="dei:EntityCentralIndexKey" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7">0001649094</ix:nonNumeric><ix:nonNumeric id="F_7678fefa-44cc-47df-a4a0-5914bc136d01" name="dei:AmendmentFlag" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7">false</ix:nonNumeric><ix:nonFraction id="F_e8d3af2f-da3d-4a8d-a3ce-fe78d26e1535" name="us-gaap:CommitmentsAndContingencies" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_b8edf648-6c56-470f-b105-b7c382767664" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_295fc304-a24b-4340-bef2-fe78e40e2989">P3Y6M</ix:nonNumeric><ix:nonFraction id="F_01e56683-a72d-4e07-a927-c99f3d7b0a4c" name="us-gaap:CommitmentsAndContingencies" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_702b2ee1-c8d3-4b6c-aa18-57f4ed887283" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_41f2bc47-1b64-456b-8eb3-0bfe5b57516c">P3Y</ix:nonNumeric><ix:nonNumeric id="F_b4831c24-3135-411b-b171-2bbf2a2a3369" name="dei:DocumentFiscalPeriodFocus" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7">FY</ix:nonNumeric><ix:nonFraction id="F_8e741145-af74-425d-8be3-d82ab7aec016" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_adfec910-931f-4fe2-b666-3a64354787e5" unitRef="U_pure" decimals="3" scale="0">0.593</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pcvx-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_6c1fa594-ab7b-4dd7-8b89-83fe6abb5568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4156e2c-f054-42e7-a026-6dd2300deca6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9ef3af6-0ed6-4232-82f8-f00e3b3f9c04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebee093b-a58f-4627-85e8-192d773f305e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0462dcf5-a925-4711-9836-298b3b1a0bba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d40cfd0-136e-4c2d-a988-0b2942394d6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f24288b7-094a-4c0a-ad36-62c7652ebabb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc8ae2fa-cfee-4adf-934b-b757251456e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf009615-d1f6-4a3a-935f-7b0d3b6dca01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e5bb009-c911-4eb4-9225-759eaada18dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:ComputersAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93ae0419-91bb-4c85-9618-57fe0afc3264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_037574d0-71b1-40d4-9227-c5f9299b9dd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7cbd95b2-0c54-4116-8364-7ddbdd457679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5498ed60-351d-4bfe-8d0d-3748e9cc3710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fb2cd419-f42a-43d4-8173-6fb63ccd1d36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_215eff92-aeb1-4823-b975-c15a670cc803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:PaloAltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0c5e803-6cf5-4387-8896-428a21286a2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34ff63dc-cde8-47e8-9597-b638326cc368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_81984893-bd31-4052-aaed-e6928b5494fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f016bde-e771-439c-ab98-f01eb018c718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87eb225f-5c0d-43e6-859d-fe29381daaa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17293867-6c59-44bc-b2a6-797596102857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8656ce44-0eee-45cd-8119-542db136b9e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81569ea5-c187-4394-8eea-071974a031f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13165d69-2eff-4eec-af08-7f5b5519d9b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da57a27c-5363-490e-93b7-2f25eccde933"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c14f87d8-1d33-40ea-b99b-b33fe6411911"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b71d1ae0-0191-4fcc-9eb1-6928e92a2341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ea235fe-244e-4bbf-8025-1963f440f2aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a9d9224-9fa8-4858-a34f-83f9703e9715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66f9bfcc-ebad-40de-95bf-47b87ed044a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b6dde0d-1098-4728-82b4-9050d56dcc05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d308ed79-6102-4437-9f98-f586c059dc9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c4d15b9-2c87-4cf6-be74-87bda32cea0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:ComputersAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adfec910-931f-4fe2-b666-3a64354787e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-05</xbrli:startDate><xbrli:endDate>2020-06-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24822c38-0fa4-483a-956a-7108b2fb1a10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5b73419-0c99-4891-9305-ef5424ea8616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_330c2634-585b-4669-bdd0-9bfa256e2032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5787b64-58e9-406e-ab46-d4feaf208a20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5603f34-fe33-4aa9-bba2-7bcef1212dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84e39903-4e50-46bc-a706-ef2201e6c504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bd83283-29d6-47da-874d-4c54c292d4ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d6c3586-ec99-4387-90b9-c66ada981bf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df172351-baa3-4411-9c37-3b0b3e33fab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0489234b-730f-4827-9f6d-d815f1a09ff7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e17de957-4ef6-4075-bc74-6780bc32c66b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c80a26a1-b95a-44f9-acc5-6127ef778da7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2fdc0e7-955d-4a1b-9894-ad28840b67da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22b9506a-6924-44d6-a115-432bb54e29f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85dd075c-01fc-4937-bc97-63808bb2e3a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52a9c5b1-8f71-49a0-af0c-9cb853cc2232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e926f4ca-4dd1-450a-81bd-dc676a9925ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a1db5ca-4032-454e-b64f-84afc6e86567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45c64528-2381-42d2-9b60-787dd273ce67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51a0df40-cbb7-4e5a-855d-40d7ff36c161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9894bfc2-b8d0-4aa2-bdea-70d5be6112ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c77accc-7d52-4157-8c4c-e2e27e2e2b05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75637c01-f692-4f45-a633-9d4eb7b8df37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:SutroStockPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d173051-b96b-48bb-8554-d94b4601af7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b92aaa0b-aeff-4d69-a84f-c6311d27ad82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff59dd17-1515-4475-9b29-d6981afba232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adf7111c-3503-433b-85ea-ba5266a3bec4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a8383e7-fefb-449e-97bd-c449db6e963c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e4a1e9d-b20b-44bb-aaf3-49bc4856bac7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2a47633-779f-4ee5-bc2a-ade49b683a08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:OtherRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8842095a-a719-4e20-84ac-651814b90d5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb41f55f-e7d1-436d-992c-c9ae66000f84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3a3620f-8e54-449e-9e7d-3e9250cb8220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c325a933-95d0-4782-a705-8f73c8708fb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff0b5242-8612-45db-87e3-a8572449c172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1e5de9a-c565-4d52-a50d-b1a74b68669d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cf6689c-2254-4c4c-9717-295b1177cd54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28391222-5a1c-470d-ab50-f5f6861c6e11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fdff316-147b-4b2b-bcfe-6871447ed8e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c544cf31-11ab-4456-8095-c7c6e411d5d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e350f80-8b0a-485c-813b-204158cbec02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98587108-31fb-4048-8311-ad1171d7b550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69e656bb-2569-41bf-9f6a-4c464b33253f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e25d9bc-8da8-4125-95f2-eb869be71853"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a8dc7cf-7734-4350-9266-07d83e2f4a3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b29a7753-469a-481c-993c-8a5ee73c666c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ff4f253-5e79-4f0f-9621-48e669f7b797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9bb12da7-1bd7-4afd-815f-80e30d2186ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b043466b-5227-4835-be5f-8ac1b25eac10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebe97179-a864-486e-a92b-54ddbdfb9b14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57fb732d-890e-48c0-9e93-f41e83529309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a4f0832-de96-4079-b3c1-db1efe6e81b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ac2f60b-8289-45da-8d07-c31dcf594253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05578dce-4d37-4f18-96b3-f10bddcbaf51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01155b0a-67b5-469f-9b55-5c9a7412e381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc63e8f2-1888-4fcd-a8d4-a880d9bb2f86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5d59d19-2f5b-474d-ad5f-5eb6826a0e4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34d44816-59db-4fff-99c9-27216e95713d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9301909a-a6de-4293-bf83-22071eaf9f32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ff2a197-ccf8-4a47-9068-2d3aca352aec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69ba85f7-550d-45b3-a266-5784d58b8189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ace7762d-3569-458c-9040-9f42331af172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d262603-bbcb-4d32-8649-c7dde0f3cba1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0598ec3b-a113-4d19-ae05-d08550eafaae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c850b73-588c-41c3-b04b-a21bc0ff9e82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cec58be-bb3d-44e1-8f46-324ba1e7a4d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93cfc9bc-cf41-46c8-8d8c-3c249f9e296f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_180236c9-658c-46b2-8320-cd9fd9ee3932"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41f2bc47-1b64-456b-8eb3-0bfe5b57516c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_415e98bb-bdbd-4558-a741-01b294239326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9126c57-d4e4-4b9e-8373-4b493ee1f1c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d0c5e64-a420-486e-ae76-8b1696c5a6ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32c0e264-4ab1-4f71-99a3-932ea28e946c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_605b60d5-91b3-4448-ba68-5bd37a009e74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ab2007d-2325-4131-b251-a78960367bd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f071a04d-8d88-4c59-91cc-56470ac8c360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a36c4830-4b5f-44a3-8402-0567ef69ef94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_43290d81-1ade-4236-b12a-f4dfbc9a2de2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92495c05-9763-4ff7-855f-1743d26c34ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cf027a0-a614-4616-8ba2-757303a3ef4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a2fe8c2-7190-4ba0-9807-0bf83b739c1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82ee469c-c1fb-46f6-bd16-0bd5b700dbdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:PaloAltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42dcecda-101e-4ddd-8695-6548e530de78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2851b72e-f235-4e1b-8ad0-09f3525757c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_180b3546-613a-47fb-a45e-b43467ddc5e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fea95f2-1b19-4123-9ac1-3c958efccee9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c174ac3-2385-4026-a502-02872bdce024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69861e0f-f897-430a-8634-87b91fd0c8b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_443140ce-af83-4051-90d8-0a039e3d6625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-14</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_132ccca8-d60e-4222-bb51-935509c790c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f29cb1b4-51e8-42fe-ba43-bfae1134ea34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:NewCorporateHeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_db08c559-8805-4810-a9ad-817d3efd45a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c729b163-a362-4fd1-896f-64744eecd71c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1af9b85c-d59e-4494-bcdc-b8097aa831e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2621b640-8d9b-4efa-a67c-bc201f6864e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:OtherRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcab4237-fc1e-4b3b-a82d-9d53bb21e6b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb2e21b9-03b4-445b-a4c8-52e92a39f940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c411c849-9449-415d-836c-57f752c96e04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_323a4631-8d67-46bd-b2bd-7c01a7ec7d2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d081aa6-31a3-4423-a381-77023efa1448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad2a30c9-052d-4eba-928a-c4c5ab6c20db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:SutroStockPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_295fc304-a24b-4340-bef2-fe78e40e2989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:OtherRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53f32d39-f32f-4c9e-8927-e638758556c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c04110eb-23bc-459e-a813-d93f70e70acf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6044654-8564-4024-bef2-b41b4aedd272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_202f07f9-5156-457e-9195-d19a2910d156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cffd01a3-53b4-4cbf-9aef-3e5b1f46b78f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acd4f53c-e76e-4bcc-8f97-102bcec4707b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b1a0eec-bf5e-4892-9967-715b22960941"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59365215-3504-4f12-b752-122da006773a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8212113-420d-4afe-a557-faeb55c9fc93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81e20c4f-e0c6-4cea-b677-93b2e39c7f30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ddc89e57-5630-47be-9bd0-27808be55284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6713bc72-bbf6-4c8d-848a-8ca3bd191ee0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7812bcb-1a97-4787-be8b-59a98d64a890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd141812-a700-48fc-9a93-5d2fa4df6de7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02afd6c9-f14c-4595-b698-8d1af3e8c0a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_837815d3-4f60-4133-8174-f837af239d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf5ec869-94b5-4ffc-91dc-e1f40e3f1d68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33283eca-8ea2-4ccd-9fe1-36145a063453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1121605e-be53-44bc-b6eb-31b279bad82d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a97fce7-5ef2-4cc8-85f5-b620ca762566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cae38a4-c4a8-47aa-a3e3-61aaee5e44b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49cc4baf-48fc-47b3-962c-c338dcbc9399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9b4f586-2146-4cbd-aa92-140916b46d25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3a1f2bbd-3a84-4def-8008-4279ed957a96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ba486b2-d8aa-4ca6-9756-5c9748b4e008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b694d80e-fe68-400d-b770-ba2619d82563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1ef036e-43c1-4748-ba90-b2fce246fad4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e301df95-054d-4248-b434-a97368723f9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b219256c-6df8-41ce-b765-2f529e35b517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb33c9e9-15f8-4620-9baa-1c636358bb0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:SanCarlosMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1477851-b8b1-4483-a4bf-02d65b12c4e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10a9faa2-6408-4b48-8d11-d8c2958b964d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a24e83d-869b-46cd-a362-36d31d8ac8ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ab2dcd4-25fb-4d25-a652-57453b4b393b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5620db3e-07c5-48e8-80c5-b68b2362d81c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8457603-d007-4a06-8019-118bd0a48904"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d608b3d-cdf6-4c26-9877-9e1ba7a21a78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20d86c4a-c1e6-415d-8039-887d6b20d17f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52984cc7-0416-45ea-9199-ee6f2a1b640f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a07caa24-b5b1-41b0-bf5a-a85de3830de2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93593151-df16-4d93-bf9c-30716b99adb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:NewCorporateHeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_16219b98-47a8-4997-a3e1-39a5a065b63c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16916817-1032-4d1c-9ab3-a2e5e372cb09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86059fb6-8a98-4604-99c1-7846fc457e76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:SutroStockPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bc5fec4-d3ad-4cc4-9828-b81bfbdb4992"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c80638b-879a-4eff-b0d3-6917912c5862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76248553-c6a5-451e-b7e1-10f5d684fa65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d68821a-459d-4683-8345-23cec20bbda0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3303683-5d29-4add-a4a5-c77ccff026b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78621854-c804-4c5b-8406-1b035bcdf270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86a6494f-286c-4378-b602-52e8e5e8f4b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6be8964-6e18-48ad-a7a4-2310c767319e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:CommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_042e7705-d42e-4637-8ecc-6de667d73494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc891ca2-75ea-4415-b513-14e4b37dc9b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6eb96b6-2f08-472a-ba13-12abc92474e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58188e6f-33df-4637-971c-bb69de27b7a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_563ab83e-909f-4129-bbf2-6d8fd0542811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_522586e0-c2a8-4187-8dfd-3a928a099df2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7051fb3-6833-4895-a7ab-ff07923b921b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7cc4ab4f-7bad-4d16-9545-b64979b11e87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5174e359-4705-4039-af81-628498b266ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_71794c0f-76e0-44c9-b988-61b9c2402e78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f949711a-cc58-4c69-8736-3e85b3424551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d94724f5-308f-4538-9078-b37164cc96a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-11</xbrli:startDate><xbrli:endDate>2020-06-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae85f674-5889-4534-aba6-cf137accf611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3d2b846-b46a-4469-a0a3-586d1c69fc46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fffa34b2-595e-4a00-a483-b9a4cb5243ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f9806ed-b5a6-4aef-bf04-0c1827f34b0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6584fbf6-caf6-435c-8531-3189f88ffaef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_898a2a2d-e260-47fb-85c7-5b4d4065a867"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-01</xbrli:startDate><xbrli:endDate>2016-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79e53c50-0fb4-4714-84d0-e5a2a573e00b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3912106f-3c31-4ffc-9141-7807cf18d485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9400b621-8b2f-4a08-b570-b9c92478f198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1be3eda5-a43a-436d-b315-ddea1f184d88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_627bc919-0f57-4ed7-9267-0f6ca3c2b3c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_043847b8-3b71-486a-a3f8-651e1b7e0b0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7329b071-f8d6-4b42-988b-4c5a585bc452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58769e66-aeef-44e4-85ca-41149ca8f5e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef8a5bfd-8fc9-43e4-974f-36c738247627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4995092-b32b-457d-9712-2e5592bba095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b67a24d-307d-4950-a7b7-2cbe7eaae283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAmendmentATwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06c078e9-1e6f-4493-a040-ad253c029b6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1cb91b7d-ce25-4f69-a837-9352b82a8fb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05a0d0fb-b481-4721-8b79-6232b8304ad5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_783f07a1-06d5-4961-9f5d-5e2270a1613f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99bb839f-a7de-4946-a60c-d6f300ec4d73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acde4ea0-fa6f-4cb1-9b72-08bcadf7a728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001649094</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAmendmentATwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-28</xbrli:startDate><xbrli:endDate>2018-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Security"><xbrli:measure>pcvx:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_RenewalOption"><xbrli:measure>pcvx:RenewalOption</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lease"><xbrli:measure>pcvx:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>pcvx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_2e45e8e0-02af-425c-8676-e3d2b46597cc" fromRefs="F_7bf9f156-a8b5-43ba-a0a0-d7a76ae82463 F_df4ab314-c5c6-42db-9ded-1707241de39d"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_ae976684-1799-4dc9-8326-1dcb7053a127" fromRefs="F_10840e29-68b1-42d2-9040-bb0bdcec4e88 F_bec0d669-934c-45fb-8ac2-b3ee2f080725 F_e3446735-f111-4e41-9a5e-3fea9fe6170e F_7bf9f156-a8b5-43ba-a0a0-d7a76ae82463"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_79671d51-a749-4741-8688-eea6386e55d4" fromRefs="F_99b7e5aa-ca0b-4683-a754-60df640d4e91"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_2acf8d31-1a88-47ed-9dad-dbe995d6b697" fromRefs="F_6bbbaf9f-9437-4277-81df-fdccd0343c70"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6" fromRefs="F_183651b9-50a6-4cb9-89bd-4b35bbe4e5cc F_044aa6a6-d895-4aa0-a08e-4ca031bbd5f3 F_802af70f-cd71-4dcf-a22f-17f9b1443f1e F_759d25eb-ab69-42e5-b66f-2cb749e67d44 F_5134f00b-6328-4caa-a1ac-c88e5bb8d286 F_d28bdfa9-f518-49b5-89a3-e1fa6de3ae6a F_258d9aaa-c513-470e-888b-eb8ae243e82b F_b5f45fc2-7fd3-42d9-8568-e859afbbf42a F_80af353b-9ba2-4df8-98f1-59c9d525d769 F_757b47b6-8c79-43eb-acf1-3e019ca5b5b9 F_6e4703a6-3c7e-4543-a0f2-f26f51d5137f F_b8426126-c1d6-4c57-88bd-4a9f4048b799 F_0fe8f767-164a-4796-8d2d-e46722f6bd17 F_04c41bd8-0f83-4a77-a909-a9bba4018be6"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_c4653557-9b4f-4d3f-bf1c-d79a8f314a27" fromRefs="F_33105149-d815-4139-9962-2039b98c9033 F_ac4250ee-eb65-4511-b237-429ee9e59929 F_d15ce071-280d-4dbc-b955-df724acecf1e F_78c4db69-b1e9-4eef-a9b3-72a61579c018"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:13.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_084bcac3-2bbb-4a4a-a911-17aaa60cb28c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:14.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2a080c8e-d8e5-4e63-b281-5de6e1fd3261" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82f54efb-27b1-4691-8243-e336db252ea0" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_486ccfb5-e383-4320-97a8-6d8615471c95" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:CurrentFiscalYearEndDate" format="ixt:datemonthdayen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0622e167-ec53-4c13-a488-6b3b065bea4e" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0dadc724-2a27-4a98-a0b1-54e1c47288ab" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the transition period from _________  to ___________</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c4d2e11-2b49-45cd-9941-c1f418aeaeed" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:17.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9f220f01-bffc-4785-aae0-be2d34e4bc32" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:17.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_788d7aa0-816d-46d8-be40-d9aa32e188a5" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_867a6dbf-5111-4e30-9151-e29b3527d78a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46-4233385</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_050cd3d1-99df-45db-9dbf-45ef1c314eae" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">825 Industrial Road</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_483bd0e0-9be2-401b-b287-7e6f1a05f160" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_55c49d26-1e00-401c-a4e9-c4234a6def20" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Carlos</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_86828a48-0d28-417d-be25-3f96d69b5f38" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c487c2f-e5b6-475f-949f-40c48a341c37" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94070ca</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_05ddf7bc-866b-427d-9075-26f585402b5c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_835a0a9a-4da3-4224-a919-1749ffcb588a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">837-0111</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:39.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe9278fd-841c-4f21-97df-94ca5606b27c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f063624-d569-4b07-b941-4f28ecd054bb" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCVX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0be74215-1830-418f-81d7-eb2c5cd2c43e" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Nasdaq Stock Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_26d62050-9908-42ad-b365-ac917990e742" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3d6b744-7b5f-4672-89ab-5c0a5c524d1b" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_319bd723-15ce-4043-8884-061b3289595a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c15c3523-f7ec-4faf-88d1-597d6a13e4cd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.333%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:52.861%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.481%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_45f356c4-f8ba-491c-85e4-af0d1f9792fb" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_826e266c-5565-4c6a-8787-bcd5299df1e5" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_177ffdec-6c6d-4337-8daa-d9d663b1cbfe" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4525fcc7-b9b6-4e62-9abe-97e14790d217" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9744; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4eb1d0ab-3407-463a-adab-48ba52f44ecd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ag</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">gregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of its Common Stock on the Nasdaq Global Select Market on June 30, 2022, the last business day of the Registrant&#x2019;s most recently completed second fiscal quarter, was approximately $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15b36965-3162-4dce-ba18-392976e720fb" contextRef="C_1c80638b-879a-4eff-b0d3-6917912c5862" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion. Shar</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">es of the Registrant&#x2019;s common stock held by each executive officer, director and holder of 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the Registrant for any other purpose.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of Registrant&#x2019;s Common Stock outstanding a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s of February 23, 2023 was </span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c4bb446-38d2-4aa4-993c-da25cc32759f" contextRef="C_c729b163-a362-4fd1-896f-64744eecd71c" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">80,033,727</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_4d4770d5-1918-4a7c-92c8-486a1ddcf201" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Part III of this Annual Report on Form 10-K incorporates information by reference from the Registrant&#x2019;s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the Registrant&#x2019;s 2023 annual meeting of stockholders.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:83.996%;"></td>
    <td style="width:6.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signatures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless the context otherwise requires, all references in this Annual Report on Form 10-K to &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;our company&#x201d; and &#x201c;Vaxcyte&#x201d; refer to Vaxcyte, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Vaxcyte,&#x201d; &#x201c;eCRM,&#x201d; and other trademarks of ours appearing in this report are our property. This report contains additional trade names and trademarks of other companies. We do not intend our use or display of other companies&#x2019; trade names or trademarks to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; or &#x201c;would,&#x201d; or the negative of these words or other similar terms or expressions. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding the potential benefits, spectrum of coverage and immunogenicity of our vaccine candidates;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations regarding our preclinical study results potentially being predictive of clinical study results;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our belief that our pneumococcal conjugate vaccine candidates could receive regulatory approval based on a demonstration of non-inferiority to the standard of care using well-defined surrogate immune endpoints rather than requiring clinical field efficacy studies;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our research and development programs; </span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to advance vaccine candidates into, and successfully complete, preclinical studies and clinical trials; </span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the commercialization of our vaccine candidates, if approved;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">estimates of our future expenses, capital requirements and our needs for additional financing;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to compete effectively with existing competitors and new market entrants;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our and our third-party manufacturers&#x2019; manufacturing capabilities and the scalable nature of our manufacturing process;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential effects of extensive government regulation;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the pricing, coverage and reimbursement of our vaccine candidates, if approved;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability and the ability of our third-party contract manufacturers to operate and continue operations in light of the COVID-19 pandemic;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to hire and retain key personnel;</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain additional financing; and</span></div></div>
  <div style="margin-left:10.0%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the volatility of the trading price of our common stock.</span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Actual events or results may differ from those expressed in forward-looking statements. You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Annual Report on Form 10-K primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form 10-K. The results, events and circumstances reflected in the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Annual Report on Form 10-K. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The forward-looking statements made in this Annual Report on Form 10-K relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Annual Report on Form 10-K to reflect events or circumstances after the date of this Annual Report on Form 10-K or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Risks Affecting Our Business</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to numerous risks and uncertainties, including those discussed more fully in the section titled &#x201c;Risk Factors&#x201d; in this Annual Report on Form 10-K. These risks include, but are not limited to, the following:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are in the clinical or preclinical phase of vaccine development and have a very limited operating history and no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future. We currently have no source of product revenue and may never achieve profitability. Our stock is a highly speculative investment.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will require substantial additional funding to finance our operations, which may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our approach to the discovery and development of our vaccine candidates is based on novel technologies that are unproven, which may expose us to unforeseen risks, require us to modify processes, and make it difficult to predict the time and cost of vaccine candidate development and the timing to apply for and obtain regulatory approvals.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our vaccine candidates are in clinical or preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of or commercialize our vaccine candidates or experience significant delays in doing so, our business would be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. Food and Drug Administration (&#34;FDA&#34;) may disagree with our regulatory plan, and we may fail to obtain regulatory approval of our vaccine candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is highly dependent on the success of VAX-24, which is in clinical development. If we are unable to obtain approval for VAX-24 and effectively commercialize VAX-24, our business would be significantly harmed. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop our vaccine candidates, or may result in others discovering, developing or commercializing products before or more successfully than us.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in our efforts to use our cell-free protein synthesis platform to expand our pipeline of vaccine candidates and develop marketable products.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently rely on third-party manufacturing and supply partners, including Lonza Ltd. and Sutro Biopharma, Inc. to supply raw materials and components for, and manufacture of, our preclinical and clinical supplies as well as our vaccine candidates. Our inability to procure necessary raw materials or to have sufficient quantities of preclinical and clinical supplies or the inability to have our vaccine candidates manufactured, including delays or interruptions at our third-party manufacturers, or our failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Health epidemics, including the effects of the ongoing COVID-19 pandemic, have impacted and could continue to impact our business, including in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our vaccine candidates.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">iv</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. Bu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">siness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF&#153; cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc., or Sutro Biopharma. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaccines are one of the most successful and cost-effective global health interventions and prevent millions of deaths worldwide each year. Routine pediatric vaccinations are estimated to prevent 20 million cases of disease each year, saving over $180 billion in direct and societal costs in the United States alone. Adult vaccination rates are lower than pediatric vaccination rates, but new technologies are driving adult vaccine development, which in turn is fueling the growth of the overall vaccine market. Given the critical role vaccines play in preventing disease from childhood to adulthood, the global vaccine market is large, durable and growing. Therefore, there are areas of unmet medical need, including vaccines that can provide broader protection than currently marketed vaccines and novel vaccines that target pathogens for which there are no currently approved vaccines. We are driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We carefully select our target disease areas and vaccine candidates based on the following criteria: areas of significant unmet medical need, well-defined commercial landscape and efficient market adoption, acceptable biological risk and established clinical pathways. We are leveraging our scalable cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications using these criteria.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pipeline includes:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pneumococcal conjugate vaccine, or PCV, candidates that we believe are among the most broad-spectrum PCV candidates currently in development, targeting the approximately $7 billion global pneumococcal vaccine market. Pneumococcal disease is an infection caused by Streptococcus pneumoniae, or pneumococcus, bacteria. It can result in invasive pneumococcal disease, or IPD, including meningitis and bacteremia, and non-invasive pneumococcal disease, including pneumonia, otitis media and sinusitis. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of IPD. VAX-24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults by covering the serotypes that are responsible for most of the pneumococcal disease currently in circulation. </span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-24 Adult Program: On October 24, 2022, we announced positive topline results from both the Phase 1 and Phase 2 portions of a clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24 in 800 healthy adults aged 18-64. The Phase 1 portion of the study evaluated the safety and tolerability of a single injection of VAX-24 at three dose levels, 1.1mcg, 2.2mcg and 2.2mcg/4.4mcg, and compared to PCV20 in 64 healthy adults 18-49 years of age. The Phase 2 portion evaluated the safety, tolerability and immunogenicity of a single injection of VAX-24 at the same three dose levels and compared to a single injection of Prevnar 20&#153;, or PCV20, in 771 healthy adults 50-64 years of age. In this study, VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to PCV20, for all doses studied. In this study, VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2mcg dose, which we intend to move forward into a Phase 3 program. At this dose, VAX-24 met the standard opsonophagocytic activity, or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:13.593%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OPA, response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses. Additionally, at all three doses, VAX-24 met the standard superiority criteria for all four serotypes unique to VAX-24. VAX-24 has the potential to cover an additional 10-28 percent of strains causing IPD in adults over the current standard-of-care PCVs. We have a separate Phase 2 study in approximately 200 healthy adults aged 65 and older for which we have completed enrollment, and we anticipate announcing topline safety, tolerability and immunogenicity results from this study in the second quarter of 2023. We anticipate final results with the six-month safety data from both Phase 2 adult studies in the first half of 2023 and expect to hold regulatory interactions with the U.S. Food and Drug Administration, or FDA, in the second half of 2023 to inform the Phase 3 program. We expect topline safety, tolerability and immunogenicity data from the Phase 3 pivotal, non-inferiority study in adults in 2025. The FDA has granted Fast Track and Breakthrough Therapy designations for VAX-24 in adults.</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-24 Pediatric Program: In late February 2023, we announced that the FDA cleared the VAX-24 IND application for the prevention of IPD in infants. We plan to initiate the infant Phase 2 study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data following the primary three-dose immunization series expected by 2025. The study design will include a primary immunization series consisting of three doses followed by a subsequent booster dose.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our second PCV candidate, VAX-31 (formerly VAX-XP), builds on what has been established with VAX-24 and is designed to expand the breadth of coverage to 31 strains without compromising immunogenicity due to carrier suppression. VAX-31 was designed to provide coverage for approximately 95% of IPD currently circulating in the adult U.S. population. We anticipate submitting an IND application to the FDA for VAX-31 in adults in the second half of 2023. We expect topline safety, tolerability and immunogenicity data from a Phase 1/2 study in adults in 2024. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus, or Group A Strep. Group A Strep is pervasive globally and causes 700 million cases of illness annually, including pharyngitis, or strep throat, and certain severe invasive infections such as sepsis, necrotizing fasciitis and toxic shock syndrome. There is currently no vaccine against Group A Strep, which is one of the leading infectious disease-related causes of death and disability worldwide and a significant contributor to the prescription of antibiotics in the very young. We believe we have demonstrated preclinical proof of concept for VAX-A1, the data for which were published in December 2020. We nominated the final vaccine candidate for VAX-A1 in the first quarter of 2021 and initiated IND-enabling activities in the second half of 2021. We continue to advance the development of VAX-A1 and intend to provide further information about the anticipated timing of an IND application as the program progresses.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis, a chronic oral inflammatory disease affecting an estimated 65 million adults in the United States. We believe we have generally demonstrated preclinical proof of concept for a periodontitis protein vaccine, the data for which was published in February 2019.We nominated a final vaccine candidate for VAX-PG in the fourth quarter of 2022 and continue to progress the program. Our initial goal is to develop a therapeutic vaccine to slow or stop disease progression; however, the results from clinical trials may inform the potential adoption of prophylactic immunization. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-GI, a new vaccine program designed to prevent Shigella, a bacterial illness that affects an estimated 188 million people worldwide each year and results in approximately 164,000 deaths annually, mostly among children under five years of age in low- and middle-income settings.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have other discovery-stage programs that leverage our cell-free protein synthesis platform, which, if proven successful in preclinical studies, could also be advanced into IND-enabling activities and clinical studies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, offer several advantages over conventional cell-based protein expression methods, which we believe enable us to generate superior, novel, more broad-spectrum and/or more immunogenic vaccines. In the context of conjugate vaccines, we believe we can add more antigenic strains without compromising the overall immune response. In particular, our ability to specify the attachment point of antigens, including polysaccharides, on protein carriers represents a significant improvement over the random conjugation that occurs with conventional technologies. This site-specific conjugation is designed to ensure that B-cell and/or T-cell epitopes are optimally exposed, maximizing the immune response, whereas random conjugation blocks these critical immunogenic epitopes, which dampens the immune response and may lead to a phenomenon known as carrier suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe this precise control of conjugation chemistry enables us to design broader-spectrum conjugate vaccine candidates using carrier-sparing conjugates that use less protein carrier without sacrificing immunogenicity. We are also able to design novel conjugate vaccine candidates using standard amounts of protein carrier to generate heightened immunogenicity. Beyond conjugate vaccines, we believe we can also design novel protein vaccine candidates based on well-appreciated but highly complex antigens that currently cannot be made using conventional technologies to address diseases for which there are no available vaccines. In addition, our platform enables us to rapidly screen vaccine candidates, requiring less effort than conventional chemistry which allows us to produce and iterate conjugate candidates, thereby dramatically accelerating the development cycle of designing, producing and testing vaccine candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To address areas of significant unmet medical need, we carefully select the disease areas we target and are developing vaccine candidates based on the following criteria:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Well-defined commercial landscape and efficient market adoption:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We select vaccine targets that are characterized by an established patient population and significant unmet medical need. Our lead vaccine candidate, VAX-24, is a PCV intended to improve upon the standard-of-care for both children and adults by covering the serotypes that are responsible for most of the residual pneumococcal disease currently in circulation without sacrificing immunogenicity. We believe that by providing the broadest coverage of serotypes for PCVs, as well as providing novel vaccines for diseases for which there are no currently approved vaccines, we can leverage the U.S. Centers for Disease Control, or CDC, its Advisory Committee on Immunization Practices, or ACIP, and similar international advisory body recommendations to drive rapid and significant market adoption. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acceptable biological risk:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We choose vaccine targets with well-understood mechanisms of action and strong precedents for positive preclinical study results that we believe will translate to positive clinical trial results. For example, conjugate vaccines have demonstrated effectiveness in both preclinical and clinical trials against a range of bacteria, including pneumococcus, meningococcus and Haemophilus influenza B. There is consistent evidence that antibodies directed against these bacteria are protective against their respective diseases. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Established clinical pathways:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We pursue vaccine targets that we believe have clear and established clinical development pathways in order to accelerate the potential time to market. For example, we believe that our PCVs could receive regulatory approval based on successful completion of clinical studies utilizing well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies. However, while there have been approvals granted for both PCVs and meningococcal conjugate vaccines based on surrogate immune endpoints rather than field efficacy studies, we will not be able to confirm this approach&#x2019;s applicability for our PCVs until we complete our interactions with the FDA prior to the initiation of our Phase 3 clinical development program. For our novel vaccine candidates, where we believe clinical field efficacy studies will be necessary, we select disease areas with high attack rates, such as Group A Strep, which may allow for more manageable study sizes. For novel protein-based therapeutic vaccine candidates, such as our periodontitis vaccine candidate, we select disease areas where we believe clinical efficacy may be evaluated based on </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disease progression rather than prevention, which could allow for smaller and faster trials relative to preventative vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Platform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications using the above criteria by taking advantage of the following:</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Site-Specific Conjugation. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are able to specify the attachment point of antigens, including polysaccharides, on protein carriers to ensure optimal exposure of B-cell and/or T-cell epitopes, thereby creating protein carriers designed to have enhanced potency. We believe this precise control of conjugation chemistry enables us to create broader-spectrum conjugate vaccine candidates using carrier-sparing conjugates that use less protein carrier without sacrificing immunogenicity. We are also able to design novel conjugate vaccine candidates using standard amounts of protein carrier to generate heightened immunogenicity.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Production of Novel Protein Vaccines</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We can design novel protein vaccine candidates based on well-appreciated but highly complex antigens that currently cannot be made with conventional technologies to address diseases for which there are no available vaccines, and we believe we may be able to leverage our platform to rapidly respond to new or emerging pathogens. We can design and produce these &#x201c;tough-to-make&#x201d; antigens that conform to the target pathogens, thereby increasing the likelihood that the vaccine will elicit a protective immune response.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Speed, Flexibility and Scalability of the Discovery Engine. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are able to rapidly screen vaccine candidates and produce conjugates, thereby accelerating the process of making and testing vaccine candidates. Because cell viability is not required for cell-free protein synthesis, we can utilize a broader range of reaction conditions as we seek to optimize proteins. This flexibility enables us to develop novel vaccine candidates unachievable with current technologies. Furthermore, we believe our platform can scale linearly from discovery to commercial scale.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to become a leader in the vaccines industry by using our cell-free protein synthesis platform to develop superior and/or novel vaccines to prevent or treat serious infectious diseases. Key elements of our strategy include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance VAX-24 through clinical development and regulatory approval.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our lead vaccine candidate, VAX-24, targets the pneumococcal vaccine market. We expect to advance VAX-24 along a well-understood clinical development pathway in an effort to obtain regulatory approval in adults and infants based on successful completion of clinical studies using previously established surrogate immune endpoints, potentially without the need to conduct clinical field efficacy studies, consistent with how other conjugate vaccines have obtained approval. In the fourth quarter of 2022, we announced positive topline results from both the Phase 1 and Phase 2 portions of a clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy adults aged 18-64. We have a separate Phase 2 study in approximately 200 healthy adults aged 65 and older for which we have completed enrollment, and we anticipate announcing topline safety, tolerability and immunogenicity results from this study in the second quarter of 2023. We anticipate final results with the six-month safety data from both Phase 2 adult studies in the first half of 2023 and expect to hold regulatory interactions with the FDA to inform the Phase 3 program in the second half of 2023. We expect topline safety, tolerability and immunogenicity data from the Phase 3 non-inferiority study in adults in 2025. The FDA has granted Fast Track and Breakthrough Therapy designations for VAX-24 in adults. For our VAX-24 pediatric program, we announced in late February 2023 the FDA cleared the VAX-24 IND application for the prevention of IPD in infants. We plan to initiate the infant Phase 2 study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data following the primary three-dose immunization series </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expected by 2025. The study design will include a primary immunization series consisting of three doses followed by a subsequent booster dose.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance VAX-31 through IND-enabling activities, clinical development and regulatory approval.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Our second PCV candidate, VAX-31, leverages our scalable and modular platform and builds on the technical proof of concept established by VAX-24 and is designed to expand the breadth of coverage to 31 strains without compromising immunogenicity due to carrier suppression. VAX-31 was designed to provide coverage for approximately 95% of IPD currently circulating in the U.S. adult population. We anticipate submitting an IND application to the FDA for VAX-31 in adults in the second half of 2023. We expect topline safety, tolerability and immunogenicity data from a Phase 1/2 study in adults in 2024.</span></div></div>
  <div style="margin-left:9.167%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.669371263747757%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Establish scalable production of VAX-24 and VAX-31.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We believe high-quality and scalable manufacturing is critical to our long-term success. We have designed and developed a proprietary, scalable and portable manufacturing process that we have scaled to supply clinical volumes and believe can scale to supply initial commercial volumes of VAX-24 and VAX-31 needed to support commercial launch. For our VAX-24 program, we have completed the production of clinical trial materials for our Phase 1 and 2 studies in both adults and infants and are conducting scale-up activities to support potential regulatory approval and commercial launch. We have access to substantial manufacturing resources through our contract manufacturer, Lonza, that we believe can facilitate an independent path to market. For our next-generation VAX-31 program, for which we use the same components and core manufacturing processes established for VAX-24, we are currently conducting IND-enabling activities.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Create a long-lasting PCV franchise by offering the broadest-spectrum PCV available.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The two leading pneumococcal vaccine franchises to date, Prevnar and Pneumovax 23, or PPSV23, have generated over $100 billion in combined sales, have been on the market for over 40 years and 20 years, respectively, and can attribute their success to being the broadest-spectrum vaccines on the market. If approved, we believe VAX-24 may obtain an ACIP preferred recommendation and potentially replace both lesser-valent incumbents for pneumococcal disease prevention in both adult and pediatric populations because of its broader coverage. We designed VAX-24 to address the 24 pneumococcal strains covered by Prevnar and PPSV23 that drive most pneumococcal disease today with the durable, boostable immune response of a conjugate vaccine. Further, we have designed VAX-31 to address these 24 strains plus seven additional epidemiologically significant emerging strains expected to cause increasing pneumococcal disease and antibiotic resistance in the future. With these broad-spectrum vaccine candidates, we believe we are well-positioned to obtain an ACIP preferred recommendation and potentially replace the current standard of care for pneumococcal disease prevention in both adult and pediatric populations, thereby creating a long-lasting PCV franchise.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance our novel vaccine candidates and leverage our platform to expand our pipeline. </span></div></div>
  <div style="margin-left:15.796%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9582442639304545%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance VAX-A1 through IND-enabling activities, clinical development and regulatory approval</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. VAX-A1 is designed to prevent Group A Strep, a pervasive disease that results in 700 million cases of illness each year and is one of the leading infectious disease-related causes of death and disability worldwide. Some of the most serious consequences of Group A Strep include flesh eating disease (necrotizing fasciitis) and invasive diseases such as sepsis and rheumatic heart disease. However, the majority of Group A Strep cases are pharyngitis, commonly known as strep throat. Pharyngitis is highly prevalent in school-age children and a significant source of antibiotic prescriptions, which further exacerbates the growing problem of antibiotic resistance globally. VAX-A1 is a conjugate vaccine candidate designed to confer broad protective immune responses against all subtypes of Group A Strep and be boostable to offer long-lasting protection from infection. We believe our data published in December 2020 demonstrated preclinical proof of concept for VAX-A1. We nominated the final vaccine candidate for VAX-A1 in the first quarter of 2021 and initiated IND-enabling activities in the second half of 2021. We </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:15.796%;text-indent:0;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9582442639304545%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to advance the development of VAX-A1 and we intend to provide further information about the anticipated timing of an IND application as the program progresses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:15.833%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9599843168937943%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance VAX-PG to final vaccine candidate nomination and IND-enabling activities, clinical development and regulatory approval.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-PG is our novel protein vaccine candidate which targets the keystone pathogen responsible for periodontitis, a chronic oral inflammatory disease affecting an estimated 65 million adults in the United States. Our initial goal is to develop a therapeutic vaccine to slow or stop disease progression; however, the results from clinical trials may inform the potential adoption of prophylactic immunization. We have established preclinical proof of concept for VAX-PG. We nominated a final vaccine candidate for VAX-PG in the fourth quarter of 2022 and we continue to progress the program. </span></div></div>
  <div style="margin-left:15.833%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9599843168937943%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Advance VAX-GI program research and development.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-GI is new vaccine program designed to prevent Shigella, a bacterial illness that affects an estimated 188 million people worldwide each year and results in approximately 164,000 deaths annually, mostly among children under five years of age in low- and middle-income settings.</span></div></div>
  <div style="margin-left:15.833%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.9599843168937943%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leverage our platform for other discovery stage programs.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We are also able to leverage our platform as a discovery engine given our ability to uniquely create building blocks to construct potential novel conjugate and protein vaccine candidates, and we have other discovery-stage programs which leverage this platform. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Continue to build a robust intellectual property portfolio.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> We have developed and are continuing to develop a comprehensive intellectual property portfolio related to vaccine applications, including manufacturing, formulation and process applications as well as protection for our specific vaccine candidates. We have rights to a robust portfolio of patents and patent applications related to the XpressCF platform through our exclusive license from Sutro Biopharma. We currently have one issued U.S. patent, as well as patents issued in Japan and Mexico, and multiple pending patent applications in the United States and internationally that cover vaccine formulations, protein-antigen conjugates, methods of making conjugate vaccines with various protein-antigen conjugates and other processes related to vaccine production, enhancements of immunogenicity and methods of use. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have utilized our cell-free protein synthesis platform to generate a pipeline of vaccine candidates that we believe, if approved, may offer important advantages over existing vaccines or for which there are no vaccines available today. The following table summarizes our current pipeline:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_0.jpg" alt="img70551829_0.jpg" style="width:624px;height:365px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Global Vaccine Market (Excluding COVID-19 Vaccines)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global vaccine market, excluding COVID-19 vaccines, was approximately $45 to $50 billion in 2022 and is expected to grow at an 10% CAGR to approximately $67 billion by 2026. The World Health Organization, or WHO, has reported that non-COVID vaccine revenues have grown at nearly twice the rate of therapeutic products over the last two decades. Conjugate vaccines, including PCVs, have historically represented the largest segment (approximately a third) of the global non-COVID vaccine market. The Prevnar franchise from Pfizer Inc., or Pfizer, comprised of Prevnar 13, or PCV13, and PCV20, was among the highest selling non-COVID vaccine products in the world in 2022, accounting for approximately 14% of global non-COVID vaccine sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pediatric vaccine market is large and well-established in the United States and European Union and growing in emerging countries. The annual new birth cohort, which in the United States and Europe approached approximately 11 million in 2022, drives ongoing sales year after year. In the United States, once a new vaccine is approved by the FDA, the ACIP considers whether to recommend the use of the vaccine. New pediatric vaccines that receive a preferred recommendation from ACIP are nearly universally adopted by pediatricians and parents and are required by many schools, contributing to a national immunization rate for the diseases targeted by such vaccines of approximately 90%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the adult vaccine market is currently undergoing rapid growth. Vaccination rates among adults have historically been lower and vary by disease, though strong initiatives are underway to increase awareness and utilization. Excluding the impact of the COVID-19 pandemic, studies estimate that 40,000 to 80,000 adults in the United States die annually of vaccine-preventable diseases, and hundreds of thousands more are hospitalized. In recent years, manufacturers have started developing more vaccines for the adult market, with Pfizer&#x2019;s PCV13 and PCV20, Merck &amp; Co., Inc.'s, or Merck, Vaxneuvance, or PCV15, and GSK plc's, or GSK, Shingrix each representing successful examples. The U.S. adult pneumococcal market generated annual sales of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">over $2 billion, and Shingrix, a vaccine for shingles (herpes zoster) debuted with over $1 billion in sales in 2018 as it replaced Merck&#x2019;s incumbent vaccine, Zostavax, after receiving an ACIP preferred recommendation, and generated over $2.5 billion in sales in 2020.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The complex development and production processes of vaccines create a high barrier to entry and long product lifecycles. In recent history, four multinational companies&#x2014;GSK, Merck, Pfizer and Sanofi have been responsible for developing and introducing most new vaccines to the world. As a result of the COVID-19 pandemic, there have been a number of new entrants into the vaccines market, including multinational companies such as Johnson &amp; Johnson, and emerging biopharmaceutical companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pneumococcal Disease</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pneumococcal disease is an infection caused by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Streptococcus pneumoniae </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(pneumococcus)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">bacteria. It can result in IPD, including meningitis and bacteremia, and non-invasive pneumococcal disease, including pneumonia, otitis media and sinusitis. The global incidence of pneumococcal disease is driven by emerging serotypes not covered by currently available vaccines. In the United States, approximately 320,000 people get pneumococcal pneumonia each year, which is estimated to result in approximately 150,000 hospitalizations and 5,000 deaths. Pneumococci also cause over 50% of all cases of bacterial meningitis in the United States. Antibiotics are used to treat pneumococcal disease, but some strains of the bacteria have developed resistance to treatments. The morbidity and mortality due to pneumococcal disease are highly significant, particularly for young children and older adults, underscoring the need for a more broad-spectrum vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Evolution of Pneumococcal Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are currently two types of vaccines targeting pneumococcal disease&#x2014;polysaccharide-only vaccines and polysaccharide-conjugate vaccines. Polysaccharide vaccines contain polysaccharide antigens, which induce antibodies (B-cell responses) that bind to a bacteria&#x2019;s outer coating of polysaccharides and clear the bacteria. PCVs improve on polysaccharide vaccines by attaching, or conjugating, the polysaccharide antigen to a non-disease specific protein carrier. PCVs induce both an improved B-cell response and a T-cell response, resulting in a stronger and more durable immune response and longer-lasting protection, as compared to polysaccharide vaccines, which only induce a B-cell response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pneumococcal Polysaccharide-Only Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PPSV23, manufactured and marketed by Merck is the only pneumococcal polysaccharide vaccine widely available. PPSV23 is indicated for the prevention of pneumococcal disease in adults and was first approved in the United States in 1977, at which time it contained 14 different strains of pneumococcal bacteria. In 1983, it was replaced by the current version containing 23 different strains. PPSV23 is routinely administered to adults to provide protection against bacteremia and generates sales of over $600 million per year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Polysaccharide vaccines induce a B-cell response only and do not induce a T-cell dependent immune response. In the absence of immunological memory responses, the resulting antibody responses are transient and cannot be boosted. Without the ability to provide long-lasting durable immunity, polysaccharide vaccines are not effective in children below two years of age. In addition, the antibody responses primarily consist of immunoglobulin M, or IgM, antibodies that, due to their size, are restricted to blood and are unable to penetrate into lung tissue to protect against pneumonia. Therefore, polysaccharide vaccines such as PPSV23 are only thought to protect against blood-borne infections, such as bacteremia. Figure 1 below illustrates polysaccharide-induced T-cell independent antibody responses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_1.jpg" alt="img70551829_1.jpg" style="width:288px;height:206px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Graphics adapted from Strugnell et al, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Understanding Modern Vaccines</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Vol 1, Issue 1, 61-88.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Polysaccharide vaccines also interfere with optimal use of PCVs, as they create a hyporesponsive immune effect. In particular, absent T-cell inducement, polysaccharide vaccines actually clear the memory B-cells that are formed following primary immunization with a PCV, thereby eliminating the ability to boost with subsequent vaccination. This historically has been a significant drawback of vaccination in older adults, which consisted of the administration of a limited spectrum PCV followed by the administration of a polysaccharide vaccine. Despite these shortcomings, PPSV23 historically has been widely used primarily to provide protection against circulating strains not contained in the currently available PCV. The current standard of care, which consists of the administration of either PCV20 alone or PCV15 followed by the administration of PPSV23, in adults, or PCV13 or PCV15 in infants, continues to include the alternative of a polysaccharide vaccine.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pneumococcal Conjugate Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCVs overcome the limitations of polysaccharide vaccines by conjugating the polysaccharide to a more immunogenic protein carrier containing T-cell epitopes. These T-cell epitopes provide CD4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> help, which is critical to the conversion of a traditional B-cell dependent immune response to a more robust combined B-cell and T-cell dependent immune response. The T-cell response causes immediate class switching of the B-cells from more rudimentary IgM antibodies prevalent with polysaccharide vaccines to more refined IgG antibodies. IgG antibodies are refined enough to penetrate into lung tissues to prevent pneumonia. Furthermore, as polysaccharide strands attach to multiple copies of the protein carrier, they create an inter-strand cross-linked matrix structure, which the immune system easily recognizes as foreign. The T-cell dependent immune response also generates memory B-cells that can be re-stimulated, creating a prime-boost immune response and enabling a more robust and durable immune response, enabling the use of PCVs in young children. Figure 2 below illustrates this immune response:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_2.jpg" alt="img70551829_2.jpg" style="width:268px;height:210px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The first PCV, Prevnar, was a 7-valent vaccine that was launched in the United States in 2000. It included purified capsular polysaccharides of seven serotypes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (4, 6B, 9V, 14, 18C, 19F and 23F), each of which was individually conjugated to a T-cell-epitope-containing, nontoxic variant of diphtheria toxin known as CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to produce seven separate conjugates. To obtain approval, a large field efficacy study was conducted that demonstrated the vaccine&#x2019;s efficacy in infants. Efficacy correlated with serological immune endpoints, as measured by IgG titers (a measurement of concentration), and a seroconversion threshold (or reference antibody concentration) of protection was defined. Prevnar is credited with tremendous medical and commercial success, having dramatically reduced circulating disease in children. However, after a number of years of widespread use, IPD incidence caused by strains not contained in the vaccine started to opportunistically rise, a phenomenon called serotype replacement, which led to the need for a broader-spectrum version of the vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the race to develop a broader-spectrum PCV than Prevnar, two vaccines were successfully developed: Synflorix, a 10-valent PCV from GSK, and PCV13, a 13-valent PCV from Wyeth (subsequently acquired by Pfizer). Based on its broader coverage of then-emerging strains, PCV13 was adopted as the standard of care in the United States and Europe. Synflorix continues to be used primarily in emerging countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCV13 contains the seven serotypes originally included in Prevnar plus six more serotypes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (1, 3, 5, 6A, 7F and 19A) and was approved and launched in the United States in 2010. Each polysaccharide is conjugated to CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to produce 13 individual conjugates, which are mixed into a final vaccine formulation and then adsorbed to alum. In 2010, PCV13 obtained FDA approval for the prevention of IPD in infants based on non-inferior IgG antibody responses relative to Prevnar, using the surrogate immune endpoints established by the prior Prevnar field efficacy study. While PCV13 failed to achieve non-inferiority on two of the common seven strains relative to Prevnar, it was granted approval across all 13 strains. Upon receipt of the ACIP preferred recommendation, PCV13 replaced Prevnar in the infant market as the standard of care. This also created a &#x201c;catch-up&#x201d; population for those children previously vaccinated with Prevnar to provide protection against the incremental serotypes covered by PCV13.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCV13 has also received accelerated approval for the prevention of IPD and pneumonia in adults in the United States based on non-inferior OPA responses as compared to PPSV23. To fulfill a post-marketing commitment, a large-scale field efficacy study of adults in the Netherlands was completed in 2013, which showed protection against community-acquired pneumonia and concordance between OPA and protection from community-acquired pneumonia. Thus, OPA was established as a validated surrogate immune endpoint in adults to support future regulatory approvals. PCV13 subsequently received an ACIP preferred recommendation for adults 65 years and older, and the standard of care was amended to first vaccinate with PCV13, and then after a waiting period, PPSV23. This dual vaccine regimen provides some protection against the circulating strains over and above PCV13 but we believe creates coverage gaps and patient compliance and convenience challenges.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCV13 quickly became the highest selling product in the global vaccine market. However, at the time of ACIP&#x2019;s recommendation in 2014, it was determined that the recommendation would be revisited in four years to evaluate the impact of PCV13 on pneumococcal disease burden in older adults. In June 2019, the ACIP downgraded its recommendation of PCV13 for older adults, given the lack of disease caused by the incorporated strains, and instead began directing physicians and patients to decide whether to vaccinate on a case-by-case basis while still recommending universal vaccination with PPSV23 due to its broader coverage.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In an effort to develop even broader-spectrum PCVs than PCV13, two vaccines were successfully developed for the adult population: PCV20, a 20-valent PCV from Pfizer, and PCV15, a 15-valent PCV from Merck.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCV20 contains the 13 serotypes included in PCV13 plus seven more serotypes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (8, 10A, 11A, 12F, 15B, 22F and 33F) and was granted regulatory approval and launched in the United States in 2021 for the prevention of IPD in adults based on non-inferior OPA responses relative to PCV13 without the need for a field efficacy study. While PCV20 failed to achieve non-inferiority on serotype 8 relative to PPSV23, it was still granted approval across all 20 strains.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCV15 contains the 13 serotypes included in PCV13 plus two more serotypes of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S. pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (22F and 33F) and was granted regulatory approval and launched in the United States in 2021 for the prevention of IPD in adults based on non-inferior OPA responses relative to PCV13 without the need for a field efficacy study.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the ACIP voted to recommend universal vaccination for the use of either PCV20 alone or PCV15 with PPSV23 for routine use in adults aged 65 years and older as well as for those between the ages of 19 and 64 years with certain underlying medical conditions or other risk factors. In October 2022, the ACIP voted to recommend a dose of PCV20 for adults aged 65 years and older at least five years after the last pneumococcal vaccine dose for those who haven't previously received PCV20.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCV15 was granted regulatory approval and launched in the United States in June 2022 for the prevention of IPD in infants. Pfizer has a Prescription Drug User Fee Act, or PDUFA, goal date of April 2023 for PCV20 in infants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Drawbacks for Current PCVs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Routine immunization with PCVs has been effective in dramatically lowering the incidence of IPD in both adults and children in the United States and other industrialized nations. However, due to a phenomenon called serotype replacement, strains that are not covered by existing vaccines are increasing in prevalence. As published in 2020, over 71% of IPD incidence in 2017 for both children and adults was caused by strains beyond the 13 strains covered by PCV13. Efforts to improve upon current standard of care vaccines center around expanding the valency of PCVs to address the strains driving residual pneumococcal disease. However, limitations due to conventional conjugation chemistry and carrier suppression have complicated those efforts, and notwithstanding the recent approvals of PCV20 and PCV15, there remains a significant need for broader-spectrum PCVs, as evidenced by the fact that despite PCV20&#x2019;s broader coverage, the combination of PCV15 and PPSV23 remains universally recommended in adults, as an alternative to PCV20 alone, given its broader-spectrum coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While vaccination with current PCVs has been effective in dramatically lowering the incidence of IPD in both adults and children in the United States and other industrialized nations, current PCVs suffer from the following drawbacks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Serotype Replacement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current PCVs do not address circulating strains causing the majority of pneumococcal disease. Since its introduction, there has been a decrease in the incidence of disease attributable to the serotypes covered by PCV13 but an increase in incidence attributable to the incremental 11 strains that now cause most residual disease. Such change is driven by the void created when serotypes are taken out of circulation after widespread vaccination, which is a phenomenon known as serotype replacement. As a result of such change, broader-spectrum PCVs are required</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to maintain protection against historically pathogenic strains while expanding coverage to address current circulating and emerging strains.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, the most comprehensive pneumococcal disease surveillance has been conducted by the CDC in the United States and by the National Institute of Health and Care Excellence, in the United Kingdom. As shown in Figure 3, IPD cases in adults in the United States initially declined after the introduction of PCV13 but have since plateaued. As published in 2020, non-covered serotypes were responsible for over 71% of IPD incidence in 2017 for both children and adults. The rate of serotype replacement has been more pronounced in the United Kingdom. Figure 4 shows the approximate IPD incidence rates in the United Kingdom caused by the incremental 11 strains over and above those in PCV13, which increased over the last three years of surveillance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.142%;"></td>
    <td style="width:0.996%;"></td>
    <td style="width:0.182%;"></td>
    <td style="width:0.171%;"></td>
    <td style="width:50.509%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:49.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 3.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:49.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 4.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">US IPD Incidence in Adults </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&gt;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:bold;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UK IPD Incidence in Adults </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&gt;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:bold;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img70551829_3.jpg" alt="img70551829_3.jpg" style="width:298px;height:187px;" />&#160;</p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img70551829_4.jpg" alt="img70551829_4.jpg" style="width:302px;height:177px;" />&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;US CDC Active Bacterial Core Surveillance Annual Reports</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Ladhani et al, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lancet Infectious Disease, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2018 Apr.; 18(4):441-45 inclusive of unpublished raw data</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While these 11 strains are covered by PPSV23, that vaccine only protects against blood-borne infections and not pneumonia, leaving patients vulnerable to infection. Although PCV20 and PCV15 address more disease-causing strains than PCV13, we believe there remains a significant need for even broader-spectrum vaccines to address a greater number of currently circulating and emerging strains.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Carrier Suppression</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Technical constraints inherent to conventional conjugation chemistry limit the coverage of current PCVs due to a phenomenon known as carrier suppression. In particular, traditional conjugation methods cannot control where conjugation of the polysaccharide occurs on the protein carrier. The protein carrier used in all versions of Prevnar is CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a diphtheria toxin with a single point mutation rendering it non-toxic. The CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> protein contains 39 lysines, approximately 20% of which border relevant T-cell epitopes. Conventional conjugation chemistry randomly attaches the polysaccharide to any of the numerous lysines located on the protein carrier. When a polysaccharide is covalently bound to a protein carrier at a lysine residue that is co-resident with a T-cell epitope, it blocks the presentation of the T-cell epitope to the immune system, thus preventing the induction of a T-cell response. The masking of these critical epitopes prevents the conversion to a T-cell dependent immune response and negates the benefit of the protein carrier.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Meanwhile, the B-cell epitopes of both the protein carrier and the antigen are presented to the immune system, causing B-cells to the respective immunogens to compete with one another for the T-cell help engendered by unblocked T-cell epitopes. This competition for T-cell help diminishes the immune response to the polysaccharide antigen of interest, resulting in carrier suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The result of carrier suppression is a decrease in the targeted immune response to the disease-specific polysaccharides, which intensifies with higher cumulative amounts of protein carrier. This phenomenon impedes the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ability to expand coverage of current PCVs and has been shown consistently when broader-spectrum versions of conventional PCVs have been compared to lesser-valent versions. When PCV13 was compared to Prevnar (Pfizer&#x2019;s first generation 7-valent PCV) in a well-controlled Phase 3 study in infants, the IgG antibody responses directed against the polysaccharides of interest for all seven of the common strains in each vaccine were lower for PCV13 (Figure 5). In 2020, Pfizer presented results of a well-controlled Phase 3 study in adults, aged 60 and over, where they compared PCV20 to PCV13. In that study, the OPA responses directed against the polysaccharides of interest for all thirteen of the common strains were lower for the 20-valent development candidate (Figure 6). In 2021, Pfizer presented results of a well-controlled Phase 2 in infants, where they compared PCV20 to PCV 13. In that study, the IgG Geometric Mean Concentrations, or GMCs, one month after the third dose were lower for all 13 of the common strains of the 20-valent development candidate (Figure 7).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.581%;"></td>
    <td style="width:2.206%;"></td>
    <td style="width:0.161%;"></td>
    <td style="width:49.052%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:49.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 5.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:49.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 6.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Infant Immune Responses (IGG):</span></p><p style="text-indent:-12.0pt;padding-left:12.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prevnar 7 vs PCV13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">1</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Adult Immune Responses (OPA):</span></p><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCV13 VS PCV20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.9865pt;white-space:pre-wrap;font-weight:bold;font-size:5.695pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img70551829_5.jpg" alt="img70551829_5.jpg" style="width:298px;height:119px;" />&#160;</p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><img src="img70551829_6.jpg" alt="img70551829_6.jpg" style="width:302px;height:121px;" />&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 7.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img70551829_7.jpg" alt="img70551829_7.jpg" style="width:303px;height:207px;" />&#160;</p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:2.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yeh et al, Pediatrics. 126:e493 (2010)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PCV20 BLA Clinical Review Memorandum. STN: 125731/0 June 8, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clintrials.gov NCT03512288 Phase 2 study (N=460), posted March 2, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conventional Chemistry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The problem of carrier suppression is compounded by conventional conjugation chemistry used to make current PCVs, including PCV13, PCV20 and PCV15, which requires a higher amount of CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> protein carrier than polysaccharide antigen to complete the conjugation reaction, as well as long reaction times and harsh conditions that can damage the critical epitopes on the polysaccharide antigens. This results in a higher ratio of protein carrier to polysaccharide antigen in their monovalent conjugates (approximately 1.1 on average), as well as a much higher amount of cumulative protein carrier in the final formulation compared to the amount of any given polysaccharide antigen. For example, in the marketed PCV13 formulation, there are 34 micrograms of the protein carrier, CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, relative to 2.2 micrograms of each polysaccharide (except serotype 6B at 4.4 micrograms), and in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the marketed PCV20 formulation, there are 51 micrograms of CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> relative to 2.2 micrograms of each polysaccharide (except serotype 6B at 4.4 micrograms). With substantially more protein carrier in the vaccine than polysaccharide antigen, the carrier suppression effect discussed above is exacerbated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Solution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are leveraging our cell-free protein synthesis platform to develop potentially superior conjugate vaccines for adult and pediatric indications. Our solution to the drawbacks with conventional conjugate vaccine techniques represents the first of three main applications of our platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platform Application One: Creating Superior Conjugate Vaccines</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Using our cell-free protein synthesis platform, we are developing superior, novel carrier-sparing PCVs designed to have broader-spectrum coverage in an effort to address current and future residual disease in ways that conventional technologies cannot. We are able to design our investigational PCVs using site-specific conjugation in an effort to ensure optimal exposure of targeted immunogenic T-cell epitopes on protein carriers. This enables us to create broader-spectrum conjugate vaccine candidates using carrier-sparing conjugates designed to minimize carrier suppression while maintaining protective immunogenicity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Synthesizing proteins outside of a living host cell provides us greater freedom to design and produce specific proteins of interest under optimized conditions. We separate the precise cellular machinery required for transcription, translation and energy production&#x2014;the critical components for protein production&#x2014;into an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Escherichia coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-derived extract. We can then optimally express a single protein carrier by adding the plasmid-DNA encoding that protein into the extract mixture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Site-Specific Conjugation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Within a protein carrier, we can substitute non-native amino acids, or nnAAs, for native amino acids at specific sites. These inserted nnAAs serve as conjugation anchors that permit the attachment of antigens, including polysaccharides, at a specific site on a protein carrier to ensure optimal exposure of B-cell and/or T-cell epitopes to induce the desired immune response. This precise site-specific linkage is not possible using conventional conjugation chemistry with conventional carrier proteins and affords an advantage to our conjugate vaccine candidates. Figure 8 below depicts our method of inserting nnAAs into a protein carrier, where the DNA sequence has been modified to permit nnAA incorporation into the protein at pre-selected sites using a nnAA-RNA permitting transcription and translation of the protein in the ribosome to yield the protein carrier with nnAAs site-specifically incorporated, facilitating site-specific conjugation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 8.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_8.jpg" alt="img70551829_8.jpg" style="width:351px;height:208px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Most conjugate vaccines available today use a non-disease-specific protein carrier, CRM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in order to leverage T-cell epitopes to induce a T-cell dependent immune response. This traditional method produces a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">heterogeneous mixture of conjugates with blocked and unblocked T-cell epitopes in a large immunogenic cross-linked matrix structure. In contrast, the precision and flexibility of cell-free protein expression, together with our ability to insert nnAAs, allow us to construct our proprietary enhanced protein carrier, or eCRM, with pre-determined conjugation sites. Our method produces homogenous conjugates that provide for the consistent exposure of T-cell epitopes and likewise form a large, immunogenic cross-linked matrix structure. By precisely conjugating polysaccharides to eCRM in a way that provides for optimal exposure of T-cell epitopes to the immune system, we can heighten immunogenicity attainable with conjugate vaccines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The figures below illustrate the site-specific conjugation process. Figure 9 shows site-specific conjugation of the polysaccharide to the protein carrier, avoiding the T-cell epitopes. Figure 10 shows the inter-strand cross-linked matrix, which is the structure of each monovalent conjugate included in the final vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:21.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:43.2pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 9.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:43.2pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 10.</span></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:19.45pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Precise, Site-Specific Conjugation Sites on Proprietary eCRM Protein Carrier</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Final VAX-24 Conjugates in</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customary Matrix Form</span></p></td>
   </tr>
   <tr style="height:108.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img70551829_9.jpg" alt="img70551829_9.jpg" style="width:278px;height:117px;" />&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><img src="img70551829_10.jpg" alt="img70551829_10.jpg" style="width:273px;height:159px;" />&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe consistent exposure of T-cell epitopes should translate to higher potency of the protein carrier on a weight-to-weight basis. To harness this potential potency advantage, we have elected to construct conjugates with a lower ratio of protein carrier to polysaccharide than conventional PCVs. We have observed in animal models that despite having approximately half as much protein on average in each monovalent conjugate, VAX-24 had comparable immunogenicity relative to PCV13 on a strain-by-strain basis. As a result, we believe we can incorporate more monovalent conjugates to create an even more broad-spectrum vaccine with less protein carrier per conjugate in order to minimize carrier suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Better Chemistry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also employ a rapid and less harsh chemistry method called copper-free click chemistry to site-specifically conjugate the polysaccharides to eCRM. We believe this distinctive technique is a better controlled, more efficient and faster method of conjugation relative to conventional chemistry used to make traditional PCVs. The click chemistry conjugation reaction is designed to cause less damage to the critical immunogenic epitopes on the protein carrier or the target antigen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our PCV Franchise</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing broad-spectrum investigational PCVs designed to minimize carrier suppression.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VAX-24</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead vaccine candidate, VAX-24, is designed to improve upon the standard of care by potentially covering an additional 10-28 percent of strains causing IPD in adults over the current standard-of-care PCVs.  The 24 serotypes that comprise VAX-24 eclipse the coverage of all currently available conjugate and polysaccharide-only vaccines to prevent IPD. The 24 serotypes included in VAX-24 cover a significant portion of the IPD currently in circulation and are associated with high case-fatality rates, antibiotic resistance and meningitis. On October 24,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022, we announced positive topline results from both the Phase 1 and Phase 2 portions of a clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy adults aged 18-64 .</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-24 includes 24 purified capsular polysaccharides of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F), each of which is conjugated to eCRM to produce 24 monovalent conjugates. These conjugates are mixed into a final vaccine formulation and then adsorbed to alum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As shown in Figure 11 below, there are critical differences between VAX-24 and other currently available PCVs relating to the protein carrier, particularly the use of site-specific conjugation and the milder reaction conditions. We achieve site-specific conjugation through the insertion of multiple nnAAs, which is not possible with the conventional chemistry used for making other PCVs. The click chemistry we use for site-specific conjugation may also minimize damage to the critical immunogenic epitopes on the protein carrier and the polysaccharides through milder and shorter reactions, while other PCVs use conventional chemistries that involve harsher and longer reaction conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 11.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_11.jpg" alt="img70551829_11.jpg" style="width:624px;height:215px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, VAX-24 nearly doubles the serotype spectrum of coverage of PCV13, yet contains a similar aggregate amount of protein carrier. We believe the resulting decreased carrier burden per conjugate of VAX-24 is critical for minimizing carrier suppression and producing broader-spectrum pneumococcal vaccines without sacrificing immunogenicity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where appropriate, we capitalize on the efficiencies of well-established clinical, manufacturing and regulatory precedents by leveraging conventional methods for the development of VAX-24. For example, our polysaccharide antigens are primarily made using conventional fermentation and purification techniques and activated through conventional methods. They are also labeled through conventional amination methods prior to being conjugated to eCRM. In addition, we use the same critical quality attribute assays for molecular weight and free polysaccharide that have served as the physicochemical measures of conjugates and also serve as predictors of their immunogenicity in vivo. We also use conventional IgG and OPA serological assays to gauge the immunogenicity of our conjugates, which have served as surrogate immunological endpoints in clinical studies that enabled the approval of PCV13, PCV20 and PCV15.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We leveraged the same animal models that were utilized in the development of approved PCVs. In particular, our preclinical studies utilized a recognized rabbit model that Pfizer used in its development of Prevnar, PCV13 and PCV20, that Merck used in its development of PCV15 and that GSK used in its development of Synflorix. We believe the demonstration of conjugate-like immune responses in rabbits that results in killing of bacteria via OPA and induction of IgG antibody responses are key development milestones and are critical readouts for the development of PCVs. In our preclinical studies, the rabbit model showed consistent immunological responsiveness across all strains for which we tested our conjugates and differentiated conjugated versus</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unconjugated polysaccharide responses (i.e., T-cell dependent versus T-cell independent responses). The rabbit model also provided evidence regarding VAX-24&#x2019;s potential to generate a booster response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are pursuing what to date has been a well-characterized clinical development path for VAX-24, consistent with other PCV developers. We anticipate that we will be able to conduct smaller and shorter clinical trials that target immune endpoints (e.g., OPA and IgG responses) previously recognized by regulatory authorities. Pfizer applied this approach to the development of PCV13 and PCV20 and Merck applied it to the development of PCV15. Based on this standard to date, as a prerequisite for regulatory approval, we believe that any investigational PCV will have to be compared to the standard of care at the time a clinical trial is initiated. Currently, the standard of care is either PCV20 alone or PCV15 followed by PPSV23 in adults and PCV13 or PCV15 in infants.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To obtain preclinical proof of concept on our way to the clinic, we evaluated VAX-24 compared to the then standard of care, PCV13, and assessed the comparative immune responses of VAX-24 using the same rabbit model utilized by other PCV developers. We dosed rabbits in our preclinical studies with 0.11mcg, as measured by the amount of polysaccharide in each conjugate, for each of the 24 conjugates in VAX-24, as well as 0.11mcg for the thirteen conjugates in PCV13 (except serotype 6B at 0.22mcg) and compared both PCVs immunogenically to each other and to PPSV23, where each of the 23 polysaccharides were dosed at 1.1mcg. The doses are representative of body weight differences in humans versus rabbits and roughly correspond to the dose differential between PCVs and polysaccharide-only vaccines. In humans, PCV13 is dosed at 2.2mcg per conjugate (except serotype 6B at 4.4mcg) or approximately one-tenth the dose of PPSV23, where each polysaccharide is dosed at 25mcg. The species of rabbits used were approximately five percent of the average weight of humans in North America, thus 0.11mcg approximates to the 2.2mcg dose for PCVs and the 1.1mcg dose approximates to the 25mcg dose for PPSV23.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We completed multiple preclinical proof-of-concept studies of VAX-24 compared to PCV13 and PPSV23 in rabbits. The endpoints of the studies were to measure, on a serotype-specific basis, IgG antibody responses, the surrogate endpoint for pediatrics, and OPA responses, the surrogate endpoint for adults. Initial proof of concept was obtained with research-grade raw materials and conjugates made at Vaxcyte prior to initiating technology transfer to Lonza and production scale-up. For subsequent preclinical studies, conjugates were made at Vaxcyte at small-scale using optimized processes and procedures using Lonza-produced raw materials, including our proprietary eCRM carrier and all 24 polysaccharides that had already been tech transferred and scaled up. In anticipation of clinical evaluation and potential commercial launch, we further scaled our manufacturing, completing a technology transfer of the optimized processes and procedures for the production of each of the 24 conjugates in VAX-24. The conjugates were then produced at Lonza at an over fifteen-fold scale increase to the prior scale at Vaxcyte. At each stage, all 24 of the conjugates in VAX-24 met the critical quality attributes and the combination vaccine was administered in the rabbit model.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In each of our preclinical studies, VAX-24 showed comparable or superior OPA responses at 1/10th the dose of PPSV23 and comparable OPA responses to an equivalent dose of PCV13 on a serotype-by-serotype basis. Additionally, VAX-24 showed superior IgG antibody responses at 1/10th the dose of PPSV23 and comparable IgG responses to an equivalent dose of PCV13 on a serotype-by-serotype basis.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VAX-24 Clinical Development Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To accelerate our time to market, we are pursuing clinical development first in the United States for adults and then in the pediatric population. We achieved clinical proof of concept in October 2022 when we announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy adults aged 18-64, and we continue to advance our adult clinical development program. For adults, the FDA has granted VAX-24 Fast Track and Breakthrough Therapy designations which are designed to facilitate the development and expedite the review of drugs, including vaccines, that treat or prevent serious conditions and fill an unmet medical need. For the pediatric population, we announced in late February 2023 the FDA cleared the VAX-24 IND application for the prevention of IPD in infants. We plan to initiate the infant Phase 2 study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data following the primary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three-dose immunization series expected by 2025. The study design will include a primary immunization series consisting of three doses followed by a subsequent booster dose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Adult Indication</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are using OPA titers as the primary immunogenicity endpoint for the VAX-24 program in adults. OPA is believed to be the primary protective mechanism against pneumococcal disease. In addition, we are measuring IgG responses as a secondary endpoint, as such responses may serve as supportive evidence of immunogenicity for comparison. We currently believe that these endpoints, if met in a Phase 3 trial, will be sufficient to obtain regulatory approval of VAX-24 and do not anticipate the need for a clinical field efficacy trial. However, we have not yet obtained feedback from the FDA regarding our pivotal Phase 3 clinical development plans or the acceptability of our approach.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA has previously approved pneumococcal vaccines upon the establishment of non-inferiority based on a head-to-head comparison using established surrogate immune endpoints in the target population. For adults, PCV13 was approved based on the establishment of non-inferiority of OPA responses relative to PPSV23, on a strain-by-strain basis, where non-inferiority was defined as greater than or equal to 0.50 of the lower limit of the two-sided 95% confidence interval of the OPA geometric mean titer ratio. PCV20 and PCV15 were approved based on the same non-inferiority criterion but compared with PCV13 and PPSV23.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 1/2 Clinical Proof-of-Concept Study in Adults Aged 18 to 64</span></p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our first-in-human study was a randomized, observer-blind, dose-finding, controlled Phase 1/2 clinical proof-of-concept study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults. The Phase 1 portion of the study evaluated the safety and tolerability of a single injection of VAX-24 at three dose levels, 1.1mcg, 2.2mcg and 2.2mcg/4.4mcg, and compared to PCV20 in 64 healthy adults aged 18 to 49. Participants were randomized equally in four separate arms and were evaluated for safety 8 and 29 days after dosing. The Phase 2 portion evaluated the safety, tolerability and immunogenicity of a single injection of VAX-24 at the same three dose levels and compared to a single injection of PCV20 in 771 healthy adults 50 to 64 years of age. Participants were randomized equally in four separate arms and approximately 28 days after participants were dosed, samples were collected to assess immunogenicity. The immunogenicity objectives of the Phase 2 portion of the study included an assessment of the induction of antibody responses, using OPA and IgG, at each of the three VAX-24 doses and compared to PCV20, and for the additional four serotypes contained in VAX-24 (and PPSV23), but not in PCV20, the percentage of subjects that experienced a four-fold rise in antibody titers. Participants in the study are evaluated for safety through six months after vaccination.</span></p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Figure 12 is a schematic of the overall study design of our Phase 1/2 study:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 12.</span></p>
  <p style="margin-left:4.533%;text-indent:9.497%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_12.jpg" alt="img70551829_12.jpg" style="width:544px;height:132px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span>&#160;</p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On October 24, 2022, we announced positive topline results from both the Phase 1 and Phase 2 portions of the study.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In this study, VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to PCV20 for all doses studied. Frequently reported local and systemic reactions were generally mild-to-moderate, resolving within several days of vaccination, with no difference observed across the cohorts. No serious adverse events or new onset chronic illnesses were considered to be related to study vaccines.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 13.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_13.jpg" alt="img70551829_13.jpg" style="width:263px;height:138px;" /><img src="img70551829_14.jpg" alt="img70551829_14.jpg" style="width:268px;height:138px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In this study, VAX-24 demonstrated robust OPA and IgG immune responses for all 24 serotypes at all doses studied (1.1mcg, 2.2mcg, 2.2mcg/4.4mcg). At the conventional 2.2mcg dose, which we intend to move forward into a Phase 3 program, VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes. At this dose, VAX-24 met the standard OPA response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 serotypes (3, 4, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 23F and 33F) achieved higher immune responses and four serotypes (9V, 18C, 19F and 33F) reached statistical significance. Additionally, at all three doses, VAX-24 met the standard superiority criteria for all four serotypes (2, 9N, 17F and 20B) unique to VAX-24. VAX-24 has the potential to cover an additional 10-28 percent of strains causing IPD in adults over the current standard-of-care PCVs.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 14.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_15.jpg" alt="img70551829_15.jpg" style="width:511px;height:235px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 15.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_16.jpg" alt="img70551829_16.jpg" style="width:509px;height:227px;" />&#160;</p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the results of this study, the FDA granted Breakthrough Therapy designation for VAX-24 in adults. The FDA&#x2019;s Breakthrough Therapy process is designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition. The designation is based upon preliminary clinical evidence indicating that the drug or vaccine may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints. With Breakthrough Therapy designation, we will have access to all of the elements of the FDA&#x2019;s Fast Track program, as well as the ability to receive guidance and support from the FDA on an efficient drug development program and an organizational commitment from senior managers within the FDA.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 2 Clinical Study in Adults 65 and Older</span></p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To add to the body of data in adults, we are conducting a separate Phase 2 study for which we have completed enrollment. This study is a randomized, observer-blind, dose-finding, controlled Phase 2 study designed to evaluate the safety, tolerability and immunogenicity of a single injection of VAX-24 at the same three dose levels evaluated in the Phase 1/2 study, 1.1mcg, 2.2mcg and 2.2mcg/4.4mcg, in approximately 200 healthy adults aged 65 and older. Participants were randomized equally in four separate arms and approximately 28 days after participants were dosed, samples were collected to assess immunogenicity. The immunogenicity objectives of the study include an assessment of the induction of antibody responses, using OPA and IgG, at each of the three VAX-24 doses and compared to PCV20, and for the additional four serotypes contained in VAX-24 (and PPSV23), but not in PCV20, the percentage of subjects that experience a four-fold rise in antibody titers. This study was designed to inform the powering of a Phase 3 study and was not powered to demonstrate non-inferiority. We anticipate announcing topline safety, tolerability and immunogenicity results from this study in the second quarter of 2023. Participants in the study also are evaluated for safety through six months after vaccination.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 16.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_17.jpg" alt="img70551829_17.jpg" style="width:556px;height:239px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:9.497%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adult Program Next Steps</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We anticipate final results with the six-month safety data from both Phase 2 adult studies in the first half of 2023 and to hold regulatory interactions with the FDA to inform the Phase 3 program in the second half of 2023. The purposes of the VAX-24 Phase 3 program in the adult population will be to demonstrate non-inferiority to PCV20 for immunogenicity, generate a sufficient safety database in adults and establish consistency of manufacturing through a lot-to-lot consistency study. The Phase 3 non-inferiority results would then be used to seek approval of VAX-24 in the adult population. This approach is similar to the approaches utilized by Pfizer to develop PCV20 and Merck to develop PCV15, where the immunogenicity of the investigational PCVs was compared to PCV13, which was the standard of care at that time. We expect topline safety, tolerability and immunogenicity data from the Phase 3 non-inferiority study of VAX-24 in adults in 2025.</span></p>
  <p style="margin-left:9.067%;text-indent:9.971%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on Pfizer&#x2019;s experience with PCV13, we believe that VAX-24, if approved, would have the potential to serve as a &#x201c;catch-up&#x201d; or booster for those who have previously received PPSV23 or a lower-valent PCV. We believe a study exploring serial vaccination with PCV20 and/or PPSV23 followed by VAX-24 at different intervals could generate valuable data supporting a recommendation for VAX-24 vaccination in previously vaccinated adults.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Pediatric Indication</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also developing VAX-24 as a pediatric vaccine. In August 2022, we announced successful completion of a pre-IND meeting with the FDA regarding our pediatric clinical program for VAX-24. We received positive written feedback from the FDA supporting the initiation of a pediatric study that proceeds directly into infants contingent on satisfactory topline safety, tolerability and immunogenicity results from the VAX-24 Phase 1/2 clinical proof-of-concept study in adults 18 to 64 years of age, which we have since demonstrated. This approach provides us with an accelerated clinical path to deliver a potentially best-in-class PCV, VAX-24, to the pediatric population, which represents the largest portion of the pneumococcal vaccine market in the United States. We announced in late February 2023 the FDA cleared the VAX-24 IND application for the prevention of IPD in infants. We plan to initiate the infant Phase 2 study in the second quarter of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 2, randomized, observer-blind, dose-finding two-stage clinical study will evaluate the safety, tolerability and immunogenicity of VAX-24 at three dose levels (low dose/1.1mcg, middle dose/2.2mcg, mixed dose/2.2mcg or 4.4mcg) and compared to PCV15 in healthy infants. The Stage 1 portion of the study will evaluate the safety and tolerability of a single injection of VAX-24 at three dose levels compared to PCV15 in approximately 48 infants in a dose-escalation approach. The Stage 2 portion will evaluate the safety, tolerability and immunogenicity of VAX-24 at three dose levels and compared to PCV15 in approximately 750 infants. In line with recommendations from the ACIP, the study design includes a primary immunization series consisting of three doses given at two months, four months and six months of age, followed by a subsequent booster dose at 12-15 months of age. The key prespecified immunogenicity study endpoints include an assessment of immune responses for all three VAX-24 doses and compared to PCV15 on the shared serotypes measured at 30 days post-dose three, or PD3, and post-dose four, or PD4. Immune responses will be assessed based on anti-pneumococcal polysaccharide serotype-specific IgG responses (proportion of participants achieving the accepted IgG threshold value of &#x2265;0.35mcg/ml) at 30 days PD3 and IgG geometric mean titer ratios at 30 days PD4. All participants in the study will be evaluated for safety through six months following the booster dose. We expect topline safety, tolerability and immunogenicity data following the primary three-dose immunization series expected by 2025.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 17.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_18.jpg" alt="img70551829_18.jpg" style="width:544px;height:147px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If dose-finding is performed in infants, the data would inform on the dose levels for each of the conjugates in the final VAX-24 infant formulation. Consistent with the approval processes for PCV13 and PCV15 in infants, we do not anticipate that a clinical field efficacy trial will be required for VAX-24 in the pediatric population. We expect the clinical development of VAX-24 to follow the same approach utilized for PCV13 and PCV15, where vaccine effectiveness against IPD was inferred from immunologic correlates. In contrast to the adult population, VAX-24 approval in the pediatric population is expected to be based on a non-inferiority comparisons of IgG responses to PCV15, the current standard of care in infants. However, we have not yet obtained feedback from the FDA regarding our clinical development plans or the acceptability of our approach.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our Phase 2 trials are completed successfully, we expect to conduct pivotal Phase 3 trials in the pediatric population that focus on evaluating non-inferiority to PCV15 for immunogenicity and seroconversion or antibody concentration threshold; assessing U.S. routine vaccination responses following concomitant administration with VAX-24; and generating a sufficient safety database in infants. The Phase 3 non-inferiority results would then be used to seek approval of VAX-24 in the pediatric population. This approach is similar to the approach utilized to develop PCV13, where the immunogenicity of PCV13 was compared to the original 7-valent Prevnar product, which was the standard of care at the time, as well as PCV15 which was compared to PCV13.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VAX-31 (formerly VAX-XP)</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-31 is a franchise extension of VAX-24 that, if approved, would expand strain coverage to 31 strains and demonstrate the scalable and modular nature of conjugate vaccines we can develop. VAX-31 includes all of the strains contained in VAX-24 plus incremental strains that were selected based on the epidemiological evidence demonstrating their role in circulating IPD and is designed to protect against these emerging strains and to help address antibiotic resistance. The serotypes in VAX-31 cover approximately 95% of the circulating IPD in the United States adult population.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have completed multiple preclinical proof-of-concept studies for VAX-31 in rabbit models compared to PCV13, as well as more than 30 polysaccharides adsorbed onto alum. IgG responses in rabbits were superior to polysaccharide alone plus alum and comparable with PCV13 in the common 13 strains. We completed the process of transferring and scaling the conjugation processes at Lonza for each of the incremental conjugates contained in VAX-31 over and above those contained in VAX-24. The data shown below in Figure 18 was generated using those conjugates produced at larger scale at Lonza and confirm that the eCRM and polysaccharide raw materials and the conjugation processes for each of the conjugates in VAX-31 demonstrate immunogenicity comparable to PCV13 and superior to polysaccharide alone, consistent with prior lots of VAX-31.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 18.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_19.jpg" alt="img70551829_19.jpg" style="width:572px;height:263px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:9.067%;text-indent:-2.943%;padding-left:2.6%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platform Application Two: Novel Conjugate Vaccine Opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also developing novel conjugate vaccine candidates for other diseases for which there are no existing vaccines. By leveraging our platform, we have been able to generate novel protein carriers with site-specific incorporation of nnAAs designed to provide optimal exposure of both B-cell and T-cell epitopes on the carrier. Using these novel protein carriers, we can produce highly stable conjugate vaccine candidates through site-specific conjugation of antigens, including polysaccharides. Functionally, one significant advantage of using carriers may be the additional protective immunity that the protein itself can provide beyond the conjugated antigen itself.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Group A Strep Disease Background and Market Opportunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Streptococcus pyogenes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S. pyogenes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or Group A Strep) bacteria cause a wide spectrum of both acute and chronic clinical conditions that lead to considerable disease burden globally. Group A Strep results in 700 million cases of illness each year and is one of the leading infectious disease-related causes of death and disability worldwide. An estimated 500,000 deaths globally result from Group A Strep, which is in line with the impact seen from the Measles, Rotavirus and Pertussis. The annual mortality and loss of productivity costs in the United States attributable to Invasive Group A Strep disease and related acute respiratory infections exceed $6 billion, excluding the impact of significant antibiotic use on individuals and contribution to antimicrobial resistance. Among older adults (&#x2265; 65 years) in the United States, rates of invasive disease and deaths caused by Group A Strep have more than doubled over the last decade. Some of the most serious consequences of Group A Strep include flesh eating disease (necrotizing fasciitis) and invasive diseases such as sepsis and rheumatic heart disease (RHD). Approximately 40 million people are currently affected by RHD worldwide. Importantly, the majority of Group A Strep infections lead to pharyngitis, commonly known as strep throat, which is highly prevalent in school-age children. In the United States, an estimated 17% of outpatient antibiotic prescriptions dispensed to children aged 3 to 9 years are for the treatment of suspected Group A Strep infections. Studies have indicated that antibiotic resistance to Group A Strep has significantly increased over the past decade, leading the CDC to categorize Group A Strep as a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">concerning threat. Additionally, the development of vaccines against Group A Strep has become a priority for the WHO amid recognition of the rising disease incidence globally, as well as the need to combat avoidable antibiotic consumption.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It has been established that the repeated natural infection of children with Group A Strep results in immune responses that are protective against subsequent Group A Strep infection. We believe this observation justifies the development of a rationally designed vaccine for Group A Strep that is focused on conserved antigens expressed by all strains of the bacteria.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VAX-A1</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have developed a conjugate vaccine candidate, VAX-A1, designed to confer broad protection against subtypes of Group A Strep by virtue of polyrhamnose, a conserved polysaccharide, conjugated to Group A Strep specific immunogenic protein carrier using our site-specific conjugation technology. The resulting conjugate is designed to ensure optimal exposure of both the B-cell and T-cell epitopes on the protein carrier to confer robust, boostable and durable protective immune responses. We believe this single conjugate could potentially cover all Group A Strep strains. The vaccine is a combination of this novel protein-polysaccharide conjugate along with two additional conserved surface proteins.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our initial preclinical proof-of-concept study was published in the journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Infectious Microbes &amp; Diseases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in December 2020. In the study, a novel protein and polysaccharide conjugate of the Group A Strep polysaccharide was constructed for inclusion in a universal subunit vaccine against infections by the pathogen. The VAX-A1 vaccine candidate, based on SpyAD-conjugated to a modified polyrhamnose backbone (lacking N-acetyl glucosamine) and including SLO and C5a peptidase, demonstrated protection from subcutaneous and systemic challenge in mice, antibody binding and opsonophagocytic killing for multiple Group A Strep M Protein Gene, or emm, types and no evidence of cross-reactivity to human heart and brain tissue antigens (Figure 19), which is a key leading indicator of vaccine safety. The study was carried out in collaboration with researchers at the Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_20.jpg" alt="img70551829_20.jpg" style="width:409px;height:180px;" />&#160;</p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VAX-A1 vaccine development program currently is funded in part by a grant obtained from CARB-X, a global non-profit partnership dedicated to accelerating antibacterial innovation to tackle the rising global threat of drug-resistant bacteria. The award committed initial funding of up to $1.6 million. In July 2020, the initial funding amount was amended from $1.6 million to $2.7 million and, if options to extend are exercised by CARB-X, up to $15.1 million in total funding available upon achievement of development milestones through Phase 1 human clinical trials. In April 2021, we received approval for the next phase of CARB-X development and executed the cost-reimbursement sub-award agreement with the Trustees of Boston University in August 2021. Pursuant to the agreement, the award committed additional funding of $3.2 million for IND-enabling activities and total potential funding of up to $29.7 million (including $6.6 million awarded funding to date) upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $29.7 million to $14.6 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We nominated the final vaccine candidate for our VAX-A1 program in the first quarter of 2021 and initiated IND-enabling activities in the second half of 2021. We continue to advance the development of VAX-A1 and we intend to provide further information about the anticipated timing of an IND application as the program progresses. Upon completion of the preclinical development program and IND-enabling activities for VAX-A1, we intend to conduct a multi-center, randomized, placebo-controlled Phase 1/2 study in adults. The primary objectives of the initial clinical trial will be to evaluate safety and tolerability. Secondary exploratory endpoints will be to measure IgG immune response to the vaccine antigens and to evaluate the ability of the antibodies produced in response to vaccination to inhibit and prevent infections caused by Group A Strep.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platform Application Three: Protein Vaccine Opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe we can also develop novel protein vaccine candidates constructed using &#x201c;tough-to-make&#x201d; protein antigens uniquely able to be expressed using the platform. In particular, the lack of a cellular membrane in our platform allows for the exogenous addition of components to manipulate transcription, translation and folding by modification of reaction conditions. Furthermore, removal of the typical restriction to maintain cell viability also creates unique avenues for optimizing and promoting protein production for antigens that might be cytotoxic to a cell-based system or require non-physiological conditions for optimal protein folding. Thus, utilizing these advantages, we believe we can express and purify important protein targets to generate unique candidates that are beyond the scope of traditional production systems. Our therapeutic periodontitis vaccine candidate is the first example of a &#x201c;tough-to-make&#x201d; protein-based vaccine.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Periodontitis Disease Background and Market Opportunity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodontal disease is a highly complex, chronic oral inflammatory disease that leads to the destruction of the soft and hard tissues supporting the teeth. The subgingival niche (below the gum margin of teeth) is populated by a diverse polymicrobial plaque. It is increasingly understood that the shift from periodontal health to disease is associated with changes in the microbial composition of the subgingival plaque, including activities of bacteria such as Porphyromonas gingivalis (P. gingivalis). The development of precise approaches to control this keystone pathogen, such as a vaccine, could then positively impact the periodontal disease burden.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Those with periodontitis also have an increased risk for heart attack, stroke and other serious cardiovascular events. In addition to gum and tooth disease, periodontal inflammation and infection with P. gingivalis have been linked to atherosclerotic heart disease mediated by P. gingivalis residing in atherosclerotic plaque. While we are focused on the treatment of periodontal disease with this vaccine candidate, if P. gingivalis is found to be causative in other chronic disorders, our vaccine candidate could potentially be a highly effective treatment and allow disease intervention at a much earlier stage of the disease. For example, recent research has suggested the potential for a link between P. gingivalis and Alzheimer&#x2019;s disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neither the natural host immune response nor currently available treatments are curative for periodontal disease. Existing treatment includes highly aggressive and invasive procedures, including scaling and root planing and surgical intervention, coupled with antibiotic use. Despite these types of aggressive treatments, diseased sites frequently progress, leading to tooth loss. Thus, the development of an effective vaccine for periodontitis would be highly desirable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodontitis is a highly prevalent disease impacting &gt; 40% of US adults above the age of 30, and with similar rates globally. Periodontal disease caused an estimated loss of $330.6 billion in the United States and Europe in 2018, with the direct costs alone exceeding $6 billion. The indirect costs are multiples of the direct costs as a result of high rates of edentulism (loss of teeth) and increased risk of many other diseases mentioned above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VAX-PG</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing a novel protein vaccine candidate, VAX-PG, targeting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">P. gingivalis </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that incorporates protein antigens that we believe are uniquely enabled with our technology. Our initial goal is to develop a therapeutic vaccine to slow or stop disease progression; however, the results from clinical trials may inform the potential adoption of prophylactic immunization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-PG, which includes cell-free produced P. gingivalis virulence factors, including gingipains, were tested in a preclinical model that mimics periodontal disease. The results, which we believe generally demonstrate preclinical proof of concept for a periodontitis protein vaccine, were published in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Journal of Clinical Periodontology </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in February 2019. The vaccine elicited protein-specific IgG response following immunization and protected mice from P. gingivalis-elicited oral bone loss. Shown in Figure 20 is the objective bone loss of VAX-PG with alum, Monophospholipid A, or no adjuvant. Immunization with all formulations of VAX-PG provided significant protection against oral bone loss compared to the no vaccine oral challenged control group (p&lt;0.01, ANOVA with Dunns multiple comparisons).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 20.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_21.jpg" alt="img70551829_21.jpg" style="width:285px;height:249px;" />&#160;</p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ABC = alveolar bone crest</span></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CEJ = cement-enamel junction</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shown below in Figure 21 are pictures of representative mouse jaws from the experiment. As can be seen, the vaccinated mice had considerably less bone loss than the unvaccinated and challenged control animals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Figure 21.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_22.jpg" alt="img70551829_22.jpg" style="width:392px;height:326px;" /><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We nominated a final vaccine candidate for our VAX-PG program in the fourth quarter of 2022. Upon completion of the preclinical development program and IND-enabling activities for VAX-PG, we intend to conduct a multi-center, randomized, placebo-controlled Phase 1/2 study in adults with mild to moderate chronic periodontal disease. The primary objectives of the initial clinical trial will be to evaluate safety and tolerability. Secondary exploratory endpoints will be to measure IgG immune response to the vaccine antigens and to evaluate the ability of the antibodies produced in response to vaccination to inhibit the formation of the poly-microbial biofilm, which is characteristic of periodontal disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VAX-GI</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We announced that we have added VAX-GI, designed to prevent Shigellosis, to our pipeline. Shigella is a bacterial illness that causes dysentery with symptoms including bloody diarrhea, fever, and stomach cramps. Currently there are no prophylactics and treatment is primarily oral rehydration therapy, with antibiotics (mainly ciprofloxacin and azithromycin) used to shorten the duration of infection. However, the growing incidence of antibiotic resistance has complicated this approach with an increasing rate of extensively drug resistant (XDR).  Shigella affects an estimated 188 million people worldwide each year and results in approximately 164,000 deaths annually, mostly among children under five years of age in low- and middle-income settings.  Further, in young children Shigella can cause to malnutrition and induce or exacerbate stunting, leading to a long-term impact on both physical and cognitive development. This has resulted in the WHO including Shigella vaccine development as a priority goal.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing and Supply</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have designed and developed a proprietary, scalable and portable manufacturing process for VAX-24 and VAX-31 that we believe can scale to address clinical and commercial vaccine supply needed to serve both adult and pediatric populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VAX-24 and VAX-31 Process</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacturing process for our VAX-24 and VAX-31 vaccine candidates consists of four key components: (i) our proprietary eCRM protein carrier; (ii) the 24 or 31 pneumococcal polysaccharides; (iii) the 24 or 31 conjugate drug substances and (iv) the mixture of these 24 or 31 drug substances into the final drug product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">eCRM</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our proprietary eCRM protein carrier is produced using our cell-free protein synthesis platform, which is exclusively licensed from Sutro Biopharma for the Vaccine Field (as defined in the Sutro Biopharma License Agreement (as defined below)). eCRM, contains multiple copies of non-native para azido-methyl-phenylalanine, or pAMF, amino acid. The pAMF amino acids have a specific structure that enables eCRM to participate in the site-specific click chemistry conjugation reaction with activated pneumococcal polysaccharides.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The cell-free reaction is performed in a manner analogous to traditional fermentation but without the cells. The first step in the production of eCRM is the manufacture of critical raw materials, namely E. coli extracts and lysates that contain the cellular machinery required for in vitro DNA transcription and translation. The eCRM protein is then manufactured by combining these E. coli extracts and lysates with classic media components such as amino acids, minerals and salts, with the in vitro reaction driven by the addition of plasmid DNA coding for the eCRM protein&#x2019;s amino acid sequence. This cell-free reaction takes place in a standard fermenter, followed by standard protein purification chromatographic and filtration processes. The manufacturing process has consistently yielded a product of the desired quality.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pneumococcal Polysaccharides</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of the 24 or 31 pneumococcal polysaccharides is individually isolated from S. pneumoniae bacterial strains. Each individual S. pneumoniae strain is cultured in a bioreactor using an improved single standardized fed-batch bioreactor process and a single standardized downstream purification process. Overall, this standardized upstream and downstream process is simple and streamlined, thereby reducing manufacturing cost of goods and providing an efficient path of progression for the program from process characterization and validation through to commercialization, if our vaccine candidates are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conjugate Drug Substances</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of the 24 or 31 conjugate drug substances is manufactured individually, as monovalent conjugates, by conjugating each of the 24 or 31 activated pneumococcal polysaccharide strains, one at a time, to the eCRM carrier protein.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Click chemistry provides for a conjugation reaction that is quick, consistent and high-yielding, and which we optimized to be largely standardized across the various polysaccharides. Through statistical design of experiment, or DoE, studies, we have gained a significant understanding of which variables to adjust to maximize product quality and, accordingly, immunogenicity in rabbit models. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Drug Product</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All 24 or 31 conjugate drug substances are mixed, formulated with appropriate excipients and adsorbed onto alum. Clinical doses are filled in vials and stored refrigerated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Key Achievements and Status</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For VAX-24, we have completed the manufacturing, testing and release of all 24 drug substance conjugates and the final drug product for the Phase 1/2 and Phase 2 studies in adults and the Phase 2 study in infants. We are now progressing to Phase 3 clinical manufacturing and commercial supply activities.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For VAX-31, we have completed the manufacturing, testing and release of all 31 drug substance conjugates for the Phase 1/2 and Phase 2 studies in adults, and must complete the manufacturing, testing and release of the final drug product prior to initiation of these studies and contingent on the submission and acceptance of an IND filing.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently do not own or operate any manufacturing facilities, but our strategic partnerships with Lonza and other contract manufacturing organizations, or CMOs, provide us with access to substantial resources to facilitate an independent supply path to the market. We have entered into agreements with Lonza, a leading global contract manufacturer with deep domain expertise and experience in large and small-scale production of clinical, as well as commercial-stage products, to secure capacity, technical expertise and resources to support the production of eCRM, polysaccharides and drug substance for our VAX-24 Phase 3 program and VAX-31 Phase 1/2 and Phase 2 studies in adults. We believe we can satisfy the expected initial eCRM, polysaccharide and drug substance supply requirements following a potential launch of VAX-24 in adults using the existing facilities at Lonza; however, we would need to secure additional capacity at a new facility or facilities to satisfy the expected eCRM, polysaccharide and drug substance production requirements to support expected increased commercial quantities upon the potential approval and launch of VAX-24 in infants and to expand into other markets outside of the United States. We have relationships with other leading CMOs for the production of the final drug product for VAX-24 and VAX-31, for the extract and lysates that we use to manufacture eCRM and for certain raw materials. We have an agreement with Sutro Biopharma pursuant to which Sutro Biopharma supplies us with extract and custom reagents for use in manufacturing preclinical and certain clinical supply of vaccine compositions. In December 2019, we exercised our right to require Sutro Biopharma to establish a second supplier for extract and custom reagents to support future clinical and commercial needs. In December 2022, we entered into a separate agreement with Sutro Biopharma pursuant to which we enhanced our rights with the second supplier of extract and acquired an option to access expanded rights to develop and manufacture extract, among other rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lonza Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2016, we entered into a non-exclusive development and manufacturing services agreement, as amended, with Lonza, or the 2016 Lonza DMSA, pursuant to which Lonza is obligated to perform manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, we entered into a letter agreement with Lonza, or the Lonza Letter Agreement, pursuant to which we agreed to certain terms for potential future payments in shares of our common stock as partial satisfaction of future obligations to Lonza. The Lonza Letter Agreement states that the initial pre-IND cash payments under the 2016 Lonza DMSA would be subject to a specified dollar cap, or the Initial Cash Cap. After the Initial Cash Cap has been reached, we would have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $10.0 million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued 399,680 shares of our common stock to Lonza at a price of $25.02 per share to pay for $10.0 million of the pre-IND payments due April 30, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2018, we entered into a second non-exclusive development and manufacturing services agreement with Lonza, or the 2018 Lonza DMSA, pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we entered into a third non-exclusive development and manufacturing services agreement with Lonza, as amended, or the 2022 Lonza DMSA, effective as of March 22, 2022. Pursuant to the 2022 Lonza DMSA, Lonza will perform manufacturing process development and clinical manufacture and supply of our proprietary PCV.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under each of the 2016 Lonza DMSA, 2018 Lonza DMSA and 2022 Lonza DMSA, collectively the Lonza Agreements, we will pay Lonza agreed-upon fees for its performance of development and manufacturing services and pass through expenses incurred by Lonza for raw materials, as well as customary procurement and handling fees. Under each Lonza Agreement, we will own all right, title and interest in and to any and all New Customer Intellectual Property (as defined in each Lonza Agreement), and Lonza shall own all right, title and interest in New General Application Intellectual Property (as defined in each Lonza Agreement). Subject to the terms and conditions set forth in the Lonza Agreements, Lonza granted us a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property (as defined in each Lonza Agreement), to research, develop, make, have made, use, sell and import the Product (as defined in each Lonza Agreement) manufactured under each Lonza Agreement.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated, each Lonza Agreement will remain in place for a period of five years and includes customary conditions for termination prior to that period. The 2016 Lonza DMSA has been amended to extend its term until March 31, 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sutro Biopharma Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Biopharma is a clinical stage, publicly traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Sutro Biopharma&#x2019;s proprietary XpressCF platform technology) to advance next-generation oncology therapeutics. Following our corporate formation, we acquired an exclusive license to Sutro Biopharma&#x2019;s proprietary cell-free protein synthesis platform, XpressCF, for the discovery, development and sale of vaccines for the treatment or prevention of infectious diseases, excluding cancer vaccines. Under a related supply agreement with Sutro Biopharma, we have an exclusive relationship in our field to buy extract and certain custom reagents for use in manufacturing the vaccine compositions covered by the exclusive license, which we use to produce our protein carriers and certain of our antigens. Under a separate agreement with Sutro Biopharma, we enhanced our rights with respect to access to a second supplier of extract and acquired an option to access expanded rights to develop and manufacture extract, among other rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated License Agreement with Sutro Biopharma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are party to a license agreement with Sutro Biopharma, or the Sutro Biopharma License Agreement, on August 1, 2014. The Sutro Biopharma License Agreement was amended on October 12, 2015 and again on May 9, 2018 and May 29, 2018. Under the Sutro Biopharma License Agreement, we received an exclusive, worldwide, royalty-bearing, sublicensable license under Sutro Biopharma&#x2019;s patents and know-how relating to cell-free expression of proteins to (i) research, develop, use, sell, offer for sale, export, import and otherwise exploit specified vaccine compositions, such rights being sublicensable, for the treatment or prophylaxis of infectious diseases, excluding cancer vaccines, and (ii) manufacture, or have manufactured by an approved contract manufacturing organization, such vaccine compositions from extracts supplied by Sutro Biopharma pursuant to the Sutro Biopharma Supply Agreement (as described below). We are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize the vaccine compositions. In consideration of the rights granted under the Sutro Biopharma License Agreement, we are obligated to pay Sutro Biopharma a 4% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a 2% royalty on such net sales of vaccine products for animal health. Such royalty rates are subject to specified reductions, including standard reductions for third-party payments and for expiration of relevant patent claims. We are also obligated to pay Sutro Biopharma any royalties due to Stanford University (the upstream licensor of Sutro Biopharma), to the extent the royalties payable by Sutro Biopharma to Stanford University are greater than the royalties payable by us to Sutro</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biopharma. Royalties are payable on a vaccine composition-by-vaccine composition and country-by-country basis until the later of expiration of the last valid claim in the licensed patents covering such vaccine composition in such country and ten years after the first commercial sale of such vaccine composition. The latest expiration date of a licensed Sutro Biopharma patent application, if issued, would be 2036, subject to any adjustment or extension of patent term that may be available in a particular country. In addition, we are obligated to pay Sutro Biopharma a percentage of net sublicensing revenue received in the low teen percentages. In addition, in the event we sublicense our non-manufacturing rights under the Sutro Biopharma License Agreement before a specified date, we are obligated to pay Sutro Biopharma a percentage, in the low double-digits, of the sublicensing revenue we receive under such agreement.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Sutro Biopharma License Agreement will remain in effect until terminated. The agreement may be terminated by either party for the other party&#x2019;s material breach uncured within 60 days&#x2019; notice, by us at will with 60 days&#x2019; notice, or by Sutro Biopharma if we challenge Sutro Biopharma&#x2019;s patents or if we undergo a change of control with a specified competitor of Sutro Biopharma. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Supply Agreement with Sutro Biopharma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2018, we entered into a supply agreement, or the Sutro Biopharma Supply Agreement, with Sutro Biopharma pursuant to which we purchase from Sutro Biopharma extract and custom reagents for use in manufacturing non-clinical and certain clinical supply of vaccine compositions utilizing the technology licensed under the Sutro Biopharma License at prices not to exceed a specified percentage above Sutro Biopharma&#x2019;s fully burdened manufacturing cost. If any extracts or custom reagents do not meet the specifications and warranties provided, then we will not have an obligation to pay for the non-conforming product, and Sutro Biopharma will be obligated to replace the non-conforming product within the shortest possible time with conforming product at our cost. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2022 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Sutro Biopharma Supply Agreement.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Sutro Biopharma Supply Agreement may be terminated by either party for the other party&#x2019;s material breach uncured within 60 days&#x2019; notice, by us at will with 60 days&#x2019; notice, or by mutual agreement of the parties. In December 2019, we exercised our right to require Sutro Biopharma to establish a second supplier for extract and custom reagents to support our anticipated clinical and commercial needs. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Agreement with Sutro Biopharma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we entered into an option grant agreement with Sutro Biopharma, or the Option Agreement. Pursuant to the Option Agreement, we acquired from Sutro Biopharma (i) authorization to enter into an agreement with an independent alternate CMO to directly source Sutro Biopharma&#x2019;s cell-free extract, allowing us to have direct oversight over financial and operational aspects of the relationship with the CMO; and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract (including the right to make improvements to the extract manufacturing process as well as cell lines) for use in connection with the exploitation of certain vaccine compositions, or the Option. We and Sutro Biopharma have agreed to negotiate the terms and conditions of a form definitive agreement to be entered into in the event we exercise the Option, which shall include the terms and conditions set forth in an executed term sheet between us, or the Term Sheet, and such terms that are necessary to give effect to each of the terms and conditions set forth in the Term Sheet, or the Form Definitive Agreement. The Option period is five years from the date of the Option Agreement, subject to potential acceleration in the event we undergo a change of control.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we agreed to pay Sutro Biopharma upfront consideration of $22.5 million, consisting of (i) $10.0</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">million in cash and $7.5 million worth of shares of our common stock (the number of shares to be calculated based on the arithmetic average of the daily volume weighted average price of our common stock as traded on Nasdaq in the three consecutive trading days immediately prior to the issuance thereof), and (ii) $5.0 million payable within five business days after we and Sutro Biopharma mutually agree in writing upon the Form Definitive Agreement. The 167,780 shares of common stock issued was recorded at fair value of $8.0 million on the date of settlement, December 22, 2022. In the event that we elect to exercise the Option, we would pay Sutro Biopharma an aggregate Option exercise price of $75.0 million in cash in two installments and, upon the occurrence of certain regulatory milestones, certain additional milestone payments totaling up to $60.0 million in cash. In the event that we undergo a change of control, certain rights and payments may be accelerated. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">University of California, San Diego License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are party to a license agreement with the University of California, San Diego, or the UCSD License, dated February 2019 whereby we are the exclusive licensee of an issued U.S. patent and pending U.S. patent application related to a non-cross-reactive Group A Strep carbohydrate antigen and methods of producing the antigen. We licensed this technology for the development of our Group A Strep vaccine candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon execution of the UCSD License, we made an upfront payment of $10,000, and each year during the term we are obligated to pay an annual license maintenance fee in the single digit thousands. We are also obligated to pay UCSD up to approximately $1 million in development and regulatory milestone payments for each licensed product under the agreement. Additionally, we are obligated to pay UCSD a fixed royalty on net sales of licensed products in the low single digits. Such royalty rate is subject standard reductions for third-party payments. Royalties are payable until expiration of the last licensed patent. Additionally, in the event we sublicense commercial rights under the UCSD License, we are obligated to pay UCSD a percentage of all sublicensing revenue received, excluding any earned royalties or reimbursements of research and development expenses, of 20% up to a maximum of $2.5 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are obligated to use commercially reasonable efforts to diligently develop, manufacture and sell licensed products and to achieve specified research and clinical development milestone events. If we are unable to meet our diligence obligations and do not agree with UCSD to modify such obligations or do not cure such obligations, then UCSD may terminate the license or convert the license to non-exclusive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The UCSD License will remain in effect until the expiration of the last licensed patent. The UCSD patent and patent application, if issued, would expire in 2032, subject to any adjustment or extension of patent term that may be available in the United States. The UCSD License may be terminated by us at will with 90 days&#x2019; notice or by UCSD for our breach uncured within 90 days&#x2019; notice or if we challenge the licensed patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Partners</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to those listed above, we seek to partner with various academic, governmental and public or private research institutions as needed to advance the discovery or development of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In recent history, the global vaccine market has been highly concentrated among a small number of multinational pharmaceutical companies. Pfizer, Merck, GSK and Sanofi have been responsible for developing and introducing most new vaccines to the world. As a result of the COVID-19 pandemic, there have been a number of new entrants to the vaccines market, including multinational companies such as Johnson &amp; Johnson, and emerging biopharmaceutical companies. Other pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions are also working towards new solutions given the continuing global unmet medical need.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Within the current pneumococcal vaccine market, Pfizer, Merck and GSK have historically dominated, with Pfizer&#x2019;s PCV13 and PCV20, Merck&#x2019;s PPSV23 and PCV15 and GSK&#x2019;s Synflorix totaling a combined $7.4 billion in global pneumococcal vaccine sales in 2022 (approximately 85%, 10% and 5%, of such sales for these three products, respectively). While PCV13 covers fewer pneumococcal strains than PPSV23, it delivers a T-cell dependent immune response leading to a stronger and more durable immune response than PPSV23.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Existing vaccine makers, as well as new entrants, are competing to develop the next generation of pneumococcal vaccines. For use in adults, Pfizer's PCV20 was approved by the FDA in June 2021 and Merck's PCV15 was approved in July 2021. As a result of these approvals, the current standard of care in adults consists of the administration of either PCV20 alone or PCV15 followed by the administration of PPSV23. For use in infants, Merck&#x2019;s PCV15 was approved by the FDA in June 2022. Based on this approval, the current standard of care in infants is PCV13 or PCV15. Pfizer has a PDUFA goal date of April 2023 for PCV20 in infants.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, Pfizer announced topline results from its U.S. Phase 3 study in infants evaluating PCV20 for the prevention of IPD, and in January 2023, the FDA accepted for priority review a supplemental Biologics License Application for PCV20 for the prevention of IPD in infants and children. Merck announced in April 2022 that V116, the company&#x2019;s investigational 21-valent PCV for adults, received Breakthrough Therapy designation from the FDA, and later announced that it enrolled the first patient in their Phase 3 clinical trial. In June 2022, Merck presented positive results from its Phase 1/2 study evaluating V116 in pneumococcal vaccine-na&#xef;ve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). Also in June 2022, Merck announced that the CDC's ACIP unanimously voted to provisionally recommend use of Merck's PCV15 as an option for pneumococcal vaccination in infants and children and in September 2022, Merck announced it received a positive CHMP Opinion for PCV15 in infants and children. Sanofi and SK Chemicals have partnered to develop a 21-valent PCV, and GSK, which recently acquired Affinivax, is developing an affinity-bound pneumococcal vaccine that includes 24 pneumococcal serotypes. GSK also has a 30-plus valent pneumococcal candidate vaccine in preclinical development. We believe success will ultimately be based on the combination of immunogenicity, boostability and the broadest coverage of serotypes, as well as safety and tolerability. Convenience and pricing may also be factors. Other vaccines in development may obtain FDA approval and commercially launch before VAX-24. However, if approved, we believe VAX-24 may obtain an ACIP preferred recommendation and potentially replace both incumbents for pneumococcal disease prevention in both adult and pediatric populations because of its broader coverage should compare favorably to these PCV candidates as a 24-valent alternative, based on our unique site-specific conjugation and carrier-sparing technology. We also believe VAX-31 has the potential to compete favorably in the PCV market based on its further expanded spectrum.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The competitive landscape for vaccine development for Group A Strep was dormant for more than three decades. However, the FDA lifted a 30-year ban on Group A Strep vaccine clinical trials in 2005, and research has slowly started to resurface in academic institutions. However, we are not aware of other Group A Strep vaccines in clinical development that would cover all strains of the bacteria. Additionally, we are not aware of any other vaccines under clinical development to treat periodontitis. We believe the success of our vaccine candidates in these areas will be based on potential efficacy, safety, tolerability, convenience and pricing. We are aware of some companies developing treatments for other diseases that target the same underlying pathogens that cause Group A Strep and periodontitis.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize vaccines that are safer, more effective, more convenient, less expensive or with a more favorable label than VAX-24, VAX-31 or any other vaccine we may develop. Many of the companies against which we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compete have significantly greater financial resources, and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have developed, and are continuing to develop, a comprehensive intellectual property portfolio related to vaccine applications, including manufacturing, formulation and process applications as well as protection for our specific vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends in part on our ability to obtain and maintain proprietary protection for our vaccine candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements and vaccine candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our vaccine candidates and components thereof, their methods of use and processes for their manufacture and any other inventions that are commercially important to our business. We may also rely on trademarks, trade secrets and know-how to develop and maintain our proprietary position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the U.S. Patent and Trademark Office, or USPTO, in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. In addition, we cannot provide any assurance that any patents will be issued from our pending or future applications or that any issued patents will adequately protect our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patent portfolio as of February 27, 2023 contains one issued U.S. patent, one issued Japanese patent, one issued Mexican patent, seven pending U.S. patent applications and three pending patent cooperation treaty applications that are solely owned by us, as well as certain foreign counterparts of a subset of these patent applications in foreign countries, including Australia, Brazil, Canada, China, India, Israel, Japan, South Korea, Taiwan, Mexico, New Zealand, the Philippines, Singapore, South Africa and countries within the European Patent Convention and the Eurasian Patent Organization. For our pneumococcal vaccines, these applications are directed to vaccine formulations, protein-antigen conjugates, methods of making protein-antigen conjugates and other processes related to vaccine production, and the promotion of immunogenicity using the protein-antigen conjugates and vaccines. For our Group A Strep vaccine, these patent applications are directed to vaccine formulations, protein-antigen conjugates, vaccines and components thereof, as well as processes for their manufacture. For our periodontitis vaccine, the patent and applications relate to vaccine formulations, protein antigens, and methods of using the vaccine. If issued, the 20-year term expiration dates of our patents will expire between 2037 and 2042, not including any extension of the patent term that may be available in certain jurisdictions. We continue to seek to maximize the scope of our patent protection for all our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to patents, we also rely upon trademarks, trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. We maintain and are seeking both registered and common law trademarks. Common law trademark protection typically continues where and for as long as the mark is used. Registered trademarks continue in each country for as long as the trademark is registered. We believe that we have certain know-how and trade secrets relating to our technology and vaccine candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future vaccine candidates. However, trade secrets can be difficult to protect. We seek to protect our proprietary information, including trade secrets, in part, by using confidentiality agreements with our commercial partners, collaborators, employees and consultants, and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our commercial partners and selected consultants. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining the physical security of our premises and physical and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">electronic security of our information technology systems. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining patents does not guarantee our right to practice the patented technology or commercialize the patented product. Third parties may have or obtain rights to patents that could be used to prevent or attempt to prevent us from commercializing our vaccine candidates. If third parties prepare and file patent applications in the United States or other jurisdictions that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO or similar proceedings in other jurisdictions to determine the priority of invention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of our products in the United States will depend, in part, on the extent to which the costs of the products are covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. The process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product is typically separate from the process for setting the price of such a product or for establishing the reimbursement rate that the payor will pay for the product once coverage is approved. As a result, a third-party payor&#x2019;s decision to provide coverage for a pharmaceutical or biological product does not imply that the reimbursement rate will be adequate. Certain Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, ACA, marketplace and other private payor plans are required to include coverage for certain preventative services, including vaccinations recommended by the ACIP without cost share obligations (i.e., co-payments, deductibles or co-insurance) for plan members. Children through 18 years of age without other health insurance coverage may be eligible to receive such vaccinations free-of-charge through the CDC&#x2019;s Vaccines for Children program, or VCF. For Medicare beneficiaries, vaccines may be covered under either the Part B program or Part D depending on several criteria, including the type of vaccine and the beneficiary&#x2019;s coverage eligibility. If our vaccine candidates, once approved, are covered only under the Part D program, physicians may be less willing to use our products because of the claims adjudication costs and time related to the claims adjudication process and collection of co-payments associated with the Part D program.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As such, one third-party payor&#x2019;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. Further, coverage policies and third party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products that receives regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, safety, effectiveness, manufacture, quality control, approval, post-approval monitoring and reporting, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new biological product must be licensed by the FDA through the approval of a BLA, before it may be legally marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, pharmaceutical products are regulated by the FDA under the Federal Food, Drug and Cosmetic Act and other laws, including, in the case of biologics, the Public Health Service Act, or PHS Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with FDA requirements, both before and after product approval, may subject us or our partners, contract manufacturers and suppliers to administrative or judicial sanctions, including FDA refusal to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approve applications, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, fines and/or criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The steps required before a biologic may be approved for marketing of an indication in the United States generally include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of preclinical laboratory tests, animal studies, formulation studies conducted in accordance with good laboratory practices and other applicable regulations; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission to the FDA of an IND application, which must be active before human clinical trial commencement; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an institutional review board, or IRB, or ethics committee at each clinical site before a clinical trial is commenced; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish that the biological product is &#x201c;safe, pure and potent,&#x201d; which is analogous to the safety and efficacy approval standard for a chemical drug product for its intended use; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation and submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity and potency from results of nonclinical testing and clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with applicable current good manufacturing practices, or cGMPs, to assure that the facilities, methods and controls are adequate to preserve the products identify, strength, quality and purity; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review of the BLA and issuance of a biologics license, which is the approval necessary to market a vaccine. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before conducting studies in humans, laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and efficacy of the biologic candidate, must be conducted. Preclinical toxicology studies in animals must be conducted in compliance with FDA regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The results of the preclinical tests, together with manufacturing information, known as CMC, and analytical data, are submitted to the FDA as part of an IND application. Some preclinical testing may continue even after the IND application is submitted. In addition to including the results of the preclinical testing, the IND application will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase or phases of the clinical trial lend themselves to an efficacy determination. The IND application will automatically become effective 30 days after receipt by the FDA unless the FDA within the 30-day time period places the IND application on clinical hold because of safety concerns about the vaccine candidate or the conduct of the trial described in the clinical protocol included in the IND application. The IND application sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. Submission of an IND application therefore may or may not result in FDA authorization to begin a clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All clinical trials for new drugs and biologics must be conducted under the supervision of one or more qualified principal investigators in accordance with GCPs, which include the requirement that all research subjects</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provide their informed consent for their participation in any clinical trial. They must be conducted under protocols detailing, among other things, the objectives of the applicable phase of the trial, dosing procedures, research subject selection, exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND application, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors must also report to the FDA within specified timeframes, serious and unexpected adverse reactions, any clinically significant increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#x2019;s brochure or any findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the vaccine candidate. An IRB at each institution participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution, approve the information regarding the trial and the consent form that must be provided to each research subject or the subject&#x2019;s legal representative and monitor the trial until completed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials are typically conducted in three sequential phases, but the phases may overlap, and different trials may be initiated with the same vaccine candidate within the same phase of development in similar or differing patient populations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials may be conducted in a limited number of patients or healthy volunteers, as appropriate. The vaccine candidate is initially tested for safety and immunogenicity. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: The vaccine candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may also be made a condition to approval of the BLA. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND application safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects or any clinically relevant increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND application safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#x2019;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of all required testing in accordance with applicable regulatory requirements, the results of the preclinical studies and clinical trials, together with other detailed information, including information on the manufacture and composition of the vaccine candidate, are submitted to the FDA as part of a BLA requesting approval to market the vaccine candidate for a proposed indication or indications. The BLA must include all relevant data available from preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s CMC and proposed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">labeling, among other things. Under the Prescription Drug User Fee Act, the fees payable to the FDA for reviewing a BLA, as well as annual program user fees for approved products, can be substantial but are subject to certain limited deferrals, waivers and reductions that may be available. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. Each BLA submitted to the FDA for approval is reviewed for administrative completeness and reviewability within 60 days following receipt by the FDA of the application. If the BLA is found complete, the FDA will file the BLA, triggering a full review of the application. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission. The FDA&#x2019;s established goal is to review 90% of priority BLAs within six months after the application is accepted for filing and 90% of standard BLAs within 10 months of the acceptance date, whereupon a review decision is to be made. Priority review will direct overall attention and resources to the evaluation of applications for products that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#x2019;s continued safety, purity and potency. The FDA may also convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions regarding approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response Letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response Letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor the safety or efficacy of a product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product is approved, the approval may impose limitations on the uses for which the product may be marketed, may require that warning statements be included in the product labeling, may require that additional studies be conducted following approval as a condition of the approval and may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a Risk Evaluation and Mitigation Strategy, or REMS, or otherwise limit the scope of any approval. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. In most cases, the FDA must approve a BLA supplement or a new BLA before a product may be marketed for other uses or before specific manufacturing or other changes may be made to the approved product. As a condition of approval, the FDA may also require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. Also, product approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occur following initial marketing. In addition, new government requirements may be established that could delay or prevent regulatory approval of our vaccine candidates under development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Both before and after the FDA approves a product, the manufacturer and the holder or holders of the BLA for the product are subject to comprehensive regulatory oversight. For example, quality control and manufacturing procedures must conform, on an ongoing basis, to cGMP requirements, and the FDA periodically inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to spend time, money and effort to maintain cGMP compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any drug products manufactured or distributed by us or our partners pursuant to FDA approvals will be subject to pervasive and continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, distribution requirements, complying with individual electronic records and signature requirements and complying with FDA promotion and advertising requirements. Once approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. After approval, most changes to the approved product, such as adding new indications, specific manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Biologic manufacturers, their subcontractors and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. Changes to the manufacturing process are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discovery of previously unknown problems, including adverse events of unanticipated severity or frequency, or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal or suspension of an approval or license, clinical holds, warning or untitled letters, product recalls, product seizures, safety alerts, Dear Healthcare Provider letters, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, consent decrees or civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market and imposes requirements and restrictions on drug manufacturers, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or inpatient populations that are not described in the product&#x2019;s approved labeling (known as &#x201c;off-label use&#x201d;), industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict the manufacturer&#x2019;s communications on the subject of off-label use of their products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Additional Controls for Biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To help reduce the increased risk of the introduction of adventitious agents, the PHS Act emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHS Act also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After a BLA is approved, the product will also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform specific tests on each lot of the product before it is released for distribution. If the product is subject to an official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of the manufacture of the lot and the results of all the manufacturer&#x2019;s tests performed on the lot. The FDA may also perform specific confirmatory tests on lots of some products, such as vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing and are subject to periodic inspection after approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A sponsor may seek approval of its vaccine candidate under programs designed to accelerate the FDA&#x2019;s review and approval of new drugs and biological products that meet certain criteria. Specifically, new drugs and biological products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. For a fast track product, the FDA may consider sections of the BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. A fast track designated vaccine candidate may also qualify for priority review, under which the FDA sets the target date for FDA action on the BLA at six months after the FDA accepts the application for filing. Priority review is granted when there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious disease or condition. If criteria are not met for priority review, the application is subject to the standard FDA review period of 10 months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the accelerated approval program, the FDA may approve a BLA on the basis of either a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the biologic&#x2019;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, a sponsor may seek FDA designation of its vaccine candidate as a breakthrough therapy if the vaccine candidate is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a product as a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast track designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if a drug or biologic qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biosimilars and Exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">United States Healthcare Reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, there has been and continues to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of vaccine candidates, restrict or regulate post-approval activities and affect the profitable sale of vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Among policymakers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things: (1) increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; (2) created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">are inhaled, infused, instilled, implanted or injected; (3) established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in specific government healthcare programs; (4) expanded the eligibility criteria for Medicaid programs; (5) created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; (6) created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; and (7) established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been judicial and political challenges to certain aspects of the ACA. By way of example, the Tax Cuts and Jobs Act of 2017, or the Tax Act, was signed into law and included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on specific individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; The Bipartisan Budget Act of 2018, among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#x201c;donut hole.&#x201d; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#34;individual mandate&#34; was repealed by Congress. Prior to the U.S. Supreme Court ruling on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how any additional healthcare reform measures of the Biden administration will impact the ACA and our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted since the ACA was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, including the Infrastructure Investment and Jobs Act, will remain in effect through 2031, with the exception of a temporary suspension and reduction from May 1, 2020 through June 30, 2022, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries, presidential executive orders and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level in July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. The IRA will also, among other things, (i) allow HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics under Medicare Part B and Medicare Part D, and subject drug manufacturers to civil monetary penalties and a potential excise tax if they do not offer  Medicare a price that is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law, and (ii) impose rebates for certain drugs and biologics sold under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. Unless an exception applies, single-source vaccines can qualify for Medicare price negotiations 11 years after their BLA is approved and become subject to the IRA&#x2019;s negotiated maximum fair price ceiling two years after that.  However, certain vaccines, including pneumococcal virus vaccines, are excluded from the Medicare Part B inflation rebate. Additionally, CMS has stated in guidance released on February 9, 2023, that it will not impose Medicare Part D inflation rebates at this time on vaccines and other drugs and biologics that are not &#x201c;covered outpatient drugs&#x201d; under Medicaid or otherwise do not have an obligation to report drug pricing data to Medicaid. Further, as of January 1, 2023, the IRA eliminates patient cost sharing for FDA-approved adult vaccines that are recommended by the ACIP, and covered under Medicare Part D and mandates that all state Medicaid programs cover FDA-approved adult vaccines that are recommended by the ACIP and their administration without cost sharing starting October 1, 2023. However, the IRA does not change either VFC or the related provisions added in 2010 under the ACA. VFC was established to give first-dollar coverage to children up to 18 years of age whose families could not pay for vaccinations while the ACA guaranteed coverage of vaccines without cost sharing for Americans who are either privately insured or newly covered in states that expanded Medicaid. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. The Biden administration also released an additional executive order on October 14, 2022, directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to regulate pharmaceutical product pricing, including price or reimbursement constraints, discounts, restrictions on specific product access, marketing cost disclosure and transparency measures and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Further, it is possible that additional government action is taken in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">United States Healthcare Fraud and Abuse Laws and Compliance Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal and state healthcare laws and regulations restrict certain business practices in the biopharmaceutical industry, including anti-kickback and false claims laws and regulations, data privacy and security laws and regulations and transparency laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in-kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, prohibit, among other things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. Private individuals, commonly known as &#x201c;whistleblowers,&#x201d; can bring civil False Claims Act qui tam actions, on behalf of the government and such individuals and may share in amounts paid by the entity to the government in recovery or settlement. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal civil and criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, imposes specific requirements relating to the privacy, security and transmission of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">protected health information on HIPAA covered entities, which include certain healthcare providers, health plans and healthcare clearinghouses and their business associates and covered subcontractors who conduct certain activities for or on their behalf involving protected health information on their behalf.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners) and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Similar state, local and foreign healthcare laws and regulations may also restrict business practices in the pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efforts to ensure compliance with applicable healthcare laws and regulations can involve substantial costs. Violations of healthcare laws can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to regulations in the United States, we expect to be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our vaccine candidates. Whether or not we obtain FDA approval for a vaccine candidate, we must obtain approval from the comparable regulatory authorities of foreign countries or economic areas, such as the European Union, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain countries outside of the United States have a process that requires the submission of a clinical trial application, much like an IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial application, or CTA, must be submitted to the competent national health authority and to independent ethics committees in each country in which a company intends to conduct clinical trials. Once the CTA is approved in accordance with a country&#x2019;s requirements, clinical trial development may proceed in that country. In all cases, the clinical trials must be conducted in accordance with GCPs and other applicable regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">indications such as the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the centralized procedure, a marketing application is submitted to the European Medicines Agency, or EMA, where it will be evaluated by the Committee for Medicinal Products for Human Use, and a favorable opinion typically results in the grant by the European Commission of a single marketing authorization that is valid for all European Union member states within 67 days of receipt of the opinion. The initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To market a medicinal product in the European Economic Area, or EEA, (which is comprised of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein), we must obtain a Marketing Authorization, or MA. There are two types of marketing authorizations:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the European Economic Area, or EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced therapy products and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in the various Member States through the Decentralized Procedure. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the above-described procedures, before granting the MA, the EMA, or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Additional Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations. These and other laws govern our use, handling and disposal of various biological and chemical substances used in, and waste generated by our operations. Our research and development involve the controlled use of hazardous materials, chemicals, bacteria and viruses. Although we believe that our safety procedures for handling and disposing of such materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of such an accident, we could be held liable for any damages that result and any such liability could exceed our resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biological products, government control and other changes to the healthcare system of the United States. It is uncertain what legislative proposals will be adopted or what actions federal, state or private payors for medical goods and services may take in response to any healthcare reform proposals or legislation. We</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cannot predict the effect medical or healthcare reforms may have on our business, and no assurance can be given that any such reforms will not have a material adverse effect.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Privacy and Data Protection Laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are, or may become subject to numerous data privacy and security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards related to data privacy, security, and the protection of health-related and other personal data. Such obligations may include, without limitation, the Federal Trade Commission Act, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or the CPRA, and collectively, the CCPA, the European Union&#x2019;s General Data Protection Regulation 2016/679, or EU GDPR, and the EU GDPR as it forms part of United Kingdom, or UK, law by virtue of section 3 of the European Union (Withdrawal) Act 2018, or the UK GDPR, and the ePrivacy Directive. In addition, several states within the United States have enacted or proposed data privacy laws. For example, Virginia passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These privacy and security laws (including the EU GDPR and UK GDPR) may impose significant and complex compliance obligations on entities that are subject to those laws. For example, the EU GDPR applies to any company established in the European Economic Area, or the EEA, and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#x20ac;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties;; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See the section titled &#x201c;Risks Related to Government Regulation&#x201d; for additional information about the laws and regulations to which we are or may become subject to and about the risks to our business associated with such laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employees &amp; Human Capital</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 158 full-time employees, 30 of whom have Ph.D. degrees. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through the granting of stock-based compensation awards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate and Other Information</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are headquartered in San Carlos, California. We were incorporated in the state of Delaware on November 27, 2013 as Sutrovax, Inc. and we changed our name to Vaxcyte, Inc. in May 2020. Our website is located at https://www.vaxcyte.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K including their exhibits, proxy and information statements, and amendments to those reports filed or furnished pursuant to Section 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein or therein by reference. In addition, our filings with the SEC may be accessed through the SEC&#x2019;s website at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Ris</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">k Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISK FACTORS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business involves significant risks, some of which are described below. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and the financial statements and the related notes. Many of the following risks and uncertainties are, and will be, exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Position and Capital Needs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are in the clinical or preclinical stages of vaccine development and have a very limited operating history and no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have devoted substantially all of our resources to performing research and development, undertaking preclinical studies, clinical trials and manufacturing activities in support of our product development efforts, acquiring and developing our technology and vaccine candidates, organizing and staffing our company, performing business planning, establishing our intellectual property portfolio and raising capital to support and expand such activities. As an organization, we have not yet demonstrated an ability to successfully complete clinical development, obtain regulatory approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization or arrange for a third party to conduct these activities on our behalf. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current vaccine candidate pipeline includes five preclinical programs. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives, including with respect to our vaccine candidates. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future. We currently have no source of product revenue and may never achieve profitability. Our stock is a highly speculative investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage biotechnology vaccine company. Investment in clinical-stage companies and vaccine development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential vaccine candidate will not gain regulatory approval or become commercially viable. We do not have any products approved for sale and have not generated any revenue from product sales. As a result, we are not profitable and have incurred losses in each year since inception. Our net losses were $223.5 million and $100.1 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $522.1 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to spend significant resources to fund research and development of, and seek regulatory approvals for, our vaccine candidates. We expect to incur substantial and increasing operating losses over the next several years as our research, development, manufacturing, preclinical testing and clinical trial activities increase. As a result, our accumulated deficit will also increase significantly. We may encounter unforeseen</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. However, we do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our vaccine candidates, which we expect will take a number of years. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital. Even if we eventually generate revenue, we may never be profitable and, if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will require substantial additional funding to finance our operations, which may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and investments of $957.9 million. We believe our existing cash, cash equivalents and investments will fund our current operating plans through at least 12 months from the filing date of this Annual Report on Form 10-K. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. We have raised substantial capital, however, we will need to raise substantial additional capital to complete the development and commercialization of our drug candidates. We expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements or any combination of these approaches. In July 2021, we entered into an Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, or the ATM Sales Agreement with Jefferies LLC, or Jefferies, which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $150.0 million through Jefferies acting as our sales agent or principal. As of December 31, 2022, we have sold 4,488,573 shares of our common stock under the ATM Sales Agreement at an average price of $25.56 per share for aggregate gross proceeds of $114.7 million ($111.2 million net of commissions and offering expenses). Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions, including higher inflation rates and changes in interest rates and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide, including the trading price of common stock, resulting from the ongoing COVID-19 pandemic and civil and political unrest in certain countries and regions. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, scope, progress, results and costs of research and development, testing, screening, manufacturing, preclinical development and clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for any of our vaccine candidates for which we receive marketing approval;<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our exercise of the Option (as described below) with Sutro Biopharma, Inc., or Sutro Biopharma;<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform field efficacy studies for our pneumococcal conjugate vaccine, or PCV, candidates, require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of establishing additional manufacturing capacity to meet potential incremental supply requirements following the initial commercial launch of VAX-24;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of building a sales force in anticipation of any product commercialization; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any product liability or other lawsuits related to our products; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the revenue, if any, received from commercial sales, or sales to foreign governments, of our vaccine candidates for which we may receive marketing approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing our patents or other intellectual property rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of operating as a public company; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our vaccine candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations or milestones under the agreements. We could be required to seek collaborators for our vaccine candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, or relinquish or license on unfavorable terms our rights to our vaccine candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Due to the significant resources required for the development of our vaccine candidates, and depending on our ability to access capital, we must prioritize development of certain vaccine candidates. Moreover, we may expend our limited resources on vaccine candidates that do not yield a successful vaccine and fail to capitalize on vaccine candidates that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due to the significant resources required for the development of our vaccine candidates, we must decide which vaccine candidates to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, management and financial resources toward particular vaccine candidates may not lead to the development of any viable commercial vaccines and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate, license or collaborate with third parties in respect of certain vaccine candidates may subsequently also prove to be less than optimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our vaccine candidates or misread trends in the biopharmaceutical industry, in particular for vaccines, our business could be seriously harmed. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other vaccine candidates that may later prove to have greater commercial potential than those we choose to pursue or relinquish valuable rights to such vaccine candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business and Industry</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our approach to the discovery and development of our vaccine candidates is based on novel technologies that are unproven, which may expose us to unforeseen risks, require us to modify processes, and make it difficult to predict the time and cost of vaccine candidate development and the timing to apply for and obtain regulatory approvals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing a pipeline of vaccine candidates utilizing our cell-free protein synthesis platform, which is comprised of the XpressCF platform exclusively licensed from Sutro Biopharma, and our proprietary know-how for vaccine applications against infectious disease, and our future success depends on the successful application of this approach to vaccine development. We are in the clinical or preclinical stages of developing our vaccine candidates and there can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. For</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">example, although we have achieved proof-of-concept for our carrier-sparing approach with VAX-24, our approach may not be validated for our other vaccine candidates or subsequent trials of VAX-24. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to manufacturing partners, which may prevent us from completing our clinical trials or commercializing our products on a timely or profitable basis, if at all. In addition, since we have not yet completed clinical development, we do not know the specific doses that may be effective in the clinic or, if approved, commercially. Finding a suitable dose may delay our anticipated clinical development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our vaccine candidates and understand these critical factors. Conjugate vaccine development is highly complex, and development of broad-valency PCVs is further complicated by the number of components, analytical assays and potential for adjustments, including but not limited to changes in raw materials, composition, formulation, manufacturing methods and dosing, which could result in drug substances and/or drug product that may vary between preclinical and clinical studies over time. Over the course of the development and manufacturing of VAX-24, we have encountered process-related matters that have required us to make adjustments to our processes. We encountered such process-related matters during our drug substance manufacturing campaign for VAX-24 at Lonza, Ltd., or Lonza. The cumulative impact of the time required to make adjustments to our processes led to a delay of our drug substance manufacturing campaign due to scheduling conflicts and capacity constraints at Lonza. There can be no assurance that we or Lonza will be able to successfully manufacture drug substances in a timely manner in the future, or at all. Such process changes and manufacturing delays have caused a change in our Investigational New Drug, or IND, application timelines in the past and future changes or delays could impact future timelines for VAX-24 or for our other product candidates.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the preclinical and clinical trial requirements of the FDA, European Medicines Agency, or EMA, and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a vaccine candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. Approvals by the FDA and EMA for existing pneumococcal vaccines, such as PCV13, PPSV23, PCV20 and PCV15 may not be indicative of what these regulators may require for approval of our vaccine candidates. For example, we have used opsonophagocytic activity, or OPA, titers as the primary immunogenicity surrogate endpoint for the VAX-24 program in adults because PCV13 and PCV20 were approved based on the establishment of non-inferiority of serotype-specific OPA responses relative to PPSV23 and PCV13 respectively; however, there can be no assurance that this streamlined non-inferiority approach will be sufficient for regulatory approval or that regulators will not require field efficacy trials. Furthermore, while there have been approvals granted for both PCVs and meningococcal conjugate vaccines based on surrogate immune endpoints rather than field efficacy studies, we will not be able to confirm this approach&#x2019;s applicability for our vaccines until we complete our Phase 2 clinical development program. Additionally, novel aspects of our vaccine candidates and manufacturing processes may create further challenges in obtaining regulatory approval. The regulatory approval process for our novel vaccine candidates can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other vaccine candidates. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new vaccine candidates. Moreover, our vaccine candidates may not perform successfully in clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our vaccine candidates are in clinical or preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If we are unable to complete development of or commercialize our vaccine candidates or experience significant delays in doing so, our business would be materially harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None of our vaccine candidates have been the subject of late-stage or pivotal clinical trials. On October 24, 2022, we announced positive topline results from our Phase 1/2 clinical proof-of-concept study of VAX-24 in adults ages 18 to 64. We also announced in July 2022 the initiation of a separate Phase 2 study of VAX-24 in healthy adults aged 65 and older and expect to announce topline safety, tolerability and immunogenicity results from this study in the second half of 2023. Final results with the six-month safety data of the Phase 2 adult studies are anticipated in the first half of 2023. Regulatory interactions to inform the Phase 3 program are anticipated in the second half of 2023 following the receipt of the final safety reports from the two adult Phase 2 studies, and topline safety, tolerability and immunogenicity data from the pivotal Phase 3 non-inferiority study in adults are expected in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025. With regard to our VAX-24 pediatric program, in late February 2023, we announced that the FDA cleared the IND application for the prevention of IPD in infants. We plan to initiate an infant Phase 2 study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data following the primary three-dose immunization series expected by 2025. We anticipate submitting an IND application to the FDA for VAX-31 (formerly VAX-XP) in the second half of 2023. Topline safety, tolerability and immunogenicity data from a Phase 1/2 study in adults are expected in 2024. In addition to our PCV franchise, our pipeline includes VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Strep; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a vaccine designed to prevent Shigellosis; and other discovery-stage programs. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully commercializing our vaccine candidates, either alone or with third parties, and we cannot guarantee that we will ever obtain regulatory approval for any of our vaccine candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Before obtaining regulatory approval for the commercial distribution of our vaccine candidates, we must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy of our vaccine candidates.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have the financial resources to continue development of, or to enter into new collaborations for, a vaccine candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, vaccine candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">negative or inconclusive results from our preclinical or clinical trials, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product-related adverse effects experienced by volunteers in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulty achieving successful development of our manufacturing processes, including process development and scale-up activities to supply products for preclinical studies, clinical trials and commercial sale, if approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">timely completion of our preclinical studies and clinical trials, including any field efficacy studies that may be required, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability of us or any third-party contract manufacturer to scale up manufacturing of our vaccine candidates to supply the needs of preclinical studies, clinical trials and commercial sales, and to manufacture such products in conformity with regulatory requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in submitting IND applications or compatible foreign applications or delays or failures in obtaining necessary approvals from regulators to commence a clinical trial, or suspension or termination of a clinical trial once commenced; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conditions imposed by the FDA or similar foreign authorities regarding the scope or design of our clinical trials, including any requirements to perform field efficacy studies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in enrolling subjects in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inadequate supply or quality of vaccine candidate components or materials or other supplies necessary for conducting clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to obtain alternative sources of supply for which we have a single source for vaccine candidate components; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of coverage and adequate reimbursement and pricing from third-party payors, including government authorities, pertaining to the vaccine candidate, once approved, and patients&#x2019; willingness to pay out-of-pocket if third-party payor reimbursement is limited or not available; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">greater than anticipated costs of our clinical trials, including chemistry, manufacturing and controls, or CMC, activities related to our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">harmful side effects or inability of our vaccine candidates to meet efficacy endpoints; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unfavorable FDA or other regulatory agency inspection and review of one or more of our clinical trial sites or our contract manufacturers&#x2019; facilities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their obligations in a timely manner, or at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology or vaccine candidates in particular; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">varying interpretations of our data by the FDA and comparable foreign regulatory authorities. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In particular, while we believe our PCVs could receive regulatory approval based on well-defined surrogate immune endpoints, consistent with how other PCVs have obtained regulatory approval in the past, rather than requiring clinical field efficacy studies, there can be no assurance that the FDA or comparable foreign regulatory authorities will provide approvals on such basis. In addition, changes to the standard of care or the approval of new vaccines could change the threshold for achievement of non-inferiority using the established surrogate immune endpoints that our PCVs will need to meet in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inability to complete development of or commercialize our vaccine candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business is highly dependent on the success of VAX-24, which is in clinical development. If we are unable to obtain approval for VAX-24 and effectively commercialize VAX-24, our business would be significantly harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business and future success depends on our ability to obtain regulatory approval of, and then successfully commercialize, our most advanced vaccine candidate, VAX-24. Although VAX-24 has produced positive topline results in a Phase 1/2 clinical study, it may not demonstrate the same results in future pivotal studies. VAX-24 will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient clinical and commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We cannot provide any assurance that we will be able to successfully advance VAX-24 through the development process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical and commercial success of VAX-24 and future vaccine candidates will depend on a number of factors, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to raise any additional required capital on acceptable terms, or at all; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to complete IND-enabling studies and successfully submit IND or comparable applications;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of third parties with whom we contract to manufacture adequate clinical study and commercial supplies of our lead vaccine candidates or any future vaccine candidates, remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMP, and do so in a timely manner; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">timely completion of our preclinical studies and clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials, including field efficacy studies, or other studies beyond those planned to support the approval and commercialization of our vaccine candidates or any future vaccine candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance of our proposed indications and primary surrogate endpoint assessments for our PCV candidates by the FDA and similar foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any changes to the required threshold for the achievement of non-inferiority using established surrogate immune endpoints that our PCVs will need to meet in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities the safety, efficacy and acceptable risk to benefit profile of VAX-24 or any future vaccine candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the pace and prevalence of serotype replacement following the introduction of VAX-24 or VAX-31 or other vaccines targeting pneumococcal disease; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any vaccine-vaccine interference studies that may be required, particularly with the standard of care pediatric vaccine regimen; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our vaccine candidates or future approved products, if any; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timely receipt of necessary marketing approvals from the FDA or comparable foreign regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">achieving, maintaining and, where applicable, ensuring that our third-party contractors achieve and maintain compliance with our contractual obligations and with all regulatory requirements applicable to our lead vaccine candidates or any future vaccine candidates or approved products, if any; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining and maintaining an Advisory Committee on Immunization Practices, or ACIP, preferred recommendation or comparable foreign regulatory authority&#x2019;s recommendation of our vaccine candidates and the willingness of physicians, operators of clinics and patients to utilize or adopt any of our future vaccine candidates to prevent or treat age-associated diseases; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to successfully develop a commercial strategy and thereafter commercialize our vaccine candidates or any future vaccine candidates in the United States and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, whether alone or in collaboration with others; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience of our treatment or dosing regimen; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acceptance by physicians, payors and patients of the benefits, safety and efficacy of our vaccine candidates or any future vaccine candidates, if approved, including relative to alternative and competing treatments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patient demand for our vaccine candidates, if approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and enforce intellectual property rights in and to our vaccine candidates or any future vaccine candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our vaccine candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our vaccine candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our vaccine candidates or any future vaccine candidates to continue our business or achieve profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop our vaccine candidates, or may result in others discovering, developing or commercializing products before or more successfully than us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The vaccine market is intensely competitive and is dominated by a small number of multinational, globally established pharmaceutical corporations with significant resources; in recent history, Pfizer Inc, or Pfizer, Merck &amp; Co., Inc., or Merck, GSK plc, or GSK and Sanofi have been responsible for developing and introducing most new vaccines to the world. We may also face competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaccine candidates that we successfully develop and commercialize may compete with existing vaccines and new vaccines that may become available in the future. Many of our competitors have substantially greater financial, lobbying, technical, human and other resources than we do and may be better equipped to develop, manufacture and market technologically superior vaccines, including the potential that our competitors may develop chemical processes or utilize novel technologies for developing vaccines that may be superior to those we employ. In addition, many of these competitors have significantly greater experience than we have in undertaking preclinical studies and clinical trials of new products and in obtaining regulatory approvals, including for many vaccine franchises. Accordingly, our competitors may succeed in obtaining FDA approval or a preferred recommendation for their products. For example, PCV13 obtained FDA approval for the prevention of invasive pneumococcal disease, or IPD, in infants based on non-inferior IgG antibody responses relative to Prevnar, using the surrogate immune endpoints established by the prior Prevnar field efficacy study. Pfizer implemented a similar approach to development of its 20-valent PCV vaccine candidate, PCV20, which was approved by the FDA in June 2021 for use in adults. In August 2022, Pfizer announced topline results from its U.S. Phase 3 study in infants evaluating PCV20 for the prevention of IPD and in January 2023, the FDA accepted for priority review a supplemental Biologics License Application for PCV20 for the prevention of IPD in infants and children. Merck received approval for PCV15, its 15-valent PCV, in July 2021 for use in adults and in June 2022 for use in infants. Merck announced in April 2022 that V116, the company&#x2019;s investigational 21-valent PCV for adults, received Breakthrough Therapy designation from the FDA, and later announced that it enrolled the first patient in their Phase 3 clinical trial. In June 2022, Merck announced positive results from its Phase 1/2 study evaluating the safety, tolerability and immunogenicity of V116 in pneumococcal vaccine-na&#xef;ve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). In addition, Sanofi and SK Chemicals have partnered to develop a PCV, and GSK, which recently acquired Affinivax, is developing a 24-valent affinity-bound pneumococcal vaccine. Affinivax also has a 30-plus valent pneumococcal candidate vaccine in preclinical development.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors have established distribution channels for the commercialization of their vaccine products, whereas we have no such established channels or capabilities. In addition, many competitors have greater name recognition, more extensive collaborative relationships or the ability to leverage a broader vaccine portfolio. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize vaccines that are safer, more effective, more convenient, less expensive or with a more favorable label than any vaccine candidates that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of these factors, our competitors may obtain regulatory approval of their products before we are able to, which may limit our ability to develop or commercialize our vaccine candidates, or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors may also develop vaccines that are safer, more effective, more widely accepted or less expensive than ours, and may also be more successful than we are in manufacturing and marketing their products. These advantages could render our vaccine candidates obsolete or non-competitive before we can recover the costs of such vaccine candidates&#x2019; development and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We and our contract manufacturers may face difficulty satisfying chemistry, manufacturing and controls requirements imposed by the FDA and comparable foreign regulatory authorities. To date, no product developed using a cell-free manufacturing platform has received approval from the FDA or been commercialized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we are designing and developing a manufacturing process that we believe can scale to address clinical and commercial vaccine supply, we do not own or operate any manufacturing facilities. We rely on contract manufacturing organizations, or CMOs, including our strategic partnership with our contract manufacturer, Lonza, to access resources to facilitate the development and, if approved, commercialization of VAX-24 and our other vaccine candidates. Advancing our vaccine candidates may create significant challenges, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing our vaccine candidates to our specifications, including process development, analytical development and quality control testing, and in a timely manner to support our preclinical and clinical trials and, if approved, commercialization; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">sourcing the raw materials used to manufacture our vaccine candidates for preclinical, clinical and, if approved, commercial supplies; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of our vaccines. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before we can initiate a clinical trial or commercialize any of our vaccine candidates, we must demonstrate to the FDA that the CMC for our vaccine candidates meet applicable requirements, and prior to authorization in the European Union, or EU, a manufacturing authorization must be obtained from the appropriate EU regulatory authorities. Because no product manufactured on a cell-free manufacturing platform has been approved in the United States, there is no manufacturing facility that has demonstrated the ability to comply with FDA requirements, and, therefore, the timeframe for demonstrating compliance to the FDA&#x2019;s satisfaction is uncertain. Delays in establishing that our manufacturing process and the facilities we utilize for manufacturing comply with cGMP or disruptions in our manufacturing processes, implementation of novel technologies or scale-up activities, may delay or disrupt our development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approval of our vaccine candidates, the products may not gain market acceptance among regulators, advisory boards, physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if any of our vaccine candidates receive marketing approval, they may fail to receive recommendations for use by regulators or advisory boards that recommend vaccines, or gain market acceptance by physicians, patients, third-party payors and others in the medical community. If such vaccine candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any vaccine candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">receiving Centers for Disease Control and Prevention, or CDC, and ACIP recommendations for use, as well as recommendations of comparable foreign regulatory and advisory bodies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prevalence and severity of the disease targets for which our vaccine candidates are approved; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">physicians, hospitals, third-party payors and patients considering our vaccine candidates as safe and effective; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the potential and perceived advantages of our vaccine candidates over existing vaccines, including with respect to spectrum of coverage or immunogenicity; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the prevalence and severity of any side effects; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product labeling or product insert requirements of the FDA or comparable foreign regulatory and advisory bodies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitations or warnings contained in the labeling approved by the FDA or comparable foreign regulatory and advisory bodies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing of market introduction of our vaccine candidates as well as competitive products; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost in relation to alternatives; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of coverage and adequate reimbursement and pricing by third-party payors, including government authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors, including government authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relative convenience and ease of administration, including as compared to competitive vaccines and alternative treatments; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of our sales and marketing efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the CDC and ACIP develop vaccine recommendations for both children and adults, as do similar agencies around the world. To develop its recommendations, ACIP forms working groups that gather, analyze and prepare scientific information. The ACIP also considers many of the factors above, as well as myriad additional factors such as the value of vaccination for the target population regarding the outcomes, health economic data and implementation issues. ACIP recommendations are also made within categories, such as in an age group or a specified risk group. For example, the ACIP may determine that a preferred recommendation in a smaller child population may be more economical than recommending vaccinations for a larger adult population, which could adversely impact our market opportunity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">New pediatric vaccines that receive an ACIP preferred recommendation are almost universally adopted, and adult vaccines that receive a preferred recommendation are widely adopted. For example, in 2014, the ACIP voted to recommend PCV13 for routine use to help protect adults aged 65 years and older against pneumococcal disease, which caused PCV13 to become the standard of care along with continued use of PPSV23. ACIP can also modify its preferred recommendation. For instance, in June 2019, the ACIP voted to revise the pneumococcal vaccination guidelines and recommend PCV13 for adults 65 and older based on the shared clinical decision making of the provider and patient, rather than a preferred use recommendation, which means the decision to vaccinate should be made at the individual level between health care providers and their patients. In October 2021, the ACIP voted to recommend the use of either Pfizer&#x2019;s PCV20, or Merck&#x2019;s PCV15 with PPSV23, for routine use in adults aged 65 years and older as well as for those between the ages of 19 and 64 years with certain underlying medical conditions or other risk factors. In June 2022, ACIP voted to recommend that Merck&#x2019;s PCV15 may be used as an option to the currently available PCV13 for children aged under 19 years according to currently recommended PCV13 dosing and schedules.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our vaccine candidates are approved but fail to receive CDC and ACIP recommendations, or recommendations of other comparable foreign regulatory and advisory bodies, or achieve market acceptance among physicians, healthcare providers, patients, third-party payors or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to use our cell-free protein synthesis platform to expand our pipeline of vaccine candidates and develop marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The success of our business depends in large part upon our ability to identify, develop and commercialize products based on our cell-free protein synthesis platform. We intend to pursue clinical development of additional vaccine candidates beyond VAX-24, including VAX-31 for PCV, VAX-A1 for Group A Strep, VAX-PG for periodontitis and VAX-GI for Shigellosis. Our research programs may fail to identify potential vaccine candidates for clinical development for a number of reasons or we may focus our efforts and resources on potential programs or vaccine candidates that ultimately prove to be unsuccessful. In addition, we cannot provide any assurance that we will be able to successfully advance any of our existing or future vaccine candidates through the development process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our potential vaccine candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. If any of these events occur, we may be forced to abandon our development efforts for a program or for multiple programs, which would materially harm our business and could potentially cause us to cease operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we receive FDA approval to market additional vaccine candidates, we cannot provide assurance that any such vaccine candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. In addition, current PCVs do not address the majority of circulating strains causing pneumococcal disease. There has been a decrease in the incidence of disease attributable to the strains covered by existing vaccines but an increase in incidence attributable to non-covered strains that now cause most residual disease. Such change is driven by the void created when strains are taken out of circulation after widespread vaccination, which is a phenomenon known as serotype replacement. As a result of such change, broader spectrum PCVs are required to maintain protection against historically pathogenic strains while expanding coverage to current circulating and emerging strains. There can be no assurance that we will be able to develop higher-valent vaccines to address serotype replacement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because VAX-24 is our most advanced vaccine candidate, and because our other vaccine candidates are also based on our cell-free protein synthesis platform, if VAX-24 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently rely on third-party manufacturing and supply partners, including Lonza and Sutro Biopharma, to supply raw materials and components for, and manufacture of, our preclinical and clinical supplies as well as our vaccine candidates. Our inability to procure necessary raw materials or to have sufficient quantities of preclinical and clinical supplies or the inability to have our vaccine candidates manufactured, including delays or interruptions at our third-party manufacturers, or our failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efficient and scalable manufacturing and supply is a vital component of our business strategy. We currently do not own or operate any manufacturing facilities. We are designing and developing a manufacturing process that we believe can scale to address clinical and commercial vaccine supply. However, our assumptions as to our ability and our CMOs&#x2019; ability to produce vaccines at the scale needed for clinical development and commercial demand, in particular for our PCVs, may prove to be wrong. If we encounter substantial problems in our manufacturing processes or in our ability to scale to address commercial vaccine supply, our business would be materially adversely affected. Examples of potential issues related to our manufacturing processes or our ability to scale include difficulties with production costs, yields and quality control, including stability of the drug substance or drug product.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third-party contract manufacturers to manufacture preclinical and clinical trial product materials and supplies for our needs. There can be no assurance that our preclinical and clinical development product supplies will not be limited or interrupted or be of satisfactory quality or continue to be available on acceptable terms. Over the course of the development and manufacturing of VAX-24, we have encountered process-related matters that have required us to make adjustments to our processes. We encountered such process-related matters during our drug substance manufacturing campaign for VAX-24 at Lonza. The cumulative impact of the time required to make adjustments to our processes led to a delay of our drug substance manufacturing campaign due to scheduling conflicts and capacity constraints at Lonza. There can be no assurance that we or Lonza will be able to successfully manufacture drug substances in a timely manner in the future, or at all. Such process changes and manufacturing delays have caused a change in our IND timelines in the past and future changes or delays could impact future timelines for VAX-24 or for our other product candidates. As a third-party manufacturer, we are also subject to Lonza&#x2019;s scheduling commitments for its other clients. Scheduling conflicts with Lonza&#x2019;s other clients have contributed to manufacturing delays in the past, and there is no guarantee that future scheduling conflicts or related capacity constraints will not affect our manufacturing campaigns and related timelines. In addition, certain aspects of our manufacturing process for our clinical trial product materials and supplies were adversely affected by the COVID-19 pandemic, and could be adversely affected by the ongoing COVID-19 pandemic, earthquakes and other natural or man-made disasters, equipment failures, labor shortages, power failures and numerous other factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the future. Please see the risk factor titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Health epidemics, including the effects of the ongoing COVID-19 pandemic, have impacted and could continue to impact our business, including in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The manufacturing process for a vaccine candidate is subject to FDA or comparable foreign regulatory authority review. Our suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of elements of our vaccine candidates. Moreover, we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills, raw materials or technology required to manufacture our vaccine candidates may be unique or proprietary to the original manufacturer or supplier, and we may have difficulty applying such skills or technology or sourcing such raw materials ourselves, or in transferring such skills, technology or raw materials to another third party, or such transfer may be subject to certain consent obligations and payment terms to Lonza. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to enable us, or to have another third party, manufacture our vaccine candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines, and we may be required to repeat some of the development program. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop vaccine candidates in a timely manner or within budget.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to rely on third-party manufacturers and suppliers, including Lonza, if we receive regulatory approval for any PCV or any other vaccine candidates. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. In December 2019, we exercised our right to require Sutro Biopharma to establish a second supplier for extract and custom reagents to support our anticipated clinical and commercial needs. In December 2022, we entered into an option agreement with Sutro Biopharma, or the Option Agreement, pursuant to which we acquired, among other thing, authorization to enter into an agreement with an independent alternate CMO to directly source Sutro Biopharma&#x2019;s cell-free extract, allowing us to have direct oversight over financial and operational aspects of the relationship with the CMO. If we are unable to obtain or maintain third-party manufacturing for vaccine candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our vaccine candidates successfully. Our or a third party&#x2019;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an inability to initiate or complete clinical trials of vaccine candidates under development; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory approvals, for our vaccine candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subjecting third-party manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">requirements to cease distribution or to recall batches of our vaccine candidates; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the event of approval to market and commercialize a vaccine candidate, an inability to meet commercial demands for our products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, because VAX-24 is our most advanced vaccine candidate, and because our other vaccine candidates are also based on our cell-free protein synthesis platform, if VAX-24 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we and our contract manufacturers may experience manufacturing difficulties due to limited vaccine manufacturing experience, resource constraints or as a result of labor disputes or unstable political environments. If we or our contract manufacturers were to encounter any of these difficulties, our ability to manufacture sufficient vaccine supply for our preclinical studies and clinical trials, or to provide product for patients once approved, would be jeopardized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our vaccine candidates may cause undesirable side effects or have other properties, including interactions with existing vaccine regimens, that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adverse effects or other undesirable or unacceptable side effects caused by our vaccine candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In such an event, our clinical trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our vaccine candidates. Such side effects could also affect trial recruitment or the ability of enrolled subjects to complete the clinical trial or result in potential product liability claims. A data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research volunteers are being exposed to an unacceptable health risk. Vaccine-related side effects could also affect recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, any vaccine to be approved in pediatric populations may need to undergo extensive vaccine-vaccine interference studies with the standard of care pediatric vaccine regimen. Further, to the extent field efficacy studies are required, prophylactic vaccines typically require clinical testing in thousands to tens of thousands of healthy volunteers to define an approvable benefit-risk profile. The need to show a high degree of safety and tolerability when dosing healthy individuals could result in rare and even spurious safety findings, negatively impacting a program prior to or after commercial launch. Any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Negative developments and negative public opinion of new technologies on which we rely may damage public perception of our vaccine candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Negative developments and negative public opinion of new or existing technologies on which we rely may damage public perception of our vaccine candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our vaccine candidates. Public perception may be influenced by claims that vaccines are unsafe, and products incorporating new vaccine technology may not gain the acceptance of the public or the medical community. Adverse public attitudes may negatively impact our ability to enroll subjects in clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, our vaccine candidates in lieu of, or in addition to, existing, more familiar vaccines for which greater clinical data may be available. Any increase in negative perceptions of the technologies that we rely on may result in fewer physicians prescribing our products or may reduce the willingness of patients to utilize our products or participate in clinical trials for our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to file IND applications to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our timing of submitting the IND applications for our product candidates is dependent on preclinical and manufacturing success, and if we experience additional delays, we may fail to meet our anticipated timelines. In addition, we cannot be sure that submission of an IND application or IND application amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on study design; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in reaching agreement on acceptable terms with prospective CROs and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in obtaining required institutional review board, or IRB, approval at each clinical study site; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raise FDA concerns about risk to patients of the technology broadly; or if the FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in adding a sufficient number of trial sites and recruiting volunteers to participate in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure by our CROs, other third parties or us, to adhere to clinical study requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">failure to perform in accordance with the FDA&#x2019;s good clinical practice, or GCP, requirements or applicable regulatory guidelines in other jurisdictions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development or commercialization partner for the manufacture of vaccine candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in having subjects complete participation in a study or return for post-injection follow-up; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subjects dropping out of a study; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">occurrence of side effects associated with our vaccine candidates that are viewed to outweigh their potential benefits; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of clinical trials of our vaccine candidates being greater than we anticipate; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical studies of our vaccine candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our vaccine candidates for use in clinical studies or the inability to do any of the foregoing. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, based on the positive topline results from the VAX-24 Phase 1/2 proof-of-concept study, which evaluated the safety, tolerability and immunogenicity of VAX-24 in adults 18-64 years of age, the FDA supported the initiation of a pediatric study in infants. This study could uncover risks in this study population that could have potentially been discovered during a child and/or toddler study, which could then delay completion of clinical development. Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our vaccine candidates, we may be required to or we may elect to conduct additional studies to bridge our modified vaccine candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our vaccine candidates and may harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we encounter difficulties enrolling subjects in any clinical trials we may conduct, including any field efficacy trials that may be required, our clinical development activities could be delayed or otherwise adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may experience difficulties in enrolling subjects in any clinical trials we may conduct for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of subjects who remain in the study until its conclusion. The enrollment of subjects depends on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the eligibility and exclusion criteria defined in the protocol; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the size of the population required for analysis of the trial&#x2019;s primary endpoints; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the proximity of volunteers to study sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the design of the trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain and maintain subject consents; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to monitor volunteers adequately during and after injection; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk that volunteers enrolled in clinical trials will drop out of the trials before the injection of our vaccine candidates or trial completion; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risks and disruptions caused by the COVID-19 pandemic related to patient and physician investigator recruitment and retention and study site initiation and clinical trial activities.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent we are required to conduct any field efficacy studies, enrollment of a sufficient number of subjects may require additional time and resources given widespread vaccination rates in the United States, particularly in the pediatric population. As a result, we may be required to conduct any such trials outside the United States, which could cause additional complexity and delay. Delays in enrollment may result in increased costs or may affect the timing or outcome of any clinical trials we may conduct, which could prevent completion of these trials and adversely affect our ability to advance the development of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publish interim topline or preliminary data from our preclinical or clinical trials. For instance, on October 24, 2022, we announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy adults aged 18-64. Interim topline data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as more patient data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data when we publish such data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we may publish. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular vaccine candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular vaccine candidate or our business. If the topline data that we report differ from final results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, vaccine candidates may be harmed, which could significantly harm our business prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our vaccine candidates, but we may not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our vaccine candidates will receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek Breakthrough Therapy or Fast Track designation for some of our vaccine candidates. For instance, in August 2022 we announced that the FDA granted Fast Track designation to VAX-24 in adults ages 18 and older and, in January 2023, we announced that the FDA granted Breakthrough Therapy designation for VAX-24 for the prevention of IPD in adults. A sponsor may seek FDA designation of its vaccine candidate as a Breakthrough Therapy if the vaccine candidate is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For vaccines that have been designated as Breakthrough Therapies, the FDA may take actions to expedite the development and review of the application, and interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A vaccine designated as a Breakthrough Therapy by the FDA may also be eligible for expedited review and approval. If a vaccine candidate is intended for the treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address unmet medical needs for this condition, the sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular vaccine candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain Fast Track designation for one or more of our vaccine candidates, we may not experience a faster development process, review or approval compared to non-expedited FDA review procedures. For instance, although the FDA has granted Fast Track designation to VAX-24 in adults, we may not experience a faster development, review or approval process compared to the conventional process. In addition, the FDA may withdraw Fast Track designation from VAX-24, or from any other of our vaccine candidates that may receive the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designation in the future, if it believes that the designation is no longer supported. Fast Track designation alone does not guarantee qualification for the FDA&#x2019;s Priority Review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whether to grant Breakthrough Therapy or Fast Track designations are within the discretion of the FDA. Accordingly, even if we believe one of our vaccine candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of either of these designations for a vaccine candidate may not result in a faster development process, review or approval compared to vaccine candidates considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our vaccine candidates qualify for either of these designations, the FDA may later decide that the vaccine candidate no longer meets the conditions for qualification and rescind the designations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We currently have no marketing and sales organization, and as an organization have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our vaccine candidates, we may not be able to generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have no sales, marketing or distribution capabilities and as an organization have no experience in marketing products. If we develop an in-house marketing organization and sales force, we will require significant capital expenditures, management resources and time, and we will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our vaccine candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or overseas. If we are unable to develop in-house sales and distribution capabilities or enter into relationships with third-party collaborators on acceptable terms or at all, we may not be able to successfully commercialize our products. If we are not successful in commercializing our products or any future products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">A variety of risks associated with potentially conducting research and clinical trials abroad and marketing our vaccine candidates internationally could materially adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we pursue approval and commercialization for our vaccine candidates overseas and conduct CMC and other operations overseas, we will be subject to additional risks related to operating in foreign countries, including:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differing regulatory requirements in foreign countries; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased difficulties in managing the logistics and transportation of storing and shipping vaccine candidates abroad; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">import and export requirements and restrictions;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differing and changing data protection and privacy regimes and requirements; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">economic weakness, including inflation and interest rates, or political instability in particular foreign economies and markets; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign taxes, including withholding of payroll taxes; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">difficulties staffing and managing foreign operations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">differing payor reimbursement regimes, governmental payors or patient self-pay systems and price controls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential liability under the U.S. Foreign Corrupt Practices Act of 1977, as amended, or comparable foreign regulations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">business interruptions resulting from geopolitical actions, including war and terrorism. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These and other risks associated with our international operations and our collaborations with Lonza, based in Switzerland, may materially adversely affect our ability to attain or maintain profitable operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain highly qualified personnel, we may not be able to successfully implement our business strategy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer, our President and Chief Financial Officer, our Vice President of Research and our Executive Vice President and Chief Operating Officer. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in product development and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conduct substantially all of our operations at our facilities in the San Francisco Bay Area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock units, or RSUs, that vest over time. The value to employees of stock options and RSUs that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management and scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#x201c;key person&#x201d; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As our discovery, development and commercialization plans and strategies develop, we have rapidly expanded our employee base and expect to continue to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">managing our internal development efforts effectively, including the clinical and FDA review process for our vaccine candidates, while complying with our contractual obligations to contractors and other third parties; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future financial performance and our ability to commercialize our vaccine candidates will depend, in part, on our ability to effectively manage our growth. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our vaccine candidates and, accordingly, may not achieve our research, development and commercialization goals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our vaccine candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our vaccine candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining and maintaining regulatory approval of our vaccine candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a vaccine candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the vaccine candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a vaccine candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of vaccine candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our vaccine candidates will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our discovery, development and commercialization efforts with respect to our vaccine candidates and any future vaccine candidates that we may seek to develop. Any of these relationships may require us to incur non-recurring and other charges, increase our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our vaccine candidates because they may be deemed to be at too early of a stage of development for collaborative effort, and third parties may not view our vaccine candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our vaccine candidates could delay the development and commercialization of our vaccine candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue from any &#x201c;catch up&#x201d; opportunity may decline over time as more of the patient population is vaccinated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to initially seek approval of our VAX-24 vaccine candidate in adults. If approved, we believe it may have the potential to serve as a &#x201c;catch up&#x201d; or booster to those adults who have previously received PPSV23 or a lower-valent PCV. Previous vaccines with a &#x201c;catch up&#x201d; opportunity have seen a high initial capture rate, but sales may decline over time as the number of individuals who remain unvaccinated with the new vaccine, and eligible for &#x201c;catch up&#x201d; opportunities, declines. Such decline could adversely affect our revenue over time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our security measures, or those maintained on our behalf by CROs, service providers or other third parties, are compromised now, or in the future, or the security, confidentiality, integrity or availability of our information technology, software, services, networks, communications or data is compromised, limited or fails, this could result in significant fines or other liability, interrupt our development programs, harm our reputation, or otherwise adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of our business, we collect, use, retain, safeguard, disclose, share, transfer or otherwise process proprietary, confidential and sensitive information, including personal data (including, key-coded data, health information, data we collect about trial participants in connection with clinical trials and other special categories of personal data), intellectual property, trade secrets, and proprietary business information owned or controlled by ourselves or other parties, and other sensitive third-party data (collectively, &#x201c;Sensitive Information&#x201d;).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may use third-party service providers and subprocessors, including our CROs, to help us operate our business and engage in processing on our behalf in a variety of contexts, . including, without limitation, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email and other functions. We may also share Sensitive Information with our partners or other third parties in connection with our business. Our ability to monitor these third parties&#x2019; cybersecurity practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences.  While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cyberattacks, malicious internet-based activity and online and offline fraud are prevalent and continue to increase. In addition to traditional computer &#x201c;hackers&#x201d;; threat actors; software bugs; malicious code (such as viruses and worms); employee error, theft or misuse; denial-of-service attacks (such as credential stuffing); advanced persistent threat intrusions; natural disasters; terrorism; war; telecommunication and electrical failures; and ransomware attacks, sophisticated nation-state and nation-state supported actors are threats to our information technology assets and data. Ransomware attacks, including those perpetrated by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, loss of data and income, reputational harm and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments. We may also be the subject of server malfunction, software or hardware failures, supply-chain cyberattacks, loss of data or other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">computer assets and other similar issues. Remote and hybrid work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations. Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to data and could disrupt our ability (and that of third parties upon whom we rely) to provide our products or operate our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. While we take steps to detect and remediate vulnerabilities, we may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. These vulnerabilities pose material risks to our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to expend significant resources, fundamentally change our business activities and practices, or modify our operations, including our clinical trial activities, or information technology in an effort to protect against security breaches and to mitigate, detect and remediate actual or potential vulnerabilities. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and Sensitive Information. While we have not experienced any such material system failure or security breach to date, if we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, including interruptions in our operations, which could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our vaccine candidates could be delayed. Furthermore, consequences from an actual or perceived security breach may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause customers to stop using our platform/products/services, deter new customers from using our products, and negatively impact our ability to grow and operate our business.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, applicable data protection requirements, including, without limitation, laws, regulations, guidance as well as our internal and external policies and our contractual obligations, may require us to notify relevant stakeholders of security breaches, including affected individuals, partners, collaborators, regulators, law enforcement agencies, credit reporting agencies and others. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to litigation or other liability, fines, harm to our reputation, significant costs, or other materially adverse effects. There can be no assurance that any limitations or exclusions of liability in our contracts would be enforceable or adequate or protect us from liability or damages.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We cannot be sure that our insurance coverage, if any, will be adequate or otherwise protect us from or adequately mitigate liabilities or damages with respect to claims, costs, expenses, litigation, fines, penalties, business loss, data loss, regulatory actions or other materially adverse impacts arising out of our processing activities, privacy and security practices, or security breaches we may experience. The successful assertion of one or more large claims against use that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large excess or deductible or co-insurance requirements), could result in substantial cost increase or prevent us from obtaining insurance on acceptable terms. Additionally, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, and those of our CMOs, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The impact of climate change may increase these risks due to changes in weather patterns, such as increases in storm intensity, sea-level rise, melting of permafrost and temperature extremes on facilities or operations. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to manufacture our vaccine candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster or other business interruption, including the COVID-19 pandemic. Our corporate headquarters are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Health epidemics, including the effects of the ongoing COVID-19 pandemic, have impacted and could continue to impact our business, including in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Health epidemics could adversely impact our business, including in regions where we have concentrations of potential clinical trial sites or other business operations, and cause significant disruption in the operations of our contract manufacturer and other third parties upon whom we rely. For example, the COVID-19 pandemic has presented a substantial public health and economic challenge around the world and has affected and could continue to affect employees, patients, communities and business operations, as well as the U.S. economy and financial markets. Our headquarters is located in the San Francisco Bay Area, and our contract manufacturer, Lonza, is located in Switzerland. Many geographic regions imposed and in the future may impose, &#x201c;shelter-in-place&#x201d; orders, quarantines or similar orders or restrictions to control the spread of COVID-19. The effects of these orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In connection with these measures, we may be subject to claims based upon, arising out of or related to COVID-19 and our actions and responses thereto, including any determinations that we may make to continue to operate or to re-open our facilities where permitted by applicable law. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, we rely on third parties to supply raw materials and manufacture our preclinical and clinical product supplies of our vaccine candidates, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic. In addition, public health guidelines could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. For example, the COVID-19 pandemic slowed raw material supply chains and travel restrictions delayed the qualification of key analytical equipment used in manufacturing and curtailed in-person CMO oversight of manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some of our suppliers of certain materials used in the production of our vaccine candidates are located in Europe. Any manufacturing supply interruption at Lonza&#x2019;s facilities in Switzerland could adversely affect our ability to produce our vaccine candidates for use in the conduct of our preclinical studies or clinical trials. In any event, if the COVID-19 pandemic continues and persists for an extended period of time or more acutely impacts geographies with particular impact on our business, we could experience significant disruptions to our preclinical and clinical development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our planned clinical trials may be affected by the COVID-19 pandemic. Site initiation and subject enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some subjects may not be able to comply with clinical trial protocols if quarantines impede their movement or interrupt healthcare services. Similarly, our ability to recruit and retain subjects and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may adversely impact our planned clinical trial operations. Additionally, our clinical trial vendors, including testing labs, may experience short interruptions, delays or reductions in capacity as a result of staff exposure to COVID-19, which could adversely affect our timelines for planned clinical operations.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic resulted in significant and prolonged disruption of global financial markets, which may reduce our ability to access capital, which could in the future negatively affect our liquidity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While the ultimate impact of the COVID-19 pandemic on our business is highly uncertain, any negative impacts that materialize could materially adversely affect our clinical development and operations, financial performance and stock price. In addition, to the extent the evolving effects of the COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#x201c;Risk Factors&#x201d; section.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability as a result of the clinical testing of our vaccine candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our vaccine candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our vaccine candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for our vaccine candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">initiation of investigations by regulators; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a diversion of management&#x2019;s time and our resources; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">exhaustion of any available insurance and our capital resources; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any vaccine candidate; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a decline in our share price. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtain clinical trial insurance for our clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violate (i) the laws and regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad and (iv) laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in tax laws or tax rulings could affect our financial position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2017, the Tax Cuts and Jobs Act, or Tax Act, was signed into law. The Tax Act, among other things, contains significant changes to corporate taxation, including (i) changes to the expensing of research and development expenses for tax years beginning after December 31, 2021, (ii) reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, (iii) limitation of the tax deduction for interest expense to 30% of adjusted earnings (with certain exceptions, including for certain small businesses), (iv) limitation of the deduction for post-2017 net operating losses, or NOLs, to 80% of current-year taxable income and elimination of net operating loss carrybacks for post-2017 NOLs, (v) immediate deductions for certain new investments instead of deductions for depreciation expense over time and (vi) modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#x201c;orphan drugs&#x201d;). Effective January 1, 2022, we are also subject to mandatory capitalization of Section 174 research and development expenditures.  The capitalized expenses are subject to amortization over five and fifteen years for expenses incurred within the U.S. and outside of U.S., respectively.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Coronavirus Aid, Relief, and Economic Security, or CARES, Act was signed into law. The CARES Act changed certain provisions of the Tax Act. Under the CARES Act, NOLs arising in taxable years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the CARES Act eliminated the limitation on the deduction of NOLs to 80% of current year taxable income for taxable years beginning before January 1, 2021, and increased the amount of interest</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expense that may be deducted to 50% of adjusted taxable income for taxable years beginning in 2019 or 2020. Notwithstanding the reduction in the corporate income tax, these benefits do not impact our current tax provision.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 21, 2020, the President of the United States signed into law the &#x201c;Consolidated Appropriations Act, 2021,&#x201d; which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program, or PPP, loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable contribution deductions and a temporary full deduction for business expenses for food and beverages provided by a restaurant for tax years 2021 and 2022.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Infrastructure Investment and Jobs Act was signed on November 15, 2021, and it contained several tax provisions including changes to the Employee Retention Tax Credit and changes to excise taxes. These provisions do not have a material impactful to our current tax provision.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the 2017 Tax Act, research and experimental (R&amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;E expenses are required to be amortized over a period of five years for domestic expenses and 15 years for foreign expenses. We have capitalized research and experimental expenditures in our current tax provision as a result.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax (&#34;CAMT&#34;) on adjusted financial statement income on applicable corporations for taxable years beginning after December 31, 2022. There is no impact to our current tax provision.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The American Rescue Plan Act was signed on March 11, 2021.  One of the provisions of the Act included expanding the definition of covered employees subject to IRC 162(m) to include an additional top five highest compensated officers beyond the CEO, CFO, and three highest paid employees currently covered under IRC 162(m). This expanded provision is applicable for tax years beginning after Dec 31, 2026. The Company does not believe that this update to IRC 162(m) would have a material impact on its income tax provision currently and will continue to monitor this.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are unable to predict what tax changes may be enacted in the future or what effect such changes would have on our business, but such changes could affect our effective tax rate and could have an adverse effect on our overall tax position in the future, along with increasing the complexity, burden, and cost of tax compliance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred substantial losses since inception and do not expect to become profitable in the near future, if ever. As of December 31, 2022, we had federal and state NOL carryforwards of $340.2 million and $453.1 million, respectively. The federal and state loss carryforwards, except the federal loss carryforward arising in tax years beginning after December 31, 2017, begin to expire in 2034 unless previously utilized. Federal NOLs arising in tax years beginning after December 31, 2017 have an indefinite carryforward period and do not expire. As of December 31, 2022, we also had federal and state research credit carryforwards of $4.4 million and $2.8 million, respectively. The federal research and development tax credit carryforwards expire beginning in 2039 unless previously utilized, and the state research and development tax credits can be carried forward indefinitely. In general, under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, a corporation that undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period) is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We have experienced ownership changes in the past. There were no ownership changes identified in 2022, as such we have determined that no federal research credits will expire unutilized or are excluded from our research carryforwards as of December 31, 2022. We do not expect any ownership changes during the year ended December 31, 2022 to result in a limitation that would materially reduce the total amount of net operating loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years. As a result, if, and to the extent that we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we intend to maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any vaccine candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely and will continue to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently do not have the ability to independently conduct preclinical or clinical studies that comply with the regulatory requirements known as good laboratory practices and GCP. The FDA and regulatory authorities in other jurisdictions require us to comply with GCP requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners, to conduct our preclinical and clinical trials under agreements with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will need to negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for vaccine candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test subjects. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of subjects may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any third parties conducting our preclinical studies and clinical trials will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our vaccine candidates. As a result, our financial results and the commercial prospects for our vaccine candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our relationships with trial sites or any CRO that we may use in the future terminate, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties, including Sutro Biopharma and Lonza, to supply raw materials and manufacture our preclinical and clinical product supplies of our vaccine candidates, and expect to rely on third parties to supply raw materials and produce and process our vaccine candidates, if approved. The loss of these suppliers or their failure to comply with applicable regulatory requirements or provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not have the infrastructure or capability internally to manufacture supplies for our vaccine candidates or the materials necessary to produce our vaccine candidates for use in the conduct of our preclinical studies or clinical trials, and we lack the internal resources and the capability to manufacture any of our vaccine candidates on a preclinical, clinical or commercial scale. We have entered into an agreement with Sutro Biopharma to supply us with extract and custom reagents for use in manufacturing non-clinical and certain clinical supply of vaccine compositions. Pursuant to the Option Agreement, we also acquired, among other things, a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract (including the right to make improvements to the extract manufacturing process as well as cell lines) for use in connection with the exploitation of certain vaccine compositions, or the Option. The Option period is five years from the date of the agreement, and we have not yet exercised the Option and we may never exercise the Option. We have engaged Lonza to perform manufacturing process development and clinical manufacture and supply of components for VAX-24, including the manufacture of polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances. We also engaged Lonza to perform manufacturing process development and clinical manufacture and supply of VAX-24 finished drug product. Our agreements with Lonza are denominated in Swiss Francs. Fluctuations in the exchange rate for Swiss Francs may increase our costs and affect our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza is currently in the process of manufacturing our vaccine candidates on a clinical scale. We have not yet caused our vaccine candidates to be manufactured on a commercial scale and may not be able to achieve commercial scale manufacturing and may be unable to create an inventory of mass-produced product to satisfy demands for any of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our vaccine candidates, and the actual cost to manufacture and process our vaccine candidates could materially and adversely affect the commercial viability of our vaccine candidates. As a result, we may never be able to develop a commercially viable product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our anticipated reliance on a limited number of third-party suppliers and manufacturers exposes us to the following risks:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our third-party suppliers and manufacturers might be unable to timely formulate and manufacture or supply raw materials for our vaccine candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#x2019; compliance with these regulations and standards. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our third-party suppliers and manufacturers could breach or terminate their agreement with us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of these risks could delay our clinical trials, the approval, if any, of our vaccine candidates by the FDA or the commercialization of our vaccine candidates, or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our vaccine candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that we and our suppliers&#x2019; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business prospects, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products, including biologics such as conjugate vaccines, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We expect that our vaccine candidates will be regulated by the FDA as biologics. We are not permitted to market any biological drug product in the United States until we receive approval of a Biologics License Application, or BLA, from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign regulatory authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the vaccine candidate&#x2019;s safety and effectiveness for each desired indication. Further, because our vaccine candidates that are subject to regulation as biological drug products, we will need to demonstrate that they are safe, pure and potent for use in their target indications. The BLA must also include significant information regarding the CMC for the product, including with respect to chain of identity and chain of custody of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies of our vaccine candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our vaccine candidates may not be predictive of the results of later-stage clinical trials. The results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of clinical trials in one set of patients or indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same vaccine candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Vaccine candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most vaccine candidates that begin clinical trials are never approved by regulatory authorities for commercialization. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit a BLA or other marketing application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining regulatory authorization to begin a trial, if applicable; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of financial resources to commence and complete the planned trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtaining approval at each clinical trial site by an independent IRB; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recruiting suitable volunteers to participate in and complete a trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical trial sites deviating from trial protocol or dropping out of a trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addressing any safety concerns that arise during the course of a trial; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">adding new clinical trial sites; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturing sufficient quantities of qualified materials under cGMPs and applying them for use in clinical trials. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our vaccine candidates in lieu of using existing vaccines that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a vaccine candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial or based on a recommendation by the data safety monitoring board. If we experience termination of, or delays in the completion of, any clinical trial of our vaccine candidates, the commercial prospects for our vaccine candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The FDA may disagree with our regulatory plan, and we may fail to obtain regulatory approval of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two Phase 3 clinical trials of the relevant biologic or drug in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and are time consuming. While</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have not had extensive discussions with the FDA regarding our regulatory plan, as a prerequisite for FDA approval, we believe that any new PCV, such as VAX-24, will have to be compared to the current standard of care, PCV13 and PCV15 in infants and PCV20 in adults. We believe that a successful comparison for an adult study would be based on demonstrating clinical non-inferiority of the immune response to PCV20 for common serotypes. In addition, we expect to use OPA titers as the primary immunogenicity surrogate endpoint for the VAX-24 program in adults because PCV13 was approved based on the establishment of non-inferiority of OPA responses relative to PPSV23, on a strain-by-strain basis. On October 24, 2022, we announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy adults aged 18-64. In this study, VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to PCV20for all doses studied. In this study, VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2mcg dose, which we intend to move forward into a Phase 3 program. At this dose, VAX-24 met the standard OPA response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses. Additionally, at all three doses, VAX-24 met the standard superiority criteria for all four serotypes unique to VAX-24. VAX-24 has the potential to cover an additional 10-28 percent of strains causing IPD in adults over the current standard-of-care PCVs. We believe these topline results support clinical non-inferiority to PCV20, but there can be no assurance that this approach in pivotal studies will be sufficient for regulatory approval or that regulators will not require field efficacy trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek Accelerated Approval from the FDA for our vaccine candidates and, if granted, the FDA may require us to perform post-marketing studies as a condition of approval to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint. If the results from such post-marketing studies are not positive or otherwise fail to show the predicted effect, the drug or biologic may be subject to expedited withdrawal procedures by the FDA. In addition, the standard of care may change with the approval of new products in the same disease areas that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our vaccine candidate is non-inferior or superior to the new products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical trial results may also not support approval. In addition, our vaccine candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our vaccine candidates are safe and effective; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be unable to demonstrate that our vaccine candidates&#x2019; clinical and other benefits outweigh their safety risks; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any changes to the required threshold for the achievement of non-inferiority using established surrogate immune endpoints that our PCVs will need to meet in our clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any vaccine to be approved in pediatric populations may need to undergo extensive vaccine-vaccine interference studies with the standard of care pediatric vaccine regimen; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the need to perform superiority or field efficacy trials, which can be larger, longer and more costly, if an existing vaccine is approved for a disease indication; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the data collected from clinical trials of our vaccine candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the FDA or comparable foreign regulatory authorities will inspect the commercial manufacturing facilities we may utilize and may not approve such facilities; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of our vaccine candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any regulatory approvals that we receive for our vaccine candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including post-marketing clinical trials, and surveillance to monitor the safety and efficacy of the vaccine candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if the FDA or a comparable foreign regulatory authority approves our vaccine candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, conduct of post-marketing studies, storage, sampling, advertising, promotion, import, export and recordkeeping for our vaccine candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration and continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved uses (known as &#x201c;off-label use&#x201d;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with our vaccine candidates, including side effects of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of our vaccine candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of regulatory approvals; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal to permit the import or export of our vaccine candidates; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our vaccine candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#x2019;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#x2019;s ability to exercise its regulatory authority.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If these executive actions impose restrictions on the FDA&#x2019;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We expect the vaccine candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, ACA, to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#x201c;interchangeable&#x201d; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until twelve years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that any of the vaccine candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject vaccine candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our relationships with customers, physicians and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, health information privacy and security laws and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers, including physicians and third-party payors, in the United States and elsewhere will play a primary role in the recommendation and prescription of any vaccine candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our vaccine candidates, if approved. Such laws include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. federal civil and criminal false claims laws, including the civil False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalties laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by engaging in impermissible marketing practices, such as the off-label promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which also impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy and security of individually identifiable health information of covered entities subject to the rule, including health plans, healthcare clearinghouses and certain healthcare providers and their business associates, independent contractors of a covered entity that perform certain services involving the use or disclosure of individually identifiable health information for or on their behalf, as well as their covered subcontractors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Federal Food Drug or Cosmetic Act, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as information regarding ownership and investment interests held by the physicians described above and their immediate family members; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which require tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laws governing the privacy and security of certain protected information, such as the EU GDPR, and the CCPA, which impose obligations and restrictions on the collection, use and disclosure of personal data (including health data) relating to individuals located in the European Economic Area, or EEA, and California, respectively. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to other laws, such as the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibit, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof, as well as federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, injunctions, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace. In addition, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and reimbursement may be limited or unavailable in certain market segments for our vaccine candidates, which could make it difficult for us to sell our vaccine candidates, if approved, profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Successful sales of our vaccine candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any vaccine candidates for which we obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patients who receive vaccines generally rely on third-party payors to reimburse all or part of the associated costs. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#x2019;s determination that use of a product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our vaccine candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our vaccine candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for administering the product. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from third-party payors and reduce the willingness of physicians to use our vaccine candidates. Certain ACA marketplace and other private payor plans are required to include coverage for certain preventative services, including vaccinations recommended by the ACIP without cost share obligations (i.e., co-payments, deductibles or co-insurance) for plan members. Children through 18 years of age without other health insurance coverage may be eligible to receive such vaccinations free-of-charge through the CDC&#x2019;s Vaccines for Children Program, or VFC. For Medicare beneficiaries, vaccines may be covered under either the Part B program or Part D depending on several criteria, including the type of vaccine and the beneficiary&#x2019;s coverage eligibility. If our vaccine candidates, once approved, are covered only under the Part D program, physicians may be less willing to use our products because of the claims adjudication costs and time related to the claims adjudication process and collection of co-payments associated with the Part D program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We intend to seek approval to market our vaccine candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our vaccine candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a vaccine candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular vaccine candidate to currently available vaccines. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The marketability of any vaccine candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of vaccine candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any vaccine candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private payors in the United States. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part D; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">extension of a manufacturer&#x2019;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a requirement that certain ACA marketplace and other private payor plans include coverage for preventative services, including vaccinations recommended by the ACIP without cost share obligations (i.e., co-payments, deductibles or co-insurance) for plan members; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been executive, judicial and Congressional challenges to the ACA. For example, the Tax Act included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the &#x201c;individual mandate.&#x201d; On June 17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Moreover, prior to the United States Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#x201c;donut hole&#x201d; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how additional healthcare reform measures of the Biden administration will impact the ACA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the BBA and the Infrastructure Investment and Jobs Act, will remain in effect until 2031 unless additional Congressional action is taken. COVID-19 pandemic relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under the current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which ended the use of the statutory formula for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, the full impact of the introduction of the Medicare quality payment program on overall physician reimbursement remains unclear. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, in the United States there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug and biological product pricing, reduce the cost of prescription drugs and biological products under government payor programs and review the relationship between pricing and manufacturer patient programs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Further, the IRA will, among other things, (i) allow HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law, and (ii) impose rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. However, the IRA does not change either the VFC or the provisions added in 2010 under the ACA. VFC was established to give first-dollar coverage to children up to 18 years of age whose families could not pay for vaccinations while the ACA guaranteed coverage of vaccines without cost sharing for Americans who are either privately insured or newly covered in states that expanded Medicaid. The IRA did help with vaccine access by eliminating cost sharing for adult vaccines covered under Medicare Part D and mandating that all state Medicaid programs cover many adult vaccines and their administration without cost sharing. Further, many vaccines are excluded from Medicare Part B rebate requirements. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. The Biden administration also released an additional executive order on</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 14, 2022, directing HHS to submit a report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. No legislation or administrative actions have been finalized to implement these principles. It is unclear whether these this executive order or similar policy initiatives will be implemented in the future. It is unclear whether these or similar policy initiatives will be implemented in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs, biological products and suppliers will be included in their healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our current or any future vaccine candidates or additional pricing pressures. Further, it is possible that additional governmental action is taken in response to the ongoing COVID-19 pandemic. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing or new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future vaccine candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, which could have an adverse effect on demand for our vaccine candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in response to the global COVID-19 pandemic, the FDA has adopted a risk-based system for the conduct of inspections of manufacturing facilities. Additionally, the FDA is conducting voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. Regulatory authorities outside the United States have adopted similar restrictions and policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to increasingly stringent and rapidly changing U.S. and foreign laws, regulations, rules and other obligations related to privacy and data security. The restrictions and costs imposed by these requirements, or our actual or perceived failure to comply with them, could harm our reputation, subject us to significant fines and liability, and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, we process personal data and other Sensitive Information. We are subject to or affected by numerous evolving federal, state and foreign laws and regulations, as well as policies, contracts and other obligations governing the collection, use, disclosure, retention, and security of personal data. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, HIPAA, as amended by HITECH, imposes requirements relating to the privacy and security of individually identifiable health information on health plans, healthcare clearinghouses and certain healthcare providers, and their respective contractors and their covered subcontractors that perform services for them involving individually identifiable health information. Additionally, certain states have adopted healthcare privacy and security laws and regulations comparable to HIPAA, some of which may be more stringent than HIPAA. In the event we fail to properly maintain the privacy and security of individually identifiable health information governed by HIPAA or comparable state laws, or we are responsible for an unauthorized disclosure or security breach of such information, we could be subject to enforcement action under HIPAA or comparable state laws, and significant civil and criminal penalties, and fines.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Domestic privacy and data security laws beyond HIPAA and other healthcare privacy laws are also changing rapidly and becoming more complex. For example, the CCPA imposes obligations on businesses to which it applies. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal data. The CCPA allows for administrative fines for noncompliance (up to $7,500 per violation). In addition, the CPRA expanded the CCPA&#x2019;s requirements, including by adding a new right of individuals to correct their personal data and establishing a new California Privacy Protection Agency to implement and enforce the CCPA. Other states have enacted data privacy laws that become operative in 2023, such as Virginia and Colorado, and other local, state, and federal laws are under consideration. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely. If we become subject to new data privacy laws, at the state level, the risk of enforcement action against us could increase because we may become subject to additional obligations, and the number of individuals or entities that can initiate actions against us may increase (including individuals, via a private right of action, and state actors).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also become subject to a growing body of privacy, data security and data protection laws outside of the United States as we expand our business and clinical trial activities. For example, the EU GDPR and the UK GDPR impose strict requirements for processing the personal data of individuals located, respectively within the EEA and the United Kingdom. Under the EU GDPR, government regulators may impose temporary or definitive bans on data processing, as well as fines of up to 20 million euros or 4% of annual global revenue, whichever is greater. Further, individuals or consumer protection organizations may initiate litigation related to our processing of their personal data.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, many jurisdictions have enacted data localization laws and cross-border personal data transfer laws. These laws may make it more difficult for us to transfer personal data across jurisdictions, which could impede our business. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the EEA, such as the United States, which the European Commission does not consider to be providing an adequate level of data privacy and security. The European Commission released a set of &#x201c;Standard Contractual Clauses&#x201d; that are designed to be a valid mechanism by which entities can transfer personal data out of the EEA to jurisdictions that the European Commission has not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">found to provide an adequate level of protection. Currently, these Standard Contractual clauses are a valid mechanism to transfer personal data outside of the EEA, but are subject to legal challenges. Due to these legal challenges, there exists some uncertainty regarding whether the Standard Contractual Clauses will remain a valid mechanism for transfers of personal data out of the EEA. In addition, laws in Switzerland and the UK similarly restrict transfers of personal data outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. If we need but cannot implement a valid compliance mechanism for cross-border privacy and security transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or elsewhere. The inability to import personal data to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties that are subject to European and other data privacy and security laws; or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. In addition, these obligations may require us to change our business model. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to operate our business and proceedings against us by governmental entities or others. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal data; orders to destroy or not use personal data; and imprisonment of company officials. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our vaccine development programs and vaccine candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to VAX-24 and any future vaccine candidates, as well as methods of making our vaccine candidates and components thereof. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our development programs and vaccine candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents and patent applications that we own or in-license may fail to result in issued patents with claims that protect VAX-24 or any future vaccine candidate in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover VAX-24 or any future vaccine candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any vaccine candidates or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a vaccine candidate under patent protection could be reduced.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the patent applications we hold or have in-licensed with respect to our development programs and vaccine candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for VAX-24 or any future vaccine candidate, it could dissuade companies from collaborating with us to develop vaccine candidates and threaten our ability to commercialize future vaccines. Any such outcome could have a materially adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has been and will continue to be the subject of litigation and new legislation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, many countries restrict the patentability of methods of treatment of the human body. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or the USPTO, or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension), or both. The scope of patent protection may also be limited. Without patent protection for our current or future vaccine candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new vaccine candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have licensed certain intellectual property rights related to the XpressCF platform, components of our PCV candidates, and methods of making components of VAX-24 from Sutro Biopharma and University of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Georgia Research Foundation, Inc. We also license certain intellectual property rights related to a non-cross-reactive Group A Strep carbohydrate antigen and related methods of production from the Regents of the University of California. If, for any reason, these agreements are terminated or we otherwise lose those rights, it could adversely affect our business. These agreements impose, and any future collaboration agreements or license agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor(s) may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering VAX-24 or any future vaccine candidate, or the XpressCF platform, our competitors might be able to enter the market, which would have an adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development and commercialization of VAX-24 and any future vaccine candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter partes review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous U.S. and foreign-issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing vaccine candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our vaccine candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Also, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our vaccine candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our vaccine candidates may infringe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, third parties may obtain patent rights in the future and claim that use of our technologies infringes upon these rights. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our vaccine candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such vaccine candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable vaccine candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our vaccine candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, as the vaccine patent landscape is crowded and highly competitive, even in the absence of litigation we may need to obtain licenses from third parties to advance our research or allow commercialization of our vaccine candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our vaccine candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against vaccine candidates resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter-claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement, written description, or lack of patentable subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future vaccine candidates. Such a loss of patent protection could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system takes effect June 1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court, or the UPC. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to rely on trademarks as one means to distinguish any of our vaccine candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our vaccine candidates and have not yet begun the process of applying to register trademarks for our current or any future vaccine candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, any proprietary name we propose to use with our current or any other vaccine candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents covering our current vaccine candidates and any future vaccine candidate throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Eurasian patent applications. Recent Russian decrees may also significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because we expect to rely on third parties to manufacture VAX-24 and any future vaccine candidates, and we expect to collaborate with third parties on the development of VAX-24 and any future vaccine candidates, we must, at times, share trade secrets with them. We also conduct joint research and development that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Further, disputes may arise under these agreements regarding inventorship or ownership of proprietary information generated during research and development.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#x2019;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#x2019; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The price of our stock may be volatile, and the value of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In particular, the COVID-19 pandemic has further heightened the volatility of the stock market for biopharmaceutical companies. In addition to the factors discussed in this &#x201c;Risk Factors&#x201d; section and elsewhere in this Annual Report on Form 10-K, these factors include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the commencement, enrollment or results of our planned or future preclinical studies or clinical trials of our vaccine candidates and those of our competitors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">regulatory or legal developments in the United States and abroad; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the success of competitive vaccines or technologies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of expenses related to our vaccine candidates or preclinical and clinical development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the results of our efforts to develop additional vaccine candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations or reports by securities analysts; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of expenses and capital investment related to manufacturing our vaccine candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our inability to obtain or delays in obtaining adequate supply for any approved vaccine candidate; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">variations in our financial results or those of companies perceived to be similar to us; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the structure of healthcare payment systems, including coverage and adequate reimbursement for any approved vaccine; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">general economic, political and market conditions, including higher inflation rates, changes in interest rates and the Russia-Ukraine war, and overall fluctuations in the financial markets in the United States and abroad; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">investors&#x2019; general perception of us and our business. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the stock market in general, and the Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources, which would harm our business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our executive officers, directors and principal stockholders beneficially own a significant portion of our common stock. Accordingly, these stockholders have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to significantly affect the outcome of elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">As a public company, we are subject to more stringent federal and state law requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Stock Market LLC, or Nasdaq, and other applicable securities rules and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sarbanes-Oxley as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of Sarbanes-Oxley, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and regulations in these areas, such as mandatory &#x2018;&#x2018;say on pay&#x2019;&#x2019; voting requirements. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. Compliance with the various reporting and other requirements applicable to public companies requires considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If we are unable to comply with these requirements on a timely basis or if the attention of our management and personnel is diverted from other business concerns, it could have a material adverse effect on our business, financial condition and results of operations. The increased costs will increase our net loss or decrease our net income, and may require us to reduce costs in other areas of our business. In addition, as we expand, it may be more difficult or more costly for us to obtain certain types of insurance, including directors&#x2019; and officers&#x2019; liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified personnel to serve on our board of directors, our board committees or as executive officers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also subject to more stringent state law requirements. Compliance costs and penalties or other adverse impacts as a result of non-compliance (including reputational impacts) may adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expectations relating to environmental, social and governance programs may impose additional costs and expose us to new risks.</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is an increasing focus from certain investors and other key stakeholders concerning corporate responsibility, specifically related to environmental, social and governance, or &#x201c;ESG,&#x201d; factors. As a result, there is an increased emphasis on corporate responsibility ratings and a number of third parties provide reports on companies in order to measure and assess corporate responsibility performance. In addition, the ESG factors by which companies&#x2019; corporate responsibility practices are assessed may change, which could result in greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. Alternatively, if we are unable to satisfy such new criteria, investors may conclude that our policies with respect to corporate responsibility are inadequate. We risk damage to our brand and reputation if our corporate responsibility procedures or standards do not meet the standards set by various constituencies. We may be required to make investments in matters related to ESG, which could be significant and adversely impact our results of operations. Furthermore, if our competitors&#x2019;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">corporate responsibility performance is perceived to be greater than ours, potential or current investors may elect to invest with our competitors instead. In addition, if we communicate certain initiatives and goals regarding ESG matters, we could fail, or be perceived to fail, in our achievement of such initiatives or goals, or we could be criticized for the scope of such initiatives or goals. If we fail to satisfy the expectations of investors and other key stakeholders or our initiatives are not executed as planned, our reputation and financial results could be materially and adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future sales of a substantial number of shares of our common stock, or the perception that such sales could occur, could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the public&#x2019;s perception that such sales could occur, could have an adverse effect on the market price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish a classified board of directors such that not all members of the board are elected at one time; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limit the manner in which stockholders can remove directors from the board; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">prohibit our stockholders from calling a special meeting of our stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called &#x201c;poison pill,&#x201d; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require the approval of the holders of at least 66 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2044;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case, to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any breach of the director&#x2019;s duty of loyalty to the corporation or its stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any transaction from which the director derived an improper personal benefit. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated bylaws provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and agents. Our amended and restated bylaws also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors and executive officers. With certain exceptions, these agreements provide for indemnification for related expenses, including attorneys&#x2019; fees, judgments, fines and settlement amounts incurred by any of these individuals in connection with any action, proceeding or investigation. We believe that these amended and restated certificate of incorporation and amended and restated bylaws provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we maintain directors&#x2019; and officers&#x2019; liability insurance, such insurance may not be adequate to cover all liabilities that we may incur, which may reduce our available funds to satisfy third-party claims and may adversely impact our cash position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will, to the fullest extent permitted by applicable law, be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware), to the fullest extent permitted by applicable law, is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding asserting a claim against us by any of our directors, officers or other employees governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may seek additional capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements, including through the use of our &#x201c;at-the-market&#x201d; facility. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or vaccine candidates, or grant licenses on terms unfavorable to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including as a result worsening global economic conditions, including higher inflation rates and changes in interest rates, and the COVID-19 pandemic and civil and political unrest in certain countries and regions. Such volatility and disruptions have caused and may continue to cause severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, including higher inflation rates and changes in interest rates, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">An active trading market for our common stock may never develop or be sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock is currently listed on the Nasdaq Global Select Market under the symbol &#x201c;PCVX.&#x201d; However, we cannot assure you that an active trading market for our shares will develop or be sustained. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we will incur significant legal, accounting, investor relations and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Stockholder activism, the current political environment and the current high level of U.S. government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may in turn lead to additional compliance costs and impact the manner in which we operate our business in ways we do not currently anticipate. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by management related to the internal control over financial reporting in our Form 10-K for the year ended December 31, 2022 and we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the Sarbanes-Oxley Act, the requirements of being a reporting company under the Exchange Act and any complex accounting rules in the future, we may need to upgrade our information technology systems, implement additional financial and management controls, reporting systems and procedures, and hire additional accounting and finance staff. We are currently in the process of hiring additional accounting and finance staff as we grow our business. If we are unable to hire the additional accounting and finance staff necessary to comply with these requirements, we may need to retain additional outside consultants. If we or, if required, our auditors, are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There can be no assurance that there will not be material weaknesses in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accounting firm determines that we have a material weakness in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board, the SEC and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations and may require us to make costly changes to our operational processes and accounting systems.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. We do not have control over these analysts. If securities or industry analysts do not publish research or reports about our business, the trading price for our stock would likely be negatively impacted. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolve</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters is located at 825 Industrial Road, Suite 300, San Carlos, California 94070, where we lease and occupy 77,734 square feet of laboratory and office space. Our lease for our San Carlos headquarters expires on December 31, 2025. We use our corporate headquarters primarily for corporate research, development, regulatory, manufacturing and quality functions. We believe that our existing facilities are adequate to meet our current needs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined unfavorably to us, would have a material adverse effect on our business, financial condition, operating results or cash flows. Regardless of the outcome, litigation can, among other things, be time consuming and expensive to resolve and divert management resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Safe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information for Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock commenced trading on the Nasdaq Global Select Market under the symbol &#x201c;PCVX&#x201d; on June 12, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 23, 2023, there were approximately 14 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not declared or paid any cash dividend on our common stock. We intend to retain any future earnings and do not expect to pay cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Performance Graph</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This performance graph shall not be deemed &#x201c;soliciting material&#x201d; or to be &#x201c;filed&#x201d; with the SEC for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act, except to the extent that we specifically incorporate this information by reference therein, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following stock performance graph compares our cumulative total stock return relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index for the period from June 12, 2020 (the date our common stock commenced trading on the Nasdaq Global Select Market) through December 31, 2022. The figures below assume an investment of $100 in our common stock at the closing price of $26.15 on June 12, 2020, the date of our IPO, and in each index on the same date and the reinvestment of the full amount of all dividends into shares of common stock; however, no dividends have been declared on our common</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stock to date. The stockholder returns shown on the graph below are based on historical results and are not indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img70551829_23.jpg" alt="img70551829_23.jpg" style="width:624px;height:325px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unregistered Sales of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 19, 2022, we entered into an option grant agreement, or the Option Agreement, with Sutro Biopharma, Inc., or Sutro Biopharma.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we agreed to pay Sutro upfront consideration of $22.5 million, consisting of (i) $10.0 million in cash and $7.5 million in shares of our common stock (the number of shares to be calculated based on the arithmetic average of the daily volume weighted average price of our common stock as traded on Nasdaq (as reported by Bloomberg L.P., or if not reported therein, in another authoritative source mutually selected by the Parties) in the three consecutive trading days immediately prior to the issuance thereof).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 22, 2022, we issued 167,780 shares of our common stock to Sutro Biopharma as partial consideration under the Option Agreement, which were not initially registered under the Securities Act of 1933, as amended, or the Securities Act, and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506 of Regulation D thereunder. Pursuant to the Option Agreement, we subsequently filed a resale registration statement on December 22, 2022, covering the shares of our common stock issued. <br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds from our Initial Public Offering of Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, we closed our IPO of 17,968,750 shares of our common stock, including shares issued upon the exercise in full of the underwriters&#x2019; option to purchase 2,343,750 additional shares of common stock, at a public offering price of $16.00 per share. We received gross proceeds to us of $287.5 million. All of the shares issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-238630), which was declared effective by the SEC on June 11, 2020. BofA Securities, Inc., Jefferies LLC and Evercore Group L.L.C. acted as joint book-running managers for the offering. Cantor Fitzgerald &amp; Co. and Needham &amp; Company, LLC acted as co-managers for the offering. Shares of our common stock began trading on</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Nasdaq Global Select Market on June 12, 2020 and, following the sale of all the shares upon the closing of the IPO, the offer terminated. The net proceeds to us, after deducting underwriting discounts and commissions of $20.1 million and net offering expenses of $3.4 million, were $264.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There has been no material change in the planned use of proceeds from our IPO from those disclosed in the prospectus for our IPO dated as of June 11, 2020 and filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on June 15, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. </span><span id="item_6_selected_financial_data"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes and other financial information included elsewhere in this Annual Report on Form 10-K. This discussion and analysis contains forward-looking statements based upon our current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report on Form 10-K. You should carefully read the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled &#x201c;Special Note Regarding Forward-Looking Statements.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc., or Sutro Biopharma. Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pipeline includes:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pneumococcal conjugate vaccine, or PCV, candidates that we believe are among the most broad-spectrum PCV candidates currently in development, targeting the approximately $7 billion global pneumococcal vaccine market. Pneumococcal disease is an infection caused by Streptococcus pneumoniae, or pneumococcus, bacteria. It can result in invasive pneumococcal disease, or IPD, including meningitis and bacteremia, and non-invasive pneumococcal disease, including pneumonia, otitis media and sinusitis. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of IPD. VAX-24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults by covering the serotypes that are responsible for most of the pneumococcal disease currently in circulation. </span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-24 Adult Program: On October 24, 2022, we announced positive topline results from both the Phase 1 and Phase 2 portions of a clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24 in 800 healthy adults aged 18-64. The Phase 1 portion of the study evaluated the safety and tolerability of a single injection of VAX-24 at three dose levels, 1.1mcg, 2.2mcg and 2.2mcg/4.4mcg, and compared to PCV20 in 64 healthy adults 18-49 years of age. The Phase 2 portion evaluated the safety, tolerability and immunogenicity of a single injection of VAX-24 at the same three dose levels and compared to a single injection of Prevnar 20&#153;, or PCV20, in 771 healthy adults 50-64 years of age. In this study, VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to PCV20, for all doses studied. In this study, VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2mcg dose, which we intend to move forward into a Phase 3 program. At this dose, VAX-24 met the standard opsonophagocytic activity, or OPA, response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses. Additionally, at all three doses, VAX-24 met the standard superiority criteria for all four serotypes unique to VAX-24. VAX-24 has the potential to cover an additional 10-28 percent of strains causing IPD in adults over the current standard-of-care PCVs. We have a separate Phase 2 study in approximately 200 healthy adults aged 65 and older for which we have completed enrollment, and we anticipate announcing topline safety, tolerability and immunogenicity results from this </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:13.593%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">study in the second quarter of 2023. We anticipate final results with the six-month safety data from both Phase 2 adult studies in the first half of 2023 and expect to hold regulatory interactions with the U.S. Food and Drug Administration, or FDA, in the second half of 2023 to inform the Phase 3 program. We expect topline safety, tolerability and immunogenicity data from the Phase 3 pivotal, non-inferiority study in adults in 2025. The FDA has granted Fast Track and Breakthrough Therapy designations for VAX-24 in adults.</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">&#x25aa;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-24 Pediatric Program: For our VAX-24 pediatric program, in late February 2023, we announced that the FDA cleared the infant investigational new drug, or IND, application for the prevention of IPD in infants. We plan to initiate an infant Phase 2 study in the second quarter of 2023. We expect topline safety, tolerability and immunogenicity data from the infant Phase 2 study primary three-dose immunization series by 2025. The study design will include a primary immunization series consisting of three doses followed by a subsequent booster dose.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our second PCV candidate, VAX-31 (formerly VAX-XP), builds on what has been established with VAX-24 and is designed to expand the breadth of coverage to 31 strains without compromising immunogenicity due to carrier suppression. VAX-31 was designed to provide coverage for approximately 95% of IPD currently circulating in the U.S. population. We anticipate submitting an IND application to the FDA for VAX-31 in adults in the second half of 2023. We expect topline safety, tolerability and immunogenicity data from a Phase 1/2 study in adults in 2024. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus, or Group A Strep. Group A Strep is pervasive globally and causes 700 million cases of illness annually, including pharyngitis, or strep throat, and certain severe invasive infections such as sepsis, necrotizing fasciitis and toxic shock syndrome. There is currently no vaccine against Group A Strep, which is one of the leading infectious disease-related causes of death and disability worldwide and a significant contributor to the prescription of antibiotics in the very young. We believe we have demonstrated preclinical proof of concept for VAX-A1, the data for which were published in December 2020. We nominated the final vaccine candidate for VAX-A1 in the first quarter of 2021 and initiated IND-enabling activities in the second half of 2021. We continue to advance the development of VAX-A1 and we intend to provide further information about the anticipated timing of an IND application will be provided as the program progresses.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis, a chronic oral inflammatory disease affecting an estimated 65 million adults in the United States. We believe we have generally demonstrated preclinical proof of concept for a periodontitis protein vaccine, the data for which was published in February 2019. We nominated a final vaccine candidate for VAX-PG in the fourth quarter of 2022 and we continue to progress the program. Our initial goal is to develop a therapeutic vaccine to slow or stop disease progression; however, the results from clinical trials may inform the potential adoption of prophylactic immunization. </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAX-GI, a new vaccine program designed to prevent Shigella, a bacterial illness that affects an estimated 188 million people worldwide each year and results in approximately 164,000 deaths annually, mostly among children under five years of age in low- and middle-income settings.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have other discovery-stage programs that leverage our cell-free protein synthesis platform, which, if proven successful in preclinical studies, could also be advanced into IND-enabling activities and clinical studies. <br /><br />Since January 1, 2022, key developments affecting our business include the following:</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Dosed First Participants in both the Phase 1 and Phase 2 Portions of VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In February 2022, we announced that the first participants were dosed in the Phase 1 portion of the VAX-24 Phase 1/2 clinical study. This was followed by an announcement in April 2022 that the first participants had been dosed in the Phase 2 portion of this study. The initiation of the Phase 2 portion occurred after an independent Data </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Monitoring Committee completed a prespecified review of initial Phase 1 safety and tolerability data and recommended that the study progress as planned.</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The VAX-24 Phase 1/2 clinical proof-of-concept study was a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults (NCT05266456).</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 1 portion of the study evaluated the safety and tolerability of a single injection of VAX-24 at three dose levels and compared to Prevnar 20 in 64 healthy adults 18 to 49 years of age. </span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 2 portion evaluated the safety, tolerability and immunogenicity of a single injection of VAX-24 at three dose levels and compared to Prevnar 20 in 771 healthy adults 50 to 64 years of age. The prespecified immunogenicity endpoints of the Phase 2 portion of the study included an assessment of the induction of antibody responses, using opsonophagocytic activity, or OPA, and immunoglobulin G, or IgG, at each of the three VAX-24 doses and compared to Prevnar 20&#153; and, for the additional four serotypes contained in VAX-24 and Pneumovax</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 23, but not in Prevnar 20&#153;, the percentage of subjects that experienced a four-fold rise in antibody titers.</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Participants in the study were evaluated for safety through six months after vaccination.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Successful $115 Million Follow-On Financing: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, we completed an underwritten public offering of 3,250,000 shares of our common stock, which included the full exercise of the underwriters&#x2019; option to purchase additional shares, and pre-funded warrants to purchase 2,500,000 shares of common stock. The aggregate gross proceeds to us from the offering were $115.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by us, and excluding the exercise of any pre-funded warrants.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Enrollment of Phase 2 Portion of VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: In July 2022, we announced the completion of enrollment in the Phase 2 portion of the Phase 1/2 clinical proof-of-concept study. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initiated Separate VAX-24 Phase 2 Clinical Study in Adults 65 Years and Older: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, we announced that we dosed the first participants in a separate Phase 2 study in adults 65 years of age and older. This study is intended to further build the body of clinical evidence to support the potential of VAX-24 as the broadest-spectrum PCV in adults.</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This VAX-24 Phase 2 clinical study (VAX-24 Study 102, NCT05297578) is a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in approximately 200 healthy adults 65 years of age and older.</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The study is evaluating the safety, tolerability and immunogenicity of a single injection of VAX-24 at three dose levels and compared to a single injection of Prevnar 20&#153;. The prespecified immunogenicity endpoints of the study include an assessment of the induction of antibody responses, using OPA and IgG, at each of the three VAX-24 doses and compared to Prevnar 20&#153; and, for the additional four serotypes contained in VAX-24 and Pneumovax</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> 23, but not in Prevnar 20&#153;, the percentage of subjects that experience a four-fold rise in antibody titers.</span></div></div>
  <div style="margin-left:13.593%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.250732000879558%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Participants in the study are evaluated for safety through six months after vaccination. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Development Program: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, we successfully completed a pre-IND meeting with the FDA regarding the pediatric clinical program for VAX-24. We received positive written feedback from the FDA supporting the initiation of a pediatric study that proceeds directly into infants contingent on satisfactory topline safety, tolerability and immunogenicity results from the ongoing VAX-24 Phase 1/2 clinical proof-of-concept study in adults 18 to 64 years of age. This approach provides us with an accelerated clinical path to deliver a potentially best-in-class PCV, VAX-24, to the </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pediatric population, which represents the largest portion of the pneumococcal vaccine market in the United States.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Received FDA Fast Track Designation for VAX-24 in Adults: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In early August 2022, we announced that the FDA granted Fast Track designation to VAX-24 in adults ages 18 and older. The Fast Track designation is an FDA process that has been designed to facilitate the development and expedite the review of drugs, including vaccines, that treat or prevent serious conditions and fill an unmet medical need. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, we announced the completion of enrollment in the Phase 2 portion of the ongoing VAX-24 Phase 1/2 clinical proof-of-concept study in adults 65 years and older.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Announced Positive Topline Results from VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults 18-64 Years of Age:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In October 2022, we announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24 in healthy adults aged 18-64. In this study, VAX-24 met the primary safety and tolerability objectives, demonstrating a safety profile similar to PCV20 for all doses studied. The study also showed VAX-24 met or exceeded the established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2mcg dose, which we intend to move forward into a Phase 3 program. At this dose, VAX-24 met the standard opsonophagocytic activity response non-inferiority criteria for all 20 serotypes common with PCV20, of which 16 achieved higher immune responses. Additionally, at all three doses, VAX-24 met the standard superiority criteria for all four serotypes unique to VAX-24. VAX-24 has the potential to cover an additional 10-28 percent of strains causing IPD in adults over the current standard-of-care PCVs.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Confirmed VAX-31 Serotype Composition:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In October 2022, we unveiled the serotype composition for VAX-31, the follow-on vaccine in our carrier-sparing PCV franchise, which is designed to contain 31 serotypes that collectively cover approximately 95% of the circulating strains causing IPD in adults in the United States. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Completed Successful $690 Million Follow-On Offering: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we completed an underwritten public offering of 17,812,500 shares of our common stock, which included the full exercise of the underwriters&#x2019; option to purchase additional shares, and pre-funded warrants to purchase 3,750,000 shares of common stock. The aggregate gross proceeds to us from the offering were $690.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by us, and excluding the exercise of any pre-funded warrants.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Entered into Option Grant Agreement with Sutro Biopharma for the Development and Manufacturing Rights of Cell-Free Extract: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we and Sutro Biopharma, Inc., or Sutro Biopharma announced an option grant agreement pursuant to which we acquired from Sutro Biopharma an option to access expanded rights to develop and manufacture cell-free extract, among other rights. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Received FDA Breakthrough Therapy Designation for VAX-24 for the Prevention of IPD in Adults: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2023, we announced that the FDA granted Breakthrough Therapy designation for VAX-24, for the prevention of IPD in adults. With Breakthrough Therapy designation, Vaxcyte will have access to all of the elements of the FDA&#x2019;s Fast Track program, as well as the ability to receive guidance and support from the FDA on an efficient drug development program and an organizational commitment from senior managers within the FDA. The FDA&#x2019;s decision was based on positive topline results from the Phase 1/2 proof-of-concept study of VAX-24 in adults 18-64 years of age. </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In late February 2023, we announced that the FDA cleared the VAX-24 IND application for the prevention of IPD in infants. We plan to initiate the infant Phase 2 study in the second quarter of 2023, with topline safety, tolerability and immunogenicity data following the primary three-dose immunization series expected by 2025. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The study design will include a primary immunization series consisting of three doses followed by a subsequent booster dose.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Announced new vaccine program VAX-GI: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In late February 2023, we announced that we added a new vaccine program, VAX-GI, designed to prevent Shigella, a bacterial illness that affects an estimated 188 million people worldwide each year and results in approximately 164,000 deaths annually, mostly among children under five years of age in low- and middle-income settings. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since our inception in November 2013, we have devoted substantially all of our resources to performing research and development, undertaking preclinical studies, advancing our vaccine candidates through clinical trials and manufacturing activities in support of our product development efforts, acquiring and developing our technology and vaccine candidates, organizing and staffing our company, establishing our intellectual property portfolio and raising capital to support and expand such activities. We do not have any products approved for sale and have not generated any revenue from product sales. To date, we have financed our operations primarily with proceeds from the sales of our common stock, pre-funded warrants to purchase our common stock and, prior to our initial public offering, or IPO, in June 2020, redeemable convertible preferred stock. We will continue to require additional capital to develop and commercialize our vaccine candidates and fund operations for the foreseeable future. Accordingly, until such time as we can generate significant revenue from sales of our vaccine candidates, if ever, we expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred net losses in each year since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing activities, and our expenditures on other research and development activities. Our net losses were $223.5 million and $100.1 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $522.1 million and cash, cash equivalents and investments of $957.9 million, We believe our cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the filing date of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not expect to generate any revenue from commercial product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our vaccine candidates, which we expect will take a number of years. We expect our expenses will increase substantially in connection with our ongoing activities, as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">advance our vaccine candidates through preclinical studies and clinical trials;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require the scale-up of our manufacturing capabilities, in particular to prepare for our Phase 3 program for VAX-24;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">incur additional costs that may be required for secondary supply sources;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">require the manufacture of supplies for our clinical trials, in particular our clinical trials for our PCV candidates, VAX-24 and VAX-31; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pursue regulatory approval of our vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">establish additional manufacturing capacity to meet potential incremental supply requirements following the initial commercial launch of VAX-24; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hire additional personnel; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operate as a public company; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">acquire, discover, validate and develop additional vaccine candidates; and </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain, maintain, expand and protect our intellectual property portfolio. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely and will continue to rely on third parties to conduct our preclinical studies and clinical trials and for manufacturing and supply of our vaccine candidates. We have no internal manufacturing capabilities, and we will continue to rely on third parties, of which the main suppliers are single-source suppliers, for our preclinical and clinical trial materials. Given our stage of development, we do not yet have a marketing or sales organization or commercial infrastructure. Accordingly, if we obtain regulatory approval for any of our vaccine candidates, we also would expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with vaccine development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from the sale of our vaccines, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Certain Significant Relationships</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lonza</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2016, we entered into a non-exclusive development and manufacturing services agreement, as amended, with Lonza, or the 2016 Lonza DMSA, pursuant to which Lonza is obligated to perform manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, we entered into a letter agreement with Lonza, or the Lonza Letter Agreement, pursuant to which we agreed to certain terms for potential future payments in shares of our common stock as partial satisfaction of future obligations to Lonza. The Lonza Letter Agreement states that the initial pre-IND cash payments under the 2016 Lonza DMSA would be subject to a specified dollar cap, or the Initial Cash Cap. After the Initial Cash Cap has been reached, we would have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $10.0 million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued 399,680 shares of our common stock to Lonza at a price of $25.02 per share to pay for $10.0 million of the pre-IND payments due April 30, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2018, we entered into a second non-exclusive development and manufacturing services agreement with Lonza, or the 2018 Lonza DMSA, pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we entered into a third non-exclusive development and manufacturing services agreement with Lonza, as amended, or the 2022 Lonza DMSA, effective as of March 22, 2022. Pursuant to the 2022 Lonza DMSA, Lonza will perform manufacturing process development and clinical manufacture and supply of our proprietary PCV.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under each of the 2016 Lonza DMSA, 2018 Lonza DMSA and 2022 Lonza DMSA, collectively the Lonza Agreements, we will pay Lonza agreed-upon fees for its performance of development and manufacturing services and pass through expenses incurred by Lonza for raw materials, as well as customary procurement and handling fees. Under each Lonza Agreement, we will own all right, title and interest in and to any and all New Customer Intellectual Property (as defined in each Lonza Agreement), and Lonza shall own all right, title and interest in New General Application Intellectual Property (as defined in each Lonza Agreement). Subject to the terms and conditions set forth in the Lonza Agreements, Lonza granted us a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property (as defined in each Lonza Agreement), to research, develop, make, have made, use, sell and import the Product (as defined in each Lonza Agreement) manufactured under each Lonza Agreement.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless earlier terminated, each Lonza Agreement will remain in place for a period of five years and includes customary conditions for termination prior to that period. The 2016 Lonza DMSA has been amended to extended its term until March 31, 2023.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For additional details regarding our relationship with Lonza, see Note 6, &#x201c;Commitments and Contingencies,&#x201d; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sutro Biopharma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Biopharma is a clinical stage, publicly traded drug discovery, development and manufacturing company using precise protein engineering and rational design (enabled by Sutro Biopharma&#x2019;s proprietary XpressCF platform technology) to advance next-generation oncology therapeutics. Following our corporate formation, we acquired an exclusive license to Sutro Biopharma&#x2019;s proprietary cell-free protein synthesis platform, XpressCF, for the discovery, development and sale of vaccines for the treatment or prevention of infectious diseases, excluding cancer vaccines. Under a related supply agreement with Sutro Biopharma, we have an exclusive relationship in our field to buy extract and certain custom reagents for use in manufacturing the vaccine compositions covered by the exclusive license, which we use to produce our protein carriers and certain of our antigens. Under a separate agreement with Sutro Biopharma, we enhanced our rights with respect to access to a second supplier of extract and acquired an option to access expanded rights to develop and manufacture extract, among other rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated License Agreement with Sutro Biopharma</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are party to a license agreement with Sutro Biopharma, or the Sutro Biopharma License Agreement, on August 1, 2014. The Sutro Biopharma License Agreement was amended on October 12, 2015 and again on May 9, 2018 and May 29, 2018. Under the Sutro Biopharma License Agreement, we received an exclusive, worldwide, royalty-bearing, sublicensable license under Sutro Biopharma&#x2019;s patents and know-how relating to cell-free expression of proteins to (i) research, develop, use, sell, offer for sale, export, import and otherwise exploit specified vaccine compositions, such rights being sublicensable, for the treatment or prophylaxis of infectious diseases, excluding cancer vaccines, and (ii) manufacture, or have manufactured by an approved contract manufacturing organization, such vaccine compositions from extracts supplied by Sutro Biopharma pursuant to the Sutro Biopharma Supply Agreement (as described below). We are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for and commercialize the vaccine compositions. In consideration of the rights granted under the Sutro Biopharma License Agreement, we are obligated to pay Sutro Biopharma a 4% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a 2% royalty on such net sales of vaccine products for animal health. Such royalty rates are subject to specified reductions, including standard reductions for third-party payments and for expiration of relevant patent claims. We are also obligated to pay Sutro Biopharma any royalties due to Stanford University (the upstream licensor of Sutro Biopharma), to the extent the royalties payable by Sutro Biopharma to Stanford University are greater than the royalties payable by us to Sutro Biopharma. Royalties are payable on a vaccine composition-by-vaccine composition and country-by-country basis until the later of expiration of the last valid claim in the licensed patents covering such vaccine composition in such country and ten years after the first commercial sale of such vaccine composition. The latest expiration date of a licensed Sutro Biopharma patent application, if issued, would be 2036, subject to any adjustment or extension of patent term that may be available in a particular country. In addition, we are obligated to pay Sutro Biopharma a percentage of net sublicensing revenue received in the low teen percentages. In addition, in the event we sublicense our non-manufacturing rights under the Sutro Biopharma License Agreement before a specified date, we are obligated to pay Sutro Biopharma a percentage, in the low double-digits, of the sublicensing revenue we receive under such agreement.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Sutro Biopharma License Agreement will remain in effect until terminated. The agreement may be terminated by either party for the other party&#x2019;s material breach uncured within 60 days&#x2019; notice, by us at will with 60</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">days&#x2019; notice, or by Sutro Biopharma if we challenge Sutro Biopharma&#x2019;s patents or if we undergo a change of control with a specified competitor of Sutro Biopharma.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Supply Agreement with Sutro Biopharma </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2018, we entered into a supply agreement, or the Sutro Biopharma Supply Agreement, with Sutro Biopharma pursuant to which we purchase from Sutro Biopharma extract and custom reagents for use in manufacturing non-clinical and certain clinical supply of vaccine compositions utilizing the technology licensed under the Sutro Biopharma License at prices not to exceed a specified percentage above Sutro Biopharma&#x2019;s fully burdened manufacturing cost. If any extracts or custom reagents do not meet the specifications and warranties provided, then we will not have an obligation to pay for the non-conforming product, and Sutro Biopharma will be obligated to replace the non-conforming product within the shortest possible time with conforming product at our cost. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2022 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Sutro Biopharma Supply Agreement. The Sutro Biopharma Supply Agreement may be terminated by either party for the other party&#x2019;s material breach uncured within 60 days&#x2019; notice, by us at will with 60 days&#x2019; notice, or by mutual agreement of the parties. In December 2019, we exercised our right to require Sutro Biopharma to establish a second supplier for extract and custom reagents to support our anticipated clinical and commercial needs.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Agreement with Sutro Biopharma</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we entered into an option grant agreement with Sutro Biopharma, or the Option Agreement. Pursuant to the Option Agreement, we acquired from Sutro Biopharma (i) authorization to enter into an agreement with an independent alternate CMO to directly source Sutro Biopharma&#x2019;s cell-free extract, allowing us to have direct oversight over financial and operational aspects of the relationship with the CMO; and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract (including the right to make improvements to the extract manufacturing process as well as cell lines) for use in connection with the exploitation of certain vaccine compositions, or the Option. We and Sutro Biopharma have agreed to negotiate the terms and conditions of a form definitive agreement to be entered into in the event we exercise the Option, which shall include the terms and conditions set forth in an executed term sheet between us, or the Term Sheet, and such terms that are necessary to give effect to each of the terms and conditions set forth in the Term Sheet, or the Form Definitive Agreement. The Option period is five years from the date of the Option Agreement, subject to potential acceleration in the event we undergo a change of control.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we agreed to pay Sutro Biopharma upfront consideration of $22.5 million, consisting of (i) $10.0 million in cash and $7.5 million worth of shares of our common stock (the number of shares to be calculated based on the arithmetic average of the daily volume weighted average price of our common stock as traded on Nasdaq in the three consecutive trading days immediately prior to the issuance thereof), and (ii) $5.0 million payable within five business days after we and Sutro Biopharma mutually agree in writing upon the Form Definitive Agreement. The 167,780 shares of common stock issued was recorded at fair value of $8.0 million on the date of settlement, December 22, 2022. In the event that we elect to exercise the Option, we would pay Sutro Biopharma an aggregate Option exercise price of $75.0 million in cash in two installments and, upon the occurrence of certain regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">milestones, certain additional milestone payments totaling up to $60.0 million in cash. In the event that we undergo a change of control, certain rights and payments may be accelerated.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For additional details regarding our relationship with Sutro Biopharma, see Note 6, &#x201c;Commitments and Contingencies,&#x201d; and Note 15, &#x201c;Related Party Transactions,&#x201d; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impact of COVID-19 and Other Trends</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are continuing to closely monitor the impact of the global COVID-19 pandemic on our business. In particular, the COVID-19 pandemic slowed raw material supply chains and travel restrictions delayed the qualification of key analytical equipment used in manufacturing and curtailed in-person CMO oversight of manufacturing, affecting our manufacturing processes. As the pandemic continues, we could see an additional impact on our ability to advance our programs, obtain supplies from our contract manufacturers or interact with regulators, ethics committees or other important agencies due to limitations in regulatory authority, employee resources or otherwise. In any event, if the COVID-19 pandemic continues and persists for an extended period of time, we could experience significant disruptions to our development timelines, which would adversely affect our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the recent trends towards rising inflation may also materially adversely affect our business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of our clinical trial materials and supplies, interest rates and overhead costs may adversely affect our operating results. Rising interest and inflation rates also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates continue to rise) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with COVID-19 and the ongoing conflict between Russia and Ukraine, and employee availability and wage increases, which may result in additional stress on our working capital resources.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses represent costs incurred in performing research, development and manufacturing activities in support of our own product development efforts and include personnel-related costs (including salaries, employee benefits and stock-based compensation) for our personnel in research and development functions; costs related to acquiring, developing and manufacturing supplies for preclinical studies, clinical trials and other studies, including fees paid to CMOs; costs and expenses related to agreements with contract research organizations, or CROs, investigative sites and consultants to conduct non-clinical and preclinical studies and clinical trials; professional and consulting services costs; research and development consumables costs; laboratory supplies and equipment costs; and facility and other allocated costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses are expensed as incurred. Non-refundable advance payments for services that will be used or rendered for future research and development activities are recorded as prepaid expenses and recognized as expenses as the related services are performed. We do not allocate our costs by vaccine candidates, as our vaccine candidates are at an early stage of development and our research and development expenses include internal costs, such as payroll and other personnel expenses, which are not tracked by vaccine candidate. In particular, with respect to internal costs, several of our departments support multiple vaccine candidate research and development programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our research and development expenses to increase substantially in absolute dollars for the foreseeable future as we advance our vaccine candidates into and through preclinical studies and clinical trials, scale up our manufacturing activities, establish additional manufacturing capacity to meet potential incremental supply requirements following the initial commercial launch of VAX-24, pursue regulatory approval of our vaccine candidates and expand our pipeline of vaccine candidates. The process of conducting the necessary preclinical and clinical research and completing the manufacturing requirements to obtain regulatory approval is costly and time-consuming. The actual probability of success for our vaccine candidates may be affected by a variety of factors, including the safety and efficacy or immunogenicity of our vaccine candidates, clinical data, investment in our clinical programs, competition, manufacturing capabilities and commercial viability. We may never succeed in achieving regulatory approval for any of our vaccine candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or if, when and to what extent we will generate revenue from the commercialization and sale of our vaccine candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We accrue for costs related to research and development activities based on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors, including CMOs and CROs, that conduct research, development and manufacturing activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors exceed the level of services provided and result in a prepayment of the research and development expense. Advance payments for goods and services to be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. We make significant judgments and estimates in determining accrued research and development liabilities as of each reporting period based on the estimated time period over which services will be performed and the level of effort to be expended. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development costs may vary significantly based on factors such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of our chemistry, manufacturing and controls, or CMC, activities, including fulfilling good manufacturing practice, or GMP, related standards and compliance, and identifying and qualifying second suppliers; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs related to raw materials estimates from our third-party manufacturing and supply partners;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of clinical trials of our vaccine candidates being greater than we anticipate; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of sites included in the trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the countries in which the trials are conducted; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in adding a sufficient number of trial sites and recruiting suitable volunteers to participate in our clinical trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of subjects that participate in the trials; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of doses that subjects receive; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subjects dropping out of a study or lost in follow-up; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the duration of subject participation in the trials and follow-up; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of manufacturing our vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the phase of development of our vaccine candidates; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of establishing additional manufacturing capacity to meet potential incremental supply requirements following the initial commercial launch of VAX-24; </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs that may be required for secondary supply sources; and</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and safety profile of our vaccine candidates. </span></div></div>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses consist primarily of costs and expenses related to personnel (including salaries, employee benefits and stock-based compensation) in our executive, legal, finance and accounting, human resources and other administrative functions; legal services relating to intellectual property and corporate matters; accounting, auditing, consulting and tax services; insurance; and facility and other allocated costs not otherwise included in research and development expenses. We expect our general and administrative expenses to continue to increase in absolute dollars for the foreseeable future as we increase our headcount and expand our services to support our continued research and development activities and grow our business. We expect continued increases in general and administrative expenses related to compliance with the rules and regulations of the SEC and The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;), insurance expenses, investor relations and corporate communications activities and other administrative and professional services.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net includes interest income earned from our cash and cash equivalents, grant income, foreign currency transaction gains (losses) related to our Swiss Franc and Euro cash and liability balances, loss on disposals of fixed assets and interest expense.</span></p>
  <p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grant Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2019, we received a cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, a public-private partnership funded under a Cooperative Agreement from Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and Development Authority and by awards from Wellcome Trust, Germany&#x2019;s Federal Ministry of Education and Research, the United Kingdom Global Antimicrobial Resistance Innovation Fund and the Bill &amp; Melinda Gates Foundation. In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the Trustees of Boston University, the administrator of the program, or the CARB-X agreement. CARB-X has awarded us total funding to date of $6.6 million, with potential funding of up to $29.7 million upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $29.7 million to $14.6 million (inclusive of the $6.6 million awarded to date). Separately, the National Institute of Health, or NIH, awarded us up to $0.5 million in April 2021 to advance the development of a vaccine against Shigella infection. Grant income pursuant to our award agreements is recognized as we incur and pay qualifying expenses over the periods of the awards. We recognized $1.9 million, $1.6 million and $2.5 million in grant income for funding research and development under these awards during the years ended December 31, 2022, 2021 and 2020, respectively. Grant income is included as a component of Other income (expense), net in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2022 and 2021</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the periods presented:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.304%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.158%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.232%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.905000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.991%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.800999999999998%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169,451</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,411</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,040</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired manufacturing rights</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,995</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,995</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39,810</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,259</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,551</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">232,256</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,670</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128,586</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(232,256</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(103,670</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(128,586</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124.0</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(71.4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,356</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">344</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,012</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">*</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,931</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,585</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">346</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.8</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized gain on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on disposal of fixed assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(44</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(44</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign currency transaction gain (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,470</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,669</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(3,139</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(188.1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,771</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,593</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,178</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(223,485</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100,077</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(123,408</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123.3</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-3.52%;padding-left:3.4%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">* not meaningful</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses for the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.603%;"></td>
    <td style="width:1.116%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.817%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.127%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.15%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.127%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.753%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.009%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.299000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product and clinical development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,869</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,215</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43,654</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117.3</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel-related</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33,776</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,476</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,300</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional and consulting services</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,811</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,351</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,460</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33.6</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development consumables</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,533</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,848</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,685</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">243.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facility related and other allocated</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,243</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,098</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,145</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112.9</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory supplies and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,498</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,421</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,077</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60.7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,721</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,002</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,719</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">171.6</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169,451</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,411</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91,040</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes expenses for third-party manufacturing and outsourced contract services, including preclinical studies, clinical trials and outsourced assays. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes travel-related expenses and other miscellaneous office expenses. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses increased by $91.0 million, or 116.1%, in 2022 compared to 2021. The increases of $43.7 million in product and clinical development expenses and $2.1 million in laboratory supplies and equipment were primarily due to increased VAX-31 IND readiness activities, increased VAX-24 Phase 3 readiness activities, the initiation of the VAX-24 Phase 1/2 clinical proof-of-concept study in adults 18-64 years of age and the initiation of the VAX-24 Phase 2 clinical study in adults 65 years and older, partially offset by a decrease in VAX-24 IND readiness activities as the IND application for our VAX-24 adult program was submitted in late 2021. The increase of $16.7 million in research and development consumables was primarily related to costs incurred for extract and reagents for VAX-24 Phase 3 readiness and commercial preparation activities. The increase</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of $16.3 million in personnel-related expenses was primarily due to growth in the number of employees in our research and development functions and higher compensation costs, including salaries, benefits and stock-based compensation expense. The increase of $9.1 million in facility related and other allocated expenses was primarily due to an increase in lease expense related to our current corporate headquarters.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquired Manufacturing Rights</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we entered into the Option Agreement with Sutro Biopharma pursuant to which we acquired, among other things, the Option. As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we paid Sutro Biopharma upfront consideration. As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the Option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses increased by $14.6 million, or 57.6%, in 2022 compared to 2021. The increase was mainly due to increases of $11.5 million in personnel-related costs related to growth in the number of employees in our general and administrative functions and higher compensation costs, including salaries, benefits and stock-based compensation expense and $2.9 million in professional and consulting services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net increased by $5.2 million, or 144.1%, in 2022 compared to 2021. The increase was mainly due to an increase of $8.0 million in interest income resulting from higher cash balances generated from our follow-on financings in the first and fourth quarters of 2022 and our ATM program during the year and higher interest rates. This was partially offset by an increase in foreign currency losses due to the appreciation of the U.S dollar against the Swiss Franc and Euro.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the periods presented:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.298%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.16%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.233%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.202%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.907%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.991%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.804%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,411</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,564</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,847</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,259</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,017</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,242</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57.7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103,670</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,581</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,089</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.7</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(103,670</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(89,581</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(14,089</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">344</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">244</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41.0</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,585</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,478</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(893</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(36.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized gain on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign currency transaction gain (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,669</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(2,351</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(171.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,593</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">364</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,229</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">887.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(100,077</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(89,217</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(10,860</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.2</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our research and development expenses for the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.211%;"></td>
    <td style="width:1.117%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.718%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.117%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.048%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.117%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.889000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.783%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product and clinical development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,215</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,072</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(13,857</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(27.1</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel-related</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,476</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,943</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,533</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.8</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Professional and consulting services</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,351</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,184</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development consumables</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,848</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,288</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,560</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">199.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facility related and other allocated</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,098</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,957</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,141</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">173.9</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory supplies and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,421</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,032</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,389</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68.4</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,002</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,088</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(86</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(7.9</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78,411</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,564</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,847</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes expenses for third-party manufacturing and outsourced contract services, including preclinical studies and outsourced assays. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes travel-related expenses, other miscellaneous office expenses and warrant expense. </span></div></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses increased by $4.8 million, or, 6.6% in 2021 compared to 2020. The increase was primarily attributable to increases in (i) personnel-related expenses of $7.5 million related to the increase in the number of employees to support our research and development activities and higher stock-based compensation expense, (ii) facility related and other allocated expenses of $5.1 million resulting from increases in rent and lease expense as well as expenses allocated to research and development, (iii) research and development consumables of $4.6 million related to higher critical raw materials expenses and (iv) laboratory supplies and equipment expenses of $1.4 million mainly related to our VAX-24 and VAX-A1 programs. These increases were partially offset by a decrease of $13.9 million in product and clinical development expenses, which represented the net impact of a decrease in outsourced manufacturing expenses related to our VAX-24 program and an increase in such expenses related to our VAX-31 program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative expenses increased by $9.2 million, or, 57.7% in 2021 compared to 2020. The increase was mainly due to increases of $7.0 million in personnel-related costs related to higher stock-based compensation expense resulting from an increase in the number of options granted during the year and growth in the number of employees in our general and administrative functions, $1.3 million in professional and consulting services related primarily to compliance activities under the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, and technology infrastructure enhancements and $1.1 million in directors and officers insurance expense as a result of operating as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net increased by $3.2 million, or, 887.1% in 2021 compared to 2020. The increase was mainly due to an increase of $4.0 million in foreign currency gains resulting from the appreciation of the U.S. Dollar against the Swiss Franc in 2021 compared to 2020, partially offset by a decrease of $0.9 million in grant income for the CARB-X program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From inception through December 31, 2022, we have incurred losses and negative cash flows from operations and have funded our operations primarily through the issuance of common stock, pre-funded warrants to purchase our common stock and, prior to our IPO, redeemable convertible preferred stock, totaling approximately $1.49 billion in aggregate gross proceeds and $1.42 billion net of underwriting discounts, commissions and offering expenses. As of December 31, 2022, we had $834.7 million of cash and cash equivalents, $123.2 million in investments and an accumulated deficit of $522.1 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 2, 2021, we filed a shelf registration statement on Form S-3ASR, or the Shelf Registration Statement, under which we may, from time to time, sell securities in one or more offerings of our common stock, preferred stock, debt securities or warrants. The Shelf Registration Statement became automatically effective upon the filing of the Form S-3ASR on July 2, 2021.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, we entered into an Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the ATM Sales Agreement, with Jefferies LLC, which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $150.0 million through Jefferies acting as our sales agent or principal. Under the ATM Sales Agreement, Jefferies may sell the shares of common stock by any method permitted by law deemed to be an &#x201c;at-the-market offering&#x201d; as defined under the Securities Act of 1933, as amended, in block transactions or in privately-negotiated transactions with our consent. Jefferies will use commercially reasonable efforts to sell the shares of common stock subject to the ATM Sales Agreement from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions that we may impose). We will pay Jefferies a commission of up to 3.0% of the gross sales proceeds of any common stock sold through Jefferies under the ATM Sales Agreement; however, we are not obligated to make any sales of common stock. As of December 31, 2022, we have sold 4,488,573 shares of our common stock under the ATM Sales Agreement at an average price of $25.56 per share for aggregate gross proceeds of $114.7 million ($111.2 million net of commissions and offering expenses).</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, we completed an underwritten public offering in which we issued 2,500,000 shares of common stock at a price of $20.00 per share and pre-funded warrants to purchase 2,500,000 shares of our common stock at a price of $19.999 per underlying share. In February 2022, the underwriters exercised their option to purchase an additional 750,000 shares of common stock. In aggregate, we received approximately $107.6 million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us,  and excluding the exercise of any pre-funded warrants.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we completed an underwritten public offering of 17,812,500 shares of our common stock, which included the full exercise of the underwriters' option to purchase an additional 2,812,500 shares, at a price of $32.00 per share and pre-funded warrants to purchase 3,750,000 shares of our common stock at a price of $31.999 per underlying share. In aggregate, we received $651.6 million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us, and excluding the exercise of any pre-funded warrants.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our primary uses of cash are to fund our operations, which consist primarily of research and development expenditures related to our programs and, to a lesser extent, general and administrative expenditures. We anticipate that we will continue to incur significant expenses for the foreseeable future as we continue to advance our vaccine candidates, expand our corporate infrastructure, including the costs associated with being a public company, further our research and development initiatives for our vaccine candidates and scale our laboratory and manufacturing operations. We are subject to all of the risks typically related to the development of new drug candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We anticipate that we will need substantial additional funding in connection with our continuing operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our existing cash, cash equivalents and investments as of the date of this Annual Report on Form 10-K will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the filing date of this Annual Report on Form 10-K. We have raised substantial capital, however, we will need to raise substantial additional capital to complete development and commercialization of our drug candidates. Until we can generate sufficient revenue from the commercialization of our vaccine candidates or from collaboration agreements with third parties, if ever, we expect to finance our future cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. The sale of equity, pre-funded warrants or convertible debt securities may result in dilution to our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. Debt financings may subject us to covenant limitations or restrictions on our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Our ability to raise additional funds may be adversely impacted by deteriorating global economic conditions, including higher inflation rates and changes in interest rates, and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable or acceptable to us. If we are unable to obtain adequate financing when needed or on terms favorable or acceptable to us, we may be forced to delay, reduce the scope of or eliminate one or more of our research and development programs.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, scope, progress, results and costs of research and development, testing, screening, manufacturing, preclinical development and clinical trials;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of establishing additional manufacturing capacity to meet potential incremental supply requirements following the initial commercial launch of VAX-24;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our exercise of the Option with Sutro Biopharma;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the outcome, timing and cost of seeking and obtaining regulatory approvals from the FDA and comparable foreign regulatory authorities, including the potential for such authorities to require that we perform field efficacy studies for our PCV candidates, require more studies than those that we currently expect or change their requirements regarding the data required to support a marketing application;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of building a sales force in anticipation of any product commercialization;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of future commercialization activities, including product manufacturing, marketing, sales, royalties and distribution, for any of our vaccine candidates for which we receive marketing approval;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any product liability or other lawsuits related to our products;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the revenue, if any, received from commercial sales, or sales to foreign governments, of our vaccine candidates for which we may receive marketing approval;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs to establish, maintain, expand, enforce and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may receive, in connection with licensing, preparing, filing, prosecuting, defending and enforcing our patents or other intellectual property rights;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses needed to attract, hire and retain skilled personnel;</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of operating as a public company; and</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.398%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7367350305163027%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A change in the outcome of any of these or other variables could significantly change the costs and timing associated with the development of our vaccine candidates. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such change.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.621%;"></td>
    <td style="width:1.374%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.036%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.374%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.036%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.395%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.163%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(170,597</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(121,393</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(46,628</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74,585</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(212,308</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,105</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">861,547</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,796</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">374,870</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(439</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">765,672</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(316,344</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">327,224</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2022 was $170.6 million, which primarily resulted from a net loss of $223.5 million, partially offset by non-cash charges of $40.2 million and a net change in operating assets and liabilities of $12.7 million. Non-cash charges primarily consisted of $23.7 million in stock-based compensation, $8.0 million in non-cash payments for the acquired manufacturing rights, $6.6 million in amortization of right-of-use, or ROU, assets and $2.6 million in depreciation and amortization. The net change in operating assets and liabilities of $12.7 million was primarily due to increases in cash flows from accrued expenses of $7.2 million, accrued payable of $2.9 million and accrued manufacturing expenses of $3.8 million, partially offset by a decrease in cash flows from accrued compensation of $2.3 million.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2021 was $121.4 million, which primarily resulted from a net loss of $100.1 million and a net change in operating assets and liabilities of $37.0 million, partially offset by non-cash charges of $15.7 million. The net change in operating assets and liabilities of $37.0 million was primarily due to decreases in cash flows due to operating lease liabilities of $12.9 million resulting from leasehold improvements costs applied against such liabilities upon the commencement of our San Carlos office lease in December 2021; accounts payable of $12.5 million resulting primarily from the payment of deferred Lonza payables in December 2021; accrued manufacturing expenses of $8.6 million resulting from timing of payments; and prepaid and other current assets of $7.4 million related to a receivable for reimbursement of tenant improvement allowance and prepayments on various contracts, including repairs and maintenance, production of critical raw materials, research and clinical trial preparation. These changes were partially offset by increases in cash flows due to accrued expenses of $4.6 million primarily related to costs associated with the manufacture of extract in connection with our relationship with Sutro Biopharma. Non-cash charges consisted of $10.7 million in stock-based compensation expense, $1.8 million in depreciation and amortization, $1.7 million in amortization of operating lease ROU assets and $1.4 million in net amortization of premiums on investments.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities for the year ended December 31, 2020 was $46.6 million, which primarily resulted from a net loss of $89.2 million, partially offset by a net change in operating assets and liabilities of $35.3 million and non-cash charges of $7.3 million. The net change in operating assets and liabilities of $35.3 million was primarily due to increases in accounts payable of $26.1 million resulting from the deferral of completion payments until April 2021 in accordance with our contract with Lonza, accrued manufacturing expenses of $7.2 million related to outsourced manufacturing activities and accrued expenses of $2.2 million related primarily to increases in contract research services related to the VAX-24 program. Non-cash charges primarily consisted of $5.4 million in stock-based compensation expense, $1.4 million in depreciation and amortization and $0.3 million in asset impairment charges.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash from investing activities for the year ended December 31, 2022 was $74.6 million, which related primarily to $168.7 million in maturities of investments and $14.5 million in sales of investments, partially offset by $102.7 million in purchases of investments and $5.8 million in purchases of lab equipment and furniture and fixtures.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in investing activities for the year ended December 31, 2021 was $212.3 million, which related primarily to $336.3 million in purchases of investments and $6.6 million in purchases of lab equipment and furniture and fixtures, partially offset by $100.5 million in maturities of investments and $30.1 million in sales of investments.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash used in investing activities for the year ended December 31, 2020 was $1.1 million which related primarily to purchases of lab equipment and leasehold improvements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2022 was $861.5 million, which primarily consisted of net proceeds from the follow-on offerings in the first and fourth quarters of 2022 of $759.2 million, net proceeds from shares issued under our ATM Sales Agreement of $97.3 million and proceeds from exercises of common stock options of $4.9 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2021 was $17.8 million, which primarily consisted of net proceeds from shares issued under our ATM Sales Agreement of $13.9 million and proceeds from exercises of common stock options of $3.0 million.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash provided by financing activities for the year ended December 31, 2020 was $374.9 million, which primarily consisted of net proceeds of $264.0 million from our IPO and $109.9 million from the issuance of our Series D redeemable convertible preferred stock.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contractual Obligations and Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our material cash requirements include the following contractual and other obligations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have operating lease agreements for our office spaces. As of December 31, 2022, we had lease payment obligations totaling $20.6 million, of which $6.7 million is payable within one year.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Option Agreement, we and Sutro Biopharma have agreed to negotiate the terms and conditions of the Form Definitive Agreement. Within five business days after we and Sutro Biopharma mutually</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">agree in writing upon the Form Definitive Agreement, we have agreed to pay Sutro Biopharma $5.0 million. Additionally, in the event that we elect to exercise the Option, we would pay Sutro Biopharma an aggregate Option exercise price of $75.0 million in cash in two installments and, upon the occurrence of certain regulatory milestones, certain additional milestone payments totaling up to $60.0 million in cash. In the event that we undergo a change of control, certain rights and payments may be accelerated.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Purchase Obligations</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have certain payment obligations under various license agreements. Under these agreements, we are required to make milestone payments upon successful completion and achievement of certain intellectual property, clinical, regulatory and sales milestones. The payment obligations under the license agreements are contingent upon future events such as our achievement of specified development, clinical, regulatory and commercial milestones, and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under these agreements. As the achievement and timing of these future milestone payments are not probable or estimable, such amounts have not been included in our balance sheets as of December 31, 2022 or December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into agreements in the normal course of business with CMOs and other vendors for manufacturing services and raw materials purchases. We rely on several third-party manufacturers for our manufacturing requirements. As of December 31, 2022, we had the following amounts of non-cancelable purchase commitments related to manufacturing services and raw materials purchased due to our key manufacturing partners. These amounts represent our minimum contractual obligations, including termination fees. If we terminate certain firm orders with our key manufacturing partners, we will be required to pay for the manufacturing services scheduled or raw materials purchased under our arrangements. The actual amounts we pay in the future to the vendors under such agreements may differ from the purchase order amounts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:85.35%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.649999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,099</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,471</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total non-cancelable purchase commitments due to key manufacturing partners</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125,570</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management&#x2019;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses, stock-based compensation and leases. We base our estimates on historical experience, known trends and events and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While our significant accounting policies are described in the notes to our financial statements included elsewhere in this Annual Report on Form 10-K, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.239%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into various agreements with CMOs and CROs. As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses, including</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">accrued manufacturing expenses, as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel and third parties to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued research and development expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></p>
  <p style="margin-left:0.933%;text-indent:9.239%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We accrue for costs related to research and development activities based on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors, including CMOs and CROs, that conduct research, development and manufacturing on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received. We make significant judgments and estimates in determining accrued research and development liabilities as of each reporting period based on the estimated time period over which services will be performed and the level of effort to be expended. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly.</span></p>
  <p style="margin-left:0.933%;text-indent:9.431%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.935%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.252%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense related to awards to employees is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period, net of the impact of actual forfeitures recorded in the period in which they occur.</span></p>
  <p style="margin-left:0.8%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.8%;text-indent:9.328%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense related to awards to non-employees is recognized based on the then-current fair value at each measurement date over the associated service period of the award, which is generally the vesting term, using the straight-line method. The fair value of non-employee stock options is estimated using the Black-Scholes valuation model with assumptions generally consistent with those used for employee stock options, with the exception of the expected term, which is the remaining contractual life at each measurement date. Refer to Note 2, &#x201c;Basis of Presentation and Summary of Significant Accounting Policies,&#x201d; and Note 10, &#x201c;Equity Incentive Plans,&#x201d; to our financial statements for more information on assumptions used in estimating stock-based compensation expense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.484%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:3.463%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Black-Scholes option-pricing model requires the use of subjective assumptions, such as volatility, which determine the fair value of stock-based awards. The assumptions utilized in the Black-Scholes option-pricing model are as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term represents the period that our stock-based awards are expected to be outstanding. The expected term for employee equity instruments is calculated using the simplified method where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the time from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term. The expected term for non-employee stock options is the remaining contractual term.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.252%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility is estimated from the average historical volatilities of publicly traded companies within the life sciences industry that are considered to be comparable to our business over a period approximately equal to the expected term for employees&#x2019; options and the remaining contractual life for non-employees&#x2019; options. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available.</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have not paid and do not anticipate paying any dividends in the near future. Accordingly, we have estimated the dividend yield to be zero.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon notes with remaining terms corresponding with the expected term of the option.</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value of Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For valuations after the completion of our IPO, the fair value of each share of underlying common stock is based on the closing price of our common stock as reported on the Nasdaq Global Select Market on the date of grant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Leases</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We adopted Accounting Standards Update, or ASU 2016-02, Leases (Topic 842) on January 1, 2021, using the modified retrospective transition approach. There was no cumulative-effect adjustment recorded to retained earnings upon adoption.</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.204%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under ASC 842, we assess all arrangements that convey the right to control the use of property, plant and equipment, at inception, to determine if it is, or contains, a lease based on the unique facts and circumstances present in the arrangements. In addition, we determine whether leases meet the classification criteria of a finance or operating lease at the lease commencement date considering: (i) whether the lease transfers ownership of the underlying asset to the lessee at the end of the lease term, (ii) whether the lease contains a bargain purchase option, (iii) whether the lease term is for a major part of the remaining economic life of the underlying asset, (iv) whether the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset, and (v) whether the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2022, our lease population consisted only of operating real estate leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.204%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a lease is identified and its classification determined, we recognize a ROU asset, and a corresponding lease liability. Lease liabilities are recorded based on the present value of lease payments over the expected least term. The corresponding ROU asset is measured from the initial lease liability, adjusted by (i) accrued or prepaid rents, (ii) remaining unamortized initial direct costs and lease incentives, and (iii) any impairments of the ROU asset.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant assumptions utilized in recognizing the ROU asset and corresponding lease liabilities included the expected lease term and the incremental borrowing rate. The expected lease term includes both contractual lease periods and, as applicable, extensions of the lease term when we have determined the exercise of the option to extend is reasonably certain to occur. The incremental borrowing rate was utilized to discount lease payments over the expected term given our operating leases do not provide an implicit rate. We estimated the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances.</span></p>
  <p style="margin-left:0.933%;text-indent:9.265%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:1.204%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For additional details regarding the impact of adoption and disclosure, see Note 5, &#x201c;Leases,&#x201d; to our financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 2, &#x201c;Basis of Presentation and Summary of Significant Accounting Policies,&#x201d; to our financial statements for additional information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ive Disclosures About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Rate Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our cash and cash equivalents as of December 31, 2022 and December 31, 2021 consisted of readily available checking and money market funds. As of December 31, 2022, we also invested in U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition or results of operations. We believe that our exposure to interest rate risks is not significant and that a hypothetical 10% movement in market interest rates would not have a significant impact on the total value of our portfolio or our interest income. In addition, we do not believe that our cash and cash equivalents have significant risk of default or illiquidity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to market risk related to changes in foreign currency exchange rates, mainly relating to our contract with Lonza, our CMO in Switzerland. We have also entered into a limited number of contracts with other parties with payments denominated in foreign currencies. Payments under these contracts are made in foreign currencies and are subject to fluctuations in foreign currency rates. We do not currently have a formal program in place to hedge foreign currency risks. However, from time to time, we buy Swiss Francs, or CHF, which is the majority of our foreign currency exposure, at market and are holding CHF in our bank accounts. As of December 31, 2022 and December 31, 2021, we had approximately $21.8 million and $18.8 million of CHF cash and cash equivalents, respectively, held at one financial institution. As of December 31, 2022 and December 31, 2021, we had foreign currency denominated accounts payable and accrued expenses of $13.9 million and $6.9 million, respectively. To date, foreign currency transaction gains and losses have not been material to our financial statements. The following table shows the impact of a hypothetical 10% increase or decrease in current exchange rates on our net assets as of December 31, 2022 and our net loss for the twelve months ended December 31, 2022:</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:69.61%;"></td>
    <td style="width:0.078%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.534%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.078%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.700000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impact on Net Assets as of December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impact on Net Loss for Twelve Months Ended December 31, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Hypothetical Change in Currency Exchange Rates</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10% increase</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">789</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,644</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10% decrease</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(789</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(4,644</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As our foreign currency risk increases in the future, we will evaluate alternative strategies, including hedging, to mitigate our foreign currency exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Effects of Inflation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recently, the rate of inflation in the United States has risen to levels not experienced in decades. Inflation generally affects us by increasing our cost of labor and research and development contract costs. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long the elevated inflation levels persist and if the rate of inflation were to further increase, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, the purchasing power of our cash and cash equivalents may be eroded, our expenses could increase faster than anticipated and we may utilize our capital resources sooner than expected. We do not believe inflation had a material effect on our results of operations during the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements_supplement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Fina</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ncial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.996%;"></td>
    <td style="width:6.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm - PCAOB ID No. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_932b5872-1eaa-4e93-afa6-625d17880ce7" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></ix:nonNumeric></span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statementsofoperations1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_of_comprehensive_loss_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_redeemable_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_unaudited_interim_condensed_fin"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Regist</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the stockholders and the Board of Directors of Vaxcyte, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying balance sheets of Vaxcyte, Inc. (the &#34;Company&#34;) as of December 31, 2022 and 2021, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders' equity (deficit), and cash flows, for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#34;financial statements&#34;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#x2014; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 27, 2023, expressed an unqualified opinion on the Company's internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Audit Matter</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Manufacturing Expenses &#x2014; Refer to Notes 2 and 6 to the financial statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Critical Audit Matter Description</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurs research and development expenses related to the costs of research and development activities, including those performed by Lonza, a contract manufacturing organization under a development and manufacturing services agreement, to provide research and development services related to preclinical vaccine development. At the end of each period, the Company accrues for costs related to manufacturing expenses based on their estimates of the services received for each phase and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on their behalf. This estimation process involves reviewing open contracts and purchase orders, communicating with Company personnel and third parties to identify services that have been performed on their behalf, and estimating the level of service performed and the associated costs incurred for the services for each phase when the Company has not yet been invoiced or otherwise notified of the actual costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We identified the Company&#x2019;s accrued manufacturing expenses as a critical audit matter primarily due to judgments necessary for management to estimate the cost of services provided but not yet invoiced and the significant volume of transactions. The amount of the accrual at period end is based on the terms and conditions per the agreements and is dependent on management&#x2019;s gathering of information from various sources, including Lonza, regarding the progress of the uninvoiced services at the reporting date. Accordingly, this estimate is subjective as it involves management&#x2019;s judgment to analyze the various sources of information. This required extensive audit effort due to the volume and nature of available information from various sources, including Lonza, and required a high degree of auditor judgment when performing audit procedures to audit management&#x2019;s estimates of accrued manufacturing expenses and evaluating the results of those procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audit procedures related to the accrued manufacturing expenses included the following, among others:</span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We tested the effectiveness of controls over the Company&#x2019;s accrued manufacturing expense process, including controls over the estimation of activities completed to date.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We met with internal research and development personnel and inspected Board of Directors materials to understand the status of contract manufacturing activities. We then compared this information to the judgment applied in management&#x2019;s estimate of the recorded expenses and corresponding accrual.</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We evaluated the completeness of phases used by the Company by comparing to the tracker obtained from Lonza, as Lonza is the most significant contract manufacturer.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a sample of phases, we evaluated the accrued manufacturing expenses by:</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sending written confirmations directly to the contract manufacturing organization to confirm the total budgeted amount and percentage of completion incurred as of year-end.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inspecting the development and manufacturing services agreement and related amendments, change orders, statements of work, and agreeing key provisions of the agreements including timeline, budget, and relevant rates, to the Company&#x2019;s analysis of estimated expenses incurred to date.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining invoices, if available, for each selection to substantiate when the transaction should have been recorded.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Obtaining cash disbursements to test the accuracy of the accrual.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performing a lookback analysis by comparing the estimated accrual balance as of December 31, 2021, to the invoices received after year-end to evaluate the Company&#x2019;s ability to estimate the accrual.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ea36448d-0b77-4e72-8145-8d9f40d8ca47" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c7f112f5-9bc8-4eea-9bb2-36f4e6d7c463" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Francisco, California</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company's auditor since 2017.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">heets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.416%;"></td>
    <td style="width:1.306%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.83%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.306%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.141%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8a0c393-db27-4634-b470-d6732ddd4bd5" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">834,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f99c71f-a9d1-4bf0-b708-f9f5d4e64715" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a069a30-80ec-43fd-a596-c745f77bb92e" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc9fca5f-ef7d-4393-b526-d663b19d1a26" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">176,985</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_422cbfb0-c354-46ce-b70e-196cc9cb7e76" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9f8563f-e992-41d9-b7af-93b13388878a" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,378</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73d8f465-fdab-4098-a2ee-3bcc05c7f538" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">942,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_863422a5-acac-4d14-acfa-e9caea2e1e73" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">256,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9a96dfa-cb7b-4b4c-a909-6e6a8979ad27" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,360</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1b5daa8-25eb-482c-a66d-fe1ad692377d" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,954</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6910f50-ee40-4ede-908e-9499063e336e" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,288</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d8424da-66ac-431c-a4c2-a0c6dba89a3d" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,958</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6623361e-94dc-4260-b4ac-003b653dd118" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e81d64f2-5341-448e-bb16-086f49bada19" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,117</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b75de9da-af9b-4848-b568-2ab59179cd7e" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">871</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84aec3b7-3147-4da7-8595-26dbff1e6be3" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">871</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c500642-17cb-4e50-8ed4-db6c8692550e" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9fc02ff-75e0-4f4a-ae74-e02e83dfcad4" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total noncurrent assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8847f1c-c806-4125-8fbb-8e2a7cfd5b69" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,623</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e744a3a-8412-4a66-8304-3ed13b9742f7" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,989</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c9e8dfc-5731-4977-8f05-3de1c0bb1c0b" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,006,178</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9353aea6-3715-4c9d-8404-7a799aec6396" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">324,337</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities and Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eda63bb-1f6d-44b5-bc1f-27660381027f" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,795</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85866a13-6267-41dd-8fb7-efd7731779c7" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,758</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a976b04-bf6d-47f6-b339-1bcc017b3bfb" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1711e08b-c6e3-426b-a836-72456f00d096" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,455</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued manufacturing expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fda9359a-2d2a-4392-b7b5-f37e860922e6" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:AccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6d2d66f-f102-4e7c-a867-385f8d945003" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:AccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f22b764a-19c1-4964-8e07-a8032d0a6fd4" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,375</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0305bf96-32fe-4ce4-9e3c-a3abf749d00e" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities &#x2014; current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd8aa74d-f622-45ee-a6b6-d08e9bd61eba" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,910</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b695dd8-2da2-45b3-8ffd-f2a00f414fb8" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,276</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2565a7b5-5479-46a0-bcde-a6939eb45ad0" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,525</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c37800e-cab3-4766-b933-3e27e9ff31d6" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,716</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities &#x2014; long-term</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fa7b5abc-001e-4502-b582-5a95008ea84d" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e1eec72-21ed-4a32-aeff-f84a667712e4" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9aa72d04-7fce-4f3b-9256-97faaf75f9c2" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a0e6881-a97e-43db-9fe9-eaefce2e8fef" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b8d0d22-5068-400b-a0d5-07d4264308c6" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,565</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26464ca1-bb53-433d-a644-6cefa51a0765" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e8d3af2f-da3d-4a8d-a3ce-fe78d26e1535;"><span style="-sec-ix-hidden:F_01e56683-a72d-4e07-a927-c99f3d7b0a4c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 6)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbe89649-a95c-4a1d-8d48-5f469bdfad28" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_f6d21062-949a-41e7-9ad7-996b63b713ab" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value &#x2014; </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58f981fd-ca00-4bf2-a31e-9e2a76b2edc9" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_5f38d0ab-4b9a-41c5-8030-f41707e93447" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;authorized at December 31, 2022<br />&#160;&#160;&#160;and December 31, 2021; </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78fdb991-5a35-40ce-ab2b-91e8c26cde81" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_60541522-0eb6-4a83-a490-0c5fe84af573" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_36030bf4-c1dc-4e8e-9cda-d3e0e5a985f2" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_21bc53f7-e69a-4268-b8b9-2b1c0885fbeb" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022<br />&#160;&#160;&#160;and December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53adcc76-f44a-4910-84e0-2de09ee05ffc" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5442fbb7-7a0b-44a2-8fc4-ed2539c8ee80" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_934d78c6-6ec1-4c18-a67f-4059268e38b3" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_3c0a19b1-2324-427e-b4b0-fad40b8e9eb7" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value &#x2014; </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a8e2e46c-4eb0-4f8d-b2c8-fd5beb293667" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_70a69112-ea93-4ec8-b19c-eb30772d955e" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized at December 31, 2022 <br />&#160;&#160;&#160;and December 31, 2021; </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebe0bd2a-6152-4e7d-911a-4c0a56c9a229" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_1df93f62-fd98-4a36-9551-396d44349b22" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">79,470,670</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5c221d6-6281-4d6d-9ca7-dd581925f367" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ca2df803-55eb-489f-9bab-48ff38db069a" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">53,031,978</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding<br />&#160;&#160;&#160;at December 31, 2022 and December 31, 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55d1a6fb-c2b6-440b-bb81-46d1949f8811" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3">82</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca06bb3d-e525-4e5f-bfa5-0daf234e063a" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdf344a2-f7aa-4764-a0e2-6a1ff2735089" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,476,018</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52e5bbad-fe7d-4220-9e51-5852eb99d916" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80ee7b50-3dfe-4024-bbcd-821733d7d159" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b1d494f-c761-442f-88ca-dae1de577f9a" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dcd7c64-6e10-4efa-bf8b-ac10f59b3258" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">522,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1b0d039-4dcd-42d7-ba47-816594e9a3d8" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,641</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d21f53e-48f3-4d69-96af-3fb9c13b1c90" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">953,613</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03b77302-7f8c-4e94-83f4-d8d8ea601fd4" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">284,018</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08a05d0a-b318-4f31-ac4b-dc4517a1003a" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,006,178</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_158efa55-1685-4d49-85bf-65a56b6c1c03" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">324,337</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statementsofoperations1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.176%;"></td>
    <td style="width:1.49%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.395%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.49%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.395%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.49%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.565000000000001%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development (including related party expenses of $</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6c2383e5-f5a3-48b3-a7bb-d712ccad6a75" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ResearchAndDevelopmentExpenseToRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,  <br />&#160;&#160;&#160;$</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be336aff-e828-4fb8-929b-c2da09d726de" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:ResearchAndDevelopmentExpenseToRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,359</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and $</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40e4ae67-4cdc-48aa-ac13-7a1c2c8f2e3c" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:ResearchAndDevelopmentExpenseToRelatedParty" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,331</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;in 2022, 2021 and 2020, respectively)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8e93a83-3c57-4a97-b079-f0e3f21e4278" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62b493b2-8d85-4889-bcc8-0d01fc6a1d00" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_130dd359-7367-4f52-941c-e007b39d74d1" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,564</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquired manufacturing rights (Note 6)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e3ed987-0031-4f6a-b224-707e7f81ed86" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:AcquiredManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6882663e-cecc-44bd-8af6-5621bb8ee6e7" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:AcquiredManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f173401c-ac39-4683-bd48-cc6991fceafb" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:AcquiredManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c66568e5-997c-422d-8522-33ba7582a023" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7b62dc8-42c2-4e78-9c8b-0a279dc6ce1f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04fb80cd-4c88-4208-87e0-77333dcd99cc" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad45fb74-6bc3-43b7-89a5-939daa11abbd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a192afe-d8dc-40b0-a5d8-fda2fbcf2464" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">103,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81755ac9-6433-49b5-a7b1-8102ead96960" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa9f3937-c15c-4795-aa31-86b6f0a48aa0" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">232,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e158a35-fd46-4cc4-b799-c35fed4df6a8" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">103,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ad982ac-befe-4ef4-a1d4-04dff3cd7191" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83be0c97-457b-49a8-9538-788f4c7b9d19" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a7ad823-dff2-4579-a5c8-fd2080a5a969" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad031f63-f9df-4b7e-b72b-4e080bc93221" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af2e62c0-ed37-4d66-9e5f-19057a39cfe4" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb757ee7-da7e-4f15-8d88-74369037e1ba" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ba4acf8c-2ac5-4251-8544-76fc4cfc46d5" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_406f17af-c893-44a7-ad6c-7fca5ebfb830" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:GrantIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,931</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6832a7b-afdc-4b60-a007-2b0cc6e101ee" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:GrantIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7b3cb2d-ee53-4022-b7af-b59fb4512355" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:GrantIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,478</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Realized gains on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66522696-3ad6-45db-98cb-928cac984e85" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:MarketableSecuritiesRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e825f5a4-1e60-4d43-82cf-2cdf5c32e40c" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:MarketableSecuritiesRealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4bd2ff3-1d7e-4874-8663-77a2b13720a0" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on disposal of fixed assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6161766-2052-42bf-9078-71e8100090a1" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66d7bd1a-fcb0-41da-89bb-a38d0d05623a" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ceccbab3-b344-40bf-afe0-da6d2b050c7d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign currency transaction (losses) gains</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7374387-dc9d-4aea-a9aa-3a3d6c28cb77" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_372df499-b391-4b5d-b627-ddfa99c4597c" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5d7ada6-1916-403d-9f98-81ead3c87407" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,351</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09175632-c319-4b85-a5ff-90c18f8a63bc" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,771</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1794dab-9d5b-4a62-8235-7bad62eb31d6" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,593</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bb3329e-be9e-4057-a625-8b63542a0b48" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">364</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68dba904-ec9d-41b9-8fd6-ee9cff7a95c5" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,485</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c41e17e3-7c53-44e5-8b48-d38c3bf1722d" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81931250-e3de-49fd-acc1-5daa37d197b5" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1c5c049-3ab9-478b-b0c7-d07d09ef02ff" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_e451d592-58d2-4eda-9384-5bd2cbde958c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.44</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6d32f73-c4f4-478a-a011-d01c4cfd271f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_1bc70f62-dc8c-48f8-8863-9957b992d53a" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.93</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32c227ef-04df-4c5e-bcb2-b471d9ea137d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_85e020fd-145d-44e9-bf40-adce349d761b" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.02</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49868336-755e-4fa2-82c7-a3c1e2530339" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_57b54ca1-15b4-4dca-83f9-d179a70f09e1" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">64,877,988</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_306c5895-0675-4cf1-b0dd-09324afc7a15" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_d9895fac-ef57-494c-bec1-7f32475845de" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">51,922,108</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20547c0a-3b0b-4e4d-bec1-dd71dd7d20fc" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_de87fcc7-b608-4543-ac41-a6ff49ab2ef3" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">29,545,810</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_of_comprehensive_loss_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Compr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.347%;"></td>
    <td style="width:1.474%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.283%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.485%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.283%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.602%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.527999999999999%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3799367b-7e64-4cc9-8e7a-950e1225f700" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,485</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d1f9978-ff66-4d31-a89d-92e881092062" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6dd1b5e-0add-477d-8253-530e225dc328" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized losses on investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0423ed92-0b35-47f0-8686-0c3d25535e74" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ede360e-d91c-4e6a-9ac2-d68d2ebd5bbc" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive Loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bbdf84b-a0a0-459d-b759-f9d4504b4b9e" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,605</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a91cd4b4-3d63-4ec1-82ae-4adb28a81175" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,318</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4f88117-e030-4a38-a881-c4c3980d23d2" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_redeemable_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statements of Redeemable Convertible Preferre</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">d Stock and Stockholders&#x2019; Equity (Deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:14.724%;"></td>
    <td style="width:0.964%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.6470000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.964%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.6470000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.964%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.6470000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.994%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.964%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.6470000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.071%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.404%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.693%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.0020000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.7329999999999997%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.439%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.176%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.972%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.358%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Series A</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Series B</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Series C</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Series D</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemable Convertible</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemable Convertible</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemable Convertible</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemable Convertible</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2014; December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67fbe40d-c0d4-4f43-b97d-c1f0d0a7491f" contextRef="C_bc63e8f2-1888-4fcd-a8d4-a880d9bb2f86" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,225,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b925bdcc-cfd5-421e-b2ee-f5fef860028f" contextRef="C_bc63e8f2-1888-4fcd-a8d4-a880d9bb2f86" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ea7cea1-43ab-4ea9-8f15-cfdeb13f6993" contextRef="C_b29a7753-469a-481c-993c-8a5ee73c666c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,786,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc851ab0-77bf-4a18-b0d9-3969164d62c8" contextRef="C_b29a7753-469a-481c-993c-8a5ee73c666c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,151</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7da602e6-f905-41fc-b130-87bfef343e9e" contextRef="C_6d40cfd0-136e-4c2d-a988-0b2942394d6c" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,377,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_081c027b-b51b-4c18-b30d-7aa422930335" contextRef="C_6d40cfd0-136e-4c2d-a988-0b2942394d6c" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e661461-4172-4f58-a8d8-fd37eca67a06" contextRef="C_f071a04d-8d88-4c59-91cc-56470ac8c360" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,059,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47b77ef4-cd75-4722-af0f-7b21bfe4d675" contextRef="C_f071a04d-8d88-4c59-91cc-56470ac8c360" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4666174-3259-43e2-8a7e-5bbf40734153" contextRef="C_d7812bcb-1a97-4787-be8b-59a98d64a890" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4575d72-bac3-4822-81f1-fef1c4a214f6" contextRef="C_bf009615-d1f6-4a3a-935f-7b0d3b6dca01" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">109,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3f6009b-eebe-4b2e-b931-0c8f130a6f2c" contextRef="C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,373</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of Series D redeemable<br />&#160;&#160;&#160;convertible preferred stock, net<br />&#160;&#160;&#160;of issuance costs of $</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_320bc716-9f9b-435c-b27e-8168431c7626" contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67" name="pcvx:TemporaryEquityStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f139cfd1-2b39-4489-a299-7108bba1a130" contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67" name="pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,220,242</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f4b57b5-4f04-44c6-906e-58f27519ce92" contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of preferred stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7608426-6043-447a-87e5-cff070b26ea5" contextRef="C_da57a27c-5363-490e-93b7-2f25eccde933" name="pcvx:TemporaryEquityConversionOfPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">6,225,719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_177f74b5-a8f3-4b72-8ab5-8ab8bc157e67" contextRef="C_da57a27c-5363-490e-93b7-2f25eccde933" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4253dc6e-7fac-423f-bf5d-ff1f9942082f" contextRef="C_cffd01a3-53b4-4cbf-9aef-3e5b1f46b78f" name="pcvx:TemporaryEquityConversionOfPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">6,786,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bfc5d23-f2f9-4ce5-9f1d-f65bbf914bb3" contextRef="C_cffd01a3-53b4-4cbf-9aef-3e5b1f46b78f" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55,151</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aca64a5a-8578-4239-ab3c-3789722f5ee8" contextRef="C_8a1db5ca-4032-454e-b64f-84afc6e86567" name="pcvx:TemporaryEquityConversionOfPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">7,377,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4fd6f41a-6566-4ed6-9298-16ed24be3c32" contextRef="C_8a1db5ca-4032-454e-b64f-84afc6e86567" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">80,192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf474531-d56c-43e0-bc9b-5507c0b2dd55" contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67" name="pcvx:TemporaryEquityConversionOfPreferredStockShares" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">8,220,242</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47fde73c-fc68-4f26-9865-a0b6eaa0a619" contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">109,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_535d2f59-907c-4853-bb6e-d52f759b86d3" contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,610,337</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a8919ed-4853-4468-afd1-44f807501e3f" contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a78e883-ed43-4b02-9f65-302379099893" contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,161</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f32d5f84-8f87-4078-bd20-c11f643413e8" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:TemporaryEquityConversionOfPreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of common<br />&#160;&#160;&#160;stock warrant</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e1573d5-f900-46bb-a791-fdb7a03545e9" contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880" name="pcvx:StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of preferred<br />&#160;&#160;&#160;stock warrant</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15079ef8-7218-4436-acdc-f909b1abab50" contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880" name="pcvx:StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,591</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrant liability write-off</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e1be6d3-2221-4bca-890c-9e543a7d28cf" contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94" name="pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fadfdefd-5ef2-448b-a99c-d825a01ff43e" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">629</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock upon<br />&#160;&#160;&#160;initial public offering, net of<br />&#160;&#160;&#160;issuance costs of $</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fdc69d8d-69a3-4fea-bc28-fa1af2a0cbc6" contextRef="C_99bb839f-a7de-4946-a60c-d6f300ec4d73" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2b90de4-378a-48d6-a9aa-4a4480ab7dcd" contextRef="C_99bb839f-a7de-4946-a60c-d6f300ec4d73" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,968,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe610f39-f1ab-476d-ae00-caf5b53f6fcc" contextRef="C_99bb839f-a7de-4946-a60c-d6f300ec4d73" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c38ff7e3-7fdf-4511-ae51-f9d6da8d72b1" contextRef="C_522586e0-c2a8-4187-8dfd-3a928a099df2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">263,989</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5bd93f84-0823-4e85-90fb-5d8d73cfbaf2" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61685653-6730-44e0-9874-7c48fd18a0f4" contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">343,444</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a1ca8ce-8227-4527-be1f-8cb458e2af90" contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83c0ac52-4797-4304-924d-3f9217b6d7c9" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock related<br />&#160;&#160;&#160;to early exercised stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee209d3f-167a-4399-ab11-6eabe860a137" contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880" name="pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">14,819</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under<br />&#160;&#160;&#160;Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52daaa4d-a041-4783-ad65-c2f76b73fe21" contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,465</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76563054-0c5a-44d9-8c01-d3955301776b" contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a904caf-45d8-44c7-a564-12800c394e2c" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of early exercised<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10905fed-e9a0-40a2-8312-58ac336a16f7" contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40cd216c-9441-473a-a38a-15cf1b69b98f" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of preferred stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_722da82a-c237-435c-b15d-55d62a633cb4" contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce9f5dcc-8606-43d3-8592-bf4a2005477a" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ad82e38-5908-4425-a4eb-b85178ef9864" contextRef="C_8c77accc-7d52-4157-8c4c-e2e27e2e2b05" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e0c4f4b-20ab-45c0-8fc6-1451f8c48614" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2014; December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7883c50-5176-4f40-858f-1727f5223757" contextRef="C_b71d1ae0-0191-4fcc-9eb1-6928e92a2341" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">51,071,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7dfbe6ea-ec56-41a3-8337-0584a48c9826" contextRef="C_b71d1ae0-0191-4fcc-9eb1-6928e92a2341" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_029133b6-8f7a-4bbf-8678-145a90ebe250" contextRef="C_2a97fce7-5ef2-4cc8-85f5-b620ca762566" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544,353</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca9be74c-5346-4fe1-a5c0-1663ec04a2ea" contextRef="C_7a8dc7cf-7734-4350-9266-07d83e2f4a3a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">198,564</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_359db087-db8f-41fd-912e-0f8ecb8a30e8" contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345,843</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b978a96b-2db4-4036-a952-cd11aab73e16" contextRef="C_85dd075c-01fc-4937-bc97-63808bb2e3a9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">931,114</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_113b6adb-8ffb-46bb-939f-14ca75547b6b" contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48a0933c-cfe7-4b7f-b8cf-23169a1349c9" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock to<br />&#160;&#160;&#160;Lonza Ltd.</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b26eeee-8265-4270-8d2f-0fd0e06bb3b8" contextRef="C_85dd075c-01fc-4937-bc97-63808bb2e3a9" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">399,680</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f54c7ebe-321c-48d9-8c45-63d5d1dad556" contextRef="C_85dd075c-01fc-4937-bc97-63808bb2e3a9" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa6a0c30-b682-40a3-bbd2-21cc024cfd7a" contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea7c3f0c-fe17-467c-8ace-efdd43649089" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,001</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in<br />&#160;&#160;&#160;connection with at-the market<br />&#160;&#160;&#160;offering, net of issuance costs<br />&#160;&#160;&#160;of $</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_009e999b-1b6d-4dd3-9425-66a39fbeb7f0" contextRef="C_9a4f0832-de96-4079-b3c1-db1efe6e81b7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06d5d8be-0909-4abf-852f-4e616c77e694" contextRef="C_d4156e2c-f054-42e7-a026-6dd2300deca6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">567,045</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2626d74c-fe93-4601-ad65-12972dcb6a0b" contextRef="C_d4156e2c-f054-42e7-a026-6dd2300deca6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b8af938-ccbd-4490-99db-b1e2d659c8a5" contextRef="C_93ae0419-91bb-4c85-9618-57fe0afc3264" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,846</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1464529a-8198-4a4d-a31e-c68f026debc5" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,847</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under<br />&#160;&#160;&#160;Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6341a2e2-3fd8-48e3-8200-3244225e5b67" contextRef="C_85dd075c-01fc-4937-bc97-63808bb2e3a9" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">62,546</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e9cbeeb-0f24-46a3-b83a-41e2653a7ba3" contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dcfdb3d-a332-4740-9665-4b545852c4f2" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of early exercised<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34c3e62c-575d-4fcf-8145-32b46958dcfc" contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed1d581a-3ee5-4b80-8abd-97d51252f272" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24024dfe-d973-4c5a-b333-890a8e05bb99" contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23883c2a-0143-418b-a781-8e482719019d" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized losses on investment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea20e012-d63a-45cc-800a-560e161d120d" contextRef="C_7b1a0eec-bf5e-4892-9967-715b22960941" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15aca712-0eef-475e-a2ab-e5f621c39631" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f8b964f-ba7e-40c7-8182-7e5c7b8cd6da" contextRef="C_5cae38a4-c4a8-47aa-a3e3-61aaee5e44b7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5c393d1-4a74-4967-a530-72829b9cbb2d" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2014; December 31, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f1aa446-93d5-413b-a7fb-6dcfd77ad001" contextRef="C_16916817-1032-4d1c-9ab3-a2e5e372cb09" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">53,031,978</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ef47724-2cc5-4205-b692-d9a36cd236bd" contextRef="C_16916817-1032-4d1c-9ab3-a2e5e372cb09" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cc7bfc0-cab5-4301-a4bb-9af157e5d368" contextRef="C_ebe97179-a864-486e-a92b-54ddbdfb9b14" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">582,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70d4db57-469e-44dc-8c74-83e02c4c92d0" contextRef="C_6c850b73-588c-41c3-b04b-a21bc0ff9e82" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,641</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20d494ce-095e-48c7-87df-e416254c5e2b" contextRef="C_202f07f9-5156-457e-9195-d19a2910d156" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6486285d-0b36-4fa5-8d14-9ccd5794673d" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">284,018</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45b2065f-36f5-4198-a04d-57e12f099b5c" contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,178,572</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41d81a71-d879-481e-b7ac-059b6b073167" contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71035458-904c-4121-82ac-575ee585182a" contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,894</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5004420-acdf-4785-a165-06694c5b236a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,895</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock and <br />&#160;&#160;&#160;&#160;pre-funded warrants in <br />&#160;&#160;&#160;&#160;connection with public follow<br />&#160;&#160;&#160;&#160;-on offerings, net of issuance <br />&#160;&#160;&#160;&#160;costs of $</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_def7f49a-3fdf-4d73-bc99-4174a1a743a3" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ca62c3c-35da-4e1e-82f2-6736615f3b5f" contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">21,062,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aabfe90e-3a26-44ea-a792-dbab931bafea" contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_310ebc17-4792-42b3-affc-d013677ecc02" contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">759,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f35b2743-8c5e-4d18-bf8b-35745f6185f6" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">759,181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in<br />&#160;&#160;&#160;connection with at-the market<br />&#160;&#160;&#160;offering, net of issuance costs<br />&#160;&#160;&#160;of $</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26c35c29-6845-4966-ab63-c5f328a9392b" contextRef="C_fffa34b2-595e-4a00-a483-b9a4cb5243ce" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4e2d01d-119c-43bc-8986-06839549f81d" contextRef="C_42dcecda-101e-4ddd-8695-6548e530de78" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,921,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93b1a38d-e1bf-4327-8ce8-15e3449cbde2" contextRef="C_42dcecda-101e-4ddd-8695-6548e530de78" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e02d7a74-0a8d-40d3-8fde-c54b781d44a9" contextRef="C_837815d3-4f60-4133-8174-f837af239d75" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23f43847-ed95-416e-bea9-d2ee8c345173" contextRef="C_2fdff316-147b-4b2b-bcfe-6871447ed8e0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock for<br />&#160;&#160;&#160;Sutro stock payment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_250cce00-e1cd-43ab-86f9-b74f7163e037" contextRef="C_86059fb6-8a98-4604-99c1-7846fc457e76" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">167,780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_544acc7b-ad9d-4cb4-a408-03f016799403" contextRef="C_ad2a30c9-052d-4eba-928a-c4c5ab6c20db" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a0defea-5413-4527-94d0-35fa8c13d906" contextRef="C_75637c01-f692-4f45-a633-9d4eb7b8df37" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under<br />&#160;&#160;&#160;Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4829463-5bb7-4b9f-9278-c74b7dd04909" contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,709</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_942b8c03-8d75-4af6-adc2-53ea578044d2" contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_319fdcd6-0567-4cfe-8a32-da468bfb3975" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release of restricted stock units</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0baccd7d-cf20-49ce-bfed-6de0c107afad" contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02" name="pcvx:ReleaseOfRestrictedStockUnitsShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">46,603</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9850ea6b-f9c6-42d2-859f-6358a3737c5b" contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091" name="pcvx:ReleaseOfRestrictedStockUnitsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">861</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3606ebe-5dfb-4022-8817-6f374f56594c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ReleaseOfRestrictedStockUnitsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">861</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of early exercised<br />&#160;&#160;&#160;stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42edfa41-da36-4876-bdc6-ee0914e654fc" contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60c7455b-7a15-45cc-b3ab-80206476479d" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b03eeb3-c53d-4a3f-8f0d-a91399859337" contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b58f9ada-c55e-499b-a218-e1014aaf5621" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized losses on investment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af64ab32-a069-4ea2-b382-4a48a3e3649b" contextRef="C_06c078e9-1e6f-4493-a040-ad253c029b6b" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_57b83a5b-2e82-4019-9db5-56e6a6fe9a7f" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_079462a1-8d32-4a1f-98c0-d1cb55fe7836" contextRef="C_3a1f2bbd-3a84-4def-8008-4279ed957a96" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,485</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17a25db7-ca2d-4c0e-ad30-e031d4658f29" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,485</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance &#x2014; December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fb06e5b-a452-4afb-8c21-4c7d626886b3" contextRef="C_81569ea5-c187-4394-8eea-071974a031f5" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">79,470,670</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdfb6e78-5995-4b49-9987-5f0a767dce25" contextRef="C_81569ea5-c187-4394-8eea-071974a031f5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3113a62-e32f-43d2-8d15-ae3391f70575" contextRef="C_cc891ca2-75ea-4415-b513-14e4b37dc9b4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,476,018</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de4bdc3e-b938-43ef-95db-ac30e112e51f" contextRef="C_13165d69-2eff-4eec-af08-7f5b5519d9b9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">522,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cd83a76-c93c-413a-94a1-18d537de785a" contextRef="C_c3d2b846-b46a-4469-a0a3-586d1c69fc46" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a8c5890-c314-4b04-9141-5f418a12609a" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">953,613</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statemen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ts of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.921%;"></td>
    <td style="width:1.145%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.792%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.145%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.792%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.145%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.059%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dcedfc2-2a69-4b07-b478-3bd23f56b03d" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,485</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aada342e-f761-4a21-8bd3-50a77fbe894c" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8eba5bb4-94b5-4e4f-b6a1-aae099852c5c" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caeaae05-a106-4bfc-a10e-05842fd04368" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,577</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_757c1b89-e315-4827-a5f1-3ff6238d56f5" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,800</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_303bc1cc-1d41-4182-af23-994a13e4ce11" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,405</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bf2bfcb-bac2-4766-89d6-de01c658af03" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_403e4e49-247e-41d0-a140-731c3db2578b" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fdd2c87-4df2-4ed3-8b09-01037e005a85" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-cash payments for acquired manufacturing rights</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfd28b4d-accd-459b-aa4c-5965823904db" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:NonCashPaymentsForAcquireManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f88f910-4712-4b4b-8201-2ed78580d560" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:NonCashPaymentsForAcquireManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a26ef032-b5f5-41b1-a9c5-0393578b1af1" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:NonCashPaymentsForAcquireManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of redeemable convertible preferred stock warrant</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d4931ef-fc20-4b5e-adf3-d98cea815473" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_129d51a1-2389-42b8-91bc-a39d3d7aee8a" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be7cf5a0-b8d9-4820-8129-a2b148bed1a8" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Loss on disposal of assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8bb3fc9-1848-4c53-bcad-0cdf031a2539" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b45f0c8-2e56-4c05-9a5d-1b6b97c8111d" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a158327b-10c7-4ab5-a758-451e23202f4f" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset impairment charges</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f50ab101-0e41-461f-b89f-00584c4077a1" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3">213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2cae7704-cdf6-428b-bc6e-322c14693d2f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff2f06f8-40e2-4c44-9154-11b377f5df1b" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3">267</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c79bc36-577e-4de9-85c7-c40ccb728fdb" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,619</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab28a9ca-2ea3-47fb-88eb-bd3ab30b120a" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2bddc0c-cfe9-4193-ac15-e6400d0be8b4" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net amortization of premiums on investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77f35ba0-f29b-4173-8dbc-25614b8662d8" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df90b4c7-6e21-49a6-ad75-bd0b41433a81" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,406</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_710bf287-5df6-48bc-acb7-84b77711504d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07f4828c-2f29-48ae-9a8e-13fcc2fbf64f" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ce0a108-a054-4720-b80d-3267f5b217a5" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_478039e7-5bb3-4b2c-82f7-37daf9f1390a" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3">58</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e27b0b2-dbc9-4418-ac29-6ad889d4cfa2" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">465</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22503bd3-79a8-4daf-9118-764f69e2ce05" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,539</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08c0f8c8-15d9-4627-88a6-f2f46f948874" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3">75</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b803246-efe9-447c-b132-a9b1e543e736" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,151</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_893123ac-4b56-41c8-a721-4bad0fe1fe18" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43fbffe3-24b3-4ecf-a68a-bd01da583583" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ded44c63-7760-4ecc-b9fa-3bb689d5281e" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83d0e322-73cb-43e1-9498-d08bfc43d9c2" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2726f8ec-4f34-4212-8254-3f0a7648fe68" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,102</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_612381c1-b3f6-404c-b4a1-8ee4cd0bbb47" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:IncreaseDecreaseInAccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,275</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46edb2de-e45c-42e0-819a-1cfd20d98e0b" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:IncreaseDecreaseInAccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,170</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa92d0ed-4f8e-4ae9-a3ae-8018ddf5de0e" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:IncreaseDecreaseInAccruedCompensation" unitRef="U_USD" scale="3" decimals="-3" sign="-">130</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued manufacturing expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9127dd33-f8c2-44d2-8380-e42a4d40a598" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:IncreaseDecreaseInAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9975000-81de-4c5e-b471-b318d884801d" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:IncreaseDecreaseInAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,572</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08d070a7-5eb4-4a34-90ca-8cace19a255d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:IncreaseDecreaseInAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ace06f6-257d-47d1-911e-ff5304006930" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06c5fb52-9fff-47c8-b4c2-0f0938dc927c" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15b51e72-1d97-44a5-96fe-cec57734f7ae" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred rent and other long-term liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4b71bff2-b68a-4cfe-9841-b0358d238e1a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ca49a07f-c9f4-4797-bd0b-9834c93e44f5" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b95f8c92-4e4c-45cf-b1c8-a1904a136067" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fa9c554-e8f0-48b6-b8ad-d43de341e5d9" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">170,597</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8365b7e0-12d9-4c18-82c4-2ca7760d6734" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">121,393</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee1b7751-c989-48f1-92e1-58bcc6d32089" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">46,628</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_264252f0-a9af-4349-844a-8bbb45ff4cbf" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,848</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbe3651d-aab8-4f8e-ab1b-81ab6c565224" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,555</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbb34bb2-ecc3-4a52-8982-115b6fa904b7" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97e9d523-18e8-463c-9556-35b15bbea960" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,745</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f50a8ab9-68d0-4d5a-9e3b-baee7b7a924d" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">336,341</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a3bb07ba-7f76-4f5c-a7e2-3acb35bfdb99" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e5ee21b-5a79-4376-9963-b05333a86359" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,691</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5eb2fa0c-0220-41fc-a99b-daaa43117326" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e07043d2-e77f-4e34-8bbc-4ae6eb8822c6" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales of investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b21876e-e7c8-40b9-94c4-8fad4151b924" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_19a63232-2e00-41bf-ad88-2f115e2bc28f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,062</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fef60ab-032c-47db-820d-90be42a3f9ec" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sales of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78d84b37-462b-4960-91f3-892615396043" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eca913a3-a7c1-4388-89c1-37e78caeb7df" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5de17821-db47-4703-8ade-584a472cef36" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_64f57ac7-e42b-49a4-8b92-0fc58c0f216d" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7208331c-9f0c-415c-bb5b-20df3d78e62f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">212,308</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc183c0e-3eb4-450e-83f4-f1e39bf0703f" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,105</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments of capital lease obligations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9fa2d565-e920-4498-8e32-b2bb4feaec7a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:PaymentsOfCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79133583-1d35-4299-b0e6-d473f4fb302f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:PaymentsOfCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df6fdc89-9d21-49fe-a761-649762680dc6" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:PaymentsOfCapitalLeaseObligations" unitRef="U_USD" scale="3" decimals="-3">61</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from initial public offering, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1491197-fcc6-4a55-a4d4-8d2baa9bd56a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8597c16b-be57-4b3c-a19a-62c74d2d9e6a" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f02bbec-e07f-4702-86e6-34f55c5a4882" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">264,007</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock and pre-funded warrants from <br />&#160;&#160;&#160;&#160;follow-on offerings, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06e13a12-ca62-4769-a73f-316bcfe50d1f" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">759,181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c44ebcff-a5c4-42b6-a903-c3ebc23f9359" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20f5198f-585a-4dd6-99da-de75bb1c65c3" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock under ATM Sales Program, net<br />&#160;&#160;&#160;of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a2df14e-2113-4dec-b076-306697f2c5cf" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97,299</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f516c8b-389b-4dce-90f0-4c48ac94e93f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,896</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1c26e74-597e-4252-ad3f-f4a66c4e051d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of redeemable convertible preferred stock, net of<br />&#160;&#160;&#160;issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3490014-fe42-40b7-bc4c-59627c052a20" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32387656-1bb3-4593-b9ab-d048f7330ba4" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_184830d2-9e0c-4a42-9287-2352e48fed05" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,879</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of common stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3592e264-2c89-42fb-9aa4-683ca9e4f307" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,895</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f907f3b-b796-409b-810e-98a1b1d68dc3" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bceac9b-5cdf-4702-bc10-4208a11c4627" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3">635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock related to early exercised stock<br />&#160;&#160;&#160;options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1798d7f5-47de-4cfd-96b9-4a7b581827dd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a578baa-0d44-4ab8-9b8b-d9a27e08004d" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c61ffd5-d004-45c7-a082-75db61e122b8" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" unitRef="U_USD" scale="3" decimals="-3">36</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock under the Employee Stock <br />&#160;&#160;&#160;Purchase Plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_059a83ed-7bde-46b2-8f96-feb4e385c337" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,033</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ef0c7e1-284b-4b31-86c1-a19e8ba9b059" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_826ae7d8-d2d0-42ed-a91b-2fdb6b8c3c5a" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3">374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Release of restricted stock units</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f789eb4-5ba2-455b-b29a-dc1b4c1b7d8d" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ReleaseOfRestrictedStockUnitsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">861</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b95f252-3610-4244-a468-90fe7f36d704" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:ReleaseOfRestrictedStockUnitsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faba9920-adb7-4e7e-bea8-bd558882e1e2" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:ReleaseOfRestrictedStockUnitsValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:40.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84e2d772-fc34-4295-9754-b353f667f0d6" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">861,547</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bbc48410-ad94-4371-9e81-8e5e73175aa0" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,796</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f7c77d7-8c3f-4a79-8423-6f3278115b07" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">374,870</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of exchange rate changes on cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07eb7484-7694-4410-8d3b-35fcef6aaed6" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3">137</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_515c3939-debf-4719-a1cb-f53812f27027" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bde5499a-cd2b-41b9-9475-6f3ea4db6b2c" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3">87</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c983c196-0330-480c-9194-326c9c2d570a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">765,672</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88ae5de6-8ad3-463a-8b8b-e508ac5bee88" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">316,344</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61532eef-fe38-424a-9151-9a9102bc424a" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">327,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fddcf83f-450c-4c6c-9121-f10e8adecfd6" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb8e2e4f-1df8-4406-9f85-25be8d6dd343" contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d96e189-de81-4b26-b8a2-1320a3d6210a" contextRef="C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,976</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:30.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f74f4632-980d-457f-85bd-51f0e50b77a2" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">835,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_891f9f8b-e53f-4aea-9300-b1537b878413" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdff87b9-c0a3-4ec1-a0fe-561243e93608" contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosure of cash flow information:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_258b758d-bcb3-4a2b-bfaa-acf1d8f434be" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e534ec7-4043-4b71-8c18-af2ae2d50380" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1323dd04-eb54-4178-b9b2-bdbfda8a1caa" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supplemental disclosures of non-cash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment recorded in accounts payable and accrued<br />&#160;&#160;&#160;expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf3254e1-ce26-4df4-a56b-7da93da16f7a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3">110</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83816067-2367-4c31-8454-bff67fdf0fb8" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3">766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d0b0ef1-f0a1-454a-9693-91bfa13cad0d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3">494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock for acquired manufacturing rights</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28fa22e1-e2fd-4f5e-8286-70678661828c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_deb38e5d-c5d6-454e-aa0b-2395ab89c56f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85917831-5bee-4665-a2d6-0f6d6b2c8d07" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conversion of convertible preferred stock into common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_993ac8fc-0cbc-4dcc-b8b2-654b8bb3b404" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49730542-3352-43cc-a71b-1af86ef9fbaa" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6278cb4e-9632-49af-a145-3b1e3e8da102" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">270,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock issued for payment of accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ba07a33-4680-471a-a877-7db9feeb04f8" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2131a283-efc6-42b2-82f7-8d13ded8f0ca" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb865b43-1013-4839-8961-311713d261c0" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f082096d-e6ca-42dd-b9f2-6fd7000a45d5" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2361e612-b38e-4ea9-8fb9-e28ac52c7123" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37545605-fd9b-4e8c-8b15-386dad6c31a4" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3">134</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The accompanying notes are an integral part of these financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_unaudited_interim_condensed_fin"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c534afc6-6dbb-4739-a94b-cca0dd790ec4" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_c534afc6-6dbb-4739-a94b-cca0dd790ec4_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Company Organization and Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;the Company,&#x201d; or &#x201c;Vaxcyte&#x201d;), headquartered in San Carlos, California, was incorporated in the state of Delaware on November 27, 2013 as SutroVax, Inc. and we changed our name to Vaxcyte, Inc. on May 15, 2020. We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. (&#34;Sutro Biopharma&#34;). Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our primary activities since incorporation have been to perform research and development, undertake preclinical and clinical studies and conduct manufacturing activities in support of our product development efforts; organize and staff our Company; establish our intellectual property portfolio; and raise capital to support and expand such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 5, 2020, we filed a certificate of amendment to our amended and restated certificate of incorporation to affect a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ab2de938-c3f0-4be7-9a42-431d8533edd0" contextRef="C_adfec910-931f-4fe2-b666-3a64354787e5" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-for-1.6870</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock split of our issued and outstanding common stock, preferred stock, stock options and warrants effective on June 5, 2020. Accordingly, all share and per share amounts for all periods presented in the financial statements and notes thereto have been retroactively adjusted.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, we completed an initial public offering (&#x201c;IPO&#x201d;) in which we issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f694d7e8-085c-4e2a-a719-8e87df909ec0" contextRef="C_ace7762d-3569-458c-9040-9f42331af172" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">17,968,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, including shares issued upon the exercise in full of the underwriters&#x2019; option to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d63f6ade-c5b6-4096-a0da-41c483f489e2" contextRef="C_ace7762d-3569-458c-9040-9f42331af172" name="pcvx:SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,343,750</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d867312-1bbb-447a-8162-32331597481e" contextRef="C_22b9506a-6924-44d6-a115-432bb54e29f6" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">16.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. We received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_634d257c-dd01-402f-b16b-8a2bf6c82e7d" contextRef="C_5ff4f253-5e79-4f0f-9621-48e669f7b797" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5">264.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_040fb4b5-31ce-48a0-a306-0393eec58435" contextRef="C_5ff4f253-5e79-4f0f-9621-48e669f7b797" name="pcvx:PaymentsOfUnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5">20.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83da5785-8495-4d81-bdd5-8bd14f914593" contextRef="C_5ff4f253-5e79-4f0f-9621-48e669f7b797" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_c534afc6-6dbb-4739-a94b-cca0dd790ec4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immediately prior to the completion of our IPO, all outstanding shares of redeemable convertible preferred stock were converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d2f177f-34e0-4161-af90-140d7748c53e" contextRef="C_443140ce-af83-4051-90d8-0a039e3d6625" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,610,337</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. Subsequent to the completion of the IPO, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b1ab66b-0064-49e4-9a3b-aa2c48083d93" contextRef="C_6ea235fe-244e-4bbf-8025-1963f440f2aa" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of redeemable convertible preferred stock outstanding.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_bcbe763c-1995-4d7b-a2ac-6636c8165b7c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c965ad7-ead5-4242-86df-aec707088cab" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) regarding annual reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bafba52b-033c-4d1f-bc8f-a3c70e73e2fc" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">taxes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_00212fec-4348-4a5d-b4ab-43b7b20c8598" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to supplier concentration risk from our suppliers. Although we are working to establish secondary sources of supply, we currently source several of our critical raw materials from single source suppliers. We also use one contract manufacturing organization (&#x201c;CMO&#x201d;), Lonza Ltd. (&#x201c;Lonza&#x201d;), to handle most of our manufacturing activities for our VAX-24 and VAX-31 programs. If we were to experience disruptions in raw materials supplied by our suppliers, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and immunogenicity or efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5d3def4a-ea80-486c-b980-e7ea006ef7a4" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment and Geographical Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate and manage our business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d28d1b28-8558-4a6e-800e-1f2a06c90f7d" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6eb86c7-9e00-4a87-b769-bec917cdec75" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our current corporate headquarters. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_92558b3c-3156-4f23-9f07-e3050424956c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" escape="true" continuedAt="F_92558b3c-3156-4f23-9f07-e3050424956c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:</span></ix:nonNumeric></span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:continuation id="F_92558b3c-3156-4f23-9f07-e3050424956c_1"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
         <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:38.052%;"></td>
          <td style="width:6.663%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:15.244%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:2.235%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:15.116%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:2.235%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:14.456%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbff1e49-017c-4480-a8f6-5ca9d41a3f6d" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">834,657</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e8118d5-0e5f-4e5e-8987-bd588efa4994" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,985</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9581705c-abec-4ce5-bfa6-25bcdcb16223" contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aeb5a447-a981-49bb-b04e-df1287c4f4bc" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">871</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf2b21ef-8077-43e3-86d0-c72df6d651d7" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">871</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfe23858-3c72-48bc-b475-845a050ddb51" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">835,528</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e0278c7-dfd1-49d6-afd5-2b0eb3b0bc63" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,856</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_147c89ad-609a-4c9e-819b-a1172c108637" contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">386,200</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e1b9905-8253-4add-a8bc-d22e9d85146e" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investments have been classified and accounted for as available-for-sale securities. Fixed income securities consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses are also included in other income (expense), net. When the fair value of a debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in our statements of operations. When the fair value of a debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in our statements of operations only if we sell or intend to sell the security before recovery of its cost basis.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_acdc07b3-2a5e-4a74-b266-5f74a66fea5e" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:DeferredChargesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6beaf5a9-0b2d-40f4-b7d9-a546242b2643" contextRef="C_c3a3620f-8e54-449e-9e7d-3e9250cb8220" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbaf2f43-ee53-45d1-aa68-3fbfafd873ed" contextRef="C_f949711a-cc58-4c69-8736-3e85b3424551" name="us-gaap:DeferredOfferingCosts" unitRef="U_USD" scale="6" decimals="-5">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of deferred offering costs, respectively, were included in Other assets on the balance sheets.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a382ed10-7190-47d7-8823-0a293febb627" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_702b2ee1-c8d3-4b6c-aa18-57f4ed887283;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1d104096-19bf-4e70-8afe-1e5c7da416a7" contextRef="C_132ccca8-d60e-4222-bb51-935509c790c4" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations in the period realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_51cc8f6d-e9a8-47fa-9b98-bf208107b2e2" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Financial Accounting Standards Board (&#34;FASB&#34;) Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and its associated amendments (&#x201c;ASC 842&#x201d;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2022, our lease population consisted of real estate operating leases. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_050cdd18-e396-4343-96fe-21b6a2714b95" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:NumberOfFinanceLease" unitRef="U_Lease" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any finance leases.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases are included in Operating lease right-of-use (&#34;ROU&#34;) assets, Operating lease liabilities - current and Operating lease liabilities - long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_137d2f88-efa2-4539-9cb9-1a686349234d" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recogni</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zed is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94a85ccc-7249-40ae-b658-f6c127503a6b" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11136dd9-2cd3-45b5-a6c3-0000ca04ba47" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_08a1158f-a09a-427b-aff6-2083e847bb2d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of impairments of long-lived assets during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_410c420f-21a6-423b-990d-643b93ff13cb" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (See Note 3, &#34;Fair Value Measurements and Fair Value of Financial Instruments&#34;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_36349b1e-06f9-42f3-b0a1-2f14d1a1eed0" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#x201c;CROs&#x201d;) and investigative sites that conduct preclinical studies, clinical trials other supplies and costs associated with product development efforts, preclinical activities, clinical trials and regulatory operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_db42945a-02a5-4e03-93cf-0c2dbd327e49" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:AccruedResearchAndDevelopmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c586ca7a-9a5c-4657-ba72-2c1d77af1736" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:OptionToAcquireManufacturingRightsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquired Manufacturing Rights</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we entered into an option agreement with Sutro Biopharma, Inc. (the &#34;Option Agreement&#34;). As of December 31, 2022, the option granted under the Option Agreement is a right, but not an obligation, to obtain certain exclusive rights to internally manufacture or source extract from certain CMOs and the right to independently develop and make improvements to the extract for use in connection with the exploitation of certain vaccine compositions (the &#x201c;Option&#x201d;). As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we paid Sutro Biopharma upfront consideration. As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the Option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022. See Note 6, &#34;Commitments and Contingencies, Sutro Option Agreement,&#34; for further details.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d767240a-b349-4b35-a13c-d1d9ca5302d3" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2022 and 2021, we have recorded a full valuation allowance on our deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2464cefb-b92a-473d-846b-066d45cdd995" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For options granted to employees, non-employees and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The fair value of restricted stock and restricted stock unit (&#x201c;RSU&#x201d;) awards is determined based on the number of units granted and the closing price of the Company&#x2019;s common stock as of the grant-date. The grant-date fair value of awards is amortized over the employees&#x2019; requisite service period or the non-employees&#x2019; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16655577-c1c4-48ea-82dd-3f9e5b4ea14b" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8e95ff86-281e-4631-b09c-78498560bd5e" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b43ce25d-b4bc-4e92-be22-0acfc087a790" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding, including pre-funded warrants, during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little consideration, are fully vested and are exercisable after the original issuance date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c9336f05-4351-4cc5-80ab-87ce717a1d24" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the FASB issued ASU 2021-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Subtopic 958-605), Not-For-Profit Entities - Revenue Recognition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The required disclosures include (i) the nature of the transaction and the related accounting policy used to account for the transaction, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures. In Note 12, &#34;Funding Arrangement,&#34; we included disclosures on our cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#34;CARB-X&#34;). We have adopted this standard as required by the effective date. The adoption of this standard did not have a material impact on our financial statements.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and has subsequently issued related amendments, collectively referred to as &#x201c;Topic 326.&#x201d; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. We have adopted this standard as required by the effective date on January 1, 2022. The adoption of this standard did not have a material impact on our financial statements.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_f6134196-b38f-4e4e-947b-40e398dea866" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements and Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> 3</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 securities consist of highly liquid money market funds for which the carrying amounts approximate their fair values due to their short maturities. U.S. Treasury securities are valued using Level 1 inputs based on unadjusted, quoted prices in active markets that are observable at the measurement date for identical assets or liabilities. Level 2 securities, consisting of corporate debt, commercial paper, U.S. government agency securities and asset-backed securities, are measured based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted prices in active markets for identical assets or liabilities are not available, we rely on non-binding quotes from our investment managers, which are based on proprietary valuation models of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">independent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pricing services. These models generally use inputs such as observable market data, quoted market prices for similar instruments or historical pricing trends of securities relative to our peers. To validate the fair value determinations provided by our investment managers, we review the pricing movement in the context of overall market trends and trading information from our investment managers. In addition, we assess the inputs and methods used in determining the fair value in order to determine the classification of securities in the fair value hierarchy. We had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4622103b-665f-4ddb-9b17-14bad8babb68" contextRef="C_cf5ec869-94b5-4ffc-91dc-e1f40e3f1d68" name="pcvx:NumberOfSecurities" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f51f8f15-36f4-44b7-ada1-018113103443" contextRef="C_6ab2007d-2325-4131-b251-a78960367bd8" name="pcvx:NumberOfSecurities" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Level 3 securities either as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 or 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cc1e80a-c394-45d3-99b2-7d8d948be61b" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7e444b82-90c9-4408-8c37-91fef39c3397" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bfeb4851-fde1-4d92-92a4-5fc520d21264" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a0d49f6d-d343-4507-bf47-e179bfddf4ea" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers within the hierarchies during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or 2</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f9f947f-0153-44f2-98b5-5bc9d343cad8" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_1be4fff4-54ff-462b-8dd9-bcfc6bd92219" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_957fed1f-d93e-4f2f-a22a-e73e0834b7f4" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_f052523e-0def-495e-b8e5-38be954e7c49" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invested in money market funds as of December 31, 2020. In January 2021, we started to invest some of our funds in corporate debt, commercial paper, U.S. Treasury securities, U.S. government agency securities and asset-backed securities. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2661036c-8a4d-459f-9aba-62023b32b1c5" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_2661036c-8a4d-459f-9aba-62023b32b1c5_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_2661036c-8a4d-459f-9aba-62023b32b1c5_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.076%;"></td>
        <td style="width:13.785%;"></td>
        <td style="width:7.058%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.571%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.274%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.571%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.858%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.496%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.997%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.312%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br />Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br />Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br />Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00f4ba6c-aa46-4bdf-af7f-5484209c6603" contextRef="C_fb2cd419-f42a-43d4-8173-6fb63ccd1d36" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,198</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5b527ceb-8f41-487b-b98d-5570415cc267" contextRef="C_fb2cd419-f42a-43d4-8173-6fb63ccd1d36" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,198</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da6ba73e-0ff5-4782-861e-447c5cd7d4f6" contextRef="C_6ff2a197-ccf8-4a47-9068-2d3aca352aec" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">680,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb36206d-8ca9-4964-b045-b88c897eac87" contextRef="C_6ff2a197-ccf8-4a47-9068-2d3aca352aec" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">680,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a714071-57ce-4638-9452-fea55a827896" contextRef="C_58769e66-aeef-44e4-85ca-41149ca8f5e6" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_803e8c4d-d876-4eca-9fb7-7a52ef708fd9" contextRef="C_58769e66-aeef-44e4-85ca-41149ca8f5e6" name="pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_283cd759-4270-4c67-a7dc-54b6028b89f7" contextRef="C_58769e66-aeef-44e4-85ca-41149ca8f5e6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,547</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f6cb47b-c50b-44f0-a34e-fd44e5ce3824" contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,978</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_626b582a-9475-4b49-9325-d18d78d5b40f" contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,978</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f87d7673-651b-4a88-999d-c6b6d098bc53" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">834,691</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_495e9463-171d-47ec-9444-92cf68409862" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18dc7854-781a-44e6-b041-dced3eb7f857" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">834,657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_080a10c1-b7d4-4c45-9881-bc3ecf88a5c1" contextRef="C_180236c9-658c-46b2-8320-cd9fd9ee3932" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e7221b2-12b6-48ef-942e-af9918809fb7" contextRef="C_180236c9-658c-46b2-8320-cd9fd9ee3932" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de90cf1a-18ae-45ff-8a69-ef68bccdc64f" contextRef="C_180236c9-658c-46b2-8320-cd9fd9ee3932" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76dbc0b7-91bf-4340-bb35-6fc167b96d00" contextRef="C_5620db3e-07c5-48e8-80c5-b68b2362d81c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,161</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_865a4e11-1c34-46f8-a8e0-12ec79b2cdee" contextRef="C_5620db3e-07c5-48e8-80c5-b68b2362d81c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a6e2bb2-e30b-4566-8fc5-7be55db8e427" contextRef="C_5620db3e-07c5-48e8-80c5-b68b2362d81c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,144</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_412b664f-c15d-4526-9cd6-e3343b6da66e" contextRef="C_1e25d9bc-8da8-4125-95f2-eb869be71853" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,402</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_692608df-da0b-47f7-8731-d8878ad8ff96" contextRef="C_1e25d9bc-8da8-4125-95f2-eb869be71853" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_106e9d99-516c-46fb-817d-850daac5a182" contextRef="C_1e25d9bc-8da8-4125-95f2-eb869be71853" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b489e1f5-794d-4eee-8254-c9fe3c63f5ca" contextRef="C_4a24e83d-869b-46cd-a362-36d31d8ac8ae" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,954</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ca59769-98be-41d1-8c19-1be600b109c9" contextRef="C_4a24e83d-869b-46cd-a362-36d31d8ac8ae" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1ce589c6-36d2-419c-bfb5-02cf876a387a" contextRef="C_4a24e83d-869b-46cd-a362-36d31d8ac8ae" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b312267-78b7-46a8-bdf7-34f4a503c024" contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd4cadc9-f502-4da0-9337-0375440edfd3" contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d300fa7-8681-419c-b427-ab14b6aa85c5" contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">148</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7aa25b37-6507-489c-85f7-8f0097f469ca" contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,298</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e6f1058-c42c-47ed-8358-f15eab6b9357" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_844779c7-0d7b-498f-a088-647890f847b8" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9230e5de-20c4-49ce-ab52-b8fc892794aa" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">366</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03cafbfa-274a-49d0-a063-d60e2ea992e6" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96654932-207b-44e2-9f96-157b949718b8" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">958,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55a4f47b-c2b7-426e-82c3-1a4f40a4dad1" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f4607c2-27a4-458f-a83b-b72baeea262c" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74661a5a-1d79-4ac3-9623-43ba90cd9dd4" contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54" name="pcvx:CashAndCashEquivalentsAndInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">957,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br />Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br />Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br />Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_726842f4-01a0-4a6b-9cdb-441ff5604fad" contextRef="C_e17de957-4ef6-4075-bc74-6780bc32c66b" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42d437d0-93c9-446d-a160-27e70370d732" contextRef="C_e17de957-4ef6-4075-bc74-6780bc32c66b" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d63727c-1da3-433d-b45c-d256e2d9188f" contextRef="C_7cbd95b2-0c54-4116-8364-7ddbdd457679" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_527e5e84-c810-45cc-b962-b85c9a07097c" contextRef="C_7cbd95b2-0c54-4116-8364-7ddbdd457679" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e215da64-8c93-45ff-8d35-e76797274d62" contextRef="C_f24288b7-094a-4c0a-ad36-62c7652ebabb" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00d7f63c-ebd8-4778-b752-dad151a6766b" contextRef="C_f24288b7-094a-4c0a-ad36-62c7652ebabb" name="pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_138b4cc8-384a-43b4-8359-d0ccb1efa04e" contextRef="C_f24288b7-094a-4c0a-ad36-62c7652ebabb" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,596</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e22ba2ea-4ead-46cd-9f2e-9be99c91a23f" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="pcvx:CashAndCashEquivalentsAmortizedCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,986</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ace88069-0a27-4060-b35d-7d47abecd941" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6aa60fda-db82-45b5-8281-3047cf5a47f5" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,985</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b39441f7-8360-47e7-a700-59298ee70817" contextRef="C_415e98bb-bdbd-4558-a741-01b294239326" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81efdf0f-a10c-4124-904c-d7d2c8fada54" contextRef="C_415e98bb-bdbd-4558-a741-01b294239326" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8c4259a-da6d-47fa-a108-1186437d9f20" contextRef="C_415e98bb-bdbd-4558-a741-01b294239326" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d62d2115-3c04-4a90-be63-ebdaaa52f508" contextRef="C_d308ed79-6102-4437-9f98-f586c059dc9c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,941</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e74e2665-f62c-47ba-9579-0a5cd7e37751" contextRef="C_d308ed79-6102-4437-9f98-f586c059dc9c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_831f602c-6e00-481e-b797-5d36d1d1582a" contextRef="C_d308ed79-6102-4437-9f98-f586c059dc9c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cba89af-12ae-4895-9038-3bd333bcb637" contextRef="C_79e53c50-0fb4-4714-84d0-e5a2a573e00b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,498</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd4f67e0-b15b-4d7e-80de-c616c6899e79" contextRef="C_79e53c50-0fb4-4714-84d0-e5a2a573e00b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0e0b798-630e-466f-8389-8b4eff2c6cef" contextRef="C_79e53c50-0fb4-4714-84d0-e5a2a573e00b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4c495cd-4f4b-41d6-997f-642482177820" contextRef="C_01155b0a-67b5-469f-9b55-5c9a7412e381" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b8ecfd7-040b-4ed9-85c0-af9879c57a75" contextRef="C_01155b0a-67b5-469f-9b55-5c9a7412e381" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f76d379b-e0c4-4723-8b35-b7cd32e43575" contextRef="C_01155b0a-67b5-469f-9b55-5c9a7412e381" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be3e7a55-c19a-4317-a2d4-c65262a7c2a3" contextRef="C_e926f4ca-4dd1-450a-81bd-dc676a9925ba" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,714</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c34c2310-233b-4cff-85c6-41141633d5af" contextRef="C_e926f4ca-4dd1-450a-81bd-dc676a9925ba" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_54ee090b-cfd4-40ff-bb74-ad6c2333b97c" contextRef="C_e926f4ca-4dd1-450a-81bd-dc676a9925ba" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,668</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b87e5b04-2f07-4459-b5c0-31740e3a32a8" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e05584d-8d93-4d34-a993-fffb372754dd" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">240</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85208aa1-5a5f-4123-91b3-10b0f4ecf1d8" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,102</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bd52d72-2939-4248-bb2e-bfcdd339cd08" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_326bcf93-901f-4da4-a55d-6dd938a2b86b" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d13bb98-ce78-4993-ba08-717d662d850e" contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c" name="pcvx:CashAndCashEquivalentsAndInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">273,087</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e3ffc576-e013-4742-b48d-2aff5069af5a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the contractual maturities of our investments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.229%;"></td>
        <td style="width:5.326%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:22.446%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3d2f0b7-c513-4267-9f52-b28725815103" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,719</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one to five years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1f4f332-51ee-4047-bd2a-29ff5ab632a1" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,549</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83aeecf1-1e2f-412b-9f08-3383839c2eab" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,268</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_94abb745-9e72-4901-a87c-a7563fc1f2a5" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet Details</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_02d4eecd-7747-488e-a28f-ecadb6832cfd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.929%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.011%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.086%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b646f6c7-8a99-4e6d-b30f-97697a1ee81f" contextRef="C_d1ef036e-43c1-4748-ba90-b2fce246fad4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,608</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24dc668f-7137-40c3-87fd-470aaa5e0ece" contextRef="C_e4995092-b32b-457d-9712-2e5592bba095" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,619</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers and computer software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1722b7b-8e82-4828-83fc-7a1649547c5d" contextRef="C_3c4d15b9-2c87-4cf6-be74-87bda32cea0e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">416</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04daf87c-1834-47b5-a401-98bd6f1d1dea" contextRef="C_1e5bb009-c911-4eb4-9225-759eaada18dd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">430</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f81684d0-9c4c-4781-b681-035808016414" contextRef="C_eb2e21b9-03b4-445b-a4c8-52e92a39f940" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3acc7fff-a433-4740-b428-543bc92c6de7" contextRef="C_3d68821a-459d-4683-8345-23cec20bbda0" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_13f02077-1a9d-4dfb-9f16-ea12868131e3" contextRef="C_71794c0f-76e0-44c9-b988-61b9c2402e78" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,353</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_854069e0-44b8-4ce1-8d72-4d4a53b8997b" contextRef="C_6bd83283-29d6-47da-874d-4c54c292d4ab" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5df27c2-c7ce-43ee-9abd-6529dc95e96f" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d299bd70-7799-485d-bb56-089ceff812cb" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07a01fed-78ab-4999-beed-c7a8130d2822" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_426ffede-92da-4cb9-8535-0eda9dbcc47f" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,548</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45e21b20-a47e-4cac-9a07-df04e5f28c7a" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,360</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a172a2d-f897-4cc3-9561-e4ce812b1c58" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,954</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense for the years ended December 31, 2022, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a94e0741-5ca1-4b49-9efa-bfbb09575008" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ffbaf1b-b6b9-4970-aadb-87899a3e0748" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc2ddfd0-57c8-4981-b2f8-b96888100626" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2fee67d4-a0ed-41c6-acb3-58b0b1dda2a6" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.226%;"></td>
        <td style="width:1.421%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.806000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.421%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.127%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52488e1e-6591-41ca-bf46-c23a9e424e95" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:ClinicalStudies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,518</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bec0d669-934c-45fb-8ac2-b3ee2f080725" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:ClinicalStudies" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">453</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other research and development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df4ab314-c5c6-42db-9ded-1707241de39d" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:OtherResearchAndDevelopmentLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,446</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bf9f156-a8b5-43ba-a0a0-d7a76ae82463" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:OtherResearchAndDevelopmentLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,676</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95b5f754-4aff-4931-8f9e-1dd748d3cab9" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,411</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10840e29-68b1-42d2-9040-bb0bdcec4e88" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d338f4b0-28a4-43bf-8c5f-937f66addefb" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3446735-f111-4e41-9a5e-3fea9fe6170e" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,787</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_2e45e8e0-02af-425c-8676-e3d2b46597cc" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c71c08c-17a8-4b27-8683-afdc8dd9c57d" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:AccruedManufacturingRightsExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48be215c-8dfa-4bb0-b786-0494aec2c399" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:AccruedManufacturingRightsExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accrued manufacturing rights as of December 31, 2022 and 2021, respectively. See Note 6, &#34;Commitments and Contingencies, Sutro Option Agreement,&#34; for further details.</span></ix:footnote></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</span><div style="display:inline;"><ix:footnote id="FNT_ae976684-1799-4dc9-8326-1dcb7053a127" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The breakout and categorizations of the 2021 total accrued expenses have been updated to conform to the 2022 presentation.</span></ix:footnote></div></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_321136e8-2ce9-4acc-a2ab-6287c5202368" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Lease Obligations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, we entered into a lease agreement for our current corporate headquarters facility located in San Carlos, California and a license agreement for temporary lab and office space in Palo Alto, California. The lease term for our current corporate headquarters facility began on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d91da811-5f48-4ba1-8391-7787af461303" contextRef="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03" name="pcvx:LesseeOperatingLeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 22, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d896b12-5650-4926-9a66-e4c07128c936" contextRef="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2025</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We have </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4c394702-3352-4894-b349-da692cd3e19d" contextRef="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03" name="pcvx:NumberOfRenewalOptions" unitRef="U_RenewalOption" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e3eed19-95de-4ce5-af94-f8beba5d88b8" contextRef="C_f29cb1b4-51e8-42fe-ba43-bfae1134ea34" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month renewal options. The original term of the license agreement for the temporary space in Palo Alto terminated when the San Carlos office leasehold improvements were completed and we moved into our current corporate headquarters. We extended the license agreement for the Palo Alto office by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8fff8563-e612-4728-9b2f-14a14bdd1cc2" contextRef="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03" name="pcvx:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_82e5076a-14ec-4c1d-a24d-dc3063f6d7fa" contextRef="C_215eff92-aeb1-4823-b975-c15a670cc803" name="pcvx:LesseeOperatingLeaseExtendedMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 3, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to accommodate our relocation plan. These two agreements are accounted for as a combined lease because the contracts were negotiated as a package with the same commercial objective. Upon commencement of the San Carlos lease in December 2021, we recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b09a270-2dd8-496a-b3dc-7806253d1646" contextRef="C_bb33c9e9-15f8-4620-9baa-1c636358bb0e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52908f7d-c13e-43c8-b95d-5574ae6c321e" contextRef="C_bb33c9e9-15f8-4620-9baa-1c636358bb0e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_96713828-f81f-4d0c-a7be-0ca8f2eb51b5" contextRef="C_9301909a-a6de-4293-bf83-22071eaf9f32" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2016, we entered into a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7175f6c7-b1b5-4894-961d-c0f3a73a50a0" contextRef="C_1af9b85c-d59e-4494-bcdc-b8097aa831e7" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3581b454-2419-42b7-869e-d4f364b9816e" contextRef="C_898a2a2d-e260-47fb-85c7-5b4d4065a867" name="pcvx:LesseeOperatingLeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 1, 2016</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_123543b0-ecf6-43ce-99fb-f073d4476fb4" contextRef="C_898a2a2d-e260-47fb-85c7-5b4d4065a867" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_214cfc10-282f-4ca5-a841-84deae9fcad5" contextRef="C_898a2a2d-e260-47fb-85c7-5b4d4065a867" name="pcvx:LesseeOperatingLeaseRenewalOption" unitRef="U_RenewalOption" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c7ff405-f8e1-4641-9285-59924b8438ac" contextRef="C_92495c05-9763-4ff7-855f-1743d26c34ea" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf8a6387-5974-46a5-979d-10f35b3e3af3" contextRef="C_1af9b85c-d59e-4494-bcdc-b8097aa831e7" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c00e1a06-e1a1-46d0-9e7b-ad15b3dc9319" contextRef="C_898a2a2d-e260-47fb-85c7-5b4d4065a867" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">renewal options</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_af3dd0e4-f7c0-477e-8b59-d79abe93f942" contextRef="C_32c0e264-4ab1-4f71-99a3-932ea28e946c" name="us-gaap:LesseeOperatingLeaseDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1235f020-ae2b-4c3d-a2b3-bc297cd8c19f" contextRef="C_dd141812-a700-48fc-9a93-5d2fa4df6de7" name="pcvx:LesseeOperatingLeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 1, 2019</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_20811335-35e5-45fa-b3ed-3749119192ac" contextRef="C_dd141812-a700-48fc-9a93-5d2fa4df6de7" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 31, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eb637e46-b38e-4b68-88d2-d3f44a31263d" contextRef="C_32c0e264-4ab1-4f71-99a3-932ea28e946c" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6a6a9762-ee2e-4130-bd60-a8563664aa55" contextRef="C_dd141812-a700-48fc-9a93-5d2fa4df6de7" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal options</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In November 2020, we extended the terms of both of these leases for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5ee6320c-6e01-4b90-90d0-7f032f0e55de" contextRef="C_6713bc72-bbf6-4c8d-848a-8ca3bd191ee0" name="pcvx:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_8fb5b763-6409-419d-ab74-d30e40f62236" contextRef="C_17293867-6c59-44bc-b2a6-797596102857" name="pcvx:LesseeOperatingLeaseExtendedLeaseTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2f57c573-3811-4527-b7f9-43b376b8bb11" contextRef="C_6713bc72-bbf6-4c8d-848a-8ca3bd191ee0" name="pcvx:LesseeOperatingLeaseExtendedMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a3375539-60e5-4bd8-a1d9-74d732e71b78" contextRef="C_17293867-6c59-44bc-b2a6-797596102857" name="pcvx:LesseeOperatingLeaseExtendedMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 30, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. In February 2022, we entered into an early termination agreement for one of the facilities in Foster City and terminated our lease on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_da3a8cc2-9371-48b9-bc92-c3b3ab81fe75" contextRef="C_9a2fe8c2-7190-4ba0-9807-0bf83b739c1b" name="pcvx:LeaseTerminationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 12, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> instead of April 30, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8cb6cde3-8935-4ebc-be04-6f3a248f79bc" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.665%;"></td>
        <td style="width:3.444%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.29%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.871%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.729999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_074639a4-c2e3-4133-9dc0-94b31333b514" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,374</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5716a52f-a28c-45fc-929c-53303db03bd4" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">924</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce47327f-7651-4ea9-8199-648d424fb21f" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70f4e8de-2512-4981-8b8e-80f1ba2efb61" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ff79b3c-f544-4d4b-a345-4ec409bd2641" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,910</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb0181ca-325b-4168-b1b8-d2a6d84f1568" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,276</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c7abaca-ab76-447d-b5e0-1099b7e82784" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8c730cc-aee4-4693-94be-f3b7cc5788fb" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b2b8e3a-65c1-4474-bae6-d9d535fc9e74" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,941</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e2f78a7-3683-42b7-a109-c982523a89e4" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_710a5a8b-e3e5-49fa-9937-908aa3f36f3b" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.78</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7fd5f65a-6079-4786-bda5-52d6d6b6dd44" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.75</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_394292ee-a159-4f2d-9c1f-74381a292d22" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_509adcdd-37b0-4bcc-a6a4-6a4c85f1cd9f" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0cdeae1f-a29d-4e60-b17f-6660cec78a7c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.111%;"></td>
        <td style="width:1.795%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.094%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8daa879c-f23b-4760-9201-58bcdc69e1f6" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,684</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5c3b307-6304-4fb5-9046-0d58d3fb52e3" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,850</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bba7db4e-eec5-4212-adda-f220477e8637" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,022</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6972401-816d-4a7f-8193-2224f42129f7" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfc3e5fa-ada8-43cc-b2d9-81c4104059c3" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,615</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc28c3d0-8cb7-42f2-bb32-15f249fd1db3" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,941</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum payments required under operating leases as of December 31, 2021 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.097%;"></td>
        <td style="width:1.781%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.122%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99b7e5aa-ca0b-4683-a754-60df640d4e91" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02982b57-1671-4ee8-ae77-9f1dd00fa37a" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,639</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e98c9969-9622-417f-994e-6a472fdfc428" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fa30b11-5ac5-48f9-86fd-2627adf99b13" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,976</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fda597da-0fff-48c4-bc08-ee67cfd4f6f5" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,315</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7501ad20-bd9f-4613-a992-3a77c0f81dcd" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42faba48-ca08-47dd-9c3d-573d3a17ba63" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,783</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_79671d51-a749-4741-8688-eea6386e55d4" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities for 2022 are net of lease incentives of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5aefd7ae-39b5-4a46-8c43-abbdf9be1a92" contextRef="C_82ee469c-c1fb-46f6-bd16-0bd5b700dbdb" name="pcvx:LeasePaymentReceivableNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million allocated to the Palo Alto office.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rent expense recognized under the leases was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e962e5d-fa40-49fc-ac32-56c68d356e77" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fd6f9d1-4144-468e-956d-0856a50821fe" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3aec171f-4d79-41fc-8bf1-a27a9e490466" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021 and 2020, respectively.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_a3517253-5eca-4478-b66c-efc9f307cbdd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. We do not believe that there is any litigation or asserted or unasserted claim pending that could, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Guarantees and Indemnifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, we enter into agreements that contain a variety of representations and provide for general indemnification. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. As of December 31, 2022, we did not have any material indemnification claims that were probable or reasonably possible and consequently have not recorded related liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent permitted under Delaware law, we have agreed to indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the director&#x2019;s or officer&#x2019;s service. The maximum potential amount of future payments we could be required to make under these indemnification agreements is not specified in the agreements; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We have not incurred any material costs as a result of such indemnification and are not currently aware of any indemnification claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and Manufacturing Services Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2016, we entered into a non-exclusive development and manufacturing services agreement, as amended, with Lonza (the &#x201c;2016 Lonza DMSA&#x201d;) pursuant to which Lonza is obligated to perform manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the September 2017, we and Lonza agreed to defer the completion payments for any stage that commenced after December 31, 2019 or had not been completed by December 31, 2019 until the earlier of the completion of all Investigational New Drug (&#x201c;IND&#x201d;)-enabling activities or December 31, 2020. In March 2020, Lonza agreed to defer the completion payments until the earlier of the completion of all IND-enabling activities or April 30, 2021. In April 2021, Lonza further agreed to defer </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffbcbb61-424c-4ac0-b84d-d1b6892c5215" contextRef="C_34ff63dc-cde8-47e8-9597-b638326cc368" name="pcvx:PercentageOfPaymentsCompletionAgreedToDefer" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the completion payments until the earlier of the completion of all IND-enabling activities or December 31, 2021. Pursuant to this agreement, all deferred completion payments were paid in December 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, we entered into a letter agreement with Lonza (the &#x201c;Lonza Letter Agreement&#x201d;) pursuant to which we agreed to certain terms for potential future payments in shares of our common stock as partial satisfaction of future obligations to Lonza. The Lonza Letter Agreement states that the initial pre-IND cash payments under the 2016 Lonza DMSA would be subject to a specified dollar cap (the &#x201c;Initial Cash Cap&#x201d;). After the Initial Cash Cap has been reached, we would have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53983d96-fd1f-4f13-82b0-3d11c01b3ee2" contextRef="C_dc8ae2fa-cfee-4adf-934b-b757251456e3" name="us-gaap:GuaranteeObligationsMaximumExposure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31232a27-39ce-4cb5-b3d7-df60c618f3c8" contextRef="C_d5787b64-58e9-406e-ab46-d4feaf208a20" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">399,680</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock to Lonza at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ef2c43a-8f54-4e68-a4a0-7e1239038942" contextRef="C_66f9bfcc-ebad-40de-95bf-47b87ed044a4" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">25.02</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share to pay for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29d3f676-78bc-44e8-952c-14d34197a347" contextRef="C_2851b72e-f235-4e1b-8ad0-09f3525757c9" name="pcvx:DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the pre-IND payments due April 30, 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2018, we entered into a second non-exclusive development and manufacturing services agreement with Lonza (the &#x201c;2018 Lonza DMSA&#x201d;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we entered into a third non-exclusive development and manufacturing services agreement, as amended, with Lonza (the &#x201c;2022 Lonza DMSA&#x201d;) effective as of March 22, 2022. Pursuant to the 2022 Lonza DMSA, Lonza will perform manufacturing process development and clinical manufacture and supply of our proprietary PCV.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under each of the 2016 Lonza DMSA, 2018 Lonza DMSA and 2022 Lonza DMSA (collectively, the &#x201c;Lonza Agreements&#x201d;), we will pay Lonza agreed-upon fees for its performance of development and manufacturing services and pass through expenses incurred by Lonza for raw materials, as well as customary procurement and handling fees. Under each Lonza Agreement, we will own all right, title and interest in and to any and all New Customer Intellectual Property (as defined in each Lonza Agreement), and Lonza shall own all right, title and interest in New General Application Intellectual Property (as defined in each Lonza Agreement). Subject to the terms and conditions set forth in the Lonza Agreements, Lonza granted us a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property (as defined in each Lonza Agreement), to research, develop, make, have made, use, sell and import the Product (as defined in each Lonza Agreement) manufactured under each Lonza Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Option Agreement</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we entered into an Option Agreement with Sutro Biopharma, pursuant to which we acquired from Sutro Biopharma (i) authorization to enter into an agreement with an independent alternate CMO to directly source Sutro Biopharma&#x2019;s cell-free extract, allowing us to have direct oversight over financial and operational aspects of the relationship with the CMO; and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract (including the right to make improvements to the extract manufacturing process as well as cell lines) for use in connection with the exploitation of certain vaccine compositions (the &#x201c;Option&#x201d;). We and Sutro Biopharma have agreed to negotiate the terms and conditions of a form definitive agreement to be entered into in the event we exercise the Option, which shall include the terms and conditions set forth in an executed term sheet between us (the &#x201c;Term Sheet&#x201d;), and such terms that are necessary to give effect to each of the terms and conditions set forth in the Term Sheet (the &#x201c;Form Definitive Agreement&#x201d;). The Option period</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is five years from the date of the Option Agreement, subject to potential acceleration in the event we undergo a change of control.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we agreed to pay Sutro Biopharma upfront consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e39a2aa-124c-45ff-b993-c1d816c909c0" contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189" name="pcvx:UpfrontConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, consisting of (i) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7279ad40-830b-456a-a2fc-04cf8f11e8cc" contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189" name="pcvx:UpfrontConsiderationInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f38716d9-f284-4400-9821-fd2d6a7c807a" contextRef="C_84e39903-4e50-46bc-a706-ef2201e6c504" name="pcvx:UpfrontConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million worth of shares of our common stock (the number of shares to be calculated based on the arithmetic average of the daily volume weighted average price of our common stock as traded on Nasdaq in the three consecutive trading days immediately prior to the issuance thereof), and (ii) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f7ec2c9-1324-4f91-9ac1-96a33e575297" contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189" name="pcvx:UpfrontConsiderationInCashAfterAgreementDate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payable within five business days after we and Sutro Biopharma mutually agree in writing upon the Form Definitive Agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f969309f-baf3-4b5a-8f9d-b138b0d8f482" contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">167,780</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued was recorded at fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e4eb81d-26f9-4399-a4c9-e2c064532345" contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189" name="pcvx:FairValueOnDateOfSettlement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the date of settlement, December 22, 2022. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that we elect to exercise the Option, we would pay Sutro Biopharma an aggregate Option exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0dd3df2-80c5-49ae-a92d-66a3ba22765a" contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189" name="pcvx:OptionExercisePriceInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">75.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash in two installments and, upon the occurrence of certain regulatory milestones, certain additional milestone payments totaling up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7163bbb5-b8a3-4dcc-bd89-d0639b229a03" contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189" name="pcvx:AdditionalMilestonePaymentsInCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash. In the event that we undergo a change of control, certain rights and payments may be accelerated.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022. Part of the total cost incurred as reported on the statement of operations for the year ended December 31, 2022 is a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbe34cae-fca9-461e-8992-3fd1e7094936" contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189" name="pcvx:AccruedCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million accrued commitment that remains outstanding as of December 31, 2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into agreements in the normal course of business with CMOs and other vendors for manufacturing services and raw materials purchases. We rely on several third-party manufacturers for our manufacturing requirements.</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b6d26212-f5ea-49c5-9bfa-630a1b9aa027" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock" escape="true" continuedAt="F_b6d26212-f5ea-49c5-9bfa-630a1b9aa027_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, we had the following amounts due of non-cancelable purchase commitments related to manufacturing services and raw materials purchased due to our key manufacturing partners. These amounts represent our minimum contractual obligations, including termination fees. If we terminate certain firm orders with key manufacturing partners, we will be required to pay for the manufacturing services scheduled or raw materials purchased under our arrangements. The actual amounts we pay in the future to our vendors under such agreements may differ from the purchase order amounts. </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_b6d26212-f5ea-49c5-9bfa-630a1b9aa027_1"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.35%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.649999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff009a55-560b-4533-81ac-630ba33ed3e4" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:NoncancelablePurchaseCommitmentsDueInOneYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6297db34-f9ed-4f87-b25d-730ea69920ae" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,471</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total non-cancelable purchase commitments due to key manufacturing partners</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58184048-ad75-4f0d-be3d-5c1bf7765250" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:NonCancelablePurchaseCommitments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125,570</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e965efae-926c-400b-bf52-26d5af2dddc8" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:RedeemableConvertiblePreferredStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41b3e8c3-51a1-4d3e-bf52-68881071fb65" contextRef="C_e5603f34-fe33-4aa9-bba2-7bcef1212dc9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ad86c756-e98b-484b-a1b2-5a1997ab48fa" contextRef="C_e5603f34-fe33-4aa9-bba2-7bcef1212dc9" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of redeemable convertible preferred stock authorized or outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our IPO in June 2020, the outstanding shares of our Series A, Series B, Series C and Series D Redeemable Convertible Preferred Stock automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20f37527-4e84-495e-8ebc-73d2d45d118e" contextRef="C_52984cc7-0416-45ea-9199-ee6f2a1b640f" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,610,337</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">147</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e58f6507-588f-4310-b24c-632462cc7f21" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our certificate of incorporation authorizes us to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa0a1e84-d5a5-4568-9796-d3144097f7ed" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_c75e07d0-481d-4cde-bb17-783265db33a2" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5bbe6b6-32f6-41fd-b5af-c9c15d4b4ca7" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal"><ix:nonFraction id="F_d6acd5cd-cac9-4b02-af08-bb4c98f5724a" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> par value per share, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_287c2138-71e8-4f49-b6de-a955f1fc08ec" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_01ce074b-0b90-4506-b3b7-60180cfb96d2" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">79,470,670</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbaa1395-fc56-45e9-a6ee-1994afa3792c" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_9e501eff-e98a-4147-8a99-7262a1ebafc3" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">53,031,978</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were issued and outstanding as of December 31, 2022 and 2021, respectively. The holders of our common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by our board of directors. As of December 31, 2022 and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8a34a60-f995-479f-a98d-fdc37b9362a2" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:CommonStockDividendsPerShareDeclared" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0ab0c774-e12a-41a1-85b3-f1993bd0811b" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:CommonStockDividendsPerShareDeclared" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends have been declared. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_23df03bd-5040-4b78-929a-16028a34cf7c" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each share of common stock is entitled to one vote.</span></ix:nonNumeric></span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, we entered into an Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;ATM Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b334432-69f1-40ba-99e3-3e506de37fe7" contextRef="C_c14f87d8-1d33-40ea-b99b-b33fe6411911" name="pcvx:SaleOfCommonStockAuthorizedAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">150.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through Jefferies acting as our sales agent or principal. We are obligated to pay Jefferies a commission of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82a25bc0-6a7a-49a4-aa02-16f45adb3f87" contextRef="C_b92aaa0b-aeff-4d69-a84f-c6311d27ad82" name="pcvx:MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" unitRef="U_pure" scale="-2" decimals="INF">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross sales proceeds of any common stock sold through Jefferies under the ATM Sales Agreement; however, we are not obligated to make any sales of common stock. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we have sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_75e962a6-a116-4907-b957-52a4d6e8ee2c" contextRef="C_c9b4f586-2146-4cbd-aa92-140916b46d25" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,488,573</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock under the ATM Sales Agreement at an average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4c839b5-e99b-402c-a2f0-c3e33289bfcf" contextRef="C_605b60d5-91b3-4448-ba68-5bd37a009e74" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">25.56</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e37258f-a8e7-46a6-b61f-e93ba682dbc7" contextRef="C_c9b4f586-2146-4cbd-aa92-140916b46d25" name="pcvx:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">114.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0abb7af5-bb50-446d-a095-eb7f03821af7" contextRef="C_c9b4f586-2146-4cbd-aa92-140916b46d25" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">111.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million net of commissions and offering expenses).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, we completed an underwritten public offering in which we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7799abd-2b27-460b-8afd-0ae056d90a13" contextRef="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e" name="pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11e11467-eee6-4331-b6c0-7bccaa0795bd" contextRef="C_59365215-3504-4f12-b752-122da006773a" name="pcvx:SharesIssuedPricePerShareUponFollowOnOffering" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">20.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ff5cd037-2917-4c7f-971a-de3c010b48eb" contextRef="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e" name="pcvx:SharesPreFundedWarrantsToPurchase" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b72faa2a-d1c0-4f2a-b857-32be0e815b6c" contextRef="C_59365215-3504-4f12-b752-122da006773a" name="pcvx:PrefundedWarrantsPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">19.999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per underlying share. In February 2022, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he underwriters exercised their option to purchase an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0949036f-7a7a-4708-97e6-e36968bf6343" contextRef="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e" name="pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. In aggregate, we received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77e4d027-96a8-4e07-8c92-c1b74934615d" contextRef="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e" name="pcvx:ProceedsFromIssuanceFollowOnOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">107.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we completed an underwritten public offering in which we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a12b099b-ed68-4116-9fe5-8c860ef5d7af" contextRef="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3" name="pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d855f6ec-f777-4dce-97bc-107206af895f" contextRef="C_a5d59d19-2f5b-474d-ad5f-5eb6826a0e4c" name="pcvx:SharesIssuedPricePerShareUponFollowOnOffering" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">32.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad924f98-adb3-4369-81e0-c44e211ebf96" contextRef="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3" name="pcvx:SharesPreFundedWarrantsToPurchase" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,750,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_406f47cb-94a1-4864-8b4c-782c05abb03c" contextRef="C_a5d59d19-2f5b-474d-ad5f-5eb6826a0e4c" name="pcvx:PrefundedWarrantsPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">31.999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per underlying share. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he underwriters exercised their option to purchase an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d243af4b-d7a1-45f8-a7be-3a9e8d11ebe7" contextRef="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3" name="pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,812,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. In aggregate, we received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb8f8505-1213-4d80-92ab-65f5262cbe54" contextRef="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3" name="pcvx:ProceedsFromIssuanceFollowOnOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">651.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us, and excluding the exercise of any pre-funded warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_abce17e8-3319-459f-a49d-a30f14d5241a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) and the 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) was as</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> follows, and excludes </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2dbe6b9-65fc-4046-b5a0-b3dbabf8878d" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">36,710</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares issued outside of the 2014 Plan and 2020 Plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.479%;"></td>
        <td style="width:1.018%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.229999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.031%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.243%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3514cf91-39c7-4575-b8f7-052d182590ad" contextRef="C_5d6c3586-ec99-4387-90b9-c66ada981bf1" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,715,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d39c7543-9524-4757-8eeb-b74e812f75c4" contextRef="C_f9ef3af6-0ed6-4232-82f8-f00e3b3f9c04" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,295,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Restricted stock units issued and outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84ed59c9-6d4c-417d-bdc8-b81debdfd1f5" contextRef="C_043847b8-3b71-486a-a3f8-651e1b7e0b0e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">456,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad637c56-7470-4241-9a8c-c469199d92aa" contextRef="C_87eb225f-5c0d-43e6-859d-fe29381daaa2" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Shares available for future stock option grants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e2238f0-febf-419d-a8d9-0848c51b3f8d" contextRef="C_0cec58be-bb3d-44e1-8f46-324ba1e7a4d9" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,679,598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_48909ff5-d119-4c8f-819d-b93105d7ed6e" contextRef="C_ff59dd17-1515-4475-9b29-d6981afba232" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,104,756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c07483e-13c4-45cc-9793-ef8a46cfa4f5" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,851,858</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd7bbc3a-c28d-43ba-80d7-a3d86e31c352" contextRef="C_042e7705-d42e-4637-8ecc-6de667d73494" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,399,763</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b5ec554e-ae72-4d90-b847-f44770afe531" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:WarrantsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">re-Funded Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our underwritten public offering in January 2022, we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db6be5df-5c34-4adc-a9cf-61ce524fce22" contextRef="C_a6eb96b6-2f08-472a-ba13-12abc92474e8" name="pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6038b104-0ab9-4ab0-8836-c51307ee6700" contextRef="C_98587108-31fb-4048-8311-ad1171d7b550" name="pcvx:SharesIssuedPricePerShareUponFollowOnOffering" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">20.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b70c30fb-dc5b-4f96-8e05-c9b60c5e4225" contextRef="C_a6eb96b6-2f08-472a-ba13-12abc92474e8" name="pcvx:SharesPreFundedWarrantsToPurchase" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21e3d084-3688-4fdc-90bd-2eb4df8a7ad4" contextRef="C_98587108-31fb-4048-8311-ad1171d7b550" name="pcvx:PrefundedWarrantsPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">19.999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per underlying share. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ebee7a2-1189-40d1-bc74-cef7d67f0c37" contextRef="C_93cfc9bc-cf41-46c8-8d8c-3c249f9e296f" name="pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" unitRef="U_shares" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our underwritten public offering in October 2022, we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3cc0bba-2703-41f8-948e-4b4e9ffd682b" contextRef="C_627bc919-0f57-4ed7-9267-0f6ca3c2b3c9" name="pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d84e45ad-8479-432e-90e2-e25c4a310179" contextRef="C_93593151-df16-4d93-bf9c-30716b99adb7" name="pcvx:SharesIssuedPricePerShareUponFollowOnOffering" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">32.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_990c8c7a-4b3e-42d8-83f6-31f3a8fcc932" contextRef="C_627bc919-0f57-4ed7-9267-0f6ca3c2b3c9" name="pcvx:SharesPreFundedWarrantsToPurchase" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,750,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ee81ebe-3397-42a5-b73b-c1884cd93c7f" contextRef="C_93593151-df16-4d93-bf9c-30716b99adb7" name="pcvx:PrefundedWarrantsPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">31.999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per underlying share. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ce5ef9d-d5cf-4c86-a2ad-ba7277fe4bdb" contextRef="C_c80a26a1-b95a-44f9-acc5-6127ef778da7" name="pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" unitRef="U_shares" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The public offering price for the pre-funded warrants was equal to the public offering price of our common stock, less the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7c31d81-4958-4b0b-8e8f-498b2972658d" contextRef="C_a6eb96b6-2f08-472a-ba13-12abc92474e8" name="pcvx:PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal"><ix:nonFraction id="F_94f4bc45-5b76-4900-b49a-0ae285e62731" contextRef="C_627bc919-0f57-4ed7-9267-0f6ca3c2b3c9" name="pcvx:PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> exercise price of each pre-funded warrant and was recorded as a component of stockholders' equity within additional paid-in-capital.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment of the exercise price. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. The holder of the pre-funded warrants may also satisfy its obligation to pay the exercise price through a &#34;cashless exercise,&#34; in which the holder receives the net value of the pre-funded warrant in shares of common stock determined according to the formula set forth in the pre-funded warrant.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The pre-funded warrants will not expire until they are fully exercised. However, we may not effect the exercise of any pre-funded warrants, and a holder will not be entitled to exercise any portion of any pre-funded warrants that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of our common stock beneficially owned by such holder (together with affiliates) to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a6eb7af-9aa1-4c1a-bdcd-3d2d2c511c36" contextRef="C_db08c559-8805-4810-a9ad-817d3efd45a5" name="pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_d0f94906-426a-4b75-81c8-7600fcedfc6c" contextRef="C_783f07a1-06d5-4961-9f5d-5e2270a1613f" name="pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.99</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cc6da17-9301-4281-a08b-7e98b2047d7c" contextRef="C_adf7111c-3503-433b-85ea-ba5266a3bec4" name="pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_f0b75f6f-be47-4ddb-9b51-20863a4d1513" contextRef="C_58188e6f-33df-4637-971c-bb69de27b7a1" name="pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.99</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as applicable; or (ii) the combined voting power of our securities beneficially owned by such holder (together with its affiliates) to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd056b37-61fc-4077-a911-43c14f4a239b" contextRef="C_db08c559-8805-4810-a9ad-817d3efd45a5" name="pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_75f1c78c-82f7-4b04-84f0-076aa48992bc" contextRef="C_783f07a1-06d5-4961-9f5d-5e2270a1613f" name="pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">4.99</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0da43196-d87a-4c3b-9d80-280376f93607" contextRef="C_adf7111c-3503-433b-85ea-ba5266a3bec4" name="pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_427d13f5-74af-4ade-bb51-239adb2dcac0" contextRef="C_58188e6f-33df-4637-971c-bb69de27b7a1" name="pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">9.99</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the combined voting power of all of our securities outstanding immediately after giving effect to the exercise, as applicable, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. However, any holder of a pre-funded warrant may increase or decrease such percentage to any other percentage not in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dd7db05-ee79-4901-a0a1-a83730a11f32" contextRef="C_e9126c57-d4e4-4b9e-8373-4b493ee1f1c1" name="pcvx:IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal"><ix:nonFraction id="F_04a5251b-d65f-43b4-b553-374f50efc162" contextRef="C_52a9c5b1-8f71-49a0-af0c-9cb853cc2232" name="pcvx:IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">19.99</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon at least 61 days' prior notice for the holder to us. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee876944-07e0-445b-a05a-05f01e163cda" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares underlying the pre-funded warrants had been exercised.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <div><ix:nonNumeric id="F_43162c2a-b812-48a6-bff5-1049258e1038" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Incentive Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 and 2014 Equity Incentive Plans</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Plan, which became effective on June 11, 2020. Under the 2020 Plan, we may grant stock options, appreciation rights, restricted stock and restricted stock units (RSUs) to employees, consultants and directors. Stock options granted under the 2020 Plan may be either incentive stock options or nonqualified stock options. Incentive stock options may be granted only to our employees, including officers and directors who are also employees. Nonqualified stock options may be granted to our employees, officers, directors, consultants and advisors. The exercise price of stock options granted under the 2020 Plan must be at least equal to the fair market value of the common stock on the date of grant, except that an incentive stock option granted to an employee who owns more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f03f76a5-8df3-4286-be2e-91df78e32370" contextRef="C_43290d81-1ade-4236-b12a-f4dfbc9a2de2" name="pcvx:IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" unitRef="U_pure" scale="-2" decimals="2">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of our common stock shall have an exercise price of no less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cefa694-fff3-4ed3-b69e-b23ba1d6167b" contextRef="C_d94724f5-308f-4538-9078-b37164cc96a1" name="pcvx:PercentageOfFairValuePerShareOnTheGrantDate" unitRef="U_pure" scale="-2" decimals="2">110</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair value per share on the grant date and expire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe97d24f-1e58-4d37-9a72-f5720e097df6" contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11" name="pcvx:ExercisePriceExpireInYearsFormTheDateOfGrant" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. The maximum term of stock options granted under the 2020 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e0c1ad2b-3363-468e-9692-018a4288c9c0" contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11" name="pcvx:StockOptionsGrantedTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, unless subject to the provisions regarding </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f9b9d56-c4fc-44b5-ac87-04c57d199772" contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11" name="pcvx:PercentageOfProvisionsSubjectToStockholders" unitRef="U_pure" scale="-2" decimals="2">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% stockholders. Our stock options granted to new employees generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc9c46fb-fbb6-4340-ba13-5a83fa4c22d5" contextRef="C_5174e359-4705-4039-af81-628498b266ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b075b631-3aaf-441a-a10e-5e5c009ffb42" contextRef="C_5174e359-4705-4039-af81-628498b266ac" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon the first anniversary of the vesting commencement date and monthly thereafter. Our other stock options granted to employees generally vest on terms consistent with stock options granted to new employees or monthly over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c93b7b7c-0287-48f5-bfe1-4c1902b3d062" contextRef="C_5174e359-4705-4039-af81-628498b266ac" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the vesting commencement date. Our RSUs granted to new employees generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7c5dd4eb-499c-4c6c-93e3-8aa0f487a69c" contextRef="C_acd4f53c-e76e-4bcc-8f97-102bcec4707b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac13dace-50c2-4182-aa1d-2df82db2eef3" contextRef="C_acd4f53c-e76e-4bcc-8f97-102bcec4707b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon one year from the grant date, then </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e4dd252-90c0-46b6-a970-3e434cbf656b" contextRef="C_acd4f53c-e76e-4bcc-8f97-102bcec4707b" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% every six months thereafter. Our other RSUs granted to employees generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b8edf648-6c56-470f-b105-b7c382767664;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three and a half years</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87333512-2e17-4112-88bb-29cda88e1b2e" contextRef="C_5174e359-4705-4039-af81-628498b266ac" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon six months from the grant date, then </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a120ba86-7b33-4f10-9b67-10378aee3c06" contextRef="C_295fc304-a24b-4340-bef2-fe78e40e2989" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">12.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% every six months thereafter. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0823a93d-5b86-4684-b76a-082aa2babebf" contextRef="C_20d86c4a-c1e6-415d-8039-887d6b20d17f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,150,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were approved to be initially reserved for issuance under the 2020 Plan. The number of shares that remained available for issuance under the 2014 Plan as of the effective date of the 2020 Plan, and shares subject to outstanding awards under the 2014 Plan as of the effective date of the 2020 Plan that are subsequently canceled, forfeited or repurchased by us, will be added to the shares reserved under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan is automatically increased on the first day of each calendar year during the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_14afdb15-bc14-42de-b3eb-96a33131d449" contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea61eb49-8bae-4143-ba55-ba0ba0b95d0a" contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23afa9d1-7374-4d8e-80d2-969891193c2e" contextRef="C_8842095a-a719-4e20-84ac-651814b90d5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,679,598</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were available for issuance under the 2020 Plan. Effective January 1, 2023, the number of shares of common stock available under the 2020 Plan increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a9b4dfa1-3b4d-4027-b608-0ae27f06e802" contextRef="C_323a4631-8d67-46bd-b2bd-7c01a7ec7d2f" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,973,533</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares pursuant to the evergreen provision of the 2020 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our 2014 Plan permitted the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Subsequent to the adoption of the 2020 Plan, no additional equity awards can be made under the 2014 Plan. Shares reserved and remaining available for issuance under the 2014 Plan were added to the 2020 Plan reserve upon its effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the 2014 Plan permit the exercise of options granted prior to vesting, subject to required approvals. The unvested shares are subject to our lapsing repurchase right upon termination of employment at the original purchase price. Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as other liabilities on the balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dd0258e-6bfc-4a12-8c1d-ba8a877218b9" contextRef="C_c411c849-9449-415d-836c-57f752c96e04" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,576,161</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7d67b23-1022-4855-b3c1-4552f9d2f3e0" contextRef="C_16219b98-47a8-4997-a3e1-39a5a065b63c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,596,099</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were subject to outstanding options and RSUs under the 2014 Plan and 2020 Plan, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e66ae989-6715-4782-9320-c969ef484f44" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:EarlyExercisedStockOptions" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,705</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eb6dc0e-e2de-4f8d-b8fb-2b07954ec907" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:EarlyExercisedStockOptions" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,410</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, respectively, remained subject to our right of repurchase as a result of the early exercised stock options. The remaining liabilities related to early exercised shares as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021 were both less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acf00274-5f5a-4e98-8fcb-e505ca9912ce" contextRef="C_b1477851-b8b1-4483-a4bf-02d65b12c4e5" name="pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares" unitRef="U_USD" scale="6" decimals="-5"><ix:nonFraction id="F_480bc27b-1cea-4599-aefe-71a4178f2d44" contextRef="C_0598ec3b-a113-4d19-ae05-d08550eafaae" name="pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares" unitRef="U_USD" scale="6" decimals="-5">0.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and were recorded in other liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_55a0209d-3146-4957-bf25-e59aedd20686" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under our 2020 Plan and 2014 Plan, which excludes options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a6aa4fc-0c0b-4f2f-a158-fa33f7963b78" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">36,710</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares granted outside of the 2020 Plan and 2014 Plan, was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.622%;"></td>
        <td style="width:0.077%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.203999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.945%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.733%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.077%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:5.434%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.077%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.455%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.077%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.302%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Option and Restricted Stock Units Activity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options<br />and RSUs<br />Available<br />for <br />Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number<br />of<br />Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Exercise<br />Price Per<br />Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Remaining<br />Contractual <br />Term<br />(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#x2014; December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db5686fa-a786-4a9c-95af-51b4eee1225f" contextRef="C_6d173051-b96b-48bb-8554-d94b4601af7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,651,149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_31592bab-c094-4ada-8699-de329e36758b" contextRef="C_6d173051-b96b-48bb-8554-d94b4601af7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,121,549</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27c852f0-1142-4227-a822-1dd9b6a3b406" contextRef="C_6d173051-b96b-48bb-8554-d94b4601af7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.99</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c302424-5afc-466f-bbd9-125f824a6793" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,553,579</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_995e3c1d-8ceb-4983-a9c5-218de77343e4" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,616,021</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c292bd85-7447-4505-a874-c4271a64cc13" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,616,021</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41b7e0e4-b42a-45ef-a6d1-4955ec78b8c5" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">21.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c421fbd6-9d80-467c-9997-ac3d7e50b4d9" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">926,514</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dc8ff29-cd1e-4a22-ac10-abdfed8de01a" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7294c00-b025-44a0-833f-b85bfb71e07e" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">516,049</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e94de92-ab4f-465a-bc13-63de9126ecdd" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">516,049</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a017cbe-5dfa-4bbc-99ad-d71680b1163f" contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">16.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#x2014; December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eecbdbef-aef2-4864-963e-d21199014219" contextRef="C_042e7705-d42e-4637-8ecc-6de667d73494" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,104,756</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25af9122-4f44-4409-80f1-dcc547aed7d2" contextRef="C_042e7705-d42e-4637-8ecc-6de667d73494" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,295,007</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_238cdf2a-a498-492f-8f3b-de56e1d7af76" contextRef="C_042e7705-d42e-4637-8ecc-6de667d73494" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_871da325-32cd-49a5-ba8e-3d3c143a4c68" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,651,598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5920847f-135d-4a40-a3e9-f194da93ff40" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,850,981</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b4214e3-0e46-4d7f-b750-466df84bebc8" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,850,981</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_851928d0-c80b-4c8d-a89f-c66cc91e2359" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">27.67</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6bbbaf9f-9437-4277-81df-fdccd0343c70" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">385</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2744f254-cbcc-4dcb-ae5e-bc6a90bca6e7" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,153,285</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1dc06946-e22a-4b79-b6e0-59965d1bcddc" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afbb2f1c-40a1-4111-bd2b-1e69a30f3fc3" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">277,209</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5eaf8045-379f-450e-8aa1-8958288f9b3e" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">277,209</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f290c10-4c64-4588-b1e8-4c66af1b8208" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">23.54</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e170180c-8fc8-46ca-881d-e8bdfa4d5c7c" contextRef="C_76248553-c6a5-451e-b7e1-10f5d684fa65" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">581,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units withheld</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a21aad1-dce6-4f90-939f-fceb836e9bae" contextRef="C_76248553-c6a5-451e-b7e1-10f5d684fa65" name="pcvx:RestrictedStockUnitsWithheld" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5725d8b7-864a-4b0b-a941-6ffcd6800568" contextRef="C_76248553-c6a5-451e-b7e1-10f5d684fa65" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,052</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#x2014; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f87e7989-f7e6-4bb8-a290-2f094297e549" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,679,598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef244725-5cf8-4bfb-b2df-303694f1bf2e" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,715,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97271713-07cf-4f90-a3f5-ba5f24a56dd3" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e2d39db4-d08e-4a66-97fa-e3c41cedc0e0" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.20</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62dcddb0-c3c0-4a0a-8232-9074db7abd19" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest &#x2014; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36f72904-df7b-4513-8197-09c138f751dd" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,715,494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f8348175-8750-4368-b959-0679bc001404" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">18.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_60dea154-8ed2-44de-ae8a-f562d83be2e8" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.20</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8385e05a-0aa4-401b-a75b-a70dc658cbdb" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">225,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5fa8caf-951a-40cb-bd98-c25a511f3bc3" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,921,091</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_db295fa2-0b1b-4457-a514-ea45cf56049c" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.41</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d984bb58-5d0a-4cbd-8504-d95029c45c6a" contextRef="C_4c174ac3-2385-4026-a502-02872bdce024" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.81</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7430f91c-d2a2-4811-a33c-76c71d8a9e7a" contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_2acf8d31-1a88-47ed-9dad-dbe995d6b697" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net exercise - shares returned to the Plan.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6badd016-5dd5-4e10-815e-5d906e22a921" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,153,285</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_602e528f-eea6-4cf8-9efd-ef2ae8a76b7f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">926,514</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aaabbf44-6b0b-403f-bc16-c4ece4fcd6e3" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">358,264</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of stock options, respectively, were exercised for cash at a weighted-average price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6087ab7f-1cbe-42f2-aa0b-07d5e4b8343a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b9cccff-fcb8-4dc9-ae27-8da98f57ede5" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59fd26fb-6588-4c7a-bb90-f35d35db6f79" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">1.88</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The weighted-average grant date fair value of options granted for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5c7f882-0042-4d7b-a6a5-c5262f203b0b" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">18.88</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6c96489-38d2-43fb-81be-b14592b70a1f" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">14.65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2372a072-dbb6-45f0-a6b5-2f1d7676a63c" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The intrinsic value of the stock options exercised was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_83b25994-5e95-4241-8e57-9167e8c63d42" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ceed63bd-ba80-4dd3-ba10-0288338be8bd" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36362710-2a76-481c-b685-96ea3504e55d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 , 2021 and 2020, respectively.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units Activity</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, our board of directors authorized the issuance of RSUs under our 2020 Plan and adopted a form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement (the &#34;RSU Agreement&#34;), which is intended to serve as a standard form agreement for RSU grants issued to employees. </span><span><ix:nonNumeric id="F_f2f46e78-8bd1-4ac4-a222-c013154fad83" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true" continuedAt="F_f2f46e78-8bd1-4ac4-a222-c013154fad83_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 was as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_f2f46e78-8bd1-4ac4-a222-c013154fad83_1"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.919%;"></td>
        <td style="width:3.349%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:17.579%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:3.831%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.322000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Grant-Date<br />Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e1afb34-8c4c-4042-9e47-03714da05d39" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">581,047</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40a23e5e-47f1-4a54-9296-7052d2e999d2" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" unitRef="U_USD" scale="3" decimals="-1" format="ixt:numdotdecimal">26.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and released</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d6f2a925-c469-4c3d-bcad-1143c6f86b5f" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">79,229</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_310947c9-b63d-4da5-a8f8-645f7177ecbd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="U_USD" scale="3" decimals="-1" format="ixt:numdotdecimal">24.79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6d7f09a-8a44-4461-be0c-b02d4e5c009a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">45,052</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cd6b1dc-b56d-44ec-a650-0a6351261f38" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled" unitRef="U_USD" scale="3" decimals="-1" format="ixt:numdotdecimal">24.32</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e0d50cd-b0e4-42c3-a7ec-a205daf63a66" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">456,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96d73be2-21ab-4dd1-ab47-1b03f9533e7d" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" unitRef="U_USD" scale="3" decimals="-1" format="ixt:numdotdecimal">26.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a110f585-ec4f-4494-a0fe-eecb34cc4e27" contextRef="C_d2a47633-779f-4ee5-bc2a-ade49b683a08" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">26.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The aggregate fair value of unvested RSU is calculated using the closing price of our common stock on the grant date. As of December 31, 2022, the unrecognized stock-based compensation cost of unvested RSUs was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_edf4828a-edb0-4959-b92e-3303bc49a99f" contextRef="C_2621b640-8d9b-4efa-a67c-bc201f6864e5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_16045ea3-ec60-4aad-9192-477286bd739b" contextRef="C_d2a47633-779f-4ee5-bc2a-ade49b683a08" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;), which became effective on June 11, 2020. The 2020 ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb9ab827-5b29-48a3-b6df-ff52894902fb" contextRef="C_ff0b5242-8612-45db-87e3-a8572449c172" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation. Employees enrolled in the 2020 ESPP, purchase shares of common stock at a price per share equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be2b324a-fb82-4622-bbf3-41fc242663c8" contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value at the start or end of the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f08b2039-d83e-4f36-9585-a9b213cede39" contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2" name="pcvx:PurchasePeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> purchase periods within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e41fb11-4aad-47d8-b47c-5c83e70e718d" contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2" name="pcvx:OfferingPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> offering period. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b31ea296-df0d-444f-93a4-cf1540cced93" contextRef="C_ff0b5242-8612-45db-87e3-a8572449c172" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">650,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were approved to be initially reserved for issuance under the 2020 ESPP. In addition, the number of shares of common stock available for issuance under the 2020 ESPP is automatically increased on the first day of each calendar year during the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf462f8e-a2e6-4d04-a2d8-653627836a50" contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7c538321-d545-4ede-8695-b1e5d7597e5b" contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2cbbe32a-cc21-40d7-bde9-5473529a81bb" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" escape="true" continuedAt="F_2cbbe32a-cc21-40d7-bde9-5473529a81bb_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity under our 2020 ESPP was as follows:</span></ix:nonNumeric></span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><ix:continuation id="F_2cbbe32a-cc21-40d7-bde9-5473529a81bb_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.151%;"></td>
        <td style="width:11.21%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:25.639%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df7acf8c-3627-4c5c-bd82-fa222931dba6" contextRef="C_7cc4ab4f-7bad-4d16-9545-b64979b11e87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_708c669b-119d-417c-8188-85fed656c06c" contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">650,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f23b9cf-7f03-484d-839f-8c7f7456d569" contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,465</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01d8b650-18a6-4bea-a7b7-f68f748fc64f" contextRef="C_e8457603-d007-4a06-8019-118bd0a48904" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">622,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec474de2-aa5c-44b1-8e84-6302fdd2ffce" contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">510,715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c18f4da5-2059-45a5-b196-3e5c82449566" contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">62,546</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a42a3895-8b79-4538-b8a2-aead16f6d1e2" contextRef="C_9400b621-8b2f-4a08-b570-b9c92478f198" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,070,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c0b15669-3968-4fc8-8b45-b0310a571ea2" contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">530,319</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc270758-6ade-4308-b6bd-3dd0704c26a8" contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">61,709</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c4b61e9-9d7d-4801-94af-5cc6f7bd5dd3" contextRef="C_10a9faa2-6408-4b48-8d11-d8c2958b964d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,539,314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:continuation></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective January 1, 2023, the number of shares of common stock available under the 2020 ESPP increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28176ee0-9a9d-4457-94d4-ff6214895b48" contextRef="C_1cf027a0-a614-4616-8ba2-757303a3ef4f" name="pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">794,706</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares pursuant to the evergreen provision of the 2020 ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4ed719c-fe13-4b92-9cf3-f420094e1e68" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.321%;"></td>
        <td style="width:1.357%;"></td>
        <td style="width:15.203%;"></td>
        <td style="width:1.357%;"></td>
        <td style="width:15.203%;"></td>
        <td style="width:1.357%;"></td>
        <td style="width:15.203%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f565271e-3ab8-4bb0-b435-78c63f0d92b5" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">78.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8be2b80-8fe0-4e74-b983-81dc968ebbde" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">85.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d595286a-61a6-4be8-b4f2-831c890cc784" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b74a719-99ac-4f9c-a42a-0bc03c63a244" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">84.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d909158c-735e-4f55-8d46-425e5dc8f51a" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">81.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8992331-51ba-437a-b76c-378be877a21f" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">94.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a1af37b-ee4d-419a-bc5a-48a42388e33e" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9915d657-bad9-4d92-9073-812647533b14" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f901465d-d8a1-4206-87ce-ec5b0017c62b" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c093f72a-6c38-4182-9b98-b712184e738f" contextRef="C_41f2bc47-1b64-456b-8eb3-0bfe5b57516c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b88d1722-d7aa-4016-9b49-476cbd5e56da" contextRef="C_132ccca8-d60e-4222-bb51-935509c790c4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e8d3c5ab-5e60-4d3b-8831-56a4b226b4e0" contextRef="C_9894bfc2-b8d0-4aa2-bdea-70d5be6112ef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_30275f93-4d6f-4eb9-8a81-47badae44a3b" contextRef="C_78621854-c804-4c5b-8406-1b035bcdf270" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3ff7fc12-b7f5-491d-9b50-06e60a63b779" contextRef="C_e0c5e803-6cf5-4387-8896-428a21286a2d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c55323cb-5dbe-404b-b069-874087f1dc31" contextRef="C_a07caa24-b5b1-41b0-bf5a-a85de3830de2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9735b0a1-648f-48cb-a8b8-1c2f12e9e8d4" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4bdf0633-0583-4429-a282-aaeb20e3fc2f" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_afcf3471-e242-43d6-8bc4-003124c10f9a" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d543c55c-4030-4fa8-9c07-a7f61a93cbf2" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_67719a2c-8dc4-4842-81c0-fed025a19039" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1c0bb61-48c5-4979-a38e-51655e70823d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d4ac98be-3a74-4323-ac2b-9443854ce1af" contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.12%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:15.385%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:16.998%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:15.363%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a3ff9a8-afc1-464d-b4da-887dd19164bc" contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">78.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40669cbb-808c-4538-92e6-dffb0a9af303" contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">99.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69abb67b-7f10-4c9d-80a5-911cf464a637" contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">79.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_643b74a8-cf7b-4fba-8619-d9f7db5a15f6" contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">126.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26a4875b-3d9c-4fdf-9f99-8a7263c0f379" contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">105.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cfc1902-2bb9-4495-b10e-e8888ff0c908" contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">158.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1caa3502-a728-4f49-a8d3-e3c20b5d08a1" contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cdff936-d393-4cec-b0dc-ab4c7c893434" contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e48cec07-c9ab-4629-b766-983b7bedb631" contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e1a4c7df-9d7f-4c32-a71f-06203f59c9a4" contextRef="C_6bc5fec4-d3ad-4cc4-9828-b81bfbdb4992" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c5d2c979-84b7-4abf-a90b-93d9a2240302" contextRef="C_8e4a1e9d-b20b-44bb-aaf3-49bc4856bac7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3972cbcc-0a55-4816-888d-692995289dad" contextRef="C_df172351-baa3-4411-9c37-3b0b3e33fab0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_950128c2-482f-44e7-a881-cba1aef21e24" contextRef="C_0489234b-730f-4827-9f6d-d815f1a09ff7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e7c96f36-e998-4547-ab90-a5b74374378c" contextRef="C_02afd6c9-f14c-4595-b698-8d1af3e8c0a9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f1ab2b21-bd37-46d8-a270-9e87c3aaac93" contextRef="C_7f9806ed-b5a6-4aef-bf04-0c1827f34b0f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5ef6f23-f9e4-4486-bc70-0d0f9c4d70ad" contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2f021d5-4f92-40aa-b294-87645175b124" contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab6975a2-59a1-475f-9489-6bef4a7e2ac3" contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d342929-5599-4f77-8e44-6de3e7aad337" contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1fd573d3-dc51-4631-8e60-fdae2fd7f9e0" contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd293a96-e7df-426d-b845-9f9157d50fe2" contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7a92e464-4f66-4ca9-9e6d-c0e4ee9729e7" contextRef="C_81e20c4f-e0c6-4cea-b677-93b2e39c7f30" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recorded total stock-based compensation expense for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.07%;"></td>
        <td style="width:1.359%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.359%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.84%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.359%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.173%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c055635-cb9a-484d-b983-d075e260a8bd" contextRef="C_8ba486b2-d8aa-4ca6-9756-5c9748b4e008" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61f1dc33-f22c-4cf3-8a5a-ce76cdd70322" contextRef="C_ae85f674-5889-4534-aba6-cf137accf611" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,954</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f16f80c3-ad8c-4d85-a521-ea711f397e9d" contextRef="C_57fb732d-890e-48c0-9e93-f41e83529309" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56fc4465-5ae7-4914-8407-6a2fd11bbd94" contextRef="C_0462dcf5-a925-4711-9836-298b3b1a0bba" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,751</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0011130-c80b-450e-a1ce-9ffecc741758" contextRef="C_51a0df40-cbb7-4e5a-855d-40d7ff36c161" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_985e57a5-c5df-4aef-a899-d865bc298735" contextRef="C_b694d80e-fe68-400d-b770-ba2619d82563" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01ee9aa4-da26-4681-8b14-14bc9e23ad19" contextRef="C_81e20c4f-e0c6-4cea-b677-93b2e39c7f30" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c49dd963-9209-4b3b-be9e-6d2b3214057e" contextRef="C_86a6494f-286c-4378-b602-52e8e5e8f4b6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,729</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40922604-6eec-4ba9-8ec8-3d7b4e400685" contextRef="C_7d262603-bbcb-4d32-8649-c7dde0f3cba1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,434</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon our IPO, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cbfa52c-9aca-4bc2-872e-49256ff2c233" contextRef="C_34d44816-59db-4fff-99c9-27216e95713d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">362,935</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance-based awards vested and, as a result, we recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c09b8042-9d19-415e-b9c5-bf66e1418f33" contextRef="C_7329b071-f8d6-4b42-988b-4c5a585bc452" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of stock-based compensation expense during the three months ended June 30, 2020, which amount is included in the above table for the year ended December 31, 2020.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5c074a1-be78-422f-a8e6-5ed873200805" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">87.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to the employee and non-employee awards, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_30bbece8-5c3a-406b-8cd0-41b7af17dfd4" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6e5e256-56b9-44b0-811e-6e0f30231b17" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Retirement Plan</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company sponsors a qualified 401(k) Plan. The retirement plan is a defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. For the year ended December 31, 2022, the Company contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7917f5cb-4506-4059-8cad-c829cc3d14a6" contextRef="C_3912106f-3c31-4ffc-9141-7807cf18d485" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the retirement plan.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_57966c8a-526d-4021-a8b6-dc35ac6060f4" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:FundingArrangementTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Funding Arrangement</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2019, we received a cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#x201c;CARB-X&#x201d;), a public-private partnership funded under a Cooperative Agreement from Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;) and by awards from Wellcome Trust, Germany&#x2019;s Federal Ministry of Education and Research, the United Kingdom Global Antimicrobial Resistance Innovation Fund and the Bill &amp; Melinda Gates Foundation. In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the Trustees of Boston University, the administrator of the program. The initial award provided the potential for funding up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dea183d8-0187-4194-9fb0-9ae51b97e20f" contextRef="C_037574d0-71b1-40d4-9227-c5f9299b9dd2" name="pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo and necrotizing fasciitis. The initial award committed initial funding of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a98a0aed-b807-481a-b793-83a3b436711e" contextRef="C_9a9d9224-9fa8-4858-a34f-83f9703e9715" name="pcvx:InitialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for our VAX-A1 program and, subject to a CARB-X decision to extend the options, up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1bbb466a-1001-41e3-ac59-f3d65c99b5ef" contextRef="C_9a9d9224-9fa8-4858-a34f-83f9703e9715" name="pcvx:FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in total funding available upon achievement of development milestones over the next </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_829b9d91-dfad-47c5-be74-5fd380dec43a" contextRef="C_037574d0-71b1-40d4-9227-c5f9299b9dd2" name="pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Specified research expenditures are reimbursable expenses associated with agreed-upon activities needed to advance the research project supported by the grant. These expenditures can include labor, laboratory supplies, travel, consu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lting and third-party vendor research and development support costs. CARB-X has awarded us total funding to date of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6c5aea2-b453-47cf-8a46-e1aa59998ae4" contextRef="C_5498ed60-351d-4bfe-8d0d-3748e9cc3710" name="pcvx:PotentialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, with potential funding of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e003a0e5-1367-49ef-91b7-9e9d3c24a66f" contextRef="C_9ab2dcd4-25fb-4d25-a652-57453b4b393b" name="pcvx:InitialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f05bddcc-5628-4284-8899-267d3fd77ff5" contextRef="C_9ab2dcd4-25fb-4d25-a652-57453b4b393b" name="pcvx:PotentialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_003b909d-0a74-47e1-8611-ad9c6b6cc1d8" contextRef="C_c04110eb-23bc-459e-a813-d93f70e70acf" name="pcvx:PotentialFundingCommittedByAward" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, we received a cost-reimbursement research award from the National Institutes of Health (&#x201c;NIH&#x201d;). In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the University of Maryland, Baltimore, the administrator of the program. The award provides for potential funding up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f331c69f-97e4-4602-a035-99ddec8b1edf" contextRef="C_ef8a5bfd-8fc9-43e4-974f-36c738247627" name="pcvx:PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> totaling approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_729547c2-a10b-46c1-864f-3d5220f63ff9" contextRef="C_1121605e-be53-44bc-b6eb-31b279bad82d" name="pcvx:PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" unitRef="U_USD" scale="6" decimals="-5">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to develop a vaccine to prevent infections caused by Shigella.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income from grants is recognized in the period during which the related specified expenses are incurred, provided that the conditions under which the grants were provided have been met. We recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73f82c66-274e-42fb-8937-7e18b40349c4" contextRef="C_bcab4237-fc1e-4b3b-a82d-9d53bb21e6b4" name="pcvx:GrantIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7247476b-68a1-4695-8d13-08f7ef4158f1" contextRef="C_f1e5de9a-c565-4d52-a50d-b1a74b68669d" name="pcvx:GrantIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c45a3089-3a32-44e8-9416-2491461fbf29" contextRef="C_b043466b-5227-4835-be5f-8ac1b25eac10" name="pcvx:GrantIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of grant income and recorded the amounts in Other income (expense), net in the statement of operations during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 respectively. A grant receivable of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a0ab294f-52f6-44eb-af01-cfcc1f6d874c" contextRef="C_c325a933-95d0-4782-a705-8f73c8708fb5" name="us-gaap:GrantsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dedd936f-9614-4aa1-b597-5f7493f395b3" contextRef="C_c7051fb3-6833-4895-a7ab-ff07923b921b" name="us-gaap:GrantsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million representing unreimbursed, eligible costs incurred under the CARB-X agreement was recorded and included in Prepaid expenses and other current assets in the balance sheets as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, respectively.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ba95bbc-cd6c-4785-b861-f0dc86c72134" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d87c620d-3818-47ab-ba8b-cc9bd9f87166" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.374%;"></td>
        <td style="width:1.261%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.916%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.271%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.916%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.271%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.99%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e97e14cf-6e23-4bfb-9d6d-2f1c72c60ea8" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">223,485</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd911838-b77b-48b5-b0ef-ef969dc4b547" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e6dbaef-fb22-43ff-b3f4-6c6fb126824e" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">89,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding used in computing net<br />&#160;&#160;&#160;loss per share, basic and diluted</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c65f1584-bd70-4148-aaf9-8d07d0b9ee57" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_694f7a1e-3e06-4408-ad9a-ffad513bf345" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">64,877,988</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e9a8586-379f-4e42-a15a-c3130c119705" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_2fb31e33-b132-459a-9af3-4658f920b684" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">51,922,108</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1548a76f-25a1-4f15-8005-1ce3bed8cd17" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_492834d3-065b-4571-ab29-2502ede47106" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">29,545,810</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87a86458-b7a5-4bb1-99ba-8c214af88029" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_20eb356d-3f77-4291-a39c-ef701fea34f7" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.44</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81518c9e-e638-4262-8e17-3f13294e4bbf" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_fe510417-9894-4807-af54-4830ed488791" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">1.93</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40d34fda-1435-4a1c-8c96-11a61ab124a7" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_7599c270-b4f3-4f81-b911-a115c63d04a9" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">3.02</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">____________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes shares of common stock into which pre-funded warrants may be exercised. See Note 9, &#34;Pre-Funded Warrants&#34;.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div></ix:nonNumeric></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_de7e9eea-3a00-4858-818b-1d0f33953e65" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.529%;"></td>
        <td style="width:1.009%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.64%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.64%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.139999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4269d367-c39c-46e2-a07f-4b7c764c56f8" contextRef="C_9bb12da7-1bd7-4afd-815f-80e30d2186ff" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,752,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68e1a843-da0a-4b00-a951-27fd035b921f" contextRef="C_ddc89e57-5630-47be-9bd0-27808be55284" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,357,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99bbfd46-7df8-4f50-a3f2-c33cf4dc4708" contextRef="C_563ab83e-909f-4129-bbf2-6d8fd0542811" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,188,531</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd2427eb-ee1b-4e36-a5bd-91fd6254f6d6" contextRef="C_33283eca-8ea2-4ccd-9fe1-36145a063453" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">456,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12cf58d6-8e61-4883-aed9-dc3b3f8a05c4" contextRef="C_b219256c-6df8-41ce-b765-2f529e35b517" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17b3cc10-5bdb-44f1-a994-d59ae46a8d0a" contextRef="C_4fea95f2-1b19-4123-9ac1-3c958efccee9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plans</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0b5682b-51f1-49ad-a078-6ccbc458ac07" contextRef="C_d2fdc0e7-955d-4a1b-9894-ad28840b67da" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">113,240</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4a40b51c-2a57-4fd8-b11c-92656aa279e4" contextRef="C_f5b73419-0c99-4891-9305-ef5424ea8616" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">66,404</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfadbdec-5fde-48f8-aa01-53b11602f98f" contextRef="C_1be3eda5-a43a-436d-b315-ddea1f184d88" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">87,887</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aec3f61b-b5cf-4bd3-8e00-ebffed558c94" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,322,210</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de07baac-072d-4010-a198-06abe37f0424" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,423,793</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bafb7e95-cd5d-4100-9d37-3c8b921f5e94" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,276,418</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_0117089f-675f-4f8a-a77f-3dbbe039f418" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pre-tax book loss was derived from our business operations within the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c556f905-63d1-453c-9805-aa7405480982" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.469%;"></td>
        <td style="width:0.98%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.57%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.98%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.57%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.98%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.45%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_258d9aaa-c513-470e-888b-eb8ae243e82b" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4bec698-c45d-4477-b2d0-8fc16d1805ac" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_757b47b6-8c79-43eb-acf1-3e019ca5b5b9" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8426126-c1d6-4c57-88bd-4a9f4048b799" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7de1e26f-9c9c-4573-897b-c3179531a299" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04c41bd8-0f83-4a77-a909-a9bba4018be6" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80af353b-9ba2-4df8-98f1-59c9d525d769" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdfb4f5a-dd56-40f3-970d-642ae8a3d48a" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_759d25eb-ab69-42e5-b66f-2cb749e67d44" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5f45fc2-7fd3-42d9-8568-e859afbbf42a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">21.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8372ea01-cdfd-4966-b3a3-8b5a67895f5b" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">23.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5134f00b-6328-4caa-a1ac-c88e5bb8d286" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">22.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d28bdfa9-f518-49b5-89a3-e1fa6de3ae6a" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:Section162MLimitation" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f29b9b2-2993-4d21-a6ed-60a724ef789c" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:Section162MLimitation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_802af70f-cd71-4dcf-a22f-17f9b1443f1e" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:Section162MLimitation" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fe8f767-164a-4796-8d2d-e46722f6bd17" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17959fcf-7f4e-42b0-906d-6f70266dfaad" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_183651b9-50a6-4cb9-89bd-4b35bbe4e5cc" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_044aa6a6-d895-4aa0-a08e-4ca031bbd5f3" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_be5fb6c1-34bd-4c37-8979-a4ef57bf3875" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e4703a6-3c7e-4543-a0f2-f26f51d5137f" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 effective tax rate reconciliation has been updated to conform to the 2021 and 2022 presentation.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_049ee17e-3e5d-46d5-b46f-9f26f2c658f4" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_049ee17e-3e5d-46d5-b46f-9f26f2c658f4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents significant components of our deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_049ee17e-3e5d-46d5-b46f-9f26f2c658f4_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.929%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.011%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.487%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.086%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1de3c13-26d8-4e25-8697-3626617e0773" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,555</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e04b9473-4283-4a22-a82b-35b29bbb6eff" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,574</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05257656-9bf0-4876-b3b3-024ef6853bfb" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,062</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e5a1859-64db-485d-816c-b04f0e700af1" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued &amp; others</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d15ce071-280d-4dbc-b955-df724acecf1e" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33105149-d815-4139-9962-2039b98c9033" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f6ac7c6-75c4-4791-ad1a-72731c697302" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,436</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c127d18a-0b16-4362-9066-490c5d72db2e" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,865</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized R&amp;D expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ce0a376-fc19-4980-8e27-ad5e84db3f50" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,873</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad1d8393-5b75-4747-bc49-5e51343a3d41" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,984</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37460370-c2ab-49b5-9f83-bf3506d7aec2" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,063</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e566848c-bca9-4a56-b7c4-0689debbd297" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,006</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faa2ef01-28f8-481d-ac58-194141fd4d8e" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:LeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,358</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3225430f-5337-42fb-bfc8-b7411f104d87" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:LeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe1a25f3-8674-4487-ba7e-178d58efc279" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,867</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac4250ee-eb65-4511-b237-429ee9e59929" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78c4db69-b1e9-4eef-a9b3-72a61579c018" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,956</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_465d1b4d-cd7c-419c-8525-366df1e27a55" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170,791</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_173f9615-f1d6-4941-9133-a911e19fe15a" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104,934</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87d40ed2-49fe-438c-a170-09fa22ac7358" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,357</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cf19cc7-ec81-4e92-b7e6-3398ae6b38ed" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f00c5109-856d-4f41-b76b-1c013efb02fd" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,357</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb62485e-1103-4016-8350-11227be54245" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93f8c33d-9c3e-4bd4-b1b9-d3b7c590b50f" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,433</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e87bd217-29e0-45cc-b04b-61257af3a379" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_907c7827-9132-4cea-ac34-da7ef733f006" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164,433</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cd131d4-6f1f-47cc-b030-9db2534eabe4" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_c4653557-9b4f-4d3f-bf1c-d79a8f314a27" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Accrued &amp; others and Stock compensation lines have been updated to conform to the 2022 presentation.</span></ix:footnote></div></div></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, we have net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d803279-7a26-4650-95c8-7d4bd2c6c613" contextRef="C_eb41f55f-e7d1-436d-992c-c9ae66000f84" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">340.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9dda15bb-11b4-467c-b303-22d1c377703b" contextRef="C_6584fbf6-caf6-435c-8531-3189f88ffaef" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">453.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards, except the federal loss carryforward arising in tax years beginning after December 31, 2017, begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_289325e8-edad-427e-97a3-37c91cef4ec0" contextRef="C_c544cf31-11ab-4456-8095-c7c6e411d5d1" name="pcvx:OperatingLossCarryForwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless previously utilized. Federal net operating losses arising in tax years beginning after December 31, 2017 have an indefinite carryover period and do not expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, we have research credit carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2848022-0e24-4bf4-9b64-4bd844ad734a" contextRef="C_49cc4baf-48fc-47b3-962c-c338dcbc9399" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eec277d3-d0a3-4a4f-972e-a8db509b0ef1" contextRef="C_81984893-bd31-4052-aaed-e6928b5494fe" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available to offset future income tax liabilities, if any, for federal and California income tax purposes, respectively. The federal research and development tax credit carryforwards expire beginning in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_00005f68-5c33-40e1-a342-abf1045a632e" contextRef="C_49cc4baf-48fc-47b3-962c-c338dcbc9399" name="pcvx:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless previously utilized. The California tax credits can be carried forward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of the net operating loss carryforward and research credit carryforward may be subject to an annual limitation due to the ownership percentage change limitations under Section 382 and Section 383, respectively, provided by the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and similar state provisions. The annual limitation may result in the expiration of the net operating loss before utilization. We have experienced ownership changes in the past. There were no ownership changes identified in 2022, as such we have determined that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_79b265a0-84d3-45d6-939a-1376ffe2a6af" contextRef="C_c3303683-5d29-4add-a4a5-c77ccff026b8" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> federal research credits will expire unutilized or are excluded from our research credit carryforwards. The Company does not expect any ownership changes during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 to result in a limitation that would materially reduce the total amount of net operating loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have uncertain tax benefits (&#x201c;UTBs&#x201d;) totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acf8b237-0b9b-4c27-8e53-4254b63631d9" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3c6bab4-77a3-4d4a-84fb-98856d55987e" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs had no effect on the effective tax rate. We recognize interest and penalties related to UTBs, when they occur, as a component of income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period such determination is made. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34b4dead-0f6c-4a4c-b264-4415618f202e" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f08f7476-adb5-4899-8db5-0f0ca6182b25" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest or penalties recognized for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. We do not expect our UTBs to change significantly over the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1508abed-9b4e-46da-8098-3fbba9dea47f" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" escape="true"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.721%;"></td>
        <td style="width:1.323%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.008%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.323%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.774%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.334%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.517000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3246d361-5dee-4ee1-abc5-ab085ccd15e8" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">924</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56dbdd88-825a-4b9f-922e-32123eb550f6" contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e77da0c0-f0c0-4174-8d09-f0c97cf25c43" contextRef="C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">271</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c247661-8dd2-4fb3-b0a0-2775450b44dd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">876</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_558acc0a-0d4b-4d8b-ac1e-d209210fba7b" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">461</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4f26a3d-092f-44af-8eb0-00d48b7a60fa" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions based on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_10b74cbc-da76-4ce1-8241-c4bf3e9233dd" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6707fd7-f3a9-4fdd-8b05-d2ed4ecb57ad" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ec73bbe-ddaa-4e7a-af44-e9aa659d282d" contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448" name="pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">165</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1c38cc2-17e5-4ff1-b437-e5f984d5ddd5" contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,754</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b224d6b2-310b-41dc-9b60-bcd8630d0302" contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">924</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b43d1aee-fce1-4169-bddc-2fa2707f01eb" contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">393</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We file U.S. federal and state tax returns. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2017. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the net operating loss, or NOL, and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. We do not have any tax audits or other issues pending.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (the &#34;CARES Act&#34;). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact our current tax provision.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 21, 2020, the President of the United States signed into law the &#x201c;Consolidated Appropriations Act, 2021&#x201d; which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program, or PPP, loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contribution deductions and a temporary full deduction for business expenses for food and beverages provided by a restaurant. These benefits do not have a material impact on the current tax provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Infrastructure Investment and Jobs Act was signed on November 15, 2021, and it contained several tax provisions including changes to the Employee Retention Tax Credit and changes to excise taxes. These provisions do not have a material impactful to the Company&#x2019;s current tax provision.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the 2017 Tax Act, research and experimental (R&amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;E expenses are required to be amortized over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7d6705e5-9f73-475b-8e41-cb39095eda62" contextRef="C_49cc4baf-48fc-47b3-962c-c338dcbc9399" name="pcvx:ResearchAndExperimentalExpensesAmortizedPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for domestic expenses and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8a8115bd-6290-41cd-b1cb-c1bba683ba41" contextRef="C_330c2634-585b-4669-bdd0-9bfa256e2032" name="pcvx:ResearchAndExperimentalExpensesAmortizedPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for foreign expenses. The Company has capitalized research and experimental expenditures in its current tax provision as a result.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax (&#34;CAMT&#34;) on adjusted financial statement income on applicable corporations for taxable years beginning after December 31, 2022. There is no impact to the Company&#x2019;s current tax provision.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The American Rescue Plan Act was signed on March 11, 2021.  One of the provisions of the Act included expanding the definition of covered employees subject to IRC 162(m) to include an additional top five highest compensated officers beyond the CEO, CFO, and three highest paid employees currently covered under IRC 162(m). This expanded provision is applicable for tax years beginning after Dec 31, 2026. The Company does not believe that this update to IRC 162(m) would have a material impact on its income tax provision currently and will continue to monitor this.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8086d482-24df-4ca3-9b93-acc9fd63ad30" contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have an ongoing relationship with Sutro Biopharma. In 2013, Sutro Biopharma provided support to facilitate the establishment of our Company. As of December 31, 2021 and 2020, Sutro Biopharma owned approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7f76a77-3152-412d-94b9-fb40919c12dd" contextRef="C_8656ce44-0eee-45cd-8119-542db136b9e9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="6" decimals="-5"><ix:nonFraction id="F_a06eb04c-1387-449e-ad90-766f220d320a" contextRef="C_e301df95-054d-4248-b434-a97368723f9f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="6" decimals="-5">1.6</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million shares of our common stock. As of December 31, 2019, Sutro Biopharma also owned warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93b73b35-f0e5-4209-aa23-a7fb0990ea64" contextRef="C_180b3546-613a-47fb-a45e-b43467ddc5e3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,857</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock (the &#x201c;Common Stock Warrant&#x201d;) at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae3919ea-d9e2-4122-bad5-53863cf81edd" contextRef="C_180b3546-613a-47fb-a45e-b43467ddc5e3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="5" format="ixt:numdotdecimal">0.79289</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77b529b1-e234-48ab-bbb7-9778e6b0d502" contextRef="C_24822c38-0fa4-483a-956a-7108b2fb1a10" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,276</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our Series C redeemable convertible stock (the &#x201c;Preferred Stock Warrant&#x201d;) at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e6212ce-053c-4f29-97cb-d1d7ee5fae60" contextRef="C_24822c38-0fa4-483a-956a-7108b2fb1a10" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:numdotdecimal">11.5215</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Common Stock Warrant and the Preferred Stock Warrant were automatically net exercised pursuant to their terms for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1af8f4f0-ed0f-4363-841d-2d818cf1502c" contextRef="C_d6be8964-6e18-48ad-a7a4-2310c767319e" name="pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,278</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22b654f1-4a16-4c2d-a5f4-4e8043f38626" contextRef="C_f6044654-8564-4024-bef2-b41b4aedd272" name="pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,591</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, respectively, of our common stock in connection with the IPO. In the agreements and amendments identified herein, we licensed certain intellectual property and acquired certain supply rights from Sutro Biopharma, including the right to use the XpressCF platform to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases. On October 12, 2015, we and Sutro Biopharma (&#x201c;the Parties&#x201d;) entered into the Sutro Biopharma License Agreement, which amended and restated an agreement dated August 1, 2014. The Sutro Biopharma License Agreement was subsequently amended on May 9, 2018 (&#x201c;License Amendment A1&#x201d;) and May 29, 2018 (&#x201c;License Amendment A2&#x201d;). In consideration for the License Amendment A2, we issued to Sutro Biopharma the Preferred Stock Warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b4c4d74-46de-44f8-a261-a86a3b743f32" contextRef="C_8b67a24d-307d-4950-a7b7-2cbe7eaae283" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">59,276</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series C redeemable convertible preferred stock at a purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e9d41d3-6b19-44be-a149-f2a6a5e17563" contextRef="C_8b67a24d-307d-4950-a7b7-2cbe7eaae283" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4">11.5215</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. We also entered into a separate supply agreement with Sutro Biopharma on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fbdd3305-94d6-4a83-98c8-31ce59bf35cd" contextRef="C_acde4ea0-fa6f-4cb1-9b72-08bcadf7a728" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2018</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;Sutro Biopharma Supply Agreement&#x201d;). As of June 2, 2021, Sutro Biopharma was no longer considered a related party.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Sutro Biopharma License Agreement, Sutro Biopharma granted us an exclusive, worldwide license to research, develop, manufacture and commercialize vaccine products addressing infectious disease, which are discovered or produced based on the use of Sutro Biopharma&#x2019;s proprietary cell-free protein expression technology, known as XpressCF, which utilizes extracts derived from strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In connection with the Sutro Biopharma License Agreement, under the Sutro Biopharma Supply Agreement, Sutro Biopharma has agreed to manufacture and supply extracts and reagents for us on a cost-plus basis. In consideration for the rights licensed, we are obligated to pay a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ec58dc3-06b6-4df3-bf39-35cbd80c6eb4" contextRef="C_69861e0f-f897-430a-8634-87b91fd0c8b1" name="pcvx:PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" unitRef="U_pure" scale="-2" decimals="2">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43482c0d-9caa-44a6-bd61-fd8204470905" contextRef="C_69861e0f-f897-430a-8634-87b91fd0c8b1" name="pcvx:PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" unitRef="U_pure" scale="-2" decimals="2">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty on annual net sales of vaccine products for animal health. In License Amendment A1, the Parties amended the license agreement to remove a pre-IND regulatory meeting as a diligence milestone and to agree that certain other diligence milestones had been satisfied. In License Amendment A2, the Parties amended the license agreement to add certain terms confirming our obligation to purchase Sutro Biopharma&#x2019;s proprietary extract from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#x201c;Extract&#x201d;) from Sutro Biopharma. In addition, the Parties amended the license agreement to specify our rights</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to a transfer of certain know-how relating to the manufacture of Extract in the event of a declaration of bankruptcy by Sutro Biopharma. Finally, the Parties agreed to terms providing for injunctive relief in the event of a breach or threatened breach by the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the Sutro Biopharma Supply Agreement, the Parties agreed to terms for the supply of manufactured Extract and custom reagents by Sutro Biopharma for us to use in manufacturing vaccine compositions in non-clinical research or in Phase 1 or Phase 2 clinical trials. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2021 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of Extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Supply Agreement. In February 2021, we entered into an amendment to the Sutro Biopharma Supply Agreement and extended the term to July 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As Sutro Biopharma was no longer considered a related party as of June 2, 2021, we excluded expenses after that date from related party transaction expenses. We recognized expense related to the Supply Agreement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5fced04-8d1b-40ec-8725-75da26f3a86c" contextRef="C_69e656bb-2569-41bf-9f6a-4c464b33253f" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2396e253-e1d6-47a1-ba53-59704860ef93" contextRef="C_6c1fa594-ab7b-4dd7-8b89-83fe6abb5568" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2608e1cc-284a-4302-8e1d-11a3f66999ab" contextRef="C_2d608b3d-cdf6-4c26-9877-9e1ba7a21a78" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively. In addition, we recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e8d2c695-e978-46cd-9bbc-37ac3096d490" contextRef="C_05578dce-4d37-4f18-96b3-f10bddcbaf51" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1c446242-1776-41c3-b9a6-e60fa0e163d9" contextRef="C_3d0c5e64-a420-486e-ae76-8b1696c5a6ed" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ca243b5-8f8a-4713-bdaf-49f62e5209ad" contextRef="C_05a0d0fb-b481-4721-8b79-6232b8304ad5" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the change in fair value of the Preferred Stock Warrant for the years ended December 31, 2022, 2021 and 2020, respectively. The expense related to the changes in the fair value of the warrant is included in research and development expenses in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8b253f3f-cac2-460f-97b9-f556b7a086a8" contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Subsequent Events</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to December 31, 2022, through February 24, 2023, we sold a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1495ea59-f5bf-42e7-bd8b-f299ceb13d00" contextRef="C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">507,136</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock under the ATM Sales Agreement at an average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_267f1d99-be58-421d-9bc3-2b989f47616c" contextRef="C_1cb91b7d-ce25-4f69-a837-9352b82a8fb7" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">45.79</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, generating aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5366cf28-918b-4cb1-aa6a-c732149c6ec4" contextRef="C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814" name="pcvx:GrossProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb048e8f-925a-4c3f-932a-6fdcc6740523" contextRef="C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814" name="pcvx:ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">22.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million net of commissions and offering expenses).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation of our Chief Executive Office, or CEO, and our Chief Financial Officer, or CFO, our principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of December 31, 2022. Based on this evaluation, our CEO and CFO have concluded that our disclosure controls and procedures as of December 31, 2022 were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Annual Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in its 2013 Internal Control - Integrated Framework. Based on this assessment, our management has concluded that our internal control over financial reporting was effective as of December 31, 2022. Pursuant to Section 404(c) of the Sarbanes-Oxley Act, our independent registered public accounting firm has issued an attestation report on the effectiveness of our internal control over financial reporting for the year ended December 31, 2022, which is included below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the stockholders and the Board of Directors of Vaxcyte, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br />We have audited the internal control over financial reporting of Vaxcyte, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2022, based on criteria established in Internal Control &#x2014; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control &#x2014; Integrated Framework (2013) issued by COSO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the balance sheets, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders' equity (deficit), and cash flows as of and for the year ended December 31, 2022, of the Company and our report dated February 27, 2023, expressed an unqualified opinion on those financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#x2019;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Francisco, California</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_foreign_jurisdictions"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain information required by Part III is omitted from this Annual Report on Form 10-K since we intend to file our definitive proxy statement for our 2023 Annual Meeting of Stockholders (the &#x201c;2023 Proxy Statement&#x201d;) pursuant to Regulation 14A of the Exchange Act, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, and certain information to be included in the 2023 Proxy Statement is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item of Form 10-K will be included under the captions &#x201c;Proposal No. 1&#x2014; Election of Directors,&#x201d; &#x201c;Executive Officers,&#x201d; &#x201c;Delinquent Section 16(a) Reports,&#x201d; &#x201c;Corporate Governance and Board Matters,&#x201d; and &#x201c;Code of Business Conduct and Ethics&#x201d; in our 2023 Proxy Statement, and is incorporated herein by reference.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have adopted a written Code of Business Conduct and Ethics (&#x201c;Ethics Code&#x201d;) that applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Ethics Code is available on our website at www.vaxcyte.com. If we make any substantive amendments to the Ethics Code or grant any waiver from a provision of the Ethics Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8-K.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item of Form 10-K will be included under the captions &#x201c;Executive Officers,&#x201d; &#x201c;Executive Compensation,&#x201d; &#x201c;Director Compensation,&#x201d; &#x201c;Corporate Governance and Board Matters,&#x201d; and &#x201c;Certain Relationships and Related Person Transactions&#x201d; in our 2023 Proxy Statement, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item of Form 10-K will be included under the captions &#x201c;Security Ownership of Certain Beneficial Owners and Management,&#x201d; &#x201c;Director Compensation,&#x201d; and &#x201c;Executive Compensation&#x201d; in our 2023 Proxy Statement, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item of Form 10-K will be included under the captions &#x201c;Certain Relationships and Related Person Transactions,&#x201d; and &#x201c;Corporate Governance and Board Matters&#x201d; in our 2023 Proxy Statement, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The information required by this item of Form 10-K will be included under the caption &#x201c;Proposal No. 2&#x2014; Ratification of Independent Registered Public Accounting Firm&#x201d; in our 2023 Proxy Statement, and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following documents are filed as part of this Annual Report on Form 10-K: </span></div></div>
  <div style="margin-left:7.861%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.924082093358947%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All Financial Statements</span></div></div>
  <p style="margin-left:11.293%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial statements and Report of Independent Registered Public Accounting Firm filed as part of this Annual Report on Form 10-K are listed in the &#x201c;Index to Financial Statements&#x201d; under Part II, Item 8 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:7.861%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.924082093358947%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:11.293%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All financial statement schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <div style="margin-left:7.861%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.924082093358947%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></div></div>
  <p style="margin-left:10.84%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The list of exhibits filed with this Annual Report on Form 10-K is set forth in the Exhibit Index preceding the signature page and is incorporated herein by reference or filed with this Annual Report on Form 10-K, in each case as indicated herein (numbered in accordance with Item 601 of Regulation S-K).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit Index</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.938%;"></td>
    <td style="width:26.464%;"></td>
    <td style="width:14.615%;"></td>
    <td style="width:13.782%;"></td>
    <td style="width:13.344%;"></td>
    <td style="width:18.857%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule/Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.034%;"></td>
    <td style="width:26.464%;"></td>
    <td style="width:14.615%;"></td>
    <td style="width:13.782%;"></td>
    <td style="width:13.344%;"></td>
    <td style="width:18.761%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520170425/d944845dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of Vaxcyte, Inc., as amended</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 16, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520170425/d944845dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of Vaxcyte, Inc.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 16, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520162659/d802328dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of common stock certificate of the Registrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 8, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000156459021016110/pcvx-ex42_374.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Capital Stock</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 29, 2021</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312522008768/d259937dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 13, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312522270039/d374961dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Pre-Funded Warrant</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 27, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc. Amended and Restated 2014 Equity Incentive Plan and forms of agreements thereunder.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520162659/d802328dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc. 2020 Equity Incentive Plan and forms of agreements thereunder.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 8, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000095017022008485/pcvx-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Unit Grant Notice</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 9, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001649094/000119312520162659/d802328dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc. 2020 Employee Stock Purchase Plan</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1/A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 8, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officer.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Agreement entered into by and between the Registrant and Grant Pickering, dated January 21, 2016.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Agreement entered into by and between the Registrant and Jeff Fairman, dated January 21, 2016.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.034%;"></td>
    <td style="width:26.464%;"></td>
    <td style="width:14.615%;"></td>
    <td style="width:13.782%;"></td>
    <td style="width:13.344%;"></td>
    <td style="width:18.761%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule/Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex108.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter entered into by and between the Registrant and Paul Sauer, dated April 12, 2016.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Employment Agreement entered into by and between the Registrant and Jim Wassil, dated November 15, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1013.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter entered into by and between the Registrant and Andrew Guggenhime, dated April 16, 2020.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pcvx-ex10_11.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter entered into by and between the Registrant and Harpreet Dhaliwal, dated September 29, 2021.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000095017022008485/pcvx-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Offer Letter entered into by and between the Registrant and Mikhail Eydelman, dated March 4, 2022.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-Q</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 9, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Executive Change in Control and Severance Agreement entered into by and between the Registrant and each eligible employee.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd, dated October 29, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pcvx-ex10_15.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and Manufacturing Services Agreement by and between the Registrant and Lonza Ltd, dated October 21, 2016, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter Agreement by and between the Registrant and Lonza Ltd, dated June 19, 2018.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pcvx-ex10_17.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Master Services Agreement for Drug Product Development and Manufacturing between Registrant and Lonza Ltd., dated March 22, 2022, as amended.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">166</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.034%;"></td>
    <td style="width:26.464%;"></td>
    <td style="width:14.615%;"></td>
    <td style="width:13.782%;"></td>
    <td style="width:13.344%;"></td>
    <td style="width:18.761%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule/Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated SutroVax Agreement by and between the Registrant and Sutro Biopharma, Inc., dated October 12, 2015, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex10_19.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply Agreement by and between the Registrant and Sutro Biopharma, Inc., dated May 29, 2018, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="pcvx-ex10_20.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Grant Agreement by and between Registrant and Sutro Biopharma, Inc., dated December 19, 2022.</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312520150234/d802328dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement by and between the Registrant and The Regents of the University of California, represented by its San Diego campus, dated February 4, 2019.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">S-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">333-238630</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 22, 2020</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22+&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1649094/000119312521016229/d844599dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement by and between the Company and ARE-San Francisco No. 63, LLC, dated as of January 21, 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">001-39323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 25, 2021</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="#power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney. Reference is made to the signature page hereto.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.034%;"></td>
    <td style="width:26.464%;"></td>
    <td style="width:14.615%;"></td>
    <td style="width:13.782%;"></td>
    <td style="width:13.344%;"></td>
    <td style="width:18.761%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule/Form</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">File Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing Date</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as amended.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><a href="pcvx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 13a-14(b) or 15d-14(b) of the Securities Exchange Act, as amended, and 18 U.S.C. Section 1350.</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">X Filed herewith.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain portions of this exhibit have been omitted (indicated by &#x201c;[***]&#x201d;) because we have determined that the information is not material and is the type that we treat as private or confidential.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134; Schedules and exhibits to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request; provided, however, that we may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule or exhibit so furnished.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIG</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NATURES</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 27, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Grant E. Pickering</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ATTORNEY</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Grant E. Pickering and Andrew Guggenhime, and each of them, as his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.085%;"></td>
    <td style="width:1.186%;"></td>
    <td style="width:41.998%;"></td>
    <td style="width:1.175%;"></td>
    <td style="width:25.556%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Grant E. Pickering</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Andrew Guggenhime</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.75pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;President and Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Andrew Guggenhime</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial Officer)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Elvia Cowan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:1pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Vice President, Finance</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elvia Cowan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Carlos Paya, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Carlos Paya, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Annie Drapeau</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annie Drapeau</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Halley Gilbert</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Halley Gilbert</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Peter Hirth, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Peter Hirth, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Michael Kamarck, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Michael Kamarck, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Teri Loxam</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Teri Loxam</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Heath Lukatch, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Heath Lukatch, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:122.4pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:122.4pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>pcvx-ex10_11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img123395336_0.jpg" alt="img123395336_0.jpg" style="width:222px;height:113px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">September 29, 2021</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Harpreet S. Dhaliwal</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">_________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">_________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Dear Harp,</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I am pleased to offer you a position with Vaxcyte, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;) as Senior Vice President, Commercial Manufacturing &amp; Supply Chain reporting to me, on the following terms (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;). If you accept our offer, your first day of employment will be October 1, 2021, or as otherwise mutually agreed (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Start Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">You will receive a base salary of $375,000.00 per annum ($31,250.00 monthly)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> which will be paid semi&#x2011;monthly in accordance with the Company&#x2019;s normal payroll procedures (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;). You will also be eligible to earn an annual cash bonus up to 35.0% of your Base Salary (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Annual Bonus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), prorated for 2021 based on your Start Date. The actual amount of the Annual Bonus will be determined at the sole discretion of the Company&#x2019;s Board based upon measures of Company performance and shall not be earned until paid. Any Annual Bonus will be paid within two and one-half (2.5) months after the end of the calendar year to which the Annual Bonus relates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">You will also receive a $15,000.00 one-time sign on bonus, payable on the first payroll after your start date. If you voluntarily terminate employment from the Company at any time before your one-year anniversary of employment with the Company, you will be required to repay this bonus amount in full.  By signing this offer letter, you agree that the Company may deduct the full amount of your sign on bonus from your final paycheck.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As an employee, you will be eligible to receive certain employee benefits including participation in the Company Option Plan. The details of these employee benefits are explained in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vaxcyte, Inc., 353 Hatch Drive, Foster City, CA 94404</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company is excited about your joining and looks forward to a mutually beneficial and productive relationship. Nevertheless, you should be aware that your employment with the Company is for no specified period and constitutes at&#x2011;will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to conclude its employment relationship with you at any time, with or without cause, and with or without notice. We request that, in the event of resignation, you give the Company at least two weeks&#x2019; notice.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your date of hire, or our employment relationship with you may be terminated.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also ask that, if you have not already done so, you disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company&#x2019;s understanding that any such agreements will not prevent you from performing the duties of your position and you represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment, occupation, consulting or other business activity, nor will you engage in any other activities that conflict with your obligations to the Company. Similarly, you agree not to bring any third party confidential information to the Company, including that of your former employers, and that in performing your duties for the Company you will not in any way utilize any such information.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a Company employee, you will be expected to abide by the Company&#x2019;s rules and standards, including any policies and procedures. Specifically, you will be required to sign an acknowledgment that you have read and that you understand the Company&#x2019;s rules of conduct which are included in the Company&#x2019; Employee Handbook.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a condition of your employment, you are also required</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">to sign and comply with an At&#x2011;Will Employment, Confidential Information, Invention Assignment (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CIIA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non&#x2011;disclosure of Company proprietary information.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Agreement will in all respects be governed by the laws of the State of California, without regard to its conflict of law rules. In the event of any conflict between the terms of this Agreement and the terms of any other agreement between you and the Company, the terms of this Agreement will be controlling. This Agreement will inure to the benefit of, be binding on, and enforceable by the parties and their successors or assigns to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession or assignment had taken place.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vaxcyte, Inc., 353 Hatch Drive, Foster City, CA 94404</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Agreement, including its exhibits and any documents referenced in it or Exhibit A, constitutes the entire agreement between you and the Company regarding the terms of your employment with the Company and supersedes any prior representations or agreements regarding such employment, including, but not limited to, any representations made during your recruitment, interviews or pre&#x2011;employment negotiations, whether written or oral. This Agreement, including, but not limited to, its at&#x2011;will employment provision, may not be modified or amended except by a written agreement signed by the CEO of the Company and you. To accept the Company&#x2019;s offer, please sign and date this letter in the space provided below. This offer of employment will terminate if not accepted, signed and returned by September 30, 2021.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Your employment is contingent upon the following: (1) passing background and reference checks; (2) executing a Confidential Information and Invention Assignment Agreement (CIIAA); and (3) providing legal proof of your identity and authorization to work in US.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We look forward to your favorable reply and to working with you at</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vaxcyte.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:36.667%;text-indent:5.263%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sincerely,</font></p>
  <p style="margin-left:30.0%;text-indent:3.581%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.0%;text-indent:3.581%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.0%;text-indent:3.581%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.0%;text-indent:3.581%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.0%;text-indent:3.581%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.0%;text-indent:3.581%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:30.0%;text-indent:3.581%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">		/s/ Grant E. Pickering</font></p>
  <p style="border-top:0.5pt solid;margin-left:40.0%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Grant E. Pickering</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CEO</font></p>
  <p style="margin-left:36.667%;text-indent:5.263%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vaxcyte, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Attachments:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employee Benefits (Exhibit A)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Agreed to and accepted:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Signature:	 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">__/s/ Harpreet S. Dhaliwal</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">______</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Printed Name: ___</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Harpreet S. Dhaliwal_______</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date:	 __</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sept. 29, 2021</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">_____________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vaxcyte, Inc., 353 Hatch Drive, Foster City, CA 94404</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employee Benefits</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the commencement of your employment, the Company will grant you an option to purchase 100,000 shares of the Company&#x2019;s Common Stock with an exercise price equal to the fair market value on the date of the grant.  </font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has also agreed that, in connection with the Company&#x2019;s 2022 annual equity grant to current employees (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Annual Equity Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), the Company will grant to you either an option to purchase 25,000 shares of the Company&#x2019;s Common Stock with an exercise price equal to the fair market value on the date of grant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additional Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;), or, if the Annual Equity Grant includes awards of RSUs, an RSU award with a value equivalent to the value of the Additional Grant based on the ratio of options to RSUs that is utilized by the Company in the Annual Equity Grant. For clarity, the Additional Grant (or equivalent RSU award) will be in addition to, and not in lieu of, any equity grant you may receive as a current employee pursuant to the Annual Equity Grant.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employee Benefit Plans. You will be eligible for Medical, Dental, Vision, Life, Short-term Disability and Long-term Disability insurance benefits Applicable to all similarly situated employees. You will also be eligible to participate in the Company&#x2019;s 401(k) Plan, Employee Stock Purchase Plan (ESPP), Flexible Spending Plan(s) (FSA), Health Savings Plan (HSA) and Commuter Plan.</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company will reimburse you for all reasonable business expenses, in accordance with the Company&#x2019;s expense reimbursement policies.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vaxcyte, Inc., 353 Hatch Drive, Foster City, CA 94404</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>pcvx-ex10_15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and Manufacturing Services Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(the &#x201c;Agreement&#x201d;)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:53.44%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:45.556%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">by and between</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza Ltd</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">M&uuml;nchensteinerstrasse 38</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CH-4002 Basel</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Switzerland</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- hereinafter &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; -</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400 E Jamie Ct #205</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">South San Francisco, CA 94080</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United States</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- hereinafter &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; -</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective as of October 21, 2016 (the &#x201c;Effective Date&#x201d;)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.989%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:83.718%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:7.276%;"></td>
    <td style="width:1.004%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definitions and Interpretation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance of Services</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Management / Steering Committee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quality</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Insurance</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forecasting, Ordering and Cancellation</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delivery and Acceptance</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price and Payment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capital Equipment</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warranties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification and Liability</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidentiality</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.989%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:83.718%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:7.276%;"></td>
    <td style="width:1.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term and Termination</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Force Majeure</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix B</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix C</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img127089420_0.jpg" alt="img127089420_0.jpg" style="width:120px;height:29px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recitals</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Lonza and its Affiliates have expertise in the evaluation, development and manufacture of products;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Customer wishes to engage Lonza for Services relating to the development and manufacture of the Product as described in this Agreement; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WHEREAS, Lonza, or its Affiliate, is prepared to perform such Services for Customer on the terms and subject to the conditions set out herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the parties intending to be legally bound, agree as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1	Definitions and Interpretation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:83.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Affiliate&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means any company, partnership or other entity which directly or indirectly Controls, is Controlled by or is under common Control with the relevant Party. &#x201c;Control&#x201d; means the ownership of more than fifty percent (50%) of the issued share capital or the legal power to direct or cause the direction of the general management and policies of the relevant Party.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Agreement&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means this agreement incorporating all Appendices, as amended from time to time by written agreement of the Parties.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Applicable Laws&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means all relevant U.S. and European Union federal, state and local laws, statutes, rules, and regulations which are applicable to a Party&#x2019;s activities hereunder, including, without limitation, the applicable regulations and guidelines of any Governmental Authority and all applicable cGMP together with amendments thereto.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Approval&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the first marketing approval by the FDA or EMA of Product from the Facility for commercial supply.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Background Intellectual Property&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means any Intellectual Property either (i) owned or controlled by a Party prior to the Effective Date or (ii) developed or acquired by a Party independently from the performance of the Services hereunder during the Term of this Agreement, and, in the case of Lonza, without use or reliance on Customer Materials or Customer Information, and, in the case of the Customer, without use or reliance on Lonza materials or Lonza Information.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Batch&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the Product derived from a single run of the Manufacturing Process at a scale to be mutually agreed by the Parties.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Batch Price&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the Price of each Batch.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Campaign&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means a series of no less than [***] cGMP Batches manufactured consecutively.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Cancellation Fee&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has the meaning given in Clause 6.5.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Capital Equipment&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means those certain pieces of equipment described in the Project Plan: (i) that are specific to the production of the Product and (ii) that are purchased by Customer or for which Customer reimburses Lonza, including, without limitation, the related documentation regarding the design, validation, operation, calibration and maintenance of such equipment.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Certificate of Analysis&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means a document prepared by Lonza listing tests performed by Lonza or approved External Laboratories, the Specifications and test results.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:83.996%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;cGMP&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means those laws and regulations applicable in the U.S. and Europe, relating to the manufacture of medicinal products for human use, including, without limitation, current good manufacturing practices as specified in the ICH guidelines, including without limitation, ICH Q7A &#x201c;ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients&#x201d;, US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610) and the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC. For the avoidance of doubt, Lonza&#x2019;s operational quality standards are defined in internal cGMP policy documents.</font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img127089420_1.jpg" alt="img127089420_1.jpg" style="width:120px;height:29px;">&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.31%;"></td>
    <td style="width:1.645%;"></td>
    <td style="width:83.045%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;cGMP Batches&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means any Batches which are required under the Project Plan to be manufactured in accordance with cGMP.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Change&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means any change to the Services or pricing incorporated into a written amendment to the Agreement in accordance with clause 16.2 or effected in accordance with the Quality Agreement.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Commencement Date&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the date of commencement of manufacturing activities for a Batch hereunder.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Confidential Information&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means Customer Information and/or Lonza Information, as the context requires.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Customer Information&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means all technical and other information which at the time of disclosure by Customer was not known to Lonza or in the public domain relating to the Manufacturing Process and the Product, from time to time supplied by the Customer to Lonza, including any materials supplied by Customer to Lonza in accordance with the Project Plan.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Customer Materials&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means any Raw Materials, components of Product, or other materials of any nature provided by Customer.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;EMA&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the European Medicines Agency or any successor agency thereto.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Engineering Batches&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means a Batch that is intended to demonstrate the transfer of the Manufacturing Process to the Facility.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;External Laboratories&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means any Third Party instructed by Lonza, with Customer&#x2019;s prior consent, which is to conduct activities required to complete the Services.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Facility&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means Lonza&#x2019;s manufacturing facilities in Visp, Switzerland, or such other Lonza facility as may be agreed upon by the Parties.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;FDA&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the United States Food and Drug Administration, or any successor agency thereto.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Governmental Authority&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means any Regulatory Authority and any national, multi-national, regional, state or local regulatory agency, department, bureau, or other governmental entity in the U.S., Switzerland or the European Union.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Intellectual Property&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means (i) inventions (whether or not patentable), patents, trade secrets, copyrights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential information (including know-how) and any other intellectual property rights, in each case whether registered or unregistered, (ii) all applications (or rights to apply) for, and renewals or extensions of, any of the rights described in the foregoing clause (i) and (iii) and all rights and applications that are similar or equivalent to the rights and application described in the foregoing clauses (i) and (ii), which exist now, or which come to exist in the future, in any part of the world.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Lonza Information&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means all information that is proprietary to Lonza or any Affiliate of Lonza and that is maintained in confidence by Lonza or any Affiliate of Lonza and that is disclosed by Lonza or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.31%;"></td>
    <td style="width:1.645%;"></td>
    <td style="width:83.045%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any Affiliate of Lonza to Customer under or in connection with this Agreement, including without limitation, any and all Lonza know-how and trade secrets.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Manufacturing Process&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the production process provided by Customer for the manufacture of Product, as such process may be improved or modified from time to time by agreement of the Parties in writing.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Master Batch Record&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the document, proposed by Lonza and approved by Customer, which defines the manufacturing methods, test methods and other procedures, directions and controls associated with the manufacture and testing of Product.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;New Customer Intellectual Property&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has the meaning given in Clause 10.2.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;New General Application Intellectual Property&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has the meaning given in Clause 10.3.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img127089420_2.jpg" alt="img127089420_2.jpg" style="width:120px;height:29px;">&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.299%;"></td>
    <td style="width:1.603%;"></td>
    <td style="width:83.098%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Party&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means each of Lonza and Customer and, together, the &#x201c;Parties&#x201d;.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Price&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the price for the Services and Products as set out in Appendix A.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Process Validation Batch&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means a Batch that is produced with the intent to show reproducibility of the Manufacturing Process and is required to complete process validation studies.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Product&#x201d; or &#x201c;Products&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the proprietary molecule identified by Customer as CRM12 (Lonza code: SUO-001) and Polysaccharide + CRM12 Conjugates (Lonza code: SUO-002), to be manufactured using the Manufacturing Process by Lonza for Customer as specified in the Project Plans.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Project Plan&#x201d; or &#x201c;Project Plans&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the plans describing the Services to be performed by Lonza under this Agreement, including any update and amendment of the Project Plan to which the Parties may agree from time to time. The initial Project Plans are attached hereto as Appendix A.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Quality Agreement&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the quality agreement, attached hereto as Appendix B, setting out the responsibilities of the Parties in relation to quality as required for compliance with cGMP.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Raw Materials&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means all ingredients, solvents, consumables and other components of the Product required to perform the Manufacturing Process or Services set forth in the bill of materials detailing the same (including Resins but excluding any consumables or wearables).</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Raw Materials Fee&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the procurement and handling fee of [***] of the acquisition cost of Raw Materials (save for polysaccharides for conjugation that are provided by Sutrovax) by Lonza that is charged to the Customer in addition to the cost of such Raw Materials. Resins are charged at a fee of [***] as set forth in Clause 8.3.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Regulatory Authority&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the FDA, EMA and any other similar regulatory authorities as may be agreed upon in writing by the Parties.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Release&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has the meaning given in Clause 7.1.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Resin&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the chromatographic media and/or UF membranes intended to refine or purify the Product, as specified in the Master Batch Record.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Services&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means all or any part of the services to be performed by Lonza under this Agreement (including, without limitation, process and analytical method transfer, process development, process optimization, validation, clinical and commercial manufacturing, as well as quality control and quality assurance activities), particulars of which are set out in a Project Plan.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Specifications&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means the analytical tests and acceptance criteria of the Product as specified in Appendix C, which may be amended from time to time in accordance with this Agreement.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Term&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">has the meaning given in Clause 14.1.</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Third Party&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">means any party other than Customer, Lonza and their respective Affiliates.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img127089420_3.jpg" alt="img127089420_3.jpg" style="width:120px;height:29px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In this Agreement references to the Parties are to the Parties to this Agreement, headings are used for convenience only and do not affect its interpretation, references to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any subordinate legislation made under the statutory provision, references to the singular include the plural and vice versa, and references to the word &#x201c;including&#x201d; are to be construed without limitation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2	Performance of Services</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Performance of Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Subject to Clause 2.3, Lonza shall itself and through its Affiliates, diligently carry out the Services as provided in the Project Plan and use commercially reasonable efforts to perform the Services without any material defect and according to the estimated timelines as set forth in the Project Plan. Lonza shall retain appropriately qualified and trained personnel with the requisite knowledge and experience to perform the Services in accordance with this Agreement. Lonza may subcontract or delegate any of its rights or obligations under this Agreement to perform the Services; provided, that any External Laboratories shall be subject to the same obligations and other provisions contained in this Agreement or any applicable Project Plan, including obligations of confidentiality at least as stringent, and as protective of Customer, as those obligations of confidence and non-use imposed upon Lonza and provided that such External Laboratories shall be subject to obligations to act diligently. Lonza shall not be responsible for analytical lab services performed by External Laboratories.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Technology Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Parties expressly agree that they shall work together to transfer the Manufacturing Process to the Facility, including implementing the technology transfer plan set forth in Project Plan. Customer shall fully support such technology transfer as reasonably requested by Lonza.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Engineering Batches</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Lonza shall manufacture Engineering Batches in accordance with the Project Plan. Customer shall have the- right to make whatever further use of the non-cGMP Engineering Batches as it shall determine, provided that Customer pays for such Batches, such use is not for human use and does not violate any Applicable Laws. Lonza makes no warranty that Engineering Batches will meet cGMP or the Specifications. If Lonza determines that an Engineering Batch does meet cGMP and the Specifications, it will release such Engineering Batch as a cGMP Batch. Regardless of whether any Engineering Batch meets cGMP or the Specifications, Customer shall pay to Lonza the Price for such Engineering Batch that were executed in accordance with mutually agreed plans and meet a mutually agreed specification for bioburden, plus the Raw Materials Fee associated with such Engineering Batches. If the Engineering Batch was not performed in accordance with mutually agreed plans or does not meet the agreed bioburden specification, then Lonza shall bear the costs of replacing the Batch, the Raw Materials and Customer Materials for any replacement Engineering Batch. For each CRM12 batch, the Raw Materials liability may be up to a maximum amount of [***]. For each bioconjugate batch, the Raw Materials liability (i) during storage of each bioconjugate batch is limited to [***], (ii) for manufacturing of each bioconjugate batch is limited to [***] and (iii) per manufacturing campaign is limited to [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cGMP Batches</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Lonza will, in accordance with the terms of this Agreement and Quality Agreement, manufacture at the Facility and Release to Customer, cGMP Batches that comply with the Manufacturing Process, cGMP and the Specifications, together with a Certificate of Analysis; provided, however, that cGMP manufacture shall not commence until at least [***] has been manufactured in compliance with cGMP and Specifications. Lonza will bear the risk of replacing any Raw Materials or Customer Materials that were consumed in any cGMP Batch that does not meet the Specifications and is not released to Customer, and after [***], Lonza will bear the risk of replacing any Batch that does not meet the Specifications. For each CRM12 batch, the Raw</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Materials liability may be up to a maximum amount of [***]. (i) during storage of each bioconjugate batch is limited to [***], (ii) for manufacturing of each bioconjugate batch is limited to [***] and (iii) per manufacturing campaign is limited to [***]. Prior to commencement of cGMP manufacturing, Lonza shall review the process assumptions. In the event that there is a material difference in the process assumptions as compared with the process results demonstrated during the manufacture of Engineering Batches, the Parties shall meet to discuss in good faith a revision to the Batch Price to reflect such difference.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Process Validation Batches</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Lonza shall manufacture and deliver Process Validation Batches as mutually agreed by Parties sufficient to document the operability and reproducibility of the Manufacturing Process and permit the Parties to complete and file the necessary regulatory documents.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5.1	Prior to commencement of Process Validation Batches, Lonza and Customer shall agree a process validation plan identifying the validation requirements of the Manufacturing Process. All process validation activities are excluded from the Price of Process Validation Batches shall be approved by the Customer in advance and shall be paid for by the Customer at the Price set out in the applicable Project Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5.2	Any regulatory support activities (including pre-Approval inspection) required and agreed to by Customer to support the Approval of the Product from the Facility shall be performed and supported by Lonza as reasonably requested by Customer. All such regulatory support activities are excluded from the Price of Process Validation Batches, shall be approved by the Customer in advance, and shall be paid for by the Customer at the Price set out in the applicable Project Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply of Customer Information and Customer Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Customer shall supply to Lonza all Customer Information and Customer Materials and other information or materials that may be reasonably required by Lonza to perform the Services. Lonza shall not be responsible for any delays arising out of Customer&#x2019;s failure to provide such Customer Information, Customer Materials, or other information or materials reasonably required to perform the Services to Lonza, and [***]. Lonza hereby undertakes not to use the Customer Materials or Customer Information (or any part thereof) for any purpose other than the performance of the Services under this Agreement. With respect to any Customer Materials, title shall remain with the Customer and shall not transfer to Lonza.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Raw Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Lonza shall procure all required Raw Materials as well as consumables other than those Raw Materials that are Customer Materials. Customer shall be responsible for payment for all consumables and Raw Materials ordered or irrevocably committed to be procured by Lonza hereunder. Upon cancellation of any Batch or termination of the Agreement, all unused Raw Materials shall be paid for by Customer within [***] days of invoice and at Customer&#x2019;s option will either be (a) held by Lonza for future use for the production of Product, (b) delivered to Customer, or (c) disposed of by Lonza.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3	Project Management / Steering Committee</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plans</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. With respect to a new project to be governed by this Agreement, a new Project Plan shall be added by agreement in a writing signed by the Parties and appended to Appendix A. Each Project Plan shall include a description of the Services to be provided, the Product to be manufactured, Specifications, a schedule for completion of the Project Plan, pricing details, and such other information as is necessary for relevant Services. In the event of a conflict between the terms of a Project Plan and this Agreement, the terms of this Agreement will govern.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Management</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. With respect to each Project Plan, each party will appoint a project manager who will be the party responsible for overseeing the Project Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Steering Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3.1	discuss and seek resolution of issues around management of the Services;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3.2	agree and monitor deadlines and milestones for the Services; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3.3	discuss and recommend any changes to the Services (although such changes will not take effect until they have been incorporated into a written amendment to the Project Plan which has been signed by the Parties).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Person in Plant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Customer shall be permitted to have, [***], [***] at the Facility as reasonably requested by Customer, [***] for the purpose of observing, reporting on, and consulting as to the performance of the Services. Such [***] shall be subject to and agree to abide by confidentiality obligations to Third Parties and Lonza&#x2019;s customary practices and operating procedures regarding persons in plant, and such [***] agrees to comply with all instructions of Lonza&#x2019;s employees at the Facility.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4	Quality</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1	Responsibility for quality assurance and quality control of Product shall be allocated between Customer and Lonza as set forth in the Quality Agreement and in Lonza standard operating procedures. If there is a conflict between the terms and conditions of this Agreement and the Quality Agreement, the terms and conditions of this Agreement shall prevail. If the Quality Agreement is not in place at the Effective Date, Lonza and Customer commit to enter into the Quality Agreement in a timely manner, but in no event later than the commencement of cGMP manufacturing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2	Provisions regarding inspections by Regulatory Authorities and audits shall be set out in the Quality Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5	Insurance</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1	Customer shall, during the Term prior to any clinical use of the Product, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance in the amount of at least [***]. Customer shall at least [***] days prior to the first clinical use of a Product manufactured or Services provided under this Agreement, and for [***] years after delivery of the last such Product, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to product liability coverage in the amount of at least [***]. Lonza shall, during the Term and for [***] years after delivery of the last Product manufactured or Services provided under this Agreement, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to product liability coverage in the amount of at least [***]. Each Party shall provide the respective other Party with a certificate of such insurance upon reasonable request.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6	Forecasting, Ordering and Cancellation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forecasting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. No later than the[***] day of each [***], Customer shall supply Lonza with a written forecast showing Customer&#x2019;s good faith estimated [***] requirements for Batches for the following [***] month period (the &#x201c;Forecast&#x201d;). No later than [***] following Lonza&#x2019;s receipt of a Forecast, Lonza shall provide written notice to Customer of [***] and shall provide Customer with an estimated production schedule showing the estimated Commencement Date and delivery date of each Batch. The forecast and [***] given in this Section 6.1 shall not be binding on Customer or Lonza.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase Orders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Customer shall place purchase orders binding on Customer for the number of Batches it wishes to order at least [***] months (or earlier as may be [***]) prior to the Commencement Date for such Batches in accordance with Lonza&#x2019;s most recent response to the Forecast. Each binding purchase order shall be signed by Customer and shall authorize Lonza to manufacture such Batches of the Product as are set forth therein. Lonza shall not be obligated to commence manufacture of any Batch unless and until such written purchase order is accepted in writing by Lonza. Any delivery date set forth in Lonza&#x2019;s written confirmation of a purchase order shall be an estimated delivery date only. All ordered Batches shall be scheduled in a single Campaign in each calendar year unless otherwise agreed by Lonza. Any additional or inconsistent terms or conditions of any Customer purchase order, acknowledgement or similar standardized form given or received pursuant to this Agreement shall have no effect and such terms and conditions are hereby rejected.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rescheduling</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Lonza shall have the right to reschedule a Commencement Date of any Batch or Campaign upon reasonable prior written notice to Customer, provided that the rescheduled Commencement Date is no earlier</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or no later than [***] from the Commencement Date originally estimated at the time of Lonza&#x2019;s acceptance of the binding purchase order, and further provided that Customer is able to provide the necessary Customer Materials. If the Customer requests to change the Commencement Date, Lonza will make all reasonable attempts to accommodate the request; provided, however, in the event that this change would impact other projects scheduled for occupancy in the designated suite or suites, manufacture of the Customer&#x2019;s Batch or Campaign may be delayed until an adequate time period is available in the Facility schedule. Any such change requested by Customer may result in a rescheduling fee. Any delay requested by Customer of more than [***] shall be considered a cancellation pursuant to Section 6.5.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancellation of a Binding Purchase Order for Polysaccharide + CRM12 Conjugates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Customer may cancel a binding purchase order for Polysaccharide + CRM12 Conjugates upon written notice to Lonza, subject to the payment of a cancellation fee as calculated below (the &#x201c;Cancellation Fee&#x201d;):</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4.1	In the event that Customer provides written notice of cancellation to Lonza less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4.2	In the event that Customer provides written notice of cancellation to Lonza more than [***] but less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4.3	In the event that Customer provides written notice of cancellation to Lonza more than [***] but less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4.4	In the event Customer provides written notice of cancellation more [***] prior to the Commencement Date of a subject Batch, then [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4.5	Notwithstanding the provisions of this Clause 6.4, Lonza will use commercially reasonable efforts to reschedule its Facility to mitigate any losses from a cancellation, and if Lonza is able to reallocate any reserved capacity for the performance of services for any third party during the applicable period, then Customer&#x2019;s obligation to pay the amounts under Sections 6.4.1, 6.4.2 or 6.4.3, shall be reduced pro-rata based on the use of such capacity for such third party during the applicable period.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancellation of a Binding Purchase Order for CRM 12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Customer may cancel a binding purchase order for CRM 12 upon written notice to Lonza, subject to the payment of a cancellation fee as calculated below (the &#x201c;Cancellation Fee&#x2019;):</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5.1	In the event that Customer provides written notice of cancellation to Lonza less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5.2	In the event Customer provides written notice of cancellation more than [***] prior to the Commencement Date of a subject Batch, then [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding the provisions of this Clause 6.4, Lonza will use commercially reasonable efforts to reschedule its Facility to mitigate any losses from a cancellation, and if Lonza is able to reallocate any reserved capacity for the performance of services for any third party during the applicable period, then Customer&#x2019;s obligation to pay the amounts under Sections 6.4.1, 6.4.2 or 6.4.3, shall be reduced pro-rata based on the use of such capacity for such third party during the applicable period</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of Cancellation Fee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Any Cancellation Fee shall be payable within [***] following the written notice of cancellation associated with the cancelled Batch. Any Cancellation Fee shall include all costs associated with the cancelled Batch, including any Raw Materials.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Replacement Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Notwithstanding the foregoing, Lonza will use commercially reasonable efforts to secure a new project [***] for the cGMP manufacturing space, [***], and then, in such case, the Cancellation Fee for each Batch cancelled that is replaced by a Batch of the new project shall be reduced by an amount equal to [***] of the production fees associated with such replacement Batch.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred Partnership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Customer and Lonza recognize the mutual strategic value of forging a long-term business relationship (hereinafter a &#x201c;Preferred Partnership&#x201d;). Reflecting this Preferred Partnership, Customer agrees [***] from the Effective Date of this Agreement to contract exclusively with Lonza for the manufacture of any and all [***] provided that Lonza can manufacture said product a) [***], b) [***], and c) [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7	Delivery and Acceptance</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delivery</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. All Product shall be delivered [***] (as defined by Incoterms&#174; 2010). Lonza shall deliver to Customer the Certificate of Analysis and such other documentation as is reasonably required to meet all applicable regulatory requirements of the Governmental Authorities not later than the date of delivery of Batches (the &#x201c;Release&#x201d;). With respect to any Customer Materials, title and risk of loss shall remain with the Customer and shall not transfer to Lonza. With respect to Product, title and risk of loss shall remain with Lonza until Release, and shall transfer to Customer upon Release in accordance with this provision.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Storage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Customer shall arrange for shipment and take delivery of such Batch from the Facility, at Customer&#x2019;s expense, within [***] after Release or pay applicable storage costs. Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to [***]; provided that any additional storage beyond [***] will be subject to availability and, if available, will be charged to Customer and will be subject to a separate agreement. In addition to Section 8.2, Customer shall be responsible for all value added tax (VAT) and any other applicable taxes, levies, import, duties and fees of whatever nature imposed as a result of any storage. Notwithstanding anything to the contrary contained in this Agreement, in no event shall Lonza be required to store any Batch for more than [***] after Release. Within [***] following a written request from Lonza, Customer shall provide Lonza with a letter in form satisfactory to Lonza confirming the bill and hold status of each stored Batch.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acceptance/Rejection of Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3.1	Promptly following Release of Batches, Customer shall inspect such Batches and shall have the right to test such Batches to determine compliance with the Specifications. Customer shall notify Lonza in writing of any rejection of a Batch based on any claim that it fails to meet Specifications within [***] of Release, after which time all unrejected Batches shall be deemed accepted.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3.2	In the event that Lonza believes that a Batch has been incorrectly rejected, Lonza may require that Customer provide to it Batch samples for testing. Lonza may retain and test the samples of such Batch. In the event of a discrepancy between Customer&#x2019;s and Lonza&#x2019;s test results such that Lonza&#x2019;s test results fall within relevant Specifications, or there exists a dispute between the Parties over the extent to which such failure is attributable to a given Party, the Parties shall cause an independent laboratory promptly to review records, test data and perform comparative tests and/or analyses on samples of the Product that allegedly fails to conform to Specifications. Such independent laboratory shall be mutually agreed upon by the Parties. The independent laboratory&#x2019;s results shall be in writing and shall be final and binding save for manifest error. Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3.3	Lonza shall replace any Batch that failed to conform with the Specifications (a &#x201c;Failed Batch&#x201d;), in the event that it is determined (by the Parties or the independent laboratory) that such failure was [***] (&#x201c;Lonza Responsibility&#x201d;). If any replacement cGMP Batch provided as replacement for a Failed Batch also fails to conform to the Specifications, then the Steering Committee shall decide in its sole discretion, [***]. Such replacement shall be made as promptly as practicable, in light of available manufacturing capacity, after the confirmation of Lonza Responsibility, and in any case as soon as reasonably possible after confirmation of Lonza Responsibility. Where possible, such replacement Batch shall be manufactured with the next scheduled cGMP Batch or Campaign. [***] acknowledges and agrees that [***] with respect to a Failed Batch that is a Lonza Responsibility [***], and in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">furtherance thereof, [***]. Lonza shall not be responsible for the cost of Raw Materials or Customer Materials consumed in any Failed Batch except to the extent set forth in this Clause 7.3.3.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8	Price and Payment</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1	Pricing for the Services provided by Lonza are set out in, and based on the assumptions and information set out in, the applicable Project Plan. In the event of changes to the Services based on Customer&#x2019;s request, Customer shall bear all additional costs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2	Unless otherwise indicated in writing by Lonza, all Prices and charges are exclusive of value added tax (VAT) and of any other applicable taxes, levies, import, duties and fees of whatever nature imposed by or under the authority of any government or public authority and all such charges applicable to the Services (other than taxes on Lonza&#x2019;s income) shall be paid by Customer. When sending payment to Lonza, the Customer shall quote the relevant invoice number in its remittance advice.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.3	Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon commencement thereof and [***] upon Release of applicable Batches or completion of applicable Services, unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch. Charges for Resins shall be invoiced by Lonza upon placement of purchase orders for such Resins by Lonza at cost plus a fee of [***]. All invoices are strictly net and payment must be made within [***] of date of invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.4	If in default of payment of any undisputed invoice on the due date, interest shall accrue on any amount overdue at the lesser of (i) rate of [***] per month above the London Interbank Offered Rate (LIBOR) or (ii) the maximum rate allowable by applicable law, interest to accrue on a day to day basis until full payment; and Lonza shall, at its sole discretion, and without prejudice to any other of its accrued rights, be entitled to suspend the provision of the Services and or delivery of Product until all overdue amounts have been paid in full including interest for late payments.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5	Price adjustments.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5.1	Not more than once per calendar year, Lonza may adjust the Price in accordance with the [***] for the previous calendar year. The new Price reflecting such Batch Price adjustment shall be effective for any Batch for which the Commencement Date is on or after the date of Lonza&#x2019;s notice to Customer of the Price adjustment.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.5.2	In addition to the above, the Price may be changed by Lonza, upon reasonable prior written notice to Customer (providing reasonable detail in support thereof), to reflect (i) an increase in variable costs (such as energy or Raw Materials) by more than [***] (based on the initial Price or any previously amended Price), or for a process adjustment or assumption changes, and (ii) any material change in an environmental, safety or regulatory standard that substantially impacts Lonza&#x2019;s cost and ability to perform the Services.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9	Capital Equipment</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1	Any Capital Equipment required for the performance of the Services shall be acquired on terms to be agreed by the Parties prior to commencement of the relevant Services.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10	Intellectual Property</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1	Except as expressly otherwise provided herein, neither Party will, as a result of this Agreement, acquire any right, title, or interest in any Background Intellectual Property of the other Party.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2	Subject to Clause 10.3, Customer shall own all right, title, and interest in and to any and all Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or agents of Lonza develops, conceives, invents, first reduces to practice or makes, solely or jointly with Customer or others, in the performance of the Services, to the extent such Intellectual Property is a direct derivative of or improvement to the Product, Customer Materials, Customer Information and/or Customer Background Intellectual Property (collectively, the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;New Customer Intellectual Property&#x201d;). For avoidance of doubt, &#x201c;New Customer Intellectual Property&#x201d; shall include any material, processes or other items that solely embody, or that solely are claimed or covered by, any of the foregoing Intellectual Property, but excluding any New General Application Intellectual Property.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3	Notwithstanding Clause 10.2, and subject to the license granted in Clause 10.5, Lonza shall own all right, title and interest in Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or agents of Lonza, solely or jointly with Customer, develops, conceives, invents, or first reduces to practice or makes in the course of performance of the Services to the extent such Intellectual Property (i) [***], or (ii) [***] (&#x201c;New General Application Intellectual Property&#x201d;). For avoidance of doubt, &#x201c;New General Application Intellectual Property&#x201d; shall include any material, processes or other items that embody, or that are claimed or covered by, any of the foregoing Intellectual Property.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4	Lonza hereby assigns to Customer all of its right, title and interest in any New Customer Intellectual Property. Lonza shall execute, and shall require its personnel as well as its Affiliates, External Laboratories or other contractors or agents and their personnel involved in the performance of the Services to execute, any documents reasonably required to confirm Customer&#x2019;s ownership of the New Customer Intellectual Property, and any documents required to apply for, maintain and enforce any patent or other right in the New Customer Intellectual Property.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5	Subject to the terms and conditions set forth herein (including the payment of the Price as required above), Lonza hereby grants to Customer a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property, to research, develop, make, have made, use, sell and import the Product manufactured under this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6	Customer hereby grants Lonza the non-exclusive right to use the Customer Information, Customer Background Intellectual Property and New Customer Intellectual Property during the Term solely for the purpose of fulfilling its obligations under this Agreement; provided, however, that no license is granted to any Customer Background Intellectual Property that is owned or controlled by Sutro Biopharma, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7	Customer will have the right to transfer the Manufacturing Process to itself and/or to any Third Party; provided, however, to the extent such technology transfer includes Lonza Confidential Information, or Lonza Background Intellectual Property, such technology transfer shall be subject to [***], and a reasonable royalty and/or licensing fee and terms to be agreed upon by the Parties. [***]. If [***] the Manufacturing Process includes the use of any such additional royalty-bearing Lonza Confidential Information or Lonza Background Intellectual Property, then Customer will pay to Lonza an agreed royalty and/or other agreed payments for the use of Lonza Confidential Information or Lonza Background Intellectual Property. Lonza shall provide reasonably necessary documents to complete such technology transfer, including transfer of New General Application Intellectual Property, if applicable, and, subject to the terms and conditions of this Clause 10.7, Lonza Confidential Information or Lonza Background Intellectual Property, [***] and Customer shall reimburse Lonza for any costs [***] and expenses, provided that the total cost of such assistance (excluding any costs paid to Lonza for the use of Lonza&#x2019;s Confidential Information or Lonza Background Intellectual Property) will not exceed [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11	Warranties</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1	Lonza warrants that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1.1	the Services shall be performed in a professional and workmanlike manner and in accordance with all Applicable Laws;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1.2	Lonza will not knowingly include in the Manufacturing Process any elements that infringe any such intellectual or industrial property rights vested in any Third Party;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1.3	except with respect to any development services and Engineering Batches, the manufacture of Product shall be performed in accordance with cGMP and will meet the Specifications at the date of delivery;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1.4	it or its Affiliate holds all necessary permits, approvals, consents and licenses to enable it to perform the Services at the Facility;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1.5	it has the necessary corporate authorizations to enter into and perform this Agreement;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1.6	Lonza has never been debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335a (a) or (b) (the &#x201c;Act&#x201d;). In the event that during the term of this Agreement, Lonza (i) becomes debarred, suspended, excluded, sanctioned, or otherwise declared ineligible under the Act; Lonza agrees to promptly notify Customer. Lonza also agrees that in the event that it becomes debarred, suspended, excluded, sanctioned, or otherwise declared ineligible under the Act, it shall promptly cease all activities relating to this Agreement;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1.7	subject to payment of undisputed invoices, title to all Product and all New Customer Intellectual Property provided to Customer under this Agreement shall pass free and clear of any security interest, lien or other encumbrance in favour of Lonza; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.2	Customer warrants that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.2.1	as of the date of this Agreement to the best of the Customer&#x2019;s knowledge and belief, the Customer has all the rights necessary to permit Lonza to perform the Services without infringing the Intellectual Property rights of any Third Party and the performance of the Services shall not infringe any Third Party Intellectual Property rights;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.2.2	Customer will promptly notify Lonza in writing if it receives or is notified of a formal written claim from a Third Party that Customer Information and/or Customer Intellectual Property or that the use by Lonza thereof for the provision of the Services infringes any Intellectual Property or other rights of any Third Party; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.2.3	Customer has the necessary corporate authorizations to enter into this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DISCLAIMER</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES, AND ALL OTHER WARRANTIES, BOTH EXPRESS AND IMPLIED, ARE EXPRESSLY DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.4	Debarment.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.4.1	In the event a party receives a notice from the other party (&#x201c;Defaulting Party&#x201d;) or otherwise becomes aware that a debarment, suspension, exclusion, sanction, or declaration of ineligibility action has been brought against the Defaulting Party; then the party receiving such notice shall have the right to terminate this Agreement immediately; provided that if such event shall occur, the party receiving such notice shall not have such right of termination. If the Defaulting Party is disputing and defending such action and the Defaulting Party is otherwise able to perform its services in the manner required under this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.4.2	Each party shall ensure that it will not knowingly use in any capacity the services of any individual, corporation, partnership or association which has been debarred under 21 U.S.C. Sec. 335a(a) or (b), or listed in the DHHS/OIG List of Excluded Individuals/Entities or the General Services Administration&#x2019;s Listing of Parties Excluded from Federal Procurement and Non-Procurement Programs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12	Indemnification and Liability</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification by Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Lonza shall indemnify the Customer, its Affiliates, and their respective officers, employees and agents (&#x201c;Customer Indemnitees&#x201d;) for any loss, damage, costs and expenses (including reasonable attorney fees) that Customer Indemnitees may suffer as a result of any Third Party claim arising directly out of [***] except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Customer Indemnitees. Notwithstanding the foregoing, Lonza shall have no obligations under this clause 12.1 for any liabilities, expenses, or costs to the extent arising out of or relating to claims covered under clause 12.2.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification by Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Customer shall indemnify Lonza, its Affiliates, and their respective officers, employees and agents (&#x201c;Lonza Indemnitees&#x201d;) from and against any loss, damage, costs and expenses (including reasonable attorney fees) that Lonza lndemnitees may suffer as a result of any Third Party claim arising directly out of [***]; except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Lonza Indemnitees. Notwithstanding the foregoing, Customer shall have no obligations under this clause 12.2 for any liabilities, expenses, or costs to the extent arising out of or relating to claims covered under clause 12.1.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification Procedure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the Party to be indemnified intends to claim indemnification under this Clause 12, it shall promptly notify the indemnifying Party in writing of such claim. The indemnitor shall have the right to control the defense and/or settlement thereof; provided, however, that (i) the indemnitor must obtain the prior written consent of the indemnitee (not to be unreasonably withheld) before entering into any settlement of such third party claim, and (ii) any indemnitee shall have the right to retain its own counsel at its own expense. The indemnitee, its employees and agents, shall reasonably cooperate with the indemnitor in the investigation of any liability covered by this Clause 12. The failure to deliver prompt written notice to the indemnitor of any claim, to the extent prejudicial to its ability to defend such claim, shall relieve the indemnitor of any obligation to the indemnitee under this Clause 12.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DISCLAIMER OF CONSEQUENTIAL DAMAGES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, LOST PROFITS OR LOST REVENUES ARISING FROM OR RELATED TO THIS AGREEMENT, EXCEPT TO THE EXTENT RESULTING FROM FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT AND/OR FOR EITHER PARTY&#x2019;S BREACH OF ARTICLE 13 HEREOF.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIMITATION OF LIABILITY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. LONZA&#x2019;S LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED, IN THE AGGREGATE, [***], EXCEPT TO THE EXTENT RESULTING FROM LONZA&#x2019;S FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13	Confidentiality</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.1	A Party receiving Confidential Information (the &#x201c;Receiving Party&#x201d;) agrees to strictly keep secret any and all Confidential Information received during the Term from or on behalf of the other Party (the &#x201c;Disclosing Party&#x201d;) using at least the same level of measures as it uses to protect its own Confidential Information, but in any case at least commercially reasonable and customary efforts. Confidential Information shall include information disclosed in any form including but not limited to in writing, orally, graphically or in electronic or other form to the Receiving Party, observed by the Receiving Party or its employees, agents, consultants, or representatives, or otherwise learned by the Receiving Party under this Agreement, which the Receiving Party knows or reasonably should know is confidential or proprietary.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.2	Notwithstanding the foregoing, Receiving Party may disclose to any courts and/or other authorities Confidential Information which is or will be required pursuant to applicable governmental or administrative or public law, rule, regulation or order. In such case the Party that received the Confidential Information will, to the extent legally permitted, inform the other Party promptly in writing and cooperate with the Disclosing Party in seeking to minimize the extent of Confidential Information which is required to be disclosed to the courts and/or authorities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.3	The obligation to maintain confidentiality under this Agreement does not apply to Confidential Information, which:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.3.1	at the time of disclosure was publicly available; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.3.2	is or becomes publicly available other than as a result of a breach of this Agreement by the Receiving Party; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.3.3	as the Receiving Party can establish by competent proof, was rightfully in its possession at the time of disclosure by the Disclosing Party and had not been received from or on behalf of Disclosing Party; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.3.4	is supplied to a Party by a Third Party which was not in breach of an obligation of confidentiality to Disclosing Party or any other party; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.3.5	is developed by the Receiving Party independently from and without use of the Confidential Information, as evidenced by contemporaneous written records.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.4	The Receiving party will use Confidential Information only for the purposes of this Agreement and will not make any use of the Confidential Information for its own separate benefit or the benefit of any Third Party including, without limitation, with respect to research or product development or any reverse engineering or similar testing. The Receiving Party agrees to return or destroy promptly (and certify such destruction) on Disclosing Party&#x2019;s request all written or tangible Confidential Information of the Disclosing Party, except that one copy of such Confidential Information may be kept by the Receiving Party in its confidential files for record keeping purposes only.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.5	Each Party will restrict the disclosure of Confidential Information to such officers, employees, professional advisers, finance-providers, consultants and representatives of itself and its Affiliates who have been informed of the confidential nature of the Confidential Information and who have a need to know such Confidential Information for the purpose of this Agreement or an applicable financing or acquisition. Both Parties may disclose Confidential Information of the other Party and its Affiliates to potential and actual acquirers provided such disclosure is limited to the terms of this Agreement. Customer also may disclose to its potential and actual: (i) acquirers and (ii) bona fide collaborators in the research, development and commercialization of the Products, the work product provided to Customer by Lonza as a consequence of the provision of the Services. Prior to disclosure to such persons, the Receiving Party shall inform the Disclosing Party and it shall bind its and its Affiliates&#x2019; officers, employees, consultants and representatives to confidentiality and non-use obligations no less stringent than those set forth herein. The Receiving Party shall notify the Disclosing Party as promptly as practicable of any unauthorized use or disclosure of the Confidential Information.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.6	The Receiving Party shall at any time be fully liable for any and all breaches of the confidentiality obligations in this Clause 13 by any of its Affiliates or the employees, consultants, potential and actual acquirers, and representatives of itself or its Affiliates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.7	Each Party hereto expressly agrees that any breach or threatened breach of the undertakings of confidentiality provided under this Clause 13 by a Party may cause irreparable harm to the other Party and that money damages may not provide a sufficient remedy to the non-breaching Party for any breach or threatened breach. In the event of any breach and/or threatened breach, then, in addition to all other remedies available at law or in equity, the non-breaching Party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the non-breaching Party.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14	Term and Termination</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Agreement shall commence on the Effective Date and shall end on the fifth (5th) anniversary of the Effective Date unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the &#x201c;Term&#x201d;). Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project Plan does not extend beyond the Term.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Agreement may be terminated as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2.1	by either Party for any reason upon [***] prior written notice; provided that Lonza may not provide such notice until after [***]. In such an event all cancellation terms in this Agreement shall apply (except, in the case of termination by Lonza pursuant to Clause 14.2.1, the Cancellation Fees shalt not apply), and the Customer shall make payments for work commenced and performed under any purchase order(s) by Lonza prior to the termination notice date;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2.2	by either Party if the other Party breaches a material provision of this Agreement or a Project Plan and fails to cure such breach to the reasonable satisfaction of the non-breaching Party within [***] following written notification of such breach from the non-breaching party to the breaching party; provided, however, that such [***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">period shall be extended as agreed by the Parties if the identified breach is incapable of cure within [***] and if the breaching Party provides a plan and timeline to cure the breach, promptly commences efforts to cure the breach and diligently prosecutes such cure [***];</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2.3	by either Party, immediately, if the other Party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, or files or has filed against it, a petition in bankruptcy or has a receiver appointed for a substantial part of its assets; or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.2.4	by either Party pursuant to Clause 15.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consequences of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In the event of termination hereunder, Lonza shall be compensated for (i) Services rendered up to the date of termination, including in respect of any Product in-process; (ii) all costs incurred through the date of termination, including Raw Materials costs and Raw Materials Fees for Raw Materials used or purchased for use in connection with the Project Plan; (iii) all unreimbursed Capital Equipment and related decommissioning charges incurred pursuant to Clause 9; (iv) all amounts due under Clause 6.4, without proration of the final calendar year and (v) any applicable Cancellation Fees. In the case of termination by Lonza for Customer&#x2019;s material breach, Cancellation Fees shall be calculated as of the date of written notice of termination.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The rights and obligations of each Party which by their nature survive the termination or expiration of this Agreement shall survive the termination or expiration of this Agreement, including Clauses 5, 10-13 and 16 (to the extent relevant).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15	Force Majeure</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.1	If Lonza is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure and gives written notice thereof to Customer specifying the matters constituting Force Majeure together with such evidence as Lanza reasonably can give and specifying the period for which It Is estimated that such prevention or delay will continue, Lonza shall be excused from the performance or the punctual performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue. Provided that, if such Force Majeure persists for a period of [***] or more, Customer may terminate this Agreement by delivering written notice to Lonza.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.2	&#x201c;Force Majeure&#x201d; shall be deemed to include any reason or cause beyond Lonza&#x2019;s reasonable control affecting the performance by Lonza of its obligations under the Agreement, including, but not limited to, any cause arising from or attributable to acts of God, strike, labor troubles, restrictive governmental orders or decrees, riots, insurrection, war, terrorist acts, or the inability of Lonza to obtain any required raw material, energy source, equipment, labor or transportation, at prices and on terms deemed by Lonza to be reasonably practicable, from Lonza&#x2019;s usual sources of supply.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.3	With regard to Lonza, any such event of Force Majeure affecting services or production at its Affiliates or suppliers shall be regarded as an event of Force Majeure.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16	Miscellaneous</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If any provision hereof is or becomes at any time illegal, invalid or unenforceable in any respect, neither the legality, validity nor enforceability of the remaining provisions hereof shall in any way be affected or impaired thereby. The Parties hereto undertake to substitute any illegal, invalid or unenforceable provision by a provision which is as far</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as possible commercially equivalent considering the legal interests and the Purpose.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Modifications and/or amendments of this Agreement must be in writing and signed by the Parties.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assignment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Lonza shall be entitled to instruct one or more of its Affiliates to perform any of Lonza&#x2019;s obligations contained in this Agreement, but Lonza shall remain fully responsible in respect of those obligations. Neither Party may assign its interest under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed, provided, however that either Party may assign</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">this Agreement to (i) any Affiliate of such Party or (ii) any third party in connection with the sale or transfer (by whatever method) of all or substantially all of the assets of the business or Product of such Party to which this Agreement relates, whether by merger, consolidation, acquisition or other form of business combination. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party of responsibility for the performance of any obligation that accrued prior to the effective date of such assignment. Lonza shall be entitled to sell, assign and/or transfer its trade receivables resulting from this Agreement without the consent of the Customer.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. All notices must be written and sent to the address of the Party first set forth above. All notices must be given (a) by personal delivery, with receipt acknowledged, (b) by facsimile followed by hard copy delivered by the methods under (c) or (d), (c) by prepaid certified or registered mail, return receipt requested, or (d) by prepaid recognized next business day delivery service. Notices will be effective upon receipt or at a later date stated in the notice.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law/Jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Agreement is governed in all respects by the laws of [***], without regard to its conflicts of laws principles. The Parties agree to submit to the jurisdiction of the state and federal courts [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:11.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Agreement contains the entire agreement between the Parties as to the subject matter hereof and supersedes all prior and contemporaneous agreements with respect to the subject matter hereof. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. Each party acknowledges that an original signature or a copy thereof transmitted by facsimile or by .pdf shall constitute an original signature for purposes of this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img127089420_4.jpg" alt="img127089420_4.jpg" style="width:120px;height:29px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, each of the Parties hereto has caused this Development and Manufacturing Services Agreement to be executed by its duly authorized representative effective as of the date written above.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.44%;"></td>
    <td style="width:1.763%;"></td>
    <td style="width:89.797%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Bart A. M. van Aarnhem</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bart A. M. van Aarnhem</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Legal Counsel</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26 October 2016</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax Inc.</font></p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Grant E. Pickering</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President &amp; CEO</font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.44%;"></td>
    <td style="width:1.763%;"></td>
    <td style="width:89.797%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 21, 2016</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img127089420_5.jpg" alt="img127089420_5.jpg" style="width:120px;height:29px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">APPENDIX A</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan A-1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Attached]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan A - 2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Attached]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{16 pages omitted}</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">APPENDIX B</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quality Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Attached]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{37 pages omitted}</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">APPENDIX C</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specifications</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{9 pages omitted}</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img127089420_6.jpg" alt="img127089420_6.jpg" style="width:120px;height:29px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FIRST AMENDMENT TO DEVELOPMENT AND MANUFACTURING SUPPLY</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This First Amendment (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which comes into effect on January 1, 2017 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and SutroVax Inc (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This First Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and Sutrovax, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	Lonza and SutroVax entered into the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which the Parties now desire to amend;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Sutrovax wishes to extend the Original Agreement in order to add the conjugation to the protein development and manufacturing;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties hereby agree that the following amendments are made pursuant to the Original Agreement:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	Project Plan A-2 (Polysaccharide + CRM12 Conjugates, Lonza code SUO-002), version 4, dated 04 January 2017 shall be added to Appendix A of the Original Agreement, in addition to the pre-existing Project Plan A-1 (Technology Transfer and cGMP Manufacturing of CRM12, Lonza code SUO-001). Project Plan A-2 is attached to this First Amendment as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	All capitalized terms used herein shall have the meaning set forth in the Original Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this First Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.	No modification of or amendment to this First Amendment, nor any waiver of any rights under this First Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this First Amendment, effective as of the First Amendment Effective Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Signatures on following page]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.15%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:32.863%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.16%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:41.816%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUTROVAX INC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Bart A M. van Aarnhem</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bart A M. van Aarnhem</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President &amp; CEO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Legal Counsel</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.011in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Cordula Altekr&uuml;ger</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cordula Altekr&uuml;ger</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Legal Counsel</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex 1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan A-2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and Manufacturing Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{24 pages omitted}</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECOND AMENDMENT TO DEVELOPMENT AND MANUFACTURING</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUPPLY AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Second Amendment (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which comes into effect on July 1, 2017 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and SutroVax Inc (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Second Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and SutroVax, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.403%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:88.895%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and SutroVax entered into the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which the Parties now desire to amend;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.403%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:88.895%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#149;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax wishes to extend the Original Agreement in order to add generation of RCB/PCB for 24 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S. pneumoniae</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;strains.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties hereby agree that the following amendments are made pursuant to the Original Agreement:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan A-3 (Generation of RCB/PCB of 24 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S. pneumoniae</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> strains, Lonza code SUO-005), version 2, dated 19 June 2017 shall be added to Appendix A of the Original Agreement, in addition to the pre-existing Project Plan A-1 (Technology Transfer and cGMP Manufacturing of CRM12, Lonza code SUO-001) and Project Plan A-2 (Polysaccharide + CRM12 Conjugates, Lonza code SUO-002); Project Plan A-3 is attached to this Second Amendment as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	All capitalized terms used herein shall have the meaning set forth in the Original Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Second Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	No modification of or amendment to this Second Amendment, nor any waiver of any rights under this Second Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this Second Amendment, effective as of the Second Amendment Effective Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Signatures on following page]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.506%;"></td>
    <td style="width:1.378%;"></td>
    <td style="width:37.425%;"></td>
    <td style="width:1.421%;"></td>
    <td style="width:7.425%;"></td>
    <td style="width:1.421%;"></td>
    <td style="width:39.423%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUTROVAX INC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Marina Eiting</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Marina Eiting</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President &amp; CEO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PM</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">/s/ Andreas Brunner</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Andreas Brunner</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex 1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan A-3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and Manufacturing Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{11 pages omitted}</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">THIRD AMENDMENT TO DEVELOPMENT AND MANUFACTURING</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUPPLY AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Third Amendment (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which comes into effect on September 26, 2017 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and SutroVax Inc (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Third Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and SutroVax, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Where</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.403%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:88.895%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and SutroVax entered into the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which the Parties now desire to amend;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.403%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:88.895%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax wishes to extend the Original Agreement in order to add the production of 25 Polysaccharides to the pneumococcal conjugate vaccine project.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties hereby agree that the following amendments are made pursuant to the Original Agreement:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	All capitalized terms used herein shall have the meaning set forth in the Original Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Project Plan A-4 (cGMP Supply of 25 Polysaccharides for a Multi-Valent Pneumococcal Vaccine, Lonza code SUO-005), version 5, dated September 15, 2017 shall be added to Appendix A of the Original Agreement, in addition to the pre-existing Project Plan A-1 (Technology Transfer and cGMP Manufacturing of CRM12, Lonza code SUO-001), Project Plan A-2 (Polysaccharide + CRM12 Conjugates, Lonza code SUO-002), version 4, dated 22 December 2016, and Project Plan A-3 (Generation of RCB/PCB of 24 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">S. pneumonia </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strains, Lonza code SUO-005), version 2, dated 19 June 2017. Project Plan A-4 is attached to this Third Amendment as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	The Parties hereby agree that the current definition of &#x201c;Background Intellectual Property&#x201d; shall be deleted in its entire and shall be replaced by the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.071%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:79.925%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;Background Intellectual Property&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">means any Intellectual Property either (i) owned, licensed or controlled by a Party prior to the Effective Date or (ii) developed or acquired by a Party independently from the performance of the Services hereunder during the Term of this Agreement, and, in the case of Lonza, without the use or reliance on Customer Materials or Customer Information, and, in the case of the Customer, without use or reliance on Lonza materials or Lonza information.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.	The Parties hereby agree that the current definition of &#x201c;Product&#x201d; shall be deleted in its entire and shall be replaced by the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.611%;"></td>
    <td style="width:0.609%;"></td>
    <td style="width:80.78%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;text-indent:45.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-left:45.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">means the proprietary molecules identified by Customer in the applicable Project Plan, including: (a) CRM12 (Lonza code: SUO-001); (b) Polysaccharide + CRM12 Conjugates (Lonza code: SUO-002); (c) RCB/PCB of 24 S. pneumoniae strains (Lonza code SUO-005); and (d) 25 Polysaccharides (Lonza code SUO-006).</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.	The Parties hereby agree that the current definition of &#x201c;Raw Material Fee&#x201d; shall be deleted in its entire and shall be replaced by the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:78.996%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:middle;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;text-indent:45.0pt;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="margin-left:45.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raw Material Fee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.007in;word-break:break-word;white-space:pre-wrap;padding-left:0.007in;vertical-align:top;padding-bottom:0.007in;padding-right:0.007in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">means the procurement and handling fee of [***] of the acquisition cost of Raw Materials by Lonza that is charged to the Customer in addition to the cost of such Raw Materials. Resins are charged at a fee of [***] as set forth in Clause 8.3.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.	The Parties hereby agree that the current clause 6.5 shall be deleted in its entire and shall be replaced by the following clause:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;6.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cancellation of a Binding Purchase Order for CRM12 and/or for the manufacturing of polysaccharides Batches</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. Customer may cancel a binding purchase order for CRM12 and/or for the manufacturing of polysaccharides Betches upon written notice to Lonza, subject to the payment of a cancellation fee as calculated below (the &#x201c;Cancellation Fee&#x201d;):</font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">6.5.1	In the event that Customer provides written notice of cancellation to Lonza less than or equal to [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">6.5.2	In the event Customer provides written notice of cancellation more than [***] prior to the Commencement Date of a subject Batch, then [***]; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">6.5.3	Notwithstanding the above, the Parties hereby agree that [***] shall apply with respect to [***], unless Customer [***], in which case [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.	The Parties hereby agree that the current clause 7.2 shall be deleted in its entire and shall be replaced by the following clause:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">7.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Storage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. CRM12 and polysaccharide Batches (required intermediates for the production of Conjugate Drug Substances) will be stored at no charge for up to [***] after Release of Conjugate Drug Substances; provided that any additional storage beyond [***] will be subject to availability and, if available, will be charged to Customer and will be subject to a separate agreement. Except for CRM12 and polysaccharide Batches, Customer shall arrange far shipment and take delivery of such Batch from the Facility, at Customer&#x2019;s expense, within [***] days after Release or pay applicable storage costs, unless otherwise agreed to by the Parties. Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to [***]; provided that any additional storage beyond [***]) days will be subject to availability and, if available, will be charged to Customer and will be subiect to a separate agreement. In addition to Section 8.2, Customer shall be responsible for all value added tax (VAT) and any other applicable taxes, levies, import, duties and fees of whatever nature imposed as a result of any storage. Unless otherwise agreed to by the Parties, in no event shall Lonza be required to store any Batch for more than [***] calendar days after Release. Within [***] days following a written request from Lonza, Customer shall provide Lonza with a letter in form satisfactory to Lonza confirming the bill and hold status of each stored Batch.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.	The Parties hereby agree that the current clause 8.3 shall be deleted in its entire and shall be replaced by the following clause:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">8.3 Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon commencement thereof (the &#x201c;Initiation Payment&#x201d;) and [***] upon Release of applicable Batches or completion of applicable Services (the &#x201c;Completion Payment&#x201d;), unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch. Charges for Resins shall be invoiced by Lonza upon placement of purchase orders for such Resins by Lonza at cost plus a fee of [***]. Charges for consumables and wearables, as well as charges for Services provided by External Laboratories, shall be invoiced upon the Release of the applicable Batch at cost plus a fee of [***]. Notwithstanding the above, Parties agree that in the event that Lonza does not complete stages of the IND enabling work (i.e. the stages necessary for Customer to submit the IND application, including in any event the Release of at least one (1) GMP Drug Product Batch plus one (1) month of GMP Drug Product stability testing before 31 December 2019), Lonza shall for any stage that commences after 31 December 2019 or has not been completed by 31 December 2019, invoice the Initiation Payment for Products or Services upon commencement thereof. The Completion Payment for Products or Services shall be invoiced by Lonza either (i) [***] or (ii) on [***]. All invoices</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">are strictly net and payment must be made within [***] days of date of invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim, except as set forth in the Agreement or any Amendments. The provisions of this Clause 8.3, including the rate of markup charges set forth herein and in the definition of Raw Materials Fees, shall apply prospectively to all Services under the Agreement, including those Services to be performed after the Amendment Three Effective Date under Work Plan A-1, Work Plan A-2, Work Plan A-3 and Work Plan A-4.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.	The Parties hereby agree that the current clause 10.3 shall be deleted in its entire and shall be replaced by the following clause:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">10.3 Nowithstanding Clause 10.2, and subject to the license granted in Clause 10.5, Lonza shall own all </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">right, title and interest in Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or agents of Lonza, solely or jointly with Custorner, develops, conceives, invents, or first reduces to practice or makes in the course of performance of the Services to the extent such Intellectual Property (i) is generally applicable to the development or manufacture of chemieal or biological products or product components, and could reasanably have been made without the use of the Customer Materials, Customer Information, or Customer Baekground Intellectual Property or (ii) is an improvement of or direct derivative of, any Lonza Background Intellectual Praperty (&#x201c;New General Application Intellectual Property&#x201d;). For avoidance of doubt, &#x201c;New General Application Intellectual Property&#x201d; shall include any material, processes or other items that embody, or that are claimed or covered by, any of theforegoing Intellectual Property.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.	The Parties hereby agree that the current clause 10.5 shall be deleted in its entire and shall be replaced by the following clause:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">10.5 Subject to the terms and conditions set forth herein (including the payment of the Price as required above), Lonza hereby grants to Customer a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property, to research, develop, make, have made, use, sell and import the Product.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.	The Parties hereby agree that the current clause 10.7 shall be deleted in its entire and shall be replaced by the following clause:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">10.7 Customer will have the right to transfer the Manufacturing Process to itself, its Affiliates and/or any third Party, provided, however, to the extent such technology transfer includes Lonza Confidential Information, or Lonza Background Intellectual Property, such technology transfer to any Third Party shall be subject to [***], and a reasonable royalty and/or licensing fee and terms to be agreed upon by the Parties. Lonza will not include in the Manufacturing Process any Lonza Confidential Information or Lonza Background Intellectual Property that would require Customer to pay any additional payment and/or royalty to Lonza in order to transfer the Manufacturing Process to itself, its Affiliates and/or any Third Party without first obtaining Customer&#x2019;s prior written consent and advising Customer as to the royalty structure and any other payment that would apply for the use of such additional technologies. If Customer has provided such consent and the Manufacturing Process includes the use of any such additional payment-bearing or royalty-bearing Lonza Confidential Information or Lonza Background Intellectual Property, then Customer will pay to Lonza an agreed royalty and/or other agreed payments for the use of Lonza Confidential Information or Lonza Background Intellectual Property. Lonza shall provide reasonably necessary documents to complete such technology transfer, including transfer of New General Application Intellectual Property, if applicable, and subject to the terms and conditions of this Clause 10.7, Lonza Confidential Information or Lonza Background Intellectual Property, if incorporated into the Manufacturing Process with Customer&#x2019;s consent, and Customer shall reimburse Lonza for any costs (based on a full-time employee rate for such support) and expenses, provided that the total cost of such assistance (excluding any costs paid to Lonza for the use of Lonza&#x2019;s Confidential Information or Lonza Background Intellectual Property) will not exceed [***].</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.	The Parties hereby agree that the current clause 14.2.1 shall be deleted in its entire and shall be replaced by the following clause:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">14.2.1 by either Party for any reason upon [***] prior written notice; provided that Lonza may not provide such notice until [***]. In such an event all cancellation terms in this Agreement shall apply (except, in the case of termination by Lonza pursuant to Clause 14.2.1, the Cancellation Fees shall not</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:8.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">apply), and the Customer shall make payments for work commenced and performed under any purchase order(s) by Lonza prior to the termination notice date.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.	All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Third Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.	No modification of or amendment to this Third Amendment, nor any waiver of any rights under this Third Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Signatures on following page]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this Third Amendment, effective as of the Third Amendment Effective Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.53%;"></td>
    <td style="width:5.556%;"></td>
    <td style="width:1.229%;"></td>
    <td style="width:1.891%;"></td>
    <td style="width:8.953%;"></td>
    <td style="width:1.912%;"></td>
    <td style="width:15.171%;"></td>
    <td style="width:1.229%;"></td>
    <td style="width:8.707%;"></td>
    <td style="width:1.261%;"></td>
    <td style="width:44.562%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUTROVAX INC.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Bart A. M. van Aarnhem</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.006in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bart A. M. van Aarnhem</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President &amp; CEO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Legal Counsel</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="4" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(255,255,255,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.006in;border-bottom:0.75pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/Lee Newton</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lee Newton</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director, Commercial Development</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex 1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan A-4</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and Manufacturing Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{23 pages omitted}</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALL REFERENCES TO THE &#x201c;FIFTH AMENDMENT&#x201d; CONTAINED HEREIN SHOULD BE READ AS THE &#x201c;FOURTH AMENDMENT.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FIFTH AMENDMENT TO DEVELOPMENT AND MANUFACTURING SUPPLY AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Fifth Amendment (&#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;), which comes into effect retrospectively as per 10 June, 2018 (the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fifth Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;), is made by and between Lonza Ltd (&#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;) and SutroVax Inc (&#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;). This Fifth Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax, as amended from time to time (the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement'</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">'). Lonza and SutroVax, hereafter referred to as a &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34; and collectively as the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#34;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and SutroVax signed the Original Agreement in October 2016;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties now wish to change the production of CRM12 from the [***] facility into the [***] facility;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The current Project Plan A-1 therefore needs to be adjusted and/or partly replaced by a new Project Plan A-1.1, which shall be attached to this Fifth Amendment as Annex 1.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties hereby agree that the following amendments are made pursuant to the Original Agreement:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All capitalized terms used herein shall have the meaning set forth in the Original Agreement.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.691%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:7.403%;"></td>
    <td style="width:7.403%;"></td>
    <td style="width:77.801%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The proposal (Technology Transfer and cGMP Manufacturing of CRM12, Lonza code SUO-001), version 4.0, dated 21 October 2016 (the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proposal [***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;) attached to the Original Agreement under Appendix A as Project Plan A-1, will be amended as follows:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The stages 2-C, 2-D, 2-E and 2-F of the Proposal [***] will be replaced by the stages 2-C, 2-D, 2-E and 2-F as further set out in the proposal (cGMP Manufacturing of CRM12 in [***] facility, Lonza code SUO-001), version 1 dated 22nd June 2018 (&#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proposal [***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;). This Proposal [***] shall be attached to the Original Agreement under Appendix A as Project Plan A-1.1, in addition to the existing Project Plans. For the avoidance of doubt, the remaining of Proposal [***] does not change and shall remain in full force and effect.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the above, the Parties hereby agree that the following new sub-clause 6.5.3 shall be added to the existing clause 6.5:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5.3.</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial campaign in the [***] covering [***] Batches, of which the first Batch will always be an Engineering Batch, is currently scheduled for [***] (the &#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CRM12 Campaign</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;). As part of the transition from Proposal [***] to Proposal [***], Customer shall be entitled to cancel [***], that are part of the CRM12 Campaign up to [***] prior to the commencement of such CRM12 Campaign, without paying any cancellation fees to Lonza for such cancelled Batches. In such event, Lonza will deduct an amount of CHF [***] per cancelled Batch from the Price stated in the Purchase Order for the CRM12 Campaign. The remaining, un-cancelled Batches of the CRM12 Campaign shall be manufactured in accordance with Clause 2.3 and Clause 2.4 of the Original Agreement. For the sake of clarity, the Raw Materials purchased by Lonza for manufacturing the full CRM12 Campaign shall remain payable by Customer and shall not be (pro-rata) refunded in the event of (partly) cancellation of this Purchase Order.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For illustrative purposes:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the event that Customer cancels the Purchase Order for the CRM12 shall pay an amount equal to the Price stated in Campaign in full, Customer that Purchase Order (i.e. [***] Batches and raw materials) CHF [***]; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ii)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">minus an amount of in the event that Customer cancels one of the Batches of the Purchase Order for the CRM12 Campaign, Customer shall pay an amount equal to the Price stated in that Purchase Order minus an amount of CHF [***].</font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.691%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.607%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Fifth Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control unless Parties specifically deviated from such terms via this Fifth Amendment.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No modification of or amendment to this Fifth Amendment, nor any waiver of any rights under this Fifth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this Fifth Amendment, effective as of the Fifth Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUTROVAX INC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Grant E. Pickering</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Grant E. Pickering</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: President &amp; CEO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Axel Evlev</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Axel Evlev</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Commercial Development</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annex 1 - to Fifth Amendment</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan A-1.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{7 pages omitted}</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALL REFERENCES TO THE &#x201c;SIXTH AMENDMENT&#x201d; CONTAINED HEREIN SHOULD BE READ AS THE &#x201c;FIFTH AMENDMENT.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:7.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIXTH AMENDMENT TO DEVELOPMENT AND MANUFACTURING SUPPLY AGREEMENT</font></p>
  <p style="margin-left:5.867%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Sixth Amendment (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sixth Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which comes into effect on March 16, 2020 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sixth Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and SutroVax Inc (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Sixth Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and SutroVax (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and SutroVax, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font></p>
  <p style="margin-left:5.867%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.458%;"></td>
    <td style="width:3.605%;"></td>
    <td style="width:81.815%;"></td>
    <td style="width:4.123%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and SutroVax entered into the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, as amended, which the Parties now desire to amend;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.458%;"></td>
    <td style="width:3.605%;"></td>
    <td style="width:74.239%;"></td>
    <td style="width:11.699%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties wish to modify the payment terms as agreed in the Original Agreement, as amended.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:5.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1.295%;"></td>
    <td style="width:6.184%;"></td>
    <td style="width:90.298%;"></td>
    <td style="width:2.223%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All capitalized terms used herein shall have the meaning set forth in the Original Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties hereby agree that the current clause 8.3 shall be deleted in its entire and shall be replaced by the following clause:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="margin-left:9.173%;text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;8.3 Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon commencement thereof (the &#x201c;Initiation Payment&#x201d;) and [***] upon Release of applicable Batches or completion of applicable Services (the &#x201c;Completion Payment&#x201d;), unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch. Charges for Resins shall be invoiced by Lonza upon placement of purchase orders for such Resins by Lonza at cost plus a fee of [***]. Charges for consumables and wearables, as well as charges for Services provided by External Laboratories, shall be invoiced upon the Release of the applicable Batch at cost plus a fee of [***]. Notwithstanding the above, Parties agree that in the event that Lonza does not complete stages of the IND enabling work, i.e. the stages necessary for Customer to submit the IND application, including in any event the Release of at least one (1) GMP Drug Product Batch plus one (1) month of GMP Drug Product stability testing before 31 December 2019 (the &#x201c;IND-Enabling Activities&#x201d;), Lonza shall for any stage that commences after 31 December 2019 or has not been completed by 31 December 2019, invoice the Initiation Payment for Products or Services upon commencement thereof. The Completion Payment for Products or Services shall be invoiced by Lonza upon release of such Products or completion of such Services, provided, however, that Customer shall not be required to effect any payment before either (i) within thirty (30) days following completion of all IND-Enabling Activities or (ii) 30 April 2021, whichever event occurs first. All invoices are strictly net and payment must be made [***]. Payment shall be made without deduction, deferment, set-off, lien or counterclaim, except as set forth in the Agreement or any Amendments. The provisions of this Clause 8.3, including the rate of markup charges set forth herein and in the definition of Raw Materials Fees, shall apply prospectively to all Services under the Agreement, including those Services to be performed after the Amendment Three Effective Date under Work Plan A-1, Work Plan A-2, Work Plan A-3 and Work Plan A-4.&#x201d;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1.22%;"></td>
    <td style="width:5.677%;"></td>
    <td style="width:90.46%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.64%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Third Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No modification of or amendment to this Sixth Amendment, nor any waiver of any rights under this Sixth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Signatures on following page]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,35,35,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, SutroVax and Lonza hereby enter into this Sixth Amendment, effective as of the Sixth Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUTROVAX INC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Grant Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Michael Stanek</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Grant Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name Michael Stanek</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: President &amp; CEO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: General Counsel</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Bart van Aarnhem</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name Bart van Aarnhem</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Associate General Counsel</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ALL REFERENCES TO THE &#x201c;SEVENTH AMENDMENT&#x201d; CONTAINED HEREIN SHOULD BE READ AS THE &#x201c;SIXTH AMENDMENT.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEVENTH AMENDMENT TO DEVELOPMENT AND MANUFACTURING SUPPLY AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Seventh Amendment (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Seventh Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which comes into effect as per April 1, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Seventh Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Vaxcyte, Inc., having its principal place of business at 353 Hatch Drive, Foster City, CA 94404, USA (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Seventh Amendment is to be incorporated as part of the Development and Manufacturing Agreement, dated October 21, 2016, between Lonza and Vaxcyte (at that time known as SutroVax, Inc.), as amended from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and Vaxcyte, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.335%;"></td>
    <td style="width:1.522%;"></td>
    <td style="width:95.144%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(A)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and Vaxcyte have entered into the Original Agreement, as amended;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(B)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte now wishes to engage Lonza for the process development and manufacturing of [***], a [***] for the 24-valent vaccine against pneumococcal infections, to serve [***] to be manufactured in a larger scale at Lonza&#x2019;s [***] facility;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(C)</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties wish to enter into this Seventh Amendment in order to (i) modify the payment terms as agreed in the Original Agreement, (ii) to ensure a slot reservation for Customer in Lonza's [***] facility and (iii) expeditiously negotiate in good faith an amendment to the Original Agreement regarding the [***] of the [***] by Lonza in [***] facility (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Technology Transfer Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now, therefore,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the Parties hereby agree that the following amendments are made to the Original Agreement:</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All capitalized terms used herein shall have the meaning set forth in the Original Agreement.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties hereby agree that the current clause 8.3 shall be deleted in its entirety and shall be replaced by the following clause:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">8.3Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon commencement thereof (the &#x201c;Initiation Payment&#x201d;) and [***] upon Release of applicable Batches or completion of applicable Services (the &#x201c;Completion Payment&#x201d;), unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch. Charges for Resins shall be invoiced by Lonza upon placement of purchase orders for such Resins by Lonza at cost plus a fee of [***]. Charges for consumables and wearables, as well as charges for Services provided by External Laboratories, shall be invoiced upon the Release of the applicable Batch at cost plus a fee of [***]. Notwithstanding the above, Parties agree that in the event that Lonza does not complete stages of the IND enabling work, i.e. the stages necessary for Customer to submit the IND application, including in any event the Release of at least one (1) GMP Drug Product Batch plus one (1) month of GMP Drug Product stability testing before 31 December 2019 (the &#x201c;IND-Enabling Activities&#x201d;), Lonza shall for any stage that commences after 31 December 2019 or has not been completed by 31 December 2019, invoice the Initiation Payment for Products or Services upon commencement thereof. The Completion Payment for Products or Services shall be invoiced by Lonza upon release of such Products or completion of such Services, provided, however, that Customer shall not be required to effect any payment before either (i) within thirty (30) days following completion of all IND-Enabling Activities or (ii) 30 April 2021, whichever event occurs first. If all IND-Enabling Activities are not complete by 30 April 2021, Customer will pay an amount equal to 50% of the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">current Completion Payment totals. The rest of the 50% Completion Payment to be paid at the completion of all IND-Enabling Activities or 31, December 2021, whichever event occurs first. All invoices are strictly net and payment must be made [***]. Payment shall be made without deduction, deferment, set-off, lien or counterclaim, except as set forth in the Agreement or any Amendments. The provisions of this Clause 8.3, including the rate of markup charges set forth herein and in the definition of Raw Materials Fees, shall apply prospectively to all Services under the Agreement, including those Services to be performed after the Amendment Three Effective Date under Work Plan A-1, Work Plan A-2, Work Plan A-3 and Work Plan A-4.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon execution of this Seventh Amendment, Customer agrees that it commits to a firm capacity reservation for Lonza&#x2019;s manufacturing capacity as follows: Customer and Lonza agree that upon signature of this Seventh Amendment Lonza will issue an invoice to Customer for the reservation of capacity in the amount of [***] (the &#x201c;Reservation Fee&#x201d;). The payment terms as per the Original Agreement apply ([***]). The Reservation Fee will serve as a [***] reservation, by Lonza, of sufficient capacity within Lonza`s [***] facility in [***], personnel and resources to start the [***] for the [***] on behalf of Customer in [***] and commencement of manufacturing the first campaign of the [***] in the [***] facility in [***], subject to execution of the Technology Transfer Amendment within the timeframe set forth in clause 3.c) below and a successful technology transfer. Upon signature of the Technology Transfer Amendment, the Reservation Fee [***]. In the event, however, the Parties do not reach an agreement regarding the Technology Transfer Amendment before the term mentioned in clause 3.c) below, despite good faith negotiations, Lonza shall [***]. Moreover, in such case, Lonza may release such capacity and allocate it to other customers without liability to Customer.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to the negotiations and specific terms and conditions of the Technology Transfer Amendment, the Parties wish to record the following intentions:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon execution of this Seventh Amendment, the Parties shall enter into good faith negotiations regarding the Technology Transfer Amendment.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">b)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties intend that the Technology Transfer Amendment will include, all additional terms and activities or suitable to manufacturing the Product in Lonza&#x2019;s [***] facility.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">c)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties intend to execute the Technology Transfer Amendment as soon as practicable, but in any event not later than [***]. In the event that the Parties are unable to sign the Technology Transfer Amendment by such date, despite good faith efforts by both Parties, a [***] extension for proper cause can be granted at the request of either Party.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties agree that any activities performed by Lonza while negotiations for the Technology Transfer Amendment are in process shall be performed in accordance with the Original Agreement as currently in force.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms and conditions of the Original Agreement shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Seventh Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control, unless Parties specifically deviated from such terms via this Seventh Amendment.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No modification of or amendment to this Seventh Amendment, nor any waiver of any rights under this Seventh Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <hr style="page-break-after:always;">
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Seventh Amendment shall be governed by the law, and be subject to the jurisdiction of the courts of the state specified in Section 16.5 of the Original Agreement.</font></p></td>
   </tr>
  </table>
  <p style="margin-left:19.173%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Signatures on following page]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, Customer and Lonza hereby enter into this Seventh Amendment, effective as of the Seventh Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE. INC.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Grant Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Marina Eiting</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Grant Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name Marina Eiting</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: CEO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Senior Program Manager</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Michael Stanek</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name Michael Stanek</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: General Counsel</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EIGHTH AMENDMENT (VAXCYTE SEVENTH AMENDMENT) TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Eighth Amendment (Vaxcyte Seventh Amendment) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eighth Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which comes into effect on September 7, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eighth Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc., having its principal place of business at 353 Hatch Drive, Foster City, CA 94404, USA (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Eighth Amendment is to be incorporated as part of the Development and Manufacturing Services Agreement, dated October 21, 2016, between Lonza and Vaxcyte (at that time known as SutroVax, Inc.), as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and Vaxcyte, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and Vaxcyte entered into the Original Agreement which the Parties now desire to amend;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties wish to modify the payment terms as agreed in the Original Agreement, as amended.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.817%;"></td>
    <td style="width:94.183%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All capitalized terms used herein shall have the meaning set forth in the Original Agreement</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties hereby agree that a new clause 7.3.4 shall be added to the Agreement with the following wording:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#34;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">7.3.4Vaxcyte has decided to use certain critical Customer Materials (hereinafter referred to as &#x201c;[***]&#x201d;) for the manufacturing of Batches of the CRM12 intermediate in future campaigns, [***] as described in Deviation Report 774098 [***] </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(attached hereto as Appendix A).</font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The</font><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;concerned are the following lots (the &#x201c;[***]&#x201d;):</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.07013888888888889in;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">`</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">1.    [***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2.    [***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">3.    [***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">4.    [***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.06944444444444445in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">5.    [***]</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;margin-right:0.07013888888888889in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Notwithstanding any provision of this Clause 7.3, in the case of any Batch of the cell free produced CRM12 intermediate that [***], where [***], Customer will [***].</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.817%;"></td>
    <td style="width:94.183%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of any conflict between the terms and conditions of this Eighth Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.817%;"></td>
    <td style="width:94.183%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No modification of or amendment to this Eighth Amendment, nor any waiver of any rights under this Eighth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.817%;"></td>
    <td style="width:94.183%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Eighth Amendment shall be governed by the law, and be subject to the jurisdiction of the courts of the state specified in Section 16.5 of the Original Agreement.</font></p></td>
   </tr>
  </table>
  <p style="margin-left:19.173%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Signatures on following page]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, Vaxcyte and Lonza hereby enter into this Eighth Amendment, effective as of the Eighth Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Grant Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Axel Erler</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Grant Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Axel Erler</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: CEO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Commercial Development</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Michael Stanek</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Michael Stanek</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: General Counsel</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Appendix A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deviation Report 774098</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{4 pages omitted}</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NINTH AMENDMENT (VAXCYTE EIGHTH AMENDMENT) TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Ninth Amendment (Vaxcyte Eighth Amendment) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ninth Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which comes into effect on October 15, 2021 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ninth Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Vaxcyte, Inc., having its principal place of business at 353 Hatch Drive, Foster City, CA 94404, USA (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Ninth</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment is to be incorporated as part of the Development and Manufacturing Services Agreement, dated October 21, 2016, between Lonza and Vaxcyte (at that time known as SutroVax, Inc.), as amended from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and Vaxcyte, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.702%;"></td>
    <td style="width:3.702%;"></td>
    <td style="width:92.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and Vaxcyte entered into the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;which the Parties now desire to amend;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties wish to extend the term of the Original Agreement with six (6) months.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.817%;"></td>
    <td style="width:94.183%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All capitalized terms used herein shall have the meaning set forth in the Original Agreement</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties hereby agree that clause 14.1 of the Original Agreement shall be replaced in its entirety by the following new clause 14.1:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.436%;"></td>
    <td style="width:95.564%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;14.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. This Agreement shall commence on the Effective Date and shall end on May 2, 2022, unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the &#34;Term&#34;). Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project Plan does not extend beyond the Term.&#x201d;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.817%;"></td>
    <td style="width:94.183%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Ninth Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No modification of or amendment to this Ninth Amendment, nor any waiver of any rights under this Ninth Amendment, will be effective unless in writing signed by the duly authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Ninth Amendment shall be governed by the law, and be subject to the jurisdiction of the courts of the state specified in Section 16.5 of the Original Agreement.</font></p></td>
   </tr>
  </table>
  <p style="margin-left:19.173%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Signatures on following page]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, Vaxcyte and Lonza hereby enter into this Ninth Amendment, effective as of the Ninth Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LONZA LTD</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Bart van Aarnhem</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Bart van Aarnhem</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Chief Executive Officer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: Associate General Counsel</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Michael Stanek</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Michael Stanek</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: General Counsel</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FOURTH AMENDED AND RESTATED TENTH AMENDMENT (VAXCYTE NINTH AMENDMENT) TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amended and Restated Tenth Amendment (Vaxcyte Ninth Amendment) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tenth Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which retrospectively comes into effect on May 2, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tenth Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and Vaxcyte, Inc., having its principal place of business at 825 Industrial Road, Suite 300, San Carlos, California 94070, USA (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Tenth</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment is to be incorporated as part of the Development and Manufacturing Services Agreement, dated October 21, 2016, between Lonza and Vaxcyte (at that time known as SutroVax, Inc.), as amended from time to time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and amends and restates in its entirety that certain Tenth Amendment dated May 2, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Tenth Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by and between Lonza and Vaxcyte. Lonza and Vaxcyte, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and Vaxcyte entered into the </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> which the Parties now desire to amend;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties wish to extend the term of the Original Agreement by eleven (11) months.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now, therefore, the Parties hereby agree that the following amendments are made to the Original Agreement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.685%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.204%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All capitalized terms used herein shall have the meaning set forth in the Original Agreement</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.204%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties hereby agree that clause 14.1 of the Original Agreement shall be replaced in its entirety by the following new clause 14.1:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:4.0%;text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#x201c;14.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. This Agreement shall commence on the Effective Date and shall end on 31 March 2023, unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the &#34;Term&#34;). Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project Plan does not extend beyond the Term.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.204%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect. In the event of any conflict between the terms and conditions of this Tenth Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.204%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No modification of or amendment to this Tenth Amendment, nor any waiver of any rights under this Tenth Amendment, will be effective unless in writing signed by the duly </font></div></div>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.204%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">authorized representatives of both Parties, and the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.204%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Tenth Amendment shall be governed by the law, and be subject to the jurisdiction of the courts of the state specified in Section 16.5 of the Original Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, Vaxcyte and Lonza hereby enter into this Tenth Amendment, effective as of the Tenth Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-87.501%;padding-left:46.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC		LONZA LTD</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Grant Pickering		By: /s/ Bart Van Aarnhem	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Grant Pickering 		Name: Bart Van Aarnhem	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: CEO		Title: Associate General Counsel	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		By: /s/ Iwan Bertholjotti	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		Name: Iwan Bertholjotti	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						     Title: Senior Director, Commercial Development</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>pcvx-ex10_17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 10.17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Master Services Agreement for</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Drug Product Development and Manufacturing</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(the &#x201c;Agreement&#x201d;)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">by and between</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza Ltd <br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">M&uuml;nchensteinerstrasse 38<br>CH-4002 Basel<br>Switzerland</font></p>
  <p style="margin-left:53.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- hereinafter &#x201c;Lonza&#x201d; -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vaxcyte, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">825 Industrial Road</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Suite 300</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">San Carlos, CA 94070</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(34,34,34,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">United States of America</font></p>
  <p style="margin-left:53.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">- hereinafter &#x201c;Customer&#x201d; -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective as of March 22, 2022 (the &#x201c;Effective Date&#x201d;)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">178751579 v5</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Table of Contents</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Page</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Definitions and Interpretation	1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Performance of Services	6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Project Management / Steering Committee	8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Quality	8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Insurance	9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forecasting, Ordering and Cancellation	9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Delivery and Acceptance	11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Price and Payment	12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capital Equipment	13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Intellectual Property	13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Warranties	15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indemnification and Liability	16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Confidentiality	17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Term and Termination	19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Force Majeure	20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Miscellaneous	20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Appendix A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recitals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">WHEREAS, Lonza and its Affiliates have expertise in the evaluation, development and manufacture of products;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">WHEREAS, the Parties have entered into a development and manufacturing services agreement, dated 29 October 2018, for manufacturing services related to the drug product VAX-24, under which Customer was originally named SutroVax, Inc. (the &#x201c;Original Agreement&#x201d;);</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">WHEREAS, Customer wishes to engage Lonza for Services relating to the development and manufacture of the Product as described in this Agreement; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">WHEREAS, Lonza, or its Affiliate, is prepared to perform such Services for Customer on the terms and subject to the conditions set out herein</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the Parties intending to be legally bound, agree as follows:</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Definitions and Interpretation</font></div></div>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Affiliate&#x201d;	means any company, partnership or other entity which directly or indirectly Controls, is Controlled by or is under common Control with the relevant Party.  &#x201c;Control&#x201d; means the ownership of more than fifty percent (50%) of the issued share capital or the legal power to direct or cause the direction of the general management and policies of the relevant Party.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Agreement&#x201d;	means this agreement incorporating all Appendices, as amended from time to time by written agreement of the Parties.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Applicable Laws&#x201d;	means all relevant U.S. and European Union federal, state and local laws, statutes, rules, and regulations which are applicable to a Party&#x2019;s activities hereunder, including, without limitation, the applicable regulations and guidelines of any Governmental Authority and all applicable cGMP together with amendments thereto.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Approval&#x201d;	means the first marketing approval by the FDA or EMA of Product from the Facility for commercial supply.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Background Intellectual Property&#x201d;	means any Intellectual Property either (i) owned, licensed or controlled by a Party prior to the Effective Date or (ii) developed or acquired by a Party independently from the performance of the Services hereunder during the Term of this Agreement.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Batch&#x201d;	means the Product derived from a single run of the Manufacturing Process at a scale to be mutually agreed by the Parties.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Batch Price&#x201d;	means the Price of each Batch.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Campaign&#x201d;	means a series of no less than [***] cGMP Batches manufactured consecutively.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Cancellation Fee&#x201d;	has the meaning given in Clause 6.4.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Capital Equipment&#x201c;	means those certain pieces of equipment described in the Project Plan: (i) that are specific to the production of the Product and (ii) that are purchased by Customer or for which Customer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">reimburses Lonza, including, without limitation, the related documentation regarding the design, validation, operation, calibration and maintenance of such equipment.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Certificate of Analysis&#x201d;	means a document prepared by Lonza listing tests performed by Lonza or approved External Laboratories, the Specifications and test results.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;cGMP&#x201d;	means those laws and regulations applicable in the U.S. and Europe, relating to the manufacture of medicinal products for human use, including, without limitation, current good manufacturing practices as specified in the ICH guidelines, including without limitation, ICH Q7A &#x201c;ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients&#x201d;, US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600, 610, and 820) and the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC.  For the avoidance of doubt, Lonza&#x2019;s operational quality standards are defined in internal cGMP policy documents.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;cGMP Batches&#x201d;	means any Batches which are required under the Project Plan to be manufactured in accordance with cGMP.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Change&#x201d;	means any change to the Services or pricing incorporated into a written amendment to the Agreement in accordance with clause 17.2 or effected in accordance with the Quality Agreement.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Commencement Date&#x201d;	means the date of commencement of manufacturing activities for a Batch hereunder.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Confidential Information&#x201d;	means Customer Information and/or Lonza Information, as the context requires.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Corruption Laws&#x201d;	means all applicable anti-bribery and anti-corruption laws and regulations, including but not limited to the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010, and the Organization for Economic Co-operation and Development (OECD) Convention on Combating Bribery and Foreign Public Officials in International Business Transactions.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Customer Information&#x201d;	means all technical and other information which at the time of disclosure by Customer was not known to Lonza or in the public domain relating to the Manufacturing Process and the Product, from time to time supplied by the Customer to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza, including any materials supplied by Customer to Lonza in accordance with the Project Plan.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Customer Materials&#x201d;	means any Raw Materials or other materials of any nature (e.g., antibodies used in product-specific assays), proprietary to Customer, provided by Customer to Lonza under or in connection with this Agreement, and previously not possessed by or not available to Lonza. For the avoidance of doubt, Drug Substance shall be considered Customer Material.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Drug Product&#x201d;	means the formulation of the Drug Substance(s) filled into its final containers (e.g., vials).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Drug Substance&#x201d;	means any proprietary molecule(s) identified in the Project Plan that are to be included in the Drug Product. For clarity, the term Drug Substance may be used interchangeably with Active Pharmaceutical Ingredient (API).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;EMA&#x201d;	means the European Medicines Agency or any successor agency thereto.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;External Laboratories&#x201d;	means any Third Party analytical service provider contracted directly by Customer.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Facility&#x201d;	means Lonza&#x2019;s manufacturing facilities in Visp and/or Basel Switzerland,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">or such other facility, including [***], as may be agreed upon by the Parties.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;FDA&#x201d;	means the United States Food and Drug Administration, or any successor agency thereto.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;GDPR&#x201d;	means any applicable data protection or privacy laws, rules and regulations, including but not limited to, the European Union e-Privacy Directive 2002/58/EC, the European Union General Data Protection Regulation 2016/679, the UK Data Protection Act 2018, and any other laws equivalent thereto.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Governmental Authority&#x201d;	means any Regulatory Authority and any national, multi-national, regional, state or local regulatory agency, department, bureau, or other governmental entity in the U.S., Switzerland or the European Union.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Intellectual Property&#x201d;	means (i) inventions (whether or not patentable), patents, trade secrets, copyrights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential information (including</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">know-how) and any other intellectual property rights, in each case whether registered or unregistered, (ii) all applications (or rights to apply) for, and renewals or extensions of, any of the rights described in the foregoing clause (i) and (iii) and all rights and applications that are similar or equivalent to the rights and application described in the foregoing clauses (i) and (ii), which exist now, or which come to exist in the future, in any part of the world.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;International Trade Restrictions&#x201d;	means any export control requirements and trade, financial and economic sanctions which apply to this Agreement and the Services under the laws, regulations and rules of the United Nations, the European Union, the United Kingdom, Switzerland and any other relevant jurisdiction; and all necessary export and re-export written consents, permits, and authorizations required by International Trade Restrictions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Lonza Information&#x201d;	means all information that is proprietary to Lonza or any Affiliate of Lonza and that is maintained in confidence by Lonza or any Affiliate of Lonza and that is disclosed by Lonza or any Affiliate of Lonza to Customer under or in connection with this Agreement, including without limitation, any and all Lonza know-how and trade secrets.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Manufacturing Instructions&#x201d;	means the document compiled by Lonza and approved by Customer, which defines the manufacturing methods, test methods and other procedures, directions and controls associated with the manufacture and testing of Product.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Manufacturing Process&#x201d;	means the production process for the manufacture of Product to be developed by Lonza and approved by Customer, as described in the Project Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;New Customer Intellectual Property&#x201d;	has the meaning given in Clause 10.2.</font></p>
  <p style="text-indent:-66.703%;padding-left:40.013%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;New General Application Intellectual</font></p>
  <p style="text-indent:-66.703%;padding-left:40.013%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property&#x201d;	has the meaning given in Clause 10.3.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Non-Clinical Batches&#x201d;	means a Batch manufactured under the Project Plan that is not intended as a cGMP Batch, which shall include &#x201c;Technical Batches&#x201d;, &#x201c;Toxicology Batches&#x201d;, &#x201c;Proof-of-Concept Batches&#x201d; and any other non-cGMP Batches in the Project Plan.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Party&#x201d;	means each of Lonza and Customer and, together, the &#x201c;Parties&#x201d;.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Price&#x201d;	means the price for the Services and Products as set out in Appendix A.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Product&#x201d;	means the Drug Product manufactured using the Manufacturing Process by Lonza for Customer as specified in the Project Plans. .</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Project Plan&#x201d; or &#x201c;Project Plans&#x201d;	means the plans describing the Services to be performed by Lonza under this Agreement, including any update and amendment of the Project Plan to which the Parties may agree from time to time.  The initial Project Plans are attached hereto as Appendix A.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Quality Agreement&#x201d;	means the quality agreement entered into between the parties on May 21 and 22, 2021 by Lonza and Customer respectively.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Raw Materials&#x201d;	means all ingredients, excipients as well as materials needed to perform the Services, including solvents, consumables/disposables, kits, capillaries, columns, antibody reagents, and other &#x2018;non-standard&#x2019; reagents, filters, chromatography resins, cross flow membranes, bags, HPLC columns, specific reagents, infusion sets, pumps, and other components of the Product required to perform the Manufacturing Process or Services (including primary and secondary packaging materials, labels, filters, bags, tubings, dose administration kits and pumps, specific reagents, bioassay etc.). For the avoidance of doubt, Drug Substances are not considered to be Raw Materials.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">   </font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#34;Raw Material Fee&#34; 	means the procurement and handling fee of [***] ([***]%) of the acquisition cost of Raw Materials  by Lonza that is charged to the Customer in addition to the cost of such Raw Materials.  For clarity, the [***]% Raw Material Fee shall not apply to any Customer Materials or materials produced by Lonza (or any of its Affiliates), under or pursuant to any other written agreement between Lonza and Customer (such as Drug Substances).</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Regulatory Authority&#x201d;	means the FDA, EMA and any other similar regulatory authorities as may be agreed upon in writing by the Parties.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Release&#x201d;	has the meaning given in Clause 7.1.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Services&#x201d;	means all or any part of the services to be performed by Lonza under this Agreement (including, without limitation, process and analytical method transfer, process</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">development, process optimization, validation, non-clinical and clinical manufacturing, as well as quality control and quality assurance activities), particulars of which are set out in a Project Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Services Data&#x201d;	means data generated by Lonza or any Affiliate or Subcontractor in the course of Lonza&#x2019;s or such entities&#x2019; performing Services hereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Specifications&#x201d;	means the analytical tests and acceptance criteria of the Product as agreed between Customer and Lonza during the execution of the Services.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Subcontractor&#x201d;	means a Third Party contracted directly by Lonza for the purpose of providing services to the Customer as agreed between Customer and Lonza.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Technical Batch&#x201d;	means a Batch that is intended to demonstrate the transfer of the Manufacturing Process to the Facility.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Term&#x201d;	has the meaning given in Clause 14.1.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Third Party&#x201d;	means any party other than Customer, Lonza and their respective Affiliates.</font></p>
  <p style="text-indent:-66.667%;padding-left:40.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In this Agreement references to the Parties are to the Parties to this Agreement,  headings are used for convenience only and do not affect its interpretation,  references to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any subordinate legislation made under the statutory provision, references to the singular include the plural and vice versa, and references to the word &#x201c;including&#x201d; are to be construed without limitation.</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Performance of Services</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">2.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Performance of Services</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Subject to Clause 2.3, Lonza shall itself and through its Affiliates, diligently carry out the Services as provided in the Project Plan and use commercially reasonable efforts to perform the Services without any material defect and according to the estimated timelines as set forth in the Project Plan.  Lonza shall retain appropriately qualified and trained personnel with the requisite knowledge and experience to perform the Services in accordance with this Agreement.  With Customer&#x2019;s prior written consent, Lonza may subcontract or delegate any of its rights or obligations under this Agreement to perform the Services, provided, that Lonza shall remain primarily responsible for the actions of any such Subcontractor and/or delegate. Specifically, and without limiting the foregoing, any and all such Subcontractors shall be subject to the same obligations of confidentiality at least as stringent, and as protective of Customer, as those obligations of confidence and non-use imposed upon Lonza and provided that such External Laboratories shall be subject to obligations to act diligently. Lonza shall not be responsible for analytical services performed by External Laboratories. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">2.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Technology Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  The Parties expressly agree that they shall work together to transfer the Manufacturing Process to the Facility, including implementing the technology transfer plan set forth in the Project Plan.  Customer shall fully support such technology transfer as reasonably requested by Lonza.  </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">2.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Non-Clinical Batches</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Lonza shall manufacture the Non-Clinical Batches (including the Technical Batches) in accordance with the Project Plan.  Customer shall have the right to make whatever further use of the Non-Clinical Batches as it shall determine, provided that Customer pays for such Batches, such use is not for human use, and does not violate any Applicable Laws.  Lonza makes no warranty that the Non-Clinical Batches (including the Technical Batches) will meet the Specifications, but will manufacture all such Batches in accordance with and for the intended purpose set forth in the Project Plan.  </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">2.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">cGMP Batches</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Lonza will, in accordance with the terms of this Agreement and Quality Agreement, manufacture at the Facility and Release to Customer, cGMP Batches that comply with the Manufacturing Process, cGMP and the Specifications, together with a Certificate of Analysis; provided, however, that cGMP manufacture shall not commence until at least [***] has been manufactured in compliance with the Specifications. Prior to commencement of cGMP manufacturing, Lonza shall review the process assumptions. In the event that there is a material difference in the process assumptions as compared with the process results demonstrated during the manufacture of the Technical Batches, the Parties shall meet to discuss in good faith a revision to the Batch Price to reflect such difference. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">2.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Supply of Customer Information and Customer Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Customer shall supply to Lonza, free of charge, all Customer Information and Customer Materials and other information or materials that may be reasonably required by Lonza to perform the Services. Lonza shall not be responsible for any delays arising out of Customer&#x2019;s failure to provide such Customer Information, Customer Materials, or other information or materials reasonably required to perform the Services to Lonza, and [***]. The parties shall agree the responsibility for shipment of Customer Materials in the respective Project Plan.  Lonza hereby undertakes not to use the Customer Materials or Customer Information (or any part thereof) for any purpose other than the performance of the Services under this Agreement.  With respect to any Customer Materials, title shall remain with the Customer and shall not transfer to Lonza.  </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">2.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Raw Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Lonza shall procure all required Raw Materials as well as consumables other than those Raw Materials that are Customer Materials.  Customer shall be responsible for payment for all consumables and Raw Materials ordered or irrevocably committed to be procured by Lonza hereunder for the manufacture of the Batches and/or the performance of the Services as agreed upon between the Parties. Upon cancellation of any Batch or termination of the Agreement by Customer, all unused Raw Materials shall be paid for by Customer (to the extent Customer has not previously made such payment to Lonza and to the extent that Raw Materials cannot be used by Lonza for its own use or the use of one of its customers) within [***] of invoice and at Customer&#x2019;s option and cost will either be (a) held by Lonza for future use for the production of Product, (b) delivered to Customer, or (c) disposed of by Lonza. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">2.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Review of Regulatory Submission</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Prior to Customer&#x2019;s submission of any information to the Regulatory Authority related in any way to Lonza or the Services provided under this Agreement (including without limitation information related to a Regulatory Authority&#x2019;s request for additional information or an inspection, and Customer&#x2019;s answer or other response thereto), Customer shall provide to Lonza copies thereof. Any regulatory support activities (including pre-Approval inspection) required and agreed </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">to by Customer to support the Approval of the Drug Product or Product from the Facility shall be performed and supported by Lonza as reasonably requested by Customer.  All such regulatory support activities shall be approved by the Customer in advance, and shall be paid for by the Customer at the Price set out in the applicable Project Plan. For the sake of clarity, the Parties agree that Lonza shall provide regulatory review, at the agreed hourly rate/day rate, with respect to all documents related to any regulatory submission. Customer shall submit those documents in time to Lonza in order for Lonza to review and provide comments for Customer&#x2019;s consideration at Customer&#x2019;s sole discretion on those sections referring to Lonza and related to the Services hereunder.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Project Management / Steering Committee</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Project Plans</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  With respect to a new project to be governed by this Agreement, a new Project Plan shall be added by agreement in a writing signed by the Parties and appended to Appendix A.  Each Project Plan shall include a description of the Services to be provided, the Product to be manufactured, Specifications, a schedule for completion of the Project Plan, pricing details, and such other information as is necessary for relevant Services.  In the event of a conflict between the terms of a Project Plan and this Agreement, the terms of this Agreement will govern.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Project Management</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  With respect to each Project Plan, each Party will appoint a project manager who will be the Party responsible for overseeing the Project Plan.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Steering Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Each Party shall name a mutually agreed upon roughly equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as otherwise mutually agreed by the Parties.  In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and discuss and resolve any issues arising under this Agreement.  In addition to the primary function described above, the Steering Committee shall also take on the following responsibilities:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">3.3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">discuss and seek resolution of issues around management of the Services;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">3.3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">agree and monitor deadlines and milestones for the Services; and </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">3.3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">discuss and recommend any changes to the Services (although such changes will not take effect until they have been incorporated into a written amendment to the Project Plan which has been signed by the Parties).</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">3.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Person in Plant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  During manufacturing of a Technical Batch, Customer shall be permitted to have [***] at the drug product manufacturing Facility as reasonably requested by Customer, at any time during the Manufacturing Process for the purpose of observing, reporting on, and consulting as to the performance of the Services. During manufacturing of the GMP Batches, Customer shall be permitted to have [***] at the drug product manufacturing Facility as reasonably requested by Customer, at any time during the GMP Manufacturing Process for the purpose of observing and reporting on the performance of the Services.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furthermore, unless otherwise agreed to by the Parties, if Lonza does not have suitable space at Lonza&#x2019;s Services site for drug product (&#x201c;Drug Product Services Site&#x201d;),</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Customer shall [***].  In addition,  Customer shall be permitted [***] within the Drug Product Services Site as visitor(s), for visits over periods to be determined by mutual agreement to (a) facilitate real-time (same time-zone) communications between Customer technical drug product team and the Lonza drug product team, (b) facilitate transfer of process and analytical technology between the companies; (c) facilitate master batch record review and approval process; (d) perform technical review of manufacturing batch data; and/or (e) augment program management by providing local input.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Each such Customer employee or authorized representative shall be subject to and agree to abide by confidentiality obligations to Third Parties and Lonza's customary practices, and such employee agrees to comply with all instructions of Lonza&#x2019;s employees at the drug product manufacturing Facility and/or Drug Product Services Site.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Quality</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Responsibility for quality assurance and quality control of Product shall be allocated between Customer and Lonza as set forth in the Quality Agreement and in Lonza standard operating procedures.  If there is a conflict between the terms and conditions of this Agreement and the Quality Agreement, the terms and conditions of this Agreement shall prevail.  If the Quality Agreement is not in place at the Effective Date, Lonza and Customer commit to enter into the Quality Agreement in a timely manner, but in no event later than the commencement of cGMP manufacturing.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Provisions regarding inspections by Regulatory Authorities and audits shall be set out in the Quality Agreement.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Insurance</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">5.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Customer shall, during the Term prior to any clinical use of the Product, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance in the amount of at [***].  Customer shall at least [***] prior to the first clinical use of a Product manufactured or Services provided under this Agreement, and for [***] after delivery of the last such Product, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to product liability coverage in the amount of at least [***]. Lonza shall, during the Term and for [***] after delivery of the last Product manufactured or Services provided under this Agreement, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to product liability coverage in the amount of at least [***] per claim.  Each Party shall provide the respective other Party with a certificate of such insurance upon reasonable request.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forecasting, Ordering and Cancellation</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">6.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forecasting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  To the extent not already set forth in the then-current Project Plan, no later than the [***], Customer shall supply Lonza with a written forecast showing Customer&#x2019;s good faith estimated [***] requirements for Batches for the [***] period (the &#x201c;Forecast&#x201d;).  No later than [***] following Lonza&#x2019;s receipt of a Forecast, Lonza shall inform the Customer of [***] and shall provide Customer with an estimated production schedule showing the estimated Commencement Date and estimated delivery date of each Batch.  The forecast and [***] given in this Clause 6.1 shall not be binding on Customer or Lonza.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">6.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchase Orders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Customer shall place purchase orders binding on Customer for the number of Batches it wishes to order at least [***] (or earlier as [***]) prior to the Commencement Date for such Batches in accordance with Lonza&#x2019;s most recent response to the Forecast. Each binding purchase order shall be signed by Customer and shall authorize Lonza to manufacture such Batches of the Product as are set forth therein.  Lonza shall not be obligated to commence manufacture of any Batch unless and until such written purchase order is accepted in writing by Lonza. Any delivery date set forth in Lonza&#x2019;s written confirmation of a purchase order shall be an estimated delivery date only.  All ordered Batches shall be scheduled in a single Campaign in each calendar year unless otherwise agreed by Lonza.  Any additional or inconsistent terms or conditions of any Customer purchase order, acknowledgement or similar standardized form given or received pursuant to this Agreement shall have no effect and such terms and conditions are hereby rejected.  For clarity, the then-current Project Plan shall be deemed a binding Purchase Order for the Batches set forth in the Project Plan with the Commencement Date of such Batches being the commencement dates set forth in the Project Plan, and Customer shall not be required to place separate Purchase Orders for such Batches to make them binding.  Customer shall have the right to reschedule and/or cancel any of the Batches in the Project Plan in the same manner and pursuant to the same terms and conditions as the rescheduling and cancellation set forth in Clauses 6.3 through 6.6 as if they were the Batches ordered through a Purchase Order.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">6.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Rescheduling</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Lonza shall have the right to reschedule a Commencement Date of any Batch or Campaign upon reasonable prior written notice to Customer, provided that the rescheduled Commencement Date is less than [***] from the Commencement Date originally estimated at the time of Lonza&#x2019;s acceptance of the binding purchase order, and further provided that Customer is able to provide the necessary Customer Materials. If the Customer requests to change the Commencement Date, Lonza will make all reasonable attempts to accommodate the request; provided, however, in the event that this change would impact other projects scheduled for occupancy in the designated suite or suites, manufacture of the Customer&#x2019;s Batch or Campaign may be delayed until an adequate time period is available in the Facility schedule.  Unless otherwise agreed, any such change requested by Customer may result in a rescheduling fee.  Ordinary updates to the schedule during the execution of the Project Plan (via contract amendment /scope change) shall not be subject to a rescheduling fee. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">6.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cancellation of a Binding Purchase Order</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Customer may cancel a binding purchase order upon written notice to Lonza, subject to the payment of a cancellation fee as calculated below (the &#x201c;Cancellation Fee&#x201d;):</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">6.4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Development work: If Customer provides written notice of cancellation of any Development Work, Customer shall pay for any of the cancelled Development Work Lonza performed prior to the date of notification of cancellation and for any of such cancelled Development Work which would (were it not for the cancellation) have been performed during the period of [***] days post cancellation notification, unless otherwise agreed in the specific scope of work..</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">6.4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Batches scheduled in a cGMP Facility: In the event that Customer provides written notice of cancellation to Lonza:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">less than or equal to [***] prior to the Commencement Date of the first subject Batch, then [***] ([***]%) of the Batch Price of each such Batch cancelled is payable;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">more than [***] but less than or equal to [***] prior to the Commencement Date of the first subject Batch, then [***] ([***]%) of the Batch Price of each such Batch cancelled is payable; </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">more than [***] prior to the Commencement Date of a subject Batch, then no Cancellation Fee is payable.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">6.4.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notwithstanding the provisions of Clause 6.4.2, (i) Lonza will use commercially reasonable efforts to reschedule its Facility to mitigate any losses from a cancellation, and if Lonza is able to reallocate any reserved capacity for the performance of services for any third party during the applicable period, then Customer&#x2019;s obligation to pay the amounts under Clauses 6.4.1 or 6.4.2, shall be reduced pro-rata based on the use of such capacity for such third party during the applicable period; and (ii) notwithstanding anything to the contrary, no Cancellation Fee is payable by Customer for any cancellation or rescheduling to the extent resulting from Lonza&#x2019;s action or inaction, either under this Agreement or the Original Agreement or otherwise. In particular, Customer may ask to replace the cancelled Services with another Customer project, subject to Lonza&#x2019;s feasibility review and approval.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">6.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Payment of Cancellation Fee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Any Cancellation Fee shall be payable within [***] following the written notice of cancellation associated with the cancelled Batch.  Any Cancellation Fee shall include all costs associated with the cancelled Batch, including any Raw Materials.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">6.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Replacement Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Notwithstanding the foregoing, Lonza will use commercially reasonable efforts to secure a new project (but excluding any project then under contract with Lonza) for the cGMP manufacturing space, and for the same dates and duration that would have been occupied by Customer, and then, in such case, the Cancellation Fee for each Batch cancelled that is replaced by a Batch of the new project shall be reduced by an amount equal to [***] ([***]%) of the production fees associated with such replacement Batch. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Delivery and Acceptance</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">7.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Delivery</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  All Drug Product shall be delivered FCA to the Facility (as defined by Incoterms&#174; 2020), unless otherwise agreed in the Statement of Work.  Lonza shall deliver to Customer the Certificate of Analysis and such other documentation as is reasonably required to meet all applicable regulatory requirements of the Governmental Authorities not later than the date of delivery of Batches (the &#x201c;Release&#x201d;).  With respect to Drug Product, title and risk of loss shall remain with Lonza until Release and shall transfer to Customer upon Release in accordance with this provision. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">7.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Storage.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  Product Batches will be stored at no charge for up to [***] after Release; provided that any additional storage beyond [***] will be subject to availability and, if available, will be charged to Customer and will be subject to a separate agreement.  Customer shall arrange for shipment and take delivery of such Batch(es) from the Facility, at Customer&#x2019;s expense, within [***] after Release or pay applicable storage costs, unless otherwise agreed to by the Parties.  Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to [***]; provided that any additional storage beyond [***] will be subject to availability and, if available, will be charged to Customer and will be subject to a separate agreement.  In addition, Customer shall be responsible for all value added tax (VAT) and any other applicable taxes, levies, import, duties and fees of whatever nature imposed as a result of any storage.  Unless otherwise agreed to by the Parties, in no event shall Lonza be required </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">to store any Batch for more than [***] after Release.  Within [***] following a written request from Lonza, Customer shall provide Lonza with a letter in form satisfactory to Lonza confirming the bill and hold status of each stored Batch.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">7.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Acceptance/Rejection of Product</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">7.3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Promptly following Release of Batches, Customer shall inspect such Batches and shall have the right to test such Batches to determine compliance with the Specifications.  Customer shall notify Lonza in writing of any rejection of a Batch based on any claim that it fails to meet Specifications within [***] of Release, after which time all unrejected Batches shall be deemed accepted.  </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">7.3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event that Lonza believes that a Batch has been incorrectly rejected, Lonza may require that Customer provide to Lonza Batch samples for testing.  Lonza may retain and test the samples of such Batch.  In the event of a discrepancy between Customer&#x2019;s and Lonza&#x2019;s test results such that Lonza&#x2019;s test results fall within relevant Specifications, or there exists a dispute between the Parties over the extent to which such failure is attributable to a given Party, the Parties shall cause an independent laboratory promptly to review records, test data and perform comparative tests and/or analyses on samples of the Product that allegedly fails to conform to Specifications.  Such independent laboratory shall be mutually agreed upon by the Parties.  The independent laboratory&#x2019;s results shall be in writing and shall be final and binding save for manifest error.  Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">7.3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza shall replace any Batch that failed to conform with the Specifications (a &#x201c;Failed Batch&#x201d;). In the event that it is determined (by the Parties or the independent laboratory) that such failure was [***] (&#x201c;Lonza Responsibility&#x201d;), Lonza agrees to [***]. The compensation is capped at [***]% of the price of that Failed Batch. If any replacement cGMP Batch provided as replacement for a Failed Batch also fails to conform to the Specifications due to Lonza&#x2019;s Responsibility, then the Steering Committee shall decide in its sole discretion, if Lonza shall either replace such cGMP Batch or refund the amounts paid by Customer for such cGMP Batch.  Such replacement shall be made as promptly as practicable, in light of available manufacturing capacity, after the confirmation of Lonza Responsibility, and in any case as soon as reasonably possible after confirmation of Lonza Responsibility.  Where possible, such replacement Batch shall be manufactured with the next scheduled cGMP Batch or Campaign.  Customer acknowledges and agrees that its [***] with respect to a Failed Batch that is a Lonza Responsibility is [***].</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Price and Payment</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">8.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pricing for the Services provided by Lonza are set out in, and based on the assumptions and information set out in, the applicable Project Plan.  In the event of changes to the Services based on Customer&#x2019;s request, Customer shall bear all additional costs.  Conversely, if Services scope of work within the Project Plan is reduced by formal contract amendment / scope change, Lonza shall revise quoted price to accurately reflect the reduced Services. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">8.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unless otherwise indicated in writing by Lonza, all Prices and charges are exclusive of value added tax (VAT) and of any other applicable taxes, levies, import, duties and fees of whatever nature imposed by or under the authority of any government or public </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">authority and all such charges applicable to the Services (other than taxes on Lonza&#x2019;s income) shall be paid by Customer.  When sending payment to Lonza, the Customer shall quote the relevant invoice number in its remittance advice.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">8.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza shall issue invoices to Customer for [***] ([***]%) of the Price for Products or Services upon commencement thereof (the &#x201c;Initiation Payment&#x201d;) and [***] ([***]%) upon Release of applicable Batches or completion of applicable Services (the &#x201c;Completion Payment&#x201d;), unless otherwise stated in the Project Plan. Charges for Raw Materials and the Raw Materials Fee for each Batch shall be invoiced upon the Release of each Batch or completion of applicable Services.  Charges for consumables and wearables, as well as charges for Services provided by External Laboratories, shall be invoiced upon the Release of the applicable Batch or completion of applicable Services at cost plus a fee of [***] ([***]%). All invoices are strictly net and payment must be made within [***] of date of invoice.  Payment shall be made without deduction, deferment, set-off, lien or counterclaim, except as set forth in the Agreement or any Amendments. The provisions of this Clause 8.3, including the rate of markup charges set forth herein and in the definition of Raw Materials Fees, shall apply prospectively to all Services under the Agreement.  </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">8.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If in default of payment of any undisputed invoice on the due date, interest shall accrue on any amount overdue at the lesser of (i) rate of [***] ([***]%) per month above the Swiss Average Rate Overnight (SARON) or (ii) the maximum rate allowable by applicable law, interest to accrue on a day to day basis until full payment; and</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza shall, at its sole discretion, and without prejudice to any other of its accrued rights, be entitled to suspend the provision of the Services and or delivery of Product until all overdue amounts have been paid in full including interest for late payments.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">8.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Price adjustments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">8.5.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Not more than once per calendar year, Lonza may adjust the Price in accordance with [***] for the previous calendar year.  The new Price reflecting such Batch Price adjustment shall be effective for any Batch for which the Commencement Date is on or after the date of Lonza&#x2019;s notice to Customer of the Price adjustment.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">8.5.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to the above, the Price may be changed by Lonza, upon reasonable prior written notice to Customer (providing reasonable detail in support thereof), to reflect (i) an increase in variable costs (such as energy) by more than [***] ([***]%) (based on the initial Price or any previously amended Price), or for a process adjustment or assumption changes, and (ii) any material change in an environmental, safety or regulatory standard that substantially impacts Lonza&#x2019;s cost and ability to perform the Services, in each case to the extent not already passed through to Customer. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capital Equipment</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">9.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upon agreement between the Parties, Lonza shall use commercially reasonable efforts to purchase Capital Equipment in a timely manner so as not to delay any of the Services to be performed by Lonza under a Project Plan. Parties shall notify each other in writing sufficiently in advance in the event that a Party foresees such purchase requirement. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Intellectual Property</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">10.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Except as expressly otherwise provided herein, neither Party will, as a result of this Agreement, acquire any right, title, or interest in any Background Intellectual Property of the other Party.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">10.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subject to Clause 10.3, Customer shall own all right, title, and interest in and to any and all Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or agents of Lonza develops, conceives, invents, first reduces to practice or makes, solely or jointly with Customer or others, in the performance of the Services, to the extent such Intellectual Property is a direct derivative of or improvement to the Drug Product, Product, Drug Substances, Customer Materials, Customer Information and/or Customer Background Intellectual Property (collectively, the &#x201c;New Customer Intellectual Property&#x201d;).  For avoidance of doubt, &#x201c;New Customer Intellectual Property&#x201d; shall include any material, processes or other items that solely embody, or that solely are claimed or covered by, any of the foregoing Intellectual Property, but excluding any New General Application Intellectual Property.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">10.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notwithstanding Clause 10.2, and subject to the license granted in Clause 10.5, Lonza shall own all right, title and interest in Intellectual Property that Lonza and/or its Affiliates, the External Laboratories or other contractors or agents of Lonza, solely or jointly with Customer, develops, conceives, invents, or first reduces to practice or makes in the course of performance of the Services to the extent such Intellectual Property (i) is generally applicable to the development or manufacture of chemical or biological products or product components, and could reasonably have been made without the use of the Drug Product, Drug Substances, Customer Materials, Customer Information, or Customer Background Intellectual Property or (ii) is an improvement of, or direct derivative of, any Lonza Information or Lonza Background Intellectual Property (&#x201c;New General Application Intellectual Property&#x201d;).  For avoidance of doubt, &#x201c;New General Application Intellectual Property&#x201d; shall include any material, processes or other items that embody, or that are claimed or covered by, any of the foregoing Intellectual Property. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">10.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza hereby assigns to Customer all of its right, title and interest in any New Customer Intellectual Property.  Lonza shall execute, and shall require its personnel as well as its Affiliates, External Laboratories or other contractors or agents and their personnel involved in the performance of the Services to execute, any documents reasonably required to confirm Customer&#x2019;s ownership of the New Customer Intellectual Property, and any documents required to apply for, maintain and enforce any patent or other right in the New Customer Intellectual Property. Customer hereby assigns to Lonza all of its right, title and interest in any New General Application Intellectual Property. Customer shall execute, and shall require its personnel as well as its Affiliates and their personnel involved in the performance of the Services to execute, any documents reasonably required to confirm Lonza&#x2019;s ownership of the New General Application Intellectual Property, and any documents required to apply for, maintain and enforce any patent or other right in the New General Application Intellectual Property.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">10.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subject to the terms and conditions set forth herein (including the payment of the Price as required above), Lonza hereby grants to Customer a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property, to research, develop, make, have made, use, sell and import the Product.   </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">10.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Customer hereby grants Lonza the non-exclusive right to use the Drug Substances, Drug Product, Product, Customer Materials, Customer Information, Customer Background Intellectual Property and New Customer Intellectual Property during the Term solely for the purpose of fulfilling its obligations under this Agreement. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">10.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Customer will have the right to transfer the Manufacturing Process to itself, its Affiliates and/or any third Party, provided, however, to the extent such technology transfer includes Lonza Confidential Information, or Lonza Background Intellectual Property, such technology transfer to any Third Party shall be subject to [***] and a reasonable royalty and/or licensing fee and terms to be agreed upon by the Parties.  Lonza will not include in the Manufacturing Process any Lonza Confidential Information or Lonza Background Intellectual Property that would require Customer to pay any additional payment and/or royalty to Lonza in order to transfer the Manufacturing Process to itself, its Affiliates and/or any Third Party without first obtaining Customer&#x2019;s prior written consent and advising Customer as to the royalty structure and any other payment that would apply for the use of such Lonza Confidential Information or Lonza Background Intellectual Property.  If Customer has provided such consent and the Manufacturing Process includes the use of any such additional payment-bearing or royalty-bearing Lonza Confidential Information or Lonza Background Intellectual Property, then Customer will pay to Lonza an agreed royalty and/or other agreed payments for the use of Lonza Confidential Information or Lonza Background Intellectual Property.  Lonza shall provide reasonably necessary documents to complete such technology transfer, including transfer of New General Application Intellectual Property, if applicable, and subject to the terms and conditions of this Clause 10.7, Lonza Confidential Information or Lonza Background Intellectual Property, if incorporated into the Manufacturing Process with Customer&#x2019;s consent, and Customer shall reimburse Lonza for any costs (based on a full-time employee rate for such support) and expenses, provided that the total cost of such assistance (excluding any costs paid to Lonza for the use of Lonza&#x2019;s Confidential Information or Lonza Background Intellectual Property) will not exceed [***].</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">10.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Data Usage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Notwithstanding the confidentiality provisions in Clause 13 as they may relate to the use of Services Data, the Parties agree that all Services Data may be collected, aggregated, hosted, mined or otherwise stored and maintained by Lonza and its Affiliates, Subcontractors and External Laboratories in a data platform utilized by Lonza to develop and improve services for the benefit of Lonza&#x2019;s customers (the &#x201c;Data Platform&#x201d;). Customer hereby grants to Lonza a non-exclusive, royalty-free, worldwide, perpetual and irrevocable license solely to use Services Data in a blinded and aggregated format for Lonza&#x2019;s purposes of (i) research, development, commercialization of, and securing rights to, development, manufacturing and testing systems, platforms, and service offerings, and (ii) use of the Data Platform for provision of services to Lonza&#x2019;s customers, provided that the obligations set forth in this Clause shall at all times apply. As used in this Clause, &#x201c;blinded&#x201d; means neither Customer nor Drug Substances, Drug Product, Product, Customer Materials, Customer Information, Customer Background Intellectual Property and New Customer Intellectual Property or any other Customer property or information are identifiable. </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Warranties</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">11.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza warrants that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.1.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the Services shall be performed in a professional and workmanlike manner and in accordance with all Applicable Laws;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.1.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza will not knowingly include in the Manufacturing Process any elements that infringe any intellectual property rights controlled by any Third Party;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.1.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">except with respect to any development services and Non-Clinical Batches (including the Technical Batches), the manufacture of Product shall be performed in accordance with cGMP and will meet the Specifications at the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">date of delivery;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.1.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the manufacture of the Non-Clinical Batches (including the Technical Batches) shall be performed as required in the Project Plan;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.1.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">it or its Affiliate holds all necessary permits, approvals, consents and licenses to enable it to perform the Services at the Facility; </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.1.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">it has the necessary corporate authorizations to enter into and perform this Agreement;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.1.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonza has never been debarred under the Generic Drug Enforcement Act of 1992, 21 U.S.C. Sec. 335a (a) or (b) (the &#x201c;Act&#x201d;).  In the event that during the term of this Agreement, Lonza becomes debarred, suspended, excluded, sanctioned, or otherwise declared ineligible under the Act; Lonza agrees to promptly notify Customer. Lonza also agrees that in the event that it becomes debarred, suspended, excluded, sanctioned, or otherwise declared ineligible under the Act, it shall promptly cease all activities relating to this Agreement; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.1.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">subject to payment of undisputed invoices, title to all Product and all New Customer Intellectual Property provided to Customer under this Agreement shall pass free and clear of any security interest, lien or other encumbrance in favour of Lonza. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">11.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Customer warrants that:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.2.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">as of the date of this Agreement to the best of the Customer&#x2019;s knowledge and belief, the Customer has all the rights necessary to permit Lonza to perform the Services without infringing the Intellectual Property rights of any Third Party and the performance of the Services shall not infringe any Third Party Intellectual Property rights; </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.2.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Customer will promptly notify Lonza in writing if it receives or is notified of a formal written claim from a Third Party that Customer Information and/or Customer Intellectual Property or that the use by Lonza thereof for the provision of the Services infringes any Intellectual Property or other rights of any Third Party; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.2.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Customer has the necessary corporate authorizations to enter into this Agreement.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">11.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DISCLAIMER</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">: THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES, AND ALL OTHER WARRANTIES, BOTH EXPRESS AND IMPLIED, ARE EXPRESSLY DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">11.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Debarment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event a Party receives a notice from the other party (&#x201c;Defaulting Party&#x201d;) or otherwise becomes aware that a debarment, suspension, exclusion, sanction, or declaration of ineligibility action has been brought against the Defaulting Party; then the Party receiving such notice shall have the right to terminate this Agreement immediately; provided that if such event shall occur, </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the Party receiving such notice shall not have such right of termination if the Defaulting Party is disputing and defending such action and the Defaulting Party is otherwise able to perform its services in the manner required under this Agreement.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">11.4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Each Party shall ensure that it will not knowingly use in any capacity the services of any individual, corporation, partnership or association which has been debarred under 21 U.S.C. Sec. 335a(a) or (b), or listed in the DHHS/OIG List of Excluded Individuals/Entities or the General Services Administration's Listing of Parties Excluded from Federal Procurement and Non-Procurement Programs.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">12</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indemnification and Liability</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">12.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indemnification by Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Lonza shall indemnify the Customer, its Affiliates, and their respective officers, employees and agents (&#x201c;Customer Indemnitees&#x201d;) for any loss, damage, costs and expenses (including reasonable attorney fees) that Customer Indemnitees may suffer as a result of any Third Party claim arising directly out of [***] except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Customer Indemnitees. Notwithstanding the foregoing, Lonza shall have no obligations under this Clause 12.1 for any liabilities, expenses, or costs to the extent arising out of or relating to claims covered under Clause 12.2.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">12.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indemnification by Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Customer shall indemnify Lonza, its Affiliates, and their respective officers, employees and agents (&#x201c;Lonza Indemnitees&#x201d;) from and against any loss, damage, costs and expenses (including reasonable attorney fees) that Lonza Indemnitees may suffer as a result of any Third Party claim arising directly out of [***]; except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Lonza Indemnitees. Notwithstanding the foregoing, Customer shall have no obligations under this Clause 12.2 for any liabilities, expenses, or costs to the extent arising out of or relating to claims covered under Clause 12.1.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">12.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indemnification Procedure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  If the Party to be indemnified intends to claim indemnification under this Clause 12, it shall promptly notify the indemnifying Party in writing of such claim.  The indemnitor shall have the right to control the defense and/or settlement thereof; provided, however, that (i) the indemnitor must obtain the prior written consent of the indemnitee (not to be unreasonably withheld) before entering into any settlement of such Third Party claim, and (ii) any indemnitee shall have the right to retain its own counsel at its own expense.  The indemnitee, its employees and agents, shall reasonably cooperate with the indemnitor in the investigation of any liability covered by this Clause 12.  The failure to deliver prompt written notice to the indemnitor of any claim, to the extent prejudicial to its ability to defend such claim, shall relieve the indemnitor of any obligation to the indemnitee under this Clause 12.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">12.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DISCLAIMER OF CONSEQUENTIAL DAMAGES</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, LOST PROFITS OR LOST REVENUES ARISING FROM OR RELATED TO THIS AGREEMENT, EXCEPT TO THE EXTENT RESULTING FROM FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT AND/OR FOR EITHER PARTY&#x2019;S BREACH OF ARTICLE 13 HEREOF.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">12.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LIMITATION OF LIABILITY</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  LONZA&#x2019;S LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED, IN THE AGGREGATE, [***], EXCEPT TO THE EXTENT RESULTING FROM LONZA&#x2019;S</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">13</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Confidentiality</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">13.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A Party receiving Confidential Information (the &#x201c;Receiving Party&#x201d;) agrees to strictly keep secret any and all Confidential Information received during the Term from or on behalf of the other Party (the &#x201c;Disclosing Party&#x201d;) using at least the same level of measures as it uses to protect its own Confidential Information, but in any case at least commercially reasonable and customary efforts.  Confidential Information shall include information disclosed in any form including but not limited to in writing, orally, graphically or in electronic or other form to the Receiving Party, observed by the Receiving Party or its employees, agents, consultants, or representatives, or otherwise learned by the Receiving Party under this Agreement, which the Receiving Party knows or reasonably should know is confidential or proprietary.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">13.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notwithstanding the foregoing, Receiving Party may disclose to any courts and/or other authorities Confidential Information which is or will be required pursuant to applicable governmental or administrative or public law, rule, regulation or order.  In such case the Party that received the Confidential Information will, to the extent legally permitted, inform the other Party promptly in writing and cooperate with the Disclosing Party in seeking to minimize the extent of Confidential Information which is required to be disclosed to the courts and/or authorities.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">13.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The obligation to maintain confidentiality under this Agreement does not apply to Confidential Information, which:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">13.3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">at the time of disclosure was publicly available; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">13.3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is or becomes publicly available other than as a result of a breach of this Agreement by the Receiving Party; or </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">13.3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">as the Receiving Party can establish by competent proof, was rightfully in its possession at the time of disclosure by the Disclosing Party and had not been received from or on behalf of Disclosing Party; or </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">13.3.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is supplied to a Party by a Third Party which was not in breach of an obligation of confidentiality to Disclosing Party or any other party; or </font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">13.3.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is developed by the Receiving Party independently from and without use of the Confidential Information, as evidenced by contemporaneous written records.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">13.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Receiving Party will use Confidential Information only for the purposes of this Agreement and will not make any use of the Confidential Information for its own separate benefit or the benefit of any Third Party including, without limitation, with respect to research or product development or any reverse engineering or similar testing.  The Receiving Party agrees to return or destroy promptly (and certify such destruction) on Disclosing Party&#x2019;s request all written or tangible Confidential Information of the Disclosing Party, except that one copy of such Confidential Information may be kept by the Receiving Party in its confidential files for record keeping purposes only.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">13.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Each Party will restrict the disclosure of Confidential Information to such officers, employees, professional advisers, finance-providers, consultants and representatives of itself and its Affiliates who have been informed of the confidential nature of the Confidential Information and who have a need to know such Confidential Information for the purpose of this Agreement or an applicable financing or acquisition.  Both Parties may disclose Confidential Information of the other Party and its Affiliates to potential and actual acquirers provided such disclosure is limited to the terms of this Agreement.  Customer also may disclose to its potential and actual: (i) acquirers and (ii) bona fide collaborators in the research, development and commercialization of the Products, the work product provided to Customer by Lonza as a consequence of the provision of the Services.  Prior to disclosure to such persons, the Receiving Party shall inform the Disclosing Party and it shall bind its and its Affiliates&#x2019; officers, employees, consultants and representatives to confidentiality and non-use obligations no less stringent than those set forth herein.  The Receiving Party shall notify the Disclosing Party as promptly as practicable of any unauthorized use or disclosure of the Confidential Information.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">13.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Receiving Party shall at any time be fully liable for any and all breaches of the confidentiality obligations in this Clause 13 by any of its Affiliates or the employees, consultants, potential and actual acquirers, and representatives of itself or its Affiliates.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">13.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Each Party hereto expressly agrees that any breach or threatened breach of the undertakings of confidentiality provided under this Clause 13 by a Party may cause irreparable harm to the other Party and that money damages may not provide a sufficient remedy to the non-breaching Party for any breach or threatened breach.  In the event of any breach and/or threatened breach, then, in addition to all other remedies available at law or in equity, the non-breaching Party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the non-breaching Party.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">14</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Term and Termination</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">14.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  This Agreement shall commence on the Effective Date and shall end on the fifth (5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) anniversary of the Effective Date unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the &#x201c;Term&#x201d;).  Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project Plan does not extend beyond the Term.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">14.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  This Agreement may be terminated as follows:</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">14.2.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">by either Party for any reason upon [***] prior written notice; provided that Lonza may not provide such notice until the [***] anniversary of the Effective Date. In such an event all cancellation terms in this Agreement shall apply (except, in the case of termination by Lonza pursuant to Clause 14.2.1, the Cancellation Fees shall not apply), and the Customer shall make payments for work commenced and performed under any purchase order(s) by Lonza prior to the termination notice date;</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">14.2.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">by either Party if the other Party breaches a material provision of this Agreement or a Project Plan and fails to cure such breach to the reasonable satisfaction of the non-breaching Party within [***] ([***] for non-payment) following written notification of such breach from the non-breaching party to the breaching party; provided, however, that such [***] period shall be extended as agreed by the Parties if the identified breach is incapable of cure within [***] and if the breaching Party provides a plan and timeline to cure the breach, promptly commences efforts to cure the breach and diligently prosecutes such </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">cure [***];</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">14.2.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">by either Party, immediately, if the other Party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, or files or has filed against it, a petition in bankruptcy or has a receiver appointed for a substantial part of its assets; or</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:7.14323979728499%;">14.2.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">by either Party pursuant to Clause 15.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">14.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consequences of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  In the event of termination hereunder, Lonza shall be compensated for (i) Services  rendered up to the date of termination, including in respect of any Product in-process; (ii) all costs incurred through the date of termination, including Raw Materials costs and Raw Materials Fees for Raw Materials used or purchased for use in connection with the Project Plan; (iii) all unreimbursed Capital Equipment and related decommissioning charges incurred pursuant to Clause 9; (iv) all Cancellation Fees due under Clause 6.4.  In the case of termination by Lonza for Customer&#x2019;s material breach, Cancellation Fees shall be calculated as of the date of written notice of termination.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">14.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  The rights and obligations of each Party which by their nature survive the termination or expiration of this Agreement shall survive the termination or expiration of this Agreement, including Clauses 5, 10-13 and 16 (to the extent relevant). </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">15</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Force Majeure</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">15.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If Lonza is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure and gives written notice thereof to Customer specifying the matters constituting Force Majeure together with such evidence as Lonza reasonably can give and specifying the period for which it is estimated that such prevention or delay will continue, Lonza shall be excused from the performance or the punctual performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue.  Provided that, if such Force Majeure persists for a period of [***] or more, Customer may terminate this Agreement by delivering written notice to Lonza.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">15.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Force Majeure&#x201d; shall be deemed to include any reason or cause beyond Lonza&#x2019;s reasonable control affecting the performance by Lonza of its obligations under the Agreement, including, but not limited to, any cause arising from or attributable to acts of God, strike, labor troubles, restrictive governmental orders or decrees, riots, insurrection, war, terrorist acts, or the inability of Lonza to obtain any required raw material, energy source, equipment, labor or transportation, at prices and on terms deemed by Lonza to be reasonably practicable, from Lonza&#x2019;s usual sources of supply. </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">15.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With regard to Lonza, any such event of Force Majeure affecting services or production at its Affiliates or suppliers shall be regarded as an event of Force Majeure.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">16</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additional Covenants</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">16.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Each Party shall comply with, and shall cause its Affiliates, subsidiaries, subcontractors, directors, officers, employees, agents or any other person acting on behalf of Lonza to comply with, all applicable Corruption Laws and International Trade Restrictions, and shall obtain all necessary export and re-export written consents, permits, and authorizations required by International Trade Restrictions; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">16.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the preparation and the performance of this Agreement, each Party shall take appropriate technical and organizational measures to comply with the GDPR, to the extent it is applicable. Lonza shall in compliance with GDPR as well as on Customer&#x2019;s request, destroy all personal data, unless Applicable Law prevents Lonza from such destruction. Lonza confirms that any personal identifiable data shared with Customer for the purposes of the Services, the preparation and the performance of this Agreement is done in accordance with the requirements of the GDPR.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;">17</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Miscellaneous</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">17.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  If any provision hereof is or becomes at any time illegal, invalid or unenforceable in any respect, neither the legality, validity nor enforceability of the remaining provisions hereof shall in any way be affected or impaired thereby.  The Parties hereto undertake to substitute any illegal, invalid or unenforceable provision by a provision which is as far as possible commercially equivalent considering the legal interests and the Purpose.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">17.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amendments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Modifications and/or amendments of this Agreement must be in writing and signed by the Parties.  </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">17.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assignment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  Lonza shall be entitled to instruct one or more of its Affiliates to perform any of Lonza&#x2019;s obligations contained in this Agreement, but Lonza shall remain fully responsible in respect of those obligations.  Neither Party may assign its interest under this Agreement without the prior written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed, provided, however that either Party may assign this Agreement to (i) any Affiliate of such Party or (ii) any third party in connection with the sale or transfer (by whatever method) of all or substantially all of the assets of the business or Product of such Party to which this Agreement relates, whether by merger, consolidation, acquisition or other form of business combination.  Any purported assignment without a required consent shall be void.  No assignment shall relieve any Party of responsibility for the performance of any obligation that accrued prior to the effective date of such assignment. Lonza shall be entitled to sell, assign and/or transfer its trade receivables resulting from this Agreement without the consent of the Customer.  </font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">17.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All notices must be written and sent to the address of the Party first set forth above.  All notices must be given (a) by personal delivery, with receipt acknowledged, (b) by facsimile followed by hard copy delivered by the methods under (c) or (d), (c) by prepaid certified or registered mail, return receipt requested, or (d) by prepaid recognized next business day delivery service.  Notices will be effective upon receipt or at a later date stated in the notice.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">17.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Governing Law/Jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  This Agreement is governed in all respects by the laws of [***], without regard to its conflicts of laws principles.  The Parties agree to submit to the jurisdiction of the state and federal courts located in [***].</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Arial;justify-content:flex-start;min-width:6.667%;">17.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.  This Agreement contains the entire agreement between the Parties as to the subject matter hereof and supersedes all prior and contemporaneous agreements with respect to the subject matter hereof.  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document.  Each Party acknowledges that an original signature or a copy thereof transmitted by facsimile or by .pdf shall constitute an original signature for purposes of this Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, each of the Parties hereto has caused this Development and Manufacturing Services Agreement to be executed by its duly authorized representative effective as of the date written above.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">[SIGNATURES FOLLOW ON THE NEXT PAGE]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LONZA LTD<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Albert Pereda	</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name Albert Pereda</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Title</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date 13-Apr-2022</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Bernd Stefer	</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name Bernd Stefer</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Title</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date 13-Apr-2022</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vaxcyte, Inc.</font></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By: </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Grant Pickering	</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name Grant Pickering</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Title CEO</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:18.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date 4/12/2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">APPENDIX A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Project Plan A</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FIRST AMENDMENT TO DEVELOPMENT AND MANUFACTURING</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SERVICES AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This First Amendment (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), comes into effect on May 12, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and Vaxcyte, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This First Amendment is to be incorporated as part of the Development and Manufacturing Services Agreement, dated March 22, 2022, between Lonza and Vaxcyte (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and Vaxcyte, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and Vaxcyte entered into the Original Agreement which the Parties now desire to amend;</font></div></div>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties wish to amend the Original Agreement by adding a new Project Plan B, attached hereto, in the Appendix A of the Original Agreement.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:5.824%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, the Parties hereby agree that the following amendments are made to the Original Agreement:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All capitalized terms used herein shall have the meaning set forth in the Original Agreement.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties hereby agree that the wording attached herein shall be added to the Original Agreement Appendix A as Project Plan B.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect. In the event of any conflict between the terms and conditions of this First Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, Vaxcyte and Lonza hereby enter into this First Amendment, effective as of the Tenth Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC	LONZA LTD</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:  /s/ Grant Pickering	By:  /s/ Bernd Stefer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:  Grant Pickering	Name:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:     CEO	Title:</font></p>
  <p style="margin-left:14.813%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.813%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:	By:  /s/ Albert Pereda</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:	Name:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:	Title:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">27</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">APPENDIX A</font></p>
  <p style="margin-left:14.813%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan B</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECOND AMENDMENT TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Second Amendment (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), comes into effect on November 21, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is made by and between Lonza Ltd (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Customer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). This Second Amendment is to be incorporated as part of the Development and Manufacturing Services Agreement, dated March 22, 2022, between Lonza and Vaxcyte (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Original</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Lonza and Vaxcyte, hereafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Whereas:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lonza and Vaxcyte entered into the Original Agreement which the Parties now desire to amend;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties wish to modify the Project Plan A for the manufacturing of the Customer&#x2019;s [***].</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE, the Parties hereby agree that the following amendments are made to the Original Agreement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.685%;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.104121564080728%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All capitalized terms used herein shall have the meaning set forth in the Original Agreement.</font></div></div>
  <p style="margin-left:2.627%;text-indent:-4.209%;padding-left:3.933%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.104121564080728%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties hereby agree that the wording attached herein shall replace the Original Agreement Appendix A as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Project Plan A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. [***].</font></div></div>
  <p style="margin-left:2.627%;text-indent:-4.209%;padding-left:3.933%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:2.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.104121564080728%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All other terms and conditions of the Original Agreement, as amended, shall remain in full force and effect.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event of any conflict between the terms and conditions of this Second Amendment and the Original Agreement, the terms and conditions set forth in the Original Agreement shall control.</font></div></div>
  <p style="margin-left:6.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, Vaxcyte and Lonza hereby enter into this Second Amendment, effective as of the Tenth Amendment Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:-87.501%;padding-left:46.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC		LONZA LTD</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Grant Pickering		By: /s/ Albert Pereda</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Grant Pickering 		Name</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: CEO		Title:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:		By: /s/ Bernd Stefer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:		Name</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:		Title:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CONFIDENTIAL</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Appendix A</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Project Plan A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">30</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>5
<FILENAME>pcvx-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.19</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUPPLY AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUPPLY AGREEMENT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is made as of May 29, 2018 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by and between SutroVax, Inc., a Delaware corporation having principal offices at 353 Hatch Dr., Foster City, CA 94404 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and Sutro Biopharma, Inc., a Delaware corporation, having principal offices at 310 Utah Ave, Suite 150, South San Francisco, CA, 94080 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). SutroVax and Sutro may be referred to herein by name or individually, as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively, as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">BACKGROUND</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A. Sutro controls certain proprietary technology which permits cell-free expression of proteins, and Sutro licensed such technology to SutroVax under that certain Amended and Restated SutroVax Agreement dated as of October 12, 2015 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B. SutroVax is a vaccine company primarily in the business of developing, manufacturing and marketing vaccine products; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">C. SutroVax desires to purchase from Sutro, and Sutro desires to supply to SutroVax, the Extracts and Custom Reagents (as defined below) upon the terms and subject to the conditions set forth herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW, THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in consideration of the covenants, conditions and undertakings hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DEFINITIONS/ INTERPRETATION</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the purposes of this Supply Agreement, the following capitalized words and phrases shall have the following meanings:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, with respect to either Party, any business entity controlling, controlled by, or under common control with such Party. For the purpose of this definition only, &#x201c;control&#x201d; means (i) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities, by contract or otherwise, or (ii) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of a business entity. Notwithstanding the above, in no event shall Sutro (or any entity that would be an Affiliate of SutroVax solely because it is an Affiliate of Sutro) be deemed an Affiliate of SutroVax, or SutroVax (or any entity that would be an Affiliate of Sutro solely because it is an Affiliate of SutroVax) an Affiliate of Sutro.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Applicable Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means all laws, ordinances, rules, rulings, directives and regulations of any Governmental Authority that apply to the development, manufacture or supply of any Product or the other activities contemplated under this Supply Agreement, including (i) all applicable federal, state and local laws, rules and regulations; (ii) the U.S. Federal Food, Drug and Cosmetic Act; (iii) regulations and guidelines of the FDA and other Regulatory Authorities, including cGMPs, if applicable; and (iv) any applicable non-U.S. equivalents of any of the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foregoing, including guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (as amended from time to time).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cGMPs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means current good manufacturing practices and standards as set forth (and as amended from time to time) in the current Good Manufacturing Practice Regulations of the U.S. Code of Federal Regulations, including 21 C.F.R. Sections 210 and 211, the European Community Directive 2003/94/EC and the ICH Harmonised Tripartite Guideline, Good Manufacturing Practice Guides for Active Pharmaceutical Ingredients (Q7).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any product or material used in the Manufacture of the Products including the packaging materials.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extract</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means Sutro&#x2019;s extract derived from strains of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> identified on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> attached hereto, as may be amended from time to time in accordance with Section 12.7, and any new versions and improvements thereof that may be included in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> by written agreement of the Parties in accordance with Section 12.7.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facility</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Facilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the facilities where Product will be Manufactured as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> may be amended from time to time in accordance with this Supply Agreement to add or remove facilities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.7 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the United States Food and Drug Administration, or any successor agency thereto performing similar functions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fully Burdened Manufacturing Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, with respect to a Product, Sutro&#x2019;s costs of manufacturing such Product, which manufacturing costs shall mean: (a) [***], and (b) [***], in each case to the extent directly allocated to and incurred in the manufacture by Sutro of such Product supplied to SutroVax, its Affiliates and Sublicensees. Fully Burdened Manufacturing Costs shall not include any [***] and shall be calculated in accordance with the foregoing, GAAP and Sutro&#x2019;s policies and procedures for its other products, in each case consistently applied (and such plant operations and support services costs shall be allocated consistent with GAAP and other products of Sutro in that facility).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governmental Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any court, agency, department, authority or other instrumentality of any nation, state, country, city or other political subdivision, including any Regulatory Authority.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.10 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacture</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the processes and procedures for the supply of the Products, including, (a) the supply and quality control of the Components; (b) the manufacture of the Products in bulk; (c) the Packaging and labeling of the Products; (d) the quality control of the Products; and (e) the storage of the Products until shipment.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.11 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Package</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Packaging</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means packaging Product(s) in accordance with applicable Specifications.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.12 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means an individual, a corporation, a partnership, an association, a trust or other entity or organization, including a government or political subdivision or an agency thereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.13 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the price to be paid by SutroVax for each Product as set forth on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of this Supply Agreement and as may be modified from time to time in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.14 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product(s)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Extract and Custom Reagents.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.15 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Custom Reagents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means Sutro&#x2019;s custom reagents identified on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> attached hereto, and any new versions and improvements thereof that may be included in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> by written agreement of the Parties in accordance with Section 12.7.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.16 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory Approval</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, with respect to a product, all approvals, licenses, registrations or authorizations necessary to market and sell such product in a particular jurisdiction in the Territory (including applicable approvals of labeling, price and reimbursement for such product in such jurisdiction).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.17 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory Authority</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity, including the FDA, with authority over the development, Manufacture or commercialization (including approval of Regulatory Approvals) of any Product(s) in any jurisdiction in the Territory.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.18 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means regulatory applications, submissions, notifications, communications, correspondence, registrations, Regulatory Approvals and/or other filings made to, received from or otherwise</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">conducted with a Regulatory Authority (including minutes of meeting with Regulatory Authorities) that are necessary or reasonably desirable to access in connection with the development, manufacture, marketing, sale or other commercialization of any Product in a particular country or regulatory jurisdiction. Regulatory Materials include, without limitation, INDs, NDAs, BLAs, clinical trial applications, marketing approval applications and applications for pricing approvals.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.19 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Required Standards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means Applicable Law, the Specifications, and the warranties given by Sutro in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, provided that Required Standards shall not include compliance with cGMPs for Custom Reagents, Extract identified as &#x201c;research grade&#x201d; Extract or Other Extracts.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.20 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specifications</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, with respect to a Product or applicable Component thereof, all written product, regulatory, Manufacturing, release criterion, quality control and quality assurance procedures, processes, practices, standards, instructions and specifications applicable to the Manufacture of such Product or Component, as agreed to by the Parties in writing from time to time. The initial Specifications for the Products are attached hereto as Schedule 2.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.21 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax CMO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any contract manufacturer responsible for supplying or manufacturing a Vaccine Composition on behalf of SutroVax or its Affiliates, selected in accordance with Section .2.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.22 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Territory</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means worldwide.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.23 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any Person other than SutroVax, Sutro, or their respective Affiliates.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.24 Additional Definitions.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Each of the following terms shall have the meaning described in the corresponding Section of this Supply Agreement indicated below:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.218%;"></td>
    <td style="width:1.656%;"></td>
    <td style="width:1.72%;"></td>
    <td style="width:33.761%;"></td>
    <td style="width:1.645%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section Defined</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alternate Supplier</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acceptance Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COA/COC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMC</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delivery Time Period</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disputed Matter</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug Master File</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preamble</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Force Majeure</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forecast</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnify</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Latent Defect</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Background</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing Change</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSDS</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Extract</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.16</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party or Parties</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preamble</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:73.301%;"></td>
    <td style="width:1.143%;"></td>
    <td style="width:1.517%;"></td>
    <td style="width:22.895%;"></td>
    <td style="width:1.143%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section Defined</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3/Commercial Supply Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.14</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Q1, Q2 or Q3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quality Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Management</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short Dated Product</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.11</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preamble</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Activity Criteria</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Activity Test</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Indemnitees</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preamble</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax Activity Criteria</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax Activity Test</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax Indemnitees</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply Agreement</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preamble</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-Party Claim</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1.1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Addendum</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Work Order</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:0.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.25 Interpretation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The captions and headings to this Supply Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Supply Agreement. Unless specified to the contrary, references to Articles, Sections, Schedules or Exhibits mean the particular Articles, Sections, Schedules or Exhibits to this Supply Agreement and references to this Supply Agreement include all Schedules and Exhibits hereto. Unless context clearly requires otherwise, whenever used in this Supply Agreement: (i) the words &#x201c;include&#x201d; or &#x201c;including&#x201d; shall be construed as incorporating, also, &#x201c;but not limited to&#x201d; or &#x201c;without limitation;&#x201d; (ii) the word &#x201c;or&#x201d; shall have its inclusive meaning of &#x201c;and/or;&#x201d; (iii) the word &#x201c;notice&#x201d; shall require notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Supply Agreement; (iv) the words &#x201c;hereof,&#x201d; &#x201c;herein,&#x201d; &#x201c;hereunder,&#x201d; &#x201c;hereby&#x201d; and derivative or similar words refer to this Supply Agreement (including any Schedules and Exhibits); (v) provisions that require that a Party or the Parties &#x201c;agree,&#x201d; &#x201c;consent&#x201d; or &#x201c;approve&#x201d; or the like shall require that such agreement, consent or approval be specific and in writing; (vi) words of any gender include the other gender; (vii) words using the singular or plural number also include the plural or singular number, respectively; (viii) references to any specific law, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement thereof; (ix) neither Party shall be deemed to be acting &#x201c;under the authority&#x201d; of the other Party; and (x) any capitalized terms used and not defined in this Supply Agreement shall have the meaning set forth in the License Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUPPLY</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.1 Supply.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Pursuant to the terms and conditions of this Supply Agreement, Sutro agrees that it will Manufacture the Product(s) at the Facility(ies) for SutroVax and shall supply the Product(s) to SutroVax, its Affiliates, and any SutroVax CMO, for purposes of production of Vaccine Compositions (including development of processes for the production of Vaccine Compositions), solely for non-clinical research purposes or in Phase I or Phase II clinical trials of such Vaccine Compositions..</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2 Transfer of Product.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Subject to Section 2.1, SutroVax may transfer Products to SutroVax CMOs selected by SutroVax and that are reasonably acceptable to Sutro (the acceptance of which by Sutro not to be unreasonably withheld, conditioned or delayed) or previously approved by Sutro.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3 Work Orders.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> From time to time, Sutro and SutroVax may execute one or more work orders, that describe the Product to be Manufactured, the quantities of each Product to be Manufactured and supplied to SutroVax, the Price to be charged by Sutro (which shall be as set forth in Section 3.2) and paid by SutroVax for the Product, and the delivery date(s) for such Product, (as executed, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Work Order</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Each Work Order will expressly refer to this Supply Agreement, will form a part of this Supply Agreement, and will be subject to the terms and conditions contained herein. Sutro shall not unreasonably withhold its agreement to any proposed Work Order requested by SutroVax. Sutro shall be obligated to execute proposed Work Orders requested by SutroVax (except with respect to Other Extracts) with respect to quantities in such proposed Work Order for delivery at least [***] months after SutroVax&#x2019;s request to the extent such quantities of Product (when added to the quantities of such Product in Work Orders previously agreed between the Parties for delivery within the one (1) calendar year period prior to the requested delivery date of the proposed Work Order) are less than (a) [***] liters with respect to Extract or (b) a corresponding amount of each Custom Reagent to support use of [***] liters of Extract. Sutro shall notify SutroVax as soon as possible if Sutro believes it will be unable to deliver Product in accordance with the applicable Work Order. Sutro&#x2019;s providing of such notification shall not be interpreted in any manner as relieving Sutro of its obligations under this Supply Agreement, nor shall it prevent SutroVax from pursuing any and all rights and remedies SutroVax may have based on Sutro&#x2019;s failure to be able to deliver any Product in accordance with the terms of this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4 Orders.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase Orders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Once both parties have executed a Work Order, SutroVax shall place a purchase order for the amounts of Products to be purchased under such Work Order with delivery dates for such amounts consistent with such Work Order. Additionally, SutroVax may from time to time place purchase orders for additional quantities specifying requested delivery dates in accordance with reasonable delivery schedules and lead times; in each case, as may be agreed upon from time to time by the Parties. Each purchase order placed by SutroVax shall specify the quantity of Product, destination(s) and requested delivery dates. Sutro shall promptly accept all purchase orders with respect to the amounts of Products to be purchased under the applicable Work Order and shall accept or reject any amount in the purchase order in excess of the amounts of Products to be purchased under the applicable Work Order and all other purchase orders for Product submitted by SutroVax in accordance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> within [***] days from receipt of the order; provided however that Sutro shall use Commercially Reasonable Efforts to accept such amounts and purchase orders. Accepted purchase orders may not be cancelled without the prior written agreement of both Parties except as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections 2.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Unless otherwise directed by SutroVax, Sutro shall fill all accepted purchase orders for Product in accordance with the requested due dates as set forth in further detail in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2.9.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Conflicting Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The terms and conditions of this Supply Agreement shall be controlling over any conflicting terms and conditions stated in SutroVax&#x2019;s purchase order or Sutro&#x2019;s invoice, confirmation or other standardized document. Any purchase order, order acknowledgement, invoice, proposal or other document which conflicts with or adds to the terms and conditions of this Supply Agreement with respect to the Manufacture and supply of Product for the Territory is hereby rejected, unless the Parties mutually agree to the contrary in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Order</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Notwithstanding </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, Sutro accepts and agrees to fulfil the order previously placed by or on behalf of SutroVax (or to be placed by or on behalf of SutroVax, if no already placed) for the quantities of Product set forth in Schedule 3 by the delivery date set forth therein (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Order</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5 Cancellation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Notwithstanding anything herein to the contrary, SutroVax may not modify or cancel purchase orders with respect to the amounts of Product to be purchased under the applicable Work Order, however SutroVax may modify or cancel other purchase orders (including amounts in a purchase order in excess of the amounts of Product to be purchased under the applicable Work Order) for the Products provided that such modification or change is made further in advance of the originally requested delivery date than the required lead time, where the agreed required lead time for the applicable purchase order has been evidenced in writing (including, for example, by email) between the Parties.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6 Delivery and Risk of Loss.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall mark Product for delivery to the destination(s) specified by SutroVax. All shipments of Product(s) shall be delivered [***] (lncoterms 2010) Sutro Facility. Title and risk of loss and damage to the Product(s) shall remain with Sutro until the Product(s) are delivered in accordance with the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">foregoing, at which time title and risk ofloss and damage to the Product(s) shall pass to SutroVax. SutroVax will arrange for shipping from Sutro&#x2019;s Facility to the destination specified by SutroVax at SutroVax&#x2019;s cost and expense.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7 Packaging.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall provide the Product to SutroVax in Packaged form in accordance with the Required Standards.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8 Conformance to Required Standards.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall Manufacture the Product(s) in accordance with the Required Standards, as the same may be amended or supplemented from time to time. Each Party shall keep the other promptly and fully advised of any new requirements of the applicable Regulatory Authority or Applicable Law of which it becomes aware and Sutro shall promptly implement such requirements as described in Section 6.6.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9 Supply and Delivery.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shortage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Sutro shall use reasonable efforts to promptly notify SutroVax in writing in the event that Sutro is unable or anticipates that it will be unable to supply compliant Product in accordance with the requirements of this Supply Agreement, including the Quality Agreement and all Required Standards, and each Work Order. Sutro shall use Commercially Reasonable Efforts to overcome any inability or anticipated inability to so supply compliant Product to SutroVax.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delivery Delays</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Subject to Section 2.4.1 (including applicable lead times agreed upon in accordance with Section 2.4.1) Sutro shall make deliveries of Product(s) in accordance with Section 2.6, no more than [***] days before or [***] after the delivery dates specified by SutroVax in the relevant purchase order (provided that such delivery date is in accordance with the applicable Work Order or such purchase order was otherwise accepted by Sutro) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delivery Time Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). For any failure to supply compliant Product(s) in the later of the Delivery Time Period and the period ending [***] after the delivery date specified under the Work Order, without limiting SutroVax&#x2019;s other remedies, subject to this Section 2.9.2 and Section 9.3 (Limitation of Liability), Sutro shall be liable for any non-cancelable Third Party penalties, costs and expenses incurred by SutroVax as a result of Sutro&#x2019;s failure to supply Product(s) as aforesaid, subject to receipt by Sutro of appropriate documentary evidence of such penalties, costs and expenses to the extent such evidence of such amounts may be provided by SutroVax without breaching SutroVax&#x2019;s or its Affiliates&#x2019; duties of confidentiality to such Third Party (and provided that SutroVax shall use commercially reasonable efforts to (i) minimize or eliminate such penalties, costs and expenses and (ii) where provision of such evidence to Sutro would result in a breach of such duties of confidentiality, to obtain the consent of the applicable Third Party to the provision of such evidence to Sutro). In the event that Sutro makes a Manufacturing Change and is not able to Manufacture and supply Product in conformance with the Required Standards within [***] days of the delivery date identified on the applicable purchase order, Sutro shall Manufacture such Product without such Manufacturing Change. The rights of SutroVax set forth in this paragraph are in addition to any other rights set forth in this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.10 Allocation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Without limiting any other rights or remedies available to SutroVax, if the demand for a Product in aggregate exceeds available supply or Sutro otherwise concludes that it may be unable to supply a Product in accordance with the requirements of this Supply Agreement in the quantities and within the time periods specified in each Work Order and the corresponding purchase orders that have been accepted by Sutro, Sutro shall immediately notify SutroVax of such shortfall (or anticipated shortfall), and shall use Commercially Reasonable Efforts to procure Components and capacity adequate to meet accepted purchase orders and supply compliant Product in accordance with the requirements of this Supply Agreement. Sutro shall allocate its available Components and manufacturing capacity to provide SutroVax with quantities of such Product at least equal to the greater of (a) [***] of the amount of Product (or products equivalent to Product) that Sutro allocates for itself and its Affiliates (but in no event less than [***] liters of Extract per month and the minimum allocation volume set out in Schedule 1 of each Custom Reagent per month), provided that SutroVax demonstrates actual need for the applicable quantities of Extract, and (b) the [***]. Without limiting the foregoing, if there is a shortage of supply of Product, Sutro shall provide Product to SutroVax for any quantities of Product ordered by SutroVax in accordance with the applicable Work Order or purchase order in priority to any subsequent Third Party purchase orders, but not in priority to any Third Party purchase orders or other binding commitment placed before placement of the applicable SutroVax Work Order or purchase order.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.11 Short Dated Product.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro agrees to ship all Product(s) so that they are delivered to SutroVax and will remain compliant with the Specifications for at least [***] months from the date of delivery in accordance with this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.12 Subcontracting by Sutro.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall (a) ensure that any subcontractor or delegatee of Sutro&#x2019;s obligations under this Supply Agreement has and maintains all appropriate qualifications; (b) enter into a quality agreement with each such subcontractor and delegatee which terms are similar to the terms of the Quality Agreement between SutroVax and Sutro; and (c) be responsible for each subcontractor&#x2019;s and delegatee&#x2019;s performance hereunder (including performance or non-performance by such subcontractor or delegatee that would constitute a breach of this Supply Agreement or such quality agreement if conducted by Sutro) as if Sutro were itself performing such activities. Sutro shall not subcontract the Manufacture of Product to a Third Party without SutroVax&#x2019;s prior consent other than to an Alternate Supplier as expressly set forth in Section 2.15.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.13 CMOs.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Notwithstanding anything to the contrary in this Supply Agreement, SutroVax shall have the rights to purchase Available Extracts and Extracts from CMOs (as defined in the License Agreement) to the extent provided in section 3.1 of the License Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.14 Phase 3/Commercial Supply Agreement.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> If requested by SutroVax in writing (which request shall not be made prior to [***]), the Parties shall negotiate in good faith reasonable terms and conditions of an agreement for the supply by Sutro of the Products for the production of Vaccine Compositions for use in phase 3 clinical studies and for commercial purposes (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phase 3/Commercial Supply Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). The price for the Products Manufactured by Sutro under the Phase 3/Commercial Supply Agreement shall not exceed [***] of the Fully Burdened Manufacturing Cost thereof. If the Parties have not entered into the Phase 3/Commercial Supply Agreement within [***] after SutroVax&#x2019;s request to negotiate the Phase 3/Commercial Supply Agreement, upon either Party&#x2019;s request by written notice to the other Party the terms and conditions of the Phase 3/Commercial Supply Agreement shall be determined by binding arbitration in accordance with the procedures set forth in Section 11.4. Upon the selection of one draft Phase 3/Commercial Supply Agreement by the arbitrator pursuant to Section 11.4, unless SutroVax elects not to enter into such Phase 3/Commercial Supply Agreement by written notice thereof to Sutro within [***] days after such selection, the Parties shall execute the definitive Phase 3/Commercial Supply Agreement selected by the arbitrator (but excluding, for clarity, any provision granting to SutroVax or its Affiliates or Sublicensees any right to obtain or use any Sutro Core Know-How); and if SutroVax elects to not enter into the Phase 3/Commercial Supply Agreement selected by the arbitrator by providing notice thereof within such [***] day period, then neither Party shall be obligated to enter into the Phase 3/Commercial Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15 Qualification of Alternate Supplier.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Addendum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:14.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Transfer Addendum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Upon SutroVax&#x2019; written request, the Parties agree to negotiate in good faith an addendum to this Supply Agreement setting forth the terms and conditions pursuant to which Sutro will conduct a Process Transfer to a Third Party contract manufacturer (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and/or engage such CMO to establish Capacity to Manufacture Extract (as Process Transfer and Capacity are defined below), in each case for the Manufacture and supply of such Extract for SutroVax&#x2019; (or its Affiliate&#x2019;s or SutroVax CMO&#x2019;s) use to manufacture Vaccine Compositions, consistent with the remainder of this Section 2.15 (such addendum, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Addendum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). As requested by SutroVax, this procedure may also be used in the event that SutroVax wishes Sutro to conduct a Process Transfer to a Third Party CMO in order to establish Capacity to Manufacture Custom Reagents. In connection with such request, SutroVax shall provide to Sutro a description of the desired Process Transfer and/or Capacity, including timing and other requirements thereof. Such Transfer Addendum shall:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:20.4%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i) include a plan and budget for the conduct of the Process Transfer and/or establishment of such Capacity, which shall include amounts charged by the CMO (as defined further below, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Alternate Supplier</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to receive and conduct such Process Transfer and/or establish such Capacity, as well as reasonable FTE costs for Sutro personnel performing and managing technology transfer activities in accordance with the Transfer Addendum&middot;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:20.4%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(ii) require SutroVax to fund the costs incurred by Sutro to conduct Process Transfer and/or establish such Capacity in accordance with such budget;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:20.4%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iii) provide for initiation and completion of the Process Transfer and establishment of Capacity as requested by SutroVax, to the extent possible;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:20.4%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(iv) to the extent requested by SutroVax, be designed to enable the Alternate Supplier to Manufacture Extract of suitable quality for use in Phase 3 clinical trials and commercialization of a Vaccine</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Composition at a capacity to support SutroVax&#x2019; projected commercial requirements for Extract (or other capacity identified by SutroVax in connection with the negotiation of the Transfer Addendum), as requested by SutroVax;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:20.4%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(v) require the Parties to fully cooperate to verify that the Extract supplied by the Alternate Supplier meets the Specifications, to validate the Manufacturing process implemented at the Alternate Supplier and to qualify the Alternate Supplier, in each case to supply Extract for SutroVax&#x2019; use in Phase 3 clinical trials and commercialization of a Vaccine Composition (collectively, with respect to Capacity established, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Validating</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; such Capacity);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:20.4%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(vi) include mechanisms for keeping SutroVax fully informed, at scheduled intervals not to exceed once per quarter, of the progress of the Process Transfer and establishing such Capacity, as applicable, including with respect to the anticipated date for qualifying the Alternate Supplier and any changes to such anticipated date;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:20.4%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(vii) provide a right for SutroVax to modify the timing of or terminate the Process Transfer, Capacity or specified aspects thereof on reasonable notice, subject to SutroVax&#x2019; agreement to bear any resulting termination or cancellation fees charged by the Alternative Supplier; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:20.4%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(viii) include a mechanism for Sutro to cooperate with SutroVax and keep SutroVax reasonably informed with respect to Sutro&#x2019;s negotiation of an agreement with a potential Alternate Supplier for a Process Transfer and/or establishment of Capacity, including with respect to pricing for Extract from the Alternate Supplier to Sutro and any commitments to purchase quantities of Extract from the Alternate Supplier that SutroVax would be obligated to assume (e.g., in connection with establishing Capacity), if any, and require Sutro to obtain SutroVax&#x2019; approval (not to be withheld unreasonably) of the terms of such agreement prior to entering into such agreement to the extent that the terms apply to SutroVax (it being understood that Sutro may redact any terms that are not relevant to SutroVax).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:14.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Scope</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. As used above, &#x201c;Process Transfer&#x201d; means a technology transfer of Sutro&#x2019;s know-how and information as is necessary or useful for the Third Party CMO to Manufacture in its own facilities Extract that meets SutroVax&#x2019; requirements, including any such information and know-how as would be needed for such CMO to scale up such Manufacture to the requested commercial volumes. To establish &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capacity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means that the CMO would take such actions as are necessary (including validation and if necessary adapting or reserving existing facilities, establishing new facilities and/or procuring necessary equipment) to Manufacture Extract meeting SutroVax&#x2019; requirements for Phase 3 and commercial supply in such quantities as SutroVax designates. It is understood that SutroVax may request that the Process Transfer and establishment of Capacity be undertaken in separate steps, for example by undertaking an initial Process Transfer to demonstrate the CMO&#x2019;s ability to Manufacture Extract, and then later establishing Capacity for Phase 3 and commercial supply, as requested by SutroVax in accordance with Section 2.15.1(a) (i.e., in separate requests).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:14.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Selection of Alternate Supplier</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The &#x201c;Alternate Supplier&#x201d; will be selected by Sutro, provided that Sutro must select an &#x201c;Alternate Supplier&#x201d; that is substantially similar to those CMOs identified on Schedule 2.15.1 hereto and provided further that SutroVax shall have the right to veto such selection based only on a genuine and material conflict of interest between SutroVax and the Alternate Supplier. Additional CMOs may be added to Schedule 2.15.1 by Sutro with SutroVax&#x2019;s approval (not to be withheld unreasonably).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:14.733%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Alternate Supplier as Subcontractor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. It is understood that the Alternate Supplier established under the Transfer Addendum shall operate as a subcontractor of Sutro under this Supply Agreement and the Phase 3/Commercial Supply Agreement, and as such SutroVax will order from Sutro thereunder any Extract to be Manufactured by such Alternate Supplier. Subject to the foregoing, the Transfer Addendum and the Phase 3/Commercial Supply Agreement will include reasonable and customary rights for SutroVax to conduct audits/inspections, site visits, quarterly meetings, each such audit/inspection, site visit and quarterly meeting to be coordinated by Sutro and to occur in the presence of a representative for Sutro and SutroVax, in connection with the Alternate Supplier&#x2019;s manufacture of Extract for supply to SutroVax. For clarity, SutroVax shall not conduct any business discussions for the supply of Extract with the Alternate Supplier in a manner that induces the Alternate Supplier to breach its agreement with Sutro. Notwithstanding the foregoing, in the event Sutro undergoes a Change of Control or Sutro permits any third party to acquire Extract directly from an Alternate Supplier established under the Transfer Addendum, then SutroVax shall thereafter have the right to establish a supply agreement with and obtain supply of Extract directly from such Alternate Supplier.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:14.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Quotations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Upon SutroVax&#x2019;s request (which request, for clarity, may be before a request to negotiate a Transfer Addendum), Sutro shall seek quotations from one or more Third Party CMO(s) for such a Process Transfer and/or establishment of such Capacity, in each case as requested by SutroVax, and the Parties shall reasonably cooperate to establish requests for quotations for such purposes.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:14.733%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Arbitration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. If the Parties have not agreed upon a Transfer Addendum within [***] after SutroVax&#x2019; request, upon SutroVax&#x2019; request by written notice to Sutro, the terms and conditions of the Transfer Addendum shall be determined by binding arbitration in accordance with the procedures set forth in Section 11.4. For clarity, however, it is understood that a Transfer Addendum shall not include any provision granting to SutroVax or its Affiliates or Sublicens.ee s any right to obtain or use any Sutro Core Know-How.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Source of Supply</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. It is understood that after the Alternate Supplier is qualified, SutroVax shall have the right under this Supply Agreement and the Phase 3/Commercial Supply Agreement to specify whether Extract ordered from Sutro pursuant to this Agreement or the Phase 3/Commercial Supply Agreement will be Manufactured at Sutro&#x2019;s Facility or at the Alternate Supplier&#x2019;s facilities (and to the extent Extract from the Alternate Supplier is ordered under this Supply Agreement or the Phase 3/Commercial Supply Agreement, the facility of the Alternate Supplier shall be deemed a Facility for purposes of this Supply Agreement and the Phase 3/Commercial Supply Agreement). Notwithstanding the foregoing, to the extent the FDA and EMA have confirmed that Extract manufactured at Sutro&#x2019;s Facility and the Alternate Supplier&#x2019;s Facility are interchangeable and can be supplied from either such Facility without any additional regulatory requirements or regulatory delay with respect to the applicable Vaccine Composition, and such Extract otherwise meets SutroVax&#x2019; requirements, then with SutroVax&#x2019; consent (not to be withheld unreasonably) Sutro may supply Extract from either Sutro&#x2019;s Facility or the Alternate Supplier&#x2019;s Facility.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. To the extent Sutro or its Affiliate Manufactures Extract supplied to SutroVax, the Price (per unit volume or unit weight) under this Supply Agreement and the Phase 3/Commercial Supply Agreement for such Extract shall not exceed [***] of the Fully Burdened Manufacturing Costs of such Extract; and to the extent the Extract to be supplied to SutroVax is Manufactured by a Third Party (including the Alternate Supplier), the Price to be charged to SutroVax under this Supply Agreement and the Phase 3/Commercial Supply Agreement for such Extract shall equal the amount Sutro paid such Third Party for such Extract (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OOP Cost</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) plus an amount reasonably calculated to cover Sutro&#x2019;s FTE costs to procure and manage the relationship with such Third Party, such amount not to exceed [***] of the OOP Cost for such Extract. To the extent that Sutro or its Affiliate receives any portion of the amounts paid to such Third Party to Manufacture Extract (e.g., as a profit share or otherwise), the Price to be charged SutroVax shall be the lesser of i) [***], or ii) [***]; in either case, [***]. For clarity, Section 3.4 of the License Agreement shall apply with respect to the Alternate Supplier.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro/Third Party use of Alternate Supplier</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Once the Alternate Supplier is qualified pursuant to this Section 2.15, SutroVax shall have the first right (as between SutroVax and Sutro or Third Parties supplied or authorized by Sutro) to obtain Extract Manufactured by the Alternate Supplier up to the Capacity established pursuant to the Transfer Addendum for a period ending the later of [***] or [***], and provided SutroVax commits to [***] or [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.16 Other Extracts.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> From time-to-time, subject to an agreed-upon Work Order, SutroVax may place purchase orders for quantities of research grade extract derived from strains of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. Coli</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> other than that set forth on Schedule 1 attached hereto (each an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Extract</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Sutro shall use Commercially Reasonable Efforts to accept such purchase orders (and shall accept such purchase orders placed consistent with an agreed-upon Work Order) and manufacture and supply to SutroVax such Other Extracts. For the purpose of calculating the Price for Other Extracts in accordance with this Section, the Price will be the cost of materials and Sutro&#x2019;s labor at an FTE rate of [***] per year for Sutro laboratory scientists. Upon Sutro&#x2019;s acceptance of a purchase order for Other Extract, such Other Extract in such purchase order shall be deemed Extract for purposes of Sections 2.1, 2.2, 2.3, 2.4.1 (solely with respect to the last two sentences thereof), 2.5, 2.6, 2.7, 2.8, 2.9.1 , 3.1, 4, 5, 6, 7 and 9.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.17 Manufacture of Custom Reagents.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> For clarity, SutroVax may Manufacture Custom Reagents itself or obtain supply thereof through a Third Party independent of this Supply Agreement and nothing in this Supply Agreement is intended to restrict SutroVax from doing so. Upon SutroVax&#x2019;s request, and subject to the remainder of the terms of this Section 2.17, Sutro shall (a) transfer to SutroVax or a contract manufacturer designated by SutroVax (which contract manufacturer is reasonably acceptable to Sutro, the approval of which shall not be unreasonably withheld, conditions or delayed by Sutro) as soon as reasonably practicable the process to Manufacture each Custom Reagent and the items of Sutro Know-How reasonably necessary for SutroVax or its</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designee to Manufacture each Custom Reagent, including cell lines, standard operating procedures, protocols, batch records, analytical method standard operating procedures and analytical method transfer protocols and (b) make Sutro Personnel reasonably available to SutroVax or its designee for scientific and technical explanations and on-site support that may reasonably be requested by SutroVax or its designee to Manufacture the Custom Reagents; provided however, that SutroVax shall fully reimburse Sutro for all documented time spent by Sutro&#x2019;s personnel to perform such transfer (on an FTE basis, each such FTE charged at an annual rate of [***]) and out-of-pocket costs incurred by Sutro in connection with all of the activities under the preceding sub-clauses (a) and (b), in accordance with a budget reasonably approved in advance by SutroVax. Upon such SutroVax request, Sutro and SutroVax shall, within [***] days, agree on a scope of work for such transfer, including scale, timeline, estimated budget, and required materials; both parties shall use reasonable efforts to complete the transfer as soon as reasonably practical. If requested by SutroVax (including if such request is prior to agreement on a scope of work), Sutro shall promptly transfer to SutroVax or its designee the cell lines, manufacturing instructions and analytical methods used for Manufacture of each Custom Reagent. For clarity, SutroVax shall have the right to enter into an agreement directly with such designee for the Manufacture and supply of Custom Reagents directly to SutroVax, its Affiliates, and any SutroVax CMO and, upon SutroVax&#x2019;s request, to the extent necessary, Sutro shall authorize such designee to enter into such agreement with SutroVax and perform such activities. For further clarity, Sutro shall not be responsible for any damages resulting from delay or failure in establishing the processes for Manufacture of Custom Reagents at SutroVax&#x2019;s designee resulting from action or inaction on the part of the designee or to the extent beyond Sutro&#x2019;s control. SutroVax shall have the right to obtain from such designee such items of Sutro Know-How transferred to such designee and use such items in connection with the exercise of its rights pursuant to the License Agreement, including for the Manufacture of Custom Reagents and the management of such designee. SutroVax shall use such Sutro Know-How transferred under this Section 2.17 (to the extent it is Discloser&#x2019;s Information of Sutro and does not meet one or more the criteria in clause (a) through (e) of Section 10.1 of the License Agreement) only for the Manufacture of Custom Reagents or otherwise within the scope of rights and licenses granted SutroVax in the License Agreement. In case of such a transfer to SutroVax or its designee, SutroVax will share with Sutro (i) the proposed process for manufacture of Custom Reagents through a Third Party so that Sutro may provide feedback and ensure that the process and Specifications are consistent with Sutro&#x2019;s process, and (ii) all regulatory submissions (including DMFs with respect to Custom Reagents) at least [***] days in advance of their intended date of submission to a Regulatory Authority in the Territory, and shall take into account Sutro&#x2019;s feedback to ensure alignment with Sutro&#x2019;s regulatory submissions and Regulatory Approvals with respect to Custom Reagents. Following completion of the transfer set forth above, Sutro shall provide reasonable support for the use of Third Party Custom Reagents in conjunction with Extract supplied by or on behalf of Sutro. In addition, Extract supplied by Sutro that conforms to the Required Standards when tested with Custom Reagents supplied by Sutro but not with Custom Reagents manufactured under this Section shall be deemed to conform to the Required Standards and SutroVax may not reject such Extract as a result of such non-conformance to the Required Standards when tested with Custom Reagents. SutroVax shall not prevent Sutro from separately contracting with the contract manufacturer for Manufacture of Custom Reagents for use on its own behalf or on behalf of other third parties.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.18 Sutro Core Know-How.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Notwithstanding anything to the contrary, except as set forth in Section 15.3 of the License Agreement, in no event shall SutroVax, its Affiliates or Sublicensees have the right to access any Sutro Core Know-How (as defined in the License Agreement), whether directly from Sutro or its Affiliates or through a CMO or otherwise, and SutroVax, its Affiliates and Sublicensees shall not require, request or solicit any CMO to deliver any Sutro Core Know-How to SutroVax, its Affiliates and/or its Sublicensees, and no agreement between any CMO and Sutro, its Affiliates and Subsidiaries shall contain any provision granting to SutroVax or its Affiliates or Sublicensees any right to obtain or use any Sutro Core Know-How. Without limiting the foregoing, in the event any item of Sutro Core Know-How is delivered to SutroVax, its Affiliates and/or its Sublicensees (except as set forth in Section 15.3 of the License Agreement), SutroVax, its Affiliates and Sublicensees shall immediately return such item to Sutro. Notwithstanding the foregoing, to the extent SutroVax or any of its Affiliates or Sublicensees is required by a Regulatory Authority (or Applicable Law) in the United States, Europe or Japan to confidentially disclose, as part of the applicable regulatory filings with respect to a Vaccine Composition, any Sutro Core Know-How (for clarity, excluding any tangible embodiments of such Sutro Core Know-How other than information and documentation), Sutro shall, upon SutroVax&#x2019;s written request, confidentially disclose such Sutro Core Know-How as part of the applicable regulatory filings, subject to the payment obligations set forth in Section 5.4 of the License Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.19 Express Rights.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Except as expressly set forth in this Supply Agreement, no rights or licenses are granted to SutroVax under this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.20 Extract Requirements.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> SutroVax agrees to purchase all its requirements of Extract from Sutro in accordance with this Agreement, except to the extent SutroVax is allowed to purchase Extract from (a) Alternate Suppliers engaged by Sutro in accordance with Section 2.15 of this Agreement; (b) a CMO engaged or established and authorized by Sutro under Section 3.l(d) of the License Agreement; or (c) a CMO authorized by Sutro under Section 3.l(e) of the License Agreement. Manufacturing of Extracts in breach of this Section 2.20 shall be deemed a material breach of this Agreement and the License Agreement by SutroVax.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PRICING AND PAYMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1 Invoices.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall invoice SutroVax at the time of each shipment of Product(s) for the Price for such shipment. SutroVax will pay such invoices within [***] days of receipt of invoice (including all required documentation) by SutroVax.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2 Prices.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Prices for the Products shall not exceed [***] of the Fully Burdened Manufacturing Costs of such Product at the time such Product is manufactured and shall be set forth in the applicable Work Order. Upon SutroVax&#x2019;s request from time-to-time, Sutro shall disclose to SutroVax the then-current Price for Product. The Price for the Products as of the Effective Date is set forth in Schedule 1.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3 Recordkeeping.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> During the Term and for [***] years thereafter, or for such longer period as may be required by Applicable Law, Sutro shall prepare and retain, and shall cause its subcontractors to prepare and retain, accurate books and records related to transactions made pursuant to this Supply Agreement and Prices. Such records shall be made available for reasonable review, audit and inspection upon reasonable notice and with reasonable frequency, upon SutroVax&#x2019;s request for the purpose of verifying Sutro&#x2019;s calculations of amounts due hereunder, the basis for such calculations (including Sutro&#x2019;s calculation of the Fully Burdened Manufacturing Costs) or payments and Sutro&#x2019;s compliance with the terms and conditions of this Supply Agreement. Audits and inspections may be conducted by SutroVax&#x2019;s own personnel or retained consultant(s), subject to the confidentiality obligations set forth in this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4 Taxes.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Prices are exclusive of all Taxes. SutroVax will pay all taxes and duties that are assessed by any national, federal, state or local governmental authority on SutroVax&#x2019;s purchase or use of the Products, including, without limitation, sales, use, excise, value-added and withholding taxes, but excluding any taxes based on Sutro&#x2019;s income or gross receipts (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Sutro will separately identify all such Taxes on Sutro&#x2019;s invoice.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 4</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PRODUCT TESTING</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1 Product Testing and Inspections.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Each shipment of Product shall be accompanied by a certificate of analysis describing all current requirements of the Specifications and results of tests performed on such Product and a certificate of conformity certifying that the quantities of Product supplied have been Manufactured, controlled and released according to the Required Standards (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COA/COC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) as set forth in the applicable Quality Agreement (subject to SutroVax&#x2019;s conduct of the SutroVax Activity Test to confirm Extract meets the SutroVax Activity Criteria). The COA/COC acceptance criteria for each Product shall be set forth in the Specification for such Product. Two of the tests and corresponding COA/COC acceptance criteria for the Extract shall be the performance of a productivity (Activity) test of the applicable Sutro protein (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Activity Test</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Activity Criteria</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and the performance of a productivity (activity) test of the applicable Vaccine Composition (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax Activity Test</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax Activity Criteria</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). Sutro shall perform the Sutro Activity Test to confirm that all shipments of Extract meet the Sutro Activity Criteria and SutroVax (or its designee) shall perform the SutroVax Activity Test to confirm that all shipments of Extract meet the SutroVax Activity Criteria. Sutro will also provide SutroVax with Material Safety Data Sheets (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MSDS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) or an equivalent instrument recognized by the applicable Regulatory Authority as required for the Product(s), and updates of the same as necessary.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2 Acceptance/Rejection of Non-Conforming Goods.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> SutroVax or its designee shall have a period of [***] calendar days from the date of delivery of the Product(s) in accordance with Section 2.6 and the COA/COCs or the equivalent instrument recognized by the applicable Regulatory Authority for such Product(s) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acceptance Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), to inspect any shipment of Product(s) and conduct the SutroVax Activity Test to determine whether such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shipment conforms to the Required Standards. If SutroVax determines that the Product(s) do not conform to the Required Standards, it hall notify Sutro within the Acceptance Period, and, if requested by Sutro, SutroVax shall ship a sample of such non-conforming Product(s) to Sutro at Sutro&#x2019;s expense. SutroVax&#x2019;s failure to notify Sutro of the non-conformity within the Acceptance Period will be deemed for purposes of this Supply Agreement to constitute SutroVax&#x2019;s acceptance of such shipment, provided, however, that such acceptance shall be subject to SutroVax&#x2019;s right to reject Product(s) until [***] days from the delivery date of the applicable Product, in each case, due to discovery by SutroVax or SutroVax&#x2019;s Affiliates or designees that the applicable Product does not conform to the Required Standards and such non-conformance could not reasonably be discovered within the Acceptance Period (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Latent Defects</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) provided that SutroVax gives Sutro with written notice of such Latent Defect within [***] days of SutroVax or any SutroVax Affiliate or designee becoming aware of such defect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3 Disputes Regarding Conformance to Required Standards.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> If Sutro does not agree with SutroVax&#x2019;s determination that Product fails to conform to the Required Standards, then Sutro shall so notify SutroVax in writing within [***] days of its receipt of SutroVax&#x2019;s notice of non-conformity with respect to such Product and (if requested) Product sample. Sutro and SutroVax shall use reasonable efforts to resolve such disagreement as promptly as possible.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Without limiting the foregoing, Sutro and SutroVax shall discuss in good faith mutually acceptable testing procedures pursuant to which both Sutro and SutroVax will re-test a sample of the disputed Product to determine whether such Product meets the Required Standards. Notwithstanding the foregoing, in the event that Sutro and SutroVax are unable to resolve such disagreement within [***] days of the date of the applicable rejection notice, either Party may submit a sample of the allegedly non-conforming Product for testing and a determination as to whether or not such Product conforms to the Required Standards to an independent testing organization, or to a consultant of recognized repute within the United States pharmaceutical industry, in either case mutually agreed upon by the Parties (such organization or consultant, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), the appointment of which shall not be unreasonably withheld or delayed by either Party. The determination of the Laboratory with respect to all or part of any shipment of Product shall be final and binding upon the Parties. The fees and expenses of the Laboratory making such determination shall be borne by Sutro, in the event that the Laboratory determines that the Product was non-conforming and by SutroVax, in the event that the Laboratory determines that the Product did conform to the Required Standards.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4 Return and Replacement of Non-Conforming Goods.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Product that is either rejected by SutroVax as not meeting the Required Standards, or that is determined by the Laboratory not to meet such Required Standards, shall, [***], be returned by SutroVax to Sutro, or destroyed pursuant to Applicable Law, at Sutro&#x2019;s reasonable expense. Sutro shall replace any non-conforming Product(s) within the shortest possible time. SutroVax shall have no responsibility to Sutro for the amounts invoiced for non-conforming Product(s), and shall be credited for any amounts paid, but shall pay Sutro the applicable Price for the replacement Product(s) under the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 5</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INSPECTION</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1 Right to Audit.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> During the Term and the [***] period thereafter, SutroVax or a SutroVax Affiliate may, during normal working hours and upon reasonable advance notice perform site audits and inspect, or request information relating to, Sutro&#x2019;s or its subcontractor&#x2019;s Facilities and records directly or indirectly involved in the performance of this Supply Agreement or related to the Product(s). Such requests should be made in writing and Sutro will allow for such audits or inspection to occur within [***] days from request (excepting for cause audits) for Sutro&#x2019;s Facilities and within [***] days&#x2019; from request (excepting for cause audits) for Sutro&#x2019;s subcontractor&#x2019;s facilities. Reasonable advance notice for audits for cause shall not require more than [***] advance notice. During such an inspection or request for information the inspectors may inquire about the progress of the work being carried out by Sutro or its subcontractor, and are in particular but not exclusively authorized to:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1.1 Inspect the Facilities, documents and equipment used, or to be used, in the Manufacture of the Product(s);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1.2 Verify the qualifications of the employees and subcontractors carrying out such work and their use of the relevant equipment;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1.3 Evaluate all scientific techniques used by Sutro, its subcontractors and their respective employees in the performance of this Supply Agreement and the procedures used in the creation and storage of samples of the Product(s), provided that nothing in this Section 5.1.3 shall require Sutroto disclose any Sutro Core Know-How;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1.4 Verify and evaluate information relating to the utilization of the Manufacturing capacity of Sutro&#x2019;s Facilities or its subcontractor&#x2019;s Facilities;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1.5 Review correspondence, reports, filings and other documents from Regulatory Authorities to the extent related to the Manufacturing activities hereunder;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1.6 Evaluate the implementation of all Manufacturing and process changes made with respect to the Product, including pursuant to any corrective action plan; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.1.7 Ascertain compliance with Applicable Laws, the Specifications and this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2 Access.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall provide SutroVax&#x2019;s and its Affiliate&#x2019;s and Sublicensee&#x2019;s inspectors with access to its Facilities, and information related to such Facilities, in order that the inspectors may carry out the inspections or inquiries referred to in the provisions of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. For the avoidance of doubt, neither SutroVax nor any of its Affiliates or Sublicensees (or their respective inspectors) shall have the right to observe the Manufacture of the Extract or be present at Sutro and its subcontractors&#x2019; Facilities at such times when Extract is being Manufactured. Sutro shall use Commercially Reasonable Efforts to obtain from its subcontractors commitments similar to those contemplated in this Section 5.2. Audits and inspections may be conducted by SutroVax&#x2019;s own personnel or retained consultant(s), subject to the confidentiality obligations set forth in this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3 Sutro Audits.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Without limiting the foregoing; Sutro is responsible for auditing the facilities of the suppliers of Components, if any, periodically, and Sutro agrees to provide SutroVax, upon SutroVax&#x2019;s request with a current copy of the audit report of such facilities and to incorporate SutroVax&#x2019;s comments with respect to any corrective action plan related to the Product.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 6</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REGULATORY AND QUALITY RESPONSIBILITIES</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1 Regulatory Responsibilities.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall obtain and maintain any and all regulatory and governmental permits, licenses and approvals that are necessary for Sutro to Manufacture the Product(s) for SutroVax or its Affiliates in accordance with the terms of this Supply Agreement and Applicable Law. As between the Parties, SutroVax shall have the sole responsibility for all Regulatory Approvals of the Vaccine Compositions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2 Right of Reference; Drug Master Files.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall (a) file Drug Master File(s) for the Products with the FDA as requested by SutroVax, and with Regulatory Authorities in the European Union (including the United Kingdom) and Japan in accordance with timelines to be mutually agreed upon (such agreement not to be unreasonably withheld by either Party) (provided at SutroVax&#x2019;s request, Sutro shall do so within [***] of SutroVax&#x2019;s request using Regulatory Filings that comprise versions of the DMF(s) filed with the FDA that have been reformatted to comply with EU and Japanese requirements), and (b) provide the appropriate authorizations to such Regulatory Authority(ies) allowing the Regulatory Authority the right to review and SutroVax or its designee to reference such Drug Master File(s) in support of (and other Regulatory Materials, to the extent necessary to support) an application for Regulatory Approval submitted by SutroVax (or its permitted designee) for any Vaccine Composition produced using the Product the subject of the applicable Drug Master File (it being understood that SutroVax, its Affiliates&middot; and Sublicensees shall not have access to the information contained in such Drug Master Files (or other confidential Regulatory Materials submitted for a similar purpose as a Drug Master File (e.g., a clinical trial application for such purpose in the European Union)) as a result of such authorization and right to reference). Sutro shall file such Drug Master File in coordination with SutroVax&#x2019;s efforts to file and prosecute the applicable regulatory filings to such Regulatory Authority and Sutro shall be responsible, at SutroVax&#x2019;s sole expense (subject to a budget reasonably approved in advance by SutroVax), for providing the applicable Regulatory Authorities with such additional data as they may request (which may in some cases require Sutro to conduct additional studies), and for correcting any deficiencies of such Drug Master File identified by such Regulatory Authority, in each case in a reasonably prompt and efficient manner so as to prevent any delay in obtaining</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory Approvals for any Vaccine Composition based on such Drug Master File. In addition, Sutro shall be responsible for maintaining such Drug Master File in accordance with applicable Laws as necessary to support filing and prosecuting the applicable regulatory filing(s) and obtaining and maintaining the applicable Regulatory Approval(s) for Vaccine Compositions produced using the Products. For further clarity, to the extent Sutro discloses. Sutro Know-How to SutroVax, SutroVax shall have the right to include (and authorize the inclusion of) such Sutro Know-How in Regulatory Materials to the extent it is necessary or useful for the purpose of obtaining Regulatory Approval of a Vaccine Composition. Sutro&#x2019;s obligations under this Section 6.2 shall [***]. Sutro shall cause its personnel to record time spent performing such activities to a job code specific to such activities. For purposes of this Article 6 &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Drug Master File</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DMF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a submission to a Regulatory Authority of information concerning the chemistry, manufacturing and controls (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CMC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) of the Products to permit such Regulatory Authority to review this information in support of any application for Regulatory Approval for a product submitted by a party that has been granted a right to reference such submission without disclosing the contents of such submission to such party. Sutro shall file DMF(s) for the Products with other Regulatory Authorities in the Territory in accordance with the terms and conditions of the Phase 3/Commercial Supply Agreement referenced in Section 2.14 (and, for clarity, shall file DMF(s) for the Products with Regulatory Authorities in the European Union (including the United Kingdom) and Japan as necessary to comply with the requirements of such Regulatory Authorities, to the extent not filed under this Supply Agreement).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Subject to the foregoing, Sutro shall provide the information set forth under this Section 6.2 in a timely manner and compliant with the reporting requirements of the Regulatory Authorities.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Safety Data</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Each Party understands and acknowledges that the other Party and its Affiliates and respective licensees or sublicensees may need to access and utilize and include certain safety data (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">e.g</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">., adverse event reports) pertaining to product made using Products that is generated or received by such Party and its Affiliates and respective licensees or sublicensees in its Regulatory Materials in its respective Territory as required by applicable Laws. Each Party shall have the right to share any and all such safety data generated by the other Party or the other Party&#x2019;s Affiliates or licensees or sublicensees with its Affiliates and Third Parties (including its licensees and sublicensees) as permitted under section 10.2 of the License Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cooperation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Each Party agrees to (i) make its personnel reasonably available at their respective places of employment to consult with the other Party on issues related to the activities conducted in accordance with this Article 6 or otherwise relating to the development of the Products or Vaccine Compositions and thereafter in connection with any request from any Regulatory Authority, including with respect to regulatory, scientific, technical and clinical testing issues, or otherwise, throughout the Term, and (ii) otherwise provide such assistance as may be reasonably requested by the other from time-to-time in connection with the activities to be conducted under this Article 6 or otherwise relating to the development of the Vaccine Compositions or Products.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3 Recalls.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Each of SutroVax and Sutro will immediately inform the other in writing if it believes one or more lots of any Product(s), or any products made by Sutro or its licensees using the Products (to the extent such products are made using Products from the same batch provided to SutroVax), or any Vaccine Compositions should be subject to recall from distribution, withdrawal or some other field action, or that potential adulteration, misbranding, and/or other issues have arisen that relate to the safety or efficacy of such Product. SutroVax shall have the final decision-making authority as to any such recall or field action and the sole right to initiate any such recall or field action with respect to Vaccine Compositions made using the Products. Sutro shall cooperate in the conduct of any recall or field action with respect to the Vaccine Compositions as reasonably requested by SutroVax. In the event it is determined that such a recall resulted from a breach by either Party of any of its representations, warranties, duties or obligations under this Supply Agreement, such Party shall be responsible for the costs of the recall and shall reimburse the other Party as necessary; provided that if both Parties share responsibility with respect to such recall, the costs shall be shared in the ratio of the Parties&#x2019; contributory responsibility.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4 Retention of Samples.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall prepare and retain, and shall cause its subcontractors to prepare and retain, such samples and records in respect of the Product(s) and the Manufacture thereof as are required by Applicable Law (including, as applicable, cGMPs).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5 Regulatory Authority Inspections and Correspondence.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall permit Regulatory Authorities to conduct such inspections of any Facility at which any of the Manufacturing activities relating to the Product(s) are performed, as such Regulatory Authorities may request, including pre-approval inspections,&middot; and shall cooperate with such Regulatory Authorities with respect to such inspections and any related matters, in each case that is related</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to the Manufacture of Product(s). Sutro shall give SutroVax or its Affiliates prior written notice of any such inspections, and shall keep SutroVax informed about the results and conclusions of each such regulatory inspection, including actions taken by Sutro to remedy conditions cited in such inspections. Sutro shall provide SutroVax with copies of any written inspection reports issued by anyRegulatory Authority and all correspondence between Sutro and any Regulatory Authority with respect thereto, including any notices of observation and all related correspondence, in each case relating to the Product(s) or its Manufacture or to general manufacturing concerns (e.g., facility compliance or the like) that are reasonably likely to impact the Product(s) to the extent such general manufacturing matters would be reasonably expected to have a material effect on the manufacture of Vaccine Compositions; provided that Sutro may redact from any such report and correspondence any Sutro Core Know-How and any information subject to an obligation of confidentiality to a Third Party. In addition, Sutro agrees to promptly notify and provide SutroVax copies of any material request, directive, or other written communication to or from Regulatory Authorities related to the Product or its Manufacture that would reasonably be expected to have a material effect on the manufacture of Vaccine Compositions (it being understood that SutroVax, its Affiliates and Sublicensees shall not have access to Sutro Core Know How (which Sutro may redact from such reports or correspondence provided to SutroVax) or Sutro&#x2019;s Drug Master Files or other confidential Regulatory Materials submitted for a similar purpose as a Drug Master File). Sutro shall provide SutroVax with a copy of the applicable portion of any correspondence made by Sutro to a Regulatory Authority for review and comment prior to submission to the applicable Regulatory Authority solely to the extent such correspondence made by Sutro is related to SutroVax or is in response to a request, directive or correspondence from the applicable Regulatory Authority regarding SutroVax or a Vaccine Composition (e.g., in response to a report regarding a pre-approval inspection for SutroVax). Sutro will consider in good faith any comments received from SutroVax within the time period indicated by Sutro (which shall not be less than [***], to the extent consistent with the require timeline for Sutro&#x2019;s response) with respect to any matter that relates to SutroVax. In addition, Sutro shall notify SutroVax of any occurrences or information that arise out of Sutro&#x2019;s Manufacturing activities that have, or could reasonably be expected to have, adverse regulatory compliance or reporting consequences concerning any Product(s) or which might otherwise be reasonably expected to adversely affect the supply by Sutro of Product(s) to SutroVax.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6 Changes or Modifications in Manufacturing Activities.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro shall not make any changes to the Specifications, processes, Facilities, raw materials, raw material suppliers or any other item that would affect the Manufacturing activities related to the Product (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing Change</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) that (a) would require a change to the applicable Drug Master File, (b) would be reasonably expected to cause SutroVax to be materially delayed obtaining any Regulatory Approval with respect to Vaccine Compositions or (c) causes the Product to not meet the Specification therefor (including the Activity Test with respect to Extract); without SutroVax&#x2019;s prior written consent (not to be unreasonably withheld, conditioned or delated). Notwithstanding the foregoing, Sutro shall promptly make and implement such changes as are required by Applicable Law provided that, prior to implementation, Sutro shall provide notice thereof to SutroVax and confer with SutroVax with respect to its timelines, estimated effect on Price and other issues regarding such implementation. Sutro shall provide SutroVax at least [***] days&#x2019; written notice prior to implementing any Manufacturing Change. Sutro shall not make any change to the Specification for a Product without SutroVax&#x2019;s prior written consent. In addition, SutroVax shall have the right to request changes in or modifications to the Specifications and Sutro will consider in good faith any such requested changes or modifications. All such changes or modifications shall be documented in writing and shall be signed by an authorized representative of SutroVax and Sutro. If such changes or modifications result in a material change in Sutro&#x2019;s Manufacturing costs or lead times, the Parties shall agree upon an appropriate adjustment to the Price or in the delivery schedules, as the case may be, for Product(s) to be provided by Sutro hereunder. Sutro shall promptly implement any agreed upon changes to the Specifications.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.7 Quality Agreement.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As soon as reasonably practicable after the Effective Date, the Parties shall enter into a quality agreement governing Sutro&#x2019;s supply of Products (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quality Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which Quality Agreement shall include the Specifications for the Product(s) consistent with the Specifications set forth in Schedule 2. Accordingly, to permit the Quality Agreement to be finalized within such period, Sutro shall provide SutroVax or its designee access to Sutro&#x2019;s Facilities and records to enable SutroVax or its designee to complete an audit pursuant to Section 5.1 within [***] days after the Effective Date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 7</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPRESENTATION AND WARRANTIES</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1 SutroVax Warranties and Representations.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> SutroVax represents and warrants the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1.1 SutroVax is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1.2 SutroVax has all requisite power and authority to enter into this Supply Agreement. The person signing this Supply Agreement has the necessary corporate authority to legally bind SutroVax to the terms set forth herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1.3 SutroVax&#x2019;s execution of this Supply Agreement and performance of the terms set forth herein will not cause SutroVax to be in conflict with or constitute a breach of its organizational documents nor any other agreement, court order, consent decree or other arrangement, whether written or oral, by which it is bound.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1.4 SutroVax&#x2019;s execution of this Supply Agreement and performance hereunder are in, and will be in, compliance with any Applicable Law in all material respects.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.1.5 This Supply Agreement is its legal, valid and binding obligation, enforceable against SutroVax in accordance with the terms and conditions hereof, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#x2019; rights generally or by the principles governing the availability of equitable remedies.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2 Sutro Warranties and Representations.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro represents and warrants the following:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.1 Sutro is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.2 Sutro has all requisite power and authority to enter into this Supply Agreement and has the requisite skill, knowledge, staffing, financial resources, capacity and ability to carry out its obligations hereunder. The person signing this Supply Agreement has the necessary authority to legally bind Sutro to the terms set forth herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.3 Sutro&#x2019;s execution of this Supply Agreement and performance of the terms set forth herein will not cause Sutro to be in conflict with or constitute a breach of its organizational documents nor any other agreement, court order, consent decree or other arrangement, whether written or oral, by which it is bound.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.4 Sutro&#x2019;s execution of this Supply Agreement and performance hereunder are in, and will be in, compliance with any Applicable Law in all material respects.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.5 Sutro has and will maintain throughout the Term all permits, licenses, registrations and other forms of governmental authorization. and approval as required by Applicable Law in order for Sutro to execute and deliver this Supply Agreement and to perform its obligations hereunder in accordance with all Applicable Law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.6 as of the Effective Date, to the best of Sutro&#x2019;s knowledge, the practice of the Sutro Platform, including the use of the Products, does not infringe any Third Party patents.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.7 7.2.7 Sutro is not debarred and Sutro has not and will not use in any capacity the services of any person debarred under subsection 306(a) or (b) of the U.S. Generic Drug Enforcement Act of 1992, or other Applicable Law, nor have debarment proceedings against Sutro or any of its employees or permitted subcontractors been commenced.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.8 This Supply Agreement is its legal, valid and binding obligation, enforceable against Sutro in accordance with the terms and conditions hereof, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#x2019; rights generally or by the principles governing the availability of equitable remedies.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.2.9 As of the Effective Date, there are no claims, judgments or settlements against or owed by Sutro or its Affiliates, or pending or, to the best of Sutro&#x2019;s knowledge, threatened claims or litigation, relating to the Product(s).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3 Product Warranties.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Sutro represents and warrants that:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3.1 Sutro&#x2019;s Facility and all Product (as delivered in accordance with Section 2.1 and until the expiration date thereof) supplied hereunder (and the Manufacture thereof) shall comply with this Supply Agreement,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">all Applicable Law (including cGMPs, if applicable),&middot;be free from defects in material and workmanship, and meet all Specifications.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3.2 Title to all Product(s) provided under this Supply Agreement shall pass to SutroVax as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2.6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, free and clear of any security interest, lien, or other encumbrance.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4 Disclaimer.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> EACH PARTY AGREES AND ACKNOWLEDGES THAT, EXCEPT AS SET FORTH IN THIS </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, IMPLIED OR STATUTORY, AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, IMPLIED OR STATUTORY, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AGAINST NON-INFRINGEMENT OR THE LIKE, OR ARISING FROM COURSE OF PERFORMANCE.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 8</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONFIDENTIALITY</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 10 of the License Agreement (Confidentiality) is hereby incorporated into this Supply Agreement by reference. The terms and provisions of this Supply Agreement (which shall be the Discloser&#x2019;s Information of both Parties) and all other information and data, including all notes, books, papers, diagrams, documents, reports, e-mail, memoranda, visual observations, oral communications and all other data or information in whatever form, that one Party or any of its Affiliates or representatives supplies or otherwise makes available to the other Party or its Affiliates or representatives pursuant to this Supply Agreement shall be deemed Discloser&#x2019;s Information pursuant to Article 10 of the License Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 9</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INDEMNIFICATION AND INSURANCE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1 Indemnification.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1.1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification by Sutro</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Sutro hereby agrees, at its sole cost and expense, to defend, hold harmless and indemnify, to the extent permitted by Applicable Law, (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnify</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) SutroVax and its Affiliates and their respective agents, directors, officers and employees of such Persons and the respective successors and assigns of any of the foregoing (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax Indemnitees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) from and against any and all liabilities, damages, penalties, fines, costs and expenses (including, reasonable attorneys&#x2019; fees and other expenses of litigation) (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liabilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) resulting from suits, claims, actions and demands, in each case brought by a Third Party (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-Party Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) against any SutroVax Indemnitee and arising from or occurring as a result of: [***]. Sutro&#x2019;s obligation to Indemnify the SutroVax Indemnitees pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 9.1.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall not apply to the extent that any such Liabilities are the result of a material breach by SutroVax of its obligations, representations, warranties or covenants under this Supply Agreement or the License Agreement or any SutroVax Indemnitee&#x2019; s negligence or willful misconduct.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1.2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification by SutroVax</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. SutroVax hereby agrees to Indemnify Sutro and its agents, directors, officers and employees and the respective successors and assigns of any of the foregoing (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro lndemnitees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) from and against any and all Liabilities resulting from Third-Party Claims against any Sutro Indemnitee arising from or occurring as a result of: [***]. SutroVax&#x2019;s obligation to Indemnify the Sutro Indemnitees pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 9.1.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall not apply to the extent that any such Liabilities are the result of a material breach by Sutro of its obligations, representations, warranties or covenants under this Supply Agreement or the License Agreement or any Sutro Indemnitee&#x2019;s negligence or willful misconduct.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.1.3 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Procedure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. To be eligible to be Indemnified hereunder, the indemnified Person shall provide the indemnifying Party with prompt written notice of the Third-Party Claim giving rise to the indemnification obligation pursuant to this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 9.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and the right to control the defense (with the reasonable cooperation of the indemnified Person) or settlement any such claim; provided, however, that the indemnifying Party shall not enter into any settlement that admits fault, wrongdoing or damages without the indemnified Person&#x2019;s written consent, such consent not to be unreasonably withheld or delayed. The indemnified Person shall have the right to join, but not to control, at</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">its own expense and with counsel of its choice, the defense of any claim or suit that has been assumed by the indemnifying Party.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.2 Insurance.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Each Party shall procure and maintain insurance, including clinical trials and product liability insurance, adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated at all times during which any Product or Vaccine Compositions is being clinically tested in human subjects or commercially distributed or sold by such Party. It is understood that such insurance shall not be construed to create a limit of either Party&#x2019;s liability or indemnification obligations under this Article 9, or that the maintenance of such insurance shall not be construed to relieve either Party of its other obligations under this Supply Agreement. Each Party shall provide the other with written evidence of such insurance upon request. Each Party shall provide the other with written notice at least [***] days prior to the cancellation, non renewal or material change in such insurance.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.3 LIMITATION OF LIABILITY.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> EXCEPT (I) WITH RESPECT TO ANY BREACH OF </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (CONFIDENTIALITY), (II) FOR THIRD PARTY PENALTIES, COSTS AND EXPENSES AS SET FORTH IN </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 2.9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, OR (III) FOR [***], TO THE MAXIMUM EXTENT PERMITTED BY LAW, (A) NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, OR ANY OTHER THEORY OR FORM OF ACTION, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY THEREOF; AND (B) EACH PARTY&#x2019;S TOTAL LIABILITY TO THE OTHER PARTY UNDER THIS SUPPLY AGREEMENT SHALL NOT EXCEED [***]. SUTRO&#x2019;S LIABITY TO SUTROVAX FOR THIRD PARTY PENALTIES, COSTS AND EXPENSES UNDER </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 2.9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> SHALL NOT EXCEED [***].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 10</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TERM AND TERMINATION</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1 Term.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The term of this Supply Agreement shall begin on the Effective Date first set forth above and shall remain in effect until the later of (a) July 31, 2021 or (b) the date that the Parties enter into the Phase 3/Commercial Supply Agreement and Sutro is supplying to SutroVax each Product under the Phase 3/Commercial Supply Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), unless it is terminated earlier in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 10.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2 Termination.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Notwithstanding anything to the contrary in this Supply Agreement, this Supply Agreement may be terminated:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2.1 in its entirety or with respect to one or more Products, on a Product-by-Product basis, by mutual written consent of Sutro and SutroVax;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2.2 in its entirety by a Party if the other Party materially breaches any of the material terms, conditions or agreements contained in this Supply Agreement to be kept, observed or performed by the other Party, by giving the Party who committed the breach [***] days&#x2019; prior written notice, unless the notified Party shall have cured the breach within such [***]-day period; and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2.3 in its entirety or with respect to one or more Products, on a Product-by-Product basis, by SutroVax upon [***] days&#x2019; prior written notice to Sutro for any reason.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3 Effects of Termination.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Upon the expiration of the Term or termination of this Supply Agreement, in its entirety or with respect to one or more Products, this Supply Agreement shall, except as otherwise provided in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 10.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 10.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, be of no further force or effect; provided, however, that (a) in the event this Supply Agreement is terminated by SutroVax pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 10.2.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and there are outstanding Work Orders or other purchase orders accepted by Sutro that would not be fulfilled as a result of such termination, SutroVax shall reimburse Sutro for all supplies and materials purchased by Sutro and time incurred by Sutro personnel (to the extent incurred solely for manufacture of Product for SutroVax) for the manufacture, or preparation for the manufacture, of Products for any Work Orders placed by SutroVax and any other purchase orders accepted by Sutro prior to such expiration or termination, in each case to the extent Sutro cannot otherwise reasonably mitigate such the costs and expenses of such supplies, materials and time (e.g., by use of resulting supplies, materials and work-in-progress Product for other purposes); provided that to the extent SutroVax pays for any supplies or materials, upon</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SutroVax&#x2019;s request Sutro shall promptly transfer and deliver such supplies and materials to SutroVax; and (b) if this Supply Agreement is terminated with respect to one or more Products, but not all Products, then this Supply Agreement shall continue in full force and effect with respect to the applicable Product(s) for which it is not terminated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4 Nonexclusive Remedy.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Exercise of any right of termination afforded to either Party under this Supply Agreement (i) shall not prejudice any other legal rights or remedies either Party have against the other in respect of any breach of the terms and conditions of this Supply Agreement, and (ii) shall be without any obligation or liability arising from such termination other than such obligations expressly arising from termination of this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5 Survival.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Expiration of the Term or termination of this Supply Agreement (for any reason) shall not affect any accrued rights or liabilities of either Party. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Product Testing), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Inspection), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Confidentiality), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Indemnification and Insurance), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Disputes), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Article 12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Miscellaneous), and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections 2.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Transfer of Product), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Phase 3/Commercial Supply Agreement), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.15</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Qualification of Alternate Supplier), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.17</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Manufacture of Custom Reagents), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Recordkeeping), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Taxes), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Right of Reference; Drug Master Files), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Recalls), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Retention of Samples), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Regulatory Authority Inspections and Correspondence), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Product Warranties), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Disclaimer), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Effects of Termination), </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Nonexclusive Remedy), and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (Survival) shall survive any expiration of the Term or termination of this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 11</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DISPUTE RESOLUTION</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.1 Principal Contacts.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Each Party will appoint an individual employed by it to serve as its &#x201c;Principal Contact&#x201d; for purposes of this Supply Agreement. Either Party may from time to time replace its Principal Contact with a different employee, but unless required due to events beyond its control, neither Party will replace its Principal Contact without at least [***] days prior notice to the other Party. The two Principal Contacts shall communicate with each other regularly during the Term as the Parties may agree or as the Principal Contacts shall mutually determine to be useful.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.2 Escalation.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The Parties intend that, to the maximum extent practicable, they shall reach decisions hereunder cooperatively through discussions among the Principal Contacts and by mutual consent of the Parties. In situations in which that does not occur, disputes or differences arising out of or in connection with this Supply Agreement shall initially be referred for review by the Parties&#x2019; respective Senior Managements (as defined below). Such Senior Managements shall discuss the proposed dispute or difference, and shall meet with respect thereto if either of them believes a meeting or meetings are likely to be useful. If the Senior Managements do not resolve the dispute or difference within [***] days (or such lesser or longer period as they may agree is a useful period for their discussions), then either Party may pursue its other available remedies, consistent with this Supply Agreement. As used herein, Sutro&#x2019;s &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Management</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means its then-current CEO, and SutroVax&#x2019;s &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Senior Management</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means its then-current CEO. For clarity, there shall be no obligation for any Disputed Matter arising out of Section 2.14 or 2.15 to be referred to the Senior Management to review prior to such matters being resolved by arbitration pursuant to Sections 11.3 and 11.4.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.3 Arbitration.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> If the Senior Managements are not able to resolve such dispute referred to them under Section 11.2 within such [***] day period, then such dispute shall be resolved by final and binding arbitration as follows: The Parties shall select a mutually agreeable arbitrator who has significant relevant experience in the subject matter of the disputed issue and no affiliation or pre-existing relationship with either Party. If the Parties cannot agree on an arbitrator within [***] days after the end of the [***] day period referred in Section 11.2 (or with respect to a Disputed Matter described in Section 11.4, after referral by a Party of such Disputed Matter to arbitration), either Party may request the Judicial and Mediation Services (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">JAMS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) in San Francisco, CA to appoint an arbitrator on behalf of the Parties in accordance with the commercial arbitration rules of JAMS, and the proceeding shall be conducted in accordance with JAMS rules. The arbitrator may decide any issue as to whether, or as to the extent to which, any dispute is subject to the arbitration and other dispute resolution provisions in this Supply Agreement. The arbitrator must base the award on the provisions of this Supply Agreement and must render the award in a writing which must include an explanation of the reasons for such award. Judgment upon the award rendered by the arbitrator may be entered by any court having jurisdiction thereof. The arbitrator&#x2019;s fees and expenses shall be shared equally by the Parties, unless the arbitrator in the award assesses such fees and expenses against one of the Parties or allocates such fees and expenses other than equally between the Parties. Each Party</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">shall bear and pay its own expenses incurred in connection with any dispute resolution under this Section 11.3. Notwithstanding the foregoing, either Party shall have the right, without waiving any right or remedy available to such Party under this Supply Agreement or otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such Party, pending the selection of the arbitrator hereunder or pending the arbitrator&#x2019;s decision of the dispute subject to arbitration.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.4 Baseball Arbitration.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In the event (a) the Parties do not enter into a Phase 3/Commercial Supply Agreement as described in Section 2.14 or (b) the Parties do not enter into a Transfer Addendum as described in Section 2.15 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disputed Matter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), then upon either Party&#x2019;s request with respect to the Disputed Matter in clause (a) or SutroVax&#x2019;s request with respect to the Disputed Matter in clause (b), such Disputed Matter shall be resolved by binding arbitration conducted pursuant to Section 11.3, except that the procedures for the conduct of such arbitration shall be as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.4.1 Each Party shall provide the arbitrator and the other Party with a written report setting forth its position with respect to the substance of such Disputed Matter and a full draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable, and may submit a revised report, position and draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable, to the arbitrator within [***] days of receiving the other Party&#x2019;s report and draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable. If so requested by the arbitrator, each Party shall make oral and/or other written submissions to the arbitrator in accordance with procedures to be established by the arbitrator; provided that other Party shall have the right to be present during any oral submissions. The arbitrator shall select one of the Party&#x2019;s draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable, as his or her decision, based on what is most reasonable and equitable to each of the Parties under the circumstances and reflective of reasonable and customary terms in the biopharmaceutical industry for agreements of this type and most closely reflects the Parties&#x2019; intent as expressed in this Supply Agreement and the License Agreement, and shall not have the authority to render any substantive decision other than to so select the draft Phase 3/Commercial Supply Agreement or Transfer Addendum, as applicable, of Sutro or SutroVax (as initially submitted, or as revised in accordance with the foregoing, as applicable). For clarity, it is understood that the Parties intend the arbitration under this Section 11.4 to be a &#x201c;baseball arbitration&#x201d; type proceeding; and the arbitrator may fashion such detailed procedures as the arbitrator considers appropriate to implement this intent. Notwithstanding anything to the contrary, in no event shall the Phase 3/Commercial Supply Agreement or Transfer Addendum contain any provision granting to SutroVax or its Affiliates or Sublicensees any right to obtain or use any Sutro Core Know-How.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:10.2%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.4.2 In any arbitration under this Section 11.4, the arbitrator and the Parties shall use their best efforts to resolve such Disputed Matter within [***] days after the selection of the arbitrator, or as soon thereafter as is practicable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ARTICLE 12</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">MISCELLANEOUS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.1 Expenses.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Except as otherwise expressly provided herein, each Party shall bear its own costs, fees and expenses incurred by such Party in connection with this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.2 Licenses and Permits.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Each Party shall, at its sole cost and expense, maintain in full force and affect all necessary licenses, permits, and other authorizations required by Applicable Law in order to carry out its duties and obligations hereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.3 Force Majeure.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No Party shall be liable for a failure or delay in performing any of its obligations under this Supply Agreement if, but only to the extent that such failure or delay is due to causes beyond the reasonable control of the affected Party, including: (a) acts of God; (b) fire, explosion, or unusually severe weather; (c) war, invasion, riot, terrorism, or other civil unrest; (d) governmental laws, orders, restrictions, actions, embargo or blockages; (e) national or regional emergency; (f) strikes or industrial disputes at a national level which directly impact the affected Party&#x2019;s performance under this Supply Agreement; or (g) other similar cause outside of the reasonable control of such Party (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Force Majeure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); provided that the Party affected shall promptly notify the other of the Force Majeure condition and shall use reasonable efforts to eliminate, cure or overcome any such causes and</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">resume performance of its obligations as soon as possible. If the performance of any obligation of a Party under this Supply Agreement is delayed owing to such a Force Majeure for any continuous period of more than [***] days, the other Party shall have the right to terminate this Supply Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.4 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Neither Party may assign or transfer this Supply Agreement, including by merger, operation of law, or otherwise, without the other Party&#x2019;s prior written consent (which shall not be withheld unreasonably) except each Party may assign this Supply Agreement without the other Party&#x2019;s consent in the case of assignment or transfer to a Third Party that succeeds to all or substantially all of the assigning Party&#x2019;s business and assets relating to the subject matter of this Supply Agreement, whether by sale, merger, operation of law or otherwise. Any attempted assignment by a Party in violation of this Section without the written consent of the other Party will be null and void. Except as above limited, this Supply Agreement is binding upon and will inure to the benefit of each of the Parties, its successors and assigns. Without limiting the foregoing, in the event that a Party is acquired, the acquiring Party shall agree in writing to abide by the terms of this Supply Agreement. Sutro agrees that if it assigns the License Agreement to any successor as allowed under section 15.1 of the License Agreement, it will also assign to such successor this Supply Agreement in accordance with this Section 12.4.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Supply Agreement incorporates the Exhibits referenced herein. This Supply Agreement, together with the License Agreement, constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, between the Parties hereto with respect to its subject matter. To the extent of any conflict between this Agreement and the License Agreement, the License Agreement shall govern and control.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All notices, requests or other communication provided for or permitted hereunder shall be given in writing and shall be hand delivered or sent by confirmed facsimile, reputable courier or by registered or certified mail, postage prepaid, return receipt requested, to the address set forth below, or to such other address of which either Party may inform the other in writing. Notices will be deemed delivered on the earliest of transmission by facsimile, actual receipt or [***] days after mailing as described herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to Sutro: Sutro Biopharma, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310 Utah Ave., Suite 150</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">South San Francisco, CA 94080</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attention: Chief Executive Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to SutroVax: SutroVax, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">353 Hatch Dr.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foster City, CA 94404</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attention: Chief Executive Officer</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.7 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Supply Agreement may be amended, modified or waived only in a writing signed by the Party or Parties to be bound thereby.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.8 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any provision of this Supply Agreement shall be held invalid, illegal or unenforceable, such provision shall be enforced to the maximum extent permitted by law and the Parties&#x2019; fundamental intentions hereunder, and the remaining provisions shall not be affected or impaired.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.9 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nothing herein contained shall constitute this a joint venture agreement and nothing herein shall constitute any Party as a partner, principal or agent of any other, this being an agreement between independent contracting entities. Except as expressly set forth herein, no Party shall have the authority to bind any other in any respect whatsoever to Third Parties. Except as provided herein, nothing contained in this Supply Agreement shall be construed as conferring any right on any Party to use any name, trade name, trademark or other designation of any other Party hereto, unless the express, written permission of such other Party has been obtained.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.10 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Supply Agreement has been submitted to the scrutiny of, and has been negotiated by, both Parties and their counsel, and shall be given a fair and reasonable interpretation in accordance with its terms, without consideration or weight being given to any such term&#x2019;s having been drafted by any Party or its counsel.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.11 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Supply Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California, without regard to any conflict of laws rules to the contrary.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.12 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each Party acknowledges that the other Party may likely suffer irreparable harm from such Party&#x2019;s breach or threatened breach of this Agreement and the other Party, in such cases, would therefore be entitled,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">without waiving any other right or remedy available to, to injunctive relief (including specific performance) without the requirement to post a bond, provided the waiver by such Party of the other Party&#x2019;s requirement to post a bond shall expire on the Change of Control of the other Party, and each party agrees that the arbitrator selected under Section 11.3 shall have the power to grant such injunctive relief (or order specific performance). The Parties shall comply with any such injunctive relief (including specific performance) ordered by the arbitrator and agree that such order may, to the extent not precluded by applicable law, be enforceable as a final award in any court of competent jurisdiction.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.13 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Supply Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile and other electronically scanned signatures shall have the same effect as their originals.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The remainder of this page is left intentionally blank</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Parties have caused this Supply Agreement to be executed by their respective duly authorized officers as of the Effective Date, each copy of which will for all purposes be deemed to be an original.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.816%;"></td>
    <td style="width:1.1%;"></td>
    <td style="width:37.618%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:10.705%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:34.744%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUTRO BIOPHARMA, INC.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUTROVAX, INC.</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ William J. Newell</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.75pt solid rgba(0,0,0,1);text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Grant E. Pickering</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">William J. Newell</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CEO</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President &amp; CEO</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCHEDULE 1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PRODUCTS AND PRICE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCHEDULE2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SPECIFICATIONS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">{6 pages omitted}</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCHEDULE3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INITIAL ORDER</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SCHEDULE 2.15.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPRESENTATIVE CMOS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to Supply Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Between</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Biopharma, Inc. and Vaxcyte, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Amendment No. 1 (&#x201c;Amendment&#x201d;) to the Supply Agreement is entered into this 22</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day of February, 2021 (&#x201c;Effective Date&#x201d;) between Sutro Biopharma, Inc. (&#x201c;Sutro&#x201d;) and Vaxcyte, Inc., formerly SutroVax, Inc. (&#x201c;VAX&#x201d;), (each herein referred to individually as a &#x201c;Party,&#x201d; or collectively as &#x201c;Parties).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	WHEREAS </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro and VAX have entered into a Supply Agreement effective as of May 29, 2018 (&#x201c;the Agreement&#x201d;),</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AND WHEREAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> the parties wish to amend the Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NOW THEREFORE</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, in consideration of the premises hereof and the mutual covenants and conditions hereinafter set forth and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties agree to amend the Agreement such the language in section 10.1(a) (Term) is deleted and replaced with &#x201c;July 31, 2022 or&#x201d;.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.601958220310592%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conflicts, Use of Terms. In the event of a conflict between the terms and conditions of the Agreement and the terms and conditions of this Amendment, the terms and conditions of this Amendment shall control.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.601958220310592%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Other Modifications. Except as provided above, the terms and conditions of the Agreement remain unchanged.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Parties have caused this Amendment to be duly executed as of the Effective Date.  The Parties agree that this Amendment may be signed in counterparts.</font></p>
  <p style="margin-left:7.507%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ACCEPTED AND ACKNOWLEDGED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc. 		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">				</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Biopharma, Inc.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.021%;"></td>
    <td style="width:49.979%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ Jane Wright-Mitchell</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: Jane Wright-Mitchell</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: General Counsel</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By: /s/ David Pauling</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: David Pauling</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: General Counsel</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>6
<FILENAME>pcvx-ex10_20.htm
<DESCRIPTION>EX-10.20
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 19, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><img src="img151100966_0.jpg" alt="img151100966_0.jpg" style="width:194px;height:52px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Biopharma, Inc.<br>111 Oyster Point Boulevard<br>South San Francisco, California 94080<br>Attention: William J. Newell, CEO, Sutro Biopharma, Inc.<br>[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Re: Option on Extract Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dear Mr. Newell:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The purpose of this letter agreement (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), dated as of December 19, 2022 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is to set forth certain terms and conditions between Vaxcyte, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and Sutro Biopharma, Inc. (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) (each of Vaxcyte and Sutro, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) with respect to (i) the Option (as defined below), and (ii) the grant from Sutro to Vaxcyte of certain rights and authorizations related to [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference is made to the Amended and Restated SutroVax Agreement, dated October 12, 2015, by and between Vaxcyte and Sutro, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), the Supply Agreement, dated May 29, 2018, by and between Vaxcyte and Sutro, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supply Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and the Key Process Transfer Terms regarding [***], by and between Vaxcyte and Sutro (the &#x201c;[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Term Sheet</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; and collectively with the other agreements, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Existing Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Any capitalized terms used in this Agreement but not defined herein have the meaning set forth in the applicable Existing Agreement.  Section 1.25 (Interpretation) of the Supply Agreement hereby is incorporated into (and shall apply to) this Agreement, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">mutatis mutandis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Sutro and Vaxcyte hereby agree to the following terms:</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the terms and conditions of this Agreement, Sutro hereby grants Vaxcyte an irrevocable (during the Option Period) option to obtain the Manufacturing Rights, as defined</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in the term sheet attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term Sheet</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; and such option, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), on the terms and conditions as set forth in the Term Sheet and, when finalized, the Definitive Agreement.  Vaxcyte may exercise the Option at any time following the Effective Date until and including the date that is five (5) years from the Effective Date of this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; as such period may be modified pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Negotiation of Definitive Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Promptly following the Effective Date, the Parties shall negotiate, in good faith and using reasonably diligent efforts, the terms and conditions of the form of definitive agreement to be entered into by the Parties in the event that Vaxcyte exercises the Option (such form, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form Definitive Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; and the executed version of such form, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definitive Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Vaxcyte shall be responsible for preparing the initial draft of the Form Definitive Agreement.  The Parties shall use good faith and reasonably diligent efforts to agree upon the Form Definitive Agreement within [***] following the Effective Date of this </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement Deadline</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that if the Parties are using good faith and reasonably diligent efforts to agree upon the Form Definitive Agreement, the Parties may (but shall not be obligated to) mutually agree in writing to extend the Agreement Deadline for an additional period agreed upon by the Parties.  In the event that the Parties have not mutually agreed upon the Form Definitive Agreement by the Agreement Deadline, the procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall apply.  For the avoidance of doubt, the Definitive Agreement shall include the terms and conditions set forth in the Term Sheet and such terms that are necessary to give effect to each of the terms and conditions set forth in the Term Sheet.  The Definitive Agreement shall also include such additional terms and conditions as the Parties, each acting reasonably, agree are customary for an arrangement of the type described in (and that are consistent in all respects with) the Term Sheet.  Within [***] after the Parties mutually agree in writing upon the Form Definitive Agreement (or, if the Parties do not so mutually agree, within [***] of an arbitration determination pursuant to the procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the Parties shall each execute the Form Definitive Agreement (and deliver such executed copy to the other Party), and the resulting Definitive Agreement shall be held in escrow by the Parties&#x2019; respective legal counsel pending Vaxcyte&#x2019;s exercise of the Option pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the foregoing escrow procedure shall not apply if the Parties execute the Form Definitive Agreement after Vaxcyte exercises the Option pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">further</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that for the avoidance of doubt, if the foregoing escrow procedure applies, the Definitive Agreement shall not be deemed effective until released from escrow under the terms and conditions of this Agreement, but shall automatically be deemed effective, without any further action by the Parties, once released from escrow.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upfront Consideration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  As consideration for the Option and the other rights and authorizations granted to Vaxcyte under this Agreement (including as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), Vaxcyte shall pay Sutro an irrevocable, non-refundable, non-creditable payment of twenty two and a half million dollars ($22,500,000) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Purchase Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), payable as follows: (i) within five (5) business days of execution of this Agreement, ten million dollars ($10,000,000) in cash, (ii) within seven (7) business days of execution of this Agreement, seven and a half million dollars ($7,500,000) (a) worth of shares of Vaxcyte common stock (the number of shares to be calculated based on the arithmetic average of the daily volume weighted average price of Vaxcyte common stock as traded on Nasdaq (as reported by Bloomberg L.P., or if not reported therein, in another authoritative source mutually selected by the Parties) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VWAP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) in the three (3) consecutive trading days immediately prior to the issuance thereof) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), [***] or Vaxcyte can otherwise provide such shares that are freely tradeable upon issuance, or (b) [***] and cannot otherwise provide such shares that are freely tradeable upon issuance, in cash, and (iii) within five (5) business days after the Parties mutually agree in writing upon the Form Definitive Agreement (or, if the Parties do not so mutually agree, within [***] of an arbitration determination pursuant to the procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), five million dollars ($5,000,000) in cash.  On or prior to the date of issuance of the Vaxcyte Common Stock (if any), Vaxcyte shall use Commercially Reasonable Efforts to register the issuance or resale of the Vaxcyte Common Stock pursuant to its existing Form S-3 registration statement or a new registration statement.  [***].</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Exercise; Execution of the Definitive Agreement; Exercise Price; Vaxcyte Acquisition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to the terms of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in respect of the consequences of a Termination Event (if and to the extent applicable), Vaxcyte may exercise the Option at any point during the Option Period by delivering a written notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Option Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to Sutro notifying Sutro that Vaxcyte has elected to exercise the Option.  The Option Notice shall be in writing and shall be sent to Sutro at the address and/or contact information for Sutro indicated at the top of this Agreement.  The Option Notice shall be deemed to have been delivered to Sutro: (i) when delivered by hand (with written confirmation of receipt); (ii) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (iii) on the date sent by email as a PDF document; or (iv) on the third day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid.  Notwithstanding anything in this Agreement to the contrary, Vaxcyte is under no obligation to exercise the Option, and the decision as to whether or not to exercise the Option shall be at Vaxcyte&#x2019;s sole and absolute discretion.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following receipt by Sutro of the Option Notice: (i) if the Definitive Agreement is held in escrow by the Parties&#x2019; respective legal counsel, it shall be deemed automatically released from escrow and effective immediately upon payment of the Exercise Price by Vaxcyte to Sutro, without any further action by the Parties; (ii) if the Form Definitive Agreement has been agreed in writing by the Parties (including pursuant to an arbitration determination pursuant to the procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) prior to the Option Notice but not yet executed, the Parties shall execute the Definitive Agreement as soon as reasonably practicable, and in any event, within [***] of the date of the Option Notice; and (iii) if the Form Definitive Agreement has not yet been agreed in writing by the Parties (or the Form Definitive Agreement has not been determined pursuant to an arbitration determination pursuant to the procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) as of the date on which the Option Notice is delivered to Sutro, the Parties shall meet (in person, telephonically or by means of videoconference) within [***] of the date of the Option Notice to agree upon a process and timeline to finalize the terms of the Definitive Agreement as soon as practicable and the Parties shall execute the Definitive Agreement as soon as reasonably practicable, and in any event within [***], after the terms of the Definitive Agreement has been agreed in writing by the Parties (or, if the Parties do not so mutually agree, within [***] of an arbitration determination pursuant to the procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).  For clarity, without limiting the generality of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, if the Form Definitive Agreement has not yet been agreed to in writing (including as of the date on which the Option Notice is delivered to Sutro), each Party shall at any point after the Agreement Deadline have the right to refer the finalization of the Definitive Agreement to arbitration pursuant to the procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Vaxcyte shall pay Sutro: (A) an irrevocable, non-refundable, non-creditable payment of [***] in cash, [***], either (x) if the foregoing clause (i) of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> applies, within [***] of the date of the Option Notice, or (y) if the foregoing clauses (ii) or (iii) of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 4(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> apply, upon [***] (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); and (B) an irrevocable, non-refundable, non-creditable payment of [***] in cash within [***] of the date of the Option Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delayed Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,&#x201d; and collectively with the Initial Exercise Price, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that in the event that a Change of Control ([***], hereinafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change of Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) occurs [***].</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that Vaxcyte undergoes a Change of Control at any point during the Option Period, [***].</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once the Definitive Agreement becomes effective (including, for clarity, by release from escrow), Vaxcyte shall pay Sutro the following amounts upon the occurrence of each of the following milestone events or acceleration events (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone Payments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;):</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A payment of [***] in cash upon [***]; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that:</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.8512312652391463%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the milestone event set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is achieved prior to the exercise of the Option by Vaxcyte, and Vaxcyte exercises the Option thereafter, the Milestone Payment set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall be deemed due and payable by Vaxcyte to Sutro [***];</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.8512312652391463%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the milestone event set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> has not been achieved prior to the exercise of the Option by Vaxcyte, [***];</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.8512312652391463%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If Vaxcyte undergoes a Change of Control [***]; and</font></div></div>
  <div style="margin-left:13.463%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:1.602%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:1.8512312652391463%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If Vaxcyte undergoes a Change of Control [***].</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the avoidance of doubt, Vaxcyte shall have no payment obligations to Sutro resulting from the milestone event set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless and until Vaxcyte exercises the Option; and</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A payment of [***] in cash upon [***].  If the milestone event set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is achieved prior to the exercise of the Option by Vaxcyte, and Vaxcyte exercises the Option thereafter, the Milestone Payment set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall be deemed due and payable by Vaxcyte to Sutro [***]; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that for the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">avoidance of doubt, Vaxcyte shall have no payment obligations to Sutro resulting from the milestone event set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless and until Vaxcyte exercises the Option.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the avoidance of doubt, in no event shall any Milestone Payments (or any other amounts due hereunder) be accelerated, except as expressly set forth herein.  For clarity, the Milestone Payments set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 5(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shall be payable one-time only (and only if such events have occurred), regardless of the number of times such events may occur.  Following the occurrence of each milestone event, Vaxcyte shall notify Sutro in writing within [***], and Vaxcyte shall pay the applicable Milestone Payment to Sutro within [***] after receipt of an invoice from Sutro with respect to such milestone event and Milestone Payment (for clarity, the foregoing shall not apply to any accelerated Milestone Payments in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sections 5(a)(i)-(iv)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which shall be due and payable as set forth therein).</font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any consideration payable pursuant to this Agreement is exclusive of VAT.  If any VAT is chargeable on any of the transactions contemplated under this Agreement and is payable to the respective tax authority by the Party making the supply or providing the service for VAT purposes, upon receipt of a valid invoice in accordance with the applicable VAT law from the supplying or service providing Party, the other Party shall pay such VAT in addition to the consideration otherwise due pursuant to this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte shall be entitled to deduct and withhold, or cause to be deducted and withheld, any amounts from any consideration payable pursuant to this Agreement as are required to be deducted and withheld under applicable law with respect to taxes and will secure and send to Sutro written evidence that such deducted and withheld amounts were paid over to the applicable taxing authority.  Vaxcyte and Sutro shall reasonably cooperate, and shall cause their respective affiliates to reasonably cooperate, in order to reduce or eliminate any amounts that would be required to be deducted and withheld on payments made pursuant to this Agreement under applicable law.  To the extent such amounts are so deducted or withheld and paid over to the applicable taxing authority, such amounts will be treated for all purposes of this Agreement as having been paid to the person to whom such amounts would otherwise have been paid.  Notwithstanding the foregoing, if, directly as a result of any assignment or transfer of this Agreement by Vaxcyte as a direct result of a (i) Change of Control of Vaxcyte, or (ii) redomicile, change in tax residence or similar corporate restructuring by Vaxcyte, the tax withholdings hereunder exceed the tax withholdings that would have resulted in the absence of such action, then Vaxcyte shall pay to Sutro such additional amounts as are necessary so that Sutro receives the amounts that it would have received if there had been no such action.</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrent with the execution of this Agreement, each of Vaxcyte and Sutro shall execute the letter agreement by and between Vaxcyte and Sutro, attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#x201c;[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Letter Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which [***] Letter Agreement shall be effective as of the Effective Date.  [***].</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that Vaxcyte or any of its affiliates, without the written consent of Sutro and prior to the exercise of the Option hereunder, intentionally or with gross negligence breaches in any material respect any of the following clauses (i) through (v): [***] (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); then Sutro may terminate the Option upon [***] prior written notice to Vaxcyte (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination Notice Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  [***], Vaxcyte shall have the right to exercise the Option during the Termination Notice Period, and if Vaxcyte exercises the Option during the Termination Notice Period, (A) Vaxcyte shall pay in cash to Sutro an irrevocable, non-refundable, non-creditable (except as expressly set forth herein) amount equal to the sum of [***], i.e., a payment of [***] in cash, within [***] of a receipt of invoice from Sutro therefor (provided that, for clarity, the foregoing shall be deemed [***], (B) (subject to (C) and (E) below) any violation of the foregoing clauses (i), (ii), (iii) or (iv) shall be deemed fully cured (other than to the extent such violation involves [***] (other than to the extent permitted under any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">subsequent agreement between Vaxcyte and Sutro or their respective affiliates or of any rights Vaxcyte would have under the Definitive Agreement), [***], (C) [***], (D) the termination of the Option by Sutro shall not be effective, and (E) Vaxcyte shall have no liability (including damages and losses) to Sutro (and Sutro shall have no remedies) in respect of such violation to the extent such violation was cured pursuant to (B); [***].</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.692662720527998%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that the Existing Agreements Tech Transfer (as defined in Section 4 of the [***] Letter Agreement) has not been Successfully Completed (as defined in the Term Sheet) within [***] of the Effective Date, and Vaxcyte exercises the Option following such failure but in no event later than [***] following the Effective Date, Sutro shall immediately commence and use Commercially Reasonable Efforts to conduct a Tech Transfer (as defined in the Term Sheet) to Vaxcyte (or an affiliate or Approved CMO designated by Vaxcyte), and notwithstanding anything to the contrary in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 7(c)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, shall [***].</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Arbitration of Definitive Agreement Disputes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  If the Form Definitive Agreement is not agreed to in writing by the Agreement Deadline in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, then the Parties agree that any disagreement relating to the content or form of the Form Definitive Agreement (each, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definitive Agreement Dispute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and any question of the arbitrator&#x2019;s jurisdiction over any Definitive Agreement Dispute or the existence, scope or validity of this arbitration provision or the arbitrability of any Definitive Agreement Dispute, shall be resolved by final and binding arbitration administered by the American Arbitration Association (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AAA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) in accordance with its Commercial Arbitration Rules in effect at the time (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rules</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), except as modified herein.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The seat of the arbitration shall be [***].</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When a Definitive Agreement Dispute arises, any Party shall initiate arbitration by delivering a written notice of such Definitive Agreement Dispute (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dispute Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to the other Party and AAA.  The Dispute Notice shall state that a Definitive Agreement Dispute has arisen with respect to the negotiation of the Form Definitive Agreement and shall include a copy of this Agreement.  The Dispute Notice shall not include any substantive submissions regarding the Form Definitive Agreement, which shall be reserved for the Parties&#x2019; submissions pursuant to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There shall be one arbitrator who shall be agreed upon by the Parties within [***] days of receipt by the respondent of the Dispute Notice.  If the Parties do not agree upon an arbitrator within this time limit, such arbitrator shall be appointed by AAA in accordance with the Rules.  Any arbitrator not selected by the agreement of the Parties must be a senior transactional attorney with at least fifteen (15) years of experience, including at least five (5) years of experience with pharmaceutical license, supply and manufacturing agreements.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On the day that is [***] following the confirmation of the appointment of the arbitrator by AAA, the Parties will submit a copy of this Agreement (including the Term Sheet) to the arbitrator, and each Party shall submit to both the arbitrator and the other Party its proposed language for the Form Definitive Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proposed Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  On the day that is [***] following the submission of the Proposed Terms, each Party shall submit to both the arbitrator and the other Party its memorandum in support of its Proposed Terms (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Supporting Memorandum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  On the day that is [***] following the submission the Supporting Memorandums, each Party shall submit to both the arbitrator and the other Party its memorandum in response to the other Party&#x2019;s Supporting Memorandum.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In any arbitration hereunder, any question of the arbitrator&#x2019;s jurisdiction over any Definitive Agreement Dispute or the existence, scope or validity of this arbitration provision or the arbitrability of any Definitive Agreement Dispute (each an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Arbitrability Dispute</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) shall be decided by the arbitrator appointed in such arbitration.  The arbitrator shall, in his or her own discretion, decide the procedures for the resolution of any Arbitrability Dispute, including the time </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="margin-left:6.667%;text-indent:0;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to decide such Arbitrability Dispute.  Should an Arbitrability Dispute arise, the arbitrator shall have the power to extend any time-periods in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> including, without limitation, the time-period for rendering an Award relating to a Definitive Agreement Dispute.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There shall be no discovery of any kind in connection with the arbitration.  Following the briefing in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the arbitrator, in his or her sole discretion, may request that the Parties provide additional information or documents that the arbitrator believes may be material and relevant to the resolution of the Definitive Agreement Dispute.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The arbitration award (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) will be based on the documents submitted (as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(f)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) and there shall be no oral hearing unless the arbitrator determines in his or her sole discretion that one is necessary.  Any hearing, if ordered, shall not [***].</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(e)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, within [***] from the date on which AAA confirms the appointment of the arbitrator, the arbitrator shall deliver his or her Award to the Parties in writing.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In rendering the Award, other than in respect of an Arbitrability Dispute, the arbitrator shall be limited to choosing, without modification, either the claimant&#x2019;s Proposed Terms (in its entirety) or the respondent&#x2019;s Proposed Terms (in its entirety), whichever proposal the arbitrator determines most accurately comports with the terms in the Term Sheet and this Agreement.  If the arbitrator determines that each Party&#x2019;s Proposed Terms equally comport with the terms in the Term Sheet and this Agreement, the arbitrator shall choose, without modification, that side&#x2019;s Proposed Terms that most closely aligns with customary industry practice.  [***].  The arbitrator shall not award any relief or damages of any kind except as set forth in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8(i)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(j)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any time limit in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> may be extended by the mutual agreement of the Parties or by the arbitrator in the arbitrator&#x2019;s sole discretion.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(k)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Award of the arbitrator shall be final and binding upon the Parties thereto and shall be the sole and exclusive remedy between the Parties regarding any Definitive Agreement Dispute presented to the arbitrator.  Judgment upon any Award may be entered in any court of competent jurisdiction.</font></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(l)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any arbitration hereunder shall be confidential and, except as may be required by law, the Parties agree not to disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Binding Effect</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  This Agreement is intended to be a binding and enforceable commitment and agreement of the Parties on the terms and subject to the conditions set forth herein, and can only be terminated as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Parties agree that irreparable damage may occur if any provision of this Agreement or the [***] Letter Agreement were not performed in accordance with the terms hereof or thereof and that, in addition to any other remedy to which the Parties are entitled at law or in equity, the Parties shall be entitled to seek equitable relief, including injunctive relief or specific performance of the terms hereof or thereof, in each case as permitted under applicable law.  Notwithstanding the generality of the foregoing, in the event that Vaxcyte exercises the Option in compliance with this Agreement (including payment terms), each Party shall be bound and obligated to enter into the Definitive Agreement or release the Definitive Agreement from escrow (as applicable) in accordance with the terms and conditions of this Agreement, in each case as permitted under applicable law, and each Party acknowledges and agrees that in such event, the other Party shall be entitled to specific enforcement of the other Party&#x2019;s obligation to enter into the Definitive Agreement without the necessity of proving the inadequacy of money damages as a remedy and without any requirement to post a bond or other security.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Publications</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">event that either Party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Announcing Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) proposes to make any public announcement or press release regarding this Agreement, the Definitive Agreement, or the transactions contemplated hereby or thereby, such Announcing Party shall first provide the other Party with an advance copy of each proposed publication or press release at least [***] prior to its proposed date of publication.  The Announcing Party shall reasonably consider in good faith any modifications to the publication or press release requested by the other Party.  Subject to the foregoing, each Party shall not issue any press release or other public statement, whether oral or written, disclosing the existence of this Agreement, the terms hereof or any other information relating to this Agreement without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that neither Party shall be required to obtain the consent of the Party prior to issuing any press release or other public statement to the extent such press release or other public statement contains information that has already been publicly disclosed by either Party in compliance with this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Notwithstanding anything to the contrary in this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, neither Party shall be required to obtain the consent of the other Party to make any disclosures required of it to comply with any duty of disclosure it may have pursuant to applicable law, governmental regulation or the rules of any recognized stock exchange; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the Party to make such required disclosure (i) shall reasonably cooperate with the other Party with respect to the timing, form and content of such required disclosure (including any reasonably requested redactions thereto), and (ii) if requested by such other Party, shall use Commercially Reasonable Efforts to obtain an order protecting to the maximum extent reasonably possible the confidentiality of the provisions of this Agreement.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement may not be terminated by either Party, except: (i) upon mutual written agreement by both Parties; (ii) upon written notice by Vaxcyte to Sutro that Vaxcyte has elected not to exercise the Option; (iii) upon expiration of the Option Period (unless Vaxcyte exercises the Option before the expiration of the Option Period); (iv) upon execution of the Definitive Agreement by both Parties or release of the Definitive Agreement from escrow (as applicable) following exercise of the Option by Vaxcyte; or (v) [***].  In the event of termination of this Agreement, each of the Parties shall be released from all obligations under this Agreement, except for any obligations accrued prior to the effective date of the termination (or that survive pursuant to the last sentence of this </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 11</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">).  Notwithstanding the foregoing, the following provisions shall survive the termination of this Agreement: [***].</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Representations &amp; Warranties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  Each Party represents and warrants to the other Party, as of the Effective Date of this Agreement, that: (i) it is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of formation; (ii) it has full corporate power and authority to execute, deliver and perform this Agreement, and has taken all corporate action required by law and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; (iii) this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms; (iv) all consents, approvals and authorizations from all governmental authorities or other third parties required to be obtained by it in connection with this Agreement have been or will be obtained; and (v) the execution and delivery of this Agreement, and the consummation of the transactions contemplated thereby, do not and shall not (x) conflict with or result in a breach of any provision of its organizational documents, (y) result in a breach of any other agreement to which it is a party, or (z) violate any appliable law.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties acknowledge that this Agreement contains certain terms and conditions that may be in conflict with the terms and conditions of the Existing Agreements.  In the event of any conflict between the terms and conditions of this Agreement and the terms and conditions of the Existing Agreements, the terms and conditions of this Agreement shall prevail.  Except to the extent expressly modified in this Agreement, the [***] Letter Agreement or another written agreement between the Parties, the terms and conditions of the Existing Agreements shall continue unmodified and in full force and effect; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the Parties acknowledge and agree that once the Parties mutually agree in writing upon the Form Definitive Agreement (or, if the Parties do not so mutually agree, upon an arbitration determination pursuant to the procedures set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">), the provisions in such Form Definitive Agreement governing the matters set forth in the [***] section of the Term Sheet shall become effective.  Each of the Parties shall be responsible for its own costs and expenses incurred in connection </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with entering into this Agreement, preparing the form of the Definitive Agreement, exercising the Option, and entering into the Definitive Agreement (if applicable).  Article 10 of the License Agreement (Confidentiality) shall apply to this Agreement, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">mutatis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">mutandis </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(and, for clarity, the terms of the [***] Letter Agreement shall be considered each Party&#x2019;s Discloser&#x2019;s Information (as defined in the License Agreement); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that unless and until Vaxcyte exercises the Option, Vaxcyte will not be allowed to disclose [***], except in accordance with Section 10.2 of the License Agreement).  Neither Party may assign or transfer this Agreement, in whole or in part, by operation of law or otherwise, without the prior written consent of the other Party (which shall not be unreasonably withheld, conditioned or delayed); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that each Party, without the other Party&#x2019;s consent, may assign or transfer this Agreement, in whole or in part, by operation of law or otherwise, to (i) one or more of its affiliates, or (ii) the successor to all or substantially all of the business or assets of such Party to which this Agreement relates (whether by sale, merger, operation of law or otherwise).  This Agreement shall not be amended or modified without the written consent of both Parties.  This Agreement shall be governed and construed in accordance with the laws of the State of Delaware, without regards to its conflict of laws principles.  The Parties agree to waive trial by jury.  Except for Definitive Agreement Disputes and Arbitrability Disputes, which are governed by </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Parties agree that any other disputes arising out of or relating to this Agreement shall be resolved by final and binding arbitration in accordance with the arbitration provisions set forth in Section 14 of the License Agreement, which hereby is incorporated into (and shall apply to) this Agreement, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">mutatis mutandis</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may be executed in one or more counterparts, all of which shall be considered an original, with the same effect as if the signatures were upon the same instrument, and shall become effective when one or more such counterparts have been signed by each Party and delivered (by facsimile, email or otherwise) to the other Party.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* * * * *</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">[End of page intentionally left blank]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Parties have caused this Agreement to be executed as of the Effective Date.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.714%;"></td>
    <td style="width:28.581%;"></td>
    <td style="width:35.704%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VAXCYTE, INC.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUTRO BIOPHARMA, INC.</font></p></td>
   </tr>
   <tr style="height:51.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Grant E. Pickering</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ William J. Newell</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: 	Grant E. Pickering</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: 	Chief Executive Officer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name: 	William J. Newell</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title: 	Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 1<br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Term Sheet</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 2<br>[***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Letter Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>7
<FILENAME>pcvx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">											Exhibit 23.1											</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement Nos. 333-257622 and 333-268954 on Form S-3ASR and Nos. 333-254824, 333-239135 and 333-263093 on Form S-8 of our reports dated February 27, 2023 relating to the financial statements of Vaxcyte, Inc. and the effectiveness of Vaxcyte, Inc.'s internal control over financial reporting, appearing in this Annual Report on Form 10-K of Vaxcyte, Inc. for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Deloitte &amp; Touche<br>San Francisco, California</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 27, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>8
<FILENAME>pcvx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Grant E. Pickering, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	I have reviewed this Annual Report on Form 10-K of Vaxcyte, Inc.;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.748%;"></td>
    <td style="width:1.015%;"></td>
    <td style="width:7.158%;"></td>
    <td style="width:46.079%;"></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:  February 27, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.013in;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Grant E. Pickering</font></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering</font></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>9
<FILENAME>pcvx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Andrew Guggenhime, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.	I have reviewed this Annual Report on Form 10-K of Vaxcyte, Inc.;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.	The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(c)	Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(d)	Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.	The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.759%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:5.641%;"></td>
    <td style="width:57.596%;"></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date:  February 27, 2023</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.013in;border-bottom:0.5pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Andrew Guggenhime</font></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Andrew Guggenhime</font></p></td>
   </tr>
   <tr style="height:10.1pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:bottom;padding-bottom:0.01in;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>10
<FILENAME>pcvx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering, Chief Executive Officer of Vaxcyte, Inc. (the &#x201c;Company&#x201d;), and Andrew Guggenhime, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Annual Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dated: February 27, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Grant E. Pickering	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                                             	               </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Andrew Guggenhime	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant E. Pickering		                                                         	Andrew Guggenhime</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Executive Officer		                                                 	President and Chief Financial Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Vaxcyte, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img70551829_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_0.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S-@  DI(
M @    ,S-@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$(!+X(&0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MC-JJ]K?V=]O^Q74%QY9P_E2!]OUQTILDEM?:5(ZRAK::$_O(SGY2.H_"N2\
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M.W/&?J?P-<GX&U34[GQ>UO?:A<W"K')E'F9ER#UP>*=M+BN>FT444AA1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY4XIV$]SV^BJ.C:E_:^CV]_Y7D^>N[9NW;><=<#TJ]4%!1110 4444 %%%%
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M3]0MYY#"S&$Q!>A))!R1CG///7VI*]M!DGA'4M0T7Q>V@W]RTL)9HMI8LJ,
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M-I=E)(YW,[VZ$L?4G%,_X1[1?^@18?\ @,G^%:-% "*H50J@!0,  =*6BB@
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MX]EO$D29SM10H_2GT44 49=#TF9]\VF6<C>KVZ$_RJW##%;Q+%!&D4:_=1%
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M_P"$>T7_ *!%A_X#)_A3T%J9W_">^&O^@E_Y D_^)H_X3WPU_P!!+_R!)_\
M$UH_\(]HO_0(L/\ P&3_  H_X1[1?^@18?\ @,G^%&@:F=_PGOAK_H)?^0)/
M_B:/^$]\-?\ 02_\@2?_ !-:/_"/:+_T"+#_ ,!D_P */^$>T7_H$6'_ (#)
M_A1H&IG?\)[X:_Z"7_D"3_XFC_A/?#7_ $$O_($G_P 36C_PCVB_] BP_P#
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M D_^)H_X3WPU_P!!+_R!)_\ $UH_\(]HO_0(L/\ P&3_  H_X1[1?^@18?\
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M3_XFC_A/?#7_ $$O_($G_P 36C_PCVB_] BP_P# 9/\ "C_A'M%_Z!%A_P"
MR?X4:!J9W_">^&O^@E_Y D_^)H_X3WPU_P!!+_R!)_\ $UH_\(]HO_0(L/\
MP&3_  H_X1[1?^@18?\ @,G^%&@:F=_PGOAK_H)?^0)/_B:/^$]\-?\ 02_\
M@2?_ !-:/_"/:+_T"+#_ ,!D_P */^$>T7_H$6'_ (#)_A1H&IG?\)[X:_Z"
M7_D"3_XFC_A/?#7_ $$O_($G_P 36C_PCVB_] BP_P# 9/\ "C_A'M%_Z!%A
M_P" R?X4:!J9W_">^&O^@E_Y D_^)H_X3WPU_P!!+_R!)_\ $UH_\(]HO_0(
ML/\ P&3_  H_X1[1?^@18?\ @,G^%&@:F=_PGOAK_H)?^0)/_B:/^$]\-?\
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M&IG?\)[X:_Z"7_D"3_XFC_A/?#7_ $$O_($G_P 36C_PCVB_] BP_P# 9/\
M"C_A'M%_Z!%A_P" R?X4:!J9W_">^&O^@E_Y D_^)H_X3WPU_P!!+_R!)_\
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M  &3_"C0-3._X3WPU_T$O_($G_Q-'_">^&O^@E_Y D_^)K1_X1[1?^@18?\
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MT$O_ "!)_P#$UH_\(]HO_0(L/_ 9/\*/^$>T7_H$6'_@,G^%&@:F>/'GALD
M:CDGH!!)_P#$TG_">^&O^@E_Y D_^)J]-X=TIK>06^F6,4I4A'%N@*MC@Y X
MYI__  CVB_\ 0(L/_ 9/\*- U,[_ (3WPU_T$O\ R!)_\31_PGOAK_H)?^0)
M/_B:T?\ A'M%_P"@18?^ R?X4?\ "/:+_P! BP_\!D_PHT#4SO\ A/?#7_02
M_P#($G_Q-'_">^&O^@E_Y D_^)K1_P"$>T7_ *!%A_X#)_A1_P (]HO_ $"+
M#_P&3_"C0-3._P"$]\-?]!+_ ,@2?_$T?\)[X:_Z"7_D"3_XFM'_ (1[1?\
MH$6'_@,G^%'_  CVB_\ 0(L/_ 9/\*- U,[_ (3WPU_T$O\ R!)_\31_PGOA
MK_H)?^0)/_B:T?\ A'M%_P"@18?^ R?X4?\ "/:+_P! BP_\!D_PHT#4SO\
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M$O\ R!)_\31_PGOAK_H)?^0)/_B:T?\ A'M%_P"@18?^ R?X4?\ "/:+_P!
MBP_\!D_PHT#4SO\ A/?#7_02_P#($G_Q-'_">^&O^@E_Y D_^)K1_P"$>T7_
M *!%A_X#)_A1_P (]HO_ $"+#_P&3_"C0-3._P"$]\-?]!+_ ,@2?_$T?\)[
MX:_Z"7_D"3_XFM'_ (1[1?\ H$6'_@,G^%'_  CVB_\ 0(L/_ 9/\*- U,[_
M (3WPU_T$O\ R!)_\31_PGOAK_H)?^0)/_B:T?\ A'M%_P"@18?^ R?X4?\
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M  &3_"C0-3._X3WPU_T$O_($G_Q-'_">^&O^@E_Y D_^)K1_X1[1?^@18?\
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M((X(@<A(D"J/P%2TAA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&S1XK&".7[ZQJK<YY
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHK$\0>*+30XS'_KKLKE(1V]V/85
M%2I&G'FF[(F4E%7D:MW>6]C;M/>3+#$O5F-<5K'Q )S%HL>.>9Y5_DO^/Y5R
MFJ:O>ZQ<>=?2E_[J#A5^@JE7@8C,ISTIZ+\3S:N+E+2&B)[N]N;^<S7D[S2'
MNYSCZ>E0445Y;;;NSB;;U84444@"BBB@ HHHH *D@N)K:42V\KQ..C(V#4=%
M--K8#K](\?W=MMBU6/[5'T\Q<"0?T/Z?6NZT_4K35+83V4RRJ0,@'E?8CL:\
M6JQ97]SIUTMQ9RM%(IR"._U'>O2P^85*>D]5^)UTL5*.DM4>UT5S7ASQA;ZO
MLM;O$%Z1T_AD^GO[5TM?04ZL*L>:#NCTX3C-7B%%%%:%A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4,$K237"MC$
M<@5<>FQ3_,FIJBBF\R2=<8\IPF?7Y5/]: ):*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ALY6
MGL8)7QNDC5CCU(S4U16TWVBTAF(V^8BOCTR,T 2T444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !116%XI\1#0K)1" ]W-D1J>BCNQ_SS45*D:<7.6R
M)E)07,RIXI\6KI&;2PVR7A'S$\B(>_O[?G[^;S327$S2SNTDCG+,QR2:2662
M>9Y9G9Y'.YF8Y)--KY7$XF=>5WMT1XU6K*H[O8****Y3$**** "BBB@ HHHH
M **** "BBB@ HHHH 56*L&4D$'((/2N^\*^,3<LEAJS@2\+%.?X_9O?W[_7K
MP% )!!!P1T-=%#$3H2YHFM.K*G*Z/<Z*\:_MS5O^@I>_^!#_ .-']N:M_P!!
M2]_\"'_QKU_[5A_*SN^NQ['LM%>-?VYJW_04O?\ P(?_ !H_MS5O^@I>?^!#
M_P"-']JP_E8?78]CV6BO&O[<U;_H*7G_ ($/_C1_;FK?]!2\_P# AO\ &C^U
M8?RL/KL>Q[+17C7]NZM_T%+S_P "&_QH_MW5O^@I>?\ @0W^-']JP_E8?78]
MCV6BO&_[=U;_ *"EY_X$-_C1_;NK?]!2\_\  AO\:/[5A_*P^NQ['LE%>-_V
M[JW_ $%+S_P(;_&C^W=6_P"@I>?^!#?XT?VK#^5A]=CV/9**\;_MW5O^@I>?
M^!#?XT?V[JW_ $%+S_O^W^-']JP_E8?78]CV2BO&_P"W=6_Z"=Y_W_;_ !H_
MMW5O^@G>?]_V_P :/[5A_*P^NQ['LE%>-_V[JW_03O/^_P"W^-']NZM_T$[S
M_O\ M_C1_:L/Y6'UV/8]DHKQO^W=6_Z"=Y_W_;_&C^W=6_Z"=Y_W_;_&C^U8
M?RL/KL>Q[)17C?\ ;NK?]!.\_P"_[?XT?V]JW_03O/\ O^W^-']JP_E8?78]
MCV2BO&_[=U;_ *"=Y_W_ &_QH_M[5_\ H)WG_?\ ;_&C^U8?RL/KL>Q[)17C
M?]O:O_T$[S_O^W^-']O:O_T$[S_O^W^-']JP_E8?78]CV2HXG1I)@BX9' <X
M^\=H.?R('X5X_P#V]J__ $$[S_O^W^-(-<U52Q74KL%CEB)FY.,>OL*/[5A_
M*P^NQ['LM%>-_P!O:O\ ]!.\_P"_[?XT?V]J_P#T$[S_ +_M_C1_:L/Y6'UV
M/8]DHKQO^WM7_P"@G>?]_P!O\:/[>U?_ *"=Y_W_ &_QH_M6'\K#Z['L>R45
MXY_;VK_]!.[_ ._[?XT?V_J__03N_P#O\W^-']JP_E8?78]CV.BO'/[?U?\
MZ"=W_P!_F_QH_M_5_P#H)W?_ '^;_&C^U8?RL/KL>Q['17CG]OZO_P!!.[_[
M_-_C1_;^K_\ 03N_^_S?XT?VK#^5A]=CV/8Z*\<_M_5_^@G=_P#?YO\ &C^W
M]7_Z"=W_ -_F_P :/[5I_P K#Z['L>QT5XY_;^K_ /03N_\ O\W^-']OZO\
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M7_?TT?\ "0ZQ_P!!.Z_[^FC^U:?\K#ZY'L>Q45X[_P )#K'_ $$[K_OZ:/\
MA(=8_P"@G=?]_31_:M/^5A]<CV/8J*\=_P"$BUC_ *"=U_W]-'_"1:Q_T$[K
M_OZ:/[5I_P K#ZY'L>Q45X]_PD6L?]!.Z_[^FC_A(M8_Z"=U_P!_31_:M/\
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MS_T$KG_OX:/^$CUG_H)7/_?PT?VK3_E8?7(=CV"BO'_^$CUG_H)7/_?PT?\
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M!<[ZBN7UV]U30=#@$FH>:\UR(Y=0>W7_ $=#WV+P>G^>*TM"-XRSM<ZO;ZK
M2ODS1(JD'G<#MX],4K :,\L431><!\SD*QQ\IVDY]N ?SJMINLZ?J_G?V;<B
M<0L%<JI !/N1S^%)JVG6>JV\5KJ 9HVE!"*Q&\@$X..V,UB>$(8[;6/$$,""
M.*.Z5451PH .!1T&;.I^(-+T>1(]1NUBDD&50*SL1ZX4$XX//M4NFZM8ZQ;F
M?3;A9XP<$@$$'W!Y%<MJ=W+H7CQ[NTA.I/>P!9+6$$S1!<<CK\IQ_GK4WA*[
MM?)UC7)[F*+[1())[=<_Z,%SPV0"2<GMSCBG;05SKZQ[WQ7HNGW#P75\JRQ\
M.J(S[?KM!Q43>*=-O=,U!])O5EGMK9YN$/RX!YP1SS6!X>U'4-(\+Q7-KX?D
MN86!FGN3<*KR'/+;>2?_ *U*P7.Y@FCN;>.>!@\4JAT8?Q C(-4[;7-.O-5G
MTVVN1)=VX)DC"-\N" ><8ZD=ZS-0U]9O#]HVA*6N=2'E6:%<;/[Q..FT9]>G
MI5+1]+BT?QU%9PG=LT;+R$8,C&;EC]318#KZ***0PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (V=!=1H5S(R,5;'0 KD9_
M$?E4E1-Y7VN/=_K=C;?]W*Y_7;4M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% %;4;^+3-.FN[@_)$I.,XW'L![D\5X_J6H3:IJ$MW<G+R-D#
M/"CL!["NE\?:R;B_738'/E0#,N#PSGM^ _4FN0KYS,,1[2I[-;+\SRL55YI<
MJV04445Y9QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 *C^7(K@
M*2I!PPR#]1WKU+0HM%UK2H[I-,L1)C;*@MU^1NXZ5Y970^#-9.EZRL,K8M[H
MA'S_  M_"?S./H:[L%6C3J6ELSHP]11G9[,]$_L/2?\ H%V7_@.G^%']AZ3_
M - NS_\  =/\*O45]-[.'9'K\L>Q0_L/2?\ H%V?_@.O^%']A:3_ - NS_\
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M^A1_PCNC_P#0,M?^_0K2HH]E3_E7W!R1[&;_ ,([H_\ T#+7_OT*/^$=T?\
MZ!EM_P!^Q6E11[*G_*ON#DCV,W_A'='_ .@9;?\ ?L4?\([H_P#T#+;_ +]B
MM*BCV5/^5?<')'L9O_".Z/\ ] VV_P"_8H_X1W1_^@;;?]^Q6E11[*G_ "K[
M@Y(]C-_X1W1_^@;;?]^Q1_PCNC_] VV_[]BM*BCV5/\ E7W!R1[&;_PCNC_]
M VV_[]BC_A'-'_Z!MM_W[%:5%'LJ?\J^X.2/8S?^$<T?_H&VW_?L4?\ ".:/
M_P! VV_[]BM*BCV5/^5?<')'L9,WAO1F@D!L+>,%3EP@&WCK4G_".:-_T#;;
M_OV*NW,/VBTFA!V^8C)G'3(Q4M'LJ?\ *ON#DCV,S_A'-&_Z!MM_W[%'_".:
M-_T#;;_OV*TZ*/94_P"5?<')'L9G_".:-_T#;;_OV*/^$<T;_H&VW_?L5IT4
M>RI_RK[@Y(]C,_X1S1O^@;;?]^Q1_P (YHW_ $#;;_OV*TZ*/94_Y5]P<D.Q
MF?\ ".:-_P! VV_[]BC_ (1O1O\ H&VW_?L5IT4>QI_RK[@Y(=C,_P"$;T;_
M *!MM_W[%'_"-Z-_T#;;_OV*TZ*/8T_Y5]P<D.QF?\(WHW_0-M_^^!1_PC>C
M?] VW_[X%:=%+V-/^5?<')#L>>>.]%M]/%I<V-ND,39C<(N!GJ/Z_E4GP\U)
M8[BXT^0@>;^\C]R.H_+!_"NQUC3(]7TJ:SEXWC*-_=8=#7DD\%WHVIF.3=!<
MP/D$'H>Q!]*\?$Q>%Q"K16C."LG1JJHEH>TT5Q^C>/;6>)(M7!@F'!E5<HWO
MQR*W_P#A(='V;O[3M<?]=1G\J]6GB:-2-XR1VQJPDKIFC7 ?$/4EDN+?3XR#
MY7[R3V)Z#\LG\:OZSX]M8(GBT@&>8\"5EPB^_/)KAH(+O6=3$<>Z>YG?))/4
M]R:\W'8N,X^QI:MG+B*RDN2&MSKOAS:-OO;P_=P(E]SU/]/SKNZHZ/ID>D:5
M#9Q<[!EV_O,>IJ]7HX6DZ-%0>YU48<D%$*YS7M%FUW7].AN8"VE6ZO)*PD"[
MG/ 7@[N, Y'K71T5T[&IR.M>![(:8\N@V[Q:C"RR0,+A^H(./F; _P <5)/9
M:Q::]!KEG8)<RW%HL5Y:^<J%&X/RDG'48ZGH:ZJBG<5CEM(L-8;QG+JVJ6D5
MO%-9>6JQRA_+.\$*?4X&<@8IL%KK>AZSJ9T_3$OK>^G\Y)3<+&(V/7<#R>3V
M]/>NKHHN%CDM(T34K7PGKME=PI]JNI+@Q!'&V3<@ (YX!/K@^M2:EI&I/X3T
M6.SA1[W37MYF@=P-S(N"N<XZGU[5U-%%PL8DUYKDEA%*-$A+,[)/9R7*EBF.
M"&^[]0:J>&M'N[35[_4)[./3(;D*J64<H< CJYQ\H_#U/X]-11<91U62XAAA
MEL[0WDR2Y2$2K'N^5@>6]B:Y[0DUVQUB^FN-"98]0N5=F^UQGR5Z$\'+8SFN
MJEA\R2!LX\IR^,=?E8?UJ6BX'*_8=7T3Q)J%[I^FIJ5O?E6SYZQR1D#D9;MG
M/'TJ?0=*OEUZ_P!9U*WBLWND5%MHWWD8ZEB.,\#I71T47%8BNH!=6<UNQP)H
MV0G&<9&*Y*VM_$NFZ"VB0:9%/M5HHKX7*JH4D\E.N0#79447&<];^"])_LNR
MM;^ W,EI&4$@D9.22S?=(XR35%/!-E'XL65+%AIRV@(;[0W$^_\ WMWW?PKK
MZ*+L5@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH C:-#=1R%OG5&4+GJ"5R?T'YU)430[KN.;/W$9,8ZY*G_V6I: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF?&&L7VE2Z4MA-Y0
MN+G9+\@;<O''(..M-:@=-1112 **** "BBB@ HKF/"5W<7.K>($N+B658;YD
MC61RP1=S<#/05T5W=165G+<W#;8H4+L?84P):*XVRO/%'B9&O=/N8=)L2<0!
MX@[R#U.0?\_G6[H9UM//@UX02&,KY-S"<>:#G.1V(X[#K^-%A&K1112&%%%%
M !117'>$9]4U'P-,T%ZS7[2.L4]RQ?:>.N<\4P.QHJMIJ7D6FP)J<J37:KB6
M2,85C[<#^5&I.T>DW;HQ5E@<JP."#M/-("S16#X*N)KOP?9374TDTK>9NDD8
MLQ_>,.2?:MZ@ HK)\2:Y_P (]I/VTV_V@>8J;-^WKGG.#Z5K4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !574[Y--TRXNY2 (D
M+#/<]A^)P*M5QOQ$OO+L+:R4\S.9&X[+T_4_I6&(J^RI2F9U9\D'(X"65YYG
MEE8O)(Q9F/<GDFFT45\>>$%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'KOAK5?[8T.&X8YE7]W+_ +P[_B,'\:UJ\^^'>H>7?7-@
MY^69/,3)_B7J!]0?_':]!KZW"5?:T5)[GMT)\]-,****ZC8**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H8(V2:X9NDD@9>>VQ1_
M,&IJA@\SSKCS,[?,&S/IL7I^.: )J*** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M0M&QOHI!]Q8W4\]R5Q_(U-4+>9]NBQGR_+?=Z9RN/ZU-0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?9O]/_YY>8O_ #WW=<XZ<]:H16N?!T,WAAM4NKVYEU);;[0LV_ 4A=P4#L.
M/P[=*NC7+R+X6C5#(6NO(V"0\G)?9N^O?ZUNR6DS>%6LPG[\V1BVY'WMF,9Z
M=:R[#P]-/\/4T74%\B=HF4C(;8V\LIXR#SBE<90TWP+;2:5;7@OKJ+4Y(UE^
MU+(3M8@'IW':L_0_^22ZE]9/Z5I68\9IIL>E?8[: (HB%_YJG:HXR%!Z@>W:
METKP_J-M\/K_ $N: )=R&3RT+K\V0,<@X&<4Q$5UJUQI?PKM)[9V6>2&.%)
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M_A8FD_\ /O>_]\)_\56%_P *[U;_ )^++_OM_P#XFC_A7>K?\_%E_P!]O_\
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M_P +$TG_ )][W_OA/_BJ/^%B:3_S[WO_ 'PG_P 56%_PKO5O^?BR_P"^W_\
MB:/^%=ZM_P _%E_WV_\ \31[;'_R_@'M,3V-W_A8FD_\^][_ -\)_P#%4?\
M"Q-)_P"?>]_[X3_XJL+_ (5WJW_/Q9?]]O\ _$T?\*[U;_GXLO\ OM__ (FC
MVV/_ )?P#VF)[&[_ ,+$TG_GWO?^^$_^*H_X6)I/_/O>_P#?"?\ Q587_"N]
M6_Y^++_OM_\ XFC_ (5WJW_/Q9?]]O\ _$T>VQ_\OX![3$]C=_X6)I/_ #[W
MO_?"?_%4?\+$TG_GWO?^^$_^*K"_X5WJW_/Q9?\ ?;__ !-'_"N]6_Y^++_O
MM_\ XFCVV/\ Y?P#VF)[&[_PL32?^?>]_P"^$_\ BJ/^%B:3_P ^][_WPG_Q
M587_  KO5O\ GXLO^^W_ /B:/^%=ZM_S\67_ 'V__P 31[;'_P OX![3$]C=
M_P"%B:3_ ,^][_WPG_Q5-7XA:2"Q^RW8R<Y")SQW^:L3_A7>K?\ /Q9?]]O_
M /$TQ/ &J.TBK<V>8VVM\[\' /\ =]"*/;8_^7\ ]IB>QT'_  L32?\ GWO?
M^^$_^*H_X6)I/_/O>_\ ?"?_ !587_"N]6_Y^++_ +[?_P")H_X5WJW_ #\6
M7_?;_P#Q-'ML?_+^ >TQ/8W?^%B:3_S[WO\ WPG_ ,51_P +$TG_ )][W_OA
M/_BJPO\ A7>K?\_%E_WV_P#\31_PKO5O^?BR_P"^W_\ B:/;8_\ E_ /:8GL
M;O\ PL32?^?>]_[X3_XJC_A8FD_\^][_ -\)_P#%5A?\*[U;_GXLO^^W_P#B
M:/\ A7>K?\_%E_WV_P#\31[;'_R_@'M,3V-W_A8FD_\ /O>_]\)_\51_PL32
M?^?>]_[X3_XJL+_A7>K?\_%E_P!]O_\ $T?\*[U;_GXLO^^W_P#B:/;8_P#E
M_ /:8GL;O_"Q-)_Y][W_ +X3_P"*H_X6)I/_ #[WO_?"?_%5A?\ "N]6_P"?
MBR_[[?\ ^)H_X5WJW_/Q9?\ ?;__ !-'ML?_ "_@'M,3V-W_ (6)I/\ S[WO
M_?"?_%4?\+$TG_GWO?\ OA/_ (JL+_A7>K?\_%E_WV__ ,31_P *[U;_ )^+
M+_OM_P#XFCVV/_E_ /:8GL;O_"Q-)_Y][W_OA/\ XJC_ (6)I/\ S[WO_?"?
M_%5A?\*[U;_GXLO^^W_^)H_X5WJW_/Q9?]]O_P#$T>VQ_P#+^ >TQ/8W?^%B
M:3_S[WO_ 'PG_P 51_PL32?^?>]_[X3_ .*K"_X5WJW_ #\67_?;_P#Q-'_"
MN]6_Y^++_OM__B:/;8_^7\ ]IB>QN_\ "Q-)_P"?>]_[X3_XJC_A8FD_\^][
M_P!\)_\ %5A?\*[U;_GXLO\ OM__ (FC_A7>K?\ /Q9?]]O_ /$T>VQ_\OX!
M[3$]C=_X6)I/_/O>_P#?"?\ Q5'_  L32?\ GWO?^^$_^*K"_P"%=ZM_S\67
M_?;_ /Q-'_"N]6_Y^++_ +[?_P")H]MC_P"7\ ]IB>QN_P#"Q-)_Y][W_OA/
M_BJ/^%B:3_S[WO\ WPG_ ,56%_PKO5O^?BR_[[?_ .)H_P"%=ZM_S\67_?;_
M /Q-'ML?_+^ >TQ/8W?^%B:3_P ^][_WPG_Q5'_"Q-)_Y][W_OA/_BJPO^%=
MZM_S\67_ 'V__P 31_PKO5O^?BR_[[?_ .)H]MC_ .7\ ]IB>QN_\+$TG_GW
MO?\ OA/_ (JC_A8FD_\ /O>_]\)_\56%_P *[U;_ )^++_OM_P#XFC_A7>K?
M\_%E_P!]O_\ $T>VQ_\ +^ >TQ/8W?\ A8FD_P#/O>_]\)_\51_PL32?^?>]
M_P"^$_\ BJPO^%=ZM_S\67_?;_\ Q-'_  KO5O\ GXLO^^W_ /B:/;8_^7\
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MO>_]\)_\51_PL32?^?>]_P"^$_\ BJPO^%=ZM_S\67_?;_\ Q-'_  KO5O\
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MH **** "BBB@ HHHH BED5)(%9=Q=RJG^Z=K'/Y C\:EJ.4QB2'S/O%SY?\
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M\.HM*BYU&2<::$WX;K_+;A?3G\*-T!H>$;JWT[1;WQ!J\ZV_]I73/N<]0"<
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M@ HHHH C98S=1L6_>!&"C/4$KG^0_.I*B:+-W'-N^XC+MQUR5.?_ !W]:EH
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M0NBT9D:46ICX#D8+9SZ\]*Z6BBD 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H8&D::X$F=JR
M)D=MBG^9-35##*TDUPK 8BD"C'IM4_UH FHHHH **** "BBB@ HHHH ****
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M*>9 "T<;, >F0,U-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!#.TBS6XCSM:0A\#ML8_P P
M*FJ&:5HYK=5 Q+(5.?3:Q_I4U !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $+-(+Z)!GRS&Y;
MCN"N.?Q-35"TK"]CA &UXW8GOD%1_P"S&IJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %1Q+&))C&<L7!D]CM'],5)4<4:I),RMDR.&(]#M Q^GZT 24444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5';+&MK$L!S$$ 0^HQQ4E1VT:PVL42-N5$"AO4 =: )****
M"BBB@ HHHH **** "BBB@ HHHH \Y\8>%WLKB34;%"UM(2TBJ/\ 5'U^G\JR
MM$\37^AY2!A) 3DPR=,^H]*];(#*0PR#P0>]<QJG@73KYS+:,UE(>H090_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS'_O-^='F/\ WF_.@"[15+S'_O-^='F/_>;\Z +M%4O,?^\WYT>8_P#>;\Z
M+M%4O,?^\WYT>8_]YOSH NT52\Q_[S?G1YC_ -YOSH NT52\Q_[S?G1YC_WF
M_.@"[15+S'_O-^='F/\ WF_.@"[15+S'_O-^='F/_>;\Z +M%4O,?^\WYT>8
M_P#>;\Z +M%4O,?^\WYT>8_]YOSH NT52\Q_[S?G1YC_ -YOSH NT52\Q_[S
M?G1YC_WF_.@"[15+S'_O-^='F/\ WF_.@"[15+S'_O-^='F/_>;\Z +M%4O,
M?^\WYT>8_P#>;\Z +M%4O,?^\WYT>8_]YOSH NT52\Q_[S?G1YC_ -YOSH N
MT52\Q_[S?G1YC_WF_.@"[15+S'_O-^='F/\ WF_.@"[15+S'_O-^='F/_>;\
MZ +M%4O,?^\WYT>8_P#>;\Z +M%4O,?^\WYT>8_]YOSH NT52\Q_[S?G1YC_
M -YOSH NT52\Q_[S?G1YC_WF_.@"[15+S'_O-^='F/\ WF_.@"[15+S'_O-^
M='F/_>;\Z +M%4O,?^\WYT>8_P#>;\Z +M%4O,?^\WYT>8_]YOSH NT52\Q_
M[S?G1YC_ -YOSH NT52\Q_[S?G1YC_WF_.@"[15+S'_O-^='F/\ WF_.@"[1
M5+S'_O-^='F/_>;\Z +M%4O,?^\WYT>8_P#>;\Z +M%4O,?^\WYT>8_]YOSH
M NT52\Q_[S?G1YC_ -YOSH NT52\Q_[S?G1YC_WF_.@"[15+S'_O-^='F/\
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MS'_O-^='F/\ WF_.@"[15+S'_O-^='F/_>;\Z +M%4O,?^\WYT>8_P#>;\Z
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M*I>8_P#>;\Z/,?\ O-^= %VBJ7F/_>;\Z/,?^\WYT 7:*I>8_P#>;\Z/,?\
MO-^= $\QD$UOY>=ID/F8';:W]<5-6;+<2)) H8XD<J>>VTG^E2^8_P#>;\Z
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MB@".XE\FVEE SL0MCUP*DID[HEO(\J[D5"67&<C'(I] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $<DOER1+C/F/M^GRD_TJ2F2.BR1!UR6?"G'0[2<_D#3Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** (S+BY2+'WD9L_0C_&I*8707"(5^<HQ#8Z $9'ZC\J?0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 6X/]2M25'!_J5J2@ HHHH **** "BBB@"A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<SX
ML\<:=X6B\N3_ $B^9<I;(>GNQ_A'\Z:BY.R*C"4WRQ1NZAJ-II5F]WJ-PEO
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M+J2XN9&EFE8N[L>6)ZFHJ]*G34$>]0H1HQLMPHHHK0Z HHHH **** "BBB@
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M "BBB@ HHHH *CMM_P!DA\W/F;%W9ZYQS4E1VSM):Q/)]]D!;COB@"2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ([G?\ 9)O*SYFQMN.N<<5)4=R[1VLKQ_?5"5X[XJ2@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@".7?YD&S.-YWX]-I_KBI*CE=EDA"]&<AN.VTG^8%24 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 1MO\ M<>,^7L;=Z9RN/ZU)4;.PNHT'W"C$\=P5Q_,
MU)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 6X/]2M25'!_J5J2@ HHHH **** "BBB@"A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+6M2
MCT?1+O4)3A;>)G&1G)[#\3@5=KSGXPZJ8-%L],C;#74IDD Q]U.@/U)!_P"
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M;T (X_4?E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\36&D7_V2\\Q7\CS@54$,,D!1SG<2/2HQXKL?[(_M"2*ZB3S?)6-XOG9L9X
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MN8'N'MTFC:9 "T8<%E'J1U%24 %%,GGAMH6FN94AB7[SR,%4=NII] !1110
M44C,J(6=@JJ,DDX %06VH65XQ6SNX+@@9(BE5L?D: +%%%% !1110 45 ]_9
MQW2VTEU EPV-L32 ,<],#K4] !1110 4444 %%%% !1110 4R QFWC,/$>P;
M/ICBGTR!42WC6([D" *<]1CB@!]%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,G,8MY#-S'L._Z
M8YI],G5'MY%E.U"A#'/08YI] !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)#'YD6_P"]O^3Z
M[3_3-/IDBH9(BYP5?*<]3M/],T^@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!A,?VA ?]9L;
M;],C/]*?3"J&X1B?G",%&>HR,_R%/H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** +<'^I6I*C@_U*U)0 444
M4 %%%% !1110!0HHHH **** "N7U/_DH^C?]<)/_ $%ZZBJ,^D6]QK5KJ;M(
M)[565 "-I!!'(Q[FF@,#5Q_PCGBNWUB/Y;*]/DW8'16[-_(_@?6L_13*/A??
MF#<'S)]WKCC/Z9KM-0T^WU2QDM+M-T4@P<=0>Q'N*@TG1K71]--C;[Y(226\
MXAB<]<\ 4[Z"L8.@Z=J\^@6<ECX@6"!HQMB6QC.SU&<\\YYZ^M:.G:-:Z!X=
MNK;4KE;BU9FDE9X]BA2 ", GT[>M,_X0ZRC9_L=[J%G%(<M#;W&U#^&*L2^&
M+*72$TWS;E+99/,=5DYE.<X8D=/IBBX'&^&#Y6O:<NJB7[*T;G31*00I+<<>
MO!_''M71>//^038_]?T?_H+5KZKH=GJ]C':3AHDB8-&T.%*8XXXX%+J>C6VK
MZ6+&],CHN") WSA@,;L],]>W>B^MPL2ZE;WES;*FGWWV&4."9/)$F1@\8/X<
M^U9<^CZK+I-_!>:K]O,UNRQ1_9TBP_;D?E5_2='AT>&1(9KB8R-N9YY-S>PK
M0I <OX1N;75/"G]F2G$D2/#/%G#!23S^1_.LV_T&QT+Q1H/]GJZ>=.V_<Y.<
M;<?S-;^H^$M,U"\-UB6VN&)+26[["Q]3U&:;8^$--LKU+MFN;JXC.4>XEW%3
M^&*=T!E>(([B?Q]IT4%XMFQMCY4KQK(%;+= W&3P*N77AC5+^2W:_P!?\X6\
MHE3%FJ,"/1@<BM?5M%LM:A1+U&W1G,<B-AD/&<'\!5.W\+6\-Y'<SWVH7CQ,
M&07-QN (Z=AWYHN%BA?1)+\3K#S$5PMEN&X9P07P:7Q2H'B+PZX&&^TE<]\9
M7BMJ32+>37HM69Y//BB\I5!&TCGMC.>3WI;_ $BWU&[LKB=I%>SD\R/80 3Q
MUXZ<47 YOQ!'<3^/M.B@O%LV-L?*E>-9 K9;H&XR>!5RZ\,:I?R6[7^O^<+>
M42IBS5&!'HP.16OJVBV6M0HEZC;HSF.1&PR'C.#^ JG;^%K>&\CN9[[4+QXF
M#(+FXW $=.P[\T7"Q0OHDE^)UAYB*X6RW#<,X(+X-:FO:TVD1VZ06_VBZNY!
M%"A;:NX^I_$5/)I%O)KT6K,\GGQ1>4J@C:1SVQG/)[TNKZ/::U9BWO5;"MN1
MT.&0^H-+0#D/%3:VUG8MK"Z<B&Z0HMN7\P'!X.>,>N.^*U?%O_(6\/?]?R_^
MA+4S>"]/E5/M%U?7$D979)-/N9 #G:,C 'X5I:SHEIKEJD%YO78V]'C(#*?8
MXIW06*GC+_D4;[_=7_T,5A:ZR#3_  LMU_QYEHS,"?E^ZN,_@6_6NA3PW:KH
M<^EM/<R13MN>220,^>.^,?PCM5F?1[.ZTA--NH_-@1%1=Q^8;1@'(Z&A.P$/
MB;R?^$7U#[2 4\AL9'\7\/\ X]BN3U577X66 E!#;D(R.V6Q^F*W(? VEQR1
MF:6[N8XSE89I<H/P %:FKZ-;:SIPLKEI(X@P8>40",=!R#1=("KXCMH8?!U[
M!%&J11P85%& ,=*F\,,6\+Z>6))\A1S5V^LXM0L9K2?=Y<R%&*G!&>XI+"RC
MTZPAM("S1PKM4N<DCWQ2Z 6****0PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH *^7+B8W%S+,WWI'+G\3FOJ.OEIU*.R,,,IP1[UUX;J>IE_VOE^HVBB
MBNP]0**** "O9/"8_P"$N^#=[HWWKFU#Q(,8R0?,C/'OQ^!KQNO0O@[K'V'Q
M;)I\C8CU"(J!_MIEE_3</QK*JKQNNAS8F+=/F6ZU,3X=Z.=9\<Z?$5)BMW^T
MRD$<!.1^!;:/QK:\?S/XK^*46DVC$K$T=DK)\X!SEVP/0L0?]W\NWT30X?!N
MJ^+M<FBS A+P849V;?,90?JRKC_9KC_A'8/J_C.]UN](D:U1I&<G!\V0D9P.
M.F_]/PSY[MS[(P=52E*JMDM/5GI=S_9NJQZGX.@"1^18(NU2,('#!1@=-N$/
M_ A7@6B:G<>%_%%O>[,36<Q$D9&>.5=?R)%>NZ18Z5:_$&?Q"/&VFW4EXSHU
MJK1@LK8"H").V$[<X]ZX7XI^'SIOC8R6D3,FICSD51DF0G#* .^<'_@532LG
MR]R,-RJ3I]&O^'.T\:^"T\9:CHNL:2P,5T5CN9$/_++!8/GD9 R/J5K ^+VM
MP(UEX7T]$6"Q"R2!1C8VTA%&.F%.?Q%=UH,EGX'T/0- U*XS=7CF-><@.V6/
MX;B%'NP]Z\J\=^'4T;XA,-0ED73]0G%QYX!)5'?Y^QR5Y]3C![TJ>LK/9;$X
M=WJ)-Z*]O,XRO0]$^(:Z)9Z?IOA3P_$\VQ!=/(I:6YDP-^W;SUS@G/&.!TJM
MJ>E?#B+2KJ32]?U*>]6)C!$\9"N^. ?W0XS[BH/#7Q-U;PSI<.FVMI9S6L;E
MCYBOO()R1D-@?E^=;2]];?H=<_WL=(W\GH=7\9[&P72M,OO(C@U&24H0N S)
MMR<^NT[1GMGWI_PPN/"UK<6-IIT;W.MW,#/<W#H<08&2@S^7R]>YZ5)\4-)L
M]6\&6WB=%FM[H)$VR1F.4DQ\A7.%(+ Y'ICTQR7PC_Y*!!_UPE_]!K)*]'T.
M:*4L*]7I<I?$S_DHVJ_[T?\ Z+6N4KJ_B9_R4;5?]Z/_ -%K7*5T0^!'=1_A
MQ]$%%%%6:A1110 5[!IOQ:T.TTJTMY[746DAA2-V$:$$A0">7KQ^NXL?A1KM
M_I]O>17-@B7$2RJLDCA@& (!&SKS6510:]\YL1&E)+VC.Q_X7%X?_P"?/4O^
M_4?_ ,71_P +B\/_ //GJ7_?J/\ ^+KE?^%.^(/^?S3?^_LG_P 11_PIWQ!_
MS^:;_P!_9/\ XBL.6CW.3V>$[G5?\+B\/_\ /GJ7_?J/_P"+H_X7%X?_ .?/
M4O\ OU'_ /%URO\ PIWQ!_S^:;_W]D_^(H_X4[X@_P"?S3?^_LG_ ,11RT>X
M>SPG<ZK_ (7%X?\ ^?/4O^_4?_Q='_"XO#__ #YZE_WZC_\ BZY7_A3OB#_G
M\TW_ +^R?_$4?\*=\0?\_FF_]_9/_B*.6CW#V>$[G5?\+B\/_P#/GJ7_ 'ZC
M_P#BZ/\ A<7A_P#Y\]2_[]1__%URO_"G?$'_ #^:;_W]D_\ B*/^%.^(/^?S
M3?\ O[)_\11RT>X>SPG<ZK_A<7A__GSU+_OU'_\ %T?\+B\/_P#/GJ7_ 'ZC
M_P#BZY7_ (4[X@_Y_--_[^R?_$4?\*=\0?\ /YIO_?V3_P"(HY:/</9X3N=5
M_P +B\/_ //GJ7_?J/\ ^+H_X7%X?_Y\]2_[]1__ !=<K_PIWQ!_S^:;_P!_
M9/\ XBC_ (4[X@_Y_--_[^R?_$4<M'N'L\)W.J_X7%X?_P"?/4O^_4?_ ,71
M_P +B\/_ //GJ7_?J/\ ^+KE?^%.^(/^?S3?^_LG_P 11_PIWQ!_S^:;_P!_
M9/\ XBCEH]P]GA.YU7_"XO#_ /SYZE_WZC_^+H_X7%X?_P"?/4O^_4?_ ,77
M*_\ "G?$'_/YIO\ W]D_^(H_X4[X@_Y_--_[^R?_ !%'+1[A[/"=SJO^%Q>'
M_P#GSU+_ +]1_P#Q='_"XO#_ /SYZE_WZC_^+KE?^%.^(/\ G\TW_O[)_P#$
M4?\ "G?$'_/YIO\ W]D_^(HY:/</9X3N=5_PN+P__P ^>I?]^H__ (NC_A<7
MA_\ Y\]2_P"_4?\ \77*_P#"G?$'_/YIO_?V3_XBC_A3OB#_ )_--_[^R?\
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M9,,Z;6Q^9J[J.IVFE6IN+^98D'0'JQ] .YIV M450T?6+?7+$W5FLBQARF)
M <C'H3ZU?I %%9S:W;)X@32'25;AX_,1B!L88/0YSV/;M6@S!5+,0 !DD]J
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M*BK(N$(P5HA1115%A1110 5]/V$!MM-MH& #10HA Z @ 5\Y^'+,ZAXFTVU
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M(?CMM)_GBI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (V#_ &J-AGRPC!N>^5QQ^=25&S.+
MN-1G848GCOE<?S-24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% %N#_4K4E1P?ZE:DH **** "BBB@ HHHH
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MN#A1_,_C7;5YU:7-,\'%3YZK\M HHHK$Y0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH S=1\.Z/JYW:CIMO._]]HQN_[Z'-8]O\/_
M  M]HG/]CQ_(X49DD(^Z#T+8[UU5,CD#R2J!CRWVD^OR@_UJE*2V9:J32LFR
M"QTRQTR+RM.LX+9/2*,+GZXZU:HHJ26V]6%%%% @HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CMI#-:Q2M@
M,Z!CCW%24R"036\<@&T.@8#TR* 'T444 %%%% !1110 4444 %%%% !1110
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MI*9($,D6\X8/E/<[3_3-/H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(_K4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% ##&#<))GYE1E ]<D?X4^HVC)NDER,*C*1]
M2O\ A4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!;@_P!2M25'!_J5J2@ HHHH **** "BBB@"A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKCBI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** (Y49I("O17);GMM(_F14E1REQ)#LSM+G?C
MTVG^N*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH C9&-W&X^X$8'GN2N/Y&I*C8O]JC SY>
MQMWURN/ZU)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 6X/]2M25'!_J5J2@ HHHH **** "BBB@"A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !4<]O#=0/!<Q)-$XP\<BAE8>A!ZU)10!PNM_"C1M1W
M2::[Z=,>@0;H^F/NGGMV/<UP>I_"_P 2:>Q,%O'?1 _?MY!G&>/E;!_+->[4
M5M&M.)UT\75AI>_J?,%U8W=C)LO;6:V?)&V:,H?UJO7U+)&DL925%=&X*L,@
MUE77A/P_>MNN-'LV;.2RPA2?J1C-;+$KJCJCCU]J)\WT5] 2?#GPI*^YM(4'
M_9FD4?D&H3X;^$XVRNDJ>/XIY#_-JKZQ#L:?7Z?9GS_4MO;3W<PBM89)I",A
M(T+$_@*^B+;P=X=M<>3HMGD="\0<C\6S6M!;06L>RVACA0<!8T"C]*EXE=$1
M+'KI$\'TOX;^)-29"UB;.)CR]T=F!_N_>[>E=SHGPBTRU6.76KB2]F!R8HSL
MB^G]X_F/I7H=%92KSD<E3&59Z+0AM;2WL;9;>S@C@A0?+'&H4#\!4U%%8'(%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5'%(7DG4XQ&X4?3:#_ %J2HXY?,DE7&/+?;]?E!_K0!)11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !4=M(9K2&1\;G16./4BI*CMY?.MHI2,;T#8],B@"2BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** ([F0PVDTB8W(C,,^H%25'<2^3;2R@9V(6QZX%24 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 1RR%)(%&,2.5/TVD_TJ2HY)?+DB7&?,?;]/E)_I4E !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% $;2$7<<8QM9&8_4%?\34E1F7%RD6/O(S9^A'^-24
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %N#_4K4E1P?ZE:DH **** "BBB@ HHHH H45;\B/^[^M'D1_P!W
M]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?UH J45;\B/^[^M'D1
M_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?UH J45;\B/^[^
MM'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?UH J45;\B
M/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?UH J4
M5;\B/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?U
MH J45;\B/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_
M '?UH J45;\B/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT
M>1'_ '?UH J45;\B/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_
M[OZT>1'_ '?UH J45;\B/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15
MOR(_[OZT>1'_ '?UH J45;\B/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@
M"I15OR(_[OZT>1'_ '?UH J45;\B/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\
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MY$?]W]: *E%6_(C_ +OZT>1'_=_6@"I15OR(_P"[^M'D1_W?UH J45;\B/\
MN_K1Y$?]W]: *E%6_(C_ +OZT>1'_=_6@"I15OR(_P"[^M'D1_W?UH J45;\
MB/\ N_K1Y$?]W]: *E%6_(C_ +OZT>1'_=_6@"I15OR(_P"[^M'D1_W?UH J
M45;\B/\ N_K1Y$?]W]: *E%6_(C_ +OZT>1'_=_6@"I15OR(_P"[^M'D1_W?
MUH J45;\B/\ N_K1Y$?]W]: *E%6_(C_ +OZT>1'_=_6@"I15OR(_P"[^M'D
M1_W?UH HR.BR1!UR6?"G'0[2<_D#3ZGEAMQ)#YB_,7_=\G[VT_TS4GD1_P!W
M]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?UH J45;\B/^[^M'D1
M_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?UH J45;\B/^[^
MM'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?UH J45;\B
M/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?UH J4
M5;\B/^[^M'D1_P!W]: *E%6_(C_N_K1Y$?\ =_6@"I15OR(_[OZT>1'_ '?U
MH J45;\B/^[^M'D1_P!W]: *)=!<(A7YRC$-CH 1D?J/RI]3M#;_ &I 5_>[
M&V\G[N5S_P"RU)Y$?]W]: *E%6_(C_N_K1Y$?]W]: *E%6_(C_N_K1Y$?]W]
M: *E%6_(C_N_K1Y$?]W]: *E%6_(C_N_K1Y$?]W]: *E%6_(C_N_K1Y$?]W]
M: *E%6_(C_N_K1Y$?]W]: *E%6_(C_N_K1Y$?]W]: *E%6_(C_N_K1Y$?]W]
M: *E%6_(C_N_K1Y$?]W]: *E%6_(C_N_K1Y$?]W]: *E%6_(C_N_K1Y$?]W]
M: *E%6_(C_N_K1Y$?]W]: *E%6_(C_N_K1Y$?]W]: "#_4K4E(JA5PO I: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH) !). .IK(O?%
M.CV)*R7BR.!G;%\_ZCBLZE6G25ZDDO4TITIU':";]#7HKBKKXB1AL6=@S#^]
M*^/T&?YUFR^/M5?_ %<=M$/9"3^IKS)YQ@X;2OZ(]"&58J6\;>K/1Z*\N;QI
MKK8Q>*OTA3^HI%\9ZZ&R;T-[&%/\*P_M["]I?<O\S?\ L7$=U^/^1ZE17FT7
MCW5XVRZV\H]&C(_D:T[?XB#I=Z>1_M12?T(_K6T,YP<]Y6]48SRG%1V5_1G;
M45AV?C#1KQ@OVGR&(SB<;?UZ?K6VKJZAD8,IZ$'(->G2K4JJO3DGZ'GU*-2D
M[3BT+1116ID%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5%$B)).4;<7<%QG[IVJ,?D ?QJ6HHH?+DG
M;.?-</C'3Y5']* ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *BMD2*TA2)MZ*BA6SG< .#4M
M16T/V>TAA)W>6BIG'7 Q0!+1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $5RB2VDR2ML1D8,V<;
M01R:EJ*YA^T6DT(.WS$9,XZ9&*EH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BE1'D@+MM*.
M2@S]X[6&/R)/X5+44L/F20-G'E.7QCK\K#^M2T %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 0WD;36,\<?WWC95Y[D5-4-YYAL9_(SYGEMLV]<XXJ:@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"&>-GFMV7I'(6;GML8?S(J:H9_,\ZW\O.WS#OQZ;&Z_CBIJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%=3&WLYI@,F.-G /? S4M !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,[NDUN$Z/(5?CML8_
MS J:HIIC'+ H&?-D*'V^5C_2I: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (6=Q?11C[C1NS
M<=P5Q_,U-433%;R.''#QL^?H5'_LU2T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 175S'9VDMQ.VV.)2S'V%>2ZUJ\VLZE)<RDA,D1)_<7L/
MKZUTWCW6"9$TJ!OE #S_ %ZJ/Z_B*XFOC<ZQKJ5/80>D=_7_ (!]9E.$5.G[
M:6[V]/\ @A1117SY[@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%BPO9M.OHKJV;;)&V1[CN#[&O7-,U"+5-.BNX.%D7E<YVGN/PKQNNH\$:Q]A
MU/[#,?W-T0%)/W7[?GT_*O;R?&NA6]E)^[+\&>/FN$]M2]I'XH_D>CT445]N
M?'A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %112*\DZJNTHX5C_>.U3G\B!^%2U'$8S)-Y?W@X\S_>VC^F* )**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *BMI%EM(9(UV*Z*RKZ CI4M1VQC-K$;?B(H-G^[CC]* )****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH BN9%BM)I)%WJB,S+Z@#I4M1W)C%K*;CF((=_^[CG]*DH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH BED5)(%9=Q=RJG^Z=K'/Y C\:EJ.4QB2'S/O%SY
M?^]M/],U)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!$TBB[CC*Y9D9@WH 5R/U'Y5+4;&/[
M5&&_UNQMO^[E<_KMJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>!&"C/4$KG^0_.I*B:+-W'-N^XC+MQUR5.?_ !W]:EH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KS3QU=FX\1&$'*V\:I@>I^8_S_2O2Z\?UN;[1
MKU]+U#3OCZ X'Z5\_GU3EP\8+J_R/<R6GS5W+LOS*%%%%?&GU@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 :WABZ^Q^);*0XPTGE
MG/\ M?+_ %KUFO$XI&AF26,X9&#*?0BO:T8.BL.C#(KZW(*EZ<Z?9I_?_P ,
M?+YY"TX3[JWW?\.+1117TI\^%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %8NN^)[/1!Y; SW)&1"IZ>Y/:I/$FLC1=):9,&>0[(E/KZ_A
M7F%O;W>KZD(X@TUQ.Q))/4]R37AYEF,J#5&BKS?X?\$]C+\!&LG5JZ17X_\
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M10 4444 %0VD3064$+D%HXU4D=,@8J:H;19$LH%GSYHC4/DY.<<\T 34444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!#=Q-/93PH0&DC903TR1BIJANUD>RG6#/FF-@F#@YQQS4U
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M: -:BL_2]>TS6@YTR[6<Q_>&TJ1^! -:% !17*^.YGGLK+1H&VRZG<K&3V"
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MR!FIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]I"T"[8BBE!Z#'% $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 1W,H@M99BNX1H6*^N!G%25%
M<M&EI,TZ[H@C%QZC'-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 1RRB.2%2N?,<J#Z?*3G
M]*DJ*5HQ) )%RS.0A]#M;^F:EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C:4"ZCAV\LC-N
M],%1C_Q[]*DJ)FC%W&I7]Z48J?097/\ ,5+0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%4M3UC3]&A674KE8%<X7()+?0#DT 7:*SM+U_2]9
MW#3;Q)V499,%6 ]<$ XK1H **** "BBB@ HHHH **IW6K65E?6UG=3>7/='$
M*E&PY],XQGD=^XJY0 454L]5LK^ZNK>TF\R6T?9, I&QN>,D8/0]*MT %%%%
M !115>_O[;3+*2[OI/*@CQO?!.,G X'/4B@"Q52TTNSL;NZN;6'9-=L&G;<3
MO(SC@G ZGI4\$\=U;17$#;XI4#HV.JD9!J2@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@OB'9E;RTO /E=#$Q
MZ$'(_F?RKO:Q_%6G'4O#T\<:[I8\2QCW'7],C\:\_,:#KX6<5ONOD=V K>QQ
M,9/;;[SRBBBBOST^Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!$PC^UQDG][L8*/\
M9RN?Z5+4;1J;J.4M\RHRA?4$KS^@_.I* "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH *BM(C;V<,+$$QQJI([X&*EJ&S1XK&".7[ZQJK<YY YH FHHHH
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M*B[!$_S#'H<YS^-9(\#>'!)YG]F+GT\U\?ENQ6_13NP&HB11K'&JHB@*JJ,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]>W4Y[PYX3GU9DN;L&&RSG)X:3Z>WO7I%O;Q6END%M&L<48PJKT J0    8
MZ"BOM<%@:6$A:.K>[/D<7C*F*E>6BZ(****[SB"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HHIO,DG7&/*<)GU^5
M3_6I:CB=&DF"+AD<!SC[QV@Y_(@?A0!)1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45M-]HM(
M9B-OF(KX],C-2U';.DEK$\*[(V0%%QC QP,4 24444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<
MS?9[2:8#=Y:,^/7 S4M1W+I':RO,N^-4)=<9R,<C%24 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?T6C[2_HM %FBJWVE_1:/M+^BT 6:*K?:7]%H^TOZ+0!9HJM]I?T6C[2_HM
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M?H!71'"5Y;1.&IF.$IZ.:^6OY'945P+^/=0/W+:V'/<,?ZTT>/-3SS;VF/\
M<;_XJM?J%?L<_P#;&$[O[CT"BN&C\?W((\VQB;UVN5_QJ_;^/;)R!<VLT.>Z
MD.!_*HE@Z\?LFL,TPD].>WJF=516=9^(-+OL>1>1AB/N.=I_(UHUS2C*+M)6
M.^%2%17@[KR"BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHILLJ0Q-)*X1$&69C@ 4!>VK'5G:IKUA
MI"'[3*#+CB%.6/X=OQKF==\:.Y>VT<[$Z-<$<G_=';Z_RKD7=I'+R,79CDLQ
MR37J4, Y>]4T78^?QF<QIMPH:OOT_P""='J7C:_NPR6:K:1GNIW/^?;\!7/3
M32W$ADGD>5SU9V))_$U'17K4Z4*:M!6/FJV(K5W>I*X4445J<X4444 %%%%
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M=1<HA7YF1B&] "./U'Y5)0 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% !1110 4444 6X/]2M25'!_J5J2@ HHHH
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MEF 75+(DG  N$Y_6I(M2M)M2FL(Y=US H:2/:?E! (YQCN* +5%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGG0?:O)\S?\ N?,QG=C^'/?'I0!/1114C"BBB@ HHHH **** "BBB@ HHHH
M**** "N7\=W1BTF&V'6>3)Y[+_\ 7(KJ*X'Q[-NU>WA[1PY_$D_X"NS!1YJZ
M\CS,UJ<F$E;KH<M1117T9\*%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %O2[K[%JMM<\XCE4M@XXSS^E>N5XQ7KNES&YTBTF8Y+P
MHQ^N!FO'S*/PR/I\BJ?'3]&6J***\@^F"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "J&JZU9Z/"'NY/F8?)&HRS?A1K6JQZ/IKW+@,WW8
MTS]YCV_K7F,LMWJ^H[FWSW,S8 '))] /2N["X7VWO2TBCR,PS#ZM:G35YO\
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M4R20))$I&?,?:#Z?*3_2GT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 1M(1=1Q<;61F/X%?\
M:DIAD N$CQRR,V?3!'^-/H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %%%% !1110 5YMXR??XFG']Q$'_CH/\ 6O2:\R\7?\C5>?\  /\
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M9>:'J*:;9V\5S9GEHX55L@!B..3D''UKA-#O+:QUB&6^MXI[8G;*LJ;@%/\
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M&)_Y]?F>G?VQIG_01M/^_P"O^-']L:;_ -!"T_[_ *_XUYC_ &/J?_0.N_\
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M$32JY8X"G\?K0P1-XIOK?4? 5U=64GF0R;-K;2,XE4'@\]14NN>*(M)U6TM
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,G9$MY&E&Y
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ME=O,;!]0<#\:ZF,LT:F1=CD LN<X/IGO1:PRA'K=M)K\ND;9$N(XQ)E@ KC
M/'.2>?3L:O3S+;V\DTGW(T+MCT S7+^*U;3=:TK74R$A?R)\8^X<]OH6_2KG
MC2]:U\.R0P\S7C"! #R<]?TR/QHL(TM(U2+6=/6\MHY8XG)"B4 $X.,\$]ZN
MUA-#J^F6=EI^AVEM(D<05Y[B0[0W?@<\\FHK/6]3A\11:1K5O;![A"\4UJS;
M3@$G@\]O;]:+ =%17.ZGKU__ &V=)T*TCGN(T#S/,2$0'!'0CL?UJWI6HZBW
MVJ/7;-;5[<!Q+'DQNO.<'GICIG/-%AFO5#6-8M]$LTN;M)71I!&!$H)R03W(
M]*PX->\0:LKW6BZ;;_80Q$9N&(>0#TY _I[\59U7Q#>6/ANTU 6BPW$LJQR0
MSJ?ESG/H>W%%A7.BHK \1Z_<:+>Z=';VPN%NBX:, EV(VX"\]R?0U2G\1:[I
M-Q;R:YI]LEG/((RT+DLA/J<D=,G^M%@N=9169KFLC2+>(10M<75P_EP0J<;F
M]_85EW>LZ]HT<=WK%I9R618"4VA;?$#W.[@\G_.:+ =/12*RN@9&#*PR"#D$
M4M(84444 %%%% !1110 4444 %><>-8RGB1V)SOC5A[<8_I7H]<-X_MRM]:7
M'9XS'^1S_P"S5WX"5JUNYX^<QYL(WV:_R_4Y&BBBOH#XH**** "M/P]JHT;6
MH;QPS1KE9%0<E2/_ -1_"LRBIE%2BXOJ:4YRIS4X[HZSQ5XMMM:T^.TL(IXD
M\S?(9 %SZ# )SR<_@*@B\1VEKX*?2;6.9;N7/F2;%"G+<]\_=XZ5S5%8K#TU
M%06R=SJECJTJDJC>K5OEY%O2KXZ;JMM>!=WDR!BH/4=Q^5=/=^)M#O/$UIJD
MEM=D6\9!78GS,#\I^]VR3]0*XVBJG1C.7,]]C.EBJE*')':Z?S1N:SXDFO\
MQ&FI6I:-8"/(5N" /7![\YJSXJU_3M?AMI;>">*[B^5RZJ%*GMD')P>GU-<U
M125""<6N@WBZLE.,G?FU85U&J^)[6^\)6FE0PS":%8U=G "_*N..<G]*Y>BK
MG3C-IOH9TZ\Z491C]I685TWA_P 6_P!F6)T[4+;[59-D #&5!ZC!X()_F:YF
MBBI3C4CRR"C7J4)\]-V9V]GXH\,Z7-)<Z;I5S'/("">,8SG ^8X'T%<GJ=[_
M &EJEQ>>7Y?G.6V;LX_&JE%13HPIRYEOYFE;%U*T%!V271)(****W.0****
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MBBB@ HHHH *9!&(K>.-3N5$"@^N!3ZCMXS#:Q1,02B!21["@"2BBB@ HHHH
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MSMD0,,^N#3I(DFC:.9%D1A@JPR#^%%PL<CXIUZQU316TW2IA>75VZ*D<0)(
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M++(=J)<[F..@!>NABTZR@N#/!9V\<QZR)$H8_B!FI8K:"&222&&.-Y3F1D0
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MD:.TA23[ZHH;G/.*DJ.VW_9(?-SYFQ=V>N<<T 24444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'
M<HTEI,D?WV1@O..<5)4=SO\ LDWE9\S8VW'7..*DH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH CE1FD@*]%<EN>VTC^9%25'+O\ ,@V9QO._'IM/]<5)0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!&R,;N-Q]P(P//<E<?R-25&V_[7'C/E[&W>F<KC^M24 %%%% !1110
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M444 %%%% !1110 4444 1W,AAM)I$QN1&89]0*DJ.XE\FVEE SL0MCUP*DH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH CED*20*,8D<J?IM)_I4E1R2^7)$N,^8^WZ?*3_2I
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** (VD(NXXQC:R,Q^H*_XFI*C,N+E(L?>1FS]"/\
M&I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"W!_J5J2HX/]2M24 %%%% !1110 4444 4**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?#''4[0<_D13Z9'Y?F2^7][?\_UVC^F* 'T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R!T>W
MC>)=J,@*KC&!C@4^F0>7]GC\C_5[!L^F..M #Z*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9.Z
M);R/*NY%0EEQG(QR*?3)_+^SR>?_ *O8=_TQSTI] !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M #)'19(@ZY+/A3CH=I.?R!I],D\OS(O,^]O^3Z[3_3-/H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH 8707"(5^<HQ#8Z $9'ZC\J?3#Y?VA,_P"LV-M^F1G^E/H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M +<'^I6I*C@_U*U)0 4444 %%%% !1110!0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_/-35X6)Q<JVBT1]A@<MAA5S/67?MZ!1117$>J%%%% !1110 4444 %%%%
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M>U3IPIQY8*R"BBBI+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *M%6OLR>K4?9D]6H JU';.TEI"\GWV12W&.<5>^S)ZM4-JBW%G#,<@R1JY
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M>K4?9D]6H JT5:^S)ZM1]F3U:@"K15K[,GJU'V9/5J *M%6OLR>K4?9D]6H
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M>K4?9D]6H JT5:^S)ZM1]F3U:@"K15K[,GJU'V9/5J *M%6OLR>K4?9D]6H
MJT5:^S)ZM1]F3U:@"K15K[,GJU'V9/5J *M%6OLR>K4?9D]6H JT5:^S)ZM1
M]F3U:@"K15K[,GJU'V9/5J *M%6OLR>K4?9D]6H 6#_4K4E(JA%"CH*6@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ!&+CU7'-2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M34U0LLAO8V&?*$;AN>,Y7''X&IJ "BBB@ HHHH **** "BBB@ HHHH ****
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M)!GRS&Y;CN"N.?Q-35"TK"]CA &UXW8GOD%1_P"S&IJ "BBB@ HHHH ****
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MBBB@ J.VE$]K%,%VB1 P7TR,XJ2H[9HWM8FA7;&R H,8P,<4 24444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!'<RB"UEF*[A&A8KZX&<5)4=RT:6LK3+NC5"7&,Y&.:DH ****
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M#:Q1(VY40*&]0!UH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*Y$;6DPG.(BC!SZ+CFI:CN
M8UFM98G;:KH5+>@(ZU)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!%*(S)!YAPP<F/W;:W],
MU+4<L:O)"S-@QN6 ]3M(Q^OZ5)0 4444 %%%% !1110 4444 %%%% !1110
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M7_XFC_A!O%O_ $*VM?\ @OE_^)I6//\ [/H_S_D?67_"<^$O^AHT7_P81?\
MQ5'_  G/A+_H:-%_\&$7_P 57R;_ ,(-XM_Z%;6O_!?+_P#$T?\ "#>+?^A6
MUK_P7R__ !-%@_L^C_/^1]9?\)SX2_Z&C1?_  81?_%4?\)SX2_Z&C1?_!A%
M_P#%5\F_\(-XM_Z%;6O_  7R_P#Q-'_"#>+?^A6UK_P7R_\ Q-%@_L^C_/\
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MM_Z%;6O_  7R_P#Q-'_"#>+?^A6UK_P7R_\ Q-%@_L^C_/\ D?67_"<^$O\
MH:-%_P#!A%_\51_PG/A+_H:-%_\ !A%_\57R;_P@WBW_ *%;6O\ P7R__$T?
M\(-XM_Z%;6O_  7R_P#Q-%@_L^C_ #_D?67_  G/A+_H:-%_\&$7_P 51_PG
M/A+_ *&C1?\ P81?_%5\F_\ "#>+?^A6UK_P7R__ !-'_"#>+?\ H5M:_P#!
M?+_\318/[/H_S_D?67_"<^$O^AHT7_P81?\ Q5'_  G/A+_H:-%_\&$7_P 5
M7R;_ ,(-XM_Z%;6O_!?+_P#$T?\ "#>+?^A6UK_P7R__ !-%@_L^C_/^1W'Q
MY\66NO\ B2QL=)OH;RQL[?>9+>82(TCGGE20< +^9KI_V>/"D2V5YXHNH@TK
MN;:T+#[J@?.P^I(7/L?6O#+_ $V^TJZ-KJEG<65P "8KB)HW /0X8 U]0_ V
M6*3X3:<L>-T4LZR8/\7F,?Y$4=#7%KV.$4(;;'H5%%%(\ *^5/C1X4B\,>/9
M'LHA'9:BGVF)5& C$X=1Z<\X[!A7U77@7[2<L9U'P_"N/-2*=FYYVDH!^JM3
M1Z&72:KI+J=5\ -<?4O ,NGS,6?3;DQH2<_NV&Y?U+#Z 5ZG7A_[-<;BQ\0R
M$_NVD@51[@/G^8KW"AF6,BHXB2056U"]33M-N+R7&R"-G()QG Z?CTJS7*>.
M+X[+'24BFG%Y,&GCMUWR&)""0%]_7V-"W.0M>&-?N]4DN+75H8H;R)$F5800
MK1NH(/)/(SS6U=7UI8JK7MU#;JW0S2! ?SKB[S6TA\9:=JOV"_LH9%-I</=6
MQC# \KSW.>?HOY7(+6#4_B1J@U&)+A;2WC6".50RJ"H).#[D_G3L*Y8TN_DN
M?'^J1+=/+:K;1M&@D+(#A<D#I710W5O<6PN+>>.6 @D2HX93CKR..U<GH%C;
MZ=\0]7MK.,10K;(50'A<[2<?B32^">/ ,JGJIF!'H:&@+WB[4?\ BB+N]TN\
M_N>7/;R_]-%!PRGZBK&L>)K32-2L[21X6:XDVREIPI@7^\P]/KBN5_YHC_G_
M )^:V/%=I;R>(= 9X(F:6Z*2$H"77 X/J*+ =$=3L%LUNVO;86S'"SF5=A/3
M ;..QJ6WN8+N$2VLT<\9Z/&X8'\17/Z_H$LEQIUUI=G:W$5D7W:?+A8W#=U&
M,!NIR?KVYL>%KRQN;:[CL[ Z=-'.?M-L1]UR,9';! [8Z?FN@&S/<P6L1ENI
MHX8QU>1@H'XFF6M[:WR%[*YAN%4X+12!P/RK$\275@FH6,$VE-JM]AV@@ R%
M7'S,<\=N,BLSPV)8O'FH(^G#2Q)9J[6J2*RY# !OEX[G\SZT6T"YU4NK:="I
M::_M8U5S&2\R@!AU7KU&>E6%FB>'S4D1H\9WA@5QZYKD?#6B:??7FO7-[:QW
M$AU*>']X-P"Y!X'8\]>M8;S2VWPXO;:*1EA74FM^3G;'D'&>W/\ ,T[!<Z#Q
MIK<7_",SMI&IIY\<B FUN!N49P?NG(KK:X;QUH6FV/A)7M+2.&2!T1710I8'
M@[L=?7GO7<TGL!BV.L7%SXLU32Y$C$%FD;1LH.X[E!.3G'?TJ\VLZ8B*[ZC:
M*K':K&=0"?3K6%I'_)1]?_ZY0?\ H"U2\&:%IM]I-W/>6<<\LEQ+$6D&<+GH
M/3KU'-.P&]XDUI-*\/3W4%Q"LS1YM]S#YR>ZC^+KFJ_A=;=-.^U#6YK]VA1K
M@2W0E2%L9./[O4\9[>U<W!&D_P )+CSU64VY=8F=02GS]C^-;=ZFD6'A.S-W
MIHG%QY(6"!,&>7;E0<8SWZYHMT Z"VU*QO9&CL[VWN'4998I58@>X!HEU&R@
M>1)[RWB:, NKRJ"@/0G)XKB9!+'XPT*;^PET;S)'4F.1/WPVC@A>F/?UJ\--
MM-1^)5_]N@6=8;:-T5^5#<<X[_C18+G4+J-D]HUTEY;M;K]Z82J4'U;..]9N
M@>*+/7(R/,@@N#*R);^>&=P/X@.#C&3T[5FZ+96]OXSUZPBA06;QQ2& J"F2
M,G@_4\4WP+86KZ+-+Y$:S+<RHDRH Z#IPW4=319 =*-4T]KLVJWUL;@':81,
MN\'TVYS5JN"MK5/#(M+?Q!H\$T2W0,>J0<MOSN4N/O9S[^W..>]I, J*UA-O
M9PPDY,<:H2.^!BI:ALT>*Q@CE^^L:JW.>0.:0R:BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (K
MJ$W%G-"#@R1L@)[9&*EJ&\1Y;&>.+[[1LJ\XY(XJ:@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@"*:$R2P,#CRI"Y]_E8?UJ6H9T=YK<IT20L_/;8P_F14U !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% $30EKR.;/"1LF/J5/_LM2U"R.;Z*0?<6-U;GN2N/Y&IJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KDM5_Y*AH?_7O+_P"@O76UGW&B
MVUSKMIJSM(+BT1D15(VD,".1CW/>F@.<UD?\(QXPMM;C^2QOR(+P#HK=G/Z'
M\&]:R=):5?A#J)@)#;V!P<?*2N[],UW^I:;;:MI\MG>IOBD&#CJI[$>XJOI&
MA6FC:4=/M]\T#%BPGPV[/4'@#'X4[Z"L,\,?9SX6T[[( (O(7@?WL?-^.[-<
M_P"!X()SX@CBC!T^6[9(@ 0I7YN!_P !*^]6W^'NDEY/)N+ZWAD.6@BG 0_@
M03^M=%8V%KIEFEK8PK#"GW57_'J3[T: >?6^KOI7@_5-!:3=?V]PUI H(!97
M.,CO_>_,?A8\5:<VC^'O#]@LPCAAN%6:78&0/UW%3P1G<<'\:Z:Z\)Z==^(H
MM:D\T7,95MJL-C,O0D$9ST[]A6CJ.FVNJV+VE]$)8G['J#Z@]C1=!8Y^^\,:
MYJ5E):7OB82P2 !T.GQC.#D<@YZBJOB6V-E<>$K4R&4P7<4>\CEL%!G]*OCP
M/9^6(9-3U62W7I;M=?NQ[8Q6GJ&A6NHRZ>\K2I_9\JRPB-A@D8P#D'(X%%P-
M*J=Y9Z=JZ26EY'#<^7C?&2"T>>1[KD5<K"U7PCI^JZ@;YY+FVN64*TMM)L+
M>O![<?A2&8.G6A\-?$*#2M-NF>QO(FDD@<[C&0K$?J.OH?QJWX,BC_X2#Q)-
ML7S1?.H?'(&YCC/I6OHOA;3=#E::U226X<8,\[;GQZ>@_*K&F:+;Z5<WT]N\
MK-?3&:02$$!B2>, <<^]-L5C"TQ53XIZN$&T-:(Q [GY.:CT&1(?'GB220[4
M159B>P%=%#HMM!K]QJZ-+]HN(A$ZDC;@8Y QG/ [U5ETFWTJ75M9M4DFN+B
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1Q>5YDWE?>WCS.OWMH_IBI*BB1$DG*-N+N"XS]T[5&/R /XT 2T444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5%=6EO?6LEM>V\5S;RC;)%,@=''H0>#4M
M% 'D?BG]G[1-3D>Y\.73Z1,W)@8&2$GV!.Y>_<CT KR77OA#XST#<TFE-?0J
M"?.L#YPP#C[H^8=CR.GT./K:BG<[Z6/K4]'JO,^%98I()6BGC:.13AD=2"/J
M#3:^W=2T/2=90KJVF6EZ,;?](@5\#\1QU-<I??!CP+?$L=%%NY&-UO/(F/PW
M8_2BYWPS2#^*+1\FT5]-7'[/?@Z8_NYM4M^>D=PA_P#0D-0K^SKX1# F_P!9
M8 ]#/%S_ .0Z=S;^T:'F?-=%?4EI\!_!%MGSK6[N^0?WUTP_#Y-M=#IOPW\'
M:2!]C\.V.1T::+SF'&.KY/;^?K2N9RS.DMDV?)NC^&]:\03"+1=+NKUB0"88
MB57)QDMT ]R:]-\-_L]:W>R1R^)KN'3;?J\,+"6;Z<?(/KD_2OHM5"*%4!5
MP !TI:+G'4S*K+2"L<MX4^&_AGP<4ETBP#7:KM-Y<-YDI['GHN1Q\H%=3112
M/-E.4W>3NPHHHH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ J.-W:24.FT*^%/]X;0<_F2/PJ2B@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ J.!WDMXWE38[("R_W3CD5)10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'
M.[QV\CQ)O=4)5?[QQP*DHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CD=UDB")N#/AC_=&
MTG/Y@#\:DHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH C+N+A$"90HQ+>A!&!^.3^52444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img70551829_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #9 2\# 2(  A$! Q$!_\0
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MQ"#T S6_'M\M-ARN!@YSD4HRNVNQ#C9)CJ***LD**** "BBB@ HHHH ****
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M/AU<O&H>3Y<(N&8CKD8/% '>457L+DWNGVUTT31&:)9#&QR5R,XJQ0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 55^S"RM+@:?;Q"5B\H0_*'D/.6/N>]6J* ,+P_P")(]8,
MMG<PFRU:VXN;.0\K_M*?XE/8UNUA^(/#<.M"*Y@F:SU2VYMKR/[R'T/]Y3W!
MJMH7B26:\.BZW"MGK,8SM'^KN5_OQGO[CJ*T<5)<T?N_KH!TM%%,EE2%"[G
M%9@/J-9XWDV*P+8W<>E5PLUWRQ,<?8#J3V(/I4L,:Q2O&J@#[R\>O6@">BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K$\4Z)%K6CR(+<R7D(,EHZ2>6\<G8J_:MNBG&3
MB[H#B? C>)+1=1@\3QRB0R++'/(RLK9&TJ"#@=!Q[UU<4;7$@GE! 'W%/4?C
MW%$A^T7(B4_(G+X(_(BI"?LW)_U/_H/_ -:JG/GES6L!/4$F]KE?+(!53G(Z
MY[4]9HV8!6R3[4X(%9F'5NM0 (S,/F7:1VS3JQ="\11ZY=ZI;I;O"^GW)MWW
M,#NQW'MQ6P[K&A=V"J!DDG@4Y)Q^(!U%8=QXE@C8K!$TO^T3M%11^*8]V)K9
ME'JC9_2N)YAAE+EYC54*C5['0T5#;74-W")8) Z'N.WUJ:NM--71FTUHPHHH
MIB"BBB@ HHHH 0'(!P1GL:6BB@ HKBK#QE?W/B==/FM(EM)+^XLED\N1<&,,
M0=Y^1B=OW1SU]#6K=^+K*SDU!I+:[-I8;EN+M4!C5U0.4Z[LX(YQC)QF@#H*
M*X>]\>LUL)]/ML;8YS(EP.0Z&+&"IP01+U!/Z&M_2?$EKJ^I7UC#%-'+:,5<
M2[03ABN0N=P&1QD#(P10!LT444 %,EEC@A>::18XHU+.[' 4#DDGL*?67J=G
M%XBT4VT-X4MK@J6EAP2Z!@2 >G.,9YX- &@L\36XN%E0PE=XD##:5QG.?3'>
MF1WMM+<&".=&E W% ><<<_3D?G7*#P!"8Q%)J$DJI$;>,NF2L.)1L/.#Q*.W
M/EC\$;P&6N;>8:B$,6T QPX9 /+_ -6=WR?ZO'?AB* .OGGBMHC+-(L<8(!9
MC@9)P/U(%25PR_#U@L(?4UD6.16,;6YV_*8SN4;OE<^7\S<YWMP*W?#.ESZ-
MI<HO92TSR,YR^_RXQ\L:9[X0*">YR: -RBF0S1W$*30NLD4BAD=3D,#T(I]
M!1110 4444 %-=MB,Q[#/7%.J"\.+5N#SQPN[]* &V:GRC(^=SG/S8SCMR*F
ME7=$Z^H-$2A(D4    <#'Z4YF"D GDG H 2,DQJ2,'%8_B./Q#+! OAZ>SAE
M+GSGN5) 7'&/?-;55+[4[+3?)^VW44'GR"*+>V-['H!51;3T5P/.[>R\6^![
MZ\U>6"#6;>^<27JVP*NI&?F48]SV_*MNZU]-=M()K42):R('"R+M8GW%=I7
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MN 1[4Z9S*ICB&[D9.< <TR[BPPG5<D<, ,EAZ#TJQ$4:,&/&WVH 16E) :(
M>H:L/QAI4NIZ/YD&JR:;-:-]H2=6P@*C^/V_SS70'I67K&D6_B/1)+"[>5(9
M@"QB?:>#G\O:J@^628'#Z+XI\=>(M*B;3M*L0.4:_F8A'(.,A?\ ]=:?]D:W
M:69N-8NH+NX=R7>!-H4=A_\ 7Q79VEK!8VD5K;1K'!$@1$7H *E(# @@$'J#
M66.IPQ5-T[)+H73FX2NCSXU&U=?<^'K29BT9:$GLO(_*HH_#%L&S+-)(/08%
M?-_V5B%*VGWG='%4[:G.Z9ICZE>*F#Y*G,C>WI]37>@!0 !@#@"F06\5M$(H
M8U1!V%25[F#PJP\+;M[G+7K.J_(****ZS **** "BBB@ J&[MUNK62!C@.,9
M]#4U%*45)-/9C3MJ<'<VLUI,8YD*D=#V/TKG[J=YIFR3M!P!7I.O(6TJ0@9V
MD']:\^NK"0RL\0!#'.,XQ7R./PRP]7DB]-SVL!6C+617MI65PF25;MZ5T>D:
M/+?R1.Z%;9<%F(^]["L*&U:([Y, @<"O2-&1DT>T5A@^6*WRS#*M/W]EJ/'U
MN17AU+PX%%%%?4'AA44]U;VVWSYXHMQPOF.%R?;-2UEZWX=TKQ%!'#JEJ+A(
MF+("Q7:3QG@BG&U]=@,/QGXDCAMAH6G0)J&JZBACCMQ\RJA&"[>U96F_#O7+
M'3H+:+QE>VRHO^JA3Y$/4@?-TS4GP[T*WT[5_$4L=FT21W9M[9I%.X1CT)Y(
M/'Y5Z#71.I[+W("/-?#TTGP^UF30]8VM9ZA*9;;4\8WN>JR>A_SWKT,7EJTX
M@%S"9CTC#C<?PK'\:Z?'J7@_4X6A$KK TD8VY(=1D$>]9/@?PCHUGI>F:PFG
MM%J;0!GDD9]P8C#<$\=^U$W&I'VDMP.UHHHKF&%%%% !1110 4444 ! ((/0
MU3)-D^>?(/\ X[Z "KE(0",&@"-Y0  F&9N@IJ6P5 K.[8]347V=[9]\&"G0
MJ>PZD_6I8KN.3 8['XRK>_04 3@8&!1110 4444 %%%% !1110 4444 %%%%
M !1110 V1%EC9' *L,$'N*YB[\.W"2$VQ62,] QP174T5S8C"4\0ESK8TIU)
M0>AR]EX:D:97O2HC!SY:G);ZFNG    & *6BJP^&IT(V@@J595'>04445N9A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1R0I*.0,]0??UJ2B@
M"K:2<O 6!,9P.<G'N:M55@W?;)\EL<8R1BK5 !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% #%B1)&=5 9NI]:?110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img70551829_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &E A<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV,D#'^-#_A4NOZ*=06*[ML+?6Q#Q-_>P<[37/BZ4G-58;K\4803=.,ENM/\
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M?YE^/^0N=]G^'^9J45E[=:_Y_;#_ , W_P#CM&W6O^?VP_\  -__ ([1[O\
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MO^?VP_\  -__ ([1MUK_ )_;#_P#?_X[1[O\R_'_ "#G?9_A_F:E%9>W6O\
MG]L/_ -__CM&W6?^?RP/_;HX_P#:M'N_S+\?\@YWV?X?YFI16<9]4A7+06UQ
MCJ(W,;'Z Y'YD5-:ZC!=2>2"T5P%W-!*-K@>N.X]QD>]%NJU&IINQ;HHHI%A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63)(^JR/
M'&[)8H=K.O!F(Z@'LO;(Z_3K/JDDGDQVL#;9;EO+W_W%QEF^N.GN14\<:0Q)
M'&H5$ 50.P%#ER*_4SE[SY>@1QI#&L<2*B*,!5& *=116 PHK!\:Z[+X:\&:
MKK$"*\UM 6C##(W$@#/MDBLMO!JP:$TXU&^.MK$93?M<,29=O79G9MSQC'3W
MYH&=E17CNK:WK_B"+P3J6E3&'4)()[AH 2(YV0+E2/?G'UK?;Q&FO>(/!]W9
MRR1Q3F<30[B-KJHRK#U!S3L!Z'15+4M)L]7B2*]C=T0[E"2O'S]5(KA?AOI%
MI/I=UJ-Q]HFNK?49TC9KJ5MJJWRC!;!Q]*0'H]%>?W?Q#N-.EMI;VWL8H+B<
M1"U^T$W2J7V;F7&!R<XSTK2C\5W\OB#7;46=M'IVBNGVBXDD;>Z-&')50.HY
MZ^U.P'745PC^,M>@M-$U&XT6U6PU>ZAAC G)EA25OD+C&,[>P)P>*DNO&]XU
MQJLFG6ME)9Z7*T4WVBYV2S,G^L$:XQQT&<9(HL!V]%<#'K>HZI\0M&DL7@.E
M7.F&X"O(P.TGK@#!;/'7I4_Q/G,&B:=S<^6^HPI(MN6#NO.1\O-%@.WHKCM'
MMM%&HQM9:-K-O<*"4DNTN%C!]RQ(KSZ\N-?;PKXDU9G@^TMJ;6CS"ZF#*F4&
MU1T Z<\'DT6 ]RHKAHM?O+"\ET'2K73E?3H%>Y>ZO'">8^2$0MEF.,G)Z9%6
M(O'#:I:Z.FCVB27^I^:1'/)M2$1-MD+$9Z' &.N118#L:*\[\4:SXD.GZ=&+
M.*RN5UF*WE)D81SC.5*,!DH>_<8Q7H@S@9ZTA!4%U:0W<8653D'*.IPR'U![
M&IZ*:;3N@:3T95L[J5+@V5XVZ;&Z*7;@2K_\4.X_$>VA5"^MWN+?]RP2>,B2
M)CT##IGV/0^Q-6;2X%W:17 4KYB@[3_">X_"M[\RYA1;3Y634444C0**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BD5@RAE(*D9!'0TM !1110 4444
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M)F6-Y2=S=<GN:R6D=FW,YSZYKYR>:5>;W4K'JT<"IJ[9Z#%K-I*X7>R9_O#
MJY)/'$F^1U5?4FN!LIFD0JYR5[U<>9W55=RRH,*#VJX9K-1?,KLRJ83EE8ZK
M^UK+_GNOY&E75+-FP)US[\5Y_/=2M(0&**.@'%36=R[OY<ASZ&I6:U+[(T>
MM'FN>BJP89!!%+7/:)>E':WD?Y,97)Z5NK-&QPLBD^@->OA\1&M!2."<'%V)
M****Z" HHHH **** "BO)-8N=1CE\2ZA'+.HL]1PMT-2=3 @6,D+!]U^">#U
MSBNU\87LL5CI<2W,EK:WE]%!=7"-L:.-@3C=_#N(5<]MU '345Q5_>VWA*WO
MCI5[-=R9MT^Q33&9;=I'VA\L=P!S]W=SCMG-5QJVHW^IZ*E]&(I(=6:+<GR"
M5?L[MR@9MI!/0D] : .]HKS*P\3:GI/A?1S$(6M4L?/N)I%,S+\Y'S!6#*N
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M5KE58*$G%.X4445L9A1110 51U+2+/5FM3>1>8+6;SHU/3=M*\CN,,>*O44
M1I!#&$"1(NQ=J;5 VCT'H*:EG;1&4QV\2&8YDVH!O/OZU'J&HV>EVC75]<)!
M I ,CG !/ JR"&4$=#R* (!8VBR12"VA#PKMC81C*#T!["GBV@ ($,8!4J0%
M'0\D?2I:,T ( %4   #@ 4M%% !1110 4444 %%%% !1110 4444 %%%% !1
M63J/BC0M(NA;:AJUI:SD B.64*2#TXJW+J=C!IW]HS7<,=EL#^>[@)M/0YH
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M;'453G>.S*3.9U8F7Q'+9Y(2:V@,F.Z*TQ(^A)4'VS5LG J"[0'Q;</W6QA
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MCMZU'HMM/;:&(+B^_M"53\\A;A6R<X[]<]:CC\/7R>-9-7:Y0VDD95H^<G@
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M_B,C]:L0S)<0I+&<JPR*C$+WE)=E^1KA_AMYO\SPVYM;G1M4,,Z%9H'R,]&
M/!'L:ZFWUBRGA#^>B'NKG!%=_J&CZ?JB!;VUCFQT+#D?0]:RO^$&\/\ _/D?
M^_K?XUK]9C)+F6IM8\WUW4X[UTBA.8XR26]344NA:E#I,6I/;/\ 9I"><<@=
MB1V!]:]4M?"&A6DHECT]&<<@R$MC\":VMH*[<#'3%#QBC9006/'M(UR&WMEM
M[DD!/NN!GCWIVJZ]#-;-!:DMO&&<C  KU%M"TEV+-IMH2>I\H4BZ!I",&73+
M0$=#Y0H^LPO>P6//? V@3W>J1ZC+&5M8#N4L/OMVQ]*]2"@= !2*H10J@ #H
M!VIU<U6JZDKL84445D 4444 %%%% !1110 4444 %%%% !1110 5'X5D\Y=6
MD[-?G'T$48'Z"H;V:1(UB@(%Q,=D>1G;ZMCT YJWX<A2W&I0IG:ETJC/M!%7
M505HR?\ 6Z.:N[N/K^C-N@@$8/2BBJ(.(O\ X:Z'<^*-(U"#1](CL;5)Q<V_
MV51YQ< (<8P<$$\^M=A9V5KIUI':65O%;V\8PD42!54=> .!4]% '"3^!KZ7
M1O&UF+JV$FOS/) QW8C#1JH#\>H[9JY+X1NI/$'A/4#/#Y.C6DUO.G.9"\:H
M"O'3CO77T4 >367PKO;&!-)^S:%<:>DQ87MRDKSF+=NVF/.PMVW9QWQ75#PE
M=+KWBR_$\ CUFSBMX%YS&4C9"6XZ9(Z5U]% '"1^!KY-$\$V)NK??H%Q%+<-
M\V) J,IV\>I[XIA\+>)M'NM<AT"XTM[#6)WN6:]#B2VD<8<@*,..,@$BN^HH
M X70OA^V@>(-"NH+J.6STO27L/G!\QW9PQ<=@.O?O6)\3D.H>)-)T_0+P)XB
MN$>QN(XU)9;.5?G=B.@7&03WKU6DVKNW8&[UQ0!7TZPM]+TVVL+5 EO;1+%&
MH[*HP/Y59HHH **** "BBB@ JA?ZQI^FX^V7<<6?7GT].G45<SL3+'.!R:X"
MZN-$U^PN]8O(VN5L)S\L2,FY<@JKC!)_^MZ5<(\SUV$SL[@JRK=0CSO3:<C'
M/I5/2XK/6K&SU"XTMH98I&>)+D R1MR-WU(J;1+VRU;1HYK(@VS H% V[<=1
MCL:G5S:2E7XB)PBCD_6D]-!EZH#*RW8B.-K)E?7/>I\U2N5::[ACC<HRY9F'
M]WIBI M>;'YOE[AOQG&>:XOXB>&-1\10Z8VEI&T]K.7)=PH"X']0*[*&WCA'
MR+R>I/)-(9\7(A88RN5.>OK5PFX2YD!(F[RUW_>P,_6E)Q41G'GB)06/5B/X
M?K576M-.L:/=6 N9;8SH5\V(X9?_ *WK4K5Z@>1>,_%-I)\0;'5--1[A-+"K
M.Z?=?#'(!].2,UZYHNM6.O:='?6$PDA?J.Z'N".QK,\->#--\/:*]@(DN'G7
M%S)(O^M]L>GM3?#7@JR\+W]]<V<TQ2Y(VPLWRQCT]S[GM735G2E'ECTV\Q&U
M?:58ZF]NU[;1SFW?S(PXR V,=/QKB]0\.:GX2O9-7\)@R6K'==:4Q^5AW*>A
M]O\ ]5>@48K"%24=.G89@>'O%^D^(H ;:<17*\26LQVR(>XQW^HK=>1(T+.Z
MJHY)8X KG];\$:#KTOGW5GLN?^?B!O+?\QU_&LA?A;HQ8?:;W5+F(?\ +*6Y
M.W]!5VI/6[0#]:\=HUP=(\,Q?VGJK_*#'S%#[LW0XKH-#T^^MM#BM=9NQ?W)
M!,KLHVG/\/N!5"VOO!_A=FTV&\TS3Y%X>(RJKY]\G)_&ND5@RAE(((R".]3*
M4;6BO\P.9O/A[X6O9"\FD1(Q.28F9/T!J?3_  1X;TN19+;28!(O1Y 7(_[Z
MS709JDFL:=+="U2\B:<RO"(PW.]5W,OU (-'M9VM=@7 ,#%+4$=Y;S74]M',
MC3P;?-0'E-PR,_45)++'!"\TKA(XU+,QZ #DFLP'T5'!/%<V\<\#B2*50Z.O
M1E(R"*DH PI_^1ENO^O.#_T.:JLT$MI,]Q:IOC<[I81U)_O+[^H[_7K:G_Y&
M6Z_Z\X/_ $.:IJ*K][Y+\D;4(WI_-_FRK;W,-TA>&0. =K#NI]".Q]JEJ*XL
M(+EQ(0T<PZ2Q-M;\2.H]CD5&UI?+_JK]3_UV@#?^@E:P=-/9FOO+=%FBJGV;
M5/\ G^M/_ 1O_CE'V;5/^?ZT_P# 1O\ XY1[/S7X_P"0KOM^7^9;HJI]FU3_
M )_K3_P$;_XY1]FU3_G^M/\ P$;_ ..4>S\U^/\ D%WV_+_,MT54^S:I_P _
MUI_X"-_\<H^S:I_S_6G_ ("-_P#'*/9^:_'_ ""[[?E_F6Z*J?9M4_Y_K3_P
M$;_XY1]FU3_G^M/_  $;_P".4>S\U^/^07?;\O\ ,MT54^S:I_S_ %I_X"-_
M\<H^S:I_S_6G_@(W_P <H]GYK\?\@N^WY?YENBJGV;5/^?ZT_P# 1O\ XY1]
MFU3_ )_K3_P$;_XY1[/S7X_Y!=]OR_S+=%5/LVJ?\_UI_P" C?\ QRC[-JG_
M #_6G_@(W_QRCV?FOQ_R"[[?E_F6Z*J?9M4_Y_K3_P !&_\ CE'V;5/^?ZT_
M\!&_^.4>S\U^/^07?;\O\RW153[-JG_/]:?^ C?_ !RC[-JG_/\ 6G_@(W_Q
MRCV?FOQ_R"[[?E_F6ZK7%ZD#B% 9;EAE84^\?<^@]S1]AN)%VSW[X/40H$S^
M/)'X&K%O:P6B;(8PH/4]2WN2>2?K34(K=W'[S\B*UM&CD>XG*M<.,9'1%_NC
M_'O^56]#_P!?JW_7X/\ T3%11H?^OU;_ *_!_P"B8JVIN_-Z?JC&NDE%+O\
MHS7HHHH,@HHHH ***KW=]:V*!KJXCB#' W'&: +%%4M5@NKK3)X;*813NN%<
MD\?B.GUKDX/$FKZ#,+76[9Y8^BR_Q8]CT:E<I1;V.YHK/M-;TZ\M3<17<0C4
M9;>P4K]0>E9__"8:8^I0V<)>7S'"&4#"@GI]>:=Q<K.@HHHH$%%%% !1110
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M8((X5+%8U"@L<G '>B>WANH6BGB22-NJN,BI*X_P]<SCQ=JEI-/(Z#>45F+
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MC2SPS260:2)40$R-\P3[NX9^?';=FK":+IT=PEPEH@E2=[A6YR)'&UF^I'%
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M'%4T\=W-M8ZN^I6$<5S87*6J1QR?+*[=#D]!FBP<R.XHKCF\57@NGTR4:?\
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MO_BZ/^$>L/6\_P# Z;_XNBBJYY=Q<D>P?\(]8>MY_P"!TW_Q='_"/6'K>?\
M@=-_\7111SR[AR1[!_PCUAZWG_@=-_\ %T?\(]8>MY_X'3?_ !=%%'/+N')'
ML'_"/6'K>?\ @=-_\71_PCUAZWG_ ('3?_%T44<\NX<D>P?\(]8>MY_X'3?_
M !='_"/6'K>?^!TW_P 7111SR[AR1[!_PCUAZWG_ ('3?_%T?\(]8>MY_P"!
MTW_Q=%%'/+N')'L'_"/6'K>?^!TW_P 71_PCUAZWG_@=-_\ %T44<\NX<D>P
M?\(]8>MY_P"!TW_Q='_"/6'K>?\ @=-_\7111SR[AR1[!_PCUAZWG_@=-_\
M%T?\(]I_K>?^!TW_ ,7112YY=PY(]B:+1M/B(86J.PY#2DR$?BV:O444FV]Q
II);!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img70551829_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'M Q(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  H ?13,R_W$_P"^S_A1F7^XG_?9_P * 'T4S,O]Q/\ OL_X49E_N)_WV?\
M"@!]%,S+_<3_ +[/^%&9?[B?]]G_  H ?13,R_W$_P"^S_A1F7^XG_?9_P *
M 'T4S,O]Q/\ OL_X49E_N)_WV?\ "@!]%,S+_<3_ +[/^%&9?[B?]]G_  H
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M +[/^%&9?[B?]]G_  H ?13,R_W$_P"^S_A1F7^XG_?9_P * 'T4S,O]Q/\
MOL_X49E_N)_WV?\ "@!]%(,XY !]C2T %%%% !1110 4444 %%%% !48MX1<
M&X$,8F9=ID"C<1Z9ZXJ2B@"O;V%G:,S6UI!"S?>,<84GZXJQ110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^>+_ )C_ !H\QO\ GB_YC_&@!]%,\QO^>+_F/\:/,;_GB_YC_&@!]%,\QO\
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MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*\DKUOX)?\QW_MW_ /:E55^%EXC^&SUJBBBN0\P**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***CN-YMI?+D\N38=KA-^TXX.WO\ 3O0!
M)17)C5[U3=6\5Y*^^YMX(9;B%4ECW_>)3:O'!VDKR<]0*U]*N+G[?J-C<3M<
M?9G0I*ZJK%67.#M '!SSB@#5HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&X2_M3,P9%7RVQN^7 '';G-=/0 44UF*]%+?3']:3S&_YXO^8_QH \H^-O\
MS O^WC_VG7DE>L_&MBW]AY1E_P"/CKC_ *9^E>35UTOA1Z>'_AH*^B/AE_R3
MS2_^VO\ Z->OG>OH7X9NP^'NE@1L?];R,?\ /5_>IK?"1BO@7J=A13/,;_GB
M_P"8_P :/,;_ )XO^8_QKF//'T4SS&_YXO\ F/\ &CS&_P">+_F/\: 'T4SS
M&_YXO^8_QH\QO^>+_F/\: 'T4SS&_P">+_F/\:/,;_GB_P"8_P : .5^)O\
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M^>+_ )C_ !H\QO\ GB_YC_&@!]%,\QO^>+_F/\:/,;_GB_YC_&@!]%,\QO\
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M^&7_ "3S2_\ MK_Z->IK?"1BO@7J=;1117,>>%%%% !1110 4444 <E\3?\
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M%/7)5UOPR_Y*'I?_ &U_]%/6LOA9U5/@?H?1%%%%<9Y(4444 %%%% !1110
M5\[_ !-_Y*'JG_;+_P!%)7T17SO\3?\ DH>J?]LO_125K1^(Z<+\;]#DJ***
MZ3T#ZUHHHKA/&"BBB@ HHHH **** "BBB@ HK&EOM1M=5M[>86TB7(F*)$C;
MHP@R"6)^;/ / Y(_%F@ZI=7^$OI(X[KRA(UK]DDA=,G&<NQW 'C('I0!N444
M4 %%%% !1110 4444 %%%% !161K-[?Z=$UW%]F-NA1?*96,DI+ $ Y 4\\<
M-4$>K78UF2VNI([:'[1Y4(DLY/WPV@C$NX)DG( QVH WJ*** "BBB@ HHHH
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M2OG>OH7XF2*WP]U0 -_RRZJ1_P M4KYZKIH_">AA?@?J%>M_!+_F._\ ;O\
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MH_\ WP?\* 'T4SS5]'_[X/\ A5.^UK3-,\O[??06GF9V>>_E[L8SC/7&1^=
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MDHL4)C4#)))RS$]:U:** "BBB@#R7XV_\P+_ +>/_:=>25ZW\;?^8%_V\?\
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MUY)772^%'IX?^&@KT7POXFU?3_#MK:VMWY<*;]J^6AQEV)Y(SU->=5U^B?\
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M-!77Z)_R"(/^!?\ H1KD*Z_1/^01!_P+_P!"-5+8N>QH4445!F>[44SSHO\
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M.FZ%;VS7"7$@+O)+']UG=V9L>V6(H U**** "BBB@ HHHH **** /)?C;_S
MO^WC_P!IUY)7K?QM_P"8%_V\?^TZ\DKKI?"CT\/_  T%=?HG_((@_P"!?^A&
MN0KK]$_Y!$'_  +_ -"-5+8N>QH4445!F>[4445RGFA1110 4444 <E\3?\
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M^(\[$_Q"]16?::K]LO)H8K*Y\N&5H7G)C"!EZ\;MWIV[UH5D<X4444 %%%%
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M\E4445W'LGHGP:_Y&^[_ .O!_P#T9'7JVJ"\;6]-FATZXFAM7=G='C .Y"O
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MJ%4?0"I*D@9Y,7_/)/\ OD4>3%_SR3_OD4^B@!GDQ?\ /)/^^11Y,7_/)/\
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MED5C]J;J,_PK7F]>E?#W_D 3_P#7TW_H*5G4V.>O\!U/DQ?\\D_[Y%'DQ?\
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MYQ6K0 4444 >2_&W_F!?]O'_ +3KR2O6_C;_ ,P+_MX_]IUY)772^%'IX?\
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MH **** "BBB@!&)"DA2Q Z#J:Y>TTZ_DEUV.6RE@340WEN[QD+E2/FVL3W[
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MJOHCXF_\D\U3_ME_Z-2OG>NFC\)Z&%^!^H5O^&?^7K_@']:P*W_#/_+U_P
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ML*EJ#,9Y,7_/)/\ OD4>3%_SR3_OD4^B@!GDQ?\ /)/^^17SS\3%"_$+5 H
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M-NWS8U?;G.,C.*\LKT[2O^019?\ 7"/_ -!%29ENBBB@ KYW^)O_ "4/5/\
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M^)O_ "3S5/\ ME_Z-2JC\2+I_&O4^=Z***[#UC?\,_\ +U_P#^M=!7/^&?\
MEZ_X!_6N@J'N92W"O9]$_P"0!IW_ %ZQ?^@BO&*]GT3_ ) &G?\ 7K%_Z"*Q
MJ;'+B-D95S&HUA7TZWU"&]:\0W#$2"%XP,,QS^[/R\#OG'>NDHHK(Y0HHHH
M**** /DJBBBNX]DV/#G_ "$)/^N1_F*Z>N8\.?\ (0D_ZY'^8KIZB6YE/<*]
M*^'O_( G_P"OIO\ T%*\UK2T_P#X]V_WOZ"LZFQSU_@/9**\FHK XSUFBJFE
M?\@BR_ZX1_\ H(JW0 4444 %%%% !1110 4444 %%%% !45U'YMI-&8Q*'C9
M?++;=V1TSVSZU+10!@:18WEOJSLD5S:Z8MNL:6]Q/YIWYZJ S;0 ,=?_ *V_
M110 UE#=<_@2/Y4GE+ZO_P!]G_&GT4 >1_&M O\ 8>"W/VCJQ/\ SS]:\FKU
MOXV_\P+_ +>/_:=>25UTOA1Z>'_AH*Z_1/\ D$0?\"_]"-<A77Z)_P @B#_@
M7_H1JI;%SV-"BBBH,S=HHHKE/--7PT WB"U!S_'T./X#7H/E+ZO_ -]G_&O/
M_#/_ ",-K_P/_P! ->AT ,\I?5_^^S_C1Y2^K_\ ?9_QI]% ''_$R-5^'NJ$
M%O\ EEU8G_EJE?/5?1'Q-_Y)YJG_ &R_]&I7SO731^$]#"_ _4*W_#/_ "]?
M\ _K6!6_X9_Y>O\ @']:T>QO+8Z"BBBH,C6L_P#CT3\?YU/4%G_QZ)^/\ZGK
MFENSSY_$PKU;RE]7_P"^S_C7E->LTB1GE+ZO_P!]G_&CRE]7_P"^S_C3Z* &
M>4OJ_P#WV?\ &ODVOK6ODJMZ/4[,)U"M#1/^0O!_P+_T$UGUH:)_R%X/^!?^
M@FMWL=CV.OHHHK,Q+^F_\M?P_K5ZJ.F_\M?P_K5ZN>?Q'#6^-A7I>EQ*=)LC
ME_\ 4)_&?[H]Z\TKT[2O^019?]<(_P#T$5)F6/*7U?\ [[/^-'E+ZO\ ]]G_
M !I]% #/*7U?_OL_XU\\_$P!?B%J@&?^674Y_P"625]$U\[_ !-_Y*'JG_;+
M_P!%)6M'XCIPOQOT.2HHHKI/0._HHHK,P)[/_C[3\?Y5K5DV?_'VGX_RK6K&
MIN<E?X@KM?!Z!M)E)+?Z\]&(_A6N*KN/!O\ R")?^NY_]!6LS WO*7U?_OL_
MXT>4OJ__ 'V?\:?10 SRE]7_ .^S_C7DWQK0+_8>"W/VCJQ/_//UKURO)?C;
M_P P+_MX_P#:=:4OB1MA_P"(CR2BBBNH],Z_1/\ D$0?\"_]"-:%9^B?\@B#
M_@7_ *$:T*S>YB]R:TD>&]@EC;:Z2*RGT(/%=5_PD.J_\_K_ )#_  KDX/\
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MF;M%%%<IYIK>&?\ D8;7_@?_ * :]#KSSPS_ ,C#:_\  _\ T UZ'0 4444
M<E\3?^2>:I_VR_\ 1J5\[U]$?$W_ ))YJG_;+_T:E?.]=-'X3T,+\#]0K?\
M#/\ R]?\ _K6!6_X9_Y>O^ ?UK1[&\MCH****@R-:S_X]$_'^=3U!9_\>B?C
M_.IZYI;L\^?Q,*]9KR:O6:1(4444 %?)5?6M?)5;T>IV83J%:&B?\A>#_@7_
M *":SZT-$_Y"\'_ O_036[V.Q['7T445F8E_3?\ EK^']:O51TW_ ):_A_6K
MU<\_B.&M\;"O3M*_Y!%E_P!<(_\ T$5YC7IVE?\ ((LO^N$?_H(J3,MT444
M%?._Q-_Y*'JG_;+_ -%)7T17SO\ $W_DH>J?]LO_ $4E:T?B.G"_&_0Y*BBB
MND] [^BBBLS GL_^/M/Q_E6M639_\?:?C_*M:L:FYR5_B"NX\&_\@B7_ *[G
M_P!!6N'KN/!O_((E_P"NY_\ 05K,P.AHHHH *\E^-O\ S O^WC_VG7K5>2_&
MW_F!?]O'_M.M*7Q(VP_\1'DE%%%=1Z9U^B?\@B#_ (%_Z$:T*S]$_P"01!_P
M+_T(UH5F]S%[DD'_ !\1_P"\/YULUC0?\?$?^\/YULUC4W.3$;H*Z'P;_P A
M>7_K@?\ T):YZNA\&_\ (7E_ZX'_ -"6LSG.XHHHH *Y+XF_\D\U3_ME_P"C
M4KK:Y+XF_P#)/-4_[9?^C4JH_$BZ?QKU/G>BBBNP]8W_  S_ ,O7_ /ZUT%<
M_P"&?^7K_@']:Z"H>YE+<*V8/^/>/_='\JQJV8/^/>/_ '1_*L:FQRXC9$E6
M]*_Y"]E_UWC_ /0A52K>E?\ (7LO^N\?_H0K(Y3TZBBB@ HHHH ^2J***[CV
M38\.?\A"3_KD?YBNGKF/#G_(0D_ZY'^8KIZB6YE/<*TM/_X]V_WOZ"LVM+3_
M /CW;_>_H*SJ;'/7^ MT445@<9Z=I7_((LO^N$?_ *"*MU4TK_D$67_7"/\
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MA$NU8>[?WN/7.">PZ5T%94>AK#J,]]%?W:S3ME^(VX[*"4)"^V:U:0!1110
M4444 %%%% !6?K#R0V$MPM]]DCB1G9@BDDXX&6R,9[8R>,$=]"L[5-'BU5H#
M+<3QB%MZHFTJ6]2&4@XH Q[;5-4N_P"Q+.:0VT]U$\L\JHNXA0<8# @9X)X^
MF*HOK^LOHMK=+-"@6Z%O,X0%Y#N/;& ,?KZ5TL^CK<-;2O>7/VJW9C'<#8'P
M1@J1MVD?A5:;PQ:RV$%DMS<Q00L'"H4RSY)WL2I)//T]J8#?$MY=65F\UM=3
MQ.J918[?<I.>2[D$ 8^G?D]M>TE::S@E<H6>-6)C.5R1G@]Q52[TDWD#0OJ%
MZJR1^7+M9/W@YZ_+@'G^'&:NP016MO'!"@2*-0J*.P%("2BBB@ HHHH ****
M "HYTEDB*PR^4QXW[=Q [XSQGTSD>QZ5)574+)=1L9+1YIHDD&&:(@,1W&2#
MP: .8.O:C#IFI2I,+A%NA;VETZ+R"<$_* &QV..I[]*GN-2U6"YU>P@N4E:V
MB$Z3SH-RJ4R1A0 3GID?7-:C:!!)ICZ=-<SR6Y4!%(C4QX.05VJ.?KFE.A1F
M.[S>7)FN\":?Y-[*%V[?NX QZ#/O3 IIK%S_ ,(Q8RAQ)J-XJQQ9 &7/\6.F
M .:G\+7UUJ&D&:[E\V43.F[:%X!XX  J>VT*S@LHK2=1>10\1"ZC1]@]!A14
MFDZ/:Z-;/!:AL.Y9F;&X^V0!P* +]%%%( HHHH **** "D;<5.T@-C@D9 -+
M2,"R$!BI(P&&,CWYH YLZC?VNN7$"W1O;>WM&EN-T:J(Y.2 " ,9QT))Q5:T
MU;50VDNURDS:E%*?*D0*D;@97!49QT!SFMBPT&+3XVACN[F2%]QDCD$9\PMG
M)9@H8GGUIMKX=M[1HF2ZNF\A'2W#LI\G=U*_+R?][-,"CI^H:K+H6LN\OGWU
MM<30Q&.(=5 QA0.>2>N:NZ)>BX+12W]S+>)&C307$(C,9([#8I(_/M4MGHB6
M2W2I?7;"Y=I'R4!#MC+ JH(/'3I[5)9Z3%:WTUZT\UQ=2J$,DI7A1V 4 ?I0
M!H4444@"BBB@ HHHH **** .>UJZU"SO;-+6\,D]Q<!5M!$NTQ8^8GC=QW.0
M/:J-]K6I1PZKJ$5P$BL+I85M]BE77(!R2,Y.>Q%;0T-5U.>_CO[M)YL!B!&V
M%'\(W(2![4R;PY:37$[F6X6*XE66:W5ALD8=SQG\C3 @L[W43XNN+&ZEB, M
MC+''&O"_. ,DC)..O;FJ>G:_+=W4<]U)=PP3W;00B-(S#QT5B<ODXZ\#GM6N
MFBJFKG4_MUT9RNP@^7M*9SMQLZ>_7WJ.'PW9PSHZRW!ACG-PEN6'EK(>XXS^
M9H V****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+;"Y822[ H)P%R <G.>V..M6;/2+>QD@>)Y28;?[,NXCE<YR>.O%01Z!#!'
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M,#G)..*U]+T:WTCS?L[RMYN-WF$'IGI@#UJS:6<=F)A&S'SIFF;<>A;KCVH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img70551829_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &9 KD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **:[I
M'&TDC*J*"69C@ #N34%MJ%E>.5M;RWG91DB*56('X&@"S1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 45%=7"6EI-<R!BD2-(P7J0!GBL^/Q#9R:(VJJLIA0[63:-ZG(&",
MX[COTH U:*** "BBB@ HHHH ***@DEN%O(8DMM\#*Q>;>!L(Z#;U.: )Z***
M "BHIY7AB+I!).V?N1E0?_'B!^M4K+5S?2ND>GW:K'*8I'<QX1AU!PY)_ &@
M#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ"BDY2?43G)[L9%#%!&(X8TC0=%10 /P%/HHJ2 HHHH **** "BBB@ HHHH
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MBP7.LHJO8/=26,3WL217)'[Q$.0#]:L4AA1110 4444 %%%% !1110 4444
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MR"!_#WK6HH SM)T^2R2XDN&1KFYF,TGEYV@G@ 9Z@8ZUHT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4
M%W96E_ 8+RVAN(CU25 P_(U/10!PVI_"O0KJ3S].>XTRY!RK0.2H/K@_T(K,
MD?QSX(Q/--_PD&E+]_KYJ#USRP_\>%>F457.^NIHJCV>IA>'?%VD>)X-]A<8
MF R]O)Q(GX=Q[C(K=KC/$7P\L-5G_M'2Y6TO55.Y9X/E5F]P.A]QS]:RK+QO
MK'ABZ33?&EFP0G;'J,*Y5QZG'7\.?44^5/X0Y%+6)Z114%G>6VH6J7-I/'/
MXRLD;9!J>H,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML=M;H$BC&%457TG2K?1]/2UMQP.7<]7;N35ZAL04444AA1110 4444 %%%%
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M<<5JTU$2.-8XU544 *JC  '8"G4 %%%% !1110 4444 %%%% !1110 4444
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M#T?6;'7M.COM/G$L+]?53W5AV-)QMJMARC;5;%^BBBI("BBB@ HHHH ****
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M3C+)';K;-<.(G*,YW!0-P(( SGBI]8TZYU2V:VCNHH86VEMT)=LJP88.X#'
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MT5+DWNR7.3W84444B0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBL+4E6\\2V%C<*'M?)DF,;#*NPP!D=#B@#=HK$T+]Q?:M91\6\%P#$HZ)N
M4,5'H,]JVZ "BH+N[CLH#-*LS*"!B&!Y6_[Y0$_I6?\ \))8_P#/#5/_  57
M7_QN@#7HK(_X22Q_YX:I_P""JZ_^-T?\))8_\\-4_P#!5=?_ !N@#7HK(_X2
M2Q_YX:I_X*KK_P"-T?\ "26/_/#5/_!5=?\ QN@#7HK(_P"$DL?^>&J?^"JZ
M_P#C='_"26/_ #PU3_P577_QN@#7HK(_X22Q_P">&J?^"JZ_^-T?\))8_P#/
M#5/_  577_QN@#7HK(_X22Q_YX:I_P""JZ_^-T?\))8_\\-4_P#!5=?_ !N@
M#7HK(_X22Q_YX:I_X*KK_P"-T?\ "26/_/#5/_!5=?\ QN@#7HK(_P"$DL?^
M>&J?^"JZ_P#C='_"26/_ #PU3_P577_QN@#7HK(_X22Q_P">&J?^"JZ_^-T?
M\))8_P#/#5/_  577_QN@#7HK(_X22Q_YX:I_P""JZ_^-T?\))8_\\-4_P#!
M5=?_ !N@#7HK(_X22Q_YX:I_X*KK_P"-T?\ "26/_/#5/_!5=?\ QN@#7HK(
M_P"$DL?^>&J?^"JZ_P#C='_"26/_ #PU3_P577_QN@#7HK(_X22Q_P">&J?^
M"JZ_^-T?\))8_P#/#5/_  577_QN@#7HK(_X22Q_YX:I_P""JZ_^-T?\))8_
M\\-4_P#!5=?_ !N@#7HK(_X22Q_YX:I_X*KK_P"-T?\ "26/_/#5/_!5=?\
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M_P""JZ_^-T?\))8_\\-4_P#!5=?_ !N@#7HK(_X22Q_YX:I_X*KK_P"-T?\
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MDUMCJ-MH]FD,F70R7,B-)[X3@$^_K7:5Q3RVL4DD>EZAK MHR<BV@,D<?)R
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MK72ZRMDVF2&_E,4"D-YBDAD;/!7'.<US'G6\P"7^IZVME)P3/!L1QZ%@.E-
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MR1NX_P#UUU]8JZGI^JW=O;3)=6]Q'()HHYXC&6(!Z9Z\'I6U0 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
..%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img70551829_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "K :P# 2(  A$! Q$!_\0
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M6.XQ[/N97&[=_A5 >,S_ ,(\NJ^5IK[W"A(M1WJAV%]KMY?ROQM"X.20,\T
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M)3=D$YY;&>H(XID6@Q+#=I->W=Q+=E//FD**[(O\'R*H QD' S\QYZ8N'4K
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MP!_"DH(P>A(&0".G)':UYWXMN-)OO$;07MYI=K=:>%\HWWF?,DBY. DBYY%
M'6^%HWB\,V"/!!;D1_ZFW5%2,9.% 3Y1@<''&0:UZS?#Z01Z!9);-:M L8"&
MT4K$1_L@DG'XFKMQ<):V[S2+(R(,D11M(WX*H)/X"@"6N?O/^2AZ-_V"K_\
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M %7PKKT%C8V]E)%);+,3.C%LEF'9AQ\HKE?^%R^(O^?+2_\ OU)_\71\9?\
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M5K@^6'6,?ZW;N<90DH0%YKMK6.6*TACFD$DJ1JKNJ[0S <D#M]*EHH ****
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img70551829_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O ;,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@"I>
M:KIVGSVT%[?VMM-=/Y=O'-,J-,V0-J G+')' ]14<>MZ3-+>11:I92260)NT
M6X0FWQG.\9^7H>N.AK'\5)>SSVMK;Z#<WUK+@W=Q;/ LBHKJPB'F2(<,1R1G
M ' R<KSG_".:U/916YTKRWTRREM]SR1;=08W$,OR88X#"%L^8%YD'N: .U'B
M;0&@M9UUS33#=N8[:07<>V9P<%4.?F.>,"M6O,+O0-<NKKQ+=#0I0OB.![:.
M-Y8=U@?+2/?+B3!#%=_[LL?E'&:]/H "<#)Z572_LY+?[1'=P/#NV>8L@*[L
MXQG.,Y-9.GWVJ7_B'68O-LUT_3[A;583 WFR,8(I=QDWX S+C&P].M4;CP]J
MU[:$R2V4%RUQY[H-TL;-A%4CA"NU4P!SG.>O(B<FME<Z,/2IS_B2Y5_70Z=;
MF!VVI/&QWF/ <'YP,E?KCG%2US\.A7-MK'VRU>..(R-F,MNPI*DD9!Y.&X!&
M./<'H*<6WNB:T(1:Y)7N%%%%48A1110 4444 %%%>2GXV\\>'N/^OW_[751B
MY;%1A*6QZU17DO\ PNW_ *E[_P G?_M=;5A\0+_6]+BN].TQ(YC+-']G(><R
ME$1@H90NS<7QN((&,FAPDM6.5.45=H] HKFI/$%W"W]H2M:QZ2E\UG*K(WFQ
MX<QARV[&"X7C;PISFG6&N:C=:C:6TUM!$+K3GO$'S%E8,@56'T<9]Q4D'1T5
MD^']3FU2SG:Y4+-!</"P$31'C!!*,25)!!QD\$'OBK.IZG#I5LL\ZR,K.$ 0
M G.">Y'I0!=HKGO^$RT[_GC=?]\K_P#%58L?$MGJ%Y':Q13J[YP74 < GU]J
M -FBN.TGQ)K&IZ?IVZ*VAGORABN)+:18P#"96 C9@S$8QD, >3VQ5B+Q%>W
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M6BN7_M_5##O6U@,D8B!B<,C3&1V1"N3\HX5L'/4CC%7M'UI]1NI;>951XU)
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MK=]\$T:R1O@C<I&0>?8T[-#::U9+1112$%%%% !1110 445R7Q-./AYJF/\
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M\ASQ9_V%8_\ TBM:Z"N?\/?\ASQ9_P!A6/\ ](K6N@H **** "BBB@ HHHH
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MRJ'<OR!MI]1UQ0H65HE2Q'M*BG56B/#_ (@R3R^/-6:YC$;B4* .Z!0%/XJ
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M?_7A/_Z+:O#?AJRQ>/M.ED8)'&)2[L<!1Y;#)/;D@?C7N7BK_D4-;_Z\)_\
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M8@VPGG[Q7/OQ7BVJ_P#)1[W_ +"\G_HXU[GX>_Y#GBS_ +"L?_I%:UX9JO\
MR4>]_P"PO)_Z.-:TNIO0ZGK?@W_D+R_]<#_Z$M=Q7#^#?^0O+_UP/_H2UW%9
M& 4444 %>'?&7_D;[3_KP3_T9)7N->'?&7_D;[3_ *\$_P#1DE:4OB-J'QFQ
MX5Z:)_VP_P#9:]9KR;PKTT3_ +8?^RUZS4/<RENPHKDO&_C?_A#18_\ $O\
MMANO,_Y;>7MV[?\ 9.<[OTJWX-\4_P#"7:/+?_8_LGESM#Y?F[\X53G.!_>_
M2CE=KCY'R\W0Z*O._C+_ ,BA:?\ 7^G_ *+DKT2O._C+_P BA:?]?Z?^BY*<
M/B15+XT<%X!NKBV_M#[//+%N\O=Y;E<_>ZXKV[P]+)/H5M)+(TCG=EG.2?F/
M>O"_ _\ R_\ _;/_ -FKW'PS_P B]:_\#_\ 0S3J?$QUOC8GBK_D4-;_ .O"
M?_T6U>!^#/\ D,3?]>[?^A+7OGBK_D4-;_Z\)_\ T6U>!^#/^0Q-_P!>[?\
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MZ5J$][/)/&+!/)\U?)?RY26,@CPK8&0YY8#K3;;T*<FU9COL?C#_ *#NA_\
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MOA1JVD>;]G\363>;C=YFE.>F>F)QZUU5CH_BO3[..UBU[161,X+Z/*3R2?\
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7:TZ** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img70551829_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_7.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,R.   DI(
M @    ,R.   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( _T%V0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!<?W<_X5L_$/_D)VG_7$_P ZV/#'A+^R9A>7SJ]SC"*O2/(YY[GM6/\ $/\
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MYCY+Y.  2.?P.*['QW_R+1_Z[+_6NC#5_:Y7.+WBFO\ (PQ%'V690DMI-/\
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M"U/;1LTVUZ?+YG=^(_\ D6[_ /ZXM7(?#W_D,W/_ %[_ /LPKK_$?_(MW_\
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M ,BZ_P#U\-_):M>,O^12O/\ @'_HQ:J^ ?\ D77_ .OAOY+5KQE_R*5Y_P
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MSH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK_[-7:T5A'+(K!O"N5_.QM+,)/%+$*/RN<%\/].9[R?4'4[(U\N,GH6/7'T
M_6G?$13]JL6P=NQAG'&<BN[HI_V9%8/ZJI?.WG?8/[0D\7]9<?E?R[F9X<_Y
M%NP_ZXK7G^I:=>^%=;2:+(57W02CHP]#^'!%>ITV2*.:,QS(LB-U5AD'\*K%
M9>J]*$%*TH;,C#XYT:LI-7C+='!O\0[DVNU+&-9\?ZS>2O\ WSC^M5/"VC76
MKZPNH72L8(Y/->1Q_K'SG ]>>M=Z-'TQ7WKIUH&SG(@7/\JN !5 48 X ':N
M>.6UJM2,\54YE'96-Y8^E3IRCAJ?*Y;NYB>,06\)WH )X0\?[ZUF?#U2-)NF
M((!FX..ORBNNHKOEA.;%QQ-]E:WW_P"9QQQ7+AGA[;N]_N_R.5\<:*U[8I?6
MT9>:WX<*,ED_^L?YFN8\&(S>*K5E4E4#EB!T^1A7J-%<M;*X5,5'$J5K--JV
M]CHI9C*GAGAVKWNK]KG$?$8';IQP< R@G_OFL;3/&.H:5IT5G;PVS1Q9P75B
M>23V8>M>H45-;+:D\1+$4ZO*WY>GGY%4LPIQH1H5*?,EY^OEYG*^%O%%[K>I
M2V]W# B)"7#1*P.<@8Y)]:ZJBBO1P].I2I\M2?,^YP5ZD*D^:$>5=@KRSQ(C
M_P#"8W*[6RTRX&.N0*]3HKGQV#^N04.:UG?N;X+%_59N5KW5@K@/B&#_ &C:
M-@X\HC/XUW]%:8S#?6J+I7M<SPF(^K554M<R?"X(\,6.>/W?]36/\0E)TFU8
M D";DXZ?*:ZZBE5POM,+]7OT2OZ#IXGDQ'M[=6[>IS/@($>'&)! ,[$>_ JW
MXQ!;PG>@ GA#Q_OK6W13CA>7"_5[]+7"6(OB?;VZWL>2Z+X@N]"\_P"R1POY
MVW=YJDXQG&,$>M;VF^.-2O-4M;:2WM=DTRHQ1&R 3C(^:N\HKSZ.6XBBE&-=
MV72W_!.VMF%"LW*5%7?6_P#P#COB(";&S(!P)&R?3@5>\"@CPTN>\SX_2NCH
MKLC@K8QXGFW5K6_4Y98N^%6'ML[W/,O%^FMI>OFX@4I%.?-C8= W<?GS^-=!
MJ_B2^BT#3=3L%"^<?WP,>5SC&/89SWS76T$!E(89!X(/>L(Y=*G*HZ53EY_+
M9_?ZFTL?&<::J0OR^>Z^XX/_ (6+/Y)']G1^;V;S3M'X8_K6=X?TRZ\0>(/M
MEPO[E9?-FDVX#'.=H^I_*O03H^F,^]M.M"V<Y,"Y_E5M5"*%0!548  P *R_
MLVO5G%XFIS*/2UC3Z_1I0DL/3Y6^MQ:***]P\<**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BJVI7JZ=IEQ=OTB0L >Y[#\3@5GZ)K,U
MUX?.IZOY-NF6(* @;!QGDGG.?TK"5>$:GLV];7^1M&C.5/VBVO;YFS17,_\
M">Z1YVS;<[<_?\L8_GG]*T=7U26W\/OJ6E>5-A5D&\$AD/4\$>N:SCC*$XRE
M"5^75V-'A*T91C.-K[7-6BJ&B:FNKZ3#=@!688=1_"PZU?KHA.-2"G'9F$X2
MA)QEN@HHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ GN.#Q],?E5OX@W_EV-O8H>97\Q_H.GZG]*VIX[_A.]NWJE;Y[?\$RG@_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^S^6F[/E[L\X]17HOB*"6Y\/7D4"-)(R855&2>17->!-/O+34+I[NTG@4Q
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M7L)I;C3K>6XC:*5XP71Q@JV.>/K5BOJXR4DFNI\S).+:91UO_D7]0_Z]9/\
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M"7AG^RHOM=ZJF[D'RKU\H>GU/?\ *JWQ#C)TRTE_A68J?Q7_ .M63_:_C/\
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M03T_0"MFBBG1I1I4XTX[)6%5J.K-SENPHHHK4S"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY.#NS^E=Q7S1X0_Y/,UG_KI<_P#HNOI>@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_"S]!L[R-I[*RLTFD@#;=^^4[AGME4 S6['^UCI\,21Q>#IDC10JJM\H"@=
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MZ_@0<>V*7Q[HEOXB^'^MZ9=1AUFLY-N1]UPI*-]0P!KP;X%>()]/^!OCS8[
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M_(Z>-/K'_P"C)*^D: "BBB@#S/\ :%_Y(CK7^]!_Z.2H/V<O^2*:;_UWG_\
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MO?J!ZT =G^S3(;[Q]XO\0R*RP^06<X)QYDI?'Y(:]5BN/AM\<[6[MUABU?\
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MPY\:%UOXOWW@>\T<6#6[SQ17#7&XS/&>!MVC&5!/6O4J^<?CQ\,M=L_%D?Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\]GXUZQX.^.>K:#XYO"?#ZW$B0D6R[K=6PT39499=I
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Y_\ $OXOZ+\,IK&WU&VN+VZO%9Q#;E040<;FR>A/ ^A]*[F_
MOK?3-/N+Z^E6&VMHFEED;HJJ,D_D*^$?B'X@U+QOXDO/%UW$Z6-W<M;6F[HB
M1@$(/<*RD^[>] 'W=87:W^FVUXBE%N(EE"MU 8 X_6IZS?#O_(KZ5_UYP_\
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MFRJ,#W )R?85XUX>^!7B?XDZ&OBOQ7XIFM[[4$\^V26,RMM/*LQW#:#P0%'
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M#_D]:Y_Z\!_Z3+0![Y1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;H]Z;"^N;18X+D.R^4QE?#97D?A4Y^!GQ5D&R7XDRE&X8?;[H\?3O6A\4?\
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MG!!QUKSL>(M7CT^;3)_.-V[*J.PQ(H/4>OTJLUGK7AR2*^='B!;J'# ^S8H
M].HJ&RN5O;&&YCX65 P'ID5-0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>!P?\GK7/_7@/_29:]\KP.#_ )/6N?\ KP'_ *3+
M0![Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YG\;])T^/X9^(-5
M2SA%_+#!"]SL&\H)E(7/IR:] TC_ ) =C_U[1_\ H(KB_CE_R1O6_P#=B_\
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M+[5@>8;@W77=USCY?I0,]XHI$)9%)&"1DCTI:!!1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^#?#$GAG3+G[==B^U/4+E[R^N@FP22MCA1V4   >U '14444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Q
M]XK_ .2I^*O^O^3_ -"JC5[Q7_R5/Q5_U_R?^A51KMI? CTZ'\-'<_ 3_DKE
M_P#]@UO_ $*.OI:OFGX"?\E<O_\ L&M_Z%'7TM7)/XF<%3XV%%%%29A1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?'WBO
M_DJ?BK_K_D_]"JC5[Q7_ ,E3\5?]?\G_ *%5&NVE\"/3H?PT=S\!/^2N7_\
MV#6_]"CKZ6KYI^ G_)7+_P#[!K?^A1U]+5R3^)G!4^-A1114F84444 %%%%
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MGXLZ-X0TP-*!;Q_9[<-A6FD9LL>W0#D] #6.G[+?CED!:\T=21RIN'X_\<H
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M6_\ 0Q4/ASQ=#HWA^XLYHY&FRS0%1P21T/IS6G\-K%UCO+YP<.1$A]<<G^E
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M** "BBB@ HHHH **** /C[Q7_P E3\5?]?\ )_Z%5&KWBO\ Y*GXJ_Z_Y/\
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M+10!@WG@S1;V\-S+;,KL<N(W*JQ]Q6S;6T-I;I!;1K%%&,*BC@5+10 4444
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MY]JZ^@#R3_AFCX>?\^^H?^!A_P *X7P9X5TWP7^UHVB:(LJV<%BS()7WMEH
MQY^IKZ5KP.#_ )/6N?\ KP'_ *3+0![Y1110 4444 %%%% !1110 4444 9>
MN>'[/7K7R[E=LJC]W,H^9/\ $>U<K8:QJ/@^\73==5IK(G$4Z\[1[>H]NHKO
MJK:AIUKJEF]M>Q"2-NQZ@^H/8T 2P3Q74"36\BR1.,JZG((J2O/FCU3P'>;X
MMUYI,C<C^[_\2WOT-=KIFJ6FKV:W-C*'0]1W4^A'8T 7**** .7U3X;^%-;U
MVYUC6M)BO[NXC6-FN"65548&T9P/KUKE/@G MI'XLTW3Y6FT.TUB2+3V+;AM
MQ\P4]QTKJ/'7@5/'%G!!)K6I:6(0XQ92[5EW ??'\0&.GN:Y[X2W]SI-YK'@
M'4XK9;CP^R&&>VC\M;B%^0Q7^]R,GOG\: *'COX6^!=#^&6KW$>G16L]M;O-
M%>LY,QEZK\Q/.6P,>])KDU]JGPQ\ Z3K1DW:W>6-O?AB09(]I<JW^]M&:L?$
M7X5SZS<7?B/3M:NY;VW874.FWI$UFS(H^41GIG;[\FKUNTGQ;^%6DZK8RIIF
MJQ3)=V\FW<D-S"Q'(ZE3@CZ&@8VSMK'PK\;[B#388;#3[_0/M5S%$H2-7BEV
MA\#@?*2*VOA_#)?6=]XHNT9;C7I_/C5NL=LHVP+_ -\_-]7-<;JWA_7[K6TC
M\37EG)K?B55TT1Z<&$5II\9\RX8%N26X7/JPK/N'UG4?!^M_$#3M<OK.32KJ
M4:9I\,NVU6U@?84>/HQ8*V3]* /<**KZ?=KJ&F6MX@PMQ"DH'H& /]:L4""B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#X^\5_P#)4_%7_7_)_P"A51J]
MXK_Y*GXJ_P"O^3_T*J-=M+X$>G0_AH[GX"?\E<O_ /L&M_Z%'7TM7S3\!/\
MDKE__P!@UO\ T*.OI:N2?Q,X*GQL\#^._P#R5KX?_P#723_T-*U:ROCO_P E
M:^'_ /UTD_\ 0TK5J3,X#XI?Z[PQ_P!A5/Z5]35\L_%+_7>&/^PJG]*^IJ "
MBBB@ HHHH **** "BBB@ HHHH **** "@]#10>AH \"_9W_Y'[XB_P#7^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHH **** "BBB@ HHHH **** "BBN1\?>-YO"%E!'IND7&K:G>+(;>&)3L4(
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M 3_DKE__ -@UO_0HZ^EJ^:?@)_R5R_\ ^P:W_H4=?2U<D_B9P5/C9X'\=_\
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M[K?B"[\,^*]'.BZ_:Q^<(0^Z.>/IN0_C[_7@UVLFI6,-\ME->01W3)YBPO(
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MK.^.?_(JZ+_V';7^;4 :?QAM9[CX;W<MO&TILYX+MXT&2R1RJS<?0$_A7/\
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M]37C_P %/B[XV\8?$RUTK7]36YL)(96=!:QIRJ$CE5!ZU]+4 %%%% !1110
M4444 %>!P?\ )ZUS_P!> _\ 29:]\KP.#_D]:Y_Z\!_Z3+0![Y1110 4444
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M8E"?RX/XTW_A)?%&B<:SIWVB(=9-N/\ QY>/TH [ZBN7L/'^D7>%N3):.?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***BNY6@LYI4QNCC9AGU H
MEK-A\/:7;^)+C7H;4+J=U"L$T^]OF13D#&<=O2OG.+]HKQQ-&'CTW2G'JMM)
M_P#'*?\ \-">//\ H%:7_P" TG_Q=.S*Y9=CW/Q9\.?#/C::*?7[ RW$*;(Y
MXY6C=5SG&0>1D]ZO>&/"&A^#M/:S\/6"6D3MND8$L\A]68\FN0^#GQ!U?Q_I
MNJSZY#:PR6<Z1H+9&4$%23G+'TKTFD24-3T6SU>6Q>^5W^PW*W4*!R%\Q00I
M([XSD>^#4?B#P[IGBC2'TW6K87%LS!P-Q5D8=&5AR"/45IT4 9/ASPQI7A33
M#8Z+;F*-W,DCNY=Y7/5F8Y+'ZUK444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !45U;1WMG-:S@F*:-HW
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M %%%% !1110 4444 %%%% !1110 4444 %!Z&B@]#0!X%^SO_P C]\1?^O\
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MZ&HHHH **** "BBB@ KP.#_D]:Y_Z\!_Z3+7OE>!P?\ )ZUS_P!> _\ 29:
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M4 %%%% !1110 4444 %%%% !1110 57U'_D%W7_7%_Y&K%5]1_Y!=U_UQ?\
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MWBO_ )*GXJ_Z_P"3_P!"JC7;2^!'IT/X:.Y^ G_)7+__ +!K?^A1U]+5\T_
M3_DKE_\ ]@UO_0HZ^EJY)_$S@J?&SP/X[_\ )6OA_P#]=)/_ $-*U:ROCO\
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M@#T"BBBD 5AZJ^BZI=-I>I2!)X\%"3M(R/X6Z?A6Y7)^)/"ESJ5\]]9RHSL
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MGX"?\E<O_P#L&M_Z%'7TM7)/XF<%3XV>!_'?_DK7P_\ ^NDG_H:5JUE?'?\
MY*U\/_\ KI)_Z&E:M29G ?%+_7>&/^PJG]*^IJ^6?BE_KO#'_853^E?4U !1
M110 4444 %%%% !1110 4444 %%%% !0>AHH/0T ?&?AVR^(MYXZ\7_\*SEN
M(RNH2?;/)FCCS^]DV9WD9_BZ5U(T3]HW/-UJ'_@;;_\ Q5=-^SO_ ,C]\1?^
MO]?_ $;-7OM %+15NTT&P74R3>K;1BX+$$F3:-W(XZYJ[17$>-=5U72-9M);
M:XD6S< ^6N &93R"?<8H S/$/ARZT"X_MN.>*YS<%V1XN%).1P>H[5J^)-3&
ML?#Q+U5VF1TWJ/X2&P1^=4O%OBZPU70UM+ NSRLK2;E(V <X]SGTJ[#H\Q^%
MSVY0^<R&X"8Y^]N _(4Q&CX$_P"11B_WW_G7.?#WGQ+>D=/);_T,4>%_%EII
M/ARXM;DMYR,S0@*3OR.F>W-6OAK9OF]OG'!Q$I]3U/\ 2@#O:***0PHHKA/$
M\^JWNORZ=9M-)$JKB*(8'([X_K0!NZSXBT:WB>"YV7C=X4 ;\ST%<!.4O;X_
M8+,Q!S\L*$N:Z;3/ DCX?5)O+'_/*(Y/XG_"NLL=,L]-CV65ND7J0.3]3UH
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MHH *KZC_ ,@NZ_ZXO_(U8JOJ/_(+NO\ KB_\C0!\3Z%_R#1_O'^E:-9VA?\
M(-'^\?Z5HUW0^%'JT_@1Z_\ LT?\@GQ)_P!?J?\ H)KW"O#_ -FC_D$^)/\
MK]3_ -!->X5Q/<\N6X4444A!1110 4444 %<YXN\>:#X'CM7\17,D"W998MD
M+/DKC/0<=171UX3^TPH>/PNK#(,\P(_!*!K5V.M_X7[X _Z"=Q_X"2?X4H^/
M?@%F &I7&2<#_1)/\*^;_P"S;/\ YX+^M4]1M(+>*)H8@C&51D5LZ32N=$L.
MXJ]S[C5@RAAT(R*6F0_\>\?^Z/Y4^L3F"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /&?VEO\ D2M'_P"PFO\ Z+>O%J]I_:6_Y$K1_P#L
M)K_Z+>O%JZ:'4[<+LRAK7_(+?ZC^=?9/A?\ Y%#1_P#KP@_]%K7QMK7_ ""W
M^H_G7V3X7_Y%#1_^O"#_ -%K45OB,\3\9H75S'9VDUS.=L4*&1R!G  R:\Q_
MX:.^&_\ T%;G_P  I?\ "O0?$7_(KZI_UZ2_^@&OE?X9>#_#^L^"8KS5-+AN
M;@SR*9'+9P,8'!K$YCV?_AH[X;_]!6Y_\ I?\*[#P;X\T'Q[87%YX:N9+B&W
MD$4ADA:/#8ST8>E>+#X<^$<_\@*W_P"^G_QK9_9?18O#GB2.,;435"JCT 6@
M#W.BBB@ HHHH ^/O%?\ R5/Q5_U_R?\ H54:O>*_^2I^*O\ K_D_]"JC7;2^
M!'IT/X:.Y^ G_)7+_P#[!K?^A1U]+5\T_ 3_ )*Y?_\ 8-;_ -"CKZ6KDG\3
M."I\;/ _CO\ \E:^'_\ UTD_]#2M6LKX[_\ )6OA_P#]=)/_ $-*U:DS. ^*
M7^N\,?\ 853^E?4U?+/Q2_UWAC_L*I_2OJ:@ HHHH **** "BBB@ HHHH **
M** "BBB@ H/0T4'H: / OV=_^1^^(O\ U_K_ .C9J]]KP+]G?_D?OB+_ -?Z
M_P#HV:O?: "JFI:9:ZM9M;7T0DC/(YP5/J#V-6Z* .9LO 6D6=T)V\ZXVG*I
M*P*C\ !FNFHHH YF\\!:1=WC7 \Z#<<M'$P"D_B./PK?LK*WTZS2ULXQ'%&,
M!1_/ZU/10 4444 %8^O:[!H4(;RQ)<S?=0<9QW)]*V*X34K;^VO'YM)F/E)A
M3@_PA=Q'XYH [2QN?MFGP7/ \V-7('8D5A1^+XE\036%T@2%9/+CF!Z'IS^/
M>N@@@BMH$A@0)&@PJCL*Y#QKHMM#:C4;:,12>8%E"C ;/?ZYH [.BJ.BSM<Z
M'9S/RS1+D^IQBKU !1110 4444 %%%% !1110 4444 >?_%+XKV'PVAT^*2W
M^UW^H2@1P[MJI&" TC'VSP.Y^E<Y\<?C+=_#UK'2O#L=O+J=W'Y[RSKN6&+.
M!A<C))!Z],>]<I\2=&MO&'[5GA_0M8!DL/L:;X]Q&]5$LA7\2,5R/C:WB\;_
M +5$>CLOFV:7UO9-'GCRHU7S%_1Z /6_@C\:)OB')<Z/K\,,&L6T?G(\ *I<
M1YP3@DX8$CZY]J]AKYRAT73O"7[8>FV?AZWCL[2ZM2[V\(PB%H'R .W*AL>]
M?1M !1110 45#=W=O86<MU?3QV]O"I>265PJH!W)/ KC['XQ_#_4M473K3Q1
M9M<LVQ0X=%8^@=@%/YT =M1110 5X'!_R>M<_P#7@/\ TF6O?*\#@_Y/6N?^
MO ?^DRT >^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#X@\)V>N(9 !;W8'RS
M*.OLP[_SK>HH X*Q\0ZIX7NET[Q)$\MOTCG'S$#V/\0_45W%K=07MND]I*LL
M3C*NIR#3+ZPMM2M6M[V%98F[,.GN#V-<1<Z1J_@VY:]T61KJP)S)$W.!_M#_
M -F%,#MM2%XVEW0TMHUO3"XMVE^X),':6]LXKQCPWX%^+/A;[8^FW_AU[B_F
M,]U<W!>269CZL4Z#L/<UZQH/B:QUZ']RWE7 &7@<\CW'J*V*0'%2VWQ%/@6%
M8[[2!XFCN-\C;";>6($_)TR"1CFL"'PCXX\::]IUS\19-.L]*TN<7,>G6!+?
M:)5^ZSDYX'U]L<YKU2B@"AKC:BN@WIT.-)=1\EA;+(P5?,(PI)/8'G\*YZ\\
M P7/PK;P?'/L;[,%%R1D^>#O\P_63YC]:["B@#@/#^@^*]4\6V&N>.([&V.C
MVTD%I%9RF3SI)  \S$@;05& ON:[^BB@ HHHH **** (+Z]MM-L)[V^F2"VM
MT,DLKG 10,DFO.?AS!<^+?%6I_$3486A@NH_L6CPR#E+93RY]"Q&?S]JK?&/
M3/&?B"ZT[2M T4ZCH:[9[Z-;E(OM+!N(F)8$+@ \=<^U:'AC7_B')J]AI^K>
M!;32M)'[N2:*\1O)0*<84-[ 4 <7X?\ BMX7C\=ZYXF\227BWDC?8K"%+1W%
MO:H?4#[SMDFI_@]J>A>*O!VM^";DSM-?37=PX\H@"%V !#=-PR#BO<MJ_P!T
M?E7#_";P_J7ASPG=VFM6GV6XDU.XF5"RME&8%3E2>M SF=7\/>)?#]E9:AK^
MN6^K7.EK]A\/V\%N8VDN9AY222DDY95.>..":9IW@Y/$6NZIX;?4[ZVT_P +
M6EO:V@M+AHBUU(AD>X;!^9LGOQR:[F\T^[UGXD6<MS;NFE:);F:%W'RSW4F5
M!'KL0-^+^U<_J\7B3PAXXUK5/#^@2ZW:^(((BH@D53;7,:E 7W$?(1@Y]J -
M_P"&>MW?B'X=:5?ZE)YMX4:&>3^^\;LA;\=N?QKJJY_P)X>D\*^!],T>X=9+
MBWB)G=>AD9BSX]MS&N@H$%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 57U'_D%W7_7%_P"1JQ5?4?\ D%W7_7%_Y&@#XGT+
M_D&C_>/]*T:SM"_Y!H_WC_2M&NZ'PH]6G\"/7_V:/^03XD_Z_4_]!->X5X?^
MS1_R"?$G_7ZG_H)KW"N)[GERW/#_ (F_&_Q%X,^(,OAW0]!M=25+>.8%ED:0
M[AD\*>@KE_\ AH[Q_P#]"1#_ -^)_P#&KGB_C]J:?_L%+_Z!739/J:0C'\$?
M'SQ1XB^(.D^'M9\.6NGQW\A4N5E5P I.0&/J*]^KYI8Y_:.\%9_YYO\ RDKZ
M6H **** "O"OVEON^%?^OB;^25[K7A7[2WW?"O\ U\3?R2FMRH[H\EJAJ_\
MQ[P_]=EJ_5#5_P#CWA_Z[+7;4^%GIU?@9]MP_P#'O'_NC^5/ID/_ ![Q_P"Z
M/Y4^N$\H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9_:
M6_Y$K1_^PFO_ *+>O%J]I_:6_P"1*T?_ +":_P#HMZ\6KIH=3MPNS*&M?\@M
M_J/YU]D^%_\ D4-'_P"O"#_T6M?&VM?\@M_J/YU]D^%_^10T?_KP@_\ 1:U%
M;XC/$_&/\1?\BOJG_7I+_P"@&OG'X/?\D[A_Z^9?Z5]'>(O^17U3_KTE_P#0
M#7SC\'O^2=P_]?,O]*Q.8[H=:J?LQ?\ ( \3?]A8_P#H-6QUJI^S%_R /$W_
M &%C_P"@T >XT444 %%%% 'Q]XK_ .2I^*O^O^3_ -"JC5[Q7_R5/Q5_U_R?
M^A51KMI? CTZ'\-'<_ 3_DKE_P#]@UO_ $*.OI:OFGX"?\E<O_\ L&M_Z%'7
MTM7)/XF<%3XV>!_'?_DK7P__ .NDG_H:5JUE?'?_ )*U\/\ _KI)_P"AI6K4
MF9P'Q2_UWAC_ +"J?TKZFKY9^*7^N\,?]A5/Z5]34 %%%% !1110 4444 %%
M%% !1110 4444 %!Z&B@]#0!X%^SO_R/WQ%_Z_U_]&S5[[7@7[.__(_?$7_K
M_7_T;-7OM !1110 4444 %%%% !1110 5PNNRR:'XUCU'86CD ; [C&UA]:[
MJJ.K:3;:Q9^1= C!RCKU0^HH AA\2Z1-$'%]$O'*N=I'X&N9\6>(+?4X8[#3
MF,J[PSN!P3V ]:9+X"OEDQ#=0.F>"V5/Y8-;&A^#XM-N%N;R47$R<HJC"J?7
MW- &WI=J;+2;:W;[T<2AOKCFK5%% !1110 4444 %%%% !1110 445'<7$-I
M;27%U*D,,2EY))&"JB@9))/04 ?._P"T3IVN>&/'6A_$/P^&4VT0@DF";EBD
M4L5W#T97(_#W%<[^SKX?U3Q-\2K_ ,97Z,Z6JS2?:77Y9+J7(P/7 9B<=./6
MOHCPKXW\/?$&VU+^PI?MMM9S_9YFDBPDAQG(!ZJ?4CL:=XK\6:%\.?#<>HZI
M&;>P\](%2UB'REL]%&.!@DX]* /!?@58Z]XU^,NI>-O$3M,;!7C><KM4S,NP
M(HZ *F>!TX]:^GJR?#%SH5[X?M[KPH;1M,FR\1M%"H23SP.ASUSSGK6M0 44
M44 ?/?[4^KZF=/T;0+".<VMPSW%T8U.UBI 121QUW''L#VKC/B'^S\O@CX9K
MXCBU:2YO;;ROML#Q@)\Y"_(>O#,.O4>G2OK<@$8(R*^=?VD_B%%=0Q> -#_T
MJ[FFC>^\KYBISE(0!U8G!([8'K0!Z+\!]?N_$7P@TJXU&1I;BW+VID8Y+A&P
MI)]=N!^%>BUR7PN\)OX*^&^DZ+<8^TQ1&2YQVE<EF'X$X_"O$M4^/GQ,M-7O
M+:W\+VSPPSO'&QL)SN4,0#G=Z"@#Z:KP.#_D]:Y_Z\!_Z3+7+_\ #0GQ1_Z%
M2U_\%]Q_\547PJ\2ZMXM_:8CUCQ#9I9W\UG(LD*1-&%"P[1\K$GH!0!]4T44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <EKW@M+B;[?H;_ &2]4[MJ
MG:K'V_NG]*S5\::K:V4UC?VOEZA'A1*PQQZD>OTXKOZ\_P#'F[^W(<_=\@8_
M[Z- &.NMZHL_G"_N-^<\N2/RZ5Z#X<UK^VM-\R0!9XSME Z9[$?6O+ZU-%UZ
MXT%YI(+0W22 !P"1MQG!R : /4Z*XN#XE63'%S8SQ'OL8-_A6E!XZT*?&ZY>
M$_\ 32(C^6: .BHK/M]>TJZ_U&HVS'T\T _D:OJZNN48,/4'- "U\[?&KQ?X
MJTGXFC3= UR[L;<V,4GE12;5W$MD]/85]$U\Q?''_DLZ_P#8.B_F]5%7:1<$
MG))G,_\ "<?$3_H:K[_O_P#_ %JW? /C?QI<?$S0+#5O$5[<VUS<A9(6ERKK
M@\'BN6K4\#?\E@\+?]?7]#6U2G&,;HZJM&,871]=T453O-6L+!PEY=Q1,>BL
MW/Y5SG$7**CM[F&[A$MM*DL9Z,AR*DH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J^H_\ (+NO^N+_ ,C5
MBJ^H_P#(+NO^N+_R- 'Q/H7_ "#1_O'^E:-9VA?\@T?[Q_I6C7=#X4>K3^!'
MK_[-'_()\2?]?J?^@FO<*\/_ &:/^03XD_Z_4_\ 037N%<3W/+EN?.?B_P#Y
M.EG_ .P4O_H%=+7->+_^3I9_^P4O_H%=+2$<@W_)QW@K_KF_\I*^EJ^:6_Y.
M.\%?]<W_ )25]+4 %%%% !7A7[2WW?"O_7Q-_)*]UKPK]I;[OA7_ *^)OY)3
M6Y4=T>2U0U?_ (]X?^NRU?JAJ_\ Q[P_]=EKMJ?"STZOP,^VX?\ CWC_ -T?
MRI],A_X]X_\ ='\J666.&)I)G6.-1EF<X 'N:X3RAU%4?[;TK_H)V?\ X$)_
MC1_;>E?]!.S_ / A/\: +U%1P7,%U%YEM-'-'G&^-@P_,5)0 4444 %%%% !
M1110 4444 %%%% !1110 4444 >,_M+?\B5H_P#V$U_]%O7BU>T_M+?\B5H_
M_837_P!%O7BU=-#J=N%V90UK_D%O]1_.OLGPO_R*&C_]>$'_ *+6OC;6O^06
M_P!1_.OLGPO_ ,BAH_\ UX0?^BUJ*WQ&>)^,?XB_Y%?5/^O27_T U\X_![_D
MG</_ %\R_P!*^CO$7_(KZI_UZ2_^@&OG'X/?\D[A_P"OF7^E8G,=T.M5/V8O
M^0!XF_["Q_\ 0:MCK53]F+_D >)O^PL?_0: /<:*** "BBB@#X^\5_\ )4_%
M7_7_ "?^A51J]XK_ .2I^*O^O^3_ -"JC7;2^!'IT/X:.Y^ G_)7+_\ [!K?
M^A1U]+5\T_ 3_DKE_P#]@UO_ $*.OI:N2?Q,X*GQL\#^._\ R5KX?_\ 723_
M -#2M6LKX[_\E:^'_P#UTD_]#2M6I,S@/BE_KO#'_853^E?4U?+/Q2_UWAC_
M +"J?TKZFH **** "BBB@ HHHH **** "BBB@ HHHH *#T-%!Z&@#P+]G?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[K_KB_\ (T ?$^A?\@T?[Q_I6C6=H7_(-'^\?Z5HUW0^%'JT_@1Z_P#LT?\
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M\3."I\;/ _CO_P E:^'_ /UTD_\ 0TK5K*^._P#R5KX?_P#723_T-*U:DS.
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MADO(O)L8Y!AO+)!:0@^N ![9/<5]!U3MM6TVZE$-G?VLTF.(XIE8X'L#5R@
MHHHH **** "BBB@ KP.#_D]:Y_Z\!_Z3+7OE>!P?\GK7/_7@/_29: /?****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MYB^./_)9U_[!T7\WKZ=KYB^./_)9U_[!T7\WJH?$C2E\:.-K4\#?\E@\+?\
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M^- '6T4R*6.>-9(761&&0RG(/XT^D 445Q/Q'\9SZ!9V^C>'T%SXEU<^58P
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M[2O//W?\\O(&S/MMZ5U7PT6=?A=X;%UGS?[.ASGKC:,?IB@1U%%%% !1110
M4444 %%%% !1110 4444 %5]1_Y!=U_UQ?\ D:L57U'_ )!=U_UQ?^1H ^)]
M"_Y!H_WC_2M&L[0O^0:/]X_TK1KNA\*/5I_ CU_]FC_D$^)/^OU/_037N%>'
M_LT?\@GQ)_U^I_Z":]PKB>YY<MSYS\7_ /)TL_\ V"E_] KI:YKQ?_R=+/\
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M#GK['\*]TH **** "BBB@ HHHH *\#@_Y/6N?^O ?^DRU[Y7@<'_ ">M<_\
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MK9U;_D"WW_7M)_Z": -C]FK_ )(W;_\ 7Y/_ #%>M5Y+^S5_R1NW_P"OR?\
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MOF7^E8G,=T.M5/V8O^0!XF_["Q_]!JV.M5/V8O\ D >)O^PL?_0: /<:***
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KYB^./_)9U_P"P=%_-Z^G:^8OCC_R6=?\ L'1?S>JA\2-*7QHXVM3P
M-_R6#PM_U]?T-9=:G@;_ )+!X6_Z^OZ&NJK\!WU_X;/KND9E099@H]S2UXK^
MU&6'PST_8Q4G5HQD'_IG)7&>8>S^=%_ST3_OH4>=%_ST3_OH5\A+\$G90?\
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MK9U;_D"WW_7M)_Z": -C]FK_ )(W;_\ 7Y/_ #%>M5Y+^S5_R1NW_P"OR?\
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M /V#6_\ 0HZ^EJ^:?@)_R5R__P"P:W_H4=?2U<D_B9P5/C9X'\=_^2M?#_\
MZZ2?^AI6K65\=_\ DK7P_P#^NDG_ *&E:M29G ?%+_7>&/\ L*I_2OJ:OEGX
MI?Z[PQ_V%4_I7U-0 4444 %%%% !1110 4444 %%%% !1110 4'H:*#T- 'Q
MGX=UGXA:1XZ\7?\ "MK2>X:34)/MGDVBS[0)9-F<@XZM75#QG^T/G_D$W_\
MX*(__B:Z7]G?_D?OB+_U_K_Z-FKWV@"EHTEW-H-A)J2E;Q[:-KA2NTB0J-PQ
MVYSQ5VBN2\>:\^G6*6%JVV>Z!W,#RJ=_SZ?G0!B^*]8D\1ZM#H^DCS8TDQE>
MDC^OT'/-:_BNQ73/ $=G$<K"T:D^IW<G\ZSO"-_X=T2S\^ZO5^W2CY_W;'RQ
M_=''YUN^))8-<\$W5QI[^=&!O5@I&=K<\'Z&F(/ G_(HQ?[[_P ZYSX>\>)+
MT#IY+?\ H8JWX/\ $-C8>%KB*ZN$CE@9F5&/+@C(QZ\U'\-;9FNKZ\8<!1'G
MW)R?Y"@#T"BBBD,***#T- '(Z7KEU<ZOJE[+N-E;Q,$&?E7!X_$X-<O$VJ3&
M;68V<F%P9)0W0G^E78=2CLO#FIZ<Y*W,D^T#'49P?Y'\ZMI/%IO@$Q2Y\[4&
M8QC';(&?R% ':Z==?;M-M[G&/-C#$>AQS5FL[P_$T/AZR1Q@^4#CZ\_UK1H
M**** "BBB@ HHHH **** "D(!Z@&EKR?]H3Q[=^"_ <=MI$S0:CJTA@CF4X:
M*,#+L#V/(&>V[/:@#T^"]L;HSBVN()C;.8YA&X;RF SM;'0X(.#7'GXR?#D'
M_D:=/_\ 'O\ "O/OV8M.UBS\$:Y=:C:2Q6-_*LUI-(?]<0K*Y ZXX7GO7@W@
M;X:Z[\1KO48O#S6@>Q57D%S*4W!B<!< \_*>N* /N#0/$&C>)]-_M#P]?07]
MKO,?FPG(##J#Z'D?G6G7RW^R[KUQI?C35_"M[NC6YB,RQ-_!-$<,,>I4G/\
MNBOJ2@ HHHH **** "BBB@ KP.#_ )/6N?\ KP'_ *3+7OE>!P?\GK7/_7@/
M_29: /?**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KYB^./_)9U_P"P=%_-Z^G:^8OCC_R6=?\ L'1?S>JA\2-*7QHX
MVM3P-_R6#PM_U]?T-9=:G@;_ )+!X6_Z^OZ&NJK\!WU_X;/KNO%?VH_^2::;
M_P!A>+_T7)7M5>*_M1_\DTTW_L+Q?^BY*XSS!8_]4G^Z/Y5R'Q7_ .2:ZC_O
M1?\ HQ:Z^/\ U2?[H_E7(?%?_DFNH_[T7_HQ: />? ?_ "3KPY_V"[;_ -%+
M6_6!X#_Y)UX<_P"P7;?^BEK?H **** (+Z^MM,L)[V_G2WMK=#)+*YPJ*.I-
M<O\ \+7\"?\ 0TZ=_P!_:F^)O_)+?$?_ &#Y?_0:^0[+2[:>RCDD#;F'.&JH
MQ<G9&D*;F[(^MO\ A:_@3_H:=._[^UT&C:YIGB'3Q?:)>PWUJ7*>;"V5W#J*
M^+WT>T$;$*^0"?O5]&?L[?\ )*$_Z_IOYBG*#CN.I3<-SU.BBBH,@HHHH **
M** (Y[:"Y3;<0QRKZ.H8?K6+=^"]#N\DV8A8_P 4+%?TZ?I6]10!P]Q\.%C<
MR:9J4L+=A(O]1BHO[.\;:3_Q[7?VQ%[>8'_1N:[VBG<#@QXWUK3B%UC1S@=6
M"M'_ #R*CUCQI'K&D_9K&.:!G;][NQ]WT!'K7H! (P1D'L:XCQSIL4"VUU;0
M1QJQ9)"B 9/49Q^-(#CZ[+P'J+F2?3Y&)0+YD8/\/."/U%<;6CI#ZM:S/>Z+
M;&=H1MD&S<,'MCKV[4 >K45QEC\1(-_E:O9R6L@X9D&0/J#R/UKI['5K#4UW
M6-W%-_LJWS#\.M %RBBB@ JOJ/\ R"[K_KB_\C5BJ^H_\@NZ_P"N+_R- 'Q/
MH7_(-'^\?Z5HUG:%_P @T?[Q_I6C7=#X4>K3^!'K_P"S1_R"?$G_ %^I_P"@
MFO<*\/\ V:/^03XD_P"OU/\ T$U[A7$]SRY;GSGXO_Y.EG_[!2_^@5TM<UXO
M_P"3I9_^P4O_ *!72TA'(-_R<=X*_P"N;_RDKZ6KYI;_ )..\%?]<W_E)7TM
M0 4444 %>%?M+?=\*_\ 7Q-_)*]UKPK]I;[OA7_KXF_DE-;E1W1Y+5#5_P#C
MWA_Z[+5^J&K_ /'O#_UV6NVI\+/3J_ S[;A_X]X_]T?RKD/B[_R1_P 3_P#8
M/D_E77P_\>\?^Z/Y5R'Q=_Y(_P")_P#L'R?RKA/*/)OAW_R3O1O^N!_]#:MG
M5O\ D"WW_7M)_P"@FL;X=_\ ).]&_P"N!_\ 0VK9U;_D"WW_ %[2?^@F@#8_
M9J_Y(W;_ /7Y/_,5ZU7DO[-7_)&[?_K\G_F*]:H **** $/W3]*^*+?_ )"&
MI_\ 7[+_ .A&OM<_=/TKXHM_^0AJ?_7[+_Z$:UI?&=&'^,LUZE^S9_R%O%7U
MA_G)7EM>I?LV?\A;Q5]8?YR5K7V1OB?A1[[1117*< 4444 %%%% !1110!XS
M^TM_R)6C_P#837_T6]>+5[3^TM_R)6C_ /837_T6]>+5TT.IVX79E#6O^06_
MU'\Z^R?"_P#R*&C_ /7A!_Z+6OC;6O\ D%O]1_.OLGPO_P BAH__ %X0?^BU
MJ*WQ&>)^,?XB_P"17U3_ *])?_0#7SC\'O\ DG</_7S+_2OH[Q%_R*^J?]>D
MO_H!KYQ^#W_).X?^OF7^E8G,=T.M5/V8O^0!XF_["Q_]!JV.M5/V8O\ D >)
MO^PL?_0: /<:*** "BBB@#X^\5_\E3\5?]?\G_H54:O>*_\ DJ?BK_K_ )/_
M $*J-=M+X$>G0_AH[GX"?\E<O_\ L&M_Z%'7TM7S3\!/^2N7_P#V#6_]"CKZ
M6KDG\3."I\;/ _CO_P E:^'_ /UTD_\ 0TK5K*^._P#R5KX?_P#723_T-*U:
MDS. ^*7^N\,?]A5/Z5]35\L_%+_7>&/^PJG]*^IJ "BBB@ HHHH **** "BB
MB@ HHHH **** "@]#10>AH \"_9W_P"1^^(O_7^O_HV:O?:\"_9W_P"1^^(O
M_7^O_HV:O?: "N8UWP6NNZH;R2_>+Y @01@X ]\^]=/10!PW_"LX?^@G)_WY
M'^-=1HVD)I&CII_F>>B[LLRXSDYZ?C6C10!Q%Y\-X);PO9WI@@8Y\MH]VWV!
MS75:1I-OHVGI:6@.U>69NKMW)J[10 4444 %%%!X% '/:EX2TZ]U W<DSP%S
MF1%( 8^O/2I]2T6POTLEEE6*VM,X0$888'&?3BN(NHK[6I;_ %+EXH&)8EON
MKV 'TJ*;1+V'2XM0=5-K)@[U;.W/J* /4XGC>%6A*M&1\I7H1[4^JNF0_9])
MM8@ZR!(E&]>C<=15J@ HHHH **** "BBB@ HHHH *^8_VL79]>\,PL<1B"8C
MZED!_D*^G*\#_:J\-S7WA;2=?MT++IL[PSX'W4DQAC[;E _X%0![=IUC#9^'
M[:PLE5((;988E'0*%P*\M^"/PFUOX;:EK-QK=U93K?QQK&+5V8@J6)SE1_>%
M5OA1\=_#FJ>%++3?%.IQ:7JUG$L+M=-MCN HP'#],D8R#CFNC\6?'/P1X9TJ
M:>WUBVU:\"GR;2QD$A=NP+#A1[D_G0!X_H$*:?\ MHW,5EQ&][<%@O3YX&9O
MU)KZFKY7_9WL;_Q=\7]6\9:B-WD+++))C@S3$@*/^ [_ *<5]44 %%%% !11
M10 4444 %>!P?\GK7/\ UX#_ -)EKWRO X/^3UKG_KP'_I,M 'OE%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX,N(-2L78E(+B0131CT)/RM]<CZ5E^'_ -F7QMJ5ZBZU]DT>US\\CS+*^/\
M95"<GZD5]?T4 <]X)\%:3X"\,PZ-HD9$2'?+,_+SR'J['UX_  "NAHHH ***
M* "BBB@ HHHH *\#@_Y/6N?^O ?^DRU[Y7@<'_)ZUS_UX#_TF6@#WRBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G+
MQ_\ %GQQHWQ&UG2-$O85M;255C1K:-BH**>I'/)K _X7/\3/^?V#_P !(O\
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M^F?\@V'_ '?ZUO1^(ZL-\3+$G^J?_=/\J]^_9V_Y)0G_ %_3?S%> R?ZI_\
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M+;!_UXR_R%?45?+OP6_Y+;!_UXR_R%?45<T_B9PU?C84445!F%%%% !1110
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M[65S))JGABQ!^013R8[9+(/Z5],5\Z?M9:/,]GX=UJ-28H7EMI& ^Z6"LO\
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M_P!D];['R/I;X'_\D=T3Z2_^C7KOZX#X'_\ )'=$^DO_ *->N_K@/)"BBB@
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MG/\ :&_Y*1H/_7@?_0VKSRO0_P!H;_DI&@_]>!_]#:O/*ZJ/PGH8;X"?0O\
MDH7A?_L)P_\ HQ:^R*^-]"_Y*%X7_P"PG#_Z,6OLBL:OQLYJ_P#$845QWQ6\
M3ZAX-^&FJ:[H_E?;+7RO+\Y-R_-*JG(R.S&O#+?XR?&:[MHKBVT2UDAE0/&Z
MV)PRD9!'S5F8'U)17RU<_&7XRV=K+<W6B6L4,*%Y)&L3A5'4GYJ]Y^%WB2_\
M7?#72-<U?ROMEXDAD\E-J\2,HP,GLHH ZRBBB@ JOJ/_ ""[K_KB_P#(U8JO
MJ/\ R"[K_KB_\C0!\3Z%_P @T?[Q_I6C6=H7_(-'^\?Z5HUW0^%'JT_@1Z_^
MS1_R"?$G_7ZG_H)KW"O#_P!FC_D$^)/^OU/_ $$U[A7$]SRY;GSGXO\ ^3I9
M_P#L%+_Z!72US7B__DZ6?_L%+_Z!72TA'(-_R<=X*_ZYO_*2OI:OFEO^3CO!
M7_7-_P"4E?2U !1110 5X5^TM]WPK_U\3?R2O=:\*_:6^[X5_P"OB;^24UN5
M'='DM4-7_P"/>'_KLM7ZH:O_ ,>\/_79:[:GPL].K\#/MN'_ (]X_P#='\JY
M#XN_\D?\3_\ 8/D_E77P_P#'O'_NC^5<A\7?^2/^)_\ L'R?RKA/*/)OAW_R
M3O1O^N!_]#:MG5O^0+??]>\G_H)K&^'?_).]&_ZX'_T-JV=6_P"0+??]>\G_
M *": -C]FK_DC=O_ -?D_P#,5ZU7DO[-7_)&[?\ Z_)_YBO6J "BBB@!#]T_
M2OBBW_Y"&I_]?LG_ *$:^US]T_2OBBW_ .0AJ?\ U^R?^A&M:7QG1A_C+->G
M?LZV\5W?>+8+A \4GDAE/?EZ\QKU+]FS_D+>*OK#_.2M:^R-\3\*/2IO &;@
MF"^VPD]'CRP'Y\UY%\0].BTG]H+PK9V[.T:Z:SDL>K$R@G';H/RKZ0KYZ^+'
M_)RGAC_L%G^<U<IP&]7$>*O^2L_#S_L*)_Z-CKMZXCQ5_P E9^'G_843_P!&
MQT ?3U(R*XPZAAZ$9I:* *4VC:9<?Z_3[9_<Q+FJ$W@S09NM@J'UC=E_D:W*
M* /%OC!!!X"T&PU#1HR\EQ>"!TG<LH78S<8YSE17 KXS+<7%@C#_ &7_ ,17
MH/[2W_(E:/\ ]A-?_1;UXM6]**E>YU4*<9I\R.J'B#0;F>!;W2P"\R*"8U(#
M%@ ?SKOSU.>M>$ZNQ33F93AE92".QS7T#_8]_#I-A=M&\\5S:Q2^:BYY9 2#
MCIR:FJDI61%>*C*R*=<]X8M[#3M)DAT&47-H;F1]X;< Y/S+D>E=A'H5Y=:7
M>W+1R000V\CF1A@DA20!GWKS?X/DGX>Q$\DW,N3^59&!V'VF0'F/]#47PON(
M_ &GZI!9_P#$TCO;LW#.K!?+.,;>,U?'6JG[,7_( \3?]A8_^@TP.X7XEQ#_
M %FER+])1_A4J?$O3S]^RN%^A4_UKL6AB?[\:-]5!J)M/LG^_9P-]8E/]* .
M:3XC:0WWH;I?^ *?ZU.OQ T-NKSK]8C_ $K7?0]*?[VFVA_[8K_A4#^%]#?[
MVF6_X)C^5&@'S-X@\/ZG?>.]>U.VM]]K>W;RPMO4%E)XX)XJBWA[55ZV4A^A
M!_K5SQ#K^IV7Q"\0V%M=%+6UO'CABVJ0B@\ <5"OBG5E_P"6ZGZQBNFGS<NA
MW4O:<BY;6.E\$:!_9L5U?W4)2[N7V#<.5C4#C\3S^ KJZP_">L'5])<RLIN(
M)"D@48ZC(./H?TK<KGE?F=SDG?F=SB_B-J#WOC[X?),2TEO-(FX]QO3'^%=I
M7/>)M5BTK7O#UG=67G/JTCK;S<?NBK*-W(]3V]*V/+N%Z/G\:D@XGXI?Z[PQ
M_P!A5/Z5]35\W^*K/3+Q]+'B"Y^SM%=![3YPN^0=%Z<_2O5/^$ZUBU.-0T0K
MCKPZ?S!IV [RBN+A^)5BQQ<V-Q'Z[6#?X5HP>/-"F^]/)#_UTB/],T@.CKRO
M]HG_ ))2_P#U^P?S->@P>)-&N/\ 5:E;$^C2!?YUYU^T)/%/\*',,J2#[;#R
MC ]SZ4 >"1Q1^4G[M?NC^$>E5M3C1=-F*HH..H'O5N(_ND_W1_*E?3Y]5 L;
M-=TT[!%'8<]3[#K7=+X6>K)+D9]5_#C_ ))GX=_[!T/_ *"*Z6O)M'US5-&T
M'3M+M[E1'8VZ0 K&/GVC&3G-=OX;\3'5D>"Z"I=1KN!7@./7'K7">4=%17RM
M9_'+XLZL9Y-'TRRNX(I6B+QV1(!';[WIBK/_  MSXV?] "W_ /  _P#Q5 'U
M!17D?P-^(WB7QW<>((/%<=M%-ICPHJ0PF,JS;PP;D_W17KE !0>AHH/0T >!
M?L[_ /(_?$7_ *_U_P#1LU>^UX%^SO\ \C]\1?\ K_7_ -&S5[[0 445S_BO
MQ(?#]I&(H?,GGW",D_*N,<G\^E %R7Q#I\.M)I32,;IR %"$@$C/)K4KR303
M<MXVLWOM_GR3!W+]3D9S^1KT;Q-?/IWAN\N(CMD";4/H3P#^M,""[\8Z+97A
MMIKO+J<,40L%/N16Q;W$5U;I/;2+)$XRKJ<@BO-?#OA&+6= N;V6619MS+"%
M/&0.I]<FM3X;7SM#=V$A.(R)4'IG@_TH [JBBBD 4444 >>"_O?".M7<"Q*\
M,K;@K\!AG@@_CBHM4\1WWB%8[&*W6-7<?NXR6+GMS78:]?Z-;QK%K"QRL>5C
MV;F^OM46F7&A6]O;75I EJ+MBD;.F&)';/..E &IIMI]ATRWM>IBC"D^I[_K
M5FBB@ HHHH **** "BBB@ HHHH **** /G/]H?2-/\3?$;PUX?TZ$MXBU%4B
M-P\I\N"#>V/E'4Y+DGT7WK<'[*_A'^R/(.J:K]NV_P#'UO3;N]=FWI[9S[UQ
M_P >+^^\%_'O0/%D4/FQ);Q21JQP'V.P=,]N&'_?5>B#]I?X?_V5]J,]]]HV
M9^Q_96WY_NY^[^.: /(?AS\)O#FN>,_$'@KQ=+?0:WIC,T,]I,JQS1@@$[64
M\\JW7D-[5T7P MKCPA\;?%'A"2<RQ1PR*6Z!S%(H5L=OE<_G6'\*O$=WX@^.
M'B'QW-;%8+6QNK^>)6X5 N$CSZX _(FM?]G^_N?&'QS\2>*IX1")K661D4Y$
M9DD7:N>_"G\J /IVBBB@ HHHH **** "O X/^3UKG_KP'_I,M>^5X'!_R>M<
M_P#7@/\ TF6@#WROCSQ1_P E0\5_]A*7_P!#-?8=?'GBC_DJ'BO_ +"4O_H9
MK2E\:-Z'\1%.N^_9^_Y*GJ__ &#3_P"AQUP-=]^S]_R5/5_^P:?_ $..MZWP
MG3B?@/I&BBBN0\\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^2?B'_P EG\2_]=5_] 6L:MGXA_\ )9_$O_75?_0%K&KLI? >E0_AHZWX
M+?\ );8/^O&7^0KZBKY=^"W_ "6V#_KQE_D*^HJYI_$SAJ_&SPS]IK_CQ\(?
M]A;^@JZWWC]:I?M-?\>/A#_L+?T%76^\?K4&9P/QE_Y)^?\ K[C_ )-7TOHW
M_("L/^O:/_T$5\T?&7_DGY_Z^X_Y-7TOHW_("L/^O:/_ -!% %VBBB@ KAOC
M1_R1WQ!_UQ3_ -&I7<UPWQH_Y([X@_ZXI_Z-2@#YBL?^/"#_ '!2W?\ QY3?
M[A_E26/_ !X0?[@I;O\ X\IO]P_RKO\ LGK?8^1]+? __DCNB?27_P!&O7?U
MP'P/_P"2.Z)])?\ T:]=_7 >2?+W@O\ Y*/\0?\ L+R?^C9:[JN%\%_\E'^(
M/_87D_\ 1LM=U0!A_![_ ).)\7_]@]?YQ5]!U\^?![_DXGQ?_P!@]?YQ5]!T
M %%%% !7S%\<?^2SK_V#HOYO7T[7S%\<?^2SK_V#HOYO50^)&E+XT<;6IX&_
MY+!X6_Z^OZ&LNM3P-_R6#PM_U]?T-=57X#OK_P -GUW7BO[4?_)---_["\7_
M *+DKVJO%?VH_P#DFFF_]A>+_P!%R5QGF"Q_ZI/]T?RKD/BO_P DUU'_ 'HO
M_1BUU\?^J3_='\JY#XK_ /)-=1_WHO\ T8M 'O/@/_DG7AS_ +!=M_Z*6M^L
M#P'_ ,DZ\.?]@NV_]%+6_0 4444 <M\3?^26^(_^P?+_ .@U\GZ9_P @V'_=
M_K7UA\3?^26^(_\ L'R_^@U\GZ9_R#8?]W^M;T?B.K#?$RQ)_JG_ -T_RKW[
M]G;_ ))0G_7]-_,5X#)_JG_W3_*O?OV=O^24)_U_3?S%.OT*Q70]3KYGL_\
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M/>'_ *[+7;4^%GIU?@9]MP_\>\?^Z/Y5R'Q=_P"2/^)_^P?)_*NOA_X]X_\
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M .@U;'6JG[,7_( \3?\ 86/_ *#0![C1110 4444 ?'WBO\ Y*GXJ_Z_Y/\
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M&DOH_/2(P. ,[CUS_P#6KV.O*_VB?^24O_U^P?S- 'EJ^(M$ND!NM+VY&?\
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M_DH_Q!_["\G_ *-EKNJ ,/X/?\G$^+_^P>O\XJ^@Z^?/@]_R<3XO_P"P>O\
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M;#_N_P!:^L/B;_R2WQ'_ -@^7_T&OD_3/^0;#_N_UK>C\1U8;XF6)/\ 5/\
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MO)_Z":QOAW_R3O1O^N!_]#:MG5O^0+??]>\G_H)H V/V:O\ DC=O_P!?D_\
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M6OA__P!=)/\ T-*U:DS. ^*7^N\,?]A5/Z5]35\L_%+_ %WAC_L*I_2OJ:@
MHHHH *\K_:)_Y)2__7[!_,UZI7E?[1/_ "2E_P#K]@_F: / H_\ 5)_NC^55
MM4_Y!DWT'\ZLQ_ZI/]T?RJMJG_(,F^@_G7?+X6>M+X&?6/P\@BE^&GAPRQ(Y
M&G0X+*#CY173OQ&WTKG/AQ_R3/P[_P!@Z'_T$5TC_P"K;Z&N \D^5_@[_P B
M]JO_ &$G_P#05KT,=:\\^#O_ "+VJ_\ 82?_ -!6O0QUH S/V=?^1P^(7_7]
M'_Z'-7O->#?LZ_\ (X?$+_K^C_\ 0YJ]YH *#T-%!Z&@#P+]G?\ Y'[XB_\
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M_DX+QW_O+_[+7.<9V-<WX%_Y.ED_[!!_]!6NDKF_ O\ R=+)_P!@@_\ H*T
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MT4322*<JTK;MOT'2@"WHML]GHMI!+PZ1C</0]<5>HHH **** "BBB@ HHHH
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M^Z/Y5R'Q7_Y)KJ/^]%_Z,6@#WGP'_P DZ\.?]@NV_P#12UOU@> _^2=>'/\
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M#_R0_7O^V'_H^.N+\)_\B9HW_7C#_P"@"LS C\9_\B/K7_7E+_Z":[[X#_\
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M\3."I\;/ _CO_P E:^'_ /UTD_\ 0TK5K*^._P#R5KX?_P#723_T-*U:DS.
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M@<AZ".HK._9O_P"0UX^_[":_^A2UHCJ*SOV;_P#D->/O^PFO_H4M 'N]%%%
M!1110!\D_$/_ )+/XE_ZZK_Z M8U;/Q#_P"2S^)?^NJ_^@+6-792^ ]*A_#1
MUOP6_P"2VP?]>,O\A7U%7R[\%O\ DML'_7C+_(5]15S3^)G#5^-GAG[37_'C
MX0_["W]!5UOO'ZU2_::_X\?"'_86_H*NM]X_6H,S@?C+_P D_/\ U]Q_R:OI
M?1O^0%8?]>T?_H(KYH^,O_)/S_U]Q_R:OI?1O^0%8?\ 7M'_ .@B@"[1110
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MA>+_ -%R5[57BO[4?_)---_["\7_ *+DKC/,%C_U2?[H_E7(?%?_ ))KJ/\
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M_P#83A_]&+7V16-7XV<U?^(SS;]H'_DA^O?]L/\ T?'7%^$_^1,T;_KQA_\
M0!7:?M _\D/U[_MA_P"CXZXOPG_R)FC?]>,/_H K,P(_&?\ R(^M?]>4O_H)
MKOO@/_R0_P ._P#7.;_T?)7 ^,_^1'UK_KRE_P#037?? ?\ Y(?X=_ZYS?\
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M^09-]!_.K,?^J3_='\JK:I_R#)OH/YUWR^%GK2^!GUK\./\ DF?AW_L'0_\
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M3\)_^23>'/\ KQ2E6^(6)^)'6R_ZE_\ =-?+7P<_Y%2^_P"PC)_Z"M?4LO\
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M_HM:^-M:_P"06_U'\Z^R?"__ "*&C_\ 7A!_Z+6HK?$9XGXQ_B+_ )%?5/\
MKTE_] -?./P>_P"2=P_]?,O]*^CO$7_(KZI_UZ2_^@&OG'X/?\D[A_Z^9?Z5
MB<QW0ZU4_9B_Y 'B;_L+'_T&K8ZU4_9B_P"0!XF_["Q_]!H ]QHHHH ****
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MFFP7B6HM$AVS(H;<-V> 3QS7TK_PI;X=?]"I8_\ C_\ C1_PI;X=?]"I8_\
MC_\ C33L[CBW%W1\E_\ "8:?_P \Y_\ OD?XU<\-^.]+TCQ[HNM7,5RUM83>
M9*J("Q&#T&?>OJC_ (4M\.O^A4L?_'_\:/\ A2WPZ_Z%2Q_\?_QJY5)25F:R
MK3DK,X[_ (:F\$?\^.L_]^(__BZ\[^-'QI\.?$+P?::7HMMJ$4\-\EPQN8E5
M=H1P>C'GYA6A\;O GACPYXR\#VFAZ-;V<&H7C)=)'NQ*OF1#!R?1C^=>R_\
M"EOAU_T*EC_X_P#XUF8GA:_&KPVJ*#;:AP /]6O_ ,56#XX^)^B^)/"%WI=C
M!>)/,R%3*BA?E<$]">PKZ2_X4M\.O^A4L?\ Q_\ QH_X4M\.O^A4L?\ Q_\
MQH \Z\,_M*>#M'\)Z3IEU9:LTUG90P2%(4*ED0*<?/TR*U/^&IO!'_/CK/\
MWXC_ /BZ['_A2WPZ_P"A4L?_ !__ !H_X4M\.O\ H5+'_P ?_P : .._X:F\
M$?\ /CK/_?B/_P"+H_X:F\$?\^.L_P#?B/\ ^+KL?^%+?#K_ *%2Q_\ '_\
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M!K$VX1(U,F[ '3=C''K7T3_PI;X=?]"I8_\ C_\ C1_PI;X=?]"I8_\ C_\
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M^)[*YBC6-)@5D#'*CI^=?7W_  I;X=?]"I8_^/\ ^-'_  I;X=?]"I8_^/\
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MK/\ WXC_ /BZ^=XO%=BEU>2&.;;/</*ORC@$DC/-?77_  I;X=?]"I8_^/\
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M_P"&IO!'_/CK/_?B/_XNNQ_X4M\.O^A4L?\ Q_\ QH_X4M\.O^A4L?\ Q_\
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MY_X4M\.O^A4L?_'_ /&C_A2WPZ_Z%2Q_\?\ \: .._X:F\$?\^.L_P#?B/\
M^+H_X:F\$?\ /CK/_?B/_P"+KL?^%+?#K_H5+'_Q_P#QH_X4M\.O^A4L?_'_
M /&@#CO^&IO!'_/CK/\ WXC_ /BZ/^&IO!'_ #XZS_WXC_\ BZ['_A2WPZ_Z
M%2Q_\?\ \:/^%+?#K_H5+'_Q_P#QH ^4];\<:9J/C76]6@BN!;W]TTT090&
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MVK_AJ;P1_P ^.L_]^(__ (NNQ_X4M\.O^A4L?_'_ /&C_A2WPZ_Z%2Q_\?\
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M/\C1T VJ***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXX_Z]9/_ $.&O?*\#^'7_)V'CC_KUD_]#AKWR@ HHHH **** "BBB@ HHHH
M*\X^/_\ R0_7_I!_Z/2O1Z\X^/\ _P D/U_Z0?\ H^.@#1^#G_)'/#7_ %YC
M^9KMJXGX.?\ )'/#7_7F/YFNVH **** "BBB@ HHHH **** "O ]0_Y/2TW_
M *\#_P"B)*]\KP+4/^3TM,_Z\#_Z(DH ]]HHHH **** "BBB@ HHHH ****
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M!P3@'.,D5L4 %%8^G^+O#FK:DVGZ7KNG7EXH8M;V]TCR#'7Y0<\5L4 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9Z$C\:^7_C+KW_"V/BWI'A#PP?M$5E*UMYZ<JTC$>:P_V5"CGV;VH ]$^/\
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M0<?*>]>[UX1\ _C!JOBK4;CPMXNE\[48HS+;7+(%>0+PR.!_$.N?0'/2O=Z
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M<@,P&1\_O0!]'^&M(/A_PKI>CM,)S86D=N90NW?L4+G&3C..E:=%% !1110
M4444 %%%>=?&[Q[_ ,(+\/;A[279JFH9MK, \J2/F?\ X".?J5H ^=_V@/'W
M_"8?$!["REWZ9HY:WAVGB23/[Q_S&T>R^]?7'A?_ )$_1O\ KP@_]%K7QYXZ
M\"?\(9\*_"<][%MU35YIKJY+#YD4JGEI^ .3[L:^P_"__(H:/_UX0?\ HM:
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M=MYLQMY)62W5H\DY1AN X^Z3C&.,5RO[*=G)/XH\1ZL5VQI;)$2!P"[[L?\
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img70551829_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" KL$ET# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG(:K%<AX&U3[38+:ELF-:Z^O2I3YXJ1\CBZ#H5I4WT"BBBM#G"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\M^(KD:U&N>/+_PKU*O*_B-_P AV/\
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M8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5YK\1("U^LVWHF,UZ57)
M>.;'S=(DG4988%<^)CS4V>EE-7V>+BWUT/)Z*4C!(]*2O%/T **** "BBB@
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M=7/C)1<9.+Z!1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR^@#T'X+?\E,T_Z'^8KZ^KXJ^'?B&T\+>,;35;T,8(@=P4<]J]Z_X:#\*_\
M/*Y_[Y/^% 'K=%<WX3\::=XP@DEL%D54Z[Q724 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKV2N8\(>";'P=!)#92R2+)UWUT] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 07-M'=0-%(,J:\D\4: ^FW;.JG8Y)KV*J6HZ=!J-LT,JCD8SCD5A7
MHJI'S/2RW'RPE2_V7N>#T5TOB#PM<:9*SQH3#G@GTKFL8KQYP<'9GW5"O"O!
M3@[H****@V"BBB@ HHHH **** "K%I9RWDPCB4EC4NG:9<:C.(X$W>M>I>&O
M#$6EPK)*N9<="*Z*-"51^1YN89C3PD.\NQYMJN@7>EE?-3@@'BLFO>KW3X+Z
M$QRHIR.N*\O\1^%)M/E:6!2T/4D]JTKX5PUCL<F6YQ'$>Y5TD<Q%*\+AD8@C
MT->@>&/&1(6VO& QPIKSUE*D@T*Q4Y4D'U%84ZLJ;NCTL7@Z6*ARS7S/H"*9
M)HPZ$$&I*\J\-^+I+%UAN&S&>,DYKTRSO(;V!9H6W(W2O7I5HU%H?#X[+ZN$
MG:6W<LT445L< 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SW^TE_Q
M\:/_ +I_K7T)7SW^TE_Q\:/_ +I_K0!X)77_  Z_Y&BV_P"NBUR%=?\ #K_D
M:+;_ *Z+0!]G1_ZM?H*=38_]6OT%.H ^7/VA/^1[B_ZX#^0KR.O7/VA/^1[B
M_P"N _D*\CH ]!^$VAKJGBRTED7=&CX((XKZZ@@2WA6*-0JJ, "OF?X% '5<
MXY\ROIN@!:^?_P!H+18+6UM]110))I<$XKZ KQ3]HS_D6]/_ .NQH ^:Z[3X
M82M%XLC*]<5Q==C\-?\ D:HOPH ^R;8YM(3_ +"_RJ4]*AM?^/.'_KFO\JF/
M2@#X=\9_\CCJO_7PU85;OC+_ )''5?\ KX-85 'T-\"/#MN$EOI8PY= 5W#I
M7O(  P*\S^#4:+X4MF"@$Q\FO3* $(# @C(/!%?.GQV\-PV]TVIPQA!@+A1Q
M7T97E7QZBC_X0)I-HW^:.: /E6NT^%VHOI_CJPE#':&Y7/!Y%<770^"CCQ3:
M8]: /MBUF^T6L<O]\9J:J.C\Z/:_]<Q5Z@#XU^+'_)1]5_ZZ5Q5=K\6/^2CZ
MK_UTKBJ /HOX"?\ 'JOT->Z5X7\!/^/5?H:]TH 1_N'Z5\C?%_\ Y&7\37UR
MWW&^E?(_Q?\ ^1D_$T ><U[W^S;_ ,?&K_[H_I7@E>]_LV_\?&L?[H_I0!]"
M4444 ?/OQ\[_ .\*\"KWWX^=_P#>%>!4 >@_!;_DIFG_ $/\Q7U]7R#\%O\
MDING_0_S%?7U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGDSA>K0V['?T4R*59D#HP(/I3Z[SYMJVC"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPKK-!^%^MZU*FV/8IZ[QB@#E=)TJYU:]2WMT9F8]AFOKGX;>$4\+Z$JE0'F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !44UK;W&//@BEQTWH&Q^=2T4 5?[,L/^?&
MV_[]+_A3DL+.-MR6D"GU$8']*L44 %%%% $,MG:SMNFMH9&]70$_K4?]F6'_
M #XVW_?I?\*M44 0Q6EM"<Q6\49_V$ J:BB@ J.:WAN !-#'(!T#J#_.I**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HJ.:58(7D=@JJ"<DUXMK_QN@T[4GMX&8A"5/&>E 'M
MM%?/P^/>XX&\GT"5ZKX'\07?B"R>YN%(0@%,KCB@#K**** "BO/O$OQ?\/\
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M'^>M '6T444 %%%% !137=8T+,0 !GFO,M0^.?AC3KZ:TE6<O$Q5B%XR/PH
M]/HKR;_AH'PI_<N?^^3_ (4H_: \*$@;+G_OD_X4 >L45F:!KMIXBTF'4;,G
MRI1D ]:TZ "BBB@ HHKB?'OBJ[\,0K<1*3"JY;"YH [:BOGW_A?>#@EL_P"[
M6[X6^,]OK&J1VDS$&1@JY&* /9:*165AN5@1Z@TM !1110 4444 %%%% !11
M10!QGQ,\)7GC+PN=,LI4CEWALOTKQ;_AG;Q'_P _UK_G\:^G** /F+_AG;Q)
M_P _UK_G\:/^&=O$G_/]:_Y_&OIVB@#YB_X9V\2?\_UK_G\:/^&=O$G_ #_6
MO^?QKZ=HH ^8O^&=O$G_ #_6O^?QH_X9V\2?\_UK_G\:^G:* /F+_AG;Q)_S
M_6O^?QH_X9V\2?\ /]:_Y_&OIVB@#YB_X9V\2?\ /]:_Y_&C_AG;Q)_S_6O^
M?QKZ=HH ^8O^&=O$G_/]:_Y_&C_AG;Q)_P _UK_G\:^G:* /F+_AG;Q)_P _
MUK_G\:/^&=O$G_/]:_Y_&OIVB@#YB_X9V\2?\_UK_G\:/^&=O$G_ #_6O^?Q
MKZ=HH ^8O^&=O$G_ #_6O^?QH_X9V\2?\_UK_G\:^G:* /F+_AG;Q)_S_6O^
M?QH_X9V\2?\ /]:_Y_&OIVB@#YB_X9V\2?\ /]:_Y_&C_AG;Q)_S_6O^?QKZ
M=HH ^8O^&=O$G_/]:_Y_&C_AG;Q'_P _UK_G\:^G:* /F/\ X9V\2?\ /]:_
MY_&JUU\ ?$5J 3=V[9_NC_Z]?4M(0#U - 'R+>_![7[)0S,KY_NK_P#7KF]2
M\':SIIP]G-)[K&:^W#'&>J*?J*CDL[:5"KP1D$8^X* /@Z6SN8#^]MY$_P!Y
M2*@K[.U;X:^']8+&X@.3_=P*\Q\3? 5F+MH@50.?G:@#Y_HKH->\'ZKX?N#%
M<P.Q'=$)%8#*5.""#Z&@!T4SPN'C8AA7J?@7XO:AHDL=MJ,S2VH( 51T%>4T
M=* /N3P_XIT[Q%91W-K*HWC.PL,BMNOB7PIXQU#PS?I+!*?+)&\$D\5]2>!O
MB#8>*[10LFVX RVXXH [:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I",@@]#2T4 <GXD\)PZA"TENH6;U->87MA/8S-'*I&#UQ7O1K#UWP[
M;ZM QV#S<8!KCQ&%4_>CN>]EF<2H-4ZNL?R/%ZNZ;J<^FW"R0OCG)J;5]&N-
M*N"CH=N>"!697EM.#\SZ].G7AIJF>O\ A[Q1!J<021L2@<ECUKI>O2O ;:YE
MM9EEB8AE.1S7I'AGQ@MTJP7;?O/7M7I8?%*7NSW/E,SR9TKU:.J[';4M-5U<
M;E((/H:=7<?.A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M81W-N^Y649/OB@"]6=K?_(*EK1K.UO\ Y!4M 'Q-XE_Y&34/^NQK*K5\2_\
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M>":^N8)5GA61#D$4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%Q?++<****9(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:^8;FVEM)VAF7:Z]17WO+$D\31N RL,$'O7R7\8?#ZZ7XMNKB)=L3MA5 X%
M'G )4@@X(Y!KZ*^!/BEKF!='EE+R#+<GG%?.E=S\*]4.E>+8Y=^T$;?SH ^Q
MJSM;_P"05+5RV?S+:)\_>0']*IZY_P @J6@#XF\2_P#(R:A_UV-4[%!)>Q*>
M035SQ+_R,FH?]=C5.P8)?1,QP W- '0^)_#<FE:?:WY4B.X/RURP)!!'6OIG
M4O#,/B+X4V<Z*&:"$NO'6OFJ>"2VF:*5"KCJ#0![[\"_%P;&C3R<(I89->^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,[7_P#D7M0_Z]W_ )5\+W?_ !^S_P#71OYU]UZTH?1+U3T,+#]*^(=?MDM=
M7GCC!"[B?UH IV?_ !^V_P#UT7^=?<^@?\B_I_\ U[I_*OA>T.+R ^DB_P Z
M^X?"]W'=^';(QY^6% <_2@#8HHHH **** /D/XV?\E,O_P#='\S7GE>A_&S_
M )*9?_[H_F:\\H ]C^ __(R1_0U].5\Q_ ?_ )&2/Z&OIR@ HHHH *^=?C[J
M/G.EGO!\N3.,]*^@-1O8M/L9KF5@%C7<<FOCOXDZ_P#V]XNN[B)LP,V5H XZ
MND\$6#:AXB@B3&0P/ZUS=>K?!#09+WQ2MS(N8 AY]Z /J&Q79I]LG=8E'Z56
MUO\ Y!4OTJ^B[$51T Q5#7/^05+]* /B;Q+_ ,C)J'_78UE5J^)?^1DU#_KL
M:RJ /LWX5_\ ).M*_P"N===<0K<6\D3C*NI!KD?A7_R3K2O^N==E0!\G_%_P
M=)HNO2WL2@6CD  #OFO,.]?97Q)\+Q^)/#DD6P%H@9/R&?Z5\>WML]I>2PNI
M4JY&"/>@#V3X'^+OLEXNBRN0LK%N3Q_GFLWX\6[0^(K1B00\9(Q7FNBZG-I&
MIQ7<#;74]:[CXL:Y%KDFD2QMN9;8!_K0!YO7OW[-G^LUCZ#^E> U[]^S9_K-
M8^@_I0!] T444 8/B_5X]'T&XFD.-R,H^N*^*M4NGN]1N)7;),C8_.OH[X\Z
MX(/#BV438E$@)^G%?,Q.YB3U-  IPP)[&O=_!?QE\/>&M(6TEL[@O@;BOK^5
M>#T4 ?3O_#1/AK_GRNO\_A535/C[X;O],N+465SF5-O/_P"JOFVB@"_K-W!>
MZI-<6R%8F/ -4*** /HKX"Z]NLUTDR#Y<M@FO=:^,_AIKIT+Q1'-O(#X3\S7
MV-:RB:TAD!SO16_,4 34444 %<_XW_Y$K5O^O<_TKH*YWQU(J>"]5!/)@.*
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M-::$?9HF^\.:X=I&=B6))/O3L!Z!_P )S8?\\9*/^$YL/^>,E>>T46$>A?\
M"<V'_/&2C_A.;#_GC)7GM%%@/0O^$YL/^>,E'_"<V'_/&2O/:*+ >A?\)S8?
M\\9*/^$ZL/\ GC)7GM%%@/18O&MA*X7RW'UK=M+Z&\C#QN.>V:\=%:>CZK-8
M72E6.UC@YHL!ZQ15>SN4N[99D^Z:L4AA114<\RP1&1^@H ;<745LA:1U&.Q-
M8,_C.Q@D*&-VQW%<EKVL2WUVR[CM4X&*Q22>IIV$>A?\)S8?\\9*/^$YL/\
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M6VO5!C<#/8FKU>/6=[+:3JZ,>#SS7IVBZB-1L4ES\U(9IT444 %,EE2%"SL
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M8XS4T/BBRF?: 1]37F&3ZTH9AT)_.BP'LL-S%.N8W4_0U+7E>D:U<6$Z /\
M(2 <UZ99W27=NLJ'@BD,L4444 %%%(6"CYB />@!:*IS:G;0'#2*?H:6'4;:
M?[LBCZF@"W131(C='4_0TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_.J=_K%EIL#37$Z!5&3AA7R8WQ7UUEQG_P ?KG=3\5:MJ;EI;R8 _P (<XH
M]2^*'Q7.H;].TN3,?*N>G%>)EBQRQ)/J:&9G8LS$D]2:=%$\TJQQC+,< 4 /
MM8&N;J*%%)+L%X]S7UM\*?"8\/\ AR,S)B=CG\#7GGPG^%TKRIJFIPE4(RN1
MD9%?0<4:PQJB  * !B@!]9VM_P#(*E^E:-9VM_\ (*EH ^)O$O\ R,FH?]=C
M656KXE_Y&34/^NQK*H ^S?A7_P DZTK_ *YUV5<;\*_^2=:5_P!<Z[*@!DL8
MEB>-APRD&OEGXS>$FTG7GNX(\6Q')QW-?5-<=\0_"Z>)/#TL(3,BY;('/ H
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MS0!]/VXQ;1#T0?RJ2D4;5 '88I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0D 9)H 6BLV[UV
MQL\B67!%<]?>--@(M@K_ %H [$NJCE@/QJI)JMK$VUG&:\WO/$%Y>9RQ3/\
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M(/44E4(**** "BBB@ HHHH **** "N@\(N5U4X/\-<_75^#;%VO#.P^3;UI
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M-+7FUEXMN[;"E0P]2:Z.R\7VLH N'"L>PI6&=-15:WOK>Z7,3Y%6: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KQ/X\Z$TNC"_B3+EP#].*]LK#\6:+'KFASV\F/E1F&?7% 'PZ1@D'J*]
M*^#6OG3O%]M:N<0N22?Q%<)K6GS:;JD\$R%")&P#Z9J/3+Z33KZ.YB)#J>HH
M ^\(I%EB613D,,BGUS'@77HM<\.VSQL&:.,!\>M=/0 4444 ?(?QK_Y*9?\
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M#_#UC,)K;2;>*0=&4'- %K0[-+'1K6%%"XB7./7%:-(%"J% P!T%+0 4444
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M;PQG*Q@5+1<8BJ%& ,"EHHI %!&:** .7U_PVMYF6!<..P'6N-FT._A8AH"
M*]:J-X(I/O(#]:=P/(_[,N_^>1H_LR[_ .>1KUG[%;?\\5H^Q6W_ #Q6BXCR
M;^S+O_GD:/[,N_\ GD:]9^Q6W_/%:/L5M_SQ6BX'DW]F7?\ SR-']F7?_/(U
MZS]BMO\ GBM'V*V_YXK1<#R;^S+O_GD:/[,NS_RR->L_8K;_ )XK1]BMO^>*
MT7 \SM/#E_<.N86"GJ:[O1-%CTV <9?&"2*UDC2,850![4ZD,**** "H;FW2
MYA:)P"IJ:B@#S_5_"<T<C26RLX/./2L%])O4.&A(->ND C!J)K6!CEHE-.X'
MDO\ 9EW_ ,\C1_9EW_SR->L_8K;_ )XK1]BMO^>*T7$>12Z/<R+S$<UE7>FW
M%IS(A"U[E]BMO^>*U7N]'L[J(HT"<CKBN:OAXU%=;GK9=FE3"2L]8GA-*"0<
MCBNI\1^%)].F:2!6>(\D@<"N68%6P1@BO(G"4'9GVU"O3Q$.:#NB[;7!8A#6
MO%IMU. 8XB0>E<T"5.1UKJ_#'B-;*;R[E0ZG@%OX:[L/B[>[,^?S/)5*]6AO
MV-;2?"MS-,KW*,BCGZUWMK:I:0+$@P!3;.[ANX%DA<%3Z59KT;WU/E7%Q=F%
M%%% @K*UG1X]3@(/#8P#6K10!Y9>>&[^VD;;"Q0'@U2_LR['_+(UZ\Z*XPR@
MBHOL=O\ \\5IW$>3?V9=_P#/(T?V9=_\\C7K/V*V_P">*T?8K;_GBM%P/)O[
M,N_^>1H_LR[_ .>1KUG[%;?\\5H^Q6W_ #Q6BX'DW]F7?_/(T?V9=_\ /(UZ
MS]BMO^>*T?8K;_GBM%P/)O[,N_\ GD:FAT2^F8!8"0:]3^Q6W_/%:>D$4?W4
M ^E%QG+Z%X7%JPFGSO\ [I'2NK "C I:*0!1110 A (P:Y37O# N29K<?/UP
M!UKK** /)9M$OX&P\!%0_P!F7?\ SR->N/;Q2??0'ZTS[%;?\\5IW \F_LR[
M_P">1H_LR[_YY&O6?L5M_P \5H^Q6W_/%:+B/)O[,N_^>1H_LR[_ .>1KUG[
M%;?\\5H^Q6W_ #Q6BX'DW]F7?_/(T?V9=_\ /(UZS]BMO^>*T?8K;_GBM%P/
M)AI=V3CRC5^R\-WMS( \3*GK7I7V.W!_U*U*D:)]U0*+C,W1](BTRW55 +]S
MCFM2BBD 4444 075M'=0F.0 @^M<'J_A6XBF:2V1G4G/TKT.D(!&",B@#R)M
M*O%.&A(--_LR[_YY&O6C:6[')B4TGV*V_P">*T[@>3?V9=_\\C1_9EW_ ,\C
M7K/V*V_YXK1]BMO^>*T7$>3?V9=_\\C1_9EW_P \C7K/V*V_YXK1]BMO^>*T
M7 \F_LR[_P">1H_LR[_YY&O6?L5M_P \5H^Q6W_/%:+@>4)I-[(<+"2:WM'\
M*3R2J]TK(!S]:[I;2!#E8E!J8  8%%QD5O EM$(T  'I4M%%( HHHH Q]:T2
M+4X\]' XP*X2\\.7UM(0L+%.QKU.FO&D@PZ@_6@#R'^S+L=8C1_9EW_SR->L
M_8K?_GBM'V*V_P">*T[B/)O[,N_^>1H_LR[_ .>1KUG[%;?\\5H^Q6W_ #Q6
MBX'DW]F7?_/(T?V9=_\ /(UZS]BMO^>*T?8K;_GBM%P/)O[,N_\ GD:/[,N_
M^>1KUG[%;?\ /%:/L5M_SQ6BX'ED.AW\[ + 2*['0/#0L\3SCYS_  D=*Z5(
M(H_N(!]*DHN,.@HHHI %(0&&",BEHH X[7?"QF=IK8$L><"N4ET:^A;#PD5Z
MY43VT,AR\88^].X'DG]F7?\ SR-']F7?_/(UZS]BMO\ GBM'V*V_YXK1<1Y-
M_9EW_P \C1_9EW_SR->L_8K;_GBM'V*V_P">*T7 \F_LR[_YY&C^S+O_ )Y&
MO6?L5M_SQ6C[%;?\\5HN!Y-_9EW_ ,\C2C3+LG B->L?8K;_ )XK0+.W!R(5
MHN,\WL/#-[<R 21,J>M=]I.E1:9;K&G+#JW>KZHJ#"@"G4@"BBB@ JM>V<=[
M;M%(!SWJS10!YQJGA:[AF9K>-G3/6L=M+O%8@Q'->O$ C!Z5";.W)R8E)IW
M\F_LR[_YY&C^S+O_ )Y&O6?L5M_SQ6C[%;?\\5HN!Y-_9EW_ ,\C1_9EW_SR
M->L_8K;_ )XK1]BMO^>*T7$>3?V9=_\ /(T?V9=_\\C7K/V*V_YXK1]BMO\
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M #Q6BX'E,>CWLK82$DUT>B^$Y#(LMT"F.<5VBVL*'*QJ*FQBBXQD<:Q($4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C*&4J>A&*6B@#YO\
MC?X->&_.K6T9$(4 @#O7B)!!P>HK[G\1Z+!KVD2V5P@9""0#ZXKY(\3^ M9T
MK6)8H;&::-F)4HG &: .T^"GC+^SM1&EW$F$G?[Q/ KZ81UD0.C!E/(([U\1
M6.@^(["Z2XATN[61>A\LU]5_#G6;S4]"CBO;6:&6! I,@QN- ':4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB2N-Y'H:R/\ A.(_,SY3[?2@#M**Q-.\2VE_QQ&?]HULHZN,JP(]J '4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH *\7^/?_ "+S?[XKVBO%_CW_ ,B\W^^* /FBBBB@#Z(_9O\
M^0?JW^^/Z5[O7A'[-_\ R#]6_P!\?TKW>@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***@NKN&SA,LS;5% $S,%&20!7,ZSXHBM0T<# N..:Q-;\427.Z&W("'C<#S
M7,.[.V68D^].P%B\U":\E+R.>3TS56BBF(<DCQL"K$$>AKM_"FMM,PM96S@9
MYKAJT=%F:&_0KW(%(#UKJ**9$<Q(?]D4^D,*8\4;_>13]13Z* *G]FVV_=Y2
M9_W15A(8XQA44?04^B@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0.]&X
M>HH 6BDW#U%&X>HH 6O%_CW_ ,B\W^^*]GW#U%>+_'L@^'FY'WQ0!\TT444
M?1'[-_\ R#]6_P!\?TKW>O"/V;R!I^K9/\8_I7NVX>H_.@!:*3(]11N'J* %
MHI-P]1^= (/<4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-%<UHGB:*[58IV"R=!72!@PR.E(8M%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !103@9-8&M^(H=/
MB98\/(>,>E %W5-8@TZ(EG&_TKSO5M;N-1F/S%4Z8!X-5+R_FO92\CDY[&JM
M.P@-%%%, HHHH 0UN^&;)KK41QP!FJNG:/<W\B[8VV'^*O1='TB+3+=0 "_]
MZDP-)!M11Z#%.HHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 4U
MXUD4JP!![&G44 CA/$W@X3AKBT7YQ_"HZUYS/;R6\K1R+A@<&OH \C!KE_$7
MA2#48FDA41R8[#K7!B,+S>] ^CRS.73M2K[=SR.M;2-<N=+G5E=F0'[N>*J7
M^G3Z?.T<J$ ' )[U4KSTY0?F?52C3KPL]4SVO1/$-OJT"D,!+CE1VK:KP:PU
M&?3YUDB=A@\@=Z]1\/>*[?48529ECD]":].AB5/26Y\?F>42H/VE+6/Y'444
M@Y&12UV'A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (RJXPPR*
MQ=4\.V]\A*J$;V'6MNB@#RK4]"N;!S\A*#H:R:]EGMHKF,K(@8>]<=K7A/EI
MK;_OA13N(XNBI9[>6W<I*A4CUJ*F 4444 .CD>)@R,5([BNR\-^(V+BWN#R>
M 2>M<74UI(8KJ-QU!S0![("",BEJEI,QN-.BD;J15VI&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\
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MHHH **** "BBB@""ZM8KN%HY5!4C%>:^)?![V;M/:K^Z/\(Y->HTR2-94*N
M01CFL:M&-169W8+'U<).\=NQ\_.K(Q5@01ZT@.#Q7H_B7P:)0UQ9K\W4YKSR
M:"2"1D=2"#CD5Y%6E*F[,^XP>-I8J'-!_(Z/P]XJFTR54F8F'/(%>I6&HP7\
M"R1..1G&>:\&S6SHNOW&E3J0Y\O/(-;X?$N'NRV/.S/*(UU[2EI+\SVRBLC1
M]=M]4@4JXWXY!-:U>I&2DKH^-J4Y4Y.,U9BT4451 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%)0 M%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 UD5QAAD5GS:'8SONDCR:TJ* ,Z#0[&W</''
M@BM!5"C &*6B@ HHIKN$0LQX S0 ZF&6,=77\ZX_6_%;0RM%:G\ZYM]?O78L
M7IV ]5#JWW6!^AIU>8V7B>]MI!E@5[UW>DZQ#J4 *M\PZ@T@-.BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:4*E62FKGHO@^_EOK)WE/(KI:Y#P%_R#Y?J*Z_%;T&W339YV8Q4<3-1V//\
MQAK-U83J(CP6]:YN#Q9?).C,WR@\\UI^/O\ CY3_ 'JY.&RFN(RT:YVC)KS:
MU2:J-)GUF7X>A+"Q<XH]IT/5H]5L4F!&X]JU*\>\)ZXVEWX5V^1OEP:]=AE6
M:)74Y!&:[\/6]I'S/F<SP+PM:R^%[$E<AXSU2?3T'DG^&NOK@OB#]P?[M/$-
MJFVB<JA&>*C&2NBEX6UZ[O=2CCE/!;UKTJO(?!7_ "&(O]ZO7JSPDG*&ITYY
M3A3Q"4%;0****ZSQ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@!"H8$$9!KD_$GA.+4(VFMUQ+Z#@5UM%1.$9JS-\/
MB*F'FITWJ>!WMC-93F.52"#5:O:=<\.VVJV[#:%<]U%>4ZOHUQI5PR2(0N?E
M/J*\FOAW3=^A]MEV9T\4K/21#IVIW&G7"RQ,<J<XSQ7J?A_Q5!J<*I*P$V.1
M7C]36UU+:S+)&Y!4YX-*C7E3?D7C\MIXN.NDNY[]D&EKB?#7C&*Y5;>\<*W0
M>YKM58,H(/!KUJ=2-17B?#XG"U,-/DJ(6BBBM#G"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"[N4M;=I7. !4]<CXXU/[-
MIS0H?G)K.I/DBY'1A:#KUHTUU.>NOB%J,=PZ1)$45B!D4MI\0M0DN56=(A&>
MI KE+"T?4;X0J"6;)J&X@:VG:-N"IQ7D^WJ[W/MO[-P7\/D5['O%E.+JTCF!
M'SKFIZY'P3J@O+$Q%LF, 5UU>O3GSQ3/B<50="M*F^@44459SA1110 5D:_K
M TG3Y)5(\T#*@UK'I7F7CS5#-=) A^4#!K'$5/9P;._+<+]9Q"@]NI"WQ&U7
M)Q'%CZ?_ %JU-#\<W=]>K!=+&NXX&!7$V6F27EK/,@)$76H+28VE['(3C8V:
M\R->JFFWH?6U,MP<XRA""NCWVBLS0;X7VE13;LEA6G7L1=U<^&J0=.;@]T%%
M%%,@**** "BBB@ KB?B;XMOO!_A^.^L41I&DVD...U=M7E7QY_Y$V'_KK_A0
M!YF?VA?%()'V>U_[Y'^%)_PT+XI_Y][7_OD?X5Y-&GF7"I_><#]:]FT;X)QZ
MKI\=RLDOS*#Q[B@"E_PT+XI_Y][7_OD?X4Z/]H7Q.7&^"UV]_E'^%;G_  H!
M?^>DU5[GX!RH/W)E;ZT /T[]H"_=S]M2%5[;5'^%>G^%?B?HGB)$B2?_ $G^
M($ "OGOQ+\)]=T*!KD6K&!!EF)/ KB[#4;K2KQ)H)&1D.< XS0!]X@@C(((]
MJ6O-OA/XU?Q)I,<$Y'VA%RPS7I- $=PYBMI9!U1"P_ 5\XZS\>/$NGZI/;10
M6Q2.1E&5'8_2OHN]_P"/&X_ZY-_*OB#Q1_R'[O\ Z[/_ #H ],L?VA/$+7:"
M[AMEA_B(49_E7T#X;UZ#7])ANHG!9D!;'8U\.")VC+@?*.IKU_X.^/#I5^--
MNI/DF8 ;CT% 'T[13(9DGB66,Y1AD&GT %>3_$[XDZOX/G*6$<+ $#YQ_P#6
MKUBOG3X]_P#'TWU% %SP5\:?$'B'Q!'8W4-N(V&2549_E7O<+F2%'/5E!KX[
M^%?_ ".4/^[7V':_\>L7^X* ):*** "O,OB?\2IO!\,2Z=Y;W!;#AQG%>C7E
MPMI:2SL<!%R:^/\ XH:^^L>++L!LPA\KS0!TO_#0OBG_ )][7_OD?X5Z7\,/
MBA=^,;K[+?B))MI8A !7SM-X9N(_#%OK 0^7*Q7/Y?XU<\ :\= \213ERH8A
M.OJ: /M2BJUA<)=6,$J'(:-3^E6: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:ZKN6Z***W//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?+T&:[U&#J&4Y!J1CJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^/?-TWU% '!?"O\ Y'*'_=K[#M?^/6+_ '!7QY\*_P#D<H?]VOL.U_X]8O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7.^(M"2_A:6, 2 =:Z*@C(Q0!XQ/"]O*T;@@@XJ.N\\4:
M LB-<P+R!R*X5T*,58<BF(;1113 5&*.&4X(Y%>@>%M<%Q"MM,WS@9W'O7GU
M3VEU):3K(AQ@C-(#V2BLK1-434K-7!^;I@]:U:0PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTK;K$\6_\B[<_2NJK\#/'P?^\0]4>,2?ZP_6O7_!W_(*C_W:\@D_UA^M>O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBLK7;\66GR,#\^.* .:\6:SO<6\+=.&KCJEN)VN)VE8\L<U%5""BBB@ K?\
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M0M%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMF8\DF,4 >4?L[1NGAS4 Z,I\X=1BO::KVEA:6"%+2WCA4\D(N,U8H ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJX<^M=53(XQ'&JJ, #%/J1A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4456N+ZWM@?-E5<>M %FCMFN7U#Q
MA!;9$*K+]#7,WGB>[N<^6[1Y]#18#T*?5+.WSYLP7%8]UXMM8L^4RO7G\MY<
M3G,DK-]:@/-.PCK;GQM-(2$A 'J#65<>(KR?.'9/H:QZ* ++:C>/]ZX<_C43
M7$S=9&-1T4P%)+')/-)110 52O>H^E7:I7O4?2N;%_PF>KDW^^1*5%%%>(??
M!3A(Z]&(IM%,32>Y8CO[N(?).Z_0U<AU_48CS=2-]36715*<ELS*="E-6E%'
M6V/CJ[M2"T?F8]36]9_$%)F FC2,?6O-**VCBJD>IP5LGPM3[-CVVW\3:7<!
M0MRNX]JU8Y%E0.ARIZ&O (YI(CE&(/M6K:>)=1MB ;F1E';-=,,<OM(\FOP[
M):TI?>>VT5Y]IOQ!!5(IH/JY-=;9Z]I]XJ[+A-Y_AKKA6A/9GAU\#B*#]^)J
M44<$9HK4Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 2BE/2L75_$-KID39=6D'\-3*2BKLTI4IU9<L%=FG<
MW45I&9)6VKZFN&\0^-@-T%F0P_O US&M>)[K4Y6VNT<9_AS6"22<DYKSJV+;
MT@?5Y?D<86G7U?8FN+J:ZD+RR,Q)[U''(T;AD)!'<4W&36[H_AF[U21<HR1G
M^/%<<8RF]-SW:E2G1A>;LCO?!VM_;[/RI#\R84>]=76/HF@PZ1;[0 SGO6Q7
MMTE)02EN?GN-G2G7E*EL%%%%:'*%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !12&B@!&574JP!!Z@UQO
MB7PC'=HT]LNUQSA1UKM*0@$8-9U*<9JS.C#8JIAY\]-G@5U:36<QBF0JPZ@U
M!7L7B'PS!JD!:-524<Y Y->6:GI5QIL[)*C #N:\FM0E3?D?;Y?F5/%Q[2[#
M]*UBXTRX5XW8J/X<\5ZIH'B2WU6%5+*LW3;7C-6;*^FL9Q)"Y4CTIT,1*F[=
M!9AEE/%QNM)=SWRDKD?#7BR*^C6&<A).@R>M=:I# ,#D&O6A.,U='Q&(PU3#
MSY*B'4E+15F 4444 %8^LZ_;Z2GSLOF=E-,U_7X-)MF^8-+V6O)-2U.?4;HR
MRN2,\ UR8C$*GHMSVLLRJ6)?/4TC^9[?:7 N;:.9>C+FIZYKP;??;-,QG.S
MKI:Z*<N:*9YF)I.C5E!] HHHJS **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBHY9HX4W2,
M%'J: )**H-K6G*<&Z0&I8=1M+@XBG5C[4 6J*2EH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILD:R(5<94]13J*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45#<7,=M&7D8 #WKF+OQE LA6$GCCD4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!S/C*W:33-RC)W5YT1@XKV2\MTN;=T<9&#7E&J63V5XZ,,9
M)(IH12HHHI@%=YX/U3S8C;.W"#C-<'6AHUXUI?QD' +<T@/6Z*B@F6XA613D
M&I:0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D=@B%CT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L+Q!K\&DVK L#*1\H/-+X@\00Z1;-\P\[&54]Z\
MDU/4YM1N6DD8X)R!FN3$8A05H[GMY5E<L3+VE32/YD>H7C7UW).P +'/%5:*
M*\EN[NS[6,5%**V04444B@HHHH *[/P%??9[IX<_ZQJXRM7P]<FVUFW?/ ;F
MM:,N6:9R8ZE[7#RAY'N%%16\HG@60?Q"I:]T_.6K.S"BBB@04444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?R[>1_[HS7E.M71N]1DDSG-- 9]%%%,04Z-&D<(HR33:VO#=D;G4HV(RH/-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E8FO^((=(MF^8&;'"
MFK6M7\MA9-)%$9&Z8%>/:M>7=Y=-)<[NIP#V%<N)K^S5EN>SE66K$RYYOW41
MZGJ<VHW+22.2"> 3TJC117D-MN[/MX0C"*C%:!1112*"BBB@ HHHH *?#(89
M5<=13**!-7T/;?#=T+G1;<Y^;;S6Q7$> +T3020D_<6NWKW:,N:FF?G6/I>R
MQ,H^84445J<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4'D8HHH X'QCIQCN!,@^7'-<E7JGB&S%
MWI<J@?-VKRZ9#'*R'JIQ30AE%%%,"2WD,4Z.#]TYKU71+S[;IJ2YSGBO)J[?
MP7J&[_1">%&:3 [2BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,;Q'>?9-//.-X(KRYCEB?>NO\ &=Z9'%OG[C5Q]-""BBBF 5W_ (.L/)MW
MD<9).17"VL)N)UC7J:]:TR!8+"%0,':,TF!<HHHI#"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N>\0ZZEA"8HSF0C@BKVLZK%IMHSD_-
MZ#K7F%]>27MPTLC9Y./I3 BGF:>9I&.2QS4=%%,04444 %%%% !1110 4444
M %%210R3.%12Q]A75:/X3:4+-< ;3_": .=L]-N+QP$C;![XKKM+\'JF'N"K
MCT-=/::?;V2A8$VU:I7&5;73K:T $,07Z5:HHI %%%% !1110 4444 %%%%
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M[SLNP4445N>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA^749 [KB('FO0;'3X;&$)&HZ>E*X&?I/ARWL$5F4&7N:W  .@HHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3 I:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>LX@HV#P:XH5L1A)69LX0JH[V*9)E#(<BI*X>VOYK9P0Q(]":Z2QUB*X4*[
M/Z5[6%S&G6TEHSCJ8>4-4:E%,+JHR3Q5=]1MHS\TF*[Y3C'=F*BWL6Z*S)-=
MLEZ2C-5G\0P@_*P(K&6+HQWDC14:CZ&Y17./XEP?E"FF_P#"3-_=6L_[0H=R
MOJU3L=+17,_\).W]U:E3Q(A'S;0:%CZ#ZA]6J=CH:*Q$\16Q'S.!5E-;L9,
M3#-:QQ5&6TD2Z-1=#2HJ"*[AE^X^:FZULI)ZHS::W%HHHJA!1110 4444 %%
M%% !1110 4444 %%%% !1110 44A. 2>@K/N=8M+<$-( 1VJ)SC!7D[%1A*6
MB1HTFX>HKD[KQ1)R(E4CUK*?6+EI-VXC\:X9YE2B[+4ZX8&I+?0]"HK-T:]:
M\M=S#E>*TJ[J<U.*DNIR3BX2<6%%%%62%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKS+;J>"T5K^(-'DTF_DBP3&#@-V-9%>+*+B[,_0*-6-6"G#9A1114F@4444
M%%%% !70>$5M6U;%UMVXXW>M<_4MM,T%Q'(IQA@:NG)1DFS#$TW4I2@G:Y[[
M$J)$H0 +CC%/K)\/ZDNI:8DHZCBM:O=BTU='YO4A*$W&6Z"BBBJ("BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBFNZQJ68X I-V 4D*,GI61
MJ.KK""D>&;I]*J:GK!8F.+@#C(K#+,[9)R37B8W,[>Y2^\ZZ5#K(DFN))V)9
MB:(;:2=@(U)JW8Z7)=."P*KZUTUK916R *HSZUQX7 5,0^>>B-:E:,-$9MAH
MBIAY>3Z&MF.&.,810/I3Z*^AHX:G15H(XI3E)ZA1116Y 4444 9FN:>FH:>Z
M, =H)%>=^&;V32-<:&7(3D &O5F *D'H:\Q\9Z>UGJHO(AMCR.GUKT,%)23H
MRV9Y68P<'&O'='IJ-OC5O49IU8_AS4EU+3%D!SMPM;%<,XN,G%GI4YJ<5)=0
MHHHJ2S#\46(N]+E;&2BDBN2\ WYCNY+:4X"KQ7HEQ$)[=XCT88KRB]231/%)
M" B/>!GUYKT<)^\I2I,\G')TJT*Z]&>M]J6JUE<K=6J2J<@CM5FO.:L[,]5-
M-70444E PI:0D#DU3N=2@@4_."?2HG.,%>3L-1;V+C*K## $5CZE96C*26$9
M'I6?=Z^\F5C4K[BLF6ZGF/SR$UX^+S"A)<J5SLI8>:=V["3!$<A&W#UJ-9&0
MY4D&D +' &34RV5RXRL3$5XBBY.\4=NBW!KVY(QYS?G4332-U<FAHV4X88-2
MVX02C> 1[U7-*3LV'NI:(K9I51G^Z,UU]GI]E,@951O45>73K1>D*BO2IY5.
M:YN9'/+&16ECA%MI7^ZI-.^QS_\ /,UW:V=NO(B44[[+#_SS%;K*.\B/KOD<
M";.?_GF:C,$@ZK7H7V6#'^K%59DT^($NJ ^]3/*E%7YBHXV_0X(@@\T!F'0X
MKHKN]L "J6J$^HK&F*2$[4"UYM6$:;LI7.N%7FW5B);J=/NRL*MP:S<PXR[-
MCU-4C%[TPH:4*TX[,MQA+='2VWB@G"R1@#UK8M]9M)P/WJ[O2O/R#W%*LC(<
MJ<&NZEF56/Q:F$\%3EMH>G*ZN,J<BG5Y[:ZQ=0.,RLR^E=38Z]%< "0",^]>
MG1S"E4T>C.&KA)T_,V:*8DB2#*$$4ZNY.^QRBT444P"BBB@ HHHH **1F"C)
M.!65?:W#;*=A#MZ"LZE6--7DRH0E-VBC4>18U+,< 5D7VOP6X(C8.WI7-WNL
M7%RQVNRKZ5FDEVR>2:\BOFC>E)'H4L"MYFE>:Y<77W24^AK-DD>0Y=B?K5JV
MTVXN6&V-L'O7067AE5 >5\^Q%<D*.(Q#NSI=2E15CEXK:68_NT)K1M= NI2/
M,1E%=C#I]O !LB4&K0&!@5Z%+*XK6;.6ICWM%%33K(64&P'.>M7***]2,5%<
MJ//E)R=V%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHK-UC4%L+-F)PQ'% $E[JUI8@^;*%8=C6.?%]N#QMQ7"7M_-?3%Y')SV-5
M:=A'J5GXCLKHA3*H8]JV%8,H(.0:\7CD>)PR'!KO/"FLM<J+>5MSD\9HL,ZV
MBBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%-=@BECT% '-^+=2^RVHB4\R
M#!KSKKUK9\1WS76HR)G*HW%8U,04444P"BBB@ HHHH *<B%W"CJ3@4VN@\,:
M5]MN][K\J<@F@#I?"^C+:VRW$B_.PP:Z:FH@10HZ"G5(PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#G_$^AIJ=BS #>@+?6O'[B![>9HY%*L.QKW\@,I!
MZ&O-/'.AF&9KZ->'.,"N'&4;KG1]%D>/<)^PF]'L<-1117EGV 4444 %%%%
M!1110!V_@+53'>"T>3;%@GGUKTT'(R.E>"6%PUM=QNIQ\P_G7N&FW*75E$Z,
M#\HSCZ5ZN#J<T>5]#XS/L+[.LJJVD7****[3P HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,:#"K@5)17IPHP@K11S.<I;LQ=2T=)@9(@%-<S+$T+E6!&*[^LK5-+6Y0N@
M>O,QV7J:]I36ITT*]GRR.?T_4'M)1R=N>177VMRES$'4]>U<--$T+E6!&*O:
M7J+VTH4GY2<&N+ 8V5&7LY[&U:BIKFCN=E4<LR0J2[ 8]:JSZE#%;^8&!R.
M#7+WVI2W;D;CL["O6Q6/A16FK.6E0E-FI?Z]C*1 @^HK"FNI9R?,8FHU5G.%
M!)K5L=$EGPS\+Z&O#=3$8N5D=JC3I(R51G/RJ3]*MP:7<3$?(R_45U5OI5M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Q?CF<^7"@!'-=I7(^.("]O"R]CDT <%1115""M;P[.8-6C<'
M%9-3V<ODW*/[T >PQ-NB5O49I]063;K*%O5!4]2,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0]V&Y4L=*ALU&%^;O5_I2T5[L(1@N6*/-E)R=V%%%%62%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8/BB'S;
M G^Z,UO50UF)9-+G)ZA#B@#R.BCZT50@I5^^OUI*4=10!ZUH\IDT^+)SA0*T
M*PO"\@DT_@],5NU(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /+_$LS2:BZL>%
M;BL2M#6V+:O<@GH]9],04444P.P\%2M]H\O^'!KNZX;P7$/-\S/.#7<TF,**
M**0!1110 4444 %%%% !1110 4444 %%%% !1110 C$*,GI7E>OW1N-1D7.0
MK8%>CZO/]GTV67.,"O*+J3S;J1_[QS30$-%%%,04444 %%%% !3D0R.%7DGI
M3:U= M#=:E%Q\H;F@#O?#MD+738VQAV7FMFF11B*,(O04^I&%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!G:S8)J&GO$_0 FO$KN%H+F1",
M88@?G7OC#<I4]QBO)O'.GK9ZL#&/E*Y-<.-IWCS=CZ+A_$\M5T7U.5HHHKRS
M[ **** "BBB@ J>TF:"Y1U..:@H'!!IIV=R914HM,]YTN99M.@8'/R#-7*Y7
MP-=FZTM\G.P@5U5>]3ES13/S;$TW2K2@^C"BBBK, HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!**6H;FXCM86DD.%49H2N)M)787-Q';1-)(V
M !FO//$/B^2\<VEEAD)QGO5?Q!XBFUB[^QV9_=[N&4]:Z#PUX32S5;BZ3=(1
M]UA7I4Z4*$>>KOT1Y%6O4Q4_94-%U9D>'O#5],XFNMP0\_>-;]WH<D(S""0!
MWKIT147"J /04I (P17CXZA3Q;YI*S\CU<)%X:/+%W.">-HV*L,&H]J'[R*?
MJ*[6ZTV&Y'0*?4"N<OM*EMLL%)0=Z^<K8&OAGSPV\CTHU85%:1R6H:05N5N+
M;.[.6'3%>D>'2YT6#S#\V.>:Y+@BM&PU)[3"CE*]&CGM24%2Q&MNIQK+*=.H
MZE+2_0[&BJ=G?Q7:C:PW>E7*]6$XS7-%W1+33LPHHHJQ$;01,VYHT)]2*D
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M,DUT^DZ)Y>)9QSZ4NA:9'Y*W#<EO6N@ P,"O7P. 22J5#BQ&)=^2(BJ$7
M]J=117LG %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 56U 9L)Q_LU9J&Z&ZUD'^S0!Y#=KLN6&
M,5!5[5D*:C(I&*HU0@H[T44 >B>"Y ^GR8[-73UQ_@:0"TE3U:NPJ1A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#QY8)+I+W
M&7&!77UFZW9_;=-DB_&LZD>:#1T82K[*O&?9GAA&#BBIKN/RKN5/[K$5#7A/
M<_2(NZ3"BBBD4%%%% !1110!W_P]OO+W6O\ ?:O1J\>\$RE?$5NF>":]AKV,
M)*],^%SRER8MOOJ%%%%=1XX4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4R7_ %3?2GTA&010!Y1K_P#R&)JS*V/%"A->
MN%'8UCU0@HHHH [7P21L<?[5=M7 ^#&(GQGC=7?5+&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !56_<I9NWI5JJFI_\>$GTH \GOVW7TS>K57J>\_X_)?\ >J"J$%%%
M% 'HG@R(_P!EB3/<\5T]<[X,_P"0&O\ O&NBJ1A1110 4444 %%%% !1110
M4444 %%%% !1110 4'I12'[I^E 'G'C"8S7Z9.=HQ7.5K>()/,U!_8FLFJ$%
M%%% !1110 4444 6M.B\^]CC]37K-BGEV4*>BXKS/PW%YFM0 CC->IJH50!V
MI,8M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FR#,
M;#V-.I,<8H \0\06_P!GU27C&YB:RJ['XAVZ0:M%Y:X!3)KCJ\*O'EJ-'Z+E
M]3VF&A+R"BBBLCM"BBB@ HHHH T] N&M=7AE4X*]Z]KM)#+:12'DLN:\'MG\
MN=6]*]RTEMVE6Q]4%>G@7HT?)\1P]^,R[1117>?,A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y=XK!
M_M^X..,UBUV?C#2WWFZ1<[CS@5QAX--""BBE52[  9-,#J_!@)N >VZN_KF/
M"6FM;6IDD7YB<BNGJ6,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M" 5WX%^\T?-\1QO2@_,VJ***],^1"BBB@ HHHH **** "BBB@ HHHH ****
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M^%>Z1ZR?G2O@GNF/ES!;-$;?$72RIVQRY[<?_6JE)X_C8?NDDS_NFM(?#[2
M0<R?G27GAC2["#S &SVS4SJX*G%RL]!QIYA-V;2,QM=NM3BRQ(C]",&H%4NX
M &2:3:%X4 "MS0; RRB=A\HXKXFI*6-Q-XJR?Y'T]*/U>BE)W9L:18+:VX)'
M)YK4I%   ':EKZ2E35.*C'H>=.3D[L*X+6/^0G-]:[SH*X/5SG4YOK7FYO\
MPX^IUX+XV6_#O_'VWTKLATKC?#O_ !]M]*[+M6F5_P  G&?Q HHHKTCD"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M445V'@A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%U=
M1VD)DD8  <9KB-3\7R2.8X5P!_$#4GC'47\PVR,1M/-<=30C7'B*]#9\U_SK
M<TCQ>?,6*X4!3_$37&4=* /9X9EFB5T.01FI*Y+P?J3S0&&1BQS@9[5UM(84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQTN*U4$J"WK6@JA0 !P**]+#8"G1UW9E4KRGH+1117>8!1110 4444 %%%%
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MN:]04!0 .@K@O!MMON!-C[K5WU)C"BBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<_P"I:N(G
M_P!>_P!379Z@VRU8UQ<AS(Q]Z^?SE^]%'9A5HSH/#?\ JI?K6]7F4OB*_P!'
ME"6Z91N3\N:MP>/9>//4CU^6O>RW!57A(21Y6)S"C&M*$GJCT*DKD8?'VF8_
M?,X/TJ['XSTJ50RNV#ZBNEX:JMXA'&4);21T5%8Z^)-/89$G%2Q:[92G"R#\
MZATIK=&BK4WM(TZ*I?VK:_\ /1?SJ*77+*+[T@_.DJ<NPW5@MV:-(SJB[F8
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M-88PBC %.50HP  /:BO;PV%A0C9;G!5JRJ.[%HHHKI,@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \N\5?\ (P7'UK%K:\5?\C!<?6L6F(****8'6>#?^/@?[U=_
M7 >#?^/@?[U=_28PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5-3.+"3'I5NJFI_P#'
MA)]* /)KWF\E_P!ZH*GO?^/R7_>J"J$%%%% 'I/@S_D!K_O&NBKG?!G_ " U
M_P!XUT52,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*\0P^?HT
MZ <D5Y7(GER,I[&O9)XA-"8SWKR7583#J,ZD8&[BFA%.BDI:8!1110 4444
M%=%X3O?L]\(LX\QJYVI[.<VUTDH/W3F@#V2BJ6EW/VK3XI,Y)'-7:D84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7%>-+W:WV7/4 XKLIG
M$<3L3T!->4ZY>?;;]GSG:2* ,VBBBJ$%%%% !1110 4 <XHI\2&255 R<T >
M@^#;;R;!R1R3FNGJCI-N+>PB '5035ZI&%%%% !1110 4444 %%%% !1110
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M:Z_U;Y-7.M>=QS21$%'(QZ5TFDZSYA$4I ]Z]#"YFJCY:FC.>KA7%7B=!12
MY&1WI:]8Y HHHH *3%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'EWBK_D8+CZUBUM>*O\ D8+CZUBTQ!1113 ZSP;_ ,? _P!Z
MN_K@/!O_ !\#_>KOZ3&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JIJ?_'A)]*MU4U/
M_CPD^E 'DU[_ ,?DO^]4%3WO_'Y+_O5!5""BBB@#TGP9_P @-?\ >-=%7.^#
M/^0&O^\:Z*I&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YYXQ
MLQ;W4;@??Y->AUSWBNP^TV+3=XUH0'FM%!!!P:*H04444 %%%% !1110!W/@
M[4MRM!(V-HPM=E7D6DWAM+Z)\X7=S7JUI<K=VZS)C#4F,GHHHI %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%-D<1HS'H!F@#"\4:A]DL"%;YR<5YHY
MW.S'N<UN^)]2^V7[!&R@["L&FA!1113 **** "BBB@ K6\.VWVG58TQD5DUV
MO@NPR/M1&"#BD!V<2[(E7T&*?112&%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >7>*O^1@
MN/K6+6SXJ_Y&"X^M8U,04444P.L\&_\ 'P/]ZN_K@/!O_'P/]ZN_I,84444@
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KG_$VJBRLRBM\[<$"MFZN%MK=Y&.,#->7:WJ3:A?.X)V
M=A0!FNQ9RQ[FDHHJA!1110 4444 %%%% #X4,DJ*HSDBO5]%LQ96"H/X@#7"
M>%K W6H L/D KTM5VHJ^@Q28"T444AA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%5[B]@MAF5]M %BBLT:[I
MY.//%78;B.X7=&V10!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)(TE4
MJZAE/4&L6\\,6MTQ*A8_H*W:* .:@\(6\,FYG#CT(K=MK."U7$,:K]*L44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<
MP)<0-&Z@Y&*\OUS3'T^\9<'9ZUZM6/K^E)J%F< !QSF@#RRBI;B![>9D=2"#
MWJ*J$%%%% !1110 4444 %36US):RB2-BI'I4-% 'H>@>)([I!%.P5QP,]ZZ
M=6#*".AKQB.5XG#HQ##H:[#0?%!4K!<G(/&XGI2L!W%%1PSQ3H&C<,#W%24A
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !0::[K&NYV 'J:Y;7O$\=NK0VQ#-_>4T :&M:]#I\#!6#2=EKSN_U&:_
MF+R,2.P-0W-U+=2EY6+'WJ&F(****8!1110 4444 %%%% !5JPM'O+I(U!()
MP3Z571&=PJC)/:O0/"VBBVA\^5<LPZ'M2 VM*T]-/LTB &X=35^BBD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)$D&48,/8T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "@C(P:** ./\4Z'YBFYA7D=A7"LI5BI'(KVAT$BE6&0:\^\3:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#R[Q5_R,%Q]:Q:VO%7_(P7'UK%IB"BBBF!UG@W_CX'^]7?
MUP'@W_CX'^]7?TF,****0!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /+O%7_(P7'UK%K:\5?\C!<?6L6F(****8'6
M>#?^/@?[U=_7 >#?^/@?[U=_28PHHHI %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 445%<&18&,6-^.,T .$J%BNX _6G9&<9YK@+K4KU-18L"&1N@
MK=T'4Y[R[E,XQD>E '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>["C3PZYZNK['ASQ%7%R]G0TCW,;0?"5Q?R"ZO\ <%)RO.<UZ):6<-E"L42
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M]>!PLV%]ZV8+N&X&8WS7MT<52K+W6<DZ<H;HGHHHKH,PHHIDL@AB:1N%49-
M/0Y_Q=J@T_3BH.#("M>/NQ=B2223WKH_%^L&_P!0>)6S&IR*YJOHL%1]G3UW
M9\EF.(]M6=MD%%%%=AP!1110 4444 %%%% !1110 55OC((&*>E6J1U#J5/0
MT%TIJ$U)F;IUV6)1SST%:=<_'\FI[1TW5T<0!E4'N:2>AVYA2C&HI1^TKGL/
M@O\ Y%>U^E=#6+X54)X?MP.E;5?+UW>K)^9]+AE:C%>2"BBBLC<**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \N\5?\C!<?6L6
MMKQ5_P C!<?6L6F(****8'6>#?\ CX'^]7?UP'@W_CX'^]7?TF,****0!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %5[J\@M$W3-@58KE=?@E\Q2[,
M(C]X^E %JYB2ZN+>>WC1HV;+$CM6O%9PQ2M+&H&[L!7&627,-S$S.PMB?D.>
MHKN(6#1 @\4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534_^/"3Z5;JIJ?_
M !X2?2@#R:]_X_)?]ZH*GO?^/R7_ 'J@JA!1110!Z3X,_P"0&O\ O&NBKG?!
MG_(#7_>-=%4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IKHLBE6&0:=10!RFN>%TN TMO\K?W5%<-=6<UI
M(4E0J1ZU[)67J>BV^H1G**)/[U.X'D]+6UJOAZYL')56=/4"L8@@X(P:8A**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***.M !3XH7F<)&N2:O:?H]S?R!51@I_BQ7>:1X<M[
M% TBJ[CO2N!B:'X58[9KG([[2*[2&".WC"1H% ["I ,# I:0PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/]
MIG_CW\,_[US_ "BKR'X>?\E'\-_]A*#_ -#%>O?M,_\ 'OX9_P!ZY_E%7D/P
M\_Y*/X;_ .PE!_Z&* /MJBBB@ K+\2_\BKK'_7E-_P"@&M2LOQ+_ ,BKK'_7
ME-_Z : /A2O7_AU\9K/P/X431I]'GNG69Y?,28*/FQQ@BO(*[GPK\)O$WC#1
M5U;2A9_9FD:,>;-M;*]>,4 >I?\ #2VF_P#0MW?_ ($K_A6'K7[2&K7,#1:-
MHMO8L1@33RF9A[@84 _7-<W=_ ;QW;1,\=E:W.!G;#=+D_\ ?6*X#4]*U#1K
MY[+4[.>TN4^]%,A5OKSV]Z %U/5-1U[4Y+[4;F:\O9V^:1SEF/8#T'H!7MGP
MC^#=W]NM_$?B>V,$4)$EK8RC#NPY#R#L!U"GDGKQUXSX4>/-'\'ZRBZOHMK+
M%*^/[1$>Z>WSW&<_+Z@8/UZ5]:P3Q75O'<02)+#*H=)$.592,@@]Q0!)1110
M!Q7Q<_Y)5X@_ZX#_ -#6OC6OLKXN?\DJ\0?]<!_Z&M?&M 'K_P (/A+_ ,)2
MZ:]KL3+HT;?N83P;I@>?^ #OZGCUKZ<@@AM8(X+>)(H8U"I'&H55 Z  =!6#
MX &/AUX:Q_T"[;_T6M=%0 5\^_M%>$8(?L/BJUB"22R?9;S:/OG!*,??"D$_
M[M?05><_'2%9?A-JCL,F*2!U]CYJK_)C0!\HZ5J$NDZO9:C 2);6=)DQZJP(
M_E7WC%*LT*2H<HZAE/J#7P'7W9X;<R>%M(<]6LH2?^^!0!IUR_BCX>^'/&-_
M97FM6;SRV@*IMD*!U)SM;'49_F:ZBB@"O8V%GIEG'9V-K#;6T8PD4*!54>P%
M6**IWNK:;IHS?:A:6O?]_,J?S- %RO$/VC?#MO-H&G^(8XP+JWG%M*X'+1L"
M1GZ,./\ >->G/X]\'QG#>*M%SZ"_B/\ [-7G7QI\6^&]8^'%S::;KNG7ER;B
M)EB@N4=B W)P#F@#YPTV]DTS5;._A)$MM.DR$>JL"/Y5]Z*P= RG*D9!KX!K
M[WL.=.MO^N2_R% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $90RD$9!
MKG-8TLJ3+$O![#M724QT$BE6&0:YL3AHUX<K-*=1P=T<",JWH16[I6K;"(I3
MQZFFZII)1C+$,CT%8A!1N>"*^;7M<%5_K4[_ ':L3OXY%D7<IR*=7)Z;JSV[
M!)"66NF@N8[A R,#["OH<+C(5XZ;G#4I.#):Y[7-0_Y9(?8XK5U&Z%M;L<_-
MCBN-FE,TK.>]<>:8KDC[*.[-<-3N^9C%4NP Y)KJ=)LUM;?SI>#CG-85H]O;
M9GN'50O*@]ZQM:\57.HR?9;!649ZJ>M:9)E<ZO[Z2T.?,<PIT%R7N^QOZ_XP
MALU:*V*R/TX-<E::=J7B.[WS&3RB?O&M70O!TMTXNKUNO\+"O0+6S@LXA'#&
M% ]*^GE6IX=<M+5]SQ(4*V+?/6TCV,[1_#]KID  C5I/[V.:V ,44M>=*<IN
M\CUH4XP7+%:!1114EA1110 4444 9/B*3RM&E:N-\$Q^;J$LN.DE=3XRD\KP
MW._T_K7/_#N+S8;B;.,/TKT*/NX64CRL1[V-A'R._HHHKSSU0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBL^?5[.VF\N:=$.<<FDVEN5&$INT5<T**AANH+@9BE5Q[5-1<33
M6C"L3Q!_Q['ZUMUA^(&'D%>]<F/_ -WD:4?C1S-%%%?(GI@**!10,2BBDIC"
MI8[F6(_)(1]*BI*<9-:H+7W-JUU^2+ ==WN:V;?5[>8?,X4^E<90"5.0>:]"
MCF5:GH]483PT)'H:2+(,J<BN/\8^(4M+<VT+ NXVMCM59-1NHT*K*PKF-6TZ
M>YF>=I2Y8YQ7T.6YEAJE1>U=CQ\RP^(A2?L5<YUF9V+,<D]S25-+;2Q??0BH
M:^SA.,E>+NCXJ491=I*P44451(4444 %%%% !1110 4444 %,D?9&6/:GUFZ
MG<[$\L?Q"@VP])U:B@BE"/-U'>.@:NA1MCAL9Q63I<!52[#KTK4I(ZLQJ*55
M17V=#V?PA<+/X>MST;'2MZO+_!6OK:2_9IFPF,#->FQR)*@=&!4]Q7SF+I.G
M5=^I[^ KQJT5;=#Z***Y3M"DI::S!%+,< =Z '45D7_B&QLE/[]&8?PYKB]5
M\>R2LT=NC)C^(&NBEA:E79')7QM&C\3/1)KN"W&99 OUJB_B/24.&O$!KR&Y
MUW4+DGS+ER#V-9[R-(<L<FN^&5JWOL\NIG3O[D?O/;/^$GT?_G]CJW;ZG9W7
M^IF5_I7@XJY;:K=VA!BF9<>E5+*XV]V1,,ZE?WXZ'NX.:6N!\-^,Q*RV]WU/
M&]CTKNXY$E0.A!4\@BO+K4)TI6D>UA\1"O'F@Q]%)2UD;A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'EWBO\ Y&"X^M8M;7BK_D8+CZUBTQ!1113 ZSP;_P ? _WJ[^N
M\&_\? _WJ[^DQA1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ JIJ?_'A)]*MU4U/_ (\)/I0!Y->_\?DO^]4%3WO_ !^2_P"]
M4%4(**** /2?!G_(#7_>-=%7.^#/^0&O^\:Z*I&%%%% !1110 4444 %%%%
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M7E'5JET>YL+6%888RF..:W5FC?[KJ?QK[99A3J05.@[11\_2R]TYNI6UDQX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "HYY1#$7(SBI*CF$;J8W(Y[9H Y]=9E-^$Y\K/+=A5W270
MW%PR?-N;J*Q+K3;L3O9Q3)Y<YSBM70M,NM.WK*ZE3TQ0!NT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9U]_U\8_%'PS_P (K\0-2L8TV6LK_:;; X\M^0![ Y7_ (#0![[\"/$_]N^
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ME)^@K5T"U#%I&'(/%="\2.I#*#GVKGPV6JM1YV[-FE3$<DK' ?,I[BIH;R:
MY5OSKIKC1+>7)&0:RY]!G7F,<>]83P&(HN\=?0N->G/<2'7[A>'(Q]*NQ>(H
MO^6F?P%8<MA/$3N6JY1AU4_E2CC<52T;^\;HTY'7IKEJ_3-3+J<#$#=UKB?F
M'J*-S#^)OSKHCFU5?$B'A8]#NQ>PG^,?G1]LA_O#\ZX3S'_OM^='F/\ WV_.
MK_MB7\HOJB[G=_;8?[P_.D-]"!G</SKA/,?^^WYT>8_]]OSH_MB7\H?4UW.V
M_M2WSUJ-]:M4."37&;G]6_.C+'UJ7FU7HBEA(]RSXKD754VP=<=ZMZ!J4.FV
M7E3 [O:LG#'L:-K?W3^55+.\4X>STMZ&4<LH*HZNMSJ#XD@SQNQ]*:?$D6.,
M_E7,;&_NG\J-CDXVG\JY_P"T<0=/U6D="?$ASQG\J/\ A)#_ )%80M92,[3^
M5'V2;^Z?RH^NXGN5["B= GB5,?-G\JD7Q-;Y^8-CZ5RSQ.AP5/Y4THP_A/Y5
M2S#$(/JM)G9)XELW. &J_:W\-V/D;\":\\J]I$D@U",!CC/K6]#,ZCFHR1G4
MP<%%N)W]%-CSL&>M.KWCS HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** (+JTBNX6CD4$,,=*\N\5>&'TV4SP+^Y8\ <F
MO6*JW]HE[:O$Z@Y! XK"M152/F>AE^/GA*B:>G4\(BE:&574D$'-=E8:L=11
M3(V7 Q7/Z_I+Z5J#Q$';UJMIMT;:Z#9XZ5X6(IMQ<#[#%488NASQWZ';44R-
MPZ*P[C-/KR3YAJV@"B@44 )1124#(;F(RQ[5ZUFFVD!Q6Q2$#TH:N;4ZS@K&
M2MK*QZU.MC_>J]@9HH444\1)[%)[$8^6JDL#1'FMBHY$#J1BAQ*A7DMS'!P<
MUI6TF^,9ZU0FB,;D=JEM'VR>U3%V9O5BIPNC0-(1GK2TE;'$4;O3HKA2<?-V
MKG;JRDMGY''M78&H9H$F0JX'->[EF=UL(U&>L3Q\QR:EBES0TD<716E?Z:T)
M+(/EK.K[_"XJEB::J4W='PF)PM3#3Y*BLQ**9+((T+&JMK?"=RM=%R8T9R@Y
MI:(NT444&12U-";5B*KZ5,H#(>":TW02(5/0UD-8R178*=":3/3PTX5*$J,W
M;J;-%-0$( >M.IGF-684444 %%%% !1110!7NY1% WKCBLJPA-Q.9&[<U)J<
M_F2+&O4'%7K"'RX%)')'-+=GK1_V;"W^U(MT444SR0HHHH **** .H\(:X=.
MO1"[';*0*]:BD66,.A!!]*^?T8HX93@BO1_"'B=&B2TN'Y P*\K'X6_[R)[>
M5XQ1_=3?H=Y12!@1D'(I:\8^A"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:55NJ@_44ZB@!GE
M1_\ /-?RIP51T 'T%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 C'"DCL*Y*ZO;F>X9U8*4) SQ72W-[#:KF1N.E8NK65M<S)M+!V7(V\"
M@"/3[F.[OXC&3E.'SZUT]8>G:#%92I-&6SU.36Y0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5'/'YL+)ZU)10!Y'K%L]OJ,VX8!;BJ%>FZ_H*:C%O08
MD4< #K7!7.BWMLQ#PD 4Q&?3HTWR*H[G%6(M.NIB D9)KJ-!\+2>8LUTI3'.
M#0!T/AJT:STI8V'.<UL4U$"(% P *=2&%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3616^\H/UIU% %>2RMI 0T*?7;6?/X=LY\Y&WZ"MBB@#E9
M?!%FQ++*^?2J$O@LK_JRQKN:* /.G\'WH)VQDCZU5;PEJV>(./K7I]%.X'EK
M^%]5C&6@_6HO^$>U+_GC^M>K%0W49IOE)_=%%P/+D\,ZI)]V#/XU+_PB>K_\
M^_ZUZ:$5>@ IU%P/-X_"%^0-T1'XU<B\%N?]9N%=Y11<#DHO ]H0#)+(#6E!
MX8LH,8^;'J*VZ*0%6+3[6(8$*'WVU.L:)]U0/H*?10 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5P/C#X0>%_&-R][/#+9:@_+W-H0ID/JRD$'Z\
M'WKOJ* /!'_9GA,N8_%<BQ_W6L 3^?F#^5=)X9^ ?AK0M0@O[RZNM3G@<.B2
MX2+<.02HY//8G'M7J]% !45U;17EI-:SKNAFC:-USC*D8(_(U+10!XY+^SAX
M6>8M'JFKQQDYV;XSCZ'97I/A3PMIW@[08M'TOSC;QLS[IGW.S$\DD #\@*VJ
M* "BBB@ KC?'/PST/Q\;:74FN8+FV4K'/;. VT\[3D$$9Y_.NRHH \ETC]GW
MPSI6JVU^VH:I</;2K*D;.BJ64Y&<+G''8BO6J** ,[7=%L_$6AW>D7X<VMU'
MLDV-M8#KD'UR!7EB_LW^%Q+DZMJYCS]W?'G'UV?TKV2B@"KINGV^DZ7::=:*
M5MK2%((E)R0J@ 9/?@5:HHH *RO$GAZQ\5>'[O1=2\S[+<A0YB;:P(8,"#Z@
M@5JT4 >-Q_LX>%UF#/JNKO&#G9OC&?;.RO7K2UBLK."T@7;#!&L<:YSA5& /
MR%344 %,FABN(7AFC26*12KHZAE8'J"#U%/HH \I\0_ 'PGJ\SW&GO<Z3*QR
M4@(>+/\ N-T^@('M7*G]F8^9QXL_=_\ 8/Y_]&5] 44 >4>'?@!X4T>9+C47
MN-6E4Y"SD)%G_<7K]"2/:O2KK2K.[T6?2&A6.QGMVMFBB&P"-E*D#'3@U=HH
M \=C_9Q\*K<AVU/5WB!SY9DC&1Z$A*]@C18HUC0850 !Z 4ZB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC MG)'.:^8P,?:8I-GH5GRTS;HHHKZH\X**** "BBB@ HHHH **** "BBB@
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M+P!18/K].'\*%F4[6P2$ L Q]ZN@8'%%%,\^K5G5ES384444&84444 %%%%
M!1110 4444 %%%% !1110 4^-VC<,IP1Z4R@4 CV7PG?M>Z:-W5 !705R'@(
M$:?)GU%=?7S&)BHU9)'V>#DY4(MA1116!TA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <KXLU<VT/DQ-A\X.*X!W:1B
MS$DFMOQ7(QUV="> :PJ:$%/BE>%PZ,5(]*913 ]+\+ZH;^S(D/S+P/>N@K@?
M!C$3[<\%J[ZI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DE2)2SM@#O52?5+>!
MF5W4$=C3+BYAN=,=\CYE.!0 L>K6TTI174KZUA:GI":AJSF*;8VW.!68DSV<
M2,+5B"V U=5I48E NBFUR,4 9FB6%S;7P69&91_&:ZFD Q2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 45%<7$=M$9)&  ]ZYF\\9VT;
M%(U?([T =717&1>-HMPWJY%='IVL6VHQAHS@GL3S0!H4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1152YU&VMD+23)QVW#-)M+<J,7)V2+=%<K=>.]-M6(
M*.V/[IJM_P +'TS_ )X2_P"?PK)XBDMV=D<LQ<E=4V=G17*6WCW3;APHC=<]
MR:W[74[6[4%)4Y[;JJ-6$OA9C5PE>C_$BT7**0<TM:'.%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLHK+9HWZ*S8-41R%;.:T$D5QE2#0<%;#U*3M-#J***9B%%%% @HHHH&%%%%
M!1110 444$X!)H J7EV+=1W.:EMI_/B#X(K'O&,U]M'W<UM01B*(**29Z&(H
M0I4(_P S)*51E@*2KVDVOVS4(X1SFB3LKLX(Q<FDCU?PG:&UTQ21C> :Z"JU
MA'Y5C#'_ '5 JS7RM67--L^VHPY*:B@HHHJ#4**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R[Q5_P C!<?6L6MKQ5_R
M,%Q]:Q:8@HHHI@=9X-_X^!_O5W]<!X-_X^!_O5W])C"BBBD 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !139'$
M4;.W11FL]-:MI(1(O=MN,\T :)8*,DX%()$)P&&:RM>N_(TX.C88D5F64ERF
MHQ>=<QLK+G@T :^I:F+*14"EF8< 4S3=5^UF3<I4*><]JS;SS;^_22!2KQ\!
MB.*J:6MY)<W,);@MA^.M #=3B5;F>61#<*3E=O\ #5G2KZ*[A2V^QN O\1Z5
MNPZ;#';.@7EQAJDLK)+1-J@8H ;)IT,END)4;5.0*LPQ+#&$48 J2B@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D)P,FEJM?N8[.1EZB
M@#@_$VM27%RUNC85#@US-6;]B]],QZEJK50@JYIU]+972.C$<@'Z53HH ]@T
MZ[6]M%E7TQ5NN>\'$MHBDG^(UT-2,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***1F"*6/0<F@!:*S'UZP1BK3*"/<4W_A(=/_Y[
MK^8H U:*S8M<L9G"),I)]Q6BI#*".AH 6BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \N\5?\ (P7'UK%K:\5?\C!<?6L6F(****8'6>#?^/@?[U=_7 >#
M?^/@?[U=_28PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQP)'&$ & ,4RWLXK9W>,<N<FK%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^0=;_P"X*!,M4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 54U/_ (\)/I5NJFI_\>$GTH \FO?^/R7_
M 'J@J>]_X_)?]ZH*H04444 >D^#/^0&O^\:Z*N=\&?\ (#7_ 'C715(PHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCK'_(&O/^N3
M?RJ]5'6/^0->?]<F_E0!\@:]_P A:;ZG^=9M:6O?\A:;ZG^=9O:@HZ#P7_R,
MD'^>]?6NG?\ (.M_]P5\E>"_^1D@_P ]Z^M=._Y!UO\ [@H$RU1110(****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4A (P1Q2T4 <3J,)CNW)& 3Q52NFURR\Q/-0?='-<R1@X-?'XV@Z-5IGITI\
MT0JAJ*GRP?>K]5[N/?%]*Y&=-&7+-,J:>WS[<]JTJQ;>3RIL_A6RIRH-"-<3
M&T[BU0U2R%U;M@?/CBKYHJHR<7=&-.HZ<E*/0\_EB:*1D;J#6CI>I-:R!&Y4
M\<]JT]8TL2J98AAAU [US3HT;88$&O2C*-6.I]32J4\91LSO(9TG3<A!!I]<
M79ZE+:D?,2OI6];:W%*HW@*?>N2="4=CQL1EU6F[QU1K&BJPO[8C/G+4<NI6
MZ=)%-9<DNQQJC4;MRLN4TD*,GI6-/KZ+D*F?>LNXU>>7.UBH]*UCAYL[*66U
MI[JQTDU_!$#F09]*S)]?"<(@;WK >5Y#EFS2+&[G"J3]*Z(X>*W/3I992@KS
MU-"769G.1E:?:7,T\IWN2N.E4ULICU0BM"UMS".>M37Y(P:0ZLL-"+A"UQUU
M.T$>Y3SFH8=:DC/S#=3[N!YEPN:RY()(_O*0*6'A%PU(P_U:K'DDU<Z2'5$F
M Z ^E6//XZ5RMM'(\HV9!]:Z*)2L:ACDXISIQCL?,YU2>#J+V=3?IV+'G'TH
M\X^E145'*CQ/KE?^8D\T^E'F>U1T460?7:_\P_S/:J]S"+A=IXJ6BM*525*2
MG!V:(JXBI5@X3=TS..E+_>J,Z.,_ZRM6BO1CG6-CM/\ (\YX*@_LF0VD$='S
M4+Z;(O3)K=HKHI\08R/Q.YG++Z+VT.::UF3JAQ41!!P:ZED5AR*K36,4@.%
M/K7JX;B:+=JT;>ARU,M:U@SGJ*MW-D\)R.153O7TM"O3KPYZ;NCS)TY0?+)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 454O;Z.R0O)@ =S56SU=+HL4&5SU% $5QKT<33(0-R<?6
MG/?_ &K2B2NWS%XKGKZRDN)[J>,$A#DJ.]7=$@FO$0.Q1$YV&@#+>TDM(X9"
M#RW!]:ZK3[=;A%FGB!?U-7Y+.WE14>,%5.0/2I5147:HP* *QL8S>_:#C.,8
MJW110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 54U/\ X\)/I5NJFI_\>$GTH \FO?\
MC\E_WJ@J>]_X_)?]ZH*H04444 >D^#/^0&O^\:Z*N=\&?\@-?]XUT52,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZQ_P @:\_Z
MY-_*KU4=8_Y UY_UR;^5 'R!KW_(6F^I_G6;VK2U[_D+3?4_SK-[4%'0>"_^
M1D@_SWKZUT[_ )!UO_N"ODKP7_R,D'^>]?6NG?\ (.M_]P4"9:HHHH$%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% ''>+M*>1?M$:Y)/.*X8@J<$<U[/+$LJ%'&01@UR
MVI>#XYV+6H"$^M.XC@*<B-(P5023Z5T__"#7^?\ 6QXK<TOPI#:,'G4,X[BB
MX"^%-+-G:EY!\S'(KI:15"*%48 I:0PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***0D#J<4 *3@9/2J4VJ6T0XD5N<<&K$CH\;H'7)4CK7"7,<-D[P/$\DK.6#
MKR!S0!T?B&%+S364.H9AD"L2 20-#;VJF'<,-G^*M/3 FJO'(ZG$8V\UN-8V
M[S1RE/FC^[0 VTM$CM\,OS./G/K4T5M% 28UP3UJ6B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "JFI_\>$GTJW5745+V4BCJ10!Y+>_\?DO^]4%6+X%;
MV8'J&JO5""BBB@#TGP9_R U_WC715SO@S_D!K_O&NBJ1A1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(/\ />OK73O^0=;_ .X*^2O!?_(R0?Y[U]:Z=_R#K?\ W!0)EJBBB@04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !124M !1110 4444 %</\1?^02_
MX5W%</\ $7_D$O\ A0!Y,/O#ZU]!:)_R!+/_ *YBOGT?>%?0.B?\@2S_ .N8
MH T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFO R]VKGL8Q7HG44445]$>*%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4M%% !1110
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MU'4FY,^SH4E2IJ"Z!11169J%%%% !1110 4444 %%%% !1110 4444 %%%%
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M-=]SJ48]JW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=5_(=1117E'N!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH8T/S1_*V?6I=:M+:^A,Z,PD7@;>*ET_P_;1&&X#OO SUH W.W-+2 8&*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ?
M_'A)]*N54U/_ (\)/I0!Y->_\?DO^]4%3WO_ !^2_P"]4%4(**** /2?!G_(
M#7_>-=%7.^#/^0&O^\:Z*I&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M6J?\>,GT-7:IZI_QXR?0U4/B1%3X&>&WG_'[-_OFH*GO/^/V;_?-05]6MCX>
M6[/=- _Y -G_ -<Q6C6=H'_(!L_^N8K1KY6I\;]3[>E_#CZ(****@T"N'^(O
M_()?\*[BN'^(O_()?\* /):N+]T53JXOW17JY7\4CQ,Z^"'J>N>"?^0?_P !
MKJJY7P3_ ,@__@-=57#B?XLCT<'_  (A1116!U!1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >7>*O^1@N/K6+6UXJ_Y&"X^M8M,04444P.L\&_\ 'P/]
MZN_K@/!O_'P/]ZN_I,84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L/7KRZM(B\<0:+N36YVJE+<6T\A
MM7VLY&=IH XU=:81F&(!XW.68]C79Z=*DMHA5L\<UF:980J98Y;=06<D<=JW
M(XDB7:B@#VH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 54U/\ X\)/I5NJFI_\>$GTH \FO?\ C\E_WJ@J>]_X_)?]
MZH*H04444 >D^#/^0&O^\:Z*N=\&?\@-?]XUT52,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *HZQ_P @:\_ZY-_*KU4=8_Y UY_U
MR;^5 'R!KW_(6F^I_G6;VK2U[_D+3?4_SK-[4%'0>"_^1D@_SWKZUT[_ )!U
MO_N"ODKP7_R,D'^>]?6NG?\ (.M_]P4"9:HHHH$%%%% !1110 4444 %%%%
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *1N5/TI:* .)UF/R[S&,9YI=$EV:A&O8FKG
MB2#_ $A9!T"UC6LODW*R>E?+5?W.+OYGK0]^C8]!R,9SQ7F'C#4&U'5$L8VY
M5]O%=[=W?E:&]R#T3->=Z#;?VOXA>Z/.UPU?;X!*SK/H?*YE)MQH+JSNO#&E
MKIVEQ KB7&&/>MVD "C I:Y)S<Y.3/1ITU3@HKH%%%%06%%%% !1110 5A^)
MIO*L%QU+8K<KCO$UUON#!G@<UQXZIR47YG3A8<U5'/CF0>YKO]%A,5B >_-<
M-:0F:Y11ZBO1H%"0( /X17!E4-7(Z\PGHHDM%%%>V>6%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 4-7B\^P=*\S)\F\;V8UZAJ,@CLW:O,;Y-MRY]237S
MN=6YX]SV<K=U*+-9#F-3[4ZJ]G)OB ]*L5XP35I-!11102'>DI:0D#DTQA2$
M@#)-4KO4X;8'Y@Q]*P+S6I9B1&2@K6G1E,[</@:M;5*R-ZYU2"W!^8%AVK!O
M-:EG)"90>U9;R-(<L<FI(K:69@$0D>HKLA0A#5GMT,OHT%S2U9&\CR'+L2:E
M@M)IR-B$@]ZV;+0CP\IX]#6Y#:Q0#$: 5,\1&.D3/$9G3I^[3U9D6.AJF'E.
M?]DUL1Q)$NU% 'M4AZTAKDE4E/<\2MB*E9WFPI*7O25)B%)2TE Q*2E-)3&)
M2'BE) &:Q]3U,1@QQ'GU%=>#P=3%U%3IHY\7BZ>%INI48S5=1"J8HVY/<5@,
MQ8DDY)I7<NQ8G-)7Z7E^ IX*DH1WZL_/,?CJF,JN<MNB$HHHKO.$*9)&)$*D
M9I]% TVG='-WEL8)2,<>M5JZ6[MA<1D=ZYZ:)HG*L"*AH^HP&+5:%GNB.BBB
M@[Q\*[YE7U-=- @CA516!8QE[A2!T-='T%-'@9O4O)0"BBBJ/&"BBD9E49)P
M* 2OL+5&_NUCB* \FH[O4E0%8^3ZBL>25I6RQS2;/7P.7RDU4J;#H09+A<]S
M72PKLB"^E8^EVQ=]Y'3D5MT(6:UE*:@N@4444SR0HHHH **** ,;54\N1' [
MUH6,GF6R^M,U"'S82>NT52TR?8Q1CCTJ>IZUO;X-6WB;-%%%4>2%%%% !111
M0 4444 %*#@@TE% 'JW@&Z$NCLI^]OZ5U]>4>!M3-OJ26['"')KU96#*".AK
MYS'4^2LWW/K<MJJI02["T445R'>%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!Y=XJ_Y&"X^M8M=#XMMF35Y9CT8USU,04444P.L\&_\? _W
MJ[^N$\&0LTGF8. U=W28PHHHI %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 0W*N\#!"0<=JX:>&_@NVFR^>0&
MKL[^_2RCW$;CG&*RKB6+4,,DZHOI0!!X>>\$V+H,2QR"WI745##$BQH1@D#K
M4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 54U/_CPD^E6ZJ:G_P >$GTH \FO?^/R7_>J"I[W_C\E_P!ZH*H04444
M >D^#/\ D!K_ +QKHJYWP9_R U_WC715(PHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &%XBT8:C;;D WKS]:\ZN+*>WD*O&PQWQ7L
M54KK2[6\SYR9SZ4[@>0X)/'6KMCIEQ>SJB(P![XXKT)?">E*VX0G/UK3M;"W
MLUVPI@47$5=&TQ--M B@ MR:TZ**0PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %4]4_P"/&3Z&KE4]4_X\9/H:J'Q(
MBI\#/#;S_C]F_P!\U!4]Y_Q^S?[YJ"OJX['P\MV>Z:!_R ;/_KF*T:SM _Y
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MU\UBJ7LZK2/L<#6]M14GN%%%%<QUA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5!=0"XA9"2,CBIZQ-8UI++]VA_
M> \Y% &#?:+>6K95AL)P.>:V=!TZ]L<";;L//O5(:K!>;)&<^<6 V]JZN,YB
M4^PH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '%>)_#[N_VBW3.>6KBY$:-RK#!'6O9V57&&&0>U9EUH
M5I<MGRU4^PIW \I'-;6B:'/?SJY0^6"#FNWA\-VD3[BJM[$5JPV\, Q%&J#V
MHN EM;K;0+&O  J:BBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 51UC_D#7G_7)OY5>JCK'_(&O/^N3?RH ^0->_P"0M-]3_.LW
MM6EKW_(6F^I_G6;VH*.@\%_\C)!_GO7UKIW_ "#K?_<%?)7@O_D9(/\ />OK
M73O^0=;_ .X*!,M4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *IZI_P >,GT-7*IZI_QXR?0U4/B1
M%3X&>&WG_'[-_OFH*GO/^/V;_?-05]7'8^'ENSW30/\ D V?_7,5HUG:!_R
M;/\ ZYBM&OE:GQOU/MZ7\./H@HHHJ#0*;)_JW^AIU-D_U;_0T(&>(Z__ ,A2
M7_>-95:NO_\ (4E_WC657U=+X$?#UOXC/6_!/_(/_P" UU5<KX)_Y!__  &N
MJKYO$_Q9'UV#_@1"BBBL#J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "DI:* (W@C?[R U"=.M&ZP*:M45+A%[H:DULRH--LU/%NE3);PQGY$ J6B
MDJ<5LAN4GNPQ1115DA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44AH 9<.(X)&8X 4UX]XBU3SKMXXFRN>HKL?&?B'[+ ;6%L29P2/2O,&)D<D
M\DFO)QTHSDEV/J\CP%E[>I\@56D; &2:ZC2-)6)1)(,MU&:KZ+I><32C\#71
M    =!7C8BM]F)T9ECKOV5-^H8 &!2$!@0:<:2N,\,R+F,PS;QTS6A;3"6(<
M\TMS")8SQR*S8)&MIMII;,[/XU/S1L4@I%8.,@TZF<EK"4444P 44E+0,2DI
M:BFE$:$D\T#2;=D,N9Q$O7FLP!IY/6DDD::3GFM"TM_+7)'-3NSN25&%^I+#
M"(T [U)2TE6CC;;=V%4-4?;:L,]15^LO6?\ CW_"N_+HJ6*@GW./'R<<--KL
M<I1117ZP?F84444 9^I&8+F,G&.U-L+[?\CGYNG-:+H'4J1Q6'>6SVTOF)]<
MCM29ZF%=.O3]A)6?1FZ**IV%T)X\$_,*N4SSZM.5.3A+H(PW*0>]8-PIMKW*
M\#-;]9FJP_NQ(.N:3.S+JG+5Y'LS0B<21AAZ4^J&F3!H I/S5?IHY*]/V=1Q
M"BBB@R"BBB@ HHHH **** "BBFR2+&A9CTH!)MV022+&I9C61<ZB\C%(@?J*
MCNKI[J7RTSC-7;*P6-0SC)I7N>M"A3PL/:5M9=$16,5P'WR%N?6M6@<#%%-'
MGXBNZTN9JP4444&(4444 %%%% !1110 4444 )M&<XI:** N+2444 %%%% !
M1110!H:,I?5(5'4FO;;%2MC$#U"UY#X2M3/KENV/E#<U[*JA5"CH*\7,Y7FH
MGT630M"4A:***\L]H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_.LWM04=!X+_ .1D@_SWKZUT[_D'6_\ N"ODKP7_ ,C)!_GO7UKIW_(.M_\
M<% F6J***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%0S7,,*DO*@QV+5@7WC33[+((9C_LG-:0I3G\*N95*
MU.FKS=CI:2O/+CX@J6/D[P.V16>?'M_GB3]*Z8X"L^AQRS3#KK<]4HKRQ/'M
M\&^9^/I6E:?$*)?^/@.WT%$L!670(YIAY=;'H-%<_8>+M/O\!24/^T<5N131
M3*"CJWT.:Y9TYPTDK';3JPJ*\'<DHHHJ#0*IZI_QXR?0U<JGJG_'C)]#50^)
M$5/@9X;>?\?LW^^:@J>\_P"/V;_?-05]7'8^'ENSW30/^0#9_P#7,5HUG:!_
MR ;/_KG6C7RM3XWZGV]+^''T04445!H%-D_U;_0TZFR?ZM_H:$#/$=?_ .0I
M+_O&LJM77_\ D*2_[QK*KZNE\"/AZW\1GK?@G_D'_P# :ZJN5\$_\@__ (#7
M55\WB?XLCZ[!_P "(4445@=044UI$099@H]S67?>(+*Q!WN&Q_=:JC"4G:*(
MG4C!7D[&M25PU[\0K7D6ZR CU%9,OCZ[)'EN0/I75' UI=+'%/,\/'K<]0HK
MRK_A/=0_YZ?I5NW\?RKCSB3ZX%4\OK(E9KAV]STJBN1L?'NGW.$97#>IKHK7
M4K6Z0,DJ<]MPKFG0J0^)'73Q%*I\$KERB@$'H:*R-PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!4%W+Y-L[CM4]4]3_P"/"3Z4 >5:E(9=1G8GJU5:GO/^/R7_ 'J@JA!2@E2"
M.HI** /3?",K3:*K.<G=6]7.^#/^0&O^\:Z*I&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %4=8_Y UY_UR;^57JHZQ_R!KS_ *Y-
M_*@#Y U[_D+3?4_SK-[5I:]_R%IOJ?YUF]J"CH/!?_(R0?Y[U]:Z=_R#K?\
MW!7R5X+_ .1D@_SWKZUT[_D'6_\ N"@3+5%%% @HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSOI4*=)6@K!11169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >7>*O\ D8+CZUBUM>*O^1@N/K6+3$%%%%,#K/!O_'P/]ZN_K@/!
MO_'P/]ZN_I,84444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTE"S1FIS;/I."59XED0Y5NE25FZ"C1:/;HYRP7DUI5\_)6;184444@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IK,J#+' I3]TX]*Y35]7DANOLC94
M]=QH GU^(QWJ7WE^:B+C9ZUG6[7,MPB*K6JOSCUK3CN1J#)$LH9<<@5MBTA8
M1LZ L@P#0 ^W4I BEMQ Y/K4M(  ,"EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFI_\>$GT
MJW534_\ CPD^E 'DU[_Q^2_[U05/>_\ 'Y+_ +U050@HHHH ])\&?\@-?]XU
MT5<[X,_Y :_[QKHJD84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN *^G_AKX6BT+1(YRO[Z= 7R.AH$=E9V<5C:I;PC")P*L444""BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K&\31";274_6MFJ]["L]K(C=-
MI_E5TY<LDS.K'F@XG@TPQ.X]&-.M91#<*Y[5+J,#V]]*KC'SG'YU5KZE6:/B
M7>,CW?27$FE6S ]4%7:Y3P5J7VRP,9/^K %=77S%:#A4:9]IAZBJ4HR04445
MD;!1110 4444 %%%% !1249Q0 M%)D>M&1ZT +129'K2T %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !36X4_2G50U>\%CI\DQ.,
M<4XIMV1,I*,6V>3>*9Q-JC8.=I(K"JQ?2^=>S29SN8FH ,G KZJG'E@D?$UI
M<]1R/3/A[#Y<,[X^\!7<5SOA"R-OI,4A&/,6NBKYS%2YJK9]=@H<E"*"BBBN
M<Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHKB/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!DDBQ(78X &37+:EXP2W<K;;7QZU'XNU9HE^SQ,58'!Q7"LQ8Y)R:=A'6
M?\)U=Y_U"5LZ9XLM[HA9V5'/85YS3D<HP93@BBP'M"L'0,IX/(I:YOPKJAO+
M0I(?F4X%=)2&%%%% !1110 4444 %%%% !1110 4444 %%%0S3I"I9CBA*X$
MU%<WJ'BFWL\^8ZJ/6LB/X@:=YNW[0AY]:W6'J-72*Y>YUFHWZV<)8D=*\SU_
MXAI:3O'!(&D'5<U;\9>(-VDF6)N)5.TBO$9)'E<N[%F/4FN_"856O(4Y\FBW
M/1;7XH79F F1%3ZUK:W/#XQT/%H0T@.XA?:O(JZ3P?JKZ?JR L3&WRE3TYKK
MG0C'WH+5&<:K>DC!N;:2UG:*088$BI=.TVYU2\2VM8]\K=!7T;_PCFBZA%'*
M;>'<R DX]JT=/\-Z9I[B2&TB$@Z,!R*YI9BDMM1>S(/"FD?V3H\,;#$A0;QZ
M&MV@<# I:\B4G)W9H%8WB+3FU#2YHHQERAP*V:",BG&3B[H:=CY3UC1KO1[U
MX[F,H0<\UTUI;RZMX*\J-<N'S@>E>[W.BZ;>.7N+.*0GNPI%T;3X(&CAM(XU
MP> *]%Y@FEIJ0HV9\Z^'O"TFIRL\P98$8JS#L170SW.@:2OD*Z2..#N6MCQO
M=1:-8S6]FHC9CN^7BO(Y97F<NY)).>:[H7J^\]@DU3T6YWG]I:)J$36[R)$'
MX^45S6I:)):W48@!:.4_NV]:Q@2IR#@UW/@HC4KI?M+;O(/RAJN2]FKHE/GT
M9ZYX.=;#PK9QW#8D"<@UM+JUN3@N*\>\8^+VM6:QM3M*\':>E<)!KVI).C&\
ME(!R>:\]8)U+S;W-'*,=#VWQOK M+1Y%;A@0*\%N[F2YN'>1B22>M>@:W<S:
MKX/AGR22_P#A7!IIMW*"R1$C-=F&@H1L35;;215'45UVG3K/;#:?NC!KEIK6
M:W.)4*FI]/FN(YAY(+?[-99AA/K5+E3U.C+L8\)752QUU Y.*LZ1IM]J.-]N
M4![UW6C>!4+K--(?EYVD=:^1EE]6$N61]A//<.J?-'?L6/A_82VZ/.Z861>#
M7=5#;6T=K"(XU  ]*FKT81Y8I'QU>JZU1U'U"BBBJ,@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M****@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPUXGFN[<&[A>(C^_750:C!/]V1?SKDG2E!V8.);HH!R,CI168@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *0L!U-+7-:W=3QW9CCF\L8SF@#H#<1B<0[AO(SBI:X6"6
M^EU))%=I"!C<*[: -Y*[SEL<T 24444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8!XQCU-6K?X=WX;]\\9'L:;Q=%?:)6 Q#^PSB,9-68+"YN&"QPN<]P*](LO
M5HF#<+N(]#72V.D6=@,01@?6N:KF4%\"N=E'**DOC=CAM"\#/(RS7FTI_=/6
MN_L[*&QA$4"[5JP!CH*6O*K8B=9^\SW,/A*=!6@@HHHK Z0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!S0!%=7,=I TDC   UY/XF\2R:G.T4;?N1Q6GXU\0&:5K.!_D'.0:X?J:]O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>3>W7%1\GUHP>N*?"X1\D<4@&<CUJ:WNGMY P)XJVS630G+$/Z8K.;&XXZ4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\3:HNF::
MS$X+@J*VZ\Q\?:CYEXUGN^X<XKIPE+VE5)G'CJ_L:+DMSC9YFFF9V)))ZFHU
M&6 '<TE;WA;2CJ.J(K+^[ZYKZ*<E3BY/H?)TX.K-16[.M\'>&A"BW=RGS=5!
M'45W(    P!VJ.")88$C48"@"I:^9K5959N3/L</0C1@HQ"BBBLC<**** "B
MBB@ K \1Z%'J=DY1!YH'&!6_15PFX2YD9U*<:D7&1X%>6KV=R\+C!4XJ $@Y
M%=[X[T7RW2YA7KDN17 U]+0JJK!21\?B:#H5'!GI/@/6#-']C=O]6O%=X*\0
M\/WK6>IQ%3C>P!KVR%Q)$K*<@BO&S"ER5.9=3Z#*J_M*7*]T/HHHK@/4"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *J:G_P >$GTJW534_P#CPD^E 'DU[_Q^2_[U05/>_P#'
MY+_O5!5""BBB@#TGP9_R U_WC715SO@S_D!K_O&NBJ1A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!%</Y=O(_P#=&:\6\27!NM;FE/>O9-1.-.N#
M_L&O#M0):\<D\UZN5QU;/#SJ3Y8Q*U>F_#^P"Z<;EAAMQ%>9Q\RH/]H5[-X4
MC$>D*!ZUTYC.U*RZG)E%-2K<SZ&Y2T45X)].%%%% !1110 4444 '>BDI: ,
MGQ#:BYT>X!&6V<5XI/$8)FC/45[U>*'M)%/0BO$M<0)K%PHZ!J]C+)[Q/ SF
MFKQF4[9MES&P[,#7M7AR<W&CQ2$YS7B(X.17L/@=B_AJ$L<G)K3,X_NTS+)I
M?O7'R.CHHHKPSZ0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPQBL_5+5HIRP!V^M=-$@CC"BFS01SIM=<UQ7"QQ5174?F0,O7-=#=:*02T9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]3_P"/"3Z5<JGJ
M?_'A)]* /)[S_C\E_P!ZH*GO/^/R7_>J"J$%%%% 'I/@S_D!K_O&NBKG?!G_
M " U_P!XUT52,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *NI?\
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M/-W<J6'[OO7:QQB*-4 X Q7LY9A;OVLOD<6+K67(A]%%%>Z>:%%%% !1110
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MCM4.<I.T2E&,5>0W5/#%UYLEP)4DSSA>M:?PZ,]GKS(RLI. 017.V_B;4()
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MB]X1TZY:"XO6#KU 4?XT =W2,<*3Z"N<T#QSH7B4XTVYW\9Y %=$_P#JV^E
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&2Y:Z*]M46K$HHHKLR3#.K7Y^D3BXPS&.&P3HI^],NZ5 T^HP*HR-XS7N%E
M+>V2,=A7G/@32C+=-/(OR8RIKTT# KVLRJ\TU%=#X/**+C3<WU%HHHKS3V H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4 07-K%=1&.10<CJ17+WO@N%V+Q2-D]A77T4 <1#X*#$>8[BNDTW1;?3D"H
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M^9/%7C6;Q0G[^ *^<[L\UW7P+\2FUUI-+E?;"06Z]Z /IJBD5@RA@<@\BEH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)70"BBBLRQ*2EI*!A2&EI#3 .])2TE,84U@&!!IU+'&\K;4&332OHAWL95S
M48L!Q6CHEE+>RA "5'-=!I^@&7#W Q[&NAM[."U'[J-5/J*]/"97.;4YZ(SK
M8]*'(M616.GQV<8"@$^N*NT45]#"$8+EBCR)2<G=A1115B"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%7NK"N\TW0K/347RH@''4BMJF,HT8\M)'FT\#B,5+VE=OY[F)X<\(Q6*)/.
M\AY (Y%=<%"C X%+17CU:LJDN:3/?HT848\L$%%)2UF:A1110 4444 %%%%
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MS@T>"O@W9^'W2:_\NYE'.X"O58T6.-8T&%48 ]J /-OC/_R)=[_N5Y#\$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Y=XJ_Y&"X^M8M;7BK_D8+CZUBTQ!1113
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114<TGE1%S
MVH Q]=UV/382JG,C#C':N$NM>OKICOER*CUFZ>XU&;<V0&XK/IB+D6JW<+92
M3!KJ=!\4N[K%=L6)XS7%4Z-S'(KCJ#FF![0K!U# \&EK'\-WAO=*61NN<5L5
M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBHS<0@X,T8/^\* )**B^TP?\]H_P#OH4?:8/\ GM'_ -]"@"6BHOM,
M'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\
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MM,'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\ WT*
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M6BHOM,'_ #VC_P"^A1]I@_Y[1_\ ?0H EHJ+[3!_SVC_ .^A1]I@_P">T?\
MWT* ):*B^TP?\]H_^^A1]I@_Y[1_]]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H
M EHJ+[3!_P ]H_\ OH4?:8/^>T?_ 'T* ):*B^TP?\]H_P#OH4?:8/\ GM'_
M -]"@"6BHOM,'_/:/_OH4?:8/^>T?_?0H EHJ+[3!_SVC_[Z%!NK<=9XO^^Q
M0"5R6BH?M=M_S\1?]]BC[7;?\_$7_?8I717++L345#]KMO\ GXB_[[%'VNV_
MY^(O^^Q1=!R2[$U%0_:[;_GXB_[[%'VNV_Y^(O\ OL470<LNQ+BEJ'[7;?\
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M]]"C[3!_SVC_ .^A0!+147VF#_GM'_WT*/M,'_/:/_OH4 2T5%]I@_Y[1_\
M?0H^TP?\]H_^^A0!+147VF#_ )[1_P#?0H^TP?\ /:/_ +Z% $M%1?:8/^>T
M?_?0H^TP?\]H_P#OH4 2T5%]I@_Y[1_]]"C[3!_SVC_[Z% $M%1?:8/^>T?_
M 'T*/M,'_/:/_OH4 2T5%]I@_P">T?\ WT*/M,'_ #VC_P"^A0!+147VF#_G
MM'_WT*/M,'_/:/\ [Z% $M%1?:8/^>T?_?0H^TP?\]H_^^A0!+147VF#_GM'
M_P!]"C[3!_SVC_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]H_\ OH4 2T5%]I@_
MY[1_]]"C[3!_SVC_ .^A0!+147VF#_GM'_WT*/M,'_/:/_OH4 2T5%]I@_Y[
M1_\ ?0H^TP?\]H_^^A0!+147VF#_ )[1_P#?0H^TP?\ /:/_ +Z% $M%1?:8
M/^>T?_?0H^TP?\]H_P#OH4 2T5%]I@_Y[1_]]"C[3!_SVC_[Z% $M%1?:8/^
M>T?_ 'T*/M,'_/:/_OH4 2T5%]I@_P">T?\ WT*/M,'_ #VC_P"^A0!+147V
MF#_GM'_WT*/M,'_/:/\ [Z% $M%1?:8/^>T?_?0H^TP?\]H_^^A0!+147VF#
M_GM'_P!]"C[3!_SVC_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]H_\ OH4 2T5%
M]I@_Y[1_]]"C[3!_SVC_ .^A0!+147VF#_GM'_WT*/M,'_/:/_OH4 2T5%]I
M@_Y[1_\ ?0H^TP?\]H_^^A0!+147VF#_ )[1_P#?0H^TP?\ /:/_ +Z% $M%
M1?:8/^>T?_?0H^TP?\]H_P#OH4 2T5%]I@_Y[1_]]"C[3!_SVC_[Z% $M%1?
M:8/^>T?_ 'T*/M,'_/:/_OH4 2T5%]I@_P">T?\ WT*/M,'_ #VC_P"^A0!+
M15=M0LE.&N[<'WD'^--_M*P_Y_;?_OZO^- %G ]*7 JK_:5C_P _MM_W]7_&
MC^TK'_G]MO\ OZO^- %JBJO]I6/_ #^VW_?U?\:/[2L?^?VV_P"_J_XT 6J*
MJ_VE8_\ /[;?]_5_QH_M*Q_Y_;;_ +^K_C0!:HJK_:5C_P _MM_W]7_&C^TK
M'_G]MO\ OZO^- %JBJO]I6/_ #^VW_?U?\:/[2L?^?VV_P"_J_XT 6L T8%5
M?[2L?^?VV_[^K_C1_:5C_P _MM_W]7_&@"U157^TK'_G]MO^_J_XT?VE8_\
M/[;?]_5_QH M455_M*Q_Y_;;_OZO^-']I6/_ #^VW_?U?\: +5%5?[2L?^?V
MV_[^K_C1_:5C_P _MM_W]7_&@"U1445S!/\ ZJ:.3_<8&I: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#R[Q5_R,%Q]:Q:VO%7_ ",%Q]:Q:8@HHHI@=9X-_P"/@?[U
M=_7 >#?^/@?[U=_28PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<]XKT :[I4ML,98=ZZ&DJH3<)<R ^9M8\&:EIM]Y(A>16/!1
M<@5W7@3X=S6]S%J-YMRI#(",$5ZZ8HV.6C4_44X*%'  'M794Q\Y0Y2.17N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/4_P#CPD^E7*J:G_QX
M2?2@#R:]YO)?]ZH*GO/^/R7_ 'J@JA!1110!Z3X,_P"0&O\ O&NBKG?!G_(#
M7_>-=%4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH :_P!QOI7D6H3RC4)\2OC>?XC7KK_<;Z&O']0_Y"-Q_OFF@(O/
MF_YZO_WT://F_P">K_\ ?1J.BF(D\^;_ )ZO_P!]&CSYO^>K_P#?1J.B@"3S
MYO\ GJ__ 'T://F_YZO_ -]&HZ* )//F_P">K_\ ?1H\^;_GJ_\ WT:CHH D
M\^;_ )ZO_P!]&CSYO^>K_P#?1J.B@"3SYO\ GJ__ 'T://F_YZO_ -]&HZ*
M)//F_P">K_\ ?1H\^;_GJ_\ WT:CHH D\^;_ )ZO_P!]&CSYO^>K_P#?1J.B
M@"3SYO\ GJ__ 'T://F_YZO_ -]&HZ* )//F_P">K_\ ?1H\^;_GJ_\ WT:C
MHH D\^;_ )ZO_P!]&CSYO^>K_P#?1J.B@"3SYO\ GJ__ 'T://F_YZO_ -]&
MHZ* )//F_P">K_\ ?1H\^;_GJ_\ WT:CHH D\^;_ )ZO_P!]&CSYO^>K_P#?
M1J.B@"3SYO\ GJ__ 'T://F_YZO_ -]&HZ* )//F_P">K_\ ?1H\^;_GJ_\
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M&CSYO^>K_P#?1J.B@"3SYO\ GJ__ 'T://F_YZO_ -]&HZ* )//F_P">K_\
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M -]&CSYO^>K_ /?1J.B@"3SYO^>K_P#?1H\^;_GJ_P#WT:CHH D\^;_GJ_\
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M_P!_#_C5>B@"Q]OO/^?N?_OX?\:/M]Y_S]S_ /?P_P"-5Z* +'V^\_Y^Y_\
MOX?\:/M]Y_S]S_\ ?P_XU7HH L?;[S_G[G_[^'_&C[?>?\_<_P#W\/\ C5>B
M@"Q]OO/^?N?_ +^'_&C[?>?\_<__ '\/^-5Z* +'V^\_Y^Y_^_A_QH^WWG_/
MW/\ ]_#_ (U7HH L?;[S_G[G_P"_A_QH^WWG_/W/_P!_#_C5>B@"Q]OO/^?N
M?_OX?\:/M]Y_S]S_ /?P_P"-5Z* />/@M/-,Q\R61_D_B8FO9Z\4^"/WF_ZY
MU[702%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%Y
M>0V%LUQ.VV->IH GHJK9ZC;7R;X) PJU0 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "JFI_P#'A)]*MU4U/_CPD^E
M'DU[_P ?DO\ O5!4][_Q^2_[U050@HHHH ])\&?\@-?]XUT5<[X,_P"0&O\
MO&NBJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 -?[C?0UX_J'_(1N/]\U[ _W&^AKQ_4/^0C<?[YIH"M1113$%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5.][?2KE4[WM]*YL7_  F>IDW^^1*-%%%>(??A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% #XOOBM9?NCZ5DQ??%:R_=
M'TKT\!LSY/B3XH"T445Z)\P%%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 54U/\ X\)/I5NJFI_\>$GTH \FO?\ C\E_WJ@J>]_X_)?]
MZH*H04444 >D^#/^0&O^\:Z*N=\&?\@-?]XUT52,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_<;Z&O']0_Y"-Q_O
MFO8'^XWT->/ZA_R$;C_?-- 5J***8@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4M(WW3]* /*/%'_(2/XUAUN>*/\ D)'\:PZGJ4@HHHH&%%%% !1110 4444
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M>T5P7_"TM)]5_P"^J/\ A:6D^J_]]4 =[17!?\+2TGU7_OJC_A:6D^J_]]4
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M5""BCO10!Z3X,_Y :_[QKHJYWP9_R U_WC715(PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O]QOH:\?U#_D(W'^^:
M]@?[C?0UX_J'_(1N/]\TT!6HHHIB"BBB@ HHHH **** "BBB@ HHHH ****
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M0 5!<6<%TNV5,BIZ* ,L>'].!R(>:O06T5NNV-<"IJ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "D(R*6B@"..)8\[1@'FI*** "BBB@ HHHH ****
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MFN5M&<WS),I5L>&9)HM=M&C!($@SBL@(S' 4D^@%>@^'=.BT?2SJ5TN&=-R
M]<TZLDHV)A'F9ZI=ZJTD>TR!1[UGJRN?E8'Z&O(-2\:ZA=SMY<@$?;BGZ5XT
MU"VN$$D@,9(!XKSOJ#M<UYX7.C^(-^\<1ME..AKS/EF]2:] \31-KZ)<VH)#
M8!^M36'A*PTVV$VIE2_7"L*ZZ<XTX)/<)Q<Y:;'#6.E75_<K#'&PW?Q$<5VM
MIX5T_38EDU%XW;&<!@#700W6G66DS7MK'@0G&2*\OUG5Y]2O'=G.T'Y<&FI2
MJ.RT0G&--:ZL[>^?0-1CCMQ&!Y?"DL.*NQ#3_#VE^?:H'D9>2AS7E6]O[Q_.
MMK2M7D2-K61BRR#:,TY47;<%5UV)=0\7:E=SLRS80]!BJT/B74X'#+/T-4+^
MW^RW;Q>E5JU4(VV,W*5]SV+P7X]:>9+>Y<ECW->MQ2"6)7!R",U\EV-S);7<
M;QG!W#^=?3?A:Z:ZT:)V.2% _2O*Q]!0M*)K&7,M38FE$,1=N@KSOQ-\0;?2
MIO)8F3=V0]*[K5 QLW(]*^9M8M[B[\0W4:*['S"!P3BIP5&-2[D4Y<L;HV_&
MEV-6M[2Z@!8-R0.2.O6N16UN'&5A<CV%=GH?A_4(A^_9/L[??#'G%1ZQK=OI
M=V+73U 6-OF)&>*].$K>Y'4SE&_O2.G^$6A75M?R7\RE8Y(\ $8KV2N(^'WB
M&#5=-2!5Q*HR>,5V]>+BY2E5?,4E9:!1117,,*S=8TU=0MF7^,#@UH.X1"QZ
M"N9NO$$B7P5<^4I^<8H R8_#UQ<N85E7,76NMTBUFL[589&!"CC%9^FW]G<W
MLC6RL'8_-FNAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*XC\V!D'>I:* /
M(-5B,6I3J1C#53KOO$OAXW/[^W7+#DUPTUM+ Y212"*8B*E4;B .II0C$X .
M:WM$\/3W=PLDB$1@@@TP.M\)0O!HRJXP=V:WJCAA6&)448 %25(PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O]QOH
M:\?U#_D(W'^^:]@?[C?0UX_J'_(1N/\ ?-- 5J***8@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*IWO;Z5<JG>]OI7-B_X3/4R;_?(E&BBBO$/OPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!\7WQ6LOW1]*R8OOBM9?NCZ5Z> V9\GQ)\4!
M:***]$^8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "D;[I^E+2-]T_2@#RCQ1_P A(_C6'6YXH_Y"1_&L.IZE(****!A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >Z?!'[S?]<Z]KKQ3X(_>;_K
MG7M=!(4444 %%%% !1110 4444 %%%% $%W$9[9XQU->&ZS\(-4O]8N;I$7;
M(^X?-7O-% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
M?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'S
MQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B
M_P#?5?0]% 'SQ_PI75O[B_\ ?5'_  I75O[B_P#?5?0]% 'SQ_PI75O[B_\
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MFEI8'.%)]:UA/2S5C.4.J=S&M8FENHE4$DL/YU]/^%;1K318588)53^E>9^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD_*@"I15O^S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_ )]I/RH
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MD_*@"I15O^S+W_GVD_*C^S+W_GVD_*@"I15O^S+W_GVD_*C^S+W_ )]I/RH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!F:]#YNDS^H7BO*74HQ4]
M17L-]'YMG(GJ*\FU&/RK^5/0TT!5HHHIB%4X8'T->E^$[@7&E$YZ-BO,Z[?P
M5<@1>1GJQ.*3 [2BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KS;Q9-YE^R9^ZU>BS2>5"S^@KRC7)O/U:=\\$TT!GT444
MQ!6UX6B\W6HQCC%8M=9X,M]UR)L=#BD!WRC:H'I2T44AA1110 4444 %%%%
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MKS5;V&[EC(@4A@?6OH&VMTM8%B0845Y>858NT$:05D34445Y984444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@Y&<URRQ%3#OEW1\UC,+[*>NQXMX3^&-VUVD^IQ-$%/W2.#7L]I:QV=K'!&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N?\56GVBQWXSL&:Z"JNHQ^;I\R8ZKB@#QZBI[N'[/<M&1C%050@I5.
M&!]Z2B@#U'PU=_:M.S_=P*VJX?P7>[,VQ/WFS7<5(PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M42<WK/A6+65+*@#_ -[%<->> +RVE(W,1]*^@HK."VB^Z!@5S^IW"33_ "#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUOKLOV;4),3' !/ S7K2.DBAD8,IZ%3D4 .HHK%\4:E/I>CRW-N0)%4D9^E
M&U17RK)\<O%ZWS1>?#M$A7[O;->@7?QD^P>']T\@:_905*C(Z4 >RR7,,/\
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M]:?=&3CY%H ^D:*RM"UZSUZQ6YM) 5('&>:U: "BBB@ HHHH **** "BBB@
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MWZZ.R.;5":YP.;J[C51\@/%=/$GEQ!?2DQH?2T44AA3)51D.\<4^HYUWQ%:
M,6\>%9A=1NJ^3P1GK5ZPU*.['##/UKE;JVW&>&59#*[?(1G%;6B:?9JBLFX2
MI][)[T =!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]2LU
MO+-T(R=IQ7E5_8RV5RT<BG(KV&LW4=&MM13$@VGU YH \FHQFNUG\%*K_NBQ
M%6;+P9!&X>5FR.U.XC&\+:2]Q>I.RGRU/.:]$10BA1T%1V]M';1A(T  ]!4U
M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.NW\!>![OQG>(TN\V@.UCN-<3<#=J,H]9B/UKZK^"VFQV/A1SL&YG#9QSWH
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M-05)N>0A,_K30A/2DY!]ZY23I-+T]84$C?>-:M9>CW/G0["?N"M2H*"BBB@
MHHHH JW<L%K"TLB+QWVUS[:G;6LOF6Y;$ARV16YJT$ES821Q+ER.*YM-.OHX
M\W,"JB=Q0!TFG:C%?)\F<J.<BKU4=,2%;53& ,CGBKU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '*?$C_D1-2_ZYU\87/\ Q\/]:^S_ (D?\B)J7_7.OC"Y_P"/A_K0!]0?
M!S3[2X\-0-+;QN?+ZD5Z9_8^G?\ /G%_WS7GGP6_Y%B#_KG7J- %'^Q]./\
MRYQ?]\USWB?P-I&JZ7,JV<,;A20RKSTKKZCN/^/:7_</\J /A76K%M.U:X@(
MQMD8#Z U[K\!?$4IM9=/F<N7D 7<>@KRSXEQK'XGD"*!DMT^M=C\"O\ D,)_
MUTH ^FZ\_P#BS_R*]Q_US->@5Y]\6?\ D5[C_KF: /DW2O\ D*VW_705]H>!
M?^14M?\ /85\7Z5_R%;;_KH*^T/ O_(J6O\ GL* .@F_U$G^Z?Y5\@_%S_D;
MV_W:^O9_]1)_NG^5?(7Q<_Y&]O\ =H [+X"E?M@!Z[S7T?7R-\(/$*:3XMMH
MIF"PG))/3J*^M8)EN($E0Y5QD&@"2JFI_P#(-N/]RK=<_P",=6M]*\-WDDLH
M1S$=@/<T ?(WC[_D<;W_ 'J](_9Z_P"1BN/^N/\ C7D.LWS:GJLMR>6<U]%?
M K03:Z-'J;1X:52N?P_^O0!V7Q-_Y%63\:^.Y/\ D(O_ -=3_.OM[Q1IJZIH
MEQ">R,1^5?%.KVDECJUQ&ZD$2L1GZT ?6GPK*GPNNW_9KNZ\2^!?BJ&72WTZ
M>0"=I/D4GG%>V]>: "N=\=-&O@S5-^,F XKHJ\J^,OB2'3]$^R+,-\RE2M '
MRJ,YXKZ[^"8(^&UENZ[C_(5\G:=:M>:A!;J#F1PM?97P[T=]#\(6UE)G<ISS
M]!0!U9&1@]*XGQ?\.-,\5!FD ADQC<J\UN^)=>3P[IAO9%#*#C!K@!\;M-\P
M(4B'..M 'F&M_!+6K6:3^S[>6=<G!KC[WX?>)=/;]_I[I7V3I6J6^K64=S;R
M!U903CM4D^G6=U_K[='^M 'PVTFIZ/+M$LD#Y_A.*['PG\4=6T6\B%Q.\\1(
M#&1N@KZ \:^ -&U+1IWBM(8953A@.<U\FZU8?V9JL]H&W>6<9H ^U/"_B*W\
M2:/#?0,I\P9P*\,^/?\ Q^-_O#^==/\  BYD?24A+'8L? J/X\Z$TVB+>QC+
MF09QZ<4 >,_#DJ/%,.[IQ_.OLJS_ ./*#_KFO\J^&-'OGTS589E)!5P#^=?:
M'A/7+;6]#MY;>17VQJK8]<4 ;U%%,EE2&,R2-M4=30!X!^T>T9_L@+C()S^M
M>/\ @T,?%^E[?^>ZUV'QCU]-7UXV\<@=8)".*H_"KP]-K/B2*9 <6[ASB@#Z
M_7[H^E<UXZ_Y%R?_ '&_E72C[HKFO'7_ "+D_P#NM_*@#XOF_P"0I)_UV/\
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M7%M',O1U#"@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D8[5)/84M9'
MB&_%EISL&^?TH X?Q-J'VV_PIX3(K#I\TAEE=S_$<TRJ$%%%% '8>!IG:[EC
M).T+P*[NN&\#VSI<23$':R\5W-2,**** "BBB@ HHHH **** "BBB@ HHHH
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MM,T9!YVU>\%>)9;LFTNF+,J_?8]:XJ^$T=2)\YC8J%9Q.[J6WA,\H05&HW8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#-&RC>64D=LU]P5R/B_P#I?BJ%FG@4W.,!SV% '@/@#XL3^&5%M<QO/$3Z\
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M .A5]<?"?_D5A^%>82?L[ZJ]V\PU.'#2%L8]\U[3X-\.R^&M(^QS2K(W'*T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (3@$^E>>>+M2^T7GE(V4QSBNRUJ_6PL6?/)XKRJXE,T[NQSEB
M:: CHHHIB"GPQF:9(QU8XIE;WAC3OM=Z'*\(0: .W\/V7V/3(E(PX'-:U(
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M ;HZ"BF1R"1 R]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<UXQ=QI3J/NY%=+69KMD;_37A YZT >3T5)/&89WC(QM.*CJA!3HY&BD5U."
M#D4VB@#TWPSJ?VRQ1';,@'-;U>6^'M3-A?#)X<A:]/BD62,,I!!J6,?1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48S110 FU?[H_*E
M Z"BB@ HHHH **** "D*@]A^5+10 FU1T4?E2T44 %%%% !1110 8!I-B_W1
M^5+10 F .PI:** "BBB@ HZT44 )M7^Z/RHP!T I:* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *3:#U _*EHH 3:H_A'Y4M%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M](M[Z!0MQ,KICC;6M63IUV(Y#9RL#(HR2#6MUH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "D(R"/6EHH \Z\6:8;:[$D:_(1DUS->LZU8+?V$D
M>W+'H:\LNH&M[AXV&-IQ30B&BBBF JDJP8=17H'A/5A/;K;.WSJ,UY]5S3;Z
M2QNUD0]2 ?I2 ]?HJKI]Y'>VJRH<C&*M4AA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,ED
M$43.>BC->9>(]4:^OG53F,=*[K7YVAT]]O\ $"*\K8DN23DYIH!****8@IR(
M9&"J,DTVNA\+Z6;N\69ERB'F@#K?#6FBRLED(^:1<FMVFH@C0*HX%.J1A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !BN&\6Z/L;[3$OR@9;%=S5:]M4O+
M9X6 ^84 >.T5?U:Q>QO9$92%W?*:H50@HHHH ZGPKK/V><02MA/>O05(90PZ
M$9KQ>-S&X93@@UZ/X9UA;VU$<C?O!P :3&=%1112 **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(SO$I;:O>O"O^%VZG::@L-U9LA5OF!;I^M 'TO17-^#O%=KXHTB*YB=1*W5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKH:^1?A3XOET#7TCEE(MW^4+[GBOK6WF6>WCE4Y#*&_,4 2T444 %%12W$,
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MY%2+\/Y5V- !1110 4444 %%%% !1110 44C.J*68@ =S55M4L4.&NH@?=J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !534+)+VU>-QDXXJW10!Y+J
MFE3:?<LA4[1W K.KV"]TZWOH]LJY^E8+^#+,L=JG'UIW$>? %C@#)KJ?"VBR
M2W"W,JX0<8(K>MO"-C"X=E.1[UOQ0I"@1%  HN ]5"J%'04M%%(84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "N+\<^ ;3Q=:HK(OFAMQ)KM** /#X/@3%!<QRCR_D<-U]#7LNG6K6=E'
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MJ<USA\5^)YCNS*V?1#74?"OX>Q^(]0674H9!;X[C!S7O]M\.]"M8PB0< 8Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0HR>E<CK?BL0,T%L0Q
M'!]J .MWK_>'YTH93T(/XUY1)KEW(Y;>P^AJS9>)KNUD!)W#ODT[ >GT5DZ/
MK<.IQ###S<9(%:U( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /G[]HJ54N=.4]2AQ^M>=?"RREN?%]E+&!MCE!;->C_M$*#/IY(R=A
M_K7FWPNN7A\86**>'F - 'V11110!3U7_D#WO_7O)_Z":^%=1_Y"=W_UV?\
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MX^%6@IHOA*!-N'SGD<U\W?#;0WUOQ+$JIN$3*Y_.OL>VB6&WCC10H"@8'TH
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M\'PA>TI/\J^9]#?R];MSDC]ZHX_WJ^F?CI,8?!\) !S*1_*OF71%\S6[?/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?A@AN[A]C*[ -V!K["LT,=G C?>6-0?KBO-_A;\/5\,6B7<_-RRX.1SS7IU
M'B7QYN'73VA#'84!(KPGPA;Q77B6UBFQY;'G-?3WQ;\,MK?A:XD@0M.  H Y
MZ5\H'[1I6H$ M'+$V,]Q0!]P^'[6"UT6U2!%5=@Z#K6G7SWX.^. M=.CL[VW
M7,2A=[-U_6NEN?CII\,3,D,;D#@;NOZT =SXZU6/3/#-WYA ,D3*,U\674OG
MW+N1C)->@^,_B%JGC>9H[6)XHE.2BGC%>=RQ/#(4D4JW<&@#ZM^!'_).XO\
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M=^/3:;I<5I+IP?RE"@EO_KU[/X.\6#Q58FY$ BP,X!H Z:BBD9@BEF. .IH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5D:S>-!&!')M?T]:UZS=1TR*
M[ 88$B\@GUH YMM:VB!9HB)MWS,:["UE6:!75@P/<5S=GI4=Q?RQ7L?F,H^_
MV-=':VL=I (HQA1VH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***0T 9^IZ6E_'C@-US7/66B*-5:WN&$H"Y%7M;UB:UF5(6(
M^89 ]*KIJ\#Z@I0;)" "Q- '16-I]DA,>[(SQ5JFH<HI]1FG4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8V
MMZ)%J4!.T>8!\IKS>]L)K&=HY%/!ZXXKV&LO5](AU&W*E1O X(]:8'E%%7]2
MTN;3YV213@=P*H4Q"4M%% #XY7A<.AP178Z#XIP5@NF)SP#Z5Q= )!R#@T@/
M:(I4F0.A!!]*?7&>$-5=P\$K9 X6NSI#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"CJ6F0ZA;E'49[$"O-]7T2?3922IV
M9X->K57NK.*[B*2(#D=2* /'**Z/7/#<EB[20J6B]37.D$'!JA"4444 ;?AI
MF&HH!TW<UZA7#>#]+8LT\BX'5:[FDQA1112 **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[](/_1\=?']>\?$/XU^&_%O@74M#L++58[JZ\O8\\480;9$<Y(D)Z*>U>#T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY /KYL= 'T!H>J-/<F:0;%D& G85U8Y%9.C6D"V48>%5E'4=Q6O0!\,>+/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM0"G@^5)Y9_-<&N5FFEN)GFFD>25SEG=B2Q]237U1!^S[X(B8%_[2F [27(
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MQ1\"ZKX-UO3X=?@EFN;&:*)!%)\SE"%'*^N*^4:[S_A3'Q!_Z%V3_P "8?\
MXNG1_!7X@R2*G_"/LN3]YKJ$ ?\ C] 'T7\(;AKKX4Z!(QR1"T?X+(RC]!7;
M5SO@3P[+X4\$Z7HD\JR36T1\QD^[O9BS8]@6(KHJ /D?XZ?\E8U/_KE!_P"B
MEJS\"W:/QAJ+)+Y;_P!FOM_VCYD?%5OCI_R5C4_^N4'_ **6K'P*@$WCBYR,
M[+%F^G[R/_&@#Z+\.W-U(Y%S$X?'.ZNEJ&!48>:""S=2*FH ^&/%G_(Y:Y_V
M$)__ $8U>\_LU_\ (MZW_P!?:?\ H%>#>+/^1RUS_L(3_P#HQJ]Y_9K_ .1;
MUO\ Z_$_] H ]NHHHH " 1@C(-? ][$(+^XA7[L<K*/P)%??%?!>J_\ (8O?
M^OB3_P!"- 'TI^SBY;X?7ZGHNJ28_P"_45>P5X[^SA_R(.H_]A1__145>Q4
M%%%% !1110 4444 %%%% !1110 5'+-'"A:1@H'<U)5/4K5;NSDC.,D8!- %
M&/68KB2>($!1P&SUIUA9QN\C,XD#C!%<RNDW*LX@D&(OO*.]=/H:8MPQC*$C
MO0!I06\5M$(H5"H.@%2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR,&A?]>LG_H= 'G/PU_Y*7X<_P"O^+^=?:M?%7PU_P"2E^'/^O\ B_G7VK0
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M *_$_P#0* /;J*** "O@O5?^0Q>_]?$G_H1K[TKX+U7_ )#%[_U\2?\ H1H
M^DOV</\ D0=1_P"PH_\ Z*BKV*O'?V</^1!U'_L*/_Z*BKV*@ HHHH ****
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M%% !13)94A0LYP!6-<>*-.A)43#<.U &Y17-_P#"7V/_ #U%'_"7V/\ SU%
M'245S?\ PE]C_P ]11_PE]C_ ,]10!TE%<W_ ,)?8_\ /44?\)?8_P#/44 =
M)17-_P#"7V/_ #U%'_"7V/\ SU% '245D6GB/3[I@B3 N>U:RL&4$=#0 M%%
M% !1110 455N]0MK)=T[[161)XMT]6PLP(H Z&BN;_X2^Q_YZBC_ (2^Q_YZ
MB@#I**YO_A+['_GJ*/\ A+['_GJ* .DHKF_^$OL?^>HH_P"$OL?^>HH Z2BN
M;_X2^Q_YZBG)XNT\MAI@!0!T5%4K35+6^_U$FZKM !1110 444$X&30 45F7
M>OV%F2LLV&]*SCXOL<\2C% '245S?_"7V/\ SU%'_"7V/_/44 =)17-_\)?8
M_P#/44?\)?8_\]10!TE%<W_PE]C_ ,]11_PE]C_SU% '245S?_"7V/\ SU%3
M0>*]-D.&F - &]144%Q'<)OC;(J6@ HHHH ***CFGC@0O(<+0!)16%/XJTV(
MD+."P[5!_P )?8_\]10!TE%<W_PE]C_SU%'_  E]C_SU% '245S?_"7V/_/4
M4?\ "7V/_/44 =)17-_\)?8_\]11_P )?8_\]10!TE%<W_PE]C_SU%7[3Q!8
M7;!8YLL>U &K12 A@".E+0 4444 %%%4[S4K6Q&9Y-M %RBN>?Q=IX/RS BF
M?\)?8_\ /44 =)17-_\ "7V/_/44?\)?8_\ /44 =)17-_\ "7V/_/44?\)?
M8_\ /44 =)17-_\ "7V/_/44?\)?8_\ /44 =)17/1^+M/+@/, *UK34[6]&
M8)-U %NBBB@ HHHH **0D $GH*RKKQ%I]J2KS88=J -:BN;_ .$OL<_ZT4?\
M)?8_\]10!TE%<W_PE]C_ ,]11_PE]C_SU% '245S?_"7V/\ SU%'_"7V/_/4
M4 =)17-_\)?8_P#/44?\)?8_\]10!TE%8=OXITV8[3. QZ"MB*9)D#H<@T 2
M4444 %%%% !144]Q';1[Y6PM8\_BK38SA9@30!NT5S?_  E]C_SU%'_"7V/_
M #U% '245S?_  E]C_SU%'_"7V/_ #U% '245S?_  E]C_SU%'_"7V/_ #U%
M '245S?_  E]C_SU%'_"7V/_ #U% '245EVFOZ?>$+%-ECVK3!!&1WH 6BBB
M@ HHHH **I7FK6EB/W\FVLI_%VGAOEF!% '145S?_"7V/_/44?\ "7V/_/44
M =)17-_\)?8_\]11_P )?8_\]10!TE%<W_PE]C_SU%'_  E]C_SU% '245S?
M_"7V/_/44Y/%VGE@&F % '1452L]5M+[_42;JNT %%%% !116;JVKPZ; 69A
MN[ T :)8#J0*CDN(H_O./SKS6]\37=U(Q!V#H-IK+:^NF))GDY_VJ=@/4)=>
ML820\E9USXPL$'[ER6]Q7G;32M]YV/U-,ZT6$=?<^-KD<0JA'N*R+GQ)>W6=
MQVY]#6/10!*]S-(<M*Y_X$:B))/)S113 **** -SPYJ<EI?)&6/EL><FO3(Y
M!+&''0UX]:9%RFWKFO6=,S_9T&>NVDQENBBBD!E:QHT6IP%6'S=<BN%O/#%]
M;N=L?R_6O3Z:R*WWE!^M 'E<7A^_F;:L8KI=+\'(N)+K(8=@:ZY8HU/" ?A3
MZ=P*]O9PVR!41>.^*L444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]"#P:\QUSX >#]4E::Q-YI<C<[;>0-'G_=8$_@"* /++7]H7QK;Q!)8]*N6
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M3/<NI"KD' "@#J!USTH ]!4[ES2T=** /ACQ9_R.6N?]A"?_ -&-7O/[-?\
MR+>M_P#7XG_H%;.L_ +PKK&KW6HF\U2VDN96EDCBE0H&8Y.-R$CDGO78>"_
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M\72-'8+M.,UYL>M-"#.>31113 **** "BBB@ HHHH *E@N9;=@T;LN/2HJ*
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M%SQBM>O/_&<C&\9,_+QQ0!SMW?37<C-([$$]":K4450@HHHH **** "BBB@
MHHHH LVM]/:2!HY&&.P->E:!JHU*T'.60<UY975>#+AHIWC'1C28'H-%%%(8
MV1MD;-Z#->8^);Y[K46&[Y?2O3)QFWD [J:\GU>-HK]PW6F@*%%%%,04444
M%%%% !112JC.<*,F@!**NPZ3>S_<MW(]JV['P?-.P,S&,>XH H>'M.DO-0C8
M*3&IY->GPQB*)4'0"JFG:9#IT(1%&<<D=ZO5(PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MS]5M9;FU81.RMC@"KY(49)P*Q;C685ODC24$9PV.U '/^3?S!X8XV4IPQ'\7
MUKH]"2XB@$<\.S:.OK4=M-";TF*4-O/(%;F* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRH^QW/\ SP?\J (**G^QW/\ SP?\J/L=S_SP?\J (**G^QW/_/!_RH^QW/\
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M/W5%- <S14YLKD'!@?\ *C['<_\ /!_RIB(**G^QW/\ SP?\J/L=S_SP?\J
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M5/\ 8[G_ )X/^5'V.Y_YX/\ E0!!14_V.Y_YX/\ E1]CN?\ G@_Y4 045/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 -<*1ANE<IJ>AQI*TT<B
MH2<[?6KFMZT;8^0B,LA'#53@UBWO7C2:,O(.,T .TC1I[2X6<ON5SG'I75U'
M!CR$P,#%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?8;?^X*LT4 5OL-O_<%'V&W_ +@JS10!6^PP?W!4L<,<8PJ@?A4E% !1110
M4444 %(5!'(!I:* *YLH"<[!2?88/[@JS10!6^PV_P#<%'V&W_N"K-% %;[#
M;_W!1]AM_P"X*LT4 5OL,']P4?88/[@JS10!7%E #G8*G"JHP !2T4 %%%%
M!1110 4R2%)%PR@CZ4^B@"M]AM_[@H^PV_\ <%6:* *WV&W_ +@H^PV_]P59
MHH K?8;?^X*/L-O_ '!5FB@"M]AM_P"X*/L,']P59HH A2UAC.509^E3  =*
M** "BBB@ HHHH 0@'J*A>TA<Y9!FIZ* *WV&W_N"C[#;_P!P59HH K?8;?\
MN"C[#;_W!5FB@"M]AM_[@H^PV_\ <%6:* *WV&W_ +@H^PP?W!5FB@!B1)&,
M*H_*GT44 %%%% !1110 UD5A@@&H#8P$YV"K-% %;[#;_P!P4?8;?^X*LT4
M5OL-O_<%'V&W_N"K-% %;[#;_P!P4?8;?^X*LT4 5OL-O_<%*+* 'A!5BB@!
M%15&  *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "F22"-<FGUA>()[RUB,T(!C'!&.: &ZU%;75LT^PLR<?+3+308
M$2*:W0JQ&3NK#L=5NXLQ8!#G)W"NWM&=K9&?&2.U $D2E(U4]0*?110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !2%@",G&:;)N,;!#ANQKE+O6)DOQ"TF/+;G/>@
M"37(3!>>:Z;UE. *KP/.+A;928XU(.TUJK(-5DCY#!#D5IMI]N\WG,F7]: +
M"#"*/:G4@X'%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5:\O$LX3)("0/2EN;V&UC+R,,#MFJ&IW$5UI4A7/(XH CLM:%S(Y((3/&1
M5)M'@U&ZNI)%.3RAK-$6I6S0G:OE/]W [5U]@C"V5F W$<T 4=$TTV (/I6S
M1BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FEUSMSS5
M>_<QVS,#R.:YBRU)Y+@W=RY2W4E2<T .UJ*-M5C$\CB$CG::73Y9;US @!A4
MX![XK3M;:VOKE;F-_-0<'-6K?2(K:X,J,1DYQ0!;C@1841E!VC'(J4 *,#I2
MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$A023@"@!:S+
MO5H[::2)R 5'%6IKV*+9\P.\X%87B&Q2YD0QR!9-PR!UQ0!>M;YKK32Y0,Q)
M&*SWT%Y[5N2F6SL%1V]E=1ZD(U9EA !QVKJUX0 ^E %73[46ML(PN*MT44 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%,!)"Z@\XJOJ-
MY]BA,I!*@9.*P[#6)+B:5S*$5ONYH S;I[R/4'!5I(XCD =JV='E&I7!GEC(
MXZ&KEE:N\TTLCAUD&.*N6ME':GY!@4 6/+7.<<TZBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "HYIXX%R[ >V:DKG]?CVS1W,A;R4'S
M8- %R>\MKZRG0J651A@*P#H3SJKV_P L8['K38;LVDR+9JQ2?EMXKK[7)MD+
M 9QSB@"'3+<VUC'&>H%7*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC.!7F/Q$^*L?A%C;V
M8CFNU(S&WI0!Z=17S=%^T/KDTRQIIEN2Q '->W^$=5U?5M+6YU6S6VD?!55[
M@T =%1139)%B0NYPHZT .HK/.LV(.#,*/[:L?^>PH T**S_[:L?^>PH_MJQ_
MY["@#0HK/_MJQ_Y["C^VK'_GL* -"BL_^VK'_GL*/[:L?^>PH T**CAGCG0/
M&V0:DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 444R65(4W2' H R-4UE+0^4#^\/055FOQ?6963'([4NOV,%QBX+D,
M!@ 54LM$N+2XB>+=+$_+;NU &_!90R6L/R@;5X.*NH@10HZ"DC&V-1C''2GT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110!!>?\>4__7,_RKXV^(__ "-<W^>]?9-Y_P >4_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#PQHLNN:U#;1*6PZE@/3- 'I7P=\ '5;M-5NXMUN.,,.,U]+PQ+!"D: !5
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MYYSBK]MXBU.R*^3.5*]* /N:.6.50T;!@>XI]?)_ACXQZ[IMQ&E]=-+;@\J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHJA?WPMT8!@& H Q];C:&]-PZEXSP%]ZSX;J]>Z6,1O'!
MZ'I6F]W]MTZ/S)567S.C'GK6U%"DD*[QG@4 3Q?ZE,^@I](!@ #I2T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >+?'K4B-!:R!/W@:^::^A?CY_J3^%?/5 'O\
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MT<\4@+JH# GG-?&6JZ;/I5_);3(596(&1VS7:?#+QS+X:U>**:0_9&.6R<T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH **** /"OCW;R?8FFQ\F0,U\ZU];_&?2?[1\&2!%RX<'BODN5/+E=#U4D4
M?0G[/-\L6F7=L2-TDO%>\5\F_!K7UTWQ3;6LC!8I'R37UA'(LL:R(<JPR#0
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MS/\ *OC;XC_\C7-_GO0!#\/O^1KM_P#/>OLW3O\ D'6__7,5\9?#[_D:[?\
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M*3>5V1'@=Z^,Z .H\&>.+[P3>37-C#%*\J[3Y@Z?I7<?\-$>)O\ GTM?R_\
MK5Q_@7P4_C*[F@A+;HEW$+7=?\*'O/26@"K_ ,-$>)O^?2U_+_ZU'_#1'B;_
M )]+7\O_ *U6O^%#7GI+1_PH:\]): ,Z\^/OB.]MF@DM+7:W7C_ZU>6WMT][
M>37,@ >5MQ KV/\ X4/>?]-:7_A0]YZ2T <;\*[T6WC*QB+$>9*!CUK[&KP+
MPO\ !JZT;Q)9:@PDVP2;CFO?: /&/VA+MH?#MDL;<F4@U\S]37T9^T1:^7HM
ME/O)WR_=["OG,=: /0/"/Q9UCP=I TZQMK=XPV[<XY_E70?\-#^)O^?2U_+_
M .M63X.^%L_BO11J$/F%2VWY:Z#_ (4/>>DM %7_ (:(\3?\^EK^7_UJ/^&B
M/$W_ #Z6OY?_ %JM_P#"A[STEH_X4/>>DM '.>(?C-KGB/3Y+.ZMK=4==I*C
MG^5>;U[7_P *'O/26D_X4/>>DM %[]GN]$FIW-MN)*19Q7T/7D_PN^'$_@[6
M+FZEWXDCV_-7K% !1110 4444 (2%&3TKX[^+5V\WC_4H\Y17XK[!FC\V%H\
MD;AC(KXT^*$/V?X@:G'N+8?J: .6L[E[.]AN4 +1.' /3(KU:']H/Q)#$D:6
M=H%4 #@?X5Y9I]J+V^AMLX,CA1CWKUZ/X$WDD2.!+\P!H K_ /#1'B;_ )]+
M7\O_ *U'_#1'B;_GTM?R_P#K5:_X4/>>DM'_  H:\]): *O_  T1XF_Y]+7\
MO_K5P?BWQG?>,+F.>]BCC9.FP5Z-_P *&O/26C_A0]YZ2T >-VDODW4<N<;3
MG-?9?PTN!=>!-/F#$[EZFO&?^%#WGI+7N?@G17\/>%;/37SNA7!S0!T-(0""
M#T-+10!XG\9/AVE_;OK%C'_I"@#:HP*^;Y$>WF9&RKH<'%?8?Q)\7VGAS0I@
MX22<C C?T(KY!OI_M5]//@#S'+8';- $<DTLV/,D=\=-QSBO8/A#\.WU2\74
M[Y/W<3!D'4$>]>-U[C\&O'Z6<_\ 9=T57S"%3/>@#Z)@@CMXEBB4*J] !BI:
M;&ZRH'4Y4]#3J "BBB@"*Y_X]9O]QOY5\,^(_P#D9-1_Z^'_ )U]S7/_ !ZS
M?[C?RKX9\1_\C)J/_7P_\Z -_P"%/_)1M*_ZZ5]F5\9_"G_DHVE?]=*^S* "
MBBB@#YW^/G^L/^^/YUX2J[G5?4XKW;X^?ZP_[X_G7AEO_P ?,7^^/YT ?4'P
M,T)++PR]Q(@\TR9!QVYKUNN+^&2A?"Z8&.G\J[2@ HHHH *YSQ'XUTCPU S7
MUQM;H ,'FCQGXAB\/Z'/,[A7*'9GN:^/O$7B2^U_49+B>9RK'A-W H ]AUKX
M_7,3,NF)#(.@W#_ZU<?=?&WQ%<L28XESZ'_ZU<GX:\):EXFNQ#90-)W./2O7
MM(_9]AN(U-_<S0L1R * //#\5=>))W#_ +ZI/^%JZ]_>'_?1KUK_ (9ST;_H
M)S_E2?\ #.>C?]!.?\J /G[5]9N=9N/.N3ELYZU/X3_Y&K3O^NP_E6KX\\*6
M_A34A;6\S2*21EJRO"?_ "-6G?\ 78?RH ^U]'_Y!D7TJ_5#1_\ D&1?2KW7
M(H ^5?CM=R'QU-;?P! :\PM1F[A'K(O\Z]&^.:[?B).,Y_=BO.K3B]@/_31?
MYT ?;OA*R2R\.V:H,;X48_E6Y65X<FCF\/6)0YQ @/Y5JT %%%% #6C1OO(I
M^HIOD1?\\T_*I** $  X P*6BB@#S_XT?\DRU'\/Y&OD"OK_ .-'_),M1_#^
M1KY H ^@?V;/]7K'U']*]^KP']FS_5ZQ]1_2O?J "BBB@ HHHH **** *NI?
M\@^;_=KXO\>_\CEJ'^_7VE?1M+9RH@RQ' KXP^(<3P>-]1CD&&#\B@#JO@?_
M ,C/-_N"OJQ?N#Z5\E_!FX\CQ._^T *^LTY13["@!U%%% !7.>._^1.U#_<K
MHZYSQW_R)VH?[E 'Q=J?_(0F_P!ZNT^%6GP:AKQCG0,N1U&:XO4_^0A-_O5W
MWP=_Y&,_44 ?2(\$:-@?Z-%_W[%+_P (/HW_ #[1?]^Q71CH*6@#F_\ A!]&
M_P"?:+_OV*/^$'T;_GVB_P"_8KI** .;_P"$'T;_ )]HO^_8J2W\'Z3;3K-'
M;QAU.00@KH** &HH10HZ"G444 %%%% !1110!QOQ2G:V^'VIRI]X)Q7QK+(T
MTK2-U8Y-?8?Q<3/PYU0YZ)7QS0![9^SW8)=ZEJ$C#)C (_2OI.OG7]G*>.*^
MU17;!90!^E?15 !1110 A (P1FF>1%_SS3\JDHH :L:+]U%'T%.HHH \-_:)
MO&BTW34C;[SD'GZU\Y5] _M%6OE6VG2[R=[G@]NM?/U 'U9\#;!$\#VUWCYV
M)&:]3KS3X'SQGX=VD0;YPQ)'Y5Z70 4444 9/B2W%UH5S"1D,N,5\6>)H1;^
M([V(# 63&*^VM9<)I<S,< "OBOQ>P?Q7J##H9: -GX97IM/%%LN<>9(!7V2.
M@KXK^'UH+GQ98L7*[)E/'>OM0=!0!'=?\>DW_7-OY5\;_$O_ )&J3\?YU]D7
M7_'I-_US;^5?&_Q+_P"1JD_'^= %/P%_R-=M_GN*^SM,_P"09;?]<Q7QCX"_
MY&NV_P ]Q7V=IG_(,MO^N8H MUYG\9/^1>/^X:],KS/XR?\ (O'_ '#0!\F5
M]*? ?_D&)_N5\UU]*? ?_D&)_N4 >UT444 %%%% 'RC\:/\ D/+_ +QKCO W
M_([Z1_U\#^1KK?C+/'+XAVH<E7.:Y/P-_P COI'_ %\#^1H ^WJ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.9G2%F098#@4 172P7$,
MD4N,$8/M7+6V@6DM]) DCE%&152]UBZ746W+M*G)7-;&AZH+V_D8QJN5[4 ;
M&FV?V*W$0S@>M7:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJUA'J.G
MS6\BA@5. ?7%?&7CCP]+X=\0S02@CS&9USZ9_P#KU]M5Y9\6O ">(-.DO[=
M;I%P !S_ )XH ^6K.[EL;E;B%BKKT(KZX^&OC>TU_1(+9I5\^% I&>2:^2+V
MSEL;J2"92K(V#FM'P]XCO?#M^EQ:RNJ@Y95/6@#[FHKQWPC\;+'48D@U!%MV
M48,CMUKT2'QGX>F0,FJVY!]S0!O45AMXP\/(,MJMN!]37)^)OB[HVDPR"SGB
MNVP0-C4 ;_C;Q7:^&]'EEDD428("GW%?(NJ>)M3N]2GF6]E"LY( /;-7?&'C
M6_\ %-\[RR.L/:,GBN=M+6:]N%@MXS)(W11UH [[X:Q:OKGBFU5KF9K?=ASG
MBOK.SA^SVD4.<[%QFO-_A-X('A_21<7"YFEPXR.5KT^@#)\36_VKPU?P8SOB
M(Q7Q3K]D=/UB>V(QL/2ONIT61"C#*GJ*^8OC/X,FL-9EU6WC)BF?H!TH P/A
M%KD>A^*C)(X02J(QG\?\:^NH9!+"C@Y#*#7P3;3O:W,<R$AD8,,>U?1WPW^+
M=K-81V6JRK&XX\R0T >V45F0>(-*N4#0WT3 C/!I)O$6D0(7EOXE4=230!?N
M+B*UA::9@J+U)K#?QQX>C<HVHQAAU%>3?%#XKP/92Z9ICAS(,>:AZ5X0=3OY
MI,^>[.U 'VS8^*-'U*3R[2]21O05L5XE\%?"]W##)J5[(S+*H*!ATKVV@""\
M_P"/*?\ ZYG^5?&WQ'_Y&N;_ #WK[)O/^/*?_KF?Y5\;?$?_ )&N;_/>@"'X
M??\ (UV_^>]?9NG?\@ZW_P"N8KXR^'W_ "-=O_GO7V;IW_(.M_\ KF* +->7
M_&C_ )%\_P#7,UZA7E_QH_Y%\_\ 7,T ?*%?3'P(_P"02G_7.OF>OICX$?\
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M9;?]<Q7QCX"_Y&NV_P ]Q7V=IG_(,MO^N8H MUYG\9/^1>/^X:],KS/XR?\
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M HHHH **** "BBB@ HHHH **** "HYIXX5S(P ]ZDKF?$$LV](<%4<X+]EH
MDO[:*>XAFAA617;YC[5JP:=!!.98E"Y'05R4#W5M)'$DS20J>''0UV=I)YEN
MK>M $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^OU%?7WPG_Y%I?\ =% ^#'@D'/\ 9?ZC_"NOTG1;'1+86]C%Y<8[4 :%%%%
M'GOQ:_Y%IO\ =-?(;?>/UK[NU?1+'7+;[/?Q>9'TQ7('X,>"2?\ D%_J/\*
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MZ]M"4VNP^8XZUC^'6*>(;%E.")!BOL/7OA]X=\2S)+J=GYKIT.?_ *U9EO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *S+R6WN%DAF0'' ![U=NEF:V<0,%DQP37 W5SJ-O>.LNYI,_*P'>@#J--L8
M"S(<%%'"?W:VHXUB0(@PH[5S/AR>9YI&N(W\PCEB.M=10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 5[N[CLX6DDZ 9K)NFCOO(
MNHF0*GS$,1DT[Q';W,UL3"/E ^:N;ALKN\5!;D@P_?!.* .ZMF22%750 ?:I
MJI:8DJ64:R]0*NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4R2*.5=LB*P]&&:?10!!]BM?^?>+_ +Y%21PQQ#$:*H_V1BGT4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'BCE&)$
M5A[C-/HH @^Q6O\ S[Q?]\BI(X8XAB.-4!_NC%/HH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0@,,$ CT-9]KIXANII,8#'@"M&
MB@! ,=.E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img70551829_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "E 8@# 2(  A$! Q$!_\0
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M2AD/_+O$2$_X$>K?H/:K%I9Q6:$1@EV.7D<Y9SZDU8H ;'&D48CC141> JC
M'X4ZBO)O&GC_ ,2:-K]]IT-LEK:*@6&Z>(GD@$-GH>XQ6M*C*K+EB&QZNSJN
M-S 9Z9/6G5\SZIKVJZDCW.N7ES-B3; L9"?,!DLK 8"_GG->R>%_&5B_P_@U
M>_N)%2V'D3/+RS.OTZD\5O6P<J<4[W$FF6_'.NRZ-H[*FFS7<=S%*DCQD@1
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M>M:M)JSL0U9V"BBBD(*P=*DU#5HO[2_M!X8VN&"6JQ(T?EJY7#$C=N(4\A@
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M223MQ_C6[12YF3[204445) 4444 %%%% !1110 4444 %%%% !1110 4444
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MK33\V24445F9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img70551829_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "M 2D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **JZC?)INFW-]*CO';QF1E098
M@#)Q7'Z_X[N+6TG6PTF^CW1$PWL\86+=MW C/48Y[9Z=:N%.4W:('=4UG5!E
MB *\VA\9^(CX)?4[FS1+@L(XVV%-P;"J_/')/:NXT+3I=/TN"*ZN9+FY"YDD
MD;<=QY('MFB=.4'J-6:O<O?:(^Y8?534BLKC*L"/:EJ-H58[A\K?WEJ!$E%1
M;Y$X="P_O+_A1]HC[DCZJ: ):*B^T1?W_P!*43Q$\-^AH DHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBF.^S!VL1WQVH ?12*ZN,J<BEH **
M** "BJ&KZF=)L3="SN;O#!?+MU!;GOR1Q7(WOC*+4M=T?2K*\ET^XE0S3>9$
M=R$QDK&RD8/4,<\<"M(4Y3U0'>$A1DD >]1F>/. 2Q_V1FO,=9E\67=U9Z=<
MR07MF9\S/"AB#)D8WCJ,8SQ^M=WH.N0:PMU'##)&;.7R7RIVDCT/?&.:)4W'
M7=#TMYFG]HC_ (B5_P!X$4K3Q@<.">P!R34G6D"@= !68C@]6N_%6LZ5K%HF
MDP0QR1B*%7F!8,3AAGHQQD_45SE]>WP^'\&D:_8R7%\;H1V\,$J)(H5<@$ '
M!"G&,="*[;4M:TFP\0-IM[J!MWG0.L:AP26!7((& <YY[<4L7P]\-11OYUDU
MP6.YGN)W8D\_-G/7GK753J*$5SKS6@Y.[NE8OV^D6]IX5M]/MX'2.&%2L3X+
M;ASS[YZ^],MS<6DCM#*9H0RAA@ <XX'OSVI=8\0:;X7M;-+D3F*0^3%Y2&0C
M XSWYQCZU!I4DMR6GB5U$Y#@S J5SWVG^M8-2MS/J2=$I)4$C!]*6@<"BH&%
M%%% !1110 444A( R3@4 +14?GQ?\]$_.CSXCTD3\Z )**** "BBB@ HHHH
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M,IZ&N;UO[#XB)L;?6IXY8!NDMK25?FY &[@]#V_2M_3Y;8VL45L$18T"^4H
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M"CH>HP!G'3FNST:Y@O+-+F"=98Y%5E(CV';CC(/->;6(TO3O![0B^LXKJ_\
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M_>3Y_A3C\:EI%4*,*,"EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M@$8/2H?+DC_U3#;_ '6[?C4U% #$DW':PVN.U/J.5-R[@<,O(-.C??&K8QD9
4H =1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img70551829_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_11.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (+!>P# 2(  A$! Q$!_\0
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MBBB@ HHHH **** "BBB@ HHHH **** "BBLOQ5JDNA^&-8U&!4>>SLYKB-9
M2I9$+ '!'&1ZTUKH-+F=D:E%?"?AS]L[XU^,(II=!\!Z;K<<#!97TW1[VX$9
M/(#%)C@GWKN?@K^V;K?BCXBVG@[QUX<M]%OKV06\,UK'+"8IB/E22*0LPW<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^(OP^^'&N6^C#QCIVCI;VDGD:>+V5;= Q!Q&HW*&X!.SD<9Q6'\1/V9/"'Q
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M"MYEW136JQNOJIN,$?E7T!^U=9P:?^S7XMMK6".VMH;:!(X84"(BBXB   X
M'I6=\:/V9)OC)XH\+ZY<^*5TZXT:!(Y433?,6X97WEA^]&P$]OFQZFO1OBY\
M/_\ A:GPZUGPK]O_ ++_ +11$^U^3YWE[9%?.S<N?NXZCK7/[6%J2O\ #O\
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M+[I-*^SLR/\ [^V958^Y2M7B*4G)7ZWU3['1+'8><IQNOBNFTVMDNEG<[?\
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MOM8F-UJFGZM#IT]RP^:8HT;JS>IV2*">Y!--\<?\H_/"'_7ZO_I1/7H/Q?\
M!/B'5/V4KBQM_A]9^']=O+Z"YET#PM:^9_&HWLD2_?VJ,XW8 &3Q@<YXR\!^
M)KK]ASPMH,/AW5IM<ANU:73([&5KE!Y\QRT07<!@@\CN*QC*-HVT]\YJ=2G:
M'+9+VNUUV_(XF?\ 9[D\2_LRP_$C5/%>J7>M66G+-96;./LMO;0GRTA QNR$
M4$$$ 'L>M?1G[%_C'4O&7P.LY=5O9-0NK&[FLA/,2TA1=K*&8]<!P,^@ [5E
M:;X6UJ/]B1]";2+]=;_L.6'^S3;.+G>78A?+QNS[8S5G]B'PSK'A/X.W5EKF
MDWVC7C:M/(+?4+9X)"ACB ;:X!P2#S[&L:T^>E*[VEH<F*K>VPU13=[3T]#,
M_;^O+BU^!]G'"6$=SK5O%/MS@H(IG&?;<B?I7>_LK:38Z3\ O!XL88XEN+3[
M3,T8&9)78EV8]SGCGH !VK?^-7POM?C#\.M3\-7$@MY9@);6X()$,ZG*,1Z=
M0?9C7R#X5U;]HC]G6QF\*V'A2XU[2HF?[,5T^6_ABW'):)X2" 22=K< DY7.
M:BFE6H>SB[-.YE1BL5@_80DE)2O9NUT?6P\"?#=?BA+K9LM'/CIMLK,TX-R#
MLVJXB+?*=H^\%R>N:^:OC]X.\-:M\8-1NOB?\5%CT,1'['H.CAWO;?IY<9C"
M2*N022Q&6)'0'(T_V=O@7XY\3?%B3XI?$V*6VO(V,MM:W8"S2RE=BL8Q_JT1
M>BD Y"\8'/*:3HOQ)^ _Q\\6:ZGPZOO'7]J2W'V:^AADD4"23>D@E5'V'H&4
MX/49'6M:<>2;2G=I?TDV=-"FJ562C5YI*/=;]DW>UA/V,/$5UH?QXUOPMIFI
M:A<^%I;2=X;?4D:-\(R&.0QYPC[3@XZ@].F.;\'_  O?XR?M2?$GPO/JMWI>
MC/J>I7FH_8F"R31QW954!((^_(IY!'&<<#'=_ ?P?\0-#_:JNM>\8^%[ZT?6
M(+B6>\MK61[*%Y4$H3S0"@QC9RW!XR>^]^SOX(\1Z)^UM\3=8U'0-4L-(O/[
M3^S7]U921P3;[^)TV2,H5MR@L,'D FMYS493E%Z\J.NK65.=6I!J[@NVYYO^
MV!X)M?A3=?"_0/#DMPB:;;3?9KBX<-,9//5@[,  3N/H , 8P*].\;?LVZ-\
M%?@3\0M5@U34M9UW4-+2&\NKV52A/FHS%%"@C+ ?>+'@<]:H_MQ>!?$GBSQK
MX'GT/P]JNLP6\4@FDT^REG6(F1"-Q13C@'KZ5[O^TEI-]KOP-\7V&FV5QJ%]
M/:!8K6UB:660[U.%5023]*P]J^2DK[O7[SD>)G[+#+FW;YO_  +J?*7@WXGZ
MM\*_V)S>Z),;74M1\02Z;'=+]Z .A=G7T;;&0#V+9'(KSNXT_P"'6F_#^/Q'
MIWQ2UAOBBL:73PK;7*QF4X+0B7R@=PY^<O@D=,<U[/X._9_\2>//V09/#,VF
MW6C^([/6I-3M++4X6MFE95V[2' P&5WP3QD#ZCG]!U+Q=H?AK3_#TO[,VEZG
MK]J$@;6+SP_NBG50!E\1 %R!R_F8SSBNJ,HWER[WUU7Z]#T85*?--TWKS.^L
M5=>=]UZ%WXQ_$J[^*G[%GAO6=2<RZK'K4=G>2;<>9)&DPW_5EVD^Y->A?LN_
ML[Z;-I?A/XGZWJ^IZKXCEMO-@ADE46T,>TI$NW;N.U ,?, ./EXJK^T1X#U_
M5?V9-%T[3_ <&DZT^JQ75SH/A>T,R0_)*"VV).N"FXX(!.,GK7N'[/\ IEYH
MOP5\&V.H6D]C>P:=&DUM<QM')&P'(96 (/L:XZE3EHVAI=O[CRJ]?DPC5%VO
M*6FFW;T/0****\L^<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[D\JWB&7?:6QSCH!GO0!:HJ.WN([JWBGB;?%(H=&P1D$9!J2@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Q/CS_ )&3PA_U^G^:UVU<3X\_Y&3PA_U^G^:UVU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5S/Q(_Y$C5?]Q?_ $-:Z:N9^)'_ ")&J_[B_P#H
M:T :WAW_ )%_3/\ KUB_] %:%9_AW_D7],_Z]8O_ $ 5H4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_*9%_C75T4 <SX%U"_OK75(]0N_MLUIJ$MJ)O+6/*J%[+[DG\:Z:N4\ ?\
M,Q_]AJY_]EKJZ .?\?:I=:+X3OKVRE\FYC\O8^T-C,B@\$$=":J?\([XG_Z&
M[_RF1?XT?%+_ )$34_\ ME_Z-2NKH Y3_A'?$_\ T-W_ )3(O\:/^$=\3_\
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MO/KZ5Z!7*?%+_D1-3_[9?^C4KJZ "BBB@ HHHH **** "BBB@ HHHH ****
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M/H **** "BBB@ HHHH ***\W^+GQG@^&NH>&_#^G:5)XF\;>*)Y;?1="AG6
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MXIW/Q6368+"TB\)^-K_PW9M9HZ;[6"&WD5Y2SMF3,S9(VK@#Y1SGK? _QB\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M;-FWQ"TW]F?]H'4-+U'3[CP"/'7B2/Q%I-CIC)KG]EM>,M_):7DD[0+(("Y"
MO;' #$,&VFOI7Q[?_"-]%^%/@U?!-[\68KO2/.\,^%;***ZMI-.B@B_TR:.[
MFBM,(GDJDD[>8#,1']]Z]C\+_"?PIX-T'7M%TC2$M]+UV]O-1U*VDFDF6XGN
MF+7#'>S$!R3\HPHSP!7,3?LO_#B3P_X1T>'1[_3X/"<#VFB76F:Y?V=]90.N
MUH5NX9UG,9  *-(5^5>/E& #X?\ $NH7-O\ L(_M7Z''IM]X;TK0/&$]KI.@
MWLL3/H]NTEC-]E3R9)(U19))&"QN5&\X->^_$#X:^'/@C^T?^SY?>#-.31=2
MUS4]2T?6]0C8M=:U UB\Q-],3ONI/-A23S)2S;@3GDU[!#^RM\+;;X=^*O L
M/A5(O"OBBY%YK%@E[<C[7,%B7S#()-ZL?(C+%6!9@6;)9B>T\3?#GP]XP\0>
M&-<U?3_M>J>&KJ2]TJ?SI$^S3/$T3MM5@KY1V&'!'.<9YH ^.?"?P[\*_&+X
M7_M#>/?'\$=SXRL?$'B&P3Q!<3&*]\/6UCO%M#:W&0ULB)\Y"D!_-??N5B#F
M_#>WC\;^#_V,/AWKTC2^!M9\+W6I:EH\A86VLW%I90/;6TX! EC7?+,86RK^
M4-RD+7U9XB_9G^&_BOQ)JFM:IX>>>XU9HY-3LTU&ZBT_47C&$DNK))1;W#KA
M</)&S HASE5Q;O\ ]GSP!J7P[\/>")M!V^'_  []G.C+!>W$-WIK08\I[>[2
M07$3@#&]9 Q4LI)#$$ \!OO#.G?"?]H7XC^#? ]G!H7@K5?AA<Z]J7A[38Q%
M86FHI-]GAGB@7$<+S0B0-M4>9]G5CDJ37BTGPC\.>'_V,?V=/&FE076E^.;G
M4_#ENWBRSNY8]66WNR+::W2[#>:L/DS/&L08(@QM Q7WGX3^"?@WP5IWB&TT
MS2YF;Q"-NKW^H7]S?7^H 1^4HFNYY'G<+'\JAG(0'"XJ&;X#^!;CX?>&O!$F
MA[O"_AN:SN-*L?M<X^SO:L&MSYF_>^PJ#AV(./FS0!XIH'@W0_@]^W-H6A^"
M]+MO#6B^(O MY<:KI^GH(H+RXMKR(0W$BCAY@)Y096R[!SDFOJJN;NOASX>O
MOB#I_CB?3]_BBPT^;2[:^\Z0;+:5T>2/RPVPY9$.XJ2,<$<UTE !1110 444
M4 %%%% !1110 4444 %>+?&;X(^#/C9XPTR2/Q1?>$_B?X:MOM%AK'AC4UM]
M5L[:9^DL7S"6WD>(C;*A4[9 I&Y\^TUR?CGX1^!OB@]F_C+P7X>\6M9!Q:MK
MFE07I@#XWA/-1MN[:N<==H]* /B#Q#\3?%?Q,^ _A$^+M3L_$MWX?^.&EZ!:
M>*M/MUMX-?MK>]C"7JQIE%W,SH1&2FZ)L$U[WX)/E?M]_$]'^1Y?!.BR1JW!
M=1<72EAZ@'C/K7N<_@/PS=:)I.C3>'=)ET?2'MY--T^2QB:WLF@QY#0QE=L9
MCP-A4#;@8Q4'B+X:^$?&&N:1K6O>%=$UO6-'D$VFZAJ.G0W%Q8N&#AX9'4M&
MP95;*D'*@]10!\1_!WX=^)_BM^SG\6M!UOQQX)T"SU'7-?A\91Z]X7FN;^PN
M/M$N9I[K^THDW1PK!)&[1 (B1_>"9/U?9R?$OPSI/AS2?#^E>%_&FEVNFVL$
MWB#5_$US87-W(L85Y1!'87"D-C<#YW.[MU.]XA^"OP\\7>)H/$FN^ _#.M>(
M8#&8M6U#1[>>[C,9S'ME="XVGD8/':NSH ^4OCG\*=#TN+Q]\:OA;\4'^&_C
M'3H9AKMY8W<-WHVH7%JH4PZC:2;H_.50T092CHTI8AFX/ W?C'2/B)^U#^RG
MXE^)&EV.BZSK7@V\O[73;]66.#5G^S21HBOT<'>8P_(8)CYPIKZUUKX'_#CQ
M)XL7Q3JWP_\ "^J>)EDBF76KW1;::]#QA1&PF9"^4"KM.<C:,=*XOXA_ 5_B
M'^T%X5\7:K:Z-JW@ZP\.:EHNHZ3J<?G-<M<2P.@\IHS&\>(FSN(YQP>P!\R_
M&Y]5$/[;USX#>X%@ND:/'=MIOW!?BW?^TC'@@>8MJ8O-P<YP#\P./7;7X2W_
M (JU#X&>([GXF^ +;P_X=OX;CPH/#/A:739+ZW>RD3[#;2R:G,/*DM@6*(A)
M6 'HIKZ0\*^$-!\":';Z+X:T33O#VC6Y8PZ=I5I':V\99BS%8XP%&6))P.22
M:PO"OP5^'G@7Q!/KOAOP'X9\/ZW.KI+J6E:/;VUS(KL&<-(B!B&(!()Y(% '
MA7[,$GABZ\%_'=O':Z<;S_A-=;'BY?$0C\H6ROBW\_S?E^S"T$6S/[O8#CC-
M9VB_\G&?MC?]BSX?_P#3=?5]$^(/@U\/_%GBBU\2ZYX&\-ZSXCM3&;?5]0TB
MWGNX3&VZ/9,Z%UVMR,'@\BME/!^@QZEK.H)HFFI?ZU%'!J=TMI&);Z.-66-)
MVQF155W4!B0 Q ZF@#X=UK_E'Y^S5_V&/!W_ *4PU[-\$Y+.X_:K_:+37U!\
M0K)I*6JWH_Y@OV)3'Y.[@PF<W._;QO)W<U[J_P /O"TGA_3-!?PUI#Z'ICPR
M6&F-81&VM&A(,+11;=J%" 5*@;2!C%4/''P?\!_$Z>TG\8^"?#OBR:T5DMY-
M<TFWO6A5B"P0RHVT$@9 ZX% &QX3_L/_ (171O\ A&/[/_X1O[%#_9?]D[/L
M?V7RU\GR/+^3RMFW;M^7;C'%:U,BB2")(HD6.- %5%& H'  '84^@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KYC^+U]'X!_;6^$/BW7[B.Q\+ZMH>I>%K:
M^N"$@@U.22*>*)W/"M,D3J@)RQC('/7Z<K/U_P /Z7XJT:[TC6]-L]8TF\0Q
M7-CJ$"3P3(>JO&X*L/8B@#QK]L_39O'7[.GQ(\#Z%=0S^,-1\.W-Y9Z-%.OV
MRZAB9/,*19W,I)6/(&-TBJ?O 'IOA]\;/!&H_L^Z+\1T\06%OX,31XKN;4FE
M BMU1 KH^.CHP*%/O!AMQGBNF\#?"GP3\+TO$\&^#] \)+>E#=+H>F060G*9
MV%_*5=VW<V,]-Q]:R=0_9]^%NK>))?$5[\-?"%YX@EF^TR:M<:#:O=/+_P ]
M#*8]Q;_:SF@#X:SXC\/?\$__ (?_  WT[2;Z3Q9\7-9NH[31+5HH[N/2KFZF
MO;@KYKI&#]CPIW,H!G )&":]-D\7:G\,OVT/A_XCO/AYKWP^\(^-M'7P+<'6
MKC3GC:^A+SV!3[)=SD,55X1NVY##&<<>[_"?]E+X=_!;Q-J&L>&-+EA6:0RZ
M=I]Y*+FVT-G#?:/[.#@M:K.6S(J-M;8@  4"O2_$/A31/%UO:0:[H^GZU#:7
M,=[;QZA:I.L-Q&<QS('!VNI.0PY'8T :M%%% !1110 4444 %%%% !1110 4
M444 %%%% !7@OQ@^!?A3XJ>-KKQ5X<\=W?P^^+'AJR6VE\0^';Z(S6\#*TT,
M&HVKY2:V+A9?+D"EQ&,.!FO>JXWQM\%_A]\3+^"^\8>!/#/BN]MXO)AN=;T>
MWO)(X\D[%:5&(7))P.,DT ?$MY\3O'7Q>\,_LO:YXDU70["-_&&I64GB+4M+
M>YT;4;ZWBGBTJ\:V2>'F9T9XML@42E67C"UZUXN^%.J>%[SX\>+]?\=^'-6\
M2:U\/)+?4- \/:,^F;DBCNQ;WT\<E[<.[$>="KG Q&0/NM7T[K7A71/$GAZ;
M0-6T?3]4T*>(02Z7>VJ36TD8QA&B8%2HP.",<"LKPS\)_!'@G0-0T+P]X.\/
MZ#HFH[OMNFZ9I<%M;7.Y-C>9&B!7RH"G<#D<=* /CKQ5X?L?"W_!+WX<V]A:
MO8>&[S3O#-]XF:SSN>SN9[6;497/WB'\R1I.ORL^1MS7J?[1EKI$WQ+_ &:X
M_"8LU\40>*4DT_\ LP)O30193"^V[>!;%/(4XXR8@.U?1^G:)IVCZ+:Z/86%
MK9:3:VZVD%A;PK'!#"JA%B2,#:J!0%"@8 &*Y[P/\'_ ?PQGNY_!W@GP[X3F
MNU5+B30])M[)IE4DJ',2+N ). >F30!\'^)G9?@G^T.+HRIX:;X\!?$;QDX7
M2C+IGVHOC_EGMX;J-I;/&:^A?VA+73)OC-^S='X5%LOBJ#Q"\D/]GA-R:!]A
MG%Y]WI 3]F7^[N* <XKZ#TWPCH6BQ:K'I^BZ?8QZM<R7FHI;6L<8O)Y%"R2S
M!0/,=E506;)(4 GBLCP/\(? GPQEO)?!W@KP[X3DO JW+Z'I4%D9PN2H<Q(N
MX#<<9Z9/K0!^=</C?1/'G@'XG_!Q)M!TOQ%XG^)E_/#XGUWQ#I-K)"%U12)Y
M;1[H7HN5$+11(L)W 0D,H8A?HGXBR:O#^VIX_?P^LSZ\OP1+:>MN,R&Y&I7?
ME!?]K?MQ[TZU_9Z^+6E_!/Q;\'XH_ ^JZ-XBNM26X\;:EJ%V=0:&_N'EGN9=
M/^RLDUT@FDVYNE4LD>2H!%?1O@_X;Z)X/M]'DBLK>[UO3=&M]"_MZXMT-_/:
MP@;8WF W%2V7VYV[F)QDT >3?LF_\(%-^RG\%I(O[(DL_L%FUHUYY9;^V"C?
M:2A?_EZ^T&ZW;?FW&3WKYO\ VB/C$?B%^R[I.O\ AGP3X7\)_#V3QG8#P_>2
MZVL&JF[CU4>9)%I\=J8DE9DNF91<;PGF.PSN6ON'2_@S\/\ 0_&,_BW3O WA
MNP\5SR22RZ[:Z1;QWTCR9\QFG5 Y+9.XD\Y.:JR? 7X92ZSJ>KO\.O";ZMJ;
M%[^_;0[4SW;&59299/+W.3(B/EB?F56Z@&@#RGPK_P I!/B!_P!B!I/_ *67
M5?2-9L/AG1[?Q!<:]%I5C'KEQ;I:3:FEL@N9848LD32XW%%+,0I. 6)[UI4
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M : /0/ _[5"ZA^RWXC^)_BG3X-&UGPI'J-IKFG0.6A74+)GCDCB+?-MD=5V
MG(\P*22,G(_9"^)_Q U'7O&'P\^*^L+KGC71[;3-;AOELXK42V=[:HS1A(E5
M3Y-PD\>[&2"N<UY!KW[/OQ(NOAG\//A*]O\ 8]6\<>+[WQOXUU86$E_I&EJD
MQO5LIF1HU??-]GC"B12YB<@@<CO/&W@/XJ_#[]J/X7?%;4+RQ\:VE\K>"==@
M\(>%[JT>VL9R\T-Q,&N[HF..X"LSX4*"<_>R !WA?Q!\2_B5=?'W4H/BYJOA
M?_A#/$U]INCV2:9I4FFQPPVL,Z"X\RT,SKND8,1,IV]"",U[O^SO\2[[XR?
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M]2>W<6TDJ75R6B64C:SJK*2H.0"">M>1_$CX&^,?B7JW[9VC:7I%S;7'B=-
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M>'/B5=ZSI-A<1Q:]XVF\0+!9),R!H(TU>4%VE"9S#&X B^=D)C# 'T+1110
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M\3?"OXE?LI:+=:?=7\7A7PAK5CK&IV=N\EG:W,D-J?+:4#: 7#JF[!8(2!U
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M\0/!VAO&FL:QH\]M9B5MJO*5RJ%L_*&("Y/ W9KQ?XI:YJ?[1WPC\._##2/
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M*15U2:U,G[J.>5GN(TG(R/*4AA@&@#ZI^)'C;_A7/@G5?$?]@ZYXG^P1J_\
M9/ANS^UW]SEU7;#%N7>1NR1D< GM706MQ]JM89O+DA\Q%?RY5VNN1G##L1WK
MX:^)'Q:TJV_9#^.,W@36_B-X0\6Z+9Q2WGA_QEJ=X=:T*5I0B2I-/++,$G1
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M^(GP&@NX6\OP3HDWBSQ3;S X36U:73;>%ESE)%E2^F ;G:J'H?F /N*BBB@
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M4^M?#FP_LC^U/^$P\2P^'?,^T^3]D\R&:7SL;&WX\G&WY?O9SQ@^DU\.>*_
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MFXJ#@$#BNB^)7CS3_A;\/?$GC'58;FXTS0=.GU*YBLU5IGCBC+L$#,JEB%.
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MK$)FO3_C[$EK;_LF+"BPK'XVTN-!&-H5?[.N1M&.@QQBOK*B@ HHHH ****
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M, <9KYU\8>)(?&'[&_[:.M6UI?V5K?>.)9H8=3M'M;CRR-.VLT4@#IN&& 8
MX89 /%?IW10!XE^T=\7KOX"^%O!\&A6^B:%8ZIJ]OHLGB#7(W71_#UN5)\Z=
M(V3*X01(ADB7?(F74#!^:? _B:X\7>-/VP-5E\2:/XMCNO M@4UKP[ILMCI]
MXJ6>H1AX5DGG\U059/-65E)5@,8(K] Z* /)OV5KB*U_91^#\\\B0PQ^"M'=
MY)&"JJBQA)))Z #O7RY\+?"'Q'_:'^'/QI\86OA+PKJ6A_&::YBL+W7/$5UI
M]Y;:7#&]I8Y@33YQ\H#3*?,&3)G"YR?ORB@#\X=6^*_B?XY_LL_#7X'VRV]S
M\4-8UV7P=XELKR[>!8X='(DOC-,D;LGF)'; G8?^/D\'H?2O'&I>.OA%^UE\
M+OB5XK\-^&_#'AKQ)"/AYJ7]@:[/J*EI6::Q>0265L(PLR[ WS?*Y&0.#]J4
M4 ?$-KXRL_@W\8]-L_@]\0X?%]IXN\8R0Z_\)M1A22_TV>YF9[[48CA+JTCB
M$+N4G5HB)&((+H:^WJ** "BBB@ HHHH **** "BBB@#YD\3&+X@?M_>'O#.M
MK]KT;P?X(/BG2]/F4&+^TI[XVWVHJ?O-'''M1C]PR.5P2<]]^TIXXMO@5\*_
M&7Q2TSP[I^I>+K'38K&UFFA59)R\X2VADE&',*S3[BFX#YGP5)S5OXI_!.;Q
MGXP\/^.?#'B%O"'C[0HGM+74WM!>6ES9R21O-:7=MO0RQ-LR-DD;H^&#<$&G
MX@^".M_%;P-XK\*_%+Q;:^(-)UZQ^P"T\-Z,-*AM,-O6Y3S9KF0W"OM96,GE
MCRT_=9W%@#@_B#K'Q+_9YA\"^*=6^(=UX\L=0UVPT+Q#HU]IEC;6T8O)4B%Q
M8&"&.:,QRLN$FEF#(S!CN :J7A35OBG\8/C%\=/#MK\3+CPCH7A75+:TT7^R
M](L9;E));&*3;*]Q#(KP!F+;=@D)8_O54!3V<7P"\7^++[P;'\2OB%9^+]"\
M*W4.I6UCIN@'39=1OH !;W%]*US,)=AW2;(DA4R%6(VJ$KK/AG\'?^%=?$'X
MF^)_[7_M#_A--4M]2^R_9O*^Q^5:QP;-^\^9GR]V<+C.,'K0!X!IO[4'C/QA
M\!?V8/&MO=0Z/J?CCQGINC:]';V\;QW$#1WBSHHD#>6'>W5@5(9>@;KGUKX&
M_$;Q#XP^,7QTT/5]0^UZ7X:UZSLM*@\B-/LT+V,,KKN50SY=V.7)/.,XXKP;
MQ)\,=/\ A+H'[+/P*TOQ/:^+/%GACQS9ZS<6\$:PW7]GQQ7\DEW);AW:*(&0
M)N8X)Z'L/<]2_9X\16/Q(\<>(?!OC_\ X133/' M6URS.D"ZNXIH8C"UQ87)
MF5;>1X0@_>13J&0,%YVT >,?#S]H;XB^-?V<?V<9[SQ0-*U_XCZVVEZOXQ^P
M6WF6ZI]JE6."(Q_9UGF^SK$A>-U&6.QFP1VGP9U_X@:EXU^/6D:C\6[O6-,\
M(W]OINF:YK6DZ<+2V5[6&YN&D%O#;[YX-[QEC($&0S1\8/D?Q>^!'AWX.^#O
MV:OA;XP\3I:>"M&O=6%_XXU+3+0V$3&"0PV\T5Y'<6L;S&=@CS @>0^WYF&W
M=\%_#NS^.GACXI_ _P *>*[?7/@_:VFG7.D>,=-T73DM+;5#/]IELE6SA@L[
MV%6BBDD5$!'GO&[ABI4 ZWX=_&R75OVCHOASX>^-\/Q5\->(/"EW>KJMK)I%
MQ?Z%?P3*H=)+.!(2KQS B.:%_FA!SM+*>;_9+TOQ!X-^!/Q=\36WCK7+M].U
MOQ7Y.G75OIYMOM,5Q*1=G9:K(92R[BN_RLL<1@8 ]K\/_ /Q4_QP\/\ Q,\6
M^.M/UB^T?2KS1X-)T;P^=.LUAG,+!EWW,\@<-$^XL[*P*!5CVL9&^#?V<]7\
M$:5\1O#-EXMLI?!/BRXU6^@L9M&<W^GW-\=TG^E"Y"2Q(S2%4,*OAE!D.W)
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M"XMY^RKX3O?V;;#X)OJ&M#PK916<,=XL\/VXBVN8[F/+^5LR7B4'Y.A.,'D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117S#\8/VS
M-5^'/QBO/A[H7PTOO&FI00QRK]@OG$LNZ(2G;"D$APJGDY[$\4[7 ^GJ*^=_
M@3^V1I7Q>\;3>"]8\-:AX*\6JKM'I]\YD$A1=SIDHC*X4%L,HX!Y[5RGQ/\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHKS[XQ?%2W^&^@_N2LVM72E;6
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M(+F(YBF19$)'8C(_G4U?I*=U='U>X4444P"BBB@ HHHH *_//XO?%72?@O\
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MA?PS?^,-<M=)TV+S;J=L#/W47NS'L .:H6-E/J5Y#:6L+SW,SB..*,99F)P
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M444 %%%% !117S]\7/VV? ?P8\?7/A'7-/UZXU"W2)Y9[&VA>%1(H8<M*K'
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M9FX\_;Y;E<[]BYSC/2O1Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/#OWWN^R_S?X(XLUS#V*]A2?O/?R_X)#UY-'7@45[_^SS\'?MTD'BK6H/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWHNO=_C\YFV8>T;P])Z=7W\@K9\(^$]0\:Z];:3IL6^XF/+'[L:CJ['L!_\
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M[<^J5^M\.9)]1A]9KK]Y+;^ZO\WU^[N?;97E_P!7C[:HO>?X+_,****^W/H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNWJJ^I./;U'U7##';PI%$BQQ1J%1$& H P !V%/HKU<LRJAE=)PHZM[M[O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P!
M#_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^
M*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<
MN/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X
M61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\
MXY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2
M_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1R
MY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2_P"A
MHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1RY?\
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MSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\
MP*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX
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MPA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P!
M#_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^
M*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<
MN/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X
M61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\
MXY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2
M_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1R
MY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2_P"A
MHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1RY?\
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MSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\
MP*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX
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MPA_^*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P!
M#_R<N/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^
M*H_X61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<
MN/\ XY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*H_X
M61X2_P"AHT7_ ,&$/_Q5<[_PSWX _P"@!_Y.7'_QRC_AGOP!_P! #_R<N/\
MXY1RY?\ S3^Z/^8<V=?R4O\ P*?_ ,B=%_PLCPE_T-&B_P#@PA_^*K2T?Q)I
M/B#S?[+U2RU+R<>9]CN$EV9SC.TG&<'KZ&N+_P"&>_ '_0 _\G+C_P".5RG[
M/6GV^D>,OB58VD?E6MK?I!#'N+;462X51DG)P .M4\/A:E&I4HRE>-MTNK2Z
M-F4<9F%'%T:&*A#EJ-J\7)O2+?5+L>X4445Y!],%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C'[*?\ R3O4
M?^PK)_Z)AKV>O&/V4_\ DG>H_P#85D_]$PU[/7JYI_OM7U/GN'O^15A_\(44
M45Y1]"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>,? S_DHGQ4_["H_]'7->SUXQ\#/^2B?%3_L*C_T=<UZF%_W7$>D?_2D?
M.YA_R,,%_BG_ .D2/9Z***\L^B"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHKC_B=\1[+X;^'7O9]LU[+E+2USS*^._P#LCJ3_ %(K"O6IX>G*K5=HK<SJ
M5(TH.<W9(Z.^US3M+DCCO;^UM))/N)/,J%OH">:N=>17Y^Z]KU]XFU:YU+4K
MAKF\N&W.[?H .P'0#M7K'P/^-U[X=U"R\/ZO(UWH\TBPPRN<O:DG Y[ID].W
M4=,'XC!\6T<1B?958<L7L[_GV_3\3YZAG5.I5Y)QLGL_\SZKHHHK[X^E"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJ&L6&D*C
M7][;V2N<*UQ*L8;Z9/-97CKQMI_@'P]/JNH/\J_+%"I^::0CA%_SP 37Q1XQ
M\8:CXXUZXU74I2\TAPD8/R1)V11V _\ KGDU\MG6>T\JM"*YIOIV7=_H>/C\
MQC@[12O)]#[VCD2:-7C971AE64Y!'J#3J^-OA+\:=1^'=U'9W+/>Z#(_[RV8
MY:')Y>/T]=O0^QYK[%@GCNH8YHF#Q2*'1AT((R#79E.;T<VI.4%:2W7;_-&^
M"QL,;"\=&MT24445[IZ(4444 %%%% 'C'[*?_).]1_["LG_HF&O9Z\8_93_Y
M)WJ/_85D_P#1,->SUZN:?[[5]3Y[A[_D58?_  A1117E'T(4444 %%%% !11
M10 4444 %%%% !67JWBK1=!GA@U/5[#3IIO]5'=W*1,_./E#$9Y]*X_XY?&;
M2_@GX+FU>\VW&H39BT^PW8:XEQ^B+U9NPXZD _E]XP\8:MX\\17NN:W=O>ZC
M=N7DD8\#T51V4#@ =!7T>5Y-/,$ZDGRP[]V>'F&:0P34(KFE^1^PE+7P'^RK
M^U1J?A'5M+\&^)IGU#P]=2I;6EU(Q,MBS':HS_%%D@8/W1R.!BOORO/Q^ JY
M?5]G4U3V?<[<'C*>-I\\/FNP4445YAWA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%8_B[Q9I?@;PY?:[K5TMGIME'YDLK?D% [L20 !U
M) JHQ<FHQ5VQ2DHIM[&Q17Y9_&K]H#Q%\8/%4][)>7.GZ-&Q6QTR*8JD*=BP
M!PSGJ6_ < "O3?V;_P!L#4O!%U;>'O&=S-JGAV1Q'%J$S%Y['/ R3R\8].JC
MIG&VOJJG#F)IT/:IWEUC_P 'JSYVGGF'G6]FU:/?^MC[_HIL<BR(KHP=&&0R
MG((]13J^3/HPHHHH **** "O&/@9_P E$^*G_85'_HZYKV>O&/@9_P E$^*G
M_85'_HZYKU,+_NN(](_^E(^=S#_D88+_ !3_ /2)'L]%%%>6?1!1110 4444
M %%%% !1110 4444 %%%>,_'SXQ#PC9OH.CSXUJX3]],AYM8R/7LY'3T'/I7
M#C<92P%"5>L]%^+[(Y\17AAJ;J5-D>L)KFG27YL4U"U>]7.;99E,@QU^7.:O
M5^>$=S-#<+/'*Z3JV]958A@V<Y!ZYSWKZF^ OQHN?&C-H.M8?5(8O,AN@,>>
M@P"&']X9SD=1GTY^6RKB>ECZWL*L.23VUNGY>OYGCX/-X8FI[.<>5O8]IHHH
MK[<^@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MBFN:=)?FQ34+5[U<YMEF4R#'7Y<YKR?X^?&(>$;-]!T>?&M7"?OID/-K&1Z]
MG(Z>@Y]*^5H[F:&X6>.5TG5MZRJQ#!LYR#USGO7Q.:\34\OK^PI0YVOBUM;R
M]?R/G\9FT,-4]G"/,UN?H?17BWP%^-%SXT9M!UK#ZI#%YD-T!CST& 0P_O#.
M<CJ,^G/M-?3X'&T<PH*O0>C_  ?9GKX?$0Q--5*>P4445WG2%%%% !1110 4
M45\T_!K]ICQ-XI_:+\8_"_QA8:382:;YYTZ;3X98WG$<@QNWR,#NB8.,!>AI
M@?2U%?/G[6_[1FM? JR\*V7A:PT_5/$FO7C0Q6^H*[H(U !PJ.AW%Y(P#G'W
MN#V]\L?M/V&W^VF(WGEKYQ@!$>_ W;<\[<YQGG% $]%%%( HHHH ***\O\>?
MM#>&_A[\4_"W@'4K34YM9\1>7]EFM88VMX]\AC7S&+AA\RGHIXH ]0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ^H:A
M;:38SWEY,MO:P(9)99#@*H&232;45=[";LKLS_%GBK3_  7H-SJVI2^7;0CA
M1]Z1NR*.Y/\ GBOB?Q[XYU#X@>(I]4OVV@_)# IRL,8/"C^I[DDUN?&#XI7/
MQ*U[=&7AT>U)6TMVXSZR,/[Q_0<>I/ 5^+<0YT\QJ>PHO]U'_P F??T[?>?!
M9GF#Q4_9TW[B_'S_ ,@KTSX&_#&Y\=>)H;V56BT?3Y5EGEQ_K&!!$2^Y[^@^
MHKF_AWX!O_B)XBBTVS!CA'SW-R1E88^Y/J>P'<_B:^U_#7ANP\):+:Z5IL(A
MM+==JCNQ[LQ[DGDFM.'<E>/JK$UE^[B__ GV]._W%97@'B9^UJ?"OQ9J4445
M^S'W@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 50US7++
MPWI-SJ6HSK;6=NF^21OY#U)/ '<FK=Q<1VL$DTTBQ0QJ7>1SA54#))/85\@?
M&[XN2_$+5OL5@[)H%HY\I>GGN./,8?R'8>YKP<XS:GE5#G>LW\*_KHCS<=C(
MX.GS/XGLC!^*'Q)O?B3XA:\FW0V,.4M+7/$:9ZGU8]2?PZ 5QM%;'A+PIJ'C
M37K;2=-B\RXF/+'[L:CJ['L!_P#6ZFOPVI.MCJ[E*\IR?WL_/)2J8BI=ZR9K
M_#'X<WOQ(\1)8V^Z*SBP]W=8XB3/ZL>@'] :^W[6VCL[6&WA7;%$@C1?10,
M?E6#X"\#Z?\ #_P[!I=@N<?//.PPTTF.6/\ 0=A@5T=?M6190LKH>_K4EO\
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M?YCJ***_4S[$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOBMXK7QC>:\TJW#1$B""!XA&T<>Y5 'WCPBC)Z4K@?+O[0WQ:N?VD/!7P/\
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MO-DT[1D*"[ ! 23;#"""3SNW=.E%] /IJBBBLP"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KD=1^+7A#2=9.E7>O6L5Z&V,GS%4;T9P-JGGN1BN'_:)
M^*=YX-L;?1=*<P:A?QL\EROWHHLX^7T8D'GM@]^1\IDEB23DFOA,ZXE_L^M]
M7P\5*2WOMZ+S/G,?FWU:I[*DKM;W/T01UD171@R,,AE.01ZTZOE?X(?'1_"K
M0:#KTK2:.QVP73'+6N>Q]4_E]*^IHY$FC22-EDC<!E93D$'H0:^CRO-*.:4?
M:4M&MUU3_P NS/5P>,IXRGSPWZKL*2%!). *^4/CY\8CXPOGT+2)O^));/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *QM:\9>'_  U<06^KZYINE3S_ .JBO;N.%I.OW0Q!/0]/2N%_
M:*^-T'P/\#_VDL"WFL7CFWT^V?.PR8R7?'\*CD@<DD#C.1^9/BCQ1JOC37KO
M6=:O9=0U*Z<O+/*<D^P'0 = !P!P*^ERO)9YA%U9RY8?F>#F&:QP4E3BN:7Y
M'[$*P8 @Y!Y!%+7P)^RQ^U?)X#DMO"?B^Y>?PX[!+2_D)9K D_=;UB_]!^G
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M** "BBB@ HHHH *JZIIMOK.FW>GW:&2TNH7@F179"R,I5@&4@C@GD$$5:HH
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M\37M8A_XDMN_[F%QQ=2 _P#H /7U/'K7U8 %  & *^_X9R/G:QV)6GV5^O\
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MO^0M%%%?GQ]H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7E_QA^"MI\1+<WUB8[+7XUPLS<).H_A?'Z-U'3IT]0HKDQ6%HXVDZ->-XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>,? S_ )*)\5/^PJ/_ $=<
MU[/7C'P,_P"2B?%3_L*C_P!'7->IA?\ =<1Z1_\ 2D?.YA_R,,%_BG_Z1(]G
MHHHKRSZ(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /&/V4_^2=ZC_P!A63_T3#7L]?/WA3X2_%7P1ITECHGB
M31;*UDE,[1X,F7("DY> GHH_*MK_ (1?XV?]#AHO_?E?_D:OH<;AZ>(Q$ZL*
M\+-]W_D?$Y7C*^!P5+#5,)4<HJSLHV_]*1[/17C'_"+_ !L_Z'#1?^_*_P#R
M-1_PB_QL_P"APT7_ +\K_P#(U<?U&/\ S_A][_\ D3U?[7J?] E7[H__ "9[
M/17C'_"+_&S_ *'#1?\ ORO_ ,C4?\(O\;/^APT7_ORO_P C4?48_P#/^'WO
M_P"1#^UZG_0)5^Z/_P F>ST5XQ_PB_QL_P"APT7_ +\K_P#(U'_"+_&S_H<-
M%_[\K_\ (U'U&/\ S_A][_\ D0_M>I_T"5?NC_\ )GL]%>,?\(O\;/\ H<-%
M_P"_*_\ R-1_PB_QL_Z'#1?^_*__ "-1]1C_ ,_X?>__ )$/[7J?] E7[H__
M "9[/17C'_"+_&S_ *'#1?\ ORO_ ,C4?\(O\;/^APT7_ORO_P C4?48_P#/
M^'WO_P"1#^UZG_0)5^Z/_P F>ST5XQ_PB_QL_P"APT7_ +\K_P#(U'_"+_&S
M_H<-%_[\K_\ (U'U&/\ S_A][_\ D0_M>I_T"5?NC_\ )GL]%>,?\(O\;/\
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M +\K_P#(U'_"+_&S_H<-%_[\K_\ (U'U&/\ S_A][_\ D0_M>I_T"5?NC_\
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MXQ_PB_QL_P"APT7_ +\K_P#(U'_"+_&S_H<-%_[\K_\ (U'U&/\ S_A][_\
MD0_M>I_T"5?NC_\ )GL]%>,?\(O\;/\ H<-%_P"_*_\ R-1_PB_QL_Z'#1?^
M_*__ "-1]1C_ ,_X?>__ )$/[7J?] E7[H__ "9[/17C'_"+_&S_ *'#1?\
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MM8-+:3ZGIU%%%>&?7!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ]9^-(_#?B:#3_/N[9KJSNM,WB-MIPR,KDG/?-<1X+\<7/A;X5^!]/TY+/\
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MIOCK6M'UG7=.\4P6!.GZ9_:R7&E[PKP@L&!5R3G*G\JYV/XP:Y9Z7::_J/\
MPCYT:9T:73[6Y+7\$+D ,<MM9@""5 'X8..TU;P/)K7B[5+VXDC&F7^A?V2Z
MHQ\T,9'+'&,8VOUSU[5Q-K\'=:CM;33&LO!\=K"RJVJKI:R7DD:GNCH4W$=3
MDTZ+P<M9V3=K_=K;^O06)CF=-\M)R:7-;:][^[?NK=[+>[V.BU#Q?XIO_'NL
M^'-#@TE5LH(+A;K4!(0 P.Y2$/S$DC&,8 .<Y%<1XT\::YXP^'6DWBI:6%Q'
MKBV5Y&N\JTJ2 )MY^YU)!YZ8KT[2?"=Y8_$C7?$$DD!L[ZU@@BC5F\P,@Y+#
M&,?0FN2D^$NL?\(+<Z4EU8C41K9U:!F=_*(W[@K';D'&>@-.A5PT)P>BMRZ_
M+WOQ%B\/CJM.I&\FI>TT\E)<EO57]3O[7_A(AJE@+DZ6VG?9!]K,0D$QN>_E
M@\>7]>:Q_BUX;U'Q5X/DL],1+B=9XIVM)'V)=(C9,1/8'CKQQ6Q:_P#"1'5+
M W(TM=.^R#[6(C(9A<]_+)X\OZ\U5\>>$Y/%NE6Z6MW]@U*QN4O;*Y*!U29,
MXW+W4@D$>^><8KS*<_9UX2NE;KT^9[M>G[;"5::C*5[JS=F].C>GWZ7W/-I-
M6\-7VK:'#KOA74/ 6IV]XCVE[%;QQPEQTC\T+@J>A!7'3D5J^,-:U"?_ (6C
M::=;:;9S6&GP.]YY++/-&UO*S[G4\LH!"'H,]ZOZMX1\9>-K>VTSQ'/H=MI"
MSQS7#::)7GFV'<%&\ )D@9/)_KH77@*]N]3\?S-/ L'B*QAM;?!8M&5ADC8N
M,<#+C&":]/VM%-.3U2VNVOBB]+^5]-3P%A\5).,8NS>]E&3_ '<UJEIH^5)I
M*][;(Y:Q\>ZYX?\ #OA'1%?1AJU]9K.EU=L\=M!:K&NTR9;+.>G! R*Z/PA\
M3!=7FLZ?XAN])M[G35CF-]9W&+26)S@,&8_*0V%()ZD8K#NOA3K6H:?X?NKN
M'P_=ZQI%O]A^RW<;SV5Q;A0%+;EW*X()R!WK=\&_#E[%]5DUW3?#RQ7JI&NF
MZ7IT:P*BG)W,R!G)(!P>!C@>BK/"2IMZ7\M[\W3Y?+YEX59E&M&.O*K6OM;D
MZ^?-\_+E'>-OBE9Z3X;&H:%?:9JC&[BM9+C[1YMO:[\_O)?+).T8_456T3QQ
MK\VB^(+VZ_L/4K>RL6NK74-(G+PNX1F\MT+EP1@=Q6SK7@V2QT=H?"%OI.BW
M#3+)-"]D@M[I!D&.0*N<'/4<_G7&?\*]O]#M?%VOW\&CZ8\VAW%H+'0T=86^
M4L9'W ?-P!P.A/XY45A94^72]^N^Z_KJNYOB)9A"NI.]K:VTBM'K=WOTT:3O
ML[%A?B+XPTSP[I?BC5]-TI= N3"9X+<R"ZACD(42<G:>6!V]?F SU-6=6^)6
MKWWBC5M,T.?0;&WTLK%+-KDSJT\I&2L85A@#H2<\UE>'?"7BKQGX$\,Z7JM]
MIJ^&VM[6XDDMQ)]KFB55=(F!&T8(4%@<_+GVK0UKX4WD7B;5=3TO3O#>KPZF
MXFDC\06Q=X),8;RV"G*GK@]ZZ+86,W&=N97M;;=6O?K:_P#PYQ*68SI1G2YG
M!\M[_%?E=[6UY;\NW6]M"4?&"?4O"NASZ78P/K^JWC:>MK-(3##*F?,9F'50
M #QV8>]2>(M<\6:/X5\2/XBTG1;^WM[+SX9H59K:5LX,4D3MN/KGI22?"N_A
M\,:(MI>:?#XBTJ[-]%-%9I!:L[<-&4C484K@;L;OEHU7P1XO\4:9X@_M?4[&
M.XO;#[%:Z?9R2_9(R6#&1RPR6.,9V\#BLU]54DX6Y;ZWO?XM+>5OUN;R682@
MU54G/ETMRV^#7FWUYNWE;2Y@QV>J:_\ %;P[*;71&L_["BN$MYK9V$4!>+S
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !6M;SOTL>FU#]L@^U"U\Z/[24\WR=XW[,XW;>N,\9KPCQ-\2]6\.:?/??\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ6M[73UU3ML[HYO3O!_]G^.=7\1?:_,_M"WA@^S>5CR]G?=GG/I@4>!?!_\
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img70551829_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_12.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,P,@  DI(
M @    ,P,@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( Q$,I@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M->)+#Q7HD>J:5YGD.Q4K*FUD8=0>H_(D5SOQ.L?"5[I=G_PFE_-8Q)(WV>2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  (TZZ >1KF&TDNV7)^4H&)/MOV\FN(^&]M\.[ZQ>U\8*5U-YL1M/-)'&RG
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M_F?V3J5G?>5CS/LTZR;,YQG:3C.#^1JF!=KS7XM_#VZ\66\&J:-M;4+.,QM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK'PPTO4--E\ZUN-1C:.3:5W#RY>Q (K0^!7_ "3V7_K^D_\ 04I] /+/ O\
MR6BR_P"OZ7^3UTG[0'_(Q:3_ ->K?^AUS?@7_DM%E_U_2_R>ND_: _Y&+2?^
MO5O_ $.GU$;7@7X3Z'J_A6'5O$9FO[S4D,V[SF3RMW0\'YF[DG(YZ>O >#%E
M\-?&:UL8I2QM]1>R=AT<;C&>/UKWKX>_\DZT+_KS3^5>%6O_ "7YO^QA?_T>
M:2 [K]H+_D"Z-_U\2?\ H(K0^&VJ#1/@?+J9 8VBW,JJ1D,020/Q.!6?^T%_
MR!=&_P"OB3_T$5)X,LYK_P#9YOK6V7=-)#=!%S]XY)Q^E'09P'PW\+1^/O&%
MTVNW$TL449N+AM_SS.6  +=1G))/MCOFO66^#GAZVU_3=4T8RV#65RD[0[FE
M23:P('S'(.1UR?I7FWP/UJTTOQC<6U]*D(O;;9'([!1O# A>?49_$8[U[QJ7
MB'2=(N[2UU&^BAN;V58;>$G+R,QP,*.<9XST'<T.]P.,\>>!O#NJ^((]?\5:
MVUE:1VXA\AI%0,5+'Y6//\7W0,Y^M>>^,;;X6#PW./"UTZZM$%,(7[0PE.1D
M$N-O3/3'/Y54^)MZVN?%Q]/U*\-M8PSQ6RNQRMNA"[WQT[EC_P#6KJ/'_@CP
M+X5\#S-;*HU5U7[)))=.TDA+==H.W&T-SMQ^- $W[/=U*]CKMHS?N8I(957)
MX9PX/Z(OY5Q5K_R7YO\ L87_ /1YKKOV>?\ F8O^W;_VK7(VO_)?F_[&%_\
MT>:?41],50UW_D7=1_Z]9?\ T U?JAKO_(NZC_UZR_\ H!J!GS'\//$UGX2\
M71:KJ44\L"1.A6!06RPP."0/UK=^)GQ.A\:V=KIVFV4MO9PR^>[SD;W< JO
MR  &/<YS[<Y7PNT+3O$7CB'3]9M_M-JT,C&/>R9(''*D&O?M*^'7A/1;A9]/
MT6!)4)*O(S2E21CC>35NUQ'FEGH=_P"%_P!GG6I[M6AN=0=)/*<8,<;21H 1
MZD9/T(]ZK_L_1(?$&KRG;YBVJJO'."^3^'RC]*]:\;Z3)K?@?5M/@!,LMLQC
M4#)9E^91CW( _&O!OA)XHM?"WC)_[5;R;:[A,#R,<")L@AF]N"/QI;H9]+UX
M!\?D4>,M/<#YC8 $^PD?_$U[M+J5C!8_;)[VWCM<9\]Y5"8_WB<5\T?$7Q /
M''Q W:0C3Q@)96FT<S?,<$# ZLQQGVHCN!W?B"]FC_9KTX>8Q,R0PL2>=H?(
M'T^4#Z5%^SW;Q%M>N#@RJ((QZJIWD_F0/RKL/%?A.1O@S)H-J/,N+*SB*;<G
M>T6UFQTZX;\^E>4_!SQ9:>&O%$]OJDZV]GJ$80RNV$1U.5+'L.6&>V:.@'TA
M14#WUI'9&\>ZA6U R9S( F,XSNZ55T77],\0VLUQHMVMW##,87D0$ . "0"1
MSPPY''-2!HU\P_%__DJVL?\ ;#_T1'7T]7S#\7_^2K:Q_P!L/_1$=5'<#N?$
MOQTTR\T*YM-#TZ\-S<1M%ONU15C##&<*S9//3BL/X&^'+RZ\4MKK(T=E91NB
MR$<22,,;1] 23Z<>M>H0_";P1!)O30D)QCY[B5Q^18BNMM[:"TMU@M88X(4&
M%CC4*J_0#I1== /F?XM(9?BUJL:X!=H%&?>&.O1KSX+:!8^![D,9)=6AMWE^
MVF1@-X7.-F<;>/3/O7GOQ3_Y+'J/_72W_P#1,=?1.N_\B[J/_7K+_P"@&A@>
M&? 6_D@\9WMEN;RKFS+%1T+HRX)^@9OSKOO'G@;P[JOB"/7_ !5K;65I';B'
MR&D5 Q4L?E8\_P 7W0,Y^M>;? W_ )*+_P!N<O\ -:C^)MZVN?%Q]/U*\-M8
MPSQ6RNQRMNA"[WQT[EC_ /6I]1%OQC;?"P>&YQX6NG75H@IA"_:&$IR,@EQM
MZ9Z8Y_*NC_9[NI7L==M&;]S%)#*JY/#.'!_1%_*H?'_@CP+X5\#S-;*HU5U7
M[)))=.TDA+==H.W&T-SMQ^-)^SS_ ,S%_P!NW_M6ET \]L&TL?$:9O'D5Q]E
M:ZE-VJ[@P<D\MCYL9.3CGZU[5X9\#^!+K5+/Q!X1F8&T;<%@N2ZDG</G5\L.
M_ITINJ^%/ WQ,DENK"[C%^N5DFLF"R$CC,B$<\XY(R1@9Z5Y%IYNO 'Q4AM=
M-OTOOL]W'$SP'Y+A&QE2.><,1CG##CI3W Z;X\Z]/<>(K70TD86MK")G3H&E
M;//OA<8_WFK4TGP1\,SX5AAU+7=/;4Y809+K^U$5HG(Z!0^W /J#[US7QRM)
M8/B$)G4B.XM(V1L<'&5(_3]:ZO0/@_X*\0:/;W^GZQJ4ZRQJS>7/%\C$<@CR
M\@YSP?2CH!RGP>OYM*^*(TRWF$MO=K-!(RD;7"*SJPQG/W?7^*OHRO.O"GPX
M\(:!XJ@O='UF>[U"V1W6W>[B?"D%&8JJ@X&[&?4BO1:EC"N%^*GC6'PMX9DM
M;>4?VI?(8X(U(W1J<@R$>@Z#U/T.-GQMXNMO!GAU]1N$\Z5F\NWA!QYCD''X
M#&2:^?M#MX_'_C2>^\7:Y:Z?"S>;<2SSK$7'01Q[CZ<>P]>XD!T'P4\'3:EX
M@7Q#=QLME8D^2QZ2S8QCZ*#GZX]Z^@JYW3O$7@W3+&"PTW7-&@MX5"111WL6
M /\ OKD^_4FNBH8&9XCT2#Q'X=O=(NFV1W4>S>%SL;JK8[X(!_"OFK4]!\5?
M#;6_M \^T924BOK?)CE![9Z<_P!T_E7TSK&MZ=H%A]MUBY6UMMZQ^8RDC<QP
M.@-/6YTS5K!RD]I>VCIER'62-E]^HQQ0G8#RSP'\:?[3OXM,\5I%!+,P2*\B
M&U"QZ!QVSTR./7'6G?&OP=IS:5<^*O-N1?+Y4/EAU\HC.,XQG.#ZUY9X\MM(
MM_'6H0^&FCDL/,7RQ"=RABHW*I[C=G&..PKVSXL17"_!^1;K+SQ_9_.;K\VY
M023]:?4#SGX7?#K2?&VGW\^JW%["UM*J(+9T4$$9YW*:Z7XZ6D>G^%?#UG!N
M\JW<Q)N.3M5 !G\J?\ ;F"+1M;$LT:%)4D8,P&U=I^8^WO4GQ_\ WGA_1I4(
M:/[0^&!R#E,C^5'41T'P6_Y)E:?]=IO_ $,UY+\4_P#DL>H_]=+?_P!$QUZ?
M\&-6T]/AP(I+R&-[2:4SJ[A?+!;()SVP1ST_*O'_ !OK5KX@^)E[J6GL7MI9
MXEC?&-P153=]#MS^--;C/7_CEK$FG^!X[*!F5M0N!&^.\:C<1GZA?PS7*?"C
MX::/XC\.W&K>(87N!+*T-O&)&0(%QE\J1DY)&#P,=\\;WQ^M)9/"^FW2*3'#
M=E7('3<IP3_WS5OX'ZO:3^ WL1*BSV,[F5&89"M\P?Z<D9]C2Z >1?$3P@G@
MOQ4VGP3F>VFB%Q 6^\J%F&UO<%3R.O!XZ5ZY\1_#RZU\(;2[C0M<Z9:Q7$9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *YGQYX-7QQX?CTUKTV1BN%G641>9R%9<$9'9CWKIJ* .8\!>#1X'T
M"731?&^,MRTYE\KR\955QC)_N^O>NGHHH YCQ[X-'CC0(M--\;$Q7*SB7RO,
MSA67&,C^]Z]JD\#>$5\%>'?[+6\-X3,TS2F/R\DX& ,GL!WKHZ* /-?!GP?3
MPCXHBUC^VFO/)1U2'[+Y?WACEMQ[$]JZ'QSX#T_QQIT<5U(UM=P$F"Z1=Q3/
M4%<C<#@<9'3KUSU-%.X'S^_P"\1B7$>I:6T>?O,\@/Y;#_.O0_A_\+;+P9,=
M0N9_MNJ,A3S-N(X@?[@ZY(X)]..,G/>T478&1XI\.6WBOPW=:1>,8TF *2JH
M+1N#D,,^XY]02.]>,)\ =?-T%?5--%OGF0&0OC_=VX_6O?J*+V ;&GEQ(FYG
MVJ!N8Y)]S[UG>(]%7Q%X<O=)>8P+=1[#(%W%><YQWZ5IT4@.$^'_ ,,QX%O[
MRZ_M8WYN8A&%^S^5MP<Y^\V:[NBB@#+\2Z*/$7AN^TEIS;B[BV>:$W;.<YQD
M9Z>M<Y\/OANG@2:^E_M-K][M47_4>4$"Y/\ >;/6NWHH XSXA?#U?'J:>#J1
ML&LC)@^1YH</MSQN&/NBM?0/#$&C>#(/#MS(+Z!(7AE9DV"56)W#&3@?,1UK
M<HH \+U;X ZC_:+'0]4M&LV8E1=EE=%[#Y5(;Z\5IGX 6CZ1;Q#6FBO@Q:>?
MR-ZL"!\JKN& #GGJ<U[#13NP./\ $7@%-=^'UEX:%^T)L8X5CN/+SO,:;1E<
M]#]:\O\ ^% ^(OM&/[3TSR<_?W2;L?[NS'ZU] 4478',^!O ]EX'TF2UM96N
M;B=@]Q<L@4R$<  =@,G R>I]:Y3QQ\&8/$6K2ZKHEY'87,Y+3PR(3'(YZOD<
MJ3WX.>OU]1HHN!\_1? +Q(7Q-J6EHOJDDC'\M@KV/P7X:'A+PG::09A/)#N:
M24# 9F8L<#T&<?A6]11>X!7G7CKX3+XT\1+JJZR;$^0L1B-KYN2"><[U]>GM
M7HM%(#Q7_AGG_J9__*?_ /;*Z_X?_#,>!;^\NO[6-^;F(1A?L_E;<'.?O-FN
M[HIW8!7F?Q"^$K^+]:.KV&IK;W+1JCPSQY0XZ$,.1^1KTRBD!X#:_ 'Q ]PH
MO=4TV*$GYGB:21@/92J@_F*]:\%>"=.\$Z2]K8%IIYB&N+EQAI2,XX[ 9.![
MGUKI**=V!Y-XZ^"[:]K4^J^'KR"UFN6WSV]QN"%R>6# $C/4C!Y^O%'2/@$H
MTVY&MZHGVV1-L)MD+1PG(.XYVECU&.!S7L]%%V!S'@+P:/ ^@2Z:+XWQEN6G
M,OE>7C*JN,9/]WU[U@7/PCCN?B&OBC^V74+>)=FU^S Y96#8W[NF0.U>C447
M KWUC;:G8365_"L]M.A22-^C _YZUXKK'P!OA>.V@ZM;/;L242\#(R#/W<J&
MW<=\#Z5[E11>P'A.D_ 76([^"75-4L5BCE5G6#>Y90<D<JN#7LOB#1+;Q'H%
MWI-Z6$-TFTLN,J<Y!&>X(!_"M&BBX'@+_ '7Q=%4U333;YXD)D#X_P!W;C]:
M]UTZT_L_2[6S\PR_9X4B\QA@MM4#/XXJS2-N"G8 6QP"< GZT7N!\K_$2SM(
MOB7JUMH^7C>Y^[CI*P!=1[;RPKZ6\.:.F@>&M/TJ/;_HL"QL5)PS8^9N?5LG
M\:\P\,?![6K3QO!KOB34+*=8K@W3"W=W>27)8$EE&/FP>_\ 6O8J; ****D
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7C'PW+I,UR]KN=9$E50VUATR.X_$5X[/\ ?$2S$6NIZ9)'V:1I$)_ (?YU]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:FH **** "BBB@ HHHH ***SM8U_2?#]L)]:U""SC;.WS7PSXQG:O5NHZ T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5S\'A#X>^$[9;>_M])1F4$R:J\;NXSC/[SISZ "O/F_L;0?CMHS^#KNW>QO
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MPZT31_#LFNZ)$;"2-T26",DQRAB!T)^4CCIQQT[T]+@>@?#/_DFNB?\ 7O\
M^S&M+0/%6B^*$N'T&]%VMNP64B-UVD]/O 9Z'D5F_#/_ ))KHG_7O_[,:X3]
MGO\ X\==_P"ND/\ )Z0'JVLZUI_A_2Y-1UBX%M:Q%0TA4M@D@#A02>3V%2Z;
MJ-IJ^FP7^G3":UN$WQR!2-P^AY'XUQ7QI_Y)E=_]=H?_ $,5J_#/_DFNB?\
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MCD <=RC9/^[7L5>+W$@M/VHXW^;$P56 QWM=H_4"D@/:****0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M["XCN+>5[9DEB8,K#[2>A%>MZWKNF^'--;4-9N1;6JL%+[&;D]!A037AFO\
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M<C&:Z#1_"^FZ'X:_L*P61;,HZMO?+-NSN.?7FA@>?_ #_D5]4_Z_!_Z *O\
MQU_Y)[%_U_1_^@O74^$/!NG>"M-GL]*DN94GE\UWN7#-G &. !CCT[U+XK\*
MV/C'11IFJ23QPB590UNP5@P!'<$=SVHOJ [0;:&]\"Z;:W48E@GTV*.1&Z,K
M1 $?B#7A>F^(9_A_:^,_"\\C;F5DM W(WEA&6&.A,;!O^ #Z'Z%L+./3M-MK
M*$LT=M$L2%SDD* !GWXKQ'QUI5AXL^.MCI5DF[<L::@\; ;MN6?GU$8"_4 8
MXY: ]!^$^@+H7P_LF>()<WR_:IC@9.[E!^"[>#W)KM:;'&D4:QQ*J(@"JJC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\5^&W_)>?%G_ &^?^E25[57,:+X"TK0O%VH>(K*:[:[U 2>;'(ZF,;W#MM 4
M'J.Y-=/38'C<_P#R=+;_ /7,_P#I(U;'QTTF2^\#PWT"%S87*O(<_=C8%2<=
M_F*?K73MX%TQ_'R>+C/=_;T7:(]Z^5_JS'TVYZ'UZUT<L4<\+Q3(LD<BE71Q
MD,#P01W%%P."\#6O@CQ-X9L9;?1]%EO%MU%S";2(R(X #$C&<9[]\BM9;?P)
MIOB*SL(;+1(-6D<_9XX;6/S5903GY1E.AP3CD8'-8FH?!#PE?7+S0B^L0QSY
M=M.-H^@=6Q6MX;^&7AKPO>)>6-K)-=H/DGN7WLO&"0. "?7% '&_'/6=0@DT
MK1HKA[33KT,UQ(H.),,!@GN #DCW&>U:TGPU^&VB:*MWJJI);[-XN[B^<>8,
M9R-C -GMM'.>*[3Q%X8TGQ5I_P!CUNU$\:G=&P)5HVQU4CD?R/?-<?9? [PG
M:7JW$C7]VJG(@GF78><\[5!/YT7 YCX$>3_PD7B'[+_J-J>7U^[O;'7GI5GQ
M_P#\E^\*_P#7.V_]'R5Z#X>\#Z5X8UG4M2TLSJ^HMNDA8KY<?S$X0!1@<],F
MC5? ^EZSXOT_Q'=O<B\T]56)$<"-MK,PW#&>"QZ$4[Z@9_Q;C>7X5ZPL:EB%
MB; ]!,A/Z U4^%>N:6GPQTM9K^VA:$O#(LLJJ5?S&(')[@@_B*[FZM8+ZTEM
M;R%)X)E*21N,JP/4$5Y_%\#_  G%J*W2MJ!57#"W,X\O@@X^[NQQ_>[TN@&-
M^T%_R!=&_P"OB3_T$5ZKIW_(+M/^N*?^@BL;QAX)TWQM9VUOJLMU$MM(71K9
MU4Y(P0=RGBN@CC6&)(XQA$4*HST HZ >1_\ -T'_ &[_ /MO74_%GP\NO> +
MQECWW5@/M4)&,C;]\?0INX]0/2M,^"=-/CL>+/-NA?B/R_+WKY1&S9G&W.<>
M];EY+;PV,\M\T:VJ1LTQD^Z$ RV?;&: /GBY\0S^/-%\'>$DD=IUEV7;'V.Q
M&SWQ'N)[_P!?HFVMX;2UBMK6-8H84$<<:C 50, #V KQ'X(:%;WWBC5/$"0%
M;>U)CLPYY0OG/3N$X_X%7N5# *\-U^P3XE?'"71Y)I5T_386BE>%AN4(/FQD
M$ ^8P7GT_"O<JYCPIX!TKPA>7MUI\UY<7%Z1YDMW*'8<D\$ =2<G.30@.7_X
M4'X7_P"?_5_^_P!%_P#&ZXS6M"A^$OQ-T.]L)[F33I,,TD^TMC)25<@ '"L#
MVZCZU]!5SWB_P3I7C6R@M]6,\?V=R\<MNX5ER,$<@C!X[=J+@<=\>M-FNO!]
MG?0AF2SNOWH"_=5QC<3V^8*/^!5U?A#Q?I&L^$K2\2_AC,<*I<++(J-$ZC#9
M&>!QG/I6U%I-JNA1Z3<*;NU2W6W87 #&10NWYN "3CTKA9O@9X2DO#,C:A#&
M3G[.EP"@]LE2WZT <7XL\3Z;XF^-7AJ31IOM$%K=6T#3 85V\_)V^HY'/?G'
M')] ^,ME)>?#2]:+G[/+',P]5#8/_H6?PJ]/\,_#KW>BSVD$EA_8TPF@CMF
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5RVB_#[2M#\67OB*&>[N+Z\,A<W#(RH7;<2H"C'I
MUZ<5U-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53U;2[;6M(
MNM-OTWV]U$T;C R 1U&>A'4'L0*N44 9'A?PW:^$]#CTJPGN9[>-V9#<N&9=
MQR0, #&<GIW-:]%% !1110 4444 %%%% !1110 4444 9^O:/#X@T.ZTJZFF
M@ANDV.\! <#() )!'.,=.AIOA_0;+PUH=OI6FAA;VX(#.068DY+,0!DDFM*B
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?]"=XM_\%?\ ]G18#MZ*XC_A9B?]"=XM_P#!7_\ 9T?\+,3_ *$[Q;_X*_\
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M;_XBC_A:/@[_ *#'_DK-_P#$4>SGV#V-7^5_<=;17)?\+1\'?]!C_P E9O\
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M.9=A8 E=Q X!HL!Z/13(9H[B".:%@\<BAT8=&!&0:?2 **** "BBB@ HHHH
M**** "BBL_Q!J$ND^&=4U&W5&FL[.6>-9 2I9$+ '&.,B@#0HKSO3=7^).J:
M5::A;IX56*[@2=%<7(8*RA@#@GG!JS]I^)WIX2_\F: .[HKA/M/Q.]/"7_DS
M1]I^)WIX2_\ )F@#NZ*X3[3\3O3PE_Y,T?:?B=Z>$O\ R9H [NBN$^T_$[T\
M)?\ DS1]I^)WIX2_\F: .[HKA/M/Q.]/"7_DS1]I^)WIX2_\F: .[HKC_!GB
M'7M3U[7=)\2QZ<L^E_9\-IZR!6\U6;JYR> .P[]:["@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***JZGJ$6E:1>:C<*[0VD#SR+& 6*HI8@9QS@4
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M;_XBC_A:/@[_ *#'_DK-_P#$4>SGV#V-7^5_<=;17)?\+1\'?]!C_P E9O\
MXBC_ (6CX._Z#'_DK-_\11[.?8/8U?Y7]QUM%<E_PM'P=_T&/_)6;_XBC_A:
M/@[_ *#'_DK-_P#$4>SGV#V-7^5_<=;17)?\+1\'?]!C_P E9O\ XBC_ (6C
MX._Z#'_DK-_\11[.?8/8U?Y7]QUM%<E_PM'P=_T&/_)6;_XBC_A:/@[_ *#'
M_DK-_P#$4>SGV#V-7^5_<=;17)?\+1\'?]!C_P E9O\ XBC_ (6CX._Z#'_D
MK-_\11[.?8/8U?Y7]QUM%<E_PM'P=_T&/_)6;_XBC_A:/@[_ *#'_DK-_P#$
M4>SGV#V-7^5_<=;17)?\+1\'?]!C_P E9O\ XBC_ (6CX._Z#'_DK-_\11[.
M?8/8U?Y7]QUM%<E_PM'P=_T&/_)6;_XBC_A:/@[_ *#'_DK-_P#$4>SGV#V-
M7^5_<=;17)?\+1\'?]!C_P E9O\ XBC_ (6CX._Z#'_DK-_\11[.?8/8U?Y7
M]QUM%<E_PM'P=_T&/_)6;_XBC_A:/@[_ *#'_DK-_P#$4>SGV#V-7^5_<=;1
M7)?\+1\'?]!C_P E9O\ XBC_ (6CX._Z#'_DK-_\11[.?8/8U?Y7]QUM%<E_
MPM'P=_T&/_)6;_XBC_A:/@[_ *#'_DK-_P#$4>SGV#V-7^5_<=;17)?\+1\'
M?]!C_P E9O\ XBC_ (6CX._Z#'_DK-_\11[.?8/8U?Y7]QUM%<M;_$KPC=7,
M<$6L+OD8*N^"1!D^K%0!]2:ZFI<6MT1*$H_$K!1112)"BBB@ HHHH **** "
MBBB@ HHHH **@OKG[%I]Q=;-_D1-)MSC=@$XS^%<9_PLG_J%?^3/_P!C7/5Q
M-*BTJCL93JPINTF=U17"_P#"R?\ J%?^3/\ ]C1_PLG_ *A7_DS_ /8UC]?P
MW\WX/_(CZS2[_F=U17"_\+)_ZA7_ ),__8T?\+)_ZA7_ ),__8T?7\-_-^#_
M ,@^LTN_YG=45PO_  LG_J%?^3/_ -C1_P +)_ZA7_DS_P#8T?7\-_-^#_R#
MZS2[_F=U17"_\+)_ZA7_ ),__8T?\+)_ZA7_ ),__8T?7\-_-^#_ ,@^LTN_
MYG=45PO_  LG_J%?^3/_ -C1_P +)_ZA7_DS_P#8T?7\-_-^#_R#ZS2[_F=U
M17"_\+)_ZA7_ ),__8T?\+)_ZA7_ ),__8T?7\-_-^#_ ,@^LTN_YG=45PO_
M  LG_J%?^3/_ -C1_P +)_ZA7_DS_P#8T?7\-_-^#_R#ZS2[_F=U17"_\+)_
MZA7_ ),__8T?\+)_ZA7_ ),__8T?7\-_-^#_ ,@^LTN_YG=45PO_  LG_J%?
M^3/_ -C1_P +)_ZA7_DS_P#8T?7\-_-^#_R#ZS2[_F=U17"_\+)_ZA7_ ),_
M_8T?\+)_ZA7_ ),__8T?7\-_-^#_ ,@^LTN_YG=45PO_  LG_J%?^3/_ -C1
M_P +)_ZA7_DS_P#8T?7\-_-^#_R#ZS2[_F=U17"_\+)_ZA7_ ),__8T?\+)_
MZA7_ ),__8T?7\-_-^#_ ,@^LTN_YG=45QMC\0/MNH6]K_9FSSY5CW?:,[<D
M#.-OO795T4J].LFZ;N:0J1J*\6%%%%;&@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 445YU:>)/'>MZCK T2/PZEII^I3V*_;%G$C
M;#P3M)'0CTYSQ0!Z+17"_:?B=Z>$O_)FC[3\3O3PE_Y,TP.ZHKA?M/Q.]/"7
M_DS1]I^)WIX2_P#)F@#NJ*X7[3\3O3PE_P"3-'VGXG>GA+_R9H [JBN%^T_$
M[T\)?^3-'VGXG>GA+_R9H [JBN N+[XG6]K+,(?"TQC0OY<8N2SX&<#)')KJ
MO#&NP^)/#5EJL& +B,%T'\#CAE_ @BD!JT444 %%%% !1110 4444 %%%% !
M1110 445P-[XD\8WOC;6]'\-QZ&+?2_(RU^LV]O,CW=4.#R#V';K0!WU%<)]
MI^)WIX2_\F:/M/Q.]/"7_DS0!W=%<)]I^)WIX2_\F:/M/Q.]/"7_ ),T =W1
M7"?:?B=Z>$O_ "9H^T_$[T\)?^3- '=T5PGVGXG>GA+_ ,F:/M/Q.]/"7_DS
M0!W=%<)]I^)WIX2_\F:99>)/&-EXVT31_$D>AFWU3S\-8+-O7RX]W5S@<D=C
MWZ4 =]1110 4444 %%%% !1110 4444 %</XN_Y*AX'_ .W_ /\ 1*UW%</X
MN_Y*AX'_ .W_ /\ 1*TT!U-%%%( HHHH **** "BBB@ KD/B!_K/"G_8R6?_
M +-77UR'Q _UGA3_ +&2S_\ 9J: [ZBBBD 4444 %<1\3/\ 5^%?^QDM/_9Z
M[>N(^)G^K\*_]C):?^STT!U%%%%( HHHH **** "BBB@ HHHH YGX0?\DIT?
M_MO_ .CY*[6N*^$'_)*='_[;_P#H^2NUIO< HHHI %%%% !1110 4444 %%%
M% 'AWQJ_Y'2T_P"P>G_HR2O.J]%^-7_(Z6G_ &#T_P#1DE>=5Z=+X$?0X;^#
M$**<K%'##&5.1D C\CUKU'XD:/I5QX)TCQ#HFG0V:R%=ZV\"H-LB9R^T=BH'
M7^+WIRE9I=RIU%"48OJ>645Z7\*=!TZ:QU?7-<M(+BTM4\M1<1AU&!O<X;C(
M&WGW-<KX8TT>)_'EK ($C@GN3-)$B_*D8)9E Z 8&!^%+G5WY"]LKR7\ISU%
M>V^,- \/ZSX-UB70+"RM[K2)F#O! L9W1@%U)4<C:3[9 ]*\U\"ZAIFG^*H#
MKEI:W-E.##)]JC#K%DC#X((X(Z^A-*-3FBVD3"MSP<DMNASE%>OZI\,DF^)E
MJUM;!-&G'VB940!(RN,QX P 3MP/0GTKCOB1>Z7/XJDM-#L;6TM[',+FW@6/
MS) ?F)P!G!X'T/K1&HI.R"%>-1I1[7]#D:*FM3 MY";M6:W$BF54^\5SR![X
MKU7PQXB\':UX@@T*V\'6L4$RE(KB9$DD)"Y^;()['G<>Q^E2DXZV+J5'!72N
M>245V/Q-\/V/ASQ:L&EH8H+BW6?RLY"$LRD#V^7/XUU_P]\+Z18:+8W7B&P@
MNKW6I2MK%<1!PL84MG!R!D*3GW4=ZEU$H\Q$J\8TU/N>/T5U'Q'L[:P^(&I6
MUC;Q6\">5MBB0*JYB0G ' Y)-'PXL[:_^(&FVU];Q7$#^;NBE0,K8B<C(/!Y
M -5S>[S&GM%[/VGE<Y>BNH^(]G;6'Q U*VL;>*W@3RML42!57,2$X X'))K(
MT?0-4\07#PZ/9273QC+[< +Z9)P!T/UIJ2<>8<9IP4WHC.HKH-6\#>)-$LS=
M:EI4L<"_>D1UD"^YVDX'N:J_\(QK'_"-_P!O_9/^)9G'GB5./GV?=SN^]QTH
MYH]P52#5TS)HK8M/"FM7V@S:S:V7F6$(8R3>:@VA>ORDYX^E-TSPQK&L:;=7
M^FV33VUH"9G#J-N!DX!.3QV&:.9=Q\\>YDT45[3?2:#X6^&^A:K/X7T[49;B
M&WC??"BL6:(L6+%#DY7]:4Y\MM#.I5Y+)*]SQ:BO8+/2/"7Q+T>[.BZ>NC:I
M;8X1 JC.=IPORLIQ@\9'\_+K+0]2U+56TVQLY9[M"0T2#[N#@Y/0 'N>*49I
MWOI8(5E*Z>C6Y0HKI;[X>^*M.LVNKK1Y1$@RQC=)"!Z[5)/Z5E:/H6IZ_=FV
MTBT>ZE4;F"D *.F23@#\:KFBU>Y:J0:NGH9]%;.M^$]<\.1QR:S8/;1RL51]
MZNI.,XRI(!_P/H:L:5X$\2ZU8I>:=I;R6[\H[2)&&]QN(S1S1M>X>TA;FNK'
M/45<U32;_1;YK/5+62VG49V..H]0>A'N*IT]RDTU=!1113&%%%% $MO<36ES
M'<6TK131,&21#@J1T(->]?#_ .($/BBV%CJ#+%JT2\CH)P/XE]_4?B..G@%2
MV]Q-:7,=Q;2M%-$P9)$."I'0@UG4IJ:,*]"-:-GN?6-%<1\/_B!#XHMA8Z@R
MQ:M$O(Z"<#^)??U'XCCIV]>=*+B[,\&<)4Y<L@HHHJ2 HHHH **** "BBB@#
MQK7/^1AU'_KZE_\ 0S5&KVN?\C#J/_7U+_Z&:HU\94^-^IX$OB84445F2%%%
M% !1110 4444 %%%% !1110 4444 %%%% !7<_#;_F)?]LO_ &>N&KN?AM_S
M$O\ ME_[/7=@/]YC\_R9T8;^*OZZ'=4445]2>R%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<1\3/]7X5_P"QDM/_ &>NWKB/B9_J_"O_ &,EI_[/30'4
M4444@"BBB@ HHHH **** "BBB@ J"_LX=1TZXLKE=T-Q$T3CU##!_G4]% '.
M_#*_FE\*'2KYLWNBSO83>X0_(?IMP/PKL:X*W;_A'_B[C[MIXCM?H/M$(_JG
MYDUWM, HHHI %%%% !1110 4444 %8OC3_D0M?\ ^P9<_P#HIJVJQ?&G_(A:
M_P#]@RY_]%-0!2\'_P#(CZ%_V#K?_P!%K6Q6/X/_ .1'T+_L'6__ *+6MB@
MHHHH **** "BBB@ HHHH Y7PC_R5#QQ_VX?^B6KN:X;PC_R5#QQ_VX?^B6KN
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%\9_P#(AZ__ -@RY_\
M135M5B^,_P#D0]?_ .P9<_\ HIJ *7@__D1]"_[!UO\ ^BUK8K'\'_\ (CZ%
M_P!@ZW_]%K6Q0 4444 %%%% !1110 4444 <S\(/^24Z/_VW_P#1\E=K7%?"
M#_DE.C_]M_\ T?)7:TWN 4444@"BBB@#S_X3_P#)+])_[;?^CGKL:X[X3_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K@?A_P#ZSQ7_ -C)>?\ LM=]7 _#
M_P#UGBO_ +&2\_\ 9:8'7T444@"BBB@ HHHH **** "N0\,-_P (Q\0-2\//
M\MCJH.H6 [*__+6,?^A8[ 5U]<KX_P!/N)-%BUC3%SJ.BRB\@Q_$J_?3Z%>W
M? I@=S15/2-3M]:T>TU*S;=!=1+(GMD=#[CI5RD 4444 %%%% !1110 4444
M %%%% !7!Z#_ ,E6\;_]N'_H@UWE<'H/_)5O&_\ VX?^B#0!UM%%% !1110
M4444 %%%% !7):]_R5;P1_V__P#H@5UM<EKW_)5O!'_;_P#^B!0!WE%%% !1
M110 4444 %%%% !1110 5P_B[_DJ'@?_ +?_ /T2M=Q7#^+O^2H>!_\ M_\
M_1*TT!U-%%%( HHHH **** "BBB@ KD/B!_K/"G_ &,EG_[-77UR'Q _UGA3
M_L9+/_V:F@.^HHHI %%%% !7$?$S_5^%?^QDM/\ V>NWKB/B9_J_"O\ V,EI
M_P"STT!U%%%%( HHHH **** "BBB@ HHHH YGX0?\DIT?_MO_P"CY*[6N*^$
M'_)*='_[;_\ H^2NUIO< HHHI %%%% !1110 4444 %%%% 'AWQJ_P"1TM/^
MP>G_ *,DKSJO1?C5_P CI:?]@]/_ $9)7G5>G2^!'T.&_@Q"O6_ FWQ5\*]6
M\-OL:>VW>2IR,;OGC)/_ %T#=.W;U\DKHO!?BZ;P?K$EY';FZBEB,<D'F[ W
M((.<'D8].Y]:*D7*.FX5X.</=W6J.W\0R_\ "'_!O3]'4;;S5%S+D\J#\[_7
M&53\:7X+:&X%_KLB*>/LUON)&3PS'Z?=&?K7%>-O&,OC+5(+E[;[)%!%Y:0^
M9OYR26S@=>/RJS)X[(^'B>%K73_LXX\RY$^3)\^X_+MXR??IQ6?)+DMU>Y@Z
M51TN7K)ZGJ7@?PMKN@ZAJTFNW%G<PZDWFN()7.)"3D[64#!#')SG@=>WC.H>
M&[NV\93^'[6-Y)Q<F&$'DLI/RL<?[)!/I4'A[6I?#WB"TU6WC65[=R=C' 8$
M%2,]N">:ZL?$BR_X39O$K>'5,YMA"L?VH</G!DSY?7;A?89]>&HSC)M:CC"K
M3FVM;KTU/7;2YM+%K3PN;YS?K8 JY(W%5 3=_O=_P/I7@UOH6GZ9XSFTGQ==
MRV=K;,ZR30H2S<?(1P< Y!Z'BHYO%E]+XW/B5?EN?M'FJF> HX"9QR-ORYQS
M5GQMXOB\87UM=II8L98D*.PF\PR#.1GY1TY_.E"G*+]14:,Z;MT:U\F2>*-/
M\%VNEQOX5U>\O;PS /'.A"B/:V3S&O.=O?O77^#=!L_ NAOXL\6(8KDC;:VY
M&77(X 7^^W/'89SCG'EVG72V.J6MW)")UMYDE:)C@2!6!VGZXQ7I%]\8+#4T
M1=2\'VUXJ'*BXN%D"GVS'Q3G&5N5:HJK"IRJ$;M==KF#IUT_Q!^*5K)JV%BN
M)<^3N)5(T4L(QGU"\],DD\9KU&Y\,ZY>?$BQUN::Q32[ ,D$".WF!2A!.-N,
MDGUX %>.>*_$6G>()+5M,T"VT;R0P<6Y7][G&,X5>F#Z]:J>&=;_ .$=\1VF
MJ_9_M/V<L?*W[-V5*]<''7THE!M76FFPIT92C>.FEK'4_%[1+FQ\7-JDSQ&#
M4L>2JD[E\N.-6W#&!R>,$UG?"W_DI6E_]MO_ $2]9'BC73XE\276K&W^S?:-
MG[K?OV[4"]<#/W?2CPOKI\->)+75A;_:?L^_]UOV;MR%>N#C[WI5<K]GR];&
MJA+V'(][&O\ %+_DI6J?]L?_ $2E=EX?N9O#_P "9]3T7 O9'=W<#<4)E$9;
M'L@!_6LFZ^*6BWUR]Q>^!K"YG?&Z6:1'9L# R3%D\ "LCPU\1;GPY)>6Z6,5
MSI=S*T@LG?'E;NRMCIC ((QQVYJ'&3@E;:Q@X5)4XQ<=K=M;':?";5M0U_3-
M8L]=FEO[50BAKEB^0P8.I8]1C'%4OA>PUWP'KOAQI'60AC&S<A1(F!@9[,I)
M''7WK%U7XJSS:&^E^'](M]$AD!#&!@2H/7;A5"D\\X[]CS7.^#O%,OA'7O[1
MCMQ<JT3121%]FY3@\'!QR >A_K2]G)INUA.C.49NUF[67H>S>&$M-(\/Z)X7
MOXD$NHV,LCHQ'S'AF0@]20[?]\GM7+7-O+X)^"UU:S#9>ZA=26\F,D9+%3CV
M,<9].M<OJ7Q&NK[QU8^(X[,1"R01I:M*6!4Y#?-@<D,><>G7%1^./'\WC*.T
MA^Q"R@MRS%!+YF]CQDG Z#^9I*G*ZOZLF-"IS*^SU?KJ<A7K?C[_ )(OX9_[
M=?\ TG:O)*]'MOBI9KX>L-)U+PM;ZC%9PQQCSYPRL47:&VF,X.,_G6M1-M-+
M8Z:\9-QE%7LRS\$[&X_M?4=1.Y;5+?R22#M9RP;KTR O_CU;/@FYCC\/>,O$
M&D*)KJ2[N)(L@_,JJ7C^7ZN>.IZ5R6N_%.]U'1_[,T;3X='M678XA;+;>RJ0
M %&..!^58_@_QK?^#[R1[5%N+:;'G6\AP&QT(/8_YQTQFX2E=LQE1J5%*36K
MMIZ';?";Q+K>K>);VWU*]N+RW:!IB96+"-]RXQ_=!!/ XJKX8\3Z/X6\4^*-
M+O\ =96ES=R)#<6Z$F(*[J!P"< 'C X_&JUQ\7&@L+B#P]X?M-)EG)+2QL&^
M8]6VA%!;W.?QK%\+^-X]"L[RTU/1K?68;N43/]H;DM[DJP/.#TZYHY&[NPG1
ME+F;C:]M+_TCI_%OAR^32;"Y_P"$EDUGP[+>1N[7<@9H=V%W>9GE>3D#&,].
MIKL?&EQHEB+&#5O$6J:''L(ACTXL@<# Y*HQXR.,X]J\K\5?$&;Q#I,6DV.G
M0Z5IT9!,$)#;L=!P   >< 5I6GQ6,NE0V7B3P_9ZUY&-DDI Z#&2&5ANZ\C'
M7I4NG-I-DNC5:BVMK]O^&)/BAXDT#Q#I^F?V/?->75LS*[M"Z$J0.22H!Y Z
M#UZ5YQ71^+O%S>*IK;9I\&GVUJ&$4,/.-Q!))P!V'85SE=%./+&QV48<E-1"
MBBBK-@HHHH **** );>XFM+F.XMI6BFB8,DB'!4CH0:]Z^'_ ,0(?%%L+'4&
M6+5HEY'03@?Q+[^H_$<=/ *EM[B:TN8[BVE:*:)@R2(<%2.A!K.I34T85Z$:
MT;/<^L:*XCX?_$"'Q1;"QU!EBU:)>1T$X'\2^_J/Q''3MZ\Z47%V9X,X2IRY
M9!1114D!1110 4444 >-:Y_R,.H_]?4O_H9JC5[7/^1AU'_KZE_]#-4:^,J?
M&_4\"7Q,****S)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KN?AM_S$
MO^V7_L]<-7<_#;_F)?\ ;+_V>N[ ?[S'Y_DSHPW\5?UT.ZHHHKZD]D**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *XCXF?ZOPK_P!C):?^SUV]<1\3/]7X
M5_[&2T_]GIH#J****0!1110 4444 %%%% !1110 4444 <G\1;.9O#2ZK8KF
M\T:=+^''<(?F'TVY/X5V>GWT.I:;;7UJVZ&YB66,^JL,C^=5I8DGA>*90\<B
ME64]"#P17-?#*=[73-1\-W+EI]#NV@7/5H6):-OQ!/Y4P.VHHHI %%%% !11
M10 4444 %8OC3_D0M?\ ^P9<_P#HIJVJQ?&G_(A:_P#]@RY_]%-0!2\'_P#(
MCZ%_V#K?_P!%K6Q6/X/_ .1'T+_L'6__ *+6MB@ HHHH **** "BBB@ HHHH
M Y7PC_R5#QQ_VX?^B6KN:X;PC_R5#QQ_VX?^B6KN: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K%\9_P#(AZ__ -@RY_\ 135M5B^,_P#D0]?_ .P9
M<_\ HIJ *7@__D1]"_[!UO\ ^BUK8K'\'_\ (CZ%_P!@ZW_]%K6Q0 4444 %
M%%% !1110 4444 <S\(/^24Z/_VW_P#1\E=K7%?"#_DE.C_]M_\ T?)7:TWN
M 4444@"BBB@#S_X3_P#)+])_[;?^CGKL:X[X3_\ )+])_P"VW_HYZ[&F]P"B
MBBD 4444 %%%% !1110!REM_R70_]BW_ .W-=U7"VW_)=#_V+?\ [<UW5, H
MHHI %%%% !1110 4444 %%%% 'G?QJ_Y$NT_[""?^BY*\-KW+XU?\B7:?]A!
M/_1<E>&UZ%#X#V\%_!"O1/@WJXL_%,^FRE1'J$.%!!Y=,D#_ +Y+]?:O.ZN:
M5J,VD:O:ZA;$^9;2K(!G&[!Z'V(X/L:TG'FBT=-6'M(.)[#H&CI\/+'Q7K$\
M:[892EJA8X:,<H,GGDNH/N/SX/X=:1+XC\>PSW/[Q+=S>7#M_$0<C\2Q''IF
MK?C+XG2^+-$738]-^PIYHDD;[1YF\ '"XVC'.#^%4/!GC@>#K:_6+31<W%V%
M"S&;;Y> <<;3GDY[5DHSY6^K.6-.JJ<I->\SU.Z\,>()?BA!XCBN+,6,*B 0
MF9PYBVD,"-N"=S%@,XSCZUY[\7]'.G^,A?(I\K4(A)DD8WK\K ?@%/\ P*N#
M9F=RSL69CDDG))KN-<^(T'B.#25U;0DEDL)EED<7'$X ^9,%#M5B%)Y/ Q[@
M4)1DGN$:-2G.+6JM;L=_X&6/P5X%L3KL[0OJ-TI2.3CRVDP%7GIP-Q].:X'X
MJ:+-8^.FN[J5C;:EMD28KG9@!67WVX!^A%9?C;QI-XRO;60VOV.WM8RD< D#
MX8GYFSM'4!1C_9J[KOQ#;Q#X.@T;4-,#W4(3%\9LG<O!;;MZD9!Y[THPDI<W
M?<5.E4A-5'N]_(L:CI/PVCTNZ?3O$&HRWBPN8(WC(5Y-IV@_NAP3CN*/AWX)
M75YCK6N((M%M 7+2G:LQ7D]?X!@Y/X>N.#KTG3?BQ;67ANUT:X\-174$,"PN
M'N1MEP.25,9')Y[U<E-1M'4TJ1J1A:#;O_7D9/Q$\;CQ7J,=O8!DTRT)\H'(
M\UNF\CMQP!U )]<#T+Q%X%U6[\(:=X=\.S6,%E"H:Y>9V#3..<_*IXSDGUX]
M*\\\0>,]%UC19;*Q\(6.F3N5*W4)3<F"">D8/(XZ]ZXVDH-I6TL)49.,4O=M
M\SVKXQZ%<W?A^RU*-XA#I883*Q.YO,:-1MXP>1SDBO%:ZSQMXW/C%-/7^S_L
M8L@X_P!=YF_=M_V1C[OZUR=52BXPLS3#0E"FHR/6_CG_ ,P+_MX_]IU6^"-K
M"VH:O=E0UQ##''&,_P +%BWZHO--OOB[IVJ"/^U/!UK>F/.S[1.K[<XSC=&<
M9P/RKGE\>OI_BW^V?#VEV^EQ-$(I;)"#'(.Y. N#TY [>YK)1G[/DL<\:=7V
M'LFK?\.;O@/Q?XBU3XCQQ7]W/+%=&3S[8D[(L*2-J_PX( _G6SI=]#I/Q]U2
MSC!2&_C";4X7S#&DA8CU)#<^K'UK';XPI";B?3/#%G:7MP/WEQY@)<^K812W
MXFN!&LWIUY-9FF,UZLZW'F2?Q."".G;CH.U/V;DW=6T&J,IMMQY5:Q[7H]E!
MX&N/$>JW^WRKG4XT1R=N(W93G)XPOFG/KL/M4EGHL?A[QQXI\1SPA+=;19HM
M@Z@J6E_'='G_ (%]:\Y\:_$F7Q?I,-@FG_88TE\UR+CS-^ 0!]T>N?RJUKOQ
M9N];\*R:2=.6":>-8YKE9B=PXW87;QG'J>":CV<WOUW,O85GJ]WH_30X.\NI
M;Z^GN[@[I9Y&E<^K,<G]37JO@'_DB_B;_MZ_])UKR2NV\'_$*/PMX?N=*GT9
M-1AN)FD??/M!#*JE2I4Y&%_6MZD6XV1V8B$I0M%=C,\ 6-Q?^.]*6UWCR9UG
MD903M1#DYQT!Z?C7J@^QZC\=SE@TNG:7P#D8D)Z>_P DO^<5R!^+:V5C+!X=
M\-66E/)SO1@5![G:J+DX%<7I_B/4]-\0KK4%RSWP<N[R?-YF>H;U!'_UL5#C
M*;;>FAC*G4JMR:MI9';R>,/$3?%X6QNIQ NH_9?L:D^7Y6_;]WH3MYW?TK4\
M8ZO9^%_C+IVJS6ZM&UDOV@HN6R2Z;_J%"CZ#%9__  N*$7'VU?"UH-1,>QKO
MS1N(]/N;L>V:YFP\>7\'C%_$.HPQ7\LB-&T+_*JH>BKUV@?CWSR<TE!OIT)5
M*3=W&VEM]ST'5[&?Q1I6IZMX,\5W-U%-$Z3Z=<-F/:>J*K8\LX!P2.>Q YJ[
MH8TO3O@_923ZI<:9:2('GN[$_O [-@C(5B#G@XY&,<5Q5W\4U32;BS\.>';/
M16N!AY82I]LX"*,XSR<UG^%OB)<^'M)DTF\T^#5--?=B"4X(R>1G!!7KP1U/
M7M4^SFXV(]A5<+6V?E?_ ".LU[Q3X3F^'M[HMOK]YJL[+NA>\CD>0MN# ;RB
M]QW[?E7D-=IXB^($.KZ#)I.E^'[/2;>8J9?)().UMP PJ@<_7O7%UM3CRHZ\
M/3<(NZM_7D%%%%:G0%%%% !1110 5ZM\-_B1]G\K0_$,W[GA+:Z<_<]$<^GH
M>W0\=/*:*B<%-69E5I1JQY9'UM17C_PW^)'V?RM#\0S?N>$MKIS]ST1SZ>A[
M=#QT]@KSIP<'9G@U:4J4N604445!D%%%% !1110 4444 4=<_P"1>U'_ *]9
M?_0#7C5>RZY_R+VH_P#7K+_Z :\:KP,U^./H>9C?B04445XYPA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7M#_ .1AT[_K
MZB_]#%>RUXUH?_(PZ=_U]1?^ABO9:]_*O@EZGIX+X6%%%%>P=P4444 %%%%
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M_*)!_C1_PC'CG_HH?_E$@_QKM:*P.,XK_A&/'/\ T4/_ ,HD'^-'_",>.?\
MHH?_ )1(/\:[6B@#BO\ A&/'/_10_P#RB0?XT?\ ",>.?^BA_P#E$@_QKM:*
M /%+^*>#4KF*\N/M5Q',ZRS[ GFN"06VC@9/.!TS5>KVN?\ (PZC_P!?4O\
MZ&:HU\94^-^IX$OB84445F2%%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_A&/'/_ $4/_P HD'^-=K10!Q7_  C'CG_HH?\ Y1(/\:/^$8\<_P#10_\
MRB0?XUVM% '%?\(QXY_Z*'_Y1(/\:/\ A&/'/_10_P#RB0?XUVM% '%?\(QX
MY_Z*'_Y1(/\ &C_A&/'/_10__*)!_C7:T4 <5_PC'CG_ **'_P"42#_&C_A&
M/'/_ $4/_P HD'^-=K10!Q7_  C'CG_HH?\ Y1(/\:YSQ;HWB33KOPQ+KOBK
M^V+=M?M%6#^SH[?:^6(;<IR> 1CW]J]8KB/B9_J_"O\ V,EI_P"STT!U%%%%
M( HHHH **** "BBB@ HHHH **** "N0O&_X1_P"*^F:@/EM=<@-A/Z"9?FC)
M]S]T5U]<UX_TN74_!UTUID7ED5O+9AU$D9W<>^,C\:8':45GZ#JT6N^'['5(
M,;+J!9,#^$D<C\#D?A6A2 **** "BBB@ HHHH *Q?&G_ "(6O_\ 8,N?_135
MM5B^-/\ D0M?_P"P9<_^BFH I>#_ /D1]"_[!UO_ .BUK8K'\'_\B/H7_8.M
M_P#T6M;% !1110 4444 %%%% !1110!ROA'_ )*AXX_[</\ T2U=S7#>$?\
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M^+FTD*F$M'T^*X:-.P9FP<^W..![!OPX^' TI8M9UZ(&^(W06[#_ %'^T?\
M;_E]>GI5<-:HI>ZCQ\9B(S]R)Q7_  C'CG_HH?\ Y1(/\:/^$8\<_P#10_\
MRB0?XUVM%<QYYQ7_  C'CG_HH?\ Y1(/\:/^$8\<_P#10_\ RB0?XUVM% '%
M?\(QXY_Z*'_Y1(/\:/\ A&/'/_10_P#RB0?XUVM% '%?\(QXY_Z*'_Y1(/\
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M*_X1CQS_ -%#_P#*)!_C1_PC'CG_ **'_P"42#_&NUHH XK_ (1CQS_T4/\
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M.^HHHI %%%% !7$?$S_5^%?^QDM/_9Z[>N(^)G^K\*_]C):?^STT!U%%%%(
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MH,YQ[8K+KL6J/63NKA1113&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXF?ZOPK_ -C):?\ L]=O7$?$S_5^%?\ L9+3_P!GIH#J****0!1110 4444
M%%%% !1110!S/P@_Y)3H_P#VW_\ 1\E=K7%?"#_DE.C_ /;?_P!'R5VM-[@%
M%%%( HHHH XKPQ_R5;QS_P!P_P#]$&NUKBO#'_)5O'/_ '#_ /T0:[6FP"BB
MBD 4444 >'?&K_D=+3_L'I_Z,DKSJOJB]T/2=2F$VHZ99W<JKL#SVZ.P7.<9
M(Z<G\ZK?\(GX<_Z &E_^ 4?^%=4*ZC%*QZ5+&1A!1:V/F"BOI_\ X1/PY_T
M-+_\ H_\*/\ A$_#G_0 TO\ \ H_\*OZRNQK]?C_ "GS!17T_P#\(GX<_P"@
M!I?_ (!1_P"%'_")^'/^@!I?_@%'_A1]978/K\?Y3Y@HKZ?_ .$3\.?] #2_
M_ */_"C_ (1/PY_T -+_ / */_"CZRNP?7X_RGS!17T__P (GX<_Z &E_P#@
M%'_A1_PB?AS_ * &E_\ @%'_ (4?65V#Z_'^4^8**^G_ /A$_#G_ $ -+_\
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M<_Z &E_^ 4?^%'UE=@^OQ_E/F"BOI_\ X1/PY_T -+_\ H_\*/\ A$_#G_0
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MN5:(****P.,**** "BBB@ HHHH **** /&M<_P"1AU'_ *^I?_0S5&KVN?\
M(PZC_P!?4O\ Z&:HU\94^-^IX$OB84445F2%%%% !1110 4444 %%%% !111
M0 4444 %%%% !7<_#;_F)?\ ;+_V>N&KN?AM_P Q+_ME_P"SUW8#_>8_/\F=
M&&_BK^NAW5%%%?4GLA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;% !1110 4444 %%%% !1110!S/P@_Y)3H__ &W_ /1\E=K7%?"#_DE.C_\
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M2_\ P"C_ ,*/^$3\.?\ 0 TO_P  H_\ "CZRNP?7X_RGS!17T_\ \(GX<_Z
M&E_^ 4?^%'_")^'/^@!I?_@%'_A1]978/K\?Y3Y@HKZ?_P"$3\.?] #2_P#P
M"C_PH_X1/PY_T -+_P# */\ PH^LKL'U^/\ *?,%%?3_ /PB?AS_ * &E_\
M@%'_ (4?\(GX<_Z &E_^ 4?^%'UE=@^OQ_E/F"BOI_\ X1/PY_T -+_\ H_\
M*/\ A$_#G_0 TO\ \ H_\*/K*[!]?C_*?,%%?3__  B?AS_H :7_ . 4?^%'
M_")^'/\ H :7_P" 4?\ A1]978/K\?Y3Y@HKZ?\ ^$3\.?\ 0 TO_P  H_\
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M24Z/_P!M_P#T?)7:TWN 4444@"BBB@#BO#'_ "5;QS_W#_\ T0:[6N*\,?\
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MH7Y8[6X^QWA_Z82\9/LK<_4UV-9OB+2$U[PW?Z9)C%S"R*3_  MU4_@0#^%
M'0T5S?P_UE];\$V,USD7<"FVN5/421_*<^YP#^-=)0 4444 %%%% !6+XT_Y
M$+7_ /L&7/\ Z*:MJL7QI_R(6O\ _8,N?_134 4O!_\ R(^A?]@ZW_\ 1:UL
M5C^#_P#D1]"_[!UO_P"BUK8H Y?4_&T6D>(9=/O+-_)0+^^1LDY4'.T]N<=>
MWX5K:?XATK5,"SO(V<_\LV.UOR/-9OB3Q%HED7L]1@%[,HYA\L-M) (R3TSD
M=*X,V$OB"_8Z#I#01=U$A91]6;@=#Q5V31-SV"J][?VNG0B6^G2"-FVAG. 3
MUQ^AKBM,L?%FB:I9Q2/)<63R(LFUO,55)&[KRN/4<5UNLZ-;:Y9I;7ID")()
M!Y; '(!'H?6IM89BZ5XTM[G4-1CU&XM8((9=MLXR/,7+<G).> OIUHU_QK;6
M5K$^CW-M=2M)AT(+87!YX(QV_.J%M\/[6&XNFU6YVVYDQ;>7+AMN3][*XSC'
M3WK0L?"'AVUO(Y4E,[JP*I),I!/;@8S5>Z+4ZFBBBH*.5\(_\E0\<?\ ;A_Z
M):NYKAO"/_)4/''_ &X?^B6KN: "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K%\9_\ (AZ__P!@RY_]%-6U6+XS_P"1#U__ +!ES_Z*:@"EX/\ ^1'T
M+_L'6_\ Z+6MBL?P?_R(^A?]@ZW_ /1:UL4 %%%% !1110 4444 %%%% ',_
M"#_DE.C_ /;?_P!'R5VM<5\(/^24Z/\ ]M__ $?)7:TWN 4444@"BBB@#S_X
M3_\ )+])_P"VW_HYZ[&N.^$__)+])_[;?^CGKL:;W **YSQ7KEYI[6MAI"AK
MZ\;"D@':,X'7CD^O P:S?#>JZM=Z#K#S7>^YM>8F=0<$ DC\<46TN*YVM%8_
MA;59-8T"*YN#F;<R2$# )!_PQ6Q2&%%%% !1110!REM_R70_]BW_ .W-=U7"
MVW_)=#_V+?\ [<UW5, HHHI %%%% '%?$G_F4_\ L9;/_P!GKM:XKXD_\RG_
M -C+9_\ L]=K3 ****0!1110!GZSK-OH=FES=I*Z/((P(@"<D$]R/2L3_A8F
MD_\ /O>_]\)_\51\1/\ D7H/^OI?_0'KS>O%QF,JT:O)#8\^O7G"?+$](_X6
M)I/_ #[WO_?"?_%4?\+$TG_GWO?^^$_^*KS>BN/^TL1Y?<8?6ZIZ1_PL32?^
M?>]_[X3_ .*H_P"%B:3_ ,^][_WPG_Q5>;T4?VEB/+[@^MU3TC_A8FD_\^][
M_P!\)_\ %4?\+$TG_GWO?^^$_P#BJ\WHH_M+$>7W!];JGI'_  L32?\ GWO?
M^^$_^*H_X6)I/_/O>_\ ?"?_ !5>;T4?VEB/+[@^MU3TC_A8FD_\^][_ -\)
M_P#%4?\ "Q-)_P"?>]_[X3_XJO-Z*/[2Q'E]P?6ZIZ1_PL32?^?>]_[X3_XJ
MC_A8FD_\^][_ -\)_P#%5YO11_:6(\ON#ZW5/2/^%B:3_P ^][_WPG_Q5'_"
MQ-)_Y][W_OA/_BJ\WHH_M+$>7W!];JGI'_"Q-)_Y][W_ +X3_P"*H_X6)I/_
M #[WO_?"?_%5YO11_:6(\ON#ZW5/2/\ A8FD_P#/O>_]\)_\51_PL32?^?>]
M_P"^$_\ BJ\WJ86ER;4W0MY3;@X,NP[ ?3/2FLQQ#V_(?UJJ>A?\+$TG_GWO
M?^^$_P#BJ/\ A8FD_P#/O>_]\)_\57F]3K8W;VK7*6LS0+]Z41DJ/QZ4+,<0
M]OR#ZU59Z#_PL32?^?>]_P"^$_\ BJ/^%B:3_P ^][_WPG_Q5>;U.MC=O:M<
MI:S- OWI1&2H_'I0LQQ#V_(/K55GH/\ PL32?^?>]_[X3_XJC_A8FD_\^][_
M -\)_P#%5Y[]BNOLGVK[--]G_P">WEG9UQ][IUXJ&AYCB%O^0?6JJ/2/^%B:
M3_S[WO\ WPG_ ,51_P +$TG_ )][W_OA/_BJ\WHI?VEB/+[A?6ZIZ1_PL32?
M^?>]_P"^$_\ BJ/^%B:3_P ^][_WPG_Q5>;T4?VEB/+[@^MU3TC_ (6)I/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M -TYW,P]MW'XUUR=27ME4^'6U^]]+&[<G[3GVU_X!EZ?X,>?2TO]1U"&PAD
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M_P#+7_[+^==97AJL58,I((.00>E>C>$_%@U%5L=1<"[ PDA_Y:__ &7\Z]_
MX[FM3J/7HSTL/B+^Y,ZRBBBO8.\**** "BBB@ HHHH \:US_ )&'4?\ KZE_
M]#-4:O:Y_P C#J/_ %]2_P#H9JC7QE3XWZG@2^)A11169(4444 %%%% !111
M0 4444 %%%% !1110 4444 %=S\-O^8E_P!LO_9ZX:NY^&W_ #$O^V7_ +/7
M=@/]YC\_R9T8;^*OZZ'=4445]2>R%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %<1\3/\ 5^%?^QDM/_9Z[>N(^)G^K\*_]C):?^STT!U%%%%( HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH Y+PVW]@_$S6=&/RVVK1C4K8=O,^[*/
MJ3S]!7>5Y_\ $ -I8TGQ1 I+Z-=JTVT<F"3Y)!^H_6N^1UDC5XV#(P!5@>"/
M6F ZBBBD 4444 %8OC3_ )$+7_\ L&7/_HIJVJQ?&G_(A:__ -@RY_\ 134
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ME.C_ /;?_P!'R5VM<5\(/^24Z/\ ]M__ $?)7:TWN 4444@"BBB@#S_X3_\
M)+])_P"VW_HYZ[&N.^$__)+])_[;?^CGKL:;W Y;Q?IMZ;NQUC2X3<36;?-$
M 6+#.1@#D]\X]:XW3=7U&VM;ZQLK-FDOVP2%)9<Y! 'XUU_BSQ/>Z%J=K%:1
MQ21O&7=74Y;G'7/'2KFG^++/5M,G>U;R;R.%W\A^2,#J.Q%4KV)ZECPKI;Z3
MX>@MY^)FS)(/[I/;\!@5L5A^$=4NM7T/[3>LK2^:RY50.!BMB>XAMHC)<RI#
M&.K2,% _$U+W*)**Y^Y\<:%;MM%TTQ'7RHR?U.!3(/'FA2OM>>6'T,D1P?RS
M19BNCHZ*JV.J6.I)NL;J*?'4(W(^HZBK5(9REM_R70_]BW_[<UW5<+;?\ET/
M_8M_^W-=U3 ****0!1110!Q7Q)_YE/\ [&6S_P#9Z[6N*^)/_,I_]C+9_P#L
M]=K3 ****0!1110!RGQ$_P"1>@_Z^E_] >O-Z](^(G_(O0?]?2_^@/7F]?,Y
ME_O'R1Y&+_BA7>:"PUKP!>:<5WS6ZL$7=R3]]#[<\?A7!UT_@*_-KX@^S,3L
MND*XQ_$.0?YC\:RP<DJO*]I:?>10DE.SZZ$'@JP^W>)(G89CM@9FX[C[OZD'
M\*C\57;:IXJF6'YPC"",#OCC_P!"S76QV:^$].UN_4*&>7]P-O !^X,>Q8C\
M*YGP5IQU'Q$L\O*6O[YB><M_#^O/X5T2HN,(8?K)W?Y&K@U&-+JV=Q;_ &2V
M:'PXZ;_]"W-GHPSM/XGDUY?-'-H^LL@.)K2?Y6*XR5/!Q[X!KO9[>P?Q8NL'
MQ%9*T1 $#%>%Q@KG?[GMWK"^(%@+?6H[M  MU'SSU9>#^FVML9%RI\_\KT].
MAI73<.;L_P #9UC3T\8Z+97^GX$X8*V?X03A@?H>?I]:SO&M_#965MH%CPD*
MJTN".,= ??N?PK7TN2W\'^'[1-0;;-=S NN[[I.,GZ*,9_\ KUS_ (WTK[)K
MBWQWM;79!9ASM8=0/PY'X^E5B+JBYKXG;F\O^''5O[-R6[M<Y6NET_QE)I5G
M;V]CIULBH!YS-G=*?7(Q@_7-+=WWA%[.9;32[M)VC81.S'"MC@GYSWJQX4T&
M..$Z[J^U+2%2\:M_$1_%CT]!W/Z\5&G4C4M2DO-KHOFCGIQFI6@S1^(%G;?V
M7;7J0JEPTP0L!@E2I//KR!65X3M(K&TN?$&H(#%;J5@5OXW]L_@ ?<^E9OB/
M7Y->OQ(5\NWBR(8SU /4GW.!_GFNLU6STO4=,M+"W\0V=K:VZ@; ZMO/8GYA
M_DUTWC6KRJPZ;=+ON:W4ZCG'I^93^(YW+I;'J1)G_P <KAZ]#\?V<,NEV]P]
MVD<EN#Y<)QF;<4!QSVZ]#7GE<V8)K$-OK;\C+%)JJSV:]\BZ9M+G Q<P.0,=
MA@'_ -"!_"O,-$TE[KQ3#83IGRICYPVY&$/(/L<8_&NR\4W_ /9GB/1+DG"*
MTBR<_P )V@_H<_A5ZZM+?0YM4UT;=TD(PIX^89XS_M';^(KTZ].->K=_8>OI
M:YUU(JI/7[._IN-\0W$-YX3U(Q ,D>4!(_B5@#^1!_*N4CEUA?AZVW[(-.!*
MY^;S2#)S[=3^5:=DS/\ "^Y=V+,V\DDY).^H5_Y)(_\ O?\ M85E5;J2Y]O<
M;(F^=\W]TPM'\*ZEK5N;BV$<4.<!YF(#'OC )_&NK;3I]*^'5W:7842HK9VG
M(.6S5;6#,/AK8?8=VPK'Y^P?P[3G/MNQ4T7VG_A6,_VWS/,\ML>;G=MW<=:F
ME2A2O%)WY;WZ:BA",+I;V.7T?PKJ6M6YN+81Q0YP'F8@,>^, G\:ZMM.GTKX
M=7=I=A1*BMG:<@Y;-5M8,P^&MA]AW;"L?G[!_#M.<^V[%31?:?\ A6,_VWS/
M,\ML>;G=MW<=:*5*%*\4G?EO?IJ$(1A=+>Q4;_DDB?[W_M8U@Z/X5U+6K<SV
MPCBA!P'F) 8]\8!S6\W_ "21/][_ -K&M21].3P)8/?VT]U:"*/>EN2,'').
M",@']:ET8U7%SV4$+V<9M<W2*.*UGPWJ&AA'O%1HG.T2Q-E<^G.#GCTK)KLM
M6US3KCPA)9:9I]]% &41R2IE%.[.-VX^]<;7GXB%.$_W;TL<M6,8R]T]0\6>
M(KGP^;+[)%#(LV_>) >B[>F",=36?Y5EXU\/SW*VJV^H09&Y<9+ 9'/=3[].
M?Q@^)/\ S#?^VO\ [)4OA&UDT3P_J.HZA%)$'7(1A@E5!['U)(YKUYSE/%2I
M2UA;[M#NE)RK.#^'_@'):1H5]K<K)8Q@JGWY'.%7\?\ "M*]\#:O9VSS#R)P
M@R5A<EL?0@9K:\.!A\/[XZ;N-V3)NV [MV!T]]N,8[TSX=_:C)>LXD-NX!W-
MG!?)Z>_K^%<E+#4GR0DFW)7OV,(48/EB]V<SHWAZ^UQG^QJBI']Z20D*#Z=#
MS3M:\.7NA"-KPQ.DA(5HF)&?3D UKZ1K=OIZZE;7=G)+I-Q.X\V%3A<\8[<8
MQT.1^-6-2T6SLFT>^L;J5M-FNX_W,K$JN[G< ?8<YYK-8>G*E>.KZZ[:]NWS
M)5*+A=;F=9^!-7N[5)B8(-XR$F9@P'N #BL;4M,NM)O#;7T>R3&X8.0P]0?3
MBO0/%5QHMM>0/K5C>3MMS%)$Y"KST^^,'CT]*YOQGJ\>JM9-%:75OL5^;F/;
MO!QC')ST-5B</1IQ:B]5;Y_AH.K2IP3L]4<Q1117F'(=MX1\7>5LTW59/W?W
M89V/W?\ 98^GH>W\N]KPRNV\(^+O*V:;JLG[O[L,['[O^RQ]/0]OY>W@<=:U
M*J_1GH8?$?8F=[1117N'HA1110 4444 %%%% !1110!1US_D7M1_Z]9?_0#7
MC5>RZY_R+VH_]>LO_H!KQJO S7XX^AYF-^)!1117CG"%%%% !1110!OZCX7-
MEX=@U:"Z\^.4(S)Y>W8&'KDYYP/QJEH.C/KNJ"T23RAL+O)MW;0/;CN0/QKI
M_#)&M>"K[2#M,D.?+'(Z_,I/_ @:3P:J:3X=U#6KC XVID]0O8?5CC\*]18>
MG.<))>ZU=_+<[%2C*46MFM?EN<EJ5B+'5I[*&7[1Y3[-X7&X]QC)[\5T6H>
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M\$O4]/!?"PHHHKV#N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N!^'_^L\5_]C)>?^RUWU<#\/\ _6>*_P#L9+S_ -EI@=?1112
M**** "BBB@ HHHH **** "BBB@ HHHH YWQQHLVL>&W-AE=1L76[LG7J)4Y
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MFIH#OJ***0!1110 5Q'Q,_U?A7_L9+3_ -GKMZXCXF?ZOPK_ -C):?\ L]-
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M_P#!K_\ 8T 'AC_DJWCG_N'_ /H@UVM>1:%X(^U?$#Q78_\ "3^(X?L?V/\
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MO_!K_P#8T?\ "MO^IS\7?^#7_P"QH [6N(^)G^K\*_\ 8R6G_L]._P"%;?\
M4Y^+O_!K_P#8USGBWPC_ &!=^&+K_A(-=U/?K]I'Y.HWOG1KDL=P&!\W&,^A
M-- >DT444@"BBB@"*>ZM[50;J>*$'H9'"Y_.E@N8+I-UM-',OK&X8?I7!WSV
MS>-+@>(-[6X8A1R !CY>G.,>E=5H^F:99>;=Z4^^.8 ?*^\#&>!W[_I7%2Q$
MJM1I)63MOK]QSPJN<FELOO-:BN7;QE*T;3V^C7$ELI.9B2 ![X4@?G5\Z]]I
M\//J.G6[SNIVM$/O(>_8YQD'Z5I'%497L]M>I:K0>S+!\0:7]N6T%VIG9P@5
M5)^;.,9 QUK1KS[PBP^V;#I?VK=*I^TXSY&.<YP<?F*Z"[\5[+^2UTVPFU!H
MOOF,G@]^@/YUA0QBE3YZCM?U_I_(RIUTX\TSH:*Q;#Q&FHV-S)!:R?:[9<M:
MD\GV![]/3\*Y;0-3NK36+N2#3Y;EIB=\:$YC^;OP?Z5<\93BXVU4BI5XIJW4
M]#HK'M_$ E\12Z3-;>4Z9V/OSOP,],<<<TLVO;/$<>DPVID9@"\F_&WC/3'/
M%;>WIVO?K;Y]C3VD+7OUM\S7HHHK<T*NIZ?#JNDW6GW(S%=1-$_'0$8S65\-
M-2FO/!T=E>G_ $W297L+@$\YC.!_X[MK?KD=/;_A'_BY<6Q^6T\16OG1^GVB
M+A@/JIR:8'>T444@"BBB@ K%\:?\B%K_ /V#+G_T4U;58OC3_D0M?_[!ES_Z
M*:@"EX/_ .1'T+_L'6__ *+6MBL?P?\ \B/H7_8.M_\ T6M:4E[;174=M+<1
MI/*,I&S ,WT% '">*A<:UXBOK+S_ "K?3;-I]G9R%#=/4E@/H*)5'_"I;:3S
M3&\4A9,-@L?-88_(D_A6CXG\.S:EJCW.C7<:7AA\NX@,F"ZD8_D0,'CI61:^
M#_$-W%#87\WV>PB;=M,H8#G)P!U/)ZUII8D[S29GN=%LIY#EY;>-V)[DJ#5N
MFQ1)!"D42[4C4*H] .!3JS*/._$6O:Q=WVH_V;.]O9Z:P20QMM));;DGJ><\
M>@K4UC6-2TSPUH>H6]SPZQ"X#J&,N4#<DC/\+="#S65XETC5M/NM3^PP-<V.
MID22&.,L4(;=VZ8.?8@^O2"VMM;\3_V?87-FT-C9!49_+*C  !))/)QV'K6F
MA)Z9111691ROA'_DJ'CC_MP_]$M7<UPWA'_DJ'CC_MP_]$M7<T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !6+XS_Y$/7_^P9<_^BFK:K%\9_\ (AZ_
M_P!@RY_]%-0!2\'_ /(CZ%_V#K?_ -%K6Q6/X/\ ^1'T+_L'6_\ Z+6MB@ H
MHHH **YGQOJMYIVFV\6GLT<MS+L,BG!4>@]"?7VK%'@KQ%(-\FKJ';ELSR$Y
M^N*JPKGH%%8?AC1[_1[>>/4;L7)D<,F'9MO'/6MRI&%%%% ',_"#_DE.C_\
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MR9&Q<$;2<'Y><X]0*V?^%;?]3GXN_P#!K_\ 8T#.UHKBO^%;?]3GXN_\&O\
M]C1_PK;_ *G/Q=_X-?\ [&D!VM%<5_PK;_J<_%W_ (-?_L:/^%;?]3GXN_\
M!K_]C0 ?$G_F4_\ L9;/_P!GKM:\B\;>"/[-_P"$>_XJ?Q'=_:M<MK?_ $K4
M-_E;MW[Q/E^5QCANV374?\*V_P"IS\7?^#7_ .QI@=K17%?\*V_ZG/Q=_P"#
M7_[&C_A6W_4Y^+O_  :__8T@.UHKBO\ A6W_ %.?B[_P:_\ V-'_  K;_J<_
M%W_@U_\ L: +7Q$_Y%Z#_KZ7_P! >O-ZZ?Q+X1_L#38[K_A(-=U/?,(_)U&]
M\Z-<@G<!@?-QC/H37,5\SF7^\?)'D8O^*%26\[VMU%/$<21.'4GU!R*CJ6WM
M+F[<I:6\L[#J(D+$?E7GJ]]#F5[Z&MK/BN_UNS6VND@CC5P_[I6&3CODGUJ'
M1_$5WHD$\=G'"?/QN=U)88!Q@@CUJA<V=U9L!=VTT!;H)8RN?SJ&MI5JO/SM
M^\6ZD^;F;U"MVY\77UY'9I=0VTOV219$9D;+,!@;L-^/&.E8]O:7-VY2TMY9
MV'41(6(_*EN;.ZLV N[:: MT$L97/YU,)5(1;CLQ1<HK0MZUKEWKMRDUYL7R
MTVJD>0HYSG!)Y_P%3W7B>^O=#32[A(7B0*!)M._Y>G.<>W2L>BCVU2[=]]P]
MI*[=]PKI;3QUJ=E90VT4%H4A0(I9&R0!CG#5S5%%.K.D[P=@C.4/A9OZKXQU
M#5]/>SN8;58W(),:,",'/=C6!112J5)U'>;NQ2G*;O)FIK7B"[UT6XNTA06X
M8)Y2D9SC.<D^@K+HHI3G*<N:3NQ2DY.[-36_$%WKQ@-XD*&$$+Y2D9SCKDGT
MJ:_\5:CJ6DII]QY0B4*&95.Y\=,G/X\ 5BT5;K5&V[[[E>TGKKN:L7B*\A\/
MOI"+%]G?.6*G>,G)&<X_2@>(;L>'3HWEP_9B<[MIW_>W=<XZ^U95%+VU3OTM
M\NP>TEW\C<TCQ;J6C6@MK?R98025652=N>3C!'^32W7B_5+VPNK2X:)TN6R3
MLY0<?*O.,<=\GK6%15?6*JCR\SL/VL[6OH;FD>+=2T:T%M;^3+""2JRJ3MSR
M<8(_R:6Z\7ZI>V%U:7#1.ERV2=G*#CY5YQCCOD]:PJ*/K%51Y>9V#VL[6OH:
MA\079\.C1MD/V8'.[:=_WMW7..OM4VD>*]2T:#R+=HY(1G;'*N0O?C!!K%HI
M*M434D]5I\A*I-.Z9LZSXIU'6[=8+KRHXE;=LB4@,>V<DFL:BBHG4E4?--W8
MI2<G=G5CXAZM_P ^]F?^ -_\565J_B74=:54NY%6)>?*C&%)]3ZUDT5K/$UI
MKEE)V+E5J25FS1TC7;[1)F>RD&U_OQN,JWX?X5H:AXVU?4+5H"8;='&&,"D$
MCTR2?TKGJ*F->K&/(I.Q*J32Y4]#9T7Q3?Z';/!:)"\;N7(E4G!P!V(]!46L
M^(;_ %QD^V,JQQ\K%&"%SZ]3DUET4>VJ.')?0/:3Y>6^ATMIX\UBUMQ$WV>X
MV]'E0[OT(K(U;6+O6KL7%ZREE7:JH,*H]JHT42KU9QY92;0Y5)R5FPHHHK$S
M"BBB@#MO"/B[RMFFZK)^[^[#.Q^[_LL?3T/;^7>UXE9V<]_=QVUI&9)9#A5'
M\_I7<_\ "NY)D1I_%GB2WDV@-'9ZB8XEP/X5(.!7T.6UJE2+C):+K^AZF%J3
MDK/9':45Q7_"MO\ J<_%W_@U_P#L:/\ A6W_ %.?B[_P:_\ V->L=IVM%<5_
MPK;_ *G/Q=_X-?\ [&C_ (5M_P!3GXN_\&O_ -C0!VM%<5_PK;_J<_%W_@U_
M^QH_X5M_U.?B[_P:_P#V- ':T5Q7_"MO^IS\7?\ @U_^QH_X5M_U.?B[_P &
MO_V- '3ZY_R+VH_]>LO_ * :\:KMK_X?_8M-N;K_ (2WQ3<>1$\GDSZENCDP
M"=K#;RIQ@CTKB:\#-?CCZ'F8WXD%%%%>.<(4444 %%%% &_X,U1-,U]?M$@C
M@G0QNS-A5[@G\1C\:V/&FJ60TB#3]+N(94DE:63R7# <DX./4MG\*XBBNJ.*
ME&BZ7<VC6:IN!V?A.^LM&\.W][)<0?:WSLA:0;CM'RC'7DDTRV^(6H-=1"ZA
MM%@+@2,J/D+GDCYNN*X^BJ6,JQC&,-$AJO-)*.ECNM9M=(U/Q=9W1U&R^S-'
MNN/WR\[", G/4Y ^@/I4>J>+_*\6P/:R![&V_=OL((<-C<1CKC Q]*XFBJEC
M):N"LV[C==Z\JM=W.J\8-:Q:Q#J>C7\;23 ^8;>8%D8#&<@Y&0<?A[US\^J:
MA=1&*YOKF:,]4DF9@?P)JK17/4K.<G):7Z&<YN4FUI<]-C&DVOA[^S=+UNRL
MW8#?<"568GN?O#D_IVKD=0TRUT%K6^T_6+;4)8YU81H!QCD$X8\9%8%%;U<4
MJB7N6:VU>AI.LI+X=CL;/Q_J,U]!%<164<3R*KOM8;5)Y.2W'%)X[UQ+R2&P
MM);>>V4+,9(FW$/\PQD''0UQ]%)XRK*FX2=[B=>;BXMA1117&8!1110 4444
M 7M#_P"1AT[_ *^HO_0Q7LM>*6%M]MU*VM?.FM_/F2/SH'VR1Y(&Y3V89R#Z
MUVW_  K;_J<_%W_@U_\ L:]_*O@EZGI8+X6=K17%?\*V_P"IS\7?^#7_ .QH
M_P"%;?\ 4Y^+O_!K_P#8U[!WG:T5Q7_"MO\ J<_%W_@U_P#L:/\ A6W_ %.?
MB[_P:_\ V- ':T5Q7_"MO^IS\7?^#7_[&C_A6W_4Y^+O_!K_ /8T =K17%?\
M*V_ZG/Q=_P"#7_[&C_A6W_4Y^+O_  :__8T =K17%?\ "MO^IS\7?^#7_P"Q
MH_X5M_U.?B[_ ,&O_P!C0!VM%<5_PK;_ *G/Q=_X-?\ [&C_ (5M_P!3GXN_
M\&O_ -C0!VM%<5_PK;_J<_%W_@U_^QH_X5M_U.?B[_P:_P#V- ':T5Q7_"MO
M^IS\7?\ @U_^QH_X5M_U.?B[_P &O_V- ':T5Q7_  K;_J<_%W_@U_\ L:/^
M%;?]3GXN_P#!K_\ 8T =K17%?\*V_P"IS\7?^#7_ .QH_P"%;?\ 4Y^+O_!K
M_P#8T =K17%?\*V_ZG/Q=_X-?_L:/^%;?]3GXN_\&O\ ]C0!VM%<5_PK;_J<
M_%W_ (-?_L:/^%;?]3GXN_\ !K_]C0!VM%<5_P *V_ZG/Q=_X-?_ +&C_A6W
M_4Y^+O\ P:__ &- ':T5Q7_"MO\ J<_%W_@U_P#L:/\ A6W_ %.?B[_P:_\
MV- ':T5Q7_"MO^IS\7?^#7_[&C_A6W_4Y^+O_!K_ /8T =K17%?\*V_ZG/Q=
M_P"#7_[&C_A6W_4Y^+O_  :__8T =K17%?\ "MO^IS\7?^#7_P"QH_X5M_U.
M?B[_ ,&O_P!C0!VM%<5_PK;_ *G/Q=_X-?\ [&C_ (5M_P!3GXN_\&O_ -C0
M!VM%<5_PK;_J<_%W_@U_^QH_X5M_U.?B[_P:_P#V- ':T5Q7_"MO^IS\7?\
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M[ACCD(:&?>-NX="#G![_ *TUN)G->$M-;2/'5[9/+YK16GS.!C)/EL?YU?\
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M/8"JD)&W7):]_P E6\$?]O\ _P"B!76UR6O?\E6\$?\ ;_\ ^B!4%'>4444
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MI3E-2=M#@8[JYU+3KJZOO$#0,N0+8,<R<=-H(X/3@'O6WX-_Y%>\_P"NK_\
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MU%%%04<S\(/^24Z/_P!M_P#T?)7:UQ7P@_Y)3H__ &W_ /1\E=K3>X!1112
M**** .*\,?\ )5O'/_</_P#1!KM:XKPQ_P E6\<_]P__ -$&NUIL HHHI %%
M%% 'F_Q$_P"1A@_Z]5_]#>N4KM/'>G7UYKL,EI9W$Z"V52T43, =S<9 ]ZYG
M^P]6_P"@7>_^ [_X5\KBX3=>32ZGC5XR=1Z%&KJZUJB*%34KQ548 $[  ?G2
M_P!AZM_T"[W_ ,!W_P */[#U;_H%WO\ X#O_ (5SJ-6.R9DE-;$=QJ=_=Q>7
M=7MS-'G.R25F&?H34<MY<SPQPS7$LD48PB.Y*I]!VJQ_8>K?] N]_P# =_\
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M]6_Z!=[_ . [_P"%']AZM_T"[W_P'?\ PH]G/LPY9=BC15[^P]6_Z!=[_P"
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MHHIC"BBB@ HHHH **** /&M<_P"1AU'_ *^I?_0S5&KVN?\ (PZC_P!?4O\
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M4 %%%% !1110 4444 %%%% !6+XS_P"1#U__ +!ES_Z*:MJL7QG_ ,B'K_\
MV#+G_P!%-0!2\'_\B/H7_8.M_P#T6M;%8_@__D1]"_[!UO\ ^BUK8H ****
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M;<N;OI(&QMYQTQS3$:]%%%(9S/P@_P"24Z/_ -M__1\E=K7%?"#_ ))3H_\
MVW_]'R5VM-[@%%%%( HHHH XKPQ_R5;QS_W#_P#T0:[6N*\,?\E6\<_]P_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'DO(<'_QW-=7H^F0Z-HMGIMM_JK6%8E/K@8S^/6GT N4444@"L7QI_R(6O\
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M?^"K_P"RH_X63_U)GB[_ ,%7_P!E7:T4@.*_X63_ -29XN_\%7_V5'_"R?\
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M<X/I7-?\++_ZA/\ Y,__ &-=%/#5:D>:"T^1Q5L?AJ$^2I*S]'_D=W17"?\
M"R_^H3_Y,_\ V-'_  LO_J$_^3/_ -C6GU+$?R_BC'^UL'_/^#_R.[HKA/\
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MDO/_ &6N^K@?A_\ ZSQ7_P!C)>?^RTP.OHHHI >?F2^B\<7;:7"DUQO?"2'
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M_P!W&?W7_ \X_P" UW]<;\-M-G31;C7M33;J&NR_:Y >J1_\LT^@7G\:[*F
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M%/4M U/2(4EU"U,4;MM5MZL,]<<$U6L;"ZU*Z6VL83-*P)"@@<#N2>!7I.L
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M'K7=:-H6B67B6/\ L[4WEO+0L)89,'.5(..!R,\XSC'-<MXQ_P"1NOO]Y?\
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M+5W-<-X1_P"2H>./^W#_ -$M7<T %%%% !1110 4444 %%%% !1110 4444
M%%%% !6+XS_Y$/7_ /L&7/\ Z*:MJL7QG_R(>O\ _8,N?_134 4O!_\ R(^A
M?]@ZW_\ 1:UL5C^#_P#D1]"_[!UO_P"BUK8H **** ,+Q5H\>KV<(GU%;!(V
M.7< JV>QR17./\.8HH#-)K:)$!N,C0 *!ZYWU?\ B*'_ +-LG*EK=;C]X >I
MQQ^FZM0^+/#[V)+7<1C*8,)0Y(Q]W;C\/2K5[:$Z7$\*:'#HUE*;>^2^CN&#
M"1% 7CCC!.:WJX_X=-(=+O -WV<3_N@PZ<<_TKL*E[C6P4444AG,_"#_ ))3
MH_\ VW_]'R5VM<5\(/\ DE.C_P#;?_T?)7:TWN 4444@"BBB@#S_ .$__)+]
M)_[;?^CGKH-8T*SUR&..^#XB8LI1L$5S_P )_P#DE^D_]MO_ $<]=C3Z@>:>
M(O#FG:?K&GZ=:%XOM3#?-*^0H)QTK7U7P)I-MI-Q-!--%)%&7#R."O'8\#KT
MK;\1^'(O$5O$CS-!)"24<+NZ]01^ KEQ\/\ 59,17&J1^0.P+M@?[IP/UJK^
M9-CH?!$L,WA>$P0B$JS+( 3AF'\7)[C%5?']C/<Z)'<V['%J^Z11W4\9_"M[
M2M-ATC38K*VR4C'WCU8GDDU;90RE6 ((P01UJ;ZW'T/,M+\&WFK:=%>6NI1>
M7(.C%LJ>X-&J>"K_ $S3)[R:^CD2)<LJELGG%=E/KVBZ%J":6$%NS$';#$ B
MEO7%6->U?3M*M%&K)YD4YVB/R]X;'/(/'I578K(B\)?\BG8?]<S_ #-;-5M-
MEM)]-@ETY52V=<QJB;0!].U6:E[E'*6W_)=#_P!BW_[<UW5<+;?\ET/_ &+?
M_MS7=4 %%%%( HHHH XKXD_\RG_V,MG_ .SUVM<5\2?^93_[&6S_ /9Z[6F
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M1(AP/7 .:R%5G=412S,<!0,DGTKV2ZO$36+>PFP4NX9, ]RN./R+?E7!>'M
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M* "BBB@ HHHH **** "BBB@ HHHH *X'X?\ ^L\5_P#8R7G_ ++7?5P/P_\
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M;[2S9'$9Y/\ X]\M<HCM'(KQL4=2"K*<$'U%6_[8U,3&4:C=^85"E_/;) Y
MSGIR?SH^KRA-RA+=6UU%]=IU*<858;.^EEIV/0V\4P1>+H]'0*+55\DL,8$G
M&!]!]W'J?:N7U6";P=XJ^U6<431R!GMQ("0H/!'!!XSCZ5S32R-,96=C(6W%
MR>2?7/K4MS?7=[M^V74UQLSM\V0MM^F:*>%5-Z;-6?F%;,'6B^9>\G>+[>1L
M:EXDU'Q.EOITT-NI:=2GEJP)8Y4#DGCYJ['^R;SP]X>^R^';?[3>2G]Y.S*N
M#C[V"?P _/W\P1VCD5XV*.I!5E."#ZBKO]NZM_T%+W_P(?\ QHJX9M*,+)+H
M&'QT8N4ZUW)Z76Z7D:-M;W7AGQ%:7WB"VDVLSOPZNSG!YZ]<D'DUTFF:QX=U
M3Q/%-;V-VNH2L2LTC< [3VWD=!CI7!W-]=WNW[9=37&S.WS9"VWZ9J.&>6VF
M66WE>*1?NNC%2/Q%5/#^T5Y/WK6TV(I8U4)<L%>%[ZV;^\Z7Q[)9-KQ2VA=+
MM/\ CYD8_*^57;CGL/8?C53P5_R.%E_VT_\ 1;5BS3RW,S2W$KRR-]YW8L3^
M)HAGEMIEEMY7BD7[KHQ4C\15JBU1]E?I8REB5+%?6+=;V^9WMKJ'V3XH7D#'
M"706,_[P0$?R(_&D\=2Q:9H=OI=F"BW$K2,!R,9W$?\ ?3 _A7"/=7$ES]ID
MGD>?(;S6<ELCH<]:6XNKB\D$EW/+.X& TKECCTR:Q6%M.,K[)?>CJEF-Z-2F
ME\3=GV3=VCM_B!_R!],^I_\ 012?$"&2X;1H85WR2%T11W)V "N*GO+JZ6-;
MJYFF6,802.6"CVSTZ"I'U34))8Y)+ZY>2+/ENTS$IGK@YXHIX:4.37X;_B%;
M'PJ^T33]_E_ ]/T^XMM$73M!N+AGN'B.&+=^N/8=0/IBN=T*U'AWQ]+:73EE
MGB80RO\ Q D,#]?E(^M<;)>7,UR+B:XEDG4@B5G)88Z<]:+F[N+R027<\L[@
M;0TKEB!Z9/UJ8X1JZ;^):^O<NIF49.+4?@>GIV?^9Z?>7/BM-2>*RLK&2VW'
MRYG)&%[9&_.?H*R/#E_*?'FHQZ@T N94V$PD["R8&!GGH#^1KCAK&IB,1C4;
ML(!@*)VQCZ9JHKLCJZ,593D,#@@^M$<':+B[:JVB"IF=ZD9QN[.]F_P6AW^D
M>%[^R\9R:A<^6ELDKLC;P?,W@@ #J.O?\,US7C'_ )&Z^_WE_P#0%K.DU34)
M6C:6^N7:(YC+3,2A]1SQ4$TTMQ,TL\CRR-]YW8DGZDUK3HSC4YYN^ECGKXJE
M.C[*G%KWKZOR.S^&W_'U?_[B?S-5_P#A"-4OM;G>X1;:V>9F\PNK$J23P >O
MUQ7+VUY=6;,UG<S0,PP3$Y4D?A4SZSJDJ%9-2NW4]0T[$']:4J-55)3@TKE0
MQ5!T(4JL6^6^SWN=EK_B&T3Q5I<,3+)!92?OF!X4GCK_ +(YI/%7AC4-9UN*
M[T_RY8)8U!<R !,=_H<]L]ZX&K<.J:A;0B*WOKF*,=$CF90/P!I+#.GRNF]4
MK:E/'QK<\:\=)-/3I;3\CM?&3^9_9&CVTX-[YJ?-NQL. H)[C).?PK5T^+5K
MP/9>)].MIK=4XN0RG<>.W7/O@=*\M,CF4R%V,A;<6)YSZY]:LR:MJ,L)BEU"
MZ>,C!1IF((],9J)81\B@FM.O7Y&L<RC[65247KTOI9='=';^";BUAO=6TZT9
M2%F9X'+9WH"0/KC@_C5Q+OQB9'$EEIL2+G]X[-M(]>&)_2O,D=HY%>-BCJ05
M93@@^HJS+JNHSQ&*>_NI8SU1YF(/X$T3PG--R5M>XJ69J-)0::M?9V^_3H5Y
MI3-,\K@!G8L0!@9)IE%%>@>,]=0HHHH$%=;X2\6G366QU%RUH3A)#UB/_P 3
M_*N2HK*K2C5CRR.C#XBIAZBJ4WJ>ZJP=0RD,I&00>"*6O-O"7BTZ:RV.HN6M
M"<)(>L1_^)_E7I"L'4,I#*1D$'@BOG*]"5&5F?<X3%T\53YH[]5V%HHHK [
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU8KYW$XF5>7D?;X# QPD.\GN_P!#BO\ A4'@;_H!_P#DW/\ _%T?\*@\#?\
M0#_\FY__ (NNUHKD/2.*_P"%0>!O^@'_ .3<_P#\71_PJ#P-_P! /_R;G_\
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MZ/\ A4'@;_H!_P#DW/\ _%UVM% '%?\ "H/ W_0#_P#)N?\ ^+H_X5!X&_Z
M?_DW/_\ %UVM% '%?\*@\#?] /\ \FY__BZ/^%0>!O\ H!_^3<__ ,77:T4
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MN?\ ^+H_X5!X&_Z ?_DW/_\ %UVM% '%?\*@\#?] /\ \FY__BZ/^%0>!O\
MH!_^3<__ ,77:T4 <5_PJ#P-_P! /_R;G_\ BZ/^%0>!O^@'_P"3<_\ \77:
MT4 <5_PJ#P-_T __ ";G_P#BZ/\ A4'@;_H!_P#DW/\ _%UVM% '%?\ "H/
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MI8D]2HHHK,HY7PC_ ,E0\<?]N'_HEJ[FN&\(_P#)4/''_;A_Z):NYH ****
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M>3]LURVM)_\ 2)6WQ/NW+RQQG Y'/O74?\*@\#?] /\ \FY__BZ/B3_S*?\
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M-C1?#&H:[$\MIY21(VPR2O@9QG' )[BI-7\):GHUK]IN!%+"#AGA;(7/ SD
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M?]?47_H8KV6O?RKX)>IZ6"^%G%?\*@\#?] /_P FY_\ XNC_ (5!X&_Z ?\
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M;_H!_P#DW/\ _%UVM% '%?\ "H/ W_0#_P#)N?\ ^+H_X5!X&_Z ?_DW/_\
M%UVM% '%?\*@\#?] /\ \FY__BZ/^%0>!O\ H!_^3<__ ,77:T4 <5_PJ#P-
M_P! /_R;G_\ BZ/^%0>!O^@'_P"3<_\ \77:T4 <5_PJ#P-_T __ ";G_P#B
MZ/\ A4'@;_H!_P#DW/\ _%UVM% '%?\ "H/ W_0#_P#)N?\ ^+H_X5!X&_Z
M?_DW/_\ %UVM% '%?\*@\#?] /\ \FY__BZ/^%0>!O\ H!_^3<__ ,77:T4
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MN?\ ^+K/^&5G!IUIXCLK-/+M[;7[J*),D[44( ,GD\#O7HM<#\/_ /6>*_\
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M7***0!1110 4444 %<'H/_)5O&__ &X?^B#7>5P>@_\ )5O&_P#VX?\ H@T
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M==/AC..<8P,#..X4$\=ZVOAV7/AIP^=HN6"?3:O]<U3V$CJJY+7O^2K>"/\
MM_\ _1 KK:Y+7O\ DJW@C_M__P#1 J"CO**** "BBB@ HHHH **** "BBB@
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M\A':4445F4%%%% !1110!S/P@_Y)3H__ &W_ /1\E=K7%?"#_DE.C_\ ;?\
M]'R5VM-[@%%%%( HHHH XKPQ_P E6\<_]P__ -$&NUKBO#'_ "5;QS_W#_\
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M\#KHWES?: ?OX&S_ %F[KG/3VKG:*'BJC;;ZJWR$ZTV[^5CHM)\0VMAX5O\
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M^6H0@$8'IDGFN=LX]*B^(>EC0C&;8V[$^6Y;YMLF<YYSC'6N_H=@05R6O?\
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M>/TJW10 4444 %%%% !1110!S/P@_P"24Z/_ -M__1\E=K7%?"#_ ))3H_\
MVW_]'R5VM-[@%%%%( HHHH XKPQ_R5;QS_W#_P#T0:[6N*\,?\E6\<_]P_\
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MY\/_ "-'_P#%5ZQ11_:-7LOQ_P P_L/#?S2^]?Y'D_\ PA7B#_GP_P#(T?\
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M:-7LOQ_S#^P\-_-+[U_D>3_\(5X@_P"?#_R-'_\ %4?\(5X@_P"?#_R-'_\
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M"O\ V,EI_P"SUV]<1\3/]7X5_P"QDM/_ &>F@.HHHHI %%%% !1110 4444
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MWZ<'\<5WM%.[%9!1112&<KX1_P"2H>./^W#_ -$M7<UPWA'_ )*AXX_[</\
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M_P#XJO6**/[1J]E^/^8?V'AOYI?>O\CR?_A"O$'_ #X?^1H__BJ/^$*\0?\
M/A_Y&C_^*KUBBC^T:O9?C_F']AX;^:7WK_(\G_X0KQ!_SX?^1H__ (JC_A"O
M$'_/A_Y&C_\ BJ]8HH_M&KV7X_YA_8>&_FE]Z_R/)_\ A"O$'_/A_P"1H_\
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MIW_7U%_Z&*]EKW\J^"7J>G@OA84445[!W!1110 4444 %%%% !1110 4444
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MF.(Y#R83_P#$_P JF4>Q29ZI12*RNH9"&5AD$'((I:S*"BBB@ HHHH ****
M"BBB@#QK7/\ D8=1_P"OJ7_T,U1J]KG_ ",.H_\ 7U+_ .AFJ-?&5/C?J>!+
MXF%%%%9DA1110 4444 %%%% !1110 4444 %%%% !1110 5W/PV_YB7_ &R_
M]GKAJ[GX;?\ ,2_[9?\ L]=V _WF/S_)G1AOXJ_KH=U1117U)[(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*Q_!_P#R(^A?]@ZW_P#1:UL4 %%%% !1110 4444 %%%% ',_"#_ ))3H_\
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M +]O_P#%T?\ "T-:_P"?6P_[]O\ _%UQE%'*@NSL_P#A:&M?\^MA_P!^W_\
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M$VM+]#%HHHKSCE"BBB@ HHHH O:'_P C#IW_ %]1?^ABO9:\:T/_ )&'3O\
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MBBB@ KA_%W_)4/ __;__ .B5KN*X?Q=_R5#P/_V__P#HE:: ZFBBBD 4444
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M%H7A^QTN#&RU@6/(_B(')_$Y/XUH4 %%%% !1110 4444 %8OC3_ )$+7_\
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MBBBO8.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA?A?_H6](_\  "+_ .)H_P"$+\+_ /0MZ1_X 1?_ !- !_PFGA?_ *&32/\
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MJC_A-/"__0R:1_X'Q?\ Q5'_  A?A?\ Z%O2/_ "+_XFC_A"_"__ $+>D?\
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M- !_PFGA?_H9-(_\#XO_ (JC_A-/"_\ T,FD?^!\7_Q5'_"%^%_^A;TC_P
M(O\ XFC_ (0OPO\ ]"WI'_@!%_\ $T '_":>%_\ H9-(_P# ^+_XJC_A-/"_
M_0R:1_X'Q?\ Q5'_  A?A?\ Z%O2/_ "+_XFC_A"_"__ $+>D?\ @!%_\30
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MAZ__ -@RY_\ 134 4O!__(CZ%_V#K?\ ]%K6Q6/X/_Y$?0O^P=;_ /HM:V*
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M10 4444 %%%% !1110 4444 %%%% !1110 5Z%X,\<K%&NG:[.J(HQ%=2-@
M#^%B?YUY[7H7@SP,LL:ZCKL"NC#,5K(N00?XF!_E4RM;4I7.L_X33PO_ -#)
MI'_@?%_\51_PFGA?_H9-(_\  ^+_ .*H_P"$+\+_ /0MZ1_X 1?_ !-'_"%^
M%_\ H6](_P# "+_XFLBP_P"$T\+_ /0R:1_X'Q?_ !5'_":>%_\ H9-(_P#
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M%O2/_ "+_P")H /^$T\+_P#0R:1_X'Q?_%4?\)IX7_Z&32/_  /B_P#BJ/\
MA"_"_P#T+>D?^ $7_P 31_PA?A?_ *%O2/\ P B_^)H /^$T\+_]#)I'_@?%
M_P#%4?\ ":>%_P#H9-(_\#XO_BJ/^$+\+_\ 0MZ1_P" $7_Q-'_"%^%_^A;T
MC_P B_\ B: #_A-/"_\ T,FD?^!\7_Q5'_":>%_^ADTC_P #XO\ XJC_ (0O
MPO\ ]"WI'_@!%_\ $T?\(7X7_P"A;TC_ , (O_B: #_A-/"__0R:1_X'Q?\
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M+>D?^ $7_P 31_PA?A?_ *%O2/\ P B_^)H /^$T\+_]#)I'_@?%_P#%4?\
M":>%_P#H9-(_\#XO_BJ/^$+\+_\ 0MZ1_P" $7_Q-'_"%^%_^A;TC_P B_\
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M"_\ T,FD?^!\7_Q5'_":>%_^ADTC_P #XO\ XJC_ (0OPO\ ]"WI'_@!%_\
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MVCL9O<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NT\%^"VU1DU'5$*V2
MG,<9X,Q_^)_G1X+\%MJC)J.J(5LE.8XSP9C_ /$_SKU-55%"H JJ,  8 %1*
M71%) JJBA4 55&  , "EHHK,L**** "BBB@ HHHH \:US_D8=1_Z^I?_ $,U
M1J]KG_(PZC_U]2_^AFJ-?&5/C?J>!+XF%%%%9DA1110 4444 %%%% !1110
M4444 %%%% !1110 5W/PV_YB7_;+_P!GKAJ[GX;?\Q+_ +9?^SUW8#_>8_/\
MF=&&_BK^NAW5%%%?4GLA1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$?$
MS_5^%?\ L9+3_P!GKMZXCXF?ZOPK_P!C):?^STT!U%%%%( HHHH **** "BB
MB@ HHHH **** .3^(MY,OAI=*L6Q>:S.EA#CL'/S'Z;<_G79Z?90Z9IMM8VJ
M[8;:)8HQZ*HP/Y5Q5NO_  D'Q=S]ZT\.6OU'VB8?T3\B*[VF 4444@"BBB@
MHHHH **** "L7QI_R(6O_P#8,N?_ $4U;58OC3_D0M?_ .P9<_\ HIJ *7@_
M_D1]"_[!UO\ ^BUK8K'\'_\ (CZ%_P!@ZW_]%K6Q0 4444 %%%% !1110 44
M44 <KX1_Y*AXX_[</_1+5W-<-X1_Y*AXX_[</_1+5W- !1110 4444 %%%%
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MT"BBBD,**** "BBB@ HHHH HZY_R+VH_]>LO_H!KQJO9=<_Y%[4?^O67_P!
M->-5X&:_''T/,QOQ(****\<X0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** +VA_\C#IW_7U%_P"ABO9:\:T/_D8=._Z^HO\
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M )*MXW_[</\ T0:[RN#T'_DJWC?_ +</_1!H ZVBBB@ HHHH **** "BBB@
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M_P"^W_\ B:/J>(_E8>PJ]CE**ZO_ (5WJW_/Q9?]]O\ _$T?\*[U;_GXLO\
MOM__ (FCZGB/Y6'L*O8Y2BNK_P"%=ZM_S\67_?;_ /Q-'_"N]6_Y^++_ +[?
M_P")H^IXC^5A["KV.4HKJ_\ A7>K?\_%E_WV_P#\31_PKO5O^?BR_P"^W_\
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M7%S8S11)D#<[1D 9/ Y/>@#,\'_\B/H7_8.M_P#T6M;%<-H]]XYTG0['3O\
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M;-1]LCGW/YP<?=Y'!/;MUYKOJ "BBBD 4444 %%%% !1110 4444 <9\4/\
MD6+?_K\7_P! >O*J]H\9:#=>(='BM+*2%)$G$I,Q(& K#L#SR*XK_A5^M?\
M/U8?]_'_ /B*TBU8AK4XRBNS_P"%7ZU_S]6'_?Q__B*/^%7ZU_S]6'_?Q_\
MXBJYD*S.,HKL_P#A5^M?\_5A_P!_'_\ B*/^%7ZU_P _5A_W\?\ ^(HYD%F<
M9179_P#"K]:_Y^K#_OX__P 11_PJ_6O^?JP_[^/_ /$4<R"S.,HKL_\ A5^M
M?\_5A_W\?_XBC_A5^M?\_5A_W\?_ .(HYD%F<9179_\ "K]:_P"?JP_[^/\
M_$4?\*OUK_GZL/\ OX__ ,11S(+,XRBNS_X5?K7_ #]6'_?Q_P#XBC_A5^M?
M\_5A_P!_'_\ B*.9!9G&45V?_"K]:_Y^K#_OX_\ \11_PJ_6O^?JP_[^/_\
M$4<R"S.,HKL_^%7ZU_S]6'_?Q_\ XBC_ (5?K7_/U8?]_'_^(HYD%F<9179_
M\*OUK_GZL/\ OX__ ,11_P *OUK_ )^K#_OX_P#\11S(+,XRBNS_ .%7ZU_S
M]6'_ '\?_P"(H_X5?K7_ #]6'_?Q_P#XBCF069QE%=G_ ,*OUK_GZL/^_C__
M !%'_"K]:_Y^K#_OX_\ \11S(+,XRBNS_P"%7ZU_S]6'_?Q__B*/^%7ZU_S]
M6'_?Q_\ XBCF069QE%=G_P *OUK_ )^K#_OX_P#\11_PJ_6O^?JP_P"_C_\
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M^HK_ .2W_P!E1_PK;_J*_P#DM_\ 94?4,3_+^*_S#ZM5[?D<-17<_P#"MO\
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M[U\)?^3-,LO#GC&]\;:)K'B230Q;Z7Y^%L&FWMYD>WHXP>0.X[]: .^HHHH
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M%_Z"]A_X$I_C1_PD.B_]!>P_\"4_QH_X1[1?^@18?^ R?X4?\(]HO_0(L/\
MP&3_  HT#4/^$AT7_H+V'_@2G^-'_"0Z+_T%[#_P)3_&C_A'M%_Z!%A_X#)_
MA1_PCVB_] BP_P# 9/\ "C0-0_X2'1?^@O8?^!*?XT?\)#HO_07L/_ E/\:/
M^$>T7_H$6'_@,G^%'_"/:+_T"+#_ ,!D_P *- U#_A(=%_Z"]A_X$I_C1_PD
M.B_]!>P_\"4_QH_X1[1?^@18?^ R?X4?\(]HO_0(L/\ P&3_  HT#4/^$AT7
M_H+V'_@2G^-'_"0Z+_T%[#_P)3_&C_A'M%_Z!%A_X#)_A1_PCVB_] BP_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6G@^]FM=.M(95\O;)' JL/WBC@@>E=?0 4444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ2#;^H)_6N@TS3;?2--BL;,,(8L[=QR>22>?J32;N"1;HHHJ2@HHHH ****
M"N=\>_\ (D7_ /VS_P#1BUT5<[X]_P"1(O\ _MG_ .C%IK<3V.BHHHI#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML!T5%<[_ ,5I_P!0'_R-1_Q6G_4!_P#(U%@.BHKG?^*T_P"H#_Y&H_XK3_J
M_P#D:BP'145SO_%:?]0'_P C4?\ %:?]0'_R-18#HJ*YW_BM/^H#_P"1J/\
MBM/^H#_Y&HL!T5<[X]_Y$B__ .V?_HQ:/^*T_P"H#_Y&JGJNE^+-:TR73[Q]
M&2&8KO:+S=PPP/&>.U"W ZZBBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .=UG_D=_#7_ &]?^BQ715A:_I>I7>IZ9J&CO:B:Q,ORW6[:
MV]0/X>>QJ+_BM/\ J _^1J8CHJ*YW_BM/^H#_P"1J/\ BM/^H#_Y&HL!T5%<
M[_Q6G_4!_P#(U'_%:?\ 4!_\C46 Z*BN=_XK3_J _P#D:C_BM/\ J _^1J+
M=%17._\ %:?]0'_R-1_Q6G_4!_\ (U%@.BHKG?\ BM/^H#_Y&H_XK3_J _\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%4X-3AN)EB19 S9QD#'3ZU<H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BJ5[J/V281^
M5ORN[.[']*M1/YL*28QN4-CTS0 ^BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BJ][=?9(1)LWY;;C.*+*Z^UPF39LPVW&<T 6**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .?TS_D)1?C_ "-=!7/Z9_R$HOQ_D:Z"@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8FL_\?B?]<Q_,UK6G_'G#_US7^59.L_\?B?]<Q_,
MUK6G_'G#_P!<U_E0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5DZY_RP_X
M%_2M:LG7/^6'_ OZ4 6],_Y!L7X_S-6ZJ:9_R#8OQ_F:MT %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^L_\>:?]=!_(T:-_
MQYO_ -=#_(4:S_QYI_UT'\C1HW_'F_\ UT/\A0!H4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#:* .CHKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\
M"C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3
MO/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ
M/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\
M"C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3
MO/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ
M/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\
M"C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3
MO/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ
M/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\
M"C^T[S_GM_XZ/\* .@HKG_[3O/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@HKG_[3
MO/\ GM_XZ/\ "C^T[S_GM_XZ/\* .@K)US_EA_P+^E5?[3O/^>W_ (Z/\*AG
MNIKG;YS[MO3@"@#;TS_D&Q?C_,U;JIIG_(-B_'^9JW0 4444 %%%% !1110
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M #WB_P"^Q63_ &-<?WXOS/\ A1_8UQ_?B_,_X4 :WVNW_P">\7_?8H^UV_\
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M^>\7_?8H^UV__/>+_OL5D_V-<?WXOS/^%']C7']^+\S_ (4 :WVNW_Y[Q?\
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M7;_\]XO^^Q63_8UQ_?B_,_X4?V-<?WXOS/\ A0!K?:[?_GO%_P!]BC[7;_\
M/>+_ +[%9/\ 8UQ_?B_,_P"%']C7']^+\S_A0!K?:[?_ )[Q?]]BC[7;_P#/
M>+_OL5D_V-<?WXOS/^%']C7']^+\S_A0!K?:[?\ Y[Q?]]BC[7;_ //>+_OL
M5D_V-<?WXOS/^%']C7']^+\S_A0!K?:[?_GO%_WV*S-8ECE\GRY%?&[.ULXZ
M4S^QKC^_%^9_PJO=64EGL\PJ=V<;3Z4 :FG7$*6$:O+&K#.06 /4U:^UV_\
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M9_PH UOM=O\ \]XO^^Q1]KM_^>\7_?8K)_L:X_OQ?F?\*/[&N/[\7YG_  H
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M?Y"M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,G7/^6'_ OZ5;TS_D&Q?C_,U4US_EA_P+^E6],_
MY!L7X_S- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)US_EA_
MP+^E:U9.N?\ +#_@7]* +>F?\@V+\?YFK=5-,_Y!L7X_S-6Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#$UG_C\3_KF/YFM:T_X\X?^N:_RK)UG_C\3_KF/YFM
M:T_X\X?^N:_RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R=<_P"6'_ O
MZ5K5DZY_RP_X%_2@"WIG_(-B_'^9JW533/\ D&Q?C_,U;H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0!5TU2NGQA@0>>"/<U:HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKG-:\<:;H6I-97<-T
M\JJ&)B12.?JPJM:_$C0KB98Y/M-L&.-\T8VC_ODFG9BNCK**:CI+&LD;*Z,
MRLIR"#W!IU(9BZPC->)M4G]V.@]S6K:\6<.?^>:_RJ6B@ HHJIJ6IVFD6+W=
M_*(HEXSU+'L .YH MT5R,/Q*T*6X$;BZA4_\M)(QM'Y$G]*ZU'61%=&#*PRK
M Y!'K3LT M%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BL;Q!XGLO#8M_MT<\GVC=L$*@XVXSG)'J*R(_B
M;HCN%:&]C']YHUP/R8FG9BNCL**KV5];:E:+<V,RS0OT=?\ /%6*0PJM>627
MFS>S+LSC'O\ _JJS10!';P"W@6)22%SR?KFI**KWM];:;:-<WTRPPIU=O\\T
M 6**X]?B9H9FV&.\5<_ZPQ+C_P!"S^E=.^I6<>FG4'N(Q:!-_G9^7%.S LT5
MR'_"R]#\[9LN]N?]9Y0V_P#H6?TKJK6ZAO;6.YM9%EAE7<CKT(HLT!+1112
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M"=WXCZ4_2/\ BHOBA=7Q^:WLL[/0[?E7]<M_G%*P[GHM%%%2,**** "BBB@
MHHHH **** "BBB@ HHHH **Y+_A9&BB\^SR1W:8?89&C7:.<9X;./PKK:=K
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MGP[U5M0\-_9YI"\UF_E\DD[#RO/YCZ"N-\9W;ZYX@OY;=RUMIL80'M]\*?\
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MQYXB^0>_7=C\*=M N=912(ZR(KHP96&58'((]:Y/Q_KMQI>GV]IITK1W5V^
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M6M=UF/4/%DT0CC/%NISN .=O' !]<D_SJYXU\-:AJ>HV>IZ5''<26X"M;R8
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M\5Q'G.R5 PSZX-2T4AF=_P (]HO_ $"+#_P&3_"K,5A9P6IMH+2".!CDQ)&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5E^(M'DUW2&L8[LV@=@7
M<)NW =L9'M^5:E% &;H&C1Z#H\5C%(9=A+/(1C>Q/7';T_"M*BB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAK
M>G2ZMH\]C#=&U,X"M*$W$+GD8R.HX^A-7Z* ,GPWH,?AW2191S&8ES(\A7;N
M)P.G;@#O6M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW$4DC;G6)P%8]SR#U]J=T*QTU%,@A6WMXX8\[(T"+GT Q3Z@H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img70551829_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,M!@L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **SY-;TZ+4UTU[D"[8@"/8W?D<XQ^M:% !1110 4444 %%%% !115
M'4=8L-)6-KZ?RA(2$^5FSCKT!H O44V.198UD0Y1P&4^H-.H **** "BBB@
MHHHH **** "BBB@ HHJ"\O+?3[1[JZD\N&/&YL$XR<=![F@">BJUC?VVI6JW
M-I+YD+$@-@CI[&K- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%9^HZWIVDO&E]<B)I!E1L8Y_(&M"@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BL^'6].N-2?3HKD-=(2&CV-QCK
MSC%:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45GKK>G/JATQ;D&\!(\O8W89ZXQT]ZT* "BBB@ HHHH
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M]=C_ "KI-#_Y &F_]>L7_H(I]!=2_117%Z_XCOY]7_L;1 ?.!V/(!SN[@9Z
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MTUC5=4DMGUJ\AEMSN='E=L@-@CK6_P#$+_D 0?\ 7TO_ *"].UF%]#8\-?\
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M19M0M(;RUC+RV^0ZJ,DH?3Z?UI+<'L=8JA5"J % P .U<I\040Z#"Y W+<*
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M=6T,X4Y42QAL?3-3T4 (JA5"J % P .U0V]C:6A8VUK!"7^\8XPN?KBIZ*
MC(P:I_V1IA??_9UIO_O>2N?Y5<HH     !@#H*KI8VD=RUREK L[9W2K& Q^
MIZU8HH *J2:7I\LIEDL+5Y"<EVA4DGZXJW10 @ 4    < "J]QI]E=MNN+.W
MF;UDB5C^HJS10!!;V5I:9^S6T,.>#Y<87^53T44 5[C3[*[8-<VEO,1T,D8;
M'YBG"TMA;FW%O$(",&+8-I_#I4U% $<%O#:Q"*WACBC'1(U"@?@*DHHH KS6
M-I<3I/-:P22IC;(\8++CG@GI5BBB@ JNUA9O="Z:T@:X&")3&"_'3G&:L44
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MK']15FB@".&"&WC\N"*.),YVHH4?D*9<V5K>;?M5M#/L^[YL8;'TS4]%
M  , =!1110!4FTO3[B0O/8VLKGJSPJQ/YBIX8(;>/RX(HXDSG:BA1^0J2B@
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M?<\FK%-NX(****0%>WL+.T=GMK2"%F&"8XPI/Y"K%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@#E_&'C#_A$_L7^@_:OM._\ Y;;-NW;_ +)S][]*YC_A<'_4"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .-\
M>>$[_P 4?V?]BFMH_L_F;_/9AG=MQC /]TUQW_"IM>_Y^]-_[^/_ /$5['16
MD:LHJR-X8F<(\J/-/"OP\U;0_$MIJ5U<63PP[]RQ.Y8Y1E&,J!U/K7I=%%3*
M3D[LBI4E4=Y'/>*/#]QK(MIK*6.*ZA)&YR0"I'/(!_R36II&GKI>DVUDN"8D
MPQ'=NI/YYJ[14F9AZ%HMQ87NH7UZ\3W-U)D&,DA5ZXY _P @59\0:5_;.CS6
M8*K(<-&S= P_R1^-:=% ',WVA:IJ6F:;IT]Q;K#%M^U,C-F3' QQZ>N.?I6G
MJ^C0ZGHKZ> $"J/)/9".G^%:=% %'1X+VUTN&WOWCDGC&W?&20P'3J!SBI=0
MCNI;">.RD2.Y92(W?HI]:LT4 <7IF@>)=)606T^F;Y6W22.79F/N=M=+I2:H
MD#C59+9Y=WR&W!QMQWR!5^BBX%#6[&34M&N;.%D625<*7) Z@\XIVD6<FGZ1
M:VDK*TD485BO0GVJ[10 V3?Y3^45$FT[=W3/;-<??:'XHU&XM)Y[G3-]K)YD
M>W>.<@\_+["NRHH RK6'67TRZBOY[873JPADM]P"Y& 3D>M&C6>I6.CF"\NE
MN+P%BLC,S 9Z D\FM6B@#C;[0_%&HW%I//<Z9OM9/,CV[QSD'GY?85MP6VKS
MZ1>6VI2VC3RHR1M#D* 5QSD>M:]%.X&=H5A+I>BVUE.R-)$"&*$D<L3QGZU7
M\-:3/HVFR6]P\;NTS2 QDD8('J!Z5LT4@,;2-)GL-7U:[E>-H[R16C"DY &[
MKQ[UG?\ "/:MIE_<3:'>6Z07#;WAN%.%/M@'^E=511<#A_$-I<6NAQP7]Z]S
MJ%W>*T; [4C8#''MCZ=?:M"]M_$>FZ?)=C78IQ"A=DDME4$ =,CK6WJ>E6FK
MVGV>\CW)G<I!P5/J#64?!UFZJD]_J5Q"IR(9;C*?EBF!J:-?MJFD6UZ\?EM*
MN2HZ YQQ[<5>ID44<$211($C0!54= !3Z0!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;<!\H!/N<4W,O\
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M 'V?\*,R_P!Q/^^S_A3Z* &9E_N)_P!]G_"C,O\ <3_OL_X4^B@!F9?[B?\
M?9_PHS+_ '$_[[/^%/HH 9F7^XG_ 'V?\*,R_P!Q/^^S_A3Z* &9E_N)_P!]
MG_"C,O\ <3_OL_X4^B@!F9?[B?\ ?9_PHS+_ '$_[[/^%/HH 9F7^XG_ 'V?
M\*,R_P!Q/^^S_A3Z* &9E_N)_P!]G_"C,O\ <3_OL_X4^B@!F9?[B?\ ?9_P
MHS+_ '$_[[/^%/HH 9F7^XG_ 'V?\*,R_P!Q/^^S_A3Z* &9E_N)_P!]G_"C
M,O\ <3_OL_X4^B@!F9?[B?\ ?9_PHS+_ '$_[[/^%/HH 9F7^XG_ 'V?\*,R
M_P!Q/^^S_A3Z* &9E_N)_P!]G_"C,O\ <3_OL_X4^B@!F9?[B?\ ?9_PHS+_
M '$_[[/^%/HH 9F7^XG_ 'V?\*,R_P!Q/^^S_A3Z* &9E_N)_P!]G_"C,O\
M<3_OL_X4^B@!F9?[B?\ ?9_PHS+_ '$_[[/^%/HH 9F7^XG_ 'V?\*,R_P!Q
M/^^S_A3Z* &9E_N)_P!]G_"C,O\ <3_OL_X4^B@!F9?[B?\ ?9_PHS+_ '$_
M[[/^%/HH 9F7^XG_ 'V?\*,R_P!Q/^^S_A3Z* &9E_N)_P!]G_"C,O\ <3_O
ML_X4^B@!F9?[B?\ ?9_PHS+_ '$_[[/^%/HH 9F7^XG_ 'V?\*,R_P!Q/^^S
M_A3Z* &9E_N)_P!]G_"C,O\ <3_OL_X4^B@!F9?[B?\ ?9_PHS+_ '$_[[/^
M%/HH 9F7^XG_ 'V?\*,R_P!Q/^^S_A3Z* &9E_N)_P!]G_"C,O\ <3_OL_X4
M^B@!F9?[B?\ ?9_PHS+_ '$_[[/^%/HH 9F7^XG_ 'V?\*,R_P!Q/^^S_A3Z
M* &9E_N)_P!]G_"C,O\ <3_OL_X4^B@!F9?[B?\ ?9_PHS+_ '$_[[/^%/HH
M 9F7^XG_ 'V?\*,R_P!Q/^^S_A3Z* &9E_N)_P!]G_"C,O\ <3_OL_X4^B@!
MF9?[B?\ ?9_PHS+_ '$_[[/^%/HH 9F7^XG_ 'V?\*,R_P!Q/^^S_A3Z* &9
ME_N)_P!]G_"C,O\ <3_OL_X4^B@!F9?[B?\ ?9_PHS+_ '$_[[/^%/HH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XWQ[_S#_P#MI_[+
M7&5W/C6SN;O[#]FMYIMOF;O+0MC.WKBN3_LC4_\ H'7?_?AO\*\'&PDZ\FEV
M_(\W$1;J/0N>%/\ D9;3_@?_ * U>F5Y[X9TV^@\0VLLUE<1QKORSQ, /D/<
MBO0J[\N35)W[_P"1TX5-0=^YR/AG.E>(=4T1N(RWGP GL?\ ZQ'Y&GZ+_P 3
M;Q;J6JG#16W^C0'^9'Z_]]4WQ99WT&H66KZ9!++<(&B<1(6."#@X'U/Z5K>&
M=..F:#;PNI$SCS)0>NYN<'Z<#\*] Z3+\3$ZGK6EZ&O*,_GS@?W1G^@;]*CO
MC_8OCRVN\[;?44\J3C W<#^>T_B:98:$NO:QJ6H:S9S",R!((Y-T9VCOQ@],
M?K2Z]X.L(M)EFTJT=+N(AU".[E@#R "3]?PH ZNZAAN;26&X"F%T(?=TQ7FN
M@>7=Z[96%U<-)I]O)(UH'7 D;/ Y^F?T[UTFKW6JZCH=C96]G<I<WJA;AVB(
M$0Z-GCC)_3ZU-K7AI&\/006"D7-B-\#+]YB.OXGK]:$!K:EKFG:0T:WUQY1D
M!*_(S9QUZ T[3=7L=721[&?S5C(#'8RX/X@4:/=SWVEPS75O)!<8Q(DB%3N'
M4X/8]:EU"XEM+">>&!YY44E8D&2Q]*0&3XKU5;+2WM(_WEY=J8HHEY)SP3C_
M #S19"/PIX30W6-\2%G4'[SDYVC\\?A7.Z5=WEOJ$VIZCH>IW5](<*PMR%C7
MT7-=1#Y'B;3WCU#3+F"-9!^[N R$X'48P>],#G9+<)X3U2_O)HWU&^4.XW#*
M+D84?AV_PKI/"[HWARQ564E81N /2LC6_"&E0Z-<R6&G.;I5S&$=V.<CH,G-
M:7A728=-TB)Q;-#<SQJ9PQ;)(SU!Z=30!N5@>*]56RTM[2/]Y>7:F**)>2<\
M$X_SS6MJ%Q+:6$\\,#SRHI*Q(,ECZ5P^E7=Y;ZA-J>HZ'J=U?2'"L+<A8U]%
MS0@.M\/::VDZ);VDF/-4%I,'^(G)_+I^%:E95KJMQ>Z9=7*Z;<V\\2MY<-PA
M!<A<C'X\5#9:IJ<GAR2^N].<7B;MMNB,"WIP<FD!'XKU5;+2WM(_WEY=J8HH
MEY)SP3C_ #S26NFMI/@J:TDQYJVTK28/\1!)_+I^%<]I5W>6^H3:GJ.AZG=7
MTAPK"W(6-?1<UTXOIM6T'4"=/NK:3RG18YD(9_EXP.],#G]!\+Q:QH,%Q?74
M[%E*P*K86( D<#USS3/#ND/XBTW?JM[/+;V[&&*%6P!CG)/?KQ72^%H9;?PU
M913Q/%(JMN1U((^8]0:J>"[:XM-&FCN()(7-R[!9%*DC YYHN!#X0::WN=6T
MMYGEALY@(BQR0#N_P%4-+TU?%TUYJ.IR3-"LQB@A5\!0/_UC]:U?#]K<0>(-
M?EE@DCCEF0QLRD!Q\W0]^HK.L&U/PK<W=I_9EQ>V<LIEADMUW$9]<?0?E[T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%% !1110 4444 %%%% !1110 R:9+>"2:5ML<:EV/H ,FN6\(Q27]W?:_<
MA[ES'$#_  H/_P!0'X5K>(]/O=4TIK*RDBC,C 2-(2/EZX& >^*O6-I'86,%
MI$/DB0*/?WI@<YIYQ\2-6!X+6R$>_$='CX@Z591 _.UVI"^ORM_B*MZQH-U<
M:G%JNEW*6]ZB[&\P95Q[]?Y?RJ&#0-2O=4M[W7+N"46QS%! #MW>IR![4 7M
M0\/6M[>/>_:;JUF9-DCV\NS>OH>#7,"2VBA?4HXLZ1I1V6<1/^OF)QO/KR<_
MY-=1K]O?WUM%8V0*1W#;;B<,!Y<?< =23[?UI=0T*"[\/-I,.(D" 1G&=I!R
M#_C]: *4.L:K::G8VVK06HCO01&UONRC<<-GZXXKHZYV'1]5N]2L;G5I[4I9
M F-;?<2[$ 98GZ=JZ*D 4444 %%%% !1110 4444 %%<9X^_YA__ &T_]EKB
MZ[J.#]I!3YK7\CR<5FGL*KI\E[>?EZ'L]0W=W#8VLES</LAC&6;:3@?0<UYQ
MX3_Y&:S_ .!_^@-7I%S!'=6TMO*,QRH48>Q&*PQ%'V,N6]SKP>*^LTW.UM;!
M:W,-Y;1W%NX>&0;E8#J*AO=3L]/>!+J;8T[[(AM+%F].![BL#P3.\-M>:1.?
MWUE,0!G^$D]/Q!_,4U\:QX^1>&@TR+)]/,/_ -<C_OFL;'6=1//';023S.$B
MC4LS'L!4&G:I9ZK T]E.)8U;:3M(P?H0#6+XSN':QMM+@/[^_F6,#_9!&?UQ
M^M4M&B7P_P",+G25W"VNXQ)#GU __:_(46 Z:]U6RT^:"*[G\IIVVQY4X)X[
MXP.HZU8GFCMH))IG"1QJ69CV K/U_2$UK29+8X$H^:)CV8=/\*Y!=3OO$=M9
M^'F62.=7(O9#UV(?\Y]P/6BP'=V5[;ZC:I=6KEX7SM8J5S@X[@5.S*B%F8*J
MC)). !3+>"*UMXX(4"11J%51V HGACN;>2"5=T4BE'7.,@C!%(#(;Q=H*R^4
M=13=G&0C$?GC%;*.DJ*\;*Z,,JRG((K$UVPTNT\-7:M:P1Q)"=F$ (;'RX/K
MG%-\'B2#PI;-<-M7#."QQM3)(_#O3 T]1U6QTF%9;ZX$2,=J\$DGZ $U/;7,
M-Y;1W$#[XI!N5L$9'XUPFIJ^O6.IZY*&%I ABLD(Z\@,_P#G^E=7X9_Y%K3_
M /KB* -1F5$+,P55&22< "L5O%V@K+Y1U%-V<9",1^>,5KSPQW-O)!*NZ*12
MCKG&01@BL;7;#2[3PU=JUK!'$D)V80 AL?+@^N<4@-M'25%>-E=&&593D$4K
M,J(69@JJ,DDX %87@V.:/PO:><3SN9 >RDG'^/XUM3PQW-O)!*NZ*12CKG&0
M1@B@#(;Q=H*R^4=13=G&0C$?GC%;*.DJ*\;*Z,,JRG((K$UVPTNT\-7:M:P1
MQ)"=F$ (;'RX/KG%)X-CFC\+VGG$\[F0'LI)Q_C^-,"?Q'J[Z-I9GA17N'<1
MQ(W()/T]LUJ0F4P1F8*)=HWA>F['./;-<Q?8UCQO:68^:WTY/.EZ8WG&!_Z#
M^M7?$NHS0P1:;8\W]Z?+CP?N+W8^G^?2@"Y:Z]IE[?O96UTLEPF<J%;''7G&
M#^=:-<+I&GQ:5X\6RAY6.TQN/5C@9/XFNZI, K..O:8-4_LW[4IN\[?+"L><
M9QG&/UJ/Q!JQTK3BT0WW4Q\JWC')9S[>W^>M<DFE?V3XHT*)VWW$@,L[G^)S
MG/\ A32 ]"HHKF];\0WFF:W;V-M:+<^=#N5!D,7R0.<XQQZ4@.DHKD)O$^KZ
M1>1Q:QIT12=3Y/V4DDL.W).>H'XTZ?Q%KFER6]QJNG6\=C,X4^6Q+QY]><9_
M#M3L!UM%96O:TFB6(F\LRS2-LBB!^\W^%9\.I^)+>:!]0TN!K:1U1OLQ)>/)
MQDC)S2 Z6BN<FUK4[S6;C3]&M[8BUP)IKDMM#'L-O/K^51Z%K.M:AK%Q9WD=
MC$MJ<3*@?><@X*\D8SBG8#IZ***0!1110 C;@/E )]SBFYE_N)_WV?\ "GT4
M ,S+_<3_ +[/^%&9?[B?]]G_  I]% #,R_W$_P"^S_A1F7^XG_?9_P *?10
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M +[/^%&9?[B?]]G_  I]% #,R_W$_P"^S_A1F7^XG_?9_P *?10 S,O]Q/\
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M  I]% #,R_W$_P"^S_A1F7^XG_?9_P *?10 S,O]Q/\ OL_X49E_N)_WV?\
M"GT4 ,S+_<3_ +[/^%&9?[B?]]G_  I]% #,R_W$_P"^S_A1F7^XG_?9_P *
M?10 S,O]Q/\ OL_X49E_N)_WV?\ "GT4 ,S+_<3_ +[/^%&9?[B?]]G_  I]
M% '*_$(R?\(-J.Y5 _==&S_RU3VKPJO=_B)_R(FI?]LO_1J5X1770^$]/!?P
MWZA1116YV!1110 4444 %=U\*-P\4W.T G[$_4X_C2N%KO/A-_R-5U_UY/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#E_B)_R(FI?]LO_1J5X17N_P 1/^1$U+_ME_Z-
M2O"*ZZ'PGIX+^&_4****W.P**** "BBB@ KO/A-_R-5U_P!>3_\ H:5P==Y\
M)O\ D:KK_KR?_P!#2LZGP,QQ'\*1['1117">,>-4445\H>*%%%% !1110 44
M44 7=&_Y#=A_U\1_^A"O6*\GT;_D-V'_ %\1_P#H0KUBO9RSX)>IWX3X6%>8
M^*_^1EO/JG_H"UZ=7F/BO_D9;SZI_P"@+7T& _B/T_R./.?X"]?T9C4445ZQ
M\T%%%% !1110 4444 >MZ3_R!K'_ *]X_P#T$5<JGI/_ "!K'_KWC_\ 015R
MOG9_$S[BE\$?1'!_$C[VF_27_P!EKA*[OXD?>TWZ2_\ LM<)51V&]PHHHIB"
MBBB@ HHHH *]+^'W_(OS?]?+?^@K7FE>E_#[_D7YO^OEO_05I2V*1UE%%%9E
M!1110 4444 </?6T]W\0I((KN2U9K8?O$'S8P,@>GUJ35X[_ ,+S6E[!JMY=
M6\DPCDANI-^<\\?D:UM<T*YO+ZWU+3;E;>_@&T%Q\K+SP?S/YU57P_JFI7]O
M/KMY!)%;MO2"W4X)]R0*8#-/./B1JP/!:V0CWXCH\?$'2K*('YVNU(7U^5O\
M15O6-!NKC4XM5TNY2WO478WF#*N/?K_+^50P:!J5[JEO>ZY=P2BV.8H( =N[
MU.0/:@"]J'AZUO;Q[W[3=6LS)LD>WEV;U]#P:Y@26T4+ZE'%G2-*.RSB)_U\
MQ.-Y]>3G_)KJ-?M[^^MHK&R!2.X;;<3A@/+C[@#J2?;^M+J&A07?AYM)AQ$@
M0",XSM(.0?\ 'ZT 4H=8U6TU.QMM6@M1'>@B-K?=E&XX;/UQQ71USL.CZK=Z
ME8W.K3VI2R!,:V^XEV( RQ/T[5T5( HHHH **** "BBB@ HHHH Y+QMK.H:1
M]A^PW'E>;YF_Y%;.-N.H/J:Y/_A,]?\ ^?\ _P#(,?\ \36]\2/^89_VU_\
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MS_A1F7^XG_?9_P *DHH CS+_ '$_[[/^%&9?[B?]]G_"I** (\R_W$_[[/\
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MG_?9_P *,R_W$_[[/^%244 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY_@+U_1F-1117K'S04444 %%%% !1110!ZWI/_(&L?\ KWC_ /015RJ>D_\
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MX'XBERVF[@HXEZ'/]VN&KN_B1][3?I+_ .RUPE5'8;W"BBBF(**** "BBB@
MKTGP 7&@3;54C[2W5L?PK[5YM7I?P^_Y%^;_ *^6_P#05I2V*1U.9?[B?]]G
M_"C,O]Q/^^S_ (4^BLRAF9?[B?\ ?9_PHS+_ '$_[[/^%/HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!R_P 1/^1$U+_ME_Z-2O"*]W^(
MG_(B:E_VR_\ 1J5X1770^$]/!?PWZA1116YV!1110 4444 %=Y\)O^1JNO\
MKR?_ -#2N#KO/A-_R-5U_P!>3_\ H:5G4^!F.(_A2/8Z***X3QCQJBBBOE#Q
M0HHHH **** "BBB@"[HW_(;L/^OB/_T(5ZQ7D^C?\ANP_P"OB/\ ]"%>L5[.
M6?!+U._"?"PKS'Q7_P C+>?5/_0%KTZO,?%?_(RWGU3_ - 6OH,!_$?I_D<>
M<_P%Z_HS&HHHKUCYH**** "BBB@ HHHH ];TG_D#6/\ U[Q_^@BKE4])_P"0
M-8_]>\?_ *"*N5\[/XF?<4O@CZ(X/XD?>TWZ2_\ LM<)7=_$C[VF_27_ -EK
MA*J.PWN%%%%,04444 %%%% !7I?P^_Y%^;_KY;_T%:\TKTOX??\ (OS?]?+?
M^@K2EL4CK****S*"BBB@ HHHH **HZOJ<6D:;+>2\[1A%_O,>@KD_#]QJR^+
MA;ZC=SNTEN97A9SM0G! V]!C- '=45R^K7=_J?B)=#L+EK6../S;B9/O8] ?
MQ'YU4NVU'PKJ-E+)J=Q>V%Q)Y<JW!+%?<']?PIV [.BN8ECN=9\3:C9G4;FU
M@LXX]BV\FPLS+G)]0/\ "DTKQ"\'A)KZ_?S987:%3WE8?='U_P ,T6 ZBBL7
MP]ILUM#)?7WS:A>'?*2/N#LH^G^>E;5( HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .7^(G_(B:E_VR_P#1J5X17N_Q
M$_Y$34O^V7_HU*\(KKH?">G@OX;]0HHHK<[ HHHH **** "N\^$W_(U77_7D
M_P#Z&E<'7>?";_D:KK_KR?\ ]#2LZGP,QQ'\*1['1117">,>-4445\H>*%%%
M% !1110 4444 7=&_P"0W8?]?$?_ *$*]8KR?1O^0W8?]?$?_H0KUBO9RSX)
M>IWX3X6%>8^*_P#D9;SZI_Z M>G5YCXK_P"1EO/JG_H"U]!@/XC]/\CCSG^
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M 'P?\:,2_P!]/^^#_C3Z* &8E_OI_P!\'_&C$O\ ?3_O@_XT^B@!F)?[Z?\
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M 'T_[X/^-/HH 9B7^^G_ 'P?\:,2_P!]/^^#_C3Z* &8E_OI_P!\'_&C$O\
M?3_O@_XT^B@!F)?[Z?\ ?!_QHQ+_ 'T_[X/^-/HH 9B7^^G_ 'P?\:,2_P!]
M/^^#_C3Z* &8E_OI_P!\'_&C$O\ ?3_O@_XT^B@!F)?[Z?\ ?!_QHQ+_ 'T_
M[X/^-/HH 9B7^^G_ 'P?\:,2_P!]/^^#_C3Z* &8E_OI_P!\'_&C$O\ ?3_O
M@_XT^B@!F)?[Z?\ ?!_QHQ+_ 'T_[X/^-/HH 9B7^^G_ 'P?\:,2_P!]/^^#
M_C3Z* &8E_OI_P!\'_&C$O\ ?3_O@_XT^B@!F)?[Z?\ ?!_QHQ+_ 'T_[X/^
M-/HH 9B7^^G_ 'P?\:,2_P!]/^^#_C3Z* &8E_OI_P!\'_&C$O\ ?3_O@_XT
M^B@!F)?[Z?\ ?!_QHQ+_ 'T_[X/^-/HH 9B7^^G_ 'P?\:,2_P!]/^^#_C3Z
M* &8E_OI_P!\'_&C$O\ ?3_O@_XT^B@!F)?[Z?\ ?!_QHQ+_ 'T_[X/^-/HH
M 9B7^^G_ 'P?\:,2_P!]/^^#_C3Z* &8E_OI_P!\'_&C$O\ ?3_O@_XT^B@!
MF)?[Z?\ ?!_QHQ+_ 'T_[X/^-/HH 9B7^^G_ 'P?\:,2_P!]/^^#_C3Z* &8
ME_OI_P!\'_&C$O\ ?3_O@_XT^B@!F)?[Z?\ ?!_QHQ+_ 'T_[X/^-/HH 9B7
M^^G_ 'P?\:,2_P!]/^^#_C3Z* &8E_OI_P!\'_&C$O\ ?3_O@_XT^B@!F)?[
MZ?\ ?!_QHQ+_ 'T_[X/^-/HH 9B7^^G_ 'P?\:,2_P!]/^^#_C3Z* &8E_OI
M_P!\'_&C$O\ ?3_O@_XT^B@!F)?[Z?\ ?!_QHQ+_ 'T_[X/^-/HH 9B7^^G_
M 'P?\:,2_P!]/^^#_C3Z* &8E_OI_P!\'_&C$O\ ?3_O@_XT^B@!F)?[Z?\
M?!_QHQ+_ 'T_[X/^-/HH 9B7^^G_ 'P?\:,2_P!]/^^#_C3Z* .5^(0D_P"$
M&U'<RD?NNBX_Y:I[UX57N_Q$_P"1$U+_ +9?^C4KPBNNA\)Z>"_AOU"BBBMS
ML"BBB@ HHHH *[KX4!CXIN=I /V)^HS_ !I7"UWGPF_Y&JZ_Z\G_ /0TK.I\
M#,<1_"D>P8E_OI_WP?\ &C$O]]/^^#_C3Z*X3QCQJBBBOE#Q0HHHH **** "
MBBB@"[H^?[:L<=?M"?\ H0KU7$O]]/\ O@_XUY5HW_(;L/\ KXC_ /0A7K%>
MSEGP2]3OPGPL9B7^^G_?!_QKS/Q3G_A)+O<03\G08_@%>GUYCXK_ .1EO/JG
M_H"U]!@/XC]/\CCSG^ O7]&8U%%%>L?-!1110 4444 %%%% 'K&DB7^Q['#I
MC[/'_#_LCWJYB7^^G_?!_P :K:3_ ,@:Q_Z]X_\ T$5<KYV?Q,^XI?!'T1P/
MQ%#AM-W,#Q+T&/[M<-7=_$C[VF_27_V6N$JH[#>X4444Q!1110 4444 %>D^
M  YT";:R@?:6ZKG^%?>O-J]+^'W_ "+\W_7RW_H*TI;%(ZG$O]]/^^#_ (T8
ME_OI_P!\'_&GT5F4,Q+_ 'T_[X/^-&)?[Z?]\'_&GT4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M117K'S04444 %%%% !1110!ZWI/_ "!K'_KWC_\ 015RJ>D_\@:Q_P"O>/\
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M/BO_ )&6\^J?^@+7T& _B/T_R./.?X"]?T9C4445ZQ\T%%%% !1110 4444
M>L:2)?['L<.F/L\?\/\ LCWJYB7^^G_?!_QJMI/_ "!K'_KWC_\ 015ROG9_
M$S[BE\$?1' _$4.&TW<P/$O08_NUPU=W\2/O:;])?_9:X2JCL-[A1113$%%%
M% !1110 5Z3X #G0)MK*!]I;JN?X5]Z\VKTOX??\B_-_U\M_Z"M*6Q2.IQ+_
M 'T_[X/^-&)?[Z?]\'_&GT5F4,Q+_?3_ +X/^-&)?[Z?]\'_ !I]% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'+_$3_D1-2_[9?\ HU*\(KW?XB?\B)J7_;+_ -&I7A%==#X3T\%_#?J%%%%;
MG8%%%% !1110 5WGPF_Y&JZ_Z\G_ /0TK@Z[SX3?\C5=?]>3_P#H:5G4^!F.
M(_A2/8Z***X3QCQJBBBOE#Q0HHHH **** "BBB@"[HW_ "&[#_KXC_\ 0A7K
M%>3Z-_R&[#_KXC_]"%>L5[.6?!+U._"?"PKS'Q7_ ,C+>?5/_0%KTZO,?%?_
M ",MY]4_] 6OH,!_$?I_D<><_P !>OZ,QJ***]8^:"BBB@ HHHH **** /6]
M)_Y UC_U[Q_^@BKE4])_Y UC_P!>\?\ Z"*N5\[/XF?<4O@CZ(X/XD?>TWZ2
M_P#LM<)7=_$C[VF_27_V6N$JH[#>X4444Q!1110 4444 %>E_#[_ )%^;_KY
M;_T%:\TKTOX??\B_-_U\M_Z"M*6Q2.LHHHK,H**** "BBB@"AJ^K6VC6+75P
M?9$'5V]!63X?TJZEOI==U1=MW.,11?\ /)/\<?YYI=:\+SZMJJ7RZH8?+ $<
M9A#A#ZC)'\J?#H>M1SQN_B261%8%D-N!N&>GWJ8%2Q81_$G4U8X,ELNS/? 3
M_ T>/&#Z?86R\RRW:E1ZX!'_ +,*TM9\/)J=U#>074EG>Q#"S1C/'H1QZ^M0
MV7AAH]2CO]1U&6_GB_U6]=JI[XR: +FIZ+I-\QNK^V1C&AW2;BN%'J01D?6N
M6:<16<WB%8%2VM1Y&F0,O R<%R/7J?\ (KJ-<TVYU:*"TCE2.T9\W1R0[*.B
MKQCGW]JGOM*MK[2'TTKY<#(%79_#CICZ8% &,+O5])U?38+^]2[BOLHRB)4,
M;\=".HY[UT]8-IX>G6^M;G4-2>\^R*1 GE! IQC)P3DUO4@"BBB@!&W$?*0#
M[C--Q+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QH
MQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?
M3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@
M_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-
M/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH
M9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^
M^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?
M!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QH
MQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?
M3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@
M_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-
M/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH
M9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^
M^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?
M!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QH
MQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?
M3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@
M_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-
M/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH
M9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^
M^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?
M!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QH
MQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?
M3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@
M_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-
M/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH 9B7^^G_?!_QHQ+_?3_O@_P"-/HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&]PHHHIB"BBB@ HHHH *]+^'W_(OS?\ 7RW_ *"M>:5Z7\/O^1?F_P"OEO\
MT%:4MBD=91116904444 %%%% !161K%CJ>H21V]K>+:697]\Z@^8?8>@K+^'
MXQHET,DXNWY/^ZM '5T5R.J++K_BLZ,9I(K*VB$DZHV#(3@X_4?K534]/7PA
M?6-_ITDRVTDHBGB9L@@\_P @?RIV [FBN2DL;76?%NJ0:DS/';0Q^1&7*A05
M!9A@]C_.HM)UR6Q\'K+(S7%P96@M%/)D.<+]0/Z8HL!UJ7,#SO DT;3(,O&&
M!9?J.U2UE:!I3:99%IV,E[<-YEQ(3DECV^@K5I %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%5KC4;&SD$=S>V\#D;@LLJJ2/7!-0_VY
MI/\ T%++_P "$_QH OT50_MS2?\ H*67_@0G^-']N:3_ -!2R_\  A/\: +]
M%4/[<TG_ *"EE_X$)_C1_;FD_P#04LO_  (3_&@"_15#^W-)_P"@I9?^!"?X
MT?VYI/\ T%++_P "$_QH OT50_MS2?\ H*67_@0G^-6X9X;F%98)4EC;HZ,&
M![=10!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '+_$3_
M )$34O\ ME_Z-2O"*]W^(G_(B:E_VR_]&I7A%==#X3T\%_#?J%%%%;G8%%%%
M !1110 5WGPF_P"1JNO^O)__ $-*X.N\^$W_ "-5U_UY/_Z&E9U/@9CB/X4C
MV.BBBN$\8\:HHHKY0\4**** "BBB@ HHHH NZ-_R&[#_ *^(_P#T(5ZQ7D^C
M?\ANP_Z^(_\ T(5ZQ7LY9\$O4[\)\+"O,?%?_(RWGU3_ - 6O3J\Q\5_\C+>
M?5/_ $!:^@P'\1^G^1QYS_ 7K^C,:BBBO6/F@HHHH **** "BBB@#UO2?^0-
M8_\ 7O'_ .@BKE4])_Y UC_U[Q_^@BKE?.S^)GW%+X(^B.#^)'WM-^DO_LM<
M)7=_$C[VF_27_P!EKA*J.PWN%%%%,04444 %%%% !7I?P^_Y%^;_ *^6_P#0
M5KS2O2_A]_R+\W_7RW_H*TI;%(ZRBBBLR@HHHH **** "N4\ _\ (%N_^OQ_
M_05K6U73=0OI8VL]7>R55PRK$'W'UZBLK3?"FH:6P%OKSK#YGF/&+<88\9_B
M[@4P&V+"/XDZFK'!DMEV9[X"?X&CQXP?3["V7F66[4J/7 (_]F%:6L^'DU.Z
MAO(+J2SO8AA9HQGCT(X]?6H;+PPT>I1W^HZC+?SQ?ZK>NU4]\9- %S4]%TF^
M8W5_;(QC0[I-Q7"CU((R/K7+-.(K.;Q"L"I;6H\C3(&7@9."Y'KU/^174:YI
MMSJT4%I'*D=HSYNCDAV4=%7C'/O[5/?:5;7VD/II7RX&0*NS^''3'TP* ,87
M>KZ3J^FP7]ZEW%?91E$2H8WXZ$=1SWKIZP;3P].M]:W.H:D]Y]D4B!/*"!3C
M&3@G)K>I %%%% "-N(^4@'W&:;B7^^G_ 'P?\:?10 S$O]]/^^#_ (T8E_OI
M_P!\'_&GT4 ,Q+_?3_O@_P"-&)?[Z?\ ?!_QI]% #,2_WT_[X/\ C1B7^^G_
M 'P?\:?10 S$O]]/^^#_ (T8E_OI_P!\'_&GT4 ,Q+_?3_O@_P"-&)?[Z?\
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MR_[X?_XJO0=.N'O-,M+F0*'FA21@O0$J"<4FK!<FQ+_?3_O@_P"-&)?[Z?\
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M_P 76D:<I*Z-Z>'G-<T3V#$O]]/^^#_C1B7^^G_?!_QKQ_\ X6SKW_/IIO\
MW[?_ .+H_P"%LZ]_SZ:;_P!^W_\ BZKV$R_J=4]@Q+_?3_O@_P"-&)?[Z?\
M?!_QKQ__ (6SKW_/IIO_ '[?_P"+H_X6SKW_ #Z:;_W[?_XNCV$P^IU3V#$O
M]]/^^#_C1B7^^G_?!_QKQ_\ X6SKW_/IIO\ W[?_ .+H_P"%LZ]_SZ:;_P!^
MW_\ BZ/83#ZG5/8,2_WT_P"^#_C1B7^^G_?!_P :\?\ ^%LZ]_SZ:;_W[?\
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M3_O@_P"-/HJ"AF)?[Z?]\'_&C$O]]/\ O@_XT^B@!F)?[Z?]\'_&C$O]]/\
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M7^^G_?!_QI]%9E#,2_WT_P"^#_C1B7^^G_?!_P :?10 4444 %%%% !1110
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M[?XU2HH]I/N'-+N='X9U*^G\0VL4U[<21MORKRL0?D/8FO0J\S\*?\C+:?\
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M:+8A[A1113$%%%% !1110 5ZSX,_Y%.R_P"VG_HQJ\FKUGP9_P BG9?]M/\
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M>O&*]_+OM?+]3R<[_P"7?S_0****](\$**** "BBB@ J[H__ "&[#_KYC_\
M0A5*KNC_ /(;L/\ KYC_ /0A4S^%FE+^)'U1ZU1117SI]P>3>,_^1LO?^V?_
M *+6L&M[QG_R-E[_ -L__1:U@UJMB&%%%% @HHHH **** "O:-#_ .0!IO\
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MJO)=8_Y#=_\ ]?,G_H1KZ#+_ (F>?G7\./J4J***]0^="BBB@ HHHH ****
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MDO\ [+7"54=AO<****8@HHHH **** "O2_A]_P B_-_U\M_Z"M>:5Z7\/O\
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MA_A3Z* ,/5O".CZY=+=:E \\RH(PWF,N%!)QA<#J35#_ (5OX7_Y\'_[_O\
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MN1A?\(?HW_/N_P#W];_&C_A#]&_Y]W_[^M_C6[11[:I_,_O#ZK0_D7W(PO\
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M^B@!GEM_SV?\A_A1Y;?\]G_(?X4^B@!GEM_SV?\ (?X4>6W_ #V?\A_A3Z*
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MN1A?\(?HW_/N_P#W];_&C_A#]&_Y]W_[^M_C6[11[:I_,_O#ZK0_D7W(PO\
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M ._K?XT?\(?HW_/N_P#W];_&MVBCVU3^9_>'U6A_(ON1A?\ "'Z-_P ^[_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **BGN;>U0/<3Q0H3M#2.%!/ISWJ6@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **BBN8)WD2*:.1XCMD5'!*'T/I1%<P3O(D
M4T<CQ';(J."4/H?2@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD-<%W>>,[/3HM0N
MK6&2UWGR)"O(+G./P%=?7%:[%=S>/;&.QN1;W!M/ED9 P'+YX/M30!<MJ7A?
M6-/!U.XOK6[D\MHYR68<@<<^]=;>W]KIUN9[N=(8P<98]3Z =ZXVTAFA\9P0
M^()GN;C;OLY00(\_[N!S_4=^*?KLUQ/XWM($L1?+!#O2V:0(I)SELGCT_*@#
MH[#Q%I.IS>3:7J/+U"%2I/TR!FK5]J-GID'G7DZPQDX!/<^P')KE=6MM<U6>
MSFCT 6D]O*'$PNXV.WT[>U2ZBB:A\0;*TN4#P0P%UC;D%N3G'Y?E18"KXMUK
M3M6T6W^PW2RE+Q"RX*D?*W8@&NOO-1M+!H%NIA&9W$<>03ECVXZ?C7*>.].M
M(K*TO(H$CG^T+&608RI!//KT%3^.XUFATN)\[7N@IQZ&@#67Q3HCW8MEU",R
MEMHX;:3_ +V,?K6L\B11M)(ZHBC+,QP /<US/BS2K&'PI.(;6*/[.%,950"/
MF Z_0U1\4W4Q\)Z3$"S?:?*\P;L;_ESC/N?Y4 ;D?BS0I9Q"NH1[R<#*L%_[
MZ(Q^M:EU=V]E;-<7,R10KU=CQ7+7T>JWFD/IP\*1Q1E"L9%Y&?+/8@8I][HF
MIWWA"PM7"_;;9E=HG8$/MR ">G3% &Q8>(M)U.X\BTO%DEP2%*LI./3(&:2]
M\2:1IUP;>ZO424=5"LV/K@'%4=.UV&XU*&RU'3#8Z@JXBWJ"#QSM;MWJALO_
M  SJ>HW3Z<;ZRNI#(TT>"Z G."/3GZ46 ZVVN8;NW2XMY%DB<95EZ&I:I:5=
MV=[IT4]@%6W;.U54+M.>1CL<U=I %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5R_B2_O#K&G:1:W1M%NN7F7KUX _+
M]1745F:UH5IKENL=QN62/)CE0X*G^HH0%.RT74].OXI$UF:ZMCD3171+'&.J
MGUS]*U(-3L[F^GLHIMUS!S(A4C'YC!_"N72[U?POJ=I:7]T+W3[E_+21OOIT
M'U[CCFK&H@Z7X\L+P9$5^A@?W;H/_9*8&^=5LEU1=-,X^V,NX1[3TZ]<8IUU
MJ5I9W-M;SS;);EML2[2=QX]!QU'6N N9I/[5D\3AB88M1$(QQF,#&?RX_&M^
M+&J^/WD!#0Z= %!'(+M_^L_]\T6 W-1UC3]*"F]NDB+?=4@DG\!S1IVL:?JH
M8V5TDNW[P ((_ \UR5G/>R>+M7NH=*&HRPR")2TZQ^2,D#&X=\=O?UJ[;6FK
M3>+;;4WT=;&+8R3[;A&WY!Y..^<=NU%@)O"__(<\1?\ 7T/YM2>&0&UOQ&#G
M!NL<''=J7PO_ ,ASQ%_U]#^;4>%_^0YXB_Z^A_-J +?AY=)L-&N'T^ZEEM$D
M=Y)) <@@#/8=@.U22^*M$ACB=[] )5W* C$X]P!D?C6)X:_Y$G5?]Z?_ - %
M7/!^DV)\-PS/;1R27 8R,ZAL\D8Y[<4 =';74%Y;I<6\JR1.,JR]#67<^*]#
MM)VAFOU$BG#!49L'Z@$5C>$0R:/K-LDFQ(II C$XV_+C.?P%9^BZUI-GX5EL
M;B%C=2*^4$1/GDDX(/3CC\J+ =GINLV&KB0V-QYHBQO^1EQG..H'H:OUB>$[
M2YLO#EM#= K)\S!&ZJ"<@?Y]:VZ0!1110 4444 %%%% !1110 4444 %%%%
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M#G;S0;Z#6)-4T:YABEF&)HIP2C^_%6["'7C>B74;JS$ !_<VR'!/;EN:UZ*
M,;1M)GT[4M5N)7C9+N;S(PA.0,GKQ[T:-I,^G:EJMQ*\;)=S>9&$)R!D]>/>
MMFB@#G](T*YL/#M[I\LD+2SF0JRD[1N7 SQ5_0K"72]%MK*=D:2($,4)(Y8G
MC/UK1HH Y>VTUM!T;6Y+]U>&=G?$+'.TC&.1P>:JZ!INNG0;:2VUI8(V7='
MUNK@ GNW6NOFACN('AF0/&ZE64]"#6 O@ZSC5HX+_4H(&ZPQW&$_+%.X$GAG
M5KK45O+>]$;3VDOEF6/[K]?\/Y5O54TW3+72;06UI'L3.3DY+'U)JW2 ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *]] UUI]S;H0'EB9%)Z D$54\/Z=+I.AVUE.R-)%NW%"2.6)XS]
M:TZ* *.L:<-6TFXL6?9YH&&QG!!!'ZBL)M&\27&F?V;-J%DEN(_+WQ*V]QC
M!R.!V./UKJZ* ,:VTF>'PFVE,\9G-L\6X$[<L#CMG'/I5:70+J3P4-&$D/VD
M*HW$G9PX;KC/0>E=%10!3^R/_8WV/<OF?9_*SVSMQ^50>'].FTG0[:RG9&EB
MW;BA)'+$]P/6M.B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
..BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img70551829_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,L!BH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[G_"G85SN:*X?PAKNL:KJ\D5W<":WCB);]VHP<@#D 5W%#5AH****0!1110
M5P_Q$LYGAL[M0S11ED?T4G&#^./Y5W%,EBCFB:*5%>-AAE89!%-.P,Q/#WB.
MPU.S@A$JQ7*H$,+G!) Q\OJ*WJXW5? -M,6ETR8V\G7RW.4_ ]1^M4_#>NZA
MIVLC1-5+."WEJ7.6C;MSW!_PIVOL*Y;BU[4K3QLVF7UQOM7D*QJ448#<IR!]
M!79UPWQ L61K358N&0^6Y';NI_G^E;EYKBCP@VJH0KR0#;@XPYXX^A_E0T!E
MZ9KNHZKXQFMX)Q_9T)8E0B\J. <XSR<&EU?Q'J4^MG1]$C0S(</(P!Y YQG@
M 4O@#3_(TJ6]=?GN'PI(_A7C^>?RJGK&E:KHWB"36],B\^-R6=0NXC/W@1UQ
M[BC2X="RD_C+3YXGNHX[V!G <1JI(!_W0#^-6_%L>N-!,]C/&E@+9O/0A<G@
M[NHST]*;I/CBRO95M[R-K2<D+ECE"?KV_'\ZVM<_Y &I?]>LO_H)HZ@>?>&(
MO$,EI.=&N(HHMXWAPO)Q[@UW]O//I^B+/J\RF:)"TSJ!@\]L8]JYWX=?\@V\
M_P"NP_E5KQ]*T?AU54G$DZJWTP3_ $%#U=@6QG0ZYXE\02R/I$4=M;(<;V"G
M\RV<GZ"AO$/B#P_>1)KD2SV\G\:!0?P(XX]"*K:)KVKV&D06]IH,LT*@D2K&
MY#Y/7@4W7-2UO7+ 6DGA^YC <.&6)R01GV]Z=A'H<4B31)+&P9'4,K#N#T->
M=Z;XTU5H98&4WE[*RK;KY8 7KGA0,]J['PW'/#X=LH[E&CE5,%7&"!DXR/IB
MN0^'<:-J-XY4%UB&TD<C)YI+J,DOM5\8:,J75[Y;0%@"NQ"H]CMY'YU;?QA?
M:J(;71+,F[= TK,,B,]\9XQ[FMSQ6 ?"]_D9^0?^A"LOX?11KH4LH11(TY!;
M')  P/U-'2X&9+X@\2Z!>PC6%6:"3MM49'?!7O\ 6N]AF2X@CFC.4D4.I]01
MD5RWQ!16T")B!N6X7!_X"U:_ALD^&]/R<_N5I/:X(Q/#6NZCJ/B6^M+J</!&
MCE$V*,8< <@9Z&MS7M;AT/3S<.N^1CMCCSC<?\*Y'P;_ ,CCJ/\ USE_]&+2
M^/V:76;"V).SR\@>[-@_R%.VH7T);>^\9ZK%]KM!'% W*+M0 CVW9./>MCPY
MK>H7EY/INJVWE74*;]V,;AG'3\>HXKHHXUBC6-%"HH"J!V HV+OW[1OQC=CG
M'I2N%AU<EX_LY;C1X9XP66"3+@=@1C/^?6NMI&574JP!4C!!'!%"=AG,>%?$
M=A<Z9;6,DJ07,*+'L<X#XX!![GVKJ*Y+5O =E=EI;%S:RGG9U0_AU'^>*QM(
MUC4_#FLII6IL6MRP4ACNV ]&4^GM3M?85SN-6U2#1]/>[N,E1PJCJS=@*Y"W
MU?Q;KH:XTZ.."WS@':N/S;.?PH^(T[;["W'W<.YYZG@#^OYUVUE;I:6,%O'M
MV1QJHV]#@=:-D!Q*^)]=T.^2'78!)$_\04 X]05X/T_E7=12I/"DT3!HY%#*
MP[@\@US7CV%)/#OF,HW1RJ5..1G@U:\&RM+X6M-P/R[U!/<!C_\ J_"A[7 Y
MOP!_R&K_ /ZY?^S5K>-=:O\ 2/L/V&?RO-\S?\BMG&W'4'U-9/@#_D-7_P#U
MR_\ 9JG^)'_,,_[:_P#LE/[0NAVL4V;-)I6 'EAV8\ <9-<7+XHUG6M0>VT"
M$+&F?WC*"2/4[N!]*W->E:'P7.Z$@FW5>/0X!_0U2^'\*)H,DH WR3G<?8 8
M'\_SI+:XRC_;7B;0YXVUB!9[5V"EU5>,^Z]#]:W/%NHW6EZ(;BSD\N7S%7=M
M!X.?6MMT612KJ&4]01D5S7CW_D6_^VR?UI;L"SI]UJ>I>#X[B"9/[0D0[9&4
M 9#$=,8Z#TKA+J/61XLC2>:,ZIN3;( N,X&.V.F.U=]X0_Y%6Q_W6_\ 0C7,
M:E_R4V'_ *ZQ?^@BFMQ,Z/0H?$<=Y(=8N8I(/+PH0+G=D>@';-4]?\47%MJ"
MZ5I,(FO#@,Q&0I/8#U_05U=>4:/J=Y!X@N[ZWL'OKA]Y*JI)7+<G@?A^-"U&
MSH)G\<6<+7+R12H@W-&JH2!^ !/X&MWPWX@37K-G*".XB($B Y'/0CV/-8W_
M  E7B#_H6[C_ +]R?X57\%6=_!KMY-<6,]M#)$Q_>1E1G<" ,CTS0UH!L^*?
M$O\ 8<<<-NBR7DHRH;HJ],GU]JQX[GQPL(O"BO'C=Y)1,D?0<_AUJMJ*BY^)
ML<4H#(LD> ?9 W\Z]#HV#<\MM]2.K>.+.\,1B9Y8PR9S@@ '^5>I5YW?HD?Q
M-B"*%!FC8X&,DJ,FO1*) @K(\3ZA_9N@7,P.)'7RT^K<?RR?PK7KS_Q]?"XU
M&TTQ7553#R$] S<#/T'/XTDM08NEZ#YW@"Z<J//G)G3_ (!T'XX;_OJM+P!J
M'VC29+)SE[9_E_W6Y_GFM.VU[0K6UBMX]1MPD2!%^;L!BN+T.\@TGQJT=O,K
MV<[F(,IR"K<K^1Q^M/<6QZ1>?\>4_P#US;^5<+\/;F"W_M'SIHXMWE8WL%S]
M_P!:[J\_X\I_^N;?RKS/PEX>M->^V?:I)T\G9M\I@,YW9SD'T%"V&STD:C9$
M@"\MR3T E7_&I9YDMX))I#A(U+L?0 9-<PGP_P!)1U87%Z<'."Z__$UTMU;K
M=V<]LYPLL;1DCT(Q2T&<5!K7B;Q#--)I BMK:-MN6"G\R0<GZ5KZ)=>(DU)K
M/6+</$4++<(HQD=LCC\.#7.VDVM>"I98I;3[18L^XL,[2?4'L<#H?2NMT7Q+
M8:W\D+-'.!DQ2=<>H]:;$C9K/URUDO=#O+:'_6/$=H'<]<?CTK0HJ1GGG@K7
MK33$FT^^/D%Y=ZR,, ' !#>G3^=>@HZ2H'C971AD,IR#6)K'A/3M79I64P7!
MZRQ]S[CO_.N.GBUGP3>(Z3"2V<\8)V/[$=C5:,6QZ+J$SV^FW4T9P\<+NIQG
M! )%8'@O6+[5[:[:^F\UHW4*=@7 (/H!6I<7D>H>%Y[N+[DMH[ 'M\IXKG?A
MS_QZ7_\ UT3^1I= ZDWB7Q%=Z/XDLXEF*V9B626,(I+?,P/)&>@JM_:7B_5H
MVO=/@6WM3DQIA"6'_ NOZ55\:JK^+M/1@"K11@@]QYC5Z$ %4*H  & !VI[(
M#@[#Q[-%:3QZA!ONTXCV+MWG/(;TQ2W-]XU6V;4"BQ0 ;S$$0E5^ARU5K"&.
M3XES*Z*RB:1@".,@$Y_.O1&4,I5@"I&"#WH=D",3PQK_ /;M@[R($N(2%D"]
M#GH1^OY5G^-=:O\ 2/L/V&?RO-\S?\BMG&W'4'U-9GP]^74-10$[0B\?B:D^
M)'_,,_[:_P#LE%M1=#L'<R:2SM]YH"3]=M<?\-_^8G_VR_\ 9ZZ__F"_]N__
M ++7(?#?_F)_]LO_ &>A;,?4V?$.MZC9WD.GZ79^?<RIOWD9"C)'3\.IXK*F
M_P"$Y@A:X:6)E4;C&JQDX_+G\ZWM<\266A!5FW23N,K$G7'J3V%8@\8ZO<#S
M+7P].\1Z$!VS^(6A :OA;Q$==M9!,BI<PD;PO1@>A'Y&JGC76;_2(K(V,_E&
M1GW_ "*V<8QU!]:QOAZQ.K7V<C,62/\ @56OB/\ ZG3O]Z3_ -EHMJ+H$FN>
M)-;GEET*$QV<9VJS*F7_ !;O[#I76Z6]W)I=N]\NVZ*?O!C'-)I$,<&CV<<2
M!4$*G ]QD_K5VDV,K:@MV^GSK8NJ714^6S#@&O+[Z/61XJA2YFC;4RR;' 7
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MU^^TC5[&.WG\NW90THV*V1NYZCT]*R?#RBS^(%U;0@K%OF3 [*"2!^@IWQ!
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M3*\BNVTZ^CU+3H+R($)*N<'L>A'YUF>,45_"U[N4':%(SV.X5!X&/_%,1?\
M71_YT/57#J9>J^*[O2?%ES!)(7LHE&V$(O),8(YQGJ:6TO?&5S<6]VT*K:2R
M+F/8@PA/_?0&*HW\,<_Q.$<J!T,L>5/0XC4UZ+0] .>\2^)TT-4AAC6:\D&0
MAZ*/4_X5CH_CJXC$Z%(U;D1E8P?R(R/QJHBC4/B:5GY6.4X!_P!A>/U%>B4;
M!N<?H'BVYFU'^R]7A$5R3M5PNWYO1A_6MKQ->W&G>'KJZM9/+F39M; .,N >
M#QT-<AX[46_B&SN8AB4QJQ([D-P:Z?QG_P BG>_]L_\ T8M'8"QX9O;C4?#U
MK=74GF3/OW-@#.'(' XZ"JGC'5+S2='BGLI?*E:=4+;0W&UCW'L*?X,_Y%.R
M_P"VG_HQJH?$+_D 0?\ 7TO_ *"]+J'0WM$N9;S1+.YG;=+)&&9L8R?PKEY?
M$>LZWJ<MKH"(D,6<RL <CIDYX'L,9K>T"/S?"=G&#C?;[<_45R7@[5K71+J]
MLM0=869@!)U&5R""1]:: 35=6\7:,\8O+L*LGW76.,J?_':Z[P[_ &NUF\FJ
MW$4YD(:%D 'RX]@*YGQIK=GJMO;:?8/]HD\T.609'0@ >I.:[738'M=+M+>3
M[\4*(WU"@&A[ MSS:+5/['\8ZG="$S2>=,B(.[%^*U[F\\;0VS7[JL<*C<T2
MHA*CZ<FJ^@QI)\1+[>@;;-.RY&<'<>:]#90RE6 *D8(/>AL2,3PQK_\ ;UB[
MR(J7$)"R*O0YZ$?K^5;E<!\/1MU'45'0(O'XFN_I/<:"O/?AS_Q^WW_7-?YF
MO0J\]^'/_'[??]<U_F:%LP>YZ%7G/C6S_LG7+74K0>69?G^7IYBD9/XY'ZUZ
M-7!_$>5"=/A!^<;V(]!\H'\C^5$=P>QUT^I)!HK:EY991")0@/)R,XS7+QWG
MC+5E^T6L<5G"W*!E49'_  ($_C746DD=CH5O)<N(TAMTWLW;"BN<D\=F>9HM
M+TJ>Z(Z-SG_OD TT!6M_$NM:1J\=EKJ(R2$?O H! /&05X(]:T_&6H:GI=I;
MW6GS^7'O*2_(K=>G4'T-<=XGU.^U*XMWO=/DLG12%#*PW#/7D"O2=:T\:IH]
MS:8^9T^3V8<C]0*'H [2;X:EI-K>#K+&"W^]T/Z@UA>,M>NM*2UM["4)<2DL
M3M#$*.!P1W)_2JGP^OB;>ZTV3AHF\Q0>N#P1^! _.J8'_"0?$,G[UO:-]1A/
MZ%OYT6U"^AW5D)Q8P"Z??<>6OF-@#+8YZ>]3T45(PKG?&FJ?V=H;Q(V)KG]V
MN.P_B/Y<?C715YQJ;'Q1XVCLT.;:%O+)'3:O+'\3Q^5-"9T?@K2_[/T-9G7$
MUT?,.>R_PC\N?QKI*155%"J % P !P!2TF,**** "BBB@ K!UCQ3;Z)JD5I<
MV\ACDB$GFH<XY(QC\/6MZJUYI]GJ$?EW=M',HZ;UR1]#VH0&4?&>A"'S/MI)
MQG8(VS].E<KIQE\2^-QJ,,3);Q.LC$]@HX!]SBNL'@[0 V[^SQG_ *ZOC\LU
MKVUK!9PB&VA2*,=%1<"JNEL(JZUIXU31[FTP"SI\GLPY'ZUY6E]<W.E6^AHI
M/^D[@/4G@#\R?SKV)F5$9V("J,DGL*\Y\+VZ:OXPN=06(+;Q.TRKV!)^7^I_
M"B(,] LK1+&Q@M8_N1($!QC.!UK)B\7Z/)-+#)<&"2-RA$JXS@XR",BMVLN\
M\-Z1?S-+<V,;2-RS*2A)]3@C-+U&<5XRO--U6ZM4TP+/=$D.\2_>SC ]S7<7
M=O,_AN>U(+3M:-'@<Y;9C^=)8:!I6FR>9:64<<G9R2Q'T))Q6E0V*QYYX)UN
MPTRVNX+V<0LSAU+ D'C':NAUZ!?$GA9I+ F3GS8AC!;:2",?3-6KGPMHMW.T
M\U@AD8Y)5F4$_0$"M.WMX;2W2""-8XD&%5>@H;ZA8XWPIXIL;;3$T^_D^SRP
M$A68'##.?P(S6S>>,=%M(BRW7GOV2(9)_'I5N]\/:3J$IEN;&-Y#U925)^I!
M&:9;>&-%LY \.GQ;AT+DOC_OHFC0-31MIA<VL4ZJ5$B!P#U&1FN"^'/_ !^W
MW_7-?YFO0JS].T33M)>1[&V$32##'>QS^9-%P*_BK_D6+_\ ZYC^8K-^'_\
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M&9"^,]":+>;TJ<?=,;9_E7(W$S^+_%T#6D3K!&%4L1R$!)+'TZG'X5V!\':
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M;)_$FE?0+'%>,O\ D<=._P"N<7_HQJ]"K/O-$TZ_O(KNZMA)/$ $?>PQ@Y'
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M6-;Z#S1&24^9EQGKT(HOK<+:$NF_\@NT_P"N*?\ H(JS38XUBC6-!A$ 51Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF0YVZ&S16-_Q4W_4)_\ (E'_ !4W_4)_\B4O:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7
M]P<_DS9HK&_XJ;_J$_\ D2C_ (J;_J$_^1*/:_W7]P<_DS9HK&_XJ;_J$_\
MD2C_ (J;_J$_^1*/:_W7]P<_DS9HHHK4L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI_\ %UJ?$3_D1-2_[9?^C4KPBNBE3C*-V=N&H0J0O(]C_P"%LZ#_ ,^FI?\
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M?@:\X\2>2_B"^DM%F-DK1B^\LX4MGG_/KFA =EX8N]2U*WGU"]?$$S_Z-"%
MV*"><XR?Q]*WJHO>P6FDQW-K!-<6X11'';)O8KT&!4%AKGVZZ$']EZG;Y!/F
M7%OL08]\T@*5Q!XHN[F=H+RVL8%=EA7RP[.H/!.0<9_R*3PQK5Y?RWEAJ*K]
MKM&VLR# ;DCZ=16GK&KV^C6#7$YRW2.,=7;T%97A?3IM/L[O5-1^2YNV,T@(
MY1>3S^9./I3 N^(=6DTVTCAM 'O[IO+MTQGGNWX53\'ZG?:E;7GV^<320S;
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M<]U=3R2L0WGREPNTD?+GIG^E=)2 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC]K;[/C[N.^/;I0!T]%%%( HHI-J[MV!NZ9QS0 M%%% &-XK_P"1:N_^ ?\
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M$73/E@A^3RR,,A]Q_6M.L/PYI%QIL=W<7C(;N\E\V18_NKUX'YFMRD 4444
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M)B_YY)_WR* 'T4SR8O\ GDG_ 'R*/)B_YY)_WR* 'T4SR8O^>2?]\BCR8O\
MGDG_ 'R* 'T4SR8O^>2?]\BCR8O^>2?]\B@!]%,\F+_GDG_?(H\F+_GDG_?(
MH ?13/)B_P">2?\ ?(H\F+_GDG_?(H ?13/)B_YY)_WR*/)B_P">2?\ ?(H
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MJ@8  P!5>UT^ULY;B6"+9)</OE;<26/X_P JLT4 0W-G;7BA;JVAG4<@2H&
M_.GQ11PQK'%&L:+P%08 _"GT4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5'6?^0'?_P#7O)_Z":O51UG_ ) =_P#]>\G_ *":J'Q(SJ_PY>C/)J***^B/
MAPHHHH *];TG_D#6/_7O'_Z"*\DKUO2?^0-8_P#7O'_Z"*\_,/AB>WDOQS]"
MY1117EGT(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 45B^+/^19O/^ ?^AK7F5=>'POMH\U['F8S,?JU10Y;Z7W_X
M![/17C%>SU.(P_L;:WN:8+&_6N;W;6MUON4[#5+/4UE-G-YGE-L?Y2I4_0@5
M-=W<%C:R7-S)Y<,8RS8)Q^5<O:?\2;Q[<6WW;?4D\Q.>-_)_GN_,5+XRD:[^
MP:+$V)+R8%_9!_\ 7Y_"N>QWG26UQ%=VT=Q VZ*10R-@C(/L:JVNM:=>W\ME
M;W*O<19WIM(Q@X/)&#^%)JEW'HVASSH JP1;8U]^BC\\5PT5F_AU-#UMM^9F
M(NB>>'Y'_CI/XBBP'H-[>V^GVKW5TY2%,;F"EL9..@!-/M[B*[MX[B"0212+
MN5AW%+-#'<V[PRJ'BD4JP]0:X :E>^%UOM"57ED<C["X']XX_P ^^: .WM-4
ML[ZXN(+:;S)+<[90%.%/IG&#T/2KE97A_2%T;2H[?@S-\\S^K'_#I6K2 RKW
MQ+H^GSF&YOD613AE56<@^^T'%7;*^M=1MQ/:3I-&>,J>A]".U11Z5I\+3.MI
M#NF=GD9E#%B>3DG^5<SX*C7^T]:DM>+#SML0'0\G&/PQ^8I@==<7$-I;R7$\
M@CBC&YF/857T[5K'5HGDL9_-1#M8[2N#^(%8FJL?$.N)HT1/V*V(EO&'1CV3
M_/\ 2H/ 0 M]2 & +DX ^E%@.OK*O?$NCZ?.8;F^19%.&559R#[[0<5JU2CT
MK3X6F=;2'=,[/(S*&+$\G)/\J0$ME?6NHVXGM)TFC/&5/0^A':K%<9X*C7^T
M]:DM>+#SML0'0\G&/PQ^8KLZ ,J]\2Z/I\YAN;Y%D4X955G(/OM!Q5VROK74
M;<3VDZ31GC*GH?0CM44>E:?"TSK:0[IG9Y&90Q8GDY)_E7,^"HU_M/6I+7BP
M\[;$!T/)QC\,?F*8'775PEI:RW$IPD2%V^@&:S_#VH7>J:0E[=QQQM*S%%C!
M VYP,Y)YZUG^,KAWLK;2H#^_OYECQ_L@C/ZX_6M.]NK;P]HAD(_=6\82-,\L
M>@% "W>O:98WJ6=S=*EP^,(%9NO3.!Q^-:->:ZEITULNEWU[DW][=B27(^Z,
MC"_@/\\5Z50P"L_4M;TW26C6^NA$T@)4;2Q(_ &K5U<Q6=K+<SL%BB4LQ]A7
MG6M6TU[H<^OWBE9KJ9%@0_\ +.+G'Y_YZT(#TI'61%=3E6&0?:EJ&S_X\K?_
M *YK_*LSQ+K$VB:;'=0HCDS*C!P3\I!SC!'/%(#9HKD+KQ%K]I;+J4VE0)IY
M890L?-"D\$\X'Y4^;Q!KLUI)J5AID(T] 6'GD^8ZCJP / _.G8#K**S;;6K:
M?05U=@8X/++L#R1C@CWY&*Q8-;\2WUM]OL]+M3:')1'<^8RCTY_I2L!UE%<[
M?^(KE%TZWL;(F_OEWK%/D",8YW?K^54IM9\2VVLV^F31Z4LEP,QR 2;#CMUS
MG\*=@.OHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >:?$+Q7K>A^((;73KWR(6MED*^4C?,689RP)["N3_P"%
MB>*O^@I_Y+Q?_$UI?%?_ )&NW_Z\T_\ 0WKA:[:<(N*T/6H4X.FFTCJ/^%B>
M*O\ H*?^2\7_ ,31_P +$\5?]!3_ ,EXO_B:Y>BKY(]C7V5/^5?<=1_PL3Q5
M_P!!3_R7B_\ B:ZWX>>*M:UW7;BVU*]\^%+9I%7RD7#;E&<J!V)KRJN]^$W_
M ",]W_UYM_Z&E14C%1=D95Z<%3;21[%117GFH>)M8@U.ZACN]L<<SJH\M#@
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MT(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:TDU2U9](BAVQ!8]T:M[C^GTJGJ!TO5KVSC\-VNVZ696:XAB,:(H]>![=NU
M'H%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QKXK_ /(U
MV_\ UYI_Z&]<+7=?%?\ Y&NW_P"O-/\ T-ZX6N^G\"/9H?PHA1115FP5WOPF
M_P"1GN_^O-O_ $-*X*N]^$W_ ",]W_UYM_Z&E9U?@9CB/X4CV*O)M6_Y#-]_
MU\2?^A&O6:\FU;_D,WW_ %\2?^A&OGLS^&)\WB]D4Z***\<X HHHH ] \#_\
M@27_ *^&_P#05K7UG_D!W_\ U[R?^@FLCP/_ ,@27_KX;_T%:U]9_P"0'?\
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M; .,N >#QT)KSS_A,]?_ .?_ /\ (,?_ ,332N)NQZS17DW_  F>O_\ /_\
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M9P0))F=<]QP/Z&NGID44<$*11($C0!551@ 4^D 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!_AP/17^[_(\FHHHKZD^,"BBB@ KUO2?^0-8_P#7O'_Z"*\DKUO2?^0-8_\
M7O'_ .@BO/S#X8GMY+\<_0Y[XA_\@*W_ .OE?_06KS6O2OB'_P @*W_Z^5_]
M!:O-:\^.Q[SW"BBBF(*5?O#ZTE*OWA]:!GNU%%%9%A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"2_]?#?^@K6OK/\ R [_ /Z]Y/\ T$U]-@?X<#T5_N_R/)J***^I/C HHHH
M*];TG_D#6/\ U[Q_^@BO)*];TG_D#6/_ %[Q_P#H(KS\P^&)[>2_'/T.>^(?
M_("M_P#KY7_T%J\UKTKXA_\ ("M_^OE?_06KS6O/CL>\]PHHHIB"E7[P^M)2
MK]X?6@9[M1116184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >-?%?_D:[?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>8?\ "X/^H%_Y-_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)I)/7T_S/1****XCU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'R*?10 SR8O^>2?]\BCR8O^>2?]\BGT4 ,\F+_GDG_?(H\F+_GDG_?(I]%
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M)B_YY)_WR*?10 SR8O\ GDG_ 'R*/)B_YY)_WR*?10 SR8O^>2?]\BCR8O\
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MG_?(I]% #/)B_P">2?\ ?(H\F+_GDG_?(I]% #/)B_YY)_WR*/)B_P">2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KY@KZ?KY@KIP_4]# _:^7ZA11172=X4444 >Q
M_";_ )%6Z_Z_7_\ 0$KH_%?_ "+5W_P#_P!#6N<^$W_(JW7_ %^O_P"@)71^
M*_\ D6KO_@'_ *&M>7C/@GZ/\CP\9O/YGF=%%%?+'A!1110 5ZQI'_(%L/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\P5]/U\P5TX?J>A@?M?+]0HHHKI.\**** /8_A-_P BK=?]?K_^@)71^*_^
M1:N_^ ?^AK7.?";_ )%6Z_Z_7_\ 0$KH_%?_ "+5W_P#_P!#6O+QGP3]'^1X
M>,WG\SS.BBBOECP@HHHH *]8TC_D"V'_ %[Q_P#H(KR>O6-(_P"0+8?]>\?_
M *"*]/+/CD=>$^)G,^/O^8?_ -M/_9:XNNT\??\ ,/\ ^VG_ ++7%U]G@_X,
M?ZZG@YG_ +U/Y?D@HHHKI. *NZ/_ ,ANP_Z^8_\ T(52J[H__(;L/^OF/_T(
M5,_A9I2_B1]4>M5YK\0O^0_!_P!>J_\ H3UZ57FOQ"_Y#\'_ %ZK_P"A/7S\
M=S[=[')44459 4444 =;\/?^0_/_ ->K?^A)7I5>:_#W_D/S_P#7JW_H25Z5
M42W+6P4445(PHHHH **** "BBB@ HHHH \:^*_\ R-=O_P!>:?\ H;UPM=U\
M5_\ D:[?_KS3_P!#>N%KOI_ CV:'\*(44459L%=[\)O^1GN_^O-O_0TK@J[W
MX3?\C/=_]>;?^AI6=7X&8XC^%(]BKR;5O^0S??\ 7Q)_Z$:]9KR;5O\ D,WW
M_7Q)_P"A&OGLS^&)\WB]D4Z***\<X HHHH ] \#_ /($E_Z^&_\ 05K7UG_D
M!W__ %[R?^@FLCP/_P @27_KX;_T%:U]9_Y =_\ ]>\G_H)KZ; _PX'HK_=_
MD>34445]2?&!1110 5ZWI/\ R!K'_KWC_P#017DE>MZ3_P @:Q_Z]X__ $$5
MY^8?#$]O)?CGZ'/?$/\ Y 5O_P!?*_\ H+5YK7I7Q#_Y 5O_ -?*_P#H+5YK
M7GQV/>>X4444Q!2K]X?6DI5^\/K0,]VHHHK(L**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *^8*^GZ^8*Z</U/0P/VOE^H4445TG>%
M%%% 'L?PF_Y%6Z_Z_7_] 2NC\5_\BU=_\ _]#6N<^$W_ "*MU_U^O_Z E='X
MK_Y%J[_X!_Z&M>7C/@GZ/\CP\9O/YGF=%%%?+'A!1110 5ZQI'_(%L/^O>/_
M -!%>3UZQI'_ "!;#_KWC_\ 017IY9\<CKPGQ,YGQ]_S#_\ MI_[+7%UVGC[
M_F'_ /;3_P!EKBZ^SP?\&/\ 74\',_\ >I_+\D%%%%=)P!5W1_\ D-V'_7S'
M_P"A"J57='_Y#=A_U\Q_^A"IG\+-*7\2/JCUJO-?B%_R'X/^O5?_ $)Z]*KS
M7XA?\A^#_KU7_P!">OGX[GV[V.2HHHJR HHHH ZWX>_\A^?_ *]6_P#0DKTJ
MO-?A[_R'Y_\ KU;_ -"2O2JB6Y:V"BBBI&%%%% !1110 4444 %%%% 'C7Q7
M_P"1KM_^O-/_ $-ZX6NZ^*__ "-=O_UYI_Z&]<+7?3^!'LT/X40HHHJS8*[W
MX3?\C/=_]>;?^AI7!5WOPF_Y&>[_ .O-O_0TK.K\#,<1_"D>Q5Y-JW_(9OO^
MOB3_ -"->LUY-JW_ "&;[_KXD_\ 0C7SV9_#$^;Q>R*=%%%>.< 4444 >@>!
M_P#D"2_]?#?^@K6OK/\ R [_ /Z]Y/\ T$UD>!_^0)+_ -?#?^@K6OK/_(#O
M_P#KWD_]!-?38'^' ]%?[O\ (\FHHHKZD^,"BBB@ KUO2?\ D#6/_7O'_P"@
MBO)*];TG_D#6/_7O'_Z"*\_,/AB>WDOQS]#GOB'_ ,@*W_Z^5_\ 06KS6O2O
MB'_R K?_ *^5_P#06KS6O/CL>\]PHHHIB"E7[P^M)2K]X?6@9[M111618444
M4 %%%% !117+MX=UFXB:6X\0W*71R0L!*Q*?3 QD4 =117-^%M9GN_#DUW?O
MO:V=U9P.655!S]>:HZ9::MXEMVU.?5KFRCD8B"*W8J  <<\\\T[ =E17(:7K
M-_:P:U87LOG76G1/)'*1]\ $\_I^=57>_P!.TC2]:&JW4\UQ*GFQ/)NB8/DX
M"]L=*+ =S17.:]<S:A>1Z!9.5>4;KJ5?^6<7I]3_ )ZUO6UO%:6T=O"@6*-0
MJ@=@*0$M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?,%?3]?,%=.'ZGH8'[7R_4****Z3O"BB
MB@#V/X3?\BK=?]?K_P#H"5T?BO\ Y%J[_P" ?^AK7.?";_D5;K_K]?\ ] 2N
MC\5_\BU=_P# /_0UKR\9\$_1_D>'C-Y_,\SHHHKY8\(**** "O6-(_Y MA_U
M[Q_^@BO)Z]8TC_D"V'_7O'_Z"*]/+/CD=>$^)G,^/O\ F'_]M/\ V6N+KM/'
MW_,/_P"VG_LM<77V>#_@Q_KJ>#F?^]3^7Y(****Z3@"KNC_\ANP_Z^8__0A5
M*KNC_P#(;L/^OF/_ -"%3/X6:4OXD?5'K5>:_$+_ )#\'_7JO_H3UZ57FOQ"
M_P"0_!_UZK_Z$]?/QW/MWL<E1115D!1110!UOP]_Y#\__7JW_H25Z57FOP]_
MY#\__7JW_H25Z542W+6P4445(PHHHH **** "BBB@ HHHH \:^*__(UV_P#U
MYI_Z&]<+7=?%?_D:[?\ Z\T_]#>N%KOI_ CV:'\*(44459L%=[\)O^1GN_\
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M&:\_X!_Z M=^!2=1W[?Y'F9O)QH)IVU_1E+^V-3_ .@C=_\ ?]O\:/[8U/\
MZ"-W_P!_V_QJE17J\D>Q\Y[6I_,_O+O]L:G_ -!&[_[_ +?XT?VQJ?\ T$;O
M_O\ M_C5*BCDCV#VM3^9_>=;X/O[ZYU>5)KJ:=1 2%EE8@'<O/.:[?,O]Q/^
M^S_A7!>!?^0W-_U[-_Z$M>@5Y&-2570^FRJ3EATV^K.#_P"%D?\ 4)_\F/\
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ME;J<?Q+7I.9?[B?]]G_"O./A[_R'Y_\ KU;_ -"2O2JB6Y:V&9E_N)_WV?\
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M-:\^.Q[SW"BBBF(*5?O#ZTE*OWA]:!GNU%%%9%A1110 4444 %%%% !1110
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M\1/^1$U+_ME_Z-2JA\2-*7\2/JCPBBBBO0/;"BBB@ KZ+\-?\BKI'_7E#_Z
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MLS^&)\WB]D4Z***\<X HHHH ] \#_P#($E_Z^&_]!6M?6?\ D!W_ /U[R?\
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M2?\ H*67_@0G^-4/&?\ R*=[_P!L_P#T8M>35Y25SZ1NQ[1_;FD_]!2R_P#
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M_P#7TW_H*5YK7I7P]_Y $_\ U]-_Z"E*6Q2W.MHHHK,H**** "BBB@ HHHH
M**** "OF"OI^OF"NG#]3T,#]KY?J%%%%=)WA1110!['\)O\ D5;K_K]?_P!
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M(UZS7DVK?\AF^_Z^)/\ T(U\]F?PQ/F\7LBG1117CG %%%% 'H'@?_D"2_\
M7PW_ *"M:^L_\@.__P"O>3_T$UD>!_\ D"2_]?#?^@K6OK/_ " [_P#Z]Y/_
M $$U]-@?X<#T5_N_R/)J***^I/C HHHH *];TG_D#6/_ %[Q_P#H(KR2O6])
M_P"0-8_]>\?_ *"*\_,/AB>WDOQS]#GOB'_R K?_ *^5_P#06KS6O2OB'_R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>-C?XI]3E/\ NR]6>$4445B=X4444 %>E?#W_D 3_P#7TW_H*5YK7I7P]_Y
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M>[_Z\V_]#2LZOP,QQ'\*1[%7DVK?\AF^_P"OB3_T(UZS7DVK?\AF^_Z^)/\
MT(U\]F?PQ/F\7LBG1117CG %%%% 'H'@?_D"2_\ 7PW_ *"M:^L_\@.__P"O
M>3_T$UD>!_\ D"2_]?#?^@K6OK/_ " [_P#Z]Y/_ $$U]-@?X<#T5_N_R/)J
M***^I/C HHHH *];TG_D#6/_ %[Q_P#H(KR2O6])_P"0-8_]>\?_ *"*\_,/
MAB>WDOQS]#GOB'_R K?_ *^5_P#06KS6O2OB'_R K?\ Z^5_]!:O-:\^.Q[S
MW"BBBF(*5?O#ZTE*OWA]:!GNU%%%9%A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]_Y $_\ U]-_Z"E>:UZ5\/?^0!/_ -?3?^@I2EL4MSK:***S*"BBB@ HHHH
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M3?\ (SW?_7FW_H:5P5=[\)O^1GN_^O-O_0TK.K\#,<1_"D>Q5Y-JW_(9OO\
MKXD_]"->LUY-JW_(9OO^OB3_ -"-?/9G\,3YO%[(IT445XYP!1110!Z!X'_Y
M DO_ %\-_P"@K6OK/_(#O_\ KWD_]!-9'@?_ ) DO_7PW_H*UKZS_P @._\
M^O>3_P!!-?38'^' ]%?[O\CR:BBBOJ3XP**** "O6])_Y UC_P!>\?\ Z"*\
MDKUO2?\ D#6/_7O'_P"@BO/S#X8GMY+\<_0Y[XA_\@*W_P"OE?\ T%J\UKTK
MXA_\@*W_ .OE?_06KS6O/CL>\]PHHHIB"E7[P^M)2K]X?6@9[M1116184444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'F'Q@_Y@W_ &W_ /:=>7UZA\8/^8-_
MVW_]IUY?7;1^!'KX7^$OZZA1116IT!74?#O_ )'O3?\ MK_Z*>N7KJ/AW_R/
M>F_]M?\ T4]3/X69U?X<O1GN]>9^*_\ D9;O_@'_ * M>F5YGXK_ .1EN_\
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MS+Q9_P C->?\ _\ 0%K[; ?Q'Z?Y%9S_  %Z_HS%HHHKUCYD**** .G\"_\
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M$E>E5YK\/?\ D/S_ /7JW_H25Z542W+6P4445(PHHHH **** "BBB@ HHHH
M\:^*_P#R-=O_ ->:?^AO7"UW7Q7_ .1KM_\ KS3_ -#>N%KOI_ CV:'\*(44
M459L%=[\)O\ D9[O_KS;_P!#2N"KO?A-_P C/=_]>;?^AI6=7X&8XC^%(]BK
MR;5O^0S??]?$G_H1KUFO)M6_Y#-]_P!?$G_H1KY[,_AB?-XO9%.BBBO'. **
M** /0/ __($E_P"OAO\ T%:U]9_Y =__ ->\G_H)K(\#_P#($E_Z^&_]!6M?
M6?\ D!W_ /U[R?\ H)KZ; _PX'HK_=_D>34445]2?&!1110 5ZWI/_(&L?\
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M?]?K_P#H"5T?BO\ Y%J[_P" ?^AK7EXSX)^C_(\/&;S^9YG1117RQX04444
M%>L:1_R!;#_KWC_]!%>3UZQI'_(%L/\ KWC_ /017IY9\<CKPGQ,YGQ]_P P
M_P#[:?\ LM<77:>/O^8?_P!M/_9:XNOL\'_!C_74\',_]ZG\OR04445TG %7
M='_Y#=A_U\Q_^A"J57='_P"0W8?]?,?_ *$*F?PLTI?Q(^J/6J\U^(7_ "'X
M/^O5?_0GKTJO-?B%_P A^#_KU7_T)Z^?CN?;O8Y*BBBK("BBB@#K?A[_ ,A^
M?_KU;_T)*]*KS7X>_P#(?G_Z]6_]"2O2JB6Y:V"BBBI&%%%% !1110 4444
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M=C_Z^%_DU- =//,EM;RSR9V1H7;'H!DUR.F6FK>);=M3GU:YLHY&(@BMV*@
M''///-='K8)T#40.IM9?_035+P>0?"EC@YP&'_CYH S-+UF_M8-:L+V7SKK3
MHGDCE(^^ ">?T_.JKO?Z=I&EZT-5NIYKB5/-B>3=$P?)P%[8Z5;L$CN?'^MJ
M0'B:W6-QV/" C]#1J.D:;H%I'=-+=W'DO_HEG++N3S#TPN/7F@"WKUS-J%Y'
MH%DY5Y1NNI5_Y9Q>GU/^>M;UM;Q6EM';PH%BC4*H'8"N2L/[1TZ^6PMDMY=6
MNXS=7D]P2509P%^7GC^M;FA:M+J4=S%=1)%=VLIBE5#E2?44 :U%%%( HHIK
M&3/RJI'NV/Z4 .HIF9?[B?\ ?9_PHS+_ '$_[[/^% #Z*9F7^XG_ 'V?\*,R
M_P!Q/^^S_A0 ^BF9E_N)_P!]G_"C,O\ <3_OL_X4 /HIF9?[B?\ ?9_PHS+_
M '$_[[/^% #Z*9F7^XG_ 'V?\*,R_P!Q/^^S_A0 ^BF9E_N)_P!]G_"C,O\
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M /HIF9?[B?\ ?9_PHS+_ '$_[[/^% #Z*9F7^XG_ 'V?\*,R_P!Q/^^S_A0
M^BF9E_N)_P!]G_"C,O\ <3_OL_X4 >9_&#_F#?\ ;?\ ]IUY?7IWQ>+G^QMP
M4?Z_H<_\\_:O,:[:/P(]?"_PE_74****U.@*ZCX=_P#(]Z;_ -M?_13UR]=/
M\/<_\)SIVT G][U./^63U,_A9G5_AR]&>\5YGXK_ .1EN_\ @'_H"UZ3F7^X
MG_?9_P *\U\59_X22[W  _)T.?X%KY_,OX2]?T9\UB_@7J8]%%%>(>>%%%%
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M )A__;3_ -EKC*['QV7/]G[@H_UG0Y_N^U<=7RN._CR^7Y'S>(_B,****Y#
M*NZ1_P AJP_Z^(__ $(52JYI&?[:L<=?M$?_ *$*NG\:*C\2/6:\R\6?\C->
M?\ _] 6O2LR_W$_[[/\ A7FGBO/_  DMWN !^3H<_P "U]M@/XC]/\BLY_@+
MU_1F-1117K'S(4444 =/X%_Y#<W_ %[-_P"A+7H%>>^!]PUJ;: 3]G;J<?Q+
M7?YE_N)_WV?\*\;&_P 4^IRG_=EZL\+HHHK$[PHHHH *]*^'O_( G_Z^F_\
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MLS^&)\WB]D5****\<X HHHH ] \#_P#($E_Z^&_]!6M?6?\ D!W_ /U[R?\
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M1S[@KKG(Y'/_ .H5-H>DRZ;'<RW,JRW5U*996084$]A[5K44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YA\8/^8-
M_P!M_P#VG7E]>H?&#_F#?]M__:=>7UVT?@1Z^%_A+^NH4445J= 5U'P[_P"1
M[TW_ +:_^BGKEZZCX=_\CWIO_;7_ -%/4S^%F=7^'+T9[O7F?BO_ )&6[_X!
M_P"@+7IE>9^*_P#D9;O_ (!_Z M?/YE_"7K^C/FL7\"]3&HHHKQ#SPHHHH [
M/P%_S$/^V?\ [-795QO@+_F(?]L__9J[*OH,#_ C\_S/4P_\-'C%%%%?7GQ(
M4444 %>F^$_^19L_^!_^AM7F5>F^$_\ D6;/_@?_ *&U<6/_ (:]?\SU\F_C
MOT_5$?C/_D4[W_MG_P"C%KR:O6?&?_(IWO\ VS_]&+7DU>7'8^CD%%%%42%%
M%% 'M&A_\@#3?^O6+_T$5?JAH?\ R --_P"O6+_T$5?K(T"BBB@ HHHH ***
M* "BBB@ KE_B)_R(FI?]LO\ T:E=17+_ !$_Y$34O^V7_HU*J'Q(TI?Q(^J/
M"****] ]L**** "OHOPU_P BKI'_ %Y0_P#H KYTKZ+\-?\ (JZ1_P!>4/\
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MD:!1110 4444 %%%% !1110 5R_Q$_Y$34O^V7_HU*ZBN7^(G_(B:E_VR_\
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MD:!1110 4444 %%%% !1110 5R_Q$_Y$34O^V7_HU*ZBN7^(G_(B:E_VR_\
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M )%6Z_Z_7_\ 0$KH_%?_ "+5W_P#_P!#6N<^$W_(JW7_ %^O_P"@)71^*_\
MD6KO_@'_ *&M>7C/@GZ/\CP\9O/YGF=%%%?+'A!1110 5ZQI'_(%L/\ KWC_
M /017D]>L:1_R!;#_KWC_P#017IY9\<CKPGQ,YGQ]_S#_P#MI_[+7%UVGC[_
M )A__;3_ -EKBZ^SP?\ !C_74\',_P#>I_+\D%%%%=)P!5W1_P#D-V'_ %\Q
M_P#H0JE5W1_^0W8?]?,?_H0J9_"S2E_$CZH]:KS7XA?\A^#_ *]5_P#0GKTJ
MO-?B%_R'X/\ KU7_ -">OGX[GV[V.2HHHJR HHHH ZWX>_\ (?G_ .O5O_0D
MKTJO-?A[_P A^?\ Z]6_]"2O2JB6Y:V"BBBI&%%%% !1110 4444 %%%% 'C
M7Q7_ .1KM_\ KS3_ -#>N%KNOBO_ ,C7;_\ 7FG_ *&]<+7?3^!'LT/X40HH
MHJS8*[WX3?\ (SW?_7FW_H:5P5=[\)O^1GN_^O-O_0TK.K\#,<1_"D>Q5Y-J
MW_(9OO\ KXD_]"->LUY-JW_(9OO^OB3_ -"-?/9G\,3YO%[(IT445XYP!111
M0!Z!X'_Y DO_ %\-_P"@K6OK/_(#O_\ KWD_]!-9'@?_ ) DO_7PW_H*UKZS
M_P @._\ ^O>3_P!!-?38'^' ]%?[O\CR:BBBOJ3XP**** "O6])_Y UC_P!>
M\?\ Z"*\DKUO2?\ D#6/_7O'_P"@BO/S#X8GMY+\<_0Y[XA_\@*W_P"OE?\
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M0 SR8O\ GDG_ 'R*/)B_YY)_WR*?10 SR8O^>2?]\BCR8O\ GDG_ 'R*?10
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M 'R*?10 SR8O^>2?]\BCR8O^>2?]\BGT4 ,\F+_GDG_?(H\F+_GDG_?(I]%
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M)B_YY)_WR*?10 SR8O\ GDG_ 'R*/)B_YY)_WR*?10 SR8O^>2?]\BCR8O\
MGDG_ 'R*?10 SR8O^>2?]\BCR8O^>2?]\BGT4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%4M2U>QTF-'OI_*5SA?E+9/X T 7
M:*P1XS\/D@?VAU_Z8R?_ !-;U !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1156_U&UTRV^T
M7DPBBR%W8)Y/L.: +5%0VEW!?6L=S;2"2&095@",_G4U !1144%U;W)<03Q2
MF,[7\MPVT^AQTH EHK*N-:^S^([/2/L^[[1&S^;OQMP&.,8Y^[Z]ZU: "BBB
M@ HHHH **R-$US^V7O5^S^3]FE\O._=NZ\]!CI6O0 445EZ/KD&LM=+##+']
MGDV'S .>O^% &I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%5(]3LY=3ETY)LW<2;WCVG@<<YQCN/SJ:YN8;.VDN)WV11K
MN9L$X'X4 2T5#:74-]:QW-N^^&095L$9'T-34 %%%% !1110 45D+KF[Q,VC
M?9_NQ>9YN_VSC&/ZUKT %%%% !1165I.M?VI>ZC;_9_*^Q3>5NWYW\D9Z<=*
M -6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBF331V\$D\K;8XU+NWH ,DT /HK!_P"$T\/_ /00_P#(,G_Q-:MA
MJ%KJ=J+FSE\V(DKNVD<CV(S0!9HHIDTT5O$TL\J11K]YW8*!]2: 'T4U'22-
M9(V5D8 JRG((/<&LW2=<AU>XO88H98S:N$8N!\W7I^5 &I1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !15:_U"UTRU-S>2B*($#=@GD^PYI+#4;35+;[193"6+<5W $8/I@\T
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M)2))(IG82@@EL#'W>>O-4KWPGJ-] (KWQ$\L08-M:W &?^^O>G>+0&UCPZ"
M0;L @_[R4 :.CW>NW-RS:E806UJT>Z/:WS@Y& W/IGMVK:HHI %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R>NJ-:\4:?
MH^-UO /M%P.<>P/\O^!5U4DB11/)(P5$!9B>P%<'HD.NZA<WNMZ>]G']JE*_
MZ1N)VCH!@'CH/PIH#2\'2/8W&HZ%,?GM92\?NI_R#_P*K?B7Q#-H5Q8!(4EB
MG+^8""6XVX"\]>?>L&[&JZ)XFL-6U1[5A.WDR-;[L;<8YR!V.?\ @-:GBH ^
M(?#8(R/M#?S2@"S;7GBF:&=I-/LX6,8: ,QZ[APWS9^[GTYKG?"\FNK/J'V"
M*R?-Q^_\TMPV3]W!Z=:]$KD/!!_?ZR/^GG^K4 0^([QM/\;Z9<I \[K;D+$G
M5B=X _,U8N/$.MZ1-!+J]A;)92OL+0L2R?4Y(_\ U4[4?^2CZ1_U[O\ ^@R4
M_P ?#_BF_P#MNG]: +WB?6)]$TQ+J!(V8S*A$@)&""3T(]*ATO4]<U&]BF?3
MHH=+ER59F_>!<':<9[G';O6=XU.?"%H3U\R/_P!!-=;+(MM;/)M^2-"V%'8#
MM0!SIU+Q1=%Y+/2;>"$$A5NF.]OPR,5=\/:V^L03K<6_D75M)Y<R#H#_ )!_
M*L;39=>\2V[WJ:K'I]MO(2.*(.1CU)P?U_"E\$ K>ZXK3B=A< &8?\M#EOF_
M'K0 [P20)M:). +GDG_@5/AU_7=7,T^C6%J;2-RBM<,=SD>G(J#PBT:)K[R@
MF-9F+@>GS9JGX9GUZVT@_P!F6$%U:R2,R,\JAD.<889'IF@#:\+ZUJFLO,]W
M%:)!%E"(PP</QP02>,9JQX=UJXU>34%G2)1;S>6GE@C(YZY)]*?X9T>;2+"0
M7+J]S<2&63;T!/:L?P?*(!KLS D).6('7C<: +AU+Q1=%Y+/2;>"$$A5NF.]
MOPR,5=\/:V^L03K<6_D75M)Y<R#H#_D'\JQM-EU[Q+;O>IJL>GVV\A(XH@Y&
M/4G!_7\*7P0"M[KBM.)V%P 9A_RT.6^;\>M '8T444@"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .(74+33?B-J<UY,L,;6ZJ&;/7;&<?
MH:NZ]XCTBZT*]@@OHWE>(A5 /)_*JT%I;WGQ(U2.YMXIT%LK!94# '$?.#]:
MT?$.D:9!X>OI8M.M(Y%B)5D@4$'V.*8#_#UU%9>#+6YG;;%%"68^P)JE;ZUX
MDU* WFGZ9:K:DGRQ,QWN/;D57='D^%H"9R(0>/029/Z TNBZ3JEWHUK-:^)7
MCB,8 C6W!"8'*_>[4 ;NB:XFL:>\_DM'/"2LT(Y(8>GUK._M+Q5<H9[;2;6&
M+JL=PQ\PC\Q@_6IM,TL^&[75+V6[-[(X,\GR;#E06/<\G-9^GC7]?L1J+:S'
M8V[EBD<40; !QR<CT]: -KP]K7]N:>TS1>5-&YCD3.<'VK+C\0ZQJUU<?V)8
MV[VL#;#+<,?G/M@BJG@E'DTC5T1]\C2,%;U.WK5OP!(AT&2($>9'.V]>XR!C
M_/M0!0TB[GO/B \ES;-;3BW*21DYP0 .#Z5NZAJ&NG4)+72]-B,<8&;BY)"L
M2 ?EY&>N*RK::*?XES-%(KA;?:2IR,@#(J5]0U?6]=O=/T^[CL;>T.UW*!G;
MG&0#].V/UH MZ1KU]+K,FDZM:Q0W03>C1$E6'YG^=+JFO7B:N-)TFUCN+L+O
MD:4X1!UYZ>WYUBZ=!/;?$*.&YOC>RK <RE0I'!XP":M:*P@\?:Q%-Q+*NZ/)
MZC@\?AC\J -;3-0UAM0-GJMA'&60ND\!)0X(R#DG'6N;TF_OK?7]<M=-LQ<7
M,UV[;G.$C 9N3^==V9X5G6 RH)F4LJ$\D#J<5S'A/_D->(_^OP_^A/0!8TK7
MKY]:;2-7M8H;DIOC:$G:PZ]R>W\JEUG7Y[74(=,TVV6YOY1NPQPJ#U-4M1_Y
M*/I'_7L_\I*SKVVN9OB%<QQ:@;"26%3%)L#;AM7Y1R/0_E0!J+K^JZ;?V\&N
MV=O'#<-L2:W)PK>^2:ZBN2N_">H7J1I>^(7FB20.%:W YZ#^+W_6NMH8!111
M2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:Y_R+^I?
M]>LO_H!J_5#7/^1?U+_KUE_] - &)X2BTUO#%F;A+0R_/N,@7=]]NN:V+^Z?
M3]-5],L1=,S;8XX<!03GDX[5SGACPQH^H^';6ZNK/S)GW[F\UQG#D#@''0"M
M#7+W_A&-(M;/2H41I9#'%O)*IDY)Y/J>]/J!7O-<\2:3"+S4-.LVM P#B%CN
M7/OD_P J=XON+Z?P^TMJD!T^6)7E9\[QD@C'./2L[Q+IVKV^@SSZAKHF!V@V
MPB"JYW#@'(Z=>G:M36?^2=_]NL/_ ++0!+X9?6VM+-;J*S6P%LGELA;S"-HV
MYYQTZU9T36+C4]0U:WF2)4LYS%&4!!(RPYR>O%6M"(/A_32"#_HL8X_W16'X
M6=8]6\2NWW5NR3]-ST +'K^MZM+</HMC;-:1.4$EPQRY'I@BI/#6MZOK%S,+
MJ&TCA@)20(&#A^PY)'K^58OABXUNWTZ;^R;"&YM))F*>9*JM&>G/([ 5TOAK
M2+C3+:XEO75KNZE,LNTY /I^IH8">'=:N-7DU!9TB46\WEIY8(R.>N2?2AM:
MN!XP32 D7V=H?,+8.[.">N<?I6;X*(6\UN)CB07.2IZCEJ:)8Y?B:OENK;("
MC8.<$*<B@#2U?7[B#4X]*TNV6YOF&YMYPB+[U7BU_5+#4[>TURS@C2Y.V.:!
MCM#>AR3ZBLF6TNYO']_#%J9L9I(PR2! V]<+\HY'I^E:-SX3O[QH3?>('F2*
M0.JM;@<_7=0!UE%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** .7\??\ (M_]MD_K5#PVQT7Q"VGN<07\"3PYZ;L9(_\
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M#/TK1K71Q<+:;PDTGF%6((7V''2L^Z\'Z;<WDETDEU;/(<N()-H;U[&N@HH
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img70551829_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_15.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,P-   DI(
M @    ,P-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$(!4$+<@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M1110 445XM\;OB[XI^&FOZ;;:+IVF36-[;-()KR.1V,BMAE&UUP "A[_ 'J
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M\+ZRM]<P1>=)%Y$L1"9 W#>HR,D#CU% '5T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !139)$BC:21@B("S,QP !WKS?P?\=?"_CCQ>OA[0[353
M.PD9;B6W182J#.[(<L >V5'4 X- 'I5%%5)=5TZ&7RYK^UCD_N/,H/Y9II-[
M$RE&/Q.Q;HIJ.LB!HV5U/0J<@TZD4%%%% !156;5=/MY/+GOK:)_[KS*#^1-
M6$D25 \3JZGHRG(--Q:U9*E%NR8ZBBBD4%%%% !1110 4444 %%%% !1110
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MC;%$#\\\F.(T'<G'T R3@ FOD">?Q9\>_B8%16+2'"("3#I]OGJ?8=SU8^Y
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M)(ZLIR#_ -_&2OM2OGW]E+PY]G\/ZSXCF7YKN=;2$D?P1C<Q'L2X'_ *^@J
M."^-_P#R17Q)_P!>Z_\ HQ:\&_95_P"2J:C_ -@:7_T=#7O/QO\ ^2*^)/\
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M]]9KJK:G+>SB5Y3!Y(4!< !=S>_.>_M0!WU?+_[6=X7\1>';+G$-K+*/3YW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_&GP_\ ^$*^!_AVZOH=FK:O?&XN=P^:-/+/EQ^V%.2.S,1VK6^'VEW?QO\
MCC=^(M=BW:;9R"ZGA;YD5 <0P?0[>>.0K>M=Y^UA_P B=H7_ %_M_P"BS0!?
M_94_Y)9J7_89E_\ 1$->VUXE^RI_R2S4O^PS+_Z(AKVV@#C/B_\ \D>\3?\
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M]_[%23_TD-?/W[+O_)6I_P#L%S?^AQU] ZK_ ,FYWO\ V*DG_I(:^?OV7?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0+2;K;3@PZ <22#ZG*#Z/ZU]&T %>=?''7/$&A_#=G\)-.FI75W%:JUM&7E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M++N/&6D( &/PZFNF\^;78]#FJ^T]ZW(>G?#KQ)<>)_":75]AKJ"5H)7 QO(
M(;'T89]\U\I_'/49?%'QRU*UL,7!AEBT^W1.I=0%*_7S"PKZJT'1IO GP]N$
MM[=M0OX89+EX;=<F>;;D(H[]%4>N*^??@O\ #'Q)JWQ4'B/QGH]_9P64C7K2
M7]LT)GN"<K@, 3AB7R!@%1ZUPSMS.QXU7E<WR['T]H&E1Z%X;TW28.8[&UBM
MU/J$4+_2M"BBI,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /D/]IWPS_8_Q)AUB%-L&LVX=CZRQX1__'?+/U)KC/&?
MC'4?B1J/AVU6.:6XM-/@TY(SC,T^<,X]V)7\A7UQ\4_AG:?$[P[;Z=<7S:?/
M:S^=!<K$)-O!!4KD9!SZCD"N$\#?LTVOA'QE8:]>^(SJBV+^;';"P\D&0#Y6
M+>8W0\XQU YH ]=\+Z%#X9\*:9HEL<QV%K'!N_OE5P6^I.3^-?-W[5/BG[9X
MFTSPS;R9BL(?M-PH/_+63A0?<(,_\#KZFKP_Q5^S='XL\?7WB*_\52B&]N!+
M):_8@6"8 V"3S/08!V\#'6@#RO1?V:/&FMZ%8ZI#>Z-;QWL"3I%<33+(BL 0
M& B(!P>F:37?V:_&6@>'[_5[F^T6>&QMWN)([>>4R,J L=H,0!. >]?8B(L<
M:I&H5% "J!P!Z4V:*.>%X9D#QR*5=6'# C!% 'R5^S!XI_LCXAW&A3OB#6H,
M(#_SVB!9?_'?,'UQ7:?M/_$$V>G6_@K3)<378%QJ#*>5B!^2/_@1&X]\*.S5
M:T']F)?#WC*QURQ\7RA+&]2YC@^P88JKY"%_,[C@G;SSQVJ3Q#^S3_PD_C:^
MU_5O&$TB7MT9I(!8 .$SQ&'\S'"X4';T'2@"E^SS\+K.7P#J6L^(K42?\)!"
M]I%&XP5M<X)'<%F&?HBD=:\1N8=8^#_Q8^7/VW1KO=&Q&!<1'H?]UT./;<>X
MK[KL[.WT^Q@L[&%(+:WC6*&*,85$48"@>@ KS7XK_!.R^)U_9:@FJ'2;ZVC,
M+S"V\X31YR 1N7!!)P<]S0!UQB\/?$WP'";N!;_1M5A27RV9E)Y# 94@JP8<
MX/4$5S'_  SY\,?^A9_\G[G_ ..5J_"[P!/\-_"TFB2ZV^KQ&X::)F@\H1!@
M,J!N;C()Z]2:[2@#F8+/PS\*_ URUG --T;3U>X=0[2').3RQ)))P ,^@KX_
M\<^-]4^+WCR$SSV]A9[S#8Q7=PL4-K&>K.[8 )QECWP .@%?8GCWPE'XZ\#Z
MCX<FNVLUO50"=4WE"CJX.W(R,J,C(X[BO#_^&1O^IV_\I/\ ]NH [OX:+\,_
MAMX;6QL?&/AV>^F :]OCJ4 :=_\ OOA1D@+VZ]22>H\1G3OB1\/]=T?PKK>F
M7LMS;- )8+E9HXW(RH<H3@''U]C7CG_#(W_4[?\ E)_^W5Z7\(_A&OPK35L:
MT=5;4C#D_9?)$8CWXXWMG.\_E0!XA_PRIXW_ .@KX?\ _ B?_P",UR'Q"^#O
MB#X:Z;:7VNWFFW$5W,84%G+(S @9YW(O%?<M<'\5_ABGQ0T.SL&U5M,:TG,R
MRBW\X-E<$%=R_P Z /GSX!_#+6O$&O:=XRLKRRAT[2M3\N>-Y'$S%45B% 7!
M!#@<L._X_7]<7\+/AVGPR\)S:,FI-J337;W3SF'RAEE5<!=S8&$'?KFNTH X
MSXO_ /)'O$W_ %X/7SY^RK_R534?^P-+_P"CH:^G_%GA]/%7A+4M"EG:V2_M
MVA,RKN*9[X[_ $KS[X4_ V+X9>(KK6#K[ZI-/:M:A/L@A55+JQ/WVR<H/3O0
M!Y_^U=X8$=WHWBB!,"4&QN6_VAEX_P!/,_(5XSX>LM2^(7C;0M$NKF69I3#8
MH_&8;=!CCV5 3^%?;/C_ ,%VGC_P;=:!>SM;"8J\=PB!C$ZG(;!Z]P1QP3R*
MX;X7_ *U^'/BI]=GUPZM.(&B@3[&(1$6QEL[VR<#';J: .G^+$$=M\%?$4%N
M@CBBTYD1!T50  *\ _95_P"2J:C_ -@:7_T=#7T_XL\/IXJ\):EH4L[6R7]N
MT)F5=Q3/?'?Z5Y]\*?@;%\,O$5UK!U]]4FGM6M0GV00JJEU8G[[9.4'IWH \
M:_:C_P"2M6__ &"X?_0Y*]R;39M7_9=M[&U4O/+X5A\M%ZLPME('XD8K-^*7
MP(7XE>*HM:'B(Z8T=JMN8C9><#M9B#G>N/O=*]-\/Z0F@>&=,T>.5IDT^TBM
M5E88+B- N2.V<4 ?('[.WB6Q\-_%B(ZG.EO#J-I)9"61@%5V977)/3)0#ZD5
M]!_'/QKH_ASX:ZII]Y<H]_JUJ]M:VJ,"[;Q@OCLH!SG\.IKA/'_[,!U76[C4
MO!&HVEBER^]["[5ECC8GYBCJ"0OHNWCUQ@!? _[+D%A?)>^.-2AO_+Y2RLPW
ME,W8N[ %@.NT 9QR2,@@'#_LN_\ )6I_^P7-_P"AQU1_:3TN2P^,][=.#LU"
MV@N$)Z8""(_K&:]P^%_P(3X;>+IM;7Q"VI>9;/;K ;/RMH9E.2V]L_=]!71_
M%'X6Z9\3=%B@NY39ZA:DFTO47<4SU5AQN4X'&1TX]P"Q\//&6DZ_\,=-UE;Z
MWCCM[-$O2\@46TB* X?.-N""<G&1@]#7R-\9/%>G^,OBCJ6K:.6>R(2&*1AC
MS0BA=P'8$@X]L5Z!;?LH>)6U'9>:_I,5EG_71+(\F/\ <*J/_'J['7?V6-%O
MK;3X="UN32_LT)2XDEM?M#73DYWD[UV^F!Q_4 [S5?\ DW.]_P"Q4D_])#7S
M]^R[_P E:G_[!<W_ *''7U%=>&8[GP!-X6-RZQ2Z8VG&X"C<%,7E[L>O?%>?
M?"WX#K\-?%4NMGQ$=39[5K<1"R\D#<RG.=[9^[TH \L_:KTN>W^(.EZFP_T>
M[TX1(W^W&[;A^3H?QKKOA-\.?A-XY\"Z?<R:5%<ZO'"$OXCJ$ZR"4<%BBR#
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MS^?0=A6/_P *V_ZBO_DM_P#94?\ "MO^HK_Y+?\ V5>)1I8JG-U'"\GUNO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"\&:YI'AWQ'#J>NZ#_;L5O\ -%:-<^2A?L7^1MP']WCWR.*]R_X:XQT\$_\
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MEE4G+L3T5>,XXKWSX&^ O#6D^"]%\4:?IHBUF^TX+<7/GR-O#$$_*6*CE1T
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MQ7CWC'_DXZ__ .Q@7_T:*]A_9._Y$_7O^O\ 3_T6*\>\8_\ )QU__P!C O\
MZ-% 'VZR+)&4D4,K##*PR"/2O@3QU!I^@?$O68/"5W(+.UO'6VEC)0QD?>52
M.RMN4'N #WKZO^.OQ#_X03P$\=C+LU?5=UO:;3S&,?/+_P !! '^TR^]>0?L
M[?"RT\4PZKKWB2U\[3C%)86T;#&]G7$C@]MJG ([L>ZT 3?LIV.C3>*=8N[I
MPVL6]LHM(F P(F)$CKSR<[ >!@-U.XXZ/]K.:1?#OAV$,1&]U,[+ZD(H!_\
M'C^=>, ZQ\%OB^>K7&DW/^ZMU P_DR'\#[BOH?XTZ!_PM'X.V6M^%5:]DM]M
M_;QQKEY8F4AT Z[AD''7*XZT >/?"[Q_\1_"WA)[+P3X.75M/>Z>5KH:7<3Y
MD(4$%XV X 7CK2?$34_BG\3(+"/7O %[!]@9VB:ST:Z5CO"Y!+%N/E'3%+\&
M/C='\-]/NM'UJPGO=+GF^T1O;,/-A<@!AAB 5(4=Q@@]<\>B:W^UAHL=H?\
MA'/#]_<7!'!OV2)%]_D9B?IQ0 ZQT_5_#O['&HVFK6DUA=K!,/(G0I(J//\
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M*%'_ *&?RKHOV8=*:P^$K7C@_P#$QOY9E/\ LJ%C_FC5YA[Y['1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MLB,DBAE8896&01Z5B6/@CPIIETMUIOAC1K2X4$++;Z?%&X!&",A<\@D5N44
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MH **** "BBJUUJ%K97-E!<R[);Z8P6Z[2=[B-Y".!Q\D;G)P.,=2* +-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445#>WD&GV%Q>WDGEV]M$TLKX)VHHR3@<G
M@4 344V.198EDC.Y' 93Z@TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?W)?R'^-']NVW]R7\A_C6!10!O\ ]NVW]R7\A_C1_;MM_<E_(?XU@44 ;_\
M;MM_<E_(?XT?V[;?W)?R'^-8%% &_P#V[;?W)?R'^-6;.^BO=_E*XV8SN [_
M /ZJY>MG0/\ EX_X#_6@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L3QK_R(/B#_ +!ES_Z*:MNL3QK_ ,B#X@_[!ES_ .BFH TM-_Y!5I_U
MP3_T$59JMIO_ ""K3_K@G_H(JS0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %5M2U"UTC2KO4M0E\FTLX7GGDVEMB(I9C@ DX / &:LUS?Q'_Y)9XK_ .P+
M>?\ HAZ .DHK,U#5);2Z\I$1AM!R<U5_MV?_ )Y1_K0!NT5A?V[/_P \H_UH
M_MV?_GE'^M &[16%_;L__/*/]:/[=G_YY1_K0!NT5A?V[/\ \\H_UH_MV?\
MYY1_K0!NT5A?V[/_ ,\H_P!:/[=G_P">4?ZT ;M%87]NS_\ /*/]:/[=G_YY
M1_K0!NT5A?V[/_SRC_6C^W9_^>4?ZT ;M%87]NS_ //*/]:/[=G_ .>4?ZT
M;M%87]NS_P#/*/\ 6C^W9_\ GE'^M &[15'3;][WS?,55V8QM]\_X5>H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]O;?3K&:\O95AMX$+R
M2-T51U-3US?Q$_Y)QKO_ %Y2?RH Z2BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***Y_P 1W,\&O>$XX)I(TN-6DCF5'($B_8;IMK =1N53@]U![4 =
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !16!XXNI[+P;?7%G,\$R>7MD
MC;!&9%'7Z&M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,?%7P:\
M+ZKXCUWQCK,<U_>3VVY+>5\0Q-'"$!P,%C\@/)(]J\7_ &5/^2IZE_V!9?\
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MU-_\71_PJWP=_P! ?_R:F_\ BZX?<\SQ+4.[^Y?YFY_PD.B_]!>P_P# E/\
M&C_A(=%_Z"]A_P"!*?XUA_\ "K?!W_0'_P#)J;_XNC_A5O@[_H#_ /DU-_\
M%T>YYA:AW?W+_,W/^$AT7_H+V'_@2G^-'_"0Z+_T%[#_ ,"4_P :P_\ A5O@
M[_H#_P#DU-_\71_PJWP=_P! ?_R:F_\ BZ/<\PM0[O[E_F=):ZG8WS,MC>V]
MRRC+"&57('O@U9K&T/PCH?AR>6;1;+[-),H5SYKOD Y_B8ULU#M?0RERW]W8
M****1(4444 %%%% !6)XU_Y$'Q!_V#+G_P!%-6W6)XU_Y$'Q!_V#+G_T4U &
MEIO_ ""K3_K@G_H(JS5;3?\ D%6G_7!/_015F@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BN8\<_$+P_\/=)6^\173(TVX6]M$NZ6X*XR%'MD9)( R,GD5XEHG[3.O\
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M_P DXUW_ *\I/Y4 =)1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /$_B7=_&A_%FI67@S3HYO#\D2) X6
ME@T8WY+MG.XL/RKRGP=\/OC+X#UB74_#?AYX+J: V[M(]O("A96(P7]4%?85
M% '/^!)O$<_@G3I/&T20ZXRO]J2,* /G;;]TD9V;<X[YKH*** "N.\??\?\
MX2_[#3_^D-W78UQWC[_C_P#"7_8:?_TANZ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *V= _Y>/\ @/\ 6L:MG0/^7C_@/]: +U]I=AJ:*FI6
M5O=JOW1/$K[?ID<4^TLK6P@\FPMH;:+.?+AC"+^0J>BG=CN[6"BBBD(****
M"BBB@ HHHH **** "BBB@ HHHH *Q/&O_(@^(/\ L&7/_HIJVZQ/&O\ R(/B
M#_L&7/\ Z*:@#2TW_D%6G_7!/_015FJVF_\ (*M/^N"?^@BK- !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %K8H **** "BBB@#-O/$6E6%TUO>7BQ3)C<I5CC(SV%0?\ "7:%_P!!!/\
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M_?#?X5RG@WPS)<W0O]1MQ]E53Y:2H")21CH>PZ_7%=M_8>D_] NR_P# =/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS1_PF'_4$U/_ +\UTE%7STOY/Q,O8XC_ )^_@CF_^$P_Z@FI_P#?FC_A,/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 >(^-/COK5GXLU#PUX!\(W&LWNGN8YYFBDE <=<1QC)7/<L,^G>N9T;]I
M[7-.\0C3_B!X;@M$60)/]FCEAFMP<<F.0L3ZXXX_7V/Q+\0/!'P\OQ;:]>PZ
M7<WP-R5BLY&,W."[&-#SD=3S7S1\1[]_C?\ %R$> =-N+A$MH[3SFCV!L,Y,
MKG^%?FQEN<*/I0!]BPRQSPI-"X>.10R,IR&!&0:?5/2+ :5HECIP?S!:6\<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )$>VA_29W]%<O\ \)9J'_0LZA_WRW_Q-'_"6:A_T+.H?]\M_P#$T?6J/?\
M!_Y![:'])G445R__  EFH?\ 0LZA_P!\M_\ $T?\)9J'_0LZA_WRW_Q-'UJC
MW_!_Y![:'])G445R_P#PEFH?]"SJ'_?+?_$T?\)9J'_0LZA_WRW_ ,31]:H]
M_P '_D'MH?TF:VJZ]I^C ?;9\.PRL:C+$>N/\:@TOQ7I6JS"&"9HYF^['*NT
MM].U>8:K>37^J7%S<AED=SE6ZKZ+^'2JJ.T;J\;%64Y# X(->3+-)JIHO=.)
MXN7-HM#W*BN2M?%NI-9PEO#U],2BDRHK8?CJ/EZ'K4O_  EFH?\ 0LZA_P!\
MM_\ $UZRQ=%K?\'_ )'9[:'])G445R__  EFH?\ 0LZA_P!\M_\ $T?\)9J'
M_0LZA_WRW_Q-'UJCW_!_Y#]M#^DSJ**Y?_A+-0_Z%G4/^^6_^)H_X2S4/^A9
MU#_OEO\ XFCZU1[_ (/_ "#VT/Z3.HHKE_\ A+-0_P"A9U#_ +Y;_P")H_X2
MS4/^A9U#_OEO_B:/K5'O^#_R#VT/Z3.HHKE_^$LU#_H6=0_[Y;_XFC_A+-0_
MZ%G4/^^6_P#B:/K5'O\ @_\ (/;0_I,ZBBN7_P"$LU#_ *%G4/\ OEO_ (FM
MW3+R6_L$N)[22T=B08I00PP?<"M(5Z=1VB_P8XU(R=D6Z***V- HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*+5@I(Z@$X]3UH Z"N%\?_\ (R>$/^PG)_Z175:WV[QO_P!"]X?_ /!]/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*QO%_B:S\'>$M0U[4C^YLXBX3.#(_14'NS$#\:^0[OXZ_%&&ZAO9M<:WCN@;
MB"+[)#Y93>R\ J3MRK#DYXZ]Z /M6BBB@ KCO'W_ !_^$O\ L-/_ .D-W78U
MQWC[_C_\)?\ 8:?_ -(;N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD8,L%NJN1Z;L9Q^- $/@+1+GPW\/M#T>^(-U9V4<<VTY ?'S 'N >*Z&BB@
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MDMK9)M1>23U8^I/<TJN(C6IKF7O+J/#X.>&KOV<OW;Z=GY%NBBBN,]0****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8>L>-O"_A^\
M%IKGB#3=/N2H?R;BZ1'VGH=I.<59\1Z]9>%_#=]K>J/LM;*$ROZMZ*/<G 'N
M17Q+XJLM6\2>'[WXDZVQ5M6UC[- F.& C8MC/\*[40?1O2@#[EL-0L]5L(KW
M2[N"\M)AF.>WD#HXSCAAP>015BO-OV?/^2$^'O\ MY_]*9:])H *YOXC_P#)
M+/%?_8%O/_1#UTE<W\1_^26>*_\ L"WG_HAZ 'ZU_P A#_@ K/K0UK_D(?\
M !6?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &SH'_+Q_P'^M
M;%8^@?\ +Q_P'^M;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<W\1/^2<:[_P!>4G\JZ2N;^(G_ "3C7?\ KRD_E0!TE%%% !1110 4444
M%%!( ))P!U)KB-5^(7E7+1Z5;I(BG!EFSAOH!VK"M7IT5>;,YU(TU>1V]%<S
MX=\8Q:S.+6YB%O<D$K@Y5_IZ&NFJJ56%6/-!W0X3C-7B%%%%:EA1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P B)J'_ &S_ /1JUTE<W\0?^1$U#_MG_P"C5KI*XCU0HHHH **** "BBB@
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M8^E;E%%;0@H*R;?KJ7&/*@HHHJR@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FR.L4;.YPJ@DG
MT IU-D198V1QE6!!'J#0!\H^#/%^A>,_CO?>./'&JV^G65AAM-MKN3!R,K$
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M4_\ O^/_ (FC_A";3_H):G_W_'_Q-=)15_6*O\QE]1P_\IS?_"$VG_02U/\
M[_C_ .)H_P"$)M/^@EJ?_?\ '_Q-=)11]8J_S!]1P_\ *<W_ ,(3:?\ 02U/
M_O\ C_XFLCQ+X0%IHSW-E<WERT3!G2>0,-O.2  .1_+-=W15PQ56,D[F=3+\
M/.#BHVN>%UT7A'0&UF\E>5YX;>)>986VDL>@SCZUW-QX1T2YN#-)8J&8Y(1V
M4'\ <5J6UM#9VZP6L2Q1(,*JC %=M;,%*%H+4\G#9+*%7FJM-+MU.'\6^&;?
M2?"]W>Q7E[,\6S$<\H9#EU'(P/6MC_A";3_H):G_ -_Q_P#$TOQ!_P"1$U#_
M +9_^C5KI*\_ZQ5_F/:^HX?^4YO_ (0FT_Z"6I_]_P ?_$T?\(3:?]!+4_\
MO^/_ (FNDHH^L5?Y@^HX?^4YO_A";3_H):G_ -_Q_P#$T?\ "$VG_02U/_O^
M/_B:Z2BCZQ5_F#ZCA_Y3F_\ A";3_H):G_W_ !_\31_PA-I_T$M3_P"_X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "N;^(G_ "3C7?\ KRD_E725S?Q$_P"2<:[_ ->4G\J
M.DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ "C_A7^C_ -ZZ_P"_@_PH]I7_ )%]_P#P YJG\OX_\ ZBBN7_ .%?Z/\
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M_'_X2_[#3_\ I#=T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5LZ!_P O'_ ?ZUC5LZ!_R\?\!_K0!L4444 %%%% !1110 4444 %%%% !12,
MRHI9R%51DDG  KRO7?C2EO>O!H-@MQ&C8\^X8@/SSA1SCT)/X5<82GL:TZ4Z
MKM%'JM%<5X+^)-GXKN#8SP?8K_!98]VY90.NT^OMZ5VM*47%V9,X2IRY9(**
M**D@*Q/&O_(@^(/^P9<_^BFK;K$\:_\ (@^(/^P9<_\ HIJ -+3?^05:?]<$
M_P#015FJVF_\@JT_ZX)_Z"*LT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y1\4[[XKZ3X
MIM+[X>6J:AH_V,)/:M'&^)P[$M@D/RI4?*<<&O,?$7_"\_B?8C0M2\/FPL)7
M4S((1;1M@@@LSL20",X'IT)Q7U+10!POPE^'$?PU\'_V=).MU?W,GGWDZ A2
M^,!5SSM4#&3U.3QG [JBB@ KF_B/_P DL\5_]@6\_P#1#UTE<W\1_P#DEGBO
M_L"WG_HAZ 'ZU_R$/^ "L^M#6O\ D(?\ %9] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ;.@?\O'_  '^M;%8^@?\O'_ ?ZUL4 %%%% !1110
M 4444 %%%% !5'4-%T[5"#?VB2L!@-R&Q]1S5ZBIE&,E:2N)I-694L=+LM,0
MK86R0ANI4<GZGK5NBBG&*BK) DDK(****8PHHHH *YOXB?\ ).-=_P"O*3^5
M=)7-_$3_ ))QKO\ UY2?RH Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_\ B*/L7Q,_Z"6@_P#?+_\ Q%=S11S^2#VS_E7W'#?8OB9_T$M!_P"^7_\
MB*/L7Q,_Z"6@_P#?+_\ Q%=S11S^2#VS_E7W'FOB*S^(G_"-ZA]NO](DMOL[
M^<ENK[V3'S 90=LUXG7UL>>M>:Z[\&K"_P!0>YTF^.GI(<M 8MZ@]]IR,#VY
MK>E52T9VX;%0C=3T]#RCPS'J$OBC3DT8JMZ9U\IF!VJ<]6Q_"._MFO:/L7Q,
M_P"@EH/_ 'R__P 15SP=\/-.\).URLK7E\RE?M#KM"@]E7)Q]<DUUM34JJ3T
M1GB,3&<O=2:\T<-]B^)G_02T'_OE_P#XBC[%\3/^@EH/_?+_ /Q%=S167/Y(
MYO;/^5?<<-]B^)G_ $$M!_[Y?_XBLWQ):?$%/"FK-J>H:,]D+*8W"Q*^]H]A
MW!<H.<9Q7I=8GC7_ )$'Q!_V#+G_ -%-1S^2#VS_ )5]QS=G9_$@V,!@U'0Q
M'Y2[ ROD#'&?DJ;[%\3/^@EH/_?+_P#Q%=AIO_(*M/\ K@G_ *"*LT<_D@]L
M_P"5?<<-]B^)G_02T'_OE_\ XBC[%\3/^@EH/_?+_P#Q%=S11S^2#VS_ )5]
MQPWV+XF?]!+0?^^7_P#B*/L7Q,_Z"6@_]\O_ /$5W-%'/Y(/;/\ E7W'#?8O
MB9_T$M!_[Y?_ .(KJ]%34X](A779;>6_&[S7MP=A^8XQD#MCMUJ]12<K]"95
M.96L@HHHJ3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K@?BK\5M.^&.D0236YOM2O"1;6BOMR!U=CV4<#H22?J1WU?'WQFU6SU#]I
M$IXA<KI&GS6D$V5+8@ 620 #).2[X^M '5V?Q3^..N60UC1_"<+Z<XWQ".P<
MK(OJN7W,/<=>U>Z> =;U;Q'X%TW5?$>FG2]3N%?[1:&-DV%790=K?,,A0V#Z
M]Z\J_P"&J_"45RL,6A:M]D7Y0ZK$" /1-^/PS7L/AGQ-I7B_0(-9T&Y%S9SY
MVM@J5(."I!Y!![4 <-\<_B9>_#CPS8OHGV<ZI?W!2,3KN"QJ,NV,\\E!_P "
MKE/@I\;->\9>-KCP[XN6U21X&>V,4)C82(?F0C/]W)]MIKDOB1)_PM#]IK3?
M#$),EAI\J6DH!XPF9+@^QQE?^ "L_P"+4,GPS_:+M/$EA&R6\\D.I!8UP&&=
MLR#MEMK9_P!^@#ZWHJ.VN(KNUBN;=Q)#,@DC<=&4C(/Y5F:KXL\.:#=+:ZYK
M^EZ;<.@D6*\O8X7922 P#$'&01GV- &O7-_$?_DEGBO_ + MY_Z(>C_A8_@C
M_H<O#_\ X-(/_BJY_P ?>/O!]Y\-O$MK9^+-#GN)M)NHXHHM2A9Y&,+ *H#9
M)). !0!T>M?\A#_@ K/K0UK_ )"'_ !6?0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% &SH'_+Q_P !_K6Q6/H'_+Q_P'^M;% !1110 4444 %%
M95[XFTC3KM[6\N_+F3&Y?*<XR,CD#'>J_P#PFF@?\_\ _P"09/\ XFL77HIV
M<E]Z(=2"=FT;M%87_"::!_S_ /\ Y!D_^)H_X330/^?_ /\ (,G_ ,32^L4?
MYU]Z%[6G_,OO-VBL+_A-- _Y_P#_ ,@R?_$T?\)IH'_/_P#^09/_ (FCZQ1_
MG7WH/:T_YE]YNT5A?\)IH'_/_P#^09/_ (FC_A-- _Y__P#R#)_\31]8H_SK
M[T'M:?\ ,OO-VBL+_A-- _Y__P#R#)_\345WXWT:.SE:TNQ+.$)C0Q. S=AG
M%)XF@E?G7WH/:T_YD;=S?6EGC[7=0P;NGFR!<_G4D4T<\8DAD61#T9&!!_&O
M%+JZGO;EY[J1I97.2S&M7PSKLFBZI&7D86DC;9EY( _O8]17G0S12J6E&R.6
M.,3E9K0]9KF_B)_R3C7?^O*3^53_ /"::!_S_P#_ )!D_P#B:Q/&?B/2M6\%
M:M8:?=>;<W%L\<4?ENNYB.!D@ ?C7I?6*/\ .OO1U>UI_P R^\[BBL+_ (33
M0/\ G_\ _(,G_P 31_PFF@?\_P#_ .09/_B:/K%'^=?>@]K3_F7WF[16%_PF
MF@?\_P#_ .09/_B:/^$TT#_G_P#_ "#)_P#$T?6*/\Z^]![6G_,OO-VBL+_A
M-- _Y_\ _P @R?\ Q-'_  FF@?\ /_\ ^09/_B:/K%'^=?>@]K3_ )E]YNT5
MA?\ "::!_P __P#Y!D_^)H_X330/^?\ _P#(,G_Q-'UBC_.OO0>UI_S+[S=H
MK"_X330/^?\ _P#(,G_Q-'_"::!_S_\ _D&3_P")H^L4?YU]Z#VM/^9?>;M%
M87_"::!_S_\ _D&3_P")H_X330/^?_\ \@R?_$T?6*/\Z^]![6G_ #+[S=HI
M$<.BNARK#(/M2UN:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SQ
M\2_C-XHU/QZ? WPMC/VN.8V\MRB*TDLH^^J;OE55P<L?0G( R?H.XD,-K+*H
M!*(6 /L*^'_A7X]N/!GC"]U>'1I==U:]MWAMXE8@[V=69L $DX4]/4T >P:3
MX2^/>CZQ87D_B%-0MS<QFZMS>+)B/<-^1(H'0G[ISQQVKZ$KYRT_]IS5]-U^
M*R\<^$SIT+D>88Q)'+$IZ-L<?,/RKWG6-?L]'\*WFORN)+.UM&NMR'[ZA=PQ
M]>WUH ^;OC3\2_%DOQ3O=%\&:K?6MMI-J1,EF^T,R(999"1_=''/]SCKSZ?^
MSWXZO/&G@&:/6KMKO4]-N3%++(<N\;#<C'_QY?\ @%>=_LW: WBKQ!XL\5:X
M@F^U(]J^1\LCSDO+^@ ^CUC? V^G\ _'G4/"=](PBNGFT]\C"M)&Q:-_Q"L!
M_P!=* /K.BBN?N?$>J074L47@O7+E(W*K-%-8A) #@,NZY#8/49 /J!0!T%<
M+X__ .1D\(?]A.3_ -(KJM;_ (2C5_\ H1/$'_?_ $__ .2JY3Q5K%]J/BSP
ME'>>'-3TI5U&1A+>26S*Q^QW/RCRIG.><\@#@\]* -ZBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .QHHHH **CGD,-O)(D;2,B%@B]6('0
M5S?_  EFH_\ 0LZA_P!\M_\ $UI"E.?PF%7$4Z+2F_P;_(ZBBN7_ .$LU'_H
M6=0_[Y;_ .)H_P"$LU'_ *%G4/\ OEO_ (FM/JU7M^*_S,?KV'[O[G_D=117
M+_\ "6:C_P!"SJ'_ 'RW_P 31_PEFH_]"SJ'_?+?_$T?5JO;\5_F'U[#]W]S
M_P CJ**Y?_A+-1_Z%G4/^^6_^)H_X2S4?^A9U#_OEO\ XFCZM5[?BO\ ,/KV
M'[O[G_D=15'4]8L='A$E_,(]WW5'+-]!6+_PEFH_]"SJ'_?+?_$UPWB'4;C4
M]:FGNHI(&&$6&3K&!V_K^-;T,'*<[3T7R./&9I"E3O2U?FFO\CT/3_&>D:A<
M"%97@=CA1,NT,?KDBMZO"Z] TGQ9J0TFW5M$O;PJFWST5B'QQG[IK7$X'DLZ
M9SX'-O:7C7^])_\ !.THKE_^$LU'_H6=0_[Y;_XFC_A+-1_Z%G4/^^6_^)KC
M^K5>WXK_ #/4^O8?N_N?^1U%%<O_ ,)9J/\ T+.H?]\M_P#$T?\ "6:C_P!"
MSJ'_ 'RW_P 31]6J]OQ7^8?7L/W?W/\ R)/B#_R(FH?]L_\ T:M=)7G_ (KU
MZ[U+PQ=VEQHMW91R;,SS*0J8=3SE1UQC\:V/^$LU'_H6=0_[Y;_XFCZM5[?B
MO\P^O8?N_N?^1U%%<O\ \)9J/_0LZA_WRW_Q-'_"6:C_ -"SJ'_?+?\ Q-'U
M:KV_%?YA]>P_=_<_\CJ**Y?_ (2S4?\ H6=0_P"^6_\ B:/^$LU'_H6=0_[Y
M;_XFCZM5[?BO\P^O8?N_N?\ D=117+_\)9J/_0LZA_WRW_Q-:6C:Q<ZG)*MS
MI5S8A "&F!&[V&0*F5"I%7:_%%PQ=&I)1B]?1_Y&M1116)U!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9NL^'
M=%\10I%KVDV6I1QG*+=VZR[#ZC<#@_2M*H[BXAM;=Y[J6.&&-=SR2,%51ZDG
M@"@#-T;PKH'AW>=!T6PTTR##M:VR1EQ[D#)J/6/!OAKQ#>QWFO:#IVHW,:"-
M);JV21@H)(7)'3))Q[FL.3XR?#R*[^SMXLT\OG&5<LG_ 'V!M_6NNMM0L[S3
MDU"TNH9[.2/S4N(Y T;)C.X,."/>@"P    , =!5'5]%TS7[ V6MZ?;:A:E@
MQAN8A(N1T.#WKD#\;_AP&(/BJTX](Y#_ .RULZ!\0O"7BFX%OH'B"QO+@@D0
M+)MD('4A&P?TH UM(T32_#]C]BT/3[;3[7<7\FVB$:[CU.!WJ]110 5QWC[_
M (__  E_V&G_ /2&[KL:X[Q]_P ?_A+_ +#3_P#I#=T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5LZ!_R\?\!_K6-6SH'_+Q_P !_K0!L444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6)XU_P"1!\0?]@RY_P#1
M35MUB>-?^1!\0?\ 8,N?_134 :6F_P#(*M/^N"?^@BK-5M-_Y!5I_P!<$_\
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MA:_]^5_PJW11R1[!RKL     P!T HHHJQA1110 4444 %%%% !1110 4444
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M&Y:-BW<A5^4#T!!]R>M=U:>'+/PC\-9-"TQYGM;*QECC:=@SL-K')( &<D]
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M3]BNCN'E0HV>,<G')XZ8 -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 5S?Q'_ .26>*_^P+>?^B'KI*YOXC_\DL\5_P#8%O/_ $0] #]:_P"0A_P
M5GUH:U_R$/\ @ K/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#9T#_EX_X#_6MBL?0/\ EX_X#_6MB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N;^(G_ "3C7?\ KRD_E725S?Q$_P"2<:[_ ->4G\J .DHH
MHH **** "BBB@ HHI'=8XV>1@B*,LS'  ]: %HKF+CQ]I$-P8D6XF53@R1H-
MI^F2#6[I^I6NJ6HN+&42(>#ZJ?0CM6,*]*H^6,DV1&I"3LF6J***V+"BBB@
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MNDKF_B#_ ,B)J'_;/_T:M=)0 4444 %%%% !1110 4R::.WA>:=UCC099F.
M!3Z9/!%<P/#<(LD;C#*PR"*:M?43O;3<S-&\26&MR2QVK,LD9/R.,%E_O#V_
ME6M7F&OZ!=^&-02^TYW^S[\QRCK&?[I_SS75:1XSL;O29)[^1;>>!<RI_>]U
M]<^G:NVMAE95*.L6>3AL>^9T<3[LU]S1NWU];Z;9O=7D@CB0<GU]AZFJVBZY
M::Y:>=:DJRG#Q-]Y#_GO7GE_?ZCXRUI(+9"(P?W<6?EC'=F/]?P%>@:%H5MH
M5D(H!OE;F64CES_0>U*K0A1I^^_?96'QE7%5VZ:_=KKW?D:E%%%<1ZH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RY\>_"&N^&/B?
M!\0M"M7FM6>&Y>5$++;SQ #YP.BD(IST.2/K]1T4 ?)_C?X[:M\4/"__  B7
MA[PO-#<W[(+CR96N'<*P;:BJH/) R3VR,<YKU[X6^ ;SP'\&;S3]30#4[Z.>
MZN8D;=Y;-'M5,CJ0JKG'&2<$CFO3XX(H<^5$D>[KM4#-/H ^'/A#\2X/AEX@
MOM0N=-DU!;JU\@)'*(RIWAL\@YZ5TOQ"^)6N?'%K#0?#7A:X6&WG$NR(F>1G
M(*@L0 J*,MUX[DC%?6YLK4DDVT))ZDQBI8XTB7;$BHOHHP* .3^%OA*?P/\
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M:_Z%B;_P('_Q-'_"0ZU_T+$W_@0/_B:Z2BCV53_GX_N7^0<DOYOR_P CF_\
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M_P"AA\/_ /@AG_\ DRN4\56_B&'Q9X2.N:IIEY"=1D"I9Z;);L&^QW/)9IY
M1C/&!U'/'/I]<+X__P"1D\(?]A.3_P!(KJ@"S1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '8T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '!^)-,\17'B"YETT77V9MNSRY]H^X,\9]<UE_P!C>+O2]_\  G_[
M*O4**[HXV48J/*M#R*F54ZDW-SEJ[[_\ \DU73M?M=-EFU87/V1<>9YLVY>H
M R,GOBK?]C>+O2]_\"?_ +*NL^(/_(B:A_VS_P#1JUTE5]?G_*B/['I_SR^_
M_@'E_P#8WB[TO?\ P)_^RH_L;Q=Z7O\ X$__ &5>H44?7Y_RH/['I_SR^_\
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MI_PU7X(_Z!7B#_P'@_\ CU>;?M5_\E3TW_L"Q?\ H^>OHNS^'7@EK&!F\':
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M_L&7/_HIJ -+3?\ D%6G_7!/_015FJVF_P#(*M/^N"?^@BK- !1110 4444
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M110 4444 ;.@?\O'_ ?ZUL5CZ!_R\?\  ?ZUL4 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=IOC+2_"T\/Q#OTO]3:\9XI%D#[8=B +D ?Q!S^-;NJVWB.:Z5M#U72[.WV
M-'>:9)<.6R<D,L\8 QCC!Z'GG  ->N;^(_\ R2SQ7_V!;S_T0]'V'QO_ -##
MX?\ _!#/_P#)E<_X^L_&*_#;Q*UYKNARVXTFZ,L<6BS([+Y+9"L;I@I(Z$@X
M]#TH Z/6O^0A_P  %9]:&M?\A#_@ K/H **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,@U9H *X[Q]_Q_\ A+_L-/\ ^D-W78UQWC[_ (__  E_V&G_ /2&[H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K9T#_EX_X#_6L:MG0/^7C_
M (#_ %H V**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K$\:_P#(
M@^(/^P9<_P#HIJVZQ/&O_(@^(/\ L&7/_HIJ -+3?^05:?\ 7!/_ $$59JKI
MQ"Z1:EB ! A)/;Y15B.1)4#Q.KJ>C*<@T .HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6?VHO&#
M:IXHL/"%@S/'IX$]RB<[IW'R+CU5#_Y$]J]X^%WA >"/ASI>CN@6Z6/SKLCO
M,_S-^7W1[**Z633K&:Y%Q-9V\DXQB5HE+#'3G&:LT >)?M5_\DLTW_L-1?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2,VU2V"<#. ,DTM% 'R?X?\#>*?B)\?6UWQ7X>U33M-:]-Y,U[:/$O
ME1X\N++##<*BD#MDU]8444 ?,?[2?@[Q+X@^)&F76A:#J.I6_P#9<<)EM+9Y
M55Q-*2&*@A>&4\XZU]+VB-%9PHXPRQJ"/0@5+10 4444 %<+X_\ ^1D\(?\
M83D_](KJNZKA?'__ ",GA#_L)R?^D5U0!9HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#L:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML*[ER\GD>W'V7LM/A/H&V\=^&KBTAF;6+.$R(KF.290R9&<$>HJ7_A-O#/\
MT';#_O\ K52V^'?A>"UBBDTBWF:- K2.#ER!C)YZFI?^$ \*_P#0$M?R/^-<
M/[OS/%?L+]?P)O\ A-O#/_0=L/\ O^M'_";>&?\ H.V'_?\ 6H?^$ \*_P#0
M$M?R/^-'_" >%?\ H"6OY'_&CW/,7[CS_ F_X3;PS_T';#_O^M'_  FWAG_H
M.V'_ '_6H?\ A /"O_0$M?R/^-'_  @'A7_H"6OY'_&CW/,/W'G^!-_PFWAG
M_H.V'_?]:/\ A-O#/_0=L/\ O^M0_P#" >%?^@):_D?\:/\ A /"O_0$M?R/
M^-'N>8?N//\  F_X3;PS_P!!VP_[_K6M:7=O?6L=S9S)/!(,I)&<JP]C6'_P
M@'A7_H"6OY'_ !K;LK*WTZSCM+*%88(AA(UZ**E\O0B?L[>[<GHHHJ3,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOP>@8GCU !Z$5[70 5S?Q'_Y)9XK_P"P+>?^B'KI*YOXC_\ )+/%?_8%O/\
MT0] #]:_Y"'_   5GUH:U_R$/^ "L^@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** -G0/\ EX_X#_6MBL?0/^7C_@/]:V* "BBB@ HHHH ****
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M5/\ OH4>?%_SU3_OH5M=&EQ]%,\^+_GJG_?0H\^+_GJG_?0HN@N/HIGGQ?\
M/5/^^A1Y\7_/5/\ OH4707'T4SSXO^>J?]]"CSXO^>J?]]"BZ"X^BD5E<91@
MP]0:6F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 %;.@?\O'_ ?ZUC5LZ!_P O'_ ?ZT ;%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5B>-?^1!\0?\ 8,N?_135MUB>-?\ D0?$
M'_8,N?\ T4U &A8(DNCVJ2*KJT"95AD'Y15B&"*WCV6\21)_=10H_2H=-_Y!
M5I_UP3_T$59H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M _Y>/^ _UK8K'T#_ )>/^ _UK8H **** "BBB@ HHHH **** "BBB@ HHHH
M:Z"2-D;HP(-<[_P@>B_W)O\ OZ:Z2BLITJ=3XU<B4(R^)'-_\('HO]R;_OZ:
M/^$#T7^Y-_W]-=)16?U6A_(ON)]C3_E.;_X0/1?[DW_?TUC>+_"VFZ-X/U34
M;)9!<6MLTD99\C('<5WM<W\1/^2<:[_UY2?RH^JT/Y%]P>QI_P H?\('HO\
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M1?<'L:?\IS?_  @>B_W)O^_IH_X0/1?[DW_?TUTE%'U6A_(ON#V-/^4YO_A
M]%_N3?\ ?TT?\('HO]R;_OZ:Z2BCZK0_D7W![&G_ "E/3-+MM(L_LUF&$>XM
M\S9.35RBBNB,5%66QHDDK(****8PHHHH **** "BBB@ HHHH **** "BBB@
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M QSS7<FWC(5I0 N?H>W!H ]A^$WB6]\7_"O1-:U4AKR>)TF< #S&CD:/?@<
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M  8 %+12<F]RE&,=D%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %;.@?\O'_ ?ZUC5LZ!_P O'_ ?ZT ;%%%% !1110 4444
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M_*APDE=H4J-2*NXF]1114&04444 %%%% !1110 4444 %%%% !1110 4444
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M$";6+WQ+<02Z=:A(H?+MUCS*V2<$>B@=?[PKVF@ KF_B/_R2SQ7_ -@6\_\
M1#UTE<W\1_\ DEGBO_L"WG_HAZ 'ZU_R$/\ @ K/K0UK_D(?\ %9] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ;.@?\O'_ ?ZUL5CZ!_R\?\
M ?ZUL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?Q$_Y)QK
MO_7E)_*NDKF_B)_R3C7?^O*3^5 '24444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%([K&C/(P55&69C@ 4 +
M15&'6M,N)Q#!?V[R$X"B0?,?;U_"KU3&49;,2:>P44450PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (;JZ@LK9[B[E
M6*)!EF;M4D<B2QK)$P=&&593D$5B^*M!?7=-58)62:$ED0M\KGT/OZ&N0\-^
M))] NSI^J*XM@VUE8?-"WK]/;_)ZZ>']K2<H/WET/-K8YX>NH58V@]GYGI=0
M7=]:V$2R7DZ0HS! 7.,DU!J&L6>G:9]NGE!A(RFTY,F>@'K7G$DFI^-=<"J-
MJ#HO\$*>OU_G10P[J7E+2*ZCQF.5"T*:YIO9'JH.>E%5M.LET[3H;1)'D$2[
M0[G)-6:Y7:^AWQ;:3:LPHHHI%!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!^*/@]X&\;:G)
MJ>JZ6&O6.V6XM9VC+D<?,%."1C&2,\5WE>!>(/V<=6N/$^IZKX;\:2V$>HW,
MEP\!B=2A=BQ&Y'^89/H* ///CMX?\$^$;C3/"_@FRC_M)7::_D$K32J2 (XR
M23@GD[1C^$XY%?3W@+0Y?#WP[T/1[Q1Y]K8Q1SKU ?;EQ[\DBO//A]^SGHWA
M+6H=:UW49-<U&!_,A5HO+AC?.0^TDEF!Y!)QWQD CV6@#X]\/S1_!S]I>6UO
M)?L^EI<O;NY/RBVF&Z,DGLN8R3_LFMKX'VLOQ ^/6L>,KQ&,-HTMVN\YV/*2
ML2'Z)NQ_N"O2/B]\#7^)'B&TUG3M5ATZXCM_L\ZRPEQ( Q*D8/7YB/RKH_A'
M\-%^&7ABXT^2\2^N[NX,\TZ1[!C 55 ST&"?JQH [VBBB@ KCO'W_'_X2_[#
M3_\ I#=UV-<=X^_X_P#PE_V&G_\ 2&[H **** "BBB@ HHHH **** "BBB@
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M^'NO:YJ$<3V$]G;Y!DN+B,HJKWQG[Q]A^E?0-GI5E8V,%I!;Q^5!&L:;E!.
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M #R3_OD4>1%_SR3_ +Y%'+B/YE]S_P PM4[K[O\ @F%_PG&A?\_+_P#?IO\
M"C_A.-"_Y^7_ ._3?X5N^1%_SR3_ +Y%'D1?\\D_[Y%'+B/YE]S_ ,PM4[K[
MO^"87_"<:%_S\O\ ]^F_PH_X3C0O^?E_^_3?X5N^1%_SR3_OD4>1%_SR3_OD
M4<N(_F7W/_,+5.Z^[_@F%_PG&A?\_+_]^F_PH_X3C0O^?E_^_3?X5N^1%_SR
M3_OD4>1%_P \D_[Y%'+B/YE]S_S"U3NON_X)A?\ "<:%_P _+_\ ?IO\*/\
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MH4?\)YK?_/2'_OT*]0HH^M4?^?2_KY!_9^*_Z"']W_!/+_\ A/-;_P">D/\
MWZ%'_">:W_STA_[]"O4**/K5'_GTOZ^0?V?BO^@A_=_P3R__ (3S6_\ GI#_
M -^A1_PGFM_\](?^_0KU"BCZU1_Y]+^OD']GXK_H(?W?\$\O_P"$\UO_ )Z0
M_P#?H4?\)YK?_/2'_OT*]0HH^M4?^?2_KY!_9^*_Z"']W_!/+_\ A/-;_P">
MD/\ WZ%'_">:W_STA_[]"O4**/K5'_GTOZ^0?V?BO^@A_=_P3R__ (3S6_\
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M?_PGFM_\](?^_0H_X3S6_P#GI#_WZ%>H44?6J/\ SZ7]?(/[/Q7_ $$/[O\
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M !6SH'_+Q_P'^M8U;.@?\O'_  '^M &Q1110 4444 %%%% !1110 45R^O\
MQ#\/>';HVMW<O-<K]^*W7>4]B<@ ^V<U=\/>+M&\3HW]E70>5!EX7&UU'K@]
M1[BJY96O8T=.:CS-:&W1114F84444 %%%% !6)XU_P"1!\0?]@RY_P#135MU
MB>-?^1!\0?\ 8,N?_134 :6F_P#(*M/^N"?^@BK-5M-_Y!5I_P!<$_\ 015F
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M BWUHY+(ID5'C'H=Q&?J.OH*V? ?PLN]/U2'5?$81&MVW0VJL'.\=&8CCCJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH]:_Y"'_   5GUH:U_R$/^ "L^@ HHHH **** "BBB@ HHHH **** "BBB@
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M@L-<1OL;E9%&6BD&& ]?<5J5XYH5U=VFM6\FGQ^;/NPL><;\]J[O^V?%'_0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#COB-\-M+^)>DVECJ]U=VJ6DYF1[4J"25(P=P/'->>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!1114EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRY/KWA;3=6N_%/V"6^MDN#;'3=YB#C< 6\T9.".PKD/BU\&)_A=9Z;=KJ_\
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M9]:&M?\ (0_X *SZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MV= _Y>/^ _UK8K'T#_EX_P" _P!:V* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH Y@Z!KY8X\1N!GIY7_UZQ_%FDZM9>$=3N=0UAKVUBMV:6W*
M8$JXY7.:[^N;^(G_ "3C7?\ KRD_E7-]5I^?WO\ S,O8Q\_O9R/BW3-1L;J!
M]1O&O0Z824KC&#]W]<_C7/5[5?:?;:G:FWO8EEC/.#V/J#V-<_'\/M)28.\M
MS(@.=C.,'V) KRL1EM252]/9]SCJX63E>)B>%-'U:[TV2>QU)[&%I,!=F=Y
MZ_TK<_X1_P 0?]#(_P#WZ_\ KUTL,,=O"D,"+'&@PJJ, "GUZ-/!PA!1;?WO
M_,Z84(QBD_S9SMIH>MPWD,D^OO-$CAGC,>-XSR.M=%11733IQIJT?SN;1BH[
M!1116A04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110 4444 %%%% %/4]+M=7M1;WR%XPX< ,1R,CM]:RO^$'T+_GV?_O\
M-_C70T5I&K4@K1DT85,-1J2YIP3?FCA/%_AG2](\*WE]8P,D\6S:QD8XRZ@\
M$^A-<?J.GSZ9?26MTFUT/X,.Q'M7H_Q!_P"1$U#_ +9_^C5K;O-.L]00+>VT
M4X7IO4$CZ'M770QLZ;]_5'G8S*J5:*]DE%KR/'],TVXU6_CM;5<LYY..%'<G
MVKT@>!M"_P"?9_\ OZW^-;-I86E@A6RMHH >OEH!GZ^M6**^-G4?N:(,'E5*
MC%^U2DWY'/?\(/H7_/L__?YO\:UM-TVVTJT^S62%(MQ;!8GD_6K=%<DJM2:M
M*39Z-/#T:;YH02?D@HHHK,W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *1W6-&>1@JJ,LS'  ]:6O&/BCX$\?^
M/_%%U81:TFD>#H8$8 ,"9WVDME%(9N>,.0O (YH ],T?QIX9\07SV6A:_IVH
MW*(7:*UN4D8*" 6P#TR1S[UMU\A?LN?\E:N/^P7-_P"AQU].^.]!U'Q/X)U'
M1M&U(Z7=WBHBW8S^[7>I?ISRH9?QH -2\>^$M'O#::IXFTFTN%^]#+>1JZ_4
M9R/QK8L=0L]4LTN],NX+RVD&4FMY1(C?1@2#7@^L?LO>&K+P;>R6>JZD^JV]
MN\R3RL@C=U4G:4"Y"G'J2/4]*X/]F+7M0LOB8='AF<V&H6TC30D_*&0;E?'K
MQC/H?I0!]3:WXJT#PT81X@UFQTTSY\H74ZQE\8S@$\XR/SK)_P"%I^ _^APT
M7_P-3_&O"OVL_P#D8_#O_7I+_P"ABNN\/?LW>!M2\,:7?7+:H9KJSBFD*W2@
M;F0$X&WU- 'M&F:I8:UIL6H:1>07MG-GRYX) Z/@D'!'!P01]15NL?PIX8T_
MP;X8M-!T?S?L5IO\OSGW-\SLYR<#NQK8H *X[Q]_Q_\ A+_L-/\ ^D-W78UQ
MWC[_ (__  E_V&G_ /2&[H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M5Y;\4OCAIGP_NCH]A:2:IK[(I6V *QQ;ONEVZG.<A5Y/J,T >I45X9\"?BWX
MF^(?B?4['Q";0PV]IYT8MX-A#;P.N3Q@UZGXZ\60>!O!.H^([JVDNX[)4/D1
ML%+LSJBC)Z#+#)YP,\'I0!T%%?-&M?&'XRQ:6^OIX1CTO1D^8-)8R,53/!<L
MV<?[6 .:[KX+_&MOB1-<:1K-G%::Q;0^>&M\^5/&" 2 <E2"R\9.<Y'0X /7
M:*\3^/7Q6\1_#S5-'M?#GV14NX9))6GAWDD,  .>.]<U:^.OV@+VSANK7PY#
M)!/&LD;BT7#*PR#]_P!#0!](T5B>#KG6[SP=IMQXJMEM=7DAS=0J,!6R>V3C
MC%;= !7"^/\ _D9/"'_83D_](KJNZKA?'_\ R,GA#_L)R?\ I%=4 6:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH [&BBB@ HHHH **** "
MBBB@ HHHH ***IW>KZ?82!+R\AA?^XSC/Y4U%R=D3*48*\G8N45';W,%W");
M6:.:,]&C8,/S%24MMQIIJZ"BBB@84444 <W\0?\ D1-0_P"V?_HU:Z2N;^(/
M_(B:A_VS_P#1JUTE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(/;R[+[D<#_PC'C_ /Z'&+_P''_Q-'_",>/_ /H<8O\ P''_ ,37?44>T?\
M2#V\NR^Y'RWX@M+RQ\17]OJC%[M)W\V0C'F$G.[Z'K^-9W7I7T?XI\!:/XK9
M9KQ7@NU  N(2 Q'H0>"/U]ZR_#_PGT31+Z.\N))M0FC.4$H 13V.T=3]3BNE
M5X\NIZ4<=3Y-=S.TCPOX[&B60A\3I:1^0FRW> %HAM&%.1U'2KO_  C'C_\
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M>-A"Q#*0N001D$4 ='K7_(0_X *SZT-:_P"0A_P 5GT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!LZ!_R\?\  ?ZUL5CZ!_R\?\!_K6Q0 444
M4 %%%% !1110 4444 %%%% !1110 R2:.%0TTBQ@G +,!4?VZT_Y^H?^_@J/
M4=+L]6@6'4(?-C5MX&XK@XQV(]:S?^$+T#_GP_\ (TG_ ,56,W6O[B5O-O\
MR(ESWT2-;[=:?\_4/_?P4?;K3_GZA_[^"LG_ (0O0/\ GP_\C2?_ !5'_"%Z
M!_SX?^1I/_BJB^([+[W_ )$WJ]E]_P#P#6^W6G_/U#_W\%<[\0+JWF^'NN1P
MSQR.UFX55<$DX["KG_"%Z!_SX?\ D:3_ .*K$\9^'-*TGP5JU_I]KY5S;VSR
M12>8[;6 X."2#^-%\1V7WO\ R"]7LOO_ . =C]NM/^?J'_OX*/MUI_S]0_\
M?P5D_P#"%Z!_SX?^1I/_ (JC_A"] _Y\/_(TG_Q5%\1V7WO_ ""]7LOO_P"
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M (!K?;K3_GZA_P"_@H^W6G_/U#_W\%9/_"%Z!_SX?^1I/_BJ/^$+T#_GP_\
M(TG_ ,51?$=E][_R"]7LOO\ ^ :WVZT_Y^H?^_@H^W6G_/U#_P!_!63_ ,(7
MH'_/A_Y&D_\ BJ/^$+T#_GP_\C2?_%47Q'9?>_\ (+U>R^__ (!K?;K3_GZA
M_P"_@H^W6G_/U#_W\%9/_"%Z!_SX?^1I/_BJ/^$+T#_GP_\ (TG_ ,51?$=E
M][_R"]7LOO\ ^ ;H(8 @Y!Y!'>BFQ1K#$D<8PB*%49Z 4ZNDU"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%N_#>BIJ%[KH
MTRU.JRP%&O6C!EVA< !CR!CTK:J"^_Y!US_UR;^1H ^7/V4/^1YUO_L'#_T8
MM?5#QI(NV15=<@X89&0<BOE?]E#_ )'G6_\ L'#_ -&+7U#J6HV>D:9<:AJ=
MQ';6EM&9)9I#A44=Z .:^*FN6'A_X7:]=:H5,<MG);1Q-_RUDD4HJ8[Y)Y]
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M1#G!!9>,CN!G%>BT 4[_ $?3=4*'4].M+PQ_<^T0+)M^F0<5;5510J*%51@
M#  H9@JEF("@9))Z5Y?+^T7\.8;Y[<ZM<,$<H9DM)&0X[@@9(_"@#U&BBB@
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M -$/0 _6O^0A_P  %9]:&M?\A#_@ K/H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#9T#_ )>/^ _UK8K'T#_EX_X#_6MB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N;^(G_).-=_Z\I/Y5TE<W\1/^2<:[_U
MY2?RH Z2BBB@ HHHH **** "J]UI]G>D&\M89RHP#(@)'T-6**32:LQ-)[D<
M%O#:Q>7;0QPIG.V-0H_(5)110DEHAA1113 **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ3W4LL7C37+9)'++#%#8E(P3D*NZV+8'09)/J30!T%<=X^_X_P#PE_V&G_\
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M2(IY04;*D<C'O2Y8]Q.%.VDOP.PHHHJ#$**** "BBB@ HHHH **** "BBB@
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MHT!,+ ;G:$*H]22 .I- '1ZU_P A#_@ K/K0UK_D(?\  !6?0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &SH'_+Q_P'^M;%8^@?\ +Q_P'^M;
M% !1110 4444 %%%% !1110 4444 %%%% !139'$<;.W102<5S/_  L#1_[M
MU_W['^-95*U.G\;L1*<8?$SJ**Y?_A8&C_W;K_OV/\:/^%@:/_=NO^_8_P :
MR^MT/YT3[:GW.HKF_B)_R3C7?^O*3^51_P#"P-'_ +MU_P!^Q_C61XL\6:=K
M?A'4]-LUF$]U;M%&9$ 7)'<YH^MT/YT'MJ?<[^BN7_X6!H_]VZ_[]C_&C_A8
M&C_W;K_OV/\ &CZW0_G0>VI]SJ**Y?\ X6!H_P#=NO\ OV/\:/\ A8&C_P!V
MZ_[]C_&CZW0_G0>VI]SJ**Y?_A8&C_W;K_OV/\:JZGX]LY-,G331.MRRX1G0
M +GJ>OIFE+&4$K\R$Z]-*]SHKS7M+L)O)N[V*.3."F<D?7'3\:MV]S#=PK-;
M2I+&W1D.17B3,68LQ)).23WK:\+Z\=#U+?,7-K(")449[<$#US^F:\^EFG-4
MM-61RPQ=Y6DM#UBBN7_X6!H_]VZ_[]C_ !H_X6!H_P#=NO\ OV/\:]'ZW0_G
M1U^VI]SJ**Y?_A8&C_W;K_OV/\:/^%@:/_=NO^_8_P :/K=#^=![:GW.HHKE
M_P#A8&C_ -VZ_P"_8_QH_P"%@:/_ ';K_OV/\:/K=#^=![:GW.HHKE_^%@:/
M_=NO^_8_QH_X6!H_]VZ_[]C_ !H^MT/YT'MJ?<ZBBN7_ .%@:/\ W;K_ +]C
M_&C_ (6!H_\ =NO^_8_QH^MT/YT'MJ?<ZBBN7_X6!H_]VZ_[]C_&C_A8&C_W
M;K_OV/\ &CZW0_G0>VI]SJ**Y?\ X6!H_P#=NO\ OV/\:/\ A8&C_P!VZ_[]
MC_&CZW0_G0>VI]SJ**IZ7J<&KV*W=J'$;$@;Q@\5<KIC)25UL:)IJZ"BBBF,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *XWXG^+]7\'>%8KKPWHLFLZG>72VEO B,^UF1VWE5&6 V=!CKU%=
ME10!\5ZSK7Q#M_BKI4?C;4KZVO[BYMI6M4N-J)&T@PNQ#M48'3KZ\YK[4KY/
M^./_ "<EI7_;E_Z,KZPH X[XI^-X_ 'P_OM7!7[8P\BR1N=\[ [>.X&"Q'HI
MKY)T_4_&.D^-?#IU?6M46:_EMKM5>]D+&.23Y2V3_$!GZ$?2O4_%D[?&O]H*
MS\+VI+^'O#[,;IE/ROM(\T_BVV,'\>]8/QN18_VC](2-0JJ+$*JC  W]* /K
M*BBN?N?$>J074L47@O7+E(W*K-%-8A) #@,NZY#8/49 /J!0!T%<+X__ .1D
M\(?]A.3_ -(KJM;_ (2C5_\ H1/$'_?_ $__ .2JY3Q5K%]J/BSPE'>>'-3T
MI5U&1A+>26S*Q^QW/RCRIG.><\@#@\]* -ZBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .QHHHH **** "BBB@ HHHH **** "BBB@ HIDS
M.D$C1+O<*2J^IQP*YK^V?%'_ $ $_P"_H_QK2%-SV:^^QA5KQI-<R?R3?Y'4
M45R_]L^*/^@ G_?T?XT?VSXH_P"@ G_?T?XUI]7EW7WHQ^NT_P"67_@+_P C
MJ**Y?^V?%'_0 3_OZ/\ &C^V?%'_ $ $_P"_H_QH^KR[K[T'UVG_ "R_\!?^
M1)\0?^1$U#_MG_Z-6NDKS_Q7J.N77AB[AU/2EM+5MF^82 [?G4CC/K@?C6Q_
M;/BC_H )_P!_1_C1]7EW7WH/KM/^67_@+_R.HHKE_P"V?%'_ $ $_P"_H_QH
M_MGQ1_T $_[^C_&CZO+NOO0?7:?\LO\ P%_Y'3NZQHSNP55&2Q. !7*7?Q!T
MV"Y\NW@FN$!P9!A0?IGK^E9_B/5O$$FB2QWNEBT@<A7E63)QGIU[UP]=V&P4
M9)RJ:^C/(Q^:U*<E"BK>J_1GLFCZW9ZW;&6R<Y7AXV&&3ZBM"O(?#-Y?6>MH
MVF0_:)G5E,.<!QC//TQG\*[;^V?%'_0 3_OZ/\:PKX3DG:+5O-HZ\'F2JTKU
M(N_DFU^!U%%<O_;/BC_H )_W]'^-']L^*/\ H )_W]'^-8?5Y=U]Z.SZ[3_E
ME_X"_P#(ZBBN7_MGQ1_T $_[^C_&C^V?%'_0 3_OZ/\ &CZO+NOO0?7:?\LO
M_ 7_ )'445R_]L^*/^@ G_?T?XT?VSXH_P"@ G_?T?XT?5Y=U]Z#Z[3_ )9?
M^ O_ ".HHKE_[9\4?] !/^_H_P :/[9\4?\ 0 3_ +^C_&CZO+NOO0?7:?\
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M]F44 <_X,\$Z+X"T632_#D,D-M+.UPXEE,A+E54G)]E7CVKH*** "N.\??\
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M15FJVF_\@JT_ZX)_Z"*LTA!1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4[#E<J#0!;^'=CXGT[P7;6_CF\2\UA9)#)*K!LJ6.T9 &>*ZBBB@ KA?'_\
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MI+FEN;T:,*,%"FK)!1114&H4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJUU=)C[%='A)9&4'CJ!GJ,\FO1ZX[Q]_Q_\ A+_L-/\ ^D-W0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6SH'_+Q_P !_K6-6SH'_+Q_P'^M
M &Q5#6=#T[Q!8BSU>W^T6X<.$WLGS#.#E2#W-7Z*+VV&FT[HY+_A5O@[_H#_
M /DU-_\ %T?\*M\'?] ?_P FIO\ XNNMHJ^>?<T]M5_F?WG)?\*M\'?] ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI8:CN.GWUM=!>OD3*^/R-6J!M-;A1110(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X6
M?X*_#NXN))IO"UHTDC%V(>09).3P&KNJHZSK>F>'M+EU'6[Z"QLXOOS3N%4'
ML/<GL!R: .0'P0^' /\ R*MK_P!_)/\ XJNHUSPOH7B6UCM]?TBSU"*+_5K<
M0J_E_P"Z3RO3M6-X/^*'A3QW?7%GX9U%[J>VC\V16MY(\+G&<L!GDBNM=UC1
MGD8*JC+,QP /6@#B[/X._#ZPN1/;^%-/+@Y'FH95_P"^7)'Z5VB(L:*D:A54
M855& !Z5YWJ/Q[^&^FW;6TGB-)W4X8VMO+*GX.JE3^!-=1X7\;>'/&EK)<>&
M-6@U!8L>8J95X\YQN1@&7.#C(YP: ,W6?A3X'\0:M/J>L>';:YO;@@RS%G4N
M0,9."!T%0V7P=^'UA<+/;^%-/+J<CSD,H_)R1787-U;V5K)<WD\=O!$I:265
MPJH!U))X KSV\^/WPVLKQK=_$0E93AG@M9I$'_ @N#^&: /18XTBC6.)%1$
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M4445B=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -D198V1QE6!!'J#7@7QU\$^'?!?P
M3%MX:TJ"Q5M1A#R*-TDG#_><Y9OQ/%>_UX[^T]_R2%?^PC#_ .@O0 ?LP_\
M)(6_[",W_H*5SO[3W@36-973?$ND6TEY!8P-!=Q1 L\:[MPD"CDCD@GMP>F2
M.B_9A_Y)"W_81F_]!2N)_:6\>:N/$EOX*T^[^Q:>]NDMVP<IYS.2-KG^X  <
M=\G.<"@"+6OVC-*U;X.W.A_V1-'K5U9&PDCP/LZ*R;#(ISGIR%QP<<X&:[3X
M#>"+_P"'/@+6-<\11&WNK]!<-;,PS'#$KE=WHQW,<=AC/.0*?B']FWPC:_#R
M<6$UQ#JUE;//_:,DQQ,RKG#K]T)QV (]3WYW]F[Q#JGB'2/$/@O4+A[BP%@3
M;&5B?LX;*% >NT[@<=L''6@#D?@3I:>//C?+J7B'%W);QS:I(L@RLLN]5&0>
MP:0,/]T5]BU\<?L^ZS!X/^,SV6ND6;W4$NFL92 (YMZL%)[9:/;]2*^QZ (+
M2RM=/M_(L+:&UAWL_EPQA%W,2S' [DDDGN36-<^/O!]G=2VMYXLT."XA<QRQ
M2ZE"KQL#@JP+9!!&"#6S:7MK?PF6QN8;F-79"\,@<!E."N1W!X([5/0!S?\
MPL?P1_T.7A__ ,&D'_Q5<YXI\6>'->UGPI:Z'K^EZE<)JSR-%9WL<SJHLKH%
MB%).,D#/N*]'KCO'W_'_ .$O^PT__I#=T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5LZ!_R\?\!_K6-6SH'_ "\?\!_K0!L4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6)XU_Y$'Q!_P!@RY_]%-6W6)XU_P"1
M!\0?]@RY_P#134 :6F_\@JT_ZX)_Z"*6_O[;3+&6\OI1#;PC<[D$[1^%)IO_
M ""K3_K@G_H(J::"*YA:&XB26)QAD=0RGZ@T#5KZG-?\+(\)?]!J+_OV_P#\
M31_PLCPE_P!!J+_OV_\ \36O_P (]HO_ $"+#_P&3_"C_A'M%_Z!%A_X#)_A
M5^YYFMZ/9_A_D9'_  LCPE_T&HO^_;__ !-'_"R/"7_0:B_[]O\ _$UK_P#"
M/:+_ - BP_\  9/\*/\ A'M%_P"@18?^ R?X4>YYA>CV?X?Y&1_PLCPE_P!!
MJ+_OV_\ \31_PLCPE_T&HO\ OV__ ,36O_PCVB_] BP_\!D_PH_X1[1?^@18
M?^ R?X4>YYA>CV?X?Y&1_P +(\)?]!J+_OV__P 31_PLCPE_T&HO^_;_ /Q-
M:_\ PCVB_P#0(L/_  &3_"C_ (1[1?\ H$6'_@,G^%'N>87H]G^'^1D?\+(\
M)?\ 0:B_[]O_ /$T?\+(\)?]!J+_ +]O_P#$UK_\(]HO_0(L/_ 9/\*/^$>T
M7_H$6'_@,G^%'N>87H]G^'^1D?\ "R/"7_0:B_[]O_\ $UX]\0/%\WB;7ID@
MG8Z; ^VW120K <;R/4\_AQ7O'_"/:+_T"+#_ ,!D_P *\:^(_@.[TG6+C4],
MM6DTVX;S#Y2?ZACU4@=!GH>G.*VHN',=F$=%5--_,XG3]1N]*OH[S3[A[>>,
MY5T./P]Q[5[UIGQ/\-W.EVTU_J45M=/&#-%L<[&QR.G3->(Z%X:U3Q%?);:9
M:O)N.&E(PB#N2W:OH73/".C:=I=M9MIUG.T,81I9+="SD#DGCN:NNX:7-<:Z
M6BEOY%+_ (61X2_Z#47_ '[?_P")H_X61X2_Z#47_?M__B:U_P#A'M%_Z!%A
M_P" R?X4?\(]HO\ T"+#_P !D_PKF]SS/.O1[/\ #_(R/^%D>$O^@U%_W[?_
M .)H_P"%D>$O^@U%_P!^W_\ B:U_^$>T7_H$6'_@,G^%'_"/:+_T"+#_ ,!D
M_P */<\PO1[/\/\ (R/^%D>$O^@U%_W[?_XFC_A9'A+_ *#47_?M_P#XFM?_
M (1[1?\ H$6'_@,G^%'_  CVB_\ 0(L/_ 9/\*/<\PO1[/\ #_(R/^%D>$O^
M@U%_W[?_ .)H_P"%D>$O^@U%_P!^W_\ B:U_^$>T7_H$6'_@,G^%'_"/:+_T
M"+#_ ,!D_P */<\PO1[/\/\ (R/^%D>$O^@U%_W[?_XFC_A9'A+_ *#47_?M
M_P#XFM?_ (1[1?\ H$6'_@,G^%'_  CVB_\ 0(L/_ 9/\*/<\PO1[/\ #_(R
M/^%D>$O^@U%_W[?_ .)H_P"%D>$O^@U%_P!^W_\ B:U_^$>T7_H$6'_@,G^%
M'_"/:+_T"+#_ ,!D_P */<\PO1[/\/\ (R/^%D>$O^@U%_W[?_XFC_A9'A+_
M *#47_?M_P#XFM?_ (1[1?\ H$6'_@,G^%'_  CVB_\ 0(L/_ 9/\*/<\PO1
M[/\ #_(H6'CKPWJ=]%9V.J1S7$QVH@1QN/XBN@JE#HNE6TRS6^F6<4J'*NEN
MJL/H0*NU+MT(ERW]T****1 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH V= _Y>/^ _UK8K'T#_EX_P"
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M'L1S7H6DZI!K&FQW=OP&X92>4;N#7C-=KX6\/ZA<Z/Y\>J7%A')(2L<8X88
MW=?P_"N# XJNYN+O+^O,Y\/6J.5MSOJ*YO\ X1G4_P#H9;W\O_LJ/^$9U/\
MZ&6]_+_[*O8]K5_Y]O[U_F=W//\ E_(Z2BN;_P"$9U/_ *&6]_+_ .RH_P"$
M9U/_ *&6]_+_ .RH]K5_Y]O[U_F'//\ E_(Z2BN;_P"$9U/_ *&6]_+_ .RH
M_P"$9U/_ *&6]_+_ .RH]K5_Y]O[U_F'//\ E_(Z2BN;_P"$9U/_ *&6]_+_
M .RH_P"$9U/_ *&6]_+_ .RH]K5_Y]O[U_F'//\ E_(Z2BN;_P"$9U/_ *&6
M]_+_ .RH_P"$9U/_ *&6]_+_ .RH]K5_Y]O[U_F'//\ E_(Z2BN;_P"$9U/_
M *&6]_+_ .RH_P"$9U/_ *&6]_+_ .RH]K5_Y]O[U_F'//\ E_(Z2BN;_P"$
M9U/_ *&6]_+_ .RH_P"$9U/_ *&6]_+_ .RH]K5_Y]O[U_F'//\ E_(Z2BN;
M_P"$9U/_ *&6]_+_ .RH_P"$9U/_ *&6]_+_ .RH]K5_Y]O[U_F'//\ E_(Z
M2BN;_P"$9U/_ *&6]_+_ .RH_P"$9U/_ *&6]_+_ .RH]K5_Y]O[U_F'//\
ME_(Z2BN;_P"$9U/_ *&6]_+_ .RJ[I6CWFGW32W.KW%ZA0J(Y1P#D<]?;]:J
M-2HW9PM\T-2DWK$UZ***W- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO^%'_"N=._Y^[K_QW_"CEP?\S_KY![3-/Y(_U\S2_P"$TT#_ )__ /R#)_\
M$T?\)IH'_/\ _P#D&3_XFLW_ (5SIW_/W=?^._X4?\*YT[_G[NO_ !W_  HY
M<'_,_P"OD'M,T_DC_7S-+_A-- _Y_P#_ ,@R?_$T?\)IH'_/_P#^09/_ (FL
MW_A7.G?\_=U_X[_A1_PKG3O^?NZ_\=_PHY<'_,_Z^0>TS3^2/]?,TO\ A--
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M_P!AI_\ TANZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V=
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M)9XK_P"P+>?^B'H ?K7_ "$/^ "L^M#6O^0A_P  %9] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ;.@?\O'_ ?ZUL5CZ!_P O'_ ?ZUL4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?Q$_Y)QKO_ %Y2?RKI
M*YOXB?\ ).-=_P"O*3^5 '24444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5[ZPMM2M6M[V)98SV/8^H/8U8HI
M-)JS$TFK,YNW\":/!<"5A/* <B.1QM_0 UT:(L:*D:A54855& !Z4M%9TZ5.
MG\"L3&$8?"@HHHK4L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQX/&/XLUW'P#^(VH>/\ PC>#Q!<)<:MI]QLED5%0O&XRC%5  Y#C@?PUYC\
MM);Q]\4?$GC#6X1+&$ERK_,!)<%AM!]!'O7'HPZ5F?!V\D^''[0=[X8OG=8+
MJ67327.-S!LPOCWP /\ KI0!];445S]SXTTNUNI;>6UUQGA<HQBT"^D0D'!V
MNL)5AZ$$@]0: .@KCO'W_'_X2_[#3_\ I#=U=_X3S2/^?/Q!_P"$YJ'_ ,8K
MG/%/B6QUG6?"EO9P:I&ZZL[DWFDW5JF/L5T.'EC52>>@.>IQP: -:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *V= _Y>/^ _UK&K9T#_EX_P"
M_P!: -BBBB@ HHHH **** "BBN-O/B7865]/:OHVM2-!(T9>.U4JQ!QD'=R.
M*I1<MBXPE/X4=E17#?\ "U=._P"@'KW_ ("+_P#%T?\ "U=._P"@'KW_ ("+
M_P#%T_9R[%^PJ]CN:*X;_A:NG?\ 0#U[_P !%_\ BZ/^%JZ=_P! /7O_  $7
M_P"+H]G+L'L*O8[FH+V]MM.LY+J^GCMX(QEI)&P!7&_\+5T[_H!Z]_X"+_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5\D^//\ D\FU_P"PUI7_ *!;U[W\5?AY>?$71;&RL-<;1WM;@S,ZQE_,
M!4C'#+ZUY*W[*.I/<>>_C5&FR#YALF+9'0Y\S- 'TK7!:Y\(_A[XTOGU6]T>
MWGN9&/F7%G<-'YC=]VQ@"?4GFH/A-\,K[X;Q:JFH>(9-9^WM$4#1L@AV;\XR
MS<G</3[HKS_5_P!EHSZI=SZ)XPFM+:[=F>"6UW$ DG!97 8<GJ!0!YQ\6](\
M,7/Q!TGP;\,M/M@;<_9I7MV+^9<2/C:TA)+;0!DY.,L.,&O9OVA=<3PG\&X=
M"LWVRZ@T=C&%^4B% "YQZ855/^_6M\-O@3X>^'M\NJ&>75M752J74Z!%AR,$
MH@S@D'&22<<#&3FO\6_@S>?%#7-/NU\1+IUK96YB6W:T,N&+$LX.\=1M&/\
M9Z\T >/?#JR^-7AOPJA\$Z.!IFHL+Q)'2W8R;E4!OG;.,*./\:Y/Q2?&_A#X
MDV7BKQ?IYL=7FN$O4VE%68QE0?N$@9Q@CW]Z^W;&S@T[3[>RM$$=O;1+#$@_
MA51@#\A7!_%WX51_%'2]/A34%TZ[L)F>.=H?-!1AAEQN'4JIS_L^] '=:;?V
M^JZ5:ZA9.)+:[A2>)Q_$C*&!_(U9KG? 7AJZ\'^!].T"^U$:E)8HT8N!%Y>4
MW$J,9/0$#KVKHJ "N%\?_P#(R>$/^PG)_P"D5U7=5POC_P#Y&3PA_P!A.3_T
MBNJ +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =C1110
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M<=X^_P"/_P )?]AI_P#TANZ[&N.\??\ '_X2_P"PT_\ Z0W= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %;.@?\O'_ ?ZUC5LZ!_R\?\  ?ZT
M ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>-?\ D0?$'_8,
MN?\ T4U;=8GC7_D0?$'_ &#+G_T4U &EIO\ R"K3_K@G_H(JS5;3?^05:?\
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M4$W X)56*_F!BM>*6.>)9(762-AE64Y!'UJ(U(3=HM,E2C+9CJ***LH****
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M4 %%%% !1110 4444 %%%% '-_$'_D1-0_[9_P#HU:Z2N;^(/_(B:A_VS_\
M1JUTE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5>Y\1ZI!=2Q1>"]<N4C<JLT4UB$D . R[KD-@]1D ^H%=!10!S?_  E&K_\
M0B>(/^_^G_\ R57.>*=9OM1UGPI%>>&M4TI%U9V$UY):LC'[%=#:/*F=L\YY
M&.#STSZ/7'>/O^/_ ,)?]AI__2&[H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ K9T#_EX_P" _P!:QJV= _Y>/^ _UH V**** "BBB@ HHHH
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M_P ^6H?]^E_^*H_X3W3_ /GRU#_OTO\ \57444>SK_S_ (?\$.6I_-^!R_\
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M]^E_^*H_X3W3_P#GRU#_ +]+_P#%5U%%'LZ_\_X?\$.6I_-^!R__  GNG_\
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MR#@\&@#YO^'GQPUWX=^'8_!USX3EU"XMY7^S1M(\$J;F+%638Q;YBQ[=:R?
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MBB@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YOX@_\
M(B:A_P!L_P#T:M=)7-_$'_D1-0_[9_\ HU:Z2@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *X/7K[Q1%KMRFFI>&V##RS';[EQ@=#M]:[RBMJ-14Y7<
M4_4Y<30=>"BI./H>9_VEXS_N:A_X"?\ V-']I>,_[FH?^ G_ -C7IE%=/UR/
M_/M'!_9D_P#G]+[SS/\ M+QG_<U#_P !/_L:/[2\9_W-0_\  3_[&O3**/KD
M?^?:#^S)_P#/Z7WGF?\ :7C/^YJ'_@)_]C1_:7C/^YJ'_@)_]C7IE%'UR/\
MS[0?V9/_ )_2^\\S_M+QG_<U#_P$_P#L:/[2\9_W-0_\!/\ [&O3**/KD?\
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M110 4444 %%%% !1110 4444 %;.@?\ +Q_P'^M8U;.@?\O'_ ?ZT ;%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5B>-?^1!\0?]@RY_\ 135M
MUB>-?^1!\0?]@RY_]%-0!I:;_P @JT_ZX)_Z"*LU6TW_ )!5I_UP3_T$59H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KA_B;\+[#XG6-A;:C?W-D+&1I$: *=VX $$'Z5W%% '@?_#)WA_\
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M0_X *SZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH V= _Y>/\
M@/\ 6MBL?0/^7C_@/]:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *YOXB?\DXUW_KRD_E725S?Q$_Y)QKO_ %Y2?RH Z2BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG5@0>1A#VX(ZG/'MO[.WB[5/%GPU?^VYWNKC3KMK1;B0Y>2,(K+N/<C<1GN
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MCT [5K_\*?\ A]_T*6F_]^JLZ?\ "_P3I6HP7^G>&=/M[JW<213)%AD8="*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M110 4444 %%%% &SH'_+Q_P'^M;%8^@?\O'_  '^M;% !1110 4444 %%%%
M!1110 4444 %%%% !1110!!>V4&H64EK=)OBD&"/ZUQ$_P .9OM/^CWT?DY_
MC4[@/PX/Z5WU%<];#4JUG-&4Z4*GQ(R]"T"VT&T,<!,DKX,DK#EC].PK/^(G
M_).-=_Z\I/Y5TE<W\1/^2<:[_P!>4G\JVA",(J,59&D8J*LCI****H84444
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M ",GA#_L)R?^D5U0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#L:*** "BBB@#/U30[#6(U%] '9?NNIPP_'^E5-,\):3I=P)X86EE7E
M7F;=M^@Z5MT5HJM11Y4]#"6'HRG[1Q5^]@HHHK,W"BBB@ HHHH **** "BBB
M@ HHHH YOX@_\B)J'_;/_P!&K725S?Q!_P"1$U#_ +9_^C5KI* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *R->\6:!X7A67Q#K%GIRN,H+B8*S_[J]3^ K7KRK5/@'X?
M\2>.M4\2>*[V\U(WL@,-HKF)(4"@ $@[FQCC! YZ&@#J]#^)W@KQ)?)9:-XD
ML;BZD.(X"^QY#Z*& +'Z5U+,%4LQ 4#))/2OB3XV>"-/^'/Q&BL?#TLR6TUI
M'>PJTA+0$NZX#=>"F0>O-?3?]CW_ ,2_@'I^GWFI/8WFL:;://>",L3]QW.W
M(SN (ZX^;TH O7_Q>\ :9=M;7?BK3Q*I*L(G,H4CJ"4! KI-&UW2O$-@+W0M
M1MM0MB<>;;RAP#Z''0^QKR74/V;/ 5EX2NU#7J74-N[C49KGE" 3N*C";1CI
MCIW[UY?^RW>WL/Q0N[.W=OLMQI[M<1C[IVLNUC[@MC/^T?6@#Z9\3>.O#/@Y
M[=/$VKP:>]R"8ED#$N!C)P ?45A?\+P^''_0U6O_ '[D_P#B:\;_ &L_^1C\
M._\ 7I+_ .ABN_\ #GP ^'FH>%=*O;O1YGGN;*&65A>S#+,@). W')H ]3T3
M6]-\1Z/!JNB727EC<;O*G0$!MK%3UYX((_"K]9?AOP[IGA/P_;:)H4!M["UW
M>5&TC.1N8N>6))^9B:U* "N.\??\?_A+_L-/_P"D-W78UQWC[_C_ /"7_8:?
M_P!(;N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MG0/^7C_@
M/]:QJV= _P"7C_@/]: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *Q/&O_(@^(/\ L&7/_HIJVZQ/&O\ R(/B#_L&7/\ Z*:@#2TW_D%6G_7!
M/_015FN+\4>-X?!_AFP\N-;B^N(%\F)CP %'S-[9[=Z\W@^+WBB.]\Z66WFB
MSS T "X^HY_6M8TI25T=-/"U*D>9'OE%8_A;Q):^*M#CU&T4QDDI+"3DQN.H
MSW]0?0UL5FTT[,YY1<79A1112$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8GBCQEX?\&6"WGB;5(;")R1&')+R$=0J#+-U'
M0<9K;KD/%OPQ\.>.->T[4_$L$MW_ &?&R16OF%8FW$'+ <G&.F<>H- '*0_M
M+?#N2[\E[J_A3.//>S8I]<#+?I7J.G:C9ZMIT%_IES'=6EP@>*:)MRNI[@U\
MZ?M)^ ?"WASPCI>K:#I5KIEXU\+9EM4"+)&8W8DJ."05'/O74?LL27;_  OO
M5N"YMX]4D6WW= /+C+ >V2?Q)]Z .F\2?'CP#X9OI+*XU5KVYB;;)'8Q&4(<
MX(+<+D>F:N>#OC)X,\<:@NGZ/J31W[ E+6[C,3R8&3M[,< G .<"JGAWX$_#
M_P .Z>87T6+4Y"/WESJ6)G;\.%7_ ("!^-?,]SIME9_M%0V/@)C):1:U"+,P
M/O"X92P#=U4[AGG@<D]: /L+Q?XNTOP1X<FUO7&E6TA94(A3>S%C@ "O./\
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MI1KPKPYH%4ZD:BO$****V- HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5]: /5OBU\9E^%U_IMJ-".JM?1/(3]K\@1A2 /X&SG)],8[UYY_PUS_U)/\
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M1ECUKHJ*3G)JS)E6G)6?Y(****@R"BBB@ HHHH **** "BBB@ HHHH ****
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MB667QIKERD>DW3-#+#8A) (6)5MML&P>AP0?0BO1*YOXC_\ )+/%?_8%O/\
MT0] #]:_Y"'_   5GUH:U_R$/^ "L^@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** -G0/\ EX_X#_6MBL?0/^7C_@/]:V* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH KW]J;VQEMUF> R#'F1G#+]*XCQ9X=DTKP
MCJ=\^J7=VMO;LY@F;*28'0C/2N_KF_B)_P DXUW_ *\I/Y5C4HTZCO)$2IQD
M[LC_ .$.F_Z#VH?]]G_&C_A#IO\ H/:A_P!]G_&NHHK/ZI1[?BR?8P['+_\
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MO_PATW_0>U#_ +[/^-'_  ATW_0>U#_OL_XUU%%'U2CV_%A[&'8Y?_A#IO\
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ML9SAL'.#S71T45M3I0IJT47&$8[!1116A04444 %%%% !1110 4444 %%%%
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M?X,? >?P+K'_  D7B:Z@N-46-DMK>WRR6^X89BQ )8@E>. ">N> #C/VL_\
MD8_#O_7I+_Z&*Z30?V8_!FJ>&]-U"XU/75EN[2*=U2XA"AF0,0,Q'C)J;]H;
MX:^*O'.KZ+<^%M,%]':P21S?Z1%&5)8$??89_"O9O#]E+IOAG2[&YV^=:V<4
M,FTY&Y4 .#]10 [0=&MO#WA[3]&L6D:VL+=+>)I2"[*B@ L0 ,G'. ![5G7/
M@'P?>74MU>>$]#GN)G,DLLNFPL\C$Y+,2N223DDUT%% '-_\*X\$?]";X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q/&O_(@^(/\
ML&7/_HIJVZQ/&O\ R(/B#_L&7/\ Z*:@#2TW_D%6G_7!/_015FJVF_\ (*M/
M^N"?^@BK- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%>=_%/XN6GPU%E:C2[C5-3U ,;>WC;8O! Y;!/4\
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M'Y/V<M!+'YV_?N^_UQM7I_>KT:@ KF_B/_R2SQ7_ -@6\_\ 1#UTE<W\1_\
MDEGBO_L"WG_HAZ 'ZU_R$/\ @ K/K0UK_D(?\ %9] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ;.@?\O'_ ?ZUL5CZ!_R\?\  ?ZUL4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5S?Q$_Y)QKO_7E)_*NDKF_
MB)_R3C7?^O*3^5 '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%-=U09=E49QR<4Z@ HHHH **** "BBB@ HHHH **** "BBB@
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M^%7,JE:G3^.27JS<HI$=9(U>-@Z,,JRG((I:@U"BBB@ HHHH **** "BBB@
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M +1DN_M?EKYWES#;OQSCY>F:NM&&G0TQE.DK-NS]#T:BN!_X4WX9_P">E_\
M]_E_^)H_X4WX9_YZ7_\ W^7_ .)KGM#O^!P<M+^9_=_P3OJ*X'_A3?AG_GI?
M_P#?Y?\ XFC_ (4WX9_YZ7__ '^7_P")HM#O^ <M+^9_=_P3OJ*X'_A3?AG_
M )Z7_P#W^7_XFC_A3?AG_GI?_P#?Y?\ XFBT._X!RTOYG]W_  3OJ*X'_A3?
MAG_GI?\ _?Y?_B:/^%-^&?\ GI?_ /?Y?_B:+0[_ (!RTOYG]W_!.^HK@?\
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M>Y:TF:/'W"V"1^&:XSX&?"/P=XV^'9U7Q%ITES>?;9(MZW,D8V@+@85@.YH
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M_P#A%]$_Z!T/Y&C_ (1?1/\ H'0_D:/]I_N_B'[WR)/^$BT?_H)VO_?T4?\
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M]=:_\$5[_P#&:/\ A,M,_P"?76O_  17O_QF@#>HK!_X3+3/^?76O_!%>_\
MQFC_ (3+3/\ GUUK_P $5[_\9H WJ*P?^$RTS_GUUK_P17O_ ,9H_P"$RTS_
M )]=:_\ !%>__&: -ZBL'_A,M,_Y]=:_\$5[_P#&:/\ A,M,_P"?76O_  17
MO_QF@#>HK!_X3+3/^?76O_!%>_\ QFC_ (3+3/\ GUUK_P $5[_\9H ]/HKE
MHOB+H,\DT<$6N2/;N(YE3P]?DQMM#;6 AX.UE.#V8'O4O_">:1_SY^(/_"<U
M#_XQ0!TE%<W_ ,)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_"<U#_XQ0!TE%<W_
M ,)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_"<U#_XQ0!TE%<W_ ,)YI'_/GX@_
M\)S4/_C%'_">:1_SY^(/_"<U#_XQ0!TE%<W_ ,)YI'_/GX@_\)S4/_C%'_">
M:1_SY^(/_"<U#_XQ0!TE%<W_ ,)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_"<U
M#_XQ0!TE%<W_ ,)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_"<U#_XQ0!TE%<W_
M ,)YI'_/GX@_\)S4/_C%'_">:1_SY^(/_"<U#_XQ0!TE%<W_ ,)YI'_/GX@_
M\)S4/_C%'_">:1_SY^(/_"<U#_XQ0 ?$'_D1-0_[9_\ HU:Z2O.O'7C;2KCP
M;>0);:VKRO"B>;H%]&I8RH -S0@9)P ,\D@#DUT/_">:1_SY^(/_  G-0_\
MC% '245S?_">:1_SY^(/_"<U#_XQ1_PGFD?\^?B#_P )S4/_ (Q0!TE%<W_P
MGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\ "<U#_P",4 =)17-_\)YI'_/GX@_\
M)S4/_C%'_">:1_SY^(/_  G-0_\ C% '245S?_">:1_SY^(/_"<U#_XQ1_PG
MFD?\^?B#_P )S4/_ (Q0!TE%<W_PGFD?\^?B#_PG-0_^,4?\)YI'_/GX@_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_DRC[#XW_P"AA\/_ /@AG_\ DRNDHH YO[#XW_Z&'P__ ."&?_Y,H^P^-_\
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MR[VZM=O]B3MGR;B2'=G[6.OE[L=LXYQFM+[#XW_Z&'P__P""&?\ ^3*/ ?\
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M^A-\/_\ @K@_^)KI** .;_X5QX(_Z$WP_P#^"N#_ .)H_P"%<>"/^A-\/_\
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M!THH YO_ (5QX(_Z$WP__P""N#_XFC_A7'@C_H3?#_\ X*X/_B:Z2B@#F_\
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M_P#B:/\ A7'@C_H3?#__ (*X/_B:Z2B@#F_^%<>"/^A-\/\ _@K@_P#B:/\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S?PY_Y);X5_[
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M7M(_MO38K7S_ "/+O;6ZW;-V?(N(YMN,C[WE[<]LYYQBM*BB@ HHHH ****
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MKYT))&>,*:]:^&G@WXIZ)XO%YXX\3)J.EB!U, O'ERYQM."H'KS0!Z_1110
M4444 %%%% !1110 4444 %%%% !16'XTU;4M"\&:GJ6A6#:CJ-O#FVM5C9_,
M<D ?*O)QG.!R<5X+K>D?M!WNBSZ_=ZL;,11F4Z=:3K%*J#DX5!@D#L6+<>M
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M=X?_ .ACU+_OW'_A7N]K;K:VD-O&6*PQJBECDD 8YH EHHHH **** "BBB@
MHHHH **** "BBH;R26&QGEMX_-F2-FCC_O,!P/Q- "W%S!:1>;=31P1YQOD<
M*/S-.AGBN85EMY4EC;[KQL&4_B*^._BUI'Q*O?#T'BSXC7"6UO/>);VNE))@
M0ED=MPC&57A",DE^>>E>_?L^?\D)\/\ _;S_ .E,M 'I-%%<K\3/%S>!OAWJ
MNNPJKW,$82W1AD&5V"KD=P"<D>@- '1W-]:60!O+J&W#=/-D"Y_.ID=9$#QL
M&5AD,IR#7R7\./A%J'QDL]0\5^+/$%U&99VBB?:)))6 !+<\! 3@ >AZ8YE^
M%.LZS\+_ (XOX%U*^>;39[IK-XR3Y9=AF*5%_A+97/LW.<"@#ZPHHHH ****
M "BBB@ HHHH **** "BBB@ JN=0LENQ:F[@%P>!"91O]?NYS7!_%F?X@RV^F
MZ3\-;=5DOS*+R_)53:JNS;AF.%W;FYP3\O'-?.G@C1=0\/?M+Z7I>M78O-0M
M]0Q<7"NSB1S&23N;D]>IZT ?9]%%% $%U?6ED%-[=0V^_.WS9 F['IFJ_P#;
MVD?]!6R_\"$_QKYO_:S8G7_#BY.T6LQ SP#N7_"NB'[)_A_'_(QZE_W[C_PH
M ][BECGB66%UDC895T.01[&G5C^$O#D'A'PGI^@VD\D\-C%Y:RRXW-R3DX^M
M;% !1110 4444 %%%% !1110 4444 %1SW$-M$9;F5(8QU>1@H'XFI*\%U#]
MGW6_&^NWVK>/?%L[/)/)]DM[=?,$,>X[1EL!1C'RJ/QS0![K;W4%W%YEK/'/
M'G&Z-PP_,5+7PS%<ZW\%OBW-:6=_)(^G72I.("52\A."%9,X.5;H<X)X.1FO
MN8'(H *CGN(;:(RW,J0QCJ\C!0/Q-)=7,5G9S7-PVR*&-I';T4#)/Y"OD?0M
M.UO]HWXE7\VL:G+9:59J90BC<+>,MA(T7IN/=N^"?04 ?7%O=07<7F6L\<\>
M<;HW##\Q4M?'/B72-8_9Y^)UC/HFIS75E/&LXR-@N(PQ#Q2*#@D>ON",&OL&
MTN8[VSANK<[HIXUD0^JD9'\Z ):*** "BBB@ HHHH **** "BBB@ HHKC?B?
MH'B?Q-X5ATOP;JPTFXFNT^UW/F%"+?:VX J,YSLX&,XQG!- '4R:C90W @FO
M+>.8](VE4,?PSFK-?*?Q'_9U3P?X#N?$-EKTVH7-GM>Z2:$() S!2R\D@@G.
M"3D?KU7[+?C#5=6L=7T#4[F2ZMM/2*6T:0EFB5MP9,G^'A<#MS0!]!5'<7,%
MK"9;J:.&,<%Y&"@?B:DKQ3]JAV7X4V(5B VL1!@#U'E3'!_$"@#US^WM(_Z"
MME_X$)_C5JVN[>\C,EI/%.@."T3AAGTR*^:? _[-VB^*O ^DZY<ZY?P2WUNL
MKQQQH54GL,BO:OAK\.;'X::#<Z7IU[<7B7%R;AGG !!*JN !_NT =C1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!XA^U/JD]I\-]/L(79$OM0438_B5$9MI_X%M/_  &ND_9^TFVTSX+Z1) B
MB2^,MS.X7!=C(P&?7"JH_"N3_:NMY'\":-<*,QQ:CL8^A:-L?^@FNS^ MY%>
M?!/0#"<F))8G!ZJRRN#_ $/T(H \&TB%/"G[70M=,&R#^V7B6-?E"I,#E0!V
M ? 'L*^O:^1K4IKW[8FZP;>JZTS;L=?)4E_P_=MS7UG+>6T$T<4]Q%'))]Q'
M<!G^@/6@#PW]JS5)K;P1H^FQ,RQWE\9),?Q"-. ?Q<'\!7:_ S1[72O@QH:V
M\:YO(6N9VV@&1W8GGUP,+]%%<%^UE;2/X8\/70'[J*\DC8_[3("/_0#7HOP3
MO8;[X,>&Y+=MRI:F%L]F1V5A^8- 'S[X*A7PM^UFVGZ8!':KJMU;+$@VJ(F#
MX7'H,C_OD5]>U\C>%\:Y^U_+-89>)=8NI=X&1M0/EOH<<'W%?7- !1110 44
M44 %%%% !1110 4444 >6?M&:I-IOP9OTMV9#>SPVS,O]TMN(_$)C\:S/V8-
M(MK+X6RZC&@-SJ%[(99-HSM3"JN?088_5C5K]IBVDG^#<TD8RMO?022>RDE?
MYL*9^S)>PW/P@6")LR6M_-'*#V)VN/PPP_6@#R#XA0)X6_:JBN-* A#:E9W6
MR,;1N?89!_P(EB?]XU]?5\C?$_&M_M66]I89D<7]C;DJ,X8"/=^ SS]#7UG<
M7EM:;/M5Q%!O.$\QPNX^@SUH YKXI?\ ))?%/_8+N/\ T UX-\"/BYX4\ ^!
M;S2_$=Q<174VI/<((K=G&PQ1J.1[H:^G-0L+75=-N+#485N+6ZC:*:)^CHPP
M0?PKC)_@G\.I[-K9O"UFB$8WQEU<>^X'/ZT ;/A/Q]X9\<022>&-6AO3$,R1
M8*21CIDHP# >^,5T5?%_PWAD\,?M+6^EZ'/+-!;ZK<6(;>,S0 NI+8X/RC=Z
M9 ([5]H4 %%%% !1110 4444 %%%% !1110 5X)\7_AGX5\&?!G7+O1-,07T
MT\+/>3'S)OFG7(#'[H]EP/6O>Z\O_:*_Y(AJ_P#UUM__ $<E '-?LH_\D]UC
M_L*'_P!%1U[K7A7[*/\ R3W6/^PH?_14=>XW%S!:0F6ZFCAC!P7D8*!^)H X
MKXT:M+HOP;\1WEN660VP@#+U'FNL1/Y/7FW[)^E6R>&]=U?RU-W+=K:[R.51
M4#8!]R_/T'I7?_'2W?4?@;XA6T*R?N8I@0<@JDT;D\?[*FN'_9/O(7\&Z[9*
MX,\6H+*Z9Y"O& I_-&_*@#S_ /:2MUT#XTVFI:8!!<SV4%ZS*,?O5D=0WU_=
MK7UO;R^=;12XV^8@;&>F1FODS]IMO[4^,=A8V \ZY338+8QJ1GS&ED8+^(=?
MSKZSMXO)M8HB<[$"Y]<"@"2BBB@ HHHH **** "BBB@ HHHH *\H^('PS\*Z
M9X1\:^)8],2?5[RRN9VNK@^88F*'_5@\)]0,^]>KURGQ2_Y)+XI_[!=Q_P"@
M&@#Q']DG_D)>*/\ KE;?SDKZ9KYF_9)_Y"7BC_KE;?SDKZ7EEC@B:29UCC49
M9W. ![F@!U?(_A7QGH_@3]I/QAJWB&66*U:[U" -%&7.XW.1P/\ =-?6L,\5
MS"LMO*DL;='1@P/XBN2N_A/X%O\ 4;J_O?#-C/=7DK33RR*27=CDMUX)))XH
M J>&/C1X%\6Z@EAI>M*EY(<1P7430F0^BEA@GV!S7=U\8_'SP9HO@/Q_:1>%
M@UI%<VBW)MUE+>0^]AE23D [<@=B#CT'UQX5N[N_\&Z-=ZDI6\N+""6X4]I&
MC4L/S)H UJ*** "BBB@ HHHH **** "BBB@ JE;:-IMEJ=WJ-I86\-[>E?M-
MRD0$DVT8&YNIP!TJ[7G'QA^+%I\-M!$=MLN-=O%/V.V/(0=#*_HH[#^(\#@$
M@ \,_:BN=-F^*%M%9;#>0:?&EX4[,69E#>^T@_0K7TE\---NM(^&'AVQU!&C
MN8;"(2(W5"5SM/N,X_"O"/@I\*-0\7Z\/'_CKS);=YC<VT4X^:]E)SYK#^X#
MR!_$<?PCGZ?) &3P!0 5\B_"Q$\8_M.W&I:K^^*7-U>JD@R-RDA!_P !R"/3
M:*^M+>[MKM"]I<13JIP3$X8 ^G%?)7P2=='_ &D)[&^.R9WO+4#MY@))'_CA
MH ]-_:FTJVN?AO8ZDR*+JSU!423;EMCJVY<]@2%/_ :WOV=[^:]^"NEK.Q8V
MTDT*L3GY1(2!^ ./PK'_ &H[R&#X5VUL[?O;C4HQ&H[[4<D_3I^8K7_9TLY;
M3X*Z8TRE?M$T\J@C'R^8P!_'&?QH ]1HHHH **** "BBB@ HHHH **** "J3
M:-IKZTNL/86[:DD/D+=M&#(L>2=H;J!DDX]ZNURWQ!\>Z7\//"\NK:HV^4Y2
MUM5.&N),<*/0=R>P_ $ \<_:RN-.^Q>'K8A#J?F2R @?,L. #GV+8Q]#7;?L
MWZ;<Z?\ !RT>[1D%Y<RW$2N,'83M!^AVDCU!S7CO@/P1KWQU\=3^*O&3R#1U
ME_?.N467'2"+T4=">P[[CFOK2VMX;.UBMK6)88(4$<<:#"HH&  .P H DKYD
M_:4NHK'XK>$[NX)$5O!'*Y R0JSDG]!7TK%>6T\TD4%Q%)+']]$<%D^H'2L7
MQ#X#\,>*[Z"\\1Z-;:A/;H8XGF!.U3SC&<'KWH X^P_:(^'-[=) =7FMBQP'
MN+614S[D X^IXKTNVNH+VUBN;.:.>"90\<L3!E=3T((X(KYX_: ^%G@[P]X$
M_M[0M.CTN^CN8X@L+D),&S\NPG&1C.1SP<UTO[+M]>W?PKN(;LLT%IJ,D5L6
M/1"B,5'MN9C^- 'L]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!R_P 3)Y+?X5>*)86*.-*N,,#@C,;#(KQ/]D>-3+XMD*C>
MHLU!] ?.S_(?E7O/C329=>\"ZYI-O_KKVPGAB_WV0A?UQ7S7^S)XNTKPQXCU
MS2M>O(=..H1Q&*2Z<1KYD3.-A+8 8^8< ^F.M &I^UK&@U;PQ*%&]H+A2WJ
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M>SLX(X*KYAYZ?*: /KFT=I+*!W.6:-23ZG%0:TCRZ!J$<:L[M:R!549))4\
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M^=?,,;16L).#-,P.U1_,^@!-;'B'7]/\+^'[O6M9G\BRLTWR/C)ZX  [DD@
M>I%?(]WJ.H?'SXF>;J^J6VB:+:\)]IN%1;:'/10Q&Z1L<D>G/ % &K^S'X0N
MM4\?/XG>,K8Z3&Z)(<@/-(A7:/7",Q/IE?6OK6N7\*S^#?#^D67A_P -ZII:
MPP@1PPQ7<;/(WJ<'+,3R3W-4?'/Q:\+?#W4+6Q\0SW'VFYC\U8[>'>53)&YN
M1@9!]^#0!QO[4MQ)!\)[5(VPL^K11R#U7RY6Q^:C\JU?V<8T3X)Z:R* 9)[A
MF([GS6&?R JC^T)9IXJ^!J:KI+FYMK>>#4HVC&?,B92N['7&)=WL!FLG]G3Q
M_P"'K7X9G1]6U:RTZZTV>5BEW.L6^-COWC<1D9)!],<]10!YQ\1@+?\ :X0P
M#81JVG.,?WBD!S^=?7U?(4;Q_$W]JY+W1LS60U&*<RJ/E,-LJ OGL&\L8/\
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M-8@>VO-2N6O&@D&'B0JJJ&'8X7=CJ-V#R,5ZE0 4444 %%%% !1110 4444
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MZBP<.]M'*\SSXZ*\C 87M@9X[BOHA0%4*H  & !VI:* "BBB@ HHHH ****
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M\%>&?#4AET#0=/L)2"#+!;JLA'INQG'MFMRBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***Y3X@WUU8Z7H[65Q+;M-KVG0R-$Y4M&UR@921V(X([@D=#0!U'G1?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ J"^LXM0T^XLKD$PW$312!3@[6!!Y^AJ>B@-CAO\ A4/A7_GE=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNN-^)?\ R"="_P"QCTS_ -*DJ]_PB^K_ /0]^(/^_&G_ /R+7+^.=#U"QM]
MGNO%.K:E&/$6F@V]U%:*A_TE.<QP(W'^]0!MT444 %%%% !1110 4444 %%%
M% !1110 5-9_\?T'_71?YU#4UG_Q_0?]=%_G0!U=%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !17,R:1XF:1BFO(JDD@>4.!^
M5-_L;Q1_T'T_[]#_  KF]O/_ )]O\/\ ,R]I+^5_A_F=117+_P!C>*/^@^G_
M 'Z'^%!T;Q1@_P#$_3_OT/\ "E[>?_/M_A_F+VDOY7^'^92U[QVUK>/:Z3'&
M_EDJ\TF2"?\ 9 _G2:%X\:ZO$MM6BCC$A"I-'D '_:!_G7"2QO#,\<JE'1BK
M*1@@BB*-Y94CB4N[L%50,DD]J\'Z_7]IS7^1YWUBIS7N>XT5RXT;Q0%'_$_3
M_OT/\*/[&\4?]!]/^_0_PKWO;S_Y]O\ #_,]'VDOY7^'^9U%%<O_ &-XH_Z#
MZ?\ ?H?X4Y-(\3+(I?7D901D>4.1^5/V\_\ GV_P_P Q^TE_*_P_S.FHHHKI
M-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45DZ[XBM-!A4SYDF<92%>I]R>PK!L_B+;RW"I>
M6301D_ZQ9-^WZC K>&'JSCS1CH<=7'8>E/V<Y69VE%-CD2:))(F#HX#*P/!!
M[TZL#LW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J.M_\@#4/^O6
M3_T$U>JCK?\ R -0_P"O63_T$T <5X5_Y)UX1_[ -E_Z*6M*LWPK_P DZ\(_
M]@&R_P#12UI4 %%%% !1110 4444 %%%% !1110 5-9_\?T'_71?YU#4UG_Q
M_0?]=%_G0!U=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P
MM9\(Z?K$_GOO@G/WGCQ\WU%&C>$=/T>?STWSSC[KR8^7Z"MVBL/J]+GY^57,
M_90YN:VH4445N:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7CG[0OQ*M/#'@ZY\-6<BRZOK$#0M&#GR(&X=V
M_P!X94#W)[<]5\7O'[_#GP%+JUK L][/,MI:*_W%D96;<WL C''<@#C.:^4?
M!6M^%[SQO/XC^*US?:FWF"86Z0B074GK(20-@P/D'!X'"C! /:?V9OAS=:-8
MS^,=6C,4NHP"&QB8<^02&,A_WBJX]AGHU>X:K+JL-JK:'9V=Y<;P&CO+MK=
MN#DAECD).<<8'4\\8/ ^%?CQX-\6^)+/0=(&H)=W198O-M@J?*I;&0QQPIKT
MR@#F_MWC?_H7O#__ (/I_P#Y#H^W>-_^A>\/_P#@^G_^0ZZ2B@#A;%[N2&5M
M2@AM[HW$WF16\QE13YK='*J3_P!\BK-(/]?<_P#7U-_Z,:EH **** "BBB@
MHHHH **** "BBB@ HHHH TM"_P"/Y_\ KF?YBM^L#0O^/Y_^N9_F*WZ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@ HHHH **** "IK/_C^@_P"NB_SJ&IK/_C^@_P"NB_SH ZNBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH HZOHFE^(+'[%KFGVVH6NX/Y-S$)%W#H<'O6#_PJ
MSP'_ -"?HO\ X!)_A7644 <[IOP_\(Z/J,5_I7AK2[.[A),<\-JBNF00<$#C
M@D5T5%% !1110!QH_P!?<_\ 7U-_Z,:EI!_K[G_KZF_]&-2T %%%% !1110
M4444 %%%% !1110 4444 :6A?\?S_P#7,_S%;]8&A?\ '\__ %S/\Q6_0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  MCPE_S_P O_@,_^%=;]DMO^?>+_O@4?9+;_GWB_P"^!1>'8.:C_*_O_P"
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M!G_PKK?LEM_S[Q?]\"C[);?\^\7_ 'P*B\.QGS4?Y7]__ .2_P"%L>$O^?\
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M]?G0!MT444 %%%% !1110 4444 %%%% !1110 5-9_\ ']!_UT7^=0U-9_\
M']!_UT7^= '5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15>_EN(+&62RA$\ZC
M*1DXW&N?_MGQ1_T $_[^C_&L:E:--V:?R39$IJ+LSJ**Y?\ MGQ1_P! !/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=T\R"-MP\I]M9?\ P@VF?\][W_O]_P#6KI**UC6J05HLYJF%H5)<TXILYO\
MX0;3/^>][_W^_P#K4?\ "#:9_P ][W_O]_\ 6KI**KZQ6_F(^HX;^1'-_P#"
M#:9_SWO?^_W_ -:N7\7^&AI!AN+,RR6[#:[2-N*M_@1_*O3*;)&DT;1RHKHP
MPRL,@CZ5K2Q=2$TV[HPQ&6T*M-QBK/N>&UVOA;PA'?Z6;O46N(O,;]TL;[<K
MZGBNGC\*:'%/YR:?'OSGYBQ'Y$XK8 P,#I737Q_/&U/0X<'D_LI\U=I^1S?_
M  @VF?\ />]_[_?_ %J/^$&TS_GO>_\ ?[_ZU=)17#]8K?S'J_4<-_(CF_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5QOQ+_ .03H7_8QZ9_Z5)795QO
MQ+_Y!.A?]C'IG_I4E "T444 %%%% !1110 4444 %%%% !1110 5-9_\?T'_
M %T7^=0U-9_\?T'_ %T7^= '5T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% '&C_7W/\ U]3?^C&I:0?Z^Y_Z^IO_ $8U+0 4444 %%%% !1110 4
M444 %%%% !1110!I:%_Q_/\ ]<S_ #%;]8&A?\?S_P#7,_S%;] !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Q7Q/\ B1;?#;0(+V73Y]1N;R;R+6WB(4,^,_,>H'T!/M7:
MU%+;03R123P1R/"VZ)G0$H<8R">AQZ4 ?(<WQA^)<_Q)LK;6+^XT@RW=N'TU
M(!&L<;E2%*L"W*L#\Q)YKZ^E#F%Q"0LA4[2>Q[5\>_%K_DZ:X_Z_]/\ _14%
M?8M 'SG_ ,(?^T-_T,\7_@6G_P 17!^-/&GQ9\!:XFDZ[XND-VT*S%;>1) J
MDD#)V\'C./3'K7U]JFI6NCZ3=ZEJ$GE6MG"\\S_W549/Z"ODCX::?=?%[X_3
M>(-6C+6L-P=1N%;D*JD"&+/?&$'NJF@#V[XB^(/$OAG]G>+5/MDEKX@CL[);
MFX"J665C&)>V,DEAT[\5Y'X(N?C=\0-$FU7P]XI8VT-PULWGSHC;PJL>-O3#
MBO7_ -HO_DB&K_\ 76W_ /1R5XI\'?C=I?PU\'W6CZAI-Y>2SW[W0D@=0H!C
MC7'/?Y#^= 'N7PHT;XC:3/JA^)&JI?QR+$+0+,'V$%M_11CJM>DUPWPR^*-A
M\3K/4+C3M/N;(6,B(XG93NW D8Q]*Z+5=9OM.NEBL_#6J:JC(&,UG):JBG)&
MT^;,C9XSP,<CGK@ UZHZW_R -0_Z]9/_ $$UD_\ "4:O_P!")X@_[_Z?_P#)
M54]7\3:L^AWRMX'UY ;>0%FGL,+\IY.+HF@#,\*_\DZ\(_\ 8!LO_12UI5F^
M%?\ DG7A'_L V7_HI:TJ "BBB@ HHHH **** "BBB@ HHHH *FL_^/Z#_KHO
M\ZAJ:S_X_H/^NB_SH ZNBBB@ HHHH **** "BBJNI375OI=S-I]N+FZ2,M%"
M3C>V.!F@:U=BU17 _P#"3^/_ /H3HO\ P('_ ,51_P )/X__ .A.B_\  @?_
M !5:>S?],V]A+NOO1WU<=XF^)FB^&[QK-O-O+M/OQP8Q&?1F/?V&??%9TWBC
MQ^L$A_X1&-,*3N$X.WCKC/->'32R33/+,S/([%F9CDDGJ2:UIT4W[QU8?"*;
M;F_N9]#>%_B-HOBBZ%I#YMK>$96&<#Y_7:0><?@:ZVOD^UN)K2\AN+5V2:)P
M\;+U# \5[C_PD_C_ /Z$Z+_P('_Q5%2C9^Z+$810:Y'IYL[^BN!_X2?Q_P#]
M"=%_X$#_ .*H_P"$G\?_ /0G1?\ @0/_ (JLO9O^F<WL)=U]Z.^HJ&TDFEL8
M)+J+RIWC5I(P<[&(Y'X&IJS, HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGXF_&
MC0?AO_H4L<FH:R\>^.RB^4*#G#.YX4<=LGV[UZ-6+)X/\/S>*?\ A))])MYM
M8$:QK=RKO9%7.-H/"GD\@ GUH \;^#WQP\3>/_B(=&UBVTZ*S>VEF46\3JZE
M2,#)8YZ^E>L?$+5/$6C>";R]\&V U#5XVC$-N8C)N!=0QV@@G"DGK7S!^S+_
M ,EB3_KPG_\ 9:^Q: /G+_A9/Q[_ .A(C_\ !9+_ /%UG^&/V@/'^I?$;2_#
M>J:=IL;3:G'9W<26D@DC'F!9/X^"HW'VQS7NOQ'\7Q^!O &IZXQ7SXHBEJK#
M.^9N$&.XSR?8&O!OV8?"<NL>*-3\::GF869:&"23DO<2#+OGU"G_ ,B4 =_\
M=OBOKWPVGT2'P_!8O]N69I6NHV?&PH !AAC[QSU[5QUG\5/CGJ%C!>67@Z&>
MVN(UEAE33I2KHPRK [^A!!J']K;_ )"/A;_KE<_SCKK_  9\>?A]H_@/0-,O
M]7FCNK+3+:WG06<K;72)589"X/(/(H ]$^'FJ>(M9\$V=[XRL!I^KR-()K<1
M&/: Y"_*22,J >M=-6=H.NZ?XFT*UUC1YC/97:EX9"A0L 2.A (Y!JA<^--+
MM;J6WEM=<9X7*,8M OI$)!P=KK"58>A!(/4&@#H*XWXE_P#()T+_ +&/3/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKPC_ -@&R_\ 12UI5F^%?^2=>$?^P#9?^BEK2H **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI[5V=%% !1110!QH_P!?<_\ 7U-_Z,:EI!_K[G_KZF_]&-2T %%%% !1110
M4444 %%%% !1110 4444 :6A?\?S_P#7,_S%;]8&A?\ '\__ %S/\Q6_0 44
M44 %%%% !1110 4C*&7# $>A%+10 SR(O^>2?]\BCR(O^>2?]\BGT4[L7*AG
MD1?\\D_[Y%>9^(?"%[87TDEA;O<6CME/*4L4]B.O'K7I]%;T,1.C*Z.+%X*G
MBH*,M+;,\JT7PEJ&I7BBXMY+:V4@O)(NTD>B@]37J"VT"(%6% %& -HJ6BG7
MQ,Z[NQ8/ T\)%J.K?49Y$7_/)/\ OD4>1%_SR3_OD4^BN>[.[E0BJJ#"*%'H
M!BEHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "J.M_\@#4/^O63_T$U>JCK?\ R -0_P"O63_T$T <5X5_Y)UX1_[
M-E_Z*6M*LWPK_P DZ\(_]@&R_P#12UI4 %%%% !1110 4444 %%%% !1110
M5-9_\?T'_71?YU#4UG_Q_0?]=%_G0!U=%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5QOQ+_ .03H7_8QZ9_Z5)795QOQ+_Y!.A?]C'IG_I4E "T
M444 %%%% !1110 4444 %%%% !1110 5-9_\?T'_ %T7^=0U-9_\?T'_ %T7
M^= '5T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&C_7W/\ U]3?
M^C&I:0?Z^Y_Z^IO_ $8U+0 4444 %%%% !1110 4444 %%%% !1110!I:%_Q
M_/\ ]<S_ #%;]8&A?\?S_P#7,_S%;] !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55OM3L-
M,C$FI7UM9H> UQ,L8/XDU8D#F)Q$0KE3M)['M7@-K^S-/KL<FH^/_%M[>:S/
MDNUL0RQGTW."6'T"CL* />+._L]1@\[3[J"ZBZ>9!('7\Q5BOAWPQ=:S\,?C
M7'IMC?,SVNJ+97*QL5CNH_,V$,O<$'(SG!P>HKW3]I7Q_J'ACPY8:'HEQ):W
M6K%S//$VUTA3 *@]1N+=1V4CO0!Z[-XAT6WN_LL^L6$5QG'DO=('S_NDYK1!
M! (.0>AKYBT3]F&/5/AS;ZI-K%Q%KMW:"YBM]B^2A9=RQMWSR 2#P3T..;7[
M+WCG49M2OO!VIW$DUM%;FYLA*<F$JP5XP>P.X''0;3ZT ?05YXBT73KDV^H:
MQ86LX )BGND1@#TX)S19^(M$U"<0V&L6%U*>D<-TCL?P!KY$^)NE1:_^U#<Z
M1=2/'#J&J6=K(\>-RJZQ*2,\9 -;_P 6?@'I7@'P5)XAT76KR5K>:-'ANPI+
M[FVY4J!@@D''IF@#ZMHKRO\ 9W\2:MXE^%8EUV:6XFL[V2UBN)B2\L85&!)/
M7!<KG_9KU2@ JCK?_( U#_KUD_\ 035ZJ.M_\@#4/^O63_T$T <5X5_Y)UX1
M_P"P#9?^BEK2K-\*_P#).O"/_8!LO_12UI4 %%%% !1110 4444 %%%% !11
M10 5-9_\?T'_ %T7^=0U-9_\?T'_ %T7^= '5T444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !117">/\ XBKX6==/TV..XU%U#-O.5A!Z9 ZD^GXU48N3LBZ=
M.527+$[NBO#-+^,>O6UZ&U1(+RW+?,@C",!_LD?US7M&EZG;:QI<&H6#^9!.
MFY#_ #!]P>#[BJG3E#<TJT)TOB+=%%%9F 4444 %%%% !1110 4444 %%%%
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MT_[[;_&M6"".VMXX(%V1QJ%51V J2BKC3A#6*2&HQCL@HHHJR@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD?]H;XH:EK
MOBB\\(V3M;:/ILWESHIP;J9>I;_94]%]1N.3C'UQ7.:A\/?!^K:A+?:GX9TJ
MZNYCNEFFM$9G.,9)(YZ4 >&?#/XI?"OX;>'Q:6*:I<7\X#7E\UDH:9O0?/P@
M[#\>I)KOO&SVOQJ^!-_<^$HYI7W^;:QS1[7:2)^5 SU(W <]Q76?\*L\!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $%]90:C926MTF^*08(_J/>N(G^'$OVC_1[]
M/)S_ !H=P'X=?TKOJ*WI8BI2T@SDQ&#H8EIU(W:,O0M!MM!M#%;DO(^#)*PY
M8_T'M6I1164I2F^:6YT4Z<:<5""LD%%%%26%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4'V&T_Y]8?^_8J>B@"#[#:?\^L/_?L5/TZ444 ,\B+S
MO-\I/,_O[1G\Z?110!%);03-NEAC=L8RR FECMX86)AACC)&"54"I** "BBB
M@ JCK?\ R -0_P"O63_T$U>JCK?_ " -0_Z]9/\ T$T <5X5_P"2=>$?^P#9
M?^BEK2K-\*_\DZ\(_P#8!LO_ $4M:5 !1110 4444 %%%% !1110 4444 %3
M6?\ Q_0?]=%_G4-36?\ Q_0?]=%_G0!U=%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5QOQ+_P"03H7_ &,>F?\ I4E=E7&_$O\ Y!.A?]C'IG_I
M4E "T444 %%%% !1110 4444 %%%% !1110 5-9_\?T'_71?YU#4UG_Q_0?]
M=%_G0!U=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QH_P!?<_\
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M'A?5R!_Q7?B#_OQI_P#\BT =+17-_P#"+ZO_ -#WX@_[\:?_ /(M'_"+ZO\
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MW5%(IRHSZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 54U6)Y]&O8HE+226\BJH[DJ0!5NB@#R3POXGLQ
MX!\+Q+8ZY(8=%M(G:+0KUT+")0=K+$0P]""0>QK2_P"$FM?^@;X@_P#">OO_
M (S72_#C_DEGA3_L"V?_ *(2NDH \V_X2:U_Z!OB#_PGK[_XS1_PDUK_ - W
MQ!_X3U]_\9KTFB@#S;_A)K7_ *!OB#_PGK[_ .,T?\)-:_\ 0-\0?^$]??\
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M!_X3FH?_ !BC_A/-(_Y\_$'_ (3FH?\ QBNDHH YO_A/-(_Y\_$'_A.:A_\
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M?B#_ ,)S4/\ XQ7244 <W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\
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MH,\DT<,6N2/;N(YE3P]?DQL5#;6'D\':RG![,#WJ7_A/-(_Y\_$'_A.:A_\
M&*/#'_(R>,O^PQ'_ .D%I724 <W_ ,)YI'_/GX@_\)S4/_C%'_">:1_SY^(/
M_"<U#_XQ7244 <M;?$70;RUBN;.+7)[>9!)%+%X>OV212,A@1#@@CG(J7_A/
M-(_Y\_$'_A.:A_\ &*/AS_R2WPM_V![3_P!$K724 <W_ ,)YI'_/GX@_\)S4
M/_C%16WQ%T&\M8KFSBUR>WF0212Q>'K]DD4C(8$0X((YR*ZFN;^'/_)+?"W_
M &![3_T2M !_PGFD?\^?B#_PG-0_^,5%<?$70;6,2746N0H76,-)X>OU!9F"
MJN3#U+$ #N2!74US?CS_ )%NV_[#&E_^E\% !_PGFD?\^?B#_P )S4/_ (Q1
M_P )YI'_ #Y^(/\ PG-0_P#C%=)10!RT'Q%T&ZC,EK%KDR*[QEH_#U^P#*Q5
MER(>H8$$=B"*E_X3S2/^?/Q!_P"$YJ'_ ,8H\"?\B_=_]AK5/_2^>NDH S=%
M\0:?X@AN9--:X_T6;R)X[FTEMI(WV*^"DJJWW74YQC!K2KF_#'_(R>,O^PQ%
M_P"D%I724 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7(?$S3;?4_#%DEUYP$>MZ8R-!<20LI:\BC)W(P/W
M7;'/!P1@@$=?7-^//^1=M?\ L-:5_P"G"WH A_X5OX?_ +^M?^%!?_\ QZC_
M (5OX?\ [^M?^%!?_P#QZNJHH Y7_A6_A_\ OZU_X4%__P#'J/\ A6_A_P#O
MZU_X4%__ /'JZJB@#E?^%;^'_P"_K7_A07__ ,>H_P"%;^'_ ._K7_A07_\
M\>KJJ* .5_X5OX?_ +^M?^%!?_\ QZC_ (5OX?\ [^M?^%!?_P#QZNJHH Y7
M_A6_A_\ OZU_X4%__P#'J/\ A6_A_P#OZU_X4%__ /'JZJB@#E?^%;^'_P"_
MK7_A07__ ,>H_P"%;^'_ ._K7_A07_\ \>KJJ* .5_X5OX?_ +^M?^%!?_\
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M$W9$49ZG&3DUZ!6;H.D?V)ITMKY_G^9>W5WNV;<>?<23;<9/W?,VY[XSQG%
M&;_P@>D?\_GB#_PH]0_^/UAZ]X3LK+6O#,%MJ'B!([[4W@N%_P"$BOSO06=S
M(!S-Q\\:'(P>,=":] K-U32/[2U'1KKS_*_LN]:[V[,^;FWFAVYSQ_KMV>?N
MX[Y !F_\('I'_/YX@_\ "CU#_P"/UB>-/"=EI/@'Q!J6GZAX@AN[/3+F>"3_
M (2*_;8Z1,RG!F(."!P1BN_KF_B-_P DM\5?]@:\_P#1+T (/ >D8_X_/$'_
M (4>H?\ Q^E_X0/2/^?SQ!_X4>H?_'ZZ0=!10!S?_"!Z1_S^>(/_  H]0_\
MC]'_  @>D?\ /YX@_P#"CU#_ ./UTE% '-_\('I'_/YX@_\ "CU#_P"/T?\
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MF^SKI*Y_PY;3P:]XLDGADC2XU:.2%G0@2+]AM5W*3U&Y6&1W4CM704 %%%%
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M#@  8 %2444 %%%% !4=Q;0748CNH8YD5TD"R(& 9&#*V#W#*"#V(![5)10
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MXK;HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK6[A6:&4 @.C %3@\\@BJ>O^)=%\+:?]M\0ZG;:=;D[5>>0+O/7"CJQ]ADT
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MW17RAXB_:B\57&J&3P[IUIIVGX_=)<QF6209(W$Y [=!TY&37U5;2F:TAE;
M9T#''3)% $M%>(?%/X\WGASQ1_PBG@?38]3U=65)I'1I LAZ1HBX+M@COP>,
M$YQR<WQW^)G@C6;2/X@^&X%M;CYMA@,+NHZ['#%21D9!!ZCIF@#Z;HJAH>LV
M7B+0K/5]+D\VTO85FB8C!P1T([$="/6K] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%<A\1/B7H?PVTF&[UOSI9[DLMK:P+EYBN-W)X
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M_L*'_P!%1U[I7A?[*/\ R3S5_P#L*'_T5'7NE !1110 4444 %%%% !1110
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MB@ HHHH **** "BBB@ HHK(\5Z1<Z]X2U/2K"]:PN;RW:*.Y7.8V(Z\$'\J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH QO%WAN#Q?X3U#0;R>2"&^C\MI8L;EY!R,_2O'/^&3O#__ $,>I?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH X+XG_"C3OB@FF#4M0NK(Z<9?+-NJG=YFS.<C_8'
MZUP'_#)WA_\ Z&/4O^_<?^%>^44 <%\,?A1IWPPCU)=-U&ZO3J!C+FX"C;LW
M8P!_OG]*P_&7[.WA'Q;K,VJQ2W>DW=PQ>86A7RY&/5MA!P3[$>N*]9HH \P\
M"_ /PGX'U9-5C-SJFH1',,MXR[83_>55 &?<YQVQ7?:]H.F^)M$N-)URU2[L
MKE=LD;_H0>H(/((Y%:-% 'A4_P"REX5>\+P:WJT4!.?*S&Q ] VW^E>I^"_
MNA> =%_LWP[:F)'.Z::1MTDS?WF;O]!@#L*Z*B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW#)X@UY%O;B[D)19!E0 <=/J,8[ "F:OI]EH?CS0I-'C%O+<2$31H/EVD@9
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M#XCM_#\'_'K;[;B_;V_A3ZX.?Q'I3>K!;&#X7CGU?X@?VC?*/,\@W10\B,,
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MU=G?7]KIML;B_G2"('&YSC)]!ZFN0LO$_B8^*;31]3L;&!YOG<)EB$Y).0Y
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MCN=_I>NZ;K2N=,NUGV?>4 J1^! -.NM9L+*_BLKJX$<\R%T4JV-H!)).,
M]3VKA/#3+=_$836>F-ID:V[/);D;< C ..."64\"K5_IT?BCXFRVUP^^TL8
M) C8W#&=N1_M-S[ T65PN=+#XQT">[6VBU*,RL=HRK $YQ]XC'ZUM5P'CS1M
M-MM/TZTTVPA@NKBY6.-HHP"PQ@@GJ>2M=_28&-XONC9^$=1E7J8?+_[[(7_V
M:N7T7X<Z=?:):75]/>)//&)&6-U"@'D=5/;%7?B5*\FEV.GPH6ENKD;0.^!C
M'YL*KRZ?X]TW3A]GU&UF2! %A@C4MM [9C&>!]:I;"ZE'Q#X8C\'6L6KZ+J%
MRDJ2JNV0J<YSZ <<="#7?'4H(-)COK^5+>-HU=F<[0"1G'U]JX?0=&F\8M%J
M>N:Q]MBA;FU1=NUL#((P .@Z#GUJ_P"-K[0?[0M8-6:\NI8 7%G;%=G/]_OS
MCL<@?7DWT V;;QGX?N[E8(-20R,<*&1U!/3J0!47C+7XM%T66-+DQ7T\9%N%
M4D]0"<]!@'O^%<'X@U/3K[1]MEX:-AL< 70C"X]B0.20#U-=#XSL_,TG0=.E
MA1K^XDCA,A"[P  &&?3+ ^E%E<+FKX4U?3QX.5OMI/V.+==2%6S&QRQZCD\G
MIG\:N>&;/3-,T#S-+N9);*5FG,UP<'T)/ P/E[BLOQM'9Z+X+G@L+6&W6YD2
M+$2A<GKDXZG"FL_6[:>9O#_A"%_(22%6N@N.0HY_]!8^YQ2W&=#_ ,)MX=\[
MRO[3CW9QG8^W_OK&*VFN(EM3<^8IA">9O7D%<9R,=>*Q)_!_AY-)>"2QBCC1
M"3,!^\7 ^]NZ^^.GM5'X=NUUX-\FY DB25XE5ER"AP2#ZC+&EI;0-3H=,U6R
MUBU-SILWG0ABA;8R\CM@@>M7*BMK2WLH?*L[>*WCSG9$@49]<"BZN%M+.:XD
MQMAC9VR<< 9I#.-\/,-4^)&M7_WDMU\E""<#D+G\0A_.NWKC?AK ?[$NKZ3F
M6ZN22?4 ?XEJ[*G+<2.(UAAJ7Q2TJS#-LLT\UAV#8+?KA:[>N)\,?\3+Q]KN
MI%ED2$^0C#GC. 1^"=??WKMJ&",:_P#%VB:7?26=]>^5/'C>GE.V,@$<A<="
M*K?\)[X:_P"@E_Y D_\ B:SM>\1^&+#7+BVU31OM-TFWS)?LL3[LJ".6.3P0
M*SO^$O\ !?\ T+W_ ))0_P#Q5.P7/0+>XCN[6*XMVWQ3('1L$94C(.#[5%J-
MV+#2[F[;&((FDY[X&<4NG30W&EVLUI'Y4$D*/%'M"[5*@@8' P.PK"\?WGV3
MP?<J" T[+$O/J<G] :7496^&UL8O#+W#Y+W,[.6.>0./Y@UUU9OAVT%CX;T^
MW P5@4M_O$9/ZDU!XMU1]'\,W5S"VV8@1Q'T9CC(]P,G\*'JQ;(=J'BK1-+N
M#!?:A&DH^\BJSE?KM!Q^-7=/U.RU6W\_3KF.XCS@E#R#Z$=1^-<[X9\':9#H
ML,VH6L=W=7,>^1YAOQNYP,]/KUSGFJ.AVL.D?$V^L--4K;-;;GCZA#\I_#K^
MM.R#4Z[3-6LM9M6N=-G\^)7*%MI7#  XP0#W%,M-<TZ^U*?3[6Y$EU;Y\U C
M#;@X/)&#SZ5Q7A[53X=T#Q")-H>TNR$3<.9#\N/?[OZ&CPU:-X?\81I?C;+/
MI9FF9FY#%MS$^XVD?A18+G;S:O8V^JP:;+/B\N%W1Q!&)(YYR!@=#U]*KZEX
MFT?2)_)U"^2*7C*!6=AGU"@XKE;*]D^R:WXSF7YV!AL0_15!"@_G@?@WK6-H
MTDD$ N;OP==ZO<SDR-=3!V60-R" 4(Z'KSGK1RA<]-T[5++5K?S].N4GCS@E
M3R#[CJ/QJ.YUS3;._-G<W2QSK$9F4@X5!W)Q@=/6N+\+1WH\;M<PZ)=:197$
M3"6)HV\O/7J5 '/04L.FQ^)_B-JCW.39VH6.1 >'(P I([94G\,46"YV>EZY
MIVL^=_9EQYXA(#D(R@$YQR0,].U5?%U[]@\)ZA*#AFB,2\XY;Y>/?G/X5I6=
MC:Z?!Y-C;Q6\><E8D"@G&,G'4\#FN3^)4['2+.PC(\R[N1@9Z@#_ !84EN'0
MU?!5I]C\'V*X(:1#*<]]Q)'Z8K;FF2W@DFF;;'&I=V] !DFDMX$MK:*"+A(D
M"+GT P*Q?&M[]B\(7S!MK2IY*\==QP1^6:-V&R(=!_L+1M#NM4LKN:2SFD,D
MMS.K9)SC@;1QG/0=2:LW'C'0;5(FGU!4\U Z#RW+;3R"0!D9'//:N9U_=IGP
MOTVPB;,EUY:E>YS\Y_7 _&K]UX6T?0O!=VUU;137"VIWW$@W,9,8&T_PC<0!
MC';-.R W[OQ'I%C:17-SJ$*Q3#,9!W%QZ@#)-3Z;JUCK%N9]-N%GC!P2 00?
M<'D5RO@OPG8-H5M?:G;"YGF4LBSC<L:$G "GCG.[IWJ+P/(EKI^OZM%$$M/.
M9XHPW 5 S8'MA@,XHL@N:4%UX>M-8U37_P"T97DCQ;W)924C.0 % 7)^[V)]
M:SO >NQ7^H7YO+MGOKR7='&RMQ&H)'; ')XSVJGH\,5O\+M2OKRWBD:X>21#
M(JM\WW%/.>C9Q_\ 7KH_!FC6UAX=L9S:Q+=R1;VFV#>0W(&[KTQQ3>PC5T[6
MK#5GG73Y_.-NVV3Y&4 \]R!GH>E7J@M;&TL49+*UAME8Y80QA 3^%3U!1Q?B
M+6]2U+7!X=\--LE S<W*G'ECN,]@,C)'.>!SU9_PK*T:)GFU2[>[/_+;C&?<
M<G_QZF?#M%FU#6[R3YIVGP23V)8G\S_*NZJF[:(6YR_A-]:L[JZT?68Y9H[8
M9@O&4[77TW'KU!]1R.U4+#&I?%F]G ^2Q@V*2!][ 4_^A-780WUI<B4V]U#*
M(3B0QR!MA]\=*Y#X=(;K^U]6D'S7=S@$@#U8_P#H?Z4=V!VU<[_PGOAK_H)?
M^0)/_B:Z*O._^$O\%_\ 0O?^24/_ ,522N#.FM_&OA^[NHK>WU#?+,X1%\F0
M98G &2OK6]7":=XI\)7&J6L-IH7E3R3(D4GV.)=K%@ <@Y&#W%=W0U8$8WB?
MQ!'X=TAKDJLD[G9#&3]YO4^PZ_IWKF[/P7J&OQK?>*]1N1))\RVR8!C';KD+
M] /UI_C%%NO'&@6MQS"6!*YZY?G\\"NZI[(-S@CHNJ^#-2@N-%>YU'3YGV36
MVPLRCUP/;^+ QT[UVM]?VNFVQN+^=((@<;G.,GT'J:=+>VL%Q'!/<PQS2_ZN
M-Y &?Z \FN*%F/&'CJ^%^Q?3])/EI"&P"V<'/U*L3] *-]PV.BL?%VA:C<I;
MVFH(TKG"JR,FX^@W <UHW]_;:78R7E])Y4$>-[[2V,D <#GJ17'^.O#^CV?A
MM[RVM([6YB9%B:$;=WS<@@=>,G/7CK3/&EW/>^%=&M/O76HO&2.FX[1GC_>8
M4607.ANO%^@V;(MQJ,:LZA@H5F(!Y&0!Q]#BK%UXATNRTR'4;B[46DS!8Y55
MG#$@G' )['\JR9O"^B:-X9NS+:0S/';NSSS*&=F"GD$YP<^E8%G!#9_".6>\
MA@E:0NT/FH&*%FV C/0]\BBR#4H^&[73?$FJ27>LZI<C4WE,B1IP JC.2Q4C
M';'& *[;PS!I(6_U32;R:Y2\F+S23#: PR3C*CCYJR8K&UT'X;->&T@^V-9D
M--L ?,G0%L9XW#\JRKKS[/P#H>C6NV.?5Y/F/'S*S9Y_[Z3\!BGN+8[ ^+]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB*95VV]L!_JQR,X[=3@>IS78T4KA8X>6Y\3>&];O'6QN-8L+B0M$!*SF,<X
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MV[R5=E>;H=K="1^ %'B72]5LO$D'B'0X/M3(@2:$<DCIP.IR#VY%=E11<+'
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MKO4OB%HZB"8V=HOFM-Y3>6KY+8STR=J#\:Z^BB@#B]/LKW0?B'<K#;SMIFH
MN7CB8QHQR1DC@8.1]&JK>Q:OX>\;7FJP:3+JL-TOR,@)9,@<9 .,8QTZ8KOJ
M*+BL>9ZX?$OB&6RDO=)GMK%;@8@C1F;KRS#KP.,X'4UK^+5U"W\6:7J5MI4V
MHV]M&V$A!)W\]< D8^4].:[6BG<+''^*K:[UB[\/VWV2X\EYA+=JB,RQ?=X+
M8QW8<_UIWBW2]436++7]#C$]Q:*8WAQDE>>@[_>(/?GBNNHI7"QP5_JGB?Q+
M&VF6NB2Z7%,-DTT^[[O?D@<8] :U[NX'@;PU:0V5C)?*C;78'8 3U=C@XR2
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M2(L.A4@@G\1R:YFPU[Q1I&FII<GAV:YFMU$<<ZJVS:.!G:,' [Y%=]12N%C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img70551829_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_16.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,W-0  DI(
M @    ,W-0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$(!2 +@@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M*9QND<*,^F30!+152VU73[V3R[._MKA_[L4RL?R!JW0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY 0(<8R >3D_EZ5S'P[_ .1Q@_ZYR?\ H-.VCL(]@JI<ZKI]E)Y=Y?VUN_\
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M[ZGX'^V2X\R6R8N1W;:03^8KS3P%_P CO8?]M/\ T6U"V8/<ZCXJ?\>.G?\
M71_Y"K?PO_Y%BX_Z_&_] 2JGQ4_X\=._ZZ/_ "%6_A?_ ,BQ<?\ 7XW_ * E
M'V0ZG9UC^*=8;0_#\]W%_KN$BR,@,>A_K6Q4<UO#<H$N(8Y5!R%D4,,^O-04
M>-:#H5]XPU.=I+HC8 TT\N7/)X&.YZ^G2G^(O#5WX2O+::.Z\U'.8IT&QE88
M[9./SKU^VLK6SW?9+:&#?C=Y487=CIG'UKR_XA>(8-6U"&SL7$D%INW2#H[G
MKCU QU[Y/M6B;;):LCN/">N_VMX72\NV D@W1SMCC*C.?^^2"??->;W5S?\
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M:O#+"XN_#GB1<,5FMI_+E53PV#@CW!KW.AJP)W"BBBI&%%%% !1110 4444
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M7?ZY?V]V=?61&C95C$D'EGH23T'J.U=/7/Z!XC:^\*-K&J^5"(RY?R@0,+Z
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MMBME=K'&"#W K#\)^/;N]U2+3]8V/Y[;8YE7:0V. 0.,'^9J_P#%#_D6+?\
MZ_%_] >BUGJ%]"7P!KFHZW:WKZG<>>T3J$.Q5P"#Z 5UU<#\*_\ CQU'_KHG
M\C7?4I;@M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#RKXH?\ (SV__7FO_H;U8UFS\_X4Z5<J
M#FV8$X'\+$C^>*K_ !0_Y&>W_P"O-?\ T-ZZO3; WWPOCM "7ELVV!>[<E?U
MQ6G1$]3S"YU1[C0[+3B&Q:R2,"3D$-@@8[8(;\ZZGQ59_8?A_H,&<G.\\8Y9
M2Q_4UR.F69U#5;6T7K/*J9] 3UKTGXH(I\.6KD?,MV #[%&S_(4WNA="+X6_
M\@F^_P"NX_\ 0:\^TRWN;G6;>WM9_L]U)*%24N5VM]1S7H/PM_Y!-]_UW'_H
M-8OBWPEJ&F:Q)J>D12/;-)YRF$?- W4\#H >01TI7U8="^_@[QE(C(^OAE88
M93>S$$>GW:F\,>!-4T7Q%;7]S<6C11;]RQNQ8Y0@=5'<BN<N_&^O:I8-IKE"
M9 4<Q18DD!Z@_P N *ZOP!X?U*P\R^U1YX5==L5LSD9_VF7] #ZGVH=TAZ7,
M?XI?\AFR_P"O<_\ H1KK? 7_ ")%A_VT_P#1C5A?$S2+JY%I?VL+RI$K1R[%
MR5YR#].O^367X+\3:HMSI^B01HUJLIW,L9+A223D],9)/3\:6\0ZGJ=5-5_Y
M U[_ ->\G_H)JW535?\ D#7O_7O)_P"@FH*/(_ :AO&VGA@",R'D?],VKU;Q
M#_R+&J?]><O_ * :\J\!?\CO8?\ ;3_T6U>J^(?^18U3_KSE_P#0#5RW)6QY
MA\._^1Q@_P"N<G_H-/\ B.KCQ<Y<$*T*%,CJ/_UYIGP[_P"1Q@_ZYR?^@UVO
MC?PK)K]O%<6.W[9 "H5CCS%/;/;'7\33;M(70U_##QR>%=,,)4K]F0';_>"X
M;]0:Y/XJ.GV?3DW+YF]SCOC KG--\2Z]X25[(PA4!SY-U$?E)[C&#S]<4D5G
MKOCC5EFF#,.%,Q3;'$O)X_6A*SN.^ECJ? X8?#W4BW0O,5^GEC^N:Y/P&H;Q
MMIX8 C,AY'_3-J]0&F0:/X2GL;;E(K:0;B "QVG).*\P\!?\CO8?]M/_ $6U
M"ZAV/5?$/_(L:I_UYR_^@&O,/AW_ ,CC!_USD_\ 0:]/\0_\BQJG_7G+_P"@
M&O,/AW_R.,'_ %SD_P#0:2V8/<ZOQEJ7B>SUB*/0$N6MC &8PVHE&_<V>=IY
MP!Q6+9ZUXZ>^@6XBOO*:10^;  ;<\\[..*]/HI7'8\J^*'_(SV__ %YK_P"A
MO7<^#/\ D3M._P"N9_\ 0C7#?%#_ )&>W_Z\U_\ 0WKN?!G_ ")VG?\ 7,_^
MA&F_A$MSRKPH,^+--SS_ *0O\Z]FU7_D#7O_ %[R?^@FO&?"G_(VZ;_U\+7L
MVJ_\@:]_Z]Y/_031+<(['DG@+_D=[#_MI_Z+:NL^*7_()L?^NY_]!KD_ 7_(
M[V'_ &T_]%M76?%+_D$V/_7<_P#H--_$+H'PM_Y!-]_UW'_H-<IX^!'C:^ST
M(CQ]/+6NK^%O_()OO^NX_P#0:?X^\)W&JLFI:9'YEQ&FR:(8!=1R"/4CD>_&
M.E%[2'T,VU\*>+Y;.&2W\0!87C5HP+R884CCC;Z56E^&VOS3---?6<DK'<SO
M-(6)]2=M4+3QIK^B6?\ 9K;1Y0V(+B([X@.W;Z<YQBKOA#0-9U'6DU"Z>ZMK
M82&624NR-,<Y('<Y).3]>]&J%H=#\4/^18M_^OQ?_0'JI\*P/L>HGN9$'Z&K
M?Q0_Y%BW_P"OQ?\ T!ZJ?"O_ (\=1_ZZ)_(TOLCZG6^(?^18U3_KSE_] ->8
M?#O_ )'&#_KG)_Z#7I_B'_D6-4_Z\Y?_ $ UYA\._P#D<8/^N<G_ *#0MF#W
M'_$=7'BYRX(5H4*9'4?_ *\UZ3X8>.3PKIAA*E?LR [?[P7#?J#61XW\*R:_
M;Q7%CM^V0 J%8X\Q3VSVQU_$UP^F^)=>\)*]D80J Y\FZB/RD]QC!Y^N*-T&
MS.C^*CI]GTY-R^9O<X[XP*O_  R##PM*6Z&Z<K]-J_US7&16>N^.-66:8,PX
M4S%-L<2\GC]:]8TG3(-'TN&QMN4B&-Q !8]R<4/16!;W/&O"H#>+-,!_Y^%/
MZU[C7AWA3_D;=-_Z^%KW&B>X1/#O%?\ R-NI?]?#5[!XA_Y%C5/^O.7_ - -
M>/\ BO\ Y&W4O^OAJ]HU*U-[I5W:J0#/"\8)Z#<I']:)= 1Y1\._^1Q@_P"N
M<G_H->JZI8KJ>DW5D_2>)D!/8XX/X'!KQ>QN]1\*:V)S;>7<Q!E,=PAP<C'J
M/T->O>&;ZZU+P[:W>H+MN)-Q<;=O1R!Q] *)=PCV/+_"-[+H7C**&X)C#2&V
MG4G !)QS]&Q2ZBQ\5>/VCB.8Y[@1*RJ>(UXW8_W03_A5KXBZ5_9_B,7<61'>
M+YGT<<-C]#^-7_AAI0FO+G5)5.(!Y41P<;B/FY]AC_OJJZ7%Y'I$,*6\$<,*
M[8XU"(OH , 4^BBLBS \5>%8?$ELG[SR+F'/ER;<Y_V3[9_*O/;SP'XAT]F>
M& 7"KC#V\G)^@.#^E=7X]\/:E?F.^TEII=J[)K=)#R.S*N?J"!_C7+V'C;7M
M!MEL)(XW6$;%2ZB;=&!_#P0?SZ8%:*]M"78;8>+O$'A_4O+U&2XF52/-M[LD
MMCV+<CK]/K7?^*KA+OP'=W$6=DUNLBY'."017G,&G:UXSULW$D;9E(\R<IMC
MC7''Z#IWKU/5]*^U>%KC3+4<_9_+B!/<#Y1^@I.UP1Y]\+_^1GN/^O-O_0TK
MM?%WB8>&]/C>.-9;F<E8E;[HQC)/?'(_.O+M)U34?"NK/+%;A+@H8FBN(ST)
M';(/4"NP\2:7JGB3P=I>H^6\EY"K-)"$PSAL<@?\!''H:;6H+8I6#>,_%B&Y
M@OS:VQ;:'63REXZX"_,?K^M<WXCTB;1=6-K=7/VF8HKM)SW^O7I5S0O%>L:%
M;OI]C%'('8LJ21%F1L<XP1^N>E5?$-GK$=Q%?Z\K+->@L-XP?EP,$=N,<4UN
M+H>G?\TQ_P"X/_[1K@?AX,^,H,]HY,?]\UW%K=17?PM=X3D)I;Q-[,L94_J*
MX?X=_P#(XP?]<Y/_ $&I6S'U1Z)XS_Y$[4?^N8_]"%<-\+_^1GN/^O-O_0TK
MN?&?_(G:C_US'_H0KAOA?_R,]Q_UYM_Z&E"^$'N4/'X8>-KTMG!$97Z>6O\
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M'CU#7HR&4AHK4_H7_P /S]*\_M+J:QNXKFU8)-$VY&*AL'UP>*W/^$]\2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+2HL@D>9D*@X' &>>YSD4[68NAI?"LG[!J SQYJ<?@:Y;Q[_ ,CO?_\ ;/\
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MB?:0OH-O=%!YT=P$#]]I4Y'Y@?E7/^!O%UMH2366I;UMY7$BR*N=C< Y'7&
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MZZ/_ "%6_A?_ ,BQ<?\ 7XW_ * E'V0ZF5\58$6YTR<??=)$/T4J1_Z$:UO
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M3>Z$MBI\*_\ CQU'_KHG\C7?5P/PK_X\=1_ZZ)_(UWU3+<I;!1114C"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"\94]A7344786([>%;:VB@0DK$@12>N ,5S.H?#W2M2U&>\GN+Q9)W+L$=
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MZ=K\*IJ$1+)]R5#M9?H?Z&LBS^'.A6DXD<7%UCHD\@*_DH&:ZNBB["QR]_X
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M_4+A((^Q8]?H.I_"D!:HK"A\;>'9YA$FIQACW=&1?S8 5N*P90RD%2,@@]:
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MZ$DTQ7[5$?+G &.>S8]Q^N?2O*_%?_(VZE_U\-22ULQMGI__  GOAK_H)?\
MD"3_ .)JW8>*M$U.98;/4(GD;[J,"A8^@# 9/M7/0?#/2)K..3[5>J[QAOOI
M@$CTVUQWBOPT_AG4(D68S03*6BD*X.0>1]1Q^=.R8KL]IJCJFM:?HL*2ZG<"
M!)&VK\I8DXST )K-\$:M+J_AB*6Z<R3PN89')Y8CD$^^"*XOXF:D;G7HK%2=
MEI'\PQ_&W)_3;22UL.^AVT'C?P]<7$<,6H@R2,$4&&09).!R5P*WJ\(U32KC
M1I+3S3@W%NEPA';/;ZBO:-#U$:KH5I>CK-$"W^\.&_4&B2ML"9?HHHJ1C)IH
M[>%I9Y$BC099W8 */<FN7N_B/H-M*4C-Q<X.-T,8Q_X\17&^./$4^L:P]C Q
M^R6TA140Y$C@X+>_H/\ Z]=+H7PWL8K-)-<#3W+#+1+(51/;(Y)]\X_K=DEJ
M3=]"Y;?$C09Y%60W-N#_ !2Q<#_ODFNIAFCN(5E@D26-QE71@0P]B*X+Q1\/
MK2+3I;S0P\3PKO:!G+*R@<X)YSWZU1^&U_?0:DUB89GLIU+[MIVQL!][..^,
M?E2LK70[OJ=_JNN:=HD<;ZG<>0LI(0[&;)'T!JC;>-?#]W=16UOJ&^69PB+Y
M,@RQ. ,E<5SWQ4_X\=._ZZ/_ "%>=1F2 QW"<8?Y6]Q@_P!1344T)O4^@ZQ]
M1\5Z+I-XUKJ%YY4R@$KY3MP>G(!%:-C="^TZVNU7:L\2RA<YP& ./UKQ'7KP
MZKX@U"\0ET:4E6)_@!VK^F*45<;=CV'2_$NDZU</!IEWY\B+O9?+=<#.,\@>
MM)JGB;2-%NEM]2N_)E9 X7RG;*Y(SD ]P:X+X7?\C!=_]>I_]"6F?%#_ )&>
MW_Z\U_\ 0WI\JO85]#L_^$]\-?\ 02_\@2?_ !-.3QUX<D;:NI*#_M1./U*U
MS/ASP#I>K^'[6^N9[Q99@Q81NH488CC*GTI=?^'-G8Z-<7FG75P9+>,R,DQ4
MAE')Z 8XSZT6B&IZ!:W=O>VZSVDR31-T=&R*EKR;X<:G-;>)%L0S&"[1@4SP
M&"[@WUP"/QKUFI:LQIW"BBHKBY@M(3+=31P1CJ\CA0/Q-(9+17/GQUX<$FS^
MTESG'^J?'Y[<5M6EY;7]N)[*>.>(\;XV##/I]:=F!*S!5+,0% R23TK!F\<>
M'8)6C?4T+*<$I&[C\P"#5/Q]JMO!X9N[-+J(74FQ3$)1O"E@2=O7&!^M>?\
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M#/)  YYQ]*?*MA79Z]16!X+U9]8\,02SNSSQ$PRLW5B.A]^"/QK?J"@HHHH
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MRZOO#L\E[<S7$@NF4/-(7(&Q.,GMR:=M+BOK8ZRBBBD,**** "BBB@ HHHH
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MLM;YON[< %AN7 'H25_$UZ)2:L""BBBD,**** "BBB@ HHHH **** "BBB@
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MC/\ NGE3^N/PJYXVTW^T_"ETJKF2 >>GU7K_ ..YKRW0]=DT>UU.).1>6QB
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M;B*$'YI&]![>I[5Y3H=A<^*O%@:<;Q)*9[EL<!<Y(_'H/K4T%KK'CW79)68
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M.BK ^3^8 KS+7]3;Q'XDEN;:%_WS+'#'CYB.@&!W-=^/AAHH/_'S?'V\Q/\
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MFE+<:V"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ@5:^)6N36EI#I=OE?M2EYG]4!P%'U/7Z>YIO71"6FI@ZU?7/CKQ7'8:<?\
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M'H<=J;O8$+XT\6MX>BBMK((]Y,I;YQD1KTW8[G.<?2N*M5\:ZK:F_M)]1DA
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MO8D>I[?2N+MY/&FN(]Y:3ZA(@!):.7RE./0 @'Z"J7C*=[CQAJ#2$G;+L'L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5V1,ENY5B0"QZ>O&1Z"O4**+ZW"VAB>$-+.D>&+6"5-DSCS90<Y#-S@YZ$#
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MDY.0""?<\_3BO3ZP[GP9X>NYC+-ID88]?+9HQ^2D"DFK68[=CBH/'/B'5?$
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M?Q(CLM)CM=2M9998(]D<D1'S@# W9/'UY^E<AKNISZSJTNHW$1B$_,:]0%'
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M[Z427MA;7$@7:'FA5R!Z9(Z<FH5T#1T<.FDV*LIR"+9 0?RK0HJ2CS3XJ?\
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M  [ 4ZBG=L KE;?X>Z5;:I%?I<7AEBF$R@NFW<&S_=Z5U5%%P"BBBD 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?:G;Z=-91W)8->W MH=JYR^QFY]!A#5N@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQNL .WS[AE^XOL6!/L 3VKE?@3X-OKRXO/B7XNS+K.N$O:[L_NH&Q\P!Z;@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX>(IU8QRQCT#J0<>QX]JR_"GP;\$>#=474M&TG-\@(CN+B5I6CS_ '03@'W
MS[T >,_'GP-=Z)\)O [A2_\ 8L'V*\* L%=T0[L]EW(P_P"! 5V%A\>?"T'P
M6BFDU)/[=ATT6WV JWF-<"/:.Q^4D9W=,>_%>SW^GVFJZ?-8ZE;175K.NR6&
M9 R./0@UYN/V=?AN+W[1_8TQ7=GR/MDNS_T+./QH XG]E'P[<6^E:YXAN(V2
M&[>.UMBP(WA,ER/4991GU5A70_'?QQ>Q0VGP_P#"6Z;7M>(CD$1YAA8XQ[%N
M1GLH8\<&O7K*RM=-L8;/3[>.VMH$"10Q*%5%'0 #H*XSPW\*M,T'X@:GXQN;
MZZU35[]FV2707%NK=0H _N@*#V48'4T >3?&+P2GP\_9ZTC0]+^<?VI&^I7"
M+CSY3%)EC_LY  STPHK*^,*:"VD_#D>"!IXU5E40_80N_I%LW;>?O],\YW>]
M?3.N:'IOB31;C2=<LX[RQN5VRPR9P><@@CD$$9!&"#TKC_#7P2\"^%-;CU;2
M])9KR%MT+W$[RB(^J@G&?<Y(H [^BBB@ KQ+]JO_ ))7IO\ V&8O_1$U>VUX
ME^U7_P DKTW_ +#,7_HB:@#TGX<?\DK\*?\ 8&L__1"5TE<W\./^25^%/^P-
M9_\ HA*Z2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KQ+]JO_DE>F_\ 89B_]$35[;7B7[5?_)*]-_[#,7_HB:@#TGX<?\DK
M\*?]@:S_ /1"5TE<W\./^25^%/\ L#6?_HA*Z2@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS)E%233/,/\ A ];_N0_]_11_P ('K?]R'_OZ*]/HKS_ .S*'F<WU2F>8?\
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MCZI3/)+[PMJ6G2V<=RL8:]N!;0[7SERK-SZ#"&KG_"!ZW_<A_P"_HKJ_%O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX%_Z":Z6N:TG_D*0_P# O_0372T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!S?BW_ )"'A?\ [#*_^D\]=)7-^+?^0AX7_P"PRO\ Z3SUTE !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XE
M^U7_ ,DKTW_L,Q?^B)J]MKQ+]JO_ ))7IO\ V&8O_1$U 'I/PX_Y)7X4_P"P
M-9_^B$KI*YOX<?\ )*_"G_8&L_\ T0E=)0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<5
M\5-5\7Z9X3A7X>V#7FL7EVML&$0?[.A1V,GS?*,%5&6^7YOI7BGB7P3\==,T
M2Y\27WB^>7[+'Y\UI9:G*KJJ\L?+"K&<#)(!.0._2@#Z@HKP/]GOXNZWXNU2
M[\->*)OMMQ#;FYMKPJ Y56561L<'[P(/7@YSQ7OE !1110!Q'BO_ )*+X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#-\1ZO_PC_A75=9\C[1_9UE-=
M^3OV>9Y:%]N[!QG&,X-?,?C#]I[4?$?AB]TC2_#T>E->Q-!)<->&9E1AAMH"
M+@X)&><5],ZUXHT/PY-9QZ]JEOIYO7,=N;A]BNP&2-QX'4=2.M5?%L?AB^\)
MW3^+?L,VC^4S/)<;2H&.JD_Q>A'.<8YH \6_9?\ #6A6WV_78=;M;_69(1 U
MG#O5K2(D$[@P!))"C(! Q@$Y-?0ES*\%K++%!)<O&A988BH>0@9"KN(7)Z#)
M ]2*^)_@$;X?&O0QIQ<9:7S]N<&+RVW;O;IU[X[XK[<H YO_ (2C5_\ H1/$
M'_?_ $__ .2J/^$HU?\ Z$3Q!_W_ -/_ /DJNDHH \VU35+O4OB+HOVS0M0T
MCR]*O]OVV2W;S<RV>=ODROTQSG'48SSC8J'Q7_R47P__ -@K4?\ T;9U-0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %S2?^0I#_P+_P!!-=+7
M-:3_ ,A2'_@7_H)KI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BM7
M\<W.G:M<6:6<3K"^T,6.35/_ (6-=_\ /A#_ -]FNSFT/2[B9I9["WDD<Y9F
MC!)-1_\ ".Z/_P! RU_[]"O-E1Q;DVJFARNG6OI(X#5/&%QJD^FRR6L<9L+L
M72A6/SD(Z8/M\Y/X5H?\+&N_^?"'_OLUH>)M(T^UOO#JV]E#&L^K+%*%0#>G
MD3':?494'\*W_P#A'='_ .@9:_\ ?H5/L,9_S\_K[A>SK_S'(?\ "QKO_GPA
M_P"^S1_PL:[_ .?"'_OLUU__  CNC_\ 0,M?^_0H_P"$=T?_ *!EK_WZ%'L,
M9_S\_K[@]G7_ )CD/^%C7?\ SX0_]]FC_A8UW_SX0_\ ?9KK_P#A'='_ .@9
M:_\ ?H4?\([H_P#T#+7_ +]"CV&,_P"?G]?<'LZ_\QY]K?C"\UJR%JT201;L
MN$)._P!!]*Y^O3/$/@^UO=/_ .)5;0V]S&<J%&T..X/]*X%]$U2.?R6T^Y\S
MG $3'/T]:\K%T:\9WJ:^9Q5J=12][4N:#XGNM!65(D6:*3G8Y( /J*V/^%C7
M?_/A#_WV:T?"_@Y+>W>?6K>.26082)QN"#U/O_*M[_A'='_Z!EK_ -^A7=0P
M^+5-6G9=CIITZ_*K2L<A_P +&N_^?"'_ +[-'_"QKO\ Y\(?^^S77_\ ".Z/
M_P! RU_[]"C_ (1W1_\ H&6O_?H5O[#&?\_/Z^XT]G7_ )CD/^%C7?\ SX0_
M]]FC_A8UW_SX0_\ ?9KK_P#A'='_ .@9:_\ ?H4?\([H_P#T#+7_ +]"CV&,
M_P"?G]?<'LZ_\QR'_"QKO_GPA_[[-'_"QKO_ )\(?^^S77_\([H__0,M?^_0
MH_X1W1_^@9:_]^A1[#&?\_/Z^X/9U_YCD/\ A8UW_P ^$/\ WV:/^%C7?_/A
M#_WV:Z__ (1W1_\ H&6O_?H4?\([H_\ T#+7_OT*/88S_GY_7W![.O\ S'(?
M\+&N_P#GPA_[[-=MI5XVH:3;7;J$::,.5'05!_PCNC_] RU_[]"K\,,=O"L4
M"+'&@PJJ, "NC#TZ\)-U971I3C4B_?=Q]%%%=AN%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M47U^8G.0: /=:*** "O$OVJ_^25Z;_V&8O\ T1-7MM>)?M5_\DKTW_L,Q?\
MHB:@#TGX<?\ )*_"G_8&L_\ T0E=)7-_#C_DE?A3_L#6?_HA*Z2@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH Y;Q]\/-$^(VB1Z=KZS+Y+^9!<6[[9(FQ@XR""".H(/YX->
M/']DFT^V[AXOF^RY_P!5_9XWX_W_ #,?^.U]%44 <5\/OA3X;^'%O)_8L4D]
M[,NV:^N6#2NN<[1@ *N<< =AG.*[6BB@ HHHH XCQ7_R47P__P!@K4?_ $;9
MU-4/BO\ Y*+X?_[!6H_^C;.IJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH N:3_P A2'_@7_H)KI:YK2?^0I#_ ,"_]!-=+0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '-^+?\ D(>%_P#L,K_Z3SUTE<WXM_Y"
M'A?_ +#*_P#I//724 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\>V>N3?!3]H
M75[O6K">:UDEG4A,!Y+>5]Z2)G /1>_4$9XJO\;_ (MZ5\37TJ+1M,NK:+3C
M(WGW94.^_;E=JD@#Y!SGGT%?2NM^*?AMJ>HW.C^*-0T"6XL)-DMOJXC'EM@'
MCS1@]1R,U\__ !?UK2/B!XQ\.^"OAM;6SVEK(T:M8PA(7ED*@D!1C:BIDMTY
M;L,T ,^.-S(WPS^%<)9MO]B"0\_>)AMQD_K^9KZ=\&QHO@'08U11&-,MU" <
M >4O&/2O$_VH/#)M_ GAB[LU=K;1Y&LC@9VJZ*%)]/\ 4@9]3[BNH\)_&;PI
M8_!:PO;S6K0:EI^FK#)8-*HN))HTV@"/J=Q .>G/)'- 'BW[/6D+XD\1^)_#
M\TOE0:EX>GB9@H.QC)$%;\-Q-=6GPW^,<?@:3X;"PT@Z#)/O.HFX7@;Q)C.[
M?MWC/^KW?AQ5C]D_09OM.O>()(RL.Q+*%R/O'.]P/IA/SKO_ (Z?$.?PQH,/
MAWP\S2>(]=/D6Z1'YXD8[2XQ_$2=J^^3_#0!Y;J%O;^.?$VE?#ZQOQ!X)\%P
MAM5U%SL21X^)9"Q.!D[E7ZNW(KV[PQ\4_AWJ=[;^'?#6NV@DB46]M:B)X4(7
MY51"RA6Z8 4G/:O(/B)X$D^&?[-<&F6P5[W4-1@?69E.=QVLP4'^ZKJ@'XG'
M)K)^+6A>'M$^&OP^U#PK9VEKJT\<;K-9@"6?]VK%CCER'QR<D$X[T ?5]?,'
MBS]I7QCH/C36](L]-T-[?3]0GM8FE@F+LJ2,H+$2@9P.< 5].Q%S"AE $A4;
M@.@/>G4 ?)/_  U7XW_Z!7A__P !Y_\ X]7+?$#XU^(_B/H$&D:Y9:7!;PW2
MW2M9Q2*Y8*R@$M(PQASV]*^WZ\2_:K_Y)7IO_89B_P#1$U 'I/PX_P"25^%/
M^P-9_P#HA*Z2N;^''_)*_"G_ &!K/_T0E=)0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%<5\0OBKX=^&J68UX74TUYN,5O9QJ[[5QECN90!R.IYYQT- ':T5Q'P[^*^@
M?$S[<N@P7\#V.PRI>1*A(;."-K,/X3WKMZ "BBB@#B/%?_)1?#__ &"M1_\
M1MG4U0^*_P#DHOA__L%:C_Z-LZFH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"YI/_ "%(?^!?^@FNEKFM)_Y"D/\ P+_T$UTM !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNU#PGJ&FS6,=PT):^N1;1;7)^<HS\\<#"&KG_"O]8_O6O_?P_P"%<WUO$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7B7[5?_)*]-_[#,7_ *(FKVVO$OVJ_P#DE>F_]AF+_P!$34 >D_#C
M_DE?A3_L#6?_ *(2NDKF_AQ_R2OPI_V!K/\ ]$)724 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '+>+/AIX2\<WEO=>*=(%]/;QF.)_M$L152<X^1AGGUKA?&7P*^'NF>!-
M>O\ 2_#A2]M=-N)K9EO;ARLBQ,5.TR$'D#@@U['10!\F?LU>"=#\5:QJUYX@
MTW[8VF-;2V;F1U6.3<YZ*0&^ZO!R*^LZ** "BBB@#B/%?_)1?#__ &"M1_\
M1MG4U0^*_P#DHOA__L%:C_Z-LZFH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@"YI/_ "%(?^!?^@FNEKFM)_Y"D/\ P+_T$UTM !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV.L7ELMK-<ART*YPN'9>_/09K=H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\_ZK\3?'/Q5U"72?A!836&EQ.\<^MSC9O\
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M(2%4EB  ,DGM38Y8YEW0R+(N<95LT /HHIAFC641M(@D89"%AD_A0 ^BBB@
MHHIOF()!&77>1D+GG'KB@!U%%% !7B7[5?\ R2O3?^PS%_Z(FKVVO$OVJ_\
MDE>F_P#89B_]$34 >D_#C_DE?A3_ + UG_Z(2NDKF_AQ_P DK\*?]@:S_P#1
M"5TE !1110 4444 %%%% !7BO[2'_(%T/_KXE_\ 05KVJO%?VD/^0+H?_7Q+
M_P"@K0!['8?\@ZV_ZY+_ "%3U!8?\@ZV_P"N2_R%3T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7EG[0G_ "3BW_[",?\ Z!)7J=>6?M"?\DXM_P#L(Q_^@24
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MG  KYR^!\RZM^T3XZU?2OWFERBZ(F1\HY>Z5D;_@05V'IS0!]'4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B#Q;H?A4V9\1:E#
MIZ7LIAADG)5"P4M@MT48'4D"EU3Q1H&E:-+J6J:M90V*)N:5YE*L/0?WB>@
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M.ULU9;.VA@5CEA%&%S^5344*$4[I#44MD%%%%6,**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME^U7_P DKTW_ +#,7_HB:O;:\2_:K_Y)7IO_ &&8O_1$U 'I/PX_Y)7X4_[
MUG_Z(2NDKF_AQ_R2OPI_V!K/_P!$)724 %%%% !13)YH[:WDGF;;'$A=VQG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDUKQ?XLLKNQGO(F@C2[C\N29GD#R.4(!'*+C@ Y.* /H*BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-O# \<6/BVTT];+5K-I&,EJ BS[XV0^8N,'AB<C!SC)(XKJZ "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]&V=34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<TG_D*0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!4U75;'1-*N-2U:ZCM+.V0R332'"J/\\ =2>!7@.O_M86<4S1^&?#
MDUQ&#Q/?3B//_ %#?^A?A2_M'WE_XA\:^%? &GSB);]XYGR&V[Y)#$C-CJ%P
MYZ<<UZYX0^&GA;P5I<-II.DVS31IB2]FB5YYCW+.1GGT& .PH \7TK]K.3[4
MJZWX646Y)W26EU\ZCV5A@_F/\?>O"GB[1?&NA)J_AR\%U:,YC8[2K1N "493
MR",C\"",@@TS7_!7AOQ/ILECK>C6=S%(N,F(!TZ\JPY4C)Y![FO!OA/;W/PS
M_:,U7P&+J6;3[V-A$)%'SE8_.C<X[A-ZDC ))XZ8 /I:BBB@#*\5:M+H/@[6
M=8MXTDFT^PGNHTDSM9HXV8 X[9%?-'_#5_BC_H Z1_Y%_P#BJ^JV574JX#*P
MP01D$5!_9UE_SYV__?I?\* /EO\ X:O\4?\ 0!TC_P B_P#Q5'_#5_BC_H Z
M1_Y%_P#BJ^HUL+!AE;6W(R1D1KU'!I?[.LO^?.W_ ._2_P"% 'RW_P -7^*/
M^@#I'_D7_P"*KU;X)?%?5/B?_;?]K6%G9_V=]G\O[-N^;S/,SG<3TV#\S7HM
M@=$U6S2[TO[!>VTGW)[;9(C?1ER#5V*WAM\^1#'%NZ[% S^5 $E%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B7[5?\ R2O3?^PS
M%_Z(FKVVO$OVJ_\ DE>F_P#89B_]$34 >D_#C_DE?A3_ + UG_Z(2NDKF_AQ
M_P DK\*?]@:S_P#1"5TE !1110!1US_D7M1_Z]9?_0#7C5>RZY_R+VH_]>LO
M_H!KQJO S7XX^AYF-^)!1117CG"%<3\2?^/*Q_ZZ-_(5VU<3\2?^/*Q_ZZ-_
M(5VX'_>(_P!=#?#_ ,5'90?\>\?^X/Y5)4<'_'O'_N#^525QO<P>X4444@+V
MA_\ (PZ=_P!?47_H8KV6O&M#_P"1AT[_ *^HO_0Q7LM>_E7P2]3T\%\+"BBB
MO8.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"CK?\ R+^H?]>LO_H!KQJO9=;_ .1?U#_KUE_] ->-5X&:_''T/,QO
MQ(****\<X0KE?B'_ ,BW'_U\K_Z"U=57*_$/_D6X_P#KY7_T%JZL)_'AZFU#
M^)$VM!_Y%W3O^O6/_P!!%:%9^@_\B[IW_7K'_P"@BM"L:GQOU,Y_$PHHHK,D
MO:)_R,&G_P#7U%_Z&*]EKQK1/^1@T_\ Z^HO_0Q7LM>_E7P2]3TL%\+"BBBO
M8.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF8PP3V\Z+G@-(KJQQZXC7\AZ4 ?1%%%% !1110 4444 %%%% !1110 4444
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M6O&M$_Y&#3_^OJ+_ -#%>RU[^5?!+U/2P7PL****]@[PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BFK(CLZHZL8VVN <[3@'!]#@@_B*=0 4444 %
M>8?$SXZ:#\.KQM+2VDU;6556>TBD$:Q!N1ODP=IV\@ $\CH#FO3Z^2/@]X8M
M/BS\7M;\0>)HOM5E!(UZ]M*_$DDCGRT8=T4!N,X^51R"10!UFC_M96\NH)'K
MOAA[>U8X::TNO,9/?8RKG\Q^-?0&E:K8ZWI5OJ6DW4=W9W*"2&:,Y5A_G@CJ
M#P:X;Q]\(/"OB3PC>VUAH%A9:C';-]BGL[98F1P,JOR@9&1C![$XKYR\)?&?
M6/"7PHN?"VCO*=2FO";.?&[[+"P!<+G/);.!C@LQZXH ^D?B+\9/#7P\MVBN
M)AJ.K$'R].MG&\''61N1&.G7)YX!P:X#X*_$CQ3\2/BKJ-YK.Z/2K?3)5@MX
M(R((7::' +?Q/M!Y)SC=C S7._#O]G#4==G&M_$B:XMHYG,IL0_^D3DG),KG
M.T'G(^]SU4U]*Z3I&G:%IL6GZ-906-G",)!!&$4>IP.Y/)/4F@"Y1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%<YX^\8VO@/P7?:_>)YWV=0L
M,&['G2L<*N>W/4]@": .CHKY1\-Z9\5OCE+<ZQ+XDDTK2DD,:E)GAAW#G;'$
MGWL9'S-^9(->I?"_X;^.O!'BZ:77O%7]L:)):,BPM<RL5EW*0=C@@<!N0: /
M7**^8_VH];U73O&.BP:?J=Y:PFP+F."=D4MYC#. >N *9<_ _P"(EMX;_MG2
M?'$]S<+;BX2V6YFB=AMW;5;=C=V&<#W% 'T_17SU^SC\4]>\1ZM=^&/$MY+J
M)BM3<VMU,=TBA6561FZMG<""<G@\\C'T+0 4444 <1XK_P"2B^'_ /L%:C_Z
M-LZFJ'Q7_P E%\/_ /8*U'_T;9U-0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% %S2?^0I#_P "_P#0372US6D_\A2'_@7_ *":Z6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** .;\6_\A#PO_P!AE?\ TGGKI*YO
MQ;_R$/"__897_P!)YZZ2@ HHHH **** "BBB@ HK+U7Q'INC,$O)LRD9\J,;
MF_\ K?C4>E>*=+U>016TK),>D4HVL?IV-9>VI\_)S*Y'M(<W+?4V****U+"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MD?Q1?:S\%/VAM1\1-IYN[349Y[B(.Y1+J*8[F4. <%6('0XP."""?KBHKFUM
M[R'RKN"*>/.=DJ!AGZ&@#XS\1?&G^W_BYH?CC^P/L_\ 9,"0_8OMF[S=K2-G
M?L&W_6?W3T]Z[_\ X:Y_ZDG_ ,JW_P!IKT+Q%\'TUCXN:'XLM7L+;3].@2.:
MP^S?ZXAI"3QQT<=?2NPUR/PGX:T:?5M<LM.M+&WV^;,]HI"[F"C@*3R6 _&@
M#PW_ (:Y_P"I)_\ *M_]IKI?A]^T7_PG?CO3_#G_  B_V#[;YO\ I']H>;LV
M1-)]WRESG9CJ.M>B^&KKP5XPTV2_\-P:;?VL<QA>5+0* X 8CYE!Z,#^-;EO
MHVF6LZS6NG6D,JYVR1P*K#C'! ]* +E%%% %/5].CUC0[[3)\>5>V\EN^5R-
MKJ5/'?@U\W?LY>)%\'^,M:\"^(@+2[N9P(2Y  GCRK1Y/4L,;?7;[BOIVO%O
MC+\"SXTOCXC\*2Q6FN*H\Z%SL2ZVCY2&'W9.,9/!XR1C- 'M-%?($/Q$^-'P
M[8Z=JT-_)'$VQ1J=F9U../EF'+CCJ&(]*FC_ &@_BGKT+6^BV=N93G$EAIK2
MNN.N 2P[]Q0![]\8O&UOX)^'.H7!N!%J%Y"]M8(I&\R,,;@#V7.XGZ>H%</^
MROH,UAX#U+6)X?+&J786%R.9(X@5S]-[./J#7#^&/@GXX^)'B&/7OB9=7=I:
ML09/M;?Z5(@Y"*G2,<GKC'/RU]1:=I]II.F6VGZ= MO:6L2PPQ+T1%& /RH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"CK?\ R+^H?]>LO_H!
MKQJO9=;_ .1?U#_KUE_] ->-5X&:_''T/,QOQ(****\<X0KE?B'_ ,BW'_U\
MK_Z"U=57*_$/_D6X_P#KY7_T%JZL)_'AZFU#^)$VM!_Y%W3O^O6/_P!!%:%9
M^@_\B[IW_7K'_P"@BM"L:GQOU,Y_$PHHHK,DO:)_R,&G_P#7U%_Z&*]EKQK1
M/^1@T_\ Z^HO_0Q7LM>_E7P2]3TL%\+"BBBO8.\**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^5?$WC+XA?%KXF:AH/P_U"YM=.T]Y%C%G<FV5HU;899'!!;<<87L
M",#.2?JJOG7]E(>3+XPM[I66^26V\X.>3CSACKU!SGZB@#SF;PY\3+?XE1>!
MKCQ5=1:K/'YD3MJTWDN-A?AAR#A2.0.1[C-?QMX<^*?@B&)_$^J:JMC,P072
M:C)+"&/.&(.0>,\CG'&:]0^-[_\ "/\ Q]\">(E<1*YBBE) QL2?Y\_592,]
MN,5[1X]TNTUKX>Z]8:BJ&WEL)<EP"$(4LK\]U8!@>Q H Y[X+>"9/ _@-K:7
M5K?5O[1NCJ"W5L#L99(XP,$_>!"9SQG->@UY+^S5K,VK?!^&"<LQTR\ELU9C
MG*X60?@/,Q^%>M4 %%%% !7S+^R3_P A3Q1_UQMO_0I*^FJ^*?@Q\5++X87F
MK2ZAIUQ?+?QQ*OD.JE"A8\Y]=WZ4 ?:U?)W[+GAK3=7\9:GJVHP+/-I,,;6J
MN,JDCL?WF/[P"\>F[/4 CL_^&L=!_P"A;U'_ +_1UY/\&/BI9?#"\U:74-.N
M+Y;^.)5\AU4H4+'G/KN_2@#[6HKP'_AK'0?^A;U'_O\ 1UU_PU^-^F?$KQ)<
M:/8:1=V4D%HUT9)I%8$!T7''?YQ^5 'I]%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5X#^UC>.GA'0+(9V37SRGGC*1X'_H9KWZO#/VJ='FO/ .
MF:G#&76POMLI'\"2+C)]MRJ/Q% '"^!/'OQ0B\!:=I7P\\(!]-L(V#7CVS2^
M>Y=F<JQ*J>2?E )'K78?"K]H#5/$/C"+PMXUT^WMKN=FBAN(4:(K*O\ RSD1
MB>3@C(Q@X&.<C=^ ?CC0IOA#865YJMG:W6E>9%<QSS+&47>S*WS'H5(YZ9!]
M*\9TUD\;_M617OAW=):G6UNQ*J\&*%@S/QT#;#@G^\.YQ0!N?M7_ /(\Z)_V
M#C_Z,:GZG\?O'*>##96OA+^S4%J(?[0>*5MB[=NX9 4'N"<CV-,_:O\ ^1YT
M3_L''_T8U?0^F^(]!M/"=G)?:QI\4,=G'YK2W*!5&P9SDT >#?LM)X6BUB]F
MDU"0^)YH6BCM94V((<AF,9R=Y.U2>A !P,9)^D]0NIK*PDN+:PN-0E3&VVMF
MC61\D#@R,J\9SRPX'<\5\8>"4AU/]I&QD\%HT5@VMM/;A$VA;4.688Q\J^7D
M8/0'%?;% '-_\)1J_P#T(GB#_O\ Z?\ _)5'_"4:O_T(GB#_ +_Z?_\ )5=)
M10!YMJFJ7>I?$71?MFA:AI'EZ5?[?MLENWFYEL\[?)E?ICG..HQGG&Q4/BO_
M )*+X?\ ^P5J/_HVSJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** +FD_\A2'_ (%_Z":Z6N:TG_D*0_\  O\ T$UTM !1110 4444 %%%% !1
M110 4444 %%%% &9XAU.71]%EO($1W1E 5\XY..U<=_PL74/^?2U_P#'O\:]
M GMX;J$Q7,,<T9ZI(H8'\#57^P])_P"@79?^ Z?X5Q5Z5><KTYV1A4A4D[QE
M8XG_ (6+J'_/I:_^/?XT?\+%U#_GTM?_ ![_ !KMO[#TG_H%V7_@.G^%']AZ
M3_T"[+_P'3_"L/J^+_Y^F?LJW\YYUJ7B^[U.?3Y9K>%#870ND"Y^9@CI@\],
M.?RJ_P#\+%U#_GTM?_'O\:UO%&F6%O?>'%@LK:)9M66.4)$HWKY$QVG Y&0#
M@^@KH/[#TG_H%V7_ (#I_A1]7Q?_ #]#V5;^<XG_ (6+J'_/I:_^/?XT?\+%
MU#_GTM?_ ![_ !KMO[#TG_H%V7_@.G^%']AZ3_T"[+_P'3_"CZOB_P#GZ'LJ
MW\YQ/_"Q=0_Y]+7_ ,>_QH_X6+J'_/I:_P#CW^-=M_8>D_\ 0+LO_ =/\*/[
M#TG_ *!=E_X#I_A1]7Q?_/T/95OYSB?^%BZA_P ^EK_X]_C1_P +%U'_ )]+
M7_Q[_&NV_L/2?^@79?\ @.G^%']AZ3_T"[+_ ,!T_P */J^+_P"?HO95OYSQ
MZXN);NYDGN'+R2,69CW--CD>*19(V*NI!5@<$&NEU[P9>V5V\FFP-<6K$E5C
MY9/8CJ?K4.C^#M1U"Z7[7!):6X.7:0;6(] #SFO%>&K^TY>5W.!TJG-:VI<7
MXB:D$ :UMF(')PW/ZT[_ (6+J'_/I:_^/?XUVJZ#I*J%&F6> ,<P*3^>*7^P
M])_Z!=E_X#I_A7M?5\7_ ,_3O]E7_G.)_P"%BZA_SZ6O_CW^-'_"Q=0_Y]+7
M_P >_P :[;^P])_Z!=E_X#I_A1_8>D_] NR_\!T_PH^KXO\ Y^C]E6_G.)_X
M6+J'_/I:_P#CW^-'_"Q=0_Y]+7_Q[_&NV_L/2?\ H%V7_@.G^%']AZ3_ - N
MR_\  =/\*/J^+_Y^A[*M_.<3_P +%U#_ )]+7_Q[_&C_ (6+J'_/I:_^/?XU
MVW]AZ3_T"[+_ ,!T_P */[#TG_H%V7_@.G^%'U?%_P#/T/95OYSB?^%BZA_S
MZ6O_ (]_C1_PL74/^?2U_P#'O\:[;^P])_Z!=E_X#I_A1_8>D_\ 0+LO_ =/
M\*/J^+_Y^A[*M_.<3_PL74/^?2U_\>_QH_X6+J'_ #Z6O_CW^-=M_8>D_P#0
M+LO_  '3_"C^P])_Z!=E_P" Z?X4?5\7_P _0]E6_G.)_P"%BZA_SZ6O_CW^
M-'_"Q=0_Y]+7_P >_P :[;^P])_Z!=E_X#I_A1_8>D_] NR_\!T_PH^KXO\
MY^A[*M_.<3_PL74/^?2U_P#'O\:Z_P -ZM+K6CK=SHD;EV7:F<<?6I_[#TG_
M *!=E_X#I_A5J"V@M8O*M88X8\YV1H%'Y"MZ%&O"=ZD[HNG"I&5Y2N24445V
MG0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5YM^T'_ ,D)\0_]NW_I3%7I-<S\1?"3^.O
M.H^'(KM;)[WRL3M'O";)4?ID9SLQU[T ><?LJ?\ )+-2_P"PU+_Z(@KVVN%^
M$OP[E^&?A.YT:?44U%I[Y[H2I"8P R(NW!)_N9S[UW5 !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &5/XJ\/6UQ)!<Z[ID,T;%7CDO(U9
M2.H()X-1_P#"8>&?^ABTG_P.C_\ BJ\PUC]F/PMK.N7VJ3:OJ\4E[<27#HCQ
M;5+L6(&4SC)KP?XH^ =)\)_$.U\*>%+J\U&Z=(EE^T,A(FD/R1C:HQP5//\
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M2<C\!7DQC*3M%7.))MV1?KE?B'_R+<?_ %\K_P"@M6A_PE^@_P#013_OAO\
M"N>\::]IFIZ&D%C=K-()U8J%(XPW/(]Z[<+1JQKQ;B]^QT4:<U43:.KT'_D7
M=._Z]8__ $$5H5S.D>*=%M]$L89K]$DCMXT=2K<$* 1TJY_PE^@_]!%/^^&_
MPK&I0JN;]U_<9RISYGHS:HJM8ZA:ZE;^?8RB:+)7< 1S^-6:YVFG9F333LR]
MHG_(P:?_ -?47_H8KV6O&M$_Y&#3_P#KZB_]#%>RU[V5?!+U/2P7PL****]@
M[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBLGQ1XET[P?X;NM=UIY$LK79YK1IO8;G5!
M@=^6% &M7S5\0? 'CGX??$6^\;?#..XGLKUS/<0VJ^8T;,P+H\75T+98;1\H
MSTV@GW3P5XXT;Q]HLNJ>'9)I+6&X:W<RQ%#O"JQX/;#BN&_X:5^'?_/W?_\
M@&U %+XS?#[6OB%\+]%U&.#?XBTNW$\MJB%3(71?.15SPVY00#D_+@<FO(K[
MXW_$7Q%X;E\%"P#ZA(OV2::VMI?MD@'RLI7)^<GAB%'4C ->U?\ #2OP[_Y^
M[_\ \ VH_P"&E?AW_P _=_\ ^ ;4 ;GP7\%W/@7X9V>G:E&(M0N)&NKM 0=C
MO@!21U(55!]Q7?5SW@KQQHWC[19=4\.R326L-PUNYEB*'>%5CP>V'%=#0 44
M44 %<5_PIWX>_P#0IZ=_W[/^-=K10!Q7_"G?A[_T*>G?]^S_ (T?\*=^'O\
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MUTM<UI/_ "%(?^!?^@FNEH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#F_%O\ R$/"_P#V&5_])YZZ2N;\6_\ (0\+_P#897_TGGKI* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[;6UKX#\)[YO$&O8B80GYH86.,>Q?D9[*&/'!H \WD;2O'?BJUTQ[S[/\-O
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M^./H>9C?B05D:SX:L==FCDO3,&C4JOEL!Q^5:]%>5"<H/FB[,XHR<7='+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&9!@9SSN&#D9R:]2KQWQG^TCX7\+ZM+INF6L^MW$#M'.T#".)'!P5#$?-WY
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MSP3*4DBE4,KJ>""#P17GK? #X:M?F[/AP E]YC%W,(\YS]W?C'MT[8Q7H]%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQB6SQM\YVV]><8SQGH*V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH N:3_P A2'_@7_H)KI:YK2?^0I#_ ,"_]!-=+0 4444 %%%% !1110 4
M444 %%%% !1110!1_MS2?^@I9?\ @0G^-']N:3_T%++_ ,"$_P :XG_A76H?
M\_=K_P"/?X4?\*ZU#_G[M?\ Q[_"O+^L8O\ Y]''[6O_ "';?VYI/_04LO\
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M_P"%=:A_S]VO_CW^%>E]8Q?_ #Z.OVM;^0[;^W-)_P"@I9?^!"?XT?VYI/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\2_X:K\$?] KQ!_X#P?_ !Z@#S;_ (94\;_]!7P__P"!$_\ \9H_X94\;_\
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M@\Y8CMA3WKK?@#X)D\'?#6%[^!X=2U5_M=PDB[6C7&(T((!&%&<'H6:O3Z*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_0Q7LM>_E7P2]3TL%\+"BBBO8.\**** "BBB@ HHHH **** "BBB@ HHHH
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M$^C7NC+8WMO:-=--#-NCD =%P%(RI^<=ST/- 'KM%%% !1110 4444 %%%%
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MQ_R2OPI_V!K/_P!$)724 %%%% %'7/\ D7M1_P"O67_T UXU7LNN?\B]J/\
MUZR_^@&O&J\#-?CCZ'F8WXD%%%%>.<(4444 %%%% !1110!>T/\ Y&'3O^OJ
M+_T,5[+7C6A_\C#IW_7U%_Z&*]EKW\J^"7J>G@OA84445[!W!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=;_Y%_4/
M^O67_P! ->-5[+K?_(OZA_UZR_\ H!KQJO S7XX^AYF-^)!1117CG"%%%% !
M1110 4444 7M$_Y&#3_^OJ+_ -#%>RUXUHG_ ",&G_\ 7U%_Z&*]EKW\J^"7
MJ>E@OA84445[!WA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX/!("G /&2,@@8/C/A'X<?$CXG>&5\4S>.)X%NVD^S)/=S$OM8J3A>$&Y2,
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M\^]E_P!\/_\ %4?\+$U;_GWLO^^'_P#BJ/[2P_G]P?6J9Z117F__  L35O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+0 4444 %%%% !1110 4444 %%%% !1110!4_LK3_P#GPM?^_*_X4?V5I_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA' 3=(Q!^5F..O'L: /J3X<?\DK\*?\ 8&L__1"5TE<W\./^25^%/^P-9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_R47P__ -@K4?\ T;9U-0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %S2?^0I#_P+_P!!-=+7-:3_ ,A2'_@7_H)KI: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH YOQ;_R$/"__897_P!)YZZ2N;\6_P#(0\+_
M /897_TGGKI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N:\9?#[PWX]L!;>)-.2=T&(KE/DFA_W7'./8Y![@UTM% 'S/JO[-WBWPS=
MR7_PX\4N6Q\J&9[2XQTVAT.UN#U.WO\ C173/VC],D\N.74I0 0&-U;3 C/7
M+,?UYKZFHH ^6(_ 7Q^\4L(M6U>]T^ KM)N=5$:,,_Q)"23^*UV'A']F'2+.
M9+_QQJ<NMWC'S);>(E(2YY.6^^_.>?ESW%>[T4 5[&PM-+L(;+3K:*UM8$"1
M0PH%5%'8 =*L444 %%%% !1110 4444 %%%% 'R3]NA^&7[65Y?:V6M]/EOI
MY7E*' BN%8AA@?=5G&<?W2*UOVDO'F@>*K31-%\,W\6JSQSM/(]HV]5R-JKD
M<%CD\#ICWKW7QK\-/"_C^.+_ (2/3_-GA&V*ZB<QRH/3<.H]CD5D>$_@?X'\
M'ZHFI:?ITEU>Q',4U[*93$?55X4'T.,CL: /)_CIX.OM.^"7@:6XC)FT.%+2
M["#(C,D29)]@T87/J1ZUV?A3XW^%-/\ @O8W-YJ\2ZKI^G+;M8L<S231IL&%
M[AB <]!GG&#7K^H:?::KI\]CJ5M'=6MPA26&5=RNI[$5Y<W[-?P[-]YXL[Y8
M\Y^S"\;9],_>_P#'J .&_9/\/3J^N^(IHF6!U2S@<C[YSN?'TPGYUV_QV^(%
MSH6D6_A+PR6E\1Z]B"-(F^>&)CMW#T9C\J_\".>*]0TK2K'1-+@TW2+6*TL[
M==D4,2X51_GG/>N+T;X46EA\3K_QQJNJ3ZMJ-P6^S)/&JK:*> %QUPOR@\<9
M[G- 'E7Q+\"M\-OV:[;2+$"2YNM1@?5YU_Y:$JQ_[Y#JBCZ9ZDUB?%S3O#EC
M\,_A_<^%+:QAU62.,K)8JOG2?NU))V\L?,/4Y.XGN37T_KNA:;XET2YTC7+5
M+NQNEVRQ/D9YR"".000"".017"^'?@'X$\-:]#J]G8W%Q<V\@EMQ=7!=(6!R
M"%XR1VW9Q@'KS0!Z1%O\E/-QYFT;L=,]Z=110 5XE^U7_P DKTW_ +#,7_HB
M:O;:\2_:K_Y)7IO_ &&8O_1$U 'I/PX_Y)7X4_[ UG_Z(2NDKF_AQ_R2OPI_
MV!K/_P!$)724 %%%% %'7/\ D7M1_P"O67_T UXU7LNN?\B]J/\ UZR_^@&O
M&J\#-?CCZ'F8WXD%%%%>.<(4444 %%%% !1110!>T/\ Y&'3O^OJ+_T,5[+7
MC6A_\C#IW_7U%_Z&*]EKW\J^"7J>G@OA84445[!W!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 4=;_Y%_4/^O67_P!
M->-5[+K?_(OZA_UZR_\ H!KQJO S7XX^AYF-^)!1117CG"%%%% !1110 444
M4 7M$_Y&#3_^OJ+_ -#%>RUXUHG_ ",&G_\ 7U%_Z&*]EKW\J^"7J>E@OA84
M445[!WA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHH XCQ7_R47P__P!@K4?_ $;9U-4/BO\ Y*+X?_[!6H_^C;.IJ "BBB@
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M/]N:3_T%++_P(3_&C^W-)_Z"EE_X$)_C1[2'=!S1[EZBJ/\ ;FD_]!2R_P#
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M )&'3O\ KZB_]#%>RU[^5?!+U/3P7PL****]@[@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.M_P#(OZA_UZR_^@&O
M&J]EUO\ Y%_4/^O67_T UXU7@9K\<?0\S&_$@HHHKQSA"BBB@ HHHH ****
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M?(QPA#CC//2@#S*7X.?%"#PY<VOB;QXEGX>L[9VF2.^FF'E*I)780H*X'0L
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M$MGC;YSMMZ\XQGC/05L5#XK_ .2B^'_^P5J/_HVSJ:@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** +FD_\ (4A_X%_Z":Z6N:TG_D*0_P# O_03
M72T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S?BW_ )"'A?\
M[#*_^D\]=)7-^+?^0AX7_P"PRO\ Z3SUTE !1110 4444 %%%% !1110!PEY
M\/[JYOIYUO85$LC. 5/&3FH?^%<W?_/_  _]\&O0:*X'E^';NU^)S?5J3Z'G
MW_"N;O\ Y_X?^^#1_P *YN_^?^'_ +X->@T4O[.P_;\6'U6EV//O^%<W?_/_
M  _]\&C_ (5S=_\ /_#_ -\&O0:*/[.P_;\6'U6EV//O^%<W?_/_  _]\&C_
M (5S=_\ /_#_ -\&O0:*/[.P_;\6'U6EV//O^%<W?_/_  _]\&C_ (5S=_\
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M_BC[?<I(2\2E][\^;(3G;GU///TK5/JR&NA7GU?6=9ACL_-GFAC0(EO"IV@
M8' Z_4YKHO!7AW7K#7[>^>R>"W&5E\U@A*D?W>OH>G:L[PEXKF\.7AMKO>UB
M[8DC(YB/]X#^8KUZ&:.>%)8762-U#*RG((/>E)VT&E<?1116904444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRG+"%A^[!/7@JZ\] H_  ]BHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#0372US6D_\A2'_@7_ *":Z6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .;\6_\A#PO_P!AE?\ TGGKI*YOQ;_R$/"__897_P!)YZZ"XN(;
M2W>>YD6*)!EG8X I-I*[ DHKEG^(.DK,4$=RR@XWA!@^_6NALKZVU&U6XLIE
MEC;N.Q]".QK*G7I5':$KD1J0D[198HHHK8L**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFG(0 O*LZC)/1EY'K@<<\8O[1&M+XU^*FB^%M"N([IK0+:@JV5%S.X!7(ZX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-Q9C[]!7N^E:58Z)I5OINDVL=I9VR".&&,851_GDGJ3R:MT4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7R]^UG_R,?AW_ *])?_0Q7TW=WEM86KW-
M]<16T"8W2S.$5<G')/ YKY9_:DU;3M5\0: VEW]K>K':RAS;3+(%)<==I.*
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M"D>D6[R7ZQSW,HY&W(0>@S^M>?AL+7E4TO&W4YJ5&HY::'+_ /"P-8_NVO\
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MF8;D(YP6/0CK7G$?P=^+?@-3_P (#XR6\LX%)BLVE,08DY.(9-T0)/<MU)H
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MX[4 >T4444 %%%% !1110 4444 %%%% &=>>(M%TZY-OJ&L6%K. "8I[I$8
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MH3_=5@I'LQ'0"N='AW6[KX+7'Q7F\8:N=:2ZW*@F(4+YXBQG.<Y.>.,<8[T
M?7M56U.P74ET]KVV%ZR[EMC*OF$=<A<YQP:X*Q^*$&F? ?3_ !KX@8/.]DH*
M#@W-QRNT>FYE)]AD]JYGX%>#K[4;R\^)WC >;K&M%FLPP_U4)XW@'IN  7T0
M#^]0![;1110 5XE^U7_R2O3?^PS%_P"B)J]MKQ+]JO\ Y)7IO_89B_\ 1$U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!+2$>H!V#/KN':NI^._CF]MK:U\!^$]\WB#7L1,(3\T,+'&/8OR,]E#'C@T
M>;R-I7COQ5:Z8]Y]G^&W@.W59[IW^6Z*_+NXZM(PP .=N2,$XKU[P[\>_ &M
MZU;Z+87D]J\K"&V,]L8XG/15!_AST&<=A7 ?%?P*/A]^S;9Z-I1#L-1AEU2=
M5QY[%6R3[;_+ SV [USOQ:O/#NH_#/X>VGA*:QGU4)&B1V)7SD/EJ"#MY4^9
MC@X.[/<&@#ZNKP#Q'\5_C#IWBK5;'2/ /VO3[:]FAM;C^QKM_-B5R$?<KX;*
M@'(X.>*]]B#B%!*09 HW$=">].H ^;?^%R?&_P#Z)Q_Y0[W_ .+KB?BKX_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_ADZ=#?3K!]J&H>;Y;,<*2OEKQDC)SQUH ][HHHH **** .(\5_\E%\/_\
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M?B#0X9KOO<1.T,C?[Q0C=^.:F\*?#7PCX)E:;PWHD%K<,NTW#,TLN#U&]R2
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M *]8O_0!5^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH HZW_P B_J'_ %ZR_P#H!KQJ
MO9=;_P"1?U#_ *]9?_0#7C5>!FOQQ]#S,;\2"BBBO'.$**** "BBB@ HHHH
MO:)_R,&G_P#7U%_Z&*]EKQK1/^1@T_\ Z^HO_0Q7LM>_E7P2]3TL%\+"BBBO
M8.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^(NB_P!@Z-I^F>?I5_YOV*U2'S-LMGC=M SC)QGU-;% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 7-)_Y"D/_  +_ -!-=+7-:3_R%(?^!?\
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M1CBO6HU<3*=JD+([:<ZKE:4;(W****[CH"BBB@ HHHH **** "BBB@ HHHH
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M_H J_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 4=;_ .1?U#_KUE_] ->-5[+K?_(O
MZA_UZR_^@&O&J\#-?CCZ'F8WXD%%%%>.<(4444 %%%% !1110!>T3_D8-/\
M^OJ+_P!#%>RUXUHG_(P:?_U]1?\ H8KV6O?RKX)>IZ6"^%A1117L'>%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5'<7$-K TUU-'#$N-TDC!5'..2?>I*YOX@^$?\ A._
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU5@3HL[ ')4WTV#^34 <1XJ_:GL)--EM?!&D7K:A+F.*YOD15C)XW*BEBY]
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M[J4W-X4.X*Q  0-W"J /3.['6@#OZ*** "BBB@ HHHH **** "BBB@ HHHH
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M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ0#CT/2@"2BN;^W>-_\ H7O#_P#X/I__ )#H^W>-_P#H7O#_ /X/I_\ Y#H
MS/%?_)1?#_\ V"M1_P#1MG4U8^J3ZY-\1=%_M[3M/LL:5?\ E?8K][G?^]L\
M[MT,>W'&,9SD],<[% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 7-)_P"0I#_P+_T$UTM<UI/_ "%(?^!?^@FNEH **** "BBB@ HHHH ****
M"BBB@ HHK$\6:K<Z/HPN;(J)#*J?,N1@@_X5%2:IP<WLB9248\S-NBO,/^$\
MUO\ OP_]^A1_PGFM_P!^'_OT*\_^TZ'F<WUNF>GT5YA_PGFM_P!^'_OT*/\
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MU%+_ %2WCN%$B":_C@)!_P"F>X%?H0* /JNBOEW_ (0G]H;_ *#-]_X.$_\
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M8_.+_P"(KN_AI\*-*^&']I_V1?7EW_:/E>9]J*?+Y>_&-H']\_D* .[HHHH
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MKP,U^./H>9C?B04445XYPA7&_$C_ )!5I_UV/_H)KLJXWXD?\@JT_P"NQ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVTI-MX@U6./LLBQN?S"C^5=5X*_9_P#!O@Z_BU$Q3ZO?Q$-'+?E62)A_$J
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MW9X"HO.0.N: /+/VA_C P:Y\#^&Y2N!Y>J7*]\]8%_\ 9B/]WUK0^".@^ ?
MNFQZSK_BOPY)XCN$Y!U6!A9(?X%.[&XC[S#Z XR3U'B/]G'P?XF\27^M7M_K
M,-Q?3&:5+>>((&/7 :,GKSU-9G_#*G@C_H*^(/\ P(@_^,T >OZ3K>E:]:O<
MZ'J=GJ4"/Y;2V=PDRJV =I*D@'!!Q[BODC]F7_DL2?\ 7A/_ .RU]-?#[X=Z
M3\-M%N=,T.XO)X;BX-P[7CHS!MH7 VJHQA1VK#\$? _POX \3-KFBW.IR7)C
M>)8[F9&C16/. $![=R: /1Z*** "BBB@#B/%?_)1?#__ &"M1_\ 1MG4U0^*
M_P#DHOA__L%:C_Z-LZFH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"YI/_ "%(?^!?^@FNEKFM)_Y"D/\ P+_T$UTM !1110 4444 %%%% !11
M10 4444 %(RJXPZAAZ$9I:* &>1%_P \D_[Y%'D1?\\D_P"^13Z*5D%AGD1?
M\\D_[Y%'D1?\\D_[Y%/HHL@L<QXLBC74/#&U%&[65!P.H^SS5TGD1?\ /)/^
M^17/>+?^0AX7_P"PRO\ Z3SUTE%D%AGD1?\ /)/^^11Y$7_/)/\ OD4^BBR"
MPSR(O^>2?]\BCR(O^>2?]\BGT4606&>1%_SR3_OD5R_BOPD=59;O3@B7"KAH
MSP)!VY]?K75T5E5HPJPY)+0B<(SCRL\J@\%ZW-/Y;6ODC.&=W&T>_!Y_#->A
MZ/HEMI&FQVJ*LC#EY"O+MW-:5%8X?!TJ#O'5^9G3H0INZ&>1%_SR3_OD4>1%
M_P \D_[Y%/HKKLC>PSR(O^>2?]\BCR(O^>2?]\BGT4606&>1%_SR3_OD4>1%
M_P \D_[Y%/HHL@L,\B+_ )Y)_P!\BCR(O^>2?]\BGT4606&>1%_SR3_OD4>1
M%_SR3_OD4^BBR"PSR(O^>2?]\BCR(O\ GDG_ 'R*?119!89Y$7_/)/\ OD4>
M1%_SR3_OD4^BBR"PSR(O^>2?]\BE6)$.415/J!BG4460!1113 **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#YL_:!MTTSXW>"_$&JQL=) MXYGV\$17)>0=>NV0>G^'TDK*
MZAD(96&00<@BO!_VA[OQ9J-Q'X9T?P6=>TF:S2X^V1Z=<326UQO=?DDC.U2%
M"G!!^]SD'%>=^&_%?QU\,:?'866C>(+FTA&(XKW1I9M@Q@ ,4W8'&!G QQ0!
M]>T5\N_\+1^/7_0J7_\ X3\W^%=1\-O'OQ;UKXA:;I_B_P /W=GH\WF_:)Y-
M'D@5<1.RY<C RP4>^<=Z />J*** "BBB@#YOE'_"GOVFKK6M95HO#_B7SL7Q
M!*H9661@>O*RJ 1V4@^U?0]CJ-EJ=LMQIMY;WD#J&66WE616!Z$$'&*\$\7?
ML[>)?%'B/5+Y_%\?V.\OI;J&UF61UA#NQ48SC(#8XK!_X9-UK_H9[#_P'?\
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M/$/WOO[OF)R&QVQWI?V;]*AU[QCXBT>],GV._P##\\$P0XX:2)<_4 G%=O\
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M)7X4_P"P-9_^B$KI* "BBB@"CKG_ "+VH_\ 7K+_ .@&O&J]EUS_ )%[4?\
MKUE_] ->-5X&:_''T/,QOQ(****\<X0HHHH **** "BBB@"]H?\ R,.G?]?4
M7_H8KV6O&M#_ .1AT[_KZB_]#%>RU[^5?!+U/3P7PL****]@[@HHHH ****
M"BBB@"CKG_(O:C_UZR_^@&O&J]EUS_D7M1_Z]9?_ $ UXU7@9K\<?0\S&_$@
MHHHKQSA"N-^)'_(*M/\ KL?_ $$UV5<;\2/^05:?]=C_ .@FNS!?[Q$WP_\
M%1U5A_R#;;_KDO\ (58JO8?\@VV_ZY+_ "%6*Y9?$S%[A1114B+VB?\ (P:=
M_P!?47_H8KV6O&M$_P"1@T[_ *^HO_0Q7LM>_E7P2]3T\%\+"BBBO8.X****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTFF*,%P!E& ''K7VU7!?#WX?Z1\(]#OXAK+26UU,)9)KTI$$(7&,]* /&O\
MAH7XJ_\ 0H6'_@LNO_CE'_#0OQ5_Z%"P_P#!9=?_ !ROHC_A,_"__0R:1_X'
M1?\ Q5'_  F?A?\ Z&32/_ Z+_XJ@#G/A!XR\0>./"-UJ7BO38=.O(KY[=(H
MH)(@8Q'&P;#L3G+,,YQQ7>U5L-3L-5MVGTN]MKV%6V-);2K(H; .,J3S@CCW
MJU0 4444 %>3?&_X;^+/B5'IECH-_IEKIEH6FECNY9%:28\*<*C#"KG'(^^W
MM7K-% &7X:T"T\+^&=/T33QBWL85B4_WB.K=^2<G\:Q?B?X(3X@^ ;W1!Y27
M9(FLYI20L4R]"2 2 064X!X8UUU% 'B.F_"3QE%\!-8^'^HZAI$L\T\;Z=*D
MTGEQ)YR2NC'R@1RK$'!R7QP!7=_"?P??^!/AW9:!J\UM-=6\DK,]JS,A#.6&
M"R@]#Z5V=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!Q'BO_DHOA__ +!6H_\ HVSJ:H?%?_)1?#__ &"M
M1_\ 1MG4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7-)_P"0
MI#_P+_T$UTM<UI/_ "%(?^!?^@FNEH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#F_%O\ R$/"_P#V&5_])YZZ2N;\6_\ (0\+_P#897_TGGKI
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *Y*P^*7@[4_&3^%+'6/-UM)I8&M?LLR
MX>(,7&\IMXV-SG!QQFNMKA]-^$7A72?'S^,;."Y&KO<37!=K@E-\H8/\OI\[
M4 6_%?Q2\'>"-5CTWQ/K'V&[EA$Z1_99I,H690<HA'56XSGBL/\ X:#^&/\
MT,W_ )(7/_QNM'QK\(O"OC[6HM4\107,EU#;K;H8K@H-@9F' [Y<USO_  S5
M\._^?2__ / QJ -'_AH/X8_]#-_Y(7/_ ,;K3\/?&+P)XJUZWT;0==^UZA<[
MO*A^QSINVJ7/S,@ ^52>3VKF_P#AFKX=_P#/I?\ _@8U:_A?X'^#/!_B2UUW
M1;>[2]M=_E-)<EU&Y&0Y'?AC0!Z'1110!E^)]6?0/".L:Q%$LTFGV,]TL;'
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M_P! ->-5X&:_''T/,QOQ(****\<X0HHHH **** "BBB@"]H?_(PZ=_U]1?\
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M&J]EUO\ Y%_4/^O67_T UXU7@9K\<?0\S&_$@HHHKQSA"BBB@ HHHH ****
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M_P#1MG4U0^*_^2B^'_\ L%:C_P"C;.IJ "BBB@ HHHH **** "BBB@ HHHH
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M(HV3(RJE?F.."6R<DYKVV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O$OVJ_^25Z;_V&8O\ T1-7MM>)?M5_\DKTW_L,
MQ?\ HB:@#TGX<?\ )*_"G_8&L_\ T0E=)7-_#C_DE?A3_L#6?_HA*Z2@ HHH
MH HZY_R+VH_]>LO_ * :\:KV77/^1>U'_KUE_P#0#7C5>!FOQQ]#S,;\2"BB
MBO'.$**** "BBB@ HHHH O:'_P C#IW_ %]1?^ABO9:\:T/_ )&'3O\ KZB_
M]#%>RU[^5?!+U/3P7PL****]@[@HHHH **** "BBB@"CKG_(O:C_ ->LO_H!
MKQJO9=<_Y%[4?^O67_T UXU7@9K\<?0\S&_$@HHHKQSA"N-^)'_(*M/^NQ_]
M!-=E7&_$C_D%6G_78_\ H)KLP7^\1-\/_%1U5A_R#;;_ *Y+_(58JO8?\@VV
M_P"N2_R%6*Y9?$S%[A1114B+VB?\C!IW_7U%_P"ABO9:\:T3_D8-._Z^HO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.R0_[7RL#] ?XL4 >KT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1M/TSS]*O_-^Q6J0^9MEL\;MH&<9.,^IK8J'Q7_R47P__P!@K4?_ $;9U-0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGG<(B#IR3QUKR_4/VE/AY8W30PW5]?!3CS;:T.T_3>5)_+M0!Y9_PTO\1_\
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M4 %%%% !1110 4444 %%%% '$>*_^2B^'_\ L%:C_P"C;.IJA\5_\E%\/_\
M8*U'_P!&V=34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!<TG_
M )"D/_ O_0372US6D_\ (4A_X%_Z":Z6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .;\6_P#(0\+_ /897_TGGKI*YOQ;_P A#PO_ -AE?_2>
M>NDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%9L&5\?*B]R2?;U/0&O&OV5-/N#HWB;7)DVQZA>11*1T+1AF; ZX_>CG_ T
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M3_\ L)+_ .BY* /1/"?_ ")>B_\ 7A!_Z+6M>LCPG_R)>B_]>$'_ *+6M>@
MHHHH **** "BBB@ HHHH **** "BBB@"CK?_ "+^H?\ 7K+_ .@&O&J]EUO_
M )%_4/\ KUE_] ->-5X&:_''T/,QOQ(****\<X0HHHH **** "BBB@"]HG_(
MP:?_ -?47_H8KV6O&M$_Y&#3_P#KZB_]#%>RU[^5?!+U/2P7PL****]@[PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#YP^-\-MJ/[17@C3=90/I<D=L)%<':^^Y<,I[8.%!]C7T<JJBA4 5
M5&  , "O)?CY\,KWQSX?M=3\/H7UK22S1Q*V#/&<$J#G[P(##\1U(KS?P_\
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M %2V%^4CIZ5Z9_PU!X!_YYZO_P" J_\ Q= 'GMA\!_B7XWU&*?XBZU);6T;
M,+J]^U3!?]A5)0?F.N<'FOI'PWX=TWPGX=M-%T6'R;.T38@/+,>I9CW8G))]
M37DVI_M0>"_[*NO[/@U9[HQ,(5-NJC>1QD[^!GO61^RE%?SV7BG5;UY9H[B:
MV@2:5BQ9T$C,,GT\U3^- 'T)1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5XE^U7_ ,DKTW_L,Q?^B)J]MKQ+]JO_ ))7IO\ V&8O
M_1$U 'I/PX_Y)7X4_P"P-9_^B$KI*YOX<?\ )*_"G_8&L_\ T0E=)0 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\U?LO6\>G>-/%^G:JNW6H$2/#GYPJ2.LW7_;\
MO/X5]*U\6>(?%_BW4O'<7C#P]X7OO#FL[2)Y;2"1UG.,99&7&<<'.0>.,\D
M^TZ*^6(/V@/BQ#$%D\+6DY_OR:7< G_OEP/TJ7_AH7XJ_P#0H6'_ (++K_XY
M0!]145P7P@\9>(/''A&ZU+Q7IL.G7D5\]ND44$D0,8CC8-AV)SEF&<XXKO:
M"BBB@ HHHH ***\9^)_QNU#P]XH?PCX$T1M9UV-09F,3RK$2 P58TY=MI!)R
M ..O( ![-17SE_PG_P ?K&875WX/6X@5B6@2P+9&#Q\C;OI^'7I7I_PK^*EC
M\2M+N"+8Z?JEB0MW9N^<9_C7N5R".1D$8/8D [ZBBB@ HHHH **** "BBB@
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M92Z[^T!:ZAH5F]M86]Q<7;*H^6V@*N%4_P#?2I^-?9M '-_;O&__ $+WA_\
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M\_Z^9K["I_/_ %]YYA_PGFM_WX?^_0H_X3S6_P"_#_WZ%>GT4?4Z_P#S^?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M***]@[@HHHH **** "BBB@"CKG_(O:C_ ->LO_H!KQJO9=<_Y%[4?^O67_T
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M"TYD+V]/N=717*?\+$TG_GWO?^^$_P#BJ/\ A8FD_P#/O>_]\)_\51]<P_\
M,@]O2[G5T5S-KX[TR[O(;:."[#S2+&I9%P"3@9^:NFK:G5A55X.Y<9QG\+"B
MBBM"PHHHH **** "BBB@"CK?_(OZA_UZR_\ H!KQJO9=;_Y%_4/^O67_ - -
M>-5X&:_''T/,QOQ(****\<X0HHHH **** "BBB@"]HG_ ",&G_\ 7U%_Z&*]
MEKQK1/\ D8-/_P"OJ+_T,5[+7OY5\$O4]+!?"PHHHKV#O"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M02/KNKUSX??#[2/AQX=.E:*99?-D,UQ<3D%YG( R<    8 '3W))(!U5%%%
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MRUXUH?\ R,.G?]?47_H8KV6O?RKX)>IZ>"^%A1117L'<%%%% !1110 4444
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M+!?"PHHHKV#O"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^+?^0AX7_[#*_\
MI//725S?BW_D(>%_^PRO_I//724 %%%% !1110 4444 %%%% !1110 4444
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M_P"ABO9:]_*O@EZGIX+X6%%%%>P=P4444 %%%% !1110!1US_D7M1_Z]9?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH_@_QMXD73S>:M=V]Y>?:+QO,\EW#/\ NUP%7!/!QN'K7L-<G\4_^22^*?\
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MU\PY\1_*OZ^9T/\ PEVA?]!!/^^&_P */^$NT+_H()_WPW^%<]_PK;_J*_\
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M***]@[@HHHH **** "BBB@"CKG_(O:C_ ->LO_H!KQJO9=<_Y%[4?^O67_T
MUXU7@9K\<?0\S&_$@HHHKQSA"BBB@ HHHH **** +VB?\C!IW_7U%_Z&*]EK
MQK1/^1@T[_KZB_\ 0Q7LM>_E7P2]3T\%\+"BBBO8.X**** "BBB@ HHHH HZ
MW_R+^H_]>LO_ * :\:KV76_^1?U'_KUE_P#0#7C5>!FOQQ]#S,;\2"BBBO'.
M$*Y#XC?\@&W_ .OD?^@M77UR'Q&_Y -O_P!?(_\ 06KKP?\ O$?4VH?Q4='I
M/_(%LO\ KW3_ -!%7*IZ3_R!;+_KW3_T$5<KGG\3,I;L****@1>T3_D8-/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^P-9_\ HA*Z2N;^''_)*_"G_8&L_P#T0E=)0 4444 4=<_Y%[4?^O67_P!
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M?^0+9?\ 7NG_ *"*N53TG_D"V7_7NG_H(JY7//XF92W84445 B]HG_(P:?\
M]?47_H8KV6O&M$_Y&#3_ /KZB_\ 0Q7LM>_E7P2]3TL%\+"BBBO8.\**** "
MBBB@ HHHH HZW_R+^H?]>LO_ * :\:KV76_^1?U#_KUE_P#0#7C5>!FOQQ]#
MS,;\2"BBBO'.$**** "BBB@ HHHH O:)_P C!I__ %]1?^ABO9:\:T3_ )&#
M3_\ KZB_]#%>RU[^5?!+U/2P7PL****]@[PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBD1UD17C8,K#*LIR"/6EH **K1:E8SW!@@O;>28=8TE4L/P!JS0 44$@ DG
M'4U4@U;3KJ816U_:S2'HD<RL3^ - %NBBB@ HHHH XCQ7_R47P__ -@K4?\
MT;9U-4/BO_DHOA__ +!6H_\ HVSJ:@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** +FD_P#(4A_X%_Z":Z6N:TG_ )"D/_ O_0372T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!S?BW_D(>%_^PRO_I//725S?BW_
M )"'A?\ [#*_^D\]=)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1117CG"%%%% !1110 4444 7M#_Y&'3O^OJ+_P!#%>RUXUH?_(PZ=_U]1?\
MH8KV6O?RKX)>IZ>"^%A1117L'<%%%% !1110 4444 4=<_Y%[4?^O67_ - -
M>-5[+KG_ "+VH_\ 7K+_ .@&O&J\#-?CCZ'F8WXD%%%%>.<(4444 %%%% !1
M110!>T3_ )&#3O\ KZB_]#%>RUXUHG_(P:=_U]1?^ABO9:]_*O@EZGIX+X6%
M%%%>P=P4444 %%%% !1110!1UO\ Y%_4?^O67_T UXU7LNM_\B_J/_7K+_Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OECX.>*[/X2?$CQ%X
M0\6R?8[:><1I=R\+&\9;:6_V75L[N@PO8DCZGKSCXG_!?0_B3MO9)'T[6(H]
MB7D0R' !VK(O\0!/48/;- 'H2W5NUI]J6>(V^TOYP<;-HZG/3'O7R]\=/%%I
M\2_B'X>\'^%9!?K;7!ADF@(*O+*R@A6Z84+RW3D^E#_LH^(UF:.'Q)IK6Q8'
M<R2*Q [E<$9Y/?\ &O7?AC\$]"^&\SWZ3OJFKNNS[9-&$$2]Q&G.W/<Y)[9
M)% ';ZWXBT?PW8M>:_J=KI\ 4D/<2A=V.H4'EC[#)KP/X RS>*/C3XT\8PQ>
M793)(@![&:8.@]R%B.?KVKTWXI_":U^*+Z-]LU.2PCTUY2WE0AVE639D D@*
M?D')#5TWA+PAHW@CP_'H_AVU^SVJ,7<EBSRN0 7=CU8X'MP    * -NBBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5_P"T;+_G\M_^_J_X
MT 6**K_VC9?\_EO_ -_5_P :/[1LO^?RW_[^K_C0!8KYE^!7_)R?C+_KC??^
MED=?27]HV7_/Y;_]_5_QKYM^!7_)R?C+_KC??^ED= 'TU1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q'BO\
MY*+X?_[!6H_^C;.IJA\5_P#)1?#_ /V"M1_]&V=34 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!<TG_D*0_P# O_0372US6D_\A2'_ (%_Z":Z
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;\6_\ (0\+_P#8
M97_TGGKI*YOQ;_R$/"__ &&5_P#2>>NDH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K'U_P (^'O%21+XBT:SU'R<^6UQ"&://4*W4 X&<'G%;%>->'M.^+<?QPFN
M=:>Y/@XWUXR!KJ!D\DK)Y/R!M^,F/C&1W[T 4/$7P%MKGXN:'J&BZ'IT7A:&
M!%O[;?M\Q]TA8[>_!3\J[_\ X4[\/?\ H4]._P"_9_QKC_B_IWQ;O/%UK)\-
M7N5TL6*+*(KJ"(>=YDF>)&!SM*<]*X+^P_VDO^>M_P#^#"T_^+H ]M_X4[\/
M?^A3T[_OV?\ &KNC_#7P;X?U:'4]&\/65G>P;O*GB0ADW*5..>X)'XUX+_8?
M[27_ #UO_P#P86G_ ,774?#;2OC=;?$+39?'$EV="7S?M0DO+=U_U3A,JC%C
M\^WH* />J*** ,GQ7IK:SX,UK3$W;KW3Y[<;!DY>-EX]^:\(_9/\0VXM-=\.
MRE$N/,2]AR_S2*1L<8_V=J?]]5]&U\O_ !;^'>O?#GQHWQ#\ M)'9M,9YEMU
M)-FYY?<O>)CGV&2I &,@'U!17S_X=_:MT:>W5/%6AW=G.!@R6++-&W'7#%2O
M?CYOK6WJ'[4/@6UB)LX-5OI,?*L=LJ#//!+,,#W /7O0!Z/XXURW\-^ ]:U:
M[D$<=M9R,I/\3D;44>Y8J![FO&_V3=*F@\.^(M6="(;RYAMXR3]XQ*Q.!_VU
M'/\ @:X37?%?C']HCQ3;:%HED;'2H7WF$.6BB'/[Z9\<G' &/8 DG/U#X-\*
MV7@KPE8:#IH!BM8P'EV[3,YY9R/4G)]NG:@#<HHHH **** "BBB@ HHHH **
M** /D;X]_$F7Q=XV;PG;W/V'1-+N_(GD=6(>=6*O(P )*IR  ">"><C'IG@3
MXE_!SP!X6@T;2/$>=OS7%PVG7(>XD[NW[O\ (=A@5UVI_ [X=ZSJUUJ>H^'1
M+=WDS3SR"\N$WNQRQPL@ R23P*J_\,^?#'_H6?\ R?N?_CE '&?M+Z2/$_PX
MT/Q5HP:\M;-_,\V,''V>=%(DQZ96/_OKZU%X9_:%\,:3\';2VN)Y_P#A(=/T
M\6L=GY+GS9$38C>9C: < DDYZ\'O[M;:796FCPZ5!;1BPA@6V2W8;E$07:$P
M<Y&!CFN,?X&_#=]2^W'PK;"7=NVB641Y_P"N8;9CVQB@#S3]E/PO<VUCK'B:
MZB9(;O;:VC,,;PI)D(]1G:,^H/I71?'?QM>[;3X>>$MTVNZ\1',(^L4+'&">
MQ;G)[*&)QD&O8K:V@LK6*VLX8X((5"1Q1*%5%'   X KD="^%NAZ%X]U+Q@L
M]]?ZOJ!;,E[*KK &/(C 48&,*,Y(48'?(!Y3\6_ B^ OV;K/1M'(80ZA#-J<
MZKC[0Q5@6/MO\L#/0*HKF?BSJ_A[7_AO\/=+\*7-G>:M&D<26]F5,L),:*4;
M'*$OC@XR1GM7U/?V%IJEA-9:C;175K.I26&9 RNI[$&N5T'X2>!?#6L#5-&\
M.V\%ZK;DE=WE\L^J!V(4\_P@4 =A$'6%!*P9PH#$=SWIU%% !7B7[5?_ "2O
M3?\ L,Q?^B)J]MKQ+]JO_DE>F_\ 89B_]$34 >D_#C_DE?A3_L#6?_HA*Z2N
M;^''_)*_"G_8&L__ $0E=)0 4444 4=<_P"1>U'_ *]9?_0#7C5>RZY_R+VH
M_P#7K+_Z :\:KP,U^./H>9C?B04445XYPA1110 4444 %%%% %[0_P#D8=._
MZ^HO_0Q7LM>-:'_R,.G?]?47_H8KV6O?RKX)>IZ>"^%A1117L'<%%%% !111
M0 4444 4=<_Y%[4?^O67_P! ->-5[+KG_(O:C_UZR_\ H!KQJO S7XX^AYF-
M^)!1117CG"%%%% !1110 4444 7M$_Y&#3O^OJ+_ -#%>RUXUHG_ ",&G?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5\I_\,H>*/\ H/:1_P"1
M?_B:^K** /E/_AE#Q1_T'M(_\B__ !-'_#*'BC_H/:1_Y%_^)KZLHH ^4_\
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MKI:YK2?^0I#_ ,"_]!-=+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M4?YU]Z-O:T_YE]YNT5A?\)IH'_/_ /\ D&3_ .)H_P"$TT#_ )__ /R#)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5'<7$%I;R7%W-'!#&NYY)6"JH]23P!4E?,?QV\2ZYXY^)5M\-?"[,\,;HLT4
M;_+/,5WY<C^&->2.@()/(& #N_$7[3'@C1KJ2VTY+[69$QB2UC582>,_.Q!]
M>BD<?C7-Q_M::89 )O"EVJ=RMVK$?AM'\ZZCP=^SCX-T'38_^$@MCKNHD RS
M3NRQ*?1$4@8_WLD^P.*ZUOA+X :'RSX1TG;@#(M@#^?6@#GO"?[0G@;Q1<K:
MRW4VC73MM1-14(K^F'!*C\2*]1KP[QS^S+X=U6QDG\%EM&OT5F6%Y&D@F/93
MN)*<]QD#/0UG_LT^-M2FDU+P-X@ED:?3$WVB3??B16V219]%)7 [9(' X /H
M&BBB@ I&574JX#*PP01D$4M% '"Z_P#!;P!XCN?M%_X=MXI]Q9I+-FMRY/4L
M$(#'ODC/YFLBR_9T^&]I+ODTB>[Z86>\EP#]%(S^.:]1HH I:1HVFZ!IL=AH
MEA;V%I']V&WC"+GN<#J3W/4U=HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O$OVJ_P#DE>F_]AF+_P!$35[;7B7[5?\ R2O3
M?^PS%_Z(FH ])^''_)*_"G_8&L__ $0E=)7-_#C_ ))7X4_[ UG_ .B$KI*
M"BBB@"CKG_(O:C_UZR_^@&O&J]EUS_D7M1_Z]9?_ $ UXU7@9K\<?0\S&_$@
MHHHKQSA"BBB@ HHHH **** +VA_\C#IW_7U%_P"ABO9:\:T/_D8=._Z^HO\
MT,5[+7OY5\$O4]/!?"PHHHKV#N"BBB@ HHHH **** *.N?\ (O:C_P!>LO\
MZ :\:KV77/\ D7M1_P"O67_T UXU7@9K\<?0\S&_$@HHHKQSA"BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]F_1/"GBO3]=MM<U">6QE\U(G5%5C@\$CG'->PW-M!>6LMK>0QSV\R&.6*5
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M /?D?XT?\*WB_P"@D_\ WY'^-=M11]0PW\OYA]7I=CB?^%;Q?]!)_P#OR/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(\5_\E%\/_\
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M2YI%CBU*S=W.%59U)8^@&:NUXCHG[,6A:)X@T_58]>U&5[&ZCN5C9$ 8HP8
MD#VKVZ@ HHHH XCQ7_R47P__ -@K4?\ T;9U-4/BO_DHOA__ +!6H_\ HVSJ
M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +FD_P#(4A_X%_Z"
M:Z6N:TG_ )"D/_ O_0372T %%%% !1110 4444 %%%% !1110 4444 %%%5[
MZ_M]-LWN;R01Q+U/J?04FTE=B;25V6**XIOB/ )\)ITABS]\R@-CZ8_K74Z7
MJMKJ]F+FR?<N<,I&"I]"*PIXFC5?+"5V9PJPF[19C^+?^0AX7_[#*_\ I//7
M25S?BW_D(>%_^PRO_I//725T&H4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBT@BO6!\FZ))9R>J\\ X],9_'G3^*;N-+L$&=C3,3]0O'\S6!XE\):AI.O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 7-)_Y"D/\ P+_T$UTM<UI/_(4A_P"!?^@FNEH **** "BBB@ HHHH
MX#Q'XBURQ\075O97#) A78HA5L?*#U(]367_ ,);XD_Y^G_\!T_^)KU.BO-G
M@ZLI.2JM7_KN<LJ$VV^=GEG_  EOB3_GZ?\ \!T_^)H_X2WQ)_S]/_X#I_\
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MJ_!'_0*\0?\ @/!_\>KWLKBU3DWW/2P:?(V>VT5XE_PU7X(_Z!7B#_P'@_\
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M_P#Q=>-F-"I5E%P5S@Q5.<Y+E1Z%17G\7QD\.23(CV^HQ*S &1X4VH/4X<G
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M15+6=9T_P_HUSJNM7<=G8VJ;YII#PH_F23@ #))( !)H 36_^1?U#_KUE_\
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MECN0DV[(Z31/^1@T_P#Z^HO_ $,5[+7REIWQO\-VFJ6MS)9:J4AF21@L4>2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<"EHHKSCE/'#\$-<O-9-OIE[IXAFN/+MS<2ON"EL+NQ'C.",XKH/^&5/&_\
MT%?#_P#X$3__ !FO4=$_Y&#3_P#KZB_]#%>RU]-@*\ZT&Y]#U\-4E4B^8^9/
M!G[,_BK1/&^C:MJNK:.+33[V*ZD%M)+)(WEL'"@,BCDJ!G/ .><8/TW117HG
M44M:TJ#7=!U#2+MI$M[^VDMI6B(#JKJ5)!((S@\9!KY;N?V4O&"W<JV>LZ'+
M;AR(I)99D=ESP641L%..H!./4]:^L:* /DG_ (94\;_]!7P__P"!$_\ \9KK
M?AC^SKX@\)_$#3]>\0:KIYMK#=(L>GSS>9(^TJJD[4PO))Y((&T@AC7T310
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MX\;W&GV$%M*T1)1F2,*2I(!QD=P*V*** "BBB@ HHHH **** "BBB@ HHHH
M**** *.M:D-(T6ZOBF_R8]P7U/0#\R*\ZT_Q+XSU^ZE_LEE81_,Z)%&%0$\#
M+_XYXK<^(O\ ;7V%OL?_ ""_*'VK[G7=QU^;TZ5R'A3_ (27_2_^$7_V//\
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MV"YZ517FEQKGCJ6S.IQ0-!9XW@)"APO7.#EL8[UO>#/&1U[=9WZI'>HNX,O
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MN%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%% !1110!<TG_D*0_\  O\ T$UTM<UI/_(4A_X%_P"@FNEH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#F_%O_(0\+_\ 897_ -)YZZ2N;\6_
M\A#PO_V&5_\ 2>>NDH **** "BBB@ HHHH **** "BBB@ HHHH ***.G6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBN;T7X9>"_#VJC4M&\.6-M>*24F"%C&>>5R3MZGIBNJHH **** "O$OVJ_\
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M_P#7K+_Z :\:KV76_P#D7]1_Z]9?_0#7C5>!FOQQ]#S,;\2"BBBO'.$****
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MHYJ#<-R9<W+[NYS?B+Q'I5_>:"]K=>8MIJ:SSGRW&Q/)E7/(YY91@<\UM_\
M"::!_P __P#Y!D_^)KE=9\'P:7<Z1%'=22"_OA:L64#8#'(^1[_(!^-:O_"N
M;3_G_F_[X%<'M,?_ "+^OF<W-B.R_KYFK_PFF@?\_P#_ .09/_B:/^$TT#_G
M_P#_ "#)_P#$UE?\*YM/^?\ F_[X%'_"N;3_ )_YO^^!1[3'_P B_KYAS8CL
MOZ^9J_\ "::!_P __P#Y!D_^)H_X330/^?\ _P#(,G_Q-97_  KFT_Y_YO\
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M3_G_ )O^^!1_PKFT_P"?^;_O@4>TQ_\ (OZ^8<V([+^OF:O_  FF@?\ /_\
M^09/_B:/^$TT#_G_ /\ R#)_\365_P *YM/^?^;_ +X%'_"N;3_G_F_[X%'M
M,?\ R+^OF'-B.R_KYFK_ ,)IH'_/_P#^09/_ (FC_A-- _Y__P#R#)_\365_
MPKFT_P"?^;_O@4?\*YM/^?\ F_[X%'M,?_(OZ^8<V([+^OF:O_"::!_S_P#_
M )!D_P#B:/\ A-- _P"?_P#\@R?_ !-97_"N;3_G_F_[X%'_  KFT_Y_YO\
MO@4>TQ_\B_KYAS8CLOZ^9J_\)IH'_/\ _P#D&3_XFC_A-- _Y_\ _P @R?\
MQ-97_"N;3_G_ )O^^!1_PKFT_P"?^;_O@4>TQ_\ (OZ^8<V([+^OF:O_  FF
M@?\ /_\ ^09/_B:/^$TT#_G_ /\ R#)_\365_P *YM/^?^;_ +X%'_"N;3_G
M_F_[X%'M,?\ R+^OF'-B.R_KYFK_ ,)IH'_/_P#^09/_ (FC_A-- _Y__P#R
M#)_\365_PKFT_P"?^;_O@4?\*YM/^?\ F_[X%'M,?_(OZ^8<V([+^OF:O_":
M:!_S_P#_ )!D_P#B:GLO$^D:A>):V=WYDTF=J^4XS@9/)&.@K#_X5S:?\_\
M-_WP*N:3X*M])U2&]CNY9&BSA64 '*D?UJH3QKDN:*MU_JXXRKW5TK?UYG34
M445Z)U!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ",&G_\ 7U%_Z&*]EKW\J^"7J>E@OA84445[!WA1110 4444 %%%% %'6_\
MD7]0_P"O67_T UXU7LNM_P#(OZA_UZR_^@&O&J\#-?CCZ'F8WXD%%%%>.<(4
M444 %%%% !1110!>T3_D8-/_ .OJ+_T,5[+7C6B?\C!I_P#U]1?^ABO9:]_*
MO@EZGI8+X6%%%%>P=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Y7XKTC4KGQY/<6^GW4L)D
MB(E2!F4X1<\@8[5ZI133L)JX4444AA1110 4444 %%%% !1110 4444 %%%%
M !1110!RWBS6/$&FW$46AZ>;F.6([I%MWD9&SCL<>G45S_@WPEJ$NN#5M;BD
MB$;F11-G?))_>QUX/.3UKTFBG?05@HHHI#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_V&5_\ 2>>NDKF_%O\ R$/"_P#V&5_])YZZ2@ HHHH **** "BBB@ HHHH
M**** "BBB@ JE>Z/I^HMNO;2*5L8W$8;'U'-7:*F45)6DKB:35F06EE;6,7E
MV<$<*$Y(1<9/OZU/113225D-*VP4444P"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@"YI/_(4A_P"!?^@FNEKFM)_Y"D/_  +_ -!-=+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-^+?^0AX7_P"PRO\
MZ3SUTE<WXM_Y"'A?_L,K_P"D\]=)0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !114<]Q%:V[SW,BQ1(,L[G  H DHJ&TNH+ZTBN;2020R
MJ&1QW%,OM0M--MQ-?SI!$7"!G.!D]!0!9HI%8.H92&4C((/!%+0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%_Z&*]EKW\J^"7J>G@OA84445[!W!1110 4444 %%%% %'6_^1?U'_KUE_\
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M/4_S6DMA]3T*BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY_[\#_XFC_A(/%'_ #VN?^_ _P#B:/[3I_RL/K<>S/4Z*\L_X2#Q1_SVN?\
MOP/_ (FC_A(/%'_/:Y_[\#_XFC^TZ?\ *P^MQ[,]3HKRS_A(/%'_ #VN?^_
M_P#B:/\ A(/%'_/:Y_[\#_XFC^TZ?\K#ZW'LSU.H+V]@T^T>YNY!'$@Y->9_
M\)!XH_Y[7/\ WX'_ ,35+4]4U>]A2/5)9FC#;E5TVC/Y"HGF<%%\L7?S)EBU
M;1,ZF3XD()B(=-9H@>"TN"1],'%=/H^M6FMVIFLV.5.'C;AD/O\ XUXY5W3+
M[4+&=FTN21)&7#>6N[(^E<=',JJG^\U1A3Q4U+WM4>S45Y9_PD'BC_GM<_\
M?@?_ !-'_"0>*/\ GM<_]^!_\37?_:=/^5G3];CV9ZG17EG_  D'BC_GM<_]
M^!_\31_PD'BC_GM<_P#?@?\ Q-']IT_Y6'UN/9GJ=%>6?\)!XH_Y[7/_ 'X'
M_P 31_PD'BC_ )[7/_?@?_$T?VG3_E8?6X]F>IT5Y9_PD'BC_GM<_P#?@?\
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M\DKTW_L,Q?\ HB:O;:\2_:K_ .25Z;_V&8O_ $1-0!Z3\./^25^%/^P-9_\
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MZ@CN*=10!#:V=K8Q&.RMH;>,MN*0QA 3ZX'?@5))&DT9CE171NJL,@_A3J*
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MQUH_LNMW7X_Y!]3J=T>P45PG_"%_'[_GP_\ (UA_\51_PA?Q^_Y\/_(UA_\
M%4?V76[K\?\ (/J=3NCNZ*X3_A"_C]_SX?\ D:P_^*H_X0OX_?\ /A_Y&L/_
M (JC^RZW=?C_ )!]3J=T>DZ'_P C#IW_ %]1?^ABO9:^5(/"7[05M<1SPV6V
M2)PZ-YM@<$'(/6MG_C)W_/\ 9E>G@L-/#Q:EU.S#TI4DTSZ2HKYM_P",G?\
M/]F4?\9._P"?[,KO.D^DJ*^;?^,G?\_V91_QD[_G^S* /I*BOFW_ (R=_P _
MV91_QD[_ )_LR@#Z2HKYM_XR=_S_ &91_P 9._Y_LR@#Z$US_D7M1_Z]9?\
MT UXU7.SP_M,W-O)!,NZ.5"CKG31D$8(K&_X0OX_?\^'_D:P_P#BJ\S&X2IB
M))Q:T./$4)56G$[NBN$_X0OX_?\ /A_Y&L/_ (JC_A"_C]_SX?\ D:P_^*K@
M_LNMW7X_Y'-]3J=T=W17"?\ "%_'[_GP_P#(UA_\56'XK3XP^"-*CU+Q./L-
MI+,($D_T23+E68#"9/16YQCBC^RZW=?C_D'U.IW1ZO17!_\ "%_'[_GP_P#(
MUA_\52_\(7\?O^?#_P C6'_Q5']EUNZ_'_(/J=3NCNZ*X3_A"_C]_P ^'_D:
MP_\ BJ/^$+^/W_/A_P"1K#_XJC^RZW=?C_D'U.IW1Z3HG_(P:=_U]1?^ABO9
M:^5(/"7[05M<1SPV6V2)PZ-YM@<$'(/6MG_C)W_/]F5Z>"PT\/%J74[,/2E2
M33/I*BOFW_C)W_/]F4?\9._Y_LRN\Z3Z2HKYM_XR=_S_ &91_P 9._Y_LR@#
MZ2HKYM_XR=_S_9E'_&3O^?[,H ^DJ*^;?^,G?\_V91_QD[_G^S* /H36_P#D
M7]1_Z]9?_0#7C5<[/#^TS<V\D$R[HY4*.N=-&01@BL;_ (0OX_?\^'_D:P_^
M*KS,;A*F(DG%K0X\10E5:<3NZ*X3_A"_C]_SX?\ D:P_^*H_X0OX_?\ /A_Y
M&L/_ (JN#^RZW=?C_D<WU.IW1W=%<)_PA?Q^_P"?#_R-8?\ Q5<UXNO?BOX$
M^R?\)7)]@^V[_(^6UEW[-N[[F[&-R]?6C^RZW=?C_D'U.IW1[!17!_\ "&?'
MX_\ +A_Y&L/_ (JE_P"$+^/W_/A_Y&L/_BJ/[+K=U^/^0?4ZG='=T5PG_"%_
M'[_GP_\ (UA_\51_PA?Q^_Y\/_(UA_\ %4?V76[K\?\ (/J=3NCTG1/^1@T_
M_KZB_P#0Q7LM?*D'A+]H*VN(YX;+;)$X=&\VP."#D'K6S_QD[_G^S*]/!8:>
M'BU+J=F'I2I)J1])45\V_P#&3O\ G^S*/^,G?\_V97>=)])45\V_\9._Y_LR
MC_C)W_/]F4 ?25%?-O\ QD[_ )_LRC_C)W_/]F4 ?25%?-O_ !D[_G^S*/\
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MC4#)8DPX  &234O_  GFD?\ /IX@_P#"<U#_ .,4 =)17-_\)YI'_/GX@_\
M"<U#_P",4?\ ">:1_P ^?B#_ ,)S4/\ XQ0!TE%<W_PGFD?\^?B#_P )S4/_
M (Q1_P )YI'_ #Y^(/\ PG-0_P#C% '245S?_">:1_SY^(/_  G-0_\ C%'_
M  GFD?\ /GX@_P#"<U#_ .,4 =)15'2M7MM9M6N+..\C17*$7EE-:MG /"RH
MK$<]0,=>>#5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@ KYN_:YZ>$?^WW_ -H5](U\W?M<]/"/_;[_ .T* /I$=**!THH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+]JK_DE>G?]AF+_
M -$S5[;7B7[57_)*]._[#,7_ *)FH ]M'044#H** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *^;OVN?N^$?K>?\ M"OI&OF[]KG[OA'ZWG_M
M"@#Z07[H^E+2+]T?2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KYO\ VN/N>$OK>?\ M"OI"OF_]KC[GA+ZWG_M"@#Z/7[B_2EI%^XOTI:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M10 4444 %<3\1?A5HGQ-&G?V]=:A;_V=YOE?8I$3=YFS.[<C?W!C&.]=M10
M#@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/Q%^%6B?
M$T:<->NM0M_[.\WROL4B)N\S;G=N1O[@QC'>NVHH  , "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY_\ )$=)_P"NUQ_Z.>O4: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M74VIQV[RB-7.PQR,0-P(ZH* /4Z*^7_#TW[07BC0+76=(U@265VI:)G:U4D
MD="O'(KUCX367Q+M'U7_ (6==QW",(OL0#1$J?GW_P"K _V>OX=Z /2****
M"BBB@ HHHH **** "BBB@ HHKE?B)X_T[X<>%O[:U2">Y5YA;PPP 9DD*LP!
M)X PIR?;H>E '545\<^*_CY\2I]86>.5_#MM+&)+:S6U7YHR3A]TBDOG&,C
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MY[BO4/A=I_Q=M?%,S_$:^CGTDVC!$WPL?-W+M(\L ]-W7B@#UJBBB@ HHHH
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M!DD1OND)Q_"3GC@5+\&_C_KFM^++7PWXS,-W]N)CM[Y(UB=9,$A7"X4@XP,
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M;G'))Z9/YT ;]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_M[^P_[=T[^U=VW[%]J3S=V,[=N<YQSCK7S-^U7ITL'Q$TO4"#Y%UIHC5O\
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M#[7HHHH **** "BBB@ HHHH **** "BBL_7M>T[PSH=UJ^M7*VME:IODD;]
M!W).  .I- '-_%SQ)8>&?A;K<^H/'NNK22TMX9.?.DD0J%QWZDD>@-?/G[,'
MAN[U#XB3:Z$9;+3+=U:3'#22#:$_+<?; ]:HWUWXH_:-^)8MK(/::5;GY ^6
MBL8>[MC[TC8Z=SQD 9'U3X.\(Z5X'\,VVAZ'$4MX02SN<O,Y^\[GN3^G &
M* -RO'/VG[Z2T^$20QYVWFI0P28.. KR?CS&*]-UKQ5H'ALPCQ!K5AIIGSY0
MNKA8R^.I )Y R.?>O,_VE;0:O\&%OK.19H+6^@N_,C8,K(P:,$$=0?-'- "_
MLQV<5M\(O/C'SW5_-(Y]QM0?HHKQ_P#::@2T^,*SV^8Y9K"&5V4X.X%E!S]%
M'Y5ZO^R[J\%Y\,;C3E=?M%A?.'CSR$<!E;Z$[A_P$UY/^T#./%'QU32M)*S7
M"1V^GC!X,S,3MS[&0 ^X- 'U[:2--90R/C<\:L<>I%2TR"(06\<0)(10H)]A
M3Z "BBB@ HHHH **** "BBB@ HHJ&\O+?3[*:\OIX[>VMT,DLLC;510,DD]@
M!0!2\1^(+#PMX<O=:U:58K6SB,C$G&X]E'N3@ >IKXZ^!N@7?B;XQZ==6\/E
MV]A,;ZX:-<)&JY*J/3+8 'IGTK<\?>-->^.OCVW\,^$(Y?[)CDQ;Q'*J^#@W
M$O'  /&>@Z#)P?HWX;?#K3/AMX873=./GW,Q$EY>,N&GDQZ=E'0+V]R22 =?
M4-X"UC.%!),;  =^*J:SXAT;PY;)<:_JEGIL,C;4>ZG6,.?09/)J1=9TU]%.
MKIJ%LVFB(S?;%E4Q>6!DMOSC&.] 'Q;\*/B+??#6]U/4;30FU6.ZB$;GS&C6
M/:=V<A3ZU[AX'_:9T3Q)K$&EZ_I<FB37#B.&<3B:$L>@8X4KD\="/4BO;(9X
MKF!)K>5)8I%#))&P96!Z$$=17QC^T)::1%\8;N+P]'%ODBC-U';@8%P<@C Z
M,1MR/4GOF@#[1HJKI:31Z19I=DF=8$$A)R=VT9_6K5 !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >"_M76%Q-X-T2^B5F@MKUDEP,A2Z?*3Z?=
M(_&M_4/CA\/KKX:7,T>I1J\U@T2Z68SYH8IM\K;C'4XS]WOG%>F:WHFG>(]%
MN=)UNT2[L;I-DL3]".H(/4$'!!'((!%>-S?LI^$Y+\R1ZSJ\5L6SY :,D#T#
M%?Y@T +^R]:M=?"G5H+^+S;*?4I4$<JY5U,4888/4'IZ=?>LK]F%1:^(?'%C
M9NSV$,\(BRQ(&&F /U('XX'I7N>@>'-,\,>';?1-$M_LUC;H51%8D\\DD]22
M23FLWP5\/_#_ ,/[*YMO#5J\*W4@DF:20NS$# &3V'/'N: .FHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /F[]KG[OA'ZWG_M"O2?%'P5\'>.=-
MBN+RP^P:B\*G[=8XC<G Y8?=?ZD9]"*=\6OA(GQ3320VLMI9TUI3D6WG>8)-
MF1]Y<8V#GGK7H<$0@MXX@<B-0H)[X&* /D'Q%\$/B#\.+YM7\+7$VH0P\K>:
M4S).B\?>C!W8]0I88'->O?L^?$GQ!X\T_6;3Q.\4\^E& )<+&$>02>9D.!QD
M>7U '6O8ZK6^G65I=W-U:V=O!<71!N)8X@K3$="Q RV,GK0!9HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /%_VF_%%[H7P_M--TV=[=M6N#',\9
M()B5<LN1TR2N?49'0US'A?\ 96L[G1K:Z\3:]=+<SQK(T%E&JK%D9V[FSN(]
M<"NW_:%\#7_C+P!%-HL#W-_I<WGK;QKEY8R,.JCN>AQU.W !)%>;^&OVH]0T
M;2H-,\3^'#>W5HGDO<Q7'DNQ7CYD*G#<<\CGL* -G7/V4-._LV5O#?B"[6\5
M28TOD5DD;'"DJ 5SQS@X]#6K^S+XMU+5/#^J^&]8EDFDT61/(>1MS+&^X>7G
MT4H<>S8' KF=:_:QN);*2+0/#*VUPR82XNKKS!&WKL"C/Y_A72_LR>#]3T;0
M-5\0:U#-!+K$D8@2<$.T:;CYA!Y^8N<9Z@9Z&@#W.BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXG:=9)/?SZ=?:<SM:7$8W*I?;N#+QD?(O0@C%=Y10!\W7/[.'C;5<6FL^/\
M[3IZGY5E>:;&.G[MFQ^M>N?#?X7:'\--,EATKS+F\N<?:;V?&^3'0 #A5&3Q
M^9-=K10 4444 %%%% !1110 4444 %%%% !7&?%'PGKWC'PK!I_A;7'T2\CN
MTF:=99(]Z!'!0E.>K ^GRUV=% 'R_J'[,GC75[D7&J^+;*^G"A!+<R32,%';
M+ G')KT'X9?"[QMX0\6#4?$?C!M5L!;/%]E^TS2 L<8.'XXQ7K]% 'AOQ2^
M.H^/_'[Z]9:W:VD$\4:2QS1,S)M&W*XX;@=R*]6\3>$=,\6^$9_#NLJSVDT8
M3>APZ,OW74]F!&?3UR*W** /FS_AF;Q5I4T\'ASQNL%C<<2C]["77T94)#<>
MIKT;X5?!32_AJ\M_)='4]8F3RS=-'L6)"<E47)QGC))R<=N17IM% !1110 4
M444 %%%% !1110 4444 %<C\2_#&M^+?"!TSPSK+:/>^>DGVA9'3*C.5RG/.
M1^5==10!\P:C^S+XWUBX6XU;Q=9WTRIL62YEFD8+DG + G&2>/>NZ^&OPH\<
M>$/%]OJ.O^,FU+3H87C-F+F9U;*X7Y6XP.OX5[+10!XC\6?@/J/Q#\;QZYI^
MLVMI$UND,L<\3%EVD\KCKP>AQ7>>-OAOIWCKP+;^&]2NIX5M3')!<0XW+(B%
M Q4\$88Y'OUKLJ* /F^X_9R\<30_V<WQ ,VE8V^5(\^-OIY6XK^&:](^&'P6
MT3X:L]['/)J6KRIY;WDJ!0BGJJ)SM!QR22??M7I%% !1110 4444 %%%% !1
M110 4444 %>>_&3X=7_Q*\*V>EZ9?P6<EO>"X)N Q5@$9<<=_FKT*B@#YETW
M]G#Q_HT;QZ1XV@L$D.YUM;B>(,?4A0,UTOA/X._$71/%VF:EJOCQ[VRM;A9)
M[?[9<-YJ#JN&X.?>O=:* /(/C-\&+_XF:SIVH:9JMM9M:P&"2.X1B"-Q;<".
M_/3]:[W2?"%I:?#FT\(ZIMO[6+3ULIR5VB4!-I.,\>HYR*Z*B@#YQN?V9-=T
M?5)9_!/C-[.&3('FF2&4+_=+1GYOR'TKKOAC\ ;#P1K8U[6]1_MG5D),)\O9
M'"QZMR26;D\G&,],\U[!10 4444 %%%% !1110 4444 %%%% !7)?$[PA=>.
MOA]?^'[&[CM)KIHRLDH)7Y9%;!QS_#76T4 ?,.F_LT^.=&D=](\8VM@\@P[6
MLT\18>A*@9K7L_@=\4+>^@FD^(LCI'*KLOVZY.0#DCFOH>B@#R[XT_">]^)]
MKI']G:E!93::TN1<(Q602;,\CD$;!VYS6YX4^'<.B?"*/P-JET;N%K:>">:$
M>62)6=FVYSC&_ )].G:NUHH ^=;C]G'Q9I326WA'Q]-;Z<Q)$$DDL. >Q"$A
MOK@9]*Z#X>_LX:5X5UJ'6?$.HMK5];OYD$0B\N&-QR&())<@\C.![5[510 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_ORT ?1U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img70551829_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_17.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Q,P  DI(
M @    ,Q,P  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( U\'U0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YA
M\?/^1#LO^PG'_P"BI:3X"JK^ +Y7 96U*0$$9!'E14OQ\_Y$.R_["<?_ **E
MKROPGH7CO5=&F?PC)?#3_.9)5@OQ ADVKG*EQD[2O./Y5700_P"+%MIUI\1;
MZ+28X8XPJ&1(?NB0C+<#@'U'K7?_ !:>23X->'7F),C36Q<MU)^SOFL_PA\$
M+XZI'>^+WB6WC?>;2-][3'@X9AP%SU[G'OFNB^/G_(AV7_83C_\ 14M 'F7A
M'5?&=_HA\->"XYD"R/<3RV[!'^8 8,A("CY>.02:M^'OB#XI\)>+H[3Q)>WD
M\"2B*\M[R0R,BD\L"3P0#D<X->C? B-%\ 3.J*&:^DW,!R<*F,UYM\:P!\2[
MD@ 9MXB??Y:?6P'O/C'6+G0/!VI:I8QB2XMH=T:E<@'(&2/09S^%>)I!\7/$
MV+R!M6BCDRZ!+@6BX/H"R\>GM7L^M^)[?PMX+&L:@'FV0H%0'YI78# R??J?
M3/6O)[+Q[\3O&D\K^%[:.*&-L'R(8]B\="\N1G'O20RMX)^(_B71/%]OHGB>
MYFN+>2X%M,EZ?WD#,0N[>>< XSDD8S]:[_XM>.[WP?I=I!HYC2^OF;$K -Y2
M+C)"GC)+#&>.#Q7A^I?VQ_PL'_BI?^0I]KC^T_<^]E?[GR],=*]P^+'@&[\8
MZ=:W.D%3?V6X")WVB5&QD G@-D#&<#DY/2AVN!YK9V'Q9O["+6;2YUB2WF42
MQD7X&Y3T(B+YP>H^7D<U[-X8U>]M_AU:ZIXL,L%U#;O)=F>/RW 4MU4@<X ^
MM>)Z-\0?&/P_DBTO4[>1K6$$+9WT10JO/W7QG'IU'I7I'C/Q1;>)O@7J.KZ8
M7C698D=&^\C><BLI_/KZ&A@<!>>._'/Q UR6S\+M<VT/+1V]DPC9$SPSR9!S
MTSR![4VV\:^._AYX@BM?$TEU<1G#R6MY*)?,0]TDYQWZ'&1@CC%9GP]\0^)_
M#XOW\*:$-4,VP3O]DEF,>-V!E",9R>O7'M5[QE=^//'"V8U;PE=PFS+^6;;3
MIUSOVYSN)_NBF(^B;&\AU#3[>]M6W07,2RQMCJK#(/Y&IZYSX?6EQ8?#_1[:
M]@DMYX[?#Q2J593DG!!Y!KHZ@9#:V=M91M'96T-NCN9&6*,(&8]6('<^M?/G
MQUN;2?Q]%%;$&>WLT2XP,88EF /J=K _B*]6^(_CZ'P5HX%OY<VJW(Q;P,?N
MCG]XP_NC]3]#CR?X<^ [SQSKK:YX@$DFF"5GFDD)#7<G7:#Z9ZG\!STI=P/6
M/A-IT^F_#734NE9))M\VQEP0K.2OYC!_&NSI%544*@"JHP !@ 4M2!\O_$N"
MXTKXJZC+<H'W3I<1YSAT(! _I^!KW+PK\2_#WBI8HH+I;2^< &TN&"L6P.%/
M1N3VYXZ5H>*?!NC>,+,0:Q;DN@(BN(CMDBSUVG\.A!%>"^//A?J'@F-=0ANT
MO-.:0(LP&R2-CR R_P!0>W;BJT8'N?BX7^A^ KW_ (0RT$5["%-M#:6RMC=*
M-Y6, @G!8]/4U\SR7FMGQ@+R19O[=^V"0*8 )/M&_('EXZ[L?+CVQ7N?P6\6
M7OB'P[=6.IR-//IK(JS,?F:-@=H/J1M;GTQ]3YC=?\E^7_L84_\ 1XH0'JGP
MLU?QGJ<NIKXT@O$2-8C;M<V8M^3NW  *N[MZXP/6N4^&GQ(\3^(?'UOI^KWZ
MSVDZ2DQ"WC7:0I88( /;N37M]?,_P:_Y*A8?]<YO_1;4 >S?%/7]2\-^"7O]
M&N!;W7GQH)-BO@$G/# CMZ51^$/BK5_%7AZ]GUVX6YF@N=B2"-4.TJ#@A0!^
ME1_&_P#Y)N__ %]1?UKG_@O*\'P[\12Q,4DCD=E8=01%D&CH!SWC/XF>(?$/
MBF32O"UU/;6BS^1;I:';)<,"5W;A\W.>!P,8[C-9OB/4_'>@Z!=:!XO6XDMM
M1";'NY/.*E'#_)("<] ""3QZ5-\$H(YOB3"\@RT-M*Z>QQM_DQKUKXQ11R?"
MS5&D16:-H60L,E3YR#(]#@D?0FGL[".4^ HE;PWKJVS*DQE41LPR%;8<$_C6
M=X*^)GBA_B+!HWBN]#PR3/:R0F&)/*EY"C*J"?F 7KW[UJ_L^_\ (%UG_KXC
M_P#037)?&32)M!^(:ZK:!HTOE6YBD'02I@,![Y"M_P "I=1GLOQ!\2/X5\%7
MFHVSJMW\L5MN7/[QCC./89//'%<S\'?$GB3Q3;ZG>>(+XW-M"R10?N$0;\$M
MRJCH"O'O7'?&'Q:FOZ-X:CM7Q%<VWVZ5 > Q^0#'JI$@_.O4OAIH8T'X?:;;
MLH$T\?VF;!ZL_P W/N%VC\*.@'5T445(!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MII]LMO86L-K OW8H(PBC\!Q4]%% !1110 4444 %%%% !1110 4444 %%%%
M!1152XU73K.\AM+N_M8+FX.(8)9E5Y.<?*I.3SZ4 6Z*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBL;Q?K7_".^#]3U4'#V\!\HX!_>'Y4Z_P"T10!Y%XW^*7B:R\::C%X>
MNO+TW3I5A=#;HX+CAMQ() +!AP1T'0U[7I>HPZMI%IJ-L<PW4*S)ST##.*\H
M\#^ QJGP8U%71#?:WF:-W8\&,_N@3V^8,<^C]^E:?P.UZ6]\,76BWC'S]+EP
MBL,,(VR0#]&#?3@53 ]/HK*\3>(+7POX>NM6O<%($^2/=@RN?NJ/<G_&O+M,
MUWXK>,H#JVB&TTZP9B(HVC0+)CT+AF/UX&<TK .^-<LB^+/"RJ[!1(6 !X!\
MQ.?K7LE?-GC'7]<U?Q/H=GXJTT6.IZ?*$D*\+*&=<,.H['D$@]O2O;/B-K-]
MH'P_U+4]*F$-W"(_+D*!MNZ5%/!!'0FFP.GHKG? &K7FN>!-,U'4Y1-=3QL9
M) H7<0[#.!@#@=JY;XH>,-;\.>(O#]KH]TMO#=.?/4Q*_F#>HQE@<<$],=?I
M2 Z+XF?\DUUO_KW_ /9A65\%O^296G_7:;_T,UJ_$S_DFNM_]>__ +,*Y?X<
MV^KW7P36'PW=Q6>IM,_D3S*&5<2Y.05;JN1T/6CH!OZ3\04U3XC7_A7^SFB^
MQJY%UYV[>5V\;-HQU/.3T]^.RKYOT2P\92?%C4K;3M6LXO$"B3[1=N@,;]-V
M!Y9Z\?PBO:O#Y\0Z#X9O[KQWJ5M?S6Y><26J !850$C[J G(;M^/H- =-17D
M&E:]\2?'PGU+PU=6&C:8)2D0F56)QVR48D\C)P!Z5V_@EO%XM[R#QM' 98G7
M[/<0E/WRX^;A>F"!U ZFBP'452UG5[30=&NM4U%]EM;)O<CJ>P ]R2 /<BKM
M>1_'_4)(]%TC348JMU</*W. =@  )_[:9_#VH0#=.\3_ !&\?^;=^%H[+1=-
M5]L<UPH8MCKR5;=]0H';UKI/"J?$:S\1"U\5R65_IAC8M=P! 0V,@  *>O'W
M:RT^+W@OPU8VNDZ>;V^AM(EA62U@&WY0!_&RYSZC/UKJ/"WQ T#Q>[Q:5<,M
MR@)-O.NR0J,?,!D@CGL: .;^+GBG7O#MQH-OX=O5M'OY)4D9HD?)!C"_>4X'
MSGI5'^S/C/\ ]!RP_P"^(?\ XU57X\3K;:AX5GD!*Q2SNP7J0#":UHOCSX5D
M?:]KJD0_O/ F/T<FGT ZSP9#XF@T61/&=S#<W_GL4DA"@>7M7 .U0,YW=JZ"
MJ6E:QI^N6"WND7<5W;L<!XVS@^A'4'V/-7:D!D\JP6\DS@E8U+$#K@#->#^&
M-)O_ (R:SJ6H>(M5N+>QMF14M;=A@;B2%4'@  =2"23]:]Z95=2K@,K#!!&0
M17SQ#KS?"/X@ZO9Z8T>HZ=(I A$^=IP2@8CHRM\IR,XSZTT!:\3Z7=_!SQ-I
M=]X>U2YFL;O=NMISG<$V[U;&%8'?D' (_#->_5Y)X>\&ZUXXU^V\6>.W1+95
M#V5A$W\.<KG'1>_4D]^.OH5OXMT2Z\2S>'X+X-JD()>W\IQC !/S$;3P1T-#
M V:**YGXBZG)I'P[UF[AP)/L_E*3V,C!,_4;J0'&ZY\4=8UG77T'X<Z?]KF1
MMLEZR;E'(&X \*N>-S<?H:BF@^-%M";H7EI<[3DVR)!DC_OD?SS6G\#M%BLO
M YU,Q+]HU"9SYO?RT.P+]-RL?QKTJGL!YSX#^*#:[JCZ!XEM1I^LQDJ!@JLK
M+U7!Y5NO'?!^E:/Q?_Y)3K'_ &P_]'QUP7QB5/#_ ,1]#U^SQ%.ZK)(R_P 3
M1N.3Z_*0OT&*[WXO_P#)*=8_[8?^CXZ8$WPJ_P"27Z-_US?_ -&-77UQWPND
M2+X5Z1)*RHB0R,S,<!0)&R2:XUO'GC7QQKUW9^ (8;2QM&(^U2(K;AG +,X(
M&<9"@9QGKBD!T_QFD=/AE>[&9=TL2M@XR-XXK4^&A+?#71"Q)/V;'/U->4>/
M=<\;67AB;0O&]E%,ERZ-;ZA"  2I!*G;QT!XPI^HKU;X9_\ )-=$_P"O?_V8
MT= .IHKRFZ\=^*?&7B"YTSX;Q0165J0)-3N$R"<XR,Y ![#:6(&?:JU_XF^(
MGP_N(+OQ<UIK.DR2".22V104SZ$*N#UQD8/(]#18#U^BLN75H[OPG)JVERYC
MDLVN(),?[&X'![^QKQ[P]\1_''BC34T;0@MSK(=Y9KZ2.)5CAX  & N<GJ1Z
M<&BP'NM%<WX)3Q5%I4\?C66":[6<B*2(*-Z8')V@#KGL#724@/*/C9J]Q/%I
M7A/3\_:-4G5G /##=M13[%^?^ BO3-+T^'2=(M-.MAB&UA6%..H48S7DL[MK
M?[34,;'=#IT8"^P6$MW_ -MZ]EIL HKPKPO\4/&FMV#:1IUO_:FM2S[ENWA5
M8[>' 'S!0!USR?7OD 6=3\6?$KP%>6EWXK>#4=.EDV,$CC"MQDKN505;&2,^
MAZX-%@/;**H?VH)_#G]K:=;O=B2T^TP0*<-+E-RKWP3P/QKS;_A9_C;_ *)Y
M?_\ ?F;_ .(HL!ZQ4=Q<P6EO)<7<T<$,:[GEE8*JCU)/ %>5_P#"S_&W_1/+
M_P#[\S?_ !%;GB73-<^(?PSMH+>%='O;J1)+BVO&=-JJ3E3\N>H5AD>E%@-.
MP^)?@_4M12QM-<A,[G""1'C5CZ!F4+GVS727-U;V5L]S>3QV\$8R\LKA54>I
M)X%</K_PD\/:CX5&FZ79065Y G^CW87YV;_IHPY8'OG.,\5R]YH?Q4UK0AX5
MU&"P6P.Q'U RKN=%P0#ALD9 _@!..O)R: >EZ]XD@T?PC<Z]:H-2ABC#QK;O
MD2Y( PPSQSUYXKS\S?&/68C>VPL](C9<I:%(PQ_!PQ!^I'7M7IFB:7%HFA66
MF0,7CM($A#MU; QG\>M7J /*_A_\2]5OO$\GACQC L6H;F6*4)L.]1DHP''0
M$@CZ<Y%=UXL\3V?A'P]-JM\K2!"$CB3K(YZ+GMTZ]@#UZ5Y)IZ1^)/VD9[S2
MBQM+6;S))8UX_=Q!"<CC#.,9[YK2^/,[7%UX=TM=VV:21V [G**O\V_.G;4!
M+#5_BUXMM!JNDM::992#,*&.,"0>HWAFY]3@'Z5I^!OB-K$GBN7PIXXMTM]2
M!*Q2@!<N!G80/E.1R&'!XZY%>FVUO%:6L5M;H$AA01QH/X5 P!^5>+_&)1IO
MQ(\-:M#M24;"6QGF.7<"1W^]^E&X'I7C?QA:^"_#S:C<1F:5V\JWA!QYCD$C
M)[ 8))_Q%>?V=]\8/$%DFK6+6EC;RJ'BMC'$OF+Z@.&8 ^Y''/O47QEW:IX\
M\+Z(X+PRLN4!QN,DH0\_1?PKV955%"H JJ,  8 %+9 >:?#SXC:CJNNS^&?%
ML"6^K0[@CA=IE9<EE*CC('.1P0/S?\:]%:Z\)PZW: K>:3.L@D0?,$) /Y-M
M/M@USOQ"1-*^._AV_0A1<&V:4D9_Y:E"<?[H%>J>++%=3\'ZO9N,^=9R@<9P
MVTX..^#@TP%\*ZTOB'PIIVJJ1FY@5GQV<<./P8$5K5Y=\!M0:X\&7=F_/V6[
M.WV5E!Q^8;\Z]1I, HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5X]\==7N)VTKPQI\<DTURWVB2*-
M-S/R5C4 <G)W\>PKV&O)/#VC:IX@^-U_XBUC2[JSL[(,+7[5;E0Y \M,9X/&
MYLC/./44T!)8?$;Q'INFVUC;?#/6!#;1+#&"TF=J@ ?\L?05R7A/Q!<Z!\9&
MN=0TBYT6'6W*/:7(9=GF/PWS*,C>#S@ #(KZ$KR[XU^%K_5[#3=5T6UN+F\L
MY3&Z6REGV-R& '/##M_>_)H"3X\R.G@&U5&($FHQJP]1Y<A_F!79^#8XHO V
MAK; "/\ L^ K@8SF,'/U.<_C65K&BS>/_AG':WT<EA?W$$<NV="AAG7DAEZX
MSD=.ASBN"\.^(/B'X,TT:#/X3NM26W)%O*$=@B\_+O4$$9Z<Y XZ8PN@$OQL
M_P"1O\+_ .\?_1B5V7Q?_P"24ZQ_VP_]'QUYMXG\+^.=4U32->\06\EU<37
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M$GG X& >37I'@*PDA^&^EV.I6TD3_9C'-!,A1ADG((/(X-'0#R+X8:7XXO-
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MX^\,Z9"-TT@4!0P!.^4*.O Y4U)H_BSXC>&--CT>_P#"-UJ<D V17 C=\+T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ///C%X9O-<\-VU_I,4DVH:7/YD<<2EG=&P
M&"@ DD$*?HIKM-"O[C4]!LKV]M)+*YFA5IK>5"K1OCYA@\XSG&>V*OT4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5YM\8+/5]=M=(\/Z-8W$
MZW5T)+B=(6,<('RKN<# 'S$_\!_/TFB@"II6FV^C:1:Z;9*5@M8EB3.,D 8R
M<=SU)]:MT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!YUI/Q$\4:YI<.HZ7X$\^UFW>7)_;$
M2YPQ4\,H/4&KO_"7>-?^B??^5J'_ .)JO\)_^27Z3_VV_P#1SUV-,#EO^$N\
M:_\ 1/O_ "M0_P#Q-'_"7>-?^B??^5J'_P")KJ:* .6_X2[QK_T3[_RM0_\
MQ-'_  EWC7_HGW_E:A_^)KJ:* .6_P"$N\:_]$^_\K4/_P 31_PEWC7_ *)]
M_P"5J'_XFNIHH Y;_A+O&O\ T3[_ ,K4/_Q-'_"7>-?^B??^5J'_ .)KJ:*
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M5M.U31?[)NM+\GS(_M2S[O,5F'*@#H!Z]?:NHKA_"/\ R5#QQ_VX?^B6KN*
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M/_)6;_XBOG:BCZO /J%+N_Z^1]$_\+1\'?\ 08_\E9O_ (BC_A:/@[_H,?\
MDK-_\17SM11]7@'U"EW?]?(^B?\ A:/@[_H,?^2LW_Q%'_"T?!W_ $&/_)6;
M_P"(KYVHH^KP#ZA2[O\ KY'T3_PM'P=_T&/_ "5F_P#B*/\ A:/@[_H,?^2L
MW_Q%?.U%'U> ?4*7=_U\CZ)_X6CX._Z#'_DK-_\ $4?\+1\'?]!C_P E9O\
MXBOG:BCZO /J%+N_Z^1]$_\ "T?!W_08_P#)6;_XBC_A:/@[_H,?^2LW_P 1
M7SM11]7@'U"EW?\ 7R/HG_A:/@[_ *#'_DK-_P#$5:TWX@>&-6U"*RL-55[B
M4XC1HI$W'TRR@9]J^;*4$JP*D@@Y!':CZO'N)X"G;1L^M:*\U^''Q'&JK%HV
MO2@7P&V"X8_Z_P#V3_M_S^O7TJN.47!V9Y=2G*G+ED%%%%29A1110 4444 %
M%%% !1110 4444 %%%% '*:UXW_LC5YK'^S_ #O*V_/YVW.5!Z;3ZU0_X63_
M -0K_P F?_L:P_&G_(WWO_;/_P!%K6%7S=;'8B-645+1-]$>34Q%53:3ZG<_
M\+)_ZA7_ ),__8T?\+)_ZA7_ ),__8UPU%9?7\3_ #?@O\B/K-7O^1W/_"R?
M^H5_Y,__ &-'_"R?^H5_Y,__ &-<-11]?Q/\WX+_ "#ZS5[_ )'<_P#"R?\
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MUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.]/"7_DS1]I^)WIX2_\ )FNKHH S?!?B27Q)H;2WT26^I6LSVU[;H"!'(I[
MDG!&#_\ JKH:\^O'_P"$2^(UMJ@^33->VVEYV6.X'^K<_4?+^9KT&D 4444
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M?,<=!CIBG9BN=517*6_BHZAXTMK+3IUFL)(CO/ED'<%8]3SV%=71:PPHHHI
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MN9%4\/&$W-'K?P,(SKH[_P"C_P#M2N=U;X3Z[H^D7.HW%SI\D5M&9'6*5RQ
MZXR@'ZUPU%'(U)R3W#V4E4<XRWMT['M?B'2H?BKX?TV_T*_MH[NV!\V&5B I
M;&Y6P"005XXP?RJAXPETWPE\,$\))?+>7TI4D)CY1Y@D+$9^4=AGD_GCR.BD
MJ5K*^B(CAVK+FT3O8]P^&5Q!XD\")IEZ=[Z9=H0&;<=JN)$)'89!7'HOX4[0
MM4M?&6M>+]#O71[6:53 A/)"CRRP&>@*(PQT)KPVBDZ.K=Q/"IN33W_ [[XP
M:JM_XS6UADW1V,"QL <@2$EF_0J/PKF/"A \9Z*3P!J$'_HQ:R**T4;1Y3>-
M-1I\B/<?B!\/-2\6^)+:^M+JT@MH[989#,S;AAV)( 7!X;U%9/BC4M,\%?#]
MO"6EWWVK4)AMG=,':&(+EO3(X ZX/XUY)14*D]$WHC&.':24I72\CV.VM[7X
MC_#'3])L+Z&#4]-$8,4AQRBE.1UVD'.0#SQZBEGM[+X<_#/4=*O]0CN=1U))
M%$47/S.FS@==HQG<<?G@5XW11[+I?0/J[O;FTO>QZ_X$T'Q19Z1I][X=UZQF
ML;C][<6=P"50G@J" 3GKG!7D=Z/%6NZ'I7Q;T?4;9H6EBRE_)'T&Y=@)/0D*
MQ/K@#TQ7D%%'LKRNV/ZO>;E)]^EMSZ#UBV\6ZI?+?>$?$UC'I4RJ0KQH^S@9
M*ML;=GKR:\B\?3W<OBEXM0UF/6)K>)8C<1Q+&HZDH O'!8\^OY5S-%.%/E?_
M  !TJ'LW>_X?J%%%%:G2%%%% !1110 4444 %%%% !1110 4444 %%%% "@E
M6!4D$'(([5[7\./B.-56+1M>E O@-L%PQ_U_^R?]O^?UZ^)TH)5@5)!!R".U
M9S@IJS,:U&-6-F?6M%>8> /B?;W5J-.\4W<=O<0K^[O9W"I*H[.QX#>YZ_7K
MVO\ PFGA?_H9-(_\#XO_ (JO.E%Q=F>#4IRIRY9&U16+_P )IX7_ .ADTC_P
M/B_^*H_X33PO_P!#)I'_ ('Q?_%5)F;5%8O_  FGA?\ Z&32/_ ^+_XJC_A-
M/"__ $,FD?\ @?%_\50!M45B_P#":>%_^ADTC_P/B_\ BJ/^$T\+_P#0R:1_
MX'Q?_%4 ;5%8O_":>%_^ADTC_P #XO\ XJC_ (33PO\ ]#)I'_@?%_\ %4 ;
M5%8O_":>%_\ H9-(_P# ^+_XJC_A-/"__0R:1_X'Q?\ Q5 '!^-/^1OO?^V?
M_HM:PJUO%%[:ZCXDNKK3[F&ZMY-FR:"0.C810<$<'D$?A637Q^(_C3]7^9X5
M7^)+U84445@9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD?\ @?%_\50!M45B_P#":>%_^ADTC_P/B_\ BJ/^$T\+_P#0R:1_X'Q?_%4
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MUKBOA!_R2G1_^V__ */DKM: "BBB@ HHHH **** "BBB@ HHHH **** //\
MX3_\DOTG_MM_Z.>NQKCOA/\ \DOTG_MM_P"CGKL:;W ****0!1110 4444 %
M%%% !1110!REM_R70_\ 8M_^W-=U7"VW_)=#_P!BW_[<UW5, HHHI %%%% !
M7%?%_P#Y)3K'_;#_ -'QUVM<5\7_ /DE.L?]L/\ T?'36X'34444@"BBB@ H
MHHH **** "BBB@ HHHH XC0M%TO5_BAXT_M;3;.^\K[#Y?VF!9-F83G&X'&<
M#\A76?\ "%^%_P#H6](_\ (O_B:P?"/_ "5#QQ_VX?\ HEJ[BF!B_P#"%^%_
M^A;TC_P B_\ B:/^$+\+_P#0MZ1_X 1?_$UM44@,7_A"_"__ $+>D?\ @!%_
M\31_PA?A?_H6](_\ (O_ (FMJB@#%_X0OPO_ -"WI'_@!%_\31_PA?A?_H6]
M(_\  "+_ .)K:HH \V^%GAC0=1^&FE76H:)IUU<2>=OFGM(W=L3.!DD9/  _
M"NO_ .$+\+_]"WI'_@!%_P#$UB?"#_DE.C_]M_\ T?)7:TWN!B_\(7X7_P"A
M;TC_ , (O_B:/^$+\+_]"WI'_@!%_P#$UM44@,7_ (0OPO\ ]"WI'_@!%_\
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M[9_^BUK"KX_$?QI^K_,\*K_$EZL****P,PHHHH **** "BBB@ HHHH ****
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M\+_]"WI'_@!%_P#$T?\ "%^%_P#H6](_\ (O_B:VJ* ,7_A"_"__ $+>D?\
M@!%_\31_PA?A?_H6](_\ (O_ (FMJB@#%_X0OPO_ -"WI'_@!%_\31_PA?A?
M_H6](_\  "+_ .)K:HH Q?\ A"_"_P#T+>D?^ $7_P 31_PA?A?_ *%O2/\
MP B_^)K:HH Q?^$+\+_]"WI'_@!%_P#$T?\ "%^%_P#H6](_\ (O_B:VJ* ,
M7_A"_"__ $+>D?\ @!%_\31_PA?A?_H6](_\ (O_ (FMJB@#%_X0OPO_ -"W
MI'_@!%_\31_PA?A?_H6](_\  "+_ .)K:HH Q?\ A"_"_P#T+>D?^ $7_P 3
M1_PA?A?_ *%O2/\ P B_^)K:HH Q?^$+\+_]"WI'_@!%_P#$T?\ "%^%_P#H
M6](_\ (O_B:VJ* ,7_A"_"__ $+>D?\ @!%_\31_PA?A?_H6](_\ (O_ (FM
MJB@#%_X0OPO_ -"WI'_@!%_\31_PA?A?_H6](_\  "+_ .)K:HH Q?\ A"_"
M_P#T+>D?^ $7_P 31_PA?A?_ *%O2/\ P B_^)K:HH Q?^$+\+_]"WI'_@!%
M_P#$T?\ "%^%_P#H6](_\ (O_B:VJ* ,7_A"_"__ $+>D?\ @!%_\31_PA?A
M?_H6](_\ (O_ (FMJB@#%_X0OPO_ -"WI'_@!%_\31_PA?A?_H6](_\  "+_
M .)K:HH Q?\ A"_"_P#T+>D?^ $7_P 31_PA?A?_ *%O2/\ P B_^)K:HH Q
M?^$+\+_]"WI'_@!%_P#$T?\ "%^%_P#H6](_\ (O_B:VJ* //OAS#%;)XG@M
MXTBAB\0W:1QQJ%5%&P  #H .U=E7(?#_ /UGBO\ [&2\_P#9:Z^FP"BBBD 4
M444 %%%% !1110 4444 %%%% &9XCT2'Q%X>N],GX$Z81_[CCE6_ @5'X"UZ
M;7/#:KJ/RZG8.;2^0]1(G&[_ ($,'/KGTK7KC;Y_^$2^(MKJP^33-=VV=[_=
MCG'^JD/U^[GZFF!Z#1112 **** "BBB@ HHHH **** "BBB@ KA+G_DNH_[%
MO_VYKNZX2Y_Y+J/^Q;_]N: .LHHHH **** (;V.::PN(K:3RYGB98WS]UB.#
M^=< G@3Q!&SM%J%M&7.6V3.N3^"UW][<BSL+BZ9=P@B:0C/7 S_2O-;>[UBY
MU;1=0OKR1HKZ\Q'&LA  610?EZ <X_"JC<3-[0?"VMZ=K<%U?:A'+!'NW(LS
ML3E2!P0!U-=E7,2WMY:_$>&S:X=[6[M]XA)^5,*?ZI^M=/28(****0PHHHH
MYGX0?\DIT?\ [;_^CY*[6N*^$'_)*='_ .V__H^2NUH **** "BBB@ HHHH
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M^1G \JW+@>V3UJHW$S2\-:1JUUX@;7->0QR!"L:D!6)QM^Z.@ SZ'FNSKCM
MU/Q3<ZU#%JMK(EH0WF,T&S'RG'/UQ78TGN""BBBD,**** .9^$'_ "2G1_\
MMO\ ^CY*[6N*^$'_ "2G1_\ MO\ ^CY*[6@ HHHH **** "BBB@ HHHH ***
M* "BBB@#S_X3_P#)+])_[;?^CGKL:X[X3_\ )+])_P"VW_HYZ[&F]P"BBBD
M4444 %%%% !1110 4444 <I;?\ET/_8M_P#MS7=5PMM_R70_]BW_ .W-=U3
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M , H_P#"C_A$_#G_ $ -+_\  */_  K?ZRNQV_7X_P I\P45]/\ _")^'/\
MH :7_P" 4?\ A1_PB?AS_H :7_X!1_X4?65V#Z_'^4^8**^G_P#A$_#G_0 T
MO_P"C_PH_P"$3\.?] #2_P#P"C_PH^LKL'U^/\I\P45]/_\ ")^'/^@!I?\
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ME_\ @%'_ (4?65V#Z_'^4^8**^G_ /A$_#G_ $ -+_\  */_  H_X1/PY_T
M-+_\ H_\*/K*[!]?C_*?,%%?3_\ PB?AS_H :7_X!1_X4?\ ")^'/^@!I?\
MX!1_X4?65V#Z_'^4^8**^G_^$3\.?] #2_\ P"C_ ,*/^$3\.?\ 0 TO_P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_H*67_@0G^->-44?VK/^5!]=EV/9?[<TG_H*67_ ($)_C1_;FD_]!2R_P#
MA/\ &O&J*/[5G_*@^NR['LO]N:3_ -!2R_\  A/\:/[<TG_H*67_ ($)_C7C
M5%']JS_E0?79=CV7^W-)_P"@I9?^!"?XT?VYI/\ T%++_P "$_QKQJBC^U9_
MRH/KLNQ[+_;FD_\ 04LO_ A/\:/[<TG_ *"EE_X$)_C7C5%']JS_ )4'UV78
M]E_MS2?^@I9?^!"?XT?VYI/_ $%++_P(3_&O&J*/[5G_ "H/KLNQ[+_;FD_]
M!2R_\"$_QH_MS2?^@I9?^!"?XUXU11_:L_Y4'UV78]E_MS2?^@I9?^!"?XT?
MVYI/_04LO_ A/\:\:HH_M6?\J#Z[+L>R_P!N:3_T%++_ ,"$_P :/[<TG_H*
M67_@0G^->-44?VK/^5!]=EV/9?[<TG_H*67_ ($)_C1_;FD_]!2R_P# A/\
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M=ZIZ^8G&[_@0P<^N:V:XS4G_ .$1^(EIK2_)INM[;*_]$F'^JD/_ *#GTS3
M]"HHHI %%%% !1110 4444 %<)<_\EU'_8M_^W-=W7"7/_)=1_V+?_MS0!UE
M%%% !1110!7U"Y-GIEU=* Q@A>0 ]\*3_2N3?Q5?6W@B/4IVA:[NI62':,;
M,C..^-I_,?2NPN($N;:6"49CE0HP]01@UPMOX,CM]7@@U'6('M8I-T5LSX=B
M2.-N>,\9(ZU2MU$[EOP[K>M1:]'I?B $M<Q&6(LH#+P3V[<'@],5V=8;Z'<3
M>-(]8FGC\B&+9%& =W0CG_OIC6Y28(****0PHHHH YGX0?\ )*='_P"V_P#Z
M/DKM:XKX0?\ )*='_P"V_P#Z/DKM: "BBB@ HHHH **** "BBB@ HHHH ***
M* //_A/_ ,DOTG_MM_Z.>NQKCOA/_P DOTG_ +;?^CGKL:;W ****0!1110
M4444 %%%% !1110!REM_R70_]BW_ .W-=U7"VW_)=#_V+?\ [<UW5, HHHI
M%%%% !7%?%__ ))3K'_;#_T?'7:UQ7Q?_P"24ZQ_VP_]'QTUN!TU%%%( KG-
M=TC1_$-^+::[6+485P C#?C&[!4]1@YX]:Z.O.M5T637?'^IV\$X@ECA25&(
MX)"QC''3KUJHB9>7P)I>D@WNKW[R6T1!92FU<Y &>IQSVKM(9H[B".:%@\<B
MAT8=P1D&O--6US6+?1;C1-?MV:60+Y<['!PK ]N&Z=?SS7?Z%_R+NF_]>D7_
M * *'?J"+]%<;J?C#4I=2N-/T'36E>!VC>5E+G(."0!P.?4^GTJ@]MX\O LC
M221Y'"B2./CZ#^O-'*%ST&BO/E7QW8#=^\F7N"8Y/7\:T_#_ (ON[W5(M+U6
MQ,-T^[#@%>BD\J>1THY0N==1114C.6\(_P#)4/''_;A_Z):NXKA_"/\ R5#Q
MQ_VX?^B6KN*; ****0!1110 4444 <5\(/\ DE.C_P#;?_T?)7:UQ7P@_P"2
M4Z/_ -M__1\E=K3>X!1112 **** "O&M<_Y&'4?^OJ7_ -#->RUXUKG_ ",.
MH_\ 7U+_ .AFO'S7X(^IP8WX44:***\ \T]"TJ!/%'@>&SD;$EO*L98=5"D<
M_P#?!Q63X^U#SM5BT^)OW5J@RHS]\_SXQ^9K"TW6]1T@2#3[DPB3&X;58''U
M!JK<W,UY=27%S(9)9&W,Q[FO0J8J,Z*@E[VB?HCIG64J?*M^OR/0;2UT_1?!
M,=OJMS):"^&975"6RPSMQ@X^48Z?D:GT"+1)]+N]*TJ]ENHG4EQ*I!4,,<?*
M/2O/]1UB_P!6\K^T)_.\D$)\BKC.,] /04S3]2N]+N?M%A,89=I4L #D'M@\
M=JT6-A&:2C[J5O.WWV+6(BI*RT6GF=!X/T%YM>EENUQ'I[D-D<&0'@?AC/Y5
MT4>H6GC/3]2L$PIC;]RQ!&1_"_Y@Y'I]:XAO$VK/;W$)N@([G<9@(4&_(P<D
M#TJG8:C=Z7=?:+"8Q2[2N[ /![8/%33Q5.E%0BO==[^8HUH02BEIU-+2]1M]
M!DN;?4]%BO)MX!\XC]WC/ RIHFV^*->MX=,L(K#<FPI'C:,$DL< =C^E95Y=
MSW]V]S=OOFD.6;:!GC'0<4^PU&ZTRZ^T6,OE2X*[MH/!]CQ7*JJT@_@OV5[?
MUYF//]E_"=[J0N?#FC1Z7X>LKF:9U)DN8X2V,]3D#[W\A^%<_P"$[FST/6+A
M];,EI,L6U%>)L@G!/&,@XQ^!JM_PFFO_ //_ /\ D&/_ .)K+O\ 4+G4[HW-
M]+YLI !;:!P/8"NFKB:?/&=.^FR:T_,UG6CS*4>G3H>B>&4T0ZE=SZ3?W%W<
M2C=-YJXZG.?NCO7#^)([*/7)QITSRH6)D+CH^3N'0<56TW5KW297DT^;R6<;
M6.Q6R/Q!JK)(TLK22'<[DLQ/<FLZV)C4I*'+9_UYDU*RG!1L=K\.O]5JO^['
M_P"SU+X0\G6_"]WH]V>(V^7'55;D$9[A@:Y#3M8O])\W^SY_)\X /\BMG&<=
M0?4TW3M5O=)G:73YS"[+M8[0<CZ$$5I2Q4(1A%K173^94*T8J*?2]_F=QJ5\
MLWQ#TNRCQLM 00!T9ER1^06JFJ?\E0M/K'_*N174[Q=3_M 3M]KW[_-(!.?I
MT_"GR:Q?2ZJNHR3EKM2")-HXP,#C&/TIRQ<9)W7VK_('73W[W.YN9$3XH6OF
M#EK;:IQT.&__ %?C5&[T74Y?B(MU';R>1YT<OG?P[!C(SZ\$8Z_A7)7NJ7NH
M7JW=W.7N% "R* I&.1C&*N3>*];GA$4E^^P$'Y552?J0,FF\52G=23^*Z_X)
M3K0E>]][G8W<B)\3K+S!RUJ54XZ'Y_\ ]7XUGW>BZG+\1%NH[>3R/.CE\[^'
M8,9&?7@C'7\*Y*]U6]U"\6[N[AGG0 +( %*X.1C&*N3>*];GA$4E^^P$'Y55
M2?J0,FG+%4IWYD_BNO\ @@ZT)7O?>YU]]_R5+3O^O8_^@R5'82QQ_%&_60X,
MD.U/<[4/\@:XZ37M2DU2/47N<W<:[4DV+P,$8QC'<]JK3ZA=7-^U[+.WVECD
MR+\ISC';I2EC(7NE]J_RM83KQO=+K<]!N+V>RUIQ;>$5EE#DI=1@#?G/S;MG
M!/?FN)\17$MUX@NY;FW^S2E@'BWA]I"@=1UZ5./&&O",)_:#8QCF-,_GC-8\
MDCRR-)*S.[DLS,<DD]2366)Q$:L>6+>]]DOR(JU5-67Z'9_#?_CZO_\ <3^9
MK*?PSJNHZ]<*EI+%&\[$RRH54 L>>>OX5F:;J]]I$COI\_DM( &^4-D?B#5Y
M_&.O2*5;4& /]V- ?S IQK4)48TZE]+[6&ITW!1E?0ZKQ!J=I%XGT:R8JZV\
MH:3G.PG 7/ICK^59WC31=3O_ !#'):VTMQ')$%1E&0N,Y!/;KGGUKC&9G<N[
M%F8Y))R2:UK?Q7K=K;K##?OL48 958@?4@FKEBH55)54TF[Z#=:,[J?7L=5X
MRDF2VT>TA?=J'G*R $?>  SS_M$=:LV\8\12-;>(=!DM[E(_^/D*0IQZ-^.<
M9(ZUY[+?W<U\+R6XD>X#!A(QR00<C'IBM&3Q=KLL)B?4&VD8.U%4_F!FK6,I
MNI*4D[/IH_ON4J\7)M[=CJO!:06TFL::O[UX9R/FQB11E1_+GZTZSU2]MYY!
M9>#?LS_=9E81@_\  M@!'%<!:7EQ8W"SV<SPRKT9#C\#ZCVK2F\6ZY<0F*2_
M?8PP=J*I_,#-*GC(Q@HZJU]K/\PCB$HI;6]/U,J>7SKB27;MWN6V@YQD]*91
M17F;G&%%%%( HHHH **** "BBB@ HHHH L6-]<:=>)<VDACE0\'U]CZBO5/#
M_B"WUVSWIB.X0?O8L]/<>HKR.K%C?7&G7B7-I(8Y4/!]?8^HKMPF+EAY?W3H
MHUG2?D>UT5D>'_$%OKMGO3$=P@_>Q9Z>X]16O7T\)QG%2B]#UXR4E=!1115E
M!1110 4444 %%%% !1110!Y3XT_Y&^]_[9_^BUK"K=\:?\C?>_\ ;/\ ]%K6
M%7Q^(_C3]7^9X57^)+U84445@9A1110 4444 %%%% ';>&+&QUGPI>6S6L'V
MR+<JR^6"XR,J<XSUR/PKG/#FG_VGX@M;=EW1[]\F5R-J\D'ZXQ^-:/@6_P#L
MGB(0,<)=(8S_ +PY'\B/QKI=.TM- U37-5F3,,8)BP>2I&]@/QP/PKUJ=-5X
M4Y=M'\M?R.V$%4C!]MSE?&9M4\0-;V-O% D"*K"*,*&8\D\?4#\*Z[2M'TJU
MLK'3;ZQADN[BW:1G>-2P/&1NZ\;N/]VN,T.TDU_Q2AF"D/*;B?C(QG)&#ZGC
M\:[?4=&U2Z\5VFIV\MNMO;84(\C;B/XN-N 2"1U["M,,G.4JRC>[M\NOX%45
MS-U+;L\[NH#I&N/#+&LOV:?[CC(< Y&?8C^===K^@VVL:59:CX?MXEWD*R0H
M%!#'&3@=0>#^/I5+XA6'DZM#>H/EN$VL<?Q+_P#6(_*M[PV$\/>&K;^TI#&U
MW,-J-_ 7P /;@9/IS44J*56I0FO=[]NPH4TIRIRV,/Q=#IVCZ9::5:VT)NBH
M:2?RAOVCON]20?RKCZZ7QMITEMXE,\SGR;O#+(1G;C (]\<?@12W=CX12SF:
MTU2[>=8V,2,IPS8X!^0=ZY\13<ZLME;I>QE5BY3>RL1:5K6C:=I\23Z,MY<D
MGSI)<$8R<;<Y[8]*VO%VB:;_ & FJV%NML_R'")M#*W8KV//I6)X7\--K%Q]
MHNU*6$1^=LXWG^Z#_,U-XN\1IJDB66G_ "V4!ZC@2'MQZ#M6D96PS=5*STCI
MKZEIVI/G7H0^$M(AO;N6]U!0;&S4O(6^ZQZ@>_J1]/6M?QM9V,6BV5S96<-N
M99 <QQA205S@XK0G\.7<GA&UTO2WMHUD"R7+NQ_>-P>,*<\XYXX44[Q?I,]Q
MX7@"/&/L2AY,D\@+@XX_PKI6'<,/*'+K:]_/_@(U]DXTG&W0\VHHHKPSS@HH
MHH **** "BBB@ J]H?\ R,.G?]?47_H8JC5[0_\ D8=._P"OJ+_T,5I3^->I
M4/B1[+1117V9[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!P/P_\ ]9XK_P"QDO/_ &6N
MOKD/A_\ ZSQ7_P!C)>?^RUU]-@%%%%( HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *S?$6BP>(O#]WI=S@+<1D*V/N-U5OP.#6E10!C> -=GUGPV(-2R
M-4TV0V=ZIZ[TX#?\"&#GUS745Y[J;_\ "(_$2SUM?DTW6MME?^B2C_52'_T$
MGL,UZ%3 ****0!1110 4444 %<)<_P#)=1_V+?\ [<UW=<)<_P#)=1_V+?\
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M<_\ \71_PJ#P-_T _P#R;G_^+KM:*0'%?\*@\#?] /\ \FY__BZ/^%0>!O\
MH!_^3<__ ,77:T4 <5_PJ#P-_P! /_R;G_\ BZXF_LX-.U*YLK-/+M[:9XHD
MR3M120!D\G@=Z]KKQK7/^1AU'_KZE_\ 0S7CYK\$?4X,;\**-*H+,%4$DG
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M_DW/_P#%UVM% '%?\*@\#?\ 0#_\FY__ (NC_A4'@;_H!_\ DW/_ /%UVM%
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M_A4'@;_H!_\ DW/_ /%UVM% '%?\*@\#?] /_P FY_\ XNC_ (5!X&_Z ?\
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MWXBEU2SDF-\L>/+EX"K@+N _3KWZ5T])@@HHHI#"BBB@#F?A!_R2G1_^V_\
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MY P?8]NU;E4X])L(M1:_CM(ENFSF4+SSU/U]Z0S-U[Q)I6EWD5EJEO),742
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M(3YDY=5(..6Y(Y/;TKS=[^\EN5N)+J=YT^[*TA++]#UJ?^W-6_Z"E[_X$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X'X?_ZS
MQ7_V,EY_[+77UR'P_P#]9XK_ .QDO/\ V6NOIL HHHI %9FMP:G)#%+H\VR:
M)B3&3Q(#VYX_.M.BHG%3CRLF4>96.0O-.\1:^\4.IQ06ENC;CL8'/OC)R<?3
MK4_B#P_=S7%G=:6JRFV18Q#(1C"G(//!]ZZBBN9X.#34FVWUZZ&7L(M.[>IQ
MTNE:]?ZY8:A?P1#RY4W)&RCRU5@<]>>_<_RJ]K6DWEYXFTZ[MXMT$)3S&W ;
M</D\$YZ5T=%'U2%FFWJT_N#V$;-7W,+Q-H<NK0PRV95;F DKNXW#TSZY''UJ
MLDOBZ=DB>"VMEZ--E3GWQD_RKIJ*N6'C*;FFU?>PW23ES)M&!XLT:YU:T@-F
M TD+'Y"0,@CU/T'YU?TEM2GLW&MP0QN3M")SN7'?DBM"BJ5&*J.HGOOV*]FE
M/G/.-.TQI/%:Z:7\R"WN&<C/&!U_$[0#7H]9FF:!::5=37$#2R2S##-*P..<
MG& .I_E6G66$H.C%WW;_ .&(H4_9IWZA11178;A1110 5F^(=%@\0^'[O2[K
M[EQ&5#8^XW56_ X-:5% &+\/]=GU?PY]FU/C5-,D-G>J>I=. WON&#GUS74U
MY[JC_P#"(_$*SUU?DT[6=MCJ'HDO_+*0_P#H)/85Z%3 ****0!1110 5PES_
M ,EU'_8M_P#MS7=UPES_ ,EU'_8M_P#MS0!UE%%% !1110!5U2W>[T>\MXN7
MF@=%^I4@5YA'<W6IZ78>&K6U9)(YF:4_WCDX)'8 $_D*]3NKVVL8O,O+B.!/
M61@,URNI^/\ 3;64_P!G0&\E"[?-QL7Z9(R?RJHW$RM;V-I8?$NSM=*B\N.&
MV(G .>=C<G\TKN:XGP_K>O:UX@@GFMA%888.R0X4C:2!N//7'0UVU$@04445
M(PHHHH YGX0?\DIT?_MO_P"CY*[6N*^$'_)*='_[;_\ H^2NUH **** "BBB
M@ HHHH **** "BBB@ HHHH \_P#A/_R2_2?^VW_HYZ[&N.^$_P#R2_2?^VW_
M *.>NQIO< HHHI %175M'>6LMO.NZ.52C#V-2U2UF^.FZ+=W:C+11DKQ_%T'
MZXH X>X\":S:W2-IMXDB1,3"QD*-'SG\/PKH?#'AB;1KB>]U"Y%Q>3C:64D@
M#.3R>220/RKD=,6]_P"$DT:\O;IYGO7$G+$D#<1@_ETKIK6\N8/B1<V1NII;
M>6+<(G<E8S@-P,\=_P ZMW)5CK****@H**** .4MO^2Z'_L6_P#VYKNJX6V_
MY+H?^Q;_ /;FNZI@%%%%( HHHH *XKXO_P#)*=8_[8?^CXZ[6N*^+_\ R2G6
M/^V'_H^.FMP.FHHHI %<EX@\&#5=2FU";5?LT; ?(\653  Z[AUQ76UP>O6U
MWXF\:OHZS^3;VL09NX (!+8SR?F JH[B9##\/;:X8K;Z]%*0,D)"&Q^3UW=C
M;?8M/M[4-O$$2Q[L8W;0!G]*\_UCPE<>&;4:MINH.Q@8;^-C $XX(//7!%>@
M6%S]MTVVNL;?/B63'ID _P!:&"./\<:IJ^G:G:BPN7@MI(\ C !?<<Y)]MM4
M_LGCW^]-_P!_HO\ &NWU32K76+(VM\A:/<&!!P5([@_G4EHUM#&EE!.KM @3
M:7#.  !S1?0+'F'B"#Q-'IZ'7S(;;S0%W2(WSX./NG/3->KUF:WI^G:M!%9:
ME,$_>!T42!68X('UZUIT-W!(****D9RWA'_DJ'CC_MP_]$M7<5P_A'_DJ'CC
M_MP_]$M7<4V 4444@"BBB@ HHHH XKX0?\DIT?\ [;_^CY*[6N*^$'_)*='_
M .V__H^2NUIO< HHHI %%%% !7C6N?\ (PZC_P!?4O\ Z&:]EKF;OP)IEY>3
M7,L]V'FD:1@KK@$G)Q\OO7GX[#SKQ2AT.7$TI5$E$\RHKTC_ (5WI/\ S\7O
M_?:?_$T?\*[TG_GXO?\ OM/_ (FO)_LW$>7WG%]4JGF]%>D?\*[TG_GXO?\
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M 'VG_P 31_PKO2?^?B]_[[3_ .)H_LW$>7WA]4JGF]*JEF"J"23@ #K7H_\
MPKO2?^?B]_[[3_XFKNE>#],TB\%U#YTTJCY#,P(0^HP!S51RVLW9V2&L)4OJ
M4?"?A,:<JWVHH#=D92,_\LO_ ++^5=9117OT:,*,.2!Z<(1IQY8A1116I844
M44 %%%% !1110 4444 %%%% !1110!Y3XT_Y&^]_[9_^BUK"K=\:?\C?>_\
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MW_\ 1\E=K0 4444 %%%% !1110 4444 %%%% !1110!Y_P#"?_DE^D_]MO\
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M#S[UT=>7^(_&7]NZ:EK%:O;%91(6\W.0 1CH/7]*]0H=[:@@HHHJ1G+>$?\
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MW?&G_(WWO_;/_P!%K6%7Q^(_C3]7^9X57^)+U84445@9A1110 4444 %%%%
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MG1A.C*"N9E%%%<IB%%%% !1110 4444 %7M#_P"1AT[_ *^HO_0Q5&KVA_\
M(PZ=_P!?47_H8K2G\:]2H?$CV6BBBOLSWPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?
MA_\ ZSQ7_P!C)>?^RUU]<A\/_P#6>*_^QDO/_9:Z^FP"BBBD!C>+?^16N_\
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M"#_DE.C_ /;?_P!'R5VM<5\(/^24Z/\ ]M__ $?)7:T %%%% !1110 4444
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MX6V_Y+H?^Q;_ /;FNZI@%%%%( HHHH *XKXO_P#)*=8_[8?^CXZ[6N*^+_\
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M*='_ .V__H^2NUIO< HHHI %%%% !7C&N_\ (Q:C_P!?4O\ Z&:]GKQC7?\
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MF?:PG&<5*+NF%%%%(H**** "BBB@ HHHH **** "BBB@#RGQI_R-][_VS_\
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MOA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% ' _#_\ UGBO_L9+S_V6NOKD/A__ *SQ7_V,
MEY_[+77TV 4444@"BBB@ HHHH **Q=9\0C2+ZVMC;&;SADMOV[><=,<UK7,W
MV:TFG*[A$C/C/7 S6:JP;:3VW)4XMM+H245FZ%K']MV#W/D>3MD,>W?NZ '.
M<#UK2IPG&<5*.S",E)704445904444 %%%% !1110 4454U74K?1])NM1O&V
MP6T9D?WQV'N>E '+>)E/BKQ?IWA*/YK.+%_JA'3RU/R1G_>;MZ8->A@   #
M'05QWPYTFXAT>?7=53&IZY)]JFSUCC_Y9Q_0+_.NQI@%%%%( HHHH *X2Y_Y
M+J/^Q;_]N:[NN$N?^2ZC_L6__;F@#K**** "BBB@"IJP5M%O@\ODJ;>0&3!.
MP;3S@<\5R?A_P5I-U9QWT]T^H))DK@-&A()!X^\>1[=*L>,X->=I)-.=AIRV
MA\\!U&?O;N#S]W%8&BVOBR32(7TB5ELSN\L"1!_$<\'GKFK6VY/4[VWN=+TZ
M]BT:V"6\S)O2%(B PQUSC!Z'G/:KR0112/)'$B/)]]E4 M]3WZUR&@>'M:/B
M&/5=?GR\"%4!<,QR",<< <D_6NRJ6-!1112&%%%% ',_"#_DE.C_ /;?_P!'
MR5VM<5\(/^24Z/\ ]M__ $?)7:T %%%% !1110 4444 %%%% !1110 4444
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M ,C#IW_7U%_Z&*HU>T/_ )&'3O\ KZB_]#%:4_C7J5#XD>RT445]F>^%%%%
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MY9Q_0+_.F!V   P!@"BBBD 4444 %%%% !7"7/\ R74?]BW_ .W-=W7"7/\
MR74?]BW_ .W- '64444 %%%% $=S<):VLMQ+G9"C.V/0#)KSV#Q)KUYK&F3S
MR&"RO+L)'&@ #*'4,/4]<9^M>@7ML+RPN+5FVB>)HR<=,C']:\KNI-5TF73;
M6]LR!I<[21':<298-U[C(Z^]5$EG<-J][!X]32YF4VEQ#OB7:,KA3W^JM^==
M%7#>'(]1U[Q4-=OX&@AAB*Q<$*>"N%SVY8D^M=S28T%%%%(84444 <S\(/\
MDE.C_P#;?_T?)7:UQ7P@_P"24Z/_ -M__1\E=K0 4444 %%%% !1110 4444
M %%%% !1110!Y_\ "?\ Y)?I/_;;_P!'/78UQWPG_P"27Z3_ -MO_1SUV--[
M@%%%%( HHHH **** "BBB@ HHHH Y2V_Y+H?^Q;_ /;FNZKA;;_DNA_[%O\
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MUHH XK_A&/'/_10__*)!_C1_PC'CG_HH?_E$@_QKM:* .*_X1CQS_P!%#_\
M*)!_C1_PC'CG_HH?_E$@_P :[6B@#BO^$8\<_P#10_\ RB0?XT?\(QXY_P"B
MA_\ E$@_QKM:* .*_P"$8\<_]%#_ /*)!_C1_P (QXY_Z*'_ .42#_&NUHH
MXK_A&/'/_10__*)!_C1_PC'CG_HH?_E$@_QKM:* .*_X1CQS_P!%#_\ *)!_
MC1_PC'CG_HH?_E$@_P :[6B@#BO^$8\<_P#10_\ RB0?XT?\(QXY_P"BA_\
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M'K5O2_B%]CTV*"]MYKJ=<[IC(/FR21V]"!^%=O?Z79ZE!)'=0(Q>,QB38"Z
MCL2.#S7+0ZGX/T>%;'"79A)!E>W$A)R3][ S^';%7H^A.J+>C>.(-8U:&Q2R
MDB:7=ARX(&%)_I74US>DZ[X<O-4B@TRWC2Y?.QEM@G0$GG'H#725+&@HHHI#
M"BBB@#F?A!_R2G1_^V__ */DKM:XKX0?\DIT?_MO_P"CY*[6@ HHHH ****
M"BBB@ HHHH **** "BBB@#S_ .$__)+])_[;?^CGKL:X[X3_ /)+])_[;?\
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MR\VW[JG 4?@.*I45'M)\O+=V["YI6Y;Z!1114$A1110 5>T/_D8=._Z^HO\
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MBBB@#RGQI_R-][_VS_\ 1:UA5N^-/^1OO?\ MG_Z+6L*OC\1_&GZO\SPJO\
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M^HO_ $,5I3^->I4/B1[+1117V9[X4444 %%%% !1110 4444 %%%% !1110
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MY(5B!GYNO%-*XKV/2J*\J_X6AK7_ #ZV'_?M_P#XNC_A:&M?\^MA_P!^W_\
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M_P"_;_\ Q='_  M#6O\ GUL/^_;_ /Q='*PYD>JT5Y5_PM#6O^?6P_[]O_\
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M/^_;_P#Q='*PYD>JT5Y5_P +0UK_ )];#_OV_P#\71_PM#6O^?6P_P"_;_\
MQ='*PYD>JT5Y5_PM#6O^?6P_[]O_ /%T?\+0UK_GUL/^_;__ !='*PYD>JT5
MQ_A/QRFMS&SU)8K>\)_=[,A)!Z#).#_.NPI-6&%%%%( HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$Y^]QTS75TF""BBBD,**** .9^$'_)*='_[;_P#H^2NUKBOA!_R2G1_^V_\
MZ/DKM: "BBB@ HHHH **** "BBB@ HHHH **** //_A/_P DOTG_ +;?^CGK
ML:X[X3_\DOTG_MM_Z.>NQIO< HHHI %%%% !1110 4444 %%%% '*6W_ "70
M_P#8M_\ MS7=5PMM_P ET/\ V+?_ +<UW5, HHHI %%%% !7%?%__DE.L?\
M;#_T?'7:UQ7Q?_Y)3K'_ &P_]'QTUN!TU%%%( HHHH **** "BBB@ HHHH *
M*** .6\(_P#)4/''_;A_Z):NXKA_"/\ R5#QQ_VX?^B6KN*; ****0!1110
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M^HO_ $,5I3^->I4/B1[+1117V9[X4444 %%%% !1110 4444 %%%% !1110
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M /H^2NUKBOA!_P DIT?_ +;_ /H^2NUH **** "BBB@ HHHH **** "BBB@
MHHHH \_^$_\ R2_2?^VW_HYZ[&N.^$__ "2_2?\ MM_Z.>NQIO< HHHI %%%
M% !1110 4444 %%%% '*6W_)=#_V+?\ [<UW5<+;?\ET/_8M_P#MS7=4P"BB
MBD 4444 %<5\7_\ DE.L?]L/_1\==K7%?%__ ))3K'_;#_T?'36X'34444@"
MBBB@ HHHH **** "BBB@ HHHH Y;PC_R5#QQ_P!N'_HEJ[BN'\(_\E0\<?\
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MB1[+1117V9[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!P/P__P!9XK_[&2\_]EKKZY#X
M?_ZSQ7_V,EY_[+77TV 4444@"BBB@ HHHH **** "BBB@ HHHH *XSQ G_"5
M^-=/\+I\UC9XO]4]" ?W<1^IY(].>U=-K&J6^B:-=:E>'$-M&9&]_0#W)P/Q
MK.^'>D7%GH<NK:HO_$TUJ3[9<YZH#]Q/HJGIVR13 ZVBBBD 4444 %%%% !1
M110 4444 %%%% !7"7/_ "74?]BW_P"W-=W7"7/_ "74?]BW_P"W- '64444
M %%%% %;4_..DW?V3<)_(?RBO7=M.,>^:X7POX2TO6M(^U75S.UQO99(XV"^
M7SP#D'DCG/O[5WM[#)<6%Q#!*899(F1) <%"1@'CTK@O^%=ZGN9O[1AW,<L?
MFR35+83.DTSP9IFDZC'>VS7!ECSMWN".01Z>AK?KC= \&7VDZW!>W%['+'%N
MRB[LG*D=_K794F""BBBD,**** .9^$'_ "2G1_\ MO\ ^CY*[6N*^$'_ "2G
M1_\ MO\ ^CY*[6@ HHHH **** "BBB@ HHHH **** "BBB@#S_X3_P#)+])_
M[;?^CGKL:X[X3_\ )+])_P"VW_HYZ[&F]P"BBBD 4444 %%%% !1110 4444
M <I;?\ET/_8M_P#MS7=5PMM_R70_]BW_ .W-=U3 ****0!1110 5Q7Q?_P"2
M4ZQ_VP_]'QUVM<5\7_\ DE.L?]L/_1\=-;@=-1112 **** "BBB@ HHHH **
M** "BBB@#SNSU37=-^*'B_\ L#P[_;7F?8O._P!.2W\K$/R_>'S9R>G3'O6]
M_P )/XY_Z)Y_Y6X/\*9X1_Y*AXX_[</_ $2U=Q3 XK_A)_'/_1//_*W!_A1_
MPD_CG_HGG_E;@_PKM:*0'%?\)/XY_P"B>?\ E;@_PH_X2?QS_P!$\_\ *W!_
MA7:T4 <5_P )/XY_Z)Y_Y6X/\*/^$G\<_P#1//\ RMP?X5VM% 'F/A&;QQX4
M\+6FC+X%-T+;?^^.L0)NW.S].<?>QU[5L_\ "3^.?^B>?^5N#_"NUHH XK_A
M)_'/_1//_*W!_A1_PD_CG_HGG_E;@_PKM:* .*_X2?QS_P!$\_\ *W!_A1_P
MD_CG_HGG_E;@_P *[6B@#BO^$G\<_P#1//\ RMP?X5YOJDL\^L7DMY;_ &6X
MDG=I8-X?RG+$E=PX.#QD=<5[[7A'B'_D9]4_Z_)?_0S5Q)D9U%%%:$'K_C2#
MP_,]@WB.[F@"%S"D0)$GW=P.%/MZ=:Y[5/%-GJNNZ)INEQA=/M;R%M[+M!P0
M  #T !/7_P#7E^-?%%GXD^P_8HIX_L^_?YP SNV],$_W:Y96*L&4D,#D$'I4
M):%-G;_%))1K=F[$^2UOA1DX#!CG]"M</7=0^.=,U/2TM?%>FO=R1C EB ^;
MWZC:?H:R/$&O:7>:;%INA:;]CMDD$K.^-[L 0,]<\'J2::OL#.CO0WB;X6P3
MINENK$C< VYB4^4Y^JG=CKTZ]X_&4JZ%X-T[P_%_K)%!EQTPO)_-SG\#63X,
M\6V_AZ&ZM]0CFEMYB&58E4X;H<Y(ZC'Y5F>*M<7Q!KSWD2ND(18XE<#<%'K@
MGN2:5M0OH6?"'AA_$&H;YU9+"$YFDZ!C_<!]3^@_"K_CSQ/#J\\>GZ<V^TMF
MRT@Z2/C&1[ 9Y[Y/L:T-.\:^'[;PS#I%S97I3R!',(PH#DCYN0X."<_G6'K%
M[X1GTN1-&TN[M[PD;))&)4<\Y^<]L]J?74.AO_%0;HM)=5.S][SCIG9@4_5"
M1\'[7><$K&!GO\_'Z50M?&FDWV@PZ=XHT^:Z,  5XCDM@8#9+ @^O//XXK-\
M5^*TUV*WLK"V-K86W*(<98@8' X&!D  ]Z23V YFBBBK)"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_"NUHK[,]\XK_A)_'/\ T3S_ ,K<'^%'_"3^.?\ HGG_ )6X/\*[6B@#BO\
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M*[6B@#BO^$G\<_\ 1//_ "MP?X4?\)/XY_Z)Y_Y6X/\ "NUHH XK_A)_'/\
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M "MP?X4?\)/XY_Z)Y_Y6X/\ "NUHH XK_A)_'/\ T3S_ ,K<'^%'_"3^.?\
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MDOTG_MM_Z.>NQKCOA/\ \DOTG_MM_P"CGKL:;W ****0!1110 4444 %%%%
M!1110!REM_R70_\ 8M_^W-=U7"VW_)=#_P!BW_[<UW5, HHHI %%%% !7%?%
M_P#Y)3K'_;#_ -'QUVM<5\7_ /DE.L?]L/\ T?'36X'34444@"BBB@ HHHH
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MR?;+G/\ "#]Q/HJ]NV33 ZVBBBD 4444 %%%% !1110 4444 %%%% !1110
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MPCVM?] B_P#_  &?_"@#.HK1_P"$>UK_ *!%_P#^ S_X4?\ "/:U_P! B_\
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M_A1_PCVM?] B_P#_  &?_"@#.HK1_P"$>UK_ *!%_P#^ S_X4?\ "/:U_P!
MB_\ _ 9_\* ,ZBM'_A'M:_Z!%_\ ^ S_ .%'_"/:U_T"+_\ \!G_ ,* ,ZBM
M'_A'M:_Z!%__ . S_P"%'_"/:U_T"+__ ,!G_P * ,ZBM'_A'M:_Z!%__P"
MS_X4?\(]K7_0(O\ _P !G_PH SJ*T?\ A'M:_P"@1?\ _@,_^%'_  CVM?\
M0(O_ /P&?_"@#.KM/!?@MM49-1U1"MDIS'&>#,?_ (G^=/\ "/@6:\N!=ZY;
MR06\;?+!(I5I3[@\A?YUZ@JJBA4 55&  , "IE+L-(%544*@"JHP !@ 4M%%
M9EA1110 4444 %%%% !1110 4444 %%%% 'E/C3_ )&^]_[9_P#HM:PJ[WQ!
MX,U#5M=N+VWFM5CEV[1([ C"@=E/I6;_ ,*[U;_GXLO^^W_^)KYBOA:\JLFH
M]6>/4HU'-M+J<I175_\ "N]6_P"?BR_[[?\ ^)H_X5WJW_/Q9?\ ?;__ !-8
M_4\1_*R/85>QRE%=7_PKO5O^?BR_[[?_ .)H_P"%=ZM_S\67_?;_ /Q-'U/$
M?RL/85>QRE%=7_PKO5O^?BR_[[?_ .)H_P"%=ZM_S\67_?;_ /Q-'U/$?RL/
M85>QRE%=7_PKO5O^?BR_[[?_ .)H_P"%=ZM_S\67_?;_ /Q-'U/$?RL/85>Q
MRE%=7_PKO5O^?BR_[[?_ .)H_P"%=ZM_S\67_?;_ /Q-'U/$?RL/85>QRE%=
M7_PKO5O^?BR_[[?_ .)H_P"%=ZM_S\67_?;_ /Q-'U/$?RL/85>QRE%=7_PK
MO5O^?BR_[[?_ .)H_P"%=ZM_S\67_?;_ /Q-'U/$?RL/85>QRE%=7_PKO5O^
M?BR_[[?_ .)H_P"%=ZM_S\67_?;_ /Q-'U/$?RL/85>QRE%=7_PKO5O^?BR_
M[[?_ .)H_P"%=ZM_S\67_?;_ /Q-'U/$?RL/85>QRE%=7_PKO5O^?BR_[[?_
M .)H_P"%=ZM_S\67_?;_ /Q-'U/$?RL/85>QRE%=7_PKO5O^?BR_[[?_ .)H
M_P"%=ZM_S\67_?;_ /Q-'U/$?RL/85>QRE%=7_PKO5O^?BR_[[?_ .)H_P"%
M=ZM_S\67_?;_ /Q-'U/$?RL/85>QRE%=7_PKO5O^?BR_[[?_ .)H_P"%=ZM_
MS\67_?;_ /Q-'U/$?RL/85>QRE%=7_PKO5O^?BR_[[?_ .)H_P"%=ZM_S\67
M_?;_ /Q-'U/$?RL/85>QRE7M#_Y&'3O^OJ+_ -#%;O\ PKO5O^?BR_[[?_XF
MK.F^!-3L]4M+F6>T*0S)(P5VR0&!./E]JN&$KJ:;BRHT*BDM#OZ***^J/9"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .!^'_^L\5_]C)>?^RUU]<#ID7C+PWJ.NQV?A#^
MT;>^U>XO(I_[3ABRCD8^4Y/1<\XZ]*T?[>\<_P#1/_\ RM0?X4P.MHKDO[>\
M<_\ 1/\ _P K4'^%']O>.?\ HG__ )6H/\*+ =;17)?V]XY_Z)__ .5J#_"C
M^WO'/_1/_P#RM0?X46 ZVBN2_M[QS_T3_P#\K4'^%']O>.?^B?\ _E:@_P *
M+ =;17)?V]XY_P"B?_\ E:@_PH_M[QS_ -$__P#*U!_A18#K:*Y+^WO'/_1/
M_P#RM0?X4?V]XY_Z)_\ ^5J#_"BP$6O)_P )7XWL/#"?-8V.V_U/T;'^KB/U
M/)'ISVKT&N7\":!=Z/I=S>:TH&L:I.US>88-L/14!!QA1Z>IKJ*0!1110 44
M44 %%%% !1110 4444 %%%% !1110 5PES_R74?]BW_[<UW=<#XCLO$EE\2H
M]>T+0/[7MSI LF'VV.#:_G%S][D\ =N_7B@#KZ*Y+^WO'/\ T3[_ ,K4'^%'
M]O>.?^B??^5J#_"@#K:*Y+^WO'/_ $3[_P K4'^%']O>.?\ HGW_ )6H/\*
M.MHKDO[>\<_]$^_\K4'^%']O>.?^B??^5J#_  H ZVBN2_M[QS_T3[_RM0?X
M4?V]XY_Z)]_Y6H/\* .MHKDO[>\<_P#1/O\ RM0?X4?V]XY_Z)]_Y6H/\* .
MMHKDO[>\<_\ 1/O_ "M0?X4?V]XY_P"B??\ E:@_PH G^$'_ "2G1_\ MO\
M^CY*[6N7^&^CWV@?#_3=-U:#[/=P>;YD>]6VYE=ARI(Z$=ZZB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <[X]_Y$
MB_\ ^V?_ *,6NBKG?'O_ ")%_P#]L_\ T8M=%3Z"ZA1112&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[K/_([^
M&O\ MZ_]%BNBKG=9_P"1W\-?]O7_ *+%-"9T5%%%(84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!SOA#_F.?\ 88N/_9:Z*N=\(?\ ,<_[#%Q_[+714WN)!1112&%%%% !
M1110 44R::.WA:6>1(HT&6=V "CW)HAGBN85FMY4EB<95XV#*?H10 ^BBB@
MHHHH **@M[VUNVD6TN89S$<2"*0-L/H<=.E3T %%%% !1110 4444 %%%0PW
MEM<2RQ6]Q%+)"=LJ(X8QGT('3H>OI0!-1110 4444 %%%% !7.^/?^1(O_\
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MD+S2L$*QQKECAU)P/H*B_P"$O_ZE[7O_  "_^RKHJ*8CG?\ A+_^I>U[_P
MO_LJ/^$O_P"I>U[_ , O_LJZ*BC0#G?^$O\ ^I>U[_P"_P#LJ/\ A+_^I>U[
M_P  O_LJZ*BC0#G?^$O_ .I>U[_P"_\ LJ/^$O\ ^I>U[_P"_P#LJZ*BC0#G
M?^$O_P"I>U[_ , O_LJ/^$O_ .I>U[_P"_\ LJZ*BC0#G?\ A+_^I>U[_P
MO_LJ/^$O_P"I>U[_ , O_LJZ*BC0#G?^$O\ ^I>U[_P"_P#LJ/\ A+_^I>U[
M_P  O_LJZ*BC0#G?^$O_ .I>U[_P"_\ LJ/^$O\ ^I>U[_P"_P#LJZ*BC0#G
M?^$O_P"I>U[_ , O_LJ/^$O_ .I>U[_P"_\ LJZ*BC0#G?\ A+_^I>U[_P
MO_LJ/^$O_P"I>U[_ , O_LJZ*BC0#G?^$O\ ^I>U[_P"_P#LJ/\ A+_^I>U[
M_P  O_LJZ*BC0#G?^$O_ .I>U[_P"_\ LJ/^$O\ ^I>U[_P"_P#LJZ*BC0#G
M?^$O_P"I>U[_ , O_LJ/^$O_ .I>U[_P"_\ LJZ*BC0#G?\ A+_^I>U[_P
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MX!?_ &5'_"7_ /4O:]_X!?\ V5=%11H!SO\ PE__ %+VO?\ @%_]E1_PE_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH :\B1KF1U09QECBA)$D7,;JXSC*G-4=9_
MX\T_ZZ#^1HT;_CS?_KH?Y"@#0HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***BNI_LULTNW=
MMQQG'?% $M%5+&^^V;_W>S9C^+.<Y_PJW0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %(SJBEG8*HZDG I:J:G_ ,@V7\/YB@"PDL<N?+D5\==K9Q3ZR=#_
M .6__ ?ZUK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!GZS_QYI_UT'\C1HW_ !YO_P!=#_(4:S_QYI_UT'\C1HW_ !YO_P!=#_(4
M :%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !534_^0;+^'\Q5NJFI_\ (-E_#^8H J:'_P M
M_P#@/]:UJR=#_P"6_P#P'^M:U !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M54U/_D&R_A_,5;JIJ?\ R#9?P_F* *FA_P#+?_@/]:UJR=#_ .6__ ?ZUK4
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MH M_VG9_\]O_ !T_X4?VG9_\]O\ QT_X54_L3_IX_P#'/_KT?V)_T\?^.?\
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M/_KT?V)_T\?^.?\ UZ +?]IV?_/;_P =/^%']IV?_/;_ ,=/^%5/[$_Z>/\
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M3_A53^Q/^GC_ ,<_^O1_8G_3Q_XY_P#7H M_VG9_\]O_ !T_X4?VG9_\]O\
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M/^%']IV?_/;_ ,=/^%5/[$_Z>/\ QS_Z]']B?]/'_CG_ ->@"W_:=G_SV_\
M'3_A1_:=G_SV_P#'3_A53^Q/^GC_ ,<_^O1_8G_3Q_XY_P#7H M_VG9_\]O_
M !T_X4?VG9_\]O\ QT_X54_L3_IX_P#'/_KT?V)_T\?^.?\ UZ +?]IV?_/;
M_P =/^%']IV?_/;_ ,=/^%5/[$_Z>/\ QS_Z]']B?]/'_CG_ ->@"W_:=G_S
MV_\ '3_A1_:=G_SV_P#'3_A53^Q/^GC_ ,<_^O1_8G_3Q_XY_P#7H M_VG9_
M\]O_ !T_X4?VG9_\]O\ QT_X54_L3_IX_P#'/_KT?V)_T\?^.?\ UZ +?]IV
M?_/;_P =/^%']IV?_/;_ ,=/^%5/[$_Z>/\ QS_Z]']B?]/'_CG_ ->@"W_:
M=G_SV_\ '3_A1_:=G_SV_P#'3_A53^Q/^GC_ ,<_^O1_8G_3Q_XY_P#7H M_
MVG9_\]O_ !T_X4?VG9_\]O\ QT_X54_L3_IX_P#'/_KT?V)_T\?^.?\ UZ +
M?]IV?_/;_P =/^%']IV?_/;_ ,=/^%5/[$_Z>/\ QS_Z]']B?]/'_CG_ ->@
M"W_:=G_SV_\ '3_A1_:=G_SV_P#'3_A53^Q/^GC_ ,<_^O1_8G_3Q_XY_P#7
MH M_VG9_\]O_ !T_X4?VG9_\]O\ QT_X54_L3_IX_P#'/_KT?V)_T\?^.?\
MUZ +?]IV?_/;_P =/^%']IV?_/;_ ,=/^%5/[$_Z>/\ QS_Z]']B?]/'_CG_
M ->@"W_:=G_SV_\ '3_A5>_O[::RDCCDW,<8&T^HIG]B?]/'_CG_ ->HKK2O
MLULTOG;MN.-N.^/6@ TJZAMO-\Y]N[&."?6M#^T[/_GM_P".G_"LJQL?MF_]
MYLV8_ASG.?\ "K7]B?\ 3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\
M'3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV
M?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_
M (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\
MSV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_
M &G9_P#/;_QT_P"%']IV?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_
M %Z +?\ :=G_ ,]O_'3_ (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\
M3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#K
MT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV?_/;_P =/^%5/[$_Z>/_
M !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_ (4?VG9_\]O_ !T_X54_
ML3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\
M'3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV
M?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_
M (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\
MSV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_
M &G9_P#/;_QT_P"%']IV?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_
M %Z +?\ :=G_ ,]O_'3_ (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\
M3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#K
MT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV?_/;_P =/^%5/[$_Z>/_
M !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_ (4?VG9_\]O_ !T_X54_
ML3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\
M'3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV
M?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_
M (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\
MSV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_
M &G9_P#/;_QT_P"%']IV?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_
M %Z +?\ :=G_ ,]O_'3_ (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\
M3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#K
MT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV?_/;_P =/^%5/[$_Z>/_
M !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_ (4?VG9_\]O_ !T_X54_
ML3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\
M'3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV
M?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_
M (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\
MSV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_
M &G9_P#/;_QT_P"%']IV?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_
M %Z +?\ :=G_ ,]O_'3_ (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\
M3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#K
MT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV?_/;_P =/^%5/[$_Z>/_
M !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_ (4?VG9_\]O_ !T_X54_
ML3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\ SV_\=/\ A1_:=G_SV_\
M'3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_ &G9_P#/;_QT_P"%']IV
M?_/;_P =/^%5/[$_Z>/_ !S_ .O1_8G_ $\?^.?_ %Z +?\ :=G_ ,]O_'3_
M (4?VG9_\]O_ !T_X54_L3_IX_\ '/\ Z]']B?\ 3Q_XY_\ 7H M_P!IV?\
MSV_\=/\ A1_:=G_SV_\ '3_A53^Q/^GC_P <_P#KT?V)_P!/'_CG_P!>@"W_
M &G9_P#/;_QT_P"%5[^_MIK*2..3<QQ@;3ZBF?V)_P!/'_CG_P!>HKK2OLUL
MTOG;MN.-N.^/6@"70_\ EO\ \!_K6M63HG_+?_@/]:UJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH S]9_X\T_ZZ#^1HT;_CS?_KH?
MY"C6?^/-/^N@_D:-&_X\W_ZZ'^0H T**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFI_\@V7
M\/YBK=5-3_Y!LOX?S% %30_^6_\ P'^M:U9.A_\ +?\ X#_6M:@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *J:G_R#9?P_F*MU4U/_ )!LOX?S% %30_\
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&JP7%Z2%;=E41!_=POK["O0Z*.9A8Y7QKX7O/$AL?L4L$8M_,W^<Q&=VW&,
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M0:*:=A#8XTAB2.-=J(H50.P%*Z+(C(ZAE8892,@CTI:*0S._X1[1?^@18?\
M@,G^%6;6PL[!66QM(+8,<L(8PF?KBK%% !1110 4444 %%%% !1110 4444
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MUS^>*O44 ,F@BN86AN(DEB<89)%#*?J#3;:UM[.$16D$<$8.0D2!5'X"I:*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M45C@'.-W'H>W3M3-: ;XNV88 CS(3S]*Z72/ NCZ/>K=1":XF0Y0W#!@A]0
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M4 @"5P0 >O0"BZL!T5%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img70551829_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +2"FH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **@N[VUL(1->7,-O$3MWS2!!GTR:?;W$%W L]
MM-'-"_W9(V#*?H10.SM<DHHHH$%%%% !1110 4444 %%%% !12,P52S$!0,D
MD\ 56M-3T_4"PLKZVN2OWA#*KX^N#0.S+5%%% @HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>.?#E_XETZVMK&XAB\N7>XF8A6XP.@/-<\4F]3A@DY)2=D><WEUJ?Q&\4I!
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MJRBJ:IQ=SQ>];SOBXI4=-3B'7^ZRY_E7MM>,>!8'U[Q_)J4H!$;273Y_O$X
M_-L_A7L].MND&*T<8]D%%%%8G*%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !69KN@6/B*P^Q
MWZ,5#;D=#AD/J#_C6G133MJAIM.Z/,I/A!&6_=ZVRKZ-;;C^>X5O^'?A[I>@
MW2WCN]W=(<QO(,*G'4+Z]>377453J3:LV:RQ%22LV%%%%08A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_BSPK!XJL887G^
MSS0ONCF";\ ]1C(X/'Y"K^A:8VC:):Z<]R;@P*5\TIMR,DCC)Q@''X5HT4^9
MVL4YR<>7H%%%%(D**** "BBB@ HHHH **** &R!FC94;8Q! ;&<'UQ7(^%?
MD?AO4YK^6^^VS.A12T.PKDY)^\>3_CZUV%%-2:5D5&<HII=0HHHI$A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P.J_"O3KVZ>>
MSO);/>2QCV"103Z<@@>V:[ZBJC)QV+A4E!WBSS:U^$5K',K76K231@@E(X0F
M1W&=QKT&PL+73+**SLX1#;Q#"("3CG/?GJ:L442G*6['.K.?Q,****DS"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **R/\ A*O#O_0?TO\
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MX2KP[_T']+_\#(_\: ->BLC_ (2KP[_T']+_ / R/_&C_A*O#O\ T']+_P#
MR/\ QH UZ*R/^$J\._\ 0?TO_P #(_\ &C_A*O#O_0?TO_P,C_QH UZ*R/\
MA*O#O_0?TO\ \#(_\:/^$J\._P#0?TO_ ,#(_P#&@#7HK(_X2KP[_P!!_2__
M  ,C_P :/^$J\._]!_2__ R/_&@#7HK(_P"$J\._]!_2_P#P,C_QH_X2KP[_
M -!_2_\ P,C_ ,: ->BLC_A*O#O_ $']+_\  R/_ !H_X2KP[_T']+_\#(_\
M: ->BLC_ (2KP[_T']+_ / R/_&C_A*O#O\ T']+_P# R/\ QH UZ*R/^$J\
M._\ 0?TO_P #(_\ &C_A*O#O_0?TO_P,C_QH UZ*R/\ A*O#O_0?TO\ \#(_
M\:/^$J\._P#0?TO_ ,#(_P#&@#7HK(_X2KP[_P!!_2__  ,C_P :/^$J\._]
M!_2__ R/_&@#7HK(_P"$J\._]!_2_P#P,C_QH_X2KP[_ -!_2_\ P,C_ ,:
M->BLC_A*O#O_ $']+_\  R/_ !JQ9ZYI&H3^19:K8W,V-WEPW".V/7 - %^B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPBOAW_H :7_X!Q_X5KT4 9'_  BOAW_H :7_ . <?^%'_"*^'?\ H :7_P"
M<?\ A6O10!D?\(KX=_Z &E_^ <?^%'_"*^'?^@!I?_@''_A6O10!D?\ "*^'
M?^@!I?\ X!Q_X4?\(KX=_P"@!I?_ (!Q_P"%:]% &1_PBOAW_H :7_X!Q_X4
M?\(KX=_Z &E_^ <?^%:]% &1_P (KX=_Z &E_P#@''_A1_PBOAW_ * &E_\
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M_P" <?\ A6O10!D?\(KX=_Z &E_^ <?^%'_"*^'?^@!I?_@''_A6O10!D?\
M"*^'?^@!I?\ X!Q_X4?\(KX=_P"@!I?_ (!Q_P"%:]% &1_PBOAW_H :7_X!
MQ_X4?\(KX=_Z &E_^ <?^%:]% &1_P (KX=_Z &E_P#@''_A1_PBOAW_ * &
ME_\ @''_ (5KT4 9'_"*^'?^@!I?_@''_A1_PBOAW_H :7_X!Q_X5KT4 9'_
M  BOAW_H :7_ . <?^%<UXOT72M-F\-36.F65K*VNVJEX(%1B/F.,@=.!^5=
MY7(^//\ F6?^P_:_^S4 ==1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)=8_Y#=_\
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M "/_ /8UQ=%'U.C_ "_F']IXK^?\%_D=I_PGW_4,_P#(_P#]C1_PGW_4,_\
M(_\ ]C7%T4?4Z/\ +^8?VGBOY_P7^1VG_"??]0S_ ,C_ /V-'_"??]0S_P C
M_P#V-<711]3H_P OYA_:>*_G_!?Y':?\)]_U#/\ R/\ _8T?\)]_U#/_ "/_
M /8UQ=%'U.C_ "_F']IXK^?\%_D=I_PGW_4,_P#(_P#]C1_PGW_4,_\ (_\
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M ,C_ /V-<711]3H_R_F']IXK^?\ !?Y':?\ "??]0S_R/_\ 8T?\)]_U#/\
MR/\ _8UQ=%'U.C_+^8?VGBOY_P %_D=I_P )]_U#/_(__P!C1_PGW_4,_P#(
M_P#]C7%T4?4Z/\OYA_:>*_G_  7^1VG_  GW_4,_\C__ &-'_"??]0S_ ,C_
M /V-<711]3H_R_F']IXK^?\ !?Y':?\ "??]0S_R/_\ 8T?\)]_U#/\ R/\
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M  7^1VG_  GW_4,_\C__ &-'_"??]0S_ ,C_ /V-<711]3H_R_F']IXK^?\
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M  GW_4,_\C__ &-'_"??]0S_ ,C_ /V-<711]3H_R_F']IXK^?\ !?Y':?\
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M &-'_"??]0S_ ,C_ /V-<711]3H_R_F']IXK^?\ !?Y':?\ "??]0S_R/_\
M8T?\)]_U#/\ R/\ _8UQ=%'U.C_+^8?VGBOY_P %_D=I_P )]_U#/_(__P!C
M1_PGW_4,_P#(_P#]C7%T4?4Z/\OYA_:>*_G_  7^1VG_  GW_4,_\C__ &-'
M_"??]0S_ ,C_ /V-<711]3H_R_F']IXK^?\ !?Y':?\ "??]0S_R/_\ 8T?\
M)]_U#/\ R/\ _8UQ=%'U.C_+^8?VGBOY_P %_D=I_P )]_U#/_(__P!C1_PG
MW_4,_P#(_P#]C7%T4?4Z/\OYA_:>*_G_  7^1VG_  GW_4,_\C__ &-'_"??
M]0S_ ,C_ /V-<711]3H_R_F']IXK^?\ !?Y':?\ "??]0S_R/_\ 8T?\)]_U
M#/\ R/\ _8UQ=%'U.C_+^8?VGBOY_P %_D=I_P )]_U#/_(__P!C1_PGW_4,
M_P#(_P#]C7%T4?4Z/\OYA_:>*_G_  7^1VG_  GW_4,_\C__ &-'_"??]0S_
M ,C_ /V-<711]3H_R_F']IXK^?\ !?Y':?\ "??]0S_R/_\ 8T?\)]_U#/\
MR/\ _8UQ=%'U.C_+^8?VGBOY_P %_D=I_P )]_U#/_(__P!C1_PGW_4,_P#(
M_P#]C7%T4?4Z/\OYA_:>*_G_  7^1VG_  GW_4,_\C__ &-'_"??]0S_ ,C_
M /V-<711]3H_R_F']IXK^?\ !?Y':?\ "??]0S_R/_\ 8T?\)]_U#/\ R/\
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M1110!3GV?;!][S/+_#&:2EG4?:P^X9\O&WOUZTE !1110 4444 -D.(G)&0
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M'?HCE8H9;B01PQ/(YZ*BDG\A3Y[2YM2!<6\L)/02(5S^=/L[R\M&=;.5XWE
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M#&"$YP#]:\/$4?93MT/KL%BEB:?-U6Y)1116!V!1110 4444 %%%% !1110
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M)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M +@D6TI!P0A_E5.(YA0G^Z*NS,4@D=>JJ2/RJG&Q:)&/4@&@!U%%% !1110
M4B!#=Q%FPPW;1CKQ2TB1EKN)QC";L_E0!>HHHH B@_U9_P!]_P#T(U+44'^K
M/^^__H1J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH \EUC_D-W_P#U\R?^A&J57=8_Y#=__P!?,G_H1JE7T4/A1\/5
M_B2]6;_AW5M.TE9I+F&=KEN$DC53M7';)ZU#<7&B/>13A=1N-TNZ<7#*-R]\
M;><UC45/LES.5]6:_69<BIV5EY'0:9JFC6.LSW?V.;R1C[.@PQ3U)R>OYTZX
MU/2)-2BU!6U.2Y69)#YNS;M# D #VZ5SM%+V,;WNQK%S4>6RM>^W4Z6W\0VD
M7BJXU1HYS!(FT*%&[H!ZX[>M5K'6K>WTO5+:2.3S+O)3: 0,YZG-8=%'L(?E
M^ ?6ZM[^OX[G1RZSI6I6EH-4M[IKFW7;F$J!(/?)SS[5T-F\D&BZ8D4=Y&LJ
M_P#+BJ.!N.1O+#CKU^M>=U9AU&]MXA%#>7$<8_@25@/R!K.IADTE$WHX]QDY
M36MK76_3_(ZZVTQ-(UK4=2>8SI;1%PS8W&1AG!]\?^A"N+EE>>9Y9&W2.Q9F
M]2>3369G8LS%F)R23DDTE:4Z;B[MW9SUZZJ)1BK*[?WA1116IS!1178>$O#P
MFVZE=I\H.84/<C^(_P!*SJU8TH\S-\/AYUZBA$T?"WAW^SD%[=+_ *4Z_*I_
MY9@_UK5A54B"J^]1G#8Z\UHUG01M%"$<889S^=>%4J2J2YI'V%"C"C!0AL24
M445!J%%%% &+XNEN(/".JRVI83+;.0R]0,<D?09-2>&)K2?PUI[64PFA$"KN
MW$G<!\V<\YSG-7KZ[MK&QFN;QU2VC7,C,,@#Z5X[>V'P^ENGEL?$EU91OR8D
MMY64?3*YQ]<T =O]MC?XKI#93M)G3V6\1&W*I#97/HW0?B/6NSK@O ;>#K&=
M[+0[]KN_E3<\LL3JS*,9 )4 #/..OUQ7>T %%%% !1110!-9OOM(V"JO7A1Q
MUJ>H+,H;2/RP0O.,]>M3T %9'BK_ )$_6_\ KPG_ /1;5KUD>*O^1/UO_KPG
M_P#1;4 'A7_D3]$_Z\(/_1:UKUD>%?\ D3]$_P"O"#_T6M:] !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !74>&/
M$C63I8W9+6['$;=3&?3Z5S !9@J@DDX '>N^\,^&18JM[>J#=$91#_RS_P#K
M_P JYL5*FJ=IGH9="M*LG2TMOVL=11117B'U@4444 %%%% !1110!3G=OM@C
MS\OE[L>^:2EG8?:PFT9\O.[OUZ4E !1110 4444 ,E.(7(_NFKEN2;:(DY)0
M?RJI(2L3L.H!(JY"Q>"-FZLH)_*@ F(6"0LNX!22/7BJ<9!B0@8! P/2KDP4
MP2!R0NTY(],53CQY2;3D8&* '4444 %%%% !354F]@(!(&[)QTXIU-5F%Y H
M) ;=D>O% %^BBB@"*#_5G_??_P!"-2U%!_JS_OO_ .A&I: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R76/^0W?_\
M7S)_Z$:I5=UC_D-W_P#U\R?^A&J5?10^%'P]7^)+U9IZ'IR:A?\ [_*VD*F6
M=^P4=OQ_QJYXITZST^YMOL<1B26+<5W%N<^]&FZIID&A2Z?=+>*TS[I'MPOS
M =!DG^E:WBJUAO;O3;:)V6YE4*AD(";?<]<YQ7-*<E65]%K_ ,.>A"C3>%?+
M9RT]=7L<MI>GR:GJ,-JF<.?G8?PKW-;OB#1[".WT]]*A(-S(47#D[\XQU/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4 LP5022<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6Z/%Q>$EAY6>J>S)*SH7$D08*%!SP.@YK1K.@V>2/+W;.<;NO6NTY"2BBB@
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MO_(K_P"-'_")Z)_SY?\ D5_\:/K]/L_Z^8?V-7[K\?\ (\RHKTW_ (1/1/\
MGR_\BO\ XT?\(GHG_/E_Y%?_ !H^OT^S_KYA_8U?NOQ_R/,J*]-_X1/1/^?+
M_P BO_C1_P (GHG_ #Y?^17_ ,:/K]/L_P"OF']C5^Z_'_(\RHKTW_A$]$_Y
M\O\ R*_^-'_")Z)_SY?^17_QH^OT^S_KYA_8U?NOQ_R/,J*]-_X1/1/^?+_R
M*_\ C1_PB>B?\^7_ )%?_&CZ_3[/^OF']C5^Z_'_ "/,J*]-_P"$3T3_ )\O
M_(K_ .-'_")Z)_SY?^17_P :/K]/L_Z^8?V-7[K\?\CS*BO3?^$3T3_GR_\
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MF5%>F_\ ")Z)_P ^7_D5_P#&C_A$]$_Y\O\ R*_^-'U^GV?]?,/[&K]U^/\
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M_(\RHKTW_A$]$_Y\O_(K_P"-'_")Z)_SY?\ D5_\:/K]/L_Z^8?V-7[K\?\
M(\RHKTW_ (1/1/\ GR_\BO\ XT?\(GHG_/E_Y%?_ !H^OT^S_KYA_8U?NOQ_
MR/,J*]-_X1/1/^?+_P BO_C1_P (GHG_ #Y?^17_ ,:/K]/L_P"OF']C5^Z_
M'_(\RHKTW_A$]$_Y\O\ R*_^-'_")Z)_SY?^17_QH^OT^S_KYA_8U?NOQ_R/
M,J*]-_X1/1/^?+_R*_\ C1_PB>B?\^7_ )%?_&CZ_3[/^OF']C5^Z_'_ "/,
MJ*]-_P"$3T3_ )\O_(K_ .-'_")Z)_SY?^17_P :/K]/L_Z^8?V-7[K\?\CS
M*BO3?^$3T3_GR_\ (K_XT?\ ")Z)_P ^7_D5_P#&CZ_3[/\ KYA_8U?NOQ_R
M/,J*]-_X1/1/^?+_ ,BO_C1_PB>B?\^7_D5_\:/K]/L_Z^8?V-7[K\?\CS*B
MO3?^$3T3_GR_\BO_ (T?\(GHG_/E_P"17_QH^OT^S_KYA_8U?NOQ_P CS*BO
M3?\ A$]$_P"?+_R*_P#C1_PB>B?\^7_D5_\ &CZ_3[/^OF']C5^Z_'_(\RHK
MTW_A$]$_Y\O_ "*_^-'_  B>B?\ /E_Y%?\ QH^OT^S_ *^8?V-7[K\?\CS*
MBO3?^$3T3_GR_P#(K_XT?\(GHG_/E_Y%?_&CZ_3[/^OF']C5^Z_'_(\RHKTW
M_A$]$_Y\O_(K_P"-'_")Z)_SY?\ D5_\:/K]/L_Z^8?V-7[K\?\ (\RHKTW_
M (1/1/\ GR_\BO\ XT?\(GHG_/E_Y%?_ !H^OT^S_KYA_8U?NOQ_R/,J*]-_
MX1/1/^?+_P BO_C1_P (GHG_ #Y?^17_ ,:/K]/L_P"OF']C5^Z_'_(\RHKT
MW_A$]$_Y\O\ R*_^-'_")Z)_SY?^17_QH^OT^S_KYA_8U?NOQ_R/,J*]*G\*
MZ*D$C+98(4D'S7]/K3_^$3T3_GR_\BO_ (T?7Z?9_P!?,/[&K]U^/^1YE17I
MO_")Z)_SY?\ D5_\:/\ A$]$_P"?+_R*_P#C1]?I]G_7S#^QJ_=?C_D>945Z
M;_PB>B?\^7_D5_\ &C_A$]$_Y\O_ "*_^-'U^GV?]?,/[&K]U^/^1YE17IO_
M  B>B?\ /E_Y%?\ QH_X1/1/^?+_ ,BO_C1]?I]G_7S#^QJ_=?C_ )'F5%>F
M_P#")Z)_SY?^17_QH_X1/1/^?+_R*_\ C1]?I]G_ %\P_L:OW7X_Y'F5%>F_
M\(GHG_/E_P"17_QH_P"$3T3_ )\O_(K_ .-'U^GV?]?,/[&K]U^/^1YE17IO
M_")Z)_SY?^17_P :/^$3T3_GR_\ (K_XT?7Z?9_U\P_L:OW7X_Y'F5%>F_\
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M_")Z)_SY?^17_P :/^$3T3_GR_\ (K_XT?7Z?9_U\P_L:OW7X_Y'F5%>F_\
M")Z)_P ^7_D5_P#&C_A$]$_Y\O\ R*_^-'U^GV?]?,/[&K]U^/\ D>945Z;_
M ,(GHG_/E_Y%?_&C_A$]$_Y\O_(K_P"-'U^GV?\ 7S#^QJ_=?C_D>945Z;_P
MB>B?\^7_ )%?_&C_ (1/1/\ GR_\BO\ XT?7Z?9_U\P_L:OW7X_Y'F5%>F_\
M(GHG_/E_Y%?_ !H_X1/1/^?+_P BO_C1]?I]G_7S#^QJ_=?C_D>945Z;_P (
MGHG_ #Y?^17_ ,:/^$3T3_GR_P#(K_XT?7Z?9_U\P_L:OW7X_P"1YE17I0\*
MZ*9W7[%P%4@>:_J??VI__")Z)_SY?^17_P :/K]/L_Z^8?V-7[K\?\CS*E +
M,%4$DG  [UZ9_P (GHG_ #Y?^17_ ,:GM/#VE65PL]O:!95^ZQ=FQ^9I/'T[
M:)C635KZR5OG_D97AGPR+%5O;U0;HC*(?^6?_P!?^5=1117F5*DJDN:1[U"A
M"A!0@@HHHJ#8**** "BBB@ HHHH **** *4Z-]M#X^7R\9]\T4DY/V\#)QY6
M<?C2T %%%% !1110 V0;HG&0,@C)JY"NR"-<@X4#(Z'BJ4H)B<#DE35R!2MO
M$I&"$ (_"@ N"5MI2"00A((^E4XB3"A)R2HJ[,Q2"1AC*J2,_2J<9W1(QZD
MT .HHHH **** "D15-W"2^"-V!CKQ2TB1LUW$XZ)NS^(H O4444 10?ZL_[[
M_P#H1J6HH/\ 5G_??_T(U+0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNZ]:GH *R/%7_(GZW_UX3_\ HMJUZR/%7_(GZW_UX3_^BVH /"O_ ")^B?\
M7A!_Z+6M>LCPK_R)^B?]>$'_ *+6M>@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** *UZC/''M&=L@)^E1T^_)$<6"1F4 _K3* "BBB@ HHHH *D
MLDV1R?,IW2$\'I4=/L498Y=PQF0D>XH M519&6\F8C ;;@^O%7JH,2;V<$G
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MW#_*I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (I?\
M60?[Y_\ 034M12_ZR#_?/_H)J6@ HHHH **** "BBB@ HHHH **** "BBB@
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M?^1/T3_KP@_]%K6O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%:\"&./>2/W@VX[FHZDO$+QQX(&V0-SWJ.@ HHHH **** "I+(J8Y-J[<2$'
MGJ?6HZDLP@CDV-G,A+<=#Z4 6:HN$%W*5)+';N'IQ5ZJ+H5NY7R"&V\#J.*
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M_/[_ .0D_P *3_A*=9+AOMG(! /E)_A[5CT4>WJ_S/[V'M)]V;/_  E>M_\
M/[_Y"3_"C_A*];_Y_?\ R$G^%8U%'MZO\S^]A[2?=FS_ ,)7K?\ S^_^0D_P
MH_X2O6_^?W_R$G^%8U%'MZO\S^]A[2?=FS_PE>M_\_O_ )"3_"C_ (2O6_\
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M_P#G]_\ (2?X5C44>WJ_S/[V'M)]V;/_  E>M_\ /[_Y"3_"C_A*];_Y_?\
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MZW_S^_\ D)/\*QJ*/;U?YG][#VD^[-G_ (2O6_\ G]_\A)_A1_PE>M_\_O\
MY"3_  K&HH]O5_F?WL/:3[LV?^$KUO\ Y_?_ "$G^%'_  E>M_\ /[_Y"3_"
ML:BCV]7^9_>P]I/NS9_X2O6_^?W_ ,A)_A1_PE>M_P#/[_Y"3_"L:BCV]7^9
M_>P]I/NS9_X2O6_^?W_R$G^%'_"5ZW_S^_\ D)/\*QJ*/;U?YG][#VD^[-G_
M (2O6_\ G]_\A)_A1_PE>M_\_O\ Y"3_  K&HH]O5_F?WL/:3[LV?^$KUO\
MY_?_ "$G^%'_  E>M_\ /[_Y"3_"L:BCV]7^9_>P]I/NS9_X2O6_^?W_ ,A)
M_A1_PE>M_P#/[_Y"3_"L:BCV]7^9_>P]I/NS9_X2O6_^?W_R$G^%'_"5ZW_S
M^_\ D)/\*QJ*/;U?YG][#VD^[-C_ (2G60Y;[9R0 3Y2?X>]+_PE>M_\_O\
MY"3_  K&HH]O5_F?WL/:3[LV?^$KUO\ Y_?_ "$G^%3V?C#5(;I'N91/#GYD
MV*N1[$#K7/T4+$54[\S^\:JS75GKUG>07]JEQ;N'C8<'T]C[U/7EVBZU/H]U
MO3+P,?WD>>ON/>O2K.\@O[5+BW</&PX/I['WKV\-B8UH^9Z%&LJB\R>BBBNH
MV"BBB@ HHHH **** "BBB@"E.K?;@^#M\O&??-%$['[<%R=OE9QGC.:* "BB
MB@ HHHH ;(-T3J.I!%7(5*01J<950#CZ52E!,+@#)*FKEN"MM$"""$ (/TH
M)V*V\K X(0D'\*IQ$F)">25%79FV02-@'"DX/0\53C.Z)#@#(!P* '5ROC3Q
M9<^%UL/LVFF\:Z=DSN("D8P. <DY./H:ZJJ.K:19ZW9?9+V-FCWJZE6*LK#H
M01T- '#?\)[XK_Z$J\_[]2__ !-;/P^U&]U33-4N;\S+-_:<H\F9F)A&$/EC
M/( )(Q5[2_&>C:Q9:A=VDLIAL$\R<M&00N&.0._"FE\)7FC:AI]Y>:*L@BGO
M)))_,!!,S %CS[%>G% &_2(H-W$Q8 KNP/7BEI$1FNX6 ^5=V3Z<4 7J***
M(H/]6?\ ??\ ]"-2U%!_JS_OO_Z$:EH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,U?7+;1?)^TQ
MS-YN[;Y8!QC'7)'K6G7&^/?^8?\ ]M/_ &6L,34E3I.<=_\ @F=:3A!R1<_X
M3C3/^>%W_P!\+_\ %4?\)QIG_/"[_P"^%_\ BJX"BO)_M"L</UJH=_\ \)QI
MG_/"[_[X7_XJC_A.-,_YX7?_ 'PO_P 57 44?VA6#ZU4._\ ^$XTS_GA=_\
M?"__ !5'_"<:9_SPN_\ OA?_ (JN HH_M"L'UJH=_P#\)QIG_/"[_P"^%_\
MBJ/^$XTS_GA=_P#?"_\ Q5<!11_:%8/K50[_ /X3C3/^>%W_ -\+_P#%4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG\J=2([+=PJ#\K;LCUXH O4444 10?ZL_P"^_P#Z$:EJ*#_5G_??_P!"-2T
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M .BVK7K(\5?\B?K?_7A/_P"BVH /"O\ R)^B?]>$'_HM:UZR/"O_ ")^B?\
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MU]R*=*\K-E/QQ?POY%BC!I$;>^#]WC@?K_G-7=;.BZ+/#+)I44KS#:$5%"J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  U;N 3;2@#)*'^54XAB% ?[HH ?7(:[X2U2ZU6?5-&\07-C<3!=T#$F)BH
M'3IP.X/.?6NOHH \^-C\3E;R_P"UM.8=/-V+^?\ J^WTJ?3_  9KMQJMMJ'B
M'Q%+<&WD65;>WR$+*<CL!C([+SZBNZHH *1& NXE*@EMV#Z<4M(FS[7#NW;O
MFVXZ=.] %ZBBB@"*#_5G_??_ -"-2U%!_JS_ +[_ /H1J6@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N-\>_\P__ +:?^RUV5<;X]_YA_P#VT_\ 9:Y,=_ E\OS,<1_#9QE%%%?/
MGEG43>*8I?#OV/RI?MIA$+2'!!'0\YSR/;J:IZ;KB:5HL\-J'6_ED#>;L7:J
MCMSG/?MWK#HK=XFHVI7U2L:NK)NYT</B9KK3KRSU=I)A,H$;QQK\A]QQGG!_
M"EN/$R1W>GC3TDCL[0#]VXP6['/)[?J37-T4_K-2V_SZ]P]M/N:NI:G&VJ2W
M>E27-LLPRXW;#N[_ '3T[_7-7-#URSL7GN+];F:]DX6<8<A<8ZL>M<]14QKS
M4^="522ES&U/J=I;7 O-*GOQ>LQWR7(1@0>OXU>M_&%RNEW,=Q+(]XQ_<R"-
M-JCW_7L:Y>BG'$5(N\78%5DGH%%%%8&84444 %3VEW-8W27-N^V1#D'^E044
MTVG=#3MJ>I:?J\>J:2UU"0LBJ=Z==C8J2,EHD8]2H)KA_"T-Z;]I[?BWC4^?
MN^ZRX^[]?Y5W$9S$A P"!QZ5]#A:TJM/FDCU*,W.-V.HHHKI-0HHHH **KWM
M];:;9R7=Y,D-O'C?(YX&3@?J14R.LD:NARK $'U!H =156VU*SO+JZMK>=7G
MM6"SH,Y0D9&?K5J@ HHHH *;*"T3@=2I IU,E.(7(_NF@"Y I6WC5A@A0"/P
MJ2H[<DVT1)R2@_E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5D>*O^1/UO\ Z\)__1;5KUD>*O\ D3];_P"O"?\ ]%M0 >%?^1/T3_KP@_\
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M1110 4444 %%%% !61XJ_P"1/UO_ *\)_P#T6U:]9'BK_D3];_Z\)_\ T6U
M!X5_Y$_1/^O"#_T6M:]9'A7_ )$_1/\ KP@_]%K6O0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% %6^4M'%@$XE!.!T%,I]\[+'%M.,R 'W%,H
M*YGQ[9W%]X7EAM+*6[N/-1HUC/*,#G=@@@CU!]:Z:N:\=:K=Z1X9DFLI4AGE
MD2$2MP(PQY;V^M &"/%GCC SX2!/?&[_ !KOK9Y)+6&29-DK(I=/[I(Y%>80
M7FHZ7X<\3A]>NIY]/N(Q!<RRD[SQP,D\'TS7IUG,UQ903NNUY(U=E]"1G% $
MU26<;1QR;OXI"P^E1T^P!$<N01F4D?I0!:J@RD7LY((!VX..O%7ZH,[->3J3
MD+MP/3B@!U8/B36-6T?[+-IVC/J<#%A<+$WSITVX R3W['IVS6]10!Y_!\5]
M!BC\J:PO[5UZQB)< ^WS#^0IDGQ-%])Y?A[0+V]N&PI9UP!_WSGCZD=:[^2"
M*;'FQ(^.FY0<4]5"J%4 *!@ =!0!#8O<R6%L]Y$L5TT2F:-3D(^!N .3T.>]
M/FC:6(HOWCC'YU)4-R"UNP )/' ^M &G1110!XU17L%M_P >L/\ N#^52UY7
M]F?W_P /^"<7U/\ O'C5%>RT4?V9_?\ P_X(?4_[QXU17LM%']F?W_P_X(?4
M_P"\>-45[+11_9G]_P##_@A]3_O'C5%>RT4?V9_?_#_@A]3_ +QXU17LM%']
MF?W_ ,/^"'U/^\>-45[+11_9G]_\/^"'U/\ O'C5%>RT4?V9_?\ P_X(?4_[
MQXU17LM%']F?W_P_X(?4_P"\>-45[+7(^//^99_[#]K_ .S4?V9_?_#_ ((?
M4_[QQ%%>RT4?V9_?_#_@A]3_ +QXU17LM%']F?W_ ,/^"'U/^\>-45[+11_9
MG]_\/^"'U/\ O'C5%>RT4?V9_?\ P_X(?4_[QXU17LM%']F?W_P_X(?4_P"\
M>-45[+11_9G]_P##_@A]3_O'C5%>RT4?V9_?_#_@A]3_ +QXU17LM%']F?W_
M ,/^"'U/^\>-45[+11_9G]_\/^"'U/\ O'C5%>RU$W_'U'_N-_-:/[,_O_A_
MP0^I_P!X\?HKV6BC^S/[_P"'_!#ZG_>/&J*]EHH_LS^_^'_!#ZG_ 'CQJBO9
M:*/[,_O_ (?\$/J?]X\:HKV6BC^S/[_X?\$/J?\ >/&J*]EHH_LS^_\ A_P0
M^I_WCQJBO9:*/[,_O_A_P0^I_P!X\:HKV6BC^S/[_P"'_!#ZG_>/&J*]EHH_
MLS^_^'_!#ZG_ 'CQJBO9:*/[,_O_ (?\$/J?]X\:HKV6HE_X^I/]Q?YM1_9G
M]_\ #_@A]3_O'C]%>RT4?V9_?_#_ ((?4_[QXU17LM%']F?W_P /^"'U/^\>
M-45[+11_9G]_\/\ @A]3_O'C5%>RT4?V9_?_  _X(?4_[QXU17LM%']F?W_P
M_P""'U/^\>-45[+11_9G]_\ #_@A]3_O'C5%>RT4?V9_?_#_ ((?4_[QXU17
MLM%']F?W_P /^"'U/^\>-45[+11_9G]_\/\ @A]3_O'C5%>RT4?V9_?_  _X
M(?4_[QXU17LM%']F?W_P_P""'U/^\>-45[+11_9G]_\ #_@A]3_O'C5%>RT4
M?V9_?_#_ ((?4_[QXU17LM%']F?W_P /^"'U/^\>-45[+11_9G]_\/\ @A]3
M_O'C5%>RT4?V9_?_  _X(?4_[QXU17LM%']F?W_P_P""'U/^\>-45[+11_9G
M]_\ #_@A]3_O'C5%>RT4?V9_?_#_ ((?4_[QXU17L%S_ ,>LW^X?Y5+1_9G]
M_P##_@A]3_O'C5%>RT4?V9_?_#_@A]3_ +QXU17LM%']F?W_ ,/^"'U/^\>-
M45[+11_9G]_\/^"'U/\ O'C5%>RT4?V9_?\ P_X(?4_[QXU17LM%']F?W_P_
MX(?4_P"\>-45[+11_9G]_P##_@A]3_O'C5%>RT4?V9_?_#_@A]3_ +QXU17L
MM%']F?W_ ,/^"'U/^\>-45[+11_9G]_\/^"'U/\ O'C5%>P2_P"L@_WS_P"@
MFI:/[,_O_A_P0^I_WCQJBO9:*/[,_O\ X?\ !#ZG_>/&J*]EHH_LS^_^'_!#
MZG_>/&J*]EHH_LS^_P#A_P $/J?]X\:HKV6BC^S/[_X?\$/J?]X\:HKV6BC^
MS/[_ .'_  0^I_WCQJBO9:*/[,_O_A_P0^I_WCQJBO9:*/[,_O\ X?\ !#ZG
M_>/&J*]EHH_LS^_^'_!#ZG_>/&J*]EHH_LS^_P#A_P $/J?]X\:HKV6BC^S/
M[_X?\$/J?]X\:HKV6BC^S/[_ .'_  0^I_WCQJBO9:*/[,_O_A_P0^I_WCQJ
MBO9:*/[,_O\ X?\ !#ZG_>/&J*]EHH_LS^_^'_!#ZG_>/&J*]EHH_LS^_P#A
M_P $/J?]X\:HKV6BC^S/[_X?\$/J?]X\:HKV6BC^S/[_ .'_  0^I_WCQJBO
M9:*/[,_O_A_P0^I_WCQJBO9:*/[,_O\ X?\ !#ZG_>/&J*]EHH_LS^_^'_!#
MZG_>/&J*]@7_ (^I/]Q?YM4M']F?W_P_X(?4_P"\>-5/9V<]_=);VZ%Y'/ ]
M/<^U>O44++%?67X?\$:P?=F7HFB0:/:[5P\[C]Y)CK[#VK4HHKTX0C"/+'8Z
MXQ459!1115#"BBB@ HHHH **** "BBB@"G._^F!-J_ZO.<<]:2EG*?:P,'?Y
M?7MC-)0 5QGQ#E\-C3;>'7EN'D9S]G6TQYP/&2,\8Z#G^==G7$>.-.U--0M-
M;TVQ^W^3;RV\D"CYU#@C<O<GGL#_ ( %'PEI'A72=0TR^M/M[7&I1.;1KS:0
MF,[@-H #$?7@UZ+7EOA>VUS5+KP_976C3V%GHVZ1YYU93*Q!P "!W[<_6O4J
M &RDK$Y'4*2*MP,6MXV8Y)4$G\*J2'$3G . >#5R%MT$;8 RH.!T'% !-M\B
M3?G;M.<=<8JG'CRDVYQ@8S5R8!H)%)"@J02>W%4XQB) #D #GUH =116-<Z!
M]H\5V>N"]F0V\+0FW'W'!W<G_OK]!Z4 <1I/P[U2PT2TO["\ETSQ!&'\R,N'
MCD^9MH.,C[N/4>U=/X%T_5+'3=1;6+<0W=UJ$MP55@0=P7)&">,@UP]WH7AN
MQG>&?QU<B1&VLJY?!]/ES7=>!8=/@T29=-U:74X3<L3-(I!5MJ_+S[8/XTP.
MGIJDB]@ )P=V1Z\4ZD21ENX4!X?=G\J0%ZBBB@"*#_5G_??_ -"-2U%!_JS_
M +[_ /H1J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N-\>_\P__ +:?^RUV5<;X]_YA_P#VT_\
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M3_J5O_)BC_BXG_4K?^3% '745R/_ !<3_J5O_)BC_BXG_4K?^3% '745R/\
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MHH **** (KG_ (]9O]P_RJ6HKG_CUF_W#_*I: "BBB@ HHHH **** "BBB@
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M^XW\UJ6HF_X^H_\ <;^:T 2T444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5O3-3N](OXKVRE,<T9X(Z$=
MP1W!JI12!I-69] >%?%5IXFL/,CQ'=Q@>= 3RI]1Z@UOU\UZ9J=WI%_%>V4I
MCFC/!'0CN".X->Z^%?%5IXFL/,CQ'=Q@>= 3RI]1Z@UR5:7+JMCRL1AW3?-'
M8WZ***Q.4**** "BBB@ HHHH **** *<[C[6$VC/EYW=^O2DI9]GVP?>\SR_
MPQFDH **** "BBB@!LA*Q.PZA215N!B\$;,<DJ"3^%5)#B)R1D 'CUJY"0T$
M; !05! ';B@ FV^1)OSMVG..N,53CQY2;<XP,9JY,NZ"1<@94C)Z#BJ<8Q$@
MR#@#D4 .K$UCPEH>O7:76IV/GS)&(U;S77"@DXPK =2:VZ* /&?#ECX$?39O
M[=;R=0,SAX9))%\@9("KCK@8Y.>:[+X8B%?#-PELA^SI?2K%,4*F=.,.0>^.
M./[M<U?Z]INNWTUY9^ )]5BW%/M:!E\PCN=J'GIU.<8KO/"5_+?:-F30Y-&6
M&0Q1VK@CY0 =PRJ\9)'3L:8&[358B]@ ) .[(SUXIU(DA6[B08P^[/Y4@+U%
M%% $4'^K/^^__H1J6HH/]6?]]_\ T(U+0 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@"G.H^UA]PSY>-O?KUI*6=&^V"3'R^7MS[YI* "BBB@ HHHH
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M% $=N"MM$"""$ (/TJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=N=)BURR>6UC1YI1$GEINY53^[SDCGI6SX4O/$R>*K[2O$6HQ3-%;"6*-(E
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MK5_^OV;_ -#-9=:GB7_D:M7_ .OV;_T,UEUZ,=CW8?"@HHHIE!1110 4444
M%%%% !1110 5UO@?QA)X=OA;7+,VFSM^\7KY9_O#^OM]*Y*BE**DK,F<%./*
MSZ=1TEC62-U=& 964Y!!Z$&G5Y-\.O&7V.1=%U*;%NYQ;2N?]6W]TGT/;T/Z
M>LUPS@XNS/&JTG3E9A1114&84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5D>*O^1/UO\ Z\)__1;5KUD>*O\ D3];_P"O"?\ ]%M0 >%?^1/T
M3_KP@_\ 1:UKUD>%?^1/T3_KP@_]%K6O0 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS[5%X7LM<_X2F:_\1W%H+[["((K>*1=S1A\ERH[9[^]<GJ.C6GA?[#/X<\4
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M[\5?] O_ ,F(O_BJ]WHH]O(/KM3LCPC_ (5WXJ_Z!?\ Y,1?_%4?\*[\5?\
M0+_\F(O_ (JO=Z*/;R#Z[4[(\(_X5WXJ_P"@7_Y,1?\ Q5'_  KOQ5_T"_\
MR8B_^*KW>BCV\@^NU.R/"/\ A7?BK_H%_P#DQ%_\51_PKOQ5_P! O_R8B_\
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M $"__)B+_P"*H_X5WXJ_Z!?_ ),1?_%5[O11[>0?7:G9'A'_  KOQ5_T"_\
MR8B_^*H_X5WXJ_Z!?_DQ%_\ %5[O11[>0?7:G9'A'_"N_%7_ $"__)B+_P"*
MH_X5WXJ_Z!?_ ),1?_%5[O11[>0?7:G9'A'_  KOQ5_T"_\ R8B_^*H_X5WX
MJ_Z!?_DQ%_\ %5[O11[>0?7:G9'A'_"N_%7_ $"__)B+_P"*H_X5WXJ_Z!?_
M ),1?_%5[O11[>0?7:G9'A'_  KOQ5_T"_\ R8B_^*H_X5WXJ_Z!?_DQ%_\
M%5[O11[>0?7:G9'A'_"N_%7_ $"__)B+_P"*I/\ A7OBDN5_LOD $C[1%_\
M%>U>\5$O_'U)_N+_ #:CV\@^NU.R/#?^%=^*O^@7_P"3$7_Q5'_"N_%7_0+_
M /)B+_XJO=Z*/;R#Z[4[(\(_X5WXJ_Z!?_DQ%_\ %4?\*[\5?] O_P F(O\
MXJO=Z*/;R#Z[4[(\(_X5WXJ_Z!?_ ),1?_%4?\*[\5?] O\ \F(O_BJ]WHH]
MO(/KM3LCPC_A7?BK_H%_^3$7_P 51_PKOQ5_T"__ "8B_P#BJ]WHH]O(/KM3
MLCPC_A7?BK_H%_\ DQ%_\51_PKOQ5_T"_P#R8B_^*KW>BCV\@^NU.R/"/^%=
M^*O^@7_Y,1?_ !5'_"N_%7_0+_\ )B+_ .*KW>BCV\@^NU.R/"/^%=^*O^@7
M_P"3$7_Q5'_"N_%7_0+_ /)B+_XJO=Z*/;R#Z[4[(\(_X5WXJ_Z!?_DQ%_\
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M_P#BJ]RN?^/6;_</\JEH]O(/KM3LCPC_ (5WXJ_Z!?\ Y,1?_%4?\*[\5?\
M0+_\F(O_ (JO=Z*/;R#Z[4[(\(_X5WXJ_P"@7_Y,1?\ Q5'_  KOQ5_T"_\
MR8B_^*KW>BCV\@^NU.R/"/\ A7?BK_H%_P#DQ%_\51_PKOQ5_P! O_R8B_\
MBJ]WHH]O(/KM3LCPC_A7?BK_ *!?_DQ%_P#%4?\ "N_%7_0+_P#)B+_XJO=Z
M*/;R#Z[4[(\(_P"%=^*O^@7_ .3$7_Q5'_"N_%7_ $"__)B+_P"*KW>BCV\@
M^NU.R/"/^%=^*O\ H%_^3$7_ ,51_P *[\5?] O_ ,F(O_BJ]WHH]O(/KM3L
MCPC_ (5WXJ_Z!?\ Y,1?_%4?\*[\5?\ 0+_\F(O_ (JO=Z*/;R#Z[4[(\(_X
M5WXJ_P"@7_Y,1?\ Q5'_  KOQ5_T"_\ R8B_^*KW>BCV\@^NU.R/"/\ A7?B
MK_H%_P#DQ%_\51_PKOQ5_P! O_R8B_\ BJ]WHH]O(/KM3LCP<_#WQ2I4'2^6
M.!_I$7U_O>U+_P *[\5?] O_ ,F(O_BJ]RE_UD'^^?\ T$U+1[>0?7:G9'A'
M_"N_%7_0+_\ )B+_ .*H_P"%=^*O^@7_ .3$7_Q5>[T4>WD'UVIV1X1_PKOQ
M5_T"_P#R8B_^*H_X5WXJ_P"@7_Y,1?\ Q5>[T4>WD'UVIV1X1_PKOQ5_T"__
M "8B_P#BJ/\ A7?BK_H%_P#DQ%_\57N]%'MY!]=J=D>$?\*[\5?] O\ \F(O
M_BJ/^%=^*O\ H%_^3$7_ ,57N]%'MY!]=J=D>$?\*[\5?] O_P F(O\ XJC_
M (5WXJ_Z!?\ Y,1?_%5[O11[>0?7:G9'A'_"N_%7_0+_ /)B+_XJC_A7?BK_
M *!?_DQ%_P#%5[O11[>0?7:G9'A'_"N_%7_0+_\ )B+_ .*H_P"%=^*O^@7_
M .3$7_Q5>[T4>WD'UVIV1X1_PKOQ5_T"_P#R8B_^*H_X5WXJ_P"@7_Y,1?\
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M@SA\YR3@CDY.?6L.BBJLD:**3NCKY/B%>SVD%K<:-HL\,"A8DEM2P4 8X!;
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MVT>O%7JHHFZ[A;<HV[N">3QVJ]0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !61XJ_Y$_6_P#KPG_]%M6O61XJ
M_P"1/UO_ *\)_P#T6U !X5_Y$_1/^O"#_P!%K6O61X5_Y$_1/^O"#_T6M:]
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MHH BMO\ CUA_W!_*I:BMO^/6'_<'\JEH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KD?'G_,L_P#8?M?_ &:NNKD?'G_,L_\ 8?M?_9J .NHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)O^/J/_<;^:U+
M43?\?4?^XW\UH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ J)?\ CZD_W%_FU2U$O_'U)_N+_-J ):*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** (KG_CUF_W#_*I:BN?^/6;_ '#_ "J6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@"*7_60?[Y_]!-2U%+_K(/\ ?/\
MZ":EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@")?^/J3_
M '%_FU2U$O\ Q]2?[B_S:I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"C.3]O R<>5G'XTM+/(WVL1_P /E[OQS24 %%%% !1110 R4$Q.!R2IJY I
M6WB4C!" $?A5.4D0N0<$*:N6Y+6T1)))0$D_2@!9F*02,,9521GZ53C.Z)&/
M4@&KDQ402%AE0IR/48JG'@Q(5&!@8% #J*** "BBB@ I$C9KN)QT3=G\12TU
M03>P$ X&[)].* +]%%% 'SIXE_Y&K5_^OV;_ -#-9=:GB7_D:M7_ .OV;_T,
MUEUZ,=CW8?"C4\-?\C5I'_7[#_Z&*U/B)_R/>I?]LO\ T4E9NAZ])H,[S16%
MA=2$JR-=0[S&5.05.1@_X"M2X\>7\^JV^I_V;I<=Y Y?S4@(:3Y2F&.[)&#^
M@J&GS71FU+VG,ET,/1O^0[I__7S'_P"A"NH^*7_(WC_KV3^;5BVOBBYM]:NM
M5EL=/NKFX?>1<P[UC.<Y49&#[U)X@\6W7B2)!>6&GQRJP;SX82)" "-I8D_+
MSG'THL^9,'&3J*5C=\)6VFKX'UG4KS3+>\EMY04\T<\!2!GJ!GJ!UZ&K]]?:
M3;^#M,\2+X:TLWES(8&B,7[H %MQV],G9QGD9ZGOQ5CXCO+#0;W1XHX#;WAS
M(S*=XZ=#G';TIMQK]W<^'+/0W2$6MK(TB,JG>22QY.<?Q'M2<&W?S(=*3E=]
M_P +'H,WA32)_B1%!]DCCM!IXO&MD&%=@Q7&/3H<=\>YK TS4M-\4^(=.L)]
M L;1#=%]UI'MW1A6(1@!SSC)XZ=!67<^-M6N-?M=97R8;FWB$(6)2$= 2<,"
M3G.3^G0\UMZ!XQ2^\36;:C'8Z;;K*T[26L(C#RE6&9"2>"&89]_QJ>626O8C
MDG&-WKIW-K7X+?2O#&K37OAW1K2;SO(L (U+21D@;LCG=C<<Y!XZ<<^3UZAK
M4VA'1]7?4&\.2W$@;[$=+7]\6YPSD'KG:3VZ]:\OJJ6QIAOA=PHHHK4Z I\,
M,EQ/'#"C/+(P1$49+$G  IE>O?#SP:MA;Q:UJ$9^V2#,$;?\LE/<C^\1^0/K
M43FHJYE5JJG&[-CP5X23PS8,\VU]0G \UQT0?W![>OJ?H*W9PGVL')\SR^G;
M&:N53G3_ $P/N7_5XVYYZ]:X6VW=GCSDYOF8E%%%(D**** "N U;5I?!?C.^
MU2[LY9M*U5(@TT*Y,4D:E0.<#GDXS].A%=_7F_B;QQK5EXINM#L;32WA15 -
MZ^S?N0$\LZKWQB@"'7/B/;:[ITVC:%87<]Y?(8!YBJ  PP< $YXSZ8ZYKT'1
M[1]/T2PLI""]O;1Q,1W*J ?Y5PEK>?$"$"6T\+:*@=00\10;AVY$O(KT&Q>Y
MDL+9[R)8KIHE,T:G(1\#< <GH<]Z )Z*** "BBB@!JHS7D# 9"[LGTXJ_5!6
M(O8 "0#NR,]>*OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5D>*O^1/UO_KPG_\ 1;5KUD>*O^1/UO\ Z\)_
M_1;4 'A7_D3]$_Z\(/\ T6M:]9'A7_D3]$_Z\(/_ $6M:] !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 5;\D1Q8)&90#^M,J2\D:../;_%(%/T
MJ.@ HHHH **** "GV*,L<NX8S(2/<4RGV+%HY<DG$I R>@H M508DWLX).!M
MP/3BK]47D9KN5#T3;C\10 M%%% !1110 5%<(SP,JC+'&!^-2U%<L5MV9201
MC!!]Z -*BBB@"*V_X]8?]P?RJ6L^WU73EMH@=0M00@!!F7T^M2?VMIO_ $$+
M3_O\O^-9^VI_S+[S3V4_Y67**I_VMIO_ $$+3_O\O^-']K:;_P!!"T_[_+_C
M1[:G_,OO#V4_Y67**I_VMIO_ $$+3_O\O^-']K:;_P!!"T_[_+_C1[:G_,OO
M#V4_Y67**I_VMIO_ $$+3_O\O^-']K:;_P!!"T_[_+_C1[:G_,OO#V4_Y67*
M*I_VMIO_ $$+3_O\O^-']K:;_P!!"T_[_+_C1[:G_,OO#V4_Y67**I_VMIO_
M $$+3_O\O^-']K:;_P!!"T_[_+_C1[:G_,OO#V4_Y67**I_VMIO_ $$+3_O\
MO^-']K:;_P!!"T_[_+_C1[:G_,OO#V4_Y67**I_VMIO_ $$+3_O\O^-']K:;
M_P!!"T_[_+_C1[:G_,OO#V4_Y67**I_VMIO_ $$+3_O\O^-']K:;_P!!"T_[
M_+_C1[:G_,OO#V4_Y67*Y'QY_P RS_V'[7_V:NB_M;3?^@A:?]_E_P :Y?QI
M>6MU_P (]]GN89O*UNVED\MPVQ!NRQQT ]:/;4_YE]X>RG_*SM**I_VMIO\
MT$+3_O\ +_C1_:VF_P#00M/^_P O^-'MJ?\ ,OO#V4_Y67**I_VMIO\ T$+3
M_O\ +_C1_:VF_P#00M/^_P O^-'MJ?\ ,OO#V4_Y67**I_VMIO\ T$+3_O\
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MO#V4_P"5ERBJ?]K:;_T$+3_O\O\ C1_:VF_]!"T_[_+_ (T>VI_S+[P]E/\
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MO#V4_P"5ERBJ?]K:;_T$+3_O\O\ C1_:VF_]!"T_[_+_ (T>VI_S+[P]E/\
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M453_ +6TW_H(6G_?Y?\ &C^UM-_Z"%I_W^7_ !H]M3_F7WA[*?\ *RY15/\
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M<2".&\MY'/14E4D_@#356#=E)"=.:U:99HHHJR HHHH **** "BBB@ HHHH
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M?_*3#_C1_P (_P",/^AY_P#*3#_C0!UU%<C_ ,(_XP_Z'G_RDP_XT?\ "/\
MC#_H>?\ RDP_XT ==17(_P#"/^,/^AY_\I,/^-'_  C_ (P_Z'G_ ,I,/^-
M'745R/\ PC_C#_H>?_*3#_C1_P (_P",/^AY_P#*3#_C0!UU%<C_ ,(_XP_Z
M'G_RDP_XT?\ "/\ C#_H>?\ RDP_XT ==17(_P#"/^,/^AY_\I,/^-'_  C_
M (P_Z'G_ ,I,/^- '745R/\ PC_C#_H>?_*3#_C1_P (_P",/^AY_P#*3#_C
M0!UU%<C_ ,(_XP_Z'G_RDP_XT?\ "/\ C#_H>?\ RDP_XT ==17(_P#"/^,/
M^AY_\I,/^-'_  C_ (P_Z'G_ ,I,/^- '745R/\ PC_C#_H>?_*3#_C1_P (
M_P",/^AY_P#*3#_C0!UU%<C_ ,(_XP_Z'G_RDP_XT?\ "/\ C#_H>?\ RDP_
MXT ==17(_P#"/^,/^AY_\I,/^-'_  C_ (P_Z'G_ ,I,/^- '745R/\ PC_C
M#_H>?_*3#_C1_P (_P",/^AY_P#*3#_C0!UU%<C_ ,(_XP_Z'G_RDP_XT?\
M"/\ C#_H>?\ RDP_XT ==17(_P#"/^,/^AY_\I,/^-'_  C_ (P_Z'G_ ,I,
M/^- '745R/\ PC_C#_H>?_*3#_C1_P (_P",/^AY_P#*3#_C0!UU%<C_ ,(_
MXP_Z'G_RDP_XT?\ "/\ C#_H>?\ RDP_XT ==17(_P#"/^,/^AY_\I,/^-'_
M  C_ (P_Z'G_ ,I,/^- '745R/\ PC_C#_H>?_*3#_C1_P (_P",/^AY_P#*
M3#_C0!UU%<C_ ,(_XP_Z'G_RDP_XT?\ "/\ C#_H>?\ RDP_XT ==17(_P#"
M/^,/^AY_\I,/^-'_  C_ (P_Z'G_ ,I,/^- '745R/\ PC_C#_H>?_*3#_C1
M_P (_P",/^AY_P#*3#_C0!UU%<C_ ,(_XP_Z'G_RDP_XT?\ "/\ C#_H>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2+'4H+9;:2;&Z-.!@C/3^OO7,5QXJDZ=2SMTV.O#5%4IW5_F%%%%<YN%%%%
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MBBB@ HHHH **** (K;_CUA_W!_*I:BMO^/6'_<'\JEH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 'P:[6BC^RL)_)^+_P P_M+%?S?@O\CBO^$&G_Y_8_\ O@T?\(-/_P _L?\
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MNG_YYQ_]_#_A1NG_ .><?_?P_P"%2T4 1;I_^><?_?P_X4;I_P#GG'_W\/\
MA4M% $6Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (5+10!%NG_YYQ_]_#_A1NG_ .><
M?_?P_P"%2T4 1;I_^><?_?P_X4;I_P#GG'_W\/\ A4M% $6Z?_GG'_W\/^%&
MZ?\ YYQ_]_#_ (5+10!%NG_YYQ_]_#_A1NG_ .><?_?P_P"%2T4 1;I_^><?
M_?P_X4;I_P#GG'_W\/\ A4M% $6Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (5+10!%
MNG_YYQ_]_#_A1NG_ .><?_?P_P"%2T4 1;I_^><?_?P_X4;I_P#GG'_W\/\
MA4M% $6Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (5+10!%NG_YYQ_]_#_A1NG_ .><
M?_?P_P"%2T4 1;I_^><?_?P_X4;I_P#GG'_W\/\ A4M% $6Z?_GG'_W\/^%&
MZ?\ YYQ_]_#_ (5+10!%NG_YYQ_]_#_A1NG_ .><?_?P_P"%2T4 1;I_^><?
M_?P_X4;I_P#GG'_W\/\ A4M% $6Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (5+10!%
MNG_YYQ_]_#_A1NG_ .><?_?P_P"%2T4 1;I_^><?_?P_X4;I_P#GG'_W\/\
MA4M% $6Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (5+10!%NG_YYQ_]_#_A1NG_ .><
M?_?P_P"%2T4 1;I_^><?_?P_X4;I_P#GG'_W\/\ A4M% $6Z?_GG'_W\/^%&
MZ?\ YYQ_]_#_ (5+10!%NG_YYQ_]_#_A1NG_ .><?_?P_P"%2T4 1;I_^><?
M_?P_X4;I_P#GG'_W\/\ A4M% $6Z?_GG'_W\/^%&Z?\ YYQ_]_#_ (5+10!%
MNG_YYQ_]_#_A1NG_ .><?_?P_P"%2T4 1;I_^><?_?P_X4;I_P#GG'_W\/\
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MA_:6*_F_!?Y''_\ ""?]1+_R!_\ 94?\()_U$O\ R!_]E7844?V5A/Y/Q?\
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M9OS\W4YQCIQ]:]'KD?'G_,L_]A^U_P#9J/[*PG\GXO\ S#^TL5_-^"_R&_\
M""?]1+_R!_\ 94?\()_U$O\ R!_]E7844?V5A/Y/Q?\ F']I8K^;\%_D<?\
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M'D<=LUG:5\11?:[;:;=Z;%:BZ=HXGCOXYV##/#HG*9Z<_P#UZ/[*PG\GXO\
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MP_M+%?S?@O\ (X__ (03_J)?^0/_ +*C_A!/^HE_Y _^RKL**/[*PG\GXO\
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MAN*P>"TU+5II89)VC#(GED E03U.0<'OQ4XU[Q7IUQK^AF2+5M2M+=+BTG6
M(75BH8%%X) ;('J.^:7]E83^3\7_ )A_:6*_F_!?Y&K_ ,()_P!1+_R!_P#9
M4?\ ""?]1+_R!_\ 95S+:MJ.N_#_ %[?KXN9((E>57L1#*@(;=&Z_=P<## G
MH:ZWX>PWT7@^P>\U W220HT"F()Y*;0 F1]['J:/[*PG\GXO_,/[2Q7\WX+_
M "(/^$$_ZB7_ ) _^RH_X03_ *B7_D#_ .RKL**/[*PG\GXO_,/[2Q7\WX+_
M "./_P"$$_ZB7_D#_P"RH_X03_J)?^0/_LJ["BC^RL)_)^+_ ,P_M+%?S?@O
M\CC_ /A!/^HE_P"0/_LJ/^$$_P"HE_Y _P#LJ["BC^RL)_)^+_S#^TL5_-^"
M_P CC_\ A!/^HE_Y _\ LJ/^$$_ZB7_D#_[*NPHH_LK"?R?B_P#,/[2Q7\WX
M+_(X_P#X03_J)?\ D#_[*C_A!/\ J)?^0/\ [*NPHH_LK"?R?B_\P_M+%?S?
M@O\ (X__ (03_J)?^0/_ +*C_A!/^HE_Y _^RKL**/[*PG\GXO\ S#^TL5_-
M^"_R./\ ^$$_ZB7_ ) _^RH_X03_ *B7_D#_ .RKL**/[*PG\GXO_,/[2Q7\
MWX+_ "./_P"$$_ZB7_D#_P"RH_X03_J)?^0/_LJ["BC^RL)_)^+_ ,P_M+%?
MS?@O\CC_ /A!/^HE_P"0/_LJ/^$$_P"HE_Y _P#LJ["BC^RL)_)^+_S#^TL5
M_-^"_P CC_\ A!/^HE_Y _\ LJ/^$$_ZB7_D#_[*NPHH_LK"?R?B_P#,/[2Q
M7\WX+_(X_P#X03_J)?\ D#_[*C_A!/\ J)?^0/\ [*NPHH_LK"?R?B_\P_M+
M%?S?@O\ (X__ (03_J)?^0/_ +*C_A!/^HE_Y _^RKL**/[*PG\GXO\ S#^T
ML5_-^"_R./\ ^$$_ZB7_ ) _^RH_X03_ *B7_D#_ .RKL**/[*PG\GXO_,/[
M2Q7\WX+_ "./_P"$$_ZB7_D#_P"RH_X03_J)?^0/_LJ["BC^RL)_)^+_ ,P_
MM+%?S?@O\CC_ /A!/^HE_P"0/_LJ/^$$_P"HE_Y _P#LJ["BC^RL)_)^+_S#
M^TL5_-^"_P CC_\ A!/^HE_Y _\ LJ/^$$_ZB7_D#_[*NPHH_LK"?R?B_P#,
M/[2Q7\WX+_(X_P#X03_J)?\ D#_[*C_A!/\ J)?^0/\ [*NPHH_LK"?R?B_\
MP_M+%?S?@O\ (X__ (03_J)?^0/_ +*C_A!/^HE_Y _^RKL**/[*PG\GXO\
MS#^TL5_-^"_R.._X03G_ )"/_D#_ .RI?^$$_P"HE_Y _P#LJ["BC^RL)_)^
M+_S#^TL5_-^"_P CC_\ A!/^HE_Y _\ LJEM?!$,5PCW%V9HU.3&(]N[\<FN
MKHIK+,(G=0_%_P"8GF.):MS?@O\ (155%"JH50,  8 %+117><04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HJAJ&LV&E3V<-[<>5)>2B& ;&;>Y( ' ..HZXJ_0 4444 %%%%
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M0;O5K[3A?10R6?62:1%208))0[N=N.>F*UVU73DM(KMK^U6VE(6.8S*$<GH
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M21 DO!)V'=SC'/3%:IU?3!IXU ZC:"R)P+DSKY9.<?>SCKQ0!<HHHH ****
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MHU%1V]Q!=P)/;31S0N,I)&P96'L1P:DH **** "BBB@ HHHH **** "BBB@
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MV%A#YUU+Y>Q-P7.)%)Y) Z UBP>%K[0_$FB:GHUDD<,D"VVJ6\11%' _>8R
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MN/*"G;C:H& 1D\]?ISFK?2ZO+IOB[54\0:I$VF:HZVT,<Y" >8!@]R,$ +D
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M&-9CM4;7)7!X"GC('7%5Q'>^'_A]H/B"QU349(X)HIKF![@F/RVPI0*,#;D
M8/3)YKTN/0=,BGU&9;5=^I +=[F9A* " ""<#@D<8ZUE7/A"RL_"^J:5H-G;
M0M>H05N)':/<1C)ZD8'3'<"@"CX+U&ZU_7-?UDW4SZ:9Q;646\^7A1RP4]"?
ME.>.I_#'O/[:_P"%OW_]A?8/M7]FKN^W;]FS*9QLYSG'ZUVOAG1(_#OAVSTU
M-I>),RLO\<AY8_3.<>V*K:MX)\.ZY?M>ZEI_GW+*%+^=(O Z<*P%(#!\6OJ\
MNM>$=/&IRV$]X)DNVL7(0L$3. >HR6QGD9SUKG;GQ#K.B:/XKT^+4[J<V-W#
M#!=7+[Y8TD+9.[&<_*.>V>,5Z5!X9T>V.FF*R"_V8'%I\['R]_WNIYS[YIK>
M%M%?^TM]BKC4RK789V(D*DE3@GC!/;% '$VFFOI7Q0T&V?6KC5#]CE??<N'=
M25;//7:>H!SCU-8GVO4W\(:MKO\ PE.I)=V%\T<5N+C*8+@ ,IY.<G&>!CI7
MI6E^"O#VC7<-WI^FK!<0[MD@D<GYA@YR3GCUZ=JQ-$^&NEPPR2:Y9VUW>&YD
ME1T=]H0D$ C@-^(/6F!G)<:EXM\67-C<:S>:3;6MA#/Y=E+Y99W16+;O[H+8
M_ 50/B+5[GX=V$\FH2_:8M72U-S"Y4S1C/4CJ#T]\<Y-=_K/A#0?$%PL^IZ<
MD\RC:) [(V/0E2,_C4]QX<TBYTRVTV2R3[';.LD,2,4"LN<'Y2/4_7- '#ZC
M%J6J^,O%=LFO:E9VUC;Q31Q6TQ4;O)!&/09R2!C.:P+PW'B&U\"7][J5ZD]W
M,UL[QR[=I67:)%XX<Y&3WP*];71-.6\O[L6P^T:@BI<ON;+JJ[0.O''IBJ4O
M@WP_/HD&CRZ<CV-NQ:*,R/E"22<-G=R2>] &S;P_9[:*#S))?+0)YDK;F; Q
MECW)[U)4=O;Q6EM%;0+MBB01HN2<*!@#)]JDI %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%075Y:V,:R7=S#;HS!%:60("QZ $]_:IZ
M "N,^*%C=ZAX.:"RM9[F;[1&?+AC+MCGG KK)[RUM9(8[BYAA>9MD2R2!3(W
MHH/4^PJ>@#SG6)=4\>7FFZ?!H>H:=86UTMU/<ZA%Y1^4$85>Y^8_ITYJG)%?
M:)?>*[6X\.7^HOJ\KM;3V\.]"C9PKO\ P@9%>I44 >4:CH6I:/H.@HMEJIU:
MSMG$5WI@$NQV)/ER+_=Y'S=.HYJ'5-&ULW7A_5;^SU:-([ PS)H@59H7W,1A
M1P 0RYQZ&O5_M=M]L^Q_:(OM7E^;Y.\;]F<;MO7&>,U-3 Y;P#I:Z7X>=$M+
M^U2:X:98[^16EP0HR0%&W..AY[]ZY#Q5X&UVST#5)+75IM12ZN1<2V<=B#)(
MQ8 '?DL=O' XZ\#FO6**0%;3X;FWL(8;R[^UW*KB2?RQ'O/KM' JS110 44U
MW6-&=V"HH)9F. !ZFF6US;WENEQ:SQ3PORLD3AE;MP1P: ):R/%7_(GZW_UX
M3_\ HMJUZ* /(;:RAU"'X;VUQ L\+K<EXW7<& "GD=QQ55=#TSR/B#(UA!OM
M'86V4_U(RQ^0?P]!T[>U>T44P/*9;5=3;X:P7T N$>"0O'(N0RB.,C([C !]
MZS5T/3/(^(,C6$&^T=A;93_4C+'Y!_#T'3M[5[110!Y']L_LB^\!Z[JAD2QC
MT]HI)MA;:3&0N0!GG<OUYJC<W2WO@WQY=(DB)-?PR*LB[6P95(R.W%>U44 >
M77&EQ:-X_P##D&D6L=G-+ITX(1 NY_+<@MGJ<XZ^E<PL6COX*CT6'3YO^$Q^
MU<J(&$ROYG4N1PNSMG@X/J:]XHHN!XCXN>$^,];M;Z[TR-YH;:(RWT,DC)^[
M&6A**=ASSSC.:G\36EG%?>&Y8]1AAT"/3O+BOCIZW,7F9;<6CQC<W'4<'/H:
M[R_\ :;?:C>7BWVJ6GVT_P"E0VMSLCGXQAA@Y')XSW-=#IVGVVDZ=!86<?EV
M\"[47.>/\: /(9-+MT\!:/:PS3WMI<^(8_+:6V\G>K(00J[B=I.>>._%;]E9
MVVF?$[6[.Q@CMK;^QMWE1*%7(*#.!WY/YUZ311<#Q.&./_A"?!%SJ$+R:+!=
M7#7N%+*O[T[2P )Q][^5;>K2Z-.GAB70K7R+)_$$3#$1C5R=N653T'3L.G2O
M4:*0'EVDVVD6'Q4UJQU"QAC:[V_80;?(.5RVP@?+D$Y/'?O6/H=E>W'BC3_!
M=U&YM-&OIKMRW(>,8:/(Z8))Y]).GK[365IWA^UT[6-1U1)9YKJ_*F1IF#;
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M;%<17-G,8I,D?,<\_>ZD5HZ%H5EX=TT6%@'\K>79I&W,S'J2?R_*D!I4444
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M7=C-69X(;F!X+B))87&UXY%#*P]"#UJ2B@"K9:;8Z:C)8V5M:HW++!$J _7
MJU110 4444 %%%% !1110 4444 4M8U!=)T:]U!QD6T+28QU(&0*X9_%/B*Q
M\,^&I%>VN=2UF<(7NXMJ('/R8"8XP5YY-=1XUMFNO!6L1(?F^RN_UVC=C]*X
M/7+<ZOX+\$R1:=>:A:0^4+J*UB9V**JJX^7IG:P'(H Z72?%.KW%QX@TO5(;
M2/4-,@\Q9K+)B.5)'WLG(X_7TJ70O&%K;>"-,U7Q%J4:37(?+LG+D,1PJCL
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MP;8Q'(R.N#QFI*CM_/\ LT7VGR_M&P>;Y6=N['.W/.,],U)2 **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (X
M95GB6100#ZU)5;3_ /CQC_'^9JS0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %1^:OG^3@[MN[/;&<5)5;_ )BG_;'_ -FH LT444 %%%% !1110 44
M44 %%%% !1110 5'YJ^?Y.#NV[L]L9Q4E5O^8I_VQ_\ 9J +-%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 UW$<;.<X4$G%".)(U<9PP!&:9<_\
M'K-_N'^5%M_QZP_[@_E0!+1110 4444 %%%% !1110 4444 %%%% !4<,JSQ
M+(H(!]:DJMI__'C'^/\ ,T 6:*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J.&59XED4$ ^M256T_P#X\8_Q_F: +-%%% !1
M110 4444 %%%% !1110 4444 %%%% !37<1QLYSA02<4ZHKG_CUF_P!P_P J
M 'HXDC5QG# $9IU16W_'K#_N#^52T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !37<1
MQLYSA02<4ZHKG_CUF_W#_*@!Z.)(U<9PP!&:=45M_P >L/\ N#^52T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5R/CS_ )EG_L/VO_LU==7(
M^//^99_[#]K_ .S4 ==1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !4?FKY_DX.[;NSVQG%256_YBG_ &Q_]FH LT444 %%%% !1110 444
M4 %%%% !1110 C*&4JP!4C!!'!%5-+TJRT6Q6RT^$PVRDLL>]F"Y.3C<3@9S
MQ5RB@ HHHH **** "HTE5Y9(P#E,9_&I*K0?\?UU_P  _E0!9HHHH **** "
MJ*Z/8)K#ZN+<?;WC$1F+$G8.P!.!^%7J* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M.:58(FD8$@>E256U#_CQD_#^8JS0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!&\JI+'&0<OG'X5)5:?_ (_K7_@?\JLT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!&DJO+)& <IC/XU)5:#_C^NO^
M ?RJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<%=V#CZ&J-G<^7:HGD3-C/*KD'FM"JVG_P#'C'^/\S0 ?;/^G:X_[]T?;/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:X_[]U9HH K?;/\ IVN/^_='VS_IVN/^_=6:* *WVS_IVN/^_='VS_IVN/\
MOW5FB@"M]L_Z=KC_ +]T?;/^G:X_[]U9HH K?;/^G:X_[]T?;/\ IVN/^_=6
M:* *WVS_ *=KC_OW1]L_Z=KC_OW5FB@"M]L_Z=KC_OW1]L_Z=KC_ +]U9HH
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M:X_[]T?;/^G:X_[]U9HH K?;/^G:X_[]T?;/^G:X_P"_=6:* *WVS_IVN/\
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MS10!6^V?].UQ_P!^Z/MG_3M<?]^ZLT4 5OMG_3M<?]^Z/MG_ $[7'_?NK-%
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M*** "BBB@ HHHH BN?\ CUE_W#_*BV_X]8O]P?RJ6B@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHHH **** "BBB@ HHKD?'?BB7P[;6,-O/#;37LI7[3,A<0HH!9MH^\>1@>]
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M?*GS ;=@P23GU &* .GHK#EU#6+CPQ9WFEVEO/J%S%&^V5]L4>Y<ECSD@=,
MYYK+\)>*=3U;6]5T;5K:T6YL" TMF6,;<XQR2?\ )X% '845G:W=ZA9::\NF
MV<=U<9QB278B#!^=NY ]!R:QO#/BR34? [^(=42*/RA*\BP*0-J9Z!B>>/7K
M0!U5%<5X:\4ZMKFHVK2RZ EI<(TGV2&[+W<2X)7<.A_ASP.O;I71ZMK^EZ$L
M+:G=K;+.Q6-F4D$@9/(''XT :5%<M_PL;PE]F^T?VS'LW;<>5)NS_N[=V/?&
M*U;WQ'H^G:9%J5UJ$,=G*,QRYW!^,_*!R>/2@#4HK#M?&.@7NE76IVVHI):6
MF//8(VZ//0E<;L'MQS@^E)IWC/P]J^I#3[#4XYKH@E4"L-V!DX)&#QZ&@#=H
MKAM.^)&G:W+JEG:DPW$*2-9OAF\]55COP5 7IG!IWA'Q[IM]I>F6FIZM&^LW
M PR[,98N0HRHV@XQQUZ>M ';T5B77B_0+/6$TFXU.)+YV""+#'#'H"0, _4U
MMT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%4]3GO;>R9]/LUN[DD*L;2B,#/\1)[#KZ^E %RBN/\ #/BV]U/P
M;J.M7]M 9K-IOW5L"H<(@;'))R>:R-(\>:U<ZCHGVR#2GL]6=ECBM'9IXL<9
M?)QC/7\>F* /1Z*@O9+B*QGDM(!/<*A,418*';' )/09[UQVG^*?$%MXUM/#
MVO6FG WD)EB>R9OD #'YMQY^X1V_&@#N**XV/Q1K0\>VFAW>GVMK:7,4DB_.
M9)2%W8;(.T9VYQ@\?IU.H7]MI=A->WDOE6T*[I'VEL#Z $T 6:*YE?B%X3:2
M1!K4&8UW'*L 1[$C!/L,FK]GXHT2_P!(FU6WU&%K*'(EE;*[#Z$$ CVXYSQ0
M!KT5AZ1XPT#7KM[73=2CFG49,91D)'MN S^&:JM\0O"B3+$VL1JY<I@QN,$'
M!S\O'XT =-17'S?$32K;Q@^@S@HJ@)]I&X_OB0/+V[??[V<50TCQ_9VFHZU;
M>(-62,Q:G+!:H8N5C4X&=B]/=OSH [^BL;5O%>A:'Y']HZE%"9QNB !<LO\
M>PH/'OTK6AFCN((YHG#Q2*'1AT((R#0 ^BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N#N?"6HZ]XXU'4[ZYO],M8HD@LI;*Y5'D7DMDC)
M SDX..HKO** /%]?T>\\*>&=5TJY1Y--FU*&2PG>5,N2"6!/!4X4<D8X/KSH
M>$9K75+G7-$-O='4;^Q99+^;44OODV[0#(@ 'WNG/09Z"O4[FUM[R!H;J"*>
M)NJ2H&4_@:BLM-L=-1DL;*VM4;EE@B5 ?K@4P/,O#G@>\LM1TU+KPI:QRVLP
MDEU-M19P^UL@K&K#!X[C'J.U=AXYC\07&ABU\/0&2:=]LSI,L;)'CG!;')Z9
MZBNGHI <MX+@OM/L_P"S9?#(TBUA3*2?;4G:5^Y;:!S[_A3I='OG^)D&L"(?
M88]+,!E+C_6>83MQG/0YSC'O73T4 >6?\(=KH^&>H:/]B!OI=0,R1B9/F3*\
MYSCL>IS6S>:1KNB^+$UW2M.BU19;%;2:#[0L+(5Q\P9AT^45W5% 'F)\%:T=
M'MF>"'[=<Z^FHW,,3@);QX;."3SC/;/7C.*WDT&_;XD:EJ;P[+"XTS[,D^Y3
M\^4XVYSV/;M7844 >5V_AKQ,GPWU/PQ+I*>:KHUO,ETA$_[U688)&W !.3C-
M='>:%J+^/?#FHI 'L[*UDBGE#J K%& X)R>2.@KL:* /-_#GAWQ!8>+HKM=.
M32;#YC>1Q7OF0W#%2 R1]5YQUZ9_"O2*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH QO$'B>Q\."V6Z2YFGNG*06]M%ODD(Q
MG _$=^]0Q>,=).DC4;IKBRB^T?962Y@9727&=K*,X^O2LKQO:Z->WEBMSKBZ
M/J]NK2VEPS[!@\$$G QD#C.>OK7">(=0G\1^!DO]6$5S-IVIFTCOH<JLT9&6
M;:,=<+S@=L8.:8'M]%>0^+8=#-[I&CZ:NE_88[1IXIKZ]E^S%=[?*K(V2V=W
M<^E4Q?W4_P )=.CDN"\;:L+=U:4HLD7S'8SG[JY[GH!18#VJBO%['3CI?A+Q
M5K6F);6\\J)'#!:WPN6MXBXWY=&QR,D'J-IJQX%LI+7Q9IMQ#JVCE9[=C/;6
M5S-+)+E"=T@;(#9QG) XX&:0'I>MZ_;Z''#YEK>7<TY(BM[.$R2-CDG'H./S
MJ/PYXGT_Q19R7-AYJ^4^R2.9-KH??DC\C5;QAXKA\+:8DFU);RX;R[:)W"J6
M[LQ)&%&1D^XZ9S6+X/.C>%O#5]?76N6EW,T@GU">WE$HC9SA1A,]\]N3G\ #
MN+B=+:VEGDSLB0NV.N ,FN.@^)VDRV\5W+INL6UC*VT7LUJ/)SG'W@Q[@]/0
MUTNI3)<>';N:)MT<EH[J<8R"A(KS32O$.C6GP9_LZXO('O9;>XB2U5@\F]G?
M;E>HY(.3]: /68Y$FB26)U>-P&5U.0P/0@]Q3J\>>T4W_A71?%4[VVF)I>]X
MYIS$C2 G".<C& $XZC@571//\,:QIUIK"0Z-'JJI8-=2LL,Z[7+0[^RG /4#
M/.><T >TT5XM<ZJ3\,)4TB*2QC755M[@"Y:2-%V@G8XYV%MO&3U/7(K=^'=B
MVG^);Z.'4](EM7MLFTTRXEF1&#+ALOD=V_BSST] #K]?\56F@2+%)9W]Y+Y9
MF=+.#S#'&/XVY  X/Y5<T/6[+Q#I<>H6#LT+DC#KAE(Z@BN?\=^*ETBWCT>U
MDA74M00HCS2B..!#P9&)Z=\>X/I@W_!.GZ;I7AJ&RTW4(+](V/FSPR!U:0\G
MH2!U''IB@#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N2\<Z+J/B)-*TRVB;["UV)+V=)%5HT7IC)Y)R>@/(%=;10!P \&ZAHG
MC+2=7TV[U#4XVW0WS7MRKND9& 03@D#).!D\>]>>:?JUC;S?;;JVN+RQ&H-.
MMO'J<:(S;LJWV4@L3[YP>E?054%T/24O/M::79+<YSYPMT#Y]=V,T ><ZSX)
MNY/$FHZC_P (W'K4%_MEAWWIMFMFQR& (W<G].HKT+1[)]*\.VMJEM$DL, _
M<1NVP-C.T,Q)QGC)K3HH \RT*S\5V>O3ZOJGA4WVHSOM%R^HPJ+>+^ZB<XXS
MWY_$YZ7Q[H]]K?AY+33X1+-]IC<J7"X4'DY)%=110!R1T34!\41K/D@V!T_R
M?-#CA\],9S^F*YJW\$ZV? GV(P1QZA!JOV^*%Y%(D & "02!G)KU*B@#@/['
M\0:_K[ZSJ6EQ:9]FL9;>"W%PLSRLZL.6' 'S54N_"FM/\//#NE)9AKVTODFG
MC$J?(H,A)SG!^\.A->E44 <6VE:SI_Q+FUFVL$N]/OH$@D<3JA@QMRQ!Y;[O
M0>O6LG_A%-:'PTUO2?L8-]=7QFBB\U/F7S$.<YP.%)ZUZ510!YGXD\-:[=R6
M3Z?I*B]AM8HXM1@O1"\)4#<LB_Q\YQCUKT:S2:*RMX[EQ).L:K(XZ,P')_.I
MJ* "BBB@ HHHH **** "L3Q'X8M?$J6BW-U>6S6LOG1/:R!&#=CD@\CMBMNB
M@#A?"G@^^T7Q=K%[<7FH26S>6+>26Y#_ &D%3N,@ZDJ< 9 ZG&:TM0T>^N/B
M'H^JQP@V5M;2I+)O PS @#&<GKZ5U%% 'F:>$M:C\)>+-/\ L8-Q?7IEME$J
M8D3>#G.>.!WP:M)HGB#P_KEGK.G:9%J1?2XK*XMOM"Q-&RA>0S<$?*.G^%>A
M44 >8S^"]:?PA=Q&"$ZE?ZH+V6WB=0D*D] 2><?YS6]J.@W]W\2+;4TAQ8#3
M&MGGW+\KDOQMSD_>':NPHH \KM_#7B9/AOJ?AB724\U71K>9+I")_P!ZK,,$
MC;@ G)QFNCO-"U%_'OAS44@#V=E:R13RAU 5BC <$Y/)'05V-% 'F_ASP[X@
ML/%T5VNG)I-A\QO(XKWS(;ABI 9(^J\XZ],_A7I%%% !1110 4444 %%%% !
M1110 5R'CC0M1U*;1]3TN"*ZN=-N"_V:5@HE5L9&2<#[HZ^OMSU]% '(^$M&
MU.'6M9U[5;2&QGU%D"6D4@?RU4$98C@D\'CW/? A/A_4F\1>,;OR (=1LXX;
M5BZ_O&$6T\9XP>.<5VE% 'F;^$M:D\)>$]/^Q@7%C>B6Y4RIB--Y.<YYX/;)
MJ_)IOB/P_P"(]<N]*TB#5;?5MKAGN%B\E@",,#]X98\#MW%=[10!YSIG@K4M
M+F\'1@)*NGO<RWDH<!8RX!  /)Z8X'OQ4\7A;5)9_'*R0K$FJA19NSJ0Y ?K
M@Y')'7UKOZ* /-3H/B*]\):#I=QI*V\VFZE 6;[2C!H5#9DX/'4<<FM6?0M4
M;Q[K&J)9Q26EQI#6T)E<;))?EPK '< <')Q7:T4 <!X(T'7-)URYEFLFTS2'
MB(6Q:\%POFE@=R8^Z,9Z\_7K7?T44 %%%% !1110 4444 %%%% !7'6FB:EJ
M'Q%NM<U2W\JRLXA!IR,R-NSU?@G'\77!PP]*[&B@#G?'>EWFL^#+^PL(?.NI
M?+V)N"YQ(I/)('0&J,^@ZC_PL#0]36$-9VMBT$TH<?*V& X)R>HZ"NPHH \O
M7P+K%UX6\064D<<%S<:F;JV5W5A(HZ9QD#.3U[CFM>#3O$'B#Q9I.JZQI,.E
M0:8KD*MPLSS.PQU7HHP#S[^O'<T4 >62^#M=/PF@T5;('41=&5H!*G"[C_%G
M;TP>O>MW5-)UJU^(UMK^GV"7UK);"VF7SUC:+YN6YZX&#QUY%=M10!Y[_P (
MQJ__  COC*V^RCS]2OY9;5/,7+H6!!SG S[D'BJFN>&-;N-*T.*UT97O;33X
M85O(KT0RVLJC#9YPRCCISG/->FT4 4])BNX-'LHK^02WB0(L[C^)P!D^_/>K
ME%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!YAJFK7;?$>QUE/#>OO:V4$EN^VQ)+GYQE><%>1SD4OBV[O
MM5\4BQU'1-<F\/V;!O+LK,O]JD]6;(&WGL?R/3TZB@#FKC1E\2VEG>)?:]HJ
M"+:MK;S?9BHS_$F#@_TKF_B#/=W%YI5C::-K%U_9]U'/)<1VI=)% _A8=6_+
MFO2:* .*UW4K.[BM;B_\$7^HQ7%N=C?8UDFA;)!1EZIQ@Y![\=*E^&NCWVB^
M%3!J$+0227+RI"W6-2  /T)_&NPHH \U?1;V2+X@-_9TQ>Z/^C$Q',H 8_)Q
M\W..G>H1HM\EM\/_ "M-G1[:7=<[82#%G9DOQ\N<=_2O4** /)A;:EI6D^)-
M N/#>H7][J5Q(\5Y#%NBD#8VL\F>"IRV#W],DUK6GA^]M/%?A&.YMGGCL--:
M.:8(6CC<*<#=TR#C%>AT4 >0W?A[5KCP_P"-+:#3K@-)JOG6\9C*^:@D/* C
MD8P>/2MO58[GQ G@^8:-?1I#>C[1#<VY!C5< EAV7C@GK7H=% 'F.IZ//+XI
M\8M-H]]=6%S;V^U8%*><1Y>2C$8+*<G'L16M\/1K(.H#48+P6BB-+2:_@$5P
MZC=D/CD@=LD]>.O'<44 %%%% !1110 4444 %<;\1[JX?PW<:3:Z5J5Y->(-
MKVMN9$3#*?F(Y'3CBNRHH X=;TWGP_@@N_#&JW$$7E6MW:/&8IBJJI,B*#EA
MNP.H[^E9'@_P_>MJFLI:V^K:)X?NHL0QROY<ZR97YESDC ##G/!'6O3Z* .7
MGMCX3T"Y"R:]K;3MM 8_:94)4CCIA>/UKE?"]CJ%]\.;_P ,2:5J%I>>5(RR
M74!BB<EL@!CW_"O4J* /(="T:ZN]3\,0V_ABXTJXTMB]_>RP^4LN,#ANK[L?
MAN..,FNN\9Z?<7^L^%S%:27$4.H!YBL9947CENP''>NPHH \WCT6Z'B7QS-)
MILI6XM"+:0PDB0M&<A#CDG/(%4!H^J6_AKP9>3:5=72:9+(UU9",F7#-E3L.
M,D <#W%>KT4 >47NF:EK \5ZY#HUY9PWEFL$-M+$1/,X*Y;8.1T_7ZUI7ND7
M<6I?#\V^GS*MJA6Y,4)Q%\L>=Y XYW=?>O1:* /.-,@U#3/$7BZSGTJ^9=3,
MDUO<QQ;HB-KG!;L3D #DY]*S;G0K^/X:^&((M+N!>Q:BDLT:0'S$&9,LP R/
MX>3[5ZS10!Y;K=GJT'B^>31=*U-)KFYC-PCQ++97"#I(6/"MT.,<=<UZE110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 52U;4O[*L&N_L5Y>;2!Y-G%YDAR>RY%7:* /+/!TVMV7A'6-+MM&U.V
MU,^=<V\MQ;&.,YV@ ,V/GZD#&.*SO#^CWMIKF@RZ5H6L65]$^W5KB[CVPRH2
M-^TG@_Q8QCMU/->R44 <Q%HTOA>SOM1@U'7=8F6!@EK<W'G;FZC:N!SQ^6:Y
MGP;<3?VZVHZUH>O2:W>ML:ZEL2EO;)V523P,=\>WKGTVB@#S#5-6NV^(]CK*
M>&]?>ULH)+=]MB27/SC*\X*\CG(KL/&]O/=^"]4@MH9)IGAPD<:EF8Y'0#DU
MOT4 >;W6A7)U[P*W]F.UO;VVRXQ#E8F"#A^..?7OFLR^\-ZS>V/C2&VLYU\[
M44GBC=2@N%#,6V]-W8^^!WKUNB@#SRW2Z\1^--"U"UT"^TFUTN)Q+)=P^26!
M7"QHO<#G\&/''.1_8-\/A;X@@_LJX^W3ZAOCC^SGS742)@@8R1C=^&:]:HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img70551829_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_19.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S,P  DI(
M @    ,S,P  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C R,SHP,3HR,R Q,CHP-SHR-0 R,#(S.C Q.C(S
M(#$R.C W.C(U    00!N &< 90!L &$ ( !( &$ ;@!S    _^$+'FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2?ON[\G
M(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S
M9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q
M.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(^/'AM<#I#<F5A=&5$871E/C(P,C,M,#$M,C-4,3(Z,#<Z,C4N,S(V/"]X
M;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD
M,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\
M<F1F.FQI/D%N9V5L82!(86YS/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D
M8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP
M;65T83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG
M=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>
M)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<
M&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*O_  !$(!$,)1@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M\+_]"WI'_@#%_P#$T ;5%8O_  AGA?\ Z%O2/_ &+_XFC_A#/"__ $+>D?\
M@#%_\30!M45B_P#"&>%_^A;TC_P!B_\ B:/^$,\+_P#0MZ1_X Q?_$T ;5%8
MO_"&>%_^A;TC_P  8O\ XFC_ (0SPO\ ]"WI'_@#%_\ $T ;5%8O_"&>%_\
MH6](_P# &+_XFC_A#/"__0MZ1_X Q?\ Q- &U16+_P (9X7_ .A;TC_P!B_^
M)H_X0SPO_P!"WI'_ ( Q?_$T ;5%8O\ PAGA?_H6](_\ 8O_ (FC_A#/"_\
MT+>D?^ ,7_Q- &U16+_PAGA?_H6](_\  &+_ .)H_P"$,\+_ /0MZ1_X Q?_
M !- &U16+_PAGA?_ *%O2/\ P!B_^)H_X0SPO_T+>D?^ ,7_ ,30!M45B_\
M"&>%_P#H6](_\ 8O_B:/^$,\+_\ 0MZ1_P" ,7_Q- &U16+_ ,(9X7_Z%O2/
M_ &+_P")H_X0SPO_ -"WI'_@#%_\30!M45B_\(9X7_Z%O2/_  !B_P#B:/\
MA#/"_P#T+>D?^ ,7_P 30!M45B_\(9X7_P"A;TC_ , 8O_B:/^$,\+_]"WI'
M_@#%_P#$T ;5%8O_  AGA?\ Z%O2/_ &+_XFC_A#/"__ $+>D?\ @#%_\30!
MM45B_P#"&>%_^A;TC_P!B_\ B:/^$,\+_P#0MZ1_X Q?_$T ;5%8O_"&>%_^
MA;TC_P  8O\ XFC_ (0SPO\ ]"WI'_@#%_\ $T ;5%8O_"&>%_\ H6](_P#
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M&>%_^A;TC_P!B_\ B:/^$,\+_P#0MZ1_X Q?_$T ;5%8O_"&>%_^A;TC_P
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M^ADTC_P.B_\ BJ/^$S\+_P#0R:1_X'1?_%5M44 8O_"9^%_^ADTC_P #HO\
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M1?\ Q5;5% &+_P )GX7_ .ADTC_P.B_^*H_X3/PO_P!#)I'_ ('1?_%5M44
M8O\ PF?A?_H9-(_\#HO_ (JC_A,_"_\ T,FD?^!T7_Q5;5% &+_PF?A?_H9-
M(_\  Z+_ .*H_P"$S\+_ /0R:1_X'1?_ !5;5% &+_PF?A?_ *&32/\ P.B_
M^*H_X3/PO_T,FD?^!T7_ ,56U10!B_\ "9^%_P#H9-(_\#HO_BJ/^$S\+_\
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MCC4*B(,*H'   Z"@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_">^&O^@E_Y D_^)IV8'145SO\ PGOAK_H)?^0)/_B:TX=;T^?5I=,CN/\
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M%(ZMIVI_(2"1 N./^!5&GQ(TR1=T=AJ;KZK"I'_H5%F*Z.OHKGW\96$+:?\
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M+9O/H.3S6_2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTJS/JNF7^N2^';RW:27R]^)4!C?@' YSG!].QK/O_AYHUT"UFLEC-@;7B8D
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M3?)A/GY@9MXV@],G'0FA; ='XS_Y$[4?^N8_]"%1>#[6WD\(Z>\D$3L8^69
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MYI'Z@4 ;WVSPK_S\:/\ ]]Q4_5/L9\'ZF^G>08'M)F#08VL=A&>.#T_2F?\
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MG\!D_A54 ZAX;\3:ZX)^VEHX"RX/E)P,'W[^Z]Z2ZLI;WX0VP@4NT*B4J.I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4C$A25&3C@9ZTM% '+GQ+K@U0:?\ \(VGVEH3.%_M
M!<; =N<[?4UTT;,T2F1-CD LN<[3Z9K!?_DH\7_8*;_T:M=!0!C>*O\ D!-_
MUVC_ /0Q6R.@K&\5?\@)O^NT?_H8K9'04 %%%% !1110 5SES!%_PG]BOE)M
M-C*<;1C[RUT=<_=?\E!L?^O"7_T-: .@    & .@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&D:I;6_BBQMX;>Y.U;BV)(4Y[Y)X_P#U^U4O#WC*UTOPW:6\^G:D_DQX:2.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%<?/_PDD7B2WTL:_'B>!YO,^P)\NT@8QGGKUS76PJZ0(LTGF2*H#/MV[CCD
MX[4 4+OQ!I=C=/;W5VL<J8W*5)QD9]/0U:LKZVU"W\^SE$L>2NX CG\:SO$W
M_'E:?]?L/_H5;- !1110 4444 %%%<O<>)=:M]5AL#X=0S3AVB_T]?F5>I^[
MQ0!U%%1V[RR6T3W$7DRL@+QAMVQL<C/?'K4E !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% '/O_P E'B_[!3?^C5KH*Y]_^2CQ?]@I
MO_1JUT% &-XJ_P"0$W_7:/\ ]#%;(Z"L;Q5_R F_Z[1_^ABMD=!0 4444 %%
M%% !7/W7_)0;'_KPE_\ 0UJ#Q+XQ.@:E#90:<UY+)%YS?OA&%7.!V.3D']/P
MYB7QK=R>(8-4_L7'DP-#Y7VL<[B#G.WV]*QG7I0=IR2?J2Y16[/3JS+_ %R+
M3IBD]K=L-P42)%E6)Z '-<W8_$22XU.UM;O1FMTN)EA$BW(<JS<#C:._O_A6
M]XF_X\;7_K\B_P#0JTA.,U>+NAII[&E:7/VN'S/(FAYQMF3:WY5/115#"BBB
M@ HHHH YJ;Q5?0ZA'9MX>NO.E#-&OG1_.%ZGK[UT-O(\UM%)+$T+N@9HV()0
MD=#CTK#U'_D>M'_Z]Y__ &6N@H SKS7],L+@P7=VL4J@$J5)Z_058L=0M=2@
M,UE,)8PVTL 1S^/UK/\ %/\ R!U_Z[Q?^A"MD=!0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &-J/B>TTS7K329H+F2>Z"
M%&C0%5#-M!)SD<CTK9K@O$G_ "5#2/\ KC%_Z.-=[6<9MSE'M82>M@HHHK08
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E^(S
MJ:Z%.^B.5O$ 9 $#%@#R #GG&:R=(\>:3<:?&-2NOLMVBA9DD0C+#J1@8Y/:
MNJJI<:3IUY(9+NPM9W/5I858G\2*>@CC);JU\2_$'3IM#3>EG\]S=*A4,!T!
MSUZ8''?TIM]?VVF_%AKF^F6&%;< NW;*5WD%O!:Q"*UACAC'1(U"@?@*KW&D
M:;>3&:[T^UGE(P7E@5F/XD4[A8S_ /A,_#W_ $%(OR;_  JKXCU*SU7P+J4^
MGSK/$%V%E!QG*\<_6M7_ (1[1?\ H$6'_@,G^%6$TVQCLWM8[*W2W<Y:%8E"
M,?=<8/04M U,SP9_R)VG?]<S_P"A&N=U%7\#^*X]1MPXTB_;;/$@PJ-[ >G4
M>V17=PP16T*PV\211(,*D:A5'T IMS:V]Y"8KN".>,G)25 RG\#1?4#G?&6D
MS:OI-M?:2QDNK-Q/!Y;9W@X/'J> 1BI-.\<:/=6R_;+@65RHQ+#.I4JW?'M^
MM=!##';PK%!&D4:#"HB@!1[ 57N-)TZ\D,EW86L[GJTL*L3^)%%P..UF^/C;
M4K;2='2273H9@]U=!2$^G;MGZGZ9KNU4*H50 H&  .E,@MX;:/R[:*.%/[L:
MA1^0J2AL9P_AC_DHVO\ X_\ H0KN*@BLK2"YDN(;:&.:7_62I& S_4]34]#U
M XCXF?\ 'AIO_7S_ $KMZ@NK*UO55;RVAN ARHEC#[3ZC-3T= .'_P":Q?\
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MQ1MV0@ 'UYQW]JW8M%TN"830:;9QRJ<AT@4,#ZY J[1?0 KC/A?_ ,BQ<?\
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M&LD3*Z, 593D$>HIU4=#_P"1?T__ *]H_P#T$5>KF.(**** /-?'O_(Z0?\
M8/'_ *,:L*MWQ[_R.D'_ &#Q_P"C&K"KY+-?]Y?HCAK_ !CK;_D-Z1_V$(?_
M $*O3/$W_'C:_P#7Y%_Z%7F=M_R&](_["$/_ *%7IGB;_CQM?^OR+_T*O9RG
M_=EZLWH? ;-%%%>H;A1110 4444 <_J/_(]:/_U[S_\ LM=!7/ZC_P CUH__
M %[S_P#LM=!0!C>*?^0.O_7>+_T(5LCH*QO%/_('7_KO%_Z$*V1T% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <%XD_Y*
MAI'_ %QB_P#1QKO:X+Q)_P E0TC_ *XQ?^CC7>UST_XL_D2OB84445T%!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXH_Y!L'_ %]Q?^A5LUC>*/\ D&P?]?<7_H5;- !1110 4444 %%%% !1110
M4444 %%%% !7,>)?&)T#4H;&#3FO)7A\YOWPC"KG [')R#Z=NO;IZ\U\>?\
M(ZP_]@]?_1C5SXFHZ5&4X[HF;<8MHBF\9W<OB*WU7^Q<>1 \/E?:Q\VX@YSM
M]O2MBP^(DESJEI:W>C-;I<S+")%N0Y5FX'&T<9]_\*X^G6O_ "'='_["$/\
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M/_0Q715SMQ_R4>S_ .P=)_Z&*F\7:^_AKP_)J$<2RLK8PW8!2QXXSPN.HZT
M/\2_\>]A_P!?\/\ .MFO#;[XU)?I"LUDRB&99EV1=2O3/[SI5ZV^.4EU=16\
M=BH>5PBEH> 2<?\ /2M/9R[&GLI]CV2B@45F9A1110 4456.HV0.#>6X/_75
M?\: +-%(K!U#(0RD9!!R"*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \U\>_\CI!_V#Q_Z,:L*MWQ[_R.D'_8/'_HQJPJ^2S7_>7Z(X:_QCK;_D.:
M1_V$(?\ T*O3O$G_ !X6_P#U]P_^A5YC;?\ (<TC_L(0_P#H5>G>)/\ CPM_
M^ON'_P!"KV<I_P!V7JS>A\!KT445ZAN%%%% !7FOCW_D=(/^P>/_ $8U>E5Y
MKX]_Y'2#_L'C_P!&-7'CO]VGZ&=3X&859'B'_CR?_KWG_P#0#6O61XA_X\G_
M .O>?_T U\WE?^^0^?Y,Y:'\5'EU7-(_Y#=C_P!?$?\ Z$*IU<TC_D-V/_7Q
M'_Z$*_0'L?32V9]:Z'_R+^G_ /7M'_Z"*O51T/\ Y%_3_P#KVC_]!%7J\\\<
M**** /-?'O\ R.D'_8/'_HQJPJW?'O\ R.D'_8/'_HQJPJ^2S7_>7Z(X:_QF
M1XG_ .0%/_NM_P"@FO+J]1\3_P#("G_W6_\ 037EU?19'_NOS/5R_P#ALN:1
M_P ANQ_Z^(__ $(5]A#[H^E?'ND?\ANQ_P"OB/\ ]"%?80^Z/I7IU]T:8K="
MT445SG(%</\ $/\ X^M+_P!R?^<==Q7#_$/_ (^M+_W)_P"<=<>._P!VGZ&=
M3X&<A65XD=H]%E>-BK*"593@@[3S6K61XG_Y 4W^ZW_H)KY? ?[U#U..C_$1
MYW_;&I_]!&[_ ._[?XU:TO5=0DU>S22_NF5IT#*TS$$;AQUK(JYI/_(:L?\
MKXC_ /0A7Z&TK'TTHJST/K;1G>70[%Y&9W:W0LS'))VCDFKM4=#_ .1?T_\
MZ]H__015ZN \D**** "BBB@ HHHH *Q_$VFV5[HEY-=VL4TD%M*T3.H)0[2<
MCTZ"MBJ&N_\ (NZC_P!>LO\ Z : */A+3;*T\/6%Q;6L44T]I$99$4 N=H/)
M[UNUF>&O^15TK_KSB_\ 0!6G0 4444 %%%% '.^-?^0+!_U^P_\ H==$.@KG
M?&O_ "!8/^OV'_T.NB'04 %%%% !1110!P7B3_DJ&D?]<8O_ $<:[VN"\2?\
ME0TC_KC%_P"CC7>UST_XL_D2OB84445T%!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M '6_]!:OE\!_O4/4Y*/\2)Y=5S1_^0Y8_P#7S'_Z$*IU<T?_ )#EC_U\Q_\
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M ,E TG_KUF_I0!T58WBC_D&0_P#7U%_Z%6S6-XH_Y!D/_7U%_P"A4 ;-%%%
M!1110 4'.#C@^M%% ''O_P )(OB6/2?^$@C^>U-QYOV!.,-MVXS^N:ZZ,,L2
MB1M[@ ,V,;CZXKGY?^2E6_\ V"W_ /1@KHJ "BBB@ HHHH **** /-?'O_(Z
M0?\ 8/'_ *,:L*MWQ[_R.D'_ &#Q_P"C&K"KY+-?]Y?HCAK_ !BPNL>L:4\C
M!$6_A+,QP -W4FO1/$&JZ?-90+#?6TA%U$Q"3*< -R>M>1^)_P#D!3_[K?\
MH)KRZO>R:GS8:_FSOP='VE.]S["_MK2O^@G9_P#@0O\ C5VOCS2/^0W8_P#7
MQ'_Z$*^M=$_Y%_3_ /KVC_\ 017ISAR&M6G[-VN7J***S,0KS7Q[_P CI!_V
M#Q_Z,:O2J\U\>_\ (Z0?]@\?^C&KCQW^[3]#.I\#,*LCQ#_QY/\ ]>\__H!K
M7K(\0_\ 'D__ %[S_P#H!KYO*_\ ?(?/\F<M#^*CRZKFD?\ (;L?^OB/_P!"
M%4ZN:1_R&['_ *^(_P#T(5^@/8^FELSZUT/_ )%_3_\ KVC_ /015ZJ.A_\
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MBB@ JAKO_(NZC_UZR_\ H!J_5#7?^1=U'_KUE_\ 0#0!'X:_Y%72O^O.+_T
M5IUF>&O^15TK_KSB_P#0!6G0 4444 %<?\2O^1?LO^O^/_T%J["N/^)7_(OV
M7_7_ !_^@M6=3X)>@GL<145S_P >DW^XW\JEJ*Y_X])O]QOY5\-3^./J>:MS
MUCPS_P BII7_ %YQ?^@"M2LOPS_R*FE?]><7_H K4K[T],**** ."\2?\E0T
MC_KC%_Z.-=[7!>)/^2H:1_UQB_\ 1QKO:YZ?\6?R)7Q,****Z"@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7#CO]:\BGFT*DU!1>KL<ZKINUCV*BFQG,2D]=HIU>R= 4444 %%%% !1110
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M0_\ C\TO_KG/_..NXKA_B'_Q^:7_ -<Y_P"<=<>._P!VGZ&=3X&<A61XH_Y
M,W^ZW_H+5KUD>*/^0#-_NM_Z"U?+X#_>H>IR4?XD3RZKFC_\ARQ_Z^8__0A5
M.KFC_P#(<L?^OF/_ -"%?HCV/IY;,^M=$_Y &G_]>T?_ *"*O51T3_D :?\
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M4#H**\\\<**** .'^(?_ !]Z7_N3_P XZY"NO^(?_'WI?^Y/_..N0KY+-?\
M>7Z(X:_QF1XG_P"0#/\ [K?^@FO+J]1\3_\ (!G_ -UO_037EU?19'_NOS9Z
MV7_PV7-(_P"0Y8_]?$?_ *$*^M=$_P"1?T__ *]H_P#T$5\E:1_R'+'_ *^(
M_P#T(5]:Z)_R+^G_ /7M'_Z"*].MNB\5NB]1117.<@5YKX]_Y'2#_L'C_P!&
M-7I5>:^/?^1T@_[!X_\ 1C5QX[_=I^AG4^!F%5_PU_R/6D?6;_T6:H5?\-?\
MCUI'UF_]%FOFLM_WN'S_ "9QT?C1Z!XB_P!5IW_80A_]"K8K'\1?ZK3O^PA#
M_P"A5L5]B>@%%%% !1110!YKX]_Y'2#_ +!X_P#1C5A5N^/?^1T@_P"P>/\
MT8U85?)9K_O+]$<-?XS(\3_\@*?_ '6_]!->75ZCXG_Y 4_^ZW_H)KRZOHLC
M_P!U^;/6R_\ ALN:1_R&['_KXC_]"%?6NB?\B_I__7M'_P"@BODK2/\ D-V/
M_7Q'_P"A"OK71/\ D7]/_P"O:/\ ]!%>G6W1>*W1>HHHKG.0*\U\>_\ (Z0?
M]@\?^C&KTJO-?'O_ ".D'_8/'_HQJX\=_NT_0SJ? S"K(\0_\>3_ /7O/_Z
M:UZR/$/_ !Y/_P!>\_\ Z :^;RO_ 'R'S_)G+0_BH\NJYI'_ "&['_KXC_\
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M?6NA_P#(OZ?_ ->T?_H(J]5'0_\ D7]/_P"O:/\ ]!%7J\\\<**** "BBB@
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MQ3_R/6J?[L/_ *+%9U?'YE_O4OE^2."M\;-OP+_R.S_]>+?^AK7IE>9^!?\
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M?^O'_P!G-8-;WC[_ )'"U_Z\?_9S6#7R>;?[S\D<-?XQ8?\ D+:9_P!?T/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M-_X1S0_^@-I__@*G^%:5<3_:GQ#_ .@%I_\ W\'_ ,=H RO!,:0_$[6XH46.
M-%G5448"@3+@ =A6G\0_^/S2_P#KG/\ SCK(\ /</\1-6>^C6.Y:*8S(O17\
MU=P')XSGN:U_B'_Q^:7_ -<Y_P"<=<>._P!VGZ&=3X&<A3[7_D/:/_V$(/\
MT*F4^U_Y#VC_ /80@_\ 0J^6P/\ O,/4XJ?QH]+\4_\ ('3_ *^(O_0A6S6-
MXI_Y Z?]?$7_ *$*V:^U/1"BBB@ HHHH *S?^$CT/_H,Z?\ ^!2?XUI5R<^E
MZ>/B#:0BQMA$=/=BGDKM)WCG&.M '5HZR(KQL&5AE64Y!'K2TBJJ*%0!548
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M(/\ L'C_ -&-6%6[X]_Y'2#_ +!X_P#1C5A5\EFO^\OT1PU_C,CQ/_R I_\
M=;_T$UY=7J/B?_D!3_[K?^@FO+J^BR/_ '7YL];+_P"&RYI'_(;L?^OB/_T(
M5]:Z)_R+^G_]>T?_ *"*^2M(_P"0W8_]?$?_ *$*^M=$_P"1?T__ *]H_P#T
M$5Z=;=%XK=%ZBBBN<Y KS7Q[_P CI!_V#Q_Z,:O2J\U\>_\ (Z0?]@\?^C&K
MCQW^[3]#.I\#,*LCQ#_QY/\ ]>\__H!K7K(\0_\ 'D__ %[S_P#H!KYO*_\
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MUO\ T$UKUD>)_P#D!3?[K?\ H)KY? ?[U#U.2C_$B>75<TG_ )#5C_U\1_\
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MZ/QGIE%%%?6G<%0WETEE8SW4H8QP1M(P4<D*,G'Y5-6?X@_Y%G4_^O.7_P!
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M,5\5AOX\/5?F>=#XD>WQ?ZE/]T4ZFQ?ZE/\ =%.K[D](**** "BBB@ HHHH
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M_P"0AH?_ &W_ ))7*U\MG'\=>GZLXL1\1D>)_P#D S?[K?\ H)KRZO4?$_\
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M]CB*BN?^/2;_ '&_E4M17/\ QZ3?[C?RKX:G\<?4\U;GK'AG_D5-*_Z\XO\
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MUI_U_1_R:NOKD/B5_P B]:?]?T?\FK.I\#]!/8X>JNI?\@^7Z#^8JU574O\
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M@WC_ %D+;77GL:YC0+*>?6=16;5M2D2RN=D:-<9## /S#'- '6T444 %%%%
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MI'_(<L?^OB/_ -"%?6NB?\B_I_\ U[1_^@BO3K;HO%;HO4445SG(%>:^/?\
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M_3_^O:/_ -!%7JHZ'_R+^G_]>T?_ *"*O5YYXX4444 >:^/?^1T@_P"P>/\
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M_NP_^BQ6=6CXI_Y'K5/]V'_T6*SJ^/S+_>I?+\D<%;XV;?@7_D=G_P"O%O\
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M /0A7Z(]CZ>6S/L.BBBO//'"BBB@#@OB3_R$-#_[;_R2N5KJOB3_ ,A#0_\
MMO\ R2N5KY;./XZ]/U9Q8CXC(\3_ /(!F_W6_P#037EU>H^)_P#D S?[K?\
MH)KRZO>R/_=?FSU<O_ALN:/_ ,ARQ_Z^8_\ T(5]:Z)_R -/_P"O:/\ ]!%?
M)6C_ /(<L?\ KYC_ /0A7UKHG_( T_\ Z]H__017IUMT7BMT7J***YSD"O-?
M'O\ R.L'_8/'_HQJ]*KS7Q[_ ,CK!_V#Q_Z,:N/'?[M/T,ZGP,PJS?$'_(&N
M/^N4G_HMJTJS?$'_ "!KC_KE)_Z+:OE\!_O4/4Y*/\2)Y35S2/\ D.6/_7Q'
M_P"A"J=7-(_Y#EC_ -?$?_H0K]$>Q]/+9GV&.@HH'045YYXX4444 </\0_\
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MV>ME_P##9<TC_D-V/_7Q'_Z$*^M=$_Y%_3_^O:/_ -!%?)6D?\ANQ_Z^(_\
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MZKFD_P#(:L?^OB/_ -"%4ZN:3_R&K'_KXC_]"%?HCV/IY;,^M=#_ .1?T_\
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M?+]!_,5\5AOX\/5?F>=#XD>WQ?ZE/]T4ZFQ?ZE/]T4ZON3T@HHHH \V\??\
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M@_X]X_\ ='\JZ\G_ ($O7]$7A_A'T445[)T!7$_$/_6Z9])?_9*[:N)^(?\
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MDGPG_P C1:?\#_\ 0&KZVKTJD5%V1=:"A*R"BBBLC$*X?XA_\?FE_P#7.?\
MG'7<5P_Q#_X_-+_ZYS_SCKCQW^[3]#.I\#.0K(\4?\@&;_=;_P!!:M>LCQ1_
MR 9O]UO_ $%J^7P'^]0]3DH_Q(GEU7-'_P"0Y8_]?,?_ *$*IU<T?_D.6/\
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M_P -ES2/^0W8_P#7Q'_Z$*^M=$_Y%_3_ /KVC_\ 017R5I'_ "&['_KXC_\
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M^0OI?_7]#_Z%7LU>OE/^[?-F]#X HHHKU3<**** "BBB@ K"\:?\BC>?6/\
M]&+6[6%XT_Y%&\^L?_HQ:BI\#]!/8\UJ.Y_X]9?]P_RJ2H[G_CUE_P!P_P J
M^$I_&O4\U;GJWA?_ )%/2O\ KTC_ /016K65X7_Y%/2O^O2/_P!!%:M??'IA
M1110!YMX^_Y'"U_Z\?\ V<U@UO>/O^1PM?\ KQ_]G-8-?)YM_O/R1PU_C%A_
MY"VF?]?T/_H5>S5XS#_R%M,_Z_H?_0J]FKU\I_W;YLWH? %%%%>J;A7CM_\
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MZ+Q6Z+U%%%<YR!7FOCW_ )'6#_L'C_T8U>E5YKX]_P"1U@_[!X_]&-7'CO\
M=I^AG4^!F%6;X@_Y UQ_URD_]%M6E6;X@_Y UQ_URD_]%M7R^ _WJ'J<E'^)
M$\IJYI'_ "'+'_KXC_\ 0A5.KFD?\ARQ_P"OB/\ ]"%?HCV/IY;,^PQT%% Z
M"BO//'"BBB@#A_B'_P ?>E_[D_\ ..N0KK_B'_Q]Z7_N3_SCKD*^2S7_ 'E^
MB.&O\9D>)_\ D S_ .ZW_H)KRZO4?$__ " 9_P#=;_T$UY=7T61_[K\V>ME_
M\-ES2/\ D.6/_7Q'_P"A"OK71/\ D7]/_P"O:/\ ]!%?)6D?\ARQ_P"OB/\
M]"%?6NB?\B_I_P#U[1_^@BO3K;HO%;HO4445SG(%>:^/?^1T@_[!X_\ 1C5Z
M57FOCW_D=(/^P>/_ $8U<>._W:?H9U/@9A5C^(O^/)_^O>?_ - K8K'\1?\
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M>UZ%\/?^1'L?K)_Z,:LLE_Y>?+]18?J=+1117T)U!7'_ !*_Y%^R_P"O^/\
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M7E9/_O#]/U1A0^(] HHHKZD[0JAKO_(NZE_UZ2_^@&K]4-=_Y%W4O^O27_T
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MA+4/^N,7\WKNZ^GP'^[0]#LI? @HHHKM- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***H:S83ZEIK06=]+8SY!2:(G@^A'<4 1
M:QJ>GV]Q::9J41E_M)C$B% RG&,Y_P"^A7/W?PPTF8D6MU=VT9;=Y0<,@/MD
M9_,FLK5/!GB5]3TUO[8FO=LA/V@C'V7[OS8+9.?;TK5_X1'Q+_T-]Q_WP?\
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M_P ARQ_Z^8__ $(53JYH_P#R'+'_ *^8_P#T(5^B/8^GELSZUT3_ ) &G_\
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M6%7R6:_[R_1'#7^,R/$__("G_P!UO_037EU>H^)_^0%/_NM_Z":\NKZ+(_\
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M^7GR_46'ZG2T445]"=05Q_Q*_P"1?LO^O^/_ -!:NPKC_B5_R+]E_P!?\?\
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ME?1X#_=H>AUTO@04445VFAGZ_P#\BWJ?_7I+_P"@&O(K3_CRA_W!_*O7=?\
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MO[5\0?\ GQTW_OK_ .RKI](;4'TJ%M9CCCO3N\Q8ONCYCC')[8J[10 4444
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MW^ZW_H+5KUD>*/\ D S?[K?^@M7R^ _WJ'J<E'^)$\NJYH__ "'+'_KYC_\
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M>_\ (Z0?]@\?^C&K"KY+-?\ >7Z(X:_QF1XG_P"0%/\ [K?^@FO+J]1\3_\
M("G_ -UO_037EU?19'_NOS/5R_\ ALN:1_R&['_KXC_]"%?80^Z/I7Q[I'_(
M;L?^OB/_ -"%?80^Z/I7IU]T:8K="T445SG(%</\0_\ CZTO_<G_ )QUW%</
M\0_^/K2_]R?^<=<>._W:?H9U/@9R%9'B?_D!3?[K?^@FM>LCQ/\ \@*;_=;_
M -!-?+X#_>H>IR4?XD3RZKFD_P#(:L?^OB/_ -"%4ZN:3_R&K'_KXC_]"%?H
MCV/IY;,^M=#_ .1?T_\ Z]H__015ZJ.A_P#(OZ?_ ->T?_H(J]7GGCA1110
M4444 %%%% &=XA_Y%G5/^O.7_P! ->26G_'G#_US7^5>M^(?^19U3_KSE_\
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M+->LUY-X;_Y'C2/K+_Z+->LU[F6_[K'Y_FSIH_ @HHHKT34*\N\5?\C=J/\
MO1_^BDKU&O+O%7_(W:C_ +T?_HI*\O-?]V?JC&M\!DUM^!?^1V?_ *\&_P#0
MUK$K;\"_\CL__7@W_H:UXV5?[RO1G/1^,],HHHKZT[@K/\0?\BSJ?_7G+_Z
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M?DCAK_&+#_R%]+_Z_H?_ $*O9J\9A_Y"^E_]?T/_ *%7LU>OE/\ NWS9O0^
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M)_\ >'Z?JC"A\1Z!1117U)VA5#7?^1=U+_KTE_\ 0#5^J&N_\B[J7_7I+_Z
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MI]OI6GQ65FI6&$84%LGUZU9H \^TW_DM&H?]<C_Z E=)XV4MX+U(*,GR@?\
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MNT_0SJ? SD*R/%'_ " 9O]UO_06K7K(\4?\ (!F_W6_]!:OE\!_O4/4Y*/\
M$B>75=T?_D.6/_7S'_Z$*I5=T?\ Y#EC_P!?,?\ Z$*_1'L?3RV9]:Z+_P @
M#3_^O6/_ -!%7:I:+_R -/\ ^O6/_P!!%7:\\\<**** /-/'G_([0_\ 8/7_
M -&-6'6YX\_Y':'_ +!Z_P#HQJPZ^2S7_>7Z(X:_QF9X@_Y MQ_URD_]%M7E
M5>J^(/\ D"W'_7*3_P!%M7E5?19'_NOS9ZV7_P -FSX3_P"1HM/^!_\ H#5]
M;5\D^$_^1HM/^!_^@-7UM7I5OB'B?C7H%%%%8',%</\ $/\ X_-+_P"N<_\
M..NXKA_B'_Q^:7_USG_G'7'CO]VGZ&=3X&<A61XH_P"0#-_NM_Z"U:]9'BC_
M ) ,W^ZW_H+5\O@/]ZAZG)1_B1/+JN:/_P ARQ_Z^8__ $(53JYH_P#R'+'_
M *^8_P#T(5^B/8^GELSZUT3_ ) &G_\ 7M'_ .@BKU4=$_Y &G_]>T?_ *"*
MO5YYXX4444 >:^//^1UA_P"P>O\ Z,:L*MWQY_R.L/\ V#U_]&-6%7R6:_[R
M_1'#7^,IW7_'_:?\#_E7D=>N77_'_:?\#_E7D=?2Y-_ND?G^;/5R_P"!_P!=
MRYH__(<L?^OF/_T(5]:Z)_R -/\ ^O:/_P!!%?)6C_\ (<L?^OF/_P!"%?6N
MB?\ ( T__KVC_P#017H5MT:8K=%ZBBBN<Y KS7QY_P CK#_V#U_]&-7I5>:^
M//\ D=8?^P>O_HQJX\=_NT_0SJ? S"K(\4?\@&;_ '6_]!:M>LCQ1_R 9O\
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M_P"(?_'WI?\ N3_SCKD*^2S7_>7Z(X:_QF1XG_Y ,_\ NM_Z":\NKU'Q/_R
M9_\ =;_T$UY=7T61_P"Z_-GK9?\ PV7-(_Y#EC_U\1_^A"OK71/^1?T__KVC
M_P#017R5I'_(<L?^OB/_ -"%?6NB?\B_I_\ U[1_^@BO3K;HO%;HO4445SG(
M%>:^/?\ D=(/^P>/_1C5Z57FOCW_ )'2#_L'C_T8U<>._P!VGZ&=3X&858_B
M+_CR?_KWG_\ 0*V*Q_$7_'D__7O/_P"@5\WE?^^0^?Y,Y</_ !4>7UL>%/\
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M8_\ 7Q'_ .A"OT1['T\MF?6NA_\ (OZ?_P!>T?\ Z"*O51T/_D7]/_Z]H_\
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MJ^2S7_>?DCAK_&7O#?\ R/&D?67_ -%FO6:\F\-_\CQI'UE_]%FO6:]S+?\
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M9Z39:M=6$=Q;@YAD8 'YSG:",]* /0J*\VUBU\0>"I+35#KEUJML)=DT4K,
M >Q!9ASSSV.*]$M+F.]LX;J [HID$B'U!&10!+1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>;_ /%SO\_9J](KB?\ A.=<
M_P"A+U#\W_\ C= &)\//M7_"?:G_ &A_Q]^3+Y_3[_FINZ<=<].*V?B'_P ?
MFE_]<Y_YQUD> )WNOB)JUQ-"UO)+%,[0MUC)E4E3P.1TZ5K_ !#_ ./S2_\
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ML?\ KYC_ /0A7UKHG_( T_\ Z]H__017R5H__(<L?^OF/_T(5]:Z)_R -/\
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MZ_XA_P#'WI?^Y/\ SCKD*^2S7_>7Z(X:_P 9D>)_^0#/_NM_Z":\NKU'Q/\
M\@&?_=;_ -!->75]%D?^Z_-GK9?_  V7-(_Y#EC_ -?$?_H0KZUT3_D7]/\
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M!G(5D>*/^0#-_NM_Z"U:]9'BC_D S?[K?^@M7R^ _P!ZAZG)1_B1/+JNZ/\
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M<_\ ..N/'?[M/T,ZGP,Y"LCQ1_R 9O\ =;_T%JUZR/%'_(!F_P!UO_06KY?
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ML?\ KYC_ /0A7UKHG_( T_\ Z]H__017R5H__(<L?^OF/_T(5]:Z)_R -/\
M^O:/_P!!%>G6W1>*W1>HHHKG.0*\U\>_\CK!_P!@\?\ HQJ]*KS7Q[_R.L'_
M &#Q_P"C&KCQW^[3]#.I\#,*LWQ!_P @:X_ZY2?^BVK2K-\0?\@:X_ZY2?\
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M/_UXM_Z&M>F5YGX%_P"1V?\ Z\6_]#6O3*^CP'^[0]#KI? @HHHKM-#/U_\
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M+:9_U_0_^A5[-7KY3_NWS9O0^ ****]4W"O';_\ Y&+6/^OZ7^=>Q5X[?_\
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M*UU7Q)_Y"&A_]M_Y)7*U\MG'\=>GZLXL1\1D>)_^0#-_NM_Z":\NKU'Q/_R
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M!_V#Q_Z,:O2J\U\>_P#(Z0?]@\?^C&KCQW^[3]#.I\#,*L?Q%_QY/_U[S_\
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M_P"C&KTFO-O'W_(Y6W_7@/\ T8U<>._W:?H9U/@9@UI^&?\ D;-,_P"NK_\
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MN,7\WKNZX3X??\A+4/\ KC%_-Z[NOI\!_NT/0[*7P(****[30**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL7Q#XB_L#[/_P 2
M^YO//W?ZA<[,8Z_7/Z4 /\2^'H/$>E_9I7,,J-OAF4<HW]17/Q3^/=)C6W>R
MM-51!A9P^&/IGD9_+\:D_P"%A_\ 4OZE_P!^Z/\ A8?_ %+^I?\ ?N@"";2_
M%WBE1;ZV;?2M/+ R1PG+R#.<=3_,?2K?B/2]9ELK;P_X=MHX=-:$)-<.P^49
M^[UST'/!SGZU'_PL/_J7]2_[]UTVD:C_ &MI4-[]GEMO-W?NI1AEPQ'/Y9H
M=I6G1Z3I-M80G*01A-Q'WCW/XG)JW110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %<3_PM70_^?74/^_:?_%UVU9O_  CFA_\
M0&T__P !4_PH X+P!=I?_$35KR$,L=Q%-*H8<@-*I&??FM?XA_\ 'YI?_7.?
M^<=9G@F-(?B=K<4*+'&BSJJ*,!0)EP .PK3^(?\ Q^:7_P!<Y_YQUQX[_=I^
MAG4^!G(5D>*/^0#-_NM_Z"U:]9'BC_D S?[K?^@M7R^ _P!ZAZG)1_B1/+JN
MZ/\ \ARQ_P"OF/\ ]"%4JNZ/_P ARQ_Z^8__ $(5^B/8^GELSZUT7_D :?\
M]>L?_H(J[5+1?^0!I_\ UZQ_^@BKM>>>.%%%% 'FGCS_ )':'_L'K_Z,:L.M
MSQY_R.T/_8/7_P!&-6'7R6:_[R_1'#7^,S/$'_(%N/\ KE)_Z+:O*J]5\0?\
M@6X_ZY2?^BVKRJOHLC_W7YL];+_X;-GPG_R-%I_P/_T!J^MJ^2?"?_(T6G_
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M /(<L?\ KYC_ /0A7UKHG_( T_\ Z]H__017R5H__(<L?^OF/_T(5]:Z)_R
M-/\ ^O:/_P!!%>G6W1>*W1>HHHKG.0*\U\>_\CK!_P!@\?\ HQJ]*KS7Q[_R
M.L'_ &#Q_P"C&KCQW^[3]#.I\#,*LWQ!_P @:X_ZY2?^BVK2K-\0?\@:X_ZY
M2?\ HMJ^7P'^]0]3DH_Q(GE-7-(_Y#EC_P!?$?\ Z$*IU<TC_D.6/_7Q'_Z$
M*_1'L?3RV9]<ZE_R![O_ *X/_P"@FHM"_P"1?L/^O=/_ $$5+J7_ "![O_K@
M_P#Z":BT+_D7[#_KW3_T$5YYXY?HHHH X?XA_P#'WI?^Y/\ SCKD*Z_XA_\
M'WI?^Y/_ #CKD*^2S7_>7Z(X:_QF1XG_ .0#/_NM_P"@FO+J]1\3_P#(!G_W
M6_\ 037EU?19'_NOS9ZV7_PV7-(_Y#EC_P!?$?\ Z$*^M=$_Y%_3_P#KVC_]
M!%?)6D?\ARQ_Z^(__0A7UKHG_(OZ?_U[1_\ H(KTZVZ+Q6Z+U%%%<YR!7FOC
MW_D=(/\ L'C_ -&-7I5>:^/?^1T@_P"P>/\ T8U<>._W:?H9U/@9A5C^(O\
MCR?_ *]Y_P#T"MBL?Q%_QY/_ ->\_P#Z!7S>5_[Y#Y_DSEP_\5'E];'A3_D9
M[3_@?_H#5CUL>%/^1GM/^!_^@-7W\OA9])4^!GUN.@HH'045P'DA1110!YKX
M]_Y'2#_L'C_T8U85;OCW_D=(/^P>/_1C5A5\EFO^\OT1PU_C,CQ/_P @*?\
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MA6!K[T],DHHHH \U\>_\CE;_ /7@/_1C5A5N^/?^1RM_^O ?^C&K"KY+-?\
M>?DCAK_&4[O_ (_K3ZO_ "K!/4UO7?\ Q_6GU?\ E6">IKW<M_W2/S_-G31^
M!$EO_P ?47^^/YU[]H?_ "+^G_\ 7M'_ .@BO ;?_CZB_P!\?SKW[0_^1?T_
M_KVC_P#017H&I?KR[Q5_R-VH_P"]'_Z*2O4:\N\5?\C=J/\ O1_^BDKR\U_W
M9^J,:WP&36WX%_Y'9_\ KP;_ -#6L2MOP+_R.S_]>#?^AK7C95_O*]&<]'XS
MTRBBBOK3N"L_Q!_R+.I_]><O_H!K0K/\0?\ (LZG_P!><O\ Z : /([3_CSA
M_P!P?RJ6HK3_ (\X?]P?RJ6O@JO\27JSS);L]'\#_P#(IV__ %UF_P#1K5T%
M<_X'_P"13M_^NLW_ *-:N@K[FE_#CZ(]*.R"BBBM!F%XT_Y%&[_WHO\ T:M>
M:UZ5XT_Y%&[_ -Z+_P!&K7FM?-YS\</0Y,1NB.Y_X])O]QOY5ZOX9_Y%32O^
MO2+_ -!%>47/_'I-_N-_*O5_#/\ R*FE?]>D7_H(K?)O@GZE8?9FI1117NG2
M%>;>/O\ D<K;_KP'_HQJ])KS;Q]_R.5M_P!> _\ 1C5QX[_=I^AG4^!F#6GX
M9_Y&S3/^NK_^BWK,K3\,_P#(V:9_UU?_ -%O7RV!_P!YAZG%3^-'9>(K::%H
MKF#4;V(S7$<1C24!%!X.!CK6U96IL[?RC<3W'.=\[;F_/ K.\3?\>EG_ -?L
M/\ZV1TK[4]$**** /*?%/_(]:I_NP_\ HL5G5H^*?^1ZU3_=A_\ 18K.KX_,
MO]ZE\OR1P5OC9M^!?^1V?_KQ;_T-:[.]_P"1MT[_ *XR?TKC/ O_ ".S_P#7
MBW_H:UV=[_R-NG?]<9/Z5])@/]VAZ'72^!&S11178:&?K_\ R+>I_P#7I+_Z
M :\BM/\ CRA_W!_*O7=?_P"1;U/_ *])?_0#7D5I_P >4/\ N#^5>'G/\./J
M<V(V1-7:?#7_ ) ^H_\ 7\__ *"M<77:?#7_ ) ^H_\ 7\__ *"M<V3?Q)>A
M&'W9V=%%%?2G8%<A\2O^1>M/^OZ/^35U]<A\2O\ D7K3_K^C_DU9U/@?H)['
M#U5U+_D'R_0?S%6JJZE_R#Y?H/YBOBL-_'AZK\SSH?$CVP_\>9_ZY_TK.\+_
M /(N6OT/\S6B?^/,_P#7/^E9WA?_ )%RU^A_F:^Y/2-:BBB@#S;Q]_R.-M_U
MX_\ L[5@UO>/O^1QMO\ KQ_]G:L&OD\U_P!Y^2.&O\8L/_(7TO\ Z_H?_0J]
MFKQF'_D+Z7_U_0_^A5[-7KY3_NWS9O0^ ****]4W"BBB@ HHHH *PO&G_(HW
MGUC_ /1BUNUA>-/^11O/K'_Z,6HJ? _03V/-:CN?^/67_</\JDJ.Y_X]9?\
M</\ *OA*?QKU/-6YZEH'_(DZ?_UXI_Z!4GAG_D7;3_=_K4>@?\B3I_\ UXI_
MZ!4GAG_D7;3_ '?ZU]\>F:M%%% 'FWC[_D<+7_KQ_P#9S6#6]X^_Y'"U_P"O
M'_V<U@U\GFW^\_)'#7^,6'_D+:9_U_0_^A5[-7C,/_(6TS_K^A_]"KV:O7RG
M_=OFS>A\ 4445ZIN%>.W_P#R,6L?]?TO\Z]BKQV__P"1BUC_ *_I?YUY>:_[
ML_5&-;X"*NG^''_(7UC_ '(?_9JYBNG^''_(7UC_ '(?_9J\K)_]X?I^J,*'
MQ'H%%%%?4G:%4-=_Y%W4O^O27_T U?JAKO\ R+NI?]>DO_H!H \AL_\ CRA_
MW!_*IJAL_P#CRA_W!_*IJ^#K?Q)>K/,ENSM/AI_R"M1_Z_F_]!6NSKC/AI_R
M"M1_Z_F_]!6NSK[>C_#CZ(]&.R"BBBM2CD?B3_R+MM_U^Q_R:N&KN?B3_P B
M[;?]?L?\FKAJ^;SGXX>AR8C=%;4?^0?+]!_.O;8/^/>/_='\J\2U'_D'R_0?
MSKVV#_CWC_W1_*NO)_X$O7]$7A_A'T445[)T!7$_$/\ UNF?27_V2NVKB?B'
M_K=,^DO_ +)7)C?]VGZ&=3X&<=1%_P A33?^OV'_ -"HHB_Y"FF_]?L/_H5?
M*8+_ 'F'J<5/XT>ST445]L>B%%%% 'CNH?\ (R:Q_P!?LG\ZBJ74/^1DUC_K
M]D_G45?%X_\ WF?J>?5^-G6?#[_D):A_UQB_F]=W7!_#[_D):C_UQC_F];<L
MFL)K<=@-2AQ)$9=_V4<8.,8W5]/@/]VAZ'92^!'0T4V,,L:B1MS <L!C)^E.
MKM- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHKB?[4^(?\ T M/_P"_@_\ CM &;X-_Y*GKW_;Q_P"CEK0^
M(?\ Q^:7_P!<Y_YQUD> 'N'^(FK/?1K'<M%,9D7HK^:NX#D\9SW-:_Q#_P"/
MS2_^N<_\XZX\=_NT_0SJ? SD*R/%'_(!F_W6_P#06K7K(\4?\@&;_=;_ -!:
MOE\!_O4/4Y*/\2)Y=5W1_P#D.6/_ %\Q_P#H0JE5W1_^0Y8_]?,?_H0K]$>Q
M]/+9GUKHO_( T_\ Z]8__015VJ6B_P#( T__ *]8_P#T$5=KSSQPHHHH \T\
M>?\ ([0_]@]?_1C5AUN>//\ D=H?^P>O_HQJPZ^2S7_>7Z(X:_QF9X@_Y MQ
M_P!<I/\ T6U>55ZKX@_Y MQ_URD_]%M7E5?19'_NOS9ZV7_PV;/A/_D:+3_@
M?_H#5];5\D^$_P#D:+3_ ('_ .@-7UM7I5OB'B?C7H%%%%8',%</\0_^/S2_
M^N<_\XZ[BN'^(?\ Q^:7_P!<Y_YQUQX[_=I^AG4^!G(5D>*/^0#-_NM_Z"U:
M]9'BC_D S?[K?^@M7R^ _P!ZAZG)1_B1/+JN:/\ \ARQ_P"OF/\ ]"%4ZN:/
M_P ARQ_Z^8__ $(5^B/8^GELSZUT3_D :?\ ]>T?_H(J]5'1/^0!I_\ U[1_
M^@BKU>>>.%%%% 'FOCS_ )'6'_L'K_Z,:L*MWQY_R.L/_8/7_P!&-6%7R6:_
M[R_1'#7^,IW7_'_:?\#_ )5Y'7KEU_Q_VG_ _P"5>1U]+DW^Z1^?YL]7+_@?
M]=RYH_\ R'+'_KYC_P#0A7UKHG_( T__ *]H_P#T$5\E:/\ \ARQ_P"OF/\
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M$?\ Z$*^M=$_Y%_3_P#KVC_]!%?)6D?\ANQ_Z^(__0A7UKHG_(OZ?_U[1_\
MH(KTZVZ+Q6Z+U%%%<YR!7FOCW_D=(/\ L'C_ -&-7I5>:^/?^1T@_P"P>/\
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M /H*UQ==I\-?^0/J/_7\_P#Z"M<V3?Q)>A&'W9V=%%%?2G8%<A\2O^1>M/\
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M2>'M5TZ#0;6.:_M8W5>5>901SZ9K[X],Z"BHX9XKF(2V\J2QGH\;!@?Q%24
M>;>/O^1PM?\ KQ_]G-8-;WC[_D<+7_KQ_P#9S6#7R>;?[S\D<-?XQ8?^0MIG
M_7]#_P"A5[-7C,/_ "%M,_Z_H?\ T*O9J]?*?]V^;-Z'P!1117JFX5X[?_\
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MR 9O]UO_ $%J^7P'^]0]3DH_Q(GEU7-'_P"0Y8_]?,?_ *$*IU<T?_D.6/\
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M6OT/\S6B?^/,_P#7/^E9WA?_ )%RU^A_F:^Y/2-:BBB@#S;Q]_R.-M_UX_\
ML[5@UO>/O^1QMO\ KQ_]G:L&OD\U_P!Y^2.&O\8L/_(7TO\ Z_H?_0J]FKQF
M'_D+Z7_U_0_^A5[-7KY3_NWS9O0^ ****]4W"BBB@ HHHH *PO&G_(HWGUC_
M /1BUNUA>-/^11O/K'_Z,6HJ? _03V/-:CN?^/67_</\JDJ.Y_X]9?\ </\
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M?^0?+]!_.O;8/^/>/_='\JZ\G_@2]?T1>'^$?1117LG0%<3\0_\ 6Z9])?\
MV2NVKB?B'_K=,^DO_LE<F-_W:?H9U/@9QU$7_(4TW_K]A_\ 0J*(O^0IIO\
MU^P_^A5\I@O]YAZG%3^-'L]%%%?;'HA1110!X[J'_(R:Q_U^R?SJ*I=0_P"1
MDUC_ *_9/YU%7Q>/_P!YGZGGU?C9UGP^_P"0EJ'_ %QB_F]=%/\ \CG:_P#7
MH_\ Z$*YWX??\A+4/^N,7\WKHI_^1SM?^O1__0A7T^ _W:'H=E+X$;-%%%=I
MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%>;_\(;XW_P"AC_\ )Z?_ .)H /!O_)4]>_[>/_1RUH?$/_C\
MTO\ ZYS_ ,XZQOAY#/;>/M3@O)/-N(H94EDW%M["5 3D\G)[FMGXA_\ 'YI?
M_7.?^<=<>._W:?H9U/@9R%9'BC_D S?[K?\ H+5KUD>*/^0#-_NM_P"@M7R^
M _WJ'J<E'^)$\NJ[H_\ R'+'_KYC_P#0A5*KNC_\ARQ_Z^8__0A7Z(]CZ>6S
M/K71?^0!I_\ UZQ_^@BKM4M%_P"0!I__ %ZQ_P#H(J[7GGCA1110!YIX\_Y'
M:'_L'K_Z,:L.MSQY_P CM#_V#U_]&-6'7R6:_P"\OT1PU_C,SQ!_R!;C_KE)
M_P"BVKRJO5?$'_(%N/\ KE)_Z+:O*J^BR/\ W7YL];+_ .&S9\)_\C1:?\#_
M /0&KZVKY)\)_P#(T6G_  /_ - :OK:O2K?$/$_&O0****P.8*X?XA_\?FE_
M]<Y_YQUW%</\0_\ C\TO_KG/_..N/'?[M/T,ZGP,Y"LCQ1_R 9O]UO\ T%JU
MZR/%'_(!F_W6_P#06KY? ?[U#U.2C_$B>75<T?\ Y#EC_P!?,?\ Z$*IU<T?
M_D.6/_7S'_Z$*_1'L?3RV9]:Z)_R -/_ .O:/_T$5>JCHG_( T__ *]H_P#T
M$5>KSSQPHHHH \U\>?\ (ZP_]@]?_1C5A5N^//\ D=8?^P>O_HQJPJ^2S7_>
M7Z(X:_QE.Z_X_P"T_P"!_P J\CKURZ_X_P"T_P"!_P J\CKZ7)O]TC\_S9ZN
M7_ _Z[ES1_\ D.6/_7S'_P"A"OK#3O\ D5+7_KR3_P! %?)^C_\ (<L?^OF/
M_P!"%?6&G?\ (J6O_7DG_H KT*VZ-,5NA/#/_(M6/_7/^M:E9?AG_D6K'_KG
M_6M2N<Y KS7QY_R.L/\ V#U_]&-7I5>:^//^1UA_[!Z_^C&KCQW^[3]#.I\#
M,*LCQ1_R 9O]UO\ T%JUZR/%'_(!F_W6_P#06KY? ?[U#U.2C_$B>75<T?\
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MMNLSPY_R+=C_ -<A6G7.<@5YKX]_Y'2#_L'C_P!&-7I5>:^/?^1T@_[!X_\
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M_("G_P!UO_037EU>H^)_^0%/_NM_Z":\NKZ+(_\ =?F>KE_\-ES2/^0W8_\
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M9/\ T 5L5CZ3_P AS6/^NR?^@"MBOH3J"N/^)7_(OV7_ %_Q_P#H+5V%<?\
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MG_(HW?\ O1?^C5KS6OF\Y^.'H<F(W1'<_P#'I-_N-_*O5_#/_(J:5_UZ1?\
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MH_\ 7\__ *"M<V3?Q)>A&'W9V=%%%?2G8%<A\2O^1>M/^OZ/^35U]<A\2O\
MD7K3_K^C_DU9U/@?H)['#U5U+_D'R_0?S%6JJZE_R#Y?H/YBOBL-_'AZK\SS
MH?$C(GN)EN) LL@ 8X 8U']IG_Y[2?\ ?9HN?^/J7_>-15]R>D>R?#B623PR
M?,=FVRX7<<X^53_,DUUM<?\ #7_D67_ZZ_\ LBUV% 'FWC[_ )'&V_Z\?_9V
MK!K>\??\CC;?]>/_ +.U8-?)YK_O/R1PU_C%A_Y"^E_]?T/_ *%7LU>,P_\
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M?'G_ ".L/_8/7_T8U85?)9K_ +R_1'#7^,IW7_'_ &G_  /^5>1UZY=?\?\
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M#_Q4>7UL>%/^1GM/^!_^@-6/6QX4_P"1GM/^!_\ H#5]_+X6?25/@9]9S?\
M'N_^X?Y5F^%_^19LO]P_S->9S?$/7%>2(W&0"5/R)S_X[4%KX^U>RM4M[:39
M%&,*NU#C\UKA/)/::*P/!FKW6M:#]IOF5I!(5W!0,C /...^*WZ0'FOCW_D=
M(/\ L'C_ -&-6%6[X]_Y'2#_ +!X_P#1C5A5\EFO^\OT1PU_C,CQ/_R I_\
M=;_T$UY=7J/B?_D!3_[K?^@FO+J^BR/_ '7YL];+_P"&RYI'_(;L?^OB/_T(
M5]:Z)_R+^G_]>T?_ *"*^2M(_P"0W8_]?$?_ *$*^M=$_P"1?T__ *]H_P#T
M$5Z=;=%XK=%ZBBBN<Y KS7Q[_P CI!_V#Q_Z,:O2J\U\>_\ (Z0?]@\?^C&K
MCQW^[3]#.I\#,*LCQ#_QY/\ ]>\__H!K7K(\0_\ 'D__ %[S_P#H!KYO*_\
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MUO\ T$UKUD>)_P#D!3?[K?\ H)KY? ?[U#U.2C_$B>75<TG_ )#5C_U\1_\
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MKO\ X_K3ZO\ RK!/4U[N6_[I'Y_FSIH_ B2W_P"/J+_?'\Z]^T/_ )%_3_\
MKVC_ /017@-O_P ?47^^/YU[]H?_ "+^G_\ 7M'_ .@BO0-2_7EWBK_D;M1_
MWH__ $4E>HUY=XJ_Y&[4?]Z/_P!%)7EYK_NS]48UO@,FMOP+_P CL_\ UX-_
MZ&M8E;?@7_D=G_Z\&_\ 0UKQLJ_WE>C.>C\9Z9166?$NC@D'4(01UY-:4<B2
MQ+)&P9' *D=Q7UIW#JS_ !!_R+.I_P#7G+_Z :T*S_$'_(LZG_UYR_\ H!H
M\CM/^/.'_<'\JEJ*T_X\X?\ <'\JEKX*K_$EZL\R6[/1_ __ "*=O_UUF_\
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MBBB@ HHHH **** "BBB@ HHHH **:TJ(ZJ[JK/\ =!."WTIU !1110 4444
M%%-\U!*(RZ^81D+GG'KBG4 %%-DECB7=*ZHOJQP*$=)%#1LKJ>A4Y% #J**K
M:CJ-MI5A+>7THCAC&23W]AZD^E %FBH;.ZCOK&"[@SY<\:R)N&#AAD9_.IJ
M"BBB@#S?P;_R5/7O^WC_ -'+6A\0_P#C\TO_ *YS_P XZS_!O_)4]>_[>/\
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M0_\ C\TO_KG/_..NXKA_B'_Q^:7_ -<Y_P"<=<>._P!VGZ&=3X&<A61XH_Y
M,W^ZW_H+5KUD>*/^0#-_NM_Z"U?+X#_>H>IR4?XD3RZKFC_\ARQ_Z^8__0A5
M.KFC_P#(<L?^OF/_ -"%?HCV/IY;,^M=$_Y &G_]>T?_ *"*O51T3_D :?\
M]>T?_H(J]7GGCA1110!YKX\_Y'6'_L'K_P"C&K"K=\>?\CK#_P!@]?\ T8U8
M5?)9K_O+]$<-?XRG=?\ '_:?\#_E7D=>N77_ !_VG_ _Y5Y'7TN3?[I'Y_FS
MU<O^!_UW+FC_ /(<L?\ KYC_ /0A7UAIW_(J6O\ UY)_Z *^3]'_ .0Y8_\
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MBBJ=GJ]AJ$ICLKJ.9U7<54]!ZU<KG.0*\U\>_P#(ZP?]@\?^C&KTJO-?'O\
MR.L'_8/'_HQJX\=_NT_0SJ? S"K-\0?\@:X_ZY2?^BVK2K-\0?\ (&N/^N4G
M_HMJ^7P'^]0]3DH_Q(GE-7-(_P"0Y8_]?$?_ *$*IU<TC_D.6/\ U\1_^A"O
MT1['T\MF=O<_\?4O^^?YU%4MS_Q]2_[Y_G45>>>.>Z^#O^13L_\ @?\ Z&U;
ME8?@[_D4[/\ X'_Z&U;E '#_ !#_ ./O2_\ <G_G'7(5U_Q#_P"/O2_]R?\
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M'_8/'_HQJX\=_NT_0SJ? S"K(\0_\>3_ /7O/_Z :UZR/$/_ !Y/_P!>\_\
MZ :^;RO_ 'R'S_)G+0_BH\NJYI'_ "&['_KXC_\ 0A5.KFD?\ANQ_P"OB/\
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M%OYI7 UWWPK_ .0M<?\ 7%OYI7T)U'J=<?\ $K_D7[+_ *_X_P#T%J["N/\
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MO4OE^2."M\;,76?^/M/]S^IK/K0UG_C[3_<_J:SZ^CP'^[0]#KI? C9\)_\
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MR_\ UU_]D6NPKC_AK_R++_\ 77_V1:["@#S;Q]_R.%K_ ->/_LYK!K>\??\
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MYO\ \+<_Z@G_ )-__84?\+<_Z@G_ )-__84 '@W_ )*GKW_;Q_Z.6M#XA_\
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M]@]?_1C5AUN>//\ D=H?^P>O_HQJPZ^2S7_>7Z(X:_QF9X@_Y MQ_P!<I/\
MT6U>55ZKX@_Y MQ_URD_]%M7E5?19'_NOS9ZV7_PV;/A/_D:+3_@?_H#5];5
M\D^$_P#D:+3_ ('_ .@-7TNWC?PZC;7U-%(Z@QN/Z5Z5;XAXGXUZ&_17/_\
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M(/\ L'C_ -&-6%6[X]_Y'2#_ +!X_P#1C5A5\EFO^\OT1PU_C,CQ/_R I_\
M=;_T$UY=7J/B?_D!3_[K?^@FO+J^BR/_ '7YL];+_P"&RYI'_(;L?^OB/_T(
M5]:Z)_R+^G_]>T?_ *"*^2M(_P"0W8_]?$?_ *$*^F=,\9:!:Z3:6]QJ4:2Q
M0HCJ4;Y6"@$=*].MNB\5NCJJ*Y__ (3KPW_T%(_^^'_PK9LKZWU&SCNK*3S8
M),[' (S@X[_2N<Y">O-?'O\ R.D'_8/'_HQJ]*KS7Q[_ ,CI!_V#Q_Z,:N/'
M?[M/T,ZGP,PJR/$/_'D__7O/_P"@&M>LCQ#_ ,>3_P#7O/\ ^@&OF\K_ -\A
M\_R9RT/XJ/+JN:1_R&['_KXC_P#0A5.KFD?\ANQ_Z^(__0A7Z ]CZ:6S/K70
M_P#D7]/_ .O:/_T$5>KF8-;2U\/Z>ME=:>\B6Z"5)[D*5PHXQZU+I/B47:B7
M4)].MHF3*J+D;P<]"#TKSSQSH:*9#/%<PB6WE26-NCHP8'\13Z /-?'O_(Z0
M?]@\?^C&K"K=\>_\CI!_V#Q_Z,:L*ODLU_WE^B.&O\9D>)_^0%/_ +K?^@FO
M+J]1\3_\@*?_ '6_]!->75]%D?\ NOS/5R_^&RYI'_(;L?\ KXC_ /0A7UIJ
M.HOIT2N+.>Y3:68Q ?(!ZY-?)>D?\ANQ_P"OB/\ ]"%?7.H_\@>Z_P"N#_\
MH)KTZVZ-,5NB'2]5;4UWBRN((V0,DDH&'!],&M"L_0?^1?L/^O=/Y"M"N<Y
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M']IG_P">TG_?9HN?^/J7_?/\ZBKSSQSV3X<$MX78DY)G))/?Y$KK:Y+X;?\
M(JG_ *[?^R)76T >:>//^1VA_P"P>O\ Z,:L.MSQY_R.T/\ V#U_]&-6'7R6
M:_[R_1'#7^,S/$'_ "!;C_KE)_Z+:O*J]5\0?\@6X_ZY2?\ HMJ\JKZ+(_\
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MO_*L$]37NY;_ +I'Y_FSIH_ B2W_ ./J+_?'\Z]^T/\ Y%_3_P#KVC_]!%>
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M>L/^O=/_ $$5ZIN7Z*** "BBB@ K"\:?\BC>?6/_ -&+6[6%XT_Y%&\^L?\
MZ,6HJ? _03V/-:CN?^/67_</\JDJ.Y_X]9?]P_RKX2G\:]3S5N<S1117WQZ9
M[#\-?^19?_KK_P"R+785Q_PU_P"19?\ ZZ_^R+784 >;>/O^1PM?^O'_ -G-
M8-;WC[_D<+7_ *\?_9S6#7R>;?[S\D<-?XRAK'_'D/\ ?'\C6)6WK'_'D/\
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M_@2]?T1>'^$BKW/P5_R*=K]7_P#0C7AE>Y^"O^13M?J__H1KV3H-ZN)^(?\
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MSJ? S"K'\1?\>3_]>\__ *!6Q6/XB_X\G_Z]Y_\ T"OF\K_WR'S_ "9RX?\
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M )QUW%</\0_^/K2_]R?^<=<>._W:?H9U/@9R%9'B?_D!3?[K?^@FM>LCQ/\
M\@*;_=;_ -!-?+X#_>H>IR4?XD3RZKFD_P#(:L?^OB/_ -"%4ZN:3_R&K'_K
MXC_]"%?HCV/IY;,[>Y_X^Y?]\_SJ*I;G_C[E_P!\_P ZBKSSQSV/X;?\BNW_
M %V_]D6NNKD?AM_R*[?]=O\ V1:ZZ@ HHHH **** ,[Q#_R+.J?]><O_ * :
M\DM/^/.'_KFO\J];\0_\BSJG_7G+_P"@&O)+3_CSA_ZYK_*O#SG^''U.;$;(
MEKFIO]7#_N'_ -"-=+7-3?ZN'_</_H1K+)?^7GR_46'ZD5=]\*_^0M<?]<6_
MFE<#7??"O_D+7'_7%OYI7T)U'J=<?\2O^1?LO^O^/_T%J["N/^)7_(OV7_7_
M !_^@M6=3X)>@GL<145S_P >DW^XW\JEJ*Y_X])O]QOY5\-3^./J>:MSFJ**
M*^]/3/</ ?\ R).G_P"ZW_H1KH:Y[P'_ ,B3I_\ NM_Z$:Z&@#S7Q[_R.5O_
M -> _P#1C5A5N^/?^1RM_P#KP'_HQJPJ^2S7_>?DCAK_ !E.[_X_K3ZO_*L$
M]36]=_\ ']:?5_Y5@GJ:]W+?]TC\_P V=-'X$26__'U%_OC^=>_:'_R+^G_]
M>T?_ *"*\!M_^/J+_?'\Z]^T/_D7]/\ ^O:/_P!!%>@:E^O+O%7_ "-VH_[T
M?_HI*]1KR[Q5_P C=J/^]'_Z*2O+S7_=GZHQK? 9-8NL_P#'VG^Y_4UM5BZS
M_P ?:?[G]37C95_O*]&<]'XS/K9\)?\ (S67_79/_0UK&K9\)?\ (S67_79/
M_0UKZT[CWBL_Q!_R+.I_]><O_H!K0K/\0?\ (LZG_P!><O\ Z : /([3_CSA
M_P!P?RJ6HK3_ (\X?]P?RJ6O@JO\27JSS);LY_4/^/C\6_\ 0C56K6H?\?'X
MM_Z$:JU]S2_AQ]$>E'9'J'PJ_P"/2]^B?S>O0:\^^%7_ !Z7OT3^;UZ#6@S"
M\:?\BC=_[T7_ *-6O-:]*\:?\BC=_P"]%_Z-6O-:^;SGXX>AR8C=$=S_ ,>D
MW^XW\JYFNFN?^/2;_<;^5<S6^3?!/U*P^S"O8OAK_P BRW_7;_V1:\=KV+X:
M_P#(LM_UV_\ 9%KW3I.OKS;Q]_R.5M_UX#_T8U>DUYMX^_Y'*V_Z\!_Z,:N/
M'?[M/T,ZGP,P:JZA_P >X^I_]!:K55=0_P"/<?4_^@M7RV!_WF'J<5/XT<_4
MEO\ \?,7^^/YU'4EO_Q\Q?[X_G7VIZ)]&)_JU^@I:1/]6OT%+0!Y3XI_Y'K5
M/]V'_P!%BLZM'Q3_ ,CUJG^[#_Z+%9U?'YE_O4OE^2."M\;,76?^/M/]S^IK
M/K0UG_C[3_<_J:SZ^CP'^[0]#KI? C9\)_\ (S67_79/_0UKWBO!_"?_ ",U
ME_UV3_T-:]XKM-#/U_\ Y%O4_P#KTE_] ->16G_'E#_N#^5>NZ__ ,BWJ?\
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M7_V2NVKB?B'_ *W3/I+_ .R5R8W_ ':?H9U/@9QU4-8_X\A_OC^1J_5#6/\
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M_C\TO_KG/_..N/'?[M/T,ZGP,Y"LCQ1_R 9O]UO_ $%JUZR/%'_(!F_W6_\
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MHLC_ -U^9ZN7_P -ES2/^0W8_P#7Q'_Z$*[>Y_X^Y?\ ?/\ .N(TC_D-V/\
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MH_&9];/A+_D9K+_KLG_H:UC5L^$O^1FLO^NR?^AK7UIW'O%9_B#_ )%G4_\
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MK8\*?\C+9_\ 75/_ $,5]2=I[S5#7?\ D7=2_P"O27_T U?JAKO_ "+NI?\
M7I+_ .@&@#R&S_X\H?\ <'\JFJ&S_P"/*'_<'\JFKX.M_$EZL\R6[.;O/^/V
M;_?/\ZAJ:\_X_9O]\_SJ&OMZ/\./HCT8[(]*^$OW-2^J?UKT>O./A+]S4OJG
M]:]'K4HY'XD_\B[;?]?L?\FKAJ[GXD_\B[;?]?L?\FKAJ^;SGXX>AR8C=%;4
M?^0?+]!_.L.Y_P"/F3_>-;FH_P#(/E^@_G6'<_\ 'S)_O&NO)_X$O7]$7A_A
M(J]S\%?\BG:_5_\ T(UX97N?@K_D4[7ZO_Z$:]DZ#>KB?B'_ *W3/I+_ .R5
MVU<3\0_];IGTE_\ 9*Y,;_NT_0SJ? SCJH:Q_P >0_WQ_(U?JAK'_'D/]\?R
M-?*8+_>8>IQ4_C1B5)!_Q\1_[X_G4=20?\?$?^^/YU]L>B>^Z!_R+MA_U[I_
M*M"L_0/^1=L/^O=/Y5H4 >.ZA_R,FL?]?LG\ZBJ74/\ D9-8_P"OV3^=15\7
MC_\ >9^IY]7XV9>K]_HO\VK)K6U?O]%_FU9-?3X#_=H>AV4O@1U/P\_Y&NW^
MI_\ 06KVBO%_AY_R-=O]3_Z"U>T5VF@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/\ PJK0_P#GZU#_ +^)
M_P#$5VU% 'F'@"T2P^(FK6<)9H[>*:)2QY(650,^_%:_Q#_X_-+_ .N<_P#.
M.L_P;_R5/7O^WC_T<M:'Q#_X_-+_ .N<_P#..N/'?[M/T,ZGP,Y"LCQ1_P @
M&;_=;_T%JUZR/%'_ " 9O]UO_06KY? ?[U#U.2C_ !(GEU7='_Y#EC_U\Q_^
MA"J57='_ .0Y8_\ 7S'_ .A"OT1['T\MF=M<_P#'U+_OG^=15+<_\?4O^^?Y
MU%7GGCGLGPV_Y%4_]=O_ &1*ZVN2^&W_ "*I_P"NW_LB5UM 'FGCS_D=H?\
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M_P#037EU>H^)_P#D S_[K?\ H)KRZOHLC_W7YL];+_X;+FD?\ARQ_P"OB/\
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M>/\ T8U<>._W:?H9U/@9A5D>(?\ CR?_ *]Y_P#T UKUD>(?^/)_^O>?_P!
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M6=6CXI_Y'K5/]V'_ -%BLZOC\R_WJ7R_)'!6^-F+K/\ Q]I_N?U-9]:&L_\
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M2_[X_D:Q*]?*?]V^;-Z'P$D'_'S%_OC^=>_:%_R+UA_U[I_Z"*\!@_X^8O\
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M]VAZ'92^!'4_#S_D:[?ZG_T%J]HKQ?X>?\C7;_4_^@M7M%=IH%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<3
M_P *JT/_ )^M0_[^)_\ $5VU% 'F'@"T2P^(FK6<)9H[>*:)2QY(650,^_%:
M_P 0_P#C\TO_ *YS_P XZS_!O_)4]>_[>/\ T<M:'Q#_ ./S2_\ KG/_ #CK
MCQW^[3]#.I\#.0K(\4?\@&;_ '6_]!:M>LCQ1_R 9O\ =;_T%J^7P'^]0]3D
MH_Q(GEU7='_Y#EC_ -?,?_H0JE5W1_\ D.6/_7S'_P"A"OT1['T\MF=M<_\
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MC_D S?[K?^@M6O61XH_Y ,W^ZW_H+5\O@/\ >H>IR4?XD3RZKFC_ /(<L?\
MKYC_ /0A5.KFC_\ (<L?^OF/_P!"%?HCV/IY;,[>Y_X^I?\ ?/\ .HJEN?\
MCZE_WS_.HJ\\\<]Q\"_\B3IO^XW_ *&U=!7/^!?^1)TW_<;_ -#:N@H \U\>
M?\CK#_V#U_\ 1C5A5N^//^1UA_[!Z_\ HQJPJ^2S7_>7Z(X:_P 93NO^/^T_
MX'_*O(Z]<NO^/^T_X'_*O(Z^ER;_ '2/S_-GJY?\#_KN7-'_ .0Y8_\ 7S'_
M .A"NWN?^/J7_?/\ZXC1_P#D.6/_ %\Q_P#H0KM[G_CZE_WS_.O0K;HTQ6Z(
MJ]D^&W_(K'_KM_[(E>-U[)\-O^16/_7;_P!D2N<Y#K:\U\>?\CK#_P!@]?\
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M(/\ L'C_ -&-6%6[X]_Y'2#_ +!X_P#1C5A5\EFO^\OT1PU_C,CQ/_R I_\
M=;_T$UY=7J/B?_D!3_[K?^@FO+J^BR/_ '7YL];+_P"&RYI'_(;L?^OB/_T(
M5V]S_P ?4O\ OG^=<1I'_(;L?^OB/_T(5V]S_P ?4O\ OG^=>G6W1>*W1%7N
M/@7_ )$G3O\ <;_T(UX=7N/@7_D2=._W&_\ 0C7.<AT%>:^/?^1T@_[!X_\
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M?!O_ "*=G_P/_P!#:N<Y#<KA_B'_ ,?6E_[D_P#..NXKA_B'_P ?6E_[D_\
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MP2]!/8XBHKG_ (])O]QOY5+45S_QZ3?[C?RKX:G\<?4\U;G-4445]Z>F>X>
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M@&@#R&S_ ./*'_<'\JFJ&S_X\H?]P?RJ:O@ZW\27JSS);LYN\_X_9O\ ?/\
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MIW^XW_H9KH*Y_P "_P#(DZ=_N-_Z&:Z"@#@OB3_R$-#_ .V_\DKE:ZKXD_\
M(0T/_MO_ "2N5KY;./XZ]/U9Q8CXC(\3_P#(!F_W6_\ 037EU>H^)_\ D S?
M[K?^@FO+J][(_P#=?FSU<O\ X;+FC_\ (<L?^OF/_P!"%=O<_P#'U+_OG^=<
M1H__ "'+'_KYC_\ 0A7;W/\ Q]2_[Y_G7IUMT7BMT15['\-O^16/_7;_ -D2
MO'*]C^&W_(K'_KM_[(E<YR'75YKX]_Y'6#_L'C_T8U>E5YKX]_Y'6#_L'C_T
M8U<>._W:?H9U/@9A5F^(/^0-<?\ 7*3_ -%M6E6;X@_Y UQ_URD_]%M7R^ _
MWJ'J<E'^)$\IJYI'_(<L?^OB/_T(53JYI'_(<L?^OB/_ -"%?HCV/IY;,[>Y
M_P"/J7_?/\ZBJ6Y_X^I?]\_SJ*O//'/=?!W_ "*=G_P/_P!#:MRL/P=_R*=G
M_P #_P#0VK<H X?XA_\ 'WI?^Y/_ #CKD*Z_XA_\?>E_[D_\XZY"ODLU_P!Y
M?HCAK_&9'B?_ ) ,_P#NM_Z":\NKU'Q/_P @&?\ W6_]!->75]%D?^Z_-GK9
M?_#9<TC_ )#EC_U\1_\ H0KM[G_CZE_WS_.N(TC_ )#EC_U\1_\ H0KM[G_C
MZE_WS_.O3K;HO%;HBKV/X;?\BLW_ %V_]D2O'*]C^&W_ "*S?]=O_9$KG.0Z
MZO-?'O\ R.D'_8/'_HQJ]*KS7Q[_ ,CI!_V#Q_Z,:N/'?[M/T,ZGP,PJQ_$7
M_'D__7O/_P"@5L5C^(O^/)_^O>?_ - KYO*_]\A\_P F<N'_ (J/+ZV/"G_(
MSVG_  /_ - :L>MCPI_R,]I_P/\ ] :OOY?"SZ2I\#.KN?\ CZE_WS_.HJEN
M?^/J7_?/\ZBK@/)/8_AM_P BLW_7;_V1*ZZN1^&W_(K-_P!=O_9$KKJ /-?'
MO_(Z0?\ 8/'_ *,:L*MWQ[_R.D'_ &#Q_P"C&K"KY+-?]Y?HCAK_ !F1XG_Y
M 4_^ZW_H)KRZO4?$_P#R I_]UO\ T$UY=7T61_[K\V>ME_\ #9<TC_D-V/\
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M'Q/_ ,@*?_=;_P!!->75]%D?^Z_,]7+_ .&RYI'_ "&['_KXC_\ 0A7;W/\
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M_P 2)Y=5W1_^0Y8_]?,?_H0JE5W1_P#D.6/_ %\Q_P#H0K]$>Q]/+9G;7/\
MQ]2_[Y_G452W/_'U+_OG^=15YYXY[)\-O^15/_7;_P!D2NMKDOAM_P BJ?\
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MH?\ VW_DE<K7RV<?QUZ?JSBQ'Q&1XG_Y ,W^ZW_H)KRZO4?$_P#R 9O]UO\
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M]_Y'2#_L'C_T8U85;OCW_D=(/^P>/_1C5A5\EFO^\OT1PU_C,CQ/_P @*?\
MW6_]!->75ZCXG_Y 4_\ NM_Z":\NKZ+(_P#=?FSULO\ X;+FD?\ (;L?^OB/
M_P!"%=O<_P#'U+_OG^=<1I'_ "&['_KXC_\ 0A7;W/\ Q]2_[Y_G7IUMT7BM
MT15[CX%_Y$G3O]QO_0C7AU>X^!?^1)T[_<;_ -"-<YR'05YKX]_Y'2#_ +!X
M_P#1C5Z57FOCW_D=(/\ L'C_ -&-7'CO]VGZ&=3X&859'B'_ (\G_P"O>?\
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M?]XU%4MS_P ?4O\ O&HJ^Y/2/8?AK_R++_\ 77_V1:["N/\ AK_R++_]=?\
MV1:["@#S;Q]_R.-M_P!>/_L[5@UO>/O^1QMO^O'_ -G:L&OD\U_WGY(X:_QE
M#6/^/)?]\?R-8E;>L?\ 'DO^^/Y&L2O7RG_=OFS>A\!)!_Q\Q?[X_G7OVA?\
MB]8?]>Z?^@BO 8/^/F+_ 'Q_.O?M"_Y%ZP_Z]T_]!%>J;E^BBB@ HHHH *PO
M&G_(HWGUC_\ 1BUNUA>-/^11O/K'_P"C%J*GP/T$]CS6H[G_ (]9?]P_RJ2H
M[G_CUE_W#_*OA*?QKU/-6YS-%%%??'IGL/PU_P"19?\ ZZ_^R+785Q_PU_Y%
ME_\ KK_[(M=A0!YMX^_Y'"U_Z\?_ &<U@UO>/O\ D<+7_KQ_]G-8-?)YM_O/
MR1PU_C*&L?\ 'D/]\?R-8E;>L?\ 'D/]\?R-8E>OE/\ NWS9O0^ D@_X^8O]
M\?SKZ+C_ -4G^Z*^=(/^/F+_ 'Q_.OHN/_5)_NBO5-QU>.W_ /R,6L?]?TO\
MZ]BKQV__ .1BUC_K^E_G7EYK_NS]48UO@(JQ=2_U]Q_O)_(UM5BZE_K[C_>3
M^1KRLG_WA^GZHPH?$9];'A3_ )&6S_ZZI_Z&*QZV/"G_ ",MG_UU3_T,5]2=
MI[S5#7?^1=U+_KTE_P#0#5^J&N_\B[J7_7I+_P"@&@#R&S_X\H?]P?RJ:H;/
M_CRA_P!P?RJ:O@ZW\27JSS);LYN\_P"/V;_?/\ZAJ:\_X_9O]\_SJ&OMZ/\
M#CZ(]&.R/2OA+]S4OJG]:]'KSCX2_<U+ZI_6O1ZU*.1^)/\ R+MM_P!?L?\
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M859'BC_D S?[K?\ H+5KUD>*/^0#-_NM_P"@M7R^ _WJ'J<E'^)$\NJYH_\
MR'+'_KYC_P#0A5.KFC_\ARQ_Z^8__0A7Z(]CZ>6S.WN?^/J7_?/\ZBJ6Y_X^
MI?\ ?/\ .HJ\\\<]Q\"_\B3IW^XW_H9KH*Y_P+_R).G?[C?^AFN@H X+XD_\
MA#0_^V_\DKE:ZKXD_P#(0T/_ +;_ ,DKE:^6SC^.O3]6<6(^(R/$_P#R 9O]
MUO\ T$UY=7J/B?\ Y ,W^ZW_ *":\NKWLC_W7YL]7+_X;+FC_P#(<L?^OF/_
M -"%=O<_\?4O^^?YUQ&C_P#(<L?^OF/_ -"%=O<_\?4O^^?YUZ=;=%XK=$5>
MQ_#;_D5C_P!=O_9$KQRO8_AM_P BL?\ KM_[(E<YR'75YKX]_P"1U@_[!X_]
M&-7I5>:^/?\ D=8/^P>/_1C5QX[_ ':?H9U/@9A5F^(/^0-<?]<I/_1;5I5F
M^(/^0-<?]<I/_1;5\O@/]ZAZG)1_B1/*:N:1_P ARQ_Z^(__ $(53JYI'_(<
ML?\ KXC_ /0A7Z(]CZ>6S.WN?^/J7_?/\ZBJ6Y_X^I?]\_SJ*O//'/=?!W_(
MIV?_  /_ -#:MRL/P=_R*=G_ ,#_ /0VK<H X?XA_P#'WI?^Y/\ SCKD*Z_X
MA_\ 'WI?^Y/_ #CKD*^2S7_>7Z(X:_QF1XG_ .0#/_NM_P"@FO+J]1\3_P#(
M!G_W6_\ 037EU?19'_NOS9ZV7_PV7-(_Y#EC_P!?$?\ Z$*[>Y_X^I?]\_SK
MB-(_Y#EC_P!?$?\ Z$*[>Y_X^I?]\_SKTZVZ+Q6Z(J]C^&W_ "*S?]=O_9$K
MQRO8_AM_R*S?]=O_ &1*YSD.NKS7Q[_R.D'_ &#Q_P"C&KTJO-?'O_(Z0?\
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M?[K?^@FM>LCQ/_R IO\ =;_T$U\O@/\ >H>IR4?XD3RZKFD_\AJQ_P"OB/\
M]"%4ZN:3_P AJQ_Z^(__ $(5^B/8^GELSM[G_C[E_P!\_P ZBJ6Y_P"/N7_?
M/\ZBKSSQSV/X;?\ (KM_UV_]D6NNKD?AM_R*[?\ 7;_V1:ZZ@ HHHH ****
M,[Q#_P BSJG_ %YR_P#H!KR2T_X\X?\ KFO\J];\0_\ (LZI_P!><O\ Z :\
MDM/^/.'_ *YK_*O#SG^''U.;$;(EKFIO]7#_ +A_]"-=+7-3?ZN'_</_ *$:
MRR7_ )>?+]18?J15WWPK_P"0M<?]<6_FE<#7??"O_D+7'_7%OYI7T)U'J=<?
M\2O^1?LO^O\ C_\ 06KL*X_XE?\ (OV7_7_'_P"@M6=3X)>@GL<145S_ ,>D
MW^XW\JEJ*Y_X])O]QOY5\-3^./J>:MSFJ***^]/3/</ ?_(DZ?\ [K?^A&NA
MKGO ?_(DZ?\ [K?^A&NAH \U\>_\CE;_ /7@/_1C5A5N^/?^1RM_^O ?^C&K
M"KY+-?\ >?DCAK_&4[O_ (_K3ZO_ "K!/4UO7?\ Q_6GU?\ E6">IKW<M_W2
M/S_-G31^!$EO_P ?47^^/YU[]H?_ "+^G_\ 7M'_ .@BO ;?_CZB_P!\?SKW
M[0_^1?T__KVC_P#017H&I?KR[Q5_R-VH_P"]'_Z*2O4:\N\5?\C=J/\ O1_^
MBDKR\U_W9^J,:WP&36+K/_'VG^Y_4UM5BZS_ ,?:?[G]37C95_O*]&<]'XS/
MK9\)?\C-9?\ 79/_ $-:QJV?"7_(S67_ %V3_P!#6OK3N/>*S_$'_(LZG_UY
MR_\ H!K0K/\ $'_(LZG_ -><O_H!H \CM/\ CSA_W!_*I:BM/^/.'_<'\JEK
MX*K_ !)>K/,ENSG]0_X^/Q;_ -"-5:M:A_Q\?BW_ *$:JU]S2_AQ]$>E'9'J
M'PJ_X]+WZ)_-Z]!KS[X5?\>E[]$_F]>@UH,PO&G_ "*-W_O1?^C5KS6O2O&G
M_(HW?^]%_P"C5KS6OF\Y^.'H<F(W1'<_\>DW^XW\JYFNFN?^/2;_ '&_E7,U
MODWP3]2L/LPKV+X:_P#(LM_UV_\ 9%KQVO8OAK_R++?]=O\ V1:]TZ3KZ\V\
M??\ (Y6W_7@/_1C5Z37FWC[_ )'*V_Z\!_Z,:N/'?[M/T,ZGP,P:JZA_Q[CZ
MG_T%JM55U#_CW'U/_H+5\M@?]YAZG%3^-'/U);_\?,7^^/YU'4EO_P ?,7^^
M/YU]J>B?1B?ZM?H*6D3_ %:_04M 'E/BG_D>M4_W8?\ T6*SJT?%/_(]:I_N
MP_\ HL5G5\?F7^]2^7Y(X*WQLQ=9_P"/M/\ <_J:SZT-9_X^T_W/ZFL^OH\!
M_NT/0ZZ7P(V?"?\ R,UE_P!=D_\ 0UKWBO!_"?\ R,UE_P!=D_\ 0UKWBNTT
M,_7_ /D6]3_Z])?_ $ UY%:?\>4/^X/Y5Z[K_P#R+>I_]>DO_H!KR*T_X\H?
M]P?RKP\Y_AQ]3FQ&R)JYN[_X_9O]\_SKI*YN[_X_9O\ ?/\ .N;)OXDO0C#[
MLAKTOX2_ZK4_]Z/^M>:5Z7\)?]5J?^]'_6OI3L/1JY#XE?\ (O6G_7]'_)JZ
M^N0^)7_(O6G_ %_1_P FK.I\#]!/8X>JNI?\@^7Z#^8JU574O^0?+]!_,5\5
MAOX\/5?F>=#XD8ES_P ?4O\ O&HJEN?^/J7_ 'C45?<GI'L/PU_Y%E_^NO\
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M;'A3_D9;/_KJG_H8KZD[3WFJ&N_\B[J7_7I+_P"@&K]4-=_Y%W4O^O27_P!
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MB_P\_P"1KM_J?_06KVBNTT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2?\ HMJ\JKU7Q!_R!;C_ *Y2?^BVKRJOHLC_ -U^;/6R_P#ALV?"?_(T6G_
M_P#T!JZ[4/\ C_D_#^0KD?"?_(T6G_ __0&KKM0_X_Y/P_D*]*MN/$_&O0K5
M[)\-O^16/_7;_P!D2O&Z]D^&W_(K'_KM_P"R)6!S'6UP_P 0_P#C\TO_ *YS
M_P XZ[BN'^(?_'YI?_7.?^<=<>._W:?H9U/@9R%9'BC_ ) ,W^ZW_H+5KUD>
M*/\ D S?[K?^@M7R^ _WJ'J<E'^)$\NJYH__ "'+'_KYC_\ 0A5.KFC_ /(<
ML?\ KYC_ /0A7Z(]CZ>6S.WN?^/J7_?/\ZBJ6Y_X^I?]\_SJ*O//'/<? O\
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M-'_Y#EC_ -?,?_H0KM[G_CZE_P!\_P ZXC1_^0Y8_P#7S'_Z$*[>Y_X^I?\
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MQ_.O?M#_ .1?T_\ Z]H__017@-O_ ,?47^^/YU[]H?\ R+^G_P#7M'_Z"*]
MU+]>7>*O^1NU'_>C_P#125ZC7EWBK_D;M1_WH_\ T4E>7FO^[/U1C6^ R:Q=
M9_X^T_W/ZFMJL76?^/M/]S^IKQLJ_P!Y7HSGH_&9];/A+_D9K+_KLG_H:UC5
ML^$O^1FLO^NR?^AK7UIW'O%9_B#_ )%G4_\ KSE_] -:%9_B#_D6=3_Z\Y?_
M $ T >1VG_'G#_N#^52U%:?\></^X/Y5+7P57^)+U9YDMV<_J'_'Q^+?^A&J
MM6M0_P"/C\6_]"-5:^YI?PX^B/2CLCU#X5?\>E[]$_F]>@UY]\*O^/2]^B?S
M>O0:T&87C3_D4;O_ 'HO_1JUYK7I7C3_ )%&[_WHO_1JUYK7S><_'#T.3$;H
MCN?^/2;_ '&_E7,UTUS_ ,>DW^XW\JYFM\F^"?J5A]F%>Q?#7_D66_Z[?^R+
M7CM>Q?#7_D66_P"NW_LBU[ITG7UYMX^_Y'*V_P"O ?\ HQJ])KS;Q]_R.5M_
MUX#_ -&-7'CO]VGZ&=3X&8-5=0_X]Q]3_P"@M5JJNH?\>X^I_P#06KY; _[S
M#U.*G\:.?J2W_P"/F+_?'\ZCJ2W_ ./F+_?'\Z^U/1/HQ/\ 5K]!2TB?ZM?H
M*6@#RGQ3_P CUJG^[#_Z+%9U:/BG_D>M4_W8?_18K.KX_,O]ZE\OR1P5OC9B
MZS_Q]I_N?U-9]:&L_P#'VG^Y_4UGU]'@/]VAZ'72^!&SX3_Y&:R_Z[)_Z&M>
M\5X/X3_Y&:R_Z[)_Z&M>\5VFAGZ__P BWJ?_ %Z2_P#H!KR*T_X\H?\ <'\J
M]=U__D6]3_Z])?\ T UY%:?\>4/^X/Y5X><_PX^IS8C9$U<W=_\ '[-_OG^=
M=)7-W?\ Q^S?[Y_G7-DW\27H1A]V0UZ7\)?]5J?^]'_6O-*]+^$O^JU/_>C_
M *U]*=AZ-7(?$K_D7K3_ *_H_P"35U]<A\2O^1>M/^OZ/^35G4^!^@GL</57
M4O\ D'R_0?S%6JJZE_R#Y?H/YBOBL-_'AZK\SSH?$C$N?^/J7_>-15+<_P#'
MU+_O&HJ^Y/2/8?AK_P BR_\ UU_]D6NPKC_AK_R++_\ 77_V1:["@#S;Q]_R
M.-M_UX_^SM6#6]X^_P"1QMO^O'_V=JP:^3S7_>?DCAK_ !E#6/\ CR7_ 'Q_
M(UB5MZQ_QY+_ +X_D:Q*]?*?]V^;-Z'P$D'_ !\Q?[X_G7OVA?\ (O6'_7NG
M_H(KP&#_ (^8O]\?SKW[0O\ D7K#_KW3_P!!%>J;E^BBB@ HHHH *PO&G_(H
MWGUC_P#1BUNUA>-/^11O/K'_ .C%J*GP/T$]CS6H[G_CUE_W#_*I*CN?^/67
M_</\J^$I_&O4\U;G,T445]\>F>P_#7_D67_ZZ_\ LBUV%<?\-?\ D67_ .NO
M_LBUV% 'FWC[_D<+7_KQ_P#9S6#6]X^_Y'"U_P"O'_V<U@U\GFW^\_)'#7^,
MH:Q_QY#_ 'Q_(UB5MZQ_QY#_ 'Q_(UB5Z^4_[M\V;T/@)(/^/F+_ 'Q_.OHN
M/_5)_NBOG2#_ (^8O]\?SKZ+C_U2?[HKU3<=7CM__P C%K'_ %_2_P Z]BKQ
MV_\ ^1BUC_K^E_G7EYK_ +L_5&-;X"*L74O]?<?[R?R-;58NI?Z^X_WD_D:\
MK)_]X?I^J,*'Q&?6QX4_Y&6S_P"NJ?\ H8K'K8\*?\C+9_\ 75/_ $,5]2=I
M[S5#7?\ D7=2_P"O27_T U?JAKO_ "+NI?\ 7I+_ .@&@#R&S_X\H?\ <'\J
MFJ&S_P"/*'_<'\JFKX.M_$EZL\R6[.;O/^/V;_?/\ZAJ:\_X_9O]\_SJ&OMZ
M/\./HCT8[(]*^$OW-2^J?UKT>O./A+]S4OJG]:]'K4HY'XD_\B[;?]?L?\FK
MAJ[GXD_\B[;?]?L?\FKAJ^;SGXX>AR8C=%;4?^0?+]!_.L.Y_P"/F3_>-;FH
M_P#(/E^@_G6'<_\ 'S)_O&NO)_X$O7]$7A_A(J]S\%?\BG:_5_\ T(UX97N?
M@K_D4[7ZO_Z$:]DZ#>KB?B'_ *W3/I+_ .R5VU<3\0_];IGTE_\ 9*Y,;_NT
M_0SJ? SCJH:Q_P >0_WQ_(U?JAK'_'D/]\?R-?*8+_>8>IQ4_C1B5)!_Q\1_
M[X_G4=20?\?$?^^/YU]L>B>^Z!_R+MA_U[I_*M"L_0/^1=L/^O=/Y5H4 >.Z
MA_R,FL?]?LG\ZBJ74/\ D9-8_P"OV3^=15\7C_\ >9^IY]7XV9>K]_HO\VK)
MK6U?O]%_FU9-?3X#_=H>AV4O@1U/P\_Y&NW^I_\ 06KVBO%_AY_R-=O]3_Z"
MU>T5VF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-\0?\@:X_P"N4G_HMJ^7P'^]0]3DH_Q(GE-7-(_Y#EC_ -?$?_H0JG5S2/\
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M(E==7(_#;_D5F_Z[?^R)774 >:^/?^1T@_[!X_\ 1C5A5N^/?^1T@_[!X_\
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M]2_[Y_G452W/_'U+_OG^=15YYXY['\-O^17;_KM_[(M==7(_#;_D5V_Z[?\
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M_D9K+_KLG_H:U]:=Q[Q6?X@_Y%G4_P#KSE_] -:%9_B#_D6=3_Z\Y?\ T T
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M /1BUNUA>-/^11O/K'_Z,6HJ? _03V/-:CN?^/67_</\JDJ.Y_X]9?\ </\
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M\.WK6W10!YOJ-G;:?\5M&MK*!((4B3:B# 'WZ](KS[7/^2P:3_UR3_V>O0:
M..\17VO^'=9.K1M]NT=@%EM@N#"/7\\G/O@]JKZEXXDU<Q:;X.C>:\N%RTS+
M@0#OU[CN>@]ZG\2WVM:OJS^'=%MI+:,J#<WLBD+L(_A/IV]2<CL:SI_"NI>#
M'35?#,TEVJ(!=VSC_6 =2 .WMU'O0!W&E6]U:Z7!#J%S]JN47$DVW&X_Y[]Z
MS-5\(6&M:W'J&IM+,L<81+?=A.I.3W[^W2M/2K_^T]+@O#;RVYF7=Y4HPRU;
MH \[TB&.W^,5[%!&L4:0[51%P%&Q. *ZGQE,T'@W4V3@F I^#$ _H:YG3?\
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MRI/HLR0NLCE6PJ')/RGL*]=_X5]X8_Z!G_DQ+_\ %4?\*^\,?] S_P F)?\
MXJO-H97"C4512>AE"BHR4KGRY]@O/^?2?_OV:MZ59W,>L6;R6\JHLZ%F9" !
MN'->Q?$7P]I>A?V=_95MY'G>;YG[QFW8V8^\3ZFNV_X5]X8_Z!G_ ),2_P#Q
M5>][9]CT7B6U:QXM<$-<RD'(+G!'UJ.O;?\ A7WAC_H&?^3$O_Q5'_"OO#'_
M $#/_)B7_P"*K Y2KX,UO2K7P?80W.IV<,J(VZ.2X167YCU!-;G_  D>A_\
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MZJ<;%[$UU'_"1Z'_ -!G3_\ P*3_ !K-_P"%?>&/^@9_Y,2__%4?\*^\,?\
M0,_\F)?_ (J@#D/&NHV5WXMAFM;RWFB%B%+QRJR@[V.,@]:QOM5O_P ]XO\
MOL5Z1_PK[PQ_T#/_ "8E_P#BJ/\ A7WAC_H&?^3$O_Q5>7B<NAB*GM'*QC.D
MIN]SR/Q%+'/HLR0NLCE3A4.2?E/:O./L%Y_SZ3_]^S7U'_PK[PQ_T#/_ "8E
M_P#BJY;Q9X6T?3-<\/V]C9^5%>77ESKYKG>NY!CD\?>/2N_!TUA*?LXZG30G
M[&/*CP_2[.YCUBS>2VF55G0LS1D #<.:["X(:ZE*G(+G!'UKVG_A7WAC_H&?
M^3$O_P 51_PK[PQ_T#/_ "8E_P#BJZ)S<RJE1U'=GB5>S>$]<TFV\,VL5QJE
ME%(N_*/<(I'SGL34_P#PK[PQ_P! S_R8E_\ BJ/^%?>&/^@9_P"3$O\ \54&
M1I?\)'H?_09T_P#\"D_QKCO'>K:=>7&FFTO[6<(LVXQ3*VW)3&<'CH?RK?\
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M/_)B7_XJNXU-+_A(]#_Z#.G_ /@4G^-<K\0=8TV]T.TCL]1M+AUO8V*Q3JQ
MVMS@'I6Q_P *^\,?] S_ ,F)?_BJ/^%?>&/^@9_Y,2__ !53)<T6@>J/-_M5
MO_SWB_[[%1W%S UK*%FC)*$ !QSQ7IG_  K[PQ_T#/\ R8E_^*KE_'_A;1M$
M\/Q7.F6?D3-<JA;S7;Y2K'&"3Z"O&CE%.,D^9G.J"3W/.J*]>T/P/X=O/#^G
MW-SI^^::VC=V\^098J"3@-5__A7WAC_H&?\ DQ+_ /%5[9T%3P7K>E6OA"QA
MNM3LX955MT<EPBL/F/4$UN_\)'H?_09T_P#\"D_QK-_X5]X8_P"@9_Y,2_\
MQ5'_  K[PQ_T#/\ R8E_^*H Y'QMJ-E=^+()K6\MYHA9!2\<JLH.]CC(/6L7
M[5;_ //>+_OL5Z1_PK[PQ_T#/_)B7_XJC_A7WAC_ *!G_DQ+_P#%5YF)RZ&(
MJ>T<K&,Z2F[W/+;J>%KRV*RH0I;)##CBL0]:]$\6>%M'TS6M @L;/RHKRZ\N
M=?-<[UW(,<GC[QZ5U/\ PK[PQ_T#/_)B7_XJNS#T50I*FG>QI"/*K'BT! N(
MR3@!QDGZU[=HWB#1HM#L8Y=6L4=;= RM<H"#M'!&:B_X5]X8_P"@9_Y,2_\
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M .%?>&/^@9_Y,2__ !5'_"OO#'_0,_\ )B7_ .*KM-#2_P"$CT/_ *#.G_\
M@4G^->?^-M1L;OQ7;S6MY;S1"R"EXY590=['&0>M==_PK[PQ_P! S_R8E_\
MBJ/^%?>&/^@9_P"3$O\ \565:FJM-TWU)DN96/-_M5O_ ,]XO^^Q5:^N(7A
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M/4!?WMO;;RFWSI53=UZ9-=7_ ,*^\,?] S_R8E_^*H_X5]X8_P"@9_Y,2_\
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MG_DQ+_\ %5[9T&/\/M8TVR\//'>:C:6\GFYVRSJIQM7L375?\)'H?_09T_\
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M4J007."._-15Z%\/O#&D:YHMS/JEIY\B7!16\UUP-JG'RD>M=7_PK[PQ_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .6U+PS>7GCRQUN*6 6UNBJZ,QWG&[H,8[CO74T44 %%%% !111
M0!RUIX9O(/B#=:Z\L!M9D*J@8[Q\JCD8QV]:ZGKUHHH \_U+X<W<&HR7?A?4
MOL7F$GRR[)LR>@9><>V*FT/X>S1:K'J7B*_^W3QL&5 Q<$CH69N3CTQ7=44
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M_BYTTC_MM_[)7I Z"L3Q%X5L?$WV;[?+<1_9]VSR649W8SG(/]T5MT %%%%
M!1110 4444 %>;_%SII'_;;_ -DKTBL3Q%X5L?$WV?[?+<1_9]VSR649W8SG
M(/\ =% &V.@HHHH **** "BBB@ HHHH \W^+GW=(^LW_ +)7HX^Z/I6+XB\*
MV/B;[/\ ;Y;B/[/NV>2RC.[&<Y!_NBML<4 %%%% !1110 4444 %>;_%S[ND
M?6;_ -DKTBL3Q%X5L?$WV?[?+<1_9]VSR649W8SG(/\ =% &T/NCZ4M XHH
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MP2>-HV*]0&&#C\ZH>'_#UIX;L9+6QDFD223S"9F!.< =@/2@#5HHHH ****
M"N+^*7_(IQ?]?:?^@M7:5F:_H-KXCT];.]DFCC602 PL <@$=P?6@!/#'_(I
MZ5_UZ1_^@BM2J]A9QZ?I]O9PEFCMXUC4N<D@#'-6* "BBB@ HHHH \W\<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ=MJ
MUC=W]Q96]PKW-L<2Q="O^(YZB@"Y1110 4444 %%%% !1110 45AZAXST#3+
MHV]UJ">:IPRQJS[?KM!Q].M:MG>VVH6JW%E.D\+_ '70Y!H GHHHH **** "
MBBB@ HHK)7Q+II\12:*TQ2[15.'&%8D9V@]S@@_C]: -:BBB@ HHHH ****
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MJC/'4T 244BLKJ&1@RGD$'(-+0 4444 %%%% !144UW;V\D<=Q/%$\IQ&KN
M7/H,]:EH **** "BBB@ HHKE_$_BPZ?.NE:-']KU>;"I&HR(\]S[]\?B>* .
MHHJGI*7T>E0+JTL<MX%_>O&N 3_G_(JY0 4444 %%%% !17+:I\0=(TZ\:UB
M6>]E3._[,H95_$D9_"M70O$6G^(K5IM/D;*$"2-QAD/N/ZB@#4HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP.?^ _A4EUX$/_"90:A9/&E@THN+BW8G&]>F!T.<GZ<_2NT#!L[2#@X.#TH
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MO]*NY5.UO9?Z>OTZ];61X7ETF708/[!"K; 8*C[RMWW?[5:] !1110 4444
M%%%% !15:WBO$NYWN;J.6!S^ZB6':8QZ%MQW?D*LT %<+X?$.K^/M:GU8+)=
M6C^7;12#(1 2,@'\.??WKNJK1Z?:17TM[';1K<S !Y0OS,![T <K\2=,@D\/
M_P!I(HCN[212DJ\-@G&,_4@_A75:;.USI5K/)]Z2%7/U(S7._$F7R_!LR_\
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M<KIL]QX1\7'2+W4S/IDL!F1[F09BYQU/3H1COQ79V>HV6HQL]A=PW*J<,8I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;^\#ZT -UG1+'Q!8?9K^/<G5)$.&0^JFL"+X=VN$BO-5U&ZM$/%L\V$/M_\
MJQ6AX3TK5M%MIK'4KN.YM8F M& .[;[^@]!SCZ8KH* (X((K6W2"WC6.*-0J
M(HP%%2444 %%%% !6#<>'Y;GQO;:S+*C6]O;-&D7.5<Y'T((9OTK>HH X75_
M#]YX8U!]=\**/*QFZL>=K#N0/3V[=N.*Z;0/$%EXAL!<63X9<"6)OO1GT/\
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MN>X/8U+10!R$/P^AW)'?ZOJ%[9QG*6LDIV?C_P#6Q76QQI#$L<2*B( JJHP
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M9JTT_AWQ3>SV,D<-]+:8W,4SC/\ =8?T-<1H=]JVO:':^'=#5K6*)3]LNV[
MD\#\/Q/L*]%T30[/0-/6UL4P.KR-]Z1O4F@!VG:'IFD;O[-LHK<MU95^8_B>
M:OT44 %<WHOAZ\TGQ5JEXLT9L+P[PAR7W9S] !D_7BNDHH YGXA$#P7=Y[E
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 CHLB%74,I&"",@TM%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "(BQH%10JJ,  8 I:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *",C!Y%%% %>RL+73K?R+&!((LEMJ#')[U8
MHHH **** "BBB@"*ZM8;VUDMKJ,2PR+M=&Z$4L$$5M D-O&L<48"JBC 4>E2
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-:ESHPM/#]KJ4UP1)=,1';F/!VC/S9STZ=NXHBIR3:Z N9WL4?MEU_S\S?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6U5FCW:BRF/S3)M&23)QC(;WX7'%)NVGF)R44XO:_>RV,7Q!IMGJOPV;7IM
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MW_D:-+_Z^XO_ $,5[M4S'$****@H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7)GBZ+BTF2?%7_CUTW_?D_DM>;U[7XG\,1^)8[=);EK?R"Q!50V<X_PKGO\
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M  VM[#4K:\7497-O*LH4Q 9VG..OM7;5$FF4E8****D84444 %%%% !1110
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M"<GDTP)J***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPJ%;ZC&#5E$6-%1%"JHPJ@8 'I2N!P/AR1_$4>CV+AS:Z4GF7))^5Y <1I^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBH;NX%I93W+C*PQM(0.X S0!3BU<7.ORZ=:Q>8MO&&N)]V!&QZ(!CDXYZ\5#
M!XHTVZUM-+LY&N)75CYD8!C7'4;L\_AFH/"-JQ\,+->9>;46>YG)XW%_3'0;
M<5#ID"'QWJ'V>*.&#3[.*V2.-=H&\^9P.G^13T$:MSJIMM>LM.>$;;R.1DEW
M]&09*[<>AZYK0KG-5D63QYH,"_?ACN)6X[,FT?J#71T#"F32B""25@2(U+$#
MJ<#-/HI 5-+U&'5M,AOK8.L4PRH< $<XYP3Z5'INKV^JR70M%D*6TOE&4@;'
M;OM(/.*Y+3-1GT_P6^F61_XF!O9;&V3."K%LD^HVAB<]CBM'7;N+PCX3MM.L
MY_+GE_<Q2$X()Y>0]>YS]2*JPKFKIOB2PU;5;S3[0N9K0X8LORO@X)4YY /T
MZ\58CU:"37)M*V2I<10B;+* KH3C*G/.#Q7)Z)=:9#XQTVVT6X2X@_LYK9F4
M$<JQ?)'J3D_B:9XZN_(UFWN--DE2[M(2+J:%<^5$YVC)SPW)('7G/I1;4+G7
M6&L6^I7EU!9I*Z6K;'N,#RV?NH.<DCOQ_2I=0U"'3;7SYQ(X+!%2)"[.QZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^HW%G=VEV;2[LV<Q2>6)%PPPP*DC/%:M%(#$TCPZVG:Q<ZE<WTEY<7$81F9
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M)KB[B$;OQP@&<GI^&?S@G1]1UFTN]*TG4M-U(SK]JF>/;'L&0V23M?CICK3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA6E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img70551829_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $] L\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDLL<,9>1U1!
MU9C@4 /HJ.*6.=-\4B2(>ZG(J2@ HI#3))8XD+RNJ*.I8X% $E%1QRI*@>-U
M=3T93D&I* "BBDH 6BHI;B"%E669$9C\H9@,_2I* %HHHH **** "BBB@ HH
MIDLB0QM)(ZH@ZLQP!0 ^BF(Z2QJ\;*Z,,AE.0:?0 44'I2=* %HJ*6X@A91+
M,B%CA0S 9^E2"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!*\>^,&KRZOK&D^![&X\I[N027;[@ L>>.?SKV!L[3M^]CCZUY%IWPA
M?6_$NK:UXU"W#W4F;>*&4@1C/J* *WPEU:7P_P"(]1\#WUQYHB)DM&!#!AWY
M_.M;5/'?B/6O&MSX9\'P6>ZS3?/=7)RO;@#UJAK7P=.EZSIFJ^"E6VFMI TR
MRS'YQZ9-6KWP5XIT/QE/XI\*BQDEOH@MU97#;55N,D'ZT 6YM;\>2^"]9CO-
M*AL]4M$;%SG]U*F.63WQFN"\+ZIK ^#6J7NJ107ECYA,7F'+NV[G=^.:].T3
MP]XKFT;63XDU6.:ZU&%TBMHA^ZM\@@8/>N1T;X>^+H/A]J7A2[2R6)G+6TJR
M9+9.>?3O0 B>.]1\*>"O"^KV]C -%G?R[R-!\T><8V_K73:_X[OD\<Z3X;T1
M(9/M$0N+J9OF$4?)(/H<"K%CX#:;X6CPIJC1^<82GF*,A&[,/I69\+OAM=^$
MWU&]UN5;B_N?W08/N'E#I^/6@#(N?B=XAUO6]2MO#C:7:VNG$J[WT@!F(_NY
MKL_AWXZC\;:3-(\(@OK1_+N8U.5!]0?0X-<)=?"S7M$UW4;G0['1]4M;]BP%
M^!NMR3VSUKT/P)X8NO#6CM'J$MK)>S'=(;:$1H/0<=: .5^*FI167B;PQ')8
MPW!EN  \G5.>HHU?Q[XE'Q#D\*:+:6;N80\;SG 7@<FM/X@^"]2\3Z[H-Y8O
M$L5A,))=[8)&>U1Q>!]33XNMXI9XOL)M_+V[OFS@=OPH YK0_B+X[UO5;_PS
M;V.G'5[5CNNF.(@!VQ[U8TOXKZO<_#WQ'J5S;0+JVC2",[1\C_, 3^M;/@[P
M'JN@^/=9UNZ>$VMZQ,81LGGUK!LOA9KMMX2\7Z8TEN9]6F\RWP_&-X//ITH
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M-'L</_S\_#_@A[*A_P _/P/1-P]11N'J*\[_ .%4V_\ T%[W_OLT?\*IM_\
MH+WO_?9H]CA_^?GX?\$/94/^?GX'HFX>HHW#U%>=_P#"J;?_ *"][_WV:/\
MA5-O_P!!>]_[[-'L</\ \_/P_P""'LJ'_/S\#T3</44;AZBO._\ A5-O_P!!
M>]_[[-'_  JFW_Z"][_WV:/8X?\ Y^?A_P $/94/^?GX'HFX>HHW#U%>=_\
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MW_OLT>QP_P#S\_#_ ((>RH?\_/P/1-P]11N'J*\[_P"%4V__ $%[W_OLT?\
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M'7MN=B2?>NMU;P-=ZAXPT;5([F!+"*.)=2A);=.T!+P;1C!PY.<XX ZTR\\
MW6HCQ8DM[';G5;R"[LIHLLT#Q*FTLI 'WDZ GCTH E7Q!XIT/5M)A\36VE26
M6J7 M$ETX2!K>9E)56#D[P<$;ACZ56L_$WC+Q!:7.M>']/TA])CFDCMK:Y=Q
M<7:QN49@X(2/)4X!!]SWJR/#_BG7-6TF;Q-<Z3%9:7<"[2+3O,9KF95(5F+@
M; ,D[1GTS52/PEXMTG3;SP]H6IZ=!HL\LK0W4GF"[M$E8LZH%^5B"S;6R",T
M 8VI>+HO#7Q/UP&#S=5U&SL+>QLFD"^9,3)PS= H)&3^6<BO4-+&HC38/[6>
MV>_VYF-JC+'N]%#$G Z9)Y]NE<?=?#Q-4UC77U&1);+4-.MK2&7<6N(WBW'S
M"2.N=K Y.2.:Z?P[#K%OH-K!KTMO/J,2[)9K<DK+C@-R!@D8)'3.<4 :E%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW^'\[P6D$;"1?F2, ]?:O3:\Z^-?_)/+C_KHO\Z[,NG)XNGKU1$_A9T7@/\
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M*21NI(964]""*X+6)_$%GXCFTNZ?Q/'HT%M FGMH5FC_ &@A!YGFR%6*-NX
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MD8K=-&*J$Y4Y*4=&@:N>5+\$;-$")XAU-5'15. /UIW_  I2U_Z&/5/^^O\
MZ]>J4<UWO-L8]74_(CV<>QY7_P *4M?^ACU3_OK_ .O2'X*VH!_XJ/5.G][_
M .O7JO--?[I^E"S7&?S_ )?Y![./8\-^#?GP>/-=LGNYYXX(=JF1R>C=:]SK
MP[X2?\E-\2_[G_L]>XUMG;OB[^2_(5/X1:***\@T"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]S_V>O<:\.^$?_)3?$O^Y_[/7N->MG7^]?*/Y&=/X1:***\DT"BBB@ HHHH
M**2B@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YGQ/
M9>+;JY@;PYJEI9PJA$JSJ"6;/!&4;M6%_9'Q1_Z&/2_^_:__ !FL957%VY6_
MZ]3T:. C5@INM"-^C;O_ .DL]#JCK6KVN@Z+>:M>EA;6D32R;!EB .@'J>E<
MGIVE_$6+4K5]0U[3I;-95,\:1@,R9Y _=#G'N*W/&EUI=GX/U*76[6:YTPQB
M.YCA7+;&8*3U' SDG/ &>U7"?,MFO4Y\3AU0:2G&=_Y;_JD85UX[UO2; :MK
M/A"6TT;*F2>.^2::%&( 9X@HP!GG#$BNZ5@RAE(*D9!'0UY?J>F>(_ _AZ?7
M-$\9OJ.E64/G?8M61)1+&.<+.,-DC@>N11=:7IGBWXKPKJR.8)?#<%Q_9\CE
M1(3-)]\ C=MW=#QDY[59S'J-%>,'3YXO#_B:+27DN(O"FLI>:4'<OM$:*\L
M;J5PSKCWKHK'7+'4O$&N>-W?=I&C:>+:U?LY*">9A[\QK^!% &L/'D!^(/\
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MV#.H()4@@]L]CQ3['QGJ^FZ[K]CXEGTB6'2=-6^>33XW0C);*'>[<X4<>XH
MTAX\@/Q!_P"$7^Q-Y/,0O_-^7[2$$GD[<==ASG/7C%:7B7Q/!X=2TB%M->ZC
M?2&*SLH,;YF R>3PJ@<ECP!7E+:=XS_X5^+O_A&K?[<MY_PD'VW^T?WGFY\S
M_5;,_P"K_=[=W^%=7<ZQ9W?Q \%>(F<#3=2TZ>&VE<X5)G".%)Z!B 1[D$4
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MW[1#*\,A'H7C921]34:> O"\6AW.C1:/#'8W1!N$C9E:;!R-[@[FY'<UT=%
M";5V[<#;C&,<8K#C\&^'H_#0\.?V9$^D DK:RLTBJ2Q;@L21R21@\=JW:* .
M=T?P+X;T*^%]8::!=JNU)YYI)W0>BF1F*CZ8KHJ** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .'^*&AWVM^'K4:?:6MS<6MVDX2[DVQ
M +GEO4>W%<QI4WB6XN;8CPAX09%F5'E@D7*D$9V_+U YKI/BMI>IZMX8ABT^
M":YB2Y22[MH9-C2PC.Y0:\GTFRO-19=(T;PSJ]F\>M"^M99G,:P0D('#'^(D
M*: /I)<[1D8..E+38P1&H8Y8 9^M.H BN+B*U@DGGD6.*-2SNQP !7'^&OB9
MI'B8ZO);(\=KII.^=CD./45+X_T+6_$&GV=GI,MN(1<![N*<E5F08(7(YQD<
MUYKX/\.>(7O/&>FMI5O96]RI0; RKN["//44 =QI?Q9T_4M1M(FTJ_M["]E\
MFTOI /+F?.,8SD=17H->!:3;ZSJ=CX8\*'0KRWN=*O5FNKB1<1*BD$D'OTKT
MW7/ ;:UJDEZ/$.K6F\#]U;S;4'&.!0!CZT/^+V:*<'_CT?\ FM>DUXU:^'3X
M>^,FDQ'5+V_WVKG==/N(Y7I7LM !1110 4444 %%%% #:\=T[0)8?CO?:NTR
M"%MV%QSDU['CFO#I;Z?6OC5?Z 7-O$"Q$L9^;BHGS?9.G#*BVU6=M-/4]N\V
M/^^GYBE\R/\ YZ+_ -]5QG_" /\ ]!N\_.C_ (0!_P#H-WGYTN:?8T]CAO\
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M?_?0H^T0_P#/:/\ [Z%>6_\ "EW_ .ANU7]*3_A2[_\ 0W:K^E'U?!_\_O\
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M%XXV*0 *YSQWXGTJYU3PKITT\ITVXD75KEHK>24M#&-T0*(I;#2%>H_@/TH
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MA)9)(&M5G1@;9>0"1AAZY(]0:WV^'MO;Z1I4&E:E<66I:9))-!J+*)79Y/\
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M8HKB==^*OA7P[JLFFW]Y*+F/[ZQPE@#Z9J_X7\?:!XPEFBTBYDD>$997C*T
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M<ZSVVF6D,J]'2%01^-:-% $%U9VU] 8+NWCGB/5)%# _@:H#PQH(.1H]B/\
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M[FY:1A8RF>*($;&DVE0S#')4$XYZG/4# !9M83;V<$!8L8XU0L>^!C-3444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444AX% "U5U"S^WV$
MUJ9I8/-7;YL+;77W![4D&I65S.T$%Y!+,O5$D!(JU0!XY:^'%\._&328EU34
M;_?:N=U].92O(Z$U[)7FNL_\ELT7_KT?^:UZ50 4444 %%%% !1110 4444
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M?_K5/X;\*7FC^,_$6LS31-!J<@>-%!RN !S^5=?F@#B?[7^(?_0KZ9_X,?\
MZU']K_$/_H5],_\ !C_]:NWHH \O\0^/_%_A>W@GU/PU8*D\HB3R[X-\Q_"M
MA-:^(,B*Z^%],*L,C_B8C_"NLU#2=/U5$34+*"Z6-MR":,,%/J,U;50JA5
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M$+N5U $X'X5U?AO5SKWAZRU1HO*-S'O,><[:=X@T^75O#]]I\+*LMQ$45FZ
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M2:"]@\Q0F, KC^M=+X'\)IX.\-Q:6+@W$@8O))C +$\X'84 =)1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img70551829_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_21.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $W 64# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BLN^\1:7IMZMI=7028[2PVDA S;5+D#"@G@9QFKE[>V
M^G6CW5U)LA3&2 2>3@  <GDT 6**R8?$FESVM[<"X*+8C-RDL;(\0QD%E(SR
M.E6--U6WU1&>WCN550IS- \>0>F-P&: +U%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_I3)7N->'1?\?FJ_]A6^_P#2F2O3RG^,_3]4<&8_PEZ_YDU9OB+_ )%G5?\
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M &%;[_TIDKW&O#HO^/S5?^PK??\ I3)7IY3_ !GZ?JC@S'^$O7_,FK-\1?\
M(LZK_P!><W_H!K2K-\1?\BSJO_7G-_Z :]VI\#]#R:?QH]\3[B_2J%YKNDV$
MQ@N]4L;><+GRY[A$;!Z'!.<5?3[B_2N&DC1_&NO[T5L):_>4'^!Z^//I1EYX
M^NK2>SB\SPM+]JG\D,FMDB/Y&?<W[K@?)CZD5M:=XML7B<ZIJV@0.#\@MM36
M4$>Y8+@_G5/[/!_SQB_[X%4]7@A&B:B?)C_X]9?X!_<- '=(ZR(KHP9&&58'
M((]:6L[0/^1<TO\ Z](O_0!7->(?$&M6WBR;3+"YM8((K&"X)EMC*S,[S*>=
MZX&(Q^9H,JU:%&#J5'9(V+KQGH-E(Z7-Z\11MA+6TN-WIG;@U>TW6[#5FD6R
MED<QX+;X73'_ 'T!7 :G=Z_JMJMO<:I9A%D60%+ @Y4Y'_+2KO\ ;OB;_H)V
M'_@O/_QVE<X/[9P?\WX/_(]"HK!\':K=ZUX<2\OC$UP+FYA9HD**1'.\8."3
MCA1WK"\;^+M4T76+73M-^S1E[<W#RS1&3/S;=H 88]<YIG=4KTZ=+VLG[IT]
MSXCT2RGD@NM6LH98^'22=5*]^<GBI;+6]*U*8PV6HVMQ(!N*12ACCUP*\?U;
MQ-K^L:7>6%S<:;Y=U$T3LMB0V&&#@^8>:N)XW\2Q\I/I:G&,BP(_]J4KHX/[
M:P7\WX/_ "/8Z*YCP)KE]K^A37.HF%IXKN2#=#&44A<8."3SSZU-XO\ %2>$
MM/M+I[-[HW-R+=41PN#L=\DGV0_G3/252+A[2^EK_(Z&BO&-:\;:5K,=R\WA
M/=>20LB3O<*2IQ@'IVINB^,])T>&T>/PF/ML,2HUPMPN6;;@GIWYHN8?7L-_
M.CVFBN>\(>*D\6Z?=W26;VIMKDV[([ALG8CY!'LX_*NAH.F,E)*2V84444#"
MBBB@ HHHH **** "BBB@ HHHH KW\TUOI]S-;Q>;-'$S1Q_WF R!^=>=Z3XY
MM[OP"TNH>,M,LM=D5F<R*JFU?/\ JS$3DXQCGDUZ%J5Y_9^EW=[LW^1"\NW/
M7:"<?I7C4/BO4=5OK(O#X#2^O+<WRW<^6$*#'[ISU\S++SGH&XH ]3\':I?Z
MUX/TK4M3M_L][<6ZO+'C'/KCMD<X]ZW*Q/!^NR>)?"FGZO-#'#+<(2Z1MN4,
M"5.#Z9'%;= !1110 4444 >>>'/^2V^-?^O2R_\ 0*]#KSSPY_R6WQK_ ->E
ME_Z!7H= !1110 5X=%_Q^:K_ -A6^_\ 2F2O<:\.B_X_-5_["M]_Z4R5Z>4_
MQGZ?JC@S'^$O7_,FK-\1?\BSJO\ UYS?^@&M*LWQ%_R+.J_]><W_ * :]VI\
M#]#R:?QH]\3[B_2N);_D=?$'^Y:?^@/7;)]Q?I7$M_R.OB#_ '+3_P! >OCS
MZ4N53U?_ ) >H_\ 7I+_ .@&KE4]7_Y >H_]>DO_ * : .FT#_D7-+_Z](O_
M $ 5Q7B+_DHE[_V"K3_T;<UVN@?\BYI?_7I%_P"@"N*\1?\ )1+W_L%6G_HV
MYI,\W-_]RG\OS1%1114GQ!T'PZ_Y%$?]A"^_]*Y:Y+XD_P#(Z6?_ &#3_P"C
M:ZWX=?\ (HC_ +"%]_Z5RUR7Q)_Y'2S_ .P:?_1M4]C[/,/^1<_1?H<O1114
M'Q!Z1\*_^19O?^PE/_,51^,7_(#T3_L*C_TGGJ]\*_\ D6;W_L)3_P Q5'XQ
M?\@/1/\ L*C_ -)YZOH???\ ,#_VY^AY=1114GR1ZC\'?^0'K?\ V%3_ .D\
M%>C5YS\'?^0'K?\ V%3_ .D\%>C59]KA?X$/1?D%%%%!N%%%% !1110 4444
M %%%% !1110!!>/%'8SO-$98EC8O&%W%ACD8[_2O#KOQ9X=N[5Y-$\$>'TVW
M$=N5U+RHY@SNJ ^0H+8!8$].*]XK+U?PWHFO)LU72K.\]&FA#,OT;J/PH =H
M%C<:;H=K:72V23QJ0ZV41CA!))PBGH.:TJJ:9IEIH^FPZ?8QF.V@&V-"Y;:,
MYQDDFK= !1110 4444 >>>'/^2V^-?\ KTLO_0*[VZ:X6V<VD<<DX'R+(Q52
M?<@''Y5P7AS_ )+;XU_Z]++_ - KY6U^1QXCU0!V'^ER]_\ ;- 'V$=;\1C6
MQI?]E:=YQM_M&[[8^W;NVX_U?6NDM&N6MD-W'%'.1\ZQ.64'V) S^5?!'F/G
M.]OSJ[H\CG6]/R[?\?,??_:% 'WA7AT7_'YJO_85OO\ TIDKW&O#HO\ C\U7
M_L*WW_I3)7IY3_&?I^J.#,?X2]?\R:LWQ%_R+.J_]><W_H!K2K-\1?\ (LZK
M_P!><W_H!KW:GP/T/)I_&CWQ/N+]*XEO^1U\0?[EI_Z ]=LGW%^E<2W_ ".O
MB#_<M/\ T!Z^//I2Y5/5_P#D!ZC_ ->DO_H!JY5/5_\ D!ZC_P!>DO\ Z :
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MQ5WP=;/!?Z@UFM\FC%(A!]L,F7D .]E$AW!3QUZ]J .OHHHH **** "BBB@
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M.*GHH PH?!VA6T"006DD4*#"QQW,JJH]  W%;44200I%&"$0!5!)/ ]S3Z*
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M94P9/^!D@^E;EI9VMA:I:V=O%;V\8PD4*!%4>P'%3T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img70551829_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_22.jpg
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M-E)7U>$9*#1&1V>"M];Q*34W0T1%5EAF<G62IJ>R_\0 '0$  00# 0$
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M?C_'WXRXHLCSGC@X((SG/\?V_;IPD)$#D=_O]L/XV*)Y!8\3Y\^2/;[@>_0
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MCQ[=-J:6B=P@CIA\(*TE4)$ FUPKX$#V_'[_ ,)(Q@9R<']@P?/_ '_/I$&
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M,'1@P=&#%#/\H%_Z+^SO]?5#_P#5[KSHD#DQC7]1?X(Q_P"T#_JW,<ET2'D
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M!:A$D">1;X$<:[0-J&;NME"E%HE*TE)VBP,DD1(']DGD>XQ8!'9 L:\HO9<
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M+1(M;J9F00><2&@TS!\J'$)A/%?I91D9'X6(R.0!^KCD ^.H)>0D[9  M_'
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MM!ZS/%QCHC3?T/OI,:E::J<O\'-84[;@"T#/:6FTPLA0!!+>I:O*'$@BX*D
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MV!"DK2C;)D6]B.>O4 ?$<VPU55=R&X<R%QDXS@YQ@'_=YP?X=3D24"(N(O\
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M99,A!DK^K88'(Y8'F2  ?N#&J=%U*T["&U!:3<N);'QZ3UF;1[&<6=-1U.]
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M!H[)VV4"Y6O\H:AIW"E*;J"&UKF828QZWC7>L]921,7U#=I)7$4;2K\E;I
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M"\D@1*4B3R+BTUD4Z2I2O4/+(@W@VN1 _7,_BA[Y=(:G4)@IHYK,H22CBIJ
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M5YA6;@-IE,D@G<#Z8O*;1$S[#'M?-N*NQU]/+50R4E*SI'35),IC905F(G4
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MXA9-CN0)V_\ NCD7/69[@8:2XU%+*%YTY1PX!)Y@P_4>:2(V<X/U?3D+R*^
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M$W-OD(D<BUS!PM*'C=#BMW0[B .\P2;BWSP@;EH[3['U'M\8G=6,Y9$ S(2
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MZ@BW: 8 YN<-)9;0%;9*E$D@?HDP#$#H(Y-^_9]]-:Y@L<\\$U*]15)&T#I
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M(!CTP#80.HYF20/;'K64T0HD%-22O'!(5>2H0K2+RYJRK/SA5 IE# "02>
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MVOR!\<'UVJ_QRON3_JXVT/Q"^\I@"V^=_.20?_ >C?V8_P#BW]NFUM("4G:
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M2H0FZ5+2"+)FX,8Z/>FL;/@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP8H9[D]J=
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MO]&(Z$3]Q!PMK;G(S[^GY_?TWA@\I_R/V'"VH/Q+^P #^.#T<$?Y2?\ YAC
MND^T1\R)_5A>4)/$8]R% _L /O\ LSTX5)6(29(/N+CGD=L((!L<+"W<@,8^
MQ+>W@$^/O_LSTI ($'O[>W;#S5A;W^[;^["TH/!1OOD)^S##)_C^7V_9TOB"
M/C^)_=ATD[0.A'[3^["LHS]:8]^'Y'&/JSY]O;J2.#,P2+_.^'$?9'S_ %G"
MRMQ/L "I4<L_D@/$^X]\^?\ =U);X,<0(_'#B% 3N,28%CT)'2<*VG&> 4 $
M 8 \#/@C^T'/O[]+((42(F(O/,_QQUPL.(/"NW0]>.F-_3>"%'LH 'YX]O\
M8>LP)GJ,#GV">UQ\1QA0T\:!E/D%B%&#[^^?<?8X_P#;TVZE2@ D3S-XCB.O
M6^& 1>3U/3M\!VQN8TX\<>PSY./V_P#?VZCK24*4E0 ,"POVCOT&$J4"" ?P
M/?&W@0(RX/DD9'GWQ^[']^.G/+5M(2DWN+I]O>>G6^%0 E4=B?PQLT!!SCP1
M_P .D>4YVCYC]A.$(($R>?C[^V,Z'\'_ -+_ 'C/1Y:@0"#R)(XO[\?Q'.,*
M(*AR1'0$]_;&Q3/$J54C&4S[X( S[X'LN,@><]/)5O"@.1"8B)@WN1T]CAT
M?K-^;W^6/55;B#C\_N/S/[>F'$D$DBUO?F!TP$@7./"NO5%0.L<LJ\V8+QR
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M*-<%#DG)'O\ ;(&![^WC _<>EGD];G"9$%0@<6'L?]O;MA1THY\L)Y^Q R?
MSCP,_P##WZ1&T23-XDV%X GGY?/#BEK7*$-E:B) 3R0+FQZ0"3?C"IMMNKJQ
M>5-2SSB+#-Z43R<0OXF^E?V?4/?V]\]3AE^8*:\Y%&^MKG>$6(Z[>_X7ZQ)$
M</TP*FW7V6W;^@J&Z5="?T>0)OS$6OM%ADC)22.1&#9XO&RM@?;BP#><YQC^
M'5>M*E+.]MQI4B4N-E)$1$DVN+B]P3Q?"PE1.U!:68$%#H(-Y!G:!['J#/;&
MUIQE,D>2?PD>1C]X!^WY#VZ<(BWPX^'[.,"R; @CF1\XC\/QQDM,D2%Y?")@
M$Y \_D<^<_? \XR>EMH6ZXAEM)6ZX=J$ $[CUN)CGM?C""4)0I:U;0!:1.XW
ML+CM[X\:.KN-SJQ1VJC>90RJ)&!"AF;C@L!E@!C/@G'G/W'K.1>'+#M*X_G3
MC[1?;EMI(* DP((5O@GY \8I7LW<2HAB"!(V2)D3^E$ D^UAR9$865=;JJSR
M+%6@!WBBD8+RXQ\\CR6  !.<>P\'WP3UJNH='5>3H%32I%31)64J<0D)<0@&
M %("EDF(O*2JY,<8L:6N+R07FPT8$G?N!'4@;$_=<"][8Q*B=8*4SL<+&KOG
MECP V"?L1]\$X!QUI[5,I^I:;5N;2IQ/*3)BT;9'Z_\ ;,6XD(*D^H0;\=">
MQYL(]YZ83>C[73ZQU([-(9X+<T(] 1\I*FLF<$(P!)6-5Y&0C\/T*0<^.J,D
MHD9-DK#:!L#S?F*<@(!W(3,I,\!*8NF;\==6JW%*>2$J*5)(7M!F02J!%B 0
M#/(D<8E!J';Z3]!!8Z(T[I%RC: ,,97D258*<*< Y# ^?;[0_K#+KB@Z&GTJ
M41#B!$21[R2#[=^,6U&VE1*E*@D[HB)*C)&Z?E)3:+@B1B(UTO&JM)7.2GN-
M))54BG D"E7"<CQRA#8RJX]P"1D Y'59FNA\ASQ(=9 HJB=VYD64J"(("DP)
M5/6;>^+MJE4I.]!D_P!D@"QF3N^($B+1'(@K"QZLM]Y& 7AG"Y:*1&5@3GP5
M8+Q!)_VGSUY+J'0>;Y62\VE573I'VT$K"4 JO-S,08CK8] RX5-+"%-D I!W
M$P!?; $0?:_X7PJ22 #Q/G[?<?[?'[3CK1'&PA2D KWH)"TJ1LA0,$"YZ]>#
MWPH$'@R._P#'\# ""/V_EGIG&<?C$8/D>Q^_1@QX]&#'YD9QD9]\9\X_/'1@
MP\/;B>?<3L)]N&]6UX_/.-<V']V/;]O68E*C/"2?P/[L/TO^$T__ $[/_6)Q
MUL=1L;C@Z,&#HP8.C!@Z,&#HP8.C!@Z,&#HP8I<US_IL]FOZ@KI_A+=;KI+*
MOZLVI/[W,?Y]D&./,Z_KF:1_N%4_Z-U/BZ/KFW'8>#HP8.C!@Z,&#HP8Y7_Y
M67_T(^WC'_[U%L_^J3=+I;?VK]OVC$*N_HD_Y?\ V3C@IHCE03[DJ3G!R6*@
MGP!C*X'_ -_4GA('Q^\ G\"/]_)IR I1GBWSDC]8/^[@+:S44]7.E/34\U3)
M*WIK%"CRRR'(XQHJJ69V]E4$NV3QSQ8C#-.Z_O+*2M:52$I$J41<!([GI,SU
MQ&68DDA(A4J5]D R 3$& /<_+$A=-[([I7>>&FI=%7M'FQZ8KZ9K6' 1GP&N
M/RBMA S?06.!Y\^.K5G(,U>0%*I7D(4H!)=2$@*/N+S$R"8B_2<53V;43*RE
MVJIDQT"S*C/"03R?N$&>)Q++;WLBW#U)3)77JLI+-3/"*F-81%6,T7JK#XE:
MJIHA+R;BT:?,, ID">FKMU=TNAJ]VSRO(2K]*!Q8S![3';%35ZDHVHV!8A/Z
M8C=SZDV^SV)Y,B3B4UL^'1636MZNANM;5U;JLU/&*R&+]7&H,W)OT9+"TD@#
MO&O)5#8C#L 7%@_H:E8 2]75(WI2DN):00)$;A:(D2)M$38XAISU=1M4RR=L
MRI5CN38DW%K$< =>HPQ&X/;77Z*M-7<;=4UM34V@.]YME='&\RI&[<YZ9Z9(
MN*PQJ[R02IS98VECF;/I"ESC1BJ%CSZ>H#[);M-G=\;@2D6  !D18@"+WGTF
M8"I<4SY/EJ4@E))) 6%)@&8XDSSAD;9$Y8 #/C(P#CP2/)QXSX]_W>>M+0PN
M "94)!,"Y'2!' @<>]L2W 92DSO0G:KK)!FP$#@^WWX<W3UBO5TG2FM=HN5Q
MJ'R5AH:*IJY6('G]7!%(V!G). H!&3U)3E]2\$I:9*IB52;B1)CC[H$R!T&$
M><AH .1ZK S]GWL1,=CAWX=J-R+?1"YUVB=24E"%]1ZJHM-9%"B\?>1VB"IX
M/LQ4^WCJ2<HK )\E8_R/4H_ $*'QM,<=\92XVH@(="R03%OV#@6@_$&3QCTU
M/-3R,DR-%)[<74JPPPQE2!X\@@@$'[$X/4)2%MG:M#B%"Q\Q(3/NF.1,XEMS
M?Y__ "_[HPN]/VVONU;!;[=2SUM;4R(D-/3QF21RP5<@!?"C.&=N*+[LP^[]
M-2556L)IVB\=P3$@!,F+Q>Q.Z_PXP/O-,)W5#H93M)F =\28@GVZ0>?AB>^U
MG:16:ABC%]NE9'<Y422.W6J&)XH%(5N-97S*\2LI+JWI1N!Q8\F^GK=6=-(I
MFR[6/0M-O*,C<50F04D<6//2X$XIUYRIUS92,0W!_.S,1<_:W#U =0>L'&XW
M@[6KWMQ MUL35MXH(H@;E3U"QO6TP.?^50?+QQ+44;+YD 3UX&5BP9,E:VIR
MTM%2VW I%SM@6C@=S-S)/3I?$BFS=M:TT[S?YQ1&PRJ;6, ;08D6(ZV[XC]:
M;;6W&I6DH*6>JJ,*XBAC>1RBQY9BJ*2%0'DS'"J/+$#'3%'E]9F#A;IVY,_;
MY!GVD\&1;I[XLJEQ%+=0)21P.DP9D2;Q8<V.)*[;;9VZ&=+IKF"MIZ02<8+:
MKFD-02CLLTM6\,X$(*H"L$4S/R)7 &>M_P JT@MHI<!16U((40A(6PRD []X
M,I4%)W)3N!(44J$&"-6S'4#:%% 4IM)$2E10KN(4F%"\3M4)N(BQLNV?V2TN
M;127AK535$]?"DE'))0I"L49158Q13LS%9".7JL5>1>+$*20).9Y@\P]]72"
MPRTG:$) VE5@NQ$7A-I@1%L)HD)J6 ^H)6JH)"5* *O29NHC=/J')DWDSA,;
MR;!V^>FJJBBHH9I$+2>G'"L-1$I9>8C-. )& RV.2L!C!)&#6_S+,TBGK=B%
M.V;>@(5(YDHVD\1ZIX^($GR:FA&]*U)GW!'>P(//6PY!D8K2UW0U^W\LU=7T
M=1)I]6Y27&-><E%&1@S5<*HQ]"-^4<DR^(CYE2-<,:#,M.5% K=/G4RX#-0R
M=Z%$JB%DS$#D\CK'2Q8S)#XAY7D*F$B 9/SO>/QQ&C4&^VF;EJ:U::L=8U5'
M4UU%%6UE,/42GIY:F*&HJ'XH5*T\;M)Y+9"G*D*1UZ5X=Z&^M./9G5 ."G.]
M@$D"4^K8-I )L/M \@<D8@YQF5,D?5VEE2P!81Z9.TJ)C@W/;M88M_V'V-MW
MZ"M^HI86JYKG''/3&:19WI:2I!:*%"H]-I$!4/.D:-.Y9B%CX+U?9[J%0?>H
MVR6S3*+>T)2!O0(FX)CL"HP.IZQ:2E"VD.I$%4JN2JY@]3'/8 $\ 7&%YKO9
M:EJZ.J"TY"$&-V"!F7E](=\^ZAL#DC(R#!/T@XKZ3-$/_FGOSB5PE2%CTFWJ
MMQS\/B,3%MN[#N42D#@0.MP($_Q-^,5_[C: UCI2CNE'24\E=3S12K3<HWYQ
M^&"\']I03Q .%(;PW@@=1JK2V39D^FLHUBGJ$+'HW.D%<W]*EE'<63%^.<"*
MQ]MLH@N("1 M*?>0)-B!$D]A,RPW:/J^\:7WU73NMJ.6CAU%6&WTL51G JG<
M?*O&Q# L^"F/#$L"/'OZ5F8\W3@:28J*1G:I8  (0F =H&T=9 [";2<4*JIU
MS,62!L"@E"DD VW*_M3 XOTO><7[S;<15]($EH@7*#+-X/!AD@H5QALG(()^
MWC'7CK>:.ME(#A@%()]/2),Q,VZ'I,<8W1" BZ4\WDSVO%^+V Z"W&&9UMVW
MVJ]4\IFH?44HQ0(O"2)@"04EP"3Y(XM]()&#CR+RDS\A0 7ZA!))5!X'$C[Q
M?X8FM5JV4@*) X^RG@1$$I)/[)ZXA+JCMNOVG*X7&DIZM**61C3J4;U54')2
M8?2Z-GR5<9 \C[=;4SG5.\CRUK;.X$+2J% S8V,R"+<0+S>3A]59352"EP;G
M"8$2D@<C[)2!!D2;P3T( *31-]2E9I*:3$18<^)/+ P?#8*X(( 'OC)Q]O.-
M9:<HGF_K.6M)\]0+JZ9)5*R?4I>[<2._:Y@=,5CE0&U*;2H0@E(Z\& )O[0"
M3;X@83513RTLKQR HZ'BP88.?O@$?;'GKQQYDLJ*5G8Y_BN2!:3NOP3%['$E
MI2EIW*,S\/V 6^/4'&-[],8=QYM(JD@YR/V?F,]&#&-ZC\N6?(&,X'M_9CHP
M8>7MO=O\HK8/S^+>K:WEX'G.N;#G[>/X=*'V'/\ )/ZCA^E_PFG_ .G9_P"L
M3CK@ZBXW'!T8,'1@P=&#!T8,'1@P=&#!T8,'1@Q2YKG_ $V>S7]05T_PENMU
MTEE7]6;4G][F/\^R#''F=?US-(_W"J?]&ZGQ='US;CL/!T8,'1@P=&#!T8,<
ML'\K*P.R;MU)]AW56LG]W]$FZ72T<GX?M&(5=_1H_P O_LG'!30\@W$#(&03
M[8+'D?OY\$D?NZD2=L'CH;FPG]L#VG%02D*F;]1\8]NTGY8N.^%SM/IS6E[U
M9JN[6^FN=?87MUOM$<\:S/1RU457//4B)@5S)PCB5C@_JY K+R)Z](T?1,-T
MJJY<+\Y99"4R2I8G<@=CMBY $=;8T_4CJWW6*5-VE"4K'Z1$%4 P0 ;22+@D
M=<7XW;MVH*RKLAO5A_1K?\GKZ<M3- ]QHI5CD]-ID +0U,95A)R)5@0"#RQN
MC52F'ELNH4AM0;+0(*FW""1(F1Z08_7P<:X\P_2J;:6R4!U)6@J"94@&"J ;
M7(Y'R,VF#IGM>V\;051=_6MMMKX*BG@M>F*.&0R-#),QG)=7!BCB\,K,>3 $
M%B3GJ@J\_K457E^5^:")*R4Q.Y0(@>W)O/6.2^<JIGJ%Y94/K"E)"&]JBHH2
M020H6%R1!Z1;LL[!LU24]LJC14M+'#;Z8S2))*$9H@0CB)7<-*PR/H4,2,GR
M!Y@5&:.NJ$"4DR8DQ<28/,=0)G"V*-304 F"$G;,=+@"('8#MP;8A!W ;!VV
MY"MN-/1JLLD+B5HUP)$P5,51%E$F0Y/('R%)"GB2IGT[PJ4>2L@)<&U??;U(
M_P!HZ^YP!.QQ+AD+:5O '!4#  @]C8\ CK%DMM/VA[:6;2EHBL^F[6SU-%'4
M2W:KH:6X76:HF#-(SU=<DLT9B,AB]*$I$H4A45?=@T.64N\(9*?+409_2) ,
MB ;&8DW[8:J7EONJ<7(*HMSQ(D08%K"P Y/;$N-N.VBY5EYI;;9+?;YIZAGC
MBBH+334LLB\>93$06*,<5/)\( /8@> PY69?2IW[ %+$[C,))'(.TBWX=3@H
MJ=^M<4A+2E082! W7M$J,R3:.L "3AW[EM$MCCFL\UKCIYJ1I::OMU3"6YNN
M4D$Z."&))96#(5(\'R>JUZI\PI4"DMK!4E0DI/!@1\>#<QQQAURF>8=4@$M/
M(-TD7%[]Y^4SR3BNCN#[-M,ZDDFOVCJ-=+WR NU314=,K6NX([*Q5*?U85HI
MQA^#P*8"SE7ISR+]-(I:2L<2*EGSMOI!!"=@/3XF.(,=K8<3F.8,-+3O@<@0
M+B")@1;CK>.,([MNV G_ $TM#;DB-4TAI[A45M)%+70P8/S"+(\8E@DY*RK\
MOZ+ ?4K ^3L210Y91%#;.T$?FNMC8F1)$*[][3(!J!]=KWB5NP5&0F)^S%A(
M$=N1Q>(G%Q.D=JX].V^&"(Q%HXU4\:6"(N%501S1?48  X+N2?8D^2:"JJ2\
M3%QW$P((XFX[=.AZC%LQ3.H1*G-W(V@?:GK/',$_"W7'QK/2D-XHVHY8P)%C
M*HYC')>(P WT@/@^&'GD#Y]^F:=X,JW*&\3!1W!F>;0/XYNMVD2^1O204B4N
M2/28F".221<W'?K%?B[$S:,W7I]8TH%/INK2IH+Y9(Z2(4@-85472 @M-"T<
MWIR21Q\$!1F0<)&7K9<K_);+=:JF;\IU[:I))/J.P!<1($&1>.W!Q&?J7W4)
M8J#"&Y2%GD@'TD)$FPCD$]^(Q.VR;.Z7N]/2M<J""O22*$)4O E2].C%761$
M<O\ 5'X]-ED1E4E.01BG0C.:FC7_ #509!2L%!).[<@@)5MDE)F#<F+WB,-)
MRAJI4E50"]ZDA2Q *!/VDI)@D?:$$01[B9:6W::CI:6@H]'W6KO]'26Z-I$G
MIQ2STTHC=I:<P\F)CC$+>D8V=<84L690=<>S-:O74,LTSBG%_P!$99<DB%#G
M:HS>0.1:^-N1E26TI;I7GZMAM 4E3HAQ!4/4D@1*;"+0((MR4#J72DC^M#-%
M-#*H=666-E4,#Q)\^!Q(P<C(^V<=2VU%:$J)3N,F 0H\F" )Y'SO&&5L+02F
M%$"XF0+Q/)[])Z"X!Q$?</:.VW)*JGKJ".:"I62.143E&<KD,452"&8>"PY'
M+KY5V7K8:.M 3L<&Y(@0+R.P3!Z1;X\1BGJ&4I<"O[)FXX]N]_O!M.*==P.S
MFU+N+<X]H/T(=40NMSO>G*6JIRU'1U%='3O<*R@IWDJ+="6JHVQ'2K'-E<)G
MZU]AT[GK-!E:%5E*[2L.%:6WG&W&TN*2G=M;.SU2.HD6)F<4U3)4LH25*5!2
M(-^O,#H;&UN1)DW+]N=GO6C]/6C;O5(>:]6>VT\:UJTQBIZV)6])12!GD;T%
M+)&%#NZJJEL<FX^9:I-/5U#F94Q3M>=4I0!G:H)$@BQ)]-X!]AB]RD[6VFUV
M<N2D@\$V%[<6%S[XE_-I.BN-KF]*A?YRC+O62L><9I)7CA5N B5T83,B,QE(
M(95*E6^G3DU:VWFSQN4KRQ_:V E5Y[$<@'B) (Q?"^X@ A"@%$6VSP(B\S%K
M7OR9C-KG;:2Z"2G:R?.0%F#SQ0$B!) $1XG*R 2>H%!#\(I.)4Y8#.TT&8M(
MW.+=2ES;9*B0;$$P3 )/M>)'MBKJ:=3BK).WGTWDBT<SWOP/?$5;GVCTU5K[
M3.JE6GB@L5THKEZ[1R4U2TE+4(\=,X&%4&154MR8,#GP2%ZMQJ=7U.KI%L*6
MFH;+>Z8D$0(DWF>>DP(&*QW+MSK3H2H*9.\ V!()(YXX!)(]N9.+53<)-41:
M?AIK70"_L:.W7!6J)8:>OE0/$*DAO799Y!Z8E4 HW$R KD#KS1#8HQ4U#CE0
MA"2Z6TJ *)!.U%B3LG@FT'@WC96W55@;9=3L4I*&K$RHGT\S8F>!"3R8PX>N
M--:8H-:-1T3)%9XS1BN6C0S>DW"-:U8P\IQ)S]0E%D^ABR JP"=0*.JK'**
M-JRMQ4F 2"J4BT$2.P'$WF\NL0VW7!#:@4(#4E()C:DA0@F#!M$WF">N&*UI
MIRRU59<#0T@6WM4RBCCJ 976$2$Q,25_$R%?Q+R7'$LY'([#253J&&TN+W+
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M7^%L:"HO5=4R"0U:0AG:!GAJ895<9A9Y)9*=Q'S;BAD#/R)PH!*N2YL '$P
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ML,0^HA2/I&<@@''2DTOTI<K]#3W@WJ!L#:FJ>1JG+:U8$^IUMH-T:21<AL*
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MM;0=#ZP(VJ'\E<_A9 F3E%7Q8'B_3N+<W=.D)#)"E2" I""3<E-R-VT)G[1
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M([##LVO2UON,<L3S4R2L5!8DNC4X*J C1G]45!1< (I)D( 8D=07'W$00E1
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MI YF_O!Z=;<S(M^)2NJ(&F@>?G$CS5+D"EC<#.(H\F6/!!Y$9+> ?=1D@$F
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M@E\Y6E:BI3HOV2!,Q82"3V)F1]V))]0A9$"">X/M$=.;GVYPYMKT3JJQ6?\
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MZB6KJ*J2IJ!%-+6/'3K3R.LAD)2100)&905C9F$:L8R@G<M12" H!.T)1("
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M(D>/V8!\_OZSC(CK/R[X^R_@X\'[??\ [_V=&,8\I*@1#ZLDL#Q\>,@?<C!
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M72H^3LFDM+Z<TW:*&.FH;59J."'#&,*)423R?]P_#Y]\2=Z,8P=&#%+FN?\
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M)ZG_ .%0_6,.FUB"(/=,_>!)Q^^MCV(S^S_B3C^WI>$BQ_W?M!_5CZ6H*G.
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MW$UK1VFM$OZ-@1JJN6)N+RQIQXPAR/H$C,%8@%@"2N".0V;(<M;J"\ZZM.Q
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M'5AM) ($V_:?WXUM&Y,2"3<&?C^/XVQM8F*C!4$L<G/N"Q)P/W9P/W=/[CL
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MX9 U/35<WIDGEB,LQ*D$#&,^ 3G/N1[]:]J7(5(0MU*5*.U0$@G;!%[ @3,
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M^C==6U4KRSQJ6'J_HRV5,,=,60(Z127*5\DPE3*T:MT+D7@C4/)0<RS!Q!4
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M.2..DR/AR>AQIT[KK73,$2[*TC2@%VFRJJ P#99P54_=7!/GW\$=67\E5[
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MM!7ZISW(-+9%2JK<ZU)G.69#E%&E20JJS/-JMJ@H*<*) 3YU2^VWN4=J9DD
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M=&#!T8,4N:Y_TV>S7]05T_PENMUTEE7]6;4G][F/\^R#''F=?US-(_W"J?\
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M)2E#B7";%&Y;2)C@E&TR28 F"3QQB[9T4\XC>JH9:/!25@0#>_J2(OSQ-KS
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M(Q)#>(U4,F' /A0JH0IRV??I9=2#N'<$0+3U-K ]YF>V(ZH4K<#!,@PH2>8
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M-4I/"DDF".@D1UZSWZ8DU\/K3%=2?$)[-*J*&84D/<EM&P$@CS"BZRM"3 F
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M8^'(M("&,,ZLS)')&? 4^!Y+*2V50E\&Y(A1*)OP+ @@29F2>;#I8H4I Y*
M8!&\IDB\ R> 18_B<9RZ/N%$]PDN,LCK5T234I:2,/%+-)%4,/2R%9EY%&4@
M8!)!/'PGZP@I1L &Q4&QN$@CG[C(ZV,'#)42H^J0=P 3UN"# -Y(L 8/:^$=
M:[86J6BC^5,;U$<B2SR,09$;'#DN5CY8^H%L8R!Y^GJ4XOT@PJ0DB!$@1[B_
MMA!4)Y2.OJ,00?UGD^T7QKIZ!X;C4,TC5T2,2_IE@$(8 #D_!R@5F" +@D9*
MC&>EA<MI 3L)XMSWM?F+F3!G!N3$;P;7,BUQP>L\=>G PJ*"G@DJR\=$ORDP
M*LHY"2!BI".O%2[<1@E58<_;[=1UDA/VB2+S8@@&#S8>Q_?.,R"1MB# B8,D
MP"+SQ;N9'OAY]([<W2FMDUX>%X*.J@FGM-3)Z:AT12KHL<CX,_JL> =F8*I4
M("&4UU16-K6&Y"E @.) )@^Y'"8ZP)GX1C?M7M!VD*$@D)(Z6')'X#VB_P"Z
M-H;M2W":EN%#472RR%I[B[I'!<HD+*6> U#K$Y4\^:&*2-\_2RL,KBI6TI&Y
M*DH< "6P"5(GH#ME29/N/U2XDJ"@I*KDQ, [N)D\$\VC]9PKM3;85%=5&\45
M$D%-1J!'4ULB-!(9"7CB0REXY'AA)#*I8<QR8%,GJ*QF ;2&EJDJ))2@>H@<
MJ(Y 418F.L&>7_*2M14%'KZI$),  2" (M,7!^_&CO&R]WH[?;KO354E73E4
M>Y+01M4,CU*.Z"H"+]"+DIR1B"SJ%P<,%HS5LK6VL;2#"-YB0D@&"3!)YN/:
M,.>2ESTMM)"B)!0D;A D\)F-LR1TDVY#=U&A5M-S7],4,<<<[2\Y)H)SZ2,.
M2NID)0L4("^"%SYP!YL!6^:W#2[@ P"D;NAF!NYYF)]\0!3K27"M"UB1 *5$
M 29CI?Y1';&FOFVTBU$SI*DT3YDAA"$/& Y7B@1/#\1AB % ("D^Y=9K[ 24
MD6DF09CF3^N_>(QCRT] !V!3$?/C"._F=32)(&I,U/,-&1"6$<:^!SRN7D(;
M#'++['R!U,-69!D;8N2H7,F8@D)';W,7G$<LJ;!W*(O.W=;Y@\GK8?CB179!
MHZ.A[UNUBI^4"-!OMMI-QY\9(&CU5;'9S&<_1)CEC (Q[D#K7=:U6_1FJ$;N
M<BS(3$A4TCD";W D3Q>W?$_*U.?E*A -OK3&Y)M;S$\#X3P/?'>_UPGCU?!T
M8,'1@P=&#!T8,'1@P=&#!T8,'1@Q2YKG_39[-?U!73_"6ZW7265?U9M2?WN8
M_P ^R#''F=?US-(_W"J?]&ZGQ='US;CL/!T8,'1@P=&#!T8,<LG\K#U!!I_L
ML[<)9TY"M[K+;1HV 2CG:'=2;D,D '$1&2<>?((..O7?!NN30:CKW5@$*REQ
ML'J":RD5*8(O"3UB.01(Q$K&O-: !@A6X=C"5<_(XX._YY.\\!0B&-7 D-,"
MTA4 9'&,>X!!<GD&SG/W'4 SUQ:FU();0#<MV)  [1,]0#!DS$@"K^K[9-B0
MG@V%I^7PYFYP\6F=2P*(9:J1XXGXNTBMRD.0BE>$DY57P2P;@6R>2G.&ZW*A
MKVZAA/F%*2H )4I5B;#U K)!)() $*!O OAE:W@5)"D$BX#B"I!(F$J,_9Y3
M(!)%X/23VB:BFU/=[/:M+7.]5FHKC./T<E5%''325$,4DTU)/F*6F42+'EL2
MIQ@5WPC,DD2JI;=-3.5+_DHI4 %Q:5BR5%*4K!)"IW*BX,J,$$[@JN=#ZC+[
M5*4*!\LI!3Z^>QO$^F0>L7C$DJVLUS8;_ =9QU%*U!;)C';ZQ*6.GK+E%3IZ
M*50HY5:.!8O0JD9Y(A)3+%)3.P.6IV315+)-&M"PMP2X@J*DHW>HHD%))(*+
M D*W!0Q6/T^U*@M"DI62K>0"B2 +09VB()VQ$1)OA^=D.X>32=[J]07>RRWB
ML&GJ^.UT=?*[V"NN<,:-/25\=/$S!9 LLZ2Q/$%FC$0GIRX<5&<Y)];8%.U4
M>2//27%-A(>2T9 *=QB 2F1>0)A>$4Z5-OMN+/YM*1!3RHI2( E!Y[D0(N.
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M'7"T+!4I(*0204 R+GJ9$"_;\"<2.VXN]'9[/7;9:B@-?37"H2F2Y5--%/3
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M F]F]DB* H,IT4S! <K'R_FWRX)X$:EB$4*H&%'40^/>HB9_(V2\SQ6\]_\
M"8GN0!))/)Q">TC1/**C45*;D@)\JT_%LXW]-\!KM_I"##O1O*N 1CAHD!B4
MX\GXZ;!<@X89..0!(/31\=M0*$')LF/Q^NF/A-3 _B<,'1=$?_/*P#H!Y/,1
M/]'?^(.%1:_@A[%6<5HHMX-W8Q<J=J2XX72"BNI&DCG6FJN-@!EACJH8ZJ*-
MCQ2=$<#*+AE?C?GBRDJR7)R4'<B];Z%P4[D_SB02DE),S!(M.$JT72K&U68U
MVWM^8$]8)\JXFXG@_*-M%\%G8R*'T4W5W4"'@&(327)D0J5CR;$>"Y4-]'$A
MQS4JWGI"O&S/5$$Y1E%KC_#.3S,U%_G/O.$-Z&H6]W\^K5;@ -WD6CM#7P[<
M8SKE\&;8NYF,R[G;HH(E0(@&E9$$B J9%$MC?BTB\1( 0&"KGIM/C3GJ9C*L
MJN3/^%BW(%J@6!X_??#R=%T*>*NLY)Y9//Q;^'W83-S^!_L%<75EW7W7H5""
M-XZ2+1JQRJN>/,-IYLE2S$-^+ZCEC@8>1XWY^GG*<I7R94:R1/O]8GB+<6'P
MPM.D*)/_ )W5^_\ 0W'O^;QBV?X&NP%EJ#54N[6[#SB)HT>:+1I,;,Q82 )I
M] Q4D_2X9&)!92RJ0.>-V?. ).4Y2!,D UE^.]1[=+^^%_R3H_\ TFI__1?Z
MGN9'7XWQL*_X).QU= L'],&[--^N>::2GAT:'J&D.627U=/R#T\XQ&H51Q'@
MC(*$>->>(,_D?*%0 !/URT<$14 SS>9N8@XR-*4@!'UJJN(_Y*.O0MGN)^ Q
MDR?!,[?IHVCEW'W'<.82Y:BT=EO1(/G%A&3)C]83G.3C'0/&S/P01E>5@B>%
M5O41_P"D_='&$?R1I(4/KE60K_H;=('YKITYCIC9P_!CV-H[@ERM^YFX=!-'
M2)1H*:U:% 6-8EA:56DTW(XJ9%16DJ2QE9LD,#TVKQGSQ2-B\KRU22HJ,KK;
MW)VF*@>@3 2( %L+&DJ(3_.:LV@;E-G:8C<!Y8]4=3/7'G<?@R;-W2JKKA7;
MR;NU-TKI$?\ 2,JZ.>HI^*%2L.=/<<.2&8R!V/%1G QT(\9\Z0E"$9/E"6T?
MH)-8$F\W_G/2XM&$C2-&)_G549YLSUY/]'$_*W;&TI/@Z[*45F6SP;H[GH"D
MBSUJII9*RH>0QDRNR658PX,?X0AC^IOH!P>D*\9,[4Z7#E65](3-64I D0)?
M)Z\S-N<.#2M&#/UFH($V/E=P1^ATB!TB;3!&);O@S[&T)J7EW1W4K9:JEFI&
MFG.E%E2*9<-P>.PJ5884AL\OIXDE&96%^,N>*VQE>5( (5 ^MD$@S>:@^_7\
M<95I:D5M_G%2-IFWE7]OZ/ITQL;1\(/;"P57S5GWPWCHB%CC]('1\L+0PL'B
MAE233S"9$D'/$W/+8SGBN,.>,.;.IV.9+DZQ>\58()$$@BH$'X8P=*T>X*%1
M4@@S_P E>""!_1]/><*"J^%)MM<:ZGN-SWCW5KJBEF>6G1X](T]-"9/3]01T
MU'8:>).:QA&( _5DJH7P1'3XLYHA"D-Y1E2$J "KU:E&)@E2J@FTSSSSR</?
MR;IC_P"<5%C/_)]H/".O7\(QCWSX1^QVJZZDJ=7ZWUSJ>BHED2"S76BTE+;<
M,ACB5T%B$S) A 1#-Q<JK3>H0<X;\6L[8;4BFH,O861_3(55>9/54E_;N)N3
M%C,1:'!D+:2XINKJ6RX03L\L $$'T^B1Q')Y.'+T=\.':S;FS2V';W5NIM&V
MV1)XTBLMLTS \*U*E91')^BBV?+"-FRZ(QC#< JBLJ_$7,J]Y+];0T=2\D)!
M6ZNI.[:21*?.BY)F!>T\7>;R9EMTO%]]U92$DN*21 !B $B.3.%I8NR:QV,Q
MHNZ&M[A2B$03T5PH-,3TU6BDE/F(S:1S*<C@C!.2223GJ(]K9YX7RF@;7N*@
MXVNI2M))),'SC ),QP#P,*:REMIPK2\[<DA,(@3<@6F))YGGVPJ:WM%TI776
MKO$FKM215-8L<4L,%'I]*):>.(1+!%2M:W2->(!Y \@0,$ 8ZBMZPK&VD,BC
MI2AN2DE51NW&?45><)Y-K ]0<+.54Z@ 2H009 2)@@WM[1A/6[L=VXM>X&E-
MQ:+46IH;QI:_VG4*TZ)9UI;I66BK@JX(ZXK;Q,(96@5)E@DC;@2(V3 ZD.:Y
MS-W+JO+7*>F4U5,/4Y62\5MH>0I"MLN%)("B4E0-P"0<+.6L?64U(*DE&PA
+V[9;,@\3)ZWQ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img70551829_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img70551829_23.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S-0  DI(
M @    ,S-0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( P<%SP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M7,?$2_O/%OQ"L_"-A+BVBD57"$D%R-S,<?W5_+#5Z3I/@OP_HMHL%GI=LV
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK?C)_P D_;_KZC_K3/ACX2TB#PG9:K-:1W5]=(7::90Q09P%4'H  /?^0?\
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M>>/H:\GN[A/'OQKL7TL+-8Z=Y>Z8*=K)&Q<D^Q8[1ZY'UH Z'XW_ /(DV?\
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M[;>]1Z9;R:U\18M-^)EU>FZ60+%"S+Y9<\A"0<*K< ;.N1R*[;X(?\B3>?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M03:>['+"SD"J?^ L"!^ %+I/PE\+Z5=)<&&>^>,Y47<@90?4J  ?Q!%=M10
MWRT\KR]B^7MV[,<8],>E<)?_  <\+WMZUQ&+RS#')AMY0$_ ,I(^@-=[10!Q
MU[\+O#=WH4.E10S6D44HE,MNX\R1@"/F9@<]3].V!Q74M9Q/IK63;C$T7DGG
MG;C'YXJQ10!@>%/!VG^#K6X@TR6YE6X<.[7#JQR!C P!4_B?PS9>+-(&G:E)
M/'$)1*&@8*P(!'<$=SVK8HH JZ7IT&D:5;:?:;O(MHQ&F\Y) '4GUK&U?P1I
MNM>*;#7[N:Z6ZL?+\I(W41G8Y<9!4GJ?45T=% ",JNI5P&5A@@C((K@[_P"#
MGA>]O6N(Q>688Y,-O* GX!E)'T!KO:* ..O?A=X;N]"ATJ*&:TBBE$IEMW'F
M2, 1\S,#GJ?IVP.*ZEK.)]-:R;<8FB\D\\[<8_/%6** ,#PIX.T_P=:W$&F2
MW,JW#AW:X=6.0,8& *K>)OA[H/BNY%U?Q2PW6T*9[9PK,!TSD$'TR1G'X5U%
M% '$6'PD\,6%O<)Y=Q<23Q/$)IY S1!E()4 !<\\$@XQ71^'?#]IX8T2+2]/
M:5X8V9@TS LQ))YP .^.E:E% '.>*? NB^+C')J<<L=Q$NQ+B!]KA<YV\@@C
M)/4?2CPGX'TKP<+G^RVN)'N=H=[AU9L+G & ,=?Y5T=% '-V?@?3+'QC/XDA
MENC>3[MT;.OE@L,$@;<_K72444 <=9_"_P /V/B@:Y";HS+,9D@:0>4K'G(&
MW/!Y'-=C110!B>(_"&C>*80NK6H:51A+B,[9$&<X#>GL<CFN7B^"OAB.;>\V
MHRKG_5O,NW]%!_6O0Z* *6DZ/8:'IZV6DVJ6UNIR$3)R?4D\D^YJ[110 5SF
MK^"--UKQ38:_=S72W5CY?E)&ZB,['+C(*D]3ZBNCHH *Y3Q#\-_#OB6\>[O+
M>2"Z<?//;2;2WN0003[XS75T4 <+IGP@\+:=<>;+%<WY'W5NI05!^BA<_CD5
MW*JJ*%0!548  P *6B@#G/%/@71?%QCDU..6.XB78EQ ^UPN<[>001DGJ/I1
MX3\#Z5X.%S_9;7$CW.T.]PZLV%S@# &.O\JZ.B@#BM;^$_AK6]0>\9+FRED.
MZ3[)(%5V[G# @?ABF?\ "H_# TAK%$N49V!:Z$@,IQVR00!] *[BB@"&SM8[
M&QM[2#=Y=O$L2;CDX48&?RK!\.>!],\,:I>W^GRW3RWGWQ,ZE5&[=@84=_7-
M=)10 57U"RBU+3+JQN"PANH7AD*'!VL"#CWP:L44 8OA;PM8^$=*>PTR2>2*
M28S,T[!FW$ =@!C"CM5_5=-M]8TFYTZ]#&"YC,;[3@@'N/<=:MT4 8GA;PK9
M>$=-DL=.FN9HI)3*3<.&() &!@  <>E9.N_"WPUKUXUU)!+93/R[6;*@8^I!
M!&3ZXKL:* .&TWX0>%=/G$LL-S?$=%NI<J#GKA0N?QXKN%544*@"JHP !@ 4
MM% '%:[\*?#FO:G)?R_:K2:9B\OV60 2,3DL0RG!^F*Z30=#L_#FC0Z9IP<0
M0[B"YRS$DDDGOUK1HH X[Q!\+_#OB+4'OITN+2XD.Z5[5POF'U(((S[@<TMM
M\+_#=IHMWIT,$H-VH62Z9@9@ 0<*Q& ,@=!SWS7844 9^A:-;^']$MM+LGE>
M"W!"-*06.23R0 ._I6;H_@G3-$\47^O6DMRUU?[_ #%D=2B[W#G:  >H[DUT
M5% !7._\(3IG_"<?\)5YMS]OQC9O7R_]7Y><8S]WWKHJ* "N<\->"--\+:A>
MWFGSW4DE[_K!.ZD#DGC"CU]ZZ.B@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N)U_Q1K=SXDN?#?A*QAENH( ]S<W$NU8MPXP >HW _T[UVU<-XA\-Z]8
M>*Y/$_@Z2*:YN8UBN[*X.%E"@ $$D <*!U&/7DT 3> K/Q+HEM%HFM:=:QV%
MK 3%>03;BSE\[2I.>['. .*L:QJWB]M7GLO#>B6OD0%<WM]*0DN5!^51@\9(
MSD\TSPWX[_M76&T36M-FT?5@FY8)3D2@9R5.!V&?SY.*Z>^OK;3+&:\OYD@M
MX5W22.>%'^>W>@#E_!OC*[US4;_1]<L5LM5L.95B.48<#(Y)Z_7@CFJMWXO\
M0:KXAO=+\&:7:S)IS&.YN[YB$\S.-JA2.F#Z_AW@^'EM<:QKNM>,KI&C34G\
MFS0\$Q+QDC'^RH'^ZWUH^#;>9X/O)",.^HRLX)R0=J=?TH T_"7BZ\U;5K_0
M]?LH[+5[$!W2)LHZ''S#DG^(>O!%4[OQ?X@U7Q#>Z7X,TNUF33F,=S=WS$)Y
MF<;5"D=,'U_#O7O(_(^/U@T0/[_2BTG..[C\?NBE^#;>9X/O)",.^HRLX)R0
M=J=?TH T_"7BZ\U;5K_0]?LH[+5[$!W2)LHZ''S#DG^(>O!%=;7GUY'Y'Q^L
M&B!_?Z46DYQW<?C]T5Z#0 4444 %%%5+B\FAFV1VCRC'WES_ (4 6Z*S_P"T
M;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0
MHK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U
M_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;
MC_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]
M?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&
MX_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -
M"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)
M?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1
MN/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?
MU_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T
M;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0
MHK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U
M_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;
MC_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]
M?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&
MX_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -
M"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)
M?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1
MN/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?
MU_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T
M;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0
MHK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U
M_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;
MC_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]
M?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&
MX_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -
M"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)
M?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1
MN/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?
MU_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T
M;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0
MHK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U
M_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;
MC_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]
M?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&
MX_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -
M"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)
M?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1
MN/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?
MU_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T
M;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]?\*/[1N/^?"7]?\ "@#0
MHK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&X_Y\)?U_PH_M&X_Y\)?U
M_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -"BL_^T;C_GPE_7_"C^T;
MC_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)?U_PH T**S_[1N/^?"7]
M?\*/[1N/^?"7]?\ "@#0HK/_ +1N/^?"7]?\*/[1N/\ GPE_7_"@#0HK/_M&
MX_Y\)?U_PH_M&X_Y\)?U_P * -"BL_\ M&X_Y\)?U_PH_M&X_P"?"7]?\* -
M"BL_^T;C_GPE_7_"C^T;C_GPE_7_  H T**S_P"T;C_GPE_7_"C^T;C_ )\)
M?U_PH T**K6MU+.S"2V>$ 9!;//Z59H *X;6?'>J>&M4NX]9\/7$MAYP2TN[
M3D.#T#9/7_.*[FLS7-!M/$%O;07YD\NWN4N0J$#<R9P#D'@YYQ@^] '(:/9Z
MQXH^(5IXHU+29-&M-/MVAABG'[V9B&'(P"!\Y/X>YK*\9:AK&K^+/L&H>'M9
MN/#]E)GR;*V<_;''0LV/N^P]/4Y'J]% '*^'_%DVI:A#IP\+:MI<(0A9;BU,
M<2!1PO3 Z8 KFM._MSX=:QJMK!H-YJ^CW<YN+9[-2S(Q'0@9QP "<#[H/>O3
MZ* .&\):7JFI>+K[Q;K]A]@>:$6]G:OR\:9Y)]#QZ#[Q[5DZ=_;GPZUC5;6#
M0;S5]'NYS<6SV:EF1B.A SC@ $X'W0>]>GT4 <-X2TO5-2\77WBW7[#[ \T(
MM[.U?EXTSR3Z'CT'WCVKN:** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HK+\2WT^F^'+N[M&"S1J"I(SC+ =/QKS;_A/O$/\ S]I_WY3_  KJ
MHX6=:/-&QS5L3"C+ED>NT5Y%_P )]XA_Y^T_[\I_A7JFG3O<Z7:SRX+RPH[8
M'<J":5;#3HI.74='$0K-J/0LT445S'0%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5S^K>--+T;47LKM;@RH 3Y: CD9]:Z"O(O'W_(XW7^['_P"@"NO"
M48UJG++L<N*JRI0YH]SL/^%D:)_SSN_^_8_^*K3T3Q7I^OW,D%B)@\:;SYB
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M<7%NNTO(ALK22_OH;2#;YDSA%W' R3CFO3-%^'NGV&V74C]MF'.TC$8_#O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\]O_ !T_X4 6Z*J?VG9_\]O_ !T_X4?VG9_\]O\ QT_X4 6Z*J?VG9_\]O\
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M%5/[3L_^>W_CI_PH_M.S_P">W_CI_P * +=%5/[3L_\ GM_XZ?\ "C^T[/\
MY[?^.G_"@"W153^T[/\ Y[?^.G_"C^T[/_GM_P".G_"@"W153^T[/_GM_P".
MG_"C^T[/_GM_XZ?\* +=%5/[3L_^>W_CI_PH_M.S_P">W_CI_P * +=%5/[3
ML_\ GM_XZ?\ "C^T[/\ Y[?^.G_"@"W153^T[/\ Y[?^.G_"C^T[/_GM_P".
MG_"@"W153^T[/_GM_P".G_"C^T[/_GM_XZ?\* +=%5/[3L_^>W_CI_PH_M.S
M_P">W_CI_P * +=%5/[3L_\ GM_XZ?\ "C^T[/\ Y[?^.G_"@"W153^T[/\
MY[?^.G_"C^T[/_GM_P".G_"@"W153^T[/_GM_P".G_"C^T[/_GM_XZ?\* +=
M%5/[3L_^>W_CI_PH_M.S_P">W_CI_P * +=%5/[3L_\ GM_XZ?\ "C^T[/\
MY[?^.G_"@"W153^T[/\ Y[?^.G_"C^T[/_GM_P".G_"@"W153^T[/_GM_P".
MG_"C^T[/_GM_XZ?\* +=%5/[3L_^>W_CI_PH_M.S_P">W_CI_P * +=%5/[3
ML_\ GM_XZ?\ "C^T[/\ Y[?^.G_"@"W153^T[/\ Y[?^.G_"C^T[/_GM_P".
MG_"@"W153^T[/_GM_P".G_"C^T[/_GM_XZ?\* +=%5/[3L_^>W_CI_PH_M.S
M_P">W_CI_P * +=%5/[3L_\ GM_XZ?\ "C^T[/\ Y[?^.G_"@"W153^T[/\
MY[?^.G_"C^T[/_GM_P".G_"@"W153^T[/_GM_P".G_"C^T[/_GM_XZ?\* +=
M%5/[3L_^>W_CI_PH_M.S_P">W_CI_P * +=%5/[3L_\ GM_XZ?\ "C^T[/\
MY[?^.G_"@"W153^T[/\ Y[?^.G_"C^T[/_GM_P".G_"@"W153^T[/_GM_P".
MG_"C^T[/_GM_XZ?\* +=%5/[3L_^>W_CI_PH_M.S_P">W_CI_P * +=%5/[3
ML_\ GM_XZ?\ "C^T[/\ Y[?^.G_"@"W153^T[/\ Y[?^.G_"C^T[/_GM_P".
MG_"@"W153^T[/_GM_P".G_"C^T[/_GM_XZ?\* +=%5/[3L_^>W_CI_PH_M.S
M_P">W_CI_P * +=%5/[3L_\ GM_XZ?\ "C^T[/\ Y[?^.G_"@"W153^T[/\
MY[?^.G_"C^T[/_GM_P".G_"@"W153^T[/_GM_P".G_"C^T[/_GM_XZ?\* +=
M%5/[3L_^>W_CI_PH_M.S_P">W_CI_P * +=%5/[3L_\ GM_XZ?\ "C^T[/\
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M=EL]C?#5U6A=[K<C^R6__/"+_O@4?9+?_GA%_P!\"I:*Y3I(OLEO_P \(O\
MO@4?9+?_ )X1?]\"I:* (OLEO_SPB_[X%'V2W_YX1?\ ? J6B@"+[);_ //"
M+_O@4?9+?_GA%_WP*EHH B^R6_\ SPB_[X%'V2W_ .>$7_? J6B@"+[);_\
M/"+_ +X%'V2W_P">$7_? J6B@"+[);_\\(O^^!1]DM_^>$7_ 'P*EHH B^R6
M_P#SPB_[X%'V2W_YX1?]\"I:* (OLEO_ ,\(O^^!1]DM_P#GA%_WP*EHH B^
MR6__ #PB_P"^!1]DM_\ GA%_WP*EHH B^R6__/"+_O@4?9+?_GA%_P!\"I:*
M (OLEO\ \\(O^^!1]DM_^>$7_? J6B@"+[);_P#/"+_O@4?9+?\ YX1?]\"I
M:* (OLEO_P \(O\ O@4?9+?_ )X1?]\"I:* (OLEO_SPB_[X%'V2W_YX1?\
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MB_[X%'V2W_YX1?\ ? J6B@"+[);_ //"+_O@4?9+?_GA%_WP*EHH B^R6_\
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M"D@$8.#UJU;:5J%YC[+97$H/=(R1^=;T\VK<O+R\TOZZ(PJY11Y^;FY8]O\
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M(/UK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L/Q;KHT+17DC/\ I,W[N >_=OP_PK;9E1"SD*JC))/
M%>,^*M<;7=:DF4G[/'\D"_[/K]3UKLPE#VM379')BJWLH:;LIZ3IL^M:O#:0
MDEYF^9SSM'4L:]LL[2&PLHK6V7;%"H51[5S/@'0/[-TLW]PN+F[ *@CE(^P_
M'K^5=;5XVO[2?*MD1@Z/LX<SW84445P'<%%%% !1110 4444 %%%% !1110
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MEG_SQ_\ 'C_C1_9EG_SQ_P#'C_C0!-]KM_\ GO%_WV*/M=O_ ,]XO^^Q4/\
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M]F6?_/'_ ,>/^- $WVNW_P">\7_?8H^UV_\ SWB_[[%0_P!F6?\ SQ_\>/\
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MHXKRZ^%J4=7JNYZ='$PJZ+1]C9^UV_\ SWB_[[%'VNW_ .>\7_?8J'^S+/\
MYX_^/'_&C^S+/_GC_P"/'_&N4Z2;[7;_ //>+_OL4?:[?_GO%_WV*A_LRS_Y
MX_\ CQ_QH_LRS_YX_P#CQ_QH F^UV_\ SWB_[[%'VNW_ .>\7_?8J'^S+/\
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MA7L?VQ1_E?X?YGB_V+7_ )E^/^1[']KM_P#GO%_WV*/M=O\ \]XO^^Q7C?\
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M:[?_ )[Q?]]BC[7;_P#/>+_OL5#_ &99_P#/'_QX_P"-']F6?_/'_P >/^-
M$WVNW_Y[Q?\ ?8H^UV__ #WB_P"^Q4/]F6?_ #Q_\>/^-']F6?\ SQ_\>/\
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ML\,DK2L@=FRQQD\D^@XZ51UGP5X>\07'VC5M+BGGXS*K-&S8&!DJ03^-;M%
M%+2M&T[0[,6NDVD5K"#G:@ZGU)ZG\:NT44 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>9?$+7_ME^-+MF_<VQS*
M0?O2>GX?S)KL_%6N+H6BO,I'VB7Y(%_VO7Z#K^5>2Z9I]QK6K16D)+23/\SG
MG ZEC7IX&BM:TMD>;C:KTI1W9U?P[T#[1=-J]RG[N$[8 ?XG[G\/Y_2O2:KV
M-E#IUA#:6R[8H5"J/ZU8KCQ%9UJCD=="DJ4%$****P-PHHHH **** "BBB@
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M=H?_ #^_^0G_ ,* -JBO,/$FHQWVN2SV4[/"54*>1T SP?>LKS9/^>C?]]4
M>R45YCH&N_V-=2S2H\X>/:%WXYR#FM.?Q]>-G[/:0Q_[Y+?X4 =W17F4_B[6
M9_\ EZ\L>D: ?KUK.GU&]N<_:+N>7V>0D4 >K3ZC96V?M%W#%[/( :S9_%NC
M0?\ +UYA](T)_7I7G,%C=W/_ ![VTTO^Y&3_ "K2@\*:S/TLS&/61@OZ9S0
MOB?6+?6=0CFM5D5$CV'S  2<D]C[UBUHZIHEWI,T<=R%9I%W#R\D#G&.G6J/
ME2?\\V_[YH O:#J,>E:Q%=SHSH@8$)C/(([UWEMXNT>XP#<F%O25"/UZ?K7G
M^G:5<ZG>K;0 ([ D&0$#@9]*N7/A36+;)-H9%]8F#?IU_2@#TF"ZM[I<VT\<
MP]8W#?RJ6O'9(9[60>;')"XZ;E*D5=MO$.K6F/)OIL#LYWC]<T >JT5P%MX[
MU"/ N8(9QZ@%3_A^E:UMX\L9,"YMYH3ZKAP/Y']* .IHKE]:\60#2A)HUXAG
M\P @IR!@YX(^E<[_ ,)CK7_/RO\ WZ7_  H ]*HKS>/QAK)E0&X0@L,CRE_P
MKTB@ HHHH **** "BFR2)%&7E=41>2S' %5_[4L/^?ZV_P"_R_XT 6J*J_VI
M8?\ /];?]_E_QJR"&4%2"",@CO0 M%%% !1110 4444 %%%% !1110 4444
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M.#7/6P52,K4U='12QD)1O-V9W-%<4OQ-T[^*RNA]-I_K4B_$S2#]ZUO1_P
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M"$J V[:#G/J?:@#H:*Q+KQ=H]KD"X,S#M"I;]>GZUC77C\\BRLOHTS?T'^-
M':4R6:*!-\TB1K_>=@!7FMUXLUBZR/M/DKZ0J%_7K^M93/<7<WSM)/(?4EB:
M /2;KQ9H]KD?:O.8=H5+?KT_6N)\2:S%K5_'-!&\:)'L^?&3R3V^M-M?#&KW
M>"EF\:G^*7Y/T/-27WA75+)T58&N=RY)@4L%]NE &+5O3=0FTN^2[MPAD0$
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M^O'ZUZ!10!Y+?:/J&FKNO;5XESC=P5S]1Q5*O4O$6E2ZSI8MH)$C<2!\OG'
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M?KN']*C;X9ZN/NW5D?\ @;C_ -EKU"BI^O5^Y7U*CV/*V^&^MCI):-])&_\
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MWX6TZYTO1S!>($D,K-@,#Q@>GTK9H Y^W\(6=L08V!8?Q,F3_.KXTV<# OY
M/Q_QK1HH S_[.N/^?^7]?\:/[.N/^?\ E_7_ !K0HH S_P"SKC_G_E_7_&C^
MSKC_ )_Y?U_QK0HH S_[.N/^?^7]?\:/[.N/^?\ E_7_ !K0HH S_P"SKC_G
M_E_7_&C^SKC_ )_Y?U_QK0HH S_[.N/^?^7]?\:/[.N/^?\ E_7_ !K0HH S
M_P"SKC_G_E_7_&C^SKC_ )_Y?U_QK0HH S_[.N/^?^7]?\:/[.N/^?\ E_7_
M !K0HH S_P"SKC_G_E_7_&C^SKC_ )_Y?U_QK0HH S_[.N/^?^7]?\:/[.N/
M^?\ E_7_ !K0HH S_P"SKC_G_E_7_&C^SKC_ )_Y?U_QK0HH S_[.N/^?^7]
M?\:/[.N/^?\ E_7_ !K0HH S_P"SKC_G_E_7_&C^SKC_ )_Y?U_QK0HH S_[
M.N/^?^7]?\:/[.N/^?\ E_7_ !K0HH S_P"SKC_G_E_7_&C^SKC_ )_Y?U_Q
MK0HH S_[.N/^?^7]?\:/[.N/^?\ E_7_ !K0HH S_P"SKC_G_E_7_&C^SKC_
M )_Y?U_QK0HH S_[.N/^?^7]?\:/[.N/^?\ E_7_ !K0HH RY]&>Z@:&XO'D
MC<896!P?UJA_PA=A[?\ ?)_QKHZ* .<_X0NP]O\ OD_XUH#2)!"L0O'\M0 %
MP< ?G6G10!A2^%K68YE\MCZ^5S^>:K2>![%^DC)_N@_U-=-10!R$GP_A/^JO
MW7_>B!_J*I3> KU?]1=02?[P*_XUWE% 'F-UX4U>TC>1[<-&@+,R2 X ]LYK
M&KV.YA%S:RP$[1(A0D=LC%<E_P *_C_Z"+?]^O\ Z] '$U*ES/$H$<TB = K
MD5V/_"OX_P#H(M_WZ_\ KUT6GZ/;6.G16K)'/Y8(WO&,GG- 'F2ZIJ"?=OKE
M?I,P_K3QK>J#IJ-U^,S'^M>GMI>GO]^QMF^L*G^E1-H6E-UTZV_"("@#S@>(
M-6'34+C\7S3QXDU<?\O\OXD5W[>&M';K81?AD5$WA+1&ZV0'TD<?UH X@>)]
M7'6[<_6LDDLQ)ZDYKTEO!NC-T@=?I*U>=202)*R^6XPQ'W30!%78>$9(7L&M
M_P"T?L\WF$B+.,C Y'(S7)>5)_SS;_OFGM:W"0"=X9%B)P'*G&?3- #_ !Q=
MM-X@:V,[3+:J$!8_Q'D_X?A72> M$E717OA.T+7+\;1U5>!W]<UQLUO',Q9Q
M\QY+#J:[_0/%>FPV%O8SHUIY,80,?F4X'7(Z9KOJ8B#PZI0^9PT\/)5W4D;O
M]G7'_/\ R_K_ (T?V=<?\_\ +^O^-789HKB(202+(AZ,C9!I]<!W'G'C?P])
M:,NIQN95D.V8XP0W8_CT_P#UU4\&:F\6H#3I+IX8;@_(03@/^??I^5>F7EI%
M?V<MK<KNBE4JPKQG4K&;2-5FM)#B2%^&'&1U!'X8-?.XVG+"8A8BGL_Z_$^E
MP-2.,PSPU3=;>G3[CUS^SKC_ )_Y?U_QH_LZX_Y_Y?U_QK'T?QMILVEPG4KH
M0W2C;(I1CDCOP.];&GZ[INJRM'I]TLSHNYE"D8'KR*]JGB:-1+EDM?/4\*IA
M:U)OFB].MM _LZX_Y_Y?U_QH_LZX_P"?^7]?\:T**Z#G*UK:R0,QDN'F!& &
MSQ^M6:** "BBD9E12SD*JC)). !0 M%5=,U.TUG38;_39?.M9@3')M*[L$CH
M0#U!JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%5K_4+73+5KF^F
M6&)>['K[ =S7FWB+Q[=:COMM+W6MMT+Y_>2#^@^E=%'#SK/W=NYA6Q$**][<
MZSQ%XVLM%W06V+J\'&Q3\J'_ &C_ $_E7F>IZO?ZW>"6^E:5R<(@'RK[ 4_1
MM!O]=N?+L8B5!^>5N$3ZG^G6O2]$\,:3X:C6>YDC>ZQS/,0 O^Z#T_G7I7H8
M-::R_K[CSK5L6^T?Z^\YCP[\/I[O;<ZUNMX>H@'#M]?[H_7Z5Z+:6EO8VRV]
MG"D,2]$08%9ESXKT>VR#=B5O2)2WZ]/UK)N?'\*Y%I92/Z&5POZ#->96KSK.
M\CT:-"%)6B/U[Q;=:5J\EI!!"Z(%.7SGD9['WK._X3V__P"?6V_)O\:P-3U"
M35-1EO)D5'DQE5Z#  _I52L#<]"\->);C6KZ6"XABC"1[P4SZ@=S[UTM>06=
M]<Z?,9;.9HG*[2R]QZ?I4UUK.I7BXGOK@J>JK(5!_ 5,N:VA4>6_O'J%UJ-E
M9#-Y=PP>TD@!_*L2[\=Z);9$<LERP[11G^9Q7G!MT)).<GOFF_94]6_.N"K+
M'/X(Q7SO_D>A2C@%_$E)_*W^9UUW\293D6.GHOHTSEOT&/YUB7?C/7+O(^V>
M2I_AA4+^O7]:S4M8@W[S>R^BD _R-:]E<Z+:X,NBFY8?Q2W)_D!BN"6'S&J[
M3G;Y_P"1Z,<3EM%7A"_R_P S#DDN;R0R3R23/T+2.6/YFF>1)_=_6MW5[ZUO
M[B-[*R2R1(]AC3&"<DYX ]:SZUCD]-KWY._]>1C+.JB?N15OZ\R7P_HZZKK<
M%G=,\<4FXDH1GA2?Z5Z9I_AC2--P;>S1I!_RTE^=OUZ?A7GVAZA'I>L0WDR,
MZQAOE3KRI']:ZL^/[3^&RF/U85VX? T:&RN^[.'$YA7Q&[LNR.LHKD#\0(?X
M;"0_60#^E,/Q!'\.FD_6?_[&NXX#LJ*XD_$"3^'3E'UFS_2F'Q_<?PV,0^KF
M@#HM>UY="CA9H#-YQ( #;<8Q_C6+_P + C_Z!S?]_?\ ZU8&M^(9M<6%9H8X
MA$21L)YSC_"LB@#OK'QM'>ZA!;?863SG";O,SC/X5U->/6ER]G>17,04O$X=
M0PX)%=#_ ,)YJG_/"T_[X;_XJ@#T"BO/_P#A/-4_YX6G_?#?_%4?\)YJG_/"
MT_[X;_XJ@#T"BO/_ /A/-4_YX6G_ 'PW_P 51_PGFJ?\\+3_ +X;_P"*H [/
M6&M$TBX;4HS):A1YB =>1_7%<;]I\%_] N;]?_BJJZAXOO\ 4;&6TGBMECD
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M6?\ H&77_?HUZAX6MYK3PS9PW,;12JIW(PP1\Q-4?^$YTK^Y<_\ ?L?XU?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\Q_E_P#6H\G5/^?F/\O_ *U &A16?Y.J?\_,?Y?_ %J/)U3_ )^8_P O_K4
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MK#N8OA[P]_8/VC_2?/\ .V_\L]NW&?<^M;5%%,04444 %%%% !1110 4444
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M0 4444 %%%% !1110 5!<6-I=L&NK6&8J, R1AL?G4]%--K832>Y2_L;3/\
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MNI5TV1Z%'"TZ6N["BBBN0Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*AN+2WNX]EW;Q3I_=D0,/UJ:BFFUL&^YQ7B[PIH]KH%U?6EH()X@"IC8A>6
MZ=.]>9U[_)%'-&T<R+(C##*PR#^%5/[&TS_H'6G_ 'X7_"O1H8UTXVG=GGU\
M&JDKQT/"ZTM-\0ZKI)'V&\D1!_RS8[D_(\5[%_8VF?\ 0.M/^_"_X51U+PAH
MNI@F6S6*3_GI!\A_3@_B*W^OTIZ3CH8?4:D=8RU.:TSXF_=35[/ZRVY_]E/^
M-==IOB#2]6 ^PWD;N?\ EF3M?_OD\UQ&I_#2[BR^E727"_\ /.7Y&_/H?TKD
M[[2[_2Y0M]:RV[9X++P?H>A_"E]7PU?6F[/^N@_K&(H_Q%=?UU/=:*\<TSQG
MK6F85+HW$0_Y9W'SC\^H_.NOTSXDV$^$U.WDM6[NGSI_B/R-<E3 U8;:G53Q
ME*>^AVE%5+?5;"[M7N;:[BEA12SLC9V@>H[5F_\ ":>'O^@DG_?M_P#"N94Y
MO9,Z74@MVC=HK"_X33P]_P!!)/\ OV_^%:D6I6<VGK?)<Q_96&1*QVKC\:4J
M<X[I@JD);-%FBN1U7XB:99;H[!6O91W7Y4'XGK^ KBM5\8ZQJVY'N/(A/_+*
M#Y1^)ZG\ZZJ6"JU-7HO,YJF,I0T6K/2]5\5:1H^5NKH/*/\ EC%\S?\ UOQQ
M7$ZK\1[^YW1Z7"MI'_?;YW/]!^M<WINAZCJ[[=/M))1G!?&%'U8\5VFE?#1%
MVR:S=;SU\F#@?BQ_H/QKL]CAL/\ &[O^NAR>UQ-?X%9?UU.%DEO=4N\R--=W
M#GC.78_2MB+P-X@EC#BQV \@/*H/Y9XKU73]*L=*B\O3[6. =RHY/U/4_C5N
MLIY@]J<=#2& 6\WJ>1?\(#XA_P"?1/\ O\G^-=[X+TF[T;06MK] DIF9]H8-
MP0!V^E=!17-6Q=2M'EE8Z:6%A2ES1N%%%%<AU!1110 4444 %%%% !1110 4
M444 %%%% !7$ZYX)U)?$4GB#P=J::=J$X"W$,RYAFXZG@\\#M[\&NVKSW6?$
MWC'PQJK0W&GV6IVM]?\ DZ>XF$;G>?DC(XZ#C)'U- &AX8\97]WXBG\.^*+"
M.QU:-/,C^SG='*N,^IP<<]?R(YYR[BO-5^(EY=?#B1K>XB)34[J=L6LC@8"A
M<$L>#DXZ\^YW_#GAW6[OQ;)XI\6>3;W8@^SVUG;MN6).^3D\\GH>I)]JH:7H
M_BCP/JNI)HVDPZYIM[,9X_\ 2UAEC)_O%A@\>@]#GJ* *7@VY2QGU[3-8M)H
MO%,EN\T\]S*'^TC;P$(P HR#@?GQQL?!XJ?AY!MZB>7=QWS_ (8IVA:#KVH^
M-AXI\406]B\%M]FMK.&0.R@YY9AD?Q-T/?MCG.T_1O&'@:YO;3PWIUKJ^DW$
MQF@1YUC>$D8P<E?0=,CCMDT 6+ $?'W4_*V\Z4OFY//6/I[_ '?PKT&N2\&>
M&]1T^^U/7/$<D3ZMJ;C>D)RD*+T4?IZ\*.>M=;0 4444 %5+B2^6;%M"CICJ
MQ_\ KU;HH S_ #M4_P"?>+\__KT>=JG_ #[Q?G_]>M"B@#/\[5/^?>+\_P#Z
M]'G:I_S[Q?G_ /7K0HH S_.U3_GWB_/_ .O1YVJ?\^\7Y_\ UZT** ,_SM4_
MY]XOS_\ KT>=JG_/O%^?_P!>M"B@#/\ .U3_ )]XOS_^O1YVJ?\ /O%^?_UZ
MT** ,_SM4_Y]XOS_ /KT>=JG_/O%^?\ ]>M"B@#/\[5/^?>+\_\ Z]'G:I_S
M[Q?G_P#7K0HH S_.U3_GWB_/_P"O1YVJ?\^\7Y__ %ZT** ,_P [5/\ GWB_
M/_Z]'G:I_P ^\7Y__7K0HH S_.U3_GWB_/\ ^O1YVJ?\^\7Y_P#UZT** ,_S
MM4_Y]XOS_P#KT>=JG_/O%^?_ ->M"B@#/\[5/^?>+\__ *]'G:I_S[Q?G_\
M7K0HH S_ #M4_P"?>+\__KT>=JG_ #[Q?G_]>M"B@#/\[5/^?>+\_P#Z]'G:
MI_S[Q?G_ /7K0HH S_.U3_GWB_/_ .O1YVJ?\^\7Y_\ UZT** ,_SM4_Y]XO
MS_\ KT>=JG_/O%^?_P!>M"B@#/\ .U3_ )]XOS_^O1YVJ?\ /O%^?_UZT**
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MQ?G_ /7K0HH S_.U3_GWB_/_ .O1YVJ?\^\7Y_\ UZT** ,_SM4_Y]XOS_\
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M_P#W_'_Q-'_"T8O^@4__ '_'_P 375]3K_R_D<WUNA_-^9UOG:I_S[Q?G_\
M7H\[5/\ GWB_/_Z]#:YI\&GP75Y<Q6RS1K(%D<;L$9QCJ:Y[4/B1IEOE;"&6
M[;LQ&Q?S//Z5E"A4F[11K*M3@O>9T/G:I_S[Q?G_ /7J*XO[VTB,ETMM"@ZM
M(X4?F6KSO4/B!K5YE8'CLT/:)<M^9S^F*Y^2:[U&X!E>:ZF;IN)=C7;#+YO6
M;L<4\?%:05ST6\^(5M:DK'LN'':)3C\\X_*L*]^)&JS@K:106P[-MWM^O'Z5
M0T_P-KE_@FV^RH?XK@[?TZ_I74:?\,[2+#:E>23GND0V+^?)/Z5KR8.CN[O[
M_P#@&?-BZVRLON/-R2S$GDDY-)7HK?"^$L2NINJYX'D@X_6D_P"%71?]!5_^
M_ _^*KJ^NT._X,YOJ=?M^1RVC>$]2URU-S9B(0ARA9WQR,=OQK;A^&UWUN)_
MP0#^9-=MX=T-?#^EFS2<S@R&0N5V]<=OPK5KS:N.J.3Y'H>A2P=-17.M3A;?
MP!;PX\VV>X_ZZ38_]!(K5MO#T-ICR=$LLCH74.1^+$UTM%<LJ]66\F=4:-..
MT49L;:C$NV*T@11V7 '\Z=YVJ?\ /O%^?_UZT**Q-3/\[5/^?>+\_P#Z]'G:
MI_S[Q?G_ /7K0HH S_.U3_GWB_/_ .O1YVJ?\^\7Y_\ UZT** ,_SM4_Y]XO
MS_\ KT>=JG_/O%^?_P!>M"B@#/\ -U3_ )]XOS_^O5>6VN9_]=IMI)_OHI_K
M6Q133:V$TGN>4>)O#NIR:],]GI#K$RK@6T/R=!GIQ63_ ,(UK?\ T"KO_OR:
M]MHKT(8^<8J-MC@G@82DY7W/-_ ^E:QINJ7$KZ?)$&AVYF0J#\P/&<>E=QYV
MJ?\ /O%^?_UZT**Y*U5UI\[.NC25*'*C/\[5/^?>+\__ *]'G:I_S[Q?G_\
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MG:I_S[Q?G_\ 7H\[5/\ GWB_/_Z]:%% &?YVJ?\ /O%^?_UZ/.U3_GWB_/\
M^O6A10!6M7NV9OM42(,<;3_]>K-%% !1110 53OM)LM2GM)KV#S7LYA- 2Q&
MQQWX//XU<HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\ZOK37_!?C+4M:TC3'UG3-59&N((?]=&X!
MY  )(&6[=\'UKT6N*N?B?I>EZE>6.O6EYI\MM.T:,8BZRH#\K@@?Q#G&/Q-
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M/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\
MN2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V
M;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S
M_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0
MHH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_
M !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[D
MOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9
MM_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\
M:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2
M_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MF
MW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#
M/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M
M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY
M#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_
M[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/
M[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D
M/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\
MN2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V
M;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S
M_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0
MHH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_
M !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[D
MOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9
MM_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\
M:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2
M_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MF
MW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#
M/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M
M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY
M#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_
M[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/
M[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D
M/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\
MN2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S_P"V
M;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0HH S
M_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_ !K0
MHH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[DOY#_
M !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9M_[D
MOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\:/[9
MM_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2_D/\
M:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@#/_MFW_N2
M_D/\:/[9M_[DOY#_ !K0HH S_P"V;?\ N2_D/\:/[9M_[DOY#_&M"B@"M:WT
M=VS+&K@J,G<!5FBB@ HHHH *QM?\/C7;G29'NFA33KU+S8%SYI7H.HQ]>:V:
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_QT_P"% %NBJG]J6?\ SU_\=/\ A1_:EG_SU_\ '3_A0!;HJI_:EG_SU_\
M'3_A1_:EG_SU_P#'3_A0!;HJI_:EG_SU_P#'3_A1_:EG_P ]?_'3_A0!;HJI
M_:EG_P ]?_'3_A1_:EG_ ,]?_'3_ (4 6Z*J?VI9_P#/7_QT_P"%']J6?_/7
M_P =/^% %NBJG]J6?_/7_P =/^%']J6?_/7_ ,=/^% %NBJG]J6?_/7_ ,=/
M^%']J6?_ #U_\=/^% %NBJG]J6?_ #U_\=/^%']J6?\ SU_\=/\ A0!;HJI_
M:EG_ ,]?_'3_ (4?VI9_\]?_ !T_X4 6Z*J?VI9_\]?_ !T_X4?VI9_\]?\
MQT_X4 6Z*J?VI9_\]?\ QT_X4?VI9_\ /7_QT_X4 6Z*J?VI9_\ /7_QT_X4
M?VI9_P#/7_QT_P"% %NBJG]J6?\ SU_\=/\ A1_:EG_SU_\ '3_A0!;HJI_:
MEG_SU_\ '3_A1_:EG_SU_P#'3_A0!;HJI_:EG_SU_P#'3_A1_:EG_P ]?_'3
M_A0!;HJI_:EG_P ]?_'3_A1_:EG_ ,]?_'3_ (4 6Z*J?VI9_P#/7_QT_P"%
M']J6?_/7_P =/^% %NBJG]J6?_/7_P =/^%']J6?_/7_ ,=/^% %NBJG]J6?
M_/7_ ,=/^%']J6?_ #U_\=/^% %NBJG]J6?_ #U_\=/^%']J6?\ SU_\=/\
MA0!;HJI_:EG_ ,]?_'3_ (4?VI9_\]?_ !T_X4 6Z*J?VI9_\]?_ !T_X4?V
MI9_\]?\ QT_X4 6Z*J?VI9_\]?\ QT_X4?VI9_\ /7_QT_X4 6Z*J?VI9_\
M/7_QT_X4?VI9_P#/7_QT_P"% %NBJG]J6?\ SU_\=/\ A1_:EG_SU_\ '3_A
M0!;HJI_:EG_SU_\ '3_A1_:EG_SU_P#'3_A0!;HJI_:EG_SU_P#'3_A1_:EG
M_P ]?_'3_A0!;HJI_:EG_P ]?_'3_A1_:EG_ ,]?_'3_ (4 6Z*J?VI9_P#/
M7_QT_P"%']J6?_/7_P =/^% %NBJG]J6?_/7_P =/^%']J6?_/7_ ,=/^% %
MNBJG]J6?_/7_ ,=/^%']J6?_ #U_\=/^% %NBJG]J6?_ #U_\=/^%']J6?\
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MT_X4 6Z*J?VI9_\ /7_QT_X4?VI9_P#/7_QT_P"% %NBJG]J6?\ SU_\=/\
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M9_\ /7_QT_X4 6Z*J?VI9_\ /7_QT_X4?VI9_P#/7_QT_P"% %NBJG]J6?\
MSU_\=/\ A1_:EG_SU_\ '3_A0!;HJI_:EG_SU_\ '3_A1_:EG_SU_P#'3_A0
M!;HJI_:EG_SU_P#'3_A1_:EG_P ]?_'3_A0!;HJI_:EG_P ]?_'3_A1_:EG_
M ,]?_'3_ (4 6Z*J?VI9_P#/7_QT_P"%']J6?_/7_P =/^% %NBJG]J6?_/7
M_P =/^%']J6?_/7_ ,=/^% %NBJG]J6?_/7_ ,=/^%']J6?_ #U_\=/^% %N
MBJG]J6?_ #U_\=/^%']J6?\ SU_\=/\ A0!;HJI_:EG_ ,]?_'3_ (4?VI9_
M\]?_ !T_X4 6Z*J?VI9_\]?_ !T_X4?VI9_\]?\ QT_X4 6Z*J?VI9_\]?\
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MEB3RXGE/8# SV/N032>,_%MIX@UM_"D6IQZ9I\+D:C>ROM+[3@Q(._/!SQ^
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M%_WP*/LMO_SPB_[X%2T4 1?9;?\ YX1?]\"C[+;_ //"+_O@5+10!%]EM_\
MGA%_WP*/LMO_ ,\(O^^!4M% $7V6W_YX1?\ ? H^RV__ #PB_P"^!4M% $7V
M6W_YX1?]\"C[+;_\\(O^^!4M% $7V6W_ .>$7_? H^RV_P#SPB_[X%2T4 1?
M9;?_ )X1?]\"C[+;_P#/"+_O@5+10!%]EM_^>$7_ 'P*/LMO_P \(O\ O@5+
M10!%]EM_^>$7_? H^RV__/"+_O@5+10!%]EM_P#GA%_WP*/LMO\ \\(O^^!4
MM% $7V6W_P">$7_? H^RV_\ SPB_[X%2T4 1?9;?_GA%_P!\"C[+;_\ /"+_
M +X%2T4 1?9;?_GA%_WP*/LMO_SPB_[X%2T4 1?9;?\ YX1?]\"C[+;_ //"
M+_O@5+10!%]EM_\ GA%_WP*/LMO_ ,\(O^^!4M% $7V6W_YX1?\ ? H^RV__
M #PB_P"^!4M% $7V6W_YX1?]\"C[+;_\\(O^^!4M% $7V6W_ .>$7_? H^RV
M_P#SPB_[X%2T4 1?9;?_ )X1?]\"C[+;_P#/"+_O@5+10!%]EM_^>$7_ 'P*
M/LMO_P \(O\ O@5+10!%]EM_^>$7_? H^RV__/"+_O@5+10!%]EM_P#GA%_W
MP*/LMO\ \\(O^^!4M% $7V6W_P">$7_? H^RV_\ SPB_[X%2T4 1?9;?_GA%
M_P!\"C[+;_\ /"+_ +X%2T4 1?9;?_GA%_WP*/LMO_SPB_[X%2T4 1?9;?\
MYX1?]\"C[+;_ //"+_O@5+10!%]EM_\ GA%_WP*/LMO_ ,\(O^^!4M% $7V6
MW_YX1?\ ? H^RV__ #PB_P"^!4M% #$ACC),<:(3UVJ!3Z** "BBB@ HHHH
M**Y[Q1XSTGPQ9S"[O85OA"SPVQRS.V/E! Y )XR<#WI/!_BVS\4:5"R7=O)J
M"PH]U!"&7RV(Y #<X!X[_6@#HJ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M -^7\Q_A1_8UO_?E_,?X4 :%%9_]C6_]^7\Q_A1_8UO_ 'Y?S'^% &A16?\
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M/\*/[&M_[\OYC_"@#0HK/_L:W_OR_F/\*/[&M_[\OYC_  H T**S_P"QK?\
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M?S'^% &A16?_ &-;_P!^7\Q_A574-/BM8%>-G)+8^8CT/M0!M45G_P!C6_\
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MBO/_  =XQO;74_\ A%/&?[G58<+;W#GY;I>W/=CV/\7UZ^@4 %%%% !1110
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M91("S9'\1QCWP,CD5VOA7Q58>+=(6]L&VNN%GMV/S0MZ'U'H>_Y@ &W1110
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M[18PYP3CS&'\*C^]UZXZ&HM)^'_AK1-5_M'3M.$=P/N%I&<1^I4,3@^_Y8H
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MB.-JM_M=?S'?--F\*V-UXL37KUYKF:",+;02L#% >[*N.ON>_/IC;H ****
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M@#4^%;:7=^ 8X((XVFR\=_$XRS.2?O@]01^';UK&UK2;SX::T?$7AU6?0YW
MO[ <B,$]5]N>#V)QT-:?B/PQJVA:Y)XH\#J'N)<F^T\_=N!U+ 9&6[X'.>G)
M(-#6/&TWB[1I?#FF:!?QZK>_N9DNH]L=L,_,S-UXQZ#^A )_%]EKVH>,M&U7
MPBFX75BT(O67,<*MD[SZ':V1GKV!-==X9\,V?A?3/LUINEGE.^YNI.9)W[L3
M^)P.WUR3<T?3QI.AV6GARXM8$AW$YSM4#/Z5=H ***9++'!$TD\BQQKRSNV
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M.1V/\R #1\?R747@'5WL=XF6W/*9R%R-QX_V<U4\-Z!X9UCP)IZ1:=:W%I+
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MF7MOK,?R&P$1_>2= %/8$^HR/?OM_#O0KGP_X.@MM041W,LCSR1 \1ECPOY
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M3V\R[HY$/##_ #V[5PWAI?\ A$OB)J'AH@KI^I WNGCC:IP=Z#TQ@\>B@]Z
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MS9^%],^S6FZ6>4[[FZDYDG?NQ/XG [?7)(!KI&D>[RT5=S;FVC&3Z_6G444
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MH*@SPO&"PX^92.?SKB_ O@"71?)O_$4JW>HP)Y5J@.Z.UC!/W?<Y)S[_ %-
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M$>3)>1!4<'H203C/Y>]6/B-I$FI^&4U32S_Q,-)<7EK(G4@8+ 'T(&<#J5%
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M]B-Q$PD"QVJ$908YX P3TZ]CS4W@;XC:1;^%;"T\1ZPB7XRGSJ[':#\I9@"
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M!QG/3.<\=>#7%S:"_P 0?$>J'79+J#2=,G-I;6L;;/,D !:0^O48XZ$8/!R
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M9 VG'?HW\N]5H_#C?$;5-1OO$5Q=1:?:7+VME91GRRFWAG8$'YC_ )XP*S=
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M/EGCG R.AQR#0!D?"2UN+7P'%]H5ECFGDEMPY&?+.,'\2":[955%"H JJ,
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M-%$L2_Z(A P@/J,'GKSC)Q4%EX&TJS\7W?B(AY[NX;<@DP5A..2ON?7M724
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MI(?"=U*-Z6=Q?2/9QOSB/@9S]0?RSWKO:;%$D,210HL<:*%1$& H'0 =A3J
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M]P>1&/\ GFGH!T_#TKIEC19&=44.^-S <MCIF@!U%%% !1110 4444 %%%%
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M@2"WA7:D:# 45/0 4444 %%%% !4%]8VVIV,UG?PI/;S+MDC<<,/\]^U3T4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIZ "BBB@ HHHH **** "BBB@ HHHH ***1F5%+.0JJ,DDX % "T52_MK2_\
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M /00_P#(,G_Q-6K#Q+I&IW(@LKU9)2.$*LI/TR!FO.?^$)\0?] __P C1_\
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M%PMPMT-0CGVC(XVK@_>"G(]/Q&A\3+I;_P *>'_$EH-]O#=17# ')"L,^W<
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MV]E<?9XM3N)F<'C:(T)/Y5B> K[Q+&-2U^R\+'5#K%P9/M!U".' #-\H##.
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M]J:#4W$9\UTVYDDS]TC/04 :?@&WAT_XA>)K#0GW:)$(R%#%U67 R ?8[Q^
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MN*[O5/%>FZ+I%K?:EY\)NPOD6IB/GNQ .S9UW#.#Z'BN<L/^2]:G_P!@=?\
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M;0A791PS]6(^K$F@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !1110!A'P7H#,2=/')SQ*X_P#9J/\ A"O#_P#T#_\
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M:UI-SIU\I:"Y0H^#@CW'N#R/I56S\.6-MX730+@RW]DD1BQ=L&9DSD D =.
M,8Q@>E:U% '"?\*CT15,<.HZQ%;,?FMDN@(R,YP1MSCGUID/A+5_!6H&Y\$[
M;S3IV!N=*N'"MD#&Y)#W^OZ\8[ZB@ KBKGX7:9/JEY?1:MK-I)>3-/*EM<JB
MEF))XV>I/6NUHH Y[P]X)TCPW<275HLUQ>RC#W=W)YDI'IG@#IV%6M/\-66F
M^(M1UFW>;[1J(03(S H-HQ\HQD9]R:UZ* ./U+X9:'?ZI)J%M-?:7/+S(;"<
M1ASSDX(.,Y[8_GG:\/>&=,\,6+6VE0E/,;=+*[;GE/JQ_ITZ^M:U% ',>(?
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M=+*[;GE/JQ_ITZ^M)I/ANST?6-5U*VDG>;5)%DF61@54KNQMP 1]X]2:UZ*
M./U+X9:'?ZI)J%M-?:7/+S(;"<1ASSDX(.,Y[8_GF]::#I_@WPOJ']B6/G.L
M,DSK(=SW+A20&/OTQTY/'-=%10!XQX,T?X>W?A6.[UN]MDU)BYF\R\:!HCG@
M*@89 &,'!SS]!U/PJFFDLM6C@GN+C1HKPKILMP#EDR<X) XZ<=CG@<UUD_AS
M0[JY:XNM&T^:=CN,LEJC,3ZY(S6@B)%&L<:JB* JJHP !V H \QNM.M-=^/B
M-!%E=+MTFNW'(:11\GT(W)_WS]:]0JM!IUE;74UU;6=O#<3G,TL<2J\G^\0,
MG\:LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img123395336_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img123395336_0.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
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M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M\/%$U8-D)N'_V@ , P$  A$#$0 _ +_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<U['-56N:YJ]45/14(]:<6XR6$D2[&4914HM.+6*:W-'D?P_H
M
M
M
M
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MS@Y=<U[#S[0^9T+NI&*=2@WV=S1_C;>>%2*QV*?"Z<FO(G);38@PDDL
M
M
M
M
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M:FFTT<F=<[8
M
M
M
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M*56F\8RB]C33P<91:<9PDE.$U*$XQE%I=S/+/<
M
M
M
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M/UE6F_*A+8\,5A)+B@Y1P9)]AF5GF=#M[.:E#I73%]4EO3^OT8HR69@=X
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MQ4H3A)8J491:E&2>#331R)P'9
M
M
M
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M0>XGSZE-_0IJFNV\)U,JJ3>.Q)SK66+Z$E*O;I[DJU/B_(P+'1HX6>@
M
M
M
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M:DG*4YMRE*3VMRDVVVWM;;Q9A<I2G)SFVYMXMO:WXV?,<)\@
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M1
M
M
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MPQ;45CLC!8OAA%*,5LBDMA'-Q<W%W5=>YG*=5[VWB_\ _BZDMBZ#K1XYP
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MO;>&,TET.O;1EQ/':[>E%+%EJ,KR+>
M
M
M
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M2N*4OMJ=:G&I![.N,D=G///6
M
M
M
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MU--'YM-9::N]&:MS/25_MO,MOZ]M)[N)T:DJ?$O!-1XHO<TTUL,>GM&-
M  %RSX.G+#N3/"C4L);L?2,MQ'LVS<9W72/3WWT:L]?:==<L?1JMK5M?VFO3
MB<B=KOH;DZJYK^E7?>=TXLAYK7-W2CPVV96]*ZCANXFG2J[>MU*4IM;UQKH:
M+Q.Y)K%ZJY#V5A6EQ7F2W=>QEB]KA%JXH[/M8T;B%*+W/LWMQ3)3C7HVZ
M
M
M
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M#:4(8>UPBW)RB/.M0WN<SX9OL[-/9!/9XY/US^HNA+;CJN0H>
M  <]K.K;)N>9J:]J6"RVR9R^Y6U,5AJ-C(79NWIWR)!6CD>V"%J]TDCNC(VH
MKG*B(JGJ9/DN;Z@S"GE61VU>[S*J_)ITH2G-];PBFTEOE)X**VMI;3FH6]>Z
MJJC;PE.J]RBFW]3_ .D2E\&?#1R%SZ)G^=\R[&5E;'.S1=7N12Y)_P CO8SV
MP)'-4J-ZIVR0T?><YJ_-L1N0W1Y;]T"ZN.#,^9=QV-'8U9VTDZCZ<*U?!QCU
M.-'C;3V58,SW*M#SEA6S:7#'^#B]O[J6Y>*./WR)6]#XXT3C#"1Z]H&K8?5<
M2SL5]?%U6QRW)8VJQMG)7I%DOY6XC%Z+-9EEF5/17&[>F=)::T;ERRK2]E;V
M5BL,8TXX.36Q2J3>,ZD\-G'4E*7A) M+*TL*78V=.-.GX%O\+>]OPMMG=C(C
MM                        %.?XSO%\?'_ )J9O9*E9(,=RWI&I;\SVH^R
MLF3KP6M*S,;51J,6U-;U)+<Z>KE=;1Z_NRSSNM:@>=<JZ5C5EC7RV[K6^U[>
M!M5X>@E6X(^"&'04C]^;24=.<]KC-*,>&VSFPM[Q8+"/:)2M:J^^<K?M)=.-
M3%^J(G38TTY      +"?P"^1I*N[>0/$D\ZOBS>JZMR-C*SG_-K2:ME[.LYV
M>&/IZK=;N&.;*Y>O3Z/&B=.J]=*^^1D:J93DNI(+"5*XJVTWU]K!5::;^Y[&
MKA]\RRC_  Z=3RI9]J31E26,;BSM[VG''U+MZDJ%5I?=><T5)_<1+,YH46K
M
M
M
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MI<<_55JK7KJM66,YO';@WPQQPA&*V$E6&66.64NRLZ:@NE[Y/QM[7]9="1E
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MVT[DN>2R?O"97:X\-+,+6\MI>+S>=Q%;^FI;P2W[6MG2KG!5L7E
M
M
M
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M*F4:;R_*$JD%VEWAMG+>OO5NBO%MZ&V;7$W&0
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MI-[$E&O7A0DVWL24:CQ?5B7SRGH_0\
M
M
M
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MLGS'B4.PS2TJ<36*7!7IRQPVXX88X8/$_H8%*9^E4
M
M
M
M                 P?SMS_H/C_JC]BW"ZDV2MLGCUO5:4T7UYLEZ)G7V:D#
ME5:]"![F_2;CV^S7:Y.O=(^.-\<<RN:&F.5V2/-<^J<5W-25O;0:[:XFENBO
M6P3:[2JUP4TUCC*4(2\K-LXM,GM^VN7C-^I@O52?@\'6]R\>"=>?G?R"W_R
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MSXY+B<LY3D=CD]/"WCC7:\J;]4_L+P+9UXO:;"DJ'L@
M                 UY\NJEC(>)_D]0J1^[;N^//-52K%WLC]VQ9XVV6&&/O
ME<R-G?(]$ZN5&IU]51#-N6M6%'F-I^M5>%.&=V,F^I*ZI-O9MW=1&G.BC5N>
M3NK+>BN*M4TUFD8K8L92LJZ2Q>"6+?2\"@67)GYS      #F]9M5Z.R:_=MR
M)#5IYO$VK,RHYR15Z]^O+-(K6(YZHR-BKT1%7T]#J7].=:PKTJ:QJ2HS276W
M%I+TST,JK4[?-+:O6?#1A<4Y2?4E--O9U)']%\I!/TW
M
M
M
M                  U,\GO++3?'?#+3;]&V3D?)5EDP6H16.C:['*QK<MLD
ML*NEQN*8CE=&SHDUQS59%T:DDL<'<Y.>&G^5.7^;K@N]6UH8T;52]2MGMMPU
MMITUCC%;)U6N&&"4IPQ[/=0VV34N'9.]DO)AU>&74NKI?1TM5\.1>2-SY6VK
M(;GO>;LYS.Y!6M=--VQUJ=6/K]'Q^-I1(VMC\?6:JHR*)K6]55R]7N<Y:LM5
MZMU!K;.ZNH-2W,[G,JO2]D817J84X+",(1Z(Q26]O&3;<.WM[<YA<2N;N3G5
MEZ274EN274CHYC9U0        #V0PS69HJ]>*2>Q/(R&""%CI9III7(R***)
MB.?))(]R(UJ(JJJ]$/NG3J5:D:5*+E5DTDDFVVW@DDMK;>Q);6S^I.3X8[6R
M5?QB^'C?SB8[>.>X+6)Q"K';QO'$<KZV7R;.K9(I=JMP2-FP]*1GRTH7-NN[
MOQCZZM6-^[/)SNJ7.8]EJ/F=&="PV2IV";C5J+>G<RB\:4&OWJ+55X^7*DTX
MRS_(M&SJ\-UFZ<:>]4]S?W[Z%]RO*ZVMSF,PV&Q&NXNC@\#C*.&P^,KLJ8[%
MXRK#2HTJT?[B&M5KL9#%&G55Z(B=5557U4WZR_+['*K*EEV64:5O848*-.G3
MBH0A%;E&,4DEXD232I4Z--4J,5&E%8))8)+P(Y,[AR
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MCT_3H
M
M
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M!+61:8M,I2KUL*M_]MALCX()_C/:_ G@;KFQ!E
M                 !J1YZY7ZF\+_)ZVL[Z_O<+[UBO<C:KG.^O<+9P:0*C6
MN5&6ER/M.7Y$:]5541.I)/)VW\ZYIY!2P4L,UMYX/_5S53'T.'%>%$,]XB\\
MQY%ZLK.3CQ9%=T\5_K:4J6'BEQ\+\#90\+@#\\X     !W3C?'NRW(FA8ILJ
M0.R>Z:MCVS.:KVPNNYRC6256(YJO2-9.O3JG7I\IY6>UE;9)>7#6*IVM66'7
MPTY/#T<#W=+VSO-39=9I\+JW]O#'?AQ581QPZ<,3^B,4EGZ80
M
M
M
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M7_BF<_1P
M
M
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MJ-&*C2BL$DL$EX$<H=TY
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MQV;=G98]6S;BL2\N5(%_X
M
M
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M1\,NAR\&Y=.+W2EFZ)GH
M    !6_^/WN;5D\;./()/GL9R+N>4A7KZ-D75L'@I&]%Z>JQ9%%ZI^!.GX3>
M;N:Y6\,]SN:V-VU"#\7;5*B^K2*O_P#$:SQ<6EM-4WY25[<U%X_-Z5)_4K?4
M*XIO&5@@     $M?P4]478O-_$Y?VDD^P?&7(.UJ]4:JP)<K8[1_=:JL>J*J
M[GV=45J]'_+TZM76[O5YCYERFJ6V.'GE_;4?'PN5?#_88].[T5N7W$<G^,^?
ME&]PQ^+LJO+CQ<486N.Y_"<.C?OZ'</*QR[,
M
M
M
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M2\E?<K<GX=^&S=CCN 3R9&
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MBI5JS2Z'AYM!OI6*ZRS2:$EJX
M
M
M
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MHVX5576_#HV-/&:4U7-Z@
M
M
M
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MS\DN16F,HDN&K++(7,UTJ=ZY7DD_#%UW%]6&&Y&Y1%Y.
M
M
M
M
M             (>?C:\K?8?Q!AT*K/V9+F+?]=UR6%LGMRKKNL/?NN7LL5/G
M.C9E,)C:\C4Z=S;71?3JB[-]U'3OQMS,><5%C0RNSJU4^CM:OM$%X^"I5DO#
M#K-)N_GK#X@Y*QT[1EA=9WF-&@UC@^QH-W527B52E0@UTJIMV8IU"RRXI:
M    .]\6Z->Y/Y,X]XWQJO;D-_W?5=,IR1L[WQ6-FSE'#1S(WM=U2!UWO7JG
M1$;U7T/(U#F]+(,AO<]KX=C96E:O+'I5*G*;7H\.!D.DM/W&K-59;I>UQ5SF
M-_;VT6EC@Z]6%)/T.+'T#^AGCL?2Q&/H8K&UV5,=C*=7'T*L7=[=:E2@96JU
MX^Y7.[(8(VM3JJKT0I2KUZMS6G<UY.5>I)RDWO<I/%M^-O$_2M;6U"SMJ=G:
MQ4+:E",(16Z,8I1BEX$DD?8<1S@
M
M
M
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M+*+>XOJF.Y<$.QHOQQN*]&2^]\;5SLJU+S
M
M
M
M
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MQI-;T\+"AI664
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M&&+;VDH6E65Q:4J\\%.=.,GANQ:3>'@.VGN'8
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M>K4FTG)\,(5)2EA%.3P3P2;W)F4S'C+@
M    #HVX<H<:<>24(=_Y#T;1YLHRQ+C(MPVW :S)D8ZKHF6I*#,UD*3K;*SI
MV)(L:.1BO;UZ=4/7RS3^?9U&<LFLKN[C3:4W1HU*JBWC@I<$9<..#PQPQP>&
MXQ_.]6:5TU*G#4>9Y?E\ZR;IJYN*-!S4<.)P56<>)1Q6.&.&*QWHZ9]Y;QR_
M7_PG^U71?X^/4^0>N/U-FOYI<>]GA_2GRQ^<>0_VA:>_#[RWCE^O_A/]JNB_
MQ\/D'KC]39K^:7'O8^E/EC\X\A_M"T]^'WEO'+]?_"?[5=%_CX?(/7'ZFS7\
MTN/>Q]*?+'YQY#_:%I[\/O+>.7Z_^$_VJZ+_ !\/D'KC]39K^:7'O8^E/EC\
MX\A_M"T]^'WEO'+]?_"?[5=%_CX?(/7'ZFS7\TN/>Q]*?+'YQY#_ &A:>_#[
MRWCE^O\ X3_:KHO\?#Y!ZX_4V:_FEQ[V/I3Y8_./(?[0M/?A]Y;QR_7_ ,)_
MM5T7^/A\@]<?J;-?S2X]['TI\L?G'D/]H6GOQV+5^9^'MWRK,#I?*_&NWYR2
M":S'AM7WK5\_E7UJS4=8L,QV)RENXZ"!JHKWHSM:B^JH=',-+:GRFW=YFN77
M]M:)I<=6WJTX8O<N*<%'%]"QVGIY3KG1.?WBR_(LXRJ]OW%R5*A=T*U1QCZI
MJ%.I*6"Z7A@NDR4>$92
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M-%IK%=FEMPQ-TR*R=0
M                                         #A]B_V?SG^I\G_H4YT,
MU_1=S_R]3\1G'6_)2^]?UBHZ46&NP       +67#?^Z'BO\ LWT?^C&++M=
M?]"9)_5%G_-Z9L!EOZ.M_P")A^*C)!EIW0
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M*>&P_2!D.=Y?J7([/4.4S[3*[ZUI7%&6SRJ=:$:D'L;6+C)8K%X/8=G///6
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M.YUI=TXN^O,,7*6QNA0;2E"VIR]2L%*K)=K42?#"GO@0^;"@
M
M
M                   X?8O]G\Y_J?)_Z%.=#-?T7<_\O4_$9QUOR4OO7]8J
M.E%AKL       "UEPW_NAXK_ +-]'_HQBR[70'_0F2?U19_S>F; 9;^CK?\
MB8?BHR09:=T
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M:QJ:BSARHY32XH65HI-T[:CCU8X2K5,%*O5P3G)))1IPIPCJ.220P
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MG(H0B;,@
M
M                                        '#[%_L_G/]3Y/_0ISH9K
M^B[G_EZGXC..M^2E]Z_K%1THL-=@       6LN&_]T/%?]F^C_T8Q9=KH#_H
M3)/ZHL_YO3-@,M_1UO\ Q,/Q49(,M.Z
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MOJXO8JM1J5I+#<Y><1A13Z(UI^)W."K8O*
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M>>.JN"S=2WT%85)*RMWL<WMB[NNNFM5CNCM5"F^SBW)U9U([R;#6@
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M#;T
M
M                                     '#[%_L_G/\ 4^3_ -"G.AFO
MZ+N?^7J?B,XZWY*7WK^L5'2BPUV       !:RX;_ -T/%?\ 9OH_]&,67:Z
M_P"A,D_JBS_F],V RW]'6_\ $P_%1D@RT[H
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M(XV,17/>]RHB(B*JJI_)2C"+E)I12Q;>Y+K9]0A*<E"";FW@DMK;>Y)=+9;
M^%5\.&/@G#8SR%YLP?\ _NK8<>Z73=7R4+O<XLUW)5NQTUVG-&U:^^YJK*YM
MCNZOQU1_T=.R:2RU*YN\1SREJ^ZJ:*TI6_\ \K0GA7JQ>R[J1>Z,D]MO!I./
M15FN/;%4V7$=T'NP1Y>V-+F5KRW_ /\ =W-/&VH36VPHSCAC.+6R[JQ;4\=M
M&F^S\F<JJ)MS5 WT
M
M                                                    .'V+_9_.
M?ZGR?^A3G0S7]%W/_+U/Q&<=;\E+[U_6*CI18:[        M9<-_[H>*_P"S
M?1_Z,8LNUT!_T)DG]46?\WIFP&6_HZW_ (F'XJ,D&6G=
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M].8GG649QRNOJF-:TJ*_M4WB^QJN-*YC%-[(4ZJHS22]5<3;>TL*FE192
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MP[&3LA&C!:"
M
M                                                #A]B_P!G\Y_J
M?)_Z%.=#-?T7<_\ +U/Q&<=;\E+[U_6*CI18:[        M9<-_[H>*_[-]'
M_HQBR[70'_0F2?U19_S>F; 9;^CK?^)A^*C)!EIW0
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MS/X?0
M
M                                          .'V+_9_.?ZGR?^A3G0
MS7]%W/\ R]3\1G'6_)2^]?UBHZ46&NP       +67#?^Z'BO^S?1_P"C&++M
M= ?]"9)_5%G_ #>F; 9;^CK?^)A^*C)!EIW0
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M./HPY:?-W(OS"U]Z'TW\Z/G?JC^U;[W\MB?#+\U:OEOPC6H;5DJ[N;>,J]'
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M^TO=/XZ'TJ<S_G'GW]H7?OP^.,W^%7/NL_9#[PG/OZ\.7_VE[I_'0^E3F?\
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MKNB*JHEN6F-293J[(K;4625%5RVZIJ<7TI[I0FO6SA).,X]$DT?GZUMHW/\
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M'5>2:YTS9:NTY65?)+^A&K2GN>#V.,UB^&I3DI4ZD'MA4C*+VIG?SQC(P
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M*<Y)V\_&JW#!M[(PJ39D^D\Q\PS>$)O"C6\A^-^I?X6"\398J+7B9@
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M>YM5-=\LY:-S:JYZATXX44Y/&52RJ*7FLMNU]CP3MVDL(PIT<7C,F%-9#=@
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M_17%%4O>F_OGS'^(M/YM3(:UC^GJOWL/Q4:4FNYBX
M,[>+_P#Q$\*_VD:K_P!JUR2^37]Z^GOZWMO]Y$];(?TU:_QT?KEH0N7)W
M !J3Y>^2=7QZX_23%.K6N1-K;:H:;CYFMECIK$QC;^RWX'-<Q]+#).SLC<G2
MQ9>QG16>ZYD&<^.;M#E7I?BL7">J[[BA:0>U0P2X[B:W.%+%81?JZCC'#AXW
M''=1YW')K/&G@[VIBH+JZY/P+ZKP6[$KE97*Y/.9._F<S?MY3+92W/?R62OS
MR6KMZ[:D=-8M6K$SGRS3S2O5SG.5555*FKV]O,RO*N89A5J5KZM4E.I4G)RG
M.<GC*4I/%MMO%MD+U*DZLW5JMRJ2>+;VMM[VV? =4^
M        >^K:M4;5:]1LST[M.>&U4MU9I*]JK:KR-FKV:UB%S)8)X)6(YCVJ
MCFN1%145#EHUJUM6A<6\Y4[BG)2C*+<91E%XQE&2P:DFDTTTTUBC^QE*$E*+
M:DGBFMZ?6BQ;X9>2#>?>.?H^P68/ZQ]+;5QNV1-:R%V7KR,>W%[3!78C8VMR
MC(7-LMC1&1VXW]&QQOB:6P=WWFVN9^D^RS2<?E;EZC3N5L7:Q:]KN5%8)=HD
MU44=D:L98*,)01,^F<[^-[+AK->>TL%/P]4_1Z>II[DT;C$^F2@
M    BM^,#P!_7/XBY_:\53=9V[@W(,Y*Q2PL[IY]:@B7'[[05RN1K*D6O3KE
M).B*]S\5&U.B.7KL/W9=9_);F51RZXGPY;F\/-9X[E5;XK>7WSJ+LET)5I-[
MC4/OK<N/ESR7N<XLZ;GG6GZBOJ>"VN@EP7</!%47V[V8MV\4M[QIKEH11Z
M     "4_X/W/7]3?E_K>KY.Y]'U7G"A+QCDVR.Z01['<F9D-#MI&C'.DMS;)
M59C(_5J-;E'N7KT->>\SH[Y4<LZ^86\>+,<IFKJ/7V45PW$? E2;JOK=)(V[
M[E/,3Y$<ZK7*;N?#E&?TW8SQW*O)J=I+##;)UXJA'=@J\F]Q<K*O"\,
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M]M4Y+:0K_P MKP3S2M"6V%*2XHV2:>R56+4[C_5.-)XJK4C&L^;YE5@
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M1"$4H0CNC",8K8B!KNZK7MS.ZN'C6G+%_87@2V)="V'5#PSK@
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ME++1VF**HY-8T5""V<4GME.K4:2XJM6;E4J2P7%.3:26"63CP#+
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METWG6D,_N],:BH3ML[L:\J5:G+?&<>IK9*,EA*$XMQG!QG%N,DWTT]0\,
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MX2       </L7^S^<_U/D_\ 0ISH9K^B[G_EZGXC..M^2E]Z_K%1THL-=@
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MSV-[D_-.QA[76B\ONVEZ^''6M9O#>YP[>G*3PP5*E'%XI*NR;ME9@
M+.7P(.>OKG1^4O'',7>^_IF2CY+TN"63NE76=ADK8C:Z59G5$CHX78XZEA?3
MJLV9>O7Y$307O?Z.\US;+]<VL,*-U3=K7:W=K33G1D^N4Z3G'[V@BUW_  ]>
M8GGV09ORPO:F-Q8U5?6J;V]A6<:=Q&*Z(4JZIS^^N9;2P0:8%D(
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M:..*G6<Y<4H*GPR-D'&SP                          !KGY8>/6M^4/
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MKX?E*J;X<73I/AXIU);TWIFGEM.-Y>)2S!K<]JI^!?==<NC<MF+<@1M&9@
M                       "-'XE7#R;3QOAN6,55[\SQW:;0SCHHT66SJ&=
MLQ0>[(K6NFF^I,X^%[&I\V.&W8D<J(AJ!WO-!?'6DK?7%E#',,IGP5L%ME:U
MI)8OI?8UG!I;HQJU9/8C!];Y;YQ91S"FO;*+PEX82?\ HRP\2<F09E;A%0
M   !L;XH<M+PUSEIFU6K/T? 7[7V7VQSGJR%-<S\D-6U:L*WU=#A[;8+_;_S
MG5$0EKDAKGZ/^9&7YU6GP975GYO<[<%V%=J,I2\%*7!6PZ721[6G\Q^+,UI7
M$GA1;X9_>RV-OQ/"7H%FQ%14145%14145%ZHJ+ZHJ*GHJ*A<0FFL5N)S/T
M         &H'F]S#_5)P3L'U?;^C;1O7?I>N^V_MLP_6E>7Z[R<71KGQ_5V%
M;-V2IT]NS+#ZHJM(&[QFO?D+RUNO-9\&<YEC:4,'Y2[2+[:HNE=G1XL);.&I
M*GM3:,<U3F7Q=E,^!X5ZOD1Z]OJGZ$<=O6T5Q"I8A4      [3H^GYGD#<-:
MTG7X??S.T9FAA:#51?;CFO3LA6S8<G_1U:D;G2S/7T9$QSE]$/;TYD.8:ISZ
MST[E<>+,+VXA2AU)SDEQ2ZHQ6,I/HBFWL1V+6VJ7ES"UHK&K4DHKT>GQ+>_
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MEVMQ5PP<YM;DMJITT^&G'8L6Y2E-V595:Y1:JVMEMWRD]\GUO_(MR7HMYE)
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MI)8VCV=;L;9M^B]K\)?!W-9RGW;=-N;;>%^MNW8LTO4EXDDDNI+ D;(.-G@
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MKX-;>R35.F]JXY5'LG3BU(&B<G56;S:X6,(/AIX_;=,O0W+PX]*)GBP8DT
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MT^36G:V&8WL(ULRE%[86^/%1MFUNE7DE5J+%25&%--.%?;6,-^BJ(
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MFGLIMLBR6C"WRFSH0HT:4%A&%.G%1A%>));7M>]ML[$=(],
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M:953>$[W-*:EX:=*G5J/_:=D_3,+US7[/*H45OJ5ECXHIOZ^!!"5H$3
M 'DQCY'LCC8Z221S6,8QJN>][E1K6,:U%<YSG+T1$]54^HQE.2A!-R;P26UM
MOH1_4FW@MY:JX7T"KQ;Q5H6@UH8X7:YK>.J9#VT:C9\U-"EO/7%[>J=U[,V)
MYE]5]7_*77\O=+T=%Z)RS3%&*B[2SIQGAZZLUQ5I_NZLIR]$GW++.-AE]&TB
ML.""3^^WR?HR;9DXS$[X                            (?\ XG/#JH_4
M^;L/43HY(]+W-\+$1>]/>M:QE)T8G5RN;](IRRN^3MK1]?W*&AO?&T#A*QYC
M6%/8\+2[:73ME;U)8?NZ4I/JHQQW(CC766_D\TIK[B?UXOZZ;^]1$*:'D<@
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MJX=N:T(;=WMDNSZUM\KR?#AL>X]?()<&=6K_ -=%>F\/\I9]+DB=@
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M?U^;^>T7\69;*5"P4ELJ74HX5JR36V-O3EP0EN[6HW%J=%X6A2OXMG
M    !#S\53+*ZWPM@F/:B0U]YRUB-'1N>Y;,NK4Z;W,[?>B:SZ+.B+U[7JY?
M3JSTT)[Z]]C7T]EL6O)A>59+9CY3MH0>&]8<,\.AXO[4C?7]3RK6DNJHW_F)
M?6?_ -(B+-$R.@     #+/ VNMVSFOB?79(_=KY3D+4X;K.V1W7'1YJG/DO2
M)KG_ #:$4B]?1$Z=55J=53.>664K/.8F1Y5-<5*MFMLIK;^35:$JF[;ZA2\'
M6TMJ]'**/G&:6]%[I5H8^+B3?U,2U"74D^
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MC17A[-*=78\8SC2QV2VYEHO+?.\Q=Y47M-NL?'-^I]+;+P-+K)[BS@EL
M     X?8O]G\Y_J?)_Z%.=#-?T7<_P#+U/Q&<=;\E+[U_6*CI18:[
M M9<-_[H>*_[-]'_ *,8LNUT!_T)DG]46?\ -Z9L!EOZ.M_XF'XJ,D&6G=
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MFU+14LLLJDJ66PFME2YCLJW23V.-OMITG@UV[G).-2W19X- RU\
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MU+JC4.LLZK:BU3>5[_.KB6-2M6DY2?5%=$816R%."C"$4HPC&*2.DGJG@@
M                        %UOX2'_I[>/W_BM_YW<DE5'>2_OJSK_LG\PM
M2]_N9_\ MLTW_P"8?^J7Q(^0:;/@             @1^,;X'IR!KUWRPXKQ"
MOWG4<9"SES!T*ZOGVS3L9!%6J;A7BA:KI<YIU*)([G5%6?$1M=W-^A-9+N+W
M8><'Q+>PY<ZBJX91<U'YG4D]E&M-MNBV]U.O)XP^UK-K!]JW&NSON]WGY29;
M4YQ:0HXY_94DLQI06+N+:FE&-RDM]6V@L*GV]ND\5V"4ZN98(5*
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M^P1@&FI@@     !M=X/8]F2\I^):\G9VQY#8L@GN,]QO?B=,V3*1]&]4Z/\
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MZ+N?^7J?B,XZWY*7WK^L5'2BPUV       !:RX;_ -T/%?\ 9OH_]&,67:Z
M_P"A,D_JBS_F],V RW]'6_\ $P_%1D@RT[H          ,*>25M*7CYS;,K%
MD1_%>]U.U'=O1;^M9&BC^O1?2);'<J?AZ=/3Y2/.;E=6_*W451K'')+V/X=O
M4ACZ'%CZ!Y>=RX<GNG__ %ZB].+15P*8"!@
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MU:]65>O*4ZTY.4I2;<I2;Q;;>UMO:V]K>UGH/HXP
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M:./I2:]$R?1Z3S^DWO49_B27^4L4EKQ,P
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M$MB)H                !K+YC<$P>27C7RSQ%[$4N9V#6+-S3Y)G,B;6WC
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MOX2'_I[>/W_BM_YW<DE5'>2_OJSK_LG\PM2]_N9_^VS3?_F'_JE\2/D&FSX
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MRIU3\"JALMW3DGS?H-K:K"YP\'D)?6;1EFB_TY'^+G]8L'%IA,(
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MSF7'46/J[>R@JDHX=2KU;:>/0XI=)5&+%BGL
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M+_Q+8O\ _H_;/]$@-E^Z;_>_1_Y"Y_%B99HO].1_BY_6+!A:63"
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M_BM_YW<DE5'>2_OJSK_LG\PM2]_N9_\ MLTW_P"8?^J7Q(^0:;/@
M   'A++'#')--(R&&%CY9997MCCBCC:KWR2/>J-8QC455551$1#^QC*<E&*;
MDW@DM[?4CYG.-.+G-J,(K%M[$DM[;Z$BF5\4;S;?Y7\R.UC2<I)-P?Q5;O8G
M3$@>K*>WY[N6MG.0)8VN5)X<@L?T?%J_UCQS$D1L4EF=A:1W?>5"Y<Z7^,,V
MII:MS&,9U\?54:>^G;KJ<<>*KAOJOAQE&G!E&_>UY]2YPZX^*<AK.6@<HG.G
M;8/R;FMZFK>-=*GAP4,=U%*24)5:D2+TV -2P           ":_X1WGP[@W<
MZWCORKF_:X?W_++]D<OD9T2KQWO63EC8Q'V)5Z4]4VNPJ,LHJI#4O.99_%MD
MMR.U3[R?)Q:MRN6MM.TL=365/VZ$5MN;>"ZEZJM16V'KIT\:>UQII;X]S'O%
M/0&>1Y9ZOKX:*S*M_)JDWY-E=U&DL6_4V]P]E3UM.JXU?)4JTG;+*XBXT
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MG%KU>;UFW&*_BI*=%^&FWX2#,_R[XKS2I;Q6%%OBA][+<O0>,?0-=2)SQ0
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M87%&AQ49Q4HOCIK%-8IX.>*V=#V]9S/W"_+#]5/_ 'YXV_3$]#]F7G?^I/\
MOEA_2CD^26H?@_\ M*?LQ]PORP_53_WYXV_3$?LR\[_U)_WRP_I0^26H?@_^
MTI^S'W"_+#]5/_?GC;],1^S+SO\ U)_WRP_I0^26H?@_^TI^S'W"_+#]5/\
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MJ6OS;SNECE64R=&R4ELJ7DX>V55CL:MJ4\%L_*U8RBU*BRTH5\%MX
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M_P#MLY _I!<+@N3_ /=;I_\ JJW_ -W$_/+WAO[\]6?U]>?[Z1J:2.0V
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M7>2PY7:PKXZRRVA_):LWY5Y:4TEPN3]7<VT=D_7U:*57RI4Z\R;LU/-]@
M     "&?XJ6/6/8^&\KV/1+N$W''H]7-6-RXR_@+*L:U/GH]B99%<J^BHY.G
MR*5^]]:U<,VT_>X/"I;74,>CVN="6"6_%=KM\:ZF1IKZ&%:VJ=<9KTG%_P"4
MB=-'R/0     #8SQ&SWV<\E>&\AWK'](W*G@>Y'.;U^U5>SK'9U8^->DGUQV
MJG7HJ+T5')U199Y%9G\4\WL@NL<./,(4>G_\F,K?#8UO[7#JV[4UL?M:=K=A
MGEM/KJJ/X:<?\I9N+B2<P                                  1Q?$@
MX=7<^+,?R;B:GNYWC.RYV36&-73V=/S$L$&0[D9\Z5,/D4@LIU14A@=8?Z(K
MNNI?>VT#\H-%4M8V,.+,LGF^TP6V5K5:C/=O[*IP5-NR,'5ELVF%:URWSFP5
M]37MM![?#![_ $G@_ L2"(K1(G      )1?AE<M_4>[[/P_D[2,H;M4=L6MQ
MR2*C6;-@:SOK.K6CZHU9<MKS%ED<OKTQC$3Y3<[N>:Y^+=1WF@[R>%KF-/M[
M=-[KBC'VR,5UU:"<I/JMXI;S/-#9CV5U4RVH_(JKBC]]%;4O'';^Y)M2Q0E$
MU \WN8?ZI."=@^K[?T;:-Z[]+UWVW]MF'ZTKR_7>3BZ-<^/ZNPK9NR5.GMV9
M8?5%5I W>,U[\A>6MUYK/@SG,L;2A@_*7:1?;5%TKLZ/%A+9PU)4]J;1CFJ<
MR^+LIGP/"O5\B/7M]4_0CCMZVBN(5+$*@     &1N(^.,KRWR3I_'>(]QEG9
M\S7IV+4<?N_5V+C[K69RKV?(Z/%XJ":PJ?\ .2/I\JF6Z%TE>ZYU=8:4L,56
MO+B,)22Q[.FO*JU&NJG2C.;Z^'#I.[EUE4S&^IV5/U5223?4M\GZ"Q9:>P.#
MQ>LX/#ZYA*D=##8#%T,-B:477VZF-QE6*E2K,ZJKE;#6A:U%7JJ]/4NGRS+K
M+)\NM\IRZ"I9?:T84J4%NC3IQ4(17BBDB?*5*G0I1HTEA2A%12ZDE@EZ1RQW
MCD            .'V+_9_.?ZGR?^A3G0S7]%W/\ R]3\1G'6_)2^]?UBHZ46
M&NP       +6/#+FOX?XI>QR.:[C;17-<U4<US7:OBU1S53JBHJ+Z*7:<OVI
M:#R247C%Y19_S>F; 9;MRZW:W=A#\5&23+CN@          QYR[1^M.)^3\9
MV1R?6/'FZT?;F_Z%_P!+UO)U^R7T=^+=[G1WHOH8KKNV\]T1G-G@GVN57<,'
MN?%;U(X/P;=O@.GF,.TR^O#[:C->G%E4@I'-?@       6=?$Z\S(>-W#,\:
M-1L>C8FBJ,D25._&-DQLBJY$:B.62HJN;\K%ZM7JJ=2X[D?<QNN4>GZL<,%E
MM*&QX[:>--_5CM70]G03IIZ:GDELU_!)>EL_R&PI*A[(
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M:ZO*V]!93_AR6\99[JJ[<6Y0M+&'%MP2G4N9./5Y79I[=ODO#I+,QH46J@
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MPJP?7"I%2B_1BTS8:G4C5IQJPVPE%->)K%')';/L
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M,LEQ6%[;TZU-]/#4BI)/JDL<)+HDFN@GZVN*=W;PN:.VE4BI+Q-8^GUD"7Q
M>8/ZRN;[FLXVTD^M<713ZM2;&]'03; Z5DNUW4[7O3W6WXF4EZ=$Z447IU5>
MM8_>CU[\K^8U3)[2?%D^2QE;0P>QU\4[F>][>-*B_!13PVLB36&9>?9JZ$'C
M0H+@7WWKWZ?D_N31<UL,4      )BOAC<.K!2VOF[,5.DEYTFFZ:Z:-45*D$
MD5G9LI KE5CV6+;(*D<C41S5@L,Z]'*AOUW.M ]E;WO,6_AY=3&TM,5ZV+4K
MBI'H:E)0I1DMJ<*L=S9).A<MPC4S2HMK\B'B]<_3P7H21+@;T$B
M     X?8O]G\Y_J?)_Z%.=#-?T7<_P#+U/Q&<=;\E+[U_6*CI18:[
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M/Y-9OD-O3[3.+>CYY:)>J\XM4ZD81V/RJU/M+=?QKVK>J,);B?G[
M        !8W^!KXJQRR;3Y:[;C55:S\CH'$:68^B-E?%[&];;5[D17*D,R8>
MM*U>WYV0C<G5&JFCO>WYB.,;?EOEL]DE&XO,'T8XV]%^BNVDGU49+I+/.X!R
M@C.5WSESFEMBYV>7<2Z6L+NXCZ#\VA)/#;<Q:QPPLAFC!:$
M"C_\47_CU\B__P"I-;_H#J1;+W??[G<C_B*O\XK%!O>U_P#<3J?_ )JA_,[<
MT%)D-<P     "PS\ +*>SM_DUA/I/;]8:WQAE/HG;U]_ZGRFZU/I/?V+V_1?
MKSMZ=R=?>^1>G5-*>^7;\669!=\/J*]W#BZN.%!X>CV>.[UOIV5_X<EWP9UJ
MNPXL.TM;"IP]?9U+J/%CAZWM<-_KMSPV6830PM3             !0W\\/\
MC.\G_P"VSD#^D%PN"Y/_ -UNG_ZJM_\ =Q/SR]X;^_/5G]?7G^^D:FDCD-@
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MLR+76FK/5NF:\;C)+ZA&K2FM^#V.$UZVI3DG"I!^5"I&4);4S(!XID@
M!H7\1[ OS'C9;R#8W/35=VU7/2.1KG)$RP^_JZ2.5JHC&J_9&MZNZIU<B?*J
M&LO>URR5_P HJETDVK+,;:L_ I.=OCX-MPEMZ^O Q+6M'M,D<_X.K"7IXQ_T
MBOR5;D/@       L0> O*U;D;@/!X*:U&_8N,U9IN5JJ]OOMQ5=CI-5N^UW*
M]E2;#(E9CEZ(^6E*B?N2UCNPZVHZLY86V6U)IYKD^%I5CCM[.*;MIX;U%TL*
M:?3*E/#<3+I',(WN40I-^W4/(:\'K'XN'9XXLW:-BC*
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M')+&=1K[:K4<JDONI,GVQM*=A:4[.EZBG%+QOI?C;Q;\+.\&1G:
M      *A$L4D$LD,S'130R/BEC>BM?')&Y6/8]J^K7,<BHJ?@4H@G"=.;IU$
MU4BVFGO36QI^(US::>#WH\#X/X      3Y_#;WV'9>!9M0DL-=D>.MFR>.6L
MKD=,S#;#-+L6,M/3JKDBGR%R_$SK_P#XZHGHA9YW1]34\XY92R&4D[O*;RI3
MX>E4J[=>G)^"4Y5HK^+:W(ES1-VJ^4.V;\NC4:P^YEY2?IN2] D'-IC,0
M        "J3R]A5UOECDW7_:]E,+R!N.+9&C&L:V*CL.1K0]C6,CC2-T4:*W
MM:C5:J*GIT*2=>9=\4:WSC*\.%6^:75-+##9"O.*PP26&"6&"PPW;#7_ #*E
MV&85Z/VM::]*31CLQ,Z0     !-C\+O>(+V@<A<>2R)]-UW:*NT56.7H]^,V
M7'08^5D*=?GQT[^O.<]>G5KK2=5]41+$NYEJ.G<Z7S72LW_*+2]C<13WNG<4
MU!I=:C.@V^IU%CO1*&@[I3LZUF_5PJ*2\4EA]1Q^J2DFZ!GH
M                                  *,GQ%> D\<_+?E/2Z%%M'4]@R2
M<AZ)'$QL55NJ;I)/DH:-*)O3VZFOYE+N+8BHG_4>OJBHJVX<D-9?+CEMEV:U
MI\>94:?FUPWM?;4$HN4G]M4AP57_ !A^?[O-<N5RQYS9OD5M35/)KFKYY:)+
M"/F]TW-0BNB-&KVM!?Q75M-("62 @             9'X@XNVCFSE#1>)],K
M?2=EWW9,=KN-[F/?!4^F3)],REWVT5[,;AJ#);=IZ?\ 1UX'N_ >'J;4.7Z4
MT_>:CS27#86="5276^%>3"/W4Y80@NF4DNDRC16DLVUYJS+]'9%'BS7,;J%&
M&_"/$_*J2PVJ%*"E4J/HA&3Z"_7P_P 6ZOPGQ?HO$^F5_HVM:%K>.UW&]S&,
MGM_0X4^F96[[:(Q^2S-]\MNT]/\ I+$[W?A*;]3:AS#5>H+S4>:2XK^\KRJ2
MZEQ/R81^YA'"$%T1BET'Z+M%:2RG0>D\OT=D4>'*LNM848;L9<*\JI+#8YU9
MN52H^F<I/I,D'A&4              I8_%ZH34_B!<WV)71N9E*7%M^NC%<K
MF0Q\1Z+C'-F1S&HV1;&.>J(U7)V*U>O551+4N[16C5Y,93"..-.=W%^-WEQ/
M9X,)+JVX^,HH[Z5O.AWC\_J3:X:U.PFL.A++K2GMV;\8-[,=F&W'%*-,G<U8
M      )D?@>[_1U7R_S&I9"VR!O)G$^TX#$0/?V?2]AP63P.XUV,1>J2/CU_
M Y-R-]%Z=51?3HNK_>TR:KF/+.EF5"+;L,RI5)OJIU(5*+].I4I+$W@[@FHZ
M&4<ZJ^37,U%9KDUQ1IIO#BK4JE&Y276U1HUWA]C!VZ2M8N>
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M9G-KY[E5>V2QE*F\/OEY4?JI%6DI<(%       !L!XV\^9SQZY'I;=0CER.
MO1MQ6X8!DB-3,8*65KY%K][F11Y;'2)[U21RHB2(K'+[<DB+*7*+F=F7*O5M
M//;92JY9479W5!/#M:+:;X<=BJTWY=*3P\I.+?!.2?L9)F]7)KU7,/*HO9./
M7'P>%;UZ6YLLD:!O^I\G:IBMTTG+U\UK^8@26M:@7I+!*B(EBC?KN_&T<C3D
M7LF@D1'QO3HJ?(JVX:7U1D>LLDH:AT[7A<97<1QC);T_70G'?"I![)PE@XO>
M399WEO?V\;JUDI49+8_\C70UTH[D9 =D
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M:)PIU*=6FJM)J5.2Q36U-/<TSD#M'V
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M\J5K*6"N:3VN/!C4A'\K"#PQD!(9-CP          </L&P8/5,'E]FV;+X[
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M-[;FUIQVV\F]]:UBL8=,[=;L:$Y3GC-/RPP      K)>6'%C^(>=]YUF&O\
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M\$'B_:XP6Y(GC)\OCEF74K->KC'&3ZY/;+ZNQ>!(S22$>F
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MEP'RK5@?K_(&'Q>4E8Q9=<VVQ!K.?KRN3JM9M;)S1U<E+&B_.=1FM1)__?\
M*6 Z/YX\L=;48RRO-+>C>R2QM[F2MZT7]KPU&HU&NET9U(_=$F6.H<HS"*=&
MM&-3[6?DR\6#V/\ <MKPFQ<<D<T<<L4C)8I6-DBEC<U\<D;VHYDD;VJK7L>U
M45%1>BH2Q"<:D5.#4H26*:VII[FGTIGLIIK%;CS/H_H       (A?BD<=R/9
MQKRM4KJYD27M!SME.BJQKW3Y_66*B?.2/O7*]7+\U'.:GRN3KHAWS]*2E'*-
M;T(8QCQV5:75CC7MUXL?.<7NQ:6][8YU[9-JAF$5L6-.3_SH_P"F0_FAA'
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M5.+]%-'YP,]R7,=-YW>:>S>#I9K8W-6WK0?K:E&<J<UT;I1>#Z5M.LG?/*
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MI4FW*<YRIIRE*3VMM[6WO)ER:K4K95;U:LG*K*C%MO:VVM[,RD@'I
M       P?Y&\3P<U<.[GH?9&N5MX]V1UF:3T2ML^)ZW<,[W%<WVH[5F/Z-*[
MUZ03O]%^0CCFSH>GS#T#F&F<%Y[4I=I;M^MN*7ETMO0I279R?1"<MC/*SK+U
MF>6U;3]\<<8^"2VQ]-['X&RKU8KSU+$]2U#)7LUII:]BO,QT<T$\+W1S0RQO
M1'1R12-5KFJB*BIT*:*M*K0JRH5HN%:$G&46L&I)X--/:FGL:Z&00TXMQDL)
M)[3U'&?P          &^_P /3AS^L7FAFY92JLNM<5P0;!(LD;7U[.TVGRPZ
MM3=W_(ZM+#/?1S>JMDI,1?1Z&SO=6T#\K.8*U!>PXLHR6,:[Q6,97,FU;0V_
M:M3KIK=*C%/U1EVCLM\]S/SFHL:%NN+QS?J5Z&V7[E=98#+127P
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M_ARX^2G-:EK*RI\.4ZAM^TDTL(J[MU&E<+!;G.#H56]\IU*CVM-D-9M":/
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M:?2C\[%U:W-C=5+*\A.E=T:DH3A)-2A.#<91DGM4HR333VIK ^(Y3K@
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M%O[.-6_[+@+E^37]U&GOZHMO]W$G?(OT-:_Q$/K(SN26>L
M 5\/B!\/)QKS=:V?&56P:SRE#/M%/VF(R&#8HY8XMLI(B=%]R2]-'><O3I_G
MZ(G[E>E67>DT%\D.8T\YLX<.3YU&5Q'!8)5TTKF'C<W&L^CV[!;GA#VL,M\Q
MS1UX+"A<+B7WWKUZ>$OW1HH:U&)@          LH>&O#J\-<&ZUB\A5^C;3M
M*)N.UI(QK;$&1S$$"T\7,O3O:[#8F*"N]BN<UMALKF_NU+=^0&@7R_Y;VEG=
M0X,ZO?Y5<XKRE4JQ7#3?3[524(-8M*:FUZHF[366_%F50IS6%Q4\N?C>Y?N5
M@O'CUFU1-9[X                 !UW;=6PF\:QGM0V2FV_@MCQ=S$92J[H
MBR5+L+HGNB>J.6&Q"KD?%(GSHY&M<GJB'E9[DN7:CR>YR'-Z:JY;=T94JD>N
M,U@\'T26^,M\9)-;4<-Q;TKJA.VKK&E.+37@?^7J\)5^YLXCV'A'D?8./]A8
M][\;86QA\FL2Q09[7[,DJXG-5DZN:C+<,:I(U'.]FPR2)55S%*:N8NA<UY<Z
MMNM+9JFY49<5*IA@JU"3?95H^"26$DF^&:G!MN+((S3+JV5WL[.MZU[']M%[
MI+Q_4>*Z#%!@YYX             .7U[_P"_X/\ UOC?]-A._E7Z4MOX^G^.
MCEH_EH??+ZY;C+TS8@    $(GQ%_'>;5MJ;SCJ]!?LUN%B*KND59GS,1MKF]
MD.6D8QJ)#2V6%B=[^BI]/8]7N[K#$6N?O8<J:F2YW](^34O_  B_FHW:BME*
MZW*JTMT+A)8O^&4G)XU8HBW6F3.A<?&M!>T5'A/#HGU^*7XV..]$8!IJ8(
M                            6LN&_P#=#Q7_ &;Z/_1C%EVN@/\ H3)/
MZHL_YO3-@,M_1UO_ !,/Q49(,M.Z                      "-3XL' *<Z
M>'N\6\;22UMW$#V\LZVK(U=9DJZW5M1[?0C=&J2O9:T^W=E;"B/2:U6@^;W-
M:YL[]W+67R1YFVE.O/ARW,UYG5V[$ZK3HR?1LK*"XMG#"4]N#:>K/?$Y<_2!
MR3S"M:T^/.<E:S"A@O*<:$9*Y@L-N$K:562CMXJD*>S%)JE@6I%$X
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MX0DM_9N;7J3(-,Y;\99K"$UC;T_+GXH[EZ,L$_!CU%DPMT)M
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M_HQBR[70'_0F2?U19_S>F; 9;^CK?^)A^*C)!EIW0
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M_DM[PX\..+5O<\*X:=Q%)X/!0KQ7:4TFJE.E'L34:U@
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MS.A5M[^E+"=.K"5.<'U2A)*47X&C :E*I1FZ5:,HU%O3337C3VG&G3/@
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M_P!&,67:Z _Z$R3^J+/^;TS8#+?T=;_Q,/Q49(,M.Z
M      5SOCQ<!>]3XH\EL-257TWR<3;U-#&B_P";6%R&Q:/?L(Q4<QD-GZUJ
MR3/:J*Z:M'W(O8UV\'<_UEPU<QT'=3V27GENF^E<-*O%>-=E-17VM26#VM5C
M_P"(9RYXZ&3\T[&GY4&\NNVEZU\=:UF\.A2\XIRDT]LJ4<5Y*=;8WI*N0
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M2$\=F.SA;Z-OB(JS#(,]RAM9K97=JX[^UHU*>&+P6/'&.&+V>/8=7/0/(
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M=N^+J-#G-KFW_E]6'%E=O47Y.G)?\=.+7JZB>%JGZFFW72<ITI0L-&E)96
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MH[U5H5:>&"Q>/'%88+;XCR*EI=T=E:E4@UUQ:^NCJAXAUP
M   "T'XO?\.O"W]G&K?]EP%R_)K^ZC3W]46W^[B3OD7Z&M?XB'UD9W)+/6
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M55T/MJCG-2PQX'"+QX40CJ7,_C/-9U(/&WI^1#JP3VO]T\7XL.HU6(4/
M   )OOAH\/?9S0\]R_EJO9E=\G?A==?(WI)#J>%M*VW/'U:U[$S.?@<CD7JC
MF48GIZ.+&NZ!H'XITS<Z\OH87N9R=&@WO5M2EY4ETKM:Z>*W-4826\E/0^6]
MC:3S*HO;*SX8_>1>W\*7XJ)/#<@SH
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M6_N</L#L:7VL?20^SNO_ ,!X?\V4OW@?%65_!K?W.'V!V-+[6/I(?9W7_P"
M\/\ FRE^\#XJROX-;^YP^P.QI?:Q])#[.Z__  'A_P V4OW@?%65_!K?W.'V
M!V-+[6/I(?9W7_X#P_YLI?O ^*LK^#6_N</L#L:7VL?20^SNO_P'A_S92_>!
M\597\&M_<X?8'8TOM8^DA]G=?_@/#_FRE^\#XJROX-;^YP^P.QI?:Q])#[.Z
M_P#P'A_S92_>!\597\&M_<X?8'8TOM8^DA]G=?\ X#P_YLI?O ^*LK^#6_N<
M/L#L:7VL?20^SNO_ ,!X?\V4OW@?%65_!K?W.'V!V-+[6/I(?9W7_P" \/\
MFRE^\#XJROX-;^YP^P.QI?:Q])#[.Z__  'A_P V4OW@?%65_!K?W.'V!V-+
M[6/I(?9W7_X#P_YLI?O ^*LK^#6_N</L#L:7VL?21RS&,C8R.-C8XXVM9'&Q
MJ-8QC41K6,:U$:UK6IT1$]$0[T8QA%0@DHI8)+8DET(Y$DE@MQY']
M
M
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M1SQZ9R@
M
M
M
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MBZ%RW%U,TJ+8O(A]>3^LD_OD3"F^Q)
M
M
M
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MU.6"V$]Y=94\OLJ=E2]33BECUO?)^B\7Z)D4RL[H
M
M
M
M
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M?Z,<?1:9.<62$J@
M
M
M
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MUP
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ML)HIQE&$8R?%)))OK?7Z)]QV#[
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MGCBWC.6%.$Y*P$:9%CP
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M6U/Q]HG6V['&A*+WF5:0RWS[-56FL:%#RWU<7K%Z?E?N66%RU(F,
M
M                                        A]^*;N*K-Q1Q_#+Z,BSV
MXY*'N7U65];"X27M]&_-]G()U7JOKZ=/7KH7WT\_QJ9'I>F]RK751>-QHT7]
M2NO1Z-N,<:^N=MO9K[J;^I&/^D1#FB)'(     !M9X3:3]N?)7C>M+#[M'7,
MC8W2^[M[DA;JU67)XV1R?(K7YZ.G'Z_)W_\ L)M[NVG?E)S>RBC./%;6E65W
M/P>;1=2F_1K*E'T3(-+VOG6=T(OU$)<;_<+%?YV!9.+=2;0
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M!*,5&G!1IPA%9N,3,]
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MITF\7^2IJ*<<<%4E4PWMN4=,Y6\KRR,*JPNJCXI]:;W1]!?5Q-M2<C(0
M
M                                           "NGY^;@NV>3.X5V2>
M[3T_'X'3Z3O3YJ4<<S)Y&/T543VLYF+;?_850=Y_/GGG.&_I1>-"PI4;6'[B
M"J5%Z%:K41#&K[GSC/*B7J::C!>@L7_G-FF)KX8R      2P?"STU+&R<I[_
M #0__:L-A=2Q\[FJJ.?G+L^7RK8UZ*B/@9@JG=ZHJ)*GX%4W?[EV0*KF^=:H
MJ1_(6]&U@^MUINK42\*5&ECX)+K)!T%;8U[B\:]3&,%^Z>+_ !5Z9,T6!DF
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M5.D^3VDZ.D])T>&E'"5>O)+MKFM@E*M6DEMD]T8KR*<,(02BC88PDDL
M
M
M
M                   _%5$15541$15557HB(GJJJJ^B(B!M)8O<"IWR5L[M
MVY$WO<'2/E^U&X;)GV.DZH[V<MF+EZ!B-55]MD<,[6M:GHQJ(B>B%'^KLY>H
MM5YGG[;?GM_7KIOJJU932\"2:270E@MB-?+ZOYU>U;G?VE24O3;9THQTZH
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M]T8KR*<,(02BC88PDDL
M
M
M                                            &.>8<\NK<3<G;(V1
ML<F"X_W'+0.<K?6S1U_(6*S&HZ2%'R2V(VM8WO:KG*B(J*IB>O<S^)=#YSFZ
M>$[;*[JJOOH4)RBEM6+<DDEBL6TL3I9E6\WR^O7Z849OT5%M%4LI)-?P
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MO(IPPA!**-AC"22P
M
M
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M=M0A;45PT:<%&*ZE%8)>@D;$1BH148^I2P1]!RGT
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MIM*T=(Z.H=E84_*G4EA*M<56DI5J]1*/'4E@EL48QBHPIQA3C&*SH8B2
M
M
M
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M93EMW16$8QBLJF.F7@
M
M
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MDW+/F%DKFK8]]SCS@RK<9)B>/*%Q4M[#]$F;-3R_(.0K.:W.7TGC;-%2;_\
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M=*E36$8Q6UMMXN4I-N4YR;G.;E.<I2DV^YGEGN
M
M
M
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M'F/K+FCJ&IJ;6U[4O,RELBGY-*C3QQ5*A26$*5-=45C)XSFY3E*3PR908,
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MDE%))+8CDC@.T
M
M
M                                              <#M.OU-LUC8]5R
M"]*&RX'+Z_=7M[^E3,X^QCK*]G<SO_$V7>G5.O\ E0\S.LKH9YDUWDMU_P -
M>6U6A/9CY-6$J<MFS'9)[,4<-Q1C<4)V\_43@XOQ233^N5/MFU[*ZCL6=U;.
M5UJYG7,OD<)E*Z]W2&_B[<M*TQJN:Q7QI-"O:[HG<WHOX2D+.,JO<BS:YR7,
MH<&86E>I1J1ZITY.$ET8K%/!]*VFOM>C4MJT[>JL*L).+7A3P9PAYIQ
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MMQ^@_H
M
M
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MIV=3P*DU*CX</-YTECUJ6&XFC25XKO)*<6_;*3=-^AMC_FM&Y)/YDH
M                         (V/,OXG7 _B9'DM5J68^4N9H&.BBXZUJ_$V
MM@;3FO[)-[V1D=JGK;(U9\ZFQEG)N[F+]'9$_P!YL[<KN06L.8\J>8U(O+]+
MMXNYJQ>-1?\ ]>EBI5<?MVXTM_EN2X7JWSQ[U_+SDY&KE%&:S?7$5@K*A-<-
M*6W!W=?"4:"7332G7>,?:HPEQJJ1Y-^7O.7EIM?VDY;VJ6UCJ<\DFMZ1A_>Q
MND:G%(CF]F$P?OS-6VZ-RMDNV7V+TS>C9)G-:UK;%= \M-)<M\N\QTW;J->2
M2JUYX2KUG_K*F"V8[5"*C3B]JBFVW3[S6YTZ_P"<F<?&FL[QSMH2;H6M/&%K
M;I]%*EB_*PV2JS<ZLELE-I)+6,SXB<          &1N*.).1><-ZPO&_%FJY
M/<-PSTW92Q>,B1R0P,<Q+.2R5N164\5B*#'H^Q;L/CKP,]7N3T/#U'J3)-)9
M15SW4-Q3MLLHKRIR>]]$8I>5.<MT813E)[D9/H[1FIM?:@H:7TC9U;W.[B6$
M:<%N2]5.<GA&G3ACC.I-QA!;9-%N7P#^&/Q[XE4<=O\ O/U9R#S_ &*KEFV5
M8'2X#0FW*_M6L3HE>W&V1+7M2/AGR\K&6[$;G,C;7A?)&^MCG+S\SKF15GDV
M4=I9:,C+92QPJ7'"\5.X:V88I2C13<(M)R<Y*,E<[W<^ZEIKDU;TM1Z@[+,N
M8\H;:^&-&TXEA*G:1DL>+!N,[B252:;C%4X2E&4IYKR;=
M
M
M
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MN>][E55555553:B,8PBHQ244L$EN2ZD:*SG*<G.;;FWBV]K;>]M]+9X']/D
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M&$(+;@YN4Y;4D=DO
M
M
M
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M:<:<JBBE.4(O;&,I8M1>+2>&+P)'HJJJ457:=;A7$UL3?2UX,3ECO'(
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MAJC7.<U-0:OOKG,,XJ[ZM:;DTL6U""]33IQQ?#3IQC"*V1BD8^/:,;
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MP44DDBW;3NF\ATCDU#3VF;2A99+;0X:=&E%1A%=+ZY2D]LIR;E.3<I-R;9W
M\P]L
M
M
M
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M!O0
M
M
M
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M=*M5P3:3;<:<%"E!M\$(N4F]EC R5
M
M
M
M                 #K^L;7K&ZX>ML.G[%A-IP5SN2KF-?RE+,8V=S.B2,CN
MT)IZZRQ*O1[>[N8OHJ(IW;_+LPRJZE99G0JV]Y'?"I"4)+JQC))X/H>Y]!YV
M59QE.>V4,RR2YH7>7S]34HU(U(/#>E*#:Q72L<4]C.P'2/1
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MFU%JS,9YOJ>^N\PS2>^K<59U9X8XX*4VVHKHBL(I;$DCIIZAX8
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M48QC%81C&*P48Q2222226"/I.,Y0
M
M
M
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M]H#E#D_Q1HBQA0E**5:XGA4NKAKUU:LTI2VXM0BH4H-OLZ<$\#8PP<DX
M
M
M
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MN(+L*$TO_P :V;E!.+VQJU>TJJ24J;I/R24XUZ-N@
M
M
M
M                                     "K9\9/P9GT#;KGE?QEA_P#\
M$WG)0Q\LXO'UT]O5=\R,JQQ[<L4#$2'";O8<U+4CDZ19ERN>]77HF,L'[KW-
MR&<Y;'ESG]7_ ,7M*;\SG)_EK>*Q='%[ZE!>H7306"6%&3=2/?@[O]33F=3Y
MQ:4H?_Y[,*J68TX+9;W<W@KG!+92NGAVDGLC<MMR;N(14#!N$5W@
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MW(Y0ZYVP
M
M
M
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M%W^71JW/+N]JOS2X?E.C)XR\UN6DE&K%)]G-X1KTUQQ\N-6%.-TG,U>
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MW^R/(,DTSEE+)=.VEM8Y316$*-"G"E3CXH026+WMX8M[6VSM!YYZP
M
M
M
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M465++,IH4;7+:,%&G2HPC3ITXK=&%."C&,5T**2.6.L=T
M
M
M
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MNM>7&:O)=;Y;=9=?[>%58^142V.5&K'BI5H8[..E.<<=F.)B4R0PP
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MDULLVIX87==.XNN)>NC6K<3I-[VJ"I0QW11MV1H30
M
M
M
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MUH.ZKIK#RHUKEU:D&VL?(E%8[DEL-LR."9
M
M
M
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M(](
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
(       '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img127089420_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img127089420_0.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #_X0!V17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <   !     +     !53DE#3T1%  !, $4 00!$
M "  5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N "  5@ Q "X
M,  Q  #_VP!#  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<'QXC
M*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3?_VP!# 0D*"@T+#1H.#AHW
M)!\D-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-S?_P  1"  = '@# 1$  A$! Q$!_\0 'P   04! 0$! 0$
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M+32E+EQN8GHJYZDG@>],@^=[+3)O$GB1-/T2R*/=S$6\!<MY:]>6/4 <D^U
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M_P"XOY4 +L7&,<4 )Y4>00B@CH0* ';%'\(_*@!IBC+ F-21T)% #@H'0 4
M1W%M;W<1BN8(YHSU610P_(T );V=M9Q>5;6\4$><[8T"C/T% $H '0 4 ?_9
*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img127089420_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img127089420_1.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #_X0!V17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <   !     +     !53DE#3T1%  !, $4 00!$
M "  5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N "  5@ Q "X
M,  Q  #_VP!#  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<'QXC
M*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3?_VP!# 0D*"@T+#1H.#AHW
M)!\D-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-S?_P  1"  = '@# 1$  A$! Q$!_\0 'P   04! 0$! 0$
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M+32E+EQN8GHJYZDG@>],@^=[+3)O$GB1-/T2R*/=S$6\!<MY:]>6/4 <D^U
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M_P"XOY4 +L7&,<4 )Y4>00B@CH0* ';%'\(_*@!IBC+ F-21T)% #@H'0 4
M1W%M;W<1BN8(YHSU610P_(T );V=M9Q>5;6\4$><[8T"C/T% $H '0 4 ?_9
*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img127089420_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img127089420_2.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #_X0!V17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <   !     +     !53DE#3T1%  !, $4 00!$
M "  5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N "  5@ Q "X
M,  Q  #_VP!#  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<'QXC
M*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3?_VP!# 0D*"@T+#1H.#AHW
M)!\D-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-S?_P  1"  = '@# 1$  A$! Q$!_\0 'P   04! 0$! 0$
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M+32E+EQN8GHJYZDG@>],@^=[+3)O$GB1-/T2R*/=S$6\!<MY:]>6/4 <D^U
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M_P"XOY4 +L7&,<4 )Y4>00B@CH0* ';%'\(_*@!IBC+ F-21T)% #@H'0 4
M1W%M;W<1BN8(YHSU610P_(T );V=M9Q>5;6\4$><[8T"C/T% $H '0 4 ?_9
*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>img127089420_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img127089420_3.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #_X0!V17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <   !     +     !53DE#3T1%  !, $4 00!$
M "  5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N "  5@ Q "X
M,  Q  #_VP!#  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<'QXC
M*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3?_VP!# 0D*"@T+#1H.#AHW
M)!\D-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-S?_P  1"  = '@# 1$  A$! Q$!_\0 'P   04! 0$! 0$
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M+32E+EQN8GHJYZDG@>],@^=[+3)O$GB1-/T2R*/=S$6\!<MY:]>6/4 <D^U
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M_P"XOY4 +L7&,<4 )Y4>00B@CH0* ';%'\(_*@!IBC+ F-21T)% #@H'0 4
M1W%M;W<1BN8(YHSU610P_(T );V=M9Q>5;6\4$><[8T"C/T% $H '0 4 ?_9
*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>img127089420_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img127089420_4.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #_X0!V17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <   !     +     !53DE#3T1%  !, $4 00!$
M "  5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N "  5@ Q "X
M,  Q  #_VP!#  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<'QXC
M*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3?_VP!# 0D*"@T+#1H.#AHW
M)!\D-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-S?_P  1"  = '@# 1$  A$! Q$!_\0 'P   04! 0$! 0$
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M+32E+EQN8GHJYZDG@>],@^=[+3)O$GB1-/T2R*/=S$6\!<MY:]>6/4 <D^U
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M_P"XOY4 +L7&,<4 )Y4>00B@CH0* ';%'\(_*@!IBC+ F-21T)% #@H'0 4
M1W%M;W<1BN8(YHSU610P_(T );V=M9Q>5;6\4$><[8T"C/T% $H '0 4 ?_9
*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>img127089420_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img127089420_5.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #_X0!V17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <   !     +     !53DE#3T1%  !, $4 00!$
M "  5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N "  5@ Q "X
M,  Q  #_VP!#  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<'QXC
M*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3?_VP!# 0D*"@T+#1H.#AHW
M)!\D-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-S?_P  1"  = '@# 1$  A$! Q$!_\0 'P   04! 0$! 0$
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M+32E+EQN8GHJYZDG@>],@^=[+3)O$GB1-/T2R*/=S$6\!<MY:]>6/4 <D^U
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M_P"XOY4 +L7&,<4 )Y4>00B@CH0* ';%'\(_*@!IBC+ F-21T)% #@H'0 4
M1W%M;W<1BN8(YHSU610P_(T );V=M9Q>5;6\4$><[8T"C/T% $H '0 4 ?_9
*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>img127089420_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img127089420_6.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #_X0!V17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <   !     +     !53DE#3T1%  !, $4 00!$
M "  5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N "  5@ Q "X
M,  Q  #_VP!#  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<'QXC
M*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3?_VP!# 0D*"@T+#1H.#AHW
M)!\D-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-S?_P  1"  = '@# 1$  A$! Q$!_\0 'P   04! 0$! 0$
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M+32E+EQN8GHJYZDG@>],@^=[+3)O$GB1-/T2R*/=S$6\!<MY:]>6/4 <D^U
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M_P"XOY4 +L7&,<4 )Y4>00B@CH0* ';%'\(_*@!IBC+ F-21T)% #@H'0 4
M1W%M;W<1BN8(YHSU610P_(T );V=M9Q>5;6\4$><[8T"C/T% $H '0 4 ?_9
*              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>img151100966_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img151100966_0.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $%N9V5L82!(
M86YS   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,P,@  DI(
M @    ,P,@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( -H#,@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M?]^S7EM2VUM+>74=O;KNED;:HIK,Z[=DD'UNJ^QZYI>OV.L2.MBSOY8RQ*$
M5I5G:'I$6BZ7';18+?>D?'WFK1KWZ7/R+VFYZ4.;E][<****T+"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.)$[,/\ /6LJJL!]5:!\1/#GB74OL&E7PDN=A<(RE=P'IGK5SQ1H2ZWII$8
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M[:M?P[X[T3Q5>26VBS/.\2[G/ED!1]37RQ:6D]_>PVEG&TL\[A(T4=2:^I/
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M'F7_  JR]_Z"4'_?H_XUU/A#PQ-X;AN$GN$G\Y@044C%=)12<FPL@KGO'?\
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MM[XXN+KP?'I@W"Z/[N:7U0>GN> :4HW8)E'QAX@;7M98QD_98"4A7U]6K H
MP*W?"7A]_$&LK&P(MH</,WMV'U/]*K9"W.L^'/AORH?[9O$_>2#%N"/NK_>_
M'^5=_38XTBC6.-0J*,*H' %.K)N[+6@4444AA1110 5C^+?^13U#_KE_45L5
MC^+?^13U#_KE_44UN!X>.E:?AO\ Y&K2_P#KZC_]"%9@Z5I^&_\ D:M+_P"O
MJ/\ ]"%;&9[K1116!H%%%% !7/>._P#D2K__ '5_]#%=#7/>._\ D2K_ /W5
M_P#0Q36XGL>,5T/@7_D;[3\:YZK^C:H^C:K%?11K(T><*W0UJ]B#WFBO,O\
MA:5[_P! ^'\S1_PM*]_Z!\/YFL^5EW1Z;17F7_"TKW_H'P_F:/\ A:5[_P!
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M$J__ -U?_0Q36XGL>,445L^%+&WU+Q);VUXGF1/G<OK6Q!C45[/_ ,(+X?\
M^?%?SH_X07P__P ^*_G4<R'RL\8HKV?_ (07P_\ \^*_G1_P@OA__GQ7\Z.9
M!RL\8KTOX5_\@W4/^NP_]!%;G_""^'_^?%?SK2TK1;'18Y$TZ$1+(VY@.YI.
M2:&E8OT445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5YG\3M)\F]M]4B7Y91Y4I X!'3\\G\J],K*\2Z4NLZ!<
MVA WE=T9/\+#H::=F)['AE>A_#'5@/M6F2M@#]]'D_F/ZUYZ058JP*L#@@]J
MFM+N>QG,ULY1]C)D>C#!_0UJU=$+0O\ B?5#K'B*YN<DQAMD8/91_P#7S64
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M?T%=Y7!_"W_D&7O_ %V_H*[RHEN4M@HHHJ1A1110 4444 %8_BW_ )%/4/\
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M0,#J16Q7/> _^1)T_P#W&_\ 0C70UD]S1!1112 **** "BBB@ HHHH ****
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MT1%P!^%/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>44
<FILENAME>pcvx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T10:44:05.1983+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="pcvx-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="pcvx-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="pcvx-20221231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfOperationsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness" xlink:href="pcvx-20221231.xsd#Role_DisclosureCompanyOrganizationAndNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="pcvx-20221231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:href="pcvx-20221231.xsd#Role_DisclosureRedeemableConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrants" xlink:href="pcvx-20221231.xsd#DisclosurePrefundedWarrants" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlans" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlan" xlink:href="pcvx-20221231.xsd#DisclosureRetirementPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangement" xlink:href="pcvx-20221231.xsd#Role_DisclosureFundingArrangement" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="pcvx-20221231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="pcvx-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="pcvx-20221231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="pcvx-20221231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="pcvx-20221231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:href="pcvx-20221231.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTable" xlink:href="pcvx-20221231.xsd#DisclosureCommitmentsAndContingenciesTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="pcvx-20221231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="pcvx-20221231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails" xlink:href="pcvx-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#DisclosurePrefundedWarrantsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails" xlink:href="pcvx-20221231.xsd#DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails" xlink:href="pcvx-20221231.xsd#DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedManufacturingExpenses" xlink:label="pcvx_AccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="pcvx_AccruedManufacturingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AcquiredManufacturingRights" xlink:label="pcvx_AcquiredManufacturingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="pcvx_AcquiredManufacturingRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="pcvx_GrantIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ResearchAndDevelopmentExpenseToRelatedParty" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="pcvx_ResearchAndDevelopmentExpenseToRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AtTheMarketOfferingMember" xlink:label="pcvx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SutroStockPaymentMember" xlink:label="pcvx_SutroStockPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockValue" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockShares" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ReleaseOfRestrictedStockUnitsValue" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ReleaseOfRestrictedStockUnitsShares" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_27"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_28"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_29"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_30"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_MarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_AtTheMarketOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_SutroStockPaymentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_ReleaseOfRestrictedStockUnitsValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_ReleaseOfRestrictedStockUnitsShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_29" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_30" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityStockIssuanceCosts" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityStockIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_MarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaymentsOfCapitalLeaseObligations" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights" xlink:label="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NonCashPaymentsForAcquireManufacturingRights" xlink:label="pcvx_NonCashPaymentsForAcquireManufacturingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedCompensation" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ReleaseOfRestrictedStockUnitsValue" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_PaymentsOfCapitalLeaseObligations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pcvx_NonCashPaymentsForAcquireManufacturingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInAccruedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInAccruedLegalSettlement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="pcvx_ReleaseOfRestrictedStockUnitsValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RedeemableConvertiblePreferredStockTextBlock" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="pcvx_RedeemableConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrants" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_WarrantsDisclosureTextBlock" xlink:label="pcvx_WarrantsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pcvx_WarrantsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementAbstract" xlink:label="pcvx_FundingArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementTextBlock" xlink:label="pcvx_FundingArrangementTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementAbstract" xlink:to="pcvx_FundingArrangementTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock" xlink:label="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock" xlink:label="pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GlobalTargetRevenue" xlink:label="pcvx_GlobalTargetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PneumococcalConjugateVaccineMember" xlink:label="pcvx_PneumococcalConjugateVaccineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_GlobalTargetRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pcvx_PneumococcalConjugateVaccineMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_InitialPublicOfferingRelatedCost" xlink:label="pcvx_InitialPublicOfferingRelatedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfFinanceLease" xlink:label="pcvx_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pcvx_InitialPublicOfferingRelatedCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pcvx_NumberOfFinanceLease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCash" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfSecurities" xlink:label="pcvx_NumberOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="pcvx_NumberOfSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAmortizedCost" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestments" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAmortizedCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ComputersAndComputerSoftwareMember" xlink:label="pcvx_ComputersAndComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LabEquipmentMember" xlink:label="pcvx_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CapitalLeasesLabEquipmentMember" xlink:label="pcvx_CapitalLeasesLabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_ComputersAndComputerSoftwareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_LabEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_CapitalLeasesLabEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedManufacturingRightsExpenses" xlink:label="pcvx_AccruedManufacturingRightsExpenses"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="pcvx_AccruedManufacturingRightsExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ClinicalStudies" xlink:label="pcvx_ClinicalStudies"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent" xlink:label="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="pcvx_ClinicalStudies" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_HeadquartersFacilityMember" xlink:label="pcvx_HeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalFacilityMember" xlink:label="pcvx_AdditionalFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeaseTerminationDate" xlink:label="pcvx_LeaseTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NewCorporateHeadquartersFacilityMember" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseRenewalOption" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SanCarlosMember" xlink:label="pcvx_SanCarlosMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseExtendedMaturityDate" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseRentCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfRenewalOptions" xlink:label="pcvx_NumberOfRenewalOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfOperatingLease" xlink:label="pcvx_NumberOfOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_HeadquartersFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseCommencementDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_AdditionalFacilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LeaseTerminationDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_NewCorporateHeadquartersFacilityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseRenewalOption" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_PaloAltoMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_SanCarlosMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseExtendedLeaseTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseExtendedMaturityDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseRentCommencementDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_NumberOfRenewalOptions" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_NumberOfOperatingLease" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeasePaymentReceivableNoncurrent" xlink:label="pcvx_LeasePaymentReceivableNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_PaloAltoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LeasePaymentReceivableNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LonzaLimitedMember" xlink:label="pcvx_LonzaLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfPaymentsCompletionAgreedToDefer" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SutroBiopharmaIncMember" xlink:label="pcvx_SutroBiopharmaIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsideration" xlink:label="pcvx_UpfrontConsideration"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsiderationInCash" xlink:label="pcvx_UpfrontConsiderationInCash"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsiderationInCashAfterAgreementDate" xlink:label="pcvx_UpfrontConsiderationInCashAfterAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OptionExercisePriceInCash" xlink:label="pcvx_OptionExercisePriceInCash"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalMilestonePaymentsInCash" xlink:label="pcvx_AdditionalMilestonePaymentsInCash"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedCommitment" xlink:label="pcvx_AccruedCommitment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FairValueOnDateOfSettlement" xlink:label="pcvx_FairValueOnDateOfSettlement"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_LonzaLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_PercentageOfPaymentsCompletionAgreedToDefer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_SutroBiopharmaIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_UpfrontConsideration" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_UpfrontConsiderationInCash" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_UpfrontConsiderationInCashAfterAgreementDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_OptionExercisePriceInCash" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_AdditionalMilestonePaymentsInCash" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_AccruedCommitment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_FairValueOnDateOfSettlement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NoncancelablePurchaseCommitmentsDueInOneYear" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NonCancelablePurchaseCommitments" xlink:label="pcvx_NonCancelablePurchaseCommitments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pcvx_NonCancelablePurchaseCommitments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_JefferiesLimitedLiabilityCompanyMember" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ATMSalesAgreementMember" xlink:label="pcvx_ATMSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SaleOfCommonStockAuthorizedAmount" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesPreFundedWarrantsToPurchase" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PrefundedWarrantsPricePerShare" xlink:label="pcvx_PrefundedWarrantsPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceFollowOnOffering" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_JefferiesLimitedLiabilityCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_ATMSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SaleOfCommonStockAuthorizedAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_GrossProceedsFromIssuanceOfCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesPreFundedWarrantsToPurchase" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_PrefundedWarrantsPricePerShare" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_ProceedsFromIssuanceFollowOnOffering" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pcvx_SharesAvailableForFutureStockOptionGrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesPreFundedWarrantsToPurchase" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PrefundedWarrantsPricePerShare" xlink:label="pcvx_PrefundedWarrantsPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" xlink:label="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" xlink:label="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" xlink:label="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" xlink:label="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesPreFundedWarrantsToPurchase" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_PrefundedWarrantsPricePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfFairValuePerShareOnTheGrantDate" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OtherRestrictedStockUnitsMember" xlink:label="pcvx_OtherRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockOptionsGrantedTerm" xlink:label="pcvx_StockOptionsGrantedTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfProvisionsSubjectToStockholders" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_EarlyExercisedStockOptions" xlink:label="pcvx_EarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OfferingPeriod" xlink:label="pcvx_OfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PurchasePeriod" xlink:label="pcvx_PurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PercentageOfFairValuePerShareOnTheGrantDate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pcvx_OtherRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_StockOptionsGrantedTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PercentageOfProvisionsSubjectToStockholders" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_EarlyExercisedStockOptions" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_OfferingPeriod" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PurchasePeriod" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RestrictedStockUnitsWithheld" xlink:label="pcvx_RestrictedStockUnitsWithheld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_RestrictedStockUnitsWithheld" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementLineItems" xlink:label="pcvx_FundingArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementTable" xlink:label="pcvx_FundingArrangementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CostReimbursementSubAwardAgreementMember" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementAbstract" xlink:label="pcvx_FundingArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_InitialFundingCommittedByAward" xlink:label="pcvx_InitialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalFundingCommittedByAward" xlink:label="pcvx_AdditionalFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingCommittedByAward" xlink:label="pcvx_PotentialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_CostReimbursementSubAwardAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementAbstract" xlink:to="pcvx_FundingArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_InitialFundingCommittedByAward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_AdditionalFundingCommittedByAward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementTable" xlink:to="pcvx_FundingArrangementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="us-gaap_GrantsReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingCommittedByAward" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_GrantIncome" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_EmployeeStockPurchasePlanMember" xlink:label="pcvx_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RedeemableConvertiblePreferredStockWarrantMember" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pcvx_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pcvx_CommonStockWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pcvx_RedeemableConvertiblePreferredStockWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_Section162MLimitation" xlink:label="pcvx_Section162MLimitation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="pcvx_Section162MLimitation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeaseLiability" xlink:label="pcvx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="pcvx_LeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncomeTaxDisclosureLineItems" xlink:label="pcvx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncomeTaxDisclosureTable" xlink:label="pcvx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OperatingLossCarryForwardsExpirationYear" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TaxCreditCarryforwardExpirationYear" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ResearchAndExperimentalExpensesAmortizedPeriod" xlink:label="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="pcvx_IncomeTaxDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_OperatingLossCarryForwardsExpirationYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_TaxCreditCarryforwardExpirationYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="pcvx_IncomeTaxDisclosureLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SutroBiopharmaIncMember" xlink:label="pcvx_SutroBiopharmaIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LicenseAmendmentATwoMember" xlink:label="pcvx_LicenseAmendmentATwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LicenseAgreementMember" xlink:label="pcvx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreferredStockWarrantMember" xlink:label="pcvx_PreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SupplyAgreementMember" xlink:label="pcvx_SupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pcvx_SutroBiopharmaIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_LicenseAmendmentATwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pcvx_CommonStockWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_LicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pcvx_PreferredStockWarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_SupplyAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ATMSalesAgreementMember" xlink:label="pcvx_ATMSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" xlink:label="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SaleOfCommonStockAuthorizedAmount" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_ATMSalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_GrossProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_SaleOfCommonStockAuthorizedAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>45
<FILENAME>pcvx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T10:44:05.2364+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#DisclosurePrefundedWarrantsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails" xlink:href="pcvx-20221231.xsd#DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#DisclosureRetirementPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFundingArrangementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="pcvx-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AtTheMarketOfferingMember" xlink:label="pcvx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SutroStockPaymentMember" xlink:label="pcvx_SutroStockPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockValue" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockShares" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ReleaseOfRestrictedStockUnitsValue" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ReleaseOfRestrictedStockUnitsShares" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_MarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_SutroStockPaymentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_ReleaseOfRestrictedStockUnitsValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_ReleaseOfRestrictedStockUnitsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityStockIssuanceCosts" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="pcvx_TemporaryEquityStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="pcvx_MarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GlobalTargetRevenue" xlink:label="pcvx_GlobalTargetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PneumococcalConjugateVaccineMember" xlink:label="pcvx_PneumococcalConjugateVaccineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_GlobalTargetRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="pcvx_PneumococcalConjugateVaccineMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_InitialPublicOfferingRelatedCost" xlink:label="pcvx_InitialPublicOfferingRelatedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfFinanceLease" xlink:label="pcvx_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pcvx_InitialPublicOfferingRelatedCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="pcvx_NumberOfFinanceLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfSecurities" xlink:label="pcvx_NumberOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="pcvx_NumberOfSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAmortizedCost" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestments" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAmortizedCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="pcvx_CashAndCashEquivalentsAndInvestments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ComputersAndComputerSoftwareMember" xlink:label="pcvx_ComputersAndComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LabEquipmentMember" xlink:label="pcvx_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CapitalLeasesLabEquipmentMember" xlink:label="pcvx_CapitalLeasesLabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_ComputersAndComputerSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_LabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_CapitalLeasesLabEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_HeadquartersFacilityMember" xlink:label="pcvx_HeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalFacilityMember" xlink:label="pcvx_AdditionalFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeaseTerminationDate" xlink:label="pcvx_LeaseTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NewCorporateHeadquartersFacilityMember" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseRenewalOption" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SanCarlosMember" xlink:label="pcvx_SanCarlosMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseExtendedMaturityDate" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseRentCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfRenewalOptions" xlink:label="pcvx_NumberOfRenewalOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfOperatingLease" xlink:label="pcvx_NumberOfOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_HeadquartersFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_AdditionalFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LeaseTerminationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_NewCorporateHeadquartersFacilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseRenewalOption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_PaloAltoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pcvx_SanCarlosMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseExtendedLeaseTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseExtendedMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LesseeOperatingLeaseRentCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_NumberOfRenewalOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_NumberOfOperatingLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeasePaymentReceivableNoncurrent" xlink:label="pcvx_LeasePaymentReceivableNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_PaloAltoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pcvx_LeasePaymentReceivableNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LonzaLimitedMember" xlink:label="pcvx_LonzaLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfPaymentsCompletionAgreedToDefer" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SutroBiopharmaIncMember" xlink:label="pcvx_SutroBiopharmaIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsideration" xlink:label="pcvx_UpfrontConsideration"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsiderationInCash" xlink:label="pcvx_UpfrontConsiderationInCash"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsiderationInCashAfterAgreementDate" xlink:label="pcvx_UpfrontConsiderationInCashAfterAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OptionExercisePriceInCash" xlink:label="pcvx_OptionExercisePriceInCash"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalMilestonePaymentsInCash" xlink:label="pcvx_AdditionalMilestonePaymentsInCash"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedCommitment" xlink:label="pcvx_AccruedCommitment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FairValueOnDateOfSettlement" xlink:label="pcvx_FairValueOnDateOfSettlement"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_LonzaLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_PercentageOfPaymentsCompletionAgreedToDefer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_SutroBiopharmaIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_UpfrontConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_UpfrontConsiderationInCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_UpfrontConsiderationInCashAfterAgreementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_OptionExercisePriceInCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_AdditionalMilestonePaymentsInCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_AccruedCommitment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="pcvx_FairValueOnDateOfSettlement" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_JefferiesLimitedLiabilityCompanyMember" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ATMSalesAgreementMember" xlink:label="pcvx_ATMSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SaleOfCommonStockAuthorizedAmount" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesPreFundedWarrantsToPurchase" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PrefundedWarrantsPricePerShare" xlink:label="pcvx_PrefundedWarrantsPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceFollowOnOffering" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pcvx_JefferiesLimitedLiabilityCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_ATMSalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SaleOfCommonStockAuthorizedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesPreFundedWarrantsToPurchase" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_PrefundedWarrantsPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_ProceedsFromIssuanceFollowOnOffering" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pcvx_SharesAvailableForFutureStockOptionGrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesPreFundedWarrantsToPurchase" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PrefundedWarrantsPricePerShare" xlink:label="pcvx_PrefundedWarrantsPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" xlink:label="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" xlink:label="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" xlink:label="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" xlink:label="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_SharesPreFundedWarrantsToPurchase" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_PrefundedWarrantsPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfFairValuePerShareOnTheGrantDate" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OtherRestrictedStockUnitsMember" xlink:label="pcvx_OtherRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockOptionsGrantedTerm" xlink:label="pcvx_StockOptionsGrantedTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfProvisionsSubjectToStockholders" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_EarlyExercisedStockOptions" xlink:label="pcvx_EarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OfferingPeriod" xlink:label="pcvx_OfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PurchasePeriod" xlink:label="pcvx_PurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PercentageOfFairValuePerShareOnTheGrantDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pcvx_OtherRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_StockOptionsGrantedTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PercentageOfProvisionsSubjectToStockholders" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_EarlyExercisedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_OfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_PurchasePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RestrictedStockUnitsWithheld" xlink:label="pcvx_RestrictedStockUnitsWithheld"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_RestrictedStockUnitsWithheld" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementLineItems" xlink:label="pcvx_FundingArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementTable" xlink:label="pcvx_FundingArrangementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CostReimbursementSubAwardAgreementMember" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_InitialFundingCommittedByAward" xlink:label="pcvx_InitialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalFundingCommittedByAward" xlink:label="pcvx_AdditionalFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingCommittedByAward" xlink:label="pcvx_PotentialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingArrangementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_FundingArrangementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_CostReimbursementSubAwardAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_InitialFundingCommittedByAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_FundingArrangementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_FundingArrangementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_AdditionalFundingCommittedByAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="us-gaap_GrantsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingCommittedByAward" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_GrantIncome" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_EmployeeStockPurchasePlanMember" xlink:label="pcvx_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RedeemableConvertiblePreferredStockWarrantMember" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="pcvx_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pcvx_CommonStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pcvx_RedeemableConvertiblePreferredStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncomeTaxDisclosureLineItems" xlink:label="pcvx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncomeTaxDisclosureTable" xlink:label="pcvx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OperatingLossCarryForwardsExpirationYear" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TaxCreditCarryforwardExpirationYear" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ResearchAndExperimentalExpensesAmortizedPeriod" xlink:label="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_IncomeTaxDisclosureTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_OperatingLossCarryForwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SutroBiopharmaIncMember" xlink:label="pcvx_SutroBiopharmaIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LicenseAmendmentATwoMember" xlink:label="pcvx_LicenseAmendmentATwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LicenseAgreementMember" xlink:label="pcvx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreferredStockWarrantMember" xlink:label="pcvx_PreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SupplyAgreementMember" xlink:label="pcvx_SupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="pcvx_SutroBiopharmaIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_LicenseAmendmentATwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pcvx_CommonStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_LicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="pcvx_PreferredStockWarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="pcvx_SupplyAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ATMSalesAgreementMember" xlink:label="pcvx_ATMSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" xlink:label="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SaleOfCommonStockAuthorizedAmount" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pcvx_ATMSalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_GrossProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_SaleOfCommonStockAuthorizedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>46
<FILENAME>pcvx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T10:44:07.8674+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_InitialFundingCommittedByAward" xlink:label="pcvx_InitialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ComputersAndComputerSoftwareMember" xlink:label="pcvx_ComputersAndComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalFacilityMember" xlink:label="pcvx_AdditionalFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CommonStockWarrantMember" xlink:label="pcvx_CommonStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementLineItems" xlink:label="pcvx_FundingArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedManufacturingExpenses" xlink:label="pcvx_AccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceFollowOnOffering" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SutroBiopharmaIncMember" xlink:label="pcvx_SutroBiopharmaIncMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PrefundedWarrantsPricePerShare" xlink:label="pcvx_PrefundedWarrantsPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LicenseAgreementMember" xlink:label="pcvx_LicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ReleaseOfRestrictedStockUnitsShares" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAmortizedCost" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ResearchAndExperimentalExpensesAmortizedPeriod" xlink:label="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RedeemableConvertiblePreferredStockWarrantMember" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedCommitment" xlink:label="pcvx_AccruedCommitment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TaxCreditCarryforwardExpirationYear" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalMilestonePaymentsInCash" xlink:label="pcvx_AdditionalMilestonePaymentsInCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsideration" xlink:label="pcvx_UpfrontConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaloAltoMember" xlink:label="pcvx_PaloAltoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" xlink:label="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedCompensation" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NonCancelablePurchaseCommitments" xlink:label="pcvx_NonCancelablePurchaseCommitments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfFinanceLease" xlink:label="pcvx_NumberOfFinanceLease"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeasePaymentReceivableNoncurrent" xlink:label="pcvx_LeasePaymentReceivableNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OptionExercisePriceInCash" xlink:label="pcvx_OptionExercisePriceInCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FairValueOnDateOfSettlement" xlink:label="pcvx_FairValueOnDateOfSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA" xlink:label="stpr_CA"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementTable" xlink:label="pcvx_FundingArrangementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseExtendedLeaseTerm" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ATMSalesAgreementMember" xlink:label="pcvx_ATMSalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfProvisionsSubjectToStockholders" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_EarlyExercisedStockOptions" xlink:label="pcvx_EarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ReleaseOfRestrictedStockUnitsValue" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SupplyAgreementMember" xlink:label="pcvx_SupplyAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreferredStockWarrantMember" xlink:label="pcvx_PreferredStockWarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_JefferiesLimitedLiabilityCompanyMember" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestments" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfFairValuePerShareOnTheGrantDate" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncomeTaxDisclosureLineItems" xlink:label="pcvx_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfRenewalOptions" xlink:label="pcvx_NumberOfRenewalOptions"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LicenseAmendmentATwoMember" xlink:label="pcvx_LicenseAmendmentATwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" xlink:label="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LonzaLimitedMember" xlink:label="pcvx_LonzaLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SaleOfCommonStockAuthorizedAmount" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RestrictedStockUnitsWithheld" xlink:label="pcvx_RestrictedStockUnitsWithheld"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementTextBlock" xlink:label="pcvx_FundingArrangementTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PneumococcalConjugateVaccineMember" xlink:label="pcvx_PneumococcalConjugateVaccineMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" xlink:label="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" xlink:label="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfSecurities" xlink:label="pcvx_NumberOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_MarketOfferingMember" xlink:label="pcvx_MarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsiderationInCashAfterAgreementDate" xlink:label="pcvx_UpfrontConsiderationInCashAfterAgreementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseRentCommencementDate" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OperatingLossCarryForwardsExpirationYear" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PurchasePeriod" xlink:label="pcvx_PurchasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_EmployeeStockPurchasePlanMember" xlink:label="pcvx_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NewCorporateHeadquartersFacilityMember" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock" xlink:label="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OfferingPeriod" xlink:label="pcvx_OfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaymentsOfCapitalLeaseObligations" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockShares" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" xlink:label="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_UpfrontConsiderationInCash" xlink:label="pcvx_UpfrontConsiderationInCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedManufacturingRightsExpenses" xlink:label="pcvx_AccruedManufacturingRightsExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ClinicalStudies" xlink:label="pcvx_ClinicalStudies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_InitialPublicOfferingRelatedCost" xlink:label="pcvx_InitialPublicOfferingRelatedCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CapitalLeasesLabEquipmentMember" xlink:label="pcvx_CapitalLeasesLabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GlobalTargetRevenue" xlink:label="pcvx_GlobalTargetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NoncancelablePurchaseCommitmentsDueInOneYear" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AcquiredManufacturingRights" xlink:label="pcvx_AcquiredManufacturingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_StockOptionsGrantedTerm" xlink:label="pcvx_StockOptionsGrantedTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PercentageOfPaymentsCompletionAgreedToDefer" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityConversionOfPreferredStockValue" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AtTheMarketOfferingMember" xlink:label="pcvx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CostReimbursementSubAwardAgreementMember" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeaseLiability" xlink:label="pcvx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesPreFundedWarrantsToPurchase" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_HeadquartersFacilityMember" xlink:label="pcvx_HeadquartersFacilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesAvailableForFutureStockOptionGrantsMember" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TemporaryEquityStockIssuanceCosts" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_Section162MLimitation" xlink:label="pcvx_Section162MLimitation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OtherRestrictedStockUnitsMember" xlink:label="pcvx_OtherRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights" xlink:label="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent" xlink:label="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SutroStockPaymentMember" xlink:label="pcvx_SutroStockPaymentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseExtendedMaturityDate" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseRenewalOption" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PotentialFundingCommittedByAward" xlink:label="pcvx_PotentialFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LabEquipmentMember" xlink:label="pcvx_LabEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SanCarlosMember" xlink:label="pcvx_SanCarlosMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeaseTerminationDate" xlink:label="pcvx_LeaseTerminationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ResearchAndDevelopmentExpenseToRelatedParty" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AdditionalFundingCommittedByAward" xlink:label="pcvx_AdditionalFundingCommittedByAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_WarrantsDisclosureTextBlock" xlink:label="pcvx_WarrantsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock" xlink:label="pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NumberOfOperatingLease" xlink:label="pcvx_NumberOfOperatingLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_FundingArrangementAbstract" xlink:label="pcvx_FundingArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncomeTaxDisclosureTable" xlink:label="pcvx_IncomeTaxDisclosureTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_RedeemableConvertiblePreferredStockTextBlock" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NonCashPaymentsForAcquireManufacturingRights" xlink:label="pcvx_NonCashPaymentsForAcquireManufacturingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial funding committed by award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Funding Committed By Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial funding committed by award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss (in thousands)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Or Change In Accounting Principle [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ComputersAndComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computers and computer software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ComputersAndComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computers And Computer Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ComputersAndComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers and Computer Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NonCancelable Purchase Commitments Due In Second Year and Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonCancelable purchase commitments due in second year and thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment recorded in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CommonStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating lease, ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Arrangement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares issuance of common stock related to early exercised stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issuance Of Common Stock Related To Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standard update material impact</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued manufacturing expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions based on tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments based on tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award number of shares available for grant forfeited in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Grant, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance follow on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance follow on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from follow on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and investments amortized cost basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Investments Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets measured at fair value, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid In capital vesting of early exercised stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroBiopharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sutro Biopharma, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroBiopharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sutro Biopharma Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroBiopharmaIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sutro Biopharma, Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award number of shares available for grant exercised in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Grant, exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs included in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PrefundedWarrantsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prefunded Warrants Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PrefundedWarrantsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prefunded warrants price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PrefundedWarrantsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prefunded Warrants Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PrefundedWarrantsPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pre-funded warrants price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of preferred stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Preferred Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of restricted stock units, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Release of Restricted Stock Units Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Release of Restricted Stock Units Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">ROU asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Vested and released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of redeemable convertible preferred stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents amortized cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and cash equivalents, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standard update adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company Organization and Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under the Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series C Redeemable Convertible Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimental expenses amortized period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Experimental Expenses Amortized Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and experimental expenses amortized period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of payroll deductions of eligible compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued price per share upon follow on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share upon follow on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedPricePerShareUponFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents gross unrealized loss before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash and cash equivalents, Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrantIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Commitment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Commitment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued commitment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalMilestonePaymentsInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Milestone Payments in Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalMilestonePaymentsInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Payments in Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalMilestonePaymentsInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone payments in cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaloAltoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Palo alto.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaloAltoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Palo Alto [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaloAltoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Palo Alto</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount recorded with respect to the potential future payments above the initial cash cap</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-Backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset backed securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of stock, net of commission and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Stock Net Of Commission And Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of stock, net of commission and offering expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued compensation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NonCancelablePurchaseCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-cancelable purchase commitments due to key manufacturing partners</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NonCancelablePurchaseCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Cancelable Purchase Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NonCancelablePurchaseCommitments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-Cancelable Purchase Commitments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred into level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset backed securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payment on annual net sales of vaccine products for human health.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payment On Annual Net Sales Of Vaccine Products For Human Health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payment on annual net sales of vaccine products for human health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred into level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters' option to purchase additional shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Underwriting Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of finance lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Finance Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfFinanceLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of finance lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award number of shares available for grant granted in period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options Available for Grant, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital warrant liability write off.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Liability Write Off</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability write-off</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock converted into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeasePaymentReceivableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Payment Receivable Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeasePaymentReceivableNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease incentives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum commission percentage of gross proceeds from common stock sold.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Commission Percentage Of Gross Proceeds From Common Stock Sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum commission percentage of gross proceeds from common stock sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of information related to right-of-use assets and lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Information Related To Right Of Use Assets And Lease Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Information Related to ROU Assets and Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock related to early exercised stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock related to early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OptionExercisePriceInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Exercise Price in Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OptionExercisePriceInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Price in Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OptionExercisePriceInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise price in cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash, Cash Equivalents And Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value - 10,000,000 authorized at December 31, 2022 and December 31, 2021; no shares issued and outstanding at December 31, 2022 and December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares conversion of common stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Common Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of common stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FairValueOnDateOfSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value on Date of Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FairValueOnDateOfSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value on Date of Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FairValueOnDateOfSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value on Date of Settlement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_CA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Arrangement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant to purchase shares of stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended lease term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, extended term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ATMSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ATMSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A T M Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ATMSalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees purchase shares of common stock of lower of fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing services agreement payments in equity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Services Agreement Payments In Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments in equity, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of provisions subject to stockholders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Provisions Subject To Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfProvisionsSubjectToStockholders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of provisions subject to stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under ATM Sales Program, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of stock, net of commission and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Early &#8203;exercised&#8203; stock&#8203; options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Release of restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of restricted stock units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Release of Restricted Stock Units Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Release of restricted stock units value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">R&amp;D Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Supply Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supply Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supply Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreferredStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding committed by award, available upon achievement of development milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Committed By Award Available Upon Achievement Of Development Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total funding committed by award, available upon achievement of development milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies limited liability company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies Limited Liability Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_JefferiesLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Jefferies LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses related to agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Realized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fair value per share on the grant date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fair Value Per Share On The Grant Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfFairValuePerShareOnTheGrantDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair value per share on the grant date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross proceeds from issuance of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate gross proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage for stock options granted, Six months thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Compensation Arrangement By Share based Payment Award Award Vesting Rights Six Months Thereafter Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based Compensation Arrangement By Share based Payment Award Award Vesting Rights Six Months Thereafter Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of renewal options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Renewal Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfRenewalOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of renewal options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock, net of issuance cost (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting standard update adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential funding amount of award to develop vaccine to prevent infections.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Funding Amount Of Award To Develop Vaccine To Prevent Infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential funding amount of award to develop vaccine to prevent shingella infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals &amp; reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAmendmentATwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Amendment A Two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAmendmentATwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Amendment A Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LicenseAmendmentATwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Amendment A2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase or Decrease of Pre-funded Warrant Percentage Not Exceed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase or Decrease of Pre-funded Warrant Percentage Not Exceed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase or Decrease of Pre-funded Warrant Percentage Not Exceed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LonzaLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lonza limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LonzaLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lonza Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LonzaLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lonza DMSA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plan, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to renewal, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of common stock authorized amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Common Stock Authorized Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SaleOfCommonStockAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RestrictedStockUnitsWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units withheld</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RestrictedStockUnitsWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted stock units withheld</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RestrictedStockUnitsWithheld_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units withheld</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, early adoption [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PneumococcalConjugateVaccineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pneumococcal conjugate vaccine.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PneumococcalConjugateVaccineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pneumococcal Conjugate Vaccine [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PneumococcalConjugateVaccineMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pneumococcal Conjugate Vaccine</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined voting power of securities outstanding immediately after effect to the exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combined Voting Power of Securities Outstanding Immediately after Effect to the Exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined voting power of securities outstanding immediately after effect to the exercise.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants of common stock shares outstanding Immediately after effect to the exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrants of Common Stock Shares Outstanding Immediately After Effect to the Exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded warrants of common stock shares outstanding immediately after effect to the exercise.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan and two thousand fourteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan And Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan and 2014 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent - current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan and two thousand twenty equity incentive plan and two thousand twenty employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Equity Incentive Plan And Two Thousand Twenty Equity Incentive Plan And Two Thousand Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Plan, 2020 Plan and 2020 ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Number of Share Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of share authorized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value - 500,000,000 shares authorized at December 31, 2022 and December 31, 2021; 79,470,670 and 53,031,978 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Market offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_MarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercisable and vests immediately and expires date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred out of level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsiderationInCashAfterAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront Consideration in Cash After Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsiderationInCashAfterAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Consideration in Cash After Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsiderationInCashAfterAgreementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront consideration in cash after agreement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, rent commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Rent Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRentCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in one to five years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OperatingLossCarryForwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payment on net sales of vaccine compositions for animal health.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payment On Net Sales Of Vaccine Compositions For Animal Health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payment on net sales of vaccine compositions for animal health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Corporate Headquarters Facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Corporate Headquarters Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NewCorporateHeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Corporate Headquarters Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to Acquire Manufacturing Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option to Acquire Manufacturing Rights [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to acquire manufacturing rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding period of award to develop universal vaccine to prevent infections.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Period Of Award To Develop Universal Vaccine To Prevent Infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of capital lease obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Capital Lease Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of capital lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D expenditures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of preferred stock shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Preferred Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued for payment of accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrant recorded as a component of stockholders' equity within additional paid-in-capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-funded Warrant Recorded as a Component of Stockholders' Equity Within Additional Paid-in-Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-funded Warrant Recorded as a Component of Stockholders' Equity Within Additional Paid-in-Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Estimated Fair Value of Employee Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, rent expense recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax accrued manufacturing expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Accrued Manufacturing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in less than one year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsiderationInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront Consideration in Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsiderationInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Consideration in Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_UpfrontConsiderationInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront consideration in cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant receivable on unreimbursed, eligible costs incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingRightsExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing rights expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingRightsExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Rights Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedManufacturingRightsExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued manufacturing rights expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense, expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceedsfromissuanceofcommonstockandpre-fundedwarrantsfromfollowon offeringsnetofissuancecosts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Studies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Studies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClinicalStudies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Studies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise price expire in years form the date of grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Price Expire In Years Form The Date Of Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price expire in years form the date of grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right number of securities called by each warrant or right exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units RSU Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of options exercised, excludes options exercised from NPLN.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Options Exercised Excludes Options Exercised From NPLN</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Under Stock Option Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialPublicOfferingRelatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering related cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialPublicOfferingRelatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Related Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_InitialPublicOfferingRelatedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO-related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CapitalLeasesLabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital leases &#8212; lab equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CapitalLeasesLabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Leases Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CapitalLeasesLabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Leases &#8212; Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premiums on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over Allotment Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued manufacturing expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Manufacturing Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued manufacturing expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 6)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares owned</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party accrual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period, shares of follow on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares of follow on offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GlobalTargetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Global target revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GlobalTargetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Global Target Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_GlobalTargetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Global target revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments net of lease incentives remainder of fiscal year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Net Of Lease Incentives Remainder Of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Remainder of 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NonCancelable Purchase Commitments Due In One Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NonCancelable purchase commitments due In one year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to LonzaLtd.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AcquiredManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired manufacturing rights (Note 6)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AcquiredManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Manufacturing Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AcquiredManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired manufacturing rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency transaction (losses) gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Foreign Currency Transaction Gain (Loss), before Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock shares reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of the stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Due from (to) Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued expenses payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Related Party Transaction, Due from (to) Related Party, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (including related party expenses of $0, $2,359 and $1,331 in 2022, 2021 and 2020, respectively)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockOptionsGrantedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options granted term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockOptionsGrantedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Granted Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_StockOptionsGrantedTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future undiscounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of payments completion agreed to defer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Payments Completion Agreed To Defer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PercentageOfPaymentsCompletionAgreedToDefer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of defer payments agreed for completion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity conversion of preferred stock value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityConversionOfPreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of redeemable convertible preferred stock warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of redeemable convertible preferred stock tranche liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost reimbursement sub-award agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Reimbursement Sub Award Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CostReimbursementSubAwardAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost Reimbursement Sub-Award Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deffered Tax Assets Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and investments gross unrealized gain before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Investments Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at fair value, Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents and investments gross unrealized loss before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents And Investments Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total assets measured at fair value, Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options Available for Grant, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options Available for Grant, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of shares available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares pre-funded warrants to purchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Pre-Funded Warrants To Purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesPreFundedWarrantsToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-funded warrants to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Per Share, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Per Share, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued &amp; other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_HeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Headquarters facility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_HeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Headquarters Facility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_HeadquartersFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Headquarters Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for future stock option grants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Future Stock Option Grants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesAvailableForFutureStockOptionGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available for Future Stock Option Grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TemporaryEquityStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on disposal of fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued upon full exercise of underwriters option to purchase additional shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Upon Full Exercise Of Underwriters Option To Purchase Additional Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters' option to purchase additional shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting percentage for stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_Section162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Section 162(m) limitation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_Section162MLimitation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Section 162(m) Limitation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statutory Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OtherRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OtherRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OtherRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period for stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Unrecognized Tax Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, existence of option to renewal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for acquired manufacturing rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Common Stock for Acquired Manufacturing Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock for acquired manufacturing rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in deferred rent and other long term liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Rent And Other Long Term Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent and other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total noncurrent assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total noncurrent assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential funding period of award to develop vaccine to prevent infections.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Funding Period Of Award To Develop Vaccine To Prevent Infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential funding period of award to develop vaccine to prevent shingella infections</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Begining balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of the redeemable convertible preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of the redeemable convertible preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Research and Development Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other research and development liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents gross unrealized gain before tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroStockPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sutro Stock Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroStockPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sutro Stock Payment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SutroStockPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sutro stock payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, extended maturity date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseExtendedMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, extended maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease renewal option.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseRenewalOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, renewal option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, dividends, per share, declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential funding committed by award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Funding Committed By Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_PotentialFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential funding committed by award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued legal settlement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Legal Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LabEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SanCarlosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">San Carlos.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SanCarlosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">San Carlos [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SanCarlosMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Carlos</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LeaseTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonvested Restricted Stock Shares Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense to related party.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense To Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ResearchAndDevelopmentExpenseToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense to related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional funding committed by award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Funding Committed By Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AdditionalFundingCommittedByAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional funding committed by award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incentive stock option granted to Employees Owning percentage of shares of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incentive Stock Option Granted To Employees Owning Percentage Of Shares Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incentive stock option granted to employees owning percentage of shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares increase in available for grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Increase In Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for issuance of shares increased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company contributions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest or penalties recognized for the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Vested and released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-Funded Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_WarrantsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Contractual Maturities of Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock to Lonza Ltd. (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred out of level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographical Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from initial public offering, net of underwriters' commissions and discounts.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of non-cancelable purchase commitments related to raw materials [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of non-cancelable purchase commitments related to raw materials [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining liabilities related to early exercised shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Liabilities Related To Early Exercised Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining liabilities related to early exercised shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of operating right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-based Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of operating lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NumberOfOperatingLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Investments, Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding arrangement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_FundingArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets liabilities net before valuation allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net Before Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Combating antibiotic resistant bacteria biopharmaceutical accelerator agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARB-X Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_IncomeTaxDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees acquired shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Grant, Additional shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_RedeemableConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NonCashPaymentsForAcquireManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash payments for acquired manufacturing rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NonCashPaymentsForAcquireManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Payments for Acquire Manufacturing Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="pcvx_NonCashPaymentsForAcquireManufacturingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash payments for acquire manufacturing rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of diluted net loss per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_InitialFundingCommittedByAward" xlink:to="pcvx_InitialFundingCommittedByAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ComputersAndComputerSoftwareMember" xlink:to="pcvx_ComputersAndComputerSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" xlink:to="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdditionalFacilityMember" xlink:to="pcvx_AdditionalFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CommonStockWarrantMember" xlink:to="pcvx_CommonStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingArrangementLineItems" xlink:to="pcvx_FundingArrangementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:to="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:to="pcvx_SeriesDRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AccruedManufacturingExpenses" xlink:to="pcvx_AccruedManufacturingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromIssuanceFollowOnOffering" xlink:to="pcvx_ProceedsFromIssuanceFollowOnOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SutroBiopharmaIncMember" xlink:to="pcvx_SutroBiopharmaIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PrefundedWarrantsPricePerShare" xlink:to="pcvx_PrefundedWarrantsPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LicenseAgreementMember" xlink:to="pcvx_LicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ReleaseOfRestrictedStockUnitsShares" xlink:to="pcvx_ReleaseOfRestrictedStockUnitsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAmortizedCost" xlink:to="pcvx_CashAndCashEquivalentsAmortizedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="pcvx_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod" xlink:to="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_RedeemableConvertiblePreferredStockWarrantMember" xlink:to="pcvx_RedeemableConvertiblePreferredStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" xlink:to="pcvx_SharesIssuedPricePerShareUponFollowOnOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_GrantIncome" xlink:to="pcvx_GrantIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AccruedCommitment" xlink:to="pcvx_AccruedCommitment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TaxCreditCarryforwardExpirationYear" xlink:to="pcvx_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdditionalMilestonePaymentsInCash" xlink:to="pcvx_AdditionalMilestonePaymentsInCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_UpfrontConsideration" xlink:to="pcvx_UpfrontConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PaloAltoMember" xlink:to="pcvx_PaloAltoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" xlink:to="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInAccruedCompensation" xlink:to="pcvx_IncreaseDecreaseInAccruedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NonCancelablePurchaseCommitments" xlink:to="pcvx_NonCancelablePurchaseCommitments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:to="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfFinanceLease" xlink:to="pcvx_NumberOfFinanceLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" xlink:to="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LeasePaymentReceivableNoncurrent" xlink:to="pcvx_LeasePaymentReceivableNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" xlink:to="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" xlink:to="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_OptionExercisePriceInCash" xlink:to="pcvx_OptionExercisePriceInCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionPlansDefinedBenefitMember" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" xlink:to="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FairValueOnDateOfSettlement" xlink:to="pcvx_FairValueOnDateOfSettlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingArrangementTable" xlink:to="pcvx_FundingArrangementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseExtendedLeaseTerm" xlink:to="pcvx_LesseeOperatingLeaseExtendedLeaseTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ATMSalesAgreementMember" xlink:to="pcvx_ATMSalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" xlink:to="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfProvisionsSubjectToStockholders" xlink:to="pcvx_PercentageOfProvisionsSubjectToStockholders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_EarlyExercisedStockOptions" xlink:to="pcvx_EarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ReleaseOfRestrictedStockUnitsValue" xlink:to="pcvx_ReleaseOfRestrictedStockUnitsValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SupplyAgreementMember" xlink:to="pcvx_SupplyAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PreferredStockWarrantMember" xlink:to="pcvx_PreferredStockWarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" xlink:to="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_JefferiesLimitedLiabilityCompanyMember" xlink:to="pcvx_JefferiesLimitedLiabilityCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAndInvestments" xlink:to="pcvx_CashAndCashEquivalentsAndInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="pcvx_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfFairValuePerShareOnTheGrantDate" xlink:to="pcvx_PercentageOfFairValuePerShareOnTheGrantDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_GrossProceedsFromIssuanceOfCommonStock" xlink:to="pcvx_GrossProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncomeTaxDisclosureLineItems" xlink:to="pcvx_IncomeTaxDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfRenewalOptions" xlink:to="pcvx_NumberOfRenewalOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" xlink:to="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LicenseAmendmentATwoMember" xlink:to="pcvx_LicenseAmendmentATwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" xlink:to="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseCommencementDate" xlink:to="pcvx_LesseeOperatingLeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LonzaLimitedMember" xlink:to="pcvx_LonzaLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SaleOfCommonStockAuthorizedAmount" xlink:to="pcvx_SaleOfCommonStockAuthorizedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_RestrictedStockUnitsWithheld" xlink:to="pcvx_RestrictedStockUnitsWithheld_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingArrangementTextBlock" xlink:to="pcvx_FundingArrangementTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PneumococcalConjugateVaccineMember" xlink:to="pcvx_PneumococcalConjugateVaccineMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" xlink:to="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" xlink:to="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" xlink:to="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfSecurities" xlink:to="pcvx_NumberOfSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_MarketOfferingMember" xlink:to="pcvx_MarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_UpfrontConsiderationInCashAfterAgreementDate" xlink:to="pcvx_UpfrontConsiderationInCashAfterAgreementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseRentCommencementDate" xlink:to="pcvx_LesseeOperatingLeaseRentCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_OperatingLossCarryForwardsExpirationYear" xlink:to="pcvx_OperatingLossCarryForwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" xlink:to="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PurchasePeriod" xlink:to="pcvx_PurchasePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_EmployeeStockPurchasePlanMember" xlink:to="pcvx_EmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NewCorporateHeadquartersFacilityMember" xlink:to="pcvx_NewCorporateHeadquartersFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock" xlink:to="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_OfferingPeriod" xlink:to="pcvx_OfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" xlink:to="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PaymentsOfCapitalLeaseObligations" xlink:to="pcvx_PaymentsOfCapitalLeaseObligations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TemporaryEquityConversionOfPreferredStockShares" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" xlink:to="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" xlink:to="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_UpfrontConsiderationInCash" xlink:to="pcvx_UpfrontConsiderationInCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AccruedManufacturingRightsExpenses" xlink:to="pcvx_AccruedManufacturingRightsExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ClinicalStudies" xlink:to="pcvx_ClinicalStudies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" xlink:to="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" xlink:to="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" xlink:to="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_InitialPublicOfferingRelatedCost" xlink:to="pcvx_InitialPublicOfferingRelatedCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CapitalLeasesLabEquipmentMember" xlink:to="pcvx_CapitalLeasesLabEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" xlink:to="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" xlink:to="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_GlobalTargetRevenue" xlink:to="pcvx_GlobalTargetRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear" xlink:to="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AcquiredManufacturingRights" xlink:to="pcvx_AcquiredManufacturingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:to="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_StockOptionsGrantedTerm" xlink:to="pcvx_StockOptionsGrantedTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PercentageOfPaymentsCompletionAgreedToDefer" xlink:to="pcvx_PercentageOfPaymentsCompletionAgreedToDefer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TemporaryEquityConversionOfPreferredStockValue" xlink:to="pcvx_TemporaryEquityConversionOfPreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AtTheMarketOfferingMember" xlink:to="pcvx_AtTheMarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CostReimbursementSubAwardAgreementMember" xlink:to="pcvx_CostReimbursementSubAwardAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LeaseLiability" xlink:to="pcvx_LeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesPreFundedWarrantsToPurchase" xlink:to="pcvx_SharesPreFundedWarrantsToPurchase_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_HeadquartersFacilityMember" xlink:to="pcvx_HeadquartersFacilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesAvailableForFutureStockOptionGrantsMember" xlink:to="pcvx_SharesAvailableForFutureStockOptionGrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TemporaryEquityStockIssuanceCosts" xlink:to="pcvx_TemporaryEquityStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" xlink:to="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_Section162MLimitation" xlink:to="pcvx_Section162MLimitation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_OtherRestrictedStockUnitsMember" xlink:to="pcvx_OtherRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights" xlink:to="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" xlink:to="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" xlink:to="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent" xlink:to="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SutroStockPaymentMember" xlink:to="pcvx_SutroStockPaymentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseExtendedMaturityDate" xlink:to="pcvx_LesseeOperatingLeaseExtendedMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseRenewalOption" xlink:to="pcvx_LesseeOperatingLeaseRenewalOption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="pcvx_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_PotentialFundingCommittedByAward" xlink:to="pcvx_PotentialFundingCommittedByAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncreaseDecreaseInAccruedLegalSettlement" xlink:to="pcvx_IncreaseDecreaseInAccruedLegalSettlement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LabEquipmentMember" xlink:to="pcvx_LabEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SanCarlosMember" xlink:to="pcvx_SanCarlosMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LeaseTerminationDate" xlink:to="pcvx_LeaseTerminationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ResearchAndDevelopmentExpenseToRelatedParty" xlink:to="pcvx_ResearchAndDevelopmentExpenseToRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AdditionalFundingCommittedByAward" xlink:to="pcvx_AdditionalFundingCommittedByAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" xlink:to="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" xlink:to="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_WarrantsDisclosureTextBlock" xlink:to="pcvx_WarrantsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" xlink:to="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock" xlink:to="pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" xlink:to="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:to="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NumberOfOperatingLease" xlink:to="pcvx_NumberOfOperatingLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="pcvx_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_FundingArrangementAbstract" xlink:to="pcvx_FundingArrangementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" xlink:to="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_IncomeTaxDisclosureTable" xlink:to="pcvx_IncomeTaxDisclosureTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_RedeemableConvertiblePreferredStockTextBlock" xlink:to="pcvx_RedeemableConvertiblePreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pcvx_NonCashPaymentsForAcquireManufacturingRights" xlink:to="pcvx_NonCashPaymentsForAcquireManufacturingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>47
<FILENAME>pcvx-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T10:44:08.0524+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="pcvx-20221231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited" xlink:href="pcvx-20221231.xsd#Role_StatementStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="pcvx-20221231.xsd#DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails" xlink:href="pcvx-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:href="pcvx-20221231.xsd#Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="pcvx_AccruedManufacturingExpenses" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_LongTermInvestments" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AccruedManufacturingExpenses" xlink:label="pcvx_AccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="pcvx_AcquiredManufacturingRights" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="pcvx_GrantIncome" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_MarketableSecuritiesRealizedGainLoss" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_AcquiredManufacturingRights" xlink:label="pcvx_AcquiredManufacturingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_GrantIncome" xlink:label="pcvx_GrantIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_PaymentsOfCapitalLeaseObligations" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_NonCashPaymentsForAcquireManufacturingRights" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" order="6" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" order="7" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="7" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="8" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetImpairmentCharges" order="8" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="pcvx_ReleaseOfRestrictedStockUnitsValue" order="9" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="12" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" order="13" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInAccruedCompensation" order="15" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" order="16" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="17" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInAccruedLegalSettlement" order="18" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" order="19" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_PaymentsOfCapitalLeaseObligations" xlink:label="pcvx_PaymentsOfCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" xlink:label="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NonCashPaymentsForAcquireManufacturingRights" xlink:label="pcvx_NonCashPaymentsForAcquireManufacturingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" xlink:label="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ReleaseOfRestrictedStockUnitsValue" xlink:label="pcvx_ReleaseOfRestrictedStockUnitsValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedCompensation" xlink:label="pcvx_IncreaseDecreaseInAccruedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" xlink:label="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInAccruedLegalSettlement" xlink:label="pcvx_IncreaseDecreaseInAccruedLegalSettlement"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" xlink:label="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAmortizedCost" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:to="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAmortizedCost" xlink:to="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:to="pcvx_CashAndCashEquivalentsAndInvestments" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_CashAndCashEquivalentsAmortizedCost" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAmortizedCost" xlink:label="pcvx_CashAndCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" xlink:label="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_CashAndCashEquivalentsAndInvestments" xlink:label="pcvx_CashAndCashEquivalentsAndInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pcvx_ClinicalStudies" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_ClinicalStudies" xlink:label="pcvx_ClinicalStudies"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent" xlink:label="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_NonCancelablePurchaseCommitments" xlink:to="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_NonCancelablePurchaseCommitments" xlink:to="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NonCancelablePurchaseCommitments" xlink:label="pcvx_NonCancelablePurchaseCommitments"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_NoncancelablePurchaseCommitmentsDueInOneYear" xlink:label="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="pcvx_Section162MLimitation" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_Section162MLimitation" xlink:label="pcvx_Section162MLimitation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="pcvx_LeaseLiability" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" xlink:label="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="pcvx-20221231.xsd#pcvx_LeaseLiability" xlink:label="pcvx_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>48
<FILENAME>pcvx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-27T10:44:05.8510+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.vaxcyte.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:pcvx="http://www.vaxcyte.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pcvx-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations" id="Role_StatementStatementsOfOperations">
        <link:definition>100030 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical" id="Role_StatementStatementsOfOperationsParenthetical">
        <link:definition>100040 - Statement - Statements of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss" id="Role_StatementStatementsOfComprehensiveLoss">
        <link:definition>100050 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited" id="Role_StatementStatementsOfCashFlowsUnaudited">
        <link:definition>100080 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness" id="Role_DisclosureCompanyOrganizationAndNatureOfBusiness">
        <link:definition>100090 - Disclosure - Company Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments">
        <link:definition>100110 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>100120 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100130 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock" id="Role_DisclosureRedeemableConvertiblePreferredStock">
        <link:definition>100150 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100160 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrants" id="DisclosurePrefundedWarrants">
        <link:definition>100170 - Disclosure - Pre-Funded Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlans" id="Role_DisclosureEquityIncentivePlans">
        <link:definition>100180 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlan" id="DisclosureRetirementPlan">
        <link:definition>100190 - Disclosure - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangement" id="Role_DisclosureFundingArrangement">
        <link:definition>100200 - Disclosure - Funding Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100210 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100220 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100230 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100240 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables">
        <link:definition>100270 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>100280 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100290 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTable" id="DisclosureCommitmentsAndContingenciesTable">
        <link:definition>100300 - Disclosure - Commitments and Contingencies (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100310 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" id="Role_DisclosureEquityIncentivePlansTables">
        <link:definition>100320 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100330 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100340 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails" id="Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Company Organization and Nature of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100370 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100390 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails" id="Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails">
        <link:definition>100400 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100410 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Balance Sheet Details - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" id="Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails">
        <link:definition>100430 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100450 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails" id="Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails">
        <link:definition>100460 - Disclosure - Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100470 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails" id="Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails">
        <link:definition>100480 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails">
        <link:definition>100500 - Disclosure - Commitments and Contingencies - Schedule Of non-cancelable purchase Commitments Related to Raw Materials (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails" id="Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails">
        <link:definition>100530 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails" id="DisclosurePrefundedWarrantsAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Pre-Funded Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" id="Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails">
        <link:definition>100560 - Disclosure - Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails" id="DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails">
        <link:definition>100570 - Disclosure - Equity Incentive Plans - Nonvested Restricted Stock Shares Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails" id="DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails">
        <link:definition>100580 - Disclosure - Equity Incentive Plans - Summary of Activity under Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails">
        <link:definition>100590 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails">
        <link:definition>100600 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100610 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails" id="DisclosureRetirementPlanAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Retirement Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails" id="Role_DisclosureFundingArrangementAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Funding Arrangement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100640 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100650 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails" id="Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails">
        <link:definition>100660 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100670 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails" id="Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails">
        <link:definition>100690 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100700 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="pcvx_FundingArrangementAbstract" name="FundingArrangementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_AccruedCommitment" name="AccruedCommitment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AccruedManufacturingExpenses" name="AccruedManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AccruedManufacturingRightsExpenses" name="AccruedManufacturingRightsExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AcquiredManufacturingRights" name="AcquiredManufacturingRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_AdditionalFundingCommittedByAward" name="AdditionalFundingCommittedByAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AdditionalMilestonePaymentsInCash" name="AdditionalMilestonePaymentsInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" name="AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" name="AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAmortizedCost" name="CashAndCashEquivalentsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAndInvestments" name="CashAndCashEquivalentsAndInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" name="CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" name="CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" name="CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" name="CashAndCashEquivalentsGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" name="CashAndCashEquivalentsGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock" name="ChangeInFairValueOfRedeemableConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" name="ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ClinicalStudies" name="ClinicalStudies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" name="CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" name="DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses" name="DeferredTaxAssetsTaxAccruedManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" name="DevelopmentAndManufacturingServicesAgreementPaymentsInEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_EarlyExercisedStockOptions" name="EarlyExercisedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant" name="ExercisePriceExpireInYearsFormTheDateOfGrant" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_FairValueOnDateOfSettlement" name="FairValueOnDateOfSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" name="FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" name="FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_GlobalTargetRevenue" name="GlobalTargetRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_GrantIncome" name="GrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" name="IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_IncreaseDecreaseInAccruedCompensation" name="IncreaseDecreaseInAccruedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncreaseDecreaseInAccruedLegalSettlement" name="IncreaseDecreaseInAccruedLegalSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncreaseDecreaseInAccruedManufacturingExpenses" name="IncreaseDecreaseInAccruedManufacturingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" name="IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" name="IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_InitialFundingCommittedByAward" name="InitialFundingCommittedByAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_InitialPublicOfferingRelatedCost" name="InitialPublicOfferingRelatedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights" name="IssuanceOfCommonStockForAcquiredManufacturingRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_LeaseLiability" name="LeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_LeasePaymentReceivableNoncurrent" name="LeasePaymentReceivableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_LeaseTerminationDate" name="LeaseTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseCommencementDate" name="LesseeOperatingLeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseExtendedLeaseTerm" name="LesseeOperatingLeaseExtendedLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseExtendedMaturityDate" name="LesseeOperatingLeaseExtendedMaturityDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear" name="LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseRenewalOption" name="LesseeOperatingLeaseRenewalOption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_LesseeOperatingLeaseRentCommencementDate" name="LesseeOperatingLeaseRentCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" name="MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NonCancelablePurchaseCommitments" name="NonCancelablePurchaseCommitments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_NoncancelablePurchaseCommitmentsDueInOneYear" name="NoncancelablePurchaseCommitmentsDueInOneYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" name="NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_NonCashPaymentsForAcquireManufacturingRights" name="NonCashPaymentsForAcquireManufacturingRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_NumberOfFinanceLease" name="NumberOfFinanceLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfOperatingLease" name="NumberOfOperatingLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" name="NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfRenewalOptions" name="NumberOfRenewalOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_NumberOfSecurities" name="NumberOfSecurities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_OfferingPeriod" name="OfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_OperatingLossCarryForwardsExpirationYear" name="OperatingLossCarryForwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_OptionExercisePriceInCash" name="OptionExercisePriceInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent" name="OtherResearchAndDevelopmentLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PaymentsOfCapitalLeaseObligations" name="PaymentsOfCapitalLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PaymentsOfUnderwritingDiscountsAndCommissions" name="PaymentsOfUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PercentageOfFairValuePerShareOnTheGrantDate" name="PercentageOfFairValuePerShareOnTheGrantDate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PercentageOfPaymentsCompletionAgreedToDefer" name="PercentageOfPaymentsCompletionAgreedToDefer" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PercentageOfProvisionsSubjectToStockholders" name="PercentageOfProvisionsSubjectToStockholders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" name="PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" name="PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" name="PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PotentialFundingCommittedByAward" name="PotentialFundingCommittedByAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" name="PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" name="PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" name="PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_PrefundedWarrantsPricePerShare" name="PrefundedWarrantsPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" name="ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ProceedsFromIssuanceFollowOnOffering" name="ProceedsFromIssuanceFollowOnOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" name="ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" name="ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_PurchasePeriod" name="PurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ReleaseOfRestrictedStockUnitsShares" name="ReleaseOfRestrictedStockUnitsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ReleaseOfRestrictedStockUnitsValue" name="ReleaseOfRestrictedStockUnitsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares" name="RemainingLiabilitiesRelatedToEarlyExercisedShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_ResearchAndDevelopmentExpenseToRelatedParty" name="ResearchAndDevelopmentExpenseToRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ResearchAndExperimentalExpensesAmortizedPeriod" name="ResearchAndExperimentalExpensesAmortizedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_RestrictedStockUnitsWithheld" name="RestrictedStockUnitsWithheld" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SaleOfCommonStockAuthorizedAmount" name="SaleOfCommonStockAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_Section162MLimitation" name="Section162MLimitation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SharesIssuedPricePerShareUponFollowOnOffering" name="SharesIssuedPricePerShareUponFollowOnOffering" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" name="SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" name="SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_SharesPreFundedWarrantsToPurchase" name="SharesPreFundedWarrantsToPurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" name="StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" name="StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering" name="StockIssuedDuringPeriodSharesOfFollowOnOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_StockOptionsGrantedTerm" name="StockOptionsGrantedTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_TemporaryEquityConversionOfPreferredStockShares" name="TemporaryEquityConversionOfPreferredStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_TemporaryEquityConversionOfPreferredStockValue" name="TemporaryEquityConversionOfPreferredStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_TemporaryEquityStockIssuanceCosts" name="TemporaryEquityStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_UpfrontConsideration" name="UpfrontConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_UpfrontConsiderationInCash" name="UpfrontConsiderationInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_UpfrontConsiderationInCashAfterAgreementDate" name="UpfrontConsiderationInCashAfterAgreementDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="pcvx_FundingArrangementLineItems" name="FundingArrangementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_AdditionalFacilityMember" name="AdditionalFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_ATMSalesAgreementMember" name="ATMSalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_CapitalLeasesLabEquipmentMember" name="CapitalLeasesLabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" name="CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_CommonStockWarrantMember" name="CommonStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_ComputersAndComputerSoftwareMember" name="ComputersAndComputerSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_CostReimbursementSubAwardAgreementMember" name="CostReimbursementSubAwardAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_HeadquartersFacilityMember" name="HeadquartersFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_JefferiesLimitedLiabilityCompanyMember" name="JefferiesLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_LabEquipmentMember" name="LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_LicenseAgreementMember" name="LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_LicenseAmendmentATwoMember" name="LicenseAmendmentATwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_LonzaLimitedMember" name="LonzaLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_MarketOfferingMember" name="MarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_NewCorporateHeadquartersFacilityMember" name="NewCorporateHeadquartersFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_OtherRestrictedStockUnitsMember" name="OtherRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_PaloAltoMember" name="PaloAltoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_PneumococcalConjugateVaccineMember" name="PneumococcalConjugateVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_PreferredStockWarrantMember" name="PreferredStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_RedeemableConvertiblePreferredStockWarrantMember" name="RedeemableConvertiblePreferredStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SanCarlosMember" name="SanCarlosMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SeriesDRedeemableConvertiblePreferredStockMember" name="SeriesDRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SharesAvailableForFutureStockOptionGrantsMember" name="SharesAvailableForFutureStockOptionGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SupplyAgreementMember" name="SupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SutroBiopharmaIncMember" name="SutroBiopharmaIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_SutroStockPaymentMember" name="SutroStockPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember" name="TwoThousandTwentyEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_FundingArrangementTable" name="FundingArrangementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="pcvx_AccruedResearchAndDevelopmentPolicyTextBlock" name="AccruedResearchAndDevelopmentPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_FundingArrangementTextBlock" name="FundingArrangementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock" name="OptionToAcquireManufacturingRightsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_RedeemableConvertiblePreferredStockTextBlock" name="RedeemableConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" name="ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock" name="ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="pcvx_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371183472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PCVX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VAXCYTE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001649094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4233385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">825 Industrial Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Carlos<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94070ca<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-0111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,033,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Part III of this Annual Report on Form 10-K incorporates information by reference from the Registrant&#8217;s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the Registrant&#8217;s 2023 annual meeting of stockholders.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371204528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 834,657<span></span>
</td>
<td class="nump">$ 68,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">96,719<span></span>
</td>
<td class="nump">176,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,179<span></span>
</td>
<td class="nump">10,378<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">942,555<span></span>
</td>
<td class="nump">256,348<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,360<span></span>
</td>
<td class="nump">7,954<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">21,288<span></span>
</td>
<td class="nump">27,958<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">26,549<span></span>
</td>
<td class="nump">27,117<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">871<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,555<span></span>
</td>
<td class="nump">4,089<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="nump">63,623<span></span>
</td>
<td class="nump">67,989<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,006,178<span></span>
</td>
<td class="nump">324,337<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,795<span></span>
</td>
<td class="nump">6,758<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">3,455<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AccruedManufacturingExpenses', window );">Accrued manufacturing expenses</a></td>
<td class="nump">8,265<span></span>
</td>
<td class="nump">4,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">15,375<span></span>
</td>
<td class="nump">8,787<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">5,910<span></span>
</td>
<td class="nump">5,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">40,525<span></span>
</td>
<td class="nump">28,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">12,031<span></span>
</td>
<td class="nump">11,507<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">52,565<span></span>
</td>
<td class="nump">40,319<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value - 10,000,000 authorized at December 31, 2022 and December 31, 2021; no shares issued and outstanding at December 31, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value - 500,000,000 shares authorized at December 31, 2022 and December 31, 2021; 79,470,670 and 53,031,978 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,476,018<span></span>
</td>
<td class="nump">582,844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(522,126)<span></span>
</td>
<td class="num">(298,641)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">953,613<span></span>
</td>
<td class="nump">284,018<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 1,006,178<span></span>
</td>
<td class="nump">$ 324,337<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The breakout and categorizations of the 2021 total accrued expenses have been updated to conform to the 2022 presentation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371715552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">79,470,670<span></span>
</td>
<td class="nump">53,031,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">79,470,670<span></span>
</td>
<td class="nump">53,031,978<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371032096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including related party expenses of $0, $2,359 and $1,331 in 2022, 2021 and 2020, respectively)</a></td>
<td class="nump">$ 169,451<span></span>
</td>
<td class="nump">$ 78,411<span></span>
</td>
<td class="nump">$ 73,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AcquiredManufacturingRights', window );">Acquired manufacturing rights (Note 6)</a></td>
<td class="nump">22,995<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">39,810<span></span>
</td>
<td class="nump">25,259<span></span>
</td>
<td class="nump">16,017<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">232,256<span></span>
</td>
<td class="nump">103,670<span></span>
</td>
<td class="nump">89,581<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(232,256)<span></span>
</td>
<td class="num">(103,670)<span></span>
</td>
<td class="num">(89,581)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">8,356<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_GrantIncome', window );">Grant income</a></td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">2,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Realized gains on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction (losses) gains</a></td>
<td class="num">(1,470)<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
<td class="num">(2,351)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">8,771<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
<td class="nump">364<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (223,485)<span></span>
</td>
<td class="num">$ (100,077)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share Basic</a></td>
<td class="num">$ (3.44)<span></span>
</td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share Diluted</a></td>
<td class="num">$ (3.44)<span></span>
</td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number Of Shares Outstanding Basic</a></td>
<td class="nump">64,877,988<span></span>
</td>
<td class="nump">51,922,108<span></span>
</td>
<td class="nump">29,545,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number Of Diluted Shares Outstanding</a></td>
<td class="nump">64,877,988<span></span>
</td>
<td class="nump">51,922,108<span></span>
</td>
<td class="nump">29,545,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AcquiredManufacturingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired manufacturing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AcquiredManufacturingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799370968656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ResearchAndDevelopmentExpenseToRelatedParty', window );">Research and development expense to related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,359<span></span>
</td>
<td class="nump">$ 1,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ResearchAndDevelopmentExpenseToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ResearchAndDevelopmentExpenseToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371730320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (223,485)<span></span>
</td>
<td class="num">$ (100,077)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized losses on investments</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss</a></td>
<td class="num">$ (223,605)<span></span>
</td>
<td class="num">$ (100,318)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799364757984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At The Market Offering</div></th>
<th class="th"><div>Sutro Stock Payment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Market offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>At The Market Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Sutro Stock Payment</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Market offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At The Market Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Sutro Stock Payment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Series A Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series B Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series C Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Series D Redeemable Convertible Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (106,373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (109,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,225,719<span></span>
</td>
<td class="nump">6,786,896<span></span>
</td>
<td class="nump">7,377,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,967<span></span>
</td>
<td class="nump">$ 55,151<span></span>
</td>
<td class="nump">$ 80,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,059,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_TemporaryEquityConversionOfPreferredStockValue', window );">Conversion of preferred stock</a></td>
<td class="nump">270,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (24,967)<span></span>
</td>
<td class="num">$ (55,151)<span></span>
</td>
<td class="num">$ (80,192)<span></span>
</td>
<td class="num">$ (109,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_TemporaryEquityConversionOfPreferredStockShares', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,225,719)<span></span>
</td>
<td class="num">(6,786,896)<span></span>
</td>
<td class="num">(7,377,480)<span></span>
</td>
<td class="num">(8,220,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant', window );">Conversion of common stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant', window );">Conversion of preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff', window );">Warrant liability write-off</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs</a></td>
<td class="nump">264,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ReleaseOfRestrictedStockUnitsValue', window );">Release of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of preferred stock, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,220,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions', window );">Issuance of common stock related to early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(89,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,217)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">345,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,071,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs</a></td>
<td class="nump">13,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">567,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ReleaseOfRestrictedStockUnitsValue', window );">Release of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">931,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock to LonzaLtd.</a></td>
<td class="nump">10,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock to Lonza Ltd. (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized losses on investment</a></td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(100,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">284,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(298,641)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,031,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs</a></td>
<td class="nump">759,181<span></span>
</td>
<td class="nump">$ 97,299<span></span>
</td>
<td class="nump">$ 7,995<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,295<span></span>
</td>
<td class="nump">$ 7,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,062,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,921,528<span></span>
</td>
<td class="nump">167,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ReleaseOfRestrictedStockUnitsValue', window );">Release of restricted stock units</a></td>
<td class="num">(861)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(861)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ReleaseOfRestrictedStockUnitsShares', window );">Release of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,178,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized losses on investment</a></td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">23,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(223,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(223,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 953,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,476,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (522,126)<span></span>
</td>
<td class="num">$ (361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,470,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid In capital vesting of early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital warrant liability write off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ReleaseOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Release of Restricted Stock Units Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ReleaseOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ReleaseOfRestrictedStockUnitsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Release of restricted stock units value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ReleaseOfRestrictedStockUnitsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares conversion of preferred stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares issuance of common stock related to early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TemporaryEquityConversionOfPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of preferred stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TemporaryEquityConversionOfPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TemporaryEquityConversionOfPreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity conversion of preferred stock value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TemporaryEquityConversionOfPreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799368541824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 45,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pcvx_MarketOfferingMember', window );">Market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 3,107<span></span>
</td>
<td class="nump">$ 479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_TemporaryEquityStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TemporaryEquityStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TemporaryEquityStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pcvx_MarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pcvx_MarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcvx_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799375940096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (223,485)<span></span>
</td>
<td class="num">$ (100,077)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,577<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">23,650<span></span>
</td>
<td class="nump">10,729<span></span>
</td>
<td class="nump">5,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_NonCashPaymentsForAcquireManufacturingRights', window );">Non-cash payments for acquired manufacturing rights</a></td>
<td class="nump">7,995<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities', window );">Change in fair value of redeemable convertible preferred stock warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating right-of-use assets</a></td>
<td class="nump">6,619<span></span>
</td>
<td class="nump">1,657<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums on investments</a></td>
<td class="num">(947)<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">433<span></span>
</td>
<td class="num">(7,369)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(465)<span></span>
</td>
<td class="num">(3,539)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="num">(12,856)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,896<span></span>
</td>
<td class="num">(12,470)<span></span>
</td>
<td class="nump">26,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncreaseDecreaseInAccruedCompensation', window );">Accrued compensation</a></td>
<td class="num">(2,275)<span></span>
</td>
<td class="nump">3,170<span></span>
</td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncreaseDecreaseInAccruedManufacturingExpenses', window );">Accrued manufacturing expenses</a></td>
<td class="nump">3,826<span></span>
</td>
<td class="num">(8,572)<span></span>
</td>
<td class="nump">7,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">7,171<span></span>
</td>
<td class="nump">4,631<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities', window );">Deferred rent and other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(170,597)<span></span>
</td>
<td class="num">(121,393)<span></span>
</td>
<td class="num">(46,628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,848)<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
<td class="num">(1,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(102,745)<span></span>
</td>
<td class="num">(336,341)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investments</a></td>
<td class="nump">168,691<span></span>
</td>
<td class="nump">100,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of investments</a></td>
<td class="nump">14,480<span></span>
</td>
<td class="nump">30,062<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property and equipment</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">74,585<span></span>
</td>
<td class="num">(212,308)<span></span>
</td>
<td class="num">(1,105)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PaymentsOfCapitalLeaseObligations', window );">Payments of capital lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts', window );">Proceeds from initial public offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">264,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts', window );">Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs</a></td>
<td class="nump">759,181<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under ATM Sales Program, net of issuance costs</a></td>
<td class="nump">97,299<span></span>
</td>
<td class="nump">13,896<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">109,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock options</a></td>
<td class="nump">4,895<span></span>
</td>
<td class="nump">3,012<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions', window );">Proceeds from issuance of common stock related to early exercised stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the Employee Stock Purchase Plan</a></td>
<td class="nump">1,033<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ReleaseOfRestrictedStockUnitsValue', window );">Release of restricted stock units</a></td>
<td class="num">(861)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">861,547<span></span>
</td>
<td class="nump">17,796<span></span>
</td>
<td class="nump">374,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">137<span></span>
</td>
<td class="num">(439)<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">765,672<span></span>
</td>
<td class="num">(316,344)<span></span>
</td>
<td class="nump">327,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">69,856<span></span>
</td>
<td class="nump">386,200<span></span>
</td>
<td class="nump">58,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">835,528<span></span>
</td>
<td class="nump">69,856<span></span>
</td>
<td class="nump">386,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment recorded in accounts payable and accrued expenses</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights', window );">Issuance of common stock for acquired manufacturing rights</a></td>
<td class="nump">7,995<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">270,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock issued for payment of accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Deferred offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of redeemable convertible preferred stock tranche liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseDecreaseInAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseDecreaseInAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseDecreaseInAccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseDecreaseInAccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred rent and other long term liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for acquired manufacturing rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NonCashPaymentsForAcquireManufacturingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash payments for acquire manufacturing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NonCashPaymentsForAcquireManufacturingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PaymentsOfCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PaymentsOfCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from initial public offering, net of underwriters' commissions and discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceedsfromissuanceofcommonstockandpre-fundedwarrantsfromfollowon offeringsnetofissuancecosts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock related to early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ReleaseOfRestrictedStockUnitsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Release of restricted stock units value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ReleaseOfRestrictedStockUnitsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799375923536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Company Organization and Nature of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Company Organization and Nature of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vaxcyte, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;the Company,&#8221; or &#8220;Vaxcyte&#8221;), headquartered in San Carlos, California, was incorporated in the state of Delaware on November 27, 2013 as SutroVax, Inc. and we changed our name to Vaxcyte, Inc. on May 15, 2020. We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. ("Sutro Biopharma"). Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our primary activities since incorporation have been to perform research and development, undertake preclinical and clinical studies and conduct manufacturing activities in support of our product development efforts; organize and staff our Company; establish our intellectual property portfolio; and raise capital to support and expand such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 5, 2020, we filed a certificate of amendment to our amended and restated certificate of incorporation to affect a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one-for-1.6870</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reverse stock split of our issued and outstanding common stock, preferred stock, stock options and warrants effective on June 5, 2020. Accordingly, all share and per share amounts for all periods presented in the financial statements and notes thereto have been retroactively adjusted.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Public Offering</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, we completed an initial public offering (&#8220;IPO&#8221;) in which we issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,968,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock, including shares issued upon the exercise in full of the underwriters&#8217; option to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,343,750</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> additional shares of common stock, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. We received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">264.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immediately prior to the completion of our IPO, all outstanding shares of redeemable convertible preferred stock were converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,610,337</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. Subsequent to the completion of the IPO, there were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of redeemable convertible preferred stock outstanding.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372446416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding annual reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">taxes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to supplier concentration risk from our suppliers. Although we are working to establish secondary sources of supply, we currently source several of our critical raw materials from single source suppliers. We also use one contract manufacturing organization (&#8220;CMO&#8221;), Lonza Ltd. (&#8220;Lonza&#8221;), to handle most of our manufacturing activities for our VAX-24 and VAX-31 programs. If we were to experience disruptions in raw materials supplied by our suppliers, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and immunogenicity or efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment and Geographical Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate and manage our business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our current corporate headquarters. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:</span></span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:38.052%;"/>
          <td style="width:6.663%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.244%;"/>
          <td style="width:1.0%;"/>
          <td style="width:2.235%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.116%;"/>
          <td style="width:1.0%;"/>
          <td style="width:2.235%;"/>
          <td style="width:1.0%;"/>
          <td style="width:14.456%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,657</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,985</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">871</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">871</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">835,528</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,856</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investments have been classified and accounted for as available-for-sale securities. Fixed income securities consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses are also included in other income (expense), net. When the fair value of a debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in our statements of operations. When the fair value of a debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in our statements of operations only if we sell or intend to sell the security before recovery of its cost basis.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of deferred offering costs, respectively, were included in Other assets on the balance sheets.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_702b2ee1-c8d3-4b6c-aa18-57f4ed887283;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations in the period realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Financial Accounting Standards Board ("FASB") Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and its associated amendments (&#8220;ASC 842&#8221;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2022, our lease population consisted of real estate operating leases. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any finance leases.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases are included in Operating lease right-of-use ("ROU") assets, Operating lease liabilities - current and Operating lease liabilities - long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recogni</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zed is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of impairments of long-lived assets during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (See Note 3, "Fair Value Measurements and Fair Value of Financial Instruments").</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#8220;CROs&#8221;) and investigative sites that conduct preclinical studies, clinical trials other supplies and costs associated with product development efforts, preclinical activities, clinical trials and regulatory operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquired Manufacturing Rights</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we entered into an option agreement with Sutro Biopharma, Inc. (the "Option Agreement"). As of December 31, 2022, the option granted under the Option Agreement is a right, but not an obligation, to obtain certain exclusive rights to internally manufacture or source extract from certain CMOs and the right to independently develop and make improvements to the extract for use in connection with the exploitation of certain vaccine compositions (the &#8220;Option&#8221;). As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we paid Sutro Biopharma upfront consideration. As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the Option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2022 and 2021, we have recorded a full valuation allowance on our deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For options granted to employees, non-employees and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The fair value of restricted stock and restricted stock unit (&#8220;RSU&#8221;) awards is determined based on the number of units granted and the closing price of the Company&#8217;s common stock as of the grant-date. The grant-date fair value of awards is amortized over the employees&#8217; requisite service period or the non-employees&#8217; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding, including pre-funded warrants, during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little consideration, are fully vested and are exercisable after the original issuance date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the FASB issued ASU 2021-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Subtopic 958-605), Not-For-Profit Entities - Revenue Recognition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The required disclosures include (i) the nature of the transaction and the related accounting policy used to account for the transaction, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures. In Note 12, "Funding Arrangement," we included disclosures on our cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator ("CARB-X"). We have adopted this standard as required by the effective date. The adoption of this standard did not have a material impact on our financial statements.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and has subsequently issued related amendments, collectively referred to as &#8220;Topic 326.&#8221; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. We have adopted this standard as required by the effective date on January 1, 2022. The adoption of this standard did not have a material impact on our financial statements.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372480880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements and Fair Value of Financial Instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 1&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level 2&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Level</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> 3</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1 securities consist of highly liquid money market funds for which the carrying amounts approximate their fair values due to their short maturities. U.S. Treasury securities are valued using Level 1 inputs based on unadjusted, quoted prices in active markets that are observable at the measurement date for identical assets or liabilities. Level 2 securities, consisting of corporate debt, commercial paper, U.S. government agency securities and asset-backed securities, are measured based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted prices in active markets for identical assets or liabilities are not available, we rely on non-binding quotes from our investment managers, which are based on proprietary valuation models of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">independent </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pricing services. These models generally use inputs such as observable market data, quoted market prices for similar instruments or historical pricing trends of securities relative to our peers. To validate the fair value determinations provided by our investment managers, we review the pricing movement in the context of overall market trends and trading information from our investment managers. In addition, we assess the inputs and methods used in determining the fair value in order to determine the classification of securities in the fair value hierarchy. We had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Level 3 securities either as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 or 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> transfers within the hierarchies during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> or 2</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We invested in money market funds as of December 31, 2020. In January 2021, we started to invest some of our funds in corporate debt, commercial paper, U.S. Treasury securities, U.S. government agency securities and asset-backed securities. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.076%;"/>
        <td style="width:13.785%;"/>
        <td style="width:7.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.571%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.274%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.571%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.858%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.496%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.997%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.312%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br/>Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br/>Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,198</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,198</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">680,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">680,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,547</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,161</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,144</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,954</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,298</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,595</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">366</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,268</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">958,286</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">957,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br/>Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br/>Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,596</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,986</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,985</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,290</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,217</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,498</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,424</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,714</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,668</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,342</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">241</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273,087</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the contractual maturities of our investments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.229%;"/>
        <td style="width:5.326%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.446%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one to five years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,549</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,268</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371053040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet Details</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.929%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.011%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.086%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,608</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,619</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers and computer software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">416</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">430</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,117</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,548</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,360</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,954</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expense for the years ended December 31, 2022, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.226%;"/>
        <td style="width:1.421%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.806000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.421%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.127%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,518</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other research and development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,446</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,676</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,411</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,787</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accrued manufacturing rights as of December 31, 2022 and 2021, respectively. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The breakout and categorizations of the 2021 total accrued expenses have been updated to conform to the 2022 presentation.</span></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372556448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5. Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Lease Obligations</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2021, we entered into a lease agreement for our current corporate headquarters facility located in San Carlos, California and a license agreement for temporary lab and office space in Palo Alto, California. The lease term for our current corporate headquarters facility began on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">January 22, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and expires on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2025</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We have </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month renewal options. The original term of the license agreement for the temporary space in Palo Alto terminated when the San Carlos office leasehold improvements were completed and we moved into our current corporate headquarters. We extended the license agreement for the Palo Alto office by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 3, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to accommodate our relocation plan. These two agreements are accounted for as a combined lease because the contracts were negotiated as a package with the same commercial objective. Upon commencement of the San Carlos lease in December 2021, we recorded a ROU asset and lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2016, we entered into a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 1, 2016</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">August 31, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-month </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">renewal options</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">July 1, 2019</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 31, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> renewal options</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> In November 2020, we extended the terms of both of these leases for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">March 1, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">April 30, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. In February 2022, we entered into an early termination agreement for one of the facilities in Foster City and terminated our lease on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 12, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> instead of April 30, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.665%;"/>
        <td style="width:3.444%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.29%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.871%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.729999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,374</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,288</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,958</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,910</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,276</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,507</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,783</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.78</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.75</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.111%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.094%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,684</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,850</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,556</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,615</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum payments required under operating leases as of December 31, 2021 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.097%;"/>
        <td style="width:1.781%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.122%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,639</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,976</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,315</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,783</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities for 2022 are net of lease incentives of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million allocated to the Palo Alto office.</span></div></div></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rent expense recognized under the leases was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372294432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. We do not believe that there is any litigation or asserted or unasserted claim pending that could, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Guarantees and Indemnifications</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the normal course of business, we enter into agreements that contain a variety of representations and provide for general indemnification. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. As of December 31, 2022, we did not have any material indemnification claims that were probable or reasonably possible and consequently have not recorded related liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indemnification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the extent permitted under Delaware law, we have agreed to indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the director&#8217;s or officer&#8217;s service. The maximum potential amount of future payments we could be required to make under these indemnification agreements is not specified in the agreements; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We have not incurred any material costs as a result of such indemnification and are not currently aware of any indemnification claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Development and Manufacturing Services Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2016, we entered into a non-exclusive development and manufacturing services agreement, as amended, with Lonza (the &#8220;2016 Lonza DMSA&#8221;) pursuant to which Lonza is obligated to perform manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the September 2017, we and Lonza agreed to defer the completion payments for any stage that commenced after December 31, 2019 or had not been completed by December 31, 2019 until the earlier of the completion of all Investigational New Drug (&#8220;IND&#8221;)-enabling activities or December 31, 2020. In March 2020, Lonza agreed to defer the completion payments until the earlier of the completion of all IND-enabling activities or April 30, 2021. In April 2021, Lonza further agreed to defer </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the completion payments until the earlier of the completion of all IND-enabling activities or December 31, 2021. Pursuant to this agreement, all deferred completion payments were paid in December 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2018, we entered into a letter agreement with Lonza (the &#8220;Lonza Letter Agreement&#8221;) pursuant to which we agreed to certain terms for potential future payments in shares of our common stock as partial satisfaction of future obligations to Lonza. The Lonza Letter Agreement states that the initial pre-IND cash payments under the 2016 Lonza DMSA would be subject to a specified dollar cap (the &#8220;Initial Cash Cap&#8221;). After the Initial Cash Cap has been reached, we would have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">399,680</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock to Lonza at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share to pay for $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the pre-IND payments due April 30, 2021.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2018, we entered into a second non-exclusive development and manufacturing services agreement with Lonza (the &#8220;2018 Lonza DMSA&#8221;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product. <br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we entered into a third non-exclusive development and manufacturing services agreement, as amended, with Lonza (the &#8220;2022 Lonza DMSA&#8221;) effective as of March 22, 2022. Pursuant to the 2022 Lonza DMSA, Lonza will perform manufacturing process development and clinical manufacture and supply of our proprietary PCV.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under each of the 2016 Lonza DMSA, 2018 Lonza DMSA and 2022 Lonza DMSA (collectively, the &#8220;Lonza Agreements&#8221;), we will pay Lonza agreed-upon fees for its performance of development and manufacturing services and pass through expenses incurred by Lonza for raw materials, as well as customary procurement and handling fees. Under each Lonza Agreement, we will own all right, title and interest in and to any and all New Customer Intellectual Property (as defined in each Lonza Agreement), and Lonza shall own all right, title and interest in New General Application Intellectual Property (as defined in each Lonza Agreement). Subject to the terms and conditions set forth in the Lonza Agreements, Lonza granted us a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property (as defined in each Lonza Agreement), to research, develop, make, have made, use, sell and import the Product (as defined in each Lonza Agreement) manufactured under each Lonza Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sutro Option Agreement</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we entered into an Option Agreement with Sutro Biopharma, pursuant to which we acquired from Sutro Biopharma (i) authorization to enter into an agreement with an independent alternate CMO to directly source Sutro Biopharma&#8217;s cell-free extract, allowing us to have direct oversight over financial and operational aspects of the relationship with the CMO; and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract (including the right to make improvements to the extract manufacturing process as well as cell lines) for use in connection with the exploitation of certain vaccine compositions (the &#8220;Option&#8221;). We and Sutro Biopharma have agreed to negotiate the terms and conditions of a form definitive agreement to be entered into in the event we exercise the Option, which shall include the terms and conditions set forth in an executed term sheet between us (the &#8220;Term Sheet&#8221;), and such terms that are necessary to give effect to each of the terms and conditions set forth in the Term Sheet (the &#8220;Form Definitive Agreement&#8221;). The Option period</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is five years from the date of the Option Agreement, subject to potential acceleration in the event we undergo a change of control.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we agreed to pay Sutro Biopharma upfront consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, consisting of (i) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million worth of shares of our common stock (the number of shares to be calculated based on the arithmetic average of the daily volume weighted average price of our common stock as traded on Nasdaq in the three consecutive trading days immediately prior to the issuance thereof), and (ii) $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payable within five business days after we and Sutro Biopharma mutually agree in writing upon the Form Definitive Agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167,780</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock issued was recorded at fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million on the date of settlement, December 22, 2022. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that we elect to exercise the Option, we would pay Sutro Biopharma an aggregate Option exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash in two installments and, upon the occurrence of certain regulatory milestones, certain additional milestone payments totaling up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash. In the event that we undergo a change of control, certain rights and payments may be accelerated.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022. Part of the total cost incurred as reported on the statement of operations for the year ended December 31, 2022 is a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million accrued commitment that remains outstanding as of December 31, 2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enter into agreements in the normal course of business with CMOs and other vendors for manufacturing services and raw materials purchases. We rely on several third-party manufacturers for our manufacturing requirements.</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, we had the following amounts due of non-cancelable purchase commitments related to manufacturing services and raw materials purchased due to our key manufacturing partners. These amounts represent our minimum contractual obligations, including termination fees. If we terminate certain firm orders with key manufacturing partners, we will be required to pay for the manufacturing services scheduled or raw materials purchased under our arrangements. The actual amounts we pay in the future to our vendors under such agreements may differ from the purchase order amounts. </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.35%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.649999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,099</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total non-cancelable purchase commitments due to key manufacturing partners</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125,570</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372398240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_RedeemableConvertiblePreferredStockTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of redeemable convertible preferred stock authorized or outstanding as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our IPO in June 2020, the outstanding shares of our Series A, Series B, Series C and Series D Redeemable Convertible Preferred Stock automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,610,337</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_RedeemableConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_RedeemableConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371166656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our certificate of incorporation authorizes us to issue up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">500,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> par value per share, of which </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,470,670</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,031,978</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were issued and outstanding as of December 31, 2022 and 2021, respectively. The holders of our common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by our board of directors. As of December 31, 2022 and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> dividends have been declared. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each share of common stock is entitled to one vote.</span></span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, we entered into an Open Market Sales Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#8220;ATM Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million through Jefferies acting as our sales agent or principal. We are obligated to pay Jefferies a commission of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the gross sales proceeds of any common stock sold through Jefferies under the ATM Sales Agreement; however, we are not obligated to make any sales of common stock. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we have sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,488,573</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock under the ATM Sales Agreement at an average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.56</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million net of commissions and offering expenses).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, we completed an underwritten public offering in which we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per underlying share. In February 2022, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he underwriters exercised their option to purchase an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. In aggregate, we received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we completed an underwritten public offering in which we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per underlying share. T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">he underwriters exercised their option to purchase an additional </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,812,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock. In aggregate, we received $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">651.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us, and excluding the exercise of any pre-funded warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) and the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) was as</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> follows, and excludes </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,710</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares issued outside of the 2014 Plan and 2020 Plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.479%;"/>
        <td style="width:1.018%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.229999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.031%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.243%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,715,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,295,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Restricted stock units issued and outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">456,766</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Shares available for future stock option grants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,679,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,104,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,851,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,399,763</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371053040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pre-Funded Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_WarrantsDisclosureTextBlock', window );">Pre-Funded Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">re-Funded Warrants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our underwritten public offering in January 2022, we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per underlying share. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our underwritten public offering in October 2022, we issued </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and pre-funded warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,750,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per underlying share. Each pre-funded warrant has an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The public offering price for the pre-funded warrants was equal to the public offering price of our common stock, less the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> exercise price of each pre-funded warrant and was recorded as a component of stockholders' equity within additional paid-in-capital.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment of the exercise price. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. The holder of the pre-funded warrants may also satisfy its obligation to pay the exercise price through a "cashless exercise," in which the holder receives the net value of the pre-funded warrant in shares of common stock determined according to the formula set forth in the pre-funded warrant.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The pre-funded warrants will not expire until they are fully exercised. However, we may not effect the exercise of any pre-funded warrants, and a holder will not be entitled to exercise any portion of any pre-funded warrants that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of our common stock beneficially owned by such holder (together with affiliates) to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as applicable; or (ii) the combined voting power of our securities beneficially owned by such holder (together with its affiliates) to exceed </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the combined voting power of all of our securities outstanding immediately after giving effect to the exercise, as applicable, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. However, any holder of a pre-funded warrant may increase or decrease such percentage to any other percentage not in excess of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon at least 61 days' prior notice for the holder to us. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares underlying the pre-funded warrants had been exercised.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372398240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Incentive Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 and 2014 Equity Incentive Plans</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Plan, which became effective on June 11, 2020. Under the 2020 Plan, we may grant stock options, appreciation rights, restricted stock and restricted stock units (RSUs) to employees, consultants and directors. Stock options granted under the 2020 Plan may be either incentive stock options or nonqualified stock options. Incentive stock options may be granted only to our employees, including officers and directors who are also employees. Nonqualified stock options may be granted to our employees, officers, directors, consultants and advisors. The exercise price of stock options granted under the 2020 Plan must be at least equal to the fair market value of the common stock on the date of grant, except that an incentive stock option granted to an employee who owns more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the shares of our common stock shall have an exercise price of no less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the fair value per share on the grant date and expire </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the date of grant. The maximum term of stock options granted under the 2020 Plan is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years, unless subject to the provisions regarding </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% stockholders. Our stock options granted to new employees generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon the first anniversary of the vesting commencement date and monthly thereafter. Our other stock options granted to employees generally vest on terms consistent with stock options granted to new employees or monthly over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> from the vesting commencement date. Our RSUs granted to new employees generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon one year from the grant date, then </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% every six months thereafter. Our other RSUs granted to employees generally vest over </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b8edf648-6c56-470f-b105-b7c382767664;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three and a half years</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> at a rate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% upon six months from the grant date, then </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% every six months thereafter. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,150,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were approved to be initially reserved for issuance under the 2020 Plan. The number of shares that remained available for issuance under the 2014 Plan as of the effective date of the 2020 Plan, and shares subject to outstanding awards under the 2014 Plan as of the effective date of the 2020 Plan that are subsequently canceled, forfeited or repurchased by us, will be added to the shares reserved under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan is automatically increased on the first day of each calendar year during the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, an aggregate of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,679,598</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were available for issuance under the 2020 Plan. Effective January 1, 2023, the number of shares of common stock available under the 2020 Plan increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,973,533</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares pursuant to the evergreen provision of the 2020 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our 2014 Plan permitted the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Subsequent to the adoption of the 2020 Plan, no additional equity awards can be made under the 2014 Plan. Shares reserved and remaining available for issuance under the 2014 Plan were added to the 2020 Plan reserve upon its effectiveness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The terms of the 2014 Plan permit the exercise of options granted prior to vesting, subject to required approvals. The unvested shares are subject to our lapsing repurchase right upon termination of employment at the original purchase price. Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as other liabilities on the balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,576,161</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,596,099</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were subject to outstanding options and RSUs under the 2014 Plan and 2020 Plan, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022 and 2021, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,705</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,410</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, respectively, remained subject to our right of repurchase as a result of the early exercised stock options. The remaining liabilities related to early exercised shares as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021 were both less than $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and were recorded in other liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Option Activity</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under our 2020 Plan and 2014 Plan, which excludes options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,710</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares granted outside of the 2020 Plan and 2014 Plan, was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.622%;"/>
        <td style="width:0.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.203999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.945%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.733%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:5.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.455%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.302%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Option and Restricted Stock Units Activity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options<br/>and RSUs<br/>Available<br/>for <br/>Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number<br/>of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual <br/>Term<br/>(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#8212; December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,651,149</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,121,549</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.99</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,553,579</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,616,021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,616,021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">926,514</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">516,049</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">516,049</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#8212; December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,104,756</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,295,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.30</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,651,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,850,981</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,850,981</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.67</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">385</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,153,285</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">277,209</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">277,209</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.54</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">581,047</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units withheld</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,626</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,052</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#8212; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,679,598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,715,494</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.20</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest &#8212; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,715,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.20</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,921,091</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.41</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.81</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net exercise - shares returned to the Plan.</span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022, 2021 and 2020, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,153,285</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">926,514</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">358,264</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of stock options, respectively, were exercised for cash at a weighted-average price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The weighted-average grant date fair value of options granted for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively. The intrinsic value of the stock options exercised was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 , 2021 and 2020, respectively.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units Activity</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, our board of directors authorized the issuance of RSUs under our 2020 Plan and adopted a form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement (the "RSU Agreement"), which is intended to serve as a standard form agreement for RSU grants issued to employees. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 was as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.919%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.579%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.831%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.322000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">581,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and released</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,052</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.32</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">456,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2022 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The aggregate fair value of unvested RSU is calculated using the closing price of our common stock on the grant date. As of December 31, 2022, the unrecognized stock-based compensation cost of unvested RSUs was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020 Employee Stock Purchase Plan</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Employee Stock Purchase Plan (the &#8220;2020 ESPP&#8221;), which became effective on June 11, 2020. The 2020 ESPP permits participants to purchase common stock through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their eligible compensation. Employees enrolled in the 2020 ESPP, purchase shares of common stock at a price per share equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value at the start or end of the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> purchase periods within the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> offering period. A total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock were approved to be initially reserved for issuance under the 2020 ESPP. In addition, the number of shares of common stock available for issuance under the 2020 ESPP is automatically increased on the first day of each calendar year during the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity under our 2020 ESPP was as follows:</span></span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.151%;"/>
        <td style="width:11.21%;"/>
        <td style="width:1.0%;"/>
        <td style="width:25.639%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,465</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">622,535</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">510,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,546</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,070,704</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">530,319</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,709</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,539,314</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective January 1, 2023, the number of shares of common stock available under the 2020 ESPP increased by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">794,706</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares pursuant to the evergreen provision of the 2020 ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.321%;"/>
        <td style="width:1.357%;"/>
        <td style="width:15.203%;"/>
        <td style="width:1.357%;"/>
        <td style="width:15.203%;"/>
        <td style="width:1.357%;"/>
        <td style="width:15.203%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.12%;"/>
        <td style="width:1.378%;"/>
        <td style="width:15.385%;"/>
        <td style="width:1.378%;"/>
        <td style="width:16.998%;"/>
        <td style="width:1.378%;"/>
        <td style="width:15.363%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recorded total stock-based compensation expense for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.07%;"/>
        <td style="width:1.359%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.359%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.359%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.173%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,954</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,751</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,775</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,573</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,650</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon our IPO, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">362,935</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> performance-based awards vested and, as a result, we recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of stock-based compensation expense during the three months ended June 30, 2020, which amount is included in the above table for the year ended December 31, 2020.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to the employee and non-employee awards, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372584848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11. Retirement Plan</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company sponsors a qualified 401(k) Plan. The retirement plan is a defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. For the year ended December 31, 2022, the Company contributed $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to the retirement plan.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372491456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Funding Arrangement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingArrangementAbstract', window );"><strong>Funding Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingArrangementTextBlock', window );">Funding Arrangement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12. Funding Arrangement</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2019, we received a cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#8220;CARB-X&#8221;), a public-private partnership funded under a Cooperative Agreement from Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) and by awards from Wellcome Trust, Germany&#8217;s Federal Ministry of Education and Research, the United Kingdom Global Antimicrobial Resistance Innovation Fund and the Bill &amp; Melinda Gates Foundation. In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the Trustees of Boston University, the administrator of the program. The initial award provided the potential for funding up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo and necrotizing fasciitis. The initial award committed initial funding of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for our VAX-A1 program and, subject to a CARB-X decision to extend the options, up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in total funding available upon achievement of development milestones over the next </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Specified research expenditures are reimbursable expenses associated with agreed-upon activities needed to advance the research project supported by the grant. These expenditures can include labor, laboratory supplies, travel, consu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lting and third-party vendor research and development support costs. CARB-X has awarded us total funding to date of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, with potential funding of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">      </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, we received a cost-reimbursement research award from the National Institutes of Health (&#8220;NIH&#8221;). In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the University of Maryland, Baltimore, the administrator of the program. The award provides for potential funding up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> totaling approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to develop a vaccine to prevent infections caused by Shigella.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income from grants is recognized in the period during which the related specified expenses are incurred, provided that the conditions under which the grants were provided have been met. We recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of grant income and recorded the amounts in Other income (expense), net in the statement of operations during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021, and 2020 respectively. A grant receivable of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million representing unreimbursed, eligible costs incurred under the CARB-X agreement was recorded and included in Prepaid expenses and other current assets in the balance sheets as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingArrangementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingArrangementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372556448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.374%;"/>
        <td style="width:1.261%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.916%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.271%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.916%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.271%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.99%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">223,485</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding used in computing net<br/>&#160;&#160;&#160;loss per share, basic and diluted</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,877,988</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,922,108</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,545,810</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.02</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">____________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes shares of common stock into which pre-funded warrants may be exercised. See Note 9, "Pre-Funded Warrants".<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div></div><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.529%;"/>
        <td style="width:1.009%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.64%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.64%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.139999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,752,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,357,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,188,531</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">456,766</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plans</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,240</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,404</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87,887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,322,210</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,423,793</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,276,418</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372366512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our pre-tax book loss was derived from our business operations within the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.469%;"/>
        <td style="width:0.98%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.57%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.98%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.57%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.98%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.45%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 effective tax rate reconciliation has been updated to conform to the 2021 and 2022 presentation.</span></div></div></div><p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents significant components of our deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.929%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.011%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.086%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,574</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued &amp; others</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,103</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,174</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,436</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,865</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized R&amp;D expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,873</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,063</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,358</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,867</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,956</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170,791</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,357</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,349</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,349</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,433</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,433</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Accrued &amp; others and Stock compensation lines have been updated to conform to the 2022 presentation.</span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, we have net operating loss carryforwards of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">340.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">453.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards, except the federal loss carryforward arising in tax years beginning after December 31, 2017, begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless previously utilized. Federal net operating losses arising in tax years beginning after December 31, 2017 have an indefinite carryover period and do not expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At December 31, 2022, we have research credit carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million available to offset future income tax liabilities, if any, for federal and California income tax purposes, respectively. The federal research and development tax credit carryforwards expire beginning in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2039</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> unless previously utilized. The California tax credits can be carried forward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Utilization of the net operating loss carryforward and research credit carryforward may be subject to an annual limitation due to the ownership percentage change limitations under Section 382 and Section 383, respectively, provided by the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and similar state provisions. The annual limitation may result in the expiration of the net operating loss before utilization. We have experienced ownership changes in the past. There were no ownership changes identified in 2022, as such we have determined that </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> federal research credits will expire unutilized or are excluded from our research credit carryforwards. The Company does not expect any ownership changes during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 to result in a limitation that would materially reduce the total amount of net operating loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have uncertain tax benefits (&#8220;UTBs&#8221;) totaling </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs had no effect on the effective tax rate. We recognize interest and penalties related to UTBs, when they occur, as a component of income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period such determination is made. There were </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> interest or penalties recognized for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021. We do not expect our UTBs to change significantly over the next 12 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.721%;"/>
        <td style="width:1.323%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.323%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.774%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.334%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.517000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">876</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">461</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">287</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions based on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,754</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">924</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We file U.S. federal and state tax returns. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2017. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the net operating loss, or NOL, and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. We do not have any tax audits or other issues pending.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact our current tax provision.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On December 21, 2020, the President of the United States signed into law the &#8220;Consolidated Appropriations Act, 2021&#8221; which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program, or PPP, loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contribution deductions and a temporary full deduction for business expenses for food and beverages provided by a restaurant. These benefits do not have a material impact on the current tax provision.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Infrastructure Investment and Jobs Act was signed on November 15, 2021, and it contained several tax provisions including changes to the Employee Retention Tax Credit and changes to excise taxes. These provisions do not have a material impactful to the Company&#8217;s current tax provision.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with the 2017 Tax Act, research and experimental (R&amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;E expenses are required to be amortized over a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for domestic expenses and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for foreign expenses. The Company has capitalized research and experimental expenditures in its current tax provision as a result.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax ("CAMT") on adjusted financial statement income on applicable corporations for taxable years beginning after December 31, 2022. There is no impact to the Company&#8217;s current tax provision.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The American Rescue Plan Act was signed on March 11, 2021.  One of the provisions of the Act included expanding the definition of covered employees subject to IRC 162(m) to include an additional top five highest compensated officers beyond the CEO, CFO, and three highest paid employees currently covered under IRC 162(m). This expanded provision is applicable for tax years beginning after Dec 31, 2026. The Company does not believe that this update to IRC 162(m) would have a material impact on its income tax provision currently and will continue to monitor this.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372336064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have an ongoing relationship with Sutro Biopharma. In 2013, Sutro Biopharma provided support to facilitate the establishment of our Company. As of December 31, 2021 and 2020, Sutro Biopharma owned approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million shares of our common stock. As of December 31, 2019, Sutro Biopharma also owned warrants to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,857</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock (the &#8220;Common Stock Warrant&#8221;) at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.79289</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,276</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our Series C redeemable convertible stock (the &#8220;Preferred Stock Warrant&#8221;) at an exercise price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.5215</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. The Common Stock Warrant and the Preferred Stock Warrant were automatically net exercised pursuant to their terms for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,278</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,591</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares, respectively, of our common stock in connection with the IPO. In the agreements and amendments identified herein, we licensed certain intellectual property and acquired certain supply rights from Sutro Biopharma, including the right to use the XpressCF platform to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases. On October 12, 2015, we and Sutro Biopharma (&#8220;the Parties&#8221;) entered into the Sutro Biopharma License Agreement, which amended and restated an agreement dated August 1, 2014. The Sutro Biopharma License Agreement was subsequently amended on May 9, 2018 (&#8220;License Amendment A1&#8221;) and May 29, 2018 (&#8220;License Amendment A2&#8221;). In consideration for the License Amendment A2, we issued to Sutro Biopharma the Preferred Stock Warrant to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59,276</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of Series C redeemable convertible preferred stock at a purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.5215</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share. We also entered into a separate supply agreement with Sutro Biopharma on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 29, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (the &#8220;Sutro Biopharma Supply Agreement&#8221;). As of June 2, 2021, Sutro Biopharma was no longer considered a related party.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Sutro Biopharma License Agreement, Sutro Biopharma granted us an exclusive, worldwide license to research, develop, manufacture and commercialize vaccine products addressing infectious disease, which are discovered or produced based on the use of Sutro Biopharma&#8217;s proprietary cell-free protein expression technology, known as XpressCF, which utilizes extracts derived from strains of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. In connection with the Sutro Biopharma License Agreement, under the Sutro Biopharma Supply Agreement, Sutro Biopharma has agreed to manufacture and supply extracts and reagents for us on a cost-plus basis. In consideration for the rights licensed, we are obligated to pay a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% royalty on annual net sales of vaccine products for animal health. In License Amendment A1, the Parties amended the license agreement to remove a pre-IND regulatory meeting as a diligence milestone and to agree that certain other diligence milestones had been satisfied. In License Amendment A2, the Parties amended the license agreement to add certain terms confirming our obligation to purchase Sutro Biopharma&#8217;s proprietary extract from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">E. coli </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(&#8220;Extract&#8221;) from Sutro Biopharma. In addition, the Parties amended the license agreement to specify our rights</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to a transfer of certain know-how relating to the manufacture of Extract in the event of a declaration of bankruptcy by Sutro Biopharma. Finally, the Parties agreed to terms providing for injunctive relief in the event of a breach or threatened breach by the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the Sutro Biopharma Supply Agreement, the Parties agreed to terms for the supply of manufactured Extract and custom reagents by Sutro Biopharma for us to use in manufacturing vaccine compositions in non-clinical research or in Phase 1 or Phase 2 clinical trials. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2021 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of Extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Supply Agreement. In February 2021, we entered into an amendment to the Sutro Biopharma Supply Agreement and extended the term to July 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As Sutro Biopharma was no longer considered a related party as of June 2, 2021, we excluded expenses after that date from related party transaction expenses. We recognized expense related to the Supply Agreement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively. In addition, we recorded $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the change in fair value of the Preferred Stock Warrant for the years ended December 31, 2022, 2021 and 2020, respectively. The expense related to the changes in the fair value of the warrant is included in research and development expenses in the statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371053040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16. Subsequent Events</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsequent to December 31, 2022, through February 24, 2023, we sold a total of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">507,136</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of our common stock under the ATM Sales Agreement at an average price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45.79</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, generating aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million ($</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million net of commissions and offering expenses).</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371293520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and applicable rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) regarding annual reporting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">taxes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to supplier concentration risk from our suppliers. Although we are working to establish secondary sources of supply, we currently source several of our critical raw materials from single source suppliers. We also use one contract manufacturing organization (&#8220;CMO&#8221;), Lonza Ltd. (&#8220;Lonza&#8221;), to handle most of our manufacturing activities for our VAX-24 and VAX-31 programs. If we were to experience disruptions in raw materials supplied by our suppliers, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and immunogenicity or efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographical Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segment and Geographical Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We operate and manage our business as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash, Cash Equivalents and Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our current corporate headquarters. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:</span></span></p><div style="font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:38.052%;"/>
          <td style="width:6.663%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.244%;"/>
          <td style="width:1.0%;"/>
          <td style="width:2.235%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.116%;"/>
          <td style="width:1.0%;"/>
          <td style="width:2.235%;"/>
          <td style="width:1.0%;"/>
          <td style="width:14.456%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,657</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,985</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">871</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">871</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">835,528</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,856</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our investments have been classified and accounted for as available-for-sale securities. Fixed income securities consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses are also included in other income (expense), net. When the fair value of a debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in our statements of operations. When the fair value of a debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in our statements of operations only if we sell or intend to sell the security before recovery of its cost basis.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Deferred Offering Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and 2021, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of deferred offering costs, respectively, were included in Other assets on the balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_702b2ee1-c8d3-4b6c-aa18-57f4ed887283;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations in the period realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Financial Accounting Standards Board ("FASB") Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and its associated amendments (&#8220;ASC 842&#8221;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2022, our lease population consisted of real estate operating leases. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any finance leases.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating leases are included in Operating lease right-of-use ("ROU") assets, Operating lease liabilities - current and Operating lease liabilities - long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Impairment of Long-Lived Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recogni</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zed is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of impairments of long-lived assets during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (See Note 3, "Fair Value Measurements and Fair Value of Financial Instruments").</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#8220;CROs&#8221;) and investigative sites that conduct preclinical studies, clinical trials other supplies and costs associated with product development efforts, preclinical activities, clinical trials and regulatory operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AccruedResearchAndDevelopmentPolicyTextBlock', window );">Accrued Research and Development</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock', window );">Option to Acquire Manufacturing Rights</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquired Manufacturing Rights</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, we entered into an option agreement with Sutro Biopharma, Inc. (the "Option Agreement"). As of December 31, 2022, the option granted under the Option Agreement is a right, but not an obligation, to obtain certain exclusive rights to internally manufacture or source extract from certain CMOs and the right to independently develop and make improvements to the extract for use in connection with the exploitation of certain vaccine compositions (the &#8220;Option&#8221;). As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we paid Sutro Biopharma upfront consideration. As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the Option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2022 and 2021, we have recorded a full valuation allowance on our deferred tax assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For options granted to employees, non-employees and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The fair value of restricted stock and restricted stock unit (&#8220;RSU&#8221;) awards is determined based on the number of units granted and the closing price of the Company&#8217;s common stock as of the grant-date. The grant-date fair value of awards is amortized over the employees&#8217; requisite service period or the non-employees&#8217; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comprehensive Loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding, including pre-funded warrants, during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little consideration, are fully vested and are exercisable after the original issuance date.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the FASB issued ASU 2021-10, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Subtopic 958-605), Not-For-Profit Entities - Revenue Recognition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The required disclosures include (i) the nature of the transaction and the related accounting policy used to account for the transaction, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures. In Note 12, "Funding Arrangement," we included disclosures on our cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator ("CARB-X"). We have adopted this standard as required by the effective date. The adoption of this standard did not have a material impact on our financial statements.</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2016, the FASB issued ASU 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and has subsequently issued related amendments, collectively referred to as &#8220;Topic 326.&#8221; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. We have adopted this standard as required by the effective date on January 1, 2022. The adoption of this standard did not have a material impact on our financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AccruedResearchAndDevelopmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AccruedResearchAndDevelopmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option to acquire manufacturing rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372388656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Cash, Cash Equivalents And Restricted Cash</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:</span><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:38.052%;"/>
          <td style="width:6.663%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.244%;"/>
          <td style="width:1.0%;"/>
          <td style="width:2.235%;"/>
          <td style="width:1.0%;"/>
          <td style="width:15.116%;"/>
          <td style="width:1.0%;"/>
          <td style="width:2.235%;"/>
          <td style="width:1.0%;"/>
          <td style="width:14.456%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years Ended December 31,</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,657</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,985</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">871</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">871</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">835,528</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,856</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">386,200</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799374145680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.076%;"/>
        <td style="width:13.785%;"/>
        <td style="width:7.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.571%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.274%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.571%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.858%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.496%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.997%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.312%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br/>Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br/>Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,198</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56,198</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">680,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">680,934</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92,547</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,978</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,691</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">834,657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,161</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,144</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,402</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,954</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,974</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,427</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25,298</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,595</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">366</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,268</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">958,286</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">400</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">957,925</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value<br/>Hierarchy Level</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br/>Unrealized Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross <br/>Unrealized Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,834</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,596</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,986</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68,985</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. Treasury securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,290</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,217</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,919</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Corporate debt</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,498</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,424</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Asset backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,874</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,714</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,668</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,342</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">240</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,102</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total assets measured at fair value</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">241</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">273,087</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities of Investments</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents the contractual maturities of our investments as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 (in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:70.229%;"/>
        <td style="width:5.326%;"/>
        <td style="width:1.0%;"/>
        <td style="width:22.446%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in less than one year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,719</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Due in one to five years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,549</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,268</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799375924416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.929%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.011%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.086%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,608</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,619</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computers and computer software</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">416</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">430</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,353</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,117</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,548</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,360</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,954</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued expenses as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021 consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.226%;"/>
        <td style="width:1.421%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.806000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.421%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.127%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical studies</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,518</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">453</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other research and development </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,446</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,676</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,411</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,658</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,375</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,787</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accrued manufacturing rights as of December 31, 2022 and 2021, respectively. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The breakout and categorizations of the 2021 total accrued expenses have been updated to conform to the 2022 presentation.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799368637536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock', window );">Schedule of Information Related to ROU Assets and Lease Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.665%;"/>
        <td style="width:3.444%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.29%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.871%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.729999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,374</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,288</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,958</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,910</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,276</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-current operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,031</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,507</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,783</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.78</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.75</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of lease liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.111%;"/>
        <td style="width:1.795%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.094%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,684</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,850</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,556</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,615</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,941</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Future minimum payments required under operating leases as of December 31, 2021 were as follows:</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.097%;"/>
        <td style="width:1.781%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.122%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,639</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,976</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total future undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,315</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: Imputed interest</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,532</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,783</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities for 2022 are net of lease incentives of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million allocated to the Palo Alto office.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of information related to right-of-use assets and lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372621280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock', window );">Schedule Of non-cancelable purchase commitments related to raw materials [Table Text Block]</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, we had the following amounts due of non-cancelable purchase commitments related to manufacturing services and raw materials purchased due to our key manufacturing partners. These amounts represent our minimum contractual obligations, including termination fees. If we terminate certain firm orders with key manufacturing partners, we will be required to pay for the manufacturing services scheduled or raw materials purchased under our arrangements. The actual amounts we pay in the future to our vendors under such agreements may differ from the purchase order amounts. </span><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:85.35%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.649999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,099</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,471</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total non-cancelable purchase commitments due to key manufacturing partners</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125,570</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of non-cancelable purchase commitments related to raw materials [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372497552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Shares Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) and the 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) was as</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> follows, and excludes </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,710</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares issued outside of the 2014 Plan and 2020 Plan:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.479%;"/>
        <td style="width:1.018%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.229999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.031%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.243%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,715,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,295,007</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Restricted stock units issued and outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">456,766</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Shares available for future stock option grants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,679,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,104,756</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,851,858</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,399,763</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371005424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Nonvested Restricted Stock Shares Activity</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU activity for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 was as follows:</span><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.919%;"/>
        <td style="width:3.349%;"/>
        <td style="width:1.0%;"/>
        <td style="width:17.579%;"/>
        <td style="width:1.0%;"/>
        <td style="width:3.831%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.322000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">581,047</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and released</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79,229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.79</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cancelled</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,052</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.32</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">456,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Summary of Activity under Employee Stock Purchase Plan</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity under our 2020 ESPP was as follows:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.151%;"/>
        <td style="width:11.21%;"/>
        <td style="width:1.0%;"/>
        <td style="width:25.639%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">650,000</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,465</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">622,535</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">510,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62,546</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,070,704</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">530,319</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares purchased</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,709</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance - December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,539,314</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Estimated Fair Value of Employee Stock Options</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.321%;"/>
        <td style="width:1.357%;"/>
        <td style="width:15.203%;"/>
        <td style="width:1.357%;"/>
        <td style="width:15.203%;"/>
        <td style="width:1.357%;"/>
        <td style="width:15.203%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">2020 Plan and 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Under Stock Option Plans</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock option activity under our 2020 Plan and 2014 Plan, which excludes options to purchase </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,710</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares granted outside of the 2020 Plan and 2014 Plan, was as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.622%;"/>
        <td style="width:0.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.203999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.945%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.733%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:5.434%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.455%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.077%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.302%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options Outstanding</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Option and Restricted Stock Units Activity</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options<br/>and RSUs<br/>Available<br/>for <br/>Grant</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number<br/>of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Exercise<br/>Price Per<br/>Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual <br/>Term<br/>(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#8212; December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,651,149</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,121,549</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.99</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,553,579</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,616,021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,616,021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">926,514</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.25</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">516,049</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">516,049</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#8212; December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,104,756</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,295,007</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.30</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional shares authorized</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,651,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,850,981</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,850,981</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.67</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">385</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,153,285</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">277,209</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">277,209</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.54</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">581,047</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units withheld</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,626</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Units forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,052</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balances &#8212; December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,679,598</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,715,494</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.20</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest &#8212; December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,715,494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.20</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,921,091</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.41</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.81</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">______________________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net exercise - shares returned to the Plan.</span></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.12%;"/>
        <td style="width:1.378%;"/>
        <td style="width:15.385%;"/>
        <td style="width:1.378%;"/>
        <td style="width:16.998%;"/>
        <td style="width:1.378%;"/>
        <td style="width:15.363%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Assumptions</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;- </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2014 Plan, 2020 Plan and 2020 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We recorded total stock-based compensation expense for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, 2021 and 2020 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.07%;"/>
        <td style="width:1.359%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.359%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.84%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.359%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.173%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(In thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,954</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,751</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,775</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,573</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23,650</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,729</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,434</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799367902336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.374%;"/>
        <td style="width:1.261%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.916%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.271%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.916%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.271%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.99%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss (in thousands)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">223,485</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,077</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,217</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding used in computing net<br/>&#160;&#160;&#160;loss per share, basic and diluted</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,877,988</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51,922,108</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,545,810</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.02</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">____________________________</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes shares of common stock into which pre-funded warrants may be exercised. See Note 9, "Pre-Funded Warrants".<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.529%;"/>
        <td style="width:1.009%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.64%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.64%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.139999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,752,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,357,389</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,188,531</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">456,766</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employee stock purchase plans</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113,240</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66,404</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87,887</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,322,210</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,423,793</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,276,418</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372319760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Effective Tax Rate</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.469%;"/>
        <td style="width:0.98%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.57%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.98%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.57%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.98%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.45%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 162(m) limitation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 effective tax rate reconciliation has been updated to conform to the 2021 and 2022 presentation.</span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table presents significant components of our deferred tax assets as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.929%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.011%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.487%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.086%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111,555</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,574</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,062</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued &amp; others</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,103</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,174</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">R&amp;D Credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,436</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,865</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized R&amp;D expenditures</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32,873</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,984</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued manufacturing expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,063</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,006</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,358</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,674</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,867</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,956</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170,791</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104,934</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,357</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,349</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,357</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,349</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,433</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164,433</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,585</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Accrued &amp; others and Stock compensation lines have been updated to conform to the 2022 presentation.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Reconciliation of Unrecognized Tax Benefit</a></td>
<td class="text"><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.721%;"/>
        <td style="width:1.323%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.008%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.323%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.774%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.334%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.517000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">393</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">271</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additions based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">876</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">461</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">287</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reductions based on tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at end of year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,754</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">924</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">393</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371532912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Company Organization and Nature of Business - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 05, 2020</div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-for-1.6870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 264.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,062,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock (in shares)</a></td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters' option to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,343,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon full exercise of underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362470240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_NumberOfFinanceLease', window );">Number of finance lease | Lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="nump">21,288<span></span>
</td>
<td class="nump">27,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 17,941<span></span>
</td>
<td class="nump">$ 16,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements Or Change In Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799364729440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 834,657<span></span>
</td>
<td class="nump">$ 68,985<span></span>
</td>
<td class="nump">$ 386,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 835,528<span></span>
</td>
<td class="nump">$ 69,856<span></span>
</td>
<td class="nump">$ 386,200<span></span>
</td>
<td class="nump">$ 58,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799368541648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value assets transferred into level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Fair value assets transferred out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair value liabilities transferred into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair value liabilities transferred out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_NumberOfSecurities', window );">Number of securities | Security</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799367670224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">$ 123,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">834,691<span></span>
</td>
<td class="nump">$ 68,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents, Gross Unrealized Losses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">834,657<span></span>
</td>
<td class="nump">68,985<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">123,595<span></span>
</td>
<td class="nump">204,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments, Gross Unrealized Gains</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(366)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">123,268<span></span>
</td>
<td class="nump">204,102<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis', window );">Total assets measured at fair value, Amortized Cost</a></td>
<td class="nump">958,286<span></span>
</td>
<td class="nump">273,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax', window );">Total assets measured at fair value, Gross Unrealized Gains</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax', window );">Total assets measured at fair value, Gross Unrealized Losses</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAndInvestments', window );">Total assets measured at fair value, Fair Value</a></td>
<td class="nump">957,925<span></span>
</td>
<td class="nump">273,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Cash | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">56,198<span></span>
</td>
<td class="nump">27,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">56,198<span></span>
</td>
<td class="nump">27,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Money Market Funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">680,934<span></span>
</td>
<td class="nump">17,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">680,934<span></span>
</td>
<td class="nump">17,555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial Paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">92,581<span></span>
</td>
<td class="nump">23,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents, Gross Unrealized Losses</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">92,547<span></span>
</td>
<td class="nump">23,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Treasury Securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">37,651<span></span>
</td>
<td class="nump">45,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">37,581<span></span>
</td>
<td class="nump">45,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">28,161<span></span>
</td>
<td class="nump">61,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">28,144<span></span>
</td>
<td class="nump">61,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Corporate Debt | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">25,402<span></span>
</td>
<td class="nump">58,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">25,271<span></span>
</td>
<td class="nump">58,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Asset backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">6,954<span></span>
</td>
<td class="nump">13,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments, Gross Unrealized Gains</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">6,974<span></span>
</td>
<td class="nump">13,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | U.S. Government Agency Securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CashAndCashEquivalentsAmortizedCost', window );">Cash and cash equivalents, Amortized Cost</a></td>
<td class="nump">4,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, Fair Value</a></td>
<td class="nump">4,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, Amortized Cost</a></td>
<td class="nump">25,427<span></span>
</td>
<td class="nump">24,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments, Gross Unrealized Gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments, Gross Unrealized Losses</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments, Fair Value</a></td>
<td class="nump">$ 25,298<span></span>
</td>
<td class="nump">$ 24,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents amortized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and investments amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and investments gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents and investments gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799374028656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in less than one year</a></td>
<td class="nump">$ 96,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in one to five years</a></td>
<td class="nump">26,549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 123,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799363224688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 16,477<span></span>
</td>
<td class="nump">$ 11,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(6,117)<span></span>
</td>
<td class="num">(3,548)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,360<span></span>
</td>
<td class="nump">7,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,608<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_ComputersAndComputerSoftwareMember', window );">Computers and Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_LabEquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">13,100<span></span>
</td>
<td class="nump">9,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,353<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_ComputersAndComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_ComputersAndComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799368598800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AccruedManufacturingRightsExpenses', window );">Accrued manufacturing rights expenses</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AccruedManufacturingRightsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing rights expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AccruedManufacturingRightsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799373701408">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ClinicalStudies', window );">Clinical Studies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,518<span></span>
</td>
<td colspan="2" class="nump">$ 453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent', window );">Other research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">12,446<span></span>
</td>
<td colspan="2" class="nump">4,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,411<span></span>
</td>
<td colspan="2" class="nump">3,658<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15,375<span></span>
</td>
<td colspan="2" class="nump">$ 8,787<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The breakout and categorizations of the 2021 total accrued expenses have been updated to conform to the 2022 presentation.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accrued manufacturing rights as of December 31, 2022 and 2021, respectively. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ClinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Studies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ClinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other research and development liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362632736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>RenewalOption</div>
</th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>RenewalOption</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,288<span></span>
</td>
<td class="nump">$ 27,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,941<span></span>
</td>
<td class="nump">16,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating leases, rent expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_HeadquartersFacilityMember', window );">Headquarters Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseCommencementDate', window );">Operating lease, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LeaseTerminationDate', window );">Lease termination date</a></td>
<td class="text">Feb. 12,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseRenewalOption', window );">Operating lease, renewal option | RenewalOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to renewal, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30-month renewal options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In July 2016, we entered into a five-year lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from September 1, 2016 to August 31, 2021, with two 30-month renewal options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedLeaseTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedMaturityDate', window );">Operating lease, extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_AdditionalFacilityMember', window );">Additional Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseCommencementDate', window );">Operating lease, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to renewal, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no renewal options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating lease, existence of option to renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from July 1, 2019 to October 31, 2021, with no renewal options.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedLeaseTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedMaturityDate', window );">Operating lease, extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_NewCorporateHeadquartersFacilityMember', window );">New Corporate Headquarters Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseCommencementDate', window );">Operating lease, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 22,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedLeaseTerm', window );">Operating lease, extended term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_NumberOfRenewalOptions', window );">Number of renewal options | RenewalOption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_PaloAltoMember', window );">Palo Alto</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseExtendedMaturityDate', window );">Operating lease, extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  03,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_SanCarlosMember', window );">San Carlos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LeaseTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease termination date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LeaseTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease extended lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseExtendedMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, extended maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseExtendedMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseRenewalOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease renewal option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseRenewalOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of renewal options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_HeadquartersFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_HeadquartersFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_AdditionalFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_AdditionalFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_NewCorporateHeadquartersFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_NewCorporateHeadquartersFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_PaloAltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_PaloAltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_SanCarlosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pcvx_SanCarlosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799373834640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 5,374<span></span>
</td>
<td class="nump">$ 924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">21,288<span></span>
</td>
<td class="nump">27,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">5,910<span></span>
</td>
<td class="nump">5,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">12,031<span></span>
</td>
<td class="nump">11,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 17,941<span></span>
</td>
<td class="nump">$ 16,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">2 years 9 months 10 days<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799375788528">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear', window );">2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,684<span></span>
</td>
<td class="nump">6,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,850<span></span>
</td>
<td class="nump">6,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,022<span></span>
</td>
<td class="nump">6,976<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future undiscounted lease payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,556<span></span>
</td>
<td class="nump">20,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,615)<span></span>
</td>
<td class="num">(3,532)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17,941<span></span>
</td>
<td class="nump">$ 16,783<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities for 2022 are net of lease incentives of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million allocated to the Palo Alto office.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments net of lease incentives remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799368610944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcvx_PaloAltoMember', window );">Palo Alto</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LeasePaymentReceivableNoncurrent', window );">Lease incentives</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LeasePaymentReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Payment Receivable Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LeasePaymentReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcvx_PaloAltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcvx_PaloAltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799367604480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity', window );">Payments in equity, amount</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,680<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcvx_LonzaLimitedMember', window );">Lonza DMSA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PercentageOfPaymentsCompletionAgreedToDefer', window );">Percentage of defer payments agreed for completion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Amount recorded with respect to the potential future payments above the initial cash cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued</a></td>
<td class="nump">399,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price per share</a></td>
<td class="nump">$ 25.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_UpfrontConsideration', window );">Upfront Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_UpfrontConsiderationInCash', window );">Upfront Consideration in Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_UpfrontConsiderationInCashAfterAgreementDate', window );">Upfront Consideration in Cash After Agreement Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_OptionExercisePriceInCash', window );">Option Exercise Price in Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AdditionalMilestonePaymentsInCash', window );">Additional Milestone Payments in Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_AccruedCommitment', window );">Accrued Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FairValueOnDateOfSettlement', window );">Fair Value on Date of Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma Inc [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_UpfrontConsideration', window );">Upfront Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AccruedCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AccruedCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_AdditionalMilestonePaymentsInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payments in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_AdditionalMilestonePaymentsInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development and manufacturing services agreement payments in equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FairValueOnDateOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value on Date of Settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FairValueOnDateOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_OptionExercisePriceInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option exercise price in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_OptionExercisePriceInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfPaymentsCompletionAgreedToDefer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of payments completion agreed to defer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfPaymentsCompletionAgreedToDefer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_UpfrontConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_UpfrontConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_UpfrontConsiderationInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront consideration in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_UpfrontConsiderationInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_UpfrontConsiderationInCashAfterAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront consideration in cash after agreement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_UpfrontConsiderationInCashAfterAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcvx_LonzaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcvx_LonzaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcvx_SutroBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcvx_SutroBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372353568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule Of non-cancelable purchase Commitments Related to Raw Materials (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_NoncancelablePurchaseCommitmentsDueInOneYear', window );">2023</a></td>
<td class="nump">$ 123,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter', window );">2024</a></td>
<td class="nump">2,471<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_NonCancelablePurchaseCommitments', window );">Total non-cancelable purchase commitments due to key manufacturing partners</a></td>
<td class="nump">$ 125,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NonCancelablePurchaseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cancelable Purchase Commitments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NonCancelablePurchaseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NoncancelablePurchaseCommitmentsDueInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NonCancelable purchase commitments due In one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NoncancelablePurchaseCommitmentsDueInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NonCancelable purchase commitments due in second year and thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799373609984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details) - Redeemable Convertible Preferred Stock - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock converted into common stock</a></td>
<td class="nump">28,610,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799374339808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,470,670<span></span>
</td>
<td class="nump">53,031,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,470,670<span></span>
</td>
<td class="nump">53,031,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, dividends, per share, declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of common stock is entitled to one vote.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock, net of commission and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,299,000<span></span>
</td>
<td class="nump">$ 13,896,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Equity incentive plan, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering', window );">Shares issued</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_SharesIssuedPricePerShareUponFollowOnOffering', window );">Common stock price per share</a></td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_SharesPreFundedWarrantsToPurchase', window );">Pre-funded warrants to purchase shares</a></td>
<td class="nump">3,750,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PrefundedWarrantsPricePerShare', window );">Prefunded Warrants Price Per Share</a></td>
<td class="nump">$ 31.999<span></span>
</td>
<td class="nump">$ 19.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares', window );">Underwriters' option to purchase additional shares</a></td>
<td class="nump">2,812,500<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ProceedsFromIssuanceFollowOnOffering', window );">Net proceeds from follow on offering</a></td>
<td class="nump">$ 651,600,000<span></span>
</td>
<td class="nump">$ 107,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember', window );">ATM Sales Agreement | Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold', window );">Maximum commission percentage of gross proceeds from common stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,488,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_GrossProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock, net of commission and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember', window );">ATM Sales Agreement | Maximum | Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_SaleOfCommonStockAuthorizedAmount', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum commission percentage of gross proceeds from common stock sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PrefundedWarrantsPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrants price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PrefundedWarrantsPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ProceedsFromIssuanceFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance follow on offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ProceedsFromIssuanceFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SaleOfCommonStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of common stock authorized amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SaleOfCommonStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesIssuedPricePerShareUponFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued price per share upon follow on offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesIssuedPricePerShareUponFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesPreFundedWarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares pre-funded warrants to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesPreFundedWarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares of follow on offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pcvx_JefferiesLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pcvx_JefferiesLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362616384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details) - 2020 Plan and 2014 Plan - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuances</a></td>
<td class="nump">12,851,858<span></span>
</td>
<td class="nump">11,399,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuances</a></td>
<td class="nump">7,715,494<span></span>
</td>
<td class="nump">5,295,007<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">Shares Available for Future Stock Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuances</a></td>
<td class="nump">4,679,598<span></span>
</td>
<td class="nump">6,104,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">Restricted Stock Units RSU Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuances</a></td>
<td class="nump">456,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pcvx_SharesAvailableForFutureStockOptionGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pcvx_SharesAvailableForFutureStockOptionGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362447312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pre-Funded Warrants - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised', window );">Warrant exercised</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed', window );">Increase or Decrease of Pre-funded Warrant Percentage Not Exceed</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise', window );">Pre-funded warrants of common stock shares outstanding Immediately after effect to the exercise</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise', window );">Combined voting power of securities outstanding immediately after effect to the exercise</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise', window );">Pre-funded warrants of common stock shares outstanding Immediately after effect to the exercise</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise', window );">Combined voting power of securities outstanding immediately after effect to the exercise</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering', window );">Shares issued</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_SharesIssuedPricePerShareUponFollowOnOffering', window );">Common stock price per share</a></td>
<td class="nump">$ 32.00<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_SharesPreFundedWarrantsToPurchase', window );">Pre-funded warrants to purchase shares</a></td>
<td class="nump">3,750,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PrefundedWarrantsPricePerShare', window );">Prefunded Warrants Price Per Share</a></td>
<td class="nump">$ 31.999<span></span>
</td>
<td class="nump">$ 19.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital', window );">Pre-funded warrant recorded as a component of stockholders' equity within additional paid-in-capital</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of securities called by each warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combined voting power of securities outstanding immediately after effect to the exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase or Decrease of Pre-funded Warrant Percentage Not Exceed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded Warrant Recorded as a Component of Stockholders' Equity Within Additional Paid-in-Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants of common stock shares outstanding immediately after effect to the exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PrefundedWarrantsPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrants price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PrefundedWarrantsPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesIssuedPricePerShareUponFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued price per share upon follow on offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesIssuedPricePerShareUponFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_SharesPreFundedWarrantsToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares pre-funded warrants to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_SharesPreFundedWarrantsToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares of follow on offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799364090592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jun. 11, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_EarlyExercisedStockOptions', window );">Early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">7,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,153,285<span></span>
</td>
<td class="nump">926,514<span></span>
</td>
<td class="nump">358,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.88<span></span>
</td>
<td class="nump">$ 14.65<span></span>
</td>
<td class="nump">$ 9.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of the stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">$ 18.9<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Awards | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage', window );">Vesting percentage for stock options granted, Six months thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pcvx_OtherRestrictedStockUnitsMember', window );">Other Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage', window );">Vesting percentage for stock options granted, Six months thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period for stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant', window );">Exercise price expire in years form the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_StockOptionsGrantedTerm', window );">Stock options granted term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PercentageOfProvisionsSubjectToStockholders', window );">Percentage of provisions subject to stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Aggregate number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,679,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant', window );">Available for issuance of shares increased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,596,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,576,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Employees purchase shares of common stock of lower of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_OfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PurchasePeriod', window );">Purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of payroll deductions of eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Employees acquired shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,709<span></span>
</td>
<td class="nump">62,546<span></span>
</td>
<td class="nump">27,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant', window );">Available for issuance of shares increased</a></td>
<td class="nump">794,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock', window );">Incentive stock option granted to employees owning percentage of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares', window );">Remaining liabilities related to early exercised shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PercentageOfFairValuePerShareOnTheGrantDate', window );">Percentage of fair value per share on the grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_EarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early &#8203;exercised&#8203; stock&#8203; options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_EarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price expire in years form the date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incentive stock option granted to Employees Owning percentage of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised, excludes options exercised from NPLN.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_OfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_OfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfFairValuePerShareOnTheGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value per share on the grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfFairValuePerShareOnTheGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfProvisionsSubjectToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of provisions subject to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfProvisionsSubjectToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining liabilities related to early exercised shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Award Vesting Rights Six Months Thereafter Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares increase in available for grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_StockOptionsGrantedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock options granted term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_StockOptionsGrantedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pcvx_OtherRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pcvx_OtherRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799363903232">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">2020 Plan and 2014 Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options Available for Grant, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,104,756<span></span>
</td>
<td class="nump">4,651,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Options Available for Grant, Additional shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,651,598<span></span>
</td>
<td class="nump">2,553,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod', window );">Options Available for Grant, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,850,981)<span></span>
</td>
<td class="num">(1,616,021)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod', window );">Options Available for Grant, exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod', window );">Options Available for Grant, forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">277,209<span></span>
</td>
<td class="nump">516,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options Available for Grant, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,679,598<span></span>
</td>
<td class="nump">6,104,756<span></span>
</td>
<td class="nump">4,651,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,295,007<span></span>
</td>
<td class="nump">5,121,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,850,981<span></span>
</td>
<td class="nump">1,616,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,153,285)<span></span>
</td>
<td class="num">(926,514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(277,209)<span></span>
</td>
<td class="num">(516,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,715,494<span></span>
</td>
<td class="nump">5,295,007<span></span>
</td>
<td class="nump">5,121,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,715,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,921,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="nump">$ 4.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27.67<span></span>
</td>
<td class="nump">21.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.25<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Options forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23.54<span></span>
</td>
<td class="nump">16.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18.70<span></span>
</td>
<td class="nump">$ 9.30<span></span>
</td>
<td class="nump">$ 4.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 225,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">225,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 112,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember', window );">2020 Plan and 2014 Plan | Restricted Stock Units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod', window );">Options Available for Grant, granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(581,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod', window );">Options Available for Grant, forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_RestrictedStockUnitsWithheld', window );">Restricted Stock Units withheld</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net exercise - shares returned to the Plan.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_RestrictedStockUnitsWithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units withheld</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_RestrictedStockUnitsWithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award number of shares available for grant exercised in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award number of shares available for grant forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award number of shares available for grant granted in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371237600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Nonvested Restricted Stock Shares Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">581,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and released | shares</a></td>
<td class="num">(79,229)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled | shares</a></td>
<td class="num">(45,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance | shares</a></td>
<td class="nump">456,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted', window );">Weighted average grant date fair value, granted | $</a></td>
<td class="nump">$ 26,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Weighted average grant date fair value, Vested and released | $</a></td>
<td class="nump">24,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled', window );">Weighted average grant date fair value, Cancelled | $</a></td>
<td class="nump">24,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Weighted average grant date fair value | $</a></td>
<td class="nump">$ 26,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362518208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Activity under Employee Stock Purchase Plan (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance</a></td>
<td class="nump">456,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Begining balance</a></td>
<td class="nump">1,070,704<span></span>
</td>
<td class="nump">622,535<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized</a></td>
<td class="nump">530,319<span></span>
</td>
<td class="nump">510,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Shares purchased</a></td>
<td class="num">(61,709)<span></span>
</td>
<td class="num">(62,546)<span></span>
</td>
<td class="num">(27,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance</a></td>
<td class="nump">1,539,314<span></span>
</td>
<td class="nump">1,070,704<span></span>
</td>
<td class="nump">622,535<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of share authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362973696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">78.10%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">81.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">85.10%<span></span>
</td>
<td class="nump">84.10%<span></span>
</td>
<td class="nump">94.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799368571648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">78.10%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">81.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">85.10%<span></span>
</td>
<td class="nump">84.10%<span></span>
</td>
<td class="nump">94.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="nump">78.80%<span></span>
</td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">105.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="nump">99.70%<span></span>
</td>
<td class="nump">126.30%<span></span>
</td>
<td class="nump">158.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799363313712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details) - 2014 Plan, 2020 Plan and 2020 ESPP - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 23,650<span></span>
</td>
<td class="nump">$ 10,729<span></span>
</td>
<td class="nump">$ 5,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">9,899<span></span>
</td>
<td class="nump">3,954<span></span>
</td>
<td class="nump">1,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 13,751<span></span>
</td>
<td class="nump">$ 6,775<span></span>
</td>
<td class="nump">$ 3,573<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799372336064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362483760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Funding Arrangement - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,931<span></span>
</td>
<td class="nump">$ 1,585<span></span>
</td>
<td class="nump">$ 2,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember', window );">Cost Reimbursement Sub-Award Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections', window );">Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections', window );">Potential funding amount of award to develop vaccine to prevent shingella infections</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember', window );">Cost Reimbursement Sub-Award Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_InitialFundingCommittedByAward', window );">Initial funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones', window );">Total funding committed by award, available upon achievement of development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections', window );">Potential funding period of award to develop vaccine to prevent shingella infections</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember', window );">CARB-X Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant receivable on unreimbursed, eligible costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PotentialFundingCommittedByAward', window );">Potential funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember', window );">CARB-X Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_InitialFundingCommittedByAward', window );">Initial funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PotentialFundingCommittedByAward', window );">Potential funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember', window );">CARB-X Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_FundingArrangementLineItems', window );"><strong>Funding Arrangement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PotentialFundingCommittedByAward', window );">Potential funding committed by award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding committed by award, available upon achievement of development milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding period of award to develop universal vaccine to prevent infections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_InitialFundingCommittedByAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial funding committed by award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_InitialFundingCommittedByAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential funding amount of award to develop vaccine to prevent infections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PotentialFundingCommittedByAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential funding committed by award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PotentialFundingCommittedByAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential funding period of award to develop vaccine to prevent infections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcvx_CostReimbursementSubAwardAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799363217504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss (in thousands)</a></td>
<td class="num">$ (223,485)<span></span>
</td>
<td class="num">$ (100,077)<span></span>
</td>
<td class="num">$ (89,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number Of Shares Outstanding Basic</a></td>
<td class="nump">64,877,988<span></span>
</td>
<td class="nump">51,922,108<span></span>
</td>
<td class="nump">29,545,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number Of Diluted Shares Outstanding</a></td>
<td class="nump">64,877,988<span></span>
</td>
<td class="nump">51,922,108<span></span>
</td>
<td class="nump">29,545,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share Basic</a></td>
<td class="num">$ (3.44)<span></span>
</td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share Diluted</a></td>
<td class="num">$ (3.44)<span></span>
</td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (3.02)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362470320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">8,322,210<span></span>
</td>
<td class="nump">5,423,793<span></span>
</td>
<td class="nump">5,276,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units RSU Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">456,766<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pcvx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">113,240<span></span>
</td>
<td class="nump">66,404<span></span>
</td>
<td class="nump">87,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">7,752,204<span></span>
</td>
<td class="nump">5,357,389<span></span>
</td>
<td class="nump">5,188,531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pcvx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pcvx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362972160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Rate</a></td>
<td colspan="2" class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td colspan="2" class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based Compensation</a></td>
<td colspan="2" class="nump">1.50%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td colspan="2" class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits</a></td>
<td colspan="2" class="nump">0.80%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td colspan="2" class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td colspan="2" class="num">(21.30%)<span></span>
</td>
<td class="num">(23.00%)<span></span>
</td>
<td colspan="2" class="num">(22.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_Section162MLimitation', window );">Section 162(m) Limitation</a></td>
<td colspan="2" class="nump">1.80%<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td colspan="2" class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td colspan="2" class="num">(0.20%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td colspan="2" class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td colspan="2" class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td colspan="2" class="nump">0.00%<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 effective tax rate reconciliation has been updated to conform to the 2021 and 2022 presentation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_Section162MLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Section 162(m) limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_Section162MLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799371522992">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 111,555<span></span>
</td>
<td class="nump">$ 85,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,062<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accrued &amp; other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">2,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D Credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,436<span></span>
</td>
<td class="nump">2,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D expenditures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,873<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses', window );">Accrued manufacturing expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,063<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_LeaseLiability', window );">Lease Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,358<span></span>
</td>
<td class="nump">6,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,474<span></span>
</td>
<td class="nump">1,956<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,791<span></span>
</td>
<td class="nump">104,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">ROU asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,357)<span></span>
</td>
<td class="num">(8,349)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,357)<span></span>
</td>
<td class="num">(8,349)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance', window );">Net deferred tax asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">164,433<span></span>
</td>
<td class="nump">96,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (164,433)<span></span>
</td>
<td class="num">$ (96,585)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Accrued &amp; others and Stock compensation lines have been updated to conform to the 2022 presentation.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets liabilities net before valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax accrued manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799363181184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax benefits</a></td>
<td class="nump">$ 1,754,000<span></span>
</td>
<td class="nump">$ 924,000<span></span>
</td>
<td class="nump">$ 393,000<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties recognized for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">340,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carry forwards expiration year</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ResearchAndExperimentalExpensesAmortizedPeriod', window );">Research and experimental expenses amortized period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research credit carryforward</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 453,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_OperatingLossCarryForwardsExpirationYear', window );">Operating loss carry forwards expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ResearchAndExperimentalExpensesAmortizedPeriod', window );">Research and experimental expenses amortized period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit carryforwards</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_OperatingLossCarryForwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forwards expiration year</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_OperatingLossCarryForwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ResearchAndExperimentalExpensesAmortizedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and experimental expenses amortized period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ResearchAndExperimentalExpensesAmortizedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799368539312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 924<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions based on tax positions related to prior years</a></td>
<td class="num">(46)<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="nump">$ 924<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799362928192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 29, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,470,670<span></span>
</td>
<td class="nump">53,031,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth', window );">Percentage of royalty payment on annual net sales of vaccine products for human health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth', window );">Percentage of royalty payment on net sales of vaccine compositions for animal health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses related to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Series C Redeemable Convertible Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase shares of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Series C Redeemable Convertible Stock | License Amendment A2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase shares of stock</a></td>
<td class="nump">59,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price per share</a></td>
<td class="nump">$ 11.5215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant exercisable and vests immediately and expires date</a></td>
<td class="text">May 29,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase shares of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.79289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember', window );">Sutro Biopharma, Inc | Preferred Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of redeemable convertible preferred stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of securities called by each warrant or right exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payment on annual net sales of vaccine products for human health.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payment on net sales of vaccine compositions for animal health.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pcvx_SutroBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pcvx_SupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pcvx_SupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pcvx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAmendmentATwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=pcvx_LicenseAmendmentATwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pcvx_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pcvx_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=pcvx_PreferredStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=pcvx_PreferredStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139799373498032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Subsequent Event - ATM Sales Agreement<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 24, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold | shares</a></td>
<td class="nump">507,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average price | $ / shares</a></td>
<td class="nump">$ 45.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_GrossProceedsFromIssuanceOfCommonStock', window );">Aggregate gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses', window );">Proceeds from issuance of stock, net of commission and offering expenses</a></td>
<td class="nump">$ 22,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of stock, net of commission and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pcvx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pcvx_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>pcvx-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pcvx="http://www.vaxcyte.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pcvx-20221231.xsd" xlink:type="simple"/>
    <context id="C_6c1fa594-ab7b-4dd7-8b89-83fe6abb5568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d4156e2c-f054-42e7-a026-6dd2300deca6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f9ef3af6-0ed6-4232-82f8-f00e3b3f9c04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ebee093b-a58f-4627-85e8-192d773f305e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0462dcf5-a925-4711-9836-298b3b1a0bba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6d40cfd0-136e-4c2d-a988-0b2942394d6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_f24288b7-094a-4c0a-ad36-62c7652ebabb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dc8ae2fa-cfee-4adf-934b-b757251456e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_bf009615-d1f6-4a3a-935f-7b0d3b6dca01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_1e5bb009-c911-4eb4-9225-759eaada18dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:ComputersAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_93ae0419-91bb-4c85-9618-57fe0afc3264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_037574d0-71b1-40d4-9227-c5f9299b9dd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_7cbd95b2-0c54-4116-8364-7ddbdd457679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5498ed60-351d-4bfe-8d0d-3748e9cc3710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_fb2cd419-f42a-43d4-8173-6fb63ccd1d36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_215eff92-aeb1-4823-b975-c15a670cc803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:PaloAltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_e0c5e803-6cf5-4387-8896-428a21286a2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_34ff63dc-cde8-47e8-9597-b638326cc368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_81984893-bd31-4052-aaed-e6928b5494fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8f016bde-e771-439c-ab98-f01eb018c718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_87eb225f-5c0d-43e6-859d-fe29381daaa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_17293867-6c59-44bc-b2a6-797596102857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_8656ce44-0eee-45cd-8119-542db136b9e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_81569ea5-c187-4394-8eea-071974a031f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_13165d69-2eff-4eec-af08-7f5b5519d9b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_da57a27c-5363-490e-93b7-2f25eccde933">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c14f87d8-1d33-40ea-b99b-b33fe6411911">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_b71d1ae0-0191-4fcc-9eb1-6928e92a2341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6ea235fe-244e-4bbf-8025-1963f440f2aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-17</instant>
        </period>
    </context>
    <context id="C_9a9d9224-9fa8-4858-a34f-83f9703e9715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_66f9bfcc-ebad-40de-95bf-47b87ed044a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9b6dde0d-1098-4728-82b4-9050d56dcc05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d308ed79-6102-4437-9f98-f586c059dc9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3c4d15b9-2c87-4cf6-be74-87bda32cea0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:ComputersAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_adfec910-931f-4fe2-b666-3a64354787e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2020-06-05</startDate>
            <endDate>2020-06-05</endDate>
        </period>
    </context>
    <context id="C_24822c38-0fa4-483a-956a-7108b2fb1a10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_f5b73419-0c99-4891-9305-ef5424ea8616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_330c2634-585b-4669-bdd0-9bfa256e2032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d5787b64-58e9-406e-ab46-d4feaf208a20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:LonzaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_e5603f34-fe33-4aa9-bba2-7bcef1212dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_84e39903-4e50-46bc-a706-ef2201e6c504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6bd83283-29d6-47da-874d-4c54c292d4ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5d6c3586-ec99-4387-90b9-c66ada981bf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_df172351-baa3-4411-9c37-3b0b3e33fab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0489234b-730f-4827-9f6d-d815f1a09ff7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e17de957-4ef6-4075-bc74-6780bc32c66b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c80a26a1-b95a-44f9-acc5-6127ef778da7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_d2fdc0e7-955d-4a1b-9894-ad28840b67da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_22b9506a-6924-44d6-a115-432bb54e29f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_85dd075c-01fc-4937-bc97-63808bb2e3a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_52a9c5b1-8f71-49a0-af0c-9cb853cc2232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_e926f4ca-4dd1-450a-81bd-dc676a9925ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8a1db5ca-4032-454e-b64f-84afc6e86567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_45c64528-2381-42d2-9b60-787dd273ce67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_51a0df40-cbb7-4e5a-855d-40d7ff36c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9894bfc2-b8d0-4aa2-bdea-70d5be6112ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8c77accc-7d52-4157-8c4c-e2e27e2e2b05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_75637c01-f692-4f45-a633-9d4eb7b8df37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:SutroStockPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6d173051-b96b-48bb-8554-d94b4601af7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b92aaa0b-aeff-4d69-a84f-c6311d27ad82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_ff59dd17-1515-4475-9b29-d6981afba232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_adf7111c-3503-433b-85ea-ba5266a3bec4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_6a8383e7-fefb-449e-97bd-c449db6e963c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8e4a1e9d-b20b-44bb-aaf3-49bc4856bac7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d2a47633-779f-4ee5-bc2a-ade49b683a08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:OtherRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8842095a-a719-4e20-84ac-651814b90d5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_eb41f55f-e7d1-436d-992c-c9ae66000f84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3a3620f-8e54-449e-9e7d-3e9250cb8220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c325a933-95d0-4782-a705-8f73c8708fb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ff0b5242-8612-45db-87e3-a8572449c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="C_f1e5de9a-c565-4d52-a50d-b1a74b68669d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0cf6689c-2254-4c4c-9717-295b1177cd54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_28391222-5a1c-470d-ab50-f5f6861c6e11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_2fdff316-147b-4b2b-bcfe-6871447ed8e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c544cf31-11ab-4456-8095-c7c6e411d5d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2e350f80-8b0a-485c-813b-204158cbec02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_98587108-31fb-4048-8311-ad1171d7b550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_69e656bb-2569-41bf-9f6a-4c464b33253f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1e25d9bc-8da8-4125-95f2-eb869be71853">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7a8dc7cf-7734-4350-9266-07d83e2f4a3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b29a7753-469a-481c-993c-8a5ee73c666c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_5ff4f253-5e79-4f0f-9621-48e669f7b797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_9bb12da7-1bd7-4afd-815f-80e30d2186ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b043466b-5227-4835-be5f-8ac1b25eac10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ebe97179-a864-486e-a92b-54ddbdfb9b14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_57fb732d-890e-48c0-9e93-f41e83529309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9a4f0832-de96-4079-b3c1-db1efe6e81b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7ac2f60b-8289-45da-8d07-c31dcf594253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_05578dce-4d37-4f18-96b3-f10bddcbaf51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_01155b0a-67b5-469f-9b55-5c9a7412e381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bc63e8f2-1888-4fcd-a8d4-a880d9bb2f86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a5d59d19-2f5b-474d-ad5f-5eb6826a0e4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_34d44816-59db-4fff-99c9-27216e95713d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9301909a-a6de-4293-bf83-22071eaf9f32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6ff2a197-ccf8-4a47-9068-2d3aca352aec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_69ba85f7-550d-45b3-a266-5784d58b8189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ace7762d-3569-458c-9040-9f42331af172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_7d262603-bbcb-4d32-8649-c7dde0f3cba1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0598ec3b-a113-4d19-ae05-d08550eafaae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6c850b73-588c-41c3-b04b-a21bc0ff9e82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0cec58be-bb3d-44e1-8f46-324ba1e7a4d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:SharesAvailableForFutureStockOptionGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_93cfc9bc-cf41-46c8-8d8c-3c249f9e296f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_180236c9-658c-46b2-8320-cd9fd9ee3932">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_41f2bc47-1b64-456b-8eb3-0bfe5b57516c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_415e98bb-bdbd-4558-a741-01b294239326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e9126c57-d4e4-4b9e-8373-4b493ee1f1c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_3d0c5e64-a420-486e-ae76-8b1696c5a6ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_32c0e264-4ab1-4f71-99a3-932ea28e946c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_605b60d5-91b3-4448-ba68-5bd37a009e74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6ab2007d-2325-4131-b251-a78960367bd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f071a04d-8d88-4c59-91cc-56470ac8c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a36c4830-4b5f-44a3-8402-0567ef69ef94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_43290d81-1ade-4236-b12a-f4dfbc9a2de2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_92495c05-9763-4ff7-855f-1743d26c34ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1cf027a0-a614-4616-8ba2-757303a3ef4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="C_9a2fe8c2-7190-4ba0-9807-0bf83b739c1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="C_82ee469c-c1fb-46f6-bd16-0bd5b700dbdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:PaloAltoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_42dcecda-101e-4ddd-8695-6548e530de78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2851b72e-f235-4e1b-8ad0-09f3525757c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_180b3546-613a-47fb-a45e-b43467ddc5e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_4fea95f2-1b19-4123-9ac1-3c958efccee9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4c174ac3-2385-4026-a502-02872bdce024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_69861e0f-f897-430a-8634-87b91fd0c8b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_443140ce-af83-4051-90d8-0a039e3d6625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-14</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="C_132ccca8-d60e-4222-bb51-935509c790c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f29cb1b4-51e8-42fe-ba43-bfae1134ea34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:NewCorporateHeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_db08c559-8805-4810-a9ad-817d3efd45a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_c729b163-a362-4fd1-896f-64744eecd71c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-24</endDate>
        </period>
    </context>
    <context id="C_1af9b85c-d59e-4494-bcdc-b8097aa831e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-07-31</instant>
        </period>
    </context>
    <context id="C_2621b640-8d9b-4efa-a67c-bc201f6864e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:OtherRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bcab4237-fc1e-4b3b-a82d-9d53bb21e6b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_eb2e21b9-03b4-445b-a4c8-52e92a39f940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c411c849-9449-415d-836c-57f752c96e04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_323a4631-8d67-46bd-b2bd-7c01a7ec7d2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2d081aa6-31a3-4423-a381-77023efa1448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ad2a30c9-052d-4eba-928a-c4c5ab6c20db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:SutroStockPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_295fc304-a24b-4340-bef2-fe78e40e2989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:OtherRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_53f32d39-f32f-4c9e-8927-e638758556c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c04110eb-23bc-459e-a813-d93f70e70acf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_f6044654-8564-4024-bef2-b41b4aedd272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_202f07f9-5156-457e-9195-d19a2910d156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cffd01a3-53b4-4cbf-9aef-3e5b1f46b78f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_acd4f53c-e76e-4bcc-8f97-102bcec4707b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_7b1a0eec-bf5e-4892-9967-715b22960941">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_59365215-3504-4f12-b752-122da006773a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_e8212113-420d-4afe-a557-faeb55c9fc93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_81e20c4f-e0c6-4cea-b677-93b2e39c7f30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ddc89e57-5630-47be-9bd0-27808be55284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6713bc72-bbf6-4c8d-848a-8ca3bd191ee0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_d7812bcb-1a97-4787-be8b-59a98d64a890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_dd141812-a700-48fc-9a93-5d2fa4df6de7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:AdditionalFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_02afd6c9-f14c-4595-b698-8d1af3e8c0a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_837815d3-4f60-4133-8174-f837af239d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_cf5ec869-94b5-4ffc-91dc-e1f40e3f1d68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_33283eca-8ea2-4ccd-9fe1-36145a063453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1121605e-be53-44bc-b6eb-31b279bad82d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_2a97fce7-5ef2-4cc8-85f5-b620ca762566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5cae38a4-c4a8-47aa-a3e3-61aaee5e44b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_49cc4baf-48fc-47b3-962c-c338dcbc9399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c9b4f586-2146-4cbd-aa92-140916b46d25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pcvx:JefferiesLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3a1f2bbd-3a84-4def-8008-4279ed957a96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8ba486b2-d8aa-4ca6-9756-5c9748b4e008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b694d80e-fe68-400d-b770-ba2619d82563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d1ef036e-43c1-4748-ba90-b2fce246fad4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e301df95-054d-4248-b434-a97368723f9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b219256c-6df8-41ce-b765-2f529e35b517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bb33c9e9-15f8-4620-9baa-1c636358bb0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:SanCarlosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1477851-b8b1-4483-a4bf-02d65b12c4e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_10a9faa2-6408-4b48-8d11-d8c2958b964d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4a24e83d-869b-46cd-a362-36d31d8ac8ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9ab2dcd4-25fb-4d25-a652-57453b4b393b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_5620db3e-07c5-48e8-80c5-b68b2362d81c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_e8457603-d007-4a06-8019-118bd0a48904">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2d608b3d-cdf6-4c26-9877-9e1ba7a21a78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:SupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20d86c4a-c1e6-415d-8039-887d6b20d17f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-11</instant>
        </period>
    </context>
    <context id="C_52984cc7-0416-45ea-9199-ee6f2a1b640f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_a07caa24-b5b1-41b0-bf5a-a85de3830de2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_93593151-df16-4d93-bf9c-30716b99adb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:NewCorporateHeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_16219b98-47a8-4997-a3e1-39a5a065b63c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_16916817-1032-4d1c-9ab3-a2e5e372cb09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_86059fb6-8a98-4604-99c1-7846fc457e76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:SutroStockPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6bc5fec4-d3ad-4cc4-9828-b81bfbdb4992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1c80638b-879a-4eff-b0d3-6917912c5862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_76248553-c6a5-451e-b7e1-10f5d684fa65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3d68821a-459d-4683-8345-23cec20bbda0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c3303683-5d29-4add-a4a5-c77ccff026b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_78621854-c804-4c5b-8406-1b035bcdf270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_86a6494f-286c-4378-b602-52e8e5e8f4b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d6be8964-6e18-48ad-a7a4-2310c767319e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_042e7705-d42e-4637-8ecc-6de667d73494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cc891ca2-75ea-4415-b513-14e4b37dc9b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a6eb96b6-2f08-472a-ba13-12abc92474e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_58188e6f-33df-4637-971c-bb69de27b7a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_563ab83e-909f-4129-bbf2-6d8fd0542811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_522586e0-c2a8-4187-8dfd-3a928a099df2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c7051fb3-6833-4895-a7ab-ff07923b921b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7cc4ab4f-7bad-4d16-9545-b64979b11e87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_5174e359-4705-4039-af81-628498b266ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_71794c0f-76e0-44c9-b988-61b9c2402e78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f949711a-cc58-4c69-8736-3e85b3424551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d94724f5-308f-4538-9078-b37164cc96a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-11</startDate>
            <endDate>2020-06-11</endDate>
        </period>
    </context>
    <context id="C_ae85f674-5889-4534-aba6-cf137accf611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c3d2b846-b46a-4469-a0a3-586d1c69fc46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fffa34b2-595e-4a00-a483-b9a4cb5243ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pcvx:MarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7f9806ed-b5a6-4aef-bf04-0c1827f34b0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6584fbf6-caf6-435c-8531-3189f88ffaef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_898a2a2d-e260-47fb-85c7-5b4d4065a867">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pcvx:HeadquartersFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-01</startDate>
            <endDate>2016-07-31</endDate>
        </period>
    </context>
    <context id="C_79e53c50-0fb4-4714-84d0-e5a2a573e00b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3912106f-3c31-4ffc-9141-7807cf18d485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9400b621-8b2f-4a08-b570-b9c92478f198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1be3eda5-a43a-436d-b315-ddea1f184d88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pcvx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_627bc919-0f57-4ed7-9267-0f6ca3c2b3c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_043847b8-3b71-486a-a3f8-651e1b7e0b0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7329b071-f8d6-4b42-988b-4c5a585bc452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_58769e66-aeef-44e4-85ca-41149ca8f5e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ef8a5bfd-8fc9-43e4-974f-36c738247627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:CostReimbursementSubAwardAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_e4995092-b32b-457d-9712-2e5592bba095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8b67a24d-307d-4950-a7b7-2cbe7eaae283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAmendmentATwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-29</instant>
        </period>
    </context>
    <context id="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pcvx:TwoThousandTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_06c078e9-1e6f-4493-a040-ad253c029b6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1cb91b7d-ce25-4f69-a837-9352b82a8fb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pcvx:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="C_05a0d0fb-b481-4721-8b79-6232b8304ad5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">pcvx:PreferredStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_783f07a1-06d5-4961-9f5d-5e2270a1613f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_99bb839f-a7de-4946-a60c-d6f300ec4d73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_acde4ea0-fa6f-4cb1-9b72-08bcadf7a728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001649094</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">pcvx:LicenseAmendmentATwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pcvx:SutroBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pcvx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-28</startDate>
            <endDate>2018-05-29</endDate>
        </period>
    </context>
    <unit id="U_Security">
        <measure>pcvx:Security</measure>
    </unit>
    <unit id="U_RenewalOption">
        <measure>pcvx:RenewalOption</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Lease">
        <measure>pcvx:Lease</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>pcvx:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_e1ec8068-d2e5-4cc8-8234-52bb71f87e0c">0001649094</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_7678fefa-44cc-47df-a4a0-5914bc136d01">false</dei:AmendmentFlag>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      id="F_e8d3af2f-da3d-4a8d-a3ce-fe78d26e1535"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_295fc304-a24b-4340-bef2-fe78e40e2989"
      id="F_b8edf648-6c56-470f-b105-b7c382767664">P3Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      id="F_01e56683-a72d-4e07-a927-c99f3d7b0a4c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_41f2bc47-1b64-456b-8eb3-0bfe5b57516c"
      id="F_702b2ee1-c8d3-4b6c-aa18-57f4ed887283">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_b4831c24-3135-411b-b171-2bbf2a2a3369">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_adfec910-931f-4fe2-b666-3a64354787e5"
      decimals="3"
      id="F_8e741145-af74-425d-8be3-d82ab7aec016"
      unitRef="U_pure">0.593</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_084bcac3-2bbb-4a4a-a911-17aaa60cb28c">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_2a080c8e-d8e5-4e63-b281-5de6e1fd3261">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_82f54efb-27b1-4691-8243-e336db252ea0">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_486ccfb5-e383-4320-97a8-6d8615471c95">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_0622e167-ec53-4c13-a488-6b3b065bea4e">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_0dadc724-2a27-4a98-a0b1-54e1c47288ab">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_0c4d2e11-2b49-45cd-9941-c1f418aeaeed">001-39323</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_9f220f01-bffc-4785-aae0-be2d34e4bc32">VAXCYTE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_788d7aa0-816d-46d8-be40-d9aa32e188a5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_867a6dbf-5111-4e30-9151-e29b3527d78a">46-4233385</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_050cd3d1-99df-45db-9dbf-45ef1c314eae">825 Industrial Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_483bd0e0-9be2-401b-b287-7e6f1a05f160">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_55c49d26-1e00-401c-a4e9-c4234a6def20">San Carlos</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_86828a48-0d28-417d-be25-3f96d69b5f38">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_1c487c2f-e5b6-475f-949f-40c48a341c37">94070ca</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_05ddf7bc-866b-427d-9075-26f585402b5c">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_835a0a9a-4da3-4224-a919-1749ffcb588a">837-0111</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_fe9278fd-841c-4f21-97df-94ca5606b27c">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_7f063624-d569-4b07-b941-4f28ecd054bb">PCVX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_0be74215-1830-418f-81d7-eb2c5cd2c43e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_26d62050-9908-42ad-b365-ac917990e742">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_e3d6b744-7b5f-4672-89ab-5c0a5c524d1b">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_319bd723-15ce-4043-8884-061b3289595a">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_c15c3523-f7ec-4faf-88d1-597d6a13e4cd">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_45f356c4-f8ba-491c-85e4-af0d1f9792fb">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_826e266c-5565-4c6a-8787-bcd5299df1e5">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_177ffdec-6c6d-4337-8daa-d9d663b1cbfe">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_4525fcc7-b9b6-4e62-9abe-97e14790d217">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_4eb1d0ab-3407-463a-adab-48ba52f44ecd">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_1c80638b-879a-4eff-b0d3-6917912c5862"
      decimals="-8"
      id="F_15b36965-3162-4dce-ba18-392976e720fb"
      unitRef="U_USD">1100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_c729b163-a362-4fd1-896f-64744eecd71c"
      decimals="INF"
      id="F_2c4bb446-38d2-4aa4-993c-da25cc32759f"
      unitRef="U_shares">80033727</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_4d4770d5-1918-4a7c-92c8-486a1ddcf201">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Part III of this Annual Report on Form 10-K incorporates information by reference from the Registrant&#x2019;s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A, not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, in connection with the Registrant&#x2019;s 2023 annual meeting of stockholders.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_932b5872-1eaa-4e93-afa6-625d17880ce7">34</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_ea36448d-0b77-4e72-8145-8d9f40d8ca47">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_c7f112f5-9bc8-4eea-9bb2-36f4e6d7c463">San Francisco, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_d8a0c393-db27-4634-b470-d6732ddd4bd5"
      unitRef="U_USD">834657000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_2f99c71f-a9d1-4bf0-b708-f9f5d4e64715"
      unitRef="U_USD">68985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_0a069a30-80ec-43fd-a596-c745f77bb92e"
      unitRef="U_USD">96719000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_bc9fca5f-ef7d-4393-b526-d663b19d1a26"
      unitRef="U_USD">176985000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_422cbfb0-c354-46ce-b70e-196cc9cb7e76"
      unitRef="U_USD">11179000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_c9f8563f-e992-41d9-b7af-93b13388878a"
      unitRef="U_USD">10378000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_73d8f465-fdab-4098-a2ee-3bcc05c7f538"
      unitRef="U_USD">942555000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_863422a5-acac-4d14-acfa-e9caea2e1e73"
      unitRef="U_USD">256348000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_b9a96dfa-cb7b-4b4c-a909-6e6a8979ad27"
      unitRef="U_USD">10360000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_c1b5daa8-25eb-482c-a66d-fe1ad692377d"
      unitRef="U_USD">7954000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_a6910f50-ee40-4ede-908e-9499063e336e"
      unitRef="U_USD">21288000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_6d8424da-66ac-431c-a4c2-a0c6dba89a3d"
      unitRef="U_USD">27958000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_6623361e-94dc-4260-b4ac-003b653dd118"
      unitRef="U_USD">26549000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_e81d64f2-5341-448e-bb16-086f49bada19"
      unitRef="U_USD">27117000</us-gaap:LongTermInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_b75de9da-af9b-4848-b568-2ab59179cd7e"
      unitRef="U_USD">871000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_84aec3b7-3147-4da7-8595-26dbff1e6be3"
      unitRef="U_USD">871000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_8c500642-17cb-4e50-8ed4-db6c8692550e"
      unitRef="U_USD">4555000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_e9fc02ff-75e0-4f4a-ae74-e02e83dfcad4"
      unitRef="U_USD">4089000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_a8847f1c-c806-4125-8fbb-8e2a7cfd5b69"
      unitRef="U_USD">63623000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_7e744a3a-8412-4a66-8304-3ed13b9742f7"
      unitRef="U_USD">67989000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_2c9e8dfc-5731-4977-8f05-3de1c0bb1c0b"
      unitRef="U_USD">1006178000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_9353aea6-3715-4c9d-8404-7a799aec6396"
      unitRef="U_USD">324337000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_6eda63bb-1f6d-44b5-bc1f-27660381027f"
      unitRef="U_USD">9795000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_85866a13-6267-41dd-8fb7-efd7731779c7"
      unitRef="U_USD">6758000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_6a976b04-bf6d-47f6-b339-1bcc017b3bfb"
      unitRef="U_USD">1180000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_1711e08b-c6e3-426b-a836-72456f00d096"
      unitRef="U_USD">3455000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pcvx:AccruedManufacturingExpenses
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_fda9359a-2d2a-4392-b7b5-f37e860922e6"
      unitRef="U_USD">8265000</pcvx:AccruedManufacturingExpenses>
    <pcvx:AccruedManufacturingExpenses
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_d6d2d66f-f102-4e7c-a867-385f8d945003"
      unitRef="U_USD">4440000</pcvx:AccruedManufacturingExpenses>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_f22b764a-19c1-4964-8e07-a8032d0a6fd4"
      unitRef="U_USD">15375000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_0305bf96-32fe-4ce4-9e3c-a3abf749d00e"
      unitRef="U_USD">8787000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_cd8aa74d-f622-45ee-a6b6-d08e9bd61eba"
      unitRef="U_USD">5910000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_4b695dd8-2da2-45b3-8ffd-f2a00f414fb8"
      unitRef="U_USD">5276000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_2565a7b5-5479-46a0-bcde-a6939eb45ad0"
      unitRef="U_USD">40525000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_0c37800e-cab3-4766-b933-3e27e9ff31d6"
      unitRef="U_USD">28716000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_fa7b5abc-001e-4502-b582-5a95008ea84d"
      unitRef="U_USD">12031000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_7e1eec72-21ed-4a32-aeff-f84a667712e4"
      unitRef="U_USD">11507000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_9aa72d04-7fce-4f3b-9256-97faaf75f9c2"
      unitRef="U_USD">9000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_4a0e6881-a97e-43db-9fe9-eaefce2e8fef"
      unitRef="U_USD">96000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_4b8d0d22-5068-400b-a0d5-07d4264308c6"
      unitRef="U_USD">52565000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_26464ca1-bb53-433d-a644-6cefa51a0765"
      unitRef="U_USD">40319000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_dbe89649-a95c-4a1d-8d48-5f469bdfad28"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_f6d21062-949a-41e7-9ad7-996b63b713ab"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_58f981fd-ca00-4bf2-a31e-9e2a76b2edc9"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_5f38d0ab-4b9a-41c5-8030-f41707e93447"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_78fdb991-5a35-40ce-ab2b-91e8c26cde81"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_60541522-0eb6-4a83-a490-0c5fe84af573"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_36030bf4-c1dc-4e8e-9cda-d3e0e5a985f2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_21bc53f7-e69a-4268-b8b9-2b1c0885fbeb"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_53adcc76-f44a-4910-84e0-2de09ee05ffc"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_5442fbb7-7a0b-44a2-8fc4-ed2539c8ee80"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_934d78c6-6ec1-4c18-a67f-4059268e38b3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_3c0a19b1-2324-427e-b4b0-fad40b8e9eb7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_a8e2e46c-4eb0-4f8d-b2c8-fd5beb293667"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_70a69112-ea93-4ec8-b19c-eb30772d955e"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_ebe0bd2a-6152-4e7d-911a-4c0a56c9a229"
      unitRef="U_shares">79470670</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_1df93f62-fd98-4a36-9551-396d44349b22"
      unitRef="U_shares">79470670</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_f5c221d6-6281-4d6d-9ca7-dd581925f367"
      unitRef="U_shares">53031978</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_ca2df803-55eb-489f-9bab-48ff38db069a"
      unitRef="U_shares">53031978</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_55d1a6fb-c2b6-440b-bb81-46d1949f8811"
      unitRef="U_USD">82000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_ca06bb3d-e525-4e5f-bfa5-0daf234e063a"
      unitRef="U_USD">56000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_bdf344a2-f7aa-4764-a0e2-6a1ff2735089"
      unitRef="U_USD">1476018000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_52e5bbad-fe7d-4220-9e51-5852eb99d916"
      unitRef="U_USD">582844000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_80ee7b50-3dfe-4024-bbcd-821733d7d159"
      unitRef="U_USD">-361000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_4b1d494f-c761-442f-88ca-dae1de577f9a"
      unitRef="U_USD">-241000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_4dcd7c64-6e10-4efa-bf8b-ac10f59b3258"
      unitRef="U_USD">-522126000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_b1b0d039-4dcd-42d7-ba47-816594e9a3d8"
      unitRef="U_USD">-298641000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_8d21f53e-48f3-4d69-96af-3fb9c13b1c90"
      unitRef="U_USD">953613000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_03b77302-7f8c-4e94-83f4-d8d8ea601fd4"
      unitRef="U_USD">284018000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_08a05d0a-b318-4f31-ac4b-dc4517a1003a"
      unitRef="U_USD">1006178000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_158efa55-1685-4d49-85bf-65a56b6c1c03"
      unitRef="U_USD">324337000</us-gaap:LiabilitiesAndStockholdersEquity>
    <pcvx:ResearchAndDevelopmentExpenseToRelatedParty
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_6c2383e5-f5a3-48b3-a7bb-d712ccad6a75"
      unitRef="U_USD">0</pcvx:ResearchAndDevelopmentExpenseToRelatedParty>
    <pcvx:ResearchAndDevelopmentExpenseToRelatedParty
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_be336aff-e828-4fb8-929b-c2da09d726de"
      unitRef="U_USD">2359000</pcvx:ResearchAndDevelopmentExpenseToRelatedParty>
    <pcvx:ResearchAndDevelopmentExpenseToRelatedParty
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_40e4ae67-4cdc-48aa-ac13-7a1c2c8f2e3c"
      unitRef="U_USD">1331000</pcvx:ResearchAndDevelopmentExpenseToRelatedParty>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_f8e93a83-3c57-4a97-b079-f0e3f21e4278"
      unitRef="U_USD">169451000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_62b493b2-8d85-4889-bcc8-0d01fc6a1d00"
      unitRef="U_USD">78411000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_130dd359-7367-4f52-941c-e007b39d74d1"
      unitRef="U_USD">73564000</us-gaap:ResearchAndDevelopmentExpense>
    <pcvx:AcquiredManufacturingRights
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_6e3ed987-0031-4f6a-b224-707e7f81ed86"
      unitRef="U_USD">22995000</pcvx:AcquiredManufacturingRights>
    <pcvx:AcquiredManufacturingRights
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_6882663e-cecc-44bd-8af6-5621bb8ee6e7"
      unitRef="U_USD">0</pcvx:AcquiredManufacturingRights>
    <pcvx:AcquiredManufacturingRights
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_f173401c-ac39-4683-bd48-cc6991fceafb"
      unitRef="U_USD">0</pcvx:AcquiredManufacturingRights>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_c66568e5-997c-422d-8522-33ba7582a023"
      unitRef="U_USD">39810000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_c7b62dc8-42c2-4e78-9c8b-0a279dc6ce1f"
      unitRef="U_USD">25259000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_04fb80cd-4c88-4208-87e0-77333dcd99cc"
      unitRef="U_USD">16017000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_ad45fb74-6bc3-43b7-89a5-939daa11abbd"
      unitRef="U_USD">232256000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_2a192afe-d8dc-40b0-a5d8-fda2fbcf2464"
      unitRef="U_USD">103670000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_81755ac9-6433-49b5-a7b1-8102ead96960"
      unitRef="U_USD">89581000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_aa9f3937-c15c-4795-aa31-86b6f0a48aa0"
      unitRef="U_USD">-232256000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_1e158a35-fd46-4cc4-b799-c35fed4df6a8"
      unitRef="U_USD">-103670000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_9ad982ac-befe-4ef4-a1d4-04dff3cd7191"
      unitRef="U_USD">-89581000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_83be0c97-457b-49a8-9538-788f4c7b9d19"
      unitRef="U_USD">2000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_8a7ad823-dff2-4579-a5c8-fd2080a5a969"
      unitRef="U_USD">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_ad031f63-f9df-4b7e-b72b-4e080bc93221"
      unitRef="U_USD">7000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_af2e62c0-ed37-4d66-9e5f-19057a39cfe4"
      unitRef="U_USD">8356000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_cb757ee7-da7e-4f15-8d88-74369037e1ba"
      unitRef="U_USD">344000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_ba4acf8c-2ac5-4251-8544-76fc4cfc46d5"
      unitRef="U_USD">244000</us-gaap:InvestmentIncomeInterest>
    <pcvx:GrantIncome
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_406f17af-c893-44a7-ad6c-7fca5ebfb830"
      unitRef="U_USD">1931000</pcvx:GrantIncome>
    <pcvx:GrantIncome
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_d6832a7b-afdc-4b60-a007-2b0cc6e101ee"
      unitRef="U_USD">1585000</pcvx:GrantIncome>
    <pcvx:GrantIncome
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_c7b3cb2d-ee53-4022-b7af-b59fb4512355"
      unitRef="U_USD">2478000</pcvx:GrantIncome>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_66522696-3ad6-45db-98cb-928cac984e85"
      unitRef="U_USD">0</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_e825f5a4-1e60-4d43-82cf-2cdf5c32e40c"
      unitRef="U_USD">2000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_a4bd2ff3-1d7e-4874-8663-77a2b13720a0"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_a6161766-2052-42bf-9078-71e8100090a1"
      unitRef="U_USD">-44000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_66d7bd1a-fcb0-41da-89bb-a38d0d05623a"
      unitRef="U_USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_ceccbab3-b344-40bf-afe0-da6d2b050c7d"
      unitRef="U_USD">-0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_d7374387-dc9d-4aea-a9aa-3a3d6c28cb77"
      unitRef="U_USD">-1470000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_372df499-b391-4b5d-b627-ddfa99c4597c"
      unitRef="U_USD">1669000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_c5d7ada6-1916-403d-9f98-81ead3c87407"
      unitRef="U_USD">-2351000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_09175632-c319-4b85-a5ff-90c18f8a63bc"
      unitRef="U_USD">8771000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_c1794dab-9d5b-4a62-8235-7bad62eb31d6"
      unitRef="U_USD">3593000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_0bb3329e-be9e-4057-a625-8b63542a0b48"
      unitRef="U_USD">364000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_68dba904-ec9d-41b9-8fd6-ee9cff7a95c5"
      unitRef="U_USD">-223485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_c41e17e3-7c53-44e5-8b48-d38c3bf1722d"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_81931250-e3de-49fd-acc1-5daa37d197b5"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="2"
      id="F_a1c5c049-3ab9-478b-b0c7-d07d09ef02ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="2"
      id="F_e451d592-58d2-4eda-9384-5bd2cbde958c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="2"
      id="F_c6d32f73-c4f4-478a-a011-d01c4cfd271f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="2"
      id="F_1bc70f62-dc8c-48f8-8863-9957b992d53a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="2"
      id="F_32c227ef-04df-4c5e-bcb2-b471d9ea137d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="2"
      id="F_85e020fd-145d-44e9-bf40-adce349d761b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_49868336-755e-4fa2-82c7-a3c1e2530339"
      unitRef="U_shares">64877988</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_57b54ca1-15b4-4dca-83f9-d179a70f09e1"
      unitRef="U_shares">64877988</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="0"
      id="F_306c5895-0675-4cf1-b0dd-09324afc7a15"
      unitRef="U_shares">51922108</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="0"
      id="F_d9895fac-ef57-494c-bec1-7f32475845de"
      unitRef="U_shares">51922108</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="0"
      id="F_20547c0a-3b0b-4e4d-bec1-dd71dd7d20fc"
      unitRef="U_shares">29545810</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="0"
      id="F_de87fcc7-b608-4543-ac41-a6ff49ab2ef3"
      unitRef="U_shares">29545810</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_3799367b-7e64-4cc9-8e7a-950e1225f700"
      unitRef="U_USD">-223485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_3d1f9978-ff66-4d31-a89d-92e881092062"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_b6dd1b5e-0add-477d-8253-530e225dc328"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_0423ed92-0b35-47f0-8686-0c3d25535e74"
      unitRef="U_USD">-120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_7ede360e-d91c-4e6a-9ac2-d68d2ebd5bbc"
      unitRef="U_USD">-241000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_4bbdf84b-a0a0-459d-b759-f9d4504b4b9e"
      unitRef="U_USD">-223605000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_a91cd4b4-3d63-4ec1-82ae-4adb28a81175"
      unitRef="U_USD">-100318000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_d4f88117-e030-4a38-a881-c4c3980d23d2"
      unitRef="U_USD">-89217000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_bc63e8f2-1888-4fcd-a8d4-a880d9bb2f86"
      decimals="INF"
      id="F_67fbe40d-c0d4-4f43-b97d-c1f0d0a7491f"
      unitRef="U_shares">6225719</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_bc63e8f2-1888-4fcd-a8d4-a880d9bb2f86"
      decimals="-3"
      id="F_b925bdcc-cfd5-421e-b2ee-f5fef860028f"
      unitRef="U_USD">24967000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_b29a7753-469a-481c-993c-8a5ee73c666c"
      decimals="INF"
      id="F_6ea7cea1-43ab-4ea9-8f15-cfdeb13f6993"
      unitRef="U_shares">6786896</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_b29a7753-469a-481c-993c-8a5ee73c666c"
      decimals="-3"
      id="F_dc851ab0-77bf-4a18-b0d9-3969164d62c8"
      unitRef="U_USD">55151000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_6d40cfd0-136e-4c2d-a988-0b2942394d6c"
      decimals="INF"
      id="F_7da602e6-f905-41fc-b130-87bfef343e9e"
      unitRef="U_shares">7377480</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_6d40cfd0-136e-4c2d-a988-0b2942394d6c"
      decimals="-3"
      id="F_081c027b-b51b-4c18-b30d-7aa422930335"
      unitRef="U_USD">80192000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_f071a04d-8d88-4c59-91cc-56470ac8c360"
      decimals="INF"
      id="F_1e661461-4172-4f58-a8d8-fd37eca67a06"
      unitRef="U_shares">4059909</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_f071a04d-8d88-4c59-91cc-56470ac8c360"
      decimals="-3"
      id="F_47b77ef4-cd75-4722-af0f-7b21bfe4d675"
      unitRef="U_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d7812bcb-1a97-4787-be8b-59a98d64a890"
      decimals="-3"
      id="F_a4666174-3259-43e2-8a7e-5bbf40734153"
      unitRef="U_USD">2967000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bf009615-d1f6-4a3a-935f-7b0d3b6dca01"
      decimals="-3"
      id="F_d4575d72-bac3-4822-81f1-fef1c4a214f6"
      unitRef="U_USD">-109347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0"
      decimals="-3"
      id="F_f3f6009b-eebe-4b2e-b931-0c8f130a6f2c"
      unitRef="U_USD">-106373000</us-gaap:StockholdersEquity>
    <pcvx:TemporaryEquityStockIssuanceCosts
      contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67"
      decimals="-3"
      id="F_320bc716-9f9b-435c-b27e-8168431c7626"
      unitRef="U_USD">121000</pcvx:TemporaryEquityStockIssuanceCosts>
    <pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67"
      decimals="INF"
      id="F_f139cfd1-2b39-4489-a299-7108bba1a130"
      unitRef="U_shares">8220242</pcvx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67"
      decimals="-3"
      id="F_5f4b57b5-4f04-44c6-906e-58f27519ce92"
      unitRef="U_USD">109879000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <pcvx:TemporaryEquityConversionOfPreferredStockShares
      contextRef="C_da57a27c-5363-490e-93b7-2f25eccde933"
      decimals="INF"
      id="F_b7608426-6043-447a-87e5-cff070b26ea5"
      unitRef="U_shares">-6225719</pcvx:TemporaryEquityConversionOfPreferredStockShares>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_da57a27c-5363-490e-93b7-2f25eccde933"
      decimals="-3"
      id="F_177f74b5-a8f3-4b72-8ab5-8ab8bc157e67"
      unitRef="U_USD">-24967000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockShares
      contextRef="C_cffd01a3-53b4-4cbf-9aef-3e5b1f46b78f"
      decimals="INF"
      id="F_4253dc6e-7fac-423f-bf5d-ff1f9942082f"
      unitRef="U_shares">-6786896</pcvx:TemporaryEquityConversionOfPreferredStockShares>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_cffd01a3-53b4-4cbf-9aef-3e5b1f46b78f"
      decimals="-3"
      id="F_7bfc5d23-f2f9-4ce5-9f1d-f65bbf914bb3"
      unitRef="U_USD">-55151000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockShares
      contextRef="C_8a1db5ca-4032-454e-b64f-84afc6e86567"
      decimals="INF"
      id="F_aca64a5a-8578-4239-ab3c-3789722f5ee8"
      unitRef="U_shares">-7377480</pcvx:TemporaryEquityConversionOfPreferredStockShares>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_8a1db5ca-4032-454e-b64f-84afc6e86567"
      decimals="-3"
      id="F_4fd6f41a-6566-4ed6-9298-16ed24be3c32"
      unitRef="U_USD">-80192000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockShares
      contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67"
      decimals="INF"
      id="F_cf474531-d56c-43e0-bc9b-5507c0b2dd55"
      unitRef="U_shares">-8220242</pcvx:TemporaryEquityConversionOfPreferredStockShares>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_45c64528-2381-42d2-9b60-787dd273ce67"
      decimals="-3"
      id="F_47fde73c-fc68-4f26-9865-a0b6eaa0a619"
      unitRef="U_USD">-109879000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880"
      decimals="INF"
      id="F_535d2f59-907c-4853-bb6e-d52f759b86d3"
      unitRef="U_shares">28610337</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880"
      decimals="-3"
      id="F_2a8919ed-4853-4468-afd1-44f807501e3f"
      unitRef="U_USD">29000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94"
      decimals="-3"
      id="F_1a78e883-ed43-4b02-9f65-302379099893"
      unitRef="U_USD">270161000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:TemporaryEquityConversionOfPreferredStockValue
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_f32d5f84-8f87-4078-bd20-c11f643413e8"
      unitRef="U_USD">270190000</pcvx:TemporaryEquityConversionOfPreferredStockValue>
    <pcvx:StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant
      contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880"
      decimals="INF"
      id="F_0e1573d5-f900-46bb-a791-fdb7a03545e9"
      unitRef="U_shares">30278</pcvx:StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant>
    <pcvx:StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant
      contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880"
      decimals="INF"
      id="F_15079ef8-7218-4436-acdc-f909b1abab50"
      unitRef="U_shares">16591</pcvx:StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff
      contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94"
      decimals="-3"
      id="F_5e1be6d3-2221-4bca-890c-9e543a7d28cf"
      unitRef="U_USD">629000</pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_fadfdefd-5ef2-448b-a99c-d825a01ff43e"
      unitRef="U_USD">629000</pcvx:AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_99bb839f-a7de-4946-a60c-d6f300ec4d73"
      decimals="-3"
      id="F_fdc69d8d-69a3-4fea-bc28-fa1af2a0cbc6"
      unitRef="U_USD">3368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_99bb839f-a7de-4946-a60c-d6f300ec4d73"
      decimals="INF"
      id="F_e2b90de4-378a-48d6-a9aa-4a4480ab7dcd"
      unitRef="U_shares">17968750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_99bb839f-a7de-4946-a60c-d6f300ec4d73"
      decimals="-3"
      id="F_fe610f39-f1ab-476d-ae00-caf5b53f6fcc"
      unitRef="U_USD">18000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_522586e0-c2a8-4187-8dfd-3a928a099df2"
      decimals="-3"
      id="F_c38ff7e3-7fdf-4511-ae51-f9d6da8d72b1"
      unitRef="U_USD">263989000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_5bd93f84-0823-4e85-90fb-5d8d73cfbaf2"
      unitRef="U_USD">264007000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880"
      decimals="INF"
      id="F_61685653-6730-44e0-9874-7c48fd18a0f4"
      unitRef="U_shares">343444</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94"
      decimals="-3"
      id="F_5a1ca8ce-8227-4527-be1f-8cb458e2af90"
      unitRef="U_USD">635000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_83c0ac52-4797-4304-924d-3f9217b6d7c9"
      unitRef="U_USD">635000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
      contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880"
      decimals="INF"
      id="F_ee209d3f-167a-4399-ab11-6eabe860a137"
      unitRef="U_shares">14819</pcvx:StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_9ab5ad16-c7b9-4e59-aa40-d4f6c4850880"
      decimals="INF"
      id="F_52daaa4d-a041-4783-ad65-c2f76b73fe21"
      unitRef="U_shares">27465</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94"
      decimals="-3"
      id="F_76563054-0c5a-44d9-8c01-d3955301776b"
      unitRef="U_USD">374000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_0a904caf-45d8-44c7-a564-12800c394e2c"
      unitRef="U_USD">374000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94"
      decimals="-3"
      id="F_10905fed-e9a0-40a2-8312-58ac336a16f7"
      unitRef="U_USD">164000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_40cd216c-9441-473a-a38a-15cf1b69b98f"
      unitRef="U_USD">164000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_a36c4830-4b5f-44a3-8402-0567ef69ef94"
      decimals="-3"
      id="F_722da82a-c237-435c-b15d-55d62a633cb4"
      unitRef="U_USD">5434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_ce9f5dcc-8606-43d3-8592-bf4a2005477a"
      unitRef="U_USD">5434000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_8c77accc-7d52-4157-8c4c-e2e27e2e2b05"
      decimals="-3"
      id="F_6ad82e38-5908-4425-a4eb-b85178ef9864"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_2e0c4f4b-20ab-45c0-8fc6-1451f8c48614"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_b71d1ae0-0191-4fcc-9eb1-6928e92a2341"
      decimals="INF"
      id="F_c7883c50-5176-4f40-858f-1727f5223757"
      unitRef="U_shares">51071593</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b71d1ae0-0191-4fcc-9eb1-6928e92a2341"
      decimals="-3"
      id="F_7dfbe6ea-ec56-41a3-8337-0584a48c9826"
      unitRef="U_USD">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2a97fce7-5ef2-4cc8-85f5-b620ca762566"
      decimals="-3"
      id="F_029133b6-8f7a-4bbf-8678-145a90ebe250"
      unitRef="U_USD">544353000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7a8dc7cf-7734-4350-9266-07d83e2f4a3a"
      decimals="-3"
      id="F_ca9be74c-5346-4fe1-a5c0-1663ec04a2ea"
      unitRef="U_USD">-198564000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93"
      decimals="-3"
      id="F_359db087-db8f-41fd-912e-0f8ecb8a30e8"
      unitRef="U_USD">345843000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_85dd075c-01fc-4937-bc97-63808bb2e3a9"
      decimals="INF"
      id="F_b978a96b-2db4-4036-a952-cd11aab73e16"
      unitRef="U_shares">931114</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907"
      decimals="-3"
      id="F_113b6adb-8ffb-46bb-939f-14ca75547b6b"
      unitRef="U_USD">3012000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_48a0933c-cfe7-4b7f-b8cf-23169a1349c9"
      unitRef="U_USD">3012000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_85dd075c-01fc-4937-bc97-63808bb2e3a9"
      decimals="INF"
      id="F_8b26eeee-8265-4270-8d2f-0fd0e06bb3b8"
      unitRef="U_shares">399680</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_85dd075c-01fc-4937-bc97-63808bb2e3a9"
      decimals="-3"
      id="F_f54c7ebe-321c-48d9-8c45-63d5d1dad556"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907"
      decimals="-3"
      id="F_aa6a0c30-b682-40a3-bbd2-21cc024cfd7a"
      unitRef="U_USD">10000000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_ea7c3f0c-fe17-467c-8ace-efdd43649089"
      unitRef="U_USD">10001000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_9a4f0832-de96-4079-b3c1-db1efe6e81b7"
      decimals="-3"
      id="F_009e999b-1b6d-4dd3-9425-66a39fbeb7f0"
      unitRef="U_USD">479000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d4156e2c-f054-42e7-a026-6dd2300deca6"
      decimals="INF"
      id="F_06d5d8be-0909-4abf-852f-4e616c77e694"
      unitRef="U_shares">567045</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_d4156e2c-f054-42e7-a026-6dd2300deca6"
      decimals="-3"
      id="F_2626d74c-fe93-4601-ad65-12972dcb6a0b"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_93ae0419-91bb-4c85-9618-57fe0afc3264"
      decimals="-3"
      id="F_2b8af938-ccbd-4490-99db-b1e2d659c8a5"
      unitRef="U_USD">13846000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_1464529a-8198-4a4d-a31e-c68f026debc5"
      unitRef="U_USD">13847000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_85dd075c-01fc-4937-bc97-63808bb2e3a9"
      decimals="INF"
      id="F_6341a2e2-3fd8-48e3-8200-3244225e5b67"
      unitRef="U_shares">62546</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907"
      decimals="-3"
      id="F_3e9cbeeb-0f24-46a3-b83a-41e2653a7ba3"
      unitRef="U_USD">888000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_4dcfdb3d-a332-4740-9665-4b545852c4f2"
      unitRef="U_USD">888000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907"
      decimals="-3"
      id="F_34c3e62c-575d-4fcf-8145-32b46958dcfc"
      unitRef="U_USD">16000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_ed1d581a-3ee5-4b80-8abd-97d51252f272"
      unitRef="U_USD">16000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_de1ae5ac-cf11-43e1-b55b-ba09780a9907"
      decimals="-3"
      id="F_24024dfe-d973-4c5a-b333-890a8e05bb99"
      unitRef="U_USD">10729000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_23883c2a-0143-418b-a781-8e482719019d"
      unitRef="U_USD">10729000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_7b1a0eec-bf5e-4892-9967-715b22960941"
      decimals="-3"
      id="F_ea20e012-d63a-45cc-800a-560e161d120d"
      unitRef="U_USD">-241000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_15aca712-0eef-475e-a2ab-e5f621c39631"
      unitRef="U_USD">-241000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_5cae38a4-c4a8-47aa-a3e3-61aaee5e44b7"
      decimals="-3"
      id="F_9f8b964f-ba7e-40c7-8182-7e5c7b8cd6da"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_d5c393d1-4a74-4967-a530-72829b9cbb2d"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_16916817-1032-4d1c-9ab3-a2e5e372cb09"
      decimals="INF"
      id="F_5f1aa446-93d5-413b-a7fb-6dcfd77ad001"
      unitRef="U_shares">53031978</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_16916817-1032-4d1c-9ab3-a2e5e372cb09"
      decimals="-3"
      id="F_5ef47724-2cc5-4205-b692-d9a36cd236bd"
      unitRef="U_USD">56000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ebe97179-a864-486e-a92b-54ddbdfb9b14"
      decimals="-3"
      id="F_6cc7bfc0-cab5-4301-a4bb-9af157e5d368"
      unitRef="U_USD">582844000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6c850b73-588c-41c3-b04b-a21bc0ff9e82"
      decimals="-3"
      id="F_70d4db57-469e-44dc-8c74-83e02c4c92d0"
      unitRef="U_USD">-298641000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_202f07f9-5156-457e-9195-d19a2910d156"
      decimals="-3"
      id="F_20d494ce-095e-48c7-87df-e416254c5e2b"
      unitRef="U_USD">-241000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_6486285d-0b36-4fa5-8d14-9ccd5794673d"
      unitRef="U_USD">284018000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02"
      decimals="INF"
      id="F_45b2065f-36f5-4198-a04d-57e12f099b5c"
      unitRef="U_shares">1178572</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02"
      decimals="-3"
      id="F_41d81a71-d879-481e-b7ac-059b6b073167"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091"
      decimals="-3"
      id="F_71035458-904c-4121-82ac-575ee585182a"
      unitRef="U_USD">4894000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_b5004420-acdf-4785-a165-06694c5b236a"
      unitRef="U_USD">4895000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_def7f49a-3fdf-4d73-bc99-4174a1a743a3"
      unitRef="U_USD">45814000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02"
      decimals="INF"
      id="F_4ca62c3c-35da-4e1e-82f2-6736615f3b5f"
      unitRef="U_shares">21062500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02"
      decimals="-3"
      id="F_aabfe90e-3a26-44ea-a792-dbab931bafea"
      unitRef="U_USD">21000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091"
      decimals="-3"
      id="F_310ebc17-4792-42b3-affc-d013677ecc02"
      unitRef="U_USD">759160000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_f35b2743-8c5e-4d18-bf8b-35745f6185f6"
      unitRef="U_USD">759181000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_fffa34b2-595e-4a00-a483-b9a4cb5243ce"
      decimals="-3"
      id="F_26c35c29-6845-4966-ab63-c5f328a9392b"
      unitRef="U_USD">3107000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_42dcecda-101e-4ddd-8695-6548e530de78"
      decimals="INF"
      id="F_f4e2d01d-119c-43bc-8986-06839549f81d"
      unitRef="U_shares">3921528</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_42dcecda-101e-4ddd-8695-6548e530de78"
      decimals="-3"
      id="F_93b1a38d-e1bf-4327-8ce8-15e3449cbde2"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_837815d3-4f60-4133-8174-f837af239d75"
      decimals="-3"
      id="F_e02d7a74-0a8d-40d3-8fde-c54b781d44a9"
      unitRef="U_USD">97295000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_2fdff316-147b-4b2b-bcfe-6871447ed8e0"
      decimals="-3"
      id="F_23f43847-ed95-416e-bea9-d2ee8c345173"
      unitRef="U_USD">97299000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_86059fb6-8a98-4604-99c1-7846fc457e76"
      decimals="0"
      id="F_250cce00-e1cd-43ab-86f9-b74f7163e037"
      unitRef="U_shares">167780</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ad2a30c9-052d-4eba-928a-c4c5ab6c20db"
      decimals="-3"
      id="F_544acc7b-ad9d-4cb4-a408-03f016799403"
      unitRef="U_USD">7995000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_75637c01-f692-4f45-a633-9d4eb7b8df37"
      decimals="-3"
      id="F_4a0defea-5413-4527-94d0-35fa8c13d906"
      unitRef="U_USD">7995000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02"
      decimals="INF"
      id="F_e4829463-5bb7-4b9f-9278-c74b7dd04909"
      unitRef="U_shares">61709</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091"
      decimals="-3"
      id="F_942b8c03-8d75-4af6-adc2-53ea578044d2"
      unitRef="U_USD">1033000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_319fdcd6-0567-4cfe-8a32-da468bfb3975"
      unitRef="U_USD">1033000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pcvx:ReleaseOfRestrictedStockUnitsShares
      contextRef="C_2e350f80-8b0a-485c-813b-204158cbec02"
      decimals="0"
      id="F_0baccd7d-cf20-49ce-bfed-6de0c107afad"
      unitRef="U_shares">46603</pcvx:ReleaseOfRestrictedStockUnitsShares>
    <pcvx:ReleaseOfRestrictedStockUnitsValue
      contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091"
      decimals="-3"
      id="F_9850ea6b-f9c6-42d2-859f-6358a3737c5b"
      unitRef="U_USD">861000</pcvx:ReleaseOfRestrictedStockUnitsValue>
    <pcvx:ReleaseOfRestrictedStockUnitsValue
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_a3606ebe-5dfb-4022-8817-6f374f56594c"
      unitRef="U_USD">861000</pcvx:ReleaseOfRestrictedStockUnitsValue>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091"
      decimals="-3"
      id="F_42edfa41-da36-4876-bdc6-ee0914e654fc"
      unitRef="U_USD">8000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_60c7455b-7a15-45cc-b3ab-80206476479d"
      unitRef="U_USD">8000</pcvx:AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7ba9d2ec-b087-4923-ab0f-85c0108cb091"
      decimals="-3"
      id="F_4b03eeb3-c53d-4a3f-8f0d-a91399859337"
      unitRef="U_USD">23650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_b58f9ada-c55e-499b-a218-e1014aaf5621"
      unitRef="U_USD">23650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_06c078e9-1e6f-4493-a040-ad253c029b6b"
      decimals="-3"
      id="F_af64ab32-a069-4ea2-b382-4a48a3e3649b"
      unitRef="U_USD">-120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_57b83a5b-2e82-4019-9db5-56e6a6fe9a7f"
      unitRef="U_USD">-120000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_3a1f2bbd-3a84-4def-8008-4279ed957a96"
      decimals="-3"
      id="F_079462a1-8d32-4a1f-98c0-d1cb55fe7836"
      unitRef="U_USD">-223485000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_17a25db7-ca2d-4c0e-ad30-e031d4658f29"
      unitRef="U_USD">-223485000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_81569ea5-c187-4394-8eea-071974a031f5"
      decimals="INF"
      id="F_5fb06e5b-a452-4afb-8c21-4c7d626886b3"
      unitRef="U_shares">79470670</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_81569ea5-c187-4394-8eea-071974a031f5"
      decimals="-3"
      id="F_bdfb6e78-5995-4b49-9987-5f0a767dce25"
      unitRef="U_USD">82000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cc891ca2-75ea-4415-b513-14e4b37dc9b4"
      decimals="-3"
      id="F_a3113a62-e32f-43d2-8d15-ae3391f70575"
      unitRef="U_USD">1476018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_13165d69-2eff-4eec-af08-7f5b5519d9b9"
      decimals="-3"
      id="F_de4bdc3e-b938-43ef-95db-ac30e112e51f"
      unitRef="U_USD">-522126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c3d2b846-b46a-4469-a0a3-586d1c69fc46"
      decimals="-3"
      id="F_0cd83a76-c93c-413a-94a1-18d537de785a"
      unitRef="U_USD">-361000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_0a8c5890-c314-4b04-9141-5f418a12609a"
      unitRef="U_USD">953613000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_3dcedfc2-2a69-4b07-b478-3bd23f56b03d"
      unitRef="U_USD">-223485000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_aada342e-f761-4a21-8bd3-50a77fbe894c"
      unitRef="U_USD">-100077000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_8eba5bb4-94b5-4e4f-b6a1-aae099852c5c"
      unitRef="U_USD">-89217000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_caeaae05-a106-4bfc-a10e-05842fd04368"
      unitRef="U_USD">2577000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_757c1b89-e315-4827-a5f1-3ff6238d56f5"
      unitRef="U_USD">1800000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_303bc1cc-1d41-4182-af23-994a13e4ce11"
      unitRef="U_USD">1405000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_1bf2bfcb-bac2-4766-89d6-de01c658af03"
      unitRef="U_USD">23650000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_403e4e49-247e-41d0-a140-731c3db2578b"
      unitRef="U_USD">10729000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_1fdd2c87-4df2-4ed3-8b09-01037e005a85"
      unitRef="U_USD">5434000</us-gaap:ShareBasedCompensation>
    <pcvx:NonCashPaymentsForAcquireManufacturingRights
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_bfd28b4d-accd-459b-aa4c-5965823904db"
      unitRef="U_USD">7995000</pcvx:NonCashPaymentsForAcquireManufacturingRights>
    <pcvx:NonCashPaymentsForAcquireManufacturingRights
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_0f88f910-4712-4b4b-8201-2ed78580d560"
      unitRef="U_USD">0</pcvx:NonCashPaymentsForAcquireManufacturingRights>
    <pcvx:NonCashPaymentsForAcquireManufacturingRights
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_a26ef032-b5f5-41b1-a9c5-0393578b1af1"
      unitRef="U_USD">0</pcvx:NonCashPaymentsForAcquireManufacturingRights>
    <pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_1d4931ef-fc20-4b5e-adf3-d98cea815473"
      unitRef="U_USD">0</pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities>
    <pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_129d51a1-2389-42b8-91bc-a39d3d7aee8a"
      unitRef="U_USD">0</pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities>
    <pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_be7cf5a0-b8d9-4820-8129-a2b148bed1a8"
      unitRef="U_USD">-179000</pcvx:ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_e8bb3fc9-1848-4c53-bcad-0cdf031a2539"
      unitRef="U_USD">-44000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_7b45f0c8-2e56-4c05-9a5d-1b6b97c8111d"
      unitRef="U_USD">-97000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_a158327b-10c7-4ab5-a758-451e23202f4f"
      unitRef="U_USD">-34000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_f50ab101-0e41-461f-b89f-00584c4077a1"
      unitRef="U_USD">213000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_2cae7704-cdf6-428b-bc6e-322c14693d2f"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_ff2f06f8-40e2-4c44-9154-11b377f5df1b"
      unitRef="U_USD">267000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_4c79bc36-577e-4de9-85c7-c40ccb728fdb"
      unitRef="U_USD">6619000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_ab28a9ca-2ea3-47fb-88eb-bd3ab30b120a"
      unitRef="U_USD">1657000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_d2bddc0c-cfe9-4193-ac15-e6400d0be8b4"
      unitRef="U_USD">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_77f35ba0-f29b-4173-8dbc-25614b8662d8"
      unitRef="U_USD">947000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_df90b4c7-6e21-49a6-ad75-bd0b41433a81"
      unitRef="U_USD">-1406000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_710bf287-5df6-48bc-acb7-84b77711504d"
      unitRef="U_USD">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_07f4828c-2f29-48ae-9a8e-13fcc2fbf64f"
      unitRef="U_USD">-433000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_7ce0a108-a054-4720-b80d-3267f5b217a5"
      unitRef="U_USD">7369000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_478039e7-5bb3-4b2c-82f7-37daf9f1390a"
      unitRef="U_USD">58000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_9e27b0b2-dbc9-4418-ac29-6ad889d4cfa2"
      unitRef="U_USD">465000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_22503bd3-79a8-4daf-9118-764f69e2ce05"
      unitRef="U_USD">3539000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_08c0f8c8-15d9-4627-88a6-f2f46f948874"
      unitRef="U_USD">75000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <pcvx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_9b803246-efe9-447c-b132-a9b1e543e736"
      unitRef="U_USD">-1151000</pcvx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <pcvx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_893123ac-4b56-41c8-a721-4bad0fe1fe18"
      unitRef="U_USD">12856000</pcvx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <pcvx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_43fbffe3-24b3-4ecf-a68a-bd01da583583"
      unitRef="U_USD">0</pcvx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_ded44c63-7760-4ecc-b9fa-3bb689d5281e"
      unitRef="U_USD">2896000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_83d0e322-73cb-43e1-9498-d08bfc43d9c2"
      unitRef="U_USD">-12470000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_2726f8ec-4f34-4212-8254-3f0a7648fe68"
      unitRef="U_USD">26102000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <pcvx:IncreaseDecreaseInAccruedCompensation
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_612381c1-b3f6-404c-b4a1-8ee4cd0bbb47"
      unitRef="U_USD">-2275000</pcvx:IncreaseDecreaseInAccruedCompensation>
    <pcvx:IncreaseDecreaseInAccruedCompensation
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_46edb2de-e45c-42e0-819a-1cfd20d98e0b"
      unitRef="U_USD">3170000</pcvx:IncreaseDecreaseInAccruedCompensation>
    <pcvx:IncreaseDecreaseInAccruedCompensation
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_aa92d0ed-4f8e-4ae9-a3ae-8018ddf5de0e"
      unitRef="U_USD">-130000</pcvx:IncreaseDecreaseInAccruedCompensation>
    <pcvx:IncreaseDecreaseInAccruedManufacturingExpenses
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_9127dd33-f8c2-44d2-8380-e42a4d40a598"
      unitRef="U_USD">3826000</pcvx:IncreaseDecreaseInAccruedManufacturingExpenses>
    <pcvx:IncreaseDecreaseInAccruedManufacturingExpenses
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_d9975000-81de-4c5e-b471-b318d884801d"
      unitRef="U_USD">-8572000</pcvx:IncreaseDecreaseInAccruedManufacturingExpenses>
    <pcvx:IncreaseDecreaseInAccruedManufacturingExpenses
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_08d070a7-5eb4-4a34-90ca-8cace19a255d"
      unitRef="U_USD">7235000</pcvx:IncreaseDecreaseInAccruedManufacturingExpenses>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_6ace06f6-257d-47d1-911e-ff5304006930"
      unitRef="U_USD">7171000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_06c5fb52-9fff-47c8-b4c2-0f0938dc927c"
      unitRef="U_USD">4631000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_15b51e72-1d97-44a5-96fe-cec57734f7ae"
      unitRef="U_USD">2207000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_4b71bff2-b68a-4cfe-9841-b0358d238e1a"
      unitRef="U_USD">0</pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities>
    <pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_ca49a07f-c9f4-4797-bd0b-9834c93e44f5"
      unitRef="U_USD">0</pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities>
    <pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_b95f8c92-4e4c-45cf-b1c8-a1904a136067"
      unitRef="U_USD">-11000</pcvx:IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_8fa9c554-e8f0-48b6-b8ad-d43de341e5d9"
      unitRef="U_USD">-170597000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_8365b7e0-12d9-4c18-82c4-2ca7760d6734"
      unitRef="U_USD">-121393000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_ee1b7751-c989-48f1-92e1-58bcc6d32089"
      unitRef="U_USD">-46628000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_264252f0-a9af-4349-844a-8bbb45ff4cbf"
      unitRef="U_USD">5848000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_fbe3651d-aab8-4f8e-ab1b-81ab6c565224"
      unitRef="U_USD">6555000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_cbb34bb2-ecc3-4a52-8982-115b6fa904b7"
      unitRef="U_USD">1155000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_97e9d523-18e8-463c-9556-35b15bbea960"
      unitRef="U_USD">102745000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_f50a8ab9-68d0-4d5a-9e3b-baee7b7a924d"
      unitRef="U_USD">336341000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_a3bb07ba-7f76-4f5c-a7e2-3acb35bfdb99"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_3e5ee21b-5a79-4376-9963-b05333a86359"
      unitRef="U_USD">168691000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_5eb2fa0c-0220-41fc-a99b-daaa43117326"
      unitRef="U_USD">100500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_e07043d2-e77f-4e34-8bbc-4ae6eb8822c6"
      unitRef="U_USD">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_1b21876e-e7c8-40b9-94c4-8fad4151b924"
      unitRef="U_USD">14480000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_19a63232-2e00-41bf-ad88-2f115e2bc28f"
      unitRef="U_USD">30062000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_1fef60ab-032c-47db-820d-90be42a3f9ec"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_78d84b37-462b-4960-91f3-892615396043"
      unitRef="U_USD">7000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_eca913a3-a7c1-4388-89c1-37e78caeb7df"
      unitRef="U_USD">26000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_5de17821-db47-4703-8ade-584a472cef36"
      unitRef="U_USD">50000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_64f57ac7-e42b-49a4-8b92-0fc58c0f216d"
      unitRef="U_USD">74585000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_7208331c-9f0c-415c-bb5b-20df3d78e62f"
      unitRef="U_USD">-212308000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_cc183c0e-3eb4-450e-83f4-f1e39bf0703f"
      unitRef="U_USD">-1105000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <pcvx:PaymentsOfCapitalLeaseObligations
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_9fa2d565-e920-4498-8e32-b2bb4feaec7a"
      unitRef="U_USD">0</pcvx:PaymentsOfCapitalLeaseObligations>
    <pcvx:PaymentsOfCapitalLeaseObligations
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_79133583-1d35-4299-b0e6-d473f4fb302f"
      unitRef="U_USD">0</pcvx:PaymentsOfCapitalLeaseObligations>
    <pcvx:PaymentsOfCapitalLeaseObligations
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_df6fdc89-9d21-49fe-a761-649762680dc6"
      unitRef="U_USD">61000</pcvx:PaymentsOfCapitalLeaseObligations>
    <pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_a1491197-fcc6-4a55-a4d4-8d2baa9bd56a"
      unitRef="U_USD">0</pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts>
    <pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_8597c16b-be57-4b3c-a19a-62c74d2d9e6a"
      unitRef="U_USD">0</pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts>
    <pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_4f02bbec-e07f-4702-86e6-34f55c5a4882"
      unitRef="U_USD">264007000</pcvx:ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts>
    <pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_06e13a12-ca62-4769-a73f-316bcfe50d1f"
      unitRef="U_USD">759181000</pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts>
    <pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_c44ebcff-a5c4-42b6-a903-c3ebc23f9359"
      unitRef="U_USD">0</pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts>
    <pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_20f5198f-585a-4dd6-99da-de75bb1c65c3"
      unitRef="U_USD">0</pcvx:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_5a2df14e-2113-4dec-b076-306697f2c5cf"
      unitRef="U_USD">97299000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_6f516c8b-389b-4dce-90f0-4c48ac94e93f"
      unitRef="U_USD">13896000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_b1c26e74-597e-4252-ad3f-f4a66c4e051d"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_c3490014-fe42-40b7-bc4c-59627c052a20"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_32387656-1bb3-4593-b9ab-d048f7330ba4"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_184830d2-9e0c-4a42-9287-2352e48fed05"
      unitRef="U_USD">109879000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_3592e264-2c89-42fb-9aa4-683ca9e4f307"
      unitRef="U_USD">4895000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_3f907f3b-b796-409b-810e-98a1b1d68dc3"
      unitRef="U_USD">3012000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_3bceac9b-5cdf-4702-bc10-4208a11c4627"
      unitRef="U_USD">635000</us-gaap:ProceedsFromStockOptionsExercised>
    <pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_1798d7f5-47de-4cfd-96b9-4a7b581827dd"
      unitRef="U_USD">0</pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions>
    <pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_7a578baa-0d44-4ab8-9b8b-d9a27e08004d"
      unitRef="U_USD">0</pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions>
    <pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_8c61ffd5-d004-45c7-a082-75db61e122b8"
      unitRef="U_USD">36000</pcvx:ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_059a83ed-7bde-46b2-8f96-feb4e385c337"
      unitRef="U_USD">1033000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_7ef0c7e1-284b-4b31-86c1-a19e8ba9b059"
      unitRef="U_USD">888000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_826ae7d8-d2d0-42ed-a91b-2fdb6b8c3c5a"
      unitRef="U_USD">374000</us-gaap:ProceedsFromStockPlans>
    <pcvx:ReleaseOfRestrictedStockUnitsValue
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_3f789eb4-5ba2-455b-b29a-dc1b4c1b7d8d"
      unitRef="U_USD">861000</pcvx:ReleaseOfRestrictedStockUnitsValue>
    <pcvx:ReleaseOfRestrictedStockUnitsValue
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_7b95f252-3610-4244-a468-90fe7f36d704"
      unitRef="U_USD">0</pcvx:ReleaseOfRestrictedStockUnitsValue>
    <pcvx:ReleaseOfRestrictedStockUnitsValue
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_faba9920-adb7-4e7e-bea8-bd558882e1e2"
      unitRef="U_USD">0</pcvx:ReleaseOfRestrictedStockUnitsValue>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_84e2d772-fc34-4295-9754-b353f667f0d6"
      unitRef="U_USD">861547000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_bbc48410-ad94-4371-9e81-8e5e73175aa0"
      unitRef="U_USD">17796000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_0f7c77d7-8c3f-4a79-8423-6f3278115b07"
      unitRef="U_USD">374870000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_07eb7484-7694-4410-8d3b-35fcef6aaed6"
      unitRef="U_USD">137000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_515c3939-debf-4719-a1cb-f53812f27027"
      unitRef="U_USD">-439000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_bde5499a-cd2b-41b9-9475-6f3ea4db6b2c"
      unitRef="U_USD">87000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_c983c196-0330-480c-9194-326c9c2d570a"
      unitRef="U_USD">765672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_88ae5de6-8ad3-463a-8b8b-e508ac5bee88"
      unitRef="U_USD">-316344000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_61532eef-fe38-424a-9151-9a9102bc424a"
      unitRef="U_USD">327224000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_fddcf83f-450c-4c6c-9121-f10e8adecfd6"
      unitRef="U_USD">69856000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93"
      decimals="-3"
      id="F_bb8e2e4f-1df8-4406-9f85-25be8d6dd343"
      unitRef="U_USD">386200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0"
      decimals="-3"
      id="F_3d96e189-de81-4b26-b8a2-1320a3d6210a"
      unitRef="U_USD">58976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_f74f4632-980d-457f-85bd-51f0e50b77a2"
      unitRef="U_USD">835528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_891f9f8b-e53f-4aea-9300-b1537b878413"
      unitRef="U_USD">69856000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93"
      decimals="-3"
      id="F_cdff87b9-c0a3-4ec1-a0fe-561243e93608"
      unitRef="U_USD">386200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_258b758d-bcb3-4a2b-bfaa-acf1d8f434be"
      unitRef="U_USD">2000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_1e534ec7-4043-4b71-8c18-af2ae2d50380"
      unitRef="U_USD">7000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_1323dd04-eb54-4178-b9b2-bdbfda8a1caa"
      unitRef="U_USD">7000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_bf3254e1-ce26-4df4-a56b-7da93da16f7a"
      unitRef="U_USD">110000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_83816067-2367-4c31-8454-bff67fdf0fb8"
      unitRef="U_USD">766000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_9d0b0ef1-f0a1-454a-9693-91bfa13cad0d"
      unitRef="U_USD">494000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_28fa22e1-e2fd-4f5e-8286-70678661828c"
      unitRef="U_USD">7995000</pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights>
    <pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_deb38e5d-c5d6-454e-aa0b-2395ab89c56f"
      unitRef="U_USD">0</pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights>
    <pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_85917831-5bee-4665-a2d6-0f6d6b2c8d07"
      unitRef="U_USD">0</pcvx:IssuanceOfCommonStockForAcquiredManufacturingRights>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_993ac8fc-0cbc-4dcc-b8b2-654b8bb3b404"
      unitRef="U_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_49730542-3352-43cc-a71b-1af86ef9fbaa"
      unitRef="U_USD">0</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_6278cb4e-9632-49af-a145-3b1e3e8da102"
      unitRef="U_USD">270190000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssued1
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_5ba07a33-4680-471a-a877-7db9feeb04f8"
      unitRef="U_USD">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_2131a283-efc6-42b2-82f7-8d13ded8f0ca"
      unitRef="U_USD">10000000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_bb865b43-1013-4839-8961-311713d261c0"
      unitRef="U_USD">0</us-gaap:StockIssued1>
    <pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_f082096d-e6ca-42dd-b9f2-6fd7000a45d5"
      unitRef="U_USD">0</pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_2361e612-b38e-4ea9-8fb9-e28ac52c7123"
      unitRef="U_USD">0</pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_37545605-fd9b-4e8c-8b15-386dad6c31a4"
      unitRef="U_USD">134000</pcvx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_c534afc6-6dbb-4739-a94b-cca0dd790ec4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1. Company Organization and Nature of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vaxcyte, Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;the Company,&#x201d; or &#x201c;Vaxcyte&#x201d;), headquartered in San Carlos, California, was incorporated in the state of Delaware on November 27, 2013 as SutroVax, Inc. and we changed our name to Vaxcyte, Inc. on May 15, 2020. We are a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. ("Sutro Biopharma"). Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our primary activities since incorporation have been to perform research and development, undertake preclinical and clinical studies and conduct manufacturing activities in support of our product development efforts; organize and staff our Company; establish our intellectual property portfolio; and raise capital to support and expand such activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 5, 2020, we filed a certificate of amendment to our amended and restated certificate of incorporation to affect a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one-for-1.6870&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reverse stock split of our issued and outstanding common stock, preferred stock, stock options and warrants effective on June 5, 2020. Accordingly, all share and per share amounts for all periods presented in the financial statements and notes thereto have been retroactively adjusted.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2020, we completed an initial public offering (&#x201c;IPO&#x201d;) in which we issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,968,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock, including shares issued upon the exercise in full of the underwriters&#x2019; option to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,343,750&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; additional shares of common stock, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. We received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;264.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds, after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Immediately prior to the completion of our IPO, all outstanding shares of redeemable convertible preferred stock were converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,610,337&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. Subsequent to the completion of the IPO, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of redeemable convertible preferred stock outstanding.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_adfec910-931f-4fe2-b666-3a64354787e5"
      id="F_ab2de938-c3f0-4be7-9a42-431d8533edd0">one-for-1.6870</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ace7762d-3569-458c-9040-9f42331af172"
      decimals="INF"
      id="F_f694d7e8-085c-4e2a-a719-8e87df909ec0"
      unitRef="U_shares">17968750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <pcvx:SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares
      contextRef="C_ace7762d-3569-458c-9040-9f42331af172"
      decimals="INF"
      id="F_d63f6ade-c5b6-4096-a0da-41c483f489e2"
      unitRef="U_shares">2343750</pcvx:SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_22b9506a-6924-44d6-a115-432bb54e29f6"
      decimals="INF"
      id="F_7d867312-1bbb-447a-8162-32331597481e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_5ff4f253-5e79-4f0f-9621-48e669f7b797"
      decimals="-5"
      id="F_634d257c-dd01-402f-b16b-8a2bf6c82e7d"
      unitRef="U_USD">264000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <pcvx:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="C_5ff4f253-5e79-4f0f-9621-48e669f7b797"
      decimals="-5"
      id="F_040fb4b5-31ce-48a0-a306-0393eec58435"
      unitRef="U_USD">20100000</pcvx:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_5ff4f253-5e79-4f0f-9621-48e669f7b797"
      decimals="-5"
      id="F_83da5785-8495-4d81-bdd5-8bd14f914593"
      unitRef="U_USD">3400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_443140ce-af83-4051-90d8-0a039e3d6625"
      decimals="INF"
      id="F_8d2f177f-34e0-4161-af90-140d7748c53e"
      unitRef="U_shares">28610337</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_6ea235fe-244e-4bbf-8025-1963f440f2aa"
      decimals="INF"
      id="F_6b1ab66b-0064-49e4-9a3b-aa2c48083d93"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_bcbe763c-1995-4d7b-a2ac-6636c8165b7c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) regarding annual reporting.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;taxes. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We are subject to supplier concentration risk from our suppliers. Although we are working to establish secondary sources of supply, we currently source several of our critical raw materials from single source suppliers. We also use one contract manufacturing organization (&#x201c;CMO&#x201d;), Lonza Ltd. (&#x201c;Lonza&#x201d;), to handle most of our manufacturing activities for our VAX-24 and VAX-31 programs. If we were to experience disruptions in raw materials supplied by our suppliers, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and immunogenicity or efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment and Geographical Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We operate and manage our business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our current corporate headquarters. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:38.052%;"/&gt;
          &lt;td style="width:6.663%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.244%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:2.235%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.116%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:2.235%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:14.456%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;835,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our investments have been classified and accounted for as available-for-sale securities. Fixed income securities consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses are also included in other income (expense), net. When the fair value of a debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in our statements of operations. When the fair value of a debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in our statements of operations only if we sell or intend to sell the security before recovery of its cost basis.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of deferred offering costs, respectively, were included in Other assets on the balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_702b2ee1-c8d3-4b6c-aa18-57f4ed887283;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations in the period realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under Financial Accounting Standards Board ("FASB") Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and its associated amendments (&#x201c;ASC 842&#x201d;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2022, our lease population consisted of real estate operating leases. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, we did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases are included in Operating lease right-of-use ("ROU") assets, Operating lease liabilities - current and Operating lease liabilities - long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recogni&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zed is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of impairments of long-lived assets during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (See Note 3, "Fair Value Measurements and Fair Value of Financial Instruments").&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#x201c;CROs&#x201d;) and investigative sites that conduct preclinical studies, clinical trials other supplies and costs associated with product development efforts, preclinical activities, clinical trials and regulatory operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquired Manufacturing Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2022, we entered into an option agreement with Sutro Biopharma, Inc. (the "Option Agreement"). As of December 31, 2022, the option granted under the Option Agreement is a right, but not an obligation, to obtain certain exclusive rights to internally manufacture or source extract from certain CMOs and the right to independently develop and make improvements to the extract for use in connection with the exploitation of certain vaccine compositions (the &#x201c;Option&#x201d;). As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we paid Sutro Biopharma upfront consideration. As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the Option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2022 and 2021, we have recorded a full valuation allowance on our deferred tax assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For options granted to employees, non-employees and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The fair value of restricted stock and restricted stock unit (&#x201c;RSU&#x201d;) awards is determined based on the number of units granted and the closing price of the Company&#x2019;s common stock as of the grant-date. The grant-date fair value of awards is amortized over the employees&#x2019; requisite service period or the non-employees&#x2019; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding, including pre-funded warrants, during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little consideration, are fully vested and are exercisable after the original issuance date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the FASB issued ASU 2021-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(Subtopic 958-605), Not-For-Profit Entities - Revenue Recognition&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The required disclosures include (i) the nature of the transaction and the related accounting policy used to account for the transaction, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures. In Note 12, "Funding Arrangement," we included disclosures on our cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator ("CARB-X"). We have adopted this standard as required by the effective date. The adoption of this standard did not have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and has subsequently issued related amendments, collectively referred to as &#x201c;Topic 326.&#x201d; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. We have adopted this standard as required by the effective date on January 1, 2022. The adoption of this standard did not have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_2c965ad7-ead5-4242-86df-aec707088cab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) regarding annual reporting.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_bafba52b-033c-4d1f-bc8f-a3c70e73e2fc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities at the date of the financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those related to stock-based compensation expense, accruals for certain research and development costs, the incremental borrowing rate, the valuation of deferred tax assets and income&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;taxes. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management bases our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_00212fec-4348-4a5d-b4ab-43b7b20c8598">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject us to a concentration of credit risk consist primarily of cash and cash equivalents and investments. We invest in money market funds, U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. We maintain bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash and issuers of investments to the extent recorded on the balance sheets. Our investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper and asset-backed securities, and places restrictions on the credit ratings, maturities and concentration by type and issuer. We have not experienced any significant losses on our deposits of cash, cash equivalents or investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We are subject to supplier concentration risk from our suppliers. Although we are working to establish secondary sources of supply, we currently source several of our critical raw materials from single source suppliers. We also use one contract manufacturing organization (&#x201c;CMO&#x201d;), Lonza Ltd. (&#x201c;Lonza&#x201d;), to handle most of our manufacturing activities for our VAX-24 and VAX-31 programs. If we were to experience disruptions in raw materials supplied by our suppliers, or in manufacturing activities at Lonza, we may experience significant delays in our product development timelines and may incur substantial costs to secure alternative sources of raw materials or manufacturing.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our future results of operations involve a number of other risks and uncertainties. Factors that could affect our future operating results and cause actual results to vary materially from expectations include, but are not limited to: our early stages of clinical vaccine development; our ability to advance vaccine candidates into, and successfully complete, clinical trials on the timelines we project; our ability to adequately demonstrate sufficient safety and immunogenicity or efficacy of our vaccine candidates; our ability to enroll subjects in our ongoing and future clinical trials; our ability to successfully manufacture and supply our vaccine candidates for clinical trials; our ability to obtain additional capital to finance our operations; our ability to obtain, maintain and protect our intellectual property rights; developments relating to our competitors and our industry, including competing vaccine candidates; general and market conditions; and other risks and uncertainties, including those more fully described in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_5d3def4a-ea80-486c-b980-e7ea006ef7a4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segment and Geographical Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We operate and manage our business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reportable and operating segment. Our chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Long-lived assets are comprised of property and equipment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="INF"
      id="F_d28d1b28-8558-4a6e-800e-1f2a06c90f7d"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_e6eb86c7-9e00-4a87-b769-bec917cdec75">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We consider all highly liquid investments purchased with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and commercial paper and are stated at their fair values. Restricted cash consists of a standby letter of credit, which was issued in the first quarter of 2021, that serves as collateral for the lease agreement for our current corporate headquarters. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:38.052%;"/&gt;
          &lt;td style="width:6.663%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.244%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:2.235%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.116%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:2.235%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:14.456%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;835,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_92558b3c-3156-4f23-9f07-e3050424956c">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash as reported within the statement of cash flows consisted of the following:&lt;/span&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:38.052%;"/&gt;
          &lt;td style="width:6.663%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.244%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:2.235%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:15.116%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:2.235%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:14.456%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;835,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;386,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_fbff1e49-017c-4480-a8f6-5ca9d41a3f6d"
      unitRef="U_USD">834657000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_0e8118d5-0e5f-4e5e-8987-bd588efa4994"
      unitRef="U_USD">68985000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93"
      decimals="-3"
      id="F_9581705c-abec-4ce5-bfa6-25bcdcb16223"
      unitRef="U_USD">386200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_aeb5a447-a981-49bb-b04e-df1287c4f4bc"
      unitRef="U_USD">871000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_cf2b21ef-8077-43e3-86d0-c72df6d651d7"
      unitRef="U_USD">871000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_cfe23858-3c72-48bc-b475-845a050ddb51"
      unitRef="U_USD">835528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_3e0278c7-dfd1-49d6-afd5-2b0eb3b0bc63"
      unitRef="U_USD">69856000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93"
      decimals="-3"
      id="F_147c89ad-609a-4c9e-819b-a1172c108637"
      unitRef="U_USD">386200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_8e1b9905-8253-4add-a8bc-d22e9d85146e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our investments have been classified and accounted for as available-for-sale securities. Fixed income securities consist of U.S. Treasury securities, U.S. government agency securities, corporate debt, commercial paper and asset-backed securities. These securities are recorded on the balance sheets at fair value. Unrealized gains and losses on these securities are included as a separate component of accumulated other comprehensive loss. The cost of investment securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion are included in other income (expense), net. Realized gains and losses are also included in other income (expense), net. When the fair value of a debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in our statements of operations. When the fair value of a debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in our statements of operations only if we sell or intend to sell the security before recovery of its cost basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_acdc07b3-2a5e-4a74-b266-5f74a66fea5e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Deferred Offering Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred offering costs consist of fees and expenses incurred in connection with the sale of our common stock in equity transactions, including legal, accounting, printing and other issuance-related costs. Prior to the completion of equity transactions, deferred offering costs are included in Other assets on the balance sheet. In connection with and as of the closing of equity transactions, these costs are reclassified to Additional paid-in capital, representing a reduction to the gross proceeds. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of deferred offering costs, respectively, were included in Other assets on the balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_c3a3620f-8e54-449e-9e7d-3e9250cb8220"
      decimals="-6"
      id="F_6beaf5a9-0b2d-40f4-b7d9-a546242b2643"
      unitRef="U_USD">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="C_f949711a-cc58-4c69-8736-3e85b3424551"
      decimals="-5"
      id="F_cbaf2f43-ee53-45d1-aa68-3fbfafd873ed"
      unitRef="U_USD">500000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_a382ed10-7190-47d7-8823-0a293febb627">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_702b2ee1-c8d3-4b6c-aa18-57f4ed887283;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Leasehold improvements are amortized over the shorter of the expected life or lease term. Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the statement of operations in the period realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_132ccca8-d60e-4222-bb51-935509c790c4"
      id="F_1d104096-19bf-4e70-8afe-1e5c7da416a7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_51cc8f6d-e9a8-47fa-9b98-bf208107b2e2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under Financial Accounting Standards Board ("FASB") Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and its associated amendments (&#x201c;ASC 842&#x201d;), we determine if an arrangement is a lease at inception. In addition, we determine whether a lease meets the classification criteria of a finance or operating lease at the lease commencement date considering whether: (i) the lease transfers ownership of the underlying asset to the lessee at the end of the lease term; (ii) the lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise; (iii) the lease term is for a major part of the remaining economic life of the underlying asset; (iv) the present value of the sum of the lease payments and residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset; and (v) the underlying asset is such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. As of December 31, 2022, our lease population consisted of real estate operating leases. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, we did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t have any finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating leases are included in Operating lease right-of-use ("ROU") assets, Operating lease liabilities - current and Operating lease liabilities - long term in our balance sheet. ROU assets represent our right to use the underlying assets for the lease term and lease liabilities represent our obligation to make lease payments arising from the leases. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, if the rate implicit in the lease is not readily determinable, we use our incremental borrowing rate based on the information available at the lease commencement date. We determine the incremental borrowing rate based on an analysis of corporate bond yields with a credit rating similar to us. The determination of our incremental borrowing rate requires management judgment, including development of a synthetic credit rating and cost of debt, as we currently do not carry any debt. We believe that the estimates used in determining the incremental borrowing rate are reasonable based upon current facts and circumstances. Applying different judgment to the same facts and circumstances could yield a different incremental borrowing rate. The operating lease ROU assets also include adjustments for prepayments and accrued lease payments and exclude lease incentives. ROU assets and lease liabilities may include options to extend or terminate leases if it is reasonably certain that we will exercise such options. Lease payments which are fixed and determinable are amortized as rent and lease expense on a straight-line basis over the expected lease term. Variable lease costs, which are dependent on usage, a rate or index, including common area maintenance charges, are expensed as incurred. Lease agreements that include lease and non-lease components are accounted for as a single lease component. Lease agreements with non-cancelable terms of less than 12 months are not recorded on our balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <pcvx:NumberOfFinanceLease
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="INF"
      id="F_050cdd18-e396-4343-96fe-21b6a2714b95"
      unitRef="U_Lease">0</pcvx:NumberOfFinanceLease>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_137d2f88-efa2-4539-9cb9-1a686349234d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recogni&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zed is measured as the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows generated by the assets. There were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of impairments of long-lived assets during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-5"
      id="F_94a85ccc-7249-40ae-b658-f6c127503a6b"
      unitRef="U_USD">200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-6"
      id="F_11136dd9-2cd3-45b5-a6c3-0000ca04ba47"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-5"
      id="F_08a1158f-a09a-427b-aff6-2083e847bb2d"
      unitRef="U_USD">300000</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_410c420f-21a6-423b-990d-643b93ff13cb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of our financial instruments, including cash and cash equivalents, prepaid and other current assets, accounts payable, accrued expenses, and other liabilities, approximate fair value due to their short-term maturities. Prior to their automatic conversion upon our IPO in June 2020, the redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant were carried at fair value (See Note 3, "Fair Value Measurements and Fair Value of Financial Instruments").&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_36349b1e-06f9-42f3-b0a1-2f14d1a1eed0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development costs are expensed as incurred. Research and development costs include salaries, stock-based compensation and benefits for employees performing research and development activities, an allocation of facility and overhead expenses, expenses incurred under agreements with consultants, CMOs, contract research organizations (&#x201c;CROs&#x201d;) and investigative sites that conduct preclinical studies, clinical trials other supplies and costs associated with product development efforts, preclinical activities, clinical trials and regulatory operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <pcvx:AccruedResearchAndDevelopmentPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_db42945a-02a5-4e03-93cf-0c2dbd327e49">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued Research and Development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have entered into various agreements with CROs and CMOs. Our research and development accruals, which include accrued manufacturing expenses, are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development services provided, but not yet invoiced, are included in accrued expenses on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CROs or CMOs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, there have been no material differences between our estimates of such expenses and the amounts actually incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</pcvx:AccruedResearchAndDevelopmentPolicyTextBlock>
    <pcvx:OptionToAcquireManufacturingRightsPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_c586ca7a-9a5c-4657-ba72-2c1d77af1736">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquired Manufacturing Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2022, we entered into an option agreement with Sutro Biopharma, Inc. (the "Option Agreement"). As of December 31, 2022, the option granted under the Option Agreement is a right, but not an obligation, to obtain certain exclusive rights to internally manufacture or source extract from certain CMOs and the right to independently develop and make improvements to the extract for use in connection with the exploitation of certain vaccine compositions (the &#x201c;Option&#x201d;). As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we paid Sutro Biopharma upfront consideration. As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the Option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;</pcvx:OptionToAcquireManufacturingRightsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_d767240a-b349-4b35-a13c-d1d9ca5302d3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We account for income taxes using the asset and liability method. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In evaluating the ability to recover our deferred income tax assets, we consider all available positive and negative evidence, including our operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event we determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December 31, 2022 and 2021, we have recorded a full valuation allowance on our deferred tax assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained during an audit. Interest and penalties related to unrecognized tax benefits are included within the provision for income tax.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_2464cefb-b92a-473d-846b-066d45cdd995">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For options granted to employees, non-employees and directors, stock-based compensation is measured at grant date based on the fair value of the award. We determine the grant-date fair value of the options using the Black-Scholes option-pricing model. The fair value of restricted stock and restricted stock unit (&#x201c;RSU&#x201d;) awards is determined based on the number of units granted and the closing price of the Company&#x2019;s common stock as of the grant-date. The grant-date fair value of awards is amortized over the employees&#x2019; requisite service period or the non-employees&#x2019; vesting period as the services are rendered. Forfeitures are accounted for as they occur. Additionally, our 2020 Employee Stock Purchase Plan is deemed to be a compensatory plan and is therefore included in stock-based compensation expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_16655577-c1c4-48ea-82dd-3f9e5b4ea14b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss and other comprehensive loss for the period. Other comprehensive loss consists of unrealized loss on investments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_8e95ff86-281e-4631-b09c-78498560bd5e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Transactions denominated in foreign currencies are initially measured in U.S. dollars using the exchange rate on the date of the transaction. Foreign currency denominated monetary assets and liabilities are subsequently re-measured at the end of each reporting period using the exchange rate at that date, with the corresponding foreign currency transaction gain or loss recorded in the statements of operations and statements of cash flows. Nonmonetary assets and liabilities are not subsequently re-measured.&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_b43ce25d-b4bc-4e92-be22-0acfc087a790">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding, including pre-funded warrants, during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, redeemable convertible preferred stock, redeemable convertible preferred stock warrant, common stock subject to repurchase, and stock options are considered to be potentially dilutive securities. Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little consideration, are fully vested and are exercisable after the original issuance date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock is considered a participating security. Our participating securities do not have a contractual obligation to share in our losses. As such, the net loss was attributed entirely to common stockholders. Because we have reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_c9336f05-4351-4cc5-80ab-87ce717a1d24">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the FASB issued ASU 2021-10, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Government Assistance (Topic 832): Disclosure by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which requires disclosures about transactions with a government entity that are accounted for by applying a grant or contribution accounting model by analogy to other accounting guidance, such as a grant model within International Accounting Standard 20, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;(Subtopic 958-605), Not-For-Profit Entities - Revenue Recognition&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The required disclosures include (i) the nature of the transaction and the related accounting policy used to account for the transaction, (ii) the financial statement line items that are affected by the transactions and (iii) the significant terms and conditions of the transactions, including commitments and contingencies. This standard is effective for annual periods beginning after December 15, 2021, with early adoption and retrospective or prospective application&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;permitted. This standard is effective for us on January 1, 2022 and only impacts annual financial statement footnote disclosures. In Note 12, "Funding Arrangement," we included disclosures on our cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator ("CARB-X"). We have adopted this standard as required by the effective date. The adoption of this standard did not have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and has subsequently issued related amendments, collectively referred to as &#x201c;Topic 326.&#x201d; Topic 326 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. We have adopted this standard as required by the effective date on January 1, 2022. The adoption of this standard did not have a material impact on our financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_f6134196-b38f-4e4e-947b-40e398dea866">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements and Fair Value of Financial Instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheets, as well as assets and liabilities measured at fair value on a non-recurring basis or disclosed at fair value, are categorized based upon the level of judgment associated with inputs used to measure their fair values. The accounting guidance for fair value provides a framework for measuring fair value and requires certain disclosures about how fair value is determined. Fair value is defined as the price that would be received&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance also establishes a three-level valuation hierarchy that prioritizes the inputs to valuation techniques used to measure fair value based upon whether such inputs are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions made by the reporting entity. The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 1&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level 2&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:9.067%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Level&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; 3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1 securities consist of highly liquid money market funds for which the carrying amounts approximate their fair values due to their short maturities. U.S. Treasury securities are valued using Level 1 inputs based on unadjusted, quoted prices in active markets that are observable at the measurement date for identical assets or liabilities. Level 2 securities, consisting of corporate debt, commercial paper, U.S. government agency securities and asset-backed securities, are measured based on other observable inputs, including broker or dealer quotations or alternative pricing sources. When quoted prices in active markets for identical assets or liabilities are not available, we rely on non-binding quotes from our investment managers, which are based on proprietary valuation models of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;independent &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;pricing services. These models generally use inputs such as observable market data, quoted market prices for similar instruments or historical pricing trends of securities relative to our peers. To validate the fair value determinations provided by our investment managers, we review the pricing movement in the context of overall market trends and trading information from our investment managers. In addition, we assess the inputs and methods used in determining the fair value in order to determine the classification of securities in the fair value hierarchy. We had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Level 3 securities either as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 or 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; transfers within the hierarchies during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; or 2&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We invested in money market funds as of December 31, 2020. In January 2021, we started to invest some of our funds in corporate debt, commercial paper, U.S. Treasury securities, U.S. government agency securities and asset-backed securities. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:29.076%;"/&gt;
        &lt;td style="width:13.785%;"/&gt;
        &lt;td style="width:7.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.571%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.274%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.571%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.858%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.496%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.312%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross &lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross &lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;680,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;680,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;958,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;957,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross &lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross &lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;273,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;273,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the contractual maturities of our investments as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.229%;"/&gt;
        &lt;td style="width:5.326%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.446%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in less than one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in one to five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <pcvx:NumberOfSecurities
      contextRef="C_cf5ec869-94b5-4ffc-91dc-e1f40e3f1d68"
      decimals="INF"
      id="F_4622103b-665f-4ddb-9b17-14bad8babb68"
      unitRef="U_Security">0</pcvx:NumberOfSecurities>
    <pcvx:NumberOfSecurities
      contextRef="C_6ab2007d-2325-4131-b251-a78960367bd8"
      decimals="INF"
      id="F_f51f8f15-36f4-44b7-ada1-018113103443"
      unitRef="U_Security">0</pcvx:NumberOfSecurities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_6cc1e80a-c394-45d3-99b2-7d8d948be61b"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_7e444b82-90c9-4408-8c37-91fef39c3397"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_bfeb4851-fde1-4d92-92a4-5fc520d21264"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_a0d49f6d-d343-4507-bf47-e179bfddf4ea"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_3f9f947f-0153-44f2-98b5-5bc9d343cad8"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_1be4fff4-54ff-462b-8dd9-bcfc6bd92219"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_957fed1f-d93e-4f2f-a22a-e73e0834b7f4"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_f052523e-0def-495e-b8e5-38be954e7c49"
      unitRef="U_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_2661036c-8a4d-459f-9aba-62023b32b1c5">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables set forth our financial instruments measured at fair value on a recurring basis by level within the fair value hierarchy at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:29.076%;"/&gt;
        &lt;td style="width:13.785%;"/&gt;
        &lt;td style="width:7.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.571%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.274%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.571%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.858%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.496%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.997%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.312%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross &lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross &lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;56,198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;680,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;680,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;92,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,978&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,691&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;834,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;366&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;958,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;957,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;br/&gt;Hierarchy Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross &lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross &lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,596&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;68,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Corporate debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Asset backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,714&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;273,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;241&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;273,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_fb2cd419-f42a-43d4-8173-6fb63ccd1d36"
      decimals="-3"
      id="F_00f4ba6c-aa46-4bdf-af7f-5484209c6603"
      unitRef="U_USD">56198000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_fb2cd419-f42a-43d4-8173-6fb63ccd1d36"
      decimals="-3"
      id="F_5b527ceb-8f41-487b-b98d-5570415cc267"
      unitRef="U_USD">56198000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_6ff2a197-ccf8-4a47-9068-2d3aca352aec"
      decimals="-3"
      id="F_da6ba73e-0ff5-4782-861e-447c5cd7d4f6"
      unitRef="U_USD">680934000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6ff2a197-ccf8-4a47-9068-2d3aca352aec"
      decimals="-3"
      id="F_cb36206d-8ca9-4964-b045-b88c897eac87"
      unitRef="U_USD">680934000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_58769e66-aeef-44e4-85ca-41149ca8f5e6"
      decimals="-3"
      id="F_5a714071-57ce-4638-9452-fea55a827896"
      unitRef="U_USD">92581000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="C_58769e66-aeef-44e4-85ca-41149ca8f5e6"
      decimals="-3"
      id="F_803e8c4d-d876-4eca-9fb7-7a52ef708fd9"
      unitRef="U_USD">34000</pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_58769e66-aeef-44e4-85ca-41149ca8f5e6"
      decimals="-3"
      id="F_283cd759-4270-4c67-a7dc-54b6028b89f7"
      unitRef="U_USD">92547000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c"
      decimals="-3"
      id="F_5f6cb47b-c50b-44f0-a34e-fd44e5ce3824"
      unitRef="U_USD">4978000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c"
      decimals="-3"
      id="F_626b582a-9475-4b49-9325-d18d78d5b40f"
      unitRef="U_USD">4978000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_f87d7673-651b-4a88-999d-c6b6d098bc53"
      unitRef="U_USD">834691000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_495e9463-171d-47ec-9444-92cf68409862"
      unitRef="U_USD">34000</pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_18dc7854-781a-44e6-b041-dced3eb7f857"
      unitRef="U_USD">834657000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_180236c9-658c-46b2-8320-cd9fd9ee3932"
      decimals="-3"
      id="F_080a10c1-b7d4-4c45-9881-bc3ecf88a5c1"
      unitRef="U_USD">37651000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_180236c9-658c-46b2-8320-cd9fd9ee3932"
      decimals="-3"
      id="F_5e7221b2-12b6-48ef-942e-af9918809fb7"
      unitRef="U_USD">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_180236c9-658c-46b2-8320-cd9fd9ee3932"
      decimals="-3"
      id="F_de90cf1a-18ae-45ff-8a69-ef68bccdc64f"
      unitRef="U_USD">37581000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5620db3e-07c5-48e8-80c5-b68b2362d81c"
      decimals="-3"
      id="F_76dbc0b7-91bf-4340-bb35-6fc167b96d00"
      unitRef="U_USD">28161000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_5620db3e-07c5-48e8-80c5-b68b2362d81c"
      decimals="-3"
      id="F_865a4e11-1c34-46f8-a8e0-12ec79b2cdee"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_5620db3e-07c5-48e8-80c5-b68b2362d81c"
      decimals="-3"
      id="F_0a6e2bb2-e30b-4566-8fc5-7be55db8e427"
      unitRef="U_USD">28144000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_1e25d9bc-8da8-4125-95f2-eb869be71853"
      decimals="-3"
      id="F_412b664f-c15d-4526-9cd6-e3343b6da66e"
      unitRef="U_USD">25402000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_1e25d9bc-8da8-4125-95f2-eb869be71853"
      decimals="-3"
      id="F_692608df-da0b-47f7-8731-d8878ad8ff96"
      unitRef="U_USD">131000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1e25d9bc-8da8-4125-95f2-eb869be71853"
      decimals="-3"
      id="F_106e9d99-516c-46fb-817d-850daac5a182"
      unitRef="U_USD">25271000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4a24e83d-869b-46cd-a362-36d31d8ac8ae"
      decimals="-3"
      id="F_b489e1f5-794d-4eee-8254-c9fe3c63f5ca"
      unitRef="U_USD">6954000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4a24e83d-869b-46cd-a362-36d31d8ac8ae"
      decimals="-3"
      id="F_2ca59769-98be-41d1-8c19-1be600b109c9"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4a24e83d-869b-46cd-a362-36d31d8ac8ae"
      decimals="-3"
      id="F_1ce589c6-36d2-419c-bfb5-02cf876a387a"
      unitRef="U_USD">6974000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c"
      decimals="-3"
      id="F_1b312267-78b7-46a8-bdf7-34f4a503c024"
      unitRef="U_USD">25427000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c"
      decimals="-3"
      id="F_fd4cadc9-f502-4da0-9337-0375440edfd3"
      unitRef="U_USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c"
      decimals="-3"
      id="F_4d300fa7-8681-419c-b427-ab14b6aa85c5"
      unitRef="U_USD">148000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_6a8383e7-fefb-449e-97bd-c449db6e963c"
      decimals="-3"
      id="F_7aa25b37-6507-489c-85f7-8f0097f469ca"
      unitRef="U_USD">25298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_0e6f1058-c42c-47ed-8358-f15eab6b9357"
      unitRef="U_USD">123595000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_844779c7-0d7b-498f-a088-647890f847b8"
      unitRef="U_USD">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_9230e5de-20c4-49ce-ab52-b8fc892794aa"
      unitRef="U_USD">366000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_03cafbfa-274a-49d0-a063-d60e2ea992e6"
      unitRef="U_USD">123268000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_96654932-207b-44e2-9f96-157b949718b8"
      unitRef="U_USD">958286000</pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis>
    <pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_55a4f47b-c2b7-426e-82c3-1a4f40a4dad1"
      unitRef="U_USD">39000</pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax>
    <pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_9f4607c2-27a4-458f-a83b-b72baeea262c"
      unitRef="U_USD">400000</pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax>
    <pcvx:CashAndCashEquivalentsAndInvestments
      contextRef="C_0cf6689c-2254-4c4c-9717-295b1177cd54"
      decimals="-3"
      id="F_74661a5a-1d79-4ac3-9623-43ba90cd9dd4"
      unitRef="U_USD">957925000</pcvx:CashAndCashEquivalentsAndInvestments>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_e17de957-4ef6-4075-bc74-6780bc32c66b"
      decimals="-3"
      id="F_726842f4-01a0-4a6b-9cdb-441ff5604fad"
      unitRef="U_USD">27834000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e17de957-4ef6-4075-bc74-6780bc32c66b"
      decimals="-3"
      id="F_42d437d0-93c9-446d-a160-27e70370d732"
      unitRef="U_USD">27834000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_7cbd95b2-0c54-4116-8364-7ddbdd457679"
      decimals="-3"
      id="F_4d63727c-1da3-433d-b45c-d256e2d9188f"
      unitRef="U_USD">17555000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_7cbd95b2-0c54-4116-8364-7ddbdd457679"
      decimals="-3"
      id="F_527e5e84-c810-45cc-b962-b85c9a07097c"
      unitRef="U_USD">17555000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_f24288b7-094a-4c0a-ad36-62c7652ebabb"
      decimals="-3"
      id="F_e215da64-8c93-45ff-8d35-e76797274d62"
      unitRef="U_USD">23597000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="C_f24288b7-094a-4c0a-ad36-62c7652ebabb"
      decimals="-3"
      id="F_00d7f63c-ebd8-4778-b752-dad151a6766b"
      unitRef="U_USD">1000</pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_f24288b7-094a-4c0a-ad36-62c7652ebabb"
      decimals="-3"
      id="F_138b4cc8-384a-43b4-8359-d0ccb1efa04e"
      unitRef="U_USD">23596000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <pcvx:CashAndCashEquivalentsAmortizedCost
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_e22ba2ea-4ead-46cd-9f2e-9be99c91a23f"
      unitRef="U_USD">68986000</pcvx:CashAndCashEquivalentsAmortizedCost>
    <pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_ace88069-0a27-4060-b35d-7d47abecd941"
      unitRef="U_USD">1000</pcvx:CashAndCashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_6aa60fda-db82-45b5-8281-3047cf5a47f5"
      unitRef="U_USD">68985000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_415e98bb-bdbd-4558-a741-01b294239326"
      decimals="-3"
      id="F_b39441f7-8360-47e7-a700-59298ee70817"
      unitRef="U_USD">45290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_415e98bb-bdbd-4558-a741-01b294239326"
      decimals="-3"
      id="F_81efdf0f-a10c-4124-904c-d7d2c8fada54"
      unitRef="U_USD">73000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_415e98bb-bdbd-4558-a741-01b294239326"
      decimals="-3"
      id="F_f8c4259a-da6d-47fa-a108-1186437d9f20"
      unitRef="U_USD">45217000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_d308ed79-6102-4437-9f98-f586c059dc9c"
      decimals="-3"
      id="F_d62d2115-3c04-4a90-be63-ebdaaa52f508"
      unitRef="U_USD">61941000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_d308ed79-6102-4437-9f98-f586c059dc9c"
      decimals="-3"
      id="F_e74e2665-f62c-47ba-9579-0a5cd7e37751"
      unitRef="U_USD">22000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_d308ed79-6102-4437-9f98-f586c059dc9c"
      decimals="-3"
      id="F_831f602c-6e00-481e-b797-5d36d1d1582a"
      unitRef="U_USD">61919000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_79e53c50-0fb4-4714-84d0-e5a2a573e00b"
      decimals="-3"
      id="F_8cba89af-12ae-4895-9038-3bd333bcb637"
      unitRef="U_USD">58498000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_79e53c50-0fb4-4714-84d0-e5a2a573e00b"
      decimals="-3"
      id="F_cd4f67e0-b15b-4d7e-80de-c616c6899e79"
      unitRef="U_USD">74000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_79e53c50-0fb4-4714-84d0-e5a2a573e00b"
      decimals="-3"
      id="F_c0e0b798-630e-466f-8389-8b4eff2c6cef"
      unitRef="U_USD">58424000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_01155b0a-67b5-469f-9b55-5c9a7412e381"
      decimals="-3"
      id="F_e4c495cd-4f4b-41d6-997f-642482177820"
      unitRef="U_USD">13899000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_01155b0a-67b5-469f-9b55-5c9a7412e381"
      decimals="-3"
      id="F_9b8ecfd7-040b-4ed9-85c0-af9879c57a75"
      unitRef="U_USD">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_01155b0a-67b5-469f-9b55-5c9a7412e381"
      decimals="-3"
      id="F_f76d379b-e0c4-4723-8b35-b7cd32e43575"
      unitRef="U_USD">13874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e926f4ca-4dd1-450a-81bd-dc676a9925ba"
      decimals="-3"
      id="F_be3e7a55-c19a-4317-a2d4-c65262a7c2a3"
      unitRef="U_USD">24714000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e926f4ca-4dd1-450a-81bd-dc676a9925ba"
      decimals="-3"
      id="F_c34c2310-233b-4cff-85c6-41141633d5af"
      unitRef="U_USD">46000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e926f4ca-4dd1-450a-81bd-dc676a9925ba"
      decimals="-3"
      id="F_54ee090b-cfd4-40ff-bb74-ad6c2333b97c"
      unitRef="U_USD">24668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_b87e5b04-2f07-4459-b5c0-31740e3a32a8"
      unitRef="U_USD">204342000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_8e05584d-8d93-4d34-a993-fffb372754dd"
      unitRef="U_USD">240000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_85208aa1-5a5f-4123-91b3-10b0f4ecf1d8"
      unitRef="U_USD">204102000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_4bd52d72-2939-4248-bb2e-bfcdd339cd08"
      unitRef="U_USD">273328000</pcvx:CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis>
    <pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_326bcf93-901f-4da4-a55d-6dd938a2b86b"
      unitRef="U_USD">241000</pcvx:CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax>
    <pcvx:CashAndCashEquivalentsAndInvestments
      contextRef="C_4bf717e3-6544-4664-aa99-f66bf3ab5b0c"
      decimals="-3"
      id="F_3d13bb98-ce78-4993-ba08-717d662d850e"
      unitRef="U_USD">273087000</pcvx:CashAndCashEquivalentsAndInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_e3ffc576-e013-4742-b48d-2aff5069af5a">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents the contractual maturities of our investments as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:70.229%;"/&gt;
        &lt;td style="width:5.326%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:22.446%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in less than one year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Due in one to five years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,268&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_b3d2f0b7-c513-4267-9f52-b28725815103"
      unitRef="U_USD">96719000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_a1f4f332-51ee-4047-bd2a-29ff5ab632a1"
      unitRef="U_USD">26549000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_83aeecf1-1e2f-412b-9f08-3383839c2eab"
      unitRef="U_USD">123268000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_94abb745-9e72-4901-a87c-a7563fc1f2a5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance Sheet Details&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.929%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.011%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.086%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computers and computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization expense for the years ended December 31, 2022, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.226%;"/&gt;
        &lt;td style="width:1.421%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.806000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.421%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other research and development &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;______________&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Includes $&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of accrued manufacturing rights as of December 31, 2022 and 2021, respectively. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The breakout and categorizations of the 2021 total accrued expenses have been updated to conform to the 2022 presentation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_02d4eecd-7747-488e-a28f-ecadb6832cfd">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.929%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.011%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.086%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,608&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computers and computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,548&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,360&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d1ef036e-43c1-4748-ba90-b2fce246fad4"
      decimals="-3"
      id="F_b646f6c7-8a99-4e6d-b30f-97697a1ee81f"
      unitRef="U_USD">1608000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e4995092-b32b-457d-9712-2e5592bba095"
      decimals="-3"
      id="F_24dc668f-7137-40c3-87fd-470aaa5e0ece"
      unitRef="U_USD">1619000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3c4d15b9-2c87-4cf6-be74-87bda32cea0e"
      decimals="-3"
      id="F_b1722b7b-8e82-4828-83fc-7a1649547c5d"
      unitRef="U_USD">416000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1e5bb009-c911-4eb4-9225-759eaada18dd"
      decimals="-3"
      id="F_04daf87c-1834-47b5-a401-98bd6f1d1dea"
      unitRef="U_USD">430000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_eb2e21b9-03b4-445b-a4c8-52e92a39f940"
      decimals="-3"
      id="F_f81684d0-9c4c-4781-b681-035808016414"
      unitRef="U_USD">13100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3d68821a-459d-4683-8345-23cec20bbda0"
      decimals="-3"
      id="F_3acc7fff-a433-4740-b428-543bc92c6de7"
      unitRef="U_USD">9453000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_71794c0f-76e0-44c9-b988-61b9c2402e78"
      decimals="-3"
      id="F_13f02077-1a9d-4dfb-9f16-ea12868131e3"
      unitRef="U_USD">1353000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6bd83283-29d6-47da-874d-4c54c292d4ab"
      decimals="-3"
      id="F_854069e0-44b8-4ce1-8d72-4d4a53b8997b"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_a5df27c2-c7ce-43ee-9abd-6529dc95e96f"
      unitRef="U_USD">16477000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_d299bd70-7799-485d-bb56-089ceff812cb"
      unitRef="U_USD">11502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_07a01fed-78ab-4999-beed-c7a8130d2822"
      unitRef="U_USD">6117000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_426ffede-92da-4cb9-8535-0eda9dbcc47f"
      unitRef="U_USD">3548000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_45e21b20-a47e-4cac-9a07-df04e5f28c7a"
      unitRef="U_USD">10360000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_4a172a2d-f897-4cc3-9561-e4ce812b1c58"
      unitRef="U_USD">7954000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-5"
      id="F_a94e0741-5ca1-4b49-9efa-bfbb09575008"
      unitRef="U_USD">2600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-5"
      id="F_4ffbaf1b-b6b9-4970-aadb-87899a3e0748"
      unitRef="U_USD">1800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-5"
      id="F_dc2ddfd0-57c8-4981-b2f8-b96888100626"
      unitRef="U_USD">1400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_2fee67d4-a0ed-41c6-acb3-58b0b1dda2a6">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued expenses as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.226%;"/&gt;
        &lt;td style="width:1.421%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.806000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.421%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.127%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Clinical studies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,518&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;453&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other research and development &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,676&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:15.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="margin-left:15.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;______________&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:9.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Includes $&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of accrued manufacturing rights as of December 31, 2022 and 2021, respectively. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The breakout and categorizations of the 2021 total accrued expenses have been updated to conform to the 2022 presentation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pcvx:ClinicalStudies
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_52488e1e-6591-41ca-bf46-c23a9e424e95"
      unitRef="U_USD">1518000</pcvx:ClinicalStudies>
    <pcvx:ClinicalStudies
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_bec0d669-934c-45fb-8ac2-b3ee2f080725"
      unitRef="U_USD">453000</pcvx:ClinicalStudies>
    <pcvx:OtherResearchAndDevelopmentLiabilitiesCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_df4ab314-c5c6-42db-9ded-1707241de39d"
      unitRef="U_USD">12446000</pcvx:OtherResearchAndDevelopmentLiabilitiesCurrent>
    <pcvx:OtherResearchAndDevelopmentLiabilitiesCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_7bf9f156-a8b5-43ba-a0a0-d7a76ae82463"
      unitRef="U_USD">4676000</pcvx:OtherResearchAndDevelopmentLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_95b5f754-4aff-4931-8f9e-1dd748d3cab9"
      unitRef="U_USD">1411000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_10840e29-68b1-42d2-9040-bb0bdcec4e88"
      unitRef="U_USD">3658000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_d338f4b0-28a4-43bf-8c5f-937f66addefb"
      unitRef="U_USD">15375000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_e3446735-f111-4e41-9a5e-3fea9fe6170e"
      unitRef="U_USD">8787000</us-gaap:AccruedLiabilitiesCurrent>
    <pcvx:AccruedManufacturingRightsExpenses
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-5"
      id="F_8c71c08c-17a8-4b27-8683-afdc8dd9c57d"
      unitRef="U_USD">5000000.0</pcvx:AccruedManufacturingRightsExpenses>
    <pcvx:AccruedManufacturingRightsExpenses
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_48be215c-8dfa-4bb0-b786-0494aec2c399"
      unitRef="U_USD">0</pcvx:AccruedManufacturingRightsExpenses>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_321136e8-2ce9-4acc-a2ab-6287c5202368">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5. Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Lease Obligations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2021, we entered into a lease agreement for our current corporate headquarters facility located in San Carlos, California and a license agreement for temporary lab and office space in Palo Alto, California. The lease term for our current corporate headquarters facility began on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;January 22, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. We have &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-month renewal options. The original term of the license agreement for the temporary space in Palo Alto terminated when the San Carlos office leasehold improvements were completed and we moved into our current corporate headquarters. We extended the license agreement for the Palo Alto office by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 3, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to accommodate our relocation plan. These two agreements are accounted for as a combined lease because the contracts were negotiated as a package with the same commercial objective. Upon commencement of the San Carlos lease in December 2021, we recorded a ROU asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2016, we entered into a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;September 1, 2016&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;August 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-month &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;renewal options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;July 1, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;October 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; renewal options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; In November 2020, we extended the terms of both of these leases for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;March 1, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;April 30, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. In February 2022, we entered into an early termination agreement for one of the facilities in Foster City and terminated our lease on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 12, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; instead of April 30, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.665%;"/&gt;
        &lt;td style="width:3.444%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.29%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.871%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.729999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.78&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.111%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum payments required under operating leases as of December 31, 2021 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.097%;"/&gt;
        &lt;td style="width:1.781%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.122%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;______________________________________&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities for 2022 are net of lease incentives of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million allocated to the Palo Alto office.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Rent expense recognized under the leases was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <pcvx:LesseeOperatingLeaseCommencementDate
      contextRef="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03"
      id="F_d91da811-5f48-4ba1-8391-7787af461303">2021-01-22</pcvx:LesseeOperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03"
      id="F_0d896b12-5650-4926-9a66-e4c07128c936">2025-12-31</us-gaap:LeaseExpirationDate1>
    <pcvx:NumberOfRenewalOptions
      contextRef="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03"
      decimals="INF"
      id="F_4c394702-3352-4894-b349-da692cd3e19d"
      unitRef="U_RenewalOption">2</pcvx:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_f29cb1b4-51e8-42fe-ba43-bfae1134ea34"
      id="F_6e3eed19-95de-4ce5-af94-f8beba5d88b8">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <pcvx:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_ebf5473f-13ab-4049-9e7f-58fbcd55ec03"
      id="F_8fff8563-e612-4728-9b2f-14a14bdd1cc2">P60D</pcvx:LesseeOperatingLeaseExtendedLeaseTerm>
    <pcvx:LesseeOperatingLeaseExtendedMaturityDate
      contextRef="C_215eff92-aeb1-4823-b975-c15a670cc803"
      id="F_82e5076a-14ec-4c1d-a24d-dc3063f6d7fa">2022-03-03</pcvx:LesseeOperatingLeaseExtendedMaturityDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_bb33c9e9-15f8-4620-9baa-1c636358bb0e"
      decimals="-5"
      id="F_8b09a270-2dd8-496a-b3dc-7806253d1646"
      unitRef="U_USD">28400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_bb33c9e9-15f8-4620-9baa-1c636358bb0e"
      decimals="-5"
      id="F_52908f7d-c13e-43c8-b95d-5574ae6c321e"
      unitRef="U_USD">12900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_9301909a-a6de-4293-bf83-22071eaf9f32"
      id="F_96713828-f81f-4d0c-a7be-0ca8f2eb51b5">In July 2016, we entered into a five-year lease agreement for our previous headquarters facility located in Foster City, California. The original term of the lease was from September 1, 2016 to August 31, 2021, with two 30-month renewal options.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_1af9b85c-d59e-4494-bcdc-b8097aa831e7"
      id="F_7175f6c7-b1b5-4894-961d-c0f3a73a50a0">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <pcvx:LesseeOperatingLeaseCommencementDate
      contextRef="C_898a2a2d-e260-47fb-85c7-5b4d4065a867"
      id="F_3581b454-2419-42b7-869e-d4f364b9816e">2016-09-01</pcvx:LesseeOperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_898a2a2d-e260-47fb-85c7-5b4d4065a867"
      id="F_123543b0-ecf6-43ce-99fb-f073d4476fb4">2021-08-31</us-gaap:LeaseExpirationDate1>
    <pcvx:LesseeOperatingLeaseRenewalOption
      contextRef="C_898a2a2d-e260-47fb-85c7-5b4d4065a867"
      decimals="INF"
      id="F_214cfc10-282f-4ca5-a841-84deae9fcad5"
      unitRef="U_RenewalOption">2</pcvx:LesseeOperatingLeaseRenewalOption>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_92495c05-9763-4ff7-855f-1743d26c34ea"
      id="F_2c7ff405-f8e1-4641-9285-59924b8438ac">30-month renewal options</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_1af9b85c-d59e-4494-bcdc-b8097aa831e7"
      id="F_cf8a6387-5974-46a5-979d-10f35b3e3af3">P30M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_898a2a2d-e260-47fb-85c7-5b4d4065a867"
      id="F_c00e1a06-e1a1-46d0-9e7b-ad15b3dc9319">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_32c0e264-4ab1-4f71-99a3-932ea28e946c"
      id="F_af3dd0e4-f7c0-477e-8b59-d79abe93f942">In July 2019, we leased another facility in Foster City, California as a result of growth in personnel and lab space requirements. The original term of this lease was from July 1, 2019 to October 31, 2021, with no renewal options.</us-gaap:LesseeOperatingLeaseDescription>
    <pcvx:LesseeOperatingLeaseCommencementDate
      contextRef="C_dd141812-a700-48fc-9a93-5d2fa4df6de7"
      id="F_1235f020-ae2b-4c3d-a2b3-bc297cd8c19f">2019-07-01</pcvx:LesseeOperatingLeaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_dd141812-a700-48fc-9a93-5d2fa4df6de7"
      id="F_20811335-35e5-45fa-b3ed-3749119192ac">2021-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_32c0e264-4ab1-4f71-99a3-932ea28e946c"
      id="F_eb637e46-b38e-4b68-88d2-d3f44a31263d">no renewal options</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_dd141812-a700-48fc-9a93-5d2fa4df6de7"
      id="F_6a6a9762-ee2e-4130-bd60-a8563664aa55">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <pcvx:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_6713bc72-bbf6-4c8d-848a-8ca3bd191ee0"
      id="F_5ee6320c-6e01-4b90-90d0-7f032f0e55de">P6M</pcvx:LesseeOperatingLeaseExtendedLeaseTerm>
    <pcvx:LesseeOperatingLeaseExtendedLeaseTerm
      contextRef="C_17293867-6c59-44bc-b2a6-797596102857"
      id="F_8fb5b763-6409-419d-ab74-d30e40f62236">P6M</pcvx:LesseeOperatingLeaseExtendedLeaseTerm>
    <pcvx:LesseeOperatingLeaseExtendedMaturityDate
      contextRef="C_6713bc72-bbf6-4c8d-848a-8ca3bd191ee0"
      id="F_2f57c573-3811-4527-b7f9-43b376b8bb11">2022-03-01</pcvx:LesseeOperatingLeaseExtendedMaturityDate>
    <pcvx:LesseeOperatingLeaseExtendedMaturityDate
      contextRef="C_17293867-6c59-44bc-b2a6-797596102857"
      id="F_a3375539-60e5-4bd8-a1d9-74d732e71b78">2022-04-30</pcvx:LesseeOperatingLeaseExtendedMaturityDate>
    <pcvx:LeaseTerminationDate
      contextRef="C_9a2fe8c2-7190-4ba0-9807-0bf83b739c1b"
      id="F_da3a8cc2-9371-48b9-bc92-c3b3ab81fe75">2022-02-12</pcvx:LeaseTerminationDate>
    <pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_8cb6cde3-8935-4ebc-be04-6f3a248f79bc">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Information related to our ROU assets and related lease liabilities was as follows (dollar amounts in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.665%;"/&gt;
        &lt;td style="width:3.444%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.29%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.871%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.729999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,276&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.78&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_074639a4-c2e3-4133-9dc0-94b31333b514"
      unitRef="U_USD">5374000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_5716a52f-a28c-45fc-929c-53303db03bd4"
      unitRef="U_USD">924000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_ce47327f-7651-4ea9-8199-648d424fb21f"
      unitRef="U_USD">21288000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_70f4e8de-2512-4981-8b8e-80f1ba2efb61"
      unitRef="U_USD">27958000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_8ff79b3c-f544-4d4b-a345-4ec409bd2641"
      unitRef="U_USD">5910000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_bb0181ca-325b-4168-b1b8-d2a6d84f1568"
      unitRef="U_USD">5276000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_1c7abaca-ab76-447d-b5e0-1099b7e82784"
      unitRef="U_USD">12031000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_e8c730cc-aee4-4693-94be-f3b7cc5788fb"
      unitRef="U_USD">11507000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_6b2b8e3a-65c1-4474-bae6-d9d535fc9e74"
      unitRef="U_USD">17941000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_3e2f78a7-3683-42b7-a109-c982523a89e4"
      unitRef="U_USD">16783000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      id="F_710a5a8b-e3e5-49fa-9937-908aa3f36f3b">P2Y9M10D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      id="F_7fd5f65a-6079-4786-bda5-52d6d6b6dd44">P3Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="3"
      id="F_394292ee-a159-4f2d-9c1f-74381a292d22"
      unitRef="U_pure">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="3"
      id="F_509adcdd-37b0-4bcc-a6a4-6a4c85f1cd9f"
      unitRef="U_pure">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_0cdeae1f-a29d-4e60-b17f-6660cec78a7c">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.111%;"/&gt;
        &lt;td style="width:1.795%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Future minimum payments required under operating leases as of December 31, 2021 were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.097%;"/&gt;
        &lt;td style="width:1.781%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.122%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total future undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,315&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,783&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;______________________________________&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Maturities for 2022 are net of lease incentives of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million allocated to the Palo Alto office.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_8daa879c-f23b-4760-9201-58bcdc69e1f6"
      unitRef="U_USD">6684000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_d5c3b307-6304-4fb5-9046-0d58d3fb52e3"
      unitRef="U_USD">6850000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_bba7db4e-eec5-4212-adda-f220477e8637"
      unitRef="U_USD">7022000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_e6972401-816d-4a7f-8193-2224f42129f7"
      unitRef="U_USD">20556000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_cfc3e5fa-ada8-43cc-b2d9-81c4104059c3"
      unitRef="U_USD">2615000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_cc28c3d0-8cb7-42f2-bb32-15f249fd1db3"
      unitRef="U_USD">17941000</us-gaap:OperatingLeaseLiability>
    <pcvx:LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_99b7e5aa-ca0b-4683-a754-60df640d4e91"
      unitRef="U_USD">105000</pcvx:LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_02982b57-1671-4ee8-ae77-9f1dd00fa37a"
      unitRef="U_USD">6639000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_e98c9969-9622-417f-994e-6a472fdfc428"
      unitRef="U_USD">6805000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_2fa30b11-5ac5-48f9-86fd-2627adf99b13"
      unitRef="U_USD">6976000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_fda597da-0fff-48c4-bc08-ee67cfd4f6f5"
      unitRef="U_USD">20315000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_7501ad20-bd9f-4613-a992-3a77c0f81dcd"
      unitRef="U_USD">3532000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_42faba48-ca08-47dd-9c3d-573d3a17ba63"
      unitRef="U_USD">16783000</us-gaap:OperatingLeaseLiability>
    <pcvx:LeasePaymentReceivableNoncurrent
      contextRef="C_82ee469c-c1fb-46f6-bd16-0bd5b700dbdb"
      decimals="-5"
      id="F_5aefd7ae-39b5-4a46-8c43-abbdf9be1a92"
      unitRef="U_USD">900000</pcvx:LeasePaymentReceivableNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-5"
      id="F_8e962e5d-fa40-49fc-ac32-56c68d356e77"
      unitRef="U_USD">7900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-5"
      id="F_0fd6f9d1-4144-468e-956d-0856a50821fe"
      unitRef="U_USD">3200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-5"
      id="F_3aec171f-4d79-41fc-8bf1-a27a9e490466"
      unitRef="U_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_a3517253-5eca-4478-b66c-efc9f307cbdd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Legal Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From time to time, we may become involved in legal proceedings arising from the ordinary course of business. We record a liability for such matters when it is probable that future losses will be incurred and that such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. We do not believe that there is any litigation or asserted or unasserted claim pending that could, individually or in the aggregate, have a material adverse effect on our results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the normal course of business, we enter into agreements that contain a variety of representations and provide for general indemnification. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. As of December 31, 2022, we did not have any material indemnification claims that were probable or reasonably possible and consequently have not recorded related liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To the extent permitted under Delaware law, we have agreed to indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the director&#x2019;s or officer&#x2019;s service. The maximum potential amount of future payments we could be required to make under these indemnification agreements is not specified in the agreements; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We have not incurred any material costs as a result of such indemnification and are not currently aware of any indemnification claims.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Development and Manufacturing Services Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2016, we entered into a non-exclusive development and manufacturing services agreement, as amended, with Lonza (the &#x201c;2016 Lonza DMSA&#x201d;) pursuant to which Lonza is obligated to perform manufacturing process development and the manufacture of components for VAX-24, including the polysaccharide antigens, our proprietary eCRM protein carrier and conjugated drug substances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the September 2017, we and Lonza agreed to defer the completion payments for any stage that commenced after December 31, 2019 or had not been completed by December 31, 2019 until the earlier of the completion of all Investigational New Drug (&#x201c;IND&#x201d;)-enabling activities or December 31, 2020. In March 2020, Lonza agreed to defer the completion payments until the earlier of the completion of all IND-enabling activities or April 30, 2021. In April 2021, Lonza further agreed to defer &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the completion payments until the earlier of the completion of all IND-enabling activities or December 31, 2021. Pursuant to this agreement, all deferred completion payments were paid in December 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2018, we entered into a letter agreement with Lonza (the &#x201c;Lonza Letter Agreement&#x201d;) pursuant to which we agreed to certain terms for potential future payments in shares of our common stock as partial satisfaction of future obligations to Lonza. The Lonza Letter Agreement states that the initial pre-IND cash payments under the 2016 Lonza DMSA would be subject to a specified dollar cap (the &#x201c;Initial Cash Cap&#x201d;). After the Initial Cash Cap has been reached, we would have the option to make any further pre-IND payments owed to Lonza in cash, in shares of our common stock at then market prevailing prices, or a combination of both, at our election. In April 2021, we reached the Initial Cash Cap and notified Lonza that we would be exercising our option to issue approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in shares of our common stock as payment for a portion of pre-IND payments due April 30, 2021. In June 2021, we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;399,680&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock to Lonza at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.02&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share to pay for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the pre-IND payments due April 30, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2018, we entered into a second non-exclusive development and manufacturing services agreement with Lonza (the &#x201c;2018 Lonza DMSA&#x201d;), pursuant to which Lonza is obligated to perform services including manufacturing process development and the manufacture and supply of VAX-24 finished drug product. &lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2022, we entered into a third non-exclusive development and manufacturing services agreement, as amended, with Lonza (the &#x201c;2022 Lonza DMSA&#x201d;) effective as of March 22, 2022. Pursuant to the 2022 Lonza DMSA, Lonza will perform manufacturing process development and clinical manufacture and supply of our proprietary PCV.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under each of the 2016 Lonza DMSA, 2018 Lonza DMSA and 2022 Lonza DMSA (collectively, the &#x201c;Lonza Agreements&#x201d;), we will pay Lonza agreed-upon fees for its performance of development and manufacturing services and pass through expenses incurred by Lonza for raw materials, as well as customary procurement and handling fees. Under each Lonza Agreement, we will own all right, title and interest in and to any and all New Customer Intellectual Property (as defined in each Lonza Agreement), and Lonza shall own all right, title and interest in New General Application Intellectual Property (as defined in each Lonza Agreement). Subject to the terms and conditions set forth in the Lonza Agreements, Lonza granted us a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property (as defined in each Lonza Agreement), to research, develop, make, have made, use, sell and import the Product (as defined in each Lonza Agreement) manufactured under each Lonza Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Sutro Option Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2022, we entered into an Option Agreement with Sutro Biopharma, pursuant to which we acquired from Sutro Biopharma (i) authorization to enter into an agreement with an independent alternate CMO to directly source Sutro Biopharma&#x2019;s cell-free extract, allowing us to have direct oversight over financial and operational aspects of the relationship with the CMO; and (ii) a right, but not an obligation, to obtain certain exclusive rights to internally manufacture and/or source extract from certain CMOs and the right to independently develop and make improvements to extract (including the right to make improvements to the extract manufacturing process as well as cell lines) for use in connection with the exploitation of certain vaccine compositions (the &#x201c;Option&#x201d;). We and Sutro Biopharma have agreed to negotiate the terms and conditions of a form definitive agreement to be entered into in the event we exercise the Option, which shall include the terms and conditions set forth in an executed term sheet between us (the &#x201c;Term Sheet&#x201d;), and such terms that are necessary to give effect to each of the terms and conditions set forth in the Term Sheet (the &#x201c;Form Definitive Agreement&#x201d;). The Option period&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;is five years from the date of the Option Agreement, subject to potential acceleration in the event we undergo a change of control.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As consideration for the Option and other rights and authorizations granted to us under the Option Agreement, we agreed to pay Sutro Biopharma upfront consideration of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, consisting of (i) $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million worth of shares of our common stock (the number of shares to be calculated based on the arithmetic average of the daily volume weighted average price of our common stock as traded on Nasdaq in the three consecutive trading days immediately prior to the issuance thereof), and (ii) $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million payable within five business days after we and Sutro Biopharma mutually agree in writing upon the Form Definitive Agreement. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;167,780&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock issued was recorded at fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million on the date of settlement, December 22, 2022. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the event that we elect to exercise the Option, we would pay Sutro Biopharma an aggregate Option exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash in two installments and, upon the occurrence of certain regulatory milestones, certain additional milestone payments totaling up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash. In the event that we undergo a change of control, certain rights and payments may be accelerated.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, we have determined there is no current alternative future use of the acquired manufacturing rights paid and accrued for the option as of December 31, 2022. We have classified such costs incurred in entering the Option Agreement as Acquired Manufacturing Rights on the accompanying statement of operations for the year ended December 31, 2022. Part of the total cost incurred as reported on the statement of operations for the year ended December 31, 2022 is a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million accrued commitment that remains outstanding as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Purchase Commitments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We enter into agreements in the normal course of business with CMOs and other vendors for manufacturing services and raw materials purchases. We rely on several third-party manufacturers for our manufacturing requirements.&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, we had the following amounts due of non-cancelable purchase commitments related to manufacturing services and raw materials purchased due to our key manufacturing partners. These amounts represent our minimum contractual obligations, including termination fees. If we terminate certain firm orders with key manufacturing partners, we will be required to pay for the manufacturing services scheduled or raw materials purchased under our arrangements. The actual amounts we pay in the future to our vendors under such agreements may differ from the purchase order amounts. &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:85.35%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.649999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total non-cancelable purchase commitments due to key manufacturing partners&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pcvx:PercentageOfPaymentsCompletionAgreedToDefer
      contextRef="C_34ff63dc-cde8-47e8-9597-b638326cc368"
      decimals="2"
      id="F_ffbcbb61-424c-4ac0-b84d-d1b6892c5215"
      unitRef="U_pure">0.50</pcvx:PercentageOfPaymentsCompletionAgreedToDefer>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_dc8ae2fa-cfee-4adf-934b-b757251456e3"
      decimals="-5"
      id="F_53983d96-fd1f-4f13-82b0-3d11c01b3ee2"
      unitRef="U_USD">10000000.0</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_d5787b64-58e9-406e-ab46-d4feaf208a20"
      decimals="0"
      id="F_31232a27-39ce-4cb5-b3d7-df60c618f3c8"
      unitRef="U_shares">399680</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_66f9bfcc-ebad-40de-95bf-47b87ed044a4"
      decimals="2"
      id="F_5ef2c43a-8f54-4e68-a4a0-7e1239038942"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.02</us-gaap:SharesIssuedPricePerShare>
    <pcvx:DevelopmentAndManufacturingServicesAgreementPaymentsInEquity
      contextRef="C_2851b72e-f235-4e1b-8ad0-09f3525757c9"
      decimals="-5"
      id="F_29d3f676-78bc-44e8-952c-14d34197a347"
      unitRef="U_USD">10000000.0</pcvx:DevelopmentAndManufacturingServicesAgreementPaymentsInEquity>
    <pcvx:UpfrontConsideration
      contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189"
      decimals="-5"
      id="F_1e39a2aa-124c-45ff-b993-c1d816c909c0"
      unitRef="U_USD">22500000</pcvx:UpfrontConsideration>
    <pcvx:UpfrontConsiderationInCash
      contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189"
      decimals="-5"
      id="F_7279ad40-830b-456a-a2fc-04cf8f11e8cc"
      unitRef="U_USD">10000000.0</pcvx:UpfrontConsiderationInCash>
    <pcvx:UpfrontConsideration
      contextRef="C_84e39903-4e50-46bc-a706-ef2201e6c504"
      decimals="-5"
      id="F_f38716d9-f284-4400-9821-fd2d6a7c807a"
      unitRef="U_USD">7500000</pcvx:UpfrontConsideration>
    <pcvx:UpfrontConsiderationInCashAfterAgreementDate
      contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189"
      decimals="-5"
      id="F_6f7ec2c9-1324-4f91-9ac1-96a33e575297"
      unitRef="U_USD">5000000.0</pcvx:UpfrontConsiderationInCashAfterAgreementDate>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189"
      decimals="INF"
      id="F_f969309f-baf3-4b5a-8f9d-b138b0d8f482"
      unitRef="U_shares">167780</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <pcvx:FairValueOnDateOfSettlement
      contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189"
      decimals="-5"
      id="F_2e4eb81d-26f9-4399-a4c9-e2c064532345"
      unitRef="U_USD">8000000.0</pcvx:FairValueOnDateOfSettlement>
    <pcvx:OptionExercisePriceInCash
      contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189"
      decimals="-5"
      id="F_e0dd3df2-80c5-49ae-a92d-66a3ba22765a"
      unitRef="U_USD">75000000.0</pcvx:OptionExercisePriceInCash>
    <pcvx:AdditionalMilestonePaymentsInCash
      contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189"
      decimals="-5"
      id="F_7163bbb5-b8a3-4dcc-bd89-d0639b229a03"
      unitRef="U_USD">60000000.0</pcvx:AdditionalMilestonePaymentsInCash>
    <pcvx:AccruedCommitment
      contextRef="C_69ba85f7-550d-45b3-a266-5784d58b8189"
      decimals="-5"
      id="F_fbe34cae-fca9-461e-8992-3fd1e7094936"
      unitRef="U_USD">5000000.0</pcvx:AccruedCommitment>
    <pcvx:ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_b6d26212-f5ea-49c5-9bfa-630a1b9aa027">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, we had the following amounts due of non-cancelable purchase commitments related to manufacturing services and raw materials purchased due to our key manufacturing partners. These amounts represent our minimum contractual obligations, including termination fees. If we terminate certain firm orders with key manufacturing partners, we will be required to pay for the manufacturing services scheduled or raw materials purchased under our arrangements. The actual amounts we pay in the future to our vendors under such agreements may differ from the purchase order amounts. &lt;/span&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:85.35%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.649999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,471&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total non-cancelable purchase commitments due to key manufacturing partners&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;125,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pcvx:ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock>
    <pcvx:NoncancelablePurchaseCommitmentsDueInOneYear
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_ff009a55-560b-4533-81ac-630ba33ed3e4"
      unitRef="U_USD">123099000</pcvx:NoncancelablePurchaseCommitmentsDueInOneYear>
    <pcvx:NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_6297db34-f9ed-4f87-b25d-730ea69920ae"
      unitRef="U_USD">2471000</pcvx:NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter>
    <pcvx:NonCancelablePurchaseCommitments
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_58184048-ad75-4f0d-be3d-5c1bf7765250"
      unitRef="U_USD">125570000</pcvx:NonCancelablePurchaseCommitments>
    <pcvx:RedeemableConvertiblePreferredStockTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_e965efae-926c-400b-bf52-26d5af2dddc8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of redeemable convertible preferred stock authorized or outstanding as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with our IPO in June 2020, the outstanding shares of our Series A, Series B, Series C and Series D Redeemable Convertible Preferred Stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,610,337&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;</pcvx:RedeemableConvertiblePreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e5603f34-fe33-4aa9-bba2-7bcef1212dc9"
      decimals="INF"
      id="F_41b3e8c3-51a1-4d3e-bf52-68881071fb65"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_e5603f34-fe33-4aa9-bba2-7bcef1212dc9"
      decimals="INF"
      id="F_ad86c756-e98b-484b-a1b2-5a1997ab48fa"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_52984cc7-0416-45ea-9199-ee6f2a1b640f"
      decimals="INF"
      id="F_20f37527-4e84-495e-8ebc-73d2d45d118e"
      unitRef="U_shares">28610337</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_e58f6507-588f-4310-b24c-632462cc7f21">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our certificate of incorporation authorizes us to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;500,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; par value per share, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,470,670&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,031,978&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were issued and outstanding as of December 31, 2022 and 2021, respectively. The holders of our common stock are also entitled to receive dividends whenever funds are legally available, when and if declared by our board of directors. As of December 31, 2022 and 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; dividends have been declared. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Each share of common stock is entitled to one vote.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2021, we entered into an Open Market Sales Agreement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;SM&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the &#x201c;ATM Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, we&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million through Jefferies acting as our sales agent or principal. We are obligated to pay Jefferies a commission of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the gross sales proceeds of any common stock sold through Jefferies under the ATM Sales Agreement; however, we are not obligated to make any sales of common stock. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, we have sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,488,573&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock under the ATM Sales Agreement at an average price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.56&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million net of commissions and offering expenses).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In January 2022, we completed an underwritten public offering in which we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per underlying share. In February 2022, t&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;he underwriters exercised their option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. In aggregate, we received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;107.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2022, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;we completed an underwritten public offering in which we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per underlying share. T&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;he underwriters exercised their option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,812,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock. In aggregate, we received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;651.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by us, and excluding the exercise of any pre-funded warrants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) and the 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) was as&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; follows, and excludes &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,710&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares issued outside of the 2014 Plan and 2020 Plan:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.479%;"/&gt;
        &lt;td style="width:1.018%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.229999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.031%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.243%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,715,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Restricted stock units issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;456,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Shares available for future stock option grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,679,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,104,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,851,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,399,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_aa0a1e84-d5a5-4568-9796-d3144097f7ed"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_c75e07d0-481d-4cde-bb17-783265db33a2"
      unitRef="U_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="3"
      id="F_b5bbe6b6-32f6-41fd-b5af-c9c15d4b4ca7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="3"
      id="F_d6acd5cd-cac9-4b02-af08-bb4c98f5724a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_287c2138-71e8-4f49-b6de-a955f1fc08ec"
      unitRef="U_shares">79470670</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="INF"
      id="F_01ce074b-0b90-4506-b3b7-60180cfb96d2"
      unitRef="U_shares">79470670</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_dbaa1395-fc56-45e9-a6ee-1994afa3792c"
      unitRef="U_shares">53031978</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="INF"
      id="F_9e501eff-e98a-4147-8a99-7262a1ebafc3"
      unitRef="U_shares">53031978</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="INF"
      id="F_c8a34a60-f995-479f-a98d-fdc37b9362a2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="INF"
      id="F_0ab0c774-e12a-41a1-85b3-f1993bd0811b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockVotingRights
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_23df03bd-5040-4b78-929a-16028a34cf7c">Each share of common stock is entitled to one vote.</us-gaap:CommonStockVotingRights>
    <pcvx:SaleOfCommonStockAuthorizedAmount
      contextRef="C_c14f87d8-1d33-40ea-b99b-b33fe6411911"
      decimals="INF"
      id="F_9b334432-69f1-40ba-99e3-3e506de37fe7"
      unitRef="U_USD">150000000.0</pcvx:SaleOfCommonStockAuthorizedAmount>
    <pcvx:MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold
      contextRef="C_b92aaa0b-aeff-4d69-a84f-c6311d27ad82"
      decimals="INF"
      id="F_82a25bc0-6a7a-49a4-aa02-16f45adb3f87"
      unitRef="U_pure">0.030</pcvx:MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c9b4f586-2146-4cbd-aa92-140916b46d25"
      decimals="INF"
      id="F_75e962a6-a116-4907-b957-52a4d6e8ee2c"
      unitRef="U_shares">4488573</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_605b60d5-91b3-4448-ba68-5bd37a009e74"
      decimals="2"
      id="F_a4c839b5-e99b-402c-a2f0-c3e33289bfcf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">25.56</us-gaap:SaleOfStockPricePerShare>
    <pcvx:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_c9b4f586-2146-4cbd-aa92-140916b46d25"
      decimals="-5"
      id="F_3e37258f-a8e7-46a6-b61f-e93ba682dbc7"
      unitRef="U_USD">114700000</pcvx:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_c9b4f586-2146-4cbd-aa92-140916b46d25"
      decimals="-5"
      id="F_0abb7af5-bb50-446d-a095-eb7f03821af7"
      unitRef="U_USD">111200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering
      contextRef="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e"
      decimals="INF"
      id="F_e7799abd-2b27-460b-8afd-0ae056d90a13"
      unitRef="U_shares">2500000</pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering>
    <pcvx:SharesIssuedPricePerShareUponFollowOnOffering
      contextRef="C_59365215-3504-4f12-b752-122da006773a"
      decimals="2"
      id="F_11e11467-eee6-4331-b6c0-7bccaa0795bd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.00</pcvx:SharesIssuedPricePerShareUponFollowOnOffering>
    <pcvx:SharesPreFundedWarrantsToPurchase
      contextRef="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e"
      decimals="INF"
      id="F_ff5cd037-2917-4c7f-971a-de3c010b48eb"
      unitRef="U_shares">2500000</pcvx:SharesPreFundedWarrantsToPurchase>
    <pcvx:PrefundedWarrantsPricePerShare
      contextRef="C_59365215-3504-4f12-b752-122da006773a"
      decimals="3"
      id="F_b72faa2a-d1c0-4f2a-b857-32be0e815b6c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.999</pcvx:PrefundedWarrantsPricePerShare>
    <pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares
      contextRef="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e"
      decimals="INF"
      id="F_0949036f-7a7a-4708-97e6-e36968bf6343"
      unitRef="U_shares">750000</pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares>
    <pcvx:ProceedsFromIssuanceFollowOnOffering
      contextRef="C_953d36c7-37e6-4886-9a1e-f6fef5145d7e"
      decimals="-5"
      id="F_77e4d027-96a8-4e07-8c92-c1b74934615d"
      unitRef="U_USD">107600000</pcvx:ProceedsFromIssuanceFollowOnOffering>
    <pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering
      contextRef="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3"
      decimals="INF"
      id="F_a12b099b-ed68-4116-9fe5-8c860ef5d7af"
      unitRef="U_shares">15000000</pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering>
    <pcvx:SharesIssuedPricePerShareUponFollowOnOffering
      contextRef="C_a5d59d19-2f5b-474d-ad5f-5eb6826a0e4c"
      decimals="2"
      id="F_d855f6ec-f777-4dce-97bc-107206af895f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.00</pcvx:SharesIssuedPricePerShareUponFollowOnOffering>
    <pcvx:SharesPreFundedWarrantsToPurchase
      contextRef="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3"
      decimals="INF"
      id="F_ad924f98-adb3-4369-81e0-c44e211ebf96"
      unitRef="U_shares">3750000</pcvx:SharesPreFundedWarrantsToPurchase>
    <pcvx:PrefundedWarrantsPricePerShare
      contextRef="C_a5d59d19-2f5b-474d-ad5f-5eb6826a0e4c"
      decimals="3"
      id="F_406f47cb-94a1-4864-8b4c-782c05abb03c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">31.999</pcvx:PrefundedWarrantsPricePerShare>
    <pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares
      contextRef="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3"
      decimals="INF"
      id="F_d243af4b-d7a1-45f8-a7be-3a9e8d11ebe7"
      unitRef="U_shares">2812500</pcvx:SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares>
    <pcvx:ProceedsFromIssuanceFollowOnOffering
      contextRef="C_264bd6dd-602e-4f74-8ef0-f9d98988b1b3"
      decimals="-5"
      id="F_cb8f8505-1213-4d80-92ab-65f5262cbe54"
      unitRef="U_USD">651600000</pcvx:ProceedsFromIssuanceFollowOnOffering>
    <pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_abce17e8-3319-459f-a49d-a30f14d5241a">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Common stock reserved for future issuances under the 2020 Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;) and the 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) was as&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; follows, and excludes &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,710&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares issued outside of the 2014 Plan and 2020 Plan:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.479%;"/&gt;
        &lt;td style="width:1.018%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.229999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.031%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.243%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,715,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Restricted stock units issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;456,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;Shares available for future stock option grants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,679,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,104,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,851,858&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,399,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="INF"
      id="F_f2dbe6b9-65fc-4046-b5a0-b3dbabf8878d"
      unitRef="U_shares">36710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5d6c3586-ec99-4387-90b9-c66ada981bf1"
      decimals="INF"
      id="F_3514cf91-39c7-4575-b8f7-052d182590ad"
      unitRef="U_shares">7715494</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_f9ef3af6-0ed6-4232-82f8-f00e3b3f9c04"
      decimals="0"
      id="F_d39c7543-9524-4757-8eeb-b74e812f75c4"
      unitRef="U_shares">5295007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_043847b8-3b71-486a-a3f8-651e1b7e0b0e"
      decimals="INF"
      id="F_84ed59c9-6d4c-417d-bdc8-b81debdfd1f5"
      unitRef="U_shares">456766</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_87eb225f-5c0d-43e6-859d-fe29381daaa2"
      decimals="INF"
      id="F_ad637c56-7470-4241-9a8c-c469199d92aa"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0cec58be-bb3d-44e1-8f46-324ba1e7a4d9"
      decimals="INF"
      id="F_3e2238f0-febf-419d-a8d9-0848c51b3f8d"
      unitRef="U_shares">4679598</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ff59dd17-1515-4475-9b29-d6981afba232"
      decimals="0"
      id="F_48909ff5-d119-4c8f-819d-b93105d7ed6e"
      unitRef="U_shares">6104756</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="INF"
      id="F_1c07483e-13c4-45cc-9793-ef8a46cfa4f5"
      unitRef="U_shares">12851858</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_042e7705-d42e-4637-8ecc-6de667d73494"
      decimals="0"
      id="F_fd7bbc3a-c28d-43ba-80d7-a3d86e31c352"
      unitRef="U_shares">11399763</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pcvx:WarrantsDisclosureTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_b5ec554e-ae72-4d90-b847-f44770afe531">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;P&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;re-Funded Warrants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with our underwritten public offering in January 2022, we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per underlying share. Each pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with our underwritten public offering in October 2022, we issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and pre-funded warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,750,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per underlying share. Each pre-funded warrant has an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The public offering price for the pre-funded warrants was equal to the public offering price of our common stock, less the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; exercise price of each pre-funded warrant and was recorded as a component of stockholders' equity within additional paid-in-capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The pre-funded warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and payment of the exercise price. No fractional shares of common stock will be issued in connection with the exercise of a pre-funded warrant. The holder of the pre-funded warrants may also satisfy its obligation to pay the exercise price through a "cashless exercise," in which the holder receives the net value of the pre-funded warrant in shares of common stock determined according to the formula set forth in the pre-funded warrant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The pre-funded warrants will not expire until they are fully exercised. However, we may not effect the exercise of any pre-funded warrants, and a holder will not be entitled to exercise any portion of any pre-funded warrants that, upon giving effect to such exercise, would cause: (i) the aggregate number of shares of our common stock beneficially owned by such holder (together with affiliates) to exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as applicable; or (ii) the combined voting power of our securities beneficially owned by such holder (together with its affiliates) to exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the combined voting power of all of our securities outstanding immediately after giving effect to the exercise, as applicable, as such percentage ownership is determined in accordance with the terms of the pre-funded warrants. However, any holder of a pre-funded warrant may increase or decrease such percentage to any other percentage not in excess of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% upon at least 61 days' prior notice for the holder to us. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares underlying the pre-funded warrants had been exercised.&lt;/span&gt;&lt;/p&gt;</pcvx:WarrantsDisclosureTextBlock>
    <pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering
      contextRef="C_a6eb96b6-2f08-472a-ba13-12abc92474e8"
      decimals="INF"
      id="F_db6be5df-5c34-4adc-a9cf-61ce524fce22"
      unitRef="U_shares">2500000</pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering>
    <pcvx:SharesIssuedPricePerShareUponFollowOnOffering
      contextRef="C_98587108-31fb-4048-8311-ad1171d7b550"
      decimals="2"
      id="F_6038b104-0ab9-4ab0-8836-c51307ee6700"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.00</pcvx:SharesIssuedPricePerShareUponFollowOnOffering>
    <pcvx:SharesPreFundedWarrantsToPurchase
      contextRef="C_a6eb96b6-2f08-472a-ba13-12abc92474e8"
      decimals="INF"
      id="F_b70c30fb-dc5b-4f96-8e05-c9b60c5e4225"
      unitRef="U_shares">2500000</pcvx:SharesPreFundedWarrantsToPurchase>
    <pcvx:PrefundedWarrantsPricePerShare
      contextRef="C_98587108-31fb-4048-8311-ad1171d7b550"
      decimals="3"
      id="F_21e3d084-3688-4fdc-90bd-2eb4df8a7ad4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.999</pcvx:PrefundedWarrantsPricePerShare>
    <pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
      contextRef="C_93cfc9bc-cf41-46c8-8d8c-3c249f9e296f"
      decimals="3"
      id="F_2ebee7a2-1189-40d1-bc74-cef7d67f0c37"
      unitRef="U_shares">0.001</pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised>
    <pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering
      contextRef="C_627bc919-0f57-4ed7-9267-0f6ca3c2b3c9"
      decimals="INF"
      id="F_f3cc0bba-2703-41f8-948e-4b4e9ffd682b"
      unitRef="U_shares">15000000</pcvx:StockIssuedDuringPeriodSharesOfFollowOnOffering>
    <pcvx:SharesIssuedPricePerShareUponFollowOnOffering
      contextRef="C_93593151-df16-4d93-bf9c-30716b99adb7"
      decimals="2"
      id="F_d84e45ad-8479-432e-90e2-e25c4a310179"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">32.00</pcvx:SharesIssuedPricePerShareUponFollowOnOffering>
    <pcvx:SharesPreFundedWarrantsToPurchase
      contextRef="C_627bc919-0f57-4ed7-9267-0f6ca3c2b3c9"
      decimals="0"
      id="F_990c8c7a-4b3e-42d8-83f6-31f3a8fcc932"
      unitRef="U_shares">3750000</pcvx:SharesPreFundedWarrantsToPurchase>
    <pcvx:PrefundedWarrantsPricePerShare
      contextRef="C_93593151-df16-4d93-bf9c-30716b99adb7"
      decimals="3"
      id="F_0ee81ebe-3397-42a5-b73b-c1884cd93c7f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">31.999</pcvx:PrefundedWarrantsPricePerShare>
    <pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
      contextRef="C_c80a26a1-b95a-44f9-acc5-6127ef778da7"
      decimals="3"
      id="F_9ce5ef9d-d5cf-4c86-a2ad-ba7277fe4bdb"
      unitRef="U_shares">0.001</pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised>
    <pcvx:PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital
      contextRef="C_a6eb96b6-2f08-472a-ba13-12abc92474e8"
      decimals="3"
      id="F_a7c31d81-4958-4b0b-8e8f-498b2972658d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</pcvx:PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital>
    <pcvx:PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital
      contextRef="C_627bc919-0f57-4ed7-9267-0f6ca3c2b3c9"
      decimals="3"
      id="F_94f4bc45-5b76-4900-b49a-0ae285e62731"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</pcvx:PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital>
    <pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise
      contextRef="C_db08c559-8805-4810-a9ad-817d3efd45a5"
      decimals="4"
      id="F_4a6eb7af-9aa1-4c1a-bdcd-3d2d2c511c36"
      unitRef="U_pure">0.0499</pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise>
    <pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise
      contextRef="C_783f07a1-06d5-4961-9f5d-5e2270a1613f"
      decimals="4"
      id="F_d0f94906-426a-4b75-81c8-7600fcedfc6c"
      unitRef="U_pure">0.0499</pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise>
    <pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise
      contextRef="C_adf7111c-3503-433b-85ea-ba5266a3bec4"
      decimals="4"
      id="F_5cc6da17-9301-4281-a08b-7e98b2047d7c"
      unitRef="U_pure">0.0999</pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise>
    <pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise
      contextRef="C_58188e6f-33df-4637-971c-bb69de27b7a1"
      decimals="4"
      id="F_f0b75f6f-be47-4ddb-9b51-20863a4d1513"
      unitRef="U_pure">0.0999</pcvx:PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise>
    <pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise
      contextRef="C_db08c559-8805-4810-a9ad-817d3efd45a5"
      decimals="4"
      id="F_dd056b37-61fc-4077-a911-43c14f4a239b"
      unitRef="U_pure">0.0499</pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise>
    <pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise
      contextRef="C_783f07a1-06d5-4961-9f5d-5e2270a1613f"
      decimals="4"
      id="F_75f1c78c-82f7-4b04-84f0-076aa48992bc"
      unitRef="U_pure">0.0499</pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise>
    <pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise
      contextRef="C_adf7111c-3503-433b-85ea-ba5266a3bec4"
      decimals="4"
      id="F_0da43196-d87a-4c3b-9d80-280376f93607"
      unitRef="U_pure">0.0999</pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise>
    <pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise
      contextRef="C_58188e6f-33df-4637-971c-bb69de27b7a1"
      decimals="4"
      id="F_427d13f5-74af-4ade-bb51-239adb2dcac0"
      unitRef="U_pure">0.0999</pcvx:CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise>
    <pcvx:IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed
      contextRef="C_e9126c57-d4e4-4b9e-8373-4b493ee1f1c1"
      decimals="4"
      id="F_3dd7db05-ee79-4901-a0a1-a83730a11f32"
      unitRef="U_pure">0.1999</pcvx:IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed>
    <pcvx:IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed
      contextRef="C_52a9c5b1-8f71-49a0-af0c-9cb853cc2232"
      decimals="4"
      id="F_04a5251b-d65f-43b4-b553-374f50efc162"
      unitRef="U_pure">0.1999</pcvx:IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed>
    <pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="0"
      id="F_ee876944-07e0-445b-a05a-05f01e163cda"
      unitRef="U_shares">0</pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_43162c2a-b812-48a6-bff5-1049258e1038">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020 and 2014 Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Plan, which became effective on June 11, 2020. Under the 2020 Plan, we may grant stock options, appreciation rights, restricted stock and restricted stock units (RSUs) to employees, consultants and directors. Stock options granted under the 2020 Plan may be either incentive stock options or nonqualified stock options. Incentive stock options may be granted only to our employees, including officers and directors who are also employees. Nonqualified stock options may be granted to our employees, officers, directors, consultants and advisors. The exercise price of stock options granted under the 2020 Plan must be at least equal to the fair market value of the common stock on the date of grant, except that an incentive stock option granted to an employee who owns more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the shares of our common stock shall have an exercise price of no less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the fair value per share on the grant date and expire &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the date of grant. The maximum term of stock options granted under the 2020 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years, unless subject to the provisions regarding &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% stockholders. Our stock options granted to new employees generally vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; at a rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% upon the first anniversary of the vesting commencement date and monthly thereafter. Our other stock options granted to employees generally vest on terms consistent with stock options granted to new employees or monthly over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; from the vesting commencement date. Our RSUs granted to new employees generally vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; at a rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% upon one year from the grant date, then &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% every six months thereafter. Our other RSUs granted to employees generally vest over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_b8edf648-6c56-470f-b105-b7c382767664;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three and a half years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; at a rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% upon six months from the grant date, then &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% every six months thereafter. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,150,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were approved to be initially reserved for issuance under the 2020 Plan. The number of shares that remained available for issuance under the 2014 Plan as of the effective date of the 2020 Plan, and shares subject to outstanding awards under the 2014 Plan as of the effective date of the 2020 Plan that are subsequently canceled, forfeited or repurchased by us, will be added to the shares reserved under the 2020 Plan. In addition, the number of shares of common stock available for issuance under the 2020 Plan is automatically increased on the first day of each calendar year during the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,679,598&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were available for issuance under the 2020 Plan. Effective January 1, 2023, the number of shares of common stock available under the 2020 Plan increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,973,533&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares pursuant to the evergreen provision of the 2020 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our 2014 Plan permitted the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Subsequent to the adoption of the 2020 Plan, no additional equity awards can be made under the 2014 Plan. Shares reserved and remaining available for issuance under the 2014 Plan were added to the 2020 Plan reserve upon its effectiveness.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The terms of the 2014 Plan permit the exercise of options granted prior to vesting, subject to required approvals. The unvested shares are subject to our lapsing repurchase right upon termination of employment at the original purchase price. Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be issued until those shares vest according to their respective vesting schedules. Cash received for early exercised stock options is recorded as other liabilities on the balance sheet and is reclassified to common stock and additional paid-in capital as such shares vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,576,161&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,596,099&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were subject to outstanding options and RSUs under the 2014 Plan and 2020 Plan, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022 and 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,705&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,410&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, respectively, remained subject to our right of repurchase as a result of the early exercised stock options. The remaining liabilities related to early exercised shares as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021 were both less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and were recorded in other liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity under our 2020 Plan and 2014 Plan, which excludes options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,710&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares granted outside of the 2020 Plan and 2014 Plan, was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.622%;"/&gt;
        &lt;td style="width:0.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.203999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.945%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.733%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:5.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.455%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.302%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock Option and Restricted Stock Units Activity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options&lt;br/&gt;and RSUs&lt;br/&gt;Available&lt;br/&gt;for &lt;br/&gt;Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number&lt;br/&gt;of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual &lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances &#x2014; December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,651,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,121,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,553,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,616,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,616,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;926,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;516,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;516,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances &#x2014; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,104,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,651,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,850,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,850,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,153,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;277,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;277,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;581,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units withheld&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances &#x2014; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,679,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,715,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest &#x2014; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,715,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,921,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.81&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;______________________________________&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net exercise - shares returned to the Plan.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022, 2021 and 2020, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,153,285&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;926,514&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;358,264&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of stock options, respectively, were exercised for cash at a weighted-average price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The weighted-average grant date fair value of options granted for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.88&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, respectively. The intrinsic value of the stock options exercised was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 , 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units Activity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2022, our board of directors authorized the issuance of RSUs under our 2020 Plan and adopted a form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement (the "RSU Agreement"), which is intended to serve as a standard form agreement for RSU grants issued to employees. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSU activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.919%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.579%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.831%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.322000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;581,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;456,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2022 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The aggregate fair value of unvested RSU is calculated using the closing price of our common stock on the grant date. As of December 31, 2022, the unrecognized stock-based compensation cost of unvested RSUs was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2020, our board of directors adopted, and our stockholders approved, the 2020 Employee Stock Purchase Plan (the &#x201c;2020 ESPP&#x201d;), which became effective on June 11, 2020. The 2020 ESPP permits participants to purchase common stock through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their eligible compensation. Employees enrolled in the 2020 ESPP, purchase shares of common stock at a price per share equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the lower of the fair market value at the start or end of the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; purchase periods within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; offering period. A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock were approved to be initially reserved for issuance under the 2020 ESPP. In addition, the number of shares of common stock available for issuance under the 2020 ESPP is automatically increased on the first day of each calendar year during the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; term of the 2020 Plan, beginning with January 1, 2021 and ending with January 1, 2030, by an amount of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding number of shares of our common stock on December 31 of the preceding calendar year or such lesser amount as determined by our board of directors. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Activity under our 2020 ESPP was as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.151%;"/&gt;
        &lt;td style="width:11.21%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:25.639%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance - December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares purchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance - December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;622,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;510,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares purchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,070,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;530,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares purchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance - December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,539,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective January 1, 2023, the number of shares of common stock available under the 2020 ESPP increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;794,706&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares pursuant to the evergreen provision of the 2020 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.321%;"/&gt;
        &lt;td style="width:1.357%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
        &lt;td style="width:1.357%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
        &lt;td style="width:1.357%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.12%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:15.385%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:16.998%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:15.363%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We recorded total stock-based compensation expense for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.07%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon our IPO, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;362,935&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; performance-based awards vested and, as a result, we recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of stock-based compensation expense during the three months ended June 30, 2020, which amount is included in the above table for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to the employee and non-employee awards, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pcvx:IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock
      contextRef="C_43290d81-1ade-4236-b12a-f4dfbc9a2de2"
      decimals="2"
      id="F_f03f76a5-8df3-4286-be2e-91df78e32370"
      unitRef="U_pure">0.10</pcvx:IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock>
    <pcvx:PercentageOfFairValuePerShareOnTheGrantDate
      contextRef="C_d94724f5-308f-4538-9078-b37164cc96a1"
      decimals="2"
      id="F_5cefa694-fff3-4ed3-b69e-b23ba1d6167b"
      unitRef="U_pure">1.10</pcvx:PercentageOfFairValuePerShareOnTheGrantDate>
    <pcvx:ExercisePriceExpireInYearsFormTheDateOfGrant
      contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11"
      id="F_fe97d24f-1e58-4d37-9a72-f5720e097df6">P5Y</pcvx:ExercisePriceExpireInYearsFormTheDateOfGrant>
    <pcvx:StockOptionsGrantedTerm
      contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11"
      id="F_e0c1ad2b-3363-468e-9692-018a4288c9c0">P10Y</pcvx:StockOptionsGrantedTerm>
    <pcvx:PercentageOfProvisionsSubjectToStockholders
      contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11"
      decimals="2"
      id="F_5f9b9d56-c4fc-44b5-ac87-04c57d199772"
      unitRef="U_pure">0.10</pcvx:PercentageOfProvisionsSubjectToStockholders>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_5174e359-4705-4039-af81-628498b266ac"
      id="F_dc9c46fb-fbb6-4340-ba13-5a83fa4c22d5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_5174e359-4705-4039-af81-628498b266ac"
      decimals="2"
      id="F_b075b631-3aaf-441a-a10e-5e5c009ffb42"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_5174e359-4705-4039-af81-628498b266ac"
      id="F_c93b7b7c-0287-48f5-bfe1-4c1902b3d062">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_acd4f53c-e76e-4bcc-8f97-102bcec4707b"
      id="F_7c5dd4eb-499c-4c6c-93e3-8aa0f487a69c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_acd4f53c-e76e-4bcc-8f97-102bcec4707b"
      decimals="2"
      id="F_ac13dace-50c2-4182-aa1d-2df82db2eef3"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage
      contextRef="C_acd4f53c-e76e-4bcc-8f97-102bcec4707b"
      decimals="3"
      id="F_5e4dd252-90c0-46b6-a970-3e434cbf656b"
      unitRef="U_pure">0.125</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_5174e359-4705-4039-af81-628498b266ac"
      decimals="2"
      id="F_87333512-2e17-4112-88bb-29cda88e1b2e"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage
      contextRef="C_295fc304-a24b-4340-bef2-fe78e40e2989"
      decimals="3"
      id="F_a120ba86-7b33-4f10-9b67-10378aee3c06"
      unitRef="U_pure">0.125</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_20d86c4a-c1e6-415d-8039-887d6b20d17f"
      decimals="INF"
      id="F_0823a93d-5b86-4684-b76a-082aa2babebf"
      unitRef="U_shares">10150000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11"
      id="F_14afdb15-bc14-42de-b3eb-96a33131d449">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_28391222-5a1c-470d-ab50-f5f6861c6e11"
      decimals="INF"
      id="F_ea61eb49-8bae-4143-ba55-ba0ba0b95d0a"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_8842095a-a719-4e20-84ac-651814b90d5f"
      decimals="INF"
      id="F_23afa9d1-7374-4d8e-80d2-969891193c2e"
      unitRef="U_shares">4679598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant
      contextRef="C_323a4631-8d67-46bd-b2bd-7c01a7ec7d2f"
      decimals="INF"
      id="F_a9b4dfa1-3b4d-4027-b608-0ae27f06e802"
      unitRef="U_shares">3973533</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_c411c849-9449-415d-836c-57f752c96e04"
      decimals="INF"
      id="F_4dd0258e-6bfc-4a12-8c1d-ba8a877218b9"
      unitRef="U_shares">2576161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_16219b98-47a8-4997-a3e1-39a5a065b63c"
      decimals="INF"
      id="F_e7d67b23-1022-4855-b3c1-4552f9d2f3e0"
      unitRef="U_shares">5596099</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <pcvx:EarlyExercisedStockOptions
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="0"
      id="F_e66ae989-6715-4782-9320-c969ef484f44"
      unitRef="U_shares">3705</pcvx:EarlyExercisedStockOptions>
    <pcvx:EarlyExercisedStockOptions
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="0"
      id="F_6eb6dc0e-e2de-4f8d-b8fb-2b07954ec907"
      unitRef="U_shares">7410</pcvx:EarlyExercisedStockOptions>
    <pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares
      contextRef="C_b1477851-b8b1-4483-a4bf-02d65b12c4e5"
      decimals="-5"
      id="F_acf00274-5f5a-4e98-8fcb-e505ca9912ce"
      unitRef="U_USD">100000</pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares>
    <pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares
      contextRef="C_0598ec3b-a113-4d19-ae05-d08550eafaae"
      decimals="-5"
      id="F_480bc27b-1cea-4599-aefe-71a4178f2d44"
      unitRef="U_USD">100000</pcvx:RemainingLiabilitiesRelatedToEarlyExercisedShares>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      id="F_55a0209d-3146-4957-bf25-e59aedd20686">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock option activity under our 2020 Plan and 2014 Plan, which excludes options to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,710&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares granted outside of the 2020 Plan and 2014 Plan, was as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.622%;"/&gt;
        &lt;td style="width:0.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.203999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.945%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.733%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:5.434%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.455%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.077%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.302%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock Option and Restricted Stock Units Activity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options&lt;br/&gt;and RSUs&lt;br/&gt;Available&lt;br/&gt;for &lt;br/&gt;Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number&lt;br/&gt;of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per&lt;br/&gt;Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual &lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances &#x2014; December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,651,149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,121,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,553,579&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,616,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,616,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;926,514&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;516,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;516,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances &#x2014; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,104,756&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,295,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,651,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,850,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,850,981&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,153,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;277,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;277,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;581,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units withheld&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted Stock Units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balances &#x2014; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,679,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,715,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest &#x2014; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,715,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,921,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.81&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;______________________________________&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net exercise - shares returned to the Plan.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_7a6aa4fc-0c0b-4f2f-a158-fa33f7963b78"
      unitRef="U_shares">36710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_6d173051-b96b-48bb-8554-d94b4601af7b"
      decimals="0"
      id="F_db5686fa-a786-4a9c-95af-51b4eee1225f"
      unitRef="U_shares">4651149</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6d173051-b96b-48bb-8554-d94b4601af7b"
      decimals="0"
      id="F_31592bab-c094-4ada-8699-de329e36758b"
      unitRef="U_shares">5121549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6d173051-b96b-48bb-8554-d94b4601af7b"
      decimals="2"
      id="F_27c852f0-1142-4227-a822-1dd9b6a3b406"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="0"
      id="F_1c302424-5afc-466f-bbd9-125f824a6793"
      unitRef="U_shares">2553579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="0"
      id="F_995e3c1d-8ceb-4983-a9c5-218de77343e4"
      unitRef="U_shares">1616021</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="0"
      id="F_c292bd85-7447-4505-a874-c4271a64cc13"
      unitRef="U_shares">1616021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="2"
      id="F_41b7e0e4-b42a-45ef-a6d1-4955ec78b8c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">21.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="0"
      id="F_c421fbd6-9d80-467c-9997-ac3d7e50b4d9"
      unitRef="U_shares">926514</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="2"
      id="F_3dc8ff29-cd1e-4a22-ac10-abdfed8de01a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="0"
      id="F_e7294c00-b025-44a0-833f-b85bfb71e07e"
      unitRef="U_shares">516049</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="0"
      id="F_7e94de92-ab4f-465a-bc13-63de9126ecdd"
      unitRef="U_shares">516049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_8f016bde-e771-439c-ab98-f01eb018c718"
      decimals="2"
      id="F_4a017cbe-5dfa-4bbc-99ad-d71680b1163f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_042e7705-d42e-4637-8ecc-6de667d73494"
      decimals="0"
      id="F_eecbdbef-aef2-4864-963e-d21199014219"
      unitRef="U_shares">6104756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_042e7705-d42e-4637-8ecc-6de667d73494"
      decimals="0"
      id="F_25af9122-4f44-4409-80f1-dcc547aed7d2"
      unitRef="U_shares">5295007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_042e7705-d42e-4637-8ecc-6de667d73494"
      decimals="2"
      id="F_238cdf2a-a498-492f-8f3b-de56e1d7af76"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="0"
      id="F_871da325-32cd-49a5-ba8e-3d3c143a4c68"
      unitRef="U_shares">2651598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="0"
      id="F_5920847f-135d-4a40-a3e9-f194da93ff40"
      unitRef="U_shares">3850981</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="0"
      id="F_0b4214e3-0e46-4d7f-b750-466df84bebc8"
      unitRef="U_shares">3850981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="2"
      id="F_851928d0-c80b-4c8d-a89f-c66cc91e2359"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="0"
      id="F_6bbbaf9f-9437-4277-81df-fdccd0343c70"
      unitRef="U_shares">385</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="0"
      id="F_2744f254-cbcc-4dcb-ae5e-bc6a90bca6e7"
      unitRef="U_shares">1153285</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="2"
      id="F_1dc06946-e22a-4b79-b6e0-59965d1bcddc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="0"
      id="F_afbb2f1c-40a1-4111-bd2b-1e69a30f3fc3"
      unitRef="U_shares">277209</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="0"
      id="F_5eaf8045-379f-450e-8aa1-8958288f9b3e"
      unitRef="U_shares">277209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      decimals="2"
      id="F_6f290c10-4c64-4588-b1e8-4c66af1b8208"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
      contextRef="C_76248553-c6a5-451e-b7e1-10f5d684fa65"
      decimals="0"
      id="F_e170180c-8fc8-46ca-881d-e8bdfa4d5c7c"
      unitRef="U_shares">581047</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod>
    <pcvx:RestrictedStockUnitsWithheld
      contextRef="C_76248553-c6a5-451e-b7e1-10f5d684fa65"
      decimals="0"
      id="F_2a21aad1-dce6-4f90-939f-fceb836e9bae"
      unitRef="U_shares">32626</pcvx:RestrictedStockUnitsWithheld>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod
      contextRef="C_76248553-c6a5-451e-b7e1-10f5d684fa65"
      decimals="0"
      id="F_5725d8b7-864a-4b0b-a941-6ffcd6800568"
      unitRef="U_shares">45052</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="0"
      id="F_f87e7989-f7e6-4bb8-a290-2f094297e549"
      unitRef="U_shares">4679598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="0"
      id="F_ef244725-5cf8-4bfb-b2df-303694f1bf2e"
      unitRef="U_shares">7715494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="2"
      id="F_97271713-07cf-4f90-a3f5-ba5f24a56dd3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      id="F_e2d39db4-d08e-4a66-97fa-e3c41cedc0e0">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="-3"
      id="F_62dcddb0-c3c0-4a0a-8232-9074db7abd19"
      unitRef="U_USD">225667000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="0"
      id="F_36f72904-df7b-4513-8197-09c138f751dd"
      unitRef="U_shares">7715494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="2"
      id="F_f8348175-8750-4368-b959-0679bc001404"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      id="F_60dea154-8ed2-44de-ae8a-f562d83be2e8">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="-3"
      id="F_8385e05a-0aa4-401b-a75b-a70dc658cbdb"
      unitRef="U_USD">225667000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="0"
      id="F_e5fa8caf-951a-40cb-bd98-c25a511f3bc3"
      unitRef="U_shares">2921091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="2"
      id="F_db295fa2-0b1b-4457-a514-ea45cf56049c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_4c174ac3-2385-4026-a502-02872bdce024"
      id="F_d984bb58-5d0a-4cbd-8504-d95029c45c6a">P6Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5"
      decimals="-3"
      id="F_7430f91c-d2a2-4811-a33c-76c71d8a9e7a"
      unitRef="U_USD">112585000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_6badd016-5dd5-4e10-815e-5d906e22a921"
      unitRef="U_shares">1153285</pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln>
    <pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="0"
      id="F_602e528f-eea6-4cf8-9efd-ef2ae8a76b7f"
      unitRef="U_shares">926514</pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln>
    <pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="0"
      id="F_aaabbf44-6b0b-403f-bc16-c4ece4fcd6e3"
      unitRef="U_shares">358264</pcvx:NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="2"
      id="F_6087ab7f-1cbe-42f2-aa0b-07d5e4b8343a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="2"
      id="F_8b9cccff-fcb8-4dc9-ae27-8da98f57ede5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="2"
      id="F_59fd26fb-6588-4c7a-bb90-f35d35db6f79"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="2"
      id="F_f5c7f882-0042-4d7b-a6a5-c5262f203b0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="2"
      id="F_e6c96489-38d2-43fb-81be-b14592b70a1f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="2"
      id="F_2372a072-dbb6-45f0-a6b5-2f1d7676a63c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-5"
      id="F_83b25994-5e95-4241-8e57-9167e8c63d42"
      unitRef="U_USD">34000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-5"
      id="F_ceed63bd-ba80-4dd3-ba10-0288338be8bd"
      unitRef="U_USD">18900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-5"
      id="F_36362710-2a76-481c-b685-96ea3504e55d"
      unitRef="U_USD">7800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_f2f46e78-8bd1-4ac4-a222-c013154fad83">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSU activity for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 was as follows:&lt;/span&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.919%;"/&gt;
        &lt;td style="width:3.349%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:17.579%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:3.831%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.322000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;581,047&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79,229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;456,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_8e1afb34-8c4c-4042-9e47-03714da05d39"
      unitRef="U_shares">581047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-1"
      id="F_40a23e5e-47f1-4a54-9296-7052d2e999d2"
      unitRef="U_USD">26250</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_d6f2a925-c469-4c3d-bcad-1143c6f86b5f"
      unitRef="U_shares">79229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-1"
      id="F_310947c9-b63d-4da5-a8f8-645f7177ecbd"
      unitRef="U_USD">24790</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_a6d7f09a-8a44-4461-be0c-b02d4e5c009a"
      unitRef="U_shares">45052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-1"
      id="F_4cd6b1dc-b56d-44ec-a650-0a6351261f38"
      unitRef="U_USD">24320</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="0"
      id="F_9e0d50cd-b0e4-42c3-a7ec-a205daf63a66"
      unitRef="U_shares">456766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-1"
      id="F_96d73be2-21ab-4dd1-ab47-1b03f9533e7d"
      unitRef="U_USD">26700</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d2a47633-779f-4ee5-bc2a-ade49b683a08"
      decimals="2"
      id="F_a110f585-ec4f-4494-a0fe-eecb34cc4e27"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_2621b640-8d9b-4efa-a67c-bc201f6864e5"
      decimals="-5"
      id="F_edf4828a-edb0-4959-b92e-3303bc49a99f"
      unitRef="U_USD">10800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_d2a47633-779f-4ee5-bc2a-ade49b683a08"
      id="F_16045ea3-ec60-4aad-9192-477286bd739b">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_ff0b5242-8612-45db-87e3-a8572449c172"
      decimals="INF"
      id="F_cb9ab827-5b29-48a3-b6df-ff52894902fb"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2"
      decimals="2"
      id="F_be2b324a-fb82-4622-bbf3-41fc242663c8"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <pcvx:PurchasePeriod
      contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2"
      id="F_f08b2039-d83e-4f36-9585-a9b213cede39">P6M</pcvx:PurchasePeriod>
    <pcvx:OfferingPeriod
      contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2"
      id="F_6e41fb11-4aad-47d8-b47c-5c83e70e718d">P2Y</pcvx:OfferingPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_ff0b5242-8612-45db-87e3-a8572449c172"
      decimals="0"
      id="F_b31ea296-df0d-444f-93a4-cf1540cced93"
      unitRef="U_shares">650000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2"
      id="F_cf462f8e-a2e6-4d04-a2d8-653627836a50">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_05e78af0-aa05-4e1d-96d9-3606aeab03e2"
      decimals="INF"
      id="F_7c538321-d545-4ede-8695-b1e5d7597e5b"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_2cbbe32a-cc21-40d7-bde9-5473529a81bb">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Activity under our 2020 ESPP was as follows:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.151%;"/&gt;
        &lt;td style="width:11.21%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:25.639%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance - December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;650,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares purchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,465&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance - December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;622,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;510,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares purchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,070,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additional shares authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;530,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares purchased&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance - December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,539,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_7cc4ab4f-7bad-4d16-9545-b64979b11e87"
      decimals="0"
      id="F_df7acf8c-3627-4c5c-bd82-fa222931dba6"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized
      contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05"
      decimals="0"
      id="F_708c669b-119d-417c-8188-85fed656c06c"
      unitRef="U_shares">650000</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05"
      decimals="0"
      id="F_6f23b9cf-7f03-484d-839f-8c7f7456d569"
      unitRef="U_shares">27465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_e8457603-d007-4a06-8019-118bd0a48904"
      decimals="0"
      id="F_01d8b650-18a6-4bea-a7b7-f68f748fc64f"
      unitRef="U_shares">622535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc"
      decimals="0"
      id="F_ec474de2-aa5c-44b1-8e84-6302fdd2ffce"
      unitRef="U_shares">510715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc"
      decimals="0"
      id="F_c18f4da5-2059-45a5-b196-3e5c82449566"
      unitRef="U_shares">62546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_9400b621-8b2f-4a08-b570-b9c92478f198"
      decimals="0"
      id="F_a42a3895-8b79-4538-b8a2-aead16f6d1e2"
      unitRef="U_shares">1070704</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"
      decimals="0"
      id="F_c0b15669-3968-4fc8-8b45-b0310a571ea2"
      unitRef="U_shares">530319</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"
      decimals="0"
      id="F_bc270758-6ade-4308-b6bd-3dd0704c26a8"
      unitRef="U_shares">61709</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_10a9faa2-6408-4b48-8d11-d8c2958b964d"
      decimals="0"
      id="F_9c4b61e9-9d7d-4801-94af-5cc6f7bd5dd3"
      unitRef="U_shares">1539314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant
      contextRef="C_1cf027a0-a614-4616-8ba2-757303a3ef4f"
      decimals="0"
      id="F_28176ee0-9a9d-4457-94d4-ff6214895b48"
      unitRef="U_shares">794706</pcvx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_e4ed719c-fe13-4b92-9cf3-f420094e1e68">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We estimated the fair value of employee stock options using the Black-Scholes option-pricing model for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.321%;"/&gt;
        &lt;td style="width:1.357%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
        &lt;td style="width:1.357%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
        &lt;td style="width:1.357%;"/&gt;
        &lt;td style="width:15.203%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;81.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;94.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_f565271e-3ab8-4bb0-b435-78c63f0d92b5"
      unitRef="U_pure">0.781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_c8be2b80-8fe0-4e74-b983-81dc968ebbde"
      unitRef="U_pure">0.851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_d595286a-61a6-4be8-b4f2-831c890cc784"
      unitRef="U_pure">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_1b74a719-99ac-4f9c-a42a-0bc03c63a244"
      unitRef="U_pure">0.841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="3"
      id="F_d909158c-735e-4f55-8d46-425e5dc8f51a"
      unitRef="U_pure">0.812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="3"
      id="F_b8992331-51ba-437a-b76c-378be877a21f"
      unitRef="U_pure">0.941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="2"
      id="F_8a1af37b-ee4d-419a-bc5a-48a42388e33e"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="2"
      id="F_9915d657-bad9-4d92-9073-812647533b14"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="2"
      id="F_f901465d-d8a1-4206-87ce-ec5b0017c62b"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_41f2bc47-1b64-456b-8eb3-0bfe5b57516c"
      id="F_c093f72a-6c38-4182-9b98-b712184e738f">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_132ccca8-d60e-4222-bb51-935509c790c4"
      id="F_b88d1722-d7aa-4016-9b49-476cbd5e56da">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9894bfc2-b8d0-4aa2-bdea-70d5be6112ef"
      id="F_e8d3c5ab-5e60-4d3b-8831-56a4b226b4e0">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_78621854-c804-4c5b-8406-1b035bcdf270"
      id="F_30275f93-4d6f-4eb9-8a81-47badae44a3b">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e0c5e803-6cf5-4387-8896-428a21286a2d"
      id="F_3ff7fc12-b7f5-491d-9b50-06e60a63b779">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a07caa24-b5b1-41b0-bf5a-a85de3830de2"
      id="F_c55323cb-5dbe-404b-b069-874087f1dc31">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_9735b0a1-648f-48cb-a8b8-1c2f12e9e8d4"
      unitRef="U_pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_4bdf0633-0583-4429-a282-aaeb20e3fc2f"
      unitRef="U_pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="INF"
      id="F_afcf3471-e242-43d6-8bc4-003124c10f9a"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="INF"
      id="F_d543c55c-4030-4fa8-9c07-a7f61a93cbf2"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="INF"
      id="F_67719a2c-8dc4-4842-81c0-fed025a19039"
      unitRef="U_pure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="INF"
      id="F_d1c0bb61-48c5-4979-a38e-51655e70823d"
      unitRef="U_pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"
      id="F_d4ac98be-3a74-4323-ac2b-9443854ce1af">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We estimated the fair value of shares under the 2020 ESPP using the Black-Scholes option-pricing model for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020 using the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.12%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:15.385%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:16.998%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:15.363%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;99.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;79.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"
      decimals="3"
      id="F_0a3ff9a8-afc1-464d-b4da-887dd19164bc"
      unitRef="U_pure">0.788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"
      decimals="3"
      id="F_40669cbb-808c-4538-92e6-dffb0a9af303"
      unitRef="U_pure">0.997</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc"
      decimals="3"
      id="F_69abb67b-7f10-4c9d-80a5-911cf464a637"
      unitRef="U_pure">0.796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc"
      decimals="3"
      id="F_643b74a8-cf7b-4fba-8619-d9f7db5a15f6"
      unitRef="U_pure">1.263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05"
      decimals="3"
      id="F_26a4875b-3d9c-4fdf-9f99-8a7263c0f379"
      unitRef="U_pure">1.058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05"
      decimals="3"
      id="F_9cfc1902-2bb9-4495-b10e-e8888ff0c908"
      unitRef="U_pure">1.582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"
      decimals="2"
      id="F_1caa3502-a728-4f49-a8d3-e3c20b5d08a1"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc"
      decimals="2"
      id="F_3cdff936-d393-4cec-b0dc-ab4c7c893434"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05"
      decimals="2"
      id="F_e48cec07-c9ab-4629-b766-983b7bedb631"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_6bc5fec4-d3ad-4cc4-9828-b81bfbdb4992"
      id="F_e1a4c7df-9d7f-4c32-a71f-06203f59c9a4">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_8e4a1e9d-b20b-44bb-aaf3-49bc4856bac7"
      id="F_c5d2c979-84b7-4abf-a90b-93d9a2240302">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_df172351-baa3-4411-9c37-3b0b3e33fab0"
      id="F_3972cbcc-0a55-4816-888d-692995289dad">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0489234b-730f-4827-9f6d-d815f1a09ff7"
      id="F_950128c2-482f-44e7-a881-cba1aef21e24">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_02afd6c9-f14c-4595-b698-8d1af3e8c0a9"
      id="F_e7c96f36-e998-4547-ab90-a5b74374378c">P0Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7f9806ed-b5a6-4aef-bf04-0c1827f34b0f"
      id="F_f1ab2b21-bd37-46d8-a270-9e87c3aaac93">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"
      decimals="3"
      id="F_c5ef6f23-f9e4-4486-bc70-0d0f9c4d70ad"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69"
      decimals="3"
      id="F_e2f021d5-4f92-40aa-b294-87645175b124"
      unitRef="U_pure">0.047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc"
      decimals="3"
      id="F_ab6975a2-59a1-475f-9489-6bef4a7e2ac3"
      unitRef="U_pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_579afd80-071a-4e1b-8e7e-3304fc4b52dc"
      decimals="3"
      id="F_1d342929-5599-4f77-8e44-6de3e7aad337"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05"
      decimals="3"
      id="F_1fd573d3-dc51-4631-8e60-fdae2fd7f9e0"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_9b6dde0d-1098-4728-82b4-9050d56dcc05"
      decimals="3"
      id="F_fd293a96-e7df-426d-b845-9f9157d50fe2"
      unitRef="U_pure">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_81e20c4f-e0c6-4cea-b677-93b2e39c7f30"
      id="F_7a92e464-4f66-4ca9-9e6d-c0e4ee9729e7">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We recorded total stock-based compensation expense for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020 related to the 2014 Plan, the 2020 Plan and the 2020 ESPP in the statements of operations and allocated the amounts as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.07%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.84%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.359%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,751&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,434&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8ba486b2-d8aa-4ca6-9756-5c9748b4e008"
      decimals="-3"
      id="F_1c055635-cb9a-484d-b983-d075e260a8bd"
      unitRef="U_USD">9899000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ae85f674-5889-4534-aba6-cf137accf611"
      decimals="-3"
      id="F_61f1dc33-f22c-4cf3-8a5a-ce76cdd70322"
      unitRef="U_USD">3954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_57fb732d-890e-48c0-9e93-f41e83529309"
      decimals="-3"
      id="F_f16f80c3-ad8c-4d85-a521-ea711f397e9d"
      unitRef="U_USD">1861000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0462dcf5-a925-4711-9836-298b3b1a0bba"
      decimals="-3"
      id="F_56fc4465-5ae7-4914-8407-6a2fd11bbd94"
      unitRef="U_USD">13751000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_51a0df40-cbb7-4e5a-855d-40d7ff36c161"
      decimals="-3"
      id="F_a0011130-c80b-450e-a1ce-9ffecc741758"
      unitRef="U_USD">6775000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b694d80e-fe68-400d-b770-ba2619d82563"
      decimals="-3"
      id="F_985e57a5-c5df-4aef-a899-d865bc298735"
      unitRef="U_USD">3573000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_81e20c4f-e0c6-4cea-b677-93b2e39c7f30"
      decimals="-3"
      id="F_01ee9aa4-da26-4681-8b14-14bc9e23ad19"
      unitRef="U_USD">23650000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_86a6494f-286c-4378-b602-52e8e5e8f4b6"
      decimals="-3"
      id="F_c49dd963-9209-4b3b-be9e-6d2b3214057e"
      unitRef="U_USD">10729000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7d262603-bbcb-4d32-8649-c7dde0f3cba1"
      decimals="-3"
      id="F_40922604-6eec-4ba9-8ec8-3d7b4e400685"
      unitRef="U_USD">5434000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_34d44816-59db-4fff-99c9-27216e95713d"
      decimals="INF"
      id="F_8cbfa52c-9aca-4bc2-872e-49256ff2c233"
      unitRef="U_shares">362935</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7329b071-f8d6-4b42-988b-4c5a585bc452"
      decimals="-5"
      id="F_c09b8042-9d19-415e-b9c5-bf66e1418f33"
      unitRef="U_USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-5"
      id="F_a5c074a1-be78-422f-a8e6-5ed873200805"
      unitRef="U_USD">87700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_30bbece8-5c3a-406b-8cd0-41b7af17dfd4">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_e6e5e256-56b9-44b0-811e-6e0f30231b17">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11. Retirement Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company sponsors a qualified 401(k) Plan. The retirement plan is a defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited to a maximum annual amount set by the Internal Revenue Service. For the year ended December 31, 2022, the Company contributed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to the retirement plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="C_3912106f-3c31-4ffc-9141-7807cf18d485"
      decimals="-5"
      id="F_7917f5cb-4506-4059-8cad-c829cc3d14a6"
      unitRef="U_USD">800000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <pcvx:FundingArrangementTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_57966c8a-526d-4021-a8b6-dc35ac6060f4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12. Funding Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2019, we received a cost-reimbursement research award from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (&#x201c;CARB-X&#x201d;), a public-private partnership funded under a Cooperative Agreement from Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;) and by awards from Wellcome Trust, Germany&#x2019;s Federal Ministry of Education and Research, the United Kingdom Global Antimicrobial Resistance Innovation Fund and the Bill &amp;amp; Melinda Gates Foundation. In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the Trustees of Boston University, the administrator of the program. The initial award provided the potential for funding up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to develop a universal vaccine to prevent infections caused by Group A Strep bacteria, which include pharyngitis, impetigo and necrotizing fasciitis. The initial award committed initial funding of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for our VAX-A1 program and, subject to a CARB-X decision to extend the options, up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in total funding available upon achievement of development milestones over the next &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Specified research expenditures are reimbursable expenses associated with agreed-upon activities needed to advance the research project supported by the grant. These expenditures can include labor, laboratory supplies, travel, consu&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;lting and third-party vendor research and development support costs. CARB-X has awarded us total funding to date of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, with potential funding of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon the achievement of future VAX-A1 development milestones. In January 2022, CARB-X revised the parameters for the contribution of CARB-X funding and implemented maximum funding levels for all grant recipients. As a result, our total funding available upon achievement of development milestones through Phase 1 human clinical trials was revised from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;      &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2021, we received a cost-reimbursement research award from the National Institutes of Health (&#x201c;NIH&#x201d;). In connection with this funding, we entered into a cost-reimbursement sub-award agreement with the University of Maryland, Baltimore, the administrator of the program. The award provides for potential funding up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; totaling approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to develop a vaccine to prevent infections caused by Shigella.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income from grants is recognized in the period during which the related specified expenses are incurred, provided that the conditions under which the grants were provided have been met. We recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of grant income and recorded the amounts in Other income (expense), net in the statement of operations during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, 2021, and 2020 respectively. A grant receivable of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million representing unreimbursed, eligible costs incurred under the CARB-X agreement was recorded and included in Prepaid expenses and other current assets in the balance sheets as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, respectively.&lt;/span&gt;&lt;/p&gt;</pcvx:FundingArrangementTextBlock>
    <pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections
      contextRef="C_037574d0-71b1-40d4-9227-c5f9299b9dd2"
      id="F_dea183d8-0187-4194-9fb0-9ae51b97e20f">P4Y</pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections>
    <pcvx:InitialFundingCommittedByAward
      contextRef="C_9a9d9224-9fa8-4858-a34f-83f9703e9715"
      decimals="-5"
      id="F_a98a0aed-b807-481a-b793-83a3b436711e"
      unitRef="U_USD">1600000</pcvx:InitialFundingCommittedByAward>
    <pcvx:FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones
      contextRef="C_9a9d9224-9fa8-4858-a34f-83f9703e9715"
      decimals="-5"
      id="F_1bbb466a-1001-41e3-ac59-f3d65c99b5ef"
      unitRef="U_USD">15100000</pcvx:FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones>
    <pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections
      contextRef="C_037574d0-71b1-40d4-9227-c5f9299b9dd2"
      id="F_829b9d91-dfad-47c5-be74-5fd380dec43a">P4Y</pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections>
    <pcvx:PotentialFundingCommittedByAward
      contextRef="C_5498ed60-351d-4bfe-8d0d-3748e9cc3710"
      decimals="-5"
      id="F_f6c5aea2-b453-47cf-8a46-e1aa59998ae4"
      unitRef="U_USD">6600000</pcvx:PotentialFundingCommittedByAward>
    <pcvx:InitialFundingCommittedByAward
      contextRef="C_9ab2dcd4-25fb-4d25-a652-57453b4b393b"
      decimals="-5"
      id="F_e003a0e5-1367-49ef-91b7-9e9d3c24a66f"
      unitRef="U_USD">29700000</pcvx:InitialFundingCommittedByAward>
    <pcvx:PotentialFundingCommittedByAward
      contextRef="C_9ab2dcd4-25fb-4d25-a652-57453b4b393b"
      decimals="-5"
      id="F_f05bddcc-5628-4284-8899-267d3fd77ff5"
      unitRef="U_USD">29700000</pcvx:PotentialFundingCommittedByAward>
    <pcvx:PotentialFundingCommittedByAward
      contextRef="C_c04110eb-23bc-459e-a813-d93f70e70acf"
      decimals="-5"
      id="F_003b909d-0a74-47e1-8611-ad9c6b6cc1d8"
      unitRef="U_USD">14600000</pcvx:PotentialFundingCommittedByAward>
    <pcvx:PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections
      contextRef="C_ef8a5bfd-8fc9-43e4-974f-36c738247627"
      id="F_f331c69f-97e4-4602-a035-99ddec8b1edf">P5Y</pcvx:PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections>
    <pcvx:PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections
      contextRef="C_1121605e-be53-44bc-b6eb-31b279bad82d"
      decimals="-5"
      id="F_729547c2-a10b-46c1-864f-3d5220f63ff9"
      unitRef="U_USD">500000</pcvx:PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections>
    <pcvx:GrantIncome
      contextRef="C_bcab4237-fc1e-4b3b-a82d-9d53bb21e6b4"
      decimals="-5"
      id="F_73f82c66-274e-42fb-8937-7e18b40349c4"
      unitRef="U_USD">1900000</pcvx:GrantIncome>
    <pcvx:GrantIncome
      contextRef="C_f1e5de9a-c565-4d52-a50d-b1a74b68669d"
      decimals="-5"
      id="F_7247476b-68a1-4695-8d13-08f7ef4158f1"
      unitRef="U_USD">1600000</pcvx:GrantIncome>
    <pcvx:GrantIncome
      contextRef="C_b043466b-5227-4835-be5f-8ac1b25eac10"
      decimals="-5"
      id="F_c45a3089-3a32-44e8-9416-2491461fbf29"
      unitRef="U_USD">2500000</pcvx:GrantIncome>
    <us-gaap:GrantsReceivable
      contextRef="C_c325a933-95d0-4782-a705-8f73c8708fb5"
      decimals="-5"
      id="F_a0ab294f-52f6-44eb-af01-cfcc1f6d874c"
      unitRef="U_USD">1000000.0</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="C_c7051fb3-6833-4895-a7ab-ff07923b921b"
      decimals="-5"
      id="F_dedd936f-9614-4aa1-b597-5f7493f395b3"
      unitRef="U_USD">1200000</us-gaap:GrantsReceivable>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_0ba95bbc-cd6c-4785-b861-f0dc86c72134">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.374%;"/&gt;
        &lt;td style="width:1.261%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.916%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.271%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.916%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.271%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.99%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;223,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares outstanding used in computing net&lt;br/&gt;&#160;&#160;&#160;loss per share, basic and diluted&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,877,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,922,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,545,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;____________________________&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Includes shares of common stock into which pre-funded warrants may be exercised. See Note 9, "Pre-Funded Warrants".&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.529%;"/&gt;
        &lt;td style="width:1.009%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.64%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.64%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.139999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,752,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,357,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,188,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;456,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,322,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,423,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,276,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_d87c620d-3818-47ab-ba8b-cc9bd9f87166">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the computation of basic and diluted net loss per share and excludes shares which are legally outstanding, but subject to repurchase by us:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.374%;"/&gt;
        &lt;td style="width:1.261%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.916%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.271%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.916%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.271%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.99%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss (in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;223,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares outstanding used in computing net&lt;br/&gt;&#160;&#160;&#160;loss per share, basic and diluted&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;64,877,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51,922,108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,545,810&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;____________________________&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Includes shares of common stock into which pre-funded warrants may be exercised. See Note 9, "Pre-Funded Warrants".&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_e97e14cf-6e23-4bfb-9d6d-2f1c72c60ea8"
      unitRef="U_USD">-223485000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_dd911838-b77b-48b5-b0ef-ef969dc4b547"
      unitRef="U_USD">-100077000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_4e6dbaef-fb22-43ff-b3f4-6c6fb126824e"
      unitRef="U_USD">-89217000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_c65f1584-bd70-4148-aaf9-8d07d0b9ee57"
      unitRef="U_shares">64877988</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_694f7a1e-3e06-4408-ad9a-ffad513bf345"
      unitRef="U_shares">64877988</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="0"
      id="F_2e9a8586-379f-4e42-a15a-c3130c119705"
      unitRef="U_shares">51922108</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="0"
      id="F_2fb31e33-b132-459a-9af3-4658f920b684"
      unitRef="U_shares">51922108</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="0"
      id="F_1548a76f-25a1-4f15-8005-1ce3bed8cd17"
      unitRef="U_shares">29545810</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="0"
      id="F_492834d3-065b-4571-ab29-2502ede47106"
      unitRef="U_shares">29545810</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="2"
      id="F_87a86458-b7a5-4bb1-99ba-8c214af88029"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="2"
      id="F_20eb356d-3f77-4291-a39c-ef701fea34f7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="2"
      id="F_81518c9e-e638-4262-8e17-3f13294e4bbf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="2"
      id="F_fe510417-9894-4807-af54-4830ed488791"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="2"
      id="F_40d34fda-1435-4a1c-8c96-11a61ab124a7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="2"
      id="F_7599c270-b4f3-4f81-b911-a115c63d04a9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-3.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_de7e9eea-3a00-4858-818b-1d0f33953e65">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the period presented because including them would have been antidilutive:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.529%;"/&gt;
        &lt;td style="width:1.009%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.64%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.64%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.139999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,752,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,357,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,188,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;456,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Employee stock purchase plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;113,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;66,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,322,210&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,423,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,276,418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9bb12da7-1bd7-4afd-815f-80e30d2186ff"
      decimals="0"
      id="F_4269d367-c39c-46e2-a07f-4b7c764c56f8"
      unitRef="U_shares">7752204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ddc89e57-5630-47be-9bd0-27808be55284"
      decimals="0"
      id="F_68e1a843-da0a-4b00-a951-27fd035b921f"
      unitRef="U_shares">5357389</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_563ab83e-909f-4129-bbf2-6d8fd0542811"
      decimals="0"
      id="F_99bbfd46-7df8-4f50-a3f2-c33cf4dc4708"
      unitRef="U_shares">5188531</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_33283eca-8ea2-4ccd-9fe1-36145a063453"
      decimals="0"
      id="F_fd2427eb-ee1b-4e36-a5bd-91fd6254f6d6"
      unitRef="U_shares">456766</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b219256c-6df8-41ce-b765-2f529e35b517"
      decimals="0"
      id="F_12cf58d6-8e61-4883-aed9-dc3b3f8a05c4"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4fea95f2-1b19-4123-9ac1-3c958efccee9"
      decimals="0"
      id="F_17b3cc10-5bdb-44f1-a994-d59ae46a8d0a"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d2fdc0e7-955d-4a1b-9894-ad28840b67da"
      decimals="0"
      id="F_f0b5682b-51f1-49ad-a078-6ccbc458ac07"
      unitRef="U_shares">113240</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f5b73419-0c99-4891-9305-ef5424ea8616"
      decimals="0"
      id="F_4a40b51c-2a57-4fd8-b11c-92656aa279e4"
      unitRef="U_shares">66404</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1be3eda5-a43a-436d-b315-ddea1f184d88"
      decimals="0"
      id="F_cfadbdec-5fde-48f8-aa01-53b11602f98f"
      unitRef="U_shares">87887</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="0"
      id="F_aec3f61b-b5cf-4bd3-8e00-ebffed558c94"
      unitRef="U_shares">8322210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="0"
      id="F_de07baac-072d-4010-a198-06abe37f0424"
      unitRef="U_shares">5423793</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="0"
      id="F_bafb7e95-cd5d-4100-9d37-3c8b921f5e94"
      unitRef="U_shares">5276418</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_0117089f-675f-4f8a-a77f-3dbbe039f418">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Our pre-tax book loss was derived from our business operations within the United States.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.469%;"/&gt;
        &lt;td style="width:0.98%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.57%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.98%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.57%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.98%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.45%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 effective tax rate reconciliation has been updated to conform to the 2021 and 2022 presentation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents significant components of our deferred tax assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.929%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.011%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.086%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued &amp;amp; others&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;R&amp;amp;D Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized R&amp;amp;D expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;170,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2021 Accrued &amp;amp; others and Stock compensation lines have been updated to conform to the 2022 presentation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, we have net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;340.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;453.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal and state net operating loss carryforwards, except the federal loss carryforward arising in tax years beginning after December 31, 2017, begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; unless previously utilized. Federal net operating losses arising in tax years beginning after December 31, 2017 have an indefinite carryover period and do not expire.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;At December 31, 2022, we have research credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million available to offset future income tax liabilities, if any, for federal and California income tax purposes, respectively. The federal research and development tax credit carryforwards expire beginning in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; unless previously utilized. The California tax credits can be carried forward indefinitely.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on our history of operating losses, we have concluded that it is more likely than not that the benefit of our deferred tax assets will not be realized. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Utilization of the net operating loss carryforward and research credit carryforward may be subject to an annual limitation due to the ownership percentage change limitations under Section 382 and Section 383, respectively, provided by the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and similar state provisions. The annual limitation may result in the expiration of the net operating loss before utilization. We have experienced ownership changes in the past. There were no ownership changes identified in 2022, as such we have determined that &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; federal research credits will expire unutilized or are excluded from our research credit carryforwards. The Company does not expect any ownership changes during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 to result in a limitation that would materially reduce the total amount of net operating loss carryforwards and credits that can be utilized. Subsequent ownership changes may affect the limitation in future years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have uncertain tax benefits (&#x201c;UTBs&#x201d;) totaling &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and 2021, respectively, which were netted against deferred tax assets subject to valuation allowance. The UTBs had no effect on the effective tax rate. We recognize interest and penalties related to UTBs, when they occur, as a component of income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period such determination is made. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; interest or penalties recognized for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021. We do not expect our UTBs to change significantly over the next 12 months.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.721%;"/&gt;
        &lt;td style="width:1.323%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.323%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.334%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.517000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions based on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We file U.S. federal and state tax returns. In general, the Company is no longer subject to tax examination by the Internal Revenue Service or state taxing authorities for years before 2017. Although the federal and state statutes are closed for purposes of assessing additional income tax in those prior years, the taxing authorities may still make adjustments to the net operating loss, or NOL, and credit carryforwards used in open years. Therefore, the tax statutes should be considered open as it relates to the NOL and credit carryforwards used in open years. We do not have any tax audits or other issues pending.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On March 27, 2020, the President of the United States signed into law the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"). The CARES Act, among other things, includes certain income tax provisions for individuals and corporations; however, these benefits do not impact our current tax provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On December 21, 2020, the President of the United States signed into law the &#x201c;Consolidated Appropriations Act, 2021&#x201d; which includes further COVID-19 economic relief and extension of certain expiring tax provisions. The relief package includes a tax provision clarifying that businesses with forgiven Paycheck Protection Program, or PPP, loans can deduct regular business expenses that are paid for with the loan proceeds. Additional pandemic relief tax measures include an expansion of the employee retention credit, enhanced charitable&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;contribution deductions and a temporary full deduction for business expenses for food and beverages provided by a restaurant. These benefits do not have a material impact on the current tax provision.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Infrastructure Investment and Jobs Act was signed on November 15, 2021, and it contained several tax provisions including changes to the Employee Retention Tax Credit and changes to excise taxes. These provisions do not have a material impactful to the Company&#x2019;s current tax provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with the 2017 Tax Act, research and experimental (R&amp;amp;E) expenses under Internal Revenue Code Section 174 are required to be capitalized beginning in 2022. R&amp;amp;E expenses are required to be amortized over a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for domestic expenses and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for foreign expenses. The Company has capitalized research and experimental expenditures in its current tax provision as a result.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Inflation Reduction Act of 2022 specifically introduces the topic of corporate alternative minimum tax ("CAMT") on adjusted financial statement income on applicable corporations for taxable years beginning after December 31, 2022. There is no impact to the Company&#x2019;s current tax provision.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The American Rescue Plan Act was signed on March 11, 2021.  One of the provisions of the Act included expanding the definition of covered employees subject to IRC 162(m) to include an additional top five highest compensated officers beyond the CEO, CFO, and three highest paid employees currently covered under IRC 162(m). This expanded provision is applicable for tax years beginning after Dec 31, 2026. The Company does not believe that this update to IRC 162(m) would have a material impact on its income tax provision currently and will continue to monitor this.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_c556f905-63d1-453c-9805-aa7405480982">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of our effective tax rate to the statutory U.S. federal rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.469%;"/&gt;
        &lt;td style="width:0.98%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.57%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.98%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.57%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.98%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.45%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Section 162(m) limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 effective tax rate reconciliation has been updated to conform to the 2021 and 2022 presentation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="INF"
      id="F_258d9aaa-c513-470e-888b-eb8ae243e82b"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_d4bec698-c45d-4477-b2d0-8fc16d1805ac"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="INF"
      id="F_757b47b6-8c79-43eb-acf1-3e019ca5b5b9"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_b8426126-c1d6-4c57-88bd-4a9f4048b799"
      unitRef="U_pure">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_7de1e26f-9c9c-4573-897b-c3179531a299"
      unitRef="U_pure">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="3"
      id="F_04c41bd8-0f83-4a77-a909-a9bba4018be6"
      unitRef="U_pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_80af353b-9ba2-4df8-98f1-59c9d525d769"
      unitRef="U_pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_bdfb4f5a-dd56-40f3-970d-642ae8a3d48a"
      unitRef="U_pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="3"
      id="F_759d25eb-ab69-42e5-b66f-2cb749e67d44"
      unitRef="U_pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_b5f45fc2-7fd3-42d9-8568-e859afbbf42a"
      unitRef="U_pure">-0.213</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_8372ea01-cdfd-4966-b3a3-8b5a67895f5b"
      unitRef="U_pure">-0.230</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="3"
      id="F_5134f00b-6328-4caa-a1ac-c88e5bb8d286"
      unitRef="U_pure">-0.221</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <pcvx:Section162MLimitation
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_d28bdfa9-f518-49b5-89a3-e1fa6de3ae6a"
      unitRef="U_pure">0.018</pcvx:Section162MLimitation>
    <pcvx:Section162MLimitation
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_4f29b9b2-2993-4d21-a6ed-60a724ef789c"
      unitRef="U_pure">-0.011</pcvx:Section162MLimitation>
    <pcvx:Section162MLimitation
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="3"
      id="F_802af70f-cd71-4dcf-a22f-17f9b1443f1e"
      unitRef="U_pure">-0.001</pcvx:Section162MLimitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_0fe8f767-164a-4796-8d2d-e46722f6bd17"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_17959fcf-7f4e-42b0-906d-6f70266dfaad"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="3"
      id="F_183651b9-50a6-4cb9-89bd-4b35bbe4e5cc"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="3"
      id="F_044aa6a6-d895-4aa0-a08e-4ca031bbd5f3"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="3"
      id="F_be5fb6c1-34bd-4c37-8979-a4ef57bf3875"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="3"
      id="F_6e4703a6-3c7e-4543-a0f2-f26f51d5137f"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_049ee17e-3e5d-46d5-b46f-9f26f2c658f4">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table presents significant components of our deferred tax assets as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021:&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.929%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.011%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.487%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.086%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued &amp;amp; others&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;R&amp;amp;D Credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized R&amp;amp;D expenditures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;32,873&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,984&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued manufacturing expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,063&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,956&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;170,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;104,934&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,357&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;164,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:66.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.8968727694042435%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2021 Accrued &amp;amp; others and Stock compensation lines have been updated to conform to the 2022 presentation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_d1de3c13-26d8-4e25-8697-3626617e0773"
      unitRef="U_USD">111555000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_e04b9473-4283-4a22-a82b-35b29bbb6eff"
      unitRef="U_USD">85574000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_05257656-9bf0-4876-b3b3-024ef6853bfb"
      unitRef="U_USD">1062000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_5e5a1859-64db-485d-816c-b04f0e700af1"
      unitRef="U_USD">1700000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_d15ce071-280d-4dbc-b955-df724acecf1e"
      unitRef="U_USD">1103000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_33105149-d815-4139-9962-2039b98c9033"
      unitRef="U_USD">2174000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_7f6ac7c6-75c4-4791-ad1a-72731c697302"
      unitRef="U_USD">5436000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_c127d18a-0b16-4362-9066-490c5d72db2e"
      unitRef="U_USD">2865000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_5ce0a376-fc19-4980-8e27-ad5e84db3f50"
      unitRef="U_USD">32873000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_ad1d8393-5b75-4747-bc49-5e51343a3d41"
      unitRef="U_USD">2984000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_37460370-c2ab-49b5-9f83-bf3506d7aec2"
      unitRef="U_USD">2063000</pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses>
    <pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_e566848c-bca9-4a56-b7c4-0689debbd297"
      unitRef="U_USD">1006000</pcvx:DeferredTaxAssetsTaxAccruedManufacturingExpenses>
    <pcvx:LeaseLiability
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_faa2ef01-28f8-481d-ac58-194141fd4d8e"
      unitRef="U_USD">5358000</pcvx:LeaseLiability>
    <pcvx:LeaseLiability
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_3225430f-5337-42fb-bfc8-b7411f104d87"
      unitRef="U_USD">6674000</pcvx:LeaseLiability>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_fe1a25f3-8674-4487-ba7e-178d58efc279"
      unitRef="U_USD">6867000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_ac4250ee-eb65-4511-b237-429ee9e59929"
      unitRef="U_USD">4474000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_78c4db69-b1e9-4eef-a9b3-72a61579c018"
      unitRef="U_USD">1956000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_465d1b4d-cd7c-419c-8525-366df1e27a55"
      unitRef="U_USD">170791000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_173f9615-f1d6-4941-9133-a911e19fe15a"
      unitRef="U_USD">104934000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_87d40ed2-49fe-438c-a170-09fa22ac7358"
      unitRef="U_USD">6357000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_9cf19cc7-ec81-4e92-b7e6-3398ae6b38ed"
      unitRef="U_USD">8349000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_f00c5109-856d-4f41-b76b-1c013efb02fd"
      unitRef="U_USD">6357000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_cb62485e-1103-4016-8350-11227be54245"
      unitRef="U_USD">8349000</us-gaap:DeferredIncomeTaxLiabilities>
    <pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_93f8c33d-9c3e-4bd4-b1b9-d3b7c590b50f"
      unitRef="U_USD">164433000</pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
    <pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_e87bd217-29e0-45cc-b04b-61257af3a379"
      unitRef="U_USD">96585000</pcvx:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_907c7827-9132-4cea-ac34-da7ef733f006"
      unitRef="U_USD">164433000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_7cd131d4-6f1f-47cc-b030-9db2534eabe4"
      unitRef="U_USD">96585000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_eb41f55f-e7d1-436d-992c-c9ae66000f84"
      decimals="-5"
      id="F_9d803279-7a26-4650-95c8-7d4bd2c6c613"
      unitRef="U_USD">340200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_6584fbf6-caf6-435c-8531-3189f88ffaef"
      decimals="-5"
      id="F_9dda15bb-11b4-467c-b303-22d1c377703b"
      unitRef="U_USD">453100000</us-gaap:OperatingLossCarryforwards>
    <pcvx:OperatingLossCarryForwardsExpirationYear
      contextRef="C_c544cf31-11ab-4456-8095-c7c6e411d5d1"
      id="F_289325e8-edad-427e-97a3-37c91cef4ec0">2034</pcvx:OperatingLossCarryForwardsExpirationYear>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_49cc4baf-48fc-47b3-962c-c338dcbc9399"
      decimals="-5"
      id="F_b2848022-0e24-4bf4-9b64-4bd844ad734a"
      unitRef="U_USD">4400000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_81984893-bd31-4052-aaed-e6928b5494fe"
      decimals="-5"
      id="F_eec277d3-d0a3-4a4f-972e-a8db509b0ef1"
      unitRef="U_USD">2800000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <pcvx:TaxCreditCarryforwardExpirationYear
      contextRef="C_49cc4baf-48fc-47b3-962c-c338dcbc9399"
      id="F_00005f68-5c33-40e1-a342-abf1045a632e">2039</pcvx:TaxCreditCarryforwardExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_c3303683-5d29-4add-a4a5-c77ccff026b8"
      decimals="INF"
      id="F_79b265a0-84d3-45d6-939a-1376ffe2a6af"
      unitRef="U_USD">0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-5"
      id="F_acf8b237-0b9b-4c27-8e53-4254b63631d9"
      unitRef="U_USD">1800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-5"
      id="F_b3c6bab4-77a3-4d4a-84fb-98856d55987e"
      unitRef="U_USD">900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="INF"
      id="F_34b4dead-0f6c-4a4c-b264-4415618f202e"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="INF"
      id="F_f08f7476-adb5-4899-8db5-0f0ca6182b25"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_1508abed-9b4e-46da-8098-3fbba9dea47f">&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.721%;"/&gt;
        &lt;td style="width:1.323%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.008%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.323%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.334%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.517000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;271&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Additions based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;461&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reductions based on tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_3246d361-5dee-4ee1-abc5-ab085ccd15e8"
      unitRef="U_USD">924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93"
      decimals="-3"
      id="F_56dbdd88-825a-4b9f-922e-32123eb550f6"
      unitRef="U_USD">393000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0"
      decimals="-3"
      id="F_e77da0c0-f0c0-4174-8d09-f0c97cf25c43"
      unitRef="U_USD">271000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_8c247661-8dd2-4fb3-b0a0-2775450b44dd"
      unitRef="U_USD">876000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_558acc0a-0d4b-4d8b-ac1e-d209210fba7b"
      unitRef="U_USD">461000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_b4f26a3d-092f-44af-8eb0-00d48b7a60fa"
      unitRef="U_USD">287000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      decimals="-3"
      id="F_10b74cbc-da76-4ce1-8241-c4bf3e9233dd"
      unitRef="U_USD">-46000</pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      decimals="-3"
      id="F_c6707fd7-f3a9-4fdd-8b05-d2ed4ecb57ad"
      unitRef="U_USD">70000</pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_2d081aa6-31a3-4423-a381-77023efa1448"
      decimals="-3"
      id="F_6ec73bbe-ddaa-4e7a-af44-e9aa659d282d"
      unitRef="U_USD">-165000</pcvx:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ebee093b-a58f-4627-85e8-192d773f305e"
      decimals="-3"
      id="F_a1c38cc2-17e5-4ff1-b437-e5f984d5ddd5"
      unitRef="U_USD">1754000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_7ac2f60b-8289-45da-8d07-c31dcf594253"
      decimals="-3"
      id="F_b224d6b2-310b-41dc-9b60-bcd8630d0302"
      unitRef="U_USD">924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e8212113-420d-4afe-a557-faeb55c9fc93"
      decimals="-3"
      id="F_b43d1aee-fce1-4169-bddc-2fa2707f01eb"
      unitRef="U_USD">393000</us-gaap:UnrecognizedTaxBenefits>
    <pcvx:ResearchAndExperimentalExpensesAmortizedPeriod
      contextRef="C_49cc4baf-48fc-47b3-962c-c338dcbc9399"
      id="F_7d6705e5-9f73-475b-8e41-cb39095eda62">P5Y</pcvx:ResearchAndExperimentalExpensesAmortizedPeriod>
    <pcvx:ResearchAndExperimentalExpensesAmortizedPeriod
      contextRef="C_330c2634-585b-4669-bdd0-9bfa256e2032"
      id="F_8a8115bd-6290-41cd-b1cb-c1bba683ba41">P15Y</pcvx:ResearchAndExperimentalExpensesAmortizedPeriod>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_219a732d-37c2-4f43-9e3f-02498c9dc8f8"
      id="F_8086d482-24df-4ca3-9b93-acc9fd63ad30">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;We have an ongoing relationship with Sutro Biopharma. In 2013, Sutro Biopharma provided support to facilitate the establishment of our Company. As of December 31, 2021 and 2020, Sutro Biopharma owned approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million shares of our common stock. As of December 31, 2019, Sutro Biopharma also owned warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31,857&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock (the &#x201c;Common Stock Warrant&#x201d;) at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.79289&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,276&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our Series C redeemable convertible stock (the &#x201c;Preferred Stock Warrant&#x201d;) at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.5215&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. The Common Stock Warrant and the Preferred Stock Warrant were automatically net exercised pursuant to their terms for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,278&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,591&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares, respectively, of our common stock in connection with the IPO. In the agreements and amendments identified herein, we licensed certain intellectual property and acquired certain supply rights from Sutro Biopharma, including the right to use the XpressCF platform to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases. On October 12, 2015, we and Sutro Biopharma (&#x201c;the Parties&#x201d;) entered into the Sutro Biopharma License Agreement, which amended and restated an agreement dated August 1, 2014. The Sutro Biopharma License Agreement was subsequently amended on May 9, 2018 (&#x201c;License Amendment A1&#x201d;) and May 29, 2018 (&#x201c;License Amendment A2&#x201d;). In consideration for the License Amendment A2, we issued to Sutro Biopharma the Preferred Stock Warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59,276&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of Series C redeemable convertible preferred stock at a purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.5215&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share. We also entered into a separate supply agreement with Sutro Biopharma on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;May 29, 2018&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (the &#x201c;Sutro Biopharma Supply Agreement&#x201d;). As of June 2, 2021, Sutro Biopharma was no longer considered a related party.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Sutro Biopharma License Agreement, Sutro Biopharma granted us an exclusive, worldwide license to research, develop, manufacture and commercialize vaccine products addressing infectious disease, which are discovered or produced based on the use of Sutro Biopharma&#x2019;s proprietary cell-free protein expression technology, known as XpressCF, which utilizes extracts derived from strains of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;E. coli&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. In connection with the Sutro Biopharma License Agreement, under the Sutro Biopharma Supply Agreement, Sutro Biopharma has agreed to manufacture and supply extracts and reagents for us on a cost-plus basis. In consideration for the rights licensed, we are obligated to pay a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% royalty on worldwide aggregate annual net sales of our vaccine products for human health and a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% royalty on annual net sales of vaccine products for animal health. In License Amendment A1, the Parties amended the license agreement to remove a pre-IND regulatory meeting as a diligence milestone and to agree that certain other diligence milestones had been satisfied. In License Amendment A2, the Parties amended the license agreement to add certain terms confirming our obligation to purchase Sutro Biopharma&#x2019;s proprietary extract from &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;E. coli &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&#x201c;Extract&#x201d;) from Sutro Biopharma. In addition, the Parties amended the license agreement to specify our rights&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;to a transfer of certain know-how relating to the manufacture of Extract in the event of a declaration of bankruptcy by Sutro Biopharma. Finally, the Parties agreed to terms providing for injunctive relief in the event of a breach or threatened breach by the other party.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the Sutro Biopharma Supply Agreement, the Parties agreed to terms for the supply of manufactured Extract and custom reagents by Sutro Biopharma for us to use in manufacturing vaccine compositions in non-clinical research or in Phase 1 or Phase 2 clinical trials. The term of the Sutro Biopharma Supply Agreement is from execution until the later of July 31, 2021 and the date the parties enter into and commence activities under the supply agreement unless extended through a subsequent supply agreement for the supply of Extract and custom reagents for vaccine compositions for Phase 3 and commercial uses as contemplated in the Supply Agreement. In February 2021, we entered into an amendment to the Sutro Biopharma Supply Agreement and extended the term to July 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As Sutro Biopharma was no longer considered a related party as of June 2, 2021, we excluded expenses after that date from related party transaction expenses. We recognized expense related to the Supply Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022, 2021 and 2020, respectively. In addition, we recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the change in fair value of the Preferred Stock Warrant for the years ended December 31, 2022, 2021 and 2020, respectively. The expense related to the changes in the fair value of the warrant is included in research and development expenses in the statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_8656ce44-0eee-45cd-8119-542db136b9e9"
      decimals="-5"
      id="F_a7f76a77-3152-412d-94b9-fb40919c12dd"
      unitRef="U_shares">1600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e301df95-054d-4248-b434-a97368723f9f"
      decimals="-5"
      id="F_a06eb04c-1387-449e-ad90-766f220d320a"
      unitRef="U_shares">1600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_180b3546-613a-47fb-a45e-b43467ddc5e3"
      decimals="INF"
      id="F_93b73b35-f0e5-4209-aa23-a7fb0990ea64"
      unitRef="U_shares">31857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_180b3546-613a-47fb-a45e-b43467ddc5e3"
      decimals="5"
      id="F_ae3919ea-d9e2-4122-bad5-53863cf81edd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.79289</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_24822c38-0fa4-483a-956a-7108b2fb1a10"
      decimals="INF"
      id="F_77b529b1-e234-48ab-bbb7-9778e6b0d502"
      unitRef="U_shares">59276</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_24822c38-0fa4-483a-956a-7108b2fb1a10"
      decimals="INF"
      id="F_3e6212ce-053c-4f29-97cb-d1d7ee5fae60"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.5215</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
      contextRef="C_d6be8964-6e18-48ad-a7a4-2310c767319e"
      decimals="INF"
      id="F_1af8f4f0-ed0f-4363-841d-2d818cf1502c"
      unitRef="U_shares">30278</pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised>
    <pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised
      contextRef="C_f6044654-8564-4024-bef2-b41b4aedd272"
      decimals="INF"
      id="F_22b654f1-4a16-4c2d-a5f4-4e8043f38626"
      unitRef="U_shares">16591</pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_8b67a24d-307d-4950-a7b7-2cbe7eaae283"
      decimals="INF"
      id="F_3b4c4d74-46de-44f8-a261-a86a3b743f32"
      unitRef="U_shares">59276</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_8b67a24d-307d-4950-a7b7-2cbe7eaae283"
      decimals="4"
      id="F_4e9d41d3-6b19-44be-a149-f2a6a5e17563"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.5215</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_acde4ea0-fa6f-4cb1-9b72-08bcadf7a728"
      id="F_fbdd3305-94d6-4a83-98c8-31ce59bf35cd">2018-05-29</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <pcvx:PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth
      contextRef="C_69861e0f-f897-430a-8634-87b91fd0c8b1"
      decimals="2"
      id="F_7ec58dc3-06b6-4df3-bf39-35cbd80c6eb4"
      unitRef="U_pure">0.04</pcvx:PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth>
    <pcvx:PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth
      contextRef="C_69861e0f-f897-430a-8634-87b91fd0c8b1"
      decimals="2"
      id="F_43482c0d-9caa-44a6-bd61-fd8204470905"
      unitRef="U_pure">0.02</pcvx:PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_69e656bb-2569-41bf-9f6a-4c464b33253f"
      decimals="-5"
      id="F_c5fced04-8d1b-40ec-8725-75da26f3a86c"
      unitRef="U_USD">0.0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_6c1fa594-ab7b-4dd7-8b89-83fe6abb5568"
      decimals="-5"
      id="F_2396e253-e1d6-47a1-ba53-59704860ef93"
      unitRef="U_USD">2400000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_2d608b3d-cdf6-4c26-9877-9e1ba7a21a78"
      decimals="-5"
      id="F_2608e1cc-284a-4302-8e1d-11a3f66999ab"
      unitRef="U_USD">1200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_05578dce-4d37-4f18-96b3-f10bddcbaf51"
      decimals="0"
      id="F_e8d2c695-e978-46cd-9bbc-37ac3096d490"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_3d0c5e64-a420-486e-ae76-8b1696c5a6ed"
      decimals="-6"
      id="F_1c446242-1776-41c3-b9a6-e60fa0e163d9"
      unitRef="U_USD">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_05a0d0fb-b481-4721-8b79-6232b8304ad5"
      decimals="-5"
      id="F_7ca243b5-8f8a-4713-bdaf-49f62e5209ad"
      unitRef="U_USD">200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_53f32d39-f32f-4c9e-8927-e638758556c7"
      id="F_8b253f3f-cac2-460f-97b9-f556b7a086a8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Subsequent to December 31, 2022, through February 24, 2023, we sold a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;507,136&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of our common stock under the ATM Sales Agreement at an average price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45.79&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, generating aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million ($&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million net of commissions and offering expenses).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814"
      decimals="INF"
      id="F_1495ea59-f5bf-42e7-bd8b-f299ceb13d00"
      unitRef="U_shares">507136</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_1cb91b7d-ce25-4f69-a837-9352b82a8fb7"
      decimals="2"
      id="F_267f1d99-be58-421d-9bc3-2b989f47616c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">45.79</us-gaap:SaleOfStockPricePerShare>
    <pcvx:GrossProceedsFromIssuanceOfCommonStock
      contextRef="C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814"
      decimals="-5"
      id="F_5366cf28-918b-4cb1-aa6a-c732149c6ec4"
      unitRef="U_USD">23000000.0</pcvx:GrossProceedsFromIssuanceOfCommonStock>
    <pcvx:ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses
      contextRef="C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814"
      decimals="-2"
      id="F_eb048e8f-925a-4c3f-932a-6fdcc6740523"
      unitRef="U_USD">22500</pcvx:ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_7bf9f156-a8b5-43ba-a0a0-d7a76ae82463"
          xlink:label="F_7bf9f156-a8b5-43ba-a0a0-d7a76ae82463"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_df4ab314-c5c6-42db-9ded-1707241de39d"
          xlink:label="F_df4ab314-c5c6-42db-9ded-1707241de39d"
          xlink:type="locator"/>
        <link:footnote id="FNT_2e45e8e0-02af-425c-8676-e3d2b46597cc" xlink:label="FNT_2e45e8e0-02af-425c-8676-e3d2b46597cc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</xhtml:span><xhtml:span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</xhtml:span><xhtml:span style="font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of accrued manufacturing rights as of December 31, 2022 and 2021, respectively. See Note 6, "Commitments and Contingencies, Sutro Option Agreement," for further details.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7bf9f156-a8b5-43ba-a0a0-d7a76ae82463"
          xlink:to="FNT_2e45e8e0-02af-425c-8676-e3d2b46597cc"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_df4ab314-c5c6-42db-9ded-1707241de39d"
          xlink:to="FNT_2e45e8e0-02af-425c-8676-e3d2b46597cc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_10840e29-68b1-42d2-9040-bb0bdcec4e88"
          xlink:label="F_10840e29-68b1-42d2-9040-bb0bdcec4e88"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e3446735-f111-4e41-9a5e-3fea9fe6170e"
          xlink:label="F_e3446735-f111-4e41-9a5e-3fea9fe6170e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bec0d669-934c-45fb-8ac2-b3ee2f080725"
          xlink:label="F_bec0d669-934c-45fb-8ac2-b3ee2f080725"
          xlink:type="locator"/>
        <link:footnote id="FNT_ae976684-1799-4dc9-8326-1dcb7053a127" xlink:label="FNT_ae976684-1799-4dc9-8326-1dcb7053a127" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The breakout and categorizations of the 2021 total accrued expenses have been updated to conform to the 2022 presentation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_10840e29-68b1-42d2-9040-bb0bdcec4e88"
          xlink:to="FNT_ae976684-1799-4dc9-8326-1dcb7053a127"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7bf9f156-a8b5-43ba-a0a0-d7a76ae82463"
          xlink:to="FNT_ae976684-1799-4dc9-8326-1dcb7053a127"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e3446735-f111-4e41-9a5e-3fea9fe6170e"
          xlink:to="FNT_ae976684-1799-4dc9-8326-1dcb7053a127"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bec0d669-934c-45fb-8ac2-b3ee2f080725"
          xlink:to="FNT_ae976684-1799-4dc9-8326-1dcb7053a127"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_99b7e5aa-ca0b-4683-a754-60df640d4e91"
          xlink:label="F_99b7e5aa-ca0b-4683-a754-60df640d4e91"
          xlink:type="locator"/>
        <link:footnote id="FNT_79671d51-a749-4741-8688-eea6386e55d4" xlink:label="FNT_79671d51-a749-4741-8688-eea6386e55d4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities for 2022 are net of lease incentives of $</xhtml:span><xhtml:span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million allocated to the Palo Alto office.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_99b7e5aa-ca0b-4683-a754-60df640d4e91"
          xlink:to="FNT_79671d51-a749-4741-8688-eea6386e55d4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_6bbbaf9f-9437-4277-81df-fdccd0343c70"
          xlink:label="F_6bbbaf9f-9437-4277-81df-fdccd0343c70"
          xlink:type="locator"/>
        <link:footnote id="FNT_2acf8d31-1a88-47ed-9dad-dbe995d6b697" xlink:label="FNT_2acf8d31-1a88-47ed-9dad-dbe995d6b697" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net exercise - shares returned to the Plan.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6bbbaf9f-9437-4277-81df-fdccd0343c70"
          xlink:to="FNT_2acf8d31-1a88-47ed-9dad-dbe995d6b697"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_b5f45fc2-7fd3-42d9-8568-e859afbbf42a"
          xlink:label="F_b5f45fc2-7fd3-42d9-8568-e859afbbf42a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_80af353b-9ba2-4df8-98f1-59c9d525d769"
          xlink:label="F_80af353b-9ba2-4df8-98f1-59c9d525d769"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_757b47b6-8c79-43eb-acf1-3e019ca5b5b9"
          xlink:label="F_757b47b6-8c79-43eb-acf1-3e019ca5b5b9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_044aa6a6-d895-4aa0-a08e-4ca031bbd5f3"
          xlink:label="F_044aa6a6-d895-4aa0-a08e-4ca031bbd5f3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_258d9aaa-c513-470e-888b-eb8ae243e82b"
          xlink:label="F_258d9aaa-c513-470e-888b-eb8ae243e82b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b8426126-c1d6-4c57-88bd-4a9f4048b799"
          xlink:label="F_b8426126-c1d6-4c57-88bd-4a9f4048b799"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0fe8f767-164a-4796-8d2d-e46722f6bd17"
          xlink:label="F_0fe8f767-164a-4796-8d2d-e46722f6bd17"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d28bdfa9-f518-49b5-89a3-e1fa6de3ae6a"
          xlink:label="F_d28bdfa9-f518-49b5-89a3-e1fa6de3ae6a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_04c41bd8-0f83-4a77-a909-a9bba4018be6"
          xlink:label="F_04c41bd8-0f83-4a77-a909-a9bba4018be6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_759d25eb-ab69-42e5-b66f-2cb749e67d44"
          xlink:label="F_759d25eb-ab69-42e5-b66f-2cb749e67d44"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_183651b9-50a6-4cb9-89bd-4b35bbe4e5cc"
          xlink:label="F_183651b9-50a6-4cb9-89bd-4b35bbe4e5cc"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6e4703a6-3c7e-4543-a0f2-f26f51d5137f"
          xlink:label="F_6e4703a6-3c7e-4543-a0f2-f26f51d5137f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_802af70f-cd71-4dcf-a22f-17f9b1443f1e"
          xlink:label="F_802af70f-cd71-4dcf-a22f-17f9b1443f1e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5134f00b-6328-4caa-a1ac-c88e5bb8d286"
          xlink:label="F_5134f00b-6328-4caa-a1ac-c88e5bb8d286"
          xlink:type="locator"/>
        <link:footnote id="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6" xlink:label="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 effective tax rate reconciliation has been updated to conform to the 2021 and 2022 presentation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b5f45fc2-7fd3-42d9-8568-e859afbbf42a"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_80af353b-9ba2-4df8-98f1-59c9d525d769"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_757b47b6-8c79-43eb-acf1-3e019ca5b5b9"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_044aa6a6-d895-4aa0-a08e-4ca031bbd5f3"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_258d9aaa-c513-470e-888b-eb8ae243e82b"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b8426126-c1d6-4c57-88bd-4a9f4048b799"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0fe8f767-164a-4796-8d2d-e46722f6bd17"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d28bdfa9-f518-49b5-89a3-e1fa6de3ae6a"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_04c41bd8-0f83-4a77-a909-a9bba4018be6"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_759d25eb-ab69-42e5-b66f-2cb749e67d44"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_183651b9-50a6-4cb9-89bd-4b35bbe4e5cc"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6e4703a6-3c7e-4543-a0f2-f26f51d5137f"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_802af70f-cd71-4dcf-a22f-17f9b1443f1e"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5134f00b-6328-4caa-a1ac-c88e5bb8d286"
          xlink:to="FNT_1e764aa7-2424-4823-b8e3-44b720dd76c6"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_ac4250ee-eb65-4511-b237-429ee9e59929"
          xlink:label="F_ac4250ee-eb65-4511-b237-429ee9e59929"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_78c4db69-b1e9-4eef-a9b3-72a61579c018"
          xlink:label="F_78c4db69-b1e9-4eef-a9b3-72a61579c018"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_d15ce071-280d-4dbc-b955-df724acecf1e"
          xlink:label="F_d15ce071-280d-4dbc-b955-df724acecf1e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_33105149-d815-4139-9962-2039b98c9033"
          xlink:label="F_33105149-d815-4139-9962-2039b98c9033"
          xlink:type="locator"/>
        <link:footnote id="FNT_c4653557-9b4f-4d3f-bf1c-d79a8f314a27" xlink:label="FNT_c4653557-9b4f-4d3f-bf1c-d79a8f314a27" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Accrued &amp; others and Stock compensation lines have been updated to conform to the 2022 presentation.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ac4250ee-eb65-4511-b237-429ee9e59929"
          xlink:to="FNT_c4653557-9b4f-4d3f-bf1c-d79a8f314a27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_78c4db69-b1e9-4eef-a9b3-72a61579c018"
          xlink:to="FNT_c4653557-9b4f-4d3f-bf1c-d79a8f314a27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_d15ce071-280d-4dbc-b955-df724acecf1e"
          xlink:to="FNT_c4653557-9b4f-4d3f-bf1c-d79a8f314a27"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_33105149-d815-4139-9962-2039b98c9033"
          xlink:to="FNT_c4653557-9b4f-4d3f-bf1c-d79a8f314a27"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>121
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #""6U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  P@EM612Q5B^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>*';&"B;-I66G#08K;.QF;+4UC?]@:R1]^R59FS*V!]C1TL^?
M/H$:':4."5]2B)C(8KX;7.>SU''-CD11 F1]1*=R.2;\V-R'Y!2-SW2 J/1)
M'1!$53V 0U)&D8()6,2%R-K&:*D3*@KI@C=ZP<?/U,TPHP$[=.@I R\YL'::
M&,]#U\ -,,$(D\O?!30+<:[^B9T[P"[)(=LEU?=]V==S;MR!P_OST^N\;F%]
M)N4UCK^RE72.N&;7R6_U9KM[9*VH1%U4HA"KG>"2KR2__YA<?_C=A%TP=F__
ML?%5L&W@UUVT7U!+ P04    "  P@EM6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #""6U8UJX78CP@  - T   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9MM<^(X%H7_BHKIZIJI2H)?R%MWDBIB.K/L9#)L2/=,[]9^$+8 5=L6*\M)
M^/=[98R-I^0+KA)?$@S<(_M!DL^QY9LW(7]D2\84>4_B-+OM+95:?>KWLW#)
M$IJ=B15+X9.YD E5L"D7_6PE&8V*HB3N>XYST4\H3WMW-\5[$WEW(W(5\Y1-
M),GR)*%R?<]B\7;;<WO;-Y[Y8JGT&_V[FQ5=L"E37U<3"5O]2B7B"4LS+E(B
MV?RV-W0_C09%0?&-;YR]93NOB3Z4F1 _],8XNNTY>H]8S$*E)2C\>V4!BV.M
M!/OQOU*T5[6I"W=?;]4?BH.'@YG1C 4B_I-':GG;N^J1B,UI'JMG\?8/5A[0
MN=8+19P5?\G;YKOG%ST2YID225D,>Y#P=/.?OI<@=@JNG)8"KRSP_E;@#EH*
M_++ /[1@4!8,"C*;0RDXC*BB=S=2O!&IOPUJ^D4!LZB&P^>I_MVG2L*G'.K4
MW4B$.?R,BM T(E]2Q=6:C---?]*_RRGY.AV1GS_\0CX0GI)['L?P=G;35]"X
MENB'94/WFX:\EH9<C_PN4K7,H)6(14V!/NQUM>O>=M?O/51QQ,(SXKLGQ',\
MS[!# 5[^P&9GQ/.+<M]0/L++_YFGT+IC:KUQ-'[U0_B%GM^B%XA7)LE_AK-,
M21@,_S41WB@,S IZAOB4K6C(;GLP!61,OK+>W<>?W OGLXF.3;&1);$&N4%%
M;H"IUUWX9;UB)FQXN>N<_F;B@U9UY6-)K,'GO.)SCA[@$.!$!:"'F"Y,@/#Z
M.8TS$]< +>M*R))8@]!%1>CBL!XT89(+/0]&!&938V?:H[2=DUHG);2^*S1+
M8@UHEQ6TR\.@/? LI#'YSJ@D#_"F\>2 :[7!0JNZPK(DUH!U5<&ZZ@2K[&BM
MN'"UA^\F6&A-5UB6Q!JPKBM8U^CAO4@:\71!INMD)F(3'KQ^$GS[RP0(K>H*
MR))8 Y#KU*[-00^Q=&K/;,&U7X".]403XWRU1^C;\*_@^\N7$S)^"LY,T/#Z
MKM1LJ36Q[9A=]Q!L 8Q$":-P#$[TG?S&UD9PN)3C..[%X-JY'ABIH<6=J5E2
M:U+S:FH>>JA!+N7?)WKL%+E'[O34]4Y]UX@-K>R,S9):$UMMZ%W4]6X[VY^0
M:4]_I.(M)5-&,Y&RB(RS+&?2R [7_,Y,IXL K^K,[1ANWJWMO(L;\BJ%*B8W
MEP5T3Z.D[(9&:KAB&S6K%M^66I-:;?)=W*5OI[9RK#ZSE9"J.(LJJLPF8X]B
M&S6KMM^66I-:;?Q=W*^7U+Z).$\5E6N8XV(FS;1PI2=AA&75[MM2:\*J#;^+
MN_025H&(!##Y+X0TGSIQG4<J%XP,PY"!$,A$&TDC/ZL)P)9:DU^= 5S<MI?\
MI@F-8W*?9_!Q9NYJN$YK(,?K.M,Z1@9PZQ#@XBZ^I/4E87*AY[%?04$M22"2
M%4W-W0X7;,=F-1C84FM>$ZV3@8<;^G'P\$R&><25D&2H%,O4YDINV\6?/7I*
MYD9H>%E7:+;4FM#J7. =E NF2_!J6 _;(]/:P_"ZSK".$0>\.@YXN'_?.0V0
MISR9F8WL'A%(3Z?^M6^\\A[@M9UQ'2,&>'4,\ Z* 2_TG8PCL&9\SL/-B$3@
MX9*#B].!Y_O^U;F1GM4P8$NM2:\. ]Y!86 81:">G6Q?D$?X'ODC->;//9)7
MWKE._GFF)(<X^RQH9,1H-1W84FMBK-.!=U Z,&-\>3-YU_L]DM.<*T9\QS'"
MLQH2;*DUX=4AP3LH)%3P KT%9]<7R/1&<+C<E*;@GF4LC/$*+^Y,[AB)P:L3
M@W=08JC(Z2S*-+J)%*\\#<W#%]<,AD9L5H."+;4FMCHH> <%A0K;1(")B\F_
M^0K,262&ABM>#YQ+)Z1&<E9#@RVU)KDZ-'BXQR^&YE RV@X*%[@X-\]G5B."
M+;7F0H,Z(OBXI7\4Q2VHI4@Q [='Y,J_/'5<UW@9%R_MO+;@&-G K[.!?]@]
M Y$DX-FF2H0_8");4FB+_)$K&)FIOEME1&C3]@>EVGFAIM=SO=Y=.8[O7WJ7
M-_W7!K%C! 2_#@C^00%ADL]B'D+N%-1XT197Z4S':F8HU2YV6+MG;H6Y"69G
MB0_NVZN[P,,TS;7U+"[2&MG@0FVA'"_K#.$8UM^OK;^/^_1Z78^D:<:+R(00
MP\5:HSE>UQG9,6R^7]M\_R";/TY#(0%4$3-W7%<@\E3)=>NY<8_ZZ(L1H%6K
M;TNM";"V^C[NS5^XB@'5G+C>S[-?R)2%N02B1EBX4O-\\<$Y<QR7K*@DKS3.
M&5DQ23)]$C$BM9H!;*DUD=89P,?]^I8A^?(>+FFZ8*U+%?8(/0VGH^&_C+RL
MFG];:DU>M?GW#ULJE.T,8Q:1F5[M,6>2M:2F/:H3*A49C\>Z;ZLESYJG(**O
M#PN9$+T8DO"ZW0PVZL7 L ]RNP]D+D4"4FQG$<K'GZX\]_)SIA=>\Y07MVY7
M4KROB;X(S8K)7 DR@V(>PS&]<;4L)+Z>3<^V@XU#H\5BY&UWT2.)9\5"\U4N
MLYQN5*#9/-[LESL8GI!4* +;,*X4U,$ =DA$UZ UW[S'" /5XO!U^\52AK5>
MRA#JE;<;PGO(G.@ET*%(TW+1>K7_!@1Z53$<1R&5,%;<BH7&,ST?+$4<,9D9
MU]O@OV/GOGR,..;7<<S'T]3V/D3KB,?+1RP67,&YZR--5I_)B\A#@/WX.#&"
MLQK1;*DU5S37$6V IZLM.!W5=%<SP=LCH2\S/4"7#*&KBQ,2T)C#2$ZY\2(
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M'JXJ&_# A(1QU =ND?)H%-MQAWO<H1/W1Z%8=@;$T(RM3X(@Z&$TQ4@04G\
M9+0'&9T(+E!8J9[KH.JENM%K8(P*KFQ8(UN@0J\'U92*9H%O!QKO@<9.H'\
M3*;2X@%E''@&E9I0)F(UJ>!E.+BQ&35,XK@'V"(%B =".]LCGCD1_R:*A[,V
MU\P</0S\_AJU2$6PE.T8L=?QC^=$^0&0E6FB>).NK$3C&4/'$>[!.R%TC.Z
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MY'=<HIU 2DR&\[V ]"?%(D: "8>P=E1(W%3X7A23Y-MB3$S^P\2C?0JWB>'
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M($R OK_F7#UUS,;>'.3"OU!+ P04    "  P@EM6O\AU3W$%  "3%0  &
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M.@GL3G1YN));FK&;">Q_R<2.36:__H(C[S=;@-[3V>*=G!T%+^B#%[B\S[Z
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MNW7+)Z:07B#K[&-#RUX0X@?#,C&W ;'G>;%1U"W )"5CX@OOY0IVZY7?J:A
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ME\W/#:-+)C0 OJ\XG(2[!SU ?P\[^P]02P,$%     @ ,();5O/DCFF* @
MJ 8  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RM5=]/VS 0_E=.'II
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MQ:B6H%J*:AFJY:A64%I[-&CBM_7#DSX9J%9*L%K^>Q94-S_UC@9&IT>J@\%
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M6.+1@+,-XGJW8M.#S,P,K>03JJ]])KEZ2A1.CF822U#7* 5B(7J$ %1:S6-
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M0\073(B?XV '&0%J!GE(9V2BE@B'GK&:3=S4:AXU#[*+GOLTY9W4.D+T2 T
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MG*HLRWZD_4%S+1:HDPZ'12)TE0]D15<OY [F1=2LB6T:!4[OB$$:D&+4. @
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MZOYW./V;EN_4+U.>>-OR4KW<LD1LER5 _'W#>;M_([_@\&NHN_\!4$L#!!0
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M5>4(!_( 3E^X/+^\F(ESY3(EZTA!!AOND6"%,.+%VH!:.4FJE!!\S*2A8A+
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M3H<1YJ%TPL, =SZ)VIW*L@3<HYB-=O6^)D10_!Q#!\;T)Y2L'15X>!-.ZH[
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M']%"?L\&GR79K\2"%YI=O@2*%%=38"["L>)J"_&C&38%XSB(K$X;:GPW-29
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M'P3]@U4;]R/<4EFK*O>Q$!P3(6W ^Y7"L-X^D(+^5]GK_P)02P,$%     @
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M5"D*WE)#%G"KT:"T[8):P;60%!C!2UC0(A(/K8$_SY?&:F+27R^%J#4@?=D
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M605!82CEE.U!.T7N#K0([SF<F/72"#:D2)QS+&P4#D]NCV45P0%\:QX8%;?
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M#AQI1AOP^T+A*-LLR$#[)XR3OP!02P,$%     @ ,();5HMW2.EM!0  /0\
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MNXCK5AJ6N-^2YP68+YR+_0,[6-^89_\ 4$L#!!0    ( #""6U8.5U^"T@X
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M7-/X_6D$IA\]_<;I-K1[H1T-C[!L:%JC\0"RUUJ[W<8'&.;_[!=02P,$%
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M+\FK!VHZ>H*N498L&GO-;KZ??SR:3SO:>-,A"_,[?%$B7$I(L) 9Z;UX29_
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M'E_;,VX*L\;90#.+<D 0(206@S(<!9E;6_.74)?<05-QR/S&,Z#46U*9*J7
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MS,LE2+BTI#.O)ZT'T&Q(^O4GG9\4LK:.] Z'#L<S,8DF4.@*&,Q7FF(3;)I
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M\'T2)WN5Y %8A+I$/>:/VAYC]WP8G.SGXBKUW).YU]0@A*CIT#B<X 2.,HT
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MASW.AY@P=8NF[-NN@Q #$K]R)7\7B08 \[(MB.7*DBB$&&8;ZPEND-6S"L'
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M\<63,VE(<1_(U^%_.&EMV];N^$\T"YL:#SPY8T/D/F #_T]IO?A?4$L#!!0
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M@I"6H//><:C&H#_FHN/R0J[]X^\[%O?ZW>%@A+MAW+V*![CIQ<,N#KK.XJ]
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MF"P0YEX!UV@9%P9.'MA"H.E/AY9B.,MAT>%=MGC)#_#B!#XI:=<&;F2)Y6N
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MEO26DY^>72&EI*!SS^8%JI-)3Q.H>=5+-P#G#4#X D 0PK6H]%+!;U6&V5.
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M(5O+G%"XXTBLBP+S'U/(V6;D^,[NP3U99E(_<,?#%5["'.3#ZHZK.[>F)*0
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MPZN30#61K#!;W9Q)M7&:8:H.3\ U0*TO&).O$[U[-L>Q\ ]02P,$%     @
M,();5L$E,V\S P  8 L  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
MS59;3]LP%/XK5H8F)FWD4MH":ROU,C0D8(@">YCVX":GC85C%]MI0=J/GR]I
M:*:2@NC#7A)?SOG\G>_X<CI++NYE"J#08T:9['JI4O,3WY=Q"AF6!WP.3,],
MN<BPTETQ\^5< $ZL4T;]* A:?H8)\WH=.W8E>AV>*TH87 DD\RS#XFD E"^[
M7NBM!J[)+%5FP.]UYG@&8U"W\RNA>WZ)DI ,F"2<(0'3KM</3X9A8!RLQ1V!
MI5QK(Q/*A/-[TSE+NEY@& &%6!D(K'\+& *E!DGS>"A O7)-X[C>7J&?VN!U
M,!,L8<CI3Y*HM.L=>2B!*<ZINN;+[U $U#1X,:?2?M&RL T\%.=2\:QPU@PR
MPMP?/Q9"K#DTPA<<HL(A>JU#HW!HV$ =,QO6""O<ZPB^1,)8:S33L-I8;QT-
M82:-8R7T+-%^JG>*B4!WF.: +@#+7(#.D9((LP2MS?$I.B4,LYA@BLZ85")W
M=E]0/TF(R8B=</O*Y&=_! H3*C^A/408NDEY+C6H[/A*TS:+^W%!<> H1B]0
M#"-TP9E*)?K&$DBJ +Z.MPPZ6@4]B&H11Q ?H$;X&45!%*';\0CM[WU"8XAS
M0=33!H;#U^.%6_ JA!MEEAIV@<;V+/6E!*U[7^?GG. )H5I\D*OD)>@'0]=F
M84'8S%I=<B;*@0&61%HDEZ4;B%-&'G*-\.M<+XK.%&3R]Z8D.8:'FQF:V^9$
MSG$,74]?)Q+$ KS>QP]A*_BZ2<\=@57$/"S%/*Q#=V(NK)C8B:D$9G(*PNA'
MF.*(P@(H:FR2P6&W+;:Y(Q>]H.,OUF.KLZ@0;I:$F^\@K.]F<SQK*#OT9@WE
M.HL*Y59)N?5:RG1ME[Y%Z-96UG46%=;MDG7[O:RWJ]W>ND'J+"J\CTK>1[6\
MSU]F4^OXUE.[([!*C,=EC,?__15XO$LQ=P16$3,,GI_]H';+7.;9!(39RM(]
M4T;!/W5OX*! K#N1M2:.J;]6JV0@9K:$DRCF.5/N!2]'RS*Q;XNC?\8'IGRT
M-= SC*L]+["8$2;U(9UJR."@K?D(5\ZYCN)S6Q%-N-+UE6VFN@0&80ST_)1S
MM>J8!<JBNO<74$L#!!0    ( #""6U9\.=R<=P<  * R   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;+6;VV[;.!! ?X7P%HLNT,3B39=L8B 7I%N@
M 8*FZ3XS-I,(D257I)UVT8]?2G9-2:1H2Y%?$LL>#F<H<N9P*)V^9OF+>.9<
M@A_S)!5GHV<I%R?CL9@^\SD3Q]F"I^J7QRR?,ZDN\Z>Q6.2<S<I&\V2,/,\?
MSUF<CB:GY7>W^>0T6\HD3OEM#L1R/F?YSPN>9*]G(SCZ_<67^.E9%E^,)Z<+
M]L3ON+Q?W.;J:KS5,HOG/!5QEH*</YZ-SN'))0V+!J7$MYB_BLIG4+CRD&4O
MQ<6GV=G(*RSB"9_*0@53_U;\DB=)H4G9\7VC=+3MLVA8_?Q;^W7IO'+F@0E^
MF27_QC/Y?#8*1V#&']DRD5^RUW_XQB%:Z)MFB2C_@M>-K#<"TZ60V7S36%DP
MC]/U?_9C,Q"5!I"T-$";!FC?!GC3 )>.KBTKW;IBDDU.\^P5Y(6TTE9\*,>F
M;*V\B=/B-M[)7/T:JW9R<LWB''QCR9*#&\[$,N?J'DD!6#H#E=^R1W =IRR=
MQBP!GU(A\^5:[@C<J9DU6R8.F8WB&6"RIC,%7_ATF>=Q^@0NF(@%>'_%)8L3
M\9?2>W]W!=Z_^PN\ W$*OCYG2Z%L$J=CJ;PN;!]/-QY>K#U$+1Y>\>DQP/ #
M0!Y"EN:7^S>']>9C-=;; 4?; 4>E/MRB[UP(+L6)S8]U0V)O6*SG$[%@4WXV
M4@M6\'S%1Y,__X"^][?-JX&4U7S$6Q^Q2_OD4[KB0I8W_T/ECMM\7BL*2D5%
MR%E-(,+(#T_'JZHWSOYZ>D.VWA"G-]J!#WK"VGQQJNEZ_P925O.8;CVF?><H
M'=+'@935?/2W/OK.NWK)Q',9Y:;%!_Y]&:]8LIZQY_,LE_%_*F!=9D+:1F&M
MFE9F;8B)'\'&K/6-R>V'4>AOI6J&!UO#@[Z&?\PS(<!]JO)Y4MK_65US:\P,
M# ^.,&F8;Y&!=MO#K>UA7]O=82*T#C@-&A:;8L6 4[O1T=;H:/]HMGMN1(8-
M*J+1B#9,-<601S!!=ENAI_.YM[^UQH3XJ,#.GD,]PQX<-4QV]]QSO<(*J< W
M>-8^U3=JZW/=]YO.6:00\5INA\[VT)EHNZ3"C2:Z*Q=:Y-34@5[;U-%9&[K3
M]M=,*G)C9? '\PJT/19VK]89</<"V/12M2^B(0J-$3?E4( Q"EO\T/D:NA/V
M7GYT6!IDCZ5QB'0-=;Z&SE39TV/'DJ'F8B">UW3:(H5(2XJ .C%#=V;>RYD=
M2\E,T!$-(M0,PA8Y-06],&CQ0>=HZ$[25F8$OT"9 '^!SWS%$P"MICL5=R6L
MH;35AT&G>QCV!4GH)(7.?@ZDK>ZG)@3H1H0WP20T48#Z,#+"OH48@K ";?7M
MJ 8&Y :&WDR&3&2PV6T1<]FM<0"Y<:!MB=UD*?\);EC^PB6X7J8SX5YP[FXZ
M;[L'TE8?E$IQH7]U8=CRPB'J"TBC"G*CRIL6'#+!PP^]R-C_6.1@0&G+=@)I
M/D%N/NF_XDP2L1MNRKD,UYB!W)C1FM6R^9SG9=WOEBUXOEUPMGK;A;N3SA/Q
M$$4$I&$%^;T7G!-S.OLYD+:ZGQIH4.^JPQX+SJPD*!8+F^42BUBQ<VZ!,:0I
M!/6N.G1@8F06%\R2B4VH!8B1I@O4FRYVQ L3&=2XDV;5Q")6C'M+G0IKLL!N
MLF@+%_?'=\?@:UZ2_4]P5_P2RYCOR-/NSKHNIZ&TU8=&PPN&?<,&'I1'AM)6
M]U/S".Y0_M@=*+!9VL"!3YN!PB)&*(I:BC6X<FS1X=RB0VC )B@<!<W=LE4(
MMYBL60*[6:++48NECA&84=@BI@87MD1AK.$!OQD>%KOAP=U)Y]5Q"'C &AYP
M;WC @\+#4-KJ?FIXP&YXZ!H%+!P00M^8J*:8VGZVU9^PQ@7LQH7>4<"6^YNY
MUB:$6BJW6!,"[G!$L2,*6))]"$D39"QB:G!A9+>4:"8@_9C@,LL76<XD!U?\
M0;IC@+N+S@>MAR !HDF ]"8!,B@)#*6M[J<F 3(H"1#+(0<EE3..C5.F& U)
MU'*$0#0)D,.0 +$D>8B;D<LF%;04Q$CE,87!4("8.1Y1%!AVFF)J=%&;I1H%
M2#\4*-<">&#3%S7(PMP7V*/!H$0PE+;ZR&@B(+V)@ Q*!$-IJ_NIB8 ,2@3$
MDNHCVLQ9%BF(PZ@M9VD@(&\!@M9S0V*F>M3<%+A[[GL;-#>0#MS0)<PYU7:>
MBR9K'*&68B75I$$[/ CA#H?4/*+PHZ YO2Q2:GJUQ6VJ"8#V.\@HRR0?LQ7/
MT\(+</[$TZFU7F*-B^Y>.S^J=0AZH)H>:.]S#3KHN<90VNI^:NZ@!SS7H"96
MD"AHGL>Y+>CKH:84>J###VJI2UB\.\ASDY4')]UDTS&O4?,)"D6YJ+EIM(F1
M +9%'DT;U/VD1<_$1LVG)F#S@1AWSWWO@^8+VH$O.B0V:GOFD1B3S")%6LKE
M5&,&[8 9.];"6E-0FS?(.'JWB1'?;^Z.QI77!XIW-VY8_J1N/4CXHVKG'0?*
MT7S].L3Z0F:+\HV"ATS*;%Y^?.9LQO-"0/W^F&7R]T7QDL+VI93)_U!+ P04
M    "  P@EM66AS)IF\"  !T!0  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6R-E-]/VS 0Q_\5*T,32!M)W5_ TDA A<8#$J+ 'J8]N,FEL7#LSKZT
M\-_O[(2HVPK;2^*S[[[WN4O.Z=;8)U<!('NNE7:SJ$)<G\6QRRNHA3LV:]!T
M4AI;"R33KF*WMB"*$%2KF"?))*Z%U%&6AKU;FZ6F024UW%KFFKH6]N4"E-G.
MHD'TNG$G5Q7ZC3A+UV(%"\"']:TE*^Y5"EF#=M)H9J&<1>>#LXNQ]P\.CQ*V
M;F?-?"5+8YZ\<5W,HL0#@8(<O8*@UP8N02DO1!@_.\VH3^D#=]>OZE>A=JIE
M*1Q<&O5-%EC-HI.(%5"*1N&=V7Z%KIX F!OEPI-M.]\D8GGCT-1=,!'44K=O
M\=SU82> \S<">!?  W>;*%#.!8HLM6;+K/<F-;\(I89H@I/:?Y0%6CJ5%(?9
ME9"6/0K5 +L!X1H+U'%T3.B"[9R9DEU)+70NA6+7VJ%M6K_/;$'_2=&HX'-I
M-%IJ=$->-P(;*U&"\R?7>@,.VYC#.:"0RAVQ R8UNZ],XRB?2V.DBCQ7G'?T
M%RT]?X-^#ODQ&PX^,9YPSAX6<W9X</2[3$P-Z;O"^Z[PH#O\=U?FTN7*^,8X
M]OU\Z4)]/_:AMI*C_9)^N,[<6N0PBVAZ'-@-1-G'#X-)\N4=X&$//'Q//9L3
M*;52@7,,*Z&9T<!>0-A]H*W4-$CYH=UDIY/IX#2--WL(1CW!Z'\(?%XTK*11
M"_GW?M16:;P#P"?CT1L XQY@_"[ O4&A]F4;_U7N@ _YY.2/=/'.$/G[Z$;8
ME=2.>EI28'(\)1W;SGAKH%F'N5H:I"D-RXJN1;#>@<Y+8_#5\*/:7[39+U!+
M P04    "  P@EM6WX</@; #  !-$0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6RU6%V/FS@4_2L6K:I6F@Z8SV2:('4RK3K2M(J:=O=AM0\>N)F@
M J:V2=K]]6L#(9!X4".1EP3#/8=SCR_FFMF.LA]\ R#0KRS-^=S8"%'<F":/
M-I 1?DT+R.65-649$7+(GDQ>,"!Q!<I2T[8LW\Q(DAOAK#JW9.&,EB)-<E@R
MQ,LL(^SW+:1T-S>PL3_Q-7G:"'7"#&<%>8(5B._%DLF1V;+$208Y3VB.&*SG
MQGM\L\"! E01?R6PXYUCI%)YI/2'&MS'<\-2BB"%2"@*(O^VL( T54Q2Q\^&
MU&COJ8#=XSW[QRIYF<PCX;"@Z=])+#9S8V*@&-:D3,57NOL$34*>XHMHRJM?
MM&MB+0-%)1<T:\!209;D]3_YU1C1 6#W&8#= .P_!3@-P*D2K955:=T10<(9
MHSO$5+1D4P>5-Q5:9I/D:AI7@LFKB<2)\):D)(\ K:J:N0-!DI2CMV@EZR4N
M4T!TC99,5@T3OQ')8_3A9YD4<A[%%?HB$:\;R!N)^;ZZ0Z]?OD$O49*C;QM:
M<@G@,U-(G>IN9M1HNJTUV<]HNH/H&CGX"MF6;6O@BS^'XS[<E.ZT%MFM17;%
MYSS#UZ:_E%8)]+YK OKG04:C>P$9_U>7:4WMZJG5,WK#"Q+!W) /(0>V!2-\
M]0+[UCM=WB.1]5QP6A><(?;P&Q4D146W%&#O@B[QFBVHV-1:L@VQ[P;!S-QV
M,])$8<^RVZB>5+>5Z@Y*?0#.;^0"$959F1(!L7RNI2-10NJ50THG&64B^:\Z
MH5-?W\#KZ'KK8WRL7A/E>.Y$K]YKU7N#ZI=:BZ]0#EJ?O1,-V')\ZTCI:50P
M]5R]4+\5Z@\*_5BR/!$E@_ZZH!,Y2'3N4S 262_GH,TYN-Q:$(SIPDAD/1<F
MK0N34=>"R6F-^M;DJ$1U07BJ+]%I*W0Z*'1!LZ(4P'BE<3]"*[H6.\) IW60
M\-Q)&HFLESNV#J]VZW+%VG"/9,18;'TG.DT.'K5@&[IN,;K8/RI879!CZ0L6
M'YH-//@6#Q_(X_!:.HP_>V(NT5/@0U.!G0N6Z&#'<K83(['UG3CT+'BX:3F[
M1$^;#^Q@Z_C%KPF;NI[S3)4>>A0\W*0\@-PZ;6@:H_M,:MZ"DJEO]0>)SIZD
MD=CZ:1\Z'NQ?L%Q'[8+&8NL[<>B#\&"#<7ZY!J>=OM.IPR:ITZCC!=7L['75
MAX;/A#TE.4<IK"7&N@YDA;!Z[UX/!"VJ[>\C%7(S71UN@,3 5("\OJ94[ =J
M1]U^00G_!U!+ P04    "  P@EM64$GT.K\"  "X!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6RM5=]OVC 0_E>LK)HZJ6M^$&C5021H.JT/E5!9
MMX=I#R8YB-7$3FT'VOWU.SLAHQ!0)_4EL2_W?;GOSKX;KH5\5!F )L]%SM7(
MR;0NKUQ7)1D45)V+$CA^60A94(U;N715*8&F%E3D;N!Y [>@C#O1T-JF,AJ*
M2N>,PU02514%E2\3R,5ZY/C.QG#/EIDV!C<:EG0),] /Y53BSFU94E8 5TQP
M(F$Q<L;^5=PW_M;A!X.UVEH3HV0NQ*/9W*8CQS,!00Z)-@P47RNXACPW1!C&
M4\/IM+\TP.WUAOVKU8Y:YE3!M<A_LE1G(^?2(2DL:)7K>['^!HT>&V B<F6?
M9-WX>@Y)*J5%T8 Q@H+Q^DV?FSQL ?S! 4#0 ()=0'@ T&L O;<"P@80VLS4
M4FP>8JII-)1B3:3Q1C:SL,FT:)3/N"G[3$O\RA"GHPG-*4^ S.P9BT%3EBOR
MF8S3E)G"T)S<\OITF3*=-AZ?T.5A%I/3DT_DA#!.OF>B4I2G:NAJ#,N0NTD3
MPJ0.(3@0@A^0.\%UIL@-3R%]3>"BGE94L!$U"8XRQI"<DYY_1@(O"#H"NGX[
MW.^ QV^'>T?4]-H2]2Q?[P#?5.(EE_KEC$RQ5II@ELG-4\5*O'V:_!K/E99X
M?7YW9;YF#KN934NY4B5-8.1@SU @5^!$'S_X ^]+5];>DRQ^)[)7&0W;C(;'
MV+%"2)JP^DB;=-)"2,W^U 9XQIZJH"N=->V%I34-=14% P]KO-I.T[Z3?[GK
M%'<XA5M.KV3U6UG]H[+&22(K2+$]\&J!)Z*2C"^)-)U/;51UWL_^7C!];T_6
MOM.NIJ/1_6])W:V>5H!<VMF@2"(JKNM.T%K;\3.V77?'/L&Q5$^1?S3U3+NC
M<LFX(CDLD-([OT !LIX3]4:+TG;.N=#8A^TRP]$*TCC@]X40>K,Q/VB'=?07
M4$L#!!0    ( #""6U;+7U"TR@,  % *   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;*U6WX_B-A#^5T;IJKJ3*"$_01206*#J26UO==RU#ZM],,D
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M? <.))72HFC I*#(>/UD+TT>S@!>\ ; ;P#^)2!\ Q T@."]@+ !A.^5%#4
M&[I;QVX3MV2:S292'$$:;V(S+S;[%DWYRKBID[66]&]&.#V[9SGC"<+:%N42
M-<MR!3_!F@HRK7($L85YDL@*4UB]4'4J5/"A\?M(CM_62_AP]Q'N(./P=2\J
MQ7BJ)JXF<68+-VF$+&HA_AM"EICT(?!ZX ]\OP.^?#_<ZX"O;L,?O:?7()?R
MV";3;Y/I6Y;@#993HG[+V";+,YVAZL&BDA*YAL?Y1FE)!^.I*SDU<=A-;)K%
M6)4LP:E#W4"A/* S^_$'+Q[\W)6J_XGL50Z"-@?!+?;9@@Q9PG)8ZRJE!'0%
M6S,,+8-I9(>9%WFCB7LX#^+:*8R"UN>5MK#5%M[4]EGO48*)F<ED#U2HU%,.
MU"M+ZGRZ0^G];;Y'O_-;UJ#H/#P_#..+^*Z]PG@8=P<8M0%&[PB0-66(S7GM
MTAA=:PP][T+BM5,01Z-NB7$K,;XI\:O0+.]2%'<413",+B1=>XV&HV&WI*%S
M81BU&D>WOZOW1*T,84.3]YF&JZV4A&G<"9G]P\R$4Z8Q4K9MOP%M@KK*.^S9
M@4@0.51E2O"4'"$1W(QW\]K@?;#GD&O+W(=//,FKE/!W$/4'U/7SW,Y4$G$'
M [/Q::>"\6I++:62&=^!-$-1 ;/:J"%BL:%J./54BS=J>^8$E&@G=/Z]#VM$
M^$-HA+@'SD(41:;-<5 6L!!<$S?RQ#:S=:6E@,^E'?+SG40TKCT'*"385M+6
M7UI/AWY7-W'/1E6!<F?O"(J24G%=?Z#6VEY#[NVXOK O_?'*[[('XU7090_'
MJ[#+'HU749<]'J_B#OM\.%X.N^RC\=)>E]S_PJKO6K\SN<NH8'+<4HB#_I .
ME*SO+_5"B](.Z(W0-.[MZYZN?"B-0V1R2U^G69@-VDOD[%]02P,$%     @
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M4+\OI,Q>ON0%[">\O?D_4$L#!!0    ( #""6U9\>":T: ,  %4*   9
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M.1ND_&*O,LA';(>)W6#Y@KG?CPG6("MRAL?T(S"ISEWXPRO0UI/,2-4>U6%
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MAP4]G:C=!EK/E;(O@6OG_C%.?@-02P,$%     @ ,();5I\AJ:_, @  ) D
M !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&ULK59=;]HP%/TK5B9-F[0U
M(8&TZB!2"YW6:I50NX^':0\FN1"KL9W:#K3[];MV0@I=RHK$"_CCGN-[CAU?
M#U=2W>D<P) '7@@]\G)CRE/?UVD.G.HC68+ F;E4G!KLJH6O2P4T<R!>^&$0
MQ#ZG3'C)T(U-53*4E2F8@*DBNN*<JL=S*.1JY/6\]< -6^3&#OC)L*0+N 7S
MO9PJ[/DM2\8X",VD( KF(^^L=SJ);;P+^,%@I3?:Q"J927EG.Y?9R ML0E!
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M)^*5*O+IR4>__/CJIBM5]3FD.R^KNMM7Y9RI"J,'ELF50+,LHI$AWG\AWK$
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MO(#Z?<&8/'S)*SANUY[\!U!+ P04    "  P@EM6\B4Q_T0#  "&#0  &0
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M8X>V+%!:"*51*(U!:1Q%T\6C/-C >>4.+(#ZM%!:"*51*(U!:1Q%TV6F[-S
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M?)2*7K>%^T*KLEFJ8:17PVW&TA$M8"M&B-E8N'K=V^T+K4I>J:217DDWR/M
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MM P_(VK=UX+)IYG$B?#V>Y6) [HC,1"U FB58\+1!5K7B8#H!BW4VBBKBB3
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MTWPQ2T7YC0YUK&.A>"<DRVJPRB"C>?5+WFLC6@!W-@!P:X![*<"K 5X?X \
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MBR=T31(@:@70LL"$HX]H56T$1-=H)6CR\%&IFZ(%+>66XU@OVM6C:@-Z'X/
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M*X&-T- *F2MW,WV!<10G_;&_V<^-PRX,@F X?&R7.NR2$0Y_FST"ZG= _;-
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M8Y)%(Y%UU ]:]8,?;>G@E05=SP]\_\31K\-./!\-172*#]OBP\'BK_.2LA>
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MXZ#'UYRKEQ<S07=#7OX'4$L#!!0    ( #""6U8;I1\9= 0  %@0   9
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MKK<\+*C# :794!J%TAPHS872&(K6%6/K<%CZMSQ.2@N@9PS6'=3,@-(HE.9
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M7^'A>B[+?.I$^-.= $O2<()CWI3E-[AV92ZL+%8'MU>'SH__ U!+ P04
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M?P%02P$"% ,4    "  P@EM6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #""6U9%+%6+[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( #""6U:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ ,();5C6KA=B/"   T#0  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( #""6U8[PHS@M@8  !D<   8              " @=(0  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  P@EM6_II4E=0"  #4"0
M&               @(&^%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ ,();5K_(=4]Q!0  DQ4  !@              ("!R!H  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #""6U;SY(YIB@(
M *@&   8              " @6\@  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  P@EM6)G= C.@"  "<"0  &               @($O
M(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ,();5F>L
M#.<)%   ]$D! !@              ("!328  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( #""6U:^8P%F( ,  *<,   8
M  " @8PZ  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  P
M@EM6GDO8K'L*   9-0  &               @('B/0  >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ ,();5J804[3L!@  = \  !D
M         ("!DT@  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  P@EM61]G0];@?  #Z7P  &0              @(&V3P  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #""6U:64^Q:10H  *$=
M   9              " @:5O  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ ,();5M)VBWQ$!   L D  !D              ("!(7H
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  P@EM6V@SX
M;[D&   L$0  &0              @(&<?@  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( #""6U:YR#,KAP\  'DL   9
M  " @8R%  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M,();5I&.G2NG @  - 8  !D              ("!2I4  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  P@EM6DDEZZ' &  #.$   &0
M            @($HF   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( #""6U:+=TCI;04  #T/   9              " @<^>  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ,();5@Y77X+2#@
M-S   !D              ("!<Z0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  P@EM6"4%?3;P"   +!@  &0              @(%\
MLP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( #""6U:Z
MCG*:+P<  /T0   9              " @6^V  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ ,();5M.*1G('!   FP@  !D
M     ("!U;T  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #""6U8B:3:3V@(  %$&   9              "
M@<[]  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ,();
M5E[,.$?Q!   9PT  !D              ("!WP ! 'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  P@EM6332/1C $  "/"0  &0
M        @($'!@$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( #""6U;@(10]& 0  #H*   9              " @6X* 0!X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ,();5L]7N9-Q P  !0@
M !D              ("!O0X! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  P@EM6EQ7#>Q(#  #$!@  &0              @(%E$@$
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( #""6U89WWR7
M/0<  '(6   9              " @:X5 0!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ ,();5F +8YX\!   IPD  !D
M ("!(AT! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  P
M@EM6,L=&"T0%  #=#   &0              @(&5(0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #""6U:O =PPBP8  % V   9
M          " @1 G 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#
M%     @ ,();5M.<YU1@!   K!8  !D              ("!TBT! 'AL+W=O
M<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  P@EM6Q"&8EN,"  ":
M"0  &0              @(%I,@$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM
M;%!+ 0(4 Q0    ( #""6U;!)3-O,P,  & +   9              " @8,U
M 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ,();5GPY
MW)QW!P  H#(  !D              ("![3@! 'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6Q02P$"% ,4    "  P@EM66AS)IF\"  !T!0  &0
M    @(&;0 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M #""6U;?AP^!L ,  $T1   9              " @4%# 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ ,();5E!)]#J_ @  N <  !D
M             ("!*$<! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  P@EM6RU]0M,H#  !0"@  &0              @($>2@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #""6U;!:J6K;@H
M /QV   9              " @1]. 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ ,();5GQX)K1H P  50H  !D              ("!
MQ%@! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  P@EM6
MKW)/IEX#  !S"@  &0              @(%C7 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( #""6U99MJWQ-0(  .8$   9
M      " @?A? 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ ,();5J+CD1'W!0  LBD  !D              ("!9&(! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  P@EM6>=REBW4"  "8!0
M&0              @(&2: $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( #""6U:?(:FOS (  "0)   9              " @3YK 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ ,();5F(D_L1[
M!P  NCT  !D              ("!06X! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    "  P@EM6\B4Q_T0#  "&#0  &0
M@('S=0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( #""
M6U9C:#QXX 0  &D9   9              " @6YY 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ ,();5F9G=$IC#0  MY<  !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( #""6U8#F*1D_00  +(?   9
M  " @?2> 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
M,();5OI&.X1Y P  30X  !D              ("!**0! 'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    "  P@EM6-'WC*U("  !I!0  &0
M            @('8IP$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( #""6U;'F"+4# 8  !TP   9              " @6&J 0!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ ,();5J'"1.=' P
M9@H  !D              ("!I+ ! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    "  P@EM6-7G?F/@#  #T$@  &0              @($B
MM $ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( #""6U8^
M;L-C% 0  "T/   9              " @5&X 0!X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ ,();5ANE'QET!   6!   !D
M     ("!G+P! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #""6U8%V F980,  +<7   -              "
M 635 0!X;"]S='EL97,N>&UL4$L! A0#%     @ ,();5I>*NQS     $P(
M  L              ( !\-@! %]R96QS+RYR96QS4$L! A0#%     @ ,();
M5G=+#V=-!0  ^"X   \              ( !V=D! 'AL+W=O<FMB;V]K+GAM
M;%!+ 0(4 Q0    ( #""6U:P!0"]-@(  !PJ   :              "  5/?
M 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #""6U;A
MRT;(_0$  #TI   3              "  <'A 0!;0V]N=&5N=%]4>7!E<UTN
9>&UL4$L%!@    !/ $\ H!4  ._C 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>238</ContextCount>
  <ElementCount>426</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical</Role>
      <ShortName>Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Company Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness</Role>
      <ShortName>Company Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Pre-Funded Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrants</Role>
      <ShortName>Pre-Funded Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Funding Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangement</Role>
      <ShortName>Funding Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Commitments and Contingencies (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTable</Role>
      <ShortName>Commitments and Contingencies (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Company Organization and Nature of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Company Organization and Nature of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Balance Sheet Details - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Details - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitments and Contingencies - Schedule Of non-cancelable purchase Commitments Related to Raw Materials (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule Of non-cancelable purchase Commitments Related to Raw Materials (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Pre-Funded Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails</Role>
      <ShortName>Pre-Funded Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Equity Incentive Plans - Nonvested Restricted Stock Shares Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Nonvested Restricted Stock Shares Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Equity Incentive Plans - Summary of Activity under Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Activity under Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Retirement Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails</Role>
      <ShortName>Retirement Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Funding Arrangement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails</Role>
      <ShortName>Funding Arrangement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="pcvx-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  pcvx-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="pcvx-20221231.htm">pcvx-20221231.htm</File>
    <File>pcvx-20221231.xsd</File>
    <File>pcvx-20221231_cal.xml</File>
    <File>pcvx-20221231_def.xml</File>
    <File>pcvx-20221231_lab.xml</File>
    <File>pcvx-20221231_pre.xml</File>
    <File>pcvx-ex10_11.htm</File>
    <File>pcvx-ex10_15.htm</File>
    <File>pcvx-ex10_17.htm</File>
    <File>pcvx-ex10_19.htm</File>
    <File>pcvx-ex10_20.htm</File>
    <File>pcvx-ex23_1.htm</File>
    <File>pcvx-ex31_1.htm</File>
    <File>pcvx-ex31_2.htm</File>
    <File>pcvx-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img70551829_0.jpg</File>
    <File>img70551829_1.jpg</File>
    <File>img70551829_10.jpg</File>
    <File>img70551829_11.jpg</File>
    <File>img70551829_12.jpg</File>
    <File>img70551829_13.jpg</File>
    <File>img70551829_14.jpg</File>
    <File>img70551829_15.jpg</File>
    <File>img70551829_16.jpg</File>
    <File>img70551829_17.jpg</File>
    <File>img70551829_18.jpg</File>
    <File>img70551829_19.jpg</File>
    <File>img70551829_2.jpg</File>
    <File>img70551829_20.jpg</File>
    <File>img70551829_21.jpg</File>
    <File>img70551829_22.jpg</File>
    <File>img70551829_23.jpg</File>
    <File>img70551829_3.jpg</File>
    <File>img70551829_4.jpg</File>
    <File>img70551829_5.jpg</File>
    <File>img70551829_6.jpg</File>
    <File>img70551829_7.jpg</File>
    <File>img70551829_8.jpg</File>
    <File>img70551829_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="770">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>127
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pcvx-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 770,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 238,
   "dts": {
    "calculationLink": {
     "local": [
      "pcvx-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pcvx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pcvx-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pcvx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pcvx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pcvx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 651,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 5,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 8
   },
   "keyCustom": 118,
   "keyStandard": 308,
   "memberCustom": 33,
   "memberStandard": 37,
   "nsprefix": "pcvx",
   "nsuri": "http://www.vaxcyte.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Company Organization and Nature of Business",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness",
     "shortName": "Company Organization and Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Balance Sheet Details",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:RedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Redeemable Convertible Preferred Stock",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:RedeemableConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Pre-Funded Warrants",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrants",
     "shortName": "Pre-Funded Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Equity Incentive Plans",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Retirement Plan",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlan",
     "shortName": "Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:FundingArrangementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Funding Arrangement",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangement",
     "shortName": "Funding Arrangement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:FundingArrangementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_219a732d-37c2-4f43-9e3f-02498c9dc8f8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_219a732d-37c2-4f43-9e3f-02498c9dc8f8",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Balance Sheet Details (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Commitments and Contingencies (Table)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTable",
     "shortName": "Commitments and Contingencies (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Equity Incentive Plans (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_adfec910-931f-4fe2-b666-3a64354787e5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Company Organization and Nature of Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
     "shortName": "Company Organization and Nature of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_adfec910-931f-4fe2-b666-3a64354787e5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents And Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "div",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_e8212113-420d-4afe-a557-faeb55c9fc93",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_0cf6689c-2254-4c4c-9717-295b1177cd54",
      "decimals": "-3",
      "lang": null,
      "name": "pcvx:CashAndCashEquivalentsAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Schedule of Contractual Maturities of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Balance Sheet Details - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Details - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Balance Sheet Details - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails",
     "shortName": "Balance Sheet Details - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:ClinicalStudies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:ClinicalStudies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Information Related to ROU Assets and Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pcvx:ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_7ac2f60b-8289-45da-8d07-c31dcf594253",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_7ac2f60b-8289-45da-8d07-c31dcf594253",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_82ee469c-c1fb-46f6-bd16-0bd5b700dbdb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pcvx:LeasePaymentReceivableNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_82ee469c-c1fb-46f6-bd16-0bd5b700dbdb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pcvx:LeasePaymentReceivableNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_2851b72e-f235-4e1b-8ad0-09f3525757c9",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pcvx:DevelopmentAndManufacturingServicesAgreementPaymentsInEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_2851b72e-f235-4e1b-8ad0-09f3525757c9",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pcvx:DevelopmentAndManufacturingServicesAgreementPaymentsInEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:ResearchAndDevelopmentExpenseToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Operations (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical",
     "shortName": "Statements of Operations (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:ResearchAndDevelopmentExpenseToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:NoncancelablePurchaseCommitmentsDueInOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Commitments and Contingencies - Schedule Of non-cancelable purchase Commitments Related to Raw Materials (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails",
     "shortName": "Commitments and Contingencies - Schedule Of non-cancelable purchase Commitments Related to Raw Materials (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:NoncancelablePurchaseCommitmentsDueInOneYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "pcvx:RedeemableConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_e5603f34-fe33-4aa9-bba2-7bcef1212dc9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesOutstanding",
       "span",
       "p",
       "pcvx:RedeemableConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_e5603f34-fe33-4aa9-bba2-7bcef1212dc9",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Common Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
     "shortName": "Common Stock - Schedule of Common Stock Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "pcvx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_4ac94dae-3c17-44c2-9cc2-a1afce3920c5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "pcvx:WarrantsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_c80a26a1-b95a-44f9-acc5-6127ef778da7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "pcvx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Pre-Funded Warrants - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
     "shortName": "Pre-Funded Warrants - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "pcvx:IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed",
       "span",
       "p",
       "pcvx:WarrantsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_52a9c5b1-8f71-49a0-af0c-9cb853cc2232",
      "decimals": "4",
      "lang": null,
      "name": "pcvx:IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_5174e359-4705-4039-af81-628498b266ac",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Equity Incentive Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
     "shortName": "Equity Incentive Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_5174e359-4705-4039-af81-628498b266ac",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
     "shortName": "Equity Incentive Plans - Summary of Activity Under Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_4c174ac3-2385-4026-a502-02872bdce024",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Equity Incentive Plans - Nonvested Restricted Stock Shares Activity (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails",
     "shortName": "Equity Incentive Plans - Nonvested Restricted Stock Shares Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Equity Incentive Plans - Summary of Activity under Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails",
     "shortName": "Equity Incentive Plans - Summary of Activity under Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_7cc4ab4f-7bad-4d16-9545-b64979b11e87",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Summary of Estimated Fair Value of Employee Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss",
     "shortName": "Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
     "shortName": "Equity Incentive Plans - Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_1ac6515d-ab41-4ec5-8d6a-269fbda86d69",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_81e20c4f-e0c6-4cea-b677-93b2e39c7f30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Plans - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_81e20c4f-e0c6-4cea-b677-93b2e39c7f30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_3912106f-3c31-4ffc-9141-7807cf18d485",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Retirement Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails",
     "shortName": "Retirement Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_3912106f-3c31-4ffc-9141-7807cf18d485",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pcvx:GrantIncome",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Funding Arrangement - Additional Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
     "shortName": "Funding Arrangement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "pcvx:FundingArrangementTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_037574d0-71b1-40d4-9227-c5f9299b9dd2",
      "decimals": null,
      "lang": "en-US",
      "name": "pcvx:FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_219a732d-37c2-4f43-9e3f-02498c9dc8f8",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_7ac2f60b-8289-45da-8d07-c31dcf594253",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_8e8fd05e-91c7-4380-a6a7-e5642e91aad0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_ebee093b-a58f-4627-85e8-192d773f305e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_8656ce44-0eee-45cd-8119-542db136b9e9",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Subsequent Events - Additional Information (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_2fc1bf10-e27b-4e4b-b206-4b98dbbe0814",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Statements of Cash Flows (Unaudited)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited",
     "shortName": "Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "pcvx-20221231.htm",
      "contextRef": "C_53f32d39-f32f-4c9e-8927-e638758556c7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 74,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "verboseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pcvx_ATMSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM sales agreement.",
        "label": "A T M Sales Agreement [Member]",
        "terseLabel": "ATM Sales Agreement"
       }
      }
     },
     "localname": "ATMSalesAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_AccruedCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued commitment.",
        "label": "Accrued Commitment",
        "terseLabel": "Accrued Commitment"
       }
      }
     },
     "localname": "AccruedCommitment",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AccruedManufacturingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing expenses.",
        "label": "Accrued Manufacturing Expenses",
        "terseLabel": "Accrued manufacturing expenses"
       }
      }
     },
     "localname": "AccruedManufacturingExpenses",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AccruedManufacturingRightsExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing rights expenses",
        "label": "Accrued Manufacturing Rights Expenses",
        "terseLabel": "Accrued manufacturing rights expenses"
       }
      }
     },
     "localname": "AccruedManufacturingRightsExpenses",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AccruedResearchAndDevelopmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development Policy [Text Block]",
        "terseLabel": "Accrued Research and Development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentPolicyTextBlock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_AcquiredManufacturingRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired manufacturing rights.",
        "label": "Acquired Manufacturing Rights",
        "terseLabel": "Acquired manufacturing rights (Note 6)"
       }
      }
     },
     "localname": "AcquiredManufacturingRights",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AdditionalFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional facility.",
        "label": "Additional Facility [Member]",
        "terseLabel": "Additional Facility"
       }
      }
     },
     "localname": "AdditionalFacilityMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_AdditionalFundingCommittedByAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding committed by award.",
        "label": "Additional Funding Committed By Award",
        "terseLabel": "Additional funding committed by award"
       }
      }
     },
     "localname": "AdditionalFundingCommittedByAward",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AdditionalMilestonePaymentsInCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payments in cash.",
        "label": "Additional Milestone Payments in Cash",
        "terseLabel": "Additional Milestone Payments in Cash"
       }
      }
     },
     "localname": "AdditionalMilestonePaymentsInCash",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid In capital vesting of early exercised stock options.",
        "label": "Adjustments To Additional Paid In Capital Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedStockOptions",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital warrant liability write off.",
        "label": "Adjustments To Additional Paid In Capital Warrant Liability Write Off",
        "terseLabel": "Warrant liability write-off"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantLiabilityWriteOff",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering member.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_CapitalLeasesLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital leases \u2014 lab equipment.",
        "label": "Capital Leases Lab Equipment [Member]",
        "terseLabel": "Capital Leases \u2014 Lab Equipment"
       }
      }
     },
     "localname": "CapitalLeasesLabEquipmentMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_CashAndCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents amortized cost.",
        "label": "Cash And Cash Equivalents Amortized Cost",
        "totalLabel": "Cash and cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAmortizedCost",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsAndInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and investments.",
        "label": "Cash And Cash Equivalents And Investments",
        "terseLabel": "Total assets measured at fair value, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestments",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and investments amortized cost basis.",
        "label": "Cash And Cash Equivalents And Investments Amortized Cost Basis",
        "totalLabel": "Total assets measured at fair value, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and investments gross unrealized gain before tax.",
        "label": "Cash And Cash Equivalents And Investments Gross Unrealized Gain Before Tax",
        "terseLabel": "Total assets measured at fair value, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAndInvestmentsAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents and investments gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents And Investments Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total assets measured at fair value, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents gross unrealized gain before tax.",
        "label": "Cash And Cash Equivalents Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash and cash equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CashAndCashEquivalentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents Gross Unrealized Loss Before Tax",
        "negatedLabel": "Cash and cash equivalents, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of the redeemable convertible preferred stock tranche liability.",
        "label": "Change In Fair Value Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Change in fair value of the redeemable convertible preferred stock tranche liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of redeemable convertible preferred stock tranche liabilities.",
        "label": "Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liabilities",
        "negatedLabel": "Change in fair value of redeemable convertible preferred stock warrant"
       }
      }
     },
     "localname": "ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilities",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right number of securities called by each warrant or right exercised.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Exercised",
        "terseLabel": "Warrant exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRightExercised",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ClinicalStudies": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Studies",
        "label": "Clinical Studies",
        "terseLabel": "Clinical Studies"
       }
      }
     },
     "localname": "ClinicalStudies",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combating antibiotic resistant bacteria biopharmaceutical accelerator agreement.",
        "label": "Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator Agreement [Member]",
        "terseLabel": "CARB-X Agreement"
       }
      }
     },
     "localname": "CombatingAntibioticResistantBacteriaBiopharmaceuticalAcceleratorAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined voting power of securities outstanding immediately after effect to the exercise.",
        "label": "Combined Voting Power of Securities Outstanding Immediately after Effect to the Exercise",
        "terseLabel": "Combined voting power of securities outstanding immediately after effect to the exercise"
       }
      }
     },
     "localname": "CombinedVotingPowerOfSecuritiesOutstandingImmediatelyAfterEffectToTheExercise",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant.",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common Stock Warrant"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_ComputersAndComputerSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computers and computer software.",
        "label": "Computers And Computer Software [Member]",
        "terseLabel": "Computers and Computer Software"
       }
      }
     },
     "localname": "ComputersAndComputerSoftwareMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_CostReimbursementSubAwardAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost reimbursement sub-award agreement.",
        "label": "Cost Reimbursement Sub Award Agreement [Member]",
        "terseLabel": "Cost Reimbursement Sub-Award Agreement"
       }
      }
     },
     "localname": "CostReimbursementSubAwardAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs included in accounts payable and accrued expenses.",
        "label": "Deferred Offering Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Deferred offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets liabilities net before valuation allowance.",
        "label": "Deferred Tax Assets Liabilities Net Before Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_DeferredTaxAssetsTaxAccruedManufacturingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax accrued manufacturing expenses.",
        "label": "Deferred Tax Assets Tax Accrued Manufacturing Expenses",
        "terseLabel": "Accrued manufacturing expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxAccruedManufacturingExpenses",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_DevelopmentAndManufacturingServicesAgreementPaymentsInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing services agreement payments in equity.",
        "label": "Development And Manufacturing Services Agreement Payments In Equity",
        "terseLabel": "Payments in equity, amount"
       }
      }
     },
     "localname": "DevelopmentAndManufacturingServicesAgreementPaymentsInEquity",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_EarlyExercisedStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early \u200bexercised\u200b stock\u200b options.",
        "label": "Early Exercised Stock Options",
        "terseLabel": "Early exercised stock options"
       }
      }
     },
     "localname": "EarlyExercisedStockOptions",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan Member"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_ExercisePriceExpireInYearsFormTheDateOfGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price expire in years form the date of grant.",
        "label": "Exercise Price Expire In Years Form The Date Of Grant",
        "terseLabel": "Exercise price expire in years form the date of grant"
       }
      }
     },
     "localname": "ExercisePriceExpireInYearsFormTheDateOfGrant",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_FairValueOnDateOfSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value on Date of Settlement.",
        "label": "Fair Value on Date of Settlement",
        "terseLabel": "Fair Value on Date of Settlement"
       }
      }
     },
     "localname": "FairValueOnDateOfSettlement",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_FundingArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangement.",
        "label": "Funding Arrangement [Abstract]"
       }
      }
     },
     "localname": "FundingArrangementAbstract",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pcvx_FundingArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangement.",
        "label": "Funding Arrangement [Line Items]",
        "terseLabel": "Funding Arrangement [Line Items]"
       }
      }
     },
     "localname": "FundingArrangementLineItems",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_FundingArrangementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangement.",
        "label": "Funding Arrangement [Table]",
        "terseLabel": "Funding Arrangement [Table]"
       }
      }
     },
     "localname": "FundingArrangementTable",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_FundingArrangementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding arrangement.",
        "label": "Funding Arrangement [Text Block]",
        "terseLabel": "Funding Arrangement"
       }
      }
     },
     "localname": "FundingArrangementTextBlock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding committed by award, available upon achievement of development milestones.",
        "label": "Funding Committed By Award Available Upon Achievement Of Development Milestones",
        "terseLabel": "Total funding committed by award, available upon achievement of development milestones"
       }
      }
     },
     "localname": "FundingCommittedByAwardAvailableUponAchievementOfDevelopmentMilestones",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding period of award to develop universal vaccine to prevent infections.",
        "label": "Funding Period Of Award To Develop Universal Vaccine To Prevent Infections",
        "terseLabel": "Funding period of award to develop universal vaccine to prevent infections caused by Group A Strep bacteria"
       }
      }
     },
     "localname": "FundingPeriodOfAwardToDevelopUniversalVaccineToPreventInfections",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_GlobalTargetRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global target revenue.",
        "label": "Global Target Revenue",
        "terseLabel": "Global target revenue"
       }
      }
     },
     "localname": "GlobalTargetRevenue",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_GrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant income.",
        "label": "Grant Income",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantIncome",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_GrossProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from issuance of common stock.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Aggregate gross proceeds from issuance of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_HeadquartersFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Headquarters facility.",
        "label": "Headquarters Facility [Member]",
        "terseLabel": "Headquarters Facility"
       }
      }
     },
     "localname": "HeadquartersFacilityMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock option granted to Employees Owning percentage of shares of common stock.",
        "label": "Incentive Stock Option Granted To Employees Owning Percentage Of Shares Of Common Stock",
        "terseLabel": "Incentive stock option granted to employees owning percentage of shares of common stock"
       }
      }
     },
     "localname": "IncentiveStockOptionGrantedToEmployeesOwningPercentageOfSharesOfCommonStock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_IncreaseDecreaseInAccruedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued compensation.",
        "label": "Increase Decrease In Accrued Compensation",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedCompensation",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseDecreaseInAccruedLegalSettlement": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued legal settlement.",
        "label": "Increase Decrease In Accrued Legal Settlement",
        "terseLabel": "Accrued legal settlement"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLegalSettlement",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseDecreaseInAccruedManufacturingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued manufacturing expenses.",
        "label": "Increase Decrease In Accrued Manufacturing Expenses",
        "terseLabel": "Accrued manufacturing expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedManufacturingExpenses",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in deferred rent and other long term liabilities.",
        "label": "Increase Decrease In Deferred Rent And Other Long Term Liabilities",
        "terseLabel": "Deferred rent and other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "negatedLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase or Decrease of Pre-funded Warrant Percentage Not Exceed",
        "label": "Increase or Decrease of Pre-funded Warrant Percentage Not Exceed",
        "terseLabel": "Increase or Decrease of Pre-funded Warrant Percentage Not Exceed"
       }
      }
     },
     "localname": "IncreaseOrDecreaseOfPreFundedWarrantPercentageNotExceed",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_InitialFundingCommittedByAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial funding committed by award.",
        "label": "Initial Funding Committed By Award",
        "terseLabel": "Initial funding committed by award"
       }
      }
     },
     "localname": "InitialFundingCommittedByAward",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_InitialPublicOfferingRelatedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering related cost.",
        "label": "Initial Public Offering Related Cost",
        "terseLabel": "IPO-related costs"
       }
      }
     },
     "localname": "InitialPublicOfferingRelatedCost",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_IssuanceOfCommonStockForAcquiredManufacturingRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for acquired manufacturing rights",
        "label": "Issuance of Common Stock for Acquired Manufacturing Rights",
        "terseLabel": "Issuance of common stock for acquired manufacturing rights"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForAcquiredManufacturingRights",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_JefferiesLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies limited liability company.",
        "label": "Jefferies Limited Liability Company [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLimitedLiabilityCompanyMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_LabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab equipment.",
        "label": "Lab Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "LabEquipmentMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability.",
        "label": "Deffered Tax Assets Lease Liability",
        "terseLabel": "Lease Liability"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_LeasePaymentReceivableNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Payment Receivable Noncurrent",
        "label": "Lease incentives"
       }
      }
     },
     "localname": "LeasePaymentReceivableNoncurrent",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_LeaseTerminationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination date.",
        "label": "Lease Termination Date",
        "terseLabel": "Lease termination date"
       }
      }
     },
     "localname": "LeaseTerminationDate",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pcvx_LesseeOperatingLeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease commencement date.",
        "label": "Lessee Operating Lease Commencement Date",
        "terseLabel": "Operating lease, commencement date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseCommencementDate",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pcvx_LesseeOperatingLeaseExtendedLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended lease term.",
        "label": "Lessee Operating Lease Extended Lease Term",
        "terseLabel": "Operating lease, extended term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedLeaseTerm",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_LesseeOperatingLeaseExtendedMaturityDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, extended maturity date.",
        "label": "Lessee Operating Lease Extended Maturity Date",
        "terseLabel": "Operating lease, extended maturity date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedMaturityDate",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pcvx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments net of lease incentives remainder of fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Net Of Lease Incentives Remainder Of Fiscal Year",
        "negatedLabel": "Remainder of 2021",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfLeaseIncentivesRemainderOfFiscalYear",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_LesseeOperatingLeaseRenewalOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease renewal option.",
        "label": "Lessee Operating Lease Renewal Option",
        "terseLabel": "Operating lease, renewal option"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalOption",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_LesseeOperatingLeaseRentCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, operating lease, rent commencement date.",
        "label": "Lessee Operating Lease Rent Commencement Date",
        "terseLabel": "Operating lease, rent commencement date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentCommencementDate",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "pcvx_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_LicenseAmendmentATwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Amendment A Two.",
        "label": "License Amendment A Two [Member]",
        "terseLabel": "License Amendment A2"
       }
      }
     },
     "localname": "LicenseAmendmentATwoMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_LonzaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lonza limited.",
        "label": "Lonza Limited [Member]",
        "terseLabel": "Lonza DMSA"
       }
      }
     },
     "localname": "LonzaLimitedMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_MarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market offering.",
        "label": "Market Offering [Member]",
        "terseLabel": "Market offering"
       }
      }
     },
     "localname": "MarketOfferingMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum commission percentage of gross proceeds from common stock sold.",
        "label": "Maximum Commission Percentage Of Gross Proceeds From Common Stock Sold",
        "terseLabel": "Maximum commission percentage of gross proceeds from common stock sold"
       }
      }
     },
     "localname": "MaximumCommissionPercentageOfGrossProceedsFromCommonStockSold",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_NewCorporateHeadquartersFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Corporate Headquarters Facility.",
        "label": "New Corporate Headquarters Facility [Member]",
        "terseLabel": "New Corporate Headquarters Facility"
       }
      }
     },
     "localname": "NewCorporateHeadquartersFacilityMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_NonCancelablePurchaseCommitments": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cancelable Purchase Commitments",
        "label": "Non-Cancelable Purchase Commitments",
        "totalLabel": "Total non-cancelable purchase commitments due to key manufacturing partners"
       }
      }
     },
     "localname": "NonCancelablePurchaseCommitments",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_NonCashPaymentsForAcquireManufacturingRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash payments for acquire manufacturing rights.",
        "label": "Non Cash Payments for Acquire Manufacturing Rights",
        "terseLabel": "Non-cash payments for acquired manufacturing rights"
       }
      }
     },
     "localname": "NonCashPaymentsForAcquireManufacturingRights",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_NoncancelablePurchaseCommitmentsDueInOneYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails": {
       "order": 1.0,
       "parentTag": "pcvx_NonCancelablePurchaseCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonCancelable purchase commitments due In one year.",
        "label": "NonCancelable Purchase Commitments Due In One Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "NoncancelablePurchaseCommitmentsDueInOneYear",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails": {
       "order": 0.0,
       "parentTag": "pcvx_NonCancelablePurchaseCommitments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonCancelable purchase commitments due in second year and thereafter.",
        "label": "NonCancelable Purchase Commitments Due In Second Year and Thereafter",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "NoncancelablePurchaseCommitmentsDueInSecondYearAndThereafter",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfNoncancelablePurchaseCommitmentsRelatedToRawMaterialsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_NumberOfFinanceLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of finance lease.",
        "label": "Number Of Finance Lease",
        "terseLabel": "Number of finance lease"
       }
      }
     },
     "localname": "NumberOfFinanceLease",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_NumberOfOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating lease.",
        "label": "Number Of Operating Lease",
        "terseLabel": "Number of operating lease"
       }
      }
     },
     "localname": "NumberOfOperatingLease",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options exercised, excludes options exercised from NPLN.",
        "label": "Number Of Options Exercised Excludes Options Exercised From NPLN",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "NumberOfOptionsExercisedExcludesOptionsExercisedFromNpln",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of renewal options.",
        "label": "Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_NumberOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities.",
        "label": "Number Of Securities",
        "verboseLabel": "Number of securities"
       }
      }
     },
     "localname": "NumberOfSecurities",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pcvx_OfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering period.",
        "label": "Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "OfferingPeriod",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_OperatingLossCarryForwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forwards expiration year",
        "label": "Operating Loss Carry Forwards Expiration Year",
        "terseLabel": "Operating loss carry forwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryForwardsExpirationYear",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pcvx_OptionExercisePriceInCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise price in cash.",
        "label": "Option Exercise Price in Cash",
        "terseLabel": "Option Exercise Price in Cash"
       }
      }
     },
     "localname": "OptionExercisePriceInCash",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_OptionToAcquireManufacturingRightsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to acquire manufacturing rights.",
        "label": "Option to Acquire Manufacturing Rights [Policy Text Block]",
        "terseLabel": "Option to Acquire Manufacturing Rights"
       }
      }
     },
     "localname": "OptionToAcquireManufacturingRightsPolicyTextBlock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_OtherResearchAndDevelopmentLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other research and development liabilities current.",
        "label": "Other Research and Development Liabilities Current",
        "terseLabel": "Other research and development"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentLiabilitiesCurrent",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_OtherRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Restricted Stock Units [Member]",
        "label": "Other Restricted Stock Units [Member]",
        "terseLabel": "Other Restricted Stock Units"
       }
      }
     },
     "localname": "OtherRestrictedStockUnitsMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_PaloAltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palo alto.",
        "label": "Palo Alto [Member]",
        "terseLabel": "Palo Alto"
       }
      }
     },
     "localname": "PaloAltoMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_PaymentsOfCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of capital lease obligations.",
        "label": "Payments Of Capital Lease Obligations",
        "negatedLabel": "Payments of capital lease obligations"
       }
      }
     },
     "localname": "PaymentsOfCapitalLeaseObligations",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PaymentsOfUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of underwriting discounts and commissions.",
        "label": "Payments Of Underwriting Discounts And Commissions",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PercentageOfFairValuePerShareOnTheGrantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value per share on the grant date.",
        "label": "Percentage Of Fair Value Per Share On The Grant Date",
        "terseLabel": "Percentage of fair value per share on the grant date"
       }
      }
     },
     "localname": "PercentageOfFairValuePerShareOnTheGrantDate",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PercentageOfPaymentsCompletionAgreedToDefer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of payments completion agreed to defer.",
        "label": "Percentage Of Payments Completion Agreed To Defer",
        "terseLabel": "Percentage of defer payments agreed for completion"
       }
      }
     },
     "localname": "PercentageOfPaymentsCompletionAgreedToDefer",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PercentageOfProvisionsSubjectToStockholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of provisions subject to stockholders.",
        "label": "Percentage Of Provisions Subject To Stockholders",
        "terseLabel": "Percentage of provisions subject to stockholders"
       }
      }
     },
     "localname": "PercentageOfProvisionsSubjectToStockholders",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payment on annual net sales of vaccine products for human health.",
        "label": "Percentage Of Royalty Payment On Annual Net Sales Of Vaccine Products For Human Health",
        "terseLabel": "Percentage of royalty payment on annual net sales of vaccine products for human health"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentOnAnnualNetSalesOfVaccineProductsForHumanHealth",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payment on net sales of vaccine compositions for animal health.",
        "label": "Percentage Of Royalty Payment On Net Sales Of Vaccine Compositions For Animal Health",
        "terseLabel": "Percentage of royalty payment on net sales of vaccine compositions for animal health"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentOnNetSalesOfVaccineCompositionsForAnimalHealth",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PneumococcalConjugateVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumococcal conjugate vaccine.",
        "label": "Pneumococcal Conjugate Vaccine [Member]",
        "terseLabel": "Pneumococcal Conjugate Vaccine"
       }
      }
     },
     "localname": "PneumococcalConjugateVaccineMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential funding amount of award to develop vaccine to prevent infections.",
        "label": "Potential Funding Amount Of Award To Develop Vaccine To Prevent Infections",
        "terseLabel": "Potential funding amount of award to develop vaccine to prevent shingella infections"
       }
      }
     },
     "localname": "PotentialFundingAmountOfAwardToDevelopVaccineToPreventInfections",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PotentialFundingCommittedByAward": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential funding committed by award.",
        "label": "Potential Funding Committed By Award",
        "terseLabel": "Potential funding committed by award"
       }
      }
     },
     "localname": "PotentialFundingCommittedByAward",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential funding period of award to develop vaccine to prevent infections.",
        "label": "Potential Funding Period Of Award To Develop Vaccine To Prevent Infections",
        "terseLabel": "Potential funding period of award to develop vaccine to prevent shingella infections"
       }
      }
     },
     "localname": "PotentialFundingPeriodOfAwardToDevelopVaccineToPreventInfections",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded Warrant Recorded as a Component of Stockholders' Equity Within Additional Paid-in-Capital",
        "label": "Pre-funded Warrant Recorded as a Component of Stockholders' Equity Within Additional Paid-in-Capital",
        "terseLabel": "Pre-funded warrant recorded as a component of stockholders' equity within additional paid-in-capital"
       }
      }
     },
     "localname": "PreFundedWarrantRecordedAsAComponentOfStockholdersEquityWithinAdditionalPaidInCapital",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pcvx_PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded warrants of common stock shares outstanding immediately after effect to the exercise.",
        "label": "Pre-funded Warrants of Common Stock Shares Outstanding Immediately After Effect to the Exercise",
        "terseLabel": "Pre-funded warrants of common stock shares outstanding Immediately after effect to the exercise"
       }
      }
     },
     "localname": "PreFundedWarrantsOfCommonStockSharesOutstandingImmediatelyAfterEffectToTheExercise",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_PreferredStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrant.",
        "label": "Preferred Stock Warrant [Member]",
        "terseLabel": "Preferred Stock Warrant"
       }
      }
     },
     "localname": "PreferredStockWarrantMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_PrefundedWarrantsPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded warrants price per share.",
        "label": "Prefunded Warrants Price Per Share",
        "terseLabel": "Prefunded Warrants Price Per Share",
        "verboseLabel": "Pre-funded warrants price per share"
       }
      }
     },
     "localname": "PrefundedWarrantsPricePerShare",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pcvx_ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from initial public offering, net of underwriters' commissions and discounts.",
        "label": "Proceeds From Initial Public Offering Net Of Underwriters Commissions And Discounts",
        "terseLabel": "Proceeds from initial public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromInitialPublicOfferingNetOfUnderwritersCommissionsAndDiscounts",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ProceedsFromIssuanceFollowOnOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance follow on offering.",
        "label": "Proceeds from Issuance follow on offering",
        "terseLabel": "Net proceeds from follow on offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceFollowOnOffering",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceedsfromissuanceofcommonstockandpre-fundedwarrantsfromfollowon offeringsnetofissuancecosts",
        "label": "Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsFromFollowOnOfferingsNetOfIssuanceCosts",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock related to early exercised stock options.",
        "label": "Proceeds From Issuance Of Common Stock Related To Early Exercised Stock Options",
        "terseLabel": "Proceeds from issuance of common stock related to early exercised stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of stock, net of commission and offering expenses.",
        "label": "Proceeds From Issuance Of Stock Net Of Commission And Offering Expenses",
        "terseLabel": "Proceeds from issuance of stock, net of commission and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfStockNetOfCommissionAndOfferingExpenses",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_PurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase period.",
        "label": "Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "PurchasePeriod",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_RedeemableConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockTextBlock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_RedeemableConvertiblePreferredStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrant.",
        "label": "Redeemable Convertible Preferred Stock Warrant [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_ReleaseOfRestrictedStockUnitsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release of Restricted Stock Units Shares",
        "label": "Release of Restricted Stock Units Shares",
        "terseLabel": "Release of restricted stock units, shares"
       }
      }
     },
     "localname": "ReleaseOfRestrictedStockUnitsShares",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ReleaseOfRestrictedStockUnitsValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release of restricted stock units value.",
        "label": "Release of Restricted Stock Units Value",
        "negatedLabel": "Release of restricted stock units",
        "terseLabel": "Release of restricted stock units"
       }
      }
     },
     "localname": "ReleaseOfRestrictedStockUnitsValue",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_RemainingLiabilitiesRelatedToEarlyExercisedShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining liabilities related to early exercised shares.",
        "label": "Remaining Liabilities Related To Early Exercised Shares",
        "terseLabel": "Remaining liabilities related to early exercised shares"
       }
      }
     },
     "localname": "RemainingLiabilitiesRelatedToEarlyExercisedShares",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ResearchAndDevelopmentExpenseToRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense to related party.",
        "label": "Research And Development Expense To Related Party",
        "terseLabel": "Research and development expense to related party"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseToRelatedParty",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ResearchAndExperimentalExpensesAmortizedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and experimental expenses amortized period.",
        "label": "Research and Experimental Expenses Amortized Period",
        "terseLabel": "Research and experimental expenses amortized period"
       }
      }
     },
     "localname": "ResearchAndExperimentalExpensesAmortizedPeriod",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_RestrictedStockUnitsWithheld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units withheld",
        "label": "Restricted stock units withheld",
        "terseLabel": "Restricted Stock Units withheld"
       }
      }
     },
     "localname": "RestrictedStockUnitsWithheld",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_SaleOfCommonStockAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of common stock authorized amount.",
        "label": "Sale Of Common Stock Authorized Amount",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfCommonStockAuthorizedAmount",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_SanCarlosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Carlos.",
        "label": "San Carlos [Member]",
        "terseLabel": "San Carlos"
       }
      }
     },
     "localname": "SanCarlosMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of common stock shares reserved for future issuance.",
        "label": "Schedule Of Common Stock Shares Reserved For Future Issuance Table [Text Block]",
        "terseLabel": "Schedule of Common Stock Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information related to right-of-use assets and lease liabilities.",
        "label": "Schedule Of Information Related To Right Of Use Assets And Lease Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Information Related to ROU Assets and Lease Liabilities"
       }
      }
     },
     "localname": "ScheduleOfInformationRelatedToRightOfUseAssetsAndLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of non-cancelable purchase commitments related to raw materials [Table Text Block]",
        "label": "Schedule Of non-cancelable purchase commitments related to raw materials [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfNonCancelablePurchaseCommitmentsRelatedToRawMaterialsTableTextBlock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of organization consolidation and presentation of financial statements.",
        "label": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of organization consolidation and presentation of financial statements.",
        "label": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Schedule Of Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfOrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pcvx_Section162MLimitation": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Section 162(m) limitation.",
        "label": "Section 162(m) Limitation"
       }
      }
     },
     "localname": "Section162MLimitation",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C redeemable convertible preferred stock.",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Redeemable Convertible Preferred Stock",
        "verboseLabel": "Series C Redeemable Convertible Stock"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SeriesDRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D redeemable convertible preferred stock.",
        "label": "Series D Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Award Vesting Rights Six Months Thereafter Percentage",
        "label": "Share based Compensation Arrangement By Share based Payment Award Award Vesting Rights Six Months Thereafter Percentage",
        "terseLabel": "Vesting percentage for stock options granted, Six months thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsSixMonthsThereafterPercentage",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled",
        "label": "Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Cancelled",
        "terseLabel": "Weighted average grant date fair value, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueCancelled",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted",
        "label": "Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted",
        "terseLabel": "Weighted average grant date fair value, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of share authorized.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Share Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfShareAuthorized",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award number of shares available for grant exercised in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period",
        "terseLabel": "Options Available for Grant, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisedInPeriod",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award number of shares available for grant forfeited in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeited In Period",
        "terseLabel": "Options Available for Grant, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeitedInPeriod",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award number of shares available for grant granted in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period",
        "negatedLabel": "Options Available for Grant, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares increase in available for grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Increase In Available For Grant",
        "terseLabel": "Available for issuance of shares increased"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIncreaseInAvailableForGrant",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_SharesAvailableForFutureStockOptionGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares available for future stock option grants.",
        "label": "Shares Available For Future Stock Option Grants [Member]",
        "terseLabel": "Shares Available for Future Stock Option Grants"
       }
      }
     },
     "localname": "SharesAvailableForFutureStockOptionGrantsMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SharesIssuedPricePerShareUponFollowOnOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued price per share upon follow on offering.",
        "label": "Shares Issued Price Per Share upon follow on offering",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShareUponFollowOnOffering",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pcvx_SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.",
        "label": "Shares issued upon follow on offering full exercise of underwriters option to purchase additional shares.",
        "terseLabel": "Underwriters' option to purchase additional shares"
       }
      }
     },
     "localname": "SharesIssuedUponFollowOnOfferingFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon full exercise of underwriters option to purchase additional shares.",
        "label": "Shares Issued Upon Full Exercise Of Underwriters Option To Purchase Additional Shares",
        "terseLabel": "Underwriters' option to purchase additional shares"
       }
      }
     },
     "localname": "SharesIssuedUponFullExerciseOfUnderwritersOptionToPurchaseAdditionalShares",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_SharesPreFundedWarrantsToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares pre-funded warrants to purchase.",
        "label": "Shares Pre-Funded Warrants To Purchase",
        "terseLabel": "Pre-funded warrants to purchase shares"
       }
      }
     },
     "localname": "SharesPreFundedWarrantsToPurchase",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of common stock warrant.",
        "label": "Stock Issued During Period Shares Conversion Of Common Stock Warrant",
        "terseLabel": "Conversion of common stock warrant"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfCommonStockWarrant",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares conversion of preferred stock warrant.",
        "label": "Stock Issued During Period Shares Conversion Of Preferred Stock Warrant",
        "terseLabel": "Conversion of preferred stock warrant"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfPreferredStockWarrant",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares issuance of common stock related to early exercised stock options.",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock Related To Early Exercised Stock Options",
        "terseLabel": "Issuance of common stock related to early exercised stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockRelatedToEarlyExercisedStockOptions",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockIssuedDuringPeriodSharesOfFollowOnOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period, shares of follow on offering.",
        "label": "Stock Issued During Period, Shares of follow on offering",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOfFollowOnOffering",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_StockOptionsGrantedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options granted term.",
        "label": "Stock Options Granted Term",
        "terseLabel": "Stock options granted term"
       }
      }
     },
     "localname": "StockOptionsGrantedTerm",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pcvx_SupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Agreement.",
        "label": "Supply Agreement [Member]",
        "terseLabel": "Supply Agreement"
       }
      }
     },
     "localname": "SupplyAgreementMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SutroBiopharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sutro Biopharma, Inc.",
        "label": "Sutro Biopharma Inc [Member]",
        "terseLabel": "Sutro Biopharma, Inc"
       }
      }
     },
     "localname": "SutroBiopharmaIncMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_SutroStockPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sutro stock payment.",
        "label": "Sutro Stock Payment [Member]",
        "terseLabel": "Sutro Stock Payment"
       }
      }
     },
     "localname": "SutroStockPaymentMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carry forwards expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "pcvx_TemporaryEquityConversionOfPreferredStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity conversion of preferred stock shares.",
        "label": "Temporary Equity Conversion Of Preferred Stock Shares",
        "terseLabel": "Conversion of preferred stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfPreferredStockShares",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_TemporaryEquityConversionOfPreferredStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity conversion of preferred stock value.",
        "label": "Temporary Equity Conversion Of Preferred Stock Value",
        "terseLabel": "Conversion of preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfPreferredStockValue",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_TemporaryEquityStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issuance costs.",
        "label": "Temporary Equity Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuanceCosts",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of preferred stock, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "pcvx_TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen equity incentive plan and two thousand twenty equity incentive plan and two thousand twenty employee stock purchase plan.",
        "label": "Two Thousand Fourteen Equity Incentive Plan And Two Thousand Twenty Equity Incentive Plan And Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Plan, 2020 Plan and 2020 ESPP"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanAndTwoThousandTwentyEquityIncentivePlanAndTwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen equity incentive plan.",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TwoThousandTwentyEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty employee stock purchase plan.",
        "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan and two thousand fourteen equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan And Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2020 Plan and 2014 Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanAndTwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pcvx_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions",
        "label": "Adjustments based on tax positions related to prior years",
        "terseLabel": "Reductions based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_UpfrontConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront consideration.",
        "label": "Upfront Consideration",
        "terseLabel": "Upfront Consideration"
       }
      }
     },
     "localname": "UpfrontConsideration",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_UpfrontConsiderationInCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront consideration in cash.",
        "label": "Upfront Consideration in Cash",
        "terseLabel": "Upfront Consideration in Cash"
       }
      }
     },
     "localname": "UpfrontConsiderationInCash",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_UpfrontConsiderationInCashAfterAgreementDate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront consideration in cash after agreement date.",
        "label": "Upfront Consideration in Cash After Agreement Date",
        "terseLabel": "Upfront Consideration in Cash After Agreement Date"
       }
      }
     },
     "localname": "UpfrontConsiderationInCashAfterAgreementDate",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pcvx_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants.",
        "label": "Warrants Disclosure [Text Block]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://www.vaxcyte.com/20221231",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r198",
      "r199",
      "r301",
      "r306",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r392",
      "r559",
      "r586",
      "r603",
      "r604",
      "r616",
      "r628",
      "r636",
      "r682",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r392",
      "r559",
      "r586",
      "r603",
      "r604",
      "r616",
      "r628",
      "r636",
      "r682",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r257",
      "r560",
      "r617",
      "r635",
      "r677",
      "r678",
      "r683",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r257",
      "r560",
      "r617",
      "r635",
      "r677",
      "r678",
      "r683",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r344",
      "r392",
      "r424",
      "r425",
      "r426",
      "r558",
      "r559",
      "r586",
      "r603",
      "r604",
      "r616",
      "r628",
      "r636",
      "r674",
      "r682",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r344",
      "r392",
      "r424",
      "r425",
      "r426",
      "r558",
      "r559",
      "r586",
      "r603",
      "r604",
      "r616",
      "r628",
      "r636",
      "r674",
      "r682",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r198",
      "r199",
      "r301",
      "r306",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r634"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premiums on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r65",
      "r167"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r173",
      "r583",
      "r594",
      "r598"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r21",
      "r24",
      "r118",
      "r545",
      "r589",
      "r590",
      "r656",
      "r657",
      "r658",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r664",
      "r665",
      "r666",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r205",
      "r206",
      "r207",
      "r208",
      "r218",
      "r259",
      "r260",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r433",
      "r434",
      "r435",
      "r454",
      "r455",
      "r456",
      "r457",
      "r465",
      "r466",
      "r467",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r497",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r519",
      "r520",
      "r524",
      "r525",
      "r526",
      "r527",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r561",
      "r562",
      "r563",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r106",
      "r107",
      "r396"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r78",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r618",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r40",
      "r62"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges",
        "totalLabel": "Asset Impairment Charges, Total"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r133",
      "r144",
      "r169",
      "r196",
      "r245",
      "r253",
      "r255",
      "r268",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r469",
      "r473",
      "r496",
      "r634",
      "r680",
      "r681",
      "r727"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r162",
      "r174",
      "r196",
      "r268",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r469",
      "r473",
      "r496",
      "r634",
      "r680",
      "r681",
      "r727"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r196",
      "r268",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r469",
      "r473",
      "r496",
      "r680",
      "r681",
      "r727"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "terseLabel": "Total noncurrent assets",
        "totalLabel": "Total noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r263",
      "r280"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Asset backed securities",
        "totalLabel": "Investments, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r60",
      "r265",
      "r581"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due in one to five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r60",
      "r264",
      "r580"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r57",
      "r262",
      "r280",
      "r576"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Investments, Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfContractualMaturitiesOfInvestmentsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Office"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment recorded in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r164",
      "r606"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "pcvx_CashAndCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents, Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r47"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r127"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r156",
      "r157",
      "r204",
      "r259",
      "r260",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r454",
      "r465",
      "r466",
      "r475",
      "r477",
      "r478",
      "r488",
      "r497",
      "r499",
      "r500",
      "r501",
      "r504",
      "r505",
      "r519",
      "r523",
      "r524",
      "r525",
      "r526",
      "r540",
      "r541",
      "r561",
      "r562",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Accounting standard update adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r156",
      "r157",
      "r259",
      "r260",
      "r269",
      "r270",
      "r271",
      "r273",
      "r274",
      "r454",
      "r465",
      "r466",
      "r467",
      "r475",
      "r477",
      "r478",
      "r479",
      "r482",
      "r488",
      "r497",
      "r499",
      "r500",
      "r501",
      "r504",
      "r505",
      "r519",
      "r523",
      "r524",
      "r525",
      "r526",
      "r540",
      "r541",
      "r561",
      "r562",
      "r587",
      "r588",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Accounting standard update adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "auth_ref": [
      "r160",
      "r204",
      "r260",
      "r269",
      "r272",
      "r275",
      "r455",
      "r467",
      "r475",
      "r479",
      "r482",
      "r488",
      "r498",
      "r499",
      "r502",
      "r503",
      "r505",
      "r520",
      "r523",
      "r525",
      "r526",
      "r563",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was early adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, early adoption [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r205",
      "r217",
      "r261",
      "r277",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Accounting standard update material impact"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r196",
      "r222",
      "r223",
      "r226",
      "r228",
      "r235",
      "r236",
      "r268",
      "r290",
      "r293",
      "r294",
      "r295",
      "r299",
      "r300",
      "r304",
      "r305",
      "r308",
      "r312",
      "r319",
      "r496",
      "r605",
      "r648",
      "r661",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Warrant exercisable and vests immediately and expires date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant purchase price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrant to purchase shares of stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r684",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r138",
      "r150"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r283",
      "r284",
      "r600",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuances",
        "verboseLabel": "Shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, dividends, per share, declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r664",
      "r665",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common stock, shares owned"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r634"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value - 500,000,000 shares authorized at December 31, 2022 and December 31, 2021; 79,470,670 and 53,031,978 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r25",
      "r178",
      "r180",
      "r186",
      "r577",
      "r584"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r141",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of convertible preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r618",
      "r620",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r2",
      "r3",
      "r134",
      "r142",
      "r448"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r673"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r155",
      "r651",
      "r724"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as current.",
        "label": "Deferred Rent Credit, Current",
        "terseLabel": "Deferred rent - current"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "pcvx_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r117",
      "r715"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized R&amp;D expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r714"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r117",
      "r715"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r115",
      "r117",
      "r715"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Credits",
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r115",
      "r117",
      "r715"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D Credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r117",
      "r715"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r117",
      "r715"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals &amp; reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r117",
      "r715"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Accrued &amp; other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r117",
      "r715"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "ROU asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r337",
      "r347",
      "r385",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r40",
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r40",
      "r244"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r398",
      "r429",
      "r430",
      "r432",
      "r437",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r12",
      "r292",
      "r293",
      "r294",
      "r298",
      "r299",
      "r300",
      "r549",
      "r663"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party accrual",
        "totalLabel": "Due to Related Parties, Current, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r187",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r219",
      "r222",
      "r226",
      "r227",
      "r228",
      "r232",
      "r486",
      "r487",
      "r578",
      "r585",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings Per Share Basic",
        "totalLabel": "Net loss per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r187",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r222",
      "r226",
      "r227",
      "r228",
      "r232",
      "r486",
      "r487",
      "r578",
      "r585",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share Diluted",
        "totalLabel": "Net loss per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r510"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r197",
      "r441",
      "r460"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r713",
      "r716"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r713",
      "r716"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r713",
      "r716"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r713",
      "r716"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Credits",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized share-based compensation expense, expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r711"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r78",
      "r158",
      "r182",
      "r183",
      "r184",
      "r200",
      "r201",
      "r202",
      "r206",
      "r214",
      "r216",
      "r234",
      "r276",
      "r321",
      "r433",
      "r434",
      "r435",
      "r456",
      "r457",
      "r485",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r545",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r40",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of redeemable convertible preferred stock warrant"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Instruments Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r122",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r302",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r490",
      "r555",
      "r556",
      "r557",
      "r614",
      "r615",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r492",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r302",
      "r347",
      "r352",
      "r490",
      "r555",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r302",
      "r347",
      "r352",
      "r490",
      "r556",
      "r614",
      "r615",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r302",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r490",
      "r557",
      "r614",
      "r615",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Fair value liabilities transferred into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Fair value liabilities transferred out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Fair value assets transferred into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Fair value assets transferred out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r302",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r555",
      "r556",
      "r557",
      "r614",
      "r615",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r506",
      "r507",
      "r508",
      "r509"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction (losses) gains",
        "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r659"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on disposal of assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Loss on disposal of fixed assets",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grant receivable on unreimbursed, eligible costs incurred"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "terseLabel": "Amount recorded with respect to the potential future payments above the initial cash cap"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering",
        "verboseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r197",
      "r442",
      "r446",
      "r452",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r181",
      "r439",
      "r440",
      "r446",
      "r447",
      "r451",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r713"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "terseLabel": "Research credit carryforwards"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r128",
      "r140",
      "r185",
      "r243",
      "r521"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r190",
      "r193",
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r29",
      "r242"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r267",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Contractual Maturities of Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee, Operating Lease, Description",
        "terseLabel": "Operating lease, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Operating lease, existence of option to renewal"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "negatedLabel": "2021",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease, option to renewal, description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, agreement term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r196",
      "r268",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r470",
      "r473",
      "r474",
      "r496",
      "r612",
      "r680",
      "r727",
      "r728"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r135",
      "r147",
      "r634",
      "r662",
      "r672",
      "r720"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r163",
      "r196",
      "r268",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r470",
      "r473",
      "r474",
      "r496",
      "r634",
      "r680",
      "r727",
      "r728"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Long-term Investments, Total"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r69",
      "r70",
      "r285",
      "r286",
      "r287",
      "r675",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gains on marketable securities",
        "totalLabel": "Marketable Securities, Realized Gain (Loss), Total"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r41",
      "r139",
      "r151",
      "r161",
      "r177",
      "r179",
      "r184",
      "r196",
      "r205",
      "r209",
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r224",
      "r245",
      "r252",
      "r254",
      "r256",
      "r268",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r487",
      "r496",
      "r613",
      "r680"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r219",
      "r220",
      "r225",
      "r228",
      "r245",
      "r252",
      "r254",
      "r256",
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss (in thousands)",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r49",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r211",
      "r218",
      "r232",
      "r259",
      "r260",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r433",
      "r434",
      "r435",
      "r454",
      "r455",
      "r456",
      "r457",
      "r465",
      "r466",
      "r467",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r497",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r519",
      "r520",
      "r524",
      "r525",
      "r526",
      "r527",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r561",
      "r562",
      "r563",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements Or Change In Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Nonvested Restricted Stock Shares Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r245",
      "r252",
      "r254",
      "r256",
      "r613"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r721"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating leases, rent expense recognized"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Total lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r529"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r530",
      "r535"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r528"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease, ROU assets",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r659"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r537",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r536",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesScheduleOfInformationRelatedToROUAssetsAndLeaseLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Company Organization and Nature of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r175",
      "r176",
      "r266"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized losses on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized losses on investment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over Allotment Option",
        "verboseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Proceeds from issuance of common stock and pre-funded warrants from follow-on offerings, net of issuance costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r33",
      "r56",
      "r188"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r344",
      "r346",
      "r352",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r387",
      "r388",
      "r389",
      "r394",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Retirement Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r89",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r393",
      "r620",
      "r621",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Retirement plan"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based Awards"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r634"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.001 par value - 10,000,000 authorized at December 31, 2022 and December 31, 2021; no shares issued and outstanding at December 31, 2022 and December 31, 2021",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Net proceeds from initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under ATM Sales Program, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock, net of commission and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r56",
      "r188",
      "r189"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r31",
      "r56",
      "r188"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sales of property and equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r105"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of common stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r161",
      "r177",
      "r179",
      "r191",
      "r196",
      "r205",
      "r215",
      "r216",
      "r245",
      "r252",
      "r254",
      "r256",
      "r268",
      "r290",
      "r291",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r468",
      "r471",
      "r472",
      "r487",
      "r496",
      "r579",
      "r613",
      "r631",
      "r632",
      "r658",
      "r680"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r64",
      "r166"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r66",
      "r149",
      "r582",
      "r634"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r601",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r148",
      "r152",
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables",
        "totalLabel": "Receivables, Net, Current, Total"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r370",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r154",
      "r548",
      "r549",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r298",
      "r299",
      "r300",
      "r663",
      "r725"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction, Due from (to) Related Party",
        "totalLabel": "Related Party Transaction, Due from (to) Related Party, Total",
        "verboseLabel": "Accrued expenses payable"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses related to agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r370",
      "r548",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r546",
      "r547",
      "r549",
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r108",
      "r153",
      "r735"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development (including related party expenses of $0, $2,359 and $1,331 in 2022, 2021 and 2020, respectively)",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r649",
      "r660",
      "r736",
      "r738"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r599",
      "r650",
      "r660"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units RSU Member",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r85",
      "r146",
      "r593",
      "r598",
      "r634"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r158",
      "r200",
      "r201",
      "r202",
      "r206",
      "r214",
      "r216",
      "r276",
      "r433",
      "r434",
      "r435",
      "r456",
      "r457",
      "r485",
      "r589",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r89",
      "r90",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r393",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r89",
      "r90",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r373",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r389",
      "r390",
      "r391",
      "r393",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Average price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r93",
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureRetirementPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "terseLabel": "Summary of Activity under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r47",
      "r132",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents And Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r395",
      "r397",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r97",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Shares Under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r74",
      "r76",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r85",
      "r170",
      "r171",
      "r172",
      "r235",
      "r304",
      "r305",
      "r306",
      "r308",
      "r312",
      "r317",
      "r319",
      "r616",
      "r648",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment and Geographical Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period for stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Begining balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested and released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair Value Assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, Maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, Minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of payroll deductions of eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Options Available for Grant, Additional shares authorized",
        "verboseLabel": "Additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Options Available for Grant, Ending Balance",
        "periodStartLabel": "Options Available for Grant, Beginning Balance",
        "terseLabel": "Aggregate number of shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of the stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options, forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options, granted",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options, Ending Balance",
        "periodStartLabel": "Number of Options, Beginning Balance",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Ending Balance",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Equity incentive plan, shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "negatedLabel": "Shares purchased",
        "terseLabel": "Employees acquired shares of common stock",
        "verboseLabel": "Shares purchased"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfActivityUnderEmployeeStockPurchasePlanDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockScheduleOfCommonStockSharesReservedForFutureIssuanceDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options exercised",
        "verboseLabel": "Weighted-average price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r402",
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage for stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Weighted average grant date fair value, Vested and released"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureEquityIncentivePlansNonvestedRestrictedStockSharesActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Term of plan"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfEmployeeStockOptionsDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfEstimatedFairValueOfSharesUnderEmployeeStockPurchasePlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Number of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Employees purchase shares of common stock of lower of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price per share",
        "verboseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r136",
      "r137",
      "r143",
      "r653"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Short-term Investments, Total"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r196",
      "r222",
      "r223",
      "r226",
      "r228",
      "r235",
      "r236",
      "r268",
      "r290",
      "r293",
      "r294",
      "r295",
      "r299",
      "r300",
      "r304",
      "r305",
      "r308",
      "r312",
      "r319",
      "r496",
      "r605",
      "r648",
      "r661",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r78",
      "r158",
      "r182",
      "r183",
      "r184",
      "r200",
      "r201",
      "r202",
      "r206",
      "r214",
      "r216",
      "r234",
      "r276",
      "r321",
      "r433",
      "r434",
      "r435",
      "r456",
      "r457",
      "r485",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r545",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r234",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Stock issued for payment of accounts payable"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r19",
      "r78",
      "r79",
      "r85",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock (in shares)",
        "verboseLabel": "Preferred stock converted into common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r5",
      "r6",
      "r78",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Number of common stock issued",
        "verboseLabel": "Issuance of common stock to Lonza Ltd. (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r78",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock shares sold",
        "terseLabel": "Common stock shares sold",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r78",
      "r85",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options, exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansSummaryOfActivityUnderStockOptionPlansDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r5",
      "r6",
      "r78",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock to LonzaLtd."
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r78",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering or at-the-market offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r78",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r55",
      "r634",
      "r662",
      "r672",
      "r720"
     ],
     "calculation": {
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r195",
      "r305",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r318",
      "r321",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r517",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r517",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r517",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r517",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r552",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosurePrefundedWarrantsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r110",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefit"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r1",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r290",
      "r293",
      "r294",
      "r295",
      "r299",
      "r300"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Preferred stock authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Redeemable convertible preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCompanyOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of preferred stock"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r205",
      "r206",
      "r207",
      "r208",
      "r218",
      "r259",
      "r260",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r433",
      "r434",
      "r435",
      "r454",
      "r455",
      "r456",
      "r457",
      "r465",
      "r466",
      "r467",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r497",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r519",
      "r520",
      "r524",
      "r525",
      "r526",
      "r527",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r561",
      "r562",
      "r563",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFundingArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r610",
      "r618",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r610",
      "r618",
      "r620",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAndFairValueOfFinancialInstrumentsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r438",
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at the beginning of the year",
        "terseLabel": "Uncertain tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest or penalties recognized for the period",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r221",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number Of Diluted Shares Outstanding",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r219",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted Average Number Of Shares Outstanding Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vaxcyte.com/20221231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r638": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r639": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r641": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r642": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r643": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r644": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r645": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r646": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r647": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>128
<FILENAME>0000950170-23-004654-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-004654-xbrl.zip
M4$L#!!0    ( #""6U8_7KH3,2@!  P# @ 1    :6UG-S U-3$X,CE?,"YJ
M<&?LO =<%$VV/MQ(%%0$ <F#@I(S2&9$)8OD(%$8D)Q!LJ,HH$@0$! D*!E)
MDG-&DI)SSCGG-,Q\@Q'>W7=W[[[W=_?^OTOY*^P*Y]1SGG.JNWJZNA&]B%'@
MHI28I!B @H("O$;^ Q!C%Y=%'8T? H",#,     6@(8B )Q!'IU#%J2\C $T
MY#$*\E@E(O+H?X 8 "XVSY,#F,@Z9!] &)D!\OEOLJ?I-)VFTW2:3M-I^C^:
M1"P,#<QTJ21T+6P! /TUZK?5! %RU1#W&NW7<4%@P+=C5,X; ! 8^/OX]\H"
MZ^V1MM.5Q6DZ3:?I-)VFT_1_.W&P<7#RLW'PLW-1L7/S<[#Q<W+^W3KD&@2P
M  P! \ ,T 6H  GD7PL N1H!$&,XE$9V=E;\K*P6MBRZ^I9Z!BP02W-61UTK
M5G86-E9 $.QHI0LQ-;"CTC,P-+80HETI+J>E,M87HE7EEF&3L;IM8&0LX6QC
MH.A\3PGB; KATZ<%"Y_'%G3D=S2W,C>PTZ5R-#>SL.5W%+KZ33L_\OBHFO6J
ML*"-_D-^A3MB/WH@2T)7?V!Q<'!@<>!DL;0Q9&7GX^-C9>-@Y>!@1O9@MG6R
ML--U9+:PI?ZAX(Z!+<3&V,K.V-*"ZJBLJV=I;R=TU=[>6)__H>Y#;CU]?6YF
M/5U.?69V=GU=9EU]3G9F?4Y.?1YN=EZ.A^QZ5W\,KP_Y-;J5O8W9M['U(:P&
M9@;F!A9VMD@VV%FOLO[WCHFDZ->@?Y=^I(W(/ORW;0QT[0SN(+/PD7N9V3B8
MV;F4?KJ7A9.;6Y#U#_T$6?\ ]#_ EK"@/H0?<H3)TN;[\(H&UG_-VV;&PL>6
MT]^-1-9]/T!J1X;>V;-G!5F/#_RW3+#^B#SDT:\X14I2_0^DTT%.!SD=Y'20
MTT%.!SD=Y'_7(+_7N@86R 6N W(EBQ@ ;@.8Z.@8Z&B8&.@86)B86-AX.,@U
M!C8A[L5S>,2$I"3$A,27R2AIKY!17*.X3'R5Y>HU.GI&)D92*E9.5@8.6@9&
MAB,E*)A86-AGL0EP< @8R(G)&?[+"5$!X&&AE6&1H*)<!<[@H:#BH2!J !
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MT7*SX/%\6!5T*1_>(#\OC--A5H+6TS#-/5\3Y/39GZ]6U?*N[=9.2CG^YL+
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M)J%,8,#DY>[\_'*\]*6<!L&4, L:4;?>?NS(.O#RS'"01ML6"&W^42B;SN5
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MS/OGZ&I&444RB(=2QE8(,,!>RD53RF1QZ,AG%>_?*\\3E[(*^LR!H>K3*>^
MVBRMQ<15 4S@I-SJ^R%OVR+GTZC)N^7%T_.BG?IM\?;I9$09VVQFC8?95?K+
MI7^_A^D[U[L9C(7T#V[<4T$RD>F!A-2)59*?>L]FD$^1?DDB #G[JR>6:0&)
M>R(UYS]RZ?D-3 J?A]Z?I.7>>/]2\!^.M,W3H:(4/G1+32@.ET;2-I0I8SA[
MP<"07(G^U^0 + 7MIK18[?58U/L:MJND;)LN$(Z[!=9H3)"Z-U#^-1$F#..F
M8_;<>;6Z(WFE'$U,15R]1NX _'HGK0VB4OI;^NR_=7=$U%%0JASAF#X\7#O9
M7](9F!IT!PAV4WARGB8W%&I?^6BF .M_1"JQ!@_CH &$G^PW,EY]G=^1_3Y3
M=6#YZ32\<R,\9/^, LV3^D8M4<WCB7M^W+E@(BF9U&G#%% <=\CIW^MDA\=8
M;,6QNV6UMV:2[>M#E=N![H&Y#'K:O*+SA'C+L>#;+(<(#)!O,P8"[IEO/MGW
M)+CROR5O:QEQ:B^\I[1(QH4!O.Z-R4,_:)(,-RG;K&S=2MDQ#1\H \5=-O^A
M^Z=Q2;2@W9>;Q!U]-Y;DDYPTDL_*I5FM@I982"M]H-VICW]E.=+S6\( !O[]
M@W&E3L9%-OW2P%E^:?-GW9?3<%;\*[^X724]0"?T/$!7KA;9M$L#Y^HDS1DZ
M+\<?Z_*O_&KR9W%#M)QGP6EUU/2^.I>>5R=&ZO69\?/J_8J4#43I7[-A*V$
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M%O0)FLKJC[+25K>HY._&C!+TE]&Y>LZ9IXNLBJAX):MC;=Y=?4P:(M2E *^
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M6WP*&MQ(@ %^'JQ:8<#0%!Q0,/YRX*!W5%TO# ,(N<;>W83! ,'I]_CX_C#
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MOQ7?AHHC-D#*NTU=+H(CWSA^9.SOL)79S";<'2G<KOWJFE37B_/NM7YXQ_%
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MW8O<$7AS"38N!\O?+B^32<A)LO)S&E'(-R81-/Y<QO![NBYM])R?4!1S.O$
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M<A+_+&#N$W9TLA5^:83.;$>2A9Y["3F^81[:[CRM:1PL-I0;X=F'?.,'9GK
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MA0?NC=R"0[UP?J)H*LP@9DEC>N_D)U%N'FE%Q$ZV%O?:EXFGV-CVG;R\MV*
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MJ)<+*([79:,_<?.-&LM<J"[T].5"YH.6+/+^3:N4GA-SQ6>?Q \3J#O0DA&
M)LH/  K58YH#T5'(TN3.O(ZUI^ 4T9LJ4J(V;^<JK^0DT%V#$#K]ILF._1L.
MW94JTH9GR]L&AG:9Q+SCWT>*ELL8>FD35#ND1D+6KT;-^%V&?+(E0605TXI[
MEQ@H!NIFZ^HP#*@AB)NK%HIN>>;?CP"HC2R$:5'J?Y/V#KCK\,ZEG_-RS*LX
M=<)RS,"QLLK.G>I=&L-'Z+@_[QC6G6/XHR_E=:IDJC_]$[O;C.GMR>Y"Q4^*
MY-&P,ZQ_=C^SUZR$&'PEYY]1%U"6Y2J-JCC5<9QI/NR(P4H:K1B-9L1[DC54
MDC6**73820F/P?';^> J5C.:K1$%U4JM@+*X--/D$O.?+(S+%5FJ]BS8HXYU
MU)2%B*Z^$9_@>/5.L @,[*]FI8&_< *='@+AGYCE]0B I,35S++]T'3W"+^O
MQ;[OUIQ#1P<;ENN$K$6>C]JP+GGK4$M_ON/CL*M7Z 1\A "LT%DB 'J*QT6B
MU0X\Z2$)AF,!9@;3+<U-V\C-S P5\ODE\#9PM;9/L>C8E#L8Q$082;Q[X^ #
M@%H="TX&M+C-'$CQ:.A&2F!F]XF'2TK=&\^,6^+DH:-_3C8^+XD T$ [E5K'
M0M1=WT_WL??N(0"+G -@I B()%\@!.")%.RI("'L5W.%'@%8L@Y  #X)&2
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MN =R?4MQ=G;083<PY7EPBVXJ\J57X'DL.!ZX11O9&! '[?LC  \7P(NXOU!
M /8K_H30DW'0!@4"<#Z% /P_E$R DQ,XE]<7Z8W("96]1 "^^8#G67^-I9D&
M_C54[*^AD)W'$( _]1[ZU?L@R!I\@@.^WOR%E'PKW ..BT0)YQ=*&\"#F(V4
MDT<0^*7=03H<M_ )W.<Q7 &.CUS./W>+@E\9'J;#'^O;P;V/P/-RR.6V,@,>
MKQ^$@\T6P.O[2Q Q)"[YOW#Y!(Y OAZTR#@(VJ "KH!;ZJ__TL_+&&:!_)6F
M+O)7'BE??DVP@AOG\OA"&E3V#G1\?BB5"FY134,NQW/V+N1. AY$;S2=/ H^
M BT:N", ]RNK$ "Q2S GG"?E(-C:\ 0G[AB(W$=9(.1<,)%#&"*'D( 2;PUL
M)60\'U)F>=3I9S10(@ :/BI$2LB6/00IK-?>:_+3CZX8D'L?EN]77UK]O?K(
MCMHBXX>0[E #33-N03*AGR9QZ*SN=AVH*ZB5-:KXBVRF^KYV4W+P$5\O=<Z"
M&J,(CR$K L#]RR2[@Q/S\-B0S++'O.C!$H!N:)\2[/(.G JS'LKWO0AF^EI'
M)/F,6@B82HES<V\\-.DY5PO?N8+6:>EGF3>1^JHUZ0L8E5\E$V9KCN@N/7T=
M8,?Z^O9@[/!@]TLA[C3(#^!AT5 M5XW Z\VJ&RNC> DI0IZFPCNY6U<^FSHB
MH]O&YYP$2E*H=3AM"^K=*_7F#O8.GED;8TJDE0F*Y8JV0/-X$C(_%A= .'@_
MPB!R9N'I06-^KLAI?URQW-H<K?(,S=L'1UPA10#@A\0/IX4VB@;#/,XO1VS'
MZ,--E1C-:,8?/FA_GU"9GC/I$BP_SDM.M4,9\M4R9?<!V^K;Y6SY]V"HH*"+
MXH7V5&YU9_R9!1Q:5S2;[C3?>37\/;"<N0?YO0)U"OL2\WFX=#HKQE,[!F'M
M'RIU,I-3LSUK^^U9*XGV'TJ]JG^</-IG\6;"0W+,JWW557(6-&ILZZ5WLI]@
MYVL2AA-P3O$AR.=IO%[)#]6+&PG,Q\;MXV=3V:WY=3W$PA.TDR5G,?UT2B["
MIVB9XS!=@M ";6U_Q20$8*CJY4J:L4_U]M48.FP0>(RD!;QU2UD8Q2[O2@">
MW\/ 2.$JKJWV)8F)X*<J;];L-R6<H54"Z.@8H;-2F3K#%4(B.B,SEL>?TS"5
MPN\WDP<*AZ65.3:PR<WJ=!_+U_M@O>K3CA3P7Z1^ADZ30RXI5;S22#)JJ$PX
M,*LC8>-J+2 'H8]V@A^(.'0(G,#BQ*@.>ZN4+DSG!I.>](F_&TSD"$P$>E5O
MPLJT*@FNW"[J%"FPL5F7G]MEA,:G3DFJR]#"YL<I DB\F)SKQTY"22R3YSI.
M4Z"F-HUF:,_-9P[#+O$_YRD^\TZM'38VK1XN3HO:Z=9R#1<@6A]U10"$UV);
M1'"_"TODSDY8U=+R15[:S^H'KI&*S]3;=RT76]4M]BB;+M:1VE/+E3["Z)B.
M3LY&;Q(H !."NQQ:P:<P4,)(8<?;>>LKL_CW-OM%8\0OW^@7X##I6G22)9Z1
M#6E?!,@UE577E-7AMEME9E$1X1'1Q]"(0&Q'XWCKN6&*@5"2KC=#]5WGF+MV
M/"$0+P6^;I[@)1L$(#;5>8*Y$HW+&=NB]"Y]Z[D@6_&2[G3?<[.$BSF!,A9:
MI0C*F6P1=.*%*_=Q&03@@;^/[=B$E7(\>67NP^D'_:)P/KA P<T=E]T/T"=Z
MKY)-E*TT7VU(.@-0J$L<MQM4KG\<O3I+T,^*9Y#TYUCI1EO0M!75N_9TR9L-
MW./%,NB4Y01;Z+%0V%-AW/7UCH+:=>1OPFF''.72;8Q=2OM\FA^61J+;AW-?
M:! &4H>YISQLYV*)*%_@^MX%8CK%-V][3&O =C 309U^&2E5(XD]FP[)IH<X
MR+;2*))/L@?:%A8]52_YC!Y'Z?-\]=JW<[SB[987]5"Y:RRKY(X$#=M!*G'8
M7/RE^(^%,?U@G OMA(05D\D.,5BNW<GVM*?;OM8 6R%M2K=:;46U\#L4(,>J
M#-%VIU>T!?H+&P>LU7)G@E*6[UUU$2,'$G+:R60CU*/"(M:NJ+73M$'@#Q\!
M&9SH1+OA"I8C?[X#BY0O8N>U:]D:CY4A#=ER,I.5_Y!&<O>#1,"09('89B3W
M+7VAR]*QW/4"QP1\C-[)]IWXO"^<F<5-A;M0+);- "==Q+DYMS(K$T])),Q(
M)152X7A/&P/74!64^IBE>&MSB&*?9XM^U4( 9&_I#C4+-WSI*ZH=VO/+00/Z
MG)M'$..W\^XC7[UMVWD7$^C,6/7O&VR@%YN/E$A>((6.8E?P"6%19:GM":?C
MDCN6\2XI5H9MLD;O_LS][631\]2L3T9ZD N)^@]Q<D>;4\V3SX1I:[8O$]=O
MLDX*&BA<;>"/M[C$PZ]G^<F_Y*4,).R>]I%@.<M&=J_$8!W3A.6TIN8ET/NG
M#M6#GD;94]8'J;3W/!UHKC.FOQQN]#9*)AOB:5YTIY/3HI-YK?'^,-^.UF0]
MS/5IB0>I.6JO*-60#)?E]OO!MF>V*#)&$1< !XWT _V;#!N[K(O8HREHTO>=
M&25WOD7(CX<;/*'4XR^'VS.#*OO:XQ-7DR JBL5X>MA<K=IQ\A?@G(F>]MV0
M0K,\-!F6=SBI6_/GT'5@(,]E.01C@T3L,81KT6N@U-Q80* 5?YV8/IN?3.-T
MWX>U6%B=XCL;'^6'2#D[=FHI@TLH\7+)_K;.U5RP=;%EJ+EK-9LS3>XJT0>:
M8U"2T+>2_JT$X.<*3Y8)O?9O!?PHF&^4C#LXJ\($C3?E#\FXIA46B=C(9'@T
ME6G#!+FQ/J;TEZ,'\+82^2OBZQ&ABU5NE1K?P%9&9W7%X"/50ZO7JE(W*8)]
MQT^7G]Y?2 SYL"V[\%:3X"D)N#U7H6LB;BR-/[[ZWJ+[^2KG*>^4AD;#XC;H
MT52&YM?1)=IV%G/,3PC *_15&12I-A+ROE:]K<?6.GXYTL'W*:/S//)/]X-^
MZL;OP7&$SU6%A\H5:V6(RLADQ7Z*MA0U?7)T->*06\JO_!B:*6_(2>%793(6
M=6&%>A"UP5=6;X_/5-IU]WN/+:UWR)%G[LQ]&'.&EHZ+@V(DJ1;L)Y5,@J22
M5AT#[?IA 01%5]=P>DO0;T6YSYUUV=7_Y;UBX@6G+7!74=6K\FNT.&OSIMYK
M848"F+'3Z%W^W:'O;/7DU%:J!A8ZY5?*U4*9H4_<.$\[I$ZW.QBJ\53N\^P'
M#4ID,[63MZ=:+H=\3&VT;;T9!86YCT(>@KNFER!7%Q $P+Q0X4EKA.63'F?>
MWO'QX]!2O5Y7YF0\[%;O2R]\1>6#D"AK%2LWR5RV>.&>SY_L]S3/.Z209R"!
M[6,N L!K!Y^QPL'>C(U+YC]$[1MA9HD]9H"X=.E/E]IO'P4-#\$H$@SJ$]+F
M^^RI/F4TOIL9$A"NW#F<,":O'<-.26O,7]I_)&?MR>HW6M%RZ2#)W6K714-#
MXWVI^MAK[?Y;42;+IC?J ;L:T'5:#]N6R@=W;P8O-<VU2-C]FLH<!1R9KS=Y
M23>?O(Y].5WNCIEBA !L%Z[/*%<^(@4RTE ",^5(A.$*NGT7$8Y>;^WVC8;#
MIU^R4LXI7Y%=FS0UR<K9J'9=1&$ME#24^*HJTHWM 5G*#KC0WKD^N$SI+#A8
M\P8&G*Q5:7M<9H3_9&GGBZ//)CNA@#>6SS^^\'2\EC9^\M5R(5H&K_F9#4@>
M<L0XBQH:Q%@2H!5AXKF'A_::L_IJN4(PP^BWD!8#3C!A1*Y>.W1OU7%](L(
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M?I'R1ZM 7'7TZ)7;&"GTSW,<#$!H\YQQ<X'UN-(7&O88*V4$I6B<ODYM5G]
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M<XE(7YVXB<I/8_4#?YR''5'9*P\E/40OF;B1:>#I?CYJPA[GS36:00#/7,M
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MUC6!?NS)20X<A>]**%5ETDN>!U42XP87F)6>>%G:<3/*A2J<"O_ <^)=>V-
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M (IJQ2?&,8 O!;Z-LKTKZ/8V#Y\5J*IA!(G_H3L:Y=0#W^L$9;(<-?AEZ&$
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M]9I_6OLEJS29B(8OHM3?TRQ48_0>HA.IGD]V\,KV$2ZNT$)\_+6DN:?QC)%
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MX_E_=*L%.+F-7F%-Q)]PY!%U"P&YN^_$7'((3M8\.\_T.JF>8/#\OM#4S5H
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MKB.*[=7'6T5TN<P[ZBP2@P,#^UDA!283+^R+>G\Q2WN+S6P*(H/:#3X4'-S
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M<?_7>J'K;08E-V\W84 UB>_P[E#1&U3?&$RDKB)$[K6>EHV7V@=TI-.W\7,
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MSCOK/R"OMGQ_:W8C.?,O@=J_UG?V'WC9;U<+I_?<L^S))HTX2\S*'>DUE@N
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MYMDF;^S3UVU*N4S3;E+>H0#@2G\=U[)B:?C7[Z4A]?73KOTVB)!H*<QLV!G
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M=&Q\8G)J>F9V>67UV]KZQO?-K0/<X='QR>G9^<6?ND  /NB?\3_JHKK6A4=
M@$\ _E,7""_HSP0J D(.$:);R@;@1S[4G- H8AJ5]*+Z-A*(J.$^K;WO""D=
ME]@R]\&?TOZA[.\)B_Y_*?MW8?^A:Q8@QP==%P^?"E $3B_XBB-)_PK^FI+P
MW"=Y?A'\LMU>#.F91.:14!_KIQ]7WR=:P2;;81]2_=7:P^0>V2]@O2'R&M([
MR *W93VCP'B6"?&"!T[Q>"VS; QG\6?<Q[)Y8CK1GZ7F'NFVU;VY/.B5KVH:
M;MST_R5$7%/CV-Q,EL.5CF7I1H Q+@72REOBCVM]3V<AN^81QN,)?:O\GU+=
M+).+3&7C^KXN6D;=,C#P2I?ROZO8\G%9\SI+ZZ+R-8E+Q8>1VZ=7@+:!G-K^
MUZ+7)'S%"<!?\VKO+=B=ZBM+!>C(4* JJ;*G[#5> M\U155;SK!Z297!]3WR
MV_W8!U;(R_1.7\D/T$3#*?\(_CZ<C<**L:CNNEH0APBBOB$=/BXRQ$PZ2K,F
M_X!EF4,#!H2-/PX^C-1A.]%P_Q*0$VX1%.!<;MU+N)-3*"K'9T^>0[\HD^0@
M]Q2]\%WF&^/G!4URJ(;'&LZ6/Q A3QGND,NMVVTS?(3-*3^)OP+B,Z^ 8"KM
ML2XP!<D/4*\XKZ72:W_ U%Y*WG*OTW(PL]J2)X- I)<^@38DRJYC.394I$M_
MW$PZ(BQ<@:VMU/T$:FW+5,32(JS]@C/&.E()3'"G2V0X80<MZ ZK.\!WQ;Z+
MPH8,RW05M7%'64<3@09#=CKOVE*&B]-X;5B(MSDT(U>"[/45)?RFD.@)O>+G
M9C*'EA1ZNYOF'[U*K6:#3;_J8Z-&I1X9UBN0/6$^W$-^..KW\W&%-$)SBLB+
M8@'FU:B](3<;APY&KY@=C]%O>O9IYR(A6HX0_*33#?J+<49CQ'P6DCN .FWI
M"VGF4$3YQ>0-[?FA2EZUTDR")#9M2S!>0E0,C8$2X3\PO 7T2M$ C<9/PVT/
M1Q1EY,Y28=2'?UWLY.+^)ZKH7YK/4+ROMMN[GE;U5+J\)FXY.GKV<VGDY/E>
MT[7)&J<"DAD6HHN3WHI\PA\?)KI[L9L3$)HE[$;W^8"[.QOBR972-/00#5\1
M)+/-,Y(\D9 QZ>]D(@O)$Y#)]X;).=X*7JEP<R_94N!*-1WS[X\P!=8%5@JE
M610";!_X].P@6]W1F(_O6H,D#C32V9?S>'V.3E"9FS/'S*@(\BO@AFLVW0?&
MN)U1??GE!8CX9Q"_<T'K1:#8+^Z/;QVM LP[6^*X-(1IYS(*PY%NK9/-U2RN
M*)3'ZS (O>DS28_ZCWXIEPX)8V."CN83//&9AE;K'KB(5C?GL(5CKLEM=1I3
M![FO5L,UX?(H]3>;B*\/6["%+HAA:%+T5PFF&I%+>4K:T<[**\!-Q^ONF\F3
M>5%5F9O*1UZARW+*K-57 -4]N5;S7F:#*CEV:$QR"I[=C=+H3QL?(JH<] \(
MA/724/N'GBKB7WS)@;+FWN_>Q-M#XG,RAB\Y3Q_7E0RPNA_7/^O&FH7JI7H%
ME<R(X1KGHT@"U&=A'A0%8+39V\GCP'WLG!U&]&$CQR1!FK!@?@!XC)=UNF;7
MO*0)&UP*6DG7KCLFL)O*7MQ$\KP=9E(>\9^97%QTI9/%.&JFZWPC9%%9^K5+
MTNTQZ=_L3,LB5&@DX/;D3+_3$EGY9EZY\I/G<'S'':XPBIU2#.7!]:_6WME^
ML;_WO(;;AMIXBD1R\H$PCD694V5>Q",_3<0&[6R5G;= %N/\T#TWX/D4E?4\
M/\S+ZR2'YN3^JF(A_2GM:V*N)7@*)3ID(TFLP'Z[P]!F9M/=CR"KUZD__ L]
MXDO+95%P+R37N+A, !8U[KHH/!P@R_TNSC"*)M*"VSOE0P?C+$6IHW#;7BZ.
MS).'C73;TC2[>M%"+T-OB"]3XQ:TE)W!&M>!;.IALSP>(> 'J-CQHW ) 945
M.@LS/^0%USE>46-$6EO?479%$?/ZEX>%';'%: 'X "!?Z<Y!@HX KVE,_/Y^
M>6WP?^UD?T%=BUGEKSBML&"U>V'!Y!(']Y7,>.'Y!Y$D4GM6:".C,=2QC8R[
MP,L;-%4I8:P=8? !8T9#W:CU8;)GQ&>NZ[/;<M60./M3YHQC*3FS(I<]S[!R
M*[>; O<*;V$%A_26F!\W:7U@>3AC;N5JZRZ9OC!_GCW6L*26((H[3.LX945_
M/\'465AV>WK>4B=W1U,1 ;0C\?E.;]^+5YJ,;SI\J6[4KSOK[A EJ_K#R<D0
MEQ8D!@\"?+5661?<-3\S8HJ\*BV^!Z4]FI0FLY9+^FS,%M  F^]\.U3F>I;7
M=J.&+!MNU!0-Z^8H],7O4K#5?^ES,5' U(:Y4)OU6%DNS1H=017RBPAI29]T
MLX<Q\AI"8_9JSSD=^E)R$Q*@AJI4TO1]&9N;AE-WP,C@C)]![5? 7&ACJ$WR
MO)G=[4R&?HW$R/<OD4H,T@]CZP6/-B:$Y$3#*C;7F1(W^W7J,F]IO+)CD.Z9
M!3'4/F2G@L/0,(**GN\^H]B3O:Q^S?F*OKFM* L+94/BD[**65I>7T3R5NNF
MQ*#4X<V?UYU^>Y( <50K-"6.TN\PHT.5/^PM2W3-)>OY<D8NBC"&'R91>CQN
M%>TE]X/<5H@K7[.>1"T)0LPF&"]</C])-NI/#DQNPS[IV0UEG$QZZ10H[N[V
M:"8X6W\?TW 2,[\IR<_"<,CU.3S&<QXQL_3M8-.F[ AGD>%M8.Y,:G$0'4'H
M$[K^PDM^&#&E(Y,Y^*-4/=/$"@GC+4<'G.P/R!=@Y^ATE^E@=H^M(0Y%\@<F
M5NFS!OS%"=G-]7U;&2J_N1O'+Y5+SNFR/HE)SLVJ;>.B@26$'WS39@$U+HFI
MM['2XHHVH4B1@2)CFUN]?BAP\G1]M41*VS&58AHSGSY18FJ2I_0:Q1Z=>R97
M&U@1J"?CG6L#TV#Z;K><]YU![-CK1J9$8Z ._.]H:3V L8-Z>=& H.9&YP9Q
M4.VK9\]9W3/>3J(CC(R:\_1R!_=@[)SGNC][XH<@]4/,K)D1@C6H(BA9(,*@
M/WN+PB\3@C(NZ2_!+^("96A:]J#?(3;NY[=]2100$BUHP2F2XGJ+,C1&5R;$
M35MPY2V>69-F2?%O0#W'P/'J&-I5+UO^F*6@)DSLC3F1;4LYY.ML3 Y3="#V
MU INX#I%M;")F:*Z^X*Y7N!-G_ 25==>:%U/C7 ?Y;@I)UU"8H_!%X^>B%2V
M3%:'[H[7#C]7RU<WE6Z-F-2BR3QEIJUM8&L=%D:!)&LI8'U?@81).:L5IL1X
M<)R_3CMC?X-1@)NQ%J4*5!EXU*PPLVVIDE]>QW(LOF^ =:;?H!V8=LLM?<C^
M'CLAH>G(#N/PNH?XHL6>OYKD?UJ3S@6C@0H[R;<-J)KB(T.*$G8>VR[TWGKW
MXU%4MQ*X1G9*=%7U627G3!OABWJ7Q!<;K[(/E7^ Y:%@@]ZC6A7D*,EY<.8K
M?WG*C8>>%<&V':<R=R6V''X/IYAR(ZR3F[E]M5BDV.*T9Y-*&/RTWODDE;D^
MLPUY.*MKIC[IWZ_+9VDU;4MCX82+6ERZ:=$\Z%T*/Y8[M)F*:]09$&'4^66J
MLQTW)(O'F73"-K3XQO4W*29!+$(%=X);#>T+[QT<?S1(0T[N6/AIM2R W;[
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M\[BVB]LG$YCJ+"KU *\"I/EL*7)-DR"E"^M2!$.]HJV^*]@XIXYNC-<D1:C
MQ[@R+C),78HS@O"9.@3?_,KE.PIK$MRU21T0"QN/5&AYBNZV7EC<>BJ6,F0[
M9NXZ;-%#Y^];\<6,1VG>UR<2*F*Y:G'M5RIT2R@$7?;RCSL=B.?IOD\MA(/Y
ME'CQD3)CZ%J04#%6W_/-8L?AK^]_O.RE?H3U9,?=QH!J7EDRZNMO]VB"EK?+
MQUML/;*"3H4[/6JY8-Z_W66<7C#5?VIC9GL*JS7;[RH/J?J^'1+BYME?CXN2
M>Q=H+QO!+^MU8S-7+[??^9$G^:*61KH9+\MOAT'^,((PV<*[TL&/"<=9J\;
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M>=BFQ;KQ[%D;1KR7B[5+)G PMDE'^, 7!I]Y$:EWL?F13=[23Y.1?T78(E>
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MV%W=.#F=3*5\1#3\I^O43] +<ZG=NL-.28RX!1H?#EGIGKXIZ,E+ /AF.CQ
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M;O20Z"D=[\Y3<'A6OO*3N <@FDE%?E(LVL4YX;8O<_ BD*=8_]+]>V"J'@(
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M<&\6QSY1F=XXO)P_A6CG?+;I/#\W+3"]@]'&/];1PR] =V9J:_]#@D]>CYL
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M3T-?ZP&60R;R;F$MO5'<--_'2WM</MN.U"U&=G:G._.F]+R04X&\CJ4D$\T
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M#WJT[9 JRNJ+P6-V46P=FKN"-F&A/+*O=&,Q87?\<+2I^?O;=BHG -9O]2<
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M!17E=17M.Y!9*],NB.7M0"B1EWMWVT@+HI@0@AA>IBM(E0 DBOG*;W5Q=2A
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M)Z$F+;)! ^ K,'7,'/W2UQ@TBG&+(M@\(JZ)1 =:*=I7<\2<[;YFE%(CS0
M?JQC.R?UR_D;.2N(D_2PFI#K<AKL24HX8+!GC+GC.W4T67I PDK3LLA8NS\^
M]WPE\<<%P6=#7X+QDB&I<$[D"U=6W]U[(RUBSB#>H0/GXRSSFL9TQ^/&G]_;
MWFJ7E"\)_61@]><['X# ;F'Z$.=)=-]Q>2S-OVJ7'#^/[&6G)0FW5?6KZ2JD
MUE$!7\._DF-;+A&ZT9)1%!%+0K$.EUU+=8#KS="8 OO]1+[ERN<*SYL>( +H
M$#86"I%(S'6X:Z:"[B,)597%"["INMZKGY]A/^$1:IA[*I$)7R2RG8.&K)CK
M"=>)%Z9]];N/W0LJJT=M(X$?EY/[/RU[.THK'RB6EH4%B=:=<J(;!* ISB18
M4M4CL)!S>J];>VZ-(]'63\B#Y_$5MD2;%=_>V%B302@KB'<#P48Z7T(P-&6X
M[24,J[QQID'HG+1V_4X)6\1PBPX.TKXP#3]Z79W6'@2L&(3YH"-7?*HX/#1C
M+MLDW?5[[M6S_&WUD4Z71]*KX%W*)9)?);G :Y>78&Z$NXBSJJ1-N87P\SP^
MZUS.7?D'KF;=QE:X(S-?=>V-%1N:N!O'_QUR%/9E_(WK$B)BQ-(/Z\'T4"72
M:/]<S/[=?C;U*R(6\3*C)_#M71S+TEI(-21Z7GI\XN'0:3X?0/_UN_::#JSY
MGI:?T21@_;*VUKG:P7%H[&VP,R22<KD%IU^.=F5LS7=B)F=M/=6-9)N7&>71
MGZ0C?ZCL9OV12W0F&0R#I(-Z0$QXJYC5FYF[D6C&<Y/[UQ-=OHUA7OJ<XR]H
MW;6 _Z#/@/-2QE,-8$\T0TU&9"<%<*L9P@/?;**X&%@FI))%\?M2*#K ";B3
M"ICBZ)B&;^>@H1%!EVNA5[9JE)><?+8K.U]],^-^(R"2\M[%.)'5(XG6;;P&
M[@B9\NFPDL/!W\!T%OO<@!UPQADS\PH-53?9WNBZCMA6'\W%=SJMYYL+1IZ!
MZC[7(R,X*#=&F^@_SQ(:'UH*=)2^RGU4&?\D\;'!.VU;>PMY!<#%KFWO;TF5
M_]EW;\XD];[3W-/>XGE!+U/^XY%R4L"EWT!,6N<:GE+@B576U#L[1-%?>.'6
M_4$KWS)W)(O :X)EQ,<0[^F0_B0!T1$NY'X'L@WPE 1D[V[ZKC/!:)'"2R_W
M9Q3>M(.]8)!&['K#,8DB(]^OENOK#]$O0[XSK@TCR< QC.X3.B//]U_EOV0@
MCUIM=W^G2<^QL0-]\6/\4B*IUO]+(%ZXZ^F'3X#S@2DX#[0%/^/![?XK+J\V
MU!L^>=36Q4&.M3;]#KI_+=<_W#<[\K\'9B%S9)QR>C]?!M;R%/$CX^UU$OTB
M$7K6UZI/L\KFQH_ZI,=W;-_M#1"RYL+/NPYI!&WI?Q)ND]TH%BQ)&!+@'(F.
M-4JZ)/RYZO;?]K?]+32?13^--*(1S *4);6HDJ @^5']A"\/X-]+H6F&IV'C
M,7")"O#T/MS:B&\\BB*TUZ)P63%@L,>CNE@J8/DR_$"R;[S%LZR7D*%R%+?X
M&J6!!U&@:\?\O!GV/ /H#35EY BIK1HFB3X=#J=S:H-Q!C##Z_4D_YSZW(<C
M@+M36.:GD[!1^?$AV6,6Q7A%S%7[YZ\!?/5E%2 &DD@$NB5BU4*T[YME@8(A
MDS?3YYN@4&0A26I?2<)0=1PI,0C]%STI_HN>-IK^8SUA_YMZ^J]"K"](D60!
MB3B!3,K^9JLF5I$GMXX\5?TB%@;]]V>R$I9\.IPEPRF\ 1M'?0$2CX<G5'L)
MNY2?B\ED[;)HKX%7QQW^U>-?"O0G.-* +3K<OX%WZ0#>9UL$(O>1!>V;H_R[
M-ZF I++]0!"E&[7Z,6(,LUV(]*/PXQZX]^[_W-/&"L;KRI3W//=/"DAW8<,B
M*W=;=PDZKS!XOG):SPP?*D S1+VS/_A0H$&$A.(]4]:+4Q2="O,=S*N&A^R@
MXMO1:]$%A>W>WLC*M+:/,!4GF%Z1IDU+8XQ+"<.=YY&+J6"L H\WOY5:5[38
M<1/MI51H1#Q?:A\^\.F))C>00?SF ]Y3GE9V=^/?[<[_;Z%(>;S: 3TGNO9X
M5,@\0,534C!N$OX8 O"Y]?6Q@?YC;VV]@N)*L>XLQ1$*/\$[T)A<6;L2?E[1
M,4\@C'_T")!.R.C,$D'BLYJ]BIT>_TZ3J9WC]^*H$-X&4 %*I671_%<D08*$
MJ%V[.<;8TZSPL6^<&H2H%0)!#U["%.-O4P'*?IE0!QW*IHI?R^GD#X)_M)F7
M@'TG<&!6V;:0 !!KWZD?$']%D4X7?YN3]IH*2(C2NJY%O+:83/!17&EA(\DU
M$5*6;E8G>"I[<@;T98.6X)[PJM=W21 G(D1K6%R65V(&\OV-2PEV4(M'=_ ,
M"04[OM58YWK3MS>&PS)H1P7N=VIT*N#-['IO!17@*NEB$%",AR];G#+G(Y:=
M>_]Y(ME,)K>DV:FMS/:X.I^]>DK=PTZ7?OJIULH57)[>[PP2&2%Q9\\Y3;]O
ML:RB'PQ<>_4SM_Y6BQ#^.+X:&&EU(^,)TB6;],Z\L+>=<SWW)&LY?9;0CG^,
M6=)O)'X>7*\I,1Z>Q6=U:5(!+RBA"8]A%"3'$@]V54XMC(-8<*HQ%#+?M8EP
M&W7G9+0Y$_PF"#QQ]QMQD0IH(R*B^*[17WM1%6#,Z*.($:ARI@R1Z4#!:%]@
M*U=$!Y!9_8NI!#UL1+]=C,&F&+&NDG0^L!HM>6F#0C_H4I4I+RDQS]S'WRS
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M1/_M?I&CAY^'$)#;/2G?TWJ6?Z1@M66 X(-G>4B(RRDEA_IY?&5?'8JWXC@
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M)O(+:M?^<9<4" /*/IW&S5 %VLW=SG19%U7WH+V3,<VG%WAZ6W)'O;=&%$]
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MMTK;;&G%OL4:@P[AC!"3[R-?,\A/?'Q$6,"*O^\S9P6*)1!6\!FZ!*'%^NJ
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M=DVX]]0FG#75AO><:K<QAS49WPA&M64CA.>%^?GUN-@-2!Z:S<E4[KWYG-*
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MC;O)"JAAYA#D!2@;-NSU,H\/K\SKJV\[PTHIO->K'X@X9=0D;MLA=1M.IB\
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M>\?&A'6(LRH"7 9B>8<(\A)I.=-.[+[&)$_4X(7%F<S/5\\*]/K8X F-2E7
M$E_U(^CDJN%,6G*:H=<,9--!Y))[(\-E!+)_,UHH5?P87ZD/[U2%T"HCZ[S\
MT _#WI($I1]N;ZI783W"7)FI;*3 X7P'-7R'=M@98[2?V=V>XCJ+XG@UI6="
M.@)RC/B8-CKC@Y/J.@;O)1-YWS?5=7,C_8O$;XJ0[.)J2X&9%)+M!E68F+"J
MRQ6UH4.$\XO^V#Z(WS.<MO&#W.*PG&F8^LE&])6V- OG!_8S058=5:<W 2?S
MHREP<YY[^[OT)A-(D=6U_97C;0?O-3&*=@HZ$T_AHS;,KW4+]=&5Q$<AZA+]
M7]@_WOORGK,W<,!97H;T]MR8C&5=)YUZ7,$OY+0HK=NUVE2&WYV_%1F8*(^H
MF#(P@]H5>(T2O/E:I<11C.-P5^G<Z[G3$+7?!YOM5JVPO'FJ [+'_8RM4WA[
M%<,*^\7ZBMA0=/<2VX_2&)Q7S0\.F/@L'(9R]J\>B>+05=O#^<R@5CU45ASZ
M1I-1)C#FYG<R)BR5YR-NG[Y42R3L&_%:1TVM^WI/A"!0B+L;?H*-0_5"#@4(
MW'NA;B^W(J]@CZY;RD,/B:45G?T%3-26%AVBK##<GD]-UR/R#6N_K)F*JDJ5
MI+4T71.0P68&>*<.3Y:N8"X ;5&Z:\\F10TAF[UZ:MFP300[S]X'MB0)(K(]
MS%.";^[4:WN3@?XY58>W"'K3%?\4?[T.14&WXUQZ+<TI\6TY>Y.3O;G9^V7^
M\MC.\*K!VQM(H?4)):/*<?;1_IJTMX)%=K-L90Y?^-5G-SNN@X?]'D+ZEQX3
MGO@#0W?7:BN3(#Y1''D\E)\D];7+)$_,)OD6LVYN9,KAW;Y]0O#9%R2T5=A>
M5<ESK1JST/IPT_2+8B=GS$Z@L4#(.>TFG7^T:)0[:J;UQ*XJ3^0ISD!4G>8X
M.;3;-"-,\LE, +%1:FULJQ8N+K$4 <NH)$ ;7GV;Z)S W0\544_:V>B7* TS
MM$?ZCJAH?1H2V[96POL4S\W/H.D:*B!SK\/W9E?D;#X3VQO2,-CMR&Z.E-8;
MH^Q\V@T:$Q<C?/FE[=CS/*B]8:DM('V/]PK/;O[<4(-D_,"KHAYASN'92D[Y
M:;15YH4&?2/*',W)+CQ17X@!%K2KM3R(F_@T>:PNH@C_9DDE?D:7BZ.]H'#U
M6[2.<=UP[#UGJ:#PHG'!0_;E=*^J*MRI-*%4[4&T^$>V6UR/^75XH*;VN$W(
MWO:H';^5,0$\P8[I2'2RSI\I0/+_$)6NDPZ5,^BCVM,)9'C+U3UPA2VSJF(Q
MB](S#.H$#"$HD*>.,@)/GY%$B?3I3+/?U F*=TF8G*XPQ^O[V^6N"]'C[0]O
M0I^F[N0Z/=)X^X;9,Q+@7_^5*'(A4PK\<HZF%GC_?IO)6^ ;XX>5%P !SKY]
MTI972S0S@9OIN%*I^)9IC0_&/KN^?&?>F8DWK1B&,L \,#+1*OBNR;1I0^V6
MTM(@E8GG\U,Z[+W9RAJ'W*HF+QVD CVFG(L8<*/#F4)#[_P1-G]FWK.G8WID
M8%-E6!2<NFS\PDC%<;BBY(5]LVK0*LV@9%=I1?L<<T2['^W80=CW!SLW(H4&
M>WX=&V+>,[?4R!(MSN7#H!*3!VDS/_CKY4LZ7>WYCX2B\N-N\^M%S3R=F9D,
M[_GXC=M6"Y^ [*[<W0.;.HU&1 M-?N8RC2N>[W]4X^>02,B3<KB#CSDE;AUY
MA_/FS["6RV#8G]L@UYR^\3CO15SQ#72Z.T '$>(G58_UFH"[77ESE&K<%5@J
M.LGG()S89=G-6;9KM(/$(,"U=9B5,8UWWC]&*[\='+]W"V0S+(F8T+ZB!D+O
M7_G)'++;"KRZ84+6A"4]VH65;V@IB#JANX8[F2A#GGYT_)I.KO:TNQF%+/H^
MUZ(+28/Y7@!ZAY9;ZSTF6?)I'[_?K:IQ78?O>C?N9L]I*%"AF'7_VRN]_P<.
MJJR\S0FI35,26L*^I3/.@YF-OUO[:F\7;<=B5]<:_!TX<C/K3OUSZT5U2I.9
M^<=UY=@GH_"41=7B&Q8M=Y%Q^TQ^1[*0"HI0SX@.:32^Z7E?QY+%AY<NT_WK
MI0?@G2;3N*TQ<-JTJ6=6RP7@CBLCI\ZDQ>3[JD_V:J-6L31,'+K'+P^)'1G6
M&C0PX_/1,FY?86&5NW<,;+"_>P9M\D!6<(K/Y51708*F[%S=IA< W2PM&Y<G
MI<9B$].S[DU*H]GA?:B5K7$NE^(YN>WQSX;^5-6?W>TVRS;&P*D%^:@8>L\*
MX_)1L6^$)^:YE>Y;%E4J88]28D4N\^!<21I EFUG(_8"$+8C\]"<0>(!SH0E
MI@WRU<B(5W[Q\W*A;QX#42(G \8I^O-28'KJRY<GIK[\EU%RQ9DC3?.#LV-B
MXM96PP[8VLZAR<<T>TL;_'ECW[.GLX..(@1>K[':L%*Y_]NTW_PF-U7R]=>D
M;RF21U>[T3KVC:SXH.:)1L%1-]K%B4-9#KZ\BCK!3Q^+I8L>QX&)N/5<-T14
MS:S9:]C3?,6F&@TWDDV_Y*>-%*QLV_1P2ZC6&6S(;-L\VG7@,57);%;P2ER9
MCZ@G^>;IO:0]B9K<JJ)?KSQ-L["*/180N(TM#U F.]N9SUY456F[#!VA892;
MO0X%-G39P;SM>6_[OA!;R GG1N=FJG.&QQ0V@L7$>A)W$3Z&D%3> 9F-A'P.
M\6T']U.3RT0"[B!]4(:NHIAA.7U=M9]["E*7Z)Z3V!J0L-N,Q*9B8NY#5<;K
MG\ &+SWPUGG:MXV)O1MVU.KE(+L4CX#7KVXL!LN"-FZ6IJ.]T_R&-*4V-=DM
M%$%]_E:10133-%ZT'4[IU;L- U*ZNP*?65>>L)=,S^?7(61Q3RPRGI5\YM*R
MF^/:9*1$E,;[]QQX'S-%?=V<D'LTLCA6.74^:BED%K_U=F""^[<@<8BFE#O\
M-K:!HE..$TL=0J"UL/NF< ->J@*U'EL.I&FGO/?]V + ]48\,"[ZR2'<LUX>
M!23;E-H)*MQPVMA)%:V%)^7B7,-?3+M3NFI4$MKN=D[*YA3<T$@(MSU!^[[/
M0%0U<2[;*$G I!P3(FR^S>F"C-M?3JPZ6-7E^[@PI2EX^A,X&H5'H1273)'&
M"(*957#AJ%7//PL14U*TRSL.6B7U3C>[ZDE#M>4]D2=J3'<!>/VNK]C&@7U5
MT%&/.ZG#_W9']0-7 [#:-ER@=M8V;C*XCPN5R^7\8XH+8I=J)TN_12!$5 67
M>,XK#%45\SW"[?>.(<2/Q=&D\2(W[+YF%+E_^/UVP1$R@!!#,-CX$8=VC$*J
M1Q^&2T^YREM%W SNDGZ@WO2#AQQ$V)C(LBB<A]I)Q&TF\-Y[-S3[R6!" ']D
M,_]@>>FKS,[I[\/2+PNY3#;:J3:<54>ZHPY =9$/!9 GDL^BQ/,YF<,$0L"3
M(/Y!^*2V=SM5&T%G4LR7XM6P8I@+(WQ[!^Y@V?BNM8#]M^#/Z)1.-<]-_6E^
M.(J1&*7-Q#A>%8<PF$/O>C# ;1CK6C;P/Z?&[F;67P!,WBU:2OD-@]S<)TX<
M1N;#YK4$@Z7.FYMW$@_*G6?@Y\O>LIH3;FE "K0'772V9'4%TGCOI7;U#:>A
MJ^J<7ZE0&,_<3@I, \%VCOTCB;N[(<7W%[IO]2.M?1;NJ%',=@(\^NT(>EBW
MX+;,^R,.^1 ?$G2"1I-V-$@9&4/Z[=E59>N? \#0*M=.@>2JU_8;V]*F6QM'
MAC,6@TENJHLKND).T#*GU:HLZ4J3*+3OKE4<NE:\S!I%QC^C,;I&+0Z^U<BE
M??>'[\VN$[K\0L].I>'#6:!B?8.>&,\% '\4D,MXYA,8F,[P-G(I?.'\%CZZ
M?;=>87&&=MJ07B7! W8<UTU[*@/C>/;CVC5H=,;I82E).Q/G"!3D@3HSWLV/
MT?^ >GS QEBY0V7WI7K%33.WS_E,N1/J!K=9(?P*&XV'%LV*34+.'8;3#RL:
M7S%*89U6$W=+,[>/X0A=.+,V3B[AVPY+^,:MAZEBJ;24N9VL(;J:@O+$WU@K
MZGE0-Z$ZBPT2ND%,QLLD_,28,F;A<V(V3"DQ:$S&%'N]JD%%&4LJQ9$!7YYP
MU[7JYKCW!3_+(\@K[%\W4G_BZ07J3?FVM^NSN_<*MVEATR&X')$E5?MRNMCD
MI!*.-('!# V?6SM0-=2#KMUEB9;,?5T4?N-J@"2 ?)S/JZJC&-5TW[/1@6)J
MP_V$&&?Y6<1TUM 0WASO=>6AQ3WR^T'=M"6J6BCJ3P=91/A&VE)S._^G#4BD
M(7[Q=4)>?&?(8WE XAMR8MJEU#E)N@0;+IXZ&\2TNRIZM?Y0<BU-(Y\6U/*2
M)\V01^+:C(KAK/Y._/"&#X?5NASK*$$5(M:1YH3[8IZR/5LM_$9!TCR$"(9X
MB6)IQ*J'R/@L-DCK3.9.E!SF_P!';-E0Q&+;5RUO[RDYI(F%%A">3N[(  N,
MNOUKO>I-4@V1"33]9;%!3.(G'IN[:I*T(!,^Z>E!0S=CQ##N.(%W^FX&C)K>
M6'2D,5S C<>.8W[%8NH= HB5B$14 L,>)"F^<0T>+A4H0&H;U2F"B-V%)1E%
MPI?%HGPZOQ-$$CK*/,-OTKW37;>)L+BK_,;]BGO-M21 T+[UCT)88(8:N"]9
M#.ZSLULP9Q(\T5^HX7;O8]ZBS_3TX[R9\=+SNG4?W^=N7M>CZ@9=1-TQG'R\
MI51@)#N&)Q ?AIA%2[7=/!<>)7#!:"2N[\7[U.3Q>OU:"/C"J.AU^?<X/U4Y
MT$&I)W<>3?B-I-J75H>@I!5BMH=OF0M5<#$_O-[J=#9$X3T2<E7G,_O*N^ID
MD])9.#[ES7ZXI[5NNMGO7%K9)01WT[ZQ@'B#0/[9Z*EW&Z158?\"@+*RBUH(
MLO O(K]_"<>[=X323W6#O3*.PJMB;N)S5GN.-.P,IEM;CNCRTKY&LXEV2Y#M
M1<N9)@.6&D7T/4XFH^HE%F8<:.<@U4=#V^$;:PJ&HLH?A>_NY06M_28B![$%
M3=:74.;W]G+ X8UPW*AZUIQA?ZYZ5N8]*-*^VZ?0X.BHZMBX[EV,69%X+5.&
MA:^3EQUL>F;.B*'?B9*[7&5^U4S8GVZ!_U#@_N8%X-[A-I':9+)2644U\@?H
M>KJ+<GY@3U0K#?OR&M#5@E:L I/6-AUZ2>S9:XL[Q0XO7<19G>[:O:WW-Z8E
M:8FK+&5$T5IKJ\;\B2?%I4D2^='YGTH+G:5A/!(0$_Z!:22>CWRDPLV!S(9N
MG\W66R<Z9Q@3LC/+P7/PFYPG#!^,XNGG,=++QY9F+*I*=]^0G*#\49?Z3 VD
MI/5Q2RCSL!?13G&G'[,J^VSF]0=?1>8[_%\$R+Z_J(WP(.WZ'\V<Z5<2B +%
MJ6D9,Z=IP32U32V+7#(-S:UET-*G9J4H"E26"X2DN.-28YF:RZ@IA0NE::4B
MI2(%HIE;8KDF"(BX;ZB@(I(+OID_X'U\Y[T/]R^XY_SN_7#/M6O[N#OWYL-)
M-,K]0'<RZGH6)4 4:^$Y=V^LT:?/W2D8=*'VAI ;1J4C%(0K9_CZL\/4>+.;
M*4?BC8#:*1=+'G8"SNW(J.$[]EK:#=4EP@+B2D1HBL>T6]"W,G;@YTXZKKG]
M99I7KZ$*7#[2 ML1GN,TO[68I/6M3$;\(QO5^=/AR%6=S*T+%W.S-@!+/I(@
M>6YO%0>.C05)\87AX_>QW.9GG[(XAHR0MK:P>=B ])_&-LF.7$I1D-_Z_^4\
MCO0?/H-3;3Z(?*[D=+G^Z_979F(8<%25CJ@KC7*?I_O#?D0"W(,7 X]ZZK=5
M1NA3H>'-0F9F<OZY&S#?1M)N42U0(LBJ^NL299JVV-?ZUN1\@8[%TZ][BV=?
M!O90J.A3RJ'!H]4I:Y2#F&!^-.55AS/8A4[>EC>>1?8/ZDC7)8M+!EC+DWA=
MX 31FCR\2R5\I:.!WOZ6OE1<A-:1+?MP#V<?3]/(^O,F\/!2,\YK(CY$K"E<
M,\ALBH.>(TNK*:/^Z7W-@%L&'6=.&G_;=P:CMF4P&K?RC%AWKI*:3Q^038V*
M\1HU;*6%57.<@0^;X%5#%L)C= ,\!R8J71#.$F$S(9*3F,%1[-6(#MKV\!L;
MS-[,6CBQ[?0'U_.W.):Y>$X9U/KHH_>+HP31RNM_WJS5IA%L8K=,8+.N2Y4_
MWN?BU7+_?[WZ_G\5-!]EHV1396*%=E+T+FP JJB591$DGPX"ZY"AQL]5$EZ;
M8B\]!XIT+7$)*Y[=  !&&V_Y#1/T_00H^E+7S$WT0:""/8]]0JVC1B"YH*!:
M.P()_!V"9)((&KC.":O2S,S!==[4\CDM2N*<?LV)P!-AW4TE)DG)?*+)\]R2
MS/R6=R($ >*_TQ7EK\>L(82N+#$BY[RAA@W0H&<CI4(W2G FEWP@B<[E>\?5
MR-$1WN5P%$*-PV]H7C ;^41#FWY*9!GTWMV20DY=&T]0[.7S_6!G2=M>&;ZX
M6]I4U@]WRAF8NWN[(]]6P&V.^/P+!2;6>[/$DCGD8'5[(&&<<6=9@.KL C:F
MG,=@@+AP,=IK 9O@MI]':-ZEU/ &Y5B$B(Z?*ORT6^E\L['Z;[]LMKCC-E;W
M!8TG'T?2V$LGJ/AUK"^/\@BM=/7YZ80?=_2N;=)",PO((R>#+O[>DQ6!Q(O1
M:S7)A5F=(2C74C&N>I:<-5P@95+0(C2W;U _1@-%B\S.!"=$73]+\R]BT539
MI7[O?5Q7T[2WZ7X5\8D_.M>V$?]5>\)XP+0Q<JFAG94^8Q0/+[K0VKK\>04*
MA?B><O4 @=]D.)!7#,:E"VNF9U\7A@FJ!]@"6L^E5EWYD9+O0\<EK?-QQYXF
MZYSV_U"HJ4EY7E\A/QSINYF^VK$-\7WDZ:$]GM,B]*E0M'<85G95%*CVUR>>
M0U0N*5*D5YI]MD9QC"Z%ATV-WG4&?;DF/ZKHX!&X3')8 302\V[B[ ;@5\>T
M>*F&A6. )QP)(4:03<T&U=9GDMO)ZMY91QYH6XY(2NG8!GS61[:I"M(K$\HV
M55;M88MF1/ON7[037*ZW:6J=R TM'T]R5D= :V@+</AR-8?-!VI2E)2#&M @
M.!_"JF+F.#@PH]I_6QW"\JTUIV* BAZN3/5Q+4<6)5[@A_4+FF.*&>@VLQ!E
M\]D [3W\]I1]Z?G)949VHR@42)W][OIPM.=/9CO1'6:";=7J3F.!*SB]BC<O
MP/7K%S'']#>/--'.R&'' /X;@+L73B=Z@C0<<[,T=S%X='G4R6J%273$\1U/
M'!W-,:JGMBIKF]WD;@#0:BT!5";$W](51;RR/)F].D,+%>(.>,0<>.JTF\>O
MEC&SR9/E,]4+1I;((:3<GF"'I$835FVNTW[$]HH7+0N<V@O5.Q"!DRA0W?;U
MTA;V0=U5A+"":_6&&U4VU\\5,"R]>X#=+A[-U,OE-Z2]T:LY#LJV0;AG(1AK
M1@OVX^"('#ZV!B+4DW@1BZJ0U3#N2L#SMF5P:+OU<AW53Q[[><)N'C)'#8S!
M^F2T*VN$KY'_'- Y9+0]L'W\)^,VG7YR+(FLJR-L"I6)T(K++/.8 WL>%6K=
MS( Q]UUW**]F"*5VAX8IF_K1,=J5'!.!^]1^";?CCGA4W?)K?Q13Z[Y+ZI X
MJ4_R)'Y($AL?/'M@^Z)W98+M'5#*;&^.5D5C+I[=!-Q#N7;_QJ@4*8G]3KRD
M9)OG#TV.GJBED"G%+!F4YOU"<CS.^:%TE?^K.*;76[>?H/I!K5KC#HYD:)$Z
M^)O3_7/$^EJYQ]M3O!H8.'&L2YH'@Q*G&V$ZK\\D7_8.LOTNO(1(A/A]</4&
M7UMA2ITEU.0BPE"1O4E$=-^L3V]->=[L&%YS:\N7ZA[LC+C&L,SFR=RK2@<E
ML*=^(ZZ1%%R146>DD*',:W]O <>%Y!U9\C_V@XI_/D<QO?)J:Q[[C_N;-P.\
MC@$ZU&W^IN#)VD](9SPZ&-KC&L:0^F!!7ZRQ.%LB54!U"X568$*NG,F>#TA#
MT=F)PWC!A7L8DTVX4R7S<[]50"K%OF,MB"=6H >277'.*=8:#A5S&&-;CFZO
MR6I36J";A[4=+S"=S2Q("I['O7%.#R#[<D$,F( O["1R,2=[!1Y1^A;D$ P$
ML=S-.N%'P.='^TK8*S9[#1-,F2%+JPDS197X6S[O"YL;YMZJ/%R#X_($MJ"O
M(3D)2X9;:8^ESOM0^R]ZJ&H@=W84)\P5K(^'.NHI@*.*7VA Z3JPR\XH#_S=
M% _CZY!CLA>G?,<#;U?8AQ0,V7N]&]@ [,42.9P7H=Q%0^U''&M-8;^<A=P]
MR=L R"!CC<I8X[;;A,./)Z]^T'"RIMH?BELPC+.$O'0N;PT.P7?%8._0#MYV
M>-Z7O>D]UZ]^!'L=D0[!G;H;_CJ3)]CO2*5*+<:RAG1/V+O$+)NN3WD.=,,0
M+,7EX1$Y7G^\*D3?]SK<<:SK==><"^;14=<(,&$H=< :7I>*=[-;.ZEE*W*L
M[ES:I>HE#+\M(!R(J()D7^X<TXYXV*;W6;&[,YCB4) P K+SE>M;F?2,[F%)
M,N4%:^M3:#S<*L2);U&8TU-S:)TTDH=L1*(7;:KTA^)F!MPLF7G+OKDK-UT&
MD=LW %^ Q0B/=<HLR8])%,=FC<T.X&CJYBWDX&=NQI1K+H%8.VR#=XF:O<GX
M&[7I7!*R2FS(W !\-G/T'FHO/)YL:'FI0/[ ?S_X?0OP2]LMK8Y^M:W*NRM3
M^\<K"^0F4T.?3%Z8<@V410YE&N_(B]K@+:51:QD7+#Z*NIG&25QO=)-./GN2
MCB'3-3-8[S.?%>DQL;(B+#[:\&Y,M3G3KGX#P#MHWFT)D=49KEH/^%E_'_/]
M)A2&AK<4J^#V1!UBP*TG+E'GK9IHCPUT#5;<J;;I+CDXV\R]6==P?4M6Z.[)
M=_$GJ1;_!*\#M2<DK'P\RWC&U*=_A(&9[IW+P%L1[46^F%1<@T(EK4%QC&/J
M7@Z&O+-#[X$ES(^>TOMJ?2^/V_&RV8)CBI4$6,3NA/E/E;:J%GG''GOE^^X2
M0&5OY9X;KW2,!P>3%Q_^;;PR$&8P#6<$NR&?"'\$M;VO3 /%YR]#9:0S(J$K
MOR@5W*#8Q*B<-Y0I&.2SC!*[3=6T6_>JY\\_&GO_@/1\9:+8KTMQL+5PS2SN
M2Z<(;.2X ^AHWZEVQ\UX_Q:5EM3[MA'JY:RD:TVNV6(:I%O6,]ZB6;=+I;"K
M5$ 3PY8Q@H$V>&^5631H:*YH _ WBLK1BB,*WJ>># C5?>9:WXD07E-2AN>?
MX8,[.8$08)Y]95D/R?&L@\16:B25M):@P\)"^5B,)V8F8X=>P8=S__$LZ;^D
M71O<?P-02P,$%     @ ,();5EE)DO!:T@$ D^D" !(   !I;6<W,#4U,3@R
M.5\Q,BYJ<&?LNP=44UVW-KHA0$!Z[T5 07KO$%!I(B*H]"H@(B5T0@V@@/0F
MH/2F@ B(]-Z; I$N >G22T(SM.3G_<YWSOE.^>\X][]WW'/'.,Z,)UE[9^TU
MUYQKKC6?M;.#^X%;!*CN:6AK 'AX>$#BU0O +5'MJ<,<GP& KBX@    ,4"
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M7.V"[!\<@GF!("]'JYZF6-$#:C;#@-=S:G@Q5,4O7X9.3S5#(W,IP2'I#W%
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M2F(67C=G8Y-(&K .H/*KI&_$X'TJ1YLI6_;N>O8D1YH 5QM^_*M<^Y&_->2
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M?_?HS;.']S/*^O96Y!#["IX;0*4*=,<%O%(7BZ5HK@]@[8@1,!GBC=-)TWA
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MTUDJM'?T*0 -I,J]#YG$A6E\WZPI3H8K=I63>35N.-2HVI#O<YA5&_5K1L7
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M;^JLY<&RV3A?==-,@GECO$7ULULX4^2W1Z%JA_CW_Y R;13IA08^.Z):6='
M+^X):2'H$)C06F!'TNXY[-F/CBWSD9Y/B5\ J;6@N4)$78>D8TQRO^W'1?ES
M3N*$-$^= ?%^B9=]V-&[.,@W7W<SF,?))^5G'HX?4KE_6'CR([< E_)227P
MO]P6^F>%5:Z?'1VTX8'1#D@;QA\:[-W<Y_).^MY5##%7U!WEVMD)06^8'VDI
MX)#F+*<"<#)R1T0\O'+YF=J$3:HJQ2<W0HI-+?^A5T+[;887A!M^]V$7BC"3
MGNG>SVS3W1<JE!N-[F\!AI57BB\'K@AW"\PIH<MBW9EQZ>L3;B&G]"S@LAVR
M6<>)ELK#!9-?&N]&X)$YUD.]3D,),3$79;X=2S@3TG<9^R<,5_4:N2R3-Y+2
M<+*#B\374^\PB@@:K 8]U>!2R%VA-K\%H?-W;16 Z::OV7'[FNC:%6@M/7U
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M4S5N\'C:8/?!O?%_XT6Q.MR-8?S0-+L #3C8@$\I*M% ^WLT0 >N$\Z\(C2
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MA:%(>F;&X=UD9QD4:*#B(R;TO/T6>%3P[QDZ*+O], %&#VIV3<L+/O<YV(M
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MUKYX>Z2[U4KFE2Y\B)Q9LOP?[+UW5%39MCU<B(J ""@H&100D"1),J4B64!
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MILI/I;2 I1F5X\=&U(Y)*3@41X<0K7\LQ/8?>,]-C2;% ()/S#Y)@/0<<5\
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M;_1?PB"6Z9@".R7HT-W8&;.R13\NDO2 ?N_*&[%&/B#0:X%6:*#(YBR?BL$
M>%-1H15@+&LK^Y]SJ3 OA<$ZN1PWJVD]UW:#B9M;+OF?P>8R=N6'PD352LJ
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M%3<JJD/F*?3&OU(@:WT.=H>S6Q1N2_0Z,'65*'\&OE]\36TY.[OO"R6?.+,
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M2,W0+#R*HJ\S[V;VGL'M3M8;3RZ,^>3,V5A+#]OLP$7Q.;>*94EK>9.B>7$
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M"EEY_0>;FF<O:A_?5S69"Q!U&O@6/%V,JPQ&2#6P]EG-<"7/2_%)K<;+2KS
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M-/Q>C6[#-A0ZTA*@=JG-,5>#Y[,AA;V]4Y^+#\VN!B3?+9J5Q=33'=<NC!'
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M2D-]_QQ4<=5HJEM[A5@I%CLK)9 %:Y4&%N )R9H1BW.AORO^4/5%7"<NMZW
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MVC6W!G+D3%']/-5>],7UE4M PRAB]B[[<7>FMK;$P[K9E>>/C;?U[-[B*"F
M63/X;*B,T*+TX.-MUJCF(Z%9@@D+4JUG+0@%LXJ9YF)IG7=CQD-GK9$$Q>F=
M)G;[_N3JV QDCG2HPV[Q^<D@V549PMQFPTJ"AO=Q]L)4:ND0)?@%[H\=A8%'
M)74)9N&/<ZI6([<(O(2\N!1&<H$J_=:6*4Y2,;;D503BN590N3W\MH_)E8,V
M<&>?-\P,K ]PX@LD>Q?5:I0S-T:/;2\!AKJ\]R27*C1?FK0-P;2$/M:GC(E%
MITQJRF[LX,X5'8I$J.=D1)(,4<B7:'U(M/J1?$_,(>)HYPCA^'\I[5&KRB:
MCYJQ$6E)(Q"YQ/U@C+SX+5<OV>) $2)[%^;GE\TQ62!I]=KS.IT8E,#N$.T%
MBB.D",]*E1__,J!L7_)$2%1R\?SY_*+.1N G^E <\L65WA]2HR&]%04\^<4M
MT;%E>72LZZ.VZ\=+1=OE!@0XLR)VK=[OB_)$^+S<OG;F-!O>?4$>6.S9]2 ;
M&ZB76>JX,(50D64]UOY9KFPQF@UB**+,.(E0'+"D&6E<#-![_M#K79P -M5>
ML"BH?,@:7")&P]>3E54D [!+%+-$I7FYHLX#5T6 \U]SY(XW^^,T]+%N]<8V
MQ7N!DV1AGSCXK+0D50?SYP>1'2;3U@U4A'6NB_"+&U!)598^^X0)BP[O]$%[
M7_[EXG&2PR0<><1:AQ?^!!U/Y/ZT (#J?CSZ"T+)]::FE9(52*F\]LX8/3XB
M^(/?]542#PB#-^D4"3UU$0%X)@O%VE6'/2(;?NM>J/B:YU=57&+1L8H=RIG%
M("%WQG)UYAE7ZOE!QNJB(<,:3C_VCW4)3VD3I=+-3F!-3RCVPD8DWL_P^$7Z
MN1UBK^L^>"N#;AGR<YT>1%\SGZ%2KSOQ<C,W)IP NWXPHPP@;UL@8)$BE+2^
M)R<95Y[,^BH"'CXM*GH'7[GIMID9=6M2MG@6HNO;PF,S.RH",K1J.O#M*Y%7
MTYN<SYUHVS\P+GC'&$"6-<IB:;)MG,SLV$JBLD:Y6HMD*R9:*AC<%P.W2]TL
M#4:45JQPS_8W '<<FFX;'Z\*M)_9R091*"LX^);U8W8& E;'>= /Q?(9V[J'
M?0M]^:GO.,+7Q^YM$+.$9'!SN_O$MB,FAK<F@@OMG)P(P^CA/#2W)@   J^W
M.7RKJDM.P$=%@F:=7:?.F"5>1/OO3=1@A0H+[FPOEI7 .Q[[XZ:>7C 7%R>B
MMX6ATEWA[;8YX*2!6N6F.FH?\9*&YF@EPIG.D#X/F!#R^[S)Q^BP6@IVQ#XA
MP8DS_LU!['NZTF /=K X$K5I&@A:G[\U& A7\R\DRT+0I@2R_O@SRF.^FDPU
M_EOQNCG3>BHO0A[*/<P/06T"_S+2L*:*/_E,9BAJJC1YD]9D,=ZQQ_U<,7.M
MRB^;N$ACDER)HV[R_;O3L-C!\>Z2W"-0E'II(*]:I+^_DZ[";&]1L?FC#JQ.
M5I_##O(<ER@7T@=L-F[W)5B/U-+6NZ5B\K!:9713*)A3DG\O;_O?*;,&]*4J
MJ4GK"#&E(T_%O77>,TFO)PK^=)2?6+2ZVQ-F)RS/%AYM%*XZ+@Y^:J=S-"^(
MD&"LZ<J15%)3.XWO]6/?MBRQTGK#0_\JZTTCL,6G1^P+8S9?2\MQB.CT=LV/
MI<ASQL7HXXE;#2@N/=\;N:0C"WBN2@)O6UOT0**>7*FY&>*&<2'G\N\.R1OR
M60PV]B5QU67$,.IOS^[!LN++[P/U2XEZEX!)R+J:YQ/*[KFXK)05J7LY%[)[
MVM_6^=7./,9:;DZ:\U3BW8\_6HH?BE+CGW#Z]KX'S$XK,QGN)K92ENGWV81T
MIK\P[4W)\!F(ZJ8O88+-(^!=L2C52\ P*2ME)MC5 4W2[VK_?6*D\]4Y"::O
M\J!<M4<5M$"'^)62?$_!M.DND\0.O,1TS0AP&(G]P(^9[[,=Q;Z&(8+??XIE
MCJ3X$:@L5>9E:E=?3-Y7\/%17]^P3[Q15>X'^I*>*+ 4+C$&;R"=.Z1>K^H$
M$IY4L<D0EZCCRC%OV[T'A^4'B8#3VSS9!_K5G*SF?>YB';7:G:E!@@PJJM\/
MX,G),%DM?THSWEKC"FL3O  )]F?+X9O5Z [7RD0*/@M*W#3852V.DTN0](RQ
M3A,P%*1U$OQ)CU8='+82ZM(P+SM&A$S3*DDY3*'=$'RS_IE;Z\P)O*D=US%*
M6UXW ;CM6W<F>])"]74VAY3N.A.]HLGR>QS+O>5\TUI3+6[F^,/% 0]C2*6G
M'$WH:-&2V9 [+OS[XD(X@:K,&^Z<=-?5>78W5N0%-O2(:NT'W^ROC,?E1O7^
M #8)B,7C&KC\$]WO%7Y$:,UO_(EO^6ND,CMR3MRW>^ZX%3$SWVZ5-AA#V04>
M!%GH>HLRXN'K32^6ECM)=\"Q(I4 4T)[L4<Y/_:HEWW]0D<ITDM<%!&$[$Q/
M)Y-PJ-U=5@?Y9 )2P] 3>^6H4_E+P-ND"XNU&I!'W@S;Z/$6/NE HMI:F9E@
M[VBI W*/<=.E,T,2:PG[(1,PTE&/9(^D[:-193A4_-HS5=7/X63Q2V:3(3UQ
MM67WGFSBM8C170(^>(_<)WX$#1C[.!R"3=8AVJO88CU*MP=HNI'G.Q^*AW#[
M^0Q>22#P^!;J 2HVLF*F51W%B*83R8\F((0<NH%/<C9%>++U+:JT=2R<O\_H
M\^;DI#*; !S>0SQ#OE<NG4031M69)C"B/">-R7J7=9G\C]J/+D2W4WR_WF:!
M(ZCV 8(7YO7B=$J5;!YHV?+WX+_8@'$WH>&C]4L(5[H_$J.>9C/O_*MRP'_/
M!15)B(U9VY< =(#6]N\7WA!D_%59QHESS<#+HU0;6MH7Z=15$+D-J[*_C;('
M:Z7$1LY4IFJXNO_H0R,;W;#8$A5N+[[EB=#5#Z@QG-#=7#]6^V3'RFP>^S+R
ME:3=NRTI/KJ3A)(=O+$-?P4I[:AF!)[E+;=5,L%U+:BA0M0MM9D9@5?AA<E/
M(3I8@5Z/A#HHJJ@0 /$CXM(8<1W_9L*C1.)?OJO>2X!I?MW5#"UYK-F_F3[_
M/636--HV"U%]1]WBA^>*QQX!M]_0"XPU)'YP[A!Q-QHH0:+I=#H=B,T40@CF
M74-7(PX19ZO!=4W9M<$Q%NS&'R/#X@2FA-[BZ#@H]'G:77S-8@A.AQZ;FUA*
M;BC</J3=%RN%/5*H^F8C8I(ZIB<'%2ER"^,?F22GI9C)IVL6(V-J_F9!I%&*
M3&]ZYX!;^"-QBU-\O5<O=29=.VL\\Q)P>]OW$B!J>@FHERPVV;,Y#@DL:2^)
MR[Z!X!\/S7ARSZLMW1+V_?[\SAD.!LN;8]906_7N#W,T^\#2P&-C.56#0:$H
M P*/<(A%^FL+YR%%"7&I_TWL&3AQ5TW*^8-M[DY'*]5WHJ)<[B>7J;(1OVR@
M[FY]^C/?[)Q0[1*0K+N#QJX_4?^Q,/]$3YX],TB/VXG&EZ*J:B0KD(0/U*)*
M!E!HP#H=N 2\WI@]Q*O%J!XNOQBZOAW9G-V8N03,"6,45H>LX>".& :^0NK6
M3)C+@V@G#P=>MYX.!E/RL_N*G6X.(EQ-?,U%$F3?Z2I9D\0G<F%_Y[\(^/36
M?3/./_XV@$%V/N'SBIIJQ&1,:H^S#(BSMR\VXL]/H'CACX#UL?^\!&#-HE@F
MBM5&]X#U*^J)^ROKBM;6##%&9.)T4;BBQ8/)*7*=V7D#MZU-78W.PTH^Y%S@
MB*M='0-PS+W\XMH.;)<:HZQ%L^EUJ<5@Z^O69I5"LV.G'#^V.Q,VI9.._HPR
M^"27/8<_)/%0!ZT*/OX5G?2T>A:% ]M-O3*R3K6?Q7B0KI'=^H\I@Z6:F</P
M8O)0YH3@8P6'V7C@NG;?YAF)[U T-&_C2>YSHNOP96XOK%=B"8A/Z*;A^K4'
M'A@)N8,FOCIIFYD?"Q1869^41_#[:H6I?>M6.C^74ZVH&;O?8]\H]7IR+R?2
MX]^<'E#XJVS&R9<MK?+3*4$D__9]+!Z"QX;+T89_[Q[F8X>MIBC=0%[5G2U1
M;?0[E_H3@DO O-25Z1CO+2;0=&;N5Z__M^<YQ$RL2]!D+%5"[^\\MFC\.>=_
MUP'QY<U? @BGH.5Q=%W.:S /=@'%-5%Y^317B-*0313HDWG>0ZJ:\%9U[$E1
M>7>OH*"Z.-.H,KN/"^(-VY#L([Y9GT99Q$I6'K!K_:N_@TM4HY&13<9X>EZ\
MH4"HK7#$AI>\1DK@&6^XFE1.N&P[1FP8_2=+DE&C$9< ^KI)=&4+JL44)5H9
MPY>=%QD20<\0XV%,Y',6=C)2)!:3X\HXJA"M7EH*8WOR(,P^S9E5.NOQ2I_G
M0^CCX]'LK)DJ)(TV=I(U-Z!]-<\C&%SGJYU.'*W<#YV%[Z1(U-]Y\>VD7._%
M>9T!W9XA+$]E"&O4\S8=1[=8 H\Q!Q4+7?WY=6#3;D[=K6':$.4ALR'KK^]6
MFU;4<<F6(D8W9>8N#&<&-8;8\E>#A3W>Z^I)87$3UE/YG.&^RKZM#*<<T.D<
MU+U!+M$BL;5MKHT]CR24*%0N6SC;YX^&4Y'>J']8^F8H1::.:1WQR.\:?@/1
M% XMVD!-K3JWT6/QT\U@1ZBV9@J-P>ORG6O=20KCQZG-54/.:.[2(=Y3P\J[
MS97[4W?=+/.E"B_>1&HPEWK1,1>$3S$(I%L'%#1D+R("TO=$"N62V(E5X0YP
MDNM)74D_*A=!)5!*8>)GLMDB[.YSWB33%J&NL!8QW?V-_K$I2]SO2LD7N.&"
MU-SX#NX796%FQQY>C^:FVK_"#\P>!K0"D&VBHM 0$EF=?823V6JE[QLQ,^$U
MHWX)D@:'_P:5XD!?1D0DLK6@30J#R+G/WW13GMK+_&PGB=0J3*<Q)Q+, A5G
MIA0>(A+<H455I9_OBG\+[2\7+N(4V_N9%Y@%2=#K=E\3Z(S184ZI++AC\;,J
M.-V+>FG&4.+G P-*-['W&4Y&MUL)L]+YR)GK,N4D'!+O#A<X:6QW'\Z\#HJV
M:7] WIM\G!\<R&>DAFLW_H$QD^:7)\E"X\]T*^W2L[LA*.V2JO.R.MHR_H'$
M&4_/KV#54PF7X6;/YX,K-;OP<C41O?5PMHMBK';7'@A:.';CT$N!VDRB>"BO
M?ECW65'687L/F.!S0^4O;__OIF4K-8X@\-*S48Q.1^YP"4B)?<OB"D:_\,)#
M-XY< L[8H(:%J"MUZDJ0+OHAS\^976E<*B,,<^YR#:(D (:M*9,+)1EORKUR
M9G\^5M\.3:6'S=X!4RS)GQ3M7AS[.%BV+B+%^_>"/A@ ^VW!,WSK9R.%-_TS
M:J?;V7Q*[SHYB^*LGZD_L%K,,AE*35(>8#L.YQ)BU^6:I7<(^9ZG$^4BI/4C
M5C1V:NGE-]H(NH1)29A6J70N^7.6ZT2A4NY:[T.$_,ZE^U$F.0DR=)7!YF2Y
M[YZ<6E5$Z0 ]0QK<1^I1#-X8-)CDB)&.XFC,V=8LKH7[\"&;I=[*HP$=P7")
M5PX'5$L$&456QKL2/3F/![ZKWIE4,@L[YNH]'V]<S#I;*)"46>/]!9! \QA]
MA$;@#WWDWO#4*/[5=M_?I:;_W;P\D:M/?@EH]_^W+?TM1B=7W\8?8E,PB<J\
M_$&5SA-2\Q49,Z8OK^Z$8R1_:#X8LJ=2Y5V997&MBW?4X!VY_35^[QBP JB?
M#VG!AB/WQ+[5A.'](^R@+H=6#T>^@/D"HFFHEN_$E/GQ7O<=[4&+2$-W@ Q"
M^]Y/QEW&.-&H$+:6B2HY)\:+?$[G8'\:%#IR<$3*WVEY="L];FME0CJ-J\2D
MW B^*@!<4JN5FWJ#D>[/!9,^ /=E'6'G-I> U*5?%"!7V[\H2OZ*"9-03!A=
M3C\-HT387% =C8U2[R:A9;PC,%BS_M!AU$A^&X=P<7.X:,AQ_#4\;PJG.UB/
M/RRI2LK[*:HW3P5X+[^P)XD -LLWXAK2S'GBW6(<]C)"5CJ0JU5Z0^:0')A@
MOX=Z42NCN.W83+JTK_)-X)@I,+VLN;8'T13;M!G[M":<".^!R02!>)M[M-K(
M5HET:OC%^ NXZK-LRX7<L9FFK+$F%TN90).IR@W1D%J3$\1S]%3_A(#_V4LF
M3T&!ZS]Q-L Z*NMVAR#8=X^OL%[-^IW^'/>"X))U7L2'078&N8R7DJUTC2AS
M1X[;YB[N+R#9Z_@W^GZTYSW^5!&R@.UB=[:2E.?*(Q<B4>G% S%R?/#3P]A9
ML'U+7KW:SL+RQ'H#.DN@.:4K&*[^LIAH-!RD4(3BL6$K\-M*K@A*C;SK)TE&
M%Z$5R6$?K#2)EON*T75^<0)"J_))KS23_VFV2?:8T";@<W++2P!&&D(#3S#S
MS)UT 2^#G8LZE_R3(\ ^Z6HBQV'(QZ1]#HS2K2^'P1&B;K5_2MM02_</X+/B
M'M+6U#VUNR:MSZ9]_4(\MPKDQ_.9>F'+05*!?3W.WK5)-XHQ6&X+\3Y7Y/,2
M\ 1?T4>SOFS0Y-O[Y:@1G9V0-X*]>G9A)ZJLK D60=,=%\M"$1[%2DW-L64Q
M%FRY^:B*=_0<47GOO9.']O_%7QDJRJOG1'Y.J!57B563CU;6K ^1M>)COU7B
M$$'3OYE8T:OOSN;TZ1QT>RLO<]Q&S+-Y(M-9DI#>V&Y=)2OK.&)FYUME^E1]
MYJ:[7_2=0HTI-QF.64J2XLD*/IJD'+UU97+><S_?+Z\+WU-N$-[,490JB2TK
MD*_QB=6"%E83?MSF. (I+N#Y513)8,O0-!"?W2.^,S=J[I#=8N<<35K'4EI6
MNLAI"8_H%2EL[QT,W-\ Y41QV\J+VJSL_(Q[5I-2.K2&,D=H;E3EFK81/'P6
MQ(GF24P2W]S16296Y],*SIU:'FJU=XB(^(=,6O]7S:O_>1,KP6Q#<?IQ7-:;
M41S6#5U)#\Z)V6A@ DM0C?#NMG'T<D5M6(3YZHX=9O6QB)RA23K?5)7$LF=3
M+YFO6-W0O-TZ)X79YA,C/9H3&2.::9Y=)&WM-444=TU7)%[@G#+6"AC29D'W
MT@8.84M.K;FJHBY:E&<*!4:(-6=W;8L'%+I3PHHO%=2[: T<9@77&[L=$EE+
MZHI'X.Z1[56AK>F,$S>7ENZ$Z.&_T7)MG< 3UMCFE?,(L I3$HSQD^P#B&0W
M+HX4.B7H>=DH0JM#<^Q*B=P?!?O,9F<7J,6OI7>[F4][7=Q0LHOD+7!^A7GX
M'L'?'QYO HB""[E<>$E< KX&'FOMY1&B):F%T74IEX"^%@\VCU/U1@[EP4;/
MQY@W?$PP]U_%@G:%% 'G5TA8+\FO0C1NEX"B4:_?HW\S</3_B!2L% XAVM@I
M@&2:EY4-?!GS);A%3^C5H-83(E;((W]1;(Y?0;:/*NMQ7ST)*4]W>$Z$&[X<
M"'-.<OMLT:K0/I@2&+@M&=AC?M]/>MQ_"'?-^L=*];U^G3+_W-GI$Q>EJLJD
MKM@;1I26BG!&=ZQ-=10H2V=#ZSG$@R..]G,^,MGNW9KH9F(B(PF5TD:^"45A
MA-J&%08R#EA<07VM)VUBP-&2 K*GA-$6"X.*$V)')?[DX.W"WD7=2+4A2]IA
MWLDXRM+9&UU6E"&&7*=]-ZN*JFX^(]<POFM_*SW_R7Q9NO!:.05!QGDI/JY^
MD31$/02M6=]7 /1U5OE+%9\KM!VZRU=8/7BQ1D;9]G!QXII8VV_?G0*5X8B_
M!\?AKELS:4,US2*$'SU#!E=@\TF)CSS0&?0>"^4%U22K"?8(#^HVV\<BS];K
MZ/OY2LM?O[$BOB[1VO?<5NC.VPL!!(QP.L-*:_X1YT2GP)N(+/T::9PZ+*U,
MQ,FQH'5:><G@?$WI\TX%GGKJABU0UNY,@7FN.8CM,YXEG6$(H/7NT2)UY:;*
M\0-EK8K>CW*X^3%V7%*</YH;VF@LEEU@#T]'S33$F-'?QZ$7]?=EY;B_YV@+
M"O1.TTVD6S\IC*\#[6;TH^&(-D@1 <CCQ1#OA6S'RL K>M!#M6NB2?Q8ZX>/
M*JVL1QLG2+Z+VV7*\'9Q*['$;]&<VIVJR\^/'98.D!SRCD-!#UH7I*W]!>E7
M ZU'KENH7Z'JT+6ZRN1!)_SC7PO6F?\5\,[PO &S??T1"*M6'?@O+L5B9__-
ME;JB]\BT_ZC[-?M#PRJX?E6HXSGFMI>J'D'F3D"\]0G\S]Q\#:$X]'?N1[P5
M=4='#D 0'7:+,KQ>UGCZW^(_-O?[A)73^HGV@#.U9HM+^AV/ITVHXSDNEB>K
M#S;5[2UUR_RW1D(;JUVB N,*X7-&?&S$*L0DS2CYRG.23'_VFIA\D2#O$0CC
M]6GZ+P3.6=MM9-@CU197J4-N))UH@H\87:LO 3?T+R*!NT6PC9=[+FC<^G-6
MY)LT',SWB,>$3NM] )O#:+Q%J6A2R(5,XJ\P?G7,)ZF;1XS5 OO><0G(YFF9
M/6'%@%I$_)[-I_KR;107]!)P"UV=L36*I#\HI>1@Y&]\74*5%!>_V$=Q%'@E
MZHD7!_,)13@L!%'T+".W;2(9X//11E3 !B7LJ-VZKZ^_0K5*ZQ"L3;:#5IH:
M]VY=7S(K-]J1"N03IC;2'$CI7[JOF];@5@@W"GM7O1F!5#OR2+H)578;=8EC
M:KBI$3G\D3J$#!SUIC^IL4IUH=/,U;BBAVCYCNQJL !VK7X,D_G+V.<D->&L
MY+@L!I^&OPGA>I'<H!KU]91W*H XD'3'-BV]=<FPBS\4W'E)PXJ9I@]MY]2Y
M8$?C,<J$L;:9,Y<S=45-"K^Z,@ID5*Q59UQ=^,W6&;M!JD&B HRT(N]"T6+@
MI7(JYLN$70 9G$M;/*]>*)F9^YN;0:#@#F9%[O5>8.3>H?@OU'JU'?<W%SU
M46?T8XW^Q;NL-N@QL,3FHTQUSR0\G"LH<Z (-H_1:H<PF)81=DZQ$7RO9"&=
M)+/]8,-40$O9-CYW% .XZ*I3*B GFK"CVQ@9DO0K>>.?SQ$;&B'+*$7@Q!AX
M%04\I9XF^0[[WGD)R(*@7_XE.?A/#2\Y(E1]("'2$GB )D0%;P?.@__<^Y6&
M6/I'M'X+SG$9X>DE  <MY2)AF[1;= G8N'\)B #_*FWQYX92,XQCP>=<&P=U
M"?#Y^R,.R38$1^^)7^3YH&&-&,5FNE^'"?6X_NS#)6"I]X^:&']N#!4".T^2
MT2.8.\%S&*UG>RW_/II4_^(9;-_LCS25/YW_,16O8% #C-:V"UMR<53'=(G'
M@?X*/N7Y2_;QGQI'CZ7VT<S@TF^PWA/POG 5"-.E+P9[O$I"Q?PUN^5/K;,H
MNE,8\?_,\O_A66[50+THKZB1+G@<E/O2UN3 !7D6E!JX%>F39?+P,_P]X74U
M$N:A-"2?4;X?:_##)[+JWTH4)8P=?R_"\!^(KOW;$:LM]^5AL'G><C#+3<7I
M6^IG-$?X_+%3_+A_)GSZ?]I:52'OEG^_C:LT_'$TMEE44%^\EX2+4Y?>VNB@
MZP#>R?S-<5E2KT4X@6L/]!/E;04BQ>TRP3TB^T"Y2@_YFI'REV?#\?R[4N0&
MAH+T(2=$R-C5DB!^"$FO@TOV]$LZR8DLN$"O /D<5IO%MN;S;#6LS_"[4M?5
M']Z,*'CS@"<_.'1:N[M]YFE;II(@\&,N8L"\*78_L/;\U%)"FG?1HX3)G[%B
ML$;>(4TD[S&V\W3;5RJ?DT#(+Z8<;27,4FRV0+_[JCNYP;WA7HS0E;UU*U/8
M82AQ9HPZ6X0K=69]PO>P/.S6P#-^ZH;MI<39D<)TV91(X4QH??BZ_</;3)3Y
M!=L\-0\$2@>=Y/PH/[!2A>C<Y",-2JD/2$V\!*A4?UG^D:4DM"BX6BYZP\)5
M_T5544F=CY*_X10@V1J_PL!G4*Q4;?3E'NF'0>WU /SNFJ!(9UHK49[W4@)M
M60LIQ$O9@ZJ/IE2W:W;&OC3N/X\1MF#RBW7(LM BF<I[C$>9Q5!<CF/>EN%B
MFK,FY&,^P5AHQ37Y&+,C.QOM)XW:D)3/=^,N?'?;*27'UNVY14LU=S\B8C-)
M]L>H"$^6#C1"[O5=_I\"[(T-$_8\H0KN\#WYP3Q<Q7CEJJIR;=&ZN>5L,A:&
M_/H P@\VVB]CCT&1$WZ32%J:-*Q$L1R'$Q4T>:4\AU3M"(=GJV8Z7JD@6Z^.
MXT;;?G:-S/SF^/9<M,Q'[EP:.<"/3&RZ^$41*F^2OK5C)H5^9)[VCF02/[A&
M ;(AKXO+IW)*$_BD^(@U03#;OBZZO N1=A+5JUD-]=!8E5)A?QD(:/U?[+UE
M5%Q=NBU<"4D(! GND 0(! G!G2(AN+M#<"G<O0($" 370)#@6D5P=W<HW-U=
M"BV*C_3I[MOOVV?T.>=^YXYQ[ACWQ_JQU]A056NOO9XY'YF/\)X\!#0BZA&I
M)#7J"K:?QH==I+2&T!?26_T0J#QUV6N9K\OAWZ@I_M)HAGC11M;8<=Z#;*DK
MCJK?'UJMC5FA3.=,^V)24;)QH1QEQ1Q+*=UM!SZ>FU3/W([<FF%._6&-+)@@
M"):'/F&_A.<./XO];7C_:U(WI?6N!/TBLN/,F:>/OW1,&;UPR,+;C^M:U6K$
MOC\#J#[< 7XY-R&_:4V:8&1K/'S:\L@YIQQG@S0>XKSJK=8[.#/;+8JDF"U)
M+9+C>X!TA\9TVD];(#&T:16>&DL[K_*BQER9T2W4NEG_K)P_=Z/^YJK[E0@8
M1W.N5B5+IJLMPB[F$"C1AB\TO3WLHW) ^ IF%,U,V,G;@IM=;[E<ZX=OQFD3
MPB#F#LWFRLZP3)I/YHKF'<^ZG0O).NKWP""/)HZ O"U)A_Y8#GL]SMRT8B9P
MD_1123OJPG&R%L.3=-L*(<LQ$UA.%T)3-HJ"V?;RNY_PX:+%_K8&82/GA-H*
M_^ZL,[(OWI;EZQ%1$^:<[^[DD_*Q%.S_05TS''R Y?&Z;#,']/W?0%S;^&"G
MBVM[G8.XE4)M[.<['K&1,GU.65W$G8[)2\G'\(W:11++R1FQ1/P)UDQJR5(U
MYSD M6\$^'0BQ<AL^>9^6VY6CO:7=D*G5%'LR1&YN9P@0X]8'RJMWB39CK4Y
M[P*KO$XV5'!_6F_MC+$\7J= H)CHDM4+W_T.H>R=W^Z)2$JCH]7..\ T%?;9
M+-6EF("X][I[TS:A%C@1;T,=R&A#TFGGW0+]$Z86;\6^HN4#WO[.G#Y1!\D>
M_,<8_/-*T[+Q/0A(7#E$$(#/5?Z$R"LR/@O< ?[0!Z3Z\ \:/+6Z(FHEL$SQ
ML;>$!(X!-'AIO6D*O/JD7_?K13/U]=[>B%KQP;>:4X%4702916Z9[],^UH3.
M=]EOM/>6/*:)">>A#G??B+\#M.L1CNW+5L#G'#]*\$OQM, ?882TA'0UC_13
M5* 9 S:-XEL0L:3%2K)W@(?B#&Y*5-P\%A29C\YTD,D;M7SYV?/3>AK4%C;%
M5OY]LC\_LW;R%CJS.(3K:QVK+B2L\'!<%@E,94T'\LY=">P7^C!,0CF>\9A6
M5FK6=S'T3\_4>WK< :3F"Y(@E["S_$,M]A<!KE:H))L4YL\MU"/R++@F'5H-
MW"-9168@X[(,",LD%:)"DE"9NDJ\9,?P"IO(P7_IPLQY\+<JQ3_Z+._QO.0=
M(%$>V:D-O$VMT_KT]YPA1KIVK<WS)RD4D]/(D49%ROD;^\C?G31U)O\1*NGB
M'XU;BB<]DX_JT*8*3!>2BBX[^P] T$3:7W!;*/C_8<W_R5CS_ZWR_]XJ!^@'
MB]C-9S^O6?L6NGH'H(#VMB(7E<JD"WD?1?$L7: .7Y/VYE!":-T+*?!98UDQ
M"Y3J]">5.O 5-2@,_IUPUV,*1Z3HOCBRX7Y-AS'=QCW?UMS;FO-[_JUWOW!;
M3^HMZS$F5R/2-XQ\:.[?7;?-I_\K\&FYE4I1-WF_E"4]Z.YDKNY%8H[)1H!K
MTNH/R@E,JE.K1'3&)HJZG$.?*[ZYD7[DNG@LYO)QT_[:&+VU;!0*?S94.MT,
MDQU4L ]U'O3PX73,5,)\(SH?Q^#XK4S4DC$/''3=^D%7;WP*XPKT<LZ[AOC6
M,B MH/C0:?='M=;+<S6G:%SM_KE,&L 3-(1E*FFIB[T)GRI>F1@G_M:JA8G&
M*EE*MRI*#6>-X]*^W**B7X\66DZ*M"]9,H,?FYPPO&A5SE$]I ;G2Q8TRE_4
MZ=0-12,$=VL"%BFT(N$ ?H>ZJ\&5Y#T./YF>;1W@YX)E&=E"O5E5^0@^P6)=
MR?,'WPX0Y$&3; &[SV?+?\[VJCJN=V[:GY,0#SC*H)>H/7IN]WY?*ILA%LGY
M*986.QA-%%_MX]_H"U$Y\(K8Z?#Z^ML=0(1@KV)5ZX_>Y8N38C^]W%R_2XU[
M]K)'T?*O8I7_N^//OF/H=355T!U@5T#]=_K=)K)/!JLQA#X+-2V1)>.X8];"
M+FN2;!'M93,U^0758*T$G$)K4:*Q=H+9T'=%IOT5[YS]8LPB@5*?6&-09\QB
MSU/"?IW"0_(U^TY'7<SY4CW- 6N6N3CT5#ZS!O?O'IRXR=#1NM+M'0>E7)HL
MN%99V$B]D-=[T^O ;$_>J*DO+_Q#77DO]EAA64?S^T/3G+)\R_W?'LDHE S.
M&>.<Y<YHN/T0#=$6%.(Q"_C!^(;QY.:SQ.W[;?4S?6S9W"D]P;ZBA 3%2#LW
M/6P2>,_&KTPI*<7U;[+ZB8U-&R9/^0M?IRDSMH%/Z'>!!T#DM_QRLHG1>DQW
M9ZI%28TW9X;X*%=)9>E;51.I9&,0J $:9VMU&+=_<@[JBU6(=*:Y,O:S.8N9
M$'=F]I*EP-E15/^=-[!<57I-S9.F>KLOL+ $,9-M/6*^P83SF]F>L/;V[X-[
MJZ@DO+NC%?PB\:OJ1Q/YN7,)B>G"ACU]9M%$VW%4*9+69BLI; -G-Q+I;@XN
ML@T.-9NA4=?A\)+E!LQR$*_ !;8][Q/9AB=\V#XY(1S:L4K?M(1 \-'CL3>C
M]=&2$$[>.FMUV\\VS'THK_K6/GLRDM\!CE5??\N3S'5SU:A(MHJ?/<C?(6G4
M'UX]S;9%UXMXSE;TPF+ CH:)PN=0QXCW0%2R^-)1J78BYX=\L-:SR+IN9P5L
MDFZA50$U!IZO4!]UMYNFU*:H-&:5&DAE0 KZ!@NVFRP+"Z&8=K#K8SF)(10_
MX:T:B#5UNUI2/TP41-X] EW=H$<A.7]=;OU36UOBDYP:C0J5,*N2>J%4['9>
MA_3'RJH=EU;<$$G!Y_>[>\P*7U&U@NR2HX%KXWJ_\KTUF<3F% ;2Z4&_2-JE
M;O!MW.3-NSN Y1W E>1V$H'-<P?X/ G6L6VSYG(:L>'<E^7:(=UK D52YE,A
MRN1_ZH%)]_+_DOCX!XD+Z,F?%#  VYS\+G4PF_W,FU/AX^*Q?(*-X<N"7:FC
MO5J\Z2O'UY?M ;\46&G6[2=C%N\ Q3NJ>%K: JUF5<'9CYZO/S (3QZ5D25?
M]., [Z60'+X=$^=LGI,^+D&5V<S-1S T?6YMF*BPMPJMC-;!IG%!8;*_(H V
M2L T9G@5=<D)3 PBF^&/E*WW?Y9_%05AV'5B?1#S%5^CK]:(K@&2OW>*R-YQ
M^56^TNEP$,(^+S%4U1?16=O;>DQ9XYRM:S$QH2A.4U7ZO>L[%BH#/\Y\GK8_
M[S[NV*Y6:O8*A4V?<W'\@HY-UMJ#<+XGK7[LNX=:3=B&\2R8O(F:(G/LKY=G
MT7D0[PL:7QYS%=0>P\Z>7O2@'T06V#+91PO^8G1MTQJ9=#*IC2*@56?M+KQP
MQ7)#/"UP_16_4?$O>W@K*"[\0R;,WX<Z]LKA%0,EZAW@'J??XE;,_6FB?)A"
M]N^-J%6/=+1R:OA3K)4T-:JK6 --4&?M5H\*E!!"E7[FRVGZ(;PF/&&4STF0
MGYLXF2LSK;,0HF/K$V1];&^GU@PB?^Y3Y]Z\ #/HD^UZJ*7GM&"&[@K"9$A(
M62^>\&XN1O3-%"LY\7\S%VTH4O"O%O-EW_4-B<ZH8"/CN<<:NS*@IE"OJ8WL
M/'K&/XA9C$].OCQ&N34+ .X9_ZX'R__)O_,W%]0?Q"SJ//[LJM>YO? K3_EP
MK9W_I552V]$Z!H5S6%$"F_UH,8ACWU%Y3& BFH=YULJN$-$5TP,,VE7>U2+\
ML=S@*!/W(!7-N#W^A$O#\2*0=?<J9'3"ZQGM1#;S>8+WFC1[@K&=\*,3"8,A
MO:F<;2&4> HIQ@&],QWB[VR=-?Q?>4GH*CT-RYL2N?BE3K%QM[F?K5)C5 FI
MN [5OM%(R13X=/WI^$H]=]RSSU,R?=$;0RF+U\Y$>-9^SC2='W/G'C-!?W<5
M;KNJ4 T2J1ZN-\IJ<[8K*X]&?>S8Q7.HVQFQ(@O4B?Y88L'=^<#$N8NR0A,^
M@ 7&I0T=85S\>(.K_H4",OF@-J2P1)/L_VR*LM>]E8P*^6N*<C2T:H4%$:H
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MAJ2;U/NW/BD3C2MS_8+2M6B+*(EV3$'7W8&C+Y85]_TF\1H6N#-!:_AM.6&
M+241^T/U7D/[4.?N^^.IWMXM!_,UDO/*H,[4YMV'T#L 6^'5),6J]*C[BGLS
M@QK@I0[5[Z"2&#6V7"SYQ.#$#;1#+=: B'9BXIWY7YH#0C>7JQ#M3?L)R"$=
MSG\,J/ZQ]PI_ 7U&8];YO^SM\E\9_PEAN'_B$G\<XH[V%-E%57B5W>DBU"5[
M/XV3 .LT^I<20LPS6K>[^MBS9(GBMD)RSZDR$*UU.RM(XIF^U_[.Q?/YVA"'
M[8-N036!%<YK )M0Q8SROSFC_VL!KC*$XLJV$^8'1G,(H?6Q>\!T]X$84'ZB
M_$]]XDMDGYX.76JJZY]A!2&1OUV6?Y6S!Z4?HX9:.S%F5YR0KGC7)8I8H_,[
MAG3? 0(2J6X?SB+O !'(UX5K+(E3VQ?,[CFS.K56%NF2Z'< IT@LH%:)PK2.
M-[1U82T]= "WYQ=<)W0E)X]^A3/MR8ZRI;J#A:MY?!7L22J7 ^^@)#7Q"_(T
M/<N-LF7M;V'8LC"G"_FRV9Y:4\= X/Z#B//O2%U0RC%%![+$O7#H/%!:EWGB
MY7,>5):J7.A[7HBNR\FF_%%:T*&U+6W R"N,KVMH#X3=23;)/*_'=^2"[$7Q
M5? =&G'N -'IJQ%_*?-EUAVP6_C3Q+^.IG];!5X]A]\!;I[<'ZI;.9""CN,T
MQ%>/OST)A<<L]VRQ.R(=/,5WS\-%(59JP#_UU?A+:B3*LPXM 8^&Y%?>HE:X
M7+RN@$*SDAZ"06#;]XS/ Z\K@Y^3A88!T%&AKN-W@*_I]Q;=*CD?Y%Q]NX2:
MWT65LS,FQ'1T,Q4]:4_<^ZE582W4>[X:(<@POI_.IR./;FZW-:'TPW.M,7S9
M'PU'6(]G]=%&56'$I1.,XNT1YJ(9'G+KW787$%:'GE ]T?)?36CZ4]3)7V.X
M"-YM%'XI],JP5_&7J.,=X$_R+M>^&ZFOCC92<G=)?5+,]5@JWBUR%$?^3':"
M>*LW)\E6QMASX,GB1XGI"(2C'T\=\9U!FG N'5APM-LCV-_3T,3:U=7"'_D\
MK+$_N@.HQN#H6$9=H?QZ.T5UD(P]48 TGMKRPF%B=]/#>_0*MZCOQ:/E[V B
MNNH.U>/;T L^&E>N/7O+FRS%>7D2!*.GU*@!C&.J"%*JQ'H1H487+:O]]XAN
M?F,5E4A_>=.3!<L9)_7XVE@]'?],PM[4I9$"-X8[@,PH77W2-2\N;1]#?,\F
MP;1\L7DMX<\DC?<V_>]G,81?Q<,[-"8KO/FERA4+Z1+Q-\TC^A;(R$^P*>/4
M#4M?'24@0ERHX/UW '9M3FW9>)@W%YK3NDJE<[]E</F#LWTU2[UU\NPJ1(+(
M'<!P$3DWZ:S#_(]7OUVP?W4[_$'?9?*/J?<6?V>G:\A7][NP[F_Z+A7;^CC@
M-=V_Y]YK76.@'LF'#((7%C/0AZWQ%'1?6)IBG['? 9@_AGCN;R?#5[/-)CV7
M>N3RE[W%Q5W:&'Y]$$<GIQK"0$. /."T4@)]C8U!K[&^L!)0\ IJN<!Y/#W=
M;0Z,JJH^G/2V*(H[6%J+R-;!H*(-"#V5;!'K.3+_,SI8+=4#"PCW5YI4XQ>:
MZ=T&W8[-C[RY?503"V20+X^-4R6'9NAP/GI\KIG!ON<KX[709\855./1;9V9
MEUE["0D(7G(?DO'UT8 S%Q-(+PE*D$X<O-/Q6LWI>4-'N]T';DGJ1^\CV22;
MUR8+H/D4N2',Y30S+VY>/S>*;/MY!VA4JY_5*N53:W"V3*,/D>GR<U/N/=WU
M8V02>N5,IJ0&VQU>)/'/_<"@8+UKMKO&K31R6!Z,PTDL$!^)V\16*;XDRV>-
MK>@O+2L&\HZ'/M!\5LR[??_AZJ[FD6Z+;5P;AVM)"Y]H#'98D[U5D*C;]T=#
M.-RVW/)-CC:B\OS30\#.)5+8_FILM%TE>9S?LNIMXY,P!KG2&'L+AXNZPRV'
MN$*C98B^4A7>]#1_NP<[VT_;G!5V354(" )R%,S.CEM;ZOP@@B]N+O39=_(8
M6IM\?L%\*K##$!-7L+BF,L91-\^@2)EN<U3F/7="MB7^)-',Q#Y/E[8B69:I
M>$3\:J5NZ&M,)X<G#PWU/B;7$6 /W_\Z2K.6 WP4>FGH;6GW>'[FRJ7 OED0
M&W[]8%?G5WNOBLI^X0@%_-V[P#>PIMJXV9V$J^2-W(P=4F#";:;MVE7-]&FA
M&?'0!V]1!>CF"F^_AYKWO2&>9@R$',$IM*0<YM8[A\,IZ_/;3*QO\;AL!.@@
M,UH]]H+!&IE*@Q^_V@G:88%>JJ:,XTBSDS]&H4F3.I<N;)<U7&BUPJ\+E$&9
M@_(@OOFHMKAY"L<@\4PKHYZ)&KQT-5I$74,,8@FRZY3;VRC$%CBI"V*H:9,Z
MOT1GKJOC/_, ]B16I1)-6#$M[.QT9]$_,,5E-#I"Y: +/,PZ.@4Q&-[P],Q6
M'[[@@MVCD0OHKNK8D]RE!KEEUO7UD:>\CU5_87D?IW76!,!Z+EVN?1OKFFV8
MZQ?G[@!%SR[ ^A#\8P):*H^>4PW&3^:C/U0.:;O7FU:KEAS*U54$WCR^"# <
M*W=- B5C<Q&^" TGQGK"NQD#N[>901"GKT76GZ(U*_A#W:."'J/:/'FP7NN-
MZ50DROU6M>F*'+=%+91W!M:S. ER3YXGF.Y9]D:1DG@Y6:%I5!?EH$95"SP>
M]3VP3R;MG11@Y8HKG)UY3Y>:8/R4/-0X)I0J1USH3 1'SJ8/2<[P":0<P5[Y
M8WJ^<-_Q285S$[;NUI,';D<UWW$;E?%"C:#"<&C@9BLI;7#@X(6Z6_&&3H[P
M=)H2:_-0/DDN0NH.H)T+KJ-#]FDR2:5H=)+QG_&9?';Z!:=3=P9I7GC,K3(S
MFS;6AL^,"_1D\:AVDP##K*@>[ZXB=8 G'&"$JN@RU149$W@1>(T&:2*UO Y,
M6S$F5"_[4(A^;Q"J>(%MP^,J^<HS!7:5DV,AQ![8&+OCC>$SVG!Q6E<S1R,[
M@WH_"6.JUMW0",4=GET%]9\[X8VO+KUJX]K-WRZ18&^)&)3 R5<1C"SR1ZEI
ME,&4N2O/SBM#/I%R1OC[L?'Y1XOS/(RU9XP_'5E8?)>?T#=#*[G [*B[G9O8
MHZBK5[(L+5'.6FCNZJ"K_2 >B\UEDX08)==.O#A;:+2-5+8RP#KOT@]I+CJ(
M_E3]A;$QRDE,,GI3T>AZ4U__T Y!S95N9<,!Q.:"EY314A>=,0TG)R53EWE,
MZ7,?ZZ9YIYS]MG9N*Y)4^SB'0FMI,2V6'L5FS^FF&L$NI_%5;/9B]F?^4L'@
M>67X+$3?9&Z%OK"V,?%M5(&L"2N&D0 /,<;3;DZIJM#8N)$>^EY<^_@M1OTV
MY(OJ85ONKD3F.>0Y^5';F =I=T;L,DE7O#96BB0L*9DB2;#VGX*G)7KOE^\
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M 4+RFX]>&//VQ+?A0+%B*]',@86)VB@UV>M )VCWW=+L?9 FC SD?'("$2C
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MMQOS>UT/]0L+B^\J-5A]C7*T).A2\[BC9HI9O<NJJJY1*F.?R/[)3C)_XRV
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MV0/FK8[5VF?WD;7A'T,U1C22PX?7]J_N4XN'\HORP]\1(ZLNFXY$;6POA!Q
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M729B>/)B(@_.<TPO ZI7UA4E5:YX#N><OQ] P198F[JPB&O9HZCRV5=]5/D
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M_LPU)$->_!^_<Q]96PMEK]Q!BH>@ #7 2?P#M'!HZD0!-IY 3UTJ+1'('R=
MOB"@W\ YZV.MS!5_-A<"J&'O,HQR"__OF?P]D_\+,W$)<N-P6+O&K$/883 7
M\DVY:A<08]+%P,"X/<1>D.<O?AT/T])%+BV= ,+Q0D9J[-K8ZRKY&HU:NUY/
MM+G9^/)LE.%_>;0.V&C?"BU$B,39:[@:KF8)#MB#%UZKCQ^Q6>P ^^&TXZ'(
MH8V@-_Q28^R25-T,'Y$1C2WOEM4PMY(Q[;X'CL[0(H4V>6:CJ6"=0P%$.4S/
M!NI>W;,'(Q^Z8".K^]#JB-%X-"&AW[B%N,<TS(+D#JM$@^/V(5;:Z?S^3%]
M'=J'YWJ  L19H@!CC2@ *7@"MP,\3P;;0Z^ZAL+Y%%M"D@LL0VJ-%T"%W#VW
MF>,P (H1(O>4 >[WA<B-#!,O47P:/R:2;Q%(=1=!O"3WWEPXA APN17(<,KQ
M"?4TTUL"/S2,I6!NU-OE*Y8!3Z*X7O\),%EGOC'&7T/N=4#O0>C!G4.Y8_3_
M=;9K6'?46USSM>]2&?K,ZXX_;O+N##Y5\M[YV%W!"!3@P9+<T3IL0OS["PA=
MXH67U;CYKAKEDM<-^'0?)VP"[_R7,8#Y)_!-OT9NSYW!:YJLI$$!OJ6@53UC
M++)=(_._XEI[ >QEK6IBOKB"E+RBQ7B0E^JX&6S-%/'%0?O"Y>A9"U(>D(*1
M]!7/?)<3_-/$^',E-C=X],EDY(PXUV;,-_ECD5>SKT+;O9%B02B ;\*IJVR5
M^$)D9_J *WC6"JHS 8O40G\8ZF848 )K Q.Q#YTV1 'V/X-/7>WXTOWC$<I^
M>_/9\%%8TR;T%"D_$ ;.-][5"CKPWJ6X>9"TE_VG- 6MD%:$3R%UCKV]D$8N
M2X@@6O2Z!]51;DV@O0BT)3.9>N8ZO8\NX4@L6W\?!?CP]SS^GL?_[#R^$E7S
M'FCCOGDLI\AJ<0B/LW>J[3O$C:FK"\<#.W$*[N5L [-%==2(%/(=-/V:EFIF
M\N]WS04,;:&W= F^Q&\IRX0L:%,%^L?A&;##<]FD?Y([^^L9@[6\)'\Z&5V7
M1"/6&U;)76"OJKV!9&''R@ZNZYG.*!J$C>(%&^\MQ%VWQ,Y7I"=?-@#7]&,>
M0E1KVC84C#1'G#[2LY;"%,-B1IV>/H(\;L9YI9?H^P0IEI UUOAV0<PN=%6?
M]&W >6',)HB HZ-!Q:/1BUV?O$!^F<(JIHC<62)KK0]3Q#3:^&8FDMHI*W<N
MLZ_,JM6V1#0(X&'YSF=8N^#.5+J(*&_&N=L&WA%3Z**;K_6(.L+*2]U7DS4]
MMZ-Q:5/MS52S#M.E!^.[Q-29SW(*R-1#*X\?]9)P6.O3>C/KK1_T$=3O6H04
M68P^>''#7S>[0@_^N/0I&)\",:8QSD4X:K *Z[MX!,ON2^KFOZ/K,I'N(CNY
M*_TBC_U;/_U5-IQS2U5SM NJ_.R)DW&5K7N,G:9)P*ZY.Z(VI4&>UK/K1XNE
MP.GN1@K)ZVY;@)<650V\W>QC. L)#X*4X.9WW>_)$CQD"WS)5KWD&_19:7:F
MVV3T4*TG5I=O:%9[@?->FG'.TV;NHAN<G;?4QZ?<_ -3,#923'C5(SG3&=\'
MP)YC50Z;7S  SW4E]>KD=W-(Q(I5'#U44S"<'G__8EL087 !KZ #\=#MT:#+
M)#-K0U/K\GVTBF\,4(BO\!]3*=ACV622M!,G$B6 D+SZQ4IS.AM/X?C-?$I[
M9D^TE:=9/?Q'*OJ_.X!5"# *\'02=D3"#-Y574O_/MZ27[4T_SMF%C!@<L3:
MWJJ6R]$]H/OS<E$0"3/H90+YP=P\[@LX^<O8]5"$;$$.I6#T1"^1'7GOJMJQ
M*@I0)=YZT($I.IX)V#>O"2M4)(<_PH&;R4I_0^2VN]H?GE/K.8/D]-(1'Q%J
M?A/M]GHCWW",0C#C4 "T<PL[.;SS>$"NGDNS7JY(9S^MD)'R"=,==!-Y=00#
MZ=:" D I$29FOV%J5:08]I'*11Q'FU%M6<!P9"VB; 1GLSIEE\^G:<T/VB:#
MNS,F/Z  ]EDWD8=DO8/WSM6/.?.^*HI('&TVFXIOWL+_IAW45\3/HI]F=*@V
MM+CET)61TN(R@WR$8^FP%%.0*\J7JP(*AL.FT^VID6A3:/M!5F$)HQ-2JL@=
M_#,*#I8(W]??.FJ<0&B@C0R1*A3@YV"'<IGO#W^*Q$@[V^X2<@KO)CW[=-\(
MQ0=V/?^($V"= KRQW3G=-<(0+_YL1.1_,MT).,5,8DQ!T7<[_XO7P)3]A<1O
M&;+2]Y=K R^B[>KU?([L@YT<% "&-AWK.S=$D&).T,.MD\0H_TP%Y5M%5NBI
M>G[*A+9G>A\?_92\J4H*1QSV0\>*3@H;_.-CZ8$# VB#L:,/-M=7BSSI $(D
MCF#$-4&ZO "O#9UD;S;(B]-CY_W9BP*?$!F@^8@M@EZ\L6KX1[L_EUJ<(A!.
M(DJ6RM36CB3T*D#KM4+*O96?4TX-3;2VEG10 ->QDX(,5E^>QQK1L:>HL(:>
M(E%=G\ RKHP/?(J*^=,D%G^EFQ&RM86>8=)9&BW>RW]U7UY&Z^I35"2<(7**
M+B'TXM^L^N=9-1])6U=BT$-(;D9\VVW_>DT&)Z5BL'VVB#+D<9,(",<=3PBX
M56\;@[V18/0BTC9U)N/#) _^W1NH$TE$'R&>*QF3)GK[2ZF7,(F*WE7+RTD9
M7\\*@K_8,/H/0?&^[]([D7[*E[?%.)X%@YNCB<TGLY<^C<B+G@!._-N4RC_1
MDN;W&O[B@$E,Q!^L!QPC] Z6*)H BWKFH19+S9CKF928\QZUE=>Z\[^Y;A(+
MO3]L<C4 [W5RM-J[08LJJ>9) 0=Q>;1/RLESHL3P>\L@T$?GOQ=I*I7L:+YB
M:Z$ .?KM2%_CP;/>/4#A=.Y,O>[^]\Z]R;,?9/;_1[DEOU5GCG4FS?>/FJ0^
M^B_1?JHKJLEI@./\7_UY*R0K/*M<(*'>3I^,F;KM]FU]&NUTBCJKJBS0F8TW
M7TD';3JIN];R^PG[6,F(($/$\<_$ U ]%?*_0![]+;K_ UAENF\R2;D;L#?
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MT9RI25< ^ K3@O)-X]2*Z':Q ^GJICUTPD0H/?=&L]EZHOZ7JDK;;,%7FWP
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M>DP2C"#CK<]]?%?WL+;;O3YKU3KZIK:PUZ&_&0 X:[.@A3M]92+ZT>J@LO!
M&\LFGF%8-7F+)E87,X)%U\4BJZFP</K2M0B,BPV6C60XZ]S3O>87I2]F>W.,
M& \",NZ$AO+J7./Z?(A?;M*^:J,AO"L0'@[GNG(\\/PY95I6V02R0M_T8EM
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MSP],"? ^QDSN_!U8JUL;1-*]-HQ\XB'".4<N]5[9%Z>$YFC4WF',S>JZ-6/
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MX#\4OW"99.R"P&\_Z(_$KU0))3>E6NX7_C/\*U4"-M<+E'XE0#^HI1=?S8H
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MIQ5G;,BF\W&F4#M=E>I@0WLU8E&66ZRTNK),G60'5*).;5%-V,&GYR"8;8\
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M:N\C[PLD%9A)_W/UE5?_B@R6$-@?\K5I,-WL^M;V8Z#,#D)<EX4P.Y6L?^/
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M69-3GTIL3%]O%T]W#F</SEDHO;/E=;M=-PSR/M%QF&:XUOK966>Y2X6_-6J
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MC"64:9IKUM((%U-3X@L>Q2A-S(2:A88L)NCLM2EL)=+&@+D>7%;AK9EVDO$
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M-3$X,CE?,3,N:G!G[+P%5%Q/ER]Z<(>0X)Y L 9"L."-! @0-+B[2W +-)
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M7N]]EU[M[4P<U_%#OL0?%D^X)3;VE<R\1Q7;;;A^S:K'Z19S.7H)3/;3\L9
M9U3"^,2T52>@=V)F^J^@W]OT6E RC0A$0!B78LP1@U/\*%DV>/P_0GW,HLW1
M+Y-.8V?+7*^TEIE/F61OZ@2J@T:/IRG*Y2IIV_*3_BCK6\XB^XQ'4Z:QZHTO
MDI%J1?DT1F0UPU4,5-_<&CSQ77&.^C=KVIE(S,_;L3&#*AUQ7@00K_P;/H<
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M+=,,MR+$,RK1 "#6+S1J K^!%<YA[AAJ>E!?\PU1.AU3$_>*>+!4TEW:-2$
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M!.54ZIF7RCT9*/LT$Q;AU7XUB@!D.=UFV\\T'B, '_ %[NX[) X]2?]U7X,
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MH[J:!'X$15:X62A?#/^:&@D@'JCA):#5$"0S7<L;LO7N9Y?Y7FI&!""!&@@
MA  I06MT7K:YHSWZ4_AI#'?3[7I!3B!#8U5M"[N3H\GG@J4_D_YZZD)-@M1J
MDH/+XIREJCX) 4!/0?0_(MR3R5P7RJ#)<:+LKE6U)H7B705N6JQ9Z)JXV1I
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M&^4<08O'9.>V9F2_'?6HNWWZ_$,Q(521RB%N.3T:.8>XJ8<W&Y+*V4ZI%2E
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MT']%C\!D\@OI:3&%23[Z0MV."\/-E^(/C,'-"4 SJ@)/-+.BYJTHO6:_CJ)
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M2%<SEI_I59RTB$_/I,63,]EV/<G%Q4P#K5"BFWZ#PZ30SPC5PP7E#I#QKKP
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M#^N?Z,:Z'AN\LX,B.MKN@,4K)T B!5L26$8.<.LUOFE1E'2LJ-VNPS%E1Q&
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M(=,WM*A\8W^B4=Q7^/JMN1J_JRDN_P%?E/O/3T0U/ZIP_]A):#]$[0],_T[
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M0TFC!4WKRXQ6$O%%L*4<*Q<V0;"EOA96V*8&[YG[0:L8P>P0H3\%.1]=%5I
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M".NS,CV#A\<D=CW2:5=$;"JUQ*""F.Z2YZO 4GB,'\.5&FT*))^MKTW4TA&
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M#H;U;6XD<MOH;Y>0I/F7NY2V<&14M['J&!GGXK6OVBFS/0.'-U:H'1%<OS,
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M*QS]H*![[Z]0Z#7]NG6,L5*(_UI!P0\!,-8Z1[IC3%6TT%6(U5RX\),I(8!
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M0JSB2+2-^LL*TNBFW!U=A:6A=55ZV77VN,!8\1B?58O$9H8URE2OY;V$ Z2
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M"3M7XO.PX5]/?8)3JZOQ7O0^,/P%N=;]T7RF3[&/%&LY$L91R9<?H=Z\>.-
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M;PE7T1RO;E4J)F*Y-JI=D4;*_\2Q-N-14@ANX+BZK,SPT%['"7.XYPM!402
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M3@[AST]W8UU3/'7K7R<*O$F\HWY;NT5,K<DDVDV- 2IQ2M'9C'KC*)E:ES/
MV:ZI4K9$6YLJ0TO@<X9GX9&XXILX/M&SWE'[-#L^*]=UCP^2>B1NRZ3^:>B(
M>BKV\#1LL:Z6?[[L.5F;\(OI9B8SL1\UD2/@NS.W!=WC!:4[CIJZAM"#1=:Z
M1,N/W3J?UJFVWCV?0]47[(WCPOWU_AD33JN_"!/->7X+J$?,1K/Z"Z%$9S=!
M+L"ZG;8A-_?;\C\]Z%\DM?Q B=TI>59J<=R?F)\X6GS[EHK59:/Y'TLH2&LA
MU7\NG/AU86]_!S7W_!0K24IV][BL"M,9E8W'ZALN+U,K9OJ]",2KI8J>)?;
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M1PR$+@MDNTL%GPJ2^#A,7H:EO9P@?O.C8-::['?;3:_S#?0\'X6]XU91K<4
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MF%\GWC0TV).)>3>&G-A)Q];4\#V]N;8BT"B)]*2C*E^".-8Y[>2)!&^)L<F
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ML[^S7EK^W00+C\D]!>*N9%T)[/8> [?"VC.9DEZ'6#N)?C&-Z-'31?9/=>3
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MF8UD&<6U#_IE71C/?7J6]UI[\-[+ETE+.'O#*F,6@QM&0A+^ISO3.=;(W/)
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M_A.%8AG]]WV']1L_+ITUT6PLEW=ZL<&ZTDH@+MI#9$YCC=#ASS=B'W=JW'9
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MQ:6,?F0>_O0*<ZNV2G%71/>9F=JZX<(#T).8>ZB%T"P<MYC5G\-X@_@U]*!
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MDUF@-6G1!Q%@BS,->#X^T%/FCDZ4A&QL/$O<7V:JKI"<33K",SNH)S7.4-O
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MNE4X%$Z] 1VY<N0)HMJ +$4>/7U&O&P0L>:R^T('.\4<VB=%%.C]&7S<GDJ
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MSS, QI"=0DGGQ,496=8(.FUEXK^QB\Z)LQX4ZN(C8IFB8V\IH; 7C 4]-^R
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M.R[!?\9;%A2J1NCP#NC[GV[F332Z8,@P]HCWIVEJ[DQP.L#Q,V2B)&OFE-%
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M7ZXI8 2,^<OEK&@=A66G&#OVN7L*5^30W<BEM":I;KSI[Z0<*$=JS?;\O0+
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M%!+\:Q("$"DI.1DY/04%O2 ;$YO@_V/"M0.TI,1J%*\)";B :[0$A+0$N&X
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MXEO]E)CZIO;-).$'MU7G98K[!PAA!JKL%O0&JL3_ESS#HU7@Q//B76BU)!L
MPH=_$,8'V9:@:(G@&-Z7-E0@8W;CK5=_6TIYT/^ZG6/&8)PP7)4C59WAB861
M7J35'9=+XW7LVL\\K,F7E* ; AHJ-ZK<8ISE^]\4V/LHD6>%ZWU^;*!.#Q@\
M<YCPO@Q0;#RLR(<>M'RG6=<UUJ9[2G.CK&3K^VLJ&<9:NQ+UYMOR,?S_//X_
ML3^TUSUA-K<+!S"H??)W&])O^OC"I/)SBY%'1/1LJ- =:D 1!_@_!C48F'#0
MC\-/8:1.IFEP=_:*_=_E7K\H ^:8[4%LQXNU6\!_=KO_@EL&A]:&(NZT!.,
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MMXQ%U )E@IZFV5.A(^F=6V8%#W^'?.P[)FEZ&#DX*<0J6U'1RQU]K[BD;*R
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MZ>S/ D,_KBM;$\Z7Y7K&7/Q8E8FYV=%&?1KO[COCNO]]#I7U<XD'BCZFO'1
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MR#WGMS GR:G,CL*6JB22+9X7&Q[Z?;.? LIZ/:>U77-<ME%9U1#L4(1G&BL
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ME@Q'AL!%ZW1TT<J3:C3!HR*S/.6-#-.3_2X;TJL!SN<?7CTWE8EN/G/^1?L
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M45G'-EP$@<TJD9A,ZFC8AX:Z<2,S\>GI$?731Z*A;\^^/!V\H#[/9-_GBI#
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MNQ:G%([I%CFT :DUEVQB==>U3(BY2= > ZH^X%FXY;\\L&%'/%;%1P)CHDB
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M4[E)LFH9W&M<^T&?4S^6)#4Y;*MOR5\N;A,/+Y;:W1R.[H]PE<4$6Z0M?%K
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MYKNBIY>JOCC4<B_PV7;2W5\(7MH\L2)X$F 4*LMHO11[#6,W 6.J]:HM?>S
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M;';,D*WL+M>8N,(K+INVF#X4 &<I#QI441I8==>;D?(5UP^590\*7]CZUQA
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MTU NQ2S:[EH;GXG@3F)E0C$$(X<%YTWJA2[F+!23#IU@!_?JP>E.V/C-PZ0
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M=-VI2X35<A'@ 6T.PB51CFSWN5KG)-J'=;2>6RUO YLS.Q6>4MXD([RZ]&9
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MNHRC9*O5X[3R'TI=9"?D'XW\1J> (^H)2]40V *B94T",8 U0F<,()7>$U@
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M(!_'LL>J_4\&2P\Y.*4[9WWI5/>OE^3=S\^IS($V(?T_"%:69AS2<^E,D Q
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MK/]9O#H%R%C7.?'%:&PV+B-S/>ODOD!0'1<8SHP!%!>6?.^ZUH M(K/#UES
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MTNGOTUR'I%R5*F&YA+,FQF2R)&\VP._@,.*>H!Y#OJ4]>O^D.,9Y_[2/RI^
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M@HTTF-'UQ1U2G%U),AWY@0*^$,Y1Y7X3G2"Y[!C39_JA^3Q$6LEG*C>!8*Q
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M!=T%(C2K8:CS+MVH8S#Z>MAWO]6LW-J1_HC* ,TAM3YAB6T9@BY)#($W1S&
M+3(=9418(6>L72]"0+W4D#"Z,I)_]$K#X=?'E'1@@ET7XYXV&[SPKT%,*K>D
MI:@NGF\X%VJ* ; ,/G1$@,C=DIC"> N8\K]NR-WA[F >*A46RM4SG;A64E^D
MX9SZ]BGO*H,P*5(:&.+@P8B0R-=>N71TAF,O+;(]4U(ZV(6NV63EWA'!,!S8
MV%4'4O53VZ)\8.$P3I3[T;;6[CECZ#U/(71=:+J@E<M.<^^^([0=*\=\@@K
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M#[]JJ JMV0:GTILB!&OS0(B'A=#W,.V,3*N=1U)O? =[+HDQ\&]>W@N6[?Z
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M#AQGXJC!:+4CMFH/9_KN*Q[X4-8<O1YWH$HV,$U&4-U@C"&NDFY_&&H@@67
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M)QH,^=":1,7#6_?X,'-K$M)4XB(0,MNZQK>V?J%8<33_I=)FF1Y.O[Y9 OC
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MMTQ]X5 :2DQLPYB'/S1MZ4.G^[5:EK:/JP^EA?RXSA#-XX'B1&R@!QO!FU"
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M+P4G?+^!!AAJ,"9F_7W. ^BC,9%T>IA@.2L-EH,=3, [38)8,M!1J:A  H[
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M,OR*]$O]0%QA= X/.(6U#7?"3[O1XX$3#%EIBT*FJ^%0-=TIM]%CIHXM[%^
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M\80YXH!YNV[_&JIMU\;BC\-;4>]:U+5D7]M( U.D*A_R4W6)W,3>^P!$4&[
M88\*<%([S!.>;+;R$6A9C6T\BJ\]HJXLFGZYW:G,PJ;=M2[G_/:"TE6M\Y3*
M@ EK@7[:8\<+E34[AC5]N5+0G))B>U,+%BCFEN.%)*X._=B* 7 1A9.K 28R
M<QS#( E;O6EVVQ&B1#0$?1V:LX'J(B.KD55A!=S=A]/I(;=*RCZA=N)A+N/Y
MCXL#)&(EVK.!9ND]T@)5HI]N9/.;_G71Z+=L'2V,&6.=;>@KG9OV=+F[,Y0
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MI,L7QW>=TON4ZTZTG0_/[9W?<1M[Y_K(]OGT@]24 -ZD?UN$Y?_QJ5TL&M0
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M=O8A$> 7CA;</TUBF=?D;RDN&15>H19$F X/X(1+)'B$YNR!+] ])>&=MJ.
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MD_1R'OG^?W#GK1.WYX*[M.=F<YV:"!A5SX?BM,^2)I8(=!U+!%!.1'-F:,#
MD73![_W--9Q1.;]5H+@:"U]@3=[%$0%^($PQ:=:E6, G9P@,R'[+';Q:QV&!
M+\&VCH25_E9C>D]YE&T3<*><=@\%)"C\5HGBA[_"Z]MB"-XY1  <@5/;9CU$
MT8-&OD'G\* ]CFU9=_K-QQT<Z1-WVE]QO^OL6]93^*MO&:0ZD[@'/R\U=&*
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M:,A:'"*'*)Z_QQ5@GJD$L@XFN_*\GKQ?4?2JD=\O.3Y"]VI=1>$I-H7;NW(
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MVVRDTU9 /J;0(FJ!'G)]M4RXR,?E6(V"L>L3%QI7PDU69T/BOSN*@=?/N/L
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MKN^RX!R\6+%'^G3&O(#.:W.FO6".,7N>SX/#&=DXF+[9\H!0YC*S87"G3/Z
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M6-,?!S#^O<M4&L>B?\A\FB-J]%-PT#^D$.F?;?Q!V#A4;<.T>^CSLE2XJX6
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M&@;5)*_.5?=MV]SCJS U'-V/N3'XP$<AK27+-I+Y.?9<(,L9=UWV%WEG4<C
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M=!VNK7[S4FCZ3E)Z;LG]LQ7WPZ:?P(N."<*SW"U/N-A_KO!E&UT0=\TS=ZH
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M2H\77X&@*BP%*#QTI *])EU@A@".NHEPN0=/-]56^LDYW>B6@<8+;>^KYOY
MP74B$)B HMQU=\(?,2-<RO/[X:2W,OS[0AT',YJR'O-I4!J::<=LYA0EO1)G
M^6B8?-(B+#X6V"8" !Z&(DF9)Z0=Y/C&< L&'K/@F\&9"'\T>C?^H,'DN:6-
M'U.7C^C"8<7:U.^VB38C"[[11\._CKRO_+S &@;)*/W_*.Q1R5GZ45D/3,HA
M3%2@I8MJRT&I13*]HY>5[V@N@,_Z< (R&V%<$:(C+6E\<-M.-U2F4RVE DGM
MV>P]TEC8KU+<UN@*,/-T/6EZ%)5^%E5 :\.HGF;'W\B;@ACZT_7:_LLW*[Y
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MM#<C=GCSQ+S"'I?>D:(UK=]A[?>5KS]KTIQX33<Z0DY*:'T60'G?Z5PQSA_
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MU4,ZBB^?F&0CE"8KW$Y7RU$4VXO5SC04KEEP7[J;@N"G3_NGW<7]C%?.]G%
M"2%*;;?MA;#*)?PYE=8EBL]&W]*-O55Z=EZSY-35+R$TC_5J-67!7"L$-BP2
MG6E4_-JDRT@M<$CXQN6[).NV@:ZR<,_U?<[!S.>"AWW21_.QKI.?"@+]V)<5
M)W1[ORBS-T!C%FH/-JTESMPW"HCHXN#OX4T"Q:X3N'U\2IXMN7I*Q*XX=I8U
MI"OS6Z"K78J"H8%\$\<@Q[&(WN:'6&0+79QBV:-85EMNT+5>-OQ&R"3-ZT'N
M)R,%/7<T*+\EEFP\KY$K6'E,L\_T,LO.N<GITJV!1P5B]?JG:+N<33>FO+T<
MI,^ECA@W=ZN=#*%K#;FB\\SN.#34[J]&U_^=6G9\L=&O[^4:^2;>*4$L<[HP
MZ7P#96UG_G3N4*S8H);I9F'+P=BUS4<3JQMWLN:9^5>@V+S7N2WO,6_&B'?
MZ]?5)&W\U=-_=ISG;QM^P71!O8Q2<]5<P0O\U6D6-P?'GCZC<Z.M84_>!7U+
M%&:KG*480>RH\%+,J\E/0IO,F-1H()?1S_.:TM0BYL?5KFAW?BUZ0R&]P\W&
M4;K&08ZU3/.DKMM:U!56?CCX)'1NQ+] A''D%?0969=KN(NRS'L&LJTWB>2U
MW%B3M%(4*.S=M1:>!\(FJHYMD; QC?9$3.")[6SI"S@14^0+;7UL<%Y+]I57
MJA=*:#;C K_!O;C\;^V<61BH?9GB?]TIN):Z3]H=M3QSHYMCF#\ZEH]^C4;G
M2EZD,-G:FJ;/610D\]!S QT:'BWK,6&MY+GXO9V7AH$LDE):S_>OB^8_DKZV
MZ(.^\:BI4Z!,>PG-.GDV$; 8)PDI,-X7WNS/UZT'_>@$7P@G0) S2ABU#3QI
M ;8,XFW(WS.ZXB[N$CR)P,P*X1K\_\B8R[\[C RJ%-(PM1X)<>(.+9P+!>FV
M?^S\^;&Z=D[:CTEY[Y#U_%E?8=LYA+%74>I,1*5<DS0-#>W1?U" IJG2#/Q[
M;SU!:"#?W=L^Y]/Y_65Y@7D::1<)"2M>KR,)ZL<Y^E?>:% BL/:8>ZCH\"P%
MCUQ34WO%BZ.<;P0>%OT_]MX[JLENVQ=^D!*1$I5>@X""TJ1($0@@TD1$4'I5
M0$&DMP"!4 2DAJ*HB( @THE*[[U+[[U*+PDUDI!\N,^^Y[MG[]>QWWWNN>/<
M.^[^8XW!>/CE>=:::ZZYYEQK%A"/:XSVH+1\ TH'(Q4B@62".3I0F93L/;],
MM<M#S__PQYVXOB!0F55<R_-^14Y2A<T/'V_,;#A=?"8Z>4I]F4MJ"-RJ)6*Q
M9"T%P!K-UX4Q[D:?H[Q<E4R>=/@CN',15P&0FQX"GCW. M_2 ^1F%]XT="F$
M'TWX#8^@H"F'.L66:N>=YU_*MS<L5&V)M<J+:!0/SCVQW>)2O_ ^Y]Q')2A>
M+_>O=Q9_D^'62V]EELZ)>_  23E]KZC:9=TISHGT^XJD%\\+1<.#3>F-@0 )
M_GP(]FYQ[\^#D3JTBB\1:/VU(7?=/56HS$Y-'S*#.OR3 *GL?X'^#$@>&O$C
M'1N9ULO;W\!8P3-9'F.C#;9(8'.@*0D("RYY-7=HZ3M4ATZQ@^RM+(#Q?#?
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M203,%7#WOD+.7J<D*6%6:MAH&JZ+0C"O8!]Y94Z,KUU8OSC+T[XEV,+ H X
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MS+EH:5T:?0W*3K<=OF;$"Q](<X?@Y1%A)X<G7ZF_UF1D3Q4$*5%G#<9\T')
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M!5,IE&GP8T59G$VH7N0K#QEJ^0:6PF\1O[)?\\P3 ?J7OPJW;!Z(%,4_DKI
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M_EZO+ULP?WY8^"R$[\,C,2IAK0OBDOJ7/4X9DX()S0/QS/K^G.G)D@L.@/:
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MN7IF?O(B#\RQ3WI4<"<J6C$Q=.&#=G2O!/%WO0)-65:?7:>YUK%F=5(3Z_B
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MJ"<*P7.-)77Q(_MO)-SC],,]KX8',9.>#!UY[G*'E*J_=XNO>"]LN\'#V/3
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MGSU[!W.1YL7OSL 4+A5$8:&GR]#/!:?_IP5X!=FFC9GZRA[.^O*L8C0,4A_
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M6VLAKD35K^<AAV]=)%@4,YSF;VND4%CF?'HXD,64E"#O/AU;8&HM=DD@?1,
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M(FN?_M%AO;_[BN</6.H!SL@OFY=+KBA/3L)ZRU:S/UX#OS>.I>]R-H<V<:1
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M?+P!_%=7+VM$!__7 )[$/P*>#YB_L\( FB/97\7L^N8*UP3EPXH@OC]0A-]
MA/VG/YQ&1#1PNW;_N%9BE4,GZ])+^I*>I>U3J5&<6(.WC0!.E'ENH=TR.R)J
MG^@6YHYO8:X.8/Q[R!HJFJ.1T01^N?*_W?MOI/GKH9.?7V_5?(!^J(6XFFZF
M"F:D@*\734&$6QX0W33=;>/V3'CK=\C;0G/$Z=QSTW+_U@NA_[W(VZ/E+CYH
MS6I071JBG3+_CD"<19>ZX5VD5*?^K3G!/OP!O@\@HA:PH9/4MS&(6,$?K2)N
M>8N@M>7!:_VL']Q<(J0)BYU=KZ/$Z1YZWUOT$>C\!=T!D%MA_6HG['8KK++?
M(O=?@S^)>HOT+?/1XWV^K;:,%@-XJ]ZWRNP)OHWMK&9N6LCU;N*:_GY'6D9S
MWYXBIS>VV#SZT8]V30B^WG><?-6X1]1?O-$<:8/C?FML3 >,B)!SZ!GY&.2D
MWO46??C$#S%2ES&MWHUHKEP36S]RWK-\7!'%-UGD$_6M<LY!H/V9N4QU PZT
ML^N70Q!' AG$,</_7*V/=D!K'^_"ZX.V*!V71LF"S= P]-:(DMC:8$XG.M1S
MG>(!$)J^EZ2>]D(X9%7G-A;Y/AZ#!+*Q78& &Z*&6U$U%$"71&_#YXX<).!G
MO80$]K?UX(IZ2.!P:RLG#>_-_UZS:/#LT?5[&"IN?8BS#Q((1X3IJ!*BK-\0
M'"3'9G^=5?#(<?;1>/UZE%;M5K;!US:1NG+D> P[@>G"\IP?S.UN[@G3W4#!
MMX+WH[X5?,>VK.@PI)A[T](="4!ZZVI^S)5:@:^"&&9"4W^L60ZX&X<NE^7\
MR<_C_T+1@5L4E;Q%T4O($NJM91_?6K;2%@W"LT:&Z5\X:>!T'VM*PUR7S&=&
M\?".N$=N+<EM[(%%=#'OT[_V7" Q/(5;@!1L^(6G^C:QHKY5?TC*+_4/_Z7^
MIYG?3&FF-6%A#NL7>E-.!4Z5[]UG9_KP9M?#3V=*!^8ZW,.>_@F9_F;5\-\\
M=OH+F?ZN2;>H2 R7[WDUI)_2H7B(IER?G=W8]VNO5T:/:_WY*/OFJ/Q=0U?U
MQ]<1M*Z2B!OG6].]*WQKNN'CL7494,O-(<V+&\DX-W.''^]W+DCN]U62T;CU
MS*1,#?"WF?X)M']+X GT;YL4_@7;?\>' /,EH2=@CV^;13G.7M-:F[&OVV@0
M]+<I(G,7ZW#U0')T)(&-/ ;_EMT&42)&Y"K\VY7&\;E'8??T2-?4.3@N^=QJ
M0.#X,-2VLMX9Z/OG1-MR$/=QIUR8>-EM]V4K06=",N+NPD&D7B$!<U>Z:.M<
M)*%Q;KN\G"OZ^PU!R3.&9-:BU/6+N,HW;A66':FV]#.VT>?N?=7[H8=)BAC6
MOV7?T!^0?(M\U-"_E^P_U)W_@A'#:7C6O[,@_&;=!R6C)UI!^^7X]V0?F3D=
M,$.;Q3VKI(H8PD /',644K+)!'ANN9RV23.98%]1#TU=TYW3V9NJI/9HC;9L
M5Y@[YEVOYVJW?4[6\+<-)]5=SS_NY)<7X319YCA[T]6/SF/[_;)JQ+ZHL1TM
M95_' #EE*#7'8,+)W;XQ[O!=5DF)FF-$T<Z/\1\SI2)6EFL!5G8=E[M3ZWLK
M]<]_S\)QQC PHU$&'-1*'IMZ"QL4/X0YUYSI_X0;%8)BO=D8!GB8E/>#][?_
MG-%5MNG].:-C?XX)!F48WD#^+RYL0G^C$'\)J_X^J?UO-?%?KH+9_Y4*;OS.
M\C:9_M734-M3'I0,NZ,7;0EZ?KD-#'9.>N(7HV\(F,\F-Q]P)I$%\M/:2#";
M..-+-2*!5_\3(PL@]S=I9FZ(Q^RM(3M(8)KWM>;%#)^+IP'17"4=?[]MI.9+
M[W^'L$!_5FULO5'[ZY>M]^:F-N.XFAAOI;!;/,Q@Q,]US^;Y8JC:X %UA HT
MZZ],(C7P)'P7"6";U4!2SZ"[% (%[KN)M0T<=_=F(I.,^3L+:)\!_SQKM_'V
MFQV5G*^D1Z(5#X&RJA%KXU@(7*KHQA@FJ_HR58CNSIM%2LKCP3=I:A:7DJG+
MB;C& S-G0D*)>HSOG2X&L*WF4CA6#4G7G2P^H"3^-UQ#&ER^^USKD+6N_\LR
M*+A#68IUXE:2A\6XF;4?;?D@8-B'#RX=SYD'F?EDAR&E#JSO]P>.(>7LQ-OO
M>UW4*X.IJ@<@6T[&X76P*=K?8I;D;R4T(2T.N%PO?-SY>K@7G<WP91G%U#9K
M?H %>NL)$ .4L=\"1!PET(H:^076TPH&?N-B"YZ<A$/:>,D'4BMW')UXZ^5[
M]X]3B.=^@ T[VSGZ]R;797[_4'F^D![6E/3*[FLYCY>M&,,+KTI3;M/BI4<-
M%[K25C'][CM)@=&A*S#!7ZCI*W7DKNJ6?W%QI1-3EQU=NN>BP+4WEV*WOD*Z
M8NU^\$=,/@U87L":,DV@YR,6# A\%%/.C(G]"^^GI-F6PCJXG"3?IJ0+4$ZD
MJ5G]R;\73[O<2/3T:!5<\1EW5<$LJSJW?^X.6*PG&7AQ0?_K^&(=@6HGO-X"
MQ9V=ZZ,_[LO4DF8IJ3:.#)61Y0!'*0CP#+[A.UB_D;;V:]C!-T4"7]5J9/ZA
M[M1K"'8D0$<2B@1V>&AN$G>V,PJA+;$C347.)=)+4=Q58^E1Q/:T4@UORW6Z
M%92JU=\Y*0N]$?U/#U+)R/MC1-+S3$B><9LE6*6=OP;1$[\V!_-KX\EOJAS#
M4"ZI7']SB[L$S)BID 9G%QMF)^>K&CF!LQJ9!#'U1GZ+RO"RC6Q_7N#Z5[6P
MX5B;KS=$L(>X0]K#]KBO1; U-!_)<-&;9>324KZSC6#6_<OE&3J-X>Q1!YT[
M:QAAK^5&R;?T5WVZ+8U#L+V[YIZFV#9"7A;]Y:-^I&6F GX8#ZM. I>U0_:T
MYE<?)_]@67\#"8[05U7KQ9OM#AM_VB9.F+%,JM*8/?9G<AXY/D7S7-\H["?E
M*2QL($;[;RX=P#5>W6TFHT$\K7( 'U$>FTKG/=?TR/S&Q.ALDE'UGMZ0M+4'
MYD:=9'R[06;&M@25RWV?T[I'0^FR82\54L89/D4$#U PL3QG) ,ODH__N6I#
MH.%7I@_^CTP_9O@-9)'"=.>& FXV?41&6Q4@70Y3SWQ11(&I0J3O@G;?!]?^
M/RTV1?D+G53_-W3^;047I_N;3(5".)?F,"LY=U7#R'IY4";]H]+V;NQ[6.T*
M_!CE <!?%4>\<TZ42=48?EM>;C(T?-.]&H^%:L&G)-/BY<),AKI )3A>]Y=<
M3X-$4.78>4!N;"R=^"R6Q+$_(_EG9M3<)^]0PWL5+GN"QV%_$7=^&(5,JL)8
M^55N J^<S#7;6TSIIU_',0.M^(6^&K8[TVWP_$4P(1Y/G=U-<[9VAA+="D3&
MQP@?U'(K:W,1<(0:&'4(A\MS%=VR0$TB+%,A>VOZ>K2/@B'3,^[91_H8)4LT
M,3Y*JB&.%?#]$_*3V[W]27>__8?N3OQ)=RW!ZG^MN\!?#D0(D< D^?ZO$Q%[
M!^^5'M-]$4IXU/0P&6-5HG0-C.FK<A\=J3HZ\$&:$;@+S.O5B'PJ"SF7'([]
MIU]8_8LV/+G5!BW(];V8856J!S*^HH/<UX_Z,MP\1,:%U!.4L4N^^J$' L:H
M22AO<O[>"O,[0N8F++L&Y:7^_*Q+HI1*8M[*/*@H*G@ H(^B_!_%+U1M921*
M@7M?8._>2-_I]/9ZI]\]*=S"1'M&2SWV^#>U+DZ\@[J:/99..'8SO?X"!C&H
M],$2=[^#[XDV863\%5$P+1/&*#)&?P'J.42GQN #"DOF:ND-QU(<6*^D:]2?
M#1DV/8TMI%Y@L03#=E:4)%2B50E[WJB*Z@60 BJ??H4#OSDU?0H+R11-VR#W
MC'P_+%R?:DF5+_<$?4KIA4\KP.7=#^2-_L-5VG\O-7\9=!45/OWCS.;\AC[S
MA/?;"*6(Z!2?$:(T K;>?\!+O!+T2%2@NRGFNYL_X#OI92;S9XGPLZ:5AW:8
MX]BD"W6J<=_%YB)^W[BG'J7P03KW3ZKPFV,750K<I[@B5Z]K_#*,1PO5UO17
M[^4_A-&2P# F/QVG2%]B_^-D_QIJC"'V5P4*XI4^[>R\*J,G%U-.Z,WB+C@P
M%^%(TI7<=@PYRZ%_;SF1@?.(0LU8+>HR+I]"2/^/VA$V?1_A)J<?K=WI]%Z<
M4JM):G.$ -ZG?W/EEX$SLT+-,!@]S73ZHZ[<7$JB-=KA'F[Q.(\:&9JO#S[M
M<L7&/V?3__\;^5 "Y](7!_Z)9TB 8,O&].RB.1Z+97U(Q>CS%6"":A#<?) =
MQHU/L5FJ!]=% KOC@]UO(Q'Q=--P$*D#*!W/56WWWR/F-P++18'4Q <RK>X*
M^4T&(S1S;>49D0&%K>C%^Z%JL=Y%FRE,@[NG87<W=":U_3E>W8]S''_JK(_9
MA/9!2!$CC$A+<=3B)!'+NEPHQY+UK<ZP@M!',>K50VTQ*)4(A:S'F?BA7%4T
M_^R@3#$26##BO1%(PW_^-;VBVN=H7"A1.CT%2P7\H74I9O2$%H9YGONOOD6T
MBE Z?-F4@E,G"[F__5USMFH@*K*V/WTLEL>@?JK=!#7_:][F^=ET8;QECNE1
M4('5DL:73W=0TP&5Q>/.1[G;-X^'W%FSKRM;!9,KDJWDQUQ6L6M/FV'Y'OYR
M@)F2-EOD8=[26K5[K"LT:+?V_*&JU:,HH/4$Z/R&==;GI (H:0<$B3 [TS6_
M:>_1/<0MKQM. M_/Z]VP38TW5&/N*&1^V4(M<# 0^M7IH+_4TM,0)87[\;OG
M;I_T2?%STG O_U$E>^I?73#I;/>R9NPTZ&; R)0FGCM15M]^0X"1_NY%41L2
M**<N%TD#^9QL6)RL&N0)GWB^BXZ$-2ZYGG2!86Z*H%%[-1(?GI#4>\[X8F/[
M9Q[?+MN?_#R:P*[^],![)F'NW]3/B/E!VSS[,/C^TI1#@:=Q\#@O)IJ)3O*
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M.J[Z Y:Y&=:?G\Z&N9[*44BTN7I)\ ]XFH?6P.V6KI@UV*R*B@S\'\_N#3,
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M.A_(%K9EF>95WU$"6V8JD&2[J1@?D*=;,WQLDW8L,NESELC<5'\8P_.D_-X
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MJW9>7N.05^.^;A>_BU(N"FAZ*/E>I\3L M" 9!D/%!MR[WW>15B<R &P@_L
M%.,H'B=6D:@M[Q8]PD$ME3 5*+WB%L!_[=:S<=1O>K>-?L(O=NQLY*DJ3P$P
MT*S(7S'V:M9,13HL.)JGE/&_XM>W_UW_7?]=_T\4WM^?_P%02P,$%     @
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M;[&*M-/PR+FW'5?5L+<(B7"4$YV+4F_U1T677'2L)ZM)3308XF:GR/E0!TI
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M& K-D#6YZ9YWVXX23YSB9JD?"HASBH1WER7S,*T3SM!;U&(Y#S7FD.K?1JS
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MVK0DQB@JUW#0S(&#)T#H_IHUF[%Z:JE_TO.<_>$/MI+!FC=<8A4BU-"ED)P
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M"+*[Q1.O*!<%:./B=SU]LI6, <N9"/1<L#/(3TMRX!*DZ"+B1\.3$15AH0[
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M><N0C.)&45W8VLA(C0YF7L.N"0MH[;BBX!4;V?X0QM$1:0?\DVXF3%B)KGO
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M*[33*]Z,!3W!=7):+1=W!?!""1K1ZDV<-'V)%^2@JHWTW&;TF...*EO]F[K
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MJ/IR'],(Z6E&'JS-VB]"=C5O/D!0L8#!+$JL':FO$P4S/L7O:@II-1HO0 "
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M&!XAQ -MF.5'>D=Q!:3)^N]%91S:!$^(KOM^7K[ANGE5&T2,OR&_N@IM__$
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M*>B88EU4 &&TW_X,3&*-C(OE:^@_$1A82<8\!H4O8?PJ+)*_9SYI#OV>V-A
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M7VKT;!K2Q><X1QFU@.H VU YR;D,=>%OX5P;N!4H%&OXIL063^(A=; HXI
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M5D%ET0X8BYZ;D- 8WZ'F&G\EAS_B8^H:R,/,4;3W K[X +C>6R*8_#@K/V]
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MNMK('@!?4Q$(SKJ[Y$&)^5/HX>!U^&&+TXL%),JG;\'NO][U4&U$HGV$8#\
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M&P53)KELM'2TQN_Y *$%R$P:9-O6Q#'&[Q6"L2:6CCG_8IU-C>\9^.ZHS"<
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M>&ZDR&M:@OH.U%@'1BF,'>A:7PM%>PSYE%(8S^GK2L^LB285FGE%XCSZRN?
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M[2!'2K>I+9A59Z5X+\8H-?/FK^YKX=WNS_8Z7T:<BV1I+?X<BUEKH:D9(=(
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M_*0=00+/V "_&QB']G0 GY^K&6!K&#6W(YHH4H71'^=G7CW>&.W 7/02IV]
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MAC@[X?$0'6$\$HJ^FSXR;*O6Z%:GZZW8SF XCAF=^NR ?U+SC1+C^RPM/Y.
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MW:!DZ"8VT'3_VCLSN^KL[)V9W9D[^]O]XSQ//_"%JE-5Y[SOJ5/GPR0?N>K
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M6LMT X2W.8H+L9$XI^J)!U10")4IXYM(6PO#J6"NJVWM:L-72*-%+X^7#<J
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MW2FNUI5UEK! NSPU2 ?_ZK.,/U9"+YRR_;OKR)$P_1C \^*M)8"=O6P\8$+
MS$NG&FP:SH[/1V5^-?5E);S:??'T#\Z\\@<__PP/N$?M#LR"L/==-6"=#; -
MT!>M^XY_^J7+,-V\07C(9;X?HW<=%9 #6H(// S# W+4:Y6;7Z G&]7525!O
MLT*Y/DGX_P.3>\C%9[%AA\'?Q3,=</+'<G\YGJF+!&/#"/AHO(>@'1YC[2?P
M\P0<8!B%:R)8/%F;E188,_.;$<B+"[:R!*SB]@VKZ.&!'4H#ZO0,@B6LSR4
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M3J^ 3M4X@+TOHTI?2+)XV3W,T-.WX9\2^91;7J67R'BV )MA9F9*6B9:FM+
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M"^FH4H&X:V,)W")B5\A4)SGTC=3;TC%;97B@) (;J(4' F-_/00-F[4H(SC
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M2^E[YR"'_/F'Z9V;C+D!%'&ES^'E&@8AL KF:X:/UJ=JS$A(:SA8/@U#;/#
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M=X4CL5I.CF9\V*&DS<+MR (,?\9D8V@.NTU;&;M87%>$('Z*P(QW-6O^ZAF
MSB-HNMF79J1\>NM1\<MLOA0'!YCB5J\"V]>&!VC&]%F0(GI ,,3UY7*'!9^M
MWEU5<FEAX6B'Y.NRK[\0#?K2(Y,\N!>FK!\]U"1\SV%<DK+U[G5IRB%S*/X$
MR='Z@4E911TZ+;?#TX&NF9Q-E_0:(>#HRV[ /B3?=?OHDKC@\=X?S@H4=[/#
M^;6&FRB3_G<9ZYJ9QK>>')*_R Y:H@C36V+?-P>3 $Z\6(&:E>\L ^Z6A=V2
MTE.C4SNFNK;D4>GG2XK.;TZ5^#Q6;L:LD3ME>)1J6;2JE5QSXY[<4P[_QKU-
MTQ[G<R:&/0Z\,=I/>-IYF20 $:Q%62)I2L0<N6)X7'1]9X!FHBSPP'*(/#)S
M1!Y]"D2^7 7N'L$I,3S[E%AY!<;4GR%8@<\#Q;)!N2LKT,?)]Q+[AR"'/I7:
M5;7M7*7M\U+3#J:.$:A4_XJ_:RK\3]6#O(^=&0*O\%KB\-T%K!CXN8W\'NTW
M/_BK,P 3' PSL07N'O[!X1T(1!:54QZ=_,%YW%P'+7A\!E@>[-C$_?'R](_]
MY"O%THY)#, +2N!(1_GONT6C]0R#,:=3WYSX,-4Q8?#NBN]8Y0[3',_(AH!@
MG>07T^G;G]=Z.+.Y'A2#0H,0 8U=^-PC>HJGU=_\X]JXD_\<#<:NOUR0V&0U
M;A6EZ4B:?))A&^B\4ZP*2KWYB')9[PSPPYCUOWGOTP_*H:\WH=^-RMF4%Y4X
M&5(V:!4YFRCXXI60F;G7TU+H]UW-UPVYQH(]/IO8F_=4<][9M%UN?>QX.[E.
M"M2;-UJ0F5<L7AGFFFSWD@>:=-=)6W<F9YKH6"]]U91W&+*WLEQ56UG^!HG2
MX-&FK-"ZO>.U4@8YO\94E%IIQWF/(^ZS>LKG_067(F,V#JJL$=EM#B9QVQSK
M-2_@P;<I5-00Q!!KH3)/OMG(T[,3L03<Z'$:'.5?_Q:^4/LM?.%;F5[77/#
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M6\#-_#!\2UUVR!KI]:PIW^'<M3GO11=S,NF'RREYT5_T0-#RF@^!6@3G=1@
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M?U?'SMY,L\KH=4A@A0.Q>CO+HBL!RSD*NS4O9-I/@7GXT&B$1$NU!47#]<^
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M/['/+LER?$.:Y*L,E,T8PYD,K\4HC)X?<>>@O[W!,;U,7$,X(6?QOM8-L6X
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M(",@^>311,!1!'43H9_$;^:V/U5OU:L8_TDD*9U2_<^RO9W!/S* /YK^?E1
M.C#YL;SKWS3]_6\NM_Z#(?9'!:3VGQ4J?S7%:OS)%-O\/R <[*^VZMD'L.V
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MA_2Q=\:IC3]$)OOC^5\@>@T64$BG+-A_?Z7'=/#Y7J$V7>K0%@=M;C<E4=6
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M.)V)^P>G?3<0\BW[D,=H9Q1)!UPKN,C51Z ?/D0L,#5NV3[;J\1!LQ,KO(M
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MI*6<]*>Z+!594"177[[7,W(6Q<I46CDB$!)%!$A#C8_Y[%;B>WC=)>%N@MK
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M(VBP4[XP5<R-)EW?NT,?QQS!"7;NEH;'#C4[<M_+GV9_ZG-JCV'W^WF=6"Y
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MJO7GH)DNZ8()[L5*1ZC*R^OHSZWT]#3^:*UF1*SI+@; FA O<?:8J5M]+F*
M9S-H<L82I+Z,^W[N5'K?3D/#H8R1!P;0[1)U/"C>_^6I%OPN^0A_;F*S7K$J
MRNR4PJNL7*"C:%/7.$]PU3MO;5V6M?BMOXQR$Y(2H=1J\*P,*;!O^RX%=X/!
MXF#RH5GTW-T^KU@QCA@I\6,Y&[LQ1W (N=Z&6]Q=O430EB,]DQNZ<J^3"F='
M_2G$DE?Q0,-8=4[FG4@"Z;[.4!)["E1%_>NRS.:<W&I.4W196=5PH5GY^T!)
M;]LGY)W$MZ@U95L TL#<?R!5)==((N56+5<>)WP%3YX7>@-"Y/3942(/(UP?
MGY5%V2Z PS116N,-W!C@/#@:/*>?Q?@L:N;6EP=0/0JREP(>K=_D:ZRBN'#7
MSRVH: C=*<Y]<R_F9BR;LH&NEN9(:4L)Z.059.%%]<DS2^P*OIN/'KW] 5ZB
M3JA,4MAQCN#=MB5XR%\Z<6,L?6>/[ 1%S7:O4\0GZ>YMUXF6N28#..TZS&(>
M=&8E&85FK:GT7I[LOV)32$FL2\\[<&M?/0ARKLB/5B5?NKA(Y*TK^04SMAO7
M4T3=\):V/A-DJ#H3B^UD*^\,>^,D*V\6+?J6JE.6+E.W"F^#-Q15D)6.<<.W
M@D$'V[=F$.KK#4_ )*8V4-%0D[EO;00U%]3L*/O/B5Y@$NUS(A5;BTJUQEU9
MY5YJGHSN3AZK.DH/%BZH+7E;$>3 :Y'ZH<'<;4RM.U;\KO1U"-D;KO_E>/2O
M?%D_E9QT,>&[Y(BZKN=_MBPK;NJ$Q2OLN!MJ7]2NX$A5;7B'J/A,^AMIVZOQ
M>4.Z*:44K\T0@OEORRH<R?5LP]H&DRPT$\+DGN..?]$ITN*D[TZ^MORN5\48
M^S,ZU_\O (+_-I!<(HN$3]F *W0#A;Y:X*X\5K)CTR6PW:IUZO.^#Y/;%]Y]
MG/\V2)9:ZSYP'2AA1Q["^PZZ94"5(RB9H+TBMG(EBBIBQ&N*C*6M,[AD':Z7
M&V;:,4#%3$B#).&*B3#\8*K8_B6K:F-1[O+UASIWB;Q1C5Y>_KY*IJ(K58CE
MF:J1_62!$-[-&.@J5V9;Y+Z?K=7:19V>36?MRFAHT_[J:!%*'.9:7??"7J78
MP>=KUH(SP[O>E2@(X4K3&93$^+IPD7JWC'B8\IZQBKY9&,R9:WHJ*V8<=(D-
M(, C^0(H -ZIOU3&C;-)KW ,W+4W6%,;L:\,<2CBL+:4MVGFOM**!ML 0\A2
MN/=M9*(Y$Z(GV:_2X4R[%^6E8:DL?U_8.'/K/AOHS%@3GH_!^;.O$,R672.6
M,WVC%]II/"Y1Z-QMP!E4LAF%$W1]Y,0.G*)!O]"VFJ'PR#+/F2>!_]V.5+:@
M(*!51;O(FIOM9842)O"'+*5AMW3_ @S0^9D@;<*' )DX[ZMX!7UY[:ZAH6++
M];K&8ZU6R(0V.\$WB26"Y".E=C_F81].V)0:K4)P;WF%6@@93W>>I?3$ZUA?
M-4^1W&,-#[[CJVO',B3ZFQ&W+]USR!>-Z;J#/NL]IK2>38W:-[DRZFBBGUF3
M#,5+UN'1_ZS<+^ K-0J._"<LO9^3_1JK?N-N KS4?SK'P9WRFR#U7Z"=YH_.
MI+(?TP%_E]7[1V?2O,&/Z8"_<X3\WZR]\S,J^HFBZH^4WEE(K]!%A21#3IYA
M<:E"KTGU;S+QEM,HL3_#AQU,R3GPKL%8XT,/=?3-1EITP\73VIT&NW_7;E;Z
M&1!]^,EA]'M ^R= %/F3P^@7I)WP*](.^J-VQ/]&\QD]YC/LSO48[CQRRZ]W
M?4?.VI[^^JKRFJCI/JH!3;U;Y*,_!Z)%5M]%?#&Y#C\(VFH0+]RX[&E_,6;,
M)<(B)I&^FT"<($JP%SB^$W;X@ R*.]?!CQ_7-A:7OM6;_>4,9"L1=S</ GOC
M=Q4[B]Z888# #R5H<5F0IJ81;1L9O<?3;A;RNI$&W9SV7!,%G_T5*@V5"_PA
M\_<GW#C%+>D_B?T*F7X!<_3(=$2]!OP@#-0F@S?(J#]NKF%I3ME72H&+KS><
M:)]%\1B8+[D(> M3[R2BL.@95&A)J^M'9AA"'6I-T5*E2 9B=3CR8_;2S45Q
M(_/,$=RJ-9<G5HZR0XG<+;=>6R'':XT"Q>GQ[N^SX3;]WAY0PGR2V[SPHN3D
M&79$GTT:@[Z:1Z8IG@L[;VGN#VRJ>9!MD,Q#B)!/85Z3UGX7ARN)2JH[T&J5
M??7V.&5.9'<4  =T/WA;V1#=)@A9OF)@"FJ@+_:8AYWDI,+"^3W=2;.9VV]:
M*F\'BE.], H8[?9:@%A%,WJ8RB+OV[DV7W@$]1ULCD>EI,1'5KVH$>/,I5Z5
M$43&PS  L"JA5AWZ,'E:^MY'\B]9WD."+/U;W?V"#>; [A(5SBQHTA0DPX+4
M$2Z+5:Y(E1!QO#:U/GS(13H??[&4*6ZFT8N@!0-$CC=)C5C",4#HFR!A,9B@
MG,N9#?V1"_3ZWM<_><Q&P/D'].?((DUPAH08PSO'UUUIR=.O#8W)\<0Q.=4K
MW3Z>)82K3P;+-C0ADSC>QUPO&[9_2*$6G>@=F9]^EPB$) %$3W5(;*4C!KA?
M ]D5YU;O,I%"?GV'U-D>UH'W'[D^&ZQP%S18*3N[W2,9\,#0)N9UFDQETC$6
M%?4:8 V;]T;@(Z;X7>VMSAE ;U+5F2]LMU9'F.<N45#\U,35A3A9%I7C:ZMH
MBNICAT2':P\0PD/GV;TC[)*%.1=#HEY]4I9ZO?1"QO1ML8%K97SA?)2A_[-.
MIC(J13LG>O\'&6E9N-'R0TTB2&Z+:_7'L@:K#-0I4WJ&7XR,R]X=VF=<A6EA
M@)E;Z9&^*5B\--6 '<.-@V , /<%8X!+@_M;C-CIT'@:&P9A#;D>UU]"P>K%
M:@A:!?3T<,4QSR-=M.Y$R?029,MNI_X)_T8W79=+W##3NI8,%BW'AF/_]1C?
M!GPD\BGG'_IWB9*_IR/]5O%]=9Z*'Q2>#BC<U385I*0:?OFMXJM+7VIG R'9
M#IJ:=Z]I.(>7;]Z.<RYSD_K;7$2-,F$[Z%Q3- 2\]LW%FS!]X,1WZ6\S*^GF
M#BJ-K&& @:43G_8)+31D;>OO]RGS'UVRM.7N8$UIS[])M42]LJNY)X$!=@ZQ
M7[F^3PU./SH> (U)R4&*Y?'</P79?]N)>[!QJ4H PFG37Z*"^%CA7N;A!K4[
M=+&!,3([V2\5VQRWU#4VMAKJC:WRP5R=FE]Q-*!,2.L>?>W_5G3CK7LS?["Y
MKTR*)_-HYGJ"8&L7A/#+?XY'YR"H@9$C_4DU-&= &#S:D2NIGB<M:!QI_[Q5
M=Z%9,CIQ]^,5C;P/"+V_30.U>\1=L.J* 99VT$V63?_T,*]_1UGUGQQ0)>IO
MH_/&,4#ZP-%A\/L\%-9(G_X[+%->OE2^=YI1:,AXOW20^A*Z:>?OD(\-+V?^
M^IQFZU<AX+V#M.]8IPH,K"*%O8L,/DWK/NL66HX,:9E]?[:1)LRY3??.9@&Z
MR5S+AA-QNH?'C/QO!W?_F:;@[NYH9L4[NM>A,_8YS],RJ8W-1B*VVU_ZH^>G
M:H0DC#2_:\ID](FQLJ)SU=SG+Q>/*)Z!VAJV]I-&*YG-._T8X!S)_<VVDTX]
M'OH/8^6I]*7][F(!JJ_[1G.VWP>6"]7O(UWM5;4;ZB>DQJ.TPJ2_[A</R1[%
MR3)Z675  NMXVNP9MN2'%^G;H8]R..CII K-*Y] 09VF>,A$_:<JG_>0U[:*
M13TULAZ?F=(J77C'A,\)+^9#TT-:P#O#NAB@)1L#S'%;M4%P4*RS U0&MD>2
MJQS;PY $SAH=]21Z4EG-R4C 2_MT?W\LL=76C.U6)^[>&$K:UL6;ZXQ*V;(I
M+I":]7 ^8F]69SQT^&YBFT2'UWFS?.&(M8?:@>EB73X--+/,$PL((]K6<%"H
MB.F4*;R"Q6UFP3?X4\USDS2KI&C>*(E< V"I@?-88F6?Y3H"?SR,1^C#!L6J
ME?VUL2O9? YIYM0D;;LW"*:EP0SK& "FB#IE\S.80F, U5.&^5<>Z4HG&>P(
MMU*.I[S+0] CMS(B7YO,7@$0'T[Z1?MN@N0/Z/:3K.8E[#Q%$_."D77 OC82
M!(<Q78<7%<OU],>2'](4=ZL,"6T0J86K#Q9FE)8_,[L8>#U,^@[!8T_./.$=
M]7W0!CL&D,9J:;@9%I]UCK]#T94BXRQ.*C$ D=R2/5IIPF<MQ&+EF^>K[8GY
M?-<,,LV_Y4XCJI\REL&5/ND7&20M4[NH  K-T5MU8WAMJ29R!$40X!=]TP=0
M<B47$:(MJB4LR)U[8PV&<X9!PU"U.M_4O"^#2A6DQ2*Y%U'YI%Y+' WJ]X9<
M08$S3$6%NVHJ2]LY09G.VTEO7D1T7HXB]208!R*8[N-N&+P1:<PR-#F)FM<N
M#5M#>Z@\#L, ![WB)6(G;WQ</&=G@O-(8P0-9U:'?9,X%*&#BE2)%M+1"@/V
MDP07=1.L(>4QXWY4N:&<8YS&C_<_SQBV5M"%Q=12AQZ&6G1_3"-Z(K: NYK6
MR%62)$/HHSE2@0&"_'C*ZEY]48,=4[KF)-V9RY?32-\LP&>=#%G&=\ELK_LZ
MWFH;';;CT:XK,63LH$5YX8T/@D;P]1*GE',4_[2_3&-^4=[$M:PZ;Y,IHC'C
M#W86IM>C:HE>SS\UHH[N/"<TX'\$B?21;5WR9L<G./MM/AXJ+2H0MR[@K2L(
MYVX=AT8N+G5LT9&)ZHV%"[\R0^=3=L')U%J IA""@W>X4];__TSQ_4U,^E\[
M#Q6V"N/E^5;[@E_9_!$=WUV@M],%#"\52C\\:,0 3:?4>84VNKDJ4(>.6UF7
M$((%;VO5D7I8;'$\C=VWS__*HZQRRF4\<PP#(_,'UEY!OMWT]C+^5/P;MS7W
M^U,"XRPL#&C<.H&GH[0]L;*DUK=-(RNKK@B#,?/%]\9K$7LZ2%*N:3-ITS?I
M?=#,'UE83UJ;_LF2<Y)A1&PFVL.,KYZ_6,]+_9JK4]-)61;<: #Y\=GS/.J(
M[CSD<U2O'1TTRD7QJ'&B?;<@6\]^Y5+^[E% 1MB=48#,4?7TJQ]+HG8_U/?8
M9P:N2PWQV.C3 G$!Z<EU-M!4/6W=I[7.KZW^(LP;;7\F(_^-^ 5N)UKTLQ11
M5J1\1^('6\:JB4S<)[%I,*W'SFG>I'O-IE>6&8@Q0 6H2\WVWEA)%@-I(@>%
MF-Y">^TSS9S'M$YW^[U?SQ+#<2;5C_4\["TN3[4?%<;L/V(0 K\P1ZV]ASMV
ME^![?-"(5@_\-J_6E'A&3/A<VWDR<<+56TM1"Y0Q$6EG.TO:0,'["6O$)A1#
MDUH \?O#R)9NGDE.A/#B#+T,SO)UCSL''2;$E>A/=<-O;</#M5^\R@E5-/+O
M7K304&=B(H]X_9G@\Q/==!0%PF=:$*F?.SWSZ8!VOW L\;%XK]6=9VD+F9<X
M1]*+O/!_\47,^=&>9.@,WY4@Z[3G<"2QR0M8>F4DSVD7+_Z0H)RDSU/\3&-9
MJ8\ZC(2@R\"L%,&1A+\K)DD_OA3R^F%F=)(Z[@M%[\]GBXJ^-N[E&TVJ4W=0
M$&>5BKF:K2N=;7+Z[*.=Z\-YDM%@+67'7AVLFY1;U;C-H%;:\%QA)5;K>2N4
M[$K4%QL3'WYD #QG98_O&;0BN3BQIN%(>)+8.?7+E1:'LP+91KOT'PV'T1P^
M,LAL0FM3REV])Y$&M),+I@D*),.+*8L/.<%/YE>M<:MJD(OP.6C/5]$PWE1)
M-N>>3<CL)9<C71SX'77D+;20QT W@UI# I2]C=%C[ YQK""K0\N\6$0I<T.K
ML7W)^@I\>GKIH^]E[X#ZR^*.[%#I&E;6M;3XY2.')//,"26+;/U6"]L+;?)X
M9M00'%F:=[\SB:*^34O6Z]M_P^L6H'(B%3C76H(U9IZ;P0D.*AU11*9HCL:P
M, "Q>/*J :"C/,EO87F^[H(!HL:S/%+:)&@CGC1C807%H_<SLJ3W/"YERN2W
MXZO7")<K )X\IN7J[3V;J*7*YGA!])LM1JMOUV>*O'1",U;\F(;FARNXS_'P
MLAZ7WDA1]%7/.Y :"Z+":4'.SXX'^5VT=5ZM6YWF_>(4(FHX\%X@4+GG(@;P
M&)>F7>^%'XEK?Q46UW)5JI]%WR);,VE6 !X@K=H8R)Y6;+U'VMX.;*-IA?!0
M#)%_?;7XZD2E*/\7K?&_PS7V77/Q^[E.U4?D3YQA_Q<<._JO:P1/T9_1-*/W
M1Y_PA7@1DSA?>];CH*E%R:#$^2K6/$^CLWP<>#K,T2C8#J9$79HK$F!L%#4I
MU8U1/'ZTI+<861J;S4@0Y=E%*L912Q;6C+6G89;(_"E]K$$6?BS84V:HSKDN
MX[91O%7O_JIYIHL?6A.-?.AXE-J\C7U%4^]PET%(Y2>F1T03D-E;D$A5Q\*5
MQ'N%(G6164-5;MU,J_T> P#HUN'2]Y7Z5OQ ?I_2X8$>6^H(3A0[R/&8-@4=
M?9*^Z#A#J730,-8ENO1F199EZG1\>A_G0<29\1#R1U?[G.2:0BY MO(G2R@0
M[NL#F1XIG;IU'].JG7.()HF'#-GK>@HN+8:]CCCCV9T'O@6DMX#HV,>:V#W*
M;R%H2K/ELA\=4.2DLBK'>(:4"P32I:<OXL:L)>\.(&^C^+"X@B,& P0,0A#:
MVP?8W=2J8,.]B^7BD*O[R&X!LXB5JO0-8^E $ZZ8EP*;+>* *-Y>\3":_FH[
M^OE4.NJ,*?J:OW3T/60 S%[R5EV#(_D*9T]H%B&?.7L($X#[6&6>>6T ;#43
MDL:!#$2SIG0<7!%R>SYAR./$8Q/4,(0*B#NXER?6LB?>8CK)=X=4%%FV7.QY
MYJ,<ZUI=HPOLH'V#%=8=?"?^;9+%SD-!(Z,[<IZO_06<  #'GT#]L<I%9NV_
M=2Q"$V& !06CQ<UVZ21V\RFW1?S[89>L*!WL,$ A^.MD!)D!G(]P3209W&6Z
M 8ZH,LBJ"S/BB62;,+VJZ1_-9B'W$#@C\@+ !:*XEVU-HZ<)T="1W52'57N&
M'?7ZA,F@$9X/'-W<-0)/(^;?M!Z-#V  !I1AKH\Z,OZ!%#U>=8#]4-\5/':#
MU1OKBJ-2\]^ A[CCE8 ;!JC,:K*;IIB0OVE>]]!U0<0G[01YIO&XM9T%_[/L
M+,1R"HNJ*DLH3S*E+KDU$_KP>UP8X BD@2[&L5UML,Y&I\QCT=D9:O<V[&Y+
M$/2D^6F"BJLOY_Y^>FY1_B3=ZXJRM_;R]?A.3N?9$.DF7+C]V!?)>Q5TP:.Y
MPXM]OJ>J+CBX^&*B62M.=J@[F7/-7+T%\A)" $RB,ALSE\KEH;8I-?:@Z)O]
MU_K-]8%IG*JM+N_A9@L0B5'[V>HYPU=)%VO./[+I(/]V/^%%M 9I:[IQ>Z4K
MF!GEXFUO;SL+/K^5TL&P?]GL_.&;H"C^==.8M#XZ1&L&F6A,10DS,G_\MO=
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MXH*,CLQZ[N&XMQ$HVH_?XQYL?<9BM)B];N36)HV(#8LLZ75#-ORUM#O.GQD
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M;L2C+NZOI-DK:K(/C/;2'2NWIW(?7;"IU2V\>]NZ[<KT[K[(BB&-YJ5YA^/
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M,A=GHK3OL4X# $ ,3/T=^N(GH?QR4&&J"*.9?O\M6BR@-\-HT-Q5Y=5'D\S
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M"+29%!EB8W;ZLN/]4"V1!$T)P)H^:.%YL:\F=,^]SFJA0%$H[.%550[5L['
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MGSC$?Q2'B+<H7O[5Q$LA:>A1L]ANZ\,G>_AWB%C1H[!0:1!?0G;RS'6];.5
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M&/?$$LWFH2^0.F*0[*9^ VLY,@!3PB_,E)?,8W0VPX&Y=OXC_&!SC-E; 2Q
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MI6QJDVESI:&DJD([0BXQPZR?ZXN"2]J-@>%61HX*!7^5]XCJ/IH.C1:"J/;
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MTJMTE(%X.IO@8DN;6$241!>A:M 2'L=F<5S>"&E>11RC3S8@QQM@#%_=J_:
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M-L<O>JDUN=XP?+CP"5< 1'+?QFTI+%UY>RB[+4[A\Q7%!)4Q_N64S^Z2<\+
MJRM@Z\&: <KPQV](-DT,HKP3"+T2I5:>M]Z3CQ$.C[)J7^$Y/X%B/L#KFYWB
MTO.[8C2RI8RE*=@4YKT:$CQW:K'/ZVG9;E4IG?)N+EW&#9)7NEPB98&+-5=@
MW< YI@#"XF2/CS>EXZZ\J QFC*B:F9D)AQ@)7@P&:GGWCV0Y72)K<W^(^)B,
MY"[^'*\K\S7Q:%3/OX=^\X&7>NBB"L!*801\OP$$\_W#9 4<C+&$OLD5+T1
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MF:]&1+H(4%#TS.Y%GT4(J(NR?E/Z(DH\Q"-XC[&,RB^WX4[(>XI.?)PC=1F
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M8PBH++^SRPNY[S"=S_P8C>F4Y':+LE""2WB0O@LN\B4'DQ%)IS&1:GH']-!
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M8;)B4:R=T09(^P^ [#WJZ"^^>5HZ+\J)&%EP<"[F?O?@SD 0X,.AJK,_3$.
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M; 7#+IM<S?LN^@>%^<N4@5FXT*H0*&F*JN7+/[^J\=_B;.9_ 5!+ P04
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M$]%VT&E"&WEGM&PQW;O\!<"%71Q<VKU(KC77JSW14H*D78\ KW>IH(!V810
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M;3T=LI56NZTP+S:M\(*.%6NF46SGZ #<67'"30,Z&G2ZH!G#^+I =72AWA5
MX'O!L&@TYPW/3'S4AL$E(\A>GZ>-N+E<9OK.A*4UP[C!Z%5FXU0"_CCI2.9B
M*!"0!.I! 2=7]E" J3;4<!U)- #SNPZGJA)298__?,\#6S'.9@-/=@7\+/TR
MG"S"8J2%ST.V-GMHU2@O:X:S"]/ <^G +1T/BVY7Y'X;^]BY5^8&K2%>Y,2R
MNL.M*[W-B8/<VEWG"9ANGS )9'QT%[ S8YR>";:$\)'4E*?W,D(3&8XJHK25
MN=Y^U,Y5M(K.LN 5UCWI$Y8E)0 IV'[]ROX<0<CI1+)=\G@@D5Y7Z8,P=1T3
M)6+"*[CM"B0+R=:9 RD_E!&^??Q&P>R93)$WH7 QP4F@2>O91,77,Q3 :FR-
M;&-' 9\T7$WI19_5@)[:%T_C1@LD.3Z*<[^4CX6Q%U>& C#SQJS?G-^ LR,,
M.@U2HJN+Y\ZKC!P?(.$Q(K%FB4-,!B(PK^YT#KA&6X'W,M&*FP,1QYV )7*G
M3KZ!P@U"^-X#KQX037Y[#L3NND&W@?B"8Q+&HM )T%L<SWJ^/=;&8&-^ ^&?
M/_,F2!1^D?^8I10%2,@M><:^C0GT<-=65/GOWD=_\G\0=YC#-^E;L&ST5(F*
ME.X%??)V)<[HCAV,#0R,Q3"YA(^G$Q<+G>LU25.\OOF0\  4^S #XWX< 99.
M5(;37#_Z,:O,PJ*A\/EUUP%Y^\^$"=+1Q<)@<BCW@5-TX7LXFQ6W0FV+D2H3
MZ$5;?';:$=90VU4;@^G>MV-A/30)OC>I=O#OM@87$0-'C-6QYO,M]9VF-/SG
MC$N;[KFCEUON7DZ@9]!Y3;"%WSDK>7QNORD]""7=>&/J7Z?!TKE[T+Q#8A=V
M^W2WQW?86<YL#%Q7WN)@#5TFL@X[T$GA2;K+\K'/U"ZN-?Q]T$+$L5.$B=3$
M.76Q[:5-%V7.U/=<Z8FWU/H^/R#IBI,?%/3=)_'14)8AGWT[_* [46G!F^/.
M@.^AZ .R5#\7N*86XT:<;?BML/$7VI>3/Q[<2S4GVH]N'&KU(0N6(7+CZGP]
MQZC]L>:T6O8M#R;QK>(GLT);@?$;]FTUL,$0,^DALVS;B9&B@7Z27)N."_DR
M:7Z\#P$,<,U&6$DW[82$/N'90-G'TEY'SW3Z>]95DC+!9 $\12T7F7MI6E.B
M1! C)OIR!NV,#H%:7XWCY(*MIT5%]V9,N-?M9A7>8*0W](GI+[P]Q7F]5_/I
M<(KQ;-A0J>"0:C>P-O^!NG?N_=G9'K84FTNJY.[ZW 2@-,/LB#@YV4D/]1W3
M;EJOT[;CI@0="U61_8<7'SP ]]['!B[V\-YN<?%XP\^;AKSD"EGLT:QQW$&?
M,+X8#.OJ/2 %+4&CQ;08-B7J?6K+6JX0=&O7-@F7^#6R?^&*CU]H*%^.X):'
MDRBO@)[*B*V0&'9I5X4=3S!^IJ&*O\U?%7[9N<,5OY>#8=W/ 6Z" GJF#3=I
M3BT\]??52K?>T%O$Q39E+IJG0^@W]S*R]FI:P;J*&FH]TW"#Z_K+U''$1STW
M"A^+DC"J/7^?;RLN[BK8Z>MK$971C:'GCL<,"^F<#*"&K1YL/5LSL>-](\KA
M-\P64B/1_D'SNC6S?7^+-_5Z:(#  SL^4K7YO(M&9T\U"3PF>'QJ2.Q-4PT]
M]0L>S7'S>T?J1$9C=Y.,7NK+RP4%'>;YRZ_*,9\K)O9Z&2:TO>0UK[D7X?"\
M/VVF^D4'<H_)9S(\?+R-_OR&-3GW['VU&1K% 0V*OCZYJ-;3V,**PL?N[TGX
M05RWW]17/TW]6O_,W+0/0Z-]I&9'7RQ6M[*V55%*KS'4 FN##J3&CS<4( B/
M?2K'OIDXY%1P$7EK%$BQ)&MQXK@ZBZ '2Q#BN?IOUR$(\),[3]\,/'G'.=\U
M!9HK5X*")EHU1P:GW\XY?'7(J@L-^.K<0Z'\B93;CA_O?8)RB1\W(NS-2P)[
M:W/:EP%&+XW8I5AR]MGS%1]#JI=)V^&4&NE#FJ.&[V_71LT:ESI:])DH?>N@
MZUM\:+%2CBL7W#;**Z;BEZ8Y,+_/ZO9FF3,>RD;"EQ2:_MJ1[W!;A>\R'ILD
M.W[C*>FU63+NBXP@9-<$*2G)  !=O%(?(&+#5PK!-7K)+B#WFK61T>?K!@H(
MQ/,ZQVW%;!B*.%WZA&1>J'FL;__!\):2=)L7="5HTP-K?0C7IFQ9B][6QP@7
MDOO2.Y,E7N##A8\SV;+]MAUL+U":]I5_D?V;@O>$1/=4'T1_/)#"JP*NGDJL
M[XJN-:"7,AT,1:H[/_E?@17=/)PL'W^32.QUPC87X"VGUO5)@%"]2/:</"YR
M,W>A_G").+>RP</1I9.) 4@IMF/03RNY56571U-?E>.HBYYWA/[R#YWMYJ@P
M<-*B\S,>UQW35$YWM'M>9<?/@3'I'OZ]+5-//=I L[HE;&07.4'T.N3IPQ>6
M!HFI?L6:6G+/,1S_V\_U_E69A_'=Z>0Y>QO9V-$=YV,8Z.HB:!Z4)(T":A0!
M;]IHY#5(RON>E"@3EJ;]PSEIO=!/,SG!*V&S*AR8G>'8[LPDOB;)A5TEMC0I
MT54?).Z4]@_)=TE67(6! WN*8.;:!K<DIN>MHN=B<47.,K6<7@H-Y7S;-(1B
MU6XZ^0EY9,\+'1PV.D=T$;,_CB,;#O&7I+Y-II7]ID5CF<B4".&SK=_:J4*Y
M&NM)7!ZP%>L*[6EIOCT9P ,9P"JQ"1O5K+1BNSHM2G1%EBC,_&C16K04JTWL
M/1NB^NU >>>MT$"\0+_N]6V3?E-Q2*_II!B4<L,S@'M4,::@8."20@MO5IIS
M5^%7;^R0F9'6ZF7Q:O],/_!8K2RW&<DL&YA?(:AN-XD*=H.9(+]C<Z/<JX.A
M]DOCHH:(]M@:I;$6(ST'(:T+:9<D'5;0=*-3!(O@Q+G4L@#9],8W=2>2T0S9
MVVK(A_,Y] ]=.F6%)C=52".7K<\3C9V0Z+CRV.R^*4[[ZBM#Z*1M^Z&(83LE
M>#5E&WJ$CKRJ"=>03#-;WTRQ)T D<^^LBVJ&5K6$P_2Z&Z5PC(I7W65M-G"1
MB7 <,:VGDTAJY*!-6T^YXF1:L[=QR^-IH;&#Q-&%F($VIV%>&4NN=]%J,YKC
MI<MPS&=RPYX;Q$ZCGG@O?.#G;*TE7>O=TF1A3KLM7D5&IA\=35PXBP$::GF5
MLT*"/L>%V,Q/S&+4JPSZK7"NWK?^ZET&^@SB+SFOD;_2>];[^/DC+78NP,?
M:?$%'%+?$M(SW&'Y;/+K-_+G%_LK7Y9\'@:-D>9'8HSI\5D;U'QRMR^[J^W_
M8J*_M6_+%Y#M9R5SY=[Q!O5>**@<&K-K*''7&Y#QN 5Z @ 7<MH:=IP%S%WO
M1@$4+= O<PC#ZWRT&@8S3).$='72^WKU_@I!,Q--6H0%W?9@"B)3ZGY+:#[=
M5.TL!@9)5"! Z /_9L\G)P 1Z-(7;]),=W+*JGEF=I_O(6/ '3SXFW6Y'+#A
ME@P?'$L>[MMBJ-?%-X"IT;+]1B$')$C/&N/+ 'Q!\D,*3& [/2%.2S/C-;XG
MG*KTV<K]N(+MWIIX@SYZH*]#42C@D*D2!;1=1@$K>@8KW=L.A1!];PP>JNIF
MG"UYP92)R)6A4 O_"OOB6^ 6V!6P\I4,>>DAW)O+-J+W*7N\!&<73K[JJ"@$
MK>T\P*J5'_3R+ \NLC7LR2B_Q[<;[T4]U\R$%UT=LJ%\QS]6S#,75XN[TXEC
MD.#>6!56.? 1 @X3?8T"HE(&\PHAD7H-]55U%KJU]69!#0G4-Q8!/!T"C@O[
M^5=Z8R6! UW8%'&*?G#2E@5\).O6L8^Y<N'FR#5,"CG/U$M!3S<&%J[U#8IL
M:V#8=Y\:+W0.4=IZS;.,\UM5-<\U3;NE=8KOZ?=0!RW$.>.?BYA<F*@N[>%N
MFTA.[K3<7ZF_5:='9FE&"25U;>Q5W!M+7(AI"W5:GKNTW5T-"2!:G,YE3:[?
M3S4'* \H:F#*-V]B647PO$)$%O7G^EV?<%SJ2/R*U$F<ZNL4.6(LPNC9SJ#R
MB+8V]L=;&LPX;HROZ_?I;U1F=01@)>D2$J"LPOR0%<6:*QLFA@]VI,3[XBQB
MSU:A,A,9'3LT/ )8:;>[VVW&KKA]^;;_Z2O1X6PIE.&PV!=C70X+D3F]6WB*
M]\Q!*:.T1RTHN(1'0*]SS:B"&1:0E .'(E4UJU# 8_"AGT>GWR-=& KH]B<S
MK>Z^VU2:((P"*)56$K?WX]IO1.P%"*" _FL3X)UP9&S,2TH_;A208)H#G91
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MM-RE6'I@T9JZ-V!H(Z?+IR24,7HZ>&HU, 3K")SF(SM&FP#1M.%7^^@WP9M
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M"OBV"7W[(M![Z%Q@B @%#(55H .T1RA@)6G!AF&N_NDAC['A.PMUWSS>2.[
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M_+N/6'_YFND='/JT?8D*EO>E]MBT]N*U]:[?Q]?UT@7SG;WS0YKCM0\,WJ&
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M1=7<OKWJ3_F/&JP\O@BZDS>' DS9-S(0AG*D*""S%ZGV$=U]VC_(GDQ'R%4
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M)K*R;2<-+GG/?$D?D?#L'L15I9<!P(3;:%\3H6<)D8\R$E!$ =T37&_)T-X
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M,F'=BCTHQCCN6@L)U7WBR2(E_WAHN6RP<\W[N!QZQ7M%R7-)^?2^XT;CI)^
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M[K1\2AO(C7L]Q!2VM#F8WG!OS#&X)6,>."2G(X :-L++9:OS_)_QB3^EY2@
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M#&?I6V;UWFR_V5[$I;V5/NN&L1;WN=.U"'(KN=FG5KG@P70]Q"H</U%RZBN
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M<K&EI!,1VJ!H;2 1&@W-?:LO50];^Y>3D_Y6,E.^T;N)<P)PBNC#M#.QJ&8
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M5,TR=]#'8\'< XF)YJ\#&&ADEQ2Y;G;Q-*J>->&D$=P+6QGW;\;D/VYK:QF
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M-CO%1J'#&2&4( .-%B*T$9-IY[Z'#@S-/YT;KRB]^(49LO, "6@.V!A% IY
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M]4X/+&I%G;RS&=<3])=]17[7UAO#[TDB(DRH&!@KB0B!\-=N7,NU*2#Y<)8
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MN&L^![WH('QCE!:@BI%,@19H#3CJ&K8&F7JR?72VQ'M06!B<U='0SB0*%N/
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M_'BAT^6S8F"-?J:++#"V^Z'^ZCN'G4%T>-)A7'G&-3=R  #00'/9=NJZ0UR
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M)A=#Y@<[ XB5T1TB?TZU90;6WUU[>0;PPBY+09E?FS_3YDJX@M!LU\ 8S]?
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MU-+SP;U2V+9>[*&=)"=C %'<5!;"RZ]81+S W#GVM9:5;\9IZ"C#K9(Z_FK
MXQZ=+;<(\]QUPN7-IRYQ,Z^),U:L\J3'<:Q>J2P('F=/A-8*'8:U*4-]IR>$
MF[<A>>'B,32<-4E=W1 <33'";<MZ_^2J\D'Z6&W7 &.-* 6JY&[I5:XC==-
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M"_SSPT:_>"*TVG*M4\Q&?O9$Q%A#'HMV-*#-<#YO7X0T@>8L@4TKNQJCLV<
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M]CMC&B5_]:B1?VL,31[F@_&5A:J#6:$-UUF 4O8M&<?T99\@99)&Q-?;V6B
M4GD@:-U,1G74.9_$87PH6_D:D>^6+"W9!Z85K=-[A,7>5X;,V.Q#RDVQ)9<+
MU*0H!.IUP0T+(O;U-.N2E3Y!UG4R] JLG"Q^_?UV &-/*KZ:02BT(XF4*/ -
MU98QJ7@WG%YEK045,V(U79B<G\VS\[87$=DC3L&:(_E2HYPHCJ-(>7M9,@#L
M,,(^_?Q"(NTO(> S^>O5!X5Z0WJEU!Y>34]UIQT(..=:KS:,F.-._ZU;WGX
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M;\3HH]Q.[,?AA52C2][*\W\ZG.'O7C[:VYQ4,ZP<UW;9M)N:X^OX,.BQ6IJ
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MTY*0$G/',)6C 9,2H=?(BM_<1'D8/S!PCC8_^T;VI&$-:)3.!N;,SLK;"/W
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MV:%*\:KTJ^?E9EFW;CN)64^=G15X59S==Z\O)*OL6SF,?[*<U,W M0Z7MQ<
M 35Z[&/;3[7E9 J.?MXN/"]<QMZC PVTI+J*8CU;1BB W"O;.ENI0'&YM<7U
M"X$;S4E0JB@R6F35)LKI#.PEID]J]IR,.8YF/:@0]!G*VY(EJ+S8)\[K'C'M
MC)?U\*TV=+N5L:YZG!?Y96G6I#PQ.IFWHP1CFXOA_UY?^'JL6^?;-'B<46?G
MA@*<Z6LM$&TDGW$]]5\<:JWS(^MBM]043LIT4E5(+]S>1-@ZK[8=Q.Z+0NJ]
M48"==3W<5:V'>O[DK$=CRT2Z$GY@KC5-E+#JJX.\H31]GRDG&"]X$GHIG=J[
M8YIXO5&7O7)SJ_]7ECNTM*RTD"#J83J#'/?0'9E,[-KCQE19NX.*O)C4U[W(
M-J-/K+9L4<5=1KHL==M@]BBDY6J&"L?Y=DC1,G_T*/8&"K!.B+KSVGFD:81(
MZ7!7>HQ=WUH_X!1@9:TQ0<O0WK <65D\=C:K?#5E\S(PXA09ZOQ6-'7C2.V+
M1Q;/NDQ@/=FM75*ZSM1[379U8:UJ,>+0N?1D\8VI2-$Y=JQ$^A(F+X9DR.\X
MLWHSCL(;P;45$O1WNQ(RYF BXM53_=I10X<L-XOX32W3EYH*%.']Y)H*P']&
M*+ .//Q%KC5, ^9D$K(%&NG>2$Q+K6E@;S<-UER2R=-!>_4@M4]P@Z?Y9F*U
M_'K<U(ZS0C0BH >PYG(F1^<;$5[=>N>A@-AFD\0L8DE#(9#55]/P_9]KSQL3
MHR!-BMP&K&W",1&:$36)^P.N'_7)%.!4%M$S"D]=6%[Z,G(R@Z*-$=4H@%FW
M_-:/_>[C^;*O]L^Z3$JP*9MC9+'B5&J*ZZ]M;'6N\F@8Y=N7/%MUJ4^:0\@'
M4N>V_7[V_$5[9U,^IS1G,C__<WISV_,"DTY\(OBSQ5\D9Q3KT6OFY(A?QLGC
M2@T!=F^&XKK;I3X1"0R(#3.W:7=Y!1$??:S/WI7;TIHDM;,,Z:(EZ3W\1@J"
M 8!E 3?W2X1MT?SNL-_JK1I/4FJJ?.\QS&\8+9%4432?WJ"^6.@VG>5P?'](
MJ>M:NC[/Q*B@MNBV=EV1OS[SQ!DXO7S7Y2,>4A>'I'UG6O(LP&Z*L>7MP(;&
MBJ)&!7.+C>E;GLDR9]B5EUV9\",WV,"0O@M1D!.INMN,#Y28ZE,-0]AS<84Y
MUJY?F.$J\12&BJJQ)IY;U,.K>NOY_0G"B7!IY4*?H##AU1*^QX34UB-6KI7J
M!J]4&?H]/KSIX?(]&/2FQS@RG0IU>YY?7/6U3]NB&]K\BOTI^% =1P-BM X3
M.=KW#5:*00$W%ARJ"3=YD0-<@K%?-ZDDZ;GJHB'%B(#NSSMU_BGS%B*<^*7N
M9.39GX9QWBEJ2'TZ*^3SWQ'X'H <#3;S#\IWI93=0LK!/AS"^\"\24:VU"<C
M<,+A5WE!Z$WE"&T4<$YW'X5JW W=1\J^-,1DXJ8*H-G?FG(NW(E>9U+W,^18
MXQ<8&OS!Z^>C>\<]SM&M1J9_/:+J?G[0H\ZEJ]IE.!-JG(:?K%<YA0#]A+=_
M.+V5.%#<LD56S=:[_/;(:C&5>N6KU''JZZ$</[6V;:+V]$"P 8>:D<"C;U5I
MR_@\9''QT$TG16C>9=7LR4KY%:?W\OD4Y!9MK^E8(TQ2X[O#VI;25'1^?>)W
M"Q$!I8^8ZZNR].G3?#@=#&3S)I%?A"5$R]!85&E/N-%])4.&/8S&-S1] C)T
MQ)AQ_%QB3;^'?[<_,?O*TE;K6*'\[&F_"<GTQM!]B&.D5YLWHT%46X0_:V1Z
MW)9V0D&%0?V*V"5IR'Z9V'4?:7];=NF]-NAB9J5K(_ 0S$CR3N)TT":7SF7(
MZX%I(4_LBS)(#\,)ZV[6^2\48$,QHF?[J6;6*Y9X:>=(G*6ZI];PM(8V>$@Z
MB7\TY]4!R^Q/) ,*^#)\6X$"YI*F?.$&P<I'+2M^Y!H>C^7QZ$L-7GV6>C^,
M LH:OH+"I'G&ZV\C#>KJ3OG;>IN21"P+WL#.01F&=0CC(C/3\//!5^#A 0L>
MYGM;?L>QO5,GZ^Z;3GMI^5R9H[_D&$*\B:;G/N8HDC ]Q-@U^ A*'KV:8@_=
MH 219=^ N=H/[6+\#U_UB]_$F0T7VD\UJ87HZ6D^^!;U"FUYX3K+'XXT/-J5
M<C^OQ<</K6M*N'401\:X3<?(GN]E;7*%]RT7Y9H)I#?6_+6-U'8CK \5-F1_
M]7"N-_WR:;X,$HQQ7"Z-4" (TYHHQ+^I#7U9WRB&<29TB7!=<Y;IHBPL4V A
MR4H4&E.M\&FOP#BGV*:G/[K-"A/JJJ[!JO(!,P?N/)Y  :&J;E&TVBU][J'B
MZKB+U>%3K;0]1<//H:L'<D\VJY4K,4YLT_??^&[5NVI&0%>&R?;T6CEIL,O?
MG)9(=';K+?6N,*P=BO; M<!'RV85:9ZC7K4?Y[3[4_,^59R]^A8<E39UE-6Q
MO*^FX"4E=^#B,BVAB\:5%V/,'N]_0:&NN6'?G";6$5>L<ELS<3IHU&O^5J:E
MNK&1<D_X)CNU6PY]"R=>PK+%:_FH$ 7L2J" ^*S;#&=$QP]^WQCXP44]^M*E
MG=Z20#S:N.@ZK<_6M[4*LA_TSTCPM=<PC35/KBQVG=#N#ODUYDRY)2@.&G,:
MK2TKCF)#<4*=RU[?N,Y%'3[V2:JFHNH6<,PMU<#;=O<->&',689YDDJC](8(
M%V0T7\IR.$03<^)R*2F_9HN,24 !TQPHX(SFO VA6,-PC6[?AL#+6C7QB9)$
M*T8$FP?*#6V.,GOJS@L^8WP?T^]0CGP2=-_H[*\H@'T+!:PYVDSD).U[]76_
MB="JC96[#]@N1C=K6TXL*NR0!01R7,4KK\[H*A'Z7W;;B+T@Q$_38B*+)?)4
M3.OJDYB*,#-E?\)WIO.]GR]13?#"'DF'0QW8 L*_LJU(*.M@$\#J<-?UV9:)
MWFI?>%71K+-UNFU0;\QA^[5;TNW(YD]$"+QLVD0!'TR.AL/+8;*K=/[]%QH"
MFTN#R$;^CZ\TPT0/'^S]-C3'+8R6E/7#?T;,6O>2'O$ZZ_2\[+3=C#2X?:KJ
M^X!M8Q8V6 5>^/I@JC'0>#6PW<'<^>CN6_*R]'F,7*\%:+]I_2[=/^WMB$^L
M^Z2*VA#^BV%EOYP89;B?IIG6"X<!-'=L98PV(.T$"ND*>C(EJ?\\+$?E8C=!
M"*]RU;!_RX-R7Y0]RNVWL3_.NW-N9Q="<^,IFMTUC$1=FP2I1ILM^IFBMTI'
MN[N7QH'ZBJVJ?NL)@]9QJ=X@!H&*OO7U&YV.>#YWS@ .#?U :7TQ8DH[,^:Q
M4IZ"J5IY'_+8D*B%OB>*W?[/>C9,VSY UE,U[C9ZSDO][JCV]*?&AHL<.=T@
M[YA(E0];_'[%9::N$-5.(WPZZL4U@N>5&Y+9&KP2*6-999W@19@7![IBA8]-
MFFHM=O(#FM-QVEVO:,K:]OKNAX50B3\*B$#*E_J6.1._2#J89+.CL&RO3AK:
MY)EYHT$%7ZJ#$:\$JG88#4S75\\IQ[I8X./SBSTM;(H]G#!C1GAY!4!;2W+-
M66$GX,VJWH%FAMA4 ZL3]\#B1MFA?9=\$</Z>?G/QS:A:U)<[7/.CCHB;LH(
MY<&!>'(GVUR"(-UM" $*6%<-OFNZ;TRVO@BH@\[A>L[PG-":E^\(4PY,-UTN
MYBXX+HDVU>SZ8#L! >D8F3$%TR9P-_-_BH=E/E/&*:SEBE>G;!3>51C;4#_<
M^O*6C]&WR]U_OA6D<A;+ .F-*T8!#5G7--/L14C^B=PIZY91X0<\([UF/(?;
MQ[857,0:&Z:,1[571^37Y/5]PNOOLL1^4>#X.MDFQ$*"$M6Z^L#/2CA4W(JR
M+#%6<9 !N\N_NY!IC5EA\3SU,= QG[D!EMBG_G7$#/G^C]Y+<@>L^KKJ73CZ
MT:Q^+H\?D,&0<L>!VOKFKE;M-D6EQ:1Z)I_VWVS$R'A3'OZ(D1V6NI(JVHH5
M2G%O*:4#%YP%JOVF&R:G)YB(&L!&M'.P4ULH\B-1 -Z&]$/%-1XSK39F(2[B
MXL>GR)ZMER(=KB2[VH47K8VTE>6* GV":,MH[^Z\MOWI(^V_V;O-&&%4^MFX
ME/64T"3#J=P+/3A5'N:M9,Q+AJUF(6,^0Z8Y06<T>]*\D-Y'&BB@/!@%?$MS
M#?E;$2"=G! O#[NC'/$U-HO.N/>32J?085I?F[W.:V<8I8<\;<6OMLO.=XH/
M=M'N=+72 W-L$HIQ3,%26 @?%,#$=B\;SI SQVE-@SN*,=L1F(A]P0+,54CB
M4L@J2<S;10 'ZJ0GX)-@RZJ8/F\Z3/+^+P;*WB#![_PHH#4]#MGE/QT.6=>=
M1 %[_:ZWP'0R4J8V\%$/OX,;1IU%"N<IA.;S@V'7)F*X67F1W+W:+,IB8(DD
ME\55>SX>>:<N70M5\[/RG/993]V$/+@?5X)%D.D&%# 2"C[VN9.CL;UUAVQR
M!_Q8(IB0%(1XN05(E48^E267&U#WR'3/R3N>#BZ':4BEUVG/=[_6TS.,),HC
M^8!6.,S@Z-Z2)UTY& A:H2/^V+:N.P;:ZV>X!?3RM<><&31&2YWRK&WKZV/8
MK+=5BG 8DDQ*Z;=H:YVX>]^Z6I:9^*ZI%M64-,_;29:S!&8L":!_4/HU[^9T
M:M:BH,/>?VC*E3FD7PFG9SOFBZB5HE1UUG]QPYKMQ<,W:QV+22]F&=%X-*X[
MQ9C)([ZL?NK96$97T'CR==TY./IJ3IP/TS;+S10%1-: D;*K.S4W]I8Q-M;6
M K:N.))P4>3WM@]O);Q6H:3&$HVOXPUY:4PZP2_QBGH8(=XU6[&LI9[B(YY&
M];VGX#+KX_+8W)JV!CNHF7<TF3<ZT_J*]X);U'7:CJ3;2O0C]:/YY9G"69NZ
M.3'W%S\^/W/WO^R]1/+XIJR67R07LN7GF_'4C+6ELKACU/N)/:5R%]NB.M^J
MM>D[VNNB26#Q+VNAK>#L792LII#.-D ;E]IM3(Z6H/PNV]#0W^<I+$WAH*_O
M+[R8=VC&;4@N-]B']OXJ*)@!ZI%%R4*XYFCP$S,_9PLGFW<!DF5TMDSL&S3<
MD68Q.X<^*Y$7UWH6O0MIAQ4:,1PE(C6>5]*-/@X-GE[7:(4H"GT;+UJO8XM*
M+%%QM)P1JN7,,^0F($''0 %O(^H5*(;<I.3^Q3-N_TFA/$"ARH\FT\=RA,6C
MY(:^,*_JLAZ2A,=OUL!,^Q++.-)4T+02W0Y:[FR%X_AF;YA:>WZ7NPOI\\W0
MU\=4V?-*(X4ER#71G(TYH=L?/BXY#;Y7G7&S<1>Z&E,O"T6X3RK+4Z76A?MP
M *HG5!Y:57NRN#?W86'EP^@+0]B )]80D;@W4L%3MIOFU,Y'*Y%3XG316]B+
M._RPE93Z4%5HV)+:QFFCR=UC;_JX-#8$TX^F85@B!W[D<*;ZBXJOYJK41F-!
MC3H\R;<]+D:*>X!L-:;-VH/O(J@2\V4OWB-2\&-Q_V<8.]T.EAP-#2T/"D55
MTK\ME@TN?S+C;3E"U-:,?XI9>V6:;T58JT0%'*=?1VQ^[;@3@8VR3KAXI3+7
M/Q."$J2XIL2Z_&[Z%J-D:1H6_I8H[2+.$FCF#K!]&,WVQKOW&=J"X#(U"J#9
M<FY]C/CH&3&L-:U_(_;@=D ;S AXX_U N^7*YBA*4?&$8]DD[&4KK?(AHT3:
MSK<A9\+?C6KTQ<,Z2R:/5N.Y:Y..WOX(\R\F?:A13'AUK6^]DH6YC+#5;VIJ
M:JB+YV3B_Q;^I7X)AYW17Q](_NS[JWL:WY5%_*V(@-#[].1A*1G17_QB/70.
MX^IJ9=V5B=9:6AJJCT]\0=UF;!.,K@__8OXH&+U_G/'=+>-[NM6*WN_.>4BU
M+]?8 P&FCVM"W9 09K2LL48&4H2<.8ZQK ]V$[TVXSQ-,'GP;7X'[=E>EX\9
M:;(YI2_%MRE!CL\UV!IK7E0=MC<_+B^*$^9,"38/?FE*=$E/B6K@(4A!9#NN
MWDU-/W:>*(;(PLJS0<_VSLH^+J\R?MCDC*EO4%R-B#2QQ1$=NBY=)O!JD3[?
M&*W]LJ;=WABW]M:?[AL*R%(9&87AELF7&3F(MU;52[_X(-=JV0O&B#$F5PG4
M"1,?7.SV]Z</UZW%OPD4:'><KY_%Y&Z<IRX1_N6[U9%RQSH.A9:Z/(G\E1(0
M_B74Y9DXQJ!'%]NYZ*N$>"UOI?0E4P<("4SKLPR-A/5P<G3_3P9O)Q_0,,98
MBX_\*(\D*#\_.BWCW:&/E&FL'NASN6@UPFMM45*T:LKY(!C^YN.NSF),:ONI
MT9Q&J*2M?<F<B9EO\%!=C*Z]Y8W58*-'[T\3AN[ZC+0J?[JD1JM&2Y;X;1\?
MGPMODG ^WI4ZN3<T]NCH007Y'^W*GH"_);&&=^N.!G,3OU0RVI#T634>)C>>
MY4D<4;PX[+P:D&%\OTV<[^1K"TZ0/SHO^"I4\O3SQX6]=%*#>NKKM4I[]Z7K
M]#+^=36I )K)M4R>^URAF/WVK3%D&]=LV@P"1>"_G$ ZWU933-Z/LDH);LHE
M="P<#"J0SU198KS+YA?[;@$7TZCA2".SV5(O'3/:QWY$$K&ID O7_L846,-Q
M04O.3 .SE>8\/P;+^U]M&PGS^0%\GVJ\IFL>0T6K2E3:F"N&IG 8[RP:-; 0
MV+\[KCL<:$*FQJJZM5A#OQRP4TN^GV<^+@E]D5VV/9?D^]WHL([CK6&$Z%,A
M XN7<=U6NIHC #F:Z:,0EVD-A+.S_ZXAS\%&4I+_Y](>C),"Q._VE%:.#WU.
M!1]$ZFV?LK&@4Q&%8.P8I1%]FO,)?37Z.\H]*1R>\HO=$9N=D9Y8_N5Z2YJB
M5KHI50]T6*AR FD+=]R9ZKZ%PF.Q8,62B9](WPBT\6\':E ,(W+5)\Y:+/>O
M6[;F#F&UKB*#]M+:Z005V,UL"-NRG>DJ</8>F,")']9_+$8?9B>VF0-#:!;#
MW,!$A9C33PV&QI,UYZD820/6T[VAB2N9L?)EPO;=1L*N\K9K(LA/>N;G<WRW
M:-\AH>8GG/<Z:.YZ'QM![7WK.WS$?W_,'G=F"V<-'PU6_9S'P5PANJ?ERR?3
M=+04,J7O+L\"%01_">?^ !SBY%L.M&3$*(G>$!GO>0RTWFM+[P[.K?M],B9;
M5KVVA7SOB0*N$:!KW *$_ ^:K#"D7,JE_O-8/.8R)ING8"HZ'8CXPG'/1Q>8
M1L'\3ULA_E\$S?<SES+FJYAO#!OZG#US;([BG[TF$D;,PR G3/9M%],H0+'%
M<_^G3O5#<H)X#4!/*=0S]8R/<,Z^GN_Q(-'M(#6KNNG7J/=[1BD/>09KZ@Z5
MP2]S*?8^\'=9LOL)QN>J.U\EN?!X#GIWXN;4M=1^IH-VE$M::[@6E3\Z7GIO
MO;KH]61\0]HD[JI5\^V7& WJO=B_3DW9D=QJ 6H-WJ->D^&/HY>L/E?2WWAD
MW=4:C+52]D__\BEWP/?X@*] 8G/*/_)(5'1G_IBBAO9U^?,P4TZYA#:I:4M]
MK8;,O=4GF>O5?UWP)]L,&1>R2[= :'H1,DIQ)5&G3;P@[/(7L,H/-QIIW5:W
MG:-?4O6C.*G@8["?TE1[%_H"*,!V[Z$"P;ML-Y:XZL)<0#K=ID @,C)R),(C
MI+B?<&Y_!-&4MY/F:/E>,/@*<E[R[0ASM/Z]Y\4"H/"9G[V KFDRP[*#Q-&,
M.DRIH?'5,9=3PWQ"BZ+(JTSDY>^IA@#SCV9//DEE3[W^V*YWNRO_-$OTG/,=
M;D]QMFB#>QW)FPQ>Q0,;BYD%!:]C75[&SV#RM$@!\;-7!B=<** K__6:ZG/0
MF]EWTMG+H &]R=B.@ S!KKKZB_J'$-OYIF=$^]9.' MN];1U&F;GXXCZ]A'?
M7#4#0V3)%[ =:[=<P@3)]AO0D[,2+Z:\U%PHEA:/U%.S41?G^0Z]1]Q,#["^
M\[O+X*%';8U3;8U3K-/C>"6L*904]]<D?%9RVVAQ,4(*'F/_M':#*M"G&WLH
M$%0]D[YY@"%<F(V4;AI]:TU92#Z% F:/4F:^SO3+RN6"> 6'-(02HG1J%S0]
M5PH2RST%UUJCV,>=:WU_+KLLZ310]XO(!3Y;@/PH"9^"O;RN#ST+Y*EN'6?2
M@D1B.##<; D?-$TFU>7F+!DM9E2 29:6%WLDVM %$?H?$8)@\;:(_8.+WQ]%
M3O.9"[JVLBS>@&@\T]RFLPWL"]5/;MAK$.:J=]U'D]%QIE5/7^?!$?/)M^H@
MO.F<B"V7PRW,KR[[QU3D/X^=PN#BN0PW.WT, _J5#LLGV*WWF8L?Z(S,3/48
M??+,G+:KN)-H-L*D<!#I(,,LU;H-BO9?WQ6F8U,(K^!]]03WH-'WSJM6S<]P
MTG11SDPIX2T;"HC[OG<'RT(!\BHSB#840'^M<7." EA+6G&.I/-7H3:.\[,'
M+$KU_%BA7]*3M1>5+AWE>X+(6XY?4*I:"Y&T-(N]YF=\^,.3D4'%175NH5$G
M;(J\/#O@!PHX8=V!_,.JG_"(GFV8YZPGA'C6_K1)LD*I-E6P)CVA.ZBVT$!5
M;PC<W%=#KFEXO0'=N CW<7S]U,UDD/J%G_3VL,E1@$T\*W<SO3#49!!N3N?W
MO-1,S/JAC-^/*,BCBFZ#Z0:C>25;>\)29A)YFN[@49D?=[H=".X?(O0,DRQM
M$S;UR;IJ%9\,8Q;.V1F]X6U&OQV-JM3[G&*B%)2;%1\S43P?6Y0>QU^0?S?S
MT[.W%Z>A5[@;J5X[KO&1I2%3-!FA_&'Q"*.R%].V^+&[V_C[ Z5P&*Y7\1Y?
MZ8YXKI&9,KFHA8X5!_#13$EVYOI&[Q^40*LI^ASJQJH AZ2R#.%\6\ 2Y2C(
M=QN+8IJX^OA6LK:A^2@LG%'!HKI[5*$':\#I 3VR?$?GCMQ4Z5$X[RMOM((Z
M"<&%#T2@IUGM+=K*8SQ"4L\E'K/,DUJMPSW(%C(W&TQ]5D,2'/@"<\Q9FR5<
M3_*?HHNXEPI "'0YN]7!YSQZ(0L3-7^Y=LTG4OI;EZUN"L4^,5L!L"'F8TV@
ML*E8^Y42-*8J6'8^X[4@*8@_&#'-;WO4HPF;T-OJI"EJT(R>9_&C.YZI1GL?
M<99B]Q1*/30#78EEM_NAH#E#] ,OO"8GYU,)QW>'=-/A1RVN$FMK273"HF'F
MAU5;5_IUTU&^E#C3, A;/@>FXIBI- 2F#B#G0:$!4N+S>5106LM9+')-@_3L
M?^\\X7\%#-,.WUNN<1-7+N=2$#;2$5$3%X'@1I[:ZG/9!>--DOT:(23)MTMU
M_:W1S@UW :&N")_5PY1OBSSPYL7%)P.NC.V%='+7Y^O3I@K:Q<]+9TLK*5A*
M9S05*+"?_.\Z- 9:&\;[N59"]=KO;EB(KTGL@^L/*44!4<D@N?)M(TN[.=:R
M]$NVE1_Y;\>^N@LHP]FI<!A"[48U4N>ZQ/IZ4KYI*I"'__/+5(\9;:*3'EL^
ME'&RQ9FFZ$7H_XA#N&JGW1G_KAO8UE25KRA3!]_T)-Q)U\YHJH'SK71L.0I2
M7N9$<)+^>V\._N\$Q8_=-KRSO?G"S*$38ZGURMA7<;+2Z1]PZAQ;<[X+N,TT
MZ"32K0T_KT4H.-+V3QO5)"@^8&4.85-RR^ANP6YOG_ZK*F)HB(00)O_@74*,
MQW)F0:GFBT).EQ[QZJS.]@B.8L'_F?MO@N>#S]7,%9K&X4V.>@UJ'W5-9ZBI
MJ7J'%)7@!DL/CTS,*!R+I:=<"M*Y?I]<8&G.4TMIG%!,C.KDC54ZY"6:Z UP
MY$3$$T&Z,BF"N_2>M9_>9MJ9>WI@+K_SC[)ZXXL,-1^IZ1ZM4345.U3[^5[E
M*O_YNE5<M_HS(A#>:$Z68&V$1T(LG\S_TPB@D#<>S](?=:E!'*I5F[!U<-PW
M;BLJ:MW*Z[?^=K8$H81$;N912BC3$33Q"-HS9Y,I,RR24LU(@-6MH:X!-R4D
MUW:N]Q8#]RT>WEMCDOL/<&'K#_[@#_XCH1<%A)1TM)TQC*& (P'0<>X=:3D1
M"AB!J** '_>5W>^$MTMC$2HPB?LT]98/!6 PHP :T"K7T>];G+,V)$$LT@[#
M[(^9/V;^F/D/8:;2MLR>)N1.(;G$TN.YB-^;!>8ZJ3>$@'E.! ?P!W_PKZ$T
ME@+2FP5% =,A*.":I\2L2E(7!3 %U:, ,S(4L%WWC:"-T-=1-JN]27+<+LTI
MOL\:7Z+E.Z7%2U(P<X)1UE$$PN?N'8WY'5K/';FO_MV+6[([&",*&'4T.D.+
M0P$/RL,@VVCY*&"%%K*JA&1JI4,!W[!34, [-Q00ZC@J0\WP3TQ VKE7EZ\!
M>P@"AP&AUT+^Q\8?&W]L_$_8,)F./#/E5OO:H6VPDZQ75=?LD+_R7O/358P
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MES3[G>R;NR&K_TY9J(<PSN0I<&5FW#6.(,N148U)F9U&^^9G'&5;5.4CHR2
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MJY$?3JZTP4/$FZ'T&Y57\K40/VPQ[+ :,;2]%J$J2<*V5TQY,5M]91@/:?5
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M<UZ<PN1NJ4N3*+'#EM;&I</E=I113*'$2C5O;XD]VMO4;<XE%F&X*M%.];:
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M2T!F'$PH%0[8U,<.?MNR_#4BJ90_X5_*_&ML(7^5X>D;S4?F[W14?VFYN\(
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M0OJ.Q?*;7?$W!X9G@K(^/0WM; 63:'X?!T<(?U1XG[KWD$JQ>P^1J\.<G'*
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M"'[[$(L4?LR#-45A=+OX[8[EX>+2*4(+5<V$LH_5>6?;XK=+F@\Q&D8$ F]
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M$%ANGQ%/WJ>M&Y$>8+[[&C4W-P6GB6@:,^V0^I"V*$=!5,/*5M\BDT6ERBJ
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M.N3C+NK<2V0C6>_UM7JG\)1JAXP(MD5.#6+!) PTF*SC;XH='#UX,V)G5D&
M04-/%4]:") U4=KT@!"EK[L^#"P;EV5_/I'4&16;+;.&=$5X(AP2KWCE_-(
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M2L,E:RLK2U\X!KTBUT?\H T-;5$O?/UHFRN]D24^*JPE.)8-&:T'4YAX^5/
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M>.UX(3^?S'8[TZPX+E'=0$',!J#W;9U_:?CKM_6ZZ1_UK)AFSNJLD3C)AG2
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M,<3Y<MTVLGVS_Z.?&.@O'/N/F?9#=Z!D8_4(26_OPHD"8Q4R??^B_#2J+!G
MO8<)$>J*/OQ\_$9A&4@ UO(DR4=+!F>QL'R8?PY:I4MR,P/(BUZ9?AJ0^.MA
M]^S\'\@C2-2N8!M.&[1<XL[.QZX'>A?E&LK-%"/Y7$I,1:IEOT.%;Y]X:XKB
M+L@L1&N\D'UT>=3%[ZG+^U1_F<4(2CI/Z&7FWX0M5O]8G@9]5G!HW0/#-/I5
M'/*3+MA(TXL .^>QS4CM[1P5]DNFU**JI5V!$7?QEGT^9.<HZ;!'/P(\7E0
M?M)ZT63]C2X]P_N_4:?_!?TOZ/\QZ/T+*:$'W/ _P.7Z_J>P<VV\";"U'Y^3
M?K <7^VDGZT[["DJ@H#96IE<\'[3_R338*NYWVY[2JQ)Q)*CB0Q \D-E)]+V
M:/]OS:?3(@UU 0\\:8V%!WZ65OKQW:87@8D%T DW4;CS_E FRIEOW)<]E#=_
M$32E4ZJDP1ML9TNH8X;\G!^:CE2:\&1+DCJ3N%_'?;GSZD*W,3$/;B"JS(;A
M BZ90R5_)NXAN %S3,(_%)D#T]!-NNB'68F G5@?KZW#R<XY\(M!<E2X,^<I
M>.II-3XB79ZNF5YG?&7C*8E+H$6E$)N@)<"@Z4:"G\,87W#JC5+,]IAF];@S
M>(3Z.W1VK_ @GXS.QF? GZZ'P2+EIED,%](BSCZFW!F"(NV1,3'67T60(Z(-
M6.MT1,-K>K6E*X'/UR G+\S&3P$!+1_MON+KZX02X**MU(5B;U2I5"#!U0QH
M V^4W5T,/\#O =I?M,:<+U V-"  2#8YZY$9#;?[T'RA&&=7K5%^[JQ.866J
M];D)K"*6_YK0'HDA=TB,&3DWK<9_I9#9W7;?((HU9Q&6,-N#E7?9:$)G@^R*
M9W"Z%5>4Q*SD2["]?G2UQE;(EEX-UF4G]DYL >)B?+#U4!>. ^QL%EDH'78F
MYVVSFL1XAC7T1Y(73J[C<>X]%NHE]$!Q9B+&NGDU8GJP5UFQY5QY/$?YCER&
MD#YTPWX^%, 3 51;\!/N966A_CCI2SAG^8)J??TQRI%"A8<)(<!@0Z1FD&L4
M]A_]T1ITI$M75AU'%EK61<DMBZ84P8V^(OE$S<AEL=#+X!"UGU3] M+ZILXG
M6Y%_B>8Y.2#WNOU$/.FTRFUE7KCS2I[#^5:+U3W[I8+W9'65%CI5HZ<%W$\X
MC[7_U,;QZ'PY,RFFL$@?KI^'QS&V1BC^P!NAPF2E?@J[.'8*AY0RT/V^EU9H
MX\ S)V_V\)GVGYWS,SN_LA4!.SE%C%-= NH79\=2/HR;L[*O'6KU$[<=D=PN
M2^C%7IFFTL \O+TR?%M%O KJW;@Z+"1FUOPG7M<=H0'F/TU-E9ZDX*9!UNM!
M!4:@CVCU$];DA8CH9V;<=&SQB5*H*K+VRDYQ>,%\OA<*%?'(RU@V'UDW*90"
M(2BO0(&#2DS4[BTW03( 3QGB'N.;UR,GUWU?S3ZI1E'JOB$E== G"6*B;=47
M<^I2' WI$/:.O2J,+R@5_XF?I&5?9\1=5_449=64VF'2CW^SB!^/.$Q?_V!6
M=VX>/FOU0N0V1O^UN*7D7#FBUV<NK&:(/)?A(BRMRVWM!Q^R%=.U4"-)U^[R
MFQ7;W=/]L4R R[BVX!WOV/MP X]WM:_27^H'FAE4[NZ].#;Y!.6!>+JW*4>?
M\$)$?M+JJ ^ST#T' *)N#D//AEX]J.<_5<3I3\=;@:@>U.CVX7;S&,&9J)?<
M!OX1$A2 .,AQ,2H8OO&5PZ0VMEV+T'QV3UBMZO$A<S<J<($I]>2\L*Z)9FM2
M8%3**7N[5+]#*$!I'=916R*X=CPF/HXTH69DD0^.C6TB9CN!V3@NC,ZK>K@F
M,T>>WP,*'(8[0A\!3<">P*]P-K>/NI]4^=-\R^.7K#\.,@SR(X:,;H55T0UE
M'/@;A6ICNZKBL+8$9.'<]&&C<_L:$5A- _[DVY34CT_S^U;FZ>\(9N?-5VJ@
MK$)W0VRX><]_1;Q$VZ5I; A_$""1-M^*\OMCI0.^]7R3 3OGW"=/(Y',YK8?
MLSCR!( 3AKT5\A_B+.6,:5I\??"AL>2H 9OJ,\HW'(ZZ@CN=>*O<S,BCS$6*
M]X!EQO#L!8-7#!2?(^"])M5UD.D*+L$[PIF=)&&M[T8OQE:;)JSGS8-/NC\?
ME0?"#Z/G:QXST9/M0"N0JF0<2MP+K."_@N"#ZXC)636%7[ME\*?'TFAKR:X:
MB%6;0?<!!:9V&Q*1)K:6'$HUB9F!@TH)"T(+2C>+XH^)S,A%:35=AUGQ1)XK
M?3BCU.0!<ZS/UJHL0,!X%"J'!(VQ3@KKXM0,M;GNJ]88?S4D9@!*[$:H1:4G
MK2)@\[^S7/!_J<3P[R>1\XN*W#IJ#=>S;P//!+V'RK;/SGF\6UP[ZZH$F!+,
M[(52<"'_I=3+U!PP/\7;,_N%.0]U(\6G?M8?%E;]T $K.3N0IC\-<:J@Z,7J
MI4/^FMSMF%J?.;=O##%U*\<T;+9#"\;?CQKPK)H*+06$DX-O)')EV!30$HYY
M4X/G9J,EX5S0](3(BRDI&8!C;5=0,1\><5=>!QO6HZU1.+'KTZK*72I3LE6W
M@AIOK)RFP'JA+/:!8CAO'RSNO6YE&>*]:X*%*#1%V^?A;NX+%80O,1C^S5".
MN#']W9E\+Z%9:#2@E PYU&%H38<"V#9O-:0QPL$D_$PFJR\&K#-C_M/'L/)F
MX!+S!,Z,G'S0^<DI;0[L.*?TY+9)-6:;BYS)BJM[4')C]K2(M8V&6NXB/4_T
MB4?MAUB1_J]R&*+IJ)+B/T3O 26PS2MH>?86CE75U*,G+B\#J'*?)IR0(X?G
M-N>/(_TL>E709T$^C+!)J55X55(C/=+]0^@55(Z!"NI>)'%'?'J7PU>7^&&[
M5V1>$?4K%MFT;*"!H&D"B9#FSI 1N#2\G>)MK/99ZQE?+! PC\$=0.>!$M-,
M/T?#<J/>)?J"EYLA4CXU<J2L (\N0!@"6!'E6U+64)Y@1W 6WHAA:XU$RY:4
MMX\F9CH.]D6V],Q.;6G52RQY#= W\UAJ*"//]Q#MU&!,8R&Z&"RH0@\-S4VL
M[O@.S@*]K6'LKZ7LB;B C'+-8D*:S_R$XL._3'4I#>LQC7T8Y^V.8PHZI% "
M10?O=+H/9:]!ZAN))L;:OL$+/M+JUR!$>]A'AVS*Y2K"$@ S/8.(^O>U>^)W
MLV]+@LX&C?GAYO.4>ZR1)W04Y9)44P'>0BY+B31@I?RO&1ZV%"81&WU?\<4U
MYP>Y\8P/BV+*.?AF]>WPX9;0J-NL;<88?DS^=TX1*DY)8JPJ?IC,><)%I>_2
M])]WIMO3!:X2L!)_Z*/YY.>#QXOD"6'!*&:WR0HB1[R#Z Y.1ZYBCM+*H.=>
MJ?ZV//T_$<H9_()ZOW)9"L=I3+<@XG[S_/4C$\7%TT5\7SW %G/1BWJE97;T
MMZ5?VB?C',H:ODO&NF(OO8\XP6NJ,FYCJF35UCAL^L+K-6;ADR='W2QH]M:"
MQ>?L$[1A$SDEK?34F-C2D[VAH>,N$]O!@&-3UXGI1V,*LQ 5U%/#!8_44M@P
MNF%M/1O;WB#K0N=1QQ14$I!T]QT))O-VS$6)_7T/)^_U]^JJ]Y+.I]12U%)%
M ETT(@W#'&:P4?9"! -,)NI(H4R+;@.S&L6[2VAGU$\$_J>$L;RXPO.S#^%>
MOFN7R>9543;QE0AXQHI8.010)?,>),Y8UC3">RN- 'N1-(1ER)LG.@5>3S.1
M-Z\>=N@)WX6RKU0+-_@%R#)'^63RE^.F4"TF6P%&TO(-K?BU@!2&"_JS%?X0
MMK(\$DSNZ9X-Y&];FH--Z5CN"-QB$[I("$,R2+F@+0==D GNQVN90W,URMI=
ML%KKSY&)TH4ECUQ-+6^4G9J3K#U&#UG6'G\PVQ\P1,C''\<+ME'=9(N:#*/V
MLF169C\X"P4[L(^-Z(AO ?1%]$_Q%"J(W=E@[-F2Z6VFQ5FK:XBOF'?_E<V@
MY:,]&:='\WH#MJN?H\G)B@T(H"P-B-(L4%&N;ZXNO"XT;T@XE7[<;/AJ,)8Z
MRJ@Q\T-EE$\/W.7QW$K0X,- ZIOUYAI]"L$"P7",$)VD"S$:\\BXCBJN@=0]
M-P-&$]XXV59QW\_[/'*F^QS].62BNV+*0TTWR(16(',^0"!T@?)+8Z4.HP.5
M.OEWME GOVQ!ID_-)QF?-$L; CRL.=F+;B+<+GE8404WY44_\B)%>RPV/-N1
M+QU+U]TC;$; 8N#*4:_GN^W4/<1OQOD74$<+"SAM^J?&@)YO![S85N>H,XC;
M5D+Q17R<M$\2/44&'K%KW>CKI-O.W_VD*@TEY&;0J#BY$:+.K0W_2K@@QJ]/
M#&L,.EMZ1\B^ZQ#Z)$"#B9#V3([1CQ6T@#EZ<FTH2Q*%.#PE.D)DU\5[0ZOI
M]TU,BS?%6#:^U(NA!^WJ#<(11^Y*MC(UWR5B)&JKD9'A>7KN*U)U$\452SY$
MW+JG42 "=:D A5=UB=4;6:R&,$,A]F=UX&O-RN^!4%/NSXZ>@)D645746E;D
MCH7G=EA;,><@,SL:K^@J^?I?G#'83@FTB#L88VR!%;>4BWA31E=:VV/U,@4O
MJKSF#2%Z)(<NHYH4G%J6Q,;"K/DY&*PR%<37&OHC_:>NWQ5R7-^A0'#AB0WC
M;6%1P2^-RI!^?5T&U#H7R5>FZ+Q(PVJZ_(UT)<(N&>=3DZ[E R#JOBZ&WGA-
MOPV4#5L5'NW1LU%]+C?J?DYKV27N;DR"G;I, %!&K6KBY'J3*1;8 *L_TF9?
M'2Q :FEFH.&!G@(5#XE(XV0*]Z[U=,1:7.3O9JGR9A5H67/;[(6Z5'R8D:T@
M_?'MPF\\E0>S8L_&X/JY%NX?9,EW:P:Y@0"+*!G&3\O4(NV>CD:@8S04\^4/
MQMP<]8(HBP>6R.K_M%O>\-9>]O 6NDVD;DRP*^(L0B&0VWC<:!KJ*(60S,DZ
MI"FU2#&PH@CRQTDX[,Z)4,YMS]MV./;XLD;[:M)/V)-5W,=)$08BW%$OKXIB
M3WL;MT2<SL:-[-1"?YQ;Y,**)>)27=M0&8 .*(CJS<N@^<&P4IV"]59;:-F7
M,(RG9<ISX1M[X4S(A\[Y==D9%XW>Y%<[>N7;:KJ6=KGS#E1:=][^/H]6_7^S
M5IZ0M7J)Y08Y_;B)U8.UCL) >+F4VP:;GQ_&Y7?L(H=.S_7*O=-"%L3^;B4\
M,6&*GJD'ZF*Q4@Q8]^-4,S!(XJJI/KP89OLP&ECPU/L\26-=Q ([<G'E@3;2
MG?"-<Q1FP;;*#*6'YZ'8C\P71'SFUOTXU Q.P\.<16[?G[]1ZEZ)&_>O5<!G
MJ"=TI9Y;H3KIL$HT?D/A/HZ;;LD6W%S#4QRCXG!>#JU71>W]3Z;<LOY:D,D&
M30F,H7'IOSX65/L&DV*BN2#NU;]1&GU.<C2G8S6I]2V"OJZV$@MC@]:=ZV;'
MZ?<5]XYK7.:9[HA.&R//JBW&F?S?0T>?,7SS_<$538WW:BB;"&E'L>4[=\3;
MT  \%/6IJ $;D-.R#:O"86!+0.N4S.<,)P.R]"AK0$<\/9-(@_CFC97D\[H+
M'X\/M;4=V5D%(SI*'O1RU/TL&5]#' (%AP3)R;IWF\_T6-L0,!X!_T(;WNZP
MP'BK.YFIGX[[CV[RFR.<UFCTR1E,BQ6W&REU%=[E;I=TY8)B^>OH[<JWQI38
M[*L$VP2[) 0.GW3!Z(3M"-V[E ZJU3RKN'O?2D3;D2SGJ @0VJ=80(&>\Q I
MWA<L <3C+X<,*)8:V1;@V9^RR\$_M+86!.2Q_40X$*F>D2U%=7+UL(;1PK6*
MFJ#EEY#,9?M%?#19.4] P^\6"Z#9UC!FD_S8SX#KS\\%D0>XPAE4%FG\;MV+
M<'^U>IY.9A98Q5PYT]!$K7<L0A=8(^[,0AUU(:&X/&-D@N*PK7%5].\7IBU7
MA5]"G)5E;D3CG/D/Y:L<L49X%)Z&Q7I00KF!,H-" T:5!T;Y H$WFIE#%%+L
MISO*UATMVDB?7JP(HMM]]-@RBI0!>'1]%F42"ZH!N0@$LI^T@<GQG%W0'J*J
M3 5-G,!!I^Y%KXDA[$V*HI\Y.W##NX0HD'#H:"_'I,NJ *6BRRIMVT)=;= V
M MXYC^! /*ORYZK5-7A6I(*FL.@HF8+'<0%*GV_Z:HNP8]2/]R&G!59$J[R-
M6@M6%UY\,E4>KB(<3FDIX+EV_J4^Y'5-9663+D=T[QZ!N5-$USH9NG_<U"B,
M$X<UA/K9N0(>/0F^GA*-S@K#GD9/\RW+*2+3-*NSS'AA%IY.G3?6FX-Q@A('
M6,HXL$U'/?_J'$*D<\*N-=>'@9W*CA"\=-UXJB*"&R]GE;EDC#8W8P4'SUVH
M+ P4"L6KVDAE<I=0<<M2 KYM<PVI3&Q.ZD5#,T+/!"JGY.MYI%BJ:0TH8)(T
M%KD7G%JUA^D=1"S>(BX^U+<M'"GHFB)!/-4(AA/JKBRKP8;%6PW=R7H5=3XH
MUHX\X<('AR!GYFDZ*J@V^;,&7 C@./RQNXH7CN/HMAVF_E;0)#?-YC:.B.*:
M8E0>)5;"1F3S>1ZWM\0$!VQ><7 9]:X=Q\7IPX+58A\+LUJ5T"4PIZO7Q^-4
MCQDYY,(KQ2K.L.$44?,X7+W&<N5Z>Z,W[%$Q7>3.)>;>OVFPX-8=/6AX86&V
M*+I@,(:'5X 4'_XE^+$@0\0<KAAKUAB?B)@I$'+5:1ZWH!;];G:<8#I<\?@>
M@ &&:X7D7[2<LDLOS H7A.;3A_4+E"QY)C=K2U :ZWJS<^-5Z,XL[#RMXM",
MFO!;]<3I.]E8^$$S)>/!1@#R!$(0[-ZL>605,[P_XZYT&$'I@0&5,VZ//IHX
MC$7.%FH?!/:"OH'Y716HX!F>!F//YZ-GE8E[R.#]V2+&@@CA%<"RGQ@D=]LS
ML2C2;,H-VH?_5':<33<< $!38((<^F+J]<.+/N4REF;(.3UOO>RMTF@8W]9'
M-5.1%.RF1A...YNMZ]/'<G+P<,*II_,SBY.$8&SU+$>0WU$=$F<'GTPVED.6
MF2>UOA9L$Y<!F/R A>"II!O&!IC/H^T1VW<"$N 88P9Y@=U+V;T&AZ33S;=_
MKM=-&K2J,T?Y/*SHL\UJL%-)H[CA]%["A^PT/]$E9VHGO4/;Z#Q#=\]96;#0
MZUA2+D-66)?CRX;@TPWT0J>K7_ZB,MXN[%<,;K%'AC]-QP<.*-.8$(][ *;C
M*\A^PMKE(Y)4D2-\2(>OP>+R_.C (^_AE2]#;RPDLE@AY1<N'A_66WVQX+^>
M",WF]N1PTX6>]"LVKWKYGNY,,HT7V-BFPJH;*B'+ML\@"IJ&U]XI"<FMA:KH
M)'"M\NP;I7C=RA*E!O$KE "Y)WED7%5L4FN-^U([DS4^&FUC!MX:PJ\)&>)L
M5D>V8U5SK^,%T.:ALLO *<^K#PV.9;;%WA*95C9B\X,_+7QY39V_*5 YUCJ3
M,Z% )8!6@.R5!HYCW0/SV\#/XB[CC4;M<Z2"D0JK$<+(.B7N>M>O#AF#<S<G
M%:BX)2OAF?4R!'+(YS^Z45:/PQ'G/46#?:IEXZD\.@OZ\Z\+*^H)T54]5^A.
M5S^Z&/GB6U96L=LX%( .!K-QB&*9"_!24=;]1#N!7Z8JJZ:&JX+887;"2QD!
M=\I2J3K#R;4C^8\<AH!&IZ4K=AA@ =*7/4O3:HTCIF=8)>2J*-B9P'Y'=Q0W
M0>+-G)UGK.EHLH#\%]WTXQHYR-#8-C?^!?:#@DJMZXH];KB.V3?'L)K0O ,5
M%6 6&/KO"GXZ)P5/^)#S,Y_AJ\[6Y4E:'OEQ%&35V^4BT2KT"!7]-;6=*7AL
M2R/>^$DRT0#?C>#8+GT,-5]]LV/Q4YMIE A[H+'>B>(?)U +]IQT*P_NPASR
M# L*42C=V"1)A$S2 9%ST--T@_#V_4LFS^+;TGO 2*XD;NF%?^:\T2Q\;F9;
M#VRPTNUU[<O.,/2&*OE(QB5ZS>CEQ"Y?^./-*\9H%^+U?/KF]Y"93Q5F+WH8
M?$8EN)(5/Z3B/FAV5WO/\LY^>6'>L^DNMC5B;=#EB-.Q &#1A<U=:!%YDKF8
MM!;<(-<L3N6C?O>H=TSA3.DZ*-C.5 M@7B:DZMY#CAYZ;@A6!=\#T"]46&E/
M#/G7/:(TFZI]V?"GWT;)M+SH<]H4D\HV$4NJ&3#M?+ E>6U9_54:!@HLKQ?>
MZ.K,W"'6&7#E!,E%:5B?+"46Q+S2KKH;'4/LM7\=Z7K'%B6'(5*&++CEUX"Q
M-615?"BB6D9*05Q37_5$*J>+H?0ROY9OIR;($;TF SU=36UV3LKM$="&UTEZ
MY06#-;F.%T%+[M^?I<[AQ.DNK>97HC1\/-M#N/'.V[NN=%9P /C@_%HWA==A
MR_.L;VL/3BM#)QV#.3C>UVJ#H:OOO)[L#.+I;9PV/7*'7&SKG\CO<Z[6<7?E
MQB\*O ;.$40!NG([T0'.Q19I?D+T:5;(RU\GO2.L<9-7+U.[\))^#/J^T2:V
M.-@^&ACX?$<*:V1TJM+XIFHF1;[U(]J_^^P>L#-5JB9)I0_2&TP^Y+#Y &_A
M> C("3&H5'),.N=*T6.N&]"+]=9.@7C*#H=OMO#EHT!5W^3R#*6S$=9SE*Y"
ME,$2ACM;<:?9+F'D\P%I ;H_%I&VP83LX-9D.W .3(QT[QL2I>*WCG7!%4#"
MZ@F5*HJ1R.@^7S*:\;3.JPU#I;5=Y1:G8*(D!>04OA#TP.(*"4++N*0PL\@V
M!BR;//UV-2)["8]0/Q6@X-V^=]P>PM9F=V]A>=L])5 (]-P^KZ&&R5^SX+20
M52VBRS1W9EYPM>!)?N0%LB2-(5/;SJS^SJ9^&PF\*M%^5,J7,66XP!(X;SGA
M+[B17>PY?5CU&18?\L/L8)?YEV7I->HT=LXC-/7L=2'11R()F">>S/];E/._
M?1F3L.]7N+- 5>5.)I@G,W0 IZ.=/W59&A>#00 Y7'$7/"#ZO!BDQU&\@CX.
MP_*RWB[C+H *O%QH"]SV19*D\<^R<O7L3"8^#>WCJT]G::O*H2^EB;:M%Y\S
M:%L,$V>-J2X=.:6VKXAZP:PU%]A\@FG?->;WL<[3"G1E!^&KD\"QDA5[<OUT
M+4G''$1?&4N&2\G$!D / *K-!J'GC1@QI1KYFLV"*^,\,^+20%%*9[.4E7%"
M06N7O4=:DKA.D8@7WJ3F;$9/AXM-)DX<V%9XI.R<>+_U\U-=YCDB X IB\/H
M1597'5G!IF=U;8RCLP3TH77=JU0L_G/+:0=W#>!EY6=BBH-"Z8$SW]F:T;H%
MQ3!H"Y4*%N#36QH]OSELZU#_K @Z-JGFGGV#V%9PG_:!-7^P$Y9!YQ%/*Q6I
MJLYB]#8JG<@_8C(OO666ZX X ^;89[%5&D8Q.N\KOHH05@^AA._C?H^C#:G8
M<T7H,Z_45C1^M?72[ZZO 9QVJOA>G0Y='"U3&I-=\'L%IP<15?^HCWJIJ7;=
MJ"#&0N]K4^RM-XIP]I 9)^&/8I]O%TWIML^O:V*@57'??X/W.JV>WC;6:4GL
ME>XXWXLG'<'.WJEG,82=+9W$JE0KWX;LC%CV(1;R?!D3?![I#='LB[HVJ+-2
M3N9/PQ2XBE]%.;K33Q'IX%FEU8,[P0YY%_NJL)JZL<*]5%C87E,%XGD@VEOJ
M3:+0ZO=S!+.I'9X" 9_[%F^%+.JAAQ/DWA=]Q/9D@2TF&"O(V;:"&6A>WK(C
M*^-TE3&SZA#*8&Q[(P6;2@P5AVCKU=#S#I?3M3AH>9;[5 ?^\\YL<_/4+9[]
M>;Y>^OGNQ]<I24^@C9_/13T3_^$TH6-M<CA;Q9[5CJ(AIW9#-4S3(RRQ.O(M
M,3;&I?^FG-7T"-^>1#N_!'AL?<$?(ES21H_;+T*QO,=G**%P4;KL <.:9C?E
M'S89H#.<#L-%\TQ^9S _L+9Q1AK&%\8Y& YL; PV320JTG#R@#8(KTF)'0^5
M(\-SBI\'X5#*'P9%TP;R\5LR5?S89L?N-"%679;;H"Q3Z"*C<QAZZ<[A7M%$
M(%8@KHQ(9\\8?;Z7N:(8*Z;[.D>AS5ZB;BH.<$:1GK]=">>(9[^=^O$^'-D:
M7#/]S0^ \"C&&RY$(++'7(SW"EFH98IE]_FW7>N_[U]#/]&CA*LX<H/AI]<7
M%;<T(/-Q;17.KZ-;:<<H*NXHT.1D(K_T%/<^X"%:JE-VAYT7R,>V;F'AB);]
M[' 023R]6'3JE9'NXLZ7\&7;5*K88? W _U'\ 0J%+7P6*SHEE:HB/^0FE'V
M'_]58&JGO<2YD+AK';D';"KI"(=85<72\-0:^FI4*;.HGAVT"6D.XJ$W+@AC
M8YX4OI(MF; HCSO[-1 UJ,:+[L71A8+O3B^&;C#N>P#=TN=[?DU'KS$$/]KU
M'GQ\NI*[]4 WZBCGW[>>MUQ]KUT[G9DT-F\GK#X*2*R&IY@0?!LRSA;*]^$H
MYHA?WM,4E<I[#?^0LV.#[13AY^%G<DZ/ J@!F&;S;?D>A($H>3NNR6:SJ&8^
MT7_</-P?DIKBI<7>W#//T8VG,QEG!"%BO3X>]J D;-!'")(]^D$EF^R6#_K(
M=M '+%CXQ0&S'C7HX,%C5S!L>^\?V$*?G7J:)5.PD!6YLAZO7JW+7K2F]/ZX
MA N[<OBG!*<*UY;AUL%=C.W)=;H5-MSYHV$^J=U\$5>H!3IT@T_Q'M!\1SE^
MBF%7S)N34?,=?[\AUE66QT]RJ$D/L&(BG 1;IL7;^C5;&YW!<^&)L6')]#2Q
MS-'1*4C4>]XJX2/39/J%9R\?N4SOCL1,Z^G@AOQAG8/8K9C/SAB[,P['X-G"
M$99J%<E9B/F36--*?$=2E)7#G7U5N25#0G:.#65#,9S$_BS0>]</V!ODUE'R
MHKC?D3H,#*V2\ \9KEPJ:UQR.CBB^7I(CRX+L7-">V=VN86]DJJ)@:TOP?"B
MN@Q#L5_!,C]"]DC#/;AT&-YSIXGW?X[LRG2U6?3AZ'H]7G#"ZK[+P6EB^6:U
MXO,C8?-@.EJ[8C6#KB\?*:WTC*JR%P;X M-T*W4+S'XT#)%=GB=@G\,!EU^[
M% &M\1J'054.>=NN3XQ>QTR%4[P<?Q_TF(BV]K!2@(K@F%#HO"A*!P;$=S_;
M4;&Q4QW;ZTPDVJ-.N$#JIG4^ O1L4#L8\NW[U_/E6"GG&(*X%!P':N*= %WC
M.2(*5U"PNAAC)[N1C2;=HS/+=G6EZJ/TE$Y["1; ,8Y(NQYL/^B&GJUJBL9I
M1\&.-^0IFMG\R.&XR4I2=:$^X[CHJV6<CPA?0L.M2)!VTELNV:7WFAIAH\AM
MR%6IYT5%>.B;_).5KL/3>T&#BX:2C4Z)4>'+/;8?OT X1:F7;E]I4B1._GRR
M\ CO9TV0_*8\.LIUI"25>-FY'N1&JBI>M1Y_YBL-V:0I3';JN;T[IGLWM8-F
MNULC[85/RD5 U]MQ,RA&6MPZ>C6C!'M)YJ-0G!J R4G/>@.'&/H;B(^L.<SP
M*@++K>;GYY1' +H$7 PJTT)S@POIWJ'6JZSHE)E9Z:D<*?U@ZO0Y66[/2/\Q
MZN843'&L<5O8K9/QI/+X4-;/#MAW_:'80*H2C>'D[QO0[(.N^COX/2"PR?<V
M\ P/YONA:+_*;J;\18+UAE#7CF%QD+/\C<C2K!@??VPP#ROG8;>'Z<F@PQZD
M,-^=J:UV[=IH6\\WV;&7J"GQV8&P?0$JW4MOO:OZVJG/SH>Y?>_$%G]RP#NZ
MI5N>"*+G]%A;1":<%KENM L/!J=?% -#-&H3IN?;L$FU.1MU1J5G1$H3;M*3
M9E:(MU3=+>0JA4&0;LXS$P?0<>G1^2TB.^%Z/6Z!9,3X6LD'4CW>"YNV>,_
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M*Z(&8)'8=[J>,S?/OO_)V\,Y^!G#U$%W_K,]:_*WH= Y;=C#G88.F1WI[O>
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M)UC_)CJ&.\+\6);FB>X)""JP*#JVI]CFPZ19:89<\0B+Y68&G73=H4U<><4
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M<)\?KO]55,FC:Q;X+ 5(()2M-K0_K8D2)R_^Z(D"Q6'.2&^<-&VPK$S_#['
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MAFF+9205$HC5)#E*@$MXC8!'EN)H1_4>T-Y84S=V)N2B^,IK[E;ZUT83\Y,
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M\37%+>)&O!C^6OG'!"QE*U 3^<="0'R@#!Y5L+^@52FY$B(V'^0(3W3-Z7#
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M$61$.,E"8BX4CB M'RP-.ZH=LBS=+H;<[IC)D62#CW'&29BME*T4%&G:(&F
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MDI\&(/G*C^PWR?+[$)_+-=,(GCMW[4=?<7-3] /,CAU.G*+2X4^REAB@'?<
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MYY2:J"<**!2P5E7Y]:O3S(IC<OS:J:LY\_-O#*A@X8N>8T4]F9%ESAN39\_
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M?MU@,?AMFFQMF9>'A^4#[BP:#%;GY&NBU5U#B<S\F6V>)INI7>1>EW:%-9C
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M%OJ7 U44[H4T?I9LA#W]8H($VE=ROJ..HM2"P84EP\OO+CT^.7N7R<-\N[)
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M6[I_L5K+1M$J=FN"PAJ5EX/$[>PB009D29  (V00V'4,7WYT'<)!?>W0\L_
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M#:-Q*-D_V) @?7X@^"%<$.Y]]@N?FX?+;7QF?YQSD([=[/92LFB2=Y'_D1G
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MGWQUK3UG[RN0@QQ:!5/O((8]9=%OQ:$GO9'04;W&87,-^-1THR.4^>!97;D
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M1>C78<0><:/$;LPK+7UC1%9[QN:QO,_(YR"Z4_X]ZN!BEQ(,'@Z<*]CQ:]M
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M%9<*F&H-;]NE(M2[^)4'\#H'FJTJ)#B>F7 +;%)G_L5;-' LC;6BABM+=@6
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MV,LO]!63Q?05,T?25XRD$4#T%2.Z!_Y=?868#0%"CZ-<"D1&B@6P@GH*UH5
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MJPJ68\8;9BCCX1Z"47YT=WP,"SSK!4J;X6=O.%6I*;78RD0&F2<)>B*0!&U
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M+E17C#L\I^[9MB[=JW%'_]BMTVIH;%I:8/[J2>EWM9NS=Q8LS:\UI$4='A[
M(WT&,1MQT$0HV#>QY6@I1K$QK\ 34CQL.VD<-!_$N!PD >GZ U9!E%XWP.[I
M#-C:A\?\YGH8&23R!)S&X&'N,_\\/)!35.;PQ!1!,O37H/0C0ML&U=?5C.F(
M&NPAM5>A9RE*<N%PGMHP'X0RD@'48H)TK@!H[+"Y9HT.;U#WJ!7E?\"*DK"S
MQ'F:2M(;ZYE/!X,VWWAZ5?^IAAWW8I+C<W/V^)-;NR*7=.F4/G0CPQN7":"#
M21S5R1L9I&'^YVLF*YD^(!C!A\Q48J/[V<H]=MFB^1F+(ED(0+6D%B/D@M4'
M*^6N'E@[%8I$#NST\-1M8U&4R-]_V>N>:XMK V>7TP\GJW6=A:.L9AIY%<\X
MET.YKKVI^99'7>B&"3/+%OLO_J08I1P];[)4H=:TN8J1+<8-.\8]#(^V4[OT
M-&B/4F-O^%KK.3_U]\G=8^^8$*(P=_W#SIC=J:<T=W7'G'^VN_:L-J06PA-)
MJ5?_HS$5HS,L1F=8H,L%.VVK&0I(>+T*M8S-T,=J)E('.N,,Z[3,?I$^-^X
MD[+I*0(B-%Z!K$4)>>8$NGE0#[7O#(T#ODZF#HM(\5I_;8N7\HWY-W_X?J7'
M[\;=K=GRW0!QM$5CQ2B([!RM1L$8VGTS*\Z/X$P?'N&([1TQ0?>5>#T]RG%N
M9<=?D.J>PV-:^5U30CWY'*H AJ7S2W<"M[H1!1P#BEB-3%RF87Q1&N'!W(K3
MIS42/%U=7UX<PJGQ91Z7_!1"PRA['NI:/TGQMS&I--'?2">*# #I8@: ]"\-
M ',1K]0X@5>J+K8T@P9I*CR%?B-&H3]=#*2Y]!.ZF<J#S0/%)DK"L@RX@YZ4
M4]0&HWA^F?*019 OIC+S[YB/:97BY1YCL>G@58?*MQD[+"/[=68/)K=:::%%
M'\)O3^-;*3I=JR*4*BE=G>+NHC6[/#IQND1=8JOFU)*.Q%B)=M7WL3]>CJNY
MO6^WW-%,+^)9VF,.2"RNF%'I27!64)[C?.?_F!JDI%+8OF.<)'P@S]WE,5^1
M1ES450%K@;T15SVXD&CYC04.HZ69T=+,MR_-H&LPA3055?8SJ)+ EA+I0K0L
M^U]2!Z;L@F@RL.VN::[5D\$/4T+X$XN!^]Z3BCU"OXF;99Z=WU)*NL:J2G4)
ML!BVDY&UKYTBVYR&N10XQ#0Z#+L>\G56Z*X3)"OA8;+?UU-9< *;RHCYH;B4
MB>HX^90#?5K$'Z3QZ[41FDF> \A7WZ;<G]E#\<'T !%OVY$HR[N)G$OE 8/(
M<KU',1"[5E8!J8G/P[=)S_>5H@4=,["%%ZLU)C C?4Z^3OWZ*0]!.G+Z9=;!
M77-M5Z[H4#PR=>KT"7L_ >0)SGVK0FB%A<FWUW]$%!#J.XF(,AS>=!O3D:)Y
M NDRI'(A589T_VJ(+PE!/!G^RYI3[.+ -I&K1\C2:!,B@" !1YD$).T33MS(
M+T8>< _R@(N=%U,Y7F\0R4Y?1+CW;'(;K669[0]<<^X$)9R[/J9:$HO'R$)(
M^!M0NE[CP**326_?6]K FD7<_#9[S005,FM0OY\0&<-FJ_-XW132V#6\MFB5
M8*Z+/GCD58HO.-CK_]&YG^=%59-K? VJ6[%)O_P]3\E7I $9$IP",/<%GB3L
MGU=]/  !?*,!/Y&4=C^IEAEE2UDTP23]7/R*Y^-<S7M)4G8A7NR#]M.8"1?E
M+UX.7+9V&BU6.%!S^GF?%K9AB52LK:<.9VL,&\H'F;=L.NW^?[%<Y'?/U,#]
MI33=,0>6S]CP7<WE8UQ%P\$ZE;P[D[54TG0C%V:M63#OU!6.R?D8*/,RHD9;
MM#-(:/FA,4%S&6E]U!0+KZNX]R!LO:%%W*GTTS\:,I GR1K@M="U@(!<(C\8
MGFYTM&34/?/?X9X9P?JB5L)+$";I\W.C6&=D#/A!CX4?_GQ72["@:!)[B$3]
M -TTW>:MR:O8_JY\8K[^J_P!V78X M%<]/EU0[YDADH%5Q\^6=(N77X /;3[
M[[RD+]0ISS1S.SP[]UWVSSTVV6=5&KO]N1(&%B8_E+]8_/I8]E2'U;M/7_E#
M9BOS1?L&.3,'[^AJCF[A@](Z>U='N=F2<KOVS3OZL3O/G;*3HDDC-#RR)3"S
M"7T>O;*X\X?;R]MC3=UR7RYU.?=+Y<S^S/N:9H:S0\Q"K2]--+M>LY2YY%FU
MK)OWCY)U&BL_V]+Z/MHX5IA:?=3DIK/E$O,K[$ TE5+Y;G5JSL,8)>L-/3IS
M!B(6Q8VAT_U/4=;>EC0X>R!NP9;8!K.]1Y,MIV^6W&$_[G68<E+! XNUNZ_U
M& 1M]*M2T6",D>]J66EO]_)EQ=;'?GGO%LR4FJH0T%,:IK1[EG;#9GP8<4_P
M@4])11I'-\C9UJY+7 <O><^NTFJ^7%%PA3%VS.05!;M[X<366?U76MG.;QJJ
MVVHNW=N]_O@JO]J$Z@$E65^N(X$]EJA3[ZAS,O'G>3Z?IQ.J9HYYW2HWKUC=
M\^?RM_%>717!BC.6YM?<[KKMU-],W^+YP(XP747/<U#Q07+1@R-7E]5K1FD?
MO37N5/M 7\9X+?WQMB_49N[UN?\QY'ZWTF:W-9NT=7/GR%76LPLDB#,C5R_[
M6<=1[:SA^E.%R<JR!_X?>V\>#^4:OX^/H_U4CDY:A*DD1:5-BS"5@Y"$D'5.
MJ90)"=E-FY1"2,HV%;*;5$/6J="@[,MDB>S[OC,S?L\S^S/%Z:R?S^?[\X?7
M:YZ9FGF>^[GO^_U^7\]U7>]?#"X$/(RREQY\??Q<[3PG12[83X<]PP8NHRPR
MYV 6MNN_09RYC6Y\]KCA31CFO<.]2Z%*P@<//UOLX^P*4ZDO'.>SQDX,@+U0
M^,)U*7"/AKZ"QP+1.>T7EKU\\4[CES.\JOWSL&37IP:F1HJ8IFYR+3GUY3N'
MKQ,3Q^?Y\;5,P?J2$!T+IV"^:+(KG.TU3&C)%,PG HNN)E \]8K823,GZW@D
M$*^EG:-J+PY0BA>_["JXTN.W=%==W,7_WF>UY4G_5L_ IQ<^IF^#=[4)KG^\
M\^:FK]<5Q_F,U?K-,4Y-1SZ:IMK."SFS>J0SB!ABU]*]/,?$O8'O8>V)AWO:
MVMY=ZR[3;/L?,&552?(@27G@AG=K2-U8X]7.H"RM&=)!3,$6$F\!_V@SG-PW
M!:O72[D281*CO\9#UD)J;;7*7.$@[AH'WI,"V2D<UJV6'$PG)MY1</BEM#H#
MDYD;8P0YXJ#&L\9;+)A#"\3@QLNG=Y=[W1IJWQJKURW_;/=-Y:@7<X32'8>&
M8J2.15A%*6ST5T.=%^0FK'NL[^+LMCX4!XSE'OA$'Y*\4F,,39&OYIGX"A0X
M@X3=Y_^#IBZICIBQ"7_R(*GS]G0?T$16MV,J9=>@<V+15*2@T:8+LP3?I(T8
MKIZ"G5%NW;\T\7_(V049WUZ1E&+]LD;A4]_A[M5+/[YNE/&2F:]W-U//!I?H
M9V:S:'N W2\Y'Q0.>.XJ"N)Y'UDW5II9TCZZ_7GX:N]GUHO4W3;P>OH)^38B
M>*K:1NZK12F\5%P4$U^Q;ZU5D0Y78[ AWUR_[HQ0$\'R!R$7EYD87U6X9%G7
MKEGRKW.N=#ZOQ[N:[=UT47?C3BFGZQG'9[;@H5&&[,R6VUW)O7[UJ/"&I;@H
MW1 !8'*9$RAOW$M9D$DL!V02^RUDLC<+/C"/(66,@^*!["OB 3O[BM:*E$7-
MHB^(ZN]"3ZTA^WLREH+57"%8U#W%F6O#(8#@@W_=C9:%[?'.!/G)&Q'803%/
MG5E4[^^A>B9'^Q]>0X55Z=>8JH<E'+[=H9ZAO8A+D.Z')!4MCIF"W>S,1 \M
M]Z*,H?OB L4[G14*#L1LEOZ\H8  N_>U$5^27'#8X7]+/YN6WRM*B)D3#I6&
M%WK7ZS_Q$TU>I+-H'R%.)6SL@6&D_W',L<0[OF+/FBSFRRR0$2^4MGKZ[/'B
M?H/W(DE^(AXI4MM_1_.J_=N=>/5,I>ZV%XO?W=^C>>'<#JX!KDY?I$@[Y)\8
M=" &YJ<P^D(-=9I[[-!_)BBA9:9J>U?\MO"9Q3[*\P3@1_F+8LGS*?*3/!.C
M:DWBA_]WZ,^TE_\T2>%UEE65;=DGG2IO4B=$KEM+<!$S^\E0H:?DP,?.1V&>
MYT>W7%A1$M$9@@)N@=$_*4\+""0;('K@Y 5$%8.RNHYZJC]$F\++7'1SZ\?A
M%? H/BCF>$FRSDD<N'H<@6QIT>(W)*K>8<-!\$KE%*OIEHV)M(DF9)W00?2W
M[YWT $E)K109(+9;XOV<)!&>LF!1'PT4]4-#A9?ZX&"?"Q"Z?<K?A@J!')ZG
M>R$Q*5ZT3DMY=32M$DW$[7*$ZA_'3O'2)Z+[R1>&T<TG1:.PMEOI284J_-HR
M?7 70O9ZM1J1(:@OEFMZ)MBU*)<?[NFKM48WO0AG:?,\)R&OR/[,@R7O+HY.
M+$HZR9 S$3W\T&E8!:OBL?R-_;4IHW>LB;R/&S7<:S7Z>(QVN%?U]7H.5W<[
M5-5V-.Q?[R.OC=RL<&BMC<!H_-)$)Q$V;*O3L['V#]KOW!=29$,FU:GMGGMX
MFC6([[0H&])U6U2N7&RKE7$[5.+S7A^Q/33'=CS,9!OA>>FQ%V-W4<:2C61_
M=)7)+N-/PN8'&WL&2]ZHRE%D$:!+C(<6BQ,VBE@\]M3IR*O75VJ5LY/F?_J2
MNG]D5;M^>6O=(GQCR6@;)K^S"/6/DL92\^=_T)L;X68]Z>BAO/NA^/GBLE"G
ML$USK!DM?$R0H!"R+]C.@G(=V&3J>"A\V(B./0'AD<DO@DUN!YD;#$\(R3M&
M*)V#,LJ,?(W,&GO'!>+P5#DC*P=\%YWB1G+THI(CXK0,Y2@R!"IO@KVY#T(#
MG%F?P)FESH)!B54A=X9.HV.03\+#U(910\M?<S5SJ-Y>0XUZG%S.4H8E_)L\
M%]6MV6'#A#R+*M"-W8@:RO-7G:Q^PV SR'L5R.%*Q) DU@X['W(87RJ'F%;I
MYM S;5MBUEX1@QU#6XX@>4RM5H7[FPTZW7_>@A#SG'MY.7GE!W^A-2JI)]>Y
MR_O4AXD4^09Q5;J%,Q5Q[8D9ZZ\/M.:XYY&V.WOJU5QU(X=6X3ISM\H*&U3F
M6VW1[E^1[/O).>?2TAV$?$/,#6E-RX935\S7>^Z85Y2Z_%ZK;-B$3DFPF_H_
MT-+XG@JU,FADY!P?GH$V/9]=H*0K\>^;W?R AX]Z>>X*TT/OEBWF'9+T'GD\
M!6M]C1FMC#,SIDC[D_M)'J?9W&T2YF9]:-A^[O[US+4)PUB'(GR3T0O@*ZVI
M"M?%</J,P8.]#D[2>AVD:UXF,QS5V;Q^4%=>I%T ]?VM0-V\"L=')>6UX)B,
M,Q$V.-5)!.'A$&):TP(4:*#-SX\P\%BV/K40SQ^L;SZ>OMM*>HT-P'N]FE#+
M$H>9+YFM@^;<1].6 E*>0(E"?.$;#&-<7C$05Z+51N4=GC?&$"R 0'.Z KB_
MR%:C; X[869/LCE:I:1]H -S J4),2EIQ;<$>UOB]<^=N;O']ZQVPEGBCEU:
M*G6#77:WK<?07-"HMEBBN_^20!2075KS$ +JKITYR6MR:<"5JU*!2Z;@@,X]
MI<8O>OJ1\6=\=[Y?H% 59()=@T(>ZF]YY1Q7K5^X\[7%^ACQ]0,+N5_,3W=6
MKW((G@%T#?N3,CXCRZ]HWG8I&0^2E%_#.^$OKZ)?)N14S;,3*@<RM?<V]?B)
M14!<<4*,Z5074Y8[\[81SE@OUW;QCV]/*7Q,?FR=)*2]MUMC1TBP(NZ\=KB
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MF6 =^AA1*YG,5*FZ@2G;3G0:BL6J7(^UZM,AN5_!ZX#QQ.ZL(^8ZD+CC)O!
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MJ7\!*Q"G50D0+,ON"PV2HY,XD@ODXC@T4F#UQ086L;LY_W=$(VJM*"=9I(.
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M$G20T(5=P'2>.X?5A"^:A<B,2=5E^<=(YYH7F ]2$.=HY=BMYRQ(!IL4"L+
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MP8HB%M\#;T8N5&LTB@A(VA^PZ5G&V%#A#UD:ZP$?>U$*4/.2J-/9%4N5:[6
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M-+8KO<MIP=KU:I=BM[TNO8!&[?OMT0[WLV;).QKW25LC_"RF8.\S^@AD;L3
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MEWL+I1R(1S(-4[",; ?.$,>Q:-_$9NQ[')6LK[*JP"<PN<F%&9'6+'+;0(K
MV1,8 S;=U/SN:-4(2MZ,Z&J,*CUL?L]>O3%%*_B30W9@KH78LP+7Q_>OSJO/
MMQFEA9G6.<ZHJIGOX3,K*[%P1?4O(2)&V+XIV,G2+6E[3J>5F6UM&K1ZJ5M^
M;(_$:><8_9E&ZTE.R13LIA>0=3\IP !9NQ)%LK46C#@DP\6TB'-XI:?6V24M
M.SX<ZC1$_X7M$A.O*E!UM'WY[2[C^W.UYV"^O,">G'$J8/?<TEDD*?S=F>E/
MGYF?.&?FS=V]73$6P@6#3H6UN\P_?')N<%:]DED_>@OXXK6,+W:LEB4\Z]\:
M<[(?=9V_16/I(:OKLCA!QYDC\.^7[X]I&I:8I>U"\7V(.KO\+G[3Z((PI]8$
MR80_-R^W2]O&7"#ZZUUXC<<%K3^Z*GMG8LVC_B A*7A>\E_>+A&\*@(36W)_
MCO74>A%Y62W/42?(^?H@Q1DH./'G,D*AEV()9CWA;7+'*'DX9B W^TX@[_^R
M#<R9\IN2'JN;'/Z4<Y#[4DO*)&O,NKF!D=V.:-!E7"D>>@OC[^1_BF:$\4PR
M6QJ4STR#XBR@BT:=X[IO"*NPYTE$C!U1_65JO_4NO5K]_%\2%ACMUWJP]Q%A
M]?PX&R"#G7'W]3-5CMNK.KQ1O45;NJX;B/J#M1*37=K:J6*JYQM$=7F\M[\/
M&M"\9I0Z\]"[K-EZ2R@Z.MQQ]7N?FP_BG9)'?BX<'\)0R 'E??FO1RCK<3YV
M9]PEO_A;K^6Y/RK9"9]VM$UEX7;&W!01QC<WQE;AO Z?O%6J+6WT]5;R@QOW
M#;YZQ2D:5<]X0B<%GJM-,[A_)<?\WHH_66>:- 4+Z4?7G4X7GFEVIZ4=,UPL
MKW:^V7AUB:8ML%VN?[A_2-=GI:Y %#4<=1M9,D=KPHOC_F21Y/M&_)\N.3 I
M1LP93*O;-7JO.B$);H?1-!R30BU4JR1H/K_Y9=5 *&%WZH%'PW?W^M2>E0_^
M>=<ZV)+,@*YMM-RG8,$$\36/6^VJMU.P._0YI0'--E-$]^Z,/F$C6-F@U>6R
MN&(H!KG@I)Q-5&6F6(RYI\I-;?B.CH4QR+\2R6V9D7SYWX[D<5=.!!1G'8MW
MNG-K>:M/T*+ANID7RF#?^,7MPUI:XI\+EC_8 *U]XNCK./&Q%K".B^\#M0_6
MF)K.'^:W'='">K?:9YCTKDXR-I?MEWV>JMXWF;D*WK^%_LVC,J^Z''B6 7-S
MY9MU\6?7-JW<)]SY(Y4/(Q85&YGN>3A@GURYI2-BS<H$R3+T>\6G4[ B$R#Y
M?0N<(7_^C)'@R5*Y#RD>?G5W3P54#-2>=[VMT9\7^Z37^-Z-BH2,'X_D=D$I
MJ]Q#BO,^[ I[WFN50Y+?8D7+E#2IM6556N/TM<_#?A/7U\Z[#/K(Z1X8/[YF
MHK_4>+QM?-.JIOY1+^7>=Z4GE5T*I()WBW89YWGQE'31LOD+?MK66_)7,Z9G
ME'+0GXSF^?4R5DJ)??FQ.OSA#S2VD4)KUGL/AF25_=%.QSD[XP\0'!*#[2V?
M!ZI,ZK[?4GU/4]PL]ZC)?$^W 6"^S3RO\G"2VH'/)WPW#8H+68S$H,=[5Y)'
MQ"6R- BR=W<>[A2^?PD,."@BXB^FF15@,,<"P?QH-!#,S^> :7D";2?8!B1.
MJ";[#VK 3E#YH88:S&. N3E7P;J@;K"?HRP'\J6R\&,_&,P?PWF&P;(R3A":
MPANJ008N]@\6'8PS;=K]!U/;<DE]]W8G;?[MP.HY"&RILL;H0L$ZQ_V=A7JP
M(0RD8E7\<V?BDHIM&[2S5??<JI?=Y*BKI6Y^_*'(4MCJ)J)_M<';1.]Y =L/
MPPY9$OC:\3-/'L+=]XI\?"NZC?>_4V6[XR$/KGO_WKK(JGN0?SC?^&V& *X(
MV[.V-%%ER6M/C]:<2^^4YC\<CI5PHZPL'DY?Y.BA45CHMTU9W#[^C6&TI:MP
MLN2^HP*7TFKB1_FD3.>'Z%CT55 *,D\$8^._)FK^"CMW?ZVH>.<09Q4!C2ZI
M'JH<13TV2]!8-;VH6_A5F=DV00OCTPG'8@]6U7P5\DN8,69JBN2ON-;!EIX*
M9G]:@MJD&[KA*6R^0+_18X[_W4Q"UYNM^:V/I"-U%N.]RR!ZQ:!AAD:LY76U
M)UC^_?+[<F7/644OE"F4>I;N*->'<+.01D34U+1/M@14[;TRV+3Z]!/?J^5H
MCH'N#IZK-K?300M[<\NIE+*N>C^M)$61]^(\CX;G5/3^N9O?Y&0666DX]G)A
MG,76EMNZ<R4$HO.6CNS+D4&M9"8Z.F'HF3"7QW<^/KT=U2T0:RRE;#XJG=AA
MIS?P.3;R\,/<Q?L:$GCTAM16V.DKEDK&_?3S&H28^$?L-IM!@U[#G!VYC;U"
M?F708)"Z?4AKD7* ;4*8<%ZLW>LY/]_.W<?U06F"F'2^=FWQLZ(N8W_M!$5]
MZ\5QEZ_>>'U)P51BY@NL"85F@4%V_L=?8;)7#KRSG>.=NI&HQ+5D$B? VR..
MFS&2Q%\\)GAZ\^2>KM\:"R#!UD/O-Y_VQ>;Q>XS%K&J(6.C%O/%:.N9X-&/L
M1O2%).W:L^'XX&9"R_;JQ(/SUS;U.:-\E_C+\6A6;3:XK7'<-CFK(NG61O>Z
M+&T?M?7R_'DW4U\ VW\R5F?F6N?XYV_J+T4#XI!]FDPD847<Z0&9V.CHI$TJ
MR]Q@B\O0,R[?$UPMVDG;MX8=>G[OEZN_&%AFJS!7<,G,6W360_5C&I=;'()Z
MK@/WWWR\O#5O^ZF'30)3,-[H\K80KKY$K[CSQ%T=5UR<O+_L-JU%Q:\T#;JD
M&!4?P3&ONSY()ZAWF;_6WN]U*R#8U37N<T9&8N*67W^ZX+?KHP/&H0<-1:#/
MS9A(:"W&-G1;*27WI9=I5X4_>+E+\:9G_:J@(V%]/.'V4S#F/<0>F7F($2NO
M>6Y^_B7VK$9 H'1!0\L\W(.%].5N,.P@X94F'GH^!.[>>O35P$:4W^%:5%*>
MEN=V)4'7BVU&\_NZ6]V&)@.#$4ZE^@H]M4XWMIQ8=FD-G]W1#9<2+ARHL6Z/
M%,Y!E6? 4?QG_=WT#K!!E:8C&W%_D "^+OJV^*;L*;MH3M*QD(QK3BO^>6UX
MHY_NH5IJE?,'$).?J2FUR%&!(.E:V/AU=@>5C(U]BZ]1?C4*Y=S>TO3KS>!'
M*W:OVG*1%-G3DY9,S+]2FWK?V)>@69)6M=]@\PFMY2&WU)\]Z[4JZ#BR8"6O
MSR7N>[[#V LSC[E!3;$:;]NUE111*;3:^(1:?SCGA0;.N$T?%-A[1R).M#\D
M5'KE\=Q?8_7/*'%IOX==4M1[^J.S.B_K[ NL5MEEW"<1>:7:UONF)1O\CQC;
M6+Y:K1G2$DDTJ^_EN>!?]PM.=6='M7.0D(4__%&F.1%V>:G:_(I4-,<>Z<RO
M["&I:BUYSU[+:U-?5K'^F'N)4M.14-WC_E=@7&]L00SQQY^FQ)R^(YF.5O#/
MG+AI:5JQK1>U/CHN;UG6T[?<DLT5D#7L,',Z8]G0YYTM+Y]ZLN"2)GMIJX.P
MEC/,.W']9Y\%O?D.+=BOR*5Z;?[$7RY4GW6O5508;-KW>]B-C]KS,Z=@/[=-
MM-RQM(S6'1\(?R=O(4G\&7=,5D-&U>3F6\+/HAMZ+0\'W$ANQ;4A%TN*"\K*
M'$365E=;;$XJ\-.T-7HL63XSG/_$] )G6M3LLA;%;];CBA(,";UPJ=-Q#9^[
MS>EY:X*X2Q)GO)_19Y)]#PXK!I*CZRB.V5,P9_>X2(/#(SO%5-;L^ #[W9$8
M"3V59"^XG8Y"L9.,8,%CDZ:CQ$6N:43S10D?%@J_P*X/T5QDI:GA<""HX_JQ
M4>F1K[?>W+]Q_^17=\]TV\- $,<ZR9RRLHKH#4!9VUK('O*A+OFG'!-VY-@-
M>/U(PO-*._M0.N26"$)NV-.HZ#\[V;T\<.)K\'SZ^2A["^G#A1?LFK6/V_J"
M98[+CY<YC\ R)ZA'>T>PR%['$*WHPN4/KRJ*[:]=RG>M"R64:L%GYWBTU,DL
M[+.NOOT5HI!.(/P1X<H9,7M182]ESH=>AB<O2F66-AUK?B_M3G!_>_#-/=^K
MJ\Y@XAQ=[C8LX=^ZZ,-^&]1RFVO<X@9/UG[]XRC>ON7/ILN<E> 2B1E29.R>
M,>?Z[ET&R67^)Q('*Y:$G!Q<?:4IT:5=Z#KG2CX^#UH@Q5JLZ Q0+73M>994
MOB7<^Y[=D1[>.UGN#MSMFC-.;0V?%E7N<E:6+';@[J,EKY^HK@8R;\OV;]+(
M%FGG>L,U\GU#MF :N>/-B:TMJ9=H4<8N(;<].^)3@<TAT>36W3KQ;;+S^X9[
MW6*WF5N3!U7-/;M;<W8J7S_&??HU!QQ5661,DJW872W!(VT;X!&>%F)^Y:-4
MU(?R+E4;Y)]ZM.O=GQ%N;-L08V]FL;75X^*(OZ?6V?GVX%,<Y _#DN>HL.0!
MOWLF2JJUK7ZFK[)%GO#F>=IZ0B;?!>KDTR8*(0-"C 4K[]_(W2_@H&/!\=4=
MF:<JA##K;;?Q-FE+:_\T-^M,$"QS QE5&]HO=%O8H),??6@*)@$L*\R,YV0H
M$@ =A[3G(SV5P]W:\F_N^*CDKEZU+_,GN[6C?&V8F0-K_IW,6'G$N2^W@^S+
MV0H';_1ZZ=('-K\K&\_?__6;S-&#.[/J;&_65K6C*8EU)O,#J8DC[JW C1"W
MBN07R4Z72ELU,AZN7_Y L& CSDER]W&[ZV! *3Y[6/<S;%Y]#3%VQIP][.(W
M&VMXG-T-!?]#9<)WM1-L'2_P:8%EX#'8ZL@9'Y=&<G^*,_]=_\@-U57KYH%%
MHL2T>=6)\K2?ZS^:K1BQV]W],MM".-1^0. 7((SHW-WR;)FO_ZZR5NM?;9.;
M=([R]VB$_6+PU9-4IM6&Y$G;$88*V/II(CP"L]Y@N?:@X:4]480\Q3@;CG06
M>YJWV=W+V#HV]C)ZL8VXH(P-3Q(DUM3]N2TC>K5W/_?)4@GK-79=PVM4W%9Z
M)YR,T%X+ VM$@C,SB@QY_0&ZUF^WJB' K.J#UN:H$"3:\N?/.5&[+V8MAKT=
MC45=7Y)U4^ Z88Y.I%W2NY2EC^OUJS^NX1&S\U-&!*_[<'*I:T)1>3#W.R&A
M]+YNU_P"3,:%N.(O:>/SE 2"YF6C7-_'[A;X-2-)[!=@GKNG^[[G;_$UJP^T
MB[=1V7=&HU)I&^^1<:_3IH4S;OLV#[^9"4W4!PT^%^K.X'$8D\#4O,?ZYE<:
M]\F6SXQOZVH_CRZ]Y*SD T')M;9JVX6]^FF_NF?_^Q>RN Y.I%\X.T2H='?A
MZ@M[]FC7:N$(_BT18%A9.W!,4<BOI3BO7OE9@&]1WNX3ACV6N\>._/I!Z>WB
MG6C^$>S,PSZ<G[M;%:UX]]!+3T.];,'?C^<1-RW8UZ9@.OKGZN/!U,Y4$^*P
M[K*&C4K;OGC?N+[*)%(F6_%'D\@<K-][G*)Z;L<I,3$@4_ _\7#_KN:<N/?D
MBL*X<SK/],?T%7T;#&L?C-B_]/Q\),$>FWG*OL"J9O2;TJBM."RR] 11[B3!
M[^2@Q4]?]"O' A::MWHN>-?<?.F)4UP-$5AV?VI^Q[E+'3P$NW'?@5=^?:3\
MHC38]LWG_[;;T\.RM%WV]HT?!<TW_[ZBHBVZ[9-MD'G;#L_&=)O=+%J: "[B
MEL7:L1LV\6DOUNC>CWYBG.84O7\5P4*OPV$85/Z15>KS:_CO^;NL+,O(;EGF
M]+(K<*?#/"/+;O= N3''W7JQ#OZWL90OTA=7']]QZ4B;;J"OUU$=F^\K*>WQ
MV87C-]'5%N0((^^3(<)]X5YW*/DCX^;"D[+=(2J;"KI,]L^??);8!KD8[-ZQ
MY"G8=J]),]"0/4Q;]#9)W+@!_<HY0_\VI3#5Q"=O5^KJ@D.4MB=+4ABT5?J?
M=%U#*^D]HCN)DDO[P;C_X =5A2G5Z"Z_=N[PTW9WWR?*BD[NK6Y^X]4UF6B_
M)?1 0E 3O,>]&MJ]+HWMO_'=:9!8]'D,TU5G\; !\:JGLNGEO9X/5O?1*9NX
M+UI_X^E%V69=0KO ^U*+LOI7NEYT4AVQ2/IH":\<O3B@JV!KO#\'\84O"4I&
M!.Y$08 B.1'D9I:(_YIEQ)?0O[>24K<U"VWRY57NV=5?[K6NG8)9'Y_WN8W1
MVI?Q-XB^B[$],I$/#DZH5XJLWUWJ"0=V3<$XSUC\HN4WOUN8&N9\[H]_MV@R
MM%WE8,,_]].6LE)3,&__]YCAR2G8*X(A[FQ'+1Q7(?%Z,B9JHV)I\^!IWA=<
MGB=(E?.]'EAGPTPY[.VY6N$K97M\AX'\_PQ6 4G_[4J[1_IWH=.I2/OS*AC3
MG83+R'P*-F! [)N"E3@,N6?)+D^0%1=:N[/&.18]KWF TE+PJ%#-Y357$LO-
M!,%R+=G1%T&1#\1.D"S(7.(OTW JG:N[1;8(A^SQ< \Y>.J&EXNIFQM)YD)]
MZNJM6\X$'&FZGW/TT\)<V!5NSTW<VHS)]0;KCAX0 _(LY!U@=Y6Y@O/'MJW(
M$"XM*9A0"O4XLXS[9]AE+L%WC0$P:6"S7/_<;PIF9(EN^PDG]O.:?4-DV=J"
M9?F":2A^__T;N*YA'$*8DWT?1A D4M=;3)"!^]D87_5RV(*GJG-OBG-^F:_P
M9Y66+.'?N06B6M?V#W@^BE-FWD7Q?)!Q+Z*O3W6;X\<!4S["3H-PM']N1<*<
MI"66-GB'U,V'DF\(P':5.13-^\)V%P74WM>-K\0B.H?Q0W.!'QSBX:D:NU*@
MC]J\T5OD01[CZL4U6">)!Z\>*%>0%X"K3[<6 O9Q;TWE*1CV"'Z(5P'_1&_,
M2TW_0/M&3\G[1Q9OX<J98SN_(OYS)2&B?63DTL/SW8TGRY)SURY>7#1GB+Z-
M\66-#5(4_C_>WC(JKF7K&FXD:((%UP0)! WN-!(@0+ 0W-TAN-.$! DN 1*<
M$)QN@C1NP0GN[NXTT&C3O.3<<^X]]S[W'>/[QGC'\Z/^0>_:M=::<ZZ]:E7A
MX]X!IHZ00S2>$RDEWH%3NHT_ZNH3+/RP_:<_.@"8GYS&>5_)OU;#R/O;]&F=
M5X!7K-=3MS5_W* 3KY,*"F%W7R)8L"=0>C=%IG]14O&9Z@MW*YJX/-AQ^)\G
MW/S'*1IUSB' $XZ%^\?/W',,:8-HGT53>>;DFY_,T;EF3;_]8K#0&]0^F4E5
MGC#9I?!=@?$4^^M[X5::H+/L1WI_H=4J\CFHIX#L-J  &3PQJV75DCW[QTK,
M_-M*!#UNISMYOF,,W_G=N_.F9%KW/Q?&3>OO)PRZW!N63OH.4 V\%IKZKO6L
M9$6)QEB_:H+3LE;W0&!?9T8Z UQK0:"JL:?O_L_0VKRG>M#:J<[]OX$&]NYQ
MH1U)7'X\G\)ESM$1NG4?0,*?URAV@L3MG?[O4X_\GU.G6@%=$9^579_]T9!4
MHKG/OC96=>,GI,3G"2NU,UB/PQ N^5=\;R*%[@ )T3F@.;I;:OO[26@>Y\64
M@_7LO'CFV<_3/-D=<E0FYWGC5(U]Y_Z.W&TM)UH>63?.OZ^3::(OY[M_%YV=
MQ:=UDR;)*Q!.KR-M2Q9!@GOQ?K G2>7^EP?]Y\$2; T6C169LV]^/OO#A R8
M=!D %V,<T+KAO= KR[WW7 XOS:25.P#>K+?3+R5[BF?QC(G]SZS0M^[=?13Z
M3[6 E@E;0H1?Q][\/M,";'!<@XC0,[[U_7W&<T1EB6W<GLC;23)E>MD7**D\
M: \)O'LDDIA"/OMZ9CA;HUC%+'+_$>0Q+I*D?XM5CWN3XO\VJ?$UWV^3@N]-
M:JY;-7YH6:L ]OS3I-9/,IO/_HEBOP?FX_N 8TJX03:&G2@>E' "\6<[5VT]
M.A.<J_K(/O?H.*"A5?-F??;Z&S#\[XRB.;M)0:\+4JT+G N!;J+.X;++&-\(
M0-W?YOZ/8;I+RSO,UY?K[%'(G%KPL+Q$8@DR['*VIU?M53T;4CROJY+8=@?P
M&%ZG!&3^VUVT;$S^2OE9A K?JCHY1]ZN=)%\HIC%=PO&7X-G/[+[#\6 PY8Q
M[J]/37G;')NO+Y#C/B@&HS*1;NJ5R"V#0R+^_4]9OJ/S!'\G\"64Q/T?DW6;
MC8UQ?\2S RYH7&)-%PK!#9'X&,.K=^U98%VB"Y[,$AG"=:GSHY,6^;!O@SKQ
M;\T)VD_!EY!-1TUW51SZ^5VJEH#G%#$$(NMGU]?N>Y(T <33%U=*FP=<[QML
MUL1A*O]Q[VX7S'Z7^]+L4)E>AJ;#OL$U-LWF9OI,J*A1N/190_:<,2=:_:HL
M7=M:,% $,/;OZN7GI+^^>8Z]0#79[G8-=NT0XOD@!HCA;#5(L/"[O"ZA(3G/
MCQX35ZR\OS^1&8WYO>0#DE^[QH3N-"++;8RI!Y]7HBLPU"\34!#WKTO;8KE*
M)5 WUI]&6/TB'B?.)=V7MBD:8#OR;VPN^V"A:?*H4I5XCKS$QXG*ED:JVQ>0
M_#_N%%Z#&C]>LM-KVUXDG&.$53MQ3EL)M8K%@EXC-:>?+7_P>5#>BP9(!>C]
MFXT@0#V8[,%A*9\J]H-DF(IUG>GG<+Q<A.HRCR_ DUC##(]>BELKT6;^K<GC
M)=2,_](KHA58!MF9I:E-T:C3D0GHW!TZ0TN4I"36%O]^N?9RTFER<M8KQO/F
M$X_CPIDX$&?[;YE".;\SV78J?_?,D3-FND@W90H;O%NUJ\S6MRFFTOX\6F#%
M.E9(J(<U $LL M#P3\\A^;#:I*0S6FK6,')@7A<CN.!:P%3MAZ^J,1<C,HP!
M)TG+L9\T>C+6.1&Y1:U %; ]E$.2]^=4WWJ1O="3MJI/%3(SL%PW*>;MUI D
M4G]5"LF)__!\G<#U$<>_]/];#<.YN5YJK\>=CW^Y4#8$&5P_A!?]/<W90*BN
MMA<,UFM%T\W"?7X444:%G\[?7'2O>F?C?8LH^)YWYOL6MT2)NN8]R!<&00%N
M(2+J_K5L)'UV603NT2(PL)GND>7KHQN>4$V$ @6"35L:1IJURJ:5IAI?\1&;
MP254YA!8F/U(\2^#L;*5%+*#+>H:XLU"^></NX/8OHSP+^AW^.[4ET<[G@E5
M?$V2L(V]3]6%KE,!>_^"D4K^,@+;673<9[D"HUO8E(\&[TGFU@9-)6+S/J&E
MV_::0L6FM7].OB([[X>"D'H2R#^&BM6S_O>(#7P&4QO-<#_@ 4+MQF#$K+R5
MXG,(8)Z]S4[ALT34/1YYILVE13[[]W> O6S<\;_644T%0U5QC1.A#@+;?\KW
MEC=GYZ3<A$VYFZ -^\:.G\.S\08C,-[Q3C7_MUNRM^!EE#LB3$,S>;:<3@WM
M3@T1MSZ  )&1;.^N[@XR5[TY_049/ONZ9)UCP'6PR^4PIM0_IXL>@IX8),QX
M7@@^-&D(5[+G<Y/S%7,B#S0+8OJ7#2-V=W'9=#F=ONOD1'N)EB_CW$?5>I6A
MGQ:,MM[)@4$_ (\ZAZ=@@!M.MT4R.?ROM9#A6&A\+$]\02C/6'<R,H]ZN1?D
M.S[^MX@UM5_D&D4 Z=M=C_C[W(-1ZEIHVX($;2 @*5C^U[)Y:"FJO5]2[TF!
M&BZ^PV/#!_]R.RW+EG"^FVB[@.>6;%Z8;UVBYZTWX&"1?_%!X:&3:56-S^%W
MG6]1EADQ )*>7IBHG,*O4K($:2K;#',JD$8J8+^PT.'H24MES.ZH%#L/YX;I
M_-OQ_R>79OU_OEPK13G?CG(I$GZ@T7Z!096&_58V!CT*1<L@$_@1OC8%L1^W
M8W$TJ?$QPGHC\/6B1].EJ3PJZU?0"W^NU5HXU$]I&ME;+'4RX#3OQ%"D!DIQ
MGJP7V6Q47>&?F'$^FY'H+6[UDA>!M="@@:*!;;ZWFR74Y[[0].J+\Y>,^QI8
M6^6T8<WB)T+9>!%_>5*YF*67F_GRK;3?,\NO:BR6@V]) ?$Q7]!/9ZMW$CJI
MCQMYO_521VB.A,J@C1-*4E^$5$63>\N-?*NN219>?L3;$Y3BX#_#/+QN#G4-
MI)C""Q& U*M\!15.\_>^\&%1I(\ZT<_,=5YF&WO)C27VGA*K^N"D+;IV)\KW
MK:?GY*1GD:,EI?Q#!KMO[GJ P>.+3_MB\DY'5GK"YJNO&,DM+RYHX>4& FG4
MO/ZZ35F*LZ8Q<V3*= NG>$)G@Y((J0O(YK_@^K3EL;<OA^HJ4:N%P(F1KD_<
MZZ9\F6M$B=$G@]AH1D-1G6,D9)U>RMTT/E82(@P,>B1):"/!5EO>@FR#.1]R
M:81#TE>>T50$W-#>BL!W^,!V[?JANNXSB/4(&2J:[ZX23?)-+H(P _]7XZBZ
M'=7URKDT-16R*9\O<,=BG3M.W^LA'\9JC5JD28^7RL<["'9Z$07%8&\'J.[=
M$Z_'7]!F[OUC]T-["D?.#_TD@W1.G8* E@-0)K12%O NDW3<G0;M)Z:6M)[5
M4R>%)STG=X!W?EZT\]=C61V! C;-,V1A3_5?.Q&6/S-L46[=0J)=ODTQ0@<>
M?Y4JU!6S-1F-C(ST9*::RL>42<\J "H>H&$,CN+AX>$K KJ.ISZ!_14L1J7S
MJ<+#'TMV,^'#:>%0 XG0\CZ8JG:6\JRC%J"2SWJ#AZ8%(A,HU_!G/.4K\WD>
M-X[5=U/;Z2[$H+X?3S3XO$2X_]B]>M8SQ\TJ[)%[O"GPX1W 0 U3!C(S5&@C
MF%SM6L7;2TA8G^ZVDR4S!BL3/<[,*![(XT-23:Q7-U2[I@@(BN6[C3]TR?2-
MVA*;*OCYHK8FQE);,U[F@0=K.T.M.#[TG<CXUD\)09'ZET,%NZ\6W5UBUV@"
M*M/I.@M11R_WU$;6=<3T<Y6<%%IK:S:HX-WK()Q=OB8_I4D-SS0_XFX*%CSJ
M@+>G!HM?<XR\4V\]RDB>3<L+I+K<%#:7BF:5&2%<M/BYPO3$U]O\N 15OE ?
MU@ Y00OBP(=JF+JRLO9.'([F[XT4T.W(_"&Z:?.)X^-5]T$KH$#$,JN@JTY,
MU-\-P->0Q(-0=30SUH_S_UR))E6WY8NN\"M2Z7=)YPK,N#F'EV@@Y'[(Q1_P
MW>PUZ,30[@HUJ[8#ITC<C(XWLB*K:IT ?O;@]\M?$^TY?7#:(>(-:@^BN=HI
M)4+RJH#6(5WS0V*[V('"C)D?YO)<:.FFNF*+]N0E1YWYV12L,<A7-,H!@RJ2
M0H-R0ML8=A1E'DWR&M#CFD]ELE%/@Q(,_,=B5ZCJJ<\P\WW7H[0+=*9GMJ]]
MY_3DXO3;6E2+F.]IK_]X*9*]48XIACAA<9<.'J<TCJ^^R]M]1=)@@!'\6/<R
M):!DQ[:ZC?AD5NT%DS_*?6:*0#DRO/T78:$V7G0T<S9-:!T.M:7UDY97I7@5
MN@2)/D>(P,5K-X.X$-*34 Z>7RSLN=Z.AQ*ZSMH)6?NQ,C%W@"1[;XW7H^X#
M>(*C3 IK25X*'ET6XJ<[L2H3 I&L]LU$E7[+-:BK"R]_!K6GF[:HV0\AE%=N
M9=I&7E>3"6)*-<3[GT5MY)X#C;X>M8H7HA5'=J;X=G_*+3_>J##0E5S:\7*U
M>$H; 4HI.M^LG^TY;AV5^X!YCK%4$9\I<7YXTS(+]OV3*-(8/Q$[,I861F!;
MF0=A%F4_8&1-Z !@*(B7 %5A&$G%_3#;B^,!>B(<-E>7>;1QOQ@VRK55THBH
M5:$RSNPW6@HK'[C+QA-8"Q ,$B0P"SJ'D71]12RF Y6VL 5\U9X &S3H$P(I
M"LQ"")G44$BCBT=.W9PEZ.;F]=FCG2M4X#+#9&;YY5"[L4NB<:511SP+W= =
M0+JTA>@R\O74V?1F2);JI/L,^DBG:X/.<E20KW60Y*[+:) X9T3.-[OX/3T.
M*,( .Y&][@8\'-NZ6?8G\9+T>8]U3 52)JJD+@IM!&N[\+RX^@+@_C!7=,N"
M5@1AZZX/:!HLRE'P3CM8KQ48#7H7Z&^R-9=H*!%?JFN?ZKMH>W(5GTE.2T%5
MRU!>ZARNQM=,D&ISF3"ILR4M$DQ%@?@RC,'1=)YS?'W%[B'#M!C&:X8;QV-Z
MWGV&D'<QU(I?M7_DBCR<4SFU(*WMGP-Z7B%W[@#4UM7V*74MC9<?N,X#OX =
M<[O>+AC4G^P+S];= <2'<NJRM_6Z0Z!'Y=/Q/M_FB?9'"2@?WZJJI-/9 ?:W
M_[+40T=&2/FWJ$KN5K3Q5("'*ZUX8ZW[V)FH(+=$D6 *XX<*"U0@-5(R!A[@
M[['2W7 C-+[V*-V)Y2<O$D:.<(L8NGR?-S^OJ[M[[3P@D<:<5N66M+RU]$#J
MVBI(A(-9KGR$76M*-<1<3<*JNW]K(M9-:RU"2-N!N]1.@9$UB,<W]=?Q5OB!
MF&P!^_E^B<C[+:FL5%XD;6@U=FOOLAJ&85BX S^-V9%RM?6-;,%UZTX5[3N7
M3!7\4QK[-[5<^$D3$LR[LWGO%RRII7GI;Z<<6-:FDIB!:X8'_PBF-[RL3ZU-
MBG,9$X,>N(YZKU@E2WW;OKA.YZ86.\XGN /4^PP W*<((M-T3:PL==5R+(08
M&"@PR\O8CN\ H5K*>C=*9)4[]0.1CZEAW!U%W8S6$AE8RS%LC<.-AOE[HWP$
M*34-KX^JTQU=8FKAI4!J_8'O=M6T+.5O]!8^:N, /^&_1EH$OD4AZ6I8+<-F
M<71=?*320?!M4P!G<>9>I<9V5;O'TMKX5H^3 2V^P#;F$742W3F(/2[%44Z$
MJ0=IS:JLN@7&GN@#80-/*SBRN3UB<:*1*==>47DAE;T J2]S MP400IG/\K^
MLQJB,5K5X$BE'/.K4]<LRJ6N0N%0H>3S/Z"5/%-!AYX^^3X: ;LV*!/M"-D)
M#R51;T?P1/;8/8(<KE%]<?NU%N5R=;:66BUF6&P7LGX\^8%IHYC;N$J9)5P"
M6(]_=4Y\(-I933E_LEU_D*AC6--S/D5=^G4?G_H,&-YE@R;?KI4JD;9RN?0J
M60#*UG2(3>$JD@S<(DFS7O4[\.N(Q'N/*I#B-%U7GZ3">&Z\@R3I]2YHU\ZD
MU+YAO.#*-G@-YE,'/A^2F=M6K?;%.3/&4\A3R/EY&_)#[T%;,5QC7M#_>C.(
M_Y\Z]+N7SDC&-&MA'[<0P'>*B3G* _<BOI$_IP_D^)A$$.^&I&>ORNL.(*:&
M;DS(;ZBM.K86\4L@8M YV:_VRF+K\'V7T-%2 0EX14F<3O48X6ISPA@G<I2P
M4FLMWN=K/@85E(0]*(C8=S))'<E)YEJ8G^WGC;H#</^DP51<]5=?B3QZU,V[
M4SDO$/9NUSI4\"IQ^L:7+M_7%65<9C7RP*TC?O;2E3A 8J%E%+*A 6U*N?:]
MUSO0^!4?]Z_NY, ?TN ?Y*P2)S4!2P=:3?]>]]&T]RXC.O2JJX_1H4;N,H79
M1OF2SGL%2I<.HQAPA76(M,1"B^ F%89ZP!1'X@]/"8AX4!#"%Q>0W1+Y@EG9
M (Y]SQ%P?ROF9Z[^5K]A3#88\^M@5?P[@"U]^.$!XYN$LD?!+E&WKX A'GH.
M!VYY>D/,BPDD;G &_D&$0DK?L4/?/6PPR=ZZW3Z_;OED>GR89&MI2S<+?4[_
M,GB&Q\_D<<SB@NJ]V)(E25RIA7N?A8@@^IC&HXSM"FEU@&VOEM?N . AO<EL
MU&*[,67G;XL#-@T%,9@VK117P>DNB^ 126KC]NVSHD81:XFW-:.\5#4I#Z]Z
M]S*G.\UMZ_.:X]<XS (P5>I:*CW>OMHW8W]?V]NSS9MN/EGMK[M\0,.7(:-1
M4]XYVF6,M4\F/F<CM):XHY>)F="+8+#@N\UB-WE-5O85H8L O59#.\,GG=X[
M57*D5++W(ENJR7@W?9]#\3<82!3'&?IKC-X!*JO3OC!8-5@@27ZB>37C 0D-
M.P'$[O=J3.NX<8J(73V[3[0:-=9-Y].:,Y[X5!R_CLP6A<E/T-$W 605B@:2
M5#!,=CRNJ;^8L/HJ4YUU<8U"",&F-=4QRW3XH+G(KN-,@^4-"&W +9#U6,^P
M[Q::+8]=C]F?@)J36WL!@"5>W]I5AYBNJ)*TF:>]CNE3CZ37]U[(91@/PF<X
M7@UBMP^DKA\YB@T78PAJW\P<$=:5]T=!M+ NW6O,4H2"^6:K?\-'NN:@3+4[
M@/J13MA*%6E'=7SI+BF[BK?_^RM'(/A-^65 J2WR:2B2QE8"N9.'\S)*-,H5
M+V"HA0]E^ZVZ[O4@U#I')RWMXLEC**&<GLSV X"--@<,5R%1X[A/"4]W?V[P
MY.3=+N9 ]UC6T&3V'2 DN'J?[NTPG(W-2DAW/7P--@A\/:5N[6=;K ON_-SK
M@OXA5",N(/92#1,MUT:[8H=@-_/AO1HE>MB4U.XDV7Z$EUFW"Z2LR"+@<K?_
M:;XZP/OK\\.KY'T\>?,:8 ^2)#5%+^N#OTQ SH[G*JBFUN_)UD?FEA9JM]O9
M/3'Q%:&JZ8VZ"<4E.VU=P<>O!/% 'ZUK3N])5UX)AI=46BCBL>]:S6,^2 UJ
M5>7/,YA?1!UF&O_6I"^#*W?3[R(P;C['-G?<Z7Z/A+KUYS6D[_,#JE<IF*)>
M%;:)65BW\-NU(><TRF,.NS23*3 TPT[.)<91VOUE1U<-Y=JU&Q2>5?0$KY"$
MLXB^.#LZB!.W<Q]&*'UK2[PTUZ*,3F.QJ*X7OG+IPEX[83/T!!?(EM@*"O#>
MSL1!7"Y4S2^I*4_!=.JP1Q-E"'H!NR>9"U^?-9CWJZ-%X0>V'^],!@GPW0$^
M57_SA$Z5KI=G"K#L9XD$BZQ[T($]2462D@OPTPH69-]E]#O@230G915X:RN,
MG67MWP$JY,4<^Z-Y0GD$BX:N2$B_+@_0O9I(4RL/?9GH1/+P8['O,BC&!LTW
M@BUEO%'3ZUD19\I*)$JA83NR7MY!%ON,.>H^V>%#L>[R32[(NPQ4. L7Z]YA
MS'C-=KLL>@=0'+P,L,X#65+M"2,G @0%>7HO)F(UNTT1VV,(PT+]/75;([:Q
MM<K4M7#+\$T!YNQ=W[,]W4R6X^C-A+'=S,<)2A[Q6'4U(>%"A]IS<S5V@(E)
M,5TO"4B]8 B]4DGK4LO74/-PM![@.!(M,\/.:;K92M \W7W %82?/Y(E@YW'
MV1<?"V7_Z!/2I%IX=B]PIO3OL[I[&G]N_5133H$9@ /06T;8K[*5%\MFMVV]
M#G5%KSE91RV C(KZ9AD)44],P 1R()<1HJH/OU'A6F/L'LK^JD5NWP&$AVH,
M#^QE*J>JSJ$ML>]V8R1.Z-1L4#GH7HWY\W_?KYZ.+SY*7NGI@_5Q0ZA>3SCC
M1T#][@#8-@=>S@+$U/N2\AI'B8,\^/PR;VHF^-+Z5/$N(]62^#2>:5E0X&6$
M!J!T8^:[#9'L:KW0L4U]PQ07024TYEH17T/C90T? )A>>G4Q:X[GC<)%!<;@
M6%<G7]:%CF)E;MD*(:@_6U:>7\;40X-)?HR-]?&NH6K]I 8M&<?10I?NA:?&
M!+^2,IUJP@E2E9,1,7V-,C^5U?*)OZ^,P%:O:H\I/\G%9;V=P,'IC>1\>[/;
MU%P$0-GS4%F_:V0G\[D/WRV/@,2;YU=66\'Z2U,U*GC*7BFSH1DK T^41)F:
M2A5)^:2F8DCDP8*&PPZ-,@5I]NOK;M21%[D2N0BV@<XT&R1K906LLL_-%"<)
MZNG0&=,1JVK<+J:&Z;;BJ*\]B1P)"'"D@7[\&)"$)=H#O\!$P Q)! 3DHE_+
M*A+@)&W+0T6"<%A*@427(54Z.<&#^% [0<>*6;R.ZRP[P#SD*2WC98W0!#&I
MO0?IZUM,-*&+FR4PTSZMR(\J1Z4;Q=F5W ?KE:]"42_0HM(#W. %\[H_89CM
M6M?110*^G]&OG*@.A<2*&*I], OW=EG0\B;=11]Y#H#A6#*PDQXA=XGL*8:\
M7;)%G$GZ$8^BA[,66XYY(TA\\X,AAII1\+81KY]/:.+JQ T) L22*O7QLV_B
M,%U@V%G>Y0>_ H-+AUGV<@/# ?J 5*%I7M(A-<QJ^35)FA0]UN;,A,[\.:;>
M_CZB,(D"ZHD( !M^YVQH7KYWH'XT[=+@EW<#XQTMBW-+=+>^!47>Q;O*;Y2Y
MVDG1U!K";MUCIB,8ME4I@.'%UZ!(.)6C'0=;IZ^_IX9J!^]+UR@_O(*K871C
M? Z^.G9C]8CEA5W7WX=*)=Q>]B()#XZ6SDCYATA5/%Z.-')3&NX^:/%=MWP*
M.,W:VX&7'A%?RAVV*4!!V(W))SPO:H-)G_P05[P#A&UH2] HY0I$UZ@8IK2"
M\K#Q+)BG;I=48=EX;1S(-SYS_OV/YGRM9S-^?S53'Q+3JCX2;R]UD<O+F#X&
M0!00EL4+71=Z=&%6]>72(/^CJAY,PY*IJ^$'JN&^^3GHR>><M%.*M4^4O<CG
M!W:;YSV/KK65O_W\OB-!%UTUPZ#/I+P9T+X)-PNP:TXLWFGF&]X@TD^DD# X
M5II0-6HIY/]Y&=E^D4EA&:IP6'"\GQCJO>I/<BY>>;08)'+ UC$;&^XO&TT_
MHRT7E)2\JBG\^9ZRCPYVIGY *@IM$G8JMH\%(C=N8YU[& [V V[=!HS_]MDV
M8GN0PU(@(EIB;.,3'G&-PP0^OD*I4AZ;=S#YM_IY[RBX4<?[5J B8+S4F'2W
MP@9)T=!0L^J8PP!<8%P#ANGUPK@Z<)6)KM@/")WRM6E]%DZZ1*-B5\%EA#O&
M<XO4M951(3X$?!99J]2QQ]DX@?C#'&<9]&RA4DP'O["9,^K,5(6&\MR?$@N_
MRW4AYXA1=LG$AHDTXN;L;NU?AY0=QENL]:-=QZK<VE=E/TQ;(IS1L:^N?XVT
MJ:VGD)LYP:OMO>AVF(2^,WIN,>GOE6M[SNP_F>!367'Z Q4/&[X&)UF\1P4!
M7?-@LF1KG35)W:\QJ._GIY@M5PWE.R08=,[(1]S3K#H[^TN0-3.@H;JS;+PP
MW;$[ -3=ON0I@YQ55*$EH\DY0MQ^ ,&QLMD4ZI*_^WA'9"#QRHW%[(V*"C9-
M0*QZMR)<[_0.0,*W2 0S,'I:%=D?O//0K0L/Q<'W?! %\0@@XDQR&=DV&'^9
MV<562WZ@](7ZN7/[M8FVU'?OH9>3GN"FV4Y>4!\%4FZH( >!7;KPN+U&)._$
M?O'Y'$=ON_YL;!W@H+OL#E &MME=Q!F&AW*)9X>^<;6LN<*^/@>&9S^Z9J42
M?>7 O@J%*L=UY*B[JF".3P28:T-'^'JYG/4)"P!XI7XH1Y)D)?WPO5Y^8RKY
M?.^<];&SVCEN^JQD9^D_L<[Q6=/:\WZO%]Z>*+9/R:,W.FK%>X?H+@:<[?5(
M"L+=ERKMN$W+/WL ^1QCNA&;071^H/Q+KU=$_2-SLQTYYB]I DCDW70722>@
M 8X%S4W52HX2K_]$.I+V@$]5SL2Z,]Z3"D[NEY_!)956[)X]9W ZE8D][@H^
MQ>$D[K@_$! @\H=#=DXB-*QS59*;WUZD5#P$0RN<_'VS% N^7T[.J8UW9018
MNN4O"L['K+@T7+G!B5$^P/ 5@\7-^K2:=9G*$PE42,*YKU\@O<\O2LQE87)A
ME ,K VIV6A\M'2$Q*J(F6=NR'KZ37VG+<PVF^X*>29.$WX"GD1Y;J0(YJX\4
MNY&$2I+5H_JD,:L[0]Q=> )!HN<7Y]F/,H"KEE\SP- Y!79KN=E[X8$JLE5[
M:U]6,>X 9Q';P_T"88!'O^^>&JW<%V/[/KV#IGI#[=;AX_E5ALSYZ/%O%?!P
MY,Q1O6S?+-Z"#:KYG;UH+P9QLQDD6/BM#BS?57T^53&SDRSH"^X [FE-X++Z
M$?$B"E'$G%=%R_!W%!T<%_*R6)G9/D?.WUQKB%&MW(@J217SC^YJ3\FX+20V
M4.QB@(SN +]*;26>C"+T'=TL&?$26.;$P6W+[Y$@0@.O<#ZP]<]X Y"YX2^^
MR-S0N3YIU9.SGFS<9H;QW%K81J0-J1SRNE\P8ST=0ZCU05-E+X)-<:KKHKJ^
M48#VV:A*IK50C*9C7X+W4$TM?\'R'LVS,>D898J.-K6'B5G-!T<[9Z7XY//R
MJ]%F8Y*C85GL/$>U&<(Z\M*\>[?O6-!:]F3I.7LF?)=19%YHLG<#'B;XJ:&.
M&-A,B<FL"EM)D$7,SOYZ-EVC;;+Y1N2 7"R0Q+H]DW[<>M)Z1$S*F5I[.!^>
MP-5 ?XW,1;"@I:=)IW4@.:8X2PL2)OT$-6OBWN'&<&>UP\%W@(>7%4J1U2.-
MDEF6$T^OY [1%]>6KN D$\7TE3S%H>;)3SS$A4N-B2[-YCH$LA/7C63[!7$G
M5'/NK?N++?TX[["J+4#4J"I.R3:$S+B=Y0 NL5HO GA.OJ+P4X@&T[<,5*AO
MF_S&<$FQ7(9\(_:$-O^'F&"I/>5Y'O^I=/4UM^$/MK+!+: ?<-U7#5/TO%?,
M;35_#/Y\3K6\V@$<250F3-M\!^AQAT.Z]=(4AA'\[%XN'<EFO)22@*M!(35Q
MNZP(?R;:ZF\GG<T#1>T?J'^Y--"@_-ZC6\7C4486D-55@S?EF<U..EKXUHI.
M!?OH2)+HTDT'AA>_4G5#%K;HQV>5V._UDU7%VZCV8K/!^-%ES%Q'JDMMC5;$
M2U'+3W4L2T9KBV"[66AF6('XPEFPT+#I6P^W&4DXQ'[E/$/,%E2B2EAC**T\
M(NW'J8#Y1YGOOU7X_A='G6AL6*I_3>6\3*&=P)*-ZPFCQD,BWQ,I8*9]Z;<@
MEAU*_I@P"P[WZ9?J6^QNR>:[JKY-?ZMH:8IK*%9..NB-J7]4PGY:GH#%D(/N
MRKI!C$("K1+PO,>LKG(9RH.7ZD$/E/ZS%O94L#T-FS,_F49>_3VSV6A7HK5G
M0 _CQ5XF=&I$DK@*3-\G6T%:[X[*\K[W4.<Z<7YB]A\SQM->%4[WY@$QB/IW
MG+K<SM\!8E@[+\+9JX"X,ZH%/[<B/[[:/UA#\LBCUD <5QN@"8L;Z/&*>32J
M[^S[/!X!U8^UH.;L;4H+1+/+?=A=_DWS]_1^B[T5E0I82E&#'7Q'O;;'I<BE
MXYV33=@5O=@[>U90GSJUBA_,+&!;L8&W$5W'_:MQ3>*C2Y:,_CGRZ2BG@^RZ
M7G1-? U3JF1#8/8)?CG$N74D,MK><()]S>9LKR@H**DU+GCFB:_;]1H48'M)
MI96F>=S!X0YAKGF&:8WN/#=\ XNZ^6!(PD]H;EA>7+R>SM*ZE?CG#HVZLG )
M$.*I=I;UPH3@P5[-NP'WJMZ<F,W%5]92C&^>:\M1OQ CE*3>3[T-#5F>HRH1
M>MW+;DL#;@PP#-]!G"+Y,Y[EK$US(.>O Z+BW]>!-9A:$=>WV-=:&.5YN[2/
MQL%,*(=GHG[E+N1=_KD+JCEG^RJB4SFSEV&O&LMO#$1"6I)JV/4D\X"+F 5K
MDN2L]=H=L?BDW@--\\RVXD:8UQ<:US>$76*4=)'\TLVT$P4V57U6_2E*DQ9(
M$LS+EH+ (*VL#YI."'7(;C6+ADI&6]=T:WR8%EV,*@*G00\ +M@YGS6,\O3D
MQLJ),GT+XMT-V!WX<[,<701?@+P!-'3P%]S1,0/F<9+1GQET!U!!-D67B&.T
MM;]TY)Q\4GU$)7?;MVZ2X)<Z^GN/8)BV\P/P88BGBTO!X+3QN<(6W3$[TJSA
M.8."N<V&K+MIJ!8%NB_EJIBAK5NV_;!WR6OE'FZ:??/+E'P089<? =N/,2AN
M@(9JZ/G 13O/H0;BYP5F!&"3O9$A(,<[Q\D=-R_R=?KF)K;K.W' T;Z?W\7^
M7_7'=8EG2BYT'[%JY@D/":VZ+UZH(C^2UE^''D[B[BEP0-9T39,\ZP6E65!I
MGCO< <H/0M/)]D.?;H10DW3Z;%;F+]C2BF8:8\<E=-J>]SI.)0$%* 1BZM"I
M_6"SU0S'1M \T<Z5)0+QIK3JE[S/#K)4<H&2;/KMLQS)[TD6QF>#&AL\[P!*
M#4G=Y/L^:["MLWNZH9TR@>'%TNRCF=,EZYQF<72K(_TH4S2&SQ:LQ%.3TC5@
M0>NF*=OM\093003BATT^-GGN5X=W@)$&M-^.ZMJRKFTK2;+OP%'5QW+ ;J9C
M$F6J"<JJNRCYJYCI5G\8YE%\F25;UV'5U9NJP!-H,D_8'?@V$#JB+DG-6;)R
MLX1KAP_QUE22]*G_@21JV8]5:5&9=S%\%@VV7609U5V9HZ_8SUR4Q'X-1_<%
MB4Q"[%2Q&&F9P[1'.5-;N>_3_5!^*DO:]NPA4+^;)-5YLN<Y:9&C)8X43L"X
M5!"KW5^;8K/"O>B:1THA&=_&G)Q HU^H45&,L/=?*"!X9\OTO2>7D$0E8#+U
M:$=#QAGTAI.R;?P<X*TSY# O7W?WG,.V4/I92-W/Y0^[^.:2Y!*L8WSD8C2N
M%M70$*+'YU:R@*/NOJH8%14):&R.]RP-0[LG@;'M=:0LM:G>7N_MDM$+A764
M[A5-?B[\[6O\:#Y1'P;G'SVZ&04!K36B\F(F-"U9_-M3QE8WQ"T.)\B!'U?-
M5@('W<)#Y)T U\?>,BJ3KWV70CS(QC92-HFD,J+WNA^H%MX^IVHS8AS7WK^>
M^D0!QL>+>X8;*_T.:#"&I.SJ_6XLIA^2ME!>LY"I#;"P1AS;5V;C^!HE6>?J
M,.5G844P;8V7PYGK2C[_L1N,;(V+:)>6=NKL''H+K^SHTG?,W02<N(U3!U*K
M8;1$:ZT@*(IPE1>M/_/60!;:O9"BJ<[!3F!.?P8S]@CDYE/J8I&2V*;X0Q^$
MO8S\)#OT0-AIGW&)ZMVOP!/:77ES _A6^W;@#-/DAZ+Y[1.EBTE43R2 0'Y,
M*/OA$J7-3J%WGW+LJWA'N+!Y_+K[<G3D9ZONUW%R@9E)X.S=K..D[919"2A=
M2@#J%TYM&M^@]B6&4^)ZCM#W*PU[N1)@ZNO,I:4!+YXC-(CPM@CM;7%9:(1=
ML_@$O.0!T(0;B_2UR7T2R?GJ]Z46>H"TE:L6:&73*#^6 2[V+_GG=&QHO8 +
M^/4+2/.?^UE*LXCG5'U6'*5Q)?6T/QZH3Y3WTH67TH6GD%7O?<]@]3%KL$\H
M9W>.[@@2IL$7HKZ>C U!:*4.VXNNWSPKPNSC:'"IC<ES0S0$5J'0!4'M18\>
MZNOK5Y2>%VWTX?E@WDR?B;OI2O"-[</O ,2VOHY5[YTC>K<4R'NC)7\=(OS\
M;B*F)AH?Y.[6A![X[XF&,E;.O3#L@#,2^%R;%=LF>,NWD4V1NBRB-VK2NE<F
M],L;6),C'@"45CC,-@_*Q(!EQ4WP+[.==8_EQYBG"K=JZ=,*+J7W9&"2]2-<
MZ"(6,X*DH_Y+LG19F(471_AA.GO-_$VP1U7*-,'MY]X6EC^_1%DVIX.X? _^
MVMJS\FO>>\N@N29YT]Z1MDV5I1O79![HGZ4"I!<=QE0N^\EQ!P@]6JZ\VDC
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M'!SR&AX0HV1\V_/40Z;7:''5J>)3!:Q+?-34;:19N3IL'GF6@I(H+-2C<0=
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MK1Z&5LV<Q1[2DEK!)HKXF>0; *FH+C [TY,_+? =WH.9M2HQT;T,S6KEG+P
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M@1]V@.+<.:; ER-[V.N.#LHZFXG-SX>MDFPSW<?CRX( <(L%G'N]6SM$EX9
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M"&]R4UF;@'Z(@+(J'-.DKR?Y>&.J,I/)1A[F696RK?AG=JBH%4V'6,J(7.7
M@RC3:UBWRRD8VZ3T]G]L3<DP6^7"O^/O5[V-#%FJXR4+PK+ZPI.=F=,/^@^<
MFTN;4#D&X!89V:Y][V7P^4+&YI%'VV#)G\^E0V9A=M896IL?89GH0*H^-CQT
M:N\<X[HMHC'#NO(?"9FR*I'L&LJ9:IK$+!@:3M3,D?(5<-V(+*G4APT..,H\
MW[4&[(+@;U9M5K2B]W@-.?_^GLD_9)NC>E:1N"@G2&E)NI?5M_M8XBT^A]C7
M^6.8C7KJH]17*MF1I:K*PP0_"6WSE%++KG_%&%-VBOR)&VK4LMN:+[2-6(XW
M.0)*.&S$^3KYES:"6G+XAOVJ*BJS<RC_W+CYJ^Z=_\SG>_8>S8 8@G[$KD7&
ME!L2TU''#$/(66$L>0/U?4*1EAKEI;_68HZSFJ@/>=1O ;5SEX_RZ_DA[6W!
MJ.VY'N!&F<[GO;ECX>TLC:(S2.2JZ*3C+>#HRO86 -&Z-D$--=RYQE3:U>7<
MTD>3XIPRD=P.^$T>Y(X!I.C924-;^([@+>#BINH6T !%<1N(]Q>[2?V0R-TH
MS#7E<.1__@$MJEN,C_K&;*.O>8J\O;JB7TC>HL LKE!.XP*#9=G^X4J@Y0W?
M2:M<C'(Y9\Q&ZT1RP&G*+> :-7T+F!N]!9")5NS= M9.UU HY/F(,ZU3MLF*
MI-2;C['^6)'#!&^*!/TDF+NM :1T(QID&D2_'SSP>RZ1]E;H<R8>N/ Q;MY#
MHZI* I8DAN["C]\Y*?8]]&K"EI(/M(?!M67,8%K!*JS"+/IOZX#L9-V6UB;9
M]=+_7-J&13QT72>K9AZ!U"R>KN J'N[<WL\D=$;E8^BY?#!-W\61?HDFLP,6
MB.G<+:!OI^_FQNH@ZTKA%H""6$+VMB"A'S-3(E4EBG]/E.OW@PLK% V)_LES
M6!M;P*6*"U%2@1F**5P!U1_0$\9;P3)N:"C*U[$SZWMN:U2@U7<+>-@>Q,)M
MWA%1"3^LS;466&)V=SGN ROVH>-9R%V^7VKXS]165%;&KZ;T(^\^@3<.#ZQC
M]I^97C6(V?M?^ARV(2"Q6U4@99 K-M3W?!T32UAF&Q-*]EQ$!=;VGUK S*FY
MF:')97*CQX[UFY\1*^U$R%J(X:4]%)OMOE:NCU614[QVL(3WWLN)QQBF]+HB
M%H7B[:)=HWF)/%44QQ<J-<ES_[F[CC8$"=':+B"0*<9A5PHU'T;/2L(CSWOQ
MM*E712ELAT<2JYE8.=3^:%[NAGF+-X=ZE*:/Z*=WH3;I1=+2HE";D?YS/)34
M##6J7C4F:L5P6"[RDJK\X(WS)\10;8*N4&W">(NQ7['@E?W<]8W\7>#BN&"V
MZIV?#$'FHB]8G.NLI0Q6=5?"D3IW.AB>.]L?.-UJN+A,0J'(QM.:>!U2"2V^
MG(1@NO@B#2^"HC!D^JC?JXF^E_BS\7X$V9%*W,S;UH59=&FR,Z-"KVPS31SB
MS\HL$A=.D]R3VW_2,@@[;00!.O[!"[5ES5T**6C86R@\5K[7/G57A=8VK:[.
M3?XQ1"W3D]F]>@_ED7NG!/]_3#SBLD6[[Y&:*!^ZFU6<$S]%.QMXVG)I:.S(
MUY&-R?MO7(G,W*4L467(7+/.BW/6T4M22 E\R_W-*M<LRW4#RW?<RB[J?9AB
M3!&A_EMT[X<;DIZ@/WGUXWKN@S\3N5@"H/[GPGSX;S4>RH+7'%JDV>=JZTCI
MYU>%3=^21>N83ME'>T1HMM84(1(NDI5I=F &G@H=DGS!7LT&&Y39!O'-*U7C
MO!?]DVF&!VIY["E%W"4O=^[*Y=.*WDWU<I<'%&E'(:<.!0N1IMFARG(-X4JE
M,V4RBE@D?22/LP^&/0Q&@].?[]_L#)TGO5>M2HB9:7G(04&=K%:IYGONB)(,
M94/5+]X"^EM=X>^" A4E"!_\JQO3_S^#ROT/G7?9>>@MX#FYZ.4R) 4,/_R^
M=_:-BI7V_ =C9M#2Z]\V5 4@U.!%QGX[.4/%X\[,ZXLTG.,U#TW!7 F&DHM>
M47%5N+N('I&X>:'I2W[CPW>.^,Y>&NI4M3>@/))"CQ=QY#BXS>)A$HGF#AR]
MZS:$81YZUTYC!8K<3+'43:.ICJ43W,;\=L;<.E9^\*FM.M?W)<;J.Y\E%9^9
M5_#06FH-C^)F94V;QB'4GM9^C8^\B/2EBWB-QT_I3.CZ$W+(.P&9 MT0C?0$
MK.7ILD^I&,@E<C\YDOR2=R>0:]_E[BW@D@!6TR2PLYL#:[?BI',8$)MZ_HTG
MO^V!C4#:M=^>Z-9=$*U+(G\[;Y/VU2T AG/=JDNFI.X;/1,K*?]1QI'3C?VQ
M&A5]>9#3H/I$[[+]?>J84ZZN]2P0H?:[P"*RV3)?="R,0_9P61#>3+O!(K;@
MMUY:&1&#=3S2:TZML7J2&A&:-$5G?1WA/%Z,Y0[V"H0T.@PBJS*_)F%35'$+
MP,9BM\G+LW'MP>@]:P\W7Z$CBFA\&<470T-C$"9@&/GQZPD4^&%DJ3SI7;G_
MH ;AYTC\1_AKWNWU(,6A+<WXQ-#ZE(,GRDXH;5ZB3"+; 5MOO T-!RK<NO(Q
MENRZN/L581_!HM_9&;I?I]MW+AW!.MNT]R;8*O8NW<*^,?3LLL)6U8(R@N9:
MSB*U6B(E<QPR&3^(*(ZKI#X9AI1?B^-];Q07W37"S,#,A5!X5*2^O@5$(JYN
M5GZ[+Z/4O"]Y1NAMC OO17)9/+WJF*2YKHE-\Z)/=CZMVX(!C?$R@_]U]0V.
MUD'L81_4/0PG<[+U/GOA$F#>^)I]1X=.3;7,=/^\4*F8NR[!+Z98PP9P:2-]
M2;9X+/>(.\4%VZ'K&[5;=\O-0-<3]UM  N& :J+WJ1UJJJ$K[V39G.\0IGY3
MW)4!=SLT$7E<6BYF4%47O?.$PB9#&CB6<=40F7O^ZWYU6+N6EW5\*1I#.>"U
M*'/X.8[&Z+5%OM86,;YIWY.IEBEB]N4H/E&8F;NH4E+K)5%6GFY94HLBLZ :
M:?LM0"_\G-""S5@Y,43GN&RH\*A!Q^-(JA,X!!I:UG=2^U!9-O8B[&&BTRXH
MEIG&V"7U_'3K8G0M^"F*X(:%:X?CI3\VTCCQ4WA2VHDSQ3SZA4$QMVX;W7YJ
MP$V>3<,!5XT28D#TNEQOCV"K'_4VS+2><EA9'9XD/DKOJ.53/?N%KJQ!V_CD
MNMTER&-'U(#!5+BV>&CUO5UXN97:.:0Y.46]=)BU8BJM0OW7Y_@'C@ \S"U-
M8+ZY+G%E:M.K^MZW*P%Q/\@1XI_Z@Y) P_JC\&6K9YUKM.\^:W#0/K2-4)@&
MCQW!^'Z^HLL>KM]RV[LD82S*3DEP_#FJ^:G:>P,.L'_0&=8?ZB/DR4NQV_%S
M*<=06V=FPX,Q=5/=@%B&LX8V]!>V\=%6Y+DJ--Z7[0?<:9=UQ9\<Z'P_=Z^'
M7/T>'L4R-=3@/ C% FHA5G.X.,S6?Q89XIEA>ZEZPE\P$&0>FW=V<0O0)),]
MR(7]&$(E5)^=:<8W3UT%;R2:RF^&MI<T60/FL9:!>7?1$65\9WV]K MZ6\(X
M>F3'G-5(Y$?DKSG]S"!@3,MONUV3^P'7H7&B>[PH;S.V,+V#@\Q;0 WOD6S\
M?[+BV>0 ^5VB AJBK\U'4%+1 Q*$Q^TCE+> 9LY3=]Y6M0&OM:D-2P,&Y&./
M.A4UP?FB!!8AVRR91VB)AWR][I2(M(%0TVO^D>UM[J0Z4;48B;Q-1+$%)SM6
MH?1\W!(Z>8#>XK7D7, UMN."WA,8?!$[V,0NE"]!8O 7B0+XT$^QU\:%8 J=
MVS=106T3W"O+D1BO4]NKU8X8F#R_4@LC@,O_=',M>0Q1,A=],\;J)ER ?44R
M[^KW)G](JN&3:(OPS4V/F98I,@V_UMS#[M3_D:6N7"SQ8S&5F:85\>5[F HC
MO7W86M,RV!&:O(S2&Q%@3:!6;%);KU#4[&1JP**P[)':.7N>[J8RO+6[NF".
MUK'I%Z9"LAII^M99*D5]U)$\?G" 7Z9:W&N4KK1@#!4O>$Y8WEXS_#HBE '5
M!+W.@6'D/M(HYF!LY?O%,[A]K/=L=GI3#_-:U-F=LP_,O=U]R-]I4 \Z"LKX
M].G++>#!B> :W LVI*0BYT/"P;0H@FZ/'MU>ISXFNAQX;HZJ7[W+(BL%;O28
MUW34C^$0W'%YXM.,&F+%G[0['*SXUB#2"^G+R&1C;G*IM<OOQ0[$ZSF7,;5X
MGXSO5$LLYVA^_U!K/,!O.83SW93ABLRZ$Z4PDSO9D-S^F.?3ELFP%-P"5PBG
MN"G.K]T@FD?D"2!=%91/2+26!_5^ZYB_&_EBY8F&OM94*%_#A$&$X#LOO;AV
M=+J#8^Z$;,UPLFL>^/YIBA#[9K5.EVR)[)3;^G@I'741BF0M/WO%84XN2%G)
M8DZNN+IUY\62^ &OCYN$FQVE2)=R19E^TT.Q]Q:?RUY$'B9[\ZWE@MX[&[GT
M!;BQV"XTH#OE;T:]B3\:Y]EZ%ZFS(%;LW?)$Q"#M:FV?2EY3&3X3FL_=PZJ6
M=XT^PGU7%<RIZ/?9?"&ES*BA4U>I(XC+-Z3U>_=%SC.0+ C]7%!Y/ZS"_A;P
MM),HUMB<W)MJ 92HKH]>$1EF&[)& ]:8Y:Y*G6JLQ[X2.I2H'GR_;5.U*"H[
M_R55*P!'J!B(YJGSC>_:C)94EJ<^,6'(=PT4=REX/&8[)"3X,L!V >^I4X#J
M('37K>9(2([9P)JNX-TTVG,Y_(<;WK:MQDY?VJ;:9QF?SFX0(1QXB'+EDMP%
MGI+U3@B* 9:?1D[?-(=\B7Y[%[BTBWJ75P&W@+=!16[L8U"[%)O-/J7**Q98
MEN4G7K139] U2P--L2HIY2-*@0%C4RX&HBQ>RK$+VO02QV$XO&0814Z/B+9&
M*741I=#9OGG4Z!!-B>EF<+SZ0X2D0IZW%45&M-^9O]'-NKW+ ^P]T.?IM\:;
MP<+EZSH^2:5^Y'2^Z2_8\$1G:J-01B#\-)K#X@2[EKJ/6G/-CL5M'?(D:@>N
M.KPSJV@!=N6G[0U<D'LRP4>"62Q!^8K%@TA6?B[R8L,&@J$^,7$NU4)%.PQE
MV7U'@&TN41DH76]ND))M0!-S_6A#,P+Q+?.:<< ^*>5)[]4'YR]AM%P0(,^%
MB"G[62.VYZ.]\T 4W4,AWFQU)SEYFC=T48>6,@RVR+A'IZ37\0=0&*238'_L
MQKWG%I#1!5HLW_UUOL,:BB(RV!N2/Q!M%NRQMPL6YOTP9*G*P_-HI?U%J>*O
M6T!C@(V-,"Z3?WS1.AFQ/TM]9Z[FEL#)<$"OUOCCR,;TZ\)G7E'B.W/\0FAJ
M7*(7+T3H;P'%E9!COJ+LBF#-\$8!3C<>K8]?PATR?QD<O4^2E.$ A_B?+8!;
M7^[D?4^.40Z>O-E&L+N)YTYL-N DZ2:)A;\;WH&I,DA_>IU=:,V!?WH1(&R3
MEXB$Z:[7$^\C_7=?[.\F.;N[?R*(A=$\</!5ZA;;7$;.;K7JC>V<T.[GJ0>K
MCV2-V#/"LN+FWRRTH-L DNWF+=<%TJ"V$ +19:U]JQOOZ%N F*SB6:*NX=#9
M9/#DWB&?:T'<XJ%I%+V?862RI,^*F(*UL)_91BK+2(7%$W=.N006I<4WA_)D
M>-Q>'WAVM_GZ2/CWU&/4Y&2*..M:N;\XSI'< I9=J$\VJ(_,&BOJ0?@S&I-.
M>5KF@N2,0I5T1+-?6DG0 (JI/@5]LG/G=Y6>MO^W:\QN 4E*,TY,8RW55&D%
M3D3/.)RUV+ZFKEMI"'L8G.RB ? %1ME-Q;57\AC;8O@KCK8USWU,$")8_3M<
MDD%;XOY2CYS*,4U?TG^[C]9^<-R71[+64]1_+39PKK90[:2Z>BH(55K<ZDLE
MR9Y%%/V<2FWW!&]VNS\Z^E4(>91+/7_1D/9=[>V\Z 6U'>3R0G.M*&.?^CJ\
M6O3&#:I=3V2J/.\14'C]\180KL-[<R$:-8:>:_9D0S-$#;%!WDDD^TW-9MF;
M,[R=>\[M=V.2QM(HP[^[IC1OJKD4-U/*;GU(R?L^ES\]K?]9!$"!=@RCJMYB
MNZ";#+CQQ3P,*SD6QEW3JXV:[%F4"J-]Q1&%@89>(G3T!K^'5KUJP#)UM45J
MC>O+Z]TDA&&8I.N!SLL&>^&]9G>JU5W5.%/6'-9M&U#W29N:3N$MH)/E3J%;
MBZ";1^OZ;TU-O\X]MH(ESM):(W^J?O9Q(E% MV]G.,K9A^; V[P67[&R+,8N
MP'&>"F P6E][NU!ARI8OC#<@A+#SUQ%14J>W@(I'@PP6.6/80Z*[J"R^'A.3
M2\(VOX4T_)<9='+VW)%6Y5G^)L- F_&E*,A;Z2^Z"1:?,L[%[;NZ&/=V8<OL
M6JVON\%+0I%SL:+I2XG]0[F#]G./MWB-I<L1]4BX_CO%T#2[B$V\&7[,/*0P
M$RP%<"#E33.PG1/*C?TH4?Q9*++[C?JR!\NE:U!#YOK3]53" \RI6?J:N/[5
M&6U.R72>1S1G_-<--'A"L%N 6K\]BVV3!P6J"W%TG>1P).I4%.+;/DO;/X:F
M$Q_$$$?]Z-R@,W:IIV;-@"#U2=(35B>U9K59RN'>8EBM ]'H>J-_ NB[="/%
M$_:=S0><4@+R??XG/09*)4'V6N5,0%;R**S<A8[[$<" *(V7%D/2@SSL<5_'
MU'(@G2QCHEN+HC>/&$V,H"_,\8BTS'@X34YY' FT*D8/)R5*_=G'QJ($@WR:
MR9AE%K92;-;>NRM\0.E "S/T00XT]A2H@,F$_3746\>Y4[R[<'PC"U\('ANN
M91#Y9N[QU9XDY\A"7?;S$=HR3+P3Q2K\<Z?I7FON=Q1M:0U\V(VK^N,TF"MN
M[+46UT-U ZP)BJ.3)6%V]3.'N*[]MK8-BT5B'+>/N0]Y(P/FD=K6HDS]9*!O
M+,R6K">W 'R=C<B6*C'+1-6(2T"QXL8H=%$TH"AG8X^TOKR&XX)UGO29_T;:
M6?B*&&$%N:!I+0ZLC[M629YHCE523$,D(+^H-(7S_;EKSJ:MJ<.8&I0NT%]E
M(>QLY>#,$QU K5ENFBV7>4ZL@ZB-8H.7T46])=]E+]A(!B?[GVQH)!9?1\W@
MH>KI[IJ05$^N[&B)ROT0$=HD"836]^364R?)CI1O;>IH0Q2HA$+B8".8TQ-W
MK2N>R;;=WGFII'?C9??4\B]?7TO5,]X"$J5N 5;#/8(H&07H;[=#7B^E8Q-O
MY#D)RI4'7 F,W@)4J@/E.&>*OP?6>WE4D9[F6V4,G5AAA>./CS<;.1IQY'0_
M;*B.CNS0;8Z\]$G%T1RQ6SO(33'(7S]LY3[FV7K0D[N?(TVW;(R0V711$0A1
M/#=N/%H?XR60RY]3H'/*M)A5\LZ[,QK:C7NYV+-KXSRQ:K_0W5C+ HL"L>)G
M'W(Q[G(77B&*;J0!7W.#2* W.DOG8;KW*"$O$K\-O:/%CN_^*56#ZT$1"B=J
M2JU_,5@I F];+JVBB+V-=E+Z_B4&Z?4#@W7BT\3V\-951*%$<_F+*O*/#9Y4
M"8#'>,I!@!K3'Q.S6Z;FGQ;,22N&>&-7L3\/$O;R6NX,4Q#LI)YH+EUQ-HN(
M5B(2>U\=3Q?6VDK2,9*B=?2"[J,^]LO= AYIFOG+@Q010\??<W!JA<QR./L-
M5M?R^+94[!MPZDL/J"#<01K.BM,@5CX5+&+2$T'0INN'U]'-DXZ^K:ABCU(]
MK>ARD%>C?41)!X,P>$C$,TUVWM"6+F3[&1%=1.$S#X"UB'?=8[-$JY#$/7'U
M1<1=FE\F?I&+]TO %3TL&;P+[-NU6*VHBII=Y:0H+563W'R86]O2A:E:)R V
M)+1W_/KJ&AI\5F<;@H*/F" .G;2:D)>I65=5; N'%A:=%TDTURTNMFFY[A)R
M\VF/]X84JD^WG/GH-+4$+=Z(MQV"ZL'')VU <P_" ]4<KDO_;-J(POC)ER02
MZ)EAS4&L"/0D?Y1KL)8[T^9^:]Z/A;[.FJZ^!R7\?/</$K=9?[! ZREGFA>F
M8H<S(D?EJN0L#-OP'H6$5_,)G6QID'T),"AVTG^94,I=2??R792V<V??S/VE
MZI"#H=D*EJ]3/U$D(Y*E3%*.!6_T@WHH.'%)+/GX4,RW@)->1GU;D;L%3V26
MW&^]0<,QN^Z.[M.%N0LRKH;+J^"[AHUP=X23XDT08S[C_]D;!?_"[W&T%SAW
M2%!^"X!)78R1ZQ8MXF&W%T^_98YG>?1-UC,?U[G'\!;05(F\!:2'I)UM0T*=
M2'X0NL3F\$%)5U6;AV.EZ,+N!>W= A:TM>YRG"3HZE2T+?Q<C>@6<$P0C;H)
M/X!9;5]+':(8NS;AKA0/".?^2(UZ'\9R"UBG9;BYHEZ2.O6@O8 \H_Y8-#[/
M>%?H4(2M#3?W[^9O,+@VN07X@:UN >*DHGOCOVV"E!]0=YVG7T)UV]$D'&\!
M?Z!S#0R&7#[LO 5XM)\/W*0%HO1:,4?,3OFP@ W_GLP?^/Z?G(H4J94V*NK<
M OY YA: M3B'\N: S)6BN"#&BZ+Q!^(GFG5A;]_5EI<-CYP C:H01HR;72GI
M=Q7GC+#8@MK?[D;":DPY<>6%%8?@1Z2117,$-A4NT."?B35+HOV>L.HI\F1Z
MD,NL52N60B''[3(N1WC9Q_S]"N(68.= [;E8I ;Y(S>_U^CG?9($0?AY)A59
MN:/)_U*->A/GX2O7'^K_2R+_<X-G78D27#<$X16.;%L_^V><4O_/N=U5BPT\
M,VMN 7\@\@>F47TM$+9%GW^]!_$7/X1T3!B@CB#K+S//5VX!U&1L5^40+MB8
M[/X[ =4"G$W=SN>!4<_223MHQV:3ED#WFI=>,4^Z;K!X_*+ B?2?J:'*NTD\
MLZFV:6X;X1H[%OY:Y?I(-S=MO[TW1JWT3K#PNTA,'[X%G,W_)EG6]AU'W*(W
MY]1+NFO(O.DS5)54U=+_8J34W4"1?^6XV+%UI,BS83=FNQ0(BMZQOT.74E;0
M]KDUQ,_[$#R$>0P;0CUS3[O!R+LS"_K?S$)M?&>6@EO 7N.=7>)5DS;?EZH8
M0KMMXLGJO18:'LYM4)'7):G4C?! 6[?$/K\+>7KH9VGK+;6HX'2OTN54]%SQ
M%'),EH:ZQKOSF]^3#M4TS\_XED%^-97*+^%*?<UX)7J) [HS*N;?G%ND#^6C
M? N8\T)QZ\ZFV?Q?H=S_[N-B_[&-7(?]>V.8H;[MAXU)C+%PTXWDQD*SG]Q_
M[4E.69Z8H.HCKYVPN%Y9D<#P^PUEU[L6EYWZFP%2QE)SKH-9_"-.\M(U,/7.
M6]0L[KQ%!K+7_]MQOB%14KY#5:L5=^N3IJ*[!)F>W7"V_AMSA3L-ZZ_8;BZI
MET )6-U'FL#!AH6/4Y!^);VKX]\RUD>'N>-G\:B;.Y])>)#P3PE(<6!S?A]<
MV[_9];:[T;NYM\G+0GGX1KM$^#LNZ&)#N:? E(PAP/)XY\FFW%71-?/82UJR
M0O1^H&U_Y/F:$)H.YC53C=4EUET?Y!'P-[^#3:&\H^[\+@/%!?/^IZSE=?_S
MY_^O6.\Q*9;]=VH3_1V],$,BX\0!W=@_,O8'BA0=S'W<F75 %*$.\N8!_9T]
MW_XM;G]/DC]"(]5<PD7MGPAK2U,N-!IT7/Q[ ?Y <E7\BS.4<$/O]P+\@=[_
M(77@_;L^M67C%H #W>8&FK<.&]E:,?UZUH+AD+Q4#'<8>6(:$^L=Q%A \J_^
M#NB_!&V/^$7@Q?4G+EXE6M/R'FYXR0<1M9!7O>!429=4D.PH<MB2_D U[W$Y
MG0,1T<&N:N/%.-$TJ(2J<J-5$&MUA##:=#&4ZO* Q:+XK=Q+!W1R1C>7)P!1
M/^/I\_J'0DI<-YLL!B$7?<O2?:N6C8I>0W,D9YG=QO(27^;.?>2&6.\3(\7I
M@36?L_C1A_TPT;= T5I#F7!XI7D.NTYU]@,T*_9P,0!I]H-+QL*B_,;)&M.B
MRMZ(;TGHGMGS>%" 9F:!.5F,BV2T\'+RA?DAX^:V$\"#6ZW9Q0XA8!IWMEI?
M:RO<M70>OG\%>,U^DH[CPH2]5;G-=;&[>A4A.4CE,F],^$M;S\F?&B<-7RY?
MXF%3-^+% T8#ND]RU$E\P@7CN+^"5KEU%';7="M*2T>>RGW;P>F27@_18KX'
M(S_8V%/6G=%;UZ6.,SUAVR$OR);>25E0^:#NR:=;URNS(^%KQZ7&;@Z5SYDS
M*S$GGC,/ZG]#< V7,K9G^%P80C%O,'3Q=>.;QXLH"X4/A@E(9BR,<>*R771F
M=U"Q+#/'"2%(<>2'W?>!$VR_0&EKGP<)X26D+S.HG@\VE..F6^%K81Z>E44X
M0ASO&XN,9V/$$KZ5'SV^T<G6$5GJ=BJMP^+@6,M[C-9>IP(A7I=^ADBO_"SY
MAGWJR.*B\L*9\D"A&Z<0&'?@7\DBTI/;;,^=/?:D.(49S&X8D-(J3>FT$ST*
M-3T(A&MIN>J8;:JW5E6;F\<8.Q.6H1-_Q4=#49LQTWH$K<%!)":GIV.1$FZY
MJWPS*DP(;+_>_O$V"%D\:/C3P#5;7A=4%YE )ROW2ZZFE+2=E.XHB)G3)J@;
M1+"A9%H^1S^9Y&IS'UKJ]?[XUY+PS2N:@Y>1MOG8C&Q9SN,1Z>CPP$UT@_LW
M.$3Z9HK:W;H<\/A6//T0^<*V9WS(B)KW6B3S[M,N874'F@Z\+Y94AG-UWO7<
M9R[Y_EB0"$/QR*U]C\IVYT)1GVO]A\1!G.?V3WO"#C[2T+:])*NN]I[.G33=
MF/%=^JJ#Y?[L:/?4WD['],]/NQTZZ' ?36W=,):05ZA^J1*-?U!+L/FRR3S8
M-XP7_\(OS!9)61Z6YR4Q%WB<A/U-OZ96?37 \ORTU.J[H3Y:'SH"+$9FIXI;
ML%A$#L)%Y!AQ@%9IW=.6/Y.V?VGL..ME:DLIGM0Q@5A5)AC@9][D3/*$?MSG
MP%CH8YB#$^F;*VI,>M3E;I97\/"*&!;6_'IF)&@;LN#9L095O07X-KRE>]#P
M6%9P@=:!AM7QJ5<[%DC8WZ0<W2PH3P1J8)&3F\5U96'XT= Z>Q<GM!)@N$8+
M%\\_#Y<=M+Q/?/:97W9WDB#9:]/!)[PM@LQ.31BVU2_J:[7'501=?GI/AH!F
MCX[ME^O)ID@F8N>%$W.ZOQJ'$+BP/$KF,\:CSN6A>V:,F1'_ZI^/_(5_(=XZ
M6K,PYU6!8_UY(KRFT1(3D^A,N>0I\HO)"U0E21_C?9 "BU$PN[A%7/.6-_@+
MZ4QV< -<D=TRUSS4@P5]S&HNCY&'%9$:FXF+W[)I0J9"EH1+'MX"3A;KGKW%
M]^DD2 ^V[&,SF4*2M FS3V81\7AW;7\>); (<:92GPA9VSW>^@A67[-/V+&W
ML)(8JE@-,T96:551T59]"D6;CWC-82W*INGP#7P?Q37V,C+R)1MEK70O+WZA
MH[X'Z34P'5Y:4:JJ!52W&*D.-'B(MR)SBBV*N"G?CG O(CFZ+FW(%3G335:J
MI'CYC7X#-9AVI?R^-'5Q51S,\BM22)VOD=P38!#>5MW#P\(FZ]\N$684IQ+>
MXZ>W^F4Y:FFHH,C&E.SK&(9SQ9;,2X:7DEYRU.VD1=3& 3MZIH<&1Z?.'I8#
M-9:V2&%P*OBM/L_A],RD$+;0Z,K!U?A#W-I3.NH<FVIC_]V7(W#^U6%[<_>R
M'^RRAA^.F/*7HVI#4MG;1VNP#+=HISI*I%_$QOA&P';R*"@<VW.(27L[I )K
MU98Y_(<J_*<O-EA^4N!EAJ"XLT]=RLW>&(YDR>G,WR1KWG,XTYDJC]X*.V$-
MSVG/V@!KM+2]J3*.K3\.49"C;BM6M ;.D2L;T;GXM,4=%H1>MT^2O&[CW-,6
MR<C6F)4WRC!U@>Z<LT*9+:RI@$YJ, >O/C&T&[X^1[#%@^F7P'R#5,X1.K%&
M%$;4Y*_17QQQ#OU3&9NEDL^H?_ENTU*=6F'U443K4;*"&$DFDI\;3;4-S*UC
M+F@D4M95B.+9+I+TC0>3*O&R5.$C.S#=UG*%)>R@61OA-I;4"A6F798<WY^5
MBE2UV:H:>;\Z=1Z@2]7"E-_$':5\>"QRK(V+8<&[W9/7QR23"]^95\\ZLAD]
MB(RSZ0;MJ0,XQ\&3U6Q8G5R1FZ3549NC@HBPB97H;GHQ4L&:D-&1'FC=\DM@
M)6TJAXV2RN.\?:[SS+"'<7P&ZDN*?N^TT8Z?:>/J3JX.B@:2553'#H-E[A-(
M?:773W_^H5M<= ?"^;ZJJA1"-2XC=)"37\++TVV=?\B)K\50/PM!TZ'O33)P
M?='I;&1EO?D:RBS;@O=9@J4WQ<B9C'XFI7:#>EKCLRKV\7VP1.-*S[&M^65O
MW1>U[5$!9X2&YX51Q),US(PVP-;&UD>&DG"Y<SW""L7":;-[]%_:U1PPH[?Y
MKH%P'M7<ONW<R:=WD2&B/A'6X)C#LSK*;]%(M"^]G[+/7'28Y768FFPP;/-J
MFOE3)W724H_(!.[Z\19QQ-,P[)2TU =?=.6 O,%PH(K[0>9DV[P-3W'?]='Q
M,72'7+8&.<QF+ZPJK7FX9[:-G%EI"WH-Z*-+S873(KSI(S_[<VFHUWI] &R[
M1&_*$Z,'C.Q^Q?.Q@V*"G'+CMG^2//S5)A0A1_U&9FO7S$(>AAG>&6;^$ >:
M>1-K%>/[<U/YOLW#]EM 875'!53DL3,14>E"BX\AT^MF/DM,79#(\194H.V\
MH*X<604\>S\ 7#IZILT,KDY-S9-COP68TN_T5N6_Q>D>,##!<F&\?S/M,@H_
MQK];@NJD;YP.? WJY3=F]$$CMAS9V$,Y0P<^?2'"9Z%IP;2C[:*N$2G:.%=)
M?2=J>B45D^K1D_J/>)1=,$C>GVGA,->EJ4I<9.><_>[ CH9X5XFYX0UA:D[)
MO5L76'%/">+M""XQ;V>1*V:W,PRM4*6 =<:'MD>=OVA)WR]_I6%(@#.(]P;<
M<3D4USMA(?(+<8#M9M#YD,=@B/+.!C:)/3-A63 33=:TE?<ETS]^*#_.SZ_"
M3DO?V-&D(NWIS8&9/?Y9.S7WW)H/2-+(?RW_53QW?,H9\J4<&= UK=SU3<UR
MM[)QB8_T4B7NM%]34FGTX<*;UJ V+W&&@L8]V?E/9@T;'CP#4(==.:>5:O"Y
MA?*.SP<3<_1-S=,&6_@$*]4S:TX$W["AS]X-,.=*2-3L"A1-G5;>=>00.F6;
M4K45<A3TU4&U9*H6?^HM!8>QFSD)UL169/]JL%>3#%%?@(M\[7B(&6_G:KQ%
MEGF-B(*K/MZ:ILCK^)WX28H/.IK8IO11\F.8=KCK&/TMU&?^PN8%46V#YA+P
MQ%%2EF% 285^.GHNIL(KNJ$?.15:&E]W9F?8$43?9%F%B4GRK$M['S!:V5_-
M* QNG@X.Q/'MX-(&>$LZTT6'W0(65&L%,R4PO9<J '3Q<5.YT5;T*:Z72W<A
MH,/5]7 G=5:0W,@;U/"D*4-KD]U'59&(2^6W8P\*,0!4,3!,](5.ZA;%]5-6
MBLD-F57M* ^U" K)-$_22["RR61/;D*6.?'8+M2=>SECWHW8!H.0Y]+^QKP"
M"4=6A.1D$S2&_#\*7JI[-ZF;>E3;9_!UL"-']RU6G+[D0P8*[SN[@B,T8_?[
M_([+/).Z<BHC\!;%$_! GT6^PT8G4:.'IHN(!$-7QPFF\'DK6><*),>;U5F6
MT_E +?UN_1#\/"0%^!U/OU9%Z'WVED'$!1;-@ZGAI8+LF<:X(,;LU_]?G-GP
M%_YOA?_NO*8&R&8)^-CB.7HE.A>: HNV]M;AQFBI<[ 5B?FW,WW)]DRT, 7^
MK=:WF$%<4U +KAI^LD4U51%#?9(Q2LGMH_,OZ?NA1=2/F<<2G.%$K@F=2V#(
M>SMR\(>-B.<'LQFG3EG^."*]0,,P[DF,HU5K 4@D2)P,*5" &/M1L>9K41LF
M*>-X;$@*1%(%P,S?5/6H2D2W)S[&/EL(6U1=*G\Y<.FC0XF.93@82!.E>C]P
MN!2]H+%')$A,9?"$Q-Z"@WQ+?^M9,Q,%0(IO[?ZEBHMEL55AIQT+T9NXP0M)
M)8QVRRMIH<4J%D[%--"^UD:<%.HEQJD6N6$O5NG7Z$T>?P;A,*"43DUPD\A3
MQ-"/M<.U^#-V:86'#/$1)[NV)R\*FZJ*<L^CFE5'K+BNWJR:O_5G;@#.S\?R
M+Z,?;[6JAZMZR]M8  T+P,]>?"WSA/DN,=GVXA%VKL=K&HJP#UE4:/E6^ESQ
M0Q-B"'Z5ND5N*H 635,%:@ZYDUQ#>624=@>?L.;ZV:Z\6S/I[,/II+%?$XG1
M^E UIFY.=!F[,DQD"LPI^NH:@L>25NV3'"5X<,.D\_9#@#S\:.T)'S.!$AUK
M;WLZP)Y;G+YL?S7>U,+ V!Z,IA<Q*6;4!TH(NEPK=D'2]ZR,QI5O6#,IG+\0
MG!_8(5VCN6>[(XUU"0G4KQ\.]9G4F9B^\#!KMR?1V4HVU$\>LA12S/WYXVTN
M;5UK=YFSX9LJ@K33<%"CX96JJO_0C-/@!1R.7:#9](3>%[7RF8&?LI/N[*2
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M#6&(7 -NC;;&]$9\CS'8%'-B(/$YC>$9A>UQ09+"\)S<Z_JRIKUNW/A7EH4
MU(;"4K''2=''Y>&OF35:&E8L@PNE"*+8M\G'36M<C[-R3<HU-Y7-!/RN=&<Z
M\7UY8VA5Q&P],5RO!K?(.#=YB1P=XK\,[O8DMS+$T6F_;KZ7'7*@6:%HS;\%
MPI:QLK_+P 4RPC,[5;Z_!KQ*DJ_'^X8 !@"5AOTPM$]9D_0=ZA433U2I]"Y7
M%<>*NSH9&C2G,X-+U?T/7^65)0(U4'W #)5XRQW?LS8I[EY3#\(1.Z=N!Y=+
M)LZ]:'OON(BS+J).6&X0*R?/F=B0E4$RW"\MC0.YESBAX4-P5FTKE[$>-TF4
M1 DM*[!.EWLM!GUUPG>9;-]85#+]%KSJGFJR<CC==D7",TJILI1!%4L/,# 3
M$,ES%NY CB;.CBXX5&#,:!=W5>Q\=NH[ZN&X:I;CSDT@2K.SH):G[70(E,8C
M609'M]EJQ2A:<PQ)V<*TS-1X=6VG)IW1W.JJ;&P&K9TZEDARS:HIXB=C81D&
MSJ>"-?:&N)^?8"B/%]#.'4%=PG?P;_*V46;.5[P76OX[56W;]FU./<3H:<C]
M:"VMS9_VQ%'NLO2A>5$T&D[/PW5M[U92PIQJ!OUO]#:4$WZ&OT>:&(1(A41E
MR!D+60NHUCW3\8J^"9R;G P]KS&,.GS@+1SL\Q ]GW]Y+74N]*U%^BQ/CKGS
M#[,&2W/YMF=:1H&6M _"'O51RTXQ/S,*1*>Q,36I))WLC;XIM;+"EEMI)_PE
M_V)G9I4I>6>3/4WSJ>RG11ENM32'K4^6D5_;?M: ^?OX14;L69]'.7\*,YE5
M!Z]*_L!^*2DI]34HRI.SHH[.%,E[E. VP6;YN&6G;:3MW@E_N]#!: ITPT!S
MP)+K-/K74P#OS@SR/L42[6#QL",Q_J38D(X\!3LKKPSM \5>?H;9B&=V,S0;
M+IR:6MKLE=:]9TJLBX-(-5JAHRGAZK.\]>KW+JSQE-D*=U50!F@?V:=Z+:^7
MZ<G?Z0;DBIC3A&4;5#34\')*1N"T4!BA&X?,VX9OJ7%3X[7:$Z4RZWS-'EK!
M0__QR1OV6HV4@DJ4:2PS9?SA51!/$[K!"ITA^C%,J;U)$Y$BW'(Z^T)/8 $I
M!QPOXO2@KW95TY @OA>\/DHL:#C,#&7=Y?$\DK',+D4OYF\?+#R'-".J<6H"
M6VRTI;?[^/Y'>^?UU(36[N$@2"^"*$6*4A1!E"XE =%-B:$%%)6 TB7T$$(H
MTI7>D2)5D="#4D)"1X$ LBE""!!Z)U)%"$7*\;LZ5_OVS)GY]L7S!ZQ9Z_?\
M+MXU\T9=NYJS(1(CI]KG"GTXZ^#R3XEYM &4E6PF?T3?QDCLH^N6+\KH,GY%
M_K+3,J"+H[/BX-UDE!R(('NPM'_H0B[IQ@HVA0&W6+6!+^.2UXQ)M>!-E.\>
M2,-$Y0F$#N]EPQ-A.%$5ILL90.[\HY%XMGN"XM/Z[GG+L/J_$C8)("VS%..%
MP4>4Y;<HK,:Z[A)VSH^WKTI;X>IB":@:,8!S^J[3Y@J5N% (E7JZ8%+V\;,0
MW;,L8MQ1?&?N%&:\MK'FI3QX*9J/7:ZM5!QHCN4-Z1@"JE-\JI"EEC-@/P2"
M7]?Q7O-.\/L_.4=7' (%/"D&60;^O46YZ?+:-$1:KWN[BE?;Q;R1D>]&Z^9R
MGX J V@;5-&,<@[-Y)"U[T*2@AU_E]!O$M370G]A))J4!8DWDHROE(BZ;'"3
M8S T/ ] 9 3)%/S11&9#9&3?<F+Q^!<4S4_I4"SEYJOF=F\[>IF\_/B'%.#0
M#PIJKV\KR_4C:F*)KGG2NDY[(6%,N5SG3\!2VS,0SFB\A7D%&>S_P% T2>*P
M*J[\XI<UHQ=L.I<J<ST\O'HOY0XVI/IOPA>%>P:$<O:Q/Z0:Z=4-)2#SJJ@G
M&9J&C?>3W58[%NN05*+\,ZY9:DLORHX1*Z$>V-Z4__*I[H.[MH<])H@NLP0<
M":HSQC_HZZOM5ZB/5XLU""W0/V[RL&V$K  ]02!GT2L&WWU-EU6)]H2;Y[A,
M_V;:Z?/X<P7+\]O8=CT7EQ+G'2LJK4) MBGI3=W)8#^GODB.#U:#XV;%GJ'N
M$?AXM-E;=1QO6]+VO.DT[>.?PS'>8;L/E%5)5&ZOSZ7HY>H.6;;,(E*'Z=<2
M_7$V-N7:GHG!%;$$DA"Q+E;D5"/)>#3.',-KR0D]%D#0KC1K"COJ5[A+P!ED
M ),LZS UFPVBBQ&(J;=ER)%/JV%8]N^;?!G[T2:--7FJPFK8F/]TS9K5-;>]
MM0TH9GH?(BB]T95>)J>+[#<&E<4<6-S=/CE]A_(>RJ9.^UU_Q(I.9^<$15UJ
MU>$3".>*K%QJP&58C.2=R/(#H;?$)&^K*UKG=@3G[2;.K8TI0QJQ-YZH@'V_
M+$5-1 >Y6B>!%_:P1U($?O2I*"';#$_RWC#<N/TA?'USYR])GB)D=_<*<#GJ
M6)YE&,5\Q]VA@4#2.]+I]332W&2ZQ_?Y-,=\Z8\@DS%4B[34CCO*$8UAO)1D
M-E0BT/JRFL1LH-IR.;Q%J&6H#D99,^705$-CZT,AY_M]/ :,VYN]>?\4VF&3
MHCSICF0U:;$6WV(]>J'P7M55)*[G$#E@1\YVF]-V*Z*:@WV C6SYM:V;P:,J
M8.$#8N 1ZVI)P3HCA,>8K5-J,N6FN0!1>Y9\/>V]LZ#%%W=E? J1/BUR_4>%
MKA=OB[%H),X#JL_I?>!,8RM?'E8NE97=PL#M8[LYOVWLQ]3I*N[.5]R)P,ZG
MZL/\6&'PN$TQ&\*WOU5MQV?#P-09G!O4:)U=5F^]0:7J>FO)M(W@I$4G<V+.
M8@L=4PJ">D#VR9WK(AU?%.+S KN@D?)-<.;)Q[WV/!H_$[B41Z$Z'4C:J2!!
MY"IN!,<!K5S!/S%I,>I<M%L"_"2M5+J\:TCOGQXUK1U"]6!@]1(.PP4X37@R
M@:UIAT]UH&0 ZZ_,:WG+FHOC<)IOV!4X[()T6#)(D9KF<1!*85FTSU/4R8\H
M2NS@=CZ**-S/X"9V,[WEUO6=M9^ERP,9(6&[4!]%4</OM[W[C'XXX3C(&7>Y
M/,E$ "?M#. !TF+%.LQ-00Q>6XRY1,A(V-I&8R^]X\U90 #W0#K>2E!/N3T.
M-I,6EZC@NJ4$XFR^ M>U9U_SF\I.(F<1Y@5#R^%07 H;E:>?,GE?5CZIPY,_
M9X^HX8.5EB*<YX7JG_N'U6C_\G]$<J9TNNVYT!0P%?)(F6R_O5G8L_^FL##0
M1Q#P;7LRF#+_VS+GF^!AUA6[1D8-E*JEW8=^\/[*6EJ9DX^Z.;[@RP<6&U(A
M@4,B5ER#7V_F9<\98$U$Q^GV!V3!P46(VPWC])UYB!--3\AU#FP"4=&P/ZW-
MXT]1:O$A5(W H T">;3-P8)MS56MKTV>FGDC]V6=%^_$-P'O'>98EFJ^U^7Z
M51E63Y O.SAR><W0CIDXO-8H8/GKD%.FL+!-JJ!F;R4-J/7*;3X%;L!9DERT
M?$N72?A0*<*3G+2*#KI"4@Y\^H4V\6XYG:>:6RPER(17Z&3K5PRNA"W*]94&
M5W1<N\%.ZU!,A&A3U[=J[@%ZT03_4?![WZ"O7> JV>(V/)R5+WGNA9RF@A\1
MF15K,NH8X9*M\8ESQK)83)'7]NFR<'5P)+7/:H\;K3OL?7*;K#>TK&67S2-]
M.+%@I"9M?,\_S^5N^QG@IS*I\E@/D18=&O&WINY8Z-)G?_O$E:>TH\"]NECX
M7,BTX<COIE&( -,Z;7$V;G>E>%DFN,-DLNZ=6P'U@CI;P34XU*C[&O27_:Z
M$-U,UCUD!EYAQKGN^0VX1 09=%\#YM!/%[G,N2)2G/A>/$\FV*)S-$Y)1A/!
MG;YT!CC_]13W[I,O>..5HAA\OR%M&+;N)/LL;31"F%<*I#B$JQ#+6R-F9.P\
M4#+I>LDK+V!2N='EUV47_F57B0YI3#:G@72?B>W85!%2SOV.=1]3<[5+)-?
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M?Q)/*2-++TRFI]L-EB 8@6=9<, 2#L@/GU:$PX8S%"9RNVZZ)K!7X, G3SC
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MB(CJ6WM;R_17A;*W_= DHF!1S<[;QS+IKE[RX^9[G51W/]\!]!7#V1%.3K]
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M%S]JYLP,!KI['[%^V'/:JTE3BM\C7NJ'\!,!>Y6MF3(7[EH4=HLXT8,:HFG
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M="?R:T8XZW)>4;?CR2VPN/C,?R,]8@GAMZJBU7EL?^0+BX,\L*FC6V4PZ)U
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M_D7>$(6;RY1-I2&2$CL0!:<\MX#_PC4[:CD$9D-&AU"1OPX%7[[P0[5ISEN
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M&:8'#CS65VI/LX^_BO8IC[=G'G>UD[DNR1^K3==2Z7;UCABFT5*S+0FGE[M
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MK)8MTY;-E3["PNJ1Y*?*B+_SI?]$,$(1.3DK]O[TM31^!17#/17SJF2'*M5
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MU3?)0R4V4,9W3#0]W?:[@EAC4$-PJ_R0PA3W$7<%CZ!0I*]ZI'F(A>Q4-4>
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M)KU!OL>.P7$MF#/ ++Y+^?SGVV\OC1(NM/?!G(94SX22X#)42-PI]NOW:G*
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MDDI59+'1MRCA\+?V U_:>S' RX7Z.*31BKO6;]@EX+?MB9B78IPTQCZ]H-2
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ML0=:?[?[K//8UEHFU6!T7+O\69Z?6Y#PB6Y$N<B?NAST&^8'2 F[Y>=HL=3
MORN/AFDLH-VM^.270'=J(SUAAN=PY0-D%8SNPAID!?QQM^F:S(2W"Z!K@15'
M\7XGU:OCCY)3'VA;U<I#^\5M6!$XC8$/_17B4A',FJ,I6JJ/XV0EI1:!5:LK
M<= U,C4!]<]U@[Q<7S*^%E"@2*<J')9' $WL"M^"I/ 8J?$T46#@*X@>"%]G
M19VA?#VU9(F \A]DRGKD0V7Y_IHNJ?BR8UQU)N0806TSC@]45Z.E04_Y_25+
MQU@?DC,#NTE$H1VXXWP@UH,>4?V\]9J=EMW)"D*EM+%B.[#NAEC!]2V7W>E*
M52MH(G;#VS53<ESE"U)MPTU%O"(F7'$644-WBS+J" FCKAR#P+,"WS-G4_M$
M>$?BYU-@>[W\2+@R [I1 6]]MMQ)ML6;!OYR;#2']UR.QPCR"3.1,0.1AA]^
M;7APA<[+P1T9.X'-,.BDI,=8U]5:JM!/I&']1F+]50.PFD7P=$+3M^:@H6G3
MQJ6(#<?5W&0@<BT+CI;EBJRZCM+$(NQ\.%/.R.WLS>B11+Z/$^\I+%B*V3;8
MH=WB5H29+>F^I2HB[32Q,18&<8\;@6!>+51P2H&4?KP1IIVDC*8XHPRFN^FW
MY$I,D,UBO+#5? 26)\?W)2$?T"662/1="_!!P<#O'JVG6@P?S ([*@ (R2PW
M4HL[%(YIMZ<'M+9=H'(ZXW.B@%T0N8.O[H:>>2XP!6"' H"/W+?V1>"SM[VU
M>2*"JKXQWIJ>1:MPG BT3L,.J\42T3-HQ6)DU6P@!&UM#H$K<$0/ +HM$$[<
M$(HR[8E OPD6])).9<YC^\B00=JZU@4@P^H^D4A84S]-+*I'H,F=*@9-@>6B
M-"W;SZ4]31+$E_*.IA.PO7B^163['>4ZK]!I86+Y'9<C"8W=48XY#7^XZJ.X
MX"7 /<R'3^DU6R'!04"O;GI?H=;';]H+Q^$IVFSJ@6J/LAV_N_NX9%TR(_!T
M4.S[P(U /7_[RR1;VJ2-_$%WO>4 NRJX66_>!"UC?$*UG_<12&FVO]%6W^0
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M1""#  <CU/MR;.'%&Y4%]B9M A<M^W&=$J0<Y,Q[>KC@ZT"$:^Q<+1F/JQ=
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M<[0*[ )GS@;V!*"-V-''F6;P^M[A'D.LM3>A.YY_&A3=ZQ%4&$W-HQSG'DX
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MD 2UA4OCIIJL0@1:9TU&2,@*H1*F1C#X'2OM)!K)+, 2\2D:LT_GC3@#3R#
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M(NM&QHF NOKW;7G3WK8\*QI<\0"R+__,HA-04V)W]SD+?UA*;=9T=V5MW&4
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M8.F8"3!8#:"MI@'7_*:G]7K,>.NRE]9.L<][;$P+VO4%8!HR)FKI#@LZ:.'
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MA$$E\>A4_?72F:E7;DXHNO93WJ5^FTDE.W>%F2EC8!.DRS*BP;NOSZ_M+\H
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MFE$>)=G?1[HE=S!OODU$BADU!UO9F\3;/VK]FKB"E*6/1]_<N*QOYA!S8'2
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M[S2?;ES(XI$S-V[K>NB1I_N2]YG9>S]6EC2<1&0.+_=F=BZO6,RZOVAU:"]
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ME#5#PBY[6FN%,V6GJ&^/%@DOZEYSO32-I+A*G/' B6'P_49U/_I'N"ZT]*L
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MF+,6](_QSMX,MBD9^S%Q#_NY(E[<D-M?OE0,;$:#7PL2-32,[PZ]\76D'SO
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ME^C^@0;B;!2'H?E2U$%*6$XZE#&'_/VO]W=M^@7HJ_XOD!,?>_.HO&.3+4,
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MU<GVE-;MB65N5?T+P#?&JY;8F,Q7/":86)%61\-GB07\H]&%QUQ7HN]9S?A
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MJ"Q)H3Q"VE4L8&SX9=MF[4),6LW-*AZ7,;_F%G%U'X'<F*323^@84^]>>"J
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M-2WO4YC;9SJ-Q&;H^3P55EDOK";??+SIM?^NEP]<JJ$+5M,,!9:!\!K3F?F
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M'M(E]CX;07#Q._FZX.4OKH/F*I)-*O #AY=U-*>R?:">@E\1*>[F_2>!%N3
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MO=8.YSSS+M^)I-&R(O]J^53W"'#)]FAW7$VB0S%??LS=%?_@'EZ .[JJMO$
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M?^MT7!'="/1R_KU_X[(P]3=45B[Z;MXSJ9XL/'#ZIJ:B0,[88NW]EEM"N6Q
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M1%<X_=ROORW#HLP)@:*0=,IK'4#2H=E0XE,C R2FXI07D4O@DY\8>KK)))W
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M!9OHRFJE%C$GHZ%89M!@:_$DZ1^)C4K;P3BR0@)DTD#I+)_QA*"5W4H^4GX
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MT[#5XR>_8!>7ZBN?).ARZ)H0'HG1)6JL;WW7M%BSKTUS4Q32QM1KWU+OX#V
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MFRJ6OFXRWJ?(XN(5UX4>W9EJI*_EK_,Z;MCAW\XPS4'/][7FEJSAY?A8X13
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MN;F+7?OR>C5L<XER@M.>Y-//X%K&:C;!5_)'L04=B'^ Z_&KA_X:0?.U=F5
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M'8>M?1! W1(1%NYZ(P<B8@"IG]$@IE>%M^.&],J)2F#R*FWB:JY:IJ7F[LA
M79:>$Q#76PI)7D!)1/I#\,NZ*(BA]NP4&^D.@B.62HIVXOH^ BYC4"E04 66
M(07=5]STL[Y 2?.D"7C)U^M9!<Y)G2'Z;.S@I!C#-!@!(9]ING"O"0,>9R5U
MC5D5HM@ B><C&!*I'Q[>9AG57"0H9L!T^CG#((]7(]S'4UV??Q=H#.LYJO9Y
M,#76!A%'+4"F.?-_!N16.K:X^!>@)::,&R@O4R_X6_H$2+-IZDTKEBZ+*Y]
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M5HTB>4^-T/OPH4Y3!KDQ)1N8DOX&EM-C;HXA(I: >Z'30S#]L8Y=%@<8,:-
MQS^ M5SF[UEIMB2]J(HUV[4&:5-KA[EAUD3R\JR>[1UA$&>1YPH5I &W/@OC
M"TAV(>4&[7-+-.M!0KA!]':QYI:,)_JQ :%&E)>E]A4:-K7<U'+=)E"79U))
MH$-9!<MALH.7K^HGY011F0A%(V4E2%IECK4#E2X_YP#BI8=L]0_0ZGN%",[,
MA18'U0^-(W?AX _X*2U =4P@7( VE',5_]K8S#D$5;DH3DDE<1#$L%J@O?3I
M=/6P[@\N6P,E/YCV)=G\L,8DY>@DA[7![>R;7T6L>IDW/'6NGT1.<>8F9/Q:
M)>NG/TDN>@A]G?#1;A5&B.ONT*78MV0ZK'28G>\%(,#F;[M:FCAJ1!:-KFN2
M5W6;]J'ESL'!)\CH/JU&;K$Q:$VPYU<(Z/S22J=PIPU_"M$>8Y#%^JQ)\LNY
M&:_1$)E"#G.-1U':J@NSG;2:L8L$HV]C[9^V$_H0VC1#"H;,:]5\A>$<2J$)
M/8:OHK78@AQ&C@SV+)=+[J(YF*OY7KKB& )9K+QN90K</.U5JGP@4J6A\%45
MXHI='<>\6JUVO !S"^7$#;346H, =I6&%Y\"V A.H.FF%,$0*9P:O-Y@342X
MT4X$GHRS)0<FLHWS),=F0P@+2_ V#F@):UF8ZLT<<[R57=SP"[C<$KUXHQX;
M_7^<)V##KC&7HBL1;*#-KKJ:CS1=-S/57H2^':>NJ_B.SXHOX'<?FA.*$9$5
M'SE6-;:WM+QPGO=[FX3+.5XBS6S3&K[HD\&P,]#8<+V:>HTVV^-$%F(@QXC(
M]X[*!A (/XZ"#5M!DHUH:SYNSW>C<:L2#>=,FA_:UO/N'-03V/@' .FW4:92
M:.XM(/+(\\5Q$GL"$SC\E#;TL7[)'&K+(P[V:T?98Q*RVC/A/]S;97:HI,I!
M&MR:?G@BBA%!=L$3WFZI_ ZZKXW&EVANFV,*-=$8(FEI&=V:!N3:ZN2!/W_/
M3_3HP=S5ZP_*>BW+VA<M>/Y0(UW,'.H:2*=MJYCK?K'&T5K,MM(Q*0%, 1=K
M<-^KHH7\->'*D]3A]Q0E+KS(?+L&<48R5;62>5-V<7R_YM>YDOQ0QSG$9V2[
M1NSK2D%4@P;2#+P<&L+T(.TY@"UZ@3RM+J[0VGGA5]QM1?9[>B=$'7*35W_8
M<I @US"IC8#I^'(63\T;^>#ZR,28TX<VY$K$MBP9(>.K3GX>HXHK]%W<^=ZW
M+YK4P;A*73:5:A>"]_-J:@+L4FQBBLKAI-K>Y%-3$5XI/5P<)W<9W!-,4]RD
ME/E<PVZ28.(?D_KF#L#,03/RE?4WDDPGK[QN<G_97[W[A6CTA0KN0:630V'Z
MXU4$]=.\B^9&^VJ_E2Q]]RC3*$LY\2-Z&>G=QW;TK7F2**]3C4J1<QJNO'95
M638F4RU?SGJ51OTSBOW?1'9SX4)F6UX@=3;<V33Y"?( @P81KK2?1]Y')*L+
M3.N?LB+A6P.O##5-M#GE5;**RBG0W%$#P)/=Q>/O+<N><%/7K4O;<6"*_7M'
M(&\T4TUAQN4C>VK&]L"AM1V+U^Z1,J_L%^#1J_0@^B!,%A7KRD0N4:4I70^+
MNNI%X@Q;T.< [(LDA;[[O^I:S@<Q%3T')NY@F6@"ERQ>4G)HPD*LNJTTN_=[
MDZ<J.F"X/(W>;V,K#</,?5,>@WN"=.Q+L,29_'UBI&[7,2P7,K?X,!KN :;L
MHDY3<B3TD0!L7[O>5RSTI!"H1OX#G&-JRT @FI.78K?@3\MHFRCLE^+8_H2@
MP=#"&;' O/70.AJF4G+5Q;9O='V]WT['V)#(JEZY[1D32S";?[/PD3"SG%3^
M6G>1<)6;L?GBT$F=JEM-@ />0U4 )1DCHYB[3!X2:<^#(\<W\JD^O*5)I,>H
MW),')<WYIO9\-T&NE?>-7G][I:=9)6N^(ZG=# +QKBS!#Z[HM4>:I\&A''PR
MKG0P1W.Y5'!RJ(SZ7'#@KI<KJ9BS4(D@%$E&^K4*3S-K4EUJM_)5*J_$.!@I
M9>BI:Y_W&H%)39B6+IAJ-K^/];ZGZ[*PHWRJ:E59.>#8?59<RIJ?G9"Q!#5"
M:IIEUW<;J0Y9Y]=!'PTA1BC#F\;""9_ N^5@-?3%<R<#)W2OV*SF%F5991OR
MFK=(5H/>QV(^1^XNUH\5]F8W:D>PI3RO<>-TS1)F25;-'1I?3/ +-BU&'--$
M]21PF*!$'S;ZF<K$$#;->&YN%M5CKK5D6)[(7_525G?7DDI:J<Y\HN5AJ6-0
M7*)BC0C[0BRPUPQ6) ]]*^=<VFOY&P:L?1.N I-#ZG6=#(0.+SV-&18N=52!
MOR[* >#F,%<VDBLPO(+,G[KOAZXTZ^!N+:LN4 JQFCQ ,7B(.0#:[N2\R:%7
M2U_.GKQCE$3\R2&8U^6,"1+?2.@/"I[MKV*$?-1'MZ5CCDE36<<V, -G&7[R
M5TA,N)C5U9<BE36X IEJ?+D#NIELR2%%O0,_N"/DU5A^4<9TI*_:?A9PU>[8
M@D@"JQ\J9W:" [^,!@@BT)8E?QGG#" *B(Z>C5U%ZD.36MC>+>/KL#K[E%CO
MMDNRZ>:O%D4W5ON(VSHMX$52RS1_LT' 57F%Y[#;_6U AE#5C4^=2[YNXQ2=
MANF"=)_2L([3M&&;D5E5;8!JSZ^O!.]K2W$0J\]RCRQQS387N(;\Y)XMBD\;
M/G(\L$RX'#R0+E(U<1;-D5_H6@PBFDZ&I1IKO^47KO%5.:-A=[%+D&PS$@3D
M#_A 9GILPG=[XUK/OI-XM-2UV+RC>\T2ZKE 12GN)49C^C??KR<_ H&$JRCJ
M6%R2*67%3RTDA.4F?V/K-/_54!$DCI*^%#3JH#YVKSFG]C[(]XU<0]:7^HK5
M*0^1[?9;J(VCRM.B8\G+68KU3ERE*[\R2?N[%AX&RO2X]:K<%%6Y7EJ96PW'
M(<MJ%NZRX]=_(I&X8"9Q:?^J$-VO/=_,4X5@10J\^GBA,]=\JE976 K[4P)#
M^8.U?L>C'E][-M6A<4>=,R^1%Q?,K(&26L%/63JB5H)BB^^=D54QRI!%*+[H
M4UI-EZI>]8UIX>Y*<<I__/J8V6J9_G7!@6[6K"T&Z>SS0N(A 7Y/$$MVV;GF
M5R7(\[I(D)_[]G< SU58=6KL:J_&S6.3KV!MW7NQA0V. _XU2V=&L^&$A@E?
MZHPYY&?NG?W)5B /I*F&8\KE=TL.8L4/9J"C6UUP%ZV#-7=X7[OD=R#P'+';
M#!7W'8K<A$(I4$O3Y=4:L(,^5H9F?E5MU#B^L;H-5HGTG7H_3%,RM&,0 >.!
MZ6%6:?!<D-FFO9\^LY4-.HUQX^%EJJXYAX2[(((G8Z;KVSK)<[!I,;GR^@;'
M,8U#IH^9>P66N_</BK1J66N*?T)X?B\%19K6BZ7- #,P:-^3AT,7J=5>RJ&X
M!>W3O"\(-#]M2D[S_MY'U_=$X[!RM/%4EN%A"^@B,'A]-5GP@,#: 1Z&H'M*
M:<'"R;6 [!?K&'G<Y]86S^,_\1ZD.U,_.Y<0>^G(MJ;9ZBI@'=3[9?Y9F)*&
M,\PNE3V#6Q@]<\A]3<0+& V63%]:G2&@"]\-L30;6#MD;9O6@1,L3L1ON(O2
M+A>C+PE,*='U0D75E.]E-(K3=R,6(B39?GQ)DQ'MM/R(:LO*@H)=>'M.V734
M&6?[J\U>?+@MHTWPT?)J4TL784U_H16B F>N[*?3U'&_1BQ^C*ZM M/T+0J
MUO,N)/0[KK%L5;A)VJI4;//K1*;Y2/4/ALA5/\4 @%AH1%!-WW;S<!/4MT![
M 404\;.F]&)(&8<[I1B:9C-BPZLU=S>K6)#I)B<6D3"1QBR5*C8YR+F3.6XY
M$D[AP>E4AEW-MS:)H&QN%^W6-#'+;./R B=ED6+ =:8M=#Z<)=>NR^XJ@:A4
M?8=2P(T9_!0ZHFCDJ5S 73*KD:>!@;\"@WH>_65"'Y5F16EU:$?#G4N@C&..
M@0$4<@BYN*@7RQ)8WO1=9.TP@P$:EAF,T !0.+YDMV.^CUA3Y51+8?O#L&A3
M"%*3ET!&$OD_6/NJH#;<)]H P=T= @0+[M#BFN"2X%K<G2+%I;@$*5)<@T-Q
M*>Y0BA=OT0*%MGBAA?N[;_^'^WC?]F5GOCV[.W-V=O9\KCR06@8-^'5;VYSX
M_@HE\8NVCAD^%FW)=G8<F!X&G4K/TH3^F9E73>>(C(SR4CQ5<'YMPI!1993A
M(4W$[&6H/KSG05\S"IP>M_])%JNK4*FAS^DW-FN5@:D$PH4@*DF[IXV*^\JE
M\.6[%=WC[AL1#75X%4\=(S'[@:AL\]Z.BK*<YA[YMI7ZCX9MYF]&"Z^'^G6O
MQ(HX[OW+VSWLZVF5&E;@SGT#IHX4M%4YB_Y-'=4DD-;DVMPE2'I7A;[PG$A;
MIIKI2"KHK*EY7A3"3S*Y</6-@_/M\A[.;.L,@Q);? H%;SRE\""30O ;=GEF
M&&"T"BTM E/>5P24=S Y02:BJ(]]E%BA4J89WW4PNF7US<T)(H!8$<8E-%6D
MW< *=+')-G>@"F)'%HZ^V4RDQ9!C]2HA:]0H #!H JRC00_U:.2 BR1Y,L=D
M#8^\JDFH6S30XK_IZ*WGXY-(S"%\804Z\9ELQD3W=$F@;'G+0I##!/(>S$O@
MN+3/C"Y<(E?KLZ> <2ZOJ+"A@)?>].$[F5K(+<<(&7(C+XT7F,TX'2V^QZMC
M^_"6U6SF4&R8/GJIHJW5X$/\*U%O->GIZ85QY=,XW;>+F.HH?6-,.(UD[F*Z
MV8[B\,>%+2B]=3$L)CIDZB1H; 3/W48<='ZTOT+=-T1U"RZ($D(UE-:7DNH]
M4+I._AT>ODXBY='5**M(E93A_4K%_Q_/7<:8.<%72C"O=X_??%G]XRXIEF.8
M#TQ[%\K>I+M3."6=]*4@@14T;WF?Q1AAH*:RVV17H?_0TADHTQF;)9K&(,!Q
MZ73?A7**<5N0LGP#Q6<M->3%<7<UYU93/GT<>F&D2T:8D%Q6/T4NVQ@1"2JR
M)1+/XH;J*\3T(#61X%HP^LM("5*1$-N'I)NK-"KC_[=>:N6<[U.!3/Y326/Q
M-[[5LXK6IM,YE%S_;'BQ'<W^[-G#D3/S!:7.@X3!WO>'HZT IO_QEDI\@A_Z
M\PU\T-[EJ*T2D[]3<H/:6@'5 ZI]X\,L:;TBGP%SK;V.\?[ FXLPM&4QK5H1
M(P;/V?<ISO(1ZH:^>,3ZL'@6%EV%OG-Q, UME&*^O'10E/+H ^)>4V>&P>Z$
M1Z'7E/O4[?J&8M'\C\&6E&&#&R9"^?=>A/R2@6J4B&BKF/DB+=C.$F^2OL74
M'P]MA9[B+3T,_*. 5L]$=;\K*CTCO T&3/&I*AVG4CW(F83A>'I[<_Q5S\(&
MCM*(#$D&M:D@;]QJ\W.X67.0D8G#ULX8&@!O\,6B"H9JUK<=35SNI.#DG:Q+
M[*\;M[5+/:^-#@7L'C(YRS[Y; SB7YM$XP2E[RDB-QLH*7K&-*R1<UHB#7!A
M[=N<C5+%3<W V%I1K!!8K:AV^9Q?1TDIA&*]2,^PQ[28SQYSX_4BLLKE^^Y&
MUHKN2ML_1G75Z3@+!>Z1?VY=+B$VU3E<D!-03=)*54817KY1HO+![-C;F1KK
ME*^J#)BJK_!9I,^? 1')=QHHV^%PRANJS IW%>CBGRM"EW/)B9KBN@6#(PU*
M6E\P"<5WL6SI8M%:\>MMG<49Q?OX+.8*G84SI?O,_!?I2P]W4,3*O7.C2[S.
MO:6K67J'LV]M%A=7:2Q!:TQH&@OW3O;/7;VMNG28?L?T2ISUO-;#][=-+ HW
M:L#F4=DRBK0*1U"$]V*FQG7E]#]"F:\[)6Z$J-H@NFJ^!F/R4_^.:#]GL'G<
M<,3W5U^:S)X!OT*.+CN=P[),(94C_7Y9=;^N9&?HM[#+BLIJEH\\*CD4X4\C
MZ%#P>HBKZV!%?LIY/E4"/RM6CFNRV WE#$-)&R2!4#F>HBYGM%;A[OA\V8CA
M07^-)$*:>?*S!/H#=6W=KK+Q'ZBLOW 6VULRX.![0>[PKY?3.JM*N^JAY@_6
M5<F<(_5%D6/XD? ?!D8LD'_L2PTN@%R% \B2HW-C!^H,XN]/\8XC/X?N)67'
M+F9MJG+Z/P\[WW'%;D-5)XQN[,QBH(+O<.CKVF7ZWTICA4KO[?ECZ1I>5IR@
MKJMT3SFNVYL6?Z)F451VO-)+VJ/N01! 5:C<XKMA*\*U@>_/@&O[A0TKF6IR
MM:8^]5G7-]#EZ_EXG%GA6O5?8UA*N9VO8A=65O0O"I>G%;-B[;=>.D>Y&+OR
M_<>;7!U?PRL=@ZQ(2VW&E<&L'<SQ$%5XA,*\Y4Q%:Z%8R>6R7;X5:]GDY7BI
MJT=*EX52!?#/33M1]HH1G(0L&[[R\>H05UUZ.*N"R/XW]NAVR-YMX%/E;W(#
MA_PZB4"J#+T\27P*MVQ/BFY[S!<FI=-.G_>RVO0.EY>7$TS?>_-ZFBY7524Y
M0-HL-IKT])V7V[:KT]\<3B?F?<VIU#O8NX3A<65]Z)43GV?=2F";,.N:7?<7
MYV)W)H-J(HO0P!<O/8"?UH48B@7KRL6TJC*.MWT*D6U86<T50)31#EZH/!H
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M\;-1[N4B74REJWIGY' ,S<N_7<!?GJH/M*'.7J)[A5LDW)ON6MDT$96L)9C
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M".%$);T<T:_H.#13P*BS^1-,V.30Y7!KW"Z@*QWA599[@Q$R-V"2*].,*4O
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M:EVQVLG;98D91K[E!2T#LBD-CUYS;DU;YPB5 _)%-Z@@APZYS4,+5^E]0L"
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MG@OOI:>Y&VC%Q)+\R+#)CQ%2_YI16B1"K?6\\XL0D^Q$1:%M VYF[0=DX#.
MJ.89T#<N75_]#&CYS[S_KP)\TV 2Y:VXZ6J<(YGVV\(3D8U+6QI2!S_D-ZWQ
MI2YG?>;NP/X9]>TUPF*&?H0#5Z>I[\.*->TDLHB$782> 3V[G4_57VP'+^9?
MM4:PWWO\R,._#T*<+*5M%W8ROS.AFS<C$G/P#PLOAH?OV-A>6O^'->F/M,=Z
MVZGNT)AI!MBOM2]K9)C$GT+%MX;_Z*YOIH&80<R F^+#JLZ3.I&6H/90^>[C
MMR_^2W06+JB:MQIH3-KY=,:,ZBZ,5:7@'+&U3>?&#)ROFB C4C!WGUA4N,J(
M_J_)VU:W_1U>A]W<R(3QVUCZD\K]$8N",1H(2_[7X!-+%^$V2 +8KXUU:N9,
MA//2G[ 0W^,O83^((NMOFO<-'96^6>G*$0O+&F,LPW)GC#6OZ)7G YUTYIFN
M'S]\:6!2$1AY:X_J)F!6_* SEO&'K,!'[H.,C>F,J<"Y2]^)VDY/R3/@AF^M
M2I"AA/D9@/\J#"?SZK+Z9E^6\?Q'T?N6Z&^[;:0^X7HQKU^2Q65N0>4W^VBQ
MW\M*$;QGYJQ@M*A'D*.N?*G(C7_?IG5.=&+0$B^ )V>,@2%5P<^ T^[NNXF#
M@J5U\*=6V*^S]2FP;I]%W?6C)'Z1G-YFV8[(_KS\RL:HL<N;+8Q)RK2$QW>Q
M=/GZ6#_ZRUZH1S+CMY^/RSP#JIZF-U/#&!]?7CNF>M"](<W,? 9,S;\O!K\_
MN$D[=&CJ.WVSI:EI*+>4]D<A^HPBU.?VXW7Q4^Y(86LO:H.I9$>KI?/DTVA
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MV<1#CF<9E5/7(T)>7EJ3XL^D>1Z?W^TA!I]#_P$ND87DHQ(5U40$=< FB9"
M,3HO7IEKB:3BL"2T]*M1Z1DD?37&-\0LH<2?UQ=A_SFLSO(- OBCP -""'T*
MKOD/D&1S=K2X^0Y9?#D3!!^W^.]F3<@'.%'L=)]:!D%2.(>1Q;3'#R]F#E7N
MJ\_A;@( W.F1LG *ZA!\_A4]S*O0@&O)V<WS7]+2LS0V.XCCIP%>#_)#S\>7
M;OAN0RHP3>HP,J4UR>KF/*K4I&LZ37OOV/O6$@WH(#PAW:0MW7:[V/KC2_Q&
MT,L8LK^7V"G\.WF3=*'BD=8&3>JO1T3-11U?ZT&AX/&@02?2A?;0\9/?BW]P
MIUG;Y:NNW@O:([_(3O%>VZ;[YQI!LO*ORM6^&H(T/75RI@]HH!,SHS"C=Y31
MRC^1X3:+-P;JYQ_*VF5J4'.TC8@L5>*!ILIT_E_S_88SZA_=[E?]%PN/?_8I
M*M<+\GRZK-3@>AZ$-3Z<,KBUL"1M2@JW;[AQ]]9UK#>L3A)U&-T60A\T#()Z
M3TV2C,LR30\:4O(7.T<MMT(E%WF#MJ:?=_$4+08GK03#HG;[6/M,%K<N/8(Z
MPSLR%#\HK@9VNEB<X""7YDPT.C8Z7H>7OL_>VGK_;<?)]9U3XN07QY^^(]]_
M!"WD11W7^NJQ=9\FUK5HZ6BP1W#%1Z!3H%X!45A Y_'(K?[!T9.:-ONVVDWN
MZQWDXHXK\D*YF7MPMV]V)W1HOL-5@_;3N;C>=OH=V;;^^=':SV>WS!6?H'<Z
M6\2+RN[M84G!#?E:2]J0C3/PB9$O7UH7BTQR+0#%):7%7GR7V)XNYF@;\K-O
MK(/56W)=H^=YL'<E]'#;?*_NKG)CJ_W^:+MM)4T#H_*])L+1^+RJN'/;MUTL
M6%5>P[7M?*=J/;\P)<[9.3B+<7'+Z>24@2]Y=(60"V//_(.#1]\AQ<E(,T^O
M]+F 2R_K6I]DD[@B3VG]0K;X3/U2N["KGHY]]G/(4@\";-JN#_NJO^B43_MY
MP2^KKM>,0TISO*+M6\&B7R+Y2;6KOK,(PQ#Y]P0=X'7XEC1!<0AH)\GF_TO4
MX?\Z!#7C:@$GV&/#31GMR;V,Z>$?@$^P [/Y5._=IL$?Z3;K8M&7R$;H+T_I
MDB^]!ZXIYONCLL@*AX?4QSNWM>R&I9?YY' J%=((^NC#*&DW[_/_"KM?]J>T
MXR^,9\_5U&R^X1DAWE'E8HEX^M3)V9=!9)\]=A/Z;FEZ>&P_[:-L%C0SX=/]
M_:DR)"F2R))J#/Y->;'@\5JYZ^:7]^'Q9A5)U!K50BEPF%E5:M@5/0$MI[M3
M9=3/E1!$S)K#]/6!CE8J@-;9V>Y8Y[UV";UWUCQ)]C6*O<C?.('BSBZF*NW%
M3PQ8<MEE*"A,GBE'+))'O&]0B14C,Q@'"%*OR!FZ-^USY+*:WB>51M5'0 F:
MZ6R*U\+=.\'X9F9-]1#)SBXZZ24"3;XX4SD#9E"/"K'L*\0#72_58Y38*WP1
M2T]+>;0+@G0$//7\%'6N8THLJV)*KH+.3?%2F&PHI?9D0Z["A_[N7OH+A7,$
M"^;RWAYB'%C\<.NJP^?!)36'2+F**U6420NDP?.!?_5,D\&%@F[2BYDV'Q$#
MSR\OV9GYR5]1P^8$4+6H-TO.AP\\B"W#@/B24WBN!R5IU?DQ6S9LMI8Q94)H
MGERO)",'9E1HQ<;58IG-C:/4!Z7R_6,!'FFR.?0C280V%R+3>L]X!0Y;GE($
M!5$AEH^GE-"&T=UXY*/^ GHZVN/)C, <ZBO,8IO[:TS06N/B ZVT'XHU@<U3
M<UM)BFI"GTAZ19X!"I/L>'X*Z  3^DI3JPG>K]FLCM2\'E+S$4(QD@-AO[)!
MB&O$Y(?P+GYY/S/+9R5^)"I Q+2 )\-4] *G@KP98E+DD/ JY;CJXACSPERJ
M0)7:0;XG;-$5JB:!DI! HW)X_3%B,A_0(TAX@!3?T]JZTMH(*W(!5[PJO'BT
MLE]E#TUHYVFEPEEF'_ S8FV<L/5-NP_PJ>#?O$((T!&SQ?O']1QRJL-R84OI
M@_=IH/8R+:$!/8#&E^L]%&E_4[?JZMJS(\*%15W=9M/8JA10L0@P"N#51<XJ
M\ORB7/5&_3D!5XU'%A4'K,*4V_3"A U)+B$E/:<36,*/[CY?I/!>T%U N2&Y
MD1$8H+"QI?X8U4V/E]KU@%G?\-D(;4HNORD9X3Z4,Q!;.L@&5GF,"$-@_AZ5
M"@F@N$D-\:48OD05H_W\(IV"P$44#Z3>(^;) 8$!HO</5Y%_?+,'52T?))G(
MX1N@C_2!K^&7AP0VD1>AR(AQ27XY*(PPGUA+$T5"]B]C:'/6$WWM=XP_)V&L
M%T@$10$==5<G(;])PJBT!((<V:>B2I;^M2(F_;[''YGC,N.VTQR,[_YH29QQ
MGDK7_R*].Y?%+">;#L>\_^MQ7D(N?,;T8#-1UNX$*6A(2B5G?1X _@,0A!4Z
M16LW+;QA5L4"HIQLR=E?#<].8ADO1'85-K,<=PX0[ 39B$W3C/Z=O7XO*  G
M9*Y(ILF2&93(U4M7F?%0^1TNX=O66ZF[+*!Z0[PO9UE>G[[C3H0^>RJ2R"E,
MCJHB1%>?ZG;X< X?L?5:G+A2P>%W^"F**7+/$"'].3WI^/Q^Q=SN0PT(K"H7
M.MA)@_TK%%E.;.P]]6HHG1J$B>";$3PJQT1_#J]#H#T_)?>QUOP#[&LC;?#S
M#:/H']21>R#X94.JM<"S](&F="=LGQ&.W&VC6TZ%57-X1VAB/5#<//S>09)/
MI<!S$X@>E"3UJ^BIJ5\"7V@(&>F5W7*XJ=-$/M%MB#W;G*W^G5'^<8Q\D>ZM
ME_DE]<L6Y?=#^E-2V%?IPGJIX/2U?DO\$\=ZA]U_ 'BF0T4/MM.L+7$8XF--
M^1G>6O%,V7UJFV3J&=S 3,_&\?\52/M_+4=X7(IOUW^MWF'X_ -@NW6:,6>%
MZ[N"D!<V?Y_IX;0.%JL"*O\ 'K7A\SW%;Y57A1!-O_\?/!\HG 9 X$:EE4;P
M]WZ>CDDJ/"=O=19<$[;1/XXL)_DSEDU9?-5_3YIBP4"G%.*0+8N,IOLM:50Z
M78([(+#P4. 2*T/[NN\_!4PGO9W\59F;%N5F^/AZT"+\_ 6Q6!#[KN1KB&<6
M58@L4N%E2C*8O81Q2\-%V:F!^"4YDK*VV]KM'9<3/(EA[ D]:= PPA!5=2]%
MWG[,:^44=Z:G[9>,JIRJQGBL^E0P%5W\D!+$(T"8<717/-C\*N!0DSM\DS:V
MVW$SEJ9C+KON8:+%F+/&H2[1VXQ:XWINHGFJS/&'KT)^^J&L@[[!4\HJ2&F@
MP1;6QA[[XEQ2(PZ-B1;O>FNHBVM8037#H+>4[4=< RY!GZ+(S<\5$,X?&,UW
M>49=-%![+:CX5-9R'IZK;^!T!5%69CBB)"R0K7;,:=/0$3ZC2XP=1>'G;.6@
MY,B")7+H@U>.M"OG4+<W5.6RR^EKM''BFX4?!U5/+<#?Y1+M9"V].]PQ80T+
M6G!\)*8-B;X3DR,&>^*;CQ#%J9947[UTD\2]O1H>+%;ZE#S*PI+U#PN=2P3-
M;BOK5_FSO^#+;_G!OU@>#*3A.PI3UAS^&)M>KA]N/V]+DVK]?.Y3@QB8K/X#
M1()-*6QX02 L.7:RJD^<,DE-0=V."^\@46?MTR^&$0M$QQ<Q,$:@^J=/=#I'
M+&LYRQ#UCJ:F-KG8Y6#E)E11FLHPD13AY'>U]3Z9[=XGGWZ8ZFD24<;%UNI@
MVU%4^WX8+C;(&%E#G.BCTY8MGA2,EMYH'F>HVRQU;F.AKB80JOND/UB\T8#8
M-74@K4#IK["*6'.DNX;SK0T_6+BO-D $!>V&0#NU81Z+[32*WW<-M&S*4I<)
M]/3 =K?,=;G6J&(JH>]D8>DQW5A]FG\39+. C67-B1_SH[+S=;(H .3 ,?4+
MQG?H*M1#/'W:$]"T"E)V5JCU6Q8_.*."YUNAW&+!7E+[=J=NKFNG4[V2N,+]
M:DYEDD\0W"J6M)88R]-]JAF5 \\?**27NHDP5Q.G7 9F5  = 'W-(D63$BL0
M^IG8H$\2Q%LFB_9 \8H5=M0J[.VRZWY)K.'N5[>XW*K2YHO>*@DLR$UFEK4&
M#>C?,H=@,\E'3YOB&&_8+1;^X%]G<E*!RM[3^2+:/HW ) -]T:8QIU*-<@#1
M4YX^+Q)6A94-E7G[6D[E69R-R]!X]H;,I';2EK'CQ#+(\"P#]QZ !&H8<*I(
MJY.C#^S5G(!.$786:67'T,?KB">/$0/2_&6&3NNML'54A^+&L362#QZ*>+0&
M!H=W-Y+3ECJ<*>N.ZA=9&-[+*.)=I')+OB(#%94),BKP\TW&1_?@>>LI#FZR
M$\EG+20&<0Q4:4P,V6*2/H'N2$E=.?@6EP<*(#WZUXF9O=@;.85E*\5AK.EH
ME40FK3#'ADK5S1!B"57X[S]%6..8T39_?S&)XFDQ6U!(*>O4M72T^A6%*@@8
M+\C>*G_6EI/1*HA1B$@#H&W1/D+T6-+<M"'QZ-\QJXKL;;U9&+E%[!LZ-L[R
MU4A?BR^-D[@*U-N()%EZS780)-F,CUVM%(T:&8!A#'&3B?+?C!>I_![T9M$Z
M$9\$]9LHU4;,LWQ27K\H:#3L#.R;62WZ+GO7D^I/O)@>8&L2#E].LF:(E[,G
M/4KH%I//[E*]ILVS0GEG3P!3\-3,K.' >7O'H2(AD_9.I#%<0#Y?WM&B(I=U
MD3Z>&FVS/OAA)/*<=GGK8E9UR>^,):L3LED6U2@FPL%YZF!OH5%;>U1C;Y'W
MF4LF=NY=D])WJ]5:[>\:XBBN,5 P& +@C)!]PX18F0\1&O<J]?X:0S?/7Y9S
M>'N<'Q'ZNV]YNPGNT;I%.T_S?F'Q^_EKOCMP95LL(&<_AY_"$"H7-#!&$O_[
M$ WC6$<W5A"<V?.9V,3D$UJPD_:&*H[,!AA_SWVQX3?W1^+N#UU"M1I_HB5"
M^J8_FNK/5"VV4X;],%*]4H_+ S%"\[3U VR5AA/ULD XRG3UF/(QEECT.JMS
M7WC <F ]E2:2CXI(>\T%T6?ZW)Q.[T^JSIG5@6JZW(P@/O0K(FO11]P;@9C2
M&IFO\=\/KX%);&A J,#YLUC,PMQUE':9UM"..'(;03P. -'C(R5?]L/C@ 1N
M090TGGH6-76_CGY8E]5 =]U(&6))%;^3*M=!#2<PJE7M?)-)6MFSML0B"6=&
M9+,@Z&]KB>4&F=ET)QK54V1 *4R;I'J^'+IQ,WO8*@*+$8SA6Q^ 22KG#LU^
MFTMO9EU@<>/>CFM*F?-8#1G0+AUF,4XN3":, P#UX1<NZ/.O1=?;"A+HJ_D=
M/-KM\TN;Q-^=@\2D;@K*_4;-;9L[?ZWQ3QO>A<\+L[L:)\:YA&JJ051.C8L:
MB:)8*G.UL"'HP=2-'G+%-+KB"BC,98#3-!;D\05-0!&/ZXDSM,L53)T/O"/D
MP9-YP_AP+_(IZ,8K.^X?P*E)Z>]AURH$S,% \<I(P:ZE7H7I"E^>SET*^2'(
M_9WFG<B!,%T;]_<8JO$]?WH/INKOWIC0!2NPZ.TLNN&XQ-^>6_+NZ8JY]SYB
MJG.9F?/5SI1&'%3QW%P+PU\X>XGNR*1$,O9LX*E"%,F0^&JN2CD58,+Y[N]+
MR2LBLNNQ'OW"@9T5="WOR_! \E4WI:%U7W2OE>^I'[KYB=MU)U %,%CYAT6Y
MHM>$2*C_P",3VUNF93>:B+70MWRH<?.+W;T\&3@\<7!4^QBW0K>N9DU"%!30
M5O1QOR5^@6X'55E16+-?-$<Y'5-8?OW*KB0R/I'J3L%*H[MJIPJ(DTD?BF3!
M.DYX>#CY!+B% 5.3:EFKK-ZL/F2P(71/^:%OY0])W2N.X6G*SZF;M57&$"52
MOAVL%VF+[VM^;L",JURZ^+/+Y^9G&J]4KIT0SP%6]+!#P!]XLR3?6T*5%#=U
MY#$N?;JU3<,376+JKU%3?[Q0T__,8A0?<DKW'\!?M7\2\<QTCR#4XKNF:V=G
MND/^#<;]R(*X/::@,#V>;1J4?G@.I+'%IO<?;#.>Z/]UG(;W]UM 6FB-OO>%
MB=5\$\JV&?%;.!T+4@D *!9E/?\E4=3T4%J%*9Y6"B<*D=9PCI-Y=<'HCQ\I
M'_^X$YSD6[,L)?3A?Q/J\?_7#N=>S?X#E,<M_@.8M5GL:;C\WQ^92IY(-(O;
M_ZFN+-EE+$N_1ID,C#T[C/]M/4\5?;A:^N6B@-KR#HYPDS+<4!KA)=D+9?H5
M0H"VY<L,X$ AQCI =M$-CIH^ ^\ H\R7]I][Q#1V.D^>:L5Z$GPEN<V8@;_!
M7]N6O.86\XZ@'9ZW"R/OM;_RJ?X#*&3D[#^991;>:#513PBH'ARP)Y/#C$^V
M#7$#\=6<N2]TQX%8ZNE3"ON.#E/NO@\H0(";O3A6X<HI1N5]CTOVNFFCKSYN
MXOR37]>/VG@-H"9C=@,9N]PW D0"$$!-ZMX,I)8&Y0DM2T+HZZ;]O;+^JZDW
M73$P@3F4^Y[?ZF,C-+YH,UV+GX%L]'ZW$PD)46ZV6QF_O[9NO)9T7N#3;\O>
MX"@7_*;J RK1-YQ*:IPEMQRT-:# W$7_0^/\)SJQCLW\+CF64^<5< Q(ET!'
M\5>(\M4;S8^23)X@?%+SWW*)KHX";R1[$ LW5E5.]MDBZ6J?PSA*.#X"]ZA#
MO^V&;R]9GPX\*\B\2#:<DQM'Z6(Q,&Y%HO^%CVK]YGLC/.GJNC&DXBSN,Q%E
M5Q8TP31@Y^(X.R43DB;[CEQ;]_HIGU9+7]1.UKFTG53NZW"$/1:A",VAMXNQ
MI[SQIM5G!D80?4[&G/>:B@35)F78AL\(!D++Y+"F,LI/!2K*E VT!S$24$^<
M#D3I($:QZ'EG^ 664X*U]ZN-H656VH6C*J!SS[D;H51/K,F:#8@3D'PMERJK
MXT;HY)HNC%5#*JJLK").Q:K*L$)VA$D&)H>0R/) .0Q-"0E]6M%%'<]EV?FR
M0(?A)?*<\@X\Z4B8.7#.BKUYD0ZR<E]B-S@J(4$Q#".#%+SZD9[&KW4IRJFZ
M!,62\'^SB^V)S8Y-3RA+Y^-/UUMEE7AX$=V)OO0DK;/!;EP+A3[(&JEGS+<.
MZLA*1!=*+-TH[6>K&BVSQ*#=7=VN14POPYCE=$MH4.QE8['5K^ZU*O\!&%:V
MK+-;"G4'EDJ&A&^ 4U0HXTWYR!N7 \F_8KW^34Z?_*KKNYU$JKYN7+#+Y+4T
MIM=6-M3&'AG_K&G,8CA.*P=ZB8T(8("8]*T',S\$91W79"@MF(*E.N Y=V+X
M2QVEIW<5,HP**$2]1WRX+*Z)96>E!_U< RHZ75(9;F)7_/\1_2?M+J=3P8]1
M@^0'O"0E@^J6=>SHA$.C6/=G6N@1 ' $>IJP$?"F#5_RPI[/Y^QU!2K*F; P
M&=GYU9^;>+YOS[IL8)-"=#;N530V1>RQ!3V,=]SLBM8[^7$_T @Q#S1%<(*^
M37!$D1"7@=3S=[-4BAPVVZRISDN8^KVE_@$X/6<9-1!$$$=7W2=W/]<E?RQ)
M-9HC(VY?:[M7A,N#E!*6UP<.R2C,6;IC  [/Y6D]42LX)SE*92TYQGD42NU6
M!CNC$&INYB=?UCXPBM81-3#AQM KE$>0B&B0?GK6L6UC_WWCC!,:B!#YED;=
M6XT\112U%_R93ALD8R3)]4A;+AYLUP(26U9K)&7+@BJ,7*A[N8<%4YL)J$].
M5P6%30^"V/F5P3G%N8^^0XOVFSBXNOP-I/PR]42)\/'/B;91WG!@ 'P+K2!]
M6:[0>"H+M+<63O/-,'M:7#U<"<JH#M5R^P=H6;E,GH8K+2FZD4;E#J/EX<3J
M[S'+E"1]R;)4D5+"#X.N6;XY%H)]P*%*,I;AK8E^^\OS?=.^YD]>V6BT',SB
MPEEI:EG)/^<OT:8)//?#:IHU.$.W'\LT:-9J]QD;=4UAVGLZ+G)CJE8L*5H5
M%2L%SA(]-6825&Q0XN 4E0B51^O*RH2E:HD$3 ^<4Z&M*SBOBF305H&LY)?U
MTYLNL<;QAE_N&E*%%1VZ"T'I?"5%QG\<='--(A-K\'BC-2<%AKWYL^[*[4Q>
M\4]PH.>-3OIB>4RRH:KHY%,%)5<B#T1'J6M\AP.=F9P_*,AV289V7^#18I$W
MFY4L&KM-&0^"_P&8M 0EG=H5L7VK8+5[MHJWR\P*5;69_%TX$2KK?MHF7/HU
MQPN?%]#L.+"-Y62P/]"!+</25!@UCO[NUPJ^SZK!QP;#V.[\@=A1#KEO3V8=
MQ%K&013I>$Z,7O1V,LQJA%52TLMPY%]?5"T:<9_A8^W,BC2  &9#TIH/'5%X
M\'[2MD95RUFOHD8C0K,![560<R9 SZ0VH$!+]64O"=^38'DJ8G0BQ(;-\W6:
MKB3$;3>Y]Z\4>=R9"_L-53-93M<Y9O'"R> )>0G^80>:@:OFEZHEO?<W6VS5
M+C9%<1TB0$<7QA3M.1!>1%I+<54!#WJ\)M8@WN91OAXNE-J7W7C14^*-M>A?
M0,+]B) CHC2&E)3=Q#:E8A#H*]Q$%&).Y]330^/=3NF,T*,"KTIV%-I7%@DG
MNNFDH"1^PV(..);NG>TN6\(KS?O>08.C3,1?(]3]1\L\X\TGO.8?_2I9W+(<
M,@!AU^T$H&D$Z^4O/F8>H:YM6C(%:]V6*/X05*P?<4RB\,CG<"XP@S-X$5A4
M\"+]ZS]=@B8IFW/D4/IX$XB*&>9*XB__X7SUOX><>R4.&_WTC(KC.#';&D8=
M:V<IP_R5<!V-B<94&)SU8C> )1-!CQ8,U9L-"SO;!QE'R:1Q.YU+*O@6'_#I
M4WX?TNE<#71=UN*Z/\Y%5&4^Q_*H-H+<V7@E_]8\-]/(?IF8?/Z:3A-8A*73
M+=D3<L5<9<9308H!C J@04_YBD47VD4.&O?0B4N.?B5*]_'W(X<L[1],T1EE
MXXP&[L\D&].#YT2SNPF6*6[!"J'(\)2^%T0W.T H,'"&:E1JMUAEU)_CX1GQ
M8$-OALEL#>+<"W78?/D'Z+WWS:33;CZ;\I-,0A"[B=%FTZ&Y[QTH^J5[OO%7
MWOS[8?AZNP]WT$M3U!F'Z/ ?H',7_EO2ONZ)V>06U%:4$0P?JO>^9,Q>QDNY
M$ KLWZ#>_.(6I!4V^ 0;G?T_-(D.D:T5S_+B3F 3.ODPW[1!B:SC,0A/%(*[
M*KK;DD#,WPF 3VA/VWE:%Y$U%XT9<UG$:MHKG*6M%Z]R=\=7,A7=2O.FF>9K
MES4S(71PK?['YZ8#I3V\T"A_&3J'<^SG>$2GN2%!8N6YVZM5E_/X7XN=W#,7
M9.*K0P+M?;C?%IRYF^=ZQWO?7,!]V@2?>#]TK%\NF^\:"0ILG.?UN_I([9^)
M+V]Z\.AO2_K5;>$$NOGC5--_<9;'D7D%0EMIZ*27$09J 8D9,<JIWB7N!OEV
MXFHY;6_X"?<]EY>WKP:8E9Z">J%SO:$.7R],3?S7%5U)6Q#UO5G=)R:N![OR
MI<*03J2R2? "&;<K"5EOWVE/T1^;E&=9VL2\/&]RN4 <U(F(X"_/ L/D_::^
M@IOFN9O<=)L74T[3GY=\*6>=N3==*E[MGJE.RT/J7-HKL^M:%@R,V[.&=%?4
M!/7+NIU[@K*6WE)M75/P^'92G%% 5O8JJ82!12"!Q.['GREF7:XB,]+'/?'_
M "_8#3U9:O?++UKGY.6SPJ%FA65:A?".$40.#E@YBX(A-?4EGL;0%8B*OGE?
MO)OL2I5!C"W\*DPZ%?'!U=JZ'$.6R\O[ I?80]K/0]I?ZT(<0(RE;GB7BFBD
M9L\ WN6<+#Y8(',R^\JV1EI#?&S$T5-J*ROCE*Q)PB?8#W&A'BC\P/"V*T#8
M=#3KCG&=W$2\WGM7'2#;1ZH->B@V=<*>NK+(&(LNL?5W^LVH,!KE_93,V^D:
M5A7R*&7" >* @KT;-!$\V;_FAV&A[P\&9$$&C?2S&YC-$NF;B)NA?%V%:Y;5
MT\ _5Y(!0WW*[H;6Y.34LN2#W*G-4@CIXN/CZH@T@JZ]YY<MB2Q"IJYH@279
M/PBC ,[KV6%/-Z!-^@S?,07\B@Y^/F^IK,-X];!Y27<Y2DT6D]MWL+/K,_(X
M_&%5 W50FR";X1]@1404<\MADS8D.+QEM(! M!?EA!!P='\9>+;FG5B[78J^
M 2#6DF>4?3BTJCW_#)Y_;537MOW^#)@=7'W'7NXQC?5%JU#^!,%1WPXXA&)#
M(F-%>F=J0%45-=HQW V]!Q,>+'L#QU6(^&[KJ"(C$+, 6@[1$OY6[N/=2!9$
M>DK'X_9W"8^TT!A8JT."#I/B?C1HZ:V' MWG9CKXY-O)G-L;II3%@+.1?P"L
M[U'9"/NH<8ASCW;;C]PB43)!![SQ$2QK60-P6!H^>:!T6&G#Q^Q3:OE\5$N2
MZIP(VYRNZ*7-XA36-H2Y7)ZQ+$>77B0Z6ICX;OXS-9__I-FWEJ+*HK)<ARAS
MM9,Q@GU+)>5#)<^]EU!#H B4]$E?/ - M79+@REI[9[8J5T,L2=+P>*MR.U_
MI6R^MNBJN7HR :IK\/L'@#9M2@;EQYKF&B+XU5B%;)-:V*!R0[^S3%^-_<94
M_5)?[47GBR_UR/#Z/ M%2!(/%?O$Q2K0ST!]R!E#@U\%JH)U/J7PG' RC( ;
MFC2T=6+7_.1@JJZ*DV.J3OZ6$)!M+E,\_ T%<RU5*L2GXWMV3)T3#M,2E$=<
M"_&76D";F+2-C:0B!ZR1/'+Y.W^#":^QK</DBP__^BE_VDHY6?$595"%/J\N
M(RJNIX= ]#XN'2N''21JXN_F!=.GJV%EU(&B; GR8>7,V ZJS(IH_M##*11)
M959"J9-6+=JVSFW[^A0L;KWA(4&N%#)LO/$SO28W#F,1A$&2K1?U4#!^IVK(
MB84V7M<:!PNJ;N84E<9@=^YA&"MI4^RWF8.T&"CP=RZHTS##,7)UETRGE7)F
MTB-Q\D/VF=H3N+:H JRMNPR1]^F6=>*%&QEIN3DE78^HL\*".F.94[)J2XUL
M+<#\&Z%!N?8PW1]'T;.E[D(3!2J>PR554Q!'UB#HFK'<A"S6#FH)D3CS:V:7
MVRR]7]K+XMD_9B&0%?O7BQ(]' 9G:*/IB;5M'896IZ6:?ZI<ETO=7YE=+_1S
MVZK7*E3RC3"6.(Y11P>,C6)=_=+TD!H:A^M6U"VQ(.DMD-O!5Y<?4T;8"%%0
M&(/4T?BL@O]>AG#7,+3-NA?%E1F65]1%E$-4)BA9!X;*FP_5'(#1L78 @$">
M/T3[,_0 #",1P3^<(J<?1(MD2D"NM=FV&!N35%1P UV%V7G1H]TR'D+XWK;'
M5E**Y=4*)0,-8793KJ?TM")I@RHV4:(!F&FLYRO?%\ W5JJZI)$G CU7UCGY
M:Q8547SJ?\#Z%6%1#DLJ]&DJ"?D/;\*+R"75+#M6KRSC[1,^<8Z:\8\8J:3K
M?'Q'.S@$D+%$ 22,@9R:HO30)\ @,LF8 2B/\HQ&L_E!G@X].\L\X\%P<>3#
M_9">GGQ@U+ES8_,R6%M_ ^GCK8>V!#= :_N0QI?HX\O;XH4YZ!8 ])0T!"]!
MF#O3];]OX<A]%QH33L/NFQX>9]UM-ZD7,55=\\1"L5+#^2%#H:T>C1XE9U-S
M/]2JIL<\2E6HYW/%3O+2JI1R.T9AS*'S^MU9=JDQV%Q]A$DU!BJ59N2\<SWQ
M(Y-$> #TRG;\5.4%,-(+4LW?.(A2@:)(I%N*%@&O[0F:AD)K!;E?YXG0-AP9
MUG(PPI(76//?J.N+A&H"TZ=S,( 9&8>1QU4UCKNUVX<1JL!JF2T (,LB)E+@
MKX:>N7TB">NTJT+#+A=YQZ2YE(#WYE>KWJ5,LLE30>:%1"A"?8:BK+XJI8S_
M[>:=%R>+ 1JM*)[-*"_U1D<\-J]<!(=*0O>Y8U/D E]60U9U&C&Q&VH$$)7K
M=6_HX^Y)$"4'5EEE.2PEC@0KOBT=J!)?844*P>DB9Y !$+A+BEQQJ$-U;4VW
M'C[E7U$_>W^P:BG\CE6D<6DS$J-LV"]A@G_X(/*:KNJGT@*[#$=8,SL.<.P#
MX<=BYL,1$"HO9K>D$J%&P]L]=8NC(&7@F\ .KA\<V.ST U_Q7[]X+^SZ$.$5
M]74/.SKK<GS4#FB+!I#1%84'HOT#O"_NF@6?Y(!TC),P?%FAW!O;J6%!FO0-
MPY?:VV\+2YZU]A\V25FWU!(6FNVT:<P.07Q1T3SK8TQH0)0_R!EEDZ#J!<0'
M]/0YD0"^BQ+;#*(IBQ2/MEJR*%T9G&/_9B1DUK ]CB&L>)F.%SJOQA984Z2@
MK4+/2%Q77"<%H TY)#INH-/^49K85 + Q>D?2-D^GPKA\UJ(6_K>J S8>;@O
M#@\?!#W9?GD:"7F\I_O]#]"_V^ #PQ:791$G5-Z]&HHA=)\5?OC&#[T<\5IX
M-4, E0CW_+E1!.HZ)Q9/::4=\/UC"Y.[>FIF%A?JK=]>O3]_RW!W21LAPXMY
ML.3#!(@\WF7=?'YR+F7CZK(_D8L_6?S!LG.U2<PV]C1D>6?,=$#P6\I[D:;\
M3CXY__]0PNV0P1<A<0=_>0/7[+XML]9YXTWC7WT7_>!SH9JEC;!M_V^NRR]G
MI"3"5*-I72NRW(K0;QWB=FVZNG-?P2HK3Q3D3YF9EQ1)X\0H]+0*-U>7R2D9
M&V:M<WEUGNTS*7,]#AIGW-N]&^Z;I;7<0K7.)A=]O6O<1$[/-&$UW64AVP?!
M@BGD#4+]^=D*)9TE,)AAZ40&><9NBF33HJN%W3;L5\Q37)63N.\&S;=\O1..
M0K3JE+QY,E6,GI_&FPTSSV9EM=;&^I_^P,R"OFZ[+6]X 5-FC3R[]%:6YM5T
M!,;4;:&!0#BQ)@VR:6.[=]T,L\JOW^G6]Z/[_:7*PJP\[-8MIS1EO>H7B9Y@
MNP%%];G03\_7I$SZ*\NZW.]QTH8711*(>$M&18])":[F+?NZ7$5%;_J6Y.%'
M/BP=_TNS#.^0<FO_/>E_3O=]-_U^5T&Q]&!0AYL?$LGB/DS7_R,YX/8T3,)P
M]\O0<=+XZ8DC^TY+1QF'<P!J&W1BC:Z);=#!CPDG$;>;G@V(J,Z-LY+- O=9
MY.H)RBN-;?V0/W9^(VU'CVV\I7/;L>ADDL(6TQ'+%N%GQE#NJ]^_1.&7,9]+
M9E-]1_9AW_D3YR3Y.ZE]E<_FO@JE><:J/FKM>NV: LHJW_61:N?\L5R2?1V&
MG5_,SW DU5K%*.$F^(5U=Z^JMXQ/SH.4BAH=88:TQF(4UGVF"^_]\A?;$[9Q
ME)R)I9Q3&WYL]!HYHS=,$\#>_)%<^N-Z2@,^RZ0(+AD65Y,;)VW7H*DH/<IN
M8J2QX\A$U'.\I(9A!D@1IU:X)W\2@^7H.<06X2U G,TT9/94.,MG? 6]#*JN
M0P:;VPGF]'F7LBYAC=6.L$5/?<DOEY\A$(6GCWV2PIU-F:;K0HNV;<L'4"Z\
M( ^+N_<KF\?H<-+ K UUNXQLJAI6Y8!\8]6SNW,RLV^ZM2'%F@M+[Z'ABJ1Z
MB?8E* NRPET9C WF[T/QVU:/WJ_.^VL[(XLR[9_^ 48*+KGK/=F;3/X(R4R'
M0?H\<* +<\1:,#LACNK[-[W&,@YM?Q4%AP73_R29^ZFY7RZI#P$QRVM[E<F3
MD(/$&.BAKR/PPW^'-VY2K5UQ\N$ X,55+1MQXV^C8OLZ" ;6MFAY"2K"YUNJ
M;@(_SQV#&G/BP5ZSI.UQ$'WB0*P:&V[CR0@/65F=)K!M6F&?<VI\]LKW90%G
MC=@+ZW$")AUYR8YR)_]7[4S787*J\EIE[$4R6-S@.P51'6K6675* K)K[R."
MPZ,F*Q;=B7QSY3PQC/VL*C?3V'0GX\^>MD4>ST95<P;#Q$YFE5?^ ]3+O\'3
M7APG7Y7G=1/U.O4['@KKG(G7V;4U^-E_4"7ND V'K- 1THA[E?<8">(G+9NX
M=-\_JBZ=WS? ;D\=BK1U*$?\DY25@SHG65Y+&B8F.AT00&@H8/K%#8O*+J:I
MHE/+T&.?.S%Y'4A+E1[T^)S2@8,P)HOT1Q8SNPOOAY@LX1^_ I<P>N)PV2#1
M4U^-GGC/)+&K,./SM,077_@"%+5_N](R!H3J"N!(-"N4,A3J9<;VFE5QI%51
M*<K1"NKJIHI-,RL&<=(J\KF(*^RHC52%G_!\KNU:_'/'VVE63L ZJ0@V5VX+
MDAD__K&]$<D<\C;%<3W+@\3UXHC[2*ZC$-O8Q!7'C%Y_@5D "-!(E#48V/TF
M>IV;^3[3%54%I!.?L8+$.*+?HKI)R;EMF,ANV<1M97R;3'X<KW,;%9*1&CX[
M&OIMV_GTU6:H<M.VM _!5Y^BF(-A(B:?R"WXI70=E5K,^T4E,R!ZP($!.AG:
M>6H(W?]$($HPJ CM)0_1=I$Q1:S?4"$L)$Q?4[J<OK0H:@*G2@,R'E,(FI^?
M Z7"=N$U(-4)3)@^T34PW<WF(=@JMH9!%<H]C6S:%G3'IN8:$26")L?2!U+\
MY@^]RGA 5L'0V7+BCXX&E!$WJ+S?+?))H]ZM'']!OT5F)/O:_FY3EU3/G DI
MIL6&]Z<R;='-2K?? CM[/5_91-FB2 W5 ,);7W_]30@0P"PA@O_'4P;5=80)
M)+S:M6$E6OU=@W1MR'Y/VJ! ;!X.='P6]\&,WQ)^9RN/<0=163T$U9%T[^ZM
M.=Q6#ITDNQ:%D4:U/(R)J\ZP[,;Z:R/6(DA,97E%9*&D\^GZE$^;S^G$HA8'
MNQUX"@\A5#K&G[=U(^ #T;:;#ISMJN8P:G*-@S!-55=[P+*I7IGZ#K,H9"1_
M'NHGN%-.-%ZDG\L3YS&WJ18D#6*KSJ&"3F+'BNI9&%^#^^OLUETY:!NF.#*A
M>4%*M-[.B7*O@WXUYFQ]V_=U:]OI$ZV[H!3H#L6ZYS9K,K8Z@XIC=*J;0#M*
M;YEW\B#4>IBF)HVO,=9K-03Y:FHL%LRS,$9/%#$_K3@FV]7R_W@LA8#O(;5F
MOCU]3-#8(0I[D/I'DE$ST]@8F)8#WE?8DOOU LD!R:/KNR5(ZVTRK= CT]XW
M5] MN&*<?]MN+]&)\_UE2MZ/]YNMKEI?O/46!$WJ6M[F\C34:F";*0P9.:3?
M?533G2GG-E-4,LFV]RTDN4_8ZLB_L'%V$K1[39WG;F!8Q[JP65K"0UOAWX#Q
MI4$DZL'F2U6UX6EV5I52;9N>%K4[1)X1IN#S0.D22\JR"&NGD:J>6#3>M,_N
M*1P!VW<'0S]?_QTL5KN]8)#WT-S3G<A,TUU'D>5A'IV'FXL^"N8_,C?L+&8)
MNAX'>;^'N4C/;72DE4YUZIU(C)I-W!@KKW-60794H=/!KT7:!'2SV+/ZE.Z8
M-13*Z[CFBMY%/E#'CS'!.Y_%UN;HM^ALJ,/IX")7O3E4E:'3E;N=E92%R@H<
MEK6QA7/J*0T<XER1\7!!=X_05F3W+,1IJ=+@&W&)@FP^&N;&_>72?F)V=,.Y
MCC9Z%%;[?7X(3Y@-T<852,U!M2<OL6N!TM N+[#6WK T$1V\J*'#U%*K3,RI
M<MW*48UG&$NCZ;GW\QT7.D,;85D9<1HQ-GBI_ 1;I9N%'E7K;:U;PL*-3]M/
M/]C31\(X(R=<W^-"7]F.#:<V#&XXM2DSEIQJYG\@4)+!R_Y#W^9,>J^&5?L9
M=B>:3D(%T5K'Q*I) V>%+]-2%,ZD=3Z:2@J>E]Q#3*[I_GQ L]FK_N%IJL_]
M=_JMS,>D@PIX_?2P8*%09_0+5=,JU>KO']?9!-FU=:/0"<4R5)"X+VG&=5P4
M=VX9E;^?-3*979;"6(YNC1DC8T2P78^=!!23[K@:Z KD?TZ03<SCJ,6P\T=K
M7OE[/>>^9W5\;O>#'81BWS7,3'9,774ST""ZE7T-5Q2O5;(&9^FG>$>%KW?!
MJ_\ A^ZX[8IR>"1UPGZI#$ ?_8W,;^AC EWQ D+DZZ2WMK]3Z6]==BN5HP/-
MY+BU9V(F;V;?:"\,N\N939A.3";*WJ89RT5%8K#SIS<T[NY<NLR)GC..JZ&.
MI?[4<Z],*E+^$$WHETB.8#8Y14F7<>?JIA'9\3]HP<F<C>-J(\%1U:OWBFK)
M.0"G2=FB;.'Q7L9(RY.K"=*IJV\T.^G^:7M!<:G@)Q%EX/G:GGF/;=R7T$RY
M>L'4C8--]6=D_>Y1F9"V/L_$QZ>H,N?=,0W&:Y3TS6M949N'F\5H?9<G!8()
MVC>K,<Q25?SGH"Q[3B%@VJ1Z+&GX-"?P:KHI? _S9W]^SJ*%QG]*\J/4$&7=
M=S,'&/M"(ZK9%.?9)Q7UX;HQ &Z4DO!]RI/?SI"!AG*/L;#?O77IMJ5SX>"<
ML"'W:W%+]JHO;6&94,>"]-% MI)XO%[2^*!"RX#FJIJE.%]:K9I;Z)(,OD,N
MC9I/K=&>$/+=BFX;L2576\Q6!JHFR?&<^W#2^L>ZKQPK+P2/Z^J+SN%CO\^&
M)2KKA%TSHW2=6[80UZKD@0#5FOSZ:K]PH;0JK<\)T>4/!HINKW,O*5D-#'WM
MFIJXC:RZP::(R'A[0KV0BL;;+'J'+&[PD X%7HM"!=%JB9WO'ZF [QPM2:,?
M^2MUPX(22VLS80J:< D85]O>&^XNP@/UJ#0%F\^^E8DK131'G\8%1S_/ML4Y
M1\!P:&2S5NQ2I1;T.L](^HV=*O0A;*,3M7I]FGOT':=0N<1WQCO5C%&UJCW#
M.'JJP]=*NJ0&F#&6UWC>A[QH@W 3>0KONACFK&H P%@V^C?U1IA2\*8*J0;;
MN';&4I%&O_\$4P>G6IC["DZM\W'5JS+?A+E<$?AXO >-+G0@=0T_X,]S4:=Q
M2!1L&-"$"@2AR TM22N)$KU,*7CSJT+$'V1?$;M[TSSG/(\A2(5U&AT_B/7M
MIPE*"IKNY+)F,W$-UZ#CV4BAB,YVTR)=-CXS@ D[P5ELY]K$V)OHY@.1 @#X
M;)(1^*A&?S)?MIM8>?>7J]6:A\=Y6!%^ KT-$,SFDZYR,"$S^%QL<SR;ZCXI
MI7"JI@:FED,"Q[_ZDQ5%[':>KJ\%=N:K_F'YP*5 ##ANRO>!K]Y$H*2X%EBR
M,\W>T^;>?%G=1T-^M087R&+0*\3G(.[>7"8HKI.>K5[\ W3$)XAF! N=\Z6G
MUD%,X*G>BUH]6?Q[&S5L!A9N-JEAO#W:Q9(YC/+Q?9>G!P2=VP\VW44U?*W_
MNXQ3,5[KSX*S3Q_N79ZB>L)C.DT:H1/]=4(5+P]\+Z%I-JD"7\YR*\*[]*1_
M;FM]*C_+]UP+^ ^2&<:<9W$0'K+[;<;Y6>7;ARTJ-9<+<=#JTN*6C]#SCGLV
M[G"PUE?=SKI_ $__UWU;G/B%7_V.;&L[=7"IA28%)R2##<I.3]T7F,46=,F-
M_>0ZT?@<F;H.9*,O@S5YQ$&5-:FJ)]5WTXI1=28LQ:TL3;4+F9\I7W-#:O6W
MU7NBRC7FML]XA)W%T5>M#)B+H,<>C5V+FWEYE!L3>9G9#KRI<20TY'P*TA,H
M*V(.<O<-[3W1^F8G7"NUH5<EJ:LU]L>2\C^Y/>;!.H.4(!TC(UYEWH5%1:YK
M=*]JN>:W1F1&)OD&.!PXOKJZ8CD 3F<3J@7<1@X\>A6MM^"($7/GC4*[MJIB
MH9<AZS\'6QIP\@-[Y$X8K+%[4KGSB6<= T?@2=C,1(]S4L+9,*B_G#N+%ZYN
MA"JFR#QA,,Z;Q=_FO(V;'L"D?:WMS34X3 J E<8MMO?-L^/>L2M*@E1.N:R=
M\BMPQ/5_0]\U8=->JQ %[($(\=)C1;:1\ST;[P4W6E9A[I\IGV'?RUK6@;ZW
M9%WGF>W6.3E6*64-1UT]3;D.U5!C0QUU;@V&M%P):/%WO-9A O*[T:+Z+[YB
M#M][S/@7W^L!NI)FI98"@W-SOU3;LMHDS;=-+HW9#?_R!-G)_'&I5BM<2+JN
M^WEVJS<?^"W.T\@A@4[E%&GMG>RBB2J0]$G>L7ZZOL#I*[2]B7K2=+KVE+WN
ME..$1D/-[K2"/2Q4RD!'/GB[U-^H<\- ;6[3/2A<QZ0H30L2\+[MM9XFAX-B
M>NZ/JE=&.EX)>%!E56/R18YZD6*W*0FIL(2X&D?G&OWL 36[ 2H.;"IBH4]8
M9"U)/O 9L4[G[>I N.J.<8%Q9@VS*CCE![LSL+JZSA.XE<&"35[@]W(I='"L
MIL-2W-]U1Y^BE9EK*XLZ98=-$M8RHNU@CF'WJI#"Y#>2VJA$N,+%:",O;IY?
MEDVWHEH62$Z/^KKJ4,PZKT%/)@OV$4M5X0(JRI22P;0__M.S2O.LP6>*B&=B
MX7W)6Z>6VA+>U]D>>EK;IF^.=P=IC,*9#9H ,>L2V-L#S>*6:8!^&MN#S)6E
MBESYDJAR%BS,;O5\K#\/".S7HQ=%Z_)6>0@]7TAB8*Y)CF&6-EXWUY;!X /W
M9;%[:YNQ>M>37*[F4CKPJ=%ZGO80'MAT_#HTJ-TC)GE"+RTS"JI^^]78_>V(
MGDOP^63P1J?.*69>(?#H2<R V?F\Z>;X]>H2ACF?1W4*!898,8D+501+)LG5
M/P"ESXY9W<!B9F#0M^XLP2.[]1%.Z1G'&RM.UPGGRG\ D6SMI@T.8]4(?R<A
M8TK/;V5/(@&#=1*8RVU/B7$U@2GYTUO.T>:.$V4<_!H&E<7,27"NJ>N-B%IE
MYV^5=Z!)YQTG3;#4/NB&G:8.5C.^WN#%7+T@G-O(JQC480#1T&^>):PE-JF+
MHORBJ,5\AXC0;>7 6NHE&I$[EO]=5B6VE/NJ8.;4T9F:!^D<5=O 33RBH4%U
MJ=UU?RA'D-,AG^**PNZIIJH M E\TG_TACXJ(BK[YWL\AUNK#*M+9UHH]4A)
MM>WR4MG*9FNN=V>(?[ISZ5L>66B:<P;Z+$V)G&8C$EEA?6^^"9TFXH;8_S0$
M::'9SOZ)M95)SY[1ZR?3U)0!)OF>^5*ZKBQ49*=A =U4$C:TB+D /\4HNN#,
M8:80+68<7T7;8;8)&Z=#?%NJ-\_N]+L^#23Z[H75/9 !2>" <^;A)"-_DM*4
M43X3[9LAHK&:TPC;V89_ &ZN&@/ZM(P%9/FG+7]>Q:N@^A'LJINH"S"H*]52
M89#ZF2"!/,EXL\N%FW]5>*:EGF/* IJEAT,^)H_G@0M5D<(>I/E TJ,/.^_-
MHZ=%D2H]O[>^NK06-S'SUJ[SZ@,U"UB+*2B=4%]COHD34'X0H*U8\MJL.?FO
M!LT9F+G5B33G-"EP\8E3EV_ 2<!DPY9#[T&KI8USLA\"YNXY:5DR&RI;6YLK
M,M$"J-S")_&_G/G-4,'][2?8PK=%S K!MU%2 2'66T^BGX9TI?1EL#-U$^@!
M*(?9:421Q3613+1*8C#SO(!!5]D=>P*:>F+%O;],9*#9Z($+S>FOJ#F%BRYO
M!@&Y1_-+^UVKP:E.G3IJXM,X@]3N$BV)U?-DI,FYNYF1VHQEXL0+; .'*A23
M;4^^HYTB5]=S&[KM#6JJVID5I&PU:A&9,$9=/4M@O@W;-'7@_<G))N12 N'*
MOZC!#3?S'4'O6'0M]UKI)"N)8< &9Y<1IW.@D9!N&7B<]?2,BA>*%%6YWXXL
M6\W?4T;5"S;6ZP=DGT'4QO>K.Q;Z1:K+,PK<L;U9_P%>UU=&3_%+%-)R.2L>
MZ[G]MX,A1MNW;/?-2S<OU*G:<5RM_4<[RO&/][C9)PMMF5):V26*BJZ2TO,2
M1Z72\EHXU M&P0WMMV57&5IM1_4-5DYZ[M'_B2!V KXJ]F*YQ)]W;J6JX//@
M9':">73,-!-1/^4<@]Y@FJZWTVW+3]XFNBOCW <<L=!_ "XO0@ZKNES[NEBC
MB!\D7$8,D @FM(&;E9T=K[Q?"WVXD(2R^AIC8QXZ><O7#0W-3PRJS?<13 4>
M949L%?A$N!\NC+IST=*OB]RG<I*,W7IZS#L@^AO/3VMYE)]V/O=NG&?2++LV
M%&9]-G8T#!7\Y.6:Z:Q/NOP$%%"S@#SU&T-9ZVJSLZ,T#'0\KOI<H:N.4U=!
MQ\RPP VSY/9Z_A6938O/%7+>?E1-I)F@V*Y2JCQ:ZZ6X:>OMBR^HOFZRB(Y(
M]Y]]!_9.:K+Y'3=W_P#*2/><NM7*.\@XI[_\$:D"^U!5N]B ?7)&[T2M8:55
M;5Z;+=[\9F7R=A]NEYB\EDLH0\W/RQYW/6/V+_IJ66_$APSDC0BA4JK[P*KJ
MA#^+^F#="KWW>IY:( ,20=Y)8O<_W@WV2[JY*>:E>HK&D^Z+ND*ES:,%Q'BA
M%=5FG*XRW#"8BK'<0D6*S+(HOF>9+ZTO3%#QS;I2R>)ZK))1OET6: TI:,9Q
MWX BD[WM--A^ZIR=^4-23SQ9%]*%P.\X@.8G=#TY*#F%RM?=D0:6-IU\DEQX
M#FK@\_JC9E8;5_G#0IOIL($5!E)^'_DF0U03!YNIYH[=+2JQE;?>T!X:!2WK
M@ T!!;54%XH"[5%8;9QT-GC448"C#(=MI$]5DF/O.Q15:[?.P ZB]O*9.C 0
M3NW4C7-'-1O[]P04*5^U\\YN96=[$( :7"A5L$)S-B <'/:N<YOY/P\/;-AX
MV6WK\[7KO7TI3/$+MJ_8>FYO5&CLUO)+$3EC.U]JE4N'<PEF]]2Y2E1R?LP]
M%#,0O9*M;-W6T3&0KZC-MACW@5&=P4C;@OOYS J76L"(T5)L_+9)9\)8YE%3
M.QQV[P[?U<0\JI_N>GK[55'K^HHU7]TG*"C"X\.$C_]X4_2TX#VV4J04_+[D
M:'2=D.BC,)GA@+9\JZDBZ<P/2N6%3='9BBH6N%.%MK_[NSG?P<U9]FN<C!:Z
M:F]"DL436\ZMHVL9%YQT."JOIZ^E)P&E5N-4&2A*6'SB9!N[_KZB!5VTFQZ0
MRU :^L \JXXA4<$T%6@/[#I=V6?1A?UG4-H_)FZ<#1=L;R$LSFADZS@_-=80
M'*\WF%NRYX/'(3X?I*Y/JMD7 /^#M:\*B\*+OAU@2)480MH!AIBA6U*:F:&'
MH:5SZ!90E):.(224'&*&[A 0$.F6D!!I!$1:%!7O[[[=AWN?[O_MO)SSL/=>
M^UMKG^];F[*\U*7P#4[-"B, <+1XY,NJ5AB@PWN>UWP51J?#JRYFLH.64L$_
M<SH5H2"'T)*;>1X<+JBM5CRF VE$/BH7$^)9O=I&R\42J_+.5-V. J[S9")I
M[?1^,?](Z_ 2Y2:@\@Y#VP_A^E">6.'(. <J0"@Y%<4#S^1I#^02PW]TB!)2
MF4D,C/;>FM$>\$J\VK]T,V)C-Z</7!<%('I^L6M/;(_IW9:65R%8ETQG.NX)
MJR&+5)4'Z[%:JH ']G_?Z-XBA-J(7_OXZ;(58!]VA07]"26_=VOME-%:*5.=
MP$[2K[1E\. Y@WIXS1.=9_/'.J1>TAK"I-;" UQ*0J?RZ8XYA9INNUK\-&QX
M:D7&\P"*KZT/&3ZK60:] N&$6\M%9+9,'+++5<KABK3%**?O3.\O\R[FLX5,
M=J^R&;);IGAOP@AFKRNK*OV:H4&OEE$<F$&V$C=SE%[_:PT]UQ*IP&O"&TQ+
MD F;<(?8D#/NK5O\^E)E'8Z.JWB>U9V,B5 =KEOTA]>^+'K!Y<I]LP/G\.;/
MDN+-H]VD4(O%I.H #?>*2/_\=P)_UBT,&YY0>2X)D/PG .2KY5DQK575$Z%=
MN,H1,[NO-!5U#8["/BH_3W)0(?\ F])&.M(W+ZS^ 907Y'1@I.4NEL862O\
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M /;!Z]D"P'3'E[]#+W[\&"[R[@[_<0C=>3B*V/;[S?WG_&[@T3.KQ&(X@-A
M'ZLPFC'8_X!=1__]"6=[F'6-AD3H2>\*%R0C?:5B32G^^L\_@,_)(>OZ)126
M@(+KKR9<=_Y(6TB8UT$>6JRK*+M3$>O:!NU!'G@+I_Z^B4UI_Q_ZA!ST7%4^
M>>NSKG3T1>1S\,? ;S?5H;^]<OJI+]T2=;Q+<(39.7?+T$/AQ%=6;PH3^_'A
M/ :\O#L'@K6_ C]_G&MQEW3O,B!EKY! J0"3.&E";I5#'GOJWWC9!K A2F67
MG()01U[5:QY.URDLA)S)*JGS=:^6)=95W07N24*MC)*ZZL"F=TWE95U./G1U
M]@K%%P?'!1 !F65XJ+]HB?^GV>4*;M%ZG8)OE8_W+#".M8G178)ZZ*QZL8@1
MZD5O)\H/G65_)9"QRW)2F#RJ,Y1VUT\B_9=7+@ZF:9)CHX_]N/G=/WC1(CO3
M$)*A/SG%J5N(YYSMQ=YYW)AX_.Y7[ ->#@O<D+@'ZO&6LM4UY4FU#G4*N!_/
M<ULF9A=^D4?\ \ J"'_9@ '22MKCC_*<7# VO*[Q%T>$0T%WJC\$TYE#*RIU
M'"\W4^YE1J\*= V(NT-)I":N]OO(7@%47D,GL;Y!&0\8 &9]B@@WVU =_*#4
MM1ZX>Z_M=T7-O/SY)",(K>T5G3)TR5/]2M+,T#)C\O&F2XH<%;"*[MP9@L\H
MV[T7ME<Z$W9;_:$'^LID7^ZYWZNY74[(01C8V-98+[M$>#?_)13HA:\=QZMA
MWI3;UJ*/TV.^X?&$LF]IE*U,<6?5 TB?LK2$KK@T]?T;'_FZ>67*G['YHMZ:
MJK9O:O5=PWB,N_6_O8--56=U#0E.S?,U#F;73Q67C%\@=)J[!!&'=^3J9EA3
M/QL_2?B/YLO:N^/:%U!2-<J!:[72J!Y?I-P+PXJ'A] ]C9P*%@X>9[:*_#,/
MQ-&BX:UFP4?3-TG&\W>43;TT-+N[7O?,?%:'"/KKO+USQU#9>*K,O7&Z$!;^
MX(_.:8"X-5//7%Z<_D#1^=?FO1D/J3WO3-YV_[7;7+E7"[]2O$*,?XW4. NJ
M$,HK _$M0E?"I>BWVIXE3:JDSP2:9L,NT;8U596$_%Q-Q<(LWP[)069U:47_
M&XD %L6NM5P\E=:5 AB;#<2C0+AH,.*14T&4U@:98AX:JB*!4'U'8*!!2(*3
MS.G$S]J\+IQ\7K$) R^,#,NG0MPKZ@MGY;5Y25% BWNZM+ZI4A9.R5K(4SM?
M"@=M_>;7+;%XJ.6/,C>XO[W*#\@T(%OS;UEBD"&NH]/KCEK.WNPN";<GT8IJ
MUBE*][)EDR/HF-#TJ[)ZL:T"75H2:7EL8NT/A;_D9)XTW'2,J=HYCE'1DE#A
M+^_$'U2!")5%SG%6R)QV#A2K5]L,+S+(P]"+4F]71T$E(6&0P)ZR,K8(%6C:
M73"=[XC#0 ^@Z+]6TT(Q;9\5A-K:WX0ZQ93<*]<Q@@!"!I^4?Y1]^^&[%WD;
M?5M31PT9=O-)&2%_UZX)A?<.0JU7N.#RG5!#;_"LZ(R!87UW&*#2^\6BC:@T
M0<\E_C0,6R0W'QKO_TIB(3"9JU8.=^ >58"?L)ED\1FKKM-Q]T.[E8N"NQ4'
MZRI*2C1._$,<+]U*3D>3VX=>E+-5SZRP04-K5KE/MWHPK/\ @W_F(N%59:.8
MR]54[FJ1L3=5.@*3ZQ.S\!L,3<Z-Q UKMLME_0+U[+)PFX)W88%NV(4E1HGE
M^[EA#6.KI&1+MG_+B,7\M"(V6VU'R),;91)VU4.9;N2FQYN!T6W#B63RE]U]
M^9@202#X#<.J/4R38EB[E@YA=^RJI*S/YTI!#*$&0P]HF]\Q=^LOVO#N3WZK
M7P@E')&2B C_:.KN>A/G_Z=,T-F)?T++(@OU7_K/8Z 7^K:6H$H&DOKR$\MI
M^%RY4N*%K:>[%CHN7U<_(\PC/MLTR$Z1=,3VSYKK?]!P?":)>O%PU9M8>88+
MLKX_I_V]>UA]-W'L:X+(PX%]0G='0L:/1#Z#X=4ZF5=O+K_TPE[)N7FW-!8M
MO)T9UI'R2R9D0IXQOENT2XE.I]@)<TZNAZF-S<5RZ4C45EO.P?= B%69#:*)
M"8K[K^8ZYN9B.R(>M363?28"TRJ5E43.QB_V#!X)"!SAL7&A1^:(0QKC9*$U
M"E)'Q\MZL%6_H5+\=&$;E6YO.AZ8GI7Z/D*>F?AL.F"5(=5)$&9$7=Q6"DZ/
M<JR=*-SQZ^OE:<OX[A-:R]J+/7[6O+HXKFK+O*F#'B@1^&2_JV&8'K9+IQY1
M3#\F%K*=TNJ"R)HWQE,\[MI"H=%$R$1TM@;(]=N;<F-?2O"=]T_T@3*M*.6S
M4!C"QY\A SAP+0 H:N0O*$*D^\G46)]8'$*M?1AB"GD^/I'&9CT3,\E[M: .
MBE(AH4N_#P, W _G\.HQ+1UK(7"D:X.8:KK+T)^S9%;V40HUN"H42-^J496[
MMQ;_\^F3U(*#M0$/ OQR,J[7G<UYDN_6_S$FQ7CBQY]W=Y1$>3:_T\4RIA+2
M<1+"DMT9X^CJ,4XECS_8).7Q;I[JZ=2<\0N&C_-'G_6N6&]>59WSKU[,8G=K
M=B]-6@U,76HB7A7J4%5@7EG8+^ KCVB7YA\5+\T6F%4C7(N09%*:HO$W!?HB
M32_[']!83YSKMJ5)+L[7)TH?"6N:O7$)M;XG8U).F+<I+3.Q"DW1LQ;6\V+S
M7##:I9GOJY7ML$QI3UYTGVSN26%T;!WVF#5+LMZ&CWJT%AJ-&IO9NN;\O7>(
MV0MT3BS!\&4%8"UF=S/2]/9O)4,D#=)G#O2XJO%5$KI-;PAA6IF55SI>9/E(
M%<_OH]V[M>[KVU-=#.V%(HJ'.=NQKM:3M]%?=/_:5UVD>-5*22Y/$>8[4TR]
MWBR9>-A2O_8['"NOJJD<7WBN(]02$0?%8.82W>6UEG'E7EW!EFI.'"^?>PA>
M!1>7OCUP7V5*+V9H^2$X::W9UM;V&S5D;&5]SK1RN%_25MJ",6!T_^";T:.%
MS6, *X<]TS_=;7LG6YTKPDVE'JI<2FE!A@($\$6VC(+H@1?+K>'$M]FUN.'8
MJ&(VIKB6TV,N]?K+_$;*:]!S'GIU9X7%XE66:JGCH+]U74Q'[*!ISYKV=;Y*
M'#Z.0$D NS%]X=%1]RM''.Q%/<Q_9+&5,5-)"%MO2F-7Y*TN8^C\4:8NTO*Q
MBJ:>9]I=$_F8E-)K9EV_N17*?PR.RM-]4DZX(0H77A6>WWW.-/\1W79HJZK5
M<[I;F1?4^I+5/V_' _)+A MSQVM0&*;69PCE]OT'")[]O+[LV7LUW;H:4%TY
M7W"GZQK^G14YL]BCJ6[<POKCPN1@LA(S]P_@V9X0^.:\-^B2-?:PI&T>@5!2
M'W)X^UCDN7U94%O&2-!<8$7NU%1 F;2)I5F61+[0XIM)Z2+3;K8_^3%FLW,=
MWRULSK',PKRS^NVLHF1C[@28O,(!Y:7WV:O!?X"RGV?1'SBHI5S3;&B<IE!'
MR.TBS..I@@]%-!(P'D-IA6G,VHF42X'IP0K3&_]&:4)%@*1#86V7NB'GF,2W
MIE'9CX\/A/M6K =F9=\8V;>@#C^SX:6V/\-\F.;=Y7P81-5)5=/V'5W%$.AL
MY;R=;S,MQIH'$%Q@74!9X723YQ=N@7#</HNSM]5>27G]B'3@5-.KMI@O8RAL
MQZ8AO9C*(U%%L:56Y0<_HTN"KI1D=^]?ZM=\O"D[I#)"U&KIY<\M*6B4IS=]
M65S%!-YZ,LI87P!@\(=X+\%U!TQM5\MQ85V7U;>P,B_/'Y_O7LQ-,CKG_'+_
MF#6_6,V[/NY7 3+6;PT^M'2J'J_NCCUT2)K+JI%Z3N/:&00M/1VW:G@C6Q]X
MK*1L.F2;6WW8<A,7ET&<'RTV0K Y_U3/R# IHW-/<-IOL.-(N+:XI7GN"_*$
MJ+GF'T!N6AG;>X]JFDZ1\4Q6:B(H11^3V7)LZE'<O'98/K%D>'#LE=6X9^I4
M73QQ>*ANDM;BMFR_$N;>%8/.,3&[U_X/T+FBIJG7M&\46(5W<\+F?)JJ1G4$
M&=AHNL6X=SMDSEM&&!!"A@NM@RHLL#SN!<9")<0J@A)$1Q3<- -W,\AXV"6&
M#/*5X5;N:@@H($H6@E4R)C+-PSIER@R*5'T/L&C,W/5B:(OGRM)C7PC>?VM*
M.Z&N(&]2XLALHT_BJV'*E=<=%/2++H87JI[@6\#@;07/W<CRDD!$\%$J^B6U
M!1I/\8016-Q.4:9 DJ<W6.X_9S+=?28K3^O6EC$@Z:O*(G"#53@O"*I]N>Q@
M;*N(N_"&P!U(,H2,]'5<>4ITOZ\4I#54FLPYG2#C&T@R[>TAKQ]*61H"_$NH
M(+HE"$KPI]N,[C_Q]P<*R[IJIQ(L^4HJHG(IMXQ,W2JK$MUFY//*4C>!:E!]
M"_XXQ(P 9#.-$_LZ/Z;_S?!<]7UB)((;(%R5?6<,B?+I!^F\&[44_]5L>'M4
M*C/V1/NY##:4#,"?*O[+\_L7BV%U$U[GE<1)><37]T1M+=5&4M$4L[H7"#8N
MNP[%J#B[UT6?[HQ"L[:>M65MP2%9'60S1'EP>+<_7%&7VB\;8UH )R)U\8%4
M/*>FB.0@YR\YN#!8"SY<7^R">1F+0EER9!*_Z!*J<+1&VV[)[H_(\6#G<Q+[
M B5,UQ>3KR^H_<M=Y>LE*L:AV-B_-GG>H7EQ3N? 1-VV2,B\&;JFZEXMI*3X
MV<I+%GM!/V7\IFN$Y?;0/76#BD!J;,VT1T[%!R]W=%N3)S;/';RTWTD87I!8
MD>FSC#IDXGQ6.5+F4H'W$MNVJKKF-Y9:8FU9,*.9RQ97%9[;U-JB%)'X6!Q'
M@Q<W@$B=-GW\P';J GP8;'8E?_&%)/#'$^N\HVG&(!G=[KCZP>YQ@0"!CPL8
M[F;!C_+/(\?8LT.CN&#NO3TO21;NY?0357SF:KK)TU8/%[@0ILP^."&[36/E
ME\8M+/-'+,M45DX%!?'$FUJ\/DKQ>"WYYG"HR15=_K+I=5-/;#/RYC$*O:M^
MN?J&P:TJ-*W#?:6@9Y=UL_I[;U8+KI]M?GI\WX)GIUFE>9Z'A\7<"4XP88DP
MA'- <MY[A5FHH=G?X6@FD\:<^'[0.4[N\;/G2O"I&&G9O-\H]U55CZC&_ ,(
M6*U^2AJBRT]=U31M&E4N(=;0\A?&WZB:H GX*I_<Y-RUIN$)&&%BK(88:T$]
MUVX(YD+ &E$)*B8I46#^!/'YQ[3BK)E"QD[1K\"T/OZ SDA?(?Z:A-:$9,FK
MPFQ&-?3LJ.Q$)$0C'[Y(B["A-D7P<GTB=MJB+1&8;;;O6@JP5D*>!]=273&#
M91ABL!H@$_ 9Y$Z$4R!SMXX&+[AMU?4W%1)!YP8S[.1?@-!"XN,'WNF?>+^=
M';.KE%DM9[!CB&OB)T4WP+JC8VU].X.F7\L\<QV5IHEC"3>]XOI0VJ^"NQ&]
M;YX -%A69#Z*E$KN$\:])!(S^?'TV: NVSF%# F3[.GL]R@OO2^5KF'!)Y4"
M583Z\ ]>FFW0_X+S9[[5<FA!OTE$Q>?J_:\?)'WDD)"]TM.S"4).76U3)1WR
M_4E-K:98SFROYJ8IV4 86U"VCOYIE;VFWL!C5;!&!GB8_M&3SVD'7DM9_Q/F
M2$QONUG7C]L*##JM7MK-YJ?YU=_PJ+GWF-BO'G-YUG:[OPEXUFA^Y&V:PE5Y
MG/,3Y@'[?H/=-M!S+4X5,*=*'-G)PD$A2?][^9Y_S_*)RSL0Y]3UNR:;TW9!
MC[8OYJ8^G+BU%/)U:YEQE'=J\7?63<R)K=&2CY)+VW?0A\"/9P=A.JY>O^OO
M126>F)6Y5[]37=DB%+^8:\$:/(UXC\/%WEF1F="NF/7>. ]5/HLY\?CML?[
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M7YN-"OW"P%.;$\].QWTQ;>]WH>V76FI2(74^WX/V8J'S#\5J/;>(188__D/
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MSAOQ:SMAM2*:@R]A9'],A55YD]527]NXFY,6,Q%H<&0MI+BFZNI;+A!.SRP
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M"D*VRX4D@*)25 W )!PLY:Q]934@J24;"$#;MELR#Q,GK?'_V5!+ P04
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M8/Q.?RL*,#"QL'%P07CX!(1H@9J; "8&%A8F-A8.#C8V^JT_^CV 38I#=EM
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MG6TUB*SOE+E].<^+68Q],0$ B3V<B]"%3M1 &-+ZG*VY"U]!;*,YJZR#XE5
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M>:;/HK_WRJ9=W_[^K9Y6VEU3-4*1V(RU_??WIOOHJ%@O*:64RY4G B698E#
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M,%;)WRZ[X@[L#!$K9KK?@P*R"7;:M6)LT[_LNBR7?'\KD3>["UZR>)EU-'B
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MMBG(L\_.D[(/<X.F6[,(T>6* O Q3;8DRVOX]?GX:FB(DNR_<84R^Q)5@F,
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M8?7Y7=[8I)@=9'>_'8HY&X#_,*4IKIWQMCWH&:,K4^7@_1^M<\>.'>>ZG[E
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MH0@H@B0!);6"9)J6G&D%!(E-SCE#DZ$)'5][S^_LO<]]^Z3[SKMCG#'.'\4
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M"!T1(IK^ES="[=_LI$)7MWUIC=5YP-32HDB7E_J+@21*ZU4AT&0_MXT]RT/
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M%\[Z?X?T_L^0_\(APBM]&>NGP^=W%Z-;68S8P<-Y0-/5IV1L#H3M%K^/!*U
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ML,(\-:\./,_*QM^X,=>RS+C+5B?X"\U;K(!7B#AVXH88@X@?FG>I@0LIT&&
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M8.5!NJ4=Q@DY=;QV&H"KASD<T_49!VKTUJ>[];/*+9>?RA01#_#U.J9Y@>4
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M=FKZX_I7#D+DEJ;U*@=*Y$'^I654)(5++WPTDFMONQPTM E-HXRP +;IQU@
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MLSU=/D_"JOB1FVG5[^XR6Q;=U#$T9ER'_U"ZT@^QJ:3L^@1K.V?-_OI';%@
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M;MBCW-?7 V?"AL=I3UR1;SH;,QWU)%Y*N3K3W<[I7H*[C(X-9'6F?C,QK]I
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M8#A]F:8M!N]HA6A>S_?ONE>5?]?Q,<'0,8RS;8KV>S;Y<BEC+,!D HIXDU*
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MN:*371;?>=@)N;4V\&+OD:(-PGT&(UV^\A^^DOBK_/=+@7!="1)-/<\CKS7
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M^"U_"LAI670X=SVZ[U1=;0230,*I4^]]B[]!MD,70X2$DH.$LLTKA-0"MR'
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M&(#I*NUX,_6+/EIN$:=YA8][B3&([#;8K!VL2J*DEB5@,<='%R >.PH>2ER
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M %7=KVJLJ$)W(VJJT  37Z+_ 4BXN"9^1RFD@/:7<^A7S0;)S\XJ]HFF=-_
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MPUP>DEF')=X][^*$G,4<Z,LA>-!530P.[53CE60IW[JIFEV7%T/5> D0B3G
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MJ0@F^O7= NY@QV7T27_1B$%*=GV>\PU_^SQPD)S-G+_.K+JNAA]"5E\\W2I
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MQ[CPG);H;/DX3^307;[G[M%6B5AKF78Z"_]ZW2G$]V&6(+GK8>\P>1T:F"G
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MKS(O9!H5A1M>H(EUW*3);$X%JAC7IP0G,_IF9G0-8?RJDZ^V&L^_MM3S(_0
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MQV^8@KCV7I#66%?)"7AF6FJ!N629A$4?G))7JJE<W;^@-=3P.F1D2N2".KW
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M],D'7/W(SWJ2FI#_1';;?FM-(MGQ.JJ%"%^UGOT3<=%PJ!/ ,&7Y,0.^H"F
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MO"=*XT<7JR( 7BZMAJX3P)#8S]" ;V:=KZFLN6)46-,8?$3%40+U ,0@#T[
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MYJ-8$$5\OA:#5/ICP$N="K?9>[V;^[P 83WR5 H_Z [_)6JIM4\KB,C\W\V
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M$3<U&37W/SR>V@'8*'#)+QK@X6@ +[#AX+'AGKH E,]V(L+].0#_8\"]@$=
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MW \C$BRBC+$=ZZ RT#974ZYSLN@OO1\_X+KT9O$8*>F!N]\>Y6.Q6J2!77Q
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MWIJ* /7GK+D,-YL8JDGTMP1E9!@-MU"P!A&SM 1%PF9C;S ?$,F:V^81!_%
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M!3J)+EOBNF5<?WQ1[WKMN<HFN#@H?:(V=?OA&[TN-)FRLI<RA"5E M9*:$G
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M+GX"!)16/+Z1N:=+!)[]5'L"=*A//P%(LUYZL= ^XLA3WJR4^"V7[/VAL9X
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MO-N,,"6[:B+<P<=1 :XX_P/,6M/&T[SN-K*+&S^ZL2\MB"4C4'"UC@7K9\Z
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M7CG=N&>\R"FXDX;X'#WWZ^3*.).N^N*J\'OWITZD7 ?F[=RX<DS*7,HN_GB
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M=O>Q-L9U <9Q6F$LV %X*4YOEA^V:9'<LV_!2IU*=]UY!N+GGK$[RHTVE;.
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M'J%MV:.*/N'2RON"X;3S],W+9[QO?0L4'P2'3Q(^)/.7P'!J;:<"Y_\J#'Z
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M>+#[^L0#9B>3[CQ2DQGE@"2[P7)#6=LCZ7NU5A$[K+N;!WRE>4+C+[G[D(,
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M8D22)FK0#<GZ9E^2INZF/YU;IM4EU3S@)Y4LX7;"EA]RFM;$)"2_N%W:EEU
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MEYF=Q;<#'&O3E/BFL6E/Z@4!1U25!_Z\>0CG.33%]RQK1\FS'%UO$,:@:5>
M%<=N7-[V/7*&:81LS8<VFS%\C>4@13D.1XP\L6K!_?63=H*85M2%+"O7J =-
MM7AKY277F[.8_=9V)2915@SJ<;)TH5HO?^"^A>7G;+\UC!EK#OF@*O(%[$9J
M@?2%_F= ?,"(^0CJ?QND_^7+5I)+;S]X+]U@]B)R-=([_>]6;17SF[%SBR\%
M[J5.$>4+Z3>J/0C;_V4>ZZ]FB'^"WT$VD11536ZK9'B_B'Q:TTW8GUEB*N4(
MZE:W';T5+C4<='F=,Z#^7/N<U(A1=O9=G$NOX/IJ@5K%B_IG"4SS>WO_JL5*
MG4JQ?S,;Q#?WSI/I/B*N(*G# "=B^KA4"?]^&KI?O<>WOOC?$&^VR#A\S3&S
MWD(.W42! P[4-\KE(IC>;G:9+V+T!Q^E)#*H2V4):Z6Q.:PYW+:V'*S! >LI
M401=(0TBF/3A[[IL P="7<67L^9=IZQY&V7=V0<Q'G6LQU>YZ#]&T#\!A_C>
MG?B9?L+\SI^17^<0T7+*K N=^JWXV 1]Y/J2NJ)%_E/[Q)!R&7H%19 5](;/
M.SH4NFZ(@$8 XCD6GU7"HVJ[.OY&\UT,_XU:+(AN[<N]%:+:6%ZZ0E:$ P;#
M"*X:003XY^FD#'A C!A!;7&#C84\+&>T\LC>@:!2C^.0B<[A.;%1D8J#F=H!
MY^F;!1Y#O)7H*Y(_ND%(6O6(W3=J^=TDTIV\C#RAQIM$2-WBH\YXVU6V2%I>
M28BTZ^3W9QY57#BU@M-..GFUY1],-\IW7FEJ?BJ=W:WE0,8;*,K33U)%Y0:;
M^MIJQC(-P8%_3]3U. @>5?WU!X]FQC7  8RS4?&#=_?]>J\NU<:U+IU$+6#,
M1<K&OQN)_UH(2R"(W0*GW'\C_]WY._C;U:E[@Q1$U8N?YRV]0M:!3J$A#@=/
M_^C/C7(#H@0$+[Y_?+U"?1_(]ODOW3-6R F$V4?NU.@OI5.$%W1\4 :A.4(0
MZ: G]#\WV-W$& T<(C^FT<B.\_I:C&HD8Q:R=$A@K<!PP6>WA5U-3-;GQ3*F
M*TW988&R^1#JGO3OWX).P!^2"3<&^A3FI'Z>3&VH0[.]^'(^44:5BDY\>FCF
MC9O(W0P:ANP,R<(!W3CYS@4RM=*GCG'OJX=ECT784$/H;>0?K#2LU;V<S?X7
M5Q7_SPZ']5^[,_D*LQ2G\?%VAT._Q;_D[ZJ)LJI(J:)[0CQ-,[X1BL<M,"O/
M01  62QIS5!IN2D3>K,"JXC0,LC4SDG)G-6116J-Z<*5.:0H7144SQUQ+3Q3
M!2$>\M\#C+[63]A8;^*2K;^+-OOF9/J*_T@@P5UN=D;UN=+XFW<@1S^3I;H0
M YI(<[LQ%%!T?C?O-3-2JAVQ0?5$M6+S8ZWQC-#[%7LRMF*^37,3+"?'_J=8
MIC1O/?@ZYWUH)SC=ZMVT3D0_IBG&.[^R5JIULION3D^U7&PVK%B;[+A>3[:K
M#IG? :$[>:9IAQ*S-4%>MR>V&35\?;A&[Q*:HO=0OCC*^\5Q;KAK86(:#JXU
M^T (FB^=%%>,MWZTPL0-=83XMG &'%A.=KA7*)QEK+4MU>&;*.B#51"P,8,:
M4%_ZJV 5%8E^M*1D4XB)9I_RP]]=I)FTYU-LP=>A_WDP7VZM3&"GFD6:FN;O
M45Q(#?:,5FF*VGV,N_-B)Q4\1@^)D;V]O9FR='/DL/N:VLT>@.K^/&2FV9^0
M*"E/NM":2/<#.IVTQP/E]S2@!(-G@*/<$(ZI=<WBFK.#S&O?Z"[J,\H1.'"L
MA! J#%ILJPZAR5.P:N:CTB;YW&YVQS")('G'.N2T"W#ZQZEL388+& ?O3>.>
M5W$I>E4M?F68OPZWQ'1P;-U&4GIC?.0,%I"B]R!>>7O3%0X >]<.,S[I>#O%
MYW8I CN/* ZZ>-Y'VVS[=:_A7&-O0R\9$2B)RX>NL-4JD9W>VV)N9U=^U!LT
MU2!SHL70D-!BE=>262D/FDN>#[4ZI(GRU!=19W8U&0T@18V)0NH4 TW=&IRK
MU%Y&*T7O-YY[D3T/$J[9$JH37R!4>7%I4+2C.8A,Q5#VVI+S1;)B?"IH=OFM
MEB^TL#UW:5JG%Z6_>3^4UW.MCW969: ;<.U"5:D!02A%7,PG/;3L<FW0"301
MWMN_[+V D_U<@X@X1<+*.?5'IRGLPTFV3[,+Z!QG2\1Z>M(/;!MHM4=HF&22
M!)&H?_[2,60\=@B[U<CI-O-=I605S/KX HOL>4 %B/)0A9JKY/OW7=M^Z61O
MS/>DZ#1MCJ-)5%>1G[RN)Y+EI^6K#J,YQKX1V,S*IIQ#\74$4B(7+3YLY;PU
M==HST(B*7FT6&Q+6KCX@C.4)O!;Y>BH/!]+3WT[XND_X/*."Y?/,BUC(Q+[R
M<EJ+*7+YW.'BCXV*WJ7UU'7N6Q&YW4+JMXRLRU+U<?LBBZDJ#=@F<4B?U6DH
M* !,6K\WZ$QF^9WRI4*]]?*): H/K13]V,<(<ZKQ:(5?;S=5(F*+S1J"GD\P
MU=9],JF,Q0(,#A="E<8"B3&4C>PE20:)K;4)DC6?/[4(6OW,.O,ER&CTDTY_
M'.(%MP#W>JH$EWV_)XA2>?@.X2NM6ZY8JUV;I43U7M2VP(0@\O&.4:I(+(?8
MZ*3@*'2JX!\7^)C>UI8LD+"1>KD?E?RHCL!ZNHV42&;[\F)V[F*W&PZ,@W1<
M$">;BR)06.7(0#-II11_A\IAYE;RZQ^[%<VRD_:QGJK:QH$T^UNZAQ?GNX("
M;;E>OT^U'+8UO/$NIOI/F'?;3<SF2%>K3*:4NL,X>?-<&Z<4+=#YEKG0U&!@
M))2+-#0*VO4[)?ZY>>?XQ*+"<W$2Z(C',SC0QKMTFZ OW?V=4GU++TD#BC\3
MOEXOP"#S8<Z#:"'"ZZK+=V]B3UAG8DJF4GXPNW.NEUN2@O]&H)*K]6:_0/P1
MLU)Q ((A'/X/&:*XT=K0VVHC;E'1PPTEXT.^N=@[:[;T#,AB]E=(/]]2\'5M
M&%]*I/I1QZ2\R(T'N^[+$/)7S%V63%\H]Q15CK%;<NZ2>D^HDI<L9BK]8FF'
MYLT$Z\Y+XHXZW1/C=M6:LU>\\4 T7?E;I 99$B$?H62Q]36E/FO),''B9Z+9
MC7,[NL$7E;TBIFTBZ7P^2:<;#!&!(FS&YD(;_GM*-6<LO=46PO]RK/5&^#Y\
MD[<:>=W>OJMZ:.M1M&C:O$F8_O+# K])(TMO@),C,Y4^C%YBA5Z]J)ZT#1SC
MF[^^C!]Q@X%O:\+">Q@M/BZ"N1K)I SKFNHBVD/6F16OS";I9:INI51R%3<[
M>7<'=A6_Q4<XQ5X-%_G)EFJFAMHDY::R^III\]#M+N5)L#6J@-L6.&(K*C5B
M5QW?X\=*D]+R$MYEH5)4UTW'TU=.LD\^DO"&(YD_$)Y/$S/3T;7\?F"I4&-%
M<\(1Q";D;#ZFG[J,/84TUDQWZ,51;)[,IE/R53(6F0&II8RSK^43X>"LY]Q!
M;?]KG'=NT55'L928>G[[,JH\1#_+)#C!??)]9=T$AP<F/X6UDY>43MRJJU09
M&S,)(Q\\<+5V\>>" ^(:B@;'4^&WDEGZUAY^-&./T,\/K:J\GCTL(C$3H'=#
MJG;GTU-KJ1VK:FR6.8#-Z4K][&LU#]9@5Q8^?DC+9*?"_W_-#-6YEP6+%Z_N
M!^K*F\>/))Q'#;Q\[-"6O"B38JY(Q+\O<.DFV]V^S4EQ\,60B]6GB>.B =6D
M22ZG98%/<A9^F=G5NAOODHG#?G'P[W;9>4MKEYAXZN=$,QN3X#JEI#5-RD0?
M'ZF.G86_>3VU4D<3;X^0!ZP0>JJL0>%0KRY9/]N6(J=512[&O(I.-XR=MA>1
M]-H_76)$JF\&X[)ED9RZY@/1'X]P'I@]?C'B\S);CQ?7]IH'<0Q&LA]^'P-D
MK-J5DO'HA9V"]\TT9TGI8<A )$I]"#&>+"Y(L7X'5VCA1W)MM@U+H;7[Q4DG
MNSSW(5Y_Y-Z^>QS/&6.).E[ JJ!9XIJ*;;\0Y]DO:Y'M.-243;;31S!TT:MN
MY*B$/MFLW6N[W-3R3^@PD'.QU2E/#4]YS>>QD%;D"#/!J] 5PP1I0-;^5-X.
MOR]-/\*_ >JZ%JNN)@T0_)M!V+&;CA.:46IHX[BHJ]L\_@FKW_3A&#Y:<%ZJ
MH##7T+R;J%.G^P]55,;W*X6^#ZYW%<G?Q]LY49A\J4N3[VLPM\>!\#AG:SFH
MQ)A1;-G#F!^09]=[ZQ"-:6?602Z<E?!B":X3L+Y&=VA08ULGZ3Y^MU_57UAG
MGSQ&&,  0\)E+B!TSIY+Q5:&@G0_J(+T-[._V"1=#W:.M(P-?J@IMCU7+.;+
MZ2OK7?19)K'?(I>E\)Z2E0:<)JEQBCG>K%1[=:C>E2CN9(WC[6OD,$,,TEZ&
M2FN0S,7'.2NYDE$EW85GM>44'?#RW\0]:MTP[9T.CI.?K=._Z+*5@0&=4Z[-
M*NIUX^OE/S@XU,>@HHG>_!\;C?. <'PD+&^JI2BF6[8Y+V@-_<>=6)6\5KO>
M\O'GZ&7?-KD?[IN;.L7)4;A2;%5G^K-I6Y_K&F3.6I^[GR?VR&O;K6J/F*^O
M2" 5ZV3^_C=B\!O9<)K)E>13H=CU.+G[&:XH&6-4=^+IIZZ80=W9KG^T([_[
ML,#83+!>6JU K,YE9@6Y!O(;45>>!PU!/_I<&6Y13&6-2I VH'Z890QWR.5=
M-2,Z^F1V.H)JVJ;F[)ZY95.B3 "*AS6ZQO=:<^N]*)OG?4.7,.XITXVE!:&A
M<HI-UTV$ :L6QX:%;EG=)A[YV^,]%2(Y!V?O>-!)<!:S2(=Z)7NQGOK4 9QL
M-OW?KWU+PSA_Y=/4UGW[%-]7%X?"(U7XJ.N5_%3J(Z?H)EMG&,#VV&@LJC*[
M^J.24#MWN8%,_X$:KJC98M,UQ0GB#%']WF5'$C^O&M<TXM7KKG0TR-HNO&5]
MBK(%(-YQ!+$EZ[]4,&UFTS+RE=U2! ^.Z +QT,I<3J4A@EIBCHO%S1-=Q,ZI
M3D/J4]\%KEV)N*=M)D=MB+[Y&%?'VIH@!*:IW'/_S/Q(_MLM$DA&ZY[5%[1E
M>4AM),.'?KJ\A[2JF*G.CH*DN37NG[^B=B-'P'29D=*/E]Z]'MEL3I;?;QFK
M\5M3J>0O8U'O:$DT@ .><V6#:5),%"XC""!PJT&D]O +Y%X%6QBTJ9C*R/@A
M2+-MV9?+WC7?@:ZVY7ZXQG/J0'-W?YRGL.I*W*V?#3]@(IIO?%0"Y9D'IK[.
M,,:5WM?(&*_1J_ XKI^<,BN[W#R[K#;,2._>KPP\V2$F.IZ?U5G4UP\?J"'"
M1%:+9N_HIS")XB$7[#7UX!+U+UG ,Y-^KEJ0!9)H?8 X,;:/2=]KR4++?9T*
M;/ 4S1S-N-JL*28KNLSHNWS64YA 48ZHRC@DG:YGJJB6[\ZLSAX2/>07VOAD
M.GS$$#N?&O>V$G\IQU;YWWP=!3[S_P!02P,$%     @ ,();5J41;W6(; $
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M.?B=Y\YHRK)#4O0SMXS3=@P@_ON@,ZCIAP554C_".9(9H7 DMEZSJX,![F*
M%79K#*"O=ERT&I(?VFNY2YEB_7M8-,+UF-!;Q"4>*B3(2&%UIGLGMZ%OK=OT
M)?^EJH.3M_]K!L'Q<I0NATS>C&>'L!,60W(+1+KB#I=8S=T:J:"GG=KS+$E4
MA'*2C>(,U(Y;1B EK+_(VXS'O5PS::D?)Z#N?(FS#0U+%%NP%>V,ZQV?TLNG
M8 F\6EV8EYK/TSL1S\"#=R&H4"[P=8,[SG.$&"#6D.=J P/TU])>T9%>%X-E
M+QD81%!K>8743&&J%F1,"4G6'Q[/R'_UY4B\".3DR)[&&KV=;-O%]QLW8XTC
M:[2"6K".B+LDA3#0/UW_3'T/UM>Z)<TWH8P3HXGDS;M$]CFL?0KKR!C+1(B=
MH%1_508FJ-F+6'4B-FR1$I4./'8*#Q_8/.G4[ 8G,::YG1JVMMX1[I'0DYVF
M,XU,C?..W]?FJ,,/]7@K:2TU]#,2<1IQ]*W2\L$A.5JRJ&D[&_X06D^$ 9@'
M,4!)'PH4TZYV<?0#*T<A@PT/V)'OGZ/K1$X0W!G(J'4TXQ##1^R<0!F-QE(_
M5.C-T\WJUK3V.8N31RY+A-AT!N^O#/J\.!-I8G5JBN=6(VX^@$L+;#@KFF*
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M^U'[_0P$UET[2?GLP[.4?6>HW0;]<BY830ZM<G(U3NU^^D0#<<86YX=U$T+
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MAO0K?E1K_92_EPL3G*H\$W]BP9\7XN&&\"X\JVGWD2.P2W5PN)V9<;U66CY
MO46KG4:95B_<1_>ZQ=7$D_7,>-OPBZS*V\J<PWOMFH4]\TEY&;%:9<2.7V@I
MGQP_6M]>77-JO'\HNU>5KVSO?ILPG,AAB ,WU3]:\;2D(()CJ&TD7RF#2_%8
M>AW?ZT.^M)5\@AOQT< ];('4:NI4I\?%OV!:\A2AF55S^!M<(O,\>=Q]SS[@
M)TK;3KMA+*":-.P-!K":$B:1S!*XF(#+6O];2AX@"KNJ@&A,\/MP$Q[\C/9
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MM;5._OY.$)"N%;WB-6%+%>-28Z'03O6F#A\O:\$2C6]H09)7&;QM\HC*MV1
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M)\J"HY(J7#DY09]>YD3/T#$V+TQ\-MI6__*,V#[9]M37UG0P^]036BR"W_O
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MBJ:E#V(#N<V=^*7"6Q#@\I'36>%3.RY.'I9D_F??J[@B TA?R2R,YYTU16*
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MGU.:N;ALA/,Q6'&]:VL$658+,9*L+2E<9C8)K1I[4%(],I$0LE_,H*G,>5;
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M%%<T-,+;$6]KTOS@=HM_U,PXNJ8928Z$X#BO-@)@/GUF- 1F@ZVMRS,<5Q"
ML=RR[!+IBF#PX2 L"8K!)/1OP^;4VQ)5',7C>2H6>=6>EIUK>? &*+"<$-=@
M JC,CYLX6GWJ?R\) #_X,0&H(0#G,CL&R)-@;R3DT_E>:NZ3<8N^&WV,6I/]
MLBVC>X\_*^RT^9/BM#%WDI".?*V>#SO=ZX7Y#4U>O18G"WU/&A^(F.#*#9#
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M612)[D^?76@SI@BO]7;Y>)7E0!Q9^O<%WR!_S##6KI$ G#,194=K#5$DWR4
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MR;5UZ1,)/9(\M$G_$A*O<F4W>$1R4HE&89-TSE_0RQ-/#P]I6$^+:+%Z_R[
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MT@2(IM[ST[?GP8MAG54!0- JZ\7.STOXO%$)CFJ.L+C@89\-_DJ$@"%T6(H
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M5P+0_FT7=$I]K(HG$X29;+$(E:,SHV0D7XJU#0<Z<DQL=9A"K9DJD+6*TO*
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M!2: [5[\1O)(8_Y"_+4]X><OMIK5P/FVJQF7:X=7#-]%* S)G,ZE4(:-@J#
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MY//G(RZ1G^!]OERCJI:SWF[@T-B5WX5&_BQWD@"_(L7G:[<+CB5:!+T6#@*
M4@?OBY5 >[$[1,JS72 REUOBKU,6Q]Z+2H$B339^':UN^AB?="#N6XG1./4,
M!6_R90ZW_#O'/_US>1>$/.9V4RW&KI;>EJ_APY;;7><]=#-E?8QJUT"^K2AT
M>B(E1&WJ>AK-+9 _->#"D *MR8I,*4";ZR11A07_?+SQT78U4,\GZ\,MBI1!
M?]VI"5BQ>G,;PW4&<,>MJ>/]4ULC R,E3G*=P>"T03(C/G7S8<$7=0+F5J_K
M37NDBMW^)'#DU'JYA6;5A*:K*K4)Y8'2*^HY>]A//OCPX>,@$,1FNR@+E'P
MGFCL;F%LD)PEPU!.5Z25]D"'X06N5<0Y?[=8%6.Y2-'QEIZ#82UAUI"W>TOE
MVYY\P0/2 RY4)>XN=B3;5PKU;+@ZBN4DHK"6@7*\-^1NLCE20/JGILLC?Z(=
M2)6(-6+0=S,-U8N\?N[8,8O:),RDZF;<8HD'ZFZF>L-(M6Q)N]RMY)M\^7%?
M/[&23C9[MUA58S_M>H/HH!OCLQ=;1PY8/"TTWCWAC-OAU7EM #B<7^>?\^5%
M;S%T-UQ?;V%K,BQ^/L425,+BJ:?S66Z0?.S7J)792IITY,KOT*@1 *\Q0/!
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M![V<0ENC4O!7: >[WR[7+)HW?IG#R4/N ]M%")ZQ)LO%"V\.?B7$/#3H!IO
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MIIDF$14TWT!L9;8CM<Y=%(V./D0W175X'JG.GV:&VMTP]2Q:]Y11S@W^XB2
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M@"C@AIXW,V]/"-L55K]SBH5-2DPZ.:E<I';.X-O]_OZ]K_:N1[FY U?Y"/7
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M0"B-PA1]VQ5;C@.#4 P#8)):,5WGRCXD+6Y:YI1001WUX)TQ-_+582IH;EJ
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M%GV)\?VA:JYV%]J*%^^,082-:Z,*B08MV9(#<P,[9 5S?<&H:CUYYUR4R%"
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MRRFWE.K=M#KUK->/5.F1J6Q5,(8Z"*V:9% FNYX/E!>GTG6\F(_/2/M;=2]
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MD>WG*&($LQP8RE*E=&N9.W0^^8&GT."Z&JI"CSPZ\S7I7(C6'-N!?;\P#U>
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MG_=*$.[@_?Y[#3?.<8U/XL*BGT0V(3=%VR@'5)#*5PU^/-:@3R50$GA4<=4
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M[Q1FTVN: ;@NE)3WK>-&VG?!R[_GXWP7GD3YH1C(^8T;4? 5+'3^\<@7/=]
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MI^R%HH',5T_][J86:VLYER25/4OR%M)#=IA7$*>T>6 N>RA"NM="@D>0O>N
M+)]^1"#.(WOJXOZJ>H7*=P_ONXI'H4WUDD:,]A!3.S%+%_ DM%B71Z#ITHW$
M-(.'F>[7I5:XY*U6YG>=:DC"B3H!KD4]@NT/0$MY<"P=Q+72Y>X8-8E1Q-T5
MIRT4EHYNC*1(RA5OI=VD$O:5[8+>9Y4+3N\!8UOHZNTX65='E->8^(T#QS)P
M*WH5)]\P8:ZFL9Y9Z5E^WGL=1=Q<.CM"16KO'.2Q7[T;%TMR&1,2ZY]V'G1,
MRIQ &05WS*!R_"[A']9N;=1_<;I@F*O_[-".Y+,Z8?B!3+HJ9%+/@.%/8]G3
MN]'%$F.GO5ZUU-[Q47&3?WK&*=!><W#0H/YFK<B-N52NYOMF7% 7R]W)0O9/
MZ<S 1GV"P7-]L7YBJ+75DQ'OO$GO&&N>O75W-=O!5>4+A7$$B^[J61/G,3,2
MI2Q0R:)RVVRT(J+EGJ@+N^8KQZ_)+(Y&#'3-:_XJ@!5])M("?Q3K4[!M^_75
MNEB$QQ?XQ[OXJ172OQV^(?]'IV)2B:<7\PC<=3(PSC'TL;10!<YG(QTWIM4R
M;\Q':9N<W/I*@Q=%P/VVKIH0],>9W5)5CX1YM=U@Q[S9FV#',P9.7^_?5RZ?
MFL7NHR(A>YI&T!8?T$PE]G_A91.$Y:NTHS[? 35$(4A]!44Y37:<W7:_4S7J
MTO)T+]8#"Q['A.''0!1CW0O"%;F;HD_AI.3"[W.]'_ K)G?BJ%DO&J[MK!4<
MB3CSL!?^6(7&2ZQ646MX&WSXU=;X/6Y2\#['WX_:H'RG$_O/'K4A_81"#)<M
MX2(E9_9TZKMO>+1SFK1=\?3<H/^6_HJ-*(H@H3IU4BNNLSJS^M41W,T+[K;9
MGNFJ-B0AA"#5<[9X(7J%B$W X.:0 ).E;/Q0$G8?$Q8<WP3!%[H-/S4 ].O0
M#TY"@<=1,(4) \28,$'8A*HTN<]7K$H335&ZO;=$ZV7EVH".,_T;LXI$WQB@
M/GACLERM]C1AJHK6/]8M4GS5K<(=M_9-R9&;KL)WG6#9OFLS!%=C1?&D,1[S
M-0F24^?T.I3$K@=O*Z^V,UB-""N1=NS#\"K&BF,O&4:?<+P-XW'>*9PLUQ21
M$'NB(@'^IEE!Z OZ;/M !^Y)F^[S8CO37;HQAPTW>G"*QXPZIO\7E10-@S@[
MK-H; <_/F-^-*W L6'VT^(!?:E)A/OEK0C)/;$/\QOH#7]>B[L_<M<79>!QO
MGN-QF#*+,[X?Y8^>VM*(/B?5&#X;&T=8TK]X7GR'0=*PF5KIM!WGRS#QX%UA
MN];<WO=2A>/D2\%=E5_L;KCH7I_8T(VZKIPQ^UT6U53BKL^>-"JAHN#QELRT
M=X6H."W$P9.'S$1[F; 0KZYG_NK"%)V*2&$JI^GU.*68HYG'S",>B\0^R'D_
MG?:IGY+)D"^W4J74) GO&RG"S<1$JH\K1R"O3[VECXTB0P&A3'5!:C!1K[1Y
MTCG!^_Q5\3 3 XY+9\]!O()&@#P]CTTRT)0#1:$WUX)\',/ &G!K%_T@N=A"
M-=3EI=6^Z'D2U\J;%7)+TC%SXICS1#-_G:4S=MH:N\@=B>G=F>^J_(3-L![2
MM2H2D7D[7GIXD9Z'6US,T2V^&$2;.,_0/I+(&_QK88RSR^@VVI"@ )!G*HHP
M=W90%.;OQ3AN*%)UUS[#881Q[57LV7?8@.O$7Z>JS6K]I+2<PT2ENY/P?39R
MAIA^A?E=/IY]D8M2HM+0O+^/IVW+VD.WZPRA;-1Y'PEZIC&FI?$,C 8ZS/R5
M 0QL4.4 N]W*S7R7D$"=<3LK:@=FE<<<B&O;;U/ASR&\^*I*_A<JA7(.8&X#
MTV?H$#^P-(,PS+PFB_U&]GLTQX@!**A"#"!.6T"=C]T&W,.^R/C*=OT8 @X'
M^F5)K SU*X433>:-26X@Q18XWAE+#8KS*!CZ^HXSZJ/C!SS)R><RQ$96X4$8
M I1*_$ +"%LT-J;V4]RU<Y=,TU/.=):_D7NT*XI3(G&I?4[TZ>'ND1NY]>'3
M%1&?A"^^V.TO\VMZG8>2#.I.W4:.A0'#;=F#/\BH6S-AHAN -WN<(!;RWGD!
M/OT< M/(-<ANO@* \E5I*631#/BLYIPSK1['SM#9\N5OX.*2V$=NSN'(S0.4
MN-)4#V=4;DE^J_/7 J'+]?PF-TSJOA"X#9BPBFXJ >HR;H .0])-8+Y'M#PP
MY9A0<!\E),)-'UZSP;SKB;3<X?=AG$(94QKR=>/M$_=_6RSX@!8&!G*QC,!G
MH#/Z).';2Q-XJ* 1M;GFVUHKF47?[GQH-^L]#"$%#\:2P)9NQSI\%Q.<M7TH
M\T/A ([P8YV!AN@,V^Z&3#@'U#TJY"%&P 1^UJB#\6L\?YVX&1B(HT:"Y=,L
MH="TWR.(<WT"OH"XN9 JXN*N,@B:7_G@:3P^F%3@G2)$X;*<=?I47A$WR^B!
MZ4S8%^3[TJ7Y&U!P88"98RC-\/<> %X""ZAIK!_C*7[@O@0#T*=7JS#65;NJ
MG2RSS86(;0"%N%3/A+TFM/*S)]QSLIW?XJ==7P.?H!AM6-IREXO?*A85C@'+
MH;$]8@ZC[?U'ABR>"5O.[YO8;[R,K/#:ZNS/2H1'!Y& I;65K-BH[!TV?%9N
M4=)* 'JP>"041(V'U6!K/CHP857GM:X1^4M0+SR42*GIV<.@69>L#U;NHW[]
MS/&7UP\<WH]=7T"MHSR>[)2^<V53AZZ-!J7H4_R!J'LZ#6<>(HP,T;)GZ3;4
M>EM'V8:.4$>^?4F>XHZ;@PS;,(]+ATCNH7)T2S)!%X(AZ8D'H3MBZO0SJNXF
M<TJ\#H.-_?]8@7UYZ34W\C].-CD;4DU<% ,E6':'>?\&)3G]HYV@4Q+0DPK]
M4,M8QUJI@'UBRVF;18,-Z&EM*%(=FP8&I3M^W?+- 6?M#7U&!(\*8AA^K //
M!)?.,EIGL6$0@QW8 =DW81Q#VYAE[V.KC>B7(:3Y?<RG6!(]\KEOP?D2=&W4
M%KUF!+_51/PCU2WE#+O4^U NOP*E$RG#-=3@*5"EIB(K,1] SGI:?%B[R/&0
MC%?.@8!K78GTC)%UBV-]M?3X-(B!;0'BV]]?%6I?KH<H]NI3A<CC+EO2$"-H
M,P24M1H(E-$!Z;LJP:*W+L6%P5(4PU// MC6"4QW5>'+S1[R1YYD!23-A7\&
MHK+>2W)6E^T[PN6?)\2CJ7VWY(%  )=>]^N@3PTUASZ>,EM1)B];71T T3,;
M: :8);)GSTLETZV&3-9=>^SS;C3D]D&A1[T67V16S.P,L#;BW )#?"R>:1O*
M\CB977UPT$;9QF9[1*W"+'Q>C:ZB']2E/5/MXLA7YK#7\^+*P(CXQX_3]YS9
M:"5UX/4>@AKICC?/8;UHD=6&+G9.%WU)!; !>GW4B.4M+_ZO'0^\KS?7K=S0
M]6Y0>ZMXD#@'QFL&"!S A.1LKE,Z, ":1-W\Y)NJX1DYJR!0L72;SI$V>@^R
MZJJ6PUVY5S]F"M0KU_3(F]6:IR_M!]YQ5A'GMR!I//L.!U$?;&#"SJ2\P^OI
M4$^E4^102+_W)+\@U%QV=5(H2+<CFJQ^=D6]#F3$\\R%HF83>>W5Q>QY%I**
MT-05F#%C;!4/3U')V-QM)NPXP1=^'"A-[42P0C\#9-"LTE*G#;[W(7C*CNM#
MSW8RF.;;7^IMG%] =/2^,5W1U;;%R*,W0>J.A[>)5;X1(HF+UMZX88SV]$&5
MW(9/%I9\.%R)!^F.P[TP..R: 3;,#1J,N%&_G+"1M(;ZI"\G.J_OM3@]XK,Q
M$;A4[0:XK3U1_."3$J^I F=DU0QUW>@8O,*KO'WVP8'73VZ+[]EN&)&\O7\8
M.-Z=[8E^U#WP=/'I1[D^Q<2%,G6J3\RF%HN&G4YJ-;.U5#/[LPNAN--Y6=Z5
M'>ZF5BZC+2I=#;638:_#NR.-NUKR58N#AA?I#KK*F.7Q K$O0^T 93:GCQN3
MFV=V9$+]:O& B$ :\O@<BGH2=\<X7/.8=$2)"K#/_A/O=%@?B1I[H59 46DC
M;8)UY,8^CYFC3Z90XLBY%C&&O"YO1 EV/A3":",HEEOBFE$8WN<1HPT%N2;I
M%IN'6U:!;D/H/'$*BISTX<#SP(E7TW?A+B,:HFN%#1?UEG!+R52=%-.V?JW6
M2U)AO"HWITS[D$6H!9WI%%]UWU/<0@I?#HYOU#G?:#RN0G MV^+U^D04QH2N
M#'V=+8FXQ*4)8478B&-=GJ_+J>8\D<,G"@H-1<*+--;5J/LF;SO4< ,4HNQO
MC^HM6O? ,+O7S+^?((JK\-31TO+)LJ74]WW,M(W1:97)[@TSO5URXYB_CG/I
M2!CDX[A=^FT9, A#R# FC'**8VX5_P# Z2?F\:#6771[8/6U+BW%A^1GS_<]
M?)_KO%X(\NM6A1JKN)*>!38U<=WT^PAY<J2/%@2K<Y OSS4K(_S@7A.'%G\C
M%5L54CD?=3MI1@)S]6[,=/;^.CK-8%6=CV9:9=;N^RW[BZ[##&[YZS;NQDG7
M'=Q\O4<QUWL"](GANLXXJ>VR*#CKO!FM_I147'\[XO.**YK#*!B8]S9@JD9%
M-I:4_WAJ;]IZ0^Y5Z@.FU:559J8C:GEWQ'\]IBYL!LU+U9:UU2@LC3NSY<J'
M5T&J%WG3"+MQZD+HPYKNYW<HWPTU\+(-9$AR%CT+V_.K;&,H %RH4&GOYMY4
M<B"_%_OV?,(:9(24K'&5>\^.T^,7"DZW=_M-'CA=.-%P0W .#'<6K,Z4N9[S
MU?IS85E9^Y9'UY(LNKHLS37BGDV$:7]\>$'G\DS$?8[TU$[?D%\*<*,7[NY1
M3\./F=K]>&>JN@LC:38<647<6*) 8JALZMG99K)3";YGNC?0V_JKR,D3T;X"
M/05<XU@28CQR^^AC;%<^Y(\Z9KN*"9=Z$CXWEEZ#:*G<5(D 94J#<M%@,6=7
MB9%VYE6$]2O71J>M -%D.'#^ 15@Q,XGJRUT*MJ. S97%L%)OZG^Q[!I1 AR
M;<FA;(_&*M%U%->")D<O:WE-M>?O<QJV;M^,NS_SOL!*T]M,B[RBL[\"(>1C
M2%HK<:!:^, >IYL?C"1-:YUC&X=. ^M*=-S[X!&B.RC='=7G<#E%^(1=3OPK
M2&*-V3!Z:!;P&02':A#"=+V^=-*&T"R;J*B3QR[I"3@,X=<!4C#:C;]SPC,V
M4A6BE[LTJX'Y30^8,$V%>9'O@AP?NQXHR#E9//5Y"3R> %'2<ZV0^ZP]R^-.
MS%V@QZJAP?(TZ*,1!5GDI\H8?YIVF&2V9N._LHM878\: GT[I@H_UP[,KLIT
M^,QV/9Y"%HV%DY*SEJN!V=7!A6D4^6!L3>-Z1BJ^O[8",;\%#,@NZ$&:IRSI
M [61MY#CLHQ5ELXE?KC5MIR4!Z#>(C2Y(-R),6NA*='],Y%CG4C&2K,&Q#9@
M (.A+44N*OC*)0/OUE6"I1!5:]*"6;+"L6RA?AUZ%'$#0."#)F:Z9<-5HB!R
M(((:"+Y) \./PQ;#OEMRT/LNR,F&^+ 7T7K 5Y:,!'4G0UF9*>U2][FW/G (
MJ@X_\]T%M8VU9%P5U9M>"("X23+]"$M]C*$IFD]F!)'1]/O ;>2\0 STL7K+
M=MAYUD;'F% *P @D+%:CCQ :,5SX@3X?-#1.<^ ULR;7GQ',_\4(QO:)7Q-R
M6G-N:ND\]-;^;+D*8'JW'7&N'P[Z2^<Q$H&!D#'B/-2,3NU9]"UH@'YIQH_5
M(!@PTTLK_>29L"B$.30)]@"SFRT7W@*+.T 1)BS;!1A>E+Y)P=!OTP@,3]::
MQ..I,DYH*.#D*8;+$ZBQ.@W1$%;VQ&0.L;CJ"T 0 +4SOZTPG0@/G?UG)>F/
M3?@!060/LB7/L0BQ3LT<6*$&L*V#6"&6U[W)EBC\6N\RA(2>N*ZE$;+A%&C^
M2:=D.RXO,VV_9D!H6<SBT[)L$]9O99Z^W645.XG[-J)YW/UB,G+7?YP2@?V/
MDC>6./4M7FY^JWT+?GPP!/8/JM] ;"'F3S3:IW]<;[KG]^,AVO^%XR'6^(W0
MS*JW0#VQH0V*;N91C#6$SJ%)3(J/(?3.'3PH$'\1ZJYPQQ/]*A#-WW:I],3\
M9:B["\+*7C%AAZ3K'=OPEQH7N3TRQN ST3CL:Z4JNN1"Y_*@9%;69XYB#9XT
MKD3,<R,_.GQ5YAEE#THL2Z^)2D$_,)<\ U9 C"[9.A&>]O]K36@T^5*YFW.H
MX-.[+2K':)[ _=ES=8$1#-20U1?G7E@!K)OH?!M1%!H "%.LE/Y(LC/$A$5L
MT+E".4$:V+==M]_=Q/"3\_'/?WLS.%818WL-DV=^9"^ WZKP5.E6WIX9O'ZH
MWN0C](#CI3#8US2J][-ZC-S$!LS\Q7>,(]D"?:;A5WK1ZYZ>%SPQ3)^]_;9W
M_:2:"Q/6@;7&2C.> 0/W\0R_<GH#S-.!>N=8D8937FGA-B;,-!5'5W&5#C>H
M2]5Z31*36+GO[; 7I:=D_G?QJ/?Q#NW %[7 =ME-(J]OMK%*!T>2+*\'?+VA
MMM;P.$]JX]DL%,^[9FI84QIEO_'L]L'7.V,E"L(\GK@:;X]6K%':LVVE&;IW
M8HOI&Y78"KXPA9VRE4*A6QM;^=]Y#MVF0U 5Y0U9Y*L8%O):!:L0$GR^N]>T
MVG8<\EEB(55R-# 2(BB/2P=+A.;=H/=5]@DP ,C6DAJL9OY)QFNL1*FA?2@8
M=:RZMH)VROQF29OX9L][>KL;7M?=O2RVK=N+9G8*:8<-A>+/*".( L%LF;"^
MC-0?+ >L,Y?M[@P./._I&G!H4C8Y[A@L///]VJVJ$?H"C_43DMR<KWFNB<V:
MMN99.*(\)$(SZ93D_.B$',B48[BC&3 SS?YIG:!=M9X&B*71PK'(16EN"*%8
MB4O^-H^.[FZ/DU-V=7=E,%$KP?MO ]\&@GNVED*$XZD+'GY25<^+"[4+/[O?
MW(J[0U;61T*E^Y<H7.YA_DOEVZ?WCS7RGR#EK5]8(!R[ND&B[R20LD)M79CD
M\WV)9(B-J4[7_\*$W0KS11F5Q%;4G'Z9/A O#$^$&0^]4D+#)_;>>J*?<9@?
M),N&!5AD-'*/*G7XG;9SDO?_LBZ>=)-^S43 I+BP.;%9]IF0.P"7W?%1@S[,
MV7SP1$AQT\3N>U\[=[RA1=4XS)FTRJI7IG19B/YB&(2T8L*RS'^P>L(Z$ "Y
MC7JG0IK43RHU[S^YI/=FIB1:W;?,2CZJ2V(F$:Y/6? _Z'P[ 0'6=S2W)3L7
M%-Y9H8L0T?86[24#4N1!1O24>E<0Y2+"YLM"^"-B9.JX+04+D<:@1LIF,!AR
MZ0U 1205HL(;D<.7\70"79)S= KN(]:L*D=>,B9_C)3)*4MW(G]QX$U*N?[>
M3'G$?VW%+.)1!A/&"PK;$7GR#LD<=#Y@[R2LUM#VB2C-RW42)MSKC3$G S?1
MFU3/]Z'#.KR<BK%?>CZ7;);7W".DMT9W8HQ]N^-?+4$D2$(8F]2'7UH+ 5W2
MXR7>,E6*#CT6S@^YP>-HQOJ.^V4'G36IM],L%\89+!6A&63_]A!6]6>O9J?K
M%AW4D_&HM[YB6GQF.X:"_H7-^@AQ.A0T1S?VH6FC>-J*#H7+;-<WC*CPXR'D
MY@XZY)*BN[@8'O7T(%\M]-[EUV=;J8\JS?IM@_U:T91^$GR)&SAB9C&%R#)B
MI^N!\C>IT-"(TR&XZP;J,D9\A4 -4\3<! (,D!Z,O(N?1C4R?&OIC\L>-.,'
M5D'$QZH9FNT[_?<V_P\L.2QZEP/3AB#$_CY9H1A"LNXF%50Y\#BR"K'$70=]
MRB9[U'\?" ?JJJAXL'R,WH=-'!MJ#(1XBKH<-$Y>3)ARQK#*3X7_?TKA+_\9
M&HYRCRD&Y$P_.XZ$+28T@B>Y:X$I.;#^[-"V3P2E7O2BRAGD^ 9@EC\[NA"_
M@D4HH6$Y!_&(Q"R8K\ _A&L?@3PE^OUP+K"$M>5N*':8[;I=AZ2V7NDM*@FH
M.TK&,VZ16"$+^J)9#4V ?E\.@N9/)Q%0;#.O90W9N +0)]^ MT,L[J M,"#.
MU4PA")"0BYL/.M,H(2P$[_P3UBZ_ @FYUG>160 !BKS79B_U(NGW?A6!$P[A
M9WUBWU(;P6.^CF )BQ/KNQ.A&&D@A.H.%D(<.'D@$:[Y:UG3GQ4H_U8%RI(_
MJD Y]7<J4*[\KO3!A,OW%1)P*92G6X&[N<L*('S%?5L=P9SP6:C/C\][8CD)
MIVUA4]1?CU\]Q\[!LWO>1/(#=6>HGA"9/0897TX35VO;[W)>C\8)"#IVFD),
MZ+P"])JSE:Q5*[M"1Y\WS4G@DL$?R>(=^Z_\6$G_K*#*-I1:2_TC[HU-+M&"
MOKP,"L*M6 "ZNNP:50W"U\G_9I%- Y(#.9"-AAY8 3\K.3;B,("I^K@.(Z0*
M9Y/'ORYC5] [_/*1\]M-E6@9.C0!+*'A6)<VBTW_/>#\EC)[I7BB)Z!P23R%
M%:O!!^TXWR;_CK F.-3B:OU9Q,?,WS,B&0Z8Z?5/AI%/W>M)MEER-S&GZ:H!
M>_P$/:[6;SHDZ*HLD]C_E;\5O[&@I; Q!#']"QWZ>>>&@=F-EF),6(9S4C9G
MG;H9%;JY<QZB*.<E6(+*TO5N6-7O[R6N;_Q, '7@M]%S# 08HN#=X*'T'5'^
M3RE@>"^AUKX']PD2.INVWT/&OAH*JCU+T!.W/Z@O'+9-F-]&K3S-4$,4\"1W
M&GOHAX\[.IW4B#TY(!KOQI#&-LW:'915N'*ESN5IBZ[.WAY<\N\J]"B@SU=)
MO\31(O7>\<1-_&N%.TK/.21LPK6[<17']5VTA?&?/7?.NL5?^@LUN;*@^59)
M>*IAD^JA:BU;+/5"^9TS;R]8TT^L;1PZ33,+/M^.$\(%]QW++?"]^6Y5/!,F
MA;$DW_<RP71=^1IM9WU^L(;*M6UT32+O8"=I;Y9U@O#]*,V]VLH*NTQ:53'C
M&>C7<?L63^1>&]HZ9?KB.['&BS1<06'7_,.=3YQ1^SFM9]+M$M=A/IL#=*HY
M$T:,9<+6(5_G05!)QC%A>&F0WRD,AN4/>EH2H"M[+K166_<M\F$&.PO[MEZ#
M(Y&]XJ.&Z"):U",9/!X"!:KCN^3 8,=Q%>I,-6+ZE"KDV<_O 6;ES8VHS:7P
MOIU/V9*U;P2G\+93BU)>>$8@"@P1<;8@J5Q#<LR&7P-5J!@2,>3Z&8E0T:\\
M9!=X%"]]O"N>YDNR#/)API:T+30]^[$P"TOMUY6R577BEY7/6<D$G@U)<,60
M6Q%P8(CE<_QMZ?9DL 6 #R4H)V,,B&*KSG:*/N_O*$10->C2+ V&W-+"6;,J
M+,]PIVSJ'<68U*[.X[1H,=43 =IKJV&^GO\X#44IK,0XE7KXB"_:W-ZT0^F4
M]2;GRSEO^]XX4^T R*4W7H$H*0><VH;)0]"CI?$T&N3>-?EGXDVW9*W;O&+3
M*=M(AS='&JW-7;_H1SY#DI)8$F,U')R^$MEO%9(TIIBPHVE"X8IR(:[D[HF-
M;IU=J!<3: 'B&0L=:_GGDID" 5S':94D)#W:F1<@A!DJ*Q?O2]=OO6&+UN([
MM>TG6?Y)EG^2Y9]D^2=9_DF6?Y+E_T&R;,XN\T P+'QY7 !>Y, C:,J7L\3H
M.XL@M#4E:I[EBO;!DMU!K0DSL +%@C>OK6-6GNQW-+9A<K'T",0&_!@-R>!U
M6'A,=F:CS3 ^T> PN*:&Z*HEZ/G?,2@"()X ^<X&JR6K[V]]GV+CBF)I)1Z?
M? UN;</*[B79BQT0*4=]6#.LDZVECZ46*EAPVM@X[Y2YY6Q;H]NHL<K-*^%F
MVN@'T4FQ08Z;.T6R(L<,[$'^EMF1JN9C+;II4BWY$_@C+?ZRP_F-ML\ZC\CQ
M1H57-LU56_V=\XW_LJ8X&[U$GR>P9RE;'M2$#P,;^<;*&!C\0/HHJ\0-DB;L
M]I; IH7V(JYM#:7"GSN6(^V0BY*LT]/'1M$,7L&%(C*J$PX>EZB$^!Q+E1!<
M"%=MPZI12R%\_L(-36!ZN!>_YU3UU.+J8?0\'VK CG/T\>^: M7:><AI16NY
M0P9O  Q?*//^#?VN E*TS7_XTG!2\>%]Q:]%=, CN4Q8,?H4'0J7HO5)C33*
M\44+5NV%RY#/);0CH5DR$ -Y\Q*C6.?;IS&A(KY\AJ>%;_X[=T)^)F'R"'0/
MJB9806PRZ5BJ'3N%M\=2*>001A ^,2-K(;(C\4.O'_29.B1R;@$Q[4!#:T._
MF#^$X:W#F@Z+R?UR])@9Z*FO,6&[L2FSSHL<IP%"'D!;D\B=QPJR*GWL6.*#
M/CBM#T-3D"YD4SIH(/:?9L)J;R$FUUG@J=-/&)7T=!F@OP*^L$J62/?4!TF@
M"7$>93'N$YE2QD[]( <RK>.*>HZG*8SA67&J%;N&X6H9!)S1D10NL *"J,^.
M18GKD>S,;W&F=X$>CX+\Z;@H_J,4C??_3!EZ7HL_('QEKZC0KQ$OJ +FX= L
M.(*-F6U<7%T)3LUE#=-U3(7Z;$)_P/E*5J/F4. (:#)%S"V@1]^"IO((_F$:
M.NET=D@ZX<,\,'W5"L(F3V#>G':!3>1PJ.:&0@-5 #P9AUI:B6"L<GR^7..@
M@=#ZQ^+H#&:"=="H&.31L+^N=7M^]4)\=\O-D(K2Y"&S-DL:E$"C>5X9F+U
M^,Q/*0N"WLE=P1*?0GY$6]8WZC1DZ UHZMT9YTXN4-</FNJ7D;,^;M54%'BL
M00@L@2A@TZH;F#PX_1[#&_P$#%/'[I Q]-#'2@P/B,<DKOOP-K(&F!8;0\]]
ME0,#',NH<*CSD)7XN8_.#,2NJ^I_IGF0Y&P:_BG,_E\@S*[_2V%VNE\#9GH+
MQ:P#,;3+\XK7@W$HMMGAS.]['KQNBIO7IF*"1)?0:CX07L7<)]<R AIG'I<%
M81/*9("Z]Q[68+GM(JO*2"G[MLB";+%J]+2IGRCPR1 Y>]F58W;N9^WZ_Y;:
M]=+OF3 [S.(NJ&/0KP!YJW0KLR6(C]?M 6B,P,7',++D[_!J<L48/!+CRS63
ML9\)>\E2_K[L3*,'[J;!ARRGJ6?&3O3:=N!_2/F(E9&+N_U$6%X!25N3'04U
M6-!$X!C 2/][I 3_NJ[W1\443-JP,?JMML7WG#;NO4%+J'A#I.KYZ$7B&/<8
M3Z:LQX><U$L!0=B4Y,NB*].CYI>5KH4_,_E(U&R*_)CU+Y5J^)];>K9:NP0Y
MA[ICK.K3:%9$?)502@CP:P*F#=6A3B>TX6G""N\\!U.^Y7:.31F-?G+ .Z6C
MO\Y5,0W$J7\XH4'D\JS?;P4W Q?-FC!_\((6S^?/05_NC2*G>3",3EK:/U-[
M9N\[(^F!4*1^HRR="@&B^)-*S%S?_0R?HU5TW;&+RJ&WQP+1PE2_L;[(L*R]
M<JZ-@E:UZ]UY>#_CUIX:.#<+HS3XALNQR*HKH1[-A1PX50;]VKL8VKH.KAVH
M)3B$^@RX/-#[WAG<7;IY_GK''.,4]65755%I1YI"4)M!QME?6E:*?>#)2ZC*
M.B.B9>L'(?ZT(&7AUTI&1^/\U7K^H26,]MO!JCY!D6.XH1D<CH+Y;-?%>WRX
M4J!Y/.;'#=1="01+;,"C9<^P#Y9=9MO3?R%E4'(KD6Q$,IT][7CDT5NZ#60*
M?L#8)'*@?;8L'/*"TG#:/#0-CO#/Z-2@%R6&P+)^4!]]8I@XO>(59-X0\,UN
MU!!@1:#2P=1F5FJP"C%7C9QU,'-A+^3AKWZ!/:MHQ,XU,_#C"06?%A$GV"6R
M"(AF#$0,8R#4="0 K,BNM!>_"%GN!F!<3@(,CRM^2?(1@*P3T0=G!$%.J/DU
MP4UC*[!<(.LV,U0^M:B,@=[X20V(-YD5^;W^C4 M8E%FC+70@G]":,4MNV[7
M[-.&IL UW+)2'WN7';_N9D+EA?"UTI;@QL8E.S/84X_;!KD1M.>_)VD@;*Y3
M: -Z[K"HD1OE=[3+UNS#TV,L=1C#^-D+35PE5#BH1PA!C@O\=K+E&"=;)9!?
MO9=PP1\H8WW/_T%]88MF:D2F4E7]IA]H8SW6_ZBR\$G\T1Q+N#'VT3@T'+TE
M[N TU"ANMGIY"9!LE[OCCD_(<O2G,ICY-4C:.H+>'Y;1XQQ"=@J!Q[6AV6OU
M:X'ZF?>SW]T9328G! OU2K 7\^CWY0:/"T!L;5P"#MXU7]J9 UGZ8SQEVR#Q
MC]GC!/)/\I"/;B+N0H^FTX$?>X]FK"3XDA&@+A "C,43:>K'>WV@Q]RICH-^
M&0O3=A=/^4.35Y.U1'=V$&IMVH KB858W\ID,[XMZ&?'V>?[SZI]N7G_E,].
MAE1$FF+>1J+9<HLA;%PS=-+S>O=BXW*%K.-C"@!U->2VUZ$9*XK,CQY:O>Q8
M O3!@F6%17[SQ=]6#O'.6G9H06J!U.'D.H?_R"]FS/V39Q*NH((2GJ)O8J[\
M04IQ[(](Y]4$PX$_%L9V*%7B%R6\E!A7D30ATX__(\7MOMOQQU[<SI>;C6\6
MGN3T8D\N$IS9&.<PY\CH/U(6MM_I8['VC!3\P'$(.\=WXVFR8]49OU7%D/RC
M&L>4_#\HBVQHT2=?1;>F_TE*T:RYYT\(Z.:'DR'+]]=9L,MH#W),'OP]<^KC
MVX=?E/*3@II:1,Y*)9NQE;=SS'_P-O)D"+FYF[X2^HY" #*##FCR)[,.SF"O
M<'<=U6>["A6>P,56[O@,FKT@\FY;CF\K6V#C_+XI;O=[%CT6;$9.'T>#^'/@
MI5*CY5O1#G+T&K*32E-K]@1D\5=R;L>#MXU9?L) G3QYBA&8Q-H=XAH)9I4%
M%^+_UR[,+_LKM$29MKN*7#B3=JO;_O4K:;"6,VEB5J'=1/\H6/%1QD%>2U!W
M?_Y)=S^184[U46]@,_7&H*R*C:TKR2(@\Q LXHMT@B#Q=C5^'OC$RTBPFMI1
M8+V5YJ=PR9)W6_RH^H92DRAXPR8DXLC(K*I)@W3UVX9YM>O(UV?3:Z;W/5^B
M 5(P0M,X6K]9-LNF9A;]1"3T4.V8.=^*K2MXCPQL[/F9JOPWIBHOXZ'?W(J6
M]1%F*9B7P(H#P+ TVJB>59CEB\(TH;QQD5\./RX&Q?6XF^^\UHQ*'YYWAMHC
M1.)9*,2'>Z82]I$!^8L!A?XI5IGV(%F8=^G/!?"?"^ _%\!_+H#_7 #_N0#^
M<P'\YP+XO[X ?DU@/M_\P5TYZPXYGJ)C+W:N"ABP;B,XGZ8U!E_&/3*U/U&]
M3\B]-D+GS4&.D&2+3GMP?P3/[O'N(^(\@S[EKWP/**ME/&]W/:%V0:3 D-[K
M\QJ['A\Y^R+/F??S<$K/BNGC_:MU5/N;O$RS8$8M,A:_M/3EV:L2I;<K[H^*
MUK+\5VAF@R=J@K-_J7&EQQ9)5_OPLI27[\]%V" /&MY\8#.K^H(K?WP>^W2H
MJ6P'_7"K*T94H6V^[H5*R?4[ 9,G>-[O,FX[$'#592I0 ^%L>#J!A\+G)TN^
M%)M=D;1JKNC=.^1-V@%P_1JZM)/_NF^SKX0RLYOET-3-<H&LGY,)TXOS5YMF
M2[X2/KE1AL*0 R\@4ZY@ >NEO!1*LA>B2DMEN:KSJ@+1KY$X?6H.6%J-8?"J
M]!14N/;Y<8X(LK/6TLF2WQAG*'D*+&-Y#%*V9J."]++,JU60E3?%&SQ2), (
MVKPH"*.E_B,IN9^1".%\E"4KAXN@;<4F_![N=R/>E]WZX]>*))T^?M@['O)#
MTEIFV@8,""&7<'.H"F!1O <BK5B^%(N^+1)].A8_3+42VEXS8>G @KX/CNP"
M:IV86EK#6HC*.G==-. [YFH7\2P7?PER1CP>2[_N5$TZH2$Z]7,-_^<:_L\U
M_)]K^#_7\/^KBZOA?Z[A_US#_[^XAO]+G%UO4,K3#N4FFT<1,#X:25V,6 >&
MIE;IGI&7\0<$E T7!_U5[B WC@@&-7Z>D'L6;57_KK%5#5C7BI6A< 5=)$\$
MI8R;R4R>EHFWMN[?'OF^5$"K3"4NU/X&T>MTN?-"$:)-\)S5[\6U_M[Y:4S8
MA/5A9*CJ(4=,K*S-5;7/;UGYCV9U]4YM/&SOQE-7\A6+E4="3$#MDH7YUP47
M*5S!DY3ITKSFP,EL* R]E,V$]7^E&_DUMAR/6->CD!;GLO :&NIW@C#<DE+W
M029L5>;&CSY/0OO1YP>A&/#SRZ"I":7>>J&E.WJ9.)==)5F;^6_N.QXO[ .V
M)R\=,B\M*+=4Z+9N3/#4:?T &>_KCG$FC$L=T=VMIPIN>>UI<WVRUOV#7IV:
M'2=$$H)3R3ITZAARH0\)[BTI0]P57 $V;_88R<(&/YSOT8VL1RNIZ_[2?V-_
MU!A:@PFKB*-"@WDT)1)$@@K^^-R"P)#P)^:*HZXSHLW//8%"+B<EIX\N"7YY
M')!'YM'OC5RD= !350#=TD,4U^^K9$!)*,@XPO^V %_L^<S4\,V>"]J>8PV^
M%DS8.@L2@;$N#@EQ!-9J]K>7K7>NN6MIG]P[O"@';N9!@IZ-3)A/)"4;0W*N
M5H.7^RF4M>-.RUTL>),WO?%<^)E )^-W,LJ+^KY"?]IJ^_'GSS/KGY[1/Q/O
M3E=0"D .U4+>!@_1"XK;()(/W.<!U)1)DU-34BR(.KR1\G57)<)-'FZY&_[&
M&O/&JR^?^-9O*P+GX&%GUP$A7DVC9^[0I:GM^5Y#6(5Q##FE3 1H2K>&/ @3
M%GXDBH0G%]&5F##USA#&$AJ4*D2+T+5;5/5M4ZO/\W0J9(U^!!TDW_M[G4MP
M'&FD&A%Y\<.GH!"[E@FKB5Q^Z:\\175P7@DT1D",Q$^,">L;9AO%8L2_N0%5
MESY,+8:;2G@;,]QIDITB\B'F&"DME/]J5LP[:RLSQ)V\V5"^6G43C:5DNN,8
M\*>-9<M?^]3"OXLG,LJ);F:M]CQ*W"7X_,U81+\5H1?HE*M0%R(KQB03SXQB
MK]E>SM%M/AJD)WKK#1;RQ$&RY#$PZ 2"#M =8ZC)Y(RW-+F*"6_#%OHA^RN>
MS@Y6>V)N&+X^)-QR/_[IIS0C8_>+\"4CCQU1_CD=GEN9,$,(>P6LY'KAMVG(
MH-G#3]2."A5$6Q0\^D7W^97MO ,NU=Z(<GP0R$WAJK@B8-SAH^;H[JU2/]BP
M>Z(Q].SZ7AI,^LVRW^"@JWK0YS*Y!^CO,H#,"(IUJDU0MX"M)6J]^IK5FT?G
M%Z;W9GGDEL][M(>]V.MW^57Y8DB6]Q1]CW,(>E8*\L+]T#^=Y9<:PNR6Z0I4
M&GN(@3YNF"4*ZP$L(__-#2!D/;"UG:8%%.[3!-F=A186!-/PBQI;SY^Z+C]Q
M"DG:U\J$#<4S80OOF#!!6BO(5U")I?'+ !3HJY*7766)&1F::C=G*6>(#0(A
MF$UYSNM\M.Y8MITO]CZ5[Q%6$8:64>Z]AS2?!]BL<RQG^5C7E*![4>M/^[6
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MSL2NG3EUZU%::AE/FT Y#T"?#&*LU4HI<9V=RO&9C@$F&LJ+&<,;R1:D#N3
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MKX, :;#_*Z9!G;EBJAKH>)BD,H.[<'RE"AM4'2_V)-'X)B+UHZ2Q&/@JN2Q
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MA=C7'S;R[RVL[I/3&A?TEEL;7&&[9YBG?K.2"]"ML%[08."_>*0P&2S.U'2
M&TXNMSA+N;[&J^>9R')='GGL&).S'GV(_9U_!%\%*1N&4.CC2P["'%^ZBO&9
MB]/L;<_OJE+D-__.E-OU/[R8\VHN4K=DVTQV*4=!/O5.=0=TW<0!BC6*]UFI
MS)9H&;Y1?\U36;9:QT*W\?7E-]M=@D8?2WU&%)F7D?(LH%R3!>P)I0\S!T8-
MXT.F'?2,;C0<"TO/^J9T\R'9K^9(WW3@ N]:C-36@9]@?N2A*<8Y"C)[-CS"
MMSLPS;#Z\''7<QR)ZF*BQ[,$D@EO,&\"?9[(J48=F]0<YMS-'T L&EEJ6NVJ
MK=8V,I9_3@D@3*@V28%.(@;4I/F1\_=3#M<Y&+S2WT6T,7>O6;*+[9%J$&YQ
MEGT-KD]U^'A[Y 8.5SX^_'R^&[W.2:R]AA+_O5$<" B5CX 66$)*DX*LJZOL
M@KL#.^HS=)_D.T:R)88T<@1U7R7G K\W3=>JT"M,\\-#Z1"YT=6;=WAJE(\_
M33UKA#M$+ S'K(SY'(<>7,D&CN@-;D!TLG^B4A.VZ%\A/0Q#U57I6@%-&KX/
M]/U[FZ$1"%0&W*),5O/%ZZJ^6]9<KM)9OI=UFBG9(HL$H9LK%X4O*]PZ<(L'
MX%0S^Y^H[1Z\PA'&0X-:#;\RV(_N-QGBHZH722/EV;#+KVGQ^40,0XNTU:6A
M[.?G<A*?3\M2T6<8MP((S#0F-D>&UB=5,1M>YJG][FBZH&/)A9P'G(I-N[?8
M\G7)VNP):PVN&&'/,)]X+ Q8MJ#?%C3A>!CPPTS".P7TJ<=OZ?WP1QPGXUXO
M$PQWN]E7;R;9[SH]H=_;VA @S-5N"(<J-"UV+-JR !"6-(SR\(IP<'L>I%C2
MD7D6N0#_\0 I=.#-6SZ:#1B;9I<[86_Y01>0 J7[JN=&JC2D1UP@ZWDCM*:3
MW&Q=8MS<9./79BSZ:%4'$53Z]84-#V>-WGIS5RX-/,3.;]3XM7]NN2AJ2H.$
M"*,6A* .!-:6P4!XPXE($$USMVR7/Y^:QQNR?;TWD;3' I[,2R04V^'G:UV^
M_AE;%;2%#6UHU&.GLT^OI7W5[$9]V;:XN Y596H?^WKR;S!#0UM25*JI(;-:
M\3][72L-S6H?.JT5W'?"*'JS<X6R "ZZEC-.W"U.0W'#5]G[U&OHVAMH/PY,
MD23@.9[>!/.Y#*)?"F#N?WRJ'-MQS4%,TI*]# @G-,&B<;*T4++'KPA_LGG&
MI)E\]74OQ8J'2G%O+A$ZPTEUI$<(=EI3,:WD>@VE^FGA)E8T7WW,\?/!4#9*
M^S2*?SE7/Z#_Z^3?G[H;WLH"*E")0>OBRQ>QZ7/)53NDS^-7/EM*WR[]^5@_
M<;,[PL .=W(XCS+_&"MY=WW?/*FNIX7DW@-Y7P@@C((H=785M%=>TU%^;B'%
M_[3+:B;W//MQ;^V4T=5=-#8<NFKNLVW)"7<>UUR7"T8'JV49<GI,53@G06I+
M:'&SG!7TL:[:T4/9<52UJ1/@S*C5E!O(8=B&$BV<V?"G_56!_3F%N$+PFX5R
M>V3VTXH5_5#>DHU/OF>,U%YJ0S1EN?5_=9L1::I%BBR)IW_[TN\)>Q@OPU75
MIOS:Y *=H.?5J@NEF]+26G#'![;"G21,,R2X ZN-GIG41B>R^7XG"F_Q-:V#
M80A#RJTO/45>WE[JSGHU9MYCOL7OH6KR4 T@I/(_TF$/G$RX"/U-77BK,!CC
M6?5)1S7#NAR/L\;7Q_)TLW@5\\L-9N5;ZL!/]I#9[Y>J;S1Y>,!5"FSU)Q2X
MNBKDU_;7ZGM!G:?)Y@:$*<DM\Y";,-7NP=740Y<Z6_B?>U\+W^E8,\&4,$_#
MW\$X$1I#OTHN'QQ4XZB6=1/4X;A).T:<@4$15_M7*BU';9I''Z9[2Y9E5WA0
M6WE<#NB_8&Q.?JTFOTOR*T=(#$]7&*:Z7U>YK-!Q4HMGBK9P_L F)A9R&/YT
M%AR-03AG%KC.VLFZW\XZUQ'<B;P+TQ7TYPQ(O= :AEYI(7M-.!@-ZJH6_[.!
M>WG,P>!$E]*5F;2%]Z(L(%PR-@!ZF*FS .&F.>[)?3K8!?M>6>:9(F?M^^/C
MP88X'HN ,5+A/>0W+7]H:U<_G&Z8K>9[$55JH"\:XLSC V;V75R/(W]U.%8S
MZ"-!=*]OK#/3FFA?1MNO0V=2'Z(6?)^R@(,$%I!LD[.4HU9/ :^R8[SV@NI%
MM([MI8^6!LS?&;>S\+VTX%73W^ )/3JUK!GLOY!YN1"_>%0]WI_]K!@8^A6(
M ,^42=-0S5^<DP<.=\<6!,]=JPM9N5;;9G$N.?W]7PT-H:2V=2D6T,Q-V9Y9
M/352["E650%L%*!?L8!IF=PB>V!W:CN2NL.0 _-+-7<Z[;DFVT]*OH^7):Z#
M-R6,/M-))*D_*J-0P_]0&27D7*3(,T[D<C'D]58<@LR=/<K+S?A>"16'>M#8
MT];:<"U_]:U':KC_^\*1B-2D#9,;6< 1%<SY1=VRRZO#_4.$6ZX<&5(S!@+K
M"5MG=G>V/V>_:$%*18+3UW[XZS4#T"T9?2G8.P0_E;>!TC9/8/OE;&U3D]"1
MDN/PZ$:(YOKZ<4%.7I3XGL2TRAO,!.-\ JG5.J2*9'U4](17NYVXK2]7[LM[
MY%.HZ9/UQPCD^<1*[Z-F6,K/[*]5Z$*'5L_)^Y^>F7;F":Y_3TN+-'+^M45L
M@4F-,JY2'H@/52*O-"5J6=,K?IJJ/>/SO<01+@YLLH#1.#QJI(%/.= V5W")
M9. ?,ZS _%,W?%#.M^U$*NA'!!31'E+.PT:/,>\:DCG,P-H$>BF!4DAK4$3H
M[^>?S^5J'"M;E9(P(NC;KJ<W')1&-7KR)1@CCR/[PU!/RM*ZL#5PGT/7HZKW
M'8LA;RSW?^F#;?K,DZ]F:*1J\B2S*_(^DMI:^C].?4Z+H1XUI 7D)1G8J>NF
MIF8,]ZG8A[!K$_7U3,K+:XA/P$?.3ST9\. N&S?-" LD*C:)<"(B-3.8 @3M
M^45]L"K<J/4B.I$%N)>). W1<I:O)Q:K3B2!N$I60//#N$%,>E")HK?6=M.
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M_W5ED/^V_[;_SPS$&OD?4$L#!!0    ( #""6U;84B3YLS4# %0C!@ 1
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M/Y.P"FCLT#YV&B"E8Q.<NX[\8=JOEOW'# O\ARS[-\/^8M<$0 ["PSX\T 5
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M5 0EC7-CIU%T,P<#MK%_^;\5:&,% XS ^S7S2S% H7%ZKAJ>[-,&7E1^AH>
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MY4FRTXR2Q*SAQVO$%[_1A@N1%O !\-?H<X#KP_DT_H8WZ>?@:1C BIN.S,#
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M4A+I(;YGE)*QQJI>JN"\I\&0^\/E/DC2"B83 XCR<\?24&F&GA:W^RMI/6R
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M=T1Z+D!]]@V]2::H4VQGX&/;?D3")7"-FB-3ACYBBXY6+BHD5 #G.V7=0@O
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MW<^2_W? MQ.YM5- D:# :'9ERM8#DI61DT R^KX<!\&JE/3AHQ"#RM 6SV1
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M 5.60L=JF&ZB)-\^P_P]9W.CO!I;+#XID=&EFDL@"&99COE8Z/D13,4+87G
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M/^XNM-5XY@J7*>N1A$NIQ%)'##6$U*-,!67$R>),=P/=KO19X-8EL/'Q$A
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M,G9U4<287:Y%"$,[=4M'2%QN8!I_T0QSEDK^$10QOFK"0$W5+SSXRA:.V)=
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MB6:[0X)X71"?;!'^GFYLC$%VB:&FT 4-XY_L:QZ4?4W_?F=5X&3R7K?OZQ^
M5A_([GVTVX0?(/S7PEG='>F*599"T>9$:"N4Y15V:>1(]"S&HV!5Z&DRPL;4
MQB20E74I4)F&:@ED]EL"D=#X(N+=@_9DR0$<2X_#Y8@&[9YJ/=>^XK;V_2]Q
M-#XCQIYEA3 M &S>7[=X8>?QM+--57O:*H<8)?UK%C_-@S#:3 <.) R!**ZI
M"/W><EU01$81]XH^"3_=_E'DH@9@=!] @@X%7 PLY3;2SEYKN;5**08: +Q0
M4TTMD:YY ([%NWOQ\OPE#%'&QFW(N7$V8'X[?+,;[YYULF&%GPP+ZY+C4!R
M&[!#U^$RRWD73"Y5 W3[)QU^BW])UR2*5!PWVR32]@)]T3<H>TA(H2>*_P%Q
M3"!]HT^P!KS"1^!4[$Q+16$IP^7V(%;/MSL@6(4OD;XDE4R)S(5][/B8RM?R
MUNB\6=,H#?/]FZB[P9%*55*/L<,L*S0E&#0!:(,X +U?G>'UWP3.DV)6T%WI
M1]*)6+U&YIX6K"D[Y%!Q+."VYL=\Z[$IOP_SC,+-N5@Q:F]EF\G'G>G]GA <
M=B]K3E-B3TW?V^X(V08_)(Q98'U\O>!*=5W3X2YF8I9$+HN# <;!RA'YNT]E
M_(%_(-3L/>("O'W@5SDQ+KQ8B.YL-HQ@\<\!>!83%>60%.(2CD7GB\L5Z+Y]
M+-M!:^]A+P.Y*OG*[O_!&CUK'QYYZ@%N+PP6J1Q5IPZ3)BL( W HPTC^MJB7
M5DU3=1567YPV106:9<0DW%CE((!X\EY![S'HZYQ'VNZ:B'Z%YS&W#H%$ND9Y
M]<!'=@,MX?'05V8#L3TG:X=S!DK.-$7?]-X>*;4*3*<_4GSZ]"G RU]7FX*J
M(9W/33FCR(OA5J\M;^09G/P&],! 8?:%N>J0 @9-Z1>AX9]I:')G^9>:4SG>
M2!_FCP^OZ;QJ>:^6Y314P1[!WS#X9+:&0G*'%!3I:\T$KVJ"OP@B!D>[7;]+
M4?<APT] "6"UE/BO/2Z,BGJJTOKF2X7U:G>E5\V18R?I[41);Y.YPWP@?0S%
M65 811[&R_2[ZML3I].^#VS<T21FX$M3E>91%F+K3GD9"$"$#16_U),KK>*\
M]ZZ/S-!JHV+=^ES:R)N&A9*O!6F+&7W6JH:,?'*OQ3'4&#]=UH+&)K>F?!;A
MO0%SOD%U"WH/)M,>O\:G\C];M%65OFT)12[_+;+C/E1]N-35]][41A2/H9[X
M-8@S&EK/G2/G:M&+X68S,PNV(8W6FFK*K;&_=SZ!-ZC[H>VJ>9RCV"-M2SVN
MJEZ:](9\[ Y-2DSR4:'9]##6Z,H%N:G-^.@I74U=\J;$8?=7V3W5+FJIA0\?
MI!T5.Q7MUF](ZT=I#+)HK,X/#!S#<H]GSFPU\J0>?BP3_(8%\;4O/\P6Y325
M;G1UC<RT9M\@OA+#76M\J5TM*RO.:/?&.SR5<3P6]A+%#*R= O]'"B,%00%2
MFJY,S?>\_ WLW[^F?CS%?=I;V<6G.E8O)X%& DJ5<TPN%V"?*$CT/!JQ>F>H
MIVC% 7W!U)8/PO!^&/*:"Q.&9CVJIMHOMCP>;^NEV?E1D":_&7^U(1E)JWA!
M:9^PJG'@N,/6=EQLMJ10HQT^D7]#?F $^^01_4TS4*.L:)9G/&ST(_-&D=5]
MB169XSQ)0B:[68Q$B]@#Q[IAPX'7V7#I-B,6Z"4HR.F^DC]]L6N!)*!YF>PD
M@Z_/D)(PI$VC;2 Z\S&*\^B^_2US2J0<,;W!>%1VD1H[ OK^!H]NLLED^%3O
M4%%>/5VUCK-G.6P?S\F, R<MU'FJEQ-F9BRL2'V1]LW&@>U55I(7YVH>'-)2
M_>WE"$?*=C,\OHZQ-YDQS9(N)DM+Q0<E7PK9?[4J_/\O\E>2^=1=PHB\D@'1
MT$]38REYF!MH,%/D*S9\JE2=*Q6, D9&ZW\ 9\T?^'N1^X6L.]# 0EE5*?,M
MWZQ5JY%SQ2"[T?FMVK']D\726[RB@5XY1 8$?"/7C(Z.3$EWQ/B?0'<K=@18
M13 B0("(1?C0WR '-?4;)>[RA<IL14USHUFGN!8\3*XL3KX_#%^8!O78-CUS
M[]$CEN#K<TK@53=LNOCHK%[RV"AGB2Z&T:XHP/<>W')-K:Z>/UGMFQX,S/'O
M_H):XZ9(G!O,Z(12;A7%Q.^DP15O+N['$:D:/3UK^;>N#77]647;A46G(D$D
MM[IB<2 #C)FK>/BUH[OUTH["T3,%;><<CX)>U;"'KN\;2<;#1J*EPG\V01E5
M?LAG#UM:/#00?F6Z6[Y.%/7"L+LY4E6ISY,N?$F^EQ%H]\(JP!<;(3$L)&U5
M\%S7@!K_JR=H7:U=(K>KU^RPY]QJCQF^VD?TUH\3'PRL70O]?5ZGI X *QC4
MKK5NI(V355NTHVU4,;Q@Y8[;=BZ^VC!N>& XEMU';M=[9QYV#/>:"!DY$1;"
MU]8GVH-(UPY[^'?V$I^SBIR);4(&X'MYC1\:#A^:SXPZ.3F+D?(]AO3"]#0I
M\B9-V;D=2BN(&UMSJRN35\6BI S2Y9!#U_RN!0KL.0_@,EM&29GG9B,*8%\6
M4L=>G#H^3XWQC(&(/AM3S?BR;><WC_=E3*H?OB7\W@F<FYKJL+D70833Y)>+
MCDZD#5.*M2FD7G+TF*J!&=DOHY2OK=/_6%5"DC\E?-#K#.Z<Z&"[//JN"%&5
M4U73LAB!,3FI^9<+J1OL?^^,<VC.XO:=0X=V(+R0W.>@1\ZX&[6*GN[OA9AY
M4IEE<78CX43:"2&M-9#'D66]7![C<JF&M!<I2"Y9>X9H.J:E#(38_N<P7K.Y
M@S)EM,1CA. 3?_^6'"T&\<=@Y^%")KOUXU(/)IU\I[[7 Y_,XNC$#DHLA#M$
M&LK;1-BC^\;F-D([/8QMC^OEN^V?WG\^[[\.&<_1 Q$'MYD[ !UB*N)3>X'!
MB*U]&YZO[I@?#BHHP&0WGS%C7GYCYZ0 8$49R1;8.F^Z*[+TZR3W$H9HC,:O
MV6G&R3]X9J,N<V,*VW3>U&9E@>N/@*2@S%]>5;OY%#TE 4LQ2S:=>WNO[%73
M)]@>>QW8XQA^?.4V$W-H%6741^ZG,SJ>08K0QQ(<J39?+-\42DQS1?H0J6GK
M+OY1J^[7X#8O5W$#*_4' '"-;#S$[IG5B_">3KX.EQN.6NN*V7P'9R,7)5GZ
M1NZGNDG]LE]@.WMVK#K<:D#JX<(A!0*I_=6F9UF'.7Q14IS*>AN0;N[>+(@/
MT=MYS-5&HYYY0SV:3VL.V9TZF5#&7Y[0^ ?^#JC,&'2](O4D 0AO)=8?Q-Y]
MJB.[% $&N%9HDSX,?_"5PE30^\"0.+UH:O/N5>[:W%MNZ[\A?8X1O@G5343;
MM:T\S< +HUTV/>YST!MXO]9@"25N-RX&N B,0\TJ,!GN' E+4]5X[R@MWD@,
M-_DP97'QT[ZGGXO^F4:8^Q^N=0V$5V2.88%VH_1P;:EOJU5AC&_3\QPPD7:(
MS_Y_]-X:8^-J4STT[T-,5884!6U_T^B?]\\B2&7\OH=:!5)7NH]5?YAMIWF/
M])\@VW\BPX\%K,SR@.[))BR_SKB:7*W/7R(;MNI?.N3K/\K(VO8V! 9F>$1,
M:X< YF4PE3R*A_R'&TF^R!I2,JK%;LC'VWY%#4/6?YP-&W:@FYQ;:Y/3:J2]
M5H(9$_TO@;@,&MC]>'=-=.1B#>+>^9B@A37KG2-O7E6#_OK%Z53P%-\TX1NI
MVGA+)_G[RHV>HZ4)PUC(E0NR\ (SD<6^G>NS$5(Z)T7-+-AB944JSI9&(M/3
MNVE.S(&,BNL^N#E*86S',GU!=]C(::R_*G^"+[7-W;%QFS$"J!QB21J*!"_H
M&[*Q=W QHEZX[AY@'H!5Z<7M8 /A6BG'/51O8+"N_Z W*6F%#25" Z,DP:Y<
M5[^<DM(VZE5_73WOH,4YP<0P)S8-9$4%'D_JT&H3_;YC0.5H\MM4'5=0V\_(
MF:$,-5)[D VZ*0F0;G04H=_WFD%WM*ZQRVW8EGJX(W;Y&L$_%>=^)-2;8V=#
M05L_/!1%,Q^&TUWS;B?/^@6)!1\(Z""EYC]XJ1<+&PO,AH=.I>6)Y#D-?[V@
MRQ\"TTV[6[02!FB8%:'6;+8JJ*)SSO6#*W#GDJ75AVZRY0MCGX>FU^=W]F]&
MS YB;HK0#"<8I^SH!QSQ*&R9,M==D:I@K^"N_]%"S'_@SR ?""N>4N1R"DL=
M77MNLM@8?3C+]FJ6_(7)>*QMO+*%QWH;*0W4&LST\Q"K>QK!J-!$>'DU-E^?
M@VM&EA$HY_H%^:V98?2Q]?Q/279/=8F6R>+_<&?_OXJH"2IB84 ?J^66>V9/
M2V**W6T5K(>+X9;R'W/]Z+Y/[.(Y&VX<\4=KF3E'V\1)X%2;^M#&]<@4>0AS
M:3)\(C >L0N<#5.SBC=(KC78"R3Y2"'+!QS2"/O]6M//40S#'$*V3>;RW(["
MRE3CY!MAAW4DK@)N*D&EY_<^9+7:PZCW V8V[ZQ41^U =Y*6S;@F*)@"B=3O
M_36=K\D\E[6A;1NWIWH,?VF\G[2Y_&TOBE$5#%RD?/W7$C"4(9Z@[%X:I6;_
M%'3H,0+OO%.P4L=N@B5M= 5YONR1PLFA)LSL!5I1W"A=6RJ[U*F9DC=:&V1J
MB;WGA =<HR ^>!_ FK,4GIJ2YFP42A3*8KOIA-W]YS:Q^Z[LY<O)E& BK>!_
M=4+SMW9+G++$-&SM 'Z0O-KHCDMWJ/(3]0CFOM?BBQM[R]:?7I7BA^45FVHU
MV!2["Y,3ZVL3'6L9]J<;'V3S0(?TV&T$R,=3OFUJDP5TRAH<30MI:KLY)Y@I
MPW+'$[0:"H25RUI6D ZE9UJ-K>FXSP0#P#3)@\,5@HU:8D_#RLZH&I^)[\=5
M)18<XNTA@XC6%U;4!\/<K*1QBF97)E9="&[+<M%40S65A2A&U]W<[ND^+VT/
M?<N1XJREJ8E)!!"&09 Y4MQCP9WF'">E:@USJ7[1\=")Q5_OPT.A]0 310QM
MFTLXHP[]^YZ%"(GC1Z%HXE%IG/I<0XPZ<A5IIR=+,I_R+GFYW8P(F%6[LZ)K
M4,IY&L<=N2J=;P0ZF8DI 90. +503-%N=_M*IP/,4/P!-6?0WVZ_?8WA<^J=
M%RRZ15;3,[I_\J5J[-4W(<S5RBPVW5PG<YBW@5#&LG<@$-B0Z4$L?BV1@W"Y
M7BD4_&DH_=5E_ ?^ZZ']:(F5U^M1):6+.72[ )YA6^T6^0AW]:V0QTEFT;?I
MRLJ9D#9TQPZM@GMJ,";QQV!:(K3UF_M(< =4/R9>/,:0UC,RZ%E?ZLV=A7WF
M$8T5\=/L3E8B59E?+LS_P/\]:B))-Q]]'D);48*4U?BRS4G?K/=Y*E6ZV)V0
MTO0[*Z*E@U&Z1CU+*JJ5X0OWU-3^;%0M,LN,\].1V.-=?YO35SS4UPH-8SF@
M>U+OI,65?F_D]O:\"D").?[@84CT%(\?)D9W"W4E!=7!?7VI0?T2-NDYK!P'
M+H6C;L,O-"E'"K>3K=(D=MMCMA2R,Q,#,_^2444<_S-!U*TNJ:T3K7N?Z*TM
M;CJ_ 0?8&'1M@P%.S?<=F)8%#%<ZA?+E+1OO#[1IN?7<CLH.<*>JI"JO#OYN
M(%=SG.,@M/NM-:$,;;7SBU[5#99V2[2;<6N]+4--ORTEMCYX],P';!#:%N\(
MQ[7UQ9G,_$ ZM![/.#9+L*#\BE+)KBJ*LA6A*JD]8ZO$MOZE9G\WE:]U6BI=
M7,.XY50I4")_X+6V]%Q\QDCH^BMR3>L=.D?GUR)5'P#TS,= B;V%8:F/F356
M(HD(R<QR#R][%Y>1/D>'*:O(F7,NM9!T)BRO+W5#B.T(^G<Q6T8[FG"65_#:
M9*!OL3D+$<778X8##.L-[J3Y%T ^86O$B\_[<8$35'S1U)L83GIY;RVKM*+O
M*.3!!YGC/?B[7BF;$Z29%FP\<TT! ]VV9!O+!U+1\T] <K4&>C,G"VI<VJ$U
MJ,D)_;?*@XA#ZS8YH>'G@ :=L=VJ!/M8^KW2#0-A0)R)>">SGJ:%DK8TV[,[
MRD#E:.M+'$8MZ[:,GJ@/-J.K;^X?F.O731E6J:0W=>5X*:AE#Q5F8.B\(#3J
M8"K-AT?Z=9ILFMHZ*?BP$FGE/?FG9:'Z>92UXCQ4D0GV.)QN>#0.6\X^GFF[
M9C>_/G$>9[ERCU3\!1FS69FHY(Y!?^,2_QYI9A4=:..#US@U=07<\ N+5_+1
MEKD BMM]IIKRB*RIS[<=%PCX>B@W+;L@NZ'!4(S'*UV+S-6 \C ILPAJ8Y9;
M#1NEDKC)Y) K,P>(1WL )ZPI<),WXO5S7AC54-7YW&TY/<5&\.D:SVBKA>1G
M:)C@'#/,7WZ]*&H3;MQ8N#DLCOAH;TZB8Z[YQ/467!7LGAT?<I$D^V5.6243
MRAC]R_N_H4!K!KEY$BQ399](6MJ:7%ELW&OZ8AA,&%5GHAUI.Y[@GJ!(V[^;
M!S@%]KY';(_&KY7'610^8//\[$JXZ94R%=XK2QU]9_[!,(KQ>N)5[0Y4!U!C
MYW=8H^Y,Y?<G 9*.&T2JV:6JD/D.Y$/P:G]VL';H5?^;5PUC'8X4@,8'XC0T
MWSO@<XU3G*NY21=C(@EE[3TBIBC;+^]O3/+X W\/5#Q_QC[F7YOGD>S>[A8Q
M<#:(\\H+>=DQE\#T[L@-P9:$ZU1&4>"HB&U!I*IPAW690RF"8)8?H3GT3&0Z
M-[NVWP-!!__6XA6T=RSAH9JL@#\,9?CC^/?_@T!_U.Z>_F)D@&\.&\%F'D\_
M5_<#0#J71*Z_M@MR/![T^^F)-?P!\"\2^N@>U2G+#VR=:K6CUQF'(?1&GNBP
M/%5A=PL;-C'(_!U-C7\+M*4=X-?%WTO,XO\0@5TXU5](_-&Z7[EO76 \T=A(
MUMMAN'MR>6E# 3LO*2\IVSRZ"_3XWV.X:F#<&#X-M:X);<VL<\6<NZ#F1\K[
MR8"UE\?3H5UHU"\ISN'U\OM>N13SA9&2AL*YZ?8O,DP4*VWC.C4K1XJ+ ??:
M'VYHY?_UOF% MHII_=%IQWN.>P;QI?,R>7BT&3IOUZP?0VHRRU/Y!EQ<!CO&
M/NTI:0EQJ0RQ'5_@-"A7^!(+C+WRGMT);+PV,FRU [9NI6&T>+ZL*L"7.$.(
MP/&*37Q$L(0#Y:6:(FO7D!IG/#%ZW6HZDS(G0 Q'T"O28\+HZ#J4NHT2_PN?
M-P ?'^R%Y7^M7AG?LQR3!GR_SCRP<2 S)/,8G\0%5,P$3X%'"-GADQ38W;^@
MV!(IM+#[F+;(L1&CZ^11U_$(#7FUVA"Q>+FXSA!WAC9<.*Y1.MP4<K#AL,/=
M>&&8]@VR^.AN3&2%5-[,6$@:-<7^/*+8 T=FJ,:"CZHRH?TR4]_SKH.$2X<&
MQ[>O887[NY_K$N:\Z!H7MU[QDU)12?T O!A/MO7J&\MCY.R62^O,EV666YE9
M3G[EK-DNEY>Q;5+6PZ?I6KA+M+[DJ</$:"D<J%\RO.MZ1P+\R.0'@)@/(;-_
MYF]2IIF\H;F\F>V6(Q=0((P5_M5ZP7Q/L*F+XY,'C_>:KM7%/2?-8+WC<$'9
MRA'SN[BFRDY,FPSA$OG-1)LGC"KAH-RUSB5GLHF\/4&V%I1.64O[U0KW+R'-
MPLBYX]I=U!N)MY$ V*M24_8:S\SI$![*9D+F[?-$T%TULP^DEY>!S[4%O><A
M]2IRHDG'P"TBK0>M(PF2PUDIBS ;[ZQ6NJ&]>?.F*07\\P+[1YT.F^)G")^T
M*>; ::9E+>'Q )>/'V2K'S5"DCT>GNINJ2XR?%[LG L.4S4*]=X_;E(LI_IY
M\ZTM3M](REE@GY"PS&ZD7H1-8&%%)7\/T]<ZUQF:O>H/YK5Z\)YNAV;_/9V*
MH9D<TI?MJ)U-Y&ITI_&*[9-YOU KAM>LAU04O[]FM8,#^FIC4\_2#@^,87UT
MTR3/HR:=LIW;T[8S<U,G$\I<<S'XKV4-%TH$Y";=<S55Y)(2J+MQJ4UP**4%
M4J8_O#XV[H\4>7:Q_CF5S>/L<1(MD"3MMZMGB<%9.*][:W0C,S^0'W-7M!.I
MJ0W^ZD#K_T:@&TK"M$@Q&\K;B:5&5)RDT$NI&K5J4)I@XB*__%TKOK680ZPJ
M6,6OTN5NEDU^(<%B<U%!8\YSBZ8PM!1V;K0M:V>R=!5&9'?PKHIO&>,)]2]W
M=/V!_SN\&%AI'5CG4B[Z;KE@,D+W91E!A+9&]KVE9C3W]?(#79<-\NZ5C[#<
M46Q&1NM/>'LXDTDG.JE!*A20$: $@^J@"URYQ>TC*X4T^>YBW=3OZ_ J[NX4
M7\(=(=8LO&GY5"-F4!MCL>]%W]/*\";Q 2*T\&);!,RPG/A"&I@@[<7T;SK8
M2W%: U D3C9=-9&)$5U8IG"*,G@%^0)_*^3=:B-FEW)0Y[VH_(T-N7FK#1'R
MZA*PI8K%+L0!((#S?VFD9C?G9+[E $7B36YF)"U]7R G._QNWU:M]WP;7I^0
MSR2H73FJOX5M/\^A\,G_&W! GX L].L).VF. 7/YF'#D;>HQZ-:U_ +IR[L&
MTW#3QSZ0J">P%A+0,C*/09!KQV&BP"/1><1,%0Q,&O[W] 93(7_S[73;31<"
M; -;6LLX1V)/+'_=-Q3A+T;OL7<C;*O!\AZM^90,Z\S5=R5 PJL>_)T6ZGBV
M+F<^<EZ6D9!<B?M$+7O)@SF9C<^CM:0[^YU2:K-W6U$6G<RO9A__&=2 ZDB"
MGG@HH- Y;]H03AM&N,V,<]0B8-',4GKO!T!O8ST_CJ_7Q5X>J)?00A?)TWCN
M(W*GB@&K%NYUU'IVZCE37_I]R&A4@8/:%2RJ:G#8,N)M[57AO*W G9:_KTRU
M>(>7)(5P,[?1MY77Z$WPK>IOZ,F-KIF3LVM?PW O<:+;Y/V5#"13O(<S@N,8
MC2X)V/L8EQCR:R8S?Y:5"4:M0T4K35(:@LX8-S2DU6-%RYG-?3'L+[,Z9V3+
M_0X!9C6%ED0V-M[E.JHI$?'R(4ND;)]353_J58<^64ZW75FIB=;JY;C>I)K+
M.P*M:O;3'><6N4CCQF]_BVD'?/\*S:&K=>M:<8S,48G@B;WV!]EP%[['NE5K
M1/]0V_)&"IK*%^8CM](O[ZQ:.3,P6BC.?3?F[.WUILO^U0_ PZ,,TU+G6?;3
MV*C(TR3?1EG4OP:(_17Z]:K_P@_ 4;*O:H<;P2N%CH=J_A]&GR#MB/9'HQR]
MER%!S2??JNJD!NUP_!*O-S=-."I>3GDEJ76H%$R%3@2"ZBN6/+J&BSL0*'6@
M(WO-%)LLC/01*RC3EZ?4%(VSVCEPJ7XY'1U;):#CNN4^']1G#7;';7OZ]C)Y
MH:2ME C&W#F)ZRNPGO=Q-+(3;L7"8M3U&EL8F[NR6[S8X+E8][3>:=TRI^-3
M?H12A(54;OADHE+ XDM5U2YN)P:FMG2OZ/H114,2E+Q0N/6K':3_6U!@RR/O
M8[D?=1;$-$N$MIR<E@ *[,V0K!8RT?*5.[W;)W(7.<T4V:Q%,X=78HDAZ7VD
MM"AT0&UE I05::U7QK%6BF#+-8Z-0-O2UTHC*:DPZ<Z.VM)G@D*!8NA3H6$J
M[!SR_Z!5O?[ ?\++XP]2!Z(@]]?V#@P5G9I E38[F:;7Y(-8:<-#*+LOE2PA
M2L-K!*(L476EE1NU)+R./G0,,7UE2H+^*)9L*%>B_BGXF"0/^3L"WIEIIK<)
MGJYG<:-%+0KKZ.A^R+9[6>R9$DU*P]8>K>PU,G["E6]<SVPI,AJC@.+ ZG^A
MCP4& 6A".!L-H@N=C8XLF\]-1E[S?FK<[N4N>)TQUXA/HH;M1_46L",WSS,W
M)6@=SX<$8 IH(/_V(@NWG5ICI%21[,(A?9X#T&O*4Y]Q-UM=@>I*+TW0DNZ]
MK'P+8?&B@N%PL*7K D<<>_F:OXB/!4.'3 M1W*Q'6VOG;-]L9KSDD6CF.(X4
M/G-7H>)(7-)9HI !AP9R'J7?7[C^:SM)K2#!(0O&1]2\+D1I:^<:9^" "9G(
M>F2N>0S0IIPOQI[29T7V:*E/3]4SG>Q7S#R%[2>-T6JUZPFRWL[)A&X*O?T?
M=AW]W<B-Q^%48FH</=8J<.?!<W:OJZB^'<A'T5E3RK?I DQ#E!8+<":5NQ>U
M 9C"$XJ8B]4@T4X.PN%J+#HK$8JZ52-K-=2V%CZ0EL(PQ/O7I5=1DV0JN?">
M]G)7&F3)E")_*QOD4^7@4ABFD_,Z1(N/.EQ,@S+.1:7'BM56D%!(3N_YVJMC
MTD??'9I/"]X\&:2%#GPM[V5?*?/6ME!T0<TNKG\+P@K/+T-"SJ#ZA*^PW]5D
MR9O"=4'8]TOMU>/%?/0,ZI3QS'R)C%A<PN0C41+K-<6FA_M^^3KFY/B5XQ[J
M6F3QB?739_YAVJ7OL[ P])('#TLT\^XT"&L73*Q;9T(7A,508X#><RU/6'W
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M3_CU&#(;RK?_/*)Y%4F?:J75(VQQL&Z3V4S.)('E6+GF7&KC7PE@8HD^Z3.
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MD8+SB>+K^1GM)M%W920Q-!'%^,W/8$N ZNI<@ZN^LFQ1!.Q2C),1=&PO=0&
M@W05B"?S#\]&_V<&:BMN5NMPWJZ=8?=J51OG&P_6')]U_ORKA\K0=6U<JT>L
M9%G@Q[A"W1  G-EOCC"].;1=3\3A'/OM+5FU_NS/_]ON^G_RCT;=2?3K&X)^
M1DFG"P#UNCBU0E;1NNK42:5:-BSA]"5:;"(+\_B[%R+TY7K#MQ?, ^6X\\+D
ME_]*OV*=G6G\6Y<( ILDNL=PW3PW(WWK@7(#RC8-F=E.O$H0(NU[U<U?;X?6
M*^Z:A_.$5A) '&C-4^$)@;9>(;R\39RE*=5#O[?^]W\"Z.WVO)]\2F4UN<,+
M/6^S55<?VUZ3-]LY*])(?"HRN:J6"O/A>#(I I9,].P.>EYI(P^([Z[DM!=4
MGO+=^E'^]]W#FCP5J=HYA%T O+.[LYLJ[K(:$.FDN3-5OJH,9LA]<J2[\YZ)
MH^HD@%A%3SKT1YOUOQ=PK%3 AVEI-7V7F<[;(N--0[:*SVU,E6"#VSY!T1V$
M!>*C*3[OIO9RGMVP('3C&[5[(3!' ER:SI2*%<$HA<_-K,H5GN?*+U@=R=?=
MLKTS/H8V,3K4<D:WX>$1O$-\(F8+QH7-9&M 3=OINSX]YC%,)K)(2<UI]RL1
M(U^==K"T.7;:*1+2:'I]*DG]T6*9TI_UGN&NKGF@<R:F70&]V-%O\]9S\#F)
MGVQ_9KYPCAV=:L0G>5=;"T&.^A-[I(9-U-=.N/-!CT[1H"JHZ!6Q'^-K &XE
M( .=DU0J62JE!#]>>VZ N^/"NM1I?DNEQ^\E)J^Q3O@MO\E3T:CNY9/:)U?D
M'B._5O7,89P*20Q@G7C*<_<HMBTU4/YQ"6-N<D19:+<IOT>"JH/<:=9X'T*-
M$YST[CGF9)#+T%6%X2,"W">$8L&L)4(/]UY.F2$0RT6C GO BKA($P[MYI7=
MF&=4GE<;I--T*-^\%2MOEW >W2 ;& Q\6A\\YP+<*31>W]8_=.J.G$O_U"7U
MXO;E/GD3:_:GVA+RL/PJN"ZCB"7Z#DOC? DV6G"(YO2 66I_6&0JW,^>%/5&
M/%>I 7Y\AE428ZR?5F7,52^X[T&?+T)!?$SO:K$TP.3Q,E@4"N[/"E &5 /U
M&X=MU_O%:YK 5I45).3*Z78YLRBU>(CGUY=%'82I]KU23]]EKH"ZR$QE]M$/
MM,-:^TP #KH"#6(NZGRU\II$ Q1C\*<O'MZBR41]%99-[< >36'N*7VPUM#O
MTSU<2ZBFK#0E]%&R[%;2^!%PQ:2J$4W1&Y42LV#&7:^*@CM4*$DB3B:,/LSA
M:V"U>_"4F0>Q]QUS"!GW1 AMWAGU8]#QWV^ =UY)J..QSVENDJV)QT \'(\2
M-%Z+NS/RKR@H5O&70P$CI?155M17<A\/F$NCNI?5-6,?A"T&S:^3A5V*L\%,
MGVFS*P\/[AY? /:7A?&?!Z7&3)=]W6,#M7>&H1F$(KKS]B\ JWV.[B,'T)'+
MHXVV/'N<J^)CV;74*6=.E&G&#VRVAB4KW0_E#KAW3^,GBO[],?,V3O^N7@'7
M?:8J8W#]3G.7_[[(&)[ 3%;A_6:>.%!B[U[P2$5^KDHXLJ%,X3U!22.H)3,P
MCI]5/G,2-_P=4H^@H&YG(_^G/6"!;N<KD];\Q<1E/; W$[97'UWG R)*=2,(
ML>:_3;SXD_\:-<8+@/JDG/=]\FO*..^L+P [9,@"D'$#[EW]$I6A 9&?\WH(
M!FL8;!S.^UW[JX\>!B60S[JX];/_7:+8?_+' WTVEOJQ.!66A4PX=9?=2R1D
M_F([V,N7#87'[YZ+7?[^\,2L[Q$*K*5XO* +@.EK[K%M/1&G*KP+P%N*"T"%
M==)_;W\JPU5DGB^?*./$NM<:@T],%BT:G*)0,S>%VR7.7N<@/_TRYX.D<*GB
MV]#L/GB5EW5^^''\&\2N&'[#@K7R%?YV.#(#"G#]@QK3?:1MLQ$)$8R\]]17
M6+*>Y )@WL\X2_D!V8)NFJ$JD\B&S*.QGB!GLVMSJ6$A-$GS^R)I%'=V+JVI
M?*''__X>^")7IE$N[J9J?I6K(^L,CT8@]^?R%RJHAT]+^RM!8X71XZDZ-.K
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M/_* OSG'X>Y<*BNI@K[LO12TR=O(07!Y(LS/:T<D^YKC%!RYYAQ4D<WU<--
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MQLB_E>8J*Q,#!'&G*BAMJZ84PLKZ)U6_I\O\YOBU?W9NCUT ,JUFF"\ ^A<
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MV.<C[SL+YG=>/0#F)+ K$LIOF<ZOOD8/$8N\7BA'/9 HZ)F]0G9\B!+_) 4
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M><.5]AQCT$92BJ %;DLGS7RAK98N04]\T9OK.!_OW M-M6(]9342=>1=[-)
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MKN#9JAWU?IGFK#I?.7?I5)$A\#TJV@NV->C(+@[:I!2>%=T/@W ]D,_6:[T
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MK)E5.+<U;9?,YEN@K7U^>].;T3^,W'N(-<W55G5LB>\?:A+V%.+945F"PD"
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MK\,'1.^T2,^XH7KB&SHZ94,#$:#P9!7VXO5&Q[4O)9+7-'L##N-[EU\ZE'<
M*\E;+BD<\.KCW(7EU$E@]LR,N7>(VM/>@+DR. RHN\7JF_!-2]RK<%O;-$EW
MZ^Y*1C2#I9]V6#>Q?L=^^XXY>$ ;9%PN)(_AI)[LEKO$UWB,QY_E=PC5>_IM
M=):[KM&NN;6U$7%R\"EWH$,G#I;TE:=Z?HAN)=QW"!L'9#PO8$O^?7#D1L@F
M3Q@0KJVP;Y+\'0E'>2J-MM?N2,!2)>P5O?H',1S5A#^+)Z878 60>#PD_$#6
MS^XK?<TFI:L@:VSOP<_]DSOXT W?YX'@I7?+6*.-:()[+Y7YBR4:PP-](N[
M-##^TS?_--L92-!7?W#:GM%J!-.Q)V=:)QY7VFY$@YVFP*CNXX(YK5H77$ZL
M?4R;N5CAF?\#SYV<-;KX$!*ET>AD<@^87;&26)9@$\/1Z$[_@D:#H\A"DQ7S
MI34W8DTSLH>41!H<DVHZ6<#@.P#1\Y,L)7+W3OY1/;&[1L(6)!C?J?A$)<H3
M]B;"3#L]4M6(GYW""U^R'+VPNT2H4Y!41L;9]BGB'F<5GYKIN%WV&P@(;8W#
MEM<[*=TMKM8D56-XM38!/U=L5R^2A+5MB53J&NB<9FYAW.^DX"RE(F-+;^"+
M6F"SL\C=H\^X<5$HKN064ZHD!GS[-SYU5HD?>";3&5IU:8/M1UV':!BE)VG:
M8-1<U&-7HN5,ZPVE*NYW%L#8W!8UF=+M43@M.>2!Z:J)^:9A61P$M0XM;CN/
ME(U60_IN@#!H3K-Y4NF7E@&O=TX4!42X0($.GS7&V'RU^<+]!5 G%&@[?$63
M52L_G).;5_%(N=\!Q0O@"HSV7R(@H!1J%C>ZX2EA4CO<B:F0L O[<O?:)BOA
M9:Y>=(\!@7AD^]#;Y+VGCDFF3T^+F)8$*#'Q#Q%@I+53KD]C?/H27Y]QI!^Q
MA] [V33A:5<W#3'FN>SO2>P+5-QA^Y+<^9M W*[2TJ:NDN+OXA>62G2LJ]T"
M<?/,NG)5RVMF9J.9!W/]_7B)]S"M;#X<S(>U%U>=^RH0?#\IV>/!5L4,!/)_
M!/5!W[CD6A%/DCQ'.UP+(!&C9#"U^V=*NY[NX(>PX@_5DFP]_E@MR7CL_X)J
M2:0U-3(>?2S T.DX_.)7+-QJ3SJM[RK>'?]H3DS[OH"V\EV.^8>-]4BECU3D
M$CO"Y.;9, %WW))P=M@9%%DQ&V"H;A=F^A)<_E;QPUSEQC_%\?>OB*+DC!L/
MJ1.(J\H?#P#B$%:F_E1H2>$OM9?44'^IQR<9C_V[,?SG.$8T^/YR!A#]7TY>
M^2L\'T!3P)-Z1>>MP02YD.8I/YM1G-)Z&+'(:RG.YJOZG"W[X'S]#G<C>Z\4
M<[G66CF5;S_ZIFT5^?#=G[<KJ>]5;J=HH36\<YP'*G[D!1O^UR:&A#: IG"Q
M,MD-@=PD?4%#+O?BC99;CX-J?KX78,UV9ZW6D#P\90,$'>4GD]*R<] H&=,3
M2XBV,LSNB7P,.\EUC-]]MU@1:4J#H_9/ND\!Y</=F-#A_F+&>8E_G-J*$);0
M2O:%_5VKHO^&<:/W6=)#]_D_!%2-SC=9,-(+SWL )4F;_QEVP#U % ?A;.+7
M)S>[2+P3TS.Y:_C%LC&LU0T^^:^H30IM]]K? H916N-/W5NP+JF>^T_]G._7
MZ.7XZY^** 53M,O[B)MSO,,4Y;5O9=J5)Q,U+[/\8:X"7:>(=74T2 N?KPG2
MV!1K2QM".YQMR<7H2!;-N,F: F_3&RS/$[@$<1KC*A.*+"KH/5G6UQ1:HB0J
M2*37FBW]GV+PM5>EDU9'/MN26AWXT)($6#_4]9^G:AAJ)29-;&VB'W,MJ/;/
MED4'"X'9VF!+.6# =0PXXLE2735X"05;E Y%0C\LQ_3YA6H<0H?/0UP3H[:$
M=;4@=,(!"[?9@7W..))N$+D'Z#Z$,/!#*,"W?H'DDMKO(>XLU:N^^ZR] 4D[
MP+J);<;P_\XX<P\0@[JH C0R?.P>WB,&O;6]!YSXN&YPK,\3-*]$V_CK^-^2
M$ %\ @Q</0SNQ!@([AH,[P$C-@9H4[/ZK^X!T3+B]P 8KM")]O!CJ%,ZW^%9
M_ +#:[UY<YLD)P;HL\55<MB(!)Y0_Z&>GH_1H5![K$?&TN-"EZ.7'Y\D3_]P
M;NT,_!!9V.>K.8S<C..C?^C_:=5A.B[A9>!-U:2L"<#K)0F;'S5Q:ZT,$;G&
MY)K]SBWOV9WLS=Q;)MJA)@38VPO0P=Y8IS9\\BN$-%9V["R2FON%I),P]74F
M>H9NI-=5PN3H=.</!BC#4O5'ED P!5J1P/L%193.IP=CG8-?0X).^4DT486@
MJA,^+Y9\,3M@<#GLH]$)217ZLD41 63?;_H6A]MW4F;SMW\X7%%$Z8D_;PRY
M"8#Z;\?XDQH\TI@[(SG"A-\#2J1N@@":_\!E"@%/%!%+5%,[(0P7CQ3@K7Y*
M#3<RP$(;64UF?.'@+H%$84\ -"/?5IDVD+&>)W_6%#^NO^FH6TCJYZ^]NO].
M?U"6A? $EMIN1+=H-D14GS8,P0?WQUPK>0_4#B%6,%+K>"3-E [2:4?(>.2;
MO6!4J2FF'>0 T:I[N=)EQ5G!%9PQ2,<YMJ/Q0YY9K'8O:'A^O9">DA?S5-)7
MFBC2(UYKG00&X_::1-BXFH??;1?>V.PF&,GG 'DQ1R2&1OMF>>KBX;'$ "2D
M7(;7N<41P_^A;4@)A_TYEFP2WY>*?/@_]XZMWP.L*N0/5WK9SS\31M'9([TU
M&4M-OX")OB.!\,,^$S=$3SZ0L?7T@G^6B2/P/0\,_U!M1@8J6WL=V>%-"PC#
M7W6U1_XQ5S^ AAQ_29%^.O IG[9S1.!=-E "0ZT7IC)$SR_F;]BWVO\&,ZL1
M1>0P\-56F=Q1S^V:@$W )#^'9V[M3ZX2KX)BRQ4/"LR<8!2.]5:H-&/_E?4%
M(2-O!CN#W\85@I:>*.TC=9107 NB[:>M@G1LSVW<[@',1 J(<(Y-43T I@@>
ME.4TFY[-\E)J8<L(<B3;E04&K86W* EG??@D)2.&A!T3_?-U3T'"*D$3[<_<
MEQ,C')3,_0$U!?JGK\JR-G*?"$0;@X>\)X5<EK*O37]<C]=&%[7UUW,4JX3Q
MKI7MG0B+L#P3@,@_S?S)I0U/!XU\6_,(8VNDM?I^?)ADAG^E%M$X2*5C16J,
MIS#YM632VW+]$>]:Z;Z+N6REYLRF@47B(1#_;M7>]0ZEVZ0<K=)W2__H1M::
M=B\L3!01@[4IG'UBY'B7?:?UK_PE2*:_W$P0% QWSX#>M<I3:I!UBYHOE5#\
ME],!*J\:&:6O=+-N[%DBA-;9I?DC8FQ]MM5N=&7BZ/F/G$"%H_P6KH9 *G,7
MHB"G2G57VC=9E=$N$/G8!J)(S<K#V;36L$[%Z^2*>\"3\ 0^/]?ER_-LZLF:
M.1VI'2\05TE"?M[<C7!5N!9YT&>O -VFK\L,;[9!./VAWAH<4CHJWT:#N]<A
M7S0*ZRG3EV1"&$!V)G,0.;H./&,OU1" .N-7![/$'OW..K>W1I:\I_1G6W+V
MOA13U'B@3>UXZ=9Q45QC0>OZ-^BFA74)>94B8C@J/&+J=#^(;$9O\):$!%EL
M^)P$U7I@;!!.+GLSM]BOWU22VYZ+J(> >!V^)"D6Y%0)',.D0=0BXV-*8]F^
M+4WS*<F3L.0X7=.EH;+ \:6<N@<6HJSX3YH0".M-S&6FC=ZI#FNUUJ>S"O*?
ME:I8NFO)]VYMACB8L/2T>K\KM]U&RZ%V9.5? P<=5Z3N 3[)TZ,^+,YN6T<8
MA1NM7_#GT,L=PMG0C>JGK-2*H>05U9K#)DC)%?\[RE 5K,>)/G=B \=D?Q'?
M,G'BV4T&K$]IQ<T'KO<.,7Q7FZ4<_JG+ZC.34E L ^7<D3]SE$W77>>&ZCV5
MK1NK+B[)59!5?+S[>PO]OR=4Q^\!RZT*N3I%7G]@WYE8U(T/]*W'?ZZ SGOH
MXB;Q=NOC'TIJH^1<L-T)V]P=EH!KYQ_8-[K_WU7D].\9Q/IKO00Y,V3HOJ#D
M<1\B]"0;H^!SCLD186(-[\69/OH$W5N>XKSPL7URK *8A>7(W1'M%7B@8?C=
MOLA<O?\L;KXCL9*8^RN_IV$6.]>?SCE"7!>]KYVD1," MJR\Y%%+'?3PC-RW
M:B%J0O',_[FH3OLF=IBD]STV.(:;,KJJB-,O/M]VL>\Z]9W($!1@JES$YSM!
MO0$JJSC0(?3->7["T6RV" 'Q Q]E^%GI8@E5C-CM2Z(&^HJ#\L9N\,((2K&&
MIPRCNG!;LR(S"VEJ>M6]]. Q'["QVM6& 1O_Y,,G8N"UC$Z%%3%)+=)JA&<V
M]6R\Y /?EO.0"#X%CMPHY6S9IR4D1@U^/]%X=/>QJ>H"MLCC8[0 JB=0G?=%
M>IIB=G=<XF=0J-SB'6U R,OOQ,H;[TK!6OKMD1L[POE/)XHRBNBZ.F[TXOS7
M <-@5Q__15A8.M-!4PIQFJVSO:O5LQD<=T?[HZ[,UP&1QAZYXWZL'NN:#1\B
MBB>[8T#TG-9DZCP;DI=?2-Y(9F+!MO_:Z&*C_!]\,.\%<6"0)H!_#_/GNZ:U
M.^,FI7_W\[V ^$-/8K(MY0?[+])=^!9J=:;L91K =0R=UZBYB5?L#"Z /A8&
M_E.=0C@^;/< 5%@[AG0G^P\;T&W>#%(DPR7 &RG^'O!^&*7I!O50Z&S_?:Q"
MLMR4MLQM6KDG"[&)4(+&'8)^M@&%S_-#EH-[0+N,CB?)R[HOUQ3OT[E>7%><
MSGXX,3'0&?X[E/:'=_NOI%W8W'USF[]B^'7>U")T)'_#<0\PK+>_?0D?4430
M]SVLOY-Z67U:_4#H#Z<RI_Y]#.""<(3A.['H?XE3:7]U&/ K4/ !_8<H0!@?
M?N!7;4]9TEPPTX^: "I4^G:*+@)K *T91,QC[;DT>AG@?!<>RIMGMDD+$'P[
M^T1P8$HP)U+VO4M&A7FAG4NCC11CUJJY3E0^A%0O)_(KTMT5<&_BP.\S=$N0
M>,)H_ 227U4?N&JJ,/[,X_45,6BJV-^*P1IDF#@-#&]O,>F/$ \E<1*T!EQ)
M-SQ='FH78-V6]T?=[*_6(+9N_-G]0U(Z-9 8FMZ4QGNRY*-TV->13E[E+>,>
M(@UW#'Z9A,U\PB@OL0AN.9AJNS5I]^(LA(9.S\N,[9K7>">]^J3UK*K]E"+L
MQ;"O RH*I8'W=_]NWJF[6NHCX(&8[[[1/>#UML'52L8_4%?_(W(RD?G15N#U
MT1S=2)E+=3*;-Y_-O9;,;8_Y+ IAK[B@ED4VA5-!P0VMWY!^2I/+Y^76E"7_
M7(S+R(3J(8ZS6.$Z80&'&R2W1&EXSDI\.+4A2NMV \FJ[4[270C'M'MTEO94
M[U=UCDN2E]]6)U*8XO=EB*1YACGN:RH@A&;M$_D^#?=R_BGI>AVTV-TU6M*Q
M1-.\FN>/H.GT7>$Y7P(DSFA"856:^Z<: \%UY\98]%1>K?4MFPIC/M(S+M<2
MZC7BK/!^H4_-O!L1MFH^DB%!D:+UKTHSEDG22-Z%7+<=E[SH]]^O7I?X<@^8
MMQ^$71L;]#(5,:Z[GWWW;Q#B%?5%Q?LIQ+O(WW5W[>?B&7E[=K-Q]SWQ*&1\
MRKGJ;KQZ2#O\%*+*33&%5WNK<YQ-[VNM;ZN116M$_K-BJ?:5FERI:Y=7=::U
MXF:5OFK+WEEQ*LN.Y?3\K%"\:D6#2DC%Z%RP4A\-741)-6_ DB1;YXXO;7Y[
MM$G8G5K_._N]C-[P"'G.C-[:>T"E(XK"A!71DT/2(;R;@GM 8-1#G*OY9E*9
MK?).U3?FU[.1)4O>\3LT:8@>\2S'%D>%K]HG+R\#3#9U*]HW'%3O5$?#A +O
MU&28VU]?0:G<I)9TN+@1BFZA-UPF*_8MR<>]C3E2K\?)$2+8MG6&^[=X"GKP
MQK]]$ZM)N\7Y?EQJ >5M7.[_+:7$UW65X+V7$6*/F+NDC_:!'D8G/V0/F/8T
M#U"H&HV+YJ<I=R'M6Y@B2.!6.%!9T.)KXO)Z8$&RERL_&:TVGMIXE,B FSI^
MV;B2;'@B$G!H^TIF4SN@761F$F)5+3Z]P>FQJ?^2+,710; -*(Y;1W@X_W7F
MX=&VK-(]-@48Q64P-/.7^H^H)$:)1%H;VD<\L:V5-RWLJ(,3B"6-7POG'43K
ME)[N[8+*5PG-0;[C907AJ+1+[2A[/X],*))!>NL)!4>\Q<PQ#L'^JB_C3$A(
M.!E?F;*,MZU*%=JYXE9H2_(N?8+%S?S4./]IMO#H\_3*ROBR=J7ZL:P:9<=C
MMQ*WK5X9BQ7'7;T/!>8?J-Z4H'#LK2;-OB-72B_C]^FBR@7K#H]*O!*S,MB$
M/J$/6"W>NKYAI$N@2BZ4FR5Y\JEUO$TA)JL"^Y>99KBLJ*JZU1VD]XJ*W8*&
M)S>+<40,!P\'SDXU$5ITI=J+1+J0/.:"3:HR/"FJV0/\3CN<+'MR,!8DC9W-
M99<W@#/^Z#4*E#=IC</\KZ4ZC?HX,22O97!O:>!/>5.[G^/)J7>FG_%/48!>
MK22,R!1.$NS5%E"2LW<,=^.?793$V'K^W*V\D:@V(?*-S^J)RJ- DUG19F&\
MST1.8!DC8&XS;K)&DE9B:O%/#(PD4<R@WJY%^^ON]#F-,*7;\?FO<TJ2N,^C
MG&AM.@4#_UD>?-I<M;H"(27YK/=XJQ+W /ZIHWQDI6&$$YS*W]_4\7<"D:4U
MA@]MI01F9U%CH8ZF&,76X5+-53I=8FK'J\X(-;-U9K6E)THDMT=\3SZV9U+?
M'-HIKQ(R!'4Y#<FW9-&2CA77$9"7L_O=V_&[0FF().4I-51*#.!)7/;N["IL
M)AC!CB[(RZXY,R_[Y0ENM 0 $_Y-=Z.ZJE^T51BGW6(L6^Z(+F(=:,S NV6,
M*"Y5DBUR4)EN/."2RS*( 7 1Q*^T$: U,1ITUL$9%P[%00?0CO]C;[6?%+-O
MR+RU&E=$]J2'YCQBISV=T3J^<!OT6;&]0ON>]9Y'R^>Y>7MY[^5)$?8%/>RJ
MO+,^F09I,./;>69:68P@7*V!$F(1RGTUE3\BO^!I<V&@%F:6>6O-="$!9[I<
MOIJ" #'&S5-6J<_%7B'UQ;;QYF2XH=]Q,-V0>37?7-_!-[\"O1[:I(O%%=GZ
M:@5CY/G%1'?#R_5;\T6]51Q=3&DFI.EGZ#'=&%8BBY]I6")3B+.J-G*0-2NO
M-8,?T?B>C6_C4\\J"G[,^!VS+UHNVA91@FY,G,XKVA@2,F\:![ZBF0H6YSSS
M:R#QVB_(Q'KD_R/]!:/)H>YGDG/MEA</F^NEAM1BQGL__&$X*M,^8PF<9\%A
M(V:1["?/HX*5X^^IWAJ0$6%D,5=;X&K.9$7)AGEXMNL@:XYA9/=XI2)*A,PU
MMX?6&@-Q(:0+C^='$UODUQ_ZL8L*3ZWF,(>-1TZ:N6<Z^Z_S? ?[%2BB #?O
MH45_C/Q+N+J$T$^$2 BL7*EJ/Z[]D.X2J'@_H\ G+_+((F.PGHX&J<<E\L=Y
M&Z\ZQ-9O.KC0X6RTN)" ERY!)3J5T;'+&#19D/6>#3[[<JA=FV@NVH]P>E:B
M7"X<_GX[RM<)V=/X;N#N%?;*UG1MI)"[CV?7E,4)S#3K/=UFG6]3;.ZTU218
M?7H4YR,E-07=^\<*?LC:OW(:0.WIQ&6'&B%[)WHR_=<,W8IK5-,MP>BH@ID?
MM!^:&M[UT%0]<_2KDI+#@+2'??%LL/=T6T:SN'BA\H-;VR,;0IO4155#K&[5
M<44$V63<$E(/\W!*L!C=QA:>)G%FP+C*1B86[2%6"\F3K6.!SO1S7MEB)V5$
M8OI[0,VLX/L/N[J%MTF125V?A=P?@HD[_Q,S7X2'J2L1X@?P4)%(8N1X53.1
MJQ)5$15M<=NQ?4(1:7T"@=(-[HME2%JJ\^'M3O_("GV'R*F<@^ZR,#%-@]1E
M<IOJ0U=-.J,R,??:>36)'(\X,!!F&/Z29I(=5PV L(',^X_>>Z(.V(1QZVX[
MO\MJ;0\XOW[)362CHI<RT(#+CP"&Y(FM&Y"9O)[J7:;8-D[5^+HQJANWYZK]
M[BE&UO.)$ ZG%/P=,0,1!5A^/C(J3?90;'V-LO*(.FDPA5T!UJ*20"K3) =)
MD&96;BN3"_LT6X9$M8.$0NM7>ZP9YLXU($S,^"#.K$%&S;SN2\9!N([_D$3V
MW7.(_>7&:;68Q+C#/: [9'?+G45H$0]^#TB/%#Z8*!#:)J[:R-[B]E\1>?@3
MJW\I0W.#5<_7&9B3/]IX%M2(!IK%9"NXBCQJ.[Y.DBMUFV%_^^U2K8YN LW&
ME%I9H1!M6CB;6)FD-7%GV'^(XJ9(F^Z2_'NZN<3*6Z'5Y#M5S^?^0QPW1=(T
MJWH?=T)G1,?;,^+-MX4LJLM-5C/M<VU>!%&/ULSZ70_5?L\'@9<[Q\/I%.2T
MFO"Q4_LM^%*C?TZ)+<X*.7ON\:AT&&GKP/NW\4\YYG\(,^Q&"W_KXE@SJQ3(
ME7<OYW-T]33IK39[B)6: H\^_H8>E4>Y.3ENT[F-R*^YFXFU)1A"79$&9H>(
M(/U^V[X87GZUS'7)(A..^O;>KV(=^O8-A)3K(-KJ@F/D1;>)Y8FB><-[/MNB
M-4>8(/5:N<<+T-&.="R.B:DD??X*;F<T_<'Z8P0Q1'#[$G9,0LR'(-+<'/86
MOE'E\YP\YIS<G$PSF>YS*@GM; +;*%\;;9%:7&]U&8QRD[DL&9VT2DJ/R@$S
M'D1P!%(=B[)ZZ)KU8*NR\J@: F$TI!"=%<-PB]<^3C8Z+&"R#LTTE$@ZNL.+
MQ\U$ T5)FDF^8+%K]>0P[J<I?&.0<I@72%Y0# I-'UQVNOUY6M*G7,I<ZT)"
M6^RYH!7U$722RDF53O? 5C=\Z'WS$"MRU2PE;-QB,]>3*S19M8>LKV/YK"WA
MZ@;Q+26?P25(&?.9>^%@9MZE0JI<A.M!9%G&1;L(VI]+"<3%[I^ILY)+H,-C
M!2Q6T%8P'8^YI(9SJB)W1\\/;%7Q)0YNA@%3W?D>MIW(DZ_T=D1.'172Z[F$
MB&&>$.G.T=[(X7$N#1#ZV_6U72WQP4._O:VW977Q98P[7B-NN@ZJ9)=I8H:5
MX24E82%E/= %9F8Z AO7:F$4[>3 "%ES\AF%V1_O'K8*MJ@_3ULZ27,/"LPP
M$11^_ @P_9/O>R=,A.QTI;-1S_Q?J>CEPD)/9EKX"RN2#]$2^)*R[@$:Y$S#
M4\COFE)G)T/R13D@<DY]JMY;DA&UZH]4(&V[KM?7YBA#T>]WY-R)20[+9R6C
M](+D?\ $JPR4D^O&3QTN<^E@"=ILM5DI!,6A1/*J1QB\-5B*OSDOSJLOHC7G
M1JR]E>G@G PLEBUI@P-<5#4P^9V9D@(0=T^AC5SM5=4Y(%Y(^CA"_9_NF_B=
M2Y']'8@**\1A:8W=U,0/KBOC#I(\YD*/M 9\+18N]/^<I/>ZTPG+RRZEH,>]
M2 RIX*BEM=I'/;SM6T%O=!4/8#+'RP=UDXRL4"GL@_#+<2-AG$K,N-^?M?[>
M4)*R16_>)E>_>J WR"[E56$W4057J@L 9EK+W[^[__^(%-+V=[[AO! #J=49
MEH+46N/OH_7<,[7HB>@*QF)6&\Q[J5(;-L3RIB9;<BY-Q&%/+2B<DR_#T'WS
M:#F]@!D,;'9@&E@1_T+6?W8&%0M7:IS8V8E*HA)N*V,?UTV+9HT!-R1Y926O
M$3@FZ=*<EQ"H'JX/&E6%QGBQ)K>R;D^W-Q]]%_<^ \Z@HT\WS$:O3_1G9C!P
M] ^>77=X^19<4DO8RTX)N1Z^L*(%%KP[0.7 B'QO%O?)CO&Q L5S/:*,0/8-
MP/%K"4&X6ZO*_!Q;$V_5W!8/]:%YOO-=R6S7\#A&H<='DT;R%*L3CHW#C<GG
MOGVN0.:*:C!;: MBXA0M4S#259"5CQH6-WP";GBGUO4EFTBJ4"MIAMY)SG);
M67PJOT_Q%5$1-+Y>]R<=@T^P%?AJCFQ8749TDW6':Z+@>G!G_F UI&^=>X48
ME%O 8*3),"'<13A^NKU84*0Z+J\](9 S@T:358?^\3?LT4?%N]H'.C,+Q I
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M.35O;$K,":6+! 6S1ZV .3,A9ITVMAKK$O(U_=-QYK^(%;E*6%E9&/GBU?;
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M>T,WC$"]=YNM.4?#D=KW"T,-LL0*'J87L!3@?#7<*@_VGS5AWN<WL).F.ZW
MLE&$(Q\>OD"OC6$Q>&9FS::$R'%,LG\);!:X=R[Y;:&_^W':D&B>VV!L\(("
M 5/;0&V/78^8P'H7%F3DX82>Y)B/F !1'O';3I-&55;9.'EHPO4!HA=,;L91
MGRX 1CW?=B4. J>GP >64FP*$A_E0 4,/)RV'*K\W]*X#H-0%>($'0>K!,?
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M\DT7Y6P(="R8U1^0V8S24HF2D1GF8U*[T:7+8)0:XQ]YU9*7 8>9X(.H9D@
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M4=1$&KMO\+P3<\ETD0UY#.*:.)DHS\T19FGJ%P.V._Q6:_B'_<*X:.$%F,6
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M7BS #F-E@ZW*,](9>,%/G O>_ROG NN5QCC#O#R@U,C^Z*%$UZXP6U3G05U
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MR>".51<LJQK?J)Z49<U_'#$Q5_X86RR\S,B>[7QXK/9,E-7.]/[36JTBK,B
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MKJUIU=]SQTT/C-F\SY*T;LX@1(Q5]F>[V_^[ 7&[Q6;!<#<=4I!_7=M^FZ8
MV/->YO3E$5>$P%*/?E^I^A='JM$=X8'Q)[/@@?$_<%KP=S"/SM1:SVQ$VEC_
MZ8+FWT0 UL95ZC+[[6-, J*%/4$<EQ\+.-KC_IX_AAN ;:0R_^I!9W[?H,RW
M:DJMM B?IY;Q1=_]WKN\AX:L0[]^F=/4+D]8Z;/461'V9K5CMKV(LCV"Q:FF
M=YI#3 (4WSUW0NF,(X]5FBX!9@1NCE6O"PUU$+M(7-\^2FIRR#K(S@WA(T.
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M2(DKT^N0JOO9FGM3_(]VW/IO%NQ>4W:N:;XK1$?</IM*SZ?Q$3">)WYY^/
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MR_O59GKTHT/[9)G=0DE^/W+O4H,?ID\[BW3ZM93G.U*5&QU9J_V_34H?@X#
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M9JN;2' =EERNY:ZCT>NWQ00]G'.^=#?Q=X 5ZKP[0)U(IH67$U+DU"8>+8K
M;!>0[^OA7#C_]1:U\D N<\7U:4&6R\,/3C!(N\]CA#[A]@N?LD^87GGA XH8
MM ?@1I>XV=&>J<2\;DQ1%;>EVNY;8/_7^HW'MA=*"[:/I1:]'SU6062I-?/M
MZ\H![#V2FVT?UR7:KVP^H?O\BEET'WKA';/<>,N^P$7-&SIC R^=0%?&$^>
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M^,10P?)R#^B9_VB?9_91OYS$81I*NS*+Y<\N'J/N=U36@KBT0'8+W?JD-88
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M]PA<^0DX>5LL&RGPUEUQ.:RM]D&%D#75=(N^N2 M'RR!O>4&][KV%GE)B2C
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M4K[YYZYD^I95_C<[YVVIJO[O_2K\YVY"8042_Z5;P_[R#@!D)23^7#;]]U=
ME&!0Z?>7YL_/4'SX#]7_4/T_1S786KQ3GFQOAMH=XWS8I[1 9/UT_O86?CZ
MEH GH_,H_R;3Z'[,E\V?G?BTA>VR4%_<W ^[^OQ;'A1+Z-__)@0P^$GMWDJ?
M]=/IWZP<_.NLOJQ*_QWWE"0<']X!MK)"%<Y(R&+^<)>)/T($J_\<[+BL1NT.
M0(O6/E9D$7C/T#XX)^'< <(^W9ZXGC2X\=X*8UR-S@\9W9?Y_I_Z?><XQS*
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ME*HP 1/=9E"(E>"F9@=;4FL7$Q,$\"]&<:@K9\,>NC3I4D9.5N(S0/T;48J
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MH0B!%*6/?NKHI<ZJ:GPIGM, -'Z$O0S$Z11QFIHS]?9>%Y\\)>4*U@2 I06
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MK$ERZFANV600GY"*39<[19"$(;5UFRG4V-,CETH*"R,-R,??G#;\5#PUR\>
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MA319>(*C7&*B6$I&Q]IFVF3V[,(SSX8GA%&KEC[]$S2_"!9(X[;5L[HV]NW
M.%T@-4..J&7/CFLHQ]45EJ'%%@;@0N/P<$G@2^;_J;[96$GOG15L:"-%RSM!
MH=Y*%SS?+:(NMHTL,XID+!ALOK*_]BW,(G4H)91-L!Y"G?#'Q\?^L$PP\VX-
M91#BE91?Z$QD-9'ZZZ>87X&_9$<S^)L=CCM 9(_?7#Z;]_S%3<*/K8#\WZ('
MH6?_-3=:W?P#OVY<OSG^8:VP?V8$",B/SBORPQ_/;I\*TNPGG:'_+3WB^P;,
MSX29_G)*^8^0YSV]"69+W7?,<3&] [P?TF2Z _B$R,)8X ^O#W[' 4"40]]_
M,X56F/Z9&7EYX"8>^2@<2OVD[4V/UGXY"?@-4<V;5QHC?[)/'442^77+W_('
M&Z3]A1GE%<BS_(X$M]Y_94&-F@N1<XY7Z\9(Z<?_D"CRZ-U73Q!'<TKP(ZQJ
M4*KCF'=8$9+D![B/@='N -A*"J<FUUN1%_KZJH5W@'DME+EA0Y(;#@[F<;_]
M0LE%&QN)HCN KQJZM\QKDX.JJG3M.T!S_AT@,"?["O[C5(IJ%_C5KW5DQ!=\
M>Y5U2QP?L_7E?!P K?JC[C_J_G^P;B3'(?[M\^GYO(L)D[^\Y.MA9+NXH,;!
M^$"Q#+1V>>TS/DK#SYFB[N=,86L0A/]Z1^21NIJ:=@.5XK[R)R4(K^Q<D?;/
MA?2K@^!.S-W[[O4POIF%[LZF+(5#XN3BYR40-XIRLJG<9H&2<)+V^OA -D1<
MFRS*!@LPLGP#3G\0W#$-&:8J.8K[>&#NTN$5EY8%\7L8/6?^D68OY1O=^'_&
M"NJT=*VCK*+0O1CNXK:5M/8Q*:Z E"(AZ3BTB6=M0J/DT4MH!Q]='-$=@.W%
MCS;PR0_JM3,W58XXU4."#B[!&Q*'G4Y#R@>E6_DV^JY>;OGA@/L13MO@K?]I
M3(O?B\=D]\'\Q0:74%'_2TANH7X<?(J6UG>O+@,%[\-;#CQQB$JEJUTH5&>+
M IBC'+A']+<'IH)6H2U]FEHNJ>6/I"CMENWVQ'$?4JJDZQO$)"?B-Q$O"V*(
M;X6(7&M^(DJ*/51KV8ABVR/+;DCNK6$7A44'#?CBT*Z.I2L&X>J0J9 &EIJ"
M>>3UZD>EOPZ(8JV_+B9SQI-Q(6\MJR4KNN)?%KET<';I4"C6]RSW]'?.#/?O
M+RM70CBFL (==\ "83C.O"C?=8QRVJ95,(3(5L!ZCBQ)0*>Y( PXQ'W$IR+C
MV3[8ENDM50UP+;N+*(C'1H>TC[NE%+]]#E15Q;'&DX"Z9U7BFO:XUGJ7DE.A
M"[@XE1:2;WL.%]L!WW];ZUYZPTC:-Q>EWV'$H;3>>08F,9"L>)=R.F0R\5,-
M\4V8QFH%;I^>?H5+?A/CH(JAZ&LMH;1*F7A3LPR*X37XWB!#3M4(+>V--0//
M?J@KAO/.TTV46+S,E!F:J-)X_M%"E\"$0VXI7$<8%3MWP"O8W\<9.8*ME,=X
M 2C?-HPKXR18>UX@:T!= +(+2?YF68?=]\Y)E+LT][1Z6@!?W=#SNK/V(5<A
M\NRAB0$?% M#?$#D: ^$;9FD :!&K'G-1W#F12TCW,-087MMB^O,_; 1K",^
MQQO4^Q4)0:<D/SY*7HT[*AWL2) CDF[=]9(D$UT,60Z9"BGH-BL-KOQ@4[=/
MRDRBMYGOI\5M] (Y+/="PC*\L]7&;TS\W%P[YZ AO"T/"J<]HL\]#.K2K(>T
M^0WTRHBA,A_?; [UP.!6>3,F\L2DD\WO<NRR\#0%60U/AS \1%7&6VVSY5:_
MT+&[PC6K$; 1 B(6 O17QKX+GGCOLCJ HR>D4]Y@$_0/]DPO4>'KQIR,6K'S
M6O:]N^5P&1YA#>W>,DG%Z-IV(O474:VL#-_N*8DYX:?Z7TUPG)!S%BZ)?C=-
ML%EV<S)Y**;-&9]!9];\(I >X>EXPY@T^.,.8&<_OC'\55%]K2E (\S5:F3J
M34+>YN;MNWNR7W;&KXXE@XR?).L]:-U,7 N'DHAOCX(B$,*:R6%O^<Y^ZGS%
M3Y($A[[^^%1)_N%RV#=TX1*]/GM73I_*U^_7K6_)"ZR1&D9=0@@7[!KL28@V
MXGEM@!8O6R"5PO5X3K80!./LI$L?T"B"I?\O0*)^!0IM_Y2MK&1<6?56C.%*
M#3W&^"_YD,7_G"%9BS8SXN0/RO\'Y?^5E!_MW_03W)W&RGQ+Z'VK>C5UM?^G
ME'MOXHYH8%]6K+[< 4JK<,DH(@NRG$[Y8M6XH32:LLM;-BR?T69\E7_>SL[T
M)_E9XB"1&PT#&'6-#==>)2FRH/PA]I\3<_95)OO3K3\=TK7Y-ZU N__NHV=I
M39N$Q/B-) ^;(4WE^IJ:"))>H^U^9?7W3*CD3@$?RLEZX!LFF_HE!@W!A"=/
MC<ICC&:<LPO)!74TO[U+NASZZH?C9G"YU!"[XT\9QVS3X8N68[.9^[W+(?'R
M@;#PY^C=_RC?DW:R0AO9C>-A\V)!9??P4T&GH[8](1XV*/V.O)?[7]COG_*P
M6G_&6 XQ&QSV]RSXNU&A0)&^TB7-2:>GBW]PZSQ30:Q*# \78%[IX-S5Q%8N
MBR,2$3O%UL/N6^VS[L=O=:V\\JXO-D9O#)I]+TTANP#'JN\8?39_\VU&5AW)
M!F^'*]2NR*&C'OSX?B[F,[BZC@,_:YY1\8R&M85--Z\P%:\1T\=^^Q9Q0*G-
MP^Y%.4TC^_<2VH6H2"(NF4*6? =+W<?LZZA 5D.K)TL#.E02Q-$F]>B4YW#B
M<3&+?,-9 IP&4W12N@83JJT)<*_=Y#FW&- !U'<J+EYUV4JL@R-X+X]_[Q6K
MC)Q1:W'2,%7[5.SQ!=/6T\M7$7XBQ[F,GV+&D-J+UQM[59.N(1%BRQ]5[Y6Y
MX4HHB08;97\6>\@#RDU:M2<;.&;HU2Y?3&0*-:JR_DHKSPOKQNA_312S@>:%
M'^RZ4>7+O@56"G*=\3\=$*E0%& B6+,J--HJ8?!^\5:NR:H(E![W]HK\"%>I
MLSYP9G>U^[YO;=ZF,=\81^E#!5KN:)2EQOU\44-D&HF(Y ?!?4K92141\F,)
MO28%N-0AGS(\TW JX-E+FA+E5XL@7('OR@5Q3Y!8K?6;@WP+,3/,),(VY6VZ
MFV#P.0C'J6SVYKF344E>H.L/ <88=8_9\I0' *0T[D2J1?: -X3Z/C,97>,7
MO?'U,3C5Y."W-X;DMAKY.U5/G<+Y2XMW]].EQLPB9F31$UJCVV -#T=OQ',N
MS_*I98T5*9%QCH[[-(/5527&S\-+S$W[:*=X5;2,:M# 1B%N^"2V8)=*]N_/
MOID6/5LR4D''J3SA?WH[OU/C2)*C4Z)%;Q\VD^,[9'I@$JGO&3VWVF,V@RSI
MH(UG?.V,,>"38.;"B)AQ)/LZ(YGJ*[@(R:T?SG07?BSU ]3;]4VM*A-"YL*A
M')+SL-VH'NOXRR,?Z9J1W"/=1$'W9R,-)6K<E<[BH#5[T[FE_79!]<P&&JZW
M7X4*OJJ'*]41K?919#EV)ICIU%35^Q/C]J!&BYR6RM@[4%J\<A8/=/>B"3[%
M"-Z?E!B<]^%>!U*7ETQO0DV1JFK$ I<A9$M-0HIS*VZ\L8[[\INW!-9@'>21
M27^.6;080!8T"?IPX;M$RF_$3ZO=7LCCT>%^NK2TRJKMT\%H\5E=!MC/53QK
MIFST=#+AHF5AXEWM<W8OK#6'1FDZ$S3#2\4W3C! 3V0;DH3SE1Z8VZVT1AZ1
M-#C^*NHMEE"'U6;-&52P@K^BS%U2 )+QZV?/7X7,VLB!MQ^A!=:?\6G'3;EM
M-0M(V[1%]AN5%I==KJ_=^O"47X\:**'&1LG3??I0H.5 BY<;2__('P_B_?S@
MY!R*S?#A^<L 7"Z1><RG!]:]I5Q0RYI"H5>ZIEKJ_F@*_]0<MBCPO]T"AWRG
MV1/\AHS<HCDBJ/U)KT:E=#)AK!]^=9SB?QB[^#<F:%@(;6J.&PB]?23^(OG'
M$2,Y2V;CL_W6W]%DZ'_9".\)W8=-F-1+Q&TN"%CU'#)WH%AGPDY4/_UROOL;
M_I3I[K=\ BRHO7_=!W?PR+I]*G=8+)*60_NS!?]7_A(H>^GWWQS[(47.Z@__
MNC5^/_ ?3.D/C=JMJCVZ-(TIBF]HQY^<AB9GRTS3[]'P>P\0H1QWW; :&5R'
MW@%\?\L"!-:Y7;H#S&N?B/]1]$?1'T7_#8MTWB .LC2&3^H<+60P:4R2FA-*
M#99H;D)JTE4//T,E7L2)U?V6:/9%0>D=8'G/Y+R0_.?"5)97"HVM2+@U0+6L
MQ)>B322^CJ?+ZL%.FLNF\?@BS7N=,U/1U.="GUS*CE@(5M/(#AX4+6$"LT()
MK-"AP#WC1Q<VN1LLT?4.R06XW0/N$]4"$TYLTEBTZI%Q4D5$&.9.<H2[X4"Y
ML@Z)_\QLE[27G_-I :NKX5 BW:X#YXO0+@PPE5GWO=$DKW)QM>5*9[SDA"1J
M/_ <"U#^7Y<>X[V_\&>T[.Y38()W$3M#L2Z'GFJAH:@5:=XKPZW\4J]I?;>7
M%2@U=27=G(2N.,%\Q3Q_\AO$[&+*C%\2 G,ZZ=9,=2YHT&&<?L8F3\NEUZ2T
M6N,?K$PP[2K(L>1LCU8H$G#G,9+GDC!>*S*5*:^$),K1L(B-03]ZDN T57:X
MZ507.)*J"1>2=R1\2C.-2$D"4T4XPW"!3QEY8@"1U2[JZG)>4L($*0MXMAX[
MN;&+.@@^ S5PO\6&]\3W<)1%J1M6 5$RD3<QJP^/(C^YEKSF5I)Y'&AZD<R1
M-4AT7%Y/8SO<5$M\P)NN>/2$^.(* JJIJ<':$2GR JN0A^6!,N,2&H<XZWF3
M"Z")F'->,=L:J6OM^XP1WD>V)_7K9^&;\4L863/<[X'&/YJ[A+3:0#C'QJ=S
M7>+QRWSA/-L:C?+V\H2/.E5 LW:-F*\X0PGG41L_S\B5>(B'K[:#-SEJV_T/
MT'Q!$/;PQ5 KOT93M*)@*M:N^/YZ'2]*JJ' &][,%Y;'E&7"7X6+)2G[*VT$
M@MH^17A0Q_5<Q-]NV3MO2?*?%2T E%W3"(+T[!F]3P<:E3X:) UKOE9TAEKD
M)CO)+V:-EEH8]5&8;8*KAO#FMDC>*#)AD#$<=KB2)X033FPNE"%J/$CV*EEZ
M2A1NI!F,'T9JR-,IY)@&6W=1^H7;;:E6K[ \J\O*43);W!72-ZRUX4VK*S7H
MJ)B=^3)%[[2",JQ?Q^JPGB1K&=?#+(8P''5(S2/H78VAPAS 2@"M;>'E(%G'
MGH%F+JC/T>-:SO<-634;2(5+0V7&HR>VE/2&KD#-^C5\\]@&LR84\\D[BY6C
M""S%U#U<EZFNQU99QL9W@,*P6SIX7M IMM*'%5=2=#&PMO<2 =J*ET."XZ-J
M=T+P \2\6L6(W8BR>H#*?%M8V)AB\35105?=&GEOW5@V(^D;8*K1CSU$QI8&
M5UP<REXA*/W+-^UR@21]7<I%A=.25^+LXV&K> 4SG8B0G/H0+4(E_'43U0N=
MX1(^7>T@3&W)',]T_UL:U;/W36-T;.C2$TWN"ID5-=@I:*3 M>4B5@1& D:5
M*AO[!^UZ\J,!KVGE@Y4:L"U*XN!BK572[/@-U.)E!U,LZRYL$=%D]?005-CC
M2=<S_#3B2\E/]5K:.^._ "<.^;6^<G)S-TNP;5E'M^X"AA9)Y1[FA%0^2H^-
M&1 %#Z^,FN-E<95?4DQ48I>3LJN(;X^':4PP\R5/R=7?L U/()64EE0N2=#3
M0".0H3= 18.V;X^%6_@WM!>6X+M& QK??M+-==()0 %ZCHM(?!RE!E_1X)[M
M68/?2M>9N5"T]-$$=#J))5/O T_4T;M!ZWN="5G)4(,/P?.KE494TI8[9U&5
M -((J8*-?X&HQ[\,*!CW7X;!"B02(9(<6%9(H#,,,!@I6RD[%!U\4#3<0?D,
MXZT<0N*?OVSXP_K]A_7[7QY_]OA]D[YLI.P\__ .L*+<>.47#O!)A]X!:)Q_
M\Z4?+W@5[7T>P<^^6GNO(1WSAG/,K4!'J7:E)C3?5 3VX/6$B-M@CE#0!,^>
M"@"N>Q#<BKEW'TI>V,A<.N-DG+<X?\_&"P>C^;ES=]:/5Y1(C4*BESA8]]9T
M8A9W)>5K=!=JPKAN.1HG$$1JM/^9#I_-C,J'P)VV0\35O[)&C3@TKMX&Z;>N
M ,46D.2#@\[M,?LZIWHOIMY'J+C,%6@^U(E/*%)]Y5Q,&7>[*:9C3[7Y=D<'
M#'*SC6;=>F [X&*,F[@ZNC*C\+6E-#[[?Q03_W=#F],-@^,MW@)YJ':S@:BS
MPDH$8OF6[3!4FOX9A://\8#KXL%>@2TKIXV=U_MFY@"FKQ;9OF] '[@?W>N*
M *U3A#O<>F+[9DKAVXV'XA.:Z/63Y4(!)TP-<\8E&=0C^$HT<KJ;A<N#L=&J
M0OR9$Z]Y[(_&O)=J'5$OFMSD)S!)'25.-P !O,86^LYYG#H")>7]MB+>!G46
M-*QK6:/[25-JF)<*:_60#\0>,.H?V[&-U1";#_1A!Q"^'I%WWACOE6I?GA2'
MEMA_B@O#\9I035E]NB<J9UMC\;)&M_]3WDN0D@M[,52X*X=!34&XE1.2&2H'
M$S,/NAK_OIL1N?>9J)28NX1/0][&6;S(@840B**%%0U[A@5;*&Q9K3=-Z\_'
M-'NKJU^:37'NE"9"J>;?6V?A^3U/,0@6C9&DIZUEE90IZ\;O-:02#[U?,+UM
M$']EQ_+.^9[OUE;G!ZY"0([3=_.''\RPT)1DB()^ZX@6V\-B]7:98GM37N !
MZL<1NH@0';O]<WBAT;,"#1[<UVG,%_:0TGY+A<8$YNC,A@./#Z/N'[/KXB+3
MHY3J"T\94(Q4;VB-Z>N?QXL*1I%)/VBB>7ZA8)]GS-&/-/:@:6EM8B/5((WG
M4P-*48)E?+XR7S>]&!-->[:0'E1#?%[@6?B\N_O-,AZNUV2U:B4& $6J!2C.
MZ#D.&2RNR[:.JQ9+!A_$)V=OD8BDC.SU.;*UP7K?M0M<A0?EW">0H[2AZ04W
M&5WDN(DQFAGN^*PUCCY-S1JGC70BZ%X0VI'Q&GNYKIKTPCF=O3AL=(A_5,^H
M(W]#(4?^VJ?"T*SN#D"7<R@19T5=+BK'UD%RD+]IN'8(><PMX;M=N&7#9V9%
M\JI&H&)JT#3JM;=VDZ1JO?=)"#WC=W-\VR+*2"=/@KA0P@674[A#?&N?<D5-
MTY&:4*!G%T)&OS'>J#</C<G9?8YJM,K;KVJ^+UB26P?X\@*I6JW*A$(FW>$D
M03NQQT\Q2=2 ,195(T;>-L HEVALEP=.D$]+-RNT1D+[!#8F["<!>*>]%QV<
M!MK1-MBD5,TOTD#DG8-G:R\FLWCQ]Y 0XM#\^4TFT0:K8WJ3V!H-ZXH\T SG
M6HG94%'3A1E7@A&72J9\@#G(]4'YR1#Z_,SLI[U7'MJ>#$@+>\ZX1<D&!GLA
M4N8FX%H."; !*"0ZN^%-*:$O2\P%Z)(V?!+I5C-Z<LGP[#@BH.[MH2#A+@!M
M,V7<A'@+5'+Q1BG?P#D,-5+_>/.5!68>O4%V\HOCY(9).),G@[M]EQ!S#EB'
M[6OL1SDG>:]AXXYB9RJTN(V&T7788@W/DYZDKFL&_P<6K6DGU\\M83HZ]/<^
M\\J#T0;%V3203Y/KQTYI D4J.0L882GM(5_AMNBTY ?S[_4MVFR/9JK,GYI=
MFB!+O#\N8!UR3YS5DW?,8LL <?M+<' V&C[L&LH $=@&WMM0.5&#W,,QL+#%
MXB&4O?<<_\,@T;C-Z29M@PVE[^@M? )Q(^IW5L<$-7GBU$U=A=)@XWAF8![L
M9)]%)K[E]2\PP_Y2L%&$YMMG<8 *?R@#E&5<*CVJ)YC92-Q%WZE6'VH7[Q&%
M-Z]\>_ #2*DIQ_,@O W?-OJ?RJG^%-PEJ-%/[2>]".^Z7FMZ>[OL"^IU/-GN
M_)(:/_44.X524\I27><.4/G$;WU*M3=RIV_^\BSF*)<N!^AXS7-^ZYM]DW_;
MWW0'2+>19 ,4R!C\]8?DGQ_Q9_L'SW_&BM7^\N?KK+_4<^^/.O^H\_^^.K7@
MWCI=9Q;[-U<]EUJ\ULB1.T!?57K<JP_O4@6BYN,G BE?6 EFO)6QNP.T2GK?
M 22.WFCY_>5*>\U7 VZV_:6ZS*_?3-U \B!R[@XPU)@>1_/7JR>%VCLTT[J2
M:]SY)>D7<OM^ZW,__^A?+_Y[E4[]32F/V9_7:=B?35B')K-O"K^/[$MU_;PH
M:L!4U!I=D_ 3Z=1H[^6,:8)5_5US%54=P/[[*=L?=?ZWK_.W,\!%Z9,)7XYW
MF5?EIRS.1F]#F545 8?S?S8'& 6'B(D6*[W1%Q=9#!8++':\D.4?ND*;N0/,
M QGIZ6 3=X#W)H9W@,]&0S\.Y6[HKM9_W-OSVX<],!_6GS\(W4X_P?[)SYM9
M_E9,BHQ/I^;?124729"2&R0N=P ?M0?*P)([ $;SSV>D&M*OER(O9$[__#HB
ME!@9B%_KDU*_;YSKMQ=9MP2^+K=OH9+G'8!_]KMR_G\U4C<<R.T+_G"!0^ T
M%\*YQM]CSHKT'E]*AIDV!00\_>6L[S^ "C'E' %$AJHIO*SG1ALN _"\ P3=
MDFS6*U4A;:CZWZ\0BH ]<0BF.^E#[F4>  K^-U]7:&M?HUSK^)S?H>)TL[%)
M0#W%05.*&LR79A=X&#;*DIDO+;4MP_9C\?0SONR!%]'H?)@Y4D'WEBJL*Z_4
M^^WO32G B@G4@5R\O!Z4%+$1+&.8=( 5H9V0H*ZX288K(KGRYJ+DQH8M17GT
MV<J_5*$_<+W9?#-KY[=:\<;5N;EM)<&T TBN1)GNU.;+IOA\ZJO,8UH\6S*'
MS! %=M;L[[IIL#7'&["-=;M8;_"WI("ASBF?$3O>#.8?A<CO6H@=,$ADB@T;
MDK^7A4]Q#S_G17\A3SM6YX"U0L?%Q&Y&1>P=P)42/)10PP%U/1;4@?L=-K(Z
MY?6MUIIJ'8#6IS^0S[D\PO\$KGM;0PMNB@*BIHF.7U,Q;5VVR$\[GI=W.#Q;
MN"0VGW^=*MWA+MSA8$;N'-_=M! *"A5.4(O6))+WHCX=-[EY?DUA%V'"2QU4
M!P?:TDS&%^2UN.])*= H+B2&EIMZ\@=7:)OPA:]*6NUE3;GZA2CP+:A,RWHG
M[1GO#6F5/V(/2:T#'FV8YM'GPU4.'B 8VYT->I7N [!6.U[190T0:JOX4J^_
MEL7CU9 1^YB21:#,"'5=BLU=C+LIZB4HLB^I % I>8\G(CJT+S69ZI:X7MNP
ME.U9-Y?P"DC3:G05]9?$,\ &,D,QOK@4*@FU1F<UJ3.4]V07T <HZ*)I6*/X
M$].BQ!A<*0=]7:M=.>.SN9)_RA"#_DVG&X"#I1S^6$Z1)?-CZS]0+;PG7=3D
MM\@R]W 7NH).- _#*>J\W+ECR)-N#R%X0?=]T_P9ZS-!*]=O0?S3P9TBD+BB
M# 56:B!3N"]\$T,F.Y0'MZ/\O.B3(QX$JT/Y_>05>$Q@R@V1:1?$5;2I.$&\
M-QUFQE_L0D(5'^#TXN +F@?6WMDE4_/;I3"78.#TQ9E ]3".TV'YTS!?T# !
M,?]4UKVZ?:"-Z6W'VTX0/\R-K4#)=*$DX]A'@ 2,9'\<F!*_:\08Z;_'Z7Y9
M\2ED1\:-Y#?_/3TJ]1==:Z1BX[BH[0GDJ9=6+E6"6) 1-RM&CQW%/*)=CAXX
M)]\= %./@;LSVI @H*T4$EUW&)''WI"5]MSP9$#KD'\L@7RVV[VWZ$ <1%T5
MR AITGN4OV\.)9<+MV#,J,497'8X@J"V*[",D58%R8CM%;N9%F-L@736- 4B
M(M:?-)3PHY$980[TZ"4*E\R2Z!(?4@@C7?&<I3=UM73"F8J[50;7G[DL3CHH
MJ>99+AJDYDOL(YY9+=IK+&W2Q4_HQJ80T^>XF>##OU2>3"=^6@1>\J?"/=:N
M()T&K$G\F@&^$#21E$$69+S FF76C6BBO9JT2_RK8P";+_,B?_MHUI 30FLE
M0 0IF.NQKU-5I\=4"Y5REO'^$NBV@G3]5(J.TQ>-K[_:K@57%*S=Q;33'W95
MLB?NX5B0H?"&C65G-@;-I$X^'67T&,:,\C?15"V%MD.=Y:[]PPB"E,Z(_"U.
M XML">2KE[3$RH'E$#/'A^ (KN9W(W66]74UW.R:GOEMT4W$]=<"3VPH'D7+
M\:&(_^ISS+\8!(8ORJ1&:F3(X/S(TT3'TD34VUW5>PV1!(K#F[PHLY#>'H:5
M42FRG/OOOF9G?HI(;M/?B4=BX\ _14KO&W\(KP,&/^4UYL8$\1!,!GK-);QV
M8%=O(L)Z@5WU[^EH_^O!-+S!:OWY_I0X&H7<YYQ,_T?6)T3VU 'Q,(!RUC?U
M*B\L?184@4AIV3_$_A#[0^P?BE&4^]5+LHE5W2[=:FVQH#3K^[GYL0DPGX./
M\M2E<+^GSYKTAH?\&+\I&%-#=?_M=I;I;Q)N1(#9WV[G_TDB508@:/I?\B &
M$9[__Y/GVNJ^D+R@KU#S1BH8@B.L<"E9\&F_^2]99\(RT$2X7L  ^\I%2>9O
M[(\X>:6H"W)ERS</7IJQ\.IL4:A73SS>R,S]78&]4-*+9I-!3 EEZ/R+U(\/
M2[/<"JO<>>*"A:;#CHV7EUC(EQ42'[J4?XGSD$C,$"//#G?.*Q"+]#HY( @&
M.;KH:ZWJ*!)L.6R0Q]<!")6<!=*<8!O$^VK-]CDA0PC3V9F.W$F*1.DC9(0X
M)&VTF7:+&'HY\\5J=M11J+1.<ZT!-G;*-I[U3A'36"X3ET(M!L> 1EW;2BG9
M\G$.&7 :>ZWV8,28EF*.:Q8T5)KG64I9MRZ&Y"?KS8)NV+\O$3EWF!#DX[#4
M=1!08NY585L/N7%Q_)S9K!0DU)JT@D*[0K[NHVDE/H/5$_]UP.;46A%JJ7L#
MJJD*&-O9E6 UL*581OE6&-]'C1B8\U$XMK)/;GT'.\Z@A*U09E W:JJ3RV%]
MCE8!90KIJT]2DR"BIN9-="^2>.@U$G07/QT:1AF$BL9/-SBG6#:(H[<>3AF$
MSDK[&]?BOH/YKA4MNB5 9%CIPV!.2:KQ;!L.'$5]SS(N[)<F+1)VP X*#&BE
M"1UI("-^4L=.4:N2U\W4[^02= /651CO5>N*FE8VTZL<&3_G<5]9JDLE54'L
MV)#TD3!IU1UVS)Q[XOD$>&IN:@@D.,(-&6?+M6=:*F(&06%8N@LX2;LWCW-F
M6BN-%#X&2JA!2M75P/H$F"(1(V,U1;9E%V_F=^+]V+,*@/W22Q233X Y";0(
M\.%].&?^3OM:)0J;-)6,D+1NXIC/E)V;!(]LTMJ<VZI/1K1$0)W^1@F_/)Q=
M.6=-B3JHP-"ZHBL!+QF?UF%7!3_.N5S91<+< @P]V$/G';R@Q7&[ 254CN@;
MQ,JY3JF*(4LWR,W)?0,\I2P28@PO>@OY=F?40O63.E,I8NU@]L#%> 50L \L
M E96AE^>&"FM#&IXG ,UK>12'Y YRX?:S]6=##@U@PXU=84#)K]XR*$CS#UL
MC_8UFQX92J@;))T\#CCWS+:Q=G$^%1=VL%^ZS*5WG"B17DKEG THADDN/&WT
M:V]F2E*8&IG]\%Q4V3G(4\GAF$)2?X(4 ^'^HO I9X_A546;#F+L$5=]>B<<
M.7!+>&@QD>Q'I/SX:-(?GE&UC6BJ4!A;X7^]]'HP] @X"I:I9\FLD_I'GBZB
M.L252QA\W9.IK;M40_K#7QJ5K%66>RC!03[R8ROUJ0]YT726@<C C%W&T@X?
M[C4KW71B>[2%P.BGF)W>X,^;Y!W-);85K2WKU9!5]I2?FIY[PSAA&:GCK3=_
MCDU&S_R%?S+DZU?I7BJ<+,W$R;1EO:NVW0HGG8R&H%='];=N!N#0_@H?9R=C
M0V!V*01H8^NSO0PZKQ_KC6E=T5;%F2])*R+YY.=NL%;@8V!]-E6YA[[&@)2,
MQG_0'$&@0LP58PL5P2?8/**2V7M%,>+>NTM60D7Q=8"C?M98A/VY%>2UK2JF
M49\W6X<$N5 $.M$\*63/(:T5%4$OM P;//Y"QSE<(\IG47Y0!5JMHLB^/7@5
MN:IW%12,.Y!X?;^\$,_=BJEV9'\V<EVGF!^S> \U*X4:3]46;CE1$#.8%@[,
M#L]TCL"@74Z27[9Z"6#>-"+.KDZP<#@\>GD/O43;GUZ>L)5YSCNNNTCS6P*5
M<BK=6>O$]+7 HH)2A,&#NA]6*M>X/>9W ,W'O;Z@@LJ#U[JWP_G=[Z!"^._
M\.*3T W"F;)YTJF\U\5:(W'#>?2V_<?Y'#EUKZ-D^U4_#WC+M;G5#N]^GQ,B
MJ%C4.I"QT+.9<@P^.:M7HSI;7Q4MBAUK=/06R]O9(99H(\TO\-KLL,/B#JJ0
M"(C40T2545IM@Z.??[20EU2\A-&0;$7)DRJ*(#,]))?0IY@-O(-%BX)*[ZF#
M95AE#:CKM)_05S<\@TA@.$P6:"PR^ NYK;I,U";O/ET2UU6<?.S\ ,USP=Z&
MW+?8V(?B=?',/<@;H0D&C'=80J7/%+Y$+VN$]4>FW.39=+C3KJC=&_[E\7U_
M*5 2X<_6-GFO I<:<\:R@.(RWK@G;^Q30K9 /0C2FZ)+S6^C4MJ_':;1%GKI
MB^ME\GX/K3-6Q4L U+]=<Z#=3>!)MM6^%(-:]3]*V/H'_L#_C0 --.H))K[I
M2:\?WZA46'TZM 'JY>]I_*$/';H_*F7U<]1H!R(6K1MG;;DCN'41$QX\\V[=
MR51XK"CS+%.?O32&?]_JG*!?*K#G*XJJ_M&L@^[<E0(1"\"=M/2XG3Q33R_N
MOH,=[ C_X=;3B<GO@OWMR*RWN:=16POT.QEL(]_[)D[;&ZM\)7BX5"#,L@<G
M4Q$%P')0\'DQV-V&K,)9Q?8VRML)4B##_J*C2SKIU% _=%4,AC#2CW"62"HK
M.^(3XA#9#>/PC$!8N61O#:UEL/+>U)+!-8>S;5R]%6CV^5XFI7F#O--/R^D)
MOL4-@EISC$9BZH:?-A8H)3%'H4:EF&W+D9$!?D *#ZG?GKD?[R(#G.5RG,<W
M1_-S2R-SLG3X,_HCY#KTG3@=AKEKE['8(M\7-R.+/1V^N$%==HU&.Z/#*UCH
MYQ!5DM@VY0U;Q$?<M2Q@2Z%-L$CAPTHQ0W?TZ#<CHI3H88A$\SH#W62[5U)"
MRSE.*S%C:S4^>K9G]0U%[WJ8RB!>"BQ%U,^GG:'L^L;*5B)]CS[V?;-L>J0Q
M;'G(]-;>C7 OGF]F?,V,^:V)S(W8:+_^?56V>Q6T+?Q!G'D5BA#G@J91,6C;
M'$VTLJRT"QFU=$]W21.X?=/*@[VD]3UNT#(">LLE7[S+24T:16&S*@MJ*;6"
MA ;%IBD36>S^6(,P[V3&>B5+T"%X#).['VP8H$;4%1-B+ /+L[;27A3AM(C9
M']W,G!;-/1Y90,0JOM]EPW5(!ZU:JHCU)5*NJ#=& QK)TXY\.X!&S>KO!OA+
M>\(ZB5"V1,;-!O12=\L97,0<2+F[S^'.!XH".=FRI#>]<8O6X?2!ZM&0F<9'
M#:JC]HFU,U_X7Z\1GUG&7J6B=2:*,><!U=H7/DHOU5]8P591<0CV]>I+^KF9
MXV$-UX?&''U<;+.#8.F/.-#"5&65"? 3!Q7\A-,2VEV&WG=542L$&V"1P0SV
MXT.L.@V%+J_9BO+1DVUATY\KF9A!52_XLKC2-1]_F- SYG[Y!21]MNV^E4^T
MXDJNL[.+\9)&BH,@2ZO.EN88CQOFN=NL-L1/9]3G3+#Z"\^7_KGQP-5FIZI;
M[4:CX0&6JAX.5/X9Z3>'KV!79E\QV=^0U.A5?DE9/X"3'Z@&P/D-OCNLAGT@
M"D*?:'Y;7:.D2\Q JFYL_$J'\YOL1YWG8^HRGA9_W[4TS9W(B1T"_,6..^O;
MRT#9>CPX@<!U_3C$1,TK3#:QU=6BJL,W<,@KL6A%:6=G_["U6GDQ(R>G_"[2
M $99N]>@F8P'GY-D$<*NRI\T-A)>/UIC(<W[;GN\L5L_3VWUS."6NYZ#,-._
MUJ'(4$^8?YS&2R1EU#"Z2@6I>/$N_ZMSLPO^$_Y=8PKD8V35M\4*+_++=TU>
M)FU4]L6EQ&0FY\^C%?C[0MLZU=9@XT"L"'W>O,/Y@*D?Y$NS/ O@"!,;$G?"
MV&BFH3+^T^>"#XUEL3ZV7(WKG8"P@_JF.U6O VHWEBV4G7OPG#1F#F@>D-%%
MNW*7/6GIG7CR(2K!H!8'S\5$L6MQ&^.9YVM:YF$93[^(&TP7AGVH%8%="L)U
MN*/5312S:Z9"+#[BHLC%)D&M;[717,#)P O\?M_JE9.8P4N39$D52-,@JU$B
M2_6.S85CVQDR237]S4YYT&F'FXA];I2%!>,LO#\JA;!-#(D*A[P8.%/2F20,
MHVIT!IG(Q,VWU,!($W$:74Y+;3J5C9H&%EGRS,.H_(SKQIX80>-D&%@T(T!$
MRIQ^$Y(_3JP_T0A7(L7&JB=X9RF?OT<J*K)\K9XLSX9HWH>P4CB_$+CIXH_+
M;ZE&CCQ/)1KO\R6_HO@TF]F"S@_6QOV1P;DX:",[,X4[-Q5;I"D7X%A57!X-
M$-[6@_%(G9;"%3[(F3>Z&'K&@[9.#./7+8W>>Q1N4>$A?/3RV95(Z;$ >5U+
MR?$4YEKTXDZ&NQP^5A-;+BX"OHT5/J!@QDB;@[V,!SGF5 2"M("/F=7;?8V8
M!<K K2E_+/F9M2;%)D67=5C4H4>C:-N$Z[PTJW5FE7# KS9N_$( _&5Q/1U#
M[&]2=:QV!HQS#)^$EU3S::"<A_.A4\D0:3[4N0.\WQ,K>84B9*B#IC^ZAXN8
MDA>W1OV.TGT?FI//P4"H_[SE5%US[)\:->@/_('_D\@H[G\\LFYW7 ,[LLGF
MZ1WT2CJY Q#Z=?.8G$/Z;#)^SE4O "[&P0L-]DD043PH.%V6EPU? S1^HN18
MJ4NW3.'/]XE<Z_?L[*B-\Y.>7)ON23$X@;=##L/V%+L&OXV7D+H,,+F^LF%#
M:!EW,HZ/776<^SP:':E$W '0Y/@[+]==PP#*X 0#<KZR^DX&&THF<;8OD3[/
M)#]R1/4* U:HQ[=9!A18K"-F6HO-KG,J>-;*#L8X5N\ UC@1^$"7-@G*D7TQ
M&8>)&B9KR0_+&7 12TXE[A[Q;279"4Z^T+$D$CO4<^EM(\(\3IT8,0?7N?RK
MS"G&@"FAF+W\E@*(Z+-ZR #UA#OI$U*F*LBZ>9+#VGO-E@0"/@>4^Z:-^^WD
MHKJ&)&H^F:]QO62TQNS,FJK-W>XOPZ8"K52,Y8P?$6X,=1]Y->3.-\4NO(L3
M(U HT&T*''W><CA7@"S)1D:=O-F5/W\Q<<C\_O$A8][4SJT-UP,B*)P_^;=L
M'(2FH:8K5N^,BQ8'7DZIE'7[N?M"FF5@VGKWWD6E(-G+@5S[":X^$[S8.WFE
M7:$>JHOATT;95RG*#S7/?W*=RBG]+BL()8$_\,$#MI?<2H;:18.5C1%:)>6]
M%[TM,YOP*O,X_N/<+%N[?6-"+IWFLK3[:4QR:M+ U33>"Q^D,]]9(?11>BS8
M 9N ]#J:$BGF,[R,-:W+M84'R:\<VSVEH*DP%M+9F=U*'7J/\/94](UX*FZ[
M%[?@:[JW^$R_AWQ]W[2)586XP5)]+?1[;_TPIWJH#)GU-3D<+\I;+$!HD3'2
M]NJ1U,% 1$P>!EQQL M]G0IDB0N2G:^GD(=ZO37DZ==P5UP5>GXHB>LA8%%K
M$-K.6K7"NF\<3LBN_E[=7P1K$W[R:5;PZ;TX*G2O=?-GE('X]\%HMD?%>UT0
MZQ#ZNGBNIW5 B@;A/D+5)B9<<5-+^@C00QH;S#0W-1%*I-9!/F(Z#!>AJ8@(
MH</#,--QP[T#F/D]$?ZZ^70F?\\C+YRO2.&4WLE%.!Q,5ZLTC1;\!)4D\GJ\
M<EFIH8[?4J&&[O@H[300NRKJT]S3A\AA#6496QF=E-2/\>>"%.]M^UON 'B0
M>3&*Q08R5R7//7LZ&S(>*(<'/<;N!^Z>QJLK<(4/^R%?PD&?%4M+H)2&JOYZ
M9X$(],.S2G&VJ<&YX7O2A)W-,&[-81D/:-T_/(:C-X48>STE4OGJPU(5I/^6
MP99$)UZ%'J?.F-*]I.SD<BU*O7IGL?'5_:3P/KX7)GUBD8I+&9:(!EGZM6<I
M6@7Y1HF\ZZ+$6[P3GQ-#>SN"<'UQZ):*7PFS2IB[D1?<3@POIM$D&:Z.N0-[
MHB)$D9J+5)S7&DVZ2W+6*H)FN:",PYJ A5'ZXRS?NBZ SIL1K@1ZUCS^?L]\
M,J&2^VD&(/NW,'D5:2I;QGA19_!+/R\X0SB]18A$7/6:-W7"P1V@4[,T QC7
M%H_C50YWA$DS*"YGX2![D_ 3?\#Q8U(OEX&G#R(;KNF0?G/?>9,.C[&<PF(3
M-'5[MS5.N9<4P'@9P1EYP\9.LM[626;-:Q7OT\\A<8>Q3GK?NZL/"W&H26!;
M"%P9>[7"A9H77F#&0I M\5%12G0>39RK6K(FV"QT[ "SA[=;]3SRN"0=WW;;
MZDD4=SLN4IPMOCRO)V]>@>)=#W/2$)6,+UILILML1VH./% VJZ"X6Z':)?[5
M%(*?"JK\+?.:/YM B0Z'FSYES(M_)5X"OS'=R=+0;*H6.W%J;7'5K(]R@B T
MI6DWJB@Z8-3=#7O9\WYR>*S<5+K'1-KC:IMO["[Y,[V9M5=?LOH/MUX#VD%"
M..(RUILYQ?*:CK+:#^69"0(OCT<:*+!!^:ZKGLN@ :^U\,5PIK4)T>K*#^5G
M)9 [ +Z>L;XG)J&LN!2<A+N$4D;2,FK6O_0 $??<(PXXN?4&+0U3=;)/7N0
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M59$H[QHC"8DE4> S'.K8[ 7S"8O;W#+<?&?? HRJ,^(1RBJII("#+C,[?7[
MM8XBA/=!CZF,Q.TEYR[/ SPO;5L2WIRZ>!W&E#2;;T8*V '%MDU$A.[$8+JU
MAR[=E!/4Y;:FR?VH^^25GWO\M_?!IT+#N[IE*WBL;F0AN6+4#I-J EZ6]016
MCC7WN&$K=/8517B=]=>L.-6]ZP49 82B)JQ'P=B;*@V)+VLLWWPJV&9N-_A2
M83&-?) "7(E2![N+!7>11\1S?D\VCU;57WL\SM>0?2WX78=N_NC;67&JL<+*
M6"[O^N-NLI,!-7A6(%]F5,I6L^GL;GF ,TF<V5&Z_JGD>WWQ?F?#&>5'=%QH
MF%1>VHZX&\3@:BXE7\<U0!T97']XN3J@4\@^EHZV17VJ\<:80ZC>FLANSWKX
MA8V9:N."K\T7&_^3.#^1HU#&S(\\9=W".7]GS,%)A>A$*OLGO&RTXE\VIC\<
M X=S5%7?.J\#UAH<8=2VUD?UZX^]D 'EC"$.N4UA0(Q:%^Y!!TP&2$L\,H2O
MJ)K86-O7-J8W-,ZC^<W*B,VP&'*8P58O]#6:C;&'G[;W^;U.NT=(>^@LLV7_
M$S>7H@M-3[9MC<^# UF1BJ<F0&LS[='O9AP!,LXF.#<4$O$J&6Y=2;48LAAP
MM19ZX+)IT1/[ 51=40[5.$0JUKY2@VLT\W1,#S ^JJ%Y_'Y-CJ]J@8>C\CC*
MM7:MS]6$N22^CSA.JTRY5&M]UJ>NA#G]CYMG8GV+0^\<\L8?CW%F_53Z'Q-4
M,M[9UO3A:GB EER#:1D;T@C@E/]+K*3&'1FH/M@BQ^)E?BD#@=1NFM123O'
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M2E%#FWJ[SY$EY+FLN3>^<,MUL<D@J(P7U.&^0K@]USBXOP3^L+]J95.A>P?
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MIPIH/M@>)[&Z:=YW*+_&TLQ0T-*])S_@#>/?:L'!(P\F09:TLR&I,:(0!EP
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MGJ/8@SH%!9Y&_KIOLU"F\R/@&:.IS_MW]*[TWNBQZR-!DY:17OB#:2@.N]T
M]]'.A/QNYJ/=WG-H=<4C8'T ^W:K;: 5?_PX^^.T49HTLB[BS>P<Z:M9!E@+
MUI*.!_"JI^SG93? 3DF<54L9?RB!<YI$#N".>D@ZGGW@5]]'+53I_@@(%"-[
ML^OEN]TX:W0::R!GH,]YVD=B&!=#%]L!Q9:K@"?0QA'KU#M% &Y_?]ZYU>!8
MA]Z\H7X$.+0E.^<?16PUNSP"R)^&QE'=TT,5N?4T1@JR+W\^ G;4+I<[LF^
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MG+VQH.#[9$.MJA[0_C*VY>D.+S\GCHFQIQH3NKM,9\<5+6:-3#5"B-%2(QT
M7.)L)H#_$KQM$.6+71AS"),3?*:(I8;J><M:OJ35[FL[IDL%GR_)P0YUCM:_
MZ[R-6! ^QJO*6@3/.QO$GG8;5BUJLO7Y/>MN?(#!UMK\K])K#AG3-G5>]_.0
M[ \QM6* .1-9RX\!EVI/I'!W%1 @2ZM,PI,@*JB..7D)?7U*%FYWK_+9-'.Q
M_5,>Z?3,SWN"&:CIG,'@=CF#)U=P*W)W\3#>;6*WX&0&@C"Q;X=":*IV3$'=
M[#=V)2J2%S'/H47C2)9EO @1(0,#F(+3#)5QE-+CDM95POBMU.,FL\Y6-I2
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M<_A73V.6L6U]]0%V]:9#X8;JUN N>U5?Z5^FJ>FWVW,M3>V>2*T$)["L9/8
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MBOQD:/*^!&2$F1J6L<IQ-I*]V#4_.C4W&WBWY<>[C&F5-]!O2K$5[PAV_6,
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MY46MH!3>UQE*=3[K\0,^<_LS3WSM.\LY\Q;)N-('6WIJPDUJ8P14,MBIP0I
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M43!;7?@V/J8W71&WZ;/+J(M0L],,+N]E0ZM1S_8,"GB0_B_4-_VOI;Z_*:/
M8HT0SN;@Q%4?IST'+<'"4$"YCSQWH%O)KC;>)6Z3][)_**3*I;Q FM)O\'4"
M#N (QO$QNDXX<U *@@7P>;F409;\*BY@4;R <!2D?\ I"7JT.6:'YNQ'$?7&
M%? TIH#[W&-R:*;KBKBUF&W_2M"3^=S\&:;L^0G,J<R_/47VE"VTM"1BA\,
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MP*?]Z%507*6"R5D4Q0YX_VF7W+\U6ARN<R$KQL.M\$GE:Z*66-A'B)7R.;4
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MU.**?G[@[1:67 &9R-S^ON7M0G]\C@*4QV GS0JB7/A697ML]DF/VLU-9U&
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M"!FJUWJY"D&D=._[Q=O#/#KD1^VFI6L;Z^7,'L11<X@MQ'E><6W$(BR,<%'
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M78+XFK*Z7!+'8WV'KJ"Z-4C@DOS1I>8^SVY!B>/Y.TB(-X,'9(<W_;.'\]A
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MA=\AY""#..M*U-F5.=Z9+*Q'M#BWP%C#9"T(7TB-TQI F':E'PK;I)^2I*,
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MIJLOO<N*$R&]D0.J#*+&%*'5_39R#SF1WY-6E$$[]E\[YO*?^"?^/:Q<#4M
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M'BOUC$"$2^E8M!JR]1U)06MY]O^Q]YYA423;_WB3%0F*Y#0(2,Y!<EZR"HB
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ME)BL"^2Z&WNO3: ?I3]3'<01+"K'W=!HJ'D*?;:)-1:L$3\SZLG?&'7]WW&
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M^W5Z'(Y73E]_,]DUK-&-HQX C#0@#&O]N?V]Z3[J*(\I'3#TTE9^D;+^DGY
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M8-Z1<O#"N.L1P[%1NSP;!DA,UL, T"BT%\X!1SC"6@<N_EP,&1NX)$DKOGJ
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M_A329$)SR8&QZSR_^98'^MS.'M+WI\C^Q6F]:\OO_G6G,68#+<>! <J=L68
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MTX),#3$I9A+WY!XH=S,BOKI(8\#3RRP=.*5KM)Q;DG2V& 4=K7=8L S;=:>
M\5;RZ6%TGNY2(A?[UYV41SK2\[.JE-ST7;6 TQ?LFK=%A*P"8[R#JN<$XZ3+
M7_%T%]_<4Y;$3GR#F;0([ZCHTEN!=KH=-J]=5 $OL7_<5<M8J8[KFM(F6%1N
MU!4B.]+(:3,@2O1L2;G$@S1H:UXGEIEE[+Y738--#><CED&B40]DLEKXF4N>
M2Y9AH7XG#)1XF%_VP'10+LC8MVR=YOCR!TMQ0VX!YZN7!9;N#F(?IYS4L&LQ
MC&#4X_+9B)$TO&/"-4'\3, @T*DMUPMZ?T>]J^[K8LR @<!P[?OERZ%<>%_6
MS@,V^X7.@E>::HTAWEYWGRKU:_+0L=HP:70":J[\K:TO%*3E)Q^ E]Z&>,\J
M4+J@C.::U+2?R&3ST\X9W$:<P-,+.F8H^8I-4+.7$L/18CB';E;M+(NWX,]1
M_,B'F6PCXQ?J/;U?!G4U23+&#N*H4KTJVZ ^X7@AOM0.L)E_^G@><B'!G<2.
MG+7H*/_L9R6PY$(6S,,:?,N^B,?-:3O/L&:VY>T41#=:S\L9<K$VW<N(W'ZV
MCUK%6Q]-8:=3(Y$K3+*?I_,EEEN/C+(6C\]@]!5@MI*Z:^&.R.B0CH_*]4^]
M?.Q<1S)(E/]E>C(XU76&\XL+>FP' SQ^+,\VJK%(-W,\/AFDA5#AU@]Q4R,G
M0CFEI-O5O5A^NO3EJ_6V(I-O6_=M9'1>Y44@N0A:$3+IC(UOD_>@C[Q.3^-$
M#F4:C#Z+V?%,IXR VSX@U%$8(*L'&^X"P:EI0AIN247R77G0C!!J)-QL[*"2
M:FGF>484+32W$%>*,T80MMYL8C?IW+R"Y>T\!J +TBM>]0"],?,'"U$M&F(
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MO#FJ\*4\OGZ ">L3O"H$URN":'Z)N[=A9-BRKI#L.B8=M/)E<)/Y4>O,,>W
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MU@AJWSI$5P[OV7*(/2XY_F?^E6AGG%N3MOK=XS!X39QU3=QM*P)0'TP;*?<
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M7A,'7)&3G3XPAJ&E5$U*S8>X6>Z6K.N9'*-?#[B733\K5R8!<I5&07<73#$
MY8S,>[92N1S.F!5G_OM-=7?X%T0TIBB](62G<Z4FL/KY# .G%^DS/HPK,2<?
M/X(J)U3)/"O<T_? CZ;/,8.&53O;EAW<%MA2H#H0DJS+IF<E[48[UC+S;%2(
MF\TV7F?W N\)O]F'OGM%_1-7.T] S/&3!85PCC?CMF/."QS<61 F+CR\.>IZ
MYJCY'/;XBUK9PEG=**>-0AN*MG@R%2[QG1M5VTZ>C#T:-E;MS&/[ONW@)SZ5
M=]1MB_LJZA8^/!TDJM$S?NH7KE6O.#CS4TOLC@,'@CH1ER85?55O-%F1YJL
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M;?/O1>.GK*;H'"W+S_ER(WCKM$'O]>%$AIM,,EDQNCF-Q'<=ZSDU' :=5</
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M,"H5[E,1]0C+;#:9RW:P\SH02Q>N$KU<\(IY.#QYKG-X-8P9*[XGI577"%%
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MGB%%C*JT]/_R:?S_X&7AOP%02P,$%     @ ,();5HXJ(J0UB 4 ?QI3 !$
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M7GM2U\HZ?9N[C 89C/ 9&EQ-7^+T>CFGZRE)G ?]R0I.4G9]D3)'@HB,I,!
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MYYXGDCGVYS,E8(%@0U2025*MO-7#]0,-N LNT]=ORZE7UY;3N*Q$5+#12Y!
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MBT^Z9M[&W"W^W,L^]>8*Z'"__(^J^NF@ZF:'N)!H))!ZBK;G)MV@__JT@.%
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M**GJ2S7TJ>)'I4VPY F^:W*(+_]8PZOAM=44YM#@N?.'NNL#JZ9^&FL_P21
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M CC6TSB9IT7)_L77EF4JRZ2O7@D?Q:9MER-I%I#<MEBXLD$)\:%NYMWD\$A
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M#L8 IA),'Y[[_K"?(RA&T^7JA']@B?0/N7_@_DG*>&F.WWCRFL>]2G?URF^
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M>52L50VBZ>L\8>\V;'QI2=GAV^[RSQ-#0S9@C@ZC*Y8%R:!S=^9$#E+@,:0
MKEU%;BIT+#O0Y,DFI$HEV$-7>0%?66(\SN3U(T8]BID35NXW54%?:2)G]%T3
M%HB^T"]B<V'2?,WQ(7Y7N"I?!<.-W(W3,=S(Q]++X2Q)52^&\07Z&?3I8%)Z
MN3"6E744T36=U[" D01.#1 ?/1>3/]ZYF\.-VY7='V[<8^E NC0K4R#9D?S+
MF:G]49I1D,S5S#7Q8#[NR#8.5^<QKHY-6CE;4#-\".-DG+"+PG52L<W(&$K-
M@*@QF!D3<^+5AVQIVC%;#'=K1_9YN%L[8 AR[Y3*(( A"78R]1@!:#XG)7,
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M&V;-V!GH.'F:\V))NW7:?C$*GIGV,Y^$>[*_-ST-Z(V1$8)+F 3 HR#V!LN
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MRZ^K 7+-$KS*)\TT6-';8C[PW0%;%2282E98H%=!*G-E"NY";JFMRNY"JF?
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M-;>I7<+G'<K]V6ATA+JJRYQS[6W:12^/[I9)X)/L5GXHS$6F%&8?^$L7X><
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M!B4E>2%Q<=O<IP;8:!MKF->VB+.0-&.<7UJ*M1)22FD!9GSEB"2XHP$-O+1
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MKS8^JB\FG?L91L[S4IF#O_>E]^PCAO/1ZK<WC=DYN')/Y<0\=. LJ9:,_=@
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MG=4]?JQ:"-Q5BHT![=>C,6_^*>;4IWR0![BGM0!Q>QW\1N<;C;]01>##>!&
M1V71!I*7,[+X.W(%5^+L8[7<.A7:.(W''P=8%^2,K:]N$R-V86SUF4V!N_@3
MG7,2TA'^F89U%BW94)L+1,D^G1N(^_G_D;UATK6[;Q_U)MQB3:VMXFVV;3)T
MO>6CP.S.5K,-Z?:&%E*/$]QGJ0*?)W/81'ODF^H"8L\8[]0 WW%:Y6_-L1D'
MYY4,K!0"/]T_'6;?&)'T;T.]-Y+VC:*C19U9L(!CF$.\( :<"I'!)C?H6[%#
M]=\]JY#WF3M_6W-PNK\N\^98#%D\D:V$$]02QVS<_C#9[[7?/&N;G]+^)NJ
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MUW:3('K77KA P J)<J35V SF"IBL"@@&FJ)]Q2:G(D$[8!525#[4KP0!*;R
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MZ'G;*N\W];R>,]H^ZM/8\N^'%_A6C^P9HA<\>YOB/]\KKNXKD=+K3IOW"G6
MN\'PLJ+2 *Z$Z_EKI?K[O%3G='3^C-3"AGY/J_SM%[;(-S6_>I/,D#B8ID9\
MX^^HRHA_W^XJ''3\7-E?@[Q'_IJ[NW) B5YR7KG&#B_[KJF3QP7:E=)D'56L
M,2G_6.0EB94,K<*7W%M+PQW#"_\IMTW.76ND\"(&,-V_?\QSY!;HH'6-BA*V
MRMP&(M5*0$SH^(.PW:(^VN3=>E<>;==YM2LS)E61+JG;\V<_I@FZOZ)Y5['0
MQ!E]&GRH9%.9[Z\N['N0D.R?2)5B*Z\  54FW64.>T>I'_=:IV5\E<S7^894
M0[.+>J\[]EL)\2%Q)YUF;Y#U[RL -)TMK_O](7%OI. Z.9P.*ZJC.U9H%$^Z
MKUZ!#0W:,&"]7>;-1E!UB!+VTO'+.AW@"4KW+Y2V;9=O;<,$?+F(Z6)G:462
M-TJTE6\A?6:;[#I!])4+4].$X<Z[Y(=C--4M$!5&\E(4/3:/8^_5X^2&)*30
M: A3(8*O%,76Z#FY*G!TG_SK/&9XU@"\(WF6>45"2<9?A1-@,C:RAF9%Y<F+
M;QRR\#Z66=O2.6)*MY""VI$F^L.;)NCMW*!8EY,+F50S&N>*FY%[RXN&I$=E
M?:E#KFN2C>VF6/#DY_7"FC)W@XEZ4C(_#-IP(%.:YQH#'ME=7?8J;P48()L+
M-M8";)ZZBQ#BEO(W63?WO>.E!I>S$6D#'@ BT16='9+D0KI=E)TF*=28S74#
MCENZZ\P9L)* V4&@6YR'00[&- /")OKBOWW&\(!/WO;[LUGP+TV4WMX6O P5
MV66LR"8]]EYW]P](UND)O973*(R]B^*J6'"^COY="^&OV'O'>G559'F0 T;M
M=P&6?GZ@O\'@ OD90VG(<F/QSX)N5M0L!6E\8J0BL;E!_2M7OU:K,G?"#O I
M$HB+HUG6T;."2TUH<;9V]+)%?8TR]1S=@D)1J5<>)\^ON*(]E61K=&V_U2LY
MX!W<2)^*WW._-DUAXTLDSA>I9*UGT*0D,3&]6-B"G0LO:577B]8*F:\*[0('
M^KP"'>0[Y@96.@FCJG#ZQP!KPJ.L8_* I:!*&I70"\N#2SLWQJQ9U%Q_*PU=
MQTA%A6M,FJ3FBT]?TD^RY3T)]@L77'J",-!+%R6:5O[#2_7#D;VBC2WN4+ZG
M,)9).M=*J.CN0B;R+/!+213E8T^]E7MJZH$\;B \ 8SM:-ZI83_9=K:(A=JR
MDT?[?O?,Q2#BH.02VD!T/  AY$TMV?0%&,"](R!]!FC81^P/,$:&V32-(D8[
MZ.1&85V"OJO<Q1HUFS=2!P;TKW")#\,:Z-#%&JJ%"]UVBM-&ZEF03E:2QL&<
M)_4/*6.G"VU[PV&;E31USR(:#6U$D+DNUC)TC$-".9W0=K2=X(5>\W2<TZ->
MCC0^I_'6S8(;'*0";P:!/XA&&,/=9#- CIERAV;T_\P:U'M\'HPN[Q7".87/
M#ZXSZ]-+V7QWS=ZZ_2RF/,M[/G[G97FKU%[#&3VX(D8UY C#MY)"P&7Y:VL>
M+2[4HJV;&3<Y@# L^\VQ)ZA:U*W>>%EP\0J'T5R,C=PQ4 7GRZ98<;'*9^8F
M3#B:M\#1?#_A:"8<S4<O8%6[ZR-;7Q^I"O4SVB9_,=SJ?_-=<CY? WNZ<:H1
M7/[]!+AZSU+O1P< ]LZ;5NQJEZ H;IHRNZEKEY*73..+NA&QBF(K*(AL2*9R
M%++DPJF^%A<_EG^=F6\95.;:K<)?L-=75,N,^V#]Q^J5KGW<5DI)Y)H''KV\
MV8/:!UAFQ3#[^N/W%2&9]M]@_STX_?/[;P\I%^Z_M]QD$EO9(!9APWF+T1S8
MZ%P_)"71* 4/ZJ#;W U!MB 702'JH]W.:$Z;0K(/["?,0>V;N5HVU,O#*T!W
MXFF+OO?J"]^Y:E&35*&W<ETEW"!:6 '0EB46)/07RN8Y* 8("I(Z0M:\0JU#
MUG15WK3K8JO@BG_6U1]9T.B/*0I0Z!;?MFY6F7'9MAQ_NWCVG/[0R&+2MX9@
MXEP4JB[D,##S ,E!&L=<(FTZ0AD^XM/Y-N?-85*/,U\:+=YPUUT6K'Q$V4]B
M#Q1NJN''PKFDJ-K3$C[I[C,V)YHI7[+(\RVM+0I!)<#8<>].6@X)-W+5)NH2
M$=,4=Y=>>7DD52DQ;,=$.X?9K]&%7(HZ5:@?2>\\O4:*;MM\#F#//*--5G2[
M5!CO63_$HXE64/N\'D .I7MI7DYBQ@)J@&HV[10R81C@_'9RBU_1H/,X&AFV
MRYTC%)M+":2P48P-=6RDNBD4F"1OV]-"9P$)?YGUE60M=%9><TNB6<:A;=S\
M04&2@K=.T K@.M<N92@C"MZ4 82PJ_2E28ZCHK.MMT0-<GA[7#VV$K==@> 5
M1ZL0[(1@=:UU4V!-_+?/F'Z=QM)O5:X'O0LXMZOU5&-KJ-:-(^EXO94J6A2-
ML\R00]K2ANI  &>**.J%Y8\PJ2L1(UX(R6WLU$*RA*GN1=S[^( AMX?/3SU<
M2Z!E^V"X:P@N+1+V,#O.4#& "KT#Z1!F'-@/\'9^,EGEI9#,90AVW?9-B_7'
M4R3O,/P%[W!^.;H<X7CG/0KDD:99Z=9O>,Q%M8?BRN/*.!VX^U /$JVB2_+[
MOLG2P_5)/L\W,WH50+3Q(<A?8P]Q]U.2%@W4'B:B^W!O*M@>+>K^BG:-) RS
MQM@$&Q[\39,+=O2RYW=QJ-@/QW)OS&=G,N9(1] @@ V&MGG;%\7W6F?,KN"F
MWWHTX7!Z4H[O9I?-%4M)FT3;@V! HB'E%'&+-;YIV,H$!F"X'^6>J9;1RV&1
MRSZO0.M',PZG>-]G%L@1J];5%[3O[9C\Q?.XV\?F$_2I2&$\GW>UZKAOQ_0%
MBDI<$4S,Q1$)9N[AFS=7!6?=;*NE DB'1[-(([=$C1$\5KVN)\]>GJ<C>D>^
M+<B@(D6Z$CZ8VHH1#H"WA^,<JQWPR/EE$'WS1"3&BQ:9H\+0EMZJ:M%B"!+[
M&!JR4Q#K ^SF7\"OIYUE][9RF7?@11P8/O%^E,WV3_GEN=_&H^80WTEH#]6\
M!#>.[*>@J[O8;MML)XX*2LYH/TG-%I>DD2%78^'K^2N<%RZA@HG*;E+FS'V]
MD1X#[IA#C^812R'#^. 90&0V?LB B'>$@-4\(_/4#4_HB$;.IF]437L8K(K"
M":2%70PQ+E$^0YZ@6\ZG^J@+/.(BVQXGYTAVCG['%1<S-+T'"FO- L/\3O8N
MN"61LQPWV2N)^"R% LE-Q\V$:T5LA1(^E^TZ?=/Z=U:H R].^BUS0 ]APWDN
MT9Y,ZW9<[!!T&BFNQ?WRTOBO:$>>TV4EK'&)K.K4QA< \J*J.UE-&;4Y9F[M
MU06Q<D:_'D7;]OF B>IO.&".S^H6&X]7SEJ5D>/AFO@-EG9!CY*9H9LT9L>3
MU>.G<^41+9('#Q^FWWY_<M.SW4OBX $O-#>5/OOF^.0,HEXNEOK"'8\OGIJG
M-'WC..^(J?GY8!P>3AB'"3IX!S9B;,R.6@ :HOAS-NT!,_;[/V7&NL=X^_/=
M+-O,0C"[(&RY))7/#25'.2JF#?C>-J#3]J.QMVY=-.]U]X7.E=N)9V?13LR9
MYA*/RECY/LL:VHT8H+"#7P8[=?0&\C=36K^=TS62W!_NSZ$;=7GQ[VE;ON=M
M^1L;]%$)R]#I'H@O?DE[^V .JG;>2<)&FPS#2F*O\SXA(TT-.G:1CCC1LLP5
M %!TCDS <N>W/0:H$,RX<D**(Y#JJ5J1F\@.<W&X/!I/&O "A)E(#K9G4@Z"
M9)9[])K^CPU^C/<X"99O,&$_7^2A 7W@,'2:=$6GM9 %"X"V2Y1)%V*@$D9Y
M_!YO\H('0H]X2K_E%4;QZ&6#I':W&Q*(C(WCOJ DY-,6#81N-R \_2=I9$R"
M2\AV84R_^T".4?AFKB&VB/C#&@>17&$+^EJ\G&YM? _[&TD^634DEYB]91B(
M2H65%_N=_E[V)2?*"VPT<O!H'US5<Q2SI$++L.0V3+DQN RC/"Z1PP^$>ZL_
MI)%X=_C]+U<JR:,VATA.[0RD[-JFXO-N,DRPQYA;WKEXAQN7[]:ZB%L]+:Z$
MZP]NZTD OW<!S.V_Z"US7@QG0CI]I*/K+R*%!!+7BU?*BA&V#^=@D.>+EG-M
M7=2=7 M.'*=^];%2]*T(* XOR$TEA#2,^;B8C-H9DO+F;A^0XLP%#:KH4NT*
M))I)<SSXO%)QDT\ZY>'>0_YJF&.?,G*?WI;YT%TK!UN$&TYXT HP<P@NP$"!
M%=YD"_/J%T4[KZ]R4$_?;$QS%WLR0@4%!J ,8'66N\HK6N4\=S!LH4SRI<?W
MA/"-[>S!8#WW4^C2_1]TUVPO?G3L>H+JH[5?[>Y+K?$5>P$57N:*#2R).U=S
M_I&VK,A[=*DX3GYT:#<)(S?;NM'>6!ME[T!J)D";>&=;S3H\]59COQU9H,W0
M0ZQN>!<MD)(>=>2A7;Z!!_.Y<%N204<-LH.UTQ(9ICPK-F'G6#Y'5N)<EDRP
M9;GSMV]&_'C@=[1D(3X-U@@6?<G4ABAO[W<Q@LE05K>%:87MKT+\5<++)[M,
M,&N#5YCZ+)QBUI3KT4(*82*VC0:G80?+Y?KENB4T*KT1"84.7)8;<^C??>S7
M!(ZZ\U6HGYA&N;W2/E=3'IOG1<[9X<4("^G8WK]K>VBR5#YJMRV&-2#:(?@*
MW4)O$I^J\-[(@PO.G.2\7Z'ZA]W*TZ_%27TS@^ZUCXSC)I87.N6H]^DW(G-7
MK TJ\EQWR4,-@N(+_/M,/S#M<,L!<X9_GA=7 \LC]5VDTJ2I=UG9[8YFY+US
M^9(+.(5!*HW0'+93LLX59;ZJZNNC=7VMVEIJ[+SQ0@K$.-.$0@W*D?4("-A'
M E NWD2O8+E4J#(L%Y@="#ZE%H1RI3+7,"*Y&V;1!9B0,>6>"E6I:K-9SA'>
M< G20T:1-#U[7;1O;Q6ERO)>1'$PWHP::(N)6;/*T;S=I@I(YS1JRS OG2-T
M51-@S(".LH9C.T[:#^TQ18.(=N:XHEW=991HA)7D$>-<0I*U-=OR2!'1NPP-
M"UJ7F0#]\Q4X,]#>U%5&<"@J J"#'^B0*<? $.9/6N1-6&QG&\!%>=_RH.U-
M$5F'X:59\O57=N!PUGTSMVQ%=UM)W14:M)'_T?$>=Q 5FXW5*/'$USUM@F2=
MTPW72K=X%CV!]T%TK]'[T,XAZ:PW0MP<)T+OTCBFP0!IY<\4<RGJ2?*!;,>(
MZ[_68U0TBR,1TPX78_4<=& +_U)0.GF5"=LB=M>\S(J-K^/-RK:^Q8J3:RD3
M01$' #CPMFAP]+P%JF#(L&]1%G0/K]I12\KIK]DR'MSROF=+>\WCXLWC'D&#
MX%T\<IX./!F364&R\'[+JL,W%%9KONU=,WWNNOG\V0"<'IQ, *<IF/S1MZ&3
M:L=TE8DJL<!%7*$F?4P#'\UV1R,?JPKOR;39X2?Z9S++$-V2G [D8IEU%J\(
M=85\198Y<^J*JK!\KFN4838J1W/$S!LWDAB;BN]L%)PLSRO+<#G0L#0+"+DA
M-)YVZ,[B,6 2;1=.8:$=8S,_VCUK3+1@YG.]3 PLL-;40W+/3AY\FT:@:*3X
MF4'13%?M2ZL&N-R7<V><@-N0&J7[9$ :\ZMD9FCII,$="715V)2RFMNWL8&V
MM%CT2!1<HT]('N2XN7LN@HU]X+K8>R2/HD/RSU_?#L:@OY0FRM=YD#MG$PI)
M^]AH5J/O+8P]6AI2X'D,-:?YOML"I.'D%C4--S]:%*L"J /=UJ-KXST[';NT
M6YB2YA](W-W2SX]3Y8)U,^'E\NPB WQ80L^;_P%,O;R0*@(VE,W_K/UGWO,V
M0%$R8S0_/6[.7B.B'32(;T]H>^Y:^STC^N=YJN9DIH/FT,BAG]+31ZQ9DCV@
M$@# )Z]6>\NS'QH U(JOX1V[0HR&KJY66O]$(J76@81G"\(S[XINU!9W)*Y?
M)I7K9*[\F>SW('@Q!9BG'70SG)HCL8>P_(.DYL&X\G#?I6]!>$ ?SIGC9;3E
MVSLQ4\ D^C/4%$E/RJWXP[*G/IGN#=DW&U=9I^5L3*/$F*YY+DSA3@\$1F,V
M(P/^L+X1_.6L;VB/Y_MP@[8CHW')5K&+@H)+9+!BRNFTR7.)\%C'."UU9)+U
MK$&PD(,T0K4D+48JA\3%'2R)[0LEP\(QW)K?08VXT$8![ B9I=KB/5XRONUL
M8&4VN:#R#M_,K &>R;INV/^@E]@6,/#1 T#;>>U?J66$LG"_*HK6C-,WAH0+
M%W#.YSU/?L27^Z6G:Q2K=^;J2-@GXCHZN!ZTR'SD],!9P!=0#<_$%^RU/91!
MK[A'A@MRS:-@MC,N@N:>8-W^5?:._"EXTS$;#[K3%\;C-&!+Z9F_F;M[=?EF
M*QB) \T9A\L[V?E_@9V_MZ<_$8-]TS,&W.]E*TN5XW372(4,!2/=.A=O8A>:
M#/_I0+^39?Q< $V3X3_MH-L:_F^B,7,H.:G8N27B9+@1]XL?A[^(L:2C3@ @
M%%G?D8EGG>8@H4/#:3B\ <]G5M)OH=5 ]<<Y>'K8'"RG0G)YV.X.$1Z&^S-P
MK&0NV126^R4UIS^A7? 7$P=6+-\9P['-'=(W8P1CZ]+T(0+4L;W16!]Y2$5F
ME68@684-'IG?G+]50(%Y.P'"U*$:N3BM8G3"H&3T[\"?R&J8<N.787=CDD0S
M8YT*#589G+$19O)5;FT6'7VDW?G>@>JPT8M"1L7QLMBPZ!#_16?$]G[H(-+6
MK_*@\;7R8@)*X_(M-M-Q0$VTP25A/^+*B&/D2&NJ?%5WA=G\HZ5ZG"!AT#97
MEQ521^RVLW2XBH[F,"%@UDTP/L/N2JFB5B[=LER0055P;# %N$7M&O[B+.^N
MD:CH_5K\BF]?XMM4BX[ID?( 3KHP,WF.-P2D-XK_,#>-(&,W! 6SMRMC#)^H
M@_@12_?$+UT@>G[UXD:KNN"Y^:HNWM_.*].![,NG(.T4D)C.::<9VF;X1FX(
M!D_>S?ON4M0.H$_+6!5YIFF5@HPH"K6)QT<QB"OPM\=UE3O=8XFP?DN[2EH=
MQG"LOYV='7]C;#JNW9WVAX.&8[J=NV:C31"8OPH"<SI!8";7\J-OPX#(C#GK
M("S_]IT77$!W2IOH&[C&&'98]>Q=^%^*)3//RKFVB)LQ;;C2@V<-F66;O"OF
M288VV2NGD!<9S2FYJLL> 5U>!831]4>.R6R,;4V+]^BC?V7M(ONO*>IN#8L>
M(I@#N""^:X0*'*$G=-G,%X7PNP5UW$*WQH5TT"=YO;P?0)[_]DU EF: (0U_
ML<TQ0S4@D[C@&8*WN1ZW(B7*93%;C/J:EH=]#J-3?X/9<_KM=^EW$2-<M#;*
M&P<,/SDN=<.U*F1K905BO64OW'#?A_1O560ID676E:H3O2?I&&^>A@:1$>PQ
M:9]X 6,&JS'PC2-> S"Q:F5W%T]F]]TW,1<?;V&\\VM8S6U':^K N:E?RWHN
M;2_D+HZ W>.RZ98Y+1QCW.WK@)C??>W1OUV-B :_,,SX;]^>[(_LP#+=8#SZ
MIP>VC'NF89S,,@4J8XHH?AYB_R\N.@^0W+3[+NBW9%57198F+VF>3PIR:_>A
M0E.%_:>RF^Y*W9HV[7C35G.^_F\7+Y_8ODM9%RV2'_-9TR.^@(A=<@W%/-L9
M;G&TL-DZ2:D2_.WXY;$#HD*>YM*V._H\(".RDF_'W<V-QH^DKSD]Y2=Z6=OD
M/'G9-?D6]=&S>KU;:/<D+HB6^%A.+NBBU7*Q13^W8)C^B$-,#F] 9D0; A%<
M&7Q0^ZY&4/Q\%\Q",W*LV.=5I#P=R[<@2=K658!9L*8YT9FZ%CXL' ^+9!AE
M,0RL4YK*R8E8O1R]0R M67BF 0X8'@(-PXJ30C"3!T"5TNBD0Y18N@Q,0+M[
M1-57!>RBNF_I@6^JDN*)B+DUI&@.+:\A6\28F>=M*L[U8J(><*\0$A\E\@CE
MY-P9A>7N,'B:1YJ15_ :I6:^KBTJ:1L^L U1U>$"M2.E;0AT6MCR;:K6#A4^
M"+[E0'G"H!9AN HWX->##/@>:'UO7]ZTE#'Z'C'O&]'W81$K8Z:RIG*O G,'
MKV%>;&9]TVH>@FOWI(I76F8%V\@8$AG>?G;RE>U"VMZT"?N-A/^\$SV)X"]5
M!/^9LN&BA%D0I-G2?=9727X-!8?18DJCX:C,-=C1#IL2;FTO$OG\M@PSU,/8
MRQB1MD.""+:'#G(>MU#@\R+00PEHL/''1Q<7UXMBN9/D47@5G4&]B!OA#;]7
M5"+?!9ZO0RZ%]5$,@JPK,C"[Z&.DYD*RR^E$?JDG\M>!JKFYWD6RQK=2@N[&
MH6MQFW(W?@";0F<G#\[>>]6;^EQAH\2]-1@% PZ!>@]'@7J*T^/;6<_/<4S@
MX>N'53AC!8^?UXF=(E7OC'SCU.ZEMAF>0E"?RC;Y\  W"]!+\J9N(4-:3AVA
MU()=BC;/7XDGP=M'Y-I5UC#C338G1WA3S--D!317!9&K4"YAAQ3"G.(*-H>S
MI)!F*+I>#9^6D;T:+%(2QHB]D*V<_1C.7M3F2Y-W'R,[_?T=S5),F?H),C(*
M&3F;(".?\D;\I"RR0RMZH:7LI._NEO$UF5I_G:F%N"H9+VNRKVHP,L/$697U
MC,PELV2TV:-K=K"FH97<00&7,EI!&76SI-T@@NL!1)N^[+2O GIJ,B1DSF35
M]$_AVN;:K\LES:Y)DV=Y,W^5)C^]_%]!UV15O2P$FJW-+]LMX)?PB)?> #,^
M[@)8"TW(;6KR[2M:$$<FK5 @9KD[3LY;)H%N:806#KAX_N^G3XY.'R9,*<P&
M),.%@@%DP>1P<UZ! .WN'B:K%G+0Q6OA)J]<*6WR2[VN6C)Z_R?;;!_9OS1A
ML\FQ'U?)S' U8XLH#M7@>UQ.5P4)2'=%Z@SER/8=6LV("A;67DC,9_[S9OO9
MDCVTVJ^$<_,Z:Q8M+UI;E_HSP,HEL(%=650]?JK[KZ<1H.)YP?. -3XAL-]W
M4-N780N.JDNV5=YOZGD]G^^)@#0^IKP+<%+Y=(@$P:M"F+MV35S8,9/K?&W.
MY<6_3Z7RF/XZ.]$;!M]?OOSWF?N!4M+2H_PO7NZJ):UG\=KCM:SO;,ZXQZ]I
MU[O,H>ZHT;E)VHYC=F=GR;TX ?G]-U^ER>G)5SP _&UD6G*5YO);PR5:W#XU
MIG/N!P;2T75!$DNFS>XC79M?X[2&0VI)EC#W+&@790U(@'0DY4I&6M 4?SWB
M,AE?(%5L-N@KJX*1/.5<X)!" T'BL%IIL^T->*(6O31[&EX6/'(Z9>_YE/WP
M6LL%_'%Z16\SZK@6ZI*4I:<R#<FKM/(LAN?2 B5A*XCEZ,;F;A"NBBI;D/9I
M[03_WZT</*&"-B9?;2?PXY-S7.':%0OM,PZH7$;',;J,?UONM-'QOEIM<\>.
M*ZD?)VM<?ALXR:P)!FI%%J[.+EMLT*:S\W/6"G>91U8BT54W.KXEM\'P4]J_
M6K=ZN$1%M935'PJC_2F/K]39<?+8 Z.+UDW[S;/69R/Y+T+"IF*F$9M?67+Y
MY+<?STD_(]>G>%[75?.!T#KP>OA;3J?Y S0R%=IU*;_5]Y-5%4UCS@'#+:H8
M]1!HK1KZ@3$LS6@WVJY?[,)7GP.]+?SD\@X-*!:W.WEZ^2156S?Y):L4/P=%
M83L2*.(MC/*E1#E)2P);DE\5-%&E!LK5N'M<P"8LYJW'A 9X.;^?#HXEG &G
MHDG1+1I@X,Q&L&4IP@:PDN3Z]^GIMWHVI.V./W1%=963T%R9N7QV>D3K@^-#
M Q*.:)5HCI?Q,8(F1J/R*[?%V6EC'IV.%0W2*LD:"N5+\.HP*E*X>=6@G^<B
M8-7<TCU8W[*Y5'C^%)=\[\"B$75Z/S-+"0SS.=>I25GJU<CND/N=_OU,MT:P
M'[!.W.QN1,P?5:AYSI>/4'LJLO/T^Z.O'VJA)# UJSRYIW>_+X;,2?PM%]J5
M@._H[\[(9#F']5Z,3&:P7.PX/;D@W7!^\?02T(*JV-1]RY4?AO<!'U&KN"*N
M6P!7SH(E+[KN1LH%@LZ5L/,>WI^V*]X<VWMV/%[B& 2%\GL[L@OZ$?@W<_'S
ML\OD.?F4P1&@81W<Z.JDLK_ZO\G%&@X5J3HQBS4_(<O@BJSC[9R:>6NUO^*4
MHXC$BNO/ER@7N<I>IU 1D=>;9/P=6B9 CHX;N;*QK0WBV=<#NS-OZFZWA<G
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M:-,PT=@!J'4T"*"EZEBP"KQX_.FUM,)1J@@$$KNBC52.<.:)VCF8J-?3VO*
MLM:1&[HCZP][O@3WXIR&+UHDC51(*LC%?17B<? VT[;>Y$$L.-#LKKN/B&)9
M#NOEHZ87'5WC@\PV6G]8[IA?)>O6T)7Z2Q&_\5L5<1VNV"1TWJ_0>:Z%S0J4
MKYE9KH>M!M)ZX<=G:#^V%VF!LC#07N&JHI5MNHT8>N+F0C[!8=0MV)1TOEE
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M(QP>9]W<_O8C4S$J/K$H@I$STU;(@NPXVX4AR](BBGSQC7;5 04M6;XHU':
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M.4XN-%IXJ8P1ES[HBFURCL80"\Y^7&"+G'-G>IKB1G :"@7Y67;1A5D5/]#
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M\_WWLOR34OI2E=(Y"8/A/D00&B6NTJT8V]M;Y/LFCZ\A)+\7I7VV:T,^ XY
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MX/:&#O;NNN>YX#_?MLLS8-AXS*12/BL!-:&D;K^@7Y],**F)S.:C;\.A +1
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M[DX<C)_I:SHE@E1R*B0LI=[+9L99P)O'RXS\#I$3\G_)H$_/;,C&0\.CK:L
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MK#ZX'_4^0VRGJC@)4-60Y:#<X<K</)>&3CMIA[ 3&SR0KT(CRLQ)K>\H(-7
M$,9-QKI!B2NW4@>W)TZ5G@EF.NCR:Y0QBUY3:\!Z,63&>:\1V,(J5I)V+:OA
M^3@"[1OH:H-=T"I\?5_M&55>4I L"2)7:0@]X/1&</$W0\UT*?F8HPL6<O3Q
M<ZE<:=%L70@WGE;"=LP9"^Z]E<,>D6[V.RMB% Y3ZZA;:;22#(-F@-Z*:RV-
MUH,N!$Q$++]E+]::BQ79KV@&WPYG(-,$QS18:YXD3-".ML.K; NHO-0RN;JQ
MHG* L#VZCJJ^EO)@)<XA!?S=R5<)@]:/ZN41^TEV2YA]*$!?U9WD:K=( +=*
MIF,DYKR5=.\@+FC5XX+0FA<9]_GU9.8@YPPG(#'#=*SNISO("%/WG>79W).Y
M<?45OV(Q+0;K)MB[>]\-SE@B&R/84'3%_Y!-^LCOKR#'K0D#N:B]\:J7>0-P
M:,NY\ OTGL;A$$=![@?"\VSG#-%6+H"77# '_Z:F/WER)=E0P9.XS;4]IU72
M]#0"W7E^_OU#/CF]7ZIJ^E7C14@[P75SU/Z2XBB50HZ<*M)4UBK&]$?0-D2]
ML^/D\8Z]+LXF!:5KOV:ODXM>'<5?ZEGKP2&GW[G>#_C5.9@8X.0I3087:);9
MM>*IM:5])M#K5GI(;4EO\(;W2;1?2$X@O'^:XA$/911=]OI(T@"LAICG&T!<
MTR9V^(07W&7XX';6@<8*?:7K=<U%>%&[%64?\$Z[%W&<ORQ='P#).7 >SBI@
MA7V92R!)'FL)IV(-+-<0=,92EO]CEV_@!%3!+GM+>_-QOP"?@5_N[P\P9=/,
M%ZW-]^:E! R%::;7>2R\"VV#[@23=$U#V_CT5A-;U%7?H6PHF-#S*OFEK_($
M&^7LY.PT]6[WRWX+,O#DHNX;\&"WX);@[>%VK-*K<Q=,P'?X?#KPQ:I7HX*1
M3W!" <:V7@?LR7-Z#V*T >1AEL^S7J?^/__7@Z]'7@5_S%M8=J9LI M:\H9#
M,<P]8*GID6DT?:D-E6SES[ZWF5_2+=@0H5>\ *Q5<E" L+_.Y[UVZ!!'&MM)
MHBN\(LK?K=Z]0-H]T'3;-\*%CRS;+ XY222$\U_N;0<0;5X[,>^8:5^"'L/Q
M<%82-F_3S\.$J#?_('6LNU4,GD++-Z5C$8O!91LY7&>Q7EHX@PI)KW<)?N%F
MWK*,.M7X<\#!98@LF;A3ICX37,A&^IU%'N>1,VAES^RC*RZ5;]=U\VJDCZH;
MKP3)V:ZC3>=+,&990P92PX/V[V$XD9O>B!NZ"E46RW2&SOL53+[3;WDOG>WO
M)>,EHFN>5DOM,O@B-V)/)T%P+=W[Z0MN/"C2V6)Q8Y)%(D\X0VN)O2%@5RP,
M=1U*4]J%\[5 C Y/E#;-8,>U;O(0-2).:9S?R$ZD@<KNTUK1+C\D<YS(&<:B
MO+%M(;-93M9!)0P"_"R<\3A(R#::I4F\^8NXUVL.\I'5"B-[6\_A&2&FJ\2M
M8&'E A<.I87LC4/S_CAYVJG<*C'K-0SZ:A<VY@N<JH:3B$;3X"F-^/6'?7ZX
M0*DLP[IX+#DWW^B;9-:W8 >:[,8OUFY\SB<\#.1;?L/;DBYQ**V@ZBTW_RHJ
M!55:,#^OLKET^0NC_[436&=L=JC65VM&V<@#J^9TS&94J72H*2I@G!+ESE8K
M9#6[7.BK'3N6._UJ&2KUL;1VXE^<?04MFBSI7-)9@^0Q47@MQ$OP@1UGR3FY
MS*4:4@^T@Z(VMR:9R*W0NC@O"ZO,/=D21'T7J3&5V$TFRA7%@4^Y*:+S),WB
M3N58DTJ"ZBT<G8J)S[.3!Z>I3T;EK\&DY* Q78X $B18T+I*]+,I"0;L/,O4
M6#P[<7=F"^[!B>F>ON(BL"PBF&?[R/>)$3HH%*I7QXG@ I4?Q"^1@]O1M!F:
M:P-QJ8OPY?'DK[C2$>,\_4J%]QDW:V2RDJ^_LE3?DIN\!"]6Q"62?8+P 9OK
M\\!(D[>JF:H-'1^ L<BEH<?3T%^@1<HRV+%G[[!C@4A>C.]*R^J[W1GND'7=
M;@'0:*TL-<PYZ8["L-AL4I+OP#@<),F$LI6I$?!_XV=#H5L:6UIB,S.(<=(9
M7ZK.>%8W><T-=CQ*A?:1\/VPQECS.%#/%KL%[;PA5X+,&MYS&@:LP,$]'MML
M\\Z"D[I]70#:\^8Y,B 9AU<&=I)BB514L.6YKF%KAC.[4[&?,\#,")$^*[AD
MF2_XOAS:X\KC0(R%O*#CIW_&MB07)Y*-5K5H"P  JJM5D#ES',1*CM=YS,9D
MM2'Z0RWE#>Q+UV?,G!H1[VPV!A+ K. F+S:SOFF%+,4G?<VVCYJF'R?G8DK:
M0I2HKL:*_]+3#O"N_:@]Z@C2]WW=U)GREPYN$98EJ4!W,OD'VI/U9I<Z<Y\5
MGBN\<)$EFGT!?O&L&XN9 E*A\2,6<3QJ'Y+>&R-=^)*T:<YUT@_#4,83M'CH
MK-1?0'^\\#_W]'+BN/'//[],@[7@>3;Y&LJ8'G4)]P<+?R[TJ%B)G^E,22;]
M4HX$NYY2LY0#N$S:H& J^."-R?;0%R^Q:"ETHD=R?R[A-O24K*'1$CNY=HR4
M=(M<O+;/XQ:J=I-!JU&CIZ$Y,["9.6N8^_4J4RN2"W1M M[=<[T!QH_2O>(^
M@G#D*^'6=$>7U%"@F/8*LQC%FI;P2'HS%S@G*<S854G"E+RA>3X*/!C+.3P.
M O7.I125;*R7^YT&.=S&W>?0$)HQRZ[SG-94^14DBZUH.=#I.'D7-=<92'8G
M2!GH-#7L^%EIY0DC\188B;,)(S%A)#[Z-D1]3JD%O$([ NI09A;Q"6=3\Q9
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M%:7NFH?P:REX_E!W2^A1OEKO.E1'Z]DK:T=Y/0#T7A?L/3HE 5N.,<86U/4
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M+6H5-UA'7!76)#TW+T4+)EHO,X6QZ<-)"J;S\TR#8UKTH:X0_AF;%0\\VD#
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M],D%Q1N99 .XP=V:I,7W[B32.MQHHJ5,7(C.)FF^N*7RN>?=QVTH7_HM22]
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M8R@-G#@0DW#*<B06(.D&GL=JA* 9ST+ED&"3<T,U/5^MHJ%<)W:A( /&MKF
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M(@LO;?9C;';H_F!K,5$A#<#DH4Q-!@Q((WT"AJB*<VWXM="O]K6*\]\V(?)
M@_+$B_*K14J\23<Y@ALPMU9,#*7,6R:\PVR9U]-D]TYOX ::S\MBQ6(+A\4'
M,F:W+SN,1,XCR#)+J,FWY *[U.6+Y>0M ]F@+-(RD$,V KT<DC>X4SW"1<'W
MWKK2!88Q(D7J<>2LQ;!8B];D2&#2G 6M2K+"&UCT4!X%1YIR.X6"(@%[O;T?
M56-BKM(U'>_KIA+M""7Z.J3, 2[IJUC$X]9W)W/C%H?H0Q2JO86P81KW][!X
M\!,;U4E,QWMH=<'"%Z&/?B5]O#2=W$H:;Z)UH\R<*!BI=&2F5D21308R#!GR
MM>##=( !"7T6D&DY_'[F*&OP)-O".+($RM&(8DLR"<DD))/PA[]ZR9DM^2T
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MYW_XJYAF;-ZG#,L4H_Q,R MF3[5Z!0/TRC6>"R[@V5/)&T '\9!ECR"WX\]
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MUT/?-K._E<T6>T]4Y_6+L1*LUD6V3<VY #(WF?;'!,JPJ^QV4683>PVA:M,
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M:WI]RK)#EH19VC32G^^FQEQ*Z-FT +Z-BHS!QXWG)F @6WSSXE5BQDC;]S_
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MRBZ D;I1NBWS:G>9]V@G5B8M%2:[Q+A\UIVQA98*I9?5@0AM0>&,TI(RR8E
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M;]8P=;#J$F;>Y/U4-%MHH_\<6+K3ZR \4?/Q<-HI_\,\;2\/HX55": &C97
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M:AM2%:'+M",E: BWG;"M1-HN[F(7D#*@I4"+?>#_D $&F9X02&3X4P;,_@J
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M=,OVC_H:PD*M9<X^\*[VO"Y8,;\4*^;+!2MF&9%[Z%/8&RJE"Z@BT/[0HGO
M6W92Y3 >&6 ;LVZOW;9!=XH !>1TF[ZO9#P@8NM5-&U1E&,.<N$FQV@_L]$"
MZY?ODK#T)OH:'\02,QV),.P74;I9;/0LR->'$7XN>2*=A= YG'S;.J5R9X.#
M8$<A!T[8GA4,(3TL2&I!YH !XCI@:)K%1)+.&378^$,Q@(U/5<2TZMU.9E1J
MLT& @';+5.^BLLY>9?W.DZ=P!&."@7F$I2PF2U2V O-(N7!;8^",$8OJ+905
MIM= #Z XE,;^4.X/P-%L$Z+T (!4-S4#497L["D%O*=I1PFYX)JQP D$9G!E
M!NB \ 3,WN)7!<E=9H'/7/B7@/=M9H%S)L441@V%_+!IX$V;#T60UDB"U;'X
ME33%Y>K;Y-)"[&!8[89?)..Q3 "J9>S K]JZ]>M*D47^6QPJ'FGM5Y'.&>I\
MZ'=-2]M81!I'7*>;LD&'X^J#\D,AN\AO3;&PQK%Y7/SMZ[\^CX#+(Y6DUQ_K
M,2$6Y"N*FC(BK-:12V0CU'T[N$R0]UPO!98<%*2,.E,S: M[.XQ=#P<LOMD'
M):U[A$1L^I'_2G_>N(*9^P3V!9<M\AYQ>GF3KYE0E>[&#"/RXGD%UX,R2\C#
M1AAZLSMT$N0]OVZ;7*[Y07GSH7R;=]ZF9?&]N_8@V:PP3AMO#;UD/!(#V03<
MX(SGL+NX'R*AR.&1YJV:#GV Z#E)JPQ=C[?;IG3 /S$5[<W)G5#@8\[_2!J'
M]S6+!"E;O2[7KZ$XX-N"7K>@&]L*9<OQ"G"7 ^#_!3)1^#YF;VNM'=KR(3FC
MG(PGR0X_IJ2*R+'G&7*L9*C[4;N(PI-)OXAN'PMNV77\FS7M2+-G D7D$&1Y
M$=/,B-PIWN'+U2N<WDB9<(;)I!P00W(6O',P""LGO0>2V&)@**02FIXB *U*
M^B,0B9TTQH#D)81*67I<.-()2.#"-3.=I($6 V0!$QK@%0X5WB9+CZ:J[X>I
MS7D\GN^OL 'Y 4_8AK&$HAVV82X_AF_S<]V)!T0B$("DE3%+^(>%?7@R,$>2
MT0.2"M&2Y$%6I/F[4D,_W=6CL@GU$Z7O%?XI3JV J(<=(14E;&%T=:6_P577
M!H G4L$P3*J/CW$P)[!/C)%5&^L2"X?R?HI2E\;;0L&?T #%L:+D3#WB +[5
MK<"XM-HB.J[W H60S(%X4V>D/]Q.I9 V7>_V>SD"=)$$:B&&2^V#;#9M+)IC
M$%"EV(XTBK>]$LPKQP8N$RW9X!;H%#DQ!"?-="9P&Q2;UYP%%D+K@E$7<@.E
M\/Q&K.IH,_J!*<@\:(_E#"RY$,$>,/0$9@2$3LF0&A!Z,PR$_IH>BGP99IV"
M(;0[CD]V#)>PIL-00>Q(=&NU67E!_RX[IIF#PG'T!SES1;Y76G5!:R>UMFU:
M43@9*Y*2-E)^\MEK>8^^S;17AKNPU1>;@15XBAO+2BYPE'_+/.RMV"KYH205
MG_M7'=FM28P2.#T$!>4:#/*C-'K(F\"B;)EURZ=98L*R\$N&SNU8D8[01&8B
MJG!>LY1DQO8T: _Z+:L5$W&E*K&%L.D9S/UHQA3+F7&HQWJ-<V3Y& QO"O'_
MEJ#ZCQ1-?PGS'GPS'D&.YVH'9TQ<W?PG;ZKP[W: ??68/@%E,@*0;+KRU\5$
M7!(J9RYI2T+E;<@"_NK6;G]-CMC3CYY\+GC0WY-H70UJ]/]O<]VMGL,[(Z'#
M7_C?M^1+P 'B: 2@5,KK&#Z1[QN85?.Y24S%8#,[6>([J7RS8VK. TGW.$#B
M7$?T84%[/2"H%?L-DMN\7>\T' CPLO(I17Z'WCC2YSIR7^@-,S0K5UK#3GS\
M)*/=>/I$\Q0>G-XCRL7+7/$_U,FFL[62DP-/BKDR-ZN//_VC^$:;"OD#_>W3
M)W^T3$<(^.P.N&[A;[LQ5@+R6.QA<,6//_HC][P6Z-@"6FS>UJP//Y#V">61
M0CG.(/?#;N*B]HF.SECEW1?7?9AIUF.RL'11I%S["YP;\HAZ<VI  :#E+_K(
M_WSWCX[!>;^0Q;)/3V<7KX#?LD3$[$@R 7'%+K3=<WI="AS;]L@YB-$:Y%8?
MT+K+_9Y<6TX9!6*!^(%K$A,)IBR-0ALHQ+BC;Q0.D:'&O+;W<(3#M.0'-TAF
M-05%HCJ\0CZHYD48]-<G%J)K<P@,$':Z^P?AK?!9LWR;_QZ.@WPX>8H)LJ$_
MZ(PIUX94001]:%]&\"Z/V"(>H!@$\$Z2!C"?%?Q6-9)P8)ZDR*E5"+H\X!"3
M*)!(RM4,A_C#R]57/A;^OWD]8&!.9.JI#R0YC1*%#@"5DCR!EF^C7J%7"L+W
MY/-/WB#EM&ZD6"]7K(S\E80D0_9F%,62GFH#.PE>[ ;+%H)IT@L4D8JZV#"N
MXWB#(6F6101!M32:]RCF8.7X'7O^!]F.ZKC02RP6_;>UZ-^R>)"P?:3<$$U+
MP?!-V0YDR!'MOR0EZS:2^_K*V"9>^70ZG?.KYR^_>I7!D)^V]/P9_H@8Y<*K
M%J:KZ>(2A'H%EZM_,LQF'W\]8\7M::[%S6>S<"\S38J?T^-N WZ^5-L\L4X_
MV(P2'2;T0CD9KOB@S#$!<4]O"97O"E/#YC$P!0WR*#!#&6GG_I>M_.E'<?8P
M7N(8VC[9;;.02N(:V^AZ9*-IP;S"B?E=S9E?]8YF'V!^>S,M71LT(-/@<J.-
M9,#%97F_<AI+FZ/?T,\_6MH<EWS20Y]"'S )88ERU$%%BC/[Z2B*>@NM2!H?
MT"FPF%#GEZO_:7HXA%S+#E5S4\>^;A=2Y'P+NGRFB>UK\K<WB F*A@U#1-MF
MJAOFR%O8Q9M<O,G?<L(DS@^ITR+^R NR[%Q_-3<J[:$8>8S\"0L9K\@Q;"H>
M)"Q6S^.BLB::V+7PI#92?]&&&@K#A#\ML/AXOK26W5K)(DBS@[A (0]RT%Z6
M6(*D/\&^3#O]6CH ]79Y^FDTY+8:Z+-""4D3J4^1NMB6*&.^R(_KG2-W\T4
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M:";Q0-^T?HZBS6]3K*M0R!\YJHGM4B]=*&JX6!["C#B!A+C 8&X]1!8PNBA
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MZ9&VSM^;82/^>A6*ES]8]P46[I?Z(F([^>'K*YYU#V=;ZB-T#EH>-_,-'+I
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MO2QFIR(92"@;(FW>YL"7<8IHT99@18^X+JQFHM(=7KFGXP-!,(2,1S5SU;E
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MQ*Z:2\\2E(J1#YN6M28EJ\O8L74G86C:P6RK]$Z=_Q/SSU%,QT=X#@DI6=P
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MM/<A"V;/K3KF[3]9PX_=&B:N-5@S8\J),0\4SJ)I:OCTS8+V6$>3!=*OU*J
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M/L<?3(^61$AR_P%1[](G[/:/Y/3@&*0;X:C055]1W//?KJV0-@TQE_9(1 [
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MA;L#1BH^S?EBI_=%\EJ>"2W2><O\REL?X==-?0^G3">]<(H:Y#G&H65]5=S
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MDVORJTUAQR=C*::PXT;*+%%#VPAU8D*:>-&4Q9ZA"%[X1=E4H;=RS[_8;V/
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MYB4E=^&<\V,^)"S8U'MV1])>(5Z!IX^S",>'MV2A3>P]G=.I=\"%\.1<S/@
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M=!^<LXC5%*GH"!>Y5>U7J3!DLA0C",S KPMU\>@B]/PF89,PBT=]8>!G\T$
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M,_G=OR(P9',9SO9X)/ZU#$8UWL<E[")QBL>_:!I@L)#2I$5A:2,]WU*,7^[
M *-,.H=N'J<XR?)6_#.)[B.NM' 6<I9K)BU$9M:%W4O\FD,TZ[#UO%+HE-ML
M+0.@\W:W[/@42=SZ9-R!P/X0(#L4E*^$Z6U7]/CGT!O@37;9M%61^H=2M)XB
M_&E?3GCNJV?UZ_L3GGMR\V]_'3Y#3\HL]"IJ)"X-?VEA6Y4P8P?_0';GJD3,
MZ#$2F)P\6Q&H&#VI -?KTPQ ;RF5E/!^4(^6OI_+*&'E:7CW 181TZ_0+S:7
M=<B$T0/,C%Y*$.FL6L14ZSYU$Y'C^I^Q2^K:MM02D1_0/M-_&(DHO<I7K=-4
MLA5 M"O- 04QW;9MI.X&CWN\6^DU8*1^0'QCI88/$9O_]/ ,*J.!HDV]('/3
MCO25IFO 8#!>>_$:NF.1H^*Y.:76 'U9I+U\,YE@")"\[!K+%=7G=RL&F'(Y
M1S$='Z&11VM]?=X(AT:]K+@:S0C7-RV;0BWB"R5UE]<)<C6%@A1.@5=D,K[K
MV[PK U8ESFB?9"\%G?*R[_"=@GF\8RJ$]+IH:1_B<RQ!:]=0ZW* $Q5]2 (<
M*KL :A/,@!31Q\S!'_,ZWVNW\D<,!7BO\S!E##YX$/P3"$15R!X-)7'^3=.*
MG59XT%42RBG&W6\I@EB\D7.BG1>"5':G4..136N]1AXAF-:YO#: H8*2GG'Q
M3+0IR!53&F)R##["[?Z!'0.3$[P<!1P,685C&99KBHZ'@FRX?A"HU?@CO5%C
MU#5!^OSZ(N=:]>@[KO%LP4+'(B0P3$.C@3LS"/5G1==JR2?[E1RE;>!-EG X
MC 962!J2X_KVV$T"HE'%5Y8I)?/PTCP'#,]?E9N$B2D_)^=I[9T?EIL?:04:
M$X@U >LY@Z6W$L#3TS5)?R7 R/X6$NB6RZA6,PND6?2 =<>,%>$'7FP%R8-P
M'1_H[3]&"#SSXJ(4RH](O"4F2HZ56P1;$(1=A*0)C9&T6P%!C>FNU?IK.#XF
MZV+!<32R4 (4IS3MHDBYZ71CJ(:G'397]J_&Q<*]HXS;%KI-N0U$6?SD&AZS
M<C+[Y3I/A3B]+#_#U]K?28(W-^+PL>49.N,/=MNFAW;4JLLX[O1J2E[+,C8U
MA')2V,9,J?<$\^$$65XOFG8#4U#(LAPP)7K9'Q1SN;77#G2P2BD2WLNN![+Q
M>,=\7S*C0& "C(N6RGO&*16@A8W.C,O'TC"0R/(,')O89S']B2[JD39-QE3*
MR+;%D'DS6D-LW"Z')96(.3X,7& SNRN:@!/><@GU?#LSYUPL8GMFJ:T1$2-O
MR-*](N5X)3NDOS0P77C"2[5C5C8?TU22IL=MT'D\9!BO%?%,^9&CF(Z/T T:
MZ+$>/!!H>6[;<B%G@B4J=(__KG.,SW+F'^A6&7DQ>=+?@,2,XB!'8JN\8@7X
M<SU,PZ@ERUM+CZ!V^AEQH' =R!XTAF [>""C!M!'-W0Q!G=N1F!Y/F0;^;ZV
M.VKZ/^,*%Q_3R^'(QTXR7M,,6V$G*?$,V^1AP#L8[ N3&0;(3/HRS <%H/7L
MM]CQZ]OGH6W6AJJ!;;Y;V>HI)+WUR;@#^:>?WZ5*>;7J8VPV8ON+#7G)I3/!
M1O?=(%UTV"'VTFQ0J/8W;R._[@.IG4R)IR/?Y9/'=:,.%VP<WJ+E15E0C"LM
ME> 7YK(NDY S L"BW5P+[=F\;.((D3P [BRC)^FW[*?A&,YK=)F>F7-T.9XT
M2:*4*\O1R)]TQBNEAF<LGY$8H\C)B(+M-'^ 7]*3K[7&[D,UR1.X./27C!/X
MQT4P."A^=9 D#!*S04!6,A374_C5GIK?:%'3X#YI:KF9A4W&$(0=KVEQ38S,
MJ+T./.XU+^>]M[!8P/1%L0 8$8*VP$GVCT"*J%-=.^[ 05*N45"-9]W>1O*?
M1DHF/>'G?8XV;J<M\PM9#Q$J9YM(AX++9,DO$ )LR3>]3*1]N4PY/C8YNJR\
M^J27W=3U@HP6(.W"/'(=M6?WEI8NM$#B'09$OJ<KA]3(U=<]R;Y3+D@5GXZ;
MM2,"RF%STI ?T@/%/4>D/ONGQA0Y'=?39$S8W=^-W7TP87?OV*X\VE#YT(2^
M++LW7?9205MTE/T4N[(,VW@J5)^OMLWBS7'%H-,1-FV66TYNO!X2XW:\3<QI
MOT YD<O>Q@/GZ>9B$EW_D\(M*HK9IE3/)[/QIE3/C<#'PNLP3D4=;SR52+?]
M%W%)I&$\<W5FRZI?&'.E\.%UFZ:6;O2+O.7\4;:4],3,4XL+%)%CR;G;-4IV
M@41&4R6R>%HJXY(/_YN&U*]-(-!$9@1A\?2G?S__]MZ#K^D#6ASK<@$B2],A
M7V&2'3><P)#(HVGA$(2?.@&8(>X/GY?-X8S6@* 35(.:@N'42M\I) (@:,F<
M+)ZPLY ]DZ_)WXHG7,;R!2I7=4[Z/.RG9W7-D?A+)QTN-1,9KK,']^_]EU5(
M[;::IOKKQQHH%^6%#5<W)&^\OSXZ>7SZU5^>[%E !D=4^>ZOR\J]C;?[%QCC
MKWW'/?)V.WR+;#"MF"?8U/?HV=?=7QEJPB?&J D( Z<Q//SR+W?.)B1SZB>T
MK'E&[F%>K[SOT(Q>,>?Q5'[Y^/3!EU]]\>CKTX=?/OKR]/%?8/!I,YR>>I,?
MK85T6!_]G/_I;TH^NG:J;C#+7$U&K[(Z>HP*XIQFE=>UY&RMBZN%FP.+U&W[
M0OE?_=^VC _TOS_0&2A$H?ND4D_"MJ27H/\[;<]I>WXJVU,IBUFJESLJ(:@9
M2X>,D^4 #SUOF[R8-M#1O,QI ]W6^6:E,CI?8C"6GD5"[QVUBT][YFC>W[1G
M;F//) >,5.<%^;U@-858V"#I[IU9[W]$F^]IS#S26XK"TQX[FO<][;';.I<J
MWF=0.@&?"5IG?>7F0+3$P*8HXD(JS/Z1](RUS7F;KZ>-=CPO?=IHM[71!DF,
MJ)'!B'TBKLO]33?MH:-YG],>NHT]I-VFX.W=EHMR@T,J4F9R-(UK23U@6RW+
M.J]9IMZVWBSME:9!5!9Z,4LXYQ^+P'K>HKX >.V(+.JT'8]F:4S;\7A\1[B"
M^8:+^JH:C+T6N92!J<':S*>S[HA?]+2Y;F-S"=_QOAX@-+LK%FKD?^!OP-&;
MB$370REDJ>3VGJ=^;XM-.^QHWO:TPVYCA\4: \SQWY>I:J1)TBK\;M54S#(1
M&CNF#70T+W/:0+>Q@1C&%HGOTH&U%V\)+YZ"*CQ0+-NX=N'*"W$'&3RG%$QH
MO)KVU=&\XVE?W<:^&DA4=]NV%UH[VD,KQY0JBQR\U3M$5B+;FQQ=( ;)SP6B
M&NF+E>MYWW;23GC(0YRVW]$LA6G[W<;V$]ZO*G/TIV9=+F;9IF&OS^I<"H9F
M/L;2"LY^YS%&'.3Q2^5\:X7W,=K3OC^[C7"'QB-]SUBO+QG C99?WLI5M0<H
M![C:G[<RJ&O@L/B_IPU^)(MMVN"WL<$E*^F[#;Y^DMF6AU_J=>9[I<6(6; .
M[9VI*6EJ2OI@C']I%TYIU)15Z #\9]X5^7^R[ZMF3LOXE4@(_RC?![W$X:X=
MHQ2UIB$0BG VORT9C%_0?V];<AFU/XJO)NU&Z8D$TA+\MEG28U!41__3UY;V
M5_@6ZT*V*'!OO1RBLGQRQL6U(%JI%RYPI?J!QL<LTP8V=:U-0L:6[&4D]IJ>
MC.6=>Y\D-)5&) @_,+.J3C&>L5/9Z7H7]S9]P^>GO0-0FM0%V=MVYWN-( KC
M.#D$=:!<.$ZWU^@P&TJ'@KY'BYUCL^,5EC<Y<TE'Q<E%E3./JLQ+1$+"#QZ]
M&&9X*;<]SX+QO80%L6RJJKG46Y9-@2%%K6'J8PP?*M=+[ )'81C82?9_FM[+
MYM"<5[1M$'^TCF*;FINX=I+S]B4CNH^:8,_T(HUR-#D5BDZ#7WR,T_*:^]FV
MNPV^&T8&BNLPG-D[6634RZ-=QBR.>H(%]IAP\WP+]D[MK?.*JK9#A#>2;45R
M\,VBA1CE=H(#ZMWAB9/FSA[A4T/_;R>*5'TR#O[J0IFM,I#+T;\[8UM-VHZ[
M)C*004C$-_\V^\W_^.'4Z?_)[,C)J;X)J:/J0K)OYO%CGEP0VXOV&A?9M:?4
MY6@R$']P(/LQ"^STTJ3^EJ:GBQ@"$U)[W?W1;9F5(Q< 3&LL=_ X<Z;9]G;!
M[DS_3\ZP QN=C.XD.PO>$TLHA"*EV@KN>7#\PQ&KP5E?MR@'K+'OV7Q,!_B1
MF8MW3L;$H^9G]>O3B4=M\B2/S47Z"1(Q9<VG2)7:? F4/5THZ]SDL9"E9#?K
M+=<%$UXI:&"I<XD#AM4MW[IVF_Q::6A0CV#!I2W?,V*]B4$R4E/,JX]8"W)R
MZ([=0/-6H&7*LN#(.M(Z=4RF5)3DV7A2ZP.;9>YJQTK-$#$9V2J2I1S+U9'?
MM5@TT!6J=D8WE%P;6=!8A(5V!Q<$>\ZG0H]-14; 910XB!-5CE2!-LHE-OUV
MH711G 6SG1B1;X]M1&9(HMG*UQLFCAL9M')<V?Z_SNV1999>B668]5F6<Q>%
M=NW*_#7M>5Z7_YUK:U/1+'K?U6M#Q .11[MV[3GK/'5Y)0_9=8DNU3K_E7E=
M3)E+)-\DLZ?9-'X4D]Y64F\:!)N]ONX:LJYPA/,%39A../+2'?AA6EY)/"'+
MIMT/R1$L[#23N72N4MDPR43.A75;R[N<6JQ34ZN3/7G8=]9^3X[-;W1LSLA<
MJUJ2)<QG@5C=>QEK#F=9YZH^!XC)%2C<PF(RV(&1O"9]*0)[Q_O6CG0)3R[(
MM2?UFHM6>G_A4Z!\$E:GT2Q^]U8 0N1;;*7D^RIOYWGMNGL_O:W<+OS]VZ8H
M[CVC,^]-]C.?_Z^VK7/;["4G>M;8!T]9$X.U(UZ(E@@?</[G5=F-#N)U*"*#
MD]F*Q__XQU,((\AGLTB$(.BOQH6VMJ^<Z3B",@KJC7?JO)N4'(]B.CY"<S'8
MT^0@7CK:PKEM&Z[ITK[4%'71;-A/G>_$'GSW%-M*-RF'%.S+&\F&:?#05D[O
M,N/OH70>A3?I[J]3$S: 6H3 @IS:'#*07HYDG:.>98 -477E:"P2BN7O)65B
MSB)HFV@ 109__IP3#'+)#<10%BZ6?]WT;=?S,ZA=_<WVD =\>O_!_9F?7@8#
MV*Q'1 RC)DVK_1UL?1Z)R]!B*(0H3TKN7SVQ_^]R")=O<H\$\/BSBV;/*)^(
M';8XCJ>U[-8R6*UC1+A45U^4;5/[%Q-_BR&IH4]7IE?Q%12I7"1@ ,_RU\K\
M 7CA<M%HCA 'M;M,9@,UCO#.&UHFY\;&)+B"^$K1Y/*2JTJ\[8!B4 5*05/4
M-?"T!D\PO)!+BRS\!6Z*O$2'(]=:QHH])ZP[8/?SJ"&C8PY'=#CEDIT2'7FF
MB1IM&OLN^*FZDAU3?),LA6 S// B069 $$K'3+$N3Q\'F$E9JJ.Y[)8B6AW-
M+:^WH?_!2RP79H,=BT:7U_. IT/M**;C(SS4?A:TH.[7<6/YCHV3&A=17@<L
M#PM>V$:'Q\B(V0"UP!L%B8G%A$^*F)%WQ#W(Q:UMA_,OJ]U)]MPK>/6UC1$W
MV'D;T;F],S/=9%"?$U\^V><C&EYDOCK&+E8LIP:X%A\XR[99FX2@&37EN>/C
M>*L ,)%[XZR?8T+C=PBJS\8 6E>IK',88)-?Z-3" B5OI*8#EBR]D/*YP0?T
M39K_F<?MZ;PA[]G0OXK>OS3N&I18@B\Q+)PG=/(S\9:DS%Y@0C1CB;=;E)S^
M96@<(S?Y+_)RD<63.VO_O*E-,^2N$V%%LKF\DF*GQV<S_1&-(T%SS/Z/M 3G
M!O[S5T$YQ:L9T@ 64G;/%XPMUQDH<'@O=E*7-\UM[=J"DN&"DX;)KM#>$IF[
M\$0 ".>"B[1&2KN4OE%5=#9(+5*CG:XHZ!!BW_"<II,99H\6-3MCNG9PW__T
M9,>6I8M7-.]D]BG\0FSRMABDA\/?.;5:TFX1 AXH\PW3^5/H.)VRTRF+4Y8/
M*&S6P^G0 RG0V.L-Q^6& K=JJSSY:H<3"7CU+Q5S3)NX;NI[T<G[61PD;OJM
ME7?TUY^+S*E<,A211D7ECR\Y&RV"AX]G#Q_,'IX>8]H\NSNEB6.>YN_@X:HW
MBYX6R-PV<>#-_3A= U^+MU>2QQ 25&P(3<<D,;!M2?)NFLY<)<38+*3WKC/P
M1A-W#,?@5&Z9#L'?*-8E(M1Y;0$);\-ELV Q+0Z@S+OW+9Y1*N>-V_$!^<89
MY"&B$0_I1]7I*L6OIQ'1QD?:E#WPB,3N.AL?E1.3N?KNU?<S+V^E+6,GV5DX
M86<"V$V?C_OOUIN5A)CUP7%FTIIC34!UOYZ[5AS^6"P<B>+"BE%ZQ:@/L&DY
MV<A^!=W:DK<,P$ P>N#6P[ZTM'61'MLWR,UWFL7S-_61U.&K6PY8_!^,Q4ED
M*>GCF;]FVB!U3M.W9;'LV'2'KMY%WGM+2WN U\T;'S66-3T!^O@D.:'I-^1X
MV2POVA+Q-[V_:LLO6UK^9I$8>$@E'/SU+%JF>)Y&Q,HD]P>9(Z!57"=Y")X9
M4XH_-%T"1S'*#^06^0Q1W70C])ZW>+&(Y<QQX[$+WN7@FV@H;NU;<1@Y+BTH
MB.L,V[[FM+LTJ]HG'?V%WKGE5SG[POULKEZ@]>UG'R2KMQI2.*&G#^LR@)S\
M_N/ME+SY>5KB$.83\STM N[;0YD/+3"P0ST+4^$5H&RAWJEP=(*#WP ._G""
M@T^HJ=M>A=<YA-F!&!*LV6%()PL2<QV3VB!-+7S:5BM,#R2A$0!ZE?\LI]#
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MVP4-DJ7C;_S:%^>X.L0S=>EW;KM5L6VI50Z6)!:#CH\&PN%9SX C6=^U8L:
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M3]]HYY1=\)P^7N?E& *=B33L**;C(W17WM$?)"T2OI.'3TYK[KAT^1LV;W)
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MKI8NQ76,:%TF/VN*<SXX=CC0W(LG4)"SQ/E]VJT[[B?0O@DDT#MH/KF\7:S
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MUJGT]\F6_AY,I;_)F;OU=?BN7M@AXH)-Y"R"RPBJHG(&E(@.*7\@&YI#SS!
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MO%H4 %M%%5H$AV:[9FJ%^7<,_*@V:,I'$QOY;]45KCY4]^;4S8>!&H$G+9
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MU7AXFIJ-V;M^-;\;9/O(!?Y,R6QJ5+V: J6Z:65YXG\KBUBT?DM1U"**0!<
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MLI]!2<*@TZ?AO""&1]?F7$8Q:N$)&>[%9$UOGBCXNI2$F8MS3/<'^8GGD8B
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MYAP;)AY[$,G$<RCB6=,P[:V>/SOSTIAF[,$?T\QA4Z:Q[E.W&Z$PI0T=1YA
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M9F)ZEL1D&<A9BMB A4X G*5(B]KN=YF:[/:IWK?=,<NA=K+%-E%.)P#.<N@
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MU9N\;_U.W8JK/7.\(D^T-HL;A"MTVG]#CQ]%WB8I<EC^NP"+ASY%0X%^T"_
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M;0DKXMI'BVL?+6G1P=7(CS$6L.\>3T^8))]E?;]E(&=99 ,66!:Q+#K0O#[
MT<"*%LB6D60G>"#+(COPT*:+S[*(9=%A9-%XY$XG8R9)ED6'!SG+(ANPT F
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M 8\"P]66/NZ'#B6CPZES]O7WTC,>%*7B22JAP5[+/>,FR+L<*J]$DP^_[I@
M-1,P'BL%W-\X49*A"%'0(G5UC2'M>F3AK[TO3@!GQ(V< WSAX_CC+Y=AECGO
MP;KP:8._%&G"[/91>=-;(H PJW#S3PKE_-)H,@P(+?"7/K.T/3>^0,HFJB<R
MQ6 36)$K] K^&U4RZ?ND<%NSH0<_"9, 78DB0SLS.-T+X1S$YW_U4NS;YZ\
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MZ$"R:.1.IF,F299%AP<YRR(;L,"RB&718631V#T>SY@B610='N0LBFS 0B<
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MI/Q9P''^+0+GW MC)XD=./8WD7OS2,";?I&&>2@R.U(R+*/V]B@Q7<Z=Z 3
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M>HA>!SR@L@=>THKCM9WA#"9;(%V6N1IK[UQ('G+D+>"XIUYTZ6VR-R^<'Q\
M_ ZJ/8>\B4^54C)/HN#!$)7OXR9/PQSV[U\S+CD37NHO'2\.G'?B0D3)>@6_
M<GZ1[1K*W!/SW&TXF'.;>W/2ZR/[[<;->>R>'DOA+)(H2BY!@#IJH':Q@L/#
MMS(G*5(G-2]38%PFU?LC@P52)X>%UO"I),B<-;X"7PA.]W;/'AD,M[I7=C+G
MJS=YW\Q9W8JKW72\(D^T5H0;A"MTVG]#CQ]%WB8I<EC^NP#-F3Y%$U]^T"_
M-8B\=29.,['V4B\7=26*UGZQG0!Y$6;A/(S"?'.JWV](@Y2?&T][P\'@!X1G
MDR&@]M0;#&8W/M._X8F3WFQP_.!5]K,7O)9C6S9STCL^/NE7_]V,CIOWM8<G
M!KW9\>B.RSQ:\ZM]^A(T SF4^=FLV;?'K<:MJ)X*#P!U_,U_O9B^>%J<W*,J
MTTZJLM9.V74C_@EJI/,+0 UM$E^LYB)U1@/7#E+MS+6PB<AMPB 'GY@[,W?>
M?2/>+KWX7+2"E-MS"RRA:;9=VHY!METLPD,I'8<L'9^)=!SVAT]55_]<[H!-
M%&T3!ME085;,K/A:5GS?9&:^ \R*F14S*[:4#%O'BN];8,07@/DP\V'FPY:2
M8>OX<&,.O754W)X+8 DY<PO CF;=?DJ3H/!SRJCUHS!& -=2:YOR9N]Q3H3Y
MT;@W/3XQ_P.RO <$IKW9W0&P3K(P#Y/X-!61EX<7XIHJ94NJ6"V[W9:P(BZA
ML[B$SI(^#US3^AAS# !'M2HS)LGG4R5N&<A9%MF !99%+(L.(XLF [<_XPX+
M+(LL #G+(ANPP+*(9=&ANMJ-W..)%4UEF2;;UZO.,IRQ-+,!"YT . NC PBC
MX?W'KG69H"P718\]=VU?X74.NNXEZ"K2+(EC$1U1,%($=B1-6(;8]F@B79Y7
MV0F LR9R@(Z4,W<\FS)%/4N*L@SD+$ILP$(G ,ZBY.E%R8E[,AXQ03U+@K(,
MY"Q);,!")P#.DN3I)<G,G8Q8DCQ/@K(,Y"Q);,!")P#.DN0 DF32.V9Z:EF<
M[;'#;%S;:!.)?DJ3A<BR,(F]2!8X)G%61#G.%X$W+T*_&C_#.4"M5$VZG++0
M"8"S:O+T?&_LCB:< _0\"<HRD+,DL0$+G0 X2Y)#2)+!\9@)ZED2E&4@9TEB
M Q8Z 7"6) ?(!IQR@=SS)"?+0,YRQ 8L= +@+$<.8)'T[MMQO\OD]+RC;ES<
M9A.%?A:9\%)_21$WLY,H1=]6.)+]OE$W3@BR0U!V.8&A$P!GS>3I^=[4/1YS
M1M#S)"C+0,Z2Q 8L= +@+$F>7I(,W>$Q2Y+G25"6@9PEB0U8Z 3 69(<(G]C
M,GVJ":5,4'81E&4@9TEB Q8Z 7"6) ?(WS@YZ7'A-$?>N-[-7AI][_EA%.8;
M1W65I A<DB]%ZGA1E/@/Z#3).4%VB,HN)S%T N"LFSP]WSMV^R?W]9<R0;6;
MH"P#.4L2&[#0"8"S)#E$Y.V$!_D\4X*R#.0L26S 0B< SI+D  -*W<&8>W \
M3X*R#.0L26S 0B< SI+D$'-41KT3)BB.O''-F[4T^ILW3U(O3]*-DQ7K=13"
M$AA\$W\6(16_V9$981FBVZ.8=#F#H1, 9\7DZ9G>R!T/[VOB,D&UFZ L SE+
M$ANPT F LR0Y1-BM/QHR03U+@K(,Y"Q);,!")P#.DN0 SE)W='Q?9RD35+L)
MRC*0LR2Q 0N= #A+D@.T<SKNW;?S?9?IZ7E'W;C>S282_4BE;1KE#SP, O9H
MW)L>GYC_36"W=S_FM#>[^RG721;F80(<%*OWP@NQ\]ROAJ_MR/>P[ JW1^/:
M:U[&')X6:04IN+-.ED1AX-1ON&78Z@1B;B"0VZ*&-;A'\07T^_?U*C.!,H%N
MJ?(  _MPQ"*/*:I5%,4B[Y%%WKT[AS*!,H&RR&.1QQ3%(J]%(N_5\93)LZ/N
M?$O<G"PQ;67,;8J<=0+@'(D^@(2;<?UG^T37TQ: FOA0*^TO.JV0@TC0B[<3
M_X>FY*])[D5.NFM HOB^%G'&TQ%;KL3L-?VGKGL.>T-4/H.DF$>"+8O[(_BE
M'31V>^RR9O4(MV!V[(X'5I2PMI;,.\&!'TJE[ %@X<G"TSJR9.'YJ,)SY$ZF
M5J3(MY;,.\&!67BV%G7=I"H6GBP\;1>>8_=X?-]&\TSE+#M9=AX:=6T*E74"
MX!QZ/D 1=.^^R55=)B>[%<QK \_PIP?2@_ZZ"Z0_O%E[01#&YQHH@T<"\W9>
MU:Q,K-*/$QV=3N$:3F<_/%#63!^5\R% @_!B)TB#,%M'WN9T$8GO)N2&M*M_
M%5D>+C;Z _34499[:?Z&SGL$)UMEIW,O$U$8BT9H5EL=]4:CT8W@:AT[JL&T
M!&@8(T2."*[7?G?[1EX#\RN@?/'3JT&9C&B@N;Z)UD/XQ4\?8C\J GA/YR(X
MBR1U\F4(_'L-H-DXL%2Q\/R\2(%#R FS19XE1>J+P,&%4O@E?N4B]$7F.B&M
MB,_">7P $[)W@!#\3#7)-M[WLLS;9+VRIO]'@+7ZW_L26)\)K!T$-GQ>! 9T
M<B&B(SVJ6=.;JP8VK\+,%U'DQ2(I,B=9+(":*J)$LKGTTM2KLH9V$DVCF#_I
M]5&B7B?3!T-+=*=#H^SS3?E:R.- J\T C?.-\W+<.P;T15&8Q(#-U'5 ??D!
MGG&&_>$ 6.0*&"D\FB?X@W[/^;H4Y0J U0P890B0A5T[7IZGX;P@G0U?T(_A
M)YU7X6MG+=(LB>.&BP1WQGDYZTWT5LJAX+!,;GX15L)_Q\5J#O<.WA*K=91L
M!-[1A,89)&D.3#K=G;@&'#^\"'/-T)> %8'YC8G_[6A.<,%3P[8\;'"BM^C"
M"> (BUM,+:^?:M(;&*?*BBA'\;)(DU4=0"GM#5:+Z*!J#1 RSB60%OY9$53Y
M)3CSKG/2AF''.^$ =R8K5H@LN=%Q;]H$?@4?/PW)UG%2[Q+$*IBLH1=E=2)_
M%5Z\=J*;IDO4P3/HC<NOKCS@G!OSXXC(OYW]XV@XIC7PKV<#N'+)>>JM,KJ-
MF3#@>"E2X:#HA\W!2L"),I'C/??@Z.H*T5='O9/RLP!\6#$H? G_4NPW48_K
M ($#,%.Q1L#&M$^\D/"9$&@%UH#UC:_!XH;*4-='2D TGU@=DS;EQ34:R K8
MPW6OCTHH]9I:#MG(N9PM V6WQ=<-03!/HN#!P)3OXR9/PQSV[^\$[Z\B%BG<
M:KQ-9P$\%68@U;%UD_/+5BKO@V_*$Q_M5C>'E8C;DZ)Y5[SZ7=FA1ISTAG4U
M8C+KS>ZD1RCF'Q1;NH/4#/HU;GU%C_"3+,\:I-9-4GU;(F^QV;JJD:SQU<PY
M1TT6%@PD%\>'-B!B"5J Z,M\>9V:0@(A=<YW@WA1Q#Y]R47Q.-J24PN19? O
M]2H)<7D ;<668*@T,P (GCX*O1@4<T,!@DLI4MKJ%R^=@_Z>'7W\'HF-<R8%
MV;#?'[JH>W@@!0,1(&YW/.[2?G+A+V.XT><;V.XB]>!0!8H[N#CQ$K^.TE0J
M!'"V@7FV( 23&_0&96>3$9$BO+(BI7T;*I&G$"?1(A!P:-_C+];%''B%O''Q
MICW2C\7?H\H(V7X1#-ID)9Q72N*]=F'AG,5>6^[,D[3H#-4=$>4=(>6^)NY&
MV^+N^'C6&SQ WIF"1QIC-8FW2%* 0.SX10IVHK]QSN'M;%MZ(6/VUNBY#*64
M@Y7P9W_M?>DY[Y(H0B%%;^:2B5^&6>:\1^ZZ<^?N;<RI?MV:(@&IX;A0$N/M
MV>>?C_[!5HGE)+87'K8+F+^%?Q9A@.X3%/%OO35R..>SD.:Q9?8'L]TG(K'W
MRA<F2+\&9@';/U\Z[P1HBZ@^CP8NLB)01"^%L_0NB)$B(PR<*,FT\RD6YU)]
M]KULZ2RBY#*37%'IAZBYD[_/DRHV:+.DB!N_-A1FM0?R/6990?HG<#K@:*LD
MEF:%BS&B([62\F^3%W(-EWE)K!&6-]_ [^-;(;)$Z:OY\.FC"VP\$((\<:C/
M4U8!_AV67P@ZIOI>CA6YI.@"DT^^A^B&@\VB#^W$F5?\USL_3Q$: LV1#,^5
M^$($I=H]'I9/HVB#<Y$=<(DN/E@]"#,?+E .]@?N/B1[H]3*1<UUU7/.R$3;
MA2SXWO%HW)N5X@&!B @BXP7_@G[!"R\2]+V7@Z$A6O$L(< CRRNK 6ZZY_O%
MJI V3B# 3 ASZ6D=#BN+@@7,'9E)E8?4<G8R&$RW0+HLVQ>LO7,A4WN.O 4<
M]]2++KU-]N:%\^,#@-_!9$06;/NP)V+G+P4PZ"&QQ &QQ$488=3(R98B6@#G
M/U=^'Y(1P-(HV@#_> ];<[X<C<Z^?*Z<+O3.9_.=+_H=5_ER9'@"/K3R-JXR
M"V#O%$B#/W'+403_ P)4NH#0'Q4+_,0*C(R2PQ-7WQ9@[E69%(AY;BX'ZVA9
M*(V>ZS;MS(7OP>:\ JZ!1_$E )> +?@DRHMU(AUI #64.LJ>,6"#H#)AW.,[
MO.\4  5??8%)3 #^PUB:K1]!$7!^]])OH$E\\3"8> ;:AS#GR#\1"+;2,;,"
M-+M:2MT]YESL LN7W]U]S?(X-(85<SG[^OLV_@#?8;YT_B*()\!O?OOMK0Z
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MCL>Q=_W^,K'?V)G9_<L')$")$S;9(;ME*Y_^5P6 E[Y(EF6V!+:P9R=1)%Y
M%.JI!U6%*HQF+[;* HQ<Q><UO+W"\?W0HZ(T,>B6[_Z+H8G'LZWBBW /="Z_
M:3$^H*F<RN//APL$.>#G,% P.N($1A<!RV#9BC=L/1!=GM(?G,+P1WF\K<SN
MK6EVP55PO14&,E???3@C3?JS^ZRRW8 ]&AEUF$(<PB@WW8X;)O^D(-\D47U-
M$E5DDJB,&^'!UZ%PM5W OIXW:D>F4@0R=?9@2$A2V+^=B[2+?&@':C2WPU7
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M3\"3&:Q%X7B&%XO$:OP9YEGE#(BUIO>:TC0 9:CV+?5+N?(WM+3>IO!=,JM
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M&"GM%E# _RHBZRZOQ\  2""V@@IPQ&Y1P$ROSB-?[+8^;X'*%Y4;=ZL+"^L
MGBNV/8:0)0?:?Q"VQE]H;?>3A'<->]3AR7\O0?KD?7918S:D2F6!:5C6##:,
M,G%RE.XU#+=K:%BM.\<I)O8)%P'Z$@Z/8C$X6='7L1JE3XY057Q\/T,2)9=4
M[M['A?C*(K]>)F?6K]CL$.7^2PTB<A>6S%7-GO^=JKS4=[+2WY!=^'ZS7*(S
M"/XV3H ^D"2]D ]CS\5]X@V./;SB%:#Z^LIZ4V'L$$N8ORN!$ \WW93J)!(#
M:Y'@)+;T<I*J+3ETKIA1M.#:M,G.Z6/(WA1DSX_]HZ.V=^:'WBGB]H<]Q)'
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ME :D-8A--[@Z<]F67JW.1GE]MESNOYV]/[,^-"+EY$I!+&9CR,I=*@U1^'*
M*4I/#C)9Q%]XHVCR*TO>J*-Y'?^5YY< W.'5JUK6F!EES(RIM?+]2!I\+)[Y
MF#1*E^G16'5N#_.O,=OBGUVVQ<MZN80E+[+V#-(;I']@I$>??)_I"+MUC#2I
MD&G?*5[M\-^\>[LXD#XDO._M!96E%87;O[R2#@RQTJ538-=J8#5&57Y2GM+#
M-VS=0;NC3<--O]"6T3^L_RKKE);6>XXMZJU_T.9WONXND2FHRM 8?G^,TT7!
M/'#^GH\763^+:IQFQ6D)Z8\I3(NE$5@MRO>.DK7?8VZ0B+W^MI+'/ 'Y7[S_
MS7)M)R2VNU +V'KZH5X5F17[[@\(JO^75AM, Y>][)UQ)OZR9C(9I^'KIFY7
M*B450["M*FJ,SG&P#UU!@$\ ZE5M99LEYAG!Q:3;)O2U1(;#.:*, S:)QTJ7
MM,%-06N)_8+XO-M2?<T7V'QR)W2:M1FJY6\B(>+%^Y>H6K*V0-MB- ;S$&@#
M2G/.1Y6OX<9++D_"B(GIRW#4Y3@5'/1KQ1M,]%Z55!4)P>P^4;YA@=OOHE*'
M2Q;XB"$1O,CQ0#F6KI9UBU'3L)*4+"N]S=8V5?$'EEJYIOJ0RE[L_+/CCSFS
MWJ"^RJ+(XJN'$7RZX*(6LZQC;2VQW)'DAC SXKR) !&L3(N'S\5A/G5,A(OJ
M3+)&.J"1'++R-<C_0"Z)T;[A8%(7XX,;GEE/BQ_Z]P\W">C*L<I1_0E[ UT4
MJ\ZY,"*VHO9T%^0K082\?S=ZF=4-ZHGB ,_3XN#KNEF'STI!!^#'4=DM)3.X
M]?!0T?&A2F=3:TG_C64I1K45!T<*X&E5+P'2113QFL_!%UUNOZ>3ZM9!T':S
MW/[ OFJ**L52, Q8RGO.P7+ HN2R*--HMD285!3DD&5>6CS2@*MI+6LRH$JH
MM^R?1=T?.K[ZZ<[H]^15#*4)J(7&"EXECC145)1PD8=;Q77CS%H5K( A8>:J
M,%I"]T;B1PG<('Y1]A)^.^YNC[840  W/6H:ZY4PB775GR9#[2NO1LT X%,:
MCK7<Q0&IKOS[[)-'9V1V'K6Q5CN$QV&MWZ*-Z6PA9KG+.H:%*E%4 .#MF*G>
MKC%AYOKSM/"47]_^-H8JNN/5EB_I2BU=G4DFOEU[J>$#,=XRS7LHO0/+_7'<
M'M3P@O4HX7%[,/U8MZH)] DY8%(0HW?'O% ,7B(]&M>NM-2H6E(C2P4*8SB8
MITU%EUC 1IXNDT]G18.[ EG6K6]U(:B,.$+:*LP7MA%CQ'C<OVC4%TL [C]D
M&B^0R5JOAZQUSV2M&S"?SX(=GU^_[E1KA]>=<V/ 05G/\7K +OBH)<<>TBJF
MWN7WP87R8#Z@7 H/E<TW&E6E]_"]ZN$MW+"^V,X+E%@O,A$%4(I*P)CQ!Q^;
MEGP!SX,Y:&5[FEUBNET$=[!?ZB/4F:VMX*JH-X./9+)FA&K_<V5EL G%_0LF
M2XK"*>)KKO]:X0KJYQ\WID4K?%5?ME]BZ.?%I:H\MK,+;+MDHE&VOS@VEA5K
M-<__VDT0NF&8O:VEU58;+U@0JUI>47>912J$#>8=3*9\FRA&4,#ZI8VLSBOG
MI9MK.HZOW#"*_A#XT&RL+_$X+BHZ+MTH=LOM504?N(;-W_:8Y)INQ56,IVNQ
M;F EJ$(?6!9/SJ)HO233L. RV6MJMXG,J#N2*L4PKC'YA0F6S*9O(R7G6WCY
MAJ(C![T.&CG_'A68BE,\RJ&#5 U=M&6[DQ\\*K^D?+4RSZ]OPX9OX;)62#"4
M"I$NZ-N5!NDA%];;.W1\O'FSL-[ 7ZU88M:-[9!T(86SBH9=F\C&,PD:+_;C
M#N^:NH*?I2/.],G4='D<FX!UNGZTRD-?*B(T0JS1J0:]4, JV(]/0%#+CQ']
M^ =6%2_6PN&(_U%V/RL,G3MF"*2.7IQ9_V_TH4+\_T]]["&LF-UGXD?]U%L]
ML$BB((+*6<$$8+V6X$QF^_9I&5N9U6+"]3)!7Y%@8HS2],V;,]K*HO?B!]QE
M7=)2AK,.QVQ49[[MWSKCF$T^])WMCKY9V07/?N_V7<NZXE>PDQ,0D,.,M3=$
MB#!,7+8U]AOAK>K(O)UQW7+8* DOQ$+^Y1RWS)7L/G#.JVS[DF'C*O=](D[:
M").YHBL\V8@>:G1\$)2I*-[8W7UFX9RMFD*89]B0RX[*HI.S^!K,&9<U8<89
MXRT7^2"7HWID1:M:.TN'<7:! >/^@(^JK#A4ZA??M?50&,M_UY_@[\T"CQK2
MS>"I4/&\KA#LN,:-]!C@9B '!E$OQ!E(QK#YD1@!7J$^9?MMUB=1>!UWQ"G?
MCP_2H4!ZM_/9;2 ]=/JNF\.-OO<WUZ*P^FB6MZ<5)UM4(,!1;;6:K53Q(&I=
M7*UJZ0" (3CV][#X+J7[X!9?JCYM_.CAZT16?[WN8[W*B='/K0C0"Z^&>CKL
MUVIL2+27#U"K:=WY\.M54XQK/"JQ[(0G(Z=8&!]>791E ;<PC*?,/D)JJ, D
M>?AU ^^MK)?"KP2P:-C G%;+/61-RJ)J=2N1?6S31C641[8J5RLJZU84_ZSL
MB(#2A84QSO)*WBU<8[7*<U?ME(2_^.>Z^I/*7)"7_WB+SWT/O_^3-R6@GS *
M$HB1!O!QTU5JE<6RP&%5&T$;A%]ZJ_&4;';?]>,3O^H]Z[!$:N&#5IV,MC]&
MF/MWW;5=-1_>\M$K1%MP;.!T\';))+9[3>7E!B,7JGC.@1E4MOU?O5T8/-+*
M'(G->XGN_?.&8G $,]\R81\O.#OG!YZ)AG+$%V0P&T^D81(/_%OV1M]<X<2W
MK?4::PC)O+B7__UZI_RRR+0:U3TXL 96RL,)ADRMH6XF+@ D1/.O_W[=D9&4
M5K]W/=>O)X*'::<Z\+Q;A.([USF+K26:0.51^<Z)1[_!4T@P@&L-[ +YB<KF
MQ5/5%WBD#ZUR->XOAL2J6&^$&^6.P]Z;N_&2[.8$%ZP@T6(2559!WUP&WOJ=
MXYTEVY\;#K_8_IA1EYN]EXOD/RK;!)[+M#S,/*@Q2W,XLRXZXO1L[P:WDZI)
M+LK?"MT7']%>U)_:71?Y/DT3 1/9?1,F1?U<##&1;:#IV";V/Q#4_>;M2W<I
M?EK?&'/]B9>7F--=K2]:2S:WV[O]5E5\;V%U3O2 @Q+Q?AB*;M;U\U1T4A4#
MQ!14^[FXG)3TJMZLX?&?.7LN7^78@N6I&\!:EG35\F<MML@&>6\'FL2SG^#[
M80!]'L9ET18R->=9=[^Z"*YB_92)UX7)6>A\C]/YUS6[YAH84!1_X1H'!WWS
M%?Y9X/G?_)B)!N.<1?;X_[XT![N/A!^:W7F_D&1%+?G]&3_,C-P@6'3_0RX$
M@I=)-,]D*@W^XC!# H,F4$/IA=270YIRW6:B4XEC:>KAK*>'S;TY*./[D<P#
M2D*_'*AM.<"LXU]^?.(^N5^9*)SMYRU8K:VV+C%C<6N+HKU6:;M)O]8[W[N3
M?@$^\N)&ZJ*'_GYAK8Q?!S,UAT6C$P08*-9##@:*'SD4_]QM#3_(;>$_Y+;P
MU>%MH1[Z;*#Y2)"@[S['0+@>JF?D\&53&MZ7*5T6C)5<?W2;G8E\*M(3ZDU+
M*];^\,":-Q<I:Z*+$]HP.UJXO@T2=+]-@C#IN@'G#..V_ST.G;SLLWCZ(/^K
M+E*""8#M'95V*I$;<SG=SG-BF=P52&,]<#36AEH:N9RV7+Z1>#Q"N1A,TU]&
M1B[:R45#MY.A[)/4#QDE.!G_E>:$?%HY5/5\I' 'S;I')?I.#\TY:$L>2HHB
M(>X$ #**$Z./>X(\"0 TAD@/.<QIX1M#9 S1PQ@B?Q'ZOM%(#4R1B5^=\&:X
M.^&CAW=*,YG.AX-\K1SFA'BGR4&.Y]<U'&2RK)N[[X:-0CZ40MXU.\J8,F/*
M'K?F&%-VPJ;L6_;31B6U,F;=AAS^C<?X37.#:?J+FC8;@V? ]7>FU+39N-].
MM_<_&0_4]O>A2K;,4"NQTM&ALD^R]*7*:NDK6>:;M2@%]8E;GXJRM+CLM<VW
MVLFU:ZSJ<B[*<PZ]'+"8%?Q;=&U<%NOB7'2VOJGBE"ETJ.F2O.?:@*]$9551
M1>%-E<NN@J;.X5P6RY%UK^O5L)!=0@6HY%@37W6?5,#U6R4*"[Y?B_IB%[1%
M@..BOX^HRBNKSF(9MJ; -JNJ[4M&&1<]7[O'J5*^6 U9K<I-BQ5_%5(BT,F*
MB+(734G3NNE:B7+:9+)"W;BO35\\472'Z[HFX=>)6FK5E0)=56"ME>7^A@]4
MM=)2[&,MVN^JBF@':_)*U$ZQ6/**B\4F>]-<U)^LLE;-3CC,B*JBV+U$S1$\
M!\M"RY:!^34S_HG+ZK[YIA'5&CLCLK J7HC?P.6R!N$G6:12E!F#.U;8TR=;
MPWSGPR#4JP^^HAL/%LC]TG!HEL$S&U$K3S0:E)UI46*K^I,<U<UU>I?T2E1+
M;FJ&31%5-6-9MR\358;[,G<Y;=>BP*1HLP0;UF(EBP#"<S]Q\235+$J]<X6X
M@3*#_\06Q&U=5]T#NO+,XS*277GAX3M%W<2ADI]J1*Y6Q^'%P#9-U^"FZ[FE
MVB_"RXSQ?;3[M,#LTV:_3QN:K\0?^W*>'X=RGA_;S6I5BI_GPAAO;+T2GUFO
MX3-/HLF*++WZ?NCX([L(=?+"9@4_T375I=7*B91#>//+3Z_^Q_KPUGK]YI<7
MO[Q\\^)GZ_V'%Q]>_>/5+Q_>3S+51^'L#^^"F6F9V,0[2Y+P"S52PS/;]N^G
M2NH*VTA4YYT1<(KJVT^U=L^4<Z:>JD&PA%H7#<]_?/(?C6AE^!%'H#8D'QM^
MCJUG8"_P<;5)83/]$:C[-X%+E[-Y2V(EQLNP.[G@R<]$L?@2=E='W,3*AH[H
MX!AV9K_V$V&]$Q,Q;AGWNFB6%K'>O7SQ]N_6FY^L7^HSZY#Q^]8AP\07GV%F
MJE\V2_A%)GC%ZX^)YZ9!'+G$X902GR<>$$(:DM -F!/%L9WQZ(G8V\)D_HJB
M?ODQ\'+/95Y"X%\Y\;.$DSAQ(\)#+XZ". C"#.ZIZ!*&S7CQ[,6&%>NZP2]]
MPTY[ 7A#:&1KMO_6_YI^8\+RO:&+B;0?94\6?646=7A2IBB\ERWC-)(/)_5N
M3'B*: 80,+V<#R+ %SCSI!)\@(( VJGO?3#)E);81_UC>\'Y^MO:R6I/%_XN
MO]5Z+[[5< 3#$9 C>+;A"(8CG#P$&(Y@.,(=.<(0_JCS(0[JG#99&,41ZMQZ
MVW^VH0V&-@C:X!C:8&C#R4. H0V&-GPS;?A8YQ^S>@D?=,&KMKCD'['IZ,?'
M1"!>CC]?--8Q1,(0"4$D#C9.&D.1YLM"+\J@AR715UJ&"A@J\)!4H.&,\R4F
M,P$EJ,3WX,_PA3EO'A,C^+6?"" '_418[\1$-.+419W]+I,8\:>+NH0!MO_Y
M'Y]=VTF>6Z_^V!3K*^OI3SPOLF(]IA,G/(?3-%R: =H:RG0#9?*,[\7X7DX>
M @SA,H3KCH0+9ISA$3LV/KN"1_,^YF7]Z<3S/'8\+W@@\35^M?&X&/H@Z,/!
MXDN&/ACZH*%4#7TP].'>Z4-5KWG[<5U_W%04CY, CRAP[17+CP.SR(OJM'G$
M+S@+6 3A=7<2>'2ZU) )0R8$F0AN@B-3%]#4!3S6V:;0U)N8<;V);B&*DZ'W
M<IY7@V(!-YW8/8D:%#<<.]8$ $^D@-F'6A1@:D>1,1$JPU_^O:8-PT7V4]'P
M;%TWP@_T3_HYN\(R5F^J3)<:(+,J/7B=*-ZNBDJ55,/9OY$L/X[I/O+:_Q>W
M+N@EM]363,PZ&(=Z"9]UA7"C#O59\E#?WN*WGN(=__D?GO_\I;Q)_/R#1<6U
M/_&,+U/>6)ZSL%S;=85BP0^.JA;(2U&5K=URLXX*I(DR<%OY;ICNM["&T+\U
M"OU;JS[BW?81[[%>_T64D\-0-Y.A[A\60Z4YX<Y>8#54B]/L D>"8US#1I9;
M5YPV?1%66:O-0IO#]K]QT:-']WEB#VP]Q8(H "+P%>65U8\4*^.U5C^-?:FH
MT:3(.<4JB**67"VU1$[AH>N[(G)63HL&*S/"N&E9#K7IX,]8T:[=?<2J;@M9
MTU!^NY+I+:0Y?')?YZ[ ?VV+$G\US/444PV7P0* !RU1K)^*]858O\I8KIH"
M/FQ5PNR/ZD9F&5_)ZHH'*E/"4%Z(R@_:5'<Z-:@IV[K#&[DR05X-$R@CY">-
M,2P7,+UMMS04$>H6Y(@0O;W$&I3P <I8/]V2YP_64U&AY8?%>$'_!=>7J)=<
MRO*?=6G5\)R1*D@>C2^X9O$O !M;> ]H2]840K$LWN(>O0"P%*OK3?>.E^H=
M,N/&?R[^<MX(<'C=T"7_5#>_6T_A;]X/5M&V&_A]>M6-&);VFHNBFN]7H$FU
MJ!GYMCFG5?&G4BXU2Q]@H\9@?R;O:EM4Y:$<J2#,3+Z4I\T&RYBYD?@:;X%%
M+D%Y6U$CT]I4?VQ@]>4%?N"V4;[#%)I2EIJJ_%')W-]I6TB,5[3ND4WNL;<M
M%[R]QOQC25]EC!$P5$&V':/^%ZRG6]%S<<^9]586J1U?7PB/M<(%1(5KD>#@
M*'IX1/01@-^* KJBX+ E/1%C8YUC0:W!5S$8 UEB"W$,;VV0PBGBE&+]W6'W
M+^Y0W ;_/*8PUQB:W\[>GUDYL,D&!\^S#4!Y <(HZ:=A%TA7*QBK8)O-!LF$
MK"=]OBFWX??]<#]>\>IS=D&K<[Z+QOTWG?V?M+'^^K?[<E<<>4%JY9P]$27_
ME]C?L U6GQ[IT>UIDUAFUH>+NAW_5>D05K=>8SGL54GET@2ZC5Q:KGI\%:I1
MG:XIO! +:]>5T (*%*41KZ9IO8%'7'!15_S:#0DJ;MY($M/O0E GNDL6_3/8
M1E0+A\T16 [X_[R!@4A\ZC\>6UKP?K22Z=<99YM&1ME@? A9 @.+]O?VVM=V
M\W1HT%\8TF(\8;M#P'F5:,HD$.'\BZ&<6>\WL.,97=Q_#O\,ZZ42+3H0*2R@
MKVM$T0*&PB\+AF7Q$79 A%W5<+I$])1PPXHV*T7?CJ%;R('/VII*0<:' <AF
M(OW##VZD-JTJHPZDNP*&F%&81AAIL13[IR5E'+GK8%L6R* _<=A_PK]W7H&,
M$7>F:L-*QYO/PX,'C>A*KXM9'BD%S"G.$LS<:*FF/0L9;9T?V];NJ#SO)9J\
M#,0DRD5:_Z"P6VD>V00?G^N)3::89HG+2S'-Z!Q;;BKX/1H(4(SZ$](VVOV9
M N8(;H4M*U"I9(^?-5%^%?FL&Q1.F0C:;K^I;G9YV-:?%?>23\_Z':PD/_"\
MI\X/RCG6JLX0$L;@L6,4$]>BZ>BQ6SWXL(V!IS]U8?]<7=;EI;*7@@P6PN\#
M9*PL>25[(+6;]-_2%[? MZ*/L>2?K7]OV+D"&C'G_4<I7#HHA-9B-9?]2T07
M)F&=@7+B1GP$.AUM/FQKUO1W7B%"4C [=<D77:L*_'YX] )!=30>!:"'5X58
M" L%B,*'875%G'='<_@!")?5V CLRZ96+42*=2=*G5'UT0:'3VDR3,[&*&<C
M,CD;<UZ))T']7F19@[[J?]!JD]-L+=L9O>IZ,O7N[E\QV(4F0^9!RL!1>),U
M?V12F@@MY/TXS"^UP3M(VJV?> M\8+4VSMHC$/C!$PDDO+V^'UW?TJP+'RLU
M$>WID(1>>R=%0BO\C^.^G]+YH!P5,K#T<UW]28%A#KWOEEL:7(^"2Y;(CH9K
MM]X$;]Z^!;[_LL#&:?2\X6K?+SK*R3WYM6/N[QM]+4@H*XM*K,]+(*!%Q<?W
MG%DOUK)/7B5R<T0(66YHMJ)\R%T!GN3N7\[>Z"7;P^\GO?=:PX.*9N384)ND
MT7@S7N VHX]BKRZP\QQ^(,_AE_ Z\53AJ0*);]!1 B_&!<.[U 8Y_:UTX5W"
MQ9AB)/8]RN]W_<SU8TPY[&QRW+' UD\-& 4G?$QMVVV(<,B7!?\D! SC&KU=
M>+)D.S[8(&#W%UA!VYL-,<!N8K'M7UU5O%1;NJ*!^VDC/-_PA>BJ6A?YU3!9
MXHM$^#?E\.9A,>Y\A-SU=-^@]CBB 2'.OWK<Z/;>0]^V-5@0%*T4M%"R1DEG
M2VX[XOITP;>B&:(U)6[EKOA:#A:GK\CDIK=&?^"GHA5;,A4>S=4^:;T1H5#L
M(6G <V(GN%I1A4I1ZG.-9 &+5FGZ+B;U2BVVU8=WNJL&EEH#(^R\O+T+P*HX
MJ@]&R7'-# Y-X0M6N- C\VA]]IY(P-K-NE],_3KJ%NW8@0H:NED*]SBH9-4B
MDM>5\D)()^^PT.!3\2O6H^08=/J,D<N"3UOV&,,*&:9:*1=]#]$J*Z<==2.%
M^X<O'2;XG.+*%] A>GNBQ 7(",_2)<Q@O<&FF:)YYMCZ*%.S[;:&^3D7047U
M30 SW>0,=F2M8IA='@9F+IR)S _Q(-EQ=D \CM\QN'50YL5ZP+Y#']6)6OB@
M*EI>_2GEN?,Y.Y^L@+;W?XE>L2(W32XL"?[=<A+/D\+%N:ZH:"6+C64O:5$*
M%_4=IE,&(-4 J'4!:@@R/%<1%BK[]@S?)T!N%*J0 ]V)F2BMV)^F+1OX)4VK
M]L((HY0P147Z]QJ@/#+-_^_ZDP3,@W3_7Z C+QA3:3\J9B2N,'*9-*VYBU&-
M56Z'W7]!K_H8G=@PUV59?Q)^;+ -B,D(SNVS':FQXK*;M'%30/\L<./OG^^)
MDA7MJJ17S_*2?SX@QG]O6N1TW6>)RV 1 NM[+H1%L-=I^PRMD#A*>4BTPP3!
M(+SH^Y.3]=:D]C-:5#@C1$SLC>_=58\;YGP\E5'@.E$<^HGK17[D!M\+9]=G
MS%+LW5VCQ; ]K-G/N2"(&"M7VB$;;X,]KA3#4.F)K<Q/_'K^V&VDQG9X_YFC
MC9<PD]U67,66E*H+$G/*:3^PSM0_#009"'I,$+3D*@.QSXN^UG6S[3\I*I&Q
M" !QX+A9%_H6'%VXXD0:5Y?NM=X,$+?OQQM02"3.K"^$UP>P3\3M<1<SWGLH
M)M+O&D3:HR2&-VT+NDU<@P459![3:#, OU.)4') 8O-Z9N!"EZ5KX.*!X$+M
MDA5IZ4A"QUF$<U(EVPTG082#4N:!@ Z+#;;4653^WS%O0Z1JHML3_0B=LZ"5
M/XF$;KAXB>ZJL?/I 'KPQK 4 SL&=DX+=E[7&,AK*6+-@#(+3#/;AJ,O>"/2
MJV=?ITK)F1T&1I5.2)42[!P?VT$0!;YC)ZA)]6-0H?=<,ME/#>:TRM/'A6+0
MK<4$;R^OAIC]E^/K<*EZB#3E]1JV#BF0<.$S4,$?==8 \]> B$O*+Q@#/J$/
M=LJCJGB FL POY)E&QTU.GH:.OI&;JB[ -37)JZHZ)ITSU/X#5,YVNHX7Y<@
ML5VU H]PR\"<>! ^^G=^)4/![?B4X"CZ.DK2@>_$V5\HS>]"?"7891@19FZW
MBYTSC2/W)08O\9P+9L.H;3G;"AYLNEH3T@%I@$&3Q6J X5X#<6)[C/JF\@W0
MIS\*Q8^JO\"BY%EGG]M-BEZW-688#1E#HTP-J[VH-R4;I3AUWC"C:]K(W^C:
MP^B:J/@#WY=NFK8[55;+TZUJK[D!CGRUD^!TG>*8HR/??'0D-D='IC@Z8B#<
M0/A)0_B[4<:@5=;U[_@-PV9C.Q QI$#@KDDEJ7;E P_7T'+Z'4U'QX:L>@$_
MO2M#I-PJ#^4U6R!5M&8W-_<HUN1$ 4VCR9BAMORU_:MU*%KVK>^#F2D^P^"K
M7S:B,*$H\_SZ(Z=>Z/LQ(W8:1<3GD4MBQP](S)+<MUF<43]Z(AR0,-._8B^&
MEQ\#+_=<YB4$_I43/TLX06@C//3B*(B#(,S@GHHN$<UX\>R%3"3^!7XQ?_G\
MQ,L:?;;6?]+EZKGUH=YD@ \___RNUX*M:?Z;OLIAD.+XZI5%N>.X>4"2-(M!
MO3B%GU*7>&'N\Y!%F1]Z$ZG7S[4L,#%_%7L/HW^-A:&*-JL7UDLL(5DW54%G
MIV(SG/R]FI[ZSJX!L'DOM:Z6+\9.9-AQNQYD=P"I+9#\ T./3CJ;R-0TF<@Q
ME1C'U(S![?X6XE&+FOSSQ?^\_-\/KQ;6FU]>3E>Y^JA#GJ9N]60+0%!HY?KY
M*#M'S'U1_%TYLMZ?1&\A(1*SM+7$MGL_(_Q4'/RM-RVM&%::_8SM,:SV0M3I
MEFEGZK\87=,?=*OE?_L/M3192W<A#?LL<6K2(+I+'HIGT<VZ?IZ*I"<QP*(Z
M?V8_%Y>3DE[5FS4\_C-GS^6K'%O,H+H!>][05<N?=?4GN\F1_43%LY_L=MO%
MA"GISG_6W?]\O^>N?%T8G?E.B"&9@WU3U9C.//O+U]A?NL(]B[UO?\HT8_'.
M'-_YRL?<T-DX$NOKCHV-[]YD5JK(\]MVCXW.@H?713F(8ZGBW;O_&BD<2PHP
MY_B7'Y^$3^Y7(@I$^VD+T##79<&L;5M[8"H?2)(/M@><=#V, ]5ZZ.:IK 0]
MM-H8PKE!L)&"#E+H#:%K#.&C,(1X,E8/G3R5%:"1-NLDO_'K8";AC0:$#0@;
M$%8@[,Q"B6>S O30YNEV(7:T<'T;Q.Q^FYAARC7#W;GIZHNVY5O=*[Y&6Z<2
MH]G&3&5!)Y:(P<6)R*F1RZ.0BT$PW1#,2,3HA9Y2T,^G_SC8]%X:SZ3R?BG[
MU8J.WNNM"O<F/J"5^CVL:\I(Q.B%D8*1@D&G64G$2.%D2//V#F<\ORJ#>CH>
M/4Y.=D:3;:CUUU%K+,LE6C3@#]A,[I*6O#+>:WW5]0A2J.K9R. .*G9_VO2=
M'EIST)5\*QD>X:"+..-Q?;V..\W__'!6E1=YW:A2H;*^"(NIG7F)1UCJ1L0/
M/9^D?F03%D:>RQCS4Q;LUA?A*>=VXJ6$!G$.]\"-<<!CXB0NBR(O]^R =_5%
M-BTYIW3U#%'^1<7P7Z\&B'^Q?DF;YJJHSO])RPW<M*D*^9;?/O[V_B?@Q["R
MX"G>$XOQK(#9:7]\0N"_9+>@'Y\4GV':-DM6K]7?G_PM]OQ%&$1=C8_N>_]F
M@&QB%=#";ACKK8,49K3HC?4VUOMDK+>;)TD6.3FA"7.(G^8V22,[)GF2!\SG
MH1\Y>]8[HIF;AW9*8C=.B!\P2F)F1R3S');E0>*[@?=PUCN,%TD<&..MG_$^
M5F#3^&CT1Y_W%W6S)F (EE@BE[?KY3<X:(P_50>*][52,-"H4Q#!,#3M,/(P
M0[.I'2;4LTEL\XSX7LX(#9*09)$?Y%&4IHG+I_"O"(3^  #]9L#G20A9$BXB
M)YF*D!G4F3/JZ#7AQM0^O Q.8;J-J3T-4YMF29[1("<\CQB8VL0C:>"&A(6A
MESH)<Z@;3N$,.9JI=:)P2N>'@1T=G1\F065N:/.NX2M:C/J88K)*O;[@C95M
MI87KX;S72U-G0](F=17?]H"Z7K(Z!;%,7SG D#X]8/@PZ?-=-TOSU ;&%OC$
M#S..$3!.G"3,LB1+(Q[MD;Z[^%>4$7@E;<"+BKU% R"/V:O#0=-P0&?A1).Y
M6PRH&5 S-8T,13#:9"C"HZ4(69+'0>CEA">)2WR')4 1:$Z  3B>%\=Q%-,I
M_$+W1A'LA1?%AB+,%]3N(Y7&/:8WR37>I+NNB@_UFI;3.(Y,=$\'^C&IF]T
MJ*910,,*3XP51AZ+<S\,2,YH2GP[B0EU.2=>FF5VD$5YX,53.(ZFYW] /A=!
MH&>8T.#7//'+^(@,&S#:9-C 8V4#<>CYKDL#0C.:$9\Y/OR44\*3C'+@!0Z/
MO"E\1-.S 3<(%YX_F3O(X-><W4$FN6AN</2NJ5<PT5<BJ0B+WZPPGW!A57RM
M1SA$+]V<#0\T)T^UGFZ3\STWH+PFYSNA2<B J&5IE!(_]3-"$SLA(0]IG$0)
M96XT3?J/A.EW):W6+RKVJD/J7_AT0;W0UC*H9]#'F%QC<LVB-R;7F%Q,IW'2
M@%$:$S?@8')C%TQN&#*2<X>R,'&]*&+3I-,<V>1&BR3PC<75#WQ,I9G'ZP]Y
M"SI/UT5U;I6<MMP22$SJG&S@/TRVS.Q)FCF4JO5T&Y(V-\ \3-)HF#AV'MB$
M<]\F/F><)'8,__"3Q X][GGA)&5G>KC^&='Z5_S>M_EO+1=QKFGB6\["C?4,
M;QGX,3;7V%RSZ(W--387;&[(8M_U&25AB#DDGI,1ZF<NH786LI3&"?4F<8S<
M@\U%UXBQN1K"CTD5>;RND9_KZGRJ&KPF8J4#4S!.8ZVGVQ"SN4'D-<0L=#TO
M=-#[P8"8N:%-4A\HFFU[:1AXC#G.)$=]$*"/41?0#1>!KV=-& ,ZQM(:2VL6
MO;&TQM*"I>6QPT(_=TG@^0[Q_9B3-'5"8L=A[B<I9=1)IG"!',W21@O',:T#
M-00=DQ/R>!T?OX*.-T6VYK)'M!YN>;WT<39$S#B#M9YN0\3F!H[7G(N) L83
MH%(T3S!)UX])&H0Q<6D:)$Z49"R:)/]C@&;L#?E+7643'FV.(\?$H SLZ#;A
MQM8^O Q.8;J-K3T-6QO[E&=>&A'/\2/B,XIV,PF(&[(TSQT>IGR2VB'&UCX^
MV#'Y'H_7[2'*1YO60O/G8:;$MI9\S?0-,+SN1EZ7!;8=^BYQHBPE/@]L$G/F
M$Y:&61PFP&_L:<[0#&T")B9U_I1U8@V*&10S=6(-)S#:9#C!H^4$/,DSV\US
M$@7<)G[N4T)YY!-NNSSV6)Y1YD]RQN>(G,".]<PE-2BF32:,:1ZD)RC)YD%5
MCPBF(LK\F:"IN*TE$S0= PP3O+'"2AS[4>YD)(OMD/B.&Y X3X'D<9=&6<Z"
M--Q+=;Y[_Z")26#H+4+7TS+@9Q!LG@AF/$.&#QAM,GS@L?*!B$>^3SU*8N "
MQ*=A2&+/]HG'F>.E2>2[^5XE^KMW$)J:#T2+9#JOD$&P.7N%IG*![[J 'EXH
M\X,:Z>\Q*4"S)W5'=)2[9RYB(JLW:<FU!L4[Z-_]J=IW>NC7[65KF*%V<'V8
M&;I9PF.69R2(/(?X2121.+<#XC'N9'::XC^F\Q1-TXUH8=OAPHDFJP%H\$_3
M;>U]PY=Q$QE&81B%5BII&,7<&$7B!1[E-"1>Y 3$SQ)&8M_V242C)*$\"[TD
MG,[7- FC\%Q_X7EZEM:9*_H]J)/)))G,B2T8*=R/%&#.\2\_/G&?&(EH(1$C
M!2,%(P6#3GI*Q$CA@:5@XJ8/$S=-ZY(=2]H_%S0MRF)=P*VT8M;[=9W]?@$O
MY$W[%PO["*^O]/#-Z"5G/33R*RV5D8@.ELI(P4CA\4C!H)-N$C%2.!D>/=6F
MYW'PZ..&GUZJ8Z;EP*B?F;VLKCIH?#Q:2L1(P4C!2,&@DYX2,5(X&>9L2OS.
MC5^_R#(8[KJU5O2*IB4W^UM=M?1QMWLS>;:F7\/)9,^&G-'02U/BY"$COI\&
M),V<G+A1&-I>[-ANE$]R'D>!^SN)[2\G/*^=+*)$S\*^>N'6*9@)8ZQUD,*,
M%KTQUL98GXRQCH,X#*GCD= -(^([C&&9M8CP'.VN$T5)-DU9E>,9ZW 1!7H>
MI-4+MV;L>3$]I>>&-J#OS08;2M?+%:]:BCII?*0S)G2FZYS6TVWXV-P0\AKG
M"4VB,+5]D@KG292')/6\A#AIEME.E'II/DDQDU?+55E?<?XK+^F:LU%*]Y34
MS%DXL:UEV3N#0,;L&K-K%KTQN\;L@MEU(L?A=IR2+.0>\=T0C&GLA21R_2#,
M;9O9TU3\N!^SZRW\Z?H2&@32T2-B<E'F!CR=1P1NV.2@DINFJ,XM_AG=(]Q4
MGYTS23-.8ZVGVY"TN6'E89*6,YIX04*)RUQ*?"]Q21JE <F]B,>AG;@NWR-I
M7^,;6667GY\IF/['&*5?*9">A)S%"S<TN24&>;2;<&-N'UX&IS#=QMR>AKEE
M(7-9&.8D=VR7^#S*"(W#B'AQD,<L\0/;]K[%)W(_YM9?^/YD(0B#/#KZ0DQV
MR-P I_.%?*/WPX2H=. 'QD&L]70;.C8W=+S&^^&Z:13ZE#A)AFUN0I_$'*@5
MC6W/938-<^9/=*P&L?E8&2'!PHM,;,I CW83;NSMP\O@%*;;V-O3L+<V&,<T
M3T+BN3DG?L9]DG O(]2C:1[Y";-M/M')F"/:VW@1Q9-UA3'(HZ/[PZ2"S UP
MWJYX0]>8_E%RVO)Q^3_K/__CLVL[_G-+]1_7PVFOE[+.AJH=L8V6Z=2N343K
MMH(QU$\[)#Y,_3(64QKYC.2AZP*-XYS0, T)LV.>I"QT>$JG<+7T=N!G- ,=
M [R:DO\%B\31,_QEX&R><&8Z#!MR8+3)D(/'2@[\-$P"QF+B,HKD(/5(G.?
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M/+0,3F&Z9\]$C E7&1(L2IE#29ZE-O$=1L$<IRDZ@9C-["!TO4G*3,W39V1
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M2ZL'3DWV4RGY5.J=79*'@M1E0<)GX,#E,1R/NN\A58#],,%NFD[&)<-TXWH
M>[8L<%N9\4TZ(T*N03X$[+==8W\SVW^.1R?U9K3?^] .#U/O=G8IPHCK&GV,
MX)JH43$?*E!0 16*4M*3WQGLK_'!3OL!^XE6P &1_6LPAG #(H (_ 2( ")(
M>D $$(&?Z/N)5L !D?UK,(9P R* "/P$/X$K\ %\ *[ 3UWZB5;  9']:S"&
M< ,B@,C!^FEW=R)<ONKB8BCW>R<"V8][[]F$+[9W&ZPV'_)=M*NW&]"XQ(B6
M-[OI-T9\Z<P8PMW]H8C^:AUN[KK];$=REGLM+;-<*Z:UB\R[:EANC3N>I*W1
M7#W;4:)Q4;K,C++#SP1>65#),=FDJ3F7&I3ZU*'-?[/G57M]3I[M:8\W9V<S
M/W]<\RZW>=FIE&;JQ,X.=HRXM)(^L+;O2[)Q\!,M"EH4M"AH4?;1H@CGFM/)
ML.C;T&XD)YF/P[\.?_B4A7';HZ1/U:)LCY_N]M91J:?!.C0I:%*P:](+(SMR
MS1C"C98$+0FAED1+HTJVE;D6,]-2-9::*:PUT4+0DGO9KK8DN;7"151#2Y(T
MTSDU%F)M3%631-,V.=]H[)HX;Z<^6#0D:$BP:](O,SORT1C"C18%+0JA%L6E
MEDV1BC79PM!N5,-"$T.+8DU*+0B=DGJZ%N41=DTVG_\Q DT*FA3LFO3"R(Y<
M,X9PHR5!2T*H)8DY6AU-9-XXO]DU"2PFE9ER/C@IFZG57VU)?!0EF1R9YDHR
M;71ER>K&O(XMV^JM^?2 \*?:-7%3Y=Q4>XZ&! T)=DWZ969'/AI#N-&BH$4A
MU*+H5FS3(K*AK[!,UV)9D,$S86N1.E65U;51YX_7HCS"KHD?8A]V=I')B(LK
MFA3LFA!A9$>N&4.XT9*@)2'4DN2FG39*L&)L9EI5SE(.B1G#7>9)EF*NG=!Y
MZ+5J3[5KLO.;U49<6M&08->$+#,[\M$8PHT6!2T*H19%NU;JT%6PEJUGNDG+
M@K>&19YLC9%'*\+3M2B/L&NRXPOB1EQ=#Z!+P0USHVI=H (%%3HJ<6,(=_<-
M)#JOTZMYE2FRF< "=YEI;Q1+0\_%BI'-F9"\+=<^Y1MB,K$(R[)+@>DZ_'2,
MFK.BF\W#0W#O^=6K>6^YB_=T-^AB*W;Z]_4L'=4W-0_?NI[=;;OH4^>C_=0*
M/E4*9Z11G<@%'$C>OP9C"#>0/ XDR^B#"+6<TEAKZUEL10Q_:YX[PT55U\X&
M?PF2'W4SY%,4QO8'"A&Y@(.^^]=@#.$&?<=!7Q&=K]XK5LMFGFGBDH5F#5-<
M*A=X"#Y<6Q!'M8&LXL.WFS9P.BKF]?"#W%A7FPVU!;UW^KHAYA;'75&-R 6<
M$(*'F&^^\LTS^:P7/N#.-0@#82 ,5A:'R7+R/NAO9?# "Z;@IY[]1"O@@,C^
M-1A#N+$]U1N$;MZ>:DH6T[QFOGG'-'>>I2(YRT(TJY46ZOH(%%FX%S%:IC:C
MV;26BL7-9V:=XU+5%H76GL3V5,#P$X+5:'=W/%Z^>?-B*'''(\42=/F.Q[PX
M/E[,_YR6DS^>9<O%/[?W/D[^%9?+.%_3N'J7EF^[Z>1P/R[I<&,[H+/M /BI
M2S_A1#"P AL *\ *_(2U2:<J(.DI)3T@ HC 3X!(9RH@Z2DE/2 "B,!/@$AG
M*B#I*24]( *(P$^ 2&<J(.DI)3T@ HC 3P?D)W %/H /P!7XJ2L_T0HX(+)_
M#<80;D $$(&?[AINS-P?%6N@ @454*$H)3W.<)/K&&X^P\VK,$X5PUK@G&F;
M$HLN"-9*<I$KHTV]=MO1%P_X_8*!^YMCG=MO_Y_3TYL/G+:O^%0ZOZN3W*A)
M/=<D6@$'B/>OP1C"C:4WEM[P$R "B"#I 1% !'ZB[R=: 0=$]J_!&,(-B  B
M\!/\!*[ !_ !N (_=>DG6@$'1/:OP1C"#8@ (@?KI]U-3;\\R_YB*#$UG:()
M+T]-?W]^8<)C#D['%3@4^(A+)TB'&^U(9^T(_-2EGS X'5B!#8 58 5^PMJD
M4Q60])22'A !1. G0*0S%9#TE)(>$ %$X"= I#,5D/24DAX0 43@)T"D,Q60
M])22'A !1."G _(3N (?P ?@"OS4E9]H!1P0V;\&8P@W( *(P$]W#3<&IX^*
M-5"!@@JH4)22_O[$Q^#T1TJ/FP>G"\-=J,TS)X5G6BO+8BYY,T<])!%33(8_
MW>#TU^<G.W<X.UW8J0EB5[/3499Z+DNT @X6[U^#,80;JV^LON$G0 000=(#
M(H (_$3?3[0"#HCL7X,QA!L0 43@)_@)7($/X -P!7[JTD^T @Z([%^#,80;
M$ %$#M9/NYN=?GFB_<508G8Z11.>?8IF<C2+:78T6W^<_&NY>4*+UFA<6D'+
MF=UT&[A9@G2XT6UTUFW 3UWZ":/1@178 %@!5N GK$TZ50%)3RGI 1% !'X"
M1#I3 4E/*>D!$4 $?@)$.E,!24\IZ0$10 1^ D0Z4P%)3RGI 1% !'XZ(#^!
M*_ !? "NP$]=^8E6P &1_6LPAG #(H (_'37<&,T^JA8 Q4HJ( *12GI07P0
M'WX"1#I3 4E/*>D!$4 $?@)$.E,!24\IZ>\/$5S2]$CI<?,E3::*5&U13$HI
MF$XY,A]X9J$:K:(KTN=V]9*FJ#9W,2D^?+MI3.NHF-=<,FZLJ\V&VH*^=$G3
M\_+WD]7Z>'@>JY\6STN9;9Y /'H=9^7[^8OX?K:.1V>S9/YZ/DKF?S:39%ZU
M=NF*IK^]^?;99#5DV_#(ZN)-34Q]\J(F*\.N;FE"7>JY+M$*.&"\?PW&$&ZL
MZ+"B@Y_@)W %/H /P!7XJ4L_T0HX(+)_#<80;NP4]@:AFW<*6RRMU%:8J4TR
MK7UB,83,BI<F<M&:5O7J3J$LW(L8+5,BJN%GI&)1><&<XU+5%L7P,-@I1%UZ
MPAGSER?_7PSE?F?,/T(U&\>0^>]7JY,XSW6R:$-U.3Y>;%[+(O]C<O)^,?]S
M6D[^>)8W%_^<#95@%H\F[T_2T2P//]J&WS%_.YW,ZWKXMUM_[/QWY<5JO=K\
MQM^=9R.(<)T()=M0?&$V;*I[JY&E+/WP^T1L,O*<LKU*A!!2\BHT%EVI3 =M
M6;1\H(AMBO.:=7'JG @G*_8VQO=W@L*;34IL4J66\X1YL=%P)U!04V7]KK"
M"Y4H=+&X (9TN+'SU-G.$_S4I9]PQ0&P AL *\ *_(2U2:<J(.DI)3T@ HC
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MFA3XJ4L_8= ZL (; "O "OR$M4FG*B#I*24]( *(P$^ 2&<J(.DI)3T@ HC
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M?-C,=MK4J].9,CL9-"7LS@9-H43U7*)H!1Q<WK\&8P@W%G=8W,%/\!.X A_
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M4M*#^" ^_ 2(=*8"DIY2T@,B@ C\!(@\N@I#S#=?^>:9?(8*1U4D" -A4,,
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M4KF;_A>WA9$.=^^[F?TU:K@S]Q#]A!MJ@)4QM.6_ Y? I0,SY!CJ'Q8W%%1
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M_(2U2:<J(.DI)3T@ HC 3X!(9RH@Z2DE/2 "B,!/@$AG*B#I*24]( *(P$^
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M3 4D/:6D!T0 $?@)$.E,!20]I:0'1  1^ D0Z4P%)#VEI =$ !'XZ8#\!*[
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MW>+E\?NCQ<=:)]OB,7E]LLSOXJI.7A_%.8UKHV@9NIO>#I<3D0XW-@@ZVR"
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ML+BAH *2GE+2 R* "/R$Q4WWNG1D RQNP"5PB9 AQU#_L+BAH *2GE+2 R*
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M">L>D<(_QZ.3^GD(WW=>RLZFHJ$:]5R-: 4<"-Z_!F,(-Q \#@0[P971QK/
M]68^NA3,RP'!QIE:C3=B^+=K,\E2#$76S!+WCND@%8N)-S:PF ON-U>M"1H(
MUE,?=G;%"RI2SQ6)5L"!X?UK,(9PXQUHO ,-/\%/X I\ !^ *_!3EWZB%7!
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M)]CAYVH/6>3H#/H=.3O",5M5C'C#!1&L+DA=%8)H7G!?EI7/;7F,2A2 DY>
M)F\&,/GQZH_>V5>+7S: \F*+)\>*N\P*47TYJ?S(4MNGEC#'QF$O#P>%AA.3
M<I%Z(/68G.Z0>GQ=U$-K(Z2@P8%5 _7@%26UDY1(5[B*TZI0*C]&8<X34P]:
MS:KZ'JU/D'F<DMU$YH', YG'1'2'S./K8AZYKTQ5V8I( ]Q!J*HF,L3"2L]9
M)2DM].&AJO<I5'IBYL$K,9-5CM3CJS.<CU4Z=;RHW/,KY3&,EV[G]K%,U\_>
M.[,*%5'N@SE7BW<NZ]3*9>EUGX$UB_$YM;#IA?O7NKD$H[' :JF)T-,GR&!
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ME@CE'5%%4<$8G2X*4WM3CY 4<%G.6'Z/KD;/;^^0%3R[X1N7P)$5("L8T>)
M5G!BK(#;NG14AGIM28G0K"1:*D8H9[GBMF3T,%E6.NEM7CA24U,1P65.5*DJ
MXHI2,%=3I6P^/E90R%E=H:O@%.P>EE%A..ISPE$.WGQH( I+I\9 8XX3S!]T
M<-W<LC,6[*UMUWKN1LTO1YW]]V_C6%^?KUNDJ*.S[7=$LRKA1<D9J65P0A65
M)[+0EA34YZ[(=56I@V-KG78NK[DFJI">B))5\!LG":W#V67<<Z"OXZ.HDA>S
M@LEQ94!][L)"EOKL6:#C$CB2"R072"Z07(R:7,B:^MK'@JQXL(=3I.9Y3C0M
M>*5E)04]B(IAJ@QRBZ^'6Z#C KD%<@OD%L@MOK@1C?5>5KHF)@]U6\Y0HG+O
M2%%2)KBK>9D?U'YCQ@V2B^<F%W@VV/,$SA[S;+"WZ^5R[B[@#S7/;-.;>=NO
M.Q?"8S&6YN?M^ZQ9I#4.2_<[K-L:->L$F8=/_O,;]LW39@#=GWT<7T>WDH\1
M*0D5@XI!KSS:,%PJJ)AI*P9M&-HP7"JHF#$Z&>[.X:6/F<-+,8?W(3F\V5(U
M-O@4LR8L$M>OQN&'1Z2;@,L6XUP8Y\(XUUCB7*R0NBHDS NC.1&*::*]4D09
M3ZWT@@OMCG'@PJL!*-X <OSJ/K_IX \C._   U/CP2'<]XY!"\@&D T@&S@-
M-D!=P84+A>&Y #:@*TJDH9(HSY1CMLBYS(]QXL&]V<#1CM)$-O"UL 'T#2 ;
M0#: ; #9P!>S <ZXM;D@3A>""%I)HFO-B+;:6R45->HHYQT@&QB7N9MP/ F3
M5D>>M-J'K%58L21FKC:+2UCWX<R!T /&-PNU,/$O6,V7S:IQ/>:RCIL]/GT.
MQ: 1#-6/+8<"%3-2Q: _'&T8+A54S DH!FT8VC!<*JB8,?H>,)=U:F[/-^O.
MG*L^.2667;L$J5]%5T1H3[L,SHNL<R;X\VS6+#)E##S>JL^6ZDH%=U[X*KS9
MK9W]#]UE_S[,L_W_N@]+MX!;C,-+C_CYC/[A6SN&8Q3L)*)@7ZQ;C(*-#@[N
M.'O)<U8(1XEQK"3">D%446I2655SJVCIJX,HV'TR9%^J9;-2\Y\#7MAF%7SE
MKQ9FW77._KA>_=JN_J^+$;+/#X]1.K*N+I^[2#! ]NR&;%P"1Z* 1 &) A*%
M41,%R258CK(BC,-_A.&42%$(HKTO*V]][O5!R[C[),\>GRA4Y<AZRR)1& ]$
M(5$8@Q:0*"!10*)P&D2AMKG.G:?$YXH2H B*U&4-R$^U5Y0;97-[C+S:XQ,%
M40LD"B=!%!XKY1;#7N.W2J_Z?JT6)C60;2\NVO LK?DS=G11YE_K!BQ$!I=;
M>UCCZRYDY$9[?M\@%B:!C(%R'N?86RSE&A_E//+Z0LIY<I232:\8<Y0XYBT1
MOG#A *225'E9R;*D\(=Y2!!K:2X_?+?!E=?^9425MP%4?FF[%P.D_&T?47Z+
M@'*4$PRJ65T7XSH<'$O!QH-CZ, :@Q:032";0#9Q&FS".LVE*^ I"EL&!Y8C
M2N6:,%X72LO:%*5_2*3K:=G$_[BNM:H_#P;Q \NI^!ZY!'()]$R,5PO()9!+
M()<X#2XABYI6DE-2:.>(*,N"* :L(O>E+34SX73FAP3#D$L@EQA5O S+Q*9F
MN%ZV"Q!T'VQ6C)@MHMC#6H'!>!?BZ4, K5FLVFLA-:SZFC MQ=Z'ITI+L?<A
MTM)/Y&C57!GI#<F--D188XB6FI&R$/"OYEKDXBA57UML>>TC*WUQ$4J,T]LK
M9^G8>"BV2AR[3PL3O*>H!20/2!Z0/)P&>1!UQ?-",,)YP8C@0!Y4136ARLO2
M^=KK6QHGWZ<2#,D#DH=QD@?T/"!Y0/* Y ')PY>2AY)5TFCA2%UR( *U\D11
M41"NJ>-.6D5S=I3JL,<A#S=R<UD%DJY'UH<&"<2S1\&P:FQJUNIMBG#U_=JE
ML[^7ZBIV2&S]06/$<62+C&NQ3H9\8C;6J9)/S,9"\OEQ\EEHE5>* X<L94Y$
M1151LJI(977MG=.Y\ <]C.X3]HI@\BIBR>B<5)AI-78G%5: 35$+R!.0)R!/
M. V>P"BGBDE.G#<E$4PS(IFOB+246V>ES\U1(EP/YPDW_%$4I)H?S1V%5.%K
MH0KH4D"J@%0!J0)2A2\^/T'+LM  ]C2GG C):R+KDA).:05D@974Y,>(9Z%+
M 7D"%F^-#\.>V2C]M*G0:CV\"*T,3=NO^JQ9F/GZ,\[URO  KQ,@H-AN^U0)
M*+;;1@+Z<0+J<\GRNK3$E481P2S,D-HS4GI;Y7FN1&&+!_<^W,#,ZP%E7@:0
M>35@S*O%BP%AWB2 >;&P+Q*\_#R@R]@8*[;G'KMG"\N\IJ@%)!9(+)!8G :Q
M8+RDKJ2,A&Z(1#A5$^EU31R3RA3,5)3Q![=!1&*!Q&+<D(;$8@Q:0&*!Q *)
MQ6D0"UX5HBCS@GA;:R 6TA"I:4&X+*VRI>%4'32?^>*>B$]&+'Z@'$\-.PWV
ML FDP;]A4L27=\GC?SVN_=A9L">/3]'#P3] VK^?NQB NH#'N KQJ46[@JNH
M+H2A0D=!]ZY3\VRINEAJM3IWO<M\LU +T\#[_4JM7*C#ZL\V&ML7R!B?.-N;
M6O>?093A%!H$&@WL-9&>;^/<2_7.)1M)E(?'_4[-WZNK_OMOLG]_SN5[#VY^
M7)D=&+FOPI;I=FX?3:1_?_%_7O[?WW^>9:]^?7D\8_2H0SZ.*3K:!(C\+]K_
M?ZS:?ZP7:FU!.O8? 06ZYN(?,' ;R)?]!P# U*?+KQ'G5FUVVU29W-/\LD7D
MMUM$GN8:L,WE(<&\WRVW&YQ?UQ?PAAGV-Z;@0H7"@=)JV-]4O":J%IH8HW)K
MJSIWYBC--5]W[]2B^1\5=APOVT7?SAL;_X#=S)L.>-1B%?]\[;?:VRGOIZ8W
M\[9?=^YW&,6/\];\^4WF8(^S#.8!=D)IA,T"]D0O5I_[6/^@']E"/#;A>:J,
MKD>=KO0L>YG(<K:OWYBS]:L*IUP'FOSCNF\6KI_@$KQ]=M1G>5F=ROQX9#K\
M=_7!7*T<\)"%.<N^31$,\_U[-TLO[??9YKUU?_@>[+ V,VSW8=MM/Q\NO_GH
M+[/LW"G[KS5LT%R7$@K?@OQ>J@[,QPS^G3>^[1:-FF7O54P\;+MEVX&=B=\-
MMXN;N#!M?W)S]3YL_6!"_]I>N@OMNHQ5LPQNQ3/X]=OUJFMA!,/#A4G_WF7F
M7"W>A1S'=1=-8$#5ZU* Z_U-766T")=B^5GVWRYM,3,S;Q;1-P*#>.>R2]B+
MPLJ!D2W:R[2RAKUIYA8P>5Q*HCP'11+?6#=O5E>;'T4T7W: ZV:5G:]!87_"
M],U\UU[$QP05]>Y?:[<P\%5X6IA;@=< 9MJF=ZIW_79<UEVZ>;L,M])=JRQ,
M)[AHM[X(%_GG^EV05WAX&*2;IWN"+*^/ RX1VI-TV0JV/ZN]NS4+[X(;:MT?
MWACFZ_YSAF'#?BD^[_PJBF+N/NQN%'YRH2Q(_!P6R;OS[**UKH/5<[6 GZX
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M$UG8TX;UHO,Y_#?[^49\Y[?!70XK*WR.7&P2\^?QN5@,%89TD-">8#A*9-[
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MU[<)^[W!^%]D::/P%GMD;7IG;HOT#ARM9H& B]NU.^'^ QRD^@ZEV^-2?GN
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M'$"!Q8,$[5 _5SW) ;3W364>*>FUBG"L"!+*1\0ET\AP05&*5@BKJ=)FKSA
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M7\W'RW&$:110< (L[B6([[0BT^5/Q_DMN<3U<K283<9A=/=$@V5] K%Y*'/
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MS!H,83GNI7,CHN&2(:)(0%S%['%SSI&AV177//OIDI[(2W_.0UAZCFQ@:@M
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M.08@QI!4W5GG[8@35WL)J/;ZQD/R=K:TD]%X^B$NEJ7<"R;M#!-1 F^&PQM
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M/R\!"AR.^TK&Z>A34 ASG'VE& S2PF-DD]'*>*&L$F?PE<XY8T. \_2\"QP
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M<?KITVA><II?3<*/<#TX^7'B1[%Y/6K\>-HL9O$#W.,O8&;]]KM!A'-_D>V
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M2*!G-,N$,%WD)^LU%*INFN_"4OLH7-%4#V7.#7/J--$<<XUL4 +0%(8S$EE
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M7N6L'A.GHHCGAB*X-MBD)% @N:&LUPGI#"6<803G67M!QJT4GB1,"$0A(H@
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M34?/M[/7'37?INOFV;L5!7^9SG\J(/HAY2OFH"($<2A(D7(G.XZ<$ PQQ9/
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MGXZSJ]T2%_-!,QV/PF#S+/>+&?NJR@[,)K<E3O7F]4[X[O;F144-]Q@CAZE
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M5?848.W1A )<%S-TH2@P[5ZY8)))JD 0J%4R5])[Y*06R,AHF< \"K$K%T\
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M]9K,0.4 L.::6S"J?IU4-H0VWKL*#TS:(N)\P]L<A0M;CW-!QKU7SP%\NUS
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MT[T_VGEX,VLG&?\M-F!\0&.X.%_/]VZN69MF_=5G,_/K;[_<7<0AZ8EAM]>
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M\Z:M=[QUVQ"[MFT(_FI@K<*GN_?M4G;"]>U[=SMO W;A=C$&7[#T"_ JP*L
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M&(VPM"XRE3"G.^"'$F,5P!_$E*>()\Z0B2PA3+D!L!2\3AT,M8D33MF),JR
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M7^Q_L?]]-45]DJ#!$+W8_Z'8?\P])RYHA)-FX/4KA:S!!OYQSG),M(ORL9)
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MFB3F.W\6PW(<WZ2=*0:O)N$_/]/R?494[^%FK\=3_\\7502\/LOR,5^N>ZX
MQH_AU>*A3_]?I/^K/*OX-,U#'O*J:D'G1C4W;3%AG< SF"R /K"R)W&]8J?+
M.?@X:P')2VRS?-M?]ZVR'M+FI^CCN8OSBI&3E=%:6R]R^G1O>%"K,11.5=L
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MKS35/2UO&V-O_WE[T;_-X[@$:-SXMPL>Z\)6A;?[N<=@"^&[+&$/=78[RR*
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MCJE'*T.'?V9:VV]9P</\/$.U!D#A7<.$6PDCZX<01L[VQN:20&[,8IJA$[#
M4ETLP[(BBZE8F:CZGF<[D6W[GKL2^?Z9R3^[%$AM?/O&R -GWKE K@]B[<MK
MMK&XFU$,>##AAQ<B1("A478.R*)<MU57N1AW61,@E-X(H@_ *1%& [A$LTT
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M UR5]9+@NH%M^(&N<@,0D^6Q0 V"P%5]U_6X$VB1O3HI!0"6882FIVHQPW-
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M29LB"3%M(R8C*+]E2:7\%<O,E"\Y< $GM^7 C96NJ?^W5_JHGPRP4GBR-PQ
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M3Y0CRA'EB')4#D-8G[#^'.L;8_V_AJ$/>D#LFV#?H#KX&W7P".@W.0.G"\Y
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MH]H,.%E.]S3QRY59[<-95^MH%T8=C-W@ @:\)- &^;<1Z!9G FN(ZWZQK3^
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MF# ,%X"W[T%S-C:UDV;&<\LYBT 7=JCJ$'0V2M>$/+'G=W06BRX$LN_G=#9
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MD21NFZ396P_/,>," 7.#MR3-JO2$< @+<XKJ 2Q;0YAXNZ],VL7N$L[#ES!
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M3HR1)^%@Y1-SF2N",BE]$T"<K3O0FN>Q7WB!DU?A[.(-O'K@/ ;=JNK4DA"
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M>YXKWB'"0W\@@R_1',K OX39<HDB+K^0MG>0:DL^E>.=%WL@JN5]R4' "F<
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M#F4R3+I,&N0GOCB<C1!3%F!US +.HC'T!:EFJ' 6/AV&U&(7@8D!(&8TJ&H
M,_C0)#O3L7XYBX;V>=2WK<'$!M(Y;0JU3L4G%4%5#]X;X0MCU).JOM=>[K:]
MO<'J%0=?$9:4$K:U]NH0F<LLSY:,Z!0>'.(TMU%&E,PDS4+_C"JU>"-UC/';
M3E5]N-,YKJH^O>ELOJ9Y*H2/TX#),W*S;0AOHPQ;Y#:6=+!1Y<M[.R/W<IC5
M9R*K]"5L#V7RK=$G;;V.92$V(Z&V#XDHO7IF^VW#^H75^JSA06,0T^YT+5L/
ME9O% 7WZ(?H?(BJG0>BW1K"T]3(FL!TRZ<N225^\K4/,1-=_$>+E"7#*?2W
M3F:"PN=812CB-K5)['?(3V(_C$*&8,7\TBT;::/^UOX]%Y<B_YOGY.5#FJUQ
ML3#Z4TV<(?_Z]6RV+\24OS7W;B[O5FBG6I5N4&Y&:<RAK(>%!3S&F-#=<QS^
MB0(RM;)NM.B.$;6&,_'J.-TBHLDS>U\<;)]RE[_<VF=$@[%?U1-G=&Q,C3N9
M%Y7?20FAX(Q.L$@EY$=^:8W@4-R7L@6E5L-"9-B Z0I4?@],+%PUBL'SC0Q
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M?KJVDIP=*3FMW,=PIFCKU.2B[_6<G\QCA5;#RY+QWA3Y+W39Y)OL?FZLVES
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MBOO'ST D>7#J$!EE-%J;E"GIZ-OB\Q*8&"^0<NK/8#4JZJFY*BK_8J&MRK)
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M.LOP&V<I9" ()$?@%OA!FP]_J<U(U)0$YD1L2V<8/*.L@([NB1"=HOB!K&D
M>)=+$C!] = /GCDXD[D"#N-<9=:A*%GE%Q. F*3/V%7HLH#R57D&6*B/FA!9
MI2NN<CD97D]\.G7B';'H-755,L]2DW?%Y96WET,;V;G 9JV2>+F&L*&SMXIU
M\,4RS)D08;J^VE=3%30($"%7Y\[*/Y6_<9Z4=9M0$7X5BY?S(R#RQ8_8[\5-
M:KKN]<P3$I3UHQA]8CKT0GRHSYP7,'B\9*)[6J\:[_ \(5J=[:U8)WF@"1[
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M<JZBFJW(!P-"W5:;L/_/=U^_>_<>\#%%/?\)>?]N\NX=_H\$1?Z4I(A,$^0
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MSXX 8I=-R9Q\%!U[%$6'V9,V13"@T>9;4CA/8)W&RUG^1%,H7$M5\JQ(9<T
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M:/#@;NJRO/(7*D!6K$8FJV,Q3AD/)?I/&>$BX&4[)BG?X9Q7#??)R+##FU+
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M[);=.> '2]RQVW1'7^<[\D:2'P==+BHT&R,*!8PIV>#'":Z8$?G1RQ8C [Y
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MNN2UF8*G\;P3/*\5GB/&LR@]Y;#"A$7F8^Y?_#/XYABLW*F6ZBXQ5SBYV8\
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MA1,81CA.4H\9O,"@025'#5X@W_P9QX6T\_-= G&] \?@@L)_*&.Q@+N@'BW
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M6IQ:I /'@KQ?3C#(<E:@0-9F)-S%5;<I9".'K^(DBZ [C\02[.BT7D%I=>Y
MP@V^B*(8;A=7P6$U?0_18:,S)U['FJG)X\-&YTG3Q?M\K2G X5IAE_0"5CQ
MHRA(*G2>(; 4[V+5ZS1IA<9I5J*1T+++4L2Z,2^(.VYEI-D7$H*XC*E[\H^_
MQ"2'QW$_R(2F1.9)@OB)[Q>_3F!!<\JB^AF[^)R6O9N<_+TBZ7K8=U,(!I*B
MIP\VD"/U,QG9<A<9QS)\T/K#<I=_9D4$5]GG[2[)]H04R_>4X==#X_!%('06
M6C&GX;&0/->(!<GPPJ"\HB&61Q73"=A\0 #B$U(!8O1J3PZC)GTM7&U8Y@O&
M+'>\CBR?!&A!K06K)R+A30OXEYJ6^>VM5\.,?6"7$;EH6?]=-B',@"F/?;&A
M/#*@EFIP#(H9*T)"<0K\G"*(Z#L2PLC!'C+;-W3L*3$D1E\(Z=0TXDK(X41<
M?Q%<0R@_+@ 'M:D<8+9-Q[]6'^B5Y 0_KKMG5+60K.@!+$*L,W(7I^2V)-M3
MG0":[2=0" >_ ^D :3N4#L9F2S<&^>&-16F<FBW"0-S$72Z"\6_3Q5L8)Z"D
MW&0YO@5# VL0W.$9DV_6:I).J"?I%$H[?IOQHCAI$VXN3I7$##%=K"")3X:S
M )[9+;50C'M HG<CHG-$OUK^D DBD!<BEYC.DXDR?YH5UHPMVE:+E4JFC7WI
MT.)"U7QZI427)*7_*"&@[PI<<N"F@W2ORSV7V@:],[#X8;H/UBKI,^2)'P].
M/^ #8%PFB\ZL,V?4 >$V$D.Z ?.[RMY(/M#CAS0F\?,!AO Z>TD!17@5?O!E
M+&0XRP-)PX2'D0NG,/>XG,B;.B(:M,28%X$2\B+'17.)&%EXG+Z)]="U),X@
MO7QVDG5EH>!6 CQ_AEW[;?"OQ"R,L2F<Q2H4>0FA&5&U1H/O$\G?XC4I!EG2
M.#V6&L((.K2CC<I!(S*\R89+.9\^6FNJ@:'DL-Q8]NKG#Q[LLMAF%=72'DA>
MAE@Q;Y5]_@BW\%[0YH^DK/*T>,R2A H0 QQ0^K1 9.C8S7)R 9]=4$\/36Y\
M@MB-3S'X'289\%FZ='0XJ_?W*P:_W::L(N>PDEN,%FZYG"2.9;+9+8FO"HA\
MU:',E^,GJ%T]9+QLM6F#J,;CQ!1)I50]<1!.!4_&E_ #(!\&Y;1P&@X36@;/
M5',%,4*.+Y3GPQ?*\]$7RN+E)<>+\A;TG;2(U^@RDZ''0Y;E-P)A-7#K4L4$
M#/-HC,'\#:7HU'^MFH>+63(02 Z8RUFI6NONP^",@,&<O%(>XS?"Y/6Z-LTO
M60+R#E2H@6CD95JGE2SRN* _75>Y+-9]3\KEYO220<NK6\ S?2ZUY!5IW/E$
MU:A/3V%"UT8IGL-GR(H(B9!I7D=I$?VM*DJ6[LA<+T[*"\UM.=6SKZP4A+^#
M+RZE<@#L+(<(,B*BKX[;'BF5E7R"6"W*C!AA_@PTK.Z"LBM;^(@SY\=2AHNJ
M4?B3Q&[1 P!UM*B>"IC T>7^:P%"]RUN7] 16=K-0*Q'2+G *ET[/@Y<[=]5
M!0K,W_/# E=,*(<[1Y:3FELL3O:@<OM5<"L'"A83<'M#->2XA(21-+J)/^!?
MPY*P)4'4, 5)A_+K^)QH(6@:.Q- ,-31DN9$568!(=%-GFWAI:M*;LYI@KB/
M58G9DM,:B(D$&SJ30)D*=#)@V$]8CMG'RMEJ,A]<OIOF\BT]+1_$!3$<*54$
M8FY#)0BJ$+D#'F7[NN@>GTLQA67%_0KI*)(\:P2<J$KL5Q%\1WEE;M7OSY)9
MHUG24$.0",HN\\Z%'%Y@GDR\B>')1Y\G%3:J,%$+-HT2JJ\,&=1CPH971M7K
M5$T:KC_EDA@OS6QC6HF8!3$JLYL@7OHVI;=R<0=);#\-DXID)#MXY(#H18!D
M@Y^F$(W&XT<')$$&IGC1U7?B*BO*FRQO^PWJYZ-8)'0[\N?=[(, *L4EXCZ-
MDX%C>JWJ&4$<18'/&JN\X27_9L:KJ%<?W6XA]9P>=WQH/CVW907WD0P%7;#/
M5!';TEON5%7O*WN^)1D_&&?#6-%L60U^W-<JD)$3P^M_:&E@FE,+ZX&?!R^J
MV03C-;2R"ZI3:^;\&(7 ;XBCU0P^5*<,S_X.3P /9SGUX4/=A%$+V#!<$[O@
M$;,7XE>(PA*CG2O7YF+?:FX-AK\Z#:IPRJ">RG^KA/)J3)99<)>E_PB#NS+Z
MEVE44E,:XV]Q^?HUS9X+RBT(($S"U6.*'L'J NL$=0@+C&O%3 1Z'*'X^W+#
M!.(11'LU$_*=SBQ0I\8%_T"?W$4@IX=U$L'?!C.\".0<H88\K+]S>7MF"]Q*
M!48O.8? "4H^ MRH?($2YPJ)^>3AFHUJ(NNX4_E64W,H"VD'F_[6&8_W7L8O
MA_R1%]COCV0'&%^4/930QP$^YK0#2=R/(N"$14USXWR"K^1GDKWDX>XU7E/9
MYS:E;_\V=%P..DM? &]5L1$-J18 I*:Q-XTP\59) ,")5<(,9CY[15BN9Z\0
M=!:<SNJ4Y=F:D*@ 5\QM&D-5,5;/8\G+>6 <R-<T(OE['L-2(U!-46 $5!J!
M6QZCD0?&@N,DF#\M9M,(=GI=D8L@)?C4R12K-5A@OK5U:5;E.VII*F4^_\PP
M?]B,&"*9F).S,GZ^%BUI["-T+/(9!+P^C9@#8,^#HU&=1J#,@V'5B9EX@-__
M6I!-E=S%FU-=V =J#3#Z 0QP5MQI0A(WPT5!Q;A)XC?F)7%5"HIEHDI[\GV6
M7L$EE(!B\,#!WAB&%][://M[E3V&[U_HOW*Z$T?&NZ)[.,W23VLYC1IT;EU/
M1 (. O9@^!YLQ60F,<3[7[5FWODYK9Y43K.<Q"_I%=Q(^7Z$R!Y&;]X33K2Y
M-D'9G3L./]/G H+0B#2,0HE,7?FG?[RB.GA\\H,E!U%S%6&<EJ4$?F!C70AH
MH'/E7<M(823.EA5%>!_T+9VC92N83!RDGIVE?YQLJ%&!J"XD%KVD>A:L-. -
MI(GW0F WA [Y@93_51Y"3/[3?ON<)8- @!BA@%&:X623:>8I[3W5<X%P?.7G
M-_H_ TLHUM0")!< />>504;B08\O,##B#'1[R[*3%8^B%/ ^AWFRE_92=HX'
MXZKS\50/HRK $1BS#JWC9]P=NKIC]OG>K-E646X%^A1 "R+;<C!^59\KUSK$
MUDE?W&$2EH;ZAH#BRPW5>-$OM-B"Z?D?N%N' :$T\.XN&)#ZIVSS":)4N ]-
M'<Y]S)!KSC7$)94SJO+7^(>Y6(>J(,Z+0E/1#2W[5(%D6WF0GJ-0$\*4>R5G
M)!8T6VY-D@>O8>"ZP^]P&2:, 4+*.QZT-^"MY^0"I!<(@LX?^[&X4+^%F16G
MDGDS_71@5JY&L5F;Z)X9O2GUBU95HH?0;<W[$5E5E4B=W[M)8O.NZ,E_(<4X
M[EX9:<BI^O'VCLN:>J0D?]*=<.70"[58K_,*J\P9RM<,Y*I9X8,-1:4G<PT;
M9\4]'++(]Z1@[=%6C4AL4?>F<)?<:B)2D^509WF&L$<R HN*C-66A;P\QL4?
M-SDA K#M\?3ZMR.DWBDU&90Y@O1=_ 'H_Z0&EGMT6IYV=FNL*664WJ<-K$8L
M5B-W5VE80+SJ^L? N[ .;FU J[NZ!,?A@N_T&K6WH2?.>O+FX.+&^COU5\O0
M!8!Y66ZL'NRAP0D8R0%C (,-7_W%5+GV#OE5Y=E3F';N"W')NS6JJ: #88#"
MCH^%3!/W7YJ* @S,,MR#<L0QX(9\5$$QX"0E-)[S+S<.+\D!-N8^_X:@QYC8
M,9(.YZZ IL.I :PL!4%J35_0"@VOF%)60S^!$GN)D%BGFP%ZX7(I4V!I;2I2
M%\Q"0G,Y!>*:=IV,N61:]*AQ*5P:P07._C41>/N(32;% X:N?GHE)5:!X#M!
M'D"2.+Q=+>^X+G4W,H_&K\AX<FW%=O.UU.?BJ$_F_O&G'>_#[1!O,*:Q PWG
M1N$AD]5$$3'C*5+M+45UBLN]]LM(&$W6,CMPW>\;/T\(Q.1P%6QX2_:E@#(O
M$ZT$B_@D.;QUCR0B9(N2#N")YF4,89\Y-Z%B!,]I#J=F4"<.%RR"7 X(54K$
MB%3D%E9;IW4&77,M=K_@MAXH4$8*Y% \4<Z=&W$2KO4DJZ-8=\0QK]BLV-M.
M!>=N[&-1A5JI@>5JKX[' ]^58NZJ.74*I'2KZ@Z138,*;6 VUEW\AK 9Z0MN
M,!12)BA;ZX"K5IJ<B35'NZU5_5J)#KHG)5-[P##-#-E)DKV#XWK@<;I642=X
MZK0:* 1)4UPC?!-C!Z$8W-7)FV@MI.;<KHBNQHF!#YT-&<@Q SGH>2]!$V<W
M:NV'28*4J<"US)]*$+[0]R*P-D>)NZ;$H?(3(\^=4Q(Y\ZS8L\=B[T+G50(<
M\*.#B5@X@JI<+"K13<CVY[2,R_UO)$G^(\W>TR>J?6<IB1#+X%3YD]$,@.BG
M/X!J(,@RV 97A77I$CXSDP2=P'.<E?'ZD11Q4=(G\I(*&9"8=1EG.[J:VW!-
MJA+2[Q?K-4G Q)#EBY><H%PRBLXA9Q.$<CH0/,'F$SSS"07/S1D%83VE(!1S
M<O7:>%ZT^L[BBU5/(Y#S",1$@M9, F4J@9R+:Y7&\Z)I-^'B\?+3_UNS[HAC
MF1VE(/>?8IIH'!(>L ?O;20)N]KJ8_%06YI%%I=6>\"EW60L%O0"D9/RT1$@
M.2:LC"DPU$^LH2M&FZ5WIPH+=5>W#DLM%Z?6K5/7 RF=9_&^88L@3("3U8AB
MTYT$8O[4)6>9"P)- /#_%D?5Y#0ZWW@*AL $^!;Y-NHI?QZ^QSM*?,WDC!#L
M$W_[=E=/ V-A5=$A77I-;Y5<)MHUD3.=!OPWBL77LLX=_>6V)-L!X,FM0O&:
M* 4#!#B"SPJ[A>V+&Q\>499QP:HRBJ3,ASP^V=38YR05?:N;--^=BT 6DN13
MEAFM 4[Z3[GRID*;G\SK4UL%Y2JS4IRSO.-%3/$BBF+H$B9#H1[T9ZZF.P72
MPPR78[S7KP[65A9U0CB0&2VJ>AS%&9/A@"@5X%5P$4R[_7AB_D'__%BI9(]>
MHS!<,LI/3=_ "_?Y9"Z9U9$6/,9;(&I<\<K/;@$B*Y,SOX1IM8%:29"(B9@#
MPS#M$0\.:G'RD?#(2IEVJX[&H 9<Y7VZY#B1S/)2G"JS?)A &X?!2YPCK\V\
M+LJS]0,;OZ^#2TK&B0^KU+C80MS_J:D/XQ2V1)"1RFG"A(]%TO(KU)4JZI4B
MVDJM]97"#O0W"#"!PM<NO;S2#$WW]2*-X#]@VGL+$SQ-(N&SUE=/-;C#N8&4
M)?R',H26%UL/<X:<:A9WP2[>%\3,;B>/BWRM<17F:S$9^L\#\^$M_A6  \FN
M_,0^ N\.6TYU[U-IDBY9<47_N<Q7V7LJES/K;(;K\Z^33QQO_=5[MGK-JH(N
M\>J=KNM>&)%8# 8W3X&IA?E0599.(N"368Y$S4,D&=YM"94E40]IL=;=W!,C
M[0CW?M":*G:ORND8]#PM17VD/G]@E#WJ<LRZ8SYZ[7:>O^(]*=DJ@R]1JJBK
M3(F#>LV2B%Z(4-=F;?IP1Y+PS+#A>2A$=+*)NZ[VWK_=.\_ZA#HF>9;2?ZZ9
M(7*97[V"V>,V55O$]/SL$A9)8/Z2 PAZ7HR6Q-?Q36UMY[(UE1*U/[1?O1[-
M9_,T</@9):SWF(?@4&_/;%[3.Z\HX[6&;F[BR-C0]^2;H=>8'MQU:KI[^-YR
M'96YZ+6&OQ3&W=:GHT^9D>FU]/4$58?_^RG;E%0$)!:1^' 7SU_+#'O%$4%9
MN)3I6_7HYOU)+M&&E6=O<022^M<"*JK>Q&E(G\KT90%R+<O_[SAIQU/Q??K&
MQ*&"[[FF:LYU#-RG$0C_QI/K>E"?I_Z>_MY5(.4:GOTG4(FBO](S04_$ZI7D
M)-R4AOM@"#&/JM6"3BZ""=XDX4M3G])^]+S]K\)=7(8)7D117(**0#4BP'2)
M+JOR/BO_2LJ',(Y,N[AO7]\GO U!S[(/C2?3UMCGB:I=K3<AF!%*@\#6V="S
M$"!TZ=\P*;BT/_W&AIZW3R<JN&D+=7;P^27:^=)W(JRL]3$ZVOIDH5:PEOE+
MF'( ]2OZ"E(1*F*O:!H]  !L*APJ7/8($TR(PU>C9488G;C713I48!P>U.5&
M.6^VZ@9*7>#V:KD8Q?-9;Z/J-9&P:@<>8&*9CO^Q-#RS?$?HM43T.TM8+?9?
M4U%ODT2?/]:T*?-&FO@^B=#,+&^-=)<^!CA3AHRO<X_((M>]44S:1_I( KX%
M.W'E6JW">HM9"1+R:("&PS 4#PL3ADZ^]0>[:;W^$_T,:00%-+[NZ#-*;K>B
M!"5SEQEUBQ'H>A79F?U7B__AUI[V4]K5>%:;5@0X'=ZIHJ7W*Z)#2+%ZVX^Q
MMAXBY7,3 F#F.GM)(21W%7[PY(]"@!D6 LNP>"1%E<"W Z&%'K0L9\S13@\9
M<_FV=^VHU'T;/YOXWT_DQ;K3K8U]GU7(?:Q?!L7W9/?O'.KC72!7I0YVUI95
M"2@&H)Z:Y>_.+EX%M*%A_CRX7]$G,!B?_G=#XA(,[>T(CFE']KF\JN8E%-";
M#)"7EJDH==-:F3Z=O)K/C)&"]"\*0#(O)@<?MR@A4J5]69]&QK=P6=L.N*V9
M;4-PIN5OF/AY4X'=67PXHR1Y+!&?;H,JBDLZGSC?WK;"L+0?_9JC_U;Q+;/*
M:I,SF/IO4[[&OT+40/J"X<Q]+4HCT?6\:67DGZST;O<VV-K.+<!"5A>_"O-\
MO\ER+(?8*]+"W-4S@U85\L>__/ _?OC1+B[UZNB)N2(OX36+JG6YS)_HW1:O
M$71;Y</6QJM45)5Y)J&HZ)&P6:?,[;Y%@4[>:Y,+=*V1?2ZON$R$'(9E"NF'
MQZP5:1L2E4BH,,,-*59#RU""?J5;LJE2.D_N'"TP)5Z8H0UR;5=SGXS<T7G0
MQ6P S+48,#?S[3#@=A[NRE+4Y2N[#?=@I]DZ"YG]OT!/IZY7\UUUG%?P(#F?
M"T&_#EBKH.I!4=*S4O*I?4WCLF#S;W';H\\,W7M%IX.KN\=,SI\B[]N%-6MC
MWW8Z;6T;6"J/!!0 \>.*Y-L?#EO;#]/PO0WK.X^^JFIB#<-P,V[$ WWFHR0I
M,X45U^-F#JE)W9U]VU]Y\1Z["JNW\.WN@2OW^;!4_'PTY.'BA<HA *YWF]*+
M/BWB-8;A@CF"&(,C/4WE&PC.NK,&I8T]P%R2IFK#UW(CQ'73GNKL,$,CM6I/
M[FN15OOX-C^?$(.PB+*=Y4880,Y[DC 8*O-=EN.API/$$\*NLDC3/7MVF86-
M5MX(70DMEJ:^'[J6-/1(0+5BLN[3CLH3UAB&[FZ^9>,A%[N".-ZEX8P]AF\9
M30TXQ?@36PB+N:7OK8PQLC@=D".7&Z7H7T>>QL%>\]%X.DQ#,[,%8?SGU=
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MJ]G:G+>IC6_!5Z;+FB')Y!V,JK>(FZ*R?)W=6!35=L>1&OM7PAM]N+G$HL@
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M'Q 9PN)Z+,D-UI;^S[$H =JG>/11E0?'HNW[CI 6.>L,>R1]=/?US>*8]Y$
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M$_P</_S;CU_NXFW,?"QM0=G4RON7H\L+R"NWVUV>O3%'D%T][6@^)T-EK5A
MK5JH]HIX\PH.G-6>, :]>3T;O6#=#_7QKYJU*G09:T!8M+1^G3W*N7?9FL[F
M-4M)6[PS_3Y+BY!>DF51WA HN(P>YJK,\KW6N+^IZ"BROC%\S<C6)F8M3><2
M(RR\<1CP&RW31T 9AE."*!W=>$1'TO#Y=*.3S516RV)'/]#>M_8IDU":15IA
MQ=?@NH<ZK[#A^E<4.HJ4[P4X5056;5$,P\%8^G1,^N>Z5)UZZ'"J\P U:N2Q
M]JG8U*_GN7[U-G"K.T-4:Q#O6E);)[TFQ3J/=TU-KV<7WQA##TN[DB=_]+U5
MJ^V6:B3+C13P=*RFSM>K9]\9;JS/'W%1TFD240MRE7W^H'\P8NT=1<#W]QQX
M*[#X! &Q9'7*.1C&=[@PR)Q*,B<8/NV0P/;6OK]_"^7W/BM9 ,K3CLZUSOY_
MA$]FEK^.I.&UG)FIE/A-EA^#M7T"#=]/"UZX,JH<#!?=2(B='>95CD[$;#X2
M=/>SDY:E+P#8TI7%?3(E_V8W<WQ#EZ_B8"??EF(T2G3?H<TV7@&LZ 67@K$2
M L*D]DCU# 1'SG@L_J_A>DTUJ%7VD$,)G_(VW3!W0WLW#B7H^QEQEO@H,8D=
M:#;'#CZ'13[D-)B;EZ!]S?*$@T:LO;AP[7!HIU'R_<T.U !7=FEAVZ8]X&T&
M$C\_F);6!7H:F3E8N0T)7-UU1H[O/3_TBQ' /V8(]^$@9]&=06\N(60L#J,J
M\PR/))^I+67"W,ZCE_@Z6Z/P4-<?O*%_T5ZPCF9S*^K(C%*@PX+Z6NZO&U[A
MHSK.C3FJV)'W,%FV#,3]>LS0+FD*PH*]M7K/AL1Q<1*^ QI,/DYCB(*IH>\@
MR]HT=!U#=F0:R?E1"3:A_SE4S=G:SVLBV'NV>LVJ@CX<JW>Z7?9"B>(E6<'"
M8+F[^W>=A36B,S56:S$[%:M=@:Z?0M7N-[><;]6&3LREQ+N[S,EJQ$K[EI X
MC8+90:M0L\.YBKG] 42G0G?H''U>!F]Q2,E+F#R1LDQ(,P7RJ([>S=DJ_(1N
MN^FHL=FCVQP.!T_!1(09\8K;K7:&QMZ_CL5O<+GOJA'8HYMO8;I^%*"<V5&5
M4?OV]:K^A,]RT2WB6+O)7#=;CSBOOGV]VCC"]"K,D\P*!Z'_[AU!&?R><<H<
MOV8S0+N1;\F=2DL1A,!2=>() IN9V-<),'*HCW_IG@5++:KR-0/3BNW6-;?T
M/'WI0FO$9W/L$Y82N#\<^GP*'?_WV28N[^PX!?S7>:4F]<OW/-C)]T6@2H*'
M-?E&0Y]7;R>DG[TFX+%]?9O'DK HEAN. KK,,4Q* V24/Q;\U\(8?'82(:]%
M:V3>8E\KP,$>OC4=Z89NV5[H1E2DY6,27(XB-9?\+*440R'_^$M,<CB4>[L(
M<A2!&3(KZTX<QV*CFV<S"S-"-['7 '!#%$\OEN\IB\V2%0AYN(T:"6JRQ(Q%
M>VX>-9/S:+$I2<X<G)5!ZSR%RCS1(>ZZ<JX.]?$./#:\*(:P,-ZFG:4X)AK2
MOZ<"X$)YQC"8(2"Y)8^?*[0O7^[Y0;=AT?;K[#'.X2I[([E)DF[].,]T;ZD=
M/Q J27'CG0!S[@#A'T#.TT(4>0G:952M46IZ(OD;%8.+]MO<V=#[G:L"# !F
MH?$S?/Y8)Q76JT!4-'"5 VXO_0,D6(5;.%: 0D#**D^+QRQ);AB*FOG.=CNF
M;SG=69PT RD3Z5FC.NN.''L^;H4>M@=[:X\WQY?P WR>;1MUZ\<Y;.=3("Y/
M+;8D39#6#>YE-G-(A 2><_)*V99 ,75D[B]9 K>E L@KK>R+/"[H3]>8*L=.
M\#V4Z&U$ ;L>RZ<P+HQ3!Y 2#[7U;>8GI:D20(T#*+'_C,;]WKU]&S_HBQX#
M1#OB&G[ OSJ0V>RM?5^=TLQF=GXQ"8=$@,X%QZT2%8J:D98]4E/&&,'W<M68
M<NKMP512Q:@C,#(L+\315+Q['F4U4;2RQYL8SB:JII#>'"9JL/=AX^X0>K[/
MO;!>WJ9TJQ9WX%SYJ>/@VYO[WLKR7*IB"B D4AVE+8$K"62+).%9X+9T,\19
MO,00C&,L_1-.Q+=E L#W/],7;4OWMQE_3FOAWZ2%+AAIZC@03]S5WO>V[[I[
MV=]AVW$#R-&W=XO"7*XKQ=GR6UR^?DVS9RAI!8>"74VZR4/' D2_&]JN-U H
MHJ*R,KO)^OIW1AQRGOL'&1XJ -B)^&::O,!7?"2[+#\*=*U71]^6&@[LH0@E
M1A--NYG7# (5-M<$EXL:K5K?!6,%B@(-"0 /62 0G@& 8BS*_H.NS(&@]&G=
M5,E=O#'J*SVZ>?7826GIGHHW #Z$OB]1M(<%A.#NY'['5?88OE-QFGZZ,.D(
MO!B?NN^G+\M)_$)%0+H7<T-]O*YVOO,=>R MRXHP1Y3ULE'P'0)6AS7P($X6
MMOJ/@XF1S>8>O:)45@%[X]-^^YPEZK1;/_I^S!L5T3NR-RQ-_09%;IF'35$I
MY%WT.<R3O12:+!71CJ;@VZRNYZ%#W")]?@L&W[W8@F#%2HIWN*Z/I>'[Z2;Y
M)LNW\/ZP3]!1M-C<U#M,<<)F1(B$S+,=,EM;_Y=RT[G2Y9#I:#X3X\45W1XO
MI.BAM73W\!HRS!(WS='='9P=W=GW&^6Z7ONHD0E]!_6Y<T3TG/X2M/:(N9GO
MYT#12 TE7%4ES:+1]>WN.U>%@=,7=',A6%D'!*:QI>_I*Y&8L-#7Y+E4O.[K
M=;6M4,YJ ':!?]Z(^34J8>\^M&86/L8PR(-V#-RAJ:?O,TJ/$F1*6A/!E=]]
M/R[2R&$KW'>YUWXY[-H^@I#?2G@YG)<><(BVQ.0C"?ADEJ=(*>^W*0+O0%/?
MI\KV4($J;D^QZ='-YY<Y ,S#;FP0J)@ EB39.VA(K<]V(AW_BI4P7]%;89DC
MMCKS_70!@_3HYM'Z]1D+/?]&DN0_TNP]?:+O5):RPHOM<GF=C;TBE&;;9_:D
MTAD^QUD9KZFV% ,X9GE);P.P<E_&V8XN]C9<DXK^'B94_" )/,59OGBA$G\'
MT,;(]#VGR3&[LA*!V'PG.QOZ/X5->T5OKV;?OK[E'&>1]GH1EE%UZ2/'/M<E
M9K9*X5>#@)%6QK>K,?R;XQH9;O7%<->51]FKX]SW@Q5]W;B[?R-@J2?1@LK8
MX0O1P Q.VBKC#3_WA3Z415I#*?1Q.3H<SJ\S[: >9S<G']/9J^43(AF*5Y%1
M7I=GZE/AZ9C.OJUOP\+K60JCT?HV!F'?XIZQ<( TW-<OB5'>Z]NY9O+_^=>:
M1_HX_?&__@_Q%_H_D/GUO_Y_4$L#!!0    ( #""6U8.9^:83&(  &?:!P 5
M    <&-V>"TR,#(R,3(S,5]P<F4N>&UL[7U9=^0VLN;[_(H:S\O,F;'+5>[%
M[G/[SDEM;MVK4NJD4O;M>:E#D4@EVTPRS452^M</ )*97+"2( $B^=!NE02
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M1>R&(+74*UGS16GMJIB("J:)OM%Y$[Y>Z>TU3'Z%4MB&P+MVXA#RB:1RS*[
MQG=]VBH$.FI93K6H./<^HC;7I)M0ZNTQU!1:#PT+*-.@K^"$+N'_^RG['-#;
M&V%D$S:N:9.\<LXG)G2UVFJ7>8]Z'9M*.)VT74I<V$U G&?6ZV@--,,**&S]
MTT<D3-+0]A9W8F7B3SKHF:X^_5.+XJW.ML=K\?>7*CC$YP[+$2(_I+5)IF6^
MMQP7V4>9*F*L5P_+86,^P%4Q$GQ:L1PN_OM8[2127FXL!ZGK72=^A L /UD+
MH SW:C^T60X/_PID/^A9#D^?FU#@&=%R](0O1/(CI>7HR-U_ H^BEN,E=_I$
MWET+P#Y;"AB?MW-><RW'IQ=S9SPA6PZ;,%<7>J>V'"PQ)B_P7FXY3I+,7?9I
MOD#O!TO1XW-ZXAN_Y:@H,F,-A%,$I1$S<!)FZ&36;2LLTO8IFC>%Y<=,[F")
M.&Z42>$M!8S/K>GN()9#TX=E,QU1S@<W 5[%\'BQ'"<YBB(Y'I2)?RV]] 1L
M!F07GD%P,8=P^C F@=>7,X!-@"_Q'*TL!TO4'8%P[/YB*3M2I,)1G,C.!SR!
MP\?07&P%2/3 G7),#0F$(8D='C!L6Y#Z+EI3@<F<Y6%TM_0,K*/BM0_N"=^!
ME-%!>_H$.)]EC)'VL%_% XAQHC_*4@0[:U]6GJQPD:5;R!/^ ,VJ?(*=#%D&
M+O<BLX2B@R'3I]?:%>VE-[!?\HB(]-2[(,'#P>IAP@*8QX+6VH2)\P^$>.GI
M"7D^LN[-V5E4P/>?SHBL=S!2 5^;[5G_=*\.MI+96O]DI@XR4JIL>\WWW7 3
M$K,LMRXJP([*VM0:B"S$K,'7U-J1+,2+Q-1^'!(T?<:WXP_)<E,\@$3A9-*K
MYLYVQS5P;&VTUCJ#^DL72\[4Z>WUI L!\%2B(,(K\ J"" ?D%#.C+(#=1U<N
MB'MX+DID<^HHW84YVR'66<.R<,5@D'!VH]E*YPDX.<SR:+_24F&:L-\S/V[X
M/>-0!$J6,'IS+;M=^M/FV)3[2MUV2G,-4_\9A'!; \@/%M[.#WUT9%"=:S;A
M\GHIHXN?8Z=$B40'U3]K .\>I-QC4V]CPATG>K?IF.P7)_X-I"BVNZC)X8-D
M!9P *1H_.W[( %JHJXY$IH6/:ZEC7CB)[U+60&ZK@RT4@"W#1R< RTTM_O<8
M_$OC#F*=#=B+*S_(4JI=G]9:P\1OHACX+V%NPW8/N-03O/>@(E""?0$VL T]
M!:7,"!H6^"M MS?P%J^0"[T41?&6FY8BR#H]<F,HNZ,N<<V@V_#&\6-L35IN
M5L #8(=35$3PLH]3'_Y8M]N1KK..(YFS7<4)$7UZDAW%./VDDUZBW4##4=>)
MSIAM!=GR9S2N:: 1JL%2Q6V'2DJ'K^+64I.5(O53CE0(7G"R!".PZG+VJCK&
M(*^OYCAC"ITZOL7 \C?J/@>.9JFP'#*9<R>(KN4O^E(7(->,9#M8TB>R;=ZR
M'"*)$]BPJUD>8BYUT C6/-OAZ7S9B1D3+?<RDCAV%$NEY>Y$W>E+U$AJ.8 ]
M*.QH?[7<[:H[C4D9?BU'48+0),W)EGNP=91.NQJV+4>S/QG2S>26NP9VYX,\
M.[S=L;ED]\!)!NGJ\A6D/-XQ+?>U$*)FO1GI[KH/GP#?DH=DC*<-,\Y=+;UD
MU0_%]!,GDASS(8HQ):9I[#]G6&=>1SE_$?'!5#"ZKK==PM2?PKBP$OPC"M"]
M7%'TCH:$1>PG\$]7^-T!ZC-^Y/%<,(;[GI::<T<O_WP5.-U::VWB>1>$1IF=
M_,B3)&#&*4G+ZJ'[IE+,L5IRY#!GWO)7_HX'GF_7GP&3IE;I@V#YZZX"J)D<
M=)"G.2.U2P$##S&/6J/>LNDR\7'):[14GG"2-](I9%T&#KR*-CG^[SY-#J&W
MUS%Y_"B"IW#O[."/%>/U5;2#]RMM%?R..H)\'I9? ++?T4P5Q[_KE<;Y^1'I
M,CBCKXY%9<^)[_E.?*A0!(OZJ>UU2.25$\BD=D)#9=:M1RBC0K%5@*D32;O;
M&#K)/R=:=)='(;K01'@EL8^.X)3Z/)A$0VZK$WEXO8-;^",7[E-#+=,5K")N
M1MWP2DH$YMW3;J>,A>1.-,L-/.=0Z:6S"6([Q8SL0@$CDQA#PX:O 3S1,;S!
M<IH3#:3A=M-11)Y<>X])Q^P^ZJ+-T_46B!(VO;%BZKY40-T28^BG[K+2]6*'
MBCJ3#!ABY"XPCI;T'/4:-TS"IS161V%9&D=%ZJL#NH49A$1IJIC:KQ10N\08
M.F0-0>9M!K?F%]-C<V[A_LKHJ,D%, 4D\/9 GIA5$BB*>+>I2'*$\6>>DT:O
MJ1=#Z)*U\YQGU1>3?$+5"5?.[NFMA267=Q]4'1,3G\=1-/\5WE-.ZU+K/=SX
M:ZI3F(IED4=4)_!Y_\J*@I?KB")D%A\]%ISY%9(,@!(?42;L,YXY1Q&SM7OP
MAO\B>>(:?<U95$Y<'5?5[&S.LC#>9?WW7#S+8G?K) "%&W38._I8YBPZWP[J
M3#MM+F,TA5Z% 2I>A9[3RAJ.^'-/H9\F5'%$H-<X,Z2+'2+=]"N6?=A=IZ&&
MD@P[L;@> YES\C' ^&]+_+Z>7+^#V/43:K(F^7',66R^#0I6RQK(G.7B/<E_
M?1/%4)5_]=U.XD=[#',664WYW'F5M$'&$?G1[U%)L)K64;A_KZ-K)PX.1_*J
MTIRT)M#Y0Q8X#7/<- ?[W*BZU2]06H!36&[DB$;5T%I>/_A3Q\3_#,4I[*L&
M=Q?[2:T O+$3J"L6ISW?MQ5PHY<0CT*2'T?[[.R K?QA^>OGOYH@,RMZ:OSZ
M^4<#5C/>T]+7SS]-ZG'AZP_?F^.N6_.^K%?+ICH^VNXU+NPU6<OK=7).' *?
M5Q _1\8@)./K2"2J@NQLIR2>^V0-&P&R&P*OP BHZ,Z:QZA8>5=*V\E+Q.>R
MEOR%[-]X+C#17/AK02@$.CP7?.Z:#J1UUMT6KX< 9I];)5(G3LV A^D43*F>
M=6X,B"]%DEF4[4%Q4I(DP]G7<IR$+W\9]V/+,1/CVGP3PQ P39>'<URFSX6F
MZ/R<KM$,$:%KAF[2@8TS_-LM3S(LS,MEG.TMQZP3+Q<QL Z!VW29.RT>X%RH
MBR^E5^C/\J3,'7@Z-8+#<JB$.;I,0(GEF G:5*CBN%)<ILNQ)6)BSIJ@.D7C
M6)X4725BI3NNY>F])2S!/:**+$].+4!WO4*7+$]0K1(^2I14@>"/YXM@OVBL
M K^?SA(_R8"NTF)H_1-0]RN#@);U!M;.I,6(/RO!L]Z.T9W46'%L)7QGK$&(
M!,V5,*E1&TPL$-L7J(:R\.F\M85N@8$E=F>L)'0,1"R1.T_]H$=,8PG<>:H%
M?>(C2^1FA4 BU+)\=)H5 YG0S1(UI0J"F;[U'>T?W4-&2VS/6W\8+KJTQ/>,
M%0QED:HEEN?Y>#%>B&N)\WGK,.2J*9_/4SEAA]$>P5&J?^0OV-?A)"P$,G&Z
M1[B4:ATVP"46]WO$3ZGN,4G\B''&1[>( 6)TZOA843QGDO5<YTHZ(TQ^KJ0S
M/J',E73F2CKGEZ)_KJ1S'I5T)/-/(IO>992D4KDF3YWFTCFZ2^?87VY!R!QU
MLEVSJ%K)D,;H;7.2I38V<Y(E4>J9DRS-299&CN3J$)MK+7G-29;F)$M:';XJ
M,I+E(,VIEN942W.J)3-$@ [!W+9BIM 9@ZK]G@N$<V:A::3F,.,Y]]))MC=!
M])8\A4X&3]2I&HOIC[+W($63?XBC5Q_.X.+PE, S'][X(3STR*T!WDRON<\@
M^T6KPT#*#)=%GA.\$9A_W>&HE^? ?W$*1[RVI9+?2<>#9^C&:!I7(/__VW"Y
M![&#' W+ %?^5D@.8L0RX86]AS?05<$+KM^1"R!8A'D^C462 *KMM>-@>E^,
MCQQ#_*&XW45/B0W2,3\26%]^P1I(RW/X?A]@_)V@Q/\VW$3Q+K]^.9LGV%O+
M"80W*4A2)/;!K: >K7HK#1.%!++Q4T9!ETH#<\[#+=1$$A7G@360CMTH+DVH
M.;A0?8^AHA7!$YL>4'!R"CDL4NKWJ EMM\0'T/TRB+S,H>@2@)I;]3I2P_\&
M^90&R*X E&U='S,T^', ,&<+O<4N@JKX'_CW% B$NNIP""A8]3W<$_CCZ0B&
M'D&<O?(3-XB2+ :<'>\]K!8HL&B,)2BHUV0H<"MT,R15763I?93^$^#+@;ID
MP>[J5($X<@'PDANHO]ZB$!$G>,B@3.^6]C,<Y_0$M:WX#26*B1-DH_43E(@G
M@3N!8$>.W&250=G@1LC<6!H^L1,Y&9O8V80;:?'J^ $R4Z" 3*>:TNL*/ M?
M2YQ1=-7QNF@&2-$D3W)C9<>,&+T)H2K0\[XX8;:!/ L'&*[\ERWY0'499AA6
M09H(/+%0D[S)D&FFR#*%&]]$ 63CR[ \]0D^]ESGMT&_IVYG&<8#].^*!8&X
MHQ+=S1'7"3)5;[55D[)T)+$O3EIP+&P.R?D;)+%+)PB2Y8;.X.AZEH*QE=$I
ME*+P1A0?/S$-0=8CU5^+5^HI/V#.'7" 6?'&!;Q/5"]57C_-=$ED?0(T1^YG
MA""U<'.Q#A(3([2)W\\<ADA02'K;_7437OY>UTT\E!U&&9N[W#KA"R25&\>/
M<:R[4.P@<BIPM[R[6MG8NJHHYR_4-$Y8:V(,TQ- 6(H9BHPWH' (65B<,542
MB8XZ H"@3.U":?KZW<6G8>6D8(DE _0_9(Q\A:<;\NA3!CWT!RCKU']1:4G9
MOB&^9 1'E38!2XR@88&G?#E7?K*/$NP? QD^MG#0> VGD[(#6#YIEJH@5O[@
MX0HR#]VZ#8$"V5+S8U8\@1*O@=YCZJ9"<K8W/NT1^PW/*VL*!FMC)$?09"GO
MS+WR7#[M12+"P^LZ\<F<=S+LZB-.PAPAG? VV/MQ4<NK&^*2M[L]%$.Q9_[6
MB5^H2Z$T'L\J*)2CKH/U3V1<4[1=Q(3HRH54UZEQK2&8D X0ZF99;.=:;B!;
MP.>K^@);W"^4=4L/8X*P4&12%Y,0\L;#BP5WX,4)'D&:YAY#4@)!L^]\J-+D
MZU^UW&5P0W(_A@KM+S?'E]_\C6?G9[LDOWUWC/5W'$P9K8KDV6]3J4"O 4]3
MJ<VL %8E\3/U712^K$&\DWZ[$AU,MW]^=R_N8S2-@ ^UTM U$RLJ=/.^K@7^
M=W1LMAY:$=?G1BI3:3\[VT,KY7R1ZV39\/:U'*KN7NI5U*JNQ^<)F( ;<PTP
M">]@ZSG>D+[$5=#%'' MIU]5+KNUX'UAWU?+P54A7:ISR[4\ GD(&93LZ*L4
M2!,YL"*9DWD)6DZ-:@2I8:["\X2^KTC&\W^RGBN,)9?1_/4M)UN5DECW4 /+
M058MD2F/?A@B%8I!^'<7TN1C+)1":2)#5B2F,8G?<GI4(Z;)!,<, FB$GAU,
M!E16^%(3CF,Y\0XMD'4(%[(<\4&L9?QX)<M1[2>4281*C9%7;9+"E42$EN48
M#B=3#02=S5>_6."9Y10YRBVO+EI.Z6Z8J'4-(0/4@_(L)^@AKWNA(,$"7UM+
M2RNWL1!#%2T'458.&"0<TG*,AQ(8^,XSMB(ZUA,-+]13*<RV"P&*XE,M)VWU
M4@,E_+7 \<^6XCB4=$ )SK4<35DQ8>RXWT'@M\WD(!,E;#F@8PD0M,AER]G%
M&.X'0F'6!<Y_L13G@2SAK>AMRV$<]78;!LT]OC/A0N+4#$S'XK#R8>J6$_-
M"D01$E^ ]U=+P1M*:VC%[EN.XZ@<]>M?A\$SYZG7H2&VF-%DUHX9"I1N@8G&
M, 52K4C"A +''ZW%43F3%4[IH!3:Z7-=X8!QRW$;B[/*$K[EL'<1$OH]1A2
M_F15P='30M'+M1,>EO&+$Q;W-L3F'CD6PROG(DO\$)S*I)E>>;2ZC,LH3*+
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M*H["!D++\1*R)M9*39$M=^<"$\WT5RL'1Z!!R_%AVG,;I?*:9DC+H5&>6'P
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MW75)B\]\H>Z9J%+\ BGX6!CFM%*6 *G\6VI#:KK(M^WI/?KO7Z(PW2;P@,3
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M4C*&[0E5-[3>N\*PC3#9PV+,AZL5_,]7P=>KZR3U=XBB;AP_QB]Z\'=5];*
M;F+O5_/3RID^K21Q6@$&_NL$"OS'UQ6:#L&^7?_;F),A/F$V_SK2A+[XH;_+
M=M0IU?\^):/DD;LMDB3;%1X-H?<%0+')BX+HY< Y^V-\>>J EMD.?HD@/_0#
M>.FL(%\< U#*EZ<$Z(3>:WE<Q'EG<Y':WZ>T1^*D5W!*?;1?3L!2>',2T@AO
M,0%;X+WR7WT/"NMC,^S:=Z<4)<A:5)$,BX[B,!^<.BVN_.2WFQ@@!U, ]<IT
M9#[*^KR5T(['0UF?UVW#.KNW9 />-8B:.(*PI17;#D!=2"XA:.CAUM>&'U&M
M5V)HEE%^+:5@0Y\ 9 C"]IT9XM&XP;DMA9#'GNL&#MN=#ZQESD?EPO8=/$?W
M$9/PM_<$E3KD7(A],CM8-_7-1=H'V[B!S(ISY7;CCQK3DFEYGA!K]Z]QU5F3
M#KZOMUCN_CAG/YBS'\PN>K.+WNRB-^R$9A>]V45O=M&;7?34"SO#9?V8O0AG
M+T(CX9V]"&<OPMF+T'XO0ET^;E:".;MDSBZ9<SHDDTSNLPOK[,)JG(_4[,(Z
MN6>OV85U=F$U:V>FG<K,("1-R&=F !RS8^]97%FS8Z]R%W]K(;3W$)R+;^Y$
MO-NMQ=^B$S3[1L^^T?..#7K4R.\SLU/T)#>N*6C;6E+1VOUKR(B#%EHTU:D=
M/QNU4$8W2YB V7.]D^?Z393%*0 A ?@%>K9KON )-NOE":]G3K-G_>Q9;V!=
M04C7T0X2+=P[-)D[]!$T9[H3**N'.0M@,CYVGREYE+2>GJQP15X$>%S@D:=?
M7,F4)0MVUK"L%106H*RYA=?'%7@%0;1'<!<3(EY=,CW/R&5<8HH_@Q#$3@"!
M6W@[J*6@:PA=XR*HB_75K9.(>TEI$L8L?4.<O:[T8R\@O52!Y<@*EH,UC'^+
MZ%UMO>>7D"!:14Y('+"=)F?/GMFSQXC3*"@HVNX&,>1Y9-[6,[#V>R>,:?D_
MB>4KD/HQA@&K,,>*B;?A)HIW.5N8EG6_OJ(U_!)# Z<TUF+_:,Z$::6C-M=A
MZ8"'"E(!?C"Z AMX;+P+>&%L_)1I0>!VT["4&HL(O1/*IQ/#>0*0&4&KO;\.
M>;X+QRDF8C9]D3%TO.VTIG6:%<\H+-;7B$5=1F$:^\\9?KF^*&U-M.,FWE^W
M.,#FX'4MD<8T[:TUSKLH:GH-ES-;KNETX.=D8Z,0M[27Z#I=&^R3.ISAP0S(
MI"ZA*E02C-[RT]N;Z@3W8 CU.M"CV35\NFZRT//#EXJV:X.*]Y@])^#W#!F$
M7^%_N,H2O;T.";P^&::*1&ZKS!>M31TTZ9C;7/6<'G!Y^.4FM^U$Q1O 4^B_
M0O;D!+\XK@N_O8X>8H"0@;0,7,P>&1/O/J8&,D%$"J=:.;AT*P:YK0[?E(JA
M#HI;]Y#-G'ZSAC\E3HXHD^IE1YESKA*G,SRW(!D)F$TM28M( 0AY,ZR OWO.
MH 2%%@W9-^8UBY<8X%_077"%^^J_L3@F55KK >F08I+CM58VH]L0BE1.4'P*
MZIP[/TVAV'G .TB:%:>')7F2J>=D]PR%2K@I8>H_^U'JNRN0^$GJA.D%W!AX
M33L7?K3?.E \=0%4>UPG6+@N"$",/B)TG-1^0C7Q-G=\\0KE;\0BG_90NX(J
M$91 T.>1YG/T?OCB!R!)HQ"PA)R^(RM;Z4G1D#@7_$XZW"0AZTB3%7"!_\HP
MB[>:*8/R(4J1FZ$4DMP^@\V.+&;+2>R]QQQL=8M=E*'3HW)UTF,J6QVFV=SU
M@#31ZI^U&X-X2G_-<$M6LBVUEXDJ\T>_Y_Y*MJ5("FG?-0]/68W74N#./M6C
MB(I<)1P*A5F*3J><8K:!T--*=N3>XG8&RX'D&"88 H'=K@*"9I*F.-!F6Y;2
MC[2\Q#/P6.J?*WJGG4<VO$[)G)6"8%1(3_];3+$5T%*RZZK<]38Q6IJ23U90
MIPH90^!CI-Q )S4!&Z^E^0%%J8@/Z7D!1*0ENJ'=TER%T@>-_P)@:7+ WDC)
MOT98FJ:O-Y+R+Q]C),R; I*U5Y8"E!]MB25L>)S>@_0N2A)X['!4Y<F%%[GB
M9_D7EYL+)_%=%-OO!QGD8HU.$W-'O7;B$)+"<?J<"#%J<PU/VQ#XG"X1_$<-
M81VA^R4*<=::;11 @DWPCE%6)#N*AH7^"OR7+:2T!=2AG1=PGR&=L8@W3I99
MBM1.=)Y9RY0;PYQ%%H>L-4^Y95)'T;#0YA%B[1JYK0&3+@ 5G';96K?9A\?L
MJO*\-'>QU-[<!3M)AF6I\4LA<G0N:*FAJPMV%,9JJ8U"!4)'+CZ&J<)$N?ZH
M)@8'C(7_"AZ!FT$ ?)!<O[M!!J7R&XAW30$@"_Z+-(]SI%T3LV(P?IX(]#SC
MB6]L<Q%BB224?$1'OI# 29(B.SXS!)'04)D3YR.((5B+%?  V"$D+J,0WGVI
M#W]\*/D-_C+=85YZ#!W19?V(Y.) 'H 1RS+D%XT!D%L*@=M-!W\J$Z55#Q8K
M*HG:WL2,YM0L9[GM%3U!AIY0&8M!/J4G/3@4#5 5*[QS3Z&?)JO')UYB<$8?
M8\Z?,#MI&9C5<JN['L'<NJ')WR:&P:486P<HQR/(N*)J;728M:HISI=8T6&>
M2GI[Q0+1A0*!2&(,9;/O4,!'?7T=>NAFJ9+]BMV]V#&8Y+:*]_E2P3Y+C*%L
M]@*?Y&(L/<:43"VJ=5#+K<MT7?3X$"VO*5J.V0@J92U:C*N 68XW5VVKHD4B
M:-OQ&5 S;)178*E3EJ.L6@_C'W%I1<;V'2!I-E)9VSL=!/M"O61->[6G++KF
M9CGY#?.Z4:-?^D5G.;;"8JB,?FZY>\/0U[Z87<%RD&58),?883E2P[/'0?4N
MRW='F,'*&,8L]X&2/OORQCG+$1R!)]1U OO"*R?#7N_&C4[4Z-66NR>OG7>
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M@9Q[$"-%SJVN0\\,P7X% I21X0$RS\,Z=L+$P6]75@1WT=9V<:C^A>'\+3&
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M)=DXF8%/EL#O.R0='?9NZG4\BB"\8SHW7O';>-6PJ336L9@OX2H32:;T$CD
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M+>^),EH^.A%N(41:!L:AWQ6R"_>XO%\+4,N'BH;(HUGUI]O7MEZX\\@UW!T
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MY/LS"4Q(?XQY(_CW#Q\&^SV%GX\$QKY #G!H]\1/&RH46/NJ0EW3BBI2EBK
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MD/<:#(TT*\6O:79-Y1L>JLI6%B^J<:(C$6<(CKM2 -TNO\TB[&?H2G5MV>U
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M(.03L9%O;PZ,6^_U'<3&89:8CV ;02O7CZM<NF=.?:X;Y4M48WAV<)7+"W=
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MY=E2)D:FX%N;W4MUOTI9\*^5%(1.."=;7G/LZ@5N7FJ_%F7=NI70>BD;K:[
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MJ+@[,2',(KCZ!Y#4?JMB&@DS'V%123A1O6>6/@R_@[^GN9PSHNNZ[L6[+>Q
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MWL(3\?Y ZMJ6D2OE[L=%:_JP&1Z$$@6)F_+-(KV_7C6;-TW27AO" 4+4>T(
M1W5O[]X(CFAJ?=&HYGY13$>U6CG8.WP@8*-:J1]]?"CPXZBR7SMX<*+]6O6!
M,:\U3_T8!M771IEL]_UR"34'"AH@H!)0":@$5 (J 96 2D EH&XA4)\420^@
MA@6[__F7^E\($?+L"]QPE;Q!K_NE\7?6[C2)3VP)GR#Z)_J/LTB[G7\TV.7@
M[)TZ>[\=#AW"R(=:Z]8.#HSX?]7=[46Y#5^IG,Y>NP<AH5&91%,9<" AMD)
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MML LUD]U#QFF:M-%S#0J+N>Y,3YB.YV8 ^=-$WG^Y<9C,Q-)A]DX:# 6U0]
M>F.50E=H?U$<?S,&MH.HJ_I^+?M]@!E8T<5RA*.5A!X2M$^>Q2*!P-2U+]#
M5%[T%F(I0U\$'[SA$$LS"E?+[A!]B:"!VV.#">T26XR+19J>-]&+>$G2*<37
ME*I$"78A\9,:BO-XVC2_Q-EDM!G A>_A))%-\[=&':SPB*(%9!.2EP1[(JGT
M!2>L1EUNVG?"468^_C1G.JKT8V9;V15Z?DI[0<](4DX2O2N*8:JGDVXI@Q&*
MJH4*EOHU7U'JQ/V%C,S'6O9C7>TW_<T^^1=R9N/1)?&SSO/X&0X&6 %Y&$@Z
MDX?A&<J&HIV.E[&PF@E9U72_N(58X*A<,_LFN1M1VOR1@ZQ%X4U=)5(+=H /
M$EQ!]O%X1%#)<08+[, 1D3H%V@O>HP!X5Q?R3IG740PZ,MS&< BFIVY2J*IU
MKW(7H'*H[[-4O6]URZ*^!.,#6]O.*V?[GH.:&?STAV>KPMWJND:9W]+%<M=1
MW6]X'<QE"M"JU)44FMGP!T;&VQ*V(5'1U5K:!%^HPC<QUOX[%EJ*ZFE[H=0&
M^7U%P2,R4"VD ^V367U :$:">OM--5=TG,P-;#1)M/A889X'[^O8TI$8VP*F
MA)]N;6PVB1F/\06^.K#H;V5V>Z[>LVI#Z86.!9OF/D>WQDRW=U46>D;_3RJ2
M9ZN(SY5F8TT=\K0/Y)2+>SM#)&8T-A1T\?H1C(#$TP4_6B"C331&I'W'E6+L
M#0UE/FC\6M]Z@D=''7-J) 3=S=+!UI^Q(^;^CA6[%7:.R <6DQ6#W/+"6R"(
M%\T;NVV5Q:"O/N/:ZX;*D!2^GR8&8 IC7].5&-]ZUDP=L[X#QPQ%M+[B,OEW
M0I>WU\>DP8<^GF\>\O"5RRJKD? BW9M4G403>);J33F6I'J3ZOT\U?L P^+2
MJK7NS:[EMZMCB59XNW:R3K)4;M[\XH_[\]@;=5V2N/HCPE;:>_8.D3/7<S^(
M'S"Y;^,%R]23CH6+A[^'(6HP$VY;'\()*%C !^X\4\=0!5$#;*791.;!DBL/
M3QE?IUZ,-D4T4,6?Q7ZV)XE9 Z<#'55PB9DSD2YE*)W.T H/ZCH&*C@(GRA6
M1P=*Q?>$J#V553 6EHD2QWR.!*\^3X(?D00G"4X2_%D2_&@N/56@L!(Z&7$7
MRT;U[54F.?]:6X X"JA-.&#R9CTHL5\%+;Q@9$M+=S(SDG@,D'+>%"-[C55>
MB4"8(Q>]!K/Y*B);U(^4@2;&LZHJTR!7%^W[AVSO6 JO?1G>I\'2!_.ES_E(
MRJD8I0^J0&?ELO!<I4E(;\8=';6-IZ#UA;B&D K=4>J2OG>+PI-5G,#JH'4%
M((Q3B.WQR.NS&BASY\.Z,WK\$6GN.XU<,DHKRP20J.C\;)![K-1%>X^/(@E$
MMMVH$,0KHE@:3K%_2#O/O-N VZYR#B^E(>@<YSCZ&H.,XB0';N%-;^HAU$HC
M/(TWY <RU/ZN;)Q[O/_4R>D;VSB+)7):*=Q+G5N"A@KP[>'\W1BEDL0QJ<?2
M:UU_= G%I-ZJ@F06WARM^,,MJ*.J]$8"M>2KU\*G*$L\RWH0B1+TX&Y,$ M$
M%&41Z-^B)?N+A_I:ZUR=+I)0^"P54V5Y9JC7 GN8!VFMX2P9XR+&?ECX$\T'
M.QV&N/*N8Z5!MA"W@&+ >$78VAB\87IR@NYRG<7EW8.?<W]XABPCY-:[6LA_
M "MR?*M<W7I-<=R72@=B.[=<->/$;!ZT^CX$("Z9 )!X,Q'%9"31B'XX06M*
M1X-&&4F^L9# HT[2 V&:K<7&?=_626%L1UF="I[SA:"Q.4?I53@ZW^[+#WYW
M+B POD58]V2PYUA](=LP$UE1(V5<ZZJUYQB'^Y5:I4KF(9F'9!X^PSS4U'.;
MM+S6FG4L;+4:I V6=+6@;(FAQ5S8N(/S3 FJ) ,7Q6E4DR@$JG3B:.6V&XE:
M-PH\1S+-5O%2&HXRA=+MK#-1DCLZX'.Y[[3 5$@]3Q)#/0'%(D07+[J6TWQ$
MQP,LEH*+X[%A]7EC#8\'-853YQ8T"H-WC<3(6U"%\:X@:P>I[(\XT\#2T==)
M3*^^J4#RS>;G[/B[*0I(5_U*TTA$H1BB36IESL0ZD=MSM,IZY2=,B-%>A?7&
M,I9_M>$\T"Q?D#!2C#GJDZZR-9$"3:U2"A4DKT38/*4K\KU@&CX0/:9"!%.,
M:7K05M>^K7D@?LP.EM=E/.8F-A*$:W>EPMH\IT+8]IK8ME_YJ>.QL6?9P]BS
MH^/'> )7Q767X6T []5\>\JQYDJ,2,I-/T_T6/5@7 !$)$D;4?*IK<OGHFWC
MPRG/;1XKQ%B_,!AY$@X!7;X3O*5V Q7:IG 2(#6:%]"(D3&[-M0:0'7#\#@Q
MY%BC(W%0H',GL(,0*Y L/*5)45\_H)&GMQ8G]H6W/I;'@(-:FCUWI?KR[ADP
M!8;(EH"N_MF'[:C*,)A<FC+947G]UW:AQ49X[?MV;'F604)>MN><?;O#OK8'
MG5:_S[Y>M'JM[KG!^B%H E_X#\7E,R%8BG_$[OU5HF<N<GBB2"TJ,ME<PL(R
M\8*V/#VN'-0?:&=Z4#DX.'RP+6JM=OS@F(_'U0?&?*P</[B>:N6X6GMHS$&E
M>O30RQZSZ(^5H[VCA^<Y?.A=^_N5@\/:VIZP\>"UK0<!D( \[G_^I?:79_:L
MJK^P9U7]T3VKZBM[5M7SUXAL$PSZUG.LC3&=_LV@U_W2^#MK=YHK6S>]H*<9
MX4?.U)XL4!,&L$\,H)0 )J 24 FHI1'5E]W./QKL<G!&N$$$3T M*E#31MK6
M6F.Y #@1,8&4S"<"+U$L@91 2B ED!)(":2;LW9*=25U"".C*]7DVZ.#28#E
MV6R+J676#@Z,^'_5W6)8R04,,3B=G126FY05C7+B;"F<I?88?$@(KQ"84$"&
M\IO_&_NL:C*U*NS:-K\+3"\F'I,SS,H3CR$<(.Y"ZDIAT8A8":DHA6(BJ**<
M<AFP1H5=5=@=]CSATAV)\599X86Y?"X@BG7X6!174A4&,_(D>EYN*1\2@$M
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M-5:6:K  + P1U84@/2G7*)G)2%_ NS77O<_6HO B&= *&8Z*OXMF$S]L('#
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M).FM19OWPUM?_!GB02W-GG?EKCPXW.ZPK^U!I]7OLZ\7K5ZK>V[,6[DA+NB
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M7[?0=;!!$<C!*29W8:4(.&-A84LTE(Q6B+7TPV#D255P0@HX*Q\FX_BX$LP
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M2OH]B??'1;+RL3@A[7Y+V00!E<@?R)]T>V(%!%0"*@&U"$ EW9Z$^^/BHNW
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M>']_;]]@-_U&R9 ].K*28$&,U<R3Y1(YS= 'E7%>GK0D<-JML+FV6 I L9)
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ML(0GL1R2(P34;>(!IUC=]XZ[K,&E.Q)C$BR$5,^_>N1C;+1,8H7$"@%UBSD
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ML".7>L9L5_?9JI!X5(.\%-K!^D;Q!0=@=/F7[KCH>E-F"1_L.J6CHR$SYVN
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MN7_S@)6D!+O#IT:42(/,0_EJHHB!/T)I^Q;829%2@M^97BB#Q$9325@,BW6
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M#]YQ=G[\.]SNG9Y7&K[=C641P&MDUF^0?B3ZD;CK2#PEF?E9*.B!=R&SZRB
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MKO]UCM(^N-ZAX+I;RHBE\I*'>27$=":CZ:C(,-RJ8^YW\)49:%B8!@4YP4C
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M8^15BH:T!F&C;M*)U?HO8@?CV^FCV[0R:QO,[UB0"G/-VM1]>>WNVQNCW-:
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MZ(")BB]-KF4&VVM.)HU]387MU;@]FE6+E)O;1-V.6^L->&[!@6I=63S#@NV
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M!DKK))^W\6LCH,=3IGM&,H] \\)4M$CG0.N?&N\NC<N9?K$#Q%G@6"S-FWH
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M_D4R#)O8T5H_HK>6N[$ .V MKWHH;"A@E[F,\V"N%L:6C?(V9@R,.^G:?(&
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MJ8AY>[%2TSNO<5[#<]U$A&0F$@&"/6"V.CWK]_=;MT,KJP-;MU,@RX=1BZI
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M*#.)OXK&0C:"EP0QFT69DQS:$MS]R;M=9<'R47DO?&]W9VMWGWJQ^]+;J#+
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M4HS2:\P.:7LP9MDDWH8@FMTR9,89'7-;]QYTP@RU$I:A!7URA0;,QHAN&HN
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M/$KR%_VR6@(U>V^U=F"3[>_\E-7ZZ[-1&LY_^Q^_/IODT_BW_Q]02P,$%
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MLERD-5Z<92]F8-1&\BL,OZK0$@ #$&ZNX4RO1L[)GX'*EU=PY%<-/,%Y)*@
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MQ8"R@T TCRS'+P2(#+T :O:5*S50)E3PF@QN!Z-A>N/+'C9Y07*54E1%+J;
MM<!?<DD1'?.@:(M,&?Z!_'RS"!8'N%$_D$P3-H6:W'D8>FGF,DM&5LS",(#/
M$YF)&_1QH+@JY55:-!6^G*UE.]*UY>RYR>A9BDO),<H78@;GSCN178N;BG-[
M@@3XU@AR9%-NJL%P_H>R6$0UW$KZ"OS7J"# M1[[RZ\R;FITO9/7;%&4Y+3[
M A]P14;,XXFLXC*=>BJ*XE='@4E&]/N_4%%*R>\%C"X%\/GJ6UB'0>U%^=VM
MPL+O0L<GWQ;/@2(=WD8G* H1XU(1E>^FT$)O;[S+SM"E2'TAIM42-;Z1DFKH
MG<G2*UG>1 DH2UM*[R(%PERZ!:]3JP<3%\9Y\U0T]*B,T<U#6W.6T/ZS[7%T
MB!1I)\AZN/P*HZHJBGC<YBH>\>5 #@O8<XSJW*+V(S71Y>ARM8?Q2@,"ARO(
M/<<>\;$B=*9P/".[IR-0 :GVQNFKG:)P$J*2G+A315^QK%I'N?\6#+E-0<(+
MCIT8 ='SN*K_>=&6_(I'/8U/NW#Q42?DLSS\"BH'Z!G;G=\=P0'<2]S6-XD9
MG__,GR"<,EB1.OH___5?__5_07[E]1P6 P]*,R#>^[?OS7CU)L!I1BY/?),O
MM;3 PCA+'HDDL4%!_T)7)N"HW=5Q%1/<'5@E65]+F7NQ 6\ZN"3*P8H2>6MG
M.P(C1N:)**,;,'ZB)5!Y 9(,_BWUB.PN>&++"8&VUW";M#8*^(%\ST&6;:L%
MS+"]3]79&K5I>$1L3>%N(-42?T;:Q:#) H1!;<3]?E.!SA"=25!=F"!1PH-8
M1E\T7N6]"SZKQW?H/9VY&B>(]P+$.?P7YE.EJ&*F,W7+%&8.QF=E#&M2);4:
MJM;%W2A01^&((W64)DLJ*AY#,=UDUTH-RA(1!8 2%>:C_:>1JC"9PZQ3:</2
M[')'O@21E6,8!*D1QXP/XCG XY"3%?N11+@ERC:"=Y0ZOE<3L>%BV[,-=8 E
M^BUT6(LL?HP8H<"M5!!Y(1.D0D\I(.__5"#-P(1:TY^)-&M,>+Z]POB>.U:9
M1=_*:/RZ:NS/**5H]=(\0JY02!5Z!+/DU6T6R?,;\+UX 5ZY.Q"C]-$3FU^-
M=Z(GUKR?/D1TVI0Q^6N9U@=B:8RC$SSN@$3GG/4%CZ #51N+H#U9[<+QQO%1
M3FD$:%KHQ2F,TDLJ"FE:KHY:J9-8WZ!3<T@S\<P<&)"G(%;6JM6/Q7R1M"*M
MF*YO/62,U=5DK&"B4<N3.&L['=1<_)GP2X5YC*M/<Q['#>HK*W3:JD^I,":1
M8[=77@H/F @)#:EZCP\@)346F,L&:AB.'3495M$;T&E[IC*]<95V942V]HBF
MZYM"*CK#\W+-AQMG!T?H7ZG3G/B.(C^DF?4O@*\C@RZZ6-;&[4KJ77N]V[K\
MP\AHI5[L1)_4RPLT,,G()6V3;0)ES;26"C?A*\:&M)'RO0:$P^'<F#ZRTYHI
M&.,+3''S-ZM77P45=?""6&6D]J=PK*$(UF8TFYF)N*F8HTL9RW19FQRJDA+8
MV)Y#ITMQ36FMY/)TN0RMUOUBL9!EG%*&Y9F5.(<S]#=R*AJS@2=0R>WH4R((
M4;I0=GXA4:0LQQB),,MD$NE45;;ET>[7^9G6YP,SH@-'.Q64!Z;M$1T\)>N,
MZFAW_'H@Q&Q2LTT&=I2D92<@-_(H=H8N$"N:>TC-%8<K#'7G"&JD.G[;%#5K
M2LZKE+5(LTVB,2"QM^.A2,QA>5V"I?D02W-W^"Q[7,#YG<] 9Z0\:\3J'HZY
M>?'0?#2OJ@;.C"PC9[9VW\;.2O4^E^M+*,+:B;"T]'R=K68O2/.K(HTE973,
M4E@:/S\?GHW!CH3RUY,B;KA":X(!+>_1(_4&V+&\N 8]Z5)YQ<T+..[!E04J
M^5\]3V6?Z(DJ$XG-TNH/I?CU&EEN;I\)<[N&G['J@2!!I2O QDNY(FMZHTPI
MC"TWN8K4V*#1HJD;TD1)!6S7JSDE'4&P;ZY@WQN^8#_*@<J!Q8>4JC".CHL:
MY0G)0I3"@]]&JU+O#603N5!O$YQ'=N]>#63O3+(<V<ZL ^C<_0(LW@RL:^M
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M1Z0CKD'54T))&L45K&FBT_;\[,*E4EP,$C:\1;V]K_PEI].%Z[-6C:7E4K=
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MZ*CFKF$]&@E>RDJ)*L/7R__ E -"IH;GXU[EC(&#V//8S*"6RXH+IN57@7$
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MAG)=_9#F%'+@-*X*R"U" "OTY*@@/+Q9&:MH#QOP:[K=N=N]F0;2N5VM8%S
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M 0RU%2XLH"F?1G<<Q6D[?-R9I<>$UH]G8R77A<79JFKM2BL9C("(_ZZ1N,U
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M;UGO 4_./5?<IGWZE45Y*?+TWZJV1/6G<:K/%)R"=ER6$C?=M6(\C,YH.1?
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MH>*4L.?2.*IE/,]3U'1(\KM1KRYJKV5/%<Q#L$?+YP_1FDTYNLV,H/>K9\3
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MCE:I<VINXU['9V4JUATGV:A?.I*JIDKUO<YE(IHVR:7T $Y9:V7*T 4N#L>
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MMVB582K9<Q-=& AN9PBJ(\'V>U,UVX5$\MT^=! #"6W=@4LWLNX63LA.F/=
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M#0\IA+I.K-4OHDO$)*5M(3FIL,127#RDJB-NX2Q.ZB2<WI4:9V\_:IBZ/YS
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M.O*S7+-J'D&["4"Z'N1!TR_BB"./_.M ]G_S< .8:6-<J3&NV!1-+/W]AOL
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MV&I@MQ"]+-S@Z)#+$0J80H/2Q=SJ:5MZ-Q>0Q58-QA[)^ 0C ^B"J&K=]Z;
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MQ=(X]/KTE_[9YP]]MOMLV+!++4CVP/[/?<1=79Y]/KVY9B<79^S3U?EI?[-
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M$R&;[F1'G23EXM6<N]N<;V.ULRW?#E5$)5P,5635;,N.R\G;149X-7N]\]J
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M!U247]@ 2U5,<JZ IV(."3:5A3#.%U<_L\AQV/3Z8A+0O:R.E(^:-#AG&+K
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M&0NZY=+B]?>3R%_]\"^OOY^GB^"'_P-02P,$%     @ ,();5HD9(=/G @
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MO'O3J6'[#V$+&[>-(Z9A41 ]V]ONAE8#VVY("WW_(=C_ @8P*6=R'546"A1
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M2&YMQME71.C6:OU\6])N?VSZ>,OI?RS9WB656ESC;^JN3S2;[F>C>\PE177
M'^GF0+#6'&!!8 K<>?L.5_H/RY8"5U0A)[IU;.E>@L@4A$BG_I *ZH0^E_V
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M-34Q.#(Y7S N:G!G4$L! A0#%     @ ,();5ILRXM5R%P  )1H  !$
M         ( !8"@! &EM9S<P-34Q.#(Y7S$N:G!G4$L! A0#%     @ ,();
M5OO >]S#%@  W1@  !(              ( ! 4 ! &EM9S<P-34Q.#(Y7S$P
M+FIP9U!+ 0(4 Q0    ( #""6U;?W#>O=Q ! ,51 0 2              "
M ?16 0!I;6<W,#4U,3@R.5\Q,2YJ<&=02P$"% ,4    "  P@EM664F2\%K2
M 0"3Z0( $@              @ &;9P( :6UG-S U-3$X,CE?,3(N:G!G4$L!
M A0#%     @ ,();5GS@?CAQC   'AP! !(              ( !)3H$ &EM
M9S<P-34Q.#(Y7S$S+FIP9U!+ 0(4 Q0    ( #""6U:X-F4OAZ8  -9' 0 2
M              "  <;&! !I;6<W,#4U,3@R.5\Q-"YJ<&=02P$"% ,4
M"  P@EM6WK?YP&^^ @ 9& 0 $@              @ %];04 :6UG-S U-3$X
M,CE?,34N:G!G4$L! A0#%     @ ,();5FF:]>_K>@( ],0# !(
M     ( !'"P( &EM9S<P-34Q.#(Y7S$V+FIP9U!+ 0(4 Q0    ( #""6U;N
M"S\/T?4  #^\ 0 2              "  3>G"@!I;6<W,#4U,3@R.5\Q-RYJ
M<&=02P$"% ,4    "  P@EM6U_9NZ1-# 0#D P( $@              @ $X
MG0L :6UG-S U-3$X,CE?,3@N:G!G4$L! A0#%     @ ,();5BNVTB?(O@$
MB+ # !(              ( !>^ , &EM9S<P-34Q.#(Y7S$Y+FIP9U!+ 0(4
M Q0    ( #""6U:,ZM.69%T  (5G   1              "  7.?#@!I;6<W
M,#4U,3@R.5\R+FIP9U!+ 0(4 Q0    ( #""6U:4ZX$:/E   (I<   2
M          "  0;]#@!I;6<W,#4U,3@R.5\R,"YJ<&=02P$"% ,4    "  P
M@EM659LV4T\C  "1*0  $@              @ %T30\ :6UG-S U-3$X,CE?
M,C$N:G!G4$L! A0#%     @ ,();5NQ4Z%)I!P( V3X" !(
M ( !\W / &EM9S<P-34Q.#(Y7S(R+FIP9U!+ 0(4 Q0    ( #""6U;5#_\D
MD'$! -() @ 2              "  8QX$0!I;6<W,#4U,3@R.5\R,RYJ<&=0
M2P$"% ,4    "  P@EM6?'THYBI+   $>0  $0              @ %,ZA(
M:6UG-S U-3$X,CE?,RYJ<&=02P$"% ,4    "  P@EM6C%"JN_(X  #B20
M$0              @ &E-1, :6UG-S U-3$X,CE?-"YJ<&=02P$"% ,4
M"  P@EM6V;*BQHTJ  "<+@  $0              @ '&;A, :6UG-S U-3$X
M,CE?-2YJ<&=02P$"% ,4    "  P@EM61>;AHCHS  "Q.   $0
M    @ &"F1, :6UG-S U-3$X,CE?-BYJ<&=02P$"% ,4    "  P@EM6I1%O
M=8AL 0"U&P( $0              @ 'KS!, :6UG-S U-3$X,CE?-RYJ<&=0
M2P$"% ,4    "  P@EM6V%(D^;,U P!4(P8 $0              @ &B.14
M:6UG-S U-3$X,CE?."YJ<&=02P$"% ,4    "  P@EM6U"'[W00L  !I+@
M$0              @ &$;Q@ :6UG-S U-3$X,CE?.2YJ<&=02P$"% ,4
M"  P@EM6CBHBI#6(!0!_&E, $0              @ &WFQ@ <&-V>"TR,#(R
M,3(S,2YH=&U02P$"% ,4    "  P@EM6+MZ_+- :  "=3 $ $0
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M>"UE>#$P7S$U+FAT;5!+ 0(4 Q0    ( #""6U:,;"6&06T  !MX!  0
M          "  8.T( !P8W9X+65X,3!?,3<N:'1M4$L! A0#%     @ ,();
M5IOG7/Q!E   %IT& !               ( !\B$A '!C=G@M97@Q,%\Q.2YH
M=&U02P$"% ,4    "  P@EM6RMRWJ8XP  "6"@( $               @ %A
MMB$ <&-V>"UE>#$P7S(P+FAT;5!+ 0(4 Q0    ( #""6U:)&2'3YP(   83
M   /              "  1WG(0!P8W9X+65X,C-?,2YH=&U02P$"% ,4
M"  P@EM6;<%J'HL(   \10  #P              @ $QZB$ <&-V>"UE>#,Q
M7S$N:'1M4$L! A0#%     @ ,();5L+7G$>."   2D4   \
M ( !Z?(A '!C=G@M97@S,5\R+FAT;5!+ 0(4 Q0    ( #""6U9B'CFFC04
M $,B   /              "  :3[(0!P8W9X+65X,S)?,2YH=&U02P4&
/ "< )P"J"0  7@$B

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
